Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
TSPAN6	T245, TM4SF6, TSPAN-6	ENSG00000000003	Tetraspanin 6	X	100627109-100639991	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004109	Approved		Approved	Cytosol		Expressed in all	Mixed			fallopian tube: 102.1	Cell line enhanced		NTERA-2: 165.6;RT4: 203.5
TNMD	BRICD4, ChM1L, myodulin, TEM, tendin	ENSG00000000005	Tenomodulin	X	100584802-100599885	Predicted membrane proteins	Evidence at protein level	HPA034961, HPA055634	Uncertain					Mixed	Tissue enhanced		adipose tissue: 10.1;seminal vesicle: 33.2	breast: 4.3	Group enriched	19	HAP1: 6.2;NTERA-2: 14.2
DPM1	CDGIE, MPDS	ENSG00000000419	Dolichyl-phosphate mannosyltransferase subunit 1, catalytic	20	50934867-50958555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051818	Approved				Liver cancer:1.94e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.5	Expressed in all		
SCYL3	PACE-1, PACE1	ENSG00000000457	SCY1 like pseudokinase 3	1	169849631-169894267	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005624	Approved		Uncertain	Nuclear bodies<br>Microtubules	Urothelial cancer:8.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.6	Expressed in all		
C1orf112	FLJ10706	ENSG00000000460	Chromosome 1 open reading frame 112	1	169662007-169854080	Predicted intracellular proteins	Evidence at protein level	HPA023778, HPA024451	Uncertain		Approved	Mitochondria	Endometrial cancer:9.56e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 25.0	testis: 18.6	Expressed in all		
FGR	c-fgr, p55c-fgr, SRC2	ENSG00000000938	FGR proto-oncogene, Src family tyrosine kinase	1	27612064-27635277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002024	Enhanced		Approved	Plasma membrane<br>Aggresome		Expressed in all	Tissue enhanced		appendix: 85.6;bone marrow: 137.0;spleen: 90.6	lung: 56.3	Cell line enhanced		Daudi: 61.4;HMC-1: 25.8;U-266/70: 116.7
CFH	ARMD4, ARMS1, FHL1, HF, HF1, HF2, HUS	ENSG00000000971	Complement factor H	1	196651878-196747504	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016385, CAB016769, HPA038922, HPA049176, HPA053326	Supported		Approved	Vesicles	Renal cancer:1.92e-6 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 839.5	gallbladder: 205.3	Cell line enhanced		HHSteC: 100.0;RT4: 176.9
FUCA2	dJ20N2.5, MGC1314	ENSG00000001036	Fucosidase, alpha-L- 2, plasma	6	143494811-143511690	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031659, HPA031660, HPA031661	Uncertain				Liver cancer:2.70e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 154.2	Mixed		
GCLC	GCS, GLCL, GLCLC	ENSG00000001084	Glutamate-cysteine ligase catalytic subunit	6	53497341-53616970	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009569, HPA036359, HPA036360	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 80.9	Expressed in all		
NFYA	CBF-B, HAP2, NF-YA	ENSG00000001167	Nuclear transcription factor Y subunit alpha	6	41072945-41099976	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009250, HPA050779	Enhanced		Enhanced	Nucleoplasm	Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 70.9	Expressed in all		
STPG1	C1orf201, FLJ33340, MAPO2	ENSG00000001460	Sperm tail PG-rich repeat containing 1	1	24356999-24416934	Predicted intracellular proteins	Evidence at protein level	HPA024301			Approved	Nucleoplasm	Endometrial cancer:1.33e-4 (favourable), Renal cancer:2.31e-4 (favourable)	Mixed	Tissue enhanced		testis: 46.9	fallopian tube: 26.8	Mixed		
NIPAL3	DJ462O23.2, NPAL3	ENSG00000001461	NIPA like domain containing 3	1	24415794-24472976	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039978	Approved		Approved	Nucleoplasm	Renal cancer:3.03e-7 (favourable), Thyroid cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			prostate: 97.4	Mixed		
LAS1L	FLJ12525	ENSG00000001497	LAS1 like, ribosome biogenesis factor	X	65512582-65534775	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044431, HPA061463	Supported		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 40.6	Expressed in all		
ENPP4	KIAA0879, NPP4	ENSG00000001561	Ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative)	6	46129993-46146699	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016594	Approved				Renal cancer:6.95e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.4	Cell line enhanced		SCLC-21H: 21.1
SEMA3F	Sema4, SEMAK	ENSG00000001617	Semaphorin 3F	3	50155045-50189075	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035008	Approved				Liver cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 89.1	Cell line enhanced		HUVEC TERT2: 156.4;SK-BR-3: 129.8;TIME: 276.8
CFTR	ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR	ENSG00000001626	Cystic fibrosis transmembrane conductance regulator	7	117465784-117715971	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001951, HPA021939	Enhanced				Liver cancer:9.44e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 89.3	rectum: 49.0	Group enriched	19	CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
ANKIB1	DKFZP434A0225, KIAA1386	ENSG00000001629	Ankyrin repeat and IBR domain containing 1	7	92246234-92401384	Predicted intracellular proteins	Evidence at protein level	HPA019358, HPA021780	Uncertain		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
CYP51A1	CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1	ENSG00000001630	Cytochrome P450 family 51 subfamily A member 1	7	92112151-92142952	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041325, HPA043508	Enhanced		Enhanced	Endoplasmic reticulum	Cervical cancer:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 174.1	Expressed in all		
KRIT1	CAM, CCM1	ENSG00000001631	KRIT1, ankyrin repeat containing	7	92198969-92246166	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049606	Supported		Uncertain	Vesicles		Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
RAD52		ENSG00000002016	RAD52 homolog, DNA repair protein	12	912077-990053	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028957			Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.22e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.0	Expressed in all		
BAD	BBC2, BCL2L8	ENSG00000002330	BCL2 associated agonist of cell death	11	64269830-64284704	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004205, HPA028185, HPA062105	Approved		Enhanced	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 48.9	Expressed in all		
LAP3	LAP, LAPEP, PEPS	ENSG00000002549	Leucine aminopeptidase 3	4	17577192-17607972	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029606, HPA029607	Enhanced		Supported	Nucleoplasm<br>Midbody<br>Cytosol		Expressed in all	Expressed in all			appendix: 176.5	Mixed		
CD99	MIC2	ENSG00000002586	CD99 molecule	X	2691179-2741309	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000020, HPA035304	Supported		Approved	Golgi apparatus	Renal cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 375.1	Mixed		
HS3ST1	3OST1	ENSG00000002587	Heparan sulfate-glucosamine 3-sulfotransferase 1	4	11393150-11429765	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA002237	Approved		Approved	Vesicles	Renal cancer:5.99e-8 (favourable), Endometrial cancer:7.73e-4 (favourable), Urothelial cancer:8.67e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 13.9;ovary: 23.2	urinary bladder: 5.6	Cell line enhanced		CAPAN-2: 12.2;RPTEC TERT1: 9.1;RT4: 8.0;SCLC-21H: 4.3
AOC1	ABP1, DAO	ENSG00000002726	Amine oxidase, copper containing 1	7	150824627-150861504	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA031032, HPA031033	Approved				Prostate cancer:1.71e-4 (favourable)	Group enriched	Tissue enhanced		placenta: 716.9;small intestine: 247.6	duodenum: 183.2	Cell line enhanced		CAPAN-2: 17.4;HaCaT: 5.4;THP-1: 17.8
WNT16		ENSG00000002745	Wnt family member 16	7	121325367-121341104	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA027030	Uncertain					Mixed	Group enriched	7	cervix, uterine: 8.6;skin: 24.3	seminal vesicle: 2.5	Cell line enhanced		CAPAN-2: 2.0;HEK 293: 4.9;hTEC/SVTERT24-B: 1.6;U-2197: 2.4
HECW1	KIAA0322, NEDL1	ENSG00000002746	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1	7	43112599-43566001	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007203, HPA007593, HPA007609	Approved		Supported	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 10.9;kidney: 8.2	testis: 3.4	Cell line enhanced		A549: 3.9;U-266/70: 9.1
MAD1L1	HsMAD1, MAD1, PIG9, TP53I9, TXBP181	ENSG00000002822	MAD1 mitotic arrest deficient like 1	7	1815793-2233243	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003635, CAB015338	Supported		Supported	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			lymph node: 23.3	Expressed in all		
LASP1	Lasp-1, MLN50	ENSG00000002834	LIM and SH3 protein 1	17	38869859-38921770	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012072, CAB022049	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 181.3	Expressed in all		
SNX11		ENSG00000002919	Sorting nexin 11	17	48103357-48123074	Predicted intracellular proteins	Evidence at protein level	HPA044787, HPA054660	Approved		Approved	Cytosol		Expressed in all	Expressed in all			thyroid gland: 32.1	Expressed in all		
TMEM176A	HCA112, MS4B1	ENSG00000002933	Transmembrane protein 176A	7	150800403-150805120	Predicted membrane proteins	Evidence at protein level	HPA008770	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			liver: 583.9	Cell line enriched	30	HSkMC: 493.9
M6PR	CD-M6PR, CD-MPR	ENSG00000003056	Mannose-6-phosphate receptor, cation dependent	12	8940363-8949955	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034464, HPA040445	Approved				Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 175.3	Expressed in all		
KLHL13	BKLHD2, FLJ10262, KIAA1309	ENSG00000003096	Kelch like family member 13	X	117897813-118117340	Predicted intracellular proteins	Evidence at protein level	HPA046039, HPA059901	Approved		Approved	Cytosol		Mixed	Tissue enhanced		endometrium: 52.6	smooth muscle: 43.9	Cell line enhanced		HeLa: 40.3;RPTEC TERT1: 80.3;SH-SY5Y: 100.1
CYP26B1	P450RAI-2	ENSG00000003137	Cytochrome P450 family 26 subfamily B member 1	2	72129238-72148038	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012567	Uncertain		Approved	Cytosol		Expressed in all	Tissue enhanced		testis: 27.1	skin: 25.0	Cell line enhanced		HaCaT: 13.4;RH-30: 18.5;U-2 OS: 21.9
ICA1	ICA69, ICAp69	ENSG00000003147	Islet cell autoantigen 1	7	8113184-8262687	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017646, HPA061452	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:4.23e-8 (favourable)	Expressed in all	Mixed			testis: 42.6	Cell line enhanced		SCLC-21H: 73.0;SH-SY5Y: 109.7
DBNDD1	FLJ12582, MGC3101	ENSG00000003249	Dysbindin domain containing 1	16	90004865-90020128	Predicted intracellular proteins	Evidence at protein level	HPA043018	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.75e-7 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 24.0	skeletal muscle: 15.6	Cell line enhanced		MCF7: 109.1
ALS2	ALS2CR6	ENSG00000003393	ALS2, alsin Rho guanine nucleotide exchange factor	2	201700554-201781189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046588	Approved		Approved	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 16.6	Expressed in all		
CASP10	MCH4	ENSG00000003400	Caspase 10	2	201182881-201229406	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003780, HPA017059	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:6.05e-7 (unfavourable), Liver cancer:8.54e-4 (unfavourable)	Expressed in all	Mixed			spleen: 24.1	Cell line enhanced		HUVEC TERT2: 21.4
CFLAR	c-FLIP, CASH, CASP8AP1, Casper, CLARP, FLAME, FLIP, I-FLICE, MRIT	ENSG00000003402	CASP8 and FADD like apoptosis regulator	2	201116104-201176687	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019044, CAB022157, CAB025216	Uncertain		Supported	Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 159.9	Expressed in all		
TFPI	EPI, LACI, TFI, TFPI1	ENSG00000003436	Tissue factor pathway inhibitor	2	187464230-187565760	Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA005575, CAB020842	Supported		Approved	Intermediate filaments<br>Cytosol	Cervical cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 267.0	Cell line enhanced		HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9
NDUFAF7	C2orf56, MidA, PRO1853	ENSG00000003509	NADH:ubiquinone oxidoreductase complex assembly factor 7	2	37231631-37253403	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045217	Uncertain				Liver cancer:1.48e-4 (unfavourable), Lung cancer:3.08e-4 (favourable)	Expressed in all	Tissue enriched	5	testis: 69.1	adrenal gland: 12.9	Expressed in all		
RBM5	H37, LUCA15	ENSG00000003756	RNA binding motif protein 5	3	50088908-50119021	Predicted intracellular proteins	Evidence at protein level	HPA017335, HPA018011	Approved		Enhanced	Nucleoplasm	Lung cancer:6.46e-4 (favourable), Pancreatic cancer:7.58e-4 (favourable), Liver cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 112.7	Expressed in all		
MTMR7		ENSG00000003987	Myotubularin related protein 7	8	17298030-17413528	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 22.9;parathyroid gland: 15.2	thyroid gland: 5.5	Cell line enhanced		SCLC-21H: 12.4;SH-SY5Y: 6.5
SLC7A2	ATRC2, CAT-2, HCAT2	ENSG00000003989	Solute carrier family 7 member 2	8	17497088-17570573	Predicted membrane proteins, Transporters	Evidence at protein level	HPA009277			Supported	Plasma membrane<br>Cell Junctions	Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 380.7	liver: 92.6	Cell line enhanced		HHSteC: 171.6
ARF5		ENSG00000004059	ADP ribosylation factor 5	7	127588345-127591705	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 176.2	Expressed in all		
SARM1	KIAA0524, SAMD2, SARM	ENSG00000004139	Sterile alpha and TIR motif containing 1	17	28364356-28404049	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024359, HPA024759	Uncertain		Approved	Vesicles		Mixed	Mixed			duodenum: 7.5	Cell line enhanced		CACO-2: 26.9
POLDIP2	DKFZP586F1524, PDIP38	ENSG00000004142	DNA polymerase delta interacting protein 2	17	28347177-28357522	Predicted intracellular proteins	Evidence at protein level	HPA007700			Approved	Mitochondria		Expressed in all	Expressed in all			kidney: 109.1	Expressed in all		
PLXND1	KIAA0620	ENSG00000004399	Plexin D1	3	129555175-129606818	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020819	Approved				Renal cancer:5.93e-7 (unfavourable)	Expressed in all	Expressed in all			placenta: 161.3	Cell line enhanced		ASC diff: 268.0;HSkMC: 206.8;HUVEC TERT2: 287.4;TIME: 332.2
AK2		ENSG00000004455	Adenylate kinase 2	1	33007940-33080996	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018479	Approved				Breast cancer:4.37e-4 (favourable), Pancreatic cancer:6.40e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 183.3	Expressed in all		
CD38		ENSG00000004468	CD38 molecule	4	15778275-15853230	Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002493, HPA022132, CAB025255, HPA052381	Enhanced		Supported	Plasma membrane	Endometrial cancer:9.68e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 27.6	Cell line enhanced		Daudi: 91.6;Karpas-707: 24.9;MOLT-4: 26.4;REH: 23.7;U-266/70: 20.4
FKBP4	FKBP52, FKBP59	ENSG00000004478	FK506 binding protein 4	12	2794953-2805423	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006148, CAB017441, HPA062857	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.12e-5 (unfavourable), Lung cancer:1.44e-4 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 107.4	Expressed in all		
KDM1A	AOF2, BHC110, KDM1, KIAA0601, LSD1	ENSG00000004487	Lysine demethylase 1A	1	23019448-23083689	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB005884, HPA053660	Supported		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:4.47e-12 (unfavourable), Colorectal cancer:6.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 163.3	Expressed in all		
RBM6	3G2, DEF-3, DEF3, g16, NY-LU-12	ENSG00000004534	RNA binding motif protein 6	3	49940007-50100045	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026272, HPA027164	Enhanced		Approved	Nuclear speckles<br>Cytoplasmic bodies	Urothelial cancer:5.13e-5 (favourable), Pancreatic cancer:1.41e-4 (favourable), Renal cancer:8.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 83.7	Expressed in all		
CAMKK1	CAMKKA, DKFZp761M0423, MGC34095	ENSG00000004660	Calcium/calmodulin dependent protein kinase kinase 1	17	3860315-3894891	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009111, HPA028062	Approved		Supported	Cytosol	Pancreatic cancer:2.65e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 51.5	seminal vesicle: 14.7	Cell line enhanced		U-87 MG: 27.3
RECQL	RecQ1, RecQL1	ENSG00000004700	RecQ like helicase	12	21468911-21501669	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009743, HPA030960, HPA064259	Enhanced		Enhanced	Nucleoplasm	Ovarian cancer:3.15e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.1	Expressed in all		
VPS50	CCDC132, DKFZp313I2429, FLJ20097, KIAA1861, VPS54L	ENSG00000004766	VPS50, EARP/GARPII complex subunit	7	93232340-93361121	Predicted intracellular proteins	Evidence at protein level	HPA026679	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.35e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.4	Expressed in all		
HSPB6	FLJ32389, Hsp20, PPP1R91	ENSG00000004776	Heat shock protein family B (small) member 6	19	35754569-35758079	Predicted intracellular proteins	Evidence at protein level	CAB001974, HPA044153, HPA054811	Enhanced				Urothelial cancer:1.43e-6 (unfavourable), Renal cancer:1.93e-5 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 843.0	adipose tissue: 666.5	Cell line enhanced		ASC diff: 1220.3;ASC TERT1: 521.5;HHSteC: 505.3;HSkMC: 510.5
ARHGAP33	FLJ39019, SNX26, TCGAP	ENSG00000004777	Rho GTPase activating protein 33	19	35774532-35788822	Predicted intracellular proteins	Evidence at protein level	HPA030117, HPA030118	Supported		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:3.09e-8 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 25.8	Cell line enhanced		HMC-1: 50.9
NDUFAB1	ACP, ACP1, FASN2A, SDAP	ENSG00000004779	NADH:ubiquinone oxidoreductase subunit AB1	16	23581002-23596356	Predicted intracellular proteins	Evidence at protein level	HPA054364	Uncertain		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.94e-7 (favourable)	Expressed in all	Expressed in all			heart muscle: 179.6	Expressed in all		
PDK4		ENSG00000004799	Pyruvate dehydrogenase kinase 4	7	95583499-95596491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056731	Approved				Stomach cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 763.0	Cell line enriched	7	ASC diff: 333.3
SLC22A16	CT2, FLIPT2, OAT6, OKB1	ENSG00000004809	Solute carrier family 22 member 16	6	110424687-110476641	Predicted membrane proteins	Evidence at protein level	HPA036902	Uncertain					Tissue enriched	Group enriched	8	bone marrow: 12.9;parathyroid gland: 16.3;testis: 38.6	smooth muscle: 2.7	Group enriched	16	NB-4: 10.5;REH: 14.0;THP-1: 35.6;U-937: 24.4
ZMYND10	BLU, CILD22	ENSG00000004838	Zinc finger MYND-type containing 10	3	50341110-50346852	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035255			Approved	Plasma membrane<br>Cytosol	Renal cancer:6.75e-5 (favourable)	Tissue enhanced	Group enriched	16	fallopian tube: 231.5;testis: 284.6	lung: 15.8	Cell line enhanced		T-47d: 6.1;U-87 MG: 4.3
ABCB5	ABCB5alpha, ABCB5beta, EST422562	ENSG00000004846	ATP binding cassette subfamily B member 5	7	20615207-20777038	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	7	epididymis: 32.3	gallbladder: 4.3	Cell line enriched	6	SK-MEL-30: 37.0
ARX	CT121, EIEE1, ISSX, MRX29, MRX32, MRX33, MRX36, MRX38, MRX43, MRX54, MRX76, MRX87, MRXS1, PRTS	ENSG00000004848	Aristaless related homeobox	X	25003694-25016420	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:3.54e-7 (unfavourable)	Mixed	Tissue enriched	7	ovary: 97.7	testis: 14.0	Cell line enhanced		HAP1: 2.0;PC-3: 3.6;U-266/70: 6.3
SLC25A13	ARALAR2, CITRIN, CTLN2	ENSG00000004864	Solute carrier family 25 member 13	7	96120220-96322147	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018997	Approved		Supported	Mitochondria	Renal cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.3	Mixed		
ST7	ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7	ENSG00000004866	Suppression of tumorigenicity 7	7	116953238-117230103	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038325, HPA038326	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.39e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.0	Mixed		
CDC27	ANAPC3, APC3, D0S1430E, D17S978E, NUC2	ENSG00000004897	Cell division cycle 27	17	47117703-47189422	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016315, HPA028129, HPA052399	Supported		Enhanced	Nucleoplasm	Renal cancer:6.39e-5 (unfavourable), Colorectal cancer:1.77e-4 (favourable), Liver cancer:4.38e-4 (unfavourable), Lung cancer:8.15e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.5	Expressed in all		
SLC4A1	AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR	ENSG00000004939	Solute carrier family 4 member 1 (Diego blood group)	17	44248385-44268141	Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015584, CAB034438, HPA063911	Enhanced					Tissue enriched	Tissue enriched	8	bone marrow: 238.0	kidney: 30.0	Mixed		
CALCR	CTR	ENSG00000004948	Calcitonin receptor	7	93424487-93574730	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028962, HPA061428	Enhanced					Tissue enriched	Tissue enhanced		kidney: 2.1;testis: 1.4	placenta: 1.0	Cell line enhanced		RPTEC TERT1: 1.5;T-47d: 3.6
HCCS	CCHL, MLS	ENSG00000004961	Holocytochrome c synthase	X	11111301-11123078	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA002946	Approved		Enhanced	Mitochondria	Renal cancer:6.17e-8 (favourable), Liver cancer:1.35e-5 (unfavourable), Breast cancer:8.69e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 31.5	Expressed in all		
DVL2		ENSG00000004975	Dishevelled segment polarity protein 2	17	7225341-7234545	Predicted intracellular proteins	Evidence at protein level	CAB009312, HPA021611, HPA022914, HPA064732	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:4.34e-6 (unfavourable), Pancreatic cancer:3.85e-4 (favourable)	Expressed in all	Expressed in all			ovary: 36.1	Expressed in all		
PRSS22	BSSP-4, hBSSP-4, SP001LA	ENSG00000005001	Protease, serine 22	16	2852727-2858170	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA049161	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		esophagus: 7.7;stomach: 11.1	salivary gland: 3.1	Cell line enhanced		CAPAN-2: 67.3;SK-BR-3: 14.6;T-47d: 16.5
UPF1	HUPF1, KIAA0221, NORF1, pNORF1, RENT1, smg-2	ENSG00000005007	UPF1, RNA helicase and ATPase	19	18831938-18868236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019587, HPA020857	Approved		Supported	Nucleoplasm	Renal cancer:2.97e-6 (favourable), Melanoma:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.7	Expressed in all		
SKAP2	RA70, SAPS, SCAP2, SKAP-HOM, SKAP55R	ENSG00000005020	Src kinase associated phosphoprotein 2	7	26667062-26995239	Predicted intracellular proteins	Evidence at protein level	HPA005560, HPA024045	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.6	Cell line enhanced		CAPAN-2: 125.0
SLC25A5	2F1, ANT2, T2, T3	ENSG00000005022	Solute carrier family 25 member 5	X	119468400-119471319	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria	Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 769.6	Expressed in all		
MCUB	CCDC109B, FLJ20647	ENSG00000005059	Mitochondrial calcium uniporter dominant negative beta subunit	4	109560205-109688726	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048776	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 36.2	Mixed		
HOXA11	HOX1, HOX1I	ENSG00000005073	Homeobox A11	7	27181510-27185223	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006770, HPA035623	Enhanced		Supported	Nucleoplasm	Renal cancer:2.57e-5 (unfavourable)	Mixed	Tissue enhanced		endometrium: 96.3;smooth muscle: 68.5	cervix, uterine: 17.9	Cell line enhanced		HEK 293: 46.1;U-937: 37.5
POLR2J	hRPB14, POLR2J1, RPB11, RPB11A, RPB11m	ENSG00000005075	RNA polymerase II subunit J	7	102473118-102478907	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA042997, HPA044010, HPA046970	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			adrenal gland: 72.4	Expressed in all		
DHX33	DDX33, DKFZp762F2011, FLJ21972	ENSG00000005100	DEAH-box helicase 33	17	5440912-5469060	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073875			Supported	Nucleoli	Prostate cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 13.6	Expressed in all		
MEOX1	MOX1	ENSG00000005102	Mesenchyme homeobox 1	17	43640388-43661954	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045214	Uncertain		Uncertain	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		adipose tissue: 25.3	spleen: 16.4	Cell line enriched	10	HeLa: 16.8
THSD7A	KIAA0960	ENSG00000005108	Thrombospondin type 1 domain containing 7A	7	11370357-11832198	Predicted membrane proteins	Evidence at protein level	HPA000923	Supported				Renal cancer:2.24e-6 (favourable)	Mixed	Mixed			kidney: 8.4	Cell line enhanced		A549: 9.2;HUVEC TERT2: 5.6;REH: 6.5;SH-SY5Y: 10.8;THP-1: 12.8
LIG3	LIG2	ENSG00000005156	DNA ligase 3	17	34980494-35009743	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006723	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 38.7	Expressed in all		
RPAP3	FLJ21908, spag	ENSG00000005175	RNA polymerase II associated protein 3	12	47661249-47706061	Predicted intracellular proteins	Evidence at protein level	HPA038311, HPA038312	Enhanced		Approved	Cytosol	Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 34.4	Expressed in all		
ACSM3	SA, SAH	ENSG00000005187	Acyl-CoA synthetase medium-chain family member 3	16	20610243-20797581	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041013	Uncertain				Renal cancer:9.88e-6 (favourable), Ovarian cancer:1.97e-4 (favourable)	Mixed	Tissue enhanced		liver: 93.2	kidney: 90.8	Group enriched	12	HEL: 85.7;HMC-1: 339.4;K-562: 258.6
AC004381.6		ENSG00000005189	Putative RNA exonuclease NEF-sp 	16	20806429-20849668	Predicted intracellular proteins	Evidence at protein level	HPA040755, HPA040868	Enhanced		Approved	Nuclear membrane<br>Nucleoli<br>Endoplasmic reticulum		Expressed in all	Tissue enriched	33	testis: 618.5	parathyroid gland: 18.9	Mixed		
CIAPIN1	Anamorsin	ENSG00000005194	Cytokine induced apoptosis inhibitor 1	16	57428169-57447528	Predicted intracellular proteins	Evidence at protein level	HPA041350, HPA042182	Enhanced		Supported	Mitochondria	Head and neck cancer:4.35e-4 (unfavourable), Renal cancer:4.42e-4 (favourable)	Expressed in all	Expressed in all			testis: 129.0	Expressed in all		
SPPL2B	IMP4, KIAA1532, PSL1	ENSG00000005206	Signal peptide peptidase like 2B	19	2328615-2354806	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB005592, HPA039292	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome	Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
FAM214B	bA182N22.6, FLJ11560, KIAA1539	ENSG00000005238	Family with sequence similarity 214 member B	9	35104112-35116341	Predicted intracellular proteins	Evidence at protein level	HPA048831, HPA055751	Approved		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			bone marrow: 24.5	Mixed		
COPZ2	MGC23008	ENSG00000005243	Coatomer protein complex subunit zeta 2	17	48026167-48038030	Predicted intracellular proteins	Evidence at protein level	HPA055999	Uncertain				Renal cancer:3.45e-9 (unfavourable), Thyroid cancer:2.89e-6 (unfavourable), Urothelial cancer:4.66e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 73.1	Cell line enhanced		ASC TERT1: 132.1;fHDF/TERT166: 213.5
PRKAR2B	PRKAR2	ENSG00000005249	Protein kinase cAMP-dependent type II regulatory subunit beta	7	107044649-107161811	Predicted intracellular proteins	Evidence at protein level	HPA008421	Enhanced		Approved	Golgi apparatus<br>Centrosome<br>Mitochondria<br>Cytosol	Pancreatic cancer:4.03e-4 (favourable), Colorectal cancer:6.38e-4 (favourable), Thyroid cancer:8.74e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 139.4	adrenal gland: 39.1	Cell line enhanced		AN3-CA: 64.4;Daudi: 70.1;U-698: 172.6
MSL3	MSL3L1	ENSG00000005302	Male-specific lethal 3 homolog (Drosophila)	X	11758159-11775753	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034535, HPA034536	Uncertain		Approved	Nucleoplasm	Renal cancer:3.14e-9 (unfavourable), Urothelial cancer:2.17e-4 (favourable), Head and neck cancer:3.28e-4 (favourable), Liver cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 59.8	Expressed in all		
CREBBP	CBP, KAT3A, RSTS, RTS	ENSG00000005339	CREB binding protein	16	3725054-3880726	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004212, HPA055861	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.24e-5 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
TSPOAP1	BZRAP1, KIAA0612, PRAX-1, RIM-BP1, RIMBP1	ENSG00000005379	TSPO associated protein 1	17	58301228-58328760	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024662, HPA025244	Enhanced				Pancreatic cancer:9.15e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.1	Cell line enhanced		HDLM-2: 164.7;HL-60: 51.5;REH: 119.1
MPO		ENSG00000005381	Myeloperoxidase	17	58269856-58280935	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000059, HPA021147, HPA061464	Enhanced		Supported	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	82	bone marrow: 2499.6	salivary gland: 30.6	Group enriched	98	HL-60: 2786.8;NB-4: 2892.7
PON1	ESA, PON	ENSG00000005421	Paraoxonase 1	7	95297676-95324707	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001610	Uncertain				Liver cancer:7.24e-7 (favourable)	Tissue enriched	Tissue enriched	69	liver: 233.6	adrenal gland: 3.3	Not detected		
GCFC2	C2orf3, DNABF, GCF, TCF9	ENSG00000005436	GC-rich sequence DNA-binding factor 2	2	75652000-75710989	Predicted intracellular proteins	Evidence at protein level	HPA077882			Supported	Nucleoplasm	Thyroid cancer:3.09e-4 (unfavourable), Endometrial cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 17.0	Expressed in all		
WDR54	FLJ12953	ENSG00000005448	WD repeat domain 54	2	74421678-74425755	Predicted intracellular proteins	Evidence at protein level	HPA043257, HPA053558	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 113.2	testis: 48.2	Expressed in all		
CROT	COT	ENSG00000005469	Carnitine O-octanoyltransferase	7	87345681-87399795	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019052, HPA019364, HPA019365	Enhanced		Supported	Vesicles	Renal cancer:2.55e-6 (favourable), Urothelial cancer:4.02e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 68.4	Cell line enhanced		RT4: 57.9
ABCB4	GBD1, MDR2, MDR3, PFIC-3, PGY3	ENSG00000005471	ATP binding cassette subfamily B member 4	7	87401697-87480435	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049395, HPA053288	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enriched	6	liver: 69.3	adrenal gland: 10.7	Group enriched	6	SH-SY5Y: 14.2;WM-115: 25.6
KMT2E	HDCMC04P, MLL5	ENSG00000005483	Lysine methyltransferase 2E	7	105014179-105114361	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022812, HPA056125	Approved	Approved			Renal cancer:3.80e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 51.7	Expressed in all		
RHBDD2	NPD007, RHBDL7	ENSG00000005486	Rhomboid domain containing 2	7	75842602-75888926	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045074, HPA051960	Uncertain		Enhanced	Golgi apparatus	Renal cancer:8.68e-6 (favourable), Colorectal cancer:3.31e-5 (unfavourable), Glioma:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 258.6	Expressed in all		
SOX8		ENSG00000005513	SRY-box 8	16	981808-986979	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041640, HPA058665	Enhanced		Supported	Nucleus		Tissue enriched	Tissue enriched	29	cerebral cortex: 109.9	salivary gland: 3.8	Cell line enriched	5	RH-30: 112.8
IBTK	BTBD26, BTKI, DKFZP564B116	ENSG00000005700	Inhibitor of Bruton tyrosine kinase	6	82169983-82247754	Predicted intracellular proteins	Evidence at protein level	HPA023826, HPA048438	Uncertain		Supported	Nucleoplasm	Cervical cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
ZNF195		ENSG00000005801	Zinc finger protein 195	11	3339261-3379222	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030605	Uncertain		Approved	Nucleus<br>Cytosol	Urothelial cancer:4.79e-7 (favourable), Liver cancer:3.53e-5 (unfavourable), Renal cancer:7.89e-5 (unfavourable), Prostate cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 21.3	Expressed in all		
MYCBP2	FLJ10106, KIAA0916, PAM	ENSG00000005810	MYC binding protein 2, E3 ubiquitin protein ligase	13	77044655-77327050	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058807			Supported	Nucleus<br>Vesicles	Renal cancer:5.01e-5 (favourable)	Expressed in all	Expressed in all			skin: 82.7	Expressed in all		
FBXL3	FBL3, FBL3A, FBXL3A	ENSG00000005812	F-box and leucine rich repeat protein 3	13	76992598-77027195	Predicted intracellular proteins	Evidence at protein level	HPA053283, HPA065626			Enhanced	Nuclear bodies		Expressed in all	Expressed in all			thyroid gland: 80.8	Expressed in all		
ITGAL	CD11A, LFA-1	ENSG00000005844	Integrin subunit alpha L	16	30472658-30523185	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025011	Enhanced				Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 79.0;spleen: 80.9	appendix: 52.5	Cell line enriched	5	HMC-1: 570.1
PDK2	PDHK2	ENSG00000005882	Pyruvate dehydrogenase kinase 2	17	50094737-50112152	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008287	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:9.59e-5 (favourable), Cervical cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 151.5	Mixed		
ITGA3	CD49c, GAP-B3, MSK18, VCA-2, VLA3a	ENSG00000005884	Integrin subunit alpha 3	17	50055968-50090481	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008572, CAB018594	Enhanced		Supported	Plasma membrane	Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable)	Expressed in all	Mixed			lung: 99.0	Cell line enhanced		U-87 MG: 917.0
ZFX	ZNF926	ENSG00000005889	Zinc finger protein, X-linked	X	24149173-24216255	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001748, HPA003877, HPA071863	Supported		Approved	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 33.2	Expressed in all		
LAMP2	CD107b	ENSG00000005893	Lysosomal associated membrane protein 2	X	120427827-120469365	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005272, HPA029100	Enhanced					Expressed in all	Expressed in all			gallbladder: 223.2	Expressed in all		
ITGA2B	CD41, CD41B, GP2B, PPP1R93	ENSG00000005961	Integrin subunit alpha 2b	17	44372180-44389505	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018611, HPA031168, HPA031169, HPA031170, HPA031171	Enhanced					Mixed	Tissue enhanced		bone marrow: 11.2;epididymis: 29.3	testis: 4.4	Group enriched	18	HEL: 396.8;HMC-1: 636.9
ASB4	ASB-4	ENSG00000005981	Ankyrin repeat and SOCS box containing 4	7	95478444-95540232	Predicted intracellular proteins	Evidence at transcript level	HPA055240	Uncertain					Tissue enhanced	Group enriched	11	adrenal gland: 50.2;skeletal muscle: 11.5	placenta: 2.8	Cell line enhanced		A549: 4.1;Hep G2: 5.2;SCLC-21H: 5.4
GDE1	MIR16	ENSG00000006007	Glycerophosphodiester phosphodiesterase 1	16	19501689-19522145	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074747			Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:3.12e-5 (favourable), Liver cancer:7.52e-5 (unfavourable), Colorectal cancer:3.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.9	Expressed in all		
C19orf60	FLJ20850, FLJ30108, FLJ34606, FLJ37391	ENSG00000006015	Chromosome 19 open reading frame 60	19	18588685-18592336	Predicted intracellular proteins	Evidence at protein level	HPA043414	Approved		Approved	Vesicles	Urothelial cancer:8.47e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 22.2	Cell line enhanced		PC-3: 78.2
CRLF1	CISS, CISS1, CLF, CLF-1	ENSG00000006016	Cytokine receptor like factor 1	19	18572220-18607741	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041493, HPA041793	Approved				Renal cancer:3.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 17.2;placenta: 16.8	adipose tissue: 10.1	Group enriched	8	ASC diff: 706.3;Hep G2: 309.6
OSBPL7	MGC71150, ORP7	ENSG00000006025	Oxysterol binding protein like 7	17	47807372-47821834	Predicted intracellular proteins	Evidence at protein level	HPA036076, HPA053083	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.19e-5 (favourable), Renal cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			stomach: 33.1	Cell line enhanced		HaCaT: 38.6
TMEM98	DKFZP564K1964	ENSG00000006042	Transmembrane protein 98	17	32927910-32945106	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA040473, HPA053385	Uncertain		Supported	Nucleoplasm	Renal cancer:3.85e-4 (favourable), Lung cancer:7.10e-4 (favourable), Liver cancer:8.14e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 238.1	Mixed		
YBX2	Contrin, CSDA3, MSY2	ENSG00000006047	Y-box binding protein 2	17	7288252-7294615	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012332, HPA053904, HPA056744	Enhanced		Supported	Nucleoli fibrillar center	Endometrial cancer:6.50e-5 (unfavourable)	Mixed	Tissue enriched	64	testis: 385.4	adipose tissue: 6.0	Cell line enhanced		CACO-2: 8.7;MCF7: 14.2;T-47d: 25.9
KRT33A	Ha-3I, Krt1-3, KRTHA3A	ENSG00000006059	Keratin 33A	17	41346092-41350812	Predicted intracellular proteins	Evidence at protein level	HPA055194	Supported					Tissue enhanced	Group enriched	15	esophagus: 1.4;testis: 1.6	all non-specific tissues: 0.0	Cell line enhanced		RT4: 1.1
MAP3K14	FTDCR1B, HS, HSNIK, NIK	ENSG00000006062	Mitogen-activated protein kinase kinase kinase 14	17	45263121-45317040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027269, HPA027270	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Cervical cancer:5.27e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.8	Mixed		
ABCC8	ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2	ENSG00000006071	ATP binding cassette subfamily C member 8	11	17392885-17476845	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011451, HPA042318	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 11.3	adrenal gland: 7.5	Cell line enhanced		A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0
CACNG3		ENSG00000006116	Calcium voltage-gated channel auxiliary subunit gamma 3	16	24255553-24362801	Predicted membrane proteins, Transporters	Evidence at protein level	HPA059010	Approved					Tissue enriched	Tissue enriched	28	cerebral cortex: 42.5	adrenal gland: 1.5	Not detected		
TMEM132A	FLJ20539, GBP, HSPA5BP1	ENSG00000006118	Transmembrane protein 132A	11	60924463-60937159	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051979, HPA060492	Enhanced		Approved	Mitochondria	Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 94.2	placenta: 25.0	Cell line enhanced		EFO-21: 167.6
AP2B1	ADTB2, CLAPB1	ENSG00000006125	Adaptor related protein complex 2 beta 1 subunit	17	35578046-35726409	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017631, HPA056733, HPA067983	Approved		Supported	Vesicles	Renal cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 265.4	Expressed in all		
TAC1	NKNA, NPK, TAC2	ENSG00000006128	Tachykinin precursor 1	7	97731908-97740472	Predicted secreted proteins	Evidence at protein level	CAB004588, HPA014429	Approved					Mixed	Tissue enhanced		cerebral cortex: 77.7;spleen: 47.0	appendix: 13.2	Cell line enriched	14	U-266/70: 16.5
ZNF263	FPM315, ZKSCAN12, ZSCAN44	ENSG00000006194	Zinc finger protein 263	16	3263800-3301401	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035085, HPA035086	Approved		Supported	Nucleoplasm<br>Mitotic spindle<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
CX3CL1	ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1	ENSG00000006210	C-X3-C motif chemokine ligand 1	16	57372458-57385048	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026192, HPA040361	Approved		Supported	Plasma membrane	Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 100.1	lung: 69.3	Cell line enhanced		EFO-21: 28.0;HDLM-2: 78.9;Hep G2: 42.9;RPTEC TERT1: 27.3
SPATA20	FLJ21347, SSP411, Tisp78	ENSG00000006282	Spermatogenesis associated 20	17	50543058-50555852	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022023, HPA027144, HPA031442	Enhanced		Approved	Nucleoplasm	Urothelial cancer:9.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 97.7	Mixed		
CACNA1G	Cav3.1, NBR13	ENSG00000006283	Calcium voltage-gated channel subunit alpha1 G	17	50561068-50627474	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA004714	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 10.5;cervix, uterine: 8.5	endometrium: 5.2	Cell line enhanced		A549: 8.5;SCLC-21H: 3.3
TNFRSF12A	CD266, FN14, TweakR	ENSG00000006327	TNF receptor superfamily member 12A	16	3018445-3022383	Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007853	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 199.0	Mixed		
DLX6		ENSG00000006377	Distal-less homeobox 6	7	97005548-97011039	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030608, HPA061460	Uncertain		Approved	Nuclear bodies		Tissue enriched	Tissue enhanced		endometrium: 4.4;placenta: 4.3;testis: 5.4	cervix, uterine: 3.0	Cell line enhanced		AN3-CA: 9.4;BEWO: 32.1;HAP1: 15.7;SCLC-21H: 8.6;SH-SY5Y: 11.6
MAP3K9	MEKK9, MLK1, PRKE1	ENSG00000006432	Mitogen-activated protein kinase kinase kinase 9	14	70722526-70809534	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000942	Approved		Approved	Nucleus<br>Nucleoli		Mixed	Mixed			testis: 10.1	Cell line enhanced		A-431: 20.2
RALA	RAL	ENSG00000006451	RAS like proto-oncogene A	7	39623483-39708124	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA065232	Approved				Liver cancer:5.32e-5 (unfavourable), Pancreatic cancer:6.30e-4 (unfavourable), Ovarian cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			lung: 60.3	Expressed in all		
BAIAP2L1	IRTKS	ENSG00000006453	BAI1 associated protein 2 like 1	7	98291651-98401068	Predicted intracellular proteins	Evidence at protein level	HPA019484, HPA021257, HPA023874, HPA029503	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Mixed	Mixed			stomach: 55.2	Mixed		
KDM7A	JHDM1D, KIAA1718	ENSG00000006459	Lysine demethylase 7A	7	140084746-140177035	Predicted secreted proteins	Evidence at protein level	HPA012114	Uncertain		Approved	Nucleoplasm<br>Nucleoli		Expressed in all	Mixed			cervix, uterine: 14.2	Mixed		
ETV1	ER81	ENSG00000006468	ETS variant 1	7	13891228-13991425	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077249			Approved	Nucleoplasm		Expressed in all	Tissue enhanced		cerebral cortex: 106.3	lung: 43.1	Cell line enhanced		SCLC-21H: 93.4;U-87 MG: 152.1;WM-115: 77.6
AGK	FLJ10842, MULK	ENSG00000006530	Acylglycerol kinase	7	141551189-141655244	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020959, HPA053471	Supported		Supported	Vesicles<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 26.9	Expressed in all		
ALDH3B1	ALDH7	ENSG00000006534	Aldehyde dehydrogenase 3 family member B1	11	68008578-68029282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038525	Uncertain				Colorectal cancer:1.18e-4 (unfavourable), Pancreatic cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 64.4;lung: 67.7	bone marrow: 30.7	Cell line enhanced		A549: 137.9;CAPAN-2: 136.9
TTC22	FLJ20619	ENSG00000006555	Tetratricopeptide repeat domain 22	1	54779712-54801267	Predicted intracellular proteins	Evidence at protein level	HPA035072	Uncertain				Breast cancer:2.06e-4 (favourable), Liver cancer:7.73e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 40.6	skin: 22.7	Cell line enhanced		A-431: 7.9;CAPAN-2: 9.5;HaCaT: 11.0;hTCEpi: 5.0;RPMI-8226: 5.6
PHTF2	DKFZp434D166	ENSG00000006576	Putative homeodomain transcription factor 2	7	77798792-77957503	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA012312	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.09e-7 (unfavourable), Thyroid cancer:2.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 62.0	Expressed in all		
CCL26	eotaxin-3, IMAC, MIP-4a, MIP-4alpha, SCYA26, TSC-1	ENSG00000006606	C-C motif chemokine ligand 26	7	75769533-75789896	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		ovary: 12.0	rectum: 7.6	Cell line enhanced		hTEC/SVTERT24-B: 15.8;PC-3: 42.0;U-2 OS: 13.1
FARP2	FIR, FRG, KIAA0793, PLEKHC3	ENSG00000006607	FERM, ARH/RhoGEF and pleckstrin domain protein 2	2	241356243-241494841	Predicted intracellular proteins	Evidence at protein level	HPA031226, HPA055592	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 37.9	Expressed in all		
USH1C	AIE-75, DFNB18, harmonin, NY-CO-37, NY-CO-38, PDZ-73, PDZ73, PDZD7C	ENSG00000006611	USH1 protein network component harmonin	11	17493895-17544416	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB013690, HPA027398, HPA027492, HPA028033	Supported		Enhanced	Cytosol	Liver cancer:2.20e-4 (unfavourable), Renal cancer:9.41e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 99.2;small intestine: 106.9	kidney: 55.4	Cell line enhanced		CACO-2: 50.5;CAPAN-2: 7.4;HeLa: 14.4
GGCT	C7orf24, CRF21, GCTG, Ggc, MGC3077	ENSG00000006625	Gamma-glutamylcyclotransferase	7	30496621-30504844	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020735, HPA029914	Approved				Liver cancer:7.23e-4 (unfavourable), Breast cancer:7.68e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 125.5	Expressed in all		
DBF4	ASK, chif, DBF4A, ZDBF1	ENSG00000006634	DBF4 zinc finger	7	87876216-87909541	Predicted intracellular proteins	Evidence at protein level	HPA042923			Approved	Nucleus<br>Nuclear bodies	Renal cancer:6.42e-7 (unfavourable), Liver cancer:4.45e-6 (unfavourable), Melanoma:6.86e-4 (unfavourable)	Expressed in all	Tissue enriched	41	testis: 21.4	gallbladder: 0.5	Mixed		
TBXA2R		ENSG00000006638	Thromboxane A2 receptor	19	3594506-3606840	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA077366			Supported	Nuclear speckles<br>Plasma membrane	Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable)	Expressed in all	Mixed			spleen: 5.2	Cell line enhanced		HeLa: 6.4;U-2197: 6.3
IFRD1	PC4, TIS7	ENSG00000006652	Interferon related developmental regulator 1	7	112422968-112481017	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024122	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 129.9	Expressed in all		
LGALS14	CLC2, PPL13	ENSG00000006659	Galectin 14	19	39704306-39709444	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	57	placenta: 69.0	skin: 1.2	Cell line enhanced		EFO-21: 3.0;U-266/70: 5.8
COX10		ENSG00000006695	COX10, heme A:farnesyltransferase cytochrome c oxidase assembly factor	17	14069496-14208677	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA032005, HPA032006	Supported		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:4.32e-6 (favourable), Stomach cancer:8.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 43.1	Expressed in all		
GTF2IRD1	BEN, Cream1, GTF3, MusTRD1, RBAP2, WBSCR11, WBSCR12	ENSG00000006704	GTF2I repeat domain containing 1	7	74453790-74602604	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044254	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:9.71e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.9	Mixed		
PAF1	F23149_1, FLJ11123, PD2	ENSG00000006712	PAF1 homolog, Paf1/RNA polymerase II complex component	19	39385852-39391195	Predicted intracellular proteins	Evidence at protein level	HPA041875, HPA043637	Approved		Supported	Nucleoplasm	Pancreatic cancer:8.66e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.1	Expressed in all		
VPS41	HVSP41	ENSG00000006715	VPS41, HOPS complex subunit	7	38722963-38932394	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020080, HPA020299	Approved				Renal cancer:3.40e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 96.8	Expressed in all		
ARHGAP44	KIAA0672, RICH-2, RICH2	ENSG00000006740	Rho GTPase activating protein 44	17	12789539-12991643	Predicted intracellular proteins	Evidence at protein level	HPA038814	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 51.6	cerebral cortex: 33.4	Cell line enhanced		HEK 293: 9.0
ELAC2	FLJ10530, HPC2	ENSG00000006744	ElaC ribonuclease Z 2	17	12992391-13018187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019535	Approved		Enhanced	Nucleoplasm	Endometrial cancer:3.24e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.1	Expressed in all		
SCIN	KIAA1905	ENSG00000006747	Scinderin	7	12570577-12660179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020518, HPA024264	Enhanced		Enhanced	Plasma membrane	Renal cancer:4.26e-8 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 110.4	kidney: 52.0	Cell line enhanced		RPTEC TERT1: 71.2;SK-BR-3: 76.9
ARSD		ENSG00000006756	Arylsulfatase D	X	2903970-2929351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004694, HPA063835	Approved		Approved	Vesicles<br>Lipid droplets	Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 45.3	Cell line enhanced		EFO-21: 23.1
PNPLA4	DXS1283E, GS2, iPLA2eta	ENSG00000006757	Patatin like phospholipase domain containing 4	X	7898247-7927739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003656	Approved				Renal cancer:2.23e-12 (favourable), Glioma:4.67e-4 (unfavourable), Head and neck cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.2	Mixed		
MYH13	MyHC-eo	ENSG00000006788	Myosin heavy chain 13	17	10300865-10373130	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			placenta: 0.7	Cell line enhanced		U-2 OS: 3.1
ADIPOR2	ACDCR2, PAQR2	ENSG00000006831	Adiponectin receptor 2	12	1688574-1788678	Predicted membrane proteins	Evidence at protein level	HPA043737	Approved					Expressed in all	Expressed in all			adipose tissue: 77.1	Expressed in all		
CDKL3	NKIAMRE	ENSG00000006837	Cyclin dependent kinase like 3	5	134286350-134371047	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027751			Uncertain	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	9	testis: 28.9	cerebral cortex: 3.2	Mixed		
UPP2	UDRPASE2, UP2, UPASE2	ENSG00000007001	Uridine phosphorylase 2	2	157876702-158136154	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035225, HPA035226			Approved	Nucleus<br>Vesicles<br>Mitochondria		Tissue enriched	Group enriched	14	kidney: 52.2;liver: 14.3	cerebral cortex: 2.4	Not detected		
PRSS21	ESP-1, TEST1	ENSG00000007038	Protease, serine 21	16	2817180-2826304	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008477	Enhanced		Approved	Cytosol		Tissue enhanced	Tissue enriched	10	testis: 49.5	bone marrow: 4.7	Cell line enhanced		CAPAN-2: 22.0;HEL: 25.5;HeLa: 48.0;K-562: 30.5;U-698: 70.6
MARK4	FLJ90097, KIAA1860, MARKL1, Nbla00650, PAR-1D	ENSG00000007047	Microtubule affinity regulating kinase 4	19	45079288-45305283	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039186	Approved		Approved	Cytosol	Endometrial cancer:8.31e-8 (unfavourable), Head and neck cancer:3.05e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
PROM1	AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4	ENSG00000007062	Prominin 1	4	15963076-16084378	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004922, CAB011525, HPA031053	Enhanced				Renal cancer:2.56e-5 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 67.2	gallbladder: 47.5	Cell line enhanced		AF22: 36.7;CACO-2: 58.5;EFO-21: 62.9;NTERA-2: 99.9;RPTEC TERT1: 69.7
CCDC124		ENSG00000007080	Coiled-coil domain containing 124	19	17933016-17943991	Predicted intracellular proteins	Evidence at protein level	HPA041708, HPA046765	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 72.4	Expressed in all		
CEACAM21	FLJ13540, R29124_1	ENSG00000007129	Carcinoembryonic antigen related cell adhesion molecule 21	19	41549518-41586844	Predicted membrane proteins	Evidence at transcript level	HPA043411	Uncertain				Endometrial cancer:1.89e-5 (favourable)	Mixed	Tissue enhanced		bone marrow: 11.0	spleen: 6.5	Cell line enhanced		HMC-1: 6.0;Karpas-707: 3.9;U-266/70: 4.6;U-937: 3.7
PAFAH1B1	LIS1, MDCR, MDS, NudF, PAFAH	ENSG00000007168	Platelet activating factor acetylhydrolase 1b regulatory subunit 1	17	2593210-2685615	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004489, HPA020036	Approved		Enhanced	Centrosome	Renal cancer:3.16e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 178.7	Expressed in all		
NOS2	HEP-NOS, iNOS, NOS, NOS2A	ENSG00000007171	Nitric oxide synthase 2	17	27756766-27800499	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002014	Approved					Tissue enhanced	Group enriched	5	appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5	smooth muscle: 2.5	Group enriched	8	CACO-2: 13.0;SCLC-21H: 14.7
DNAH9	DNAH17L, Dnahc9, DNAL1, DYH9, HL-20, HL20, KIAA0357	ENSG00000007174	Dynein axonemal heavy chain 9	17	11598431-11969748	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052641	Enhanced				Endometrial cancer:6.79e-5 (favourable)	Tissue enhanced	Tissue enriched	5	fallopian tube: 56.4	testis: 11.1	Cell line enhanced		HDLM-2: 2.8;WM-115: 1.7
KIAA0100	BCOX, BCOX1, CT101, DKFZp686M0843, FMP27, MGC111488	ENSG00000007202	KIAA0100	17	28614440-28645454	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042781	Uncertain		Approved	Nuclear speckles<br>Cytosol	Liver cancer:3.47e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 92.4	Expressed in all		
SLC13A2	NaDC-1	ENSG00000007216	Solute carrier family 13 member 2	17	28473293-28497781	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014963	Enhanced				Renal cancer:9.00e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 68.7;small intestine: 54.3	kidney: 19.7	Not detected		
GAS7	KIAA0394, MGC1348	ENSG00000007237	Growth arrest specific 7	17	9910609-10198551	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004838, HPA064678	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Urothelial cancer:6.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 154.7	cervix, uterine: 47.6	Cell line enriched	11	WM-115: 526.3
TRAPPC6A	HSPC289, MGC2650, TRS33	ENSG00000007255	Trafficking protein particle complex 6A	19	45162928-45178237	Predicted intracellular proteins	Evidence at protein level	HPA043043	Approved				Renal cancer:2.23e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.5	Expressed in all		
MATK	CHK, CTK, DKFZp434N1212, HHYLTK, HYL, HYLTK, Lsk, MGC1708, MGC2101	ENSG00000007264	Megakaryocyte-associated tyrosine kinase	19	3777970-3802129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004847	Approved				Breast cancer:5.27e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.0	spleen: 19.8	Cell line enhanced		HL-60: 85.8;K-562: 43.3;NB-4: 47.4;SCLC-21H: 36.7
CEACAM7	CEA, CGM2	ENSG00000007306	Carcinoembryonic antigen related cell adhesion molecule 7	19	41673307-41706976	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069621	Supported					Tissue enhanced	Group enriched	7	colon: 583.2;rectum: 691.9	appendix: 91.6	Not detected		
CD79B	B29, IGB	ENSG00000007312	CD79b molecule	17	63928740-63932354	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA009178, CAB009751	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.35e-4 (favourable)	Expressed in all	Group enriched	5	appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1	bone marrow: 36.1	Group enriched	17	Daudi: 751.6;REH: 317.0;U-698: 986.5
SCN4A	HYKPP, HYPP, Nav1.4, SkM1	ENSG00000007314	Sodium voltage-gated channel alpha subunit 4	17	63938554-63972918	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053992			Approved	Nucleoplasm<br>Microtubule organizing center		Tissue enhanced	Group enriched	9	adipose tissue: 12.4;skeletal muscle: 47.2	thyroid gland: 3.3	Group enriched	13	REH: 13.6;RH-30: 43.5
ST7L	FAM4B, FLJ20284, ST7R, STLR	ENSG00000007341	Suppression of tumorigenicity 7 like	1	112523518-112620825	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA042324, HPA075418	Uncertain		Approved	Centrosome	Ovarian cancer:3.04e-5 (favourable), Colorectal cancer:8.34e-5 (favourable), Melanoma:5.16e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable)	Expressed in all	Tissue enriched	5	testis: 65.0	thyroid gland: 12.4	Mixed		
TKTL1	TKR, TKT2	ENSG00000007350	Transketolase like 1	X	154295671-154330350	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000505, CAB032191	Enhanced					Tissue enriched	Tissue enriched	141	testis: 225.8	heart muscle,lung: 1.5	Cell line enriched	147	THP-1: 315.9
PAX6	AN, AN2, D11S812E, WAGR	ENSG00000007372	Paired box 6	11	31784779-31818062	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA030775, CAB034143	Supported		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	7	cerebral cortex: 22.3;stomach: 11.2	testis: 2.5	Cell line enhanced		AF22: 15.6;AN3-CA: 19.1;HEK 293: 17.3;U-251 MG: 14.4
RPUSD1	C16orf40, MGC19600, RLUCL	ENSG00000007376	RNA pseudouridylate synthase domain containing 1	16	784974-788397	Predicted intracellular proteins	Evidence at protein level	HPA041144, HPA041938	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			appendix: 13.0	Expressed in all		
RHBDF1	C16orf8, Dist1, EGFR-RS, FLJ2235, iRhom1	ENSG00000007384	Rhomboid 5 homolog 1	16	58059-76355	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077399			Uncertain	Vesicles	Renal cancer:2.49e-5 (unfavourable)	Expressed in all	Mixed			placenta: 39.8	Mixed		
LUC7L	hLuc7B1, Luc7, LUC7B1	ENSG00000007392	LUC7 like	16	188969-229463	Predicted intracellular proteins	Evidence at protein level	HPA056424, HPA069321	Supported		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:1.30e-4 (favourable), Renal cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.4	Expressed in all		
CACNA2D2	KIAA0558	ENSG00000007402	Calcium voltage-gated channel auxiliary subunit alpha2delta 2	3	50362799-50504244	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034771, HPA071829	Enhanced		Approved	Vesicles	Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable)	Tissue enhanced	Tissue enriched	6	lung: 72.9	testis: 12.4	Cell line enriched	8	SH-SY5Y: 201.7
BAIAP3	BAP3, KIAA0734	ENSG00000007516	BAI1 associated protein 3	16	1333601-1349441	Predicted intracellular proteins	Evidence at protein level	HPA015627	Uncertain				Renal cancer:1.52e-5 (favourable)	Mixed	Tissue enhanced		adrenal gland: 24.9;cerebral cortex: 25.1;fallopian tube: 42.4	testis: 13.8	Cell line enhanced		CAPAN-2: 17.3
TSR3	C16orf42, MGC24381	ENSG00000007520	TSR3, acp transferase ribosome maturation factor	16	1349240-1351911	Predicted intracellular proteins	Evidence at protein level	HPA040760, HPA046265	Uncertain		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 36.7	Expressed in all		
PIGQ	GPI1, hGPI1	ENSG00000007541	Phosphatidylinositol glycan anchor biosynthesis class Q	16	566995-584136	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039105, HPA039828, HPA061414	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.53e-6 (favourable)	Expressed in all	Expressed in all			bone marrow: 17.5	Expressed in all		
CRAMP1	CRAMP1L, KIAA1426	ENSG00000007545	Cramped chromatin regulator homolog 1	16	1612325-1677908	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041752	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Stomach cancer:4.93e-4 (favourable)	Expressed in all	Mixed			testis: 31.8	Expressed in all		
TEAD3	ETFR-1, TEAD5, TEF-5	ENSG00000007866	TEA domain transcription factor 3	6	35473597-35497076	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028906	Uncertain				Renal cancer:1.01e-7 (unfavourable), Endometrial cancer:5.09e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 80.5	Cell line enhanced		BEWO: 114.2
SELE	CD62E, ELAM, ELAM1, ESEL	ENSG00000007908	Selectin E	1	169722641-169764705	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002143	Enhanced					Mixed	Tissue enhanced		parathyroid gland: 45.2;prostate: 46.4	urinary bladder: 27.8	Cell line enriched	6	HUVEC TERT2: 1.0
DNAJC11	FLJ10737	ENSG00000007923	DnaJ heat shock protein family (Hsp40) member C11	1	6634168-6701924	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028705	Uncertain		Approved	Cytosol	Renal cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			kidney: 38.4	Expressed in all		
FMO3		ENSG00000007933	Flavin containing monooxygenase 3	1	171090877-171117819	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013750	Enhanced				Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable)	Tissue enriched	Tissue enriched	24	liver: 556.7	fallopian tube: 22.8	Group enriched	13	ASC diff: 23.4;ASC TERT1: 17.9;HSkMC: 5.1
MYLIP	IDOL, MIR	ENSG00000007944	Myosin regulatory light chain interacting protein	6	16129125-16148248	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Lung cancer:6.44e-6 (favourable), Urothelial cancer:4.11e-5 (favourable), Renal cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			placenta: 119.3	Mixed		
NOX1	GP91-2, MOX1, NOH-1, NOH1	ENSG00000007952	NADPH oxidase 1	X	100843324-100874345	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Colorectal cancer:9.71e-4 (favourable)	Tissue enriched	Group enriched	17	colon: 58.7;rectum: 79.9	appendix: 3.9	Cell line enriched	19	CACO-2: 25.5
E2F2	E2F-2	ENSG00000007968	E2F transcription factor 2	1	23506430-23531220	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016313	Uncertain					Mixed	Tissue enhanced		bone marrow: 15.3	lymph node: 3.8	Cell line enhanced		Daudi: 33.3
PSMB1	HC5, PMSB1	ENSG00000008018	Proteasome subunit beta 1	6	170535117-170553341	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029635, HPA029637, CAB033911	Enhanced		Supported	Nucleus	Renal cancer:3.76e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 320.2	Expressed in all		
SYN1		ENSG00000008056	Synapsin I	X	47571898-47619943	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000397, CAB021929	Enhanced					Tissue enhanced	Tissue enriched	26	cerebral cortex: 378.9	adrenal gland: 14.5	Cell line enhanced		NTERA-2: 17.4;SCLC-21H: 35.6;SH-SY5Y: 8.3
JARID2	JMJ	ENSG00000008083	Jumonji and AT-rich interaction domain containing 2	6	15246296-15522040	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063889, CAB069890	Uncertain		Supported	Nucleus<br>Mitochondria		Expressed in all	Mixed			bone marrow: 36.5	Expressed in all		
CDKL5	CFAP247, EIEE2, STK9	ENSG00000008086	Cyclin dependent kinase like 5	X	18425583-18653629	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002847, CAB011577	Supported		Enhanced	Nucleoplasm	Renal cancer:5.54e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 31.0	testis: 14.4	Mixed		
CAMK1G	CLICKIII, dJ272L16.1, VWS1	ENSG00000008118	Calcium/calmodulin dependent protein kinase IG	1	209583717-209613938	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 32.3;ovary: 27.7	seminal vesicle: 7.4	Cell line enhanced		hTEC/SVTERT24-B: 7.0;SK-MEL-30: 1.6
CDK11A	CDC2L2, CDC2L3, CDK11-p110, CDK11-p46, CDK11-p58, p58GTA, PITSLRE	ENSG00000008128	Cyclin dependent kinase 11A	1	1702730-1724324	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010467, HPA025061, HPA073626	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.15e-6 (unfavourable), Melanoma:5.06e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 35.1	Expressed in all		
NADK	FLJ13052	ENSG00000008130	NAD kinase	1	1751232-1780457	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048909, HPA053368	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			spleen: 77.4	Expressed in all		
TFAP2B	AP2-B	ENSG00000008196	Transcription factor AP-2 beta	6	50818723-50847613	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034683, HPA062942	Supported		Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 39.4	breast: 9.6	Group enriched	5	AF22: 94.8;SH-SY5Y: 188.6
TFAP2D	TFAP2BL1	ENSG00000008197	Transcription factor AP-2 delta	6	50713828-50772988	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048962	Uncertain					Tissue enriched	Not detected			cerebral cortex: 0.1	Cell line enhanced		HAP1: 1.3
DLEC1	CFAP81, DLC1	ENSG00000008226	Deleted in lung and esophageal cancer 1	3	38039205-38124025	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019077	Enhanced		Supported	Cytosol		Mixed	Tissue enhanced		fallopian tube: 29.7;testis: 17.3	lung: 5.9	Not detected		
CYTH3	ARNO3, cytohesin-3, GRP1, PSCD3	ENSG00000008256	Cytohesin 3	7	6161776-6272644	Predicted intracellular proteins	Evidence at protein level	HPA013979	Uncertain		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:2.63e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 45.5	Mixed		
ADAM22	MDC2	ENSG00000008277	ADAM metallopeptidase domain 22	7	87934143-88202889	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050325			Approved	Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 47.6	prostate: 18.2	Cell line enhanced		Karpas-707: 58.7;SH-SY5Y: 81.7
SYPL1	SYPL	ENSG00000008282	Synaptophysin like 1	7	106090503-106112576	Predicted membrane proteins	Evidence at protein level	HPA014141	Approved				Renal cancer:1.25e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 194.9	Mixed		
CYB561	CYB561A1, FRRS2	ENSG00000008283	Cytochrome b561	17	63432304-63446378	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014753	Approved				Endometrial cancer:2.95e-5 (favourable), Breast cancer:8.89e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 163.4	Cell line enhanced		SH-SY5Y: 448.0
SPAG9	CT89, FLJ13450, FLJ14006, FLJ26141, FLJ34602, HLC4, HSS, JIP-4, JIP4, JLP, KIAA0516, MGC117291, MGC14967, MGC74461, PHET, PIG6, SYD1	ENSG00000008294	Sperm associated antigen 9	17	50962174-51120865	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040446, HPA061458	Approved		Enhanced	Microtubule organizing center<br>Cytosol	Urothelial cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 106.2	Expressed in all		
CELSR3	ADGRC3, CDHF11, EGFL1, FMI1, HFMI1, MEGF2	ENSG00000008300	Cadherin EGF LAG seven-pass G-type receptor 3	3	48636469-48662915	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA062866	Approved					Mixed	Group enriched	6	adrenal gland: 1.6;cerebral cortex: 5.9;testis: 3.5	parathyroid gland,stomach: 0.6	Cell line enhanced		SH-SY5Y: 19.4;SiHa: 17.5
AASS	LKRSDH, LORSDH	ENSG00000008311	Aminoadipate-semialdehyde synthase	7	122075647-122144280	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020637, HPA020728, HPA020734	Enhanced		Enhanced	Vesicles<br>Mitochondria	Liver cancer:9.81e-4 (favourable)	Expressed in all	Mixed			ovary: 30.7	Cell line enhanced		AN3-CA: 49.4;NTERA-2: 51.8
PLEKHG6	FLJ10665, MYOGEF	ENSG00000008323	Pleckstrin homology and RhoGEF domain containing G6	12	6310436-6328506	Predicted intracellular proteins	Evidence at protein level	HPA041459, HPA058230	Uncertain		Supported	Cell Junctions<br>Centrosome		Mixed	Tissue enhanced		small intestine: 47.7	duodenum: 36.5	Cell line enhanced		BEWO: 147.7;CACO-2: 41.4;RT4: 42.4
SS18L2	KIAA-iso	ENSG00000008324	SS18 like 2	3	42581840-42595114	Predicted intracellular proteins	Evidence at protein level	HPA047377	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Lung cancer:7.03e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 61.0	Expressed in all		
MPND	FLJ14981	ENSG00000008382	MPN domain containing	19	4343527-4360086	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043274, HPA045475	Approved		Approved	Nucleus<br>Nucleoli	Lung cancer:1.55e-4 (favourable), Cervical cancer:2.99e-4 (favourable), Endometrial cancer:6.12e-4 (favourable), Renal cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 30.9	Expressed in all		
MGST1	GST12, MGST-I	ENSG00000008394	Microsomal glutathione S-transferase 1	12	16347142-16609259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044840	Enhanced		Approved	Endoplasmic reticulum<br>Mitochondria	Thyroid cancer:1.97e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 1602.4	Cell line enhanced		ASC diff: 3718.8
CRY1	PHLL1	ENSG00000008405	Cryptochrome circadian clock 1	12	106991364-107093829	Predicted intracellular proteins	Evidence at protein level	CAB018762	Approved		Supported	Nucleus<br>Nuclear membrane<br>Microtubules		Expressed in all	Expressed in all			testis: 62.1	Mixed		
PGLYRP1	PGLYRP, PGRP, PGRP-S, PGRPS, TAG7, TNFSF3L	ENSG00000008438	Peptidoglycan recognition protein 1	19	46019153-46023065	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045702	Enhanced					Not detected	Tissue enriched	57	bone marrow: 421.1	spleen: 7.4	Cell line enhanced		A549: 2.9
NFIX	NF1A	ENSG00000008441	Nuclear factor I X	19	12995608-13098796	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007533	Supported		Supported	Nucleoplasm	Lung cancer:2.35e-4 (favourable), Liver cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 191.5	Cell line enhanced		U-138 MG: 192.9;U-2197: 175.5
ST3GAL1	SIAT4A, SIATFL, ST3GalA.1, ST3O	ENSG00000008513	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	8	133454848-133571940	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040466	Approved					Expressed in all	Expressed in all			thyroid gland: 115.9	Cell line enhanced		PC-3: 125.9;RT4: 84.6
MMP25	MMP20, MMPL1, MT6-MMP	ENSG00000008516	Matrix metallopeptidase 25	16	3046681-3060726	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025177	Uncertain				Head and neck cancer:1.09e-5 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 23.3;bone marrow: 24.7;spleen: 20.7	adipose tissue: 6.4	Cell line enriched	11	HMC-1: 95.7
IL32	NK4, TAIF, TAIFb, TAIFd	ENSG00000008517	Interleukin 32	16	3065297-3082192	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029397, CAB030029	Approved				Endometrial cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 620.5	Cell line enhanced		CACO-2: 405.3;HDLM-2: 655.8;RH-30: 334.4
PKD1	PBP, Pc-1, TRPP1	ENSG00000008710	Polycystin 1, transient receptor potential channel interacting	16	2088710-2135898	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB046448	Approved				Pancreatic cancer:3.38e-5 (favourable), Head and neck cancer:3.35e-4 (favourable), Colorectal cancer:7.43e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Expressed in all		
MAPK8IP2	IB2, JIP2, PRKM8IPL	ENSG00000008735	Mitogen-activated protein kinase 8 interacting protein 2	22	50600685-50613981	Predicted intracellular proteins	Evidence at protein level	HPA034780	Uncertain					Mixed	Tissue enriched	8	cerebral cortex: 78.2	adrenal gland: 10.0	Cell line enhanced		SCLC-21H: 24.1;SH-SY5Y: 19.6
MED24	CRSP100, CRSP4, DRIP100, KIAA0130, MED5, THRAP4, TRAP100	ENSG00000008838	Mediator complex subunit 24	17	40019097-40061215	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 64.3	Expressed in all		
RHOBTB2	DBC2, KIAA0717	ENSG00000008853	Rho related BTB domain containing 2	8	22987417-23020199	Predicted intracellular proteins	Evidence at protein level	HPA060938	Approved		Approved	Plasma membrane	Renal cancer:2.98e-4 (favourable)	Expressed in all	Mixed			lung: 52.7	Expressed in all		
HEATR5B	DKFZp686P15184, KIAA1414	ENSG00000008869	HEAT repeat containing 5B	2	36968383-37084342	Predicted intracellular proteins	Evidence at protein level	HPA042025, HPA055639	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 37.9	Expressed in all		
SEC62	Dtrp1, HTP1, TLOC1	ENSG00000008952	SEC62 homolog, preprotein translocation factor	3	169966635-169998373	Predicted membrane proteins	Evidence at protein level	HPA014059, HPA061450	Approved		Approved	Endoplasmic reticulum<br>Intermediate filaments		Expressed in all	Expressed in all			thyroid gland: 203.0	Expressed in all		
RPS20	S20	ENSG00000008988	Ribosomal protein S20	8	56067295-56074581	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003570	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.21e-8 (unfavourable)	Expressed in all	Expressed in all			ovary: 4364.3	Expressed in all		
CSDE1	D1S155E, UNR	ENSG00000009307	Cold shock domain containing E1	1	114716913-114758676	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018846, HPA052221	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 490.3	Expressed in all		
UBE3C	KIAA0010, KIAA10	ENSG00000009335	Ubiquitin protein ligase E3C	7	157138913-157269372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039915	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Mitochondria	Renal cancer:9.18e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.1	Expressed in all		
REV3L	POLZ, REV3	ENSG00000009413	REV3 like, DNA directed polymerase zeta catalytic subunit	6	111299028-111483715	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064853, HPA069382	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			cervix, uterine: 41.2	Expressed in all		
TENM1	ODZ1, ODZ3, TEN-M1, TNM	ENSG00000009694	Teneurin transmembrane protein 1	X	124375903-124963817	Predicted membrane proteins	Evidence at protein level	HPA002848	Uncertain					Group enriched	Mixed			prostate: 4.0	Cell line enhanced		MOLT-4: 4.7;RPTEC TERT1: 1.5;SCLC-21H: 2.3;U-138 MG: 3.2
PAX7	Hup1	ENSG00000009709	Paired box 7	1	18631006-18748866	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	7	cerebral cortex: 1.3;skeletal muscle: 2.2	esophagus,testis: 0.2	Group enriched	7	A549: 1.3;CAPAN-2: 1.4;U-2 OS: 3.5
MASP2	MASP1P1	ENSG00000009724	Mannan binding lectin serine peptidase 2	1	11026523-11047233	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA029313, HPA029314	Approved		Supported	Golgi apparatus	Liver cancer:1.60e-4 (favourable)	Tissue enriched	Tissue enriched	18	liver: 105.5	skin: 5.7	Cell line enhanced		Hep G2: 12.9
IYD	C6orf71, DEHAL1, dJ422F24.1	ENSG00000009765	Iodotyrosine deiodinase	6	150368892-150405969	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA059627	Enhanced		Supported	Plasma membrane	Liver cancer:6.22e-4 (favourable)	Tissue enriched	Tissue enriched	28	thyroid gland: 794.5	kidney: 27.9	Cell line enhanced		CACO-2: 1.1;SK-BR-3: 2.4
FAM76A	MGC34648	ENSG00000009780	Family with sequence similarity 76 member A	1	27725979-27763122	Predicted intracellular proteins	Evidence at protein level	HPA044762, HPA077897	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
TRAF3IP3	T3JAM	ENSG00000009790	TRAF3 interacting protein 3	1	209756032-209782320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040796	Enhanced		Approved	Vesicles	Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 114.8;spleen: 82.5;tonsil: 82.8	appendix: 67.8	Cell line enhanced		HDLM-2: 106.9;Karpas-707: 33.1;MOLT-4: 48.2;NB-4: 43.3;THP-1: 43.1;U-266/70: 51.7
POMT2	LGMD2N	ENSG00000009830	Protein O-mannosyltransferase 2	14	77274956-77320884	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003663	Uncertain				Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
VTA1	C6orf55, HSPC228, My012	ENSG00000009844	Vesicle trafficking 1	6	142147162-142224689	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030968, HPA030969	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:6.58e-6 (unfavourable), Breast cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 60.9	Expressed in all		
MLXIPL	bHLHd14, CHREBP, MIO, MONDOB, WBSCR14, WS-bHLH	ENSG00000009950	MLX interacting protein like	7	73593194-73624543	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA064640			Supported	Nucleus		Tissue enriched	Tissue enhanced		adipose tissue: 60.8;duodenum: 58.7	liver: 47.2	Cell line enhanced		Hep G2: 33.0;K-562: 13.2;SCLC-21H: 29.5;T-47d: 10.7
BAZ1B	WBSCR10, WBSCR9, WSTF	ENSG00000009954	Bromodomain adjacent to zinc finger domain 1B	7	73440398-73522278	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037081, CAB037158, HPA067010	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.8	Expressed in all		
RANBP9	RanBPM	ENSG00000010017	RAN binding protein 9	6	13621498-13711564	Predicted intracellular proteins	Evidence at protein level	CAB033767, HPA050007	Approved		Supported	Nucleoplasm<br>Cytosol	Ovarian cancer:2.47e-4 (favourable), Head and neck cancer:9.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 211.6	Expressed in all		
ETV7	TEL-2, TEL2	ENSG00000010030	ETS variant 7	6	36354091-36387800	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029033, HPA049689	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:2.95e-6 (favourable), Cervical cancer:5.16e-4 (favourable), Ovarian cancer:5.32e-4 (favourable)	Expressed in all	Mixed			skin: 19.9	Cell line enhanced		BEWO: 26.5;BJ hTERT+ SV40 Large T+ RasG12V: 26.4;HDLM-2: 55.2
SPRTN	C1orf124, DKFZP547N043, DVC1, Spartan	ENSG00000010072	SprT-like N-terminal domain	1	231337104-231355023	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025073	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 25.0	Expressed in all		
METTL13	CGI-01, KIAA0859	ENSG00000010165	Methyltransferase like 13	1	171781664-171814023	Predicted intracellular proteins	Evidence at protein level	HPA044498, HPA053705	Approved		Approved	Cytosol	Liver cancer:5.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
DYRK4		ENSG00000010219	Dual specificity tyrosine phosphorylation regulated kinase 4	12	4562204-4615302	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028065, HPA056073	Enhanced		Enhanced	Vesicles	Renal cancer:6.52e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 66.2	epididymis: 20.7	Mixed		
ZNF207		ENSG00000010244	Zinc finger protein 207	17	32350117-32381886	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017013, HPA063908	Enhanced		Enhanced	Nucleus	Renal cancer:4.17e-8 (unfavourable), Liver cancer:7.30e-8 (unfavourable), Colorectal cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 151.3	Expressed in all		
UQCRC1	D3S3191, QCR1, UQCR1	ENSG00000010256	Ubiquinol-cytochrome c reductase core protein I	3	48599002-48610976	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002815, HPA003525, CAB033782	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:2.35e-10 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 88.3	Expressed in all		
STARD3NL	MENTHO, MGC3251	ENSG00000010270	STARD3 N-terminal like	7	38178222-38230671	Predicted membrane proteins	Evidence at protein level	HPA019204	Enhanced		Supported	Vesicles	Liver cancer:1.44e-5 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable), Pancreatic cancer:8.48e-4 (favourable)	Expressed in all	Expressed in all			placenta: 70.6	Expressed in all		
CD9	BA2, MIC3, MRP-1, P24, TSPAN29	ENSG00000010278	CD9 molecule	12	6199715-6238271	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002490	Supported		Supported	Plasma membrane	Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1013.7	Cell line enhanced		CAPAN-2: 1447.3;TIME: 1977.3
HHATL	C3orf3, GUP1, KIAA1173, MBOAT3, MSTP002, OACT3	ENSG00000010282	Hedgehog acyltransferase-like	3	42692663-42702827	Predicted membrane proteins	Evidence at protein level	HPA018174	Enhanced					Tissue enhanced	Tissue enhanced		heart muscle: 333.1;skeletal muscle: 97.6	cerebral cortex: 53.3	Not detected		
NCAPD2	CAP-D2, CNAP1, hCAP-D2, KIAA0159	ENSG00000010292	Non-SMC condensin I complex subunit D2	12	6493356-6531955	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012423, HPA036947, HPA037363	Supported		Supported	Nucleus<br>Cytosol	Liver cancer:1.79e-8 (unfavourable), Renal cancer:1.13e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 28.7	Expressed in all		
IFFO1	HOM-TES-103, IFFO	ENSG00000010295	Intermediate filament family orphan 1	12	6538375-6556083	Predicted intracellular proteins	Evidence at protein level	HPA069344	Approved				Renal cancer:7.47e-7 (unfavourable), Pancreatic cancer:6.53e-5 (favourable)	Expressed in all	Mixed			spleen: 12.0	Mixed		
GIPR		ENSG00000010310	Gastric inhibitory polypeptide receptor	19	45668244-45683724	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022710	Uncertain					Tissue enriched	Tissue enhanced		stomach: 22.4	parathyroid gland: 12.1	Cell line enhanced		HDLM-2: 9.1;HMC-1: 18.5;SCLC-21H: 16.5;U-266/70: 13.1
PHF7	HSPC226, NYD-SP6	ENSG00000010318	PHD finger protein 7	3	52410657-52423641	Predicted intracellular proteins	Evidence at protein level	HPA036283, HPA070305	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.05e-6 (favourable), Breast cancer:7.38e-5 (favourable), Endometrial cancer:9.44e-5 (favourable)	Expressed in all	Tissue enriched	432	testis: 2183.4	rectum: 5.0	Cell line enhanced		U-266/70: 13.2
SEMA3G	FLJ00014, sem2	ENSG00000010319	Semaphorin 3G	3	52433053-52445085	Predicted secreted proteins	Evidence at protein level	HPA001761	Uncertain				Renal cancer:8.86e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 82.2	placenta: 42.3	Cell line enhanced		ASC diff: 18.3;HUVEC TERT2: 6.5
NISCH	I-1, IRAS, KIAA0975	ENSG00000010322	Nischarin	3	52455118-52493071	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023189	Approved				Pancreatic cancer:1.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 96.0	Expressed in all		
STAB1	CLEVER-1, FEEL-1, FELE-1, FEX1, KIAA0246, SCARH2, STAB-1	ENSG00000010327	Stabilin 1	3	52495338-52524495	Predicted membrane proteins	Evidence at protein level	HPA005434	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.88e-7 (unfavourable), Colorectal cancer:7.59e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 123.3	Group enriched	38	HUVEC TERT2: 86.2;NB-4: 93.1;TIME: 104.8
FUZ	FLJ22688, Fy	ENSG00000010361	Fuzzy planar cell polarity protein	19	49806869-49817376	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041779, HPA042196	Uncertain		Approved	Cytosol	Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			testis: 52.0	Mixed		
SLC6A13	GAT2	ENSG00000010379	Solute carrier family 6 member 13	12	220621-262873	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036449, HPA052726			Approved	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Tissue enriched	Tissue enriched	14	kidney: 154.0	fallopian tube: 11.3	Cell line enriched	7	RPTEC TERT1: 3.5
IDS	SIDS	ENSG00000010404	Iduronate 2-sulfatase	X	149476990-149521096	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enriched	5	cerebral cortex: 435.8	epididymis: 86.8	Expressed in all		
PRSS3	PRSS4, TRY3, TRY4	ENSG00000010438	Protease, serine 3	9	33750466-33799231	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:4.30e-4 (unfavourable)	Group enriched	Tissue enriched	64	pancreas: 6301.2	small intestine: 99.1	Cell line enriched	9	PC-3: 632.8
ZNF200		ENSG00000010539	Zinc finger protein 200	16	3222325-3236221	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018981, HPA059310	Uncertain		Approved	Mitochondria		Expressed in all	Tissue enhanced		testis: 31.6	placenta: 8.8	Expressed in all		
CD4		ENSG00000010610	CD4 molecule	12	6786858-6820808	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000011, HPA004252, HPA004472, CAB068180	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 549.0	spleen: 220.5	Group enriched	5	HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
LRRC23	B7, LRPB7	ENSG00000010626	Leucine rich repeat containing 23	12	6873569-6914243	Predicted intracellular proteins	Evidence at protein level	HPA037766, HPA057533	Enhanced		Supported	Nucleoli	Breast cancer:6.02e-4 (favourable)	Expressed in all	Group enriched	7	fallopian tube: 165.3;testis: 43.3	epididymis: 15.2	Mixed		
BTK	AGMX1, ATK, IMD1, PSCTK1, XLA	ENSG00000010671	Bruton tyrosine kinase	X	101349447-101390796	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001198, HPA002028, CAB016689	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		lymph node: 65.2;tonsil: 70.8	spleen: 52.7	Cell line enhanced		Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
HFE	HLA-H	ENSG00000010704	Hemochromatosis	6	26087281-26098343	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA017276, HPA053470	Approved		Approved	Nuclear membrane<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 27.9	Cell line enhanced		T-47d: 50.9
SCMH1	Scml3	ENSG00000010803	Sex comb on midleg homolog 1 (Drosophila)	1	41027200-41242154	Predicted intracellular proteins	Evidence at protein level	HPA048898, HPA053292			Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.82e-4 (unfavourable), Urothelial cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.0	Mixed		
FYN	MGC45350, SLK, SYN	ENSG00000010810	FYN proto-oncogene, Src family tyrosine kinase	6	111660332-111873452	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005034, CAB018387, HPA023887, HPA063770	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:1.43e-4 (unfavourable), Liver cancer:1.84e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 166.1	Cell line enhanced		U-2197: 500.5
HIVEP2	HIV-EP2, MBP-2, MIBP1, Schnurri-2, ZAS2, ZNF40B	ENSG00000010818	Human immunodeficiency virus type I enhancer binding protein 2	6	142751467-142956698	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055954			Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 31.1	Mixed		
FMO1		ENSG00000010932	Flavin containing monooxygenase 1	1	171248471-171285978	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA023680	Uncertain				Renal cancer:2.81e-4 (favourable)	Tissue enriched	Tissue enriched	9	kidney: 203.2	small intestine: 22.8	Cell line enriched	8	HSkMC: 14.8
ELOA	SIII, TCEB3, TCEB3A	ENSG00000011007	Elongin A	1	23743155-23762059	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005910	Approved		Approved	Nuclear speckles<br>Cytosol	Liver cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 38.5	Expressed in all		
LYPLA2	APT-2	ENSG00000011009	Lysophospholipase II	1	23790970-23795539	Predicted intracellular proteins	Evidence at protein level	HPA063151			Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:5.84e-5 (unfavourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 109.2	Expressed in all		
CLCN6	CLC-6, KIAA0046	ENSG00000011021	Chloride voltage-gated channel 6	1	11806096-11843144	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA032097	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 31.2	Expressed in all		
MRC2	CD280, CLEC13E, ENDO180, KIAA0709	ENSG00000011028	Mannose receptor C type 2	17	62627401-62693597	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041991	Enhanced				Renal cancer:4.94e-7 (unfavourable), Ovarian cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 39.7	Cell line enhanced		BJ: 151.9;U-138 MG: 176.9
NME1-NME2	NM23-LV, NMELV	ENSG00000011052	NME1-NME2 readthrough	17	51153590-51171744	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002169, HPA008467, HPA041113, CAB076057	Approved		Supported	Cytosol	Glioma:8.99e-4 (favourable)	Expressed in all	Expressed in all			appendix: 48.7	Expressed in all		
SLC6A7	PROT	ENSG00000011083	Solute carrier family 6 member 7	5	150189957-150222788	Predicted membrane proteins, Transporters	Evidence at protein level	HPA028907	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 16.9;rectum: 4.2	colon: 2.9	Not detected		
TSPAN9	NET-5	ENSG00000011105	Tetraspanin 9	12	3077355-3286564	Predicted membrane proteins	Evidence at protein level	HPA014002	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Melanoma:4.67e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 79.9	Cell line enhanced		RH-30: 185.6
BTBD7	FLJ10648, FUP1	ENSG00000011114	BTB domain containing 7	14	93237550-93333092	Predicted intracellular proteins	Evidence at protein level	HPA049926, HPA053406	Uncertain		Approved	Focal adhesion sites	Renal cancer:1.69e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.6	Expressed in all		
APBA3	mint3, X11L2	ENSG00000011132	Amyloid beta precursor protein binding family A member 3	19	3750819-3761699	Predicted intracellular proteins	Evidence at protein level	HPA045577	Approved		Approved	Vesicles	Pancreatic cancer:1.51e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Head and neck cancer:4.91e-4 (favourable), Endometrial cancer:5.97e-4 (favourable)	Expressed in all	Mixed			spleen: 6.6	Mixed		
MKS1	BBS13, FLJ20345, MKS, POC12	ENSG00000011143	Meckel syndrome, type 1	17	58205437-58219605	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021372, HPA021812	Enhanced				Pancreatic cancer:1.25e-4 (favourable), Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.0	Expressed in all		
ABHD5	CGI-58, NCIE2	ENSG00000011198	Abhydrolase domain containing 5	3	43690113-43734371	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020685, HPA035851, HPA035852	Approved		Approved	Vesicles	Renal cancer:9.17e-5 (favourable), Colorectal cancer:8.89e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 50.6	Expressed in all		
ANOS1	ADMLX, KAL, KAL1, KALIG-1, WFDC19	ENSG00000011201	Anosmin 1	X	8528874-8732186	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	cerebral cortex: 32.3;lung: 64.7;parathyroid gland: 48.5;thyroid gland: 15.5	testis: 7.3	Group enriched	5	NTERA-2: 36.7;U-2 OS: 18.3
AKAP8L	HAP95, NAKAP95	ENSG00000011243	A-kinase anchoring protein 8 like	19	15380048-15419141	Predicted intracellular proteins	Evidence at protein level	HPA042485, HPA042546	Enhanced		Supported	Nuclear speckles	Renal cancer:1.08e-7 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable), Pancreatic cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
MBTD1	FLJ20055, SA49P01	ENSG00000011258	Mbt domain containing 1	17	51177425-51260163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021876	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
UTP18	CGI-48, WDR50	ENSG00000011260	UTP18, small subunit processome component	17	51260528-51297936	Predicted intracellular proteins	Evidence at protein level	HPA052378	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.99e-4 (unfavourable), Colorectal cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.1	Expressed in all		
RNF216	TRIAD3, UBCE7IP1, ZIN	ENSG00000011275	Ring finger protein 216	7	5620047-5781739	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018955, HPA021123	Supported		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.24e-5 (favourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
TTC19	FLJ20343, MGC19520	ENSG00000011295	Tetratricopeptide repeat domain 19	17	15999380-16045015	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023010, HPA052380	Enhanced		Enhanced	Mitochondria	Renal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.6	Expressed in all		
PTBP1	HNRNP-I, HNRPI, pPTB, PTB, PTB-1, PTB2, PTB3, PTB4	ENSG00000011304	Polypyrimidine tract binding protein 1	19	797075-812327	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013507	Supported		Supported	Nucleoplasm	Liver cancer:2.71e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 173.4	Expressed in all		
DPF1	BAF45b, NEUD4, neuro-d4	ENSG00000011332	Double PHD fingers 1	19	38211006-38229714	Predicted intracellular proteins	Evidence at protein level	HPA049148	Enhanced		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enriched	15	cerebral cortex: 27.4	testis: 1.8	Cell line enhanced		SCLC-21H: 26.9
SYT7	IPCA-7, MGC150517, PCANAP7, SYT-VII	ENSG00000011347	Synaptotagmin 7	11	61515313-61581148	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012869	Enhanced				Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 108.7;prostate: 84.8	placenta: 26.6	Cell line enhanced		hTERT-HME1: 68.9;RT4: 30.1;SCLC-21H: 34.3;SK-BR-3: 31.0;T-47d: 38.2
LARS2	KIAA0028, LEURS, MGC26121, mtLeuRS	ENSG00000011376	Leucyl-tRNA synthetase 2, mitochondrial	3	45388506-45549421	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035951, HPA045450, HPA066085	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.32e-11 (favourable), Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.2	Expressed in all		
PIK3C2A	PI3K-C2alpha	ENSG00000011405	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	11	17077730-17207983	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037641, HPA037642	Uncertain		Supported	Nucleus	Renal cancer:1.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 94.6	Expressed in all		
PLAUR	CD87, UPAR, URKR	ENSG00000011422	Plasminogen activator, urokinase receptor	19	43646095-43670547	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050843, CAB073533	Uncertain		Supported	Plasma membrane	Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 428.5	Cell line enhanced		U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
ANLN	ANILLIN, scra, Scraps	ENSG00000011426	Anillin actin binding protein	7	36389806-36453791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005680, CAB033902, HPA050556, CAB062547, CAB068175	Enhanced		Enhanced	Nucleoplasm<br>Midbody	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.97e-7 (unfavourable), Pancreatic cancer:2.00e-6 (unfavourable), Lung cancer:6.99e-5 (unfavourable), Endometrial cancer:1.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 87.2	bone marrow: 23.1	Expressed in all		
WIZ	ZNF803	ENSG00000011451	Widely interspaced zinc finger motifs	19	15419980-15449951	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA022923, HPA023774	Supported		Enhanced	Nucleoplasm<br>Midbody	Endometrial cancer:5.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
RABGAP1	GAPCenA, TBC1D11	ENSG00000011454	RAB GTPase activating protein 1	9	122940833-123104866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041651, HPA064860, HPA072273	Enhanced		Enhanced	Cytosol	Renal cancer:6.06e-6 (favourable), Breast cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
DCN	DSPG2, SLRR1B	ENSG00000011465	Decorin	12	91140484-91183123	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003315, CAB017118, HPA064736, CAB068930	Enhanced				Renal cancer:1.46e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 3807.0	Cell line enhanced		ASC diff: 2514.0;ASC TERT1: 1962.9;BJ hTERT+: 2379.1;HSkMC: 1868.4
QPCTL	FLJ20084	ENSG00000011478	Glutaminyl-peptide cyclotransferase like	19	45692483-45703989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040797	Approved		Supported	Golgi apparatus	Renal cancer:2.15e-8 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.6	Expressed in all		
PPP5C	PP5, PPP5	ENSG00000011485	Protein phosphatase 5 catalytic subunit	19	46346994-46392981	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022641, HPA029065, HPA056933	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:3.45e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.3	Expressed in all		
CEP68	KIAA0582	ENSG00000011523	Centrosomal protein 68	2	65056366-65087004	Predicted intracellular proteins	Evidence at protein level	HPA040493, HPA040620	Enhanced		Supported	Nucleus<br>Microtubule organizing center	Renal cancer:3.93e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 28.4	Expressed in all		
MAP4K3	GLK, MAPKKKK3, RAB8IPL1	ENSG00000011566	Mitogen-activated protein kinase kinase kinase kinase 3	2	39249266-39437312	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030380	Approved		Approved	Centrosome		Expressed in all	Expressed in all			thyroid gland: 40.9	Expressed in all		
ZBTB32	FAXF, FAZF, Rog, TZFP, ZNF538	ENSG00000011590	Zinc finger and BTB domain containing 32	19	35704527-35717038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA076730	Enhanced					Mixed	Tissue enriched	11	testis: 43.3	lymph node: 3.9	Cell line enhanced		HDLM-2: 3.9;hTEC/SVTERT24-B: 2.0
TYROBP	DAP12, KARAP, PLO-SL, PLOSL	ENSG00000011600	TYRO protein tyrosine kinase binding protein	19	35904401-35908295	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB009493, HPA041899	Enhanced				Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 386.8	Group enriched	8	HMC-1: 603.3;THP-1: 266.6
TMEM159	promethin	ENSG00000011638	Transmembrane protein 159	16	21158377-21180616	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018033, HPA063509	Approved		Approved	Vesicles	Renal cancer:8.11e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable)	Expressed in all	Mixed			skin: 45.2	Mixed		
GABRA3		ENSG00000011677	Gamma-aminobutyric acid type A receptor alpha3 subunit	X	152166234-152451358	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000839	Approved	Supported				Tissue enriched	Tissue enriched	7	cerebral cortex: 28.8	placenta: 4.1	Cell line enhanced		HMC-1: 7.4;Karpas-707: 10.3;PC-3: 7.8;U-2 OS: 7.3;U-266/84: 9.5;U-87 MG: 8.1
BRCA1	BRCC1, FANCS, PPP1R53, RNF53	ENSG00000012048	BRCA1, DNA repair associated	17	43044295-43170245	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001946, HPA034966, HPA057371	Enhanced					Expressed in all	Mixed			testis: 23.9	Expressed in all		
ERCC1	RAD10	ENSG00000012061	ERCC excision repair 1, endonuclease non-catalytic subunit	19	45407333-45478828	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004390, HPA029773, HPA050182, CAB072859, CAB072860	Enhanced		Enhanced	Nucleoplasm	Renal cancer:9.00e-5 (unfavourable), Liver cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 71.3	Expressed in all		
CD22	SIGLEC-2, SIGLEC2	ENSG00000012124	CD22 molecule	19	35319261-35347355	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002418, HPA024353	Enhanced					Mixed	Tissue enhanced		lymph node: 264.4;ovary: 162.2;spleen: 151.7;tonsil: 210.1	appendix: 98.1	Group enriched	11	Daudi: 201.6;REH: 76.6;U-698: 153.7;WM-115: 49.6
SEMA3B	LUCA-1, SemA, sema5, SEMAA, semaV	ENSG00000012171	Semaphorin 3B	3	50267558-50277546	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030651	Approved				Breast cancer:1.27e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 75.5	Cell line enhanced		Hep G2: 74.9;WM-115: 171.7
MBTPS2	KFSD, S2P	ENSG00000012174	Membrane bound transcription factor peptidase, site 2	X	21839636-21885424	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA005494, CAB009486	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
PRICKLE3	LMO6	ENSG00000012211	Prickle planar cell polarity protein 3	X	49175264-49186528	Predicted intracellular proteins	Evidence at protein level	HPA000998, HPA001442	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:5.73e-6 (unfavourable), Urothelial cancer:4.84e-5 (favourable)	Expressed in all	Mixed			skin: 11.7	Mixed		
LTF	HLF2	ENSG00000012223	Lactotransferrin	3	46435645-46485234	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008646, CAB016201, HPA057177, HPA059976	Enhanced				Renal cancer:6.30e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 2804.3;cervix, uterine: 1030.7	seminal vesicle: 532.6	Group enriched	10	RPMI-8226: 28.9;TIME: 11.6
EXTL3	botv, REGR	ENSG00000012232	Exostosin like glycosyltransferase 3	8	28600469-28755599	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025387	Approved				Liver cancer:1.14e-5 (unfavourable), Renal cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.8	Expressed in all		
NR1H4	FXR, HRR-1, HRR1, RIP14	ENSG00000012504	Nuclear receptor subfamily 1 group H member 4	12	100473708-100564413	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA047699			Approved	Nucleoplasm		Group enriched	Tissue enhanced		liver: 66.6;small intestine: 44.4	kidney: 29.9	Group enriched	26	Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
ELOVL5	dJ483K16.1, HELO1, SCA38	ENSG00000012660	ELOVL fatty acid elongase 5	6	53267398-53349179	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017042, HPA047752, HPA054197	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.94e-6 (unfavourable), Thyroid cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 257.0	Expressed in all		
ALOX5	5-LOX	ENSG00000012779	Arachidonate 5-lipoxygenase	10	45374176-45446119	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071285	Enhanced		Supported	Nucleoplasm	Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 41.3	bone marrow: 28.8	Cell line enhanced		BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
KDM5D	HY, HYA, JARID1D, KIAA0234, SMCY	ENSG00000012817	Lysine demethylase 5D	Y	19703865-19744939	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049086			Approved	Nucleoli fibrillar center	Head and neck cancer:3.58e-5 (favourable)	Mixed	Mixed			small intestine: 36.5	Cell line enhanced		HEL: 49.4;U-698: 32.8
CALCOCO1	calphoglin, Cocoa, KIAA1536	ENSG00000012822	Calcium binding and coiled-coil domain 1	12	53708517-53727745	Predicted intracellular proteins	Evidence at protein level	HPA038313, HPA038314	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			skin: 160.7	Expressed in all		
UBR7	C14orf130	ENSG00000012963	Ubiquitin protein ligase E3 component n-recognin 7 (putative)	14	93207056-93229215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000861	Approved		Approved	Nucleus	Liver cancer:8.12e-5 (unfavourable), Renal cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.3	Expressed in all		
MAP4K5	GCKR, KHS, KHS1	ENSG00000012983	Mitogen-activated protein kinase kinase kinase kinase 5	14	50418501-50561126	Predicted intracellular proteins	Evidence at protein level	HPA036696	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			endometrium: 55.2	Expressed in all		
EHD3	PAST3	ENSG00000013016	EH domain containing 3	2	31234337-31269447	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA066751	Approved		Approved	Plasma membrane	Renal cancer:1.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 64.2	esophagus: 28.8	Cell line enhanced		BJ: 68.8;BJ hTERT+: 162.4;HEL: 71.6
PSMC4	MGC13687, MGC23214, MGC8570, MIP224, S6, TBP-7, TBP7	ENSG00000013275	Proteasome 26S subunit, ATPase 4	19	39971005-39981441	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002044, HPA005471	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 43.2	Expressed in all		
MAN2B2	KIAA0935	ENSG00000013288	Mannosidase alpha class 2B member 2	4	6575175-6623362	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA037005	Uncertain				Endometrial cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 37.7	Expressed in all		
SLC7A14	KIAA1613, PPP1R142	ENSG00000013293	Solute carrier family 7 member 14	3	170459584-170586074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045929	Approved					Group enriched	Tissue enriched	8	cerebral cortex: 26.7	adrenal gland: 3.1	Cell line enhanced		LHCN-M2: 2.7;SCLC-21H: 3.7
CLDN11	OSP, OTM	ENSG00000013297	Claudin 11	3	170418865-170860380	Predicted membrane proteins	Evidence at protein level	CAB009789, HPA013166	Enhanced				Breast cancer:6.31e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 89.0;testis: 183.6	ovary: 61.7	Cell line enhanced		ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4
SLC25A39	CGI-69, FLJ22407	ENSG00000013306	Solute carrier family 25 member 39	17	44319625-44324870	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA026785	Approved				Renal cancer:3.58e-5 (favourable), Liver cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 181.1	Expressed in all		
MVP	LRP, VAULT1	ENSG00000013364	Major vault protein	16	29820394-29848039	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA002321, CAB002752, CAB022717, HPA064740	Enhanced		Enhanced	Cytosol	Renal cancer:5.49e-5 (favourable), Breast cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 165.7	Expressed in all		
NUB1	BS4, NUB1L, NYREN18	ENSG00000013374	Negative regulator of ubiquitin like proteins 1	7	151341699-151378449	Predicted intracellular proteins	Evidence at protein level	HPA021220, HPA050722, HPA053648	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 97.9	Expressed in all		
PGM3	AGM1, DKFZP434B187, PAGM	ENSG00000013375	Phosphoglucomutase 3	6	83161150-83193936	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004998, HPA029759, HPA029760	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.39e-7 (unfavourable), Cervical cancer:5.67e-4 (unfavourable), Breast cancer:8.78e-4 (unfavourable), Ovarian cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			prostate: 82.2	Expressed in all		
RWDD2A	dJ747H23.2, MGC13523, RWDD2	ENSG00000013392	RWD domain containing 2A	6	83193379-83198932	Predicted intracellular proteins	Evidence at protein level	HPA030105, HPA030106, HPA030107	Uncertain				Ovarian cancer:3.82e-5 (favourable), Pancreatic cancer:1.38e-4 (favourable), Glioma:7.17e-4 (favourable)	Expressed in all	Mixed			prostate: 18.7	Mixed		
CLK1		ENSG00000013441	CDC like kinase 1	2	200853009-200864744	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033141, HPA062405	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Urothelial cancer:2.28e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 113.5	Expressed in all		
POLR3B	FLJ10388, RPC2	ENSG00000013503	RNA polymerase III subunit B	12	106357658-106510198	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA036466	Supported		Approved	Nuclear speckles	Renal cancer:1.21e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.1	Expressed in all		
ANGEL1	Ccr4e, KIAA0759	ENSG00000013523	Angel homolog 1	14	76786178-76826246	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000948	Uncertain		Approved	Nucleoplasm	Lung cancer:3.43e-4 (favourable), Pancreatic cancer:5.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 68.3	Expressed in all		
RNF14	ARA54, HFB30, TRIAD2	ENSG00000013561	Ring finger protein 14	5	141958328-141990291	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008716	Approved		Supported	Cytosol	Renal cancer:1.71e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 137.2	Expressed in all		
DNASE1L1	DNAS1L1, DNASEX, DNL1L, XIB	ENSG00000013563	Deoxyribonuclease 1 like 1	X	154401238-154412112	Predicted secreted proteins	Evidence at protein level	HPA072635	Approved				Renal cancer:2.19e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 56.6	Expressed in all		
DDX11	CHL1, CHLR1, KRG2, WABS	ENSG00000013573	DEAD/H-box helicase 11	12	31073845-31104791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065197	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Centrosome	Renal cancer:5.23e-8 (unfavourable), Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.3	Expressed in all		
HEBP1	HBP, HEBP	ENSG00000013583	Heme binding protein 1	12	12974864-13000273	Predicted intracellular proteins	Evidence at protein level	HPA056417, HPA075277	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			duodenum: 234.7	Expressed in all		
GPRC5A	PEIG-1, RAI3, RAIG1, TIG1	ENSG00000013588	G protein-coupled receptor class C group 5 member A	12	12890782-12917937	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007928, HPA046526	Enhanced		Enhanced	Vesicles<br>Plasma membrane	Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable)	Mixed	Tissue enhanced		lung: 302.0	thyroid gland: 91.3	Cell line enhanced		CAPAN-2: 1167.5;SiHa: 520.3
MAMLD1	CG1, CXorf6, F18	ENSG00000013619	Mastermind like domain containing 1	X	150361422-150514178	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003923	Uncertain		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 18.7	ovary: 16.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 22.8;U-2197: 34.4
CD6	Tp120	ENSG00000013725	CD6 molecule	11	60971680-61020377	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002489, CAB016252	Enhanced				Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable)	Mixed	Tissue enhanced		appendix: 28.5;lymph node: 49.2	tonsil: 26.8	Cell line enriched	17	MOLT-4: 31.3
TACC3	ERIC1	ENSG00000013810	Transforming acidic coiled-coil containing protein 3	4	1721490-1745176	Predicted intracellular proteins	Evidence at protein level	HPA005781, HPA006050, CAB010111, HPA022039	Enhanced		Enhanced	Vesicles<br>Mitotic spindle<br>Microtubule organizing center<br>Centrosome<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 74.9	lymph node: 55.8	Expressed in all		
UFL1	KIAA0776, Maxer, NLBP, RCAD	ENSG00000014123	UFM1 specific ligase 1	6	96521595-96555276	Predicted intracellular proteins	Evidence at protein level	HPA030558, HPA030559, HPA030560	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 47.1	Expressed in all		
POLA2	FLJ21662	ENSG00000014138	DNA polymerase alpha 2, accessory subunit	11	65261762-65305589	Predicted intracellular proteins	Evidence at protein level	HPA037570	Enhanced		Supported	Nucleoplasm	Renal cancer:4.09e-8 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Cervical cancer:4.61e-4 (favourable)	Expressed in all	Mixed			lymph node,tonsil: 12.5	Expressed in all		
ZC3H3	KIAA0150, ZC3HDC3	ENSG00000014164	Zinc finger CCCH-type containing 3	8	143437655-143541453	Predicted intracellular proteins	Evidence at protein level	HPA023658, HPA050577	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.38e-7 (unfavourable), Liver cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 13.5	Expressed in all		
CAPN1	CANP, CANPL1, muCANP, muCL	ENSG00000014216	Calpain 1	11	65180566-65212006	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005992	Enhanced		Supported	Cytosol	Renal cancer:7.06e-8 (favourable), Pancreatic cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 243.9	Expressed in all		
ACPP	ACP-3, ACP3, PAP	ENSG00000014257	Acid phosphatase, prostate	3	132317367-132368298	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000071, HPA004335, HPA063916	Enhanced					Tissue enriched	Tissue enriched	145	prostate: 6030.6	esophagus: 41.4	Cell line enhanced		BJ hTERT+: 14.1;RPMI-8226: 39.1;U-87 MG: 14.6
MDH1		ENSG00000014641	Malate dehydrogenase 1	2	63588609-63607197	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027296, CAB047333, HPA054276	Uncertain		Supported	Centrosome<br>Cytosol	Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 715.9	Expressed in all		
SLC30A9	C4orf1, GAC63, HUEL, ZNT9	ENSG00000014824	Solute carrier family 30 member 9	4	41990472-42090457	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004014	Approved				Renal cancer:2.86e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.1	Expressed in all		
MTMR11	CRA	ENSG00000014914	Myotubularin related protein 11	1	149928651-149936869	Predicted intracellular proteins	Evidence at protein level	HPA030351	Approved		Approved	Centrosome		Expressed in all	Mixed			rectum: 27.6	Mixed		
COX15	CEMCOX2	ENSG00000014919	COX15, cytochrome c oxidase assembly homolog	10	99711844-99732100	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA037727, HPA037728, HPA066096	Uncertain		Supported	Mitochondria	Renal cancer:9.21e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 36.0	Expressed in all		
CCDC88C	DAPLE, HkRP2, KIAA1509, SCA40	ENSG00000015133	Coiled-coil domain containing 88C	14	91271323-91417844	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005832	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.80e-4 (unfavourable), Lung cancer:2.90e-4 (favourable), Head and neck cancer:3.47e-4 (favourable)	Expressed in all	Mixed			lymph node: 22.2	Cell line enhanced		SCLC-21H: 60.6;U-266/84: 47.6
YAF2		ENSG00000015153	YY1 associated factor 2	12	42157104-42238349	Predicted intracellular proteins	Evidence at protein level	HPA026867	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 29.5	Expressed in all		
ZMYND11	BS69	ENSG00000015171	Zinc finger MYND-type containing 11	10	134465-254637	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015816			Supported	Nucleoplasm	Renal cancer:4.76e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 201.0	Mixed		
WAS	IMD2, THC, WASP, WASPA	ENSG00000015285	Wiskott-Aldrich syndrome	X	48676596-48691427	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002022, CAB004290	Enhanced				Renal cancer:5.58e-6 (unfavourable), Head and neck cancer:3.78e-4 (favourable), Endometrial cancer:4.95e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 69.0;lymph node: 60.8;spleen: 68.8	bone marrow: 37.5	Cell line enhanced		HMC-1: 135.1;U-937: 66.6
DPEP1		ENSG00000015413	Dipeptidase 1 (renal)	16	89613308-89638456	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA009426, HPA012783	Enhanced		Approved	Nucleus<br>Cell Junctions	Renal cancer:6.84e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 262.6;small intestine: 418.9	pancreas: 92.8	Cell line enhanced		Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
BID		ENSG00000015475	BH3 interacting domain death agonist	22	17734138-17774770	Predicted intracellular proteins	Evidence at protein level	HPA000722, CAB003771	Enhanced		Supported	Cytosol	Renal cancer:3.50e-13 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.5	Expressed in all		
MATR3	KIAA0723, MGC9105, MPD2, VCPDM	ENSG00000015479	Matrin 3	5	139293648-139331677	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033552, HPA036564, HPA036565	Enhanced					Mixed	Expressed in all			cerebral cortex: 331.3	Expressed in all		
NPC1L1		ENSG00000015520	NPC1 like intracellular cholesterol transporter 1	7	44512535-44541315	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB070127, CAB070128	Enhanced					Group enriched	Tissue enhanced		duodenum: 57.1;small intestine: 57.9	liver: 14.2	Group enriched	7	CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
XYLT2	PXYLT2, XT-II	ENSG00000015532	Xylosyltransferase 2	17	50346092-50363138	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016456			Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			stomach: 31.5	Expressed in all		
RGPD5	BS-63, DKFZp686I1842, RGP5	ENSG00000015568	RANBP2-like and GRIP domain containing 5	2	109792758-109857695	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		testis: 6.6	duodenum: 3.2	Mixed		
STMN4	RB3	ENSG00000015592	Stathmin 4	8	27235323-27258420	Predicted intracellular proteins	Evidence at protein level	HPA027765			Uncertain	Golgi apparatus<br>Vesicles		Tissue enriched	Tissue enriched	25	cerebral cortex: 338.4	adrenal gland: 13.3	Cell line enriched	29	SCLC-21H: 102.2
NUDCD3	KIAA1068, NudCL	ENSG00000015676	NudC domain containing 3	7	44379121-44490880	Predicted intracellular proteins	Evidence at protein level	HPA019136, HPA019528, HPA019529	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:9.16e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 12.4	Expressed in all		
ISL1	Isl-1, ISLET1	ENSG00000016082	ISL LIM homeobox 1	5	51383391-51394738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057416	Approved		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	5	placenta: 10.7;prostate: 15.5;seminal vesicle: 25.9;stomach: 9.8	testis: 2.9	Cell line enriched	14	SH-SY5Y: 307.2
CHDH		ENSG00000016391	Choline dehydrogenase	3	53812335-53846390	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036633, HPA058130	Enhanced				Renal cancer:1.88e-8 (favourable)	Mixed	Tissue enhanced		kidney: 40.1	small intestine: 16.4	Cell line enhanced		CACO-2: 9.5;Hep G2: 24.3;T-47d: 10.6
IL20RA	IL-20R1, ZCYTOR7	ENSG00000016402	Interleukin 20 receptor subunit alpha	6	136999971-137045180	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024990, HPA042281	Approved		Approved	Cytosol	Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable)	Mixed	Tissue enhanced		skin: 45.0	breast: 33.5	Group enriched	7	CAPAN-2: 8.4;HaCaT: 6.1;RT4: 9.2;SH-SY5Y: 11.4;T-47d: 10.0
CLCA1	CaCC, CLCRG1	ENSG00000016490	Chloride channel accessory 1	1	86468368-86500289	Predicted secreted proteins, Transporters	Evidence at protein level	HPA052787, HPA059301	Enhanced				Colorectal cancer:2.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 699.6;duodenum: 882.2;rectum: 1126.3;small intestine: 1522.4	appendix: 133.7	Cell line enhanced		BEWO: 1.9;NB-4: 1.5;RPMI-8226: 1.8;SH-SY5Y: 1.9;U-2197: 1.3
CLCA4	CaCC2	ENSG00000016602	Chloride channel accessory 4	1	86547078-86580754	Predicted membrane proteins	Evidence at protein level	HPA017045	Uncertain				Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Tissue enhanced	Group enriched	6	colon: 249.5;esophagus: 365.5;rectum: 158.4	urinary bladder: 41.0	Cell line enriched	1215	RT4: 342.2
GLT8D1	AD-017, FLJ14611	ENSG00000016864	Glycosyltransferase 8 domain containing 1	3	52694488-52706032	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010588	Approved		Approved	Mitochondria	Endometrial cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			testis: 116.9	Expressed in all		
ATP2C1	ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1	ENSG00000017260	ATPase secretory pathway Ca2+ transporting 1	3	130850595-131016712	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010207, HPA035116, HPA069684	Supported		Enhanced	Golgi apparatus	Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			prostate: 138.3	Expressed in all		
IGF1	IGF-I, IGF1A, IGFI	ENSG00000017427	Insulin like growth factor 1	12	102395867-102480645	Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA048946	Approved				Endometrial cancer:1.04e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 126.8	smooth muscle: 98.2	Cell line enhanced		ASC diff: 21.1;HDLM-2: 45.4;K-562: 19.8;U-266/70: 10.2
SLC38A5	JM24, SN2	ENSG00000017483	Solute carrier family 38 member 5	X	48458537-48470256	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047411	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable)	Expressed in all	Mixed			pancreas: 50.0	Cell line enhanced		HBEC3-KT: 233.9;HeLa: 214.9;RPMI-8226: 374.4
RALBP1	RIP, RIP1, RLIP76	ENSG00000017797	RalA binding protein 1	18	9475009-9538116	Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB046010, HPA046651	Approved		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Renal cancer:5.39e-6 (favourable), Ovarian cancer:8.47e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 70.4	Expressed in all		
RUFY3	KIAA0871, RIPx, Singar1, ZFYVE30	ENSG00000018189	RUN and FYVE domain containing 3	4	70704204-70807315	Predicted intracellular proteins	Evidence at protein level	HPA022952, HPA022970	Enhanced		Supported	Cytosol	Pancreatic cancer:8.02e-5 (favourable), Head and neck cancer:1.28e-4 (favourable), Liver cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.0	Expressed in all		
CNTN1	F3, GP135	ENSG00000018236	Contactin 1	12	40692442-41072418	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025200, HPA070467	Enhanced				Urothelial cancer:3.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 225.5	ovary: 65.6	Cell line enhanced		A549: 218.0;HaCaT: 38.4;SCLC-21H: 85.1;SH-SY5Y: 46.5
SLC11A1	LSH, NRAMP, NRAMP1	ENSG00000018280	Solute carrier family 11 member 1	2	218382029-218396894	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029590	Uncertain				Renal cancer:2.58e-8 (unfavourable)	Mixed	Tissue enhanced		appendix: 9.1;lung: 13.0	spleen: 4.6	Not detected		
WWTR1	DKFZp586I1419, TAZ	ENSG00000018408	WW domain containing transcription regulator 1	3	149517235-149736714	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA007415, CAB017483, CAB068248	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			endometrium: 71.0	Cell line enhanced		EFO-21: 230.5
AGPS	ADAP-S, ADAS, ADHAPS, ADPS, ALDHPSY	ENSG00000018510	Alkylglycerone phosphate synthase	2	177392644-177559299	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030209, HPA030210, HPA030211	Supported		Enhanced	Peroxisomes	Liver cancer:8.62e-6 (unfavourable), Pancreatic cancer:8.35e-4 (unfavourable), Renal cancer:9.45e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.4	Mixed		
CXorf56	FLJ22965	ENSG00000018610	Chromosome X open reading frame 56	X	119538149-119565408	Predicted intracellular proteins	Evidence at protein level	HPA038245, HPA038617, HPA064831	Uncertain		Approved	Nucleus<br>Centrosome	Breast cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 24.1	Expressed in all		
ATP1A2	FHM2, MHP2	ENSG00000018625	ATPase Na+/K+ transporting subunit alpha 2	1	160115759-160143591	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022230	Approved					Tissue enriched	Group enriched	6	cerebral cortex: 434.2;skeletal muscle: 307.0	heart muscle: 57.5	Cell line enhanced		AF22: 50.7;HHSteC: 12.3;RH-30: 16.2;U-87 MG: 10.1
TTC27	FLJ20272	ENSG00000018699	Tetratricopeptide repeat domain 27	2	32628032-32821051	Predicted intracellular proteins	Evidence at protein level	HPA031246	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:1.42e-5 (unfavourable), Renal cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.4	Expressed in all		
ZNF582	FLJ30927	ENSG00000018869	Zinc finger protein 582	19	56375846-56393545	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028858	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			thyroid gland: 12.4	Cell line enhanced		HEK 293: 26.0
VSIG2	CTH, CTXL	ENSG00000019102	V-set and immunoglobulin domain containing 2	11	124747472-124752238	Predicted membrane proteins	Evidence at protein level	HPA035919, HPA050147	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		stomach: 583.7	rectum: 151.1	Group enriched	7	HEL: 14.9;RT4: 55.8
PHLDB1	FLJ00141, KIAA0638, LL5a	ENSG00000019144	Pleckstrin homology like domain family B member 1	11	118606440-118658038	Predicted intracellular proteins	Evidence at protein level	HPA037959, HPA038448, HPA061506	Approved		Approved	Nucleoplasm	Renal cancer:6.36e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 56.5	Cell line enhanced		ASC TERT1: 74.2
MARCO	SCARA2	ENSG00000019169	Macrophage receptor with collagenous structure	2	118942166-118994660	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063793	Enhanced		Approved	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		appendix: 123.2;lung: 288.2	adipose tissue: 78.0	Cell line enhanced		HaCaT: 1.5;THP-1: 1.7;U-2 OS: 2.7;U-266/70: 1.1
CYP24A1	CP24, CYP24, P450-CC24	ENSG00000019186	Cytochrome P450 family 24 subfamily A member 1	20	54153449-54173973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022261, HPA063771	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Mitochondria		Mixed	Tissue enhanced		endometrium: 24.8;urinary bladder: 50.8	placenta: 14.1	Group enriched	13	A549: 372.2;Hep G2: 83.4
PRDM11	PFM8	ENSG00000019485	PR/SET domain 11	11	45095806-45235110	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057072	Approved					Mixed	Mixed			thyroid gland: 13.9	Mixed		
SYT13	KIAA1427	ENSG00000019505	Synaptotagmin 13	11	45240301-45286319	Predicted intracellular proteins	Evidence at protein level	HPA046224, HPA056602	Uncertain		Supported	Vesicles	Endometrial cancer:7.79e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 69.9;gallbladder: 32.9	small intestine: 14.4	Group enriched	9	A549: 17.3;NTERA-2: 8.8;RPTEC TERT1: 43.3;SCLC-21H: 17.8
SNAI2	SLUG, SLUGH, SLUGH1, SNAIL2	ENSG00000019549	Snail family transcriptional repressor 2	8	48917768-48921740	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011671	Supported		Approved	Nucleus	Renal cancer:4.69e-8 (unfavourable), Urothelial cancer:7.16e-4 (unfavourable), Pancreatic cancer:7.83e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 71.0	Cell line enhanced		ASC diff: 194.2;ASC TERT1: 202.4;LHCN-M2: 229.9;U-138 MG: 243.9
CD74	DHLAG	ENSG00000019582	CD74 molecule	5	150401637-150412929	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002506, HPA010592	Enhanced		Supported	Golgi apparatus	Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 6545.9	Cell line enhanced		CAPAN-2: 1796.9;Daudi: 2297.1;HDLM-2: 4315.9;REH: 2549.8
HGF	DFNB39, F-TCF, HGFB, HPTA, SF	ENSG00000019991	Hepatocyte growth factor	7	81699006-81770438	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010333, HPA040360, HPA044088	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 438.8	gallbladder: 27.5	Cell line enhanced		ASC TERT1: 118.1;HHSteC: 111.7;HL-60: 63.0;hTEC/SVTERT24-B: 86.9;Karpas-707: 174.5;U-87 MG: 60.7
ZRANB1	TRABID	ENSG00000019995	Zinc finger RANBP2-type containing 1	10	124942123-124988189	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029239, HPA029240, HPA029241	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 35.9	Expressed in all		
NCDN	NCDN-1, NCDN-2	ENSG00000020129	Neurochondrin	1	35557473-35567274	Predicted intracellular proteins	Evidence at protein level	HPA023676	Enhanced	Supported	Supported	Cytosol	Liver cancer:1.91e-5 (unfavourable), Pancreatic cancer:3.73e-4 (favourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 284.4	adrenal gland: 22.7	Expressed in all		
ADGRA2	DKFZp434C211, DKFZp434J0911, FLJ14390, GPR124, KIAA1531, TEM5	ENSG00000020181	Adhesion G protein-coupled receptor A2	8	37784191-37844896	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012393	Uncertain				Renal cancer:3.18e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 89.6	Cell line enhanced		ASC diff: 66.7;ASC TERT1: 45.4;BJ hTERT+: 61.4;fHDF/TERT166: 60.9
ZFP64	dJ548G19.1, dJ831D17.1, FLJ10734, FLJ12628, ZNF338	ENSG00000020256	ZFP64 zinc finger protein	20	52051663-52204308	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035112, HPA058387	Uncertain		Approved	Nucleus	Liver cancer:9.86e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 13.8	Expressed in all		
MNAT1	MAT1, RNF66	ENSG00000020426	MNAT1, CDK activating kinase assembly factor	14	60734742-60969953	Predicted intracellular proteins	Evidence at protein level	HPA000701, HPA001154, CAB004495	Approved		Enhanced	Nucleoplasm	Head and neck cancer:2.45e-4 (unfavourable), Renal cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
SAMD4A	DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA	ENSG00000020577	Sterile alpha motif domain containing 4A	14	54567097-54793315	Predicted intracellular proteins	Evidence at protein level	HPA043061, HPA065309	Approved		Approved	Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 102.6	skeletal muscle: 32.7	Mixed		
RUNX3	AML2, CBFA3, PEBP2A3	ENSG00000020633	Runt related transcription factor 3	1	24899511-24965121	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004195, CAB025416, HPA059006	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:5.59e-5 (unfavourable), Colorectal cancer:8.71e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 50.5	bone marrow: 45.2	Cell line enhanced		HDLM-2: 125.1;Karpas-707: 125.3;SK-MEL-30: 77.0
MRE11	ATLD, MRE11A	ENSG00000020922	MRE11 homolog, double strand break repair nuclease	11	94415578-94493908	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002691, CAB004081	Supported		Enhanced	Nucleoplasm	Liver cancer:7.14e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.7	Expressed in all		
PLEKHB1	KPL1, PHR1, PHRET1	ENSG00000021300	Pleckstrin homology domain containing B1	11	73646178-73662819	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.99e-6 (favourable), Pancreatic cancer:6.02e-4 (favourable)	Expressed in all	Group enriched	7	cerebral cortex: 494.8;parathyroid gland: 148.4	thyroid gland: 48.4	Cell line enhanced		EFO-21: 18.8;Hep G2: 52.2;U-266/84: 21.1
SERPINB1	anti-elastase, EI, ELANH2, PI2	ENSG00000021355	Serpin family B member 1	6	2832332-2842006	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018871, HPA018882, HPA052642	Enhanced		Supported	Cytoplasmic bodies		Expressed in all	Expressed in all			esophagus: 464.5	Cell line enhanced		U-937: 105.0
CYP3A43		ENSG00000021461	Cytochrome P450 family 3 subfamily A member 43	7	99828013-99866102	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066463, HPA072245	Supported		Uncertain	Cytosol	Liver cancer:3.41e-4 (favourable)	Tissue enriched	Tissue enriched	15	liver: 22.7	testis: 1.5	Not detected		
SLC7A9	CSNU3	ENSG00000021488	Solute carrier family 7 member 9	19	32830509-32869766	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042591	Enhanced					Group enriched	Group enriched	10	duodenum: 79.0;kidney: 70.1;small intestine: 123.5	liver: 8.9	Group enriched	20	BEWO: 3.3;CACO-2: 6.7;Hep G2: 5.4
SPAST	ADPSP, FSP2, KIAA1083, SPG4	ENSG00000021574	Spastin	2	32063611-32157637	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017311	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.62e-4 (unfavourable), Renal cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.0	Expressed in all		
NRXN3	C14orf60, KIAA0743	ENSG00000021645	Neurexin 3	14	78170373-79868290	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002727	Approved				Renal cancer:1.83e-7 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 43.0;smooth muscle: 28.9	seminal vesicle: 15.3	Cell line enhanced		BJ hTERT+ SV40 Large T+: 8.7;RT4: 19.0
OSBPL5	KIAA1534, ORP5	ENSG00000021762	Oxysterol binding protein like 5	11	3087116-3166739	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038335, HPA038712, HPA058727	Approved		Enhanced	Vesicles		Expressed in all	Mixed			spleen: 19.8	Cell line enhanced		NB-4: 47.3
AQR	fSAP164, IBP160, KIAA0560	ENSG00000021776	Aquarius intron-binding spliceosomal factor	15	34851782-34969839	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040624, HPA055647			Enhanced	Nucleoplasm	Renal cancer:4.83e-4 (favourable)	Expressed in all	Mixed			testis: 10.1	Expressed in all		
CPS1		ENSG00000021826	Carbamoyl-phosphate synthase 1	2	210477682-210679107	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003781, HPA021400	Enhanced		Approved	Nucleoli	Liver cancer:6.93e-5 (favourable)	Tissue enriched	Group enriched	23	duodenum: 234.5;liver: 697.8;small intestine: 144.1	testis: 15.3	Cell line enhanced		HeLa: 249.1;SK-BR-3: 84.1
C8B		ENSG00000021852	Complement C8 beta chain	1	56929210-56966140	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023694	Supported				Liver cancer:9.31e-5 (favourable)	Tissue enriched	Tissue enriched	54	liver: 435.5	lung: 8.1	Cell line enhanced		Hep G2: 1.0
FHL1	bA535K18.1, FHL1B, FLH1A, KYO-T, MGC111107, SLIM1, XMPMA	ENSG00000022267	Four and a half LIM domains 1	X	136146702-136211359	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001040, HPA001391, CAB020817	Enhanced		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 3804.7	Cell line enhanced		BJ hTERT+: 219.3
RTFDC1	C20orf43, CDAO5, HSPC164	ENSG00000022277	Replication termination factor 2 domain containing 1	20	56468585-56519449	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053986	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:1.31e-4 (unfavourable), Endometrial cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 140.4	Expressed in all		
GABRA1	EJM5	ENSG00000022355	Gamma-aminobutyric acid type A receptor alpha1 subunit	5	161847063-161899981	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022502, HPA055746	Enhanced					Tissue enriched	Tissue enriched	46	cerebral cortex: 85.0	adrenal gland: 1.8	Not detected		
NLRP2	CLR19.9, FLJ20510, NALP2, NBS1, PAN1, PYPAF2	ENSG00000022556	NLR family pyrin domain containing 2	19	54953130-55001142	Predicted intracellular proteins	Evidence at protein level	HPA020765, HPA021183	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Pancreatic cancer:2.91e-4 (unfavourable)	Tissue enriched	Mixed			testis: 5.6	Cell line enhanced		BEWO: 33.1;K-562: 11.5;U-266/84: 11.6
SLC45A4	KIAA1126	ENSG00000022567	Solute carrier family 45 member 4	8	141207166-141308305	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023154	Uncertain		Approved	Plasma membrane	Renal cancer:1.73e-6 (favourable)	Expressed in all	Mixed			testis: 21.0	Mixed		
RNF10	KIAA0262, RIE2	ENSG00000022840	Ring finger protein 10	12	120533480-120577594	Predicted intracellular proteins	Evidence at protein level	HPA052643	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:5.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 179.5	Expressed in all		
ZNF839	C14orf131	ENSG00000022976	Zinc finger protein 839	14	102317377-102342702	Predicted intracellular proteins	Evidence at protein level	HPA020434	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:4.57e-4 (favourable), Renal cancer:5.00e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.2	Expressed in all		
ZDHHC6	FLJ21952, ZNF376	ENSG00000023041	Zinc finger DHHC-type containing 6	10	112424428-112446917	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014357	Approved					Expressed in all	Expressed in all			small intestine: 50.7	Expressed in all		
GRAMD1B	KIAA1201	ENSG00000023171	GRAM domain containing 1B	11	123358428-123627774	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008557	Approved		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:4.30e-7 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 135.1	cerebral cortex: 39.5	Cell line enhanced		A549: 57.9;HDLM-2: 155.3
RNH1	RAI, RNH	ENSG00000023191	Ribonuclease/angiogenin inhibitor 1	11	494512-507300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039223, HPA040781	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.14e-5 (favourable)	Expressed in all	Expressed in all			skin: 73.1	Expressed in all		
NDUFS1	CI-75k	ENSG00000023228	NADH:ubiquinone oxidoreductase core subunit S1	2	206114817-206159603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA064605, CAB070844	Approved		Supported	Mitochondria	Renal cancer:1.47e-12 (favourable), Breast cancer:3.85e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 71.1	Expressed in all		
RB1CC1	ATG17, Cc1, DRAGOU14, FIP200, KIAA0203, PPP1R131	ENSG00000023287	RB1 inducible coiled-coil 1	8	52622456-52745843	Predicted intracellular proteins	Evidence at protein level	HPA024391, HPA053049	Approved		Supported	Nuclear membrane<br>Cytosol	Endometrial cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
ERP44	KIAA0573, PDIA10, TXNDC4	ENSG00000023318	Endoplasmic reticulum protein 44	9	99979179-100099040	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001318	Supported				Head and neck cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.4	Expressed in all		
ALAS1	ALAS, ALAS3	ENSG00000023330	5'-aminolevulinate synthase 1	3	52198086-52214327	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017498, HPA035860	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:6.06e-7 (favourable), Liver cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 761.4	Expressed in all		
BIRC3	API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49	ENSG00000023445	Baculoviral IAP repeat containing 3	11	102317450-102339403	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002317	Enhanced	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 138.1	appendix: 117.5	Cell line enhanced		CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
AKAP11	AKAP220, DKFZp781I12161, FLJ11304, KIAA0629, PPP1R44, PRKA11	ENSG00000023516	A-kinase anchoring protein 11	13	42272153-42323267	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039089	Enhanced		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Cervical cancer:9.26e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
GLRX2	bA101E13.1, GRX2	ENSG00000023572	Glutaredoxin 2	1	193096468-193106114	Predicted intracellular proteins	Evidence at protein level	HPA023087, HPA057224	Supported		Enhanced	Nucleoplasm	Renal cancer:3.30e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
SNAPC1	PTFgamma, SNAP43	ENSG00000023608	Small nuclear RNA activating complex polypeptide 1	14	61762357-61796428	Predicted intracellular proteins	Evidence at protein level	HPA067076, HPA072276			Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 35.6	Expressed in all		
DERA	CGI-26, DEOC	ENSG00000023697	Deoxyribose-phosphate aldolase	12	15911172-16037282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055897			Supported	Nucleus	Thyroid cancer:3.64e-5 (favourable), Pancreatic cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 74.7	Expressed in all		
STRAP	MAWD, pt-wd, UNRIP	ENSG00000023734	Serine/threonine kinase receptor associated protein	12	15882391-15903478	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027320, HPA055557, HPA073876	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.83e-6 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable), Thyroid cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.2	Expressed in all		
ABCC2	CMOAT, cMRP, DJS, MRP2	ENSG00000023839	ATP binding cassette subfamily C member 2	10	99782732-99852192	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004860, CAB037271	Enhanced				Renal cancer:1.93e-5 (unfavourable)	Tissue enhanced	Group enriched	10	duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5	breast: 4.4	Cell line enhanced		A549: 203.8;Hep G2: 155.8
DEF6	IBP, SLAT, SWAP70L	ENSG00000023892	DEF6, guanine nucleotide exchange factor	6	35297852-35321771	Predicted intracellular proteins	Evidence at protein level	HPA038975, HPA038976	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.02e-8 (unfavourable), Breast cancer:3.02e-6 (favourable), Cervical cancer:1.08e-4 (favourable), Colorectal cancer:1.71e-4 (unfavourable), Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Mixed			lymph node: 56.1	Cell line enhanced		U-937: 93.5
PLEKHO1	CKIP-1, OC120	ENSG00000023902	Pleckstrin homology domain containing O1	1	150149183-150164720	Predicted intracellular proteins	Evidence at protein level	HPA061018			Supported	Mitochondria	Renal cancer:6.47e-11 (unfavourable)	Expressed in all	Mixed			appendix: 78.1	Mixed		
GCLM	GLCLR	ENSG00000023909	Glutamate-cysteine ligase modifier subunit	1	93885205-93909456	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB009568, HPA023696, CAB040554	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:9.83e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Expressed in all		
UBR2	bA49A4.1, C6orf133, dJ392M17.3, KIAA0349	ENSG00000024048	Ubiquitin protein ligase E3 component n-recognin 2	6	42564062-42693504	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027869, HPA027880	Approved		Approved	Nucleoplasm<br>Plasma membrane	Ovarian cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.5	Expressed in all		
EHD2	PAST2	ENSG00000024422	EH domain containing 2	19	47713343-47743134	Predicted intracellular proteins	Evidence at protein level	HPA047394, HPA049890, HPA049986, HPA066751	Approved		Supported	Plasma membrane	Renal cancer:3.98e-4 (unfavourable), Ovarian cancer:8.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 208.8	smooth muscle: 111.7	Mixed		
DEPDC1	DEP.8, DEPDC1A, FLJ20354, SDP35	ENSG00000024526	DEP domain containing 1	1	68474152-68497221	Predicted intracellular proteins	Evidence at protein level	CAB017845	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Colorectal cancer:8.70e-5 (favourable)	Mixed	Tissue enhanced		testis: 14.5	lymph node: 5.8	Mixed		
CCDC28A	C6orf80, CCRL1AP, DKFZp586D0623	ENSG00000024862	Coiled-coil domain containing 28A	6	138773509-138793319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055125	Approved		Approved	Cytosol	Renal cancer:1.11e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.7	Expressed in all		
RRAGD	bA11D8.2.1, DKFZP761H171	ENSG00000025039	Ras related GTP binding D	6	89364636-89412270	Predicted intracellular proteins	Evidence at protein level	HPA068664	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:8.47e-8 (favourable), Liver cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 46.8	Cell line enhanced		Karpas-707: 45.9;SCLC-21H: 39.1;U-266/70: 61.2
HSF2		ENSG00000025156	Heat shock transcription factor 2	6	122399546-122433119	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016067, HPA031455	Approved		Supported	Nucleoplasm	Liver cancer:1.51e-6 (unfavourable), Renal cancer:7.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.4	Expressed in all		
PHF20	C20orf104, dJ1121G12.1, TDRD20A	ENSG00000025293	PHD finger protein 20	20	35771974-35950381	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029619, HPA029620, HPA029621	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
HSD17B6	HSE, RODH, SDR9C6	ENSG00000025423	Hydroxysteroid 17-beta dehydrogenase 6	12	56752161-56787790	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059141	Enhanced		Approved	Nucleus<br>Vesicles	Liver cancer:6.32e-4 (favourable)	Tissue enriched	Tissue enriched	10	liver: 930.6	seminal vesicle: 96.0	Cell line enhanced		SCLC-21H: 12.9
NR1H3	LXR-a, RLD-1	ENSG00000025434	Nuclear receptor subfamily 1 group H member 3	11	47248300-47269032	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036443, CAB037109	Approved				Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:3.40e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Liver cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 55.2	Mixed		
TYMP	ECGF1, MNGIE	ENSG00000025708	Thymidine phosphorylase	22	50525752-50530056	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000530, HPA001072, CAB002518	Enhanced		Approved	Nuclear bodies<br>Golgi apparatus	Renal cancer:3.50e-8 (unfavourable), Endometrial cancer:4.34e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 100.6	spleen: 53.1	Cell line enhanced		CAPAN-2: 37.3;HHSteC: 84.7;Karpas-707: 72.1;U-266/70: 36.4
NCAPH2	384D8-2, CAP-H2, hCAP-H2	ENSG00000025770	Non-SMC condensin II complex subunit H2	22	50508216-50523472	Predicted intracellular proteins	Evidence at protein level	HPA067932, HPA069056	Enhanced		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Cervical cancer:2.24e-8 (favourable), Liver cancer:8.25e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 49.4	Expressed in all		
TOMM34	HTOM34P, TOM34	ENSG00000025772	Translocase of outer mitochondrial membrane 34	20	44942130-44960486	Predicted intracellular proteins	Evidence at protein level	HPA018845, HPA056875	Enhanced		Enhanced	Cytosol	Liver cancer:8.71e-6 (unfavourable), Head and neck cancer:4.47e-5 (unfavourable), Thyroid cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 182.2	Expressed in all		
SEC63	DNAJC23, ERdj2, PRO2507, SEC63L	ENSG00000025796	SEC63 homolog, protein translocation regulator	6	107867756-107958189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053295, HPA060535	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 87.4	Expressed in all		
KPNA6	FLJ11249, IPOA7, KPNA7, MGC17918	ENSG00000025800	Karyopherin subunit alpha 6	1	32108038-32176568	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018863	Supported		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.28e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
VIM		ENSG00000026025	Vimentin	10	17228259-17237593	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000080, HPA001762, CAB058687	Enhanced		Approved	Intermediate filaments	Renal cancer:8.69e-8 (unfavourable), Endometrial cancer:9.75e-6 (favourable)	Expressed in all	Expressed in all			ovary: 4304.6	Cell line enhanced		ASC TERT1: 12818.5
FAS	APO-1, APT1, CD95, FAS1, TNFRSF6	ENSG00000026103	Fas cell surface death receptor	10	88990582-89015785	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027444	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			rectum: 32.9	Cell line enhanced		Karpas-707: 104.1
RNASET2	bA514O12.3, FLJ10907, RNASE6PL	ENSG00000026297	Ribonuclease T2	6	166929504-166957191	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029013, HPA066509	Approved				Renal cancer:1.70e-14 (unfavourable)	Expressed in all	Expressed in all			spleen: 279.9	Cell line enhanced		EFO-21: 187.2;THP-1: 346.2
CD44	CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1	ENSG00000026508	CD44 molecule (Indian blood group)	11	35138870-35232402	Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000112, CAB000316, HPA005785	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane	Renal cancer:1.78e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 530.1	Mixed		
KCNG1	K13, KCNG, kH2, Kv6.1	ENSG00000026559	Potassium voltage-gated channel modifier subfamily G member 1	20	51003656-51023129	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA039530, HPA040024	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		endometrium: 23.4;seminal vesicle: 18.1	placenta: 10.1	Cell line enhanced		hTCEpi: 38.3;U-138 MG: 39.5
AGPAT4	dJ473J16.2, LPAAT-delta	ENSG00000026652	1-acylglycerol-3-phosphate O-acyltransferase 4	6	161129979-161274061	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053287, HPA060525	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles	Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 24.7	placenta: 12.3	Cell line enhanced		AF22: 25.4
SLAMF7	19A, CD319, CRACC, CS1	ENSG00000026751	SLAM family member 7	1	160739057-160754821	CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015445, HPA055945, HPA061654	Enhanced		Approved	Vesicles	Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable)	Mixed	Mixed			spleen: 58.3	Group enriched	7	SK-MEL-30: 45.6;U-266/70: 216.2
BTN3A1	BT3.1, BTF5, BTN3.1, CD277	ENSG00000026950	Butyrophilin subfamily 3 member A1	6	26402237-26415216	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012565	Approved		Uncertain	Vesicles	Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 112.6	Mixed		
MIPEP	MIP	ENSG00000027001	Mitochondrial intermediate peptidase	13	23730189-23889419	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030676, HPA031669, HPA031670	Approved		Enhanced	Mitochondria	Renal cancer:7.66e-12 (favourable)	Expressed in all	Expressed in all			fallopian tube: 27.4	Expressed in all		
PRKCH	PKC-L, PKCL, PRKCL	ENSG00000027075	Protein kinase C eta	14	61187559-61550976	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026294, HPA053709	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:8.55e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 61.7	Cell line enhanced		BEWO: 78.7;HUVEC TERT2: 90.5;MOLT-4: 60.3;TIME: 58.5
INSRR	IRR	ENSG00000027644	Insulin receptor related receptor	1	156840063-156859018	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025285	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.8;kidney: 1.4;testis: 2.2	prostate: 0.6	Group enriched	10	SCLC-21H: 5.5;SH-SY5Y: 17.2
IFNGR1	CD119, IFNGR	ENSG00000027697	Interferon gamma receptor 1	6	137197484-137219449	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025889, HPA063871	Approved				Renal cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 221.9	Expressed in all		
B4GALT7	beta4Gal-T7, XGALT-1	ENSG00000027847	Beta-1,4-galactosyltransferase 7	5	177600100-177610347	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042330	Supported				Glioma:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.3	Expressed in all		
SH2D2A	F2771, TSAd	ENSG00000027869	SH2 domain containing 2A	1	156806243-156816862	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.26e-12 (unfavourable), Urothelial cancer:1.31e-4 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 15.0	lymph node: 10.5	Cell line enhanced		HDLM-2: 42.7;HMC-1: 29.0;Karpas-707: 57.7
VRK2		ENSG00000028116	Vaccinia related kinase 2	2	57907651-58159920	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB046459, HPA047503	Approved		Supported	Endoplasmic reticulum	Liver cancer:6.32e-6 (unfavourable), Renal cancer:4.66e-5 (unfavourable), Pancreatic cancer:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.1	Mixed		
TNFRSF1B	CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80	ENSG00000028137	TNF receptor superfamily member 1B	1	12167003-12209228	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004796	Approved				Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 100.4	spleen: 77.8	Cell line enhanced		CAPAN-2: 31.7;K-562: 41.3;THP-1: 35.7;U-87 MG: 34.0
VEZT	DKFZP761C241	ENSG00000028203	Vezatin, adherens junctions transmembrane protein	12	95217746-95302790	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004811, HPA017066	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.93e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable), Stomach cancer:3.68e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.4	Expressed in all		
POU2F2	OCT2, OTF2	ENSG00000028277	POU class 2 homeobox 2	19	42086110-42196585	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002513, HPA049056, HPA062096, HPA064404	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:7.57e-11 (unfavourable)	Mixed	Tissue enhanced		lymph node: 62.3;tonsil: 44.4	appendix,spleen: 37.6	Cell line enhanced		BJ hTERT+: 42.5;Daudi: 81.0;hTEC/SVTERT24-B: 42.8;U-266/70: 57.7;U-266/84: 54.8;U-698: 61.5
BRD9	FLJ13441	ENSG00000028310	Bromodomain containing 9	5	850291-892824	Predicted intracellular proteins	Evidence at protein level	HPA021465, HPA023197	Uncertain		Approved	Nucleoplasm	Liver cancer:5.88e-7 (unfavourable), Renal cancer:2.37e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
SNX1	HsT17379, MGC8664, SNX1A, Vps5	ENSG00000028528	Sorting nexin 1	15	64094123-64146090	Predicted intracellular proteins	Evidence at protein level	HPA047373, HPA052761	Approved		Enhanced	Endosomes<br>Lysosomes	Renal cancer:9.88e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 163.5	Expressed in all		
TBPL1	STUD, TLF, TLP, TRF2	ENSG00000028839	TATA-box binding protein like 1	6	133952170-133990432	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071810, HPA071813	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli	Liver cancer:7.91e-5 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Glioma:4.67e-4 (favourable), Pancreatic cancer:7.23e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 227.4	thyroid gland: 28.2	Expressed in all		
ARNTL2	bHLHe6, BMAL2, CLIF, MOP9, PASD9	ENSG00000029153	Aryl hydrocarbon receptor nuclear translocator like 2	12	27332854-27425289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059074, HPA065355	Uncertain		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:5.29e-6 (unfavourable), Renal cancer:1.56e-5 (unfavourable)	Mixed	Tissue enhanced		esophagus: 31.2	tonsil: 20.2	Cell line enhanced		U-2197: 148.2
BCLAF1	BTF, KIAA0164	ENSG00000029363	BCL2 associated transcription factor 1	6	136256627-136289851	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006484, HPA006669, HPA027770	Enhanced		Enhanced	Nuclear speckles	Breast cancer:1.64e-4 (unfavourable), Colorectal cancer:3.44e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 88.4	Expressed in all		
SLC39A9	FLJ11274	ENSG00000029364	Solute carrier family 39 member 9	14	69398015-69462388	Predicted membrane proteins, Transporters	Evidence at protein level	HPA007921, HPA075390	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.05e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.0	Expressed in all		
ANK1	ANK, SPH1	ENSG00000029534	Ankyrin 1	8	41653220-41896762	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004842, HPA056953	Supported					Mixed	Tissue enriched	5	skeletal muscle: 348.3	heart muscle: 63.9	Group enriched	5	HEL: 84.7;K-562: 96.3;RH-30: 157.8
IBSP	BSP, BSP-II, SP-II	ENSG00000029559	Integrin binding sialoprotein	4	87799581-87812435	Cancer-related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 1.6;cervix, uterine: 1.3	gallbladder,placenta: 0.3	Cell line enriched	6	U-138 MG: 7.3
TFB1M	CGI-75, mtTFB	ENSG00000029639	Transcription factor B1, mitochondrial	6	155257509-155314493	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029428	Approved					Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
RABEP1	neurocrescin, RAB5EP, rabaptin-5, RABPT5	ENSG00000029725	Rabaptin, RAB GTPase binding effector protein 1	17	5282265-5385812	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004549, HPA019669, HPA024235, HPA024691	Enhanced		Enhanced	Vesicles	Pancreatic cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
HMGB3	HMG2A, HMG4, MGC90319	ENSG00000029993	High mobility group box 3	X	150980509-150990775	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062583	Enhanced		Approved	Nucleus<br>Nucleoli	Ovarian cancer:9.85e-5 (favourable), Renal cancer:6.15e-4 (favourable)	Expressed in all	Expressed in all			placenta: 196.4	Expressed in all		
NUP160	FLJ22583, KIAA0197	ENSG00000030066	Nucleoporin 160	11	47778087-47848555	Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
BAK1	BAK, BCL2L7, CDN1	ENSG00000030110	BCL2 antagonist/killer 1	6	33572547-33580293	Predicted membrane proteins, Transporters	Evidence at protein level	CAB005029	Enhanced				Renal cancer:1.64e-5 (unfavourable), Endometrial cancer:1.71e-4 (unfavourable), Liver cancer:4.52e-4 (unfavourable), Lung cancer:5.64e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 47.9	Expressed in all		
MUSK		ENSG00000030304	Muscle associated receptor tyrosine kinase	9	110668771-110801620	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			testis: 3.0	Group enriched	19	LHCN-M2: 20.0;RH-30: 23.3
IKZF2	Helios, ZNFN1A2	ENSG00000030419	IKAROS family zinc finger 2	2	212999691-213152427	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059142	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Mixed			esophagus: 21.4	Cell line enhanced		MOLT-4: 24.8;RT4: 22.8
GRN	CLN11, PCDGF, PGRN	ENSG00000030582	Granulin precursor	17	44345086-44353102	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008763, CAB019394, HPA028747	Approved		Enhanced	Endoplasmic reticulum<br>Endosomes<br>Lysosomes	Glioma:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 439.4	Expressed in all		
FAM13B	ARHGAP49, C5orf5, FAM13B1, KHCHP, N61	ENSG00000031003	Family with sequence similarity 13 member B	5	137937960-138051961	Predicted intracellular proteins	Evidence at protein level	HPA036525, HPA041819, HPA071936	Uncertain		Approved	Nucleoplasm	Renal cancer:3.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
ARHGAP31	CDGAP	ENSG00000031081	Rho GTPase activating protein 31	3	119294373-119420714	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036380	Approved				Renal cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 29.1	Cell line enhanced		HUVEC TERT2: 29.2;TIME: 31.7
CENPQ	C6orf139, CENP-Q, FLJ10545	ENSG00000031691	Centromere protein Q	6	49463378-49493107	Predicted intracellular proteins	Evidence at protein level	HPA029043, HPA046634, HPA054965	Approved		Enhanced	Nucleoplasm	Liver cancer:2.21e-5 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable), Ovarian cancer:6.26e-4 (favourable)	Expressed in all	Mixed			testis: 11.0	Expressed in all		
SARS	SERS	ENSG00000031698	Seryl-tRNA synthetase	1	109213918-109238169	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016939, HPA064668	Uncertain		Enhanced	Cytosol	Liver cancer:6.13e-5 (unfavourable), Head and neck cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 240.7	Expressed in all		
RANBP3		ENSG00000031823	RAN binding protein 3	19	5916139-5978142	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043375, HPA043389	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.22e-5 (favourable), Pancreatic cancer:4.14e-4 (favourable), Thyroid cancer:8.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.1	Expressed in all		
ARID4A	RBBP1, RBP-1, RBP1	ENSG00000032219	AT-rich interaction domain 4A	14	58298385-58373887	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048899			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:1.91e-4 (favourable), Lung cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.0	Expressed in all		
TSSC1		ENSG00000032389	Tumor suppressing subtransferable candidate 1	2	3188925-3377882	Predicted intracellular proteins	Evidence at protein level	HPA031231, HPA031232, HPA031233, HPA031234	Approved		Supported	Nucleus<br>Nucleoli<br>Intermediate filaments	Liver cancer:3.67e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
PNPLA6	iPLA2delta, NTE, SPG39, sws	ENSG00000032444	Patatin like phospholipase domain containing 6	19	7534004-7561764	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007522	Uncertain				Pancreatic cancer:3.51e-5 (favourable), Head and neck cancer:5.25e-4 (favourable), Renal cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
IFT88	D13S1056E, hTg737, MGC26259, Tg737, TTC10	ENSG00000032742	Intraflagellar transport 88	13	20567069-20691437	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.33e-4 (favourable), Pancreatic cancer:5.17e-4 (favourable)	Expressed in all	Expressed in all			testis: 126.6	Expressed in all		
ALG1	CDG1K, HMAT1, HMT-1, Mat-1	ENSG00000033011	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase	16	5033960-5087379	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060392	Approved		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ZCCHC8	DKFZp434E2220	ENSG00000033030	Zinc finger CCHC-type containing 8	12	122471600-122501073	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037483, HPA037484	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.36e-4 (unfavourable), Melanoma:7.40e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 33.1	Expressed in all		
ABCF2	ABC28, EST133090, HUSSY-18, M-ABC1	ENSG00000033050	ATP binding cassette subfamily F member 2	7	151207837-151227230	Predicted intracellular proteins	Evidence at protein level	HPA020091, CAB020682, HPA021815, HPA030388	Enhanced		Supported	Cytosol	Liver cancer:9.52e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.2	Expressed in all		
CHPF2	ChSy-3, CSGlcA-T, KIAA1402	ENSG00000033100	Chondroitin polymerizing factor 2	7	151232489-151238827	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020992	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.51e-4 (favourable), Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder,spleen: 23.5	Expressed in all		
LRRC7	densin-180, KIAA1365	ENSG00000033122	Leucine rich repeat containing 7	1	69568398-70151945	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 14.4	testis,thyroid gland: 4.2	Cell line enhanced		HaCaT: 13.5;HEL: 41.5;SCLC-21H: 6.0
FUT8		ENSG00000033170	Fucosyltransferase 8	14	65410592-65744121	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017129, HPA040863, HPA043410	Enhanced		Enhanced	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 31.5	Expressed in all		
UBA6	FLJ10808, UBE1L2	ENSG00000033178	Ubiquitin like modifier activating enzyme 6	4	67612652-67701179	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037001	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.01e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 18.7	Expressed in all		
GAB2	KIAA0571	ENSG00000033327	GRB2 associated binding protein 2	11	78215297-78418348	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA000271, HPA001368, CAB022159	Enhanced		Supported	Plasma membrane	Renal cancer:9.32e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.5	Cell line enhanced		SH-SY5Y: 66.1
ATP6V0A1	a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1	ENSG00000033627	ATPase H+ transporting V0 subunit a1	17	42458844-42522611	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022144	Enhanced		Approved	Nuclear speckles<br>Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 200.9	Mixed		
PIAS1	DDXBP1, GBP, GU/RH-II, ZMIZ3	ENSG00000033800	Protein inhibitor of activated STAT 1	15	68054179-68198603	Predicted intracellular proteins	Evidence at protein level	HPA005743, CAB012304	Supported		Approved	Microtubules		Expressed in all	Expressed in all			testis: 37.7	Expressed in all		
SLC4A7	NBC3, SBC2, SLC4A6	ENSG00000033867	Solute carrier family 4 member 7	3	27372721-27484420	Predicted membrane proteins, Transporters	Evidence at protein level	CAB022494, HPA035857	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Renal cancer:7.91e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 57.7	breast: 23.8	Expressed in all		
APBA2	D15S1518E, HsT16821, LIN-10, MGC:14091, MINT2, X11L	ENSG00000034053	Amyloid beta precursor protein binding family A member 2	15	28884483-29118315	Predicted intracellular proteins	Evidence at protein level	CAB037065	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2	spleen: 3.3	Cell line enhanced		HEL: 7.6;SH-SY5Y: 21.2;U-937: 11.6
MAP2K3	MAPKK3, MEK3, MKK3, PRKMK3	ENSG00000034152	Mitogen-activated protein kinase kinase 3	17	21284672-21315240	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018548	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 129.9	Expressed in all		
EFCAB1	FLJ11767	ENSG00000034239	EF-hand calcium binding domain 1	8	48710789-48735311	Predicted intracellular proteins	Evidence at protein level	HPA023527, HPA069955	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enhanced		fallopian tube: 149.8;testis: 47.1	ovary: 23.9	Cell line enhanced		A-431: 5.8;ASC TERT1: 4.4;CAPAN-2: 2.8;SCLC-21H: 5.8
TMSB10	TB10	ENSG00000034510	Thymosin beta 10	2	84905625-84906675	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.49e-7 (unfavourable), Thyroid cancer:4.97e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 3706.7	Expressed in all		
ASTE1	HT001	ENSG00000034533	Asteroid homolog 1 (Drosophila)	3	131013875-131027649	Predicted intracellular proteins	Evidence at protein level	HPA037010, HPA037011	Enhanced		Approved	Endoplasmic reticulum	Liver cancer:4.03e-5 (unfavourable), Endometrial cancer:2.34e-4 (unfavourable), Cervical cancer:3.09e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 11.7	Expressed in all		
RNF19A	DKFZp566B1346, dorfin, RNF19	ENSG00000034677	Ring finger protein 19A, RBR E3 ubiquitin protein ligase	8	100257060-100336218	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011455, HPA023652	Approved				Urothelial cancer:3.28e-5 (favourable), Renal cancer:7.99e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 95.3	Expressed in all		
PEX3		ENSG00000034693	Peroxisomal biogenesis factor 3	6	143450807-143490010	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042830, HPA058006	Enhanced		Supported	Nucleoplasm<br>Peroxisomes	Renal cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.3	Expressed in all		
GABARAPL2	ATG8, ATG8C, GATE-16, GATE16, GEF2	ENSG00000034713	GABA type A receptor associated protein like 2	16	75566351-75577881	Predicted intracellular proteins	Evidence at protein level	HPA036726	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-8 (favourable), Head and neck cancer:7.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 319.3	Expressed in all		
MYOC	GLC1A, JOAG1, TIGR	ENSG00000034971	Myocilin	1	171635417-171652683	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA027364	Approved					Tissue enriched	Tissue enhanced		adipose tissue: 45.4	esophagus: 21.4	Not detected		
SH3YL1	DKFZP586F1318, Ray	ENSG00000035115	SH3 and SYLF domain containing 1	2	217730-266398	Predicted intracellular proteins	Evidence at protein level	HPA030926, HPA030927	Approved		Approved	Nucleus	Renal cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			kidney: 150.0	Mixed		
FAM136A	FLJ14668	ENSG00000035141	Family with sequence similarity 136 member A	2	70295975-70302090	Predicted intracellular proteins	Evidence at protein level	HPA030103, HPA030104	Enhanced		Approved	Mitochondria	Renal cancer:1.33e-6 (unfavourable), Liver cancer:2.66e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
VCL		ENSG00000035403	Vinculin	10	73995193-74121363	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002131, CAB002453, HPA063777	Enhanced		Enhanced	Focal adhesion sites	Pancreatic cancer:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 326.5	Expressed in all		
DEPDC1B	BRCC3, XTP1	ENSG00000035499	DEP domain containing 1B	5	60596912-60700190	Predicted intracellular proteins	Evidence at protein level	HPA038255, HPA072558	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Lung cancer:6.93e-5 (unfavourable), Colorectal cancer:2.42e-4 (favourable), Liver cancer:3.08e-4 (unfavourable), Endometrial cancer:8.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 33.0;testis: 22.6	lymph node: 10.8	Mixed		
DAPK2	DRP-1, MGC119312	ENSG00000035664	Death associated protein kinase 2	15	63907036-64072033	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071581			Supported	Golgi apparatus<br>Vesicles	Lung cancer:5.63e-4 (favourable)	Tissue enriched	Tissue enhanced		thyroid gland: 49.1	lung: 29.9	Cell line enhanced		HMC-1: 16.0
NSMAF	FAN, GRAMD5	ENSG00000035681	Neutral sphingomyelinase activation associated factor	8	58583504-58659844	Predicted intracellular proteins	Evidence at protein level	HPA023067, HPA023148, HPA023151	Uncertain		Approved	Nucleoli	Renal cancer:4.61e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.6	Expressed in all		
ADSS		ENSG00000035687	Adenylosuccinate synthase	1	244408494-244452134	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024400	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 117.0	Expressed in all		
STAP1	BRDG1, STAP-1	ENSG00000035720	Signal transducing adaptor family member 1	4	67558728-67607337	Predicted intracellular proteins	Evidence at protein level	HPA038529	Enhanced		Uncertain	Nucleoplasm<br>Vesicles		Tissue enriched	Group enriched	6	appendix: 23.8;kidney: 13.2;lymph node: 59.6;spleen: 26.6;tonsil: 56.3	testis: 6.1	Cell line enhanced		Daudi: 141.5;U-698: 60.7;U-937: 22.3
TIMP2	CSC-21K	ENSG00000035862	TIMP metallopeptidase inhibitor 2	17	78852977-78925387	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010203	Approved					Expressed in all	Expressed in all			ovary: 1178.9	Cell line enhanced		ASC TERT1: 1134.2
RFC1	A1, MHCBFB, PO-GA, RFC140	ENSG00000035928	Replication factor C subunit 1	4	39287456-39366375	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009520, HPA046116, HPA069306	Supported		Enhanced	Nucleus	Colorectal cancer:4.43e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 66.7	Expressed in all		
TBC1D23	FLJ11046	ENSG00000036054	TBC1 domain family member 23	3	100261000-100325251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038151, HPA038152	Approved		Enhanced	Golgi apparatus	Endometrial cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
CUL3		ENSG00000036257	Cullin 3	2	224470150-224585397	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB002678	Supported					Expressed in all	Expressed in all			testis: 403.1	Expressed in all		
MYOM2		ENSG00000036448	Myomesin 2	8	2045040-2165552	Predicted intracellular proteins	Evidence at protein level	HPA001765, HPA005953	Enhanced		Approved	Mitochondria		Mixed	Group enriched	19	heart muscle: 197.4;skeletal muscle: 110.2	breast: 8.1	Group enriched	8	HEK 293: 4.8;SCLC-21H: 2.6;U-266/84: 2.0
OTC		ENSG00000036473	Ornithine carbamoyltransferase	X	38352545-38421450	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000243, HPA000570	Enhanced		Supported	Mitochondria		Tissue enriched	Group enriched	26	duodenum: 114.4;liver: 195.4;small intestine: 96.9	colon: 5.3	Not detected		
CYP46A1	CYP46	ENSG00000036530	Cytochrome P450 family 46 subfamily A member 1	14	99684304-99727301	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040702	Uncertain					Tissue enriched	Tissue enriched	21	cerebral cortex: 64.1	heart muscle: 3.0	Group enriched	5	AF22: 2.4;U-937: 5.4
ZZZ3	ATAC1, DKFZP564I052	ENSG00000036549	Zinc finger ZZ-type containing 3	1	77562416-77683419	Predicted intracellular proteins	Evidence at protein level	HPA053663, HPA054913, HPA066197	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:6.96e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.9	Expressed in all		
SLC18A1	CGAT, VAT1, VMAT1	ENSG00000036565	Solute carrier family 18 member A1	8	20144855-20183206	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006877, HPA063797	Enhanced					Tissue enhanced	Tissue enriched	11	adrenal gland: 32.6	rectum: 3.0	Cell line enriched	9	SH-SY5Y: 70.0
USP2	UBP41	ENSG00000036672	Ubiquitin specific peptidase 2	11	119355215-119381726	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006777, HPA007222	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.09e-11 (favourable)	Expressed in all	Tissue enhanced		testis: 119.4	skeletal muscle: 59.3	Cell line enhanced		U-266/70: 43.2
CASR	FHH, GPRC2A, HHC, HHC1, NSHPT	ENSG00000036828	Calcium sensing receptor	3	122183683-122291629	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039686, HPA050335	Enhanced					Tissue enriched	Tissue enriched	58	parathyroid gland: 1441.4	kidney: 24.6	Not detected		
TUBG2		ENSG00000037042	Tubulin gamma 2	17	42659305-42667006	Predicted intracellular proteins	Evidence at protein level	CAB011495	Approved		Supported	Microtubule organizing center	Liver cancer:4.68e-5 (unfavourable), Renal cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 77.4	Mixed		
RPL26L1	RPL26P1	ENSG00000037241	Ribosomal protein L26 like 1	5	172958729-172969771	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030449	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Head and neck cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 124.9	Expressed in all		
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK 293: 14.1;T-47d: 13.7;TIME: 12.7
NSUN2	FLJ20303, Misu, MRT5, TRM4	ENSG00000037474	NOP2/Sun RNA methyltransferase family member 2	5	6599239-6633291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037896	Enhanced		Supported	Nucleus	Renal cancer:5.69e-5 (unfavourable)	Expressed in all	Expressed in all			breast: 44.2	Expressed in all		
FBXO42	Fbx42, KIAA1332	ENSG00000037637	F-box protein 42	1	16246839-16352454	Predicted intracellular proteins	Evidence at protein level	HPA025071	Approved		Approved	Nucleoplasm	Liver cancer:3.72e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 29.9	Expressed in all		
MFAP3		ENSG00000037749	Microfibrillar associated protein 3	5	154038906-154220478	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015883, HPA049198	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Cervical cancer:4.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.8	Expressed in all		
MRI1	MGC3207, MRDI, mtnA, Ypr118w	ENSG00000037757	Methylthioribose-1-phosphate isomerase 1	19	13764532-13774282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042744, CAB045988	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			placenta: 23.1	Mixed		
METTL1	C12orf1, TRM8, TRMT8	ENSG00000037897	Methyltransferase like 1	12	57768471-57772793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020914, HPA050450	Uncertain		Enhanced	Nucleus	Renal cancer:3.55e-6 (unfavourable), Liver cancer:4.25e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 22.8	Cell line enriched	6	RH-30: 242.6
HOXC8	HOX3, HOX3A	ENSG00000037965	Homeobox C8	12	54009106-54012362	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028911, CAB037020	Uncertain		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.47e-5 (unfavourable)	Mixed	Tissue enhanced		epididymis: 21.1;smooth muscle: 12.6	adrenal gland: 7.7	Cell line enhanced		ASC diff: 33.3;fHDF/TERT166: 46.1;HSkMC: 28.1;LHCN-M2: 36.5
AGA	ASRG	ENSG00000038002	Aspartylglucosaminidase	4	177430770-177442503	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031415, HPA031417	Enhanced				Liver cancer:1.99e-4 (unfavourable), Head and neck cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 35.3	Expressed in all		
PI4K2B	FLJ11105, PI4KIIB, PIK42B	ENSG00000038210	Phosphatidylinositol 4-kinase type 2 beta	4	25233975-25279092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004099	Approved		Supported	Cytosol	Colorectal cancer:9.64e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 33.9	Expressed in all		
BOD1L1	BOD1L, FAM44A, FLJ33215, KIAA1327	ENSG00000038219	Biorientation of chromosomes in cell division 1 like 1	4	13568738-13627723	Predicted intracellular proteins	Evidence at protein level	HPA036943, HPA037362, HPA041290	Approved		Enhanced	Nucleoplasm	Renal cancer:3.48e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.3	Expressed in all		
MAT2B	MATIIbeta, SDR23E1	ENSG00000038274	Methionine adenosyltransferase 2B	5	163503114-163519336	Predicted intracellular proteins	Evidence at protein level	HPA037721, HPA037722	Uncertain				Renal cancer:4.51e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 133.5	Expressed in all		
TLL1		ENSG00000038295	Tolloid like 1	4	165873258-166103895	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060767			Approved	Vesicles		Mixed	Tissue enhanced		placenta: 10.5	gallbladder: 4.4	Cell line enhanced		HeLa: 4.3;Karpas-707: 7.1;PC-3: 3.3
EDC4	Ge-1, HEDLS, RCD-8	ENSG00000038358	Enhancer of mRNA decapping 4	16	67873023-67884503	Predicted intracellular proteins	Evidence at protein level	HPA041164, HPA043038	Supported		Enhanced	Nucleoplasm<br>Cytoplasmic bodies	Liver cancer:7.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
TRIO	ARHGEF23	ENSG00000038382	Trio Rho guanine nucleotide exchange factor	5	14143702-14532128	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008157, HPA064664	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:3.11e-5 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 47.2	Cell line enhanced		hTEC/SVTERT24-B: 190.1;U-87 MG: 248.3
VCAN	CSPG2, PG-M	ENSG00000038427	Versican	5	83471465-83582303	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004726, CAB008979	Enhanced		Supported	Vesicles	Stomach cancer:1.41e-4 (unfavourable), Renal cancer:5.17e-4 (unfavourable), Melanoma:7.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 105.5;placenta: 104.6	smooth muscle: 67.1	Cell line enhanced		AF22: 296.8;RPTEC TERT1: 288.7;U-2197: 156.9
CLEC16A	Gop-1, KIAA0350	ENSG00000038532	C-type lectin domain family 16 member A	16	10944488-11182189	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035814, HPA035815, HPA061385	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:2.92e-6 (favourable)	Expressed in all	Expressed in all			testis: 60.3	Expressed in all		
MSR1	CD204, SCARA1	ENSG00000038945	Macrophage scavenger receptor 1	8	16107878-16567490	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000272, CAB032491	Enhanced					Expressed in all	Tissue enhanced		lung: 187.7	gallbladder: 50.2	Group enriched	6	BJ hTERT+: 86.3;REH: 37.8
CDH1	CD324, UVO, uvomorulin	ENSG00000039068	Cadherin 1	16	68737225-68835548	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 475.1	thyroid gland: 266.2	Cell line enhanced		BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
SKIV2L2	Dob1, fSAP118, KIAA0052, Mtr4	ENSG00000039123	Ski2 like RNA helicase 2	5	55307760-55425581	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037379	Supported		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 37.1	Expressed in all		
DNAH5	CILD3, Dnahc5, HL1, KTGNR, PCD	ENSG00000039139	Dynein axonemal heavy chain 5	5	13690331-13944543	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037469, HPA037470	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 6.2;lung: 2.6	breast: 2.0	Cell line enhanced		BJ hTERT+: 1.3;PC-3: 2.5;RPTEC TERT1: 1.1
ZFYVE16	KIAA0305, PPP1R69	ENSG00000039319	Zinc finger FYVE-type containing 16	5	80408013-80479350	Predicted intracellular proteins	Evidence at protein level	HPA035935, HPA035936	Supported		Enhanced	Vesicles<br>Cytosol		Expressed in all	Mixed			cervix, uterine: 24.0	Expressed in all		
FAM65A	FLJ13725	ENSG00000039523	Family with sequence similarity 65 member A	16	67518418-67546788	Predicted intracellular proteins	Evidence at protein level	HPA005923	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:5.82e-8 (favourable), Lung cancer:5.00e-5 (unfavourable), Head and neck cancer:6.53e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 59.5	Expressed in all		
C6		ENSG00000039537	Complement C6	5	41142234-41261438	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA043823, CAB069427	Enhanced				Renal cancer:4.31e-4 (favourable)	Group enriched	Group enriched	9	fallopian tube: 73.5;liver: 358.3	heart muscle: 23.4	Group enriched	11	ASC diff: 3.2;ASC TERT1: 4.5;HSkMC: 12.3
RAI14	DKFZp564G013, KIAA1334, NORPEG, RAI13	ENSG00000039560	Retinoic acid induced 14	5	34656237-34832627	Predicted intracellular proteins	Evidence at protein level	HPA036949, HPA036950	Supported		Supported	Nucleus<br>Actin filaments<br>Cytosol	Stomach cancer:2.05e-4 (unfavourable), Renal cancer:9.75e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 92.0	Mixed		
SOX30		ENSG00000039600	SRY-box 30	5	157625679-157671480	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006159, CAB009382	Enhanced					Mixed	Tissue enriched	94	testis: 144.4	fallopian tube: 1.5	Cell line enhanced		A-431: 1.7;CACO-2: 1.0;HDLM-2: 3.8
PNKP	PNK	ENSG00000039650	Polynucleotide kinase 3'-phosphatase	19	49859882-49878351	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006782	Supported		Supported	Nucleus<br>Nucleoli	Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			spleen: 38.1	Expressed in all		
BEST2	FLJ20132, VMD2L1	ENSG00000039987	Bestrophin 2	19	12751702-12758458	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA046229	Approved					Tissue enhanced	Tissue enhanced		colon: 15.4;rectum: 14.8	tonsil: 4.5	Mixed		
PHLPP2	KIAA0931, PHLPPL, PPM3B	ENSG00000040199	PH domain and leucine rich repeat protein phosphatase 2	16	71637835-71724701	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048598	Approved		Approved	Vesicles		Expressed in all	Mixed			small intestine: 24.2	Expressed in all		
SPDL1	CCDC99, FLJ20364, hSpindly	ENSG00000040275	Spindle apparatus coiled-coil protein 1	5	169583634-169604778	Predicted intracellular proteins	Evidence at protein level	HPA044700, HPA048146	Enhanced		Approved	Cytosol	Liver cancer:1.48e-6 (unfavourable), Renal cancer:2.13e-6 (unfavourable), Pancreatic cancer:1.19e-5 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 60.9	lymph node: 16.4	Expressed in all		
STAU2	39K2	ENSG00000040341	Staufen double-stranded RNA binding protein 2	8	73420369-73747708	Predicted intracellular proteins	Evidence at protein level	HPA019155, CAB020836	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 74.0	Expressed in all		
PQLC2	FLJ20320	ENSG00000040487	PQ loop repeat containing 2	1	19312326-19329300	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057810	Approved		Enhanced	Vesicles	Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
CTNS	CTNS-LSB, PQLC4	ENSG00000040531	Cystinosin, lysosomal cystine transporter	17	3636468-3661542	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA046947			Supported	Vesicles<br>Intermediate filaments	Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
RTN4R	NOGOR	ENSG00000040608	Reticulon 4 receptor	22	20241415-20283246	Predicted membrane proteins	Evidence at protein level	CAB012443			Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Head and neck cancer:7.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 23.8	spleen: 5.0	Cell line enhanced		NB-4: 24.1;REH: 48.8;SCLC-21H: 36.8
PHF23	FLJ16355, MGC2941	ENSG00000040633	PHD finger protein 23	17	7235028-7239722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052410	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 41.7	Expressed in all		
CDH10		ENSG00000040731	Cadherin 10	5	24487100-24644978	Predicted membrane proteins	Evidence at protein level	HPA010651	Approved					Group enriched	Group enriched	20	cerebral cortex: 32.6;prostate: 7.5	adrenal gland: 1.0	Cell line enhanced		AF22: 7.0;HAP1: 4.8;U-138 MG: 1.5
INPP4A	INPP4	ENSG00000040933	Inositol polyphosphate-4-phosphatase type I A	2	98444854-98594390	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001628	Approved		Approved	Nucleus<br>Nuclear membrane	Endometrial cancer:3.70e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 38.7	Expressed in all		
RAB27B		ENSG00000041353	RAB27B, member RAS oncogene family	18	54717860-54895516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017712, HPA019849	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.13e-4 (unfavourable)	Mixed	Tissue enhanced		prostate: 31.7;stomach: 40.5	cerebral cortex: 24.3	Cell line enhanced		HEL: 54.6;U-87 MG: 154.0
PSMA4	HC9, HsT17706	ENSG00000041357	Proteasome subunit alpha 4	15	78540405-78552419	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004973, HPA055466, HPA060613	Supported		Enhanced	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:6.74e-10 (unfavourable)	Expressed in all	Expressed in all			testis: 174.1	Expressed in all		
MYO16	KIAA0865, Myo16b, MYR8, NYAP3, PPP1R107	ENSG00000041515	Myosin XVI	13	108596152-109208007	Predicted intracellular proteins	Evidence at protein level	HPA040110, HPA058769, HPA071948	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 2.1	testis: 1.0	Cell line enhanced		SH-SY5Y: 2.4;U-2197: 1.2
LSG1	FLJ11301	ENSG00000041802	Large 60S subunit nuclear export GTPase 1	3	194640788-194672477	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037704, HPA037705	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Liver cancer:3.21e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 24.8	Expressed in all		
PARP3	ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3	ENSG00000041880	Poly(ADP-ribose) polymerase family member 3	3	51942345-51948867	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA067657	Supported				Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 53.0	Expressed in all		
TNC	DFNA56, HXB, MGC167029, TN	ENSG00000041982	Tenascin C	9	115019578-115118257	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004592, HPA004823	Approved					Expressed in all	Tissue enhanced		appendix: 239.3;smooth muscle: 528.9	adipose tissue: 78.7	Cell line enhanced		BJ hTERT+: 628.6;hTEC/SVTERT24-B: 625.8;U-87 MG: 679.1;WM-115: 1198.9
THAP3		ENSG00000041988	THAP domain containing 3	1	6624866-6635586	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067114	Approved		Approved	Nucleus	Colorectal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 18.0	Expressed in all		
FAM65C	C20orf175, C20orf176, dJ530I15.2, dJ530I15.3	ENSG00000042062	Family with sequence similarity 65 member C	20	50586108-50691528	Predicted intracellular proteins	Evidence at protein level	HPA051823, HPA054759	Uncertain		Approved	Nucleoplasm	Head and neck cancer:1.66e-5 (favourable)	Mixed	Mixed			endometrium: 18.2	Cell line enhanced		ASC diff: 24.7;HEL: 50.2;HSkMC: 24.1;K-562: 29.7
TDP1	FLJ11090, SCAN1	ENSG00000042088	Tyrosyl-DNA phosphodiesterase 1	14	89954939-90044768	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071317			Supported	Nucleus<br>Plasma membrane	Liver cancer:8.99e-5 (unfavourable)	Expressed in all	Mixed			testis: 40.6	Expressed in all		
AIFM2	AMID, FLJ14497, PRG3	ENSG00000042286	Apoptosis inducing factor, mitochondria associated 2	10	70098223-70132934	Predicted intracellular proteins	Evidence at protein level	HPA028961, HPA042309	Approved		Approved	Cytosol	Endometrial cancer:2.80e-4 (favourable), Urothelial cancer:2.92e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 42.7	thyroid gland: 17.9	Cell line enhanced		Hep G2: 113.7
C2orf83	DKFZp547H025	ENSG00000042304	Chromosome 2 open reading frame 83	2	227610090-227633320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA030319	Approved					Not detected	Tissue enhanced		placenta: 2.9	testis: 0.9	Cell line enhanced		U-2197: 1.4
SPATA7	HSD3, LCA3	ENSG00000042317	Spermatogenesis associated 7	14	88384924-88470350	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038082, HPA038083	Enhanced		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.50e-5 (favourable), Pancreatic cancer:4.16e-5 (favourable)	Expressed in all	Tissue enriched	5	testis: 102.9	thyroid gland: 20.1	Mixed		
MED17	CRSP6, CRSP77, DRIP80, TRAP80	ENSG00000042429	Mediator complex subunit 17	11	93784227-93814963	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064236			Approved	Nucleoplasm<br>Vesicles	Liver cancer:4.04e-6 (unfavourable), Breast cancer:4.94e-4 (unfavourable)	Expressed in all	Mixed			spleen: 3.2	Mixed		
RETSAT	FLJ20296	ENSG00000042445	Retinol saturase	2	85342088-85354620	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007961, HPA046513	Uncertain		Approved	Nucleoli	Renal cancer:1.95e-10 (favourable), Liver cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 265.4	Expressed in all		
CAPG	AFCP, MCP	ENSG00000042493	Capping actin protein, gelsolin like	2	85394748-85418432	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018843, HPA019080, HPA019092	Enhanced		Enhanced	Nucleus	Liver cancer:3.22e-5 (unfavourable), Renal cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 238.0	Cell line enhanced		CAPAN-2: 560.8;HMC-1: 788.5;SK-MEL-30: 524.4
AP2S1	CLAPS2, FBH3, FBHOk, HHC3	ENSG00000042753	Adaptor related protein complex 2 sigma 1 subunit	19	46838136-46850992	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.48e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.5	Expressed in all		
USH2A	RP39, USH2	ENSG00000042781	Usherin	1	215622894-216423396	Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		liver: 3.6;testis: 1.0	epididymis: 0.7	Not detected		
ZPBP	SP38, ZPBP1	ENSG00000042813	Zona pellucida binding protein	7	49850421-50121329	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058673	Enhanced					Not detected	Tissue enriched	267	testis: 252.9	epididymis: 0.9	Not detected		
TG	AITD3, TGN	ENSG00000042832	Thyroglobulin	8	132866958-133134903	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000077, HPA002740, CAB056155	Enhanced					Tissue enriched	Tissue enriched	1104	thyroid gland: 15620.0	gallbladder: 14.1	Cell line enhanced		HDLM-2: 1.9;Karpas-707: 4.0;PC-3: 2.6
ADAM28	ADAM23, eMDCII, MDC-Lm, MDC-Ls	ENSG00000042980	ADAM metallopeptidase domain 28	8	24294040-24359018	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA074034	Enhanced		Approved	Plasma membrane<br>Mitochondria	Endometrial cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 435.5	stomach: 104.6	Cell line enriched	10	CAPAN-2: 24.6
BARX2		ENSG00000043039	BARX homeobox 2	11	129375940-129452279	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB033311, HPA068414	Enhanced		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:3.06e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 103.8;salivary gland: 60.3	fallopian tube: 28.0	Cell line enriched	5	HDLM-2: 158.6
DCUN1D1	DCUN1L1, RP42, SCCRO, SCRO, Tes3	ENSG00000043093	Defective in cullin neddylation 1 domain containing 1	3	182938074-182985953	Predicted intracellular proteins	Evidence at protein level	HPA035911	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enriched	13	testis: 391.8	thyroid gland: 29.4	Expressed in all		
JADE2	JADE-2, KIAA0239, PHF15	ENSG00000043143	Jade family PHD finger 2	5	134524312-134583230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025959, HPA055789	Uncertain		Enhanced	Nucleoplasm	Renal cancer:5.36e-6 (favourable), Ovarian cancer:4.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.6	Mixed		
ZIC2	HPE5	ENSG00000043355	Zic family member 2	13	99981772-99986773	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055031			Supported	Nuclear bodies	Cervical cancer:2.64e-4 (favourable), Liver cancer:2.91e-4 (unfavourable)	Mixed	Tissue enriched	6	cerebral cortex: 7.3	testis: 1.2	Cell line enhanced		AF22: 84.4;HEK 293: 60.2;NTERA-2: 79.9;SCLC-21H: 209.9
LCP2	SLP-76, SLP76	ENSG00000043462	Lymphocyte cytosolic protein 2	5	170246237-170298227	Predicted intracellular proteins	Evidence at protein level	CAB004574, HPA036396, HPA036397	Enhanced				Renal cancer:6.22e-5 (unfavourable), Endometrial cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			spleen: 125.5	Cell line enhanced		HEL: 149.4;HL-60: 137.8;HMC-1: 372.4;MOLT-4: 84.0;U-937: 87.8
TRIT1	FLJ20061, IPT	ENSG00000043514	TRNA isopentenyltransferase 1	1	39841022-39883511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024174	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.08e-8 (unfavourable), Liver cancer:5.34e-6 (unfavourable), Endometrial cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.1	Expressed in all		
ADRB1	ADRB1R	ENSG00000043591	Adrenoceptor beta 1	10	114044056-114046908	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067972	Enhanced					Tissue enriched	Tissue enhanced		placenta: 45.4	heart muscle: 10.8	Cell line enhanced		HDLM-2: 6.7;THP-1: 3.2;TIME: 5.0
GUCA2B		ENSG00000044012	Guanylate cyclase activator 2B	1	42153421-42155824	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 87.6;small intestine: 148.3	duodenum: 37.5	Group enriched	6	A549: 1.3;CACO-2: 3.2
CUL7	dJ20C7.5, KIAA0076	ENSG00000044090	Cullin 7	6	43037617-43053945	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015449, HPA030095, HPA030096	Approved				Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 26.3	Expressed in all		
CTNNA1	CAP102	ENSG00000044115	Catenin alpha 1	5	138610967-138935034	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021089, HPA046119, HPA063535	Approved		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:7.34e-7 (favourable), Pancreatic cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 217.1	Mixed		
PHKA2	PHK, PYK	ENSG00000044446	Phosphorylase kinase regulatory subunit alpha 2	X	18892300-18984598	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002912	Approved		Approved	Nucleoplasm	Liver cancer:1.25e-5 (unfavourable), Renal cancer:1.55e-5 (unfavourable), Urothelial cancer:2.96e-5 (favourable), Pancreatic cancer:7.68e-4 (favourable)	Expressed in all	Expressed in all			ovary: 18.5	Expressed in all		
CNTLN	bA340N12.1, C9orf101, C9orf39, FLJ20276	ENSG00000044459	Centlein	9	17134982-17503923	Predicted intracellular proteins	Evidence at protein level	HPA007201, HPA036728, HPA036729	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Mixed			endometrium: 11.8	Cell line enhanced		HEL: 31.6
EPHA3	ETK, ETK1, HEK, HEK4, TYRO4	ENSG00000044524	EPH receptor A3	3	89107524-89482134	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010462	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.28e-7 (unfavourable)	Mixed	Tissue enhanced		prostate: 51.9	gallbladder: 29.8	Cell line enriched	7	AF22: 192.5
HSPA5	BiP, GRP78	ENSG00000044574	Heat shock protein family A (Hsp70) member 5	9	125234853-125241330	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005221, HPA038845, HPA038846	Enhanced		Approved	Cytosol	Renal cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 968.4	Expressed in all		
DSG2	CDHF5	ENSG00000046604	Desmoglein 2	18	31498043-31549008	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004896, CAB025122	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 251.3	rectum: 106.9	Cell line enhanced		HaCaT: 233.0;hTERT-HME1: 159.3
GEMIN8	FAM51A1, FLJ20514	ENSG00000046647	Gem nuclear organelle associated protein 8	X	14008279-14029893	Predicted intracellular proteins	Evidence at protein level	HPA028613	Uncertain		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:7.73e-5 (favourable), Liver cancer:7.78e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 31.7	Expressed in all		
OFD1	71-7A, CXorf5, JBTS10, RP23	ENSG00000046651	OFD1, centriole and centriolar satellite protein	X	13734745-13769353	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031102, HPA031103, HPA031104	Approved		Supported	Microtubules	Urothelial cancer:2.76e-7 (favourable), Renal cancer:1.63e-4 (unfavourable), Cervical cancer:9.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.7	Expressed in all		
GPM6B	M6B, MGC17150, MGC54284	ENSG00000046653	Glycoprotein M6B	X	13771031-13938638	Predicted membrane proteins	Evidence at protein level	HPA002913	Approved				Ovarian cancer:2.67e-4 (favourable)	Group enriched	Tissue enriched	17	cerebral cortex: 835.8	seminal vesicle: 48.6	Cell line enhanced		AF22: 147.7;AN3-CA: 138.3;HSkMC: 79.6;SK-MEL-30: 117.9
MAGEC2	CT10, HCA587, MAGE-C2, MAGEE1	ENSG00000046774	MAGE family member C2	X	142202345-142205290	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA062230	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	369	testis: 36.8	all non-specific tissues: 0.0	Group enriched	7	K-562: 78.0;U-266/84: 69.6
PREX2	DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129	ENSG00000046889	Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	8	67952118-68237030	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015234, HPA075956	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.61e-7 (unfavourable)	Mixed	Mixed			cerebral cortex: 11.9	Cell line enhanced		AF22: 13.9;HUVEC TERT2: 16.1;NTERA-2: 12.2;RH-30: 5.3
WDR37	KIAA0982	ENSG00000047056	WD repeat domain 37	10	1049538-1132297	Predicted intracellular proteins	Evidence at protein level	HPA037376, HPA037565	Enhanced		Uncertain	Intermediate filaments<br>Centrosome<br>Cytosol	Pancreatic cancer:1.46e-6 (favourable), Thyroid cancer:1.34e-5 (unfavourable), Head and neck cancer:1.75e-5 (favourable)	Expressed in all	Expressed in all			testis: 36.4	Expressed in all		
YTHDC2	DKFZp564A186, FLJ10053, FLJ2194	ENSG00000047188	YTH domain containing 2	5	113513683-113595285	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037364, HPA072678	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytoplasmic bodies	Colorectal cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.0	Expressed in all		
CTPS2		ENSG00000047230	CTP synthase 2	X	16588003-16712936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017437	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.37e-5 (unfavourable), Urothelial cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Mixed		
ATP6V1H	CGI-11, SFD, SFDalpha, SFDbeta, VMA13	ENSG00000047249	ATPase H+ transporting V1 subunit H	8	53715557-53843558	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009532, HPA023421	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.46e-7 (favourable), Liver cancer:7.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.6	Expressed in all		
POLR2B	RPB2	ENSG00000047315	RNA polymerase II subunit B	4	56977722-57031168	Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037506	Supported		Supported	Nucleoplasm	Renal cancer:7.17e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.2	Expressed in all		
FAM214A	FLJ10980, KIAA1370	ENSG00000047346	Family with sequence similarity 214 member A	15	52581317-52709817	Predicted intracellular proteins	Evidence at protein level	HPA039369, HPA040180	Approved		Approved	Nucleoplasm	Endometrial cancer:7.27e-6 (favourable), Lung cancer:8.68e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.9	Expressed in all		
ARAP2	CENTD1, PARX	ENSG00000047365	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2	4	35948221-36244509	Predicted intracellular proteins	Evidence at protein level	HPA035925	Approved		Approved	Actin filaments<br>Focal adhesion sites		Expressed in all	Mixed			thyroid gland: 39.1	Mixed		
TPR		ENSG00000047410	Translocated promoter region, nuclear basket protein	1	186311652-186375693	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019661, HPA019663, HPA024336	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.06e-4 (unfavourable), Head and neck cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
CP		ENSG00000047457	Ceruloplasmin	3	149162410-149222055	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001834, CAB008591	Supported				Renal cancer:1.14e-7 (unfavourable)	Tissue enhanced	Tissue enriched	9	liver: 916.0	cervix, uterine: 99.1	Cell line enriched	12	EFO-21: 273.0
KIAA0556	JBTS26	ENSG00000047578	KIAA0556	16	27550133-27780369	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035089, HPA035090	Enhanced		Approved	Nuclear speckles<br>Plasma membrane	Head and neck cancer:3.00e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 47.6	thyroid gland: 26.7	Expressed in all		
DTNBP1	BLOC1S8, DBND, Dysbindin, HPS7, My031	ENSG00000047579	Dystrobrevin binding protein 1	6	15522801-15663058	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028053, HPA029615, HPA029616	Enhanced		Supported	Microtubules<br>Midbody	Lung cancer:6.34e-5 (favourable), Cervical cancer:2.82e-4 (favourable), Liver cancer:8.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 32.7	Expressed in all		
XK	Kx, NA, NAC, X1k, XKR1	ENSG00000047597	X-linked Kx blood group	X	37685759-37732130	Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019036	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria		Mixed	Mixed			rectum: 12.1	Cell line enhanced		HEL: 39.5;K-562: 25.8
ANO2	C12orf3, TMEM16B	ENSG00000047617	Anoctamin 2	12	5531869-5946232	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036276, HPA057499	Supported		Supported	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enhanced		testis: 17.8	placenta: 5.9	Cell line enhanced		BJ hTERT+: 7.8;HUVEC TERT2: 7.9;U-2 OS: 25.6
C12orf4		ENSG00000047621	Chromosome 12 open reading frame 4	12	4487728-4538508	Predicted intracellular proteins	Evidence at protein level	HPA037871	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			testis: 16.9	Expressed in all		
SCML1		ENSG00000047634	Sex comb on midleg-like 1 (Drosophila)	X	17737449-17754988	Predicted intracellular proteins	Evidence at protein level	HPA035270, HPA035271, HPA061397	Enhanced		Approved	Nucleus		Expressed in all	Expressed in all			testis: 54.2	Cell line enhanced		U-2197: 82.3
WWC3	BM042, KIAA1280	ENSG00000047644	WWC family member 3	X	10015562-10144478	Predicted intracellular proteins	Evidence at protein level	HPA039814	Uncertain		Approved	Actin filaments<br>Cytosol	Renal cancer:1.06e-5 (unfavourable), Colorectal cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 39.8	Cell line enhanced		T-47d: 129.2
ARHGAP6	rhoGAPX-1	ENSG00000047648	Rho GTPase activating protein 6	X	11137543-11665701	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036779, HPA064390	Enhanced				Renal cancer:1.55e-8 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 44.3;seminal vesicle: 43.3	thyroid gland: 42.4	Cell line enhanced		ASC TERT1: 23.8;HEL: 32.1;HMC-1: 21.3;HSkMC: 24.5;K-562: 23.6
FAM184B	KIAA1276	ENSG00000047662	Family with sequence similarity 184 member B	4	17629306-17781512	Predicted intracellular proteins	Evidence at protein level	HPA044119, HPA048458	Enhanced					Mixed	Group enriched	6	cerebral cortex: 2.6;skeletal muscle: 1.4	kidney,parathyroid gland,skin: 0.3	Cell line enhanced		SCLC-21H: 2.5
MAP4		ENSG00000047849	Microtubule associated protein 4	3	47850690-48089272	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038149, HPA038150	Enhanced		Supported	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 241.9	Expressed in all		
GOPC	CAL, dJ94G16.2, FIG, GOPC1, PIST	ENSG00000047932	Golgi associated PDZ and coiled-coil motif containing	6	117560269-117602542	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019477, HPA024018	Approved		Enhanced	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
ROS1	c-ros-1, MCF3, ROS	ENSG00000047936	ROS proto-oncogene 1, receptor tyrosine kinase	6	117288300-117425855	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049098, HPA072424	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	18	epididymis: 70.9;lung: 47.2	seminal vesicle: 3.2	Cell line enhanced		HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
USP28	KIAA1515	ENSG00000048028	Ubiquitin specific peptidase 28	11	113797874-113875570	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006778, HPA006779	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			heart muscle: 40.2	Expressed in all		
HDAC9	HD7, HDAC, HDAC7B, KIAA0744, MITR	ENSG00000048052	Histone deacetylase 9	7	18086949-19002416	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028926	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			spleen: 24.6	Cell line enhanced		HAP1: 176.1;SH-SY5Y: 71.2
TSPAN17	FBX23, FBXO23, TM4SF17	ENSG00000048140	Tetraspanin 17	5	176647387-176659054	Predicted membrane proteins	Evidence at transcript level	HPA030447			Approved	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 34.7	Expressed in all		
NOP16	HSPC111, HSPC185, LOC51491	ENSG00000048162	NOP16 nucleolar protein	5	176383938-176388975	Predicted intracellular proteins	Evidence at protein level	HPA036506, HPA058147	Approved		Enhanced	Nucleoli	Renal cancer:5.75e-6 (unfavourable), Liver cancer:5.14e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 26.1	Expressed in all		
CC2D2A	JBTS9, KIAA1345, MKS6	ENSG00000048342	Coiled-coil and C2 domain containing 2A	4	15469865-15601557	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044124	Approved				Renal cancer:3.42e-9 (favourable), Stomach cancer:4.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 53.9	kidney: 20.8	Mixed		
RRM2B	p53R2	ENSG00000048392	Ribonucleotide reductase regulatory TP53 inducible subunit M2B	8	102204502-102239118	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006854, HPA028812	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 75.1	Expressed in all		
ZNF800		ENSG00000048405	Zinc finger protein 800	7	127346790-127431924	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023090, HPA052194	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 47.9	Expressed in all		
TNFRSF17	BCM, BCMA, CD269, TNFRSF13A	ENSG00000048462	TNF receptor superfamily member 17	16	11965107-11968068	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:1.58e-6 (favourable), Breast cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 36.7	lymph node: 30.8	Group enriched	7	Karpas-707: 114.0;RPMI-8226: 179.8;U-266/70: 561.8;U-266/84: 274.9
SNX29	FLJ12363, RUNDC2A	ENSG00000048471	Sorting nexin 29	16	11976737-12574289	Predicted intracellular proteins	Evidence at protein level	HPA008889	Approved				Renal cancer:1.38e-7 (favourable), Urothelial cancer:1.03e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 39.7	Mixed		
LMO3	DAT1, RBTNL2, Rhom-3	ENSG00000048540	LIM domain only 3	12	16548373-16610594	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:1.10e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 190.9	thyroid gland: 67.7	Group enriched	6	ASC diff: 157.0;LHCN-M2: 88.8
MRPS10	FLJ10567	ENSG00000048544	Mitochondrial ribosomal protein S10	6	42206801-42217865	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029133, HPA029134	Enhanced		Approved	Actin filaments<br>Mitochondria		Expressed in all	Expressed in all			esophagus: 41.8	Expressed in all		
GUCA1A	C6orf131, COD3, CORD14, dJ139D8.6, GCAP, GCAP1, GUCA, GUCA1	ENSG00000048545	Guanylate cyclase activator 1A	6	42155406-42180056	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005561	Supported	Approved	Uncertain	Plasma membrane		Tissue enriched	Tissue enriched	19	testis: 30.0	cerebral cortex: 1.5	Group enriched	8	NTERA-2: 3.6;SH-SY5Y: 4.7
RSF1	HBXAP, p325, RSF-1, XAP8	ENSG00000048649	Remodeling and spacing factor 1	11	77659996-77821017	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022626, HPA046129, HPA057547, HPA064567	Enhanced		Enhanced	Nucleoplasm	Pancreatic cancer:1.61e-4 (unfavourable), Renal cancer:5.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.2	Expressed in all		
VPS13D	FLJ10619, KIAA0453	ENSG00000048707	Vacuolar protein sorting 13 homolog D	1	12230067-12512047	Predicted intracellular proteins	Evidence at protein level	HPA027332, HPA051621	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:7.42e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
CELF2	BRUNOL3, CUGBP2, Etr-3, NAPOR-2	ENSG00000048740	CUGBP Elav-like family member 2	10	10798397-11336675	Predicted intracellular proteins	Evidence at protein level	CAB016395, HPA035813, HPA065098	Enhanced		Uncertain	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Head and neck cancer:7.61e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 77.8	Cell line enhanced		HEL: 179.2;HMC-1: 163.9
FAM120A	C9orf10, KIAA0183, OSSA	ENSG00000048828	Family with sequence similarity 120A	9	93451722-93566107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019734, HPA055800	Approved		Enhanced	Cytosol	Renal cancer:1.08e-7 (favourable), Endometrial cancer:5.03e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
R3HDM1	KIAA0029, R3HDM	ENSG00000048991	R3H domain containing 1	2	135531455-135725270	Predicted intracellular proteins	Evidence at protein level	HPA030936			Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.83e-7 (unfavourable), Lung cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 82.3	Expressed in all		
COL9A2	EDM2, MED	ENSG00000049089	Collagen type IX alpha 2 chain	1	40300487-40317816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056316, HPA075286	Approved		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 53.4	seminal vesicle: 32.4	Cell line enhanced		HDLM-2: 91.5;HMC-1: 79.4;THP-1: 69.5
KITLG	FPH2, Kitl, KL-1, MGF, SCF, SF	ENSG00000049130	KIT ligand	12	88492793-88580851	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA070395	Approved		Approved	Vesicles	Renal cancer:5.81e-7 (favourable), Liver cancer:4.01e-4 (unfavourable)	Expressed in all	Mixed			lung: 23.5	Cell line enhanced		CACO-2: 199.5
ERCC8	CKN1, CSA	ENSG00000049167	ERCC excision repair 8, CSA ubiquitin ligase complex subunit	5	60873831-60945073	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029328			Approved	Nuclear speckles		Expressed in all	Mixed			testis: 12.9	Expressed in all		
ADAMTS6	ADAM-TS6	ENSG00000049192	ADAM metallopeptidase with thrombospondin type 1 motif 6	5	65148736-65481920	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA043441	Enhanced					Mixed	Tissue enhanced		placenta: 2.7	gallbladder: 2.3	Cell line enhanced		HBF TERT88: 13.0;hTEC/SVTERT24-B: 12.5;TIME: 11.8;U-2197: 15.1
H6PD	GDH	ENSG00000049239	Hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase	1	9234775-9271337	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA004824, HPA005440	Approved		Uncertain	Cytosol		Expressed in all	Expressed in all			ovary: 42.8	Mixed		
VAMP3	CEB	ENSG00000049245	Vesicle associated membrane protein 3	1	7771269-7781432	Cancer-related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			lung: 135.3	Expressed in all		
PER3		ENSG00000049246	Period circadian clock 3	1	7784320-7845177	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019530	Approved		Uncertain	Cytosol	Renal cancer:2.20e-5 (favourable), Head and neck cancer:1.34e-4 (favourable), Cervical cancer:7.14e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 39.2	Mixed		
UTS2	PRO1068, U-II, UCN2, UII	ENSG00000049247	Urotensin 2	1	7843083-7853512	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017000	Uncertain					Mixed	Tissue enhanced		adrenal gland: 3.9	bone marrow,lymph node: 1.9	Group enriched	17	CACO-2: 17.2;HEL: 6.6;HMC-1: 5.3;THP-1: 17.9
TNFRSF9	4-1BB, CD137, ILA	ENSG00000049249	TNF receptor superfamily member 9	1	7915894-7943165	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA071425			Approved	Nucleoli<br>Plasma membrane	Renal cancer:2.69e-8 (unfavourable)	Mixed	Tissue enhanced		lymph node: 11.1;tonsil: 7.0	appendix: 5.2	Cell line enriched	8	HDLM-2: 92.4
EPN3	FLJ20778, MGC129899	ENSG00000049283	Epsin 3	17	50532543-50543750	Predicted intracellular proteins	Evidence at protein level	HPA055546, HPA063224	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.53e-5 (favourable)	Mixed	Mixed			stomach: 27.5	Cell line enhanced		HaCaT: 24.3;HBEC3-KT: 27.4;MCF7: 48.0;RT4: 38.6;T-47d: 51.4
LTBP1		ENSG00000049323	Latent transforming growth factor beta binding protein 1	2	32946972-33399509	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005707, CAB025428	Approved		Approved	Cytosol	Renal cancer:7.79e-6 (unfavourable), Urothelial cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 261.1	Cell line enhanced		ASC TERT1: 399.0;U-87 MG: 250.3
RCN1	FLJ37041, PIG20, Rcal, RCN	ENSG00000049449	Reticulocalbin 1	11	31812391-32105755	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038474, HPA062104	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:2.70e-13 (unfavourable), Lung cancer:7.13e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 470.5	Mixed		
ELN	SVAS, WBS, WS	ENSG00000049540	Elastin	7	74027789-74069907	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010750, HPA018111, HPA056941	Supported		Approved	Plasma membrane	Thyroid cancer:6.29e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 125.8	Cell line enhanced		BJ: 121.3;fHDF/TERT166: 160.9;U-2197: 748.2
RFC2	A1, RFC40	ENSG00000049541	Replication factor C subunit 2	7	74231499-74254458	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029493	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.09e-7 (unfavourable), Liver cancer:6.35e-4 (unfavourable), Cervical cancer:9.91e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 28.1	Expressed in all		
ARID1B	6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R	ENSG00000049618	AT-rich interaction domain 1B	6	156777374-157210779	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016511, HPA075291	Approved		Supported	Nucleoplasm	Breast cancer:1.04e-4 (unfavourable), Ovarian cancer:4.16e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 71.2	Expressed in all		
CLPTM1L	CRR9, FLJ14400	ENSG00000049656	CLPTM1 like	5	1317744-1345099	Predicted membrane proteins	Evidence at protein level	HPA014791	Approved		Approved	Endoplasmic reticulum	Liver cancer:3.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 54.1	Expressed in all		
NEDD4L	KIAA0439, NEDD4-2, RSP5	ENSG00000049759	Neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin protein ligase	18	58044367-58401540	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024618, HPA064730	Approved		Approved	Focal adhesion sites	Renal cancer:6.55e-15 (favourable)	Expressed in all	Expressed in all			prostate: 71.5	Mixed		
FOXP3	AIID, DIETER, IPEX, JM2, PIDX, SCURFIN, XPID	ENSG00000049768	Forkhead box P3	X	49250436-49264826	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026301, HPA045943	Enhanced		Supported	Nucleoplasm	Cervical cancer:1.91e-4 (favourable), Head and neck cancer:4.90e-4 (favourable), Endometrial cancer:7.02e-4 (favourable)	Mixed	Tissue enhanced		appendix: 8.7	lymph node: 6.0	Cell line enhanced		MCF7: 2.8;SiHa: 2.3
PPP1R3F	Hb2E	ENSG00000049769	Protein phosphatase 1 regulatory subunit 3F	X	49269843-49301461	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000244, HPA000918	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.85e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 26.8	epididymis: 14.6	Mixed		
HEXB		ENSG00000049860	Hexosaminidase subunit beta	5	74640023-74722647	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055409, HPA056010	Enhanced				Liver cancer:3.36e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 440.8	Mixed		
PTCD2	FLJ12598	ENSG00000049883	Pentatricopeptide repeat domain 2	5	72320367-72368395	Predicted intracellular proteins	Evidence at protein level	HPA043686	Approved					Expressed in all	Mixed			parathyroid gland: 6.9	Expressed in all		
KIAA2022	KIDLIA, MRX98, XPN	ENSG00000050030	KIAA2022	X	74732849-74925485	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA000407	Uncertain		Uncertain	Nucleoplasm<br>Midbody		Mixed	Tissue enhanced		cerebral cortex: 5.4;parathyroid gland: 5.3	prostate: 1.9	Group enriched	6	HAP1: 5.0;Karpas-707: 5.9;SiHa: 6.2
JKAMP	C14orf100, CDA06, HSPC213, HSPC327, JAMP	ENSG00000050130	JNK1/MAPK8-associated membrane protein	14	59484443-59505410	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA031172, HPA071650	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.2	Expressed in all		
DKK3	REIC, RIG	ENSG00000050165	Dickkopf WNT signaling pathway inhibitor 3	11	11963106-12009769	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011868, CAB024949	Approved		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 373.5;heart muscle: 805.5	cervix, uterine: 138.8	Cell line enhanced		BJ: 355.1;BJ hTERT+: 524.6;fHDF/TERT166: 475.8;TIME: 285.3
ARHGEF5	GEF5, P60, TIM, TIM1	ENSG00000050327	Rho guanine nucleotide exchange factor 5	7	144355288-144380632	Predicted intracellular proteins	Evidence at protein level	HPA020980, HPA029504, HPA044188, HPA045619, HPA045699	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.28e-7 (favourable)	Mixed	Mixed			thyroid gland: 42.8	Cell line enhanced		A-431: 46.6
NFE2L3	Nrf3	ENSG00000050344	Nuclear factor, erythroid 2 like 3	7	26152240-26187125	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA055889	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.58e-12 (unfavourable), Pancreatic cancer:6.62e-5 (unfavourable), Stomach cancer:2.14e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 50.3	appendix: 14.3	Cell line enhanced		BEWO: 132.0;NTERA-2: 115.5
MCUR1	C6orf79, CCDC90A, FLJ20958	ENSG00000050393	Mitochondrial calcium uniporter regulator 1	6	13786557-13814568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.32e-4 (favourable), Ovarian cancer:5.51e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.9	Expressed in all		
LIMA1	EPLIN	ENSG00000050405	LIM domain and actin binding 1	12	50175788-50283546	Predicted intracellular proteins	Evidence at protein level	HPA023871, HPA052645	Enhanced		Enhanced	Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol	Head and neck cancer:1.76e-6 (unfavourable), Renal cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			rectum: 143.8	Expressed in all		
LETMD1	HCCR, HCCR-1, HCCR-2, HCCR1, HCCR2	ENSG00000050426	LETM1 domain containing 1	12	51047962-51060424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074361			Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:3.16e-4 (favourable), Renal cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 61.7	Expressed in all		
SLC4A8	NBC3	ENSG00000050438	Solute carrier family 4 member 8	12	51391317-51515763	Predicted membrane proteins	Evidence at protein level	HPA031536			Uncertain	Actin filaments		Group enriched	Tissue enhanced		cerebral cortex: 14.5;testis: 15.4	ovary: 4.2	Cell line enhanced		BEWO: 20.3;SCLC-21H: 18.5
LAMC3	DKFZp434E202	ENSG00000050555	Laminin subunit gamma 3	9	131009082-131094473	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022814	Enhanced					Mixed	Tissue enhanced		placenta: 88.7	testis: 26.1	Cell line enhanced		AF22: 5.3;EFO-21: 19.9;Hep G2: 5.5;SiHa: 8.5;U-2 OS: 6.9
PTGER3	EP3	ENSG00000050628	Prostaglandin E receptor 3	1	70852353-71047808	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA010689	Uncertain				Renal cancer:3.50e-4 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 58.6;endometrium: 115.3;kidney: 88.3;smooth muscle: 105.2	skin: 13.9	Group enriched	5	ASC diff: 19.6;HAP1: 21.6;HDLM-2: 30.4;HEL: 14.0;T-47d: 68.0
TNIP3	ABIN-3, FLJ21162, LIND	ENSG00000050730	TNFAIP3 interacting protein 3	4	121131408-121227466	Predicted intracellular proteins	Evidence at protein level	HPA043063	Uncertain					Mixed	Tissue enhanced		appendix: 8.8	lymph node,tonsil: 2.9	Cell line enhanced		HDLM-2: 6.8;hTEC/SVTERT24-B: 8.0;U-138 MG: 30.3;U-266/70: 6.7;U-266/84: 6.5
MAPK9	JNK2, p54a, PRKM9, SAPK	ENSG00000050748	Mitogen-activated protein kinase 9	5	180233143-180292099	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB008910	Approved				Colorectal cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
COL23A1	DKFZp434K0621	ENSG00000050767	Collagen type XXIII alpha 1 chain	5	178237618-178590555	Predicted intracellular proteins	Evidence at protein level	HPA067824	Uncertain				Endometrial cancer:6.46e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 57.8	seminal vesicle: 16.2	Group enriched	8	AF22: 5.7;K-562: 10.8;NB-4: 20.8;THP-1: 22.5
BCAR1	CAS, CASS1, Crkas, P130Cas	ENSG00000050820	BCAR1, Cas family scaffolding protein	16	75228187-75268053	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000443, HPA042282	Approved	Supported	Approved	Plasma membrane<br>Cytosol	Renal cancer:4.55e-8 (favourable), Liver cancer:9.11e-5 (unfavourable), Lung cancer:1.24e-4 (unfavourable)	Expressed in all	Mixed			spleen: 41.0	Mixed		
FAM160A2	C11orf56, DKFZP566M1046, FHIP, FLJ22665, KIAA1759	ENSG00000051009	Family with sequence similarity 160 member A2	11	6211335-6234711	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055994, HPA063987	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 42.0	Expressed in all		
HERPUD1	HERP, KIAA0025, Mif1, SUP	ENSG00000051108	Homocysteine inducible ER protein with ubiquitin like domain 1	16	56932048-56944863	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037041, CAB037104, HPA040754, HPA041219	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.41e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 358.8	Expressed in all		
HOMER3	HOMER-3	ENSG00000051128	Homer scaffolding protein 3	19	18929201-18941261	Predicted intracellular proteins	Evidence at protein level	CAB032656, HPA040999, CAB079015	Enhanced	Supported	Supported	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Colorectal cancer:4.24e-5 (unfavourable), Liver cancer:4.93e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 150.5	Mixed		
RAD51	BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA	ENSG00000051180	RAD51 recombinase	15	40694774-40732339	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010381, HPA039310	Enhanced		Enhanced	Nucleoli<br>Mitochondria<br>Cytosol	Breast cancer:7.94e-4 (unfavourable), Liver cancer:9.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 45.4	lymph node: 13.0	Mixed		
POLQ	POLH	ENSG00000051341	DNA polymerase theta	3	121431427-121546641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048931, HPA053359			Uncertain	Nucleus<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.46e-5 (unfavourable), Stomach cancer:1.04e-4 (favourable)	Mixed	Mixed			testis: 4.0	Mixed		
PIK3CB	PIK3C1	ENSG00000051382	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta	3	138652699-138834938	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB031938, HPA064207	Approved		Approved	Nucleoplasm<br>Nucleoli<br>Midbody	Pancreatic cancer:3.99e-5 (unfavourable), Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 88.9	Expressed in all		
CYBA	p22-PHOX	ENSG00000051523	Cytochrome b-245 alpha chain	16	88643283-88651152	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009492	Enhanced				Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 466.1	Cell line enhanced		RPMI-8226: 1035.0
THOC3	MGC5469, TEX1	ENSG00000051596	THO complex 3	5	175917873-176034680	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042764, HPA044009, HPA045071	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			epididymis: 77.2	Expressed in all		
HEBP2	C6orf34, SOUL	ENSG00000051620	Heme binding protein 2	6	138403531-138422197	Predicted intracellular proteins	Evidence at protein level	HPA016928	Approved				Renal cancer:2.47e-5 (unfavourable), Urothelial cancer:3.07e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 114.1	Cell line enhanced		THP-1: 147.3
MPHOSPH9	MPP9	ENSG00000051825	M-phase phosphoprotein 9	12	123152320-123244014	Predicted intracellular proteins	Evidence at protein level	HPA037485	Approved		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 22.7	Expressed in all		
PLEKHA5	FLJ10667, KIAA1686, PEPP2	ENSG00000052126	Pleckstrin homology domain containing A5	12	19129752-19376400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035923, HPA035924, HPA041455	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.41e-5 (unfavourable), Renal cancer:7.42e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 55.1	Cell line enhanced		HDLM-2: 61.6;NTERA-2: 64.9
PRSS8		ENSG00000052344	Protease, serine 8	16	31131433-31135762	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030436, HPA063533	Uncertain		Uncertain	Cytosol	Renal cancer:2.05e-10 (favourable)	Mixed	Mixed			small intestine: 164.8	Cell line enhanced		BEWO: 230.2;CACO-2: 133.7;CAPAN-2: 96.1;hTCEpi: 111.3;SK-BR-3: 136.6
SIKE1	FLJ21168, SIKE	ENSG00000052723	Suppressor of IKBKE 1	1	114769479-114780685	Predicted intracellular proteins	Evidence at protein level	HPA024177, HPA025726	Supported		Approved	Vesicles<br>Focal adhesion sites		Expressed in all	Expressed in all			thyroid gland: 19.4	Expressed in all		
RRP12	KIAA0690	ENSG00000052749	Ribosomal RNA processing 12 homolog	10	97356358-97426076	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049945			Supported	Nucleoli	Liver cancer:3.12e-8 (unfavourable), Renal cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 58.2	Expressed in all		
FNIP2	FNIPL, KIAA1450, MAPO1	ENSG00000052795	Folliculin interacting protein 2	4	158769138-158908049	Predicted intracellular proteins	Evidence at protein level	HPA042779, HPA072420	Approved				Renal cancer:3.96e-11 (favourable)	Expressed in all	Expressed in all			kidney: 51.2	Cell line enhanced		HDLM-2: 167.0
MSMO1	DESP4, ERG25, SC4MOL	ENSG00000052802	Methylsterol monooxygenase 1	4	165327623-165343160	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056127	Approved				Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable)	Expressed in all	Expressed in all			liver: 297.1	Expressed in all		
TTC17	FLJ10890	ENSG00000052841	Tetratricopeptide repeat domain 17	11	43358932-43494933	Predicted intracellular proteins	Evidence at protein level	HPA038508	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.75e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.8	Expressed in all		
ALX4	FPP, KIAA1788, PFM, PFM2	ENSG00000052850	ALX homeobox 4	11	44260444-44310166	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001903			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		breast: 2.2	endometrium,testis: 1.0	Cell line enhanced		AN3-CA: 3.7;BJ: 2.8;HAP1: 4.8;HEK 293: 4.4;HEL: 6.0;K-562: 2.8;SiHa: 7.4
FSTL4	KIAA1061	ENSG00000053108	Follistatin like 4	5	133196455-133612564	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045920	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 9.5	urinary bladder: 7.3	Cell line enhanced		SCLC-21H: 66.8
FOXN3	C14orf116, CHES1	ENSG00000053254	Forkhead box N3	14	89124871-89619149	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059209	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:9.58e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 111.0	Mixed		
METTL24	C6orf186, dJ71D21.2	ENSG00000053328	Methyltransferase like 24	6	110245928-110358272	Predicted secreted proteins	Evidence at transcript level	HPA037441, HPA037442	Uncertain					Mixed	Tissue enhanced		smooth muscle: 20.5	endometrium: 12.7	Cell line enhanced		SCLC-21H: 1.8;SH-SY5Y: 1.0
AKR7A2	AFAR	ENSG00000053371	Aldo-keto reductase family 7 member A2	1	19303965-19312146	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032587, CAB032841, HPA064638	Enhanced		Supported	Cytosol	Renal cancer:2.67e-4 (favourable), Urothelial cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 81.9	Expressed in all		
MRTO4	C1orf33, dJ657E11.4, MRT4	ENSG00000053372	MRT4 homolog, ribosome maturation factor	1	19251539-19260128	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA026446	Approved		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.56e-8 (unfavourable), Renal cancer:4.11e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 25.7	Expressed in all		
NNAT	Peg5	ENSG00000053438	Neuronatin	20	37521215-37523693	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	5	cerebral cortex: 157.6;placenta: 147.3	adipose tissue: 27.9	Cell line enriched	28	SH-SY5Y: 735.9
USE1	D12, MDS032, p31, SLT1	ENSG00000053501	Unconventional SNARE in the ER 1	19	17215346-17219829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026851, HPA047562	Approved				Renal cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.9	Expressed in all		
MCF2L2	ARHGEF22, KIAA0861	ENSG00000053524	MCF.2 cell line derived transforming sequence-like 2	3	183178043-183428778	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA038946, HPA038947	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	8	adrenal gland: 10.2;cerebral cortex: 17.2;parathyroid gland: 7.7;spleen: 3.5;testis: 4.7	prostate: 1.0	Cell line enhanced		HDLM-2: 5.5;Karpas-707: 3.6;REH: 3.1
NRIP2	DKFZP761G1913	ENSG00000053702	Nuclear receptor interacting protein 2	12	2825348-2835544	Predicted intracellular proteins	Evidence at protein level	HPA039197, HPA039860	Enhanced		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Pancreatic cancer:8.69e-5 (favourable), Colorectal cancer:8.05e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 12.4	Mixed		
LAMA3	BM600-150kDa, epiligrin, kalinin-165kDa, LAMNA, nicein-150kDa	ENSG00000053747	Laminin subunit alpha 3	18	23689443-23955066	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009309, CAB010757	Uncertain		Enhanced	Endoplasmic reticulum	Pancreatic cancer:3.58e-6 (unfavourable)	Mixed	Mixed			placenta: 30.7	Cell line enhanced		CAPAN-2: 122.4;HaCaT: 195.1;HBEC3-KT: 770.3
AP5M1	C14orf108, FLJ10813, mu5, MuD, MUDENG	ENSG00000053770	Adaptor related protein complex 5 mu 1 subunit	14	57268909-57298742	Predicted intracellular proteins	Evidence at protein level	HPA055768, HPA057098	Approved				Renal cancer:1.11e-14 (favourable), Colorectal cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 43.3	Expressed in all		
ANAPC4	APC4	ENSG00000053900	Anaphase promoting complex subunit 4	4	25377213-25418498	Predicted intracellular proteins	Evidence at protein level	CAB032519, HPA038395, HPA038396	Approved		Approved	Intermediate filaments	Endometrial cancer:5.73e-7 (favourable), Urothelial cancer:1.12e-6 (favourable), Renal cancer:1.17e-5 (unfavourable), Head and neck cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 55.2	Expressed in all		
KCNQ1	JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1	ENSG00000053918	Potassium voltage-gated channel subfamily Q member 1	11	2444684-2849109	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB018656, HPA048553	Enhanced				Stomach cancer:9.85e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 133.6;thyroid gland: 102.7	seminal vesicle: 60.6	Cell line enhanced		HMC-1: 25.7;RPMI-8226: 14.2;U-266/70: 8.9;U-937: 8.8
TRAPPC3	BET3	ENSG00000054116	Trafficking protein particle complex 3	1	36136570-36156053	Predicted intracellular proteins	Evidence at protein level	HPA028408	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:2.70e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 102.1	Expressed in all		
THRAP3	TRAP150	ENSG00000054118	Thyroid hormone receptor associated protein 3	1	36224416-36305357	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012041, CAB017472, HPA063765	Supported		Enhanced	Nuclear speckles	Stomach cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 99.0	Expressed in all		
PHPT1	bA216L13.10, CGI-202, DKFZp564M173, HSPC141, PHP14	ENSG00000054148	Phosphohistidine phosphatase 1	9	136848724-136851027	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013584, HPA020952	Approved		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 73.8	Expressed in all		
ENTPD2	CD39L1, NTPDase-2	ENSG00000054179	Ectonucleoside triphosphate diphosphohydrolase 2	9	137048098-137054045	Predicted membrane proteins	Evidence at protein level	HPA017676	Approved				Renal cancer:3.51e-6 (favourable), Liver cancer:2.48e-5 (unfavourable), Stomach cancer:1.38e-4 (favourable)	Expressed in all	Mixed			duodenum: 12.2	Cell line enhanced		Hep G2: 16.3;hTCEpi: 9.2;MCF7: 12.8;SK-BR-3: 16.1;T-47d: 22.0
LY75	CD205, CLEC13B, DEC-205	ENSG00000054219	Lymphocyte antigen 75	2	159803355-159904749	CD markers, Predicted membrane proteins	Evidence at protein level	CAB001450, HPA049108, HPA054073	Enhanced		Approved	Golgi apparatus	Renal cancer:2.39e-5 (unfavourable), Urothelial cancer:3.86e-4 (favourable)	Mixed	Mixed			lymph node: 35.5	Cell line enhanced		CAPAN-2: 19.4;HDLM-2: 19.8;Karpas-707: 62.7;RT4: 24.1
ARID4B	BCAA, BRCAA1, RBP1L1, SAP180	ENSG00000054267	AT-rich interaction domain 4B	1	235131634-235328219	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027333, HPA053692	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
OPN3	ECPN, encephalopsin, ERO, NMO-1, PPP1R116	ENSG00000054277	Opsin 3	1	241590102-241677376	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB013682, HPA064443	Uncertain		Approved	Nucleoplasm	Cervical cancer:3.17e-5 (unfavourable), Glioma:2.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 26.9	lung: 12.8	Cell line enhanced		ASC TERT1: 51.2
SDCCAG8	BBS16, CCCAP, NPHP10, NY-CO-8, SLSN7	ENSG00000054282	Serologically defined colon cancer antigen 8	1	243256034-243500092	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025737, HPA044477, HPA072495	Approved		Enhanced	Centrosome		Expressed in all	Expressed in all			thyroid gland: 24.2	Cell line enhanced		WM-115: 31.8
PTPRN	IA-2	ENSG00000054356	Protein tyrosine phosphatase, receptor type N	2	219289623-219309648	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007152, HPA007179	Enhanced		Approved	Endoplasmic reticulum	Glioma:2.45e-7 (unfavourable)	Group enriched	Tissue enriched	5	cerebral cortex: 183.1	adrenal gland: 35.0	Group enriched	8	U-2 OS: 70.1;U-87 MG: 244.6
HHAT	FLJ10724, GUP2, MART-2, MART2, rasp, sit, ski, Skn	ENSG00000054392	Hedgehog acyltransferase	1	210328252-210676296	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016462	Approved		Approved	Golgi apparatus	Renal cancer:8.47e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 7.8	Cell line enhanced		HMC-1: 11.9;RH-30: 12.0
KIF1B	CMT2, CMT2A, HMSNII, KIAA0591, KLP	ENSG00000054523	Kinesin family member 1B	1	10210805-10381603	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015177	Approved		Uncertain	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.91e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.4	Expressed in all		
FOXC1	ARA, FKHL7, FREAC3, IGDA, IHG1, IRID1	ENSG00000054598	Forkhead box C1	6	1609972-1613897	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040670	Enhanced		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:3.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 66.2	kidney: 21.8	Cell line enhanced		AN3-CA: 86.7;HEK 293: 85.3
TBC1D22A	C22orf4	ENSG00000054611	TBC1 domain family member 22A	22	46762617-47175699	Predicted intracellular proteins	Evidence at protein level	HPA001173	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:2.42e-4 (unfavourable), Ovarian cancer:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.1	Expressed in all		
SYNE2	DKFZP434H2235, KIAA1011, Nesp2, Nesprin-2, NUA, NUANCE, SYNE-2	ENSG00000054654	Spectrin repeat containing nuclear envelope protein 2	14	63852983-64226433	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003435, HPA050204	Enhanced		Enhanced	Nuclear membrane	Renal cancer:3.56e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 197.1	Cell line enhanced		Daudi: 72.6
PLEKHH1	KIAA1200	ENSG00000054690	Pleckstrin homology, MyTH4 and FERM domain containing H1	14	67533301-67589612	Predicted intracellular proteins	Evidence at protein level	HPA047707, HPA051964	Uncertain		Approved	Centrosome	Renal cancer:4.03e-7 (favourable), Endometrial cancer:8.03e-5 (favourable), Urothelial cancer:2.26e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 43.3;thyroid gland: 51.2	prostate: 16.7	Cell line enhanced		AN3-CA: 9.4;BEWO: 9.4;SK-MEL-30: 9.8;T-47d: 9.1
ATP9A	ATPIIA, KIAA0611	ENSG00000054793	ATPase phospholipid transporting 9A (putative)	20	51596514-51768634	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	CAB020699, HPA035630	Approved				Renal cancer:5.67e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 155.8	Mixed		
SPO11	CT35, SPATA43, TOPVIA	ENSG00000054796	SPO11, initiator of meiotic double stranded breaks	20	57329759-57343994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	154	testis: 15.3	all non-specific tissues: 0.0	Not detected		
CBLN4	CBLNL1, dJ885A10.1	ENSG00000054803	Cerebellin 4 precursor	20	55997440-56005472	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051496, HPA074497		Supported	Approved	Midbody ring		Mixed	Tissue enhanced		adrenal gland: 24.5;cerebral cortex: 15.6;epididymis: 11.2	fallopian tube: 6.8	Cell line enriched	51	SH-SY5Y: 10.2
CHRDL2	BNF1	ENSG00000054938	Chordin like 2	11	74696429-74731385	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021771	Uncertain		Uncertain	Mitochondria	Urothelial cancer:6.08e-4 (unfavourable)	Tissue enhanced	Group enriched	9	appendix: 157.7;endometrium: 128.3;gallbladder: 168.5;smooth muscle: 183.1;urinary bladder: 43.5	cervix, uterine: 14.6	Cell line enhanced		HeLa: 1.6;PC-3: 1.2;SiHa: 2.6
FAM168A	KIAA0280, TCRP1	ENSG00000054965	Family with sequence similarity 168 member A	11	73400487-73598189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037580	Approved		Approved	Nucleoplasm	Renal cancer:6.41e-5 (favourable), Endometrial cancer:5.51e-4 (unfavourable), Urothelial cancer:9.70e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 104.4	Expressed in all		
RELT	FLJ14993, TNFRSF19L	ENSG00000054967	RELT tumor necrosis factor receptor	11	73376264-73397474	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062824, HPA071518			Supported	Nucleus	Renal cancer:4.07e-11 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 95.8	spleen: 17.2	Mixed		
GALC		ENSG00000054983	Galactosylceramidase	14	87837820-87993665	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB022196	Approved					Expressed in all	Expressed in all			testis: 44.0	Cell line enhanced		CAPAN-2: 72.3;HMC-1: 67.2
NOP58	HSPC120, NOP5	ENSG00000055044	NOP58 ribonucleoprotein	2	202265716-202303666	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018472, HPA021062	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:3.38e-9 (unfavourable), Liver cancer:1.97e-6 (unfavourable), Ovarian cancer:9.86e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 69.3	Expressed in all		
SZRD1	C1orf144, DKFZp566C0424	ENSG00000055070	SUZ RNA binding domain containing 1	1	16352575-16398145	Predicted intracellular proteins	Evidence at protein level	HPA024221	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:5.98e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 91.5	Expressed in all		
KCNH2	erg1, HERG, Kv11.1, LQT2	ENSG00000055118	Potassium voltage-gated channel subfamily H member 2	7	150944961-150978315	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 24.1;testis: 27.3	parathyroid gland: 13.2	Group enriched	6	K-562: 170.9;NB-4: 59.5;SH-SY5Y: 79.9
CUL1		ENSG00000055130	Cullin 1	7	148697914-148801036	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002676, HPA064584	Supported		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 184.5	Expressed in all		
FAM114A2	133K02, C5orf3	ENSG00000055147	Family with sequence similarity 114 member A2	5	153990128-154038936	Predicted intracellular proteins	Evidence at protein level	HPA035869, HPA035870	Approved		Approved	Vesicles		Expressed in all	Expressed in all			testis: 68.7	Expressed in all		
CYFIP2	PIR121	ENSG00000055163	Cytoplasmic FMR1 interacting protein 2	5	157266079-157395595	Predicted intracellular proteins	Evidence at protein level	CAB055519, HPA068106, HPA071459	Uncertain		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:3.21e-12 (favourable), Endometrial cancer:2.42e-6 (unfavourable), Pancreatic cancer:1.18e-4 (favourable)	Expressed in all	Expressed in all			kidney: 166.2	Cell line enhanced		Daudi: 156.3;MOLT-4: 169.6
TAB2	KIAA0733, MAP3K7IP2	ENSG00000055208	TGF-beta activated kinase 1/MAP3K7 binding protein 2	6	149218641-149411613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065436, HPA070137, HPA071215	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 70.3	Expressed in all		
GINM1	C6orf72, dJ12G14.2	ENSG00000055211	Glycoprotein integral membrane 1	6	149566294-149591748	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017210, HPA041679	Approved		Approved	Nucleoli fibrillar center<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 118.5	Expressed in all		
EIF2AK2	EIF2AK1, PKR, PPP1R83, PRKR	ENSG00000055332	Eukaryotic translation initiation factor 2 alpha kinase 2	2	37099210-37157065	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003845, HPA019795, HPA063893	Approved		Enhanced	Cytosol	Pancreatic cancer:2.08e-4 (unfavourable), Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.4	Mixed		
USP36	FLJ12851, KIAA1453	ENSG00000055483	Ubiquitin specific peptidase 36	17	78787381-78841441	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012082, HPA012395, HPA052860	Uncertain	Approved	Enhanced	Nucleoli<br>Nuclear speckles	Endometrial cancer:5.18e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 38.4	Expressed in all		
KMT2C	HALR, KIAA1506, MLL3	ENSG00000055609	Lysine methyltransferase 2C	7	152134922-152436005	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074736			Supported	Nucleoplasm	Renal cancer:8.01e-6 (favourable)	Expressed in all	Expressed in all			skin: 25.0	Expressed in all		
MCOLN3	FLJ11006, TRP-ML3, TRPML3	ENSG00000055732	Mucolipin 3	1	85018082-85048499	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018106, HPA062137	Enhanced		Approved	Nucleoli<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 57.8;parathyroid gland: 42.8	epididymis: 17.5	Cell line enhanced		HAP1: 13.4;RH-30: 15.2;SK-MEL-30: 22.2
CCDC85A	KIAA1912	ENSG00000055813	Coiled-coil domain containing 85A	2	56184123-56386173	Predicted secreted proteins	Evidence at protein level	HPA043106, HPA057020	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 21.0	thyroid gland: 15.9	Cell line enhanced		Daudi: 34.0;fHDF/TERT166: 59.7;U-266/70: 25.2
PUM2	KIAA0235, PUMH2	ENSG00000055917	Pumilio RNA binding family member 2	2	20248691-20352234	Predicted intracellular proteins	Evidence at protein level	HPA030316, HPA049670	Approved		Enhanced	Cytosol	Liver cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 98.1	Expressed in all		
MRPL43	bMRP36a	ENSG00000055950	Mitochondrial ribosomal protein L43	10	100969458-100987515	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA073022			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 57.8	Expressed in all		
ITIH4	H4P, IHRP, ITIHL1	ENSG00000055955	Inter-alpha-trypsin inhibitor heavy chain family member 4	3	52812975-52831479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001835, HPA003948, CAB072872	Enhanced		Approved	Vesicles		Tissue enriched	Tissue enriched	71	liver: 984.5	skeletal muscle: 13.8	Cell line enhanced		HDLM-2: 2.2;U-266/70: 2.1
ITIH1	H1P, IATIH, ITIH	ENSG00000055957	Inter-alpha-trypsin inhibitor heavy chain 1	3	52777592-52792068	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041639, HPA042049	Approved		Approved	Vesicles	Liver cancer:1.89e-5 (favourable)	Tissue enriched	Tissue enriched	458	liver: 786.3	spleen: 1.7	Cell line enhanced		ASC diff: 3.6;Hep G2: 1.1;HL-60: 1.0
HPF1	C4orf27, FLJ20534	ENSG00000056050	Histone PARylation factor 1	4	169729465-169757953	Predicted intracellular proteins	Evidence at protein level	HPA043467	Uncertain	Approved	Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Melanoma:5.63e-4 (unfavourable), Ovarian cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 38.5	Expressed in all		
ZFR	SPG71, ZFR1	ENSG00000056097	Zinc finger RNA binding protein	5	32354350-32444761	Predicted intracellular proteins	Evidence at protein level	HPA016666	Supported		Approved	Nucleoplasm	Liver cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 77.5	Expressed in all		
ZNF280C	FLJ20095, SUHW3, ZNF633	ENSG00000056277	Zinc finger protein 280C	X	130202711-130268899	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051494, HPA055788	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		testis: 17.5	epididymis: 6.3	Mixed		
NPFFR2	GPR74, NPFF2, NPGPR	ENSG00000056291	Neuropeptide FF receptor 2	4	72031804-72148067	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026825			Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		placenta: 2.3;seminal vesicle: 4.6	epididymis: 1.1	Group enriched	11	NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
PHF21B	BHC80L, FLJ34161, PHF4	ENSG00000056487	PHD finger protein 21B	22	44881162-45009999	Predicted intracellular proteins	Evidence at protein level	HPA053834	Uncertain		Uncertain	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.7;cervix, uterine: 5.5;testis: 6.4	endometrium: 5.4	Cell line enhanced		AF22: 11.1;AN3-CA: 9.4;SCLC-21H: 10.3;SH-SY5Y: 41.0;U-2 OS: 9.1
TRAF1	EBI6	ENSG00000056558	TNF receptor associated factor 1	9	120902393-120929173	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA001852, CAB009593	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:2.19e-5 (favourable), Renal cancer:4.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 37.6	appendix: 27.3	Group enriched	7	HDLM-2: 85.6;WM-115: 111.3
RC3H2	FLJ20301, FLJ20713, MNAB, RNF164	ENSG00000056586	Ring finger and CCCH-type domains 2	9	122844556-122905341	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042863, HPA062144	Approved		Supported	Vesicles	Renal cancer:5.50e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.5	Expressed in all		
IL17RB	CRL4, EVI27, IL17BR, IL17RH1	ENSG00000056736	Interleukin 17 receptor B	3	53846580-53865800	Predicted membrane proteins	Evidence at protein level	HPA005482	Supported				Renal cancer:6.61e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 61.7	cervix, uterine: 29.4	Cell line enhanced		Hep G2: 40.4
TRAF3IP2	ACT1, C6orf2, C6orf4, C6orf5, C6orf6, CIKS, DKFZP586G0522	ENSG00000056972	TRAF3 interacting protein 2	6	111556454-111606278	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036352	Approved		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:4.73e-5 (favourable), Renal cancer:5.16e-5 (unfavourable), Cervical cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.8	Cell line enhanced		U-2197: 94.7
GYG2	GN-2	ENSG00000056998	Glycogenin 2	X	2828788-2882820	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005495, HPA064686	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:3.01e-5 (favourable)	Expressed in all	Tissue enriched	13	adipose tissue: 173.1	breast: 13.2	Cell line enhanced		AF22: 39.5;NTERA-2: 39.5;SK-MEL-30: 68.1
DCBLD2	CLCP1, ESDN	ENSG00000057019	Discoidin, CUB and LCCL domain containing 2	3	98795941-98901689	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016909	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.32e-5 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Stomach cancer:2.87e-4 (unfavourable)	Expressed in all	Mixed			testis: 44.9	Cell line enhanced		LHCN-M2: 647.4;U-87 MG: 568.7
SERPINB3	HsT1196, SCC, SCCA1, T4-A	ENSG00000057149	Serpin family B member 3	18	63655197-63661963	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992	Enhanced		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:3.19e-4 (unfavourable)	Tissue enhanced	Group enriched	7	cervix, uterine: 298.5;esophagus: 848.0	urinary bladder: 87.5	Cell line enhanced		HaCaT: 5.5;SiHa: 4.1;U-2197: 7.3
SOAT1	ACAT, SOAT, STAT	ENSG00000057252	Sterol O-acyltransferase 1	1	179293714-179358680	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009533, HPA047171	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Tissue enhanced		adrenal gland: 218.2	prostate: 45.1	Expressed in all		
PKP2		ENSG00000057294	Plakophilin 2	12	32790745-32896840	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014314, CAB037336, HPA056908	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Lung cancer:6.79e-4 (unfavourable), Colorectal cancer:8.55e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 114.2;heart muscle: 123.3	parathyroid gland: 50.6	Cell line enhanced		CACO-2: 161.1
MSH4		ENSG00000057468	MutS homolog 4	1	75796882-75913238	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	7	epididymis: 2.3;testis: 7.7	spleen: 0.7	Cell line enhanced		AN3-CA: 1.6
F7		ENSG00000057593	Coagulation factor VII	13	113105788-113120681	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004826			Approved	Mitochondria		Tissue enriched	Tissue enriched	44	liver: 65.0	testis: 1.4	Group enriched	7	CACO-2: 11.8;Hep G2: 6.1
GDI2	RABGDIB	ENSG00000057608	GDP dissociation inhibitor 2	10	5765223-5842132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049290, HPA057668	Supported				Liver cancer:7.56e-7 (unfavourable), Glioma:7.00e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 241.2	Expressed in all		
PRDM1	BLIMP1, PRDI-BF1	ENSG00000057657	PR/SET domain 1	6	106086320-106109939	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030033	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:9.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 61.0	endometrium: 30.1	Cell line enhanced		Karpas-707: 158.5;U-266/70: 62.6;U-266/84: 39.9
ATG5	APG5, APG5L, ASP, hAPG5	ENSG00000057663	Autophagy related 5	6	106045423-106325791	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034432, CAB037309, HPA042973	Enhanced		Approved	Centrosome	Renal cancer:8.73e-4 (unfavourable), Liver cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.3	Expressed in all		
TMCC3	KIAA1145	ENSG00000057704	Transmembrane and coiled-coil domain family 3	12	94567124-94650562	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014272	Approved		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			placenta: 25.7	Cell line enhanced		HUVEC TERT2: 26.1;Karpas-707: 30.1;U-266/84: 20.9
PITHD1	C1orf128, HT014, TXNL1CL	ENSG00000057757	PITH domain containing 1	1	23778405-23788232	Predicted intracellular proteins	Evidence at protein level	HPA016936	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 208.8	Expressed in all		
MTA3	KIAA1266	ENSG00000057935	Metastasis associated 1 family member 3	2	42494569-42756947	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039433	Approved		Supported	Nucleus<br>Vesicles	Endometrial cancer:2.30e-4 (unfavourable), Liver cancer:4.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.4	Mixed		
USP13	IsoT-3	ENSG00000058056	Ubiquitin specific peptidase 13 (isopeptidase T-3)	3	179652755-179789401	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004827	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.46e-6 (unfavourable), Liver cancer:2.40e-5 (unfavourable), Urothelial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 52.2	Mixed		
ATP11B	ATPIF, ATPIR, KIAA0956	ENSG00000058063	ATPase phospholipid transporting 11B (putative)	3	182793500-182921635	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036237, HPA036238	Uncertain		Approved	Microtubule organizing center<br>Cytosol	Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.0	Expressed in all		
LAMC2	BM600-100kDa, EBR2, EBR2A, kalinin-105kDa, LAMB2T, LAMNB2, nicein-100kDa	ENSG00000058085	Laminin subunit gamma 2	1	183186238-183244900	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004257, HPA024638, CAB078165	Enhanced		Approved	Cytosol	Lung cancer:4.20e-6 (unfavourable), Pancreatic cancer:7.11e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 57.8	lung: 38.9	Cell line enhanced		A-431: 521.5;CAPAN-2: 460.7;HBEC3-KT: 1872.4;hTERT-HME1: 1202.0;RPTEC TERT1: 464.3
CDK14	PFTAIRE1, PFTK1	ENSG00000058091	Cyclin dependent kinase 14	7	90466424-91210590	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015267	Approved		Supported	Nucleus<br>Cytosol	Breast cancer:5.86e-4 (favourable), Stomach cancer:7.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.7	Mixed		
SEC61A1		ENSG00000058262	Sec61 translocon alpha 1 subunit	3	128051641-128071683	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022076			Supported	Endoplasmic reticulum	Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 218.2	Expressed in all		
PPP1R12A	M130, MBS, MYPT1	ENSG00000058272	Protein phosphatase 1 regulatory subunit 12A	12	79773563-79935460	Predicted intracellular proteins	Evidence at protein level	HPA041296, HPA071956	Approved		Enhanced	Actin filaments<br>Cytosol	Liver cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 120.9	Expressed in all		
RASGRF1	CDC25, CDC25L, GNRP, GRF1, GRF55, H-GRF55, PP13187	ENSG00000058335	Ras protein specific guanine nucleotide releasing factor 1	15	78959947-79090773	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010413, HPA041965	Approved		Supported	Golgi apparatus	Endometrial cancer:6.14e-6 (favourable)	Mixed	Group enriched	14	cerebral cortex: 30.5;lung: 11.3	lymph node: 1.5	Cell line enhanced		A-431: 7.3;BEWO: 7.5;Karpas-707: 7.5;RPMI-8226: 9.0;U-2 OS: 15.8
CAMK2B	CAM2, CAMK2, CAMKB	ENSG00000058404	Calcium/calmodulin dependent protein kinase II beta	7	44217150-44334577	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006849, HPA026307, HPA051783, HPA051785, HPA053973	Enhanced	Supported	Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 214.1	skeletal muscle: 46.1	Cell line enriched	12	SCLC-21H: 88.9
CROCC	ROLT, rootletin	ENSG00000058453	Ciliary rootlet coiled-coil, rootletin	1	16740273-16972979	Predicted intracellular proteins	Evidence at protein level	HPA021191, HPA021762	Enhanced		Supported	Plasma membrane<br>Centrosome	Endometrial cancer:8.34e-5 (favourable), Lung cancer:7.92e-4 (favourable), Renal cancer:7.97e-4 (unfavourable)	Expressed in all	Mixed			skin: 11.6	Mixed		
POLR3E	FLJ10509, RPC5, SIN	ENSG00000058600	RNA polymerase III subunit E	16	22297375-22335103	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA041419, HPA041477	Approved		Enhanced	Nucleoplasm	Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 8.9	Expressed in all		
ATP2B4	ATP2B2, MXRA1, PMCA4	ENSG00000058668	ATPase plasma membrane Ca2+ transporting 4	1	203626561-203744081	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016118, HPA040431	Enhanced		Supported	Plasma membrane	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 254.6	Expressed in all		
ZC3H11A	KIAA0663, ZC3HDC11A	ENSG00000058673	Zinc finger CCCH-type containing 11A	1	203795654-203854999	Predicted intracellular proteins	Evidence at protein level	HPA026439, HPA028490, HPA028526	Approved		Approved	Nuclear speckles	Renal cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
RIOK2	FLJ11159	ENSG00000058729	RIO kinase 2	5	97160867-97183260	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005681	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
YIPF1	DJ167A19.1, FinGER1	ENSG00000058799	Yip1 domain family member 1	1	53851719-53889834	Predicted membrane proteins	Evidence at protein level	HPA014716	Approved		Approved	Nucleoplasm	Liver cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.0	Expressed in all		
NDC1	FLJ10407, NET3, TMEM48	ENSG00000058804	NDC1 transmembrane nucleoporin	1	53765460-53838860	Predicted membrane proteins, Transporters	Evidence at protein level	HPA069751, HPA070882	Approved		Supported	Nuclear membrane<br>Plasma membrane<br>Actin filaments	Liver cancer:7.52e-7 (unfavourable), Colorectal cancer:4.48e-5 (favourable), Pancreatic cancer:3.58e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 16.4	Expressed in all		
DGKG	DAGK3	ENSG00000058866	Diacylglycerol kinase gamma	3	186105668-186362237	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036577	Approved		Approved	Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.4	placenta: 11.3	Cell line enhanced		HDLM-2: 22.1;U-87 MG: 13.9
FLYWCH1	DKFZp761A132	ENSG00000059122	FLYWCH-type zinc finger 1	16	2911937-2951208	Predicted intracellular proteins	Evidence at protein level	HPA040753, HPA041001	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
UNKL	C16orf28, FLJ23360, ZC3H5L, ZC3HDC5L	ENSG00000059145	Unkempt family like zinc finger	16	1363205-1414751	Predicted intracellular proteins	Evidence at protein level	HPA055801, HPA073949	Approved		Supported	Cytosol		Expressed in all	Mixed			endometrium: 9.6	Mixed		
TBXAS1	CYP5, CYP5A1, THAS, TS, TXAS, TXS	ENSG00000059377	Thromboxane A synthase 1	7	139777051-140020325	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031257, HPA031258, HPA031259	Enhanced		Supported	Vesicles	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Mixed			spleen: 56.3	Cell line enhanced		NB-4: 48.5;PC-3: 22.1;U-937: 48.2
PARP12	FLJ22693, PARP-12, ZC3H1, ZC3HDC1	ENSG00000059378	Poly(ADP-ribose) polymerase family member 12	7	140023744-140063721	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003584, HPA063872	Approved		Approved	Nucleus	Renal cancer:4.12e-7 (unfavourable), Liver cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			skin: 13.8	Mixed		
ALDH18A1	GSAS, P5CS, PYCS, SPG9	ENSG00000059573	Aldehyde dehydrogenase 18 family member A1	10	95605929-95656706	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008333, HPA012604	Approved		Enhanced	Mitochondria	Renal cancer:3.60e-9 (unfavourable), Endometrial cancer:4.20e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 89.5	Expressed in all		
TARBP1	TRM3, TRP-185	ENSG00000059588	TAR (HIV-1) RNA binding protein 1	1	234391313-234479103	Predicted intracellular proteins	Evidence at protein level	CAB020810, HPA024632	Uncertain		Approved	Nuclear speckles	Renal cancer:5.14e-10 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
GATB	PET112, PET112L	ENSG00000059691	Glutamyl-tRNA amidotransferase subunit B	4	151670504-151761023	Predicted intracellular proteins	Evidence at protein level	HPA042610	Uncertain		Supported	Mitochondria	Renal cancer:1.20e-10 (favourable)	Expressed in all	Mixed			kidney: 22.4	Expressed in all		
MXD1	bHLHc58, MAD, MAD1	ENSG00000059728	MAX dimerization protein 1	2	69897688-69942945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001599	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria<br>Cytosol	Endometrial cancer:8.14e-6 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 113.8;esophagus: 101.9	appendix: 56.3	Mixed		
CDK17	PCTAIRE2, PCTK2	ENSG00000059758	Cyclin dependent kinase 17	12	96278261-96400560	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015325	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.09e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.8	Expressed in all		
DNAJC25	bA16L21.2.1	ENSG00000059769	DnaJ heat shock protein family (Hsp40) member C25	9	111631352-111654351	Predicted membrane proteins	Evidence at protein level	HPA019122	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.73e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 16.7	parathyroid gland: 7.9	Mixed		
SLC2A3	GLUT3	ENSG00000059804	Solute carrier family 2 member 3	12	7919230-7936275	Predicted membrane proteins, Transporters	Evidence at protein level	CAB002763, HPA006539	Approved		Approved	Plasma membrane	Renal cancer:6.36e-8 (unfavourable), Stomach cancer:2.89e-5 (unfavourable), Colorectal cancer:8.58e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 271.2	placenta: 138.7	Group enriched	7	BEWO: 1387.7;CACO-2: 1315.8;NTERA-2: 293.2
PSD	EFA6, EFA6A, KIAA2011, PSD1, TYL	ENSG00000059915	Pleckstrin and Sec7 domain containing	10	102402617-102421539	Predicted intracellular proteins	Evidence at protein level	HPA059237	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 112.7	endometrium: 40.4	Cell line enhanced		HSkMC: 5.6;SCLC-21H: 8.7;SH-SY5Y: 6.8
CTDP1	FCP1	ENSG00000060069	CTD phosphatase subunit 1	18	79679801-79756623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032641, HPA040394, HPA070389	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.51e-5 (favourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
YBX3	CSDA, CSDA1, dbpA, ZONAB	ENSG00000060138	Y-box binding protein 3	12	10699089-10723312	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034838	Approved		Supported	Cytosol	Renal cancer:6.17e-13 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 1300.9	Mixed		
STYK1	DKFZp761P1010, NOK, SuRTK106	ENSG00000060140	Serine/threonine/tyrosine kinase 1	12	10618939-10674318	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040468, HPA048569	Uncertain		Approved	Nucleus<br>Plasma membrane		Mixed	Mixed			rectum: 17.4	Cell line enhanced		CAPAN-2: 23.5;HUVEC TERT2: 20.0;TIME: 18.2
WNK1	HSAN2, HSN2, PPP1R167, PRKWNK1	ENSG00000060237	WNK lysine deficient protein kinase 1	12	752593-911452	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046541, HPA059157	Enhanced		Supported	Cytosol	Ovarian cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 92.4	Expressed in all		
CCAR1	CARP-1, CARP1, FLJ10590	ENSG00000060339	Cell division cycle and apoptosis regulator 1	10	68721012-68792377	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA007856, HPA048513	Supported		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.41e-5 (unfavourable), Ovarian cancer:4.05e-5 (favourable), Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 34.8	Expressed in all		
OGFR	7-60	ENSG00000060491	Opioid growth factor receptor	20	62804835-62814000	Predicted intracellular proteins	Evidence at protein level	HPA017899	Enhanced		Approved	Nucleoplasm	Urothelial cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			spleen: 52.6	Expressed in all		
GNA15	GNA16	ENSG00000060558	G protein subunit alpha 15	19	3136193-3163769	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043113	Approved				Renal cancer:4.26e-6 (unfavourable), Breast cancer:7.57e-5 (favourable), Endometrial cancer:2.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 48.7;esophagus: 61.3	skin: 25.9	Cell line enhanced		HMC-1: 142.1;MOLT-4: 137.5;REH: 115.4
CREB3L3	CREB-H	ENSG00000060566	CAMP responsive element binding protein 3 like 3	19	4153601-4173054	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA040671, HPA056228	Enhanced				Renal cancer:3.53e-6 (unfavourable)	Tissue enriched	Group enriched	104	duodenum: 241.6;liver: 61.0;small intestine: 278.7	colon,stomach: 1.8	Cell line enhanced		HDLM-2: 44.9;Hep G2: 10.3;U-266/70: 7.7
PIGV	FLJ20477	ENSG00000060642	Phosphatidylinositol glycan anchor biosynthesis class V	1	26787472-26798398	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054181			Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.60e-7 (favourable)	Expressed in all	Expressed in all			testis: 79.6	Expressed in all		
PTPRU	FMI, hPTP-J, PCP-2, PTP, PTPRO	ENSG00000060656	Protein tyrosine phosphatase, receptor type U	1	29236516-29326813	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011476, HPA039832	Approved				Head and neck cancer:8.32e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 28.0	Cell line enhanced		BEWO: 92.2
SNRNP40	HPRP8BP, PRP8BP, PRPF8BP, SPF38, WDR57	ENSG00000060688	Small nuclear ribonucleoprotein U5 subunit 40	1	31259568-31296782	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026527, HPA027345	Supported		Supported	Nuclear speckles	Liver cancer:4.73e-6 (unfavourable), Glioma:9.74e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 40.9	Expressed in all		
RIMBP2	KIAA0318, MGC15831, PPP1R133, RBP2, RIM-BP2	ENSG00000060709	RIMS binding protein 2	12	130396137-130517917	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:4.16e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 95.0	cerebral cortex: 24.4	Group enriched	10	SCLC-21H: 26.1;SH-SY5Y: 41.8
COL11A1	CO11A1, COLL6, STL2	ENSG00000060718	Collagen type XI alpha 1 chain	1	102876467-103108496	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058335			Approved	Endoplasmic reticulum		Mixed	Tissue enriched	6	placenta: 27.9	gallbladder: 4.7	Cell line enhanced		AF22: 113.0;BJ hTERT+ SV40 Large T+ RasG12V: 78.6;HBF TERT88: 46.0;HSkMC: 101.5
QSER1	FLJ21924	ENSG00000060749	Glutamine and serine rich 1	11	32893178-32993316	Predicted intracellular proteins	Evidence at protein level	HPA005682	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.27e-5 (unfavourable), Liver cancer:7.94e-5 (unfavourable), Renal cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 17.4	Expressed in all		
MPC1	BRP44L, CGI-129, dJ68L15.3	ENSG00000060762	Mitochondrial pyruvate carrier 1	6	166364919-166383013	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045119, HPA055790	Enhanced		Enhanced	Mitochondria	Renal cancer:4.79e-11 (favourable), Lung cancer:1.29e-4 (favourable), Cervical cancer:1.45e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 432.9	Expressed in all		
ACAA1		ENSG00000060971	Acetyl-CoA acyltransferase 1	3	38103129-38137242	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006764, HPA007244	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable)	Expressed in all	Expressed in all			liver: 328.4	Expressed in all		
BCAT1	BCT1	ENSG00000060982	Branched chain amino acid transaminase 1	12	24810022-24949459	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048592	Uncertain				Renal cancer:1.38e-4 (unfavourable), Head and neck cancer:3.55e-4 (unfavourable), Stomach cancer:4.95e-4 (unfavourable), Urothelial cancer:8.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 21.4	Cell line enhanced		NTERA-2: 283.1;RH-30: 298.1
HDAC7	DKFZP586J0917, HDAC7A	ENSG00000061273	Histone deacetylase 7	12	47782722-47833132	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004775			Supported	Cytosol	Urothelial cancer:4.65e-4 (favourable), Melanoma:5.16e-4 (unfavourable), Renal cancer:8.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 43.9	Expressed in all		
LZTS1	FEZ1	ENSG00000061337	Leucine zipper tumor suppressor 1	8	20246165-20303963	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006294, HPA022046	Approved		Approved	Nucleoli<br>Plasma membrane	Renal cancer:9.28e-6 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 125.4	testis: 12.4	Cell line enhanced		SK-MEL-30: 59.3;WM-115: 50.1
PRDM6	KMT8C, PRISM	ENSG00000061455	PR/SET domain 6	5	123089121-123194266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030322, HPA030324	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 5.2;placenta: 5.9	lung: 4.0	Cell line enhanced		BEWO: 3.5;HEK 293: 4.7
WNT8A	WNT8D	ENSG00000061492	Wnt family member 8A	5	138083892-138092365	Predicted secreted proteins	Evidence at transcript level	HPA038539	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Not detected			testis: 0.7	Not detected		
SPAG4	CT127, SUN4	ENSG00000061656	Sperm associated antigen 4	20	35615892-35621049	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048393, HPA061789	Approved				Endometrial cancer:9.52e-8 (favourable), Colorectal cancer:1.09e-5 (unfavourable), Glioma:8.89e-5 (unfavourable), Renal cancer:1.28e-4 (unfavourable), Urothelial cancer:6.66e-4 (favourable)	Expressed in all	Mixed			testis: 22.5	Cell line enhanced		EFO-21: 25.0;U-87 MG: 46.8
NCKAP1	HEM2, Nap1, NAP125	ENSG00000061676	NCK associated protein 1	2	182909115-183038858	Predicted membrane proteins	Evidence at protein level	HPA020449	Enhanced		Approved	Cytosol	Pancreatic cancer:3.81e-4 (unfavourable), Lung cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 145.1	Mixed		
MRPS35	MDS023, MRPS28	ENSG00000061794	Mitochondrial ribosomal protein S35	12	27710773-27756295	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038513	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:1.51e-5 (favourable), Liver cancer:1.64e-4 (unfavourable), Colorectal cancer:5.01e-4 (favourable), Breast cancer:9.41e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 78.7	Expressed in all		
GUCY1B3	GC-S-beta-1, GC-SB3, GUC1B3	ENSG00000061918	Guanylate cyclase 1 soluble subunit beta	4	155758992-155807591	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010890, HPA020870	Approved		Approved	Cytosol	Renal cancer:2.42e-4 (unfavourable), Testis cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 177.3	Cell line enhanced		HEL: 42.7;MOLT-4: 24.5;RPTEC TERT1: 35.1
SFSWAP	SFRS8, SWAP	ENSG00000061936	Splicing factor SWAP homolog	12	131711081-131799737	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039362, HPA040063	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:3.33e-8 (unfavourable), Melanoma:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 18.1	Expressed in all		
TNK2	ACK, ACK1, p21cdc42Hs	ENSG00000061938	Tyrosine kinase non receptor 2	3	195863364-195911945	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041954	Approved		Approved	Cytosol	Urothelial cancer:1.00e-4 (favourable), Renal cancer:1.30e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.5	Expressed in all		
MON2	KIAA1040	ENSG00000061987	MON2 homolog, regulator of endosome-to-Golgi trafficking	12	62466817-62600479	Predicted intracellular proteins	Evidence at protein level	HPA038697, HPA057607	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Head and neck cancer:2.03e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.8	Expressed in all		
CDH3	CDHP, PCAD	ENSG00000062038	Cadherin 3	16	68636189-68722616	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001767, CAB002487	Enhanced		Uncertain	Cell Junctions<br>Cytosol	Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 31.9	ovary: 26.5	Cell line enhanced		A-431: 89.4;HaCaT: 243.8;HBEC3-KT: 95.6;hTCEpi: 75.4;RPTEC TERT1: 88.7
ARSF		ENSG00000062096	Arylsulfatase F	X	3041471-3112726	Predicted membrane proteins	Evidence at protein level	HPA000549			Uncertain	Cytosol		Tissue enhanced	Group enriched	6	adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.0;esophagus: 2.3;kidney: 8.0;skin: 6.7	liver: 0.6	Not detected		
GPBP1	DKFZp761C169, vasculin	ENSG00000062194	GC-rich promoter binding protein 1	5	57173948-57264679	Predicted intracellular proteins	Evidence at protein level	HPA037773	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
DGAT2		ENSG00000062282	Diacylglycerol O-acyltransferase 2	11	75759512-75801535	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.84e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 493.2;liver: 170.9	skin: 116.1	Cell line enhanced		ASC diff: 55.2;HDLM-2: 57.8
ZNF112	ZFP112, ZNF228	ENSG00000062370	Zinc finger protein 112	19	44326555-44367217	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023856	Approved		Approved	Centrosome	Renal cancer:1.54e-5 (favourable)	Mixed	Mixed			testis: 13.8	Cell line enhanced		U-2197: 16.1
CS		ENSG00000062485	Citrate synthase	12	56271699-56300392	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038460, HPA038461, CAB075750, CAB075751, CAB075752, CAB075753, CAB075754	Enhanced		Enhanced	Mitochondria	Renal cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 190.9	Expressed in all		
LTK	TYK1	ENSG00000062524	Leukocyte receptor tyrosine kinase	15	41503638-41513887	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059545	Uncertain		Approved	Vesicles		Mixed	Mixed			placenta: 15.2	Cell line enhanced		HEL: 4.4;NB-4: 6.1;RH-30: 4.4;THP-1: 9.9
MRPS24	HSPC335, MRP-S24	ENSG00000062582	Mitochondrial ribosomal protein S24	7	43866558-43869893	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA020983			Approved	Nucleoplasm<br>Vesicles	Lung cancer:1.91e-4 (unfavourable), Renal cancer:9.89e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 147.5	Expressed in all		
ELMO2	CED-12, CED12, ELMO-2, FLJ11656, KIAA1834	ENSG00000062598	Engulfment and cell motility 2	20	46366049-46432985	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018811	Approved		Supported	Cytosol	Liver cancer:4.08e-5 (unfavourable), Pancreatic cancer:6.10e-4 (favourable), Endometrial cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.2	Expressed in all		
WAPL	FOE, KIAA0261, WAPAL	ENSG00000062650	WAPL cohesin release factor	10	86435256-86521815	Predicted intracellular proteins	Evidence at protein level	HPA037874, HPA037875	Enhanced					Expressed in all	Expressed in all			testis: 64.5	Expressed in all		
VMP1	EPG3, TANGO5, TMEM49	ENSG00000062716	Vacuole membrane protein 1	17	59707192-59842255	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030773, HPA064780	Uncertain		Approved	Nucleoli<br>Endoplasmic reticulum	Renal cancer:2.77e-8 (unfavourable), Endometrial cancer:1.56e-5 (unfavourable), Liver cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 63.4	Expressed in all		
APPBP2	Hs.84084, KIAA0228, PAT1	ENSG00000062725	Amyloid beta precursor protein binding protein 2	17	60443149-60526219	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.6	Expressed in all		
POLD1	CDC2, POLD	ENSG00000062822	DNA polymerase delta 1, catalytic subunit	19	50384204-50418018	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004375, HPA046524	Enhanced		Supported	Nucleoplasm	Liver cancer:2.87e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 21.4	Expressed in all		
SEZ6		ENSG00000063015	Seizure related 6 homolog	17	28954901-29006440	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011777	Enhanced		Uncertain	Intermediate filaments		Tissue enriched	Tissue enriched	53	cerebral cortex: 54.3	duodenum: 1.0	Cell line enriched	6	SCLC-21H: 69.9
EIF4B		ENSG00000063046	Eukaryotic translation initiation factor 4B	12	53006158-53042209	Predicted intracellular proteins	Evidence at protein level	HPA039072, HPA046164	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			ovary: 757.9	Expressed in all		
SLC6A16	NTT5	ENSG00000063127	Solute carrier family 6 member 16	19	49289638-49325225	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076812			Supported	Golgi apparatus		Mixed	Tissue enriched	18	testis: 162.8	lymph node: 8.8	Cell line enhanced		AF22: 18.0
GLTSCR1		ENSG00000063169	Glioma tumor suppressor candidate region gene 1	19	47608196-47703277	Predicted intracellular proteins	Evidence at protein level	HPA056211	Approved		Approved	Nucleoplasm	Head and neck cancer:1.34e-4 (favourable), Renal cancer:1.82e-4 (unfavourable), Urothelial cancer:9.34e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
SPHK2		ENSG00000063176	Sphingosine kinase 2	19	48619291-48630717	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065508			Supported	Vesicles	Renal cancer:2.59e-5 (favourable), Endometrial cancer:5.19e-4 (unfavourable), Pancreatic cancer:9.30e-4 (favourable)	Expressed in all	Mixed			duodenum: 22.1	Expressed in all		
RPL18	L18	ENSG00000063177	Ribosomal protein L18	19	48615328-48619536	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046572	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2572.0	Expressed in all		
CA11	CARP2, CARPX1	ENSG00000063180	Carbonic anhydrase 11	19	48637942-48646312	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041778			Approved	Vesicles<br>Microtubules	Lung cancer:2.11e-5 (favourable), Pancreatic cancer:8.60e-5 (favourable), Cervical cancer:4.33e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 244.1	ovary: 49.5	Cell line enhanced		AN3-CA: 39.9;SCLC-21H: 35.8
ISOC2	FLJ23469	ENSG00000063241	Isochorismatase domain containing 2	19	55452985-55462343	Predicted intracellular proteins	Evidence at protein level	HPA043142	Enhanced		Approved	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			kidney: 63.1	Mixed		
U2AF2	U2AF65	ENSG00000063244	U2 small nuclear RNA auxiliary factor 2	19	55654146-55674715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010910, HPA041943, HPA043562	Supported	Supported	Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 137.2	Expressed in all		
EPN1		ENSG00000063245	Epsin 1	19	55675226-55709858	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009729, HPA061136	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			duodenum: 89.4	Expressed in all		
MED29	DKFZp434H247, IXL, MED2	ENSG00000063322	Mediator complex subunit 29	19	39391303-39400637	Predicted intracellular proteins	Evidence at protein level	HPA055956			Supported	Nucleoplasm	Renal cancer:5.15e-5 (favourable), Endometrial cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
AHRR	AHH, AHHR, bHLHe77, KIAA1234	ENSG00000063438	Aryl-hydrocarbon receptor repressor	5	304176-438291	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021483			Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	8	testis: 65.2	skin: 7.9	Cell line enhanced		HMC-1: 89.0;NB-4: 80.8;WM-115: 71.5
GSC2	GSCL	ENSG00000063515	Goosecoid homeobox 2	22	19148576-19150283	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043011	Uncertain					Not detected	Tissue enriched	31	testis: 3.0	all non-specific tissues: 0.0	Not detected		
ZNF275		ENSG00000063587	Zinc finger protein 275	X	153334155-153360110	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000566	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			adrenal gland: 79.3	Cell line enhanced		U-266/70: 46.8
MTMR1		ENSG00000063601	Myotubularin related protein 1	X	150692971-150765103	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002977, HPA018502	Approved		Approved	Microtubule organizing center		Expressed in all	Expressed in all			parathyroid gland: 26.6	Mixed		
GPC1	glypican	ENSG00000063660	Glypican 1	2	240435671-240468078	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030571	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 265.8	prostate: 67.5	Mixed		
ADCK1	FLJ39600	ENSG00000063761	AarF domain containing kinase 1	14	77800083-77935012	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA051012, HPA055014	Uncertain		Approved	Nucleoplasm	Renal cancer:5.82e-6 (favourable), Lung cancer:4.11e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.0	Mixed		
HAGH	GLO2, GLXII, HAGH1	ENSG00000063854	Hydroxyacylglutathione hydrolase	16	1795620-1827194	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043041, HPA061143	Approved				Renal cancer:1.81e-6 (favourable), Liver cancer:5.33e-6 (favourable), Cervical cancer:5.82e-5 (favourable), Urothelial cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			liver: 124.4	Expressed in all		
RNF4	RES4-26, SLX5, SNURF	ENSG00000063978	Ring finger protein 4	4	2462220-2625320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049356	Approved				Lung cancer:6.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
CASP8	Casp-8, FLICE, MACH, MCH5	ENSG00000064012	Caspase 8	2	201233443-201287711	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001302, CAB002047, HPA005688, HPA006191	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 44.8	Expressed in all		
LIMCH1	DKFZP686A01247, LIMCH1A, LMO7B	ENSG00000064042	LIM and calponin homology domains 1	4	41359607-41700044	Predicted intracellular proteins	Evidence at protein level	HPA004184, HPA063840	Uncertain		Approved	Actin filaments	Renal cancer:3.82e-7 (favourable), Breast cancer:5.55e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 190.9	Cell line enhanced		HeLa: 126.0;RT4: 144.1;SiHa: 108.5;WM-115: 142.5
INTS13	ASUN, C12orf11, FLJ10637, Mat89Bb, NET48, SPATA30	ENSG00000064102	Integrator complex subunit 13	12	26905181-26938326	Predicted intracellular proteins	Evidence at protein level	HPA039543	Uncertain				Liver cancer:1.17e-10 (unfavourable), Renal cancer:3.16e-6 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 23.1	Expressed in all		
TM7SF3		ENSG00000064115	Transmembrane 7 superfamily member 3	12	26973195-27014434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057640			Supported	Nucleus<br>Cytosol	Renal cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 190.9	Expressed in all		
DLX3		ENSG00000064195	Distal-less homeobox 3	17	49990005-49995224	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:4.61e-4 (unfavourable)	Mixed	Group enriched	5	placenta: 10.7;skin: 21.9	thyroid gland: 3.1	Cell line enhanced		BEWO: 131.0;SK-BR-3: 33.0
SPA17	CT22, SP17	ENSG00000064199	Sperm autoantigenic protein 17	11	124673798-124697518	Predicted intracellular proteins	Evidence at protein level	HPA037568	Enhanced		Approved	Vesicles	Endometrial cancer:1.03e-4 (favourable)	Expressed in all	Group enriched	7	fallopian tube: 124.1;testis: 430.2	epididymis: 38.3	Mixed		
TSPAN32	PHEMX, TSSC6	ENSG00000064201	Tetraspanin 32	11	2301997-2318200	Predicted membrane proteins	Evidence at protein level	HPA024135	Uncertain					Mixed	Tissue enhanced		bone marrow: 12.0;heart muscle: 7.6	lymph node: 6.3	Group enriched	7	HEL: 13.1;HL-60: 5.1;NB-4: 3.3;THP-1: 3.8;U-937: 6.9
WISP2	CCN5, CT58, CTGF-L	ENSG00000064205	WNT1 inducible signaling pathway protein 2	20	44714844-44728509	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019273	Approved					Tissue enhanced	Tissue enhanced		cervix, uterine: 459.5;ovary: 167.2	breast: 70.0	Cell line enhanced		ASC TERT1: 71.5;HeLa: 40.1;U-2197: 313.4
DMRT3	DMRTA3	ENSG00000064218	Doublesex and mab-3 related transcription factor 3	9	976964-991731	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077685	Approved					Tissue enhanced	Tissue enriched	6	parathyroid gland: 65.3	thyroid gland: 10.4	Cell line enhanced		HAP1: 1.3;HEK 293: 1.5;SCLC-21H: 1.1;THP-1: 1.8
ST3GAL6	SIAT10, ST3GALVI	ENSG00000064225	ST3 beta-galactoside alpha-2,3-sialyltransferase 6	3	98732236-98821201	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018792	Approved					Tissue enhanced	Mixed			liver: 28.4	Cell line enhanced		RPMI-8226: 65.1;SK-MEL-30: 85.2
ATP2C2	KIAA0703, SPCA2	ENSG00000064270	ATPase secretory pathway Ca2+ transporting 2	16	84368527-84464187	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052262, HPA075812	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Endometrial cancer:6.20e-6 (favourable)	Mixed	Tissue enhanced		rectum: 38.4	skin: 30.0	Cell line enhanced		MCF7: 18.7;RT4: 15.1;SK-BR-3: 24.6;T-47d: 10.4
NGFR	CD271, p75NTR, TNFRSF16	ENSG00000064300	Nerve growth factor receptor	17	49495293-49515017	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB000143, CAB001995, HPA004765	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Urothelial cancer:3.40e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 32.4	Group enriched	8	RH-30: 193.0;WM-115: 221.3
CDON	CDO, CDON1, ORCAM	ENSG00000064309	Cell adhesion associated, oncogene regulated	11	125955796-126063335	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB012422, HPA017377	Uncertain				Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 75.5	ovary: 53.5	Cell line enhanced		AF22: 55.0;ASC diff: 47.4;RH-30: 93.1
TAF2	CIF150, TAF2B, TAFII150	ENSG00000064313	TATA-box binding protein associated factor 2	8	119730775-119832863	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.45e-4 (unfavourable), Liver cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
HIPK2		ENSG00000064393	Homeodomain interacting protein kinase 2	7	139561570-139777778	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007611	Supported		Supported	Nucleus	Renal cancer:9.99e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.3	Cell line enhanced		HDLM-2: 113.5
TNPO3	IPO12, LGMD1F, MTR10A, TRN-SR, TRN-SR2	ENSG00000064419	Transportin 3	7	128954180-129055173	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039555, HPA041537	Approved		Enhanced	Vesicles	Liver cancer:3.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
BORCS8-MEF2B	MEF2BNB-MEF2B	ENSG00000064489	BORCS8-MEF2B readthrough	19	19145567-19192158	Predicted intracellular proteins	Evidence at protein level	HPA004734	Uncertain					Not detected	Mixed			fallopian tube: 1.4	Cell line enhanced		PC-3: 7.8;U-266/70: 6.4
RFXANK	ANKRA1, BLS, F14150_1, MGC138628, RFX-B	ENSG00000064490	Regulatory factor X associated ankyrin containing protein	19	19192229-19201869	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049157, HPA053330	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 50.1	Expressed in all		
TMEM161A	FLJ20422, FLJ39645	ENSG00000064545	Transmembrane protein 161A	19	19119169-19138513	Predicted membrane proteins	Evidence at protein level	HPA043365	Approved		Approved	Cytosol	Stomach cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
LPAR2	EDG-4, EDG4, LPA2	ENSG00000064547	Lysophosphatidic acid receptor 2	19	19623668-19628930	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019616	Approved				Renal cancer:1.61e-7 (unfavourable), Stomach cancer:1.43e-4 (favourable)	Expressed in all	Mixed			testis: 40.7	Cell line enhanced		HMC-1: 64.8
CTSA	GSL, PPGB	ENSG00000064601	Cathepsin A	20	45890144-45898820	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024930, HPA031068	Enhanced		Enhanced	Vesicles	Liver cancer:1.95e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 243.4	Expressed in all		
SUGP2	KIAA0365, SFRS14	ENSG00000064607	SURP and G-patch domain containing 2	19	18990888-19034023	Predicted intracellular proteins	Evidence at protein level	HPA041557, HPA061111	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 161.7	Expressed in all		
SLC12A2	BSC, BSC2, NKCC1, PPP1R141	ENSG00000064651	Solute carrier family 12 member 2	5	128083766-128189688	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020130, HPA063697	Approved		Approved	Vesicles<br>Plasma membrane	Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable)	Expressed in all	Expressed in all			rectum: 65.4	Expressed in all		
SNX24	SBBI31	ENSG00000064652	Sorting nexin 24	5	122843439-123029354	Predicted intracellular proteins	Evidence at protein level	HPA044566, HPA073934	Approved		Approved	Vesicles	Endometrial cancer:7.93e-6 (unfavourable), Renal cancer:1.28e-4 (favourable), Liver cancer:8.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 39.4	Mixed		
EYA2	EAB1	ENSG00000064655	EYA transcriptional coactivator and phosphatase 2	20	46894624-47188844	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027024, HPA059291	Uncertain		Supported	Cytosol	Endometrial cancer:4.30e-5 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 76.3	fallopian tube: 50.0	Cell line enhanced		HBEC3-KT: 28.0;SCLC-21H: 68.4;U-266/70: 82.5;U-266/84: 98.8
CNN2		ENSG00000064666	Calponin 2	19	1026581-1039068	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049095	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:4.70e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 208.5	Mixed		
ABCA7	ABCX	ENSG00000064687	ATP binding cassette subfamily A member 7	19	1040101-1065572	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041564	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable)	Expressed in all	Mixed			spleen: 25.3	Cell line enhanced		HMC-1: 52.2
SNCAIP	SYPH1	ENSG00000064692	Synuclein alpha interacting protein	5	122311354-122464219	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064687	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies		Mixed	Tissue enhanced		endometrium: 29.8;ovary: 43.3	cervix, uterine: 25.8	Cell line enhanced		AF22: 4.9;BJ hTERT+: 3.9;RPMI-8226: 3.7
DDX20	DP103, GEMIN3	ENSG00000064703	DEAD-box helicase 20	1	111755245-111768016	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA005516, CAB015427	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:6.35e-6 (unfavourable), Colorectal cancer:9.85e-5 (favourable)	Expressed in all	Tissue enriched	10	testis: 130.7	parathyroid gland: 12.6	Expressed in all		
BTBD1		ENSG00000064726	BTB domain containing 1	15	83016422-83067354	Predicted intracellular proteins	Evidence at protein level	HPA067671	Enhanced				Renal cancer:6.21e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 109.7	Expressed in all		
FAR2	FLJ10462, MLSTD1, SDR10E2	ENSG00000064763	Fatty acyl-CoA reductase 2	12	29149103-29340980	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015884	Approved		Approved	Nucleoli<br>Golgi apparatus	Renal cancer:4.93e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 43.9	Cell line enhanced		HUVEC TERT2: 69.5
BCAS1	AIBC1, NABC1	ENSG00000064787	Breast carcinoma amplified sequence 1	20	53936777-54070594	Predicted intracellular proteins	Evidence at protein level	CAB033558, HPA051816, HPA054745	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 108.7;stomach: 155.8	rectum: 80.7	Group enriched	6	RT4: 143.2;SK-BR-3: 277.9
POU1F1	GHF-1, PIT1, POU1F1a	ENSG00000064835	POU class 1 homeobox 1	3	87259404-87276587	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041646, HPA050624	Enhanced					Not detected	Not detected			adrenal gland,cerebral cortex,gallbladder,skeletal muscle,spleen,thyroid gland: 0.1	Not detected		
CHI3L2	YKL-39, YKL39	ENSG00000064886	Chitinase 3 like 2	1	111200771-111243440	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005443	Uncertain				Renal cancer:8.59e-7 (unfavourable), Glioma:1.55e-4 (unfavourable), Head and neck cancer:2.19e-4 (favourable)	Tissue enriched	Tissue enhanced		appendix: 152.3	tonsil: 103.1	Cell line enhanced		ASC diff: 62.1;MOLT-4: 277.3;U-698: 51.9
SBNO2	FLJ00173, KIAA0963, Sno, Stno	ENSG00000064932	Strawberry notch homolog 2	19	1107636-1174283	Predicted intracellular proteins	Evidence at protein level	HPA041867	Approved				Renal cancer:7.98e-8 (unfavourable)	Expressed in all	Mixed			adipose tissue: 13.9	Cell line enhanced		HDLM-2: 61.0
PMS1	MLH2, PMSL1	ENSG00000064933	PMS1 homolog 1, mismatch repair system component	2	189784085-189877629	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010233, HPA031013	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.86e-6 (unfavourable), Liver cancer:2.38e-6 (unfavourable), Urothelial cancer:3.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 85.0	Expressed in all		
HMG20B	BRAF25, BRAF35, HMGX2, HMGXB2, SMARCE1r, SOXL	ENSG00000064961	High mobility group 20B	19	3572777-3579088	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050220, HPA053157, HPA069832	Approved		Enhanced	Nucleoplasm	Endometrial cancer:1.72e-7 (favourable), Urothelial cancer:2.89e-5 (favourable)	Expressed in all	Expressed in all			prostate: 70.1	Expressed in all		
CALCRL	CGRPR, CRLR	ENSG00000064989	Calcitonin receptor like receptor	2	187343129-187448460	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008070, HPA046515	Uncertain		Supported	Plasma membrane		Expressed in all	Tissue enhanced		lung: 114.3	adipose tissue: 76.8	Cell line enhanced		HUVEC TERT2: 145.5;RPTEC TERT1: 30.7;TIME: 20.7
TAF11	TAF2I, TAFII28	ENSG00000064995	TATA-box binding protein associated factor 11	6	34877778-34888089	Predicted intracellular proteins	Evidence at protein level	HPA029326, HPA049127			Supported	Nucleoplasm<br>Golgi apparatus	Ovarian cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 54.8	Expressed in all		
ANKS1A	ANKS1, KIAA0229	ENSG00000064999	Ankyrin repeat and sterile alpha motif domain containing 1A	6	34889265-35091413	Predicted intracellular proteins	Evidence at protein level	HPA036768, HPA036769	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.05e-5 (favourable), Head and neck cancer:7.48e-4 (favourable)	Expressed in all	Expressed in all			placenta: 39.2	Expressed in all		
AP3D1	ADTD	ENSG00000065000	Adaptor related protein complex 3 delta 1 subunit	19	2100988-2164465	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074408			Approved	Cytosol	Renal cancer:2.61e-6 (favourable), Liver cancer:9.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 60.7	Expressed in all		
ZNF76	D6S229E, Zfp523, ZNF523	ENSG00000065029	Zinc finger protein 76	6	35258909-35295985	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030090, HPA030091	Approved		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:1.18e-4 (favourable), Pancreatic cancer:5.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.7	Expressed in all		
SLC9A3R2	E3KARP, NHERF-2, SIP-1, TKA-1	ENSG00000065054	SLC9A3 regulator 2	16	2025356-2039026	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001672, HPA066520	Enhanced		Supported	Plasma membrane	Endometrial cancer:1.03e-4 (favourable)	Expressed in all	Mixed			lung: 160.8	Cell line enhanced		MCF7: 234.6;PC-3: 259.8
NTHL1	NTH1, OCTS3	ENSG00000065057	Nth like DNA glycosylase 1	16	2039815-2047866	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025152	Supported					Expressed in all	Expressed in all			fallopian tube: 21.3	Expressed in all		
UHRF1BP1	C6orf107, dJ349A12.1, FLJ20302, ICBP90	ENSG00000065060	UHRF1 binding protein 1	6	34792015-34883138	Predicted intracellular proteins	Evidence at protein level	HPA032099, HPA032100	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
GNAI3	87U6	ENSG00000065135	G protein subunit alpha i3	1	109548611-109618321	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022099, HPA042141	Approved		Supported	Nucleus<br>Nucleoli<br>Centrosome	Liver cancer:5.30e-6 (unfavourable), Colorectal cancer:1.62e-4 (favourable), Renal cancer:4.34e-4 (unfavourable), Ovarian cancer:4.59e-4 (favourable)	Expressed in all	Mixed			esophagus: 7.9	Expressed in all		
IPO5	IMB3, KPNB3, MGC2068, Pse1, RANBP5	ENSG00000065150	Importin 5	13	97953658-98024297	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009110, HPA040983, HPA056548	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 384.5	Expressed in all		
OAT	HOGA	ENSG00000065154	Ornithine aminotransferase	10	124397303-124418976	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033576, HPA040098, HPA064742	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			small intestine: 859.8	Mixed		
WDR3	DIP2, FLJ12796, UTP12	ENSG00000065183	WD repeat domain 3	1	117929720-117966542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027509, HPA054354			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:7.33e-5 (unfavourable), Pancreatic cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.3	Expressed in all		
PKN2	Pak-2, PRK2, PRKCL2, STK7	ENSG00000065243	Protein kinase N2	1	88684222-88836255	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034861, HPA057913	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Intermediate filaments<br>Cytosol	Colorectal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.8	Expressed in all		
WDR18	Ipi3	ENSG00000065268	WD repeat domain 18	19	984271-998438	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050193, HPA050200	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 17.9	Expressed in all		
TRAM2	KIAA0057	ENSG00000065308	Translocation associated membrane protein 2	6	52497402-52576915	Predicted membrane proteins	Evidence at protein level	HPA035092, HPA057925	Approved		Approved	Cytosol	Renal cancer:1.41e-9 (unfavourable), Endometrial cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 52.1	Expressed in all		
NTN1	NTN1L	ENSG00000065320	Netrin 1	17	9021542-9244000	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056419	Approved					Mixed	Mixed			esophagus: 21.2	Cell line enhanced		BEWO: 26.7;T-47d: 15.6;U-2 OS: 15.2;U-251 MG: 18.3;WM-115: 12.7
GLP2R		ENSG00000065325	Glucagon like peptide 2 receptor	17	9822206-9892102	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022690, HPA049244	Supported		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		gallbladder: 19.3	duodenum: 10.1	Cell line enhanced		A549: 15.1;HeLa: 54.7;SiHa: 8.7
MCM10	CNA43, DNA43, PRO2249	ENSG00000065328	Minichromosome maintenance 10 replication initiation factor	10	13161554-13211104	Predicted intracellular proteins	Evidence at protein level	HPA045899, HPA071952	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Mixed			bone marrow: 5.9	Mixed		
DGKA	DAGK, DAGK1, DGK-alpha	ENSG00000065357	Diacylglycerol kinase alpha	12	55927319-55954027	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041645, HPA045462	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria	Renal cancer:1.66e-5 (unfavourable)	Expressed in all	Mixed			skin: 97.4	Cell line enhanced		HBEC3-KT: 93.1;hTERT-HME1: 102.8
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ROPN1	CT91, ODF6, ROPN1A, ropporin	ENSG00000065371	Rhophilin associated tail protein 1	3	123968521-123992178	Predicted intracellular proteins	Evidence at protein level	HPA052530	Supported					Group enriched	Tissue enriched	9	testis: 223.8	breast: 24.1	Cell line enriched	7	SK-MEL-30: 21.4
ANKRD44	PP6-ARS-B	ENSG00000065413	Ankyrin repeat domain 44	2	196967017-197311173	Predicted intracellular proteins	Evidence at protein level	HPA030122, HPA056549	Approved		Approved	Nuclear speckles<br>Mitochondria		Mixed	Mixed			lymph node: 42.7	Cell line enhanced		HDLM-2: 43.2;HMC-1: 30.0
KARS	DFNB89, KARS1, KARS2	ENSG00000065427	Lysyl-tRNA synthetase	16	75627474-75648643	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041345, HPA041550	Enhanced		Supported	Cytosol	Head and neck cancer:8.84e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 178.6	Expressed in all		
ADAT1		ENSG00000065457	Adenosine deaminase, tRNA specific 1	16	75596981-75623300	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040713, HPA040903	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 91.2	Expressed in all		
PDIA5	FLJ30401, PDIR	ENSG00000065485	Protein disulfide isomerase family A member 5	3	123067062-123225227	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030353, HPA030355	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:8.09e-11 (unfavourable), Endometrial cancer:4.55e-4 (favourable)	Expressed in all	Mixed			placenta: 70.8	Mixed		
TBC1D22B	C6orf197, dJ744I24.2, FLJ20337	ENSG00000065491	TBC1 domain family member 22B	6	37257772-37332970	Predicted intracellular proteins	Evidence at protein level	HPA027908, HPA027909, HPA027910	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:8.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 18.8	Expressed in all		
NDUFB4	B15	ENSG00000065518	NADH:ubiquinone oxidoreductase subunit B4	3	120596309-120602500	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051739	Enhanced		Supported	Nuclear membrane<br>Mitochondria	Urothelial cancer:1.79e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 364.4	Expressed in all		
SPEN	KIAA0929, MINT, RBM15C, SHARP	ENSG00000065526	Spen family transcriptional repressor	1	15847864-15940460	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015825, HPA050257	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 39.0	Expressed in all		
MYLK	MLCK, MLCK1, MYLK1, smMLCK	ENSG00000065534	Myosin light chain kinase	3	123610049-123884331	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020789, HPA031677, HPA048055	Enhanced		Enhanced	Plasma membrane<br>Actin filaments	Renal cancer:2.04e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 3002.5	Cell line enhanced		BJ: 144.8;BJ hTERT+: 209.1;fHDF/TERT166: 165.3;RPTEC TERT1: 207.7
ZC3H15	LEREPO4	ENSG00000065548	Zinc finger CCCH-type containing 15	2	186486156-186509363	Predicted intracellular proteins	Evidence at protein level	HPA031099, HPA031100, HPA031101	Enhanced		Enhanced	Cytosol	Liver cancer:1.48e-7 (unfavourable), Cervical cancer:6.45e-5 (unfavourable), Ovarian cancer:3.98e-4 (favourable), Pancreatic cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
MAP2K4	JNKK1, MEK4, MKK4, PRKMK4, SERK1	ENSG00000065559	Mitogen-activated protein kinase kinase 4	17	12020824-12143830	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007751, HPA060074	Enhanced		Approved	Nucleoplasm<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 64.0	Expressed in all		
TMEM206	C1orf75, FLJ10874	ENSG00000065600	Transmembrane protein 206	1	212363931-212414901	Predicted membrane proteins	Evidence at protein level	HPA008540	Uncertain				Liver cancer:3.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.4	kidney: 10.7	Expressed in all		
SNAP91	AP180, CALM, KIAA0656	ENSG00000065609	Synaptosome associated protein 91	6	83552880-83709691	Predicted intracellular proteins	Evidence at protein level	CAB009745, HPA029632, HPA029633	Enhanced		Uncertain	Centrosome<br>Cytosol		Tissue enhanced	Tissue enriched	7	cerebral cortex: 152.1	testis: 22.5	Group enriched	16	SCLC-21H: 27.9;SH-SY5Y: 15.7
SLK	KIAA0204, se20-9, STK2	ENSG00000065613	STE20 like kinase	10	103967201-104029233	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015757	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:2.77e-5 (unfavourable), Renal cancer:3.95e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 61.0	Expressed in all		
CYB5R4	b5+b5R, dJ676J13.1, NCB5OR	ENSG00000065615	Cytochrome b5 reductase 4	6	83859643-83967424	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018992	Approved					Expressed in all	Expressed in all			testis: 22.4	Expressed in all		
COL17A1	BP180, BPAG2	ENSG00000065618	Collagen type XVII alpha 1 chain	10	104031286-104086002	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043673, HPA052963	Enhanced		Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable)	Tissue enhanced	Tissue enriched	14	skin: 769.3	placenta: 53.1	Group enriched	6	CAPAN-2: 175.9;HaCaT: 403.2;HBEC3-KT: 525.2;hTCEpi: 673.0;hTERT-HME1: 604.3
GSTO2		ENSG00000065621	Glutathione S-transferase omega 2	10	104268873-104304945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048141	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:7.10e-7 (favourable)	Mixed	Mixed			testis: 36.1	Cell line enhanced		CAPAN-2: 45.6;hTCEpi: 32.1;hTERT-HME1: 36.7;T-47d: 36.0
SEC61A2	FLJ10578	ENSG00000065665	Sec61 translocon alpha 2 subunit	10	12129637-12169961	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:1.08e-5 (favourable), Urothelial cancer:8.75e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 51.3	testis: 32.5	Expressed in all		
PRKCQ		ENSG00000065675	Protein kinase C theta	10	6427143-6580301	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065279, HPA073098			Enhanced	Microtubule organizing center	Thyroid cancer:5.27e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 43.0	thyroid gland: 25.0	Cell line enhanced		HEL: 50.9;MOLT-4: 34.7
TLE2	ESG, ESG2, FLJ41188, GRG2	ENSG00000065717	Transducin like enhancer of split 2	19	2997638-3047635	Predicted intracellular proteins	Evidence at protein level	HPA049103	Approved		Supported	Nuclear bodies<br>Focal adhesion sites	Pancreatic cancer:2.39e-6 (favourable), Renal cancer:9.49e-6 (favourable), Endometrial cancer:2.51e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 39.6	Cell line enhanced		AN3-CA: 39.6;RT4: 27.6
ASB1	ASB-1	ENSG00000065802	Ankyrin repeat and SOCS box containing 1	2	238426742-238452250	Predicted intracellular proteins	Evidence at protein level	HPA003508	Uncertain		Approved	Nucleoplasm	Endometrial cancer:4.89e-5 (unfavourable), Pancreatic cancer:1.56e-4 (favourable), Liver cancer:5.37e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.1	Expressed in all		
FAM107B	C10orf45, FLJ45505, HITS, MGC11034	ENSG00000065809	Family with sequence similarity 107 member B	10	14518557-14774897	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039661, HPA058814, HPA073195	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 179.9	Expressed in all		
ME1		ENSG00000065833	Malic enzyme 1	6	83210389-83431071	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006493	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.81e-7 (unfavourable), Liver cancer:4.57e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 54.1	Cell line enhanced		CACO-2: 113.5
TBC1D1	KIAA1108, TBC, TBC1	ENSG00000065882	TBC1 domain family member 1	4	37891087-38139175	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA041816, HPA058158	Approved		Uncertain	Nucleoli	Renal cancer:1.47e-8 (favourable), Lung cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 251.2	Expressed in all		
CDK13	CDC2L, CDC2L5, CHED, KIAA1791	ENSG00000065883	Cyclin dependent kinase 13	7	39950037-40097134	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059241	Uncertain		Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 33.5	Expressed in all		
MTHFD2		ENSG00000065911	Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase	2	74198562-74217565	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003684, HPA049657	Approved				Renal cancer:1.11e-16 (unfavourable), Endometrial cancer:2.07e-5 (unfavourable), Glioma:8.47e-5 (favourable)	Expressed in all	Expressed in all			appendix: 39.6	Expressed in all		
SLC9A7	NHE7	ENSG00000065923	Solute carrier family 9 member A7	X	46599252-46759172	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048938, HPA075385	Approved		Supported	Vesicles	Endometrial cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.4	Mixed		
FOXJ2	FHX	ENSG00000065970	Forkhead box J2	12	8032703-8055503	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008723	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Mixed		
YBX1	BP-8, CSDA2, CSDB, DBPB, MDR-NF1, NSEP-1, NSEP1, YB-1, YB1	ENSG00000065978	Y-box binding protein 1	1	42682427-42702349	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005875, HPA040304, HPA057159	Supported		Enhanced	Vesicles<br>Cytosol	Liver cancer:9.87e-10 (unfavourable), Renal cancer:3.59e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 1542.9	Expressed in all		
PDE4A	DPDE2	ENSG00000065989	Phosphodiesterase 4A	19	10416773-10469631	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017632, HPA043310, HPA076091	Uncertain		Supported	Plasma membrane		Expressed in all	Mixed			parathyroid gland: 34.0	Cell line enhanced		HMC-1: 32.2
PPP2R5A	B56A, PR61A	ENSG00000066027	Protein phosphatase 2 regulatory subunit B'alpha	1	212285537-212361863	Predicted intracellular proteins	Evidence at protein level	HPA059288			Supported	Cytosol		Expressed in all	Expressed in all			lung: 86.5	Expressed in all		
CTNNA2	CAP-R, CT114	ENSG00000066032	Catenin alpha 2	2	79185231-80648861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037175	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 111.6;epididymis: 81.5;testis: 32.2	adrenal gland: 6.3	Cell line enhanced		AF22: 7.0;Karpas-707: 5.9;NTERA-2: 6.7;SCLC-21H: 4.5;SH-SY5Y: 11.4
ELAVL1	Hua, HUR, MelG	ENSG00000066044	ELAV like RNA binding protein 1	19	7958579-8005659	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005256, HPA046298	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
TIE1	JTK14, TIE	ENSG00000066056	Tyrosine kinase with immunoglobulin like and EGF like domains 1	1	43300993-43323108	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		placenta: 70.6	lung: 40.1	Cell line enhanced		EFO-21: 100.1;HUVEC TERT2: 199.8;TIME: 171.4
DIP2B	FLJ34278, KIAA1463	ENSG00000066084	Disco interacting protein 2 homolog B	12	50504985-50748667	Predicted intracellular proteins	Evidence at protein level	HPA038472, HPA046133, HPA056045	Enhanced		Approved	Endoplasmic reticulum	Breast cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 31.0	Expressed in all		
SMARCD1	BAF60A, CRACD1, Rsc6p	ENSG00000066117	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1	12	50084972-50100712	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004101	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.5	Expressed in all		
KDM4A	JHDM3A, JMJD2, JMJD2A, KIAA0677, TDRD14A	ENSG00000066135	Lysine demethylase 4A	1	43650158-43705515	Predicted intracellular proteins	Evidence at protein level	HPA007610	Uncertain		Supported	Nucleoli fibrillar center	Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
NFYC	CBF-C, NF-YC	ENSG00000066136	Nuclear transcription factor Y subunit gamma	1	40691648-40771603	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055011			Supported	Nucleoplasm	Renal cancer:1.24e-4 (favourable), Liver cancer:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.6	Expressed in all		
ZMYND12	DKFZp434N2435	ENSG00000066185	Zinc finger MYND-type containing 12	1	42430329-42456267	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.11e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.4;testis: 51.8	epididymis: 8.7	Cell line enhanced		HSkMC: 1.6;SK-MEL-30: 1.5;WM-115: 1.4
SLC9A3	NHE3	ENSG00000066230	Solute carrier family 9 member A3	5	473310-524332	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036493, HPA036669	Enhanced		Supported	Plasma membrane	Melanoma:8.49e-4 (unfavourable)	Mixed	Tissue enhanced		colon: 80.9;gallbladder: 66.1;small intestine: 72.6	kidney: 57.3	Cell line enhanced		HDLM-2: 30.4
NGEF	ARHGEF27	ENSG00000066248	Neuronal guanine nucleotide exchange factor	2	232878686-233013272	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008160	Approved		Uncertain	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 66.5;cerebral cortex: 151.4	duodenum: 42.8	Cell line enhanced		A-431: 46.9;HDLM-2: 42.0;PC-3: 52.8;T-47d: 30.2
ASPM	ASP, Calmbp1, FLJ10517, FLJ10549, MCPH5	ENSG00000066279	Abnormal spindle microtubule assembly	1	197084128-197146694	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017816	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.25e-4 (unfavourable), Endometrial cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.40e-4 (unfavourable), Lung cancer:2.41e-4 (unfavourable)	Mixed	Mixed			bone marrow: 9.3	Mixed		
CD84	hCD84, mCD84, SLAMF5	ENSG00000066294	CD84 molecule	1	160541095-160579516	CD markers, Predicted membrane proteins	Evidence at protein level	HPA070502	Enhanced					Expressed in all	Tissue enhanced		lymph node: 28.4	appendix: 26.8	Cell line enhanced		Daudi: 17.1;HEL: 41.2;HMC-1: 44.1;U-698: 22.1
ELOVL1	Ssc1	ENSG00000066322	ELOVL fatty acid elongase 1	1	43363397-43368074	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB033426, HPA056557	Approved		Approved	Endoplasmic reticulum	Liver cancer:2.79e-7 (unfavourable), Cervical cancer:3.63e-5 (unfavourable), Pancreatic cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 156.7	Expressed in all		
SPI1	OF, PU.1, SFPI1, SPI-1, SPI-A	ENSG00000066336	Spi-1 proto-oncogene	11	47354860-47378576	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB004079, HPA044653	Enhanced		Supported	Nucleoplasm	Renal cancer:2.07e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 212.5	Cell line enhanced		HL-60: 125.6;HMC-1: 245.7;NB-4: 167.8;THP-1: 137.9;U-937: 90.6
ZNRD1	HTEX-6, hZR14, RPA12, tctex-6	ENSG00000066379	Zinc ribbon domain containing 1	6	30058899-30064909	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA055074, HPA077979	Supported		Supported	Nucleoli fibrillar center	Renal cancer:2.17e-7 (unfavourable), Urothelial cancer:2.75e-5 (favourable)	Expressed in all	Mixed			lymph node: 5.9	Mixed		
MPPED2	239FB, C11orf8, D11S302E, dJ1024C24.1, dJ873F21.1, FAM1B, Hs.46638	ENSG00000066382	Metallophosphoesterase domain containing 2	11	30384493-30586872	Predicted intracellular proteins	Evidence at protein level	HPA062575			Approved	Nucleoli<br>Vesicles<br>Mitochondria		Mixed	Tissue enhanced		cervix, uterine: 38.7;thyroid gland: 43.7	prostate: 20.9	Cell line enhanced		HaCaT: 19.2;HAP1: 13.2;RT4: 7.3;SH-SY5Y: 7.2
CLDN18	SFTPJ	ENSG00000066405	Claudin 18	3	137998735-138033655	Predicted membrane proteins	Evidence at protein level	CAB013010, CAB013243, HPA018446	Enhanced					Group enriched	Group enriched	85	lung: 361.8;stomach: 689.7	heart muscle: 6.1	Not detected		
ZBTB11	ZNF-U69274, ZNF913	ENSG00000066422	Zinc finger and BTB domain containing 11	3	101648889-101677495	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA015328, HPA024138	Approved		Enhanced	Nucleoplasm	Endometrial cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 23.4	Expressed in all		
ATXN3	ATX3, JOS, MJD, SCA3	ENSG00000066427	Ataxin 3	14	92038652-92106621	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB021976, HPA024123, HPA069338	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Mixed	Mixed			testis: 18.6	Expressed in all		
GOLGA5	golgin-84, GOLIM5, ret-II, rfg5	ENSG00000066455	Golgin A5	14	92794231-92839963	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000992, HPA063876	Enhanced	Supported	Supported	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 65.3	Expressed in all		
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
LRRC40	FLJ20331	ENSG00000066557	Leucine rich repeat containing 40	1	70144805-70205620	Predicted intracellular proteins	Evidence at protein level	HPA026564	Approved		Approved	Nucleoli	Colorectal cancer:4.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.7	Expressed in all		
ISOC1	CGI-111	ENSG00000066583	Isochorismatase domain containing 1	5	129094751-129114028	Predicted intracellular proteins	Evidence at protein level	HPA070307			Approved	Endoplasmic reticulum<br>Vesicles		Expressed in all	Expressed in all			endometrium: 175.5	Expressed in all		
EML1	ELP79, EMAP, EMAPL, HuEMAP	ENSG00000066629	Echinoderm microtubule associated protein like 1	14	99737693-99942060	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033137, HPA049105	Uncertain					Expressed in all	Mixed			parathyroid gland: 51.3	Cell line enhanced		HDLM-2: 84.2;U-2197: 100.9
TRMT11	C6orf75, dJ187J11.2, MDS024, TRM11, TRMT11-1	ENSG00000066651	TRNA methyltransferase 11 homolog	6	125986430-126039276	Predicted intracellular proteins	Evidence at protein level	HPA030473			Approved	Nuclear bodies		Expressed in all	Expressed in all			thyroid gland: 16.5	Mixed		
THUMPD1	FLJ20274, Tan1	ENSG00000066654	THUMP domain containing 1	16	20702816-20742084	Predicted intracellular proteins	Evidence at protein level	HPA027851	Approved		Approved	Cytosol	Renal cancer:8.52e-8 (favourable), Colorectal cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 68.5	Expressed in all		
MSANTD3	C9orf30, MGC17337	ENSG00000066697	Myb/SANT DNA binding domain containing 3	9	100427156-100451711	Predicted intracellular proteins	Evidence at protein level	HPA062662			Approved	Nucleoplasm	Renal cancer:3.22e-7 (unfavourable), Liver cancer:3.23e-6 (unfavourable), Head and neck cancer:6.66e-5 (unfavourable), Lung cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 23.4	Expressed in all		
KIF26A	DKFZP434N178, KIAA1236	ENSG00000066735	Kinesin family member 26A	14	104138723-104180894	Predicted intracellular proteins	Evidence at protein level	HPA046882, HPA060346	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:7.78e-4 (unfavourable)	Group enriched	Mixed			adipose tissue: 5.0	Cell line enhanced		HeLa: 18.9;MCF7: 18.8;NTERA-2: 20.8;REH: 17.1;SCLC-21H: 22.6;SH-SY5Y: 41.6
ATG2B	C14orf103, FLJ10242	ENSG00000066739	Autophagy related 2B	14	96279202-96363870	Predicted intracellular proteins	Evidence at protein level	HPA000880, HPA001427, HPA019665	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 17.1	Expressed in all		
ARFGEF1	ARFGEP1, BIG1, DKFZP434L057, p200	ENSG00000066777	ADP ribosylation factor guanine nucleotide exchange factor 1	8	67173511-67343677	Predicted intracellular proteins	Evidence at protein level	HPA023399, HPA023822	Supported	Approved	Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:2.48e-4 (favourable), Breast cancer:8.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.5	Expressed in all		
ACSM2B	ACSM2, HXMA, HYST1046	ENSG00000066813	Acyl-CoA synthetase medium-chain family member 2B	16	20536226-20576427	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057699	Supported				Liver cancer:3.31e-4 (favourable)	Group enriched	Group enriched	136	kidney: 426.7;liver: 262.0	thyroid gland: 2.5	Cell line enhanced		AF22: 2.8;Hep G2: 3.7
ZFAT	KIAA1485, ZFAT1, ZNF406	ENSG00000066827	Zinc finger and AT-hook domain containing	8	134477788-134713049	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020989, HPA063592	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Group enriched	6	kidney: 10.5;placenta: 44.3	testis: 4.3	Mixed		
MTFR1	CHPPR, FAM54A2, KIAA0009	ENSG00000066855	Mitochondrial fission regulator 1	8	65644734-65771261	Predicted intracellular proteins	Evidence at protein level	HPA023152, HPA056120	Uncertain		Supported	Mitochondria<br>Cytosol	Breast cancer:4.06e-4 (unfavourable), Thyroid cancer:5.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
STAG3		ENSG00000066923	Stromal antigen 3	7	100177563-100221488	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049106, HPA058330	Enhanced				Cervical cancer:8.45e-4 (favourable)	Mixed	Tissue enriched	5	testis: 130.2	fallopian tube: 23.9	Group enriched	6	BEWO: 49.1;HMC-1: 56.4;U-698: 13.2
FECH		ENSG00000066926	Ferrochelatase	18	57548283-57586772	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044100, HPA048177	Approved				Renal cancer:2.38e-10 (favourable)	Expressed in all	Expressed in all			bone marrow: 93.3	Expressed in all		
MYO9A	FLJ11061, FLJ13244, MGC71859	ENSG00000066933	Myosin IXA	15	71822289-72118577	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039812, HPA040071	Approved		Approved	Plasma membrane	Renal cancer:2.14e-4 (favourable)	Mixed	Tissue enhanced		testis: 51.5	thyroid gland: 22.1	Expressed in all		
DDX3Y	DBY	ENSG00000067048	DEAD-box helicase 3, Y-linked	Y	12904108-12920478	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001648, HPA005631	Uncertain	Approved	Supported	Nucleus<br>Cytosol	Head and neck cancer:4.70e-5 (favourable)	Mixed	Tissue enhanced		testis: 128.6	prostate: 54.0	Cell line enhanced		HEL: 139.0
PFKP	PFK-C, PFKF	ENSG00000067057	Phosphofructokinase, platelet	10	3066333-3137712	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018257, HPA056484	Uncertain		Supported	Cytosol	Liver cancer:8.72e-6 (unfavourable), Head and neck cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 285.1	Mixed		
IDI1		ENSG00000067064	Isopentenyl-diphosphate delta isomerase 1	10	1039908-1049170	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039169	Approved				Renal cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			breast: 244.8	Expressed in all		
SP100		ENSG00000067066	SP100 nuclear antigen	2	230415942-230544090	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016707, HPA017384	Enhanced		Supported	Nucleus<br>Nuclear bodies	Renal cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 139.6	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 274.7
KLF6	BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9	ENSG00000067082	Kruppel like factor 6	10	3775996-3785281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013529, HPA069585	Supported		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Renal cancer:2.28e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 323.6	Expressed in all		
PLPP1	LPP1, PAP-2a, PPAP2A	ENSG00000067113	Phospholipid phosphatase 1	5	55424854-55535050	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB033331, HPA047815	Enhanced		Supported	Plasma membrane	Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable)	Expressed in all	Mixed			prostate: 339.9	Cell line enhanced		ASC diff: 295.0;HMC-1: 201.8
NEO1	HsT17534, IGDCC2, NGN, NTN1R2	ENSG00000067141	Neogenin 1	15	73051710-73305206	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009320, HPA027804, HPA027805, HPA027806	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Renal cancer:4.39e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 102.7	Mixed		
TRAM1	TRAM, TRAMP	ENSG00000067167	Translocation associated membrane protein 1	8	70573442-70608387	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023929	Approved				Cervical cancer:2.06e-4 (unfavourable), Renal cancer:7.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 317.7	Expressed in all		
PHKA1	PHKA	ENSG00000067177	Phosphorylase kinase regulatory subunit alpha 1	X	72578814-72714319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001081	Enhanced		Approved	Vesicles	Endometrial cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 40.1;skeletal muscle: 35.5	adrenal gland: 15.6	Mixed		
TNFRSF1A	CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60	ENSG00000067182	TNF receptor superfamily member 1A	12	6328757-6342114	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004102, CAB010309	Approved				Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 141.2	Mixed		
CACNB1	CACNLB1	ENSG00000067191	Calcium voltage-gated channel auxiliary subunit beta 1	17	39173456-39197703	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023343	Approved				Endometrial cancer:3.80e-4 (unfavourable)	Mixed	Group enriched	6	cerebral cortex: 46.7;skeletal muscle: 108.5	skin: 12.3	Mixed		
EVI5	NB4S	ENSG00000067208	Ecotropic viral integration site 5	1	92508696-92792404	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027339, HPA053724	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 18.0	Mixed		
STOML1	FLJ36370, hUNC-24, SLP-1, STORP	ENSG00000067221	Stomatin like 1	15	73978923-73994622	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042353	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 43.7	Expressed in all		
PKM	OIP3, PK3, PKM2, THBP1	ENSG00000067225	Pyruvate kinase, muscle	15	72199029-72231822	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019421, HPA029501	Uncertain		Enhanced	Cytosol	Liver cancer:2.74e-6 (unfavourable), Pancreatic cancer:5.17e-5 (unfavourable), Head and neck cancer:1.30e-4 (unfavourable), Lung cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 1492.3	Expressed in all		
DHX29	DDX29	ENSG00000067248	DExH-box helicase 29	5	55256245-55307722	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038317, HPA038318	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 39.2	Expressed in all		
DNTTIP2	ERBP, HSU15552, TdIF2	ENSG00000067334	Deoxynucleotidyltransferase terminal interacting protein 2	1	93866283-93879918	Predicted intracellular proteins	Evidence at protein level	HPA044502, HPA053707	Enhanced		Enhanced	Nucleoli	Liver cancer:1.90e-6 (unfavourable), Renal cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 10.5	Expressed in all		
METTL22	C16orf68, FLJ12433, MGC2654	ENSG00000067365	Methyltransferase like 22	16	8621683-8649654	Predicted intracellular proteins	Evidence at protein level	HPA040803, HPA059882, HPA074173	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:2.79e-8 (unfavourable)	Expressed in all	Mixed			testis: 15.9	Expressed in all		
TP53BP1	53BP1, p202, TDRD30	ENSG00000067369	Tumor protein p53 binding protein 1	15	43403061-43510728	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004083, HPA008788, HPA022133	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
TRO	KIAA1114, MAGE-D3, MAGED3	ENSG00000067445	Trophinin	X	54920462-54931431	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053358			Approved	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:4.41e-5 (unfavourable), Pancreatic cancer:1.93e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 30.0	endometrium: 22.2	Cell line enhanced		AF22: 36.8;SCLC-21H: 29.3;SH-SY5Y: 35.5
RRP15	CGI-115, KIAA0507	ENSG00000067533	Ribosomal RNA processing 15 homolog	1	218285287-218337983	Predicted intracellular proteins	Evidence at protein level	HPA024639	Approved		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Liver cancer:4.26e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 7.7	Expressed in all		
RHOA	ARH12, ARHA, Rho12, RhoA, RHOH12	ENSG00000067560	Ras homolog family member A	3	49359145-49412998	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005052	Approved				Renal cancer:3.21e-6 (favourable), Colorectal cancer:3.08e-4 (favourable), Liver cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 592.0	Expressed in all		
DHX8	DDX8, HRH1, PRP22, PRPF22	ENSG00000067596	DEAH-box helicase 8	17	43483865-43544463	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049285	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 55.0	Expressed in all		
PRKCZ	PKC2	ENSG00000067606	Protein kinase C zeta	1	2050470-2185395	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021851	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.64e-9 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 99.7	placenta: 62.3	Cell line enhanced		BEWO: 45.1
ZFY	ZNF911	ENSG00000067646	Zinc finger protein, Y-linked	Y	2935281-2982506	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001748, HPA071863	Uncertain		Approved	Nucleoplasm<br>Nucleoli	Head and neck cancer:3.58e-5 (favourable)	Mixed	Mixed			testis: 12.8	Mixed		
IARS2	FLJ10326	ENSG00000067704	Isoleucyl-tRNA synthetase 2, mitochondrial	1	220094102-220148041	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024212, HPA024594, HPA024596	Enhanced		Enhanced	Mitochondria	Pancreatic cancer:9.24e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 144.3	Expressed in all		
SYT1	P65, SVP65, SYT	ENSG00000067715	Synaptotagmin 1	12	78863993-79452008	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008394, HPA064788	Enhanced	Supported				Mixed	Tissue enriched	13	cerebral cortex: 476.5	smooth muscle: 36.7	Cell line enhanced		hTERT-HME1: 29.8;LHCN-M2: 26.5;SH-SY5Y: 32.1;WM-115: 28.3
NAV3	KIAA0938, POMFIL1	ENSG00000067798	Neuron navigator 3	12	77324641-78213008	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA032111, HPA032112, CAB037063	Uncertain		Approved	Nuclear membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 27.2;ovary: 24.6	spleen: 12.3	Cell line enhanced		hTEC/SVTERT24-B: 46.2;WM-115: 38.6
IDH3G		ENSG00000067829	Isocitrate dehydrogenase 3 (NAD(+)) gamma	X	153785766-153794523	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000425, HPA002017	Enhanced		Enhanced	Mitochondria	Renal cancer:5.73e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 64.9	Expressed in all		
ROGDI	FLJ22386	ENSG00000067836	Rogdi homolog	16	4796968-4802950	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041000	Uncertain				Renal cancer:2.67e-5 (favourable), Pancreatic cancer:9.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 39.2	Mixed		
PDZD4	FLJ34125, KIAA1444, LNX5, LU1, PDZK4, PDZRN4L	ENSG00000067840	PDZ domain containing 4	X	153802166-153830565	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003878	Enhanced				Pancreatic cancer:2.96e-5 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 123.5	seminal vesicle: 13.7	Cell line enhanced		AF22: 24.1;RH-30: 16.8;SCLC-21H: 34.7;SH-SY5Y: 30.4;U-2 OS: 14.9
ATP2B3	CFAP39, CLA2, PMCA3, SCAX1	ENSG00000067842	ATPase plasma membrane Ca2+ transporting 3	X	153517676-153582939	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001583	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane		Not detected	Group enriched	8	adrenal gland: 12.1;cerebral cortex: 19.0	fallopian tube: 2.0	Cell line enhanced		SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ROCK1	p160ROCK	ENSG00000067900	Rho associated coiled-coil containing protein kinase 1	18	20946906-21111851	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004562, HPA007567, HPA045639	Approved				Pancreatic cancer:9.93e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 12.3	Expressed in all		
CBFB	PEBP2B	ENSG00000067955	Core-binding factor beta subunit	16	67029116-67101058	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038852	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.89e-8 (unfavourable), Liver cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 97.5	Expressed in all		
PDK3		ENSG00000067992	Pyruvate dehydrogenase kinase 3	X	24465221-24539837	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046583, HPA072492	Approved		Supported	Nucleoli<br>Mitochondria	Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.9	Mixed		
HYAL2	LuCa-2, LUCA2	ENSG00000068001	Hyaluronoglucosaminidase 2	3	50317790-50322906	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036436	Uncertain					Expressed in all	Expressed in all			spleen: 214.2	Expressed in all		
HDAC4	BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288	ENSG00000068024	Histone deacetylase 4	2	239048168-239401654	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004431, HPA048723	Approved		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.13e-4 (favourable), Ovarian cancer:6.33e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 19.3	Cell line enhanced		MOLT-4: 40.5
RASSF1	123F2, NORE2A, RDA32, REH3P21	ENSG00000068028	Ras association domain family member 1	3	50329782-50340980	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040735	Approved				Renal cancer:8.58e-5 (unfavourable), Head and neck cancer:2.60e-4 (favourable), Cervical cancer:2.64e-4 (favourable), Liver cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 51.8	Expressed in all		
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
IFI35	IFP35	ENSG00000068079	Interferon induced protein 35	17	43006725-43014456	Predicted intracellular proteins	Evidence at protein level	HPA045946			Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.03e-5 (unfavourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			spleen: 44.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 190.3;BJ hTERT+ SV40 Large T+ RasG12V: 291.3
HEATR6	ABC1, FLJ22087	ENSG00000068097	HEAT repeat containing 6	17	60043194-60078931	Predicted intracellular proteins	Evidence at protein level	HPA030789, HPA062157	Uncertain		Approved	Mitochondria	Liver cancer:5.02e-6 (unfavourable), Endometrial cancer:2.03e-4 (unfavourable), Renal cancer:6.73e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.3	Cell line enhanced		MCF7: 80.3
COASY	CoASY, DPCK, NBP, PPAT	ENSG00000068120	Coenzyme A synthase	17	42561467-42566277	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022875, HPA022912, HPA023273	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.54e-5 (unfavourable), Endometrial cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.1	Expressed in all		
PLEKHH3	FLJ21019	ENSG00000068137	Pleckstrin homology, MyTH4 and FERM domain containing H3	17	42667914-42676994	Predicted intracellular proteins	Evidence at protein level	HPA046234	Uncertain		Approved	Golgi apparatus	Renal cancer:9.62e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 11.6	Cell line enhanced		T-47d: 46.9
MEF2A	RSRFC4, RSRFC9	ENSG00000068305	Myocyte enhancer factor 2A	15	99565417-99716466	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004499, HPA046597	Approved		Supported	Nucleoplasm	Renal cancer:6.93e-4 (favourable), Stomach cancer:7.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 68.5	Expressed in all		
OTUD5	DKFZp761A052, DUBA	ENSG00000068308	OTU deubiquitinase 5	X	48922028-48958386	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017375	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Lung cancer:1.48e-4 (favourable), Pancreatic cancer:8.20e-4 (favourable), Cervical cancer:9.57e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.9	Group enriched	8	U-266/70: 1128.2;U-266/84: 277.1
TFE3	bHLHe33, TFEA	ENSG00000068323	Transcription factor binding to IGHM enhancer 3	X	49028726-49043486	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023881	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.19e-8 (unfavourable), Liver cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 24.4	Expressed in all		
TBC1D25	OATL1	ENSG00000068354	TBC1 domain family member 25	X	48539457-48562609	Predicted intracellular proteins	Evidence at protein level	HPA029197	Approved	Supported				Expressed in all	Expressed in all			parathyroid gland: 12.9	Expressed in all		
ACSL4	ACS4, FACL4, LACS4, MRX63, MRX68	ENSG00000068366	Acyl-CoA synthetase long-chain family member 4	X	109624244-109733403	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000286, HPA005552	Enhanced		Approved	Golgi apparatus<br>Mitochondria	Urothelial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 70.7	Cell line enhanced		HMC-1: 324.7
INPP5A	5PTASE	ENSG00000068383	Inositol polyphosphate-5-phosphatase A	10	132537820-132783480	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012285, HPA066549	Enhanced		Approved	Cytosol	Renal cancer:3.15e-4 (favourable), Breast cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 60.9	Expressed in all		
GPKOW	GPATC5, GPATCH5, Spp2, T54	ENSG00000068394	G-patch domain and KOW motifs	X	49113389-49123801	Predicted intracellular proteins	Evidence at protein level	HPA000287, HPA001894	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 30.8	Expressed in all		
GRIPAP1	DKFZp434P0630, GRASP-1, GRASP1, KIAA1167, MPMGp800B12492Q3	ENSG00000068400	GRIP1 associated protein 1	X	48973720-49002264	Predicted intracellular proteins	Evidence at protein level	HPA000282, HPA000615	Enhanced		Approved	Vesicles<br>Cytosol	Renal cancer:3.92e-7 (unfavourable), Urothelial cancer:4.63e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 68.5	Expressed in all		
FTSJ1	CDLIV, JM23, MRX44, MRX9, SPB1, TRM7, TRMT7	ENSG00000068438	FtsJ RNA methyltransferase homolog 1 (E. coli)	X	48476021-48486364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002718	Approved		Approved	Cytosol	Renal cancer:5.24e-10 (unfavourable), Liver cancer:1.74e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 24.7	Expressed in all		
PRR11	FLJ11029	ENSG00000068489	Proline rich 11	17	59155499-59204705	Predicted intracellular proteins	Evidence at protein level	HPA023923, HPA052376	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.35e-7 (unfavourable), Lung cancer:1.79e-4 (unfavourable), Endometrial cancer:1.90e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 11.2	Mixed		
REEP1	C2orf23, FLJ13110, SPG31, Yip2a	ENSG00000068615	Receptor accessory protein 1	2	86213993-86338083	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058061	Enhanced					Mixed	Tissue enhanced		testis: 92.3	cerebral cortex: 54.1	Cell line enhanced		BEWO: 65.9;SCLC-21H: 38.4
ATP11A	ATPIH, ATPIS, KIAA1021	ENSG00000068650	ATPase phospholipid transporting 11A	13	112690329-112887168	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035583, HPA035584	Approved		Enhanced	Vesicles	Renal cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			lung: 59.1	Mixed		
POLR1A	DKFZP586M0122, FLJ21915, RPA1, RPO1-4	ENSG00000068654	RNA polymerase I subunit A	2	86020216-86106155	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010145, HPA031513, HPA049700	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:3.70e-9 (unfavourable), Ovarian cancer:3.37e-4 (unfavourable), Thyroid cancer:8.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.3	Expressed in all		
LAPTM4A	HUMORF13, KIAA0108, LAPTM4, MBNT, Mtrp	ENSG00000068697	Lysosomal protein transmembrane 4 alpha	2	20032650-20052028	Predicted membrane proteins	Evidence at protein level	HPA031402, HPA031404, HPA068554	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Pancreatic cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 635.0	Expressed in all		
TTC7A	KIAA1140, TTC7	ENSG00000068724	Tetratricopeptide repeat domain 7A	2	46916157-47076137	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036781, HPA036782	Enhanced				Ovarian cancer:1.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.9	lung: 17.7	Expressed in all		
IP6K2	IHPK2	ENSG00000068745	Inositol hexakisphosphate kinase 2	3	48688003-48740353	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007532, HPA070811	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions	Breast cancer:1.25e-4 (favourable), Urothelial cancer:1.83e-4 (favourable), Lung cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 131.1	Expressed in all		
STON1-GTF2A1L	SALF	ENSG00000068781	STON1-GTF2A1L readthrough	2	48529925-48776517	Predicted intracellular proteins	Evidence at protein level	HPA005715	Uncertain					Not detected	Mixed			endometrium,smooth muscle: 3.6	Cell line enhanced		ASC diff: 1.5;ASC TERT1: 1.4;HSkMC: 1.0
SRBD1	FLJ10379	ENSG00000068784	S1 RNA binding domain 1	2	45388680-45612165	Predicted intracellular proteins	Evidence at protein level	HPA030567, HPA030568	Approved		Approved	Mitochondria<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 31.8	Expressed in all		
KIF2A	HK2, KIF2	ENSG00000068796	Kinesin family member 2A	5	62306162-62537249	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004715, HPA004716	Approved		Enhanced	Nucleus<br>Nucleoli<br>Centrosome	Liver cancer:3.17e-6 (unfavourable), Renal cancer:3.81e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable), Head and neck cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 91.8	Expressed in all		
RASGRP2	CALDAG-GEFI	ENSG00000068831	RAS guanyl releasing protein 2	11	64726911-64745456	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA015667	Approved				Renal cancer:1.38e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 122.0;spleen: 107.0	bone marrow: 94.3	Cell line enhanced		HEL: 90.3;HL-60: 145.9;NB-4: 219.4;REH: 94.2;THP-1: 72.4
PSME4	KIAA0077, PA200	ENSG00000068878	Proteasome activator subunit 4	2	53864067-53970840	Predicted intracellular proteins	Evidence at protein level	HPA060922	Approved		Supported	Nucleoplasm	Liver cancer:4.84e-4 (unfavourable), Endometrial cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.1	Expressed in all		
IFT80	KIAA1374, WDR56	ENSG00000068885	Intraflagellar transport 80	3	160256986-160399880	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035868	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 46.5	Expressed in all		
SIRT2	SIR2L	ENSG00000068903	Sirtuin 2	19	38878555-38899862	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004573, HPA011165	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:7.20e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
ERLEC1	C2orf30, CL25084, ERLECTIN, XTP3-B, XTP3TPB	ENSG00000068912	Endoplasmic reticulum lectin 1	2	53787044-53818819	Predicted secreted proteins, Transporters	Evidence at protein level	HPA031501, HPA031502, HPA031503	Enhanced					Expressed in all	Expressed in all			thyroid gland: 121.9	Expressed in all		
PPP2R5B	B56B, FLJ35411, PR61B	ENSG00000068971	Protein phosphatase 2 regulatory subunit B'beta	11	64917553-64934473	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036607	Approved				Liver cancer:3.24e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 59.7	Expressed in all		
PYGM		ENSG00000068976	Glycogen phosphorylase, muscle associated	11	64746389-64760297	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056003	Enhanced					Mixed	Tissue enriched	32	skeletal muscle: 2831.9	esophagus: 89.0	Cell line enhanced		HSkMC: 2.6
PAGE1	CT16.3, GAGE-9, GAGEB1, PAGE-1	ENSG00000068985	PAGE family member 1	X	49687450-49695993	Predicted intracellular proteins	Evidence at protein level	HPA003473	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria		Tissue enhanced	Tissue enriched	168	testis: 25.1	epididymis,placenta: 0.1	Group enriched	7	A-431: 161.4;Karpas-707: 98.5;U-266/84: 157.3
PITX1	BFT, POTX, PTX1	ENSG00000069011	Paired like homeodomain 1	5	135027735-135034813	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008743	Approved		Supported	Nucleoli		Tissue enhanced	Tissue enriched	5	esophagus: 211.7	salivary gland: 38.5	Cell line enhanced		CACO-2: 116.7;K-562: 103.4;T-47d: 154.3
TRPC7		ENSG00000069018	Transient receptor potential cation channel subfamily C member 7	5	136213320-136365537	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB022592, HPA031126	Uncertain		Uncertain	Actin filaments<br>Focal adhesion sites		Not detected	Not detected			testis: 0.7	Not detected		
MAST4	KIAA0303	ENSG00000069020	Microtubule associated serine/threonine kinase family member 4	5	66596361-67169595	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000544	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:5.18e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 47.7	Cell line enhanced		HDLM-2: 40.1
ADGRF5	DKFZp564O1923, GPR116, KIAA0758	ENSG00000069122	Adhesion G protein-coupled receptor F5	6	46852512-46954943	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.84e-5 (favourable)	Expressed in all	Tissue enhanced		lung: 157.8	adipose tissue: 76.2	Group enriched	8	HUVEC TERT2: 20.7;TIME: 61.2
SDK2	FLJ10832, KIAA1514	ENSG00000069188	Sidekick cell adhesion molecule 2	17	73334384-73644089	Predicted membrane proteins	Evidence at protein level	HPA014725			Approved	Nucleoplasm		Mixed	Tissue enhanced		cervix, uterine: 9.0;testis: 18.6	fallopian tube: 4.0	Cell line enhanced		AF22: 13.8;BEWO: 11.0;U-2 OS: 5.0
ADAM7	EAPI, GP-83	ENSG00000069206	ADAM metallopeptidase domain 7	8	24440930-24526970	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008879	Enhanced					Group enriched	Tissue enriched	199	epididymis: 4534.6	seminal vesicle: 22.7	Group enriched	23	BEWO: 2.3;NB-4: 3.9;RPMI-8226: 1.1;SH-SY5Y: 1.9
NUP133	FLJ10814	ENSG00000069248	Nucleoporin 133	1	229440260-229508341	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059767	Approved		Supported	Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 33.1	Expressed in all		
NUCKS1	NUCKS	ENSG00000069275	Nuclear casein kinase and cyclin dependent kinase substrate 1	1	205712819-205750276	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062351, HPA063843	Supported		Supported	Nucleus<br>Nucleoli	Endometrial cancer:1.41e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 179.2	Expressed in all		
VPS35	FLJ10752, MEM3, PARK17	ENSG00000069329	VPS35, retromer complex component	16	46656132-46689518	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040802	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:2.10e-6 (unfavourable), Renal cancer:9.75e-5 (favourable), Colorectal cancer:7.74e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.8	Expressed in all		
DNAJA2	CPR3, DNAJ, DNJ3, HIRIP4	ENSG00000069345	DnaJ heat shock protein family (Hsp40) member A2	16	46955362-46973788	Predicted intracellular proteins	Evidence at protein level	HPA049789, HPA060538	Approved		Approved	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:1.19e-9 (favourable), Head and neck cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.0	Expressed in all		
BCL3	BCL4, D19S37	ENSG00000069399	B-cell CLL/lymphoma 3	19	44747705-44760044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002051, HPA047514	Approved		Supported	Nucleoplasm<br>Vesicles<br>Midbody	Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			appendix: 30.1	Cell line enhanced		HDLM-2: 55.4;SiHa: 65.8
KCNAB2	AKR6A5, HKvbeta2.1, HKvbeta2.2, KCNA2B	ENSG00000069424	Potassium voltage-gated channel subfamily A regulatory beta subunit 2	1	5991466-6101193	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001975	Enhanced				Renal cancer:3.50e-5 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 145.9	bone marrow: 74.8	Cell line enhanced		HL-60: 277.8;U-937: 287.1
ABCC9	CMD1O, SUR2	ENSG00000069431	ATP binding cassette subfamily C member 9	12	21797401-21942529	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007279	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.85e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 37.2	Cell line enhanced		ASC diff: 18.7;CACO-2: 21.7;HSkMC: 23.7;U-138 MG: 27.1
GAL	GAL-GMAP, GALN, GLNN, GMAP	ENSG00000069482	Galanin and GMAP prepropeptide	11	68683779-68691175	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049864	Enhanced	Supported	Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.22e-4 (unfavourable), Lung cancer:8.17e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 18.1;smooth muscle: 12.1	colon: 5.2	Cell line enhanced		CACO-2: 193.9;K-562: 111.4;NB-4: 277.5;SH-SY5Y: 179.1
CLEC2D	CLAX, LLT1, OCIL	ENSG00000069493	C-type lectin domain family 2 member D	12	9664969-9699555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017649, HPA047584	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.85e-11 (unfavourable), Urothelial cancer:1.68e-7 (favourable), Cervical cancer:1.37e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 63.4	tonsil: 38.0	Cell line enhanced		Daudi: 48.6;HDLM-2: 49.6;U-698: 71.5
FUNDC1	MGC51029	ENSG00000069509	FUN14 domain containing 1	X	44523639-44543001	Predicted intracellular proteins	Evidence at protein level	HPA038773	Uncertain				Urothelial cancer:2.58e-4 (favourable), Testis cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.6	Mixed		
MAOB		ENSG00000069535	Monoamine oxidase B	X	43766611-43882447	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA002328, CAB037200	Enhanced		Approved	Nucleoli<br>Mitochondria		Expressed in all	Mixed			seminal vesicle: 215.4	Group enriched	9	Hep G2: 28.1;SiHa: 82.8
RORA	NR1F1, ROR1, ROR2, ROR3, RZRA	ENSG00000069667	RAR related orphan receptor A	15	60488284-61229319	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009861	Approved				Renal cancer:5.42e-6 (favourable)	Mixed	Expressed in all			skin: 76.3	Cell line enhanced		Karpas-707: 52.5;U-266/70: 31.7;U-266/84: 43.2
DRD4		ENSG00000069696	Dopamine receptor D4	11	637293-640706	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			skin: 0.3	Not detected		
TGFBR3	betaglycan, BGCAN	ENSG00000069702	Transforming growth factor beta receptor 3	1	91680343-91906335	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008257, CAB018971	Supported		Uncertain	Cytosol	Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			ovary: 99.9	Cell line enhanced		ASC diff: 152.4;ASC TERT1: 75.3;U-2197: 71.9
KIAA1107		ENSG00000069712	KIAA1107	1	92166985-92184723	Predicted intracellular proteins	Evidence at protein level	HPA024216	Supported					Mixed	Group enriched	9	cerebral cortex: 45.9;testis: 10.7	adrenal gland,epididymis: 3.2	Mixed		
PLA2G10	GXPLA2	ENSG00000069764	Phospholipase A2 group X	16	14672545-14694669	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041893	Uncertain				Endometrial cancer:5.74e-5 (favourable)	Mixed	Tissue enhanced		colon: 6.9;rectum: 6.5;stomach: 10.4	duodenum: 2.2	Cell line enhanced		CAPAN-2: 1.3
HES2	bHLHb40	ENSG00000069812	Hes family bHLH transcription factor 2	1	6412418-6424670	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA039462	Uncertain					Mixed	Tissue enhanced		skin: 17.0	placenta: 9.8	Cell line enhanced		BEWO: 19.0;HaCaT: 33.0;HBEC3-KT: 23.1;TIME: 44.9
ATP1B3	CD298, FLJ29027	ENSG00000069849	ATPase Na+/K+ transporting subunit beta 3	3	141876124-141926514	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB020697, HPA048963	Enhanced		Supported	Plasma membrane	Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable)	Expressed in all	Expressed in all			skin: 310.1	Expressed in all		
NEDD4	KIAA0093, MGC176705, NEDD4-1, RPF1	ENSG00000069869	Neural precursor cell expressed, developmentally down-regulated 4, E3 ubiquitin protein ligase	15	55826922-55993746	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB001991, HPA039883, CAB072833	Approved		Approved	Cytosol	Renal cancer:3.74e-6 (unfavourable), Lung cancer:5.14e-4 (unfavourable)	Expressed in all	Mixed			placenta: 22.4	Mixed		
PIGB		ENSG00000069943	Phosphatidylinositol glycan anchor biosynthesis class B	15	55318960-55355648	Predicted membrane proteins	Evidence at protein level	HPA039929	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 22.8	Expressed in all		
MAPK6	ERK3, HsT17250, p97MAPK, PRKM6	ENSG00000069956	Mitogen-activated protein kinase 6	15	51952106-52067372	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB005184, HPA030262	Approved	Approved	Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 53.0	Expressed in all		
GNB5	GB5	ENSG00000069966	G protein subunit beta 5	15	52115105-52191369	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB032353, HPA041942, HPA044198	Uncertain		Approved	Nuclear speckles<br>Centrosome<br>Rods & Rings	Renal cancer:3.32e-11 (favourable), Endometrial cancer:1.47e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 74.6	Expressed in all		
RAB27A	GS2, HsT18676, RAB27, RAM	ENSG00000069974	RAB27A, member RAS oncogene family	15	55202966-55319113	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001333, CAB034046	Enhanced				Renal cancer:1.67e-4 (unfavourable), Breast cancer:2.56e-4 (favourable)	Expressed in all	Mixed			stomach: 115.1	Cell line enhanced		K-562: 212.3
HDHD5	CECR5	ENSG00000069998	Haloacid dehalogenase like hydrolase domain containing 5	22	17137511-17165287	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005548	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			duodenum: 26.7	Mixed		
UFD1L	UFD1	ENSG00000070010	Ubiquitin fusion degradation 1 like (yeast)	22	19449910-19479215	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030287, HPA030288, HPA073425	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:4.50e-8 (unfavourable), Liver cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 66.0	Expressed in all		
LRP6	ADCAD2	ENSG00000070018	LDL receptor related protein 6	12	12116025-12267012	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004490, HPA029925	Enhanced					Expressed in all	Mixed			parathyroid gland: 16.4	Mixed		
GUCY2C	GUC2C, STAR	ENSG00000070019	Guanylate cyclase 2C	12	14612632-14696585	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037655, HPA073759	Uncertain		Uncertain	Vesicles	Liver cancer:1.37e-5 (unfavourable)	Group enriched	Group enriched	13	colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2	appendix: 4.4	Cell line enhanced		AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
SCT		ENSG00000070031	Secretin	11	626431-627143	Predicted secreted proteins	Evidence at protein level	HPA050961	Enhanced				Colorectal cancer:3.70e-4 (unfavourable)	Mixed	Group enriched	6	duodenum: 34.9;small intestine: 7.8	spleen: 3.4	Cell line enhanced		HSkMC: 1.1
PHRF1	KIAA1542, PPP1R125, RNF221	ENSG00000070047	PHD and ring finger domains 1	11	576486-612222	Predicted intracellular proteins	Evidence at protein level	HPA019867, HPA062933	Uncertain				Liver cancer:6.00e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 4.5	Cell line enhanced		EFO-21: 13.5;Hep G2: 16.4;MOLT-4: 31.6;SCLC-21H: 13.1;U-138 MG: 20.9
IKBKAP	DYS, ELP1, IKAP, IKI3, TOT1	ENSG00000070061	Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	9	108867517-108934116	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021340, HPA049677, HPA050686	Approved		Supported	Nucleoplasm<br>Cytosol	Breast cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.5	Expressed in all		
NUCB2	NEFA	ENSG00000070081	Nucleobindin 2	11	17208153-17349974	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008395, HPA008530, CAB015931	Approved	Approved	Enhanced	Golgi apparatus	Endometrial cancer:8.27e-6 (favourable), Renal cancer:3.94e-5 (unfavourable), Ovarian cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 733.1	Expressed in all		
PFN2		ENSG00000070087	Profilin 2	3	149964904-150050788	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035611, CAB037073	Enhanced				Liver cancer:2.19e-7 (unfavourable), Endometrial cancer:2.93e-4 (unfavourable), Head and neck cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 419.6	Mixed		
PTPN3	PTPH1	ENSG00000070159	Protein tyrosine phosphatase, non-receptor type 3	9	109375466-109498313	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038343, HPA046728	Approved				Renal cancer:1.22e-15 (favourable), Endometrial cancer:1.52e-4 (favourable), Breast cancer:6.71e-4 (unfavourable)	Mixed	Mixed			skin: 35.8	Mixed		
SPTB		ENSG00000070182	Spectrin beta, erythrocytic	14	64746283-64879883	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003394, HPA003398, CAB015169, CAB016232	Enhanced		Uncertain	Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 38.3;skeletal muscle: 43.1	heart muscle: 15.1	Cell line enhanced		HEL: 35.6;K-562: 43.0;U-937: 11.1
DAPP1	BAM32	ENSG00000070190	Dual adaptor of phosphotyrosine and 3-phosphoinositides 1	4	99816833-99870154	Predicted intracellular proteins	Evidence at protein level	CAB033822, HPA046074	Approved					Mixed	Mixed			lymph node: 51.1	Cell line enhanced		HDLM-2: 80.2;RPMI-8226: 64.7;U-698: 45.0
FGF10		ENSG00000070193	Fibroblast growth factor 10	5	44303544-44389706	Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010315	Uncertain					Tissue enriched	Tissue enhanced		ovary: 41.4	adipose tissue: 16.9	Cell line enriched	9	AF22: 51.3
SLC44A1	CD92, CDW92, CHTL1, CTL1	ENSG00000070214	Solute carrier family 44 member 1	9	105244622-105439171	CD markers, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064714			Supported	Nucleoplasm<br>Mitochondria	Renal cancer:1.85e-4 (favourable), Lung cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.5	Expressed in all		
TMEM260	C14orf101, FLJ20392	ENSG00000070269	Transmembrane protein 260	14	56488354-56650606	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003502	Uncertain		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Lung cancer:7.11e-4 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 63.5	thyroid gland: 14.1	Expressed in all		
SMG6	C17orf31, EST1A, KIAA0732, SMG-6	ENSG00000070366	SMG6, nonsense mediated mRNA decay factor	17	2059839-2303771	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042932	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:1.30e-6 (favourable)	Expressed in all	Expressed in all			ovary: 47.3	Expressed in all		
EXOC5	SEC10, SEC10L1, SEC10P	ENSG00000070367	Exocyst complex component 5	14	57200507-57269008	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA060837	Approved					Expressed in all	Mixed			testis: 20.7	Expressed in all		
CLTCL1	CHC22, CLH22, CLTCL, CLTD	ENSG00000070371	Clathrin heavy chain like 1	22	19179473-19291716	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075795			Approved	Vesicles		Mixed	Tissue enhanced		skeletal muscle: 24.1;testis: 49.4	bone marrow: 10.4	Cell line enhanced		HMC-1: 56.9
FGF22		ENSG00000070388	Fibroblast growth factor 22	19	639879-644371	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enhanced		skin: 8.5	cerebral cortex: 2.0	Cell line enhanced		AN3-CA: 1.8
FSTL3	FLRG, FSRP	ENSG00000070404	Follistatin like 3	19	676365-683399	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024899, HPA045378	Approved		Approved	Nucleoplasm	Lung cancer:4.61e-7 (unfavourable), Ovarian cancer:1.65e-4 (unfavourable), Colorectal cancer:3.01e-4 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 260.8	Expressed in all		
DGCR2	DGS-C, IDD, KIAA0163, LAN, SEZ-12	ENSG00000070413	DiGeorge syndrome critical region gene 2	22	19036282-19122454	Predicted membrane proteins	Evidence at protein level	HPA000873, HPA075929	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.72e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 57.9	Expressed in all		
RNF126	FLJ20552	ENSG00000070423	Ring finger protein 126	19	647526-663277	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043050	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
MNT	bHLHd3, MAD6, MXD6, ROX	ENSG00000070444	MAX network transcriptional repressor	17	2384060-2401118	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059532, HPA067578			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 15.2	Expressed in all		
ZXDC	FLJ13861, MGC11349	ENSG00000070476	ZXD family zinc finger C	3	126437601-126475919	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049593			Supported	Nucleoli<br>Vesicles	Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 25.4	Expressed in all		
JMJD6	KIAA0585, PTDSR, PTDSR1	ENSG00000070495	Arginine demethylase and lysine hydroxylase	17	76712832-76726799	Predicted intracellular proteins	Evidence at protein level	CAB004548, HPA059156	Supported		Supported	Nucleoplasm	Renal cancer:7.59e-7 (unfavourable), Liver cancer:5.75e-6 (unfavourable), Pancreatic cancer:5.71e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 81.0	Expressed in all		
POLB		ENSG00000070501	DNA polymerase beta	8	42338454-42371808	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011616, HPA049104	Enhanced		Approved	Vesicles	Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.7	Expressed in all		
ST6GALNAC1	SIAT7A, ST6GalNAcI	ENSG00000070526	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1	17	76624761-76643838	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014975	Uncertain				Head and neck cancer:2.54e-5 (favourable)	Mixed	Tissue enhanced		colon: 162.6;rectum: 235.5	cervix, uterine: 90.7	Cell line enhanced		EFO-21: 9.1;HaCaT: 9.7;HEL: 16.1;K-562: 48.8
WIPI1	ATG18, ATG18A, FLJ10055, WIPI49	ENSG00000070540	WD repeat domain, phosphoinositide interacting 1	17	68420948-68457513	Predicted intracellular proteins	Evidence at protein level	HPA007493, CAB037230	Enhanced				Melanoma:3.11e-4 (favourable)	Expressed in all	Expressed in all			placenta: 90.1	Cell line enhanced		HHSteC: 180.5
FRMPD1	FRMD2, KIAA0967	ENSG00000070601	FERM and PDZ domain containing 1	9	37651000-37746904	Predicted intracellular proteins	Evidence at protein level	HPA042934	Uncertain					Mixed	Tissue enhanced		testis: 14.3	skin: 8.2	Cell line enhanced		SCLC-21H: 3.1
GBA2	AD035, DKFZp762K054, KIAA1605, SPG46	ENSG00000070610	Glucosylceramidase beta 2	9	35736866-35749228	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024026	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.24e-11 (favourable), Pancreatic cancer:6.00e-4 (favourable), Urothelial cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 64.2	Expressed in all		
NDST1	HSST, NST1	ENSG00000070614	N-deacetylase and N-sulfotransferase 1	5	150485818-150558211	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060532	Approved				Ovarian cancer:5.13e-4 (unfavourable), Endometrial cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 59.7	Expressed in all		
ASNS		ENSG00000070669	Asparagine synthetase (glutamine-hydrolyzing)	7	97852118-97872542	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004924, HPA029318, HPA064737	Approved		Enhanced	Cytosol	Renal cancer:6.21e-7 (unfavourable), Liver cancer:9.42e-6 (unfavourable), Head and neck cancer:8.79e-5 (unfavourable), Endometrial cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.0	Expressed in all		
AP3M2	AP47B, CLA20	ENSG00000070718	Adaptor related protein complex 3 mu 2 subunit	8	42152946-42171673	Predicted intracellular proteins	Evidence at protein level	CAB014876, HPA045591, HPA048380	Approved				Urothelial cancer:2.38e-4 (favourable), Endometrial cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 46.9	Expressed in all		
CNGB1	CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45	ENSG00000070729	Cyclic nucleotide gated channel beta 1	16	57882340-57971116	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039159, HPA060355			Approved	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 1.6	appendix,cerebral cortex: 1.5	Cell line enhanced		SCLC-21H: 2.6;SiHa: 3.1
ST6GALNAC2	SIAT7, SIAT7B, SIATL1, ST6GalNAII, STHM	ENSG00000070731	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	17	76565379-76586956	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048849	Uncertain				Pancreatic cancer:6.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 68.6;skin: 50.8	testis: 38.9	Cell line enhanced		BEWO: 20.9;HaCaT: 23.9;hTCEpi: 48.8;MCF7: 20.9;SK-MEL-30: 70.3
CHAT		ENSG00000070748	Choline O-acetyltransferase	10	49609095-49665104	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002313, HPA048547	Supported					Not detected	Tissue enriched	8	placenta: 7.2	duodenum: 0.8	Cell line enriched	9	NB-4: 7.2
PABPC1	PAB1, PABP1, PABPC2, PABPL1	ENSG00000070756	Poly(A) binding protein cytoplasmic 1	8	100685816-100722809	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011536, HPA045423, HPA067156	Enhanced		Supported	Cytosol	Renal cancer:5.70e-12 (unfavourable), Glioma:1.35e-4 (favourable), Liver cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1151.0	Expressed in all		
TESK2		ENSG00000070759	Testis-specific kinase 2	1	45343883-45491166	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027257, HPA063869	Uncertain		Enhanced	Nucleoplasm	Cervical cancer:2.22e-4 (favourable)	Expressed in all	Mixed			prostate: 25.0	Mixed		
CFAP20	C16orf80, fSAP23, GTL3	ENSG00000070761	Cilia and flagella associated protein 20	16	58113588-58129450	Predicted intracellular proteins	Evidence at protein level	HPA018195	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			fallopian tube: 54.4	Expressed in all		
CSNK2A2	CK2alpha', CSNK2A1	ENSG00000070770	Casein kinase 2 alpha 2	16	58157907-58197920	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA077719			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Head and neck cancer:1.40e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 237.6	Expressed in all		
PTPN21	PTPD1, PTPRL10	ENSG00000070778	Protein tyrosine phosphatase, non-receptor type 21	14	88465778-88554733	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011468, HPA073999	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Renal cancer:3.16e-9 (favourable)	Expressed in all	Mixed			skin: 34.5	Cell line enhanced		RH-30: 34.1
EIF2B3	EIF-2B, EIF2Bgamma	ENSG00000070785	Eukaryotic translation initiation factor 2B subunit gamma	1	44850522-44986722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024213, HPA024218, HPA024219	Supported		Supported	Vesicles<br>Cytosol	Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
CAMK2A	CAMKA, CaMKIINalpha, KIAA0968	ENSG00000070808	Calcium/calmodulin dependent protein kinase II alpha	5	150219491-150290291	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004330, HPA051783, HPA051785, HPA053973	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Tissue enriched	Tissue enriched	9	cerebral cortex: 283.6	skeletal muscle: 33.3	Cell line enhanced		SCLC-21H: 6.2;U-87 MG: 4.3
TCOF1	TCS, treacle	ENSG00000070814	Treacle ribosome biogenesis factor 1	5	150357639-150400308	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033199, HPA038237, HPA038238	Enhanced		Enhanced	Nucleoli fibrillar center	Liver cancer:2.26e-8 (unfavourable), Renal cancer:2.62e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.0	Expressed in all		
CDC42	CDC42Hs, G25K	ENSG00000070831	Cell division cycle 42	1	22052627-22092946	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004360, HPA069590	Approved		Enhanced	Microtubules<br>Cytokinetic bridge	Liver cancer:5.28e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 252.6	Expressed in all		
OSBPL3	KIAA0704, ORP-3, ORP3, OSBP3	ENSG00000070882	Oxysterol binding protein like 3	7	24796539-24981634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000691, HPA048401	Enhanced		Supported	Nucleoli<br>Cytosol	Pancreatic cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.4	Mixed		
EPHA8	EEK, Hek3	ENSG00000070886	EPH receptor A8	1	22563564-22603594	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009660, HPA031433	Uncertain					Mixed	Tissue enhanced		adrenal gland: 4.7;spleen: 2.6;testis: 1.9	cerebral cortex: 1.3	Cell line enriched	14	SCLC-21H: 70.4
SLC12A3	NCCT	ENSG00000070915	Solute carrier family 12 member 3	16	56865207-56915850	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028748	Enhanced					Tissue enhanced	Tissue enriched	109	kidney: 109.8	lymph node: 1.0	Group enriched	11	BEWO: 7.0;HAP1: 4.1;HeLa: 5.5
RAD18	RNF73	ENSG00000070950	RAD18, E3 ubiquitin protein ligase	3	8775402-8963773	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006716, HPA006724, HPA008752	Supported	Approved	Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.65e-5 (unfavourable), Liver cancer:1.12e-4 (unfavourable), Prostate cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 10.2	Expressed in all		
ATP2B1	PMCA1	ENSG00000070961	ATPase plasma membrane Ca2+ transporting 1	12	89588049-89709300	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB005605, HPA011166, HPA012945	Enhanced		Supported	Plasma membrane	Liver cancer:7.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.6	Expressed in all		
TRPM5	LTRPC5, MTR1	ENSG00000070985	Transient receptor potential cation channel subfamily M member 5	11	2404515-2423045	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA042115, HPA043315	Uncertain					Tissue enhanced	Group enriched	5	colon: 1.0;duodenum: 2.9;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9	testis,thyroid gland: 0.4	Not detected		
NCK2	NCKbeta	ENSG00000071051	NCK adaptor protein 2	2	105744897-105894274	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016116, HPA031004	Approved					Expressed in all	Expressed in all			small intestine: 58.3	Cell line enhanced		SK-MEL-30: 139.0
MAP4K4	FLH21957, HGK, NIK	ENSG00000071054	Mitogen-activated protein kinase kinase kinase kinase 4	2	101696850-101894689	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008476	Uncertain				Renal cancer:3.62e-6 (unfavourable), Lung cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 154.6	Mixed		
MGAT4A	GnT-4a, GnT-Iva	ENSG00000071073	Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A	2	98619106-98731126	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007608	Enhanced		Approved	Golgi apparatus	Endometrial cancer:6.48e-8 (unfavourable), Breast cancer:4.30e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 84.1	Cell line enhanced		BEWO: 122.6;TIME: 64.1
RPL31	L31	ENSG00000071082	Ribosomal protein L31	2	101001715-101024032	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA072263	Approved				Renal cancer:8.08e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 5539.1	Expressed in all		
WDR1		ENSG00000071127	WD repeat domain 1	4	10074339-10116949	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020804, HPA036434, HPA070293	Approved		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:1.73e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 308.6	Expressed in all		
SNX13	KIAA0713, RGS-PX1	ENSG00000071189	Sorting nexin 13	7	17790761-17940501	Predicted membrane proteins	Evidence at protein level						Renal cancer:5.98e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
MS4A12	FLJ20217, Ms4a10	ENSG00000071203	Membrane spanning 4-domains A12	11	60492778-60507430	Predicted membrane proteins	Evidence at protein level	HPA057657	Enhanced					Tissue enriched	Group enriched	19	colon: 235.5;rectum: 280.6	appendix: 13.2	Cell line enhanced		RH-30: 1.1
ARHGAP10	FLJ20896, FLJ41791, GRAF2	ENSG00000071205	Rho GTPase activating protein 10	4	147732063-148072780	Predicted intracellular proteins	Evidence at protein level	HPA039589			Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.15e-5 (favourable), Lung cancer:2.23e-4 (unfavourable), Stomach cancer:6.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Mixed		
RPS6KA2	HU-2, RSK, RSK3	ENSG00000071242	Ribosomal protein S6 kinase A2	6	166409364-166906451	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026243, HPA045061, HPA054237, CAB069428	Approved		Supported	Nucleoplasm	Renal cancer:2.86e-5 (favourable), Ovarian cancer:8.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.4	Cell line enhanced		ASC diff: 147.2;HHSteC: 133.3;hTERT-HME1: 133.1
ING3	Eaf4, FLJ20089, MEAF4, p47ING3	ENSG00000071243	Inhibitor of growth family member 3	7	120950749-120977216	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067388, HPA067575	Approved		Supported	Nucleus		Expressed in all	Expressed in all			bone marrow: 50.3	Expressed in all		
VASH1	KIAA1036	ENSG00000071246	Vasohibin 1	14	76762189-76783015	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000653	Uncertain				Pancreatic cancer:6.56e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 34.4	Cell line enhanced		AF22: 50.3;HUVEC TERT2: 78.5
LMCD1		ENSG00000071282	LIM and cysteine rich domains 1	3	8501707-8574673	Predicted intracellular proteins	Evidence at protein level	HPA024059	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:8.66e-5 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 201.9	Cell line enhanced		HSkMC: 90.7;hTEC/SVTERT24-B: 93.9
WBSCR22	MERM1, MGC19709, MGC2022, MGC5140, PP3381, WBMT	ENSG00000071462	Williams-Beuren syndrome chromosome region 22	7	73683025-73705161	Predicted intracellular proteins	Evidence at protein level	HPA052185	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.46e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 207.8	Expressed in all		
SEL1L	IBD2, SEL1L1	ENSG00000071537	SEL1L ERAD E3 ligase adaptor subunit	14	81471549-81533861	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024267	Approved					Expressed in all	Expressed in all			thyroid gland: 90.5	Expressed in all		
TRIP13	16E1BP	ENSG00000071539	Thyroid hormone receptor interactor 13	5	892643-919357	Predicted intracellular proteins	Evidence at protein level	HPA005727, HPA053093	Enhanced		Approved	Nucleus	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.30e-6 (unfavourable), Ovarian cancer:1.39e-4 (favourable), Endometrial cancer:3.93e-4 (unfavourable)	Mixed	Tissue enriched	5	testis: 53.5	fallopian tube: 9.9	Mixed		
ATP6AP1	16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3	ENSG00000071553	ATPase H+ transporting accessory protein 1	X	154428632-154436516	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015218	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 209.7	Expressed in all		
TCF3	bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR	ENSG00000071564	Transcription factor 3	19	1609290-1652605	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018351, HPA049808, HPA062476	Approved		Enhanced	Nucleoplasm	Renal cancer:1.53e-4 (unfavourable), Liver cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.3	Expressed in all		
TRIB2	GS3955, TRB2	ENSG00000071575	Tribbles pseudokinase 2	2	12716889-12742734	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA001305	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 117.2	Cell line enhanced		AN3-CA: 170.0;K-562: 229.8;WM-115: 243.3
DAZAP1	MGC19907	ENSG00000071626	DAZ associated protein 1	19	1407569-1435687	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004201, HPA004631	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:5.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.8	Expressed in all		
MBD3		ENSG00000071655	Methyl-CpG binding domain protein 3	19	1573596-1592801	Predicted intracellular proteins	Evidence at protein level	CAB013265	Supported		Supported	Nucleoplasm	Pancreatic cancer:1.76e-5 (favourable), Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			placenta: 45.8	Expressed in all		
PRLH	PRH	ENSG00000071677	Prolactin releasing hormone	2	237566574-237567175	Predicted secreted proteins	Evidence at protein level	HPA014976	Supported					Tissue enhanced	Not detected			fallopian tube,heart muscle: 0.6	Cell line enhanced		A549: 2.1;MCF7: 1.3;RPMI-8226: 1.0
HLTF	HIP116A, HLTF1, RNF80, SMARCA3, SNF2L3	ENSG00000071794	Helicase like transcription factor	3	149030127-149086554	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015284, HPA049001	Uncertain		Enhanced	Nucleus	Liver cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 83.4	Expressed in all		
FAM50A	9F, DXS9928E, HXC-26, XAP5	ENSG00000071859	Family with sequence similarity 50 member A	X	154444126-154450654	Predicted intracellular proteins	Evidence at protein level	HPA003585	Supported		Enhanced	Nucleoplasm	Liver cancer:3.15e-5 (unfavourable), Colorectal cancer:9.52e-5 (unfavourable), Cervical cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.0	Expressed in all		
FAM3A	2-19, DXS560S, XAP-7	ENSG00000071889	Family with sequence similarity 3 member A	X	154506159-154516242	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025016, HPA056991	Uncertain		Approved	Nucleus<br>Nucleoli	Colorectal cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 28.3	Expressed in all		
CPSF1		ENSG00000071894	Cleavage and polyadenylation specific factor 1	8	144393229-144409349	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065167, HPA068906			Enhanced	Nucleoplasm	Renal cancer:6.54e-5 (unfavourable), Liver cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.5	Expressed in all		
MYO3B		ENSG00000071909	Myosin IIIB	2	170178145-170655171	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045483	Approved					Mixed	Group enriched	5	epididymis: 11.8;kidney: 4.8;parathyroid gland: 15.3;urinary bladder: 4.2	thyroid gland: 1.6	Group enriched	11	HDLM-2: 8.9;HEL: 7.8;RT4: 7.8
CYBRD1	CYB561A2, DCYTB, FLJ23462, FRRS3	ENSG00000071967	Cytochrome b reductase 1	2	171522247-171558133	Predicted membrane proteins	Evidence at protein level	HPA014757, HPA056736	Approved		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 381.1	Cell line enhanced		ASC diff: 712.0;ASC TERT1: 313.5;BJ hTERT+: 328.5
CDH19	CDH7	ENSG00000071991	Cadherin 19	18	66501083-66604138	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056332	Uncertain					Tissue enriched	Mixed			heart muscle: 8.4	Group enriched	15	SK-MEL-30: 28.3;WM-115: 63.0
PDCD2	RP8, ZMYND7	ENSG00000071994	Programmed cell death 2	6	170575295-170584692	Predicted intracellular proteins	Evidence at protein level	HPA026713, HPA075534	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge	Liver cancer:1.42e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 57.9	Expressed in all		
SLC6A15	FLJ10316, hv7-3, NTT73, SBAT1, V7-3	ENSG00000072041	Solute carrier family 6 member 15	12	84859488-84913615	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008609	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 23.0	placenta: 5.5	Cell line enhanced		ASC diff: 62.0;hTERT-HME1: 99.4;SCLC-21H: 104.6
RDH11	ARSDR1, MDT1, SDR7C1	ENSG00000072042	Retinol dehydrogenase 11 (all-trans/9-cis/11-cis)	14	67676801-67695814	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB046011	Enhanced				Renal cancer:1.30e-7 (favourable), Head and neck cancer:2.89e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Tissue enriched	Tissue enriched	7	prostate: 941.3	parathyroid gland: 125.7	Expressed in all		
PRKACA	PKACa	ENSG00000072062	Protein kinase cAMP-activated catalytic subunit alpha	19	14091688-14118084	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010361, HPA071185	Approved		Approved	Cytosol	Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.4	Expressed in all		
ADGRL1	CIRL1, KIAA0821, LEC2, LPHN1	ENSG00000072071	Adhesion G protein-coupled receptor L1	19	14147743-14206187	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037974	Uncertain				Pancreatic cancer:1.14e-4 (favourable), Renal cancer:4.45e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 60.1	parathyroid gland: 24.2	Cell line enhanced		AN3-CA: 66.4;SCLC-21H: 64.6
SPP2	SPP24	ENSG00000072080	Secreted phosphoprotein 2	2	234050679-234077134	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:2.33e-6 (favourable)	Tissue enriched	Tissue enriched	2145	liver: 265.4	kidney,testis: 0.1	Not detected		
ACTN1		ENSG00000072110	Actinin alpha 1	14	68874143-68979440	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004303, HPA006035	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:9.08e-10 (unfavourable), Lung cancer:7.63e-5 (unfavourable), Head and neck cancer:2.49e-4 (unfavourable), Urothelial cancer:8.00e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 754.0	Mixed		
ZFYVE26	KIAA0321, SPG15	ENSG00000072121	Zinc finger FYVE-type containing 26	14	67727374-67816590	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055500	Approved				Renal cancer:1.54e-6 (favourable), Liver cancer:2.84e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
RPS6KA6	RSK4	ENSG00000072133	Ribosomal protein S6 kinase A6	X	84058346-84187907	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002852, HPA003904	Uncertain		Supported	Nucleus<br>Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		parathyroid gland: 18.9;thyroid gland: 21.9	kidney: 8.9	Cell line enhanced		PC-3: 13.7;RH-30: 17.3;SH-SY5Y: 15.2
EPN2	EHB21, KIAA1065	ENSG00000072134	Epsin 2	17	19215615-19336715	Predicted intracellular proteins	Evidence at protein level	HPA049809, HPA053360	Approved		Supported	Vesicles	Urothelial cancer:8.15e-5 (unfavourable), Renal cancer:9.13e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 95.0	Mixed		
PTPN18	BDP1	ENSG00000072135	Protein tyrosine phosphatase, non-receptor type 18	2	130356007-130375409	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012174, HPA053367	Uncertain		Approved	Intermediate filaments		Expressed in all	Expressed in all			lymph node: 47.5	Expressed in all		
LIMS2	PINCH-2, PINCH2	ENSG00000072163	LIM zinc finger domain containing 2	2	127638381-127681786	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058340	Enhanced		Supported	Focal adhesion sites	Liver cancer:6.53e-7 (favourable)	Expressed in all	Mixed			seminal vesicle: 137.8	Cell line enhanced		HHSteC: 27.3;MOLT-4: 32.1;TIME: 66.1
ASIC4	ACCN4, BNAC4	ENSG00000072182	Acid sensing ion channel subunit family member 4	2	219514170-219538772	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	8	cerebral cortex: 10.6	adrenal gland: 1.3	Group enriched	43	HEL: 17.6;HMC-1: 5.0;K-562: 10.2;SH-SY5Y: 5.4
SPEG	APEG1, BPEG, KIAA1297, MGC12676, SPEGalpha, SPEGbeta	ENSG00000072195	SPEG complex locus	2	219434846-219498287	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018904	Enhanced		Approved	Vesicles		Mixed	Mixed			skeletal muscle: 43.2	Cell line enhanced		U-2 OS: 22.8;U-87 MG: 23.6
LNX1	LNX, MPDZ, PDZRN2	ENSG00000072201	Ligand of numb-protein X 1	4	53459301-53701405	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002235, HPA071091	Approved		Supported	Cell Junctions<br>Cytosol	Renal cancer:3.08e-7 (favourable)	Expressed in all	Mixed			placenta: 39.4	Mixed		
ALDH3A2	ALDH10, FALDH, SLS	ENSG00000072210	Aldehyde dehydrogenase 3 family member A2	17	19648136-19677598	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014769, CAB020692	Approved				Renal cancer:3.85e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 179.0	Cell line enhanced		A549: 115.6
TFRC	CD71, p90, TFR1	ENSG00000072274	Transferrin receptor	3	196027183-196082189	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000153, HPA028598	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 157.4	Expressed in all		
SREBF1	bHLHd1, SREBP-1c, SREBP1, SREBP1a	ENSG00000072310	Sterol regulatory element binding transcription factor 1	17	17810399-17837002	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB005406, HPA043343, HPA043878	Uncertain		Supported	Golgi apparatus<br>Cytosol	Endometrial cancer:2.66e-4 (favourable), Pancreatic cancer:9.05e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 92.4	Expressed in all		
TRPC5	PPP1R159	ENSG00000072315	Transient receptor potential cation channel subfamily C member 5	X	111774315-112082776	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 1.9	liver: 0.4	Cell line enriched	5	NTERA-2: 1.7
AFF4	AF5Q31, MCEF	ENSG00000072364	AF4/FMR2 family member 4	5	132875379-132963634	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023690, HPA029634	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Thyroid cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.2	Expressed in all		
UBE2D1	E2(17)KB1, SFT, UBC4/5, UBCH5, UbcH5A	ENSG00000072401	Ubiquitin conjugating enzyme E2 D1	10	58334975-58370753	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.04e-6 (unfavourable), Liver cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 47.8	Mixed		
MPP5	FLJ12615, PALS1	ENSG00000072415	Membrane palmitoylated protein 5	14	67241109-67335819	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000993, HPA063890	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.71e-12 (favourable), Liver cancer:5.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 43.9	Expressed in all		
RHOBTB1	KIAA0740	ENSG00000072422	Rho related BTB domain containing 1	10	60869438-61001440	Predicted intracellular proteins	Evidence at protein level	HPA040205, HPA040226	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			placenta: 52.5	Cell line enhanced		Hep G2: 45.7
SMC1A	DXS423E, KIAA0178, SB1.8, SMC1L1, Smcb	ENSG00000072501	Structural maintenance of chromosomes 1A	X	53374149-53422728	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005499, CAB025404	Supported		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 52.8	Expressed in all		
HSD17B10	17b-HSD10, ABAD, CAMR, ERAB, HADH2, MHBD, MRPP2, MRXS10, SDR5C1	ENSG00000072506	Hydroxysteroid 17-beta dehydrogenase 10	X	53431258-53434373	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001432	Approved				Cervical cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			liver: 126.6	Expressed in all		
MARK2	EMK1, PAR-1, PAR-1B, Par1b	ENSG00000072518	Microtubule affinity regulating kinase 2	11	63838928-63911019	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038790, HPA074905	Approved		Supported	Nucleoplasm<br>Plasma membrane	Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 46.1	Expressed in all		
HMMR	CD168, RHAMM	ENSG00000072571	Hyaluronan mediated motility receptor	5	163460203-163491945	CD markers, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002433, HPA040025, HPA043926, HPA061524	Enhanced		Enhanced	Microtubules<br>Centrosome<br>Cytosol	Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 49.7	lymph node: 21.7	Expressed in all		
CHFR	FLJ10796, RNF196	ENSG00000072609	Checkpoint with forkhead and ring finger domains	12	132822187-132956304	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045768, HPA073826	Approved		Uncertain	Nuclear bodies<br>Microtubules	Renal cancer:4.21e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 22.8	Mixed		
TRHDE	PAP-II, PGPEP2, TRH-DE	ENSG00000072657	Thyrotropin releasing hormone degrading enzyme	12	72087266-72670757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.53e-7 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 7.9	Cell line enhanced		BJ: 25.6;BJ hTERT+: 23.6;EFO-21: 14.6
P4HA2	C-P4Halpha(II)	ENSG00000072682	Prolyl 4-hydroxylase subunit alpha 2	5	132191838-132295315	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA016997, HPA027824, CAB062557	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles	Renal cancer:2.77e-7 (unfavourable), Cervical cancer:1.24e-5 (unfavourable), Urothelial cancer:3.12e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 95.3	Mixed		
FCGR2B	CD32, CD32B, FCG2, FCGR2	ENSG00000072694	Fc fragment of IgG receptor IIb	1	161663147-161678654	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB007796, HPA014730	Enhanced				Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 576.7	adipose tissue: 36.6	Cell line enhanced		Daudi: 18.5;HMC-1: 27.5;RPMI-8226: 8.1
NFATC3	NFAT4, NFATX	ENSG00000072736	Nuclear factor of activated T-cells 3	16	68084751-68229259	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050665			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
TRNT1	CCA1, CGI-47, MtCCA	ENSG00000072756	TRNA nucleotidyl transferase 1	3	3126916-3150879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036938	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			prostate: 24.5	Expressed in all		
ACADVL	ACAD6, LCACD, VLCAD	ENSG00000072778	Acyl-CoA dehydrogenase, very long chain	17	7217125-7225273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019006, HPA020595	Enhanced		Supported	Nucleus<br>Nucleoli<br>Mitochondria	Pancreatic cancer:6.87e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 453.7	Expressed in all		
STK10	LOK, PRO2729	ENSG00000072786	Serine/threonine kinase 10	5	172042073-172188386	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015083, CAB020840	Enhanced				Renal cancer:1.63e-4 (unfavourable), Colorectal cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			spleen: 61.0	Expressed in all		
FBXW11	BTRC2, BTRCP2, Fbw11, Fbw1b, FBXW1B, Hos, KIAA0696	ENSG00000072803	F-box and WD repeat domain containing 11	5	171861549-172006873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062578, HPA072204	Approved		Approved	Nucleoli<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
ACAP1	CENTB1, KIAA0050	ENSG00000072818	ArfGAP with coiled-coil, ankyrin repeat and PH domains 1	17	7336529-7351478	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075570	Approved		Approved	Golgi apparatus	Renal cancer:1.65e-10 (unfavourable), Endometrial cancer:2.97e-5 (favourable), Head and neck cancer:4.17e-5 (favourable), Cervical cancer:3.66e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 94.2	spleen: 69.8	Cell line enhanced		HDLM-2: 59.1;Karpas-707: 44.7;NB-4: 49.0
CRMP1	DPYSL1, DRP-1	ENSG00000072832	Collapsin response mediator protein 1	4	5748084-5893058	Predicted intracellular proteins	Evidence at protein level	HPA035640, CAB037313	Approved		Supported	Centrosome<br>Cytosol	Pancreatic cancer:4.54e-4 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 133.7	endometrium: 24.5	Cell line enhanced		HAP1: 120.7;REH: 208.7;RH-30: 125.4;SCLC-21H: 196.8;SH-SY5Y: 112.2
EVC	DWF-1	ENSG00000072840	EvC ciliary complex subunit 1	4	5711197-5814305	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA008703, HPA016046	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.60e-9 (favourable), Urothelial cancer:9.47e-5 (unfavourable)	Expressed in all	Mixed			ovary: 41.5	Mixed		
DERL2	CGI-101, derlin-2, F-LAN-1, F-LANa, FLANa	ENSG00000072849	Derlin 2	17	5471251-5486811	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037287, HPA048957, HPA056551	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:6.49e-4 (unfavourable), Endometrial cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.4	Expressed in all		
SIDT1	FLJ20174, SID-1	ENSG00000072858	SID1 transmembrane family member 1	3	113532296-113629578	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035862	Enhanced				Urothelial cancer:4.09e-5 (favourable), Cervical cancer:3.78e-4 (favourable)	Mixed	Mixed			cerebral cortex: 10.6	Cell line enhanced		MCF7: 11.1;PC-3: 18.4;RT4: 11.2;T-47d: 12.3
NDE1	FLJ20101, NDE, nudE	ENSG00000072864	NudE neurodevelopment protein 1	16	15643267-15726353	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024075	Approved				Renal cancer:8.19e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.8	Expressed in all		
MRVI1	IRAG, JAW1L	ENSG00000072952	Murine retrovirus integration site 1 homolog	11	10573091-10693988	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008704	Uncertain		Approved	Nuclear bodies<br>Cytosol	Endometrial cancer:5.78e-4 (favourable), Renal cancer:9.70e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 99.6	Cell line enhanced		ASC diff: 14.2;BJ: 12.9;BJ hTERT+: 14.3
TMEM38A	MGC3169, TRIC-A	ENSG00000072954	Transmembrane protein 38A	19	16661127-16690029	Predicted membrane proteins	Evidence at protein level	HPA048100, HPA050463	Enhanced		Approved	Nucleus	Renal cancer:2.99e-10 (favourable), Lung cancer:2.78e-5 (favourable), Ovarian cancer:7.96e-4 (unfavourable)	Expressed in all	Tissue enriched	9	skeletal muscle: 199.7	cerebral cortex: 23.1	Cell line enhanced		U-698: 18.5
AP1M1	AP47, CLAPM2	ENSG00000072958	Adaptor related protein complex 1 mu 1 subunit	19	16197578-16245907	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045256	Uncertain				Renal cancer:1.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 96.5	Expressed in all		
PVR	CD155, HVED, Necl-5, NECL5, PVS, Tage4	ENSG00000073008	Poliovirus receptor	19	44643798-44663583	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012568	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.0	Cell line enhanced		TIME: 147.4
XRCC1	RCC	ENSG00000073050	X-ray repair cross complementing 1	19	43543040-43580473	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005427, HPA006717	Supported		Enhanced	Nucleoplasm	Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 34.6	Expressed in all		
SCARB1	CD36L1, CLA-1, CLA1, SR-BI, SRB1	ENSG00000073060	Scavenger receptor class B member 1	12	124776856-124882668	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066285, CAB070124, HPA072449	Enhanced		Approved	Vesicles	Renal cancer:1.49e-5 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Lung cancer:4.02e-4 (unfavourable)	Expressed in all	Group enriched	7	adrenal gland: 758.4;placenta: 287.5	liver: 72.3	Mixed		
CYP2W1	FLJ20359, MGC34287	ENSG00000073067	Cytochrome P450 family 2 subfamily W member 1	7	983199-989640	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012753	Uncertain				Urothelial cancer:5.85e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 5.5;duodenum: 6.2;skin: 9.7	placenta: 1.4	Group enriched	7	CACO-2: 11.2;Hep G2: 33.8
MCM2	BM28, CCNL1, cdc19, CDCL1, D3S3194, KIAA0030	ENSG00000073111	Minichromosome maintenance complex component 2	3	127598223-127622436	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000303, HPA031495, HPA031496	Enhanced		Supported	Nucleoplasm	Liver cancer:1.51e-7 (unfavourable), Cervical cancer:4.66e-4 (favourable)	Expressed in all	Mixed			bone marrow: 38.5	Expressed in all		
MOV10L1	CHAMP, DJ402G11.8, DKFZp434B0717	ENSG00000073146	Mov10 RISC complex RNA helicase like 1	22	50089879-50161690	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA019034	Approved					Mixed	Tissue enriched	9	testis: 39.9	endometrium: 4.2	Group enriched	6	HHSteC: 2.1;HUVEC TERT2: 10.4;TIME: 4.7
PANX2	hPANX2, PX2	ENSG00000073150	Pannexin 2	22	50170731-50180294	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004624, HPA039117	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 8.7	seminal vesicle: 2.1	Cell line enhanced		HDLM-2: 15.5;Hep G2: 13.2;SCLC-21H: 11.5
SELENOO	SELO	ENSG00000073169	Selenoprotein O	22	50200979-50217616	Predicted secreted proteins	Evidence at protein level						Urothelial cancer:8.32e-4 (favourable)	Expressed in all	Expressed in all			skin: 9.2	Expressed in all		
TP63	EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L	ENSG00000073282	Tumor protein p63	3	189631416-189897279	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000083, HPA006288, HPA007010	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:1.07e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 60.9;skin: 164.1	urinary bladder: 28.8	Group enriched	5	HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
ALPK1	FLJ22670, KIAA1527, Lak	ENSG00000073331	Alpha kinase 1	4	112285509-112442620	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA027435, HPA027443	Approved		Approved	Centrosome	Renal cancer:5.82e-7 (unfavourable), Urothelial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.2	Mixed		
LLGL2	HGL, Hugl-2	ENSG00000073350	LLGL2, scribble cell polarity complex component	17	75525080-75575208	Predicted intracellular proteins	Evidence at protein level	HPA022913	Uncertain		Supported	Vesicles<br>Cytosol	Renal cancer:6.14e-9 (favourable), Pancreatic cancer:6.00e-5 (favourable), Head and neck cancer:9.25e-4 (favourable)	Expressed in all	Mixed			stomach: 62.8	Cell line enhanced		CAPAN-2: 118.0;MCF7: 101.3;SK-BR-3: 95.4;T-47d: 90.7
PDE8A	HsT19550	ENSG00000073417	Phosphodiesterase 8A	15	84980440-85139145	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007722	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 30.2	Expressed in all		
CLCN4	ClC-4, CLC4	ENSG00000073464	Chloride voltage-gated channel 4	X	10156945-10237660	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031313, HPA063637	Enhanced		Approved	Vesicles	Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.1;epididymis: 28.1	skeletal muscle: 14.6	Cell line enhanced		HEL: 21.9;SCLC-21H: 28.6
NLE1	FLJ10458	ENSG00000073536	Notchless homolog 1	17	35128753-35142315	Predicted intracellular proteins	Evidence at protein level	HPA018807	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:8.64e-8 (unfavourable), Urothelial cancer:6.39e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 15.9	Expressed in all		
SDHA	FP, SDH2, SDHF	ENSG00000073578	Succinate dehydrogenase complex flavoprotein subunit A	5	218241-256700	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034929, HPA041981, HPA064582	Enhanced		Enhanced	Mitochondria	Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 248.9	Expressed in all		
SMARCE1	BAF57	ENSG00000073584	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member 1	17	40624962-40648508	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003916, CAB037318	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 74.3	Expressed in all		
FNDC8	DKFZp434H2215	ENSG00000073598	Fibronectin type III domain containing 8	17	35121579-35130732	Predicted intracellular proteins	Evidence at protein level	HPA026521	Supported					Not detected	Tissue enriched	461	testis: 108.6	ovary: 0.2	Cell line enhanced		HEK 293: 1.2
GSDMB	GSDML, PRO2521	ENSG00000073605	Gasdermin B	17	39904595-39919854	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB013681, HPA023925, HPA052407	Enhanced				Renal cancer:5.13e-11 (unfavourable), Urothelial cancer:5.91e-9 (favourable), Cervical cancer:3.41e-5 (favourable)	Expressed in all	Tissue enhanced		duodenum: 67.0;small intestine: 85.1	rectum: 62.6	Cell line enriched	7	SK-BR-3: 342.4
KDM5A	JARID1A, RBBP2	ENSG00000073614	Lysine demethylase 5A	12	280129-389454	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006201			Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 39.0	Expressed in all		
ADAM11	MDC	ENSG00000073670	ADAM metallopeptidase domain 11	17	44759031-44781846	Predicted membrane proteins, Transporters	Evidence at protein level	HPA074550	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 19.8	heart muscle: 4.0	Cell line enhanced		HEK 293: 18.5
PPP2R3A	PPP2R3	ENSG00000073711	Protein phosphatase 2 regulatory subunit B''alpha	3	135965673-136147891	Predicted intracellular proteins	Evidence at protein level	HPA035829, HPA035830, HPA065338	Uncertain		Approved	Golgi apparatus	Pancreatic cancer:1.14e-5 (unfavourable), Renal cancer:1.15e-5 (favourable), Urothelial cancer:3.91e-4 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 63.3	heart muscle: 34.3	Mixed		
FERMT2	KIND2, mig-2, PLEKHC1, UNC112B	ENSG00000073712	Fermitin family member 2	14	52857268-52952435	Predicted intracellular proteins	Evidence at protein level	HPA040505	Uncertain		Supported	Nucleoplasm<br>Focal adhesion sites		Expressed in all	Mixed			smooth muscle: 222.9	Mixed		
ABCB11	ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP	ENSG00000073734	ATP binding cassette subfamily B member 11	2	168922938-169031322	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019035	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	13	liver: 19.1	testis: 1.4	Not detected		
DHRS9	3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4	ENSG00000073737	Dehydrogenase/reductase 9	2	169064789-169096167	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036491, HPA036667	Approved				Pancreatic cancer:2.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 66.5;rectum: 48.1	esophagus: 30.1	Cell line enhanced		NB-4: 21.6;THP-1: 66.4;TIME: 35.4;U-2197: 29.3
CD5L	API6, Spalpha	ENSG00000073754	CD5 molecule like	1	157830914-157898256	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065686, HPA068384	Enhanced				Liver cancer:8.88e-5 (favourable)	Tissue enriched	Tissue enriched	14	spleen: 787.1	liver: 54.4	Not detected		
PTGS2	COX2	ENSG00000073756	Prostaglandin-endoperoxide synthase 2	1	186671791-186680427	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB000113, HPA001335	Approved		Supported	Endoplasmic reticulum	Renal cancer:9.79e-4 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 180.6	cervix, uterine: 99.3	Group enriched	7	BJ: 78.6;BJ hTERT+: 327.8
IGF2BP2	IMP-2	ENSG00000073792	Insulin like growth factor 2 mRNA binding protein 2	3	185643739-185825056	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017126, HPA035145	Enhanced		Enhanced	Cytosol	Head and neck cancer:5.12e-5 (unfavourable), Pancreatic cancer:7.37e-5 (unfavourable), Endometrial cancer:1.22e-4 (unfavourable)	Mixed	Mixed			placenta: 21.1	Mixed		
MAP3K13	LZK, MEKK13	ENSG00000073803	Mitogen-activated protein kinase kinase kinase 13	3	185282941-185489097	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016497, HPA036691, HPA036692	Uncertain		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:1.28e-5 (unfavourable), Pancreatic cancer:7.27e-5 (unfavourable), Ovarian cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 69.3	Mixed		
ST6GAL1	SIAT1	ENSG00000073849	ST6 beta-galactoside alpha-2,6-sialyltransferase 1	3	186930485-187078553	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB015018, CAB016122	Supported					Expressed in all	Expressed in all			liver: 270.5	Cell line enhanced		U-266/70: 590.1;U-266/84: 742.8;U-698: 257.3
TBX21	T-bet, TBLYM	ENSG00000073861	T-box 21	17	47733244-47746119	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009524, CAB030043	Enhanced					Mixed	Tissue enhanced		lymph node: 8.5;spleen: 11.1	bone marrow: 6.4	Cell line enriched	152	HDLM-2: 15.1
FRY	13CDNA73, bA37E23.1, C13orf14, CG003	ENSG00000073910	FRY microtubule binding protein	13	32031300-32299122	Predicted intracellular proteins	Evidence at protein level	HPA041635	Approved				Renal cancer:9.60e-4 (favourable)	Mixed	Expressed in all			heart muscle: 33.5	Cell line enhanced		HUVEC TERT2: 22.7;RT4: 25.4
PICALM	CALM, CLTH	ENSG00000073921	Phosphatidylinositol binding clathrin assembly protein	11	85957684-86069882	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019053, HPA019061	Enhanced		Supported	Vesicles	Renal cancer:2.02e-6 (favourable), Pancreatic cancer:6.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 297.2	Expressed in all		
NSF	SKD2	ENSG00000073969	N-ethylmaleimide sensitive factor, vesicle fusing ATPase	17	46590669-46757464	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003154, CAB009324, CAB013645, HPA071089	Enhanced		Supported	Cytosol		Expressed in all	Tissue enriched	5	cerebral cortex: 134.3	parathyroid gland: 25.6	Mixed		
GLI2	HPE9, THP1, THP2	ENSG00000074047	GLI family zinc finger 2	2	120735623-120992653	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008558, HPA074275	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		ovary: 11.6	gallbladder: 6.0	Cell line enhanced		AF22: 30.8;U-2 OS: 33.2;WM-115: 27.2
CLASP1	KIAA0622, MAST1	ENSG00000074054	Cytoplasmic linker associated protein 1	2	121337776-121649587	Predicted intracellular proteins	Evidence at protein level	HPA065219	Uncertain				Renal cancer:6.50e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
MRPS34	MGC2616, MRP-S12	ENSG00000074071	Mitochondrial ribosomal protein S34	16	1771890-1773155	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA042112	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 22.2	Expressed in all		
NOTCH3	CADASIL, CASIL	ENSG00000074181	Notch 3	19	15159038-15200981	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005393, HPA044392	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable)	Expressed in all	Mixed			skin: 93.6	Cell line enhanced		AF22: 65.5;MCF7: 51.9
CLNS1A	CLCI, ICln	ENSG00000074201	Chloride nucleotide-sensitive channel 1A	11	77514936-77637805	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB017840, HPA031707, HPA031708, HPA032045	Approved		Supported	Nucleus<br>Microtubules<br>Cytosol	Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.0	Expressed in all		
PPP2R2C	IMYPNO, MGC33570, PR52, PR55G	ENSG00000074211	Protein phosphatase 2 regulatory subunit Bgamma	4	6320578-6563600	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770	Approved				Lung cancer:4.94e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 164.4	endometrium: 53.2	Cell line enhanced		A-431: 30.5;A549: 45.5;MCF7: 32.3;PC-3: 43.7;SCLC-21H: 53.0
TEAD2	ETF, TEF-4, TEF4	ENSG00000074219	TEA domain transcription factor 2	19	49340595-49362457	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066292, HPA069963			Enhanced	Nucleoplasm	Liver cancer:8.66e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 58.9	Cell line enhanced		AF22: 134.1;AN3-CA: 137.1
EED	HEED, WAIT-1	ENSG00000074266	Embryonic ectoderm development	11	86244544-86278813	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012211, HPA060089, HPA061140	Supported		Supported	Nucleoplasm	Renal cancer:1.36e-7 (unfavourable), Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:2.27e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 30.3	Expressed in all		
CDHR2	FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC	ENSG00000074276	Cadherin related family member 2	5	176542511-176595974	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012569, HPA017053	Enhanced				Renal cancer:9.29e-4 (favourable)	Group enriched	Group enriched	12	duodenum: 276.5;small intestine: 260.3	colon: 22.6	Cell line enriched	12	Hep G2: 15.0
SNCB		ENSG00000074317	Synuclein beta	5	176620084-176630556	Predicted intracellular proteins	Evidence at protein level	CAB002681, HPA035876	Enhanced	Supported				Tissue enriched	Tissue enriched	71	cerebral cortex: 329.2	adrenal gland: 4.6	Cell line enriched	15	SCLC-21H: 68.9
TSG101	TSG10, VPS23	ENSG00000074319	Tumor susceptibility 101	11	18468336-18527232	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004283, HPA006161	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:3.74e-6 (unfavourable), Renal cancer:5.52e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 81.8	Expressed in all		
NCBP3	C17orf85, ELG, HSA277841	ENSG00000074356	Nuclear cap binding subunit 3	17	3802165-3846251	Predicted intracellular proteins	Evidence at protein level	HPA008959, HPA013195	Supported		Approved	Nuclear speckles	Melanoma:4.68e-4 (unfavourable), Prostate cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
ATP2A3	SERCA3	ENSG00000074370	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	17	3923870-3964464	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007180, CAB010882	Approved				Cervical cancer:4.69e-5 (favourable), Head and neck cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 118.4	Cell line enhanced		Daudi: 133.8;HMC-1: 234.0;MOLT-4: 202.8;SK-BR-3: 146.3
CA12	HsT18816	ENSG00000074410	Carbonic anhydrase 12	15	63321378-63382161	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008773, CAB025181, CAB062549, CAB068179, HPA073203	Enhanced		Approved	Nucleus<br>Vesicles	Pancreatic cancer:3.80e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 308.4;skin: 168.3	rectum: 102.9	Cell line enhanced		A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
MGLL	HU-K5, MGL	ENSG00000074416	Monoglyceride lipase	3	127689062-127823250	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011348, HPA011993, HPA011994	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:6.41e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 188.3	Cell line enhanced		BJ hTERT+: 193.8
NTN4		ENSG00000074527	Netrin 4	12	95657807-95791152	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049832	Approved				Renal cancer:8.12e-9 (favourable), Urothelial cancer:6.67e-5 (favourable), Pancreatic cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 246.4	kidney: 118.6	Cell line enhanced		BJ hTERT+: 407.7;TIME: 235.1
BCS1L	BCS, BJS, h-BCS, Hs.6719	ENSG00000074582	BCS1 homolog, ubiquinol-cytochrome c reductase complex chaperone	2	218658764-218663443	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037700, HPA037701	Enhanced				Urothelial cancer:3.31e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.2	Expressed in all		
NUAK1	ARK5, KIAA0537, NuaK1	ENSG00000074590	NUAK family kinase 1	12	106063340-106140033	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057143			Supported	Nucleus<br>Nucleoli fibrillar center<br>Microtubules	Stomach cancer:4.27e-4 (unfavourable), Endometrial cancer:9.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 47.0;parathyroid gland: 42.5	skin: 21.0	Cell line enhanced		AF22: 50.0;EFO-21: 47.3;RH-30: 70.1
DPP8	DP8, DPRP1, FLJ14920, FLJ20283, MGC26191, MSTP141	ENSG00000074603	Dipeptidyl peptidase 8	15	65442463-65517704	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008706	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 48.0	Expressed in all		
SLC24A1	CSNB1D, HsT17412, KIAA0702, NCKX, NCKX1, RODX	ENSG00000074621	Solute carrier family 24 member 1	15	65611366-65660995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039370	Supported		Approved	Microtubules	Renal cancer:2.33e-6 (favourable)	Expressed in all	Mixed			fallopian tube: 8.5	Mixed		
ZNF532	FLJ10697	ENSG00000074657	Zinc finger protein 532	18	58862600-58986480	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015322	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:6.46e-5 (unfavourable), Urothelial cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 104.4	Cell line enhanced		AF22: 113.9
SCARF1	KIAA0149, SREC	ENSG00000074660	Scavenger receptor class F member 1	17	1633858-1645747	Predicted secreted proteins	Evidence at protein level	HPA072936	Enhanced					Expressed in all	Tissue enhanced		spleen: 16.6	lung: 8.0	Cell line enhanced		HEL: 5.0;HUVEC TERT2: 15.4;REH: 8.9;TIME: 19.1
LMAN1	ERGIC-53, ERGIC53, F5F8D, FMFD1, gp58, MCFD1, MR60	ENSG00000074695	Lectin, mannose binding 1	18	59327823-59359962	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA002320, CAB037163	Supported		Uncertain	Cytosol		Expressed in all	Expressed in all			thyroid gland: 125.2	Expressed in all		
HACD3	B-ind1, HSPC121, PTPLAD1	ENSG00000074696	3-hydroxyacyl-CoA dehydratase 3	15	65530418-65578352	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014837, HPA060347	Enhanced		Enhanced	Nuclear membrane<br>Endoplasmic reticulum<br>Mitochondria<br>Cytosol	Renal cancer:3.09e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 138.9	Expressed in all		
IPCEF1	KIAA0403, PIP3-E	ENSG00000074706	Interaction protein for cytohesin exchange factors 1	6	154154496-154356792	Predicted intracellular proteins	Evidence at protein level	HPA028708, HPA028710	Approved		Approved	Nucleoli<br>Nuclear speckles<br>Plasma membrane<br>Cytoplasmic bodies		Mixed	Tissue enhanced		thyroid gland: 66.3	cerebral cortex: 24.9	Cell line enhanced		HMC-1: 17.9;THP-1: 7.2;U-937: 8.8
ZZEF1	FLJ10821, KIAA0399, ZZZ4	ENSG00000074755	Zinc finger ZZ-type and EF-hand domain containing 1	17	4004445-4143020	Predicted membrane proteins	Evidence at protein level	HPA031778, HPA031790	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:1.02e-4 (favourable), Pancreatic cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 25.8	Expressed in all		
NOX3	GP91-3	ENSG00000074771	NADPH oxidase 3	6	155395370-155455903	Predicted membrane proteins, Transporters	Evidence at protein level	HPA073837			Uncertain	Vesicles		Not detected	Not detected			adrenal gland: 0.1	Cell line enriched	7	MCF7: 2.9
ENO1	ENO1L1, MBP-1, MPB1, PPH	ENSG00000074800	Enolase 1	1	8861002-8879249	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018614, HPA068284, HPA068721, CAB069394	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.30e-8 (unfavourable), Glioma:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 768.2	Expressed in all		
SLC12A1	NKCC2	ENSG00000074803	Solute carrier family 12 member 1	15	48191664-48304078	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014967, HPA018107	Enhanced		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	477	kidney: 780.2	testis: 1.6	Cell line enriched	19	RPTEC TERT1: 19.2
MYDGF	C19orf10, IL-25, IL-27, IL25, IL27, IL27w, R33729_1, SF20	ENSG00000074842	Myeloid derived growth factor	19	4641374-4670370	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041872, HPA046744	Approved				Renal cancer:4.99e-12 (unfavourable), Endometrial cancer:6.50e-7 (favourable)	Expressed in all	Expressed in all			epididymis: 134.0	Expressed in all		
ANO8	KIAA1623, TMEM16H	ENSG00000074855	Anoctamin 8	19	17323223-17334829	Predicted membrane proteins	Evidence at protein level	HPA031787, HPA049206	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		cerebral cortex: 34.5	skin: 19.9	Mixed		
TUBE1	dJ142L7.2, FLJ22589, TUBE	ENSG00000074935	Tubulin epsilon 1	6	112070777-112087529	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032073, HPA032074	Approved					Expressed in all	Expressed in all			testis: 55.3	Expressed in all		
ARHGEF10L	FLJ10521, KIAA1626	ENSG00000074964	Rho guanine nucleotide exchange factor 10 like	1	17539835-17697874	Predicted intracellular proteins	Evidence at protein level	HPA026426, HPA026440, HPA028115	Approved		Approved	Golgi apparatus<br>Vesicles<br>Cytosol	Head and neck cancer:8.13e-5 (favourable), Renal cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 29.7	Mixed		
TXK	BTKL, PSCTK5, PTK4, RLK, TKL	ENSG00000074966	TXK tyrosine kinase	4	48066393-48134256	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062482			Approved	Vesicles		Mixed	Tissue enhanced		lymph node: 17.9	epididymis: 15.1	Cell line enhanced		HMC-1: 12.2;WM-115: 31.5
WSCD2	KIAA0789	ENSG00000075035	WSC domain containing 2	12	108129471-108250537	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA013346, HPA048133	Approved		Approved	Nucleoplasm		Tissue enhanced	Group enriched	5	cerebral cortex: 14.1;cervix, uterine: 5.8;endometrium: 8.6;prostate: 7.1;seminal vesicle: 19.0;smooth muscle: 10.4;thyroid gland: 28.8	urinary bladder: 2.6	Cell line enriched	20	RT4: 26.6
KCNQ2	BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2	ENSG00000075043	Potassium voltage-gated channel subfamily Q member 2	20	63400210-63472677	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016642, HPA057112	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	7	cerebral cortex: 57.2	testis: 8.2	Cell line enhanced		AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1
TACR2	NK2R, NKNAR, SKR, TAC2R	ENSG00000075073	Tachykinin receptor 2	10	69403903-69416867	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA076573			Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		smooth muscle: 67.2	esophagus: 23.1	Cell line enhanced		SK-MEL-30: 3.2;U-87 MG: 2.3
ACTR6	ARP6, FLJ13433	ENSG00000075089	ARP6 actin-related protein 6 homolog	12	100199122-100241865	Predicted intracellular proteins	Evidence at protein level	HPA038587, HPA038588	Uncertain		Approved	Plasma membrane<br>Cytosol	Liver cancer:7.70e-9 (unfavourable)	Expressed in all	Mixed			testis: 16.2	Expressed in all		
TIPIN	FLJ20516	ENSG00000075131	TIMELESS interacting protein	15	66336206-66386746	Predicted intracellular proteins	Evidence at protein level	HPA039704, HPA058799	Enhanced		Supported	Nucleus<br>Vesicles	Liver cancer:2.47e-4 (unfavourable), Cervical cancer:4.15e-4 (favourable), Prostate cancer:9.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.9	parathyroid gland: 12.6	Expressed in all		
SRI		ENSG00000075142	Sorcin	7	88205118-88226993	Predicted intracellular proteins	Evidence at protein level	HPA019004, HPA073666	Enhanced		Supported	Nucleoplasm<br>Cytosol	Lung cancer:3.08e-4 (favourable), Pancreatic cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 562.9	Mixed		
EIF4G3	eIF4GII	ENSG00000075151	Eukaryotic translation initiation factor 4 gamma 3	1	20806292-21176888	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025031, HPA025039, HPA025041	Enhanced		Approved	Cytosol	Liver cancer:9.60e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 170.1	Mixed		
NUP37	FLJ22618, MGC5585	ENSG00000075188	Nucleoporin 37	12	102073103-102120124	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA056300, HPA073708	Enhanced		Supported	Nucleoplasm	Liver cancer:7.70e-6 (unfavourable), Head and neck cancer:6.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 32.2	Expressed in all		
SEMA3A	coll-1, Hsema-I, SEMA1, SEMAD, SemD	ENSG00000075213	Semaphorin 3A	7	83955777-84492724	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029447, HPA052235	Approved		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:2.69e-5 (unfavourable)	Mixed	Mixed			placenta: 14.5	Cell line enhanced		AF22: 127.3;BJ: 86.5;fHDF/TERT166: 86.7
GTSE1	B99, GTSE-1	ENSG00000075218	G2 and S-phase expressed 1	22	46296741-46330810	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029457, HPA060544	Uncertain		Approved	Plasma membrane<br>Centrosome	Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.5	lymph node: 10.6	Mixed		
SEMA3C	SEMAE, SemE	ENSG00000075223	Semaphorin 3C	7	80742538-80922359	Predicted secreted proteins	Evidence at protein level	HPA042418	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:4.08e-5 (unfavourable), Head and neck cancer:5.72e-5 (unfavourable)	Mixed	Mixed			prostate: 103.0	Cell line enhanced		T-47d: 248.8;U-2197: 317.7
TTC38	FLJ20699	ENSG00000075234	Tetratricopeptide repeat domain 38	22	46267961-46294008	Predicted intracellular proteins	Evidence at protein level	HPA029302	Approved		Approved	Cytosol	Endometrial cancer:3.21e-6 (favourable)	Expressed in all	Expressed in all			small intestine: 88.3	Mixed		
ACAT1	ACAT, THIL	ENSG00000075239	Acetyl-CoA acetyltransferase 1	11	108121516-108147776	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004428, HPA007569	Enhanced		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Liver cancer:1.43e-5 (favourable)	Expressed in all	Expressed in all			kidney: 534.2	Expressed in all		
GRAMD4	DIP, KIAA0767	ENSG00000075240	GRAM domain containing 4	22	46576012-46679790	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			skin: 53.4	Expressed in all		
CELSR1	ADGRC1, CDHF9, FMI2, HFMI2, ME2	ENSG00000075275	Cadherin EGF LAG seven-pass G-type receptor 1	22	46360834-46537170	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052976, HPA060521			Supported	Plasma membrane		Expressed in all	Mixed			fallopian tube: 15.5	Cell line enhanced		A549: 38.6;T-47d: 28.3
WNT8B		ENSG00000075290	Wnt family member 8B	10	100463041-100483744	Predicted secreted proteins	Evidence at transcript level	HPA036570	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.1;parathyroid gland: 1.5;testis: 1.2	kidney: 0.6	Cell line enhanced		AF22: 2.3;SCLC-21H: 1.3
ZNF638	MGC26130, NP220, ZFML, Zfp638	ENSG00000075292	Zinc finger protein 638	2	71276561-71435069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036784, HPA057395	Supported		Enhanced	Nucleoplasm<br>Vesicles	Urothelial cancer:8.73e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Expressed in all		
SLC25A40	MCFP	ENSG00000075303	Solute carrier family 25 member 40	7	87833568-87876357	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055197	Uncertain				Renal cancer:1.52e-5 (favourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Mixed			prostate: 14.1	Expressed in all		
TIMM21	C18orf55, HSPC154, TIM21	ENSG00000075336	Translocase of inner mitochondrial membrane 21	18	74148511-74160530	Predicted membrane proteins	Evidence at protein level	HPA010587, HPA051543	Uncertain		Approved	Nucleoplasm	Renal cancer:1.38e-9 (favourable), Liver cancer:9.22e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 26.2	Expressed in all		
ADD2	ADDB	ENSG00000075340	Adducin 2	2	70607618-70768225	Predicted intracellular proteins	Evidence at protein level	CAB009796, HPA034509, HPA034510	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	10	bone marrow: 40.2;cerebral cortex: 44.7	testis: 4.2	Cell line enhanced		K-562: 41.5;NTERA-2: 86.7;SCLC-21H: 50.4;U-251 MG: 38.9
FGF4	HBGF-4, HST, HST-1, HSTF1, K-FGF, KFGF	ENSG00000075388	Fibroblast growth factor 4	11	69771016-69775403	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011209	Uncertain					Tissue enriched	Not detected			testis: 0.4	Cell line enriched	90	NTERA-2: 15.7
RASAL2	nGAP	ENSG00000075391	RAS protein activator like 2	1	178094141-178484147	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA018805, HPA020453	Enhanced		Approved	Plasma membrane<br>Focal adhesion sites	Urothelial cancer:2.05e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 19.4	Mixed		
VPS9D1	ATP-BL, C16orf7	ENSG00000075399	VPS9 domain containing 1	16	89707134-89720986	Predicted intracellular proteins	Evidence at protein level	HPA007847, HPA023620	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.91e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
ZNF37A	KOX21, ZNF37	ENSG00000075407	Zinc finger protein 37A	10	38094334-38150293	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003172	Approved		Approved	Vesicles	Renal cancer:2.31e-4 (unfavourable), Liver cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 18.1	Expressed in all		
MARK3	CTAK1, KP78, PAR-1A	ENSG00000075413	Microtubule affinity regulating kinase 3	14	103385392-103503831	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024652	Approved		Approved	Nuclear membrane	Melanoma:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 64.0	Expressed in all		
SLC25A3	PHC	ENSG00000075415	Solute carrier family 25 member 3	12	98593591-98606379	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045709			Supported	Mitochondria	Renal cancer:8.11e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 595.7	Expressed in all		
FNDC3B	DKFZp762K137, FAD104, FLJ23399, PRO4979, YVTM2421	ENSG00000075420	Fibronectin type III domain containing 3B	3	172039628-172401665	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007859	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:5.65e-7 (unfavourable), Cervical cancer:2.41e-5 (unfavourable), Pancreatic cancer:9.06e-5 (unfavourable), Liver cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 77.5	Expressed in all		
FOSL2	FLJ23306, FRA2	ENSG00000075426	FOS like 2, AP-1 transcription factor subunit	2	28392448-28417312	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004817, CAB013460, HPA061417	Supported		Enhanced	Nucleus		Expressed in all	Expressed in all			adrenal gland: 224.8	Mixed		
CACNG5		ENSG00000075429	Calcium voltage-gated channel auxiliary subunit gamma 5	17	66835117-66885486	Predicted membrane proteins	Evidence at protein level	HPA050115	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 1.2	lymph node: 0.6	Not detected		
CACNG4	MGC11138, MGC24983	ENSG00000075461	Calcium voltage-gated channel auxiliary subunit gamma 4	17	66964910-67033398	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005803, HPA065370	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 48.6;prostate: 20.3	lung: 9.2	Cell line enriched	7	SH-SY5Y: 436.5
FRYL	AF4p12, DKFZp686E205, KIAA0826, MOR2	ENSG00000075539	FRY like transcription coactivator	4	48497361-48780322	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031106, HPA031107	Supported		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
TMEM131	CC28, KIAA0257, PRO1048, RW1, YR-23	ENSG00000075568	Transmembrane protein 131	2	97756333-97995891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017678, HPA017682	Approved		Uncertain	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			parathyroid gland: 47.6	Expressed in all		
FSCN1	FLJ38511, p55, SNL	ENSG00000075618	Fascin actin-bundling protein 1	7	5592823-5606655	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000121, HPA005723, CAB035991, HPA050654	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.15e-7 (unfavourable), Lung cancer:2.28e-4 (unfavourable), Head and neck cancer:5.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 85.5	spleen: 54.6	Cell line enhanced		BEWO: 579.4
ACTB		ENSG00000075624	Actin beta	7	5527151-5563784	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002621, HPA041264, HPA041271	Supported				Renal cancer:3.78e-5 (unfavourable), Head and neck cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 7221.8	Expressed in all		
MOCOS	FLJ20733, HMCS, MOS	ENSG00000075643	Molybdenum cofactor sulfurase	18	36187519-36272157	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039412, HPA047958	Uncertain		Supported	Mitochondria<br>Cytosol	Renal cancer:3.03e-12 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:3.55e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 11.4	Cell line enhanced		hTERT-HME1: 38.4;SiHa: 58.4;SK-MEL-30: 30.1
PLD1		ENSG00000075651	Phospholipase D1	3	171600405-171810950	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004527, HPA042396	Enhanced		Approved	Plasma membrane	Urothelial cancer:4.76e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 138.3	small intestine: 49.2	Cell line enhanced		HUVEC TERT2: 49.2;TIME: 42.2
ATP12A	#945, 2, ATP1AL1, HK	ENSG00000075673	ATPase H+/K+ transporting non-gastric alpha2 subunit	13	24680411-24712493	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039526	Approved					Tissue enhanced	Tissue enhanced		esophagus: 12.7;placenta: 8.2;tonsil: 14.1	skin: 7.1	Not detected		
WDR62	C19orf14, DKFZP434J046, FLJ33298, MCPH2	ENSG00000075702	WD repeat domain 62	19	36054881-36105106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043255, HPA043639, CAB046468	Enhanced		Enhanced	Microtubule organizing center<br>Cytosol		Mixed	Group enriched	8	skeletal muscle: 15.9;testis: 76.4	heart muscle: 6.0	Mixed		
DLG1	dJ1061C18.1.1, DLGH1, hdlg, SAP-97, SAP97	ENSG00000075711	Discs large MAGUK scaffold protein 1	3	197042560-197299300	Predicted intracellular proteins	Evidence at protein level	CAB016307, HPA069593	Supported		Uncertain	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 94.9	Expressed in all		
RAB7A	RAB7	ENSG00000075785	RAB7A, member RAS oncogene family	3	128726122-128814796	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006964, CAB037131	Supported		Supported	Lysosomes	Liver cancer:9.89e-6 (unfavourable), Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 270.2	Expressed in all		
BCAP29	BAP29, DKFZp686M2086	ENSG00000075790	B-cell receptor associated protein 29	7	107579977-107629170	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029215, HPA049694	Enhanced		Approved	Cytosol	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 93.0	Expressed in all		
SEC31B	DKFZP434M183, SEC31B-1, SEC31L2	ENSG00000075826	SEC31 homolog B, COPII coat complex component	10	100486642-100519864	Predicted intracellular proteins	Evidence at protein level	HPA035882, HPA040819, HPA060052	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:6.41e-7 (unfavourable)	Mixed	Mixed			testis: 3.2	Mixed		
SART3	KIAA0156, p110, RP11-13G14, TIP110	ENSG00000075856	Squamous cell carcinoma antigen recognized by T-cells 3	12	108522580-108561400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044322	Approved				Liver cancer:6.32e-6 (unfavourable), Melanoma:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.9	Expressed in all		
ARHGAP15	BM046	ENSG00000075884	Rho GTPase activating protein 15	2	143091362-143768352	Predicted intracellular proteins	Evidence at protein level	HPA032125	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:6.95e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 65.4	spleen: 59.6	Cell line enhanced		HEL: 77.1;HL-60: 97.4;MOLT-4: 65.5;NB-4: 59.8;THP-1: 85.7;U-698: 65.7
TUBA3D	H2-ALPHA	ENSG00000075886	Tubulin alpha 3d	2	131476093-131482934	Predicted intracellular proteins	Evidence at protein level	CAB004972, HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules	Renal cancer:4.75e-9 (unfavourable), Breast cancer:4.65e-4 (favourable)	Mixed	Tissue enriched	31	testis: 250.3	epididymis: 8.1	Not detected		
PAX2		ENSG00000075891	Paired box 2	10	100735603-100829941	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB013024, HPA047704, HPA070751	Enhanced		Supported	Nucleoli<br>Golgi apparatus	Endometrial cancer:4.56e-4 (unfavourable)	Group enriched	Group enriched	5	epididymis: 37.1;fallopian tube: 19.0;kidney: 25.3;seminal vesicle: 20.0	cervix, uterine: 4.9	Group enriched	8	AN3-CA: 16.6;EFO-21: 23.1;RPTEC TERT1: 13.3
EXOSC7	EAP1, hRrp42p, KIAA0116, p8, RRP42, Rrp42p	ENSG00000075914	Exosome component 7	3	44975241-45036066	Predicted intracellular proteins	Evidence at protein level	HPA036182, HPA057980	Approved		Supported	Nuclear speckles	Renal cancer:2.69e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 44.9	Expressed in all		
KIFAP3	FLA3, KAP-1, KAP3, SMAP	ENSG00000075945	Kinesin associated protein 3	1	169921326-170085208	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023738, HPA023742	Supported					Expressed in all	Expressed in all			cerebral cortex: 106.0	Expressed in all		
MKRN2	HSPC070, RNF62	ENSG00000075975	Makorin ring finger protein 2	3	12557014-12583713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037559, HPA037560	Enhanced		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.58e-4 (unfavourable), Renal cancer:6.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
MCM6	Mis5	ENSG00000076003	Minichromosome maintenance complex component 6	2	135839626-135876426	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004818, CAB009577	Enhanced		Enhanced	Nucleoplasm	Renal cancer:8.29e-12 (unfavourable), Liver cancer:5.70e-7 (unfavourable), Melanoma:1.09e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 40.7	Expressed in all		
REXO2	CGI-114, DKFZP566E144, SFN	ENSG00000076043	RNA exonuclease 2	11	114439386-114450279	Predicted intracellular proteins	Evidence at protein level	HPA038450, HPA038451	Enhanced		Supported	Nucleoli<br>Focal adhesion sites<br>Mitochondria	Colorectal cancer:6.51e-4 (favourable), Urothelial cancer:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 259.4	Expressed in all		
RBM7		ENSG00000076053	RNA binding motif protein 7	11	114400030-114414203	Predicted intracellular proteins	Evidence at protein level	HPA013993, HPA048003	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:1.17e-4 (unfavourable), Colorectal cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.8	Expressed in all		
RBMS2	SCR3	ENSG00000076067	RNA binding motif single stranded interacting protein 2	12	56521929-56596196	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039225, HPA058784	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.22e-4 (favourable)	Expressed in all	Expressed in all			lung: 37.9	Mixed		
BAZ2A	KIAA0314, TIP5, WALp3	ENSG00000076108	Bromodomain adjacent to zinc finger domain 2A	12	56595596-56636816	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005782, HPA063806			Enhanced	Nuclear speckles	Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 82.7	Expressed in all		
PTPN23	DKFZP564F0923, HD-PTP, KIAA1471	ENSG00000076201	Protein tyrosine phosphatase, non-receptor type 23	3	47381011-47413441	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016845	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Expressed in all		
MLH1	COCA2, FCC2, HNPCC, HNPCC2	ENSG00000076242	MutL homolog 1	3	36993332-37050918	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013294, HPA052707, HPA060714, CAB070868	Supported		Enhanced	Nucleoplasm	Liver cancer:8.24e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 60.0	Mixed		
UNG	DGU, HIGM4, UDG, UNG1, UNG2	ENSG00000076248	Uracil DNA glycosylase	12	109097574-109110992	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011605	Uncertain		Approved	Cytosol	Melanoma:3.06e-4 (unfavourable), Liver cancer:6.40e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 56.2	Expressed in all		
FMO4	FMO2	ENSG00000076258	Flavin containing monooxygenase 4	1	171314208-171342084	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA049100	Uncertain				Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 48.2;liver: 30.1	parathyroid gland: 10.9	Cell line enhanced		EFO-21: 5.2
KLHL20	KHLHX, KLEIP	ENSG00000076321	Kelch like family member 20	1	173714941-173786702	Predicted intracellular proteins	Evidence at protein level	HPA025034, HPA053704	Approved		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			testis: 29.3	Expressed in all		
RGS11		ENSG00000076344	Regulator of G-protein signaling 11	16	268301-275980	Predicted intracellular proteins	Evidence at protein level	HPA041692, HPA043039	Uncertain				Pancreatic cancer:1.24e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.3	adipose tissue: 8.1	Cell line enhanced		HHSteC: 2.6;SCLC-21H: 3.6;SH-SY5Y: 2.5;T-47d: 2.4
SLC46A1	HCP1, MGC9564, PCFT	ENSG00000076351	Solute carrier family 46 member 1	17	28394756-28407197	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB011614	Approved		Supported	Plasma membrane<br>Cytosol	Glioma:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 95.1	Cell line enhanced		CACO-2: 169.5
PLXNA2	FLJ11751, FLJ30634, KIAA0463, OCT, PLXN2	ENSG00000076356	Plexin A2	1	208022242-208244320	Predicted membrane proteins	Evidence at protein level	CAB009763	Approved					Expressed in all	Mixed			ovary: 17.0	Cell line enhanced		BEWO: 51.1;HaCaT: 49.2;HUVEC TERT2: 58.9;TIME: 133.3
SPAG5	DEEPEST, hMAP126, MAP126	ENSG00000076382	Sperm associated antigen 5	17	28577565-28599279	Predicted intracellular proteins	Evidence at protein level	HPA022008, HPA022479	Approved				Renal cancer:5.43e-13 (unfavourable), Liver cancer:5.43e-5 (unfavourable), Pancreatic cancer:3.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 120.0	kidney: 25.1	Mixed		
ANKRD13A	ANKRD13, NY-REN-25	ENSG00000076513	Ankyrin repeat domain 13A	12	109999186-110039763	Predicted intracellular proteins	Evidence at protein level	HPA039488, HPA043218	Enhanced		Supported	Plasma membrane	Head and neck cancer:7.70e-6 (favourable), Ovarian cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 113.4	Expressed in all		
TPD52	D52, hD52, N8L	ENSG00000076554	Tumor protein D52	8	80034745-80231232	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028427, HPA062167	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:4.77e-6 (unfavourable), Breast cancer:1.11e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 168.9	Cell line enhanced		SK-BR-3: 428.2
ACACB	ACC2, ACCB, HACC275	ENSG00000076555	Acetyl-CoA carboxylase beta	12	109116595-109268226	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006554	Enhanced				Renal cancer:1.15e-5 (favourable), Pancreatic cancer:1.93e-4 (favourable)	Expressed in all	Tissue enriched	6	adipose tissue: 194.8	parathyroid gland: 30.6	Cell line enriched	13	ASC diff: 152.8
TRAF4	CART1, MLN62, RNF83	ENSG00000076604	TNF receptor associated factor 4	17	28743984-28750958	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052377	Enhanced					Expressed in all	Mixed			duodenum: 47.2	Expressed in all		
PAG1	CBP, PAG	ENSG00000076641	Phosphoprotein membrane anchor with glycosphingolipid microdomains 1	8	80967810-81112068	Predicted intracellular proteins	Evidence at protein level	HPA001632, HPA066527	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable)	Expressed in all	Mixed			placenta: 23.0	Cell line enhanced		Daudi: 25.3;HMC-1: 40.0;SK-MEL-30: 28.4
GPATCH1	ECGP, FLJ10206, FLJ38686, GPATC1	ENSG00000076650	G-patch domain containing 1	19	33080880-33130542	Predicted intracellular proteins	Evidence at protein level	HPA043430, HPA043604	Approved		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.8	Expressed in all		
ICAM3	CD50, CDW50, ICAM-R	ENSG00000076662	Intercellular adhesion molecule 3	19	10333776-10339823	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002498, HPA049820	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Mitochondria		Mixed	Expressed in all			bone marrow: 111.9	Cell line enhanced		Karpas-707: 205.5;NB-4: 121.3;RPMI-8226: 154.3;U-937: 121.2
NT5C2	cN-II, GMP, NT5B, PNT5, SPG65	ENSG00000076685	5'-nucleotidase, cytosolic II	10	103088017-103193306	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003751	Approved					Expressed in all	Expressed in all			thyroid gland: 119.6	Expressed in all		
MCAM	CD146, MUC18	ENSG00000076706	Melanoma cell adhesion molecule	11	119308529-119321521	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002147, HPA008848	Enhanced		Enhanced	Plasma membrane	Renal cancer:5.14e-4 (unfavourable), Cervical cancer:7.61e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 367.1	Cell line enhanced		HUVEC TERT2: 935.6;TIME: 901.7;WM-115: 859.1
GPC4	K-glypican	ENSG00000076716	Glypican 4	X	133300103-133415490	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030836	Approved		Approved	Vesicles	Renal cancer:1.25e-5 (favourable), Lung cancer:3.51e-4 (favourable)	Expressed in all	Mixed			placenta: 41.7	Cell line enhanced		AF22: 206.9;HAP1: 125.3;NTERA-2: 110.1;RPTEC TERT1: 208.8
MBNL3	CHCR, FLJ11316, MBLX39, MBXL	ENSG00000076770	Muscleblind like splicing regulator 3	X	132369317-132489968	Predicted intracellular proteins	Evidence at protein level	HPA001584	Enhanced		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.57e-4 (unfavourable)	Expressed in all	Group enriched	5	placenta: 242.1;testis: 81.4	liver: 30.6	Cell line enhanced		CACO-2: 102.2;Hep G2: 116.6
CAMSAP3	KIAA1543, Nezha, PPP1R80	ENSG00000076826	Calmodulin regulated spectrin associated protein family member 3	19	7595902-7618304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043830, HPA062149	Enhanced		Approved	Nucleoplasm<br>Centrosome	Renal cancer:7.55e-7 (favourable)	Expressed in all	Tissue enhanced		skin: 22.1	duodenum: 15.2	Cell line enhanced		CACO-2: 22.2
RAP1GAP	KIAA0474, RAP1GA1, RAP1GAP1, RAP1GAPII	ENSG00000076864	RAP1 GTPase activating protein	1	21596215-21669363	Predicted intracellular proteins	Evidence at protein level	HPA001922, CAB003851	Enhanced	Supported	Approved	Cytosol	Renal cancer:1.12e-6 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 122.1;thyroid gland: 232.8	adrenal gland: 93.2	Cell line enhanced		A549: 41.8;K-562: 26.3;SCLC-21H: 61.3
XAB2	HCNP, HCRN, NTC90, SYF1	ENSG00000076924	XPA binding protein 2	19	7619525-7629565	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048751			Approved	Nucleus<br>Vesicles	Cervical cancer:4.04e-4 (favourable), Endometrial cancer:4.96e-4 (favourable), Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.3	Expressed in all		
ARHGEF1	LBCL2, P115-RHOGEF, SUB1.5	ENSG00000076928	Rho guanine nucleotide exchange factor 1	19	41883161-41930150	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009502, HPA012924, HPA060784	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 144.9	Expressed in all		
STXBP2	Hunc18b, UNC18B	ENSG00000076944	Syntaxin binding protein 2	19	7636881-7647873	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015564, HPA063868	Approved		Enhanced	Cytosol	Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable)	Expressed in all	Mixed			bone marrow: 125.3	Mixed		
MAP2K7	Jnkk2, MKK7, PRKMK7	ENSG00000076984	Mitogen-activated protein kinase kinase 7	19	7903843-7914478	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001633, CAB004262, HPA064711	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Head and neck cancer:8.54e-5 (favourable), Urothelial cancer:1.56e-4 (favourable)	Expressed in all	Expressed in all			spleen: 19.1	Expressed in all		
NMRK2	ITGB1BP3, MIBP, NRK2	ENSG00000077009	Nicotinamide riboside kinase 2	19	3933103-3942416	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049909, HPA054792, HPA072450	Approved		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.19e-4 (favourable)	Tissue enhanced	Group enriched	49	heart muscle: 374.4;skeletal muscle: 218.4	esophagus: 6.1	Group enriched	9	BEWO: 28.1;NTERA-2: 24.3
DGKD	DGKdelta, KIAA0145	ENSG00000077044	Diacylglycerol kinase delta	2	233354507-233472104	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027530, HPA049101	Approved		Supported	Cytosol	Renal cancer:4.07e-8 (unfavourable), Liver cancer:1.69e-5 (unfavourable)	Expressed in all	Mixed			testis: 20.8	Expressed in all		
CTTNBP2	C7orf8, CORTBP2, KIAA1758, Orf4	ENSG00000077063	Cortactin binding protein 2	7	117710651-117874139	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009151, HPA044654	Enhanced		Approved	Midbody ring<br>Cytosol	Renal cancer:3.71e-5 (favourable)	Mixed	Mixed			parathyroid gland: 19.1	Group enriched	6	HEL: 50.6;HMC-1: 63.2
ACTL6B	ACTL6, BAF53B	ENSG00000077080	Actin like 6B	7	100643097-100656461	Predicted intracellular proteins	Evidence at protein level	HPA045126	Uncertain		Approved	Nucleoli		Group enriched	Tissue enriched	19	cerebral cortex: 45.6	adrenal gland: 2.4	Group enriched	92	SCLC-21H: 33.1;SH-SY5Y: 30.4
RARB	HAP, NR1B2, RRB2	ENSG00000077092	Retinoic acid receptor beta	3	25174332-25597932	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002617, HPA004174	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.43e-5 (favourable)	Expressed in all	Mixed			placenta: 20.6	Cell line enhanced		HEK 293: 14.7;HUVEC TERT2: 11.2;WM-115: 36.1
TOP2B		ENSG00000077097	Topoisomerase (DNA) II beta	3	25597905-25664907	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004601, HPA024120, HPA050441	Supported		Enhanced	Nucleus	Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 107.4	Expressed in all		
TM9SF3	SMBP	ENSG00000077147	Transmembrane 9 superfamily member 3	10	96518109-96587452	Predicted membrane proteins	Evidence at protein level	HPA039609	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			stomach: 180.7	Expressed in all		
NFKB2	LYT-10, NF-kB2, p105, p49/p100, p52	ENSG00000077150	Nuclear factor kappa B subunit 2	10	102394110-102402529	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008422, CAB022098, HPA023900	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 70.7	Expressed in all		
UBE2T	FANCT, HSPC150	ENSG00000077152	Ubiquitin conjugating enzyme E2 T	1	202331657-202341980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002831			Approved	Nucleus<br>Nucleoli	Renal cancer:2.22e-16 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Ovarian cancer:6.90e-6 (favourable)	Expressed in all	Mixed			testis: 36.0	Expressed in all		
PPP1R12B	MGC131980, MGC87886, MYPT2, PP1bp55	ENSG00000077157	Protein phosphatase 1 regulatory subunit 12B	1	202348699-202592706	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024171, HPA024640	Enhanced		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			endometrium: 366.8	Mixed		
DNAJC10	ERdj5, PDIA19	ENSG00000077232	DnaJ heat shock protein family (Hsp40) member C10	2	182716041-182794464	Predicted membrane proteins	Evidence at protein level	HPA031111	Approved				Renal cancer:2.19e-7 (unfavourable), Endometrial cancer:6.42e-5 (favourable), Thyroid cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 154.9	Expressed in all		
GTF3C1	TFIIIC220	ENSG00000077235	General transcription factor IIIC subunit 1	16	27459555-27549913	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051617	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.25e-4 (favourable), Liver cancer:8.73e-4 (unfavourable), Pancreatic cancer:9.56e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.8	Expressed in all		
IL4R	CD124	ENSG00000077238	Interleukin 4 receptor	16	27313668-27364778	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004451, HPA050124	Enhanced				Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Mixed		
USP33	KIAA1097, VDU1	ENSG00000077254	Ubiquitin specific peptidase 33	1	77695987-77759852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005719	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 55.5	Expressed in all		
PAK3	bPAK, hPAK3, MRX30, MRX47	ENSG00000077264	P21 (RAC1) activated kinase 3	X	110944285-111227361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA044791, HPA060219	Approved		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 34.3	thyroid gland: 10.4	Cell line enhanced		EFO-21: 10.2;HAP1: 10.2;HDLM-2: 11.9;NTERA-2: 9.6;SCLC-21H: 14.7;U-251 MG: 11.1
CAPN6	CalpM, CANPX, CAPNX	ENSG00000077274	Calpain 6	X	111245103-111270523	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040383			Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 255.9;placenta: 117.0;seminal vesicle: 100.4	endometrium: 37.2	Group enriched	9	HAP1: 3.4;HDLM-2: 9.9;NTERA-2: 16.1
DCX	DBCN, DC, LISX, SCLH, XLIS	ENSG00000077279	Doublecortin	X	111293779-111412429	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036121		Supported	Approved	Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 10.6	endometrium: 2.4	Group enriched	9	SCLC-21H: 65.0;SH-SY5Y: 24.0
SNRPA	Mud1, U1-A, U1A	ENSG00000077312	Small nuclear ribonucleoprotein polypeptide A	19	40750637-40765389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004652, HPA046440, HPA054834	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.96e-9 (unfavourable), Liver cancer:1.34e-5 (unfavourable), Cervical cancer:2.50e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 60.7	Expressed in all		
SPAG6	CT141, pf16, Repro-SA-1	ENSG00000077327	Sperm associated antigen 6	10	22345445-22454224	Predicted intracellular proteins	Evidence at protein level	HPA038440	Enhanced					Mixed	Group enriched	12	fallopian tube: 77.7;testis: 172.6	lung: 10.7	Cell line enriched	22	U-937: 82.7
EXOSC5	hRrp46p, MGC12901, p12B, RRP41B, RRP46, Rrp46p	ENSG00000077348	Exosome component 5	19	41386374-41397479	Predicted intracellular proteins	Evidence at protein level	HPA053150, HPA055677	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:3.45e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 22.1	Expressed in all		
DYNC1I2	DIC74, DNCI2	ENSG00000077380	Dynein cytoplasmic 1 intermediate chain 2	2	171687409-171748420	Predicted intracellular proteins	Evidence at protein level	CAB033836, HPA040619, HPA053987	Enhanced		Supported	Nucleoli<br>Endoplasmic reticulum<br>Microtubules<br>Cytosol	Renal cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 146.6	Expressed in all		
APBB1IP	INAG1, RIAM	ENSG00000077420	Amyloid beta precursor protein binding family B member 1 interacting protein	10	26438203-26567803	Predicted intracellular proteins	Evidence at protein level	HPA017009, HPA063903	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:7.48e-4 (favourable)	Expressed in all	Mixed			appendix: 61.2	Cell line enhanced		REH: 169.0;U-698: 134.4
LRCH4	LRN, LRRN1	ENSG00000077454	Leucine rich repeats and calponin homology domain containing 4	7	100574011-100586153	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037667, HPA037668	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Colorectal cancer:1.61e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 105.8	Expressed in all		
FAM76B	MGC33371	ENSG00000077458	Family with sequence similarity 76 member B	11	95768942-95790409	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036608	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.17e-5 (unfavourable), Urothelial cancer:2.72e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
SIRT6		ENSG00000077463	Sirtuin 6	19	4174109-4182604	Predicted intracellular proteins	Evidence at protein level	HPA049729, HPA071776	Supported		Supported	Nucleoplasm	Urothelial cancer:2.58e-4 (favourable), Endometrial cancer:2.85e-4 (favourable), Stomach cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			colon: 13.2	Expressed in all		
TYR	OCA1, OCA1A, OCAIA	ENSG00000077498	Tyrosinase	11	89177452-89295759	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000079, HPA043241, HPA050889	Enhanced		Enhanced	Vesicles		Tissue enriched	Tissue enriched	33	skin: 29.8	breast: 0.9	Cell line enriched	1211	SK-MEL-30: 256.2
POLD3	KIAA0039, P66, P68, PPP1R128	ENSG00000077514	DNA polymerase delta 3, accessory subunit	11	74493851-74669117	Predicted intracellular proteins	Evidence at protein level	HPA058846	Enhanced		Supported	Nucleus	Renal cancer:7.90e-6 (unfavourable), Melanoma:5.48e-4 (unfavourable), Liver cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 45.6	Expressed in all		
ACTN2		ENSG00000077522	Actinin alpha 2	1	236686454-236764631	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006035, HPA008315	Enhanced					Tissue enhanced	Group enriched	28	heart muscle: 477.5;skeletal muscle: 758.7	esophagus: 22.4	Cell line enhanced		HEK 293: 1.8;HSkMC: 5.5;hTEC/SVTERT24-B: 4.9
CAPZB		ENSG00000077549	Capping actin protein of muscle Z-line beta subunit	1	19338776-19485539	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031531, HPA056066	Approved		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:1.85e-4 (unfavourable), Renal cancer:3.57e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 490.8	Expressed in all		
GPR137B	TM7SF1	ENSG00000077585	G protein-coupled receptor 137B	1	236142505-236221865	Predicted membrane proteins, Transporters	Evidence at protein level	HPA026422	Approved				Colorectal cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			kidney: 70.7	Cell line enhanced		SK-MEL-30: 165.8
NAALAD2	GCPIII, NAALADASE2	ENSG00000077616	N-acetylated alpha-linked acidic dipeptidase 2	11	90131515-90192894	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060820, HPA065419	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		testis: 27.2	adrenal gland: 13.7	Group enriched	5	CACO-2: 31.5;SH-SY5Y: 13.2
JADE1	JADE-1, PHF17	ENSG00000077684	Jade family PHD finger 1	4	128809623-128875224	Predicted intracellular proteins	Evidence at protein level	HPA020016	Approved		Approved	Mitochondria	Renal cancer:8.22e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.9	Expressed in all		
SLC25A43		ENSG00000077713	Solute carrier family 25 member 43	X	119399060-119454478	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA035188	Uncertain		Approved	Nucleus	Renal cancer:5.06e-8 (unfavourable), Endometrial cancer:3.76e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 20.5	Mixed		
UBE2A	HHR6A, RAD6A, UBC2	ENSG00000077721	Ubiquitin conjugating enzyme E2 A	X	119574467-119591083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003875, HPA051765, HPA065898			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.20e-6 (unfavourable), Cervical cancer:2.16e-4 (favourable), Head and neck cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.5	Expressed in all		
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FKBP6	FKBP36, PPIase	ENSG00000077800	FK506 binding protein 6	7	73328164-73358637	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061109	Enhanced					Tissue enriched	Tissue enriched	273	testis: 83.0	parathyroid gland: 0.3	Not detected		
SMC1B	bK268H5, SMC1L2	ENSG00000077935	Structural maintenance of chromosomes 1B	22	45344063-45413619	Predicted intracellular proteins	Evidence at protein level	HPA001500	Enhanced		Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	152	testis: 57.3	lymph node,parathyroid gland: 0.3	Cell line enhanced		A-431: 7.8;EFO-21: 3.8;SiHa: 19.3
FBLN1	FBLN	ENSG00000077942	Fibulin 1	22	45502238-45601135	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001612, HPA001613, CAB004393, CAB068187	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:3.02e-10 (unfavourable), Endometrial cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 1324.4	Cell line enhanced		ASC diff: 1263.9;BJ: 870.2;BJ hTERT+: 1319.9;HSkMC: 979.4;RT4: 1182.4
ITGA8		ENSG00000077943	Integrin subunit alpha 8	10	15513949-15720125	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003432	Approved					Mixed	Tissue enhanced		prostate: 59.5	seminal vesicle: 40.5	Cell line enhanced		HEK 293: 7.4;HMC-1: 17.0;HSkMC: 6.1;U-266/84: 6.6
CST7		ENSG00000077984	Cystatin F	20	24949230-24959928	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040442	Enhanced				Renal cancer:4.37e-6 (unfavourable), Endometrial cancer:9.17e-6 (favourable), Head and neck cancer:5.85e-5 (favourable), Breast cancer:6.55e-4 (favourable), Cervical cancer:7.90e-4 (favourable)	Expressed in all	Tissue enriched	9	bone marrow: 642.9	spleen: 74.1	Group enriched	19	HL-60: 58.5;HMC-1: 170.9;NB-4: 126.6;U-937: 278.1
MAP2	MAP2A, MAP2B, MAP2C	ENSG00000078018	Microtubule associated protein 2	2	209424058-209734118	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001984, HPA008273, HPA012828	Enhanced	Supported	Supported	Nucleoli<br>Cytosol	Endometrial cancer:1.98e-6 (unfavourable)	Tissue enhanced	Tissue enriched	11	cerebral cortex: 296.5	thyroid gland: 27.9	Cell line enhanced		AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2
PIAS2	miz, PIASX-ALPHA, PIASX-BETA, ZMIZ4	ENSG00000078043	Protein inhibitor of activated STAT 2	18	46803224-46920160	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068792	Enhanced		Supported	Nucleoplasm	Thyroid cancer:1.27e-4 (unfavourable)	Expressed in all	Group enriched	5	parathyroid gland: 28.5;testis: 119.6	cerebral cortex,thyroid gland: 13.8	Mixed		
AMPH		ENSG00000078053	Amphiphysin	7	38383704-38631567	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB008559, HPA019828, HPA019829	Enhanced		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:9.96e-4 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 83.7	cervix, uterine: 8.9	Cell line enhanced		ASC diff: 44.1;ASC TERT1: 26.4;BJ hTERT+ SV40 Large T+ RasG12V: 29.1;U-138 MG: 24.3
ARAF	ARAF1	ENSG00000078061	A-Raf proto-oncogene, serine/threonine kinase	X	47561100-47571920	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046188, HPA066326	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.45e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
MCCC1	MCCA	ENSG00000078070	Methylcrotonoyl-CoA carboxylase 1	3	183015218-183116075	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008310	Approved		Enhanced	Mitochondria	Renal cancer:3.68e-4 (favourable)	Expressed in all	Expressed in all			kidney: 57.9	Expressed in all		
LAMP3	CD208, DC-LAMP, DCLAMP, LAMP, TSC403	ENSG00000078081	Lysosomal associated membrane protein 3	3	183122213-183163839	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025133, HPA051467	Enhanced		Enhanced	Vesicles	Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable)	Mixed	Tissue enriched	7	lung: 319.3	appendix: 44.9	Group enriched	8	EFO-21: 154.0;HDLM-2: 40.5;HHSteC: 50.0;hTCEpi: 40.3
FAP	DPPIV	ENSG00000078098	Fibroblast activation protein alpha	2	162170684-162245151	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059739	Approved				Head and neck cancer:4.82e-4 (unfavourable)	Mixed	Tissue enhanced		endometrium: 50.7	smooth muscle: 38.5	Cell line enhanced		ASC diff: 128.1;ASC TERT1: 137.8;BJ hTERT+: 131.5;U-138 MG: 159.0
NEBL	LASP2, LNEBL	ENSG00000078114	Nebulette	10	20779973-21174187	Predicted intracellular proteins	Evidence at protein level	HPA013994, HPA013995	Approved				Renal cancer:2.77e-8 (favourable), Urothelial cancer:5.56e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 200.0;thyroid gland: 125.4	cerebral cortex: 61.3	Cell line enhanced		SCLC-21H: 69.4;SH-SY5Y: 37.8;SK-BR-3: 42.1
ACER3	APHC, FLJ11238, PHCA	ENSG00000078124	Alkaline ceramidase 3	11	76860867-77026797	Predicted membrane proteins	Evidence at protein level	HPA070087	Approved				Liver cancer:2.49e-4 (unfavourable), Renal cancer:2.73e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.2	Mixed		
UBE2K	HIP2, HYPG, UBC1	ENSG00000078140	Ubiquitin conjugating enzyme E2 K	4	39698044-39782792	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028869, CAB033212, CAB033515	Supported		Supported	Intermediate filaments<br>Actin filaments<br>Cytosol	Pancreatic cancer:8.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 64.7	Expressed in all		
PIK3C3	Vps34	ENSG00000078142	Phosphatidylinositol 3-kinase catalytic subunit type 3	18	41955206-42087830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040718	Approved				Renal cancer:4.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
N4BP2	B3BP	ENSG00000078177	NEDD4 binding protein 2	4	40056826-40158252	Predicted intracellular proteins	Evidence at protein level	HPA036770, HPA042607	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome		Expressed in all	Mixed			endometrium: 5.6	Cell line enhanced		MOLT-4: 20.8
TIGAR	C12orf5	ENSG00000078237	TP53 induced glycolysis regulatory phosphatase	12	4307763-4354593	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034010, HPA040354, HPA044111	Approved		Enhanced	Cytosol	Liver cancer:3.18e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 9.9	Cell line enhanced		BEWO: 81.8
TULP3	TUBL3	ENSG00000078246	Tubby like protein 3	12	2877223-2941140	Predicted intracellular proteins	Evidence at protein level	HPA015285, HPA018496	Uncertain		Supported	Nucleus<br>Nucleoli<br>Plasma membrane	Liver cancer:7.97e-5 (unfavourable), Endometrial cancer:2.99e-4 (favourable), Renal cancer:7.18e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 46.5	Expressed in all		
SYNJ2	INPP5H	ENSG00000078269	Synaptojanin 2	6	157981887-158099176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031575	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:4.02e-6 (unfavourable), Breast cancer:2.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 34.8	Mixed		
ADCY2	AC2, HBAC2, KIAA1060	ENSG00000078295	Adenylate cyclase 2	5	7396208-7830081	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB031482, HPA038015, HPA038483	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 57.2;skeletal muscle: 23.6	prostate: 8.4	Group enriched	7	AF22: 5.6;NTERA-2: 4.3;SK-MEL-30: 3.8
PPP2R5C	B56G, PR61G	ENSG00000078304	Protein phosphatase 2 regulatory subunit B'gamma	14	101761798-101927989	Predicted intracellular proteins	Evidence at protein level	HPA027553	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			lymph node: 157.9	Expressed in all		
RBFOX1	A2BP1, FOX-1, HRNBP1	ENSG00000078328	RNA binding protein, fox-1 homolog 1	16	6019094-7713338	Predicted intracellular proteins	Evidence at protein level	HPA040809	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	5	cerebral cortex: 110.5;skeletal muscle: 32.9	heart muscle: 13.9	Cell line enriched	18	RH-30: 26.2
GNB1		ENSG00000078369	G protein subunit beta 1	1	1785285-1891117	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040736	Supported		Approved	Golgi apparatus<br>Plasma membrane	Liver cancer:3.61e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 447.4	Expressed in all		
HOXA9	HOX1, HOX1G	ENSG00000078399	Homeobox A9	7	27162435-27175180	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061982	Uncertain		Supported	Nucleus		Mixed	Mixed			kidney: 12.6	Cell line enhanced		HEK 293: 113.8;SCLC-21H: 133.7
EDN1	ET1	ENSG00000078401	Endothelin 1	6	12290363-12297194	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA031976, CAB032500, CAB037291	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Expressed in all	Mixed			lung: 43.5	Group enriched	6	EFO-21: 622.7;HUVEC TERT2: 372.8;T-47d: 129.1;TIME: 272.4
MLLT10	AF10	ENSG00000078403	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10	10	21524675-21743630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005747	Supported		Supported	Nucleoplasm	Head and neck cancer:8.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 177.6	Expressed in all		
ZCWPW1	DKFZp434N0510, FLJ10057, ZCW1	ENSG00000078487	Zinc finger CW-type and PWWP domain containing 1	7	100400826-100428992	Predicted intracellular proteins	Evidence at protein level	HPA020911			Approved	Golgi apparatus	Pancreatic cancer:1.93e-4 (favourable), Cervical cancer:1.99e-4 (favourable), Lung cancer:4.84e-4 (favourable), Urothelial cancer:5.26e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 71.2	thyroid gland: 8.6	Mixed		
ADCYAP1R1	PAC1, PAC1R, PACAPR	ENSG00000078549	ADCYAP receptor type I	7	31052461-31111479	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030739, HPA049877	Enhanced		Supported	Vesicles	Endometrial cancer:5.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 137.1;fallopian tube: 46.8	cervix, uterine: 20.7	Group enriched	6	AF22: 3.6;NTERA-2: 4.9;SCLC-21H: 4.8;SH-SY5Y: 7.8
FGF20		ENSG00000078579	Fibroblast growth factor 20	8	16992169-17002181	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enhanced	Mixed			cervix, uterine: 1.5	Cell line enhanced		BJ hTERT+: 1.3;CAPAN-2: 4.6
P2RY10	P2Y10	ENSG00000078589	Purinergic receptor P2Y10	X	78945332-78961954	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA036757, HPA065766	Enhanced				Renal cancer:3.63e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 33.1;spleen: 22.6;tonsil: 24.0	appendix: 19.4	Group enriched	5	Karpas-707: 90.1;U-266/70: 20.1
ITM2A	BRICD2A, E25A	ENSG00000078596	Integral membrane protein 2A	X	79360384-79367667	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002918			Uncertain	Nucleoplasm	Liver cancer:3.66e-6 (favourable)	Expressed in all	Expressed in all			ovary: 220.1	Cell line enriched	6	MOLT-4: 1365.5
NRDC	hNRD1, hNRD2, NRD1	ENSG00000078618	Nardilysin convertase	1	51789191-51878937	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053661			Approved	Nucleoplasm	Renal cancer:2.12e-9 (unfavourable), Liver cancer:5.49e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 167.5	Expressed in all		
VDAC3	HD-VDAC3	ENSG00000078668	Voltage dependent anion channel 3	8	42391624-42405897	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026864	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 327.2	Expressed in all		
PCM1	PTC4	ENSG00000078674	Pericentriolar material 1	8	17922840-18029944	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023370, HPA023374, CAB058695	Enhanced		Enhanced	Nuclear membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 277.4	Expressed in all		
TNRC6C	FLJ20015, KIAA1582	ENSG00000078687	Trinucleotide repeat containing 6C	17	77959240-78108835	Predicted intracellular proteins	Evidence at protein level	HPA022007, HPA062051	Uncertain		Approved	Nucleus	Pancreatic cancer:6.56e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.4	Cell line enhanced		MOLT-4: 27.6
CBFA2T2	MTGR1, ZMYND3	ENSG00000078699	CBFA2/RUNX1 translocation partner 2	20	33490075-33650036	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060523, HPA072433	Enhanced		Approved	Nuclear speckles	Pancreatic cancer:6.93e-6 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Expressed in all		
BRINP1	DBC1, DBCCR1, FAM5A	ENSG00000078725	BMP/retinoic acid inducible neural specific 1	9	119153458-119369467	Predicted secreted proteins, Transporters	Evidence at protein level	HPA038828	Approved		Approved	Microtubules		Mixed	Tissue enriched	8	cerebral cortex: 59.6	seminal vesicle: 7.2	Cell line enhanced		HSkMC: 6.2;NTERA-2: 16.8;SCLC-21H: 8.7
ITCH	AIP4	ENSG00000078747	Itchy E3 ubiquitin protein ligase	20	34363235-34511393	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021126, HPA049032	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 73.2	Expressed in all		
PKD2L2	TRPP5	ENSG00000078795	Polycystin 2 like 2, transient receptor potential cation channel	5	137887968-137942747	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA041903, HPA043634	Approved		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	12	testis: 14.9	adrenal gland,thyroid gland: 1.2	Mixed		
TP53INP2	C20orf110, dJ1181N3.1, DKFZp434B2411, DKFZp434O0827, DOR, FLJ21759, FLJ23500, PINH	ENSG00000078804	Tumor protein p53 inducible nuclear protein 2	20	34704290-34713439	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.26e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 86.9	Expressed in all		
SDF4	Cab45	ENSG00000078808	Stromal cell derived factor 4	1	1216908-1232031	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA011249, CAB015227	Enhanced		Enhanced	Golgi apparatus	Cervical cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 128.7	Expressed in all		
MYH7B	dJ756N5.1, KIAA1512, MHC14, MYH14	ENSG00000078814	Myosin heavy chain 7B	20	34975403-35002437	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:8.44e-5 (favourable)	Mixed	Group enriched	11	heart muscle: 46.9;skeletal muscle: 55.9;testis: 11.7	cerebral cortex,prostate: 3.3	Cell line enhanced		U-138 MG: 1.5
BPIFB2	BPIL1, C20orf184, dJ726C3.2, LPLUNC2	ENSG00000078898	BPI fold containing family B member 2	20	33007600-33023709	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049491, HPA060121	Enhanced		Approved	Vesicles	Endometrial cancer:1.97e-5 (favourable)	Group enriched	Group enriched	23	esophagus: 98.5;salivary gland: 90.5	cervix, uterine: 4.0	Cell line enriched	418	Hep G2: 146.8
TP73	P73	ENSG00000078900	Tumor protein p73	1	3652520-3736201	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002514, CAB003022, HPA027314, HPA044516	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:1.82e-4 (favourable), Cervical cancer:2.98e-4 (favourable), Head and neck cancer:9.50e-4 (favourable)	Mixed	Group enriched	5	fallopian tube: 10.8;skin: 7.7	prostate: 1.8	Cell line enhanced		SCLC-21H: 21.2
TOLLIP	IL-1RAcPIP	ENSG00000078902	Toll interacting protein	11	1274371-1309654	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038621, HPA038622	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.11e-16 (favourable), Glioma:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.3	Expressed in all		
UBE2D4	HBUCE1	ENSG00000078967	Ubiquitin conjugating enzyme E2 D4 (putative)	7	43926438-43956136	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.86e-4 (favourable), Prostate cancer:5.77e-4 (favourable), Renal cancer:6.51e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 12.5	Expressed in all		
CLUL1		ENSG00000079101	Clusterin like 1	18	596988-650334	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025264, HPA075240	Supported		Approved	Endoplasmic reticulum<br>Plasma membrane		Mixed	Tissue enhanced		prostate: 13.9	thyroid gland: 11.5	Cell line enhanced		Hep G2: 23.4
RUNX1T1	AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2	ENSG00000079102	RUNX1 translocation partner 1	8	91954967-92103286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049852, HPA070951	Approved		Supported	Nucleoplasm		Mixed	Mixed			cervix, uterine: 12.8	Cell line enhanced		Daudi: 14.0;HEL: 32.2
CDH17	cadherin, HPT-1	ENSG00000079112	Cadherin 17	8	94127171-94217303	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023614, HPA023616, CAB025143, HPA026556	Enhanced		Supported	Cell Junctions		Group enriched	Group enriched	8	colon: 256.9;duodenum: 314.3;rectum: 267.3;small intestine: 294.3	appendix: 37.5	Group enriched	6	CACO-2: 81.5;U-266/70: 121.0
THOC1	HPR1, P84	ENSG00000079134	THO complex 1	18	214520-268050	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019096, HPA019687	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.80e-6 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Ovarian cancer:2.89e-5 (favourable), Breast cancer:8.43e-4 (favourable), Urothelial cancer:9.62e-4 (favourable)	Expressed in all	Mixed			testis: 29.3	Expressed in all		
FKBP7	FKBP23	ENSG00000079150	FK506 binding protein 7	2	178463664-178478600	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA008707	Approved	Supported	Supported	Endoplasmic reticulum	Renal cancer:4.61e-6 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 60.2	endometrium: 44.1	Cell line enhanced		ASC diff: 104.3;ASC TERT1: 65.6
OSBPL6	ORP6	ENSG00000079156	Oxysterol binding protein like 6	2	178194481-178402891	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032131	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 15.5	skin: 9.2	Cell line enhanced		HEL: 43.7
SLC1A3	EA6, EAAT1, GLAST	ENSG00000079215	Solute carrier family 1 member 3	5	36606355-36688334	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002573, HPA037467, HPA037468	Enhanced		Approved	Nucleoli<br>Mitochondria		Tissue enriched	Tissue enriched	16	cerebral cortex: 518.2	adipose tissue: 31.9	Cell line enhanced		AF22: 49.5;CACO-2: 68.8;HaCaT: 55.0
XRCC5	KARP-1, KU80, Ku86, KUB2	ENSG00000079246	X-ray repair cross complementing 5	2	216107464-216206303	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004468, HPA025813, HPA064685	Supported		Enhanced	Nucleoplasm	Liver cancer:2.10e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 213.3	Expressed in all		
LXN		ENSG00000079257	Latexin	3	158645822-158672693	Predicted intracellular proteins	Evidence at protein level	HPA014179, CAB025128	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 60.9	Cell line enhanced		HUVEC TERT2: 234.3;MCF7: 120.4
SP140	LYSP100-A, LYSP100-B	ENSG00000079263	SP140 nuclear body protein	2	230203110-230313215	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006162, HPA067493	Enhanced		Approved	Nucleoli fibrillar center<br>Mitochondria		Mixed	Group enriched	6	appendix: 32.8;lymph node: 64.4;spleen: 38.3;tonsil: 50.7	urinary bladder: 7.6	Cell line enhanced		Daudi: 22.1;HDLM-2: 48.5;Karpas-707: 18.0;RPMI-8226: 11.2
MKNK1	MNK1	ENSG00000079277	MAP kinase interacting serine/threonine kinase 1	1	46557408-46616843	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB027355, CAB037310, HPA071293	Approved		Supported	Nucleoplasm	Liver cancer:1.24e-5 (unfavourable), Renal cancer:1.51e-5 (unfavourable), Cervical cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			appendix: 35.8	Expressed in all		
TNS1	DKFZp586K0617, MXRA6, PPP1R155, TNS	ENSG00000079308	Tensin 1	2	217799789-218002995	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018774, HPA036089, HPA036090	Approved		Enhanced	Focal adhesion sites	Colorectal cancer:2.41e-4 (unfavourable), Urothelial cancer:5.19e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 319.5	Cell line enhanced		ASC diff: 102.7;fHDF/TERT166: 59.1;REH: 80.9
REXO1	EloA-BP1, KIAA1138, TCEB3BP1	ENSG00000079313	RNA exonuclease 1 homolog	19	1815246-1848463	Predicted intracellular proteins	Evidence at protein level	HPA042155, HPA042552	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
SAR1A	SAR1, Sara, SARA1	ENSG00000079332	Secretion associated Ras related GTPase 1A	10	70147289-70170523	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006923, CAB022545, HPA048368	Supported		Supported	Endoplasmic reticulum	Head and neck cancer:7.00e-5 (unfavourable), Liver cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 116.4	Expressed in all		
CDC14A	cdc14, Cdc14A1, Cdc14A2, DFNB105	ENSG00000079335	Cell division cycle 14A	1	100345025-100520277	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023783	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Tissue enhanced		testis: 56.3	fallopian tube: 19.8	Cell line enhanced		K-562: 25.8
RAPGEF3	bcm910, cAMP-GEFI, EPAC	ENSG00000079337	Rap guanine nucleotide exchange factor 3	12	47734367-47771040	Predicted intracellular proteins	Evidence at protein level	CAB004386, HPA040365, HPA043518	Approved		Approved	Cytosol	Renal cancer:6.67e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 43.0	Cell line enhanced		EFO-21: 26.0
CEACAM1	BGP, BGP1, CD66a	ENSG00000079385	Carcinoembryonic antigen related cell adhesion molecule 1	19	42507304-42561234	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002146, HPA011041	Enhanced				Endometrial cancer:6.32e-7 (favourable)	Mixed	Tissue enhanced		colon: 202.3;rectum: 130.6	esophagus: 46.5	Cell line enhanced		CAPAN-2: 25.2;Hep G2: 56.7;RT4: 43.1;SK-MEL-30: 47.4
SENP1		ENSG00000079387	SUMO1/sentrin specific peptidase 1	12	48042898-48106308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011765, HPA046491			Enhanced	Nucleus<br>Focal adhesion sites	Liver cancer:7.72e-5 (unfavourable), Renal cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enriched	8	testis: 110.1	lymph node: 13.3	Expressed in all		
DUSP13	BEDP, DUSP13A, DUSP13B, FLJ32450, TMDP	ENSG00000079393	Dual specificity phosphatase 13	10	75094432-75109221	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	6	skeletal muscle: 84.9;testis: 47.5	heart muscle: 10.9	Cell line enhanced		BEWO: 4.2;EFO-21: 4.7;Hep G2: 7.4;K-562: 3.8;LHCN-M2: 7.9;RH-30: 7.7
CIC	KIAA0306	ENSG00000079432	Capicua transcriptional repressor	19	42268537-42295797	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026388, HPA044341, HPA064725	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 54.9	Expressed in all		
LIPE	HSL	ENSG00000079435	Lipase E, hormone sensitive type	19	42401507-42427426	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006567, CAB017700	Enhanced		Supported	Cytosol	Pancreatic cancer:1.15e-4 (favourable)	Expressed in all	Tissue enriched	20	adipose tissue: 870.5	testis: 44.0	Cell line enriched	6	ASC diff: 94.1
FDFT1		ENSG00000079459	Farnesyl-diphosphate farnesyltransferase 1	8	11795573-11839309	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008874	Approved		Supported	Endoplasmic reticulum	Renal cancer:6.59e-9 (favourable), Colorectal cancer:4.92e-5 (favourable)	Expressed in all	Expressed in all			testis: 215.0	Expressed in all		
PAFAH1B3		ENSG00000079462	Platelet activating factor acetylhydrolase 1b catalytic subunit 3	19	42297033-42303546	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035639	Uncertain		Approved	Intermediate filaments	Renal cancer:2.07e-4 (unfavourable), Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.7	Mixed		
OPHN1	ARHGAP41, MRX60, OPN1	ENSG00000079482	Oligophrenin 1	X	68042344-68433913	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002919	Approved		Approved	Nucleus<br>Plasma membrane		Mixed	Mixed			cerebral cortex: 20.1	Mixed		
AFM	ALB2, ALBA	ENSG00000079557	Afamin	4	73481683-73504001	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017006, HPA052437	Enhanced				Liver cancer:1.80e-4 (favourable)	Tissue enriched	Tissue enriched	6	liver: 468.3	kidney: 80.9	Cell line enriched	6	CACO-2: 1.3
KIF22	Kid, KNSL4, OBP-1, OBP-2	ENSG00000079616	Kinesin family member 22	16	29790719-29805385	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041076, HPA048213	Approved		Approved	Nuclear speckles	Cervical cancer:3.87e-8 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.9	Expressed in all		
SCGN	CALBL, DJ501N12.8, SECRET, SEGN	ENSG00000079689	Secretagogin, EF-hand calcium binding protein	6	25652201-25701783	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004005, HPA006641, CAB044060, CAB062563, CAB068232	Enhanced	Supported				Tissue enhanced	Tissue enhanced		rectum: 21.5;stomach: 20.6	colon: 17.0	Cell line enriched	6	SCLC-21H: 29.5
CARMIL1	CARMIL, dJ501N12.1, FLJ20048, LRRC16, LRRC16A	ENSG00000079691	Capping protein regulator and myosin 1 linker 1	6	25279078-25620530	Predicted intracellular proteins	Evidence at protein level	HPA029038, HPA029039	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 22.2	Mixed		
PGM1		ENSG00000079739	Phosphoglucomutase 1	1	63593276-63660245	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004666, HPA024190, HPA024637, HPA046329	Approved		Enhanced	Actin filaments	Pancreatic cancer:8.74e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 512.9	Mixed		
DDX1	DBP-RB	ENSG00000079785	DEAD-box helicase 1	2	15591178-15631111	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012280, HPA034502, HPA034503	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:9.09e-9 (unfavourable), Renal cancer:9.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 145.1	Expressed in all		
DNM2	CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII	ENSG00000079805	Dynamin 2	19	10718079-10833488	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054246	Enhanced		Approved	Golgi apparatus<br>Cytosol	Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			colon: 103.9	Expressed in all		
EPB41L2	4.1-G	ENSG00000079819	Erythrocyte membrane protein band 4.1 like 2	6	130839347-131063322	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005730, HPA006642	Supported		Enhanced	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:2.41e-5 (unfavourable), Ovarian cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 137.3	Mixed		
RIMS1	CORD7, KIAA0340, RAB3IP2, RIM, RIM1	ENSG00000079841	Regulating synaptic membrane exocytosis 1	6	71886703-72403143	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 30.2	testis: 7.5	Cell line enhanced		EFO-21: 8.3;LHCN-M2: 8.3;RPTEC TERT1: 11.5;SH-SY5Y: 11.4
MOXD1	dJ248E1.1, DKFZP564G202, MOX	ENSG00000079931	Monooxygenase DBH like 1	6	132296055-132401545	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035740	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 106.1;smooth muscle: 114.5	seminal vesicle: 53.7	Cell line enhanced		ASC diff: 111.5;fHDF/TERT166: 149.9;HBF TERT88: 116.1;U-2197: 280.6
STX7		ENSG00000079950	Syntaxin 7	6	132445867-132513198	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001467, CAB062564	Enhanced		Enhanced	Lysosomes	Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.4	Expressed in all		
RABL2B		ENSG00000079974	RAB, member of RAS oncogene family-like 2B	22	50767501-50783663	Predicted intracellular proteins	Evidence at protein level	HPA042642, HPA042700, HPA044007	Approved		Approved	Vesicles<br>Centrosome	Liver cancer:4.58e-5 (unfavourable), Endometrial cancer:5.58e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 110.4	Expressed in all		
KEAP1	INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454	ENSG00000079999	Kelch like ECH associated protein 1	19	10486120-10503741	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005558, CAB025337	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Cervical cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 49.4	Expressed in all		
DDX43	CT13, DKFZp434H2114, HAGE	ENSG00000080007	DEAD-box helicase 43	6	73394748-73417569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031381	Enhanced					Tissue enriched	Tissue enriched	5	testis: 34.6	placenta: 6.8	Cell line enhanced		BEWO: 7.5;CAPAN-2: 11.7;HHSteC: 3.0;U-2 OS: 8.7
PTPRH	SAP-1	ENSG00000080031	Protein tyrosine phosphatase, receptor type H	19	55181248-55209506	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042300			Approved	Mitochondria		Mixed	Tissue enhanced		duodenum: 68.9;small intestine: 77.0	gallbladder: 38.6	Cell line enhanced		HHSteC: 10.1;K-562: 13.5;SK-MEL-30: 17.2
DCT	TYRP2	ENSG00000080166	Dopachrome tautomerase	13	94436808-94479682	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010743, HPA010800, CAB017634	Enhanced					Tissue enriched	Tissue enriched	31	skin: 126.8	breast: 4.0	Cell line enriched	177	SK-MEL-30: 202.8
SLC35C2	bA394O2.1, C20orf5, CGI-15, OVCOV1	ENSG00000080189	Solute carrier family 35 member C2	20	46345980-46364458	Predicted membrane proteins, Transporters	Evidence at protein level	HPA027011	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.08e-4 (unfavourable), Renal cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 37.0	Expressed in all		
CRYBG3	DKFZp667G2110	ENSG00000080200	Crystallin beta-gamma domain containing 3	3	97822040-97944963	Predicted intracellular proteins	Evidence at protein level	HPA044122			Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.07e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 45.8	testis: 25.6	Cell line enhanced		SCLC-21H: 47.0
EPHA6	FLJ35246	ENSG00000080224	EPH receptor A6	3	96814581-97752460	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007397, HPA058047	Uncertain		Enhanced	Nucleoplasm		Mixed	Tissue enhanced		ovary: 7.7;testis: 15.1	cerebral cortex: 3.6	Cell line enhanced		HEK 293: 8.5;U-266/70: 21.4
SCTR		ENSG00000080293	Secretin receptor	2	119439843-119525301	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA007269	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 26.7;lung: 12.7;pancreas: 14.4	stomach: 4.1	Cell line enhanced		Karpas-707: 2.2
RFX3		ENSG00000080298	Regulatory factor X3	9	3218297-3526004	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035689	Enhanced		Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.47e-4 (favourable)	Mixed	Tissue enhanced		testis: 38.6	fallopian tube: 18.3	Cell line enhanced		AF22: 26.0;SCLC-21H: 16.6
RIF1	FLJ10599, FLJ12870	ENSG00000080345	Replication timing regulatory factor 1	2	151409883-151508013	Predicted intracellular proteins	Evidence at protein level	HPA036887, HPA036888	Supported		Uncertain	Nucleus<br>Nuclear bodies<br>Plasma membrane		Expressed in all	Expressed in all			testis: 21.1	Expressed in all		
RAB21	KIAA0118	ENSG00000080371	RAB21, member RAS oncogene family	12	71754874-71800285	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016988, CAB037048	Approved				Renal cancer:5.39e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.2	Expressed in all		
SLC4A4	hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5	ENSG00000080493	Solute carrier family 4 member 4	4	71186757-71572087	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022493, HPA035628, HPA035629	Enhanced				Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 125.8	cerebral cortex: 59.3	Cell line enhanced		BJ: 12.5;RPTEC TERT1: 11.7;U-138 MG: 8.0
SMARCA2	BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2	ENSG00000080503	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2	9	1980290-2193624	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029981, CAB037276	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Intermediate filaments	Renal cancer:1.26e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 328.7	Cell line enriched	7	HDLM-2: 1364.0
RDH8	PRRDH, SDR28C2	ENSG00000080511	Retinol dehydrogenase 8 (all-trans)	19	10013249-10022279	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Group enriched	Group enriched	11	kidney: 1.2;testis: 1.8	appendix: 0.1	Not detected		
SESN1	PA26, SEST1	ENSG00000080546	Sestrin 1	6	108986437-109094819	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073659			Supported	Nucleus<br>Nucleoli fibrillar center	Head and neck cancer:6.47e-5 (favourable), Prostate cancer:2.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
MID2	FXY2, MRX101, RNF60, TRIM1	ENSG00000080561	Midline 2	X	107825755-107927193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Stomach cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 23.4	Cell line enhanced		HUVEC TERT2: 34.7;Karpas-707: 25.8
PIH1D3	CXorf41, MGC35261, NYSAR97	ENSG00000080572	PIH1 domain containing 3	X	107206632-107244243	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA072496	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 17.4;testis: 13.8	lung: 1.9	Not detected		
COL5A3		ENSG00000080573	Collagen type V alpha 3 chain	19	9959561-10010471	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA048256	Approved				Renal cancer:7.17e-8 (unfavourable), Urothelial cancer:6.87e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 47.7	adipose tissue: 30.9	Cell line enhanced		ASC TERT1: 27.4;BJ: 20.0;BJ hTERT+: 21.4;HSkMC: 20.6;WM-115: 25.9
SRCAP	DOMO1, EAF1, KIAA0309, SWR1	ENSG00000080603	Snf2 related CREBBP activator protein	16	30698209-30741409	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028929	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 55.6	Expressed in all		
PUM3	HA-8, hPUF-A, KIAA0020, PEN, PUF6, XTP5	ENSG00000080608	Pumilio RNA binding family member 3	9	2720469-2844241	Predicted intracellular proteins	Evidence at protein level	HPA002353	Approved		Supported	Nucleoli	Liver cancer:4.89e-5 (unfavourable), Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 28.4	Expressed in all		
CPB2	CPU, PCPB, TAFI	ENSG00000080618	Carboxypeptidase B2	13	46053186-46105076	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004146	Approved				Liver cancer:2.06e-4 (favourable)	Tissue enriched	Tissue enriched	28	liver: 755.5	lung: 26.5	Cell line enriched	66	Hep G2: 117.8
CHRNA3		ENSG00000080644	Cholinergic receptor nicotinic alpha 3 subunit	15	78593052-78621295	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029430	Approved					Mixed	Tissue enriched	8	adrenal gland: 48.0	appendix: 6.3	Group enriched	25	SCLC-21H: 72.3;SH-SY5Y: 343.0
KCNN2	hSK2, KCa2.2	ENSG00000080709	Potassium calcium-activated channel subfamily N member 2	5	114360945-114496500	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA038221	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 27.3	prostate: 15.9	Cell line enhanced		BJ: 14.7;NTERA-2: 6.4;SK-MEL-30: 9.7;THP-1: 15.0;U-937: 6.2
CNOT4	CLONE243, NOT4, NOT4H	ENSG00000080802	CCR4-NOT transcription complex subunit 4	7	135361795-135510127	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005737	Approved				Renal cancer:7.67e-6 (favourable), Liver cancer:1.19e-4 (unfavourable), Ovarian cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.3	Expressed in all		
PSEN1	AD3, FAD, PS1, S182	ENSG00000080815	Presenilin 1	14	73136418-73223691	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB006844, HPA030760, HPA067496	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cell Junctions	Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.0	Expressed in all		
CPOX	CPO, CPX, HCP	ENSG00000080819	Coproporphyrinogen oxidase	3	98521132-98593723	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA015736, HPA054448			Enhanced	Mitochondria	Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 25.5	Expressed in all		
CLDND1	C3orf4	ENSG00000080822	Claudin domain containing 1	3	98497912-98523066	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029841	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:5.84e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 399.9	Expressed in all		
MOK	RAGE, RAGE1, STK30	ENSG00000080823	MOK protein kinase	14	102224500-102305200	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027292			Supported	Endoplasmic reticulum		Mixed	Tissue enhanced		testis: 71.8	fallopian tube: 34.3	Cell line enhanced		HBF TERT88: 143.8;hTEC/SVTERT24-B: 382.7;NB-4: 315.3;U-138 MG: 197.5
HSP90AA1	FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA	ENSG00000080824	Heat shock protein 90 alpha family class A member 1	14	102080738-102139699	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002058	Approved		Supported	Cytosol	Renal cancer:1.18e-5 (favourable), Liver cancer:3.09e-5 (unfavourable), Breast cancer:5.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1021.5	Expressed in all		
RBL1	cp107, p107, PRB1	ENSG00000080839	RB transcriptional corepressor like 1	20	36996349-37095995	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054962, HPA056525	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.52e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 9.2	Expressed in all		
DLGAP4	DAP4, KIAA0964, SAPAP4	ENSG00000080845	DLG associated protein 4	20	36306336-36528637	Predicted intracellular proteins	Evidence at protein level	HPA054105, HPA056378	Approved		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Liver cancer:3.73e-6 (unfavourable), Endometrial cancer:2.24e-5 (unfavourable), Melanoma:9.88e-5 (favourable), Renal cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 61.6	Expressed in all		
IGSF9B	KIAA1030	ENSG00000080854	Immunoglobulin superfamily member 9B	11	133908564-133956985	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA010744, HPA010802	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex: 9.0	Cell line enhanced		SCLC-21H: 19.6;SH-SY5Y: 9.0
CFHR2	CFHL2, FHR2, HFL3	ENSG00000080910	Complement factor H related 2	1	196943772-196959226	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726, HPA049813	Supported					Tissue enriched	Tissue enriched	4661	liver: 466.1	all non-specific tissues: 0.0	Not detected		
NDC80	HEC, HEC1, hsNDC80, KNTC2, TID3	ENSG00000080986	NDC80, kinetochore complex component	18	2571511-2616635	Predicted intracellular proteins	Evidence at protein level	HPA066330			Supported	Nucleoplasm<br>Centrosome	Liver cancer:2.53e-8 (unfavourable)	Expressed in all	Mixed			testis: 27.3	Expressed in all		
AP4E1	AP-4-EPSILON, SPG51	ENSG00000081014	Adaptor related protein complex 4 epsilon 1 subunit	15	50908672-51005900	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041749, HPA041891	Approved					Expressed in all	Mixed			parathyroid gland: 12.0	Expressed in all		
RSBN1	FLJ11220, ROSBIN	ENSG00000081019	Round spermatid basic protein 1	1	113761832-113812476	Predicted intracellular proteins	Evidence at protein level	HPA042124, HPA049484	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 22.0	Expressed in all		
MAGI3	MAGI-3	ENSG00000081026	Membrane associated guanylate kinase, WW and PDZ domain containing 3	1	113390749-113685923	Predicted intracellular proteins	Evidence at protein level	HPA007923, HPA008444	Approved		Supported	Cell Junctions	Renal cancer:2.60e-8 (favourable), Ovarian cancer:4.29e-4 (favourable)	Expressed in all	Mixed			lung: 20.9	Mixed		
CXCL2	CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, SCYB2	ENSG00000081041	C-X-C motif chemokine ligand 2	4	74097035-74099293	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.07e-6 (unfavourable), Breast cancer:5.93e-5 (favourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 110.2	lung: 95.2	Cell line enhanced		BJ hTERT+: 38.3;HHSteC: 26.8;hTCEpi: 24.9;hTEC/SVTERT24-B: 24.7;hTERT-HME1: 25.6;U-87 MG: 27.5
AFP	FETA, HPAFP	ENSG00000081051	Alpha fetoprotein	4	73431138-73456174	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010607, HPA023600, CAB024283, CAB025339	Approved		Uncertain	Cytosol		Group enriched	Tissue enhanced		liver: 1.9	breast: 0.5	Cell line enriched	158	Hep G2: 1466.5
COL4A4	CA44	ENSG00000081052	Collagen type IV alpha 4 chain	2	227002711-227164113	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.30e-13 (favourable)	Mixed	Mixed			thyroid gland: 14.1	Cell line enhanced		HeLa: 16.3;RPTEC TERT1: 10.8
TCF7	TCF-1	ENSG00000081059	Transcription factor 7 (T-cell specific, HMG-box)	5	134114711-134151865	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019403, HPA058863, HPA070505	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		lymph node: 110.1	appendix: 71.7	Cell line enriched	13	MOLT-4: 1060.4
OSTM1	GL, HSPC019	ENSG00000081087	Osteopetrosis associated transmembrane protein 1	6	108041409-108165854	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010851	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:1.34e-6 (unfavourable), Stomach cancer:1.20e-4 (unfavourable), Liver cancer:4.26e-4 (unfavourable), Breast cancer:4.36e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 33.6	Expressed in all		
CDH7		ENSG00000081138	Cadherin 7	18	65750252-65890341	Predicted membrane proteins	Evidence at protein level	HPA061419	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.8;prostate: 1.3	testis: 0.7	Cell line enhanced		AF22: 15.0;Karpas-707: 4.0;RH-30: 7.0;U-87 MG: 3.3
IMPG2	IPM200, RP56	ENSG00000081148	Interphotoreceptor matrix proteoglycan 2	3	101222546-101320560	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA008779, HPA015907	Supported					Tissue enriched	Tissue enriched	45	fallopian tube: 15.7	appendix,lymph node,spleen: 0.3	Not detected		
PCNP		ENSG00000081154	PEST proteolytic signal containing nuclear protein	3	101574095-101594437	Predicted intracellular proteins	Evidence at protein level	HPA035011	Supported		Supported	Nucleus	Liver cancer:6.00e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 80.6	Expressed in all		
EXD2	C14orf114, EXDL2, FLJ10738	ENSG00000081177	Exonuclease 3'-5' domain containing 2	14	69191511-69244020	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002906, HPA005848	Uncertain		Approved	Intermediate filaments<br>Mitochondria	Renal cancer:2.08e-9 (favourable), Liver cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.6	Mixed		
ARG2		ENSG00000081181	Arginase 2	14	67619798-67651720	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000663, CAB009435	Enhanced		Supported	Mitochondria		Expressed in all	Tissue enhanced		parathyroid gland: 94.0;prostate: 161.0;thyroid gland: 157.2	kidney: 63.4	Cell line enhanced		HAP1: 54.8
MEF2C		ENSG00000081189	Myocyte enhancer factor 2C	5	88717117-88904257	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005533, CAB068196, CAB068197	Enhanced		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 197.9	Cell line enhanced		HEL: 205.2;REH: 238.4;WM-115: 143.4
PTPRC	CD45, GP180, LCA, T200	ENSG00000081237	Protein tyrosine phosphatase, receptor type C	1	198638671-198757283	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000052, HPA000440, CAB002800, CAB056154, CAB068221	Enhanced				Renal cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 372.4	Cell line enhanced		Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5
CACNA1S	CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5	ENSG00000081248	Calcium voltage-gated channel subunit alpha1 S	1	201039512-201112566	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB009507, HPA048892, HPA056815	Enhanced					Tissue enhanced	Tissue enriched	34	skeletal muscle: 103.0	esophagus: 3.0	Group enriched	20	BEWO: 2.0;HSkMC: 1.9
PKP1	B6P	ENSG00000081277	Plakophilin 1	1	201283452-201332993	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027221, HPA027589, CAB033130	Enhanced		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	11	esophagus: 281.6;skin: 821.6	prostate: 51.7	Cell line enhanced		HaCaT: 205.1;HBEC3-KT: 102.1;hTCEpi: 358.4;hTERT-HME1: 100.7;PC-3: 176.6
UBA5	FLJ23251, UBE1DC1	ENSG00000081307	Ubiquitin like modifier activating enzyme 5	3	132654446-132678097	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017235	Uncertain		Enhanced	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 64.2	Expressed in all		
STK17B	DRAK2	ENSG00000081320	Serine/threonine kinase 17b	2	196133566-196176503	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034858	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:5.72e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 248.5	lymph node: 133.3	Expressed in all		
CDC14B	Cdc14B1, Cdc14B2, CDC14B3, hCDC14B	ENSG00000081377	Cell division cycle 14B	9	96490241-96619830	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013312, HPA064747	Approved		Supported	Nucleoplasm	Renal cancer:2.97e-10 (favourable), Thyroid cancer:2.82e-4 (unfavourable)	Expressed in all	Mixed			testis: 18.6	Cell line enhanced		ASC TERT1: 21.4
ZNF510	KIAA0972	ENSG00000081386	Zinc finger protein 510	9	96755865-96778129	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049139	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:5.94e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Expressed in all		
LRP2	DBS, gp330	ENSG00000081479	LDL receptor related protein 2	2	169127109-169362685	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005980, HPA064792	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:3.43e-5 (favourable)	Group enriched	Group enriched	6	kidney: 49.8;parathyroid gland: 155.8;thyroid gland: 37.0	breast: 14.2	Group enriched	11	AF22: 39.4;CACO-2: 56.2
ZNF506	DKFZp761G1812	ENSG00000081665	Zinc finger protein 506	19	19785839-19821751	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Expressed in all	Expressed in all			thyroid gland: 16.2	Mixed		
JMJD4	FLJ12517	ENSG00000081692	Jumonji domain containing 4	1	227730425-227735411	Predicted intracellular proteins	Evidence at protein level	HPA027260, HPA052861	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:3.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 12.9	Expressed in all		
DUSP12	DUSP1, YVH1	ENSG00000081721	Dual specificity phosphatase 12	1	161749758-161757238	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008840	Uncertain		Supported	Nucleus	Renal cancer:1.55e-7 (unfavourable), Liver cancer:1.99e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 20.3	Expressed in all		
AACS	ACSF1, FLJ12389, SUR-5	ENSG00000081760	Acetoacetyl-CoA synthetase	12	125065379-125143333	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA058815	Approved		Approved	Vesicles		Expressed in all	Expressed in all			breast: 55.0	Expressed in all		
KIAA0141	DELE	ENSG00000081791	KIAA0141	5	141923808-141942047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036548, HPA061490	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus	Ovarian cancer:6.89e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 62.3	Expressed in all		
SLC13A1	NAS1, NaSi-1	ENSG00000081800	Solute carrier family 13 member 1	7	123113531-123199986	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053615, HPA062714	Enhanced				Renal cancer:8.95e-5 (favourable)	Tissue enriched	Tissue enriched	6	kidney: 85.0	small intestine: 14.1	Not detected		
CADPS2	CAPS2	ENSG00000081803	Calcium dependent secretion activator 2	7	122318425-122886759	Predicted intracellular proteins	Evidence at protein level	HPA056398			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.01e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 45.7	Cell line enhanced		HUVEC TERT2: 36.2;Karpas-707: 40.4
PCDHB4	PCDH-BETA4	ENSG00000081818	Protocadherin beta 4	5	141121799-141125623	Predicted membrane proteins	Evidence at transcript level	HPA014466	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol		Mixed	Mixed			endometrium: 8.9	Group enriched	6	SCLC-21H: 10.2;SH-SY5Y: 6.2
PCDHA6	CNR2, CNRS2, CRNR2, PCDH-ALPHA6	ENSG00000081842	Protocadherin alpha 6	5	140827958-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059326, HPA078110	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		cerebral cortex: 4.8	parathyroid gland: 1.9	Cell line enhanced		AF22: 2.0;EFO-21: 8.1;U-2 OS: 3.7;WM-115: 5.1
PCDHGA2	PCDH-GAMMA-A2	ENSG00000081853	Protocadherin gamma subfamily A, 2	5	141338760-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA038625	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex: 8.4	Cell line enhanced		ASC TERT1: 4.3;BJ: 3.0;fHDF/TERT166: 3.3
HSPB11	C1orf41, HSPCO34, IFT25, PP25	ENSG00000081870	Heat shock protein family B (small) member 11	1	53916574-53945929	Predicted intracellular proteins	Evidence at protein level	HPA030140	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.58e-7 (unfavourable), Renal cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 116.6	Expressed in all		
PHLPP1	KIAA0606, PHLPP, PLEKHE1, PPM3A, SCOP	ENSG00000081913	PH domain and leucine rich repeat protein phosphatase 1	18	62715450-62980433	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020200	Uncertain				Renal cancer:5.35e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.9	Mixed		
ATP8B1	ATPIC, BRIC, FIC1, PFIC, PFIC1	ENSG00000081923	ATPase phospholipid transporting 8B1	18	57646426-57803101	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018673, HPA018674	Enhanced				Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable)	Expressed in all	Expressed in all			colon: 94.6	Cell line enhanced		RT4: 171.8
IL12RB2		ENSG00000081985	Interleukin 12 receptor subunit beta 2	1	67307364-67396900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024168	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 11.8	cerebral cortex: 4.4	Cell line enhanced		HMC-1: 4.6;SCLC-21H: 12.2;SK-MEL-30: 21.0;THP-1: 10.6
SMARCD3	BAF60C, CRACD3, Rsc6p	ENSG00000082014	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 3	7	151238764-151277896	Predicted intracellular proteins	Evidence at protein level	HPA063955, HPA065517	Uncertain		Enhanced	Nucleoplasm	Colorectal cancer:5.50e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 82.7	Cell line enhanced		AN3-CA: 63.9
WDR70	FLJ10233	ENSG00000082068	WD repeat domain 70	5	37379212-37753435	Predicted intracellular proteins	Evidence at protein level	HPA043064, HPA048149	Uncertain		Approved	Mitochondria<br>Cytosol	Melanoma:3.73e-4 (unfavourable), Endometrial cancer:4.34e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.1	Expressed in all		
FYB	FYB-120/130, SLAP-130	ENSG00000082074	FYN binding protein	5	39105236-39274528	Predicted intracellular proteins	Evidence at protein level	CAB025336, HPA026796	Enhanced				Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 127.4;lymph node: 109.8;spleen: 114.9	tonsil: 64.3	Cell line enhanced		HEL: 61.3;MOLT-4: 171.5;REH: 58.5;U-937: 68.8
MPP4	DLG6	ENSG00000082126	Membrane palmitoylated protein 4	2	201644870-201698694	Predicted intracellular proteins	Evidence at protein level	HPA057393, CAB079019		Supported	Supported	Actin filaments<br>Cytosol		Not detected	Tissue enhanced		skin: 1.0	testis: 0.9	Cell line enhanced		HBF TERT88: 21.5;hTEC/SVTERT24-B: 21.1;LHCN-M2: 71.6;U-87 MG: 21.4
STRADB	ALS2CR2, CALS-21, ILPIP, ILPIPA, PAPK	ENSG00000082146	STE20-related kinase adaptor beta	2	201387858-201480846	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026549, HPA028520	Approved		Supported	Aggresome<br>Cytosol	Renal cancer:1.35e-4 (unfavourable), Thyroid cancer:4.45e-4 (favourable)	Expressed in all	Expressed in all			kidney: 73.4	Cell line enhanced		LHCN-M2: 154.7
BZW1	BZAP45, KIAA0005	ENSG00000082153	Basic leucine zipper and W2 domains 1	2	200810594-200827338	Predicted intracellular proteins	Evidence at protein level	HPA047288, HPA053272	Uncertain		Approved	Vesicles	Cervical cancer:4.28e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 310.2	Expressed in all		
PGR	NR3C3, PR	ENSG00000082175	Progesterone receptor	11	101029624-101130524	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000068, HPA004751, HPA008428, HPA017176, CAB055100	Enhanced				Endometrial cancer:5.76e-8 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 96.2;endometrium: 172.3;fallopian tube: 53.3;smooth muscle: 114.9	ovary: 19.5	Cell line enriched	349	T-47d: 157.7
C1QTNF3	2310005P21Rik, Corcs, Cors, Cors-26, CTRP3	ENSG00000082196	C1q and tumor necrosis factor related protein 3	5	34019448-34043832	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064996, HPA066011	Uncertain		Approved	Golgi apparatus	Renal cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 38.8	smooth muscle: 33.0	Cell line enriched	195	U-266/84: 563.8
ME2		ENSG00000082212	Malic enzyme 2	18	50878734-50954257	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008247, HPA008880	Enhanced		Enhanced	Mitochondria	Liver cancer:8.29e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.2	Expressed in all		
C5orf22	FLJ11193	ENSG00000082213	Chromosome 5 open reading frame 22	5	31532266-31555058	Predicted intracellular proteins	Evidence at protein level	HPA043062	Approved		Approved	Nuclear membrane	Liver cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.5	Expressed in all		
CCNT2		ENSG00000082258	Cyclin T2	2	134918235-134959342	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005559	Supported		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.25e-5 (unfavourable), Prostate cancer:2.44e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
FAM135A	FLJ20176, KIAA1411	ENSG00000082269	Family with sequence similarity 135 member A	6	70412941-70561174	Predicted intracellular proteins	Evidence at protein level	HPA031743, HPA031744	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.46e-4 (favourable), Colorectal cancer:8.00e-4 (favourable)	Expressed in all	Mixed			esophagus: 33.3	Cell line enhanced		RH-30: 29.8
COL19A1		ENSG00000082293	Collagen type XIX alpha 1 chain	6	69866571-70209976	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042422	Uncertain					Tissue enhanced	Tissue enhanced		lymph node: 3.2;tonsil: 2.9	spleen: 2.1	Cell line enhanced		HDLM-2: 5.2;RH-30: 13.4;SCLC-21H: 4.6;SK-MEL-30: 9.3;WM-115: 9.7
EPB41L3	4.1B, DAL1, KIAA0987	ENSG00000082397	Erythrocyte membrane protein band 4.1 like 3	18	5392381-5630700	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028605	Enhanced		Enhanced	Plasma membrane		Mixed	Expressed in all			testis: 115.0	Cell line enhanced		SCLC-21H: 77.1;TIME: 134.0
COBLL1	KIAA0977	ENSG00000082438	Cordon-bleu WH2 repeat protein like 1	2	164653624-164843679	Predicted intracellular proteins	Evidence at protein level	HPA044933, HPA053344	Enhanced		Approved	Cell Junctions	Renal cancer:5.27e-13 (favourable)	Expressed in all	Mixed			placenta: 77.1	Mixed		
DLG3	KIAA1232, MRX90, NE-Dlg, NEDLG, PPP1R82, SAP-102, SAP102	ENSG00000082458	Discs large MAGUK scaffold protein 3	X	70444861-70505490	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001733, HPA078130	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.72e-10 (favourable), Breast cancer:1.69e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 36.6	Mixed		
KCNK2	K2p2.1, TREK-1	ENSG00000082482	Potassium two pore domain channel subfamily K member 2	1	215005775-215237093	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 75.2	thyroid gland: 17.0	Cell line enhanced		ASC TERT1: 58.1;fHDF/TERT166: 59.9;T-47d: 108.4;U-2197: 38.1
SERTAD4	DJ667H12.2	ENSG00000082497	SERTA domain containing 4	1	210232799-210246631	Predicted intracellular proteins	Evidence at protein level	HPA027344, HPA028514	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			breast: 4.6	Cell line enhanced		SCLC-21H: 8.7;T-47d: 9.8;U-2 OS: 9.1
TRAF5	RNF84	ENSG00000082512	TNF receptor associated factor 5	1	211326615-211374946	Predicted intracellular proteins	Evidence at protein level	HPA008052, CAB010277	Enhanced		Supported	Cytosol	Renal cancer:2.94e-10 (unfavourable), Urothelial cancer:7.29e-5 (favourable)	Expressed in all	Mixed			lymph node: 35.1	Cell line enhanced		HDLM-2: 33.6
MRPL22	HSPC158, MRP-L25, RPML25	ENSG00000082515	Mitochondrial ribosomal protein L22	5	154941070-154969411	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA047063	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
GEMIN5		ENSG00000082516	Gem nuclear organelle associated protein 5	5	154887416-154938209	Predicted intracellular proteins	Evidence at protein level	HPA037392, HPA037393	Uncertain		Enhanced	Nuclear bodies<br>Cytosol	Endometrial cancer:6.23e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.6	Expressed in all		
OPRK1	KOR, OPRK	ENSG00000082556	Opioid receptor kappa 1	8	53225716-53251697	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022595, HPA067549	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 3.6;prostate: 2.8;testis: 1.3	placenta,skeletal muscle: 0.3	Group enriched	7	AF22: 4.5;U-937: 17.3
NFE2L1	FLJ00380, LCR-F1, NRF1, TCF11	ENSG00000082641	Nuclear factor, erythroid 2 like 1	17	48048329-48061487	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA063384, HPA065424	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:5.79e-6 (favourable), Endometrial cancer:8.20e-5 (favourable), Head and neck cancer:2.73e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 468.1	Expressed in all		
SEMA5B	FLJ10372, KIAA1445, SEMAG, SemG	ENSG00000082684	Semaphorin 5B	3	122909193-123028605	Predicted membrane proteins	Evidence at protein level	HPA066548	Enhanced		Supported	Cytosol	Renal cancer:7.57e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 11.4	heart muscle: 4.2	Cell line enhanced		AF22: 79.6;NTERA-2: 15.7;SH-SY5Y: 22.6
GSK3B		ENSG00000082701	Glycogen synthase kinase 3 beta	3	119821323-120094417	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB016263, HPA028017	Approved		Enhanced	Nucleus	Liver cancer:8.20e-5 (unfavourable), Renal cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.4	Expressed in all		
ITGB5		ENSG00000082781	Integrin subunit beta 5	3	124761948-124901418	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001820, CAB022050	Approved		Approved	Plasma membrane<br>Mitochondria	Pancreatic cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 117.5	Cell line enhanced		WM-115: 463.5
ERC1	CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2	ENSG00000082805	ELKS/RAB6-interacting/CAST family member 1	12	990509-1495933	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019513, HPA019523, HPA024130	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:7.01e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.1	Expressed in all		
XPO1	CRM1, emb	ENSG00000082898	Exportin 1	2	61477849-61538626	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010184, HPA042933	Supported		Enhanced	Nucleoplasm<br>Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:1.84e-5 (unfavourable), Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Expressed in all		
RNF13	RZF	ENSG00000082996	Ring finger protein 13	3	149812708-149962139	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064784	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.00e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 94.4	Expressed in all		
TRPM3	GON-2, KIAA1616, LTRPC3	ENSG00000083067	Transient receptor potential cation channel subfamily M member 3	9	70529063-71446904	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 17.6	testis: 5.6	Cell line enriched	5	HAP1: 17.8
PALB2	FANCN, FLJ21816	ENSG00000083093	Partner and localizer of BRCA2	16	23603160-23641310	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB014895, HPA057000	Approved		Supported	Nucleoplasm	Pancreatic cancer:2.35e-5 (unfavourable), Colorectal cancer:2.83e-5 (favourable)	Expressed in all	Mixed			testis: 14.5	Expressed in all		
DOPEY1	dJ202D23.2, KIAA1117	ENSG00000083097	Dopey family member 1	6	83067666-83171350	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027902, HPA027904	Enhanced		Approved	Nucleus<br>Vesicles	Pancreatic cancer:7.36e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.5	Mixed		
LYRM2	DJ122O8.2	ENSG00000083099	LYR motif containing 2	6	89568144-89638753	Predicted intracellular proteins	Evidence at protein level	HPA063932	Uncertain		Approved	Cytosol	Liver cancer:2.58e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.3	Expressed in all		
BCKDHB		ENSG00000083123	Branched chain keto acid dehydrogenase E1 subunit beta	6	80106647-80346270	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA031580	Approved				Renal cancer:5.54e-9 (favourable)	Expressed in all	Expressed in all			liver: 39.9	Expressed in all		
KAT6A	MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220	ENSG00000083168	Lysine acetyltransferase 6A	8	41929479-42051990	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017023, HPA063266, HPA065052	Supported		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
ZCCHC6	FLJ13409, KIAA1711, PAPD6, TUT7	ENSG00000083223	Zinc finger CCHC-type containing 6	9	86287733-86354454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020615, HPA020620	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			prostate: 36.1	Expressed in all		
ULK2	ATG1B, KIAA0623, Unc51.2	ENSG00000083290	Unc-51 like autophagy activating kinase 2	17	19770829-19867936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009027, CAB037021	Approved					Expressed in all	Expressed in all			testis: 65.9	Mixed		
GRHL2	BOM, DFNA28, FLJ13782, TFCP2L3	ENSG00000083307	Grainyhead like transcription factor 2	8	101492432-101669726	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004820, HPA062839	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:6.27e-4 (unfavourable), Breast cancer:6.43e-4 (unfavourable)	Mixed	Mixed			prostate: 37.3	Cell line enhanced		A-431: 34.0;HaCaT: 40.9;RT4: 54.7;T-47d: 74.7
TNPO1	IPO2, KPNB2, MIP, MIP1, TRN	ENSG00000083312	Transportin 1	5	72816312-72916733	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB016325	Approved		Supported	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Liver cancer:6.55e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 110.4	Expressed in all		
PLOD1	LH1, LLH, PLOD	ENSG00000083444	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1	1	11934205-11975538	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA049137, HPA055799	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.91e-12 (unfavourable), Urothelial cancer:2.43e-4 (unfavourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
P2RX5	LRH-1, P2X5	ENSG00000083454	Purinergic receptor P2X 5	17	3672199-3696404	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021948, HPA067827	Supported		Supported	Cytosol		Mixed	Group enriched	10	appendix: 40.9;lymph node: 89.8;spleen: 74.3;tonsil: 47.1	bone marrow: 6.2	Cell line enhanced		Daudi: 36.5;RPMI-8226: 40.2;U-698: 32.6
ITGAE	CD103, HUMINAE	ENSG00000083457	Integrin subunit alpha E	17	3714628-3801243	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026461, HPA036313	Approved				Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 9.5	small intestine: 6.2	Cell line enriched	22	MOLT-4: 9.6
DIS3	dis3p, EXOSC11, KIAA1008, RRP44	ENSG00000083520	DIS3 homolog, exosome endoribonuclease and 3'-5' exoribonuclease	13	72752169-72782096	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039281, HPA058762	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 38.7	Expressed in all		
PIBF1	C13orf24, CEP90	ENSG00000083535	Progesterone immunomodulatory binding factor 1	13	72782059-73016461	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052269, HPA066120	Approved		Supported	Microtubule organizing center		Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
TDRD3	FLJ21007	ENSG00000083544	Tudor domain containing 3	13	60396457-60573878	Predicted intracellular proteins	Evidence at protein level	CAB034925, HPA067153	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.77e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.8	Expressed in all		
NUFIP1	NUFIP	ENSG00000083635	NUFIP1, FMR1 interacting protein 1	13	44939249-44989483	Predicted intracellular proteins	Evidence at protein level	HPA029958, HPA029959	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 10.2	Expressed in all		
PDS5B	APRIN, AS3, CG008, FLJ23236, KIAA0979	ENSG00000083642	PDS5 cohesin associated factor B	13	32586427-32778019	Predicted intracellular proteins	Evidence at protein level	HPA039513, HPA040015	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 31.3	Expressed in all		
OXCT1	OXCT, SCOT	ENSG00000083720	3-oxoacid CoA-transferase 1	5	41730065-41870519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012047, HPA061425	Enhanced		Enhanced	Mitochondria	Renal cancer:1.86e-8 (favourable), Liver cancer:1.03e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 162.3	cerebral cortex: 98.7	Cell line enhanced		SiHa: 338.4
RRAGB		ENSG00000083750	Ras related GTP binding B	X	55717739-55758774	Predicted intracellular proteins	Evidence at protein level	HPA003734	Approved		Approved	Golgi apparatus<br>Vesicles	Lung cancer:3.64e-6 (favourable), Glioma:5.36e-5 (favourable), Colorectal cancer:7.60e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 42.3	Expressed in all		
EPYC	DSPG3, Pg-Lb, SLRR3B	ENSG00000083782	Epiphycan	12	90963679-91005026	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038212, HPA045455	Approved				Pancreatic cancer:1.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	placenta: 8.9	endometrium: 1.5	Not detected		
CYLD	CYLD1, KIAA0849, USPL2	ENSG00000083799	CYLD lysine 63 deubiquitinase	16	50742050-50801935	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011713, HPA050095	Approved		Supported	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 70.2	Expressed in all		
SLC27A5	ACSB, ACSVL6, FACVL3, FATP5, FLJ22987, VLACSR, VLCS-H2, VLCSH2	ENSG00000083807	Solute carrier family 27 member 5	19	58479512-58512413	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007292, CAB056160, CAB068239	Enhanced				Liver cancer:1.57e-4 (favourable)	Tissue enriched	Tissue enriched	23	liver: 337.5	fallopian tube: 14.7	Mixed		
ZNF324	ZF5128, ZNF324A	ENSG00000083812	Zinc finger protein 324	19	58467045-58475436	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039774	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Renal cancer:1.34e-7 (favourable), Pancreatic cancer:4.74e-5 (favourable), Thyroid cancer:6.99e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 8.6	Expressed in all		
ZNF671	FLJ23506	ENSG00000083814	Zinc finger protein 671	19	57719751-57727624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046099	Uncertain		Approved	Nucleoplasm	Breast cancer:2.20e-4 (favourable), Pancreatic cancer:3.57e-4 (favourable)	Mixed	Mixed			parathyroid gland: 16.6	Mixed		
ZNF416	FLJ20557	ENSG00000083817	Zinc finger protein 416	19	57571566-57578927	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063318			Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.20e-5 (favourable)	Expressed in all	Mixed			testis: 7.8	Mixed		
ZNF586	FLJ20070	ENSG00000083828	Zinc finger protein 586	19	57769655-57819939	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030306, HPA060782	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Breast cancer:9.83e-5 (favourable), Urothelial cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 16.3	Mixed		
ZNF446	FLJ20626, ZKSCAN20, ZSCAN52	ENSG00000083838	Zinc finger protein 446	19	58474017-58481230	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052786			Approved	Nuclear speckles	Pancreatic cancer:1.32e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 11.6	Expressed in all		
ZNF264	KIAA0412	ENSG00000083844	Zinc finger protein 264	19	57191500-57222846	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057665	Uncertain					Expressed in all	Expressed in all			testis: 18.3	Mixed		
RPS5	S5	ENSG00000083845	Ribosomal protein S5	19	58386400-58394806	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055878, HPA061979	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:1.12e-5 (unfavourable), Renal cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2648.9	Expressed in all		
FAT1	CDHF7, CDHR8, FAT	ENSG00000083857	FAT atypical cadherin 1	4	186587783-186726722	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001869, HPA023882	Approved				Lung cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 37.6	Cell line enhanced		fHDF/TERT166: 221.3
YTHDC1	KIAA1966, YT521, YT521-B	ENSG00000083896	YTH domain containing 1	4	68310387-68350089	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036462	Supported		Approved	Nucleoplasm<br>Plasma membrane	Urothelial cancer:7.29e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 75.1	Expressed in all		
CHMP2B	CHMP2.5, DKFZP564O123, VPS2B	ENSG00000083937	Charged multivesicular body protein 2B	3	87227271-87255548	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035069, HPA052754	Uncertain		Supported	Cytosol	Renal cancer:1.74e-6 (favourable), Pancreatic cancer:2.11e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
SMAP2	SMAP1L	ENSG00000084070	Small ArfGAP2	1	40344850-40423326	Predicted intracellular proteins	Evidence at protein level	HPA021466, HPA024424	Approved				Head and neck cancer:5.34e-5 (favourable), Liver cancer:2.53e-4 (unfavourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 232.8	Expressed in all		
PPIE	CyP-33, MGC111222, MGC3736	ENSG00000084072	Peptidylprolyl isomerase E	1	39692182-39763914	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019357, HPA020131	Approved		Supported	Nuclear speckles	Renal cancer:5.05e-5 (unfavourable), Liver cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 67.3	Expressed in all		
ZMPSTE24	FACE-1, HGPS, PRO1, STE24, Ste24p	ENSG00000084073	Zinc metallopeptidase STE24	1	40258107-40294184	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006988	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 90.5	Expressed in all		
STARD7	GTT1	ENSG00000084090	StAR related lipid transfer domain containing 7	2	96184859-96208825	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033965, HPA064958, HPA064978	Supported		Approved	Mitochondria	Renal cancer:4.38e-6 (favourable), Glioma:5.94e-6 (favourable), Endometrial cancer:8.56e-5 (unfavourable), Liver cancer:2.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 108.9	Expressed in all		
NOA1	C4orf14, hAtNOS1, hNOA1, MGC3232, MTG3	ENSG00000084092	Nitric oxide associated 1	4	56963370-56978823	Predicted secreted proteins	Evidence at protein level	HPA035838, HPA035839	Approved		Supported	Mitochondria	Renal cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 16.9	Expressed in all		
REST	NRSF, XBR	ENSG00000084093	RE1 silencing transcription factor	4	56907876-56966678	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006079, CAB068222	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.2	Mixed		
HAL	HIS	ENSG00000084110	Histidine ammonia-lyase	12	95972662-95996365	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038547, HPA038548	Enhanced		Uncertain	Cytosol		Tissue enriched	Group enriched	8	liver: 51.2;skin: 72.5	bone marrow: 7.4	Cell line enhanced		BEWO: 2.1;THP-1: 7.4
SSH1	KIAA1298	ENSG00000084112	Slingshot protein phosphatase 1	12	108778192-108857590	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019845	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:5.80e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 9.5	Expressed in all		
GSTP1	FAEES3, GST3, GSTP	ENSG00000084207	Glutathione S-transferase pi 1	11	67583595-67586660	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019779, HPA019869	Enhanced		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			esophagus: 1059.9	Expressed in all		
APLP2	APPH, APPL2	ENSG00000084234	Amyloid beta precursor like protein 2	11	130069837-130144811	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039319	Approved		Approved	Vesicles	Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1056.8	Expressed in all		
FAM234B	KIAA1467	ENSG00000084444	Family with sequence similarity 234 member B	12	13044284-13142521	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010803, HPA010850	Approved		Approved	Endoplasmic reticulum		Expressed in all	Tissue enhanced		cerebral cortex: 32.4	breast: 20.8	Expressed in all		
SLCO1A2	OATP, OATP-A, OATP1A2, SLC21A3	ENSG00000084453	Solute carrier organic anion transporter family member 1A2	12	21264600-21419594	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071152			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 28.7	salivary gland: 6.6	Cell line enhanced		NTERA-2: 16.5;RPMI-8226: 8.3;U-266/70: 18.6
WBP11	NPWBP, PPP1R165, SIPP1	ENSG00000084463	WW domain binding protein 11	12	14784579-14803540	Predicted intracellular proteins	Evidence at protein level	HPA039710, HPA040037, HPA046403, HPA049126	Approved		Enhanced	Nucleoplasm	Liver cancer:9.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.0	Expressed in all		
EIF3I	eIF3-beta, eIF3-p36, eIF3i, EIF3S2, TRIP-1	ENSG00000084623	Eukaryotic translation initiation factor 3 subunit I	1	32221928-32231604	Predicted intracellular proteins	Evidence at protein level	HPA029939, HPA029940	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:4.81e-6 (unfavourable), Endometrial cancer:2.14e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 198.1	Expressed in all		
NKAIN1	FAM77C, FLJ12650	ENSG00000084628	Sodium/potassium transporting ATPase interacting 1	1	31179745-31239554	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA006873	Uncertain					Group enriched	Group enriched	5	adrenal gland: 13.9;cerebral cortex: 13.1;epididymis: 4.4;skeletal muscle: 7.4	prostate: 1.9	Cell line enhanced		AF22: 23.5;AN3-CA: 36.7;NTERA-2: 101.7;SCLC-21H: 35.5;SH-SY5Y: 50.9
COL16A1		ENSG00000084636	Collagen type XVI alpha 1 chain	1	31652247-31704319	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027235, HPA027237			Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:4.00e-9 (unfavourable), Glioma:7.08e-4 (unfavourable)	Expressed in all	Mixed			ovary: 181.5	Cell line enhanced		ASC diff: 88.5;BJ hTERT+: 91.9;fHDF/TERT166: 81.2;U-2197: 87.0
TXLNA	DKFZp451J0118	ENSG00000084652	Taxilin alpha	1	32179686-32198285	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA045383, HPA072477	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:7.21e-7 (unfavourable), Liver cancer:1.57e-6 (unfavourable), Pancreatic cancer:8.69e-5 (favourable), Head and neck cancer:5.53e-4 (favourable), Breast cancer:6.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.1	Expressed in all		
APOB		ENSG00000084674	Apolipoprotein B	2	21001429-21044073	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016070, HPA049793	Supported		Supported	Vesicles<br>Cytosol		Tissue enriched	Group enriched	120	duodenum: 182.8;liver: 618.9;small intestine: 333.2	adipose tissue: 3.1	Cell line enriched	25	Hep G2: 734.4
NCOA1	bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1	ENSG00000084676	Nuclear receptor coactivator 1	2	24491914-24770702	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019402, HPA070213, HPA070520	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
AGBL5	CCP5, FLJ21839	ENSG00000084693	ATP/GTP binding protein like 5	2	27042364-27070622	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030981	Uncertain		Supported	Microtubules<br>Cytokinetic bridge<br>Cytosol	Liver cancer:6.87e-5 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 357.5	parathyroid gland: 50.4	Expressed in all		
EFR3B	FLJ37871, KIAA0953	ENSG00000084710	EFR3 homolog B	2	25042130-25159137	Predicted intracellular proteins	Evidence at protein level	HPA038089	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 33.2	skeletal muscle: 6.8	Cell line enhanced		BEWO: 11.6;SH-SY5Y: 11.3;SK-BR-3: 13.6
KIF3C		ENSG00000084731	Kinesin family member 3C	2	25926596-25982749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035755			Approved	Nuclear membrane<br>Nuclear bodies<br>Intermediate filaments	Endometrial cancer:1.32e-5 (unfavourable), Melanoma:1.22e-4 (favourable), Renal cancer:7.57e-4 (unfavourable)	Expressed in all	Tissue enriched	14	cerebral cortex: 129.6	adrenal gland: 9.1	Cell line enhanced		SH-SY5Y: 57.6
RAB10		ENSG00000084733	RAB10, member RAS oncogene family	2	26034107-26137454	Predicted intracellular proteins	Evidence at protein level	HPA045611	Approved				Liver cancer:1.99e-5 (unfavourable), Pancreatic cancer:7.37e-5 (unfavourable), Endometrial cancer:7.40e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 185.7	Expressed in all		
GCKR		ENSG00000084734	Glucokinase regulator	2	27496842-27523684	Predicted intracellular proteins	Evidence at protein level	CAB034098, HPA064305	Enhanced		Approved	Intermediate filaments		Tissue enriched	Tissue enriched	7	liver: 44.3	stomach: 6.1	Group enriched	7	HEL: 12.0;Hep G2: 14.0;HUVEC TERT2: 5.3;TIME: 3.2
HADHA	GBP, LCEH, LCHAD, MTPA	ENSG00000084754	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit	2	26190635-26244726	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015536, HPA056070	Approved		Enhanced	Mitochondria	Renal cancer:3.68e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 235.3	Expressed in all		
MAPRE3	EB3, RP3	ENSG00000084764	Microtubule associated protein RP/EB family member 3	2	26970612-27027196	Predicted intracellular proteins	Evidence at protein level	HPA009263	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 177.3	testis: 70.2	Mixed		
CAD		ENSG00000084774	Carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2	27217390-27243943	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007781, HPA057266, HPA069341	Supported		Supported	Nucleoplasm	Liver cancer:1.72e-11 (unfavourable), Renal cancer:1.82e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 22.0	Expressed in all		
CD59	16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20	ENSG00000085063	CD59 molecule	11	33698261-33736445	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001448, HPA026494	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.39e-10 (favourable), Pancreatic cancer:2.92e-5 (unfavourable), Head and neck cancer:3.10e-5 (unfavourable), Cervical cancer:3.81e-5 (unfavourable), Stomach cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 923.3	Cell line enhanced		TIME: 2367.1;U-2197: 2401.2
CD82	IA4, KAI1, R2, ST6, TSPAN27	ENSG00000085117	CD82 molecule	11	44564427-44620363	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002508, HPA028900, HPA061418	Supported		Approved	Vesicles		Expressed in all	Expressed in all			esophagus: 131.5	Cell line enhanced		HMC-1: 349.6;U-87 MG: 273.7
BCORL1	CXorf10, FLJ11362	ENSG00000085185	BCL6 corepressor-like 1	X	129981107-130058083	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA031775, HPA031777, HPA068568	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 18.3	Cell line enhanced		HAP1: 51.8
ATRX	JMS, MRX52, RAD54, XH2, XNP	ENSG00000085224	ATRX, chromatin remodeler	X	77504878-77786269	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001906, CAB009372, HPA064684, CAB068176	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
AK6	CINAP	ENSG00000085231	Adenylate kinase 6	5	69350984-69370013	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB005361, HPA034935	Supported		Supported	Nucleoplasm	Liver cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 26.8	Expressed in all		
FCN1	FCNM	ENSG00000085265	Ficolin 1	9	134905890-134917963	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000685, HPA001295, CAB016760	Enhanced				Renal cancer:3.98e-4 (unfavourable)	Mixed	Group enriched	5	appendix: 323.4;bone marrow: 634.5	spleen: 94.6	Group enriched	7	NB-4: 12.4;U-937: 22.6
MYNN	SBBIZ1, ZBTB31, ZNF902	ENSG00000085274	Myoneurin	3	169772831-169789716	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045149	Approved		Supported	Nucleus		Expressed in all	Expressed in all			testis: 18.2	Expressed in all		
MECOM	EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3	ENSG00000085276	MDS1 and EVI1 complex locus	3	169083499-169663618	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046537	Supported		Supported	Nuclear speckles	Pancreatic cancer:2.59e-4 (unfavourable)	Mixed	Mixed			stomach: 67.3	Cell line enhanced		HUVEC TERT2: 48.0;RPTEC TERT1: 55.1;RT4: 94.4;TIME: 45.0
SCAMP1	SCAMP37	ENSG00000085365	Secretory carrier membrane protein 1	5	78360583-78479071	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044753, CAB079009		Approved	Approved	Nucleoplasm<br>Vesicles<br>Cell Junctions	Renal cancer:1.92e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.2	Expressed in all		
PREP		ENSG00000085377	Prolyl endopeptidase	6	105277565-105403084	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025414, HPA031388, HPA031389, HPA031390	Enhanced		Enhanced	Cytosol	Head and neck cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 53.9	Expressed in all		
HACE1	KIAA1320	ENSG00000085382	HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1	6	104728093-104859919	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046071			Supported	Nuclear bodies<br>Endoplasmic reticulum	Renal cancer:1.17e-5 (unfavourable), Thyroid cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.1	testis: 19.1	Mixed		
SEH1L	SEC13L, Seh1, SEH1A, SEH1B	ENSG00000085415	SEH1 like nucleoporin	18	12947133-12987536	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039964	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 33.9	Expressed in all		
WDR47	KIAA0893	ENSG00000085433	WD repeat domain 47	1	108970214-109042113	Predicted intracellular proteins	Evidence at protein level	HPA027287, HPA027289	Approved		Approved	Actin filaments	Head and neck cancer:9.86e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.3	Expressed in all		
WDFY1	FENS-1, KIAA1435, WDF1, ZFYVE17	ENSG00000085449	WD repeat and FYVE domain containing 1	2	223855716-223945387	Predicted intracellular proteins	Evidence at protein level	HPA050603	Approved					Expressed in all	Expressed in all			placenta: 38.8	Expressed in all		
OVGP1	CHIT5, MUC9	ENSG00000085465	Oviductal glycoprotein 1	1	111414314-111427777	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062205	Enhanced				Urothelial cancer:3.93e-5 (favourable), Endometrial cancer:1.36e-4 (favourable)	Group enriched	Tissue enriched	118	fallopian tube: 3146.3	endometrium: 26.7	Cell line enhanced		HEK 293: 4.3
SLC25A24	APC1, DKFZp586G0123	ENSG00000085491	Solute carrier family 25 member 24	1	108134036-108200849	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028519, HPA063636	Enhanced		Enhanced	Mitochondria	Colorectal cancer:1.01e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 22.1	Mixed		
MAP3K4	KIAA0213, MAPKKK4, MEKK4, MTK1	ENSG00000085511	Mitogen-activated protein kinase kinase kinase 4	6	160991727-161117385	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007625	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 15.4	Expressed in all		
PILRA	FDF03	ENSG00000085514	Paired immunoglobin like type 2 receptor alpha	7	100367530-100400099	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056132	Approved				Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 52.4	lung: 43.8	Cell line enhanced		ASC diff: 18.7;HMC-1: 21.9;NB-4: 12.4
IGSF9	IGSF9A, KIAA1355, Nrt1	ENSG00000085552	Immunoglobulin superfamily member 9	1	159927039-159945604	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037753	Uncertain				Endometrial cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 28.1	stomach: 13.2	Cell line enhanced		BEWO: 25.2;HaCaT: 34.4;SCLC-21H: 40.2
ABCB1	ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1	ENSG00000085563	ATP binding cassette subfamily B member 1	7	87503633-87713323	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001716, HPA002199	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 137.8;small intestine: 82.4	kidney: 37.3	Cell line enhanced		CACO-2: 56.6;HEL: 34.4;SH-SY5Y: 85.9
ZNF213	CR53, ZKSCAN21, ZSCAN53	ENSG00000085644	Zinc finger protein 213	16	3129777-3142805	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA035000, HPA056750	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.3	Expressed in all		
AKR1B1	ALDR1, AR	ENSG00000085662	Aldo-keto reductase family 1 member B	7	134442350-134459284	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026425, CAB027391, CAB047353, HPA052751	Enhanced		Supported	Nucleus<br>Cytosol	Stomach cancer:2.44e-5 (unfavourable), Urothelial cancer:7.00e-4 (unfavourable)	Expressed in all	Tissue enriched	6	adrenal gland: 2486.1	seminal vesicle: 449.2	Cell line enhanced		A549: 1469.5;BJ hTERT+: 2394.4
CPNE3		ENSG00000085719	Copine 3	8	86514427-86561498	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029552	Uncertain		Supported	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 103.4	Expressed in all		
RRN3	DKFZp566E104, TIF-IA	ENSG00000085721	RRN3 homolog, RNA polymerase I transcription factor	16	15060022-15094317	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049837	Supported		Enhanced	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 22.3	Expressed in all		
CTTN	EMS1	ENSG00000085733	Cortactin	11	70398404-70436584	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011235, HPA057242	Supported		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.19e-6 (unfavourable), Liver cancer:4.45e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 108.9	Cell line enhanced		A-431: 778.5
WNT11		ENSG00000085741	Wnt family member 11	11	76186325-76210736	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050101, HPA063569	Uncertain		Approved	Centrosome<br>Cytosol	Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 29.7;adrenal gland: 17.3	placenta: 5.7	Cell line enhanced		BEWO: 34.3;CAPAN-2: 15.3;EFO-21: 53.0
MTIF2	IF-2mt	ENSG00000085760	Mitochondrial translational initiation factor 2	2	55236595-55269347	Predicted intracellular proteins	Evidence at protein level	HPA006021, HPA061422	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 40.0	Expressed in all		
DDHD2	KIAA0725, SAMWD1, SPG54	ENSG00000085788	DDHD domain containing 2	8	38225218-38275558	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015202, HPA023143, HPA023147	Supported		Supported	Microtubule organizing center<br>Cytosol	Head and neck cancer:7.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 69.9	Expressed in all		
TTC39A	C1orf34, DEME-6, KIAA0452	ENSG00000085831	Tetratricopeptide repeat domain 39A	1	51287258-51345116	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028098, HPA043440	Uncertain		Approved	Centrosome	Liver cancer:5.05e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 87.4	breast: 53.8	Cell line enhanced		HDLM-2: 65.0;MCF7: 42.1;SK-BR-3: 123.3;T-47d: 112.3
EPS15	AF-1P, MLLT5	ENSG00000085832	Epidermal growth factor receptor pathway substrate 15	1	51354263-51519328	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008451, CAB010164, HPA061431	Approved		Enhanced	Vesicles<br>Cytosol	Cervical cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 84.6	Expressed in all		
ORC1	HSORC1, ORC1L, PARC1	ENSG00000085840	Origin recognition complex subunit 1	1	52372829-52404459	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027450	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Colorectal cancer:1.74e-5 (favourable), Liver cancer:3.22e-5 (unfavourable), Melanoma:3.69e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 17.9	lymph node: 7.9	Mixed		
MGST2	MGST-II	ENSG00000085871	Microsomal glutathione S-transferase 2	4	139665768-139740745	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010707	Approved		Approved	Nucleoplasm	Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			liver: 178.3	Mixed		
CHERP	DAN16, ERPROT213-21	ENSG00000085872	Calcium homeostasis endoplasmic reticulum protein	19	16517889-16542530	Predicted intracellular proteins	Evidence at protein level	HPA050647	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 22.2	Expressed in all		
ATG16L1	APG16L, ATG16A, ATG16L, FLJ10035, WDR30	ENSG00000085978	Autophagy related 16 like 1	2	233210051-233295674	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012577, HPA063900	Enhanced		Approved	Cytosol	Liver cancer:1.48e-5 (unfavourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Expressed in all		
USP40	FLJ10785	ENSG00000085982	Ubiquitin specific peptidase 40	2	233475520-233566782	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005821	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 31.5	Mixed		
POMGNT1	FLJ20277, LGMD2O, MEB, MGAT1.2	ENSG00000085998	Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-)	1	46188682-46220305	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044518	Approved				Liver cancer:3.52e-4 (unfavourable), Pancreatic cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
RAD54L	hHR54, hRAD54, RAD54A	ENSG00000085999	RAD54-like (S. cerevisiae)	1	46247688-46278473	Predicted intracellular proteins	Evidence at protein level	HPA028954, HPA051537	Approved		Enhanced	Nucleoplasm	Cervical cancer:6.67e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.0	tonsil: 7.9	Mixed		
MAST2	KIAA0807, MAST205	ENSG00000086015	Microtubule associated serine/threonine kinase 2	1	45786987-46036124	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039722, HPA040155	Approved		Approved	Cytosol	Renal cancer:6.85e-13 (unfavourable), Liver cancer:4.31e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 78.6	Expressed in all		
DNAJA1	dj-2, hdj-2, HSJ2, HSPF4, NEDD7	ENSG00000086061	DnaJ heat shock protein family (Hsp40) member A1	9	33025211-33039907	Predicted intracellular proteins	Evidence at protein level	HPA001306	Approved		Supported	Microtubules<br>Cytosol	Renal cancer:3.40e-4 (favourable), Ovarian cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 241.0	Expressed in all		
B4GALT1	beta4Gal-T1, GGTB2	ENSG00000086062	Beta-1,4-galactosyltransferase 1	9	33104082-33167356	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010806, HPA010807	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 140.5	Expressed in all		
CHMP5	C9orf83, CGI-34, HSPC177, SNF7DC2, Vps60	ENSG00000086065	Charged multivesicular body protein 5	9	33264879-33282069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033874, HPA042883, HPA056437	Enhanced		Supported	Microtubules<br>Midbody<br>Cytosol	Renal cancer:2.87e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.5	Expressed in all		
NFX1	MGC20369, NFX2, TEG-42, Tex42	ENSG00000086102	Nuclear transcription factor, X-box binding 1	9	33290511-33371157	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056310, HPA061382, HPA073519	Approved		Enhanced	Nucleus<br>Cytosol	Ovarian cancer:3.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.8	Expressed in all		
AQP6	AQP2L	ENSG00000086159	Aquaporin 6	12	49967194-49977139	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015278	Enhanced					Tissue enriched	Tissue enriched	9	kidney: 20.8	cerebral cortex: 2.3	Not detected		
DIMT1	DIMT1L, HSA9761	ENSG00000086189	DIM1 dimethyladenosine transferase 1 homolog	5	62387254-62403939	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042944	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.90e-12 (unfavourable), Liver cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.7	Expressed in all		
IPO11	RanBP11	ENSG00000086200	Importin 11	5	62403972-62628582	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067097	Approved		Enhanced	Nucleus<br>Nucleoli fibrillar center	Liver cancer:4.28e-5 (unfavourable), Colorectal cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 40.6	Expressed in all		
FOLH1	FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA	ENSG00000086205	Folate hydrolase 1	11	49146635-49208670	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001451, HPA010593	Enhanced				Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable)	Tissue enriched	Group enriched	6	duodenum: 298.8;prostate: 136.6;small intestine: 90.8	cerebral cortex: 31.0	Mixed		
EIF2AK1	HRI, KIAA1369	ENSG00000086232	Eukaryotic translation initiation factor 2 alpha kinase 1	7	6022244-6059230	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016496, CAB022082, HPA061675	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.4	Expressed in all		
NME8	CILD6, NM23-H8, SPTRX2, TXNDC3	ENSG00000086288	NME/NM23 family member 8	7	37848597-37900401	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016416, HPA019259	Supported					Mixed	Group enriched	14	bone marrow: 8.2;testis: 18.4	appendix,spleen: 0.9	Cell line enhanced		HMC-1: 1.1;NB-4: 1.2;NTERA-2: 1.7;THP-1: 1.1;U-937: 4.1
EPDR1	EPDR, MERP-1, MERP1, UCC1	ENSG00000086289	Ependymin related 1	7	37683843-37951941	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026298	Approved				Urothelial cancer:1.00e-4 (unfavourable), Stomach cancer:3.43e-4 (unfavourable), Liver cancer:6.97e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 73.4	Cell line enhanced		WM-115: 112.2
SNX10		ENSG00000086300	Sorting nexin 10	7	26291895-26374329	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015605, HPA064782	Approved		Approved	Nucleus<br>Nucleoli<br>Microtubules	Renal cancer:8.06e-5 (unfavourable), Glioma:9.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 94.3	lung: 60.1	Cell line enhanced		WM-115: 291.7
SEPHS1	SPS, SPS1	ENSG00000086475	Selenophosphate synthetase 1	10	13317424-13348298	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037645, HPA062118	Enhanced		Uncertain	Nucleoplasm	Liver cancer:2.16e-7 (unfavourable), Pancreatic cancer:3.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 92.9	Expressed in all		
MRPL28	MAAT1, p15	ENSG00000086504	Mitochondrial ribosomal protein L28	16	367384-370527	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030594, CAB033542, HPA055589	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
HBQ1	HBQ	ENSG00000086506	Hemoglobin subunit theta 1	16	180453-181181	Predicted intracellular proteins	Evidence at protein level	HPA062473	Enhanced		Approved	Lipid droplets		Mixed	Group enriched	8	bone marrow: 14.7;cerebral cortex: 3.0	placenta: 1.1	Group enriched	7	HEL: 19.6;Hep G2: 10.4;K-562: 49.1
ITPKC	IP3-3KC, IP3KC	ENSG00000086544	Inositol-trisphosphate 3-kinase C	19	40717103-40740860	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050760, HPA053003	Approved		Supported	Nuclear speckles	Lung cancer:4.91e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 69.3	Mixed		
CEACAM6	CD66c, NCA	ENSG00000086548	Carcinoembryonic antigen related cell adhesion molecule 6	19	41750977-41772208	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008370, HPA011041	Enhanced					Mixed	Group enriched	6	bone marrow: 110.7;colon: 180.6;esophagus: 173.5;gallbladder: 189.0;lung: 405.6;rectum: 233.8	appendix: 37.6	Cell line enriched	9	A549: 140.1
FAT2	CDHF8, CDHR9, HFAT2, MEGF1	ENSG00000086570	FAT atypical cadherin 2	5	151504093-151568944	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB033680	Enhanced					Group enriched	Tissue enhanced		skin: 66.5	esophagus: 14.3	Group enriched	9	BEWO: 33.8;EFO-21: 19.8;HaCaT: 45.7;HBEC3-KT: 16.9;hTCEpi: 51.0
RBM22	Cwc2, FLJ10290, fSAP47, ZC3H16	ENSG00000086589	RNA binding motif protein 22	5	150690794-150701107	Predicted intracellular proteins	Evidence at protein level	HPA001634	Supported		Enhanced	Nucleus	Liver cancer:5.50e-6 (unfavourable), Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 40.5	Expressed in all		
TMED2	P24A, p24b1, p24beta1, RNP24	ENSG00000086598	Transmembrane p24 trafficking protein 2	12	123584531-123598577	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA014060	Approved		Supported	Vesicles	Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 328.1	Expressed in all		
ERO1B	ERO1-L(beta), Ero1beta, ERO1LB	ENSG00000086619	Endoplasmic reticulum oxidoreductase 1 beta	1	236215555-236281985	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028085	Approved				Lung cancer:7.53e-5 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
ZFAND6	AWP1, ZA20D3, ZFAND5B	ENSG00000086666	Zinc finger AN1-type containing 6	15	80059568-80138393	Predicted intracellular proteins	Evidence at protein level	HPA034845	Uncertain				Urothelial cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			testis: 247.8	Expressed in all		
HSD17B2	HSD17, SDR9C2	ENSG00000086696	Hydroxysteroid 17-beta dehydrogenase 2	16	82035004-82098534	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021826, HPA050235	Enhanced		Approved	Endoplasmic reticulum	Urothelial cancer:3.83e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 430.9;placenta: 552.6	small intestine: 199.4	Cell line enhanced		BJ hTERT+: 47.0;Hep G2: 32.2;RT4: 77.0;TIME: 44.0
TXLNG	CXorf15, FIAT, FLJ11209, LSR5, MGC126621, MGC126625, TXLNGX	ENSG00000086712	Taxilin gamma	X	16786427-16844519	Predicted intracellular proteins	Evidence at protein level	HPA000297, HPA000841	Enhanced		Approved	Cytosol	Liver cancer:6.33e-6 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 20.8	Expressed in all		
PPEF1	PPEF, PPP7CA	ENSG00000086717	Protein phosphatase with EF-hand domain 1	X	18675909-18827921	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034577	Uncertain		Uncertain	Plasma membrane<br>Cytokinetic bridge		Mixed	Tissue enriched	7	testis: 26.4	cerebral cortex: 3.6	Cell line enhanced		A549: 1.0;HeLa: 1.1
LAT2	HSPC046, LAB, NTAL, WBSCR15, WBSCR5, WSCR5	ENSG00000086730	Linker for activation of T-cells family member 2	7	74199652-74229834	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003462	Enhanced				Renal cancer:4.10e-4 (unfavourable), Testis cancer:6.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 70.0	tonsil: 58.3	Cell line enhanced		NB-4: 128.3;REH: 209.9;THP-1: 139.1;U-937: 157.8
HUWE1	Ib772, KIAA0312, UREB1	ENSG00000086758	HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase	X	53532096-53686729	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002548, CAB022718	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 96.6	Expressed in all		
ZW10	KNTC1AP	ENSG00000086827	Zw10 kinetochore protein	11	113733187-113773811	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011565, HPA051253, HPA055410	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Colorectal cancer:2.70e-4 (favourable), Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.4	Expressed in all		
ALG9	DIBD1	ENSG00000086848	ALG9, alpha-1,2-mannosyltransferase	11	111782195-111871581	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038575	Approved		Approved	Endoplasmic reticulum	Renal cancer:7.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
MYBPC2	MGC163408, MYBPC, MYBPCF	ENSG00000086967	Myosin binding protein C, fast type	19	50432903-50466321	Predicted intracellular proteins	Evidence at protein level	HPA042991, HPA046745	Enhanced					Tissue enriched	Group enriched	124	parathyroid gland: 934.4;skeletal muscle: 1495.9	prostate: 9.7	Group enriched	19	HDLM-2: 54.5;Karpas-707: 102.8
NOX4	KOX, KOX-1	ENSG00000086991	NADPH oxidase 4	11	89324356-89498187	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015475			Approved	Nucleus	Renal cancer:6.14e-4 (favourable)	Mixed	Tissue enriched	12	kidney: 134.7	parathyroid gland: 10.9	Group enriched	6	HUVEC TERT2: 22.0;TIME: 48.5
ACOX3		ENSG00000087008	Acyl-CoA oxidase 3, pristanoyl	4	8366282-8440723	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035840, HPA035841	Uncertain		Approved	Peroxisomes	Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 22.2	Expressed in all		
MTMR2	CMT4B, KIAA1073	ENSG00000087053	Myotubularin related protein 2	11	95832882-95925315	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049831	Approved		Supported	Vesicles	Liver cancer:1.61e-8 (unfavourable), Pancreatic cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.8	Expressed in all		
PPP1R15A	GADD34	ENSG00000087074	Protein phosphatase 1 regulatory subunit 15A	19	48872392-48876057	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB018395, HPA020240	Approved		Uncertain	Vesicles	Liver cancer:1.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 358.1	Expressed in all		
HSD17B14	DHRS10, retSDR3, SDR47C1	ENSG00000087076	Hydroxysteroid 17-beta dehydrogenase 14	19	48813017-48836678	Predicted intracellular proteins	Evidence at protein level	HPA021467	Approved				Pancreatic cancer:2.87e-5 (favourable), Colorectal cancer:4.39e-5 (unfavourable)	Expressed in all	Mixed			kidney: 53.3	Cell line enhanced		HHSteC: 35.4;Karpas-707: 35.4;RT4: 28.6
TRIP6	MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1	ENSG00000087077	Thyroid hormone receptor interactor 6	7	100867138-100873454	Predicted intracellular proteins	Evidence at protein level	CAB046454, CAB046460, HPA052813	Approved		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 84.7	Mixed		
ACHE	YT	ENSG00000087085	Acetylcholinesterase (Cartwright blood group)	7	100889994-100896974	Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019704, HPA027098			Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 58.5	cerebral cortex: 14.1	Cell line enhanced		BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
FTL	MGC71996, NBIA3	ENSG00000087086	Ferritin light chain	19	48965301-48966878	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020769, HPA041602	Enhanced		Approved	Cytosol	Renal cancer:4.40e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 8050.1	Expressed in all		
SRRT	ARS2, Asr2, serrate	ENSG00000087087	Serrate, RNA effector molecule	7	100875111-100888664	Predicted intracellular proteins	Evidence at protein level	HPA042858, HPA058379	Supported		Enhanced	Nucleoplasm	Renal cancer:1.01e-6 (unfavourable), Liver cancer:1.90e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 203.6	Expressed in all		
BAX	BCL2L4	ENSG00000087088	BCL2 associated X, apoptosis regulator	19	48954815-48961798	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004206, HPA027878	Approved				Liver cancer:1.63e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 80.3	Expressed in all		
NLK		ENSG00000087095	Nemo like kinase	17	28041737-28196381	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018192, HPA056511	Approved		Supported	Nucleus<br>Nucleoli<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 52.4	Expressed in all		
PIGS		ENSG00000087111	Phosphatidylinositol glycan anchor biosynthesis class S	17	28553383-28571872	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA018149	Approved				Liver cancer:1.86e-4 (unfavourable), Urothelial cancer:5.31e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.5	Expressed in all		
ADAMTS2	ADAM-TS2, ADAMTS-3, hPCPNI, NPI, PCINP	ENSG00000087116	ADAM metallopeptidase with thrombospondin type 1 motif 2	5	179110851-179345430	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028444	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:1.71e-8 (unfavourable)	Expressed in all	Mixed			placenta: 14.7	Cell line enhanced		HHSteC: 100.5;HSkMC: 69.6
TMPRSS11E	DESC1, TMPRSS11E2	ENSG00000087128	Transmembrane protease, serine 11E	4	68447449-68497604	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA051062	Uncertain				Lung cancer:6.73e-4 (unfavourable)	Group enriched	Tissue enriched	5	esophagus: 128.2	epididymis: 25.0	Cell line enhanced		HaCaT: 1.4
ATXN7L3	DKFZp761G2113	ENSG00000087152	Ataxin 7 like 3	17	44191805-44200113	Predicted intracellular proteins	Evidence at protein level	HPA064316	Supported		Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.87e-4 (unfavourable), Liver cancer:4.03e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.8	Expressed in all		
PGS1	DKFZP762M186	ENSG00000087157	Phosphatidylglycerophosphate synthase 1	17	78378640-78425114	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022526	Approved		Approved	Vesicles<br>Cell Junctions<br>Intermediate filaments	Renal cancer:1.16e-5 (unfavourable), Pancreatic cancer:7.33e-5 (favourable), Liver cancer:1.37e-4 (unfavourable), Prostate cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.7	Expressed in all		
PSMC5	p45, p45/SUG, S8, SUG-1, SUG1, TBP10, TRIP1	ENSG00000087191	Proteasome 26S subunit, ATPase 5	17	63827152-63832026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017871, HPA064293	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.13e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 251.4	Expressed in all		
UIMC1	RAP80	ENSG00000087206	Ubiquitin interaction motif containing 1	5	176905005-177022633	Predicted intracellular proteins	Evidence at protein level	HPA037503, HPA037504	Enhanced		Enhanced	Nuclear bodies	Liver cancer:7.67e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 109.5	Expressed in all		
CETP	BPIFF	ENSG00000087237	Cholesteryl ester transfer protein	16	56961850-56983845	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Mixed	Group enriched	6	adipose tissue: 36.9;liver: 21.7;lymph node: 46.3;placenta: 50.4;spleen: 77.7	thyroid gland: 8.4	Cell line enhanced		HEL: 2.4;HUVEC TERT2: 3.6;TIME: 2.1
MMP2	CLG4, CLG4A, TBE-1	ENSG00000087245	Matrix metallopeptidase 2	16	55389700-55506691	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001939, CAB002788	Approved		Uncertain	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		gallbladder: 1682.1	urinary bladder: 910.7	Cell line enhanced		ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MT3	GIF	ENSG00000087250	Metallothionein 3	16	56589074-56591088	Predicted intracellular proteins	Evidence at protein level	HPA004011, CAB017779	Enhanced					Tissue enriched	Tissue enriched	17	cerebral cortex: 738.6	adrenal gland: 42.9	Group enriched	7	RPMI-8226: 3.1;SCLC-21H: 8.7;U-87 MG: 12.1
LPCAT2	AGPAT11, AYTL1, FLJ20481, LysoPAFAT	ENSG00000087253	Lysophosphatidylcholine acyltransferase 2	16	55508998-55586670	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007891, HPA008433	Enhanced	Supported	Enhanced	Endoplasmic reticulum<br>Lipid droplets	Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 142.6	bone marrow: 56.4	Cell line enhanced		CAPAN-2: 100.9;HMC-1: 141.4;WM-115: 114.8
GNAO1	G-ALPHA-o	ENSG00000087258	G protein subunit alpha o1	16	56191347-56357457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008387, HPA040878	Enhanced				Pancreatic cancer:5.93e-4 (favourable)	Tissue enriched	Tissue enriched	7	cerebral cortex: 166.9	seminal vesicle: 22.6	Cell line enhanced		BJ hTERT+: 24.8;BJ hTERT+ SV40 Large T+: 18.7;SCLC-21H: 72.2
OGFOD1	FLJ10826, KIAA1612, TPA1	ENSG00000087263	2-oxoglutarate and iron dependent oxygenase domain containing 1	16	56451490-56479100	Predicted intracellular proteins	Evidence at protein level	HPA003215	Approved	Approved	Supported	Nucleus<br>Cytosol	Head and neck cancer:6.65e-4 (unfavourable), Liver cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 22.1	Expressed in all		
SH3BP2	CRBM, RES4-23	ENSG00000087266	SH3 domain binding protein 2	4	2793023-2841098	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036790	Approved		Approved	Nucleus<br>Actin filaments	Endometrial cancer:5.42e-6 (unfavourable), Head and neck cancer:1.57e-5 (favourable), Urothelial cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.9	Mixed		
NOP14	C4orf9, NOL14, RES4-25, UTP2	ENSG00000087269	NOP14 nucleolar protein	4	2937933-2963385	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039596, HPA055652	Approved		Enhanced	Nucleus<br>Nucleoli	Colorectal cancer:3.93e-5 (favourable), Liver cancer:9.10e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 27.3	Expressed in all		
ADD1		ENSG00000087274	Adducin 1	4	2843857-2930076	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009794, HPA035873, HPA035874	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane	Renal cancer:1.29e-7 (favourable), Pancreatic cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 201.1	Expressed in all		
L2HGDH	C14orf160, FLJ12618	ENSG00000087299	L-2-hydroxyglutarate dehydrogenase	14	50237563-50312548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065409, HPA069708	Approved		Enhanced	Mitochondria	Renal cancer:9.75e-10 (favourable)	Expressed in all	Mixed			kidney: 20.8	Expressed in all		
TXNDC16	KIAA1344	ENSG00000087301	Thioredoxin domain containing 16	14	52430590-52552522	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002543	Approved		Approved	Mitochondria	Renal cancer:6.79e-4 (favourable)	Expressed in all	Tissue enhanced		prostate: 43.0	seminal vesicle: 18.3	Cell line enhanced		SCLC-21H: 34.2
C14orf166	CGI-99, CLE, CLE7, hCLE1, LCRP369, RLLM1	ENSG00000087302	Chromosome 14 open reading frame 166	14	51989475-52010691	Predicted intracellular proteins	Evidence at protein level	HPA039824	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 262.6	Expressed in all		
NID2		ENSG00000087303	Nidogen 2	14	52004803-52069228	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052460, HPA058772	Enhanced		Supported	Plasma membrane	Urothelial cancer:2.78e-4 (unfavourable), Stomach cancer:7.34e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 88.5	thyroid gland: 54.1	Cell line enhanced		ASC diff: 198.6;BJ: 133.5;HHSteC: 134.5;HSkMC: 435.7
GMCL1	BTBD13, FLJ13057, GCL1, SPATA29	ENSG00000087338	Germ cell-less, spermatogenesis associated 1	2	69829642-69881396	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039579	Approved					Expressed in all	Expressed in all			testis: 39.4	Expressed in all		
SF3B2	Cus1, SAP145, SF3b1, SF3b145	ENSG00000087365	Splicing factor 3b subunit 2	11	66050729-66069308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045028	Supported		Enhanced	Nuclear speckles	Renal cancer:3.51e-5 (favourable), Liver cancer:6.43e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 192.7	Expressed in all		
KLHL42	Ctb9, KIAA1340, KLHDC5	ENSG00000087448	Kelch like family member 42	12	27780020-27803040	Predicted intracellular proteins	Evidence at protein level	HPA020979	Uncertain				Renal cancer:2.98e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 32.9	Expressed in all		
GNAS	GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI	ENSG00000087460	GNAS complex locus	20	58839718-58911192	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010337, HPA018122, HPA027478, HPA028386	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1473.9	Expressed in all		
DNM1L	DRP1, DVLP, DYMPLE, HDYNIV, VPS1	ENSG00000087470	Dynamin 1 like	12	32679200-32745650	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009952, HPA039324	Enhanced		Enhanced	Vesicles<br>Cytosol	Liver cancer:6.27e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
PTHLH	HHM, PLP, PTHR, PTHRP	ENSG00000087494	Parathyroid hormone like hormone	12	27958084-27972705	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA035982	Approved	Approved	Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.82e-9 (unfavourable), Liver cancer:3.37e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		breast: 23.9	esophagus: 18.0	Group enriched	7	HaCaT: 256.2;HBEC3-KT: 257.7;U-251 MG: 64.3
PHACTR3	C20orf101, PPP1R123	ENSG00000087495	Phosphatase and actin regulator 3	20	59577509-59847711	Predicted intracellular proteins	Evidence at protein level	HPA051834, HPA054847			Enhanced	Nucleoplasm		Group enriched	Tissue enriched	9	cerebral cortex: 64.8	spleen: 7.4	Cell line enhanced		RPTEC TERT1: 18.7;THP-1: 88.0;U-937: 25.4
ERGIC2	Erv41, PTX1	ENSG00000087502	ERGIC and golgi 2	12	29337352-29381189	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049695	Approved		Supported	Nucleoli<br>Vesicles	Renal cancer:3.76e-6 (unfavourable), Pancreatic cancer:7.02e-6 (unfavourable), Liver cancer:8.06e-6 (unfavourable), Ovarian cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.3	Expressed in all		
TFAP2C	AP2-GAMMA, ERF1, hAP-2g, TFAP2G	ENSG00000087510	Transcription factor AP-2 gamma	20	56629302-56639283	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016061, CAB016079, HPA055179, HPA057076	Enhanced		Supported	Nucleoplasm	Cervical cancer:6.90e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 63.0	breast: 31.6	Cell line enhanced		BEWO: 183.4;MCF7: 128.7;SK-BR-3: 231.1;WM-115: 112.9
AURKA	AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7	ENSG00000087586	Aurora kinase A	20	56369389-56392337	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001454, HPA002636	Approved		Approved	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:1.47e-8 (unfavourable), Endometrial cancer:9.40e-5 (unfavourable), Liver cancer:1.49e-4 (unfavourable), Pancreatic cancer:6.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 53.5	lymph node: 24.0	Expressed in all		
CASS4	C20orf32, HEFL, HEPL	ENSG00000087589	Cas scaffolding protein family member 4	20	56412112-56460387	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034217	Approved					Mixed	Tissue enhanced		appendix: 17.7;lung: 23.9	spleen: 10.7	Cell line enhanced		HEL: 15.8;HMC-1: 45.4;K-562: 19.8
PIR		ENSG00000087842	Pirin	X	15384799-15493564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000697	Enhanced		Supported	Cytosol	Renal cancer:6.11e-7 (unfavourable), Cervical cancer:2.78e-4 (favourable), Ovarian cancer:4.94e-4 (favourable)	Expressed in all	Mixed			urinary bladder: 22.6	Cell line enhanced		HUVEC TERT2: 565.7;SK-MEL-30: 201.8
AAMDC	C11orf67, CK067, FLJ21035, PTD015	ENSG00000087884	Adipogenesis associated Mth938 domain containing	11	77821109-77918432	Predicted intracellular proteins	Evidence at protein level	HPA037918, HPA037919	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 231.6	Expressed in all		
RFX2	FLJ14226	ENSG00000087903	Regulatory factor X2	19	5993164-6199572	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048969	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.67e-4 (favourable), Cervical cancer:2.80e-4 (favourable), Pancreatic cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		testis: 93.1	fallopian tube: 32.8	Cell line enhanced		SCLC-21H: 27.7
METTL2A	FLJ12760, METTL2	ENSG00000087995	Methyltransferase like 2A	17	62423867-62450822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.0	Expressed in all		
SULT2B1	HSST2	ENSG00000088002	Sulfotransferase family 2B member 1	19	48552075-48599425	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB033013, HPA041724, HPA043539	Approved		Supported	Vesicles<br>Cytosol		Mixed	Tissue enhanced		esophagus: 152.2;skin: 152.4	cervix, uterine: 45.8	Cell line enhanced		CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
ALG6		ENSG00000088035	ALG6, alpha-1,3-glucosyltransferase	1	63367590-63438562	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA062536			Supported	Endoplasmic reticulum	Renal cancer:2.63e-6 (unfavourable), Colorectal cancer:4.86e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Mixed			placenta: 11.9	Expressed in all		
CNOT3	KIAA0691, LENG2, NOT3, NOT3H	ENSG00000088038	CCR4-NOT transcription complex subunit 3	19	54137728-54155681	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006408	Approved		Approved	Cytosol	Liver cancer:2.22e-4 (unfavourable), Renal cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
GP6	GPVI	ENSG00000088053	Glycoprotein VI platelet	19	55013705-55038264	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA066482	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 1.2	skin: 0.7	Group enriched	12	HEL: 8.5;K-562: 3.7;U-2 OS: 2.7
PTPN4	PTPMEG	ENSG00000088179	Protein tyrosine phosphatase, non-receptor type 4	2	119759631-119983818	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019351	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Lung cancer:5.16e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 24.5	Mixed		
DDX18	MrDb	ENSG00000088205	DEAD-box helicase 18	2	117814650-117832379	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035400, HPA041056	Approved		Enhanced	Nucleoli	Endometrial cancer:2.64e-4 (unfavourable), Liver cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Expressed in all		
KHSRP	FBP2, FUBP2, KSRP	ENSG00000088247	KH-type splicing regulatory protein	19	6413348-6424794	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034739, HPA056518	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 179.1	Expressed in all		
GNA11	FBH, FBH2, FHH2, HHC2	ENSG00000088256	G protein subunit alpha 11	19	3094410-3124004	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048886	Approved				Renal cancer:1.48e-11 (favourable), Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 155.9	Expressed in all		
ASAP3	CENTB6, DDEFL1, FLJ20199, UPLC1	ENSG00000088280	ArfGAP with SH3 domain, ankyrin repeat and PH domain 3	1	23428563-23484568	Predicted intracellular proteins	Evidence at protein level	HPA020537, HPA020546	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:5.12e-5 (favourable), Lung cancer:2.80e-4 (favourable), Endometrial cancer:5.56e-4 (unfavourable), Ovarian cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			skin: 32.5	Cell line enhanced		HSkMC: 27.9
EDEM2	bA4204.1, C20orf31, C20orf49, FLJ10783	ENSG00000088298	ER degradation enhancing alpha-mannosidase like protein 2	20	35115357-35147364	Predicted secreted proteins	Evidence at protein level	CAB037238, HPA048353	Approved				Renal cancer:4.76e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 54.7	Expressed in all		
DNMT3B		ENSG00000088305	DNA methyltransferase 3 beta	20	32762385-32809356	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001595, CAB069896	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 9.2	skin: 4.5	Cell line enhanced		BEWO: 236.9;NTERA-2: 333.3
REM1	GES, REM	ENSG00000088320	RRAD and GEM like GTPase 1	20	31475293-31484905	Predicted intracellular proteins	Evidence at protein level	HPA049821	Approved				Renal cancer:1.84e-6 (unfavourable)	Mixed	Mixed			cervix, uterine: 12.3	Cell line enriched	35	WM-115: 21.8
TPX2	C20orf1, C20orf2, DIL-2, p100	ENSG00000088325	TPX2, microtubule nucleation factor	20	31739271-31801805	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA005487	Enhanced		Enhanced	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle<br>Microtubule organizing center	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.07e-7 (unfavourable), Endometrial cancer:2.43e-6 (unfavourable), Pancreatic cancer:2.68e-5 (unfavourable), Lung cancer:6.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 55.6	lymph node: 31.4	Expressed in all		
PDRG1	C20orf126, dJ310O13.3	ENSG00000088356	P53 and DNA damage regulated 1	20	31944342-31952092	Predicted intracellular proteins	Evidence at protein level	HPA047084, HPA063542	Approved		Approved	Actin filaments	Liver cancer:2.62e-5 (unfavourable), Endometrial cancer:1.69e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
EPB41L1	4.1N, KIAA0338	ENSG00000088367	Erythrocyte membrane protein band 4.1 like 1	20	36091504-36232799	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054104, HPA056817	Enhanced		Supported	Plasma membrane	Renal cancer:4.39e-10 (favourable), Endometrial cancer:6.46e-5 (unfavourable), Pancreatic cancer:9.30e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 162.4	Cell line enhanced		HaCaT: 212.9
SLC15A1	HPECT1, HPEPT1, PEPT1	ENSG00000088386	Solute carrier family 15 member 1	13	98683801-98752654	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002827	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	5	duodenum: 153.2;gallbladder: 67.7;small intestine: 225.0	skin: 27.8	Group enriched	6	CAPAN-2: 49.1;SK-BR-3: 41.2
DOCK9	KIAA1058, ZIZ1	ENSG00000088387	Dedicator of cytokinesis 9	13	98793429-99086625	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034061, CAB034065, HPA043940	Uncertain					Expressed in all	Expressed in all			placenta: 141.8	Cell line enhanced		BEWO: 190.5;hTERT-HME1: 334.6
ANKRD10	FLJ20093	ENSG00000088448	Ankyrin repeat domain 10	13	110878540-110915069	Predicted intracellular proteins	Evidence at protein level	CAB034211, HPA038878, HPA038879	Uncertain		Approved	Microtubules<br>Cytosol	Renal cancer:1.25e-6 (unfavourable), Urothelial cancer:6.41e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 109.5	Expressed in all		
TGDS	SDR2E1, TDPGD	ENSG00000088451	TDP-glucose 4,6-dehydratase	13	94574051-94596257	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039927, HPA040857	Approved		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cleavage furrow	Prostate cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 21.7	Expressed in all		
DOCK3	KIAA0299, MOCA, PBP	ENSG00000088538	Dedicator of cytokinesis 3	3	50675241-51384198	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037543, HPA037544	Approved		Enhanced	Cytosol		Tissue enhanced	Group enriched	6	cerebral cortex: 33.7;parathyroid gland: 12.6;testis: 8.5;thyroid gland: 15.1	adrenal gland: 3.0	Cell line enhanced		AN3-CA: 5.9;U-87 MG: 8.0
C3orf18	G20	ENSG00000088543	Chromosome 3 open reading frame 18	3	50558025-50571027	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA012105	Approved		Approved	Cytosol	Renal cancer:2.80e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.3	Cell line enhanced		HDLM-2: 45.2
COQ9	C16orf49, DKFZP434K046	ENSG00000088682	Coenzyme Q9	16	57447425-57461275	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040918	Supported		Approved	Cytosol	Renal cancer:9.03e-11 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 90.6	Expressed in all		
TMEM40	FLJ11036	ENSG00000088726	Transmembrane protein 40	3	12733525-12769457	Predicted membrane proteins	Evidence at protein level	HPA044165	Enhanced		Approved	Cytosol		Tissue enhanced	Group enriched	8	esophagus: 88.8;placenta: 23.3;skin: 55.5;tonsil: 23.7	urinary bladder: 6.1	Cell line enhanced		HBEC3-KT: 182.0;hTCEpi: 40.5;hTERT-HME1: 54.0
KIF9	MGC104186	ENSG00000088727	Kinesin family member 9	3	47228026-47283451	Predicted intracellular proteins	Evidence at protein level	HPA022031, HPA022033, HPA030429	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:5.95e-6 (favourable), Colorectal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 87.6	Expressed in all		
ARHGAP28	FLJ10312, KIAA1314	ENSG00000088756	Rho GTPase activating protein 28	18	6729718-6915716	Predicted intracellular proteins	Evidence at protein level	HPA030413, HPA030414, HPA030415	Enhanced		Supported	Cell Junctions		Mixed	Tissue enhanced		testis: 133.0	placenta: 40.9	Cell line enhanced		AF22: 35.5;CACO-2: 31.8
CRLS1	C20orf155, CLS1, dJ967N21.6, GCD10	ENSG00000088766	Cardiolipin synthase 1	20	6006090-6040053	Enzymes, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:8.02e-4 (favourable)	Expressed in all	Expressed in all			liver: 87.0	Expressed in all		
DEFB127	bA530N10.2, C20orf73, DEF-27	ENSG00000088782	Defensin beta 127	20	157470-159163	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1015	epididymis: 1399.7	seminal vesicle: 1.3	Not detected		
PPP1R13B	ASPP1, KIAA0771, p53BP2-like, p85	ENSG00000088808	Protein phosphatase 1 regulatory subunit 13B	14	103733752-103847590	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006394, CAB015454	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.28e-11 (favourable), Lung cancer:1.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 43.9	Mixed		
ATRN	DPPT-L, MGCA	ENSG00000088812	Attractin	20	3471040-3651122	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008853	Uncertain		Approved	Cytosol	Renal cancer:2.19e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.8	Mixed		
SMOX	C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO	ENSG00000088826	Spermine oxidase	20	4120980-4187747	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047117, HPA060198	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.7	gallbladder: 23.5	Cell line enhanced		A549: 104.6;Karpas-707: 139.7
SIGLEC1	CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN	ENSG00000088827	Sialic acid binding Ig like lectin 1	20	3686970-3707128	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053457	Supported				Renal cancer:8.69e-5 (unfavourable), Testis cancer:4.36e-4 (unfavourable)	Expressed in all	Mixed			placenta: 27.3	Cell line enriched	14	THP-1: 1.4
FKBP1A	FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE	ENSG00000088832	FK506 binding protein 1A	20	1368978-1393172	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004639, HPA051798	Uncertain				Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 369.7	Expressed in all		
NSFL1C	dJ776F14.1, p47, UBX1, UBXD10, UBXN2C	ENSG00000088833	NSFL1 cofactor	20	1442162-1473842	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047108, HPA050628	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 35.4	Expressed in all		
SLC4A11	BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1	ENSG00000088836	Solute carrier family 4 member 11	20	3227417-3239190	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018120, HPA058377	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 27.7	salivary gland: 19.2	Cell line enhanced		HaCaT: 55.7
C20orf194	DKFZp434N061	ENSG00000088854	Chromosome 20 open reading frame 194	20	3249305-3407625	Predicted intracellular proteins	Evidence at protein level	HPA052103, HPA067418	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Pancreatic cancer:1.68e-4 (favourable), Renal cancer:7.68e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
ZNF343	MGC10715	ENSG00000088876	Zinc finger protein 343	20	2481817-2524702	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030587, HPA052438	Approved		Approved	Nucleoplasm	Liver cancer:1.38e-6 (unfavourable), Renal cancer:4.53e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.6	Expressed in all		
EBF4	COE4, KIAA1442, O/E-4, RP5-860F19.3	ENSG00000088881	Early B-cell factor 4	20	2692878-2760108	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:2.47e-5 (favourable), Colorectal cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Cell line enhanced		SH-SY5Y: 15.8
CPXM1	CPX-1, CPX1, CPXM	ENSG00000088882	Carboxypeptidase X, M14 family member 1	20	2794069-2800637	Enzymes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.62e-10 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 130.4;gallbladder: 132.2	urinary bladder: 75.0	Group enriched	5	AF22: 158.5;HSkMC: 62.0;NB-4: 92.9;NTERA-2: 34.2;REH: 136.3;SH-SY5Y: 113.9
MAVS	Cardif, IPS-1, KIAA1271, VISA	ENSG00000088888	Mitochondrial antiviral signaling protein	20	3846799-3876123	Predicted membrane proteins	Evidence at protein level	CAB009187, HPA049850, HPA053524	Enhanced		Enhanced	Mitochondria	Renal cancer:4.13e-5 (favourable), Pancreatic cancer:3.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.6	Expressed in all		
LZTS3	KIAA0552, ProSAPiP1	ENSG00000088899	Leucine zipper tumor suppressor family member 3	20	3162617-3173592	Predicted intracellular proteins	Evidence at protein level	HPA031008, HPA031009	Approved		Approved	Vesicles	Renal cancer:5.92e-8 (favourable), Endometrial cancer:7.26e-4 (unfavourable), Lung cancer:7.98e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 58.6	parathyroid gland: 20.3	Cell line enhanced		SCLC-21H: 21.3
F11	FXI	ENSG00000088926	Coagulation factor XI	4	186265945-186288806	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039808			Approved	Vesicles	Liver cancer:3.29e-5 (favourable)	Tissue enriched	Tissue enhanced		liver: 180.1	kidney: 44.7	Cell line enriched	8	Hep G2: 6.0
XRN2		ENSG00000088930	5'-3' exoribonuclease 2	20	21303304-21389827	Predicted intracellular proteins	Evidence at protein level	HPA047118, HPA050485	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:3.54e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.0	Expressed in all		
KIZ	C20orf19, HT013, NCRNA00153, PLK1S1	ENSG00000088970	Kizuna centrosomal protein	20	21125983-21246622	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.11e-8 (unfavourable), Endometrial cancer:4.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 82.2	Expressed in all		
DYNLL1	DLC1, DLC8, DNCL1, hdlc1, LC8, PIN	ENSG00000088986	Dynein light chain LC8-type 1	12	120469850-120498493	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039954			Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:7.97e-7 (unfavourable), Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 772.7	Expressed in all		
TESC	CHP3, FLJ20607, TSC	ENSG00000088992	Tescalcin	12	117038923-117099479	Predicted intracellular proteins	Evidence at protein level	HPA053200	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		epididymis: 135.9;salivary gland: 131.3;stomach: 118.8	bone marrow: 67.0	Cell line enhanced		HMC-1: 320.8;NB-4: 389.7;U-937: 158.6
SNX5		ENSG00000089006	Sorting nexin 5	20	17941597-17968980	Predicted intracellular proteins	Evidence at protein level	CAB020679, HPA051187	Approved				Liver cancer:2.30e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.4	Expressed in all		
RPL6	L6, TAXREB107, TXREB1	ENSG00000089009	Ribosomal protein L6	12	112405190-112418838	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060903, HPA068418	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:6.95e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3221.7	Expressed in all		
SIRPG	bA77C3.1, CD172g, SIRP-B2, SIRPB2, SIRPgamma	ENSG00000089012	Signal regulatory protein gamma	20	1629152-1657779	CD markers, Predicted membrane proteins	Evidence at protein level						Melanoma:7.36e-7 (favourable), Endometrial cancer:1.05e-6 (favourable), Renal cancer:1.47e-6 (unfavourable), Head and neck cancer:2.24e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 38.8;tonsil: 25.8	appendix: 16.9	Cell line enhanced		NB-4: 8.6;RT4: 2.8;THP-1: 1.6
MAPKAPK5	PRAK	ENSG00000089022	Mitogen-activated protein kinase-activated protein kinase 5	12	111841978-111902238	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004546, HPA015515	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.98e-8 (unfavourable)	Expressed in all	Expressed in all			rectum: 33.8	Expressed in all		
P2RX7	MGC20089, P2X7	ENSG00000089041	Purinergic receptor P2X 7	12	121132819-121188032	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034967, HPA034968, HPA042013, HPA044141	Approved		Approved	Golgi apparatus	Renal cancer:2.92e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.0	Cell line enhanced		Karpas-707: 28.5;RPMI-8226: 16.7;SK-MEL-30: 31.3;U-266/70: 16.4;U-266/84: 14.0
ESF1	bA526K24.1, C20orf6	ENSG00000089048	ESF1 nucleolar pre-rRNA processing protein homolog	20	13714322-13784886	Predicted intracellular proteins	Evidence at protein level	HPA047083, HPA050396	Supported		Approved	Nucleus<br>Nucleoli	Liver cancer:7.81e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
RBBP9	Bog	ENSG00000089050	RB binding protein 9, serine hydrolase	20	18486540-18497243	Predicted intracellular proteins	Evidence at protein level	HPA015830, HPA049005	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 40.8	Expressed in all		
ANAPC5	APC5	ENSG00000089053	Anaphase promoting complex subunit 5	12	121308245-121399896	Predicted intracellular proteins	Evidence at protein level	HPA039457, HPA039801	Supported		Approved	Nucleoplasm	Renal cancer:2.01e-9 (unfavourable), Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 88.7	Expressed in all		
SLC23A2	KIAA0238, SLC23A1, SVCT2, YSPL2	ENSG00000089057	Solute carrier family 23 member 2	20	4852356-5010293	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052825, HPA059314	Approved		Supported	Golgi apparatus<br>Vesicles	Urothelial cancer:6.08e-5 (favourable), Pancreatic cancer:7.14e-5 (favourable), Liver cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 98.2	Expressed in all		
SLC8B1	FLJ22233, NCKX6, NCLX, SLC24A6	ENSG00000089060	Solute carrier family 8 member B1	12	113298759-113359493	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA040668	Approved				Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 48.4	Mixed		
TMEM230	C20orf30, HSPC274	ENSG00000089063	Transmembrane protein 230	20	5068232-5113103	Predicted membrane proteins	Evidence at protein level	HPA009078, HPA061421	Uncertain		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 227.2	Expressed in all		
DZANK1	ANKRD64, bA189K21.8, C20orf12, C20orf84, dJ568F9.2, FLJ10600, FLJ30892	ENSG00000089091	Double zinc ribbon and ankyrin repeat domains 1	20	18383367-18467281	Predicted intracellular proteins	Evidence at protein level	HPA059478, HPA064255	Uncertain		Approved	Nucleoli fibrillar center		Mixed	Mixed			fallopian tube: 5.2	Cell line enhanced		THP-1: 17.4;U-266/84: 19.5
KDM2B	CXXC2, Fbl10, FBXL10, JHDM1B, PCCX2	ENSG00000089094	Lysine demethylase 2B	12	121429097-121581015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071257			Uncertain	Nucleoplasm	Head and neck cancer:6.74e-6 (favourable), Pancreatic cancer:8.64e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 35.8	Expressed in all		
CFAP61	C20orf26, CaM-IP3, dJ1002M8.3, DKFZP434K156	ENSG00000089101	Cilia and flagella associated protein 61	20	20052514-20360702	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA009079	Uncertain					Mixed	Group enriched	6	fallopian tube: 20.3;heart muscle: 8.5;testis: 29.5	skeletal muscle: 3.3	Cell line enhanced		HMC-1: 2.1;SCLC-21H: 6.6;U-87 MG: 4.1
LHX5		ENSG00000089116	LIM homeobox 5	12	113462034-113472280	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA053908	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.4	stomach: 0.3	Cell line enhanced		HMC-1: 1.0
TASP1	C20orf13, dJ585I14.2, FLJ20212	ENSG00000089123	Taspase 1	20	13389392-13638940	Predicted intracellular proteins	Evidence at protein level	HPA030824, HPA030825	Uncertain		Approved	Plasma membrane	Thyroid cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.7	Mixed		
OAS1	IFI-4, OIAS, OIASI	ENSG00000089127	2'-5'-oligoadenylate synthetase 1	12	112906777-112933222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003657, CAB021104	Uncertain		Approved	Cytosol	Urothelial cancer:6.12e-6 (favourable), Pancreatic cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 90.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 266.2;BJ hTERT+ SV40 Large T+ RasG12V: 396.9;U-266/70: 307.4;U-266/84: 229.8
GCN1	GCN1L, GCN1L1, KIAA0219	ENSG00000089154	GCN1, eIF2 alpha kinase activator homolog	12	120127203-120194710	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018799, HPA019648, HPA024367	Enhanced		Enhanced	Cytosol	Liver cancer:1.87e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.5	Expressed in all		
RPLP0	L10E, LP0, P0, PRLP0, RPP0	ENSG00000089157	Ribosomal protein lateral stalk subunit P0	12	120196686-120201235	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003512	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.66e-12 (unfavourable)	Expressed in all	Expressed in all			breast: 2860.7	Expressed in all		
PXN		ENSG00000089159	Paxillin	12	120210439-120265771	Predicted intracellular proteins	Evidence at protein level	CAB003841, HPA051309	Enhanced		Enhanced	Focal adhesion sites<br>Centrosome<br>Cytosol	Head and neck cancer:3.72e-5 (unfavourable), Glioma:6.11e-5 (unfavourable), Liver cancer:7.12e-5 (unfavourable), Lung cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 100.4	Expressed in all		
SIRT4	SIR2L4	ENSG00000089163	Sirtuin 4	12	120302316-120313249	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA029691, HPA029692	Enhanced				Renal cancer:1.75e-4 (favourable)	Mixed	Mixed			testis: 9.5	Mixed		
RPH3A	exophilin-1, KIAA0985, rabphilin	ENSG00000089169	Rabphilin 3A	12	112570380-112898881	Predicted intracellular proteins	Evidence at protein level	HPA002475	Enhanced					Tissue enriched	Tissue enriched	7	cerebral cortex: 95.2	bone marrow: 13.8	Cell line enhanced		SH-SY5Y: 17.7
KIF16B	C20orf23, dJ971B4.1, FLJ20135, SNX23	ENSG00000089177	Kinesin family member 16B	20	16272104-16573434	Predicted intracellular proteins	Evidence at protein level	HPA051198	Approved		Uncertain	Mitochondria	Renal cancer:7.61e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.9	Mixed		
TRMT6	CGI-09, GCD10, Gcd10p, MGC5029	ENSG00000089195	TRNA methyltransferase 6	20	5937235-5950558	Predicted intracellular proteins	Evidence at protein level	HPA047032, HPA050408	Approved		Supported	Nucleus	Liver cancer:4.70e-12 (unfavourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
CHGB	SCG1, SgI	ENSG00000089199	Chromogranin B	20	5911430-5925361	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008759, CAB009403, HPA012602	Enhanced	Supported	Enhanced	Vesicles	Head and neck cancer:1.89e-4 (unfavourable), Pancreatic cancer:9.96e-4 (favourable)	Tissue enriched	Tissue enriched	26	adrenal gland: 4382.4	cerebral cortex: 168.3	Group enriched	25	SCLC-21H: 405.5;SH-SY5Y: 559.4
PEBP1	HCNP, PBP, PEBP, RKIP	ENSG00000089220	Phosphatidylethanolamine binding protein 1	12	118135858-118145584	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008819, CAB013493, HPA063904	Enhanced		Supported	Plasma membrane	Renal cancer:2.15e-13 (favourable), Pancreatic cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 1642.0	Expressed in all		
TBX5	HOS	ENSG00000089225	T-box 5	12	114353931-114408442	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008786, HPA064683	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	6	heart muscle: 40.0;lung: 18.0;placenta: 46.8	prostate: 6.2	Cell line enhanced		BJ: 17.0;BJ hTERT+: 36.2;BJ hTERT+ SV40 Large T+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 12.1;HAP1: 18.0
BRAP	BRAP2, IMP, RNF52	ENSG00000089234	BRCA1 associated protein	12	111642146-111685986	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040357, HPA058820	Approved		Supported	Nuclear membrane<br>Cytosol	Liver cancer:7.65e-6 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 120.9	bone marrow: 21.3	Expressed in all		
ERP29	C12orf8, ERp28, ERp29, ERp31, PDI-DB, PDIA9	ENSG00000089248	Endoplasmic reticulum protein 29	12	112013316-112023451	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039363, HPA039456	Enhanced		Uncertain	Nucleoplasm<br>Microtubules	Endometrial cancer:7.43e-5 (favourable), Liver cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 150.9	Expressed in all		
NOS1	nNOS, NOS	ENSG00000089250	Nitric oxide synthase 1	12	117208142-117452170	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002167, HPA058312	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		skeletal muscle: 12.9	cerebral cortex: 3.0	Cell line enhanced		HaCaT: 4.0;RH-30: 9.0;RPTEC TERT1: 4.4
FUS	ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS	ENSG00000089280	FUS RNA binding protein	16	31180110-31194871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008784, CAB033036, CAB058691	Enhanced		Enhanced	Nucleoplasm	Liver cancer:4.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 145.8	Expressed in all		
IGBP1	IBP1	ENSG00000089289	Immunoglobulin binding protein 1	X	70133449-70166324	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000634, HPA001004, CAB034139	Approved		Approved	Microtubules		Expressed in all	Expressed in all			ovary: 147.3	Expressed in all		
FXYD5	OIT2	ENSG00000089327	FXYD domain containing ion transport regulator 5	19	35154730-35169883	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010817	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:3.71e-9 (unfavourable)	Expressed in all	Expressed in all			spleen: 237.1	Mixed		
ZNF302	ZNF135L, ZNF140L, ZNF327	ENSG00000089335	Zinc finger protein 302	19	34677639-34686397	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059503			Approved	Vesicles<br>Cytokinetic bridge	Endometrial cancer:2.03e-5 (unfavourable), Urothelial cancer:9.85e-5 (favourable), Renal cancer:5.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.1	Mixed		
GRAMD1A	FLJ90346, KIAA1533	ENSG00000089351	GRAM domain containing 1A	19	34994784-35026471	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008852, HPA012570	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.95e-12 (unfavourable)	Expressed in all	Expressed in all			lung: 36.5	Expressed in all		
FXYD3	MAT-8, PLML	ENSG00000089356	FXYD domain containing ion transport regulator 3	19	35115879-35124324	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010856	Enhanced				Renal cancer:1.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 1455.6;rectum: 1952.1	stomach: 557.3	Cell line enhanced		HaCaT: 792.6;hTCEpi: 1156.1;RT4: 686.4;SK-BR-3: 621.3;WM-115: 590.3
HEPH	CPL, KIAA0698	ENSG00000089472	Hephaestin	X	66162549-66268867	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005824	Approved				Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 119.0	Cell line enhanced		AF22: 28.1;HEL: 22.8;HSkMC: 26.1;K-562: 64.5;LHCN-M2: 23.8
CDIP1	C16orf5, CDIP, LITAFL	ENSG00000089486	Cell death inducing p53 target 1	16	4510675-4538828	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049352	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:1.14e-6 (favourable), Pancreatic cancer:2.14e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 72.9	Cell line enhanced		RPMI-8226: 99.5
CMTM1	CKLFH, CKLFH1a, CKLFSF1	ENSG00000089505	CKLF like MARVEL transmembrane domain containing 1	16	66566393-66579137	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013801, HPA017136	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:5.68e-5 (unfavourable)	Mixed	Tissue enriched	6	testis: 28.7	spleen: 4.4	Mixed		
KCNH4	elk1, Kv12.3	ENSG00000089558	Potassium voltage-gated channel subfamily H member 4	17	42156891-42181278	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.8	appendix: 0.7	Cell line enhanced		HDLM-2: 4.2;K-562: 3.8;RPMI-8226: 5.6;RT4: 2.3;U-266/70: 3.1
GANAB	G2AN, GIIA, GluII, KIAA0088	ENSG00000089597	Glucosidase II alpha subunit	11	62624826-62646726	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026874, HPA061426	Enhanced		Approved	Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 295.2	Expressed in all		
GMIP	ARHGAP46	ENSG00000089639	GEM interacting protein	19	19629476-19643667	Predicted intracellular proteins	Evidence at protein level	HPA042484, HPA045481	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.97e-5 (unfavourable), Stomach cancer:3.03e-4 (favourable), Urothelial cancer:5.15e-4 (favourable)	Expressed in all	Mixed			spleen: 46.7	Expressed in all		
RBM41	FLJ11016	ENSG00000089682	RNA binding motif protein 41	X	107064420-107118823	Predicted intracellular proteins	Evidence at protein level	HPA042881	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:3.04e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 19.3	Expressed in all		
BIRC5	API4, EPR-1, survivin	ENSG00000089685	Baculoviral IAP repeat containing 5	17	78214186-78225636	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002830, CAB004270	Enhanced		Enhanced	Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.28e-6 (unfavourable), Lung cancer:4.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 26.8	bone marrow: 22.6	Mixed		
LAG3	CD223	ENSG00000089692	Lymphocyte activating 3	12	6772512-6778455	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002301, HPA013967	Enhanced				Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 32.0	lymph node: 17.6	Cell line enriched	140	HDLM-2: 136.0
MLF2	NTN4	ENSG00000089693	Myeloid leukemia factor 2	12	6747996-6767475	Predicted intracellular proteins	Evidence at protein level	HPA010811, HPA010859	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 272.5	Expressed in all		
OTUB2	C14orf137, FLJ21916, MGC3102	ENSG00000089723	OTU deubiquitinase, ubiquitin aldehyde binding 2	14	94026329-94048930	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002329	Enhanced					Mixed	Tissue enhanced		testis: 9.7	skin: 4.7	Cell line enhanced		Karpas-707: 12.8;RPTEC TERT1: 8.5
DDX24		ENSG00000089737	DEAD-box helicase 24	14	94048291-94081245	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002554	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.06e-9 (favourable), Stomach cancer:2.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 45.3	testis: 26.5	Mixed		
ZBTB25	C14orf51, KUP, ZNF46	ENSG00000089775	Zinc finger and BTB domain containing 25	14	64449106-64505213	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054699	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.56e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 14.8	Expressed in all		
NECAP1	DKFZP566B183	ENSG00000089818	NECAP endocytosis associated 1	12	8076939-8097859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053980, HPA063300	Uncertain		Approved	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 117.8	parathyroid gland: 34.8	Expressed in all		
ARHGAP4	C1, KIAA0131, p115, RhoGAP4, SrGAP4	ENSG00000089820	Rho GTPase activating protein 4	X	153907367-153934999	Predicted intracellular proteins	Evidence at protein level	HPA001012, HPA001083	Enhanced		Approved	Nucleoplasm<br>Focal adhesion sites	Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 95.1	lymph node: 87.2	Cell line enhanced		MOLT-4: 72.4;RPMI-8226: 121.4
ANKRD24	KIAA1981	ENSG00000089847	Ankyrin repeat domain 24	19	4183354-4224814	Predicted intracellular proteins	Evidence at protein level	HPA041534, HPA048498	Uncertain		Uncertain	Microtubules<br>Cytosol	Liver cancer:9.13e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 13.5;testis: 7.0	prostate: 3.2	Cell line enhanced		Karpas-707: 3.5;U-266/70: 12.3
DHX32	DDX32, DHLP1, FLJ10694, FLJ10889	ENSG00000089876	DEAH-box helicase 32 (putative)	10	125836337-125896436	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048872	Approved				Pancreatic cancer:9.49e-5 (unfavourable), Prostate cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.8	Mixed		
RCOR1	COREST, KIAA0071, RCOR	ENSG00000089902	REST corepressor 1	14	102592661-102730576	Predicted secreted proteins	Evidence at protein level	CAB001956, HPA049327, HPA054241	Supported		Enhanced	Nucleoplasm	Urothelial cancer:3.72e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow,placenta: 29.6	Expressed in all		
GPATCH2L	C14orf118, FLJ10033, FLJ20689	ENSG00000089916	G-patch domain containing 2 like	14	76151916-76254342	Predicted intracellular proteins	Evidence at protein level	HPA018856	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
LTBP4	FLJ46318, FLJ90018, LTBP-4, LTBP-4L	ENSG00000090006	Latent transforming growth factor beta binding protein 4	19	40592883-40629818	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB015194	Approved				Ovarian cancer:2.36e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 244.9	Mixed		
BLVRB	FLR, SDR43U1	ENSG00000090013	Biliverdin reductase B	19	40447789-40465840	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041698, HPA041937	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 338.3	Cell line enhanced		A549: 442.0;K-562: 413.4
SLC9A1	APNH, NHE1, PPP1R143	ENSG00000090020	Solute carrier family 9 member A1	1	27098815-27166981	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022371, HPA048532, HPA052891	Enhanced		Supported	Plasma membrane	Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 65.5	Expressed in all		
SPTLC1	hLCB1, HSAN1, HSN1, LCB1, SPTI	ENSG00000090054	Serine palmitoyltransferase long chain base subunit 1	9	92031999-92115384	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA010860, CAB018747, HPA063907	Supported		Supported	Endoplasmic reticulum	Renal cancer:1.36e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 108.3	Expressed in all		
PAPOLA	PAP	ENSG00000090060	Poly(A) polymerase alpha	14	96501433-96567111	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001788	Supported		Enhanced	Nucleoplasm	Liver cancer:2.41e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
CCNK	CPR4	ENSG00000090061	Cyclin K	14	99481169-99535044	Predicted intracellular proteins	Evidence at protein level	HPA000645, HPA077073	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 84.2	Expressed in all		
PCBP4	LIP4, MCG10	ENSG00000090097	Poly(rC) binding protein 4	3	51957454-51974016	Predicted intracellular proteins	Evidence at protein level	HPA057754			Supported	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 113.5	Cell line enhanced		SH-SY5Y: 170.4
RGS1	1R20, BL34, IER1, IR20	ENSG00000090104	Regulator of G-protein signaling 1	1	192575727-192580031	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.91e-5 (unfavourable), Stomach cancer:9.57e-4 (unfavourable)	Expressed in all	Mixed			appendix: 225.9	Group enriched	26	Karpas-707: 152.1;U-266/70: 700.2
YPEL3	MGC10500	ENSG00000090238	Yippee like 3	16	30092314-30096915	Predicted intracellular proteins	Evidence at transcript level	HPA030501, HPA045621	Uncertain				Head and neck cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 117.0	Mixed		
MRPS33	CGI-139	ENSG00000090263	Mitochondrial ribosomal protein S33	7	141002610-141015228	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030425	Uncertain					Expressed in all	Expressed in all			epididymis: 96.2	Expressed in all		
NDUFB2	AGGG, CI-AGGG	ENSG00000090266	NADH:ubiquinone oxidoreductase subunit B2	7	140690777-140722790	Predicted intracellular proteins	Evidence at protein level	HPA051377	Approved				Renal cancer:7.60e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 497.1	Expressed in all		
NUDC	NudC	ENSG00000090273	Nuclear distribution C, dynein complex regulator	1	26900238-26946862	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027183, HPA028105	Enhanced		Enhanced	Cytosol	Liver cancer:1.21e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 150.6	Expressed in all		
MAEA	EMP, GID9	ENSG00000090316	Macrophage erythroblast attacher	4	1289851-1340147	Predicted intracellular proteins	Evidence at protein level	HPA036886, HPA058185	Approved		Enhanced	Nucleoplasm	Renal cancer:1.90e-4 (favourable), Head and neck cancer:5.34e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 38.1	Expressed in all		
ICAM1	BB2, CD54	ENSG00000090339	Intercellular adhesion molecule 1	19	10270835-10286615	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002126, CAB002142, HPA004877	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			lung: 255.9	Cell line enhanced		Karpas-707: 302.5
STRN4	PPP2R6C, ZIN	ENSG00000090372	Striatin 4	19	46719507-46746994	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043051, HPA043527, HPA056706	Enhanced		Approved	Cytosol	Liver cancer:6.06e-8 (unfavourable), Ovarian cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 104.8	Expressed in all		
IRAK3	IRAK-M	ENSG00000090376	Interleukin 1 receptor associated kinase 3	12	66188879-66254622	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043097	Approved		Approved	Vesicles	Renal cancer:6.23e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 51.0	adipose tissue: 19.3	Cell line enhanced		HEL: 20.3;HL-60: 24.1;THP-1: 24.3;U-937: 20.5
LYZ		ENSG00000090382	Lysozyme	12	69348341-69354234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	CAB000055, HPA048284, HPA066182	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Actin filaments	Head and neck cancer:7.45e-4 (favourable)	Expressed in all	Expressed in all			stomach: 9651.4	Group enriched	5	Hep G2: 633.5;THP-1: 321.5;U-937: 404.3
SI		ENSG00000090402	Sucrase-isomaltase	3	164978898-165078495	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011897	Enhanced					Tissue enhanced	Group enriched	15	duodenum: 547.3;small intestine: 493.2	rectum: 34.5	Cell line enhanced		BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
MUL1	C1orf166, FLJ12875, GIDE, MAPL, MULAN, RNF218	ENSG00000090432	Mitochondrial E3 ubiquitin protein ligase 1	1	20499448-20508161	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026827			Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:6.15e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
TFAP4	AP-4, bHLHc41	ENSG00000090447	Transcription factor AP-4	16	4257186-4273075	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001912	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:4.31e-6 (unfavourable), Liver cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.0	Expressed in all		
PDCD7	ES18, HES18	ENSG00000090470	Programmed cell death 7	15	65117379-65133836	Predicted intracellular proteins	Evidence at protein level	HPA049388	Approved		Approved	Nucleoli<br>Plasma membrane	Renal cancer:1.00e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.7	Expressed in all		
SPG21	ACP33, BM-019, GL010, MAST	ENSG00000090487	SPG21, maspardin	15	64963021-64990310	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040407, HPA040436	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			epididymis: 182.9	Expressed in all		
FETUB		ENSG00000090512	Fetuin B	3	186635969-186653141	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035132	Supported					Tissue enriched	Tissue enriched	16	liver: 123.3	esophagus: 7.6	Not detected		
DNAJB11	EDJ, ERdj3, HEDJ	ENSG00000090520	DnaJ heat shock protein family (Hsp40) member B11	3	186567403-186585800	Predicted secreted proteins	Evidence at protein level	HPA010814, HPA017051	Supported		Supported	Endoplasmic reticulum	Renal cancer:3.44e-9 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 88.4	Expressed in all		
P3H2	FLJ10718, LEPREL1, MLAT4	ENSG00000090530	Prolyl 3-hydroxylase 2	3	189956728-190122437	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007890, HPA013355	Approved					Expressed in all	Mixed			prostate: 60.8	Cell line enhanced		HaCaT: 97.1;RPTEC TERT1: 83.3
THPO	MGDF, MPLLG, TPO	ENSG00000090534	Thrombopoietin	3	184371935-184378144	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.48e-6 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 8.9	testis: 3.9	Cell line enhanced		CACO-2: 4.9;Hep G2: 10.6;K-562: 2.5;RPMI-8226: 2.8
CHRD		ENSG00000090539	Chordin	3	184380073-184390736	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035827	Approved				Renal cancer:6.09e-7 (unfavourable)	Mixed	Mixed			endometrium: 16.8	Cell line enhanced		Hep G2: 7.9;U-2 OS: 4.0
FLT3LG		ENSG00000090554	Fms related tyrosine kinase 3 ligand	19	49474207-49486231	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Cervical cancer:2.17e-5 (favourable)	Mixed	Mixed			lymph node: 27.7	Mixed		
RAB11FIP3	eferin, KIAA0665, Rab11-FIP3	ENSG00000090565	RAB11 family interacting protein 3	16	425619-523011	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028088, HPA028631, HPA030086	Approved		Supported	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Pancreatic cancer:3.16e-5 (favourable), Liver cancer:9.87e-5 (unfavourable), Endometrial cancer:1.22e-4 (favourable), Renal cancer:7.99e-4 (favourable)	Expressed in all	Expressed in all			kidney: 56.9	Expressed in all		
GNPTG	C16orf27, c316G12.3, CAB56184, GNPTAG	ENSG00000090581	N-acetylglucosamine-1-phosphate transferase gamma subunit	16	1351923-1364113	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004055	Approved		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 66.2	Expressed in all		
ZNF268	HZF3	ENSG00000090612	Zinc finger protein 268	12	133181409-133214831	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001794	Approved		Approved	Actin filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 23.5	Mixed		
GOLGA3	GCP170, golgin-160, MEA-2	ENSG00000090615	Golgin A3	12	132768909-132828858	Predicted intracellular proteins	Evidence at protein level	HPA039809, HPA040044	Enhanced		Supported	Nucleus<br>Golgi apparatus	Renal cancer:6.47e-5 (unfavourable), Liver cancer:2.73e-4 (unfavourable), Pancreatic cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 18.5	Expressed in all		
PABPC4	APP-1, iPABP	ENSG00000090621	Poly(A) binding protein cytoplasmic 4	1	39560816-39576790	Predicted intracellular proteins	Evidence at protein level	HPA027301, HPA056496	Approved		Enhanced	Cytosol	Renal cancer:3.00e-10 (unfavourable), Liver cancer:1.14e-7 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 206.3	Expressed in all		
CD209	CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1	ENSG00000090659	CD209 molecule	19	7739994-7747564	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB032436, CAB033831	Supported				Renal cancer:1.15e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 43.9	placenta: 33.0	Cell line enriched	9	THP-1: 2.3
CERS4	FLJ12089, LASS4, Trh1	ENSG00000090661	Ceramide synthase 4	19	8206736-8262421	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033734, HPA054729	Uncertain		Approved	Nucleus<br>Vesicles	Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 80.8	Cell line enhanced		NB-4: 63.0
MCOLN1	ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1	ENSG00000090674	Mucolipin 1	19	7522626-7534009	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031763, CAB032637	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			spleen: 48.2	Expressed in all		
USP48	FLJ11328, FLJ20103, FLJ23054, FLJ23277, MGC14879, USP31	ENSG00000090686	Ubiquitin specific peptidase 48	1	21678298-21783606	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030045, HPA030046	Approved	Approved	Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:6.09e-8 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 54.0	Expressed in all		
EFNB1	CFNS, Elk-L, EPLG2, LERK2	ENSG00000090776	Ephrin B1	X	68828997-68842147	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB031489, HPA067188	Uncertain		Supported	Plasma membrane	Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 37.8	Mixed		
PDPR	PDP3	ENSG00000090857	Pyruvate dehydrogenase phosphatase regulatory subunit	16	70113626-70162537	Predicted intracellular proteins	Evidence at protein level	HPA048092, HPA070386	Uncertain		Approved	Mitochondria	Renal cancer:8.36e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.0	Expressed in all		
AARS	AlaRS, CMT2N	ENSG00000090861	Alanyl-tRNA synthetase	16	70252295-70289543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034261, HPA040870, HPA044223	Supported		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 178.0	Expressed in all		
GLG1	CFR-1, ESL-1, MG-160	ENSG00000090863	Golgi glycoprotein 1	16	74447427-74607144	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010815	Supported		Enhanced	Golgi apparatus	Renal cancer:1.56e-7 (favourable), Cervical cancer:1.99e-4 (unfavourable), Urothelial cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 167.1	Expressed in all		
KIF4A	FLJ12530, FLJ12655, FLJ14204, FLJ20631, HSA271784, KIF4, KIF4-G1, MRX100	ENSG00000090889	Kinesin family member 4A	X	70290090-70420832	Predicted intracellular proteins	Evidence at protein level	HPA034745, HPA034746, HPA061583	Approved		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Liver cancer:7.37e-6 (unfavourable), Pancreatic cancer:9.44e-6 (unfavourable)	Mixed	Mixed			bone marrow: 7.0	Mixed		
TNRC6A	CAGH26, GW182, KIAA1460, TNRC6	ENSG00000090905	Trinucleotide repeat containing 6A	16	24610209-24827632	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015305, HPA017869	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 68.2	Expressed in all		
PLEKHG2	ARHGEF42, CLG, FLJ00018	ENSG00000090924	Pleckstrin homology and RhoGEF domain containing G2	19	39412585-39428415	Predicted intracellular proteins	Evidence at protein level	HPA017973, HPA048054	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.79e-8 (unfavourable), Colorectal cancer:3.53e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.2	Expressed in all		
DLL3	SCDO1	ENSG00000090932	Delta like canonical Notch ligand 3	19	39498895-39508481	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056533			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.94e-4 (unfavourable)	Group enriched	Tissue enriched	49	cerebral cortex: 51.3	testis: 1.0	Group enriched	6	SCLC-21H: 16.1;SH-SY5Y: 14.9;SK-MEL-30: 62.1
NAT14	KLP1	ENSG00000090971	N-acetyltransferase 14 (putative)	19	55485004-55487568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047187			Approved	Mitochondria	Renal cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 26.7	Expressed in all		
PITPNM2	NIR3, RDGB2, RDGBA2	ENSG00000090975	Phosphatidylinositol transfer protein membrane associated 2	12	122983480-123150015	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003414, HPA003978	Approved		Supported	Vesicles		Expressed in all	Mixed			ovary: 19.1	Cell line enhanced		HEL: 26.5;MOLT-4: 44.3
EXOC1	BM-102, FLJ10893, SEC3, SEC3L1, Sec3p	ENSG00000090989	Exocyst complex component 1	4	55853616-55905034	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037706, HPA044873	Uncertain		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Urothelial cancer:5.50e-5 (favourable), Liver cancer:2.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
RBM27	ARRS1, KIAA1311, Psc1, ZC3H20	ENSG00000091009	RNA binding motif protein 27	5	146203600-146289132	Predicted intracellular proteins	Evidence at protein level	HPA035944, HPA036422	Approved		Approved	Nuclear speckles	Liver cancer:8.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.0	Expressed in all		
POU4F3	BRN3C, DFNA15, DFNA42, DFNA52	ENSG00000091010	POU class 4 homeobox 3	5	146339024-146340520	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038215	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Not detected			all non-specific tissues: 0.0	Not detected		
OSBPL8	MST120, MSTP120, ORP8, OSBP10	ENSG00000091039	Oxysterol binding protein like 8	12	76351797-76559809	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001309	Uncertain		Approved	Vesicles<br>Cytosol	Pancreatic cancer:9.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
DTX2	KIAA1528, RNF58	ENSG00000091073	Deltex E3 ubiquitin ligase 2	7	76461676-76505995	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042931	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.13e-8 (unfavourable), Glioma:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 37.2	Expressed in all		
NLRC4	CARD12, CLAN, CLAN1, CLANA, CLANB, CLANC, CLAND, CLR2.1, ipaf	ENSG00000091106	NLR family CARD domain containing 4	2	32224453-32265854	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006592	Uncertain					Mixed	Tissue enhanced		appendix: 12.4	lung: 9.3	Cell line enhanced		HL-60: 2.4
PUS7	FLJ20485	ENSG00000091127	Pseudouridylate synthase 7 (putative)	7	105439661-105522267	Predicted intracellular proteins	Evidence at protein level	HPA024116	Approved		Approved	Nucleus	Renal cancer:1.03e-8 (unfavourable), Liver cancer:4.89e-6 (unfavourable), Melanoma:7.58e-5 (unfavourable), Thyroid cancer:6.28e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.0	Expressed in all		
LAMB4		ENSG00000091128	Laminin subunit beta 4	7	108023548-108130356	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020242, HPA024247	Approved		Uncertain	Cytosol		Tissue enhanced	Tissue enriched	12	skin: 46.5	placenta: 3.8	Cell line enhanced		BEWO: 1.8
NRCAM	Bravo, KIAA0343	ENSG00000091129	Neuronal cell adhesion molecule	7	108147623-108456717	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012606	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 180.4	adrenal gland: 49.5	Cell line enhanced		A549: 90.2;AF22: 93.7;EFO-21: 165.3;HMC-1: 165.2;SH-SY5Y: 122.8
LAMB1	CLM	ENSG00000091136	Laminin subunit beta 1	7	107923799-108003255	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004056, HPA004132, CAB004256	Enhanced				Liver cancer:2.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 263.7	adipose tissue: 161.4	Cell line enhanced		HSkMC: 640.2
SLC26A4	DFNB4, PDS	ENSG00000091137	Solute carrier family 26 member 4	7	107660635-107717809	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042860	Approved					Tissue enriched	Tissue enriched	28	thyroid gland: 419.0	cerebral cortex: 15.1	Cell line enhanced		LHCN-M2: 3.7;SCLC-21H: 1.9
SLC26A3	CLD, DRA	ENSG00000091138	Solute carrier family 26 member 3	7	107765467-107803225	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036055	Approved					Tissue enriched	Tissue enhanced		colon: 1075.0;duodenum: 577.9;rectum: 961.7	seminal vesicle: 185.8	Cell line enhanced		RPMI-8226: 1.9
DLD	DLDH, GCSL, LAD	ENSG00000091140	Dihydrolipoamide dehydrogenase	7	107890970-107931730	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044849	Enhanced		Supported	Mitochondria	Renal cancer:7.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 174.7	Expressed in all		
WDR7	KIAA0541, TRAG	ENSG00000091157	WD repeat domain 7	18	56651343-57036606	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042074, HPA051057	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.13e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 38.6	parathyroid gland: 17.0	Expressed in all		
TXNL1	TRP32, Txl, TXNL	ENSG00000091164	Thioredoxin like 1	18	56597208-56651600	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002828, HPA002829, CAB016446	Supported	Supported	Enhanced	Cytosol	Liver cancer:9.62e-6 (unfavourable), Ovarian cancer:6.26e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 334.3	Expressed in all		
IL5RA	CD125, CDw125, IL5R	ENSG00000091181	Interleukin 5 receptor subunit alpha	3	3066326-3126613	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 22.7	lung: 4.9	Cell line enriched	28	HMC-1: 66.2
ABCC6	ARA, EST349056, MLP1, MRP6, PXE, URG7	ENSG00000091262	ATP binding cassette subfamily C member 6	16	16148928-16223522	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038105			Supported	Plasma membrane	Liver cancer:3.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 16.9;liver: 23.4	duodenum: 13.0	Cell line enriched	6	Hep G2: 45.5
CMTM6	CKLFSF6, FLJ20396	ENSG00000091317	CKLF like MARVEL transmembrane domain containing 6	3	32481312-32503408	Predicted membrane proteins	Evidence at protein level	HPA026980	Approved					Expressed in all	Expressed in all			fallopian tube: 238.0	Expressed in all		
ITGA6	CD49f	ENSG00000091409	Integrin subunit alpha 6	2	172427354-172506282	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009009, HPA012696, HPA027582	Enhanced				Renal cancer:2.35e-11 (favourable), Head and neck cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 114.9	Cell line enhanced		HaCaT: 319.9;HBEC3-KT: 511.4
RAPGEF4	cAMP-GEFII, CGEF2	ENSG00000091428	Rap guanine nucleotide exchange factor 4	2	172735274-173052893	Predicted intracellular proteins	Evidence at protein level	CAB004388, HPA028968	Approved		Approved	Focal adhesion sites	Pancreatic cancer:1.32e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 53.3;cerebral cortex: 119.2	liver: 18.3	Cell line enhanced		Karpas-707: 15.5;SCLC-21H: 9.8;U-266/70: 8.4;U-266/84: 16.0
MAP3K20	MLK7, MLTK, MLTKalpha, MLTKbeta, MRK, ZAK	ENSG00000091436	Mitogen-activated protein kinase kinase kinase 20	2	173075435-173268010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017205	Approved		Supported	Cytosol	Renal cancer:3.41e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 133.3	Mixed		
SMPX	DFN6, DFNX4	ENSG00000091482	Small muscle protein, X-linked	X	21705972-21758163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA077360			Approved	Plasma membrane	Head and neck cancer:3.04e-5 (unfavourable)	Tissue enhanced	Group enriched	22	heart muscle: 456.2;skeletal muscle: 383.1	esophagus: 19.4	Cell line enhanced		CACO-2: 1.2;Hep G2: 2.7;HSkMC: 3.0;Karpas-707: 2.2;U-266/70: 3.3;U-266/84: 1.2
FH	fumarase	ENSG00000091483	Fumarate hydratase	1	241497603-241519761	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017785, HPA025770, HPA025948, HPA027341	Enhanced	Approved	Enhanced	Mitochondria	Renal cancer:2.76e-7 (favourable)	Expressed in all	Expressed in all			liver: 142.2	Expressed in all		
SEL1L3	KIAA0746	ENSG00000091490	SEL1L family member 3	4	25747427-25863760	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040045, HPA058792	Approved		Enhanced	Nucleus	Urothelial cancer:4.33e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 146.6	Cell line enhanced		Daudi: 205.7
TF	PRO1557, PRO2086	ENSG00000091513	Transferrin	3	133745956-133779006	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001527, HPA005692, CAB009538	Enhanced		Uncertain	Mitochondria	Renal cancer:2.35e-13 (unfavourable), Breast cancer:4.05e-4 (favourable)	Tissue enriched	Tissue enriched	14	liver: 5391.9	cerebral cortex: 385.9	Cell line enriched	50	Hep G2: 842.8
CDV3	H41	ENSG00000091527	CDV3 homolog	3	133573730-133590261	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029761, HPA029762, HPA029763	Enhanced		Enhanced	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:5.21e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 185.6	Expressed in all		
MYO15A	DFNB3, MYO15	ENSG00000091536	Myosin XVA	17	18108706-18179802	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078501	Supported					Not detected	Tissue enhanced		testis: 10.4	ovary: 2.5	Not detected		
ALKBH5	FLJ20308, OFOXD1	ENSG00000091542	AlkB homolog 5, RNA demethylase	17	18183078-18209954	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007196	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:3.75e-4 (favourable), Urothelial cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 109.7	Expressed in all		
APOH	B2G1, BG	ENSG00000091583	Apolipoprotein H	17	66212033-66256525	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001654, HPA003732, CAB022214	Enhanced		Supported	Golgi apparatus	Liver cancer:2.39e-7 (favourable), Renal cancer:1.10e-6 (unfavourable)	Tissue enriched	Tissue enriched	278	liver: 9090.4	kidney: 32.7	Cell line enriched	17	Hep G2: 846.7
NLRP1	CARD7, CLR17.1, DEFCAP, DKFZp586O1822, KIAA0926, NAC, NALP1, SLEV1, VAMAS1	ENSG00000091592	NLR family pyrin domain containing 1	17	5499427-5619424	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009189, HPA064431	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.60e-5 (unfavourable), Pancreatic cancer:7.57e-4 (favourable)	Expressed in all	Mixed			skin: 62.6	Cell line enhanced		HDLM-2: 53.6;Karpas-707: 70.7;U-266/70: 37.1
PITPNM3	ACKR6, CORD5, NIR1, RDGBA3	ENSG00000091622	PITPNM family member 3	17	6451264-6556494	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022432, HPA059005	Enhanced		Approved	Plasma membrane	Head and neck cancer:3.67e-6 (favourable)	Mixed	Tissue enhanced		spleen: 76.8	ovary: 33.7	Cell line enhanced		HaCaT: 15.7;hTCEpi: 36.7
SPAG7	ACRP, FSA-1, MGC20134	ENSG00000091640	Sperm associated antigen 7	17	4959226-4967872	Predicted intracellular proteins	Evidence at protein level	HPA024032, HPA052394	Uncertain		Supported	Nucleus	Renal cancer:5.79e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 102.8	Expressed in all		
ORC6	ORC6L	ENSG00000091651	Origin recognition complex subunit 6	16	46689643-46698394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016330, HPA072587	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Ovarian cancer:1.48e-4 (favourable), Melanoma:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.3	lymph node: 8.8	Expressed in all		
ZFHX4	FLJ20980, ZFH4	ENSG00000091656	Zinc finger homeobox 4	8	76681219-76867285	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023837	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		seminal vesicle: 8.0;testis: 12.1	cerebral cortex: 5.0	Cell line enhanced		TIME: 35.2
SLC17A6	DNPI, VGLUT2	ENSG00000091664	Solute carrier family 17 member 6	11	22338097-22379503	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037130, HPA039226, CAB078204	Enhanced	Supported				Not detected	Tissue enriched	65	cerebral cortex: 6.5	all non-specific tissues: 0.0	Cell line enriched	263	SCLC-21H: 35.7
CPA1	CPA	ENSG00000091704	Carboxypeptidase A1	7	130380339-130388114	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021836, CAB025197, HPA052215	Enhanced					Tissue enriched	Tissue enriched	367	pancreas: 48856.8	ovary: 133.1	Cell line enhanced		AN3-CA: 10.9;SCLC-21H: 2.5;U-2 OS: 1.7
ZC3HC1	NIPA	ENSG00000091732	Zinc finger C3HC-type containing 1	7	130018286-130051451	Predicted intracellular proteins	Evidence at protein level	HPA019089, HPA024023	Enhanced		Supported	Nucleus<br>Nuclear membrane	Liver cancer:1.02e-6 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.5	Expressed in all		
ESR1	Era, ESR, NR3A1	ENSG00000091831	Estrogen receptor 1	6	151656691-152129619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000037, HPA000449, HPA000450, CAB055099, CAB072858	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.47e-7 (favourable)	Group enriched	Group enriched	8	breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5	seminal vesicle: 13.5	Group enriched	11	MCF7: 34.7;T-47d: 53.2
RGS17	RGS-17, RGSZ2	ENSG00000091844	Regulator of G-protein signaling 17	6	153004459-153131249	Predicted intracellular proteins	Evidence at protein level	HPA022276, HPA056493	Approved		Approved	Vesicles		Mixed	Mixed			cerebral cortex: 5.5	Cell line enhanced		hTERT-HME1: 13.2;LHCN-M2: 14.6;U-87 MG: 14.3
ANGPT2	Ang2	ENSG00000091879	Angiopoietin 2	8	6499651-6563409	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB011437, CAB017626	Approved				Renal cancer:1.52e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Cervical cancer:7.99e-5 (unfavourable), Stomach cancer:3.87e-4 (unfavourable), Melanoma:4.48e-4 (unfavourable)	Expressed in all	Mixed			placenta: 19.6	Group enriched	7	HMC-1: 17.8;HSkMC: 34.2;HUVEC TERT2: 62.9;WM-115: 24.3
TMEM101	FLJ23987, MGC4251	ENSG00000091947	Transmembrane protein 101	17	44011188-44023946	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039739			Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 158.8	Mixed		
CD200	MOX1, MOX2, MRC, OX-2	ENSG00000091972	CD200 molecule	3	112332347-112362812	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031149	Approved					Expressed in all	Mixed			cerebral cortex: 78.6	Cell line enhanced		AF22: 74.9;NTERA-2: 47.6;REH: 38.6;WM-115: 82.4
CCDC80	DRO1, SSG1, URB	ENSG00000091986	Coiled-coil domain containing 80	3	112596794-112649530	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002266	Approved				Renal cancer:2.86e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 526.0	Cell line enhanced		fHDF/TERT166: 992.9
CMA1		ENSG00000092009	Chymase 1	14	24505353-24508265	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000363, HPA052634	Enhanced					Mixed	Tissue enhanced		breast: 23.8	esophagus: 11.4	Not detected		
PSME1	IFI5111, PA28alpha	ENSG00000092010	Proteasome activator subunit 1	14	24136158-24138967	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006632	Approved				Breast cancer:8.87e-5 (favourable), Thyroid cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 329.6	Expressed in all		
PPP2R3C	C14orf10, FLJ20644, G4-1, G5PR	ENSG00000092020	Protein phosphatase 2 regulatory subunit B''gamma	14	35085467-35122517	Predicted intracellular proteins	Evidence at protein level	HPA040835, HPA058834	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 98.1	Expressed in all		
HAUS4	C14orf94, FLJ20424	ENSG00000092036	HAUS augmin like complex subunit 4	14	22946228-22957161	Predicted intracellular proteins	Evidence at protein level	HPA029803, HPA071195	Approved		Supported	Plasma membrane<br>Focal adhesion sites	Urothelial cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 61.9	Expressed in all		
JPH4	JPHL1, KIAA1831	ENSG00000092051	Junctophilin 4	14	23568035-23578800	Predicted membrane proteins	Evidence at transcript level	CAB013492			Uncertain	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 107.1;seminal vesicle: 51.9	endometrium: 28.1	Group enriched	7	SCLC-21H: 16.8;SH-SY5Y: 37.5;U-2 OS: 27.7
MYH7	CMD1S, CMH1, MPD1	ENSG00000092054	Myosin heavy chain 7	14	23412738-23435718	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001239, HPA001349, CAB015384	Enhanced					Group enriched	Group enriched	27	heart muscle: 2309.1;skeletal muscle: 5111.1	esophagus: 135.7	Cell line enriched	23	HSkMC: 8.2
CEBPE	CRP1	ENSG00000092067	CCAAT/enhancer binding protein epsilon	14	23117304-23119616	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002928, CAB005113	Enhanced		Enhanced	Nucleoplasm		Not detected	Tissue enriched	9	bone marrow: 26.0	small intestine: 2.7	Cell line enhanced		HL-60: 143.2;HMC-1: 26.7;NB-4: 58.7
SLC7A8	LAT2, LPI-PC1	ENSG00000092068	Solute carrier family 7 member 8	14	23125295-23183674	Predicted membrane proteins, Transporters	Evidence at protein level	CAB046015, HPA051950, HPA060672	Enhanced				Urothelial cancer:1.52e-4 (unfavourable), Liver cancer:1.97e-4 (unfavourable), Lung cancer:3.15e-4 (favourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 1094.9	kidney: 135.4	Cell line enhanced		BEWO: 118.7;K-562: 122.1
OSGEP	GCPL1, KAE1, OSGEP1, PRSMG1	ENSG00000092094	O-sialoglycoprotein endopeptidase	14	20446411-20455105	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039751	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:4.64e-6 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
SLC22A17	BOCT, BOIT, NGALR	ENSG00000092096	Solute carrier family 22 member 17	14	23346306-23352912	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002728	Uncertain				Pancreatic cancer:1.73e-4 (favourable), Stomach cancer:5.95e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 275.0	prostate: 52.6	Cell line enhanced		AN3-CA: 35.6;SH-SY5Y: 46.8
RNF31	FLJ10111, FLJ23501, HOIP, ZIBRA	ENSG00000092098	Ring finger protein 31	14	24146683-24160661	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009063, HPA048745	Approved		Approved	Cytosol		Expressed in all	Expressed in all			skin: 44.4	Expressed in all		
SCFD1	C14orf163, KIAA0917, RA410, SLY1, STXBP1L2	ENSG00000092108	Sec1 family domain containing 1	14	30622112-30735812	Predicted intracellular proteins	Evidence at protein level	HPA003579	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 73.1	Expressed in all		
G2E3	FLJ20333, KIAA1333, PHF7B	ENSG00000092140	G2/M-phase specific E3 ubiquitin protein ligase	14	30559123-30620063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001601	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Tissue enriched	6	testis: 80.4	thyroid gland: 12.9	Mixed		
HECTD1	KIAA1131	ENSG00000092148	HECT domain E3 ubiquitin protein ligase 1	14	31100112-31207804	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002929, HPA054461	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 109.5	Expressed in all		
HNRNPC	hnRNPC, HNRPC	ENSG00000092199	Heterogeneous nuclear ribonucleoprotein C (C1/C2)	14	21209136-21269494	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005223, HPA051075, CAB075755, CAB075756	Supported		Enhanced	Nucleoplasm	Renal cancer:7.29e-5 (unfavourable), Liver cancer:7.72e-5 (unfavourable), Ovarian cancer:1.19e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 568.9	Expressed in all		
RPGRIP1	CORD13, LCA6, RGI1, RPGRIP	ENSG00000092200	Retinitis pigmentosa GTPase regulator interacting protein 1	14	21287939-21351301	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042955, HPA060190	Enhanced					Tissue enhanced	Tissue enriched	48	testis: 105.9	spleen: 2.1	Cell line enhanced		RT4: 3.1
SUPT16H	CDC68, FACT, FACTP140, FLJ10857, FLJ14010, SPT16/CDC68	ENSG00000092201	SPT16 homolog, facilitates chromatin remodeling subunit	14	21351472-21384266	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022551, HPA049787	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 95.7	Expressed in all		
TOX4	C14orf92, KIAA0737, LCP1	ENSG00000092203	TOX high mobility group box family member 4	14	21476597-21499175	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017880, HPA027551	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:8.38e-5 (favourable), Liver cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.4	Expressed in all		
GEMIN2	SIP1	ENSG00000092208	Gem nuclear organelle associated protein 2	14	39114223-39136973	Predicted intracellular proteins	Evidence at protein level	CAB015426, HPA046570, HPA057114	Enhanced		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies	Liver cancer:3.88e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 17.1	Expressed in all		
TGM1	ICR2, LI, LI1, TGASE, TGK	ENSG00000092295	Transglutaminase 1	14	24249114-24264432	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015159, HPA040171	Enhanced					Tissue enhanced	Tissue enriched	12	esophagus: 831.8	tonsil: 72.2	Cell line enhanced		BEWO: 33.0;HaCaT: 42.3;MCF7: 27.0;SK-BR-3: 31.6
TINF2	TIN2	ENSG00000092330	TERF1 interacting nuclear factor 2	14	24239643-24242674	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059061, HPA069807			Enhanced	Nuclear bodies	Breast cancer:4.96e-4 (favourable)	Expressed in all	Tissue enriched	24	parathyroid gland: 1349.0	smooth muscle: 56.5	Expressed in all		
DAZL	DAZH, DAZL1, DAZLA, MGC26406, SPGYLA	ENSG00000092345	Deleted in azoospermia like	3	16586792-16670306	Predicted intracellular proteins	Evidence at protein level	HPA019593, HPA019777, HPA047113	Enhanced					Tissue enriched	Tissue enriched	153	testis: 141.6	tonsil: 0.9	Cell line enriched	9	HAP1: 20.2
TBL1Y	TBL1	ENSG00000092377	Transducin beta like 1, Y-linked	Y	6910686-7091683	Predicted intracellular proteins	Evidence at protein level	HPA060073	Uncertain					Tissue enriched	Tissue enhanced		prostate: 2.6;thyroid gland: 1.4	testis: 0.5	Cell line enhanced		BEWO: 1.5;NTERA-2: 1.3;RT4: 1.2;SCLC-21H: 1.1;U-698: 6.6
SEMA6A	HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ	ENSG00000092421	Semaphorin 6A	5	116443616-116574934	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031265, HPA031267	Approved		Supported	Nucleus<br>Intermediate filaments	Liver cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 49.1	Cell line enhanced		AF22: 36.5;AN3-CA: 41.0;BEWO: 36.9;HAP1: 53.6;NTERA-2: 115.0
TRPM7	CHAK1, LTRPC7, TRP-PLIK	ENSG00000092439	Transient receptor potential cation channel subfamily M member 7	15	50552473-50686815	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA052173	Enhanced		Approved	Nucleoplasm		Expressed in all	Tissue enriched	7	parathyroid gland: 216.4	thyroid gland: 29.0	Expressed in all		
TYRO3	Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif	ENSG00000092445	TYRO3 protein tyrosine kinase	15	41557675-41583586	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071245	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 67.4;ovary: 61.6	testis: 37.0	Cell line enhanced		BEWO: 66.6
WDR76	FLJ12973	ENSG00000092470	WD repeat domain 76	15	43826963-43868419	Predicted intracellular proteins	Evidence at protein level	HPA039804, HPA040626	Uncertain		Approved	Nucleoli fibrillar center<br>Nuclear bodies	Renal cancer:1.35e-8 (unfavourable), Lung cancer:8.02e-5 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable), Liver cancer:6.98e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 23.7	Expressed in all		
CAPN3	CANP3, LGMD2, LGMD2A, nCL-1, p94	ENSG00000092529	Calpain 3	15	42359500-42412318	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040052	Enhanced					Tissue enriched	Tissue enhanced		epididymis: 217.3;skeletal muscle: 336.8	skin: 92.9	Cell line enriched	27	SK-MEL-30: 202.7
SNAP23	HsT17016, SNAP23A, SNAP23B	ENSG00000092531	Synaptosome associated protein 23	15	42491233-42545356	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001214, CAB037083, CAB037317	Approved		Supported	Plasma membrane		Expressed in all	Expressed in all			spleen: 86.7	Expressed in all		
TBX15	TBX14	ENSG00000092607	T-box 15	1	118883046-118989556	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052245, HPA053713	Uncertain		Approved	Nucleoplasm<br>Centrosome	Renal cancer:5.57e-8 (unfavourable)	Mixed	Group enriched	7	adipose tissue: 17.0;breast: 8.9;liver: 24.1;skeletal muscle: 42.2	lymph node: 3.1	Cell line enhanced		ASC diff: 36.8;BJ hTERT+ SV40 Large T+ RasG12V: 20.9;fHDF/TERT166: 22.5;HSkMC: 28.3;RH-30: 29.4;U-2197: 26.3
PHGDH	PDG, PGDH, SERA	ENSG00000092621	Phosphoglycerate dehydrogenase	1	119659798-119744215	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003681, HPA021241, HPA024031, CAB068216	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:1.48e-4 (unfavourable), Glioma:2.26e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 216.7	skin: 115.9	Mixed		
COL9A3	DJ885L7.4.1, EDM3, FLJ90759, IDD, MED	ENSG00000092758	Collagen type IX alpha 3 chain	20	62816244-62841159	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040125, HPA058323	Supported		Approved	Nucleoplasm<br>Intermediate filaments		Mixed	Group enriched	6	cerebral cortex: 7.5;salivary gland: 10.5;testis: 6.3;thyroid gland: 19.1	seminal vesicle: 1.8	Group enriched	6	BEWO: 139.2;Hep G2: 40.1;SK-MEL-30: 37.9;WM-115: 57.3
EZR	VIL2	ENSG00000092820	Ezrin	6	158765741-158819412	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004035, HPA021616, CAB047324, CAB075739	Enhanced		Enhanced	Plasma membrane	Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 537.0	Expressed in all		
MYL6	ESMLC, MLC1SM, MLC3NM	ENSG00000092841	Myosin light chain 6	12	56158161-56163496	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046859, HPA063034	Approved					Expressed in all	Expressed in all			smooth muscle: 5966.7	Expressed in all		
AGO1	EIF2C1, hAGO1	ENSG00000092847	Argonaute 1, RISC catalytic component	1	35869808-35930528	Predicted intracellular proteins	Evidence at protein level						Liver cancer:4.57e-5 (unfavourable), Renal cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.0	Expressed in all		
TEKT2	TEKTB1	ENSG00000092850	Tektin 2	1	36084075-36088275	Predicted intracellular proteins	Evidence at protein level	HPA027248, HPA027461	Approved		Uncertain	Microtubules	Renal cancer:1.98e-4 (favourable)	Tissue enhanced	Group enriched	9	fallopian tube: 97.8;testis: 63.3	lung: 8.8	Cell line enriched	5	NB-4: 23.2
CLSPN		ENSG00000092853	Claspin	1	35720218-35769967	Predicted intracellular proteins	Evidence at protein level	HPA026305, HPA026312			Enhanced	Nucleoplasm<br>Golgi apparatus	Stomach cancer:4.92e-4 (favourable)	Mixed	Tissue enhanced		testis: 10.6	bone marrow: 7.0	Mixed		
RFFL	CARP-2, CARP2, fring, rififylin, RNF189, RNF34L	ENSG00000092871	Ring finger and FYVE like domain containing E3 ubiquitin protein ligase	17	35005990-35089319	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008096, HPA017910, HPA019492	Approved		Approved	Vesicles	Renal cancer:2.43e-5 (unfavourable), Colorectal cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.1	Expressed in all		
UNC13D	Munc13-4	ENSG00000092929	Unc-13 homolog D	17	75827225-75844717	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067117, HPA073525	Enhanced		Supported	Vesicles<br>Cytosol	Renal cancer:5.28e-12 (unfavourable), Endometrial cancer:3.62e-4 (unfavourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Mixed			spleen: 38.6	Cell line enhanced		HEL: 219.6;HMC-1: 213.8;SK-BR-3: 125.9
MFSD11	FLJ20226, FLJ22196	ENSG00000092931	Major facilitator superfamily domain containing 11	17	76735865-76781449	Predicted membrane proteins	Evidence at protein level	HPA022001	Uncertain		Approved	Nuclear speckles	Endometrial cancer:7.69e-4 (unfavourable), Urothelial cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
DPYSL2	CRMP2, DHPRP2, DRP-2, DRP2	ENSG00000092964	Dihydropyrimidinase like 2	8	26514022-26658178	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002381, CAB018719	Supported		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:5.41e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 379.1	Mixed		
TGFB2		ENSG00000092969	Transforming growth factor beta 2	1	218346235-218444619	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		prostate: 30.4	placenta: 20.4	Cell line enhanced		EFO-21: 58.6;U-2 OS: 64.1
GPATCH2	CT110, FLJ10252, GPATC2, PPP1R30	ENSG00000092978	G-patch domain containing 2	1	217426992-217631082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027181, HPA027322	Uncertain		Supported	Nuclear speckles	Renal cancer:9.99e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Mixed		
NUP50	NPAP60L	ENSG00000093000	Nucleoporin 50	22	45163841-45188015	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047162, HPA048328	Enhanced		Enhanced	Nucleoplasm<br>Nuclear membrane	Stomach cancer:4.06e-4 (favourable)	Expressed in all	Expressed in all			testis: 54.6	Expressed in all		
CDC45	CDC45L, CDC45L2	ENSG00000093009	Cell division cycle 45	22	19479459-19520612	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000614, CAB009459	Enhanced		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:6.95e-6 (unfavourable), Pancreatic cancer:8.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 37.5	bone marrow: 15.3	Expressed in all		
COMT		ENSG00000093010	Catechol-O-methyltransferase	22	19941607-19969975	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001169, CAB011233	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 172.6	Expressed in all		
CECR1	ADGF, IDGFL	ENSG00000093072	Cat eye syndrome chromosome region, candidate 1	22	17178790-17221989	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007888	Approved				Pancreatic cancer:8.91e-4 (favourable), Ovarian cancer:9.26e-4 (favourable)	Expressed in all	Expressed in all			spleen: 161.4	Cell line enhanced		CAPAN-2: 22.2;Karpas-707: 30.5;MOLT-4: 33.3;U-937: 32.1
VNN3	HSA238982	ENSG00000093134	Vanin 3	6	132722787-132734765	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		bone marrow: 35.3;liver: 15.2	spleen: 9.5	Not detected		
ECHDC1	dJ351K20.2	ENSG00000093144	Ethylmalonyl-CoA decarboxylase 1	6	127288710-127343609	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035445, HPA035446	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			adipose tissue: 98.5	Mixed		
LRRFIP2	HUFI-2	ENSG00000093167	LRR binding FLII interacting protein 2	3	37052656-37183689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035956, HPA042023	Uncertain		Approved	Plasma membrane<br>Actin filaments	Cervical cancer:6.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 130.8	Expressed in all		
SEC22C	MGC13261, MGC5373, SEC22L3	ENSG00000093183	SEC22 homolog C, vesicle trafficking protein	3	42547969-42601080	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055594			Approved	Golgi apparatus	Renal cancer:1.35e-7 (favourable), Liver cancer:3.04e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 63.7	Expressed in all		
XYLB	FLJ10343, FLJ12539	ENSG00000093217	Xylulokinase	3	38346760-38421348	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037863, HPA038415	Uncertain		Approved	Nuclear speckles	Renal cancer:8.57e-4 (favourable)	Mixed	Tissue enhanced		liver: 15.2	kidney: 9.9	Mixed		
HDAC6	FLJ16239, HD6, JM21, KIAA0901, PPP1R90	ENSG00000094631	Histone deacetylase 6	X	48801377-48824982	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003714, CAB004236, HPA026321	Approved		Supported	Nucleoplasm	Urothelial cancer:3.34e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.4	Expressed in all		
OR1I1	OR19-20, OR1I1P, OR1I1Q	ENSG00000094661	Olfactory receptor family 1 subfamily I member 1	19	15086980-15088221	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GABRP		ENSG00000094755	Gamma-aminobutyric acid type A receptor pi subunit	5	170763350-170814047	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB014883	Uncertain				Cervical cancer:3.37e-4 (favourable)	Mixed	Expressed in all			breast: 177.0	Cell line enhanced		A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
KRT31	Ha-1, KRTHA1	ENSG00000094796	Keratin 31	17	41393724-41397592	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049550, HPA055194	Supported					Group enriched	Group enriched	6	esophagus: 4.6;skin: 14.4	skeletal muscle: 1.5	Not detected		
CDC6	CDC18L	ENSG00000094804	Cell division cycle 6	17	40287633-40304657	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050114, HPA065070	Approved		Supported	Nucleus<br>Cytokinetic bridge<br>Mitotic spindle<br>Cytosol	Liver cancer:5.96e-8 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)	Expressed in all	Mixed			appendix: 15.4	Expressed in all		
UPRT	DKFZp781E1243, FUR1, MGC23937, RP11-311P8.3	ENSG00000094841	Uracil phosphoribosyltransferase homolog	X	75274085-75304600	Predicted intracellular proteins	Evidence at protein level	HPA000805	Uncertain		Approved	Vesicles	Renal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Mixed		
CDC23	ANAPC8, APC8, CUT23	ENSG00000094880	Cell division cycle 23	5	138187648-138213343	Predicted secreted proteins	Evidence at protein level	HPA039593	Approved				Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 37.3	Expressed in all		
AAAS		ENSG00000094914	Aladin WD repeat nucleoporin	12	53307456-53324864	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040086	Approved		Approved	Nuclear membrane<br>Centrosome<br>Cytosol	Renal cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
CBX5	HP1, HP1-ALPHA, HP1Hs-alpha	ENSG00000094916	Chromobox 5	12	54230940-54280133	Predicted intracellular proteins	Evidence at protein level	HPA016699, CAB017548	Enhanced		Enhanced	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
FMO2		ENSG00000094963	Flavin containing monooxygenase 2	1	171185208-171211230	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA028261	Approved					Mixed	Tissue enhanced		adipose tissue: 98.3;esophagus: 102.9;lung: 158.2	breast: 55.8	Group enriched	48	ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
SUCO	C1orf9, CH1, OPT, SLP1	ENSG00000094975	SUN domain containing ossification factor	1	172532349-172611833	Predicted membrane proteins	Evidence at protein level	HPA047251	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 75.9	Expressed in all		
MSH2	COCA1, HNPCC, HNPCC1	ENSG00000095002	MutS homolog 2	2	47402969-47562311	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009572, HPA066845, CAB070867	Supported		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
MAP3K1	MAPKKK1, MEKK, MEKK1	ENSG00000095015	Mitogen-activated protein kinase kinase kinase 1	5	56815574-56896152	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004500, HPA046509	Approved		Approved	Cytosol		Expressed in all	Mixed			spleen: 28.3	Cell line enhanced		SH-SY5Y: 55.9
DHPS	MIG13	ENSG00000095059	Deoxyhypusine synthase	19	12675717-12681902	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014461, HPA029413	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 64.5	Expressed in all		
HOOK2	HK2	ENSG00000095066	Hook microtubule tethering protein 2	19	12763003-12872740	Predicted intracellular proteins	Evidence at protein level	HPA043519, HPA050351	Approved		Supported	Vesicles<br>Cytosol	Prostate cancer:7.59e-5 (unfavourable), Renal cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 96.0	Expressed in all		
NXPE1	FAM55A, MGC34290	ENSG00000095110	Neurexophilin and PC-esterase domain family member 1	11	114521715-114559895	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049133	Enhanced					Tissue enriched	Group enriched	13	colon: 111.8;rectum: 165.9	appendix: 10.5	Not detected		
ARCN1	COPD	ENSG00000095139	Archain 1	11	118572390-118603033	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037573, HPA044874	Approved		Enhanced	Golgi apparatus<br>Vesicles	Liver cancer:2.97e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 144.4	Expressed in all		
EPB41L4B	EHM2	ENSG00000095203	Erythrocyte membrane protein band 4.1 like 4B	9	109171975-109320964	Predicted intracellular proteins	Evidence at protein level	HPA042862	Approved		Approved	Plasma membrane<br>Cytosol	Breast cancer:1.02e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 74.8	Cell line enhanced		BEWO: 30.5;hTCEpi: 36.0
TMEM38B	bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B	ENSG00000095209	Transmembrane protein 38B	9	105694544-105776612	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018465	Uncertain				Renal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
PSMD5	KIAA0072, S5B	ENSG00000095261	Proteasome 26S subunit, non-ATPase 5	9	120815496-120842984	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003216	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			prostate: 28.7	Mixed		
PTGS1	COX1, PGHS-1, PTGHS	ENSG00000095303	Prostaglandin-endoperoxide synthase 1	9	122370530-122395703	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002834, CAB020315	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 161.6	fallopian tube: 86.1	Cell line enhanced		ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
NUP188	KIAA0169	ENSG00000095319	Nucleoporin 188	9	128947699-129007096	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA061750, HPA063942	Approved		Supported	Nucleus	Endometrial cancer:5.20e-5 (favourable)	Expressed in all	Expressed in all			testis: 104.6	Expressed in all		
CRAT	CAT1	ENSG00000095321	Carnitine O-acetyltransferase	9	129094810-129111189	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019230, HPA020260, HPA022815	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:0.00e+0 (favourable), Endometrial cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Mixed		
SH2D3C	NSP3	ENSG00000095370	SH2 domain containing 3C	9	127738317-127778741	Predicted intracellular proteins	Evidence at protein level	HPA047586	Enhanced				Head and neck cancer:1.98e-4 (favourable), Endometrial cancer:9.47e-4 (favourable)	Expressed in all	Mixed			spleen: 49.7	Cell line enhanced		HMC-1: 47.3;HUVEC TERT2: 50.2;REH: 55.2;RPMI-8226: 32.1;TIME: 40.8
NANS	SAS	ENSG00000095380	N-acetylneuraminate synthase	9	98056739-98083075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019223	Approved		Approved	Nucleoplasm	Endometrial cancer:1.71e-4 (favourable), Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.2	Expressed in all		
TBC1D2	Armus, PARIS1, TBC1D2A	ENSG00000095383	TBC1 domain family member 2	9	98198999-98255721	Predicted intracellular proteins	Evidence at protein level	HPA030871	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:2.77e-4 (unfavourable), Testis cancer:5.62e-4 (unfavourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HaCaT: 86.0
WHRN	CIP98, DFNB31, PDZD7B, USH2D	ENSG00000095397	Whirlin	9	114402080-114505450	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002480, CAB033194	Uncertain				Pancreatic cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 73.0	testis: 44.4	Cell line enhanced		Karpas-707: 96.9;U-266/70: 64.0;U-266/84: 64.8
PDE6C	ACHM5, COD4, PDEA2	ENSG00000095464	Phosphodiesterase 6C	10	93612588-93666010	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin: 0.6	Not detected		
CWF19L1	FLJ10998, hDrn1	ENSG00000095485	CWF19-like 1, cell cycle control (S. pombe)	10	100232298-100267680	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036889, HPA036890	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:6.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.9	Expressed in all		
SEMA4G	FLJ20590, KIAA1619	ENSG00000095539	Semaphorin 4G	10	100969518-100985871	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038362, HPA077752	Uncertain		Uncertain	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		rectum: 92.7	duodenum: 53.8	Cell line enhanced		A549: 28.9;CACO-2: 25.3;Hep G2: 76.9
BTAF1	MOT1, TAF-172, TAF(II)170, TAF172, TAFII170	ENSG00000095564	B-TFIID TATA-box binding protein associated factor 1	10	91923769-92030325	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070682			Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.04e-5 (unfavourable), Head and neck cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			skin: 59.8	Expressed in all		
IKZF5	FLJ22973, Pegasus, ZNFN1A5	ENSG00000095574	IKAROS family zinc finger 5	10	122990806-123008817	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015297, HPA051574			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 21.3	Expressed in all		
BLNK	BASH, bca, BLNK-s, Ly57, SLP-65, SLP65	ENSG00000095585	B-cell linker	10	96191702-96271587	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009333, CAB016291, HPA038309, HPA038310	Enhanced		Supported	Plasma membrane<br>Cytoplasmic bodies	Urothelial cancer:2.67e-6 (favourable)	Expressed in all	Mixed			spleen: 69.1	Group enriched	5	Daudi: 49.2;REH: 152.1;RPMI-8226: 63.9;U-698: 171.5
TLL2		ENSG00000095587	Tolloid like 2	10	96364606-96513918	Enzymes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 1.9	heart muscle: 1.0	Cell line enriched	8	RPTEC TERT1: 15.3
CYP26A1	CP26, CYP26, P450RAI, P450RAI1	ENSG00000095596	Cytochrome P450 family 26 subfamily A member 1	10	93073475-93077890	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	liver: 9.7	cerebral cortex: 1.0	Cell line enriched	8	AF22: 60.5
TDRD1	CT41.1	ENSG00000095627	Tudor domain containing 1	10	114179270-114232304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037729	Enhanced					Tissue enhanced	Tissue enriched	13	testis: 32.0	kidney: 2.3	Cell line enhanced		MCF7: 6.3;RH-30: 10.6;SK-BR-3: 38.6;U-266/84: 8.6
SORBS1	CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12	ENSG00000095637	Sorbin and SH3 domain containing 1	10	95311771-95561414	Predicted intracellular proteins	Evidence at protein level	HPA027559, HPA043084	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Centrosome	Breast cancer:2.84e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 320.1	Cell line enhanced		CACO-2: 21.9;HMC-1: 39.4;SK-MEL-30: 30.9
CRTAC1	ASPIC1, CEP-68, FLJ10320	ENSG00000095713	Cartilage acidic protein 1	10	97865000-98030828	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008175	Enhanced				Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1	urinary bladder: 12.8	Cell line enhanced		HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0
BAMBI	NMA	ENSG00000095739	BMP and activin membrane bound inhibitor	10	28677342-28682939	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010819, HPA010866	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Lipid droplets	Liver cancer:9.42e-6 (unfavourable), Renal cancer:5.25e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 87.8	adrenal gland: 50.0	Cell line enhanced		CACO-2: 120.2;SK-MEL-30: 134.8
IL11	AGIF, IL-11	ENSG00000095752	Interleukin 11	19	55364389-55370463	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044955			Uncertain	Mitochondria	Pancreatic cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 5.7;endometrium: 5.2;gallbladder: 4.9	placenta: 1.7	Cell line enhanced		BJ: 50.3;BJ hTERT+: 54.5;hTEC/SVTERT24-B: 54.2;U-251 MG: 179.7
MYO3A	DFNB30	ENSG00000095777	Myosin IIIA	10	25934267-26212527	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048951, HPA051893	Approved		Supported	Plasma membrane<br>Actin filaments<br>Cytoplasmic bodies		Mixed	Tissue enriched	9	testis: 6.8	skin: 0.8	Cell line enhanced		CAPAN-2: 2.0;HEK 293: 2.2;SCLC-21H: 2.3;U-2 OS: 3.7;U-698: 8.6
WAC	BM-016, FLJ31290, MGC10753, PRO1741, Wwp4	ENSG00000095787	WW domain containing adaptor with coiled-coil	10	28532493-28623112	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036528, HPA042609	Approved		Supported	Nucleoplasm	Liver cancer:9.27e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 132.1	Expressed in all		
CREM	hCREM-2	ENSG00000095794	CAMP responsive element modulator	10	35126791-35212958	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001818, CAB018352	Enhanced		Supported	Nucleus<br>Vesicles	Renal cancer:1.23e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 339.8	Expressed in all		
NUBP2	CFD1	ENSG00000095906	Nucleotide binding protein 2	16	1782901-1789191	Predicted intracellular proteins	Evidence at protein level	HPA041704	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:9.63e-5 (favourable)	Expressed in all	Expressed in all			spleen: 17.4	Expressed in all		
TPSD1		ENSG00000095917	Tryptase delta 1	16	1256059-1258998	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB002215, CAB032871, HPA040182, HPA049554	Supported		Uncertain	Nuclear speckles		Mixed	Tissue enhanced		lung: 26.9	gallbladder: 20.3	Group enriched	46	HEL: 25.4;HMC-1: 36.4
SMIM24	C19orf77, HSPC323	ENSG00000095932	Small integral membrane protein 24	19	3473986-3480542	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045046, HPA056027	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.13e-10 (favourable)	Tissue enhanced	Group enriched	8	duodenum: 758.8;epididymis: 1928.7;kidney: 835.9;small intestine: 682.3	stomach: 140.0	Group enriched	8	CACO-2: 128.5;HEL: 66.3;Hep G2: 79.7;MOLT-4: 90.8;REH: 56.0;U-937: 68.2
HIVEP1	CIRIP, CRYBP1, MBP-1, PRDII-BF1, Schnurri-1, ZAS1, ZNF40, ZNF40A	ENSG00000095951	Human immunodeficiency virus type I enhancer binding protein 1	6	12008762-12164999	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050724	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 25.7	Expressed in all		
TREM2	TREM-2, Trem2a, Trem2b, Trem2c	ENSG00000095970	Triggering receptor expressed on myeloid cells 2	6	41158506-41163186	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010917, HPA012571	Approved				Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.0;lung: 40.5	adrenal gland: 16.1	Cell line enhanced		HBEC3-KT: 9.0;hTCEpi: 49.6;THP-1: 26.6
KCNK16	K2p16.1, TALK-1, TALK1	ENSG00000095981	Potassium two pore domain channel subfamily K member 16	6	39314698-39322968	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enriched	Tissue enhanced		duodenum: 3.8;pancreas: 5.4;stomach: 12.4	thyroid gland: 1.7	Cell line enriched	511	SCLC-21H: 157.3
CRISP3	Aeg2, CRISP-3, CRS3, dJ442L6.3, SGP28	ENSG00000096006	Cysteine rich secretory protein 3	6	49727384-49744437	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054392	Supported					Group enriched	Tissue enhanced		fallopian tube: 1885.2;salivary gland: 915.8	esophagus: 288.4	Group enriched	59	HEL: 11.2;RT4: 3.3;SK-BR-3: 6.9;T-47d: 4.2
FKBP5	FKBP51, FKBP54, P54, PPIase, Ptg-10	ENSG00000096060	FK506 binding protein 5	6	35573585-35728583	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009315, HPA031092, HPA031093, HPA031095	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			adipose tissue: 415.3	Cell line enhanced		ASC diff: 517.9;HHSteC: 495.2;HSkMC: 518.9
SRPK1	SFRSK1	ENSG00000096063	SRSF protein kinase 1	6	35832966-35921342	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016431, HPA056486	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Liver cancer:7.90e-6 (unfavourable), Pancreatic cancer:6.53e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.0	Expressed in all		
BRPF3	KIAA1286	ENSG00000096070	Bromodomain and PHD finger containing 3	6	36196744-36232790	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022787	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
MRPS18A	FLJ10548, MRPS18-3	ENSG00000096080	Mitochondrial ribosomal protein S18A	6	43671303-43687791	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA035450, HPA035451	Approved				Thyroid cancer:4.03e-5 (favourable)	Expressed in all	Expressed in all			prostate: 58.1	Expressed in all		
PGC		ENSG00000096088	Progastricsin	6	41736711-41754109	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031717, HPA031718	Enhanced		Supported	Nucleus		Tissue enhanced	Tissue enriched	17	stomach: 22276.5	duodenum: 1302.2	Cell line enriched	11	Hep G2: 171.0
TMEM14A	C6orf73, PTD011	ENSG00000096092	Transmembrane protein 14A	6	52671109-52686588	Predicted membrane proteins	Evidence at protein level	HPA072536	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
EFHC1	EJM, EJM1, FLJ10466	ENSG00000096093	EF-hand domain containing 1	6	52362123-52529886	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035307	Approved		Uncertain	Plasma membrane<br>Cytosol	Pancreatic cancer:2.33e-4 (favourable), Renal cancer:3.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 55.6	testis: 31.3	Cell line enhanced		SCLC-21H: 22.6
NCR2	CD336, LY95, NK-p44	ENSG00000096264	Natural cytotoxicity triggering receptor 2	6	41335655-41350887	CD markers, Predicted membrane proteins	Evidence at protein level	HPA067249	Uncertain					Not detected	Not detected			duodenum: 0.5	Not detected		
HSP90AB1	HSPC2, HSPCB	ENSG00000096384	Heat shock protein 90 alpha family class B member 1	6	44246166-44253888	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005230, HPA055729, HPA072606, HPA074351	Enhanced		Supported	Cytosol	Ovarian cancer:4.03e-4 (favourable), Renal cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1461.8	Expressed in all		
MLN		ENSG00000096395	Motilin	6	33794673-33804011	Predicted secreted proteins	Evidence at protein level	HPA069392	Enhanced					Tissue enriched	Tissue enriched	6	duodenum: 253.3	small intestine: 42.3	Cell line enhanced		CACO-2: 2.4;TIME: 1.1
CDC5L	CDC5, CEF1, hCDC5, PCDC5RP	ENSG00000096401	Cell division cycle 5 like	6	44387525-44450426	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006302, HPA011361, CAB012275	Supported		Supported	Nucleoplasm	Melanoma:7.02e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.0	Expressed in all		
ITPR3	IP3R3	ENSG00000096433	Inositol 1,4,5-trisphosphate receptor type 3	6	33620365-33696574	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003915, HPA064704	Approved		Uncertain	Vesicles		Expressed in all	Mixed			skin: 65.1	Mixed		
ZNF184		ENSG00000096654	Zinc finger protein 184	6	27450743-27473118	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003226, HPA064793	Uncertain		Supported	Nucleus	Ovarian cancer:4.41e-5 (favourable)	Expressed in all	Mixed			testis: 15.2	Expressed in all		
DSP	DPI, DPII, KPPS2, PPKS2	ENSG00000096696	Desmoplakin	6	7541575-7586717	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037324, HPA045840, HPA054950	Enhanced		Enhanced	Cell Junctions	Renal cancer:1.53e-9 (favourable), Urothelial cancer:1.82e-4 (unfavourable)	Tissue enhanced	Group enriched	8	esophagus: 345.7;skin: 1016.4	placenta: 89.1	Cell line enhanced		BEWO: 263.2;HaCaT: 265.1;hTCEpi: 482.9
SIRT1	SIR2L1	ENSG00000096717	Sirtuin 1	10	67884669-67918390	Predicted intracellular proteins	Evidence at protein level	CAB003855, HPA006295, HPA052351	Approved		Enhanced	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			testis: 49.0	Expressed in all		
HNRNPH3	2H9, HNRPH3	ENSG00000096746	Heterogeneous nuclear ribonucleoprotein H3	10	68331174-68343191	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038264			Supported	Nucleoplasm	Liver cancer:2.30e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 154.2	Expressed in all		
IFT74	CCDC2, CMG-1, CMG1, FLJ22621	ENSG00000096872	Intraflagellar transport 74	9	26947039-27062930	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020247, HPA026684	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			testis: 84.2	Mixed		
JAK2	JTK10	ENSG00000096968	Janus kinase 2	9	4984390-5128183	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013089, HPA040820, HPA043870	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Mixed			appendix: 28.1	Group enriched	6	ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
IL12RB1	CD212, IL12RB	ENSG00000096996	Interleukin 12 receptor subunit beta 1	19	18058995-18098944	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074414			Approved	Plasma membrane	Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 25.9	spleen: 20.6	Cell line enhanced		Daudi: 13.1;HDLM-2: 28.9;Karpas-707: 36.8
ABL1	ABL, c-ABL, JTK7, p150	ENSG00000097007	ABL proto-oncogene 1, non-receptor tyrosine kinase	9	130713946-130887675	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002686, HPA027251, HPA027280, HPA028409	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 83.9	Expressed in all		
ACOT7	ACH1, ACT, BACH, CTE-II, hBACH, LACH1, MGC1126	ENSG00000097021	Acyl-CoA thioesterase 7	1	6264269-6394391	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025735, HPA025762	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.55e-6 (unfavourable), Liver cancer:2.31e-5 (unfavourable), Lung cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 129.2	small intestine: 62.3	Expressed in all		
SH3GLB1	Bif-1, CGI-61, KIAA0491, PPP1R70	ENSG00000097033	SH3 domain containing GRB2 like endophilin B1	1	86704570-86748184	Predicted intracellular proteins	Evidence at protein level	CAB004650, HPA015608, HPA019900	Enhanced		Enhanced	Cytosol	Liver cancer:2.90e-5 (unfavourable), Pancreatic cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 198.5	Expressed in all		
CDC7	CDC7L1, HsCdc7, Hsk1, huCdc7	ENSG00000097046	Cell division cycle 7	1	91500893-91525764	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002669, HPA035831	Enhanced		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:1.89e-15 (unfavourable), Liver cancer:3.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 32.0	spleen: 17.2	Expressed in all		
SYDE2	FLJ13815	ENSG00000097096	Synapse defective Rho GTPase homolog 2	1	85156873-85201046	Predicted intracellular proteins	Evidence at protein level	HPA027138, HPA058378	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Mixed			parathyroid gland: 7.0	Cell line enhanced		BEWO: 13.9
PCSK5	PC5, PC6, SPC6	ENSG00000099139	Proprotein convertase subtilisin/kexin type 5	9	75890644-76362339	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031072	Enhanced		Supported	Golgi apparatus	Renal cancer:9.61e-5 (unfavourable)	Mixed	Mixed			small intestine: 28.1	Cell line enhanced		BEWO: 31.5;HaCaT: 41.2;RPTEC TERT1: 32.1;U-2 OS: 68.5
SCD	FADS5, SCDOS	ENSG00000099194	Stearoyl-CoA desaturase	10	100347124-100364834	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012107, HPA063921	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:7.56e-5 (unfavourable), Urothelial cancer:7.79e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1255.0	Expressed in all		
TMED1	Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L	ENSG00000099203	Transmembrane p24 trafficking protein 1	19	10832438-10836318	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018507	Uncertain				Renal cancer:8.66e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.6	Expressed in all		
ABLIM1	ABLIM, LIMAB1, limatin	ENSG00000099204	Actin binding LIM protein 1	10	114431113-114685003	Predicted intracellular proteins	Evidence at protein level	HPA038951, HPA038952	Approved		Supported	Cytosol	Renal cancer:2.72e-5 (favourable)	Expressed in all	Expressed in all			ovary: 284.7	Mixed		
ERMP1	FLJ23309, FXNA, KIAA1815	ENSG00000099219	Endoplasmic reticulum metallopeptidase 1	9	5765076-5833117	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA020584	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.83e-10 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 124.7	thyroid gland: 44.0	Cell line enhanced		RT4: 122.7
RAB18		ENSG00000099246	RAB18, member RAS oncogene family	10	27504174-27542237	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025928	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 87.9	Expressed in all		
NRP1	CD304, NRP, VEGF165R	ENSG00000099250	Neuropilin 1	10	33177492-33336262	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004511, HPA030278	Approved		Uncertain	Mitochondria	Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 194.1	Cell line enhanced		U-87 MG: 437.4
PRTFDC1	HHGP	ENSG00000099256	Phosphoribosyl transferase domain containing 1	10	24848607-24952604	Predicted intracellular proteins	Evidence at protein level	HPA021458	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:9.27e-5 (unfavourable), Endometrial cancer:2.66e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 47.5	Cell line enhanced		CACO-2: 62.8;CAPAN-2: 82.9
PALMD	C1orf11, FLJ20271, PALML	ENSG00000099260	Palmdelphin	1	99645943-99694541	Predicted intracellular proteins	Evidence at protein level	HPA017959, HPA030549	Supported		Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Head and neck cancer:5.90e-5 (favourable), Endometrial cancer:9.42e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 141.1	placenta: 60.5	Cell line enhanced		HUVEC TERT2: 126.3;TIME: 174.6;U-87 MG: 88.7
TSPAN15	NET-7, TM4SF15	ENSG00000099282	Tetraspanin 15	10	69451473-69507669	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044657	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.25e-4 (unfavourable), Liver cancer:8.00e-4 (unfavourable)	Expressed in all	Mixed			stomach: 72.3	Cell line enhanced		CAPAN-2: 136.3;EFO-21: 199.5;MCF7: 128.3;PC-3: 248.2
H2AFY2	macroH2A2	ENSG00000099284	H2A histone family member Y2	10	70052796-70112280	Predicted intracellular proteins	Evidence at protein level	HPA035865, HPA041189	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 31.3	Cell line enhanced		AF22: 166.7;SCLC-21H: 146.5;SH-SY5Y: 128.2
WASHC2A	bA56A21.1, bA98I6.1, FAM21A, FAM21B, FLJ10824	ENSG00000099290	WASH complex subunit 2A	10	50067888-50133506	Predicted intracellular proteins	Evidence at protein level	HPA047844, HPA060975, HPA061022	Supported		Supported	Nucleoli<br>Vesicles<br>Cytosol	Liver cancer:6.75e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.7	Expressed in all		
MAST3	KIAA0561	ENSG00000099308	Microtubule associated serine/threonine kinase 3	19	18097793-18151692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035061, HPA035062	Uncertain		Approved	Nuclear speckles	Head and neck cancer:2.97e-4 (favourable), Pancreatic cancer:7.01e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 51.5	Mixed		
MZF1	MZF-1, MZF1B, Zfp98, ZNF42, ZSCAN6	ENSG00000099326	Myeloid zinc finger 1	19	58561931-58573575	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001757	Approved		Supported	Nucleus	Renal cancer:2.83e-8 (unfavourable), Urothelial cancer:4.09e-5 (favourable), Pancreatic cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.6	Cell line enhanced		HEK 293: 39.4
OCEL1	FLJ22709	ENSG00000099330	Occludin/ELL domain containing 1	19	17226204-17229219	Predicted intracellular proteins	Evidence at protein level	HPA042070, HPA043223	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 22.2	Expressed in all		
MYO9B	CELIAC4	ENSG00000099331	Myosin IXB	19	17075781-17214537	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB037190, HPA042043	Approved		Supported	Cytosol	Renal cancer:5.66e-6 (unfavourable), Ovarian cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 98.8	Expressed in all		
KCNK6	K2p6.1, TWIK-2	ENSG00000099337	Potassium two pore domain channel subfamily K member 6	19	38319844-38332076	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022637, HPA040184	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 22.6	Cell line enhanced		HEL: 33.9;HMC-1: 35.7
CATSPERG	C19orf15, DKFZp434A1022, FLJ46353	ENSG00000099338	Cation channel sperm associated auxiliary subunit gamma	19	38335775-38370943	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052777			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enriched	41	testis: 48.6	skin: 1.1	Cell line enhanced		BEWO: 1.4;HMC-1: 1.6;MCF7: 1.2
PSMD8	HIP6, HYPF, Nin1p, p31, Rpn12, S14	ENSG00000099341	Proteasome 26S subunit, non-ATPase 8	19	38374536-38383824	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006702, CAB021101	Enhanced		Approved	Nuclear speckles<br>Cytosol	Endometrial cancer:3.84e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 195.0	Expressed in all		
FBXL19	CXXC11, DKFZp434K0410, Fbl19, JHDM1C	ENSG00000099364	F-box and leucine rich repeat protein 19	16	30923055-30948783	Predicted intracellular proteins	Evidence at protein level	HPA035317			Approved	Intermediate filaments	Cervical cancer:3.27e-4 (unfavourable), Liver cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.5	Expressed in all		
STX1B	STX1B1, STX1B2	ENSG00000099365	Syntaxin 1B	16	30989256-31010661	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069176, CAB079008	Supported	Supported				Tissue enriched	Tissue enriched	22	cerebral cortex: 108.6	testis: 4.8	Cell line enhanced		hTEC/SVTERT24-B: 11.1
HSD3B7	C(27)-3BETA-HSD, SDR11E3	ENSG00000099377	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7	16	30985207-30989152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050521, HPA060847	Uncertain		Supported	Lipid droplets	Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 21.9	Cell line enhanced		HDLM-2: 83.9;HMC-1: 85.9;U-2197: 89.0
SETD1A	KIAA0339, KMT2F, Set1	ENSG00000099381	SET domain containing 1A	16	30957294-30984664	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020646, HPA058376	Enhanced		Supported	Nuclear speckles	Liver cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
BCL7C		ENSG00000099385	BCL tumor suppressor 7C	16	30833626-30894960	Predicted intracellular proteins	Evidence at protein level	HPA018676, HPA052654	Uncertain		Approved	Nucleoplasm	Cervical cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			ovary: 29.7	Expressed in all		
MAGEB2	CT3.2, DAM6, MAGE-XP-2, MGC26438	ENSG00000099399	MAGE family member B2	X	30215560-30220089	Predicted intracellular proteins	Evidence at protein level	HPA065224, HPA074544, HPA075519	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Tissue enriched	Tissue enriched	74	testis: 54.2	placenta: 0.7	Group enriched	9	HL-60: 72.9;K-562: 59.4;Karpas-707: 55.2;U-2 OS: 93.7;U-266/70: 113.8;U-266/84: 116.9
EFNA2	ELF-1, EPLG6, LERK6	ENSG00000099617	Ephrin A2	19	1286154-1300237	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005178, HPA067567	Uncertain		Approved	Mitochondria<br>Cytosol		Tissue enhanced	Group enriched	6	colon: 7.0;duodenum: 7.9;small intestine: 10.6	rectum: 1.5	Cell line enhanced		Hep G2: 6.6;NTERA-2: 5.4;REH: 6.8;SH-SY5Y: 17.8;U-2 OS: 5.8
CIRBP	CIRP	ENSG00000099622	Cold inducible RNA binding protein	19	1259384-1274880	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060537			Supported	Nucleus<br>Nucleoli	Renal cancer:3.65e-7 (favourable), Endometrial cancer:1.36e-4 (favourable), Lung cancer:2.50e-4 (favourable), Pancreatic cancer:2.69e-4 (favourable), Cervical cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1042.3	Expressed in all		
ATP5D		ENSG00000099624	ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit	19	1241746-1244826	Predicted intracellular proteins	Evidence at protein level	HPA002865	Uncertain				Renal cancer:3.46e-5 (favourable), Endometrial cancer:1.23e-4 (favourable), Pancreatic cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 217.6	Expressed in all		
CBARP	BARP, C19orf26, DOS, MGC40084	ENSG00000099625	CACN beta subunit associated regulatory protein	19	1228287-1238027	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012777			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		adrenal gland: 2.4;cerebral cortex: 7.0	skin: 1.1	Cell line enhanced		SH-SY5Y: 5.6
PCDH11Y	PCDH22, PCDHY	ENSG00000099715	Protocadherin 11 Y-linked	Y	5000226-5742224	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000432	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 4.4	placenta,seminal vesicle: 0.7	Not detected		
AMELY	AMGL	ENSG00000099721	Amelogenin, Y-linked	Y	6865918-6874027	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.2	Not detected		
IGFALS	ALS	ENSG00000099769	Insulin like growth factor binding protein acid labile subunit	16	1790413-1794971	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040692, HPA040948	Approved		Supported	Nucleoplasm	Liver cancer:5.97e-4 (favourable), Endometrial cancer:6.06e-4 (unfavourable)	Tissue enhanced	Group enriched	6	liver: 25.0;stomach: 6.6	gallbladder: 2.5	Cell line enhanced		Hep G2: 1.2;U-266/70: 1.3
HNRNPM	CEAR, HNRNPM4, HNRPM, HNRPM4, HTGR1, NAGR1	ENSG00000099783	Heterogeneous nuclear ribonucleoprotein M	19	8444767-8489114	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016113, HPA024344	Supported		Enhanced	Nucleoplasm	Liver cancer:1.80e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 203.0	Expressed in all		
MARCH2	HSPC240, MARCH-II, RNF172	ENSG00000099785	Membrane associated ring-CH-type finger 2	19	8413270-8439017	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014063	Approved		Approved	Cytosol	Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 64.8	Mixed		
NDUFB7	B18, CI-B18, MGC2480	ENSG00000099795	NADH:ubiquinone oxidoreductase subunit B7	19	14566078-14572062	Predicted intracellular proteins	Evidence at protein level	HPA002817	Approved				Renal cancer:2.41e-4 (favourable), Cervical cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 248.7	Expressed in all		
TECR	GPSN2, MRT14, SC2, TER	ENSG00000099797	Trans-2,3-enoyl-CoA reductase	19	14517085-14565980	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029780, HPA056488	Supported		Supported	Endoplasmic reticulum	Urothelial cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 404.6	Expressed in all		
TIMM13	Tim13, TIMM13B	ENSG00000099800	Translocase of inner mitochondrial membrane 13	19	2425624-2427894	Predicted intracellular proteins	Evidence at protein level	HPA048985	Uncertain		Supported	Nucleoli fibrillar center<br>Mitochondria	Renal cancer:3.88e-5 (favourable), Endometrial cancer:4.68e-5 (favourable), Pancreatic cancer:9.77e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 53.1	Expressed in all		
CDC34	E2-CDC34, UBC3, UBE2R1	ENSG00000099804	Cell division cycle 34	19	531712-542092	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002382, CAB005109, CAB047311	Approved		Supported	Nuclear speckles<br>Cytosol	Liver cancer:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.5	Expressed in all		
MTAP	c86fus, MSAP	ENSG00000099810	Methylthioadenosine phosphorylase	9	21802543-21937651	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046915			Supported	Cytosol	Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 15.7	Mixed		
MISP	C19orf21, Caprice, DKFZp686H18209, MISP1	ENSG00000099812	Mitotic spindle positioning	19	751126-764318	Predicted intracellular proteins	Evidence at protein level	HPA049511, HPA062232	Enhanced		Enhanced	Plasma membrane<br>Focal adhesion sites		Tissue enhanced	Group enriched	6	colon: 94.7;duodenum: 173.3;rectum: 52.6;small intestine: 217.1	stomach: 21.6	Cell line enhanced		A549: 110.0;HaCaT: 79.4;hTCEpi: 59.7;SK-BR-3: 101.1
CEP170B	Cep170R, FAM68C, KIAA0284	ENSG00000099814	Centrosomal protein 170B	14	104865280-104896770	Predicted intracellular proteins	Evidence at protein level	HPA000871, HPA059017	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:3.26e-4 (favourable), Prostate cancer:4.41e-4 (unfavourable), Liver cancer:6.12e-4 (unfavourable)	Expressed in all	Mixed			skin: 30.5	Mixed		
POLR2E	hRPB25, hsRPB5, RPABC1, RPB5, XAP4	ENSG00000099817	RNA polymerase II subunit E	19	1086579-1095380	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA063030, HPA068992	Supported		Supported	Nucleoplasm	Renal cancer:3.21e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.5	Expressed in all		
POLRMT	APOLMT, h-mtRPOL, MTRNAP, MTRPOL	ENSG00000099821	RNA polymerase mitochondrial	19	617224-633604	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006366	Uncertain		Supported	Mitochondria	Endometrial cancer:4.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
HCN2	BCNG-2, BCNG2, HAC-1	ENSG00000099822	Hyperpolarization activated cyclic nucleotide gated potassium channel 2	19	589893-617159	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Renal cancer:6.99e-5 (unfavourable)	Group enriched	Tissue enriched	5	cerebral cortex: 38.3	heart muscle: 7.0	Cell line enhanced		A549: 27.1;MCF7: 21.7;U-138 MG: 20.0;U-87 MG: 40.9
CDHR5	FLJ20219, MU-PCDH, MUCDHL, MUPCDH	ENSG00000099834	Cadherin related family member 5	11	616565-626078	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009081, HPA009173, CAB025004	Enhanced					Group enriched	Group enriched	9	colon: 41.7;duodenum: 82.7;kidney: 23.6;liver: 21.0;rectum: 54.3;small intestine: 64.3	gallbladder: 5.3	Cell line enhanced		CACO-2: 2.1
IZUMO4	C19orf36	ENSG00000099840	IZUMO family member 4	19	2096429-2099593	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA045099, HPA048496	Enhanced		Uncertain	Nucleoplasm<br>Vesicles	Pancreatic cancer:1.69e-4 (favourable), Endometrial cancer:7.08e-4 (favourable)	Mixed	Tissue enriched	52	testis: 341.9	ovary: 6.5	Cell line enhanced		Karpas-707: 6.0;RPMI-8226: 7.2
RASSF7	C11orf13, HRAS1, HRC1	ENSG00000099849	Ras association domain family member 7	11	560404-564021	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078015			Supported	Microtubule organizing center	Glioma:8.86e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 44.4	Cell line enhanced		CAPAN-2: 75.6;HaCaT: 76.6
GADD45B	DKFZP566B133, GADD45BETA, MYD118	ENSG00000099860	Growth arrest and DNA damage inducible beta	19	2476122-2478259	Predicted intracellular proteins	Evidence at protein level	HPA029816	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 218.1	Mixed		
PALM	KIAA0270	ENSG00000099864	Paralemmin	19	708939-748329	Predicted intracellular proteins	Evidence at protein level	HPA041713, HPA049578	Approved		Enhanced	Nucleus<br>Plasma membrane	Renal cancer:5.44e-4 (favourable), Pancreatic cancer:9.81e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 84.8	adipose tissue: 53.1	Cell line enhanced		AN3-CA: 28.0;EFO-21: 25.9;REH: 46.8;SH-SY5Y: 33.4
MADCAM1	MACAM1	ENSG00000099866	Mucosal vascular addressin cell adhesion molecule 1	19	489176-505342	Predicted membrane proteins	Evidence at protein level	CAB075699	Enhanced					Mixed	Tissue enhanced		appendix: 17.8;spleen: 11.4	gallbladder: 3.3	Mixed		
MKNK2	GPRK7, MNK2	ENSG00000099875	MAP kinase interacting serine/threonine kinase 2	19	2037465-2051244	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021875, CAB037253, HPA070499	Enhanced		Supported	Nuclear bodies	Endometrial cancer:4.86e-5 (favourable), Stomach cancer:4.01e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 174.3	Expressed in all		
ARVCF		ENSG00000099889	Armadillo repeat gene deleted in velocardiofacial syndrome	22	19969896-20016808	Predicted intracellular proteins	Evidence at protein level	CAB016162, HPA055264, HPA063675	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Urothelial cancer:5.76e-6 (favourable)	Expressed in all	Mixed			spleen: 8.8	Cell line enhanced		K-562: 18.0;SCLC-21H: 21.2;SH-SY5Y: 14.7;U-2 OS: 16.4
TRMT2A	HTF9C	ENSG00000099899	TRNA methyltransferase 2 homolog A	22	20111866-20117392	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001077	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.99e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
RANBP1	HTF9A	ENSG00000099901	RAN binding protein 1	22	20115938-20127357	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065868, HPA065931	Enhanced		Supported	Cytosol	Renal cancer:1.16e-6 (unfavourable), Liver cancer:1.58e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 152.5	Expressed in all		
ZDHHC8	KIAA1292, ZNF378	ENSG00000099904	Zinc finger DHHC-type containing 8	22	20129456-20148007	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA003422	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.04e-4 (unfavourable), Cervical cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.7	Mixed		
KLHL22	FLJ14360, KELCHL	ENSG00000099910	Kelch like family member 22	22	20441519-20495883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040766			Supported	Golgi apparatus<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:1.34e-8 (favourable), Pancreatic cancer:3.85e-6 (favourable), Endometrial cancer:4.88e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.6	Mixed		
MED15	Arc105, CAG7A, PCQAP, TIG-1, TNRC7	ENSG00000099917	Mediator complex subunit 15	22	20495913-20587632	Predicted intracellular proteins	Evidence at protein level	HPA003179	Approved		Supported	Nucleus	Endometrial cancer:7.30e-5 (favourable), Renal cancer:1.61e-4 (unfavourable), Liver cancer:3.71e-4 (unfavourable), Pancreatic cancer:9.09e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 43.5	Expressed in all		
SERPIND1	D22S673, HC-II, HC2, HCF2, HLS2	ENSG00000099937	Serpin family D member 1	22	20773879-20787720	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008639, HPA055767	Supported		Approved	Vesicles	Endometrial cancer:4.09e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 585.3	parathyroid gland: 36.2	Cell line enriched	8	Hep G2: 126.1
SNAP29	CEDNIK, SNAP-29	ENSG00000099940	Synaptosome associated protein 29	22	20858983-20891218	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031823, CAB037092, HPA056492	Supported		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 74.6	Expressed in all		
CRKL		ENSG00000099942	CRK like proto-oncogene, adaptor protein	22	20917426-20953749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000532, HPA001100	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:8.82e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 53.4	Expressed in all		
LZTR1	BTBD29, LZTR-1	ENSG00000099949	Leucine zipper like transcription regulator 1	22	20979462-20999038	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068772, HPA071248	Approved				Liver cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.9	Expressed in all		
MMP11	STMY3	ENSG00000099953	Matrix metallopeptidase 11	22	23768226-23784316	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002593, HPA068864	Approved				Renal cancer:2.62e-4 (unfavourable)	Expressed in all	Group enriched	9	cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0	smooth muscle: 6.9	Cell line enhanced		AN3-CA: 17.4;REH: 7.4
CECR2	KIAA1740	ENSG00000099954	CECR2, histone acetyl-lysine reader	22	17359949-17558149	Predicted intracellular proteins	Evidence at protein level	HPA002943	Approved		Approved	Nucleus<br>Vesicles		Tissue enriched	Tissue enhanced		cerebral cortex: 7.8	skeletal muscle: 7.5	Cell line enhanced		AF22: 15.3;HAP1: 14.9;NTERA-2: 22.8;SCLC-21H: 11.9
SMARCB1	BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1	ENSG00000099956	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	22	23786963-23834516	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009196, HPA018248, HPA019127	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:1.14e-6 (favourable), Liver cancer:6.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
P2RX6	MGC129625, P2RXL1, P2X6, P2XM	ENSG00000099957	Purinergic receptor P2X 6	22	21009808-21028830	Predicted membrane proteins	Evidence at protein level	HPA028776, HPA028777	Approved		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 3.4;skeletal muscle: 3.0	spleen: 2.3	Cell line enhanced		LHCN-M2: 5.6;RH-30: 4.0;U-87 MG: 11.5
DERL3	C22orf14, derlin-3, FLJ43842, IZP6, MGC71803	ENSG00000099958	Derlin 3	22	23834503-23839128	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037234, HPA049306	Uncertain		Uncertain	Vesicles	Renal cancer:7.76e-13 (unfavourable), Cervical cancer:8.70e-5 (favourable), Head and neck cancer:8.01e-4 (favourable)	Expressed in all	Mixed			stomach: 39.0	Group enriched	5	Karpas-707: 58.5;RPMI-8226: 33.7;U-266/70: 66.4;U-698: 14.5
SLC7A4	CAT-4, HCAT3, VH	ENSG00000099960	Solute carrier family 7 member 4	22	21028718-21032840	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031023	Enhanced					Mixed	Tissue enhanced		testis: 22.5	esophagus: 6.0	Cell line enriched	24	BEWO: 135.5
BCL2L13	BCL-RAMBO, MIL1	ENSG00000099968	BCL2 like 13	22	17628855-17730855	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002052, HPA030994, HPA050377	Uncertain		Supported	Mitochondria	Renal cancer:1.96e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
DDTL		ENSG00000099974	D-dopachrome tautomerase-like	22	23966901-23972532	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:5.98e-4 (favourable)	Expressed in all	Mixed			small intestine: 3.5	Mixed		
DDT	DDCT	ENSG00000099977	D-dopachrome tautomerase	22	23971365-23980469	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049871	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			liver: 109.9	Expressed in all		
OSM	MGC20461	ENSG00000099985	Oncostatin M	22	30262829-30266840	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.03e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 78.7	appendix: 20.1	Cell line enhanced		HDLM-2: 14.6;HMC-1: 9.7;NB-4: 4.2
CABIN1	KIAA0330, PPP3IN	ENSG00000099991	Calcineurin binding protein 1	22	24011192-24178628	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043296	Approved		Approved	Nucleoplasm<br>Aggresome<br>Cytosol	Endometrial cancer:9.57e-5 (favourable), Renal cancer:2.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.9	Expressed in all		
TBC1D10A	AC004997.C22.2, EPI64, TBC1D10	ENSG00000099992	TBC1 domain family member 10A	22	30291990-30327046	Predicted intracellular proteins	Evidence at protein level	HPA007725, HPA008142, HPA076041	Approved		Enhanced	Plasma membrane		Expressed in all	Mixed			esophagus: 31.2	Expressed in all		
SUSD2	BK65A6.2, FLJ22778	ENSG00000099994	Sushi domain containing 2	22	24181259-24189110	Predicted membrane proteins	Evidence at protein level	HPA004117	Enhanced		Approved	Plasma membrane	Renal cancer:3.29e-5 (unfavourable)	Expressed in all	Tissue enhanced		lung: 139.3	small intestine: 35.2	Cell line enriched	33	SK-BR-3: 622.4
SF3A1	Prp21, PRPF21, SAP114, SF3a120	ENSG00000099995	Splicing factor 3a subunit 1	22	30331988-30356947	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000690, HPA030083	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 88.7	Expressed in all		
GGT5	GGT-REL, GGTLA1	ENSG00000099998	Gamma-glutamyltransferase 5	22	24219654-24245142	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008121, CAB032489	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:6.36e-5 (unfavourable), Stomach cancer:4.06e-4 (unfavourable), Testis cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 67.3	Cell line enhanced		ASC diff: 113.5;ASC TERT1: 87.8;HHSteC: 197.7;HSkMC: 197.7;TIME: 90.0
RNF215		ENSG00000099999	Ring finger protein 215	22	30368811-30421771	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029427, HPA056498	Approved		Approved	Nucleoli<br>Microtubules	Renal cancer:6.37e-10 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
SEC14L2	C22orf6, KIAA1186, KIAA1658, SPF, TAP, TAP1	ENSG00000100003	SEC14 like lipid binding 2	22	30396857-30425317	Predicted intracellular proteins	Evidence at protein level	HPA064466	Approved		Supported	Nucleus<br>Cytosol	Head and neck cancer:7.63e-6 (unfavourable), Breast cancer:3.05e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 104.9;liver: 125.6;prostate: 83.0	breast: 57.3	Cell line enhanced		HBEC3-KT: 61.6
SEC14L3	TAP2	ENSG00000100012	SEC14 like lipid binding 3	22	30447959-30472049	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059450	Uncertain					Not detected	Tissue enhanced		bone marrow: 2.3;lung: 1.5;thyroid gland: 2.8	liver: 1.4	Not detected		
SPECC1L	CYTSA, KIAA0376	ENSG00000100014	Sperm antigen with calponin homology and coiled-coil domains 1 like	22	24270817-24417740	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA070614	Uncertain		Supported	Actin filaments	Pancreatic cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.2	Expressed in all		
PPIL2	CYC4, Cyp-60, UBOX7	ENSG00000100023	Peptidylprolyl isomerase like 2	22	21666009-21700015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035344, HPA055637	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
UPB1	BUP1	ENSG00000100024	Beta-ureidopropionase 1	22	24494107-24528390	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000728	Enhanced				Liver cancer:2.30e-7 (favourable)	Tissue enriched	Group enriched	23	kidney: 51.2;liver: 161.7	testis: 4.6	Cell line enhanced		CACO-2: 6.0;NB-4: 1.9;THP-1: 2.7;U-937: 3.5
YPEL1		ENSG00000100027	Yippee like 1	22	21697544-21735834	Predicted intracellular proteins	Evidence at transcript level	HPA030501, HPA045621	Uncertain				Endometrial cancer:3.09e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 36.6	cerebral cortex: 16.2	Cell line enhanced		AF22: 9.6;MOLT-4: 10.8;REH: 10.9;SCLC-21H: 13.5
SNRPD3	Sm-D3, SMD3	ENSG00000100028	Small nuclear ribonucleoprotein D3 polypeptide	22	24555503-24609980	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001170	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 78.0	Expressed in all		
PES1	PES	ENSG00000100029	Pescadillo ribosomal biogenesis factor 1	22	30576625-30607083	Predicted intracellular proteins	Evidence at protein level	HPA040210, HPA062439, HPA066670	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.84e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
MAPK1	ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2	ENSG00000100030	Mitogen-activated protein kinase 1	22	21754500-21867680	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003995, CAB004229, HPA005700, HPA030069	Approved				Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.4	Expressed in all		
GGT1	CD224, D22S672, D22S732, GGT	ENSG00000100031	Gamma-glutamyltransferase 1	22	24583750-24629005	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles	Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 161.2	small intestine: 95.9	Cell line enhanced		HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
PRODH	HSPOX2, PIG6, PRODH1, PRODH2, TP53I6	ENSG00000100033	Proline dehydrogenase 1	22	18912777-18936553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020361	Uncertain				Cervical cancer:1.54e-4 (favourable)	Tissue enhanced	Tissue enhanced		small intestine: 25.2	duodenum: 5.7	Cell line enriched	6	RPTEC TERT1: 28.5
PPM1F	CAMKP, CaMKPase, FEM-2, KIAA0015, POPX2	ENSG00000100034	Protein phosphatase, Mg2+/Mn2+ dependent 1F	22	21919420-21952837	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030989, HPA030990	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.9	Expressed in all		
SLC35E4		ENSG00000100036	Solute carrier family 35 member E4	22	30635652-30669016	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA049558	Approved		Approved	Cytosol		Mixed	Tissue enhanced		testis: 17.6	cerebral cortex: 5.1	Mixed		
TOP3B		ENSG00000100038	Topoisomerase (DNA) III beta	22	21957025-21982816	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA069678			Approved	Vesicles		Not detected	Mixed			spleen: 18.9	Expressed in all		
CRYBB3	CRYB3	ENSG00000100053	Crystallin beta B3	22	25199850-25207363	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055840	Supported					Mixed	Mixed			thyroid gland: 2.1	Cell line enhanced		HaCaT: 1.2;HEK 293: 1.3
CYTH4	CYT4, cytohesin-4, PSCD4	ENSG00000100055	Cytohesin 4	22	37282027-37315345	Predicted intracellular proteins	Evidence at protein level	HPA071573	Approved				Renal cancer:2.41e-8 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 89.2	spleen: 69.8	Cell line enhanced		HL-60: 27.2;HMC-1: 119.3;THP-1: 62.2
DGCR14	DGCR13, DGS-H, DGSI, ES2, Es2el	ENSG00000100056	DiGeorge syndrome critical region gene 14	22	19130279-19144684	Predicted intracellular proteins	Evidence at protein level	HPA001221, HPA001222	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 1.9	Mixed		
MFNG		ENSG00000100060	MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	22	37469063-37486401	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048936, HPA056479	Approved		Uncertain	Actin filaments	Renal cancer:3.31e-5 (unfavourable), Endometrial cancer:1.65e-4 (favourable), Colorectal cancer:5.12e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 68.5	Cell line enhanced		HL-60: 153.4;HMC-1: 213.3;HUVEC TERT2: 166.4;U-937: 134.0
CARD10	BIMP1, CARMA3	ENSG00000100065	Caspase recruitment domain family member 10	22	37490362-37519542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029359, HPA055612	Approved		Approved	Vesicles<br>Intermediate filaments<br>Cytosol	Liver cancer:7.73e-6 (unfavourable), Endometrial cancer:3.47e-4 (favourable)	Expressed in all	Mixed			small intestine: 39.9	Cell line enhanced		U-2197: 76.9
LRP5L	DKFZp434O0213	ENSG00000100068	LDL receptor related protein 5 like	22	25351418-25405377	Predicted intracellular proteins	Evidence at transcript level	HPA028717	Uncertain		Approved	Nucleoplasm	Urothelial cancer:6.93e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 9.7	Mixed		
SLC25A1	CTP, SLC20A3	ENSG00000100075	Solute carrier family 25 member 1	22	19175575-19178830	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			duodenum: 112.7	Expressed in all		
GRK3	ADRBK2, BARK2	ENSG00000100077	G protein-coupled receptor kinase 3	22	25564849-25729294	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000804	Uncertain		Approved	Nucleus<br>Plasma membrane	Urothelial cancer:1.29e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 32.7	Cell line enhanced		HDLM-2: 40.3;SH-SY5Y: 39.9
PLA2G3	GIII-SPLA2	ENSG00000100078	Phospholipase A2 group III	22	31134809-31140607	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA021016	Uncertain				Head and neck cancer:4.47e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 4.4;lung: 3.6;skin: 10.2	parathyroid gland: 1.5	Group enriched	6	AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2
LGALS2	HL14	ENSG00000100079	Galectin 2	22	37570246-37582616	Predicted intracellular proteins	Evidence at protein level	HPA003536, CAB025198	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enhanced		gallbladder: 537.1;small intestine: 225.0	kidney: 155.6	Group enriched	13	CACO-2: 92.0;Hep G2: 42.9
GGA1		ENSG00000100083	Golgi associated, gamma adaptin ear containing, ARF binding protein 1	22	37608475-37633564	Predicted intracellular proteins	Evidence at protein level	HPA048280, HPA051016	Supported		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:4.86e-4 (favourable), Liver cancer:6.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 199.2	Expressed in all		
HIRA	DGCR1, TUP1, TUPLE1	ENSG00000100084	Histone cell cycle regulator	22	19330698-19447450	Predicted intracellular proteins	Evidence at protein level	CAB039243, CAB039244, HPA050714, HPA052902	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.18e-6 (favourable), Pancreatic cancer:3.97e-4 (favourable), Ovarian cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 93.8	Expressed in all		
SH3BP1	ARHGAP43	ENSG00000100092	SH3 domain binding protein 1	22	37634654-37666932	Predicted intracellular proteins	Evidence at protein level	HPA000757	Enhanced		Approved	Cytosol	Renal cancer:3.48e-7 (unfavourable), Stomach cancer:3.39e-4 (favourable), Liver cancer:9.55e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.9	Mixed		
SEZ6L		ENSG00000100095	Seizure related 6 homolog like	22	26169474-26383597	Predicted membrane proteins	Evidence at protein level	HPA045135			Approved	Vesicles		Group enriched	Tissue enriched	7	cerebral cortex: 89.2	adrenal gland: 13.6	Group enriched	8	SCLC-21H: 49.2;SH-SY5Y: 11.9
LGALS1	GBP	ENSG00000100097	Galectin 1	22	37675608-37679806	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000646, HPA000687, HPA001130, CAB002157	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.18e-10 (unfavourable), Endometrial cancer:2.36e-5 (favourable), Liver cancer:3.06e-4 (unfavourable), Urothelial cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1727.9	Expressed in all		
HPS4	BLOC3S2, KIAA1667, LE	ENSG00000100099	HPS4, biogenesis of lysosomal organelles complex 3 subunit 2	22	26443423-26483837	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033106, HPA050189	Approved		Approved	Centrosome		Expressed in all	Expressed in all			testis: 24.2	Expressed in all		
PIK3IP1	HGFL, MGC17330	ENSG00000100100	Phosphoinositide-3-kinase interacting protein 1	22	31281593-31292534	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 121.1	Cell line enhanced		U-698: 23.5
SRRD	HC/HCC, SRR1L	ENSG00000100104	SRR1 domain containing	22	26483877-26494658	Predicted intracellular proteins	Evidence at protein level	HPA002945	Uncertain		Approved	Cytosol	Liver cancer:2.16e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.7	Expressed in all		
PATZ1	dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG	ENSG00000100105	POZ/BTB and AT hook containing zinc finger 1	22	31325804-31346232	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047893, HPA048315	Approved		Supported	Nucleoplasm	Renal cancer:8.54e-8 (favourable), Urothelial cancer:7.79e-6 (favourable), Glioma:6.53e-5 (favourable), Lung cancer:8.71e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
TRIOBP	DFNB28, HRIHFB2122, KIAA1662, TAP68, Tara	ENSG00000100106	TRIO and F-actin binding protein	22	37697004-37776556	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003747, HPA019769	Enhanced				Cervical cancer:4.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 65.9	Expressed in all		
TFIP11	DKFZP434B194, Spp382, TIP39	ENSG00000100109	Tuftelin interacting protein 11	22	26491225-26512505	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027085			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
GCAT	KBL	ENSG00000100116	Glycine C-acetyltransferase	22	37807905-37817176	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020460	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			prostate: 30.0	Expressed in all		
GGTLC2	GGTL4	ENSG00000100121	Gamma-glutamyltransferase light chain 2	22	22644475-22647903	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Not detected	Tissue enriched	9	testis: 7.0	small intestine: 0.7	Not detected		
CRYBB1		ENSG00000100122	Crystallin beta B1	22	26599278-26618088	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003448, CAB010058	Supported					Mixed	Tissue enhanced		epididymis: 10.9	placenta: 4.5	Cell line enhanced		HMC-1: 9.9;Karpas-707: 29.5;RPMI-8226: 53.1
ANKRD54	LIAR	ENSG00000100124	Ankyrin repeat domain 54	22	37830855-37849327	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA071287	Approved		Approved	Nucleoplasm<br>Microtubules<br>Midbody	Endometrial cancer:7.38e-5 (favourable), Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 35.8	Expressed in all		
EIF3L	EIF3EIP, EIF3S11, EIF3S6IP, HSPC021, HSPC025	ENSG00000100129	Eukaryotic translation initiation factor 3 subunit L	22	37848868-37889407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003028	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			breast: 179.8	Expressed in all		
SNU13	15.5K, FA-1, NHP2L1, SNRNP15-5, SPAG12, SSFA1	ENSG00000100138	SNU13 homolog, small nuclear ribonucleoprotein (U4/U6.U5)	22	41673930-41690504	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029199	Uncertain					Expressed in all	Expressed in all			testis: 168.8	Expressed in all		
MICALL1	KIAA1668, MICAL-L1, MIRAB13	ENSG00000100139	MICAL like 1	22	37905657-37942822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043480, HPA051956	Uncertain		Supported	Cell Junctions<br>Microtubule organizing center<br>Cytosol	Liver cancer:3.08e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 51.2	Expressed in all		
POLR2F	HRBP14.4, RPB6	ENSG00000100142	RNA polymerase II subunit F	22	37952607-38041915	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA000827, CAB009882	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Expressed in all			cerebral cortex: 120.8	Expressed in all		
SOX10	DOM, WS2E, WS4	ENSG00000100146	SRY-box 10	22	37970686-37987422	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003171, HPA068898	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enhanced		cerebral cortex: 56.6;salivary gland: 50.5	breast: 24.0	Group enriched	686	SK-MEL-30: 236.8;WM-115: 425.1
CCDC134	FLJ22349	ENSG00000100147	Coiled-coil domain containing 134	22	41800679-41826299	Predicted secreted proteins	Evidence at protein level	HPA003936	Approved				Liver cancer:7.42e-7 (unfavourable), Renal cancer:1.36e-5 (favourable), Endometrial cancer:4.09e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.1	Mixed		
DEPDC5	DEP.5, KIAA0645	ENSG00000100150	DEP domain containing 5	22	31753951-31907034	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054969, HPA055619	Uncertain		Approved	Golgi apparatus	Renal cancer:2.46e-5 (favourable), Urothelial cancer:4.86e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.5	Expressed in all		
PICK1	dJ1039K5, MGC15204, PRKCABP	ENSG00000100151	Protein interacting with PRKCA 1	22	38056311-38075701	Predicted intracellular proteins	Evidence at protein level	HPA067384, HPA072674	Approved		Approved	Mitochondria<br>Cytosol	Stomach cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.2	Mixed		
TTC28	KIAA1043	ENSG00000100154	Tetratricopeptide repeat domain 28	22	27978014-28679865	Predicted intracellular proteins	Evidence at protein level	HPA003099			Approved	Nucleoli<br>Mitochondria	Renal cancer:5.65e-5 (favourable), Thyroid cancer:1.21e-4 (unfavourable), Lung cancer:4.30e-4 (favourable)	Expressed in all	Mixed			ovary: 20.8	Mixed		
SLC16A8	MCT3, REMP	ENSG00000100156	Solute carrier family 16 member 8	22	38078134-38084093	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA075017	Supported		Approved	Intermediate filaments<br>Focal adhesion sites		Mixed	Mixed			prostate: 3.9	Cell line enhanced		BEWO: 4.3;SiHa: 5.2;T-47d: 5.5;U-266/70: 6.4
CENPM	C22orf18, CENP-M, MGC861, Pane1	ENSG00000100162	Centromere protein M	22	41938721-41947164	Predicted intracellular proteins	Evidence at protein level	HPA042404, HPA056500	Enhanced		Enhanced	Cytosol	Renal cancer:5.99e-7 (unfavourable), Cervical cancer:3.40e-5 (favourable), Liver cancer:5.50e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 28.6	bone marrow: 17.6	Expressed in all		
SEPT3	SEP3	ENSG00000100167	Septin 3	22	41976272-41998221	Predicted intracellular proteins	Evidence at protein level	HPA003548, CAB017633	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments	Endometrial cancer:1.78e-4 (unfavourable)	Tissue enhanced	Tissue enriched	11	cerebral cortex: 234.8	parathyroid gland: 21.5	Cell line enhanced		AF22: 26.2;SCLC-21H: 84.0
SLC5A1	D22S675, NAGT, SGLT1	ENSG00000100170	Solute carrier family 5 member 1	22	32043032-32113029	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015467, HPA051805, HPA055106	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable)	Mixed	Group enriched	10	duodenum: 505.0;small intestine: 313.4	gallbladder: 40.2	Cell line enhanced		CACO-2: 2.1;RPMI-8226: 1.3;SH-SY5Y: 1.0
SLC5A4	DJ90G24.4, SAAT1, SGLT3	ENSG00000100191	Solute carrier family 5 member 4	22	32218476-32255341	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Group enriched	8	duodenum: 18.0;small intestine: 21.3	lung: 2.3	Cell line enriched	15	SK-MEL-30: 21.9
KDELR3		ENSG00000100196	KDEL endoplasmic reticulum protein retention receptor 3	22	38468062-38483447	Predicted membrane proteins	Evidence at protein level	HPA043477, HPA076405	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:6.05e-10 (unfavourable), Liver cancer:1.19e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 46.5	Cell line enhanced		ASC TERT1: 179.3;fHDF/TERT166: 214.6
CYP2D6	CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D	ENSG00000100197	Cytochrome P450 family 2 subfamily D member 6	22	42126499-42130906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045223	Enhanced		Approved	Golgi apparatus		Tissue enriched	Group enriched	5	duodenum: 3.7;liver: 10.0;small intestine: 13.0	testis: 1.7	Cell line enhanced		Hep G2: 1.2;HMC-1: 2.2;REH: 1.4;U-266/70: 1.3
DDX17	P72	ENSG00000100201	DEAD-box helicase 17	22	38483440-38507660	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB024908, HPA063142	Enhanced		Enhanced	Nuclear speckles	Lung cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 336.0	Expressed in all		
DMC1	LIM15	ENSG00000100206	DNA meiotic recombinase 1	22	38518949-38570286	Predicted intracellular proteins	Evidence at protein level	HPA001232, CAB015397	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	5	testis: 22.0	endometrium: 4.0	Cell line enhanced		HDLM-2: 23.2
TCF20	AR1, SPBP	ENSG00000100207	Transcription factor 20	22	42160013-42343616	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017849, HPA036786	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:1.88e-4 (favourable), Liver cancer:4.89e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 3.7	Mixed		
HSCB	DNAJC20, HSC20, Jac1	ENSG00000100209	HscB mitochondrial iron-sulfur cluster cochaperone	22	28742031-28757515	Predicted intracellular proteins	Evidence at protein level	HPA018447, HPA031518	Uncertain		Supported	Nucleus<br>Mitochondria<br>Cytosol	Endometrial cancer:3.78e-4 (favourable), Urothelial cancer:8.38e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 13.2	Expressed in all		
CBY1	C22orf2, Cby, Chibby, PGEA1, PIGEA-14, PIGEA14	ENSG00000100211	Chibby family member 1, beta catenin antagonist	22	38656636-38673854	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.22e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 95.7	Expressed in all		
TOMM22	TOM22	ENSG00000100216	Translocase of outer mitochondrial membrane 22	22	38681948-38685421	Predicted membrane proteins	Evidence at protein level	HPA003037	Enhanced		Enhanced	Mitochondria	Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.7	Expressed in all		
RSPH14	RTDR1	ENSG00000100218	Radial spoke head 14 homolog	22	23059415-23145021	Predicted intracellular proteins	Evidence at protein level	HPA018420, HPA050425	Approved		Uncertain	Nucleoli	Renal cancer:4.04e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 18.3;testis: 29.1	kidney: 7.3	Cell line enhanced		RPTEC TERT1: 3.1;SCLC-21H: 3.2;U-266/70: 3.6
XBP1	XBP2	ENSG00000100219	X-box binding protein 1	22	28794555-28800597	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level							Not detected	Expressed in all			breast: 918.6	Expressed in all		
RTCB	C22orf28, FAAP, HSPC117	ENSG00000100220	RNA 2',3'-cyclic phosphate and 5'-OH ligase	22	32387582-32412255	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000535, HPA001103	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:4.25e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.2	Expressed in all		
JOSD1	KIAA0063	ENSG00000100221	Josephin domain containing 1	22	38685543-38701556	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001168	Uncertain				Liver cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 56.4	Expressed in all		
FBXO7	Fbx, FBX7, PARK15	ENSG00000100225	F-box protein 7	22	32474676-32498829	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032113, HPA032114, CAB034296	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:2.66e-10 (favourable), Colorectal cancer:1.08e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 225.1	Expressed in all		
GTPBP1	GP-1, HSPC018	ENSG00000100226	GTP binding protein 1	22	38705723-38738299	Predicted intracellular proteins	Evidence at protein level	HPA003166, HPA064702	Approved		Approved	Nuclear bodies<br>Golgi apparatus<br>Cytosol	Liver cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 65.0	Expressed in all		
POLDIP3	KIAA1649, PDIP46	ENSG00000100227	DNA polymerase delta interacting protein 3	22	42583721-42614962	Predicted intracellular proteins	Evidence at protein level	HPA018419, HPA048790	Approved		Enhanced	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:3.36e-4 (favourable), Glioma:6.67e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.8	Expressed in all		
RAB36		ENSG00000100228	RAB36, member RAS oncogene family	22	23145326-23164350	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059631			Approved	Vesicles	Renal cancer:4.55e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 52.9;thyroid gland: 29.6	testis: 10.4	Cell line enhanced		SCLC-21H: 20.4
TIMP3	SFD	ENSG00000100234	TIMP metallopeptidase inhibitor 3	22	32801701-32863043	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level						Ovarian cancer:1.90e-5 (unfavourable), Renal cancer:1.50e-4 (favourable)	Mixed	Tissue enhanced		placenta: 1439.9	adipose tissue: 729.9	Cell line enhanced		BJ: 988.6;fHDF/TERT166: 830.6;WM-115: 879.2
PPP6R2	dJ579N16.1, KIAA0685, SAP190, SAPS2	ENSG00000100239	Protein phosphatase 6 regulatory subunit 2	22	50343304-50445090	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030656, CAB034919	Uncertain		Supported	Vesicles<br>Cytosol	Endometrial cancer:1.70e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.3	Expressed in all		
SBF1	DENND7A, MTMR5	ENSG00000100241	SET binding factor 1	22	50445000-50475024	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA074004			Approved	Nuclear bodies	Head and neck cancer:3.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 84.1	Expressed in all		
SUN2	UNC84B	ENSG00000100242	Sad1 and UNC84 domain containing 2	22	38734725-38794143	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001209	Supported		Supported	Nuclear membrane		Expressed in all	Expressed in all			lymph node: 118.9	Expressed in all		
CYB5R3	DIA1	ENSG00000100243	Cytochrome b5 reductase 3	22	42617840-42649568	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001566	Approved		Enhanced	Endoplasmic reticulum	Liver cancer:2.13e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 339.4	Expressed in all		
DNAL4	dJ327J16, PIG27	ENSG00000100246	Dynein axonemal light chain 4	22	38778508-38794198	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003647	Approved		Approved	Nucleus<br>Nucleoli<br>Centrosome<br>Cytosol	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.7	Mixed		
C22orf31	bK747E2.1, HS747E2A	ENSG00000100249	Chromosome 22 open reading frame 31	22	29058672-29061844	Predicted intracellular proteins	Evidence at transcript level	HPA000604	Uncertain					Not detected	Tissue enriched	12	testis: 13.9	epididymis: 1.1	Not detected		
MIOX	ALDRL6	ENSG00000100253	Myo-inositol oxygenase	22	50486784-50490648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039451, HPA039562	Enhanced				Renal cancer:2.60e-6 (favourable)	Tissue enriched	Tissue enriched	30	kidney: 821.5	thyroid gland: 26.9	Cell line enhanced		HDLM-2: 23.3;Karpas-707: 9.3;U-266/70: 5.9
LMF2	TMEM112B, TMEM153	ENSG00000100258	Lipase maturation factor 2	22	50502949-50507691	Predicted membrane proteins	Evidence at protein level	HPA062626	Approved		Approved	Centrosome	Cervical cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			pancreas: 38.1	Expressed in all		
RHBDD3	C22orf3, PTAG	ENSG00000100263	Rhomboid domain containing 3	22	29259852-29268209	Predicted membrane proteins	Evidence at protein level	HPA043979	Approved		Approved	Microtubules	Endometrial cancer:2.67e-6 (favourable), Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.5	Mixed		
PACSIN2	SDPII	ENSG00000100266	Protein kinase C and casein kinase substrate in neurons 2	22	42835412-43015145	Predicted intracellular proteins	Evidence at protein level	HPA049854, HPA056520	Enhanced		Supported	Nuclear speckles<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:1.09e-13 (favourable), Liver cancer:7.33e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 95.3	Expressed in all		
TTLL1	C22orf7	ENSG00000100271	Tubulin tyrosine ligase like 1	22	43039644-43089428	Predicted intracellular proteins	Evidence at transcript level	HPA048392	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.34e-5 (unfavourable), Renal cancer:1.68e-4 (favourable), Endometrial cancer:1.85e-4 (favourable)	Expressed in all	Mixed			testis: 20.2	Mixed		
RASL10A	RRP22	ENSG00000100276	RAS like family 10 member A	22	29312933-29319679	Predicted intracellular proteins	Evidence at protein level	HPA056169	Approved					Tissue enhanced	Tissue enriched	15	cerebral cortex: 33.5	breast: 2.2	Cell line enhanced		HEK 293: 1.4;NB-4: 1.5;U-2 OS: 1.1;U-266/70: 2.0
AP1B1	ADTB1, AP105A, BAM22, CLAPB2	ENSG00000100280	Adaptor related protein complex 1 beta 1 subunit	22	29327680-29423179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065226, HPA068520	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:7.24e-6 (favourable), Liver cancer:5.55e-5 (unfavourable), Cervical cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.2	Expressed in all		
HMGXB4	HMG2L1, THC211630	ENSG00000100281	HMG-box containing 4	22	35257452-35295807	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000725	Approved				Colorectal cancer:3.24e-5 (favourable), Pancreatic cancer:1.16e-4 (unfavourable), Liver cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.8	Expressed in all		
TOM1		ENSG00000100284	Target of myb1 membrane trafficking protein	22	35299275-35347994	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000818, HPA001749	Approved		Approved	Plasma membrane<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:2.20e-5 (favourable), Renal cancer:3.72e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 54.6	Expressed in all		
NEFH		ENSG00000100285	Neurofilament heavy	22	29480230-29491390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB007786, HPA061615	Enhanced		Approved	Nucleoli<br>Cytosol	Breast cancer:2.33e-6 (favourable)	Group enriched	Tissue enriched	11	prostate: 405.8	cerebral cortex: 37.3	Cell line enriched	6	SiHa: 193.4
CHKB	CHETK, CHKL	ENSG00000100288	Choline kinase beta	22	50578949-50601455	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018797	Approved		Approved	Cytosol	Renal cancer:1.56e-5 (unfavourable), Cervical cancer:4.66e-4 (favourable)	Expressed in all	Mixed			testis: 15.1	Mixed		
BIK	NBK	ENSG00000100290	BCL2 interacting killer	22	43110748-43129712	Predicted membrane proteins	Evidence at protein level	HPA051360	Approved				Renal cancer:7.45e-5 (favourable)	Mixed	Mixed			lymph node: 14.0	Cell line enhanced		A-431: 77.8;U-698: 117.1
HMOX1	bK286B10, HO-1	ENSG00000100292	Heme oxygenase 1	22	35380361-35394214	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000635, CAB017444	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 428.5	Cell line enhanced		BEWO: 701.9;U-138 MG: 414.7;U-87 MG: 399.9
MCAT	fabD, FASN2C, MCT, MCT1, MT, NET62	ENSG00000100294	Malonyl-CoA-acyl carrier protein transacylase	22	43132206-43143394	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003122, HPA035471	Approved		Supported	Mitochondria	Renal cancer:2.18e-4 (favourable), Stomach cancer:3.89e-4 (favourable), Endometrial cancer:5.53e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 23.0	Expressed in all		
THOC5	C22orf19, Fmip, fSAP79, KIAA0983, PK1.3	ENSG00000100296	THO complex 5	22	29505879-29555216	Predicted intracellular proteins	Evidence at protein level	HPA048402			Supported	Nucleoplasm	Liver cancer:3.76e-6 (unfavourable), Renal cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 43.1	Expressed in all		
MCM5	CDC46	ENSG00000100297	Minichromosome maintenance complex component 5	22	35400063-35425430	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000101, HPA000845, HPA052880	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:2.81e-6 (favourable), Renal cancer:3.58e-5 (unfavourable), Liver cancer:1.78e-4 (unfavourable), Lung cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 88.5	Expressed in all		
APOBEC3H	ARP10	ENSG00000100298	Apolipoprotein B mRNA editing enzyme catalytic subunit 3H	22	39097224-39104067	Predicted intracellular proteins	Evidence at protein level	HPA021492	Approved				Renal cancer:8.73e-12 (unfavourable), Urothelial cancer:8.43e-7 (favourable), Cervical cancer:1.20e-4 (favourable)	Mixed	Mixed			epididymis: 4.8	Cell line enhanced		HDLM-2: 2.7;Karpas-707: 5.3;U-266/70: 3.7
ARSA		ENSG00000100299	Arylsulfatase A	22	50622754-50628173	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005554, CAB025183	Enhanced		Uncertain	Golgi apparatus<br>Cytosol	Endometrial cancer:2.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 37.4	Cell line enhanced		Karpas-707: 58.2
TSPO	BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS	ENSG00000100300	Translocator protein	22	43151514-43163242	Cancer-related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB011232, HPA046260	Uncertain		Approved	Vesicles<br>Mitochondria<br>Cytosol	Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 300.6	Mixed		
RASD2	MGC:4834, Rhes, TEM2	ENSG00000100302	RASD family member 2	22	35540868-35554001	Predicted intracellular proteins	Evidence at protein level	HPA005839	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.22e-5 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 32.2	epididymis: 18.5	Cell line enhanced		SK-BR-3: 4.2;U-2 OS: 3.3;U-87 MG: 3.9
TTLL12	KIAA0153	ENSG00000100304	Tubulin tyrosine ligase like 12	22	43166622-43187133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003054, CAB046029	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 74.3	Expressed in all		
CBX7		ENSG00000100307	Chromobox 7	22	39120167-39152674	Predicted intracellular proteins	Evidence at protein level	CAB011574, HPA048677, HPA056480	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.45e-5 (favourable), Pancreatic cancer:1.04e-4 (favourable), Cervical cancer:3.63e-4 (favourable), Colorectal cancer:3.73e-4 (unfavourable), Breast cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.6	Cell line enhanced		HDLM-2: 34.6
PDGFB	SIS, SSV	ENSG00000100311	Platelet derived growth factor subunit B	22	39223359-39244751	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB011604, HPA011972, CAB018341	Supported		Approved	Vesicles	Lung cancer:3.67e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 59.7	lung: 28.6	Cell line enhanced		EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5
ACR		ENSG00000100312	Acrosin	22	50738196-50745334	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA048687	Enhanced					Not detected	Tissue enriched	57	testis: 58.0	spleen: 1.0	Not detected		
CABP7	MGC57793	ENSG00000100314	Calcium binding protein 7	22	29720084-29731839	Predicted membrane proteins	Evidence at protein level	HPA016439	Uncertain					Tissue enhanced	Tissue enhanced		adrenal gland: 2.5;cerebral cortex: 3.4	small intestine: 1.4	Group enriched	13	HEL: 9.4;SCLC-21H: 11.7;SH-SY5Y: 3.3;U-2 OS: 3.4
RPL3	L3	ENSG00000100316	Ribosomal protein L3	22	39312882-39320389	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA003365, HPA055361	Uncertain		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			ovary: 5675.2	Expressed in all		
ZMAT5	SNRNP20, ZC3H19	ENSG00000100319	Zinc finger matrin-type 5	22	29730956-29767011	Predicted intracellular proteins	Evidence at protein level	HPA004858	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 35.5	Expressed in all		
RBFOX2	FOX-2, HNRBP2, HRNBP2, RBM9	ENSG00000100320	RNA binding protein, fox-1 homolog 2	22	35738736-36028425	Predicted intracellular proteins	Evidence at protein level	HPA006240	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			endometrium: 108.5	Expressed in all		
SYNGR1		ENSG00000100321	Synaptogyrin 1	22	39349925-39385588	Predicted membrane proteins	Evidence at protein level	HPA029673, CAB034277	Enhanced		Supported	Cytosol	Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 175.4	Mixed		
TAB1	MAP3K7IP1	ENSG00000100324	TGF-beta activated kinase 1 (MAP3K7) binding protein 1	22	39399741-39437060	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032328, HPA039988, HPA057104	Approved		Enhanced	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 23.1	Expressed in all		
ASCC2	ASC1p100, DKFZp586O0223, FLJ21588	ENSG00000100325	Activating signal cointegrator 1 complex subunit 2	22	29788608-29838304	Predicted intracellular proteins	Evidence at protein level	HPA001439, HPA052879	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			testis: 46.0	Expressed in all		
MTMR3	FYVE-DSP1, KIAA0371, ZFYVE10	ENSG00000100330	Myotubularin related protein 3	22	29883155-30030866	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034515, HPA034516, HPA061399	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			bone marrow: 52.3	Expressed in all		
MIEF1	FLJ20232, MiD51, SMCR7L	ENSG00000100335	Mitochondrial elongation factor 1	22	39499432-39518132	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA061059			Approved	Intermediate filaments<br>Mitochondria	Renal cancer:3.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
APOL4	APOLIV	ENSG00000100336	Apolipoprotein L4	22	36189124-36204840	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049797, HPA055435	Approved		Supported	Vesicles	Urothelial cancer:2.40e-6 (favourable), Renal cancer:2.00e-5 (unfavourable), Ovarian cancer:3.45e-4 (favourable)	Expressed in all	Mixed			prostate: 26.7	Cell line enhanced		BEWO: 19.1;HDLM-2: 103.0;K-562: 21.3;SCLC-21H: 56.9
PNPLA5	dJ388M5.4, GS2L	ENSG00000100341	Patatin like phospholipase domain containing 5	22	43879678-43892013	Predicted intracellular proteins	Evidence at transcript level	HPA050409, HPA054211	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 1.1;epididymis: 2.1	skin: 0.7	Cell line enhanced		NTERA-2: 1.4;RPMI-8226: 1.9;SCLC-21H: 1.0
APOL1	APOL	ENSG00000100342	Apolipoprotein L1	22	36253010-36267530	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018885, CAB056156	Supported				Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Cell line enhanced		EFO-21: 233.1;HDLM-2: 156.1;RT4: 120.9
PNPLA3	adiponutrin, ADPN, C22orf20, dJ796I17.1, FLJ22012, iPLA2epsilon	ENSG00000100344	Patatin like phospholipase domain containing 3	22	43923739-43964488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058058	Approved		Approved	Nucleoli<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		liver: 16.2	kidney: 4.7	Mixed		
MYH9	DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA	ENSG00000100345	Myosin heavy chain 9	22	36281281-36388018	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001644, CAB015386, HPA064783	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			spleen: 308.5	Expressed in all		
CACNA1I	Cav3.3	ENSG00000100346	Calcium voltage-gated channel subunit alpha1 I	22	39570753-39689737	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 4.7;thyroid gland: 2.7	adrenal gland: 2.3	Cell line enhanced		SK-BR-3: 1.4;T-47d: 1.0
SAMM50	CGI-51, OMP85, SAM50, TOB55, TRG-3, YNL026W	ENSG00000100347	SAMM50 sorting and assembly machinery component	22	43955421-44010531	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034537	Enhanced		Enhanced	Mitochondria	Renal cancer:4.43e-8 (favourable), Endometrial cancer:2.63e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 242.2	Expressed in all		
TXN2	MT-TRX	ENSG00000100348	Thioredoxin 2	22	36467036-36482030	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000994, CAB008681	Approved		Enhanced	Mitochondria	Renal cancer:1.17e-6 (favourable), Prostate cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 145.2	Expressed in all		
FOXRED2	ERFAD, FLJ23322	ENSG00000100350	FAD dependent oxidoreductase domain containing 2	22	36487190-36507101	Predicted secreted proteins	Evidence at protein level	HPA031611, HPA031612	Approved				Cervical cancer:4.86e-5 (favourable), Thyroid cancer:9.32e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		SiHa: 155.2
GRAP2	GADS, GRBLG, GrbX, Grf40, Mona	ENSG00000100351	GRB2-related adaptor protein 2	22	39901082-39973721	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005788, CAB022073	Enhanced					Mixed	Tissue enhanced		lymph node: 18.0	spleen: 12.8	Group enriched	8	HDLM-2: 22.1;HEL: 40.9;K-562: 39.9;MOLT-4: 98.1
EIF3D	eIF3-p66, eIF3-zeta, eIF3d, EIF3S7	ENSG00000100353	Eukaryotic translation initiation factor 3 subunit D	22	36510850-36529436	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045882, HPA063330, HPA066216	Approved		Supported	Cytosol	Liver cancer:8.10e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 256.0	Expressed in all		
TNRC6B	KIAA1093	ENSG00000100354	Trinucleotide repeat containing 6B	22	40044817-40335808	Predicted intracellular proteins	Evidence at protein level	HPA003180	Approved					Expressed in all	Mixed			testis: 27.6	Expressed in all		
SGSM3	DJ1042K10.2, RabGAP-5, RABGAP5, RUSC3, RUTBC3	ENSG00000100359	Small G protein signaling modulator 3	22	40370591-40410289	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048980	Approved		Supported	Golgi apparatus	Endometrial cancer:4.47e-5 (favourable)	Expressed in all	Expressed in all			stomach: 75.9	Expressed in all		
IFT27	BBS19, RABL4, RAYL	ENSG00000100360	Intraflagellar transport 27	22	36758202-36776256	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018418	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:1.91e-4 (favourable), Urothelial cancer:5.55e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 57.4	Cell line enhanced		U-138 MG: 156.6
PVALB	D22S749	ENSG00000100362	Parvalbumin	22	36800684-36819479	Predicted intracellular proteins	Evidence at protein level	CAB002515, HPA048536	Enhanced	Approved	Approved	Nucleoplasm<br>Nucleoli<br>Cell Junctions		Group enriched	Tissue enriched	13	parathyroid gland: 547.2	kidney: 43.5	Cell line enriched	144	RPMI-8226: 558.1
KIAA0930	bK268H5.C22.1, C22orf9	ENSG00000100364	KIAA0930	22	45190338-45240769	Predicted intracellular proteins	Evidence at protein level	HPA038091	Uncertain		Approved	Nuclear membrane<br>Mitochondria	Liver cancer:6.90e-8 (unfavourable), Renal cancer:8.95e-7 (unfavourable), Endometrial cancer:9.22e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.2	Cell line enhanced		THP-1: 220.8
NCF4	p40phox, SH3PXD4	ENSG00000100365	Neutrophil cytosolic factor 4	22	36860988-36878015	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010146, HPA036156, HPA057975	Enhanced		Supported	Cytosol	Renal cancer:7.06e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 119.9	appendix: 59.4	Cell line enhanced		HEL: 78.2;HMC-1: 349.8;NB-4: 93.8;RPMI-8226: 102.1;THP-1: 92.9
CSF2RB	CD131, IL3RB, IL5RB	ENSG00000100368	Colony stimulating factor 2 receptor beta common subunit	22	36913628-36940449	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA078677			Approved	Golgi apparatus	Head and neck cancer:7.47e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 89.7	tonsil: 57.2	Group enriched	7	HEL: 95.8;HMC-1: 281.8
SLC25A17	PMP34	ENSG00000100372	Solute carrier family 25 member 17	22	40769630-40819399	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052708, HPA060972	Approved		Supported	Peroxisomes		Expressed in all	Expressed in all			ovary: 24.1	Expressed in all		
UPK3A	UPK3	ENSG00000100373	Uroplakin 3A	22	45284982-45295874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018407, HPA018415	Enhanced		Uncertain	Nuclear membrane<br>Nuclear bodies		Group enriched	Group enriched	7	parathyroid gland: 13.0;prostate: 35.0;skeletal muscle: 12.6;urinary bladder: 15.4	thyroid gland: 2.6	Group enriched	6	Hep G2: 20.8;RT4: 40.2
FAM118A	bK268H5.C22.4, C22orf8, FLJ20635	ENSG00000100376	Family with sequence similarity 118 member A	22	45308968-45341955	Predicted intracellular proteins	Evidence at protein level	HPA003902	Uncertain		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.87e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.1	Expressed in all		
KCTD17	FLJ12242	ENSG00000100379	Potassium channel tetramerization domain containing 17	22	37051736-37063390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018459	Uncertain				Renal cancer:5.13e-12 (unfavourable), Liver cancer:3.59e-5 (unfavourable), Pancreatic cancer:4.22e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 55.9	testis: 35.3	Mixed		
ST13	FAM10A1, HIP, HSPABP1, P48, SNC6	ENSG00000100380	Suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting protein)	22	40824535-40857022	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043233, HPA046412, HPA047114, HPA047116	Enhanced		Enhanced	Cytosol	Renal cancer:3.10e-4 (favourable), Head and neck cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 653.8	Expressed in all		
IL2RB	CD122, IL15RB	ENSG00000100385	Interleukin 2 receptor subunit beta	22	37125838-37175054	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062657	Enhanced				Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 52.7;spleen: 67.1	lymph node: 39.8	Cell line enriched	10	HDLM-2: 476.9
RBX1	BA554C12.1, RNF75, ROC1	ENSG00000100387	Ring-box 1	22	40951347-40973309	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003038			Supported	Nucleoplasm	Ovarian cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 70.6	Expressed in all		
EP300	KAT3B, p300	ENSG00000100393	E1A binding protein p300	22	41091786-41180079	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000146, HPA003128, HPA004112	Supported		Enhanced	Nucleoplasm	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
L3MBTL2	dJ756G23.3, DKFZP761I141, H-l(3)mbt-l	ENSG00000100395	L3MBTL2 polycomb repressive complex 1 subunit	22	41205205-41231271	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000815			Approved	Nucleoplasm	Cervical cancer:6.39e-5 (favourable), Endometrial cancer:4.37e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 30.2	Expressed in all		
CHADL	SLRR4B	ENSG00000100399	Chondroadherin like	22	41229510-41240934	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005696, HPA024654	Uncertain				Lung cancer:1.56e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 28.4	skin: 6.7	Cell line enhanced		BEWO: 11.4
RANGAP1	Fug1, KIAA1835, SD	ENSG00000100401	Ran GTPase activating protein 1	22	41245611-41286251	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004293, HPA050110, HPA062034	Enhanced		Enhanced	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:1.08e-4 (unfavourable), Stomach cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 206.1	Expressed in all		
ZC3H7B	DKFZp434K0920, FLJ13787, KIAA1031, RoXaN	ENSG00000100403	Zinc finger CCCH-type containing 7B	22	41301522-41360147	Predicted intracellular proteins	Evidence at protein level	HPA001784	Uncertain		Uncertain	Cytosol	Renal cancer:5.43e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 81.6	Expressed in all		
PHF5A	bK223H9.2, INI, MGC1346, Rds3, SAP14b, SF3b14b, SF3B7	ENSG00000100410	PHD finger protein 5A	22	41459717-41468725	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028885	Supported		Enhanced	Nucleoplasm	Liver cancer:3.02e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 39.8	Expressed in all		
ACO2	ACONM	ENSG00000100412	Aconitase 2	22	41469125-41528989	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001097	Enhanced	Supported	Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			heart muscle: 308.9	Expressed in all		
POLR3H	KIAA1665, RPC8	ENSG00000100413	RNA polymerase III subunit H	22	41525804-41544606	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA046787	Approved		Supported	Nucleoplasm<br>Vesicles<br>Centrosome	Liver cancer:2.04e-4 (unfavourable), Pancreatic cancer:5.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.5	Expressed in all		
TRMU	FLJ10140, MTO2, TRMT	ENSG00000100416	TRNA 5-methylaminomethyl-2-thiouridylate methyltransferase	22	46330875-46357340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000824, HPA035273, HPA043300	Uncertain		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.63e-6 (unfavourable), Liver cancer:3.04e-5 (unfavourable), Pancreatic cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.0	Expressed in all		
PMM1	Sec53	ENSG00000100417	Phosphomannomutase 1	22	41576894-41589890	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030712	Uncertain				Endometrial cancer:6.09e-6 (favourable), Pancreatic cancer:2.05e-4 (favourable), Cervical cancer:5.92e-4 (favourable)	Expressed in all	Expressed in all			ovary: 54.9	Expressed in all		
DESI1	D15Wsu75e, FAM152B, PPPDE2	ENSG00000100418	Desumoylating isopeptidase 1	22	41598028-41621096	Predicted intracellular proteins	Evidence at protein level	HPA053415	Approved		Approved	Cytokinetic bridge<br>Cytosol	Endometrial cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.5	Expressed in all		
CERK	dA59H18.2, dA59H18.3, DKFZp434E0211, FLJ21430, FLJ23239, hCERK, KIAA1646, LK4	ENSG00000100422	Ceramide kinase	22	46684411-46738261	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064699			Approved	Vesicles	Urothelial cancer:1.58e-4 (unfavourable), Pancreatic cancer:2.35e-4 (favourable), Endometrial cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 34.3	Mixed		
BRD1	BRL, BRPF2	ENSG00000100425	Bromodomain containing 1	22	49773283-49827512	Predicted intracellular proteins	Evidence at protein level	HPA000807, HPA001063	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 58.5	Expressed in all		
ZBED4	KIAA0637	ENSG00000100426	Zinc finger BED-type containing 4	22	49853842-49890078	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045341	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 7.7	Expressed in all		
MLC1	KIAA0027, LVM, MLC, VL	ENSG00000100427	Megalencephalic leukoencephalopathy with subcortical cysts 1	22	50059391-50085902	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003040, HPA067533	Enhanced					Tissue enriched	Tissue enriched	8	cerebral cortex: 180.8	bone marrow: 23.0	Cell line enhanced		HL-60: 182.4;NB-4: 133.9;THP-1: 267.0;U-266/70: 101.9;U-266/84: 85.6
HDAC10	DKFZP761B039	ENSG00000100429	Histone deacetylase 10	22	50245183-50251405	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045977, HPA056514	Supported		Approved	Nucleoli fibrillar center	Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable)	Expressed in all	Mixed			spleen: 9.8	Mixed		
KCNK10	K2p10.1, PPP1R97, TREK-2, TREK2	ENSG00000100433	Potassium two pore domain channel subfamily K member 10	14	88180103-88326907	Predicted membrane proteins	Evidence at protein level	HPA030462	Approved					Mixed	Tissue enhanced		cerebral cortex: 5.6;duodenum: 5.1	small intestine,stomach: 2.7	Cell line enhanced		AF22: 1.0;REH: 1.6;SCLC-21H: 3.7
ABHD4	FLJ12816	ENSG00000100439	Abhydrolase domain containing 4	14	22598237-22613215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000600	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			testis: 62.8	Mixed		
KHNYN	KIAA0323	ENSG00000100441	KH and NYN domain containing	14	24429286-24441834	Predicted intracellular proteins	Evidence at protein level	HPA003402	Uncertain		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:4.38e-4 (unfavourable), Glioma:9.44e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Mixed		
FKBP3	FKBP-25, PPIase	ENSG00000100442	FK506 binding protein 3	14	45115600-45135319	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000864, CAB012232, CAB012520	Supported		Supported	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 143.3	Expressed in all		
SDR39U1	C14orf124, HCDI	ENSG00000100445	Short chain dehydrogenase/reductase family 39U member 1	14	24439766-24442905	Predicted intracellular proteins	Evidence at protein level	HPA044294	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 42.9	Expressed in all		
CTSG	CG	ENSG00000100448	Cathepsin G	14	24573522-24576260	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000110, HPA047737	Enhanced				Head and neck cancer:1.57e-4 (favourable), Urothelial cancer:8.91e-4 (unfavourable)	Mixed	Tissue enriched	84	bone marrow: 3457.0	gallbladder: 41.2	Cell line enriched	6	THP-1: 6055.4
GZMH	CCP-X, CGL-2, CSP-C, CTLA1, CTSGL2	ENSG00000100450	Granzyme H	14	24606480-24609699	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA029200	Enhanced				Renal cancer:1.74e-6 (unfavourable), Endometrial cancer:2.00e-6 (favourable)	Expressed in all	Tissue enhanced		spleen: 35.3	lymph node: 25.3	Not detected		
GZMB	CCPI, CGL-1, CGL1, CSP-B, CSPB, CTLA1, CTSGL1, HLP, SECT	ENSG00000100453	Granzyme B	14	24630954-24634267	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000376, HPA003418	Enhanced				Renal cancer:1.10e-7 (unfavourable), Endometrial cancer:1.58e-5 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 40.1	bone marrow,spleen: 36.2	Cell line enriched	6	HMC-1: 17.4
RBM23	CAPERbeta, FLJ10482, RNPC4	ENSG00000100461	RNA binding motif protein 23	14	22893206-22919184	Predicted intracellular proteins	Evidence at protein level	HPA004144	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:8.06e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 144.3	Expressed in all		
PRMT5	HRMT1L5, SKB1, SKB1Hs	ENSG00000100462	Protein arginine methyltransferase 5	14	22920511-22929585	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005525, CAB012459, HPA064708	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:4.77e-5 (unfavourable), Urothelial cancer:1.04e-4 (unfavourable), Head and neck cancer:1.82e-4 (unfavourable), Pancreatic cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.8	Expressed in all		
COCH	COCH-5B2, DFNA31, DFNA9	ENSG00000100473	Cochlin	14	30874514-30895065	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065086			Approved	Vesicles		Mixed	Group enriched	6	pancreas: 94.8;prostate: 79.0;seminal vesicle: 99.1	cervix, uterine: 15.4	Cell line enhanced		HEK 293: 92.9;K-562: 114.9;NB-4: 71.8;SCLC-21H: 130.1
AP4S1	AP47B, CLA20, SPG52	ENSG00000100478	Adaptor related protein complex 4 sigma 1 subunit	14	31025106-31096450	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039963	Approved		Supported	Vesicles	Renal cancer:2.87e-6 (favourable), Lung cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
POLE2	DPE2	ENSG00000100479	DNA polymerase epsilon 2, accessory subunit	14	49643555-49688422	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027555	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Mixed			bone marrow: 10.7	Mixed		
VCPKMT	C14orf138, METTL21D, VCP-KMT	ENSG00000100483	Valosin containing protein lysine methyltransferase	14	50108632-50116600	Predicted intracellular proteins	Evidence at protein level	HPA001146, HPA076561	Uncertain		Supported	Cytosol	Lung cancer:2.40e-4 (favourable), Prostate cancer:4.75e-4 (unfavourable), Renal cancer:6.79e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 5.3	Expressed in all		
SOS2		ENSG00000100485	SOS Ras/Rho guanine nucleotide exchange factor 2	14	50117120-50231558	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004577, HPA047368, HPA052689	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:8.48e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.7	Expressed in all		
CDKL1	KKIALRE	ENSG00000100490	Cyclin dependent kinase like 1	14	50329404-50416461	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059605, HPA065919	Uncertain		Enhanced	Nucleoplasm<br>Vesicles		Mixed	Mixed			fallopian tube: 34.5	Mixed		
NIN		ENSG00000100503	Ninein	14	50719763-50831121	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005939, HPA070691	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Centrosome		Expressed in all	Mixed			lymph node: 47.5	Expressed in all		
PYGL		ENSG00000100504	Glycogen phosphorylase L	14	50857891-50944736	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000962, HPA004119	Enhanced		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.63e-4 (unfavourable), Head and neck cancer:5.97e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 116.5	Mixed		
TRIM9	RNF91, SPRING	ENSG00000100505	Tripartite motif containing 9	14	50975262-51096061	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041489			Supported	Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 79.2	gallbladder: 6.9	Cell line enhanced		AN3-CA: 29.8;HAP1: 23.6;HDLM-2: 33.8;SCLC-21H: 38.5
PSMC6	p42	ENSG00000100519	Proteasome 26S subunit, ATPase 6	14	52707172-52728587	Predicted intracellular proteins	Evidence at protein level	HPA042823	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 91.8	Expressed in all		
GNPNAT1	FLJ10607, Gpnat1	ENSG00000100522	Glucosamine-phosphate N-acetyltransferase 1	14	52775194-52791668	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044647	Approved				Pancreatic cancer:8.52e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 39.4	Expressed in all		
DDHD1	KIAA1705, PA-PLA1, SPG28	ENSG00000100523	DDHD domain containing 1	14	53036745-53153282	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049870	Enhanced					Mixed	Tissue enhanced		testis: 34.2	cerebral cortex: 10.6	Expressed in all		
CDKN3	CDI1, KAP	ENSG00000100526	Cyclin dependent kinase inhibitor 3	14	54396849-54420218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005285, HPA039311, HPA058874			Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Lung cancer:4.52e-4 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enriched	11	testis: 342.6	lymph node: 31.7	Expressed in all		
CNIH1	CNIH, CNIL, TGAM77	ENSG00000100528	Cornichon family AMPA receptor auxiliary protein 1	14	54423560-54441431	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002544	Approved		Approved	Vesicles	Urothelial cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 119.4	Expressed in all		
CGRRF1	CGR19, RNF197	ENSG00000100532	Cell growth regulator with ring finger domain 1	14	54509812-54539309	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002930	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:2.57e-8 (favourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
ATP6V1D	ATP6M, VATD, VMA8	ENSG00000100554	ATPase H+ transporting V1 subunit D	14	67294371-67360265	Predicted intracellular proteins	Evidence at protein level	HPA031515, HPA057316	Enhanced		Approved	Nucleoplasm	Renal cancer:7.60e-13 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 195.5	Expressed in all		
C14orf105	FLJ10650	ENSG00000100557	Chromosome 14 open reading frame 105	14	57469301-57493867	Predicted intracellular proteins	Evidence at transcript level	HPA029202			Uncertain	Nucleus<br>Cytosol	Renal cancer:1.92e-4 (favourable), Liver cancer:5.61e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 43.7;gallbladder: 27.1;kidney: 63.6	liver: 11.3	Group enriched	6	A549: 10.7;RPTEC TERT1: 26.1
PLEK2		ENSG00000100558	Pleckstrin 2	14	67386983-67412200	Predicted intracellular proteins	Evidence at protein level	HPA001208	Enhanced		Uncertain	Vesicles<br>Cytosol	Pancreatic cancer:8.26e-5 (unfavourable), Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 43.1	Cell line enhanced		A-431: 77.9;CAPAN-2: 81.3;HBEC3-KT: 124.1
PIGH	GPI-H	ENSG00000100564	Phosphatidylinositol glycan anchor biosynthesis class H	14	67581955-67600287	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031624	Approved				Renal cancer:2.68e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 107.3	Expressed in all		
LRRC74A	C14orf166B, LRRC74	ENSG00000100565	Leucine rich repeat containing 74A	14	76826372-76870302	Predicted intracellular proteins	Evidence at transcript level	HPA035094	Uncertain					Not detected	Tissue enriched	19	testis: 7.1	salivary gland,spleen,stomach: 0.3	Not detected		
PSMA3	HC8	ENSG00000100567	Proteasome subunit alpha 3	14	58244831-58272012	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000905	Approved		Approved	Microtubules<br>Cytokinetic bridge	Thyroid cancer:2.91e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 150.8	Expressed in all		
VTI1B	VTI2	ENSG00000100568	Vesicle transport through interaction with t-SNAREs 1B	14	67647075-67674831	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044121, HPA048150, HPA060118	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.53e-12 (favourable)	Expressed in all	Expressed in all			epididymis: 64.9	Expressed in all		
TIMM9	TIM9A	ENSG00000100575	Translocase of inner mitochondrial membrane 9	14	58408494-58427614	Predicted intracellular proteins	Evidence at protein level	HPA002932	Approved		Enhanced	Mitochondria	Ovarian cancer:6.39e-5 (favourable), Liver cancer:9.89e-5 (unfavourable), Breast cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.7	Expressed in all		
GSTZ1	GSTZ1-1, MAAI, MAI	ENSG00000100577	Glutathione S-transferase zeta 1	14	77320884-77331597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004701	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.12e-7 (favourable), Ovarian cancer:3.73e-4 (favourable), Breast cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			liver: 134.5	Expressed in all		
KIAA0586	JBTS23, Talpid3	ENSG00000100578	KIAA0586	14	58427385-58551289	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000846, HPA050249	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.20e-4 (favourable)	Expressed in all	Mixed			testis: 29.3	Expressed in all		
TMED8	FAM15B	ENSG00000100580	Transmembrane p24 trafficking protein family member 8	14	77335021-77377109	Predicted intracellular proteins	Evidence at protein level	HPA001205	Approved					Expressed in all	Mixed			lymph node: 20.8	Expressed in all		
SAMD15	C14orf174, FAM15A, FLJ35963	ENSG00000100583	Sterile alpha motif domain containing 15	14	77376689-77391497	Predicted intracellular proteins	Evidence at protein level	HPA030673, HPA030677	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli		Mixed	Tissue enhanced		testis: 32.0	fallopian tube: 7.3	Mixed		
AHSA1	Aha1, C14orf3, hAha1, p38	ENSG00000100591	Activator of HSP90 ATPase activity 1	14	77457870-77469474	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000903, CAB006244	Supported		Supported	Cytosol	Liver cancer:5.04e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 180.4	Expressed in all		
DAAM1	KIAA0666	ENSG00000100592	Dishevelled associated activator of morphogenesis 1	14	59188646-59371405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026605, HPA064789	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.1	Expressed in all		
ISM2	FLJ32147, TAIL1, THSD3	ENSG00000100593	Isthmin 2	14	77474394-77498850	Predicted secreted proteins	Evidence at protein level	HPA039314, HPA039742	Supported		Supported	Nucleoplasm		Mixed	Tissue enriched	112	placenta: 274.5	epididymis: 2.4	Cell line enriched	21	BEWO: 345.7
SPTLC2	hLCB2a, KIAA0526, LCB2, LCB2A	ENSG00000100596	Serine palmitoyltransferase long chain base subunit 2	14	77505997-77616773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027552			Approved	Mitochondria	Renal cancer:6.69e-8 (favourable), Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 29.0	Expressed in all		
RIN3	FLJ22439	ENSG00000100599	Ras and Rab interactor 3	14	92513774-92688994	Predicted intracellular proteins	Evidence at protein level	HPA039836	Uncertain					Expressed in all	Mixed			bone marrow: 29.5	Cell line enhanced		HMC-1: 94.1
LGMN	LGMN1, PRSC1	ENSG00000100600	Legumain	14	92703807-92748702	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001426	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.70e-4 (favourable)	Expressed in all	Expressed in all			placenta: 360.0	Cell line enhanced		RPMI-8226: 587.9;U-266/70: 339.8
ALKBH1	ABH, alkB, ALKBH, hABH	ENSG00000100601	AlkB homolog 1, histone H2A dioxygenase	14	77672404-77708020	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA044087	Approved				Renal cancer:1.80e-4 (favourable)	Expressed in all	Mixed			placenta: 5.7	Expressed in all		
SNW1	Bx42, NCoA-62, Prp45, PRPF45, SKIIP, SKIP	ENSG00000100603	SNW domain containing 1	14	77717599-77761207	Predicted intracellular proteins	Evidence at protein level	HPA002457, CAB009931, HPA017370	Supported		Enhanced	Nucleoplasm	Liver cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 85.0	Expressed in all		
CHGA		ENSG00000100604	Chromogranin A	14	92923080-92935293	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000023, HPA017369, CAB040544, CAB055506, CAB058688	Enhanced		Supported	Vesicles	Breast cancer:7.85e-5 (favourable), Liver cancer:2.40e-4 (unfavourable), Urothelial cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.07e-4 (favourable)	Tissue enhanced	Tissue enriched	9	parathyroid gland: 7061.6	adrenal gland: 818.1	Group enriched	156	SCLC-21H: 285.4;SH-SY5Y: 700.4
ITPK1		ENSG00000100605	Inositol-tetrakisphosphate 1-kinase	14	92936914-93116320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055230	Approved		Approved	Mitochondria	Endometrial cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 93.1	Expressed in all		
DHRS7	retDSR4, SDR34C1	ENSG00000100612	Dehydrogenase/reductase 7	14	60144120-60169856	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031121	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.92e-10 (favourable), Head and neck cancer:2.51e-4 (unfavourable), Breast cancer:6.42e-4 (favourable), Ovarian cancer:7.99e-4 (unfavourable)	Tissue enriched	Expressed in all			prostate: 650.0	Expressed in all		
PPM1A	MGC9201, PP2CA, PP2Calpha	ENSG00000100614	Protein phosphatase, Mg2+/Mn2+ dependent 1A	14	60245752-60299087	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029209	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.57e-9 (favourable)	Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
SIX4	AREC3	ENSG00000100625	SIX homeobox 4	14	60709528-60724348	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031794	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enriched	5	parathyroid gland: 23.9	skeletal muscle: 4.7	Cell line enhanced		A-431: 29.3;RH-30: 31.5
GALNT16	GalNAc-T16, GALNTL1, KIAA1130	ENSG00000100626	Polypeptide N-acetylgalactosaminyltransferase 16	14	69259277-69357033	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059136	Approved		Approved	Nucleus	Renal cancer:5.23e-6 (favourable)	Mixed	Mixed			cerebral cortex: 28.5	Cell line enhanced		AF22: 9.0;hTEC/SVTERT24-B: 17.0;SCLC-21H: 10.5;U-2 OS: 21.2
ASB2	ASB-2	ENSG00000100628	Ankyrin repeat and SOCS box containing 2	14	93934153-93976791	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.62e-6 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 85.8	smooth muscle: 25.6	Cell line enhanced		Karpas-707: 7.3;RPMI-8226: 6.6;U-266/70: 21.0;U-266/84: 4.6
CEP128	C14orf145, C14orf61	ENSG00000100629	Centrosomal protein 128	14	80476983-80959517	Predicted intracellular proteins	Evidence at protein level	HPA000602, HPA001116, HPA018498	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Mixed	Mixed			testis: 9.5	Cell line enhanced		U-266/70: 83.9
ERH	DROER	ENSG00000100632	Enhancer of rudimentary homolog (Drosophila)	14	69380123-69398627	Predicted intracellular proteins	Evidence at protein level	HPA002567	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.89e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 112.0	Expressed in all		
HIF1A	bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8	ENSG00000100644	Hypoxia inducible factor 1 alpha subunit	14	61695513-61748259	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000907, HPA001275, CAB017442	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Expressed in all	Expressed in all			bone marrow: 292.4	Mixed		
SUSD6	KIAA0247	ENSG00000100647	Sushi domain containing 6	14	69611596-69715142	Predicted membrane proteins	Evidence at protein level	HPA030464	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 52.4	Expressed in all		
SRSF5	HRS, SFRS5, SRP40	ENSG00000100650	Serine and arginine rich splicing factor 5	14	69726900-69772005	Predicted intracellular proteins	Evidence at protein level	HPA043484, HPA056523	Approved		Enhanced	Nucleus<br>Nucleoli	Cervical cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 311.9	Expressed in all		
SLC10A1	NTCP	ENSG00000100652	Solute carrier family 10 member 1	14	69775417-69797289	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042727	Approved				Liver cancer:9.53e-6 (favourable)	Tissue enriched	Tissue enriched	394	liver: 212.4	gallbladder: 0.5	Not detected		
EIF5		ENSG00000100664	Eukaryotic translation initiation factor 5	14	103333544-103345025	Predicted intracellular proteins	Evidence at protein level	HPA000867, CAB004226	Supported		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.67e-7 (favourable)	Expressed in all	Expressed in all			testis: 174.0	Expressed in all		
SERPINA4	KAL, kallistatin, KLST, KST, PI4	ENSG00000100665	Serpin family A member 4	14	94561091-94569913	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003607	Approved				Endometrial cancer:2.95e-4 (favourable)	Group enriched	Tissue enhanced		gallbladder: 72.6;liver: 242.7	epididymis: 42.8	Group enriched	36	CACO-2: 4.7;Hep G2: 16.4
SLC8A3	NCX3	ENSG00000100678	Solute carrier family 8 member A3	14	70044217-70189070	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	6	cerebral cortex: 16.3;skeletal muscle: 6.1	adrenal gland: 1.7	Cell line enhanced		AF22: 4.3;LHCN-M2: 6.7;SH-SY5Y: 27.3
DICER1	Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1	ENSG00000100697	Dicer 1, ribonuclease III	14	95086228-95158010	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000694, CAB068185	Approved		Supported	Cytosol		Expressed in all	Expressed in all			placenta: 32.6	Expressed in all		
ZFYVE21	MGC2550, ZF21	ENSG00000100711	Zinc finger FYVE-type containing 21	14	103715730-103733668	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055721	Uncertain				Renal cancer:2.58e-6 (favourable)	Expressed in all	Expressed in all			endometrium: 88.6	Expressed in all		
MTHFD1	MTHFC, MTHFD	ENSG00000100714	Methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1	14	64388031-64463457	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000704, HPA001290, HPA015006, HPA050052	Approved		Enhanced	Cytosol	Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 198.5	Expressed in all		
TCL1A	TCL1	ENSG00000100721	T-cell leukemia/lymphoma 1A	14	95709967-95714196	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004045, HPA016604	Enhanced					Tissue enriched	Tissue enhanced		lymph node: 324.7;tonsil: 196.7	spleen: 77.8	Group enriched	147	Daudi: 334.2;REH: 557.7;U-698: 425.7
ZC3H14	FLJ11806, NY-REN-37, UKp68	ENSG00000100722	Zinc finger CCCH-type containing 14	14	88562909-88627596	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049798, HPA053510	Enhanced		Enhanced	Nuclear speckles	Renal cancer:7.08e-4 (favourable)	Expressed in all	Expressed in all			testis: 327.4	Expressed in all		
TELO2	hCLK2, KIAA0683, TEL2	ENSG00000100726	Telomere maintenance 2	16	1493344-1510457	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041348, HPA041473	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			spleen: 15.5	Expressed in all		
PCNX1	KIAA0805, KIAA0995, PCNX, PCNXL1, pecanex	ENSG00000100731	Pecanex homolog 1 (Drosophila)	14	70907405-71115382	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053532			Approved	Nucleoplasm	Renal cancer:4.05e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
BDKRB1	B1BKR, BKR1, bradyb1	ENSG00000100739	Bradykinin receptor B1	14	96255824-96268967	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA002935	Approved					Mixed	Tissue enhanced		gallbladder: 18.2	urinary bladder: 9.9	Cell line enhanced		BJ hTERT+: 19.8;HHSteC: 20.3;hTEC/SVTERT24-B: 23.1;U-2197: 23.8;U-87 MG: 82.4
GSKIP	C14orf129	ENSG00000100744	GSK3B interacting protein	14	96363452-96387288	Predicted intracellular proteins	Evidence at protein level	HPA043054, HPA046782	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			small intestine: 62.0	Expressed in all		
VRK1		ENSG00000100749	Vaccinia related kinase 1	14	96797304-96931722	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000660, HPA017929	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			testis: 59.5	Expressed in all		
PSMC1	p56, S4	ENSG00000100764	Proteasome 26S subunit, ATPase 1	14	90256495-90275429	Predicted intracellular proteins	Evidence at protein level	HPA000872	Approved		Enhanced	Nucleoplasm<br>Cytosol	Head and neck cancer:1.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 140.2	Expressed in all		
PAPLN	MGC50452	ENSG00000100767	Papilin, proteoglycan like sulfated glycoprotein	14	73237497-73274640	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048682, HPA053453	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			spleen: 20.6	Cell line enhanced		HHSteC: 12.9;HSkMC: 20.5
RPS6KA5	MSK1, RLPK	ENSG00000100784	Ribosomal protein S6 kinase A5	14	90847862-91060636	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001274, HPA001780, CAB025458	Approved		Enhanced	Nucleoplasm		Mixed	Mixed			breast: 12.1	Cell line enhanced		HMC-1: 40.2
PPP4R3A	FLFL1, FLJ20707, KIAA2010, MSTP033, PP4R3, SMEK1, smk-1, smk1	ENSG00000100796	Protein phosphatase 4 regulatory subunit 3A	14	91457611-91510554	Predicted intracellular proteins	Evidence at protein level	HPA002568, HPA063917	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 61.2	Expressed in all		
C14orf93	FLJ12154	ENSG00000100802	Chromosome 14 open reading frame 93	14	22985908-23010166	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002569	Approved		Approved	Nucleus<br>Plasma membrane	Breast cancer:5.05e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.7	Expressed in all		
PSMB5	MB1, X	ENSG00000100804	Proteasome subunit beta 5	14	23016543-23035230	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049518, HPA061796	Approved		Supported	Nucleus<br>Centrosome	Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 141.7	Expressed in all		
YY1	DELTA, INO80S, NF-E1, UCRBP, YIN-YANG-1	ENSG00000100811	YY1 transcription factor	14	100238298-100282792	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001119, CAB009392	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles	Liver cancer:3.44e-4 (unfavourable), Endometrial cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.8	Expressed in all		
ACIN1	ACINUS, fSAP152, KIAA0670	ENSG00000100813	Apoptotic chromatin condensation inducer 1	14	23058564-23095614	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000657	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:4.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 77.4	Expressed in all		
CCNB1IP1	C14orf18, HEI10	ENSG00000100814	Cyclin B1 interacting protein 1	14	20311368-20333312	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.18e-6 (favourable)	Expressed in all	Expressed in all			ovary: 120.9	Expressed in all		
TRIP11	CEV14, GMAP-210, GMAP210, Trip230	ENSG00000100815	Thyroid hormone receptor interactor 11	14	91965991-92040896	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002570, HPA070684	Supported		Enhanced	Nucleus<br>Golgi apparatus	Renal cancer:1.78e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
APEX1	APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1	ENSG00000100823	Apurinic/apyrimidinic endodeoxyribonuclease 1	14	20455191-20457772	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000956, HPA002564, CAB004294, CAB047307	Enhanced		Enhanced	Nucleus	Liver cancer:7.82e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 176.5	Expressed in all		
PABPN1	OPMD, PAB2, PABP2	ENSG00000100836	Poly(A) binding protein nuclear 1	14	23321289-23326185	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000637	Supported	Approved			Renal cancer:2.41e-7 (unfavourable), Liver cancer:3.55e-4 (unfavourable), Pancreatic cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 205.2	Expressed in all		
EFS	CASS3, EFS1, EFS2, HEFS, SIN	ENSG00000100842	Embryonal Fyn-associated substrate	14	23356402-23365752	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001581, HPA001790	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:4.09e-5 (unfavourable)	Mixed	Mixed			skin: 59.4	Cell line enhanced		AF22: 61.4;BEWO: 50.1;SH-SY5Y: 62.8
ARHGAP5	GFI2, p190-B, p190BRhoGAP, RhoGAP5	ENSG00000100852	Rho GTPase activating protein 5	14	32076114-32159728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046993, HPA056507	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.97e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 114.7	Mixed		
CINP	MGC849	ENSG00000100865	Cyclin dependent kinase 2 interacting protein	14	102341102-102362916	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 48.3	Expressed in all		
DHRS2	HEP27, SDR25C1	ENSG00000100867	Dehydrogenase/reductase 2	14	23630115-23645639	Predicted intracellular proteins	Evidence at protein level	HPA053915, HPA069551	Enhanced		Enhanced	Nucleus<br>Mitochondria	Renal cancer:3.75e-5 (unfavourable), Endometrial cancer:3.23e-4 (unfavourable), Urothelial cancer:6.45e-4 (favourable)	Tissue enriched	Group enriched	9	breast: 436.3;urinary bladder: 339.0	salivary gland: 40.8	Cell line enhanced		Hep G2: 476.9;RT4: 659.6;SK-BR-3: 2967.1;U-2 OS: 1332.4
SRP54		ENSG00000100883	Signal recognition particle 54	14	34981957-35029567	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048977, HPA062044	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 89.4	Expressed in all		
CPNE6		ENSG00000100884	Copine 6	14	24070837-24078100	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031636	Approved					Tissue enhanced	Group enriched	6	cerebral cortex: 88.0;seminal vesicle: 35.2	kidney: 9.7	Cell line enhanced		U-266/84: 1.3
CHD8	DUPLIN, HELSNF1, KIAA1564	ENSG00000100888	Chromodomain helicase DNA binding protein 8	14	21385194-21456126	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052186			Supported	Nucleoplasm	Liver cancer:4.94e-4 (unfavourable), Ovarian cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.1	Expressed in all		
PCK2	PEPCK, PEPCK2	ENSG00000100889	Phosphoenolpyruvate carboxykinase 2, mitochondrial	14	24094053-24110598	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB018734, HPA051162, HPA053502	Enhanced		Enhanced	Mitochondria	Liver cancer:2.81e-4 (favourable)	Expressed in all	Group enriched	6	duodenum: 367.6;kidney: 192.2;liver: 258.6;small intestine: 276.5	colon: 47.0	Expressed in all		
KIAA0391	MRPP3, PRORP	ENSG00000100890	KIAA0391	14	35121846-35277614	Predicted intracellular proteins	Evidence at protein level	HPA020459	Approved		Supported	Nucleus<br>Mitochondria		Mixed	Expressed in all			parathyroid gland: 42.6	Expressed in all		
DCAF11	GL014, PRO2389, WDR23	ENSG00000100897	DDB1 and CUL4 associated factor 11	14	24114195-24125242	Predicted intracellular proteins	Evidence at protein level	HPA003583, HPA031157	Approved		Enhanced	Nucleoplasm	Renal cancer:3.50e-13 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.3	Expressed in all		
PSMA6	IOTA, MGC22756, MGC2333, MGC23846, p27K, PROS27	ENSG00000100902	Proteasome subunit alpha 6	14	35278633-35317493	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003049	Approved		Supported	Nucleoplasm	Ovarian cancer:3.27e-4 (favourable)	Expressed in all	Expressed in all			testis: 390.4	Expressed in all		
NFKBIA	IkappaBalpha, IKBA, MAD-3, NFKBI	ENSG00000100906	NFKB inhibitor alpha	14	35401511-35404749	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003815, HPA029207	Approved		Enhanced	Cytosol	Breast cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 711.6	Expressed in all		
EMC9	C14orf122, CGI-112, FAM158A	ENSG00000100908	ER membrane protein complex subunit 9	14	24138959-24141588	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054715			Approved	Golgi apparatus	Ovarian cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 21.3	Expressed in all		
PSME2	PA28beta	ENSG00000100911	Proteasome activator subunit 2	14	24143362-24147570	Predicted intracellular proteins	Evidence at protein level	HPA062661			Approved	Nucleus	Renal cancer:3.47e-5 (unfavourable), Breast cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 287.9	Expressed in all		
BRMS1L	BRMS1, FLJ39177, MGC11296	ENSG00000100916	Breast cancer metastasis-suppressor 1-like	14	35826318-35932325	Predicted intracellular proteins	Evidence at protein level	HPA046623	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.87e-6 (unfavourable), Renal cancer:6.55e-5 (favourable), Liver cancer:1.34e-4 (unfavourable), Breast cancer:5.78e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 24.6	Expressed in all		
REC8	kleisin-alpha, REC8L1, Rec8p	ENSG00000100918	REC8 meiotic recombination protein	14	24171853-24180257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031727, HPA031729	Approved		Approved	Nucleoplasm	Renal cancer:1.41e-7 (unfavourable), Breast cancer:2.19e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 37.4	testis: 28.9	Cell line enhanced		AF22: 20.6;MOLT-4: 18.0;SH-SY5Y: 98.0
TM9SF1	HMP70, MP70	ENSG00000100926	Transmembrane 9 superfamily member 1	14	24189143-24195687	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059249	Supported		Approved	Golgi apparatus	Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
SEC23A		ENSG00000100934	Sec23 homolog A, coat complex II component	14	39031919-39109646	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043806, HPA069974	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.69e-4 (unfavourable), Stomach cancer:2.94e-4 (unfavourable), Colorectal cancer:3.56e-4 (favourable), Cervical cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 140.0	Expressed in all		
GMPR2		ENSG00000100938	Guanosine monophosphate reductase 2	14	24232422-24239242	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000904, HPA067884, HPA068782	Uncertain		Approved	Nucleoplasm<br>Nucleoli	Renal cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 144.2	Expressed in all		
PNN	memA	ENSG00000100941	Pinin, desmosome associated protein	14	39175183-39183218	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001378	Supported		Enhanced	Nuclear speckles	Prostate cancer:2.44e-4 (unfavourable), Liver cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 143.3	Expressed in all		
RABGGTA	PTAR3	ENSG00000100949	Rab geranylgeranyltransferase alpha subunit	14	24265538-24271739	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043488	Approved		Enhanced	Nucleoplasm	Thyroid cancer:1.51e-4 (favourable), Renal cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 34.0	Expressed in all		
NFATC4	NFAT3	ENSG00000100968	Nuclear factor of activated T-cells 4	14	24365673-24379604	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031641, CAB032859, HPA076526	Uncertain		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.81e-6 (unfavourable), Colorectal cancer:5.84e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 75.9	Cell line enhanced		BJ hTERT+: 80.5
PLTP	BPIFE	ENSG00000100979	Phospholipid transfer protein	20	45898621-45912155	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB032873	Approved				Renal cancer:9.52e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 635.6	Cell line enhanced		HSkMC: 229.0;U-87 MG: 331.6
PCIF1	bA465L10.1, C20orf67, PPP1R121	ENSG00000100982	PDX1 C-terminal inhibiting factor 1	20	45934628-45948023	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049517	Enhanced		Supported	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.50e-6 (favourable), Endometrial cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 49.1	Expressed in all		
GSS		ENSG00000100983	Glutathione synthetase	20	34928430-34955817	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054508, HPA059315	Enhanced		Supported	Nucleus	Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 105.8	Expressed in all		
MMP9	CLG4B	ENSG00000100985	Matrix metallopeptidase 9	20	46008908-46016561	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201	Enhanced		Approved	Cytosol	Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 252.6;lymph node: 117.7	appendix: 82.8	Cell line enriched	8	NB-4: 227.3
VSX1	PPCD, PPCD1, PPD	ENSG00000100987	Visual system homeobox 1	20	25070885-25082365	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enhanced		ovary: 1.7	cerebral cortex: 1.4	Cell line enriched	5	Karpas-707: 3.1
TRPC4AP	C20orf188, dJ756N5.2, DKFZp586C1223, DKFZP727M231, PPP1R158, TRRP4AP	ENSG00000100991	Transient receptor potential cation channel subfamily C member 4 associated protein	20	35002404-35092871	Predicted intracellular proteins	Evidence at protein level	HPA051197, HPA065061	Uncertain		Approved	Cytosol	Liver cancer:6.25e-8 (unfavourable), Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
PYGB		ENSG00000100994	Glycogen phosphorylase B	20	25248069-25298014	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031067	Approved		Approved	Cytosol	Lung cancer:1.10e-4 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 149.4	Expressed in all		
ABHD12	ABHD12A, BEM46L2, C20orf22, dJ965G21.2, DKFZP434P106	ENSG00000100997	Abhydrolase domain containing 12	20	25294743-25390983	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026866	Uncertain				Cervical cancer:1.30e-5 (favourable), Breast cancer:3.81e-5 (unfavourable), Liver cancer:7.18e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 137.3	Expressed in all		
PROCR	CCD41, CD201, EPCR	ENSG00000101000	Protein C receptor	20	35172073-35216240	Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039461	Enhanced				Renal cancer:7.62e-6 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 63.0	Cell line enhanced		HMC-1: 339.1;HUVEC TERT2: 510.3;TIME: 297.7
GINS1	KIAA0186, PSF1	ENSG00000101003	GINS complex subunit 1	20	25407727-25452628	Predicted intracellular proteins	Evidence at protein level	HPA051185	Uncertain		Approved	Nucleoplasm	Renal cancer:5.42e-11 (unfavourable), Liver cancer:4.61e-7 (unfavourable), Pancreatic cancer:5.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 14.7	lymph node: 6.5	Mixed		
NINL	KIAA0980, NLP	ENSG00000101004	Ninein like	20	25452705-25585517	Predicted intracellular proteins	Evidence at protein level	HPA000686	Uncertain		Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:1.03e-5 (favourable), Pancreatic cancer:1.47e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.9	Cell line enhanced		Hep G2: 25.6;SCLC-21H: 26.8
CD40	Bp50, p50, TNFRSF5	ENSG00000101017	CD40 molecule	20	46118272-46129863	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002495, HPA031567, HPA031568, CAB072868	Enhanced				Renal cancer:4.48e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 64.7	Cell line enhanced		CAPAN-2: 63.4;EFO-21: 116.6
UQCC1	BFZB, C20orf44, CBP3, FLJ10850, UQCC	ENSG00000101019	Ubiquinol-cytochrome c reductase complex assembly factor 1	20	35302566-35412141	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034875	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			parathyroid gland: 43.4	Expressed in all		
ZMYND8	PRKCBP1, RACK7	ENSG00000101040	Zinc finger MYND-type containing 8	20	47209214-47356889	Predicted intracellular proteins	Evidence at protein level	HPA020949	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.06e-5 (unfavourable), Breast cancer:2.56e-4 (unfavourable), Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 40.5	Expressed in all		
SGK2		ENSG00000101049	SGK2, serine/threonine kinase 2	20	43558968-43588237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008859, HPA011387	Uncertain		Supported	Nucleoplasm	Urothelial cancer:5.65e-4 (favourable)	Group enriched	Mixed			kidney: 43.2	Group enriched	5	A549: 16.2;CAPAN-2: 12.2;EFO-21: 6.5;Hep G2: 12.5;RPTEC TERT1: 19.0
IFT52	C20orf9, CGI-53, dJ1028D15.1, NGD2, NGD5	ENSG00000101052	Intraflagellar transport 52	20	43590931-43647296	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA063367, HPA067423	Enhanced		Approved	Cytosol	Liver cancer:3.30e-6 (unfavourable), Testis cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.3	Expressed in all		
MYBL2	B-MYB, BMYB	ENSG00000101057	MYB proto-oncogene like 2	20	43667019-43716496	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017114, HPA030530, HPA055416	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.11e-7 (unfavourable), Endometrial cancer:9.73e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 57.0;lymph node: 67.3;tonsil: 49.9	appendix: 32.7	Mixed		
R3HDML	dJ881L22.3	ENSG00000101074	R3H domain containing like	20	44336986-44351235	Predicted secreted proteins	Evidence at protein level	HPA070264	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 2.2;small intestine: 2.7	testis: 0.8	Not detected		
HNF4A	HNF4, MODY, MODY1, NR2A1, TCF14	ENSG00000101076	Hepatocyte nuclear factor 4 alpha	20	44355700-44434596	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004712, CAB019417	Enhanced		Supported	Nucleoplasm		Tissue enhanced	Group enriched	6	colon: 58.0;duodenum: 103.0;kidney: 44.7;liver: 51.0;rectum: 47.8;small intestine: 90.9;stomach: 21.9	gallbladder: 9.2	Group enriched	8	CACO-2: 126.0;Hep G2: 77.0
NDRG3		ENSG00000101079	NDRG family member 3	20	36651766-36746078	Predicted intracellular proteins	Evidence at protein level	HPA017851, HPA018256	Approved				Liver cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 125.3	Expressed in all		
SLA2	C20orf156, FLJ21992, SLAP-2	ENSG00000101082	Src like adaptor 2	20	36612318-36646216	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053746, HPA058217			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:6.77e-8 (unfavourable), Cervical cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.8	spleen: 8.9	Cell line enriched	9	HEL: 81.2
C20orf24	PNAS-11, RIP5	ENSG00000101084	Chromosome 20 open reading frame 24	20	36605734-36612557	Predicted membrane proteins	Evidence at protein level	HPA057387	Uncertain		Approved	Cytosol	Liver cancer:4.56e-6 (unfavourable), Renal cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 83.2	Expressed in all		
NFATC2	NF-ATP, NFAT1, NFATp	ENSG00000101096	Nuclear factor of activated T-cells 2	20	51386957-51562831	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008789, CAB018567, HPA024369	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 26.8	Cell line enhanced		HDLM-2: 22.7;HMC-1: 23.5;WM-115: 40.4
RIMS4	C20orf190, dJ781B1.3	ENSG00000101098	Regulating synaptic membrane exocytosis 4	20	44751808-44810338	Predicted intracellular proteins	Evidence at protein level	HPA060928	Approved		Approved	Nucleoplasm		Group enriched	Tissue enhanced		cerebral cortex: 27.3;testis: 20.3	fallopian tube: 13.3	Cell line enhanced		HAP1: 20.7;SCLC-21H: 48.2;SH-SY5Y: 22.3;SiHa: 15.5
PABPC1L	C20orf119, dJ1069P2.3, ePAB, PABPC1L1	ENSG00000101104	Poly(A) binding protein cytoplasmic 1 like	20	44910062-44959035	Predicted intracellular proteins	Evidence at protein level	HPA066650			Approved	Nuclear bodies<br>Cytosol	Renal cancer:4.00e-15 (unfavourable), Colorectal cancer:3.80e-4 (unfavourable), Urothelial cancer:8.84e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 54.1	Expressed in all		
STK4	KRS2, MST1, YSK3	ENSG00000101109	Serine/threonine kinase 4	20	44966474-45079959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004038, HPA015270	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.84e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 50.6	Expressed in all		
SALL4	dJ1112F19.1, ZNF797	ENSG00000101115	Spalt like transcription factor 4	20	51782331-51802520	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015291, HPA015791	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Group enriched	7	parathyroid gland: 6.7;prostate: 1.4;testis: 5.8;thyroid gland: 3.5	urinary bladder: 0.6	Cell line enhanced		AF22: 24.7;AN3-CA: 16.2;BEWO: 32.0;NTERA-2: 60.1;SiHa: 16.5
ADNP	ADNP1, KIAA0784	ENSG00000101126	Activity dependent neuroprotector homeobox	20	50888919-50931240	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006371	Supported		Approved	Nucleoplasm	Liver cancer:1.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.7	Expressed in all		
PFDN4	C-1, C1, PFD4	ENSG00000101132	Prefoldin subunit 4	20	54207847-54228052	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024055	Approved				Renal cancer:1.47e-10 (unfavourable), Liver cancer:7.66e-5 (unfavourable), Head and neck cancer:9.40e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 11.3	Expressed in all		
DOK5	C20orf180, dJ805C22.1	ENSG00000101134	Docking protein 5	20	54475597-54651171	Predicted intracellular proteins	Evidence at protein level	HPA054460, HPA065235	Uncertain		Approved	Focal adhesion sites	Endometrial cancer:8.99e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 22.0;fallopian tube: 20.0	skeletal muscle: 15.7	Cell line enhanced		AF22: 32.4;hTEC/SVTERT24-B: 13.7;U-138 MG: 50.6
CSTF1		ENSG00000101138	Cleavage stimulation factor subunit 1	20	56392371-56406369	Predicted intracellular proteins	Evidence at protein level	CAB019270, HPA047275, HPA065000	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
BMP7	OP-1	ENSG00000101144	Bone morphogenetic protein 7	20	57168748-57266629	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057757			Approved	Nucleus<br>Nucleoli<br>Vesicles	Endometrial cancer:2.91e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 76.7	placenta: 36.8	Cell line enhanced		Daudi: 124.6;MCF7: 154.9;SK-BR-3: 95.4;U-698: 163.1
RAE1	Mnrp41	ENSG00000101146	Ribonucleic acid export 1	20	57351010-57379211	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048795			Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.12e-7 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 183.9	bone marrow: 31.4	Expressed in all		
TPD52L2	D54, hD54	ENSG00000101150	Tumor protein D52 like 2	20	63865228-63891545	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047489	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.74e-8 (unfavourable), Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 105.2	Expressed in all		
DNAJC5	CLN4, DNAJC5A, FLJ00118, FLJ13070	ENSG00000101152	DnaJ heat shock protein family (Hsp40) member C5	20	63895182-63936031	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA012737, HPA013154	Approved		Uncertain	Golgi apparatus	Renal cancer:7.70e-6 (favourable), Liver cancer:8.82e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 73.6	Expressed in all		
NELFCD	HSPC130, NELF-C, NELF-D, TH1, TH1L	ENSG00000101158	Negative elongation factor complex member C/D	20	58981208-58995133	Predicted intracellular proteins	Evidence at protein level	HPA050641, HPA066262			Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytosol	Endometrial cancer:4.98e-5 (unfavourable), Liver cancer:1.90e-4 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.6	Expressed in all		
CTSZ	CTSX	ENSG00000101160	Cathepsin Z	20	58995185-59007247	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025114, HPA049876, HPA053504	Supported		Supported	Vesicles	Renal cancer:5.72e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 476.8	Cell line enhanced		fHDF/TERT166: 693.2
PRPF6	ANT-1, bB152O15.1, C20orf14, hPrp6, Prp6, RP60, SNRNP102, TOM, U5-102K	ENSG00000101161	Pre-mRNA processing factor 6	20	63981135-64033100	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047106	Enhanced		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			fallopian tube: 80.3	Expressed in all		
TUBB1	dJ543J19.4	ENSG00000101162	Tubulin beta 1 class VI	20	59019254-59026654	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004286, HPA043640, HPA046280	Approved					Not detected	Group enriched	5	bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5	gallbladder: 0.5	Cell line enriched	20	HEL: 24.9
PRELID3B	C20orf45, dJ543J19.5, SLMO2	ENSG00000101166	PRELI domain containing 3B	20	59033145-59042909	Predicted intracellular proteins	Evidence at protein level	HPA047721	Uncertain		Approved	Nucleus	Liver cancer:6.96e-5 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 88.0	Expressed in all		
HRH3	GPCR97	ENSG00000101180	Histamine receptor H3	20	62214970-62220267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	17	cerebral cortex: 11.1	adrenal gland: 0.6	Cell line enriched	7	SCLC-21H: 18.6
MTG2	dJ1005F21.2, FLJ10741, GTPBP5, ObgH1	ENSG00000101181	Mitochondrial ribosome associated GTPase 2	20	62183029-62203568	Predicted intracellular proteins	Evidence at protein level	HPA047379	Approved				Pancreatic cancer:6.31e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 15.8	Expressed in all		
PSMA7	C6, HSPC, RC6-1, XAPC7	ENSG00000101182	Proteasome subunit alpha 7	20	62136735-62143440	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046007, CAB046008, HPA047266	Enhanced				Liver cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 208.4	Expressed in all		
SLCO4A1	OATP-E, OATP4A1, SLC21A12	ENSG00000101187	Solute carrier organic anion transporter family member 4A1	20	62642445-62685785	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030669, HPA030670	Uncertain		Supported	Cell Junctions	Lung cancer:4.74e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 10.5	Cell line enhanced		PC-3: 178.2;RPTEC TERT1: 137.9
NTSR1	NTR	ENSG00000101188	Neurotensin receptor 1	20	62708837-62762771	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050299			Supported	Plasma membrane		Tissue enhanced	Not detected			cerebral cortex: 0.5	Cell line enriched	6	PC-3: 53.5
MRGBP	C20orf20, Eaf7, FLJ10914, MRG15BP	ENSG00000101189	MRG domain binding protein	20	62796453-62801738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017012	Enhanced		Supported	Nucleus	Renal cancer:2.48e-6 (unfavourable), Liver cancer:3.80e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 64.3	ovary: 10.6	Expressed in all		
TCFL5	bHLHe82, CHA, E2BP-1, Figlb	ENSG00000101190	Transcription factor like 5	20	62841115-62861763	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055223	Approved		Supported	Nucleoplasm	Endometrial cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 144.4	Expressed in all		
DIDO1	BYE1, C20orf158, DATF1, DIO-1, DIO1, dJ885L7.8, FLJ11265, KIAA0333	ENSG00000101191	Death inducer-obliterator 1	20	62877738-62937952	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004374, HPA049904	Supported		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:3.88e-4 (favourable), Head and neck cancer:5.13e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 48.2	Expressed in all		
GID8	bA305P22.1, C20orf11, FLJ20602, TWA1	ENSG00000101193	GID complex subunit 8 homolog	20	62938119-62948475	Predicted intracellular proteins	Evidence at protein level	HPA049929, HPA055047	Approved		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:3.22e-4 (favourable), Endometrial cancer:4.78e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 32.5	Expressed in all		
SLC17A9	C20orf59, FLJ23412, VNUT	ENSG00000101194	Solute carrier family 17 member 9	20	62952647-62969585	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047470, HPA056499	Uncertain		Approved	Nucleoplasm	Renal cancer:2.78e-15 (unfavourable)	Mixed	Mixed			stomach: 8.6	Cell line enhanced		Hep G2: 46.7;U-937: 33.7
BIRC7	KIAP, ML-IAP, mliap, RNF50	ENSG00000101197	Baculoviral IAP repeat containing 7	20	63235883-63240507	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047850			Supported	Nucleus<br>Microtubule organizing center<br>Cytosol		Tissue enriched	Tissue enhanced		placenta: 9.2	skin: 2.7	Cell line enhanced		REH: 32.5;SK-MEL-30: 145.1;U-937: 33.0
NKAIN4	bA261N11.2, C20orf58, FAM77A	ENSG00000101198	Sodium/potassium transporting ATPase interacting 4	20	63240784-63272694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029876	Approved				Endometrial cancer:3.14e-4 (unfavourable)	Tissue enriched	Tissue enriched	13	cerebral cortex: 71.8	kidney: 5.5	Cell line enhanced		BEWO: 23.2;MOLT-4: 33.2
ARFGAP1	ARF1GAP, bA261N11.3, FLJ10767	ENSG00000101199	ADP ribosylation factor GTPase activating protein 1	20	63272785-63289793	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051019, HPA056273	Approved		Supported	Nuclear membrane<br>Golgi apparatus<br>Vesicles	Renal cancer:3.48e-7 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
AVP	ADH, ARVP	ENSG00000101200	Arginine vasopressin	20	3082556-3084724	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025318, HPA071892	Supported	Supported				Not detected	Not detected			bone marrow,testis: 0.5	Cell line enriched	9	NB-4: 1.4
COL20A1	KIAA1510	ENSG00000101203	Collagen type XX alpha 1 chain	20	63293186-63334851	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051962	Uncertain					Tissue enriched	Tissue enriched	7	cerebral cortex: 16.2	testis: 2.3	Not detected		
CHRNA4	BFNC, EBN, EBN1	ENSG00000101204	Cholinergic receptor nicotinic alpha 4 subunit	20	63343223-63378401	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB034064	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 6.9;parathyroid gland: 17.4	liver: 3.9	Cell line enhanced		U-2 OS: 2.6
EEF1A2	EEF1AL, HS1, STN, STNL	ENSG00000101210	Eukaryotic translation elongation factor 1 alpha 2	20	63488013-63499315	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034019, HPA051759, HPA053862, HPA056990	Approved		Enhanced	Nucleoli<br>Cytosol	Endometrial cancer:2.90e-5 (unfavourable), Head and neck cancer:9.11e-4 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 409.3;heart muscle: 425.6;skeletal muscle: 1372.7	adrenal gland: 127.7	Cell line enhanced		MCF7: 899.8;SCLC-21H: 694.7;T-47d: 410.5;U-2 OS: 431.5
PTK6	BRK	ENSG00000101213	Protein tyrosine kinase 6	20	63528001-63537370	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB032952, HPA036070, HPA036071	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 61.0;skin: 60.4	duodenum: 29.2	Cell line enhanced		A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
GMEB2	KIAA1269, P79PIF, PIF79	ENSG00000101216	Glucocorticoid modulatory element binding protein 2	20	63587602-63627041	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009706, HPA067455	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 12.8	Expressed in all		
C20orf27	FLJ20550	ENSG00000101220	Chromosome 20 open reading frame 27	20	3753508-3768387	Predicted intracellular proteins	Evidence at protein level	HPA047483	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.18e-6 (unfavourable), Liver cancer:1.69e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 56.5	Expressed in all		
SPEF1	C20orf28, CLAMP, DKFZP434I114, SPEF1A	ENSG00000101222	Sperm flagellar 1	20	3777504-3781448	Predicted intracellular proteins	Evidence at protein level	HPA050786	Enhanced				Thyroid cancer:9.87e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 15.9;testis: 6.5	cerebral cortex: 2.9	Cell line enhanced		A549: 1.9;MCF7: 1.2
CDC25B		ENSG00000101224	Cell division cycle 25B	20	3786772-3806121	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038892, HPA038893, HPA075215	Enhanced		Supported	Vesicles<br>Mitotic spindle	Renal cancer:2.94e-13 (unfavourable), Liver cancer:1.19e-4 (unfavourable), Endometrial cancer:4.76e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 56.6	Expressed in all		
ISM1	bA149I18.1, C20orf82	ENSG00000101230	Isthmin 1	20	13221771-13300651	Predicted secreted proteins	Evidence at protein level						Renal cancer:9.32e-6 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 74.7	placenta: 24.8	Cell line enhanced		ASC diff: 40.6;Hep G2: 16.4
RNF24	G1L	ENSG00000101236	Ring finger protein 24	20	3927309-4015582	Predicted membrane proteins	Evidence at protein level	HPA011900	Approved		Supported	Golgi apparatus	Renal cancer:2.67e-7 (unfavourable), Liver cancer:3.81e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 34.2	Expressed in all		
ARFRP1	ARL18, ARP, Arp1	ENSG00000101246	ADP ribosylation factor related protein 1	20	63698642-63708025	Predicted intracellular proteins	Evidence at protein level	HPA047028, HPA050634	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			spleen: 27.9	Expressed in all		
NDUFAF5	C20orf7, dJ842G6.1	ENSG00000101247	NADH:ubiquinone oxidoreductase complex assembly factor 5	20	13784950-13821582	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051184	Uncertain				Renal cancer:2.27e-6 (favourable)	Expressed in all	Mixed			skeletal muscle: 6.9	Expressed in all		
SEL1L2	C20orf50, DKFZp434C1826	ENSG00000101251	SEL1L2 ERAD E3 ligase adaptor subunit	20	13849247-13996443	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059121	Approved					Not detected	Tissue enriched	63	testis: 12.6	endometrium: 0.2	Not detected		
TRIB3	C20orf97, dJ1103G7.3, TRB3	ENSG00000101255	Tribbles pseudokinase 3	20	362835-397559	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055442	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Renal cancer:2.07e-13 (unfavourable), Liver cancer:6.75e-5 (unfavourable), Head and neck cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 51.4	liver: 12.5	Cell line enhanced		HHSteC: 437.1;hTERT-HME1: 292.4;SK-MEL-30: 388.6
RASSF2	CENP-34, KIAA0168	ENSG00000101265	Ras association domain family member 2	20	4780023-4823645	Predicted intracellular proteins	Evidence at protein level	HPA051200	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:7.82e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 148.5	lymph node: 68.8	Cell line enhanced		HL-60: 59.0;NB-4: 60.4;U-937: 91.0
CSNK2A1		ENSG00000101266	Casein kinase 2 alpha 1	20	473591-543821	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB020680, HPA059206, HPA061698, CAB069395	Enhanced		Supported	Nucleoplasm	Liver cancer:4.11e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 129.5	Expressed in all		
SLC52A3	bA371L19.1, C20orf54, hRFT2, RFVT3	ENSG00000101276	Solute carrier family 52 member 3	20	760080-776015	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049391, HPA059078	Approved				Stomach cancer:5.51e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 62.3	small intestine: 18.1	Cell line enhanced		CAPAN-2: 33.7;SK-BR-3: 10.4;T-47d: 16.0
ANGPT4		ENSG00000101280	Angiopoietin 4	20	869899-916317	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB013260, CAB013305	Uncertain					Not detected	Tissue enhanced		cervix, uterine: 5.4	adipose tissue: 2.7	Group enriched	92	ASC diff: 23.2;BEWO: 47.4
RSPO4	C20orf182, dJ824F16.3	ENSG00000101282	R-spondin 4	20	958452-1002264	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA048887	Uncertain				Endometrial cancer:2.98e-6 (unfavourable)	Mixed	Tissue enhanced		lung: 6.8	testis: 2.4	Cell line enhanced		BEWO: 3.0;NTERA-2: 6.4;SK-BR-3: 3.3;U-2 OS: 7.7
CDS2		ENSG00000101290	CDP-diacylglycerol synthase 2	20	5126786-5197887	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA019698	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.53e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 48.9	Expressed in all		
PROKR2	dJ680N4.3, GPR73b, GPR73L1, GPRg2, KAL3, PKR2	ENSG00000101292	Prokineticin receptor 2	20	5302040-5314369	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047281	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.0	bone marrow: 0.8	Cell line enhanced		NTERA-2: 1.1;SH-SY5Y: 2.2
HM13	dJ324O17.1, H13, IMP1, IMPAS, PSENL3, PSL3, SPP, SPPL1	ENSG00000101294	Histocompatibility minor 13	20	31514428-31577923	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045089, HPA056062	Approved		Supported	Endoplasmic reticulum	Renal cancer:4.64e-12 (unfavourable), Liver cancer:1.95e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 154.2	Expressed in all		
SNPH	bA314N13.5	ENSG00000101298	Syntaphilin	20	1266316-1309328	Predicted membrane proteins	Evidence at protein level	HPA049393	Approved		Uncertain	Cytokinetic bridge<br>Mitochondria	Pancreatic cancer:6.97e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 33.6	seminal vesicle: 15.6	Mixed		
MYLK2	KMLC, MLCK2, skMLCK	ENSG00000101306	Myosin light chain kinase 2	20	31819308-31834689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059704, HPA059890	Enhanced		Supported	Endoplasmic reticulum	Glioma:5.74e-4 (favourable)	Tissue enhanced	Tissue enriched	49	skeletal muscle: 253.1	esophagus: 5.1	Cell line enhanced		RH-30: 10.2;RPMI-8226: 6.2
SIRPB1	CD172b, SIRP-BETA-1	ENSG00000101307	Signal regulatory protein beta 1	20	1563521-1620061	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047463	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		appendix: 38.7;bone marrow: 33.7	lung: 28.0	Cell line enhanced		HMC-1: 46.6;NB-4: 46.7;THP-1: 38.2
SEC23B	CDA-II, CDAII, CDAN2, HEMPAS	ENSG00000101310	Sec23 homolog B, coat complex II component	20	18507493-18561415	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008216, HPA069974	Uncertain		Supported	Vesicles	Endometrial cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 85.7	Expressed in all		
FERMT1	C20orf42, FLJ20116, KIND1, UNC112A, URP1	ENSG00000101311	Fermitin family member 1	20	6074845-6123544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039778, HPA041966	Approved				Pancreatic cancer:6.60e-4 (unfavourable)	Expressed in all	Mixed			rectum: 30.8	Cell line enhanced		CAPAN-2: 58.4;HaCaT: 68.4;HBEC3-KT: 56.3
HAO1	GOX, GOX1	ENSG00000101323	Hydroxyacid oxidase 1	20	7882981-7940474	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049552	Enhanced					Tissue enriched	Tissue enriched	305	liver: 308.6	kidney: 1.0	Not detected		
PDYN	ADCA, PENKB, SCA23	ENSG00000101327	Prodynorphin	20	1978757-1994285	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049841, HPA053342	Approved	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 63.3	testis: 5.5	Not detected		
CCM2L	C20orf160, dJ310O13.5	ENSG00000101331	CCM2 like scaffolding protein	20	32010450-32032180	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008434, HPA071063	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enriched	8	spleen: 122.6	placenta: 15.0	Cell line enhanced		EFO-21: 9.4;HUVEC TERT2: 10.0;NTERA-2: 6.4;SCLC-21H: 12.8
PLCB4		ENSG00000101333	Phospholipase C beta 4	20	9068763-9481242	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007951	Supported		Approved	Nucleoplasm<br>Microtubules	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 58.5	epididymis: 30.5	Cell line enhanced		fHDF/TERT166: 87.3;LHCN-M2: 74.5;RPTEC TERT1: 85.5
MYL9	LC20, MLC2, MRLC1, MYRL2	ENSG00000101335	Myosin light chain 9	20	36541484-36551447	Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.92e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 3139.3	Cell line enhanced		BJ: 876.7;fHDF/TERT166: 644.0
HCK	JTK9	ENSG00000101336	HCK proto-oncogene, Src family tyrosine kinase	20	32052188-32101856	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005195, HPA063768	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 149.6;spleen: 113.2	lung: 74.1	Group enriched	8	THP-1: 48.4;U-937: 161.1
TM9SF4	dJ836N17.2, KIAA0255	ENSG00000101337	Transmembrane 9 superfamily member 4	20	32109506-32167258	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064099	Approved		Approved	Mitochondria	Endometrial cancer:6.37e-6 (unfavourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.1	Expressed in all		
TLDC2	C20orf118, dJ132F21.2	ENSG00000101342	TBC/LysM-associated domain containing 2	20	36876121-36894235	Predicted intracellular proteins	Evidence at transcript level	HPA047468	Approved				Renal cancer:9.97e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 19.0;small intestine: 20.1	rectum: 13.3	Cell line enriched	10	HMC-1: 30.5
CRNKL1	CLF, Clf1, CRN, SYF3	ENSG00000101343	Crooked neck pre-mRNA splicing factor 1	20	20034368-20056046	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:8.06e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
POFUT1	FUT12, KIAA0180, O-Fuc-T, O-FUT	ENSG00000101346	Protein O-fucosyltransferase 1	20	32207880-32238667	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054519, HPA059935	Approved		Approved	Centrosome		Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
SAMHD1	AGS5, HDDC1, Mg11, MOP-5, SBBI88	ENSG00000101347	SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1	20	36890229-36951843	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047072	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 133.3	Cell line enhanced		ASC diff: 345.7;BJ hTERT+ SV40 Large T+: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 204.5
PAK5	KIAA1264, PAK7	ENSG00000101349	P21 (RAC1) activated kinase 5	20	9537389-9839041	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA020444	Approved		Approved	Nucleoplasm		Mixed	Tissue enriched	5	cerebral cortex: 13.4	adrenal gland: 2.6	Group enriched	10	SCLC-21H: 5.6;SH-SY5Y: 1.8
KIF3B	FLA8, KIAA0359, KLP-11	ENSG00000101350	Kinesin family member 3B	20	32277664-32335011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007119	Approved		Uncertain	Nucleoplasm<br>Nucleoli<br>Golgi apparatus	Renal cancer:1.44e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
MROH8	C20orf131, C20orf132, dJ621N11.3, dJ621N11.4	ENSG00000101353	Maestro heat like repeat family member 8	20	37101226-37179588	Predicted intracellular proteins	Evidence at transcript level	HPA060298	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 41.1	epididymis: 8.8	Mixed		
NOP56	NOL5A, SCA36	ENSG00000101361	NOP56 ribonucleoprotein	20	2652145-2658393	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049918, CAB075757	Enhanced		Enhanced	Nucleoli fibrillar center	Renal cancer:2.22e-16 (unfavourable), Liver cancer:1.59e-7 (unfavourable), Endometrial cancer:1.24e-4 (unfavourable), Melanoma:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 60.3	Expressed in all		
MANBAL	dJ1141E15.2	ENSG00000101363	Mannosidase beta like	20	37289638-37317260	Predicted membrane proteins	Evidence at protein level	HPA052348	Uncertain		Approved	Nucleus<br>Mitochondria	Renal cancer:3.62e-4 (favourable), Liver cancer:7.07e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 96.2	Expressed in all		
IDH3B	RP46	ENSG00000101365	Isocitrate dehydrogenase 3 (NAD(+)) beta	20	2658395-2664219	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049387, HPA054180	Enhanced		Enhanced	Mitochondria	Renal cancer:6.78e-8 (favourable), Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 100.5	Expressed in all		
MAPRE1	EB1	ENSG00000101367	Microtubule associated protein RP/EB family member 1	20	32819893-32850405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003600, CAB009337, CAB019391	Enhanced		Enhanced	Microtubule organizing center<br>Cytosol	Liver cancer:6.33e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 128.4	Expressed in all		
JAG1	AGS, AHD, AWS, CD339, HJ1, JAGL1	ENSG00000101384	Jagged 1	20	10637684-10674107	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB010343, HPA021555	Enhanced		Supported	Golgi apparatus<br>Plasma membrane	Pancreatic cancer:4.10e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 97.1	Cell line enhanced		HBEC3-KT: 150.8;hTERT-HME1: 96.7;U-251 MG: 151.3
CDK5RAP1	C20orf34, C42, CGI-05, HSPC167	ENSG00000101391	CDK5 regulatory subunit associated protein 1	20	33358839-33401561	Predicted intracellular proteins	Evidence at protein level	HPA066301			Approved	Nuclear speckles<br>Mitochondria	Prostate cancer:8.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.4	Expressed in all		
SNTA1	LQT12, SNT1, TACIP1	ENSG00000101400	Syntrophin alpha 1	20	33407955-33443892	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB037059	Approved				Endometrial cancer:9.60e-6 (unfavourable), Pancreatic cancer:3.72e-4 (favourable), Melanoma:7.08e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 102.0	Mixed		
OXT	OT, OT-NPI, OXT-NPI	ENSG00000101405	Oxytocin/neurophysin I prepropeptide	20	3071620-3072517	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA071892	Supported	Supported				Tissue enriched	Tissue enhanced		liver: 2.1;small intestine: 1.1	duodenum: 1.1	Cell line enhanced		CACO-2: 1.3;HMC-1: 1.0
TTI1	KIAA0406, smg-10	ENSG00000101407	TELO2 interacting protein 1	20	37983007-38033468	Predicted intracellular proteins	Evidence at protein level	CAB034230, HPA068338	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.40e-7 (unfavourable), Endometrial cancer:3.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis,thyroid gland: 20.3	Expressed in all		
E2F1	RBBP3, RBP3	ENSG00000101412	E2F transcription factor 1	20	33675683-33686404	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000329, HPA008003, CAB019308, HPA029735	Enhanced		Enhanced	Nucleoplasm<br>Centrosome	Cervical cancer:9.22e-6 (favourable), Liver cancer:3.83e-5 (unfavourable), Endometrial cancer:4.33e-5 (unfavourable), Renal cancer:8.99e-5 (unfavourable), Thyroid cancer:1.62e-4 (favourable), Pancreatic cancer:4.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.9	testis: 12.7	Mixed		
RPRD1B	C20orf77, CREPT, dJ1057B20.2, DKFZp434P0735, FLJ44520, NET60	ENSG00000101413	Regulation of nuclear pre-mRNA domain containing 1B	20	38033546-38127780	Predicted intracellular proteins	Evidence at protein level	HPA066290	Supported		Supported	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 29.6	Expressed in all		
PXMP4	PMP24	ENSG00000101417	Peroxisomal membrane protein 4	20	33702754-33720319	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050077	Approved		Approved	Nucleoli fibrillar center<br>Peroxisomes	Renal cancer:4.03e-10 (favourable), Lung cancer:3.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.1	Cell line enhanced		SK-BR-3: 56.7;T-47d: 60.1
CHMP4B	C20orf178, dJ553F4.4, Shax1, SNF7-2, VPS32B	ENSG00000101421	Charged multivesicular body protein 4B	20	33811304-33854366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041401, HPA051751	Enhanced				Liver cancer:5.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 140.4	Expressed in all		
BPI	BPIFD1	ENSG00000101425	Bactericidal/permeability-increasing protein	20	38260149-38337505	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA061284	Enhanced					Not detected	Tissue enriched	37	bone marrow: 961.6	testis: 25.9	Group enriched	5	AF22: 2.3;ASC diff: 1.1;ASC TERT1: 3.1;BJ: 2.1;BJ hTERT+: 2.1;HL-60: 1.1
CST9L	bA218C14.1, CTES7B	ENSG00000101435	Cystatin 9-like	20	23564732-23568749	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	testis: 108.4	epididymis: 19.6	Cell line enriched	13	HEL: 1.2
SLC32A1	bA122O1.1, VGAT, VIAAT	ENSG00000101438	Solute carrier family 32 member 1	20	38724462-38729372	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037156, HPA058859, HPA059985	Enhanced	Supported				Tissue enhanced	Tissue enriched	35	cerebral cortex: 15.9	testis: 0.4	Cell line enhanced		MOLT-4: 1.1
CST3		ENSG00000101439	Cystatin C	20	23626706-23638473	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000118, HPA013143	Enhanced		Supported	Golgi apparatus<br>Vesicles	Endometrial cancer:1.83e-4 (favourable), Urothelial cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1265.8	Cell line enhanced		ASC diff: 1105.8
ASIP	AGTIL, ASP	ENSG00000101440	Agouti signaling protein	20	34194569-34269344	Predicted secreted proteins	Evidence at protein level	HPA048636	Uncertain		Supported	Vesicles		Mixed	Group enriched	5	epididymis: 18.1;ovary: 7.4;skin: 5.7	breast: 2.0	Cell line enhanced		CACO-2: 2.6
CST4		ENSG00000101441	Cystatin S	20	23685640-23689040	Predicted secreted proteins	Evidence at protein level	HPA043706, HPA044763	Supported				Ovarian cancer:4.98e-5 (unfavourable), Urothelial cancer:2.88e-4 (favourable)	Mixed	Tissue enriched	113	salivary gland: 9926.9	gallbladder: 87.6	Cell line enhanced		CACO-2: 4.5;hTEC/SVTERT24-B: 2.1;RT4: 10.7;TIME: 1.8
ACTR5	Arp5, FLJ12785, INO80M	ENSG00000101442	ARP5 actin-related protein 5 homolog	20	38748442-38772520	Predicted intracellular proteins	Evidence at protein level	HPA042676	Approved				Liver cancer:1.84e-5 (unfavourable), Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.5	Expressed in all		
WFDC2	dJ461P17.6, EDDM4, HE4, WAP5	ENSG00000101443	WAP four-disulfide core domain 2	20	45469706-45481532	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042302	Enhanced		Approved	Cytosol	Renal cancer:4.44e-5 (favourable), Glioma:5.87e-5 (unfavourable)	Expressed in all	Tissue enriched	6	cervix, uterine: 6567.2	seminal vesicle: 1051.7	Group enriched	8	A-431: 90.4;CAPAN-2: 165.0;EFO-21: 144.7;HaCaT: 121.3;RPTEC TERT1: 108.5
AHCY	SAHH	ENSG00000101444	Adenosylhomocysteinase	20	34280268-34311802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041225, HPA044675	Approved		Supported	Cytosol		Expressed in all	Expressed in all			kidney: 159.4	Expressed in all		
PPP1R16B	ANKRD4, KIAA0823, TIMAP	ENSG00000101445	Protein phosphatase 1 regulatory subunit 16B	20	38805705-38923024	Predicted intracellular proteins	Evidence at protein level	HPA049571			Supported	Nuclear speckles<br>Plasma membrane	Head and neck cancer:7.87e-5 (favourable), Cervical cancer:2.11e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 50.9	lymph node: 44.2	Cell line enhanced		Daudi: 40.9;HMC-1: 52.2;HUVEC TERT2: 29.7;U-266/70: 73.8;U-266/84: 29.1
SPINT3	HKIB9	ENSG00000101446	Serine peptidase inhibitor, Kunitz type 3	20	45512461-45515624	Predicted secreted proteins	Evidence at protein level	HPA026852	Enhanced					Not detected	Group enriched	32	epididymis: 5.8;seminal vesicle: 15.4	skin: 0.3	Not detected		
FAM83D	C20orf129, CHICA, dJ616B8.3	ENSG00000101447	Family with sequence similarity 83 member D	20	38926312-38953106	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.81e-14 (unfavourable), Liver cancer:5.44e-6 (unfavourable), Pancreatic cancer:4.73e-5 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Lung cancer:9.69e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 76.1;smooth muscle: 131.9	prostate: 21.8	Expressed in all		
EPPIN	CT71, dJ461P17.2, EPPIN1, EPPIN2, EPPIN3, SPINLW1, WAP7, WFDC7	ENSG00000101448	Epididymal peptidase inhibitor	20	45540626-45547752	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	117	epididymis: 414.2;testis: 128.4	fallopian tube: 2.3	Cell line enhanced		U-87 MG: 2.6
DHX35	C20orf15, DDX35, FLJ22759, KAIA0875	ENSG00000101452	DEAH-box helicase 35	20	38962299-39039723	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054451, HPA062700	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Centrosome	Liver cancer:5.63e-6 (unfavourable), Endometrial cancer:4.25e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 14.9	Expressed in all		
DNTTIP1	C20orf167, dJ447F3.4, Tdif1	ENSG00000101457	Deoxynucleotidyltransferase terminal interacting protein 1	20	45791937-45811427	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042479, HPA045496			Enhanced	Nucleus	Renal cancer:1.90e-6 (unfavourable), Liver cancer:1.79e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 44.6	Expressed in all		
MAP1LC3A	ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3	ENSG00000101460	Microtubule associated protein 1 light chain 3 alpha	20	34546854-34560345	Predicted intracellular proteins	Evidence at protein level	HPA007649, CAB037174, HPA052474, HPA052484	Enhanced				Pancreatic cancer:5.31e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 119.1	Cell line enhanced		HSkMC: 49.9;SCLC-21H: 52.4;SK-BR-3: 46.8
SYNDIG1	C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B	ENSG00000101463	Synapse differentiation inducing 1	20	24469199-24666616	Predicted membrane proteins	Evidence at protein level	HPA044271, HPA059267			Supported	Vesicles	Thyroid cancer:6.16e-6 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 26.9	heart muscle: 14.4	Group enriched	9	Karpas-707: 9.0;RH-30: 34.5;RPMI-8226: 24.4;SCLC-21H: 9.7;U-87 MG: 21.0
PIGU	bA346K17.2, CDC91L1, GAB1	ENSG00000101464	Phosphatidylinositol glycan anchor biosynthesis class U	20	34560542-34698790	Predicted membrane proteins	Evidence at protein level	HPA041706, HPA046766	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.49e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.2	Expressed in all		
TNNC2		ENSG00000101470	Troponin C2, fast skeletal type	20	45823214-45833745	Predicted intracellular proteins	Evidence at protein level	HPA043174, HPA058481	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	78	skeletal muscle: 9898.9	esophagus: 126.3	Group enriched	6	Hep G2: 6.4;HSkMC: 10.1;SCLC-21H: 12.6
ACOT8	hACTE-III, hTE, NAP1, PTE-2, PTE1	ENSG00000101473	Acyl-CoA thioesterase 8	20	45841721-45857406	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010261	Approved		Supported	Vesicles<br>Mitochondria	Renal cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.1	Expressed in all		
APMAP	BSCv, C20orf3	ENSG00000101474	Adipocyte plasma membrane associated protein	20	24962925-24992979	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012863, HPA064700	Uncertain		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 323.5	Expressed in all		
CELF4	BRUNOL4	ENSG00000101489	CUGBP Elav-like family member 4	18	37243047-37566037	Predicted intracellular proteins	Evidence at protein level	HPA037986	Approved					Mixed	Tissue enriched	9	cerebral cortex: 126.9	adrenal gland: 14.7	Group enriched	15	SCLC-21H: 51.8;SH-SY5Y: 11.4
ZNF516	HsT287, KIAA0222	ENSG00000101493	Zinc finger protein 516	18	76358190-76495190	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015792	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.21e-4 (favourable), Liver cancer:2.79e-4 (unfavourable), Breast cancer:7.09e-4 (favourable), Pancreatic cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 54.4	Mixed		
CDH20	Cdh7, CDH7L3	ENSG00000101542	Cadherin 20	18	61333582-61555773	Predicted membrane proteins	Evidence at protein level	HPA015490	Uncertain					Tissue enriched	Tissue enriched	5	cerebral cortex: 26.8	adipose tissue: 4.9	Cell line enhanced		AF22: 1.8;ASC diff: 3.9;HHSteC: 2.2;SH-SY5Y: 4.1
ADNP2	KIAA0863, ZNF508	ENSG00000101544	ADNP homeobox 2	18	80109031-80147523	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007126	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:6.39e-5 (favourable), Thyroid cancer:9.90e-4 (unfavourable)	Expressed in all	Mixed			testis: 39.7	Mixed		
RBFA	C18orf22, FLJ21172, HsT169	ENSG00000101546	Ribosome binding factor A (putative)	18	80034358-80046397	Predicted intracellular proteins	Evidence at protein level	HPA040485, HPA041479	Approved		Supported	Mitochondria	Liver cancer:2.06e-6 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 20.3	Expressed in all		
USP14	TGT	ENSG00000101557	Ubiquitin specific peptidase 14	18	158383-214629	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001308	Approved		Supported	Cytosol	Liver cancer:4.30e-5 (unfavourable), Head and neck cancer:7.81e-5 (unfavourable), Ovarian cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			prostate: 48.2	Expressed in all		
VAPA	hVAP-33, VAP-A	ENSG00000101558	VAMP associated protein A	18	9914002-9960021	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA009174	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:5.72e-7 (favourable)	Expressed in all	Expressed in all			adrenal gland: 61.3	Expressed in all		
METTL4	FLJ23017, HsT661	ENSG00000101574	Methyltransferase like 4	18	2537525-2571509	Predicted intracellular proteins	Evidence at protein level	HPA040061, HPA046734	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 17.3	Expressed in all		
LPIN2	KIAA0249	ENSG00000101577	Lipin 2	18	2916994-3013315	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015223, HPA017857, HPA030550	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Head and neck cancer:8.01e-4 (favourable)	Expressed in all	Mixed			liver: 87.3	Mixed		
SMCHD1	FSHD2, KIAA0650	ENSG00000101596	Structural maintenance of chromosomes flexible hinge domain containing 1	18	2655738-2805017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039441	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.40e-4 (unfavourable), Liver cancer:5.39e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 40.5	Expressed in all		
MYOM1		ENSG00000101605	Myomesin 1	18	3066807-3220108	Predicted intracellular proteins	Evidence at protein level	HPA014305, HPA049193	Enhanced					Tissue enhanced	Group enriched	13	heart muscle: 278.1;skeletal muscle: 299.1	gallbladder: 22.9	Group enriched	12	HAP1: 13.8;HMC-1: 3.1;HSkMC: 4.5
MYL12A	MLCB, MRCL3, MRLC3, MYL2B	ENSG00000101608	Myosin light chain 12A	18	3247481-3256236	Predicted intracellular proteins	Evidence at protein level	CAB004503, HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			heart muscle: 2635.3	Expressed in all		
CEP76	C18orf9, FLJ12542, HsT1705	ENSG00000101624	Centrosomal protein 76	18	12661833-12702777	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039395	Approved					Expressed in all	Mixed			testis: 14.7	Expressed in all		
ST8SIA5	SIAT8E	ENSG00000101638	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5	18	46667821-46759257	Predicted membrane proteins	Evidence at protein level	HPA043813, HPA046771	Approved		Approved	Plasma membrane<br>Midbody		Tissue enriched	Tissue enhanced		adrenal gland: 5.5;cerebral cortex: 11.4	parathyroid gland: 3.4	Cell line enriched	7	WM-115: 121.0
CEP192	FLJ10352, KIAA1569, PPP1R62	ENSG00000101639	Centrosomal protein 192	18	12991362-13125052	Predicted intracellular proteins	Evidence at protein level	HPA039392, HPA040503	Uncertain		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			testis: 17.3	Expressed in all		
RNMT	RG7MT1	ENSG00000101654	RNA guanine-7 methyltransferase	18	13726660-13764558	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039409	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 31.0	Expressed in all		
SMAD7	MADH7, MADH8	ENSG00000101665	SMAD family member 7	18	48919853-48950711	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026212, HPA028897	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:5.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Mixed		
LIPG	EDL	ENSG00000101670	Lipase G, endothelial type	18	49560699-49599182	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016966	Uncertain					Tissue enriched	Group enriched	11	placenta: 214.4;thyroid gland: 403.2	seminal vesicle: 29.1	Cell line enhanced		AN3-CA: 113.7;HaCaT: 167.5;RPTEC TERT1: 93.8;TIME: 201.4
LAMA1	LAMA	ENSG00000101680	Laminin subunit alpha 1	18	6941744-7117814	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010179	Enhanced					Mixed	Tissue enhanced		testis: 11.2	thyroid gland: 4.3	Cell line enhanced		AF22: 55.1;BEWO: 192.1
RNF125	FLJ20456	ENSG00000101695	Ring finger protein 125	18	32018372-32073213	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041514	Uncertain		Uncertain	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 11.5	Cell line enhanced		HMC-1: 42.3
ANKRD12	FLJ20053, GAC-1, KIAA0874	ENSG00000101745	Ankyrin repeat domain 12	18	9136228-9285985	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA040705	Approved		Supported	Nucleoplasm<br>Cytosol	Melanoma:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
NOL4	CT125, HRIHFB2255, NOLP	ENSG00000101746	Nucleolar protein 4	18	33851100-34224952	Predicted intracellular proteins	Evidence at protein level	HPA046740			Supported	Nucleus		Tissue enhanced	Group enriched	7	cerebral cortex: 15.9;testis: 22.8	thyroid gland: 2.9	Cell line enhanced		SCLC-21H: 44.1;SH-SY5Y: 10.6;U-698: 5.7
POLI	RAD30B, RAD3OB	ENSG00000101751	DNA polymerase iota	18	54269404-54321266	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012000, HPA064696	Enhanced		Supported	Nuclear speckles<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 69.7	Expressed in all		
MIB1	DIP-1, KIAA1323, MIB, ZZANK2, ZZZ6	ENSG00000101752	Mindbomb E3 ubiquitin protein ligase 1	18	21704957-21870957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019100, CAB037044	Approved		Approved	Nuclear membrane<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 24.2	Expressed in all		
RBBP8	COM1, CtIP, RIM, SCKL2	ENSG00000101773	RB binding protein 8, endonuclease	18	22798261-23026488	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039890, HPA052946	Approved		Supported	Nucleoplasm	Renal cancer:1.71e-5 (favourable), Melanoma:7.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 52.7	Expressed in all		
RIOK3	SUDD	ENSG00000101782	RIO kinase 3	18	23452823-23486603	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001620, HPA024184	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Pancreatic cancer:4.10e-4 (unfavourable), Prostate cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 74.9	Expressed in all		
CSTF2	CstF-64	ENSG00000101811	Cleavage stimulation factor subunit 2	X	100820359-100840932	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000427, CAB004680	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:8.23e-6 (unfavourable), Renal cancer:1.12e-4 (favourable)	Expressed in all	Mixed			testis: 25.7	Expressed in all		
H2BFM		ENSG00000101812	H2B histone family member M	X	104039949-104042454	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			testis: 2.4	Mixed		
MXRA5	DKFZp564I1922	ENSG00000101825	Matrix remodeling associated 5	X	3308565-3346641	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA000508	Uncertain		Uncertain	Mitochondria	Glioma:2.56e-4 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 57.1	skin: 35.2	Cell line enhanced		BJ hTERT+: 102.1;fHDF/TERT166: 46.4;HaCaT: 46.3
VSIG1	MGC44287	ENSG00000101842	V-set and immunoglobulin domain containing 1	X	108044970-108079184	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001445, HPA036310, HPA036311	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	10	stomach: 185.7;testis: 91.1	gallbladder: 14.3	Cell line enhanced		HBEC3-KT: 2.5;HUVEC TERT2: 5.9;PC-3: 2.2
PSMD10	p28	ENSG00000101843	Proteasome 26S subunit, non-ATPase 10	X	108084207-108091618	Predicted intracellular proteins	Evidence at protein level	HPA002920, CAB010434	Approved		Supported	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.0	Expressed in all		
ATG4A	APG4A, AUTL2	ENSG00000101844	Autophagy related 4A cysteine peptidase	X	108091668-108154671	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036374, HPA064759	Uncertain		Approved	Actin filaments<br>Microtubules	Breast cancer:1.36e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.8	Expressed in all		
STS	ARSC, ARSC1	ENSG00000101846	Steroid sulfatase	X	7219456-7354810	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002904	Enhanced				Pancreatic cancer:3.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 36.5	adipose tissue: 18.9	Cell line enhanced		U-266/70: 79.0
TBL1X	EBI, TBL1	ENSG00000101849	Transducin beta like 1X-linked	X	9463295-9719743	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005363, HPA067703	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:1.32e-4 (favourable), Renal cancer:4.58e-4 (favourable), Breast cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 63.9	Mixed		
GPR143	OA1	ENSG00000101850	G protein-coupled receptor 143	X	9725346-9786297	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003648	Enhanced				Renal cancer:2.45e-5 (favourable), Cervical cancer:8.73e-4 (favourable)	Tissue enriched	Mixed			skin: 10.3	Cell line enriched	7	SK-MEL-30: 119.4
PGRMC1	HPR6.6	ENSG00000101856	Progesterone receptor membrane component 1	X	119236245-119244466	Predicted membrane proteins	Evidence at protein level	HPA002877	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum	Head and neck cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 339.9	Expressed in all		
POLA1	NSX, p180, POLA	ENSG00000101868	DNA polymerase alpha 1, catalytic subunit	X	24693919-24996986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002947, CAB012274	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.80e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 8.7	Expressed in all		
MID1	FXY, OS, RNF59, TRIM18	ENSG00000101871	Midline 1	X	10445310-10833654	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003715	Approved				Liver cancer:3.06e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 20.7	Cell line enhanced		A549: 168.3;AF22: 136.2
NKAP	FLJ22626	ENSG00000101882	NFKB activating protein	X	119920672-119943772	Predicted intracellular proteins	Evidence at protein level	HPA000916	Supported		Supported	Nucleoplasm<br>Cytosol	Breast cancer:4.20e-4 (unfavourable)	Expressed in all	Mixed			ovary: 6.5	Expressed in all		
RHOXF1	OTEX, PEPP1	ENSG00000101883	Rhox homeobox family member 1	X	120109053-120115937	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056506	Approved					Mixed	Tissue enriched	9	testis: 15.5	adipose tissue: 1.6	Not detected		
NXT2	P15-2	ENSG00000101888	Nuclear transport factor 2 like export factor 2	X	109535781-109544690	Predicted intracellular proteins	Evidence at protein level	HPA024199, HPA072010	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 52.0	Expressed in all		
GUCY2F	CYGF, GC-F, GUC2DL, RetGC-2, ROS-GC2	ENSG00000101890	Guanylate cyclase 2F, retinal	X	109372906-109482072	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			fallopian tube,testis: 0.4	Not detected		
ATP1B4		ENSG00000101892	ATPase Na+/K+ transporting family member beta 4	X	120362085-120383249	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	9	skeletal muscle: 20.5	prostate: 2.3	Not detected		
ALG13	CDG1S, CXorf45, FLJ23018, GLT28D1, MDS031, TDRD13, YGL047W	ENSG00000101901	ALG13, UDP-N-acetylglucosaminyltransferase subunit	X	111665811-111760649	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002853	Approved				Renal cancer:1.10e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.4	Expressed in all		
PRPS2		ENSG00000101911	Phosphoribosyl pyrophosphate synthetase 2	X	12791355-12824222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067599, CAB070417	Enhanced		Approved	Vesicles	Cervical cancer:1.90e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 242.3	seminal vesicle: 117.1	Expressed in all		
TLR8	CD288	ENSG00000101916	Toll like receptor 8	X	12906620-12923169	CD markers, Predicted membrane proteins	Evidence at protein level	HPA001608	Enhanced					Mixed	Tissue enhanced		appendix: 23.2;lung: 15.6;spleen: 18.3	lymph node: 6.6	Not detected		
MOSPD1	dJ473B4	ENSG00000101928	Motile sperm domain containing 1	X	134887626-134915267	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031158	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			fallopian tube: 42.4	Expressed in all		
AMMECR1		ENSG00000101935	Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1	X	110194186-110440233	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000590, HPA051762	Uncertain				Ovarian cancer:6.62e-5 (favourable), Thyroid cancer:8.44e-4 (favourable)	Expressed in all	Mixed			placenta: 9.8	Expressed in all		
CHRDL1	CHL, MGC1, NRLN1	ENSG00000101938	Chordin like 1	X	110673856-110795819	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA000226, HPA000250	Approved				Urothelial cancer:2.23e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 386.7	parathyroid gland: 315.6	Group enriched	8	ASC diff: 446.8;ASC TERT1: 622.4
WDR13		ENSG00000101940	WD repeat domain 13	X	48590042-48608867	Predicted intracellular proteins	Evidence at protein level	HPA000913	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center		Expressed in all	Expressed in all			fallopian tube: 91.9	Expressed in all		
SUV39H1	KMT1A, SUV39H	ENSG00000101945	Suppressor of variegation 3-9 homolog 1	X	48695554-48709012	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.91e-7 (unfavourable), Cervical cancer:8.93e-5 (favourable)	Expressed in all	Mixed			epididymis: 14.4	Expressed in all		
PAGE4	CT16.7, GAGEC1, PAGE-4	ENSG00000101951	PAGE family member 4	X	49829260-49833973	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023880	Enhanced		Approved	Golgi apparatus<br>Vesicles		Group enriched	Group enriched	6	epididymis: 1456.6;placenta: 2041.1	prostate: 269.4	Group enriched	9	CACO-2: 8.5;U-266/70: 9.3;U-266/84: 33.4
SRPX	ETX1	ENSG00000101955	Sushi repeat containing protein, X-linked	X	38149336-38220924	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:7.80e-13 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable), Urothelial cancer:3.36e-4 (unfavourable)	Group enriched	Tissue enhanced		adipose tissue: 162.7	placenta: 122.1	Cell line enhanced		ASC diff: 2526.0;ASC TERT1: 571.9;HSkMC: 899.7;HUVEC TERT2: 659.1
GLRA2	GLR	ENSG00000101958	Glycine receptor alpha 2	X	14529298-14731812	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070422	Approved					Mixed	Group enriched	10	cerebral cortex: 6.1;colon: 1.4;rectum: 4.3	testis: 0.3	Cell line enriched	41	AN3-CA: 16.1
XIAP	API3, BIRC4, hILP	ENSG00000101966	X-linked inhibitor of apoptosis	X	123859724-123913979	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009203, HPA042428	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.4	Mixed		
STAG2	SA-2, SA2, SCC3B	ENSG00000101972	Stromal antigen 2	X	123960212-124422664	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002857	Supported					Expressed in all	Expressed in all			parathyroid gland: 112.2	Mixed		
ATP11C	ATPIG, ATPIQ	ENSG00000101974	ATPase phospholipid transporting 11C	X	139726346-139945276	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030830	Approved					Expressed in all	Mixed			liver: 25.6	Mixed		
MCF2	ARHGEF21, DBL	ENSG00000101977	MCF.2 cell line derived transforming sequence	X	139581770-139708227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	11	adrenal gland: 38.3;cerebral cortex: 8.7;epididymis: 15.0;ovary: 12.9;seminal vesicle: 24.0;testis: 34.6	prostate: 2.0	Cell line enriched	12	U-251 MG: 30.6
F9	FIX	ENSG00000101981	Coagulation factor IX	X	139530758-139563458	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:6.69e-4 (favourable)	Tissue enriched	Tissue enriched	2258	liver: 365.0	kidney: 0.1	Not detected		
ABCD1	adrenoleukodystrophy, ALD, ALDP, AMN	ENSG00000101986	ATP binding cassette subfamily D member 1	X	153724868-153744762	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.50e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 19.3	Cell line enhanced		EFO-21: 65.5;PC-3: 46.4
CCDC22	CXorf37, JM1	ENSG00000101997	Coiled-coil domain containing 22	X	49235467-49250526	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000229, HPA000888	Uncertain	Approved	Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.17e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 18.4	Expressed in all		
CACNA1F	AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2	ENSG00000102001	Calcium voltage-gated channel subunit alpha1 F	X	49205063-49233371	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA068379	Supported					Not detected	Mixed			lymph node: 1.6	Cell line enhanced		U-266/70: 1.0
SYP	MRX96	ENSG00000102003	Synaptophysin	X	49187804-49200259	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000076, HPA002858, CAB055505, CAB078999	Enhanced	Supported				Group enriched	Tissue enriched	11	cerebral cortex: 571.4	adrenal gland: 51.1	Cell line enhanced		SCLC-21H: 116.7;SH-SY5Y: 38.0
PLP2	A4, A4-LSB, MGC126187	ENSG00000102007	Proteolipid protein 2	X	49171926-49175239	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042415	Approved				Renal cancer:5.55e-10 (unfavourable), Endometrial cancer:3.32e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 480.2	Mixed		
BMX	ETK, PSCTK3	ENSG00000102010	BMX non-receptor tyrosine kinase	X	15464246-15556529	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001048, CAB032495	Enhanced		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	18	epididymis: 125.0	placenta: 6.9	Cell line enriched	125	HUVEC TERT2: 295.8
LUZP4	CT-8, CT28, HOM-TES-85	ENSG00000102021	Leucine zipper protein 4	X	115289727-115307556	Predicted intracellular proteins	Evidence at protein level	HPA046436, HPA051999	Enhanced					Tissue enriched	Tissue enriched	157	testis: 15.7	all non-specific tissues: 0.0	Not detected		
PLS3	T-plastin	ENSG00000102024	Plastin 3	X	115561174-115650861	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020433, HPA076083	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:6.07e-5 (unfavourable), Renal cancer:1.01e-4 (unfavourable), Thyroid cancer:3.72e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Urothelial cancer:7.04e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 293.0	Mixed		
NAA10	ARD1, ARD1A, DXS707, TE2	ENSG00000102030	N(alpha)-acetyltransferase 10, NatA catalytic subunit	X	153929242-153935223	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB006269, HPA030711	Supported		Enhanced	Nucleoli<br>Cytosol	Renal cancer:3.29e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 25.7	Expressed in all		
RENBP	RBP, RNBP	ENSG00000102032	Renin binding protein	X	153935263-153944691	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000428, HPA000522	Enhanced				Renal cancer:3.08e-5 (favourable), Cervical cancer:3.95e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 58.5	kidney: 37.8	Cell line enhanced		EFO-21: 31.9;HMC-1: 101.6;SK-MEL-30: 61.5;U-266/84: 49.9
ELF4	ELFR, MEF	ENSG00000102034	E74 like ETS transcription factor 4	X	130064874-130110716	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058595, HPA060277	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.49e-6 (unfavourable), Urothelial cancer:1.42e-4 (favourable)	Expressed in all	Mixed			placenta: 34.9	Mixed		
SMARCA1	hSNF2L, ISWI, NURF140, SNF2L, SNF2L1, SNF2LB, SWI	ENSG00000102038	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1	X	129446501-129523500	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003335, HPA064712	Uncertain		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:3.03e-4 (favourable), Renal cancer:5.09e-4 (favourable)	Expressed in all	Mixed			testis: 113.1	Mixed		
MTMR8	FLJ20126	ENSG00000102043	Myotubularin related protein 8	X	64268081-64395431	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			fallopian tube: 3.7	Cell line enhanced		NTERA-2: 4.3
ASB9	DKFZP564L0862, FLJ20636, MGC4954	ENSG00000102048	Ankyrin repeat and SOCS box containing 9	X	15235288-15270467	Predicted intracellular proteins	Evidence at protein level	HPA003014, HPA003060, CAB004997	Enhanced				Prostate cancer:4.36e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 48.3	kidney: 16.9	Cell line enhanced		A549: 23.1;PC-3: 48.9
ZC3H12B	CXorf32, MCPIP2	ENSG00000102053	Zinc finger CCCH-type containing 12B	X	65366638-65507887	Predicted intracellular proteins	Evidence at transcript level	HPA000836	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 4.6	endometrium: 2.2	Cell line enhanced		AF22: 2.1
RBBP7	RbAp46	ENSG00000102054	RB binding protein 7, chromatin remodeling factor	X	16839283-16870414	Predicted intracellular proteins	Evidence at protein level	CAB037084, HPA060710, HPA060724	Supported				Thyroid cancer:2.43e-4 (favourable), Liver cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 376.0	Expressed in all		
PPP1R2P9	I-4	ENSG00000102055	Protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 9	X	42777368-42778247	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	584	testis: 60.2	lymph node,tonsil: 0.1	Not detected		
KCND1	Kv4.1	ENSG00000102057	Potassium voltage-gated channel subfamily D member 1	X	48961378-48971569	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA000524, HPA001066	Approved		Approved	Nucleus	Pancreatic cancer:2.66e-6 (favourable)	Mixed	Mixed			gallbladder: 3.9	Mixed		
OPN1LW	CBBM, CBP, COD5, RCP	ENSG00000102076	Opsin 1, long wave sensitive	X	154144224-154159032	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
SLC25A14	BMCP1, UCP5	ENSG00000102078	Solute carrier family 25 member 14	X	130339888-130373361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060316			Approved	Mitochondria	Renal cancer:5.52e-6 (unfavourable), Urothelial cancer:1.39e-5 (favourable), Cervical cancer:1.72e-5 (favourable), Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.4	Expressed in all		
FMR1	FMRP, FRAXA, MGC87458, POF, POF1	ENSG00000102081	Fragile X mental retardation 1	X	147911951-147951125	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012444, HPA050118, HPA056084	Approved		Enhanced	Cytosol	Endometrial cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 55.4	Expressed in all		
PIM2		ENSG00000102096	Pim-2 proto-oncogene, serine/threonine kinase	X	48913182-48919024	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000285			Approved	Cytosol	Renal cancer:1.17e-11 (unfavourable), Cervical cancer:4.05e-5 (favourable)	Tissue enriched	Mixed			lymph node: 128.7	Expressed in all		
SCML2		ENSG00000102098	Sex comb on midleg-like 2 (Drosophila)	X	18239314-18354727	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001662, HPA064713	Enhanced		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		testis: 19.2	ovary: 6.3	Cell line enhanced		NTERA-2: 35.7
SLC35A2	UGALT, UGAT, UGT, UGT1, UGT2, UGTL	ENSG00000102100	Solute carrier family 35 member A2	X	48903180-48911958	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036087	Approved		Supported	Golgi apparatus	Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 45.0	Expressed in all		
PQBP1	MRX2, MRX55, MRXS3, MRXS8, RENS1, SHS	ENSG00000102103	Polyglutamine binding protein 1	X	48897912-48903143	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001880	Supported		Enhanced	Nuclear speckles	Renal cancer:2.68e-7 (unfavourable), Cervical cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube,ovary: 49.9	Expressed in all		
RS1	RS, XLRS1	ENSG00000102104	Retinoschisin 1	X	18639910-18672109	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA059546	Supported					Not detected	Group enriched	7	cerebral cortex: 1.1;lung: 1.6	lymph node,spleen,thyroid gland: 0.1	Not detected		
PCSK1N	BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII	ENSG00000102109	Proprotein convertase subtilisin/kexin type 1 inhibitor	X	48831094-48835633	Predicted secreted proteins	Evidence at protein level	HPA003925, HPA064734	Enhanced		Approved	Vesicles	Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 93.6;kidney: 65.7	adrenal gland: 28.5	Cell line enhanced		HEK 293: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2
EMD	LEMD5, STA	ENSG00000102119	Emerin	X	154379197-154381523	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA000609, CAB001545, CAB002029, CAB062552	Enhanced		Enhanced	Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			fallopian tube: 32.7	Expressed in all		
TAZ	BTHS, CMD3A, EFE, EFE2, G4.5, TAZ1, XAP-2	ENSG00000102125	Tafazzin	X	154411518-154421726	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039557	Approved		Approved	Plasma membrane	Renal cancer:1.22e-7 (unfavourable), Cervical cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			bone marrow,spleen: 20.8	Expressed in all		
RAB40AL	RAR2, RLGP	ENSG00000102128	RAB40A, member RAS oncogene family-like	X	102937272-102938300	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			epididymis: 0.3	Not detected		
PGK1		ENSG00000102144	Phosphoglycerate kinase 1	X	78065188-78129296	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010065, HPA045385, HPA073644, HPA073656	Approved				Breast cancer:7.05e-8 (unfavourable), Head and neck cancer:2.65e-6 (unfavourable), Cervical cancer:2.69e-5 (unfavourable), Liver cancer:2.74e-4 (unfavourable), Pancreatic cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.2	Expressed in all		
GATA1	ERYF1, GATA-1, GF1, NF-E1, NFE1	ENSG00000102145	GATA binding protein 1	X	48786554-48794311	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000232, HPA000233, CAB009195	Enhanced					Not detected	Tissue enriched	19	bone marrow: 33.2	testis: 1.7	Group enriched	12	HEL: 182.0;HMC-1: 176.5;K-562: 196.6
MAGT1	DKFZp564K142, IAP, MRX95, OST3B	ENSG00000102158	Magnesium transporter 1	X	77826364-77895593	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049851	Approved				Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 137.3	Expressed in all		
SMS	MRSR, SPMSY, SpS, SRS	ENSG00000102172	Spermine synthase	X	21940573-21994835	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029849, HPA029852	Approved		Approved	Nuclear bodies<br>Cytosol	Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 202.4	Expressed in all		
PHEX	HPDR, HPDR1, HYP, HYP1, PEX, XLH	ENSG00000102174	Phosphate regulating endopeptidase homolog, X-linked	X	22032441-22251310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Thyroid cancer:2.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		endometrium: 3.5	lung: 2.9	Cell line enhanced		PC-3: 2.8;U-87 MG: 6.5;WM-115: 2.8
UBL4A	DXS254E, GDX, GET5, MDY2, TMA24, UBL4	ENSG00000102178	Ubiquitin like 4A	X	154483717-154486670	Predicted intracellular proteins	Evidence at protein level	HPA003617	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 31.8	Expressed in all		
CD99L2	CD99B, MIC2L1	ENSG00000102181	CD99 molecule like 2	X	150766337-150898816	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038782, HPA038783, HPA061400	Enhanced		Supported	Plasma membrane	Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.5	Expressed in all		
EEA1	ZFYVE2	ENSG00000102189	Early endosome antigen 1	12	92770637-92929331	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005861, CAB018782, HPA038158, HPA038159	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 16.8	Expressed in all		
GPR50	H9, Mel1c	ENSG00000102195	G protein-coupled receptor 50	X	151176653-151181465	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA049862, HPA054678	Supported		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Not detected			placenta: 0.6	Cell line enriched	7	HEK 293: 4.8
RP2	NM23-H10, NME10, TBCCD2	ENSG00000102218	Retinitis pigmentosa 2 (X-linked recessive)	X	46836940-46882358	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000234, HPA000909	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane	Liver cancer:7.97e-4 (unfavourable)	Expressed in all	Mixed			placenta: 35.0	Expressed in all		
JADE3	JADE-3, KIAA0215, PHF16	ENSG00000102221	Jade family PHD finger 3	X	46912276-47061242	Predicted intracellular proteins	Evidence at protein level	HPA006007, HPA064697	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 22.6	Cell line enhanced		BEWO: 63.4
CDK16	FLJ16665, PCTAIRE, PCTAIRE1, PCTGAIRE, PCTK1	ENSG00000102225	Cyclin dependent kinase 16	X	47217860-47229997	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000974, HPA001366, CAB016535	Approved		Uncertain	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:2.02e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.9	Expressed in all		
USP11	UHX1	ENSG00000102226	Ubiquitin specific peptidase 11	X	47232690-47248328	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003103, HPA037536	Enhanced	Approved	Supported	Nucleoplasm	Renal cancer:4.13e-5 (favourable), Endometrial cancer:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 212.7	Expressed in all		
PCYT1B	CCT-beta, CTB	ENSG00000102230	Phosphate cytidylyltransferase 1, choline, beta	X	24558087-24672677	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006367	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 17.4	fallopian tube,smooth muscle: 4.7	Cell line enhanced		AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7
BRS3	BB3, BB3R	ENSG00000102239	Bombesin receptor subtype 3	X	136487887-136493780	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	33	epididymis: 30.5	ovary: 0.9	Not detected		
HTATSF1	TAT-SF1	ENSG00000102241	HIV-1 Tat specific factor 1	X	136497079-136512346	Predicted intracellular proteins	Evidence at protein level	HPA000504	Supported		Enhanced	Nucleoplasm	Renal cancer:8.13e-8 (favourable), Cervical cancer:3.78e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 125.8	Expressed in all		
VGLL1	TDU, TONDU	ENSG00000102243	Vestigial like family member 1	X	136532152-136556807	Predicted intracellular proteins	Evidence at protein level	HPA042403, HPA064616	Supported		Supported	Nucleus	Endometrial cancer:4.54e-4 (unfavourable)	Tissue enhanced	Tissue enriched	14	placenta: 257.6	urinary bladder: 18.3	Group enriched	11	A-431: 102.6;BEWO: 166.1;CAPAN-2: 56.3;RT4: 243.2;SK-BR-3: 219.4
CD40LG	CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP	ENSG00000102245	CD40 ligand	X	136648193-136660390	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA045827	Enhanced					Mixed	Tissue enhanced		lymph node: 18.8;tonsil: 14.1	appendix: 10.5	Cell line enriched	65	MOLT-4: 19.2
TIMP1	CLGI, EPO, TIMP	ENSG00000102265	TIMP metallopeptidase inhibitor 1	X	47582313-47586789	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022360, HPA053417	Approved		Approved	Golgi apparatus	Renal cancer:2.90e-11 (unfavourable), Colorectal cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 2036.7	Expressed in all		
KLHL4	DKELCHL, KHL4, KIAA1687	ENSG00000102271	Kelch like family member 4	X	87517749-87670050	Predicted intracellular proteins	Evidence at protein level	HPA029192	Approved		Supported	Microtubules<br>Microtubule organizing center	Renal cancer:8.08e-5 (unfavourable)	Tissue enriched	Tissue enhanced		adrenal gland: 37.2	testis: 15.6	Cell line enhanced		AF22: 15.8;HUVEC TERT2: 28.7;NTERA-2: 25.8;TIME: 31.0
GABRE		ENSG00000102287	Gamma-aminobutyric acid type A receptor epsilon subunit	X	151953124-151974680	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA045918	Uncertain				Renal cancer:4.05e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 10.1	heart muscle: 6.4	Cell line enhanced		EFO-21: 10.9;HeLa: 3.5;SiHa: 5.9
PCDH11X	PCDH-X, PCDH11, PCDHX, PPP1R119	ENSG00000102290	Protocadherin 11 X-linked	X	91779261-92623230	Predicted membrane proteins	Evidence at transcript level	HPA000432	Approved					Not detected	Tissue enhanced		cerebral cortex: 4.6;ovary: 8.9;parathyroid gland: 4.9	cervix, uterine: 1.5	Cell line enhanced		AF22: 1.4;AN3-CA: 2.1
FGD1	FGDY, ZFYVE3	ENSG00000102302	FYVE, RhoGEF and PH domain containing 1	X	54445454-54496166	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000911	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.10e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.5	Mixed		
PIN4	EPVH, PAR14, PAR17	ENSG00000102309	Peptidylprolyl cis/trans isomerase, NIMA-interacting 4	X	72181353-72302926	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054483, HPA064504	Approved		Supported	Nucleus<br>Nucleoli	Testis cancer:2.58e-4 (favourable), Urothelial cancer:2.66e-4 (favourable), Lung cancer:6.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
PORCN	DHOF, MG61, por, PORC, PPN	ENSG00000102312	Porcupine homolog (Drosophila)	X	48508962-48520814	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA049215, HPA058413	Enhanced		Approved	Vesicles		Expressed in all	Mixed			adrenal gland: 31.4	Cell line enhanced		HBEC3-KT: 126.7
ITIH6	ITIH5L, UNQ6369	ENSG00000102313	Inter-alpha-trypsin inhibitor heavy chain family member 6	X	54748899-54798240	Predicted secreted proteins	Evidence at protein level	HPA000506	Uncertain					Tissue enriched	Not detected			prostate: 0.6	Cell line enriched	24	WM-115: 50.0
MAGED2	11B6, BCG1, HCA10, JCL-1, MAGE-D2, MAGED, MGC8386	ENSG00000102316	MAGE family member D2	X	54807599-54816012	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031572, HPA031573	Supported		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:2.82e-4 (favourable), Ovarian cancer:2.88e-4 (favourable), Stomach cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 325.8	Expressed in all		
RBM3	IS1-RNPL	ENSG00000102317	RNA binding motif (RNP1, RRM) protein 3	X	48574449-48579066	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003624, CAB062559	Enhanced		Enhanced	Nucleoplasm	Colorectal cancer:3.07e-7 (favourable)	Expressed in all	Expressed in all			breast: 237.2	Expressed in all		
KLF8	BKLF3, DXS741, ZNF741	ENSG00000102349	Kruppel like factor 8	X	56232421-56287889	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071740			Supported	Nucleoplasm	Head and neck cancer:3.32e-4 (favourable)	Mixed	Tissue enhanced		skin: 33.8	esophagus: 16.9	Cell line enhanced		hTCEpi: 9.9;RT4: 9.7;SK-BR-3: 7.9;T-47d: 18.2
SRPX2	SRPUL	ENSG00000102359	Sushi repeat containing protein, X-linked 2	X	100644166-100675788	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038786	Uncertain		Uncertain	Microtubules	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Mixed			adipose tissue: 18.8	Cell line enhanced		ASC diff: 191.6;ASC TERT1: 83.0;HSkMC: 77.9;HUVEC TERT2: 65.3
SYTL4		ENSG00000102362	Synaptotagmin like 4	X	100674491-100732123	Predicted intracellular proteins	Evidence at protein level	HPA001475, HPA001589	Approved		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Renal cancer:2.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 71.5;ovary: 83.7	smooth muscle: 49.0	Cell line enhanced		HAP1: 30.4;HMC-1: 52.7;RT4: 32.5;TIME: 28.4
ZDHHC15	FLJ31812, MRX91	ENSG00000102383	Zinc finger DHHC-type containing 15	X	75368427-75523502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA003618	Uncertain		Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 4.8	Cell line enhanced		HEL: 2.8;MOLT-4: 1.9;NTERA-2: 2.0;RH-30: 3.0;SH-SY5Y: 2.7
CENPI	CENP-I, FSHPRH1, LRPR1, Mis6	ENSG00000102384	Centromere protein I	X	101098218-101163681	Predicted intracellular proteins	Evidence at protein level	HPA061297			Supported	Nuclear bodies<br>Cytosol		Mixed	Mixed			lymph node: 6.6	Mixed		
DRP2		ENSG00000102385	Dystrophin related protein 2	X	101219769-101264497	Predicted intracellular proteins	Evidence at protein level	HPA002949			Approved	Nuclear speckles<br>Plasma membrane		Tissue enhanced	Tissue enriched	6	cerebral cortex: 12.3	prostate: 2.2	Cell line enhanced		RH-30: 10.4;TIME: 15.0;U-87 MG: 4.3
TAF7L	CT40, TAF2Q	ENSG00000102387	TATA-box binding protein associated factor 7 like	X	101268253-101293057	Predicted intracellular proteins	Evidence at protein level	HPA001879	Approved		Approved	Nucleoplasm	Cervical cancer:8.71e-4 (favourable)	Tissue enhanced	Tissue enriched	14	testis: 62.6	parathyroid gland: 4.6	Cell line enriched	23	SiHa: 60.1
PBDC1	CXorf26, MGC874	ENSG00000102390	Polysaccharide biosynthesis domain containing 1	X	76172936-76178204	Predicted intracellular proteins	Evidence at protein level	HPA003155	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Thyroid cancer:8.57e-4 (favourable)	Expressed in all	Expressed in all			prostate: 39.7	Mixed		
GLA	GALA	ENSG00000102393	Galactosidase alpha	X	101397803-101407925	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000237, HPA000966	Enhanced				Liver cancer:5.62e-5 (unfavourable), Stomach cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 59.2	Expressed in all		
ARMCX3	ALEX3, GASP6	ENSG00000102401	Armadillo repeat containing, X-linked 3	X	101622797-101627843	Predicted membrane proteins	Evidence at protein level	HPA000325, HPA000967, HPA001530	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.55e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 167.6	Mixed		
BEX4	BEXL1, FLJ10097	ENSG00000102409	Brain expressed X-linked 4	X	103215092-103217246	Predicted intracellular proteins	Evidence at transcript level	HPA045105, HPA051935	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.54e-14 (favourable), Pancreatic cancer:9.41e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 323.6	Cell line enhanced		HMC-1: 164.0;K-562: 205.1
RUBCNL	C13orf18, FLJ21562, KIAA0226L	ENSG00000102445	RUN and cysteine rich domain containing beclin 1 interacting protein like	13	46342000-46438190	Predicted intracellular proteins	Evidence at protein level	HPA026614	Approved		Supported	Cytosol	Endometrial cancer:3.76e-5 (favourable)	Tissue enriched	Mixed			lymph node: 35.0	Cell line enhanced		Daudi: 99.1;REH: 36.6;U-698: 157.0
NALCN	bA430M15.1, CanIon, VGCNL1	ENSG00000102452	Sodium leak channel, non-selective	13	101053776-101416492	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031889, HPA031890, HPA031958	Approved					Mixed	Tissue enhanced		cerebral cortex: 28.1	adrenal gland: 6.0	Cell line enhanced		HaCaT: 12.6;HHSteC: 12.3;TIME: 15.4;U-87 MG: 11.1
FGF14	FHF4, SCA27	ENSG00000102466	Fibroblast growth factor 14	13	101710804-102402457	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA049828			Approved	Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 14.8;cervix, uterine: 22.9;fallopian tube: 17.2	testis: 4.3	Group enriched	7	SCLC-21H: 5.4;SH-SY5Y: 20.7;U-87 MG: 4.1
HTR2A	5-HT2A, HTR2	ENSG00000102468	5-hydroxytryptamine receptor 2A	13	46831550-46897076	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014011	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 32.2	smooth muscle: 3.9	Cell line enhanced		ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6
NDFIP2	KIAA1165, N4wbp5a	ENSG00000102471	Nedd4 family interacting protein 2	13	79481124-79556075	Predicted membrane proteins	Evidence at protein level	HPA009160	Uncertain		Enhanced	Vesicles	Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.0	Mixed		
TNFSF13B	BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20	ENSG00000102524	Tumor necrosis factor superfamily member 13b	13	108251240-108308484	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009188	Enhanced				Renal cancer:2.53e-11 (unfavourable)	Expressed in all	Mixed			appendix: 35.3	Cell line enriched	9	U-937: 130.0
FNDC3A	bA203I16.5, FNDC3, KIAA0970	ENSG00000102531	Fibronectin type III domain containing 3A	13	48975912-49209779	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008927, HPA012825	Approved		Approved	Endoplasmic reticulum	Renal cancer:4.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 85.7	Expressed in all		
MLNR	GPR38	ENSG00000102539	Motilin receptor	13	49220338-49222377	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		thyroid gland: 2.8	bone marrow: 0.8	Cell line enhanced		NTERA-2: 1.3;THP-1: 2.7
CDADC1	NYD-SP15	ENSG00000102543	Cytidine and dCMP deaminase domain containing 1	13	49247925-49293485	Predicted intracellular proteins	Evidence at transcript level	HPA047615, HPA058314	Uncertain		Approved	Nucleoplasm	Renal cancer:1.19e-5 (favourable), Lung cancer:6.03e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 15.7	Mixed		
CAB39L	bA103J18.3, FLJ12577, MO2L	ENSG00000102547	Calcium binding protein 39 like	13	49308650-49444126	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003686, HPA045954	Uncertain		Approved	Vesicles	Renal cancer:1.94e-13 (favourable), Ovarian cancer:2.28e-4 (unfavourable), Prostate cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			prostate: 66.2	Cell line enhanced		CACO-2: 32.9;RT4: 33.1
KLF5	BTEB2, CKLF, IKLF	ENSG00000102554	Kruppel like factor 5	13	73054976-73077542	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040398	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Pancreatic cancer:2.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 279.6	esophagus: 216.2	Cell line enhanced		HaCaT: 113.4;hTCEpi: 113.2;RT4: 108.4;SiHa: 121.1
STK24	MST-3, MST3, MST3B, STE20, STK3	ENSG00000102572	Serine/threonine kinase 24	13	98445185-98577940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026435, HPA026502	Enhanced		Supported	Nucleoli<br>Cytosol	Lung cancer:6.23e-6 (unfavourable), Renal cancer:6.91e-5 (favourable), Pancreatic cancer:5.81e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 169.5	Expressed in all		
ACP5	HPAP, TRAP	ENSG00000102575	Acid phosphatase 5, tartrate resistant	19	11574660-11579008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002584, HPA057655, HPA059463	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		lung: 254.0	lymph node: 86.3	Cell line enhanced		BEWO: 36.2;SK-MEL-30: 85.3;U-138 MG: 97.5
DNAJC3	ERdj6, HP58, P58, P58IPK, PRKRI	ENSG00000102580	DnaJ heat shock protein family (Hsp40) member C3	13	95677139-95794989	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039336, HPA041326	Uncertain		Approved	Endoplasmic reticulum	Endometrial cancer:3.47e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 88.4	Mixed		
UGGT2	FLJ10873, FLJ11485, HUGT2, MGC117360, MGC150689, MGC87276, UGCGL2	ENSG00000102595	UDP-glucose glycoprotein glucosyltransferase 2	13	95801580-96053482	Predicted secreted proteins	Evidence at protein level	HPA047955	Uncertain				Lung cancer:5.47e-4 (unfavourable), Liver cancer:9.99e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.7	Mixed		
ARHGEF7	BETA-PIX, COOL1, DKFZp686C12170, DKFZp761K1021, KIAA0142, Nbla10314, P50, P50BP, P85, P85COOL1, P85SPR, PAK3, PIXB	ENSG00000102606	Rho guanine nucleotide exchange factor 7	13	111114559-111305737	Predicted intracellular proteins	Evidence at protein level	HPA004744	Approved				Glioma:7.29e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 96.8	Expressed in all		
FGF9		ENSG00000102678	Fibroblast growth factor 9	13	21671383-21704498	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA067007	Enhanced				Renal cancer:1.70e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 12.1	adrenal gland: 4.7	Cell line enhanced		RPTEC TERT1: 2.5;SCLC-21H: 8.0
SGCG	A4, DAGA4, DMDA, DMDA1, LGMD2C, MAM, MGC130048, SCARMD2, SCG3, TYPE	ENSG00000102683	Sarcoglycan gamma	13	23180952-23325165	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007476, HPA011922	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		heart muscle: 74.9;skeletal muscle: 54.0	adipose tissue: 14.5	Cell line enriched	5	fHDF/TERT166: 50.4
PARP4	ADPRTL1, p193, VAULT3, VPARP, VWA5C	ENSG00000102699	Poly(ADP-ribose) polymerase family member 4	13	24420926-24512810	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011739	Approved		Supported	Cytosol	Renal cancer:1.21e-5 (favourable)	Expressed in all	Expressed in all			gallbladder: 46.0	Expressed in all		
SUPT20H	bA421P11.4, C13orf19, FAM48A, P38IP, SPT20	ENSG00000102710	SPT20 homolog, SAGA complex component	13	37009312-37059713	Predicted intracellular proteins	Evidence at protein level	HPA038906, HPA038907	Uncertain		Supported	Nucleoli fibrillar center		Expressed in all	Expressed in all			testis: 100.1	Expressed in all		
MRPS31	IMOGN38	ENSG00000102738	Mitochondrial ribosomal protein S31	13	40729135-40771173	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039083, HPA046344	Uncertain		Supported	Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			testis,thyroid gland: 33.6	Expressed in all		
SLC25A15	D13S327, HHH, ORC1, ORNT1	ENSG00000102743	Solute carrier family 25 member 15	13	40789412-40810111	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042146	Approved				Renal cancer:1.74e-4 (favourable), Liver cancer:2.16e-4 (favourable), Urothelial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 49.6	Expressed in all		
KPNA3	hSRP1, IPOA4, SRP1gamma, SRP4	ENSG00000102753	Karyopherin subunit alpha 3	13	49699307-49792921	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA046852	Approved		Approved	Nucleoplasm<br>Cytosol	Glioma:1.48e-4 (favourable), Cervical cancer:2.80e-4 (unfavourable), Renal cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.8	Expressed in all		
FLT1	FLT, VEGFR1	ENSG00000102755	Fms related tyrosine kinase 1	13	28300344-28495145	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA011740, HPA014290, CAB068189, CAB068190	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:2.19e-4 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 622.5	thyroid gland: 81.9	Cell line enhanced		BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
RGCC	bA157L14.2, C13orf15, RGC-32, RGC32	ENSG00000102760	Regulator of cell cycle	13	41457559-41470882	Predicted secreted proteins	Evidence at protein level	HPA035638, HPA063701	Approved		Supported	Nucleus<br>Nucleoli	Colorectal cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 409.0	Cell line enhanced		BJ hTERT+: 255.6;Daudi: 75.1;U-698: 75.7
VWA8	KIAA0564	ENSG00000102763	Von Willebrand factor A domain containing 8	13	41566837-41961120	Predicted intracellular proteins	Evidence at protein level	HPA039075, HPA045478	Uncertain		Approved	Vesicles<br>Lipid droplets	Renal cancer:6.38e-14 (favourable), Liver cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Mixed		
DGKH	DGKeta	ENSG00000102780	Diacylglycerol kinase eta	13	42040036-42256578	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039533, HPA040355	Uncertain					Mixed	Mixed			epididymis: 8.4	Mixed		
KATNAL1	MGC2599	ENSG00000102781	Katanin catalytic subunit A1 like 1	13	30202630-30307484	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046205			Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 37.7	smooth muscle: 21.9	Mixed		
INTS6	DBI-1, DDX26, DDX26A, DICE1, HDB, INT6, Notchl2	ENSG00000102786	Integrator complex subunit 6	13	51354077-51454264	Predicted intracellular proteins	Evidence at protein level	HPA001552, HPA001846	Supported		Enhanced	Nucleoplasm<br>Actin filaments		Expressed in all	Expressed in all			testis: 103.4	Expressed in all		
ACOD1	CAD, IRG1	ENSG00000102794	Aconitate decarboxylase 1	13	76948497-76958642	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040143	Uncertain					Not detected	Tissue enriched	5	appendix: 1.9	lung: 0.3	Not detected		
DHRS12	FLJ13639, SDR40C1	ENSG00000102796	Dehydrogenase/reductase 12	13	51767993-51804157	Predicted intracellular proteins	Evidence at protein level	CAB034238, HPA057028, HPA058315	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 22.0	Mixed		
MEDAG	AWMS3, C13orf33, FLJ14834, MEDA-4	ENSG00000102802	Mesenteric estrogen dependent adipogenesis	13	30906191-30925572	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:3.29e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 153.5	smooth muscle: 32.2	Cell line enhanced		ASC diff: 206.4;ASC TERT1: 58.9;U-2197: 157.4
TSC22D1	MGC17597, TGFB1I4, TSC22	ENSG00000102804	TSC22 domain family member 1	13	44432143-44577147	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077414			Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.54e-4 (favourable), Ovarian cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 269.2	Cell line enhanced		HEL: 221.4
CLN5		ENSG00000102805	Ceroid-lipofuscinosis, neuronal 5	13	76990660-77019143	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041788	Approved				Renal cancer:1.52e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 127.1	Expressed in all		
OLFM4	GC1, GW112, OlfD	ENSG00000102837	Olfactomedin 4	13	53028759-53052057	Predicted secreted proteins	Evidence at protein level	HPA077718	Enhanced				Breast cancer:8.77e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 1193.9;rectum: 611.5;small intestine: 1437.8	colon: 445.0	Cell line enhanced		BEWO: 5.1;BJ hTERT+: 15.0;HaCaT: 22.9
MSLN	CAK1, MPF	ENSG00000102854	Mesothelin	16	760762-768865	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002216, HPA017172	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.91e-4 (favourable), Pancreatic cancer:6.66e-4 (unfavourable)	Tissue enhanced	Group enriched	9	fallopian tube: 445.8;lung: 105.4	epididymis: 29.1	Cell line enhanced		CAPAN-2: 448.3;EFO-21: 72.6;HeLa: 104.4;hTCEpi: 80.2
MGRN1	KIAA0544, RNF156	ENSG00000102858	Mahogunin ring finger 1	16	4616493-4690974	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007653	Approved					Expressed in all	Expressed in all			cerebral cortex: 56.4	Expressed in all		
ZNF629	KIAA0326, ZNF65	ENSG00000102870	Zinc finger protein 629	16	30778449-30787202	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019550, HPA056051	Uncertain		Supported	Nucleus<br>Golgi apparatus	Renal cancer:4.57e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.8	Mixed		
TRADD	Hs.89862	ENSG00000102871	TNFRSF1A associated via death domain	16	67154180-67160298	Predicted intracellular proteins	Evidence at protein level	CAB004602, HPA071341	Enhanced		Approved	Cytosol	Endometrial cancer:1.40e-4 (favourable)	Expressed in all	Mixed			spleen: 17.6	Mixed		
HSF4	CTM	ENSG00000102878	Heat shock transcription factor 4	16	67164681-67169945	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048584			Supported	Nuclear speckles	Renal cancer:2.19e-6 (unfavourable), Colorectal cancer:8.24e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 14.8	Cell line enhanced		T-47d: 12.3;U-266/70: 18.1
CORO1A	coronin-1, HCORO1, p57	ENSG00000102879	Coronin 1A	16	30182827-30189076	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046473, HPA051132	Enhanced		Approved	Cytosol	Renal cancer:5.74e-7 (unfavourable), Head and neck cancer:4.42e-4 (favourable), Endometrial cancer:6.91e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 593.1	Cell line enhanced		Daudi: 596.0;HMC-1: 850.4;RPMI-8226: 612.4;U-937: 575.5
MAPK3	ERK1, p44erk1, p44mapk, PRKM3	ENSG00000102882	Mitogen-activated protein kinase 3	16	30114105-30123506	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002683, HPA003995, HPA005700, HPA030069	Approved		Approved	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 133.7	Expressed in all		
GDPD3	MGC4171	ENSG00000102886	Glycerophosphodiester phosphodiesterase domain containing 3	16	30104810-30113856	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041148, HPA041470	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:5.89e-9 (unfavourable)	Expressed in all	Mixed			esophagus: 23.1	Cell line enhanced		MCF7: 24.3;SK-BR-3: 81.3
ELMO3	CED-12, CED12, ELMO-3, FLJ13824	ENSG00000102890	Engulfment and cell motility 3	16	67199111-67204029	Predicted intracellular proteins	Evidence at protein level	HPA021484	Approved		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:2.77e-5 (favourable)	Expressed in all	Mixed			skin: 39.3	Cell line enhanced		BEWO: 31.7;CAPAN-2: 43.1;HaCaT: 41.1;T-47d: 42.8
MT4	MTIV	ENSG00000102891	Metallothionein 4	16	56565049-56568957	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	5	skin: 13.7	testis: 2.6	Not detected		
PHKB		ENSG00000102893	Phosphorylase kinase regulatory subunit beta	16	47461123-47701523	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA073380			Approved	Golgi apparatus	Renal cancer:3.89e-9 (favourable), Thyroid cancer:3.24e-4 (unfavourable), Colorectal cancer:3.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 99.3	Expressed in all		
LYRM1	A211C6.1	ENSG00000102897	LYR motif containing 1	16	20899868-20925006	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059840			Supported	Nucleoplasm<br>Midbody	Endometrial cancer:7.48e-7 (favourable), Renal cancer:4.80e-4 (unfavourable), Urothelial cancer:9.50e-4 (favourable)	Expressed in all	Expressed in all			testis: 70.4	Expressed in all		
NUTF2	NTF2, PP15	ENSG00000102898	Nuclear transport factor 2	16	67846732-67872567	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040915, HPA040956	Enhanced		Approved	Microtubules	Head and neck cancer:1.15e-4 (unfavourable), Renal cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 83.7	Expressed in all		
NUP93	KIAA0095	ENSG00000102900	Nucleoporin 93	16	56730105-56850286	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017937	Uncertain				Liver cancer:1.72e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 74.6	Expressed in all		
CENPT	C16orf56, CENP-T, FLJ13111	ENSG00000102901	Centromere protein T	16	67828157-67847811	Predicted intracellular proteins	Evidence at protein level	HPA041220, HPA058036	Approved		Enhanced	Nuclear bodies	Renal cancer:1.57e-7 (unfavourable), Pancreatic cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			skin: 15.9	Mixed		
TSNAXIP1	TXI1	ENSG00000102904	Translin associated factor X interacting protein 1	16	67806765-67832148	Predicted intracellular proteins	Evidence at protein level	HPA053516			Approved	Nucleus<br>Cytosol	Endometrial cancer:2.22e-4 (favourable)	Mixed	Group enriched	10	fallopian tube: 15.6;testis: 39.9	parathyroid gland: 2.7	Cell line enhanced		AN3-CA: 2.8
NFAT5	KIAA0827, NF-AT5, NFATL1, NFATZ, OREBP, TONEBP	ENSG00000102908	Nuclear factor of activated T-cells 5	16	69565094-69704666	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057304, HPA069711	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.4	Expressed in all		
LONP2	LONP, LONPL, MGC4840	ENSG00000102910	Lon peptidase 2, peroxisomal	16	48244296-48363122	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008862	Uncertain				Renal cancer:6.71e-7 (favourable), Cervical cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.8	Expressed in all		
N4BP1		ENSG00000102921	NEDD4 binding protein 1	16	48538726-48620148	Predicted intracellular proteins	Evidence at protein level	HPA040849, HPA041080	Approved		Approved	Nucleoli fibrillar center	Renal cancer:9.03e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.1	Expressed in all		
CBLN1		ENSG00000102924	Cerebellin 1 precursor	16	49277917-49281831	Predicted secreted proteins	Evidence at protein level						Thyroid cancer:7.10e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 32.4	adipose tissue: 12.3	Group enriched	30	NTERA-2: 40.0;SCLC-21H: 148.4
ARL2BP	BART, BART1, RP66	ENSG00000102931	ADP ribosylation factor like GTPase 2 binding protein	16	57245098-57253635	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043066, HPA048440	Approved				Lung cancer:9.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 96.1	Expressed in all		
PLLP	PMLP, TM4SF11	ENSG00000102934	Plasmolipin	16	57248547-57284687	Predicted membrane proteins	Evidence at protein level	HPA041862	Enhanced				Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.0	Cell line enhanced		EFO-21: 25.9;Hep G2: 54.1;RPTEC TERT1: 24.7
ZNF423	Ebfaz, JBTS19, KIAA0760, NPHP14, OAZ, Roaz, Zfp104	ENSG00000102935	Zinc finger protein 423	16	49487524-49857919	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015258, HPA065820	Uncertain		Enhanced	Nucleus		Mixed	Mixed			fallopian tube: 15.4	Cell line enhanced		AF22: 53.5;NTERA-2: 27.7;REH: 22.3;SCLC-21H: 34.3;SH-SY5Y: 92.6
CCL22	A-152E5.1, ABCD-1, DC/B-CK, MDC, MGC34554, SCYA22, STCP-1	ENSG00000102962	C-C motif chemokine ligand 22	16	57358772-57366190	Predicted secreted proteins	Evidence at protein level						Endometrial cancer:2.23e-6 (favourable), Head and neck cancer:9.17e-5 (favourable), Colorectal cancer:2.98e-4 (favourable)	Mixed	Tissue enhanced		appendix: 18.6;tonsil: 13.5	skin: 7.9	Cell line enriched	21	HDLM-2: 45.9
DHODH		ENSG00000102967	Dihydroorotate dehydrogenase (quinone)	16	72008588-72027664	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010123, HPA011942	Approved		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			liver: 21.4	Expressed in all		
CCL17	ABCD-2, SCYA17, TARC	ENSG00000102970	C-C motif chemokine ligand 17	16	57404767-57416062	Predicted secreted proteins	Evidence at protein level	CAB002583	Approved				Cervical cancer:1.91e-5 (favourable), Urothelial cancer:5.80e-4 (favourable)	Mixed	Tissue enhanced		appendix: 11.1;lymph node: 9.9	tonsil: 5.4	Cell line enriched	725	HDLM-2: 2231.6
CTCF		ENSG00000102974	CCCTC-binding factor	16	67562407-67639183	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004122, CAB062550, CAB068181, CAB068182	Supported		Supported	Nucleoplasm	Renal cancer:4.06e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
ACD	Pip1, Ptop, Tint1, Tpp1	ENSG00000102977	ACD, shelterin complex subunit and telomerase recruitment factor	16	67657512-67660815	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049411, HPA057660	Approved		Enhanced	Nuclear bodies	Liver cancer:2.42e-6 (unfavourable)	Expressed in all	Mixed			testis: 18.4	Expressed in all		
POLR2C	RPB3	ENSG00000102978	RNA polymerase II subunit C	16	57462387-57472010	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA040919, HPA041826	Enhanced		Supported	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:3.03e-6 (favourable), Head and neck cancer:1.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 68.2	Expressed in all		
PARD6A	PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40	ENSG00000102981	Par-6 family cell polarity regulator alpha	16	67660946-67662778	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009733, HPA041551	Approved		Supported	Cell Junctions<br>Actin filaments<br>Cytosol	Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 20.2	cerebral cortex: 12.1	Cell line enhanced		REH: 24.9;SCLC-21H: 25.2
ZNF821		ENSG00000102984	Zinc finger protein 821	16	71859680-71895336	Predicted intracellular proteins	Evidence at protein level	HPA036372, HPA042742	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:6.32e-10 (favourable), Pancreatic cancer:4.27e-5 (favourable), Glioma:1.55e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 33.2	cerebral cortex: 13.7	Cell line enhanced		SCLC-21H: 15.5
MMP15	MT2-MMP, MTMMP2, SMCP-2	ENSG00000102996	Matrix metallopeptidase 15	16	58025566-58046901	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002611, HPA040390	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 70.1	placenta: 39.3	Cell line enhanced		BEWO: 86.0;WM-115: 73.7
USB1	C16orf57, FLJ13154, HVSL1, Mpn1	ENSG00000103005	U6 snRNA biogenesis phosphodiesterase 1	16	57999546-58021618	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041791, HPA059854	Approved		Supported	Nucleus	Liver cancer:6.69e-7 (unfavourable), Renal cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.4	Expressed in all		
CYB5B	CYB5-M	ENSG00000103018	Cytochrome b5 type B	16	69424525-69466266	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007893	Approved		Approved	Endoplasmic reticulum<br>Microtubule organizing center<br>Cytosol	Renal cancer:6.38e-5 (favourable), Head and neck cancer:2.51e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 398.0	Expressed in all		
CCDC113	DKFZp434N1418, HSPC065	ENSG00000103021	Coiled-coil domain containing 113	16	58231157-58283836	Predicted intracellular proteins	Evidence at protein level	HPA040759, HPA040869	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:7.01e-4 (favourable), Colorectal cancer:8.65e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 50.1;testis: 32.8	parathyroid gland: 16.3	Cell line enhanced		SiHa: 30.0
PRSS54	CT67, FLJ25339, KLKBL4	ENSG00000103023	Protease, serine 54	16	58279997-58295047	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041549	Enhanced					Not detected	Tissue enriched	461	testis: 63.1	cerebral cortex,urinary bladder: 0.1	Not detected		
NME3	DR-nm23, NDPKC, NM23-H3	ENSG00000103024	NME/NM23 nucleoside diphosphate kinase 3	16	1770286-1771730	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041113, HPA052733	Approved		Approved	Nucleoplasm<br>Cytosol	Breast cancer:6.81e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 36.1	Cell line enhanced		HEK 293: 64.8
NDRG4	KIAA1180, SMAP-8	ENSG00000103034	NDRG family member 4	16	58462846-58513628	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015313, HPA017587	Enhanced		Uncertain	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 146.6;cerebral cortex: 420.0;heart muscle: 150.6	testis: 72.0	Cell line enhanced		EFO-21: 30.7;SCLC-21H: 58.1
PSMD7	MOV34, P40, Rpn8, S12	ENSG00000103035	Proteasome 26S subunit, non-ATPase 7	16	74296775-74306288	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB019379, HPA049824, HPA056069	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.71e-6 (unfavourable), Head and neck cancer:6.64e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 107.1	Expressed in all		
SETD6	FLJ21148	ENSG00000103037	SET domain containing 6	16	58515479-58521181	Predicted intracellular proteins	Evidence at protein level	HPA041481, HPA053546	Uncertain		Supported	Nucleus<br>Cytosol	Prostate cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Mixed		
SLC38A7	FLJ10815	ENSG00000103042	Solute carrier family 38 member 7	16	58665109-58685104	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041777	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable)	Expressed in all	Mixed			testis: 34.7	Expressed in all		
VAC14	ArPIKfyve, FLJ10305, TAX1BP2	ENSG00000103043	Vac14, PIKFYVE complex component	16	70687439-70801161	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027766	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.56e-6 (favourable), Cervical cancer:8.33e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.6	Expressed in all		
HAS3		ENSG00000103044	Hyaluronan synthase 3	16	69105564-69118719	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031554, CAB033850	Supported		Approved	Microtubules	Pancreatic cancer:5.36e-4 (unfavourable)	Group enriched	Tissue enhanced		lung: 29.9;urinary bladder: 36.4	stomach: 11.8	Cell line enhanced		HaCaT: 46.5;PC-3: 257.9;RT4: 89.2
TANGO6	FLJ12688, KIAA1746, TMCO7	ENSG00000103047	Transport and golgi organization 6 homolog	16	68843604-69085180	Predicted membrane proteins	Evidence at protein level	HPA041312	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.20e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.2	Expressed in all		
COG4	COD1, DKFZP586E1519	ENSG00000103051	Component of oligomeric golgi complex 4	16	70480568-70523565	Predicted intracellular proteins	Evidence at protein level	HPA040924, HPA042539	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:1.64e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.1	Expressed in all		
SMPD3	NSMASE2	ENSG00000103056	Sphingomyelin phosphodiesterase 3	16	68358325-68448688	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033885, HPA065535, HPA069383	Approved		Supported	Endoplasmic reticulum	Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 61.0;small intestine: 62.9	stomach: 22.6	Cell line enhanced		HMC-1: 8.5;MOLT-4: 11.7;RPMI-8226: 8.3;SCLC-21H: 15.6
SLC7A6OS	FLJ13291	ENSG00000103061	Solute carrier family 7 member 6 opposite strand	16	68284503-68310946	Predicted intracellular proteins	Evidence at protein level	HPA041533	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.35e-4 (favourable)	Mixed	Expressed in all			lymph node: 18.9	Expressed in all		
SLC7A6	KIAA0245, LAT-2, LAT3, y+LAT-2	ENSG00000103064	Solute carrier family 7 member 6	16	68264516-68301823	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050713	Uncertain		Approved	Vesicles<br>Plasma membrane	Urothelial cancer:1.84e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 35.7	Expressed in all		
PLA2G15	GXVPLA2, LLPL, LYPLA3	ENSG00000103066	Phospholipase A2 group XV	16	68245304-68261062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041702, HPA041727	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 37.5	Expressed in all		
ESRP2	FLJ21918, RBM35B	ENSG00000103067	Epithelial splicing regulatory protein 2	16	68229111-68238102	Predicted intracellular proteins	Evidence at protein level	HPA040751, HPA048597, HPA048618	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.30e-6 (favourable)	Mixed	Mixed			skin: 37.1	Cell line enhanced		BEWO: 45.7;MCF7: 74.1;RT4: 40.9;T-47d: 73.0
FA2H	FAAH, FAXDC1, FLJ25287, SPG35	ENSG00000103089	Fatty acid 2-hydroxylase	16	74712955-74774831	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056614, HPA077840	Approved		Uncertain	Nuclear membrane	Renal cancer:5.01e-6 (favourable), Pancreatic cancer:3.74e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 51.6;stomach: 57.4	gallbladder: 28.6	Cell line enhanced		A549: 34.7;CAPAN-2: 18.4;HAP1: 50.4;SK-BR-3: 21.5
WDR59	FLJ12270	ENSG00000103091	WD repeat domain 59	16	74871367-75000173	Predicted intracellular proteins	Evidence at protein level	HPA041084, HPA048218	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 44.0	Expressed in all		
MON1B	HSRG1, KIAA0872, SAND2	ENSG00000103111	MON1 homolog B, secretory trafficking associated	16	77190835-77202405	Predicted intracellular proteins	Evidence at protein level	HPA046285	Approved		Approved	Cytosol	Renal cancer:9.42e-5 (favourable), Endometrial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.2	Expressed in all		
CMC2	C16orf61, DC13, MGC45036	ENSG00000103121	C-X9-C motif containing 2	16	80966448-81020270	Predicted intracellular proteins	Evidence at protein level	HPA006871, CAB026396	Approved		Supported	Mitochondria	Renal cancer:2.64e-5 (favourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
AXIN1	PPP1R49	ENSG00000103126	Axin 1	16	287440-352673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012987	Approved		Supported	Nucleoli<br>Vesicles	Liver cancer:3.38e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 15.5	Expressed in all		
HCFC1R1	FLJ20568, HPIP	ENSG00000103145	Host cell factor C1 regulator 1	16	3022620-3024286	Predicted intracellular proteins	Evidence at protein level	HPA059647	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 184.4	Expressed in all		
NPRL3	C16orf35, CGTHBA, HS-40, MARE, NPR3, RMD11	ENSG00000103148	NPR3 like, GATOR1 complex subunit	16	84271-138860	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011741	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 27.1	Mixed		
MLYCD	hMCD, MCD	ENSG00000103150	Malonyl-CoA decarboxylase	16	83899126-83927026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031625	Enhanced				Renal cancer:2.61e-7 (favourable)	Expressed in all	Mixed			heart muscle: 3.2	Mixed		
MPG	MDG	ENSG00000103152	N-methylpurine DNA glycosylase	16	77007-85853	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006531	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.82e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.0	Expressed in all		
NECAB2	EFCBP2	ENSG00000103154	N-terminal EF-hand calcium binding protein 2	16	83968632-84002776	Predicted intracellular proteins	Evidence at protein level	HPA013998, HPA014144, CAB068211	Enhanced	Supported	Approved	Vesicles	Renal cancer:1.58e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 46.8	kidney: 10.6	Cell line enhanced		AF22: 10.4;SCLC-21H: 47.1;U-87 MG: 13.8
HSDL1	SDR12C3	ENSG00000103160	Hydroxysteroid dehydrogenase like 1	16	84122146-84145192	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.20e-7 (favourable), Liver cancer:3.50e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.8	Expressed in all		
TAF1C	MGC:39976, SL1, TAFI110, TAFI95	ENSG00000103168	TATA-box binding protein associated factor, RNA polymerase I subunit C	16	84177847-84187070	Predicted intracellular proteins	Evidence at protein level	HPA072229			Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:8.08e-6 (unfavourable), Pancreatic cancer:1.76e-4 (favourable), Urothelial cancer:3.22e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 15.5	Expressed in all		
NAGPA	APAA, UCE	ENSG00000103174	N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase	16	5024844-5034141	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064055	Approved				Renal cancer:2.67e-5 (unfavourable), Liver cancer:4.67e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Mixed		
WFDC1	PS20	ENSG00000103175	WAP four-disulfide core domain 1	16	84294646-84329851	Predicted secreted proteins	Evidence at transcript level	HPA031411	Uncertain					Mixed	Tissue enhanced		placenta: 121.8;seminal vesicle: 135.6	prostate: 88.4	Cell line enhanced		AN3-CA: 24.0;BJ: 15.1;HEL: 13.6;HeLa: 16.0
SEC14L5	KIAA0420, PRELID4B	ENSG00000103184	SEC14 like lipid binding 5	16	4958317-5019158	Predicted intracellular proteins	Evidence at protein level	HPA041492, HPA041825			Uncertain	Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	7	cerebral cortex: 17.1	heart muscle: 2.3	Cell line enhanced		SCLC-21H: 3.2;T-47d: 1.7
COTL1	CLP	ENSG00000103187	Coactosin like F-actin binding protein 1	16	84565594-84618077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008918, CAB062328	Enhanced				Renal cancer:5.51e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 421.9	Expressed in all		
USP10	KIAA0190, UBPO	ENSG00000103194	Ubiquitin specific peptidase 10	16	84699978-84779922	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006731, HPA006749	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Expressed in all		
CRISPLD2	DKFZP434B044, LCRISP2, LGL1	ENSG00000103196	Cysteine rich secretory protein LCCL domain containing 2	16	84819984-84920768	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030054, HPA030055	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.97e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 174.3	Cell line enhanced		BEWO: 66.9;HHSteC: 135.7;HSkMC: 49.5
TSC2	LAM, PPP1R160, TSC4, tuberin	ENSG00000103197	Tuberous sclerosis 2	16	2047465-2088720	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002225, HPA030409, HPA049679	Approved		Enhanced	Cytosol	Pancreatic cancer:5.06e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 36.7	Expressed in all		
ZNF500	KIAA0557, ZKSCAN18, ZSCAN50	ENSG00000103199	Zinc finger protein 500	16	4748239-4767624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035498, HPA057963	Supported		Enhanced	Nucleoplasm<br>Cytosol	Stomach cancer:3.41e-4 (favourable)	Expressed in all	Mixed			spleen: 5.6	Expressed in all		
NME4	NDPKD, nm23-H4, NM23H4	ENSG00000103202	NME/NM23 nucleoside diphosphate kinase 4	16	396725-410367	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB045997, HPA072588	Approved		Supported	Mitochondria	Renal cancer:1.61e-7 (unfavourable), Cervical cancer:6.53e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 167.2	Mixed		
ABCC1	GS-X, MRP, MRP1	ENSG00000103222	ATP binding cassette subfamily C member 1	16	15949577-16143074	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002380	Uncertain		Supported	Plasma membrane	Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.6	Cell line enhanced		EFO-21: 84.1
NOMO3		ENSG00000103226	NODAL modulator 3	16	16232495-16294814	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Mixed	Mixed			skin: 1.9	Mixed		
LMF1	C16orf26, FLJ12681, FLJ22302, JFP11, TMEM112, TMEM112A	ENSG00000103227	Lipase maturation factor 1	16	853634-981318	Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.95e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.2	Mixed		
FOXF1	FKHL5, FREAC1	ENSG00000103241	Forkhead box F1	16	86510527-86515418	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028886			Approved	Nucleoplasm		Mixed	Mixed			placenta: 33.0	Cell line enhanced		BJ: 10.8;BJ hTERT+: 22.8;HHSteC: 22.2;U-2197: 11.1
NARFL	FLJ21988, HPRN, IOP1, NAR1, PRN	ENSG00000103245	Nuclear prelamin A recognition factor like	16	729753-741329	Predicted intracellular proteins	Evidence at protein level	HPA040851	Approved		Approved	Plasma membrane<br>Cytosol	Cervical cancer:1.32e-5 (favourable), Renal cancer:9.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.3	Expressed in all		
MTHFSD	FLJ12998	ENSG00000103248	Methenyltetrahydrofolate synthetase domain containing	16	86530176-86555235	Predicted intracellular proteins	Evidence at protein level	HPA041333	Uncertain		Approved	Nucleus<br>Vesicles	Colorectal cancer:9.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 33.0	Mixed		
CLCN7	CLC-7, CLC7, OPTA2, PPP1R63	ENSG00000103249	Chloride voltage-gated channel 7	16	1444934-1475580	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043019, HPA043586	Supported		Supported	Nucleoplasm	Testis cancer:3.21e-4 (unfavourable), Head and neck cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 41.2	Expressed in all		
HAGHL	MGC2605	ENSG00000103253	Hydroxyacylglutathione hydrolase-like	16	726936-735525	Predicted intracellular proteins	Evidence at transcript level	HPA074402	Approved				Renal cancer:1.18e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 9.1	spleen: 4.4	Cell line enhanced		RPMI-8226: 44.3;U-266/70: 49.9
FAM173A	C16orf24, MGC2494	ENSG00000103254	Family with sequence similarity 173 member A	16	720581-722601	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046262	Enhanced		Approved	Cytosol	Renal cancer:4.24e-5 (favourable), Head and neck cancer:8.88e-4 (favourable)	Expressed in all	Mixed			spleen: 9.3	Cell line enhanced		U-266/70: 49.3
SLC7A5	CD98, D16S469E, E16, LAT1, MPE16	ENSG00000103257	Solute carrier family 7 member 5	16	87830023-87869488	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052673, HPA056077	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 90.3;testis: 84.3	bone marrow: 66.1	Expressed in all		
METRN	C16orf23, MGC2601	ENSG00000103260	Meteorin, glial cell differentiation regulator	16	715115-719655	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051164	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 64.7	fallopian tube: 38.3	Expressed in all		
FBXO31	FBX14, Fbx31, FBXO14, MGC15419	ENSG00000103264	F-box protein 31	16	87326987-87392142	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030150	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:9.16e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 24.8	Expressed in all		
STUB1	CHIP, HSPABP2, NY-CO-7, SDCCAG7, UBOX1	ENSG00000103266	STIP1 homology and U-box containing protein 1	16	680224-682870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037202, CAB037209, HPA041222, HPA043531	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.49e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 137.7	Expressed in all		
RHBDL1	RHBDL, RRP	ENSG00000103269	Rhomboid like 1	16	675666-678268	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA030359, HPA030360, HPA046593	Uncertain		Approved	Nucleoplasm	Breast cancer:8.12e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.0	adrenal gland: 3.3	Mixed		
NUBP1	NBP1, NBP35	ENSG00000103274	Nucleotide binding protein 1	16	10743786-10769351	Predicted intracellular proteins	Evidence at protein level	HPA041656, HPA041799	Enhanced		Supported	Cytosol	Renal cancer:7.61e-8 (favourable), Cervical cancer:2.81e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.1	Expressed in all		
UBE2I	UBC9	ENSG00000103275	Ubiquitin conjugating enzyme E2 I	16	1308880-1327018	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003909, CAB009021	Approved		Enhanced	Cytosol	Thyroid cancer:5.68e-4 (favourable), Liver cancer:7.50e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 117.1	Expressed in all		
ZP2	ZPA	ENSG00000103310	Zona pellucida glycoprotein 2	16	21197450-21214510	Predicted membrane proteins	Evidence at protein level	HPA011296	Approved					Not detected	Not detected			placenta: 0.3	Cell line enriched	35	HDLM-2: 3.4
MEFV	FMF, MEF, TRIM20	ENSG00000103313	MEFV, pyrin innate immunity regulator	16	3242028-3256627	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 8.1;spleen: 7.0	bone marrow: 4.2	Cell line enhanced		THP-1: 4.4
CRYM	DFNA40	ENSG00000103316	Crystallin mu	16	21238874-21303083	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019086, HPA030619	Enhanced		Supported	Cytosol		Tissue enhanced	Group enriched	6	cerebral cortex: 51.1;heart muscle: 47.8;kidney: 28.4;prostate: 24.7;urinary bladder: 14.8	lung: 5.7	Cell line enhanced		HEL: 9.4;RPTEC TERT1: 32.9;U-87 MG: 8.7
EEF2K	eEF-2K	ENSG00000103319	Eukaryotic elongation factor 2 kinase	16	22206282-22288732	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB007818, HPA056061	Approved		Approved	Nucleoplasm	Renal cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 54.3	Expressed in all		
CAPN15	SOLH	ENSG00000103326	Calpain 15	16	527717-554636	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011960	Uncertain		Approved	Nucleus		Expressed in all	Mixed			small intestine: 17.8	Expressed in all		
PIEZO1	FAM38A, KIAA0233	ENSG00000103335	Piezo type mechanosensitive ion channel component 1	16	88715343-88785211	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047185	Uncertain				Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 42.0	Expressed in all		
GSPT1	eRF3a, ETF3A, GST1	ENSG00000103342	G1 to S phase transition 1	16	11868128-11916082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052488	Approved		Approved	Vesicles<br>Cytosol	Colorectal cancer:2.10e-5 (favourable), Renal cancer:3.06e-5 (favourable), Liver cancer:7.94e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 131.6	Expressed in all		
ZNF174	ZSCAN8	ENSG00000103343	Zinc finger protein 174	16	3401235-3409370	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009656	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
CLUAP1	CFAP22, FAP22, FLJ13297, IFT38, KIAA0643	ENSG00000103351	Clusterin associated protein 1	16	3500924-3539048	Predicted intracellular proteins	Evidence at protein level	HPA036976, HPA044191	Uncertain		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:3.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Mixed		
UBFD1	FLJ38870, FLJ42145, UBPH	ENSG00000103353	Ubiquitin family domain containing 1	16	23557362-23574389	Predicted intracellular proteins	Evidence at protein level	HPA051746			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 56.5	Expressed in all		
PRSS33	EOS	ENSG00000103355	Protease, serine 33	16	2783953-2787948	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA058082	Uncertain					Tissue enhanced	Tissue enriched	7	fallopian tube: 7.4	small intestine: 1.0	Group enriched	10	HMC-1: 2.4;SK-MEL-30: 4.5;U-2 OS: 2.1
EARS2	KIAA1970, MSE1	ENSG00000103356	Glutamyl-tRNA synthetase 2, mitochondrial	16	23522014-23557731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043289, HPA043633	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.16e-6 (favourable), Pancreatic cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 32.9	Expressed in all		
ELOB	SIII, TCEB2	ENSG00000103363	Elongin B	16	2771414-2777297	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 355.1	Expressed in all		
GGA2	KIAA1080, VEAR	ENSG00000103365	Golgi associated, gamma adaptin ear containing, ARF binding protein 2	16	23463542-23521995	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034422, HPA043313, HPA063634	Approved		Enhanced	Golgi apparatus	Cervical cancer:1.71e-5 (favourable), Renal cancer:3.91e-5 (favourable), Head and neck cancer:9.70e-5 (favourable), Lung cancer:1.68e-4 (favourable), Testis cancer:4.15e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 87.0	Expressed in all		
AQP8		ENSG00000103375	Aquaporin 8	16	25215731-25228940	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046259	Enhanced					Group enriched	Group enriched	129	colon: 321.2;pancreas: 269.5;rectum: 166.5	smooth muscle: 1.9	Not detected		
CPPED1	CSTP1, FLJ11151	ENSG00000103381	Calcineurin like phosphoesterase domain containing 1	16	12659799-12804017	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040938, HPA041970	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.62e-9 (favourable), Breast cancer:9.72e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.0	Cell line enhanced		Hep G2: 97.8;HMC-1: 114.2
USP31	KIAA1203	ENSG00000103404	Ubiquitin specific peptidase 31	16	23061406-23149270	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006937	Uncertain		Approved	Cytosol	Renal cancer:4.41e-5 (unfavourable)	Expressed in all	Mixed			testis: 22.2	Expressed in all		
HMOX2	HO-2	ENSG00000103415	Heme oxygenase 2	16	4474690-4510347	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025464, HPA040611	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
DNAJA3	hTid-1, TID1	ENSG00000103423	DnaJ heat shock protein family (Hsp40) member A3	16	4425805-4456775	Predicted intracellular proteins	Evidence at protein level	CAB016095, HPA040875, HPA044229	Approved		Supported	Mitochondria	Renal cancer:1.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.4	Expressed in all		
CORO7-PAM16		ENSG00000103426	CORO7-PAM16 readthrough	16	4340251-4420494	Predicted intracellular proteins	Evidence at protein level	HPA041657, HPA053586, HPA062721	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Mitochondria		Not detected	Not detected			testis: 0.2	Not detected		
BFAR	BAR, RNF47	ENSG00000103429	Bifunctional apoptosis regulator	16	14632815-14669236	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:4.74e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 23.4	Expressed in all		
SALL1	Hsal1, TBS, ZNF794	ENSG00000103449	Spalt like transcription factor 1	16	51135975-51151367	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049829	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:1.91e-7 (favourable), Endometrial cancer:1.28e-4 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 40.1	cerebral cortex: 30.3	Cell line enhanced		AF22: 29.2;NTERA-2: 48.0;RPTEC TERT1: 30.7;U-87 MG: 45.3
TOX3	CAGF9, TNRC9	ENSG00000103460	TOX high mobility group box family member 3	16	52438005-52547802	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040376	Enhanced		Approved	Nucleoplasm	Renal cancer:3.08e-12 (favourable), Urothelial cancer:3.95e-4 (favourable)	Mixed	Mixed			stomach: 18.0	Cell line enhanced		AF22: 39.9;HAP1: 20.6;RT4: 62.7;SCLC-21H: 31.8
RBL2	p130, Rb2	ENSG00000103479	RB transcriptional corepressor like 2	16	53433977-53491649	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016547, HPA019703	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.57e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 149.6	Expressed in all		
QPRT	QPRTase	ENSG00000103485	Quinolinate phosphoribosyltransferase	16	29679008-29698699	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011887	Approved				Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 112.3	Cell line enhanced		EFO-21: 469.3
XYLT1	PXYLT1, XT-I	ENSG00000103489	Xylosyltransferase 1	16	17101769-17470881	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA007478, HPA007966	Approved					Mixed	Mixed			cervix, uterine: 12.2	Cell line enhanced		ASC diff: 38.1;U-2197: 54.3
PYCARD	ASC, CARD5, TMS-1	ENSG00000103490	PYD and CARD domain containing	16	31201485-31203450	Predicted intracellular proteins	Evidence at protein level	CAB006853, CAB015948, HPA049074, HPA054496	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:6.09e-7 (unfavourable)	Expressed in all	Mixed			duodenum: 51.4	Cell line enhanced		MCF7: 97.4;NB-4: 127.0;THP-1: 98.8
RPGRIP1L	CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134	ENSG00000103494	RPGRIP1 like	16	53597683-53703938	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039405, HPA040530	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 27.9	parathyroid gland: 19.3	Expressed in all		
MAZ	Pur-1, ZF87, Zif87, ZNF801	ENSG00000103495	MYC associated zinc finger protein	16	29806106-29811164	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA048315, HPA059495, HPA065930	Approved		Enhanced	Nucleus	Thyroid cancer:2.22e-4 (unfavourable), Renal cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 197.0	Expressed in all		
STX4	p35-2, STX4A	ENSG00000103496	Syntaxin 4	16	31032889-31042975	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001330	Approved		Enhanced	Plasma membrane	Renal cancer:2.88e-9 (unfavourable), Cervical cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 64.5	Expressed in all		
CDIPT	PIS, PIS1	ENSG00000103502	CDP-diacylglycerol--inositol 3-phosphatidyltransferase	16	29858357-29863736	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056597	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Plasma membrane	Cervical cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.7	Expressed in all		
BCKDK		ENSG00000103507	Branched chain ketoacid dehydrogenase kinase	16	31106107-31112791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017995, HPA056067	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 34.3	Expressed in all		
KAT8	FLJ14040, hMOF, MOF, MYST1, ZC2HC8	ENSG00000103510	Lysine acetyltransferase 8	16	31115754-31131393	Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066324			Supported	Nucleoplasm	Lung cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			ovary: 61.6	Expressed in all		
NOMO1	PM5	ENSG00000103512	NODAL modulator 1	16	14833681-14896160	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025192, HPA046697, HPA061174	Approved		Approved	Endoplasmic reticulum	Urothelial cancer:3.15e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 11.9	Cell line enhanced		Hep G2: 80.5;SiHa: 142.9
IL21R	CD360	ENSG00000103522	Interleukin 21 receptor	16	27402162-27452042	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042296	Uncertain		Uncertain	Plasma membrane<br>Cytosol	Head and neck cancer:7.29e-4 (favourable)	Mixed	Tissue enhanced		appendix: 15.8;lymph node: 28.8;tonsil: 17.4	spleen: 7.5	Cell line enhanced		HDLM-2: 102.6;Karpas-707: 35.4;RH-30: 36.0;RPMI-8226: 42.7
SYT17		ENSG00000103528	Synaptotagmin 17	16	19167971-19268334	Predicted intracellular proteins	Evidence at protein level	HPA042059			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 39.8;parathyroid gland: 32.6	prostate: 14.9	Cell line enhanced		BEWO: 13.7;CAPAN-2: 24.6;MCF7: 16.6
TMC5	FLJ13593	ENSG00000103534	Transmembrane channel like 5	16	19410496-19499113	Predicted membrane proteins	Evidence at protein level	HPA040810, HPA042037	Enhanced		Approved	Nucleus<br>Plasma membrane	Liver cancer:7.96e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 59.1	duodenum: 45.4	Cell line enriched	6	CAPAN-2: 61.8
CCP110	CP110, KIAA0419	ENSG00000103540	Centriolar coiled-coil protein 110	16	19523811-19553408	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039402	Approved		Supported	Centrosome		Expressed in all	Tissue enhanced		testis: 65.2	cerebral cortex: 29.7	Expressed in all		
C16orf62	MGC16824	ENSG00000103544	Chromosome 16 open reading frame 62	16	19555240-19706793	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042969, HPA053547	Uncertain		Approved	Mitochondria	Renal cancer:1.31e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Mixed		
SLC6A2	NAT1, NET, NET1, SLC6A5	ENSG00000103546	Solute carrier family 6 member 2	16	55655604-55706192	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004057, HPA076311, CAB078195	Enhanced	Supported	Approved	Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		adrenal gland: 29.2;placenta: 18.4;skin: 15.7	testis: 11.4	Cell line enriched	35	SH-SY5Y: 519.4
RNF40	BRE1B, KIAA0661, RBP95, STARING	ENSG00000103549	Ring finger protein 40	16	30761745-30776307	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041330, HPA054227	Approved		Enhanced	Nucleoplasm	Renal cancer:8.11e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 78.9	Expressed in all		
KNOP1	101F10.1, C16orf88, FAM191A, TSG118	ENSG00000103550	Lysine rich nucleolar protein 1	16	19701934-19718235	Predicted intracellular proteins	Evidence at protein level	HPA041079, HPA066169	Uncertain		Supported	Nucleoli<br>Cytosol	Liver cancer:3.75e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.3	Expressed in all		
AQP9	HsT17287, SSC1	ENSG00000103569	Aquaporin 9	15	58138169-58185911	Predicted membrane proteins	Evidence at protein level	HPA074762, CAB075684	Enhanced				Renal cancer:5.72e-11 (unfavourable)	Tissue enriched	Tissue enhanced		appendix: 102.4;liver: 353.0	epididymis: 50.3	Cell line enriched	37	U-87 MG: 27.9
AAGAB	FLJ11506, p34	ENSG00000103591	Alpha- and gamma-adaptin binding protein	15	67201033-67255195	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039371, HPA040174	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:1.36e-4 (favourable), Thyroid cancer:9.48e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.7	Expressed in all		
IQCH	FLJ12476	ENSG00000103599	IQ motif containing H	15	67254800-67502260	Predicted intracellular proteins	Evidence at protein level	HPA040845	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		fallopian tube: 10.8;testis: 21.1	parathyroid gland,thyroid gland: 6.8	Mixed		
LACTB	FLJ14902, MRPL56	ENSG00000103642	Lactamase beta	15	63121800-63142061	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036361, HPA036362	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
CORO2B	ClipinC, KIAA0925	ENSG00000103647	Coronin 2B	15	68578969-68727806	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017960	Enhanced		Approved	Plasma membrane<br>Focal adhesion sites		Group enriched	Tissue enhanced		cerebral cortex: 73.3;fallopian tube: 36.7	ovary: 17.9	Cell line enhanced		ASC TERT1: 40.2;HSkMC: 30.2;hTEC/SVTERT24-B: 34.6;U-87 MG: 57.2
CSK		ENSG00000103653	C-src tyrosine kinase	15	74782057-74803198	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011203, HPA026488, HPA028425	Approved	Approved	Approved	Vesicles<br>Cytosol	Cervical cancer:5.14e-5 (favourable), Stomach cancer:1.07e-4 (favourable), Renal cancer:1.74e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 195.2	Expressed in all		
HERC1	p532, p619	ENSG00000103657	HECT and RLD domain containing E3 ubiquitin protein ligase family member 1	15	63608618-63833942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049749	Uncertain				Renal cancer:1.36e-6 (favourable), Head and neck cancer:4.87e-5 (favourable), Pancreatic cancer:3.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
TRIP4	HsT17391, ZC2HC5	ENSG00000103671	Thyroid hormone receptor interactor 4	15	64387748-64455303	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016605, HPA050666	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.34e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.2	Expressed in all		
MTFMT	FMT1	ENSG00000103707	Mitochondrial methionyl-tRNA formyltransferase	15	65001512-65029639	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040710	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.31e-8 (favourable)	Expressed in all	Mixed			smooth muscle: 2.7	Mixed		
RASL12	RIS	ENSG00000103710	RAS like family 12	15	65053337-65076690	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.20e-5 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 101.5	prostate: 64.1	Cell line enhanced		CACO-2: 11.7;EFO-21: 20.5;NTERA-2: 9.4
AP3B2	NAPTB	ENSG00000103723	Adaptor related protein complex 3 beta 2 subunit	15	82659281-82709914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039467, HPA039818	Enhanced					Mixed	Group enriched	6	cerebral cortex: 36.2;parathyroid gland: 7.4	adrenal gland: 3.8	Cell line enhanced		RT4: 11.4;SCLC-21H: 26.6;SH-SY5Y: 18.5
ACSBG1	BG1, BGM, FLJ30320, hBG1, hsBG, KIAA0631, MGC14352	ENSG00000103740	Acyl-CoA synthetase bubblegum family member 1	15	78167468-78245688	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041642, CAB045955, HPA058869	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 25.6;skin: 13.3	adrenal gland: 8.1	Cell line enhanced		NTERA-2: 3.3
IGDCC4	LOC57722, NOPE	ENSG00000103742	Immunoglobulin superfamily DCC subclass member 4	15	65381464-65423072	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008510, HPA008576	Approved	Approved	Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Mixed			ovary: 9.0	Cell line enhanced		AF22: 8.1;CAPAN-2: 6.4;NTERA-2: 6.2
RAB11A	YL8	ENSG00000103769	RAB11A, member RAS oncogene family	15	65726054-65891991	Predicted intracellular proteins	Evidence at protein level	CAB013097, HPA051697, HPA060686	Approved		Enhanced	Vesicles<br>Microtubule organizing center	Renal cancer:1.46e-5 (favourable), Pancreatic cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 524.8	Expressed in all		
CTSH	ACC-4, ACC-5, ACC4, ACC5, CPSB	ENSG00000103811	Cathepsin H	15	78921058-78949574	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000458, HPA003524	Enhanced		Supported	Vesicles<br>Cytosol<br>Cytoplasmic bodies	Endometrial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			lung: 570.6	Cell line enhanced		CAPAN-2: 219.5;HaCaT: 161.7;RT4: 558.6
TTC23	FLJ12572, HCC-8	ENSG00000103852	Tetratricopeptide repeat domain 23	15	99136323-99251223	Predicted intracellular proteins	Evidence at protein level	HPA039806, HPA040369	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.07e-4 (favourable), Breast cancer:3.17e-4 (favourable)	Expressed in all	Mixed			testis: 24.3	Mixed		
CD276	B7-H3, B7H3, B7RP-2	ENSG00000103855	CD276 molecule	15	73683966-73714518	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009285, HPA017139, CAB017826	Enhanced		Approved	Vesicles	Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable)	Expressed in all	Mixed			placenta: 30.2	Cell line enhanced		U-2197: 176.1
FAH		ENSG00000103876	Fumarylacetoacetate hydrolase	15	80152490-80186946	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041370, HPA044093	Enhanced		Approved	Cytosol	Head and neck cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 151.9	Cell line enhanced		HHSteC: 261.9
CEMIP	HYBID, IR2155535, KIAA1199, TMEM2L	ENSG00000103888	Cell migration inducing hyaluronan binding protein	15	80779343-80951776	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.65e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 53.2	appendix: 15.8	Cell line enhanced		BJ: 172.4;BJ hTERT+: 260.3;fHDF/TERT166: 200.3;HSkMC: 122.9;U-138 MG: 89.3
RPAP1	DKFZP727M111, FLJ12732, KIAA1403, MGC858	ENSG00000103932	RNA polymerase II associated protein 1	15	41517176-41544269	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041739	Approved		Approved	Nucleoplasm<br>Cytosol	Thyroid cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 13.3	Expressed in all		
HOMER2	CPD, Cupidin, HOMER-2, HOMER-2A, HOMER-2B, Vesl-2	ENSG00000103942	Homer scaffolding protein 2	15	82836946-82986153	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040134, CAB079014	Uncertain	Supported				Mixed	Expressed in all			prostate: 92.9	Cell line enhanced		Karpas-707: 66.5;SCLC-21H: 59.9
EHD4	PAST4	ENSG00000103966	EH domain containing 4	15	41895939-41972578	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA052729, HPA066751	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 24.8	Cell line enhanced		TIME: 140.3
TMEM87A	DKFZP564G2022	ENSG00000103978	Transmembrane protein 87A	15	42210452-42273663	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018104, HPA018189	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			prostate: 124.3	Expressed in all		
ZNF106	SH3BP3, ZFP106, ZNF474	ENSG00000103994	Zinc finger protein 106	15	42412823-42491123	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054267	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 144.2	Expressed in all		
CEP152	KIAA0912, MCPH9, SCKL5	ENSG00000103995	Centrosomal protein 152	15	48712928-48811146	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039408	Approved		Supported	Centrosome		Mixed	Tissue enhanced		testis: 18.1	bone marrow: 10.2	Expressed in all		
ATP8B4	ATPIM, KIAA1939	ENSG00000104043	ATPase phospholipid transporting 8B4 (putative)	15	49858238-50182817	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040254	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		bone marrow: 23.0	endometrium: 9.3	Cell line enhanced		HMC-1: 32.2;THP-1: 16.5;U-937: 60.0
OCA2	BEY, BEY1, BEY2, D15S12, EYCL, EYCL2, EYCL3, P	ENSG00000104044	OCA2 melanosomal transmembrane protein	15	27754875-28099358	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 7.4;thyroid gland: 5.8	testis: 2.5	Group enriched	6	SH-SY5Y: 6.3;SK-MEL-30: 18.3
DTWD1	MDS009, MGC111207	ENSG00000104047	DTW domain containing 1	15	49620980-49656232	Predicted intracellular proteins	Evidence at protein level	HPA042214	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles		Expressed in all	Expressed in all			cervix, uterine: 39.5	Expressed in all		
TGM5	TGX	ENSG00000104055	Transglutaminase 5	15	43232595-43266857	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	7	esophagus: 8.4;skin: 22.3	breast: 2.3	Cell line enriched	8	HEL: 16.7
FAM189A1	KIAA0574, TMEM228	ENSG00000104059	Family with sequence similarity 189 member A1	15	29120254-29570723	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA009410, HPA010637	Uncertain		Supported	Nucleus		Mixed	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 2.0	colon,testis: 0.8	Cell line enhanced		EFO-21: 4.4;HDLM-2: 11.1;REH: 2.6
GABPB1	E4TF1-47, GABPB, GABPB2	ENSG00000104064	GA binding protein transcription factor beta subunit 1	15	50275392-50355408	Predicted intracellular proteins	Evidence at protein level	HPA019653, HPA067444	Supported		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.7	Expressed in all		
TJP1	DKFZp686M05161, MGC133289, ZO-1	ENSG00000104067	Tight junction protein 1	15	29699367-29968865	Predicted intracellular proteins	Evidence at protein level	HPA001636, HPA001637, CAB010822	Enhanced		Enhanced	Cell Junctions	Renal cancer:1.72e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 49.6	Mixed		
BMF	FLJ00065	ENSG00000104081	Bcl2 modifying factor	15	40087890-40108892	Predicted intracellular proteins	Evidence at protein level	HPA010120	Approved		Approved	Nucleoplasm	Head and neck cancer:1.83e-4 (favourable), Liver cancer:6.32e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 26.1	Cell line enhanced		HMC-1: 38.8
DMXL2	KIAA0856, RC3	ENSG00000104093	Dmx like 2	15	51447711-51622833	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039375	Approved				Renal cancer:7.50e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 26.3	Cell line enhanced		U-937: 50.3
SCG3	FLJ90833, SgIII	ENSG00000104112	Secretogranin III	15	51681353-51721031	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006880, CAB033274, HPA053715	Enhanced	Approved	Enhanced	Vesicles		Group enriched	Tissue enriched	13	cerebral cortex: 278.4	adrenal gland: 21.9	Group enriched	8	NTERA-2: 50.4;SCLC-21H: 140.8;SH-SY5Y: 60.1
DNAJC17	FLJ10634	ENSG00000104129	DnaJ heat shock protein family (Hsp40) member C17	15	40765155-40807478	Predicted intracellular proteins	Evidence at protein level	HPA040914, HPA041187	Approved		Approved	Nucleoplasm	Colorectal cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 24.4	Expressed in all		
EIF3J	eIF3-alpha, eIF3-p35, eIF3j, EIF3S1	ENSG00000104131	Eukaryotic translation initiation factor 3 subunit J	15	44537057-44563029	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050977	Approved		Enhanced	Cytosol	Urothelial cancer:4.96e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 69.3	Expressed in all		
SPG11	FLJ21439, KIAA1840	ENSG00000104133	SPG11, spatacsin vesicle trafficking associated	15	44562696-44663678	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040412, HPA040947	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:6.28e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland,thyroid gland: 48.3	Expressed in all		
RHOV	ARHV, Chp, WRCH2	ENSG00000104140	Ras homolog family member V	15	40872214-40874289	Predicted intracellular proteins	Evidence at protein level	HPA053343	Enhanced				Lung cancer:2.33e-4 (unfavourable), Pancreatic cancer:4.19e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 71.5;skin: 72.6	tonsil: 20.2	Cell line enhanced		HaCaT: 66.2;SK-BR-3: 237.1
VPS18	KIAA1475, PEP3	ENSG00000104142	VPS18, CORVET/HOPS core subunit	15	40894430-40903975	Predicted intracellular proteins	Evidence at protein level	HPA040701	Approved				Renal cancer:1.61e-6 (favourable), Pancreatic cancer:8.69e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 15.8	Expressed in all		
OIP5	CT86, hMIS18beta, MIS18B	ENSG00000104147	Opa interacting protein 5	15	41309268-41332621	Predicted intracellular proteins	Evidence at protein level	HPA052271, HPA059602	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:9.34e-5 (unfavourable), Liver cancer:1.79e-4 (unfavourable), Lung cancer:2.26e-4 (unfavourable)	Mixed	Tissue enriched	6	testis: 37.2	lymph node: 6.7	Mixed		
SLC30A4	ZNT4	ENSG00000104154	Solute carrier family 30 member 4	15	45479611-45522807	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018178	Uncertain				Pancreatic cancer:6.02e-4 (favourable)	Tissue enriched	Tissue enriched	5	prostate: 64.5	testis: 11.8	Mixed		
BLOC1S6	HPS9, PA, PLDN	ENSG00000104164	Biogenesis of lysosomal organelles complex 1 subunit 6	15	45587123-45615999	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039928	Approved					Expressed in all	Expressed in all			thyroid gland: 82.7	Expressed in all		
MYEF2	FLJ11213, HsT18564, KIAA1341, MEF-2	ENSG00000104177	Myelin expression factor 2	15	48134631-48178517	Predicted intracellular proteins	Evidence at protein level	HPA004883	Supported		Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 51.3	cerebral cortex: 47.2	Cell line enhanced		AF22: 100.6;SCLC-21H: 106.7
SGK3	SGK2, SGKL	ENSG00000104205	Serum/glucocorticoid regulated kinase family member 3	8	66712418-66862022	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006699, HPA027146	Supported		Approved	Nucleoplasm<br>Vesicles	Breast cancer:5.52e-6 (favourable), Cervical cancer:8.28e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.5	Mixed		
PDGFRL	PRLTS	ENSG00000104213	Platelet derived growth factor receptor like	8	17576433-17644071	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA052801			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Mixed			breast: 49.2	Cell line enhanced		AN3-CA: 131.2;BJ hTERT+: 93.6;HSkMC: 44.1
CSPP1	CSPP, FLJ22490, JBTS21	ENSG00000104218	Centrosome and spindle pole associated protein 1	8	67062426-67196263	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056174			Supported	Microtubule organizing center	Thyroid cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.9	Expressed in all		
ZDHHC2	ZNF372	ENSG00000104219	Zinc finger DHHC-type containing 2	8	17156029-17224799	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023331	Uncertain				Renal cancer:3.24e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.7	Mixed		
BRF2	BRFU, FLJ11052, TFIIIB50	ENSG00000104221	BRF2, RNA polymerase III transcription initiation factor subunit	8	37843268-37849904	Predicted intracellular proteins	Evidence at protein level	CAB019269, HPA023378	Enhanced		Approved	Nucleoli		Expressed in all	Expressed in all			ovary: 16.1	Expressed in all		
TRIM35	HLS5, KIAA1098, MAIR	ENSG00000104228	Tripartite motif containing 35	8	27284887-27311319	Predicted intracellular proteins	Evidence at protein level	HPA019647	Approved		Approved	Nucleoplasm	Renal cancer:5.59e-7 (favourable), Head and neck cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			skin: 14.6	Expressed in all		
ZFAND1	FLJ14007	ENSG00000104231	Zinc finger AN1-type containing 1	8	81701334-81732903	Predicted intracellular proteins	Evidence at protein level	HPA023383	Approved		Approved	Centrosome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 92.5	Expressed in all		
RP1	DCDC4A, ORP1	ENSG00000104237	RP1, axonemal microtubule associated	8	54554361-54871720	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042257	Supported					Not detected	Tissue enhanced		fallopian tube: 16.3;lung: 5.4	testis: 2.4	Cell line enhanced		HDLM-2: 4.8;RPTEC TERT1: 7.7;U-2197: 2.2
CA2	CA-II, CAII, Car2	ENSG00000104267	Carbonic anhydrase 2	8	85463852-85481493	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001550, CAB010102	Enhanced				Renal cancer:5.57e-6 (favourable)	Expressed in all	Tissue enhanced		colon: 604.8;rectum: 627.5;stomach: 918.8	kidney: 308.3	Group enriched	11	HaCaT: 204.1;HEK 293: 884.1;THP-1: 278.7
FZD3		ENSG00000104290	Frizzled class receptor 3	8	28494205-28574268	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB024995	Approved				Colorectal cancer:1.17e-4 (favourable), Ovarian cancer:3.71e-4 (favourable)	Mixed	Mixed			cerebral cortex: 16.4	Cell line enhanced		AF22: 53.7;SCLC-21H: 46.9
INTS9	CPSF2L, FLJ10871, RC-74	ENSG00000104299	Integrator complex subunit 9	8	28767661-28890242	Predicted intracellular proteins	Evidence at protein level	HPA051615, HPA066822			Enhanced	Nucleoplasm	Renal cancer:1.91e-5 (favourable), Lung cancer:7.71e-4 (favourable), Endometrial cancer:9.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.8	Expressed in all		
RIPK2	CARD3, CARDIAK, RICK, RIP2	ENSG00000104312	Receptor interacting serine/threonine kinase 2	8	89757747-89791063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015273, HPA016499	Approved		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:5.00e-6 (unfavourable), Lung cancer:6.33e-5 (unfavourable), Urothelial cancer:8.05e-4 (favourable)	Expressed in all	Mixed			gallbladder: 13.9	Mixed		
EYA1	BOR	ENSG00000104313	EYA transcriptional coactivator and phosphatase 1	8	71197433-71362232	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028917			Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		parathyroid gland: 81.7;prostate: 21.2	cerebral cortex: 10.7	Cell line enhanced		AN3-CA: 28.1;RH-30: 23.1;SH-SY5Y: 57.2
NBN	AT-V1, AT-V2, ATV, NBS, NBS1	ENSG00000104320	Nibrin	8	89933336-90003228	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001429, CAB003836	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Lung cancer:5.46e-5 (unfavourable), Pancreatic cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.4	Expressed in all		
TRPA1	ANKTM1	ENSG00000104321	Transient receptor potential cation channel subfamily A member 1	8	72019917-72075617	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Colorectal cancer:6.57e-4 (favourable)	Mixed	Tissue enhanced		urinary bladder: 29.5	gallbladder: 11.4	Cell line enriched	5	HHSteC: 21.8
CPQ	LDP, PGCP	ENSG00000104324	Carboxypeptidase Q	8	96645227-97149654	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023235, HPA024490	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.40e-5 (favourable), Glioma:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 382.5	Cell line enhanced		ASC TERT1: 92.2
DECR1	DECR, SDR18C1	ENSG00000104325	2,4-dienoyl-CoA reductase 1	8	90001405-90052092	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023160, HPA023162, HPA023238	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:1.79e-7 (favourable), Breast cancer:1.49e-4 (unfavourable), Urothelial cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			liver: 262.9	Expressed in all		
CALB1	CALB	ENSG00000104327	Calbindin 1	8	90058608-90095475	Predicted intracellular proteins	Evidence at protein level	CAB002138, HPA023099, HPA056734	Enhanced		Supported	Vesicles	Endometrial cancer:1.60e-4 (unfavourable)	Mixed	Tissue enriched	15	kidney: 336.9	cerebral cortex: 22.5	Cell line enhanced		A-431: 116.6;EFO-21: 179.9;NTERA-2: 72.7
IMPAD1	FLJ20421, gPAPP, IMPA3	ENSG00000104331	Inositol monophosphatase domain containing 1	8	56957933-56993844	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009411	Supported		Supported	Nucleus<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 52.7	Expressed in all		
SFRP1	FRP, FRP-1, SARP2	ENSG00000104332	Secreted frizzled related protein 1	8	41261958-41309497	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008116, HPA064870	Approved		Approved	Nucleoli<br>Cytosol	Head and neck cancer:1.55e-4 (favourable), Urothelial cancer:3.12e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 357.2;cervix, uterine: 325.0	endometrium: 231.0	Cell line enhanced		BJ hTERT+: 563.8;HBF TERT88: 268.7;RPTEC TERT1: 319.1;WM-115: 275.2
LAPTM4B	LC27	ENSG00000104341	Lysosomal protein transmembrane 4 beta	8	97775057-97853013	Predicted membrane proteins, Transporters	Evidence at protein level	CAB020782, HPA068830	Uncertain		Approved	Golgi apparatus	Liver cancer:2.70e-6 (unfavourable), Breast cancer:5.63e-4 (unfavourable), Head and neck cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 133.2	Mixed		
UBE2W	FLJ11011, UBC-16	ENSG00000104343	Ubiquitin conjugating enzyme E2 W	8	73780097-73878910	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045161, HPA073181	Uncertain		Supported	Nucleoli		Expressed in all	Expressed in all			testis: 19.6	Expressed in all		
POP1		ENSG00000104356	POP1 homolog, ribonuclease P/MRP subunit	8	98117297-98159834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066194			Supported	Nucleoli	Liver cancer:1.26e-6 (unfavourable), Breast cancer:2.54e-4 (unfavourable), Renal cancer:5.97e-4 (unfavourable), Lung cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.0	Expressed in all		
NIPAL2	FLJ13955, NPAL2	ENSG00000104361	NIPA like domain containing 2	8	98189833-98294393	Predicted membrane proteins	Evidence at transcript level	HPA071759	Uncertain					Expressed in all	Mixed			skin: 62.2	Cell line enhanced		ASC diff: 30.5
IKBKB	IKK-beta, IKK2, IKKB, NFKBIKB	ENSG00000104365	Inhibitor of nuclear factor kappa B kinase subunit beta	8	42271302-42332653	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001249, CAB004447	Enhanced		Approved	Cytosol	Urothelial cancer:1.46e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
PLAT		ENSG00000104368	Plasminogen activator, tissue type	8	42175233-42207724	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003412, CAB009335	Supported		Approved	Actin filaments	Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Tissue enriched	5	parathyroid gland: 709.4	urinary bladder: 135.9	Cell line enhanced		CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
JPH1	JP-1	ENSG00000104369	Junctophilin 1	8	74234700-74321328	Predicted membrane proteins	Evidence at protein level	HPA008996, HPA009413, CAB013461	Enhanced		Supported	Nucleus	Lung cancer:5.77e-5 (favourable)	Mixed	Tissue enriched	10	skeletal muscle: 88.0	cerebral cortex: 8.6	Cell line enhanced		SK-BR-3: 27.1;T-47d: 24.2
DKK4		ENSG00000104371	Dickkopf WNT signaling pathway inhibitor 4	8	42374068-42377232	Predicted secreted proteins	Evidence at protein level	HPA052916	Approved					Tissue enriched	Tissue enhanced		duodenum: 2.4;esophagus: 5.4;testis: 2.7	urinary bladder: 1.4	Cell line enriched	9	Hep G2: 1.4
STK3	KRS1, MST2	ENSG00000104375	Serine/threonine kinase 3	8	98401403-98942827	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007120, CAB025316	Uncertain		Approved	Intermediate filaments<br>Rods & Rings	Pancreatic cancer:9.21e-5 (unfavourable), Endometrial cancer:1.53e-4 (unfavourable), Lung cancer:4.25e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 41.5	Mixed		
GDAP1	CMT2K, CMT4, CMT4A	ENSG00000104381	Ganglioside induced differentiation associated protein 1	8	74321130-74488872	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014266, HPA024334	Enhanced		Supported	Mitochondria<br>Cytosol	Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 76.7	parathyroid gland: 18.3	Cell line enhanced		SH-SY5Y: 49.8
RAB2A	RAB2	ENSG00000104388	RAB2A, member RAS oncogene family	8	60516857-60623627	Predicted intracellular proteins	Evidence at protein level	CAB018781	Approved				Breast cancer:8.22e-4 (unfavourable), Endometrial cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 108.0	Expressed in all		
EIF3E	eIF3-p48, eIF3e, EIF3S6, INT6	ENSG00000104408	Eukaryotic translation initiation factor 3 subunit E	8	108201216-108435333	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023973	Approved		Enhanced	Nuclear bodies<br>Cytosol	Renal cancer:3.06e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 731.0	Expressed in all		
EMC2	KIAA0103, TTC35	ENSG00000104412	ER membrane protein complex subunit 2	8	108443601-108486918	Predicted intracellular proteins	Evidence at protein level	HPA022838	Approved				Breast cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 110.0	Expressed in all		
ESRP1	FLJ20171, RBM35A	ENSG00000104413	Epithelial splicing regulatory protein 1	8	94641074-94707466	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023719, HPA023720, HPA067104	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.96e-8 (favourable), Pancreatic cancer:2.05e-4 (unfavourable), Endometrial cancer:3.56e-4 (unfavourable), Breast cancer:9.28e-4 (unfavourable)	Mixed	Mixed			skin: 72.8	Cell line enhanced		A-431: 122.3;BEWO: 98.9;CAPAN-2: 125.0;hTCEpi: 166.0;RT4: 84.1;T-47d: 103.3
WISP1	CCN4	ENSG00000104415	WNT1 inducible signaling pathway protein 1	8	133191039-133230344	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA007121, CAB012205	Uncertain		Approved	Cytosol	Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 22.1	Cell line enhanced		HSkMC: 85.7;hTEC/SVTERT24-B: 73.5;U-2197: 64.2
NDRG1	CAP43, DRG1, NDR1, RTP, TDD5	ENSG00000104419	N-myc downstream regulated 1	8	133237171-133302022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006881	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:1.47e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable), Glioma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 535.2	Cell line enhanced		hTCEpi: 403.8;hTERT-HME1: 857.9;U-87 MG: 734.9
ZC2HC1A	C8orf70, CGI-62, FAM164A	ENSG00000104427	Zinc finger C2HC-type containing 1A	8	78666047-78719765	Predicted intracellular proteins	Evidence at protein level	HPA024726	Approved		Approved	Actin filaments<br>Cytosol	Stomach cancer:5.85e-4 (unfavourable), Ovarian cancer:9.00e-4 (unfavourable)	Expressed in all	Mixed			skin: 52.9	Cell line enhanced		SK-BR-3: 58.7
IL7	IL-7	ENSG00000104432	Interleukin 7	8	78675743-78805523	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019590	Approved				Renal cancer:2.69e-4 (unfavourable)	Mixed	Mixed			skin: 10.2	Cell line enhanced		HDLM-2: 15.6;HEL: 15.9;HMC-1: 22.1
STMN2	SCG10, SCGN10	ENSG00000104435	Stathmin 2	8	79610814-79666175	Predicted intracellular proteins	Evidence at protein level	HPA026922		Supported	Approved	Endoplasmic reticulum<br>Vesicles		Group enriched	Tissue enriched	6	cerebral cortex: 489.4	adrenal gland: 88.0	Cell line enriched	10	SH-SY5Y: 696.7
ARMC1	Arcp, FLJ10511	ENSG00000104442	Armadillo repeat containing 1	8	65602456-65634217	Predicted intracellular proteins	Evidence at protein level	HPA026085	Approved		Supported	Mitochondria	Endometrial cancer:2.87e-4 (unfavourable), Breast cancer:4.81e-4 (unfavourable), Liver cancer:7.73e-4 (unfavourable), Pancreatic cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 34.7	Expressed in all		
TRPS1	GC79, LGCR	ENSG00000104447	Transcriptional repressor GATA binding 1	8	115408496-115809673	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060380, HPA071767	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:3.16e-4 (unfavourable), Head and neck cancer:9.42e-4 (favourable)	Tissue enriched	Tissue enhanced		breast: 75.9	testis: 22.6	Cell line enhanced		SK-BR-3: 58.4;T-47d: 230.2
SPAG1	CILD28, CT140, FLJ32920, HSD-3.8, SP75, TPIS	ENSG00000104450	Sperm associated antigen 1	8	100157906-100259278	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023748, HPA053682	Enhanced		Supported	Cytosol	Urothelial cancer:2.62e-4 (favourable), Renal cancer:3.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.1	rectum: 20.0	Mixed		
CHRAC1	CHRAC15, YCL1	ENSG00000104472	Chromatin accessibility complex 1	8	140511298-140517137	Predicted intracellular proteins	Evidence at protein level	HPA059008			Approved	Nucleus	Liver cancer:4.88e-5 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable), Pancreatic cancer:5.43e-4 (unfavourable), Ovarian cancer:9.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 35.0	Expressed in all		
NCALD		ENSG00000104490	Neurocalcin delta	8	101686543-102124907	Predicted intracellular proteins	Evidence at protein level	HPA043245	Approved				Pancreatic cancer:5.30e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 125.0	Group enriched	5	AF22: 133.9;HDLM-2: 161.9
SNX16		ENSG00000104497	Sorting nexin 16	8	81799581-81842866	Predicted intracellular proteins	Evidence at protein level	HPA024730, HPA024731, HPA024817	Approved		Supported	Vesicles		Expressed in all	Mixed			testis: 27.7	Expressed in all		
GML	LY6DL	ENSG00000104499	Glycosylphosphatidylinositol anchored molecule like	8	142834247-142916506	Predicted secreted proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	39	adrenal gland: 251.3	testis: 6.4	Not detected		
UBR5	DD5, EDD, EDD1, HYD, KIAA0896	ENSG00000104517	Ubiquitin protein ligase E3 component n-recognin 5	8	102253012-102412841	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053688			Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
GSDMD	DF5L, FLJ12150, GSDMDC1	ENSG00000104518	Gasdermin D	8	143553207-143563062	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004656, HPA044487	Uncertain		Supported	Nucleoplasm	Renal cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 46.5	Mixed		
TSTA3	FX, P35B, SDR4E1	ENSG00000104522	Tissue specific transplantation antigen P35B	8	143612618-143618048	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023361	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.59e-4 (unfavourable), Ovarian cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			stomach: 50.3	Expressed in all		
PYCRL	FLJ13852	ENSG00000104524	Pyrroline-5-carboxylate reductase-like	8	143603913-143609773	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063416, HPA069706	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 4.1	Expressed in all		
EEF1D	EF-1D, FLJ20897	ENSG00000104529	Eukaryotic translation elongation factor 1 delta	8	143579697-143599541	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045101, HPA051002	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.58e-5 (unfavourable), Liver cancer:3.82e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 606.8	Expressed in all		
ANXA13	ANX13	ENSG00000104537	Annexin A13	8	123680794-123737407	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018535, HPA019569, HPA019650, CAB025135	Enhanced		Supported	Plasma membrane		Group enriched	Group enriched	5	duodenum: 296.6;fallopian tube: 92.7;gallbladder: 227.6;small intestine: 235.6	rectum: 39.2	Group enriched	16	A549: 25.3;HDLM-2: 13.7
SQLE		ENSG00000104549	Squalene epoxidase	8	124998497-125022283	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018038, HPA020762	Enhanced		Uncertain	Vesicles<br>Cytosol	Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 107.8	Expressed in all		
SH2D4A	FLJ20967, PPP1R38, SH2A	ENSG00000104611	SH2 domain containing 4A	8	19313617-19396218	Predicted intracellular proteins	Evidence at protein level	HPA001871, HPA001919	Enhanced		Enhanced	Cytosol	Renal cancer:6.02e-8 (favourable)	Expressed in all	Mixed			ovary: 44.9	Cell line enhanced		fHDF/TERT166: 140.4;U-2197: 121.2
INTS10	C8orf35, FLJ10569, INT10	ENSG00000104613	Integrator complex subunit 10	8	19817140-19852083	Predicted intracellular proteins	Evidence at protein level	HPA039129, HPA050570	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.22e-4 (favourable), Colorectal cancer:4.00e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 64.9	Expressed in all		
ERI1	3'HEXO, THEX1	ENSG00000104626	Exoribonuclease 1	8	9002147-9116746	Predicted intracellular proteins	Evidence at protein level	CAB033838, HPA055548, HPA056074	Uncertain		Approved	Vesicles<br>Microtubules	Colorectal cancer:8.05e-5 (favourable), Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.8	Expressed in all		
SLC39A14	KIAA0062, NET34, ZIP14	ENSG00000104635	Solute carrier family 39 member 14	8	22367249-22434129	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016508	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable)	Expressed in all	Mixed			liver: 203.0	Expressed in all		
MTMR9	C8orf9, DKFZp434K171, LIP-STYX, MTMR8	ENSG00000104643	Myotubularin related protein 9	8	11284416-11328146	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070944			Approved	Actin filaments<br>Centrosome		Expressed in all	Mixed			cerebral cortex: 22.4	Expressed in all		
LEPROTL1	my047, Vps55	ENSG00000104660	Leptin receptor overlapping transcript-like 1	8	30095398-30177208	Predicted membrane proteins	Evidence at protein level	HPA047911	Uncertain				Renal cancer:1.94e-5 (unfavourable), Colorectal cancer:9.04e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.0	Expressed in all		
DCTN6	WS-3	ENSG00000104671	Dynactin subunit 6	8	30156297-30183640	Predicted intracellular proteins	Evidence at protein level	HPA024049, HPA024558	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:5.42e-4 (favourable), Liver cancer:5.51e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 93.9	Expressed in all		
R3HCC1	DKFZp564N123	ENSG00000104679	R3H domain and coiled-coil containing 1	8	23270120-23296279	Predicted intracellular proteins	Evidence at protein level	HPA023073, HPA023153	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.80e-5 (favourable), Colorectal cancer:4.08e-4 (favourable), Pancreatic cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
GSR		ENSG00000104687	Glutathione-disulfide reductase	8	30678061-30727926	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001538, CAB008632	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 79.3	Expressed in all		
TNFRSF10A	Apo2, CD261, DR4, TRAILR-1	ENSG00000104689	TNF receptor superfamily member 10a	8	23190452-23225126	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA050958, HPA054475	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.00e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.9	Mixed		
UBXN8	D8S2298E, REP8, UBXD6	ENSG00000104691	UBX domain protein 8	8	30732247-30767006	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017725, HPA077538	Approved		Supported	Nucleoplasm<br>Nucleoli<br>Endoplasmic reticulum	Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable)	Expressed in all	Expressed in all			ovary: 109.4	Expressed in all		
PPP2CB	PP2Abeta	ENSG00000104695	Protein phosphatase 2 catalytic subunit beta	8	30774457-30814314	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018600, HPA043236	Approved		Supported	Nucleoplasm	Renal cancer:5.82e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 207.5	Expressed in all		
ERICH1		ENSG00000104714	Glutamate rich 1	8	614746-738106	Predicted intracellular proteins	Evidence at protein level	HPA003725	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			lymph node: 24.2	Mixed		
NEFM	NEF3, NF-M, NFM	ENSG00000104722	Neurofilament medium	8	24913012-24919098	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010900, CAB012976, HPA022845, HPA023138	Enhanced		Enhanced	Intermediate filaments		Mixed	Tissue enhanced		cerebral cortex: 171.7;seminal vesicle: 42.2	adrenal gland: 28.2	Cell line enriched	22	HEK 293: 3411.6
TUSC3	MGC13453, MRT7, N33, OST3A	ENSG00000104723	Tumor suppressor candidate 3	8	15417215-15766649	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049851, HPA049974	Approved				Thyroid cancer:7.86e-4 (favourable)	Expressed in all	Mixed			epididymis: 143.1	Mixed		
ARHGEF10	Gef10, KIAA0294	ENSG00000104728	Rho guanine nucleotide exchange factor 10	8	1823976-1958641	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024649	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 15.9	Mixed		
KLHDC4	DKFZp434G0522	ENSG00000104731	Kelch domain containing 4	16	87696485-87765992	Predicted intracellular proteins	Evidence at protein level	HPA041665	Approved		Supported	Nucleoli	Pancreatic cancer:1.14e-4 (favourable), Urothelial cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 19.0	Expressed in all		
MCM4	CDC21, CDC54, hCdc21, MGC33310, P1-Cdc21	ENSG00000104738	Minichromosome maintenance complex component 4	8	47960185-47978160	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004497, HPA004873, HPA031052	Supported		Enhanced	Nucleoplasm	Endometrial cancer:2.84e-5 (unfavourable), Melanoma:1.15e-4 (unfavourable), Liver cancer:1.23e-4 (unfavourable), Colorectal cancer:2.19e-4 (favourable), Pancreatic cancer:2.38e-4 (unfavourable), Renal cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.6	Expressed in all		
ADAM2	CT15, FTNB, PH-30b, PH30	ENSG00000104755	ADAM metallopeptidase domain 2	8	39743735-39838289	Predicted membrane proteins	Evidence at protein level	CAB022390, HPA024621, HPA026581	Enhanced					Tissue enhanced	Tissue enriched	284	testis: 41.9	breast: 0.1	Not detected		
KCTD9	BTBD27, FLJ20038	ENSG00000104756	Potassium channel tetramerization domain containing 9	8	25427847-25458476	Predicted intracellular proteins	Evidence at protein level	HPA042468, HPA047902			Supported	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Colorectal cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			prostate: 28.1	Expressed in all		
FGL1	HFREP-1	ENSG00000104760	Fibrinogen like 1	8	17864380-17910365	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Stomach cancer:5.38e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	liver: 1005.3	pancreas: 137.8	Group enriched	12	A549: 49.7;Hep G2: 89.4
ASAH1	AC, ACDase, ASAH, FLJ21558, PHP32	ENSG00000104763	N-acylsphingosine amidohydrolase 1	8	18055992-18084998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005468	Supported				Renal cancer:3.08e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 547.6	Expressed in all		
BNIP3L	BNIP3a, Nix	ENSG00000104765	BCL2 interacting protein 3 like	8	26382898-26505636	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015652, CAB025371	Enhanced		Enhanced	Nuclear speckles<br>Mitochondria	Renal cancer:5.92e-5 (unfavourable), Thyroid cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 147.5	Expressed in all		
MAN2B1	LAMAN, MANB	ENSG00000104774	Mannosidase alpha class 2B member 1	19	12646511-12666742	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041530, HPA053404	Supported		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.94e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 95.1	Expressed in all		
KCNN4	hIKCa1, hKCa4, hSK4, IK, KCa3.1	ENSG00000104783	Potassium calcium-activated channel subfamily N member 4	19	43766533-43781257	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA053841, HPA059622	Approved				Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 73.7	stomach: 36.6	Cell line enhanced		CAPAN-2: 93.3;WM-115: 264.9
TULP2	CT65, TUBL2	ENSG00000104804	Tubby like protein 2	19	48880965-48898733	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	testis: 41.0	bone marrow: 3.4	Cell line enhanced		BEWO: 2.5;U-266/70: 2.3;U-266/84: 2.4
NUCB1	Calnuc, NUC	ENSG00000104805	Nucleobindin 1	19	48900050-48923372	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008176	Enhanced		Supported	Golgi apparatus<br>Microtubules		Expressed in all	Expressed in all			parathyroid gland: 227.7	Expressed in all		
DHDH	HUM2DD	ENSG00000104808	Dihydrodiol dehydrogenase	19	48933682-48944969	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044131	Approved		Approved	Nucleoplasm<br>Actin filaments	Renal cancer:3.15e-4 (favourable), Endometrial cancer:9.91e-4 (unfavourable)	Expressed in all	Group enriched	5	duodenum: 10.2;kidney: 17.8;prostate: 5.1;small intestine: 18.6	testis: 2.5	Cell line enhanced		SCLC-21H: 2.5
GYS1	GSY, GYS	ENSG00000104812	Glycogen synthase 1	19	48968125-48993310	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB007793, HPA041598	Enhanced		Approved	Microtubules<br>Cytosol	Renal cancer:3.46e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 109.7	Expressed in all		
MAP4K1	HPK1	ENSG00000104814	Mitogen-activated protein kinase kinase kinase kinase 1	19	38587641-38618882	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007419, CAB007754	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane	Renal cancer:7.99e-10 (unfavourable), Cervical cancer:6.17e-5 (favourable), Head and neck cancer:3.26e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 37.3;spleen: 23.8;tonsil: 27.2	appendix: 19.2	Cell line enhanced		Daudi: 34.0;HDLM-2: 44.1;Karpas-707: 34.0;U-266/70: 28.3;U-266/84: 27.3;U-698: 41.0
CGB2		ENSG00000104818	Chorionic gonadotropin beta subunit 2	19	49031912-49033238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Not detected			testis: 0.7	Cell line enhanced		HMC-1: 28.4;U-266/70: 9.9;U-266/84: 11.8
ECH1	HPXEL	ENSG00000104823	Enoyl-CoA hydratase 1	19	38815422-38832005	Predicted intracellular proteins	Evidence at protein level	HPA002907, HPA005835	Supported	Approved	Supported	Mitochondria	Stomach cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 188.1	Expressed in all		
HNRNPL	HNRPL	ENSG00000104824	Heterogeneous nuclear ribonucleoprotein L	19	38836388-38852347	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016326, HPA051748, HPA052661	Supported		Enhanced	Nucleoplasm	Renal cancer:1.96e-11 (unfavourable), Liver cancer:3.25e-6 (unfavourable), Pancreatic cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 110.4	Expressed in all		
NFKBIB	IKBB, TRIP9	ENSG00000104825	NFKB inhibitor beta	19	38899700-38908893	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063734			Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Tissue enhanced		testis: 16.6	appendix: 7.1	Expressed in all		
LHB	CGB4, hLHB, LSH-B	ENSG00000104826	Luteinizing hormone beta polypeptide	19	49015980-49017081	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB022241, CAB022707, HPA038925	Supported		Approved	Cytosol	Pancreatic cancer:6.78e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 3.2;pancreas: 4.8;testis: 2.9	adrenal gland,skin,small intestine: 0.7	Mixed		
CGB3	CGB	ENSG00000104827	Chorionic gonadotropin beta subunit 3	19	49022869-49024333	Predicted secreted proteins	Evidence at protein level	CAB000042, CAB010884, HPA038925, HPA038934	Enhanced		Approved	Cytosol		Tissue enhanced	Tissue enriched	21	placenta: 14.9	testis: 0.7	Cell line enriched	23	BEWO: 65.1
TUBB4A	beta-5, DYT4, TUBB4	ENSG00000104833	Tubulin beta 4A class IVa	19	6494319-6502848	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010768, HPA043640, HPA046280	Approved		Supported	Microtubules	Endometrial cancer:8.42e-7 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 137.6;cerebral cortex: 554.4	testis: 102.4	Cell line enhanced		AN3-CA: 82.5;HAP1: 52.9;HEL: 69.1
SARS2	FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS	ENSG00000104835	Seryl-tRNA synthetase 2, mitochondrial	19	38915266-38930896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052730, HPA056957	Approved					Expressed in all	Expressed in all			thyroid gland: 8.9	Expressed in all		
KCNA7	HAK6, Kv1.7	ENSG00000104848	Potassium voltage-gated channel subfamily A member 7	19	49067418-49072941	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level							Not detected	Tissue enriched	37	skeletal muscle: 26.2	esophagus: 0.7	Not detected		
SNRNP70	RNPU1Z, RPU1, Snp1, SNRP70, U1-70K	ENSG00000104852	Small nuclear ribonucleoprotein U1 subunit 70	19	49085419-49108605	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001718, HPA042050, HPA043516	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:4.59e-5 (favourable), Urothelial cancer:5.35e-5 (favourable), Renal cancer:6.12e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 59.8	Expressed in all		
CLPTM1		ENSG00000104853	CLPTM1, transmembrane protein	19	44954585-44993341	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068702			Approved	Nuclear membrane<br>Microtubule organizing center		Expressed in all	Expressed in all			parathyroid gland: 129.9	Expressed in all		
RELB	REL-B	ENSG00000104856	RELB proto-oncogene, NF-kB subunit	19	45001430-45038198	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB007753, HPA040506	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.99e-6 (unfavourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			appendix: 25.1	Cell line enhanced		HDLM-2: 73.5
CLASRP	CLASP, SFRS16, SWAP2	ENSG00000104859	CLK4 associating serine/arginine rich protein	19	45039040-45070956	Predicted intracellular proteins	Evidence at protein level	HPA060469, HPA062455	Approved		Enhanced	Nucleus	Renal cancer:1.69e-8 (unfavourable), Urothelial cancer:1.02e-5 (favourable), Colorectal cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 11.9	Expressed in all		
LIN7B	LIN-7B, MALS-2, VELI2	ENSG00000104863	Lin-7 homolog B, crumbs cell polarity complex component	19	49114324-49118460	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:7.00e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.2	Mixed		
PPP1R37	LRRC68	ENSG00000104866	Protein phosphatase 1 regulatory subunit 37	19	45091396-45148077	Predicted intracellular proteins	Evidence at protein level	HPA041500	Approved		Approved	Cytosol	Urothelial cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.3	Expressed in all		
FCGRT	alpha-chain, FCRN	ENSG00000104870	Fc fragment of IgG receptor and transporter	19	49506816-49526333	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012122, HPA015130	Approved					Expressed in all	Expressed in all			small intestine: 312.0	Mixed		
PIH1D1	FLJ20643, NOP17	ENSG00000104872	PIH1 domain containing 1	19	49446298-49453497	Predicted intracellular proteins	Evidence at protein level	HPA047258	Approved		Approved	Cytosol		Expressed in all	Expressed in all			fallopian tube: 64.8	Expressed in all		
CKM	CKMM	ENSG00000104879	Creatine kinase, M-type	19	45306414-45322977	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047859	Enhanced					Group enriched	Tissue enriched	17	skeletal muscle: 23798.9	heart muscle: 1418.8	Cell line enriched	6	SCLC-21H: 75.4
ARHGEF18	KIAA0521, MGC15913, P114-RhoGEF	ENSG00000104880	Rho/Rac guanine nucleotide exchange factor 18	19	7395113-7472477	Predicted intracellular proteins	Evidence at protein level	HPA042689, HPA071867	Approved		Enhanced	Cytosol	Renal cancer:3.11e-5 (favourable), Head and neck cancer:4.21e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.5	Expressed in all		
PPP1R13L	IASPP, RAI	ENSG00000104881	Protein phosphatase 1 regulatory subunit 13 like	19	45379634-45406349	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005016, HPA041231, HPA059883	Approved		Enhanced	Cytosol	Lung cancer:3.39e-5 (unfavourable), Ovarian cancer:5.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 191.4	esophagus: 53.8	Cell line enhanced		hTCEpi: 138.6
PEX11G		ENSG00000104883	Peroxisomal biogenesis factor 11 gamma	19	7476875-7497449	Predicted membrane proteins	Evidence at protein level	HPA069817	Uncertain				Renal cancer:1.83e-9 (favourable), Liver cancer:3.27e-4 (favourable), Endometrial cancer:3.60e-4 (favourable)	Expressed in all	Mixed			testis: 15.6	Mixed		
ERCC2	EM9, MAG, MGC102762, MGC126218, MGC126219, TFIIH, XPD	ENSG00000104884	ERCC excision repair 2, TFIIH core complex helicase subunit	19	45349837-45370918	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005375, HPA038057, HPA069266	Approved		Supported	Nucleoplasm	Pancreatic cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
DOT1L	DOT1, KIAA1814, KMT4	ENSG00000104885	DOT1 like histone lysine methyltransferase	19	2164149-2232578	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011875, HPA071217			Enhanced	Nucleoplasm	Endometrial cancer:1.69e-4 (favourable), Head and neck cancer:6.00e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 92.3	appendix,bone marrow: 14.0	Expressed in all		
PLEKHJ1	FLJ10297	ENSG00000104886	Pleckstrin homology domain containing J1	19	2230084-2237704	Predicted intracellular proteins	Evidence at protein level	HPA048989	Approved		Approved	Mitochondria	Renal cancer:1.10e-5 (favourable), Stomach cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 107.8	Expressed in all		
SLC17A7	BNPI, VGLUT1	ENSG00000104888	Solute carrier family 17 member 7	19	49429401-49442360	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037183, HPA050458, HPA063679	Enhanced	Supported				Tissue enriched	Tissue enriched	177	cerebral cortex: 584.4	adipose tissue: 3.3	Cell line enhanced		HMC-1: 18.2;K-562: 6.2;SCLC-21H: 5.7
RNASEH2A	AGS4, RNASEHI, RNHIA, RNHL	ENSG00000104889	Ribonuclease H2 subunit A	19	12802063-12813638	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042692			Enhanced	Nucleus<br>Cytosol	Renal cancer:6.29e-6 (unfavourable), Liver cancer:8.72e-5 (unfavourable), Cervical cancer:1.18e-4 (favourable), Ovarian cancer:1.22e-4 (favourable), Colorectal cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.5	Expressed in all		
KLC3	KLC2L, KLCt, KNS2B	ENSG00000104892	Kinesin light chain 3	19	45333434-45351520	Predicted intracellular proteins	Evidence at protein level	HPA052797, HPA056508	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Endometrial cancer:1.46e-4 (unfavourable)	Mixed	Tissue enriched	6	skin: 63.9	esophagus: 10.0	Cell line enhanced		A-431: 31.4;HaCaT: 14.3
CD37	TSPAN26	ENSG00000104894	CD37 molecule	19	49335171-49343335	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002492, HPA032120, HPA032121	Enhanced				Endometrial cancer:4.51e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 241.4;spleen: 208.7	appendix: 129.0	Cell line enhanced		Daudi: 215.5;HMC-1: 252.2;RPMI-8226: 75.0;THP-1: 72.1
SF3A2	Prp11, PRPF11, SAP62, SF3a66	ENSG00000104897	Splicing factor 3a subunit 2	19	2236504-2248679	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042843, HPA049439	Enhanced		Approved	Nucleoplasm	Liver cancer:3.23e-5 (unfavourable), Renal cancer:2.07e-4 (unfavourable), Cervical cancer:7.16e-4 (favourable), Colorectal cancer:8.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.3	Expressed in all		
AMH	MIS	ENSG00000104899	Anti-Mullerian hormone	19	2249309-2252073	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA066973			Approved	Vesicles<br>Aggresome	Colorectal cancer:9.21e-5 (unfavourable)	Mixed	Tissue enriched	6	testis: 1.6	cerebral cortex: 0.2	Cell line enhanced		HEK 293: 15.7;NTERA-2: 6.5;REH: 6.4;SH-SY5Y: 8.2
DKKL1	CT34, SGY-1	ENSG00000104901	Dickkopf like acrosomal protein 1	19	49361783-49375116	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025410, HPA047194	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	149	testis: 265.5	endometrium,fallopian tube: 1.7	Cell line enhanced		AF22: 5.0;AN3-CA: 8.9
LYL1	bHLHa18	ENSG00000104903	LYL1, basic helix-loop-helix family member	19	13099033-13103161	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075004			Approved	Golgi apparatus	Renal cancer:3.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.9;spleen: 20.7	appendix: 14.3	Cell line enhanced		HEL: 113.5;HMC-1: 179.8;K-562: 90.4;NB-4: 82.5;REH: 87.2
OAZ1	AZI, MGC138338, OAZ	ENSG00000104904	Ornithine decarboxylase antizyme 1	19	2269509-2273490	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009291	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Pancreatic cancer:4.10e-5 (favourable), Liver cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 268.1	Expressed in all		
TRMT1	FLJ20244, TRM1	ENSG00000104907	TRNA methyltransferase 1	19	13104902-13117567	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041130, HPA041380	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:9.87e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 26.6	Expressed in all		
STX10	hsyn10, SYN10	ENSG00000104915	Syntaxin 10	19	13144058-13150383	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035303, HPA056439	Approved		Approved	Golgi apparatus	Renal cancer:1.69e-7 (unfavourable), Lung cancer:8.26e-4 (favourable)	Expressed in all	Expressed in all			skin: 57.0	Expressed in all		
RETN	ADSF, FIZZ3, RETN1	ENSG00000104918	Resistin	19	7669044-7670454	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	bone marrow: 159.4	lung: 26.0	Group enriched	8	NB-4: 327.2;U-937: 187.7
FCER2	CD23, CD23A, CLEC4J, FCE2	ENSG00000104921	Fc fragment of IgE receptor II	19	7688758-7702146	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002624, HPA008928	Enhanced					Mixed	Group enriched	7	appendix: 21.9;lymph node: 47.4;spleen: 52.6;tonsil: 38.0	adipose tissue: 5.8	Cell line enriched	16	HDLM-2: 416.1
DMPK	DM, DM1, DM1PK, DMK, MDPK, MT-PK	ENSG00000104936	Dystrophia myotonica protein kinase	19	45769717-45782552	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007164, HPA008905	Enhanced		Approved	Vesicles<br>Cytosol	Pancreatic cancer:9.39e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 97.3	Cell line enhanced		RH-30: 99.0
CLEC4M	CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN	ENSG00000104938	C-type lectin domain family 4 member M	19	7763149-7769605	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033689, CAB033691, HPA042661	Supported					Not detected	Group enriched	8	liver: 34.7;lymph node: 20.3;placenta: 12.4	testis: 2.9	Not detected		
RSPH6A	RSHL1, RSP4, RSP6, RSPH4B	ENSG00000104941	Radial spoke head 6 homolog A	19	45795710-45815319	Predicted intracellular proteins	Evidence at protein level	HPA045382	Enhanced					Tissue enriched	Tissue enriched	7	testis: 30.4	thyroid gland: 4.5	Cell line enriched	11	RPMI-8226: 1.9
TBC1D17	FLJ12168	ENSG00000104946	TBC1 domain family member 17	19	49877425-49888749	Predicted intracellular proteins	Evidence at protein level	HPA068119	Uncertain				Pancreatic cancer:4.02e-4 (favourable), Head and neck cancer:7.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.8	Expressed in all		
IL4I1	FIG1	ENSG00000104951	Interleukin 4 induced 1	19	49889654-49929539	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045598	Enhanced				Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 24.5;testis: 32.0	lymph node: 10.5	Cell line enhanced		EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8
TLE6	FLJ14009, GRG6	ENSG00000104953	Transducin like enhancer of split 6	19	2977446-2995184	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		thyroid gland: 9.7	placenta: 6.5	Cell line enhanced		BEWO: 16.5;U-266/70: 11.1
CCDC130	MGC10471	ENSG00000104957	Coiled-coil domain containing 130	19	13731760-13763296	Predicted intracellular proteins	Evidence at protein level	HPA056977	Approved		Approved	Vesicles	Head and neck cancer:7.83e-5 (favourable), Urothelial cancer:1.82e-4 (favourable), Renal cancer:1.97e-4 (unfavourable), Pancreatic cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.7	Expressed in all		
PTOV1		ENSG00000104960	Prostate tumor overexpressed 1	19	49850735-49860744	Predicted intracellular proteins	Evidence at protein level	HPA051812, HPA075125	Approved		Supported	Nucleus	Colorectal cancer:6.64e-4 (unfavourable), Pancreatic cancer:9.20e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 59.4	Expressed in all		
AES	GRG5, TLE5	ENSG00000104964	Amino-terminal enhancer of split	19	3052910-3063107	Predicted intracellular proteins	Evidence at protein level	HPA049499			Supported	Nucleoplasm	Endometrial cancer:3.89e-4 (favourable), Renal cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 331.2	Mixed		
NOVA2	ANOVA, NOVA3	ENSG00000104967	NOVA alternative splicing regulator 2	19	45933734-45973546	Predicted intracellular proteins	Evidence at protein level	HPA045607	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:3.04e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 24.3	adipose tissue: 6.0	Cell line enhanced		AF22: 10.0;HDLM-2: 10.4;HUVEC TERT2: 14.6;TIME: 21.5
SGTA	SGT	ENSG00000104969	Small glutamine rich tetratricopeptide repeat containing alpha	19	2754714-2783371	Predicted intracellular proteins	Evidence at protein level	HPA056309	Approved		Approved	Nucleoplasm	Endometrial cancer:1.04e-4 (favourable), Renal cancer:2.35e-4 (favourable), Cervical cancer:9.70e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 64.6	Mixed		
KIR3DX1	FLJ00060, LENG12	ENSG00000104970	Killer cell immunoglobulin like receptor, three Ig domains X1	19	54532692-54545771	Predicted secreted proteins	Evidence at transcript level	HPA052110	Uncertain					Not detected	Not detected			bone marrow: 0.3	Cell line enriched	6	U-266/84: 3.2
LILRB1	CD85, CD85j, ILT2, LIR-1, LIR1, MIR-7, PIR-B, PIRB	ENSG00000104972	Leukocyte immunoglobulin like receptor B1	19	54617158-54637528	Predicted membrane proteins	Evidence at transcript level						Renal cancer:3.08e-6 (unfavourable)	Mixed	Tissue enhanced		appendix: 8.6;lymph node: 6.2;spleen: 9.9	smooth muscle: 3.7	Group enriched	17	Daudi: 4.0;THP-1: 1.9
MED25	ACID1, ARC92, DKFZp434K0512, TCBAP0758	ENSG00000104973	Mediator complex subunit 25	19	49818279-49838816	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068802			Supported	Nucleoplasm	Head and neck cancer:9.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 111.2	Expressed in all		
LILRA1	CD85i, LIR-6, LIR6	ENSG00000104974	Leukocyte immunoglobulin like receptor A1	19	54593582-54602090	CD markers, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			appendix: 0.8	Not detected		
SNAPC2	PTFdelta, SNAP45	ENSG00000104976	Small nuclear RNA activating complex polypeptide 2	19	7920316-7923250	Predicted intracellular proteins	Evidence at protein level	HPA049843, HPA077597	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.89e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 30.1	Expressed in all		
C19orf53	HSPC023, LYDG10	ENSG00000104979	Chromosome 19 open reading frame 53	19	13774168-13778462	Predicted intracellular proteins	Evidence at protein level	HPA059928, HPA061291	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			fallopian tube: 116.9	Expressed in all		
TIMM44	TIM44	ENSG00000104980	Translocase of inner mitochondrial membrane 44	19	7926718-7943920	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043052	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			heart muscle: 19.1	Expressed in all		
CCDC61		ENSG00000104983	Coiled-coil domain containing 61	19	45995461-46021318	Predicted intracellular proteins	Evidence at protein level	HPA040325, HPA061548	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
IL27RA	CRL1, IL-27R, TCCR, WSX-1, WSX1, zcytor1	ENSG00000104998	Interleukin 27 receptor subunit alpha	19	14031748-14053216	Predicted membrane proteins	Evidence at protein level						Renal cancer:2.58e-10 (unfavourable), Breast cancer:1.74e-6 (favourable)	Expressed in all	Mixed			tonsil: 30.4	Mixed		
ASF1B	FLJ10604	ENSG00000105011	Anti-silencing function 1B histone chaperone	19	14119509-14136956	Predicted intracellular proteins	Evidence at protein level	HPA054036			Supported	Nucleoplasm	Renal cancer:2.22e-16 (unfavourable), Cervical cancer:4.45e-5 (favourable), Pancreatic cancer:1.98e-4 (unfavourable), Liver cancer:2.03e-4 (unfavourable), Stomach cancer:2.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 37.2	lymph node: 24.0	Mixed		
TNNT1	ANM, FLJ98147, MGC104241, NEM5, STNT, TNT, TNTS	ENSG00000105048	Troponin T1, slow skeletal type	19	55132794-55149354	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015168, HPA058448	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:2.53e-4 (unfavourable), Colorectal cancer:4.66e-4 (unfavourable), Endometrial cancer:4.66e-4 (unfavourable)	Expressed in all	Tissue enriched	12	skeletal muscle: 7568.7	esophagus: 632.9	Cell line enhanced		HMC-1: 728.7;RH-30: 606.8
VRK3		ENSG00000105053	Vaccinia related kinase 3	19	49976467-50025946	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056489	Approved		Supported	Nucleus<br>Vesicles	Renal cancer:1.83e-4 (favourable), Urothelial cancer:5.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 168.6	Expressed in all		
FAM32A	DKFZP586O0120, OTAG-12	ENSG00000105058	Family with sequence similarity 32 member A	19	16185380-16192046	Predicted intracellular proteins	Evidence at protein level	HPA051712	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 89.0	Expressed in all		
PPP6R1	KIAA1115, SAP190, SAPS1	ENSG00000105063	Protein phosphatase 6 regulatory subunit 1	19	55229780-55258995	Predicted intracellular proteins	Evidence at protein level	HPA043989, HPA063681	Approved		Enhanced	Cytosol	Liver cancer:3.82e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 117.3	Expressed in all		
C19orf44	FLJ21742	ENSG00000105072	Chromosome 19 open reading frame 44	19	16496311-16521352	Predicted intracellular proteins	Evidence at protein level	HPA041683, HPA049414	Uncertain		Approved	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			testis: 20.2	Mixed		
MED26	CRSP7, CRSP70	ENSG00000105085	Mediator complex subunit 26	19	16574907-16629062	Predicted intracellular proteins	Evidence at protein level	HPA057997, HPA071835	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.50e-5 (unfavourable), Cervical cancer:2.46e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 42.0	bone marrow: 6.8	Expressed in all		
OLFM2	NOE2, OlfC	ENSG00000105088	Olfactomedin 2	19	9853718-9936552	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049961, HPA057771	Uncertain		Approved	Nucleoplasm	Renal cancer:2.21e-4 (unfavourable), Colorectal cancer:3.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 124.0;skin: 111.2	adipose tissue: 36.8	Cell line enhanced		AN3-CA: 23.7;SH-SY5Y: 25.7;U-2 OS: 30.2;WM-115: 25.2
RASAL3	FLJ21438	ENSG00000105122	RAS protein activator like 3	19	15451624-15464571	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043417	Enhanced				Renal cancer:1.16e-6 (unfavourable), Endometrial cancer:3.58e-5 (favourable), Head and neck cancer:3.07e-4 (favourable), Cervical cancer:8.75e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 37.5	spleen: 24.6	Cell line enhanced		HDLM-2: 28.2;HEL: 22.6;HMC-1: 40.9;Karpas-707: 37.6;TIME: 28.9;U-937: 26.4
AKAP8	AKAP95, DKFZp586B1222	ENSG00000105127	A-kinase anchoring protein 8	19	15353385-15379798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004776	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 13.1	Expressed in all		
EPHX3	ABHD9, FLJ22408	ENSG00000105131	Epoxide hydrolase 3	19	15226919-15233435	Predicted secreted proteins	Evidence at transcript level	HPA012842	Uncertain				Head and neck cancer:2.27e-5 (favourable)	Tissue enhanced	Group enriched	7	esophagus: 35.1;skin: 62.8;tonsil: 24.3	parathyroid gland: 5.5	Cell line enhanced		EFO-21: 2.3;NTERA-2: 2.3;SCLC-21H: 1.2
ILVBL	209L8, AHAS, FLJ39061, HACL1L, ILV2H, MGC1269, MGC19535	ENSG00000105135	IlvB acetolactate synthase like	19	15114984-15125785	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067682	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.2	Expressed in all		
ZNF419	ZAPHIR, ZNF419A	ENSG00000105136	Zinc finger protein 419	19	57487711-57496097	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA003152, HPA003274	Uncertain		Supported	Nucleus<br>Nucleoli fibrillar center	Urothelial cancer:2.53e-5 (favourable), Prostate cancer:6.47e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.2	Mixed		
SYDE1	7h3, FLJ13511, SYD1	ENSG00000105137	Synapse defective Rho GTPase homolog 1	19	15107403-15114988	Predicted intracellular proteins	Evidence at protein level	HPA013328	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:5.63e-7 (unfavourable), Urothelial cancer:8.27e-4 (unfavourable)	Expressed in all	Mixed			placenta: 21.8	Cell line enhanced		U-138 MG: 104.0
CASP14	MGC119078, MGC119079, MICE	ENSG00000105141	Caspase 14	19	15049384-15058293	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010059, HPA027062	Enhanced		Approved	Nucleus<br>Mitochondria<br>Cytosol	Pancreatic cancer:5.96e-4 (unfavourable), Lung cancer:7.59e-4 (unfavourable)	Tissue enhanced	Tissue enriched	55	skin: 558.6	breast: 10.1	Cell line enriched	6	hTCEpi: 34.2
SLC1A6	EAAT4	ENSG00000105143	Solute carrier family 1 member 6	19	14950034-15022990	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041505, HPA044066	Enhanced		Uncertain	Intermediate filaments	Urothelial cancer:6.88e-6 (unfavourable)	Tissue enriched	Group enriched	5	cerebral cortex: 16.2;skin: 8.9;testis: 36.9	epididymis: 3.7	Group enriched	5	HAP1: 7.6;NTERA-2: 6.0;U-698: 19.3
AURKC	ARK3, AurC, STK13	ENSG00000105146	Aurora kinase C	19	57230802-57235548	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034859	Uncertain					Mixed	Tissue enriched	11	testis: 73.7	spleen: 6.9	Cell line enriched	7	NTERA-2: 39.0
POP4	RPP29	ENSG00000105171	POP4 homolog, ribonuclease P/MRP subunit	19	29604017-29617237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042748	Approved				Liver cancer:3.31e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 15.2	Expressed in all		
CCNE1	CCNE	ENSG00000105173	Cyclin E1	19	29811898-29824308	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000308, CAB016682, HPA018169	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.35e-6 (unfavourable), Liver cancer:3.89e-5 (unfavourable), Ovarian cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 44.6	testis: 22.5	Expressed in all		
URI1	C19orf2, FLJ10575, NNX3, PPP1R19, RMP, URI	ENSG00000105176	URI1, prefoldin like chaperone	19	29923644-30016608	Predicted intracellular proteins	Evidence at protein level	HPA071709	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
PDCD5	MGC9294, TFAR19	ENSG00000105185	Programmed cell death 5	19	32581068-32587452	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018471	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 175.1	Expressed in all		
ANKRD27	DKFZp434L0718, FLJ00040, VARP	ENSG00000105186	Ankyrin repeat domain 27	19	32597007-32676597	Predicted intracellular proteins	Evidence at protein level	HPA042769	Approved		Enhanced	Cytosol	Liver cancer:1.21e-5 (unfavourable), Endometrial cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
RPS16	S16	ENSG00000105193	Ribosomal protein S16	19	39433207-39435948	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA064222	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 3703.7	Expressed in all		
TIMM50	TIM50L	ENSG00000105197	Translocase of inner mitochondrial membrane 50	19	39480412-39493785	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048843, HPA056448	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
LGALS13	PLAC8, PP13	ENSG00000105198	Galectin 13	19	39602501-39607476	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	34	placenta: 16.6	testis: 0.4	Not detected		
FBL	FIB, FLRN, RNU3IP1	ENSG00000105202	Fibrillarin	19	39834458-39846414	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001514, HPA049546	Supported		Enhanced	Nucleoli fibrillar center	Renal cancer:4.52e-6 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Breast cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			ovary: 212.6	Expressed in all		
DYRK1B	MIRK	ENSG00000105204	Dual specificity tyrosine phosphorylation regulated kinase 1B	19	39825350-39834201	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028522, HPA028786	Uncertain		Approved	Nucleus	Renal cancer:8.83e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 37.4	testis: 33.6	Cell line enhanced		SCLC-21H: 15.0;SH-SY5Y: 15.3
CLC	Gal-10, LGALS10, MGC149659	ENSG00000105205	Charcot-Leyden crystal galectin	19	39731250-39738028	Predicted intracellular proteins	Evidence at protein level	HPA041751	Enhanced					Tissue enhanced	Tissue enriched	5	bone marrow: 285.9	urinary bladder: 55.3	Cell line enriched	14	HMC-1: 6580.2
CNTD2	CCNP, FLJ13265	ENSG00000105219	Cyclin N-terminal domain containing 2	19	40222208-40226690	Predicted intracellular proteins	Evidence at transcript level	HPA045615	Uncertain					Mixed	Not detected			adipose tissue: 0.9	Cell line enhanced		SCLC-21H: 2.5
GPI	AMF, NLK	ENSG00000105220	Glucose-6-phosphate isomerase	19	34359480-34402156	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018655, HPA024305, CAB040563, HPA052171	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 314.1	Expressed in all		
AKT2		ENSG00000105221	AKT serine/threonine kinase 2	19	40230317-40285536	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004204, HPA064521	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 170.1	Expressed in all		
PLD3	HU-K4	ENSG00000105223	Phospholipase D family member 3	19	40348456-40380439	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012800, CAB020812	Approved				Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 494.9	Expressed in all		
PRX	KIAA1620	ENSG00000105227	Periaxin	19	40393768-40413366	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001868	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		lung: 28.8	parathyroid gland: 9.4	Mixed		
PIAS4	FLJ12419, Piasg, PIASY, ZMIZ6	ENSG00000105229	Protein inhibitor of activated STAT 4	19	4007646-4039386	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010598	Approved		Approved	Nucleoplasm	Endometrial cancer:1.18e-5 (favourable), Pancreatic cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.3	Expressed in all		
NUMBL	CAG3A, CTG3a, NUMB-R, NUMBLIKE, NUMBR, TNRC23	ENSG00000105245	NUMB like, endocytic adaptor protein	19	40665905-40690972	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058251, HPA058380	Approved				Renal cancer:7.55e-15 (unfavourable), Ovarian cancer:1.52e-4 (unfavourable), Colorectal cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.7	Expressed in all		
EBI3	IL27B, IL35B	ENSG00000105246	Epstein-Barr virus induced 3	19	4229498-4237531	Predicted secreted proteins	Evidence at protein level	HPA046635	Enhanced				Renal cancer:1.04e-8 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 209.2	spleen: 26.1	Cell line enriched	13	HDLM-2: 197.3
CCDC94	FLJ10374	ENSG00000105248	Coiled-coil domain containing 94	19	4247079-4269090	Predicted intracellular proteins	Evidence at protein level	HPA043606, HPA055675	Approved		Supported	Nucleoplasm	Renal cancer:6.32e-4 (favourable), Stomach cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 28.0	Expressed in all		
SHD		ENSG00000105251	Src homology 2 domain containing transforming protein D	19	4278601-4290724	Predicted intracellular proteins	Evidence at protein level	HPA017955	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 22.1	heart muscle: 3.8	Group enriched	57	RH-30: 51.7;SH-SY5Y: 181.9
TBCB	CG22, CKAP1, CKAPI	ENSG00000105254	Tubulin folding cofactor B	19	36114289-36125947	Predicted intracellular proteins	Evidence at protein level	HPA041428, HPA041722	Approved		Supported	Cytosol	Liver cancer:2.09e-4 (unfavourable), Pancreatic cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 249.9	Expressed in all		
FSD1	MGC3213, MIR1	ENSG00000105255	Fibronectin type III and SPRY domain containing 1	19	4304600-4323843	Predicted intracellular proteins	Evidence at protein level	HPA043141	Supported				Endometrial cancer:1.61e-4 (unfavourable)	Group enriched	Group enriched	12	cerebral cortex: 25.4;testis: 9.1	lymph node: 1.4	Cell line enhanced		SCLC-21H: 65.0;SH-SY5Y: 60.9
POLR2I	hRPB14.5, RPB9	ENSG00000105258	RNA polymerase II subunit I	19	36113710-36115346	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA035632, HPA045156	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 18.4	Expressed in all		
OVOL3	HOVO3	ENSG00000105261	Ovo like zinc finger 3	19	36111151-36113711	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Group enriched	5	skin: 1.0;testis: 2.8	appendix: 0.3	Cell line enhanced		U-266/84: 2.1
CLIP3	CLIPR-59, RSNL1	ENSG00000105270	CAP-Gly domain containing linker protein 3	19	36014660-36033343	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.56e-10 (unfavourable), Pancreatic cancer:2.80e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 247.6	smooth muscle: 56.2	Cell line enhanced		ASC TERT1: 58.0;HSkMC: 67.3
ZFR2	KIAA1086	ENSG00000105278	Zinc finger RNA binding protein 2	19	3804024-3869032	Predicted intracellular proteins	Evidence at protein level	HPA043275, HPA055678	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Group enriched	9	adrenal gland: 3.8;cerebral cortex: 12.7;testis: 19.0	fallopian tube: 1.3	Group enriched	12	HMC-1: 24.1;NTERA-2: 47.6;SiHa: 15.2
SLC1A5	AAAT, ASCT2, M7V1, RDRC	ENSG00000105281	Solute carrier family 1 member 5	19	46774883-46788594	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035239, HPA035240	Enhanced		Enhanced	Plasma membrane	Liver cancer:1.66e-8 (unfavourable), Renal cancer:1.18e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 119.2	Expressed in all		
PRKD2	DKFZP586E0820, HSPC187, PKD2	ENSG00000105287	Protein kinase D2	19	46674275-46717127	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021490, HPA056727	Enhanced		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.3	Expressed in all		
TJP3	ZO-3	ENSG00000105289	Tight junction protein 3	19	3708109-3750813	Predicted intracellular proteins	Evidence at protein level	CAB013244, HPA046863, HPA053337	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Renal cancer:9.36e-8 (favourable), Endometrial cancer:1.83e-6 (favourable), Head and neck cancer:9.52e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 41.5;small intestine: 41.3	colon: 30.6	Cell line enhanced		BEWO: 42.4;CAPAN-2: 39.5;SK-BR-3: 19.4;T-47d: 51.5
APLP1	APLP	ENSG00000105290	Amyloid beta precursor like protein 1	19	35867899-35879791	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028970, HPA028971	Enhanced				Urothelial cancer:2.65e-5 (unfavourable), Endometrial cancer:3.87e-4 (unfavourable)	Tissue enhanced	Tissue enriched	13	cerebral cortex: 440.4	adrenal gland: 34.5	Cell line enhanced		AN3-CA: 137.3;SCLC-21H: 100.6;SH-SY5Y: 91.5
CACTIN	C19orf29, cactin, fSAPc, NY-REN-24	ENSG00000105298	Cactin, spliceosome C complex subunit	19	3610641-3626815	Predicted intracellular proteins	Evidence at protein level	HPA042504, HPA042548	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Endometrial cancer:3.69e-5 (favourable)	Expressed in all	Expressed in all			spleen: 14.4	Expressed in all		
CCDC9	DKFZP586M1019	ENSG00000105321	Coiled-coil domain containing 9	19	47255980-47271953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045624, HPA072007	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 30.3	Expressed in all		
HNRNPUL1	E1B-AP5, E1BAP5, FLJ12944, HNRPUL1	ENSG00000105323	Heterogeneous nuclear ribonucleoprotein U like 1	19	41262496-41307598	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046290, CAB046477, HPA049475	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 150.1	Expressed in all		
FZR1	CDC20C, CDH1, FZR, FZR2, HCDH, HCDH1, KIAA1242	ENSG00000105325	Fizzy and cell division cycle 20 related 1	19	3506273-3538330	Predicted intracellular proteins	Evidence at protein level	HPA043536	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Cervical cancer:1.75e-4 (favourable), Endometrial cancer:2.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
BBC3	JFY1, PUMA	ENSG00000105327	BCL2 binding component 3	19	47220822-47232766	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007752, HPA070403	Approved		Approved	Cytosol	Urothelial cancer:2.62e-5 (favourable), Endometrial cancer:1.31e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,skin: 4.7	Mixed		
TGFB1	CED, DPD1, TGFB, TGFbeta	ENSG00000105329	Transforming growth factor beta 1	19	41301587-41353911	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000361, CAB073543	Approved		Uncertain	Cytosol	Renal cancer:1.19e-8 (unfavourable), Head and neck cancer:3.38e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 83.5	Mixed		
DENND3	KIAA0870	ENSG00000105339	DENN domain containing 3	8	141117278-141195808	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024491, HPA041668		Approved	Approved	Vesicles<br>Cytosol		Expressed in all	Mixed			bone marrow: 68.5	Cell line enhanced		HDLM-2: 60.7;HeLa: 52.8
ATP5SL	FLJ10241	ENSG00000105341	ATP5S like	19	41431318-41440717	Predicted intracellular proteins	Evidence at protein level	HPA041427	Approved		Approved	Mitochondria	Renal cancer:4.07e-5 (favourable), Liver cancer:1.77e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 50.5	Expressed in all		
CEACAM4	CGM7	ENSG00000105352	Carcinoembryonic antigen related cell adhesion molecule 4	19	41618971-41627074	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	6	appendix: 6.7;bone marrow: 13.9;spleen: 9.0	adipose tissue: 1.7	Cell line enriched	7	U-937: 3.2
PLIN3	M6PRBP1, PP17, TIP47	ENSG00000105355	Perilipin 3	19	4838341-4867768	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006427, HPA066538	Uncertain		Enhanced	Lipid droplets<br>Cytosol	Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 115.7	Expressed in all		
MYH14	DFNA4, FLJ13881, KIAA2034, MHC16, MYH17	ENSG00000105357	Myosin heavy chain 14	19	50188186-50310545	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062391, HPA067889, HPA070260	Enhanced		Approved	Nucleoplasm	Renal cancer:3.97e-8 (favourable), Stomach cancer:7.83e-4 (favourable)	Expressed in all	Mixed			small intestine: 83.5	Cell line enhanced		CAPAN-2: 50.4;HaCaT: 91.2;MCF7: 44.9;RT4: 116.8
MRPL4	CGI-28	ENSG00000105364	Mitochondrial ribosomal protein L4	19	10251901-10260045	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051261	Approved		Supported	Nucleus<br>Nucleoli<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 38.9	Expressed in all		
SIGLEC8	MGC59785, SAF2, SIGLEC-8, SIGLEC8L	ENSG00000105366	Sialic acid binding Ig like lectin 8	19	51450847-51458456	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012556	Approved		Uncertain	Cytosol		Tissue enhanced	Mixed			lymph node: 7.5	Cell line enriched	60	HMC-1: 129.9
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
LIM2	MP17, MP19	ENSG00000105370	Lens intrinsic membrane protein 2	19	51379909-51387960	Disease related genes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Not detected			testis: 0.4	Not detected		
ICAM4	CD242, LW	ENSG00000105371	Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)	19	10286967-10288522	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 8.7;lung: 14.5	epididymis: 2.9	Cell line enhanced		HEL: 67.4;K-562: 35.3;NB-4: 20.5
RPS19	DBA, S19	ENSG00000105372	Ribosomal protein S19	19	41859918-41872926	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063217			Supported	Nucleoplasm	Renal cancer:2.32e-8 (unfavourable)	Expressed in all	Expressed in all			ovary: 3251.4	Expressed in all		
GLTSCR2	PICT-1	ENSG00000105373	Glioma tumor suppressor candidate region gene 2	19	47745522-47757058	Predicted intracellular proteins	Evidence at protein level	HPA018999, HPA049600	Approved		Enhanced	Nucleoli	Endometrial cancer:2.35e-4 (favourable)	Expressed in all	Expressed in all			ovary: 534.2	Expressed in all		
NKG7	GIG1, GMP-17	ENSG00000105374	Natural killer cell granule protein 7	19	51371606-51372715	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071454			Approved	Vesicles	Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 351.3;spleen: 151.2	lymph node: 122.0	Cell line enhanced		NB-4: 109.5;THP-1: 34.5;U-937: 34.9
ICAM5	TLCN, TLN	ENSG00000105376	Intercellular adhesion molecule 5	19	10289981-10296778	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008943, HPA009083, CAB025178	Enhanced					Tissue enhanced	Tissue enriched	10	cerebral cortex: 21.6	lung: 2.0	Cell line enhanced		HEL: 14.8;K-562: 12.0;RPMI-8226: 10.5;U-266/70: 13.3;U-87 MG: 10.1
ETFB		ENSG00000105379	Electron transfer flavoprotein beta subunit	19	51345169-51366418	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018910, HPA018921, HPA018923	Supported		Enhanced	Mitochondria	Renal cancer:6.45e-5 (favourable), Cervical cancer:6.45e-4 (favourable)	Expressed in all	Expressed in all			liver: 172.1	Expressed in all		
CD33	FLJ00391, p67, SIGLEC-3, SIGLEC3	ENSG00000105383	CD33 molecule	19	51225064-51243860	CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011442, HPA035832, HPA064807	Approved		Supported	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		spleen: 33.1	bone marrow: 20.9	Cell line enhanced		HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
CEACAM5	CD66e, CEA	ENSG00000105388	Carcinoembryonic antigen related cell adhesion molecule 5	19	41708585-41729798	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000021, CAB000022, HPA011041, HPA019758	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 1012.7;rectum: 1086.0	appendix: 257.7	Cell line enriched	6	HaCaT: 11.8
CRX	CORD2, CRD, LCA7, OTX3	ENSG00000105392	Cone-rod homeobox	19	47819779-47843330	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036762, HPA036763	Enhanced					Not detected	Not detected			testis: 0.3	Not detected		
BABAM1	C19orf62, FLJ20571, HSPC142, MERIT40, NBA1	ENSG00000105393	BRISC and BRCA1 A complex member 1	19	17267350-17281249	Predicted intracellular proteins	Evidence at protein level	HPA054386, HPA068786	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 84.2	Expressed in all		
TYK2	JTK1	ENSG00000105397	Tyrosine kinase 2	19	10350529-10380676	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005157	Uncertain		Supported	Cytosol	Head and neck cancer:1.05e-5 (favourable), Pancreatic cancer:1.02e-4 (favourable), Urothelial cancer:4.16e-4 (favourable), Renal cancer:4.43e-4 (unfavourable), Endometrial cancer:9.62e-4 (favourable)	Expressed in all	Expressed in all			spleen: 68.2	Expressed in all		
SULT2A1	DHEA-ST, STD	ENSG00000105398	Sulfotransferase family 2A member 1	19	47870466-47886397	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018755, HPA041487, HPA063633	Enhanced		Supported	Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 189.9;liver: 514.2	small intestine: 91.1	Group enriched	30	Hep G2: 25.8;RT4: 20.3
CDC37	P50CDC37	ENSG00000105401	Cell division cycle 37	19	10391134-10420121	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003928, CAB004214	Supported		Enhanced	Cytosol	Stomach cancer:2.33e-4 (favourable)	Expressed in all	Expressed in all			appendix: 110.5	Expressed in all		
NAPA		ENSG00000105402	NSF attachment protein alpha	19	47487637-47515240	Predicted intracellular proteins	Evidence at protein level	CAB010100, HPA046149, HPA050196	Approved		Uncertain	Cytosol	Renal cancer:4.26e-9 (favourable)	Expressed in all	Expressed in all			prostate: 157.4	Expressed in all		
RABAC1	PRA1, PRAF1, YIP3	ENSG00000105404	Rab acceptor 1	19	41956681-41959390	Predicted membrane proteins, Transporters	Evidence at protein level	CAB019320, HPA029171	Enhanced		Approved	Nuclear membrane<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			cerebral cortex: 107.2	Expressed in all		
ATP1A3	DYT12	ENSG00000105409	ATPase Na+/K+ transporting subunit alpha 3	19	41966582-41997497	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033630, HPA045367, HPA056446	Enhanced				Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 378.4;heart muscle: 86.0	testis: 54.5	Cell line enhanced		Daudi: 39.5;SCLC-21H: 148.3;SH-SY5Y: 57.8
MEIS3	DKFZp547H236, MRG2	ENSG00000105419	Meis homeobox 3	19	47403124-47419523	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA046699	Uncertain		Approved	Nucleoplasm	Renal cancer:1.78e-6 (unfavourable)	Mixed	Tissue enhanced		endometrium: 82.4	cerebral cortex: 64.8	Cell line enhanced		AF22: 74.7
PTPRS		ENSG00000105426	Protein tyrosine phosphatase, receptor type S	19	5158495-5340803	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054747			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 70.7	Cell line enhanced		AN3-CA: 112.7;HaCaT: 110.4
CNFN	PLAC8L2	ENSG00000105427	Cornifelin	19	42387019-42390287	Predicted intracellular proteins	Evidence at protein level	HPA049073, HPA053997	Enhanced		Approved	Microtubules<br>Cytokinetic bridge	Thyroid cancer:4.02e-5 (favourable)	Expressed in all	Group enriched	32	esophagus: 1158.0;skin: 272.5;tonsil: 260.7	breast: 17.6	Cell line enhanced		A549: 17.1;HEK 293: 24.4
ZNRF4	RNF204, spzn, Ssrzf1	ENSG00000105428	Zinc and ring finger 4	19	5455431-5456856	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	494	testis: 49.3	all non-specific tissues: 0.0	Not detected		
MEGF8	C19orf49, EGFL4, FLJ22365, SBP1	ENSG00000105429	Multiple EGF like domains 8	19	42325609-42378769	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049248	Approved				Renal cancer:2.17e-7 (favourable), Pancreatic cancer:6.03e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 38.0	Expressed in all		
KDELR1	ERD2, ERD2.1, HDEL	ENSG00000105438	KDEL endoplasmic reticulum protein retention receptor 1	19	48382570-48391553	Predicted membrane proteins, Transporters	Evidence at protein level	CAB017455	Approved		Supported	Golgi apparatus<br>Vesicles	Liver cancer:1.61e-4 (unfavourable), Head and neck cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 264.3	Expressed in all		
CYTH2	ARNO, CTS18.1, cytohesin-2, PSCD2, PSCD2L, Sec7p-L, Sec7p-like	ENSG00000105443	Cytohesin 2	19	48469032-48482314	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014872, HPA060662	Uncertain		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Liver cancer:1.19e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Expressed in all	Mixed			testis: 31.2	Expressed in all		
GRWD1	GRWD, RRB1, WDR28	ENSG00000105447	Glutamate rich WD repeat containing 1	19	48445773-48457022	Predicted intracellular proteins	Evidence at protein level	HPA042643, HPA055680	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.2	Expressed in all		
GRIN2D	EB11, GluN2D, NMDAR2D, NR2D	ENSG00000105464	Glutamate ionotropic receptor NMDA type subunit 2D	19	48394875-48444931	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 2.3	placenta: 1.3	Cell line enhanced		A549: 16.7;HMC-1: 27.0
SYNGR4		ENSG00000105467	Synaptogyrin 4	19	48364395-48376376	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030075, HPA059286	Enhanced		Approved	Golgi apparatus		Mixed	Tissue enriched	10	testis: 46.8	parathyroid gland: 4.5	Group enriched	6	A549: 9.0;SCLC-21H: 28.5
CLEC11A	CLECSF3, LSLCL, P47, SCGF	ENSG00000105472	C-type lectin domain family 11 member A	19	50723329-50725718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042690	Approved		Approved	Centrosome	Renal cancer:1.02e-5 (unfavourable), Endometrial cancer:6.91e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 81.5	cervix, uterine: 18.6	Cell line enhanced		HEL: 313.4;HMC-1: 544.7;NB-4: 546.3;THP-1: 465.7;U-937: 280.7
CCDC114	CILD20, FLJ32926	ENSG00000105479	Coiled-coil domain containing 114	19	48296457-48321894	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042524	Approved					Tissue enhanced	Group enriched	5	fallopian tube: 6.3;testis: 5.7	lung: 1.1	Cell line enhanced		U-266/70: 1.0
CARD8	CARDINAL, Dakar, KIAA0955, NDPP, TUCAN	ENSG00000105483	Caspase recruitment domain family member 8	19	48180770-48255946	Predicted intracellular proteins	Evidence at protein level	HPA042071, HPA043513	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.63e-8 (unfavourable), Urothelial cancer:1.72e-5 (favourable)	Expressed in all	Expressed in all			spleen: 49.1	Expressed in all		
LIG1		ENSG00000105486	DNA ligase 1	19	48115445-48170603	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037015, HPA041431, HPA048071	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.75e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 20.9	Mixed		
SIGLEC6	CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6	ENSG00000105492	Sialic acid binding Ig like lectin 6	19	51519525-51531856	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009084, HPA018198	Enhanced					Tissue enhanced	Tissue enriched	25	placenta: 147.9	lung: 6.0	Cell line enriched	7	HMC-1: 401.5
ZNF175	OTK18	ENSG00000105497	Zinc finger protein 175	19	51571298-51592508	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002717	Uncertain		Supported	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Thyroid cancer:6.64e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 19.7	Cell line enhanced		HEL: 45.3
PLA2G4C	cPLA2-gamma	ENSG00000105499	Phospholipase A2 group IVC	19	48047843-48110817	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043083	Approved		Approved	Cytosol		Mixed	Mixed			parathyroid gland: 29.7	Cell line enhanced		HHSteC: 12.1;TIME: 17.1
SIGLEC5	CD170, CD33L2, OB-BP2, SIGLEC-5	ENSG00000105501	Sialic acid binding Ig like lectin 5	19	51611927-51645545	CD markers, Predicted membrane proteins	Evidence at protein level	HPA009085, CAB024900	Supported					Tissue enhanced	Tissue enhanced		appendix: 9.3;bone marrow: 9.7;spleen: 8.8	lymph node: 3.5	Group enriched	7	HMC-1: 52.0;U-937: 19.9
CABP5	CABP3	ENSG00000105507	Calcium binding protein 5	19	48029953-48044053	Predicted intracellular proteins	Evidence at protein level	HPA043698	Supported					Not detected	Not detected			bone marrow,epididymis,spleen: 0.1	Not detected		
HAS1	HAS	ENSG00000105509	Hyaluronan synthase 1	19	51713112-51723994	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067602	Approved		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		adipose tissue: 27.0	appendix: 8.9	Group enriched	12	hTEC/SVTERT24-B: 27.0;U-87 MG: 110.6
RAB3D	D2-2, GOV, RAB16, RAD3D	ENSG00000105514	RAB3D, member RAS oncogene family	19	11322046-11346270	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018067, HPA063283	Approved		Approved	Vesicles	Glioma:3.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 62.5	esophagus: 28.1	Cell line enhanced		SK-BR-3: 51.2
DBP	DABP	ENSG00000105516	D-box binding PAR bZIP transcription factor	19	48630030-48637438	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Lung cancer:1.16e-5 (favourable), Renal cancer:2.41e-5 (favourable), Head and neck cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.4	Cell line enhanced		NB-4: 148.5
TMEM205	MBC3205, UNQ501	ENSG00000105518	Transmembrane protein 205	19	11342776-11346518	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA041504	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 258.0	Expressed in all		
CAPS	CAPS1, MGC126562	ENSG00000105519	Calcyphosine	19	5911707-5915877	Predicted intracellular proteins	Evidence at protein level	HPA043520	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:7.63e-5 (favourable), Head and neck cancer:8.60e-4 (favourable)	Tissue enriched	Tissue enriched	10	fallopian tube: 448.7	lung: 45.1	Cell line enhanced		SK-BR-3: 46.0
PLPPR2	LPPR2, PRG-4	ENSG00000105520	Phospholipid phosphatase related 2	19	11355386-11365698	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA048973	Uncertain		Approved	Nucleoplasm	Renal cancer:7.46e-11 (unfavourable), Colorectal cancer:6.45e-4 (unfavourable), Pancreatic cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.2	Cell line enhanced		U-2197: 88.4
FAM83E	FLJ20200	ENSG00000105523	Family with sequence similarity 83 member E	19	48600810-48614854	Predicted intracellular proteins	Evidence at protein level	HPA049305	Uncertain					Mixed	Tissue enhanced		duodenum: 30.8;small intestine: 35.3;stomach: 40.7	colon: 22.5	Cell line enhanced		CAPAN-2: 2.9
RASIP1	FLJ20401, RAIN	ENSG00000105538	Ras interacting protein 1	19	48720587-48740721	Predicted intracellular proteins	Evidence at protein level	HPA077251	Approved				Head and neck cancer:7.17e-5 (favourable), Pancreatic cancer:9.46e-4 (favourable)	Expressed in all	Mixed			spleen: 17.8	Cell line enhanced		HEK 293: 12.7;HUVEC TERT2: 30.5;SiHa: 20.8;TIME: 40.9
THEG	CT56, THEG1	ENSG00000105549	Theg spermatid protein	19	361747-376670	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	9	testis: 33.5	skin: 3.9	Cell line enriched	5	HDLM-2: 79.5
FGF21		ENSG00000105550	Fibroblast growth factor 21	19	48755559-48758330	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA061286	Supported					Tissue enriched	Tissue enriched	38	liver: 6.6	thyroid gland: 0.1	Group enriched	8	HHSteC: 1.2;U-2 OS: 5.2
BCAT2	BCAM, BCT2	ENSG00000105552	Branched chain amino acid transaminase 2	19	48795062-48811029	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054091	Enhanced				Renal cancer:3.68e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.1	Expressed in all		
MIER2	KIAA1193	ENSG00000105556	MIER family member 2	19	301444-344815	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041439	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.22e-6 (unfavourable), Endometrial cancer:1.72e-5 (favourable), Colorectal cancer:2.89e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Mixed		
PLEKHA4	PEPP1	ENSG00000105559	Pleckstrin homology domain containing A4	19	48837097-48868632	Predicted intracellular proteins	Evidence at protein level	HPA042978, HPA048473	Uncertain		Approved	Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol	Breast cancer:1.97e-4 (favourable), Liver cancer:8.68e-4 (unfavourable)	Expressed in all	Mixed			ovary: 22.3	Cell line enhanced		AN3-CA: 58.6;BJ hTERT+ SV40 Large T+ RasG12V: 48.0;SK-MEL-30: 57.7
PPP2R1A	PP2A-Aalpha, PP2AA, PR65A	ENSG00000105568	Protein phosphatase 2 scaffold subunit Aalpha	19	52190039-52229533	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018599			Approved	Cytosol	Renal cancer:1.20e-4 (favourable), Liver cancer:1.76e-4 (unfavourable), Lung cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 207.6	Expressed in all		
TNPO2	FLJ12155, IPO3, KPNB2B, TRN2	ENSG00000105576	Transportin 2	19	12699194-12724011	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB046446, HPA071498	Approved		Approved	Nucleus<br>Nucleoli	Endometrial cancer:7.16e-5 (unfavourable), Renal cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 90.9	Expressed in all		
WDR83OS	C19orf56, PTD008	ENSG00000105583	WD repeat domain 83 opposite strand	19	12668071-12671356	Predicted membrane proteins	Evidence at protein level	HPA065685	Approved		Approved	Endoplasmic reticulum	Lung cancer:2.09e-4 (favourable), Ovarian cancer:8.84e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 320.1	Expressed in all		
CACNG7		ENSG00000105605	Calcium voltage-gated channel auxiliary subunit gamma 7	19	53909335-53943941	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	101	cerebral cortex: 63.7	adrenal gland: 0.6	Cell line enhanced		AF22: 52.2;HMC-1: 36.0;NTERA-2: 14.0;SH-SY5Y: 34.2
GCDH	ACAD5	ENSG00000105607	Glutaryl-CoA dehydrogenase	19	12891026-12914207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043252, HPA048492	Enhanced		Supported	Mitochondria	Renal cancer:6.79e-8 (favourable), Liver cancer:7.28e-5 (favourable), Lung cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			liver: 42.9	Expressed in all		
LILRB5	CD85c, LIR-8, LIR8	ENSG00000105609	Leukocyte immunoglobulin like receptor B5	19	54249431-54257301	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012069	Approved					Mixed	Tissue enhanced		spleen: 26.1	adipose tissue: 11.4	Not detected		
KLF1	EKLF	ENSG00000105610	Kruppel like factor 1	19	12884423-12887181	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051850	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enriched	24	bone marrow: 25.7	placenta: 1.0	Group enriched	33	HEL: 56.0;K-562: 136.3
DNASE2	DNL, DNL2	ENSG00000105612	Deoxyribonuclease 2, lysosomal	19	12875211-12881468	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA066185	Enhanced					Expressed in all	Expressed in all			thyroid gland: 59.0	Expressed in all		
MAST1	KIAA0973, SAST	ENSG00000105613	Microtubule associated serine/threonine kinase 1	19	12833951-12874951	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028181, HPA073106	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	cerebral cortex: 35.2	testis: 3.0	Cell line enhanced		AN3-CA: 21.6;SCLC-21H: 47.7;SH-SY5Y: 21.4
LENG1		ENSG00000105617	Leukocyte receptor cluster member 1	19	54155161-54159882	Predicted intracellular proteins	Evidence at protein level	HPA043541	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:3.72e-4 (favourable), Pancreatic cancer:8.12e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 1.8	endometrium: 1.0	Cell line enhanced		AF22: 3.2;HaCaT: 4.1;HDLM-2: 2.8;LHCN-M2: 2.3;U-87 MG: 3.1
PRPF31	hPrp31, NY-BR-99, PRP31, RP11, SNRNP61	ENSG00000105618	Pre-mRNA processing factor 31	19	54115410-54131719	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041939, HPA061873	Supported		Supported	Nucleus	Liver cancer:7.33e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.7	Expressed in all		
TFPT	amida, FB1, INO80F	ENSG00000105619	TCF3 fusion partner	19	54107013-54115675	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034958, HPA058534	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Pancreatic cancer:3.13e-4 (favourable), Colorectal cancer:5.13e-4 (unfavourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.6	Mixed		
JAK3	JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK	ENSG00000105639	Janus kinase 3	19	17824780-17848071	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070314	Enhanced				Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 48.4;lymph node: 46.6	tonsil: 27.2	Cell line enhanced		HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
RPL18A	L18A	ENSG00000105640	Ribosomal protein L18a	19	17859876-17864153	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055259	Approved		Approved	Nucleoli<br>Cytosol	Renal cancer:1.48e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3084.5	Expressed in all		
SLC5A5	NIS	ENSG00000105641	Solute carrier family 5 member 5	19	17871973-17895174	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022364, HPA049055	Enhanced					Mixed	Tissue enhanced		salivary gland: 28.3;stomach: 56.1;thyroid gland: 20.7	cervix, uterine: 8.3	Cell line enriched	5	BEWO: 10.8
KCNN1	hSK1, KCa2.1	ENSG00000105642	Potassium calcium-activated channel subfamily N member 1	19	17951293-18000080	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA065938			Approved	Actin filaments<br>Cytosol		Tissue enhanced	Tissue enriched	10	cerebral cortex: 21.4	testis: 2.0	Cell line enriched	13	REH: 141.4
ARRDC2	CLONE24945, PP2703	ENSG00000105643	Arrestin domain containing 2	19	18001132-18014102	Predicted intracellular proteins	Evidence at protein level	HPA053788	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.92e-4 (favourable), Ovarian cancer:5.84e-4 (unfavourable), Cervical cancer:5.93e-4 (favourable), Thyroid cancer:6.91e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 51.0	Mixed		
PIK3R2	p85, P85B	ENSG00000105647	Phosphoinositide-3-kinase regulatory subunit 2	19	18153118-18170540	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA069291	Approved		Approved	Golgi apparatus		Mixed	Expressed in all			cerebral cortex: 47.3	Expressed in all		
RAB3A		ENSG00000105649	RAB3A, member RAS oncogene family	19	18196784-18204074	Predicted intracellular proteins	Evidence at protein level	HPA003160, CAB009949, CAB078998	Enhanced	Supported	Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:6.14e-7 (favourable), Endometrial cancer:3.17e-4 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 250.5	adrenal gland: 20.6	Cell line enhanced		SCLC-21H: 43.5;U-2197: 23.9
PDE4C	DPDE1	ENSG00000105650	Phosphodiesterase 4C	19	18207961-18255419	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048975	Enhanced					Mixed	Mixed			endometrium: 7.4	Cell line enhanced		BEWO: 3.8;U-87 MG: 5.5
ISYNA1	Ino1, INOS, IPS	ENSG00000105655	Inositol-3-phosphate synthase 1	19	18434388-18438301	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007931, HPA008232, CAB020720	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:9.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 117.3	placenta: 63.8	Cell line enhanced		BEWO: 475.1
ELL	C19orf17, ELL1, Men, PPP1R68	ENSG00000105656	Elongation factor for RNA polymerase II	19	18442663-18522127	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046076	Uncertain					Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
CRTC1	FLJ14027, KIAA0616, MECT1, TORC1	ENSG00000105662	CREB regulated transcription coactivator 1	19	18683677-18782333	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022035	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 23.7	Expressed in all		
COMP	EDM1, EPD1, MED, PSACH, THBS5	ENSG00000105664	Cartilage oligomeric matrix protein	19	18782773-18791314	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077555			Approved	Golgi apparatus	Renal cancer:1.52e-6 (unfavourable), Colorectal cancer:9.08e-5 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable), Urothelial cancer:6.95e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 24.5	smooth muscle: 18.2	Cell line enriched	5	fHDF/TERT166: 666.2
UPK1A	TSPAN21	ENSG00000105668	Uroplakin 1A	19	35666516-35678483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049879	Enhanced					Tissue enriched	Tissue enhanced		esophagus: 26.9;urinary bladder: 108.7	skin: 15.6	Cell line enriched	9	RT4: 31.3
COPE	epsilon-COP	ENSG00000105669	Coatomer protein complex subunit epsilon	19	18899514-18919397	Predicted intracellular proteins	Evidence at protein level	CAB034345, HPA041605, HPA043576	Supported		Enhanced	Golgi apparatus	Cervical cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 122.6	Expressed in all		
DDX49	FLJ10432	ENSG00000105671	DEAD-box helicase 49	19	18919675-18928633	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041870, HPA048093	Enhanced		Approved	Nucleoli<br>Mitochondria	Cervical cancer:2.01e-6 (favourable), Renal cancer:7.44e-5 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
ETV2	ER71	ENSG00000105672	ETS variant 2	19	35641745-35644871	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		testis: 8.7	duodenum: 2.1	Mixed		
ATP4A	ATP6A	ENSG00000105675	ATPase H+/K+ transporting alpha subunit	19	35550043-35563658	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039154	Enhanced					Tissue enriched	Tissue enriched	260	stomach: 557.9	pancreas: 2.1	Not detected		
ARMC6	MGC19595	ENSG00000105676	Armadillo repeat containing 6	19	19033575-19060311	Predicted intracellular proteins	Evidence at protein level	HPA041420, HPA041681	Supported		Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 28.7	Expressed in all		
TMEM147	MGC1936, NIFIE14	ENSG00000105677	Transmembrane protein 147	19	35545595-35547526	Predicted membrane proteins	Evidence at protein level	HPA067837			Uncertain	Golgi apparatus<br>Actin filaments<br>Cytosol	Liver cancer:4.98e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 120.6	Expressed in all		
GAPDHS	GAPD2, GAPDH-2, GAPDS	ENSG00000105679	Glyceraldehyde-3-phosphate dehydrogenase, spermatogenic	19	35533412-35545316	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042666	Enhanced		Approved	Nucleoplasm<br>Centrosome		Tissue enriched	Tissue enriched	13	testis: 242.8	thyroid gland: 19.0	Mixed		
MAG	GMA, S-MAG, SIGLEC-4A, SIGLEC4A	ENSG00000105695	Myelin associated glycoprotein	19	35292125-35313804	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009345, HPA012499	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 163.6	ovary: 27.5	Cell line enriched	31	WM-115: 35.4
TMEM59L	BSMAP, C19orf4	ENSG00000105696	Transmembrane protein 59 like	19	18607430-18621039	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA010661, HPA070701	Approved		Approved	Nucleoplasm<br>Actin filaments	Endometrial cancer:1.62e-4 (unfavourable), Pancreatic cancer:8.80e-4 (favourable)	Tissue enriched	Tissue enriched	16	cerebral cortex: 366.3	adrenal gland: 22.2	Cell line enhanced		AN3-CA: 33.4;ASC diff: 29.2;EFO-21: 24.0;Hep G2: 18.4;SH-SY5Y: 22.4
HAMP	HEPC, HFE2B, LEAP-1, LEAP1	ENSG00000105697	Hepcidin antimicrobial peptide	19	35280716-35285143	Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Group enriched	Tissue enriched	12	liver: 259.1	heart muscle: 21.9	Cell line enriched	127	Hep G2: 135.7
USF2	bHLHb12, FIP	ENSG00000105698	Upstream transcription factor 2, c-fos interacting	19	35268978-35279821	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029764, HPA046567			Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.12e-5 (favourable), Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 215.5	Expressed in all		
LSR	ILDR3, LISCH7	ENSG00000105699	Lipolysis stimulated lipoprotein receptor	19	35248330-35267964	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007270	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			stomach: 128.7	Cell line enhanced		A-431: 435.7
KXD1	BORCS4, C19orf50, FLJ25480, KXDL, MGC2749	ENSG00000105700	KxDL motif containing 1	19	18557762-18569387	Predicted intracellular proteins	Evidence at protein level	HPA041507, HPA041599	Approved		Approved	Nucleoli fibrillar center<br>Centrosome<br>Cytosol	Renal cancer:7.71e-10 (unfavourable), Liver cancer:8.46e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 91.9	Expressed in all		
FKBP8	FKBP38, FKBPr38	ENSG00000105701	FK506 binding protein 8	19	18531751-18544077	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025346, HPA045177	Supported		Supported	Endoplasmic reticulum<br>Mitochondria<br>Cytosol	Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 354.7	Expressed in all		
SUGP1	DKFZp434E2216, F23858, RBP, SF4	ENSG00000105705	SURP and G-patch domain containing 1	19	19276018-19320844	Predicted intracellular proteins	Evidence at protein level	HPA004890	Approved		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 17.0	Expressed in all		
HPN	TMPRSS1	ENSG00000105707	Hepsin	19	35040506-35066571	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006804	Approved				Renal cancer:5.45e-5 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 99.7;liver: 155.4	prostate: 31.6	Group enriched	7	EFO-21: 29.1;Hep G2: 31.2;T-47d: 20.3
ZNF14	GIOT-4, KOX6	ENSG00000105708	Zinc finger protein 14	19	19710471-19733097	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049863	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:8.09e-6 (favourable), Lung cancer:7.96e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 13.3	Mixed		
SCN1B		ENSG00000105711	Sodium voltage-gated channel beta subunit 1	19	35030466-35040449	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.38e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 145.1	cerebral cortex: 52.4	Cell line enhanced		A549: 15.7;TIME: 21.3
PBX4		ENSG00000105717	PBX homeobox 4	19	19561707-19618916	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049859, HPA056469	Enhanced		Enhanced	Vesicles	Urothelial cancer:5.94e-7 (favourable), Cervical cancer:8.69e-6 (favourable)	Mixed	Tissue enhanced		testis: 2.6;thyroid gland: 2.2	lymph node: 0.8	Cell line enhanced		PC-3: 1.5;RT4: 1.6
ERF	PE-2, PE2	ENSG00000105722	ETS2 repressor factor	19	42247572-42255157	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058532, HPA067952	Approved		Enhanced	Nucleoplasm	Breast cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 78.9	Expressed in all		
GSK3A		ENSG00000105723	Glycogen synthase kinase 3 alpha	19	42230186-42242625	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004422, HPA028423	Approved		Approved	Cytosol	Liver cancer:1.13e-4 (unfavourable), Endometrial cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.5	Expressed in all		
ATP13A1	ATP13A, CGI-152, FLJ31858, KIAA1825	ENSG00000105726	ATPase 13A1	19	19645198-19663693	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031798, HPA049717	Approved		Approved	Vesicles	Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.5	Expressed in all		
ZNF574	FLJ22059	ENSG00000105732	Zinc finger protein 574	19	42068477-42081549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023196, HPA057274	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 36.5	Expressed in all		
GRIK5	GluK5, GRIK2, KA2	ENSG00000105737	Glutamate ionotropic receptor kainate type subunit 5	19	41998321-42069498	Predicted membrane proteins	Evidence at protein level	HPA074001			Supported	Nucleus<br>Plasma membrane	Pancreatic cancer:7.23e-4 (favourable), Renal cancer:9.32e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 30.8;parathyroid gland: 22.1	testis: 18.8	Cell line enhanced		HEL: 12.3;NTERA-2: 13.1;REH: 34.1;SCLC-21H: 12.1;SH-SY5Y: 24.1
SIPA1L3	KIAA0545	ENSG00000105738	Signal induced proliferation associated 1 like 3	19	37907228-38208372	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042072, HPA045480	Uncertain		Approved	Nuclear membrane<br>Nuclear speckles		Expressed in all	Mixed			small intestine: 19.8	Expressed in all		
ZNF85	HPF4, HTF1	ENSG00000105750	Zinc finger protein 85	19	20923222-20950697	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044760	Uncertain		Supported	Nucleus	Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 28.0	thyroid gland: 12.0	Mixed		
ETHE1	HSCO, YF13H12	ENSG00000105755	ETHE1, persulfide dioxygenase	19	43506719-43527244	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028360, HPA029028, HPA029029	Enhanced		Enhanced	Mitochondria	Lung cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 240.2	Mixed		
CADM4	IGSF4C, Necl-4, SynCAM4, TSLL2	ENSG00000105767	Cell adhesion molecule 4	19	43622368-43639839	Predicted membrane proteins	Evidence at protein level	HPA012612	Enhanced		Approved	Nucleus<br>Nuclear membrane	Renal cancer:2.28e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 163.6	parathyroid gland: 59.1	Cell line enriched	5	WM-115: 552.4
SMG9	C19orf61, FLJ12886	ENSG00000105771	SMG9, nonsense mediated mRNA decay factor	19	43727992-43754990	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041763, HPA042096	Uncertain		Approved	Mitochondria<br>Cytosol	Liver cancer:2.15e-5 (unfavourable), Renal cancer:1.71e-4 (unfavourable), Urothelial cancer:8.09e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	lymph node: 14.8	Expressed in all		
AVL9	KIAA0241	ENSG00000105778	AVL9 cell migration associated	7	32495426-32588721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050957	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 25.5	Mixed		
RUNDC3B	RPIB9, RPIP9	ENSG00000105784	RUN domain containing 3B	7	87627548-87832296	Predicted intracellular proteins	Evidence at protein level	HPA056968, HPA057155	Uncertain				Renal cancer:2.62e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 9.7	cerebral cortex: 7.2	Cell line enhanced		SCLC-21H: 3.1;SH-SY5Y: 1.3
CFAP69	C7orf63, FAP69, FLJ21062	ENSG00000105792	Cilia and flagella associated protein 69	7	90245174-90311063	Predicted intracellular proteins	Evidence at protein level	HPA062883	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 25.2	fallopian tube: 17.9	Mixed		
GTPBP10	DKFZP686A10121, FLJ38242, OBGH2	ENSG00000105793	GTP binding protein 10	7	90335223-90391455	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021076	Approved				Renal cancer:6.76e-5 (favourable)	Expressed in all	Expressed in all			testis: 20.3	Expressed in all		
RASA4	CAPRI, GAPL, KIAA0538	ENSG00000105808	RAS p21 protein activator 4	7	102573807-102616757	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA043010	Uncertain		Uncertain	Vesicles		Not detected	Expressed in all			skeletal muscle: 85.0	Cell line enhanced		SH-SY5Y: 34.2;U-138 MG: 44.7
CDK6	PLSTIRE	ENSG00000105810	Cyclin dependent kinase 6	7	92604921-92836594	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002637, CAB004363	Enhanced		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.2	Cell line enhanced		MOLT-4: 366.7;REH: 201.1
PMPCB	MPPB, MPPP52	ENSG00000105819	Peptidase, mitochondrial processing beta subunit	7	103297422-103329511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040674, HPA074168	Approved		Supported	Mitochondria	Renal cancer:2.95e-8 (favourable), Breast cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 70.0	Expressed in all		
DNAJC2	MPHOSPH11, MPP11, ZRF1, ZUO1, zuotin	ENSG00000105821	DnaJ heat shock protein family (Hsp40) member C2	7	103312474-103344873	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020454	Approved		Supported	Cytosol	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
TFPI2	PP5, REF1, TFPI-2	ENSG00000105825	Tissue factor pathway inhibitor 2	7	93885397-93890991	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010142, HPA049158	Enhanced				Breast cancer:8.33e-7 (favourable), Endometrial cancer:5.42e-4 (favourable), Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Tissue enriched	23	placenta: 1208.2	ovary: 52.0	Cell line enhanced		EFO-21: 1987.5;hTEC/SVTERT24-B: 1055.6;U-138 MG: 999.0;U-2197: 850.7;U-87 MG: 1680.0
BET1	hbet1	ENSG00000105829	Bet1 golgi vesicular membrane trafficking protein	7	93962762-94004382	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Glioma:9.38e-5 (unfavourable), Renal cancer:1.32e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.4	Expressed in all		
NAMPT	PBEF, PBEF1	ENSG00000105835	Nicotinamide phosphoribosyltransferase	7	106248285-106286326	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034349, HPA047776, HPA057722	Approved		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:2.49e-6 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable), Cervical cancer:4.78e-4 (unfavourable), Head and neck cancer:8.81e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 778.1	Expressed in all		
TWISTNB		ENSG00000105849	TWIST neighbor	7	19695462-19709087	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA019071, HPA022416	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 19.7	Expressed in all		
PIK3CG		ENSG00000105851	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	7	106865278-106907145	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069976			Supported	Plasma membrane		Mixed	Tissue enhanced		bone marrow: 28.1	lymph node: 22.0	Cell line enhanced		HMC-1: 30.6;MOLT-4: 44.8;U-266/70: 53.9;U-937: 40.5
PON3		ENSG00000105852	Paraoxonase 3	7	95359944-95396368	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA014848, CAB025250	Enhanced					Group enriched	Tissue enriched	8	liver: 328.5	breast: 43.4	Cell line enhanced		A549: 26.6;CACO-2: 7.9;Hep G2: 22.5;T-47d: 17.0
PON2		ENSG00000105854	Paraoxonase 2	7	95404863-95435329	Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025430, HPA029193	Enhanced				Renal cancer:4.30e-8 (unfavourable), Cervical cancer:1.43e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 226.2	Mixed		
ITGB8		ENSG00000105855	Integrin subunit beta 8	7	20330702-20415754	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA027796, HPA027797	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.77e-4 (favourable)	Mixed	Mixed			cerebral cortex: 30.8	Cell line enhanced		AF22: 45.0;EFO-21: 54.7;RPTEC TERT1: 68.8;WM-115: 130.0
HBP1		ENSG00000105856	HMG-box transcription factor 1	7	107168961-107202529	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020225, CAB032824	Approved		Enhanced	Nuclear speckles	Renal cancer:7.70e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.2	Expressed in all		
DUS4L	DUS4, PP35	ENSG00000105865	Dihydrouridine synthase 4 like	7	107563484-107578464	Predicted intracellular proteins	Evidence at protein level	HPA044301	Approved		Approved	Cytosol		Expressed in all	Mixed			thyroid gland: 2.4	Mixed		
SP4	HF1B, MGC130008, MGC130009, SPR-1	ENSG00000105866	Sp4 transcription factor	7	21428034-21514822	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010246, HPA040395	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 14.9	Cell line enhanced		REH: 24.6
WDR91	HSPC049, SORF-1	ENSG00000105875	WD repeat domain 91	7	135183839-135211534	Predicted intracellular proteins	Evidence at protein level	HPA024260	Uncertain				Liver cancer:1.53e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 14.7	Expressed in all		
DNAH11	CILD7, DNAHBL, Dnahc11, DNHBL, DPL11	ENSG00000105877	Dynein axonemal heavy chain 11	7	21543215-21901839	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045880, HPA056474	Approved				Renal cancer:1.49e-7 (unfavourable)	Mixed	Tissue enriched	17	parathyroid gland: 145.0	fallopian tube: 8.5	Cell line enhanced		U-2 OS: 1.1;U-2197: 1.2
CBLL1	FLJ23109, HAKAI, RNF188	ENSG00000105879	Cbl proto-oncogene like 1	7	107743697-107761667	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021773, HPA026699	Enhanced		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 36.2	Expressed in all		
DLX5		ENSG00000105880	Distal-less homeobox 5	7	97020392-97025097	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005670	Approved		Approved	Nucleus		Tissue enriched	Tissue enhanced		endometrium: 20.2;placenta: 13.5;skin: 17.1	cervix, uterine: 9.6	Group enriched	5	BEWO: 41.0;HAP1: 24.0
MTPN	GCDP, MYOTROPHIN, V-1	ENSG00000105887	Myotrophin	7	135926761-135977353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019735	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.19e-4 (unfavourable), Pancreatic cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.6	Expressed in all		
STEAP1B		ENSG00000105889	STEAP family member 1B	7	22419444-22632925	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 5.3	spleen: 3.4	Cell line enhanced		hTEC/SVTERT24-B: 75.9;HUVEC TERT2: 72.0;K-562: 46.3;WM-115: 93.7
PTN	HBGF8, HBNF, NEGF1	ENSG00000105894	Pleiotrophin	7	137227341-137343865	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB017685	Enhanced				Renal cancer:1.35e-4 (favourable)	Tissue enriched	Tissue enhanced		parathyroid gland: 725.3	cerebral cortex: 269.6	Cell line enriched	12	AF22: 1551.5
MPP6	p55T, PALS2, VAM-1	ENSG00000105926	Membrane palmitoylated protein 6	7	24573268-24694193	Predicted intracellular proteins	Evidence at protein level	HPA019085, HPA020456	Enhanced				Renal cancer:3.05e-5 (favourable), Head and neck cancer:8.85e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Thyroid cancer:5.28e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 29.9;testis: 45.3	cerebral cortex: 14.9	Expressed in all		
DFNA5	ICERE-1	ENSG00000105928	DFNA5, deafness associated tumor suppressor	7	24698353-24758113	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA011326, CAB019306	Approved		Enhanced	Cytosol	Liver cancer:2.49e-5 (unfavourable)	Mixed	Mixed			placenta: 58.7	Mixed		
ATP6V0A4	a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2	ENSG00000105929	ATPase H+ transporting V0 subunit a4	7	138706295-138799560	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018029, HPA064555	Enhanced		Approved	Cytosol	Renal cancer:1.32e-6 (favourable)	Tissue enriched	Group enriched	9	kidney: 69.6;salivary gland: 31.6	breast: 5.5	Cell line enriched	12	SK-BR-3: 42.2
ZC3HAV1	FLB6421, FLJ13288, MGC48898, PARP13, ZAP, ZC3H2, ZC3HDC2	ENSG00000105939	Zinc finger CCCH-type containing, antiviral 1	7	139043520-139109719	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047818, HPA059096	Approved		Enhanced	Golgi apparatus<br>Cytosol	Liver cancer:8.77e-7 (unfavourable), Stomach cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 54.6	Expressed in all		
TTC26	dyf-13, DYF13, FLJ12571, IFT56	ENSG00000105948	Tetratricopeptide repeat domain 26	7	139133744-139191986	Predicted intracellular proteins	Evidence at protein level	HPA036338, HPA036339	Enhanced		Approved	Nuclear speckles<br>Intermediate filaments<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 22.6;testis: 22.1	parathyroid gland: 13.6	Expressed in all		
OGDH	E1k	ENSG00000105953	Oxoglutarate dehydrogenase	7	44606572-44709066	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019514, HPA020347	Supported		Enhanced	Mitochondria	Renal cancer:2.22e-14 (favourable)	Expressed in all	Expressed in all			heart muscle: 147.8	Expressed in all		
NPVF	C7orf9, RFRP	ENSG00000105954	Neuropeptide VF precursor	7	25224570-25228486	Predicted secreted proteins	Evidence at protein level	HPA041733	Approved					Not detected	Not detected			tonsil: 0.3	Not detected		
ADAP1	CENTA1, GCS1L	ENSG00000105963	ArfGAP with dual PH domains 1	7	897901-955407	Predicted intracellular proteins	Evidence at protein level	HPA007033, HPA012049	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 80.4	colon: 37.9	Cell line enhanced		A-431: 97.9;CAPAN-2: 69.1;HMC-1: 64.7;THP-1: 87.7
TFEC	bHLHe34, TCFEC, TFECL	ENSG00000105967	Transcription factor EC	7	115935148-116159896	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032260, HPA063577	Approved		Supported	Nucleoplasm		Tissue enhanced	Mixed			appendix: 26.3	Cell line enhanced		HEL: 14.6;HUVEC TERT2: 9.2;THP-1: 14.4;TIME: 10.2;U-937: 19.1
H2AFV	H2AV, MGC10170, MGC10831, MGC1947	ENSG00000105968	H2A histone family member V	7	44826791-44848083	Predicted intracellular proteins	Evidence at protein level	HPA057236	Supported				Cervical cancer:4.66e-4 (favourable), Renal cancer:8.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 218.5	Expressed in all		
CAV2	CAV	ENSG00000105971	Caveolin 2	7	116287380-116508541	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013488, HPA044810	Enhanced		Approved	Vesicles	Head and neck cancer:5.80e-5 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 233.6	Mixed		
CAV1	CAV	ENSG00000105974	Caveolin 1	7	116524785-116561184	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB003791, HPA049326	Enhanced		Supported	Golgi apparatus	Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 859.9	adipose tissue: 640.4	Cell line enhanced		LHCN-M2: 1943.1
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
RNF32	FKSG33, HSD15, LMBR2	ENSG00000105982	Ring finger protein 32	7	156640281-156677130	Predicted intracellular proteins	Evidence at protein level	HPA073560	Enhanced				Colorectal cancer:2.21e-4 (unfavourable)	Mixed	Tissue enriched	8	testis: 110.5	epididymis: 13.4	Cell line enhanced		HDLM-2: 12.4
LMBR1	ACHP, C7orf2, FLJ11665, ZRS	ENSG00000105983	Limb development membrane protein 1	7	156668946-156893230	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016592	Approved		Approved	Cytosol	Renal cancer:1.44e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
WNT2	INT1L1, IRP	ENSG00000105989	Wnt family member 2	7	117276631-117323289	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA020920			Approved	Vesicles		Mixed	Group enriched	6	endometrium: 23.8;placenta: 93.2	lung: 9.2	Cell line enriched	6	U-2197: 19.1
HOXA1	HOX1, HOX1F	ENSG00000105991	Homeobox A1	7	27092993-27095996	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:6.73e-5 (unfavourable)	Mixed	Tissue enhanced		urinary bladder: 8.4	parathyroid gland,skin: 2.7	Mixed		
DNAJB6	LGMD1D, MRJ	ENSG00000105993	DnaJ heat shock protein family (Hsp40) member B6	7	157335381-157417439	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004670, HPA024258, HPA058593	Enhanced		Supported	Nucleoplasm	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 220.1	Expressed in all		
HOXA2	HOX1K	ENSG00000105996	Homeobox A2	7	27100354-27102811	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA078220			Approved	Nucleus<br>Vesicles		Mixed	Tissue enhanced		parathyroid gland: 8.1	epididymis: 6.2	Cell line enhanced		AN3-CA: 13.4;HaCaT: 5.3
HOXA3	HOX1, HOX1E	ENSG00000105997	Homeobox A3	7	27106184-27152581	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029157	Uncertain		Supported	Nucleoplasm	Renal cancer:2.52e-6 (unfavourable)	Mixed	Mixed			fallopian tube: 16.2	Cell line enhanced		AN3-CA: 35.4;CAPAN-2: 58.4;HEK 293: 27.2;WM-115: 35.0
LFNG	SCDO3	ENSG00000106003	LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	7	2512529-2529177	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069130	Approved				Endometrial cancer:6.36e-4 (favourable)	Expressed in all	Expressed in all			skin: 68.5	Cell line enhanced		RH-30: 44.5;U-2 OS: 52.5
HOXA5	HOX1, HOX1C	ENSG00000106004	Homeobox A5	7	27141052-27143668	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:2.28e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 109.7;epididymis: 60.1	fallopian tube: 44.1	Cell line enhanced		AN3-CA: 86.9;HEK 293: 146.8
HOXA6	HOX1, HOX1B	ENSG00000106006	Homeobox A6	7	27145396-27150603	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA004203	Approved				Endometrial cancer:1.40e-4 (unfavourable), Renal cancer:2.03e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 9.9	endometrium: 9.0	Group enriched	9	AN3-CA: 57.3;HEK 293: 77.5
BRAT1	BAAT1, C7orf27, MGC22916	ENSG00000106009	BRCA1 associated ATM activator 1	7	2537877-2555727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029455, HPA076508	Approved		Supported	Nucleoplasm	Renal cancer:3.90e-4 (unfavourable), Liver cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 14.9	Expressed in all		
IQCE	KIAA1023	ENSG00000106012	IQ motif containing E	7	2558972-2614734	Predicted intracellular proteins	Evidence at protein level	HPA019515	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
ANKRD7	TSA806	ENSG00000106013	Ankyrin repeat domain 7	7	118214669-118496171	Predicted intracellular proteins	Evidence at protein level	HPA043489			Approved	Nucleus		Tissue enhanced	Tissue enriched	643	testis: 1542.7	epididymis: 2.3	Cell line enhanced		SCLC-21H: 9.0;U-266/70: 7.5
VIPR2	VPAC2, VPAC2R	ENSG00000106018	Vasoactive intestinal peptide receptor 2	7	159028175-159144957	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062707	Approved					Tissue enhanced	Tissue enhanced		seminal vesicle: 28.3	epididymis: 14.9	Cell line enhanced		HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8
TSPAN12	NET-2, TM4SF12	ENSG00000106025	Tetraspanin 12	7	120787320-120858402	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051570, HPA058244	Uncertain		Approved	Vesicles<br>Microtubules		Expressed in all	Mixed			kidney: 91.5	Cell line enhanced		HEK 293: 47.4;HUVEC TERT2: 48.1;RH-30: 50.5;RPTEC TERT1: 63.2;RT4: 52.1
SSBP1	mtSSB, SSBP	ENSG00000106028	Single stranded DNA binding protein 1	7	141738321-141787922	Predicted intracellular proteins	Evidence at protein level	HPA002866	Enhanced		Supported	Mitochondria	Ovarian cancer:3.40e-4 (favourable), Liver cancer:4.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 147.7	Expressed in all		
HOXA13	HOX1, HOX1J	ENSG00000106031	Homeobox A13	7	27193503-27200106	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5	rectum: 13.0	Cell line enhanced		HAP1: 27.6;HEK 293: 34.0;RT4: 33.4
CPED1	C7orf58, FLJ21986	ENSG00000106034	Cadherin like and PC-esterase domain containing 1	7	120988677-121297444	Predicted intracellular proteins	Evidence at transcript level	HPA012058	Uncertain		Approved	Nucleus	Lung cancer:3.00e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)	Mixed	Mixed			ovary: 96.6	Cell line enhanced		BJ hTERT+: 70.8;K-562: 158.4
EVX1		ENSG00000106038	Even-skipped homeobox 1	7	27242700-27250493	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055132			Approved	Nucleoplasm		Mixed	Tissue enhanced		adrenal gland: 3.7;prostate: 4.5;seminal vesicle: 4.0	testis: 1.3	Cell line enriched	10	RT4: 11.7
HIBADH	NS5ATP1	ENSG00000106049	3-hydroxyisobutyrate dehydrogenase	7	27525442-27662995	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019522, HPA021002	Enhanced				Renal cancer:5.56e-11 (favourable)	Expressed in all	Expressed in all			kidney: 113.0	Expressed in all		
TAX1BP1	CALCOCO3, TXBP151	ENSG00000106052	Tax1 binding protein 1	7	27739331-27844564	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024432	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.80e-6 (favourable), Pancreatic cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 184.5	Expressed in all		
CPVL		ENSG00000106066	Carboxypeptidase, vitellogenic like	7	28995231-29195451	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003697, HPA045715, HPA056466	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:8.56e-6 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 301.8	Cell line enhanced		BEWO: 183.9;RPTEC TERT1: 604.1
CHN2	ARHGAP3, RhoGAP3	ENSG00000106069	Chimerin 2	7	29122274-29514328	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018989	Approved		Approved	Nucleus		Mixed	Tissue enhanced		duodenum: 74.8;small intestine: 68.4	cerebral cortex: 31.7	Cell line enhanced		HEL: 34.5;HMC-1: 60.7
GRB10		ENSG00000106070	Growth factor receptor bound protein 10	7	50590063-50793462	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019423, HPA027502, HPA031818	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 44.9	Mixed		
ABHD11	PP1226, WBSCR21	ENSG00000106077	Abhydrolase domain containing 11	7	73736094-73738867	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024042, HPA049641	Approved		Supported	Mitochondria	Renal cancer:3.66e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 28.6	Expressed in all		
COBL	KIAA0633	ENSG00000106078	Cordon-bleu WH2 repeat protein	7	51016212-51316818	Predicted intracellular proteins	Evidence at protein level	HPA019033, HPA019167	Enhanced		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:5.21e-12 (favourable)	Mixed	Mixed			parathyroid gland: 61.9	Cell line enhanced		BEWO: 31.3;HeLa: 39.5;RPMI-8226: 32.2
FKBP14	FKBP22, FLJ20731	ENSG00000106080	FK506 binding protein 14	7	30010587-30026684	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA013329, HPA026829	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Breast cancer:1.60e-4 (unfavourable), Urothelial cancer:4.25e-4 (unfavourable), Stomach cancer:4.57e-4 (unfavourable), Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 20.3	Mixed		
PLEKHA8	FAPP2, MGC3358	ENSG00000106086	Pleckstrin homology domain containing A8	7	30027404-30130483	Predicted intracellular proteins	Evidence at protein level	HPA072314			Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			placenta: 11.6	Mixed		
STX1A	HPC-1, p35-1, STX1	ENSG00000106089	Syntaxin 1A	7	73699206-73719672	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB008372, HPA069176	Enhanced				Endometrial cancer:1.94e-5 (unfavourable), Cervical cancer:3.63e-4 (unfavourable)	Expressed in all	Tissue enriched	15	cerebral cortex: 166.6	gallbladder: 10.8	Cell line enhanced		SCLC-21H: 164.0;U-87 MG: 90.3
NOD1	CARD4, CLR7.1, NLRC1	ENSG00000106100	Nucleotide binding oligomerization domain containing 1	7	30424527-30478784	Predicted intracellular proteins	Evidence at protein level	HPA074367			Approved	Mitochondria	Thyroid cancer:1.95e-4 (favourable), Renal cancer:6.68e-4 (unfavourable)	Expressed in all	Mixed			lung: 17.9	Mixed		
GARS	CMT2D, DSMAV, GlyRS, SMAD1	ENSG00000106105	Glycyl-tRNA synthetase	7	30594681-30634033	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA017896, HPA019097	Enhanced		Supported	Cytosol	Renal cancer:1.70e-5 (unfavourable), Urothelial cancer:3.04e-5 (unfavourable), Liver cancer:8.95e-5 (unfavourable), Breast cancer:1.02e-4 (unfavourable), Endometrial cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.0	Expressed in all		
CRHR2	CRF-RB, CRF2, HM-CRF	ENSG00000106113	Corticotropin releasing hormone receptor 2	7	30651943-30700129	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046683	Uncertain					Not detected	Tissue enhanced		seminal vesicle: 1.7	cerebral cortex: 1.2	Not detected		
EPHB6	HEP	ENSG00000106123	EPH receptor B6	7	142855061-142871094	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035784			Approved	Nuclear speckles	Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.5;skin: 25.0	cervix, uterine: 7.6	Group enriched	5	MOLT-4: 25.8;RT4: 47.4
MINDY4	C7orf67, FAM188B, FLJ22374	ENSG00000106125	MINDY lysine 48 deubiquitinase 4	7	30771417-30892387	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019475, HPA030129, HPA030130	Approved		Supported	Vesicles<br>Cytosol		Mixed	Mixed			fallopian tube: 18.6	Cell line enhanced		K-562: 17.1
GHRHR		ENSG00000106128	Growth hormone releasing hormone receptor	7	30938669-30993254	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Not detected			adrenal gland: 0.5	Not detected		
CASP2	ICH1, MGC2181, NEDD2, PPP1R57	ENSG00000106144	Caspase 2	7	143288215-143307696	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012175, HPA050678	Approved		Approved	Nucleoplasm	Renal cancer:5.01e-6 (unfavourable), Liver cancer:2.34e-4 (unfavourable), Ovarian cancer:2.89e-4 (favourable), Cervical cancer:7.38e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 24.9	Expressed in all		
CHCHD2	C7orf17	ENSG00000106153	Coiled-coil-helix-coiled-coil-helix domain containing 2	7	56101569-56106576	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027407, HPA052510	Uncertain		Enhanced	Mitochondria	Head and neck cancer:1.90e-5 (unfavourable), Liver cancer:9.41e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 585.7	Expressed in all		
CCL24	Ckb-6, eotaxin-2, MPIF-2, MPIF2, SCYA24	ENSG00000106178	C-C motif chemokine ligand 24	7	75811665-75823356	Predicted secreted proteins	Evidence at protein level						Colorectal cancer:5.41e-4 (favourable)	Tissue enhanced	Tissue enhanced		rectum: 111.7;small intestine: 96.2	urinary bladder: 51.4	Cell line enhanced		CAPAN-2: 4.8;RH-30: 2.0;U-2 OS: 5.9
HSPB1	CMT2F, Hs.76067, Hsp25, HSP27, HSP28	ENSG00000106211	Heat shock protein family B (small) member 1	7	76302544-76304295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000497, CAB004439, CAB047330, CAB047331, CAB047332	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Colorectal cancer:9.94e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1615.3	Expressed in all		
NPTX2		ENSG00000106236	Neuronal pentraxin 2	7	98617297-98629868	Predicted secreted proteins	Evidence at protein level	CAB020801, HPA049799, HPA058320	Supported		Approved	Golgi apparatus<br>Actin filaments<br>Centrosome	Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3	cervix, uterine: 12.1	Cell line enriched	8	LHCN-M2: 600.5
PDAP1	HASPP28, PAP, PAP1	ENSG00000106244	PDGFA associated protein 1	7	99392048-99408829	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021103, HPA050294, HPA060836	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 37.3	Expressed in all		
BUD31	Cwc14, EDG-2, EDG2, fSAP17, G10, YCR063W	ENSG00000106245	BUD31 homolog	7	99408641-99419616	Predicted intracellular proteins	Evidence at protein level	HPA028943	Approved		Approved	Nucleus<br>Microtubules<br>Centrosome	Renal cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 97.5	Expressed in all		
PTCD1	KIAA0632	ENSG00000106246	Pentatricopeptide repeat domain 1	7	99416739-99466163	Predicted intracellular proteins	Evidence at protein level	HPA020106, HPA047679	Uncertain		Approved	Mitochondria	Renal cancer:1.13e-4 (unfavourable), Liver cancer:2.34e-4 (unfavourable)	Expressed in all	Mixed			skin: 5.0	Expressed in all		
CYP3A5	CP35, P450PCN3, PCN3	ENSG00000106258	Cytochrome P450 family 3 subfamily A member 5	7	99648194-99679998	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol	Liver cancer:3.72e-5 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 114.8;liver: 93.2;small intestine: 187.6	stomach: 77.7	Cell line enhanced		A549: 2.5;CACO-2: 7.9;CAPAN-2: 5.7;Hep G2: 5.0
ZKSCAN1	KOX18, PHZ-37, ZNF139, ZNF36, ZSCAN33	ENSG00000106261	Zinc finger with KRAB and SCAN domains 1	7	100015572-100041689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006672	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			skin: 38.9	Expressed in all		
EIF3B	eIF3b, EIF3S9, PRT1	ENSG00000106263	Eukaryotic translation initiation factor 3 subunit B	7	2354086-2380745	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017562, HPA048983	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.41e-9 (unfavourable), Renal cancer:9.66e-6 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.1	Expressed in all		
SNX8	Mvp1	ENSG00000106266	Sorting nexin 8	7	2251770-2354318	Predicted intracellular proteins	Evidence at protein level	HPA057296, HPA060194	Approved		Supported	Vesicles	Liver cancer:8.47e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 38.0	Expressed in all		
NUDT1	MTH1	ENSG00000106268	Nudix hydrolase 1	7	2242222-2251146	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012636	Approved		Approved	Cytosol	Renal cancer:1.30e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.4	Expressed in all		
PTPRZ1	phosphacan, PTP18, PTPRZ, PTPZ, RPTPB	ENSG00000106278	Protein tyrosine phosphatase, receptor type Z1	7	121873089-122062036	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015103, CAB025106, HPA071024	Enhanced	Supported	Supported	Cytosol	Urothelial cancer:9.36e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 257.9	skin: 30.1	Group enriched	12	AF22: 420.6;NTERA-2: 119.0;WM-115: 185.9
TAF6	MGC:8964, TAF2E, TAFII70, TAFII80, TAFII85	ENSG00000106290	TATA-box binding protein associated factor 6	7	100107070-100119841	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006566	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 62.4	Expressed in all		
WASL	N-WASP, NWASP, WASPB	ENSG00000106299	Wiskott-Aldrich syndrome like	7	123681935-123749067	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005399, HPA005750	Supported		Approved	Nucleoli<br>Cytosol	Renal cancer:4.51e-8 (favourable), Pancreatic cancer:5.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.8	Expressed in all		
HYAL4		ENSG00000106302	Hyaluronoglucosaminidase 4	7	123828983-123877478	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029453	Uncertain					Tissue enriched	Tissue enhanced		placenta: 5.9;testis: 4.0	skin,spleen: 1.1	Cell line enhanced		BEWO: 3.5;CAPAN-2: 5.2;RT4: 11.2
SPAM1	HYAL5, PH-20, SPAG15	ENSG00000106304	Sperm adhesion molecule 1	7	123925237-123971414	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017984	Enhanced					Not detected	Tissue enriched	66	testis: 30.2	duodenum,small intestine: 0.4	Not detected		
AIMP2	JTV-1, JTV1, p38, PRO0992	ENSG00000106305	Aminoacyl tRNA synthetase complex interacting multifunctional protein 2	7	6009245-6023834	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019098, HPA020057	Supported		Approved	Cytosol	Renal cancer:1.38e-5 (favourable), Urothelial cancer:3.09e-4 (unfavourable), Head and neck cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.3	Expressed in all		
TFR2	HFE3, TFRC2	ENSG00000106327	Transferrin receptor 2	7	100620416-100642779	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA011937, CAB016255	Enhanced				Liver cancer:2.48e-4 (favourable)	Tissue enriched	Tissue enriched	11	liver: 155.5	bone marrow: 13.9	Group enriched	14	HEL: 62.3;HMC-1: 81.2;K-562: 58.4
FSCN3		ENSG00000106328	Fascin actin-bundling protein 3	7	127591409-127602144	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	245	testis: 105.7	skin: 0.4	Not detected		
MOSPD3	CDS3, NET30	ENSG00000106330	Motile sperm domain containing 3	7	100612102-100615384	Predicted membrane proteins	Evidence at protein level	HPA041137, HPA048240	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 29.6	Expressed in all		
PAX4	MODY9	ENSG00000106331	Paired box 4	7	127610292-127618114	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enhanced		duodenum: 1.0;rectum: 1.1	small intestine,testis: 0.6	Cell line enriched	73	SCLC-21H: 15.3
PCOLCE	PCPE, PCPE1	ENSG00000106333	Procollagen C-endopeptidase enhancer	7	100602177-100608175	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017623, HPA042927	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.68e-5 (unfavourable), Melanoma:9.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 216.8	gallbladder: 145.9	Cell line enhanced		ASC TERT1: 496.8;BJ hTERT+: 447.9;HSkMC: 595.6;SH-SY5Y: 617.5;U-2197: 961.3
FBXO24	FBX24	ENSG00000106336	F-box protein 24	7	100583982-100601117	Predicted intracellular proteins	Evidence at protein level	HPA050951	Enhanced					Mixed	Tissue enriched	36	testis: 71.4	ovary: 1.9	Cell line enhanced		U-2 OS: 2.7
PPP1R17	C7orf16, GSBS	ENSG00000106341	Protein phosphatase 1 regulatory subunit 17	7	31686715-31708455	Predicted intracellular proteins	Evidence at protein level	HPA047819, HPA073123	Supported		Supported	Nucleoplasm		Tissue enhanced	Group enriched	5	adrenal gland: 4.8;cerebral cortex: 2.6;testis: 1.1	lung: 0.5	Group enriched	225	NTERA-2: 33.8;SCLC-21H: 120.1
RBM28	FLJ10377	ENSG00000106344	RNA binding motif protein 28	7	128297685-128343908	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019058, HPA026672, HPA031519	Enhanced		Enhanced	Nucleoli	Liver cancer:2.72e-11 (unfavourable), Endometrial cancer:2.94e-4 (unfavourable), Melanoma:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.9	Expressed in all		
USP42	FLJ12697	ENSG00000106346	Ubiquitin specific peptidase 42	7	6104884-6161564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006752, HPA064800	Uncertain		Approved	Nucleus		Expressed in all	Tissue enhanced		testis: 27.8	parathyroid gland: 8.8	Expressed in all		
IMPDH1	LCA11, RP10, sWSS2608	ENSG00000106348	Inosine monophosphate dehydrogenase 1	7	128392277-128410252	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001400	Approved		Supported	Cytosol<br>Rods & Rings	Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 47.2	Expressed in all		
AGFG2	HRBL, RABR	ENSG00000106351	ArfGAP with FG repeats 2	7	100539211-100568219	Predicted intracellular proteins	Evidence at protein level	HPA019689	Enhanced				Renal cancer:1.03e-6 (favourable), Pancreatic cancer:9.64e-4 (favourable)	Expressed in all	Tissue enriched	6	salivary gland: 127.1	skin: 22.8	Expressed in all		
LSM5	YER146W	ENSG00000106355	LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated	7	32485332-32495283	Predicted intracellular proteins	Evidence at protein level	HPA019054	Uncertain				Liver cancer:7.53e-5 (unfavourable), Renal cancer:1.84e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 77.7	Expressed in all		
SERPINE1	PAI, PAI1, PLANH1	ENSG00000106366	Serpin family E member 1	7	101127089-101139266	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050039, CAB068501	Uncertain		Approved	Cytosol	Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 580.3;placenta: 600.2	adipose tissue: 215.8	Cell line enhanced		TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
AP1S1	AP19, CLAPS1, EKV3, SIGMA1A, WUGSC:H_DJ0747G18.2	ENSG00000106367	Adaptor related protein complex 1 sigma 1 subunit	7	101154397-101161596	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060945	Supported		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			cerebral cortex: 107.0	Expressed in all		
MOGAT3	DC7, DGAT2L2, MGAT3	ENSG00000106384	Monoacylglycerol O-acyltransferase 3	7	101195007-101201021	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011940	Uncertain		Approved	Centrosome		Tissue enhanced	Group enriched	6	colon: 11.3;duodenum: 30.4;rectum: 11.9;small intestine: 33.6	liver: 3.4	Cell line enhanced		CACO-2: 2.9;Hep G2: 8.1
C1GALT1	C1GALT, T-synthase	ENSG00000106392	Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1	7	7156934-7248651	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011294, HPA012819	Enhanced		Approved	Nuclear bodies<br>Cytosol	Liver cancer:1.42e-5 (unfavourable), Cervical cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 95.0	Expressed in all		
PLOD3	LH3	ENSG00000106397	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3	7	101205977-101218420	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001236	Uncertain				Cervical cancer:1.91e-5 (unfavourable), Colorectal cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 48.1	Expressed in all		
RPA3	REPA3	ENSG00000106399	Replication protein A3	7	7636518-7718607	Predicted intracellular proteins	Evidence at protein level	HPA005708	Approved				Liver cancer:5.16e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.7	Expressed in all		
ZNHIT1	CG1I, H_DJ0747G18.14, ZNFN4A1	ENSG00000106400	Zinc finger HIT-type containing 1	7	101217668-101224190	Predicted intracellular proteins	Evidence at protein level	HPA019043	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			liver: 50.6	Expressed in all		
CLDN15		ENSG00000106404	Claudin 15	7	101232092-101238820	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:5.31e-5 (unfavourable), Pancreatic cancer:2.56e-4 (favourable), Urothelial cancer:3.30e-4 (favourable)	Expressed in all	Group enriched	16	duodenum: 241.3;small intestine: 183.5	spleen: 13.3	Expressed in all		
NOBOX	OG2, Og2x	ENSG00000106410	NOBOX oogenesis homeobox	7	144397240-144410227	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Not detected			testis: 0.7	Not detected		
GLCCI1	FAM117C, GIG18, TSSN1	ENSG00000106415	Glucocorticoid induced 1	7	7968794-8094272	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001674, HPA005987	Approved		Uncertain	Nucleoli		Expressed in all	Mixed			thyroid gland: 28.1	Cell line enhanced		U-266/70: 66.1
MYL10	MGC3479, MYLC2PL, PLRLC	ENSG00000106436	Myosin light chain 10	7	101613325-101629296	Predicted intracellular proteins	Evidence at protein level	HPA019763	Uncertain		Uncertain	Microtubules		Tissue enhanced	Not detected			cervix, uterine,placenta: 0.7	Cell line enhanced		PC-3: 1.7;RH-30: 2.3
PHF14	KIAA0783	ENSG00000106443	PHD finger protein 14	7	10973872-11169630	Predicted intracellular proteins	Evidence at protein level	HPA000538, HPA017376	Supported		Approved	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 20.8	Expressed in all		
NRF1	ALPHA-PAL, EWG	ENSG00000106459	Nuclear respiratory factor 1	7	129611714-129757082	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029329	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 20.9	Expressed in all		
TMEM106B	FLJ11273, MGC33727	ENSG00000106460	Transmembrane protein 106B	7	12211241-12243367	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058342	Approved		Supported	Endosomes<br>Lysosomes		Expressed in all	Expressed in all			thyroid gland: 64.9	Expressed in all		
EZH2	ENX-1, EZH1, KMT6, KMT6A	ENSG00000106462	Enhancer of zeste 2 polycomb repressive complex 2 subunit	7	148807383-148884321	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009589	Enhanced		Supported	Nucleoplasm	Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 50.5	bone marrow: 30.0	Expressed in all		
CEP41	DKFZp762H1311, FLJ22445, JBTS15, TSGA14	ENSG00000106477	Centrosomal protein 41	7	130393771-130442433	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024090	Uncertain				Colorectal cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 80.5	salivary gland: 18.1	Mixed		
ZNF862		ENSG00000106479	Zinc finger protein 862	7	149838367-149867479	Predicted intracellular proteins	Evidence at protein level	HPA024154	Uncertain		Approved	Mitochondria	Urothelial cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.7	Mixed		
SFRP4	FRP-4, frpHE	ENSG00000106483	Secreted frizzled related protein 4	7	37905932-38025695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009712, HPA050585	Enhanced				Renal cancer:1.36e-5 (unfavourable)	Expressed in all	Group enriched	5	cervix, uterine: 935.5;endometrium: 776.1;fallopian tube: 338.6	smooth muscle: 130.5	Cell line enhanced		ASC diff: 6.5;HSkMC: 2.7;U-937: 2.9
MEST	PEG1	ENSG00000106484	Mesoderm specific transcript	7	130486171-130506296	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005623			Approved	Golgi apparatus<br>Cytosol	Renal cancer:6.20e-5 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 1087.6	adipose tissue: 131.8	Cell line enriched	5	AN3-CA: 10976.9
MEOX2	GAX, MOX2	ENSG00000106511	Mesenchyme homeobox 2	7	15611212-15686812	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053793	Enhanced					Tissue enriched	Tissue enhanced		adipose tissue: 28.5;placenta: 57.7	lung: 10.8	Cell line enhanced		AN3-CA: 217.5;SCLC-21H: 37.0;U-138 MG: 58.7
ANKMY2	DKFZP564O043, ZMYND20	ENSG00000106524	Ankyrin repeat and MYND domain containing 2	7	16599776-16645817	Predicted intracellular proteins	Evidence at protein level	HPA044900, HPA050447, HPA067100			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.05e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
ACTR3C	ARP11	ENSG00000106526	ARP3 actin-related protein 3 homolog C	7	150243916-150323725	Predicted intracellular proteins	Evidence at transcript level	HPA055957	Uncertain					Mixed	Tissue enriched	6	parathyroid gland: 87.3	adrenal gland: 15.8	Cell line enhanced		CAPAN-2: 27.5;RT4: 21.3;SiHa: 18.9
POU6F2	RPF-1	ENSG00000106536	POU class 6 homeobox 2	7	38977998-39493095	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 3.1;placenta: 1.8	gallbladder,testis: 1.2	Cell line enhanced		EFO-21: 3.0;NTERA-2: 3.1;T-47d: 5.3;U-266/70: 4.7;U-266/84: 5.5
TSPAN13	NET-6, TM4SF13	ENSG00000106537	Tetraspanin 13	7	16753535-16784536	Predicted membrane proteins	Evidence at protein level	HPA007426	Uncertain		Approved	Nucleus	Glioma:5.27e-5 (unfavourable), Ovarian cancer:2.20e-4 (favourable), Renal cancer:2.43e-4 (unfavourable), Liver cancer:2.94e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 246.2	Cell line enhanced		SCLC-21H: 223.6;SK-BR-3: 207.6;T-47d: 488.1
RARRES2	HP10433, TIG2	ENSG00000106538	Retinoic acid receptor responder 2	7	150338317-150341674	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049359			Uncertain	Cytosol	Renal cancer:6.83e-4 (unfavourable), Glioma:6.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 1522.8	parathyroid gland: 915.7	Group enriched	8	AF22: 120.4;Hep G2: 124.8;HHSteC: 130.5;NTERA-2: 372.4
AGR2	AG2, HAG-2, PDIA17, XAG-2	ENSG00000106541	Anterior gradient 2, protein disulphide isomerase family member	7	16791811-16833433	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007912	Enhanced		Approved	Cytosol	Renal cancer:8.79e-5 (unfavourable), Liver cancer:1.15e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 1322.0;stomach: 1307.3	cervix, uterine: 939.5	Cell line enhanced		A549: 239.4;RPTEC TERT1: 465.3;RT4: 298.0;T-47d: 1243.5
AHR	bHLHe76	ENSG00000106546	Aryl hydrocarbon receptor	7	17298622-17346152	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005072, HPA029722, HPA029723	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			lung: 56.4	Mixed		
CHCHD3	FLJ20420, Mic19, MINOS3, PPP1R22	ENSG00000106554	Coiled-coil-helix-coiled-coil-helix domain containing 3	7	132784868-133082088	Predicted intracellular proteins	Evidence at protein level	HPA042935	Enhanced		Supported	Mitochondria	Renal cancer:1.15e-4 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 121.2	Expressed in all		
GIMAP2	DKFZp586D0824, HIMAP2, IAN12, IMAP2	ENSG00000106560	GTPase, IMAP family member 2	7	150685697-150693641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013589	Approved				Renal cancer:1.29e-4 (unfavourable), Breast cancer:3.50e-4 (favourable)	Expressed in all	Mixed			lymph node: 88.0	Cell line enhanced		HUVEC TERT2: 52.1;MOLT-4: 63.1;REH: 30.9
TMEM176B	LR8, MS4B2	ENSG00000106565	Transmembrane protein 176B	7	150791285-150801360	Predicted membrane proteins	Evidence at protein level	HPA047509	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Expressed in all	Expressed in all			liver: 845.2	Group enriched	13	HSkMC: 462.2;THP-1: 144.5
GLI3	ACLS, GCPS, PAP-A, PAPA, PAPA1, PAPB, PHS, PPDIV	ENSG00000106571	GLI family zinc finger 3	7	41960950-42237870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005534	Approved					Mixed	Mixed			endometrium: 15.9	Cell line enhanced		AF22: 44.3;WM-115: 32.9
PSMA2	HC3, MU, PMSA2	ENSG00000106588	Proteasome subunit alpha 2	7	42916857-42932223	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008188	Uncertain				Ovarian cancer:6.73e-5 (favourable), Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 165.2	Expressed in all		
MRPL32	bMRP-59b, HSPC283, L32mt, MRP-L32	ENSG00000106591	Mitochondrial ribosomal protein L32	7	42932200-42948958	Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA048965	Uncertain					Expressed in all	Expressed in all			adrenal gland: 72.1	Expressed in all		
COA1	C7orf44, FLJ10803, MITRAC15	ENSG00000106603	Cytochrome c oxidase assembly factor 1 homolog	7	43608456-43729717	Predicted membrane proteins	Evidence at protein level	HPA011944	Approved		Supported	Mitochondria	Liver cancer:7.84e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 38.6	Expressed in all		
BLVRA	BLVR	ENSG00000106605	Biliverdin reductase A	7	43758680-43807342	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019709, HPA042865, HPA054322	Approved		Supported	Cytosol	Lung cancer:8.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 158.1	Mixed		
URGCP	DKFZp666G166, DKFZp686O0457, FLJ20654, KIAA1507, URG4	ENSG00000106608	Upregulator of cell proliferation	7	43875894-43926411	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019879, HPA020134, HPA029468	Approved		Supported	Cytosol	Renal cancer:1.90e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Expressed in all		
TMEM248	C7orf42, FLJ10099, FLJ13090	ENSG00000106609	Transmembrane protein 248	7	66921225-66958551	Predicted membrane proteins	Evidence at protein level	HPA016495	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 93.8	Expressed in all		
RHEB	RHEB2	ENSG00000106615	Ras homolog enriched in brain	7	151466012-151520120	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019436	Uncertain				Liver cancer:9.08e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 207.2	Expressed in all		
PRKAG2	AAKG, AAKG2, CMH6, H91620p, WPWS	ENSG00000106617	Protein kinase AMP-activated non-catalytic subunit gamma 2	7	151556111-151877125	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004246, CAB018641	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 81.8	Mixed		
AEBP1	ACLP	ENSG00000106624	AE binding protein 1	7	44104361-44114562	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009966, HPA047724, HPA063595, HPA064970	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:9.31e-9 (unfavourable), Glioma:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 300.4	Cell line enhanced		BJ: 163.5;fHDF/TERT166: 162.3;WM-115: 116.5
POLD2		ENSG00000106628	DNA polymerase delta 2, accessory subunit	7	44114681-44124358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026745	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 122.1	Expressed in all		
MYL7	MYL2A, MYLC2A	ENSG00000106631	Myosin light chain 7	7	44138864-44141332	Predicted intracellular proteins	Evidence at protein level	HPA013331, CAB033884, HPA039262	Enhanced					Tissue enriched	Tissue enriched	1272	heart muscle: 8172.3	breast: 6.4	Group enriched	26	BEWO: 34.4;CACO-2: 103.4
GCK	HK4, MODY2	ENSG00000106633	Glucokinase	7	44144271-44198170	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007034, HPA007093	Approved		Approved	Golgi apparatus<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 2.5	Cell line enriched	6	SCLC-21H: 7.7
BCL7B		ENSG00000106635	BCL tumor suppressor 7B	7	73536356-73558002	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049943, HPA058069	Approved		Approved	Nucleoplasm	Renal cancer:4.38e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 24.7	Expressed in all		
YKT6		ENSG00000106636	YKT6 v-SNARE homolog (S. cerevisiae)	7	44200968-44214294	Predicted intracellular proteins	Evidence at protein level	HPA030817, HPA030818	Approved		Approved	Mitochondria<br>Cytosol	Liver cancer:1.02e-4 (unfavourable), Head and neck cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 61.8	Expressed in all		
TBL2	DKFZP43N024, WBSCR13, WS-betaTRP	ENSG00000106638	Transducin beta like 2	7	73568932-73578791	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007477, HPA051533			Supported	Cytosol	Renal cancer:1.88e-5 (unfavourable), Head and neck cancer:4.93e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 83.8	parathyroid gland: 13.0	Expressed in all		
GALNTL5	GalNAc-T5L, GALNT15	ENSG00000106648	Polypeptide N-acetylgalactosaminyltransferase-like 5	7	151956379-152019934	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011140	Enhanced					Not detected	Tissue enriched	14	testis: 11.1	cerebral cortex: 0.8	Not detected		
CLIP2	CLIP, CLIP-115, CYLN2, KIAA0291, WBSCR3, WBSCR4, WSCR3, WSCR4	ENSG00000106665	CAP-Gly domain containing linker protein 2	7	74289475-74405943	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020430, CAB020767	Enhanced				Endometrial cancer:5.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.8	ovary: 21.0	Mixed		
EIF4H	KIAA0038, WBSCR1, WSCR1	ENSG00000106682	Eukaryotic translation initiation factor 4H	7	74174245-74197101	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030542	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Head and neck cancer:2.15e-4 (unfavourable), Glioma:5.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 254.3	Expressed in all		
LIMK1	LIMK	ENSG00000106683	LIM domain kinase 1	7	74082933-74122525	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028064, HPA028516	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.63e-8 (unfavourable), Liver cancer:7.79e-6 (unfavourable), Colorectal cancer:4.95e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
SPATA6L	C9orf68, FLJ10058	ENSG00000106686	Spermatogenesis associated 6 like	9	4553386-4666674	Predicted intracellular proteins	Evidence at protein level	HPA039585	Enhanced					Mixed	Tissue enhanced		fallopian tube: 5.8;testis: 6.4	gallbladder,lung: 2.3	Cell line enhanced		BEWO: 1.3;CAPAN-2: 2.1;HDLM-2: 1.3;RPTEC TERT1: 1.3;SCLC-21H: 1.8
SLC1A1	EAAC1, EAAT3	ENSG00000106688	Solute carrier family 1 member 1	9	4490444-4587469	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB015466, HPA020086	Approved				Renal cancer:2.86e-8 (favourable)	Expressed in all	Tissue enhanced		small intestine: 71.2	epididymis: 54.5	Cell line enhanced		HDLM-2: 65.4;RPTEC TERT1: 50.1
LHX2	hLhx2, LH-2	ENSG00000106689	LIM homeobox 2	9	124001670-124033301	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA000838		Supported	Approved	Nucleoplasm	Cervical cancer:9.52e-4 (favourable)	Group enriched	Tissue enriched	11	cerebral cortex: 56.3	placenta: 5.1	Cell line enhanced		AN3-CA: 22.0;HAP1: 24.5;NTERA-2: 29.4
FKTN	FCMD, LGMD2M	ENSG00000106692	Fukutin	9	105558130-105641118	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012820	Approved				Urothelial cancer:3.02e-4 (unfavourable), Liver cancer:9.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
FSD1L	CCDC10, CSDUFD1, FSD1CL, FSD1NL	ENSG00000106701	Fibronectin type III and SPRY domain containing 1 like	9	105447796-105552433	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035138	Approved		Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 17.8	testis: 13.5	Mixed		
CNTNAP3	CASPR3, CNTNAP3A, FLJ14195, KIAA1714	ENSG00000106714	Contactin associated protein-like 3	9	39072767-39288315	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Mixed	Mixed			esophagus: 8.2	Cell line enhanced		A549: 17.0;AF22: 22.2;WM-115: 37.4
SPIN1	SPIN, TDRD24	ENSG00000106723	Spindlin 1	9	88388419-88478694	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000162, HPA068784	Uncertain		Supported	Nucleoplasm	Renal cancer:8.69e-6 (favourable)	Expressed in all	Expressed in all			endometrium: 101.8	Mixed		
NMRK1	bA235O14.2, C9orf95, FLJ20559, NRK1	ENSG00000106733	Nicotinamide riboside kinase 1	9	75060573-75088217	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049795	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.70e-6 (favourable), Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 120.8	Cell line enhanced		HDLM-2: 70.8
TMEM245	C9orf5, CG-2	ENSG00000106771	Transmembrane protein 245	9	109015152-109119945	Predicted membrane proteins	Evidence at protein level	HPA023892	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.46e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 124.0	Expressed in all		
PRUNE2	A214N16.3, bA214N16.3, BMCC1, BNIPXL, C9orf65, KIAA0367	ENSG00000106772	Prune homolog 2	9	76611376-76906087	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022470, HPA031079	Uncertain				Renal cancer:1.37e-6 (favourable)	Mixed	Mixed			seminal vesicle: 89.8	Cell line enhanced		LHCN-M2: 69.0;RH-30: 68.7
MEGF9	EGFL5	ENSG00000106780	Multiple EGF like domains 9	9	120600813-120714470	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014319, HPA050238	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:5.48e-11 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.2	Mixed		
TRIM14	KIAA0129	ENSG00000106785	Tripartite motif containing 14	9	98069275-98119212	Predicted intracellular proteins	Evidence at protein level	HPA053217	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 37.6	Mixed		
CORO2A	IR10, WDR2	ENSG00000106789	Coronin 2A	9	98120975-98192640	Predicted intracellular proteins	Evidence at protein level	HPA041161, HPA041302	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:6.56e-4 (unfavourable)	Mixed	Mixed			small intestine: 38.5	Cell line enhanced		BEWO: 64.3;SK-BR-3: 33.9
TGFBR1	ACVRLK4, ALK-5, ALK5, ESS1, MSSE	ENSG00000106799	Transforming growth factor beta receptor 1	9	99104038-99154192	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002441, CAB031481, HPA056473	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 69.8	Expressed in all		
SEC61B		ENSG00000106803	Sec61 translocon beta subunit	9	99222064-99230615	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049407	Approved		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.26e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 339.1	Expressed in all		
C5	C5a, C5b, CPAMD4	ENSG00000106804	Complement C5	9	120952335-121050276	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA029339	Uncertain				Liver cancer:9.43e-4 (favourable)	Tissue enriched	Tissue enriched	21	liver: 225.6	lung: 10.5	Cell line enhanced		A549: 25.6;Hep G2: 20.6
OGN	mimecan, OIF, SLRR3A	ENSG00000106809	Osteoglycin	9	92383967-92404696	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013132	Approved		Supported	Endoplasmic reticulum	Renal cancer:1.92e-4 (unfavourable), Urothelial cancer:2.03e-4 (unfavourable), Ovarian cancer:4.04e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 374.3;parathyroid gland: 604.4	gallbladder: 276.4	Cell line enhanced		ASC TERT1: 17.1;HSkMC: 8.0;MOLT-4: 27.9
ASPN	FLJ20129, PLAP1, SLRR1C	ENSG00000106819	Asporin	9	92456205-92482506	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008435, HPA024230	Approved		Uncertain	Nucleoplasm	Renal cancer:1.64e-7 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 115.6;smooth muscle: 161.0	gallbladder: 104.1	Cell line enhanced		ASC TERT1: 11.2;BJ hTERT+: 4.6;HHSteC: 19.2
ECM2		ENSG00000106823	Extracellular matrix protein 2	9	92493554-92536655	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035347	Approved				Renal cancer:4.09e-6 (unfavourable), Liver cancer:4.50e-5 (favourable)	Expressed in all	Mixed			adipose tissue: 128.6	Cell line enhanced		ASC diff: 13.1;ASC TERT1: 24.2;HSkMC: 26.7;hTCEpi: 30.9
TLE4	E(spI), ESG, GRG4	ENSG00000106829	Transducin like enhancer of split 4	9	79571773-79726882	Predicted intracellular proteins	Evidence at protein level	HPA065357			Supported	Nucleus	Renal cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 201.9	Cell line enhanced		fHDF/TERT166: 131.2
LHX6	LHX6.1	ENSG00000106852	LIM homeobox 6	9	122202577-122229626	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047854, HPA058319	Approved		Uncertain	Nucleoli fibrillar center<br>Plasma membrane		Mixed	Mixed			cerebral cortex: 8.1	Cell line enhanced		CACO-2: 10.9;NB-4: 11.6;PC-3: 11.4;U-87 MG: 9.4
PTGR1	LTB4DH, ZADH3	ENSG00000106853	Prostaglandin reductase 1	9	111549722-111599855	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036724	Enhanced				Renal cancer:5.53e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 315.8	Mixed		
SUSD1	DKFZP761E1824	ENSG00000106868	Sushi domain containing 1	9	112040785-112175408	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048554	Approved		Approved	Nucleoplasm	Renal cancer:3.63e-6 (favourable)	Expressed in all	Mixed			placenta: 21.5	Cell line enhanced		HEL: 50.2
AMBP	EDC1, HCP, HI30, IATIL, ITI, ITIL, ITILC, UTI	ENSG00000106927	Alpha-1-microglobulin/bikunin precursor	9	114060127-114078472	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001497, CAB069436	Approved				Endometrial cancer:1.20e-4 (favourable)	Tissue enriched	Tissue enriched	23	liver: 5176.2	gallbladder: 230.0	Cell line enriched	113	Hep G2: 861.2
AKNA	KIAA1968	ENSG00000106948	AT-hook transcription factor	9	114334156-114394405	Predicted intracellular proteins	Evidence at protein level	HPA052367, HPA063993			Supported	Nucleoplasm<br>Centrosome	Endometrial cancer:2.14e-5 (favourable), Renal cancer:2.55e-5 (unfavourable), Cervical cancer:1.22e-4 (favourable), Head and neck cancer:1.25e-4 (favourable), Urothelial cancer:2.29e-4 (favourable)	Expressed in all	Mixed			spleen: 95.6	Cell line enhanced		HDLM-2: 81.7;MOLT-4: 67.8
TNFSF8	CD153, CD30LG	ENSG00000106952	Tumor necrosis factor superfamily member 8	9	114893343-114930595	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 34.4;tonsil: 26.7	appendix: 24.3	Group enriched	99	Daudi: 50.4;U-698: 39.7
DNM1	DNM	ENSG00000106976	Dynamin 1	9	128191655-128255248	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005920, HPA049910, HPA061801	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enriched	14	cerebral cortex: 364.2	cervix, uterine: 25.6	Cell line enhanced		A549: 114.8
ENG	CD105, END, HHT1, ORW, ORW1	ENSG00000106991	Endoglin	9	127815012-127854756	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000096, HPA011862, HPA067440, CAB072873	Enhanced				Liver cancer:5.62e-6 (favourable), Renal cancer:4.26e-4 (unfavourable), Head and neck cancer:6.61e-4 (favourable)	Expressed in all	Expressed in all			spleen: 167.6	Cell line enhanced		HUVEC TERT2: 402.6;TIME: 810.4
AK1		ENSG00000106992	Adenylate kinase 1	9	127866480-127877743	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006456, CAB009893	Enhanced		Supported	Cytosol	Stomach cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 774.9	Mixed		
CDC37L1	CDC37B, FLJ20639, HARC	ENSG00000106993	Cell division cycle 37 like 1	9	4679559-4708398	Predicted intracellular proteins	Evidence at protein level	HPA021175	Approved		Supported	Cytosol	Renal cancer:2.66e-7 (favourable)	Expressed in all	Expressed in all			liver: 28.5	Expressed in all		
RLN2	bA12D24.1.1, bA12D24.1.2, H2, RLXH2	ENSG00000107014	Relaxin 2	9	5299868-5304969	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 8.1	prostate: 6.0	Cell line enhanced		HEL: 19.0;T-47d: 5.6;U-266/84: 6.9
RLN1	H1	ENSG00000107018	Relaxin 1	9	5334969-5339873	Plasma proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	64	prostate: 40.0	testis: 0.6	Cell line enhanced		HEL: 1.0
PLGRKT	AD025, C9orf46, FLJ14688, MDS030, Plg-RKT	ENSG00000107020	Plasminogen receptor with a C-terminal lysine	9	5357973-5437878	Predicted intracellular proteins	Evidence at protein level	HPA008214, HPA011144	Enhanced		Uncertain	Mitochondria	Renal cancer:5.09e-5 (favourable), Breast cancer:5.56e-4 (favourable)	Expressed in all	Expressed in all			rectum: 55.2	Cell line enhanced		HDLM-2: 245.6
TBC1D13	FLJ10743	ENSG00000107021	TBC1 domain family member 13	9	128787204-128810432	Predicted intracellular proteins	Evidence at protein level	HPA045865	Approved		Approved	Nucleoli	Renal cancer:1.58e-7 (favourable), Pancreatic cancer:3.14e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.2	Expressed in all		
RIC1	bA207C16.1, KIAA1432	ENSG00000107036	RIC1 homolog, RAB6A GEF complex partner 1	9	5629025-5776557	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051578	Supported					Expressed in all	Expressed in all			testis: 21.4	Expressed in all		
KDM4C	GASC1, JMJD2C, KIAA0780, TDRD14C	ENSG00000107077	Lysine demethylase 4C	9	6720863-7175648	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA069357			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 36.0	Expressed in all		
DOCK8	FLJ00026, FLJ00152, FLJ00346, ZIR8	ENSG00000107099	Dedicator of cytokinesis 8	9	214854-465259	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003218	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria<br>Cytosol	Urothelial cancer:6.89e-6 (favourable), Renal cancer:9.21e-6 (favourable)	Expressed in all	Mixed			spleen: 62.1	Cell line enhanced		HL-60: 42.1;NB-4: 52.6;REH: 56.3;RT4: 42.9;THP-1: 105.5
KANK1	ANKRD15, KANK, KIAA0172	ENSG00000107104	KN motif and ankyrin repeat domains 1	9	470291-746106	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005539, HPA056090	Approved		Supported	Plasma membrane		Expressed in all	Mixed			smooth muscle: 55.8	Mixed		
ELAVL2	HEL-N1, HuB	ENSG00000107105	ELAV like RNA binding protein 2	9	23690104-23826337	Predicted intracellular proteins	Evidence at protein level	CAB022222, HPA063001	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	32	cerebral cortex: 37.9;testis: 80.3	adrenal gland: 1.8	Cell line enhanced		AF22: 36.8;SCLC-21H: 145.6
NCS1	FREQ, NCS-1	ENSG00000107130	Neuronal calcium sensor 1	9	130172578-130237304	Predicted intracellular proteins	Evidence at protein level	CAB018587, HPA019713	Enhanced	Supported	Enhanced	Plasma membrane	Liver cancer:1.11e-4 (unfavourable), Breast cancer:5.40e-4 (unfavourable), Thyroid cancer:8.25e-4 (unfavourable), Endometrial cancer:8.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 178.1	seminal vesicle: 92.3	Mixed		
TESK1		ENSG00000107140	Testis-specific kinase 1	9	35605305-35610041	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
KCNT1	KCa4.1, KIAA1422, SLACK, Slo2.2	ENSG00000107147	Potassium sodium-activated channel subfamily T member 1	9	135702185-135795508	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059880	Uncertain					Tissue enhanced	Group enriched	5	cerebral cortex: 11.6;ovary: 3.9;skeletal muscle: 3.8;spleen: 6.8	testis: 1.2	Cell line enhanced		RPMI-8226: 1.2;SCLC-21H: 3.0
CA9	CAIX, MN	ENSG00000107159	Carbonic anhydrase 9	9	35673856-35681159	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005100, CAB017107, HPA055207	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 36.0;stomach: 93.6	small intestine: 14.5	Group enriched	11	A-431: 152.1;HDLM-2: 84.3;U-87 MG: 337.9
FUBP3	FBP3	ENSG00000107164	Far upstream element binding protein 3	9	130578965-130638352	Predicted intracellular proteins	Evidence at protein level	HPA047658, HPA058392	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.39e-5 (favourable), Lung cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.7	Expressed in all		
TYRP1	b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP	ENSG00000107165	Tyrosinase related protein 1	9	12685439-12710290	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000937, CAB002520	Enhanced		Supported	Vesicles		Tissue enriched	Group enriched	6	heart muscle: 40.2;skin: 169.1	kidney: 17.0	Cell line enriched	51	SK-MEL-30: 1084.9
CREB3	Luman, LZIP, sLZIP	ENSG00000107175	CAMP responsive element binding protein 3	9	35732335-35737004	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA030978			Supported	Cytosol	Renal cancer:3.77e-5 (favourable), Ovarian cancer:5.40e-4 (favourable), Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 55.8	Expressed in all		
RGP1	KIAA0258	ENSG00000107185	RGP1 homolog, RAB6A GEF complex partner 1	9	35749287-35758575	Predicted intracellular proteins	Evidence at protein level	HPA020414, HPA021085	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:8.55e-13 (favourable), Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.9	Expressed in all		
MPDZ	MUPP1	ENSG00000107186	Multiple PDZ domain crumbs cell polarity complex component	9	13105704-13279590	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013512, HPA020255, HPA026686	Uncertain				Pancreatic cancer:7.40e-4 (favourable), Liver cancer:8.68e-4 (favourable)	Expressed in all	Mixed			liver: 44.3	Cell line enhanced		AF22: 57.0
LHX3		ENSG00000107187	LIM homeobox 3	9	136196250-136205109	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.4	Cell line enhanced		U-266/70: 1.0
DDX58	DKFZp434J1111, FLJ13599, RIG-I	ENSG00000107201	DExD/H-box helicase 58	9	32455705-32526324	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012643, HPA047193	Uncertain		Supported	Cytosol	Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.8	Group enriched	6	BJ hTERT+ SV40 Large T+: 118.2;BJ hTERT+ SV40 Large T+ RasG12V: 128.1
EDF1	CFAP280, EDF-1	ENSG00000107223	Endothelial differentiation related factor 1	9	136862119-136866286	Predicted intracellular proteins	Evidence at protein level	HPA035642	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			small intestine: 557.4	Expressed in all		
PIP5K1B	MSS4, STM7	ENSG00000107242	Phosphatidylinositol-4-phosphate 5-kinase type 1 beta	9	68705414-69009176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009687	Uncertain		Approved	Nucleus<br>Vesicles	Renal cancer:1.03e-9 (favourable)	Mixed	Mixed			testis: 50.3	Cell line enhanced		AF22: 47.6;HEL: 16.8;U-266/70: 14.2
GLIS3	MGC33662, ZNF515	ENSG00000107249	GLIS family zinc finger 3	9	3824127-4348392	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA056426	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		thyroid gland: 34.9	fallopian tube: 16.6	Cell line enhanced		BJ hTERT+: 19.2;HSkMC: 25.2
BAG1		ENSG00000107262	BCL2 associated athanogene 1	9	33247820-33264720	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002486, HPA018121	Enhanced		Supported	Nucleoplasm	Renal cancer:2.22e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.5	Expressed in all		
RAPGEF1	C3G, GRF2	ENSG00000107263	Rap guanine nucleotide exchange factor 1	9	131576770-131740074	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006426	Approved				Renal cancer:1.18e-5 (favourable)	Expressed in all	Expressed in all			placenta: 80.8	Expressed in all		
NPDC1	CAB-, CAB1, DKFZp586J0523	ENSG00000107281	Neural proliferation, differentiation and control 1	9	137039470-137046203	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008189	Approved		Approved	Nucleus<br>Cytosol	Colorectal cancer:2.01e-5 (unfavourable), Endometrial cancer:6.19e-5 (favourable), Pancreatic cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			prostate: 124.2	Mixed		
APBA1	D9S411E, MINT1, X11	ENSG00000107282	Amyloid beta precursor protein binding family A member 1	9	69427530-69672306	Predicted intracellular proteins	Evidence at protein level	HPA061287			Supported	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 18.4	parathyroid gland: 11.8	Cell line enhanced		HAP1: 18.1;SCLC-21H: 7.9;U-138 MG: 7.0
SETX	ALS4, AOA2, KIAA0625, SCAR1	ENSG00000107290	Senataxin	9	132261356-132354985	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024105, HPA057269	Approved		Supported	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			testis: 58.3	Expressed in all		
SH3GL2	CNSA2, EEN-B1, SH3D2A, SH3P4	ENSG00000107295	SH3 domain containing GRB2 like 2, endophilin A1	9	17579082-17797129	Predicted intracellular proteins	Evidence at protein level	CAB010056, HPA026685, HPA063573	Enhanced	Supported	Approved	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle	Renal cancer:6.68e-12 (favourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 170.1	kidney: 17.5	Cell line enhanced		HeLa: 14.7;RT4: 34.0;SCLC-21H: 31.7
PTGDS	L-PGDS, PGDS	ENSG00000107317	Prostaglandin D2 synthase	9	136975092-136981742	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004938, CAB009916	Approved		Supported	Nucleoplasm	Renal cancer:1.19e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 2581.3	Group enriched	7	HHSteC: 440.4;HSkMC: 186.3
ABCA2	ABC2	ENSG00000107331	ATP binding cassette subfamily A member 2	9	137007227-137028922	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042886	Approved					Expressed in all	Tissue enriched	6	cerebral cortex: 97.9	thyroid gland: 17.1	Cell line enhanced		T-47d: 63.1
SHB		ENSG00000107338	SH2 domain containing adaptor protein B	9	37919134-38069211	Predicted intracellular proteins	Evidence at protein level	CAB010161, HPA049911, HPA052108	Uncertain		Enhanced	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			parathyroid gland: 16.2	Mixed		
UBE2R2	CDC34B, FLJ20419, MGC10481, UBC3B	ENSG00000107341	Ubiquitin conjugating enzyme E2 R2	9	33817567-33920404	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061000			Approved	Nucleus<br>Nucleoli	Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 68.7	Expressed in all		
ABHD17B	C9orf77, CGI-67, FAM108B1	ENSG00000107362	Abhydrolase domain containing 17B	9	71862452-71910931	Predicted intracellular proteins	Evidence at protein level	HPA047862	Uncertain				Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.3	Mixed		
EXOSC3	CGI-102, hRrp-40, hRrp40p, p10, RRP40, Rrp40p	ENSG00000107371	Exosome component 3	9	37766978-37801437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020485	Enhanced		Supported	Nucleoplasm	Liver cancer:7.01e-5 (unfavourable), Melanoma:7.39e-4 (unfavourable)	Expressed in all	Mixed			testis: 28.2	Expressed in all		
ZFAND5	ZA20D2, ZFAND5A, ZNF216	ENSG00000107372	Zinc finger AN1-type containing 5	9	72351425-72365235	Predicted intracellular proteins	Evidence at protein level	HPA018129	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.43e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 310.8	Expressed in all		
DVL1		ENSG00000107404	Dishevelled segment polarity protein 1	1	1335276-1349350	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011538	Approved				Testis cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 79.4	Expressed in all		
PDLIM1	CLIM1, CLP-36, CLP36, hCLIM1	ENSG00000107438	PDZ and LIM domain 1	10	95237572-95291024	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017010, CAB072838, CAB072840	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments	Endometrial cancer:1.14e-5 (favourable)	Expressed in all	Expressed in all			small intestine: 273.0	Cell line enhanced		HaCaT: 680.7
CCNJ	bA690P14.1, FLJ10895	ENSG00000107443	Cyclin J	10	96043394-96060870	Predicted intracellular proteins	Evidence at transcript level	HPA036531, HPA058151	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 9.9	Mixed		
DNTT	TDT	ENSG00000107447	DNA nucleotidylexotransferase	10	96304396-96338564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044194			Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	8	bone marrow: 18.3	tonsil: 2.1	Group enriched	518	MOLT-4: 325.2;REH: 1262.7
GATA3	HDR	ENSG00000107485	GATA binding protein 3	10	8053604-8075198	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016217, HPA029730	Enhanced		Supported	Nucleoplasm	Renal cancer:3.13e-4 (unfavourable)	Group enriched	Tissue enhanced		parathyroid gland: 235.0;skin: 148.9	placenta: 44.3	Cell line enhanced		BEWO: 172.2;MCF7: 354.3;RT4: 149.5;SH-SY5Y: 145.4;T-47d: 506.9
ATRNL1	ALP, FLJ45344, KIAA0534	ENSG00000107518	Attractin like 1	10	115093365-115948992	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038070	Uncertain		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 33.9	testis: 22.7	Cell line enhanced		AN3-CA: 27.6;RH-30: 19.2
HPS1	BLOC3S1, HPS	ENSG00000107521	HPS1, biogenesis of lysosomal organelles complex 3 subunit 1	10	98416198-98446947	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061260	Approved				Endometrial cancer:2.93e-5 (favourable), Cervical cancer:3.37e-5 (favourable), Lung cancer:1.26e-4 (favourable), Glioma:5.53e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.2	Mixed		
PHYH	PAHX, PHYH1, RD	ENSG00000107537	Phytanoyl-CoA 2-hydroxylase	10	13277796-13302412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007598, HPA011796	Enhanced				Renal cancer:7.28e-12 (favourable)	Expressed in all	Expressed in all			liver: 334.1	Mixed		
RASSF4	AD037, MGC44914	ENSG00000107551	Ras association domain family member 4	10	44959407-44995891	Predicted intracellular proteins	Evidence at protein level	HPA038834	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 71.4	Cell line enhanced		RH-30: 158.1;U-937: 67.6;WM-115: 54.3
DNMBP	ARHGEF36, KIAA1010, Tuba	ENSG00000107554	Dynamin binding protein	10	99875577-100009919	Predicted intracellular proteins	Evidence at protein level	HPA037878, HPA058216	Uncertain		Approved	Nucleoli<br>Nuclear bodies<br>Golgi apparatus<br>Cytosol	Endometrial cancer:4.95e-6 (favourable), Urothelial cancer:6.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.6	Mixed		
RAB11FIP2	KIAA0941, nRip11, Rab11-FIP2	ENSG00000107560	RAB11 family interacting protein 2	10	118004916-118046603	Predicted intracellular proteins	Evidence at protein level	HPA037726	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:9.69e-5 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 36.4	Expressed in all		
CXCL12	PBSF, SCYB12, SDF-1a, SDF-1b, SDF1, SDF1A, SDF1B, TLSF-a, TLSF-b, TPAR1	ENSG00000107562	C-X-C motif chemokine ligand 12	10	44370165-44386493	Predicted secreted proteins	Evidence at protein level	CAB017564	Approved					Expressed in all	Expressed in all			endometrium: 618.3	Cell line enhanced		ASC diff: 349.6;BJ hTERT+ SV40 Large T+ RasG12V: 429.9;fHDF/TERT166: 388.7;HSkMC: 941.2
ERLIN1	C10orf69, Erlin-1, KE04, SPFH1, SPG62	ENSG00000107566	ER lipid raft associated 1	10	100150094-100188334	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA011252	Approved		Supported	Endoplasmic reticulum	Lung cancer:7.63e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 57.2	Expressed in all		
EIF3A	EIF3, eIF3-p170, eIF3-theta, eIF3a, EIF3S10, KIAA0139, TIF32	ENSG00000107581	Eukaryotic translation initiation factor 3 subunit A	10	119033670-119080823	Predicted intracellular proteins	Evidence at protein level	HPA038315, HPA038316	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 135.7	Expressed in all		
PKD2L1	PCL, PKD2L, PKDL, TRPP3	ENSG00000107593	Polycystin 2 like 1, transient receptor potential cation channel	10	100288154-100330486	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022621	Uncertain					Mixed	Tissue enhanced		spleen: 9.8	lung: 3.4	Not detected		
CUBN	gp280, IFCR, MGA1	ENSG00000107611	Cubilin	10	16823964-17129831	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004133, HPA043854	Enhanced				Renal cancer:1.12e-4 (favourable)	Tissue enriched	Group enriched	22	kidney: 153.7;small intestine: 54.4	thyroid gland: 4.7	Cell line enhanced		AN3-CA: 14.6;WM-115: 5.9
TRDMT1	DNMT2, RNMT1	ENSG00000107614	TRNA aspartic acid methyltransferase 1	10	17142254-17202054	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009468, HPA036945, HPA036946	Approved		Approved	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Mixed			parathyroid gland: 8.7	Mixed		
DDX50	GU2, GUB, MGC3199, RH-II/GuB	ENSG00000107625	DExD-box helicase 50	10	68901278-68946847	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037388, HPA037389, HPA058196	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			testis: 47.0	Expressed in all		
MAPK8	JNK, JNK1, PRKM8, SAPK1	ENSG00000107643	Mitogen-activated protein kinase 8	10	48306639-48439360	Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004463, CAB069396	Approved				Liver cancer:8.66e-4 (unfavourable), Renal cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
SEC23IP	p125	ENSG00000107651	SEC23 interacting protein	10	119892711-119944658	Predicted intracellular proteins	Evidence at protein level	HPA038403, HPA043305	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			smooth muscle: 30.5	Expressed in all		
ATE1		ENSG00000107669	Arginyltransferase 1	10	121740421-121928801	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038444, HPA057549	Approved		Supported	Nucleus	Renal cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
NSMCE4A	bA500G22.3, C10orf86, FLJ20003, NSE4A	ENSG00000107672	NSE4 homolog A, SMC5-SMC6 complex component	10	121957088-121975217	Predicted intracellular proteins	Evidence at protein level	HPA037459, HPA038412, HPA044872	Approved		Enhanced	Nucleoplasm	Lung cancer:2.72e-5 (favourable), Renal cancer:2.45e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 34.5	Expressed in all		
PLEKHA1	TAPP1	ENSG00000107679	Pleckstrin homology domain containing A1	10	122374696-122442602	Predicted intracellular proteins	Evidence at protein level	HPA002043, HPA064795	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			skin: 79.2	Cell line enhanced		RPTEC TERT1: 153.9
PALD1	KIAA1274, PALD	ENSG00000107719	Phosphatase domain containing, paladin 1	10	70478821-70568449	Predicted membrane proteins	Evidence at protein level	HPA015696, HPA017343	Uncertain					Expressed in all	Mixed			lung: 15.0	Cell line enhanced		AN3-CA: 20.7;Daudi: 19.8;RPMI-8226: 23.0
UNC5B	p53RDL1, UNC5H2	ENSG00000107731	Unc-5 netrin receptor B	10	71212570-71302864	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.01e-5 (unfavourable), Ovarian cancer:3.80e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 38.5	cerebral cortex: 16.9	Cell line enhanced		HHSteC: 122.9;hTCEpi: 95.5;SH-SY5Y: 131.0
CDH23	CDHR23, DFNB12, USH1D	ENSG00000107736	Cadherin related 23	10	71396934-71815947	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017232	Approved				Urothelial cancer:3.40e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 30.2	ovary: 19.4	Cell line enhanced		RT4: 11.9;SCLC-21H: 6.6
VSIR	B7-H5, B7H5, C10orf54, GI24, PD-1H, SISP1, VISTA	ENSG00000107738	V-set immunoregulatory receptor	10	71747559-71773498	Predicted membrane proteins	Evidence at protein level	HPA007968			Approved	Nucleoplasm	Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 184.9	Cell line enhanced		CAPAN-2: 162.4;HaCaT: 105.4;HMC-1: 173.0;U-937: 130.3
SPOCK2	KIAA0275, testican-2	ENSG00000107742	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2	10	72059035-72089032	Predicted secreted proteins	Evidence at protein level	HPA044605	Supported		Uncertain	Nuclear speckles	Head and neck cancer:1.95e-5 (favourable), Breast cancer:4.05e-4 (favourable), Melanoma:4.72e-4 (favourable), Ovarian cancer:7.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 161.8;lung: 127.8	lymph node: 75.1	Group enriched	8	Hep G2: 33.9;SCLC-21H: 79.9
MICU1	CALC, CBARA1, EFHA3, FLJ12684	ENSG00000107745	Mitochondrial calcium uptake 1	10	72367327-72626191	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA037479, HPA037480	Uncertain		Supported	Mitochondria	Renal cancer:4.66e-7 (favourable)	Expressed in all	Expressed in all			kidney: 107.8	Expressed in all		
PPP3CB	CALNA2, CALNB, CNA2, PP2Bbeta	ENSG00000107758	Protein phosphatase 3 catalytic subunit beta	10	73436428-73496024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008233, HPA008823	Uncertain		Approved	Mitochondria	Pancreatic cancer:6.96e-5 (favourable), Liver cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 153.2	Expressed in all		
CCSER2	FAM190B, KIAA1128	ENSG00000107771	Coiled-coil serine rich protein 2	10	84328586-84518521	Predicted intracellular proteins	Evidence at protein level	HPA037481, HPA037482	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 39.5	Expressed in all		
BMPR1A	ACVRLK3, ALK3, CD292	ENSG00000107779	Bone morphogenetic protein receptor type 1A	10	86756601-86932838	Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019398	Approved		Approved	Cytosol	Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.6	Mixed		
MINPP1	MIPP	ENSG00000107789	Multiple inositol-polyphosphate phosphatase 1	10	87504875-87553460	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026859	Approved				Renal cancer:6.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 27.6	Mixed		
ACTA2	ACTSA	ENSG00000107796	Actin, alpha 2, smooth muscle, aorta	10	88935074-88991339	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000002, CAB003761, CAB013531, HPA041264, HPA041271	Enhanced		Supported	Actin filaments	Renal cancer:1.37e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11741.0	Cell line enhanced		ASC TERT1: 273.9;fHDF/TERT166: 496.7;HHSteC: 525.6;HSkMC: 250.7
LIPA	CESD, LAL	ENSG00000107798	Lipase A, lysosomal acid type	10	89213569-89414557	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034892, HPA057052	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			spleen: 496.6	Mixed		
TLX1	HOX11, TCL3	ENSG00000107807	T-cell leukemia homeobox 1	10	101130505-101137789	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Colorectal cancer:7.32e-4 (unfavourable)	Mixed	Tissue enriched	5	spleen: 31.3	salivary gland: 6.0	Cell line enhanced		HAP1: 4.1;K-562: 10.7;SH-SY5Y: 2.9
TWNK	C10orf2, FLJ21832, IOSCA, PEO, PEO1, TWINKLE, TWINL	ENSG00000107815	Twinkle mtDNA helicase	10	100987367-100994401	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002532	Uncertain					Expressed in all	Expressed in all			testis: 13.6	Expressed in all		
LZTS2	KIAA1813, LAPSER1	ENSG00000107816	Leucine zipper tumor suppressor 2	10	100996618-101007836	Predicted intracellular proteins	Evidence at protein level	HPA044956	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.39e-4 (unfavourable), Colorectal cancer:8.23e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,seminal vesicle: 57.9	Expressed in all		
SFXN3	SFX3	ENSG00000107819	Sideroflexin 3	10	101031234-101041244	Predicted membrane proteins	Evidence at protein level	HPA008028, HPA048105	Approved		Enhanced	Mitochondria	Head and neck cancer:3.79e-4 (unfavourable), Renal cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 41.4	Mixed		
KAZALD1	FKSG28, FKSG40	ENSG00000107821	Kazal type serine peptidase inhibitor domain 1	10	101061841-101068131	Predicted secreted proteins	Evidence at protein level	HPA011800	Uncertain				Thyroid cancer:5.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 26.8	cervix, uterine: 15.7	Cell line enhanced		AN3-CA: 35.1;T-47d: 45.4
FBXW4	dactylin, Fbw4, SHFM3	ENSG00000107829	F-box and WD repeat domain containing 4	10	101610664-101695295	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043496	Approved		Approved	Golgi apparatus	Renal cancer:3.41e-5 (favourable), Pancreatic cancer:4.67e-4 (favourable), Endometrial cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
FGF8	AIGF	ENSG00000107831	Fibroblast growth factor 8	10	101770130-101780369	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Group enriched	Tissue enriched	7	skeletal muscle: 15.7	testis: 2.2	Cell line enriched	29	RH-30: 40.4
NPM3		ENSG00000107833	Nucleophosmin/nucleoplasmin 3	10	101781325-101783413	Predicted intracellular proteins	Evidence at protein level	HPA036295, HPA036296	Approved		Approved	Nucleoli<br>Actin filaments<br>Cytosol	Head and neck cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 28.8	Expressed in all		
TNKS2	PARP-5b, PARP-5c, PARP5B, PARP5C, pART6, TANK2, TNKL	ENSG00000107854	Tankyrase 2	10	91798312-91865276	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036606			Approved	Microtubules		Expressed in all	Expressed in all			thyroid gland: 50.4	Expressed in all		
PITX3	ASMD	ENSG00000107859	Paired like homeodomain 3	10	102230186-102241474	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Group enriched	11	adipose tissue: 1.2;skeletal muscle: 5.6	testis: 0.3	Cell line enriched	17	RH-30: 28.7
GBF1	ARF1GEF, KIAA0248	ENSG00000107862	Golgi brefeldin A resistant guanine nucleotide exchange factor 1	10	102245532-102382899	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037759, HPA037760	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 59.2	Expressed in all		
ARHGAP21	ARHGAP10, KIAA1424	ENSG00000107863	Rho GTPase activating protein 21	10	24583609-24723668	Predicted intracellular proteins	Evidence at protein level	HPA036610, HPA057861	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Expressed in all			cerebral cortex: 88.5	Mixed		
CPEB3	KIAA0940	ENSG00000107864	Cytoplasmic polyadenylation element binding protein 3	10	92046692-92291087	Predicted intracellular proteins	Evidence at protein level	HPA059056			Approved	Nucleoplasm<br>Nuclear bodies<br>Intermediate filaments	Renal cancer:3.84e-9 (favourable), Liver cancer:5.06e-5 (favourable)	Mixed	Mixed			testis: 16.2	Cell line enhanced		Karpas-707: 8.9
FBXL15	Fbl15, FBXO37, MGC11279	ENSG00000107872	F-box and leucine rich repeat protein 15	10	102419189-102423136	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.82e-4 (favourable), Urothelial cancer:7.92e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.4	Mixed		
CUEDC2	C10orf66, MGC2491	ENSG00000107874	CUE domain containing 2	10	102423245-102432661	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036544, HPA041829	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.9	Expressed in all		
SUFU	PRO1280, SUFUH, SUFUXL	ENSG00000107882	SUFU negative regulator of hedgehog signaling	10	102503987-102633535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008700	Enhanced		Supported	Nucleus		Expressed in all	Mixed			parathyroid gland: 16.1	Expressed in all		
ANKRD26	KIAA1074, THC2	ENSG00000107890	Ankyrin repeat domain 26	10	26991914-27100498	Predicted intracellular proteins	Evidence at protein level	HPA040654, HPA041460	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 10.7	Expressed in all		
ACBD5	DKFZp434A2417, KIAA1996	ENSG00000107897	Acyl-CoA binding domain containing 5	10	27195214-27242130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011861, HPA012145	Enhanced		Enhanced	Peroxisomes	Renal cancer:4.68e-5 (favourable), Breast cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.1	Expressed in all		
LHPP	HDHD2B	ENSG00000107902	Phospholysine phosphohistidine inorganic pyrophosphate phosphatase	10	124461834-124617888	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009163, HPA009269	Enhanced		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.6	Mixed		
LARP4B	KIAA0217, LARP5	ENSG00000107929	La ribonucleoprotein domain family member 4B	10	806914-931705	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036566, HPA042738	Approved		Enhanced	Cytosol	Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
GTPBP4	CRFG, FLJ10686, FLJ10690, NGB, NOG1	ENSG00000107937	GTP binding protein 4	10	988019-1019936	Predicted intracellular proteins	Evidence at protein level	HPA039618, HPA056468	Uncertain		Enhanced	Nuclear membrane<br>Nucleoli	Liver cancer:8.85e-12 (unfavourable), Renal cancer:2.38e-5 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.3	Expressed in all		
EDRF1	C10orf137, DKFZp586F1019, FLJ21617	ENSG00000107938	Erythroid differentiation regulatory factor 1	10	125719515-125764143	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031820			Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:3.16e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 28.2	Expressed in all		
BCCIP	BCCIPalpha, TOK-1	ENSG00000107949	BRCA2 and CDKN1A interacting protein	10	125823546-125853695	Predicted intracellular proteins	Evidence at protein level	HPA038011			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 89.5	Expressed in all		
MTPAP	FLJ10486, mtPAP, PAPD1, SPAX4	ENSG00000107951	Mitochondrial poly(A) polymerase	10	30309801-30374448	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038620, HPA058232	Approved		Supported	Mitochondria	Liver cancer:4.20e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.7	Expressed in all		
NEURL1	h-neu, neu-1, NEURL, RNF67	ENSG00000107954	Neuralized E3 ubiquitin protein ligase 1	10	103493979-103592552	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA044204	Uncertain					Mixed	Tissue enhanced		skeletal muscle: 50.9	cerebral cortex: 30.1	Cell line enhanced		BEWO: 13.2;SCLC-21H: 20.2;SiHa: 9.4
SH3PXD2A	FISH, KIAA0418, SH3MD1	ENSG00000107957	SH3 and PX domains 2A	10	103594027-103855543	Predicted intracellular proteins	Evidence at protein level	HPA037922, HPA037923	Approved				Renal cancer:2.04e-6 (unfavourable), Ovarian cancer:3.18e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 63.3	Cell line enhanced		BJ hTERT+: 68.9
PITRM1	hMP1, KIAA1104, MP1, PreP	ENSG00000107959	Pitrilysin metallopeptidase 1	10	3137728-3172841	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006753, HPA006754	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 86.6	Expressed in all		
STN1	bA541N10.2, FLJ22559, OBFC1	ENSG00000107960	STN1, CST complex subunit	10	103882542-103918205	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037924, HPA037925			Supported	Nucleus	Renal cancer:1.12e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.8	Expressed in all		
MAP3K8	c-COT, COT, EST, ESTF, MEKK8, Tpl-2	ENSG00000107968	Mitogen-activated protein kinase kinase kinase 8	10	30433937-30461833	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005120, HPA017962	Supported		Supported	Cytosol	Renal cancer:8.76e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 209.6	Mixed		
DKK1	DKK-1, SK	ENSG00000107984	Dickkopf WNT signaling pathway inhibitor 1	10	52314296-52318042	Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.35e-8 (unfavourable), Lung cancer:7.80e-6 (unfavourable), Pancreatic cancer:1.27e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 56.5;placenta: 71.9	urinary bladder: 14.5	Cell line enhanced		BJ: 975.2;CACO-2: 841.6;fHDF/TERT166: 1247.0
EBF3	COE3, DKFZp667B0210	ENSG00000108001	Early B-cell factor 3	10	129835283-129963841	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061169			Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		adipose tissue: 20.1	lymph node: 12.7	Cell line enhanced		HAP1: 23.0;LHCN-M2: 29.6;NB-4: 29.2;RH-30: 18.6;SCLC-21H: 53.2
GLRX3	bA500G10.4, GLRX4, GRX3, GRX4, PICOT, TXNL2	ENSG00000108010	Glutaredoxin 3	10	130136399-130184521	Predicted intracellular proteins	Evidence at protein level	HPA028941	Approved				Liver cancer:9.03e-6 (unfavourable), Renal cancer:9.24e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 119.3	Expressed in all		
SORCS1	sorCS1	ENSG00000108018	Sortilin related VPS10 domain containing receptor 1	10	106573663-107164534	Predicted membrane proteins	Evidence at protein level	HPA011948	Approved		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2;thyroid gland: 18.1	kidney: 4.8	Group enriched	12	RH-30: 78.2;SH-SY5Y: 111.4
FAM208B	bA318E3.2, C10orf18, FLJ20360, KIAA2006	ENSG00000108021	Family with sequence similarity 208 member B	10	5684838-5763740	Predicted intracellular proteins	Evidence at protein level	HPA038042, HPA038043, HPA061547	Uncertain		Supported	Nucleus<br>Cytosol	Liver cancer:2.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.0	Expressed in all		
XPNPEP1	XPNPEP, XPNPEPL, XPNPEPL1	ENSG00000108039	X-prolyl aminopeptidase 1	10	109864766-109923553	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025196, HPA030419, HPA030420, HPA030422	Supported		Enhanced	Cytosol	Liver cancer:2.12e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 66.1	Expressed in all		
SMC3	BAM, bamacan, CSPG6, HCAP, SMC3L1	ENSG00000108055	Structural maintenance of chromosomes 3	10	110567691-110604636	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037411, HPA043206	Uncertain		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
SHOC2	KIAA0862, SOC-2, SOC2, SUR-8, SUR8	ENSG00000108061	SHOC2, leucine rich repeat scaffold protein	10	110919547-111013667	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009164			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 65.3	Expressed in all		
TFAM	TCF6, TCF6L2	ENSG00000108064	Transcription factor A, mitochondrial	10	58385022-58399221	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA040648, HPA063684	Supported		Enhanced	Mitochondria	Renal cancer:2.22e-5 (favourable), Ovarian cancer:2.74e-4 (favourable), Endometrial cancer:8.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 62.3	Expressed in all		
CCDC6	D10S170, H4, PTC, TPC, TST1	ENSG00000108091	Coiled-coil domain containing 6	10	59788763-59906656	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019049, HPA019051	Enhanced		Supported	Cytosol	Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.95e-4 (unfavourable), Head and neck cancer:5.48e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 44.4	Expressed in all		
CUL2		ENSG00000108094	Cullin 2	10	35008551-35090642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002677, HPA024578	Approved		Enhanced	Nucleoplasm	Liver cancer:8.24e-6 (unfavourable), Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 65.1	Expressed in all		
CCNY	C10orf9, CBCP1, CFP1	ENSG00000108100	Cyclin Y	10	35247025-35572669	Predicted intracellular proteins	Evidence at protein level	HPA036290	Approved				Liver cancer:6.75e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 149.9	Expressed in all		
UBE2S	E2-EPF	ENSG00000108106	Ubiquitin conjugating enzyme E2 S	19	55399745-55407777	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB015228, HPA057150	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.00e-6 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 120.1	Expressed in all		
RPL28	FLJ43307, L28	ENSG00000108107	Ribosomal protein L28	19	55385345-55403250	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050459	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.61e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 1969.2	Expressed in all		
ZMIZ1	FLJ13541, hZIMP10, KIAA1224, MIZ, RAI17, RP11-519K18.1, Zimp10	ENSG00000108175	Zinc finger MIZ-type containing 1	10	79069035-79316528	Predicted intracellular proteins	Evidence at protein level	HPA045144	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:3.64e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 65.3	Mixed		
DNAJC12	JDP1	ENSG00000108176	DnaJ heat shock protein family (Hsp40) member C12	10	67796665-67838166	Predicted intracellular proteins	Evidence at protein level	HPA036289	Enhanced				Renal cancer:1.97e-10 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 57.7	breast: 39.4	Cell line enhanced		Daudi: 66.4;SCLC-21H: 86.3
PPIF	Cyp-D, hCyP3	ENSG00000108179	Peptidylprolyl isomerase F	10	79347469-79355337	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA077416			Supported	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 188.4	Expressed in all		
PBLD	FLJ14767, MAWBP, MAWDBP	ENSG00000108187	Phenazine biosynthesis like protein domain containing	10	68282660-68333049	Predicted intracellular proteins	Evidence at protein level	HPA038035, HPA038036	Enhanced		Approved	Vesicles	Liver cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			kidney: 278.7	Expressed in all		
TSPAN14	DC-TM4F2, MGC11352, TM4SF14	ENSG00000108219	Tetraspanin 14	10	80454166-80533123	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014773, HPA057174	Uncertain		Supported	Vesicles	Cervical cancer:3.56e-4 (favourable), Renal cancer:4.20e-4 (favourable)	Expressed in all	Expressed in all			placenta: 129.4	Mixed		
LGI1	EPITEMPIN, EPT, ETL1, IB1099	ENSG00000108231	Leucine rich glioma inactivated 1	10	93757809-93806272	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	11	cerebral cortex: 45.4	esophagus: 4.2	Group enriched	5	AF22: 9.4;NTERA-2: 6.4
TBC1D12	KIAA0608	ENSG00000108239	TBC1 domain family member 12	10	94402504-94535930	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038277, HPA038645	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Colorectal cancer:1.79e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Mixed		
CYP2C18	CPCI, CYP2C, CYP2C17, P450IIC17	ENSG00000108242	Cytochrome P450 family 2 subfamily C member 18	10	94683621-94736190	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	duodenum: 103.1;esophagus: 24.6;gallbladder: 24.5;liver: 97.8;small intestine: 88.1;stomach: 62.2	tonsil: 6.2	Cell line enhanced		BEWO: 3.0
KRT23	CK23, DKFZP434G032, HAIK1, K23, MGC26158	ENSG00000108244	Keratin 23	17	40922696-40937634	Predicted intracellular proteins	Evidence at protein level	HPA012050, HPA016959, CAB017091	Approved		Approved	Intermediate filaments<br>Cytosol	Urothelial cancer:8.26e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 68.6;skin: 70.9	salivary gland: 41.2	Group enriched	8	HBEC3-KT: 28.8;Hep G2: 17.3;T-47d: 63.7
CRYBA1	CRYB1	ENSG00000108255	Crystallin beta A1	17	29246863-29254494	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022016	Supported					Not detected	Not detected			appendix: 0.2	Group enriched	8	AF22: 3.2;BEWO: 4.1
NUFIP2	182-FIP, 82-FIP, FIP-82, KIAA1321, MGC117262, PIG1	ENSG00000108256	NUFIP2, FMR1 interacting protein 2	17	29255836-29294118	Predicted intracellular proteins	Evidence at protein level	HPA067443			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 53.3	Expressed in all		
GIT1		ENSG00000108262	GIT ArfGAP 1	17	29573469-29594054	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004059, HPA004186	Approved		Enhanced	Focal adhesion sites<br>Cytosol	Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 127.3	Expressed in all		
RPL19	DKFZp779D216, FLJ27452, L19, MGC71997	ENSG00000108298	Ribosomal protein L19	17	39200283-39204727	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043014, HPA051987	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:6.87e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4350.4	Cell line enriched	6	SK-BR-3: 28538.8
FBXL20	Fbl2, Fbl20, MGC15482	ENSG00000108306	F-box and leucine rich repeat protein 20	17	39252644-39402523	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044748, HPA050397	Uncertain		Supported	Microtubules	Ovarian cancer:9.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 23.0	Expressed in all		
RUNDC3A	RAP2IP, RPIP8	ENSG00000108309	RUN domain containing 3A	17	44308413-44318671	Predicted intracellular proteins	Evidence at protein level	HPA023548, HPA070733	Enhanced	Supported	Approved	Vesicles		Tissue enhanced	Tissue enriched	10	cerebral cortex: 178.0	adrenal gland: 18.2	Group enriched	8	SCLC-21H: 72.5;SH-SY5Y: 41.7
UBTF	NOR-90, UBF, UBF1, UBF2	ENSG00000108312	Upstream binding transcription factor, RNA polymerase I	17	44205033-44221626	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004611, HPA006385	Enhanced	Supported	Enhanced	Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 81.5	Expressed in all		
CSF3	C17orf33, G-CSF, GCSF, MGC45931	ENSG00000108342	Colony stimulating factor 3	17	40015361-40017813	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:8.45e-4 (favourable)	Mixed	Tissue enhanced		appendix: 19.1;cervix, uterine: 38.2	adipose tissue: 10.3	Cell line enhanced		BJ hTERT+: 57.2;hTEC/SVTERT24-B: 34.2;U-87 MG: 265.0
PSMD3	P58, Rpn3, S3, TSTA2	ENSG00000108344	Proteasome 26S subunit, non-ATPase 3	17	39980797-39997960	Predicted intracellular proteins	Evidence at protein level	CAB017038, HPA048972	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.47e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 83.6	Expressed in all		
CASC3	BTZ, MLN51	ENSG00000108349	Cancer susceptibility 3	17	40140318-40172183	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024592, HPA050262	Approved		Approved	Nuclear membrane		Expressed in all	Expressed in all			testis: 95.2	Expressed in all		
RAPGEFL1	Link-GEFII	ENSG00000108352	Rap guanine nucleotide exchange factor like 1	17	40177010-40195656	Predicted intracellular proteins	Evidence at protein level	HPA022895			Approved	Nucleus<br>Microtubules<br>Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Cervical cancer:3.28e-4 (favourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 277.1	esophagus: 93.2	Expressed in all		
RGS9	MGC111763, MGC26458, PERRS, RGS9L	ENSG00000108370	Regulator of G-protein signaling 9	17	65100812-65227703	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013550, HPA014137	Supported	Supported	Uncertain	Nucleoplasm	Pancreatic cancer:1.35e-4 (favourable)	Mixed	Mixed			fallopian tube: 5.5	Group enriched	9	HDLM-2: 24.5;HEL: 9.6
RNF43	DKFZp781H0392, FLJ20315, URCC	ENSG00000108375	Ring finger protein 43	17	58352500-58417595	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008079	Uncertain				Renal cancer:6.04e-9 (favourable)	Tissue enhanced	Mixed			duodenum: 23.4	Cell line enhanced		CACO-2: 20.6;Hep G2: 33.5
WNT3	INT4, MGC131950, MGC138321, MGC138323	ENSG00000108379	Wnt family member 3	17	46762506-46833154	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	6	duodenum: 2.2;parathyroid gland: 4.3;skin: 9.3	cerebral cortex: 0.9	Cell line enhanced		AF22: 6.9;U-698: 5.4
ASPA	ACY2, ASP	ENSG00000108381	Aspartoacylase	17	3472374-3503419	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022142, HPA022145	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		kidney: 39.8	cerebral cortex: 24.7	Cell line enhanced		ASC diff: 3.7;HSkMC: 5.5
RAD51C	FANCO, RAD51L2	ENSG00000108384	RAD51 paralog C	17	58692573-58735611	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045198			Supported	Nucleus<br>Vesicles<br>Cell Junctions<br>Mitochondria<br>Cytosol	Liver cancer:8.68e-5 (unfavourable), Pancreatic cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.3	Expressed in all		
SEPT4	ARTS, CE5B3, H5, hCDCREL-2, hucep-7, MART, PNUTL2	ENSG00000108387	Septin 4	17	58520250-58540818	Predicted intracellular proteins	Evidence at protein level	CAB006855, HPA021587, HPA022905	Enhanced		Supported	Nucleoplasm	Renal cancer:3.28e-7 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 217.2;cerebral cortex: 287.9	spleen: 56.8	Cell line enhanced		HHSteC: 11.8;SK-MEL-30: 25.2
MTMR4	KIAA0647, ZFYVE11	ENSG00000108389	Myotubularin related protein 4	17	58489529-58517905	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.53e-5 (unfavourable), Pancreatic cancer:5.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
TRIM37	KIAA0898, MUL, POB1, TEF3	ENSG00000108395	Tripartite motif containing 37	17	58982638-59106921	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021911	Uncertain				Liver cancer:4.99e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 117.5	Expressed in all		
P2RX1	P2X1	ENSG00000108405	Purinergic receptor P2X 1	17	3896592-3916500	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		seminal vesicle: 46.2;urinary bladder: 41.9	bone marrow: 26.3	Cell line enhanced		HEL: 12.5;HMC-1: 7.5;Karpas-707: 12.1;THP-1: 9.6;U-937: 5.8
DHX40	ARG147, DDX40, FLJ22060, PAD	ENSG00000108406	DEAH-box helicase 40	17	59565525-59608345	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044350	Uncertain		Supported	Nucleus	Colorectal cancer:4.05e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.6	Expressed in all		
KRT37	KRTHA7	ENSG00000108417	Keratin 37	17	41420753-41424523	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		skin: 1.2	cervix, uterine: 0.3	Not detected		
TUBD1	FLJ12709, TUBD	ENSG00000108423	Tubulin delta 1	17	59859482-59892945	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004609, HPA023980, HPA027090	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 12.5	Expressed in all		
KPNB1	IMB1, Impnb, IPO1, IPOB, MGC2155, MGC2156, MGC2157, NTF97	ENSG00000108424	Karyopherin subunit beta 1	17	47649476-47685505	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029878, CAB034449, HPA050302	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Liver cancer:2.55e-7 (unfavourable), Renal cancer:8.43e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 219.3	Expressed in all		
GOSR2	Bos1, GS27	ENSG00000108433	Golgi SNAP receptor complex member 2	17	46923075-46975524	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017456, HPA048956, HPA054472	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.6	Expressed in all		
PNPO	PDXPO	ENSG00000108439	Pyridoxamine 5'-phosphate oxidase	17	47941506-47948288	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023204, HPA027776	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 51.3	Mixed		
RPS6KB1	p70(S6K)-alpha, PS6K, S6K1, STK14A	ENSG00000108443	Ribosomal protein S6 kinase B1	17	59893046-59950564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003838, CAB018346, HPA039442	Approved		Supported	Nucleoplasm	Renal cancer:5.09e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
TRIM16L	TRIM70	ENSG00000108448	Tripartite motif containing 16-like	17	18697998-18736118	Predicted intracellular proteins	Evidence at protein level	HPA066431			Approved	Plasma membrane<br>Cytosol	Thyroid cancer:2.29e-5 (unfavourable), Liver cancer:2.87e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 22.7	Cell line enhanced		A549: 290.9;HeLa: 215.6
CDK5RAP3	C53, FLJ13660, HSF-27, IC53, LZAP, MST016, OK/SW-cl.114	ENSG00000108465	CDK5 regulatory subunit associated protein 3	17	47967810-47981774	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022141, HPA022882, HPA027883	Supported		Supported	Cytosol	Renal cancer:3.61e-5 (unfavourable), Urothelial cancer:7.31e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 110.2	Expressed in all		
CBX1	CBX, HP1-BETA, HP1Hs-beta, M31, MOD1	ENSG00000108468	Chromobox 1	17	48070052-48101521	Predicted intracellular proteins	Evidence at protein level	CAB012265	Supported		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 125.3	Expressed in all		
RECQL5	FLJ90603, RecQ5	ENSG00000108469	RecQ like helicase 5	17	75626845-75667189	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029971			Supported	Nucleus<br>Cytosol	Endometrial cancer:1.73e-6 (unfavourable), Pancreatic cancer:4.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.9	Expressed in all		
PIGL		ENSG00000108474	Phosphatidylinositol glycan anchor biosynthesis class L	17	16217191-16351797	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012739	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.47e-4 (unfavourable), Prostate cancer:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis,thyroid gland: 14.7	Mixed		
GALK1	GALK	ENSG00000108479	Galactokinase 1	17	75751594-75765711	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007094, HPA016960	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.55e-6 (unfavourable), Urothelial cancer:1.62e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 23.4	Expressed in all		
INTS2	INT2, KIAA1287	ENSG00000108506	Integrator complex subunit 2	17	61865367-61928016	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049524	Uncertain				Thyroid cancer:2.20e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.5	Expressed in all		
CAMTA2	KIAA0909	ENSG00000108509	Calmodulin binding transcription activator 2	17	4967992-4987652	Predicted intracellular proteins	Evidence at protein level	HPA051147			Approved	Nucleus<br>Actin filaments<br>Mitochondria	Pancreatic cancer:6.00e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.5	Mixed		
MED13	KIAA0593, THRAP1, TRAP240	ENSG00000108510	Mediator complex subunit 13	17	61942605-62065282	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA067939			Supported	Nucleus	Colorectal cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland,testis: 35.7	Expressed in all		
HOXB6	HOX2, HOX2B	ENSG00000108511	Homeobox B6	17	48595751-48604992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042063			Approved	Nucleus<br>Golgi apparatus	Endometrial cancer:2.46e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 48.7;seminal vesicle: 30.1	cervix, uterine: 26.4	Cell line enhanced		HEK 293: 71.9;RPTEC TERT1: 39.9
ENO3		ENSG00000108515	Enolase 3	17	4948092-4957131	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000793, HPA068284, HPA068721	Enhanced		Supported	Plasma membrane<br>Cytosol	Colorectal cancer:7.33e-4 (unfavourable)	Expressed in all	Tissue enriched	17	skeletal muscle: 5974.6	heart muscle: 350.1	Expressed in all		
PFN1		ENSG00000108518	Profilin 1	17	4945652-4949061	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB037134, CAB037140	Enhanced		Supported	Cytosol	Renal cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 890.4	Expressed in all		
RNF167	DKFZP566H073	ENSG00000108523	Ring finger protein 167	17	4940008-4945222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049810	Approved		Approved	Cytosol	Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Expressed in all		
SLC25A11	OGC, SLC20A4	ENSG00000108528	Solute carrier family 25 member 11	17	4937130-4940251	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021167	Approved				Renal cancer:2.84e-9 (favourable), Pancreatic cancer:6.41e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 152.4	Expressed in all		
RASD1	AGS1, DEXRAS1	ENSG00000108551	Ras related dexamethasone induced 1	17	17494437-17496395	Predicted intracellular proteins	Evidence at protein level	HPA047896	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 113.2	Cell line enhanced		ASC diff: 48.2;REH: 65.3
CHRNE	ACHRE	ENSG00000108556	Cholinergic receptor nicotinic epsilon subunit	17	4897774-4903074	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	26	heart muscle: 33.9	epididymis: 1.3	Group enriched	15	HEL: 3.9;HMC-1: 9.2
RAI1	DKFZP434A139, KIAA1820, MGC12824, SMCR, SMS	ENSG00000108557	Retinoic acid induced 1	17	17681473-17811453	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023898, HPA054906	Approved		Enhanced	Nucleoplasm	Ovarian cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.7	Expressed in all		
NUP88	MGC8530	ENSG00000108559	Nucleoporin 88	17	5360963-5420160	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002209, HPA021816	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 94.6	Expressed in all		
C1QBP	gC1Q-R, gC1qR, HABP1, p32, SF2p32	ENSG00000108561	Complement C1q binding protein	17	5432777-5448830	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA026483	Supported		Approved	Plasma membrane<br>Mitochondria		Expressed in all	Expressed in all			rectum: 157.0	Expressed in all		
SLC6A4	5-HTT, HTT, OCD1, SERT1	ENSG00000108576	Solute carrier family 6 member 4	17	30194319-30236002	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071354, HPA074728		Supported	Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Group enriched	10	duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3	esophagus: 3.1	Cell line enhanced		BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
BLMH	BH	ENSG00000108578	Bleomycin hydrolase	17	30248195-30292056	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039548, HPA064307	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			skin: 139.9	Mixed		
CPD	GP180	ENSG00000108582	Carboxypeptidase D	17	30378905-30469989	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052796, HPA055465	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Nuclear speckles		Expressed in all	Expressed in all			thyroid gland: 94.8	Expressed in all		
GOSR1	GOLIM2, GOS-28, GOS28, GS28, P28	ENSG00000108587	Golgi SNAP receptor complex member 1	17	30477362-30527592	Predicted membrane proteins	Evidence at protein level	HPA020590	Uncertain				Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.5	Expressed in all		
CCDC47	GK001	ENSG00000108588	Coiled-coil domain containing 47	17	63745250-63776351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029674, HPA072573	Approved		Enhanced	Endoplasmic reticulum	Colorectal cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 161.4	Expressed in all		
MED31	CGI-125, Soh1	ENSG00000108590	Mediator complex subunit 31	17	6643315-6651634	Predicted intracellular proteins	Evidence at protein level	HPA035947	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 32.2	Expressed in all		
DRG2		ENSG00000108591	Developmentally regulated GTP binding protein 2	17	18087886-18107971	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007716	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Endometrial cancer:1.56e-4 (favourable), Prostate cancer:7.34e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 29.4	Expressed in all		
FTSJ3	SPB1	ENSG00000108592	FtsJ homolog 3	17	63819433-63830012	Predicted intracellular proteins	Evidence at protein level	HPA055544, HPA062628	Supported		Enhanced	Nucleoli	Liver cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
AKAP10	D-AKAP2, MGC9414, PRKA10	ENSG00000108599	A-kinase anchoring protein 10	17	19904302-19978343	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028901	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
ALDH3A1	ALDH3	ENSG00000108602	Aldehyde dehydrogenase 3 family member A1	17	19737984-19748943	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB045957, HPA051150, HPA063783	Enhanced		Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Head and neck cancer:7.55e-5 (favourable)	Mixed	Group enriched	7	esophagus: 406.1;skin: 84.3;stomach: 207.2	tonsil: 31.0	Cell line enriched	21	A549: 4306.9
SMARCD2	BAF60B, CRACD2, PRO2451, Rsc6p	ENSG00000108604	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 2	17	63832081-63843065	Predicted intracellular proteins	Evidence at protein level	HPA059934, HPA061348			Enhanced	Nucleoplasm	Melanoma:3.51e-4 (unfavourable), Renal cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 104.6	Expressed in all		
ICAM2	CD102	ENSG00000108622	Intercellular adhesion molecule 2	17	64002594-64020634	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071155			Uncertain	Cytosol		Expressed in all	Expressed in all			spleen: 200.5	Group enriched	7	HUVEC TERT2: 1043.9;TIME: 259.9
SYNGR2		ENSG00000108639	Synaptogyrin 2	17	78168558-78173527	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014742	Approved		Approved	Golgi apparatus	Renal cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 154.3	Mixed		
B9D1	B9, EPPB9, MKS9	ENSG00000108641	B9 domain containing 1	17	19337554-19378182	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022957	Approved				Renal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 102.1	Mixed		
UTP6	C17orf40, HCA66	ENSG00000108651	UTP6, small subunit processome component	17	31860899-31901765	Predicted intracellular proteins	Evidence at protein level	HPA025936, HPA055806	Enhanced		Enhanced	Nucleoli	Renal cancer:1.16e-6 (unfavourable), Liver cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 15.7	Expressed in all		
DDX5	G17P1, HLR1, p68	ENSG00000108654	DEAD-box helicase 5	17	64499616-64508199	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005868, HPA020043	Supported		Enhanced	Nucleoplasm	Colorectal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 599.5	Expressed in all		
C17orf75	NJMU-R1, SRI2	ENSG00000108666	Chromosome 17 open reading frame 75	17	32324565-32350023	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004061	Approved	Approved	Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.33e-4 (favourable), Ovarian cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.6	Expressed in all		
CYTH1	B2-1, cytohesin-1, D17S811E, PSCD1	ENSG00000108669	Cytohesin 1	17	78674048-78782297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047498			Uncertain	Nucleus<br>Nucleoli	Head and neck cancer:6.48e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 92.5	Expressed in all		
PSMD11	MGC3844, p44.5, Rpn6, S9	ENSG00000108671	Proteasome 26S subunit, non-ATPase 11	17	32444261-32483318	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042275, HPA067433	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.73e-6 (unfavourable), Liver cancer:6.33e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.7	Expressed in all		
LGALS3BP	90K, BTBD17B, CyCAP, gp90, M2BP, MAC-2-BP, TANGO10B	ENSG00000108679	Galectin 3 binding protein	17	78971238-78980109	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000554, CAB002158	Supported				Renal cancer:1.07e-6 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 323.2	Cell line enhanced		SK-BR-3: 1216.4
ASIC2	ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG	ENSG00000108684	Acid sensing ion channel subunit 2	17	33013087-34174964	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA052112	Enhanced					Tissue enhanced	Group enriched	6	cerebral cortex: 8.6;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.2	adrenal gland: 0.8	Cell line enhanced		NTERA-2: 1.1
CCL7	FIC, MARC, MCP-3, MCP3, NC28, SCYA6, SCYA7	ENSG00000108688	C-C motif chemokine ligand 7	17	34270221-34272242	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 3.6;bone marrow: 15.2	gallbladder,rectum: 1.1	Cell line enhanced		BJ hTERT+: 9.3;BJ hTERT+ SV40 Large T+: 2.2;BJ hTERT+ SV40 Large T+ RasG12V: 2.8;HSkMC: 2.4
CCL2	GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF	ENSG00000108691	C-C motif chemokine ligand 2	17	34255218-34257203	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB013676, HPA019163	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 411.3	Group enriched	5	BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8
CCL8	HC14, MCP-2, SCYA8	ENSG00000108700	C-C motif chemokine ligand 8	17	34319036-34321402	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.05e-7 (unfavourable)	Mixed	Mixed			adipose tissue: 13.1	Cell line enhanced		EFO-21: 1.3;HSkMC: 1.4
CCL1	I-309, P500, SCYA1, SISe, TCA3	ENSG00000108702	C-C motif chemokine ligand 1	17	34360328-34363231	Predicted secreted proteins	Evidence at protein level	HPA049861	Uncertain					Not detected	Tissue enriched	5	rectum: 2.6	cerebral cortex,testis: 0.4	Cell line enriched	50	HMC-1: 622.2
PEX12		ENSG00000108733	Peroxisomal biogenesis factor 12	17	35574795-35578863	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069386	Enhanced				Renal cancer:3.58e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.3	Mixed		
KRT32	Ha-2, KRTHA2	ENSG00000108759	Keratin 32	17	41459811-41467429	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	14	esophagus: 7.4;skin: 2.4	breast: 0.3	Not detected		
DHX58	D11LGP2, LGP2	ENSG00000108771	DExH-box helicase 58	17	42101404-42112733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018670, HPA019570	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:3.45e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 42.1;BJ hTERT+ SV40 Large T+ RasG12V: 51.2
KAT2A	GCN5, GCN5L2, PCAF-b	ENSG00000108773	Lysine acetyltransferase 2A	17	42113108-42121358	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048958	Uncertain				Renal cancer:1.41e-8 (unfavourable), Pancreatic cancer:3.57e-4 (favourable)	Expressed in all	Expressed in all			skin: 10.9	Mixed		
RAB5C	RAB5CL, RABL	ENSG00000108774	RAB5C, member RAS oncogene family	17	42124976-42155044	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003426, HPA004167	Approved		Enhanced	Endosomes	Head and neck cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 180.6	Mixed		
NAGLU	NAG	ENSG00000108784	N-acetyl-alpha-glucosaminidase	17	42536172-42544449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038815	Supported	Approved			Renal cancer:2.58e-6 (favourable), Glioma:3.43e-4 (unfavourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.5	Expressed in all		
HSD17B1	EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1	ENSG00000108786	Hydroxysteroid 17-beta dehydrogenase 1	17	42549214-42555213	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021032, HPA065296	Enhanced		Supported	Cytosol		Mixed	Tissue enriched	14	placenta: 98.3	cerebral cortex: 7.1	Cell line enriched	8	BEWO: 331.8
MLX	bHLHd13, MAD7, MXD7, TCFL4	ENSG00000108788	MLX, MAX dimerization protein	17	42567068-42573239	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025329, HPA052766, HPA064438	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			duodenum: 46.3	Expressed in all		
CNTNAP1	Caspr, CNTNAP, NRXN4, p190	ENSG00000108797	Contactin associated protein 1	17	42682613-42699814	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011772	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-14 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 61.8;smooth muscle: 38.9	endometrium: 19.2	Cell line enhanced		TIME: 59.4;U-138 MG: 80.6
ABI3	NESH, SSH3BP3	ENSG00000108798	ABI family member 3	17	49210227-49223225	Predicted intracellular proteins	Evidence at protein level	HPA017345	Enhanced				Endometrial cancer:7.13e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 62.0	lymph node: 29.9	Cell line enhanced		Daudi: 28.2;HDLM-2: 21.3;HUVEC TERT2: 54.6;TIME: 38.1
EZH1	KIAA0388, KMT6B	ENSG00000108799	Enhancer of zeste 1 polycomb repressive complex 2 subunit	17	42700275-42745049	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005478, HPA077684	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			ovary: 58.7	Expressed in all		
DLX4	BP1, DLX7, DLX8, DLX9	ENSG00000108813	Distal-less homeobox 4	17	49968970-49974959	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059933	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		placenta: 5.4	skin: 1.2	Cell line enhanced		BEWO: 22.0;CACO-2: 13.7;HAP1: 11.5;K-562: 12.0
PPP1R9B	PPP1R6, PPP1R9, SPINO, Spn	ENSG00000108819	Protein phosphatase 1 regulatory subunit 9B	17	50133735-50150630	Predicted intracellular proteins	Evidence at protein level	CAB022461	Approved				Pancreatic cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.2	Expressed in all		
COL1A1	OI4	ENSG00000108821	Collagen type I alpha 1 chain	17	50183289-50201632	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008405, HPA011795	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 1872.5	Cell line enhanced		BJ: 2487.8;fHDF/TERT166: 3474.4;HSkMC: 1569.1;U-138 MG: 2286.9
SGCA	A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1	ENSG00000108823	Sarcoglycan alpha	17	50164214-50175931	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007537	Uncertain					Mixed	Tissue enhanced		heart muscle: 79.5;skeletal muscle: 181.4	seminal vesicle: 38.3	Cell line enriched	13	LHCN-M2: 65.0
PTGES3L-AARSD1		ENSG00000108825	PTGES3L-AARSD1 readthrough	17	42950526-42980528	Predicted intracellular proteins	Evidence at protein level	HPA021408, HPA022869, HPA023714	Approved		Approved	Nuclear membrane<br>Cytosol		Not detected	Tissue enhanced		smooth muscle: 7.5	testis: 4.0	Cell line enhanced		THP-1: 6.4
MRPL27		ENSG00000108826	Mitochondrial ribosomal protein L27	17	50367857-50373214	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA021416	Approved					Expressed in all	Expressed in all			epididymis: 131.5	Expressed in all		
VAT1	FLJ20230, VATI	ENSG00000108828	Vesicle amine transport 1	17	43014605-43025123	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045170	Uncertain				Liver cancer:1.39e-4 (unfavourable), Renal cancer:5.89e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 241.6	Expressed in all		
LRRC59	FLJ21675, PRO1855	ENSG00000108829	Leucine rich repeat containing 59	17	50375059-50397553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030827, HPA030829	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.19e-6 (unfavourable), Liver cancer:3.12e-6 (unfavourable), Head and neck cancer:1.00e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Colorectal cancer:2.60e-4 (favourable), Pancreatic cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 92.0	Expressed in all		
RND2	ARHN, Rho7, RhoN	ENSG00000108830	Rho family GTPase 2	17	43025241-43032036	Predicted intracellular proteins	Evidence at protein level	HPA077757	Approved					Group enriched	Tissue enhanced		cerebral cortex: 37.0;testis: 30.7	thyroid gland: 11.0	Cell line enhanced		AF22: 11.9;AN3-CA: 14.4;HAP1: 12.5;NTERA-2: 17.2;SH-SY5Y: 11.0
ALOX12	12S-LOX	ENSG00000108839	Arachidonate 12-lipoxygenase, 12S type	17	6996065-7010736	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010691, CAB019287	Approved		Supported	Nuclear speckles<br>Cytosol		Mixed	Group enriched	8	esophagus: 50.3;skin: 25.9	gallbladder: 5.0	Group enriched	5	A-431: 22.4;HEL: 36.7
HDAC5	FLJ90614, KIAA0600, NY-CO-9	ENSG00000108840	Histone deacetylase 5	17	44076746-44123702	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB019400, HPA030991	Approved		Supported	Nuclear speckles<br>Golgi apparatus<br>Cytosol	Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.0	Mixed		
ABCC3	cMOAT2, EST90757, MLP2, MOAT-D, MRP3	ENSG00000108846	ATP binding cassette subfamily C member 3	17	50634777-50692252	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037136, HPA048483	Enhanced		Approved	Plasma membrane	Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 20.7	Cell line enhanced		A549: 69.8;CAPAN-2: 51.3
LUC7L3	CRA, CREAP-1, CROP, FLJ11063, hLuc7A, LUC7A, OA48-18	ENSG00000108848	LUC7 like 3 pre-mRNA splicing factor	17	50719544-50756213	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018475, HPA018484, HPA020017	Enhanced		Enhanced	Nuclear speckles	Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.05e-5 (unfavourable), Urothelial cancer:5.35e-5 (favourable), Pancreatic cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 236.1	Expressed in all		
PPY	PNP	ENSG00000108849	Pancreatic polypeptide	17	43940804-43942468	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016735, HPA032122	Enhanced					Tissue enriched	Tissue enhanced		pancreas: 35.3;parathyroid gland: 33.7	rectum,skin: 8.3	Cell line enhanced		BEWO: 3.6;EFO-21: 3.2;U-2 OS: 4.0
MPP2	DKFZp761D0712, DLG2	ENSG00000108852	Membrane palmitoylated protein 2	17	43875357-43909711	Predicted intracellular proteins	Evidence at protein level	HPA026486	Approved		Approved	Mitochondria<br>Cytosol	Endometrial cancer:1.87e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 37.9;epididymis: 33.0;parathyroid gland: 43.8	testis: 24.0	Mixed		
SMURF2		ENSG00000108854	SMAD specific E3 ubiquitin protein ligase 2	17	64542295-64662068	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071508	Enhanced		Supported	Nuclear speckles		Expressed in all	Mixed			testis: 32.9	Expressed in all		
DUSP3	VHR	ENSG00000108861	Dual specificity phosphatase 3	17	43766121-43778988	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063616			Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.49e-5 (favourable), Head and neck cancer:3.00e-4 (unfavourable), Glioma:9.23e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 100.8	Mixed		
CACNG1	CACNLG	ENSG00000108878	Calcium voltage-gated channel auxiliary subunit gamma 1	17	67044590-67056797	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	25	skeletal muscle: 113.4	esophagus: 4.4	Cell line enhanced		HSkMC: 2.2;SH-SY5Y: 1.0
EFTUD2	SNRNP116, Snrp116, Snu114, U5-116KD	ENSG00000108883	Elongation factor Tu GTP binding domain containing 2	17	44849943-44899662	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022021	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.71e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 47.7	Expressed in all		
HLF	MGC33822	ENSG00000108924	HLF, PAR bZIP transcription factor	17	55265012-55325065	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068156, HPA071210			Enhanced	Nucleus	Lung cancer:2.71e-7 (favourable), Renal cancer:3.55e-6 (favourable), Head and neck cancer:1.88e-4 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 65.4	Group enriched	5	HDLM-2: 25.3;Hep G2: 110.7
SLC16A6	MCT6, MCT7	ENSG00000108932	Solute carrier family 16 member 6	17	68267026-68291267	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054459, HPA066328	Uncertain		Approved	Vesicles		Group enriched	Tissue enhanced		epididymis: 39.4	esophagus: 12.1	Cell line enriched	11	SK-MEL-30: 392.2
PRKAR1A	CNC1, PRKAR1, TSE1	ENSG00000108946	Protein kinase cAMP-dependent type I regulatory subunit alpha	17	68511780-68551319	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019378, HPA049979	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 564.4	Expressed in all		
EFNB3	EPLG8, LERK-8	ENSG00000108947	Ephrin B3	17	7705202-7711378	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA001623	Approved		Approved	Nucleoplasm	Endometrial cancer:5.52e-4 (unfavourable), Pancreatic cancer:8.21e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 48.7	endometrium: 17.4	Cell line enhanced		AF22: 53.1;AN3-CA: 29.8;SH-SY5Y: 29.8
FAM20A	DKFZp434F2322	ENSG00000108950	FAM20A, golgi associated secretory pathway pseudokinase	17	68535113-68601389	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048964	Approved				Renal cancer:9.16e-10 (unfavourable)	Mixed	Mixed			lung: 8.8	Group enriched	5	ASC TERT1: 13.0;BJ hTERT+: 36.5;HSkMC: 26.3;NTERA-2: 8.0;U-2197: 11.8
YWHAE	FLJ45465	ENSG00000108953	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	17	1344272-1400378	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008445, CAB016200, CAB021109, CAB047350	Approved		Uncertain	Cytosol	Endometrial cancer:6.48e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 451.5	Expressed in all		
MMD	MMA, PAQR11	ENSG00000108960	Monocyte to macrophage differentiation associated	17	55392613-55421992	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA026978			Approved	Vesicles	Colorectal cancer:3.52e-5 (favourable), Liver cancer:6.39e-5 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Endometrial cancer:3.88e-4 (unfavourable), Thyroid cancer:8.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 141.5	cerebral cortex: 73.0	Expressed in all		
RANGRF	HSPC165, HSPC236, MOG1, RANGNRF	ENSG00000108961	RAN guanine nucleotide release factor	17	8288497-8290092	Predicted intracellular proteins	Evidence at protein level	HPA057280, HPA057888	Approved		Supported	Nucleoplasm	Endometrial cancer:1.65e-4 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.2	Expressed in all		
DPH1	DPH2L, DPH2L1, OVCA1	ENSG00000108963	Diphthamide biosynthesis 1	17	2030110-2043430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069750			Approved	Nucleoplasm<br>Cell Junctions	Pancreatic cancer:1.78e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.5	Expressed in all		
MAP2K6	MAPKK6, MEK6, MKK6, PRKMK6, SAPKK3	ENSG00000108984	Mitogen-activated protein kinase kinase 6	17	69414698-69543331	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB007744, HPA031134	Enhanced		Supported	Nucleus<br>Cytosol	Breast cancer:2.27e-6 (favourable), Pancreatic cancer:7.52e-4 (favourable)	Mixed	Mixed			cervix, uterine: 39.1	Cell line enhanced		A549: 36.5
DHRS7B	CGI-93, DKFZp566O084, MGC8916, SDR32C1	ENSG00000109016	Dehydrogenase/reductase 7B	17	21123364-21193265	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012132, HPA016873	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
WSB1	DKFZp564A122, DKFZp564B0482, SWIP1	ENSG00000109046	WD repeat and SOCS box containing 1	17	27294076-27315926	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003293	Approved		Approved	Mitochondria	Renal cancer:1.02e-7 (unfavourable), Liver cancer:4.07e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.4	Expressed in all		
RCVRN	RCV1	ENSG00000109047	Recoverin	17	9896320-9905621	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015783, CAB022363	Supported					Not detected	Not detected			cerebral cortex: 0.3	Cell line enriched	7	WM-115: 2.3
MYH1	MGC133384, MYHa, MyHC-2X/D, MYHSA1	ENSG00000109061	Myosin heavy chain 1	17	10492307-10518543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB010759	Enhanced					Tissue enriched	Tissue enriched	738	skeletal muscle: 2753.9	esophagus: 3.7	Not detected		
SLC9A3R1	EBP50, NHERF	ENSG00000109062	SLC9A3 regulator 1	17	74748652-74769353	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB001962, HPA009672, HPA027247	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Liver cancer:9.83e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 302.4	Expressed in all		
MYH3	HEMHC, MYHC-EMB, MYHSE1, SMHCE	ENSG00000109063	Myosin heavy chain 3	17	10628526-10657309	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021808	Enhanced					Mixed	Group enriched	7	esophagus: 9.7;prostate: 46.3;seminal vesicle: 24.5	testis,urinary bladder: 4.0	Cell line enriched	30	HSkMC: 43.3
NAT9	DKFZP564C103	ENSG00000109065	N-acetyltransferase 9 (putative)	17	74770547-74776367	Predicted intracellular proteins	Evidence at protein level	HPA021820, HPA057149	Approved		Approved	Nucleoplasm	Renal cancer:6.26e-6 (unfavourable), Pancreatic cancer:3.21e-5 (favourable), Liver cancer:3.25e-5 (unfavourable), Stomach cancer:7.80e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 39.1	Expressed in all		
TMEM104	FLJ00021, FLJ20255	ENSG00000109066	Transmembrane protein 104	17	74776483-74839779	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044330	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.97e-5 (favourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 15.0	Expressed in all		
VTN	VN	ENSG00000109072	Vitronectin	17	28367276-28373091	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016695, CAB016765, HPA060933	Supported		Supported	Endoplasmic reticulum<br>Vesicles	Renal cancer:4.10e-11 (unfavourable), Liver cancer:3.74e-4 (favourable)	Tissue enriched	Tissue enriched	28	liver: 2554.5	gallbladder: 91.2	Cell line enriched	9	CACO-2: 1044.7
TNFAIP1	B12, B61, BTBD34, EDP1, MGC2317	ENSG00000109079	TNF alpha induced protein 1	17	28335602-28347009	Predicted intracellular proteins	Evidence at protein level	HPA013333, HPA014641	Uncertain		Enhanced	Nucleoli	Endometrial cancer:7.48e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 69.1	Expressed in all		
IFT20		ENSG00000109083	Intraflagellar transport 20	17	28328325-28335489	Predicted intracellular proteins	Evidence at protein level	HPA021376	Approved		Approved	Microtubules	Renal cancer:5.09e-7 (unfavourable), Liver cancer:1.96e-4 (unfavourable), Endometrial cancer:8.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 79.8	Expressed in all		
TMEM97	MAC30	ENSG00000109084	Transmembrane protein 97	17	28319095-28328685	Predicted membrane proteins	Evidence at protein level	HPA044795	Approved		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol	Renal cancer:1.24e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 110.0	Expressed in all		
CDR2L	HUMPPA	ENSG00000109089	Cerebellar degeneration related protein 2 like	17	74987632-75005800	Predicted intracellular proteins	Evidence at protein level	HPA022015	Enhanced		Approved	Cytosol		Expressed in all	Mixed			duodenum: 22.5	Mixed		
PMP22	GAS3, HNPP, Sp110	ENSG00000109099	Peripheral myelin protein 22	17	15229777-15265326	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 316.4	Cell line enhanced		ASC diff: 277.3;HMC-1: 278.9;WM-115: 491.1
FOXN1	FKHL20, RONU, WHN	ENSG00000109101	Forkhead box N1	17	28506243-28538896	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Head and neck cancer:5.00e-4 (favourable), Cervical cancer:6.43e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 7.2;skin: 35.2	tonsil: 5.1	Cell line enriched	8	HaCaT: 10.3
UNC119	HRG4, POC7, POC7A	ENSG00000109103	Unc-119 lipid binding chaperone	17	28546707-28552668	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041912	Supported				Pancreatic cancer:8.09e-5 (favourable), Melanoma:2.38e-4 (unfavourable), Thyroid cancer:9.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
ALDOC		ENSG00000109107	Aldolase, fructose-bisphosphate C	17	28573115-28577264	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003282, CAB020828, HPA067442	Enhanced	Supported	Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Renal cancer:1.29e-7 (unfavourable), Head and neck cancer:9.80e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	cerebral cortex: 766.6	heart muscle: 111.2	Cell line enhanced		RPMI-8226: 165.2;U-266/70: 119.9
SUPT6H	KIAA0162, SPT6H	ENSG00000109111	SPT6 homolog, histone chaperone	17	28662091-28702684	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012416, HPA036382	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:3.68e-5 (unfavourable), Renal cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.1	Expressed in all		
RAB34	NARR, RAB39, RAH	ENSG00000109113	RAB34, member RAS oncogene family	17	28714281-28718429	Predicted intracellular proteins	Evidence at protein level	HPA021366	Approved				Renal cancer:1.64e-7 (unfavourable), Thyroid cancer:1.06e-5 (favourable)	Expressed in all	Mixed			endometrium: 122.5	Mixed		
PHF12	KIAA1523, PF1	ENSG00000109118	PHD finger protein 12	17	28905250-28951771	Predicted intracellular proteins	Evidence at protein level	HPA021410, HPA021452	Approved		Enhanced	Nucleoplasm	Renal cancer:1.24e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 28.8	Expressed in all		
PHOX2B	NBPhox, Phox2b, PMX2B	ENSG00000109132	Paired like homeobox 2b	4	41744082-41748970	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074325, HPA074941			Enhanced	Nucleoplasm		Not detected	Tissue enriched	8	adrenal gland: 10.3	small intestine: 1.2	Cell line enriched	92	SH-SY5Y: 130.2
TMEM33	FLJ10525	ENSG00000109133	Transmembrane protein 33	4	41935120-41960572	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.35e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
GABRA4		ENSG00000109158	Gamma-aminobutyric acid type A receptor alpha4 subunit	4	46918900-46994407	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 15.1	heart muscle: 1.6	Cell line enriched	127	REH: 12.7
GNRHR	GRHR, LHRHR	ENSG00000109163	Gonadotropin releasing hormone receptor	4	67739328-67754360	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013424	Supported					Not detected	Tissue enhanced		adrenal gland: 1.0	cerebral cortex: 0.6	Not detected		
SLAIN2	FLJ21611, KIAA1458	ENSG00000109171	SLAIN motif family member 2	4	48341322-48426212	Predicted intracellular proteins	Evidence at protein level	HPA035824, HPA063599	Approved		Enhanced	Centrosome<br>Cytosol	Renal cancer:1.50e-4 (favourable), Colorectal cancer:5.77e-4 (favourable), Pancreatic cancer:6.71e-4 (unfavourable), Endometrial cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			testis: 72.9	Expressed in all		
OCIAD1	Asrij, FLJ20455, OCIA, TPA018	ENSG00000109180	OCIA domain containing 1	4	48805212-48861817	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044803	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 325.6	Expressed in all		
UGT2B10		ENSG00000109181	UDP glucuronosyltransferase family 2 member B10	4	68815993-68831196	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	87	liver: 304.0	gallbladder: 3.4	Cell line enriched	33	Hep G2: 7.9
CWH43	CWH43-C, FLJ21511	ENSG00000109182	Cell wall biogenesis 43 C-terminal homolog	4	48986247-49062081	Predicted membrane proteins	Evidence at protein level	HPA042814, HPA048140	Uncertain				Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 67.5	skin: 29.6	Not detected		
DCUN1D4	KIAA0276	ENSG00000109184	Defective in cullin neddylation 1 domain containing 4	4	51843000-51916837	Predicted intracellular proteins	Evidence at protein level	HPA036483, HPA036484	Uncertain		Supported	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
USP46	FLJ12552	ENSG00000109189	Ubiquitin specific peptidase 46	4	52590972-52659335	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007288, CAB076369, CAB076370	Uncertain		Enhanced	Nucleoli		Expressed in all	Expressed in all			cerebral cortex: 44.7	Mixed		
SULT1E1	EST, STE	ENSG00000109193	Sulfotransferase family 1E member 1	4	69810780-69860152	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028213, HPA028728, CAB047344	Enhanced		Uncertain	Nuclear membrane<br>Cytosol	Cervical cancer:4.06e-4 (favourable)	Mixed	Group enriched	7	duodenum: 27.7;liver: 18.7;skin: 7.6;small intestine: 29.7	adrenal gland: 3.1	Group enriched	17	HHSteC: 59.4;HSkMC: 23.3;hTCEpi: 19.7;HUVEC TERT2: 16.9
ODAM	APin, FLJ20513	ENSG00000109205	Odontogenic, ameloblast asssociated	4	70196496-70204576	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036543			Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	13	salivary gland: 136.2	smooth muscle: 10.1	Cell line enriched	13	Hep G2: 21.4
SMR3A	PBI, PRL5, PROL5	ENSG00000109208	Submaxillary gland androgen regulated protein 3A	4	70360761-70367158	Predicted secreted proteins	Evidence at protein level	HPA044567	Enhanced					Tissue enhanced	Tissue enriched	24	salivary gland: 24.1	thyroid gland: 0.9	Not detected		
CHIC2	BTL	ENSG00000109220	Cysteine rich hydrophobic domain 2	4	54009789-54064690	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026782, HPA026784, HPA076603	Uncertain		Enhanced	Vesicles<br>Plasma membrane	Renal cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.2	Expressed in all		
NMU		ENSG00000109255	Neuromedin U	4	55595229-55636698	Predicted secreted proteins	Evidence at protein level	HPA025926	Uncertain				Renal cancer:4.07e-10 (unfavourable), Endometrial cancer:2.60e-5 (unfavourable)	Mixed	Group enriched	6	esophagus: 34.9;skin: 45.4	tonsil: 6.8	Cell line enhanced		HaCaT: 336.7;K-562: 278.2
KIAA1211		ENSG00000109265	KIAA1211	4	56049073-56328625	Predicted intracellular proteins	Evidence at protein level	HPA043249, HPA048148	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 39.9	small intestine: 23.1	Cell line enhanced		SCLC-21H: 37.8;SH-SY5Y: 72.8
LAMTOR3	MAP2K1IP1, MAPBP, MAPKSP1, MP1, Ragulator3	ENSG00000109270	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 3	4	99878336-99894490	Predicted intracellular proteins	Evidence at protein level	HPA026858	Supported				Renal cancer:1.75e-9 (favourable), Liver cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 57.3	Expressed in all		
PF4V1	CXCL4L1, CXCL4V1, SCYB4V1	ENSG00000109272	Platelet factor 4 variant 1	4	73853189-73854155	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052485	Supported					Tissue enhanced	Tissue enhanced		spleen: 3.9	urinary bladder: 2.8	Cell line enhanced		CAPAN-2: 1.2;EFO-21: 2.0
NFKB1	KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50	ENSG00000109320	Nuclear factor kappa B subunit 1	4	102501329-102617302	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004031, HPA027305	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 56.9	Expressed in all		
AREG	AREGB, SDGF	ENSG00000109321	Amphiregulin	4	74445134-74455009	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA008720, CAB023519	Approved		Approved	Mitochondria	Lung cancer:1.05e-5 (unfavourable), Head and neck cancer:2.61e-5 (unfavourable), Pancreatic cancer:8.32e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 463.5	gallbladder: 119.8	Cell line enhanced		CACO-2: 310.7;HBEC3-KT: 461.5;hTCEpi: 463.0;hTERT-HME1: 1044.5;MCF7: 315.9
MANBA		ENSG00000109323	Mannosidase beta	4	102631488-102760994	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA053478	Approved		Supported	Vesicles	Liver cancer:3.74e-6 (unfavourable), Glioma:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.4	Expressed in all		
UBE2D3	UbcH5C	ENSG00000109332	Ubiquitin conjugating enzyme E2 D3	4	102794383-102868896	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003920	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 300.9	Expressed in all		
MAPK10	JNK3, p493F12, p54bSAPK, PRKM10	ENSG00000109339	Mitogen-activated protein kinase 10	4	86010395-86594131	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022625	Approved				Renal cancer:3.11e-4 (favourable), Urothelial cancer:5.57e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 113.0	seminal vesicle: 38.6	Cell line enriched	16	AF22: 181.7
ELF2	EU32, NERF, NERF-1A, NERF-1B, NERF-2	ENSG00000109381	E74 like ETS transcription factor 2	4	139028112-139177218	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006057, HPA071166	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 69.4	Expressed in all		
NDUFC1	KFYI	ENSG00000109390	NADH:ubiquinone oxidoreductase subunit C1	4	139266880-139302551	Predicted membrane proteins	Evidence at protein level	HPA044556	Approved		Supported	Mitochondria	Endometrial cancer:8.23e-5 (favourable), Urothelial cancer:7.25e-4 (favourable), Renal cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 86.7	Expressed in all		
UCP1	SLC25A7, UCP	ENSG00000109424	Uncoupling protein 1	4	140559434-140568805	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 3.7	breast: 0.9	Group enriched	16	BEWO: 4.9;HAP1: 3.8
TBC1D9	GRAMD9, KIAA0882, MDR1	ENSG00000109436	TBC1 domain family member 9	4	140620765-140756120	Predicted intracellular proteins	Evidence at protein level	HPA000262, HPA006317, HPA006503	Uncertain	Supported	Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.61e-6 (favourable)	Tissue enriched	Mixed			breast: 65.6	Mixed		
ZNF330	HSA6591, NOA36	ENSG00000109445	Zinc finger protein 330	4	141220887-141234697	Predicted intracellular proteins	Evidence at protein level	HPA015705, HPA056325	Uncertain		Supported	Nucleoli	Prostate cancer:3.66e-6 (unfavourable), Renal cancer:7.27e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 68.3	Expressed in all		
INPP4B		ENSG00000109452	Inositol polyphosphate-4-phosphatase type II B	4	142023160-142847432	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037681, HPA037682	Approved		Approved	Centrosome	Pancreatic cancer:1.03e-4 (unfavourable)	Mixed	Mixed			testis: 33.2	Cell line enhanced		CAPAN-2: 132.1
GAB1		ENSG00000109458	GRB2 associated binding protein 1	4	143336762-143474568	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB034333, HPA049599	Enhanced		Approved	Vesicles	Renal cancer:3.91e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.2	Cell line enhanced		REH: 67.9
KLHL2	MAV	ENSG00000109466	Kelch like family member 2	4	165207618-165323156	Predicted intracellular proteins	Evidence at protein level	HPA051637			Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:3.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.5	thyroid gland: 22.0	Mixed		
IL2	IL-2, TCGF	ENSG00000109471	Interleukin 2	4	122451470-122456725	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010310	Uncertain					Not detected	Not detected			rectum,small intestine,tonsil: 0.3	Not detected		
CPE		ENSG00000109472	Carboxypeptidase E	4	165361194-165498320	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003819, CAB024907	Supported		Approved	Nucleoplasm<br>Vesicles<br>Centrosome	Urothelial cancer:2.12e-4 (unfavourable), Renal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1560.8	Group enriched	5	Hep G2: 211.8;SCLC-21H: 493.5;SH-SY5Y: 147.0;SiHa: 668.1
RPL34	L34	ENSG00000109475	Ribosomal protein L34	4	108620566-108630412	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA035139	Uncertain		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:2.76e-5 (favourable)	Expressed in all	Expressed in all			breast: 4622.0	Expressed in all		
WFS1	DFNA14, DFNA38, DFNA6, DIDMOAD, WFS	ENSG00000109501	Wolframin ER transmembrane glycoprotein	4	6269849-6303265	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029128	Approved				Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable)	Expressed in all	Mixed			ovary: 61.5	Cell line enhanced		BEWO: 97.0
ANXA10	ANX14	ENSG00000109511	Annexin A10	4	168092515-168187690	Predicted intracellular proteins	Evidence at protein level	HPA005469	Enhanced		Approved	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:3.64e-6 (favourable)	Group enriched	Tissue enriched	8	stomach: 459.7	urinary bladder: 60.6	Group enriched	8	PC-3: 118.8;RT4: 140.1
GRPEL1	FLJ25609, GrpE, hMGE	ENSG00000109519	GrpE like 1, mitochondrial	4	7058906-7068197	Predicted intracellular proteins	Evidence at protein level	HPA036647	Supported		Supported	Mitochondria	Renal cancer:2.00e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 43.9	Expressed in all		
GAR1	NOLA1	ENSG00000109534	GAR1 ribonucleoprotein	4	109815510-109824740	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059098	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.64e-5 (unfavourable)	Expressed in all	Expressed in all			breast: 23.0	Expressed in all		
FRG1	FRG1A, FSG1	ENSG00000109536	FSHD region gene 1	4	189940788-189963204	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Stomach cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Expressed in all		
CLCN3	ClC-3, CLC3	ENSG00000109572	Chloride voltage-gated channel 3	4	169612633-169723673	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044723	Approved		Approved	Cytosol	Renal cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 104.1	Expressed in all		
AADAT	KAT2, KATII, KYAT2	ENSG00000109576	Aminoadipate aminotransferase	4	170060222-170091699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037502	Enhanced		Approved	Vesicles<br>Plasma membrane	Colorectal cancer:5.59e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 34.7	prostate: 23.4	Mixed		
GALNT7	GALNAC-T7	ENSG00000109586	Polypeptide N-acetylgalactosaminyltransferase 7	4	173168753-173323967	Predicted intracellular proteins	Evidence at protein level	HPA064243, HPA065317	Enhanced		Enhanced	Nucleus<br>Golgi apparatus	Colorectal cancer:4.53e-4 (favourable), Pancreatic cancer:7.65e-4 (unfavourable)	Expressed in all	Mixed			stomach: 62.9	Mixed		
DHX15	DBP1, DDX15, HRH2, PRP43, PRPF43, PrPp43p	ENSG00000109606	DEAH-box helicase 15	4	24517441-24584550	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047047	Approved		Enhanced	Nuclear speckles	Colorectal cancer:5.74e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
SOD3	EC-SOD	ENSG00000109610	Superoxide dismutase 3	4	24789912-24800842	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042110	Supported					Expressed in all	Tissue enhanced		adipose tissue: 179.2	fallopian tube: 66.5	Cell line enhanced		ASC diff: 41.5;PC-3: 46.6;RPTEC TERT1: 158.1
SEPSECS	SLA, SLA/LP	ENSG00000109618	Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase	4	25120014-25160442	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070409			Approved	Vesicles		Expressed in all	Expressed in all			liver: 16.7	Expressed in all		
CPZ		ENSG00000109625	Carboxypeptidase Z	4	8592660-8619759	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 121.5	placenta: 58.0	Cell line enhanced		BEWO: 63.6;BJ: 32.8;BJ hTERT+: 42.2;RH-30: 54.5;U-2197: 38.2
TRIM2	CMT2R, KIAA0517, RNF86	ENSG00000109654	Tripartite motif containing 2	4	153152342-153339320	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035853, HPA035854	Enhanced		Approved	Centrosome	Renal cancer:6.58e-14 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 155.1	thyroid gland: 110.7	Cell line enhanced		AF22: 68.3
SLC2A9	Glut9, GLUTX, URATv1	ENSG00000109667	Solute carrier family 2 member 9	4	9771153-10054936	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066229	Enhanced				Renal cancer:1.32e-11 (favourable)	Mixed	Tissue enhanced		kidney: 30.8;seminal vesicle: 27.2	placenta: 11.1	Cell line enhanced		HBEC3-KT: 34.8;Hep G2: 16.1;hTCEpi: 14.4;THP-1: 13.9;U-937: 10.7
FBXW7	AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10	ENSG00000109670	F-box and WD repeat domain containing 7	4	152321259-152536101	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB013793, CAB029987	Supported		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 87.4	Expressed in all		
NEIL3	FLJ10858, FPG2, hFPG2, hNEI3, ZGRF3	ENSG00000109674	Nei like DNA glycosylase 3	4	177309836-177362943	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065761			Enhanced	Nucleoplasm	Lung cancer:1.16e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable)	Mixed	Mixed			bone marrow: 4.3	Mixed		
TBC1D19	FLJ11082	ENSG00000109680	TBC1 domain family member 19	4	26576437-26755351	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039592	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.21e-7 (favourable), Thyroid cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 23.2	Cell line enhanced		LHCN-M2: 64.6
CLNK	MIST	ENSG00000109684	Cytokine dependent hematopoietic cell linker	4	10486395-10684865	Predicted intracellular proteins	Evidence at protein level	HPA035671, HPA035672	Uncertain		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		kidney: 5.8	lymph node: 3.4	Group enriched	6	HDLM-2: 3.9;U-937: 1.6
NSD2	KMT3G, MMSET, WHSC1	ENSG00000109685	Nuclear receptor binding SET domain protein 2	4	1871424-1982207	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015801, CAB068246, CAB068247	Enhanced		Supported	Nucleus	Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
SH3D19	DKFZp434D0215, EBP, EVE1, Kryn, SH3P19	ENSG00000109686	SH3 domain containing 19	4	151102751-151325632	Predicted intracellular proteins	Evidence at protein level	HPA016424, HPA058562	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.38e-5 (favourable)	Expressed in all	Mixed			gallbladder: 99.5	Cell line enhanced		ASC diff: 130.5;ASC TERT1: 113.0
STIM2		ENSG00000109689	Stromal interaction molecule 2	4	26857678-27025381	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036933, CAB037196, HPA057511	Supported				Liver cancer:3.97e-5 (unfavourable), Pancreatic cancer:5.01e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 45.8	Expressed in all		
NKX3-2	BAPX1, NKX3.2, NKX3B	ENSG00000109705	NK3 homeobox 2	4	13540830-13545050	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA027564	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		spleen: 2.7	smooth muscle: 1.6	Cell line enhanced		HAP1: 3.6;NB-4: 6.2;NTERA-2: 5.3;THP-1: 3.9
MFSD10	IT10C3, TETRAN	ENSG00000109736	Major facilitator superfamily domain containing 10	4	2930561-2934859	Predicted membrane proteins	Evidence at protein level	HPA043209	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:5.68e-5 (unfavourable), Liver cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 41.2	Expressed in all		
GLRB		ENSG00000109738	Glycine receptor beta	4	157076057-157172090	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052363	Approved				Renal cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 62.0;parathyroid gland: 63.1	cervix, uterine: 14.1	Mixed		
BST1	CD157	ENSG00000109743	Bone marrow stromal cell antigen 1	4	15702950-15738313	CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050121	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 105.5	duodenum: 54.8	Cell line enhanced		THP-1: 60.3;TIME: 39.6;U-937: 45.8;WM-115: 51.6
RAPGEF2	DKFZP586O1422, KIAA0313, PDZ-GEF1, PDZGEF1, RA-GEF	ENSG00000109756	Rap guanine nucleotide exchange factor 2	4	159104178-159360169	Predicted intracellular proteins	Evidence at protein level	HPA057169			Supported	Nucleoplasm<br>Vesicles<br>Centrosome	Renal cancer:1.76e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 109.8	Mixed		
HGFAC	HGFA, HGFAP	ENSG00000109758	HGF activator	4	3441887-3449495	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA058279, HPA059076	Enhanced				Renal cancer:9.31e-4 (unfavourable)	Tissue enriched	Tissue enriched	14	liver: 28.6	testis: 2.0	Cell line enriched	6	Hep G2: 3.6
SNX25	SBBI31	ENSG00000109762	Sorting nexin 25	4	185204237-185370185	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA036928			Supported	Vesicles		Expressed in all	Expressed in all			lung: 42.7	Expressed in all		
LRP2BP	DKFZp761O0113	ENSG00000109771	LRP2 binding protein	4	185363879-185395899	Predicted intracellular proteins	Evidence at protein level	HPA036664, HPA036665	Approved					Mixed	Tissue enhanced		fallopian tube: 12.3;testis: 20.3	cerebral cortex: 6.3	Cell line enhanced		U-266/70: 4.7
UFSP2	C4orf20, FLJ11200	ENSG00000109775	UFM1 specific peptidase 2	4	185399540-185425985	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039985, HPA043298	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.07e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.0	Expressed in all		
KLF3	BKLF	ENSG00000109787	Kruppel like factor 3	4	38664196-38701042	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049512, HPA065054	Supported		Enhanced	Nucleoplasm	Renal cancer:4.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Mixed		
KLHL5		ENSG00000109790	Kelch like family member 5	4	39045039-39126857	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013958	Approved					Expressed in all	Expressed in all			seminal vesicle: 91.0	Expressed in all		
FAM149A	DKFZP564J102, MST119, MSTP119	ENSG00000109794	Family with sequence similarity 149 member A	4	186104419-186172667	Predicted intracellular proteins	Evidence at protein level	HPA044019, HPA055004	Uncertain		Approved	Golgi apparatus	Endometrial cancer:2.67e-6 (favourable)	Mixed	Mixed			kidney: 37.1	Cell line enhanced		ASC diff: 7.6;RT4: 7.7;SCLC-21H: 16.7
NCAPG	CAP-G, FLJ12450, hCAP-G, YCG1	ENSG00000109805	Non-SMC condensin I complex subunit G	4	17810902-17844862	Predicted intracellular proteins	Evidence at protein level	HPA039613	Uncertain				Liver cancer:3.13e-6 (unfavourable), Pancreatic cancer:7.65e-5 (unfavourable), Endometrial cancer:8.28e-4 (unfavourable)	Mixed	Mixed			lymph node,testis: 9.9	Mixed		
UGDH		ENSG00000109814	UDP-glucose 6-dehydrogenase	4	39498755-39528311	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034444, HPA036656, HPA036657	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.51e-10 (unfavourable)	Expressed in all	Expressed in all			colon: 95.4	Expressed in all		
PPARGC1A	PGC-1alpha, PGC1, PGC1A, PPARGC1	ENSG00000109819	PPARG coactivator 1 alpha	4	23755041-23904089	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA063136			Supported	Nucleoplasm	Renal cancer:1.49e-14 (favourable), Liver cancer:3.35e-6 (favourable), Thyroid cancer:5.80e-4 (unfavourable)	Tissue enhanced	Mixed			kidney,parathyroid gland: 29.2	Cell line enriched	8	A-431: 76.6
DDX25	GRTH	ENSG00000109832	DEAD-box helicase 25	11	125903348-125943702	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020137	Enhanced					Tissue enhanced	Group enriched	12	cerebral cortex: 34.6;testis: 163.8	thyroid gland: 8.0	Cell line enhanced		NTERA-2: 10.8;SCLC-21H: 10.2
CRYAB	CRYA2, HSPB5	ENSG00000109846	Crystallin alpha B	11	111908565-111923722	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002053, CAB040560, HPA057100	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable)	Group enriched	Tissue enhanced		heart muscle: 3968.4	cerebral cortex: 1888.7	Cell line enhanced		ASC diff: 1679.2;fHDF/TERT166: 650.9;U-138 MG: 315.9
DBX1		ENSG00000109851	Developing brain homeobox 1	11	20156155-20160613	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA039802	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enriched	9	NTERA-2: 1.0
HTATIP2	CC3, FLJ26963, SDR44U1, TIP30	ENSG00000109854	HIV-1 Tat interactive protein 2	11	20363685-20383783	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006417, HPA024321	Approved		Supported	Cytosol	Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 135.2	Mixed		
CTSC	DPP1, PALS, PLS	ENSG00000109861	Cathepsin C	11	88293592-88337787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025364, HPA066610, HPA068434	Enhanced		Supported	Vesicles	Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			lung: 390.4	Expressed in all		
CCDC34	L15, NY-REN-41, RAMA3	ENSG00000109881	Coiled-coil domain containing 34	11	27330827-27363868	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037574	Uncertain		Approved	Nuclear membrane<br>Nucleoli fibrillar center	Liver cancer:1.32e-7 (unfavourable), Renal cancer:1.82e-4 (unfavourable), Ovarian cancer:8.52e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 54.8	fallopian tube: 13.4	Expressed in all		
ZBTB16	PLZF, ZNF145	ENSG00000109906	Zinc finger and BTB domain containing 16	11	114059593-114250676	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001499, CAB004540	Uncertain				Renal cancer:2.21e-4 (favourable)	Tissue enhanced	Mixed			ovary: 59.5	Cell line enhanced		ASC diff: 40.2;ASC TERT1: 23.6;HEL: 33.4;HHSteC: 21.2;HSkMC: 19.6;hTCEpi: 18.6;hTERT-HME1: 17.2
ELP4	C11orf19, PAXNEB	ENSG00000109911	Elongator acetyltransferase complex subunit 4	11	31509700-31790328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038572, HPA038573	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 15.4	Expressed in all		
ZPR1	ZNF259	ENSG00000109917	ZPR1 zinc finger	11	116773799-116788050	Predicted intracellular proteins	Evidence at protein level	CAB022596, HPA030979	Uncertain		Approved	Vesicles	Liver cancer:5.87e-6 (unfavourable), Head and neck cancer:8.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.9	Expressed in all		
MTCH2	SLC25A50	ENSG00000109919	Mitochondrial carrier 2	11	47617315-47642623	Predicted membrane proteins, Transporters	Evidence at protein level	HPA038390	Approved		Supported	Mitochondria	Renal cancer:9.05e-6 (favourable)	Expressed in all	Expressed in all			testis: 138.3	Expressed in all		
FNBP4	KIAA1014	ENSG00000109920	Formin binding protein 4	11	47716517-47767443	Predicted intracellular proteins	Evidence at protein level	HPA039485, HPA040029	Supported		Enhanced	Nuclear speckles	Renal cancer:1.91e-8 (unfavourable), Urothelial cancer:7.23e-5 (favourable), Liver cancer:7.33e-5 (unfavourable), Melanoma:2.50e-4 (unfavourable), Prostate cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 48.1	Expressed in all		
TECTA	DFNA12, DFNA8, DFNB21	ENSG00000109927	Tectorin alpha	11	121101173-121191493	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA018870	Approved					Mixed	Tissue enhanced		cerebral cortex: 2.7	parathyroid gland: 2.0	Cell line enhanced		SH-SY5Y: 1.5
SC5D	SC5DL	ENSG00000109929	Sterol-C5-desaturase	11	121292453-121308694	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066283, HPA070248	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 193.5	Expressed in all		
CRTAM	CD355	ENSG00000109943	Cytotoxic and regulatory T-cell molecule	11	122838500-122872639	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 9.8	spleen: 5.0	Cell line enriched	45	SCLC-21H: 15.2
C11orf63	FLJ23554	ENSG00000109944	Chromosome 11 open reading frame 63	11	122882528-122959798	Predicted intracellular proteins	Evidence at protein level	HPA039612, HPA040344, HPA077658, HPA077748	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:7.94e-5 (favourable), Thyroid cancer:2.58e-4 (unfavourable), Renal cancer:8.77e-4 (favourable)	Mixed	Tissue enhanced		testis: 63.8	parathyroid gland: 14.8	Mixed		
B3GAT1	CD57, GlcAT-P, HNK-1, LEU7, NK-1	ENSG00000109956	Beta-1,3-glucuronyltransferase 1	11	134378504-134411918	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002500, CAB010893, HPA069468	Enhanced		Supported	Vesicles		Group enriched	Tissue enriched	11	cerebral cortex: 115.4	thyroid gland: 10.3	Cell line enhanced		AF22: 22.9;HMC-1: 22.4;NTERA-2: 22.3;SH-SY5Y: 9.0
HSPA8	HSC70, HSC71, HSP73, HSPA10	ENSG00000109971	Heat shock protein family A (Hsp70) member 8	11	123057489-123063230	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002056, HPA052504	Uncertain		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.14e-6 (favourable), Liver cancer:1.93e-4 (unfavourable), Renal cancer:3.81e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1119.0	Expressed in all		
P2RX3	P2X3	ENSG00000109991	Purinergic receptor P2X 3	11	57338374-57370600	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057776	Uncertain					Not detected	Tissue enhanced		heart muscle: 2.5;testis: 6.1	liver: 0.9	Not detected		
VWA5A	BCSC-1, LOH11CR2A	ENSG00000110002	Von Willebrand factor A domain containing 5A	11	124115362-124147721	Predicted intracellular proteins	Evidence at protein level	HPA037813, HPA037814, HPA061500	Uncertain		Enhanced	Nucleus	Renal cancer:1.55e-5 (favourable)	Expressed in all	Expressed in all			gallbladder: 48.7	Cell line enhanced		CAPAN-2: 52.4;HEL: 39.5;HUVEC TERT2: 32.9;RPTEC TERT1: 32.4
DNAJC4	HSPF2, MCG18	ENSG00000110011	DnaJ heat shock protein family (Hsp40) member C4	11	64230278-64234286	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011947	Uncertain				Colorectal cancer:3.12e-4 (unfavourable), Renal cancer:6.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 136.6	Expressed in all		
SIAE	CSE-C, LSE, MGC87009, YSG2	ENSG00000110013	Sialic acid acetylesterase	11	124633113-124695707	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038052, HPA038053	Approved				Renal cancer:4.42e-11 (favourable), Endometrial cancer:4.66e-5 (favourable)	Expressed in all	Expressed in all			rectum: 114.5	Mixed		
SNX15		ENSG00000110025	Sorting nexin 15	11	65027408-65040572	Predicted intracellular proteins	Evidence at protein level	HPA038955	Approved		Supported	Nucleoli<br>Cytosol		Not detected	Expressed in all			cerebral cortex: 24.7	Expressed in all		
LPXN	LDPL	ENSG00000110031	Leupaxin	11	58526871-58578220	Predicted intracellular proteins	Evidence at protein level	HPA043741, CAB046478, HPA061441	Supported		Enhanced	Nuclear speckles<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:8.81e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 107.2	Cell line enhanced		HMC-1: 289.6;Karpas-707: 204.9
DTX4	KIAA0937, RNF155	ENSG00000110042	Deltex E3 ubiquitin ligase 4	11	59171430-59208587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056760, HPA059294	Uncertain	Approved	Approved	Vesicles	Thyroid cancer:5.81e-4 (favourable), Renal cancer:8.94e-4 (unfavourable)	Expressed in all	Mixed			lung: 27.3	Cell line enhanced		BEWO: 63.2;RT4: 80.7
ATG2A	KIAA0404	ENSG00000110046	Autophagy related 2A	11	64894546-64917248	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038715	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:4.79e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 39.0	Expressed in all		
EHD1	FLJ42622, FLJ44618, H-PAST, HPAST1, PAST1	ENSG00000110047	EH domain containing 1	11	64851642-64888296	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049890, HPA049986, HPA066751, HPA067747	Approved		Supported	Plasma membrane	Liver cancer:2.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 152.8	Expressed in all		
OSBP	OSBP1	ENSG00000110048	Oxysterol binding protein	11	59574398-59616144	Predicted intracellular proteins	Evidence at protein level	HPA039227, HPA043625	Enhanced		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:3.08e-7 (favourable), Colorectal cancer:2.08e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 73.9	Expressed in all		
UNC93B1	UNC93	ENSG00000110057	Unc-93 homolog B1 (C. elegans)	11	67991104-68004982	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038716, HPA038717, HPA042803	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.73e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			spleen: 54.4	Cell line enhanced		CAPAN-2: 111.1;RPMI-8226: 250.7
PUS3	FKSG32	ENSG00000110060	Pseudouridylate synthase 3	11	125893485-125903221	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038040, HPA063802	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 16.9	Expressed in all		
DCPS	HINT-5, HSL1, HSPC015	ENSG00000110063	Decapping enzyme, scavenger	11	126303752-126345749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039632, HPA058597	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 24.5	Expressed in all		
KMT5B	CGI-85, SUV420H1	ENSG00000110066	Lysine methyltransferase 5B	11	68154863-68213828	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063648			Supported	Nucleus	Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
FOXRED1	H17	ENSG00000110074	FAD dependent oxidoreductase domain containing 1	11	126269055-126278131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039620, HPA046192	Uncertain		Supported	Mitochondria	Renal cancer:2.01e-6 (favourable), Breast cancer:7.36e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 19.1	Expressed in all		
PPP6R3	C11orf23, DKFZp781E17107, DKFZp781E2374, DKFZp781O2362, FLJ11058, FLJ43065, KIAA1558, MGC125711, MGC125712, PP6R3, SAP190, SAPL, SAPLa, SAPS3	ENSG00000110075	Protein phosphatase 6 regulatory subunit 3	11	68460731-68615334	Predicted intracellular proteins	Evidence at protein level	CAB017183, HPA038467, HPA038468	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Testis cancer:8.23e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.8	Expressed in all		
NRXN2		ENSG00000110076	Neurexin 2	11	64606174-64723188	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	cerebral cortex: 142.6	testis: 17.0	Cell line enhanced		REH: 43.5;SCLC-21H: 27.0;U-2 OS: 27.6;U-87 MG: 18.3
MS4A6A	CD20L3, MS4A6	ENSG00000110077	Membrane spanning 4-domains A6A	11	60172014-60184666	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA011391	Approved				Cervical cancer:6.33e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 113.5	Cell line enriched	6	THP-1: 32.2
MS4A4A	CD20L1, MS4A4, MS4A7	ENSG00000110079	Membrane spanning 4-domains A4A	11	60280541-60308972	Predicted membrane proteins	Evidence at transcript level	HPA029323	Approved					Expressed in all	Tissue enhanced		placenta: 102.2	adipose tissue: 63.4	Cell line enriched	24	K-562: 118.6
ST3GAL4	CGS23, FLJ11867, NANTA3, SAT3, SIAT4, SIAT4C, STZ	ENSG00000110080	ST3 beta-galactoside alpha-2,3-sialyltransferase 4	11	126355640-126440344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049827	Approved					Expressed in all	Mixed			epididymis: 106.8	Expressed in all		
CPT1A	CPT1, CPT1-L, L-CPT1	ENSG00000110090	Carnitine palmitoyltransferase 1A	11	68754620-68844410	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008835	Enhanced		Supported	Mitochondria	Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 78.9	Mixed		
CCND1	BCL1, D11S287E, PRAD1, U21B31	ENSG00000110092	Cyclin D1	11	69641087-69654474	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000024, HPA027802	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 340.4	skin: 140.5	Cell line enhanced		WM-115: 1198.2
CCDC86	MGC2574	ENSG00000110104	Coiled-coil domain containing 86	11	60842071-60851081	Predicted intracellular proteins	Evidence at protein level	HPA041117, HPA041540	Enhanced		Enhanced	Nucleus<br>Nucleoli	Head and neck cancer:7.36e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Tissue enriched	11	parathyroid gland: 618.3	testis: 58.1	Expressed in all		
PRPF19	hPSO4, NMP200, PRP19, PSO4, SNEV, UBOX4	ENSG00000110107	Pre-mRNA processing factor 19	11	60890730-60906588	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012448, HPA038051, HPA059070	Supported		Enhanced	Nuclear speckles	Liver cancer:4.11e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 128.9	Expressed in all		
TMEM109	MGC5508	ENSG00000110108	Transmembrane protein 109	11	60913874-60923443	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011785	Approved		Approved	Nuclear membrane<br>Cytosol	Urothelial cancer:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 94.7	Expressed in all		
CCKBR		ENSG00000110148	Cholecystokinin B receptor	11	6259736-6272127	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	13	cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4	prostate: 0.9	Cell line enriched	8	NTERA-2: 69.8
HPX		ENSG00000110169	Hemopexin	11	6431049-6442617	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016725	Supported				Liver cancer:2.26e-4 (favourable)	Tissue enriched	Tissue enriched	506	liver: 2617.9	breast: 5.1	Cell line enriched	6	Hep G2: 13.9
TRIM3	BERP, HAC1, RNF22, RNF97	ENSG00000110171	Tripartite motif containing 3	11	6448613-6474459	Predicted intracellular proteins	Evidence at protein level	HPA043396, HPA048233	Uncertain		Approved	Mitochondria	Renal cancer:1.07e-5 (unfavourable), Pancreatic cancer:5.49e-5 (favourable), Endometrial cancer:2.20e-4 (favourable)	Expressed in all	Mixed			duodenum: 17.8	Cell line enhanced		SK-BR-3: 40.6
CHORDC1	CHP-1, CHP1	ENSG00000110172	Cysteine and histidine rich domain containing 1	11	90201160-90223364	Predicted intracellular proteins	Evidence at protein level	HPA041040	Approved		Supported	Cytosol	Liver cancer:4.93e-7 (unfavourable), Renal cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 31.4	Expressed in all		
FOLR1	FOLR	ENSG00000110195	Folate receptor 1	11	72189558-72196323	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077030			Approved	Nuclear membrane	Liver cancer:2.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 166.6;fallopian tube: 275.8;lung: 267.5	kidney: 152.7	Group enriched	6	HeLa: 298.2;RPTEC TERT1: 350.8
ANAPC15	APC15, C11orf51, DKFZP564M082, HSPC020	ENSG00000110200	Anaphase promoting complex subunit 15	11	72106378-72112780	Predicted intracellular proteins	Evidence at protein level	HPA036596	Approved		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:2.55e-4 (favourable), Liver cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 77.6	Expressed in all		
FOLR3	FR-G	ENSG00000110203	Folate receptor 3	11	72114869-72139892	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		bone marrow: 56.7	appendix: 12.4	Group enriched	5	hTERT-HME1: 55.6;U-2197: 60.1
PANX1	MRS1, PX1, UNQ2529	ENSG00000110218	Pannexin 1	11	94128928-94181972	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016930	Uncertain		Enhanced	Plasma membrane	Renal cancer:1.49e-7 (unfavourable), Lung cancer:7.09e-5 (unfavourable), Endometrial cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.5	Expressed in all		
ARHGEF17	KIAA0337, p164-RhoGEF, TEM4	ENSG00000110237	Rho guanine nucleotide exchange factor 17	11	73308289-73369091	Predicted intracellular proteins	Evidence at protein level	HPA007991	Uncertain		Approved	Cytosol	Colorectal cancer:8.27e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.6	Mixed		
APOA5	APOA-V, RAP3	ENSG00000110243	Apolipoprotein A5	11	116789367-116792420	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	273	liver: 259.2	testis: 0.9	Cell line enriched	54	Hep G2: 40.9
APOA4		ENSG00000110244	Apolipoprotein A4	11	116820700-116823306	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001352, HPA002549, CAB068250, CAB068251, CAB068252	Enhanced		Approved	Vesicles		Tissue enriched	Group enriched	126	duodenum: 2211.8;small intestine: 3441.1	liver: 22.3	Cell line enhanced		BEWO: 7.4;CACO-2: 6.6;Hep G2: 5.1;NB-4: 4.6;RPMI-8226: 8.2;SH-SY5Y: 11.1
APOC3		ENSG00000110245	Apolipoprotein C3	11	116829706-116833072	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065365			Approved	Nucleoplasm<br>Nucleoli<br>Cell Junctions	Renal cancer:6.87e-5 (unfavourable), Liver cancer:3.77e-4 (favourable)	Tissue enriched	Tissue enriched	7	liver: 8677.3	small intestine: 1178.4	Group enriched	17	CACO-2: 85.2;Hep G2: 190.9
CEP164	KIAA1052, NPHP15	ENSG00000110274	Centrosomal protein 164	11	117314557-117413268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037605, HPA037606, HPA061504	Uncertain		Enhanced	Nucleoplasm<br>Centrosome	Liver cancer:2.40e-5 (unfavourable), Renal cancer:2.89e-5 (unfavourable), Pancreatic cancer:5.93e-4 (favourable)	Expressed in all	Mixed			testis: 44.6	Expressed in all		
RNF141	ZFP26, ZNF230	ENSG00000110315	Ring finger protein 141	11	10511678-10541230	Predicted intracellular proteins	Evidence at protein level	HPA018133	Approved		Approved	Nucleoplasm<br>Microtubules	Pancreatic cancer:1.14e-4 (unfavourable), Renal cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 130.2	Expressed in all		
CEP126	KIAA1377	ENSG00000110318	Centrosomal protein 126	11	101915015-102001058	Predicted intracellular proteins	Evidence at protein level	HPA038381, HPA038399			Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:5.00e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 17.6	fallopian tube: 12.9	Cell line enhanced		EFO-21: 5.9
EIF4G2	DAP5, NAT1, p97	ENSG00000110321	Eukaryotic translation initiation factor 4 gamma 2	11	10797050-10809110	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005163, HPA006773, HPA016965	Approved		Enhanced	Cytosol	Liver cancer:6.18e-5 (unfavourable), Renal cancer:1.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 686.8	Expressed in all		
IL10RA	CD210, CD210a, CDW210A, HIL-10R, IL10R	ENSG00000110324	Interleukin 10 receptor subunit alpha	11	117986348-118003037	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.45e-5 (unfavourable), Head and neck cancer:4.47e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 86.2	lymph node: 56.0	Cell line enhanced		Daudi: 21.3;HDLM-2: 69.7;Karpas-707: 19.5;RPMI-8226: 23.7
GALNT18	GalNAc-T18, GALNT15, GALNTL4, MGC71806	ENSG00000110328	Polypeptide N-acetylgalactosaminyltransferase 18	11	11270876-11622005	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012955	Approved		Approved	Mitochondria	Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 59.3	lung: 43.2	Cell line enhanced		A-431: 36.5;HaCaT: 46.1;PC-3: 33.7;SK-BR-3: 35.3;U-87 MG: 32.9
BIRC2	API1, c-IAP1, cIAP1, hiap-2, MIHB, RNF48	ENSG00000110330	Baculoviral IAP repeat containing 2	11	102347211-102378670	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA005513, CAB020661	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			testis: 45.8	Mixed		
UBE4A	E4, KIAA0126, UBOX2, UFD2	ENSG00000110344	Ubiquitination factor E4A	11	118359585-118399211	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055035, HPA064010	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 43.7	Expressed in all		
DDX6	HLR2, RCK	ENSG00000110367	DEAD-box helicase 6	11	118747766-118791149	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004668, HPA024201, HPA026644	Approved		Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.6	Expressed in all		
UPK2	MGC138598, UP2, UPII	ENSG00000110375	Uroplakin 2	11	118925164-118958559	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043312, HPA061106	Enhanced				Renal cancer:7.30e-7 (unfavourable), Lung cancer:9.57e-4 (unfavourable)	Tissue enriched	Tissue enriched	44	urinary bladder: 68.5	adipose tissue: 1.5	Cell line enhanced		BEWO: 25.9;MCF7: 113.9;RT4: 131.8
CBL	c-Cbl, CBL2, RNF55	ENSG00000110395	Cbl proto-oncogene	11	119206276-119313926	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004350, HPA027956	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 33.9	Expressed in all		
NECTIN1	CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12	ENSG00000110400	Nectin cell adhesion molecule 1	11	119623408-119729084	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016135, HPA026846	Approved					Expressed in all	Tissue enhanced		esophagus: 108.6;skin: 161.7	cerebral cortex: 50.3	Cell line enhanced		HaCaT: 203.5
HIPK3	DYRK6, FIST3, PKY, YAK1	ENSG00000110422	Homeodomain interacting protein kinase 3	11	33256672-33357023	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028069	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 126.8	Expressed in all		
KIAA1549L	C11orf41, C11orf69, G2, MGC34830	ENSG00000110427	KIAA1549 like	11	33542072-33674102	Predicted membrane proteins	Evidence at protein level	HPA051594			Approved	Nucleoplasm		Mixed	Group enriched	41	cerebral cortex: 34.9;parathyroid gland: 146.2	skin: 2.2	Cell line enhanced		TIME: 43.4;U-138 MG: 64.2;WM-115: 44.5
FBXO3	FBA, FBX3	ENSG00000110429	F-box protein 3	11	33740939-33774543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002467			Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.46e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.6	Expressed in all		
PDHX	DLDBP, E3BP, OPDX, PDX1, proX	ENSG00000110435	Pyruvate dehydrogenase complex component X	11	34915829-35020591	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038484, HPA038485	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Renal cancer:1.83e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 53.3	Expressed in all		
SLC1A2	EAAT2, GLT-1	ENSG00000110436	Solute carrier family 1 member 2	11	35251206-35420063	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002574, HPA009172	Enhanced					Tissue enriched	Tissue enriched	30	cerebral cortex: 365.8	liver: 12.2	Cell line enhanced		fHDF/TERT166: 1.5;NTERA-2: 2.4;SCLC-21H: 1.5
COMMD9	FLJ31106, HSPC166	ENSG00000110442	COMM domain containing 9	11	36269284-36289449	Predicted intracellular proteins	Evidence at protein level	HPA009142	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Ovarian cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 48.3	Expressed in all		
SLC15A3	hPTR3, PHT2	ENSG00000110446	Solute carrier family 15 member 3	11	60937084-60952530	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA047880, HPA057642	Approved		Supported	Vesicles	Cervical cancer:4.07e-5 (favourable)	Expressed in all	Expressed in all			lung: 102.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 91.0;BJ hTERT+ SV40 Large T+ RasG12V: 114.5;HHSteC: 47.3
CD5	LEU1, T1	ENSG00000110448	CD5 molecule	11	61102395-61127852	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB015392, CAB020308, HPA043416, HPA060839	Enhanced				Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable)	Mixed	Tissue enhanced		appendix: 29.8;lymph node: 43.0	tonsil: 20.2	Cell line enriched	71	MOLT-4: 56.4
ACCS	ACS, PHACS	ENSG00000110455	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	11	44065925-44084222	Predicted intracellular proteins	Evidence at protein level	HPA018873, HPA021654	Approved		Approved	Golgi apparatus	Pancreatic cancer:4.25e-4 (favourable)	Expressed in all	Mixed			spleen: 18.8	Mixed		
SCGB2A2	MGB1, MGC71974, UGB2	ENSG00000110484	Secretoglobin family 2A member 2	11	62270155-62273156	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026270	Supported				Endometrial cancer:9.57e-8 (favourable)	Tissue enriched	Tissue enriched	7	breast: 3687.7	cervix, uterine: 507.6	Cell line enriched	95	SK-BR-3: 13.3
MDK	FLJ27379, MK, NEGF2	ENSG00000110492	Midkine (neurite growth-promoting factor 2)	11	46380756-46383837	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB010055, HPA057126	Uncertain		Approved	Vesicles	Renal cancer:3.06e-6 (unfavourable), Glioma:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 524.3	Cell line enhanced		NTERA-2: 890.9;REH: 1226.8;SH-SY5Y: 1163.1
AMBRA1	DCAF3, FLJ20294, KIAA1736, WDR94	ENSG00000110497	Autophagy and beclin 1 regulator 1	11	46396414-46594125	Predicted intracellular proteins	Evidence at protein level	CAB017825, HPA038535	Approved		Approved	Vesicles<br>Mitochondria	Renal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
MADD	DENN, KIAA0358, RAB3GEP	ENSG00000110514	MAP kinase activating death domain	11	47269161-47330031	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038568	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 103.9	Expressed in all		
PTPMT1	DUSP23, MOSP, PLIP	ENSG00000110536	Protein tyrosine phosphatase, mitochondrial 1	11	47565430-47573461	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040348, HPA043932	Approved		Supported	Mitochondria	Liver cancer:3.04e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 92.8	Expressed in all		
NAA40	FLJ13848, NAT11	ENSG00000110583	N(alpha)-acetyltransferase 40, NatD catalytic subunit	11	63938959-63957328	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037816	Uncertain		Approved	Nuclear bodies	Liver cancer:1.43e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
CARS	CARS1	ENSG00000110619	Cysteinyl-tRNA synthetase	11	3000922-3057613	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737	Enhanced		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
SLC22A18	BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5	ENSG00000110628	Solute carrier family 22 member 18	11	2899721-2925246	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA067812, HPA071461	Enhanced					Expressed in all	Tissue enhanced		duodenum: 43.2;small intestine: 31.7	colon: 10.3	Cell line enhanced		CAPAN-2: 28.3;Karpas-707: 21.3
CD81	TAPA-1, TAPA1, TSPAN28	ENSG00000110651	CD81 molecule	11	2376177-2397419	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002507, HPA007234	Supported		Supported	Plasma membrane	Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 2273.0	Cell line enhanced		ASC diff: 2031.3
SLC35F2	FLJ13018	ENSG00000110660	Solute carrier family 35 member F2	11	107790991-107928293	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048185, HPA050695	Uncertain		Approved	Mitochondria	Pancreatic cancer:5.92e-6 (unfavourable), Lung cancer:4.03e-4 (unfavourable), Glioma:7.31e-4 (favourable)	Expressed in all	Mixed			prostate: 33.8	Cell line enhanced		PC-3: 166.4
C11orf21		ENSG00000110665	Chromosome 11 open reading frame 21	11	2295645-2303049	Predicted intracellular proteins	Evidence at transcript level	HPA037607	Approved					Mixed	Tissue enhanced		bone marrow: 32.4;spleen: 17.6	lymph node: 15.9	Cell line enhanced		HEL: 45.5;HL-60: 15.4;NB-4: 11.2;U-937: 16.8
ELMOD1	DKFZp547C176	ENSG00000110675	ELMO domain containing 1	11	107591091-107666779	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038434, HPA038435			Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Group enriched	15	cerebral cortex: 71.3;skin: 36.7	adrenal gland,fallopian tube: 3.5	Cell line enhanced		HUVEC TERT2: 12.8;RH-30: 33.5
CALCA	CALC1	ENSG00000110680	Calcitonin related polypeptide alpha	11	14966668-14972354	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059886		Supported			Endometrial cancer:4.49e-5 (unfavourable)	Tissue enriched	Group enriched	78	parathyroid gland: 849.6;thyroid gland: 183.4	kidney: 6.6	Not detected		
SOX6		ENSG00000110693	SRY-box 6	11	15966449-16739591	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001923, HPA003908	Enhanced		Approved	Nucleoplasm	Renal cancer:6.47e-12 (favourable)	Mixed	Tissue enhanced		testis: 25.9	bone marrow: 16.5	Cell line enhanced		WM-115: 20.4
C11orf58	SMAP	ENSG00000110696	Chromosome 11 open reading frame 58	11	16613132-16756881	Predicted intracellular proteins	Evidence at protein level	HPA036591, HPA076406	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum	Liver cancer:5.84e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 217.7	Expressed in all		
PITPNM1	DRES9, NIR2, PITPNM, Rd9, RDGB, RDGB1, RDGBA1	ENSG00000110697	Phosphatidylinositol transfer protein membrane associated 1	11	67491768-67506263	Predicted intracellular proteins	Evidence at protein level	HPA060227, HPA062757	Approved		Enhanced	Microtubule organizing center<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			fallopian tube: 37.0	Expressed in all		
RPS13	S13	ENSG00000110700	Ribosomal protein S13	11	17074389-17077787	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA005985	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2365.9	Expressed in all		
AIP	ARA9, FKBP16, XAP2	ENSG00000110711	Aryl hydrocarbon receptor interacting protein	11	67483041-67491103	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033674, HPA050217, CAB069477	Approved		Supported	Cytosol	Colorectal cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 100.6	Expressed in all		
NUP98	NUP96	ENSG00000110713	Nucleoporin 98	11	3671083-3797792	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074810			Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 150.7	Expressed in all		
NDUFS8	CI-23k, TYKY	ENSG00000110717	NADH:ubiquinone oxidoreductase core subunit S8	11	68030617-68036644	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018524	Approved		Supported	Mitochondria	Renal cancer:3.27e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 152.6	Expressed in all		
TCIRG1	a3, Atp6i, ATP6N1C, ATP6V0A3, OC-116, OC116, TIRC7	ENSG00000110719	T-cell immune regulator 1, ATPase H+ transporting V0 subunit a3	11	68039016-68050895	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038742	Approved		Approved	Mitochondria	Renal cancer:1.50e-11 (unfavourable), Urothelial cancer:9.45e-6 (favourable)	Expressed in all	Expressed in all			spleen: 82.0	Mixed		
CHKA	CHK, CKI	ENSG00000110721	Choline kinase alpha	11	68052859-68121444	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024153, CAB072803	Approved		Approved	Endoplasmic reticulum	Liver cancer:7.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 136.1	Expressed in all		
EXPH5	SLAC2-B	ENSG00000110723	Exophilin 5	11	108505431-108593738	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.42e-6 (favourable), Head and neck cancer:1.46e-4 (favourable), Renal cancer:2.43e-4 (favourable), Lung cancer:5.12e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 16.1;skin: 31.3	esophagus: 8.2	Cell line enhanced		hTERT-HME1: 8.7;RT4: 16.3
HPS5	AIBP63, BLOC2S2, RU2	ENSG00000110756	HPS5, biogenesis of lysosomal organelles complex 2 subunit 2	11	18278668-18322198	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.9	Expressed in all		
GTF2H1	BTF2, P62, TFIIH	ENSG00000110768	General transcription factor IIH subunit 1	11	18322295-18367044	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004637, HPA046660	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.98e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 60.0	Expressed in all		
POU2AF1	BOB1, OBF1	ENSG00000110777	POU class 2 associating factor 1	11	111352252-111455630	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011193	Enhanced				Cervical cancer:1.63e-4 (favourable), Breast cancer:1.68e-4 (favourable), Head and neck cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 101.7;tonsil: 93.7	appendix: 55.5	Cell line enhanced		Daudi: 190.2;Karpas-707: 212.1;U-266/70: 217.7;U-698: 374.3
PTPN5	PTPSTEP, STEP, STEP61	ENSG00000110786	Protein tyrosine phosphatase, non-receptor type 5	11	18727928-18792721	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031014, HPA072091	Supported		Approved	Endoplasmic reticulum		Group enriched	Tissue enriched	15	cerebral cortex: 58.8	testis: 3.8	Cell line enhanced		NTERA-2: 1.7
VWF	F8VWF	ENSG00000110799	Von Willebrand factor	12	5948874-6124770	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB001694, HPA001815, HPA002082, CAB072874, CAB072875	Supported				Stomach cancer:2.31e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 155.1	lung: 115.9	Cell line enriched	57	HUVEC TERT2: 468.1
PSMD9	p27, Rpn4	ENSG00000110801	Proteasome 26S subunit, non-ATPase 9	12	121888731-121918297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040512, HPA044220	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.32e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 17.8	Expressed in all		
P3H3	GRCB, HSU47926, LEPREL2	ENSG00000110811	Prolyl 3-hydroxylase 3	12	6828410-6839851	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA043695	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.64e-4 (unfavourable), Pancreatic cancer:4.91e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 11.7	endometrium: 6.2	Cell line enhanced		BJ: 33.3
PPFIBP1	hSGT2, hSgt2p, L2, SGT2	ENSG00000110841	PPFIA binding protein 1	12	27523431-27695564	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001924	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 106.4	Mixed		
PRPF40B	HYPC	ENSG00000110844	Pre-mRNA processing factor 40 homolog B	12	49568218-49644666	Predicted intracellular proteins	Evidence at protein level	HPA038426, HPA038599	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Aggresome<br>Cytosol		Mixed	Mixed			testis: 39.2	Expressed in all		
CD69	CLEC2C	ENSG00000110848	CD69 molecule	12	9752486-9760901	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002503, HPA050525	Enhanced				Breast cancer:3.31e-5 (favourable), Renal cancer:7.87e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 105.9;lymph node: 109.1	appendix: 64.1	Cell line enhanced		HL-60: 23.7;K-562: 52.0;U-937: 76.0
PRDM4	PFM1	ENSG00000110851	PR/SET domain 4	12	107732866-107761272	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024322, HPA067437	Approved		Supported	Nucleoplasm	Renal cancer:3.15e-7 (favourable), Liver cancer:1.86e-4 (unfavourable), Melanoma:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 90.0	Expressed in all		
CLEC2B	AICL, CLECSF2, HP10085	ENSG00000110852	C-type lectin domain family 2 member B	12	9852984-9870136	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008194	Approved				Renal cancer:5.64e-13 (unfavourable)	Expressed in all	Mixed			skin: 87.2	Cell line enhanced		ASC TERT1: 56.7;U-937: 154.3
COQ5	MGC4767	ENSG00000110871	Coenzyme Q5, methyltransferase	12	120503274-120534434	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049487	Approved		Approved	Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 42.1	Expressed in all		
SELPLG	CD162, PSGL-1	ENSG00000110876	Selectin P ligand	12	108622277-108633959	Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002431	Enhanced				Cervical cancer:1.46e-4 (favourable), Thyroid cancer:2.74e-4 (favourable), Melanoma:2.92e-4 (favourable), Renal cancer:5.86e-4 (unfavourable), Head and neck cancer:6.94e-4 (favourable)	Expressed in all	Mixed			spleen: 85.3	Cell line enhanced		HDLM-2: 137.1;HMC-1: 120.1;Karpas-707: 155.1;RPMI-8226: 215.5;U-266/70: 266.2;U-266/84: 163.2
CORO1C	coronin-3, HCRNN4	ENSG00000110880	Coronin 1C	12	108645109-108731596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041737	Approved				Liver cancer:5.59e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 208.8	Expressed in all		
ASIC1	ACCN2, BNaC2, hBNaC2	ENSG00000110881	Acid sensing ion channel subunit 1	12	50057548-50083611	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA058870			Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Tissue enriched	10	cerebral cortex: 56.8	parathyroid gland: 5.7	Cell line enhanced		SH-SY5Y: 30.8
DAO	DAMOX	ENSG00000110887	D-amino acid oxidase	12	108858932-108901043	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038653, HPA038654	Enhanced				Renal cancer:4.11e-4 (favourable)	Tissue enriched	Group enriched	36	kidney: 89.8;liver: 74.1	rectum: 2.2	Not detected		
CAPRIN2	C1QDC1, caprin-2, EEG1, FLJ11391, FLJ22569, RNG140	ENSG00000110888	Caprin family member 2	12	30709552-30754951	Predicted intracellular proteins	Evidence at protein level	HPA039746	Supported		Supported	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:3.50e-5 (unfavourable), Urothelial cancer:8.36e-4 (favourable)	Expressed in all	Mixed			testis: 32.8	Mixed		
TSPAN11		ENSG00000110900	Tetraspanin 11	12	30926428-30996599	Predicted membrane proteins	Evidence at protein level	HPA066789			Approved	Vesicles	Lung cancer:3.43e-4 (favourable), Head and neck cancer:5.28e-4 (favourable)	Mixed	Mixed			cerebral cortex: 17.9	Group enriched	5	AF22: 26.8;HSkMC: 19.0;NTERA-2: 21.6;SCLC-21H: 12.2;SH-SY5Y: 21.8
KCTD10	BTBD28, MSTP028	ENSG00000110906	Potassium channel tetramerization domain containing 10	12	109448656-109477544	Predicted intracellular proteins	Evidence at protein level	HPA014273	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:5.32e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 79.7	Expressed in all		
SLC11A2	DCT1, DMT1, NRAMP2	ENSG00000110911	Solute carrier family 11 member 2	12	50979401-51028566	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032139, HPA032140	Uncertain		Supported	Mitochondria	Lung cancer:3.07e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 75.1	Expressed in all		
MLEC	KIAA0152	ENSG00000110917	Malectin	12	120686869-120701864	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:9.60e-6 (favourable), Stomach cancer:8.77e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 162.3	Expressed in all		
MVK	LRBP, MK	ENSG00000110921	Mevalonate kinase	12	109573255-109598117	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016961	Approved					Expressed in all	Expressed in all			testis: 31.6	Expressed in all		
CSRNP2	C12ORF2, C12orf22, FAM130A1, PPP1R72, TAIP-12	ENSG00000110925	Cysteine and serine rich nuclear protein 2	12	51061205-51083664	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018503, HPA019914	Approved		Approved	Nuclear speckles	Liver cancer:1.08e-4 (unfavourable), Urothelial cancer:2.78e-4 (favourable), Renal cancer:6.51e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
CAMKK2	CAMKK, CAMKKB, KIAA0787, MGC15254	ENSG00000110931	Calcium/calmodulin dependent protein kinase kinase 2	12	121237691-121298308	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017389	Approved		Supported	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 102.8	Expressed in all		
BIN2	BRAP-1	ENSG00000110934	Bridging integrator 2	12	51281038-51324668	Predicted intracellular proteins	Evidence at protein level	HPA038666, HPA038667	Enhanced				Cervical cancer:1.33e-4 (favourable), Endometrial cancer:6.34e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 65.8	spleen: 53.1	Cell line enhanced		HEL: 72.6;HMC-1: 116.1;NB-4: 87.3;THP-1: 78.0;U-937: 59.3
IL23A	IL-23, IL-23A, IL23P19, P19, SGRF	ENSG00000110944	Interleukin 23 subunit alpha	12	56334174-56340410	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA001554	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		tonsil: 8.0	urinary bladder: 6.5	Cell line enhanced		A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0
ATP5B	ATPSB	ENSG00000110955	ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide	12	56638175-56646068	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001520, HPA001528, CAB017527	Enhanced		Enhanced	Mitochondria	Renal cancer:1.43e-9 (favourable), Breast cancer:7.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 1254.0	Expressed in all		
PTGES3	cPGES, p23, TEBP	ENSG00000110958	Prostaglandin E synthase 3	12	56663341-56688408	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034319, HPA038672, HPA038673	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.44e-6 (unfavourable), Breast cancer:2.15e-5 (unfavourable), Ovarian cancer:4.36e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 347.2	Expressed in all		
SYT10		ENSG00000110975	Synaptotagmin 10	12	33374238-33439819	Predicted membrane proteins	Evidence at transcript level	HPA055426	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enriched	Tissue enhanced		fallopian tube: 3.5	seminal vesicle: 1.1	Cell line enhanced		AF22: 1.6;MCF7: 2.7;RT4: 1.1;SCLC-21H: 2.0
BCL7A	BCL7	ENSG00000110987	BCL tumor suppressor 7A	12	122019422-122062044	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019762	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 13.8	Cell line enhanced		Daudi: 37.3;U-698: 41.3
RSRC2	FLJ11021	ENSG00000111011	Arginine and serine rich coiled-coil 2	12	122503458-122527000	Predicted intracellular proteins	Evidence at protein level	HPA040070, HPA048183	Uncertain		Enhanced	Nucleoli fibrillar center<br>Nuclear speckles<br>Cytosol	Liver cancer:2.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 42.5	Expressed in all		
CYP27B1	CYP1, P450c1, PDDR, VDD1	ENSG00000111012	Cytochrome P450 family 27 subfamily B member 1	12	57762334-57768986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Thyroid cancer:6.79e-4 (unfavourable)	Mixed	Tissue enhanced		kidney: 4.3;thyroid gland: 3.9	appendix: 1.2	Cell line enriched	8	RH-30: 47.8
MYF6	bHLHc4, MRF4	ENSG00000111046	Myogenic factor 6	12	80707498-80709474	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:2.05e-4 (unfavourable)	Group enriched	Tissue enriched	15	skeletal muscle: 99.2	prostate: 6.4	Cell line enriched	20	LHCN-M2: 19.4
MYF5	bHLHc2	ENSG00000111049	Myogenic factor 5	12	80716912-80719673	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041691			Supported	Nucleoplasm		Not detected	Tissue enhanced		skeletal muscle: 1.9	prostate: 0.4	Cell line enriched	19	LHCN-M2: 398.0
LIN7A	LIN-7A, MALS-1, TIP-33, VELI1	ENSG00000111052	Lin-7 homolog A, crumbs cell polarity complex component	12	80792520-80937925	Predicted intracellular proteins	Evidence at protein level	HPA071562	Approved				Renal cancer:1.63e-11 (favourable)	Tissue enhanced	Mixed			bone marrow: 17.8	Cell line enhanced		ASC TERT1: 22.0;HAP1: 25.9;HDLM-2: 27.5;HL-60: 23.1
KRT18		ENSG00000111057	Keratin 18	12	52948871-52952901	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB000008, CAB000030, HPA001605	Enhanced		Enhanced	Cytosol	Pancreatic cancer:1.78e-4 (unfavourable), Lung cancer:5.06e-4 (unfavourable)	Expressed in all	Mixed			placenta: 658.9	Cell line enhanced		A549: 5013.4;CACO-2: 5077.2;CAPAN-2: 3861.0;MCF7: 6322.5
ACSS3	FLJ21963	ENSG00000111058	Acyl-CoA synthetase short-chain family member 3	12	80936414-81261205	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039353, HPA047956, HPA061517	Approved		Approved	Mitochondria	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			parathyroid gland: 33.7	Cell line enhanced		Hep G2: 28.4;RH-30: 18.1;SK-BR-3: 13.2
TNS2	C1-TEN, KIAA1075, TENC1	ENSG00000111077	Tensin 2	12	53046969-53064372	Predicted intracellular proteins	Evidence at protein level	HPA034659	Approved				Pancreatic cancer:1.72e-4 (favourable), Prostate cancer:9.32e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 114.4	Cell line enhanced		ASC diff: 78.4;ASC TERT1: 54.1;HSkMC: 62.2
GLI1	GLI	ENSG00000111087	GLI family zinc finger 1	12	57460135-57472262	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009460, HPA065172, HPA068903	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cervix, uterine: 15.1;endometrium: 15.1	gallbladder: 8.5	Cell line enhanced		AN3-CA: 19.3;RH-30: 59.1
PPM1H	ARHCL1, FLJ13253, KIAA1157, NERPP-2C	ENSG00000111110	Protein phosphatase, Mg2+/Mn2+ dependent 1H	12	62643982-62935037	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB020694, HPA044244, HPA058777	Approved		Supported	Nucleoplasm	Renal cancer:2.72e-5 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 54.2	cerebral cortex: 23.0	Cell line enhanced		CACO-2: 67.4;HMC-1: 56.0
METAP2	MAP2, MNPEP, p67	ENSG00000111142	Methionyl aminopeptidase 2	12	95473520-95515839	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013025, HPA019095	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.51e-6 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 142.4	Expressed in all		
LTA4H		ENSG00000111144	Leukotriene A4 hydrolase	12	96000828-96043520	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008399, CAB015221, HPA017017	Supported		Supported	Nucleoplasm<br>Cytosol	Lung cancer:8.96e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			lung: 283.5	Expressed in all		
ELK3	ERP, NET, SAP2	ENSG00000111145	ELK3, ETS transcription factor	12	96194382-96269835	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001600	Approved		Supported	Nucleoplasm<br>Mitochondria	Ovarian cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 58.4	Expressed in all		
SLC6A12	BGT-1	ENSG00000111181	Solute carrier family 6 member 12	12	190077-214570	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034973	Approved		Approved	Vesicles	Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		kidney: 29.5;liver: 43.6	cerebral cortex: 14.8	Group enriched	10	Hep G2: 4.9;RPTEC TERT1: 10.5
WNT5B		ENSG00000111186	Wnt family member 5B	12	1529891-1647243	Predicted secreted proteins	Evidence at protein level	HPA061991			Approved	Vesicles		Expressed in all	Tissue enhanced		prostate: 34.7	seminal vesicle: 27.9	Cell line enhanced		BJ: 195.3;BJ hTERT+ SV40 Large T+: 154.0;BJ hTERT+ SV40 Large T+ RasG12V: 132.9;HBF TERT88: 139.5;hTEC/SVTERT24-B: 144.8;U-138 MG: 140.4
MAGOHB	FLJ10292, MGN2	ENSG00000111196	Mago homolog B, exon junction complex core component	12	10604190-10613623	Predicted intracellular proteins	Evidence at protein level	HPA043036, HPA047754	Uncertain				Renal cancer:5.04e-8 (unfavourable), Ovarian cancer:5.56e-6 (favourable), Stomach cancer:6.50e-4 (favourable)	Expressed in all	Mixed			epididymis: 14.3	Expressed in all		
TRPV4	CMT2C, OTRPC4, TRP12, VR-OAC, VRL-2, VROAC	ENSG00000111199	Transient receptor potential cation channel subfamily V member 4	12	109783085-109833401	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA007150	Uncertain				Renal cancer:4.12e-5 (favourable), Ovarian cancer:8.10e-4 (unfavourable)	Expressed in all	Mixed			kidney: 11.8	Cell line enhanced		BEWO: 9.1;HaCaT: 13.9
ITFG2	MDS028	ENSG00000111203	Integrin alpha FG-GAP repeat containing 2	12	2812622-2859791	Predicted intracellular proteins	Evidence at protein level	HPA038664, HPA038665	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Cytokinetic bridge		Expressed in all	Expressed in all			thyroid gland: 46.0	Expressed in all		
FOXM1	FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident	ENSG00000111206	Forkhead box M1	12	2857681-2877155	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017832	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.95e-6 (unfavourable), Pancreatic cancer:3.03e-5 (unfavourable), Lung cancer:2.92e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 39.6	bone marrow: 15.9	Expressed in all		
PRR4	LPRP, PROL4	ENSG00000111215	Proline rich 4 (lacrimal)	12	10845849-11171613	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042133	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	23	salivary gland: 1528.2	stomach: 65.1	Cell line enhanced		HDLM-2: 1.4;HHSteC: 1.7
PRMT8	HRMT1L3, HRMT1L4	ENSG00000111218	Protein arginine methyltransferase 8	12	3381349-3593973	Predicted intracellular proteins	Evidence at protein level	HPA039747, HPA069769	Enhanced					Tissue enhanced	Tissue enriched	8	cerebral cortex: 19.9	testis: 2.4	Cell line enriched	11	hTERT-HME1: 37.3
PARP11	C12orf6	ENSG00000111224	Poly(ADP-ribose) polymerase family member 11	12	3791047-3873448	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026895	Uncertain					Expressed in all	Mixed			testis: 17.6	Mixed		
ARPC3	ARC21, p21-Arc	ENSG00000111229	Actin related protein 2/3 complex subunit 3	12	110434825-110450422	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006550	Approved		Uncertain	Nucleoplasm	Renal cancer:2.22e-11 (unfavourable), Pancreatic cancer:4.67e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 608.2	Expressed in all		
GPN3	ATPBD1C, MGC14560	ENSG00000111231	GPN-loop GTPase 3	12	110452484-110469268	Predicted intracellular proteins	Evidence at protein level	HPA039764, HPA047793	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.65e-6 (favourable), Liver cancer:3.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 74.2	Expressed in all		
VPS29	DC15, DC7, PEP11	ENSG00000111237	VPS29, retromer complex component	12	110491097-110502117	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039748	Uncertain		Supported	Vesicles<br>Cytosol	Liver cancer:2.79e-5 (unfavourable), Ovarian cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 109.0	Expressed in all		
FGF6		ENSG00000111241	Fibroblast growth factor 6	12	4428155-4445614	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enriched	8	skeletal muscle: 5.6	esophagus: 0.7	Group enriched	5	NTERA-2: 2.4;REH: 2.4
MYL2	CMH10	ENSG00000111245	Myosin light chain 2	12	110910819-110920722	Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019763, HPA039262	Supported		Uncertain	Microtubules	Head and neck cancer:2.60e-4 (unfavourable)	Group enriched	Group enriched	36	heart muscle: 16309.5;skeletal muscle: 9731.7	esophagus: 357.2	Group enriched	6	EFO-21: 3.7;HSkMC: 6.1;U-2 OS: 17.9
RAD51AP1	PIR51	ENSG00000111247	RAD51 associated protein 1	12	4538798-4560048	Predicted intracellular proteins	Evidence at protein level	HPA051499			Approved	Nucleus	Renal cancer:4.44e-15 (unfavourable), Pancreatic cancer:1.22e-5 (unfavourable), Liver cancer:3.53e-4 (unfavourable), Endometrial cancer:9.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.4	Mixed		
CUX2	CDP2, CUTL2, KIAA0293	ENSG00000111249	Cut like homeobox 2	12	111034024-111350554	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 12.2;liver: 9.6;prostate: 18.0	thyroid gland: 6.8	Cell line enhanced		HBEC3-KT: 4.6;SCLC-21H: 7.5;SH-SY5Y: 14.5
SH2B3	IDDM20, LNK	ENSG00000111252	SH2B adaptor protein 3	12	111405948-111451623	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005483	Approved		Approved	Nucleoplasm	Renal cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.1	Cell line enhanced		hTEC/SVTERT24-B: 141.0;U-87 MG: 207.2;WM-115: 163.2
AKAP3	AKAP110, CT82, FSP95, SOB1	ENSG00000111254	A-kinase anchoring protein 3	12	4615508-4649047	Predicted intracellular proteins	Evidence at protein level	HPA039765	Enhanced					Tissue enriched	Tissue enriched	46	testis: 179.9	fallopian tube: 3.9	Cell line enhanced		NTERA-2: 4.0
MANSC1	FLJ10298, LOH12CR3	ENSG00000111261	MANSC domain containing 1	12	12326056-12350541	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007955, HPA007956	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.30e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Cell line enhanced		HUVEC TERT2: 42.6
KCNA1	AEMK, HUK1, Kv1.1, MBK1, RBK1	ENSG00000111262	Potassium voltage-gated channel subfamily A member 1	12	4909893-4918256	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB022365	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 13.4	parathyroid gland: 2.1	Cell line enhanced		SCLC-21H: 1.2;U-2 OS: 1.0
DUSP16	KIAA1700, MKP-7, MKP7	ENSG00000111266	Dual specificity phosphatase 16	12	12474210-12562383	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020326	Approved		Supported	Nucleoplasm	Head and neck cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 33.2	Cell line enhanced		NTERA-2: 39.3
CREBL2		ENSG00000111269	CAMP responsive element binding protein like 2	12	12611827-12645108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043738	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.26e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 173.3	Expressed in all		
ACAD10	MGC5601	ENSG00000111271	Acyl-CoA dehydrogenase family member 10	12	111686056-111757107	Predicted intracellular proteins	Evidence at protein level	HPA067222	Uncertain				Renal cancer:3.71e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.6	Expressed in all		
ALDH2		ENSG00000111275	Aldehyde dehydrogenase 2 family (mitochondrial)	12	111766887-111817529	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051065	Approved				Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 441.5	Cell line enhanced		HHSteC: 81.5;SK-BR-3: 150.4
CDKN1B	KIP1, P27KIP1	ENSG00000111276	Cyclin dependent kinase inhibitor 1B	12	12715058-12722371	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB003691, CAB021888, HPA059086	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 73.1	Mixed		
GPRC5D		ENSG00000111291	G protein-coupled receptor class C group 5 member D	12	12940775-12952147	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA071909	Approved				Head and neck cancer:5.09e-4 (favourable)	Mixed	Mixed			testis: 4.9	Group enriched	10	Karpas-707: 60.7;RPMI-8226: 58.9;U-266/84: 17.2
NAA25	C12orf30, FLJ13089	ENSG00000111300	N(alpha)-acetyltransferase 25, NatB auxiliary subunit	12	112026689-112109022	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039322	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.32e-8 (unfavourable), Liver cancer:5.53e-5 (unfavourable), Endometrial cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 9.5	Expressed in all		
GSG1	MGC3146	ENSG00000111305	Germ cell associated 1	12	13083560-13103683	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	377	testis: 574.9	duodenum: 1.5	Cell line enhanced		fHDF/TERT166: 6.7;LHCN-M2: 8.2;RPTEC TERT1: 9.2;U-2 OS: 6.4
SCNN1A	ENaCalpha, SCNN1	ENSG00000111319	Sodium channel epithelial 1 alpha subunit	12	6346843-6377730	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012743	Enhanced				Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 95.1	Cell line enhanced		CAPAN-2: 264.6;HBEC3-KT: 145.5;RPTEC TERT1: 78.8;RT4: 91.1;SK-BR-3: 72.7
LTBR	D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3	ENSG00000111321	Lymphotoxin beta receptor	12	6375045-6391571	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026202, HPA061617	Uncertain		Supported	Golgi apparatus	Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.5	Cell line enhanced		HHSteC: 330.0
OGFOD2	FLJ13491, FLJ37501	ENSG00000111325	2-oxoglutarate and iron dependent oxygenase domain containing 2	12	122974580-122980043	Predicted intracellular proteins	Evidence at protein level	HPA039448, HPA040306	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Expressed in all			testis: 23.1	Expressed in all		
CDK2AP1	doc-1, DOC1, DORC1, p12DOC-1, ST19	ENSG00000111328	Cyclin dependent kinase 2 associated protein 1	12	123260971-123272334	Predicted intracellular proteins	Evidence at protein level	CAB019377, HPA057648, HPA068833	Approved		Supported	Nucleoplasm	Renal cancer:5.27e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 294.1	Mixed		
OAS3		ENSG00000111331	2'-5'-oligoadenylate synthetase 3	12	112938352-112973249	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041253, HPA041372	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.23e-5 (unfavourable)	Expressed in all	Mixed			spleen: 33.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 251.3;BJ hTERT+ SV40 Large T+ RasG12V: 285.0
OAS2		ENSG00000111335	2'-5'-oligoadenylate synthetase 2	12	112978395-113011723	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB024984, HPA045947	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.31e-6 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			spleen: 59.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 292.1;BJ hTERT+ SV40 Large T+ RasG12V: 247.3;SK-MEL-30: 98.7
ART4	CD297, DO, DOK1	ENSG00000111339	ADP-ribosyltransferase 4 (Dombrock blood group)	12	14825569-14843495	Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA075664			Approved	Rods & Rings		Tissue enhanced	Tissue enhanced		liver: 27.2;spleen: 26.9	gallbladder: 15.1	Cell line enhanced		AN3-CA: 5.6;HEL: 10.9;Hep G2: 4.9;HUVEC TERT2: 22.5
MGP		ENSG00000111341	Matrix Gla protein	12	14881181-14885926	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013949	Approved				Renal cancer:4.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		breast: 4883.1	smooth muscle: 1900.4	Cell line enriched	5	AN3-CA: 9115.9
RASAL1	RASAL	ENSG00000111344	RAS protein activator like 1	12	113098819-113136239	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA041650	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:3.26e-5 (unfavourable)	Mixed	Tissue enriched	6	parathyroid gland: 118.8	cerebral cortex: 19.4	Cell line enhanced		EFO-21: 18.2;REH: 20.3;RPMI-8226: 34.6;RPTEC TERT1: 14.4;U-698: 28.8
ARHGDIB	GDIA2, GDID4, Ly-GDI, RAP1GN1, RhoGDI2	ENSG00000111348	Rho GDP dissociation inhibitor beta	12	14942017-14961728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018584, HPA051235	Approved		Supported	Cytosol	Renal cancer:1.08e-4 (unfavourable), Urothelial cancer:3.42e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 955.5	Cell line enhanced		HEL: 1354.5;HL-60: 1418.5;HMC-1: 1684.2;MOLT-4: 1705.9;REH: 1609.3
GTF2H3	BTF2, P34, TFIIH	ENSG00000111358	General transcription factor IIH subunit 3	12	123633739-123662606	Predicted intracellular proteins	Evidence at protein level	HPA004844, HPA053562	Uncertain		Supported	Nucleoplasm	Liver cancer:6.72e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.6	Expressed in all		
EIF2B1	EIF-2B, EIF-2Balpha, EIF2B, EIF2BA	ENSG00000111361	Eukaryotic translation initiation factor 2B subunit alpha	12	123620406-123633766	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034258, HPA049509	Approved		Supported	Cytosol	Renal cancer:1.78e-9 (unfavourable), Liver cancer:6.75e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 59.3	Expressed in all		
DDX55	KIAA1595	ENSG00000111364	DEAD-box helicase 55	12	123602077-123620941	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039962, HPA044101	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.97e-12 (unfavourable), Liver cancer:2.11e-9 (unfavourable)	Expressed in all	Expressed in all			skin: 16.4	Expressed in all		
SLC38A1	ATA1, NAT2, SAT1	ENSG00000111371	Solute carrier family 38 member 1	12	46183063-46270017	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039460, HPA052272	Uncertain	Supported			Liver cancer:6.95e-8 (unfavourable), Endometrial cancer:4.76e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 154.6	Mixed		
RERGL	FLJ22655	ENSG00000111404	RERG like	12	18080869-18320107	Predicted intracellular proteins	Evidence at protein level	HPA041740	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			epididymis: 47.0	Cell line enriched	734	REH: 214.1
ENDOU	P11, PP11, PRSS26	ENSG00000111405	Endonuclease, poly(U) specific	12	47709734-47725567	Predicted secreted proteins	Evidence at protein level	HPA012388, HPA067448	Enhanced				Head and neck cancer:6.29e-4 (favourable)	Tissue enhanced	Group enriched	6	esophagus: 70.3;skin: 24.9	tonsil: 7.7	Cell line enhanced		Daudi: 1.6;SK-BR-3: 3.6
C12orf49	FLJ21415	ENSG00000111412	Chromosome 12 open reading frame 49	12	116710185-116738070	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026905	Uncertain				Renal cancer:1.91e-11 (favourable), Liver cancer:8.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 62.5	lung: 28.0	Expressed in all		
VDR	NR1I1, PPP1R163	ENSG00000111424	Vitamin D (1,25- dihydroxyvitamin D3) receptor	12	47841537-47943048	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB004617, HPA047740			Enhanced	Nucleoplasm	Renal cancer:4.89e-6 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 175.9	small intestine: 57.9	Cell line enhanced		HDLM-2: 73.7;U-937: 60.2
FZD10	CD350	ENSG00000111432	Frizzled class receptor 10	12	130162459-130165740	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014484, HPA014485	Uncertain		Supported	Nucleoplasm	Endometrial cancer:5.05e-7 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 9.4;esophagus: 8.8	skin: 5.6	Cell line enhanced		AF22: 5.4;BEWO: 6.1;hTCEpi: 2.6;RT4: 2.5
RFC5	RFC36	ENSG00000111445	Replication factor C subunit 5	12	118013588-118033130	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041037	Supported		Approved	Nucleoplasm	Cervical cancer:8.05e-5 (favourable), Renal cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.2	Expressed in all		
STX2	EPIM, EPM, STX2A, STX2B, STX2C	ENSG00000111450	Syntaxin 2	12	130789600-130839266	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA038189, HPA069176, CAB079007	Uncertain	Supported	Approved	Nucleus<br>Cytosol	Renal cancer:5.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
ADGRD1	DKFZp434B1272, GPR133, PGR25	ENSG00000111452	Adhesion G protein-coupled receptor D1	12	130953907-131141469	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042395	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:9.27e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 44.7	lung: 32.4	Cell line enhanced		BJ: 4.0;fHDF/TERT166: 4.1;HeLa: 6.4;HHSteC: 5.0;HMC-1: 11.4;U-2 OS: 6.6
COPZ1	CGI-120, COPZ	ENSG00000111481	Coatomer protein complex subunit zeta 1	12	54301202-54351849	Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.40e-5 (unfavourable), Renal cancer:7.45e-5 (unfavourable), Breast cancer:7.84e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 192.5	Expressed in all		
TBC1D30	KIAA0984	ENSG00000111490	TBC1 domain family member 30	12	64781193-64881032	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039772, HPA040043	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:3.61e-5 (favourable), Lung cancer:5.08e-4 (favourable)	Mixed	Mixed			parathyroid gland: 12.5	Cell line enhanced		MCF7: 33.4;RT4: 26.3;SCLC-21H: 35.3;SK-BR-3: 23.3
CAND1	DKFZp434M1414, KIAA0829, TIP120, TIP120A	ENSG00000111530	Cullin associated and neddylation dissociated 1	12	67269281-67319951	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055748, HPA062833, HPA069053	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.1	Expressed in all		
IL26	AK155, IL-26	ENSG00000111536	Interleukin 26	12	68201351-68225821	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		appendix: 1.2;urinary bladder: 1.4	tonsil: 0.9	Cell line enriched	19	HDLM-2: 12.4
IFNG		ENSG00000111537	Interferon gamma	12	68154768-68159747	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010344	Approved					Mixed	Tissue enhanced		appendix: 4.7;bone marrow: 7.6;lymph node: 7.9	lung: 2.5	Not detected		
RAB5B		ENSG00000111540	RAB5B, member RAS oncogene family	12	55973913-55996683	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010224, HPA068337	Approved		Supported	Vesicles	Breast cancer:2.24e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 175.6	Expressed in all		
MDM1		ENSG00000111554	Mdm1 nuclear protein	12	68272443-68332381	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040411, HPA041594	Uncertain		Supported	Centrosome<br>Cytosol	Cervical cancer:6.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.5	Expressed in all		
NUP107	NUP84	ENSG00000111581	Nucleoporin 107	12	68686734-68745809	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031679			Uncertain	Nucleoplasm<br>Nuclear membrane<br>Centrosome	Liver cancer:3.12e-9 (unfavourable), Renal cancer:1.28e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
CNOT2	CDC36, NOT2, NOT2H	ENSG00000111596	CCR4-NOT transcription complex subunit 2	12	70242994-70354993	Predicted intracellular proteins	Evidence at protein level	HPA067711	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:8.63e-5 (unfavourable), Liver cancer:2.21e-4 (unfavourable), Melanoma:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 53.9	Expressed in all		
TIMELESS	hTIM, TIM, TIM1	ENSG00000111602	Timeless circadian clock	12	56416373-56449403	Predicted intracellular proteins	Evidence at protein level	HPA060655	Enhanced		Supported	Nucleus	Melanoma:1.06e-5 (unfavourable), Renal cancer:2.61e-5 (unfavourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 18.2	Expressed in all		
CPSF6	CFIM, CFIM68, HPBRII-4, HPBRII-7	ENSG00000111605	Cleavage and polyadenylation specific factor 6	12	69239537-69274358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039973	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 55.2	Expressed in all		
KRR1	HRB2, RIP-1	ENSG00000111615	KRR1, small subunit processome component homolog	12	75490861-75511636	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043433, HPA051690	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 27.7	Expressed in all		
MRPL51	bMRP64, CDA09, HSPC241, MRP64	ENSG00000111639	Mitochondrial ribosomal protein L51	12	6491886-6493841	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039923	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 234.8	Expressed in all		
GAPDH	GAPD	ENSG00000111640	Glyceraldehyde-3-phosphate dehydrogenase	12	6533927-6538374	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005197, CAB016392, HPA040067, HPA061280	Supported		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:6.25e-10 (unfavourable), Liver cancer:1.79e-6 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 9869.6	Expressed in all		
NOP2	NOL1, NOP120, NSUN1, p120	ENSG00000111641	NOP2 nucleolar protein	12	6556863-6568691	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040119	Supported		Supported	Nucleoli	Renal cancer:2.35e-10 (unfavourable), Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 35.6	Expressed in all		
CHD4	Mi-2b, Mi2-BETA	ENSG00000111642	Chromodomain helicase DNA binding protein 4	12	6570083-6607476	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012008	Supported		Enhanced	Nucleus	Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.0	Expressed in all		
ACRBP	CT23, OY-TES-1, SP32	ENSG00000111644	Acrosin binding protein	12	6638075-6647460	Predicted secreted proteins	Evidence at protein level	HPA039081, HPA039082	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	19	testis: 432.5	thyroid gland: 22.6	Cell line enhanced		HMC-1: 5.8;U-266/70: 11.3;U-266/84: 7.3
UHRF1BP1L	KIAA0701	ENSG00000111647	UHRF1 binding protein 1 like	12	100028455-100142848	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039671, HPA040399	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			cerebral cortex: 32.9	Expressed in all		
COPS7A	CSN7A	ENSG00000111652	COP9 signalosome subunit 7A	12	6723741-6731875	Predicted intracellular proteins	Evidence at protein level	HPA026915	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 92.3	Expressed in all		
ING4	my036, p29ING4	ENSG00000111653	Inhibitor of growth family member 4	12	6650280-6663148	Predicted intracellular proteins	Evidence at protein level	HPA031817, HPA057338	Approved		Supported	Nucleus	Lung cancer:5.16e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 43.7	Expressed in all		
GNB3		ENSG00000111664	G protein subunit beta 3	12	6839954-6847393	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040736	Approved		Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Mixed			smooth muscle: 3.8	Cell line enhanced		NTERA-2: 12.8;U-698: 22.7
CDCA3	GRCC8, TOME-1	ENSG00000111665	Cell division cycle associated 3	12	6844793-6852066	Predicted intracellular proteins	Evidence at protein level	HPA026587			Approved	Cytosol	Liver cancer:6.51e-5 (unfavourable), Lung cancer:9.77e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 30.7	small intestine: 19.3	Mixed		
CHPT1	CPT1	ENSG00000111666	Choline phosphotransferase 1	12	101696947-101744140	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA067643	Approved		Approved	Vesicles	Thyroid cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			breast: 125.6	Expressed in all		
USP5	IsoT	ENSG00000111667	Ubiquitin specific peptidase 5	12	6852128-6866632	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006756	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 87.5	Expressed in all		
TPI1		ENSG00000111669	Triosephosphate isomerase 1	12	6867119-6870948	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050924, HPA053568	Uncertain		Enhanced	Nucleoplasm	Liver cancer:1.04e-5 (unfavourable), Renal cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 942.7	Expressed in all		
GNPTAB	GNPTA, KIAA1208, MGC4170	ENSG00000111670	N-acetylglucosamine-1-phosphate transferase alpha and beta subunits	12	101745497-101830938	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014558, HPA042343	Approved		Supported	Golgi apparatus	Endometrial cancer:8.48e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.1	Expressed in all		
SPSB2	GRCC9, SSB-2	ENSG00000111671	SplA/ryanodine receptor domain and SOCS box containing 2	12	6870935-6889358	Predicted intracellular proteins	Evidence at protein level	HPA055225	Approved				Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 12.6	Expressed in all		
ENO2		ENSG00000111674	Enolase 2	12	6913745-6923698	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000063, HPA068284, HPA068721, CAB073539, CAB079023	Enhanced	Supported	Supported	Plasma membrane<br>Cytosol	Renal cancer:7.89e-11 (unfavourable), Liver cancer:5.15e-4 (unfavourable), Colorectal cancer:6.96e-4 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 431.0	parathyroid gland: 64.8	Cell line enhanced		U-87 MG: 368.8
ATN1	B37, D12S755E, DRPLA	ENSG00000111676	Atrophin 1	12	6924463-6942321	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031619	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 139.5	Expressed in all		
C12orf57	C10, GRCC10	ENSG00000111678	Chromosome 12 open reading frame 57	12	6942978-6946003	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046182, HPA059163, HPA066043	Approved		Supported	Nuclear speckles	Renal cancer:2.32e-7 (unfavourable), Pancreatic cancer:8.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 522.5	Expressed in all		
PTPN6	HCP, HCPH, PTP-1C, SHP-1, SHP1	ENSG00000111679	Protein tyrosine phosphatase, non-receptor type 6	12	6946468-6961316	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001466, CAB004572, CAB072845	Enhanced		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.64e-8 (favourable), Cervical cancer:1.87e-4 (favourable), Colorectal cancer:5.42e-4 (unfavourable), Endometrial cancer:6.65e-4 (favourable)	Expressed in all	Mixed			lymph node: 161.5	Cell line enhanced		HEL: 143.6;HMC-1: 527.9;THP-1: 163.9
LPCAT3	C3F, MBOAT5, nessy, OACT5	ENSG00000111684	Lysophosphatidylcholine acyltransferase 3	12	6976186-7018510	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.89e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 123.0	Expressed in all		
NT5DC3	FLJ11266, TU12B1-TY	ENSG00000111696	5'-nucleotidase domain containing 3	12	103770453-103841197	Predicted secreted proteins	Evidence at protein level	HPA041634			Approved	Mitochondria<br>Cytosol	Renal cancer:5.72e-6 (unfavourable), Liver cancer:4.31e-4 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 16.0	Mixed		
SLCO1B3	OATP1B3, OATP8, SLC21A8	ENSG00000111700	Solute carrier organic anion transporter family member 1B3	12	20810702-20916911	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004943, HPA050892	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enriched	7	liver: 138.9	cervix, uterine: 19.5	Cell line enhanced		A-431: 56.7;A549: 15.8;CAPAN-2: 11.0;PC-3: 16.0;U-2 OS: 15.2
APOBEC1	APOBEC-1, BEDP, CDAR1, HEPR	ENSG00000111701	Apolipoprotein B mRNA editing enzyme catalytic subunit 1	12	7649400-7665903	Enzymes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Group enriched	21	duodenum: 31.9;small intestine: 31.0	stomach: 1.5	Cell line enriched	17	CAPAN-2: 2.4
NANOG	FLJ12581, FLJ40451	ENSG00000111704	Nanog homeobox	12	7787794-7799141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019380	Supported					Tissue enriched	Tissue enhanced		testis: 1.9	lung: 0.7	Cell line enriched	438	NTERA-2: 118.9
SUDS3	FLJ00052, SAP45, SDS3	ENSG00000111707	SDS3 homolog, SIN3A corepressor complex component	12	118376380-118418031	Predicted secreted proteins	Evidence at protein level	HPA040402, HPA041972	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 36.1	Expressed in all		
GOLT1B	CGI-141, GOT1, YMR292W	ENSG00000111711	Golgi transport 1B	12	21501781-21518408	Predicted membrane proteins	Evidence at protein level	HPA055909, HPA066383	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 42.4	Expressed in all		
GYS2		ENSG00000111713	Glycogen synthase 2	12	21536189-21604847	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039482	Approved				Liver cancer:7.62e-5 (favourable)	Tissue enriched	Tissue enriched	23	liver: 91.8	adipose tissue: 3.9	Cell line enhanced		CACO-2: 1.0
LDHB		ENSG00000111716	Lactate dehydrogenase B	12	21635342-21757857	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004641, HPA019007	Enhanced		Enhanced	Cytosol	Renal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			kidney: 1790.8	Expressed in all		
PRKAB1		ENSG00000111725	Protein kinase AMP-activated non-catalytic subunit beta 1	12	119667753-119681630	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004247, CAB005058	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			kidney: 53.5	Expressed in all		
CMAS		ENSG00000111726	Cytidine monophosphate N-acetylneuraminic acid synthetase	12	22046174-22065674	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039905	Supported		Uncertain	Nucleoli<br>Cytosol	Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 127.9	Expressed in all		
HCFC2	HCF-2	ENSG00000111727	Host cell factor C2	12	104064457-104106524	Predicted intracellular proteins	Evidence at protein level	HPA006227	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 17.1	Mixed		
ST8SIA1	SIAT8, SIAT8A	ENSG00000111728	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1	12	22063773-22437041	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026775	Approved					Mixed	Mixed			cerebral cortex: 9.0	Cell line enhanced		AF22: 6.4;SK-MEL-30: 4.8;WM-115: 6.4
CLEC4A	CD367, CLECSF6, DCIR, DDB27	ENSG00000111729	C-type lectin domain family 4 member A	12	8082269-8138607	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007842	Uncertain					Expressed in all	Tissue enhanced		appendix: 30.7	spleen: 17.1	Not detected		
C2CD5	CDP138, KIAA0528	ENSG00000111731	C2 calcium dependent domain containing 5	12	22448583-22544546	Predicted intracellular proteins	Evidence at protein level	HPA046194	Approved		Approved	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 51.5	Expressed in all		
AICDA	AID, ARP2, CDA2, HIGM2	ENSG00000111732	Activation induced cytidine deaminase	12	8602166-8612871	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	appendix: 4.9;lymph node: 18.7;tonsil: 11.0	spleen: 1.0	Group enriched	5	Daudi: 101.6;U-698: 81.2
RAB35	H-ray	ENSG00000111737	RAB35, member RAS oncogene family	12	120095095-120117502	Predicted intracellular proteins	Evidence at protein level	HPA054146	Approved				Liver cancer:6.46e-6 (unfavourable), Lung cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.8	Expressed in all		
PHC1	EDR1, HPH1, RAE28	ENSG00000111752	Polyhomeotic homolog 1	12	8913896-8941467	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006973	Approved		Supported	Nucleus		Tissue enriched	Expressed in all			testis: 80.4	Group enriched	6	BEWO: 158.3;NTERA-2: 593.1
COX6A1	COX6A	ENSG00000111775	Cytochrome c oxidase subunit 6A1	12	120438090-120440742	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA062394	Approved		Supported	Mitochondria	Renal cancer:6.50e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 572.6	Expressed in all		
AL021546.6		ENSG00000111780		12	120438198-120460006	Predicted intracellular proteins	Evidence at protein level	HPA062394	Uncertain		Approved	Mitochondria		Not detected	Not detected			colon: 0.9	Cell line enhanced		CACO-2: 7.5;HEK 293: 10.3;U-266/84: 7.5
RFX4		ENSG00000111783	Regulatory factor X4	12	106582907-106762803	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050527	Enhanced		Approved	Nucleus		Tissue enriched	Group enriched	236	cerebral cortex: 30.8;testis: 135.8	prostate: 0.3	Cell line enriched	13	AF22: 47.1
RIC8B	FLJ10620, hSyn, RIC8	ENSG00000111785	RIC8 guanine nucleotide exchange factor B	12	106774595-106889316	Predicted intracellular proteins	Evidence at protein level	HPA042746	Approved		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 21.8	Mixed		
SRSF9	SFRS9, SRp30c	ENSG00000111786	Serine and arginine rich splicing factor 9	12	120461668-120469793	Predicted intracellular proteins	Evidence at protein level	HPA049849	Enhanced		Approved	Nucleoplasm	Liver cancer:9.85e-7 (unfavourable), Melanoma:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 139.2	Expressed in all		
FGFR1OP2	DKFZp564O1863	ENSG00000111790	FGFR1 oncogene partner 2	12	26938383-26966650	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038308, HPA038696	Supported		Approved	Mitochondria		Expressed in all	Expressed in all			ovary: 73.7	Expressed in all		
KLRB1	CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A	ENSG00000111796	Killer cell lectin like receptor B1	12	9594551-9607886	CD markers, Predicted membrane proteins	Evidence at protein level	HPA039113	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:1.42e-5 (favourable), Breast cancer:3.51e-5 (favourable), Head and neck cancer:6.99e-5 (favourable), Thyroid cancer:5.61e-4 (favourable)	Mixed	Mixed			spleen: 40.7	Not detected		
COL12A1	COL12A1L	ENSG00000111799	Collagen type XII alpha 1 chain	6	75084326-75206051	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009143, HPA070695	Uncertain		Approved	Nucleus	Renal cancer:1.69e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 113.7	Cell line enhanced		fHDF/TERT166: 1109.7;SiHa: 894.9
BTN3A3	BTF3, BTN3.3	ENSG00000111801	Butyrophilin subfamily 3 member A3	6	26440472-26453415	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007904, HPA011871	Enhanced				Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 43.5;BJ hTERT+ SV40 Large T+ RasG12V: 41.9
TDP2	TTRAP	ENSG00000111802	Tyrosyl-DNA phosphodiesterase 2	6	24649977-24667033	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB073398, HPA074011	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Ovarian cancer:2.53e-7 (favourable), Urothelial cancer:1.47e-5 (favourable), Prostate cancer:1.86e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 189.4	Expressed in all		
FRK	GTK, PTK5, RAK	ENSG00000111816	Fyn related Src family tyrosine kinase	6	115931149-116060758	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025217, HPA030479	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:9.66e-7 (favourable)	Mixed	Mixed			kidney: 10.0	Mixed		
DSE	DSEPI, SART2	ENSG00000111817	Dermatan sulfate epimerase	6	116254173-116444860	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014764, HPA052151	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable)	Mixed	Mixed			appendix: 36.2	Mixed		
RWDD1	PTD013	ENSG00000111832	RWD domain containing 1	6	116571367-116597675	Predicted intracellular proteins	Evidence at protein level	HPA028712, HPA028713	Approved				Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 61.8	Expressed in all		
RSPH4A	CILD11, dJ412I7.1, FLJ37974, RSHL3, RSPH6B	ENSG00000111834	Radial spoke head 4 homolog A	6	116616479-116632985	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031196, HPA031197, HPA031198	Enhanced		Supported	Nucleus		Tissue enhanced	Tissue enriched	8	fallopian tube: 59.7	lung: 7.1	Cell line enhanced		RPMI-8226: 2.3;U-266/84: 1.7
MAK	dJ417M14.2, RP62	ENSG00000111837	Male germ cell associated kinase	6	10762723-10838555	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	fallopian tube: 9.7;parathyroid gland: 10.2;testis: 20.4	lung: 1.4	Cell line enhanced		HDLM-2: 1.4
TMEM14C	bA421M1.6, C6orf53, HSPC194, NET26	ENSG00000111843	Transmembrane protein 14C	6	10722915-10731129	Predicted membrane proteins	Evidence at protein level						Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.2	Expressed in all		
PAK1IP1	bA421M1.5, FLJ20624, hPIP1, MAK11, PIP1, WDR84	ENSG00000111845	PAK1 interacting protein 1	6	10694695-10709782	Predicted intracellular proteins	Evidence at protein level	HPA030111, HPA030112	Supported		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:7.02e-8 (unfavourable), Liver cancer:1.35e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 104.5	Expressed in all		
GCNT2	bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3	ENSG00000111846	Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)	6	10492223-10629368	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026776	Approved		Supported	Golgi apparatus		Mixed	Tissue enhanced		prostate: 55.7	breast: 13.9	Cell line enhanced		CACO-2: 39.6;EFO-21: 67.0
SMIM8	C6orf162, dJ102H19.2, DKFZP586E1923	ENSG00000111850	Small integral membrane protein 8	6	87322583-87399749	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007401, HPA067453	Approved		Approved	Vesicles		Expressed in all	Mixed			cerebral cortex: 13.9	Expressed in all		
NEDD9	CAS-L, CASS2, HEF1	ENSG00000111859	Neural precursor cell expressed, developmentally down-regulated 9	6	11183298-11382348	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009720, HPA038768, HPA039270	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			lung: 103.4	Cell line enhanced		EFO-21: 129.1
CEP85L	bA57K17.2, C6orf204, NY-BR-15	ENSG00000111860	Centrosomal protein 85 like	6	118460772-118710075	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029137, HPA029138, HPA029139	Uncertain					Mixed	Tissue enhanced		testis: 53.7	lymph node: 15.6	Cell line enhanced		BEWO: 24.8
ADTRP	AIG1L, C6orf105, dJ413H6.1	ENSG00000111863	Androgen dependent TFPI regulating protein	6	11712054-11807046	Predicted membrane proteins	Evidence at transcript level	HPA048113	Uncertain		Uncertain	Nucleoli	Renal cancer:1.13e-5 (unfavourable)	Mixed	Tissue enhanced		small intestine: 79.4	duodenum: 61.1	Cell line enhanced		HUVEC TERT2: 62.0;TIME: 33.0;U-138 MG: 25.7;U-266/84: 23.2
ASF1A	CIA, DKFZP547E2110	ENSG00000111875	Anti-silencing function 1A histone chaperone	6	118894220-118909167	Predicted intracellular proteins	Evidence at protein level	HPA030502, HPA071495			Enhanced	Nucleus	Liver cancer:5.02e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
MCM9	C6orf61, dJ329L24.3, FLJ20170, MCMDC1, MGC35304	ENSG00000111877	Minichromosome maintenance 9 homologous recombination repair factor	6	118813442-118935162	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031137	Approved		Approved	Nucleoplasm		Expressed in all	Mixed			epididymis: 15.5	Expressed in all		
FAM184A	C6orf60, FLJ13942	ENSG00000111879	Family with sequence similarity 184 member A	6	118959763-119149387	Predicted intracellular proteins	Evidence at protein level	HPA034571, HPA034572, HPA041955	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		placenta: 46.0;testis: 45.3	cerebral cortex: 25.1	Cell line enhanced		AF22: 19.5;HEK 293: 10.7;K-562: 15.2;SCLC-21H: 15.0
RNGTT	hCAP, HCE, HCE1	ENSG00000111880	RNA guanylyltransferase and 5'-phosphatase	6	88610272-88963721	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003750	Approved		Approved	Nucleoplasm	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 21.1	Expressed in all		
MAN1A1		ENSG00000111885	Mannosidase alpha class 1A member 1	6	119177209-119349761	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037058, HPA053198, HPA063561	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			placenta: 112.4	Cell line enhanced		ASC diff: 187.5;Karpas-707: 157.8;U-266/70: 224.6
GABRR2		ENSG00000111886	Gamma-aminobutyric acid type A receptor rho2 subunit	6	89257208-89315299	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,appendix,cerebral cortex,endometrium,gallbladder,lymph node,skin,spleen,testis,thyroid gland: 0.1	Not detected		
SERINC1	KIAA1253, TDE1L, TDE2, TMS-2	ENSG00000111897	Serine incorporator 1	6	122443354-122471822	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035738, HPA035739	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 615.4	Expressed in all		
HDDC2	C6orf74, CGI-130, dJ167O5.2	ENSG00000111906	HD domain containing 2	6	125219962-125302078	Predicted intracellular proteins	Evidence at protein level	HPA035677	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 117.1	Expressed in all		
TPD52L1	D53, hD53	ENSG00000111907	Tumor protein D52-like 1	6	125119049-125264407	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027915, HPA027916	Enhanced		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:3.26e-4 (favourable), Thyroid cancer:3.97e-4 (favourable), Urothelial cancer:5.34e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 320.2	salivary gland: 126.1	Cell line enhanced		AN3-CA: 249.0;hTCEpi: 169.3;MCF7: 277.5;RPTEC TERT1: 204.5
HINT3	FLJ33126	ENSG00000111911	Histidine triad nucleotide binding protein 3	6	125956781-125980244	Predicted intracellular proteins	Evidence at protein level	HPA027914	Approved		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:1.05e-6 (favourable), Breast cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 49.7	Expressed in all		
NCOA7	dJ187J11.3, ERAP140, TLDC4	ENSG00000111912	Nuclear receptor coactivator 7	6	125781161-125932030	Predicted intracellular proteins	Evidence at protein level	HPA030289, HPA030290, HPA030291, HPA030292	Approved		Approved	Nuclear bodies<br>Golgi apparatus	Renal cancer:1.78e-6 (favourable)	Expressed in all	Expressed in all			urinary bladder: 88.4	Expressed in all		
FAM65B	C6orf32, DIFF48, KIAA0386, MYONAP	ENSG00000111913	Family with sequence similarity 65 member B	6	24804282-25042018	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 92.5	spleen: 73.1	Cell line enhanced		AF22: 30.2;Daudi: 47.4;fHDF/TERT166: 47.6
SASH1	dJ323M4.1, KIAA0790, SH3D6A	ENSG00000111961	SAM and SH3 domain containing 1	6	148272304-148552050	Predicted intracellular proteins	Evidence at protein level	HPA029947, HPA029949	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.42e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 63.6	Cell line enhanced		ASC diff: 133.3;WM-115: 91.6
UST	2OST	ENSG00000111962	Uronyl 2-sulfotransferase	6	148747328-149076990	Predicted membrane proteins	Evidence at protein level	HPA032022	Approved					Expressed in all	Tissue enhanced		thyroid gland: 49.9	adrenal gland: 16.9	Mixed		
ULBP1	RAET1I	ENSG00000111981	UL16 binding protein 1	6	149964007-149973710	Predicted membrane proteins	Evidence at protein level	HPA007547, HPA071005	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Mixed	Tissue enhanced		testis: 11.0	thyroid gland: 3.5	Cell line enhanced		HAP1: 35.9
FBXO5	EMI1, FBX5, Fbxo31	ENSG00000112029	F-box protein 5	6	152970519-152983579	Predicted intracellular proteins	Evidence at protein level	CAB008106, HPA029048	Approved		Supported	Nucleoplasm	Stomach cancer:8.65e-4 (favourable)	Expressed in all	Mixed			bone marrow: 27.1	Expressed in all		
MTRF1L	HMRF1L, mtRF1a	ENSG00000112031	Mitochondrial translational release factor 1 like	6	152987362-153002685	Predicted intracellular proteins	Evidence at protein level	HPA036367	Uncertain				Breast cancer:4.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.0	Expressed in all		
PPARD	FAAR, NR1C2, NUC1, NUCII	ENSG00000112033	Peroxisome proliferator activated receptor delta	6	35342558-35428191	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017635	Approved				Liver cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 40.2	Expressed in all		
OPRM1	MOR1	ENSG00000112038	Opioid receptor mu 1	6	154010496-154246867	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014509, HPA067435	Enhanced	Supported				Not detected	Tissue enhanced		testis: 4.1	adrenal gland,esophagus: 1.2	Cell line enriched	29	SH-SY5Y: 7.7
FANCE	FACE, FAE	ENSG00000112039	Fanconi anemia complementation group E	6	35452361-35467103	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014893	Enhanced		Supported	Nucleoplasm	Liver cancer:2.08e-9 (unfavourable), Endometrial cancer:6.25e-4 (unfavourable)	Expressed in all	Mixed			skin: 16.1	Expressed in all		
TULP1	LCA15, RP14, TUBL1	ENSG00000112041	Tubby like protein 1	6	35497874-35512938	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Not detected			prostate: 0.7	Cell line enhanced		BEWO: 2.6;MCF7: 1.2
SLC26A8		ENSG00000112053	Solute carrier family 26 member 8	6	35943514-36024868	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038081	Enhanced					Not detected	Tissue enriched	27	testis: 76.1	bone marrow: 2.8	Not detected		
MAPK14	CSBP1, CSBP2, CSPB1, Mxi2, p38, PRKM14, PRKM15	ENSG00000112062	Mitogen-activated protein kinase 14	6	36027677-36111236	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010285, CAB040578, HPA051825	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			placenta: 63.2	Expressed in all		
RHAG	CD241, RH50A, SLC42A1	ENSG00000112077	Rh-associated glycoprotein	6	49605158-49636839	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046051, HPA055331	Approved		Uncertain	Endoplasmic reticulum		Not detected	Tissue enriched	24	bone marrow: 73.7	placenta: 3.1	Group enriched	223	HEL: 448.1;K-562: 429.7
KCTD20	C6orf69, dJ108K11.3, MGC14254	ENSG00000112078	Potassium channel tetramerization domain containing 20	6	36442767-36491143	Predicted intracellular proteins	Evidence at protein level	HPA030092	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Glioma:7.39e-4 (favourable), Renal cancer:8.02e-4 (unfavourable), Liver cancer:8.32e-4 (unfavourable), Thyroid cancer:9.31e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 47.0	Expressed in all		
STK38	NDR	ENSG00000112079	Serine/threonine kinase 38	6	36493892-36547470	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004673, HPA038623, HPA051324	Uncertain		Approved	Cytosol	Melanoma:9.44e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 40.3	Expressed in all		
SRSF3	SFRS3, SRp20	ENSG00000112081	Serine and arginine rich splicing factor 3	6	36594353-36605600	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012986, HPA056981	Supported		Supported	Nucleoplasm	Liver cancer:6.22e-5 (unfavourable), Ovarian cancer:1.37e-4 (favourable), Melanoma:1.95e-4 (unfavourable), Renal cancer:2.02e-4 (unfavourable), Colorectal cancer:2.56e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 139.5	Expressed in all		
SOD2		ENSG00000112096	Superoxide dismutase 2	6	159669057-159762529	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001814, CAB002013	Supported				Renal cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 734.4	Expressed in all		
MRPL18	HSPC071	ENSG00000112110	Mitochondrial ribosomal protein L18	6	159789812-159798436	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA028774, HPA028775	Enhanced				Renal cancer:9.02e-5 (unfavourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 85.9	Expressed in all		
IL17A	CTLA8, IL-17, IL-17A, IL17	ENSG00000112115	Interleukin 17A	6	52186387-52190638	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052258	Uncertain					Not detected	Tissue enhanced		appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5	gallbladder: 0.3	Group enriched	16	Karpas-707: 1.9;U-266/84: 1.2
IL17F	IL-17F, ML-1, ML1	ENSG00000112116	Interleukin 17F	6	52236681-52244537	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 1.8	urinary bladder: 0.9	Not detected		
MCM3		ENSG00000112118	Minichromosome maintenance complex component 3	6	52264009-52284881	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002162, HPA004789, HPA004790	Supported		Enhanced	Nucleoplasm	Thyroid cancer:3.13e-5 (favourable), Melanoma:4.40e-5 (unfavourable), Liver cancer:1.40e-4 (unfavourable), Cervical cancer:1.89e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 80.8	Expressed in all		
RNF8	KIAA0646	ENSG00000112130	Ring finger protein 8	6	37353972-37394738	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050731, HPA064925	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:3.33e-5 (unfavourable), Prostate cancer:4.99e-5 (unfavourable), Melanoma:1.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 18.5	Expressed in all		
PHACTR1	dJ257A7.2, KIAA1733, RPEL1	ENSG00000112137	Phosphatase and actin regulator 1	6	12716805-13290484	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029755, HPA029756, HPA029757	Enhanced		Uncertain	Plasma membrane	Renal cancer:5.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 26.6	bone marrow: 15.6	Cell line enhanced		HMC-1: 33.9;U-266/70: 72.3;U-266/84: 46.3
MDGA1	GPIM, MAMDC3	ENSG00000112139	MAM domain containing glycosylphosphatidylinositol anchor 1	6	37630679-37699306	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031235, HPA050382	Approved		Supported	Golgi apparatus<br>Plasma membrane		Mixed	Mixed			parathyroid gland: 10.1	Mixed		
ICK	KIAA0936, LCK2, MGC46090, MRK	ENSG00000112144	Intestinal cell kinase	6	53001279-53061802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000791, HPA001113	Approved		Approved	Nucleoli fibrillar center		Expressed in all	Mixed			adrenal gland: 23.1	Expressed in all		
FBXO9	FBX9, NY-REN-57	ENSG00000112146	F-box protein 9	6	53051991-53100873	Predicted intracellular proteins	Evidence at protein level	HPA064246			Approved	Centrosome	Ovarian cancer:1.51e-4 (favourable), Pancreatic cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 107.5	Expressed in all		
CD83	BL11, HB15	ENSG00000112149	CD83 molecule	6	14117256-14136918	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002509, HPA041454	Enhanced		Approved	Vesicles	Renal cancer:3.49e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 130.9	tonsil: 64.1	Cell line enhanced		Daudi: 54.6;HDLM-2: 64.1;U-698: 80.4
MDN1	KIAA0301, Rea1	ENSG00000112159	Midasin AAA ATPase 1	6	89642499-89819723	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029666, HPA029667, HPA029668, HPA029669	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 13.4	Expressed in all		
GLP1R		ENSG00000112164	Glucagon like peptide 1 receptor	6	39048798-39087743	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 1.9;heart muscle: 1.8	pancreas: 1.5	Cell line enhanced		NTERA-2: 1.3;SCLC-21H: 3.7
SAYSD1	C6orf64, FLJ11101	ENSG00000112167	SAYSVFN motif domain containing 1	6	39104064-39115189	Predicted membrane proteins	Evidence at protein level	HPA007959		Approved	Enhanced	Vesicles		Expressed in all	Tissue enriched	6	testis: 85.8	prostate: 14.6	Mixed		
BMP5		ENSG00000112175	Bone morphogenetic protein 5	6	55753645-55875564	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		placenta: 102.6	prostate: 24.1	Group enriched	9	AF22: 27.4;U-2 OS: 22.4
BACH2	BTBD25	ENSG00000112182	BTB domain and CNC homolog 2	6	89926529-90296908	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051384, HPA058384	Enhanced		Supported	Nucleus<br>Cytosol		Mixed	Tissue enhanced		lymph node: 21.2	tonsil: 12.1	Cell line enhanced		Daudi: 101.9;U-698: 57.4
RBM24	dJ259A10.1, FLJ30829, RNPC6	ENSG00000112183	RNA binding motif protein 24	6	17281346-17293875	Predicted intracellular proteins	Evidence at protein level	HPA066927, HPA067231	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		heart muscle: 90.9;skeletal muscle: 109.8	endometrium: 51.6	Cell line enhanced		LHCN-M2: 49.0;RH-30: 57.9;T-47d: 26.5
CAP2		ENSG00000112186	CAP, adenylate cyclase-associated protein, 2 (yeast)	6	17393216-17557792	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA050530, HPA054147	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 125.1;skeletal muscle: 220.8	heart muscle: 70.1	Mixed		
TREML2	C6orf76, dJ238O23.1, FLJ13693, TLT2	ENSG00000112195	Triggering receptor expressed on myeloid cells like 2	6	41190277-41201194	Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 9.3;bone marrow: 10.0;lymph node: 11.9	spleen: 8.8	Cell line enhanced		HEL: 26.9;HL-60: 5.6;U-698: 5.8;U-937: 4.3
ZNF451	COASTER, dJ417I1.1, KIAA0576, KIAA1702	ENSG00000112200	Zinc finger protein 451	6	57086844-57170307	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028838			Approved	Nucleus		Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
BAG2		ENSG00000112208	BCL2 associated athanogene 2	6	57172326-57189833	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018862, HPA019918	Enhanced		Supported	Nucleoplasm	Liver cancer:6.72e-6 (unfavourable), Thyroid cancer:1.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 42.0	endometrium: 37.5	Mixed		
RAB23		ENSG00000112210	RAB23, member RAS oncogene family	6	57186992-57222314	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029135, HPA029136	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			smooth muscle: 110.0	Expressed in all		
TSPO2	BZRPL1, dJ34B21.2	ENSG00000112212	Translocator protein 2	6	41042554-41044337	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA066996	Uncertain					Mixed	Tissue enriched	17	bone marrow: 30.8	placenta: 1.8	Cell line enhanced		CACO-2: 1.3
FHL5	ACT, dJ393D12.2, FLJ33049	ENSG00000112214	Four and a half LIM domains 5	6	96562548-96616636	Predicted intracellular proteins	Evidence at protein level						Glioma:3.18e-4 (favourable)	Mixed	Tissue enhanced		testis: 106.4	cervix, uterine: 43.3	Cell line enriched	9	ASC diff: 3.4
GPR63	PSP24(beta), PSP24B	ENSG00000112218	G protein-coupled receptor 63	6	96794126-96837463	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA039103	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 4.6	Cell line enhanced		HHSteC: 11.3;Karpas-707: 15.0
KHDRBS2	MGC26664, SLM-1, SLM1	ENSG00000112232	KH RNA binding domain containing, signal transduction associated 2	6	61679960-62286227	Predicted intracellular proteins	Evidence at protein level	HPA000500, HPA029392	Supported					Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;lung: 5.6;thyroid gland: 11.0	spleen: 1.8	Cell line enhanced		AF22: 7.2;NTERA-2: 1.9;THP-1: 1.0
FBXL4	FBL4, FBL5	ENSG00000112234	F-box and leucine rich repeat protein 4	6	98868538-98948006	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029140, CAB033362	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 25.3	Expressed in all		
CCNC	CycC	ENSG00000112237	Cyclin C	6	99542380-99568973	Predicted intracellular proteins	Evidence at protein level	CAB010499, HPA069322	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 99.2	Expressed in all		
PRDM13		ENSG00000112238	PR/SET domain 13	6	99606730-99615578	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA070592	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
E2F3		ENSG00000112242	E2F transcription factor 3	6	20401906-20493715	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029779, HPA065012			Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Renal cancer:1.63e-8 (unfavourable), Ovarian cancer:1.69e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 14.4	Expressed in all		
PTP4A1	PRL-1, PTPCAAX1	ENSG00000112245	Protein tyrosine phosphatase type IVA, member 1	6	63521748-63583587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281	Approved				Cervical cancer:5.53e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 354.5	Expressed in all		
SIM1	bHLHe14	ENSG00000112246	Single-minded family bHLH transcription factor 1	6	100385015-100464929	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA024385			Approved	Nuclear speckles	Renal cancer:5.32e-7 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 3.5;kidney: 11.2;seminal vesicle: 3.2	skeletal muscle: 1.2	Cell line enhanced		BJ: 13.9;BJ hTERT+: 19.3;RPTEC TERT1: 13.9
ASCC3	ASC1p200, dJ121G13.4, dJ467N11.1, HELIC1, RNAH	ENSG00000112249	Activating signal cointegrator 1 complex subunit 3	6	100508194-100881372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031608, HPA031609, HPA031610	Enhanced		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 26.5	Expressed in all		
HDGFL1	dJ309H15.1, PWWP1	ENSG00000112273	Hepatoma derived growth factor-like 1	6	22569493-22571666	Predicted intracellular proteins	Evidence at protein level	HPA045679, HPA063707	Enhanced					Tissue enriched	Tissue enriched	1395	testis: 139.4	all non-specific tissues: 0.0	Cell line enriched	8	K-562: 1.0
BVES	HBVES, POP1, POPDC1	ENSG00000112276	Blood vessel epicardial substance	6	105096822-105137174	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014788, HPA018176	Enhanced		Supported	Plasma membrane<br>Cell Junctions		Mixed	Tissue enhanced		smooth muscle: 25.0	testis: 20.7	Cell line enhanced		RH-30: 28.7;WM-115: 29.8
COL9A1		ENSG00000112280	Collagen type IX alpha 1 chain	6	70215061-70303083	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA074749	Supported					Mixed	Tissue enriched	6	prostate: 31.4	testis: 5.1	Group enriched	6	AF22: 27.0;NTERA-2: 9.9
MED23	CRSP130, CRSP3, DRIP130, Sur2	ENSG00000112282	Mediator complex subunit 23	6	131573966-131628229	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070341			Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 32.2	Expressed in all		
WASF1	KIAA0269, SCAR1, WAVE, WAVE1	ENSG00000112290	WAS protein family member 1	6	110099819-110180004	Predicted intracellular proteins	Evidence at protein level	HPA004105, CAB022161	Approved	Approved			Liver cancer:2.82e-8 (unfavourable), Renal cancer:2.79e-5 (unfavourable)	Expressed in all	Group enriched	5	cerebral cortex: 138.9;testis: 149.9	ovary: 27.8	Mixed		
GPLD1		ENSG00000112293	Glycosylphosphatidylinositol specific phospholipase D1	6	24424565-24495205	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008625, HPA012500	Uncertain				Liver cancer:1.12e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 23.6	skin: 9.0	Cell line enhanced		Daudi: 5.7;U-698: 5.6
ALDH5A1	SSADH, SSDH	ENSG00000112294	Aldehyde dehydrogenase 5 family member A1	6	24494852-24537207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029715, HPA029716	Enhanced		Enhanced	Mitochondria	Liver cancer:7.61e-6 (favourable), Renal cancer:3.68e-4 (favourable), Ovarian cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			liver: 46.8	Cell line enhanced		Daudi: 88.4;U-698: 105.9
AIM1	CRYBG1, ST4	ENSG00000112297	Absent in melanoma 1	6	106360808-106571978	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026378, HPA030948, HPA030949	Approved		Approved	Nucleus<br>Microtubules<br>Cytosol		Expressed in all	Tissue enhanced		placenta: 107.4	esophagus: 71.3	Mixed		
VNN1	Tiff66	ENSG00000112299	Vanin 1	6	132681590-132714049	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064145	Approved				Renal cancer:2.52e-4 (unfavourable)	Tissue enhanced	Group enriched	5	duodenum: 171.4;gallbladder: 174.7;liver: 142.4;small intestine: 106.3	kidney: 27.5	Cell line enhanced		EFO-21: 10.3
VNN2	FOAP-4, GPI-80	ENSG00000112303	Vanin 2	6	132743870-132763459	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.72e-7 (unfavourable)	Mixed	Tissue enhanced		spleen: 76.9	lymph node: 45.0	Cell line enriched	6	Daudi: 40.8
ACOT13	HT012, THEM2	ENSG00000112304	Acyl-CoA thioesterase 13	6	24667035-24705065	Predicted intracellular proteins	Evidence at protein level	HPA019881	Approved		Approved	Cell Junctions	Ovarian cancer:2.53e-6 (favourable)	Expressed in all	Expressed in all			kidney: 19.9	Expressed in all		
SMAP1	FLJ13159, SMAP-1	ENSG00000112305	Small ArfGAP 1	6	70667776-70862015	Predicted intracellular proteins	Evidence at protein level	HPA030574	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 51.5	Expressed in all		
RPS12	S12	ENSG00000112306	Ribosomal protein S12	6	132814441-132817564	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006124, HPA006365	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3959.0	Expressed in all		
C6orf62	DKFZP564G182, FLJ12619, XTP12	ENSG00000112308	Chromosome 6 open reading frame 62	6	24704861-24720836	Predicted intracellular proteins	Evidence at protein level	HPA030564, HPA030566	Enhanced		Approved	Cytosol	Urothelial cancer:3.62e-6 (favourable), Liver cancer:5.77e-5 (unfavourable), Ovarian cancer:4.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 174.4	Expressed in all		
B3GAT2	GlcAT-S	ENSG00000112309	Beta-1,3-glucuronyltransferase 2	6	70856679-70957038	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012059	Uncertain					Group enriched	Tissue enriched	10	cerebral cortex: 19.5	testis: 1.8	Cell line enriched	25	SCLC-21H: 25.9
GMNN	Gem	ENSG00000112312	Geminin, DNA replication inhibitor	6	24774931-24786099	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB011458, CAB047327, CAB047328, HPA049977, HPA054597	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.82e-5 (unfavourable), Ovarian cancer:4.13e-4 (favourable), Pancreatic cancer:9.77e-4 (unfavourable)	Expressed in all	Expressed in all			prostate,testis: 67.7	Expressed in all		
EYA4	CMD1J, DFNA10	ENSG00000112319	EYA transcriptional coactivator and phosphatase 4	6	133240598-133532120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004805, HPA038771, HPA038772	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		seminal vesicle: 16.0	fallopian tube: 11.5	Cell line enhanced		A549: 22.1;HeLa: 45.5;RH-30: 22.5;U-87 MG: 23.4
SOBP	FLJ10159	ENSG00000112320	Sine oculis binding protein homolog	6	107489958-107660167	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029242	Uncertain		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:1.55e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 26.4	ovary: 13.7	Cell line enhanced		AF22: 12.5;AN3-CA: 15.3
NR2E1	TLL, TLX, XTLL	ENSG00000112333	Nuclear receptor subfamily 2 group E member 1	6	108166058-108188809	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036954, HPA055642	Enhanced		Approved	Nuclear bodies		Tissue enriched	Tissue enriched	46	cerebral cortex: 11.4	adrenal gland: 0.2	Cell line enhanced		BEWO: 2.9;U-251 MG: 3.3
SNX3	Grd19	ENSG00000112335	Sorting nexin 3	6	108211222-108261260	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Breast cancer:4.37e-5 (unfavourable), Renal cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 288.7	Expressed in all		
SLC17A2	NPT3	ENSG00000112337	Solute carrier family 17 member 2	6	25912754-25930726	Predicted membrane proteins, Transporters	Evidence at protein level	HPA038270	Uncertain				Liver cancer:8.54e-4 (favourable)	Tissue enriched	Tissue enriched	85	liver: 40.8	kidney,testis: 0.4	Cell line enriched	12	Hep G2: 2.5
HBS1L	DKFZp434g247, EF-1a, eRF3c, ERFS, HBS1, HSPC276, KIAA1038	ENSG00000112339	HBS1 like translational GTPase	6	134960378-135103056	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029728, HPA029729	Approved		Approved	Nuclear bodies<br>Cytosol	Colorectal cancer:6.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.2	Expressed in all		
TRIM38	RNF15, RORET	ENSG00000112343	Tripartite motif containing 38	6	25962802-25991226	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031685	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Centrosome	Urothelial cancer:4.94e-9 (favourable), Thyroid cancer:8.20e-5 (favourable), Ovarian cancer:8.95e-5 (favourable)	Expressed in all	Mixed			spleen: 19.7	Mixed		
PEX7	PTS2R, RD	ENSG00000112357	Peroxisomal biogenesis factor 7	6	136822564-136913937	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049202	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.85e-10 (favourable), Colorectal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.3	Mixed		
ZBTB24	BIF1, KIAA0441, PATZ2, ZNF450	ENSG00000112365	Zinc finger and BTB domain containing 24	6	109462594-109483237	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017872, HPA049003	Uncertain		Approved	Nucleus<br>Cytokinetic bridge<br>Centrosome	Liver cancer:3.15e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.9	Expressed in all		
FIG4	ALS11, CMT4J, dJ249I4.1, hSac3, KIAA0274, SAC3	ENSG00000112367	FIG4 phosphoinositide 5-phosphatase	6	109691312-109825428	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017823, HPA068859	Approved		Approved	Vesicles<br>Lipid droplets	Liver cancer:4.73e-4 (unfavourable), Breast cancer:5.91e-4 (unfavourable), Renal cancer:8.19e-4 (favourable), Colorectal cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.1	Expressed in all		
PERP	dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW	ENSG00000112378	PERP, TP53 apoptosis effector	6	138088505-138107511	Predicted membrane proteins	Evidence at protein level	HPA022269	Enhanced				Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable)	Expressed in all	Group enriched	6	esophagus: 571.9;skin: 1235.5	breast: 151.1	Cell line enhanced		hTCEpi: 661.0
ARFGEF3	BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33	ENSG00000112379	ARFGEF family member 3	6	138161921-138344663	Predicted intracellular proteins	Evidence at protein level	HPA036350	Uncertain				Breast cancer:8.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 23.7;parathyroid gland: 29.7	prostate: 19.2	Cell line enhanced		RH-30: 13.0;RT4: 15.4;SK-BR-3: 16.6
SLC16A10	MCT10, TAT1	ENSG00000112394	Solute carrier family 16 member 10	6	111087503-111231194	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016860	Approved		Approved	Vesicles<br>Cell Junctions		Tissue enriched	Tissue enhanced		placenta: 38.6	skin: 22.4	Cell line enhanced		HAP1: 53.9;HEK 293: 20.6;RPMI-8226: 30.8
HECA	dJ225E12.1, HDC, HDCL, hHDC	ENSG00000112406	Hdc homolog, cell cycle regulator	6	139135112-139180802	Predicted intracellular proteins	Evidence at protein level	HPA042313	Uncertain				Renal cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 38.1	Mixed		
ADGRG6	FLJ14937, GPR126	ENSG00000112414	Adhesion G protein-coupled receptor G6	6	142301854-142446266	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017346	Approved				Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 67.2	liver: 36.9	Cell line enhanced		HUVEC TERT2: 133.3;MCF7: 118.0
PHACTR2	C6orf56, KIAA0680	ENSG00000112419	Phosphatase and actin regulator 2	6	143536845-143831185	Predicted intracellular proteins	Evidence at protein level	HPA031719, HPA031720, HPA031725	Approved				Renal cancer:1.99e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.1	Cell line enhanced		TIME: 66.9
EPM2A	LD, LDE	ENSG00000112425	EPM2A, laforin glucan phosphatase	6	145382535-145736023	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053643, HPA055468			Enhanced	Nucleoplasm	Renal cancer:4.08e-7 (favourable)	Expressed in all	Mixed			skeletal muscle: 26.8	Mixed		
OR12D3	hs6M1-27	ENSG00000112462	Olfactory receptor family 12 subfamily D member 3	6	29373423-29375291	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SLC39A7	D6S2244E, H2-KE4, HKE4, KE4, RING5, ZIP7	ENSG00000112473	Solute carrier family 39 member 7	6	33200445-33204439	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053999	Approved		Supported	Endoplasmic reticulum	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 41.1	Expressed in all		
CCR6	BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22	ENSG00000112486	C-C motif chemokine receptor 6	6	167111807-167139696	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB006820, HPA014488	Approved					Not detected	Tissue enhanced		lymph node: 20.4;tonsil: 32.4	spleen: 17.0	Cell line enriched	7	Hep G2: 6.2
UNC93A	dJ366N23.1, dJ366N23.2	ENSG00000112494	Unc-93 homolog A (C. elegans)	6	167271169-167316019	Predicted membrane proteins	Evidence at protein level	HPA035729	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 9.7;liver: 7.1;skin: 17.8	esophagus: 5.6	Group enriched	9	CACO-2: 6.1;Hep G2: 2.1;SCLC-21H: 3.7
SLC22A2	OCT2	ENSG00000112499	Solute carrier family 22 member 2	6	160171061-160277638	Predicted membrane proteins, Transporters	Evidence at protein level	HPA008567, CAB068236, CAB068237	Enhanced				Renal cancer:1.85e-7 (favourable)	Tissue enriched	Tissue enriched	83	kidney: 150.3	seminal vesicle: 1.8	Not detected		
PHF1	MTF2L2, PCL1, TDRD19C	ENSG00000112511	PHD finger protein 1	6	33410399-33416453	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031038	Approved		Approved	Nucleoplasm	Colorectal cancer:9.64e-5 (unfavourable), Urothelial cancer:1.72e-4 (favourable)	Expressed in all	Mixed			testis: 16.0	Mixed		
CUTA	ACHAP, C6orf82	ENSG00000112514	CutA divalent cation tolerance homolog	6	33416442-33418317	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016787, HPA064369	Uncertain		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:8.50e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 293.5	Expressed in all		
PACRG	FLJ32724, Glup, HAK005771, PARK2CRG	ENSG00000112530	PARK2 coregulated	6	162727132-163315492	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066293	Enhanced				Renal cancer:2.55e-6 (favourable)	Mixed	Tissue enhanced		fallopian tube: 57.1;testis: 53.0	cerebral cortex,epididymis: 11.8	Cell line enhanced		SCLC-21H: 8.2
QKI	QK3	ENSG00000112531	QKI, KH domain containing RNA binding	6	163414000-163578596	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019123, CAB022602	Enhanced	Supported	Supported	Nucleoplasm	Renal cancer:2.31e-5 (unfavourable), Liver cancer:1.27e-4 (unfavourable), Stomach cancer:3.69e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 359.6	Expressed in all		
C6orf118	bA85G2.1, MGC23884	ENSG00000112539	Chromosome 6 open reading frame 118	6	165279664-165309607	Predicted intracellular proteins	Evidence at transcript level	HPA029787, HPA029789	Approved		Uncertain	Mitochondria		Tissue enhanced	Group enriched	6	fallopian tube: 26.2;testis: 12.8	lung: 3.2	Cell line enhanced		AF22: 2.7;SCLC-21H: 1.8
PDE10A		ENSG00000112541	Phosphodiesterase 10A	6	165327287-165986603	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB045998, HPA047200	Supported				Renal cancer:4.44e-7 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 14.5	testis: 12.2	Cell line enhanced		LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
MDFI	I-mfa	ENSG00000112559	MyoD family inhibitor	6	41636882-41654246	Predicted intracellular proteins	Evidence at protein level	HPA049973	Approved		Approved	Nucleoplasm	Renal cancer:2.85e-6 (unfavourable), Lung cancer:1.32e-5 (unfavourable), Melanoma:9.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 35.9	gallbladder: 19.7	Cell line enhanced		BEWO: 88.8;HBEC3-KT: 83.8;REH: 287.1
TFEB	bHLHe35, TCFEB	ENSG00000112561	Transcription factor EB	6	41683978-41736259	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049532			Supported	Nucleoplasm	Renal cancer:1.06e-5 (favourable), Pancreatic cancer:4.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.3	Cell line enhanced		BEWO: 65.1;U-698: 44.9
SMOC2	SMAP2	ENSG00000112562	SPARC related modular calcium binding 2	6	168441151-168673445	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033979	Uncertain				Renal cancer:1.16e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 183.6	Cell line enhanced		AF22: 8.0;EFO-21: 2.6;RPMI-8226: 7.7;RPTEC TERT1: 2.8
CCND3		ENSG00000112576	Cyclin D3	6	41934933-42050357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000116	Approved				Thyroid cancer:8.08e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 159.2	Expressed in all		
BYSL		ENSG00000112578	Bystin like	6	41921188-41933046	Predicted intracellular proteins	Evidence at protein level	HPA031217, HPA031219	Enhanced		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.15e-8 (unfavourable), Liver cancer:6.43e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11.7	Expressed in all		
FAM120B	CCPG, KIAA1838, PGCC1	ENSG00000112584	Family with sequence similarity 120B	6	170290703-170407065	Predicted intracellular proteins	Evidence at protein level	HPA037518, HPA037519	Uncertain		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:1.60e-4 (unfavourable), Pancreatic cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 16.5	Expressed in all		
TBP	GTF2D1, SCA17, TFIID	ENSG00000112592	TATA-box binding protein	6	170554302-170572870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009442, HPA049805	Approved		Supported	Nucleoplasm	Liver cancer:1.51e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 61.8	Expressed in all		
GUCA1B	GCAP2, RP48	ENSG00000112599	Guanylate cyclase activator 1B	6	42184401-42194916	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055479	Supported					Mixed	Mixed			skin: 4.2	Mixed		
PRPH2	CACD2, rd2, RDS, RP7, TSPAN22	ENSG00000112619	Peripherin 2	6	42696600-42722574	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029458	Supported					Mixed	Mixed			parathyroid gland: 8.6	Cell line enhanced		ASC TERT1: 2.4;fHDF/TERT166: 4.1;HHSteC: 6.6;HSkMC: 4.4;LHCN-M2: 3.0
GLTSCR1L	KIAA0240	ENSG00000112624	GLTSCR1 like	6	42746958-42868560	Predicted intracellular proteins	Evidence at protein level	HPA029390, HPA029391	Approved		Supported	Nucleoplasm	Head and neck cancer:5.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
PPP2R5D	B56D	ENSG00000112640	Protein phosphatase 2 regulatory subunit B'delta	6	42984499-43012342	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029045, HPA029046	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.3	Expressed in all		
MRPL2	CGI-22, MRP-L14, RPML14	ENSG00000112651	Mitochondrial ribosomal protein L2	6	43054029-43059806	Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA007455, HPA064814	Approved		Approved	Nucleoplasm<br>Mitochondria	Ovarian cancer:6.01e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.3	Expressed in all		
PTK7	CCK4	ENSG00000112655	Protein tyrosine kinase 7 (inactive)	6	43076268-43161719	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003222	Approved					Expressed in all	Mixed			endometrium: 117.3	Mixed		
SRF	MCM1	ENSG00000112658	Serum response factor	6	43171299-43181507	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001819, CAB005416	Supported		Supported	Nucleus	Renal cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.2	Expressed in all		
CUL9	H7AP1, KIAA0708, PARC	ENSG00000112659	Cullin 9	6	43182175-43224587	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016434, HPA052004	Approved		Approved	Cytosol	Head and neck cancer:2.37e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Urothelial cancer:4.87e-4 (favourable), Breast cancer:5.28e-4 (favourable), Pancreatic cancer:8.07e-4 (favourable)	Expressed in all	Mixed			testis: 10.0	Mixed		
DNPH1	C6orf108, dJ330M21.3, rcl	ENSG00000112667	2'-deoxynucleoside 5'-phosphate N-hydrolase 1	6	43225629-43229484	Predicted intracellular proteins	Evidence at protein level	HPA029675, HPA029676	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			duodenum: 104.2	Expressed in all		
DUSP22	JKAP, JSP1, MKPX, VHX	ENSG00000112679	Dual specificity phosphatase 22	6	291630-351355	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031394	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
EXOC2	FLJ11026, SEC5L1, Sec5p	ENSG00000112685	Exocyst complex component 2	6	485133-693111	Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA032093			Supported	Vesicles		Expressed in all	Expressed in all			testis: 30.4	Expressed in all		
COX7A2	COX7AL, COXVIIa-L	ENSG00000112695	Cytochrome c oxidase subunit 7A2	6	75237675-75250323	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.43e-5 (favourable)	Expressed in all	Expressed in all			testis: 641.4	Expressed in all		
TMEM30A	C6orf67, CDC50A, FLJ10856	ENSG00000112697	Transmembrane protein 30A	6	75252924-75284968	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014561	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 167.6	Expressed in all		
GMDS	GMD, SDR3E1	ENSG00000112699	GDP-mannose 4,6-dehydratase	6	1623806-2245692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031528	Enhanced				Endometrial cancer:5.89e-4 (favourable), Renal cancer:5.93e-4 (favourable)	Expressed in all	Mixed			duodenum: 106.3	Expressed in all		
SENP6	KIAA0797, SUSP1	ENSG00000112701	SUMO1/sentrin specific peptidase 6	6	75601509-75718278	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024376	Approved		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:2.83e-5 (unfavourable), Renal cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.2	Expressed in all		
IMPG1	GP147, IPM150, SPACR	ENSG00000112706	Interphotoreceptor matrix proteoglycan 1	6	75921115-76072678	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027142, HPA030332, HPA030333	Enhanced					Not detected	Tissue enhanced		cerebral cortex: 1.5;skin: 1.6	duodenum,small intestine: 0.9	Cell line enhanced		HaCaT: 1.0
VEGFA	VEGF, VEGF-A, VPF	ENSG00000112715	Vascular endothelial growth factor A	6	43770184-43786487	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005429, CAB039240, HPA069116, CAB069907	Supported				Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 452.5	Expressed in all		
PRPF4B	KIAA0536, PR4H, Prp4	ENSG00000112739	Pre-mRNA processing factor 4B	6	4021267-4064983	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020638	Approved		Supported	Nuclear speckles	Urothelial cancer:6.82e-5 (favourable), Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.7	Expressed in all		
TTK	CT96, MPH1, MPS1, MPS1L1	ENSG00000112742	TTK protein kinase	6	80003887-80042527	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010166, CAB013229	Enhanced		Approved	Nucleoli<br>Cytosol	Liver cancer:3.84e-10 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Pancreatic cancer:2.54e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 60.8	bone marrow: 15.5	Mixed		
SLC29A1	ENT1	ENSG00000112759	Solute carrier family 29 member 1 (Augustine blood group)	6	44219505-44234151	Predicted membrane proteins, Transporters	Evidence at protein level	HPA012384	Approved				Renal cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 124.4	Expressed in all		
WISP3	CCN6	ENSG00000112761	WNT1 inducible signaling pathway protein 3	6	112054072-112070969	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062438, HPA078340			Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		epididymis: 3.0;skin: 2.0	fallopian tube: 1.8	Cell line enhanced		RT4: 4.6;THP-1: 1.2;U-2197: 1.2
BTN2A1	BT2.1, BTF1, BTN2.1	ENSG00000112763	Butyrophilin subfamily 2 member A1	6	26457904-26476621	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019208	Approved		Approved	Plasma membrane	Urothelial cancer:4.52e-5 (favourable), Renal cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.3	Expressed in all		
LAMA4	LAMA3	ENSG00000112769	Laminin subunit alpha 4	6	112108760-112254939	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA015693, CAB078156	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.00e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 146.3	Cell line enhanced		ASC diff: 216.1;ASC TERT1: 333.0;HSkMC: 271.2;HUVEC TERT2: 340.0;TIME: 306.5
FAM46A	C6orf37, FLJ20037	ENSG00000112773	Family with sequence similarity 46 member A	6	81491439-81752774	Predicted intracellular proteins	Evidence at protein level	HPA051067, HPA067140	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.07e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 143.7	gallbladder: 51.5	Cell line enhanced		HL-60: 75.4;THP-1: 108.4
CLIC5	DFNB102	ENSG00000112782	Chloride intracellular channel 5	6	45898451-46080395	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA074371			Supported	Nuclear speckles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		lung: 116.1;skeletal muscle: 119.2	heart muscle: 76.0	Group enriched	7	CAPAN-2: 13.3;EFO-21: 10.0;HDLM-2: 5.7;REH: 13.6;U-266/70: 10.5
FBRSL1	KIAA1545	ENSG00000112787	Fibrosin like 1	12	132489551-132585188	Predicted intracellular proteins	Evidence at protein level	HPA049880	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.17e-4 (favourable), Urothelial cancer:7.21e-4 (favourable), Prostate cancer:9.82e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.9	Expressed in all		
ENPP5		ENSG00000112796	Ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative)	6	46159187-46170971	Predicted membrane proteins	Evidence at protein level	HPA016902	Enhanced				Renal cancer:4.44e-13 (favourable), Pancreatic cancer:4.04e-4 (favourable), Lung cancer:4.57e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 296.6	thyroid gland: 85.6	Cell line enhanced		CAPAN-2: 9.8;SCLC-21H: 5.6;T-47d: 8.1;U-266/84: 5.5
LY86	dJ80N2.1, MD-1	ENSG00000112799	Lymphocyte antigen 86	6	6588108-6654983	Predicted secreted proteins	Evidence at protein level	CAB025000, HPA044895	Approved				Testis cancer:5.61e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 82.3	spleen: 66.3	Cell line enhanced		Daudi: 51.2;RPMI-8226: 162.0;THP-1: 62.7;U-937: 34.1
PRSS16	TSSP	ENSG00000112812	Protease, serine 16	6	27247701-27256624	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA017743	Uncertain				Ovarian cancer:6.46e-5 (favourable)	Mixed	Tissue enhanced		thyroid gland: 22.0	epididymis: 16.5	Cell line enhanced		hTCEpi: 14.7;RPMI-8226: 7.9
MEP1A	PPHA	ENSG00000112818	Meprin A subunit alpha	6	46793390-46839782	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025163, HPA029416	Enhanced					Tissue enriched	Group enriched	42	colon: 117.8;duodenum: 282.2;rectum: 114.3;small intestine: 538.5	appendix: 6.2	Cell line enhanced		BEWO: 1.2;CACO-2: 2.4;RPMI-8226: 1.0
TBX18		ENSG00000112837	T-box 18	6	84687351-84764519	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			adipose tissue: 6.1	Cell line enhanced		A549: 52.2
ERBIN	ERBB2IP, LAP2	ENSG00000112851	Erbb2 interacting protein	5	65926475-66082549	Predicted intracellular proteins	Evidence at protein level	HPA048606, HPA059863	Approved		Supported	Nuclear speckles<br>Plasma membrane		Expressed in all	Expressed in all			testis: 50.1	Expressed in all		
PCDHB2	PCDH-BETA2	ENSG00000112852	Protocadherin beta 2	5	141094578-141098703	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007548	Enhanced		Approved	Nucleoplasm	Urothelial cancer:4.84e-4 (unfavourable), Renal cancer:6.99e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 7.7	testis: 7.5	Cell line enhanced		AF22: 23.3;AN3-CA: 47.2;EFO-21: 26.8
HARS2	HARSL, HARSR, HO3	ENSG00000112855	Histidyl-tRNA synthetase 2, mitochondrial	5	140691426-140699291	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035941	Approved		Approved	Cytosol	Liver cancer:2.92e-4 (unfavourable), Colorectal cancer:6.19e-4 (favourable), Breast cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.5	Expressed in all		
NUDT12	DKFZP761I172	ENSG00000112874	Nudix hydrolase 12	5	103548855-103562793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045449	Supported				Renal cancer:2.86e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 45.1	Mixed		
CEP72	FLJ10565, KIAA1519	ENSG00000112877	Centrosomal protein 72	5	612272-667168	Predicted intracellular proteins	Evidence at protein level	HPA058235, HPA074879	Approved		Supported	Centrosome	Endometrial cancer:2.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 10.4	ovary: 3.3	Cell line enhanced		HDLM-2: 41.0
MAN2A1	GOLIM7, MANA2	ENSG00000112893	Mannosidase alpha class 2A member 1	5	109689366-109869625	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB022377, HPA026896	Enhanced		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 40.5	Expressed in all		
SEMA5A	SEMAF, semF	ENSG00000112902	Semaphorin 5A	5	9035026-9546075	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004632	Approved				Renal cancer:3.66e-8 (favourable), Head and neck cancer:2.45e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 19.3	Cell line enhanced		BJ hTERT+: 52.1;fHDF/TERT166: 29.1;RT4: 54.3
C7		ENSG00000112936	Complement C7	5	40909252-40982939	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001465	Approved				Liver cancer:5.89e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 1115.3	placenta: 718.4	Group enriched	11	ASC diff: 115.0;HHSteC: 185.4;HSkMC: 221.4;SH-SY5Y: 223.2
PAPD7	LAK-1, POLK, POLS, TRF4, TRF4-1	ENSG00000112941	Poly(A) RNA polymerase D7, non-canonical	5	6713007-6757048	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045487, HPA046742	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Golgi apparatus	Renal cancer:7.99e-5 (unfavourable), Urothelial cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.1	Expressed in all		
GHR	GHBP	ENSG00000112964	Growth hormone receptor	5	42423777-42721878	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045339, HPA057705	Enhanced		Supported	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Liver cancer:2.73e-6 (favourable)	Mixed	Group enriched	6	adipose tissue: 91.4;liver: 110.5	prostate: 18.0	Group enriched	7	HSkMC: 15.4;T-47d: 52.5
HMGCS1	HMGCS	ENSG00000112972	3-hydroxy-3-methylglutaryl-CoA synthase 1	5	43289395-43313512	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032907, HPA036913, HPA036914	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:3.87e-6 (favourable)	Expressed in all	Expressed in all			liver: 208.7	Expressed in all		
DAP		ENSG00000112977	Death associated protein	5	10679230-10761272	Predicted intracellular proteins	Evidence at protein level	HPA029456	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Mitochondria	Liver cancer:2.15e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 156.6	Expressed in all		
NME5	nm23-H5, RSPH23	ENSG00000112981	NME/NM23 family member 5	5	138115172-138139443	Predicted intracellular proteins	Evidence at protein level	HPA035648, HPA044555	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:7.24e-5 (favourable), Renal cancer:1.76e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 59.4;testis: 95.0	epididymis: 28.2	Cell line enhanced		RPTEC TERT1: 22.4;SCLC-21H: 8.0;U-87 MG: 5.4
BRD8	p120, SMAP	ENSG00000112983	Bromodomain containing 8	5	138139766-138178986	Predicted intracellular proteins	Evidence at protein level	HPA001841	Supported		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:1.09e-6 (unfavourable), Renal cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 148.4	Expressed in all		
KIF20A	RAB6KIFL	ENSG00000112984	Kinesin family member 20A	5	138178719-138187715	Predicted intracellular proteins	Evidence at protein level	HPA036909, HPA036910	Approved		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cleavage furrow	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.14e-12 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable), Lung cancer:6.79e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 20.2	tonsil: 11.5	Mixed		
NNT		ENSG00000112992	Nicotinamide nucleotide transhydrogenase	5	43602692-43707405	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004829, CAB004975	Enhanced		Enhanced	Mitochondria	Renal cancer:1.22e-15 (favourable)	Expressed in all	Expressed in all			heart muscle: 130.6	Expressed in all		
MRPS30	PAP, PDCD9	ENSG00000112996	Mitochondrial ribosomal protein S30	5	44808925-44820428	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018686, HPA021149	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.87e-9 (favourable), Liver cancer:5.91e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.5	Expressed in all		
HSPA9	GRP75, HSPA9B, mot-2, mthsp75, PBP74	ENSG00000113013	Heat shock protein family A (Hsp70) member 9	5	138554882-138575444	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000898, CAB005219	Enhanced		Enhanced	Mitochondria	Breast cancer:2.93e-4 (unfavourable), Colorectal cancer:4.53e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 263.5	Expressed in all		
MRPS27	KIAA0264	ENSG00000113048	Mitochondrial ribosomal protein S27	5	72219409-72320646	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA071751	Approved					Expressed in all	Expressed in all			thyroid gland: 59.5	Expressed in all		
PFDN1	PFD1	ENSG00000113068	Prefoldin subunit 1	5	140245039-140303121	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006499	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:8.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 106.3	Expressed in all		
HBEGF	DTR, DTS, HEGFL	ENSG00000113070	Heparin binding EGF like growth factor	5	140332843-140346631	Predicted membrane proteins	Evidence at protein level	HPA053243	Uncertain				Head and neck cancer:2.41e-4 (unfavourable), Prostate cancer:6.00e-4 (favourable), Pancreatic cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 89.0	Cell line enhanced		U-698: 63.3
SLC4A9	AE4	ENSG00000113073	Solute carrier family 4 member 9	5	140360202-140375143	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA051307	Uncertain					Tissue enriched	Tissue enriched	19	kidney: 12.2	seminal vesicle,testis: 0.6	Not detected		
LOX		ENSG00000113083	Lysyl oxidase	5	122063195-122078360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043930			Supported	Endoplasmic reticulum	Renal cancer:3.93e-8 (unfavourable), Urothelial cancer:3.32e-4 (unfavourable), Liver cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 29.6	Cell line enhanced		BJ: 799.4;fHDF/TERT166: 1126.5;U-138 MG: 458.1
GZMK	PRSS, TRYP2	ENSG00000113088	Granzyme K	5	55024253-55034570	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA063181	Enhanced				Renal cancer:1.06e-4 (unfavourable), Breast cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 103.9	spleen: 41.9	Not detected		
CDH9		ENSG00000113100	Cadherin 9	5	26880600-27121150	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007167	Approved					Not detected	Tissue enhanced		cerebral cortex: 11.4;kidney: 6.5	testis: 4.3	Cell line enhanced		K-562: 6.6;NTERA-2: 10.2
APBB3	FE65L2	ENSG00000113108	Amyloid beta precursor protein binding family B member 3	5	140558268-140564781	Predicted intracellular proteins	Evidence at protein level	HPA005571	Uncertain		Supported	Actin filaments<br>Cytosol	Renal cancer:2.06e-6 (unfavourable), Pancreatic cancer:6.79e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 11.5	testis: 6.6	Cell line enhanced		SCLC-21H: 7.1
TMCO6	FLJ39769, PRO1580	ENSG00000113119	Transmembrane and coiled-coil domains 6	5	140639427-140645408	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037473, HPA037474	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:6.37e-4 (unfavourable)	Expressed in all	Mixed			testis: 13.6	Mixed		
SPARC	ON	ENSG00000113140	Secreted protein acidic and cysteine rich	5	151661096-151687165	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002306, HPA002989, HPA003020	Supported				Renal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 3240.9	Cell line enhanced		ASC diff: 3432.3;BJ: 3597.1;fHDF/TERT166: 5254.9;WM-115: 4850.9
IK	RED, RER	ENSG00000113141	IK cytokine, down-regulator of HLA II	5	140647058-140662479	Predicted intracellular proteins	Evidence at protein level	HPA048798	Supported		Enhanced	Nuclear speckles	Liver cancer:2.32e-7 (unfavourable), Cervical cancer:1.29e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 230.6	Expressed in all		
HMGCR		ENSG00000113161	3-hydroxy-3-methylglutaryl-CoA reductase	5	75336329-75362104	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008338, CAB016797	Approved				Renal cancer:9.42e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 87.5	Expressed in all		
COL4A3BP	CERT, GPBP, STARD11	ENSG00000113163	Collagen type IV alpha 3 binding protein	5	75368486-75512138	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035645, HPA042608	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.24e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 70.6	Expressed in all		
FAF2	ETEA, KIAA0887, UBXD8, UBXN3B	ENSG00000113194	Fas associated factor family member 2	5	176447628-176510074	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065968, HPA071246, HPA073828	Approved		Enhanced	Endoplasmic reticulum<br>Lipid droplets	Lung cancer:1.38e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Expressed in all		
HAND1	bHLHa27, eHand, Hxt, Thing1	ENSG00000113196	Heart and neural crest derivatives expressed 1	5	154474972-154478264	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA040925	Approved		Uncertain	Nucleus<br>Nuclear membrane		Group enriched	Tissue enhanced		smooth muscle: 16.8	adrenal gland: 6.2	Cell line enriched	8	SH-SY5Y: 123.7
PCDHB3	PCDH-BETA3	ENSG00000113205	Protocadherin beta 3	5	141100473-141103827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050296	Uncertain		Supported	Vesicles		Mixed	Tissue enhanced		testis: 6.9	endometrium,prostate: 2.4	Cell line enhanced		EFO-21: 10.7;SH-SY5Y: 16.1;U-138 MG: 5.2
PCDHB5	DKFZp586B0217, PCDH-BETA5	ENSG00000113209	Protocadherin beta 5	5	141135218-141138625	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013191	Approved					Mixed	Mixed			ovary: 7.3	Cell line enhanced		AF22: 18.5;NTERA-2: 17.7;SCLC-21H: 19.4;T-47d: 16.6;U-138 MG: 32.0;U-2 OS: 15.2
PCDHB6	PCDH-BETA6	ENSG00000113211	Protocadherin beta 6	5	141150022-141153287	Predicted membrane proteins	Evidence at transcript level	HPA029566	Uncertain		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:5.52e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 7.1	testis: 3.5	Cell line enhanced		EFO-21: 15.4;SH-SY5Y: 7.4;T-47d: 5.0;U-2197: 7.0;WM-115: 10.2
PCDHB7	PCDH-BETA7	ENSG00000113212	Protocadherin beta 7	5	141172619-141176383	Plasma proteins, Predicted membrane proteins	Evidence at transcript level	HPA059271	Approved					Tissue enhanced	Tissue enhanced		endometrium: 6.6	smooth muscle: 4.5	Cell line enhanced		EFO-21: 4.4;U-138 MG: 3.1;U-2197: 8.8;U-87 MG: 3.2;WM-115: 3.2
PDE8B		ENSG00000113231	Phosphodiesterase 8B	5	77210449-77429807	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036911, HPA036912	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	6	thyroid gland: 293.7	cerebral cortex: 53.0	Cell line enhanced		BJ hTERT+: 14.6;HeLa: 32.2;SK-BR-3: 10.4
CLK4		ENSG00000113240	CDC like kinase 4	5	178602664-178630615	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043746	Approved		Approved	Actin filaments		Expressed in all	Expressed in all			testis: 22.5	Expressed in all		
PCDHB15	PCDH-BETA15	ENSG00000113248	Protocadherin beta 15	5	141245349-141249365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007172, CAB026471, HPA074676	Uncertain		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 12.7	Cell line enhanced		AF22: 5.7;LHCN-M2: 4.0;WM-115: 4.7
HAVCR1	CD365, HAVCR, HAVCR-1, KIM1, TIM-1, TIM1, TIMD1	ENSG00000113249	Hepatitis A virus cellular receptor 1	5	157029413-157059119	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007173, CAB075697	Approved		Approved	Vesicles	Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable)	Tissue enriched	Group enriched	6	colon: 4.8;kidney: 8.3;rectum: 4.1;testis: 1.7	gallbladder: 0.8	Group enriched	5	A549: 86.4;CACO-2: 95.7;RPTEC TERT1: 33.8
GRM6	CSNB1B, GPRC1F, mGlu6, MGLUR6	ENSG00000113262	Glutamate metabotropic receptor 6	5	178978327-178996206	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014511	Supported					Not detected	Not detected			testis: 0.7	Not detected		
ITK	EMT, LYK, PSCTK2	ENSG00000113263	IL2 inducible T-cell kinase	5	157142933-157255191	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 20.2;lymph node: 33.2;tonsil: 22.3	spleen: 14.0	Cell line enhanced		HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
RNF130	G1RZFP, GOLIATH, GP	ENSG00000113269	Ring finger protein 130	5	179911651-180072118	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014499	Approved				Cervical cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 74.8	Mixed		
THG1L	FLJ11601, FLJ20546, hTHG1, ICF45, IHG-1	ENSG00000113272	TRNA-histidine guanylyltransferase 1 like	5	157731197-157741448	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035877, HPA035878	Approved				Renal cancer:3.93e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 10.3	Expressed in all		
ARSB		ENSG00000113273	Arylsulfatase B	5	78777209-78986087	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA037770, HPA037771	Enhanced		Approved	Golgi apparatus	Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 18.2	Expressed in all		
CLINT1	CLINT, ENTH, EPNR, KIAA0171	ENSG00000113282	Clathrin interactor 1	5	157785743-157859175	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043280, HPA056947	Supported		Supported	Nucleoplasm<br>Vesicles	Renal cancer:8.88e-5 (favourable), Colorectal cancer:2.95e-4 (favourable), Thyroid cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 171.0	Expressed in all		
THBS4		ENSG00000113296	Thrombospondin 4	5	79991311-80083287	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004597, HPA042426	Approved		Approved	Vesicles	Urothelial cancer:3.33e-4 (unfavourable)	Expressed in all	Group enriched	6	adipose tissue: 234.3;heart muscle: 113.6;smooth muscle: 388.9	thyroid gland: 44.6	Cell line enhanced		AF22: 3.1;SCLC-21H: 2.9;THP-1: 4.7;U-2 OS: 3.0
CNOT6	CCR4, Ccr4a, KIAA1194	ENSG00000113300	CCR4-NOT transcription complex subunit 6	5	180494412-180578405	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044568	Approved		Approved	Cytosol	Liver cancer:3.61e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 25.1	Expressed in all		
IL12B	CLMF, CLMF2, IL-12B, NKSF, NKSF2	ENSG00000113302	Interleukin 12B	5	159314783-159330887	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040970	Approved					Tissue enriched	Not detected			spleen: 0.6	Cell line enhanced		SCLC-21H: 1.0
BTNL8	BTN9.2, FLJ21458	ENSG00000113303	Butyrophilin like 8	5	180899077-180950906	Predicted membrane proteins	Evidence at protein level	HPA039738	Approved					Group enriched	Group enriched	6	colon: 26.1;duodenum: 117.4;rectum: 27.7;small intestine: 94.2	gallbladder: 10.4	Cell line enriched	26	CACO-2: 31.4
TTC1	TPR1	ENSG00000113312	Tetratricopeptide repeat domain 1	5	160009113-160065543	Predicted intracellular proteins	Evidence at protein level	HPA036557, HPA057502	Approved		Enhanced	Cytosol	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 80.4	Expressed in all		
MSH3	DUP, MRP1	ENSG00000113318	MutS homolog 3	5	80654648-80876460	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA036081			Approved	Nuclear bodies	Colorectal cancer:5.90e-5 (favourable), Renal cancer:1.77e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.6	Expressed in all		
RASGRF2	GRF2, Ras-GRF2	ENSG00000113319	Ras protein specific guanine nucleotide releasing factor 2	5	80960672-81230156	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA018679	Uncertain		Supported	Endoplasmic reticulum		Mixed	Tissue enhanced		cerebral cortex: 25.5	ovary: 22.8	Cell line enhanced		BEWO: 37.2;CACO-2: 19.9;Hep G2: 21.9;HHSteC: 17.6
GABRG2		ENSG00000113327	Gamma-aminobutyric acid type A receptor gamma2 subunit	5	162000057-162162977	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079060		Supported				Tissue enhanced	Tissue enriched	12	cerebral cortex: 66.5	adrenal gland: 5.3	Cell line enhanced		CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6
CCNG1	CCNG	ENSG00000113328	Cyclin G1	5	163437569-163446151	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000350	Supported		Supported	Nucleoplasm	Colorectal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 137.7	Mixed		
POLR3G	RPC32, RPC7	ENSG00000113356	RNA polymerase III subunit G	5	90471748-90514553	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	CAB010109, HPA052658	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 10.7	Expressed in all		
DROSHA	Etohi2, HSA242976, RN3, RNASE3L, RNASEN	ENSG00000113360	Drosha ribonuclease III	5	31400497-31532196	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.5	Expressed in all		
CDH6		ENSG00000113361	Cadherin 6	5	31193750-31329146	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007047, HPA007456, CAB025274	Enhanced					Group enriched	Tissue enhanced		kidney: 16.0	gallbladder: 14.7	Cell line enriched	7	EFO-21: 458.4
LMNB1		ENSG00000113368	Lamin B1	5	126776623-126837020	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005269, HPA050524, HPA053579	Supported		Enhanced	Nuclear membrane	Renal cancer:3.33e-16 (unfavourable), Liver cancer:3.08e-6 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 41.4	appendix: 36.2	Mixed		
ARRDC3	KIAA1376, TLIMP	ENSG00000113369	Arrestin domain containing 3	5	91368724-91383359	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.25e-8 (unfavourable), Stomach cancer:2.26e-4 (unfavourable), Ovarian cancer:3.30e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 143.0	Expressed in all		
GOLPH3	GOPP1, GPP34, MIDAS, Vps74	ENSG00000113384	Golgi phosphoprotein 3	5	32124704-32174350	Predicted intracellular proteins	Evidence at protein level	HPA044564, HPA055841	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			gallbladder: 120.5	Expressed in all		
SUB1	p14, p15, PC4	ENSG00000113387	SUB1 homolog, transcriptional regulator	5	32531633-32604079	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001311, CAB015351	Supported		Supported	Nucleus<br>Nucleoli	Liver cancer:5.25e-6 (unfavourable), Melanoma:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 234.5	Expressed in all		
NPR3	ANPRC, C5orf23, FLJ14054, GUCY2B, NPRC	ENSG00000113389	Natriuretic peptide receptor 3	5	32689070-32791724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052702	Supported		Approved	Cytosol	Renal cancer:5.43e-6 (favourable)	Tissue enhanced	Tissue enriched	5	kidney: 114.1	adipose tissue: 21.9	Cell line enhanced		ASC TERT1: 24.8;HeLa: 53.7;HSkMC: 36.4;U-138 MG: 21.1
FAM172A	C5orf21, DKFZP564D172	ENSG00000113391	Family with sequence similarity 172 member A	5	93618069-94111699	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012299, HPA045505	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.0	Expressed in all		
SLC27A6	ACSVL2, FACVL2, FATP6, VLCS-H1	ENSG00000113396	Solute carrier family 27 member 6	5	128538013-129033642	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008987	Approved		Approved	Nuclear bodies		Tissue enriched	Tissue enhanced		adrenal gland: 32.6;fallopian tube: 34.0	testis: 24.3	Cell line enriched	9	BEWO: 42.4
TARS		ENSG00000113407	Threonyl-tRNA synthetase	5	33440696-33469539	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037425	Approved		Supported	Actin filaments<br>Cytosol	Liver cancer:9.88e-7 (unfavourable), Breast cancer:6.14e-5 (unfavourable), Endometrial cancer:5.17e-4 (unfavourable), Renal cancer:9.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 44.3	Expressed in all		
IRX4		ENSG00000113430	Iroquois homeobox 4	5	1877413-1887236	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064094			Uncertain	Nucleus<br>Vesicles		Mixed	Tissue enhanced		prostate: 5.8;skin: 6.9	esophagus: 1.4	Cell line enhanced		BEWO: 43.3;HaCaT: 15.1;HBEC3-KT: 6.7
LNPEP	CAP, IRAP, P-LAP, PLAP	ENSG00000113441	Leucyl and cystinyl aminopeptidase	5	96935394-97037515	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043642	Approved					Expressed in all	Mixed			parathyroid gland: 23.3	Expressed in all		
PDE4D	DPDE3	ENSG00000113448	Phosphodiesterase 4D	5	58969038-60522120	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045895	Approved		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol	Renal cancer:4.00e-5 (favourable)	Mixed	Mixed			bone marrow: 47.7	Cell line enhanced		A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
RAD1	HRAD1, REC1	ENSG00000113456	RAD1 checkpoint DNA exonuclease	5	34905264-34918989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006692	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.06e-5 (unfavourable), Breast cancer:6.30e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.9	Expressed in all		
BRIX1	BRIX, BXDC2, FLJ11100	ENSG00000113460	BRX1, biogenesis of ribosomes	5	34915376-34925996	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039614	Approved		Enhanced	Nucleoli	Renal cancer:3.07e-9 (unfavourable), Liver cancer:4.11e-8 (unfavourable), Endometrial cancer:1.10e-5 (unfavourable), Breast cancer:2.18e-4 (unfavourable), Ovarian cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			placenta: 27.6	Expressed in all		
AGXT2	AGT2	ENSG00000113492	Alanine--glyoxylate aminotransferase 2	5	34998101-35048135	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037382	Enhanced				Renal cancer:7.47e-4 (favourable)	Group enriched	Group enriched	33	kidney: 197.9;liver: 59.3	small intestine: 3.9	Not detected		
PRLR		ENSG00000113494	Prolactin receptor	5	35048756-35230589	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 70.9	kidney: 33.1	Cell line enriched	22	T-47d: 356.8
SLC12A7	DKFZP434F076, KCC4	ENSG00000113504	Solute carrier family 12 member 7	5	1050376-1112035	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041652	Approved		Uncertain	Cytosol	Liver cancer:2.12e-6 (unfavourable), Urothelial cancer:3.16e-5 (favourable)	Expressed in all	Mixed			duodenum: 24.3	Cell line enhanced		REH: 40.1
IL4	BCGF-1, BCGF1, BSF1, IL-4, MGC79402	ENSG00000113520	Interleukin 4	5	132673986-132682676	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA072995	Approved					Not detected	Tissue enhanced		parathyroid gland: 1.6	skin: 0.6	Group enriched	6	HMC-1: 3.4;MOLT-4: 17.0
RAD50	hRad50, RAD50-2	ENSG00000113522	RAD50 double strand break repair protein	5	132556019-132646344	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022103, CAB024979, HPA052291	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.95e-4 (favourable), Cervical cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.6	Expressed in all		
IL5	EDF, IL-5, TRF	ENSG00000113525	Interleukin 5	5	132541444-132556838	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010304	Approved					Not detected	Tissue enriched	9	testis: 9.6	small intestine: 1.0	Cell line enhanced		Hep G2: 1.9;TIME: 1.0
ST8SIA4	PST, PST1, SIAT8D	ENSG00000113532	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4	5	100806935-100903266	Predicted secreted proteins	Evidence at protein level	HPA051126, HPA053995	Approved		Approved	Golgi apparatus	Renal cancer:7.80e-7 (unfavourable)	Expressed in all	Mixed			appendix: 19.3	Cell line enhanced		AF22: 40.7;HDLM-2: 64.4;Karpas-707: 41.2;RPMI-8226: 30.6
GNPDA1	GNPDA, GNPI, GPI, HLN, KIAA0060	ENSG00000113552	Glucosamine-6-phosphate deaminase 1	5	141991749-142013041	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000499, HPA046891	Uncertain		Approved	Golgi apparatus<br>Vesicles	Liver cancer:2.60e-6 (unfavourable)	Expressed in all	Expressed in all			kidney: 77.6	Mixed		
PCDH12	VE-cadherin-2	ENSG00000113555	Protocadherin 12	5	141943585-141969741	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051242	Uncertain				Renal cancer:2.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 38.5	spleen: 22.5	Cell line enhanced		HUVEC TERT2: 19.4;Karpas-707: 41.2;U-937: 7.5
SKP1	EMC19, MGC34403, OCP-II, OCP2, p19A, SKP1A, TCEB1L	ENSG00000113558	S-phase kinase associated protein 1	5	134148935-134177038	Predicted intracellular proteins	Evidence at protein level	CAB012982, HPA053745, HPA058134	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:5.20e-4 (favourable), Liver cancer:5.72e-4 (unfavourable), Breast cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 934.2	Expressed in all		
NUP155	KIAA0791, N155	ENSG00000113569	Nucleoporin 155	5	37288137-37371181	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA037775	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.35e-6 (unfavourable)	Expressed in all	Tissue enriched	9	testis: 126.8	parathyroid gland: 14.4	Expressed in all		
PPP2CA	PP2AC, PP2Calpha	ENSG00000113575	Protein phosphatase 2 catalytic subunit alpha	5	134194334-134226142	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003848, HPA043236	Approved				Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.6	Expressed in all		
FGF1	AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1	ENSG00000113578	Fibroblast growth factor 1	5	142592178-142698070	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003265, CAB017519	Enhanced				Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 129.9;kidney: 59.4	heart muscle: 32.8	Cell line enhanced		BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
NR3C1	GR, GRL	ENSG00000113580	Nuclear receptor subfamily 3 group C member 1	5	143277931-143435512	Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004248, CAB010435	Supported		Enhanced	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 67.0	Mixed		
C5orf15	HTGN29, KCT2	ENSG00000113583	Chromosome 5 open reading frame 15	5	133955502-133968787	Predicted membrane proteins	Evidence at protein level	HPA011951, HPA039165	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 81.7	Expressed in all		
PPWD1	KIAA0073	ENSG00000113593	Peptidylprolyl isomerase domain and WD repeat containing 1	5	65563236-65587549	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019353, HPA019360	Enhanced		Supported	Nuclear bodies	Liver cancer:2.19e-4 (unfavourable), Renal cancer:6.72e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.6	Expressed in all		
LIFR	CD118	ENSG00000113594	Leukemia inhibitory factor receptor alpha	5	38474963-38608354	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004478, CAB010252	Approved		Approved	Nuclear speckles<br>Golgi apparatus	Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable)	Mixed	Mixed			thyroid gland: 68.0	Cell line enhanced		AF22: 93.6;SCLC-21H: 72.8
TRIM23	ARD1, ARFD1, RNF46	ENSG00000113595	Tripartite motif containing 23	5	65589680-65625975	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039605	Approved					Expressed in all	Expressed in all			cerebral cortex: 46.9	Expressed in all		
TRAPPC13	C5orf44, FLJ13611, FLJ26957, MGC48585	ENSG00000113597	Trafficking protein particle complex 13	5	65624716-65666233	Predicted intracellular proteins	Evidence at protein level	HPA037777	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.8	Expressed in all		
C9		ENSG00000113600	Complement C9	5	39284262-39424868	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002151, HPA029577	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	120	liver: 728.9	epididymis: 6.0	Cell line enhanced		U-698: 1.4
SEC24A		ENSG00000113615	SEC24 homolog A, COPII coat complex component	5	134648789-134727823	Predicted intracellular proteins	Evidence at protein level	HPA038901, HPA056825	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.8	Expressed in all		
TXNDC15	2310047H23Rik, C5orf14, FLJ22625	ENSG00000113621	Thioredoxin domain containing 15	5	134873803-134901525	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015483	Approved		Approved	Golgi apparatus	Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 85.3	Expressed in all		
TTC33	OSRF	ENSG00000113638	Tetratricopeptide repeat domain 33	5	40512333-40755975	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038252, HPA038253	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 25.6	Expressed in all		
RARS	DALRD1	ENSG00000113643	Arginyl-tRNA synthetase	5	168486445-168519299	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003979, HPA004130	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.10e-8 (unfavourable), Head and neck cancer:7.59e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 54.4	Expressed in all		
WWC1	KIAA0869, KIBRA, PPP1R168	ENSG00000113645	WW and C2 domain containing 1	5	168291651-168472303	Predicted intracellular proteins	Evidence at protein level	HPA038016, HPA038017	Approved		Approved	Golgi apparatus	Renal cancer:1.95e-8 (favourable)	Expressed in all	Mixed			salivary gland: 61.5	Cell line enhanced		RPTEC TERT1: 195.6
H2AFY	macroH2A1.2	ENSG00000113648	H2A histone family member Y	5	135333900-135399914	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189, HPA050962	Supported		Supported	Nucleus	Liver cancer:2.89e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 155.6	Expressed in all		
TCERG1	CA150, TAF2S, Urn1	ENSG00000113649	Transcription elongation regulator 1	5	146447311-146511961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064854, HPA069752, HPA069808	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.70e-11 (unfavourable), Liver cancer:5.34e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 20.7	Expressed in all		
DPYSL3	CRMP4, DRP-3, ULIP	ENSG00000113657	Dihydropyrimidinase like 3	5	147390811-147510056	Predicted intracellular proteins	Evidence at protein level	HPA010948	Approved		Supported	Cytosol	Renal cancer:3.87e-9 (unfavourable), Urothelial cancer:8.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 310.0	seminal vesicle: 223.4	Cell line enhanced		SH-SY5Y: 728.5
SMAD5	Dwfc, JV5-1, MADH5	ENSG00000113658	SMAD family member 5	5	136132845-136188747	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058931	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			endometrium: 43.1	Expressed in all		
CSNK1A1	CK1, CK1a, CK1alpha, CKIa, CKIalpha	ENSG00000113712	Casein kinase 1 alpha 1	5	149492197-149551552	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016680, HPA051334	Uncertain		Approved	Cytosol	Colorectal cancer:1.15e-4 (favourable), Pancreatic cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 219.6	Expressed in all		
HMGXB3	HMGX3, KIAA0194, SMF	ENSG00000113716	HMG-box containing 3	5	150000046-150053142	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005967			Approved	Nucleoli	Liver cancer:3.37e-5 (unfavourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 283.3	prostate: 27.4	Expressed in all		
ERGIC1	ERGIC-32, ERGIC32, KIAA1181, NET24	ENSG00000113719	Endoplasmic reticulum-golgi intermediate compartment 1	5	172834275-172952685	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018666, HPA018900	Enhanced		Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			prostate: 238.2	Expressed in all		
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
CDX1		ENSG00000113722	Caudal type homeobox 1	5	150166795-150184558	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055196	Enhanced					Tissue enhanced	Group enriched	9	colon: 129.9;duodenum: 64.5;rectum: 134.7;small intestine: 104.9	appendix: 12.1	Cell line enhanced		BJ hTERT+: 5.4;SH-SY5Y: 1.3
ATP6V0E1	ATP6H, ATP6V0E, M9.2	ENSG00000113732	ATPase H+ transporting V0 subunit e1	5	172983757-173035445	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Expressed in all			epididymis: 772.1	Expressed in all		
BNIP1	Nip1, SEC20	ENSG00000113734	BCL2 interacting protein 1	5	173144442-173164387	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008009, HPA008149	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 27.0	Expressed in all		
STC2	STC-2	ENSG00000113739	Stanniocalcin 2	5	173314713-173329503	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045372	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.17e-8 (unfavourable), Head and neck cancer:1.76e-6 (unfavourable), Liver cancer:3.07e-5 (unfavourable), Breast cancer:7.40e-5 (favourable), Stomach cancer:7.57e-4 (unfavourable)	Tissue enriched	Tissue enhanced		breast: 164.6	placenta: 33.2	Cell line enhanced		LHCN-M2: 707.5;T-47d: 753.9;U-138 MG: 321.3
CPEB4	KIAA1673	ENSG00000113742	Cytoplasmic polyadenylation element binding protein 4	5	173888280-173961976	Predicted intracellular proteins	Evidence at protein level	HPA038394			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:4.99e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 119.8	Cell line enhanced		U-266/70: 86.1;U-266/84: 121.7
HRH2		ENSG00000113749	Histamine receptor H2	5	175658030-175710756	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013770	Approved					Tissue enhanced	Tissue enhanced		bone marrow: 23.5	appendix: 16.7	Cell line enhanced		RPMI-8226: 45.4;SK-MEL-30: 15.0;THP-1: 12.1;U-937: 16.9
DBN1	D0S117E	ENSG00000113758	Drebrin 1	5	177456608-177474401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051452, HPA056940	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:8.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 82.9	Mixed		
ZNF346	JAZ, Zfp346	ENSG00000113761	Zinc finger protein 346	5	177022696-177081189	Predicted intracellular proteins	Evidence at protein level	HPA018485	Approved		Enhanced	Nucleus	Liver cancer:1.88e-7 (unfavourable), Endometrial cancer:9.54e-5 (unfavourable), Pancreatic cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.0	Expressed in all		
UNC5A	KIAA1976, UNC5H1	ENSG00000113763	Unc-5 netrin receptor A	5	176810477-176880895	Predicted membrane proteins	Evidence at protein level	HPA071450			Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.23e-4 (unfavourable)	Tissue enhanced	Group enriched	22	adrenal gland: 10.3;cerebral cortex: 35.4	lymph node: 1.0	Cell line enriched	14	SCLC-21H: 104.8
EHHADH	ECHD	ENSG00000113790	Enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase	3	185190624-185281990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036401, HPA042021	Enhanced				Renal cancer:1.28e-5 (favourable)	Group enriched	Group enriched	7	kidney: 148.6;liver: 173.1	duodenum: 21.4	Mixed		
CNTN3	BIG-1, PANG	ENSG00000113805	Contactin 3	3	74262568-74521140	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003341	Approved					Mixed	Tissue enhanced		cerebral cortex: 12.4	fallopian tube: 12.0	Cell line enhanced		BJ: 6.0;fHDF/TERT166: 15.2
SMC4	CAP-C, hCAP-C, SMC4L1	ENSG00000113810	Structural maintenance of chromosomes 4	3	160399274-160434962	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029449, CAB055509	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:8.05e-7 (unfavourable), Pancreatic cancer:4.20e-5 (unfavourable), Liver cancer:2.94e-4 (unfavourable), Endometrial cancer:7.63e-4 (unfavourable), Prostate cancer:9.00e-4 (unfavourable)	Expressed in all	Mixed			testis: 54.9	Expressed in all		
SELENOK	SELK	ENSG00000113811	Selenoprotein K	3	53884410-53891988	Predicted membrane proteins	Evidence at protein level	HPA008196	Uncertain		Approved	Nucleoplasm<br>Cytosol	Lung cancer:3.76e-4 (favourable), Endometrial cancer:7.18e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 75.4	Expressed in all		
ACTR8	INO80N	ENSG00000113812	ARP8 actin-related protein 8 homolog	3	53867066-53882202	Predicted intracellular proteins	Evidence at protein level	HPA065236			Supported	Nucleus<br>Centrosome	Renal cancer:7.88e-9 (favourable), Liver cancer:5.11e-6 (unfavourable), Colorectal cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
TBCCD1	FLJ10560	ENSG00000113838	TBCC domain containing 1	3	186546073-186570543	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.5	Expressed in all		
TIMMDC1	C3orf1, FLJ22597	ENSG00000113845	Translocase of inner mitochondrial membrane domain containing 1	3	119498532-119525090	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053214, HPA055846	Uncertain		Enhanced	Nucleus<br>Mitochondria	Liver cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.5	Expressed in all		
CRBN	MRT2, MRT2A	ENSG00000113851	Cereblon	3	3144628-3179727	Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045910	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 87.7	Expressed in all		
KNG1	BDK, BK, KNG	ENSG00000113889	Kininogen 1	3	186717276-186743954	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001616, HPA001645, CAB009809	Enhanced				Liver cancer:1.28e-6 (favourable)	Tissue enriched	Group enriched	994	kidney: 522.4;liver: 1864.6	rectum: 1.2	Cell line enhanced		CACO-2: 1.5;Hep G2: 1.2;RH-30: 1.3
HRG	HPRG, HRGP	ENSG00000113905	Histidine rich glycoprotein	3	186660216-186678240	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050269, HPA054598	Supported		Uncertain	Nucleoli fibrillar center	Liver cancer:9.64e-5 (favourable)	Tissue enriched	Tissue enriched	83	liver: 2689.0	kidney: 32.2	Cell line enhanced		HL-60: 2.0;RH-30: 2.8;SiHa: 1.1
BCL6	BCL5, BCL6A, LAZ3, ZBTB27, ZNF51	ENSG00000113916	B-cell CLL/lymphoma 6	3	187721377-187745727	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000307, HPA004899, HPA050645	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.27e-9 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 113.5	Cell line enhanced		Daudi: 112.8;U-698: 150.4
HGD	AKU, HGO	ENSG00000113924	Homogentisate 1,2-dioxygenase	3	120628173-120682571	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047374, HPA052359	Enhanced		Supported	Golgi apparatus	Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 175.8;liver: 324.3	gallbladder: 87.1	Group enriched	10	CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
CLDN16	HOMG3, PCLN1	ENSG00000113946	Claudin 16	3	190322541-190412143	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056020	Enhanced				Endometrial cancer:1.99e-5 (unfavourable)	Group enriched	Tissue enriched	6	kidney: 51.7	thyroid gland: 8.7	Group enriched	135	EFO-21: 435.6;RPTEC TERT1: 123.6
ARL6	BBS3, RP55	ENSG00000113966	ADP ribosylation factor like GTPase 6	3	97764521-97801242	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019361	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.53e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.5	Cell line enhanced		SCLC-21H: 28.0
NPHP3	CFAP31, FLJ30691, FLJ36696, KIAA2000, MKS7, NPH3, SLSN3	ENSG00000113971	Nephrocystin 3	3	132680609-132722442	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA009150	Uncertain				Renal cancer:8.28e-9 (unfavourable)	Mixed	Mixed			endometrium: 16.5	Mixed		
CD86	B7-2, B7.2, CD28LG2	ENSG00000114013	CD86 molecule	3	122055366-122121139	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004319	Uncertain				Renal cancer:9.83e-5 (unfavourable)	Expressed in all	Mixed			appendix: 47.8	Cell line enriched	10	HDLM-2: 275.8
AMOTL2	LCCP	ENSG00000114019	Angiomotin like 2	3	134355874-134375479	Predicted intracellular proteins	Evidence at protein level	HPA063027			Approved	Cell Junctions	Endometrial cancer:1.94e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 76.7	Cell line enhanced		BEWO: 266.7
NIT2		ENSG00000114021	Nitrilase family member 2	3	100334701-100361635	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036999	Approved		Supported	Centrosome<br>Cytosol	Endometrial cancer:4.62e-4 (unfavourable)	Expressed in all	Mixed			kidney: 19.0	Expressed in all		
FAM162A	C3orf28, E2IG5	ENSG00000114023	Family with sequence similarity 162 member A	3	122384176-122412334	Predicted membrane proteins	Evidence at protein level	HPA035856, HPA058113	Approved		Enhanced	Mitochondria<br>Cytosol	Urothelial cancer:3.93e-4 (favourable)	Expressed in all	Expressed in all			rectum: 162.9	Expressed in all		
OGG1	HMMH, HOGG1, MUTM, OGH1	ENSG00000114026	8-oxoguanine DNA glycosylase	3	9749944-9788219	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027514, CAB047301	Approved		Enhanced	Nucleoplasm	Liver cancer:5.77e-5 (unfavourable), Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 30.5	Expressed in all		
KPNA1	IPOA5, NPI-1, RCH2, SRP1	ENSG00000114030	Karyopherin subunit alpha 1	3	122421949-122514945	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053627, HPA063426	Enhanced		Enhanced	Nucleus<br>Cytosol	Endometrial cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.3	Expressed in all		
PCCB		ENSG00000114054	Propionyl-CoA carboxylase beta subunit	3	136250306-136337896	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036939, HPA036940	Enhanced				Renal cancer:6.47e-7 (favourable)	Expressed in all	Expressed in all			liver: 103.1	Expressed in all		
UBE3A	ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A	ENSG00000114062	Ubiquitin protein ligase E3A	15	25333728-25439056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009723, HPA039410, HPA040380	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
ARMC8	DKFZP434A043, GID5, HSPC056, VID28	ENSG00000114098	Armadillo repeat containing 8	3	138187248-138298389	Predicted intracellular proteins	Evidence at protein level	HPA036996, HPA044869	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:8.90e-5 (unfavourable), Endometrial cancer:2.05e-4 (unfavourable), Prostate cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 38.2	Expressed in all		
CEP70	BITE, FLJ13036	ENSG00000114107	Centrosomal protein 70	3	138494344-138594538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036941, HPA036942	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Prostate cancer:9.60e-5 (unfavourable), Cervical cancer:2.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 123.8	Expressed in all		
RBP2	CRABP-II, CRBP2, CRBPII, RBPC2	ENSG00000114113	Retinol binding protein 2	3	139452884-139480747	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035866	Enhanced		Approved	Golgi apparatus		Tissue enhanced	Group enriched	204	duodenum: 2746.0;small intestine: 2037.7	lung: 11.7	Cell line enriched	6	CACO-2: 65.5
RBP1	CRABP-I, CRBP, CRBP1, CRBPI, RBPC	ENSG00000114115	Retinol binding protein 1	3	139517434-139539829	Predicted intracellular proteins	Evidence at protein level	HPA007338, CAB018603, CAB019276	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		fallopian tube: 634.8;ovary: 1297.7	adrenal gland: 376.4	Cell line enriched	6	SH-SY5Y: 887.3
SLC25A36	FLJ10618, PNC2	ENSG00000114120	Solute carrier family 25 member 36	3	140941830-140979933	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA027036	Approved		Approved	Nucleus<br>Mitochondria<br>Cytosol	Urothelial cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Expressed in all		
GRK7	GPRK7	ENSG00000114124	G protein-coupled receptor kinase 7	3	141778148-141818490	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin,testis: 0.2	Not detected		
RNF7	CKBBP1, ROC2, SAG	ENSG00000114125	Ring finger protein 7	3	141738204-141747560	Predicted intracellular proteins	Evidence at protein level	HPA036995	Approved		Supported	Nucleoplasm	Renal cancer:1.54e-9 (unfavourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 86.2	Expressed in all		
TFDP2	Dp-2	ENSG00000114126	Transcription factor Dp-2	3	141944428-142149544	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018396	Supported		Supported	Nucleus<br>Vesicles	Cervical cancer:6.32e-4 (favourable), Renal cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 127.5	Expressed in all		
XRN1	SEP1	ENSG00000114127	5'-3' exoribonuclease 1	3	142306607-142448062	Predicted intracellular proteins	Evidence at protein level	HPA035005, HPA035006	Approved		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Cell line enriched	5	RH-30: 137.9
KAT2B	GCN5, GCN5L, P/CAF, PCAF	ENSG00000114166	Lysine acetyltransferase 2B	3	20040023-20154404	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004526, HPA055839	Supported		Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 85.2	Mixed		
BCHE	CHE1, CHE2, E1	ENSG00000114200	Butyrylcholinesterase	3	165772904-165837472	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001560	Approved				Head and neck cancer:1.06e-4 (unfavourable)	Group enriched	Tissue enhanced		liver: 265.5	endometrium: 67.7	Cell line enriched	7	Karpas-707: 542.1
SERPINI2	MEPI, PANCPIN, PI14, TSA2004	ENSG00000114204	Serpin family I member 2	3	167441789-167479004	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	47	pancreas: 288.1	fallopian tube: 6.1	Group enriched	10	THP-1: 6.0;U-937: 1.2
PDCD10	CCM3, TFAR15	ENSG00000114209	Programmed cell death 10	3	167683298-167734939	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027095	Approved				Pancreatic cancer:5.22e-5 (unfavourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:3.89e-4 (unfavourable), Renal cancer:5.88e-4 (favourable), Endometrial cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.8	Expressed in all		
LRRC31	FLJ23259	ENSG00000114248	Leucine rich repeat containing 31	3	169839179-169869930	Predicted intracellular proteins	Evidence at protein level	HPA037548	Uncertain					Mixed	Group enriched	5	colon: 18.2;duodenum: 8.8;rectum: 24.3;small intestine: 11.0;stomach: 9.8	liver: 2.8	Cell line enhanced		EFO-21: 1.8;HAP1: 1.4;RPTEC TERT1: 1.6
WNT5A	hWNT5A	ENSG00000114251	Wnt family member 5A	3	55465715-55490539	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Colorectal cancer:2.94e-5 (favourable)	Expressed in all	Tissue enhanced		endometrium: 45.3	urinary bladder: 35.4	Cell line enhanced		BJ: 189.9;BJ hTERT+: 249.3;SiHa: 371.6;U-87 MG: 239.2
PFKFB4		ENSG00000114268	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4	3	48517684-48562015	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047719, HPA066058	Uncertain		Approved	Nucleoli	Renal cancer:3.91e-8 (unfavourable), Cervical cancer:3.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 31.7	small intestine: 22.7	Cell line enhanced		U-87 MG: 80.8;WM-115: 72.6
COL7A1	EBD1, EBDCT, EBR1	ENSG00000114270	Collagen type VII alpha 1 chain	3	48564073-48595267	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016357, HPA042420	Enhanced				Pancreatic cancer:3.86e-4 (unfavourable), Head and neck cancer:6.31e-4 (favourable)	Expressed in all	Tissue enriched	6	skin: 114.5	endometrium,prostate: 20.1	Cell line enhanced		HBEC3-KT: 71.5;HDLM-2: 89.9;HeLa: 81.8;SiHa: 86.9
FGF12	FGF12B, FHF1	ENSG00000114279	Fibroblast growth factor 12	3	192139395-192767764	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA071557			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 46.7;cerebral cortex: 52.4;heart muscle: 89.9	spleen: 16.2	Cell line enhanced		AF22: 14.9;NTERA-2: 10.3;SCLC-21H: 28.2;U-251 MG: 12.2;WM-115: 17.4
PRKAR2A	PRKAR2	ENSG00000114302	Protein kinase cAMP-dependent type II regulatory subunit alpha	3	48744597-48847846	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005023, HPA038268	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Microtubule organizing center	Colorectal cancer:4.27e-5 (favourable), Liver cancer:1.97e-4 (unfavourable), Renal cancer:2.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 124.3	Mixed		
HES1	bHLHb39, FLJ20408, HES-1, Hes1, HRY	ENSG00000114315	Hes family bHLH transcription factor 1	3	194136145-194138732	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066929			Supported	Nucleus	Urothelial cancer:2.04e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 97.8	Mixed		
USP4	UNP, Unph	ENSG00000114316	Ubiquitin specific peptidase 4	3	49277831-49340712	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018499	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.29e-5 (favourable), Lung cancer:4.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 56.8	Expressed in all		
ACAP2	CENTB2, CNT-B2, KIAA0041	ENSG00000114331	ArfGAP with coiled-coil, ankyrin repeat and PH domains 2	3	195274736-195443078	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034807, HPA034808	Supported		Approved	Endosomes		Expressed in all	Expressed in all			thyroid gland: 34.2	Expressed in all		
ECT2	ARHGEF31	ENSG00000114346	Epithelial cell transforming 2	3	172750682-172821474	Predicted intracellular proteins	Evidence at protein level	HPA036363, HPA053261			Enhanced	Nucleus<br>Cytosol	Liver cancer:6.82e-6 (unfavourable), Renal cancer:1.19e-5 (unfavourable), Pancreatic cancer:2.24e-5 (unfavourable), Lung cancer:1.13e-4 (unfavourable)	Expressed in all	Mixed			testis: 29.1	Expressed in all		
GNAT1	CSNBAD3	ENSG00000114349	G protein subunit alpha transducin 1	3	50191612-50196516	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045393	Supported					Not detected	Tissue enhanced		testis: 1.4	cerebral cortex: 0.3	Not detected		
GNAI2	GIP, GNAI2B	ENSG00000114353	G protein subunit alpha i2	3	50226292-50259355	Predicted intracellular proteins	Evidence at protein level	HPA007704	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Breast cancer:1.03e-4 (favourable)	Expressed in all	Expressed in all			placenta: 330.6	Expressed in all		
TFG	FLJ36137, SPG57, TF6	ENSG00000114354	TRK-fused gene	3	100709331-100748966	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019473, HPA052206	Approved		Approved	Vesicles<br>Cytosol	Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 164.5	Expressed in all		
USP9Y	DFFRY	ENSG00000114374	Ubiquitin specific peptidase 9, Y-linked	Y	12701231-12860839	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057687			Uncertain	Vesicles		Tissue enhanced	Tissue enhanced		prostate: 9.9	seminal vesicle: 6.9	Cell line enhanced		RPTEC TERT1: 13.3
HYAL1	FUS2, HYAL-1, LUCA1, NAT6	ENSG00000114378	Hyaluronoglucosaminidase 1	3	50299889-50312381	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002112	Uncertain				Renal cancer:1.56e-11 (favourable), Colorectal cancer:2.07e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 71.1;spleen: 69.3	kidney: 43.5	Cell line enhanced		Hep G2: 66.6;SK-BR-3: 20.5
TUSC2	C3orf11, FUS1, PAP, PDAP2	ENSG00000114383	Tumor suppressor candidate 2	3	50320027-50328251	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA030116			Approved	Vesicles<br>Cytosol	Renal cancer:8.70e-7 (favourable), Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.1	Expressed in all		
NPRL2	NPR2, NPR2L, TUSC4	ENSG00000114388	NPR2-like, GATOR1 complex subunit	3	50347330-50351091	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038196, HPA038197	Approved		Supported	Cytosol	Lung cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.8	Expressed in all		
RPL24	L24	ENSG00000114391	Ribosomal protein L24	3	101681091-101686782	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051653	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.72e-5 (unfavourable), Thyroid cancer:8.25e-4 (favourable)	Expressed in all	Expressed in all			ovary: 2893.2	Expressed in all		
CYB561D2	101F6, TSP10	ENSG00000114395	Cytochrome b561 family member D2	3	50350695-50358460	Predicted membrane proteins	Evidence at protein level	HPA042817	Uncertain				Renal cancer:6.16e-5 (favourable), Pancreatic cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 28.5	Expressed in all		
C3orf14	HT021	ENSG00000114405	Chromosome 3 open reading frame 14	3	62318973-62336213	Predicted intracellular proteins	Evidence at transcript level	HPA048286	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.33e-5 (favourable)	Expressed in all	Mixed			breast: 62.2	Cell line enhanced		MCF7: 415.8
FXR1		ENSG00000114416	FMR1 autosomal homolog 1	3	180868141-180982753	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018246, HPA055475	Approved		Enhanced	Cytosol	Renal cancer:2.19e-5 (unfavourable), Liver cancer:2.70e-4 (unfavourable), Endometrial cancer:5.96e-4 (unfavourable), Pancreatic cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 276.6	Expressed in all		
CBLB	Cbl-b, RNF56	ENSG00000114423	Cbl proto-oncogene B	3	105655461-105869552	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018327, HPA019880	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.0	Cell line enhanced		U-138 MG: 63.4
BBX	HBP2, HSPC339, MDS001	ENSG00000114439	BBX, HMG-box containing	3	107522936-107811324	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006049, HPA050646	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 115.7	Expressed in all		
IFT57	ESRRBL1, FLJ10147, HIPPI, MHS4R2	ENSG00000114446	Intraflagellar transport 57	3	108160812-108222570	Predicted intracellular proteins	Evidence at protein level	HPA035514, HPA035515	Supported		Approved	Nuclear speckles<br>Mitochondria<br>Cytosol	Colorectal cancer:6.96e-5 (favourable), Ovarian cancer:7.63e-4 (favourable)	Expressed in all	Mixed			testis: 67.1	Expressed in all		
GNB4		ENSG00000114450	G protein subunit beta 4	3	179396089-179451590	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB018383, CAB018737, HPA040736	Enhanced		Enhanced	Plasma membrane	Renal cancer:1.39e-6 (unfavourable)	Expressed in all	Mixed			skin: 37.6	Mixed		
HHLA2	B7-H5, B7H7, B7y	ENSG00000114455	HERV-H LTR-associating 2	3	108296490-108378285	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055478	Enhanced					Group enriched	Group enriched	10	colon: 87.7;duodenum: 87.1;gallbladder: 46.0;rectum: 90.5;small intestine: 143.9	stomach: 9.2	Cell line enhanced		HDLM-2: 3.7;Karpas-707: 2.0
IQCG	CFAP122, DKFZp434B227, DRC9	ENSG00000114473	IQ motif containing G	3	197889075-197960142	Predicted intracellular proteins	Evidence at protein level	HPA042787, HPA051981	Enhanced		Approved	Actin filaments<br>Cytosol		Expressed in all	Group enriched	6	fallopian tube: 83.6;testis: 78.8	thyroid gland: 13.9	Expressed in all		
GBE1		ENSG00000114480	1,4-alpha-glucan branching enzyme 1	3	81489699-81762161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038073, HPA038074, HPA038075	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 79.6	Expressed in all		
MORC1	CT33, MORC, ZCW6	ENSG00000114487	MORC family CW-type zinc finger 1	3	108958239-109118142	Predicted intracellular proteins	Evidence at protein level	HPA036413	Supported					Not detected	Tissue enriched	68	testis: 29.7	epididymis: 0.4	Group enriched	7	Karpas-707: 1.8;RPMI-8226: 5.3
UMPS		ENSG00000114491	Uridine monophosphate synthetase	3	124730366-124749273	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036178, HPA036179	Uncertain		Supported	Cytosol	Prostate cancer:9.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland,spleen: 3.4	Expressed in all		
NCBP2	Cbc2, CBP20, NIP1	ENSG00000114503	Nuclear cap binding protein subunit 2	3	196935402-196942597	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044850, HPA062483	Supported		Enhanced	Nucleoplasm	Liver cancer:2.37e-7 (unfavourable), Prostate cancer:2.27e-4 (unfavourable), Pancreatic cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 79.3	Expressed in all		
SNX4	ATG24B	ENSG00000114520	Sorting nexin 4	3	125446644-125520197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005709	Uncertain				Renal cancer:5.01e-5 (favourable), Endometrial cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 75.4	Expressed in all		
C3orf52	FLJ23186, TTMP	ENSG00000114529	Chromosome 3 open reading frame 52	3	112086335-112131004	Predicted membrane proteins	Evidence at protein level	HPA008119, HPA011968	Uncertain				Pancreatic cancer:3.85e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 23.1	thyroid gland: 16.6	Cell line enhanced		U-698: 37.5
FRMD4B	GRSP1, KIAA1013	ENSG00000114541	FERM domain containing 4B	3	69169990-69542583	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009705	Uncertain	Supported			Renal cancer:5.01e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 44.4	Cell line enhanced		HUVEC TERT2: 42.3
SLC41A3	FLJ20473	ENSG00000114544	Solute carrier family 41 member 3	3	126006355-126101561	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045847	Approved		Supported	Plasma membrane	Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable)	Expressed in all	Expressed in all			testis: 77.4	Expressed in all		
ROPN1B		ENSG00000114547	Rhophilin associated tail protein 1B	3	125969144-125983454	Predicted intracellular proteins	Evidence at protein level	HPA052530	Supported					Tissue enhanced	Tissue enriched	8	testis: 372.8	breast: 44.7	Group enriched	7	SK-MEL-30: 40.5;WM-115: 18.2
PLXNA1	NOV, PLXN1	ENSG00000114554	Plexin A1	3	126988594-127037392	Predicted membrane proteins	Evidence at protein level	HPA007499, CAB012483	Uncertain		Enhanced	Nucleus<br>Cytosol	Liver cancer:4.13e-6 (unfavourable), Renal cancer:5.64e-5 (unfavourable), Ovarian cancer:1.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 43.5	skin: 16.8	Mixed		
ATP6V1A	ATP6A1, ATP6V1A1, VA68, Vma1, VPP2	ENSG00000114573	ATPase H+ transporting V1 subunit A	3	113747019-113812056	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB006910, HPA035083, HPA035084	Approved		Supported	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:3.82e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 151.4	Expressed in all		
ABTB1	BPOZ, Btb3, BTBD21, EF1ABP	ENSG00000114626	Ankyrin repeat and BTB domain containing 1	3	127672935-127680920	Predicted intracellular proteins	Evidence at protein level	HPA035022, HPA035023	Uncertain		Supported	Nucleoli<br>Cytosol	Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 50.2	Mixed		
PODXL2	endoglycan, PODLX2	ENSG00000114631	Podocalyxin like 2	3	127629181-127672809	Predicted membrane proteins	Evidence at protein level	CAB024934, HPA042265	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 77.1	testis: 35.9	Cell line enhanced		SCLC-21H: 195.4
UPK1B	TSPAN20, UPK1	ENSG00000114638	Uroplakin 1B	3	119173517-119205153	Predicted membrane proteins, Transporters	Evidence at protein level	HPA031799, HPA031800	Enhanced				Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		stomach: 33.1;urinary bladder: 36.1	tonsil: 15.4	Cell line enhanced		CACO-2: 33.3;RPTEC TERT1: 27.6;RT4: 115.3
CSPG5	NGC	ENSG00000114646	Chondroitin sulfate proteoglycan 5	3	47562239-47580792	Predicted membrane proteins	Evidence at protein level	HPA049529, HPA067818, HPA071779	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Ovarian cancer:2.14e-4 (favourable)	Tissue enriched	Tissue enriched	56	cerebral cortex: 156.7	testis: 2.8	Cell line enhanced		AF22: 32.2
KLHL18	FLJ13703, KIAA0795	ENSG00000114648	Kelch like family member 18	3	47282917-47346816	Predicted intracellular proteins	Evidence at protein level	HPA035027, HPA035028	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 14.2	Expressed in all		
SCAP	KIAA0199	ENSG00000114650	SREBF chaperone	3	47413694-47477126	Predicted membrane proteins	Evidence at protein level	HPA004713	Approved				Renal cancer:4.33e-5 (favourable), Pancreatic cancer:7.14e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 67.0	Expressed in all		
EFCC1	C3orf73, CCDC48, FLJ12057	ENSG00000114654	EF-hand and coiled-coil domain containing 1	3	129001629-129040742	Predicted intracellular proteins	Evidence at transcript level	HPA042798, HPA050888	Uncertain				Pancreatic cancer:9.70e-4 (favourable)	Mixed	Tissue enhanced		lung: 4.9	spleen: 3.6	Cell line enhanced		AF22: 1.3;HL-60: 3.0
KIAA1257		ENSG00000114656	KIAA1257	3	128909866-129002690	Predicted intracellular proteins	Evidence at transcript level	HPA042811, HPA048445	Uncertain		Approved	Cell Junctions<br>Cytosol		Mixed	Tissue enriched	7	testis: 34.5	placenta: 5.1	Cell line enhanced		AF22: 6.0;BEWO: 11.3;HL-60: 9.2;THP-1: 5.6
NEK11	FLJ23495	ENSG00000114670	NIMA related kinase 11	3	131026850-131350465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016908	Approved		Supported	Nucleoplasm	Renal cancer:5.92e-6 (favourable), Cervical cancer:7.10e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 34.6	testis: 28.0	Mixed		
MRPL3	MRL3, RPML3	ENSG00000114686	Mitochondrial ribosomal protein L3	3	131462212-131502983	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043665, HPA060132	Approved				Liver cancer:4.33e-7 (unfavourable), Pancreatic cancer:3.51e-6 (unfavourable), Ovarian cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 107.7	Expressed in all		
PLSCR4		ENSG00000114698	Phospholipid scramblase 4	3	146192339-146251179	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002276	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:3.90e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 80.2	Cell line enhanced		ASC diff: 41.7;HUVEC TERT2: 42.5;TIME: 86.2
HEMK1	MTQ1	ENSG00000114735	HemK methyltransferase family member 1	3	50569152-50596168	Predicted intracellular proteins	Evidence at protein level	HPA034701, HPA034702	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
CISH	CIS, CIS-1, G18, SOCS	ENSG00000114737	Cytokine inducible SH2 containing protein	3	50606490-50611831	Predicted intracellular proteins	Evidence at protein level	CAB034039, HPA040812	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:3.53e-12 (favourable), Endometrial cancer:1.13e-5 (favourable), Liver cancer:6.98e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 42.9	Group enriched	6	HDLM-2: 287.3;K-562: 65.9
MAPKAPK3	3pK, MAPKAP3	ENSG00000114738	Mitogen-activated protein kinase-activated protein kinase 3	3	50611520-50649297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058275			Supported	Nucleoplasm	Renal cancer:1.90e-8 (favourable), Colorectal cancer:8.08e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 117.6	Expressed in all		
ACVR2B	ActR-IIB	ENSG00000114739	Activin A receptor type 2B	3	38453851-38493142	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007398, CAB025115, HPA040384	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 6.4	Cell line enhanced		AF22: 20.5;NTERA-2: 25.8
WDR48	KIAA1449, P80, SPG60	ENSG00000114742	WD repeat domain 48	3	39051998-39096671	Predicted intracellular proteins	Evidence at protein level	HPA038421, HPA058015	Approved		Supported	Vesicles	Renal cancer:1.63e-7 (favourable)	Expressed in all	Expressed in all			testis: 72.5	Expressed in all		
COMMD2	HSPC042	ENSG00000114744	COMM domain containing 2	3	149738470-149752499	Predicted intracellular proteins	Evidence at protein level	HPA044190	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.69e-6 (unfavourable), Liver cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.5	Expressed in all		
GORASP1	FLJ23443, GOLPH5, GRASP65, P65	ENSG00000114745	Golgi reassembly stacking protein 1	3	39096659-39108363	Predicted intracellular proteins	Evidence at protein level	HPA056283	Enhanced		Supported	Golgi apparatus	Renal cancer:1.91e-6 (favourable), Endometrial cancer:6.92e-6 (favourable), Liver cancer:5.13e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 36.8	Expressed in all		
PEX5L	PEX5R, PXR2, TRIP8b	ENSG00000114757	Peroxisomal biogenesis factor 5 like	3	179794958-180037053	Predicted intracellular proteins	Evidence at protein level	HPA058026	Enhanced					Tissue enhanced	Group enriched	9	cerebral cortex: 67.5;parathyroid gland: 94.8	testis: 8.6	Group enriched	5	HDLM-2: 7.2;MOLT-4: 22.2;RPMI-8226: 15.1;SCLC-21H: 15.0;U-266/70: 12.8
RRP9	RNU3IP2, U3-55K	ENSG00000114767	Ribosomal RNA processing 9, small subunit (SSU) processome component, homolog (yeast)	3	51933430-51941941	Predicted intracellular proteins	Evidence at protein level	HPA038798	Uncertain		Supported	Nucleus	Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 18.9	Expressed in all		
ABCC5	EST277145, MOAT-C, MRP5, SMRP	ENSG00000114770	ATP binding cassette subfamily C member 5	3	183919934-184018015	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044067, HPA052295	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 72.6	Expressed in all		
AADAC	CES5A1, DAC	ENSG00000114771	Arylacetamide deacetylase	3	151814037-151828488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002911	Approved				Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable)	Tissue enriched	Group enriched	5	adrenal gland: 150.1;duodenum: 182.4;liver: 386.8;small intestine: 215.8	stomach: 43.5	Cell line enhanced		A549: 7.3;EFO-21: 3.9;HBEC3-KT: 2.7
ABHD14B	CIB, MGC15429	ENSG00000114779	Abhydrolase domain containing 14B	3	51968510-51983409	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036444, HPA036642	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.93e-5 (favourable), Endometrial cancer:5.42e-5 (favourable), Cervical cancer:6.92e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.8	Expressed in all		
EIF1B	GC20	ENSG00000114784	Eukaryotic translation initiation factor 1B	3	40309684-40312424	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-5 (favourable), Liver cancer:1.94e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 231.3	Expressed in all		
ABHD14A-ACY1		ENSG00000114786	ABHD14A-ACY1 readthrough	3	51974706-51989183	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036174, HPA036175, HPA038153	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 1.7	kidney: 0.7	Cell line enhanced		HUVEC TERT2: 1.3;SH-SY5Y: 1.3
ARHGEF26	DKFZP434D146, SGEF	ENSG00000114790	Rho guanine nucleotide exchange factor 26	3	154121003-154257827	Predicted intracellular proteins	Evidence at protein level	HPA017722, HPA049195	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:9.74e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,lung: 15.0	Cell line enhanced		U-251 MG: 16.6
KLHL24	DRE1, FLJ20059	ENSG00000114796	Kelch like family member 24	3	183635568-183684477	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056337	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 73.9	Expressed in all		
PLCH1	DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3	ENSG00000114805	Phospholipase C eta 1	3	155375580-155745067	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036176, HPA057978	Uncertain		Enhanced	Vesicles	Renal cancer:3.03e-5 (favourable)	Mixed	Tissue enhanced		testis: 20.6	fallopian tube: 13.0	Cell line enhanced		AF22: 38.5;NTERA-2: 20.8
VIPR1	HVR1, RDC1, VPAC1, VPAC1R	ENSG00000114812	Vasoactive intestinal peptide receptor 1	3	42489299-42537573	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026777	Approved					Tissue enhanced	Tissue enhanced		lung: 60.0	duodenum: 34.4	Cell line enhanced		CAPAN-2: 53.2;RT4: 34.8;WM-115: 77.3
DNAH1	DNAHC1, HDHC7, HL-11, HL11, XLHSRF-1	ENSG00000114841	Dynein axonemal heavy chain 1	3	52316319-52400491	Predicted intracellular proteins	Evidence at protein level	HPA036805, HPA036806	Uncertain					Mixed	Mixed			testis: 7.8	Mixed		
SSR3	TRAPG	ENSG00000114850	Signal sequence receptor subunit 3	3	156540140-156555184	Predicted membrane proteins	Evidence at protein level	HPA014906	Approved	Approved	Uncertain	Cytosol	Liver cancer:4.46e-7 (unfavourable), Renal cancer:2.84e-4 (unfavourable), Head and neck cancer:3.43e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 204.7	Expressed in all		
ZBTB47	DKFZp434N0615, KIAA1190, ZNF651	ENSG00000114853	Zinc finger and BTB domain containing 47	3	42653684-42665854	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074057			Approved	Nucleoplasm	Renal cancer:7.96e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 50.0	Cell line enhanced		ASC diff: 42.2
TNNC1	TNNC	ENSG00000114854	Troponin C1, slow skeletal and cardiac type	3	52451102-52454070	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002450, HPA044848, HPA056897	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Mitochondria		Mixed	Group enriched	16	heart muscle: 4938.6;skeletal muscle: 7104.7	esophagus: 383.0	Cell line enhanced		CACO-2: 53.1;EFO-21: 58.5;HSkMC: 46.0;U-2 OS: 99.1
NKTR	p104	ENSG00000114857	Natural killer cell triggering receptor	3	42600614-42648741	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022120, HPA051576	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.05e-5 (favourable), Head and neck cancer:1.26e-4 (favourable), Renal cancer:5.02e-4 (unfavourable), Prostate cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
CLCN2	ClC-2, CLC2, EJM6	ENSG00000114859	Chloride voltage-gated channel 2	3	184346185-184361651	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009397, HPA014545, HPA024108	Approved		Approved	Cytosol	Liver cancer:4.67e-8 (unfavourable)	Expressed in all	Mixed			testis: 17.7	Mixed		
FOXP1	12CC4, hFKH1B, HSPC215, QRF1	ENSG00000114861	Forkhead box P1	3	70954693-71583989	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003876, CAB011501	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 39.7	Expressed in all		
EIF4G1	EIF4F, EIF4G, p220, PARK18	ENSG00000114867	Eukaryotic translation initiation factor 4 gamma 1	3	184314495-184335358	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014774, HPA028487, HPA043866	Approved		Enhanced	Cytosol	Liver cancer:7.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 210.0	Expressed in all		
SPCS1	HSPC033, SPC1, SPC12, YJR010C-A	ENSG00000114902	Signal peptidase complex subunit 1	3	52704955-52711146	Predicted membrane proteins	Evidence at protein level	HPA046091, HPA055273	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 216.1	Expressed in all		
NEK4	NRK2, pp12301, STK2	ENSG00000114904	NIMA related kinase 4	3	52708449-52770949	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015750, HPA058543	Approved		Supported	Cytosol	Colorectal cancer:2.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 84.3	Expressed in all		
SLC4A3	AE3, SLC2C	ENSG00000114923	Solute carrier family 4 member 3	2	219627327-219641980	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063498			Approved	Nucleoplasm	Urothelial cancer:4.12e-4 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 30.0;heart muscle: 119.1;ovary: 47.7	testis: 10.9	Mixed		
INO80D	FLJ20309	ENSG00000114933	INO80 complex subunit D	2	205993721-206086303	Predicted intracellular proteins	Evidence at protein level	HPA043976	Approved				Head and neck cancer:5.53e-4 (favourable)	Expressed in all	Mixed			bone marrow: 11.3	Mixed		
EEF1B2		ENSG00000114942	Eukaryotic translation elongation factor 1 beta 2	2	206159585-206162928	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012477, HPA035029	Supported		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.62e-6 (unfavourable), Breast cancer:2.60e-4 (favourable), Melanoma:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 515.5	Expressed in all		
ADAM23	MDC3	ENSG00000114948	ADAM metallopeptidase domain 23	2	206443539-206621130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012130, CAB033276	Uncertain					Mixed	Group enriched	6	cerebral cortex: 55.4;parathyroid gland: 135.3	heart muscle: 16.5	Cell line enhanced		RH-30: 61.7;RPMI-8226: 120.2
DGUOK	dGK	ENSG00000114956	Deoxyguanosine kinase	2	73926826-73958961	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034766, HPA057246	Approved				Renal cancer:8.69e-7 (unfavourable), Urothelial cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.6	Expressed in all		
MOB1A	C2orf6, FLJ10788, FLJ11595, Mats1, MOB1, Mob4B, MOBK1B, MOBKL1B	ENSG00000114978	MOB kinase activator 1A	2	74152528-74178898	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047088, HPA071690	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.34e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 107.8	Expressed in all		
KANSL3	FLJ10081, KIAA1310, NSL3, Rcd1	ENSG00000114982	KAT8 regulatory NSL complex subunit 3	2	96593170-96642787	Predicted intracellular proteins	Evidence at protein level	HPA035017, HPA035018, HPA041280	Approved		Enhanced	Nucleus	Liver cancer:5.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.3	Expressed in all		
LMAN2L	DKFZp564L2423, VIPL	ENSG00000114988	Lectin, mannose binding 2 like	2	96705929-96740064	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026600	Approved					Expressed in all	Mixed			fallopian tube: 28.0	Expressed in all		
RTKN	B5	ENSG00000114993	Rhotekin	2	74425836-74442422	Predicted intracellular proteins	Evidence at protein level	HPA030259	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			cerebral cortex: 56.0	Mixed		
TTL	MGC46235	ENSG00000114999	Tubulin tyrosine ligase	2	112482154-112541739	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA066819			Approved	Nucleoplasm<br>Vesicles	Liver cancer:5.65e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.4	Mixed		
IL1A	IL-1A, IL1, IL1-ALPHA, IL1F1	ENSG00000115008	Interleukin 1 alpha	2	112773915-112784590	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level						Lung cancer:1.54e-4 (unfavourable), Stomach cancer:4.03e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 12.8;testis: 18.6	tonsil: 7.4	Cell line enhanced		HBEC3-KT: 302.4;hTCEpi: 147.6;hTERT-HME1: 205.8
CCL20	CKb4, exodus-1, LARC, MIP-3a, SCYA20, ST38	ENSG00000115009	C-C motif chemokine ligand 20	2	227813842-227817564	Predicted secreted proteins	Evidence at protein level						Renal cancer:9.19e-8 (unfavourable), Pancreatic cancer:2.73e-4 (unfavourable), Liver cancer:9.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 269.7;tonsil: 155.2	urinary bladder: 83.4	Cell line enhanced		Hep G2: 23.9;NB-4: 12.7;RT4: 12.0
PIKFYVE	FAB1, KIAA0981, MGC40423, p235, PIKfyve, PIP5K, PIP5K3, ZFYVE29	ENSG00000115020	Phosphoinositide kinase, FYVE-type zinc finger containing	2	208266267-208358751	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042604	Uncertain		Uncertain	Nuclear speckles	Head and neck cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
KCNIP3	CSEN, DREAM, KCHIP3	ENSG00000115041	Potassium voltage-gated channel interacting protein 3	2	95297304-95386083	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069797	Approved				Endometrial cancer:1.58e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 40.6;parathyroid gland: 44.0	thyroid gland: 28.0	Cell line enhanced		BJ hTERT+: 14.6;RPTEC TERT1: 26.5;U-138 MG: 16.1
FAHD2A	CGI-105	ENSG00000115042	Fumarylacetoacetate hydrolase domain containing 2A	2	95402721-95416616	Predicted intracellular proteins	Evidence at protein level	HPA042145, HPA044987, CAB045971, CAB045972	Enhanced					Expressed in all	Expressed in all			liver: 52.8	Expressed in all		
NCL	C23	ENSG00000115053	Nucleolin	2	231453531-231483641	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004210, HPA023981	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.41e-6 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 449.8	Expressed in all		
ACTR1B	Arp1B, CTRN2	ENSG00000115073	ARP1 actin-related protein 1 homolog B, centractin beta	2	97655963-97664107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047443			Approved	Microtubules	Urothelial cancer:4.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.0	Expressed in all		
SLC35F5	FLJ22004	ENSG00000115084	Solute carrier family 35 member F5	2	113705011-113756823	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034828, HPA049229	Uncertain		Uncertain	Plasma membrane	Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 97.7	Expressed in all		
ZAP70	SRK, STD, ZAP-70	ENSG00000115085	Zeta chain of T-cell receptor associated protein kinase 70	2	97713560-97739862	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002625, HPA003134	Enhanced				Renal cancer:3.02e-8 (unfavourable), Endometrial cancer:9.66e-8 (favourable), Head and neck cancer:3.93e-6 (favourable), Cervical cancer:6.89e-5 (favourable)	Mixed	Tissue enhanced		appendix: 36.2;lymph node: 64.3;spleen: 37.7	tonsil: 16.2	Cell line enriched	16	MOLT-4: 144.9
ACTR3	ARP3	ENSG00000115091	ARP3 actin related protein 3 homolog	2	113889960-113962596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005085, HPA047016, HPA051683	Approved				Renal cancer:3.81e-5 (unfavourable), Cervical cancer:6.52e-5 (unfavourable), Liver cancer:7.76e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 335.6	Expressed in all		
STEAP3	dudlin-2, STMP3, TSAP6	ENSG00000115107	STEAP3 metalloreductase	2	119223831-119265652	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA050510	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 194.5	liver: 53.0	Cell line enhanced		U-87 MG: 145.7
EPB41L5	BE37, FLJ12957, KIAA1548, YMO1, YRT	ENSG00000115109	Erythrocyte membrane protein band 4.1 like 5	2	120013005-120179119	Predicted intracellular proteins	Evidence at protein level	HPA037563, HPA037564	Uncertain		Supported	Plasma membrane	Renal cancer:2.28e-6 (favourable)	Expressed in all	Mixed			testis: 56.5	Cell line enhanced		MCF7: 63.7
TFCP2L1	CRTR1, LBP-9	ENSG00000115112	Transcription factor CP2 like 1	2	121216587-121285207	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029708	Uncertain		Supported	Nucleoli fibrillar center	Renal cancer:7.72e-6 (favourable)	Mixed	Tissue enhanced		kidney: 49.0	thyroid gland: 45.7	Cell line enhanced		BEWO: 17.6;HEL: 14.0;hTCEpi: 12.5;RPTEC TERT1: 32.4;RT4: 25.3;SCLC-21H: 15.6
SF3B6	CGI-110, Ht006, P14, SAP14a, SF3B14a	ENSG00000115128	Splicing factor 3b subunit 6	2	24067584-24076443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034829, HPA034830	Enhanced		Supported	Nucleoplasm	Liver cancer:5.57e-5 (unfavourable), Renal cancer:1.74e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 153.3	Expressed in all		
TP53I3	PIG3	ENSG00000115129	Tumor protein p53 inducible protein 3	2	24077433-24085861	Predicted intracellular proteins	Evidence at protein level	CAB017479, HPA022012, HPA028742	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			esophagus: 97.1	Cell line enriched	7	T-47d: 553.5
DNAJC27	RabJS, RBJ	ENSG00000115137	DnaJ heat shock protein family (Hsp40) member C27	2	24943636-24972094	Predicted intracellular proteins	Evidence at protein level	HPA036815, HPA036816	Uncertain		Supported	Cytosol	Renal cancer:8.48e-5 (favourable)	Mixed	Tissue enhanced		testis: 39.5	cerebral cortex: 8.7	Mixed		
POMC	ACTH, CLIP, LPH, MSH, NPP, POC	ENSG00000115138	Proopiomelanocortin	2	25160853-25168903	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002762, HPA046135, HPA063644	Enhanced				Pancreatic cancer:5.70e-4 (favourable)	Tissue enriched	Tissue enhanced		testis: 6.8	pancreas: 5.3	Cell line enhanced		HMC-1: 1.2;THP-1: 1.2
STAM2	Hbp	ENSG00000115145	Signal transducing adaptor molecule 2	2	152116801-152175992	Predicted intracellular proteins	Evidence at protein level	HPA035528, HPA035529	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 22.8	Expressed in all		
OTOF	DFNB6, DFNB9, FER1L2	ENSG00000115155	Otoferlin	2	26457203-26558698	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012410	Approved					Not detected	Tissue enhanced		bone marrow: 4.3	cerebral cortex: 1.1	Cell line enriched	20	HDLM-2: 30.8
GPD2		ENSG00000115159	Glycerol-3-phosphate dehydrogenase 2	2	156435290-156613735	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008012, HPA045506	Enhanced				Liver cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Mixed		
CENPA	CenH3, CENP-A	ENSG00000115163	Centromere protein A	2	26764289-26801067	Predicted intracellular proteins	Evidence at protein level	CAB008371, HPA073086	Enhanced		Supported	Nucleoplasm	Liver cancer:2.88e-8 (unfavourable), Pancreatic cancer:1.30e-4 (unfavourable), Endometrial cancer:2.38e-4 (unfavourable), Lung cancer:3.70e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 7.4	tonsil: 6.5	Mixed		
CYTIP	B3-1, CASP, CYBR, CYTHIP, HE, PSCDBP	ENSG00000115165	Cytohesin 1 interacting protein	2	157414619-157488961	Predicted intracellular proteins	Evidence at protein level	HPA007191	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:9.12e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 101.8;tonsil: 102.0	appendix: 92.4	Cell line enhanced		HDLM-2: 41.0;Karpas-707: 103.6;U-266/70: 185.5;U-266/84: 68.5
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
TANC1	KIAA1728, ROLSB	ENSG00000115183	Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1	2	158968671-159232659	Predicted intracellular proteins	Evidence at protein level	HPA036750	Approved					Expressed in all	Mixed			skin: 24.7	Mixed		
SLC30A3	ZNT3	ENSG00000115194	Solute carrier family 30 member 3	2	27253684-27275817	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060505, HPA067637, CAB079044	Enhanced	Approved	Approved	Nucleus<br>Nucleoli<br>Vesicles<br>Cytosol		Mixed	Group enriched	12	cerebral cortex: 36.6;epididymis: 55.4;testis: 43.5	heart muscle: 3.6	Cell line enhanced		HAP1: 10.6;Hep G2: 9.5;REH: 20.7;RH-30: 11.0
MPV17	SYM1	ENSG00000115204	MPV17, mitochondrial inner membrane protein	2	27309492-27325680	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:6.99e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 84.3	Expressed in all		
GTF3C2	KIAA0011, TFIIIC110	ENSG00000115207	General transcription factor IIIC subunit 2	2	27325849-27357034	Predicted intracellular proteins	Evidence at protein level	HPA035836	Uncertain				Liver cancer:1.21e-8 (unfavourable), Endometrial cancer:8.25e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.0	Expressed in all		
EIF2B4	DKFZP586J0119, EIF-2B, EIF2B, EIF2Bdelta	ENSG00000115211	Eukaryotic translation initiation factor 2B subunit delta	2	27364352-27370486	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB032234, HPA039993	Uncertain		Approved	Nuclear membrane<br>Actin filaments	Renal cancer:5.46e-8 (unfavourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
NRBP1	BCON3, MADM, MUDPNP, NRBP	ENSG00000115216	Nuclear receptor binding protein 1	2	27427790-27442259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029527, CAB033078	Supported		Supported	Cytosol	Liver cancer:2.22e-5 (unfavourable), Renal cancer:5.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 125.8	Expressed in all		
ITGB6		ENSG00000115221	Integrin subunit beta 6	2	160099666-160271888	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023626, CAB073536	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Pancreatic cancer:5.03e-6 (unfavourable)	Mixed	Tissue enhanced		lung: 66.9	urinary bladder: 30.3	Cell line enhanced		CAPAN-2: 122.2;RPTEC TERT1: 206.4
FNDC4	FLJ22362, FRCP1	ENSG00000115226	Fibronectin type III domain containing 4	2	27491883-27495245	Predicted membrane proteins	Evidence at transcript level	HPA051804, HPA063581	Uncertain		Approved	Nucleoplasm<br>Aggresome<br>Cytosol	Endometrial cancer:5.07e-4 (unfavourable), Urothelial cancer:6.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 72.5	cerebral cortex: 35.9	Cell line enhanced		AN3-CA: 31.3;HUVEC TERT2: 34.8;SH-SY5Y: 33.9;TIME: 31.2
ITGA4	CD49D	ENSG00000115232	Integrin subunit alpha 4	2	181457202-181536187	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074961			Approved	Plasma membrane	Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable)	Mixed	Tissue enhanced		spleen: 67.6	appendix: 49.6	Cell line enhanced		fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
PSMD14	pad1, POH1, Rpn11	ENSG00000115233	Proteasome 26S subunit, non-ATPase 14	2	161308038-161411717	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002114, HPA003828	Approved		Supported	Nucleoplasm	Liver cancer:2.66e-8 (unfavourable), Renal cancer:3.10e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.1	Expressed in all		
SNX17	KIAA0064	ENSG00000115234	Sorting nexin 17	2	27370496-27377533	Predicted intracellular proteins	Evidence at protein level	HPA043867	Supported		Supported	Vesicles		Expressed in all	Expressed in all			fallopian tube: 97.8	Expressed in all		
ASB3	ASB-3	ENSG00000115239	Ankyrin repeat and SOCS box containing 3	2	53532672-53787610	Predicted intracellular proteins	Evidence at protein level	HPA003940	Uncertain					Mixed	Expressed in all			cerebral cortex: 28.0	Expressed in all		
PPM1G	PP2CG, PP2Cgamma	ENSG00000115241	Protein phosphatase, Mg2+/Mn2+ dependent 1G	2	27381194-27409687	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035530, HPA035531	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.14e-7 (unfavourable), Ovarian cancer:6.08e-5 (favourable)	Expressed in all	Tissue enriched	5	testis: 337.3	lymph node: 65.2	Expressed in all		
PDE1A		ENSG00000115252	Phosphodiesterase 1A	2	182140036-182523192	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022151	Approved		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		thyroid gland: 76.5	testis: 63.0	Cell line enhanced		ASC diff: 25.5;HHSteC: 18.5;HSkMC: 34.2
REEP6	C19orf32, DP1L1, FLJ25383, Yip2f	ENSG00000115255	Receptor accessory protein 6	19	1490747-1497927	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA003895, HPA048015	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Group enriched	7	adrenal gland: 48.2;duodenum: 166.1;liver: 76.1;small intestine: 167.0;testis: 181.2	prostate: 19.3	Cell line enhanced		K-562: 101.6;T-47d: 84.9
PCSK4	DKFZp434B217, MGC34749, PC4, SPC5	ENSG00000115257	Proprotein convertase subtilisin/kexin type 4	19	1481428-1490752	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005572	Uncertain				Endometrial cancer:9.45e-5 (favourable)	Expressed in all	Tissue enriched	9	testis: 41.3	fallopian tube: 4.8	Cell line enhanced		AN3-CA: 6.5;HMC-1: 3.2;U-266/70: 5.8
GCG	GLP1, GLP2, GRPP	ENSG00000115263	Glucagon	2	162142873-162152404	Predicted secreted proteins	Evidence at protein level	CAB000040, HPA036760, HPA036761	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles		Tissue enriched	Tissue enhanced		pancreas: 346.3;rectum: 137.2;small intestine: 123.9	colon: 69.4	Group enriched	7	EFO-21: 100.6;U-2 OS: 158.1
APC2	APCL	ENSG00000115266	APC2, WNT signaling pathway regulator	19	1446302-1473244	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA078002			Supported	Cytokinetic bridge<br>Midbody<br>Cytosol		Tissue enriched	Tissue enriched	21	cerebral cortex: 70.5	adrenal gland: 3.3	Group enriched	10	AF22: 7.7;SCLC-21H: 11.0;SH-SY5Y: 33.6
IFIH1	Hlcd, IDDM19, MDA-5, MDA5	ENSG00000115267	Interferon induced with helicase C domain 1	2	162267079-162318703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002656	Approved					Expressed in all	Mixed			spleen: 31.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 72.5;BJ hTERT+ SV40 Large T+ RasG12V: 93.7
RPS15	MGC111130, RIG, S15	ENSG00000115268	Ribosomal protein S15	19	1438358-1440494	Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054510, HPA057793	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 1335.2	Expressed in all		
GCA	GCL	ENSG00000115271	Grancalcin	2	162318840-162371595	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035033, HPA035034	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 214.5	appendix: 88.0	Mixed		
INO80B	hIes2, HMGA1L4, HMGIYL4, IES2, PAP-1BP, PAPA-1, ZNHIT4	ENSG00000115274	INO80 complex subunit B	2	74455023-74457960	Predicted intracellular proteins	Evidence at protein level	HPA070644			Supported	Nucleus<br>Nucleoli	Renal cancer:1.56e-5 (unfavourable), Breast cancer:2.89e-4 (favourable), Stomach cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
MOGS	CWH41, DER7, GCS1	ENSG00000115275	Mannosyl-oligosaccharide glucosidase	2	74461057-74465410	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011322, HPA011969	Approved		Enhanced	Endoplasmic reticulum	Renal cancer:2.79e-8 (unfavourable), Liver cancer:2.34e-6 (unfavourable), Colorectal cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 63.1	Expressed in all		
TTC31	FLJ12788	ENSG00000115282	Tetratricopeptide repeat domain 31	2	74483073-74494886	Predicted intracellular proteins	Evidence at protein level	HPA041783	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.49e-4 (favourable), Endometrial cancer:6.70e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Expressed in all		
NDUFS7	CI-20, FLJ45860, FLJ46880, PSST	ENSG00000115286	NADH:ubiquinone oxidoreductase core subunit S7	19	1383527-1395589	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.90e-7 (favourable), Cervical cancer:2.03e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 96.7	duodenum: 40.7	Mixed		
PCGF1	MGC10882, NSPC1, RNF68	ENSG00000115289	Polycomb group ring finger 1	2	74505043-74508580	Predicted intracellular proteins	Evidence at protein level	HPA011356, HPA069156	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.69e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 5.2	Expressed in all		
GRB14		ENSG00000115290	Growth factor receptor bound protein 14	2	164492812-164621848	Predicted intracellular proteins	Evidence at protein level	CAB022294, HPA035052, HPA035053	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		epididymis: 6.1;kidney: 6.2;liver: 6.6	testis: 4.3	Cell line enhanced		HUVEC TERT2: 7.9;RPTEC TERT1: 5.9;TIME: 9.9
CLIP4	FLJ21069, RSNL2	ENSG00000115295	CAP-Gly domain containing linker protein family member 4	2	29097705-29189643	Predicted intracellular proteins	Evidence at protein level	HPA043366, HPA056246	Uncertain		Enhanced	Vesicles	Renal cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.8	Mixed		
TLX2	Enx, HOX11L1, NCX, Tlx2	ENSG00000115297	T-cell leukemia homeobox 2	2	74513463-74517147	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040969, HPA062254	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		adrenal gland: 2.7	testis: 0.8	Cell line enriched	17	SH-SY5Y: 68.4
SPTBN1		ENSG00000115306	Spectrin beta, non-erythrocytic 1	2	54456285-54671445	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012685, HPA013149	Supported		Approved	Golgi apparatus	Renal cancer:2.59e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 376.6	Mixed		
AUP1		ENSG00000115307	Ancient ubiquitous protein 1	2	74526645-74529939	Predicted membrane proteins	Evidence at protein level	HPA007674	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
RTN4	ASY, KIAA0886, NOGO, NSP-CL	ENSG00000115310	Reticulon 4	2	54972187-55112621	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB005388, HPA023977	Supported		Enhanced	Endoplasmic reticulum	Head and neck cancer:1.00e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 636.8	Expressed in all		
HTRA2	OMI, PARK13, PRSS25	ENSG00000115317	HtrA serine peptidase 2	2	74529377-74533348	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004004, HPA006602, HPA027366	Uncertain		Supported	Mitochondria	Liver cancer:7.77e-8 (unfavourable)	Expressed in all	Mixed			spleen: 9.0	Expressed in all		
LOXL3		ENSG00000115318	Lysyl oxidase like 3	2	74532414-74555690	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035281	Approved				Renal cancer:7.97e-8 (unfavourable)	Tissue enhanced	Mixed			placenta: 21.6	Cell line enhanced		U-138 MG: 238.3;WM-115: 524.2
DOK1	p62dok	ENSG00000115325	Docking protein 1	2	74549026-74557554	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004224, HPA048561	Approved		Supported	Cytosol	Renal cancer:3.16e-6 (unfavourable), Lung cancer:4.64e-4 (favourable), Endometrial cancer:8.42e-4 (favourable)	Expressed in all	Mixed			appendix,spleen: 8.7	Cell line enhanced		HDLM-2: 54.7
GALNT3	GalNAc-T3, HFTC, HHS	ENSG00000115339	Polypeptide N-acetylgalactosaminyltransferase 3	2	165747591-165794682	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007613	Enhanced		Supported	Golgi apparatus	Cervical cancer:2.08e-4 (unfavourable), Head and neck cancer:4.10e-4 (unfavourable)	Expressed in all	Mixed			stomach: 86.1	Cell line enhanced		CAPAN-2: 92.9;HaCaT: 108.1;hTCEpi: 82.6
POLE4	p12	ENSG00000115350	DNA polymerase epsilon 4, accessory subunit	2	74958492-74970128	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054979, HPA071815	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 12.8	Mixed		
TACR1	NK1R, NKIR, SPR, TAC1R	ENSG00000115353	Tachykinin receptor 1	2	75046463-75199700	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA074573	Enhanced					Mixed	Tissue enhanced		cervix, uterine: 7.3	fallopian tube: 4.7	Not detected		
CCDC88A	APE, FLJ10392, GIV, GRDN, HkRP1, KIAA1212	ENSG00000115355	Coiled-coil domain containing 88A	2	55287842-55419921	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038101, HPA038102	Enhanced				Renal cancer:5.98e-8 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable), Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 117.5	Mixed		
ACADL	ACAD4, LCAD	ENSG00000115361	Acyl-CoA dehydrogenase, long chain	2	210187939-210225491	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011990	Enhanced	Supported			Renal cancer:1.58e-11 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 32.0	prostate: 27.0	Cell line enhanced		HAP1: 1.6;HeLa: 2.5;RPTEC TERT1: 2.5;U-2 OS: 1.9
EVA1A	FAM176A, FLJ13391, TMEM166	ENSG00000115363	Eva-1 homolog A, regulator of programmed cell death	2	75469302-75569722	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008055	Approved		Supported	Vesicles<br>Plasma membrane	Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable)	Mixed	Tissue enhanced		liver: 98.9	lung: 31.1	Cell line enhanced		U-138 MG: 109.1
MRPL19	KIAA0104, MRP-L15, RLX1, RPML15	ENSG00000115364	Mitochondrial ribosomal protein L19	2	75646783-75690851	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046805, HPA056622	Approved		Supported	Mitochondria	Pancreatic cancer:1.97e-5 (unfavourable), Colorectal cancer:7.39e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 66.4	Expressed in all		
LANCL1	GPR69A, p40	ENSG00000115365	LanC like 1	2	210431249-210477652	Predicted intracellular proteins	Evidence at protein level	HPA034994	Approved		Approved	Microtubules		Expressed in all	Expressed in all			cerebral cortex: 153.3	Expressed in all		
WDR75	FLJ12519, NET16, UTP17	ENSG00000115368	WD repeat domain 75	2	189441433-189475565	Predicted intracellular proteins	Evidence at protein level	HPA038199	Approved		Approved	Nucleoplasm	Renal cancer:3.15e-11 (unfavourable), Liver cancer:6.50e-8 (unfavourable)	Expressed in all	Expressed in all			endometrium: 39.6	Expressed in all		
EFEMP1	DHRD, FBLN3, FBNL, MTLV, S1-5	ENSG00000115380	EGF containing fibulin like extracellular matrix protein 1	2	55865967-55924139	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016368, HPA049806, HPA070841, HPA071588	Supported		Uncertain	Mitochondria	Renal cancer:3.89e-8 (unfavourable), Urothelial cancer:6.68e-5 (unfavourable), Endometrial cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			placenta: 488.7	Group enriched	5	HHSteC: 719.8;HSkMC: 733.9;HUVEC TERT2: 3552.1;TIME: 3104.2
REG1A	PSP, PSPS, PSPS1, PTP, REG	ENSG00000115386	Regenerating family member 1 alpha	2	79120362-79123419	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025138, HPA045549, HPA045579	Enhanced					Group enriched	Group enriched	9	duodenum: 7122.5;pancreas: 10867.0;small intestine: 4615.5	stomach: 847.5	Cell line enhanced		BEWO: 11.1;EFO-21: 16.2;HDLM-2: 13.2;RPMI-8226: 20.2;SH-SY5Y: 12.6;U-2 OS: 28.7
FANCL	FAAP43, FLJ10335, PHF9, Pog	ENSG00000115392	Fanconi anemia complementation group L	2	58159243-58241372	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033842, HPA036685, HPA036686	Supported		Approved	Nuclear bodies<br>Vesicles	Renal cancer:1.12e-7 (unfavourable), Liver cancer:2.81e-7 (unfavourable), Urothelial cancer:7.80e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 44.6	Expressed in all		
FN1	CIG, FINC, GFND2, LETS, MSF	ENSG00000115414	Fibronectin 1	2	215360440-215436172	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000126, HPA027066	Enhanced				Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 4284.3	lung: 1167.5	Cell line enhanced		ASC TERT1: 24376.9;HSkMC: 11926.5;hTERT-HME1: 7509.7
STAT1	ISGF-3, STAT91	ENSG00000115415	Signal transducer and activator of transcription 1	2	190964358-191020960	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000931, HPA000982, CAB004049	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.22e-5 (unfavourable), Ovarian cancer:1.75e-4 (favourable), Pancreatic cancer:4.23e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 193.8	Expressed in all		
GLS	GLS1, KIAA0838	ENSG00000115419	Glutaminase	2	190880827-190965552	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036223	Enhanced		Supported	Mitochondria	Endometrial cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 333.2	Expressed in all		
PAPOLG	FLJ12972	ENSG00000115421	Poly(A) polymerase gamma	2	60756230-60802085	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017795, HPA035349, HPA035350	Approved		Enhanced	Nucleoplasm	Renal cancer:4.21e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 22.2	Expressed in all		
DNAH6	Dnahc6, DNHL1, FLJ37357, HL-2	ENSG00000115423	Dynein axonemal heavy chain 6	2	84516455-84819589	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036391	Enhanced					Mixed	Tissue enhanced		fallopian tube: 8.7;testis: 4.9	parathyroid gland: 3.2	Not detected		
PECR	HSA250303, SDR29C1, TERP	ENSG00000115425	Peroxisomal trans-2-enoyl-CoA reductase	2	215996329-216082955	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021593, HPA022539	Enhanced		Supported	Peroxisomes	Renal cancer:1.36e-5 (favourable)	Expressed in all	Expressed in all			liver: 82.8	Mixed		
UNC50	GMH1, UNCL, URP	ENSG00000115446	Unc-50 inner nuclear membrane RNA binding protein	2	98608579-98618515	Predicted membrane proteins	Evidence at protein level	HPA027009	Approved				Liver cancer:4.89e-5 (unfavourable), Breast cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 106.2	Expressed in all		
IGFBP2	IBP2	ENSG00000115457	Insulin like growth factor binding protein 2	2	216632828-216664436	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077723			Approved	Endoplasmic reticulum	Renal cancer:2.22e-5 (unfavourable), Melanoma:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 279.9	Cell line enhanced		ASC diff: 1479.2;HMC-1: 4500.9
ELMOD3	DFNB88, FLJ21977, RBED1, RBM29	ENSG00000115459	ELMO domain containing 3	2	85354394-85391752	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012126	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.09e-6 (unfavourable), Pancreatic cancer:6.16e-6 (favourable), Urothelial cancer:2.85e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 11.4	Expressed in all		
IGFBP5		ENSG00000115461	Insulin like growth factor binding protein 5	2	216672105-216695525	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059827			Approved	Nuclear bodies<br>Golgi apparatus<br>Vesicles	Endometrial cancer:1.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 2374.4;ovary: 1646.3	fallopian tube: 949.1	Cell line enhanced		BJ: 704.3;BJ hTERT+: 1787.5;T-47d: 500.8;U-138 MG: 702.9
USP34	KIAA0570, KIAA0729	ENSG00000115464	Ubiquitin specific peptidase 34	2	61187463-61470769	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025815, HPA070764	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 66.0	Expressed in all		
EFHD1	FLJ13612	ENSG00000115468	EF-hand domain family member D1	2	232606057-232682781	Predicted intracellular proteins	Evidence at protein level	HPA049331, HPA056959	Enhanced		Supported	Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:2.93e-7 (favourable)	Expressed in all	Tissue enhanced		breast: 227.6	kidney: 177.3	Group enriched	7	BEWO: 121.1;RPTEC TERT1: 51.3;SK-BR-3: 225.6;T-47d: 222.0
KCNJ13	Kir1.4, Kir7.1, LCA16	ENSG00000115474	Potassium voltage-gated channel subfamily J member 13	2	232766464-232776568	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enriched	Group enriched	5	parathyroid gland: 25.8;small intestine: 112.2	thyroid gland: 12.5	Cell line enhanced		U-2197: 1.2
CCT4	Cctd	ENSG00000115484	Chaperonin containing TCP1 subunit 4	2	61868089-61888804	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029349	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.37e-12 (unfavourable), Breast cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 133.6	Expressed in all		
GGCX	VKCFD1	ENSG00000115486	Gamma-glutamyl carboxylase	2	85544723-85561547	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA018284	Approved				Endometrial cancer:1.82e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 61.3	Expressed in all		
NEU2	SIAL2	ENSG00000115488	Neuraminidase 2	2	233032672-233035057	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022336	Uncertain					Not detected	Tissue enriched	13	skin: 1.4	breast: 0.1	Not detected		
EHBP1	KIAA0903, NACSIN	ENSG00000115504	EH domain binding protein 1	2	62673851-63046487	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035468, HPA035469	Enhanced		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 68.0	Expressed in all		
OTX1		ENSG00000115507	Orthodenticle homeobox 1	2	63050057-63057836	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012341, HPA052122	Approved		Uncertain	Nuclear speckles<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 1.7;skin: 6.1	prostate: 1.0	Cell line enriched	6	THP-1: 35.9
TXNDC9	APACD	ENSG00000115514	Thioredoxin domain containing 9	2	99318982-99340702	Predicted intracellular proteins	Evidence at protein level	HPA031844, HPA031845, HPA031846	Approved		Enhanced	Cytosol	Liver cancer:9.63e-7 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 36.4	Expressed in all		
COQ10B	FLJ13448	ENSG00000115520	Coenzyme Q10B	2	197453423-197475308	Predicted intracellular proteins	Evidence at protein level	HPA046057	Approved		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 49.7	Expressed in all		
GNLY	D2S69E, LAG-2, LAG2, NKG5, TLA519	ENSG00000115523	Granulysin	2	85685175-85698854	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025186, HPA058021	Enhanced				Endometrial cancer:3.48e-5 (favourable), Melanoma:6.60e-5 (favourable), Renal cancer:1.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 152.4;endometrium: 113.5;spleen: 112.9	lung: 51.0	Not detected		
SF3B1	Hsh155, Prp10, PRPF10, SAP155, SF3b155	ENSG00000115524	Splicing factor 3b subunit 1	2	197389784-197435091	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050275	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			endometrium: 348.2	Expressed in all		
ST3GAL5	SIAT9, SIATGM3S, ST3GalV	ENSG00000115525	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	2	85837120-85905199	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034708, HPA040425, HPA068928	Uncertain		Approved	Vesicles	Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 44.7	cerebral cortex: 40.7	Cell line enhanced		AN3-CA: 50.3;RT4: 37.4
CHST10	HNK-1ST	ENSG00000115526	Carbohydrate sulfotransferase 10	2	100391860-100417656	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012884, HPA051545	Approved		Approved	Cytosol	Pancreatic cancer:4.05e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 46.4	endometrium: 19.4	Mixed		
PDCL3	VIAF1	ENSG00000115539	Phosducin like 3	2	100562690-100576735	Predicted intracellular proteins	Evidence at protein level	HPA018469, HPA027094	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:2.55e-5 (unfavourable), Liver cancer:6.07e-5 (unfavourable), Urothelial cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 40.3	Expressed in all		
MOB4	2C4D, CGI-95, DKFZP564M112, MOB3, MOBKL3, PHOCN, PREI3	ENSG00000115540	MOB family member 4, phocein	2	197515571-197553699	Predicted intracellular proteins	Evidence at protein level	CAB034082, HPA044125	Approved				Renal cancer:4.68e-4 (unfavourable), Liver cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 79.6	Expressed in all		
HSPE1	CPN10, EPF, GroES, HSP10	ENSG00000115541	Heat shock protein family E (Hsp10) member 1	2	197499994-197503457	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017366, HPA038755, HPA048272	Supported					Expressed in all	Expressed in all			adrenal gland: 650.8	Expressed in all		
KDM3A	JHMD2A, JMJD1, JMJD1A, KIAA0742, TSGA	ENSG00000115548	Lysine demethylase 3A	2	86440647-86492716	Predicted intracellular proteins	Evidence at protein level	HPA055543, HPA065162			Enhanced	Nucleoplasm	Liver cancer:2.15e-6 (unfavourable), Renal cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 93.0	Expressed in all		
PLCD4		ENSG00000115556	Phospholipase C delta 4	2	218607765-218637184	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009914, HPA038139, HPA038140	Enhanced		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		skeletal muscle: 38.4	testis: 9.7	Cell line enhanced		SH-SY5Y: 21.8
CHMP3	CGI-149, NEDF, VPS24	ENSG00000115561	Charged multivesicular body protein 3	2	86503431-86563479	Predicted intracellular proteins	Evidence at protein level	HPA015673, HPA073383	Supported				Liver cancer:3.92e-5 (unfavourable), Renal cancer:5.32e-4 (favourable), Pancreatic cancer:7.39e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 114.0	Expressed in all		
ZNF142	KIAA0236, pHZ-49	ENSG00000115568	Zinc finger protein 142	2	218637916-218659655	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049594	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.9	Expressed in all		
IL1R2	CD121b, IL1RB	ENSG00000115590	Interleukin 1 receptor type 2	2	101991844-102028544	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027597, HPA027598	Uncertain				Renal cancer:5.58e-12 (unfavourable)	Mixed	Mixed			appendix: 50.3	Cell line enriched	24	HDLM-2: 436.8
PRKAG3		ENSG00000115592	Protein kinase AMP-activated non-catalytic subunit gamma 3	2	218822383-218832086	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	18	skeletal muscle: 23.9	esophagus: 1.3	Not detected		
SMYD1	BOP, KMT3D, ZMYND22	ENSG00000115593	SET and MYND domain containing 1	2	88067780-88113387	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062282	Enhanced					Tissue enhanced	Group enriched	9	heart muscle: 107.0;skeletal muscle: 170.8;smooth muscle: 38.5	parathyroid gland: 11.6	Not detected		
IL1R1	CD121A, D2S1473, IL1R, IL1RA	ENSG00000115594	Interleukin 1 receptor type 1	2	102064544-102179874	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005823, CAB007779, HPA029560	Approved				Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 246.0	Cell line enhanced		ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
WNT6		ENSG00000115596	Wnt family member 6	2	218859821-218874233	Predicted secreted proteins	Evidence at protein level	HPA070759	Approved					Tissue enhanced	Tissue enhanced		placenta: 2.9	spleen: 1.5	Cell line enriched	6	BEWO: 33.5
IL1RL2	IL1R-rp2, IL1RRP2	ENSG00000115598	Interleukin 1 receptor like 2	2	102186973-102240002	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015485	Uncertain					Mixed	Tissue enhanced		skin: 15.5	parathyroid gland: 8.5	Cell line enhanced		A-431: 7.2;ASC TERT1: 3.6;HaCaT: 3.3;HSkMC: 3.1
IL1RL1	DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1	ENSG00000115602	Interleukin 1 receptor like 1	2	102311502-102352037	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007406, HPA007917	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	12	placenta: 289.6	gallbladder: 23.7	Group enriched	6	HHSteC: 206.0;HMC-1: 327.3;HUVEC TERT2: 154.2
IL18R1	CD218a, IL-1Rrp, IL1RRP	ENSG00000115604	Interleukin 18 receptor 1	2	102311529-102398775	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007615	Approved		Approved	Mitochondria	Renal cancer:4.52e-4 (unfavourable)	Mixed	Mixed			placenta: 14.4	Cell line enhanced		HDLM-2: 28.1;HHSteC: 51.3;HMC-1: 36.8;U-937: 54.3
IL18RAP	AcPL, CD218b	ENSG00000115607	Interleukin 18 receptor accessory protein	2	102418689-102452565	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025270	Enhanced					Mixed	Tissue enhanced		bone marrow: 70.9	appendix: 16.9	Cell line enriched	10	U-937: 42.2
SLC9A2	NHE2	ENSG00000115616	Solute carrier family 9 member A2	2	102619707-102711318	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035121, HPA035122	Approved		Supported	Cell Junctions		Mixed	Tissue enhanced		colon: 20.5;rectum: 23.3;stomach: 25.7	testis: 10.7	Cell line enhanced		A-431: 8.9;RT4: 13.9;SK-BR-3: 11.4;T-47d: 18.0
FHL2	DRAL, SLIM3	ENSG00000115641	Four and a half LIM domains 2	2	105357712-105438513	Predicted intracellular proteins	Evidence at protein level	HPA005922, HPA006028, CAB008368	Enhanced		Enhanced	Actin filaments<br>Focal adhesion sites	Renal cancer:6.42e-5 (unfavourable), Head and neck cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 659.3	Mixed		
MLPH	exophilin-3, l(1)-3Rk, l1Rk3, ln, Slac-2a	ENSG00000115648	Melanophilin	2	237485428-237555318	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014685	Uncertain				Endometrial cancer:5.14e-6 (favourable), Renal cancer:1.50e-4 (unfavourable)	Mixed	Mixed			prostate: 97.9	Cell line enhanced		MCF7: 192.8;SK-BR-3: 174.6;SK-MEL-30: 137.5;U-87 MG: 230.5
CNPPD1	C2orf24, CGI-57	ENSG00000115649	Cyclin Pas1/PHO80 domain containing 1	2	219171897-219178106	Predicted membrane proteins	Evidence at transcript level	HPA049303	Uncertain				Renal cancer:1.62e-10 (favourable), Liver cancer:2.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 88.2	Expressed in all		
UXS1	FLJ23591, SDR6E1, UGD	ENSG00000115652	UDP-glucuronate decarboxylase 1	2	106093303-106194339	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008825	Uncertain				Liver cancer:1.38e-4 (unfavourable), Head and neck cancer:5.45e-4 (unfavourable), Ovarian cancer:7.94e-4 (favourable)	Expressed in all	Expressed in all			placenta: 76.1	Expressed in all		
ABCB6	EST45597, MTABC3, umat	ENSG00000115657	ATP binding cassette subfamily B member 6 (Langereis blood group)	2	219209768-219218990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046723, HPA058011	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Mitochondria<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 32.7	Mixed		
STK16	MPSK, PKL12	ENSG00000115661	Serine/threonine kinase 16	2	219245455-219250337	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029450	Approved		Approved	Cytosol	Endometrial cancer:6.09e-4 (favourable)	Expressed in all	Expressed in all			testis,thyroid gland: 28.6	Expressed in all		
SLC5A7	CHT1, hCHT	ENSG00000115665	Solute carrier family 5 member 7	2	107986523-108013994	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046105			Approved	Nuclear bodies<br>Cell Junctions<br>Intermediate filaments		Tissue enhanced	Mixed			thyroid gland: 2.0	Group enriched	21	RT4: 2.9;SCLC-21H: 1.2
HDLBP	HBP, VGL	ENSG00000115677	High density lipoprotein binding protein	2	241227264-241317061	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004189, CAB026457	Supported		Supported	Cytosol	Liver cancer:2.58e-5 (unfavourable), Thyroid cancer:6.39e-5 (unfavourable), Urothelial cancer:4.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 364.6	Expressed in all		
PPP1R7	sds22	ENSG00000115685	Protein phosphatase 1 regulatory subunit 7	2	241149576-241183652	Predicted intracellular proteins	Evidence at protein level	HPA034500, HPA034501	Supported		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 287.5	Expressed in all		
PASK	KIAA0135, PASKIN, STK37	ENSG00000115687	PAS domain containing serine/threonine kinase	2	241106099-241150264	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016450, HPA021079	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 25.5	prostate: 16.3	Mixed		
STK25	SOK1, YSK1	ENSG00000115694	Serine/threonine kinase 25	2	241492674-241509730	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047147	Uncertain				Liver cancer:3.91e-8 (unfavourable), Colorectal cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 168.2	Expressed in all		
TPO	TPX	ENSG00000115705	Thyroid peroxidase	2	1374223-1543711	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007987, CAB009587	Enhanced					Tissue enriched	Tissue enriched	103	thyroid gland: 1817.4	spleen: 17.6	Cell line enhanced		Karpas-707: 6.9;RPMI-8226: 2.9
PROC		ENSG00000115718	Protein C, inactivator of coagulation factors Va and VIIIa	2	127418427-127429246	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005550, CAB016721, CAB016792	Supported					Tissue enriched	Tissue enriched	12	liver: 140.4	kidney: 12.0	Cell line enriched	12	Hep G2: 105.5
ID2	bHLHb26, GIG8	ENSG00000115738	Inhibitor of DNA binding 2, HLH protein	2	8678845-8684453	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027612			Approved	Nucleoplasm<br>Nuclear bodies<br>Centrosome	Head and neck cancer:9.95e-4 (favourable)	Expressed in all	Tissue enriched	6	parathyroid gland: 1985.4	thyroid gland: 359.5	Cell line enhanced		HDLM-2: 675.4;HEK 293: 418.6
TAF1B	RAF1B, RAFI63, SL1, TAFI63	ENSG00000115750	TATA-box binding protein associated factor, RNA polymerase I subunit B	2	9843354-9934416	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071254			Supported	Nucleus<br>Nucleoli	Liver cancer:6.94e-7 (unfavourable), Colorectal cancer:8.58e-5 (favourable), Renal cancer:8.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.9	Expressed in all		
HPCAL1	BDR1, HLP2, VILIP-3	ENSG00000115756	Hippocalcin like 1	2	10302889-10427617	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043245	Approved				Renal cancer:4.39e-6 (unfavourable), Glioma:5.68e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 80.5	Expressed in all		
ODC1	ODC	ENSG00000115758	Ornithine decarboxylase 1	2	10439968-10448504	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001536, CAB035996	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 242.0	Expressed in all		
BIRC6	BRUCE	ENSG00000115760	Baculoviral IAP repeat containing 6	2	32357028-32618899	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074409, HPA074738			Supported	Golgi apparatus<br>Vesicles<br>Mitotic spindle		Expressed in all	Mixed			parathyroid gland: 31.4	Expressed in all		
NOL10	FLJ14075, PQBP5	ENSG00000115761	Nucleolar protein 10	2	10570766-10689987	Predicted intracellular proteins	Evidence at protein level	HPA035286, HPA043075	Approved		Supported	Nucleoli	Liver cancer:1.43e-7 (unfavourable), Endometrial cancer:2.92e-5 (unfavourable), Renal cancer:7.51e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 27.6	Expressed in all		
PLEKHB2	EVT2, FLJ20783	ENSG00000115762	Pleckstrin homology domain containing B2	2	131104847-131353709	Predicted intracellular proteins	Evidence at protein level	HPA075014	Approved				Renal cancer:1.72e-8 (favourable), Liver cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 125.3	Expressed in all		
GORASP2	GOLPH6, GRASP55, GRS2	ENSG00000115806	Golgi reassembly stacking protein 2	2	170928464-170967129	Predicted intracellular proteins	Evidence at protein level	HPA035274, HPA035275, CAB075758	Enhanced		Enhanced	Golgi apparatus	Renal cancer:1.38e-8 (unfavourable), Head and neck cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 42.2	Expressed in all		
STRN	PPP2R6A, STRN1	ENSG00000115808	Striatin	2	36843640-36966472	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017286	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 23.8	Expressed in all		
CEBPZ	CBF2, CTF2	ENSG00000115816	CCAAT/enhancer binding protein zeta	2	37201612-37231713	Predicted intracellular proteins	Evidence at protein level	HPA052065	Uncertain		Approved	Nucleus<br>Vesicles	Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:5.07e-4 (unfavourable), Pancreatic cancer:8.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 67.3	Expressed in all		
PRKD3	EPK2, PRKCN	ENSG00000115825	Protein kinase D3	2	37250502-37324808	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029529	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.47e-4 (unfavourable), Colorectal cancer:4.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.4	Expressed in all		
DCAF17	C2orf37, FLJ13096	ENSG00000115827	DDB1 and CUL4 associated factor 17	2	171434217-171485052	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053339, HPA055040	Uncertain		Supported	Nucleoplasm	Thyroid cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.1	Expressed in all		
QPCT	GCT, QC	ENSG00000115828	Glutaminyl-peptide cyclotransferase	2	37344574-37373322	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008406	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		adrenal gland: 158.9;epididymis: 121.6	skin: 41.1	Cell line enhanced		SCLC-21H: 130.6;SK-MEL-30: 299.7;U-266/84: 218.7
RAB3GAP1	KIAA0066, RAB3GAP, RAB3GAP130, WARBM1	ENSG00000115839	RAB3 GTPase activating protein catalytic subunit 1	2	135052265-135176394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034494, HPA034495	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 57.5	Expressed in all		
SLC25A12	Aralar	ENSG00000115840	Solute carrier family 25 member 12	2	171784370-171999859	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035333, HPA035334	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Renal cancer:2.91e-8 (favourable), Endometrial cancer:7.86e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 55.3	Mixed		
RMDN2	FAM82A, FAM82A1, FLJ32954, RMD2	ENSG00000115841	Regulator of microtubule dynamics 2	2	37923187-38067142	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034705, HPA034706	Approved		Supported	Golgi apparatus<br>Mitotic spindle<br>Cytosol	Lung cancer:2.63e-4 (favourable)	Mixed	Expressed in all			adrenal gland: 68.9	Mixed		
DLX2	TES-1	ENSG00000115844	Distal-less homeobox 2	2	172099439-172102900	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056965			Approved	Nuclear speckles		Mixed	Not detected			cerebral cortex: 0.8	Group enriched	11	AN3-CA: 73.7;HEK 293: 46.5
LCT		ENSG00000115850	Lactase	2	135787840-135837180	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	631	duodenum: 223.1;small intestine: 142.8	appendix,lymph node: 0.2	Cell line enhanced		MOLT-4: 3.9;RPMI-8226: 6.7
DARS		ENSG00000115866	Aspartyl-tRNA synthetase	2	135906677-135986100	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020451, HPA029804, HPA029805	Enhanced		Enhanced	Cytosol	Liver cancer:2.39e-6 (unfavourable), Renal cancer:1.24e-5 (unfavourable), Pancreatic cancer:6.54e-4 (unfavourable), Melanoma:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 91.0	Expressed in all		
SRSF7	9G8, AAG3, HSSG1, RBM37, SFRS7, ZCCHC20, ZCRB2	ENSG00000115875	Serine and arginine rich splicing factor 7	2	38743599-38751494	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043850, HPA056926	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.18e-8 (unfavourable), Liver cancer:2.90e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 99.7	Expressed in all		
SDC1	CD138, SDC, SYND1, syndecan	ENSG00000115884	Syndecan 1	2	20200797-20225433	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002424, HPA006185	Approved		Supported	Focal adhesion sites	Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 250.7;skin: 287.9	liver: 144.7	Cell line enhanced		U-266/84: 739.8
PLCL1	PLC-L, PLCE, PLCL, PPP1R127, PRIP	ENSG00000115896	Phospholipase C like 1	2	197804702-198572581	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031849	Enhanced				Renal cancer:3.91e-7 (favourable)	Mixed	Mixed			kidney: 34.3	Cell line enhanced		HUVEC TERT2: 7.3;K-562: 13.7;Karpas-707: 7.9;MOLT-4: 8.6
SLC1A4	ASCT1, SATT	ENSG00000115902	Solute carrier family 1 member 4	2	64988477-65023865	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034963, HPA034964	Approved		Supported	Centrosome	Liver cancer:4.23e-5 (unfavourable), Cervical cancer:3.59e-4 (favourable), Renal cancer:4.87e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 79.1	Expressed in all		
SOS1	GF1, GINGF, HGF	ENSG00000115904	SOS Ras/Rac guanine nucleotide exchange factor 1	2	38981396-39124345	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005396, HPA012613	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 41.0	Expressed in all		
KYNU		ENSG00000115919	Kynureninase	2	142877498-143055832	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031686	Enhanced		Supported	Nucleoplasm<br>Cytosol		Mixed	Mixed			liver: 45.9	Cell line enhanced		A549: 168.9;HeLa: 138.9;hTEC/SVTERT24-B: 106.9;SiHa: 109.4;U-87 MG: 309.1
WIPF1	WASPIP, WIP	ENSG00000115935	WAS/WASL interacting protein family member 1	2	174559572-174682916	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003739, CAB009737, HPA070706	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 157.5	Cell line enhanced		Karpas-707: 220.1
ORC2	ORC2L	ENSG00000115942	Origin recognition complex subunit 2	2	200908973-200963680	Predicted intracellular proteins	Evidence at protein level	CAB003693, HPA073881	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.97e-4 (unfavourable), Melanoma:8.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 38.1	Expressed in all		
COX7A2L	COX7AR, COX7RP, EB1, SIG81	ENSG00000115944	Cytochrome c oxidase subunit 7A2 like	2	42333546-42425088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059124, CAB073545			Enhanced	Nucleoli<br>Mitochondria	Liver cancer:4.13e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 254.6	Expressed in all		
PNO1	KHRBP1, RRP20	ENSG00000115946	Partner of NOB1 homolog	2	68157844-68176238	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056928			Supported	Nucleus<br>Nucleoli	Liver cancer:3.04e-8 (unfavourable), Endometrial cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 20.8	Expressed in all		
ORC4	HsORC4, ORC4L, Orc4p	ENSG00000115947	Origin recognition complex subunit 4	2	147930397-148021604	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015124, HPA064562	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:4.98e-8 (unfavourable), Renal cancer:4.10e-6 (favourable), Endometrial cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.5	Expressed in all		
PLEK	P47	ENSG00000115956	Pleckstrin	2	68365173-68397453	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031838, HPA057341	Enhanced		Approved	Nucleoli	Renal cancer:1.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 371.1	lymph node: 142.4	Cell line enhanced		HEL: 475.7;HMC-1: 170.8;THP-1: 139.2;U-937: 256.0
RND3	ARHE, Rho8, RhoE	ENSG00000115963	Rho family GTPase 3	2	150468195-150539011	Predicted intracellular proteins	Evidence at protein level	HPA060504	Uncertain				Renal cancer:1.78e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 169.5	Cell line enhanced		BJ: 570.2;BJ hTERT+: 1071.0;hTERT-HME1: 496.5
ATF2	CRE-BP1, CREB2, HB16, TREB7	ENSG00000115966	Activating transcription factor 2	2	175072250-175168382	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003769, HPA022134	Supported		Enhanced	Nucleoplasm	Liver cancer:7.08e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 54.0	Expressed in all		
THADA	ARMC13, FLJ21877, GITA, KIAA1767	ENSG00000115970	THADA, armadillo repeat containing	2	43230836-43596046	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035191, HPA035192	Uncertain		Approved	Cytosol	Liver cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Mixed		
AAK1	DKFZp686K16132, KIAA1048	ENSG00000115977	AP2 associated kinase 1	2	69457997-69674349	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017931, HPA020289	Enhanced		Supported	Plasma membrane<br>Cytosol	Ovarian cancer:3.19e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 389.6	thyroid gland: 59.4	Expressed in all		
TRAK2	ALS2CR3, CALS-C, GRIF-1, KIAA0549, MILT2, OIP98	ENSG00000115993	Trafficking kinesin protein 2	2	201377207-201451579	Predicted intracellular proteins	Evidence at protein level	HPA015827, HPA062163	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:7.42e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.1	Expressed in all		
C2orf42	FLJ20558	ENSG00000115998	Chromosome 2 open reading frame 42	2	70149880-70248615	Predicted intracellular proteins	Evidence at protein level	HPA031840, HPA031841, HPA031842	Enhanced		Enhanced	Nucleus	Pancreatic cancer:5.94e-5 (favourable)	Expressed in all	Tissue enriched	6	testis: 109.7	fallopian tube: 18.7	Expressed in all		
TIA1		ENSG00000116001	TIA1 cytotoxic granule associated RNA binding protein	2	70209444-70248660	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056961			Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.05e-7 (unfavourable), Urothelial cancer:1.02e-5 (favourable), Lung cancer:6.79e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 113.1	Expressed in all		
PCYOX1	KIAA0908, PCL1	ENSG00000116005	Prenylcysteine oxidase 1	2	70257386-70281191	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035193	Approved				Renal cancer:1.89e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 141.1	Expressed in all		
KISS1R	AXOR12, GPR54, HOT7T175	ENSG00000116014	KISS1 receptor	19	917287-921015	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071913			Supported	Vesicles<br>Plasma membrane	Renal cancer:3.33e-6 (unfavourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 1.2	appendix,lymph node,placenta: 0.2	Cell line enhanced		K-562: 14.0;RPMI-8226: 26.1;SCLC-21H: 8.9;SH-SY5Y: 21.3
EPAS1	bHLHe73, HIF2A, HLF, MOP2, PASD2	ENSG00000116016	Endothelial PAS domain protein 1	2	46293667-46386703	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031200, HPA069697			Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 642.0	Cell line enhanced		U-138 MG: 279.3
ARID3A	BRIGHT, DRIL1	ENSG00000116017	AT-rich interaction domain 3A	19	925781-975934	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004793, HPA076330	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:1.95e-5 (favourable), Renal cancer:3.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 33.4	testis: 9.7	Cell line enhanced		BEWO: 199.1;K-562: 85.1
SUMO1	GMP1, OFC10, PIC1, SMT3C, SMT3H3, SUMO-1, UBL1	ENSG00000116030	Small ubiquitin-like modifier 1	2	202206180-202238608	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004269, HPA056956	Supported		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Nuclear bodies	Ovarian cancer:7.93e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 171.0	Expressed in all		
CD207	CLEC4K, Langerin	ENSG00000116031	CD207 molecule	2	70830214-70835822	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002222, HPA011216	Enhanced		Uncertain	Cytosol		Mixed	Tissue enriched	5	skin: 104.0	esophagus: 19.4	Cell line enhanced		AN3-CA: 8.3;HAP1: 2.2;SH-SY5Y: 1.3;T-47d: 1.5
GRIN3B	GluN3B	ENSG00000116032	Glutamate ionotropic receptor NMDA type subunit 3B	19	1000419-1009732	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 2.1;spleen: 1.2	lung: 0.7	Cell line enhanced		U-266/70: 2.6
VAX2	DRES93	ENSG00000116035	Ventral anterior homeobox 2	2	70900590-70933446	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009708			Approved	Nuclear speckles		Mixed	Tissue enhanced		cerebral cortex: 3.2	adipose tissue,adrenal gland,breast,endometrium: 0.7	Cell line enhanced		SH-SY5Y: 7.0
ATP6V1B1	ATP6B1, RTA1B, VATB, Vma2, VPP3	ENSG00000116039	ATPase H+ transporting V1 subunit B1	2	70935882-70965406	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009523, HPA031847	Enhanced		Approved	Nucleus<br>Nuclear membrane		Group enriched	Group enriched	10	breast: 16.1;cervix, uterine: 47.9;fallopian tube: 21.1;kidney: 64.8;placenta: 27.8;salivary gland: 66.5	skin: 4.2	Group enriched	6	BEWO: 20.0;HaCaT: 17.4;SK-BR-3: 34.9
NFE2L2	NRF2	ENSG00000116044	Nuclear factor, erythroid 2 like 2	2	177227595-177392697	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002990, CAB020317, HPA043438	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 267.1	Expressed in all		
MSH6	GTBP	ENSG00000116062	MutS homolog 6	2	47695530-47810101	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009091, HPA028376, HPA028446, CAB070870	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.06e-7 (unfavourable), Endometrial cancer:1.34e-4 (unfavourable), Liver cancer:7.86e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 74.5	Expressed in all		
PLEKHA3	FAPP1	ENSG00000116095	Pleckstrin homology domain containing A3	2	178480468-178516462	Predicted intracellular proteins	Evidence at protein level	HPA034496, HPA034497	Approved		Enhanced	Golgi apparatus		Expressed in all	Mixed			testis: 15.1	Mixed		
SPR	SDR38C1	ENSG00000116096	Sepiapterin reductase (7,8-dihydrobiopterin:NADP+ oxidoreductase)	2	72887360-72892158	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039505	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 49.9	Mixed		
EPHA4	Hek8, TYRO1	ENSG00000116106	EPH receptor A4	2	221418027-221574202	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028368	Enhanced				Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 41.6	testis: 22.2	Cell line enhanced		AF22: 77.5;CACO-2: 49.0;U-2197: 35.7
PARD3B	ALS2CR19, PAR3beta, Par3L	ENSG00000116117	Par-3 family cell polarity regulator beta	2	204545793-205620162	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035283	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cell Junctions	Renal cancer:2.67e-10 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Cell line enhanced		ASC diff: 12.1
FARSB	FARSLB, FRSB, PheHB	ENSG00000116120	Phenylalanyl-tRNA synthetase beta subunit	2	222570536-222656337	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036677, HPA036678, HPA061398	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:6.45e-10 (unfavourable), Renal cancer:3.21e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
ALMS1	KIAA0328	ENSG00000116127	ALMS1, centrosome and basal body associated protein	2	73385758-73610793	Predicted intracellular proteins	Evidence at protein level	HPA043200	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		testis: 32.5	ovary: 9.1	Cell line enhanced		RH-30: 26.7
BCL9		ENSG00000116128	B-cell CLL/lymphoma 9	1	147541412-147626216	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020274	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 26.5	Cell line enhanced		NTERA-2: 42.4
PRRX1	PHOX1, PMX1	ENSG00000116132	Paired related homeobox 1	1	170662728-170739419	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051084, HPA063566	Uncertain		Supported	Nucleoplasm	Renal cancer:6.60e-10 (unfavourable)	Mixed	Mixed			cervix, uterine: 135.8	Cell line enhanced		ASC diff: 240.8;ASC TERT1: 194.6;BJ hTERT+: 165.0;U-138 MG: 137.1;U-2197: 125.0
DHCR24	DCE, KIAA0018, seladin-1	ENSG00000116133	24-dehydrocholesterol reductase	1	54849633-54887218	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017981, CAB037247, HPA063005	Approved				Endometrial cancer:1.05e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 1094.6	Mixed		
DNAJC16	KIAA0962	ENSG00000116138	DnaJ heat shock protein family (Hsp40) member C16	1	15526813-15592379	Predicted membrane proteins	Evidence at protein level	HPA043643	Approved		Approved	Vesicles	Colorectal cancer:6.77e-4 (favourable), Renal cancer:7.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.8	Expressed in all		
MARK1	MARK, PAR-1C	ENSG00000116141	Microtubule affinity regulating kinase 1	1	220528183-220664461	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007421, HPA008061	Uncertain				Pancreatic cancer:2.23e-5 (favourable), Melanoma:2.63e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 21.1	Cell line enhanced		RT4: 50.7
TNR		ENSG00000116147	Tenascin R	1	175315194-175743770	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022343, HPA027134, HPA027150, HPA029859	Enhanced					Tissue enriched	Tissue enriched	38	cerebral cortex: 70.6	adrenal gland: 1.8	Cell line enhanced		SH-SY5Y: 1.9;U-937: 1.1
MORN1	FLJ13941	ENSG00000116151	MORN repeat containing 1	1	2321253-2391707	Predicted intracellular proteins	Evidence at transcript level	HPA005858, HPA070703	Uncertain		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		fallopian tube: 17.7	testis: 12.1	Mixed		
GPX7	FLJ14777, GPX6, NPGPx	ENSG00000116157	Glutathione peroxidase 7	1	52602372-52609051	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA025829			Approved	Nucleoli	Renal cancer:2.26e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 42.1	Cell line enhanced		REH: 69.6;RPMI-8226: 89.3;THP-1: 68.1
CACYBP	S100A6BP, SIP	ENSG00000116161	Calcyclin binding protein	1	174999163-175011715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025753, HPA057038	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.12e-6 (unfavourable), Ovarian cancer:1.39e-5 (favourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 60.7	Expressed in all		
SCP2		ENSG00000116171	Sterol carrier protein 2	1	52927229-53051703	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027101, HPA027135, HPA027317	Supported		Enhanced	Peroxisomes	Renal cancer:7.85e-8 (favourable), Colorectal cancer:7.05e-5 (favourable)	Expressed in all	Expressed in all			liver: 601.5	Expressed in all		
TPSG1	PRSS31, TMT	ENSG00000116176	Tryptase gamma 1	16	1221651-1225257	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060458	Enhanced				Renal cancer:1.76e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 14.6;duodenum: 14.3;rectum: 9.5;small intestine: 10.5	ovary: 2.5	Group enriched	8	HMC-1: 20.4;MCF7: 6.0
PAPPA2	PAPP-A2, PAPPE, PLAC3	ENSG00000116183	Pappalysin 2	1	176463171-176845605	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018412, HPA018430	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	8	placenta: 82.7	cervix, uterine: 10.8	Cell line enriched	6	U-87 MG: 19.4
RALGPS2	FLJ10244, FLJ25604, KIAA0351	ENSG00000116191	Ral GEF with PH domain and SH3 binding motif 2	1	178725147-178921841	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027143, HPA028328	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 138.2	lymph node: 62.7	Cell line enhanced		U-266/84: 172.2;U-698: 134.0
ANGPTL1	ANG3, ANGPT3, AngY, ARP1	ENSG00000116194	Angiopoietin like 1	1	178849705-178871052	Predicted secreted proteins	Evidence at protein level	HPA009976	Approved				Renal cancer:5.11e-4 (favourable), Liver cancer:8.73e-4 (favourable)	Mixed	Tissue enhanced		placenta: 190.2	smooth muscle: 96.7	Group enriched	18	ASC diff: 102.1;ASC TERT1: 41.7;HHSteC: 54.1;HSkMC: 106.7
CEP104	CFAP256, GlyBP, JBTS25, KIAA0562, ROC22, RP1-286D6.4	ENSG00000116198	Centrosomal protein 104	1	3812081-3857214	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010126	Approved				Renal cancer:1.70e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.2	Expressed in all		
FAM20B	GXK1, KIAA0475	ENSG00000116199	FAM20B, glycosaminoglycan xylosylkinase	1	179025804-179076562	Predicted intracellular proteins	Evidence at protein level	HPA007409	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
TCEANC2	C1orf83, FLJ32112	ENSG00000116205	Transcription elongation factor A N-terminal and central domain containing 2	1	54053587-54112519	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046918	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			testis: 12.5	Expressed in all		
TMEM59	C1orf8, HSPC001	ENSG00000116209	Transmembrane protein 59	1	54026681-54053504	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			fallopian tube: 650.0	Expressed in all		
LRRC42	MGC8974	ENSG00000116212	Leucine rich repeat containing 42	1	53946077-53968168	Predicted intracellular proteins	Evidence at protein level	HPA047458, HPA050537, HPA064581	Uncertain		Enhanced	Nucleoplasm	Liver cancer:3.88e-5 (unfavourable), Lung cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.1	Expressed in all		
WRAP73	WDR8	ENSG00000116213	WD repeat containing, antisense to TP73	1	3630767-3652761	Predicted intracellular proteins	Evidence at protein level	HPA026893	Uncertain		Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:1.37e-4 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 20.4	Expressed in all		
NPHS2	PDCN, SRN1	ENSG00000116218	NPHS2, podocin	1	179550539-179575952	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037267, HPA049486	Enhanced					Not detected	Tissue enriched	87	kidney: 93.6	testis: 1.0	Cell line enriched	12	NTERA-2: 1.1
MRPL37	MRP-L2, RPML2	ENSG00000116221	Mitochondrial ribosomal protein L37	1	54184041-54225464	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA025767, HPA025826, HPA025951	Enhanced		Supported	Mitochondria	Liver cancer:6.45e-5 (unfavourable), Colorectal cancer:6.99e-4 (favourable), Stomach cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.8	Expressed in all		
ICMT	HSTE14, PCCMT, PPMT	ENSG00000116237	Isoprenylcysteine carboxyl methyltransferase	1	6221193-6235972	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA032024, HPA032025	Uncertain				Liver cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.1	Expressed in all		
RPL22	EAP, L22	ENSG00000116251	Ribosomal protein L22	1	6181269-6209389	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA068294			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 1343.4	Expressed in all		
CHD5		ENSG00000116254	Chromodomain helicase DNA binding protein 5	1	6101793-6180123	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015809, HPA055477	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Tissue enriched	7	cerebral cortex: 42.1	testis: 6.2	Cell line enhanced		SCLC-21H: 16.0;U-2 OS: 6.3
QSOX1	QSCN6	ENSG00000116260	Quiescin sulfhydryl oxidase 1	1	180154834-180204030	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042127, HPA056243	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.86e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 233.0	Expressed in all		
STXBP3	UNC-18C	ENSG00000116266	Syntaxin binding protein 3	1	108746674-108809526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027225	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 65.9	Expressed in all		
PHF13	MGC43399	ENSG00000116273	PHD finger protein 13	1	6613685-6624033	Predicted intracellular proteins	Evidence at protein level	HPA026830	Uncertain				Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.9	Expressed in all		
ERRFI1	GENE-33, MIG-6, RALT	ENSG00000116285	ERBB receptor feedback inhibitor 1	1	8004404-8026308	Predicted intracellular proteins	Evidence at protein level	HPA027206			Supported	Cytosol		Expressed in all	Expressed in all			liver: 369.4	Cell line enhanced		HHSteC: 468.0;LHCN-M2: 368.0
PARK7	DJ-1, DJ1	ENSG00000116288	Parkinsonism associated deglycase	1	7954291-7985505	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004190, CAB005870	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 515.7	Expressed in all		
KIAA1324	EIG121, maba1	ENSG00000116299	KIAA1324	1	109113679-109206781	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029869, HPA070749	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable)	Mixed	Mixed			cervix, uterine: 129.0	Cell line enhanced		MCF7: 21.5;SCLC-21H: 20.3;SK-BR-3: 15.8;T-47d: 68.2;U-87 MG: 13.3
OPRD1		ENSG00000116329	Opioid receptor delta 1	1	28812142-28871267	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA070831	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.6	adrenal gland: 0.8	Group enriched	12	RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7
AMPD2	SPG63	ENSG00000116337	Adenosine monophosphate deaminase 2	1	109616104-109632051	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027137, HPA045760, HPA050590	Approved	Approved	Enhanced	Cytosol	Renal cancer:3.78e-10 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 82.4	Expressed in all		
SRSF4	SFRS4, SRP75	ENSG00000116350	Serine and arginine rich splicing factor 4	1	29147743-29181987	Predicted intracellular proteins	Evidence at protein level	HPA050975	Supported		Supported	Nuclear speckles	Melanoma:3.27e-4 (unfavourable), Prostate cancer:4.26e-4 (unfavourable), Renal cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 78.8	Expressed in all		
MECR	CGI-63, ETR1, FASN2B, NRBF1	ENSG00000116353	Mitochondrial trans-2-enoyl-CoA reductase	1	29192873-29230942	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022018, HPA022030, HPA028740	Enhanced		Supported	Mitochondria	Renal cancer:5.81e-6 (favourable), Urothelial cancer:5.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 18.4	Expressed in all		
KCNC4	C1orf30, HKSHIIIC, Kv3.4	ENSG00000116396	Potassium voltage-gated channel subfamily C member 4	1	110211343-110283100	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA014740			Approved	Nucleoli<br>Cytosol		Mixed	Mixed			parathyroid gland: 13.6	Cell line enhanced		HDLM-2: 17.2;U-87 MG: 15.3
EDEM3	C1orf22	ENSG00000116406	ER degradation enhancing alpha-mannosidase like protein 3	1	184690231-184754913	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025754, HPA025755, HPA027297	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.63e-6 (unfavourable)	Expressed in all	Expressed in all			stomach: 34.4	Expressed in all		
WDR77	MEP50, p44	ENSG00000116455	WD repeat domain 77	1	111439890-111449376	Predicted intracellular proteins	Evidence at protein level	HPA026437, HPA026448, HPA027271	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:2.06e-6 (unfavourable), Ovarian cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 162.6	Expressed in all		
ATP5F1		ENSG00000116459	ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1	1	111448864-111462773	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046067, HPA057347	Enhanced		Supported	Mitochondria	Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 50.4	Expressed in all		
RAP1A	KREV-1, SMGP21	ENSG00000116473	RAP1A, member of RAS oncogene family	1	111542218-111716691	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 203.3	Expressed in all		
HDAC1	GON-10, HD1, RPD3L1	ENSG00000116478	Histone deacetylase 1	1	32292086-32333635	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005017, HPA029693, CAB068191	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 139.0	Expressed in all		
CAPZA1		ENSG00000116489	Capping actin protein of muscle Z-line alpha subunit 1	1	112619173-112671619	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB045963	Approved				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 133.9	Expressed in all		
S100PBP	FLJ12903, S100PBPR	ENSG00000116497	S100P binding protein	1	32816767-32858879	Predicted intracellular proteins	Evidence at protein level	HPA027242, HPA027328	Approved		Supported	Nuclear speckles	Liver cancer:1.26e-6 (unfavourable), Head and neck cancer:5.22e-5 (favourable), Renal cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.5	Expressed in all		
RNF19B	FLJ90005, IBRDC3	ENSG00000116514	Ring finger protein 19B	1	32936445-32964685	Predicted membrane proteins	Evidence at protein level	HPA049587	Approved		Approved	Cytosol	Liver cancer:5.41e-6 (unfavourable), Renal cancer:4.39e-5 (favourable), Head and neck cancer:3.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 155.3	Expressed in all		
SCAMP3	C1orf3	ENSG00000116521	Secretory carrier membrane protein 3	1	155255979-155262430	Predicted membrane proteins	Evidence at protein level	HPA071167			Supported	Vesicles	Liver cancer:2.92e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 46.9	Expressed in all		
TRIM62	DEAR1, FLJ10759	ENSG00000116525	Tripartite motif containing 62	1	33145402-33182059	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050061			Approved	Vesicles<br>Focal adhesion sites	Renal cancer:7.08e-5 (unfavourable)	Expressed in all	Mixed			skin: 11.6	Expressed in all		
ASH1L	ASH1, ASH1L1, huASH1, KMT2H	ENSG00000116539	ASH1 like histone lysine methyltransferase	1	155335268-155562807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004806	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.9	Expressed in all		
DLGAP3	DAP3, SAPAP3	ENSG00000116544	DLG associated protein 3	1	34865436-34929585	Predicted intracellular proteins	Evidence at protein level	HPA026445	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 21.9;testis: 5.7	spleen: 1.1	Cell line enhanced		Daudi: 5.7;NTERA-2: 4.2;SCLC-21H: 14.7
SFPQ	PPP1R140, PSF	ENSG00000116560	Splicing factor proline and glutamine rich	1	35176378-35193148	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009886, HPA047513, HPA054689	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 135.5	Expressed in all		
RHOU	ARHU, CDC42L1, DJ646B12.2, fJ646B12.2, FLJ10616, hG28K, WRCH-1, WRCH1	ENSG00000116574	Ras homolog family member U	1	228735077-228746669	Predicted intracellular proteins	Evidence at protein level	HPA049592	Approved				Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 62.1	Cell line enhanced		BEWO: 172.7;MOLT-4: 67.1;RT4: 62.2
GON4L	FLJ20203, GON-4, GON4, YARP	ENSG00000116580	Gon-4 like	1	155749662-155859400	Predicted intracellular proteins	Evidence at protein level	HPA006986, HPA057305, HPA074504	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:4.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.8	Expressed in all		
ARHGEF2	GEF-H1, KIAA0651, LFP40, P40	ENSG00000116584	Rho/Rac guanine nucleotide exchange factor 2	1	155946851-156007070	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043437	Approved				Renal cancer:7.17e-6 (unfavourable), Liver cancer:9.20e-6 (unfavourable)	Expressed in all	Expressed in all			lung: 95.0	Expressed in all		
LAMTOR2	ENDAP, MAPBPIP, MAPKSP1AP, p14, Ragulator2, ROBLD3	ENSG00000116586	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 2	1	156054752-156058510	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004126	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.10e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.7	Expressed in all		
MEF2D		ENSG00000116604	Myocyte enhancer factor 2D	1	156463727-156500828	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004807, HPA007114	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 55.5	Expressed in all		
DOCK7	KIAA1771, ZIR2	ENSG00000116641	Dedicator of cytokinesis 7	1	62454298-62688368	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.4	Mixed		
SRM	SPS1, SRML1	ENSG00000116649	Spermidine synthase	1	11054584-11060024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015746	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.80e-8 (unfavourable), Liver cancer:2.25e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 73.5	Expressed in all		
FBXO2	Fbg1, Fbs1, FBX2, Nfb42, OCP1	ENSG00000116661	F-box protein 2	1	11648367-11655785	Predicted intracellular proteins	Evidence at protein level	HPA005472			Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.45e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 80.5	adrenal gland: 27.7	Cell line enhanced		CACO-2: 75.6;Hep G2: 131.1;SiHa: 376.0
FBXO6	FBG2, FBS2, FBX6, Fbx6b	ENSG00000116663	F-box protein 6	1	11664124-11674354	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA051175	Approved				Renal cancer:7.83e-6 (unfavourable), Urothelial cancer:5.90e-4 (favourable), Ovarian cancer:7.12e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.4	Mixed		
C1orf21	PIG13	ENSG00000116667	Chromosome 1 open reading frame 21	1	184387058-184629020	Predicted intracellular proteins	Evidence at protein level	HPA026831	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.35e-8 (unfavourable)	Expressed in all	Mixed			skin: 30.1	Cell line enhanced		HDLM-2: 32.8
SWT1	C1orf26, FLJ20121, HsSwt1	ENSG00000116668	SWT1, RNA endoribonuclease homolog	1	185157080-185291765	Predicted intracellular proteins	Evidence at protein level	HPA024214, HPA027334	Enhanced		Approved	Cytosol	Renal cancer:5.63e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 69.4	thyroid gland: 8.7	Mixed		
MAD2L2	MAD2B, POLZ2, REV7	ENSG00000116670	MAD2 mitotic arrest deficient-like 2 (yeast)	1	11674480-11691650	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008110, HPA024176	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 73.6	Expressed in all		
DNAJC6	KIAA0473, PARK19	ENSG00000116675	DnaJ heat shock protein family (Hsp40) member C6	1	65248219-65415869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031182, HPA054917	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.81e-4 (favourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 162.8	adrenal gland: 15.6	Cell line enhanced		HDLM-2: 58.7;HEL: 150.3;K-562: 59.3
LEPR	CD295, OBR	ENSG00000116678	Leptin receptor	1	65420652-65641559	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030899	Approved		Approved	Vesicles		Tissue enriched	Mixed			liver: 67.9	Cell line enhanced		K-562: 102.4;RPTEC TERT1: 39.6
IVNS1ABP	HSPC068, KIAA0850, KLHL39, ND1, NS-1, NS1-BP	ENSG00000116679	Influenza virus NS1A binding protein	1	185296388-185317329	Predicted intracellular proteins	Evidence at protein level	HPA003405	Approved		Supported	Cytosol		Expressed in all	Expressed in all			bone marrow: 299.5	Expressed in all		
KIAA2013	MGC33867, RP5-1077B9.1	ENSG00000116685	KIAA2013	1	11919591-11926428	Predicted membrane proteins	Evidence at protein level	HPA052677, HPA060536	Uncertain		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			small intestine: 68.1	Expressed in all		
MFN2	CMT2A2, CPRP1, KIAA0214, MARF	ENSG00000116688	Mitofusin 2	1	11980181-12013514	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030554	Uncertain				Renal cancer:2.36e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.3	Expressed in all		
PRG4	bG174L6.2, CACP, FLJ32635, HAPO, JCAP, MSF, SZP	ENSG00000116690	Proteoglycan 4	1	186296279-186314562	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA028523	Uncertain					Tissue enriched	Tissue enriched	6	liver: 97.4	lung: 15.4	Cell line enhanced		ASC diff: 195.2;hTEC/SVTERT24-B: 44.2;SiHa: 34.4
MIIP	FLJ12438, IIp45	ENSG00000116691	Migration and invasion inhibitory protein	1	12019466-12032045	Predicted intracellular proteins	Evidence at protein level	HPA044948	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.26e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.4	Cell line enriched	8	HDLM-2: 334.7
SMG7	C1orf16, EST1C, KIAA0250, SGA56M, SMG-7	ENSG00000116698	SMG7, nonsense mediated mRNA decay factor	1	183472216-183598246	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029350	Supported		Supported	Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			testis: 123.1	Expressed in all		
NCF2	NOXA2, p67phox	ENSG00000116701	Neutrophil cytosolic factor 2	1	183555563-183590876	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002327, HPA006040, CAB022160	Enhanced		Enhanced	Nucleoli<br>Cytosol	Liver cancer:7.91e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 127.5	lung: 111.6	Cell line enhanced		A-431: 22.9;hTERT-HME1: 39.8;U-2 OS: 52.5
PDC	MEKA	ENSG00000116703	Phosducin	1	186443566-186461122	Predicted intracellular proteins	Evidence at protein level	HPA062235	Supported					Not detected	Not detected			cerebral cortex,testis: 0.3	Not detected		
SLC35D1	KIAA0260, UGTREL7	ENSG00000116704	Solute carrier family 35 member D1	1	66999332-67054099	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:6.55e-4 (unfavourable), Endometrial cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 38.5	Expressed in all		
PLA2G4A	cPLA2-alpha, PLA2G4	ENSG00000116711	Phospholipase A2 group IVA	1	186828953-186988981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010050, HPA050062, HPA054206	Approved		Supported	Cytosol	Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 200.5	seminal vesicle: 68.3	Cell line enhanced		RPMI-8226: 50.7;U-2197: 61.7
GADD45A	DDIT1, GADD45	ENSG00000116717	Growth arrest and DNA damage inducible alpha	1	67685061-67688338	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA053420			Supported	Nuclear speckles	Renal cancer:8.06e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.1	Expressed in all		
PRAMEF1		ENSG00000116721	PRAME family member 1	1	12791397-12796628	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
PRAMEF12		ENSG00000116726	PRAME family member 12	1	12774841-12777906	Plasma proteins, Predicted intracellular proteins	No evidence	HPA045286, HPA051704	Uncertain		Uncertain	Nucleoplasm		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
WLS	C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls	ENSG00000116729	Wntless Wnt ligand secretion mediator	1	68098473-68233120	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069520	Approved				Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 163.8	Cell line enhanced		AF22: 388.0
PRDM2	HUMHOXY1, KMT8, KMT8A, MTB-ZF, RIZ, RIZ1, RIZ2	ENSG00000116731	PR/SET domain 2	1	13700198-13825079	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005809	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			bone marrow: 51.2	Expressed in all		
RGS2	G0S8	ENSG00000116741	Regulator of G-protein signaling 2	1	192809039-192812283	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013385			Approved	Cytosol	Renal cancer:2.90e-5 (unfavourable), Breast cancer:2.43e-4 (favourable), Stomach cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 749.0	Cell line enhanced		hTCEpi: 101.7;PC-3: 208.8
RPE65	BCO3, LCA2, rd12, RP20	ENSG00000116745	RPE65, retinoid isomerohydrolase	1	68428822-68449959	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2	endometrium: 1.0	Group enriched	27	A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
TROVE2	Ro60, SSA2	ENSG00000116747	TROVE domain family member 2	1	193059422-193091777	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002835, HPA005142	Uncertain		Approved	Nucleoplasm<br>Cytosol	Thyroid cancer:3.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 28.1	Expressed in all		
AMPD1	MAD, MADA	ENSG00000116748	Adenosine monophosphate deaminase 1	1	114673090-114695618	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA026478, HPA028080	Enhanced					Mixed	Tissue enriched	12	skeletal muscle: 193.6	duodenum: 16.5	Cell line enriched	32	U-266/70: 6.6
UCHL5	CGI-70, INO80R, UCH37	ENSG00000116750	Ubiquitin C-terminal hydrolase L5	1	193012250-193060080	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005908, HPA006069, HPA075383	Approved	Approved	Approved	Nucleoplasm<br>Mitochondria	Thyroid cancer:7.10e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
BCAS2	DAM1, Snt309, SPF27	ENSG00000116752	BCAS2, pre-mRNA processing factor	1	114567557-114581639	Predicted intracellular proteins	Evidence at protein level	HPA067881	Enhanced		Supported	Nuclear speckles<br>Centrosome	Liver cancer:8.23e-7 (unfavourable), Prostate cancer:4.27e-4 (unfavourable), Thyroid cancer:5.24e-4 (unfavourable), Renal cancer:6.49e-4 (favourable), Ovarian cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 71.1	Expressed in all		
SRSF11	NET2, p54, SFRS11	ENSG00000116754	Serine and arginine rich splicing factor 11	1	70205682-70253052	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008762	Supported		Supported	Nuclear speckles	Renal cancer:6.53e-6 (unfavourable), Liver cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 96.1	Expressed in all		
CTH		ENSG00000116761	Cystathionine gamma-lyase	1	70411218-70439851	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021591, HPA023300	Enhanced				Liver cancer:8.69e-4 (favourable)	Group enriched	Expressed in all			liver: 73.2	Cell line enhanced		Karpas-707: 52.3;SK-MEL-30: 75.8
AGMAT	FLJ23384	ENSG00000116771	Agmatinase	1	15572353-15585110	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026443, HPA028321	Enhanced				Renal cancer:5.13e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 158.9	liver: 36.6	Cell line enhanced		CACO-2: 35.2;Hep G2: 70.8
OLFML3	HNOEL-iso, OLF44	ENSG00000116774	Olfactomedin like 3	1	113979391-114035572	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027991			Supported	Vesicles	Renal cancer:3.45e-5 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 266.9	Cell line enhanced		ASC diff: 395.8;BJ hTERT+: 302.6;HSkMC: 419.4;LHCN-M2: 496.4
TNNI3K	CARK	ENSG00000116783	TNNI3 interacting kinase	1	74235401-74544428	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	heart muscle: 39.5	testis: 5.3	Not detected		
CFHR3	CFHL3, DOWN16, FHR-3, FHR3, HLF4	ENSG00000116785	Complement factor H related 3	1	196774795-196795406	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:2.86e-5 (favourable)	Tissue enriched	Tissue enriched	244	liver: 314.2	adipose tissue: 1.2	Cell line enhanced		NTERA-2: 2.1;T-47d: 4.2;U-266/70: 6.1
PLEKHM2	KIAA0842	ENSG00000116786	Pleckstrin homology and RUN domain containing M2	1	15684332-15734769	Predicted intracellular proteins	Evidence at protein level	HPA032304	Approved				Liver cancer:1.36e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.0	Expressed in all		
CRYZ		ENSG00000116791	Crystallin zeta	1	74705482-74733408	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021921, HPA023290	Approved		Supported	Cytosol		Expressed in all	Expressed in all			kidney: 345.5	Expressed in all		
PHTF1	PHTF	ENSG00000116793	Putative homeodomain transcription factor 1	1	113696831-113759489	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA059486			Approved	Nucleoli<br>Nuclear bodies	Renal cancer:1.21e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 54.4	parathyroid gland: 19.0	Mixed		
ZBTB17	MIZ1, pHZ-67, ZNF151, ZNF60	ENSG00000116809	Zinc finger and BTB domain containing 17	1	15941869-15976132	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005789	Approved				Liver cancer:2.38e-6 (unfavourable), Renal cancer:3.27e-5 (unfavourable), Urothelial cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.9	Expressed in all		
CD58	LFA3	ENSG00000116815	CD58 molecule	1	116514535-116571039	CD markers, Predicted membrane proteins	Evidence at protein level						Liver cancer:2.32e-6 (unfavourable), Pancreatic cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 42.7	Expressed in all		
TFAP2E	AP2E	ENSG00000116819	Transcription factor AP-2 epsilon	1	35573370-35595328	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		skin: 7.2	lymph node: 2.1	Cell line enhanced		NB-4: 4.5;U-937: 4.6
CD2	SRBC	ENSG00000116824	CD2 molecule	1	116754385-116769228	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002430, HPA003883	Enhanced				Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 131.1	tonsil: 70.8	Group enriched	27	HDLM-2: 201.2;MOLT-4: 129.2
TTF2	HuF2, ZGRF6	ENSG00000116830	Transcription termination factor 2	1	117060303-117107453	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005776, HPA070762	Approved		Supported	Cytosol		Expressed in all	Mixed			lymph node: 8.7	Expressed in all		
NR5A2	B1F2, FTF, FTZ-F1, FTZ-F1beta, hB1F, hB1F-2, LRH-1	ENSG00000116833	Nuclear receptor subfamily 5 group A member 2	1	200027602-200177424	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005455, HPA017067	Supported		Uncertain	Nuclear speckles		Tissue enhanced	Mixed			liver: 19.5	Cell line enhanced		A549: 22.3;HAP1: 15.3;HUVEC TERT2: 17.0
KIF21B	DKFZP434J212, KIAA0449	ENSG00000116852	Kinesin family member 21B	1	200969390-201023700	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027249, HPA027274	Approved					Mixed	Tissue enhanced		cerebral cortex: 28.8	bone marrow: 22.9	Cell line enhanced		HMC-1: 37.2;Karpas-707: 36.3;U-266/70: 69.6;U-266/84: 31.7
TMEM9	TMEM9A	ENSG00000116857	Transmembrane protein 9	1	201134772-201171574	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.93e-4 (unfavourable), Cervical cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 122.7	Expressed in all		
ADPRHL2	ARH3, FLJ20446	ENSG00000116863	ADP-ribosylhydrolase like 2	1	36088875-36093932	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA027104, HPA027141	Approved		Enhanced	Nucleoplasm	Liver cancer:2.10e-7 (unfavourable), Renal cancer:3.71e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 41.1	Expressed in all		
MAP7D1	FLJ10350, FLJ39022, PARCC1, RPRC1	ENSG00000116871	MAP7 domain containing 1	1	36155579-36180849	Predicted intracellular proteins	Evidence at protein level	HPA028075	Approved		Approved	Microtubules<br>Cytosol	Liver cancer:1.49e-6 (unfavourable), Renal cancer:8.56e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.6	Expressed in all		
WARS2	TrpRS	ENSG00000116874	Tryptophanyl tRNA synthetase 2, mitochondrial	1	119031216-119140671	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069692	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:1.45e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.2	Expressed in all		
HAO2	GIG16, HAOX2	ENSG00000116882	Hydroxyacid oxidase 2	1	119368779-119394130	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.92e-4 (favourable)	Group enriched	Group enriched	300	kidney: 317.5;liver: 219.8	adrenal gland,breast: 0.8	Not detected		
OSCP1	C1orf102, NOR1	ENSG00000116885	Organic solute carrier partner 1	1	36415827-36450451	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028436, HPA052655	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:2.18e-6 (favourable), Endometrial cancer:6.88e-4 (favourable)	Expressed in all	Expressed in all			testis: 126.7	Mixed		
MRPS15	FLJ11564	ENSG00000116898	Mitochondrial ribosomal protein S15	1	36455718-36464437	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA028100, HPA028134, HPA067137	Enhanced		Supported	Mitochondria	Renal cancer:3.55e-4 (unfavourable), Liver cancer:3.59e-4 (unfavourable), Ovarian cancer:7.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 242.5	Expressed in all		
EXOC8	EXO84, Exo84p, SEC84	ENSG00000116903	Exocyst complex component 8	1	231332753-231337852	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027438	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
GNPAT	DAP-AT, DAPAT, DHAPAT	ENSG00000116906	Glyceronephosphate O-acyltransferase	1	231241207-231277973	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.29e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 59.7	Expressed in all		
TSNAX	TRAX	ENSG00000116918	Translin associated factor X	1	231528653-231566524	Predicted intracellular proteins	Evidence at protein level	HPA031054, HPA031055, CAB034263	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
C1orf109	FLJ20508	ENSG00000116922	Chromosome 1 open reading frame 109	1	37681570-37692249	Predicted intracellular proteins	Evidence at protein level	HPA027110, HPA027127	Supported		Approved	Nucleus<br>Cytosol	Liver cancer:1.76e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.2	Expressed in all		
RRAGC	FLJ13311, GTR2	ENSG00000116954	Ras related GTP binding C	1	38838198-38859823	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018247, HPA055489	Enhanced		Supported	Nucleus<br>Vesicles	Liver cancer:9.97e-9 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 40.4	Expressed in all		
TBCE	HRD, KCS, KCS1, pac2	ENSG00000116957	Tubulin folding cofactor E	1	235367360-235448968	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026552, HPA026557	Uncertain				Renal cancer:7.87e-13 (unfavourable), Head and neck cancer:7.90e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.3	Expressed in all		
NID1	entactin, NID	ENSG00000116962	Nidogen 1	1	235975830-236065162	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010044	Approved				Renal cancer:5.38e-8 (unfavourable)	Expressed in all	Expressed in all			placenta: 326.5	Cell line enhanced		ASC diff: 1062.5;ASC TERT1: 502.4;HSkMC: 444.4
LGALS8	PCTA-1	ENSG00000116977	Galectin 8	1	236518000-236552981	Predicted intracellular proteins	Evidence at protein level	HPA012734, HPA030491	Approved		Approved	Plasma membrane	Renal cancer:4.93e-7 (unfavourable), Lung cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.6	Mixed		
NT5C1A	CN-I, CN-IA, CN1, CN1A, MGC119199, MGC119201	ENSG00000116981	5'-nucleotidase, cytosolic IA	1	39659121-39672038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050283, HPA054158	Supported					Not detected	Tissue enhanced		heart muscle: 7.5;skeletal muscle: 24.9	cerebral cortex: 4.8	Cell line enriched	20	SH-SY5Y: 18.9
HPCAL4	DKFZp761G122, HLP4	ENSG00000116983	Hippocalcin like 4	1	39678648-39691689	Predicted intracellular proteins	Evidence at protein level	HPA053808			Approved	Cytosol		Group enriched	Tissue enriched	11	cerebral cortex: 145.7	adrenal gland: 13.3	Cell line enhanced		SH-SY5Y: 9.4;SK-MEL-30: 2.2;U-266/84: 2.1
MTR	cblG	ENSG00000116984	5-methyltetrahydrofolate-homocysteine methyltransferase	1	236795281-236903981	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044474, HPA054915	Approved		Supported	Cytosol	Thyroid cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
BMP8B	BMP8, OP-2	ENSG00000116985	Bone morphogenetic protein 8b	1	39757182-39788861	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 33.5	adrenal gland: 7.5	Cell line enhanced		THP-1: 80.8;U-266/84: 37.5;WM-115: 56.0
MYCL	bHLHe38, LMYC, MYCL1	ENSG00000116990	V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog	1	39895426-39902256	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063132			Supported	Nucleus	Lung cancer:4.49e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 41.6	urinary bladder: 23.7	Group enriched	7	U-266/70: 372.1;U-266/84: 268.8
SIPA1L2	KIAA1389	ENSG00000116991	Signal induced proliferation associated 1 like 2	1	232397965-232561558	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024181, HPA027224	Approved		Approved	Nuclear membrane<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:8.15e-4 (unfavourable)	Expressed in all	Mixed			placenta: 29.1	Cell line enhanced		AF22: 74.1;NTERA-2: 60.3;WM-115: 50.8
ZP4	ZPB	ENSG00000116996	Zona pellucida glycoprotein 4	1	237877864-237890922	Predicted membrane proteins	Evidence at protein level	HPA008547	Supported					Not detected	Not detected			tonsil: 0.2	Cell line enhanced		BJ hTERT+: 2.6
RLF	Zn-15L, ZNF292L	ENSG00000117000	Rearranged L-myc fusion	1	40161373-40240921	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054653, HPA057300	Uncertain		Approved	Nucleus	Renal cancer:7.68e-6 (unfavourable), Liver cancer:1.75e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 20.8	Expressed in all		
KMO		ENSG00000117009	Kynurenine 3-monooxygenase	1	241532134-241595642	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031115, HPA056942	Enhanced				Renal cancer:6.49e-8 (unfavourable)	Mixed	Tissue enhanced		kidney: 32.3;liver: 47.7	spleen: 10.8	Cell line enhanced		RPMI-8226: 6.1;RPTEC TERT1: 16.3;SK-BR-3: 8.4;U-698: 6.4
ZNF684	MGC27466	ENSG00000117010	Zinc finger protein 684	1	40531561-40548169	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059153	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:4.89e-10 (favourable)	Expressed in all	Mixed			kidney: 6.8	Cell line enhanced		THP-1: 23.3
KCNQ4	DFNA2, Kv7.4	ENSG00000117013	Potassium voltage-gated channel subfamily Q member 4	1	40784012-40840452	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018305	Uncertain					Mixed	Mixed			smooth muscle: 2.5	Cell line enhanced		HAP1: 1.9;HEK 293: 2.5;K-562: 2.6
RIMS3	NIM3, RIM3	ENSG00000117016	Regulating synaptic membrane exocytosis 3	1	40620679-40665657	Predicted intracellular proteins	Evidence at protein level	HPA055285			Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enriched	7	cerebral cortex: 60.4	adrenal gland: 8.3	Cell line enhanced		Daudi: 55.3;SCLC-21H: 23.5;SH-SY5Y: 37.4;U-87 MG: 31.5
AKT3	PKBG, PRKBG, RAC-gamma	ENSG00000117020	AKT serine/threonine kinase 3	1	243488233-243851079	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013090, HPA026441	Approved		Supported	Cytosol	Urothelial cancer:9.27e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Mixed		
ETV3	PE-1	ENSG00000117036	ETS variant 3	1	157121191-157138474	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004794	Supported		Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 45.4	Expressed in all		
ACADM	ACAD1, MCAD, MCADH	ENSG00000117054	Acyl-CoA dehydrogenase, C-4 to C-12 straight chain	1	75724347-75787575	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006198, HPA026542	Enhanced		Enhanced	Mitochondria	Renal cancer:3.83e-8 (favourable), Colorectal cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			kidney: 328.0	Expressed in all		
ST6GALNAC5	MGC3184, SIAT7E, ST6GalNAcV	ENSG00000117069	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5	1	76867441-77065711	Predicted secreted proteins	Evidence at protein level	HPA065593, HPA070354	Uncertain		Approved	Vesicles		Tissue enhanced	Mixed			lung: 8.8	Cell line enhanced		AF22: 7.6;fHDF/TERT166: 7.3;SH-SY5Y: 7.0;U-2 OS: 7.8
SLAMF1	CD150, SLAM	ENSG00000117090	Signaling lymphocytic activation molecule family member 1	1	160608100-160647295	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002438, HPA069319	Enhanced					Mixed	Tissue enhanced		appendix: 15.4;lymph node: 21.1;tonsil: 14.3	spleen: 7.9	Cell line enriched	134	HDLM-2: 142.1
CD48	BCM1, BLAST, hCD48, mCD48, SLAMF2	ENSG00000117091	CD48 molecule	1	160678746-160711851	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002497, HPA055146	Enhanced		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 311.4;spleen: 213.1;tonsil: 226.0	appendix: 148.5	Cell line enhanced		Daudi: 153.4;HMC-1: 202.6;U-266/70: 372.1;U-266/84: 244.7
ADGRL2	KIAA0786, LEC1, LPHH1, LPHN2	ENSG00000117114	Adhesion G protein-coupled receptor L2	1	81306160-81992436	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA043447			Approved	Plasma membrane<br>Cell Junctions	Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 73.2	Cell line enhanced		AF22: 246.2;hTEC/SVTERT24-B: 124.0;SH-SY5Y: 176.4
PADI2	KIAA0994, PDI2	ENSG00000117115	Peptidyl arginine deiminase 2	1	17066761-17119435	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047735	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 85.0;colon: 89.8;rectum: 99.9;skeletal muscle: 108.6	breast: 48.8	Group enriched	5	A549: 10.4;RPTEC TERT1: 25.1;SK-BR-3: 38.1;T-47d: 13.1
SDHB	SDH, SDH1	ENSG00000117118	Succinate dehydrogenase complex iron sulfur subunit B	1	17018722-17054170	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002868, CAB009822, CAB068233, CAB068234, CAB068235	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Mitochondria	Renal cancer:2.93e-7 (favourable)	Expressed in all	Expressed in all			kidney: 215.2	Expressed in all		
MFAP2	MAGP, MAGP-1	ENSG00000117122	Microfibrillar associated protein 2	1	16974502-16980835	Predicted secreted proteins	Evidence at protein level	HPA007354	Enhanced				Renal cancer:2.52e-8 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 100.7	endometrium: 82.4	Cell line enhanced		HUVEC TERT2: 193.6;SH-SY5Y: 203.2
RPF1	BXDC5	ENSG00000117133	Ribosome production factor 1 homolog	1	84479259-84497790	Predicted intracellular proteins	Evidence at protein level	HPA024642	Supported		Enhanced	Nucleoli	Liver cancer:1.60e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 58.7	Expressed in all		
KDM5B	CT31, JARID1B, PLU-1, PPP1R98, RBBP2H1A	ENSG00000117139	Lysine demethylase 5B	1	202724491-202809470	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027179, HPA053723, CAB068193	Enhanced		Supported	Nucleus		Expressed in all	Tissue enriched	7	testis: 228.1	skin: 30.6	Mixed		
UAP1	AgX, AGX1, SPAG2	ENSG00000117143	UDP-N-acetylglucosamine pyrophosphorylase 1	1	162561506-162599842	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014659	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.12e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 166.1	Expressed in all		
ACTL8	CT57	ENSG00000117148	Actin like 8	1	17755313-17827063	Predicted intracellular proteins	Evidence at protein level	HPA027176			Approved	Cytosol	Endometrial cancer:1.62e-6 (unfavourable), Head and neck cancer:7.02e-4 (unfavourable)	Mixed	Tissue enriched	35	testis: 10.0	colon,rectum: 0.2	Cell line enriched	9	U-266/84: 168.8
CTBS	CTB	ENSG00000117151	Chitobiase	1	84549606-84574480	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017043, HPA023594, HPA048810	Approved		Uncertain	Cytosol		Expressed in all	Mixed			epididymis: 3.8	Mixed		
RGS4	SCZD9	ENSG00000117152	Regulator of G-protein signaling 4	1	163068775-163076802	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030802			Approved	Intermediate filaments	Stomach cancer:1.92e-4 (unfavourable), Renal cancer:3.97e-4 (unfavourable), Glioma:4.33e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 289.2	adrenal gland: 54.0	Cell line enhanced		LHCN-M2: 245.4;SH-SY5Y: 612.2;TIME: 986.1
KLHL12	C3IP1	ENSG00000117153	Kelch like family member 12	1	202891100-202928636	Predicted intracellular proteins	Evidence at protein level	HPA071324			Supported	Vesicles<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
IGSF21	MGC15730, RP11-121A23.1	ENSG00000117154	Immunoglobin superfamily member 21	1	18107746-18378483	Predicted secreted proteins	Evidence at protein level	HPA044535	Approved					Group enriched	Tissue enhanced		cerebral cortex: 28.9;spleen: 13.2	adrenal gland: 5.9	Cell line enriched	6	SCLC-21H: 21.2
SSX2IP	hMsd1	ENSG00000117155	SSX family member 2 interacting protein	1	84643707-84690803	Predicted intracellular proteins	Evidence at protein level	HPA027306, HPA075946	Approved		Approved	Cell Junctions	Colorectal cancer:1.45e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 191.9	cerebral cortex: 45.8	Expressed in all		
ZNHIT6	BCD1, C1orf181, FLJ20729, NY-BR-75	ENSG00000117174	Zinc finger HIT-type containing 6	1	85649423-85708433	Predicted intracellular proteins	Evidence at protein level	HPA018132	Uncertain		Approved	Nuclear speckles<br>Vesicles	Liver cancer:6.08e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine,endometrium: 21.1	Expressed in all		
PLA2G2D	sPLA2S	ENSG00000117215	Phospholipase A2 group IID	1	20111939-20119566	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Cervical cancer:8.15e-5 (favourable), Breast cancer:4.35e-4 (favourable), Endometrial cancer:9.74e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 118.5;tonsil: 54.0	appendix: 20.5	Cell line enriched	6	RPMI-8226: 5.9
RBBP5	RBQ3, SWD1	ENSG00000117222	RB binding protein 5, histone lysine methyltransferase complex subunit	1	205086142-205122015	Predicted intracellular proteins	Evidence at protein level	HPA049042, HPA058085	Uncertain		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 16.4	Expressed in all		
GBP3	FLJ10961	ENSG00000117226	Guanylate binding protein 3	1	89006666-89022894	Predicted intracellular proteins	Evidence at protein level	HPA045657	Approved					Expressed in all	Mixed			duodenum: 77.0	Cell line enhanced		BJ hTERT+: 64.5;LHCN-M2: 58.7
GBP1		ENSG00000117228	Guanylate binding protein 1	1	89052319-89065360	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015450	Approved				Renal cancer:5.12e-9 (unfavourable), Ovarian cancer:5.04e-4 (favourable), Colorectal cancer:8.32e-4 (favourable)	Expressed in all	Expressed in all			appendix: 118.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 109.8;BJ hTERT+ SV40 Large T+ RasG12V: 155.2
KIF17	KIAA1405, KIF17B, KIF3X, KLP-2, OSM-3	ENSG00000117245	Kinesin family member 17	1	20664014-20718017	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032085	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	6	testis: 23.7	cerebral cortex: 3.8	Cell line enhanced		hTERT-HME1: 3.0;U-2 OS: 2.4
GPR89A	UNQ192	ENSG00000117262	G protein-coupled receptor 89A	1	145607990-145670648	Predicted membrane proteins	Evidence at protein level	HPA076096			Approved	Endoplasmic reticulum		Mixed	Mixed			kidney: 21.0	Expressed in all		
CDK18	PCTAIRE3, PCTK3	ENSG00000117266	Cyclin dependent kinase 18	1	205504595-205532793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045429	Approved		Approved	Actin filaments	Renal cancer:5.07e-6 (unfavourable), Urothelial cancer:2.81e-5 (favourable)	Expressed in all	Mixed			heart muscle: 62.0	Cell line enhanced		HBEC3-KT: 25.4
RAB29	RAB7L, RAB7L1	ENSG00000117280	RAB29, member RAS oncogene family	1	205767986-205775460	Predicted intracellular proteins	Evidence at protein level	CAB020822, HPA026303	Approved		Approved	Nuclear membrane<br>Nucleoli	Endometrial cancer:1.82e-5 (unfavourable), Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 76.2	Expressed in all		
CD160	BY55, NK1, NK28	ENSG00000117281	CD160 molecule	1	145719471-145739288	CD markers, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 19.6	small intestine: 5.1	Mixed		
ECE1	ECE	ENSG00000117298	Endothelin converting enzyme 1	1	21217247-21345504	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001490, HPA013616	Approved					Expressed in all	Expressed in all			parathyroid gland: 436.1	Expressed in all		
HMGCL	HL	ENSG00000117305	3-hydroxymethyl-3-methylglutaryl-CoA lyase	1	23801885-23838620	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004727	Enhanced				Renal cancer:5.07e-8 (favourable), Colorectal cancer:7.67e-4 (favourable)	Expressed in all	Expressed in all			liver: 154.3	Expressed in all		
GALE	SDR1E1	ENSG00000117308	UDP-galactose-4-epimerase	1	23795599-23800804	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007340	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Thyroid cancer:2.68e-4 (favourable)	Expressed in all	Expressed in all			stomach: 112.8	Expressed in all		
ID3	bHLHb25, HEIR-1	ENSG00000117318	Inhibitor of DNA binding 3, HLH protein	1	23557918-23559794	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB021353, HPA024677	Approved		Supported	Nucleoplasm	Endometrial cancer:1.27e-5 (favourable)	Expressed in all	Mixed			seminal vesicle: 91.4	Cell line enhanced		U-698: 261.7
CR2	C3DR, CD21	ENSG00000117322	Complement C3d receptor 2	1	207454230-207489895	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002659, HPA052942, HPA060715	Enhanced				Breast cancer:6.90e-4 (favourable)	Mixed	Group enriched	21	appendix: 68.3;lymph node: 206.0;spleen: 100.2;tonsil: 153.8	kidney: 6.2	Cell line enhanced		Daudi: 17.1;MOLT-4: 10.7;RPMI-8226: 3.2
CD46	MCP, MGC26544, MIC10, TLX, TRA2.10	ENSG00000117335	CD46 molecule	1	207752057-207795513	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB010401, HPA016903	Enhanced		Approved	Plasma membrane	Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 489.1	Expressed in all		
PRPF3	hPrp3, Prp3, RP18, SNRNP90	ENSG00000117360	Pre-mRNA processing factor 3	1	150321476-150353195	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027226, HPA067116	Approved		Enhanced	Nucleoplasm	Renal cancer:3.19e-5 (unfavourable), Liver cancer:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 40.6	Expressed in all		
APH1A	APH-1A, CGI-78	ENSG00000117362	Aph-1 homolog A, gamma-secretase subunit	1	150265399-150269580	Predicted membrane proteins	Evidence at protein level	CAB037272	Approved					Expressed in all	Expressed in all			thyroid gland: 161.2	Expressed in all		
P3H1	GROS1, LEPRE1, LEPRECAN, MGC117314	ENSG00000117385	Prolyl 3-hydroxylase 1	1	42746335-42767084	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA012113, HPA016980	Approved		Approved	Nucleoli<br>Vesicles	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.95e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 53.5	smooth muscle: 28.8	Expressed in all		
SLC2A1	CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR	ENSG00000117394	Solute carrier family 2 member 1	1	42925375-42959173	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002759, HPA031345, HPA058494	Enhanced	Supported	Enhanced	Plasma membrane	Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 293.0	skin: 59.3	Expressed in all		
EBNA1BP2	EBP2, NOBP, P40	ENSG00000117395	EBNA1 binding protein 2	1	43164175-43270936	Predicted intracellular proteins	Evidence at protein level	HPA026512, HPA028277	Approved		Enhanced	Nucleoli	Liver cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.8	Expressed in all		
CDC20	CDC20A, p55CDC	ENSG00000117399	Cell division cycle 20	1	43358955-43363203	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004525, HPA045842, HPA055288	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.00e-8 (unfavourable), Pancreatic cancer:1.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 64.0	tonsil: 45.2	Expressed in all		
MPL	CD110, TPOR	ENSG00000117400	MPL proto-oncogene, thrombopoietin receptor	1	43337849-43352772	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			ovary: 1.3	Cell line enriched	97	HEL: 51.8
ARTN	ENOVIN, EVN, NBN	ENSG00000117407	Artemin	1	43933320-43937241	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Ovarian cancer:8.18e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 21.2	seminal vesicle: 12.2	Cell line enhanced		A-431: 60.4;HaCaT: 62.8;HBEC3-KT: 45.5
IPO13	IMP13, KIAA0724, RANBP13	ENSG00000117408	Importin 13	1	43946939-43968022	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB070425	Uncertain				Liver cancer:8.26e-7 (unfavourable), Pancreatic cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
ATP6V0B	ATP6F, HATPL, VMA16	ENSG00000117410	ATPase H+ transporting V0 subunit b	1	43974487-43978295	Predicted membrane proteins	Evidence at transcript level	HPA044281			Approved	Cytosol	Renal cancer:3.62e-6 (favourable), Pancreatic cancer:3.24e-4 (favourable), Liver cancer:4.79e-4 (unfavourable), Urothelial cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 181.4	Expressed in all		
B4GALT2	beta4Gal-T2	ENSG00000117411	Beta-1,4-galactosyltransferase 2	1	43978943-43991170	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007620, HPA047739	Enhanced		Supported	Golgi apparatus<br>Vesicles	Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 49.4	Mixed		
ERI3	FLJ22943, PINT1, PRNPIP	ENSG00000117419	ERI1 exoribonuclease family member 3	1	44221070-44355260	Predicted intracellular proteins	Evidence at protein level	HPA027147, HPA029895	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.04e-6 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 81.0	Expressed in all		
PTCH2		ENSG00000117425	Patched 2	1	44819844-44843063	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:5.74e-5 (favourable)	Tissue enhanced	Tissue enriched	6	parathyroid gland: 203.9	salivary gland: 32.2	Cell line enhanced		U-266/84: 8.0
AKR1A1	ALR, DD3	ENSG00000117448	Aldo-keto reductase family 1 member A1	1	45550543-45570049	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006246, HPA017919, HPA019649, HPA027734	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:2.66e-6 (favourable), Endometrial cancer:2.92e-4 (favourable)	Expressed in all	Expressed in all			kidney: 380.4	Expressed in all		
PRDX1	NKEFA, PAGA	ENSG00000117450	Peroxiredoxin 1	1	45511036-45523047	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004682, HPA007730	Approved		Supported	Mitochondria	Liver cancer:1.17e-5 (unfavourable), Urothelial cancer:2.89e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1209.9	Expressed in all		
PIK3R3	p55	ENSG00000117461	Phosphoinositide-3-kinase regulatory subunit 3	1	46040140-46133036	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA005751, HPA071988	Approved		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:1.93e-4 (favourable), Head and neck cancer:3.62e-4 (favourable)	Expressed in all	Mixed			testis: 46.2	Expressed in all		
TSPAN1	NET-1, TSPAN-1	ENSG00000117472	Tetraspanin 1	1	46175073-46185958	Predicted membrane proteins	Evidence at protein level	HPA011909	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.28e-6 (favourable)	Expressed in all	Tissue enhanced		colon: 525.0;rectum: 651.6	prostate: 311.2	Cell line enhanced		CAPAN-2: 191.2;HaCaT: 134.4;hTCEpi: 125.3;RPTEC TERT1: 474.4;RT4: 246.2
BLZF1	JEM-1	ENSG00000117475	Basic leucine zipper nuclear factor 1	1	169367970-169396540	Predicted intracellular proteins	Evidence at protein level	HPA025703, HPA027331, HPA067113	Supported		Supported	Nucleus<br>Golgi apparatus	Renal cancer:2.33e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.3	Expressed in all		
CCDC181	C1orf114, FLJ25846	ENSG00000117477	Coiled-coil domain containing 181	1	169394870-169460669	Predicted intracellular proteins	Evidence at protein level	HPA027189, HPA027275, HPA027281, HPA027312	Enhanced		Approved	Nuclear speckles		Mixed	Tissue enhanced		parathyroid gland: 22.9;testis: 49.6	fallopian tube: 19.6	Cell line enhanced		NTERA-2: 13.8;SCLC-21H: 9.9;SH-SY5Y: 10.5
SLC19A2	THTR1, TRMA	ENSG00000117479	Solute carrier family 19 member 2	1	169463909-169486003	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006119, HPA016599	Uncertain		Approved	Cytosol	Renal cancer:2.70e-5 (favourable), Glioma:2.11e-4 (favourable), Breast cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
FAAH	FAAH-1	ENSG00000117480	Fatty acid amide hydrolase	1	46394265-46413848	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007425	Approved		Uncertain	Cytosol	Stomach cancer:3.63e-5 (favourable), Renal cancer:4.25e-5 (favourable), Endometrial cancer:1.51e-4 (favourable)	Expressed in all	Expressed in all			prostate: 60.0	Cell line enhanced		BEWO: 34.8;RT4: 31.9
NSUN4	MGC22960, SHTAP	ENSG00000117481	NOP2/Sun RNA methyltransferase family member 4	1	46340177-46365152	Predicted intracellular proteins	Evidence at protein level	HPA028489	Approved				Liver cancer:1.97e-5 (unfavourable)	Expressed in all	Tissue enriched	14	testis: 98.9	adrenal gland: 7.2	Expressed in all		
TMED5	CGI-100, p24g2, p24gamma2	ENSG00000117500	Transmembrane p24 trafficking protein 5	1	93149742-93180728	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050289	Approved					Expressed in all	Expressed in all			kidney: 28.2	Expressed in all		
MROH9	ARMC11, C1orf129, FLJ23550	ENSG00000117501	Maestro heat like repeat family member 9	1	170935471-171064765	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	fallopian tube: 3.9;lung: 1.2;testis: 2.7	endometrium: 0.3	Not detected		
DR1	NC2-BETA, NC2B	ENSG00000117505	Down-regulator of transcription 1	1	93345888-93369498	Predicted intracellular proteins	Evidence at protein level	HPA050785, HPA055308	Enhanced		Supported	Nucleus	Liver cancer:9.95e-7 (unfavourable), Colorectal cancer:4.79e-4 (favourable), Renal cancer:7.23e-4 (unfavourable), Pancreatic cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
CNN3		ENSG00000117519	Calponin 3	1	94896949-94927278	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009849, HPA051237	Enhanced		Enhanced	Actin filaments<br>Cytosol	Urothelial cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 345.6	Mixed		
PRRC2C	BAT2D1, BAT2L2, KIAA1096, XTP2	ENSG00000117523	Proline rich coiled-coil 2C	1	171485551-171593511	Predicted intracellular proteins	Evidence at protein level	HPA025766, HPA028659	Approved		Enhanced	Cytosol	Renal cancer:7.76e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.3	Expressed in all		
F3	CD142, TF	ENSG00000117525	Coagulation factor III, tissue factor	1	94529225-94541800	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009438, HPA049292, HPA069132	Approved		Enhanced	Vesicles	Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 191.1	Cell line enhanced		A-431: 929.2;HaCaT: 433.2;HBEC3-KT: 914.1;U-2197: 442.4
ABCD3	PMP70, PXMP1, ZWS2	ENSG00000117528	ATP binding cassette subfamily D member 3	1	94418455-94518666	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032026, HPA032027, CAB032516, CAB075749	Enhanced		Enhanced	Peroxisomes	Colorectal cancer:1.16e-5 (favourable), Renal cancer:4.84e-5 (favourable)	Expressed in all	Expressed in all			liver: 66.4	Expressed in all		
VAMP4		ENSG00000117533	Vesicle associated membrane protein 4	1	171700160-171742247	Predicted membrane proteins	Evidence at protein level	HPA050418	Enhanced		Approved	Golgi apparatus	Renal cancer:5.43e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
DPH5	CGI-30	ENSG00000117543	Diphthamide biosynthesis 5	1	100989623-101026088	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046439, HPA076234	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			ovary: 52.1	Expressed in all		
FASLG	APT1LG1, CD178, FasL, TNFSF6	ENSG00000117560	Fas ligand	1	172659018-172666874	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA054959	Approved				Renal cancer:1.59e-6 (unfavourable)	Mixed	Tissue enhanced		lymph node: 5.8	spleen: 5.1	Not detected		
PTBP2	brPTB, nPTB, PTB, PTBLP	ENSG00000117569	Polypyrimidine tract binding protein 2	1	96721665-96823738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047420	Uncertain		Approved	Nucleoplasm	Endometrial cancer:7.80e-4 (unfavourable)	Expressed in all	Mixed			testis: 47.6	Expressed in all		
TNFSF4	CD252, gp34, OX-40L, TXGP1	ENSG00000117586	Tumor necrosis factor superfamily member 4	1	173183734-173207313	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059579	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Tissue enhanced		testis: 7.5	appendix: 3.1	Cell line enhanced		fHDF/TERT166: 32.7;HUVEC TERT2: 68.0;LHCN-M2: 56.4
PRDX6	1-Cys, aiPLA2, AOP2, KIAA0106, MGC46173, NSGPx, p29, PRX	ENSG00000117592	Peroxiredoxin 6	1	173477266-173488807	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006983, CAB008663	Supported		Supported	Plasma membrane<br>Cytosol	Head and neck cancer:1.23e-5 (unfavourable), Renal cancer:9.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 370.1	Expressed in all		
DARS2	FLJ10514	ENSG00000117593	Aspartyl-tRNA synthetase 2, mitochondrial	1	173824503-173858546	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026506, HPA026528	Enhanced		Supported	Nucleus<br>Mitochondria	Renal cancer:1.74e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
HSD11B1	HSD11, HSD11B, SDR26C1	ENSG00000117594	Hydroxysteroid 11-beta dehydrogenase 1	1	209686178-209734950	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047729	Enhanced				Renal cancer:1.97e-10 (unfavourable)	Tissue enriched	Group enriched	9	liver: 492.5;placenta: 105.1	ovary: 31.6	Group enriched	6	ASC diff: 678.2;HHSteC: 173.0
IRF6	LPS, OFC6, VWS, VWS1	ENSG00000117595	Interferon regulatory factor 6	1	209785623-209806175	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063121, HPA076162	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			skin: 84.0	Cell line enhanced		HaCaT: 216.2;HBEC3-KT: 62.1;hTCEpi: 129.2;hTERT-HME1: 67.4;RT4: 69.8
DIEXF	C1orf107, DEF, MGC29875, UTP25	ENSG00000117597	Digestive organ expansion factor homolog (zebrafish)	1	209828007-209857565	Predicted intracellular proteins	Evidence at protein level	HPA026640, HPA061682	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			ovary: 8.8	Expressed in all		
PLPPR5	LPPR5, PAP2, PAP2D, PRG5	ENSG00000117598	Phospholipid phosphatase related 5	1	98890245-99005032	Predicted membrane proteins	Evidence at transcript level	HPA018072, HPA059085	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:6.22e-4 (unfavourable)	Group enriched	Group enriched	11	cerebral cortex: 12.0;testis: 4.0	adrenal gland: 0.7	Group enriched	7	PC-3: 12.4;SH-SY5Y: 25.0
PLPPR4	KIAA0455, LPPR4, PHP1, PRG-1	ENSG00000117600	Phospholipid phosphatase related 4	1	99263953-99309590	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 88.6	testis: 9.0	Cell line enhanced		BJ hTERT+: 21.8;BJ hTERT+ SV40 Large T+ RasG12V: 10.0;SH-SY5Y: 21.1;U-138 MG: 9.8;U-87 MG: 16.4
SERPINC1	AT3, ATIII, MGC22579	ENSG00000117601	Serpin family C member 1	1	173903804-173917378	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001816, CAB016790, HPA024007	Supported				Liver cancer:3.40e-5 (favourable)	Tissue enriched	Tissue enriched	670	liver: 2517.8	kidney: 3.7	Cell line enriched	26	Hep G2: 55.1
RCAN3	DSCR1L2	ENSG00000117602	RCAN family member 3	1	24502351-24541040	Predicted intracellular proteins	Evidence at protein level	HPA034533, HPA064289	Enhanced		Approved	Nucleoli fibrillar center<br>Nuclear speckles		Expressed in all	Tissue enhanced		prostate: 54.8	lymph node: 22.9	Mixed		
SYF2	CBPIN, DKFZp564O2082, fSAP29, NTC31, p29	ENSG00000117614	SYF2 pre-mRNA splicing factor	1	25222679-25232502	Predicted intracellular proteins	Evidence at protein level	HPA018265, HPA070710	Approved		Supported	Nuclear speckles	Urothelial cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			ovary: 135.9	Expressed in all		
RSRP1	C1orf63, DJ465N24.2.1	ENSG00000117616	Arginine and serine rich protein 1	1	25242237-25338213	Predicted intracellular proteins	Evidence at protein level	HPA058992, HPA067651	Uncertain		Approved	Nucleoplasm	Urothelial cancer:2.91e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 34.2	Mixed		
SLC35A3		ENSG00000117620	Solute carrier family 35 member A3	1	99969351-100035637	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015253	Uncertain					Expressed in all	Expressed in all			rectum: 58.7	Expressed in all		
RCOR3	FLJ10876	ENSG00000117625	REST corepressor 3	1	211258377-211316385	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007413, HPA071997	Enhanced		Approved	Nucleus<br>Nucleoli	Glioma:1.92e-5 (favourable), Lung cancer:5.75e-5 (favourable)	Expressed in all	Expressed in all			testis: 66.3	Expressed in all		
STMN1	C1orf215, FLJ32206, Lag, LAP18, OP18, PP17, PP19, PR22, SMN	ENSG00000117632	Stathmin 1	1	25884181-25906991	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010107	Approved		Supported	Cytosol	Liver cancer:9.90e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1039.4	Expressed in all		
MTFR1L	FAM54B	ENSG00000117640	Mitochondrial fission regulator 1 like	1	25818640-25832942	Predicted intracellular proteins	Evidence at protein level	HPA027124, HPA027130	Approved		Approved	Cell Junctions<br>Mitochondria	Renal cancer:5.89e-12 (favourable), Endometrial cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 150.7	Expressed in all		
MAN1C1	HMIC	ENSG00000117643	Mannosidase alpha class 1C member 1	1	25617468-25786207	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048352	Uncertain		Uncertain	Nucleus<br>Vesicles	Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 40.7	Cell line enhanced		AF22: 28.0;HSkMC: 74.2
NEK2	NEK2A, NLK1, PPP1R111, RP67	ENSG00000117650	NIMA related kinase 2	1	211658657-211675630	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017530, HPA064967	Enhanced		Supported	Nucleus<br>Centrosome	Liver cancer:9.47e-6 (unfavourable), Lung cancer:9.11e-4 (unfavourable)	Mixed	Tissue enriched	11	testis: 121.2	bone marrow: 11.2	Mixed		
RPS6KA1	HU-1, p90Rsk, RSK, RSK1	ENSG00000117676	Ribosomal protein S6 kinase A1	1	26529761-26575030	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003852, HPA007981	Enhanced		Supported	Nucleus<br>Cytosol	Endometrial cancer:7.20e-7 (favourable), Renal cancer:1.84e-4 (favourable), Stomach cancer:4.58e-4 (favourable), Urothelial cancer:8.33e-4 (favourable)	Expressed in all	Mixed			small intestine: 38.9	Mixed		
DHDDS	DS, FLJ13102, HDS, RP59	ENSG00000117682	Dehydrodolichyl diphosphate synthase subunit	1	26432282-26471294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026721, HPA026727	Uncertain		Uncertain	Plasma membrane	Renal cancer:4.08e-7 (favourable)	Expressed in all	Expressed in all			adipose tissue: 54.5	Expressed in all		
NENF	CIR2, SCIRP10, SPUF	ENSG00000117691	Neudesin neurotrophic factor	1	212432887-212446379	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA026763, HPA028488	Uncertain		Enhanced	Nucleus	Renal cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 82.9	Expressed in all		
NSL1	C1orf48, DC8, DKFZP566O1646, MIS14	ENSG00000117697	NSL1, MIS12 kinetochore complex component	1	212726153-212791782	Predicted intracellular proteins	Evidence at protein level	HPA045761, HPA053721	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles		Expressed in all	Expressed in all			cerebral cortex: 35.6	Expressed in all		
PROX1		ENSG00000117707	Prospero homeobox 1	1	213983181-214041502	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000842, HPA001030			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		liver: 45.3	adrenal gland: 13.3	Cell line enhanced		Hep G2: 21.7;RH-30: 15.7;SH-SY5Y: 83.1
ARID1A	B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1	ENSG00000117713	AT-rich interaction domain 1A	1	26693236-26782104	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005456, CAB016334	Supported		Enhanced	Nucleoplasm	Liver cancer:4.18e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
CENPF	hcp-1	ENSG00000117724	Centromere protein F	1	214603195-214664588	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052382, HPA064308, CAB070134	Enhanced		Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.29e-5 (unfavourable), Pancreatic cancer:1.39e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 17.7;testis: 18.8	lymph node: 10.1	Mixed		
RPA2		ENSG00000117748	Replication protein A2	1	27891524-27914746	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016538, HPA026306, HPA026309	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Cervical cancer:4.33e-4 (favourable), Head and neck cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			testis: 103.7	Expressed in all		
PPP1R8	ard-1, ARD1, NIPP-1, NIPP1, PRO2047	ENSG00000117751	Protein phosphatase 1 regulatory subunit 8	1	27830778-27851676	Predicted intracellular proteins	Evidence at protein level	HPA027406, HPA027417, HPA027452	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:2.19e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 46.5	Expressed in all		
STX12	STX13, STX14	ENSG00000117758	Syntaxin 12	1	27773183-27824452	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041038, HPA055300	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 156.0	Expressed in all		
MARC2	FLJ20605, MOSC2	ENSG00000117791	Mitochondrial amidoxime reducing component 2	1	220748225-220784815	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015085, HPA017572	Enhanced				Liver cancer:1.40e-10 (favourable), Renal cancer:3.09e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 338.5	kidney: 139.5	Cell line enhanced		T-47d: 33.9
SLC5A9	SGLT4	ENSG00000117834	Solute carrier family 5 member 9	1	48222685-48248644	Predicted membrane proteins, Transporters	Evidence at protein level	HPA050263			Approved	Actin filaments<br>Cytosol	Renal cancer:1.84e-5 (unfavourable)	Tissue enhanced	Group enriched	9	duodenum: 42.6;small intestine: 45.5	lung: 4.6	Cell line enriched	7	Hep G2: 10.2
OSBPL9		ENSG00000117859	Oxysterol binding protein like 9	1	51577179-51798427	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027378, HPA027397	Supported	Approved	Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 96.6	Expressed in all		
TXNDC12	AGR1, ERP18, ERP19, hAG-1, PDIA16, TLP19	ENSG00000117862	Thioredoxin domain containing 12	1	52020131-52056171	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.40e-12 (unfavourable), Liver cancer:1.28e-5 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable), Colorectal cancer:4.44e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 49.8	Expressed in all		
ESYT2	CHR2SYT, FAM62B, KIAA1228	ENSG00000117868	Extended synaptotagmin 2	7	158730995-158830253	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002132	Approved		Uncertain	Cytosol	Urothelial cancer:2.81e-5 (unfavourable), Pancreatic cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 80.2	Expressed in all		
CD3EAP	ASE-1, CAST, PAF49	ENSG00000117877	CD3e molecule associated protein	19	45406209-45410766	Predicted intracellular proteins	Evidence at protein level	HPA041664, HPA041734	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Liver cancer:4.79e-9 (unfavourable)	Expressed in all	Mixed			appendix,cerebral cortex: 5.4	Expressed in all		
MESDC2	BOCA, KIAA0081, MESD	ENSG00000117899	Mesoderm development candidate 2	15	80946289-80989878	Predicted secreted proteins	Evidence at protein level	HPA039414, HPA041721	Approved		Supported	Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Ovarian cancer:1.12e-4 (favourable), Endometrial cancer:2.31e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 55.7	Expressed in all		
RCN2	E6BP, ERC-55, ERC55, TCBP49	ENSG00000117906	Reticulocalbin 2	15	76931619-76954392	Predicted secreted proteins	Evidence at protein level	HPA030694, HPA030695	Enhanced	Supported	Enhanced	Endoplasmic reticulum	Liver cancer:7.36e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 391.5	Expressed in all		
CHRNB4		ENSG00000117971	Cholinergic receptor nicotinic beta 4 subunit	15	78624119-78727754	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 3.2;testis: 5.3	appendix: 0.8	Group enriched	23	SCLC-21H: 34.9;SH-SY5Y: 40.9
MUC5B	MG1, MUC5	ENSG00000117983	Mucin 5B, oligomeric mucus/gel-forming	11	1223066-1262172	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008246, CAB009396	Enhanced		Supported	Vesicles		Mixed	Group enriched	11	cervix, uterine: 350.5;gallbladder: 344.7	colon: 31.8	Cell line enriched	7	PC-3: 111.2
CTSD	CLN10, CPSD	ENSG00000117984	Cathepsin D	11	1752752-1764573	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000109, HPA003001	Enhanced				Renal cancer:4.93e-5 (favourable), Colorectal cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 1026.9	Expressed in all		
COLEC11	CL-K1, MGC3279	ENSG00000118004	Collectin subfamily member 11	2	3594832-3644644	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035241	Approved					Tissue enhanced	Tissue enhanced		gallbladder: 102.0	adrenal gland: 36.2	Group enriched	8	HHSteC: 135.6;SH-SY5Y: 158.1
STAG1	SA-1, SA1, SCC3A	ENSG00000118007	Stromal antigen 1	3	136336233-136752403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035015, HPA058653	Supported		Enhanced	Nucleus<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 31.9	Expressed in all		
A4GNT	alpha4GnT	ENSG00000118017	Alpha-1,4-N-acetylglucosaminyltransferase	3	138123718-138132387	Predicted secreted proteins	Evidence at protein level	HPA008017	Enhanced					Group enriched	Tissue enriched	8	stomach: 24.5	gallbladder: 3.2	Not detected		
STK11	LKB1, PJS	ENSG00000118046	Serine/threonine kinase 11	19	1177558-1228435	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016231, HPA017254, CAB022105, HPA067481	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.1	Mixed		
KMT2A	ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1	ENSG00000118058	Lysine methyltransferase 2A	11	118436490-118526832	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017794, CAB024270, HPA044910	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
TREH	MGC129621, TRE, TREA	ENSG00000118094	Trehalase	11	118657316-118679690	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA039913, HPA042045	Enhanced				Renal cancer:2.33e-6 (favourable), Liver cancer:3.76e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 60.6;small intestine: 72.6	kidney: 13.5	Cell line enhanced		BEWO: 1.5
IFT46	C11orf2, C11orf60, CFAP32, FLJ21827	ENSG00000118096	Intraflagellar transport 46	11	118544528-118572970	Predicted intracellular proteins	Evidence at protein level	HPA037909, HPA057550	Approved		Approved	Actin filaments		Expressed in all	Expressed in all			fallopian tube: 97.3	Expressed in all		
MMP8	CLG1	ENSG00000118113	Matrix metallopeptidase 8	11	102711795-102727050	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021221, HPA022935	Enhanced					Tissue enriched	Tissue enriched	103	bone marrow: 335.8	endometrium: 3.2	Cell line enriched	10	WM-115: 69.6
APOA1		ENSG00000118137	Apolipoprotein A1	11	116835751-116837950	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016778, HPA046715	Supported		Approved	Vesicles<br>Cytosol	Renal cancer:1.67e-8 (unfavourable), Liver cancer:5.05e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 8458.6;small intestine: 4128.6	duodenum: 1609.4	Cell line enriched	15	Hep G2: 1951.8
ZNF541	DKFZp434I1930	ENSG00000118156	Zinc finger protein 541	19	47520685-47555856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058541, HPA076453	Enhanced		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:2.94e-4 (favourable)	Tissue enhanced	Tissue enriched	11	testis: 19.2	ovary: 1.7	Group enriched	6	HEL: 1.4;SiHa: 5.3;U-87 MG: 1.6
SLC8A2	KIAA1087, NCX2	ENSG00000118160	Solute carrier family 8 member A2	19	47428017-47472168	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050818, HPA054671	Enhanced					Mixed	Tissue enriched	11	cerebral cortex: 68.2	endometrium: 6.3	Group enriched	8	NTERA-2: 3.2;SCLC-21H: 10.8;SH-SY5Y: 5.2;SiHa: 4.1;U-2 OS: 6.2
KPTN	2E4	ENSG00000118162	Kaptin, actin binding protein	19	47475144-47484268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041710, HPA041796	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:7.91e-6 (unfavourable), Renal cancer:7.82e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.9	Expressed in all		
RPS25	S25	ENSG00000118181	Ribosomal protein S25	11	119015712-119018691	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA031801	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.00e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 945.5	Expressed in all		
KIF14	KIAA0042	ENSG00000118193	Kinesin family member 14	1	200551497-200620734	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038061, HPA058220	Uncertain		Supported	Midbody ring<br>Cytosol	Lung cancer:8.64e-4 (unfavourable)	Mixed	Mixed			testis: 4.6	Mixed		
TNNT2	CMD1D, CMH2, CMPD2	ENSG00000118194	Troponin T2, cardiac type	1	201359008-201377762	Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015371, HPA015774, HPA017888	Enhanced		Uncertain	Nucleus<br>Nucleoli<br>Focal adhesion sites		Mixed	Tissue enriched	203	heart muscle: 5120.1	skin: 25.2	Cell line enriched	30	RH-30: 1495.9
DDX59	DKFZP564B1023, ZNHIT5	ENSG00000118197	DEAD-box helicase 59	1	200623896-200669969	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047166	Approved		Approved	Nucleus<br>Actin filaments	Renal cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 33.4	Expressed in all		
CAMSAP2	CAMSAP1L1, KIAA1078	ENSG00000118200	Calmodulin regulated spectrin associated protein family member 2	1	200739558-200860704	Predicted intracellular proteins	Evidence at protein level	HPA026304, HPA026511, HPA027302	Enhanced		Supported	Microtubule ends<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 64.5	Cell line enhanced		hTERT-HME1: 124.5
ATF6	ATF6A	ENSG00000118217	Activating transcription factor 6	1	161766294-161964070	Disease related genes, Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA005935	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 41.3	Expressed in all		
CRYGD	CRYG4	ENSG00000118231	Crystallin gamma D	2	208121607-208124501	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041269			Approved	Plasma membrane<br>Intermediate filaments<br>Cytokinetic bridge		Tissue enhanced	Tissue enriched	13	ovary: 21.6	bone marrow: 1.6	Cell line enriched	17	HEL: 19.0
MREG	DSU, FLJ10116, WDT2	ENSG00000118242	Melanoregulin	2	215942805-216034096	Predicted intracellular proteins	Evidence at protein level	HPA068583			Approved	Vesicles	Thyroid cancer:4.20e-4 (favourable)	Expressed in all	Mixed			esophagus: 29.4	Cell line enhanced		MCF7: 74.2
TNP1		ENSG00000118245	Transition protein 1	2	216859458-216860064	Predicted intracellular proteins	Evidence at protein level	HPA044387	Enhanced					Group enriched	Tissue enriched	2184	testis: 4403.1	thyroid gland: 2.0	Cell line enhanced		Hep G2: 1.7;U-2197: 1.0
FASTKD2	KIAA0971	ENSG00000118246	FAST kinase domains 2	2	206765357-206792509	Predicted intracellular proteins	Evidence at protein level	HPA067191			Supported	Mitochondria	Liver cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.2	Expressed in all		
NRP2	VEGF165R2	ENSG00000118257	Neuropilin 2	2	205681990-205798133	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039980, HPA054974	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 84.4	Cell line enhanced		CAPAN-2: 119.6;U-251 MG: 195.9
CREB1		ENSG00000118260	CAMP responsive element binding protein 1	2	207529737-207603431	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003803, HPA019150	Supported		Enhanced	Nucleoplasm	Liver cancer:2.77e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
KLF7	UKLF	ENSG00000118263	Kruppel like factor 7	2	207074137-207167267	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030490	Approved		Approved	Golgi apparatus	Renal cancer:4.26e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 30.5	Mixed		
TTR	CTS, CTS1, HsT2651, PALB	ENSG00000118271	Transthyretin	18	31591726-31599021	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002517, HPA002550, CAB062567, CAB073406	Supported		Approved	Golgi apparatus		Group enriched	Tissue enriched	27	liver: 6343.2	pancreas: 235.0	Group enriched	7	CACO-2: 68.3;EFO-21: 26.5;Hep G2: 87.1;U-2 OS: 38.2
B4GALT6	beta4GalT-VI	ENSG00000118276	Beta-1,4-galactosyltransferase 6	18	31622247-31685836	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020701, HPA058284	Approved				Renal cancer:6.40e-5 (favourable), Pancreatic cancer:5.65e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Cell line enhanced		WM-115: 124.6
C1orf54	FLJ23221	ENSG00000118292	Chromosome 1 open reading frame 54	1	150268200-150280916	Predicted secreted proteins	Evidence at transcript level	HPA026518, HPA043874	Approved		Approved	Plasma membrane	Renal cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 76.0	Cell line enhanced		AF22: 61.4;AN3-CA: 87.4;ASC TERT1: 75.6;HSkMC: 63.9;HUVEC TERT2: 73.1
CA14		ENSG00000118298	Carbonic anhydrase 14	1	150257159-150265078	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008482	Approved		Approved	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 10.6;seminal vesicle: 21.2	skeletal muscle: 9.4	Group enriched	23	AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CASC1	FLJ10921, LAS1, PPP1R54	ENSG00000118307	Cancer susceptibility 1	12	25108420-25195162	Predicted intracellular proteins	Evidence at protein level	HPA039662	Enhanced				Renal cancer:3.13e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 22.5;testis: 41.8	thyroid gland: 7.0	Mixed		
LRMP	JAW1	ENSG00000118308	Lymphoid restricted membrane protein	12	25004342-25108334	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002967, HPA018505	Enhanced		Supported	Nucleus<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lymph node: 207.1;tonsil: 185.6	appendix: 63.4	Group enriched	7	Daudi: 453.9;REH: 202.5;U-698: 497.6
ATP10B	ATPVB, FLJ21477, KIAA0715	ENSG00000118322	ATPase phospholipid transporting 10B (putative)	5	160563120-160852214	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034574	Uncertain					Group enriched	Tissue enhanced		colon: 36.0;rectum: 40.3	gallbladder: 21.4	Cell line enriched	23	WM-115: 13.6
SPCS2	KIAA0102	ENSG00000118363	Signal peptidase complex subunit 2	11	74949247-74979031	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013386	Approved		Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 269.1	Expressed in all		
USP35	KIAA1372	ENSG00000118369	Ubiquitin specific peptidase 35	11	78188812-78214711	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055213, HPA058592	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Tissue enhanced		parathyroid gland: 34.3	adrenal gland: 14.8	Expressed in all		
ELOVL4	CT118, SCA34, STGD2, STGD3	ENSG00000118402	ELOVL fatty acid elongase 4	6	79914812-79947580	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:6.27e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 24.0;skin: 50.7	parathyroid gland: 15.7	Cell line enhanced		MOLT-4: 25.9
FILIP1	FILIP, KIAA1275	ENSG00000118407	Filamin A interacting protein 1	6	75291859-75493738	Predicted intracellular proteins	Evidence at protein level	HPA053564	Enhanced		Uncertain	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		heart muscle: 35.3	smooth muscle: 19.5	Cell line enhanced		EFO-21: 6.6;U-266/70: 5.3
CASP8AP2	CED-4, FLASH, FLJ11208, KIAA1315, RIP25	ENSG00000118412	Caspase 8 associated protein 2	6	89829894-89874436	Predicted intracellular proteins	Evidence at protein level	HPA053573			Approved	Nucleoli<br>Nuclear bodies	Renal cancer:1.88e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 6.4	Expressed in all		
HMGN3	TRIP7	ENSG00000118418	High mobility group nucleosomal binding domain 3	6	79201245-79234738	Predicted intracellular proteins	Evidence at protein level	CAB018370, HPA027971, HPA063572	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.02e-7 (unfavourable), Lung cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 335.7	Mixed		
UBE3D	C6orf157, DKFZp434A1520, H10BH, UBE2CBP, YJR141W	ENSG00000118420	Ubiquitin protein ligase E3D	6	82892398-83065841	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027231	Uncertain		Approved	Rods & Rings		Mixed	Mixed			fallopian tube: 6.3	Expressed in all		
CNR1	CANN6, CB-R, CB1, CB1A, CB1K5, CNR	ENSG00000118432	Cannabinoid receptor 1	6	88139864-88166359	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 32.1	adipose tissue: 12.2	Group enriched	7	ASC diff: 55.8;HSkMC: 39.1
SPACA1	SAMP32	ENSG00000118434	Sperm acrosome associated 1	6	88047789-88066832	Predicted membrane proteins	Evidence at protein level	HPA026744, HPA043297	Enhanced					Not detected	Tissue enriched	512	testis: 51.2	all non-specific tissues: 0.0	Not detected		
ANKRD13C	dJ677H15.3, DKFZP566D1346	ENSG00000118454	Ankyrin repeat domain 13C	1	70260588-70354734	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 19.1	Expressed in all		
SGIP1	DKFZp761D221	ENSG00000118473	SH3 domain GRB2 like endophilin interacting protein 1	1	66533383-66748299	Predicted intracellular proteins	Evidence at protein level	HPA017963	Approved		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 36.2	endometrium: 16.9	Cell line enhanced		BJ: 24.8;BJ hTERT+: 30.5;fHDF/TERT166: 18.7;RPTEC TERT1: 20.7;SH-SY5Y: 15.7;U-138 MG: 26.6
PHF3		ENSG00000118482	PHD finger protein 3	6	63635820-63779336	Predicted intracellular proteins	Evidence at protein level	HPA024676, HPA025763	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 48.5	Expressed in all		
ZC2HC1B	C6orf94, dJ468K18.5, FAM164B	ENSG00000118491	Zinc finger C2HC-type containing 1B	6	143864436-143938356	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	74	testis: 23.4	skin: 0.3	Not detected		
ADGB	C6orf103, CAPN16, dJ408K24.1, FLJ23121	ENSG00000118492	Androglobin	6	146598965-146815462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036340, HPA036341	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Group enriched	25	fallopian tube: 14.9;testis: 58.5	lung: 1.4	Cell line enriched	25	HDLM-2: 13.3
PLAGL1	LOT1, ZAC	ENSG00000118495	PLAG1 like zinc finger 1	6	143940300-144064599	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055706			Supported	Nuclear bodies<br>Golgi apparatus<br>Vesicles	Renal cancer:4.94e-6 (unfavourable), Stomach cancer:6.61e-4 (unfavourable)	Mixed	Tissue enriched	5	placenta: 365.4	skin: 72.8	Cell line enhanced		AF22: 105.6;RH-30: 105.2
FBXO30	Fbx30, MGC21674	ENSG00000118496	F-box protein 30	6	145793502-145814753	Predicted intracellular proteins	Evidence at protein level	HPA012583			Approved	Microtubules		Expressed in all	Mixed			thyroid gland: 13.5	Expressed in all		
TNFAIP3	A20, OTUD7C	ENSG00000118503	TNF alpha induced protein 3	6	137867188-137883312	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002116, HPA067479	Approved		Supported	Vesicles	Renal cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 345.2	Cell line enhanced		Karpas-707: 118.8;REH: 135.9
AKAP7	AKAP15, AKAP18	ENSG00000118507	A-kinase anchoring protein 7	6	131135666-131283535	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027172, HPA028327	Approved				Urothelial cancer:2.56e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 72.6	Cell line enhanced		NTERA-2: 27.0
RAB32		ENSG00000118508	RAB32, member RAS oncogene family	6	146543693-146554965	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025731	Approved		Approved	Cytosol	Liver cancer:1.08e-7 (unfavourable), Colorectal cancer:1.56e-4 (favourable), Endometrial cancer:6.51e-4 (unfavourable), Renal cancer:8.62e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 91.9	Mixed		
MYB	c-myb	ENSG00000118513	MYB proto-oncogene, transcription factor	6	135181315-135219173	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017704	Approved		Approved	Nucleus<br>Plasma membrane	Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 26.3;rectum: 29.1	colon: 25.2	Cell line enhanced		HL-60: 173.9;MOLT-4: 321.7;REH: 222.8;THP-1: 230.7;U-937: 145.8
ALDH8A1	ALDH12	ENSG00000118514	Aldehyde dehydrogenase 8 family member A1	6	134917390-134950122	Predicted intracellular proteins	Evidence at protein level	HPA026292, HPA055414	Enhanced		Supported	Centrosome	Renal cancer:9.87e-4 (favourable)	Group enriched	Group enriched	29	kidney: 74.3;liver: 127.7	cerebral cortex: 3.4	Mixed		
SGK1	SGK	ENSG00000118515	Serum/glucocorticoid regulated kinase 1	6	134169246-134318112	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022085, CAB025148, HPA051251	Approved		Enhanced	Nuclear speckles	Cervical cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 793.4	Cell line enhanced		RPTEC TERT1: 354.6;TIME: 304.3
RNF146	dactylidin, dJ351K20.1, DKFZp434O1427	ENSG00000118518	Ring finger protein 146	6	127266610-127288567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027158, HPA027209	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.26e-5 (favourable), Renal cancer:7.32e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 94.6	Expressed in all		
ARG1		ENSG00000118520	Arginase 1	6	131573144-131584332	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003595, CAB009434, HPA024006, CAB056159	Enhanced					Tissue enriched	Tissue enhanced		bone marrow: 171.2;liver: 566.2	skin: 78.2	Not detected		
CTGF	CCN2, IGFBP8	ENSG00000118523	Connective tissue growth factor	6	131948176-131951373	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005123, HPA031075	Approved				Stomach cancer:5.04e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 845.3	Cell line enhanced		EFO-21: 1511.7;HUVEC TERT2: 1148.6;TIME: 2338.5
TCF21	bHLHa23, POD1	ENSG00000118526	Transcription factor 21	6	133889138-133895553	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA013189	Uncertain					Mixed	Tissue enhanced		placenta: 62.4;spleen: 46.9	ovary: 32.1	Cell line enriched	10	HHSteC: 13.5
PMFBP1		ENSG00000118557	Polyamine modulated factor 1 binding protein 1	16	72112157-72176878	Predicted intracellular proteins	Evidence at protein level	HPA056716			Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		epididymis: 16.0;testis: 32.3	skin: 5.3	Cell line enhanced		SCLC-21H: 25.3;SH-SY5Y: 11.4
FBXL5	FBL4, FBL5, FLR1	ENSG00000118564	F-box and leucine rich repeat protein 5	4	15604539-15681679	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.18e-5 (favourable)	Expressed in all	Expressed in all			kidney: 135.1	Expressed in all		
MED28	DKFZP434N185, EG1, magicin	ENSG00000118579	Mediator complex subunit 28	4	17614631-17634105	Predicted intracellular proteins	Evidence at protein level	HPA035900, HPA035901	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			endometrium: 19.0	Expressed in all		
SLC16A7	MCT2	ENSG00000118596	Solute carrier family 16 member 7	12	59596067-59789855	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005911	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.85e-5 (favourable)	Mixed	Mixed			adipose tissue,heart muscle: 24.9	Mixed		
TMEM5	HP10481	ENSG00000118600	Transmembrane protein 5	12	63779803-63809558	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064014			Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:5.24e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
ZNF430	FLJ13659	ENSG00000118620	Zinc finger protein 430	19	21020620-21060050	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain					Mixed	Mixed			ovary: 15.8	Mixed		
VAMP8	EDB	ENSG00000118640	Vesicle associated membrane protein 8	2	85561562-85582031	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006882, CAB037132, CAB037147	Enhanced				Thyroid cancer:8.07e-9 (favourable), Urothelial cancer:1.59e-6 (favourable)	Expressed in all	Expressed in all			lung: 327.6	Cell line enhanced		HL-60: 584.2;NB-4: 722.5;U-937: 587.5
DCLRE1B	FLJ12810, FLJ13998, SNM1B	ENSG00000118655	DNA cross-link repair 1B	1	113905141-113914086	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064934			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.03e-7 (unfavourable), Liver cancer:4.50e-5 (unfavourable), Pancreatic cancer:6.70e-4 (unfavourable)	Expressed in all	Mixed			spleen: 5.4	Expressed in all		
MYL12B	MRLC2	ENSG00000118680	Myosin light chain 12B	18	3261909-3278284	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA045244, HPA059197	Supported		Approved	Nucleus<br>Nucleoli fibrillar center	Thyroid cancer:6.62e-6 (favourable), Renal cancer:8.17e-5 (favourable), Pancreatic cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 586.9	Expressed in all		
FOXO3	AF6q21, FKHRL1, FOXO2, FOXO3A	ENSG00000118689	Forkhead box O3	6	108559835-108684774	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004074, HPA063104	Supported		Enhanced	Nucleus		Expressed in all	Expressed in all			ovary: 55.1	Expressed in all		
ARMC2	bA787I22.1, DKFZp434P0714	ENSG00000118690	Armadillo repeat containing 2	6	108848416-108974472	Predicted intracellular proteins	Evidence at protein level	HPA025809, HPA053696	Enhanced		Approved	Nucleus		Mixed	Tissue enhanced		testis: 62.0	fallopian tube: 33.6	Expressed in all		
GHRH	GHRF	ENSG00000118702	Growth hormone releasing hormone	20	37251082-37261835	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		adrenal gland: 1.4;duodenum: 3.4	small intestine: 1.2	Cell line enhanced		NTERA-2: 2.0;U-266/84: 5.4
RPN2	RIBIIR, RPN-II, RPNII, SWP1	ENSG00000118705	Ribophorin II	20	37178410-37241623	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008297, CAB019277, HPA025922	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 364.2	Expressed in all		
TGIF2		ENSG00000118707	TGFB induced factor homeobox 2	20	36573488-36593950	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053786			Supported	Nucleoplasm		Expressed in all	Mixed			fallopian tube: 38.3	Mixed		
CASQ2	PDIB2	ENSG00000118729	Calsequestrin 2	1	115700007-115768781	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027285, HPA055298	Enhanced				Urothelial cancer:2.25e-5 (unfavourable), Head and neck cancer:2.30e-4 (unfavourable)	Mixed	Tissue enriched	11	heart muscle: 679.4	skeletal muscle: 62.3	Cell line enriched	14	HSkMC: 9.6
OLFM3	NOE3	ENSG00000118733	Olfactomedin 3	1	101802574-101997030	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050297			Uncertain	Vesicles		Mixed	Tissue enriched	15	cerebral cortex: 26.7	adrenal gland: 1.8	Group enriched	11	AF22: 5.5;HAP1: 4.0;HEL: 3.2;SCLC-21H: 2.6;SH-SY5Y: 2.3
PKD2	Pc-2, PC2, PKD4, TRPP2	ENSG00000118762	Polycystin 2, transient receptor potential cation channel	4	88007668-88077777	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB004544, HPA015794	Approved		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			endometrium: 101.0	Cell line enhanced		BJ hTERT+: 167.9
ABCG2	ABCP, BCRP, CD338, EST157481, MXR	ENSG00000118777	ATP binding cassette subfamily G member 2 (Junior blood group)	4	88090264-88231322	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037299, HPA054719	Enhanced		Enhanced	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		small intestine: 113.8	seminal vesicle: 55.9	Cell line enhanced		A549: 47.2;BEWO: 80.5;RPMI-8226: 32.5
SPP1	BNSP, BSPI, ETA-1, OPN	ENSG00000118785	Secreted phosphoprotein 1	4	87975650-87983426	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002212, HPA027540, HPA027541	Enhanced		Supported	Golgi apparatus	Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7	cerebral cortex: 795.2	Group enriched	6	EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5
STBD1	FLJ41801, GENX-3414	ENSG00000118804	Starch binding domain 1	4	76306026-76311599	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011952, HPA012849	Enhanced		Supported	Cytosol		Mixed	Tissue enhanced		adipose tissue: 46.7;skeletal muscle: 32.8	liver: 14.5	Cell line enhanced		HDLM-2: 24.3;Karpas-707: 37.9;U-266/70: 25.8
CCNI	CCNI1	ENSG00000118816	Cyclin I	4	77047158-77076005	Predicted intracellular proteins	Evidence at protein level	CAB010206, HPA039853, HPA061470	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:2.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 453.5	Expressed in all		
RARRES1	LXNL, TIG1	ENSG00000118849	Retinoic acid receptor responder 1	3	158696892-158732696	Predicted secreted proteins	Evidence at protein level	HPA003892	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:5.88e-6 (unfavourable)	Expressed in all	Mixed			appendix: 78.0	Cell line enriched	11	CAPAN-2: 1010.9
MFSD1	FLJ14153, UG0581B09	ENSG00000118855	Major facilitator superfamily domain containing 1	3	158732198-158829719	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057924, HPA065858	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:5.60e-5 (favourable)	Expressed in all	Expressed in all			spleen: 35.2	Expressed in all		
RAB3GAP2	DKFZP434D245, KIAA0839, RAB3-GAP150, SPG69	ENSG00000118873	RAB3 GTPase activating non-catalytic protein subunit 2	1	220148293-220272454	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026273, HPA027299	Approved		Supported	Plasma membrane<br>Cytosol	Breast cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
EEF2KMT	EFM3, FAM86A, MGC19636, SB153	ENSG00000118894	Eukaryotic elongation factor 2 lysine methyltransferase	16	5084304-5097808	Predicted intracellular proteins	Evidence at protein level	HPA041610	Approved		Uncertain	Vesicles	Urothelial cancer:2.35e-4 (unfavourable), Liver cancer:8.85e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.3	Expressed in all		
PPL		ENSG00000118898	Periplakin	16	4882507-4960741	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042550, HPA059859	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:2.76e-4 (unfavourable)	Expressed in all	Group enriched	7	esophagus: 558.8;skin: 149.5	tonsil: 52.0	Cell line enhanced		HaCaT: 168.9;SiHa: 108.6
UBN1		ENSG00000118900	Ubinuclein 1	16	4846665-4882360	Predicted intracellular proteins	Evidence at protein level	HPA061029, HPA069045	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 70.4	Expressed in all		
KLF12	AP-2rep, AP2REP, HSPC122	ENSG00000118922	Kruppel like factor 12	13	73686089-73995056	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064146			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.03e-6 (unfavourable)	Expressed in all	Mixed			epididymis: 13.7	Mixed		
UCHL3		ENSG00000118939	Ubiquitin C-terminal hydrolase L3	13	75549480-75606020	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019678, CAB037139, CAB037208	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:6.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.7	Expressed in all		
PCDH17	PCDH68, PCH68	ENSG00000118946	Protocadherin 17	13	57631810-57729311	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026817	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:3.31e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 25.8;spleen: 33.8	lung: 18.3	Cell line enhanced		AF22: 13.8;HEK 293: 8.1;U-87 MG: 5.1
HS1BP3	FLJ14249, HS1-BP3	ENSG00000118960	HCLS1 binding protein 3	2	20560448-20651089	Predicted intracellular proteins	Evidence at protein level	HPA035050	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:2.97e-5 (unfavourable), Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 33.3	Expressed in all		
LDAH	C2orf43, FLJ21820	ENSG00000118961	Lipid droplet associated hydrolase	2	20684014-20823130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034729, HPA034730	Approved		Uncertain	Nuclear speckles<br>Cytosol	Liver cancer:6.09e-6 (unfavourable), Renal cancer:1.18e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.6	Mixed		
WDR35	IFT121, IFTA1, KIAA1336, MGC33196	ENSG00000118965	WD repeat domain 35	2	19910260-19990131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044147	Approved					Expressed in all	Mixed			parathyroid gland: 26.2	Mixed		
CCND2		ENSG00000118971	Cyclin D2	12	4273772-4305350	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049138, HPA054196	Approved		Supported	Nucleoplasm	Thyroid cancer:9.76e-5 (favourable), Pancreatic cancer:2.52e-4 (favourable)	Expressed in all	Mixed			epididymis: 55.9	Cell line enhanced		AF22: 155.7;HDLM-2: 235.1;Karpas-707: 252.4;RH-30: 221.5
FGF23		ENSG00000118972	Fibroblast growth factor 23	12	4368227-4379728	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Mixed			epididymis: 1.5	Cell line enhanced		AF22: 1.9
ELL2		ENSG00000118985	Elongation factor for RNA polymerase II 2	5	95885098-95962071	Predicted intracellular proteins	Evidence at protein level	HPA013569			Supported	Nucleoplasm	Renal cancer:1.31e-4 (unfavourable), Stomach cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 69.0	Cell line enhanced		BJ: 267.9;HDLM-2: 265.3
DNAH7	KIAA0944	ENSG00000118997	Dynein axonemal heavy chain 7	2	195737703-196068812	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034724, HPA044070	Approved		Supported	Cytosol		Not detected	Tissue enhanced		fallopian tube: 15.6;testis: 18.1	thyroid gland: 4.6	Cell line enhanced		PC-3: 5.5
CYP20A1	CYP-M	ENSG00000119004	Cytochrome P450 family 20 subfamily A member 1	2	203238940-203305611	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055872, HPA058461	Uncertain		Approved	Plasma membrane<br>Cell Junctions<br>Actin filaments		Expressed in all	Mixed			thyroid gland: 16.4	Mixed		
NDUFB3	B12	ENSG00000119013	NADH:ubiquinone oxidoreductase subunit B3	2	201071433-201085750	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034596	Approved				Head and neck cancer:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 180.0	Expressed in all		
GTF3C3	TFIIIC102, TFiiiC2-102	ENSG00000119041	General transcription factor IIIC subunit 3	2	196763032-196799725	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069179			Supported	Nucleus<br>Nuclear membrane	Liver cancer:1.26e-6 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 37.4	Expressed in all		
SATB2	FLJ21474, KIAA1034	ENSG00000119042	SATB homeobox 2	2	199269500-199471266	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001042, CAB023669, HPA029543, CAB062562, CAB067751, CAB068229, CAB068230, CAB068231	Enhanced		Supported	Nucleoplasm	Renal cancer:5.37e-8 (favourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 22.7;colon: 34.1;rectum: 43.2	small intestine: 6.3	Mixed		
UBE2B	HHR6B, RAD6B, UBC2	ENSG00000119048	Ubiquitin conjugating enzyme E2 B	5	134371179-134391992	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003875, HPA051765, HPA065898			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 99.1	Expressed in all		
TRPM6	CHAK2, FLJ22628, HOMG, HSH	ENSG00000119121	Transient receptor potential cation channel subfamily M member 6	9	74722495-74888094	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 13.1;rectum: 18.2	small intestine: 8.7	Cell line enhanced		BEWO: 3.7;HeLa: 1.5;RT4: 3.0
GDA		ENSG00000119125	Guanine deaminase	9	72114595-72257193	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019352, HPA024099, HPA030387	Enhanced		Approved	Nucleus	Renal cancer:2.66e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 102.2;duodenum: 95.2;small intestine: 104.1	kidney: 43.6	Cell line enhanced		A-431: 31.0;EFO-21: 125.3;HeLa: 32.0;hTCEpi: 45.2
KLF9	BTEB1	ENSG00000119138	Kruppel like factor 9	9	70384597-70414624	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029308			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:6.59e-6 (favourable)	Expressed in all	Expressed in all			smooth muscle: 88.4	Cell line enhanced		ASC TERT1: 58.2;HHSteC: 90.2
TJP2	DFNA51, X104, ZO-2, ZO2	ENSG00000119139	Tight junction protein 2	9	69121264-69255208	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001813, CAB009228, HPA070714	Supported		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.78e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 104.1	Mixed		
C2orf40	augurin, ECRG4	ENSG00000119147	Chromosome 2 open reading frame 40	2	106063246-106078159	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA008546	Uncertain				Breast cancer:4.58e-4 (favourable)	Tissue enriched	Tissue enhanced		seminal vesicle: 116.4;thyroid gland: 128.1	prostate: 61.6	Not detected		
ITGB1BP1	ICAP-1A, ICAP-1alpha, ICAP-1B, ICAP1, ICAP1A, ICAP1B	ENSG00000119185	Integrin subunit beta 1 binding protein 1	2	9403475-9423547	Predicted intracellular proteins	Evidence at protein level	HPA067348, HPA071538			Supported	Nucleoplasm<br>Nuclear bodies<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:1.03e-5 (unfavourable), Liver cancer:4.67e-5 (unfavourable), Renal cancer:7.10e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 125.4	Expressed in all		
CPSF3	CPSF-73, CPSF73, YSH1	ENSG00000119203	Cleavage and polyadenylation specific factor 3	2	9423568-9473101	Predicted intracellular proteins	Evidence at protein level	HPA034657	Uncertain				Liver cancer:3.64e-5 (unfavourable), Renal cancer:3.93e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 87.5	Expressed in all		
PIGZ	FLJ12768, MGC52163, SMP3	ENSG00000119227	Phosphatidylinositol glycan anchor biosynthesis class Z	3	196946343-196969060	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA058599, HPA059920	Approved		Uncertain	Vesicles	Renal cancer:5.60e-5 (unfavourable)	Expressed in all	Tissue enhanced		colon: 18.5;rectum: 18.1	cerebral cortex: 10.9	Mixed		
SENP5	MGC27076	ENSG00000119231	SUMO1/sentrin specific peptidase 5	3	196867856-196934714	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.14e-5 (unfavourable), Endometrial cancer:4.04e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
CCDC92	FLJ22471	ENSG00000119242	Coiled-coil domain containing 92	12	123918660-123972831	Predicted intracellular proteins	Evidence at protein level	HPA038560, HPA057580	Approved		Supported	Nucleoplasm<br>Centrosome	Pancreatic cancer:4.59e-5 (favourable), Endometrial cancer:7.15e-4 (favourable)	Expressed in all	Mixed			testis: 18.1	Mixed		
C1orf198	DKFZp667D152, FLJ14525, FLJ16283, FLJ38847, MGC10710	ENSG00000119280	Chromosome 1 open reading frame 198	1	230837119-230869589	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004798	Approved		Supported	Cytosol	Renal cancer:4.50e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 99.2	Expressed in all		
TRIM67	TNL	ENSG00000119283	Tripartite motif containing 67	1	231162112-231221556	Predicted intracellular proteins	Evidence at transcript level	HPA034776	Uncertain					Not detected	Tissue enriched	28	cerebral cortex: 10.3	adrenal gland,testis: 0.3	Cell line enhanced		SCLC-21H: 2.8
HEATR1	BAP28, FLJ10359, UTP10	ENSG00000119285	HEAT repeat containing 1	1	236549005-236604504	Predicted intracellular proteins	Evidence at protein level	HPA046917, HPA062200	Approved		Enhanced	Nucleoli fibrillar center<br>Mitochondria	Liver cancer:2.05e-4 (unfavourable), Renal cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.0	Expressed in all		
PTBP3	DKFZp781I1117, ROD1	ENSG00000119314	Polypyrimidine tract binding protein 3	9	112217716-112333667	Predicted intracellular proteins	Evidence at protein level	HPA048374			Approved	Nucleus	Pancreatic cancer:1.22e-4 (unfavourable), Lung cancer:2.10e-4 (unfavourable), Renal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.1	Expressed in all		
RAD23B	HHR23B, HR23B, P58	ENSG00000119318	RAD23 homolog B, nucleotide excision repair protein	9	107283137-107332194	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029718, HPA029720, CAB033868	Enhanced		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:2.58e-4 (unfavourable), Lung cancer:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 110.8	Expressed in all		
FKBP15	FKBP133, KIAA0674, PPP1R76, WAFL	ENSG00000119321	FK506 binding protein 15	9	113161006-113221361	Predicted intracellular proteins	Evidence at protein level	HPA007979	Approved		Approved	Nucleoli<br>Cytosol	Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.0	Expressed in all		
CTNNAL1	alpha-CATU, CLLP	ENSG00000119326	Catenin alpha like 1	9	108942569-109013529	Predicted intracellular proteins	Evidence at protein level						Stomach cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 263.0	Expressed in all		
FAM206A	C9orf6, CG-8, FLJ20457, Simiate	ENSG00000119328	Family with sequence similarity 206 member A	9	108934181-108950744	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035917, HPA035918	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 36.8	Expressed in all		
WDR34	bA216B9.3, DIC5, FAP133, MGC20486	ENSG00000119333	WD repeat domain 34	9	128633661-128656787	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040764, HPA041091	Approved		Approved	Cytosol	Endometrial cancer:7.01e-5 (favourable), Cervical cancer:1.63e-4 (favourable), Liver cancer:8.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.0	Expressed in all		
SET	2PP2A, IPP2A2, PHAPII	ENSG00000119335	SET nuclear proto-oncogene	9	128683424-128696400	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005232, HPA063683	Supported		Supported	Nucleoplasm<br>Lipid droplets	Liver cancer:9.41e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 361.2	Expressed in all		
PTPA	PPP2R4, PR53	ENSG00000119383	Protein phosphatase 2 phosphatase activator	9	129110950-129148946	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005695, CAB022068, CAB035999	Approved		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:6.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 225.9	Expressed in all		
GLE1	GLE1L, hGLE1, LCCS1	ENSG00000119392	GLE1, RNA export mediator	9	128504700-128542288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA041689, HPA043538, HPA061560	Supported		Supported	Nuclear membrane<br>Nucleoli	Stomach cancer:7.04e-4 (favourable), Endometrial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.8	Expressed in all		
RAB14	FBP, RAB-14	ENSG00000119396	RAB14, member RAS oncogene family	9	121178137-121223014	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026419, CAB037066	Approved		Supported	Vesicles	Renal cancer:1.79e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.4	Expressed in all		
CNTRL	CEP1, CEP110	ENSG00000119397	Centriolin	9	121074863-121177610	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020468, HPA020480, HPA051583	Approved		Supported	Centrosome<br>Cytosol	Head and neck cancer:9.21e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 65.8	lymph node: 29.0	Expressed in all		
TRIM32	BBS11, HT2A, LGMD2H, TATIP	ENSG00000119401	Tripartite motif containing 32	9	116687302-116701300	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050060	Approved		Approved	Intermediate filaments	Head and neck cancer:4.53e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 21.2	Mixed		
FBXW2	FBW2, Fwd2, Md6	ENSG00000119402	F-box and WD repeat domain containing 2	9	120751978-120793412	Predicted intracellular proteins	Evidence at protein level	HPA067878	Approved		Approved	Nucleoplasm	Renal cancer:1.38e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
PHF19	DKFZP727G051, MTF2L1, PCL3, TDRD19B	ENSG00000119403	PHD finger protein 19	9	120855652-120894896	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.16e-7 (unfavourable), Liver cancer:5.16e-5 (unfavourable), Endometrial cancer:7.60e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 49.5	Expressed in all		
NEK6	SID6-1512	ENSG00000119408	NIMA related kinase 6	9	124257606-124353307	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB045993, HPA056828	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Testis cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 44.3	Cell line enhanced		HMC-1: 219.5
BSPRY	FLJ20150	ENSG00000119411	B-box and SPRY domain containing	9	113349541-113371233	Predicted intracellular proteins	Evidence at protein level	HPA042889	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.56e-14 (favourable)	Mixed	Tissue enriched	5	parathyroid gland: 254.8	thyroid gland: 50.4	Cell line enhanced		A-431: 36.1;CAPAN-2: 22.7;MCF7: 46.9;RPMI-8226: 22.3;SK-BR-3: 22.3;T-47d: 28.3
PPP6C	PP6	ENSG00000119414	Protein phosphatase 6 catalytic subunit	9	125146573-125189939	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050940	Uncertain				Renal cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.7	Expressed in all		
NDUFA8	MGC793, PGIV	ENSG00000119421	NADH:ubiquinone oxidoreductase subunit A8	9	122144058-122159819	Predicted intracellular proteins	Evidence at protein level	HPA041510, HPA041600	Enhanced		Enhanced	Mitochondria	Renal cancer:4.17e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 226.5	Expressed in all		
HDHD3	C9orf158, MGC12904	ENSG00000119431	Haloacid dehalogenase like hydrolase domain containing 3	9	113373419-113376999	Predicted intracellular proteins	Evidence at protein level	HPA020427, HPA024158, HPA024585	Enhanced		Supported	Nucleoli	Renal cancer:3.54e-7 (favourable), Cervical cancer:2.72e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 86.8	Mixed		
RBM18	MGC2734	ENSG00000119446	RNA binding motif protein 18	9	122237624-122264839	Predicted intracellular proteins	Evidence at protein level	HPA057281	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Midbody	Renal cancer:8.00e-7 (favourable)	Expressed in all	Expressed in all			breast: 20.3	Expressed in all		
SLC46A2	Ly110, TSCOT	ENSG00000119457	Solute carrier family 46 member 2	9	112878920-112890913	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA020098	Approved					Tissue enhanced	Group enriched	6	cervix, uterine: 23.3;endometrium: 5.5;epididymis: 5.7;lung: 15.1;skin: 11.3	seminal vesicle: 2.1	Not detected		
HSDL2	C9orf99, SDR13C1	ENSG00000119471	Hydroxysteroid dehydrogenase like 2	9	112379937-112472410	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042890, HPA050453	Enhanced		Supported	Mitochondria	Renal cancer:9.29e-7 (favourable), Endometrial cancer:9.23e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 79.2	Expressed in all		
MAPKAP1	MGC2745, MIP1, SIN1	ENSG00000119487	Mitogen-activated protein kinase associated protein 1	9	125437393-125707234	Predicted intracellular proteins	Evidence at protein level	HPA029091, HPA029092	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.23e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.7	Expressed in all		
NR4A3	CHN, CSMF, MINOR, NOR1	ENSG00000119508	Nuclear receptor subfamily 4 group A member 3	9	99821855-99866891	Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043360	Uncertain				Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 88.9	urinary bladder: 42.2	Cell line enhanced		BJ hTERT+: 21.0;SK-MEL-30: 14.0;U-266/70: 7.9
INVS	NPHP2	ENSG00000119509	Inversin	9	100099256-100301000	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049994			Approved	Cytosol	Head and neck cancer:6.35e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.7	Expressed in all		
GALNT12	GalNAc-T12	ENSG00000119514	Polypeptide N-acetylgalactosaminyltransferase 12	9	98807699-98850081	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048292	Enhanced				Renal cancer:3.24e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 92.1	rectum: 61.4	Cell line enhanced		U-2197: 151.4
DENND1A	FAM31A, FLJ21129, KIAA1608	ENSG00000119522	DENN domain containing 1A	9	123379654-123930152	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020481			Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:4.11e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Expressed in all		
ALG2	CDG1I, CDGIi, FLJ14511, hALPG2, NET38	ENSG00000119523	ALG2, alpha-1,3/1,6-mannosyltransferase	9	99216426-99221956	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041512, HPA041601	Approved		Enhanced	Actin filaments<br>Cytosol	Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 77.1	Expressed in all		
CSF3R	CD114, GCSFR	ENSG00000119535	Colony stimulating factor 3 receptor	1	36466043-36483278	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017116, HPA048086	Enhanced				Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 211.2;bone marrow: 243.4;placenta: 147.9	spleen: 96.5	Cell line enhanced		BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
VPS4B	SKD1, SKD1B, VPS4-2	ENSG00000119541	Vacuolar protein sorting 4 homolog B	18	63389190-63422483	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040393, CAB046445, HPA057649	Approved		Approved	Vesicles<br>Intermediate filaments	Renal cancer:1.23e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 82.7	Expressed in all		
ONECUT2	OC-2	ENSG00000119547	One cut homeobox 2	18	57435685-57491297	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057058	Enhanced		Supported	Nucleoplasm<br>Actin filaments		Group enriched	Tissue enhanced		duodenum: 10.4;gallbladder: 16.3	liver: 4.5	Cell line enhanced		HDLM-2: 19.1;HeLa: 8.5;SCLC-21H: 12.1
C19orf25	FLJ36666	ENSG00000119559	Chromosome 19 open reading frame 25	19	1461143-1479556	Predicted intracellular proteins	Evidence at protein level	HPA050270, HPA067491	Approved		Approved	Intermediate filaments	Renal cancer:9.20e-8 (favourable), Endometrial cancer:1.08e-4 (favourable), Pancreatic cancer:1.21e-4 (favourable), Liver cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 21.7	Expressed in all		
ZBTB45	FLJ14486, ZNF499	ENSG00000119574	Zinc finger and BTB domain containing 45	19	58513530-58538911	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA035754	Uncertain		Approved	Cytosol	Renal cancer:5.38e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 10.5	Expressed in all		
YLPM1	C14orf170, PPP1R169, ZAP	ENSG00000119596	YLP motif containing 1	14	74763366-74859435	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048070, HPA061123	Uncertain		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:6.08e-7 (favourable)	Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
DCAF4	DKFZp434K114, WDR21, WDR21A	ENSG00000119599	DDB1 and CUL4 associated factor 4	14	72926332-72959703	Predicted intracellular proteins	Evidence at protein level	HPA047276	Approved		Approved	Nucleoplasm	Renal cancer:4.90e-4 (favourable), Liver cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.8	Expressed in all		
PROX2	FLJ36749	ENSG00000119608	Prospero homeobox 2	14	74852871-74871940	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045057	Uncertain					Not detected	Mixed			skin: 2.4	Cell line enhanced		AF22: 1.8
VSX2	CHX10, HOX10, RET1	ENSG00000119614	Visual system homeobox 2	14	74239472-74262738	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003436	Supported					Tissue enriched	Not detected			testis: 0.2	Not detected		
FCF1	Bka, C14orf111, CGI-35, UTP24	ENSG00000119616	FCF1 rRNA-processing protein	14	74713144-74738620	Predicted intracellular proteins	Evidence at protein level	HPA046681	Approved		Approved	Nucleoplasm	Liver cancer:5.54e-6 (unfavourable), Renal cancer:2.26e-4 (favourable), Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 72.6	Expressed in all		
PGF	D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760	ENSG00000119630	Placental growth factor	14	74941834-74955784	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA041624			Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 71.1;thyroid gland: 64.5	cervix, uterine: 30.1	Group enriched	6	BEWO: 398.0;HUVEC TERT2: 164.7
IFI27L2	FAM14A, TLH29	ENSG00000119632	Interferon alpha inducible protein 27 like 2	14	94127779-94130253	Predicted secreted proteins	Evidence at protein level	HPA049588			Approved	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 47.5	Cell line enhanced		Karpas-707: 135.5
BBOF1	C14orf45, CCDC176	ENSG00000119636	Basal body orientation factor 1	14	74019353-74082863	Predicted intracellular proteins	Evidence at protein level	HPA003090, HPA003136	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Microtubule organizing center	Endometrial cancer:6.34e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 70.0	fallopian tube: 35.8	Mixed		
NEK9	DKFZp434D0935, MGC16714, Nek8, NERCC	ENSG00000119638	NIMA related kinase 9	14	75079353-75127344	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001405	Approved		Approved	Mitochondria	Pancreatic cancer:5.63e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Mixed		
ACYP1		ENSG00000119640	Acylphosphatase 1	14	75053221-75069483	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034944	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.14e-7 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 46.4	Expressed in all		
IFT43	C14orf179, FLJ32173, MGC16028	ENSG00000119650	Intraflagellar transport 43	14	75902136-76084585	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003438	Approved		Supported	Microtubules<br>Microtubule organizing center		Expressed in all	Expressed in all			fallopian tube: 99.1	Mixed		
NPC2	EDDM1, HE1, NP-C2	ENSG00000119655	NPC intracellular cholesterol transporter 2	14	74476192-74494177	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA000835	Enhanced				Colorectal cancer:4.83e-5 (unfavourable), Stomach cancer:2.66e-4 (unfavourable), Liver cancer:3.13e-4 (unfavourable), Thyroid cancer:6.55e-4 (favourable)	Expressed in all	Tissue enriched	19	epididymis: 16336.0	lung: 849.0	Expressed in all		
DNAL1	1700010H15RiK, C14orf168, CILD16, MGC12435	ENSG00000119661	Dynein axonemal light chain 1	14	73644875-73703732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053129	Uncertain		Approved	Nucleus<br>Microtubule organizing center	Renal cancer:5.17e-8 (favourable)	Expressed in all	Expressed in all			testis: 99.4	Expressed in all		
IRF2BPL	C14orf4, EAP1, KIAA1865	ENSG00000119669	Interferon regulatory factor 2 binding protein like	14	77024543-77028699	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050862, HPA061333	Approved		Enhanced	Nucleoplasm	Endometrial cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.5	Expressed in all		
ACOT2	Mte1, ZAP128	ENSG00000119673	Acyl-CoA thioesterase 2	14	73567620-73575658	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043705, HPA060170	Enhanced		Approved	Mitochondria	Renal cancer:2.28e-6 (favourable)	Expressed in all	Expressed in all			adipose tissue: 96.5	Mixed		
LTBP2	C14orf141, LTBP3	ENSG00000119681	Latent transforming growth factor beta binding protein 2	14	74498170-74612378	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003415	Approved		Approved	Nucleus	Urothelial cancer:3.94e-4 (unfavourable)	Expressed in all	Mixed			lung: 75.1	Cell line enhanced		fHDF/TERT166: 185.0;TIME: 465.3
AREL1	FIEL1, KIAA0317	ENSG00000119682	Apoptosis resistant E3 ubiquitin protein ligase 1	14	74653437-74713115	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051306	Uncertain				Renal cancer:4.67e-6 (favourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
MLH3		ENSG00000119684	MutL homolog 3	14	75013764-75051532	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060570			Approved	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 24.4	Mixed		
TTLL5	KIAA0998	ENSG00000119685	Tubulin tyrosine ligase like 5	14	75633625-75955078	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032128	Uncertain		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enriched	5	testis: 104.0	parathyroid gland: 20.4	Expressed in all		
FLVCR2	C14orf58, FLJ20371, MFSD7C	ENSG00000119686	Feline leukemia virus subgroup C cellular receptor family member 2	14	75578617-75663214	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037984	Enhanced				Renal cancer:2.53e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 38.8	small intestine: 26.9	Cell line enhanced		ASC diff: 37.0;BEWO: 71.0
ABCD4	EST352188, P70R, PMP69, PXMP1L	ENSG00000119688	ATP binding cassette subfamily D member 4	14	74285423-74303056	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003396	Approved					Expressed in all	Expressed in all			fallopian tube: 13.8	Expressed in all		
DLST	DLTS	ENSG00000119689	Dihydrolipoamide S-succinyltransferase	14	74881891-74903745	Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003010	Supported				Renal cancer:1.13e-12 (favourable)	Expressed in all	Expressed in all			kidney: 106.7	Expressed in all		
PPP4R4	CFAP14, KIAA1622, PP4R4	ENSG00000119698	Protein phosphatase 4 regulatory subunit 4	14	94146128-94279735	Predicted intracellular proteins	Evidence at protein level	HPA041866, HPA050321	Approved		Supported	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 14.0;testis: 11.1	ovary: 5.4	Cell line enhanced		RH-30: 17.0;T-47d: 17.6
TGFB3	ARVD, ARVD1	ENSG00000119699	Transforming growth factor beta 3	14	75958099-75982991	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA063582			Approved	Vesicles	Renal cancer:4.01e-7 (unfavourable)	Expressed in all	Mixed			placenta: 84.9	Group enriched	5	SCLC-21H: 28.0;SK-BR-3: 99.2;T-47d: 87.5
ZC2HC1C	C14orf140, FAM164C	ENSG00000119703	Zinc finger C2HC-type containing 1C	14	75064170-75079987	Predicted intracellular proteins	Evidence at protein level	HPA050928, HPA065062	Enhanced		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:4.63e-13 (favourable)	Mixed	Tissue enhanced		testis: 118.3	epididymis: 34.2	Mixed		
SLIRP	C14orf156, DC50	ENSG00000119705	SRA stem-loop interacting RNA binding protein	14	77708071-77761104	Predicted intracellular proteins	Evidence at protein level	HPA020291	Approved		Supported	Mitochondria	Head and neck cancer:4.88e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 205.7	Expressed in all		
RBM25	fSAP94, NET52, RNPC7, S164, Snu71	ENSG00000119707	RNA binding motif protein 25	14	73058436-73123898	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003025, HPA070713	Supported		Enhanced	Nuclear speckles	Liver cancer:1.42e-4 (unfavourable), Renal cancer:4.26e-4 (unfavourable), Prostate cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.4	Expressed in all		
ALDH6A1	MMSDH	ENSG00000119711	Aldehyde dehydrogenase 6 family member A1	14	74056850-74084493	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029072, HPA029073, HPA029074, HPA029075	Enhanced		Enhanced	Mitochondria	Renal cancer:2.00e-15 (favourable), Lung cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 389.6	Expressed in all		
GPR68	OGR1	ENSG00000119714	G protein-coupled receptor 68	14	91232532-91253925	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.06e-5 (favourable)	Mixed	Mixed			appendix: 8.1	Cell line enhanced		U-87 MG: 31.4
ESRRB	DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2	ENSG00000119715	Estrogen related receptor beta	14	76310614-76501841	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Group enriched	7	heart muscle: 2.3;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4	breast: 0.3	Cell line enhanced		HMC-1: 1.0;K-562: 3.3;U-266/70: 1.2
EIF2B2	EIF-2Bbeta, EIF2B	ENSG00000119718	Eukaryotic translation initiation factor 2B subunit beta	14	75002911-75012366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005841, CAB037105, HPA048028	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites	Liver cancer:2.26e-6 (unfavourable), Renal cancer:2.95e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.2	Expressed in all		
NRDE2	C14orf102, FLJ14051	ENSG00000119720	NRDE-2, necessary for RNA interference, domain containing	14	90267856-90332137	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047050, HPA050583	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 2.9	Mixed		
COQ6	CGI-10	ENSG00000119723	Coenzyme Q6, monooxygenase	14	73949926-73963670	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051371	Uncertain				Renal cancer:1.05e-6 (favourable)	Expressed in all	Expressed in all			testis: 31.5	Expressed in all		
ZNF410	APA-1, APA1	ENSG00000119725	Zinc finger protein 410	14	73886617-73932511	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002871			Approved	Nuclear bodies		Mixed	Expressed in all			testis: 81.3	Expressed in all		
RHOQ	ARHQ, RASL7A, TC10	ENSG00000119729	Ras homolog family member Q	2	46541806-46583121	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044938			Approved	Vesicles<br>Cytosol	Liver cancer:9.60e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 167.5	Expressed in all		
GPR75	WI-31133	ENSG00000119737	G protein-coupled receptor 75	2	53852913-53859989	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 17.8	parathyroid gland: 6.5	Mixed		
SUPT7L	KIAA0764, SPT7L, STAF65, STAF65gamma	ENSG00000119760	SPT7-like STAGA complex gamma subunit	2	27650812-27663840	Predicted intracellular proteins	Evidence at protein level	HPA039565, HPA063643	Uncertain		Approved	Nucleoplasm	Liver cancer:4.46e-7 (unfavourable), Renal cancer:1.53e-4 (unfavourable), Endometrial cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 45.6	Expressed in all		
KLHL29	KBTBD9, KIAA1921	ENSG00000119771	Kelch like family member 29	2	23385217-23708611	Predicted intracellular proteins	Evidence at protein level	HPA049057, HPA057379	Approved		Approved	Mitochondria<br>Cytosol	Pancreatic cancer:2.19e-4 (favourable), Renal cancer:6.29e-4 (unfavourable)	Mixed	Mixed			adrenal gland: 12.0	Cell line enhanced		RH-30: 18.8
DNMT3A		ENSG00000119772	DNA methyltransferase 3 alpha	2	25227855-25342590	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009469, HPA026588	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.8	Cell line enhanced		NTERA-2: 59.7;SH-SY5Y: 76.5
TMEM214	FLJ20254	ENSG00000119777	Transmembrane protein 214	2	27032910-27041695	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034551			Supported	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Renal cancer:2.39e-10 (unfavourable), Liver cancer:4.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 91.6	Expressed in all		
ATAD2B	KIAA1240	ENSG00000119778	ATPase family, AAA domain containing 2B	2	23748664-23927114	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034555	Uncertain		Supported	Nucleoplasm	Renal cancer:2.35e-5 (unfavourable)	Expressed in all	Mixed			skin: 9.8	Expressed in all		
FKBP1B	FKBP12.6, FKBP1L, FKBP9, OTK4, PPIase	ENSG00000119782	FK506 binding protein 1B	2	24049701-24063681	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045572, HPA051798	Uncertain		Approved	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 24.4	duodenum: 18.6	Cell line enhanced		Hep G2: 30.2;NTERA-2: 41.7;SH-SY5Y: 31.9;TIME: 30.3
ATL2	ARL6IP2	ENSG00000119787	Atlastin GTPase 2	2	38294880-38377285	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029108, HPA075302	Approved		Supported	Endoplasmic reticulum	Endometrial cancer:4.51e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 101.4	Expressed in all		
YPEL5	CGI-127	ENSG00000119801	Yippee like 5	2	30146941-30160533	Predicted intracellular proteins	Evidence at protein level	HPA042809	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 271.5	Expressed in all		
FAM98A	DKFZP564F0522	ENSG00000119812	Family with sequence similarity 98 member A	2	33583658-33599382	Predicted intracellular proteins	Evidence at protein level	HPA036250, HPA036251	Uncertain		Supported	Vesicles	Liver cancer:4.86e-7 (unfavourable), Thyroid cancer:8.18e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 127.4	Expressed in all		
YIPF4	FinGER4, MGC11061	ENSG00000119820	Yip1 domain family member 4	2	32277910-32316594	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017884	Supported		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			cerebral cortex: 19.0	Expressed in all		
AFTPH	FLJ20080, FLJ23793, MGC33965, Nbla10388	ENSG00000119844	Aftiphilin	2	64524305-64593005	Predicted intracellular proteins	Evidence at protein level	HPA034990, HPA034991	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:2.37e-5 (favourable), Urothelial cancer:1.83e-4 (favourable), Stomach cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.7	Expressed in all		
LGALSL	GRP, HSPC159	ENSG00000119862	Galectin like	2	64453969-64461381	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046079	Approved		Approved	Nucleoplasm	Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 110.9	Cell line enhanced		AN3-CA: 46.2;HAP1: 75.2
CNRIP1	C2orf32, CRIP1, CRIP1a, CRIP1b, DKFZP566K1924	ENSG00000119865	Cannabinoid receptor interacting protein 1	2	68284171-68320051	Predicted intracellular proteins	Evidence at protein level	HPA035337			Approved	Cytosol	Renal cancer:1.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 53.8	adipose tissue: 24.9	Cell line enhanced		HEL: 139.6
BCL11A	BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856	ENSG00000119866	B-cell CLL/lymphoma 11A	2	60451167-60553567	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014891, HPA029003	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		skin: 41.0	tonsil: 30.6	Cell line enhanced		Daudi: 24.7;MOLT-4: 28.5;REH: 32.5;U-698: 43.2
CRIPT	HSPC139	ENSG00000119878	CXXC repeat containing interactor of PDZ3 domain	2	46616416-46625742	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046080, HPA056765	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:1.19e-4 (unfavourable), Renal cancer:5.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.5	Expressed in all		
EPCAM	17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1	ENSG00000119888	Epithelial cell adhesion molecule	2	47345158-47387601	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003809, HPA026761, CAB030012, CAB055098, HPA067463	Enhanced		Supported	Plasma membrane	Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		rectum: 680.5;small intestine: 714.7	colon: 659.9	Cell line enhanced		A-431: 382.2;CACO-2: 461.4;CAPAN-2: 680.1;SCLC-21H: 345.3
SLC17A5	AST, ISSD, NSD, SD, SIALIN, SIASD, SLD	ENSG00000119899	Solute carrier family 17 member 5	6	73593379-73654155	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044479			Supported	Plasma membrane<br>Cytosol	Thyroid cancer:3.52e-4 (favourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 652.6	thyroid gland: 70.0	Expressed in all		
OGFRL1	dJ331H24.1	ENSG00000119900	Opioid growth factor receptor like 1	6	71288803-71308950	Predicted intracellular proteins	Evidence at protein level	HPA027122			Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 70.3	Mixed		
SLF2	C10orf6, FAM178A, FLJ10512, FLJ25012	ENSG00000119906	SMC5-SMC6 complex localization factor 2	10	100912569-100965136	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038499, HPA057568	Approved		Supported	Nucleus<br>Vesicles		Expressed in all	Expressed in all			epididymis: 56.9	Expressed in all		
IDE		ENSG00000119912	Insulin degrading enzyme	10	92451684-92574076	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063478	Approved				Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable)	Expressed in all	Expressed in all			skin: 63.4	Expressed in all		
TECTB		ENSG00000119913	Tectorin beta	10	112283735-112305035	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.6	Cell line enhanced		Hep G2: 1.7
ELOVL3	CIG-30	ENSG00000119915	ELOVL fatty acid elongase 3	10	102226328-102229589	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036236	Supported		Approved	Vesicles<br>Cytosol	Endometrial cancer:6.25e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 3.6;breast: 4.4;skin: 3.4	testis: 2.3	Cell line enhanced		HSkMC: 10.4;SiHa: 24.5
IFIT3	CIG-49, GARG-49, IFI60, IFIT4, IRG2, ISG60, RIG-G	ENSG00000119917	Interferon induced protein with tetratricopeptide repeats 3	10	89327894-89340971	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059914	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 63.4	Group enriched	5	BJ hTERT+: 159.3;BJ hTERT+ SV40 Large T+: 419.8;BJ hTERT+ SV40 Large T+ RasG12V: 506.2
NKX2-3	CSX3, NKX2.3, NKX2C, NKX4-3	ENSG00000119919	NK2 homeobox 3	10	99532933-99536524	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047561	Uncertain		Uncertain	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		small intestine: 12.7;spleen: 29.6	duodenum: 11.5	Cell line enhanced		NB-4: 1.1;REH: 2.0
IFIT2	cig42, G10P2, GARG-39, IFI-54, IFI54, ISG-54K	ENSG00000119922	Interferon induced protein with tetratricopeptide repeats 2	10	89283694-89309276	Predicted intracellular proteins	Evidence at protein level	HPA003408	Approved		Approved	Vesicles	Renal cancer:6.99e-4 (unfavourable)	Expressed in all	Mixed			spleen: 39.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 132.1;BJ hTERT+ SV40 Large T+ RasG12V: 108.9
GPAM	GPAT1, KIAA1560, MGC26846	ENSG00000119927	Glycerol-3-phosphate acyltransferase, mitochondrial	10	112149864-112215377	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046339, HPA060090	Approved		Approved	Mitochondria	Renal cancer:4.54e-6 (favourable)	Tissue enriched	Expressed in all			adipose tissue: 315.8	Expressed in all		
CUTC	CGI-32	ENSG00000119929	CutC copper transporter	10	99702558-99756134	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA038619	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.81e-7 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 131.6	Expressed in all		
PPP1R3C	PPP1R5, PTG	ENSG00000119938	Protein phosphatase 1 regulatory subunit 3C	10	91628442-91633054	Predicted intracellular proteins	Evidence at protein level	HPA027041	Uncertain					Expressed in all	Tissue enhanced		skeletal muscle: 322.7	heart muscle: 111.2	Cell line enhanced		HHSteC: 43.7;LHCN-M2: 86.1
PYROXD2	C10orf33, FLJ23849	ENSG00000119943	Pyridine nucleotide-disulphide oxidoreductase domain 2	10	98383565-98415184	Predicted intracellular proteins	Evidence at protein level	HPA037566, HPA037567, HPA067394	Uncertain		Approved	Mitochondria	Urothelial cancer:3.37e-4 (favourable), Glioma:8.17e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 15.4	Cell line enhanced		U-937: 24.6
CNNM1	ACDP1	ENSG00000119946	Cyclin and CBS domain divalent metal cation transport mediator 1	10	99329099-99394330	Predicted membrane proteins	Evidence at protein level	HPA040408	Approved		Uncertain	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 10.2;testis: 16.8	ovary: 3.0	Cell line enhanced		A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6
MXI1	bHLHc11, MAD2, MXD2, MXI	ENSG00000119950	MAX interactor 1, dimerization protein	10	110207605-110287365	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035319, HPA056762	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.02e-5 (unfavourable), Prostate cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 88.1	Expressed in all		
SMNDC1	SMNR, SPF30, TDRD16C	ENSG00000119953	Survival motor neuron domain containing 1	10	110290730-110304951	Predicted intracellular proteins	Evidence at protein level	HPA061214			Supported	Nucleus<br>Nuclear bodies	Liver cancer:8.08e-6 (unfavourable), Pancreatic cancer:7.20e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 26.3	Expressed in all		
C10orf88	Em:AC073585.5, FLJ13490	ENSG00000119965	Chromosome 10 open reading frame 88	10	122930903-122954403	Predicted intracellular proteins	Evidence at protein level	HPA039681, HPA040991	Enhanced				Liver cancer:2.05e-5 (unfavourable)	Expressed in all	Mixed			testis: 14.3	Expressed in all		
HELLS	LSH, Nbla10143, PASG, SMARCA6	ENSG00000119969	Helicase, lymphoid-specific	10	94501434-94613905	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004491, HPA063242	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Cervical cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 23.9	lymph node: 14.9	Expressed in all		
PRLHR	GPR10, PrRPR	ENSG00000119973	Prolactin releasing hormone receptor	10	118589989-118595699	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA039361	Supported					Not detected	Group enriched	6	adrenal gland: 6.7;cerebral cortex: 3.7;endometrium: 4.0;smooth muscle: 5.5	seminal vesicle: 0.7	Not detected		
TCTN3	C10orf61, DKFZP564D116, JBTS18, TECT3	ENSG00000119977	Tectonic family member 3	10	95663396-95694143	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026987	Approved		Approved	Microtubules	Endometrial cancer:5.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
FAM45A		ENSG00000119979	Family with sequence similarity 45 member A	10	119104086-119137984	Predicted intracellular proteins	Evidence at protein level	HPA041159			Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.0	Expressed in all		
AVPI1	PP5395, VIP32, VIT32	ENSG00000119986	Arginine vasopressin induced 1	10	97677424-97687323	Predicted intracellular proteins	Evidence at protein level	HPA037649	Approved		Approved	Nucleus<br>Plasma membrane		Expressed in all	Mixed			adrenal gland: 42.1	Cell line enhanced		hTCEpi: 154.8;SK-MEL-30: 138.8;U-2197: 116.9
WDR11	BRWD2, DR11, FLJ10506, HH14, KIAA1351, SRI1, WDR15	ENSG00000120008	WD repeat domain 11	10	120851175-120909524	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038980	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:5.04e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 46.6	Expressed in all		
C10orf76	FLJ13114	ENSG00000120029	Chromosome 10 open reading frame 76	10	101845599-102056193	Predicted intracellular proteins	Evidence at protein level	HPA050913, HPA053580	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 26.4	Mixed		
KCNIP2	KCHIP2	ENSG00000120049	Potassium voltage-gated channel interacting protein 2	10	101825974-101843920	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	adipose tissue: 238.6;cerebral cortex: 81.4;heart muscle: 108.2	breast: 16.6	Cell line enhanced		HEL: 13.8;HMC-1: 9.2
CFAP58	bA554P13.1, C10orf80, CCDC147, FLJ35908	ENSG00000120051	Cilia and flagella associated protein 58	10	104353764-104455090	Predicted intracellular proteins	Evidence at protein level	HPA036555, HPA036556	Uncertain		Approved	Nucleus		Mixed	Group enriched	5	fallopian tube: 13.3;testis: 23.5	cervix, uterine: 3.3	Cell line enhanced		U-2 OS: 6.5
GOT1	AST1	ENSG00000120053	Glutamic-oxaloacetic transaminase 1	10	99396870-99430624	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064532, HPA072629	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.72e-13 (favourable), Cervical cancer:6.23e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 321.5	Expressed in all		
CPN1		ENSG00000120054	Carboxypeptidase N subunit 1	10	100042193-100081877	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040323			Approved	Nucleus<br>Nucleoli		Group enriched	Tissue enriched	22	liver: 37.1	testis: 1.7	Cell line enriched	16	SK-MEL-30: 110.4
C10orf95	FLJ14280	ENSG00000120055	Chromosome 10 open reading frame 95	10	102449837-102451543	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 15.6	thyroid gland: 8.8	Mixed		
SFRP5	SARP3	ENSG00000120057	Secreted frizzled related protein 5	10	97766751-97771952	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		duodenum: 30.9;pancreas: 31.2;small intestine: 29.4	adrenal gland: 12.9	Cell line enhanced		A549: 2.3;CACO-2: 10.5;RPMI-8226: 3.2;SCLC-21H: 2.4
GNA13	G13, MGC46138	ENSG00000120063	G protein subunit alpha 13	17	65010715-65056839	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010087	Approved		Supported	Cytosol		Expressed in all	Expressed in all			bone marrow: 99.1	Expressed in all		
HOXB8	HOX2, HOX2D	ENSG00000120068	Homeobox B8	17	48611377-48614939	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075905			Supported	Nucleoplasm	Renal cancer:1.30e-7 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 68.0;seminal vesicle: 32.7	cervix, uterine: 16.9	Cell line enhanced		EFO-21: 33.5;HDLM-2: 15.7;HEK 293: 34.4;LHCN-M2: 15.9;RPTEC TERT1: 29.7
KANSL1	CENP-36, DKFZP727C091, KIAA1267, MSL1v1, NSL1	ENSG00000120071	KAT8 regulatory NSL complex subunit 1	17	46029916-46225389	Predicted intracellular proteins	Evidence at protein level	HPA006874, HPA007208	Approved		Supported	Nucleoplasm	Liver cancer:3.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.4	Mixed		
HOXB5	HOX2, HOX2A	ENSG00000120075	Homeobox B5	17	48591257-48593961	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043851, HPA074454			Enhanced	Nucleus	Urothelial cancer:8.59e-5 (favourable), Lung cancer:4.61e-4 (unfavourable), Endometrial cancer:6.28e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.2	fallopian tube: 10.7	Cell line enhanced		HEK 293: 24.1;RPTEC TERT1: 14.7
CRHR1	CRF-R, CRF1, CRHR	ENSG00000120088	Corticotropin releasing hormone receptor 1	17	45784280-45835828	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB025251	Approved					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 0.8	Cell line enhanced		RT4: 2.7;SH-SY5Y: 2.2
HOXB3	HOX2, HOX2G	ENSG00000120093	Homeobox B3	17	48548870-48604912	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009860	Approved				Urothelial cancer:8.45e-6 (favourable)	Mixed	Tissue enhanced		epididymis: 79.4	fallopian tube: 38.7	Cell line enhanced		CAPAN-2: 35.1;HEK 293: 38.6
HOXB1	HOX2, HOX2I	ENSG00000120094	Homeobox B1	17	48528526-48530997	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044576	Uncertain					Tissue enriched	Not detected			testis: 0.3	Not detected		
DUSP1	CL100, HVH1, MKP-1, PTPN10	ENSG00000120129	Dual specificity phosphatase 1	5	172768090-172771195	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018554, HPA069577	Approved		Approved	Nucleoli<br>Cytosol	Stomach cancer:3.11e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1027.0	Expressed in all		
PANK3	FLJ12899	ENSG00000120137	Pantothenate kinase 3	5	168548495-168579600	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062358			Approved	Nucleoplasm<br>Golgi apparatus	Colorectal cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 40.8	Expressed in all		
MSX2	CRS2, FPP, HOX8, MSH, PFM, PFM1	ENSG00000120149	Msh homeobox 2	5	174724533-174730893	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005652	Uncertain		Supported	Nuclear speckles	Endometrial cancer:8.43e-5 (favourable), Lung cancer:6.93e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 47.8	parathyroid gland: 16.4	Cell line enriched	7	BEWO: 311.1
TEK	CD202b, TIE-2, TIE2, VMCM, VMCM1	ENSG00000120156	TEK receptor tyrosine kinase	9	27109141-27230175	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010359, HPA073265	Approved		Supported	Plasma membrane<br>Microtubule organizing center	Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 65.9	lung: 42.6	Group enriched	8	HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
RCL1	RNAC, RPCL1	ENSG00000120158	RNA terminal phosphate cyclase like 1	9	4792869-4885917	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071308			Approved	Nucleoplasm	Renal cancer:2.40e-7 (favourable), Breast cancer:5.48e-4 (favourable), Liver cancer:8.02e-4 (favourable)	Expressed in all	Expressed in all			liver: 123.7	Expressed in all		
CAAP1	C9orf82, CAAP, FLJ13657	ENSG00000120159	Caspase activity and apoptosis inhibitor 1	9	26840685-26892804	Predicted intracellular proteins	Evidence at protein level	HPA020404, HPA024029, HPA024100	Uncertain		Approved	Vesicles	Renal cancer:7.94e-9 (favourable), Ovarian cancer:1.27e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Mixed		
EQTN	AFAF, C9orf11, equatorin, SPACA8	ENSG00000120160	Equatorin	9	27284659-27297139	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015089, HPA015504	Enhanced					Not detected	Tissue enriched	94	testis: 67.7	ovary: 0.7	Not detected		
MOB3B	C9orf35, FLJ13204, MOB1D, MOBKL2B	ENSG00000120162	MOB kinase activator 3B	9	27325209-27529781	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Renal cancer:2.33e-10 (favourable), Thyroid cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			ovary: 32.0	Cell line enhanced		HAP1: 17.3;K-562: 44.7
INSL6	RIF1	ENSG00000120210	Insulin like 6	9	5131979-5185668	Predicted secreted proteins	Evidence at protein level	HPA021364	Enhanced					Not detected	Tissue enriched	40	testis: 21.6	placenta: 0.5	Not detected		
INSL4	EPIL	ENSG00000120211	Insulin like 4	9	5231419-5235304	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	12	placenta: 22.2	epididymis: 1.8	Cell line enriched	10	A549: 22.2
MLANA	MART1	ENSG00000120215	Melan-A	9	5890802-5910606	Predicted membrane proteins	Evidence at protein level	CAB000057, HPA048662	Enhanced					Tissue enriched	Tissue enriched	25	skin: 50.4	breast: 1.9	Cell line enriched	330	SK-MEL-30: 523.2
CD274	B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1	ENSG00000120217	CD274 molecule	9	5450503-5470566	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB030018, CAB076385	Enhanced		Approved	Cytosol	Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable)	Mixed	Mixed			appendix: 14.0	Cell line enhanced		HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
IFNA6	IFN-alphaK	ENSG00000120235	Interferon alpha 6	9	21349835-21351378	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IFNA8	IFN-alphaB	ENSG00000120242	Interferon alpha 8	9	21409147-21410185	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GRIA2	GluA2, GLUR2, GLURB	ENSG00000120251	Glutamate ionotropic receptor AMPA type subunit 2	4	157204182-157366075	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007812, HPA008441	Enhanced					Group enriched	Tissue enriched	7	cerebral cortex: 206.6	endometrium: 27.5	Cell line enriched	8	SCLC-21H: 19.9
NUP43	bA350J20.1, FLJ13287	ENSG00000120253	Nucleoporin 43	6	149724315-149749665	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027126, HPA027291, HPA028500	Enhanced				Liver cancer:7.13e-7 (unfavourable), Breast cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.6	Expressed in all		
MTHFD1L	DKFZP586G1517, FLJ21145, FTHFSDC1	ENSG00000120254	Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like	6	150865549-151101887	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015006, HPA029040, HPA029041, HPA050052, HPA074911	Approved		Supported	Mitochondria	Cervical cancer:1.68e-5 (unfavourable), Liver cancer:8.33e-5 (unfavourable), Urothelial cancer:8.69e-5 (unfavourable), Head and neck cancer:5.10e-4 (unfavourable), Endometrial cancer:7.28e-4 (unfavourable)	Expressed in all	Mixed			placenta: 20.6	Expressed in all		
LRP11	bA350J20.3, MANSC3	ENSG00000120256	LDL receptor related protein 11	6	149818798-149864026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064002			Approved	Mitochondria	Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.2	Mixed		
CCDC170	bA282P11.1, C6orf97, FLJ23305	ENSG00000120262	Coiled-coil domain containing 170	6	151494030-151621193	Predicted intracellular proteins	Evidence at protein level	HPA027114, HPA027185	Enhanced		Approved	Golgi apparatus<br>Cell Junctions	Endometrial cancer:3.64e-4 (favourable)	Mixed	Tissue enriched	6	fallopian tube: 53.5	thyroid gland: 9.4	Group enriched	6	MCF7: 7.9;T-47d: 5.5
PCMT1		ENSG00000120265	Protein-L-isoaspartate (D-aspartate) O-methyltransferase	6	149749443-149811420	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003239	Approved		Supported	Cytosol	Breast cancer:4.02e-7 (unfavourable), Head and neck cancer:1.88e-4 (unfavourable), Liver cancer:2.58e-4 (unfavourable), Endometrial cancer:4.27e-4 (unfavourable), Urothelial cancer:6.38e-4 (unfavourable), Cervical cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 194.7	Expressed in all		
PLEKHG1	ARHGEF41, KIAA1209	ENSG00000120278	Pleckstrin homology and RhoGEF domain containing G1	6	150599883-150843665	Predicted intracellular proteins	Evidence at protein level	HPA027128, HPA027319, HPA028270	Approved		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		spleen: 48.4	lymph node: 23.1	Cell line enhanced		AF22: 18.8;HAP1: 29.5;Karpas-707: 16.8
MYCT1	FLJ21269, MTLC	ENSG00000120279	Myc target 1	6	152697895-152724567	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047992			Uncertain	Nucleoplasm	Renal cancer:4.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 69.0	placenta: 29.9	Cell line enhanced		HEL: 20.7;HUVEC TERT2: 103.9;TIME: 85.0
CXorf21	FLJ11577	ENSG00000120280	Chromosome X open reading frame 21	X	30558824-30577844	Predicted intracellular proteins	Evidence at protein level	HPA001185	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			appendix: 14.4	Cell line enriched	6	THP-1: 107.8
MAGEB4	CT3.6, MGC33144	ENSG00000120289	MAGE family member B4	X	30242052-30244193	Predicted intracellular proteins	Evidence at protein level	HPA030456	Enhanced					Not detected	Group enriched	117	epididymis: 34.1;testis: 17.0	breast: 0.2	Not detected		
CYSTM1	C5orf32, ORF1-FL49	ENSG00000120306	Cysteine rich transmembrane module containing 1	5	140174642-140282052	Predicted intracellular proteins	Evidence at protein level	HPA050930	Enhanced				Renal cancer:9.69e-5 (favourable), Endometrial cancer:1.31e-4 (favourable), Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 484.3	Expressed in all		
WDR55	FLJ20195, FLJ21702	ENSG00000120314	WD repeat domain 55	5	140664676-140674124	Predicted intracellular proteins	Evidence at protein level	HPA043470, HPA048143	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:8.88e-6 (unfavourable), Breast cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 12.7	Expressed in all		
ARAP3	CENTD3, DRAG1, FLJ21065	ENSG00000120318	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3	5	141653401-141682221	Predicted intracellular proteins	Evidence at protein level	HPA042887	Uncertain				Renal cancer:1.59e-6 (unfavourable)	Expressed in all	Mixed			placenta: 17.2	Cell line enhanced		HUVEC TERT2: 62.0;TIME: 43.4
PCDHB8	PCDH-BETA8, PCDH3I	ENSG00000120322	Protocadherin beta 8	5	141177790-141180529	Predicted membrane proteins	Evidence at transcript level	HPA057773	Uncertain					Mixed	Mixed			endometrium: 2.1	Cell line enhanced		EFO-21: 19.7;T-47d: 29.4;U-138 MG: 12.0;U-2197: 31.8
PCDHB10		ENSG00000120324	Protocadherin beta 10	5	141192353-141195642	Predicted membrane proteins	Evidence at protein level	HPA013445	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 8.3	endometrium: 5.1	Cell line enhanced		EFO-21: 13.2
PCDHB14	PCDH-BETA14	ENSG00000120327	Protocadherin beta 14	5	141222932-141227759	Predicted membrane proteins	Evidence at protein level	HPA007692, HPA045248	Uncertain		Approved	Vesicles	Renal cancer:6.09e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 7.6	Cell line enhanced		SH-SY5Y: 15.2;SiHa: 12.6
PCDHB12	PCDH-BETA12	ENSG00000120328	Protocadherin beta 12	5	141208697-141212571	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Mixed			endometrium: 3.6	Cell line enhanced		EFO-21: 2.8;RH-30: 3.1
SLC25A2	ORNT2	ENSG00000120329	Solute carrier family 25 member 2	5	141302629-141304045	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042146	Uncertain					Not detected	Tissue enriched	117	testis: 11.6	all non-specific tissues: 0.0	Not detected		
TNN		ENSG00000120332	Tenascin N	1	175067858-175148066	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010907, HPA026726, HPA026764	Uncertain					Tissue enhanced	Tissue enhanced		adipose tissue: 12.4	breast: 4.1	Group enriched	11	AF22: 5.6;NB-4: 2.3;THP-1: 7.4;U-266/70: 2.1;U-937: 1.6
MRPS14	HSMRPS14	ENSG00000120333	Mitochondrial ribosomal protein S14	1	175010789-175023425	Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA051087	Uncertain		Supported	Nuclear membrane<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 39.0	Expressed in all		
CENPL	C1orf155, dJ383J4.3, FLJ31044	ENSG00000120334	Centromere protein L	1	173799550-173824720	Predicted intracellular proteins	Evidence at protein level	HPA044520	Uncertain				Melanoma:2.51e-4 (unfavourable), Ovarian cancer:3.60e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 18.2	lymph node: 7.8	Expressed in all		
TNFSF18	AITRL, hGITRL, TL6	ENSG00000120337	Tumor necrosis factor superfamily member 18	1	173039960-173050963	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 2.8;gallbladder: 3.0	parathyroid gland: 1.4	Group enriched	11	EFO-21: 48.3;HUVEC TERT2: 65.6;TIME: 89.7
SEC16B	LZTR2, PGPR-p117, RGPR, Sec16S	ENSG00000120341	SEC16 homolog B, endoplasmic reticulum export factor	1	177923956-177984303	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054292, HPA072913	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Actin filaments		Not detected	Tissue enhanced		duodenum: 28.2;small intestine: 30.9	liver: 18.8	Cell line enhanced		CAPAN-2: 6.3;EFO-21: 5.1;HDLM-2: 5.3
GORAB	FLJ11752, GO, NTKL-BP1, SCYL1BP1	ENSG00000120370	Golgin, RAB6 interacting	1	170532129-170553446	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027208, HPA027250	Approved		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:7.83e-12 (unfavourable), Head and neck cancer:1.39e-4 (favourable), Liver cancer:5.26e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 7.9	Mixed		
GPR31	12-HETER, HETER1	ENSG00000120436	G protein-coupled receptor 31	6	167156271-167158329	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA014014, HPA027108	Uncertain					Not detected	Tissue enhanced		lymph node: 1.6	spleen: 0.9	Not detected		
ACAT2		ENSG00000120437	Acetyl-CoA acetyltransferase 2	6	159760328-159779055	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB021106, HPA025736, HPA025765, HPA025811	Enhanced		Supported	Nucleus<br>Cytosol	Colorectal cancer:1.12e-4 (favourable), Endometrial cancer:7.25e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable)	Expressed in all	Mixed			liver: 45.8	Expressed in all		
TCP1	CCT1, Ccta, D6S230E	ENSG00000120438	T-complex 1	6	159778498-159789749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017460, HPA027337, HPA031082	Approved				Liver cancer:1.49e-5 (unfavourable), Breast cancer:8.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 325.2	Expressed in all		
TTLL2	C6orf104, dJ366N23.3, NYD-TSPG	ENSG00000120440	Tubulin tyrosine ligase like 2	6	167325086-167359503	Predicted intracellular proteins	Evidence at protein level	HPA027985			Approved	Nuclear membrane<br>Nucleoli		Not detected	Tissue enriched	189	testis: 34.1	liver,ovary: 0.1	Cell line enhanced		CACO-2: 1.5
SNX19	CHET8, KIAA0254	ENSG00000120451	Sorting nexin 19	11	130875436-130916509	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013447	Uncertain		Supported	Mitochondria	Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 50.8	Mixed		
KCNJ5	CIR, GIRK4, KATP1, Kir3.4, LQT13	ENSG00000120457	Potassium voltage-gated channel subfamily J member 5	11	128891356-128921035	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014722, HPA017353, CAB022569	Enhanced					Mixed	Tissue enhanced		adrenal gland: 84.8	spleen: 18.8	Cell line enriched	12	HBEC3-KT: 9.5
MSANTD2	C11orf61, FLJ23342	ENSG00000120458	Myb/SANT DNA binding domain containing 2	11	124766498-124800673	Predicted intracellular proteins	Evidence at protein level	HPA038694, HPA038695	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.50e-4 (unfavourable), Urothelial cancer:2.65e-4 (favourable)	Expressed in all	Mixed			endometrium: 14.5	Expressed in all		
TP53AIP1	p53AIP1	ENSG00000120471	Tumor protein p53 regulated apoptosis inducing protein 1	11	128934731-128943399	Predicted intracellular proteins	Evidence at transcript level	HPA044300, HPA048797	Approved					Tissue enhanced	Tissue enhanced		esophagus: 6.3;skin: 22.2	fallopian tube: 4.1	Not detected		
TEX11	TGC1, TSGA3	ENSG00000120498	Testis expressed 11	X	70528940-70908731	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002950	Approved					Tissue enhanced	Group enriched	10	pancreas: 12.3;testis: 21.1	rectum: 1.7	Not detected		
ARR3	ARRX	ENSG00000120500	Arrestin 3	X	70268305-70281840	Predicted intracellular proteins	Evidence at protein level	HPA063129	Supported					Not detected	Tissue enhanced		skin: 2.7	lymph node: 1.1	Cell line enhanced		Karpas-707: 1.5
PDZD11	PDZK11	ENSG00000120509	PDZ domain containing 11	X	70286595-70290514	Predicted intracellular proteins	Evidence at protein level	HPA003972	Approved					Expressed in all	Expressed in all			cerebral cortex,thyroid gland: 59.9	Expressed in all		
SLC10A7	C4orf13, DKFZp313H0531, DKFZp566M114, DKFZp779O2438, MGC25043	ENSG00000120519	Solute carrier family 10 member 7	4	146253975-146521964	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039996, HPA057906	Uncertain		Approved	Nucleoli		Expressed in all	Mixed			epididymis: 16.2	Expressed in all		
NUDCD1	CML66, FLJ14991	ENSG00000120526	NudC domain containing 1	8	109240919-109334385	Predicted intracellular proteins	Evidence at protein level	HPA023183	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.71e-6 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Lung cancer:4.37e-5 (unfavourable), Pancreatic cancer:6.94e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.2	Expressed in all		
ENY2	DC6, FLJ20480, Sus1	ENSG00000120533	ENY2, transcription and export complex 2 subunit	8	109334324-109345953	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024648	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:7.17e-6 (unfavourable)	Expressed in all	Expressed in all			kidney: 77.5	Expressed in all		
MASTL	FLJ14813, Gwl, THC2	ENSG00000120539	Microtubule associated serine/threonine kinase like	10	27154824-27186924	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027175, HPA054273	Approved		Enhanced	Nucleoplasm	Renal cancer:1.71e-6 (unfavourable), Liver cancer:2.52e-6 (unfavourable), Pancreatic cancer:4.81e-5 (unfavourable)	Expressed in all	Mixed			testis: 12.6	Expressed in all		
KIAA1217	DKFZP761L0424, SKT	ENSG00000120549	KIAA1217	10	23694746-24547848	Predicted intracellular proteins	Evidence at protein level	HPA004941	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:7.63e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 87.7	Cell line enhanced		BEWO: 79.6
LYZL1	LYC2, MGC33408	ENSG00000120563	Lysozyme like 1	10	29289061-29318328	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	480	testis: 53.4	parathyroid gland: 0.1	Not detected		
PLXDC2	FLJ14623, TEM7R	ENSG00000120594	Plexin domain containing 2	10	19816239-20289856	Predicted membrane proteins	Evidence at protein level	HPA017268, HPA070793	Approved		Supported	Nuclear bodies		Expressed in all	Mixed			gallbladder: 25.0	Cell line enhanced		HHSteC: 14.9;U-2197: 40.1
EPC1	Epl1	ENSG00000120616	Enhancer of polycomb homolog 1	10	32267751-32378798	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:6.02e-4 (favourable), Head and neck cancer:6.40e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 32.9	Expressed in all		
IQSEC3	KIAA1110, MGC30156	ENSG00000120645	IQ motif and Sec7 domain 3	12	66765-178460	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 16.1	fallopian tube: 5.4	Cell line enhanced		HEL: 6.3;U-266/70: 6.9;U-266/84: 1.6
CCDC77	MGC13183	ENSG00000120647	Coiled-coil domain containing 77	12	389273-442645	Predicted intracellular proteins	Evidence at protein level	HPA038854	Approved		Approved	Nuclear membrane	Liver cancer:8.11e-7 (unfavourable)	Expressed in all	Mixed			testis: 22.9	Expressed in all		
TAF12	TAF2J, TAFII20	ENSG00000120656	TATA-box binding protein associated factor 12	1	28589323-28643085	Predicted intracellular proteins	Evidence at protein level	HPA008519	Approved				Renal cancer:1.36e-7 (unfavourable), Liver cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.1	Expressed in all		
ENOX1	cCNOX, CNOX, FLJ10094, PIG38	ENSG00000120658	Ecto-NOX disulfide-thiol exchanger 1	13	43213518-43786908	Predicted intracellular proteins	Evidence at protein level	HPA038355	Supported		Supported	Plasma membrane		Mixed	Tissue enhanced		testis: 16.3	cerebral cortex: 10.5	Cell line enhanced		hTEC/SVTERT24-B: 17.3;RH-30: 23.3
TNFSF11	CD254, ODF, OPGL, RANKL, TRANCE	ENSG00000120659	Tumor necrosis factor superfamily member 11	13	42562736-42608013	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009193, HPA045142	Enhanced					Mixed	Tissue enhanced		lymph node: 17.3	appendix: 6.3	Cell line enhanced		HSkMC: 1.5;NTERA-2: 3.0
MTRF1	MGC47721, MTTRF1, RF1	ENSG00000120662	Mitochondrial translation release factor 1	13	41216369-41263577	Predicted intracellular proteins	Evidence at protein level	HPA043316	Uncertain					Expressed in all	Expressed in all			testis: 25.6	Expressed in all		
SOHLH2	bHLHe81, FLJ20449, SPATA28, TEB1	ENSG00000120669	Spermatogenesis and oogenesis specific basic helix-loop-helix 2	13	36168208-36214615	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029182						Mixed	Tissue enriched	15	testis: 46.2	prostate: 3.0	Cell line enhanced		A-431: 7.0;HL-60: 8.5;Karpas-707: 8.3;NB-4: 9.8;U-266/84: 11.1
DNAJC15	DNAJD1, MCJ	ENSG00000120675	DnaJ heat shock protein family (Hsp40) member C15	13	43023203-43114224	Disease related genes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 11.4	Mixed		
PROSER1	bA50D16.2, C13orf23, FLJ12661	ENSG00000120685	Proline and serine rich 1	13	39009866-39038076	Predicted intracellular proteins	Evidence at protein level	CAB034225, HPA055687	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			placenta: 30.3	Expressed in all		
UFM1	bA131P10.1, C13orf20	ENSG00000120686	Ubiquitin fold modifier 1	13	38349849-38363619	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039758	Approved				Head and neck cancer:1.08e-4 (unfavourable), Endometrial cancer:9.35e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 101.2	Expressed in all		
WBP4	FBP21, MGC117310	ENSG00000120688	WW domain binding protein 4	13	41061274-41084006	Predicted intracellular proteins	Evidence at protein level	HPA038965, HPA058738	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Thyroid cancer:2.89e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 27.7	Expressed in all		
ELF1		ENSG00000120690	E74 like ETS transcription factor 1	13	40932028-41061440	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001755, CAB005172	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 129.2	Expressed in all		
SMAD9	MADH6, MADH9, SMAD8, SMAD8/9	ENSG00000120693	SMAD family member 9	13	36844831-36920765	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009119, HPA031162	Approved		Supported	Nucleoplasm<br>Cytosol	Glioma:4.39e-4 (favourable), Thyroid cancer:4.92e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 62.8	prostate: 22.2	Cell line enhanced		SH-SY5Y: 41.4
HSPH1	HSP105A, HSP105B, KIAA0201, NY-CO-25	ENSG00000120694	Heat shock protein family H (Hsp110) member 1	13	31134974-31162388	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002060, HPA028675, HPA031569	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.41e-5 (unfavourable), Head and neck cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 123.7	Expressed in all		
KBTBD7	DKFZP434E2318	ENSG00000120696	Kelch repeat and BTB domain containing 7	13	41189833-41194566	Predicted intracellular proteins	Evidence at protein level	HPA043709, HPA046861, HPA048914	Uncertain				Lung cancer:5.29e-4 (favourable), Pancreatic cancer:6.62e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.0	Mixed		
ALG5	bA421P11.2	ENSG00000120697	ALG5, dolichyl-phosphate beta-glucosyltransferase	13	36949775-37000261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007989	Approved		Approved	Cytosol	Renal cancer:1.40e-5 (favourable), Head and neck cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 96.6	Expressed in all		
EXOSC8	bA421P11.3, CIP3, EAP2, OIP2, p9, RRP43, Rrp43p	ENSG00000120699	Exosome component 8	13	36998816-37009613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034240, HPA039702, HPA043942	Uncertain		Approved	Mitochondria	Renal cancer:8.39e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
ETF1	ERF, ERF1, RF1, SUP45L1, TB3-1	ENSG00000120705	Eukaryotic translation termination factor 1	5	138506095-138543300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011686, HPA037511	Approved				Colorectal cancer:9.33e-5 (favourable), Thyroid cancer:1.22e-4 (unfavourable), Liver cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 108.6	Expressed in all		
TGFBI	BIGH3, CDB1, CDGG1, CSD1, CSD2, CSD3, LCD1	ENSG00000120708	Transforming growth factor beta induced	5	136028895-136063818	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008612, HPA017019	Enhanced				Renal cancer:7.82e-10 (unfavourable), Cervical cancer:1.03e-5 (unfavourable), Ovarian cancer:1.14e-5 (unfavourable), Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			placenta: 607.8	Cell line enhanced		fHDF/TERT166: 2100.5;HSkMC: 1955.4;U-87 MG: 3543.6
FAM53C	C5orf6	ENSG00000120709	Family with sequence similarity 53 member C	5	138331935-138349729	Predicted intracellular proteins	Evidence at protein level	HPA042796	Approved				Endometrial cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 73.2	Expressed in all		
SIL1	BAP, MSS, ULG5	ENSG00000120725	SIL1 nucleotide exchange factor	5	138946720-139293557	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011949	Enhanced				Glioma:3.77e-4 (unfavourable), Endometrial cancer:4.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 60.1	Expressed in all		
PAIP2	PAIP2A	ENSG00000120727	Poly(A) binding protein interacting protein 2	5	139341587-139369720	Predicted intracellular proteins	Evidence at protein level	HPA035945, CAB037212, HPA056766	Approved		Supported	Vesicles		Expressed in all	Expressed in all			testis: 306.7	Expressed in all		
MYOT	LGMD1, LGMD1A, TTID	ENSG00000120729	Myotilin	5	137867791-137887851	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037733, HPA037734	Enhanced				Head and neck cancer:8.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	21	skeletal muscle: 766.9	esophagus: 36.1	Not detected		
KDM3B	C5orf7, JMJD1B, KIAA1082, NET22	ENSG00000120733	Lysine demethylase 3B	5	138352596-138437028	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016610, HPA057202	Supported		Enhanced	Nucleoplasm	Renal cancer:6.67e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.3	Expressed in all		
EGR1	AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268, ZNF225	ENSG00000120738	Early growth response 1	5	138465490-138469315	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019427, HPA029937, HPA029938	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 1188.8	Cell line enhanced		hTCEpi: 208.0;U-266/84: 325.4
SERP1	FLJ43424, RAMP4	ENSG00000120742	Stress associated endoplasmic reticulum protein 1	3	150541994-150603228	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038970	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:1.03e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 182.5	Expressed in all		
PLS1	I-plastin, Plastin-1	ENSG00000120756	Plastin 1	3	142596387-142713664	Predicted intracellular proteins	Evidence at protein level	HPA055744	Enhanced				Renal cancer:8.76e-6 (favourable), Pancreatic cancer:4.84e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 192.4;small intestine: 348.5	rectum: 152.0	Cell line enhanced		BEWO: 108.3;RPTEC TERT1: 108.5
ZFP30	KIAA0961, ZNF745	ENSG00000120784	ZFP30 zinc finger protein	19	37613749-37692337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030606	Uncertain		Approved	Cytosol	Renal cancer:3.86e-4 (favourable)	Expressed in all	Mixed			testis: 14.0	Cell line enhanced		U-2 OS: 34.4
NR2C1	TR2, TR2-11	ENSG00000120798	Nuclear receptor subfamily 2 group C member 1	12	95020229-95073703	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035040, HPA035041, HPA067767	Enhanced		Supported	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable)	Expressed in all	Mixed			testis: 21.9	Expressed in all		
UTP20	1A6/DRIM, DRIM	ENSG00000120800	UTP20, small subunit processome component	12	101280109-101386616	Predicted intracellular proteins	Evidence at protein level	HPA049341			Supported	Nucleoli<br>Plasma membrane	Liver cancer:1.15e-5 (unfavourable), Renal cancer:8.87e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.2	Expressed in all		
TMPO	LAP2, LEMD4, TP	ENSG00000120802	Thymopoietin	12	98515512-98550379	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008150, CAB009847	Enhanced		Enhanced	Nuclear membrane	Renal cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.3	Expressed in all		
ARL1	ARFL1	ENSG00000120805	ADP ribosylation factor like GTPase 1	12	101393120-101407820	Predicted intracellular proteins	Evidence at protein level	HPA062656, HPA073012	Approved		Supported	Golgi apparatus	Endometrial cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 142.0	Expressed in all		
GLT8D2	FLJ31494	ENSG00000120820	Glycosyltransferase 8 domain containing 2	12	103988984-104064183	Predicted intracellular proteins	Evidence at protein level	HPA026904	Approved		Approved	Cytosol	Renal cancer:1.58e-6 (unfavourable), Cervical cancer:7.37e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 57.1	Cell line enhanced		ASC TERT1: 48.9;BJ hTERT+: 73.1;HSkMC: 47.3
MTERF2	FLJ14062, MTERFD3	ENSG00000120832	Mitochondrial transcription termination factor 2	12	106977291-106987166	Predicted intracellular proteins	Evidence at protein level	HPA003526	Approved				Cervical cancer:8.50e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 29.1	Mixed		
SOCS2	CIS2, Cish2, SOCS-2, SSI-2, SSI2, STATI2	ENSG00000120833	Suppressor of cytokine signaling 2	12	93569814-93583487	Predicted intracellular proteins	Evidence at protein level	CAB010356	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:8.17e-7 (favourable), Liver cancer:1.09e-6 (favourable)	Expressed in all	Expressed in all			smooth muscle: 130.2	Cell line enhanced		CACO-2: 137.8;K-562: 124.1;REH: 295.4
NFYB	CBF-A, HAP3, NF-YB	ENSG00000120837	Nuclear transcription factor Y subunit beta	12	104117077-104138289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004211	Supported		Supported	Nucleoplasm	Renal cancer:9.28e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 123.9	Expressed in all		
WASHC3	CCDC53, CGI-116	ENSG00000120860	WASH complex subunit 3	12	102012927-102062149	Predicted intracellular proteins	Evidence at protein level	HPA038338, HPA038339	Approved		Approved	Vesicles		Expressed in all	Expressed in all			testis: 165.7	Expressed in all		
APAF1	APAF-1, CED4	ENSG00000120868	Apoptotic peptidase activating factor 1	12	98645141-98735433	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031373, CAB069399	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Colorectal cancer:5.90e-4 (favourable)	Expressed in all	Mixed			bone marrow: 21.7	Expressed in all		
DUSP4	HVH2, MKP-2, TYP	ENSG00000120875	Dual specificity phosphatase 4	8	29333064-29350668	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061967			Supported	Nucleoplasm	Renal cancer:4.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 29.6	stomach: 28.2	Cell line enhanced		A549: 90.3;SK-MEL-30: 120.4;WM-115: 120.9
CLU	APOJ, CLI, CLU1, CLU2, KUB1, SGP-2, SP-40, TRPM-2	ENSG00000120885	Clusterin	8	27596917-27615031	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000572, CAB016253	Enhanced				Thyroid cancer:7.66e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 11170.2	Expressed in all		
TNFRSF10B	CD262, DR5, KILLER, TRAIL-R2, TRICK2A, TRICKB	ENSG00000120889	TNF receptor superfamily member 10b	8	23020133-23069179	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA023625	Approved				Renal cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.3	Mixed		
SORBS3	SCAM-1, SH3D4, vinexin	ENSG00000120896	Sorbin and SH3 domain containing 3	8	22544986-22575788	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015849, HPA048034	Approved		Approved	Nucleoplasm<br>Focal adhesion sites	Urothelial cancer:1.53e-5 (unfavourable), Pancreatic cancer:4.88e-4 (favourable)	Expressed in all	Expressed in all			placenta: 95.6	Mixed		
PTK2B	CADTK, CAKB, FAK2, PTK, PYK2, RAFTK	ENSG00000120899	Protein tyrosine kinase 2 beta	8	27311482-27459391	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003850, HPA026091, HPA026276	Approved		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:3.32e-4 (favourable), Thyroid cancer:5.11e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.1	Cell line enhanced		REH: 128.1
CHRNA2		ENSG00000120903	Cholinergic receptor nicotinic alpha 2 subunit	8	27459761-27479883	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	24	prostate: 46.8	breast: 1.9	Not detected		
ADRA1A	ADRA1C, ADRA1L1	ENSG00000120907	Adrenoceptor alpha 1A	8	26748150-26867273	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029678, HPA029679	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 22.6;liver: 31.6;prostate: 20.8	seminal vesicle: 19.1	Not detected		
PPP3CC	CALNA3, PP2Bgamma	ENSG00000120910	Protein phosphatase 3 catalytic subunit gamma	8	22440819-22541142	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023396, CAB024950	Approved		Approved	Vesicles	Lung cancer:6.80e-5 (favourable)	Expressed in all	Expressed in all			testis: 101.2	Expressed in all		
PDLIM2		ENSG00000120913	PDZ and LIM domain 2	8	22578279-22598025	Predicted intracellular proteins	Evidence at protein level	HPA003880	Approved		Approved	Actin filaments<br>Focal adhesion sites	Renal cancer:1.37e-7 (unfavourable), Glioma:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 267.3	Mixed		
EPHX2		ENSG00000120915	Epoxide hydrolase 2	8	27490779-27545564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023094, HPA023660	Approved		Enhanced	Cytosol	Renal cancer:1.98e-10 (favourable), Cervical cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			kidney: 171.7	Cell line enhanced		K-562: 46.0
RNF170	ADSA, DKFZP564A022, SNAX1	ENSG00000120925	Ring finger protein 170	8	42849637-42897290	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA050931, HPA054621	Uncertain					Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
NPPB		ENSG00000120937	Natriuretic peptide B	1	11857464-11858931	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	1857	heart muscle: 3255.2	testis: 1.7	Group enriched	7	BEWO: 134.5;CACO-2: 309.8
UBIAD1	SCCD, TERE1	ENSG00000120942	UbiA prenyltransferase domain containing 1	1	11273206-11296049	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044862			Approved	Vesicles	Renal cancer:6.80e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.8	Expressed in all		
TARDBP	ALS10, TDP-43	ENSG00000120948	TAR DNA binding protein	1	11012344-11026420	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003703, HPA017284	Supported		Enhanced	Nucleoplasm	Liver cancer:1.20e-7 (unfavourable), Cervical cancer:1.15e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 178.4	Expressed in all		
TNFRSF8	CD30, D1S166E, KI-1	ENSG00000120949	TNF receptor superfamily member 8	1	12063377-12144207	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000016, HPA032081, HPA032082	Approved					Tissue enriched	Tissue enhanced		appendix: 4.1	adipose tissue: 3.1	Cell line enriched	22	HDLM-2: 528.2
PRAMEF2	FLJ43580	ENSG00000120952	PRAME family member 2	1	12857086-12861909	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
ZNF706	HSPC038	ENSG00000120963	Zinc finger protein 706	8	101177878-101206193	Predicted intracellular proteins	Evidence at protein level	HPA042793			Approved	Plasma membrane	Renal cancer:5.90e-11 (unfavourable), Endometrial cancer:3.12e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 159.9	Expressed in all		
LYPLA1	LPL1	ENSG00000120992	Lysophospholipase I	8	54046367-54102017	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050941, HPA063151	Enhanced		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 118.6	Expressed in all		
CRISPLD1	Cocoacrisp, DKFZp762F133, LCRISP1	ENSG00000121005	Cysteine rich secretory protein LCCL domain containing 1	8	74984515-75034558	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024725	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 39.6	breast: 35.0	Group enriched	5	AF22: 132.6;SH-SY5Y: 76.5
COPS5	CSN5, JAB1, MOV-34, SGN5	ENSG00000121022	COP9 signalosome subunit 5	8	67043079-67083783	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004242, HPA004845, HPA051531	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 92.4	Expressed in all		
RDH10	SDR16C4	ENSG00000121039	Retinol dehydrogenase 10	8	73294612-73325281	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049199			Approved	Lipid droplets		Expressed in all	Expressed in all			placenta: 51.8	Expressed in all		
EPX	EPO, EPP, EPX-PEN	ENSG00000121053	Eosinophil peroxidase	17	58192737-58205174	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA050507	Approved					Not detected	Tissue enriched	24	bone marrow: 20.5	cerebral cortex: 0.8	Cell line enriched	55	NB-4: 157.0
AKAP1	AKAP121, AKAP149, AKAP84, D-AKAP1, PPP1R43, PRKA1, S-AKAP84, SAKAP84, TDRD17	ENSG00000121057	A-kinase anchoring protein 1	17	57085092-57121349	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008620, HPA008691, CAB019286	Supported		Supported	Mitochondria	Renal cancer:7.86e-9 (favourable)	Expressed in all	Expressed in all			testis: 150.9	Expressed in all		
COIL	CLN80, p80-coilin	ENSG00000121058	Coilin	17	56938187-56961054	Predicted intracellular proteins	Evidence at protein level	CAB017524, HPA027885, HPA068537, CAB069400	Enhanced		Enhanced	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies	Liver cancer:1.28e-4 (unfavourable), Colorectal cancer:1.77e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 175.4	thyroid gland: 20.2	Expressed in all		
TRIM25	EFP, RNF147, ZNF147	ENSG00000121060	Tripartite motif containing 25	17	56887909-56914038	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005909	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Pancreatic cancer:3.36e-4 (favourable), Stomach cancer:9.35e-4 (favourable), Liver cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 34.8	Mixed		
SCPEP1	RISC	ENSG00000121064	Serine carboxypeptidase 1	17	56978105-57006768	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039102, HPA057200	Approved		Approved	Golgi apparatus	Liver cancer:1.96e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 621.6	Expressed in all		
SPOP	BTBD32, TEF2	ENSG00000121067	Speckle type BTB/POZ protein	17	49598884-49678234	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 121.2	Expressed in all		
TBX2		ENSG00000121068	T-box 2	17	61399896-61409466	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008586, CAB013636	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		lung: 50.0	seminal vesicle: 40.0	Cell line enhanced		AN3-CA: 124.2;MCF7: 62.0;SH-SY5Y: 65.7;WM-115: 44.0
SLC35B1	UGTREL1	ENSG00000121073	Solute carrier family 35 member B1	17	49700943-49709014	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048655, HPA057418	Approved		Approved	Nucleus<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:5.69e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
TBX4		ENSG00000121075	T-box 4	17	61452404-61485110	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032413, HPA044457	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	lung: 43.6;placenta: 29.8;prostate: 14.9	urinary bladder: 4.8	Cell line enhanced		BJ: 2.4;THP-1: 3.9
TEX14	CT113	ENSG00000121101	Testis expressed 14, intercellular bridge forming factor	17	58556678-58692055	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030620, HPA077020	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enriched	43	testis: 48.9	bone marrow: 1.1	Cell line enhanced		HDLM-2: 5.9;Karpas-707: 5.7;MCF7: 2.5
FAM117A		ENSG00000121104	Family with sequence similarity 117 member A	17	49710332-49789180	Predicted intracellular proteins	Evidence at protein level	HPA022531	Approved		Approved	Nucleoplasm	Lung cancer:8.25e-7 (favourable), Breast cancer:5.30e-5 (favourable), Pancreatic cancer:1.81e-4 (favourable)	Expressed in all	Expressed in all			spleen: 46.6	Cell line enhanced		U-266/70: 61.5
NCAPH	BRRN1, CAP-H, hCAP-H	ENSG00000121152	Non-SMC condensin I complex subunit H	2	96335787-96373845	Predicted intracellular proteins	Evidence at protein level	HPA002647, HPA003008	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:9.53e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable), Lung cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 55.4	lymph node: 21.3	Mixed		
LRAT	LCA14	ENSG00000121207	Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase)	4	154626945-154753118	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070726			Uncertain	Endoplasmic reticulum<br>Golgi apparatus		Mixed	Tissue enhanced		thyroid gland: 2.3	testis: 1.6	Cell line enriched	11	NTERA-2: 11.7
KIAA0922	DKFZp586H1322, TMEM131L	ENSG00000121210	KIAA0922	4	153466346-153636711	Predicted membrane proteins	Evidence at protein level	HPA043472, HPA048443	Uncertain		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:6.69e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 56.4	Cell line enhanced		Daudi: 75.0;MOLT-4: 79.8;U-698: 85.3
MND1	GAJ	ENSG00000121211	Meiotic nuclear divisions 1	4	153344649-153415118	Predicted intracellular proteins	Evidence at protein level	HPA043499	Enhanced				Liver cancer:2.72e-4 (unfavourable), Melanoma:3.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 28.8	lymph node: 14.3	Mixed		
TRIM6	RNF89	ENSG00000121236	Tripartite motif containing 6	11	5596109-5612958	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060514	Uncertain					Mixed	Tissue enhanced		kidney: 22.5	testis: 17.2	Cell line enhanced		NTERA-2: 22.2;U-2 OS: 22.5
ABCC11	MRP8	ENSG00000121270	ATP binding cassette subfamily C member 11	16	48166910-48247568	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031980, HPA031981, HPA031982, CAB032513	Uncertain					Group enriched	Tissue enriched	11	breast: 64.4	prostate: 6.0	Cell line enriched	5	T-47d: 64.4
PAPD5	TRF4-2	ENSG00000121274	Poly(A) RNA polymerase D5, non-canonical	16	50152918-50235310	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042968, HPA048225	Uncertain				Renal cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.5	Expressed in all		
ADCY7	AC7, KIAA0037	ENSG00000121281	Adenylate cyclase 7	16	50246137-50318135	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041218, HPA048241	Uncertain		Approved	Cytosol	Cervical cancer:5.31e-4 (unfavourable)	Mixed	Mixed			spleen: 44.0	Cell line enhanced		HMC-1: 186.7;RPMI-8226: 76.6
CEP89	CCDC123, FLJ14640	ENSG00000121289	Centrosomal protein 89	19	32875925-32971991	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039382, HPA040056			Supported	Plasma membrane<br>Cytosol	Liver cancer:8.78e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube,prostate: 14.5	Expressed in all		
TSHZ3	KIAA1474, TSH3, ZNF537	ENSG00000121297	Teashirt zinc finger homeobox 3	19	31274945-31349547	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008834	Approved		Supported	Nucleoplasm	Renal cancer:2.92e-4 (unfavourable)	Mixed	Mixed			ovary: 37.5	Cell line enhanced		RH-30: 44.3;U-138 MG: 31.7
ECHDC2	FLJ10948	ENSG00000121310	Enoyl-CoA hydratase domain containing 2	1	52895910-52927212	Predicted intracellular proteins	Evidence at protein level	HPA026731, HPA026768	Enhanced		Approved	Mitochondria	Urothelial cancer:2.70e-4 (favourable), Head and neck cancer:6.65e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 47.8	kidney: 26.3	Cell line enhanced		BEWO: 15.6;HHSteC: 9.5
TAS2R8	T2R8, TRB5	ENSG00000121314	Taste 2 receptor member 8	12	10806051-10807293	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PLBD1	FLJ22662	ENSG00000121316	Phospholipase B domain containing 1	12	14503661-14568349	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040303	Approved				Liver cancer:2.81e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 167.1	Cell line enhanced		BEWO: 77.7;CAPAN-2: 186.4
TAS2R10	T2R10, TRB2	ENSG00000121318	Taste 2 receptor member 10	12	10825317-10826358	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			breast,epididymis: 0.2	Not detected		
PRB2	cP7, PRPPRB1, Ps	ENSG00000121335	Proline rich protein BstNI subfamily 2	12	11391540-11501041	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	4978	salivary gland: 4971.2	bone marrow,skin: 0.9	Not detected		
PYROXD1	DKFZp762G094, FLJ22028	ENSG00000121350	Pyridine nucleotide-disulphide oxidoreductase domain 1	12	21437615-21471252	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038319, HPA038320	Uncertain		Approved	Nuclear speckles	Urothelial cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.4	Expressed in all		
IAPP	AMYLIN, DAP, IAP	ENSG00000121351	Islet amyloid polypeptide	12	21354959-21379978	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000352, HPA053194	Enhanced					Tissue enriched	Tissue enriched	7	pancreas: 35.0	testis: 5.3	Cell line enhanced		U-2 OS: 1.3
KCNJ8	Kir6.1	ENSG00000121361	Potassium voltage-gated channel subfamily J member 8	12	21764955-21775581	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA031066	Uncertain				Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 32.0	Cell line enhanced		CACO-2: 71.9;SH-SY5Y: 31.1
TAS2R7	T2R7, TRB4	ENSG00000121377	Taste 2 receptor member 7	12	10801532-10802627	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BCL2L14	BCL-G, BCLG	ENSG00000121380	BCL2 like 14	12	12049844-12211084	Predicted intracellular proteins	Evidence at protein level	HPA040665	Enhanced		Uncertain	Cytosol		Tissue enhanced	Tissue enhanced		rectum: 16.9;testis: 24.1	small intestine: 14.2	Group enriched	5	CAPAN-2: 1.8;NTERA-2: 1.6;RT4: 1.5
TAS2R9	T2R9, TRB6	ENSG00000121381	Taste 2 receptor member 9	12	10809094-10810168	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PSPC1	FLJ10955, PSP1	ENSG00000121390	Paraspeckle component 1	13	19674752-19783019	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038904	Supported		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Thyroid cancer:1.46e-4 (favourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
ZNF549	FLJ34917	ENSG00000121406	Zinc finger protein 549	19	57527325-57557542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039511	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 10.2	Mixed		
A1BG		ENSG00000121410	Alpha-1-B glycoprotein	19	58345178-58353499	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016673, HPA044252	Supported				Liver cancer:3.97e-4 (favourable)	Tissue enriched	Tissue enriched	331	liver: 505.6	fallopian tube: 1.5	Cell line enhanced		HEK 293: 2.2;REH: 3.0
ZSCAN18	FLJ12895, ZNF447	ENSG00000121413	Zinc finger and SCAN domain containing 18	19	58083838-58118427	Predicted intracellular proteins	Evidence at protein level	HPA024318	Supported		Approved	Nucleoplasm	Renal cancer:3.95e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 78.8	Cell line enhanced		HEK 293: 121.2;SCLC-21H: 73.3
ZNF211	CH2H2-25, ZNF-25	ENSG00000121417	Zinc finger protein 211	19	57630395-57642779	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA011340, HPA049967	Approved		Approved	Mitochondria<br>Rods & Rings		Expressed in all	Expressed in all			parathyroid gland: 32.7	Mixed		
PDZRN3	KIAA1095, LNX3, SEMACAP3	ENSG00000121440	PDZ domain containing ring finger 3	3	73382433-73624940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038822, HPA061420	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:3.65e-7 (favourable), Endometrial cancer:3.35e-5 (favourable), Pancreatic cancer:4.93e-4 (favourable)	Mixed	Mixed			ovary: 85.7	Cell line enhanced		AF22: 31.7;ASC diff: 39.1;BJ hTERT+: 34.1;HSkMC: 30.3
RGSL1	RGSL2	ENSG00000121446	Regulator of G-protein signaling like 1	1	182409192-182560599	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	6	testis: 9.1	epididymis: 1.4	Not detected		
LHX4	Gsh4	ENSG00000121454	LIM homeobox 4	1	180230286-180278982	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055705			Approved	Nuclear speckles		Not detected	Mixed			testis: 2.2	Cell line enhanced		BEWO: 10.3
RNF2	BAP-1, BAP1, DING, HIPI3, RING1B, RING2	ENSG00000121481	Ring finger protein 2	1	185045364-185102608	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026803	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.94e-7 (unfavourable), Liver cancer:1.08e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 42.2	Expressed in all		
TRMT1L	C1orf25	ENSG00000121486	TRNA methyltransferase 1 like	1	185118098-185157072	Predicted intracellular proteins	Evidence at protein level	HPA026728	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 50.4	Expressed in all		
SEC22A	SEC22L2	ENSG00000121542	SEC22 homolog A, vesicle trafficking protein	3	123201927-123274130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
CSTA	STF1, STFA	ENSG00000121552	Cystatin A	3	122325244-122341972	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000469, HPA001031, CAB047315	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:2.60e-6 (unfavourable), Head and neck cancer:5.86e-4 (favourable)	Expressed in all	Group enriched	5	esophagus: 3876.3;tonsil: 833.8	skin: 429.8	Cell line enhanced		hTCEpi: 870.0;THP-1: 525.5;U-698: 341.3
DPPA4	FLJ10713	ENSG00000121570	Developmental pluripotency associated 4	3	109326141-109337572	Predicted intracellular proteins	Evidence at protein level	CAB020678, HPA035249, HPA035250	Enhanced		Supported	Nucleus<br>Nucleoli		Tissue enriched	Group enriched	8	bone marrow: 2.8;placenta: 3.0;testis: 7.7	lung,lymph node: 0.5	Cell line enhanced		AF22: 42.6;HAP1: 92.5;NTERA-2: 327.0
POPDC2	POP2	ENSG00000121577	Popeye domain containing 2	3	119636457-119665324	Predicted membrane proteins	Evidence at protein level	HPA024255	Enhanced					Mixed	Tissue enhanced		heart muscle: 197.3;seminal vesicle: 64.1	smooth muscle: 35.3	Cell line enriched	31	SH-SY5Y: 30.8
B4GALT4	beta4Gal-T4	ENSG00000121578	Beta-1,4-galactosyltransferase 4	3	119211732-119241103	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046819, HPA063546	Approved		Supported	Golgi apparatus	Liver cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 75.8	Expressed in all		
NAA50	FLJ13194, MAK3, NAT13, NAT5, San	ENSG00000121579	N(alpha)-acetyltransferase 50, NatE catalytic subunit	3	113716460-113746300	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.51e-5 (unfavourable), Pancreatic cancer:7.92e-5 (unfavourable), Endometrial cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 111.8	Expressed in all		
CD80	B7-1, B7.1, CD28LG, CD28LG1	ENSG00000121594	CD80 molecule	3	119524293-119559602	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025368, HPA050092	Enhanced					Mixed	Tissue enhanced		appendix: 7.2;lymph node: 6.7;tonsil: 6.3	spleen: 4.7	Cell line enhanced		Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
KIF18A	DKFZP434G2226, PPP1R99	ENSG00000121621	Kinesin family member 18A	11	28020620-28108308	Predicted intracellular proteins	Evidence at protein level	HPA039312, HPA039484	Approved		Supported	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		testis: 23.4	lymph node: 5.3	Mixed		
GJA8	CAE, CAE1, CX50, CZP1	ENSG00000121634	Gap junction protein alpha 8	1	147907956-147909257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014715, HPA062940	Enhanced					Not detected	Tissue enriched	86	testis: 11.4	kidney,smooth muscle: 0.1	Not detected		
DESI2	C1orf121, CGI-146, FAM152A, FLJ21998, PNAS-4, PPPDE1	ENSG00000121644	Desumoylating isopeptidase 2	1	244652935-244709033	Predicted intracellular proteins	Evidence at protein level	HPA049950			Approved	Vesicles	Renal cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 95.0	Expressed in all		
MAPK8IP1	IB1, JIP-1, JIP1, PRKM8IP	ENSG00000121653	Mitogen-activated protein kinase 8 interacting protein 1	11	45885651-45906465	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058921, HPA070332			Enhanced	Plasma membrane	Renal cancer:1.23e-11 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 177.1	parathyroid gland: 33.1	Cell line enhanced		SCLC-21H: 89.8
CRY2		ENSG00000121671	Cryptochrome circadian clock 2	11	45847118-45883248	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037577	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.44e-15 (favourable), Liver cancer:6.82e-5 (favourable), Colorectal cancer:1.67e-4 (unfavourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.2	Expressed in all		
PEX16		ENSG00000121680	Peroxisomal biogenesis factor 16	11	45909669-45918812	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043286	Approved				Urothelial cancer:9.06e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 27.5	Expressed in all		
DEPDC7		ENSG00000121690	DEP domain containing 7	11	33015864-33033582	Predicted intracellular proteins	Evidence at protein level	HPA015800			Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:7.26e-4 (favourable)	Mixed	Tissue enhanced		liver: 37.6;testis: 50.7	small intestine: 31.2	Cell line enhanced		LHCN-M2: 44.3;RH-30: 38.6;SiHa: 39.2
CAT		ENSG00000121691	Catalase	11	34438925-34472062	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001515, HPA051282, HPA055838	Enhanced		Supported	Vesicles<br>Cytosol	Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			liver: 625.4	Cell line enhanced		HL-60: 310.1
PILRB	FDFACT1, FDFACT2	ENSG00000121716	Paired immunoglobin-like type 2 receptor beta	7	100352176-100367733	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026750	Approved		Approved	Mitochondria	Renal cancer:1.42e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 166.9	Expressed in all		
ZMYM2	FIM, MYM, RAMP, ZNF198	ENSG00000121741	Zinc finger MYM-type containing 2	13	19958670-20091829	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031765	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum	Urothelial cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 88.0	Expressed in all		
GJB6	CX30, DFNA3, ED2, EDH, HED	ENSG00000121742	Gap junction protein beta 6	13	20221971-20232395	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014846			Supported	Cell Junctions		Tissue enhanced	Group enriched	5	bone marrow: 48.1;cerebral cortex: 39.4;esophagus: 150.1;skin: 32.1	tonsil: 12.2	Cell line enriched	9	RT4: 133.4
GJA3	CX46, CZP3	ENSG00000121743	Gap junction protein alpha 3	13	20138255-20161049	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014821	Supported					Tissue enhanced	Tissue enhanced		heart muscle: 5.1;parathyroid gland: 5.9;placenta: 3.5	testis: 2.4	Cell line enhanced		CAPAN-2: 6.8;HL-60: 5.2
TBC1D15	DKFZp761D0223, FLJ12085	ENSG00000121749	TBC1 domain family member 15	12	71839707-71927248	Predicted intracellular proteins	Evidence at protein level	HPA013388, HPA015592	Supported		Supported	Mitochondria<br>Cytosol	Renal cancer:5.34e-4 (favourable), Cervical cancer:7.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.9	Expressed in all		
ADGRB2	BAI2	ENSG00000121753	Adhesion G protein-coupled receptor B2	1	31727117-31764893	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052612, HPA054617			Supported	Centrosome	Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable)	Tissue enhanced	Tissue enriched	14	cerebral cortex: 72.3	adrenal gland: 5.1	Cell line enhanced		SH-SY5Y: 26.4;T-47d: 27.3;U-2 OS: 28.9
HCRTR1	OX1R	ENSG00000121764	Hypocretin receptor 1	1	31617686-31632518	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014018	Approved					Not detected	Tissue enhanced		adrenal gland: 1.2	cerebral cortex: 0.9	Not detected		
ZCCHC17	HSPC251, pNO40, PS1D	ENSG00000121766	Zinc finger CCHC-type containing 17	1	31296982-31364953	Predicted intracellular proteins	Evidence at protein level	HPA053727	Approved		Supported	Nuclear speckles	Liver cancer:3.27e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.7	Expressed in all		
FABP3	FABP11, H-FABP, MDGI, O-FABP	ENSG00000121769	Fatty acid binding protein 3	1	31365625-31376850	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017830, HPA055754	Enhanced		Approved	Golgi apparatus	Renal cancer:1.54e-7 (favourable)	Expressed in all	Tissue enriched	6	heart muscle: 2930.0	skeletal muscle: 471.2	Cell line enriched	5	ASC TERT1: 434.0
KHDRBS1	FLJ34027, p62, Sam68	ENSG00000121774	KH RNA binding domain containing, signal transduction associated 1	1	32013829-32060850	Predicted intracellular proteins	Evidence at protein level	CAB005355, HPA051280, HPA056813	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.68e-5 (unfavourable), Renal cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 134.1	Expressed in all		
TMEM39B	FLJ10315	ENSG00000121775	Transmembrane protein 39B	1	32072031-32102866	Predicted membrane proteins	Evidence at protein level	HPA040191, HPA040224	Approved		Approved	Vesicles	Renal cancer:5.11e-9 (unfavourable), Liver cancer:2.82e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 10.1	Expressed in all		
CCRL2	ACKR5, CKRX, CRAM-A, CRAM-B, HCR	ENSG00000121797	C-C motif chemokine receptor like 2	3	46407163-46412997	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA043238	Approved				Colorectal cancer:3.72e-5 (favourable), Urothelial cancer:9.67e-5 (favourable)	Mixed	Mixed			lung: 17.7	Cell line enhanced		HEL: 18.0;PC-3: 14.0;TIME: 12.2
CCR2	CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R	ENSG00000121807	C-C motif chemokine receptor 2	3	46353734-46360928	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB003793	Approved				Lung cancer:5.87e-4 (favourable)	Mixed	Tissue enhanced		appendix: 51.7	spleen: 20.5	Cell line enhanced		Karpas-707: 195.5;THP-1: 89.5;U-266/70: 473.3;U-266/84: 185.8
POLR3GL	flj32422, MGC3200	ENSG00000121851	RNA polymerase III subunit G like	1	145964702-145978848	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA027288	Uncertain				Endometrial cancer:6.52e-5 (favourable), Breast cancer:2.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 59.5	Expressed in all		
GHSR		ENSG00000121853	Growth hormone secretagogue receptor	3	172445133-172448456	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.3	Not detected		
TNFSF10	Apo-2L, CD253, TL2, TRAIL	ENSG00000121858	Tumor necrosis factor superfamily member 10	3	172505508-172523507	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054938	Uncertain		Approved	Microtubules	Pancreatic cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 260.0	Cell line enhanced		BEWO: 70.1;HMC-1: 209.7;RPTEC TERT1: 91.4
ZNF639	ANC-2H01, ZASC1	ENSG00000121864	Zinc finger protein 639	3	179322991-179338583	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049023, HPA052163	Uncertain		Supported	Nucleoplasm	Glioma:7.36e-5 (favourable), Liver cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 69.0	Expressed in all		
SLITRK3	KIAA0848	ENSG00000121871	SLIT and NTRK like family member 3	3	165186720-165197109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017636, HPA048042	Enhanced		Approved	Mitochondria		Tissue enriched	Tissue enhanced		cerebral cortex: 17.3;endometrium: 12.3	fallopian tube: 9.8	Cell line enhanced		AF22: 2.6;HAP1: 2.3;SCLC-21H: 1.7
PIK3CA	PI3K	ENSG00000121879	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	179148114-179240093	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009985, CAB017804	Approved		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 23.8	Expressed in all		
PDS5A	KIAA0648, PIG54, SCC-112	ENSG00000121892	PDS5 cohesin associated factor A	4	39822863-39977956	Predicted intracellular proteins	Evidence at protein level	HPA036661, HPA036662	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 57.4	Expressed in all		
TMEM156	FLJ23235	ENSG00000121895	Transmembrane protein 156	4	38966744-39032922	Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.09e-4 (favourable)	Mixed	Group enriched	5	appendix: 11.8;lymph node: 27.8;spleen: 15.2;tonsil: 24.3;urinary bladder: 5.7	gallbladder: 3.0	Cell line enhanced		Daudi: 28.3;HBEC3-KT: 59.6;hTERT-HME1: 48.9;PC-3: 34.1;U-698: 30.9
LIAS	LAS	ENSG00000121897	Lipoic acid synthetase	4	39458587-39485109	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018842, HPA019076	Approved	Approved	Approved	Nucleoplasm<br>Mitochondria	Renal cancer:4.11e-7 (favourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
CPXM2	CPX2, UNQ676	ENSG00000121898	Carboxypeptidase X, M14 family member 2	10	123706207-123940267	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048375	Uncertain				Renal cancer:9.02e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 72.6;smooth muscle: 80.7	urinary bladder: 34.4	Group enriched	15	BJ: 15.4;fHDF/TERT166: 55.4
TMEM54	CAC-1	ENSG00000121900	Transmembrane protein 54	1	32894594-32901438	Predicted membrane proteins	Evidence at transcript level	HPA061992			Approved	Vesicles	Liver cancer:3.08e-4 (unfavourable)	Expressed in all	Mixed			colon: 222.7	Mixed		
ZSCAN20	KOX29, ZNF31, ZNF360	ENSG00000121903	Zinc finger and SCAN domain containing 20	1	33472645-33496507	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA017933	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 5.4	Mixed		
CSMD2	KIAA1884	ENSG00000121904	CUB and Sushi multiple domains 2	1	33513999-34165842	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008622	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.6;gallbladder: 1.8	testis: 1.0	Cell line enhanced		fHDF/TERT166: 5.3;HEL: 9.4;NTERA-2: 8.1;PC-3: 7.8;U-87 MG: 23.1
HPCA		ENSG00000121905	Hippocalcin	1	32885994-32898441	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012340, HPA043245	Supported					Tissue enriched	Tissue enriched	47	cerebral cortex: 153.0	testis: 3.2	Cell line enriched	8	SCLC-21H: 5.3
LRIF1	C1orf103, FLJ11269, RIF1	ENSG00000121931	Ligand dependent nuclear receptor interacting factor 1	1	110947185-110964079	Predicted intracellular proteins	Evidence at protein level	HPA044515	Uncertain		Supported	Nucleus<br>Microtubule organizing center	Ovarian cancer:1.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Mixed		
TMIGD3	AD026	ENSG00000121933	Transmembrane and immunoglobulin domain containing 3	1	111483348-111563962	Predicted membrane proteins	Evidence at protein level						Breast cancer:3.58e-4 (unfavourable)	Tissue enriched	Tissue enriched	15	testis: 99.0	placenta: 6.6	Cell line enhanced		HDLM-2: 6.5;HMC-1: 1.5;NB-4: 2.4
CLCC1	MCLC	ENSG00000121940	Chloride channel CLIC like 1	1	108929508-108963457	Predicted membrane proteins, Transporters	Evidence at protein level	HPA009087, HPA013210	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.6	Expressed in all		
GPSM2	DFNB82, LGN, Pins	ENSG00000121957	G-protein signaling modulator 2	1	108875350-108934545	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007327, HPA008408, CAB018962	Uncertain		Supported	Cytosol	Colorectal cancer:7.86e-5 (favourable), Renal cancer:3.02e-4 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable)	Mixed	Mixed			skin: 49.3	Expressed in all		
GTDC1	FLJ11753, Hmat-Xa	ENSG00000121964	Glycosyltransferase like domain containing 1	2	143938068-144332568	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036694	Uncertain		Approved	Cytosol	Renal cancer:6.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.4	Mixed		
CXCR4	CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R	ENSG00000121966	C-X-C motif chemokine receptor 4	2	136114349-136118165	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 771.6	tonsil: 495.9	Cell line enhanced		Daudi: 410.1;MOLT-4: 425.1;REH: 252.8;U-266/70: 489.0;U-698: 459.8
ZRANB3	DKFZP434B1727	ENSG00000121988	Zinc finger RANBP2-type containing 3	2	135136916-135531236	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035234			Supported	Nucleus		Mixed	Mixed			testis: 8.6	Expressed in all		
ACVR2A	ACTRII, ACVR2	ENSG00000121989	Activin A receptor type 2A	2	147844517-147930826	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046997	Approved		Approved	Cytosol	Renal cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 22.5	Mixed		
POLK	DINB1, DINP, POLQ	ENSG00000122008	DNA polymerase kappa	5	75511756-75601144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012035, HPA057303, HPA068117, HPA069375			Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			thyroid gland: 12.8	Mixed		
SV2C		ENSG00000122012	Synaptic vesicle glycoprotein 2C	5	76083172-76353939	Predicted membrane proteins	Evidence at protein level	HPA040722, HPA040770	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enhanced		adrenal gland: 1.6;cerebral cortex: 3.4	fallopian tube,ovary: 0.6	Cell line enhanced		Karpas-707: 6.5;SCLC-21H: 4.3;SH-SY5Y: 9.0
FLT3	CD135, FLK2, STK1	ENSG00000122025	Fms related tyrosine kinase 3	13	28003274-28100592	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA047539			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		lymph node: 7.0;spleen: 7.7	appendix: 3.9	Group enriched	14	REH: 38.7;THP-1: 17.4
RPL21	DKFZp686C06101, FLJ27458, L21, MGC104274, MGC104275, MGC71252	ENSG00000122026	Ribosomal protein L21	13	27251309-27256691	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047252	Approved		Supported	Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol	Melanoma:6.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2382.8	Expressed in all		
MTIF3	IF-3mt, IF3(mt)	ENSG00000122033	Mitochondrial translational initiation factor 3	13	27435643-27450591	Predicted intracellular proteins	Evidence at protein level	HPA039791	Approved		Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.3	Expressed in all		
GTF3A	AP2, TFIIIA	ENSG00000122034	General transcription factor IIIA	13	27424544-27435823	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007990	Supported		Supported	Nucleus	Renal cancer:3.43e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 122.3	Expressed in all		
RASL11A		ENSG00000122035	RAS like family 11 member A	13	27270327-27273690	Predicted intracellular proteins	Evidence at protein level	HPA004859, HPA053296	Supported		Approved	Nuclear bodies	Renal cancer:3.52e-4 (unfavourable), Lung cancer:5.43e-4 (favourable)	Expressed in all	Mixed			rectum: 25.0	Cell line enhanced		ASC diff: 56.5;PC-3: 18.3
UBL3	DKFZP434K151, FLJ32018, HCG-1, PNSC1	ENSG00000122042	Ubiquitin like 3	13	29764371-29850684	Predicted intracellular proteins	Evidence at protein level	HPA053772, HPA058781	Uncertain		Approved	Centrosome	Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 90.6	Expressed in all		
FYTTD1	DKFZp761B1514, UIF	ENSG00000122068	Forty-two-three domain containing 1	3	197737179-197787596	Predicted intracellular proteins	Evidence at protein level	HPA054474			Supported	Nuclear speckles	Endometrial cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.4	Expressed in all		
MTERF4	MGC61716, MTERFD2	ENSG00000122085	Mitochondrial transcription termination factor 4	2	241072169-241102332	Predicted intracellular proteins	Evidence at protein level	HPA027097	Uncertain		Supported	Mitochondria<br>Cytosol	Pancreatic cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.3	Expressed in all		
XPNPEP2		ENSG00000122121	X-prolyl aminopeptidase 2	X	129738974-129769538	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000339, CAB025136, CAB025269	Enhanced					Group enriched	Group enriched	12	duodenum: 128.1;kidney: 175.9;small intestine: 231.5	liver: 14.3	Cell line enhanced		ASC diff: 6.9;ASC TERT1: 36.6;HSkMC: 19.4
SASH3	753P9, CXorf9, HACS2, SH3D6C, SLY	ENSG00000122122	SAM and SH3 domain containing 3	X	129779979-129795201	Predicted intracellular proteins	Evidence at protein level	HPA001085	Enhanced		Approved	Plasma membrane	Renal cancer:6.51e-5 (unfavourable), Endometrial cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 136.7;spleen: 99.3;tonsil: 97.4	appendix: 80.4	Cell line enhanced		Daudi: 116.3;MOLT-4: 95.0;NB-4: 56.4;REH: 79.9;U-698: 101.7;U-937: 90.0
OCRL	OCRL1	ENSG00000122126	OCRL, inositol polyphosphate-5-phosphatase	X	129539849-129592561	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012495	Approved		Approved	Microtubules<br>Cytosol	Breast cancer:2.93e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Mixed		
PAEP	GD, GdA, GdF, GdS, MGC138509, MGC142288, PAEG, PEP, PP14	ENSG00000122133	Progestagen associated endometrial protein	9	135561756-135566955	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016762, HPA020108, HPA029473	Enhanced				Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-6 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	endometrium: 437.0	seminal vesicle: 61.5	Cell line enriched	6	SK-MEL-30: 16.7
OBP2A	hOBPIIa, LCN13, OBP	ENSG00000122136	Odorant binding protein 2A	9	135546139-135549969	Predicted secreted proteins	Evidence at protein level	HPA055955	Uncertain					Tissue enriched	Group enriched	19	fallopian tube: 35.5;testis: 7.6	skin: 1.1	Group enriched	8	U-266/70: 1.0;U-266/84: 3.7
MRPS2	CGI-91	ENSG00000122140	Mitochondrial ribosomal protein S2	9	135499984-135504673	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029487, HPA057261	Approved		Supported	Mitochondria	Renal cancer:6.96e-9 (favourable)	Expressed in all	Expressed in all			fallopian tube: 55.1	Expressed in all		
TBX22	CLPA, CPX	ENSG00000122145	T-box 22	X	80014756-80031769	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Group enriched	19	testis: 10.4;thyroid gland: 3.5	seminal vesicle: 0.3	Cell line enriched	6	HDLM-2: 1.6
FMOD	SLRR2E	ENSG00000122176	Fibromodulin	1	203340628-203351489	Predicted secreted proteins	Evidence at protein level						Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 171.7	Cell line enhanced		CACO-2: 28.0;HHSteC: 8.7;HSkMC: 14.1
MYOG	bHLHc3, MYF4	ENSG00000122180	Myogenin	1	203083132-203086036	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028336, HPA038093	Approved		Supported	Nucleoplasm		Group enriched	Tissue enriched	9	skeletal muscle: 31.7	prostate: 3.3	Group enriched	197	HSkMC: 21.2;RH-30: 55.2
LAX1	FLJ20340, LAX	ENSG00000122188	Lymphocyte transmembrane adaptor 1	1	203765176-203776233	Predicted membrane proteins	Evidence at protein level	HPA002461, HPA003887, CAB025358	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		tonsil: 15.3	lymph node: 10.3	Cell line enhanced		Karpas-707: 14.1;U-266/70: 18.2;U-266/84: 40.4;U-698: 14.6
PLG		ENSG00000122194	Plasminogen	6	160702238-160753315	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000668, CAB016678, HPA021602, HPA048823, HPA053770	Supported		Uncertain	Vesicles	Renal cancer:4.22e-4 (favourable)	Tissue enriched	Tissue enriched	6	liver: 1749.3	kidney: 313.4	Cell line enhanced		RH-30: 1.0
KIAA1191	FLJ21022, p33MONOX	ENSG00000122203	KIAA1191	5	176346061-176361968	Predicted intracellular proteins	Evidence at protein level	HPA044701, HPA048145	Uncertain		Approved	Nucleoplasm	Renal cancer:9.94e-5 (favourable)	Expressed in all	Expressed in all			kidney: 198.3	Expressed in all		
COPA	HEP-COP	ENSG00000122218	Coatomer protein complex subunit alpha	1	160289273-160343400	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028024	Supported		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.08e-4 (unfavourable), Cervical cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.9	Expressed in all		
CD244	2B4, NAIL, NKR2B4, Nmrk, SLAMF4	ENSG00000122223	CD244 molecule	1	160830160-160862855	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 23.5	bone marrow: 6.2	Cell line enhanced		HEL: 18.7;HMC-1: 61.7;U-937: 22.7
LY9	CD229, hly9, mLY9, SLAMF3	ENSG00000122224	Lymphocyte antigen 9	1	160796074-160828261	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050917	Approved					Mixed	Tissue enhanced		lymph node: 34.5;spleen: 28.2;tonsil: 28.3	appendix: 17.8	Cell line enhanced		Daudi: 10.2;Karpas-707: 20.1;U-266/70: 53.8;U-266/84: 20.4
HS3ST2	3OST2	ENSG00000122254	Heparan sulfate-glucosamine 3-sulfotransferase 2	16	22814177-22916338	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017736	Approved				Renal cancer:1.35e-4 (favourable), Glioma:2.22e-4 (unfavourable)	Mixed	Tissue enriched	30	cerebral cortex: 35.7	lung: 1.1	Group enriched	7	HaCaT: 8.5;SH-SY5Y: 17.7
RBBP6	P2P-R, PACT, SNAMA	ENSG00000122257	RB binding protein 6, ubiquitin ligase	16	24537693-24572863	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB032866, HPA041725, HPA043544	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			bone marrow: 91.5	Expressed in all		
ZC3H7A	FLJ20318, HSPC055, ZC3H7, ZC3HDC7	ENSG00000122299	Zinc finger CCCH-type containing 7A	16	11750586-11797267	Predicted intracellular proteins	Evidence at protein level	HPA040808, HPA059849	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 47.0	Expressed in all		
PRM2	CT94.2	ENSG00000122304	Protamine 2	16	11275639-11276480	Predicted intracellular proteins	Evidence at protein level	CAB032738, HPA056386	Enhanced					Tissue enriched	Tissue enriched	5145	testis: 7760.7	small intestine: 1.5	Cell line enhanced		BEWO: 1.1;U-2197: 1.7
SERAC1	FLJ14917	ENSG00000122335	Serine active site containing 1	6	158109515-158168270	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025715, HPA025716	Enhanced					Expressed in all	Expressed in all			testis: 16.5	Expressed in all		
ANXA11	ANX11	ENSG00000122359	Annexin A11	10	80150889-80205572	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004851, HPA027545	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.69e-8 (favourable)	Expressed in all	Expressed in all			esophagus: 203.1	Expressed in all		
LDB3	CMD1C, KIAA0613, PDLIM6, ZASP	ENSG00000122367	LIM domain binding 3	10	86668449-86736068	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048955	Enhanced		Supported	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Mixed	Group enriched	13	heart muscle: 568.8;skeletal muscle: 1039.8	prostate: 60.3	Cell line enhanced		HSkMC: 2.3;SCLC-21H: 6.3;SK-MEL-30: 2.1
OPN4	melanopsin, MOP	ENSG00000122375	Opsin 4	10	86654557-86666848	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039147	Approved					Not detected	Tissue enhanced		cerebral cortex: 2.2;parathyroid gland: 1.4	skeletal muscle: 0.9	Not detected		
FAM35A	bA163M19.1, FAM35A1, MGC5560	ENSG00000122376	Family with sequence similarity 35 member A	10	87094161-87191468	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036582	Uncertain		Approved	Nucleoplasm<br>Actin filaments	Glioma:5.44e-4 (favourable), Colorectal cancer:6.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.8	Expressed in all		
FAM213A	Adrx, C10orf58, MGC4248, PAMM	ENSG00000122378	Family with sequence similarity 213 member A	10	80407829-80437115	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009025, HPA024565	Approved				Urothelial cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 425.0	Cell line enhanced		ASC diff: 650.7;HUVEC TERT2: 365.0
ZNF205	Zfp13, ZNF210	ENSG00000122386	Zinc finger protein 205	16	3112560-3120517	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001791	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 14.6	Mixed		
NAA60	FLJ14154, NAT15	ENSG00000122390	N(alpha)-acetyltransferase 60, NatF catalytic subunit	16	3443611-3486963	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040916	Approved		Uncertain	Actin filaments<br>Cytosol	Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
RPL5	L5, PPP1R135	ENSG00000122406	Ribosomal protein L5	1	92832025-92841924	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043717, HPA054444	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:6.81e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4042.9	Expressed in all		
ODF2L	KIAA1229	ENSG00000122417	Outer dense fiber of sperm tails 2 like	1	86346824-86396342	Predicted intracellular proteins	Evidence at protein level	HPA028020, HPA028095, HPA028333	Uncertain		Approved	Mitochondria	Renal cancer:4.69e-7 (unfavourable)	Mixed	Expressed in all			fallopian tube: 34.3	Mixed		
PTGFR	FP	ENSG00000122420	Prostaglandin F receptor	1	78303884-78539749	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 30.5;smooth muscle: 25.7	urinary bladder: 12.9	Group enriched	7	ASC TERT1: 193.6;HSkMC: 63.3
SPATA1	SP-2	ENSG00000122432	Spermatogenesis associated 1	1	84506300-84566194	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 4.5	skin: 0.5	Not detected		
TRMT13	CCDC76, FLJ10287, FLJ11219	ENSG00000122435	TRNA methyltransferase 13 homolog	1	100133150-100150497	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028494	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Renal cancer:6.89e-6 (unfavourable), Liver cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
LRRC39	MGC14816	ENSG00000122477	Leucine rich repeat containing 39	1	100148449-100178273	Predicted intracellular proteins	Evidence at protein level	HPA077159	Enhanced					Mixed	Group enriched	10	heart muscle: 81.3;skeletal muscle: 175.6	testis: 12.3	Cell line enhanced		SK-MEL-30: 5.8
RWDD3	DKFZP566K023	ENSG00000122481	RWD domain containing 3	1	95234155-95247225	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.46e-8 (unfavourable), Urothelial cancer:2.06e-4 (favourable)	Expressed in all	Mixed			endometrium,fallopian tube: 14.6	Expressed in all		
ZNF644	BM-005, KIAA1221, MGC60165, MGC70410	ENSG00000122482	Zinc finger protein 644	1	90915298-91022272	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057795	Uncertain		Uncertain	Vesicles	Colorectal cancer:4.27e-4 (favourable), Endometrial cancer:8.39e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 31.0	Expressed in all		
CCDC18	NY-SAR-41	ENSG00000122483	Coiled-coil domain containing 18	1	93179919-93278730	Predicted intracellular proteins	Evidence at protein level	HPA028035	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 17.2	lymph node: 10.7	Mixed		
RPAP2	C1orf82, FLJ13150, Rtr1	ENSG00000122484	RNA polymerase II associated protein 2	1	92298965-92402056	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046443	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Mixed			thyroid gland: 4.8	Expressed in all		
PQLC1	FLJ22378	ENSG00000122490	PQ loop repeat containing 1	18	79902420-79951664	Predicted membrane proteins	Evidence at protein level	HPA051666	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			adipose tissue: 40.6	Expressed in all		
BBS9	B1, PTHB1	ENSG00000122507	Bardet-Biedl syndrome 9	7	33129244-33606068	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021289	Uncertain				Renal cancer:1.86e-4 (favourable)	Expressed in all	Mixed			testis: 24.0	Expressed in all		
PMS2	H_DJ0042M02.9, HNPCC4, MLH4, PMSL2	ENSG00000122512	PMS1 homolog 2, mismatch repair system component	7	5973239-6009125	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010235, HPA044400, HPA066490, HPA070310	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.23e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.2	Expressed in all		
ZMIZ2	DKFZp761I2123, hZIMP7, KIAA1886, NET27, ZIMP7	ENSG00000122515	Zinc finger MIZ-type containing 2	7	44748581-44769881	Predicted intracellular proteins	Evidence at protein level	HPA040716	Supported		Supported	Nucleoplasm	Liver cancer:6.82e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 40.7	Expressed in all		
OCM	OCM1	ENSG00000122543	Oncomodulin	7	5879827-5886362	Predicted intracellular proteins	Evidence at protein level	HPA046422	Uncertain					Not detected	Tissue enhanced		lymph node: 2.4	testis: 1.5	Not detected		
SEPT7	CDC10, CDC3, SEPT7A	ENSG00000122545	Septin 7	7	35800932-35907105	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023309, HPA029524	Enhanced		Enhanced	Nucleoli<br>Actin filaments<br>Midbody	Liver cancer:2.37e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 430.4	Expressed in all		
EEPD1	KIAA1706	ENSG00000122547	Endonuclease/exonuclease/phosphatase family domain containing 1	7	36153149-36301543	Predicted intracellular proteins	Evidence at protein level	HPA053668			Approved	Nuclear speckles<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			cerebral cortex: 27.1	Cell line enhanced		HDLM-2: 16.9;PC-3: 20.8
KLHL7	KLHL6, RP42, SBBI26	ENSG00000122550	Kelch like family member 7	7	23105758-23177914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029491, HPA029492	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.98e-5 (favourable), Liver cancer:7.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.1	Expressed in all		
HERPUD2	FLJ22313	ENSG00000122557	HERPUD family member 2	7	35632659-35695571	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015630, HPA076087	Approved		Approved	Nucleoli		Expressed in all	Expressed in all			testis: 48.2	Expressed in all		
CBX3	HP1Hs-gamma	ENSG00000122565	Chromobox 3	7	26201162-26213356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001973, HPA004902	Enhanced		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.20e-8 (unfavourable), Renal cancer:4.56e-7 (unfavourable), Pancreatic cancer:4.00e-4 (unfavourable), Breast cancer:7.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 201.3	Expressed in all		
HNRNPA2B1	HNRPA2B1	ENSG00000122566	Heterogeneous nuclear ribonucleoprotein A2/B1	7	26189927-26201529	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001666, HPA005812, CAB012403, HPA065537	Supported		Enhanced	Nucleoplasm	Liver cancer:1.03e-6 (unfavourable), Renal cancer:8.01e-5 (unfavourable), Prostate cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 753.7	Expressed in all		
WIPF3	CR16, FLJ36931	ENSG00000122574	WAS/WASL interacting protein family member 3	7	29806486-29917066	Predicted intracellular proteins	Evidence at protein level	HPA041145, HPA041211	Uncertain		Uncertain	Mitochondria	Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enhanced		ovary: 52.8;testis: 37.3	epididymis: 25.0	Cell line enhanced		HAP1: 19.3;K-562: 6.0;NTERA-2: 5.3;RPMI-8226: 8.0
NXPH1		ENSG00000122584	Neurexophilin 1	7	8433955-8752963	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA020062	Uncertain					Group enriched	Group enriched	81	adrenal gland: 52.1;cerebral cortex: 47.2	breast: 0.6	Cell line enhanced		Karpas-707: 7.7;SCLC-21H: 1.3;WM-115: 3.3
NPY	PYY4	ENSG00000122585	Neuropeptide Y	7	24284163-24291865	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016733, CAB034368, HPA036636, HPA044572, HPA056798	Supported	Supported	Enhanced	Golgi apparatus	Endometrial cancer:5.78e-4 (unfavourable)	Tissue enriched	Group enriched	18	adrenal gland: 153.2;cerebral cortex: 211.6;prostate: 495.0	appendix: 16.1	Cell line enriched	39	SH-SY5Y: 696.9
FAM126A	DRCTNNB1A, HCC, HYCC1, hyccin	ENSG00000122591	Family with sequence similarity 126 member A	7	22889371-23014130	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042873	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:6.04e-7 (unfavourable), Stomach cancer:5.99e-4 (unfavourable), Urothelial cancer:9.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.4	Mixed		
HOXA7	HOX1, HOX1A	ENSG00000122592	Homeobox A7	7	27153716-27157936	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074048			Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.15e-5 (favourable), Endometrial cancer:7.87e-5 (unfavourable)	Mixed	Mixed			epididymis: 21.6	Cell line enhanced		HAP1: 38.0;RPTEC TERT1: 34.0;SCLC-21H: 42.6
INHBA		ENSG00000122641	Inhibin beta A subunit	7	41667168-41705834	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:7.91e-8 (unfavourable), Cervical cancer:1.46e-5 (unfavourable), Head and neck cancer:4.34e-4 (unfavourable), Lung cancer:7.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 28.7;gallbladder: 35.1	lung: 16.4	Group enriched	6	HBEC3-KT: 54.3;hTEC/SVTERT24-B: 227.2;hTERT-HME1: 71.4;TIME: 97.6;U-138 MG: 172.4;U-2 OS: 52.9
FKBP9	FKBP60, FKBP63	ENSG00000122642	FK506 binding protein 9	7	32957404-33006931	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012595, HPA055256	Approved		Supported	Golgi apparatus<br>Vesicles<br>Mitochondria	Urothelial cancer:7.02e-6 (unfavourable), Head and neck cancer:2.02e-4 (unfavourable), Cervical cancer:4.22e-4 (unfavourable), Glioma:8.06e-4 (unfavourable), Liver cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 110.4	Mixed		
NT5C3A	cN-III, hUMP1, NT5C3, p36, P5'N-1, PN-I, POMP, PSN1, UMPH, UMPH1	ENSG00000122643	5'-nucleotidase, cytosolic IIIA	7	33014114-33062797	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010630, HPA029058	Uncertain				Renal cancer:1.70e-4 (unfavourable), Liver cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 46.5	Expressed in all		
ARL4A	ARL4	ENSG00000122644	ADP ribosylation factor like GTPase 4A	7	12686856-12690934	Predicted intracellular proteins	Evidence at protein level	HPA064513			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 313.8	skin: 79.3	Cell line enhanced		AN3-CA: 241.9;K-562: 291.3
CCZ1	C7orf28A, CCZ1A, CGI-43	ENSG00000122674	CCZ1 homolog, vacuolar protein trafficking and biogenesis associated	7	5898725-5926550	Predicted intracellular proteins	Evidence at protein level	HPA045114, HPA050006	Uncertain		Enhanced	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 77.0	Expressed in all		
POLM	Tdt-N	ENSG00000122678	DNA polymerase mu	7	44072247-44082540	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058900, HPA066007			Supported	Nucleus		Expressed in all	Expressed in all			spleen: 10.9	Cell line enhanced		HBEC3-KT: 47.1
RAMP3		ENSG00000122679	Receptor activity modifying protein 3	7	45157791-45186302	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 120.2	thyroid gland: 66.3	Cell line enhanced		Karpas-707: 1.8
MRM2	FJH1, FTSJ2, RRMJ2	ENSG00000122687	Mitochondrial rRNA methyltransferase 2	7	2234231-2242198	Predicted intracellular proteins	Evidence at protein level	HPA019826, HPA049622	Uncertain				Liver cancer:5.21e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 19.6	Expressed in all		
TWIST1	ACS3, bHLHa38, BPES2, BPES3, CRS, CRS1, H-twist, SCS, TWIST	ENSG00000122691	Twist family bHLH transcription factor 1	7	19020991-19117672	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 22.7;endometrium: 30.7	placenta: 17.3	Cell line enriched	6	SH-SY5Y: 272.1
SMU1	BWD, FLJ10805, fSAP57, SMU-1	ENSG00000122692	DNA replication regulator and spliceosomal factor	9	33041764-33076659	Predicted intracellular proteins	Evidence at protein level	HPA019228, HPA019708	Supported		Approved	Vesicles	Renal cancer:1.67e-5 (favourable), Ovarian cancer:1.25e-4 (favourable), Cervical cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
GLIPR2	C9orf19, GAPR-1	ENSG00000122694	GLI pathogenesis related 2	9	36136536-36163913	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029478	Approved		Uncertain	Vesicles<br>Microtubules	Renal cancer:6.54e-7 (unfavourable)	Expressed in all	Expressed in all			lung: 93.6	Cell line enhanced		TIME: 103.7
SLC25A51	CG7943, MCART1, MGC14836	ENSG00000122696	Solute carrier family 25 member 51	9	37879400-37904353	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046388, HPA058261	Uncertain		Approved	Mitochondria	Liver cancer:5.67e-5 (unfavourable), Renal cancer:1.52e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
CLTA	Lca	ENSG00000122705	Clathrin light chain A	9	36190856-36304781	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002665, HPA050918, HPA054667	Enhanced		Enhanced	Vesicles<br>Endosomes<br>Lysosomes	Liver cancer:9.46e-5 (unfavourable), Thyroid cancer:1.01e-4 (favourable), Breast cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			placenta: 178.0	Expressed in all		
RECK	hRECK, ST15	ENSG00000122707	Reversion inducing cysteine rich protein with kazal motifs	9	36036433-36124451	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025109, HPA071729	Supported		Supported	Plasma membrane	Stomach cancer:7.31e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 21.4	Group enriched	5	ASC diff: 122.8;ASC TERT1: 99.6;BJ: 49.1;BJ hTERT+: 67.5;fHDF/TERT166: 40.1;HSkMC: 46.5;TIME: 32.3
SPINK4	MGC133107, PEC-60	ENSG00000122711	Serine peptidase inhibitor, Kazal type 4	9	33218365-33248567	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007286	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Colorectal cancer:8.85e-5 (favourable)	Group enriched	Group enriched	6	colon: 631.8;duodenum: 266.4;rectum: 1071.3;small intestine: 734.5	appendix: 107.1	Cell line enriched	8	HMC-1: 152.9
TAF1L		ENSG00000122728	TATA-box binding protein associated factor 1 like	9	32629454-32635669	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056605	Uncertain					Not detected	Tissue enriched	31	testis: 3.0	all non-specific tissues: 0.0	Not detected		
ACO1	IREB1, IREBP, IRP1	ENSG00000122729	Aconitase 1	9	32384603-32454769	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019371, HPA024157	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:5.73e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 105.1	Expressed in all		
PHF24	KIAA1045	ENSG00000122733	PHD finger protein 24	9	34957608-34982544	Predicted intracellular proteins	Evidence at protein level	HPA020974	Approved					Tissue enhanced	Group enriched	36	cerebral cortex: 58.6;testis: 25.9	skin: 1.1	Cell line enhanced		WM-115: 1.1
DNAI1	CILD1, DIC1, PCD	ENSG00000122735	Dynein axonemal intermediate chain 1	9	34457414-34520989	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021649, HPA021843	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 54.3;testis: 61.2	lung: 5.6	Cell line enhanced		BEWO: 1.9;HDLM-2: 1.3
DCAF10	FLJ23201, MGC10765, WDR32	ENSG00000122741	DDB1 and CUL4 associated factor 10	9	37800502-37867666	Predicted intracellular proteins	Evidence at protein level	HPA024160	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.02e-6 (favourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
CNTFR		ENSG00000122756	Ciliary neurotrophic factor receptor	9	34551432-34590140	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025310	Approved					Tissue enhanced	Tissue enhanced		adipose tissue: 62.6;cerebral cortex: 53.4	spleen: 27.5	Group enriched	9	AF22: 107.8;SH-SY5Y: 55.3
KIAA1549		ENSG00000122778	KIAA1549	7	138831381-138981318	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA019560	Approved		Approved	Nuclear membrane<br>Intermediate filaments	Renal cancer:3.93e-7 (favourable)	Mixed	Mixed			seminal vesicle: 10.5	Cell line enhanced		SH-SY5Y: 29.9
TRIM24	hTIF1, RNF82, TIF1, Tif1a	ENSG00000122779	Tripartite motif containing 24	7	138460334-138589993	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043495, HPA061717	Approved		Enhanced	Nucleoplasm	Lung cancer:6.57e-4 (favourable), Liver cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
C7orf49	FLJ22450, FLJ27285, MGC5242, MRI, MRI-2	ENSG00000122783	Chromosome 7 open reading frame 49	7	135092363-135170795	Predicted intracellular proteins	Evidence at protein level	HPA020060	Approved		Approved	Golgi apparatus	Liver cancer:2.52e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
CALD1	CDM, H-CAD, L-CAD	ENSG00000122786	Caldesmon 1	7	134744252-134970728	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000006, HPA008066, HPA017330	Enhanced		Enhanced	Plasma membrane<br>Actin filaments	Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 1289.8	smooth muscle: 1185.8	Cell line enhanced		fHDF/TERT166: 910.7
AKR1D1	SRD5B1	ENSG00000122787	Aldo-keto reductase family 1 member D1	7	138002324-138117986	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057002	Enhanced		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.91e-5 (favourable)	Tissue enriched	Tissue enriched	31	liver: 229.4	breast: 7.2	Cell line enriched	16	Hep G2: 8.6
NUDT10	DIPP3a, hDIPP3alpha	ENSG00000122824	Nudix hydrolase 10	X	51332231-51337525	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA057684	Approved		Approved	Cytosol		Group enriched	Tissue enhanced		testis: 49.7	prostate: 24.8	Group enriched	8	AF22: 7.4;HAP1: 14.7;HEK 293: 9.7;NTERA-2: 25.9;SH-SY5Y: 6.0;U-2 OS: 13.4
SFTPA1	COLEC4, SFTP1, SP-A, SP-A1	ENSG00000122852	Surfactant protein A1	10	79610939-79615455	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB016793, HPA042638, HPA045752, HPA049368	Supported					Tissue enriched	Tissue enriched	1180	lung: 10513.5	adrenal gland: 8.9	Group enriched	6	RPMI-8226: 29.9;U-2197: 6.8
NEUROG3	Atoh5, bHLHa7, Math4B, ngn3	ENSG00000122859	Neurogenin 3	10	69571698-69573238	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039785	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 2.8;small intestine: 1.3	colon,rectum: 0.4	Group enriched	19	HMC-1: 1.7;THP-1: 7.1
PLAU	UPA, URK	ENSG00000122861	Plasminogen activator, urokinase	10	73909177-73917497	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008719	Approved				Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 60.3	Cell line enhanced		CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9
SRGN	PPG, PRG, PRG1	ENSG00000122862	Serglycin	10	69088106-69104811	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000759	Enhanced				Renal cancer:3.18e-5 (unfavourable)	Expressed in all	Group enriched	6	appendix: 1121.8;bone marrow: 5139.0	gallbladder: 509.4	Cell line enhanced		HL-60: 3514.5;THP-1: 2938.4;TIME: 2120.9;U-937: 2758.4
CHST3	C6ST, C6ST1	ENSG00000122863	Carbohydrate sulfotransferase 3	10	71964365-72013564	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047523, HPA055704	Enhanced		Approved	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			testis: 30.7	Mixed		
BICC1		ENSG00000122870	BicC family RNA binding protein 1	10	58513140-58831437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045212	Enhanced		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		kidney: 32.0	gallbladder: 19.2	Cell line enhanced		CACO-2: 79.9;RPTEC TERT1: 112.1
CISD1	C10orf70, MDS029, mitoNEET, ZCD1	ENSG00000122873	CDGSH iron sulfur domain 1	10	58269058-58289586	Predicted membrane proteins	Evidence at protein level	HPA074383			Supported	Mitochondria	Breast cancer:1.11e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable), Urothelial cancer:6.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 118.3	cerebral cortex: 27.2	Expressed in all		
EGR2	KROX20	ENSG00000122877	Early growth response 2	10	62811996-62919900	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031165			Supported	Nucleoplasm	Breast cancer:7.30e-5 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 234.3	epididymis: 73.8	Cell line enriched	7	U-87 MG: 22.2
ECD	GCR2, hSGT1	ENSG00000122882	Ecdysoneless cell cycle regulator	10	73130155-73169055	Predicted intracellular proteins	Evidence at protein level	HPA006465	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.3	Expressed in all		
P4HA1	C-P4Halpha(I), P4HA	ENSG00000122884	Prolyl 4-hydroxylase subunit alpha 1	10	73007217-73096974	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA007599, HPA026593	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles<br>Mitochondria	Renal cancer:9.40e-9 (unfavourable), Head and neck cancer:1.19e-5 (unfavourable), Cervical cancer:3.19e-5 (unfavourable), Pancreatic cancer:2.85e-4 (unfavourable), Lung cancer:5.10e-4 (unfavourable), Breast cancer:9.01e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 91.7	Expressed in all		
SLC25A16	D10S105E, GDA, HGT.1, ML7	ENSG00000122912	Solute carrier family 25 member 16	10	68477999-68527474	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036243, HPA044580	Uncertain		Approved	Mitochondria		Expressed in all	Mixed			prostate: 13.4	Mixed		
ZWINT	KNTC2AP, SIP30, Zwint1	ENSG00000122952	ZW10 interacting kinetochore protein	10	56357228-56361275	Predicted intracellular proteins	Evidence at protein level	HPA005757, HPA022264, CAB033926	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.72e-12 (unfavourable), Liver cancer:1.77e-8 (unfavourable)	Expressed in all	Mixed			testis: 47.7	Mixed		
VPS26A	Hbeta58, PEP8A, VPS26	ENSG00000122958	VPS26, retromer complex component A	10	69123512-69172861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011602, HPA057498, CAB075733	Enhanced		Enhanced	Endosomes<br>Lysosomes	Liver cancer:1.70e-6 (unfavourable), Pancreatic cancer:9.18e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.8	Expressed in all		
RBM19	DKFZp586F1023, KIAA0682	ENSG00000122965	RNA binding motif protein 19	12	113816738-113966371	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038860, HPA058732	Supported		Supported	Nucleoli	Liver cancer:5.87e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.6	Expressed in all		
CIT	CITK, CRIK, KIAA0949, STK21	ENSG00000122966	Citron rho-interacting serine/threonine kinase	12	119685790-119877291	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019082, HPA048812, HPA075506	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex: 10.4	Mixed		
IFT81	CDV-1R, CDV1, MGC4027	ENSG00000122970	Intraflagellar transport 81	12	110124335-110218797	Predicted intracellular proteins	Evidence at protein level	HPA019087, HPA020051	Enhanced		Approved	Centrosome<br>Cytosol		Expressed in all	Mixed			testis: 58.0	Expressed in all		
ACADS	ACAD3, SCAD	ENSG00000122971	Acyl-CoA dehydrogenase, C-2 to C-3 short chain	12	120725735-120740008	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004799, CAB019284, HPA022271	Enhanced		Enhanced	Mitochondria	Renal cancer:3.33e-6 (favourable), Urothelial cancer:6.34e-5 (favourable), Liver cancer:2.43e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Glioma:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 81.2	Cell line enhanced		HMC-1: 30.0
HVCN1	Hv1, MGC15619, VSOP	ENSG00000122986	Hydrogen voltage gated channel 1	12	110627841-110704950	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039329	Enhanced					Expressed in all	Mixed			testis: 82.5	Cell line enhanced		HL-60: 35.4;NB-4: 182.9;U-698: 61.5
DDX54	APR-5, DP97, MGC2835	ENSG00000123064	DEAD-box helicase 54	12	113157174-113185479	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028244, HPA070786	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Liver cancer:1.39e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 38.8	Expressed in all		
MED13L	KIAA1025, THRAP2, TRAP240L	ENSG00000123066	Mediator complex subunit 13 like	12	115953872-116277338	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039445	Uncertain		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			bone marrow: 35.9	Expressed in all		
CDKN2C	INK4C, p18	ENSG00000123080	Cyclin dependent kinase inhibitor 2C	1	50960745-50974633	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005303, CAB018398, HPA019057, HPA019764	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-10 (unfavourable), Liver cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 80.3	Mixed		
RNF11	CGI-123, MGC51169, Sid1669p	ENSG00000123091	Ring finger protein 11	1	51236271-51273455	Predicted intracellular proteins	Evidence at protein level	HPA045781	Uncertain				Renal cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 151.4	Mixed		
RASSF8	C12orf2, HoJ-1	ENSG00000123094	Ras association domain family member 8	12	25959029-26079892	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038163, HPA038164	Uncertain		Approved	Mitochondria<br>Cytosol		Expressed in all	Tissue enhanced		testis: 106.4	endometrium: 47.0	Cell line enhanced		U-2197: 100.3
BHLHE41	BHLHB3, bHLHe41, DEC2, SHARP-1, SHARP1	ENSG00000123095	Basic helix-loop-helix family member e41	12	26120026-26125127	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056035			Approved	Nucleoplasm	Renal cancer:8.73e-5 (unfavourable), Urothelial cancer:1.09e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 94.5	fallopian tube: 70.9	Cell line enhanced		RT4: 97.9;U-266/70: 39.0;U-87 MG: 42.7
SSPN	KRAG, SPN1, SPN2	ENSG00000123096	Sarcospan	12	26121991-26299290	Predicted membrane proteins	Evidence at protein level	HPA066432			Approved	Nucleus<br>Nuclear membrane	Renal cancer:2.77e-5 (unfavourable)	Mixed	Mixed			cervix, uterine: 64.4	Cell line enhanced		ASC diff: 18.2
ITPR2	CFAP48, IP3R2	ENSG00000123104	Inositol 1,4,5-trisphosphate receptor type 2	12	26336515-26833198	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059144, HPA062260	Uncertain		Supported	Nucleus<br>Endoplasmic reticulum		Expressed in all	Mixed			parathyroid gland: 26.2	Cell line enhanced		TIME: 55.9
CCDC91	DKFZp779L1558, FLJ11088, p56	ENSG00000123106	Coiled-coil domain containing 91	12	28133249-28581511	Predicted intracellular proteins	Evidence at protein level	HPA038169	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.05e-4 (unfavourable), Renal cancer:7.69e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.5	Mixed		
NECAB1	EFCBP1	ENSG00000123119	N-terminal EF-hand calcium binding protein 1	8	90791550-90959408	Predicted intracellular proteins	Evidence at protein level	HPA023252, HPA023629, HPA025963, HPA031262, CAB068208, CAB068209, CAB068210	Enhanced	Supported	Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	10	cerebral cortex: 79.7	lung: 8.1	Mixed		
WWP1	AIP5, DKFZP434D2111	ENSG00000123124	WW domain containing E3 ubiquitin protein ligase 1	8	86342738-86478420	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023180	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:5.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 183.6	Expressed in all		
ACOT9	ACATE2, CGI-16, MT-ACT48	ENSG00000123130	Acyl-CoA thioesterase 9	X	23702253-23766475	Predicted intracellular proteins	Evidence at protein level	HPA035533	Supported		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 46.9	Mixed		
PRDX4	AOE37-2	ENSG00000123131	Peroxiredoxin 4	X	23664262-23686399	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008659, CAB027389, CAB047362	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.33e-6 (unfavourable)	Expressed in all	Expressed in all			pancreas: 239.5	Expressed in all		
DDX39A	BAT1L, DDX39, DDXL, URH49	ENSG00000123136	DExD-box helicase 39A	19	14408819-14419383	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055334	Approved		Approved	Nuclear speckles	Renal cancer:1.50e-10 (unfavourable), Cervical cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			testis: 209.7	Expressed in all		
PKN1	DBK, MGC46204, PAK1, PKN, PRK1, PRKCL1	ENSG00000123143	Protein kinase N1	19	14433053-14471867	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003982, CAB010278	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			spleen: 85.9	Expressed in all		
C19orf43	fSAP18, MGC2803	ENSG00000123144	Chromosome 19 open reading frame 43	19	12730640-12734775	Predicted intracellular proteins	Evidence at protein level	HPA059965	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			spleen: 125.2	Expressed in all		
ADGRE5	CD97, TM7LN1	ENSG00000123146	Adhesion G protein-coupled receptor E5	19	14380501-14408725	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013707	Enhanced		Approved	Cytosol	Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 140.3	Mixed		
WDR83	MORG1	ENSG00000123154	WD repeat domain 83	19	12666800-12675832	Predicted intracellular proteins	Evidence at protein level	HPA042629, HPA042838	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Centrosome	Urothelial cancer:3.12e-4 (favourable), Pancreatic cancer:5.44e-4 (favourable)	Expressed in all	Mixed			testis: 9.4	Mixed		
GIPC1	C19orf3, GIPC, GLUT1CBP, Hs.6454, NIP, RGS19IP1, SEMCAP, SYNECTIN, TIP-2	ENSG00000123159	GIPC PDZ domain containing family member 1	19	14477760-14496149	Predicted intracellular proteins	Evidence at protein level	HPA043958, HPA061786	Approved		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			esophagus: 103.9	Expressed in all		
ACTRT1	AIP1, ARIP1, Arp-T1, KIAA0705	ENSG00000123165	Actin related protein T1	X	128050962-128052398	Predicted intracellular proteins	Evidence at protein level	HPA003119	Supported					Not detected	Tissue enriched	36	testis: 3.6	all non-specific tissues: 0.0	Not detected		
CCDC70	DKFZP434K1172, FLJ25853	ENSG00000123171	Coiled-coil domain containing 70	13	51861981-51866232	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	1157	testis: 115.6	all non-specific tissues: 0.0	Not detected		
SPRYD7	C13orf1, CLLD6	ENSG00000123178	SPRY domain containing 7	13	49912706-49936490	Predicted intracellular proteins	Evidence at protein level	HPA043934	Approved		Approved	Vesicles	Cervical cancer:8.48e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 18.7	Mixed		
EBPL	EBRP	ENSG00000123179	Emopamil binding protein like	13	49660723-49691475	Predicted membrane proteins	Evidence at protein level	HPA049891	Approved		Supported	Endoplasmic reticulum	Renal cancer:7.18e-8 (unfavourable), Ovarian cancer:1.38e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 61.5	Expressed in all		
ATP7B	WND	ENSG00000123191	ATPase copper transporting beta	13	51930436-52012125	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA009137, HPA013187	Supported		Supported	Golgi apparatus	Endometrial cancer:5.01e-4 (unfavourable)	Mixed	Mixed			testis: 13.9	Cell line enhanced		BEWO: 31.8;HEL: 46.9;RPTEC TERT1: 22.2
ZC3H13	DKFZp434D1812, KIAA0853	ENSG00000123200	Zinc finger CCCH-type containing 13	13	45954465-46052759	Predicted intracellular proteins	Evidence at protein level	HPA039340, HPA040140, HPA047806	Uncertain		Approved	Nuclear membrane<br>Actin filaments	Renal cancer:2.69e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 33.5	Expressed in all		
NLN	AGTBP, KIAA1226	ENSG00000123213	Neurolysin	5	65722196-65871725	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031862	Approved		Approved	Mitochondria	Renal cancer:5.58e-7 (favourable), Pancreatic cancer:7.51e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 8.2	Expressed in all		
CENPK	CENP-K, FKSG14, SOLT	ENSG00000123219	Centromere protein K	5	65517766-65563171	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 24.7	Expressed in all		
OPTN	FIP-2, FIP2, GLC1E, HIP7, HYPL, NRP, TFIIIA-INTP	ENSG00000123240	Optineurin	10	13099449-13138308	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003279, HPA003360, CAB019303	Supported		Enhanced	Cytosol	Renal cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 300.1	Mixed		
ITIH5	MGC10848	ENSG00000123243	Inter-alpha-trypsin inhibitor heavy chain family member 5	10	7559270-7666998	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038305	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			placenta: 123.4	Cell line enriched	7	WM-115: 101.4
ATF1	TREB36	ENSG00000123268	Activating transcription factor 1	12	50763710-50821122	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016222, HPA055069, HPA055406	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.53e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
TSFM	EF-TS, EF-Tsmt	ENSG00000123297	Ts translation elongation factor, mitochondrial	12	57782589-57808071	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006204			Supported	Nucleus<br>Mitochondria	Renal cancer:8.82e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 63.7	Cell line enriched	7	RH-30: 980.3
NEUROD4	ATH-3, Atoh3, bHLHa4, MATH-3	ENSG00000123307	Neuronal differentiation 4	12	55019945-55030014	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015545	Supported					Not detected	Tissue enhanced		adrenal gland: 2.3	testis: 0.5	Group enriched	8	AF22: 1.3;SCLC-21H: 3.3
ARHGAP9	10C, MGC1295	ENSG00000123329	Rho GTPase activating protein 9	12	57472255-57488814	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.90e-9 (unfavourable), Endometrial cancer:6.61e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 78.0	lymph node: 68.3	Cell line enhanced		HEL: 24.8;HMC-1: 103.7;THP-1: 23.7
NCKAP1L	HEM1	ENSG00000123338	NCK associated protein 1 like	12	54497711-54548238	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA039490, HPA040772	Approved		Uncertain	Plasma membrane<br>Cytosol		Expressed in all	Mixed			spleen: 54.9	Cell line enhanced		HL-60: 89.0;HMC-1: 98.8;THP-1: 81.4;U-937: 55.5
MMP19	MMP18, RASI-1	ENSG00000123342	Matrix metallopeptidase 19	12	55835433-55842966	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA070804			Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:8.56e-9 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 64.2;gallbladder: 97.3	placenta: 28.2	Cell line enriched	7	BEWO: 141.1
PFDN5	MM-1, PFD5	ENSG00000123349	Prefoldin subunit 5	12	53295291-53299450	Predicted intracellular proteins	Evidence at protein level	HPA008587	Approved				Renal cancer:1.54e-6 (unfavourable), Pancreatic cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 1080.1	Expressed in all		
SPATS2	FLJ13117, SCR59, SPATA10	ENSG00000123352	Spermatogenesis associated serine rich 2	12	49366584-49527424	Predicted intracellular proteins	Evidence at protein level	HPA038642, HPA038643, HPA066105	Uncertain		Enhanced	Cytosol	Liver cancer:9.57e-8 (unfavourable), Ovarian cancer:1.44e-4 (favourable), Renal cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
ORMDL2	adoplin-2, HSPC160, MST095, MSTP095	ENSG00000123353	ORMDL sphingolipid biosynthesis regulator 2	12	55817919-55821879	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 62.6	Expressed in all		
NR4A1	GFRP1, HMR, N10, NAK-1, NGFIB, NUR77, TR3	ENSG00000123358	Nuclear receptor subfamily 4 group A member 1	12	52022832-52059507	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059742, HPA070142	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 748.8	Cell line enhanced		MCF7: 67.2;SK-BR-3: 60.1;SK-MEL-30: 111.2
PDE1B	PDES1B	ENSG00000123360	Phosphodiesterase 1B	12	54549350-54579239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018492	Approved				Renal cancer:4.77e-6 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 18.4	parathyroid gland: 11.9	Cell line enhanced		HDLM-2: 10.6;HL-60: 5.1;HMC-1: 10.2;NB-4: 5.1;THP-1: 5.1;U-937: 5.0
HOXC13	HOX3, HOX3G	ENSG00000123364	Homeobox C13	12	53938765-53946544	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051634	Supported					Mixed	Tissue enriched	8	skin: 4.6	breast,testis: 0.5	Cell line enhanced		AN3-CA: 28.1;HaCaT: 56.8;SK-BR-3: 26.3;T-47d: 25.6
CDK2		ENSG00000123374	Cyclin dependent kinase 2	12	55966769-55972784	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013115, HPA066915	Enhanced		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:1.46e-10 (unfavourable), Liver cancer:8.61e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 65.5	Expressed in all		
LRP1	A2MR, APOER, APR, CD91, LRP, LRP1A	ENSG00000123384	LDL receptor related protein 1	12	57128493-57213351	Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004182, CAB018621, HPA022903	Supported		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 123.8	Cell line enhanced		ASC diff: 333.3;ASC TERT1: 342.9;HSkMC: 232.4
HOXC11	HOX3H	ENSG00000123388	Homeobox C11	12	53973126-53977643	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA038291	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		skin: 2.2	testis: 1.1	Cell line enhanced		AN3-CA: 32.1;BJ hTERT+: 14.2;T-47d: 25.7
ATG101	C12orf44, FLJ11773	ENSG00000123395	Autophagy related 101	12	52069246-52077494	Predicted intracellular proteins	Evidence at protein level	HPA039904	Approved				Liver cancer:8.07e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 43.7	Expressed in all		
NFE2	NF-E2	ENSG00000123405	Nuclear factor, erythroid 2	12	54292111-54301121	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001914	Enhanced		Approved	Nucleoplasm<br>Actin filaments		Mixed	Tissue enriched	6	bone marrow: 68.6	spleen: 11.9	Cell line enhanced		HEL: 328.8;K-562: 144.5;NB-4: 71.3
HOXC12	HOC3F, HOX3, HOX3F	ENSG00000123407	Homeobox C12	12	53954834-53958956	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055632	Uncertain					Mixed	Not detected			skin: 0.7	Group enriched	6	HaCaT: 20.3;K-562: 5.9;SiHa: 5.3
IKZF4	Eos, ZNFN1A4	ENSG00000123411	IKAROS family zinc finger 4	12	56007659-56038435	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046270, HPA049016	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Lung cancer:3.46e-4 (favourable), Pancreatic cancer:4.37e-4 (favourable)	Mixed	Mixed			parathyroid gland: 17.0	Cell line enhanced		HDLM-2: 33.6
SMUG1	FDG, HMUDG, UNG3	ENSG00000123415	Single-strand-selective monofunctional uracil-DNA glycosylase 1	12	54121277-54189008	Predicted intracellular proteins	Evidence at protein level	HPA051149, HPA071486			Approved	Vesicles<br>Centrosome	Ovarian cancer:1.31e-4 (favourable), Liver cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 48.8	Expressed in all		
TUBA1B	K-ALPHA-1	ENSG00000123416	Tubulin alpha 1b	12	49127782-49131397	Predicted intracellular proteins	Evidence at protein level	CAB011513, HPA039247, HPA043684, HPA063394	Enhanced		Supported	Microtubules	Renal cancer:2.85e-12 (unfavourable), Liver cancer:1.68e-7 (unfavourable), Breast cancer:5.49e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1433.9	Expressed in all		
METTL21B	DKFZP586D0919, FAM119B	ENSG00000123427	Methyltransferase like 21B	12	57771492-57782541	Predicted intracellular proteins	Evidence at protein level	HPA043020	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 16.8	Cell line enriched	9	RH-30: 142.0
KBTBD4	BKLHD4, FLJ10450, HSPC252	ENSG00000123444	Kelch repeat and BTB domain containing 4	11	47572197-47579015	Predicted intracellular proteins	Evidence at protein level	HPA037792, HPA037793	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:2.70e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 48.6	Expressed in all		
SARDH	DMGDHL1, SDH	ENSG00000123453	Sarcosine dehydrogenase	9	133663560-133739955	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057267, HPA058086	Approved		Approved	Mitochondria	Glioma:3.50e-4 (unfavourable)	Tissue enriched	Tissue enhanced		epididymis: 59.3;liver: 43.0	kidney: 12.5	Group enriched	5	AN3-CA: 16.3;Hep G2: 20.7;LHCN-M2: 9.2;MOLT-4: 18.0;RH-30: 17.5;RPMI-8226: 26.5;SH-SY5Y: 15.4
DBH	DBM	ENSG00000123454	Dopamine beta-hydroxylase	9	133636360-133659344	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002130, HPA005960, HPA070789	Enhanced		Enhanced	Endoplasmic reticulum<br>Vesicles		Mixed	Tissue enriched	28	adrenal gland: 356.8	liver: 12.6	Cell line enriched	370	SH-SY5Y: 1924.2
ATPAF1	ATP11, Atp11p, FLJ22351	ENSG00000123472	ATP synthase mitochondrial F1 complex assembly factor 1	1	46632737-46673867	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028382, HPA044950	Approved		Approved	Mitochondria	Renal cancer:5.33e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 176.2	Expressed in all		
STIL	MCPH7, SIL	ENSG00000123473	SCL/TAL1 interrupting locus	1	47250139-47314147	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046543			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.33e-4 (unfavourable)	Mixed	Mixed			testis: 12.9	Mixed		
HJURP	DKFZp762E1312, FAKTS, hFLEG1, URLC9	ENSG00000123485	Holliday junction recognition protein	2	233833416-233854566	Predicted intracellular proteins	Evidence at protein level	HPA008436, HPA027261	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.37e-5 (unfavourable), Pancreatic cancer:7.72e-5 (unfavourable), Lung cancer:2.46e-4 (unfavourable), Melanoma:6.49e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 28.7;testis: 20.0	lymph node: 15.1	Mixed		
IL13RA2	CD213a2, CT19, IL-13R, IL13BP	ENSG00000123496	Interleukin 13 receptor subunit alpha 2	X	115003975-115019977	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.55e-4 (favourable)	Tissue enhanced	Tissue enriched	8	testis: 52.8	prostate: 6.8	Group enriched	9	PC-3: 120.8;U-2197: 386.1;U-251 MG: 238.2;U-87 MG: 159.9
COL10A1		ENSG00000123500	Collagen type X alpha 1 chain	6	116118923-116158747	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA053268			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		gallbladder: 14.5	ovary: 4.9	Cell line enriched	6	hTEC/SVTERT24-B: 39.7
AMD1	SAMDC	ENSG00000123505	Adenosylmethionine decarboxylase 1	6	110874770-110895713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029281, HPA029282	Approved		Approved	Nucleoplasm	Liver cancer:1.91e-6 (unfavourable), Breast cancer:3.87e-4 (unfavourable), Renal cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			prostate: 323.8	Expressed in all		
NDUFAF4	bA22L21.1, C6orf66, HRPAP20, HSPC125, My013	ENSG00000123545	NADH:ubiquinone oxidoreductase complex assembly factor 4	6	96889313-96897881	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046560	Uncertain		Supported	Mitochondria	Breast cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
USP45	MGC14793	ENSG00000123552	Ubiquitin specific peptidase 45	6	99432379-99521728	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029602, HPA029604	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			gallbladder: 9.9	Expressed in all		
PLP1	GPM6C, PLP, SPG2	ENSG00000123560	Proteolipid protein 1	X	103773718-103792619	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA004128	Enhanced					Group enriched	Tissue enriched	30	cerebral cortex: 3216.6	parathyroid gland: 107.9	Group enriched	6	NTERA-2: 37.4;SK-MEL-30: 184.2;WM-115: 137.4
SERPINA7	TBG	ENSG00000123561	Serpin family A member 7	X	106032442-106038738	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002803	Approved					Tissue enriched	Tissue enriched	288	liver: 216.0	small intestine: 0.7	Cell line enriched	406	Hep G2: 71.5
MORF4L2	KIAA0026, MRGX	ENSG00000123562	Mortality factor 4 like 2	X	103675496-103688158	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031872, HPA054102	Supported		Enhanced	Nucleus	Renal cancer:7.86e-7 (unfavourable), Head and neck cancer:4.29e-5 (unfavourable), Breast cancer:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 493.3	Expressed in all		
H2BFWT		ENSG00000123569	H2B histone family member W, testis specific	X	104011147-104013687	Predicted intracellular proteins	Evidence at protein level	HPA056289	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
RAB9B	RAB9L	ENSG00000123570	RAB9B, member RAS oncogene family	X	103822322-103832228	Predicted secreted proteins	Evidence at protein level	HPA061932	Enhanced					Mixed	Mixed			heart muscle: 14.6	Mixed		
NRK	DKFZp686A17109	ENSG00000123572	Nik related kinase	X	105822543-105958610	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017238	Uncertain		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		ovary: 39.8;placenta: 34.3	adrenal gland: 21.0	Cell line enhanced		fHDF/TERT166: 45.0;RH-30: 12.4;RPTEC TERT1: 26.3
FAM199X	CXorf39	ENSG00000123575	Family with sequence similarity 199, X-linked	X	104166620-104195902	Predicted intracellular proteins	Evidence at protein level	HPA003093	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			epididymis: 43.4	Expressed in all		
ESX1	ESX1L, ESXR1	ENSG00000123576	ESX homeobox 1	X	104250038-104254933	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051992	Enhanced		Supported	Nuclear speckles		Tissue enriched	Tissue enriched	63	testis: 12.0	placenta: 0.1	Cell line enriched	9	TIME: 20.3
MAGEA9	CT1.9, MAGE9, MGC8421	ENSG00000123584	MAGE family member A9	X	149781930-149787737	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.6	Group enriched	7	U-266/70: 34.5;U-266/84: 23.0
ATXN3L	MJDL	ENSG00000123594	Ataxin 3 like	X	13318236-13320399	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024123, HPA027539	Uncertain					Not detected	Tissue enriched	37	testis: 4.9	placenta: 0.1	Not detected		
RAB9A	RAB9	ENSG00000123595	RAB9A, member RAS oncogene family	X	13689125-13710506	Predicted intracellular proteins	Evidence at protein level	HPA003094, CAB016411	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:3.35e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 68.1	Expressed in all		
METTL8	FLJ13984, TIP	ENSG00000123600	Methyltransferase like 8	2	171317405-171434802	Predicted intracellular proteins	Evidence at protein level	HPA035421	Uncertain		Approved	Cytosol	Endometrial cancer:2.00e-4 (unfavourable), Renal cancer:6.75e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 14.7	Expressed in all		
TTC21B	FLJ11457, IFT139B, JBTS11, NPHP12, THM1	ENSG00000123607	Tetratricopeptide repeat domain 21B	2	165857475-165953843	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035494, HPA035495	Uncertain		Supported	Mitochondria	Renal cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 14.4	Mixed		
NMI		ENSG00000123609	N-myc and STAT interactor	2	151270465-151290057	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008588	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.57e-7 (unfavourable), Liver cancer:1.15e-4 (unfavourable), Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 46.9	Mixed		
TNFAIP6	TSG-6, TSG6	ENSG00000123610	TNF alpha induced protein 6	2	151357592-151380048	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB032719, HPA050884	Approved				Cervical cancer:8.18e-5 (unfavourable), Urothelial cancer:9.16e-5 (unfavourable), Renal cancer:5.59e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 38.7;gallbladder: 31.8	adipose tissue: 18.7	Cell line enhanced		BJ hTERT+: 54.6;HHSteC: 33.8;hTEC/SVTERT24-B: 54.8;U-2197: 41.1
ACVR1C	ACVRLK7, ALK7	ENSG00000123612	Activin A receptor type 1C	2	157526767-157629005	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007982, HPA011933	Approved					Mixed	Tissue enriched	8	adipose tissue: 34.1	ovary: 4.3	Cell line enhanced		ASC diff: 7.5;HDLM-2: 4.8
BAZ2B	WALp4	ENSG00000123636	Bromodomain adjacent to zinc finger domain 2B	2	159318979-159616692	Predicted intracellular proteins	Evidence at protein level	HPA019819, HPA059292	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 55.5	Mixed		
SLC36A1	LYAAT-1, PAT1, TRAMD3	ENSG00000123643	Solute carrier family 36 member 1	5	151437046-151492381	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035937	Approved				Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 65.4	duodenum: 44.3	Mixed		
LPGAT1	FAM34A, FAM34A1, KIAA0205, NET8	ENSG00000123684	Lysophosphatidylglycerol acyltransferase 1	1	211743457-211830772	Predicted membrane proteins	Evidence at protein level	HPA008304	Approved					Expressed in all	Expressed in all			thyroid gland: 43.1	Mixed		
BATF3	JDP1, JUNDM1, SNFT	ENSG00000123685	Basic leucine zipper ATF-like transcription factor 3	1	212686418-212699985	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			spleen: 4.6	Cell line enriched	25	HDLM-2: 359.9
G0S2		ENSG00000123689	G0/G1 switch 2	1	209675420-209676388	Predicted intracellular proteins	Evidence at protein level						Glioma:2.22e-4 (unfavourable), Renal cancer:3.14e-4 (unfavourable), Colorectal cancer:7.72e-4 (unfavourable)	Expressed in all	Group enriched	5	adipose tissue: 956.0;bone marrow: 937.9;skeletal muscle: 240.5	appendix: 138.1	Cell line enhanced		ASC diff: 321.2;HBEC3-KT: 528.5;PC-3: 170.1;RPMI-8226: 166.8
KCNJ2	IRK1, Kir2.1, LQT7	ENSG00000123700	Potassium voltage-gated channel subfamily J member 2	17	70168673-70180048	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029109	Approved					Mixed	Tissue enhanced		parathyroid gland: 44.6	fallopian tube: 10.6	Cell line enhanced		REH: 6.8;RH-30: 28.3;U-138 MG: 10.5
RAP2C	DKFZp313B211	ENSG00000123728	RAP2C, member of RAS oncogene family	X	132203024-132219480	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.81e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 102.6	Expressed in all		
EXOSC9	p5, p6, PM/Scl-75, PMSCL1, RRP45, Rrp45p	ENSG00000123737	Exosome component 9	4	121801317-121817021	Predicted intracellular proteins	Evidence at protein level	HPA041838, HPA048257, CAB070171	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.04e-4 (unfavourable), Renal cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.4	Expressed in all		
PLA2G12A	PLA2G12	ENSG00000123739	Phospholipase A2 group XIIA	4	109709989-109730077	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA035908, HPA035909	Approved				Renal cancer:2.54e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.0	Expressed in all		
B9D2	MGC4093, MKS10	ENSG00000123810	B9 protein domain 2	19	41354421-41364173	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042229, HPA042618	Enhanced				Melanoma:6.39e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 16.8	Expressed in all		
COQ8B	ADCK4, COQ8, FLJ12229	ENSG00000123815	Coenzyme Q8B	19	40691529-40718207	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027229, HPA027277, HPA027279, HPA028303	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			fallopian tube: 41.1	Expressed in all		
PFKFB2		ENSG00000123836	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2	1	207034366-207081024	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049975, HPA063575	Uncertain		Enhanced	Nucleus	Renal cancer:3.23e-7 (favourable), Thyroid cancer:8.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 86.2	Mixed		
C4BPA	C4BP	ENSG00000123838	Complement component 4 binding protein alpha	1	207104262-207144972	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000926, HPA001578	Enhanced				Endometrial cancer:6.37e-5 (favourable), Liver cancer:2.24e-4 (favourable)	Tissue enriched	Group enriched	65	liver: 997.5;lung: 262.3	cervix, uterine: 9.6	Cell line enriched	6	Hep G2: 25.8
C4BPB	C4BP	ENSG00000123843	Complement component 4 binding protein beta	1	207088842-207099993	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051620	Approved					Tissue enriched	Group enriched	16	liver: 241.3;ovary: 52.0	placenta: 8.9	Group enriched	15	CACO-2: 94.2;HeLa: 31.3;Hep G2: 101.7
RAB38	NY-MEL-1	ENSG00000123892	RAB38, member RAS oncogene family	11	88113242-88175467	Predicted intracellular proteins	Evidence at protein level	HPA071701			Uncertain	Nuclear bodies<br>Mitochondria	Renal cancer:8.26e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 47.4	esophagus: 36.3	Cell line enhanced		hTCEpi: 216.3;hTERT-HME1: 203.2;SK-MEL-30: 129.2
GPR83	GPR72	ENSG00000123901	G protein-coupled receptor 83	11	94377311-94401419	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Group enriched	6	adrenal gland: 1.0;cerebral cortex: 4.6;thyroid gland: 5.1	skin,testis: 0.5	Cell line enhanced		CACO-2: 1.4
AGO2	CASC7, EIF2C2, hAGO2, LINC00980, Q10	ENSG00000123908	Argonaute 2, RISC catalytic component	8	140520156-140635619	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019309, HPA058075	Approved		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:1.82e-5 (unfavourable), Endometrial cancer:1.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.0	Expressed in all		
MXD4	bHLHc12, MAD4, MST149, MSTP149	ENSG00000123933	MAX dimerization protein 4	4	2247432-2262294	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053363			Supported	Cytosol	Pancreatic cancer:1.39e-5 (favourable), Head and neck cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			spleen: 41.3	Expressed in all		
CKS2		ENSG00000123975	CDC28 protein kinase regulatory subunit 2	9	89311198-89316703	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003424, HPA030762	Approved	Supported	Approved	Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol	Liver cancer:2.51e-6 (unfavourable), Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 341.7	lymph node: 122.6	Expressed in all		
DAW1	FLJ25955, ODA16, WDR69	ENSG00000123977	Dynein assembly factor with WD repeats 1	2	227871054-227924344	Predicted intracellular proteins	Evidence at protein level	HPA046118	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Group enriched	14	fallopian tube: 51.4;testis: 92.1	lung: 4.9	Cell line enhanced		HUVEC TERT2: 18.4;U-2197: 40.4
ACSL3	ACS3, FACL3, PRO2194	ENSG00000123983	Acyl-CoA synthetase long-chain family member 3	2	222860934-222944639	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011315, HPA071021	Uncertain		Approved	Nucleoli<br>Lipid droplets	Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 682.1	Expressed in all		
CHPF	CHSY2, CSS2	ENSG00000123989	Chondroitin polymerizing factor	2	219538947-219543787	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035123	Approved		Supported	Vesicles<br>Centrosome<br>Cytosol	Cervical cancer:1.57e-4 (unfavourable), Head and neck cancer:1.68e-4 (unfavourable), Urothelial cancer:2.96e-4 (unfavourable), Glioma:9.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 77.2	Mixed		
DNPEP	ASPEP, DAP	ENSG00000123992	Aspartyl aminopeptidase	2	219373546-219400022	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036398, HPA044860	Enhanced		Supported	Cytosol		Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
INHA		ENSG00000123999	Inhibin alpha subunit	2	219569162-219575713	Predicted secreted proteins	Evidence at protein level	CAB000047, HPA019141	Enhanced		Approved	Vesicles	Renal cancer:4.03e-5 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 51.5;ovary: 38.0;testis: 106.3	placenta: 14.9	Cell line enhanced		HEL: 3.7;SK-BR-3: 6.8
MOGAT1	DGAT2L, DGAT2L1, MGAT1	ENSG00000124003	Monoacylglycerol O-acyltransferase 1	2	222671786-222709930	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA049944	Uncertain					Tissue enhanced	Tissue enriched	10	gallbladder: 30.7	parathyroid gland: 2.9	Not detected		
OBSL1	KIAA0657	ENSG00000124006	Obscurin like 1	2	219550729-219571859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036404, HPA036405	Approved		Approved	Centrosome	Glioma:8.52e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 220.5	Cell line enhanced		BEWO: 148.8
FAM124B	FLJ22746	ENSG00000124019	Family with sequence similarity 124 member B	2	224378698-224402085	Predicted intracellular proteins	Evidence at protein level	HPA070240	Approved		Approved	Nucleoplasm<br>Mitochondria		Tissue enriched	Tissue enhanced		parathyroid gland: 9.8;placenta: 12.5	lung,smooth muscle: 3.6	Cell line enriched	7	HUVEC TERT2: 88.9
SLC12A4	KCC1	ENSG00000124067	Solute carrier family 12 member 4	16	67943474-67969601	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041138	Approved		Approved	Endosomes	Renal cancer:2.25e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.9	Mixed		
ENKD1	C16orf48, DKFZP434A1319	ENSG00000124074	Enkurin domain containing 1	16	67662945-67667265	Predicted intracellular proteins	Evidence at protein level	HPA041163, HPA041478	Approved		Supported	Plasma membrane<br>Centrosome<br>Cytosol	Endometrial cancer:1.68e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.7	Mixed		
MC3R	MC3	ENSG00000124089	Melanocortin 3 receptor	20	56248732-56249815	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
GCNT7	C20orf105, dJ1153D9.2	ENSG00000124091	Glucosaminyl (N-acetyl) transferase family member 7	20	56491492-56525925	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052617	Uncertain					Not detected	Tissue enriched	5	bone marrow: 2.8	skin,testis: 0.5	Not detected		
CTCFL	BORIS, CT27, dJ579F20.2	ENSG00000124092	CCCTC-binding factor like	20	57495966-57525652	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA001472	Enhanced					Tissue enhanced	Tissue enriched	20	testis: 20.6	bone marrow: 1.0	Group enriched	41	HMC-1: 70.0;K-562: 103.5
FAM210B	C20orf108, dJ1167H4.1, DKFZP434A1114	ENSG00000124098	Family with sequence similarity 210 member B	20	56358915-56368663	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042652	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			ovary: 131.4	Cell line enhanced		SK-MEL-30: 224.0
PI3	cementoin, ELAFIN, ESI, SKALP, WAP3, WFDC14	ENSG00000124102	Peptidase inhibitor 3	20	45174876-45176544	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009449, HPA017737	Enhanced		Approved	Plasma membrane	Renal cancer:1.94e-8 (unfavourable), Ovarian cancer:3.84e-6 (unfavourable), Pancreatic cancer:6.89e-4 (unfavourable), Breast cancer:6.94e-4 (favourable)	Tissue enhanced	Group enriched	15	esophagus: 2285.4;tonsil: 1739.8	appendix: 133.6	Group enriched	7	EFO-21: 78.9;HaCaT: 92.0;PC-3: 163.0
FAM209A	C20orf106, dJ1153D9.3	ENSG00000124103	Family with sequence similarity 209 member A	20	56517187-56526142	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	10	testis: 100.6	bone marrow: 9.6	Cell line enhanced		HMC-1: 1.6;U-266/84: 1.0
SNX21	C20orf161, dJ337O18.4, SNX-L	ENSG00000124104	Sorting nexin family member 21	20	45833810-45843275	Predicted intracellular proteins	Evidence at protein level	HPA046359	Approved		Approved	Vesicles<br>Microtubule organizing center		Expressed in all	Mixed			skin: 25.5	Cell line enhanced		PC-3: 28.8;U-87 MG: 27.0
SLPI	ALK1, ALP, BLPI, HUSI, HUSI-I, WAP4, WFDC4	ENSG00000124107	Secretory leukocyte peptidase inhibitor	20	45252239-45254564	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002303, HPA027774	Enhanced				Renal cancer:6.91e-5 (unfavourable)	Expressed in all	Tissue enriched	9	cervix, uterine: 41087.8	seminal vesicle: 4333.6	Cell line enhanced		EFO-21: 1622.9;hTCEpi: 1467.1;SiHa: 660.2
WFDC3	dJ447F3.3, WAP14	ENSG00000124116	WAP four-disulfide core domain 3	20	45747944-45791932	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	19	testis: 31.9	breast: 1.7	Cell line enhanced		PC-3: 1.1
TTPAL	C20orf121, dJ179M20.3	ENSG00000124120	Alpha tocopherol transfer protein like	20	44475886-44494603	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046957, HPA066532	Uncertain		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:3.47e-5 (unfavourable), Renal cancer:8.09e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			skin: 14.9	Expressed in all		
PREX1	KIAA1415, P-REX1	ENSG00000124126	Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1	20	48624252-48827883	Predicted intracellular proteins	Evidence at protein level	HPA001927	Supported		Supported	Vesicles<br>Cytosol	Head and neck cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.8	Cell line enhanced		MCF7: 124.7;SK-BR-3: 123.7;T-47d: 138.8
KCNS1	Kv9.1	ENSG00000124134	Potassium voltage-gated channel modifier subfamily S member 1	20	45092310-45101112	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Ovarian cancer:6.45e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 9.3;gallbladder: 3.8;seminal vesicle: 4.2	testis: 1.7	Cell line enhanced		HBF TERT88: 1.3;HHSteC: 1.8;THP-1: 1.2;U-87 MG: 3.0
SLC12A5	KCC2, KIAA1176	ENSG00000124140	Solute carrier family 12 member 5	20	46021690-46060152	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072058	Enhanced				Glioma:8.45e-4 (unfavourable)	Mixed	Tissue enriched	8	cerebral cortex: 94.2	adrenal gland: 11.9	Cell line enhanced		NB-4: 32.3;U-2 OS: 29.1
ARHGAP40	C20orf95, dJ1100H13.4	ENSG00000124143	Rho GTPase activating protein 40	20	38601934-38651035	Predicted intracellular proteins	Evidence at protein level	HPA042636, HPA042840	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:2.89e-4 (unfavourable)	Mixed	Group enriched	7	breast: 38.1;epididymis: 43.7;esophagus: 12.6;seminal vesicle: 11.3;skin: 53.8	prostate: 4.4	Cell line enhanced		BEWO: 8.0;HBEC3-KT: 9.7;RPTEC TERT1: 8.8;SK-BR-3: 9.5;T-47d: 14.4
SDC4	amphiglycan, ryudocan, SYND4	ENSG00000124145	Syndecan 4	20	45325288-45348424	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA005716, CAB013240	Supported		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 250.2	Mixed		
NCOA3	ACTR, AIB1, bHLHe42, CAGH16, KAT13B, p/CIP, RAC3, SRC-3, SRC3, TNRC16, TRAM-1	ENSG00000124151	Nuclear receptor coactivator 3	20	47501902-47656877	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009800, HPA024210	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.09e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 44.8	Expressed in all		
PIGT		ENSG00000124155	Phosphatidylinositol glycan anchor biosynthesis class T	20	45416067-45456934	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 123.1	Expressed in all		
SEMG2	SGII	ENSG00000124157	Semenogelin II	20	45221300-45224458	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042767, HPA042835	Enhanced					Tissue enriched	Tissue enriched	18571	seminal vesicle: 14103.4	cervix, uterine,kidney: 0.7	Not detected		
MATN4		ENSG00000124159	Matrilin 4	20	45293445-45308529	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		breast: 3.0;pancreas: 5.9;skin: 3.5	cervix, uterine: 1.4	Cell line enhanced		NB-4: 1.7;U-937: 1.0
NCOA5	bA465L10.6, CIA	ENSG00000124160	Nuclear receptor coactivator 5	20	46060985-46089952	Predicted intracellular proteins	Evidence at protein level	HPA050231	Uncertain		Supported	Nucleus<br>Actin filaments	Liver cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.09e-4 (favourable), Lung cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.0	Expressed in all		
VAPB	ALS8, VAP-B, VAP-C	ENSG00000124164	VAMP associated protein B and C	20	58389122-58451101	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013144, CAB013722	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:1.08e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.4	Expressed in all		
PARD6B	PAR-6B	ENSG00000124171	Par-6 family cell polarity regulator beta	20	50731544-50756795	Predicted intracellular proteins	Evidence at protein level	HPA013376	Uncertain		Supported	Cytosol	Liver cancer:1.02e-5 (unfavourable), Renal cancer:6.38e-5 (favourable), Pancreatic cancer:8.38e-4 (unfavourable)	Expressed in all	Mixed			kidney: 16.7	Cell line enhanced		CACO-2: 23.7;MCF7: 39.2;T-47d: 45.5
ATP5E		ENSG00000124172	ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit	20	59025467-59032382	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 132.8	Expressed in all		
CHD6	CHD5, dJ620E11.1, FLJ22369, KIAA1335, RIGB	ENSG00000124177	Chromodomain helicase DNA binding protein 6	20	41402101-41618494	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015543			Approved	Nucleus	Lung cancer:3.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.5	Expressed in all		
PLCG1	NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1	ENSG00000124181	Phospholipase C gamma 1	20	41136960-41196801	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004277, HPA036681, HPA036682	Approved		Supported	Cytosol	Pancreatic cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 47.6	Expressed in all		
TOX2	C20orf100, dJ1108D11.2, GCX-1	ENSG00000124191	TOX high mobility group box family member 2	20	43914864-44069616	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049900, HPA058396	Approved		Supported	Nucleoplasm	Renal cancer:7.45e-8 (unfavourable), Endometrial cancer:2.60e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 19.8	Cell line enhanced		HHSteC: 99.2;U-266/70: 59.6
SRSF6	B52, SFRS6, SRP55	ENSG00000124193	Serine and arginine rich splicing factor 6	20	43457928-43464247	Predicted intracellular proteins	Evidence at protein level	HPA029005, CAB034889	Supported		Supported	Nuclear speckles	Renal cancer:2.82e-4 (unfavourable), Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 83.5	Expressed in all		
GDAP1L1		ENSG00000124194	Ganglioside induced differentiation associated protein 1 like 1	20	44247099-44280917	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054182, HPA063265	Approved		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	20	cerebral cortex: 55.6	adrenal gland: 2.8	Group enriched	6	NTERA-2: 11.9;SCLC-21H: 34.5;SH-SY5Y: 15.2
GTSF1L	C20orf65, dJ1028D15.4, FAM112A	ENSG00000124196	Gametocyte specific factor 1 like	20	43726164-43726998	Predicted intracellular proteins	Evidence at protein level	HPA054694	Enhanced		Uncertain	Nucleoli		Tissue enriched	Tissue enriched	160	testis: 269.9	lymph node: 1.6	Cell line enhanced		REH: 1.0
ARFGEF2	BIG2	ENSG00000124198	ADP ribosylation factor guanine nucleotide exchange factor 2	20	48921890-49036693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026078, CAB026382	Supported		Supported	Golgi apparatus	Renal cancer:6.15e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.4	Expressed in all		
ZNFX1	FLJ11277, KIAA1404	ENSG00000124201	Zinc finger NFX1-type containing 1	20	49237946-49278426	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046629	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
ZNF831	C20orf174, dJ492J12.1	ENSG00000124203	Zinc finger protein 831	20	59123381-59259113	Predicted intracellular proteins	Evidence at protein level	HPA016839	Uncertain					Not detected	Tissue enhanced		lymph node: 7.1	spleen: 3.6	Cell line enhanced		Daudi: 2.9
EDN3	ET3	ENSG00000124205	Endothelin 3	20	59300427-59325992	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA036618		Supported			Glioma:2.38e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 39.3	duodenum: 38.3	Not detected		
CSE1L	CAS, CSE1, XPO2	ENSG00000124207	Chromosome segregation 1 like	20	49046246-49096960	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002140, HPA038059, HPA038060	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.42e-8 (unfavourable), Endometrial cancer:2.91e-5 (unfavourable), Renal cancer:1.89e-4 (unfavourable), Urothelial cancer:6.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 159.7	Expressed in all		
TMEM189-UBE2V1	CROC-1B, Kua-UEV	ENSG00000124208	TMEM189-UBE2V1 readthrough	20	50081124-50153637	Predicted membrane proteins	Evidence at protein level	HPA052535, HPA053186			Supported	Nucleoplasm		Not detected	Mixed			placenta: 5.6	Mixed		
RAB22A		ENSG00000124209	RAB22A, member RAS oncogene family	20	58309696-58367507	Predicted intracellular proteins	Evidence at protein level	HPA058894, HPA066920	Approved		Uncertain	Centrosome	Liver cancer:7.33e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
PTGIS	CYP8A1, PGIS	ENSG00000124212	Prostaglandin I2 synthase	20	49503874-49568146	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009517, HPA014193, HPA052244	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube: 78.2	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 31.6;U-2197: 133.1
STAU1	PPP1R150, STAU	ENSG00000124214	Staufen double-stranded RNA binding protein 1	20	49113339-49188367	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB020839, HPA049892	Approved		Supported	Cytosol	Prostate cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 140.5	Expressed in all		
CDH26	VR20	ENSG00000124215	Cadherin 26	20	59958427-60034011	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015722, HPA047578	Uncertain		Approved	Plasma membrane<br>Microtubules	Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable)	Group enriched	Tissue enhanced		prostate: 19.1	urinary bladder: 6.1	Cell line enriched	6	RT4: 42.4
SNAI1	SLUGH2, SNA, SNAH, SNAIL, SNAIL1	ENSG00000124216	Snail family transcriptional repressor 1	20	49982999-49988886	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005883, HPA056831, HPA069985, CAB078687	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:2.63e-7 (unfavourable), Thyroid cancer:8.82e-7 (unfavourable), Lung cancer:1.61e-5 (unfavourable), Colorectal cancer:4.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 26.2	thyroid gland: 13.4	Cell line enhanced		SiHa: 30.1;TIME: 32.4;WM-115: 25.0
MOCS3	dJ914P20.3, UBA4	ENSG00000124217	Molybdenum cofactor synthesis 3	20	50958826-50963931	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027556	Uncertain				Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable), Renal cancer:7.55e-4 (favourable)	Expressed in all	Mixed			testis: 5.2	Expressed in all		
STX16	hsyn16, SYN16	ENSG00000124222	Syntaxin 16	20	58651253-58679526	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041019, HPA042033	Uncertain		Enhanced	Vesicles	Renal cancer:1.11e-16 (unfavourable), Liver cancer:4.18e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 63.9	Expressed in all		
PMEPA1	STAG1, TMEPAI	ENSG00000124225	Prostate transmembrane protein, androgen induced 1	20	57648392-57711536	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA072291			Supported	Vesicles	Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 146.1;prostate: 179.6	endometrium: 60.3	Cell line enhanced		SiHa: 218.5;U-251 MG: 397.1;WM-115: 233.9
RNF114	PSORS12, ZNF313	ENSG00000124226	Ring finger protein 114	20	49936336-49953892	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021184	Approved		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:8.10e-6 (unfavourable), Thyroid cancer:3.01e-4 (favourable), Liver cancer:3.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.2	Expressed in all		
ANKRD60	bA196N14.3, C20orf86	ENSG00000124227	Ankyrin repeat domain 60	20	58218495-58228653	Predicted secreted proteins	Evidence at transcript level	HPA060561	Uncertain					Not detected	Tissue enriched	47	testis: 4.7	all non-specific tissues: 0.0	Not detected		
DDX27	dJ686N3.1, DRS1	ENSG00000124228	DEAD-box helicase 27	20	49219295-49244077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047087	Uncertain		Approved	Nucleoli	Liver cancer:6.70e-7 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Renal cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
RBPJL	RBP-L, RBPSUHL, SUH, SUHL	ENSG00000124232	Recombination signal binding protein for immunoglobulin kappa J region like	20	45306851-45317824	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB006846	Enhanced					Group enriched	Tissue enriched	151	pancreas: 205.8	stomach: 1.3	Not detected		
SEMG1	CT103, SEMG	ENSG00000124233	Semenogelin I	20	45206997-45209772	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042476, HPA064892	Enhanced					Tissue enriched	Tissue enriched	17692	seminal vesicle: 41483.3	cervix, uterine: 2.3	Cell line enhanced		NTERA-2: 1.2;THP-1: 2.0
C20orf85	bA196N14.1, LLC1	ENSG00000124237	Chromosome 20 open reading frame 85	20	58150904-58161150	Predicted intracellular proteins	Evidence at protein level	HPA058271, HPA065540	Enhanced					Tissue enhanced	Tissue enriched	8	fallopian tube: 729.1	testis: 91.7	Not detected		
BCAS4	CNOL, FLJ20495	ENSG00000124243	Breast carcinoma amplified sequence 4	20	50794894-50882676	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038812	Uncertain		Approved	Intermediate filaments<br>Cytosol	Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 25.3	tonsil: 21.0	Cell line enhanced		Daudi: 69.3;U-698: 59.0
KCNK15	dJ781B1.1, K2p15.1, KCNK11, KCNK14, KIAA0237, KT3.3, TASK-5, TASK5	ENSG00000124249	Potassium two pore domain channel subfamily K member 15	20	44745780-44752313	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA064861	Uncertain				Cervical cancer:3.68e-4 (unfavourable)	Tissue enriched	Tissue enhanced		fallopian tube: 8.0	testis: 2.9	Cell line enriched	8	MCF7: 35.7
TP53TG5	C20orf10, CLG01, dJ453C12.5	ENSG00000124251	TP53 target 5	20	45372563-45407889	Predicted intracellular proteins	Evidence at protein level	HPA041979	Enhanced					Not detected	Tissue enriched	12	testis: 22.2	cerebral cortex: 1.8	Cell line enhanced		CACO-2: 1.6
PCK1	PEPCK-C	ENSG00000124253	Phosphoenolpyruvate carboxykinase 1	20	57561080-57568112	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006277, HPA006507, CAB017027	Approved				Renal cancer:1.47e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 425.9;liver: 319.7	small intestine: 157.6	Cell line enriched	9	ASC diff: 14.0
ZBP1	C20orf183, DAI, dJ718J7.3, DLM-1, DLM1	ENSG00000124256	Z-DNA binding protein 1	20	57603846-57620576	Predicted intracellular proteins	Evidence at protein level	HPA041256	Enhanced					Mixed	Mixed			spleen: 29.8	Cell line enhanced		Karpas-707: 24.3;U-266/70: 12.6;U-266/84: 16.2
NEURL2	C20orf163, dJ337O18.6, FLJ30259, Ozz, Ozz-E3	ENSG00000124257	Neuralized E3 ubiquitin protein ligase 2	20	45888625-45891287	Predicted intracellular proteins	Evidence at transcript level	HPA043402, HPA059842	Approved		Approved	Vesicles		Mixed	Mixed			ovary: 8.4	Mixed		
MAGEA10	CT1.10, MAGE10, MGC10599	ENSG00000124260	MAGE family member A10	X	152133310-152138578	Predicted intracellular proteins	Evidence at protein level	HPA003333, HPA070780	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Group enriched	13	placenta: 13.5;testis: 4.8	skin: 0.7	Group enriched	9	PC-3: 7.4;SH-SY5Y: 5.3;U-266/84: 4.0;WM-115: 12.8
MTRR	cblE	ENSG00000124275	5-methyltetrahydrofolate-homocysteine methyltransferase reductase	5	7851186-7906025	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038113	Supported		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Liver cancer:6.60e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 20.5	Expressed in all		
FASTKD3	FLJ23274, MGC5297	ENSG00000124279	FAST kinase domains 3	5	7859159-7869037	Predicted intracellular proteins	Evidence at protein level	HPA068525, HPA074462	Approved		Supported	Nucleus<br>Mitochondria	Liver cancer:1.87e-5 (unfavourable), Urothelial cancer:8.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.4	Expressed in all		
PEPD		ENSG00000124299	Peptidase D	19	33386950-33521794	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015599, HPA072045	Approved		Supported	Nucleoplasm	Renal cancer:6.50e-9 (favourable)	Expressed in all	Expressed in all			kidney: 342.6	Expressed in all		
CHST8	GALNAC-4-ST1	ENSG00000124302	Carbohydrate sulfotransferase 8	19	33621955-33773509	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA016004	Supported					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.5	breast: 1.4	Group enriched	5	RPMI-8226: 16.8;SCLC-21H: 15.9;SH-SY5Y: 24.7
IQSEC2	KIAA0522, MRX1, MRX18, MRX78	ENSG00000124313	IQ motif and Sec7 domain 2	X	53225828-53321328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003973			Approved	Vesicles	Renal cancer:2.00e-4 (unfavourable), Urothelial cancer:2.38e-4 (favourable)	Mixed	Mixed			cerebral cortex: 38.5	Cell line enhanced		A549: 43.0
VAMP7	SYBL1, TI-VAMP, VAMP-7	ENSG00000124333	Vesicle associated membrane protein 7	X	155881293-155943769	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036733	Approved		Supported	Vesicles	Renal cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			placenta: 57.2	Expressed in all		
IL9R	CD129	ENSG00000124334	Interleukin 9 receptor	X	155997581-156010817	CD markers, Predicted membrane proteins	Evidence at protein level	HPA063240, HPA064557	Approved				Urothelial cancer:1.90e-7 (favourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 8.4	lymph node: 2.8	Cell line enriched	10	HMC-1: 217.8
XG	PBDX	ENSG00000124343	Xg blood group	X	2752050-2815927	Blood group antigen proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.25e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 41.1	breast: 15.4	Group enriched	6	ASC diff: 71.8;ASC TERT1: 49.4;fHDF/TERT166: 35.9;hTCEpi: 41.4;T-47d: 32.3
STAMBP	AMSH	ENSG00000124356	STAM binding protein	2	73828916-73873659	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035800, HPA035801	Uncertain		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:4.70e-5 (unfavourable), Pancreatic cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.1	Cell line enriched	11	LHCN-M2: 926.0
NAGK	GNK	ENSG00000124357	N-acetylglucosamine kinase	2	71064344-71079805	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035206, HPA035207	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:4.35e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable), Endometrial cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 148.0	Expressed in all		
MCEE	GLOD2	ENSG00000124370	Methylmalonyl-CoA epimerase	2	71109684-71130239	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035196			Approved	Nucleoli	Head and neck cancer:4.76e-4 (favourable), Liver cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			breast: 41.2	Expressed in all		
PAIP2B	KIAA1155	ENSG00000124374	Poly(A) binding protein interacting protein 2B	2	71182739-71227083	Predicted intracellular proteins	Evidence at protein level	HPA046784, HPA072371	Approved		Approved	Cytosol	Renal cancer:6.96e-12 (favourable), Endometrial cancer:8.17e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 24.6	Cell line enhanced		SCLC-21H: 27.5
SNRNP27	RY1, U4/U6.U5-27K	ENSG00000124380	Small nuclear ribonucleoprotein U4/U6.U5 subunit 27	2	69893560-69905575	Predicted intracellular proteins	Evidence at protein level	HPA034541	Approved		Approved	Nucleoplasm	Endometrial cancer:2.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.3	Expressed in all		
MPHOSPH10	CT90, MPP10, MPP10P, PPP1R106	ENSG00000124383	M-phase phosphoprotein 10	2	71130314-71150101	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035059, HPA035060, HPA049907	Enhanced		Enhanced	Nucleoli	Renal cancer:3.89e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 35.3	Expressed in all		
IL17C	CX2, IL-17C, IL-21, MGC126884, MGC138401	ENSG00000124391	Interleukin 17C	16	88638591-88640473	Predicted secreted proteins	Evidence at protein level	HPA065051	Supported					Mixed	Tissue enriched	6	endometrium: 3.5	gallbladder: 0.6	Not detected		
ATP8A1	ATPIA	ENSG00000124406	ATPase phospholipid transporting 8A1	4	42408373-42657105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052935	Enhanced		Supported	Vesicles	Renal cancer:5.54e-10 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 68.8;thyroid gland: 66.6	cerebral cortex: 58.2	Cell line enhanced		AN3-CA: 25.5;Daudi: 33.1
USP22	KIAA1063, USP3L	ENSG00000124422	Ubiquitin specific peptidase 22	17	20999593-21043760	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044980	Supported		Supported	Nuclear speckles	Renal cancer:1.53e-7 (favourable), Liver cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 154.1	Expressed in all		
POF1B	FLJ22792, POF	ENSG00000124429	Premature ovarian failure, 1B	X	85277396-85379743	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002033, HPA050027	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:2.03e-4 (unfavourable), Endometrial cancer:3.08e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skin: 144.4	rectum: 52.8	Cell line enhanced		A549: 19.6;CAPAN-2: 19.5;HaCaT: 19.9;RT4: 60.9
HIF3A	bHLHe17, IPAS, MOP7, PASD7	ENSG00000124440	Hypoxia inducible factor 3 alpha subunit	19	46297046-46343433	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041141	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:6.90e-9 (unfavourable)	Mixed	Tissue enhanced		placenta: 39.8	spleen: 19.9	Cell line enhanced		ASC TERT1: 6.5;HHSteC: 16.0;HSkMC: 12.2;TIME: 13.1
ZNF576	MGC2508	ENSG00000124444	Zinc finger protein 576	19	43596392-43601157	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050064	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 15.4	Expressed in all		
IRGC	CINEMA, Iigp5, IRGC1	ENSG00000124449	Immunity related GTPase cinema	19	43716010-43720021	Predicted intracellular proteins	Evidence at protein level	HPA046769, HPA060064	Enhanced					Not detected	Tissue enriched	627	testis: 62.6	all non-specific tissues: 0.0	Not detected		
ZNF45	ZNF13	ENSG00000124459	Zinc finger protein 45	19	43912629-43935278	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038611, HPA075124	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 18.3	Expressed in all		
LYPD3	C4.4A	ENSG00000124466	LY6/PLAUR domain containing 3	19	43460787-43465660	Predicted membrane proteins	Evidence at protein level	HPA041529, HPA041797, HPA077859	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Lung cancer:7.86e-5 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 673.8;skin: 593.4	tonsil: 114.6	Cell line enhanced		HaCaT: 85.1;MCF7: 84.1;RT4: 83.0;SK-BR-3: 114.6
PSG8		ENSG00000124467	Pregnancy specific beta-1-glycoprotein 8	19	42752686-42855691	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Tissue enriched	Tissue enriched	12	placenta: 9.1	parathyroid gland: 0.7	Not detected		
CEACAM8	CD66b, CGM6	ENSG00000124469	Carcinoembryonic antigen related cell adhesion molecule 8	19	42580241-42595055	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033676	Approved					Not detected	Tissue enriched	86	bone marrow: 142.1	lung: 1.6	Not detected		
NDP	EVR2, norrin	ENSG00000124479	NDP, norrin cystine knot growth factor	X	43948776-43973504	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003095	Uncertain		Supported	Nucleus<br>Nucleoli<br>Vesicles		Tissue enhanced	Tissue enhanced		ovary: 53.3	fallopian tube: 31.3	Cell line enriched	16	U-87 MG: 67.6
USP9X	DFFRX, FAF, MRX99	ENSG00000124486	Ubiquitin specific peptidase 9, X-linked	X	41085635-41236579	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011618, HPA047417, CAB070164	Approved		Uncertain	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 90.1	Expressed in all		
CRISP2	CRISP-2, CT36, GAPDL5, TPX1	ENSG00000124490	Cysteine rich secretory protein 2	6	49692358-49713590	Predicted secreted proteins	Evidence at protein level	HPA031248	Enhanced					Mixed	Tissue enriched	43	testis: 853.2	fallopian tube: 19.7	Not detected		
F13A1	F13A	ENSG00000124491	Coagulation factor XIII A chain	6	6144085-6321013	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001804, CAB002155	Enhanced				Renal cancer:6.61e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 670.5	Cell line enhanced		AF22: 22.5;LHCN-M2: 7.1;RH-30: 41.4
GRM4	GPRC1D, mGlu4, MGLUR4	ENSG00000124493	Glutamate metabotropic receptor 4	6	34018645-34155622	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB022096	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 2.9	testis: 0.7	Group enriched	11	BEWO: 7.2;SCLC-21H: 35.0
TRERF1	BCAR2, dJ139D8.5, HSA277276, RAPA, TReP-132	ENSG00000124496	Transcriptional regulating factor 1	6	42224931-42452051	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027771, HPA051273, HPA059943	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.67e-5 (unfavourable)	Mixed	Mixed			testis: 10.9	Cell line enhanced		HDLM-2: 133.6
PACSIN1	SDPI	ENSG00000124507	Protein kinase C and casein kinase substrate in neurons 1	6	34466061-34535231	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009929, HPA028852, HPA055491	Enhanced		Approved	Nucleus<br>Vesicles		Mixed	Tissue enriched	32	cerebral cortex: 133.6	lymph node: 4.1	Cell line enhanced		MCF7: 9.2;RPMI-8226: 9.7;T-47d: 20.2;U-266/84: 11.7
BTN2A2	BT2.2, BTF2, BTN2.2	ENSG00000124508	Butyrophilin subfamily 2 member A2	6	26383096-26394874	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051504	Uncertain		Supported	Mitochondria	Breast cancer:1.01e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.6	Mixed		
SIRT5		ENSG00000124523	Sirtuin 5	6	13574529-13615158	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021798, HPA022002, HPA022992	Approved		Enhanced	Mitochondria	Renal cancer:8.76e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.1	Expressed in all		
MRS2	MRS2L	ENSG00000124532	MRS2, magnesium transporter	6	24402908-24426194	Predicted membrane proteins	Evidence at protein level	HPA017642	Uncertain				Ovarian cancer:5.14e-11 (favourable), Endometrial cancer:5.32e-4 (unfavourable), Thyroid cancer:8.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.8	Mixed		
WRNIP1	bA420G6.2, FLJ22526, WHIP	ENSG00000124535	Werner helicase interacting protein 1	6	2765414-2786952	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031752, HPA031753	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 78.7	Expressed in all		
RRP36	C6orf153, dJ20C7.4	ENSG00000124541	Ribosomal RNA processing 36	6	43021645-43034156	Predicted intracellular proteins	Evidence at protein level	HPA029904, HPA029905	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:2.48e-5 (unfavourable), Liver cancer:5.95e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
BTN1A1	BT, BTN, BTN1	ENSG00000124557	Butyrophilin subfamily 1 member A1	6	26501221-26510422	Predicted membrane proteins	Evidence at protein level	HPA011126, CAB037340	Supported					Tissue enhanced	Tissue enriched	49	breast: 36.8	lymph node,tonsil: 0.7	Cell line enriched	5	CACO-2: 3.8
SNRPC	U1-C, Yhc1	ENSG00000124562	Small nuclear ribonucleoprotein polypeptide C	6	34757406-34773794	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034338, HPA042419, HPA055490	Supported		Enhanced	Nucleoplasm	Renal cancer:8.20e-5 (unfavourable), Liver cancer:5.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 151.1	Expressed in all		
SLC17A3	NPT4	ENSG00000124564	Solute carrier family 17 member 3	6	25833066-25882286	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	9	kidney: 168.7	liver: 18.6	Cell line enriched	177	RPTEC TERT1: 87.1
SLC17A1	NAPI-1, NPT1	ENSG00000124568	Solute carrier family 17 member 1	6	25782897-25832059	Predicted membrane proteins, Transporters	Evidence at protein level	HPA050513			Approved	Golgi apparatus		Group enriched	Tissue enriched	7	kidney: 174.5	liver: 25.1	Cell line enriched	490	RPTEC TERT1: 48.9
SERPINB6	CAP, DFNB91, PI6, PTI	ENSG00000124570	Serpin family B member 6	6	2948159-2972165	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA009668, HPA012736	Enhanced		Approved	Centrosome	Renal cancer:2.21e-4 (unfavourable), Ovarian cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 255.6	Mixed		
XPO5	KIAA1291	ENSG00000124571	Exportin 5	6	43522330-43576075	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB012357, HPA018402, HPA023959, HPA029909	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.98e-8 (unfavourable), Endometrial cancer:4.94e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
ABCC10	EST182763, MRP7, SIMRP7	ENSG00000124574	ATP binding cassette subfamily C member 10	6	43427366-43450430	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041607, HPA045464	Approved				Renal cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 12.5	Expressed in all		
HIST1H1D	H1.3, H1d, H1F3, H1s-2	ENSG00000124575	Histone cluster 1 H1 family member d	6	26234268-26234933	Predicted intracellular proteins	Evidence at protein level	HPA055907	Approved					Mixed	Tissue enriched	6	bone marrow: 17.5	lymph node: 2.9	Cell line enhanced		BEWO: 6.8;MOLT-4: 9.5;SiHa: 5.0
PEX6	PAF-2, PXAAA1	ENSG00000124587	Peroxisomal biogenesis factor 6	6	42963870-42979220	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA025924, HPA074179	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Expressed in all	Expressed in all			fallopian tube: 36.5	Expressed in all		
NQO2	DHQV, DIA6, NMOR2, QR2	ENSG00000124588	N-ribosyldihydronicotinamide:quinone reductase 2	6	2987987-3028869	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021283, HPA021332	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.40e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 201.0	Expressed in all		
RP11-298J23.10		ENSG00000124593	Prickle-like protein 4 	6	41780349-41790141	Predicted intracellular proteins	Evidence at transcript level	HPA031240			Uncertain	Mitotic spindle<br>Microtubule organizing center	Renal cancer:2.47e-4 (unfavourable), Lung cancer:8.24e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 3.2	Cell line enhanced		AF22: 2.3;ASC TERT1: 1.1;HeLa: 1.1;HSkMC: 1.1;TIME: 1.6
OARD1	C6orf130, dJ34B21.3, MGC19570, TARG1	ENSG00000124596	O-acyl-ADP-ribose deacylase 1	6	41033627-41097787	Predicted intracellular proteins	Evidence at protein level	HPA029036	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 106.4	Expressed in all		
UNC5CL	MGC34763, ZUD	ENSG00000124602	Unc-5 family C-terminal like	6	41026911-41039217	Predicted intracellular proteins	Evidence at protein level	HPA015725	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		duodenum: 37.3;small intestine: 32.4;stomach: 23.8	kidney: 15.0	Cell line enhanced		CACO-2: 5.8;RPTEC TERT1: 10.0
AARS2	AARSL, bA444E17.1, KIAA1270	ENSG00000124608	Alanyl-tRNA synthetase 2, mitochondrial	6	44299654-44313326	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035636, HPA061396	Approved		Enhanced	Mitochondria		Expressed in all	Mixed			parathyroid gland: 11.4	Expressed in all		
HIST1H1A	H1.1, H1a, H1F1	ENSG00000124610	Histone cluster 1 H1 family member a	6	26017085-26017732	Predicted intracellular proteins	Evidence at protein level	HPA043753	Supported					Not detected	Not detected			testis,thyroid gland: 0.2	Cell line enhanced		REH: 1.1;U-2 OS: 1.1
ZNF391	dJ153G14.3	ENSG00000124613	Zinc finger protein 391	6	27374615-27403904	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050886	Uncertain				Ovarian cancer:1.89e-4 (favourable)	Mixed	Mixed			testis: 9.0	Mixed		
RPS10	MGC88819, S10	ENSG00000124614	Ribosomal protein S10	6	34417454-34426125	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047268, HPA048084	Approved		Approved	Cytosol	Renal cancer:2.57e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2704.4	Expressed in all		
MOCS1	MOCOD	ENSG00000124615	Molybdenum cofactor synthesis 1	6	39899578-39934551	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045783, HPA058177, HPA075505	Uncertain		Approved	Plasma membrane<br>Cytosol	Cervical cancer:1.07e-5 (unfavourable), Pancreatic cancer:6.07e-5 (favourable)	Expressed in all	Mixed			placenta: 60.3	Cell line enhanced		CACO-2: 38.2
HIST1H2BJ	H2B/r, H2BFR	ENSG00000124635	Histone cluster 1 H2B family member j	6	27125897-27132750	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:1.51e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	prostate: 9.9	Cell line enhanced		K-562: 148.0;SiHa: 152.3;U-2 OS: 161.1;U-266/70: 101.2;U-266/84: 122.2
MED20	DKFZp586D2223, PRO0213, TRFP	ENSG00000124641	Mediator complex subunit 20	6	41905354-41921139	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040717	Uncertain		Approved	Nucleoplasm<br>Centrosome	Melanoma:1.48e-5 (unfavourable), Renal cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.8	Expressed in all		
OR2B6	dJ408B20.2, OR2B1, OR2B1P, OR2B5, OR2B6P, OR5-40, OR5-41, OR6-31	ENSG00000124657	Olfactory receptor family 2 subfamily B member 6	6	27957241-27958182	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			testis: 0.3	Cell line enhanced		K-562: 1.4;SCLC-21H: 1.5;U-266/84: 2.9;U-937: 1.5
TBCC	CFC	ENSG00000124659	Tubulin folding cofactor C	6	42744481-42746096	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035073, HPA035074	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			lymph node: 32.8	Expressed in all		
SPDEF	bA375E1.3, PDEF	ENSG00000124664	SAM pointed domain containing ETS transcription factor	6	34537802-34556333	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055707			Supported	Nucleus<br>Nucleoli	Endometrial cancer:9.26e-9 (favourable)	Group enriched	Tissue enhanced		prostate: 172.4	breast: 42.6	Cell line enhanced		MCF7: 221.8;SK-BR-3: 144.8;T-47d: 145.8
TCP11	D6S230E, FPPR, KIAA0229	ENSG00000124678	T-complex 11	6	35118071-35148610	Predicted intracellular proteins	Evidence at protein level	HPA048311	Supported				Cervical cancer:5.02e-4 (favourable)	Tissue enhanced	Tissue enriched	356	testis: 562.3	fallopian tube: 1.5	Cell line enhanced		hTEC/SVTERT24-B: 1.6;WM-115: 2.0
MAD2L1BP	CMT2, dJ261G23.1, KIAA0110	ENSG00000124688	MAD2L1 binding protein	6	43629540-43640952	Predicted intracellular proteins	Evidence at protein level	HPA028729			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 32.6	Expressed in all		
APOBEC2	ARCD1, ARP1	ENSG00000124701	Apolipoprotein B mRNA editing enzyme catalytic subunit 2	6	41053304-41064511	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA014252, HPA017957	Enhanced					Tissue enhanced	Group enriched	13	heart muscle: 120.7;skeletal muscle: 403.8	esophagus: 19.5	Cell line enhanced		CACO-2: 3.3
KLHDC3	dJ20C7.3, hPeas, PEAS	ENSG00000124702	Kelch domain containing 3	6	43014103-43021298	Predicted intracellular proteins	Evidence at protein level	HPA030131, HPA030132, HPA030133, HPA030134	Uncertain		Supported	Nucleoplasm	Endometrial cancer:4.52e-4 (unfavourable), Pancreatic cancer:9.08e-4 (favourable), Cervical cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 251.9	Expressed in all		
GNMT		ENSG00000124713	Glycine N-methyltransferase	6	42960758-42963880	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027501	Enhanced		Approved	Cytosol	Liver cancer:1.86e-4 (favourable)	Group enriched	Group enriched	9	liver: 155.0;pancreas: 55.8;prostate: 32.7	breast: 9.4	Cell line enhanced		Hep G2: 5.7;SCLC-21H: 11.3;T-47d: 5.8
DNAH8	hdhc9	ENSG00000124721	Dynein axonemal heavy chain 8	6	38715341-39030529	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028447	Uncertain					Tissue enriched	Tissue enhanced		testis: 14.3	prostate: 3.4	Cell line enriched	8	HMC-1: 41.4
TREM1	CD354, TREM-1	ENSG00000124731	Triggering receptor expressed on myeloid cells 1	6	41267926-41286719	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005563	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 67.7;bone marrow: 63.0;lung: 103.1	adipose tissue: 26.9	Cell line enriched	11	U-87 MG: 24.5
MEA1	MEA	ENSG00000124733	Male-enhanced antigen 1	6	43012094-43013968	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017921	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.29e-6 (unfavourable), Ovarian cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			testis: 246.1	Expressed in all		
KLHL31	bA345L23.2, BKLHD6, KBTBD1	ENSG00000124743	Kelch like family member 31	6	53647901-53665708	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 29.4;skeletal muscle: 51.2	adipose tissue: 9.0	Cell line enhanced		SCLC-21H: 1.2
COL21A1		ENSG00000124749	Collagen type XXI alpha 1 chain	6	56056590-56394094	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031212			Supported	Cytosol		Mixed	Tissue enhanced		cervix, uterine: 36.7;placenta: 39.0	endometrium: 19.6	Cell line enhanced		ASC TERT1: 15.7;BEWO: 7.2;HSkMC: 16.7
CDKN1A	CAP20, CDKN1, CIP1, P21, p21CIP1, p21Cip1/Waf1, SDI1, WAF1	ENSG00000124762	Cyclin dependent kinase inhibitor 1A	6	36676460-36687339	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000064, HPA005946, CAB069401	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:3.14e-5 (favourable), Renal cancer:4.95e-5 (favourable), Lung cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 204.8	Cell line enhanced		HHSteC: 654.9
SOX4		ENSG00000124766	SRY-box 4	6	21592768-21598619	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029901	Approved		Supported	Nucleoplasm<br>Mitochondria	Liver cancer:2.57e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 80.5	Cell line enhanced		AN3-CA: 194.4;MOLT-4: 151.8;SH-SY5Y: 123.8
GLO1	GLOD1	ENSG00000124767	Glyoxalase I	6	38675925-38703141	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB040541, CAB040542, HPA059791	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:5.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 274.2	Cell line enriched	5	HMC-1: 2266.7
CPNE5	COPN5, CPN5, KIAA1599	ENSG00000124772	Copine 5	6	36740775-36840002	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031369	Uncertain		Approved	Cytosol	Head and neck cancer:2.87e-5 (favourable), Renal cancer:6.00e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 119.0	testis: 34.4	Cell line enhanced		Daudi: 42.5;HUVEC TERT2: 19.9;U-266/70: 15.0;U-266/84: 11.9;U-698: 19.2
KCNK17	K2p17.1, TALK-2, TALK2, TASK-4, TASK4	ENSG00000124780	Potassium two pore domain channel subfamily K member 17	6	39299001-39314553	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at transcript level	HPA043892	Uncertain					Mixed	Tissue enhanced		lung: 5.6	placenta: 5.3	Cell line enriched	9	SCLC-21H: 91.6
RREB1	HNT	ENSG00000124782	Ras responsive element binding protein 1	6	7107597-7251980	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001756, HPA034843	Approved		Supported	Nucleoli fibrillar center<br>Nuclear speckles	Renal cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Mixed		
SSR1	TRAPA	ENSG00000124783	Signal sequence receptor subunit 1	6	7268306-7347446	Predicted membrane proteins	Evidence at protein level	HPA011276, HPA017062	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:5.79e-6 (unfavourable), Liver cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 141.0	Expressed in all		
RIOK1	AD034, bA288G3.1, FLJ30006, RRP10	ENSG00000124784	RIO kinase 1	6	7389496-7418037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017866, HPA051446	Enhanced		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Liver cancer:3.41e-5 (unfavourable), Renal cancer:5.85e-5 (unfavourable), Melanoma:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.6	Expressed in all		
NRN1	NRN	ENSG00000124785	Neuritin 1	6	5997999-6007605	Predicted membrane proteins	Evidence at protein level						Renal cancer:4.79e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 152.5	adipose tissue: 61.5	Cell line enhanced		fHDF/TERT166: 111.6;REH: 174.8
SLC35B3	C6orf196, CGI-19, dJ453H5.1, PAPST2	ENSG00000124786	Solute carrier family 35 member B3	6	8413068-8435483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA054661, HPA057801	Approved					Expressed in all	Expressed in all			epididymis: 63.2	Expressed in all		
RPP40	bA428J1.3, RNASEP1	ENSG00000124787	Ribonuclease P/MRP subunit p40	6	4994732-5004063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035685, HPA035686	Uncertain		Approved	Nucleoplasm	Renal cancer:7.54e-8 (unfavourable), Endometrial cancer:6.10e-6 (unfavourable), Liver cancer:5.41e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 11.9	Expressed in all		
ATXN1	ATX1, D6S504E, SCA1	ENSG00000124788	Ataxin 1	6	16299112-16761491	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008335, HPA070756	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 17.5	Cell line enhanced		U-266/70: 22.6
NUP153	HNUP153	ENSG00000124789	Nucleoporin 153	6	17615035-17706834	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027896, HPA027897, HPA027898	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			testis: 53.6	Expressed in all		
DEK	D6S231E	ENSG00000124795	DEK proto-oncogene	6	18223868-18264823	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015226, HPA054505, HPA057799	Enhanced		Enhanced	Nucleus	Renal cancer:3.45e-4 (unfavourable), Liver cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 158.8	Mixed		
EEF1E1	AIMP3, P18	ENSG00000124802	Eukaryotic translation elongation factor 1 epsilon 1	6	8073360-8102578	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027901, HPA057866	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:1.55e-7 (unfavourable), Cervical cancer:3.16e-4 (favourable), Ovarian cancer:3.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.7	Expressed in all		
CRISP1	AEGL1, ARP, CRISP-1, HSCRISP1D, HSCRISP1G, HUMARP	ENSG00000124812	Cysteine rich secretory protein 1	6	49834257-49877096	Predicted secreted proteins	Evidence at protein level	HPA028445, HPA030534	Enhanced					Not detected	Tissue enriched	20	epididymis: 1915.6	seminal vesicle: 96.7	Cell line enhanced		NB-4: 1.7
RUNX2	AML3, CBFA1, CCD, CCD1, PEBP2A1, PEBP2aA1	ENSG00000124813	Runt related transcription factor 2	6	45328157-45664349	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008374, HPA022040, CAB062561, CAB068226	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.97e-9 (unfavourable), Urothelial cancer:6.66e-5 (unfavourable), Stomach cancer:2.24e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 10.6	Cell line enhanced		Karpas-707: 54.6;RH-30: 54.1;U-698: 41.3
OPN5	dJ402H5.1, neuropsin, TMEM13	ENSG00000124818	Opsin 5	6	47781982-47832780	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA026084	Supported					Not detected	Tissue enriched	36	testis: 4.1	heart muscle: 0.1	Not detected		
GCM2	GCMB, hGCMb	ENSG00000124827	Glial cells missing homolog 2	6	10873223-10881941	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	997	parathyroid gland: 774.1	testis: 0.7	Not detected		
LRRFIP1	FLAP-1, FLIIAP1, GCF-2, HUFI-1, TRIP	ENSG00000124831	LRR binding FLII interacting protein 1	2	237627576-237813682	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006979	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 125.3	Expressed in all		
RAB17		ENSG00000124839	RAB17, member RAS oncogene family	2	237574322-237601614	Predicted intracellular proteins	Evidence at protein level	HPA035176	Approved				Renal cancer:3.33e-13 (favourable), Urothelial cancer:2.51e-4 (favourable), Pancreatic cancer:4.14e-4 (favourable)	Mixed	Mixed			small intestine: 64.3	Cell line enhanced		BEWO: 40.2;MCF7: 36.3;SK-BR-3: 37.2;SK-MEL-30: 95.1
CXCL6	CKA-3, GCP-2, SCYB6	ENSG00000124875	C-X-C motif chemokine ligand 6	4	73836497-73849064	Predicted secreted proteins	Evidence at protein level						Renal cancer:4.82e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 50.3;spleen: 112.9	urinary bladder: 32.4	Group enriched	6	BJ hTERT+: 36.7;EFO-21: 100.3;hTEC/SVTERT24-B: 22.6;HUVEC TERT2: 59.0;RPTEC TERT1: 62.9
EREG	ER	ENSG00000124882	Epiregulin	4	74365143-74388751	Predicted membrane proteins	Evidence at protein level	HPA054373			Approved	Vesicles	Cervical cancer:1.67e-7 (unfavourable), Lung cancer:1.45e-5 (unfavourable), Pancreatic cancer:6.57e-5 (unfavourable)	Tissue enhanced	Tissue enriched	6	bone marrow: 82.3	appendix: 14.4	Cell line enhanced		BJ hTERT+: 218.4;U-2197: 168.6;U-87 MG: 300.8
TRIM51	SPRYD5, TRIM51A	ENSG00000124900	Tripartite motif-containing 51	11	55883297-55891810	Predicted intracellular proteins	Evidence at transcript level	HPA044988, HPA077883	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enriched	Not detected			testis: 0.4	Group enriched	101	SK-MEL-30: 45.9;WM-115: 14.6
MYRF	C11orf9, MRF, Ndt80, pqn-47	ENSG00000124920	Myelin regulatory factor	11	61752642-61788518	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA018310			Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.01e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 67.4;stomach: 62.1	gallbladder: 38.3	Cell line enhanced		A549: 36.8;CACO-2: 56.7;CAPAN-2: 34.1;EFO-21: 48.7
SCGB1D2	LIPB, LPHB	ENSG00000124935	Secretoglobin family 1D member 2	11	62242210-62244808	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA035318	Approved				Endometrial cancer:3.46e-6 (favourable), Renal cancer:8.03e-6 (favourable)	Group enriched	Group enriched	9	breast: 1446.3;cervix, uterine: 5193.3	epididymis: 385.3	Cell line enriched	7	SCLC-21H: 11.2
SCGB2A1	LPHC, MGB2, MGC71973, UGB3	ENSG00000124939	Secretoglobin family 2A member 1	11	62208668-62213939	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA034584	Enhanced				Endometrial cancer:1.54e-8 (favourable), Colorectal cancer:1.22e-4 (favourable), Renal cancer:6.36e-4 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 2863.6;epididymis: 1665.3	fallopian tube: 381.7	Cell line enhanced		EFO-21: 8.1;NB-4: 1.3;SCLC-21H: 1.9
AHNAK	MGC5395	ENSG00000124942	AHNAK nucleoprotein	11	62433542-62556235	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019010, HPA019070, HPA026643	Uncertain		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:3.47e-6 (unfavourable), Pancreatic cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 397.0	Mixed		
EMC3	TMEM111	ENSG00000125037	ER membrane protein complex subunit 3	3	9962537-10011116	Predicted membrane proteins	Evidence at protein level	HPA042372	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:2.81e-6 (favourable)	Expressed in all	Expressed in all			testis: 90.8	Expressed in all		
SSUH2	C3orf32, fls485, ssu-2	ENSG00000125046	Ssu-2 homolog (C. elegans)	3	8619400-8745040	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049777	Approved					Mixed	Tissue enhanced		duodenum: 4.2;small intestine: 3.9;testis: 4.0	spleen: 1.5	Cell line enriched	13	Hep G2: 18.2
WNT1	INT1	ENSG00000125084	Wnt family member 1	12	48978453-48981676	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.3	lymph node: 1.0	Not detected		
SH3TC1	FLJ20356	ENSG00000125089	SH3 domain and tetratricopeptide repeats 1	4	8182072-8241803	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038132, HPA056807	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Mixed			spleen: 12.5	Cell line enhanced		HUVEC TERT2: 20.1;MOLT-4: 35.0;SK-MEL-30: 19.0
CNOT1	AD-005, CDC39, KIAA1007, NOT1, NOT1H	ENSG00000125107	CCR4-NOT transcription complex subunit 1	16	58519951-58629886	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046577, HPA049664	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 196.3	Expressed in all		
LRRC29	FBL9, FBXL9	ENSG00000125122	Leucine rich repeat containing 29	16	67207139-67227048	Predicted intracellular proteins	Evidence at protein level	HPA034998	Uncertain		Uncertain	Nucleoplasm	Endometrial cancer:4.33e-4 (favourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 1.8	Mixed		
BBS2	BBS	ENSG00000125124	Bardet-Biedl syndrome 2	16	56466836-56520283	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041315	Approved				Renal cancer:2.83e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.3	Expressed in all		
MT1G	MT1, MT1K	ENSG00000125144	Metallothionein 1G	16	56666731-56668065	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.67e-7 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 2350.1;thyroid gland: 4892.2	liver: 1276.9	Cell line enriched	5	U-937: 867.7
MT2A	MT2	ENSG00000125148	Metallothionein 2A	16	56608199-56609497	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.92e-9 (unfavourable), Lung cancer:5.74e-5 (unfavourable), Pancreatic cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 1202.2	Cell line enhanced		HBEC3-KT: 6860.6;LHCN-M2: 3182.4;U-87 MG: 3004.5
C16orf70	C16orf6, FLJ12076, lin-10, LIN10	ENSG00000125149	Chromosome 16 open reading frame 70	16	67109958-67148539	Predicted intracellular proteins	Evidence at protein level	HPA041131, HPA041214	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 33.3	Expressed in all		
GOT2	KAT4, KATIV, KYAT4, mitAAT	ENSG00000125166	Glutamic-oxaloacetic transaminase 2	16	58707131-58734357	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018139	Enhanced				Renal cancer:2.90e-9 (favourable), Liver cancer:5.75e-5 (favourable), Head and neck cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 240.2	Expressed in all		
DOK4	FLJ10488	ENSG00000125170	Docking protein 4	16	57471922-57487327	Predicted intracellular proteins	Evidence at protein level	HPA055849	Supported		Approved	Vesicles<br>Microtubules<br>Cytokinetic bridge		Expressed in all	Expressed in all			small intestine: 54.7	Cell line enhanced		SH-SY5Y: 254.2
PIWIL1	CT80.1, HIWI, PIWI	ENSG00000125207	Piwi like RNA-mediated gene silencing 1	12	130337887-130372637	Predicted intracellular proteins	Evidence at protein level	CAB012217, HPA018798	Enhanced					Tissue enhanced	Tissue enriched	34	testis: 5.2	cervix, uterine,duodenum,spleen: 0.1	Cell line enhanced		CAPAN-2: 2.3
GPR18		ENSG00000125245	G protein-coupled receptor 18	13	99254714-99261744	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013873	Enhanced					Mixed	Tissue enhanced		lymph node: 51.5;testis: 25.3;tonsil: 31.5	appendix: 16.4	Cell line enhanced		Daudi: 6.1;THP-1: 13.5;U-937: 2.6
CLYBL	CLB	ENSG00000125246	Citrate lyase beta like	13	99606669-99897134	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039959, HPA040691	Enhanced		Approved	Cytosol	Renal cancer:6.66e-16 (favourable)	Expressed in all	Expressed in all			kidney: 67.5	Cell line enhanced		SCLC-21H: 62.6
TMTC4	FLJ14624, FLJ22153	ENSG00000125247	Transmembrane and tetratricopeptide repeat containing 4	13	100603927-100675093	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016489	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 26.4	Mixed		
RAP2A	K-REV, RAP2	ENSG00000125249	RAP2A, member of RAS oncogene family	13	97434222-97469128	Predicted intracellular proteins	Evidence at protein level	CAB018552	Uncertain				Liver cancer:1.55e-4 (unfavourable), Renal cancer:8.06e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.9	Expressed in all		
SLC10A2	ASBT, ISBT	ENSG00000125255	Solute carrier family 10 member 2	13	103043998-103066846	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004795	Approved				Renal cancer:5.78e-5 (favourable)	Tissue enriched	Group enriched	31	duodenum: 21.0;kidney: 15.4;small intestine: 51.4	gallbladder: 0.9	Not detected		
ABCC4	EST170205, MOAT-B, MOATB, MRP4	ENSG00000125257	ATP binding cassette subfamily C member 4	13	95019829-95301446	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002476	Enhanced				Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable)	Tissue enriched	Tissue enhanced		prostate: 70.4	epididymis: 23.6	Group enriched	5	HEL: 277.0;HMC-1: 278.6
EFNB2	EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228	ENSG00000125266	Ephrin B2	13	106489731-106535114	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008999, CAB009368	Supported		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:3.11e-6 (unfavourable), Pancreatic cancer:8.70e-5 (unfavourable), Lung cancer:8.43e-4 (unfavourable)	Expressed in all	Mixed			placenta: 48.4	Cell line enhanced		AF22: 180.7;SH-SY5Y: 87.9
SOX21	SOX25	ENSG00000125285	SRY-box 21	13	94709622-94712399	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA048337, HPA064084	Approved		Approved	Nucleus	Glioma:1.34e-4 (favourable), Cervical cancer:7.60e-4 (favourable)	Tissue enhanced	Group enriched	6	cerebral cortex: 17.9;esophagus: 6.9;skin: 19.4;stomach: 33.4	tonsil: 3.1	Cell line enhanced		AF22: 80.6;HAP1: 12.8;NTERA-2: 22.0;PC-3: 11.6
TM9SF2	P76	ENSG00000125304	Transmembrane 9 superfamily member 2	13	99501417-99564006	Predicted membrane proteins, Transporters	Evidence at protein level	HPA005657	Supported				Renal cancer:5.21e-7 (favourable), Head and neck cancer:6.40e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 202.1	Expressed in all		
C17orf53	MGC3130	ENSG00000125319	Chromosome 17 open reading frame 53	17	44141906-44162476	Predicted intracellular proteins	Evidence at protein level	HPA023004, HPA023393, HPA024430	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.46e-4 (unfavourable), Endometrial cancer:8.08e-4 (unfavourable), Lung cancer:9.39e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.5	bone marrow: 6.3	Mixed		
KIF25	KNSL3	ENSG00000125337	Kinesin family member 25	6	167996241-168045089	Predicted intracellular proteins	Evidence at protein level	HPA046153	Uncertain					Tissue enhanced	Tissue enriched	5	adipose tissue: 8.7	placenta: 1.6	Cell line enhanced		HDLM-2: 1.1;U-937: 1.3;WM-115: 1.0
IRF1	MAR	ENSG00000125347	Interferon regulatory factor 1	5	132481609-132490798	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011662, HPA063131	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.09e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 135.0	Expressed in all		
UPF3B	HUPF3B, MRX62, RENT3B, UPF3BP1, UPF3BP2, UPF3BP3, UPF3X	ENSG00000125351	UPF3 regulator of nonsense transcripts homolog B (yeast)	X	119805311-119852998	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001592, HPA001800, HPA001882	Approved		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.44e-7 (unfavourable), Liver cancer:1.52e-6 (unfavourable), Melanoma:5.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 23.9	Expressed in all		
RNF113A	Cwc24, RNF113, ZNF183	ENSG00000125352	Ring finger protein 113A	X	119870475-119871827	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000160, HPA076658	Approved		Approved	Nucleoplasm	Urothelial cancer:6.23e-4 (favourable), Renal cancer:7.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.5	Expressed in all		
SEPT6	KIAA0128, MGC16619, MGC20339, SEP2, SEPT2	ENSG00000125354	Septin 6	X	119615724-119693370	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003459, HPA005665	Supported		Approved	Cytosol		Expressed in all	Mixed			lymph node: 140.7	Cell line enhanced		MOLT-4: 239.1;REH: 246.9;SH-SY5Y: 417.7
TMEM255A	FAM70A, FLJ20716	ENSG00000125355	Transmembrane protein 255A	X	120258650-120311556	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA048470	Uncertain		Uncertain	Nucleus<br>Nuclear bodies		Group enriched	Tissue enhanced		ovary: 23.5	cervix, uterine: 10.5	Cell line enhanced		Karpas-707: 18.2;RPMI-8226: 11.7;SK-MEL-30: 21.1;U-2 OS: 11.8;U-87 MG: 27.9
NDUFA1	CI-MWFE, MWFE	ENSG00000125356	NADH:ubiquinone oxidoreductase subunit A1	X	119871487-119876662	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029768, HPA054359	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 224.8	Expressed in all		
AMELX	AIH1, AMG	ENSG00000125363	Amelogenin, X-linked	X	11293413-11300761	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Not detected			epididymis: 0.4	Not detected		
ATP5S	ATPW, HSU79253	ENSG00000125375	ATP synthase, H+ transporting, mitochondrial Fo complex subunit s (factor B)	14	50312326-50335558	Predicted intracellular proteins	Evidence at protein level	HPA046967, HPA062690	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:2.37e-8 (favourable), Lung cancer:5.53e-4 (favourable)	Expressed in all	Mixed			skin: 8.4	Mixed		
BMP4	BMP2B	ENSG00000125378	Bone morphogenetic protein 4	14	53949736-53958761	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB006863, HPA066235	Enhanced					Expressed in all	Mixed			placenta: 64.1	Cell line enhanced		CACO-2: 100.3;CAPAN-2: 262.8;Hep G2: 222.2;U-2 OS: 93.4
PTGER2	EP2	ENSG00000125384	Prostaglandin E receptor 2	14	52314305-52328606	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.16e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 27.3	Cell line enhanced		ASC TERT1: 50.0;HHSteC: 38.3;HSkMC: 41.8
FAM193A	C4orf8, RES4-22	ENSG00000125386	Family with sequence similarity 193 member A	4	2536631-2732565	Predicted intracellular proteins	Evidence at protein level	HPA043116	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 30.2	Expressed in all		
GRK4	GPRK2L, GPRK4	ENSG00000125388	G protein-coupled receptor kinase 4	4	2963608-3040747	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028737, HPA057023	Approved		Supported	Vesicles		Expressed in all	Tissue enriched	9	testis: 74.7	cerebral cortex: 8.1	Cell line enhanced		SCLC-21H: 18.6
SOX9	CMD1, CMPD1, SRA1	ENSG00000125398	SRY-box 9	17	72121020-72126420	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001758, CAB022456, CAB068240	Enhanced		Enhanced	Nucleoplasm	Lung cancer:2.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 61.3	Cell line enhanced		AN3-CA: 72.2;Hep G2: 65.5;U-251 MG: 54.6
TEKT3	FLJ32828	ENSG00000125409	Tektin 3	17	15303811-15341641	Predicted intracellular proteins	Evidence at protein level	HPA044354	Uncertain					Mixed	Tissue enriched	6	testis: 46.1	fallopian tube: 7.5	Cell line enhanced		HMC-1: 1.3
MYH2	IBM3, MYH2A, MYHas8, MyHC-2A, MyHC-IIa, MYHSA2	ENSG00000125414	Myosin heavy chain 2	17	10521148-10549957	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB010760	Enhanced					Tissue enriched	Tissue enriched	100	skeletal muscle: 4306.1	esophagus: 43.2	Cell line enhanced		fHDF/TERT166: 3.1;HSkMC: 1.3;NTERA-2: 8.3
HS3ST3B1	30ST3B1, 3OST3B1	ENSG00000125430	Heparan sulfate-glucosamine 3-sulfotransferase 3B1	17	14301083-14349404	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064126			Approved	Vesicles		Mixed	Tissue enhanced		liver: 14.7	lymph node: 7.1	Cell line enhanced		AF22: 20.5;BEWO: 14.3;HSkMC: 14.6;U-251 MG: 16.3
SLC25A35	FLJ40217	ENSG00000125434	Solute carrier family 25 member 35	17	8287763-8295343	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051720	Uncertain		Approved	Vesicles<br>Mitochondria	Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable)	Expressed in all	Mixed			testis: 19.3	Mixed		
MRPS7	MRP-S, RP-S7, RPMS7	ENSG00000125445	Mitochondrial ribosomal protein S7	17	75261674-75266373	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022522, HPA023007	Supported		Approved	Mitochondria	Colorectal cancer:1.12e-4 (favourable), Liver cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 60.8	Expressed in all		
GGA3	KIAA0154	ENSG00000125447	Golgi associated, gamma adaptin ear containing, ARF binding protein 3	17	75236599-75262363	Predicted intracellular proteins	Evidence at protein level	HPA022945, HPA024645	Approved		Supported	Golgi apparatus	Liver cancer:2.77e-6 (unfavourable), Renal cancer:3.41e-4 (unfavourable), Endometrial cancer:8.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.7	Expressed in all		
ARMC7	FLJ22160	ENSG00000125449	Armadillo repeat containing 7	17	75109952-75130265	Predicted intracellular proteins	Evidence at protein level	HPA024229, HPA053076	Uncertain		Supported	Cytosol	Liver cancer:2.24e-5 (unfavourable), Renal cancer:1.27e-4 (favourable), Cervical cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			lung: 12.6	Expressed in all		
NUP85	FLJ12549, NUP75	ENSG00000125450	Nucleoporin 85	17	75205659-75235758	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA061910, HPA062595	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:1.73e-7 (unfavourable), Renal cancer:3.32e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 33.6	Expressed in all		
SLC25A19	DNC, MCPHA, MUP1, TPC	ENSG00000125454	Solute carrier family 25 member 19	17	75272981-75289510	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.21e-7 (unfavourable), Endometrial cancer:8.72e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
MIF4GD	AD023, MGC45027, MIFD, SLIP1	ENSG00000125457	MIF4G domain containing	17	75266228-75271227	Predicted intracellular proteins	Evidence at protein level	HPA051222	Approved		Supported	Nucleoli<br>Cytosol	Pancreatic cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 45.8	Expressed in all		
NT5C	cdN, DNT-1, DNT1, PN-I, UMPH2	ENSG00000125458	5', 3'-nucleotidase, cytosolic	17	75130225-75131795	Predicted intracellular proteins	Evidence at protein level	HPA021581, HPA023632	Approved		Supported	Cytosol	Liver cancer:3.05e-4 (unfavourable), Urothelial cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 31.3	Expressed in all		
MSTO1	FLJ10504, LST005, misato, MST	ENSG00000125459	Misato 1, mitochondrial distribution and morphology regulator	1	155610205-155614967	Predicted intracellular proteins	Evidence at protein level	HPA005899, HPA005914	Approved		Approved	Nuclear membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.9	Expressed in all		
C1orf61	CROC4	ENSG00000125462	Chromosome 1 open reading frame 61	1	156404250-156430701	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	129	cerebral cortex: 504.3	testis: 3.9	Cell line enriched	9	BEWO: 12.5
TTF1		ENSG00000125482	Transcription termination factor 1	9	132375548-132406851	Predicted intracellular proteins	Evidence at protein level	HPA054837	Supported		Supported	Nucleus<br>Nucleoli	Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.2	Expressed in all		
GTF3C4	KAT12, TFIIIC90	ENSG00000125484	General transcription factor IIIC subunit 4	9	132670035-132694955	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069369			Supported	Nucleus	Renal cancer:2.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.0	Expressed in all		
DDX31	FLJ13633, FLJ14578, FLJ23349, PPP1R25	ENSG00000125485	DEAD-box helicase 31	9	132592997-132670401	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020891			Supported	Nucleoli<br>Golgi apparatus<br>Vesicles	Liver cancer:1.68e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.0	Expressed in all		
BARHL1		ENSG00000125492	BarH like homeobox 1	9	132582185-132590266	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA004809	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	154	SCLC-21H: 19.7
KIR2DL1	47.11, CD158A, cl-42, nkat1, p58.1	ENSG00000125498	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1	19	54769811-54784322	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PPP1R12C	DKFZP434D0412, LENG3, MBS85, p84, p85	ENSG00000125503	Protein phosphatase 1 regulatory subunit 12C	19	55090913-55117559	Predicted intracellular proteins	Evidence at protein level	HPA043532	Approved				Pancreatic cancer:4.10e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 112.5	Expressed in all		
MBOAT7	BB1, hMBOA-7, LENG4, LPIAT	ENSG00000125505	Membrane bound O-acyltransferase domain containing 7	19	54173412-54189882	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA055967	Approved		Approved	Cytosol	Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 24.3	Cell line enhanced		HMC-1: 150.7
SRMS	C20orf148, dJ697K14.1, PTK70, SRM	ENSG00000125508	Src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites	20	63540810-63547504	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB044668, CAB044669, HPA073987	Uncertain		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol		Mixed	Mixed			stomach: 1.4	Cell line enhanced		CAPAN-2: 2.9;MCF7: 2.2;RT4: 4.8
OPRL1	KOR-3, NOCIR, NOPr, OOR, ORL1	ENSG00000125510	Opioid related nociceptin receptor 1	20	64080173-64100643	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 12.3	testis: 4.7	Cell line enhanced		REH: 4.4;SCLC-21H: 9.4;U-937: 7.1
SLC2A4RG	GEF, HDBP1, Si-1-2, Si-1-2-19	ENSG00000125520	SLC2A4 regulator	20	63739861-63743505	Predicted intracellular proteins	Evidence at protein level	HPA063050			Approved	Nuclear speckles		Expressed in all	Expressed in all			adipose tissue: 53.7	Expressed in all		
NPBWR2	GPR8	ENSG00000125522	Neuropeptides B and W receptor 2	20	64105820-64107171	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland,cerebral cortex: 0.1	Not detected		
FNDC11	C20orf195, MGC5356	ENSG00000125531	Fibronectin type III domain containing 11	20	63547891-63556708	Predicted intracellular proteins	Evidence at protein level	HPA041341			Approved	Nucleoplasm<br>Vesicles<br>Aggresome		Mixed	Tissue enriched	19	testis: 53.0	epididymis: 2.8	Cell line enhanced		CAPAN-2: 4.5;EFO-21: 2.5;SH-SY5Y: 3.4
BHLHE23	bA305P22.3, Beta4, BHLHB4, bHLHe23	ENSG00000125533	Basic helix-loop-helix family member e23	20	63005927-63007035	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030575	Uncertain					Tissue enriched	Not detected			testis: 0.1	Cell line enriched	22	MOLT-4: 10.3
PPDPF	C20orf149, dJ697K14.9, exdpf	ENSG00000125534	Pancreatic progenitor cell differentiation and proliferation factor	20	63520724-63522206	Predicted intracellular proteins	Evidence at protein level	HPA040929			Approved	Nucleoplasm<br>Nucleoli<br>Microtubules	Renal cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			stomach: 210.2	Mixed		
IL1B	IL-1B, IL1-BETA, IL1F2	ENSG00000125538	Interleukin 1 beta	2	112829751-112836903	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 68.0;bone marrow: 106.4	adipose tissue: 53.4	Cell line enhanced		BJ hTERT+: 478.0;HBEC3-KT: 193.4;HMC-1: 189.1;hTEC/SVTERT24-B: 291.2;U-87 MG: 514.6
PLGLB2	PLGP1	ENSG00000125551	Plasminogen-like B2	2	87748087-87758793	Predicted secreted proteins	Evidence at transcript level	HPA053770			Approved	Vesicles		Tissue enriched	Tissue enriched	161	liver: 245.3	skin: 1.5	Mixed		
IL37	FIL1, FIL1(ZETA), FIL1Z, IL-1F7, IL-1H4, IL-1RP1, IL1F7	ENSG00000125571	Interleukin 37	2	112912971-112918882	Predicted intracellular proteins	Evidence at protein level	HPA054371, HPA057950	Approved		Supported	Nucleoplasm<br>Vesicles		Tissue enriched	Tissue enriched	7	skin: 162.7	breast: 22.3	Cell line enhanced		BJ hTERT+: 2.2;PC-3: 5.5;RT4: 2.5
CHCHD5	C2orf9, MGC11104, MIC14	ENSG00000125611	Coiled-coil-helix-coiled-coil-helix domain containing 5	2	112584240-112589275	Predicted intracellular proteins	Evidence at protein level	HPA038263	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 33.6	Mixed		
PAX8		ENSG00000125618	Paired box 8	2	113215997-113278950	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030062, CAB055097, CAB061888, HPA064554	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.75e-5 (unfavourable)	Group enriched	Tissue enriched	10	thyroid gland: 644.0	kidney: 65.2	Group enriched	8	EFO-21: 76.3;RPTEC TERT1: 144.9
INSIG2		ENSG00000125629	Insulin induced gene 2	2	118088452-118110997	Predicted membrane proteins	Evidence at protein level	CAB033861	Uncertain				Pancreatic cancer:2.19e-6 (unfavourable), Renal cancer:4.11e-6 (unfavourable), Head and neck cancer:7.10e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
POLR1B	FLJ10816, FLJ21921, RPA2, Rpo1-2	ENSG00000125630	RNA polymerase I subunit B	2	112541915-112577150	Enzymes, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037528			Supported	Nucleoli<br>Cytosol	Endometrial cancer:2.71e-5 (unfavourable), Pancreatic cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.0	Expressed in all		
CCDC93	FLJ10996	ENSG00000125633	Coiled-coil domain containing 93	2	117915478-118014133	Predicted intracellular proteins	Evidence at protein level	HPA054183	Approved		Supported	Vesicles<br>Plasma membrane	Liver cancer:2.97e-6 (unfavourable), Thyroid cancer:9.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
PSD4	EFA6B, TIC	ENSG00000125637	Pleckstrin and Sec7 domain containing 4	2	113157325-113209396	Predicted intracellular proteins	Evidence at protein level	HPA034722, HPA034723	Enhanced				Liver cancer:9.91e-5 (favourable), Stomach cancer:4.00e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 34.0	Cell line enhanced		HMC-1: 50.4
SLC25A23	APC2, FLJ30339, MGC2615	ENSG00000125648	Solute carrier family 25 member 23	19	6436079-6465203	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA009675, HPA050883	Approved		Supported	Mitochondria	Renal cancer:1.10e-12 (favourable), Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 141.3	Mixed		
PSPN	PSP	ENSG00000125650	Persephin	19	6375148-6379058	Predicted secreted proteins	Evidence at transcript level	CAB025366	Approved					Expressed in all	Mixed			cerebral cortex,epididymis,parathyroid gland,thyroid gland: 1.4	Mixed		
GTF2F1	BTF4, RAP74, TF2F1, TFIIF	ENSG00000125651	General transcription factor IIF subunit 1	19	6379569-6393981	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022793, HPA028707, HPA070752	Supported		Enhanced	Nucleus<br>Cell Junctions	Endometrial cancer:8.39e-4 (favourable), Renal cancer:9.80e-4 (favourable)	Expressed in all	Expressed in all			ovary: 93.3	Expressed in all		
ALKBH7	MGC10974, SPATA11	ENSG00000125652	AlkB homolog 7	19	6372433-6375251	Predicted intracellular proteins	Evidence at protein level	HPA039571, HPA039872	Approved				Renal cancer:7.83e-6 (favourable)	Expressed in all	Expressed in all			testis: 252.4	Expressed in all		
CLPP		ENSG00000125656	Caseinolytic mitochondrial matrix peptidase proteolytic subunit	19	6361452-6368908	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010649	Supported		Enhanced	Mitochondria	Pancreatic cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			appendix: 48.3	Expressed in all		
TNFSF9	4-1BB-L	ENSG00000125657	Tumor necrosis factor superfamily member 9	19	6530999-6535928	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059857			Approved	Golgi apparatus	Renal cancer:1.04e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 3.4	Cell line enhanced		HMC-1: 73.8
GRIA3	GluA3, GLUR3, GLURC, MRX94	ENSG00000125675	Glutamate ionotropic receptor AMPA type subunit 3	X	123184153-123490915	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA058659	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 56.6	adrenal gland: 11.3	Cell line enhanced		BJ: 20.3;BJ hTERT+: 28.1;fHDF/TERT166: 35.8;U-2197: 14.1
THOC2	CXorf3, dJ506G2.1, MRX12, MRX35, THO2	ENSG00000125676	THO complex 2	X	123600561-123733056	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047921	Supported		Approved	Nucleoplasm	Liver cancer:5.77e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 46.6	Expressed in all		
MED1	CRSP1, CRSP200, DRIP230, PBP, PPARBP, PPARGBP, RB18A, TRAP220, TRIP2	ENSG00000125686	Mediator complex subunit 1	17	39404285-39451286	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017696, HPA052818	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 56.7	Expressed in all		
RPL23	L23, rpL17	ENSG00000125691	Ribosomal protein L23	17	38847865-38853843	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003373	Approved		Supported	Cytosol	Renal cancer:4.19e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4496.9	Expressed in all		
ATG4C	APG4C, AUTL1, AUTL3, FLJ14867	ENSG00000125703	Autophagy related 4C cysteine peptidase	1	62784135-62865513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007049	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:9.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 23.5	Expressed in all		
CD70	CD27L, CD27LG, TNFSF7	ENSG00000125726	CD70 molecule	19	6583183-6604103	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046582			Uncertain	Nucleoplasm	Renal cancer:3.22e-4 (unfavourable), Lung cancer:6.29e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 4.4	lymph node: 3.8	Cell line enhanced		SiHa: 200.2;U-251 MG: 192.3;U-266/70: 304.1;U-266/84: 216.7
C3	ARMD9, C3a, C3b, CPAMD1	ENSG00000125730	Complement C3	19	6677704-6730562	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003563, CAB004209, HPA020432	Enhanced				Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			liver: 2486.8	Group enriched	6	BJ hTERT+: 287.5;EFO-21: 689.2;Hep G2: 539.6;HSkMC: 386.3;SiHa: 220.2
SH2D3A	NSP1	ENSG00000125731	SH2 domain containing 3A	19	6752160-6767588	Predicted intracellular proteins	Evidence at protein level	HPA035722, HPA064382	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.42e-4 (favourable), Prostate cancer:6.21e-4 (unfavourable)	Mixed	Mixed			skin: 14.0	Cell line enhanced		A-431: 35.6;HBEC3-KT: 47.1
TRIP10	CIP4, HSTP, STOT, STP	ENSG00000125733	Thyroid hormone receptor interactor 10	19	6737925-6751526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041934, HPA072625, HPA073886	Approved		Supported	Nucleoplasm<br>Vesicles	Head and neck cancer:1.76e-4 (favourable), Colorectal cancer:3.61e-4 (unfavourable), Renal cancer:4.66e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 129.0	Mixed		
GPR108	LUSTR2	ENSG00000125734	G protein-coupled receptor 108	19	6729914-6737603	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041924, HPA041951, HPA063863	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 75.1	Mixed		
TNFSF14	CD258, HVEM-L, LIGHT, LTg	ENSG00000125735	Tumor necrosis factor superfamily member 14	19	6661253-6670588	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012700	Approved				Renal cancer:6.07e-13 (unfavourable)	Tissue enhanced	Mixed			adipose tissue: 6.8	Cell line enhanced		HDLM-2: 22.7;U-937: 10.8
FOSB	AP-1, DKFZp686C0818, G0S3, GOS3, GOSB, MGC42291	ENSG00000125740	FosB proto-oncogene, AP-1 transcription factor subunit	19	45467995-45475179	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010267, HPA054663	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			gallbladder: 558.7	Cell line enhanced		HMC-1: 11.7;SK-BR-3: 7.4
OPA3	FLJ22187, MGA3	ENSG00000125741	OPA3, outer mitochondrial membrane lipid metabolism regulator	19	45527427-45602212	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044881	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.30e-12 (favourable), Liver cancer:5.60e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.0	Expressed in all		
SNRPD2	Sm-D2, SNRPD1	ENSG00000125743	Small nuclear ribonucleoprotein D2 polypeptide	19	45687454-45692569	Predicted intracellular proteins	Evidence at protein level	HPA041437	Supported		Uncertain	Cytosol	Renal cancer:8.58e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 334.8	Expressed in all		
RTN2	NSP2, NSPL1, SPG12	ENSG00000125744	Reticulon 2	19	45485289-45497061	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA034941, HPA034948	Approved		Approved	Nuclear speckles	Renal cancer:5.58e-6 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 175.3	placenta: 27.5	Mixed		
EML2	ELP70, EMAP-2, EMAP2	ENSG00000125746	Echinoderm microtubule associated protein like 2	19	45606994-45645629	Predicted intracellular proteins	Evidence at protein level	HPA012757	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Mixed		
VASP		ENSG00000125753	Vasodilator-stimulated phosphoprotein	19	45506579-45526983	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004612, HPA005724	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites	Renal cancer:5.91e-7 (unfavourable), Liver cancer:3.49e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 90.5	Expressed in all		
SYMPK	SPK, SYM	ENSG00000125755	Symplekin	19	45815410-45863290	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041756, HPA042449	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 74.7	Expressed in all		
GPCPD1	GDE5, GDPD6, KIAA1434	ENSG00000125772	Glycerophosphocholine phosphodiesterase 1	20	5544404-5611026	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039556, HPA042987	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.30e-4 (favourable), Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 46.5	Mixed		
SDCBP2	SITAC18, ST-2	ENSG00000125775	Syndecan binding protein 2	20	1309909-1329239	Predicted intracellular proteins	Evidence at protein level	HPA054554, HPA064490	Enhanced		Approved	Vesicles<br>Cytosol	Lung cancer:2.42e-4 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable), Urothelial cancer:3.37e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 135.1;small intestine: 143.9	stomach: 94.5	Cell line enhanced		CAPAN-2: 16.0
PANK2	C20orf48, FLJ11729, HARP, HSS, NBIA1, PKAN	ENSG00000125779	Pantothenate kinase 2	20	3888839-3929882	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008440	Approved		Supported	Cytosol	Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.9	Expressed in all		
TGM3	TGE	ENSG00000125780	Transglutaminase 3	20	2296001-2341078	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004728	Enhanced					Tissue enriched	Tissue enriched	12	esophagus: 1513.9	tonsil: 126.4	Cell line enriched	7	EFO-21: 5.7
GNRH2		ENSG00000125787	Gonadotropin releasing hormone 2	20	3043622-3045747	Predicted secreted proteins	Evidence at transcript level	HPA004338	Uncertain					Tissue enhanced	Mixed			ovary: 2.7	Mixed		
DEFB126	bA530N10.1, C20orf8, DEFB-26	ENSG00000125788	Defensin beta 126	20	142369-145751	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	234	epididymis: 663.6	seminal vesicle: 2.8	Not detected		
FOXA2	HNF3B	ENSG00000125798	Forkhead box A2	20	22581005-22585455	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB001388, HPA066846	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:7.57e-6 (favourable), Pancreatic cancer:2.34e-4 (favourable), Ovarian cancer:6.28e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 21.4;lung: 20.5;stomach: 31.0	liver: 11.5	Cell line enhanced		A549: 16.1;HBEC3-KT: 14.5;Hep G2: 19.5;PC-3: 24.0;SCLC-21H: 52.3
CD93	C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4	ENSG00000125810	CD93 molecule	20	23079349-23086340	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA009300, HPA012368	Enhanced		Approved	Vesicles<br>Plasma membrane	Renal cancer:2.74e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 197.1	Group enriched	5	HUVEC TERT2: 286.2;TIME: 357.8;U-937: 464.4
GZF1	dJ322G13.2, ZBTB23, ZNF336	ENSG00000125812	GDNF inducible zinc finger protein 1	20	23362182-23373063	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024520	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:9.81e-7 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 25.3	Expressed in all		
PAX1		ENSG00000125813	Paired box 1	20	21705659-21718486	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	11	parathyroid gland: 185.2	tonsil: 17.5	Cell line enriched	6	SCLC-21H: 1.6
NAPB	SNAP-BETA, SNAPB	ENSG00000125814	NSF attachment protein beta	20	23374519-23421519	Predicted intracellular proteins	Evidence at protein level	CAB037225, CAB037227, HPA046149, HPA050196	Approved		Uncertain	Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 303.2	adrenal gland: 32.1	Expressed in all		
CST8	CRES, CTES5	ENSG00000125815	Cystatin 8	20	23491101-23496018	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	208	testis: 20.7	all non-specific tissues: 0.0	Not detected		
NKX2-4	NKX2.4, NKX2D	ENSG00000125816	NK2 homeobox 4	20	21395367-21398028	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074996			Approved	Nuclear bodies		Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Cell line enhanced		HAP1: 1.9;HEK 293: 3.6;SCLC-21H: 3.0;SK-MEL-30: 2.3
CENPB		ENSG00000125817	Centromere protein B	20	3783851-3786690	Predicted intracellular proteins	Evidence at protein level	CAB011626, HPA053507, HPA054405	Approved		Enhanced	Nuclear bodies	Liver cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 43.4	Expressed in all		
PSMF1	PI31	ENSG00000125818	Proteasome inhibitor subunit 1	20	1113263-1189415	Predicted intracellular proteins	Evidence at protein level	HPA041122, HPA041300	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			testis: 136.0	Expressed in all		
NKX2-2	NKX2.2, NKX2B	ENSG00000125820	NK2 homeobox 2	20	21511010-21514026	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003468	Approved					Group enriched	Tissue enhanced		cerebral cortex: 9.9;stomach: 2.6	duodenum: 2.4	Cell line enhanced		HAP1: 4.3;T-47d: 4.6;U-138 MG: 17.1;U-2 OS: 3.7;WM-115: 7.0
DTD1	bA379J5.3, bA555E18.1, C20orf88, DUEB, HARS2, MGC119131, MGC41905, pqn-68	ENSG00000125821	D-tyrosyl-tRNA deacylase 1	20	18567453-18763917	Predicted intracellular proteins	Evidence at protein level	HPA040981, HPA042653	Uncertain		Uncertain	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 55.8	Mixed		
CSTL1	CTES1, dJ322G13.4	ENSG00000125823	Cystatin like 1	20	23439685-23444930	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	37	testis: 4.6	placenta,seminal vesicle,skin,small intestine,stomach: 0.1	Not detected		
RBCK1	C20orf18, HOIL1, RBCK2, RNF54, UBCE7IP3, XAP4, ZRANB4	ENSG00000125826	RANBP2-type and C3HC4-type zinc finger containing 1	20	407498-430966	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.41e-9 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.2	Expressed in all		
TMX4	DJ971N18.2, KIAA1162, PDIA14, TXNDC13	ENSG00000125827	Thioredoxin related transmembrane protein 4	20	7977348-8019829	Predicted membrane proteins	Evidence at protein level	HPA000399, HPA015752	Enhanced		Supported	Nuclear membrane	Renal cancer:2.60e-5 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
CST11	CST8L, CTES2, dJ322G13.6	ENSG00000125831	Cystatin 11	20	23450403-23452857	Predicted secreted proteins	Evidence at protein level	HPA053399	Enhanced					Not detected	Tissue enriched	299	epididymis: 266.6	testis: 0.8	Not detected		
STK35	bA550O8.2, CLIK1	ENSG00000125834	Serine/threonine kinase 35	20	2101611-2177038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026452, HPA051673	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:9.46e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
SNRPB	COD, Sm-B/B', SmB/SmB', snRNP-B, SNRPB1	ENSG00000125835	Small nuclear ribonucleoprotein polypeptides B and B1	20	2461634-2470853	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003482, CAB009610, HPA067842	Approved		Supported	Nucleoplasm	Liver cancer:1.07e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 202.0	Expressed in all		
NRSN2	C20orf98, dJ1103G7.6	ENSG00000125841	Neurensin 2	20	346782-359660	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015967	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:1.61e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.1	parathyroid gland: 69.0	Mixed		
AP5S1	C20orf29, FLJ11168	ENSG00000125843	Adaptor related protein complex 5 sigma 1 subunit	20	3820524-3828837	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB034200, HPA043533, HPA048244	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.53e-5 (favourable)	Expressed in all	Expressed in all			testis: 12.4	Expressed in all		
RRBP1	ES/130, hES	ENSG00000125844	Ribosome binding protein 1	20	17613678-17682295	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009026, HPA011924	Enhanced		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.41e-4 (favourable), Urothelial cancer:9.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 218.2	Expressed in all		
BMP2	BMP2A	ENSG00000125845	Bone morphogenetic protein 2	20	6767664-6780280	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA058610, CAB078457			Enhanced	Vesicles		Expressed in all	Mixed			thyroid gland: 31.2	Cell line enhanced		CACO-2: 25.6;HeLa: 13.4;hTERT-HME1: 13.5;RT4: 19.5
ZNF133	pHZ-13, pHZ-66, ZNF150	ENSG00000125846	Zinc finger protein 133	20	18288283-18316996	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001493	Enhanced		Approved	Nucleus<br>Vesicles	Liver cancer:4.46e-6 (unfavourable), Renal cancer:2.20e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 20.1	Mixed		
FLRT3		ENSG00000125848	Fibronectin leucine rich transmembrane protein 3	20	14322988-14337616	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB026166, HPA056033	Enhanced		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.49e-7 (favourable), Lung cancer:9.85e-5 (unfavourable), Pancreatic cancer:1.54e-4 (unfavourable)	Expressed in all	Mixed			lung: 32.3	Cell line enhanced		AF22: 32.9;hTCEpi: 45.3;WM-115: 75.5
OVOL2	bA504H3.3, CHED, CHED1, HOVO2, ZNF339	ENSG00000125850	Ovo like zinc finger 2	20	17956979-18059188	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038531	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		stomach: 8.0	colon: 3.5	Cell line enhanced		A-431: 5.2;CAPAN-2: 6.7;HaCaT: 5.0;SCLC-21H: 10.2;SK-BR-3: 4.4
PCSK2	NEC2, PC2, SPC2	ENSG00000125851	Proprotein convertase subtilisin/kexin type 2	20	17226107-17484578	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049627	Enhanced		Approved	Vesicles		Group enriched	Tissue enhanced		adrenal gland: 37.5;cerebral cortex: 31.7	skin: 16.5	Group enriched	6	AF22: 59.2;SCLC-21H: 18.5
GFRA4		ENSG00000125861	GDNF family receptor alpha 4	20	3659292-3663399	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 1.4	testis: 0.3	Not detected		
MKKS	BBS6	ENSG00000125863	McKusick-Kaufman syndrome	20	10401009-10434222	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041071, HPA044233	Enhanced		Supported	Centrosome	Renal cancer:3.79e-9 (favourable), Liver cancer:9.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 70.6	Expressed in all		
BFSP1	CP115, CP94, filensin, LIFL-H	ENSG00000125864	Beaded filament structural protein 1	20	17493905-17569220	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040748, HPA042038	Enhanced		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:1.39e-4 (favourable)	Mixed	Mixed			testis: 6.5	Cell line enhanced		RPTEC TERT1: 14.8
DSTN	ACTDP, ADF	ENSG00000125868	Destrin, actin depolymerizing factor	20	17569863-17609919	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037094	Approved					Expressed in all	Expressed in all			seminal vesicle: 1055.1	Expressed in all		
LAMP5	BAD-LAMP, C20orf103, dJ1119D9.3, UNC-46	ENSG00000125869	Lysosomal associated membrane protein family member 5	20	9514358-9530524	Predicted membrane proteins	Evidence at protein level	HPA004802, HPA070765	Uncertain		Approved	Mitotic spindle<br>Microtubule organizing center<br>Cytosol	Renal cancer:6.46e-6 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 44.9;ovary: 24.6	fallopian tube: 14.9	Group enriched	9	Karpas-707: 298.2;SH-SY5Y: 80.2;THP-1: 100.4
SNRPB2	Msl1, U2B''	ENSG00000125870	Small nuclear ribonucleoprotein polypeptide B2	20	16729961-16742563	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050814, HPA076104	Supported		Supported	Nuclear speckles	Liver cancer:6.03e-7 (unfavourable), Renal cancer:2.79e-4 (unfavourable), Endometrial cancer:7.57e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.8	Expressed in all		
MGME1	bA504H3.4, C20orf72, DDK1	ENSG00000125871	Mitochondrial genome maintenance exonuclease 1	20	17968913-17991122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040913	Approved		Supported	Mitochondria	Liver cancer:6.98e-8 (unfavourable), Renal cancer:1.13e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 39.7	Expressed in all		
LRRN4	C20orf75, dJ1056H1.1, NLRR4	ENSG00000125872	Leucine rich repeat neuronal 4	20	6040778-6054049	Predicted membrane proteins	Evidence at protein level	HPA075974			Approved	Nucleoli<br>Cytosol		Group enriched	Tissue enriched	10	lung: 13.5	fallopian tube: 1.2	Cell line enriched	12	RPTEC TERT1: 53.0
TBC1D20	C20orf140, dJ852M4.2	ENSG00000125875	TBC1 domain family member 20	20	435480-462553	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA043613	Approved					Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
ITPA	C20orf37, dJ794I6.3, HLC14-06-P	ENSG00000125877	Inosine triphosphatase	20	3208868-3223870	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022824	Approved		Supported	Cytosol	Liver cancer:2.54e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 40.3	Expressed in all		
TCF15	bHLHa40, EC2, PARAXIS	ENSG00000125878	Transcription factor 15 (basic helix-loop-helix)	20	603797-610398	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050998, HPA060221	Uncertain		Supported	Nuclear speckles	Ovarian cancer:3.25e-4 (unfavourable)	Mixed	Group enriched	5	adipose tissue: 6.3;heart muscle: 3.4;placenta: 4.8;skeletal muscle: 4.6;testis: 1.3	lung: 0.7	Cell line enhanced		HEL: 9.5;HMC-1: 14.7
OTOR	FDP, MIAL, MIAL1	ENSG00000125879	Otoraplin	20	16748358-16770062	Predicted secreted proteins	Evidence at protein level	HPA024335	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Group enriched	50	SH-SY5Y: 2.8;SK-BR-3: 9.6;T-47d: 2.3
MCM8	C20orf154, dJ967N21.5, MGC119522, MGC119523, MGC12866, MGC4816, REC	ENSG00000125885	Minichromosome maintenance 8 homologous recombination repair factor	20	5950652-5998977	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045141			Supported	Nucleoplasm	Liver cancer:9.30e-8 (unfavourable), Pancreatic cancer:7.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 27.6	lymph node: 10.2	Expressed in all		
BANF2	BAF-L, BAF2, BAFL, C20orf179, dJ803K15.1	ENSG00000125888	Barrier to autointegration factor 2	20	17693672-17735871	Predicted intracellular proteins	Evidence at protein level	HPA042635	Approved					Not detected	Tissue enriched	29	testis: 125.1	pancreas: 4.3	Cell line enhanced		CACO-2: 1.5
TMEM74B	C20orf46, FLJ11190	ENSG00000125895	Transmembrane protein 74B	20	1180561-1185415	Predicted membrane proteins	Evidence at transcript level	HPA045213	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.55e-7 (unfavourable), Pancreatic cancer:3.07e-5 (favourable)	Mixed	Mixed			small intestine: 27.0	Cell line enhanced		CACO-2: 6.6;Hep G2: 6.9;K-562: 15.6
FAM110A	bA371L19.3, C20orf55	ENSG00000125898	Family with sequence similarity 110 member A	20	833715-857463	Predicted intracellular proteins	Evidence at protein level	CAB034110, HPA069240	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:4.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 31.3	spleen: 21.3	Cell line enhanced		SK-BR-3: 62.8
SIRPD	dJ576H24.4, PTPNS1L2	ENSG00000125900	Signal regulatory protein delta	20	1534251-1558843	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042663	Enhanced					Not detected	Tissue enriched	18	testis: 72.6	appendix: 3.9	Cell line enhanced		HL-60: 1.1;HMC-1: 1.5;NB-4: 1.5;THP-1: 3.5
MRPS26	C20orf193, dJ534B8.3, MRP-S13, MRP-S26, RPMS13	ENSG00000125901	Mitochondrial ribosomal protein S26	20	3045945-3048254	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045472, HPA054610	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			prostate: 50.0	Expressed in all		
DEFB129	bA530N10.3, C20orf87, DEFB-29	ENSG00000125903	Defensin beta 129	20	227258-229886	Predicted secreted proteins	Evidence at protein level	HPA014581	Supported					Not detected	Tissue enriched	494	epididymis: 2368.3	seminal vesicle: 4.7	Cell line enhanced		NB-4: 1.7;SH-SY5Y: 1.3
S1PR4	EDG6	ENSG00000125910	Sphingosine-1-phosphate receptor 4	19	3172346-3180332	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA060601, HPA067232			Uncertain	Mitochondria	Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 18.1;spleen: 26.4	appendix: 14.0	Cell line enhanced		HDLM-2: 22.2;HL-60: 25.5;NB-4: 19.9;REH: 81.1;U-937: 23.6
NCLN	NET59, NICALIN	ENSG00000125912	Nicalin	19	3185563-3209575	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006625	Approved		Uncertain	Nucleoplasm<br>Lipid droplets	Renal cancer:8.37e-5 (unfavourable), Stomach cancer:8.82e-5 (favourable), Endometrial cancer:1.19e-4 (favourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 33.9	Expressed in all		
CITED1	MSG1	ENSG00000125931	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1	X	72301638-72307187	Predicted intracellular proteins	Evidence at protein level	HPA049051	Enhanced		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:3.95e-4 (favourable), Testis cancer:6.10e-4 (favourable)	Tissue enriched	Tissue enriched	7	epididymis: 1798.6	testis: 258.7	Cell line enhanced		AN3-CA: 52.8;SCLC-21H: 30.2;SK-MEL-30: 179.8
HNRNPR	hnRNP-R, HNRPR	ENSG00000125944	Heterogeneous nuclear ribonucleoprotein R	1	23303771-23344336	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011687, HPA026092	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.32e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 66.5	Expressed in all		
ZNF436	KIAA1710, Zfp46	ENSG00000125945	Zinc finger protein 436	1	23359448-23369442	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043817	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			ovary: 12.4	Cell line enhanced		HSkMC: 26.4
MAX	bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8	ENSG00000125952	MYC associated factor X	14	65006174-65102695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000328, HPA003474	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Thyroid cancer:2.12e-4 (favourable), Renal cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 78.8	Expressed in all		
CHURC1-FNTB		ENSG00000125954	CHURC1-FNTB readthrough	14	64914485-65061803	Predicted intracellular proteins	Evidence at protein level	CAB009260	Uncertain					Not detected	Mixed			adipose tissue: 1.5	Mixed		
ARMCX5	FLJ12969, GASP5	ENSG00000125962	Armadillo repeat containing, X-linked 5	X	102599168-102604159	Predicted intracellular proteins	Evidence at protein level	HPA000996	Approved		Approved	Nuclear speckles<br>Cytosol	Lung cancer:6.58e-5 (favourable)	Expressed in all	Expressed in all			prostate: 33.5	Cell line enhanced		RH-30: 86.0
GDF5	BMP14, CDMP1	ENSG00000125965	Growth differentiation factor 5	20	35433347-35454746	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015648	Uncertain					Tissue enriched	Tissue enhanced		salivary gland: 4.1	seminal vesicle: 1.7	Cell line enhanced		ASC TERT1: 12.2;BJ hTERT+: 4.4;HHSteC: 4.8;HSkMC: 10.3;U-87 MG: 6.5
MMP24	MT5-MMP	ENSG00000125966	Matrix metallopeptidase 24	20	35226654-35277000	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA049280			Approved	Nucleoli<br>Plasma membrane	Renal cancer:8.17e-11 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.6	lung: 7.0	Cell line enhanced		A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
NECAB3	APBA2BP, dJ63M2.4, dJ63M2.5, EFCBP3, NIP1, SYTIP2, XB51	ENSG00000125967	N-terminal EF-hand calcium binding protein 3	20	33657087-33674463	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044785, HPA070595, HPA071786	Supported		Supported	Golgi apparatus	Pancreatic cancer:3.19e-5 (favourable), Renal cancer:7.81e-4 (unfavourable), Endometrial cancer:9.57e-4 (unfavourable)	Expressed in all	Mixed			prostate: 34.6	Expressed in all		
ID1	bHLHb24, dJ857M17.1.2	ENSG00000125968	Inhibitor of DNA binding 1, HLH protein	20	31605283-31606515	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB025915, HPA051456, HPA058518	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus	Lung cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 213.9	Cell line enhanced		EFO-21: 475.3;PC-3: 474.7
RALY	HNRPCL2, P542	ENSG00000125970	RALY heterogeneous nuclear ribonucleoprotein	20	33993646-34108308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040971, HPA043614	Enhanced		Enhanced	Nucleoplasm	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 140.8	Expressed in all		
DYNLRB1	DNCL2A, DNLC2A, ROBLD1	ENSG00000125971	Dynein light chain roadblock-type 1	20	34516409-34540958	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009845	Approved				Liver cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 341.0	Expressed in all		
C20orf173	dJ477O4.4	ENSG00000125975	Chromosome 20 open reading frame 173	20	35523186-35529652	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	137	testis: 34.3	skin: 0.2	Not detected		
EIF2S2	EIF2, EIF2beta, PPP1R67	ENSG00000125977	Eukaryotic translation initiation factor 2 subunit beta	20	34088298-34112332	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034415, HPA041262, HPA041332	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Renal cancer:9.64e-10 (unfavourable), Liver cancer:3.23e-5 (unfavourable), Endometrial cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 74.3	Expressed in all		
ERGIC3	C20orf47, CGI-54, Erv46, NY-BR-84, PRO0989, SDBCAG84	ENSG00000125991	ERGIC and golgi 3	20	35542021-35557634	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015242, HPA015968	Approved		Supported	Nucleoplasm	Liver cancer:2.20e-7 (unfavourable), Renal cancer:9.81e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 530.3	Expressed in all		
ROMO1	bA353C18.2, C20orf52, MTGMP	ENSG00000125995	Reactive oxygen species modulator 1	20	35699272-35700984	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA012782	Uncertain					Expressed in all	Expressed in all			adrenal gland: 120.8	Expressed in all		
FAM83C	C20orf128, dJ614O4.7	ENSG00000125998	Family with sequence similarity 83 member C	20	35285731-35292401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034227, HPA049978	Uncertain					Tissue enhanced	Group enriched	17	esophagus: 19.8;skin: 43.0	tonsil: 1.8	Not detected		
BPIFB1	bA49G10.6, C20orf114, dJ1187J4.1, LPLUNC1, MGC14597, VEMSGP	ENSG00000125999	BPI fold containing family B member 1	20	33273480-33309878	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA024256	Supported					Tissue enhanced	Tissue enhanced		cervix, uterine: 839.4;stomach: 443.3	lung: 157.3	Cell line enhanced		CAPAN-2: 2.2;RT4: 1.6;SK-BR-3: 3.1
CEP250	C-NAP1, CEP2	ENSG00000126001	Centrosomal protein 250	20	35455164-35519280	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064875			Supported	Centrosome	Liver cancer:1.77e-7 (unfavourable), Renal cancer:1.97e-6 (unfavourable), Pancreatic cancer:9.27e-6 (favourable)	Expressed in all	Expressed in all			testis: 35.1	Expressed in all		
PLAGL2	ZNF900	ENSG00000126003	PLAG1 like zinc finger 2	20	32192503-32207791	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005900	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
MMP24-AS1		ENSG00000126005	MMP24 antisense RNA 1	20	35201745-35278131	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			adipose tissue: 46.9	Expressed in all		
GRPR	BB2, BB2R	ENSG00000126010	Gastrin releasing peptide receptor	X	16123556-16153021	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA069604			Enhanced	Plasma membrane		Tissue enhanced	Tissue enhanced		pancreas: 4.2	breast,epididymis: 2.6	Group enriched	10	PC-3: 30.0;T-47d: 37.9;U-138 MG: 53.4
KDM5C	DXS1272E, JARID1C, MRX13, SMCX, XE169	ENSG00000126012	Lysine demethylase 5C	X	53191321-53225422	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038244, HPA046147			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 66.7	Expressed in all		
AMOT	KIAA1071	ENSG00000126016	Angiomotin	X	112774503-112840815	Predicted intracellular proteins	Evidence at protein level	HPA067290, HPA067853	Enhanced		Supported	Nucleus<br>Cell Junctions	Renal cancer:4.21e-9 (favourable), Lung cancer:3.94e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 177.9	seminal vesicle: 38.6	Cell line enhanced		AF22: 24.7;HAP1: 28.1
TMEM115	PL6	ENSG00000126062	Transmembrane protein 115	3	50354749-50359610	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB006319, HPA015497	Supported		Supported	Golgi apparatus	Renal cancer:1.04e-7 (favourable), Liver cancer:3.73e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 37.3	Expressed in all		
PSMB2	HC7-I	ENSG00000126067	Proteasome subunit beta 2	1	35599544-35641844	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026322, HPA026324	Approved		Enhanced	Nucleoplasm	Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable)	Expressed in all	Expressed in all			placenta: 43.3	Expressed in all		
AGO3	EIF2C3, FLJ12765, hAGO3	ENSG00000126070	Argonaute 3, RISC catalytic component	1	35930718-36072500	Predicted intracellular proteins	Evidence at protein level	HPA048342, HPA075436	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies	Endometrial cancer:5.70e-4 (unfavourable)	Mixed	Mixed			testis: 10.3	Expressed in all		
UROD		ENSG00000126088	Uroporphyrinogen decarboxylase	1	45012147-45015575	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027468, HPA028668, HPA030350	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 115.4	Expressed in all		
ST3GAL3	MRT12, SIAT6	ENSG00000126091	ST3 beta-galactoside alpha-2,3-sialyltransferase 3	1	43705824-43931165	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051102	Uncertain					Expressed in all	Expressed in all			skeletal muscle: 30.5	Mixed		
TMEM53	FLJ22353, NET4	ENSG00000126106	Transmembrane protein 53	1	44635238-44674555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021134	Approved		Approved	Golgi apparatus<br>Focal adhesion sites	Renal cancer:1.02e-5 (favourable), Ovarian cancer:6.96e-4 (favourable)	Expressed in all	Mixed			testis: 23.3	Expressed in all		
HECTD3	FLJ21156	ENSG00000126107	HECT domain E3 ubiquitin protein ligase 3	1	45002540-45011329	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027467	Approved				Thyroid cancer:1.85e-6 (favourable), Liver cancer:2.14e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum,parathyroid gland: 47.3	Expressed in all		
KLC1	hKLC1B, hKLC1G, hKLC1J, hKLC1N, hKLC1P, hKLC1R, hKLC1S, KLC, KNS2, KNS2A	ENSG00000126214	Kinesin light chain 1	14	103561896-103714249	Predicted intracellular proteins	Evidence at protein level	CAB009798, HPA044617, HPA052450	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.75e-4 (favourable), Renal cancer:7.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 467.9	Expressed in all		
XRCC3		ENSG00000126215	X-ray repair cross complementing 3	14	103697609-103715504	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062422, HPA068953			Enhanced	Nucleus		Expressed in all	Expressed in all			skin: 46.0	Expressed in all		
TUBGCP3	GCP3, SPBC98, Spc98p	ENSG00000126216	Tubulin gamma complex associated protein 3	13	112485005-112588167	Predicted intracellular proteins	Evidence at protein level	HPA043913	Approved					Expressed in all	Expressed in all			testis: 33.2	Expressed in all		
MCF2L	ARHGEF14, DBS, KIAA0362, OST	ENSG00000126217	MCF.2 cell line derived transforming sequence like	13	112894378-113099739	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.14e-6 (favourable), Urothelial cancer:2.63e-5 (favourable), Pancreatic cancer:4.36e-5 (favourable), Endometrial cancer:6.01e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 62.4	Cell line enhanced		SCLC-21H: 77.5;SK-BR-3: 33.1;WM-115: 59.3
F10		ENSG00000126218	Coagulation factor X	13	113122814-113149529	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 67.5	cervix, uterine: 51.6	Cell line enhanced		BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
PCID2	FLJ11305	ENSG00000126226	PCI domain containing 2	13	113177539-113208715	Predicted intracellular proteins	Evidence at protein level	HPA069107, HPA073074	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:4.24e-6 (unfavourable), Head and neck cancer:7.80e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.9	Expressed in all		
PROZ	PZ	ENSG00000126231	Protein Z, vitamin K dependent plasma glycoprotein	13	113158654-113172383	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052006	Enhanced				Liver cancer:3.46e-4 (favourable)	Tissue enriched	Group enriched	14	kidney: 14.5;liver: 27.4	testis: 1.5	Cell line enhanced		HaCaT: 1.9;Hep G2: 2.4
SLURP1	ANUP, ARS, ArsB, LY6LS, MDM	ENSG00000126233	Secreted LY6/PLAUR domain containing 1	8	142740944-142742411	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA050967	Approved					Tissue enhanced	Group enriched	33	esophagus: 740.6;skin: 297.1	tonsil: 15.7	Cell line enhanced		HaCaT: 1.1;MCF7: 1.1;T-47d: 2.4
LRFN3	FIGLER1, MGC2656, SALM4	ENSG00000126243	Leucine rich repeat and fibronectin type III domain containing 3	19	35935358-35945767	Predicted membrane proteins	Evidence at transcript level	HPA048923	Approved				Renal cancer:8.46e-7 (favourable)	Expressed in all	Mixed			cerebral cortex: 8.2	Mixed		
IGFLR1	FLJ22573, TMEM149, U2AF1L4	ENSG00000126246	IGF like family receptor 1	19	35738801-35742453	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012369	Uncertain		Approved	Focal adhesion sites	Ovarian cancer:1.59e-5 (favourable), Cervical cancer:6.55e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.8	Cell line enhanced		HMC-1: 29.7;U-266/70: 26.0
CAPNS1	30K, CANP, CANPS, CAPN4, CDPS	ENSG00000126247	Calpain small subunit 1	19	36139575-36150353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006872	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			esophagus: 515.2	Expressed in all		
PDCD2L	MGC13096	ENSG00000126249	Programmed cell death 2 like	19	34404384-34426168	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA052181	Approved		Uncertain	Mitochondria	Renal cancer:1.23e-5 (unfavourable), Liver cancer:5.81e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.5	Mixed		
GPR42	FFAR3L, GPR41L, GPR42P	ENSG00000126251	G protein-coupled receptor 42 (gene/pseudogene)	19	35370929-35372962	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA044681	Uncertain					Not detected	Not detected			appendix,small intestine: 0.3	Not detected		
RBM42	MGC10433	ENSG00000126254	RNA binding motif protein 42	19	35629030-35637686	Predicted intracellular proteins	Evidence at protein level	HPA043671	Supported		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			spleen: 38.7	Expressed in all		
KIRREL2	DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1	ENSG00000126259	Kin of IRRE like 2 (Drosophila)	19	35855861-35867109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071587, HPA074326			Supported	Microtubule organizing center		Mixed	Tissue enriched	8	pancreas: 11.6	cerebral cortex: 1.4	Cell line enhanced		HDLM-2: 20.2;HMC-1: 29.3
UBA2	ARX, FLJ13058, HRIHFB2115, SAE2	ENSG00000126261	Ubiquitin like modifier activating enzyme 2	19	34428352-34471251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041436	Supported		Supported	Nucleoplasm	Liver cancer:3.76e-4 (unfavourable), Renal cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 168.1	Expressed in all		
FFAR2	FFA2R, GPR43	ENSG00000126262	Free fatty acid receptor 2	19	35443907-35451767	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA023985	Approved					Tissue enhanced	Tissue enhanced		appendix: 25.5;bone marrow: 13.3	spleen: 10.8	Cell line enhanced		HMC-1: 3.5;U-937: 1.3
HCST	DAP10, DKFZP586C1522, KAP10, PIK3AP	ENSG00000126264	Hematopoietic cell signal transducer	19	35902480-35904377	Predicted membrane proteins	Evidence at protein level	CAB034435, HPA063026	Enhanced		Uncertain	Vesicles	Renal cancer:1.59e-10 (unfavourable), Melanoma:6.70e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 154.3	Cell line enhanced		HEL: 207.8;HL-60: 107.2;HMC-1: 130.2;THP-1: 117.5;U-937: 204.7
FFAR1	FFA1R, GPR40	ENSG00000126266	Free fatty acid receptor 1	19	35351552-35353862	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		bone marrow: 1.9	ovary: 1.2	Cell line enhanced		U-698: 1.1
COX6B1	COX6B, COXG	ENSG00000126267	Cytochrome c oxidase subunit 6B1	19	35648223-35658861	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004192	Enhanced		Supported	Mitochondria	Renal cancer:5.42e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 462.5	Expressed in all		
KRT36	KRTHA6	ENSG00000126337	Keratin 36	17	41486136-41492546	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 2.1;tonsil: 1.5	cervix, uterine,spleen: 0.5	Cell line enriched	11	Karpas-707: 2.2
THRA	AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3	ENSG00000126351	Thyroid hormone receptor, alpha	17	40058290-40093867	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009654, CAB023349	Uncertain		Supported	Cytosol	Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 238.9	Expressed in all		
CCR7	BLR2, CD197, CDw197, CMKBR7, EBI1	ENSG00000126353	C-C motif chemokine receptor 7	17	40553769-40565472	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB003796, HPA031383, HPA074467	Enhanced		Supported	Mitochondria	Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable)	Mixed	Group enriched	6	appendix: 88.8;lymph node: 97.1;spleen: 39.3;tonsil: 77.2	urinary bladder: 12.4	Cell line enriched	79	HDLM-2: 1284.5
NR1D1	ear-1, hRev, Rev-ErbAalpha, THRA1, THRAL	ENSG00000126368	Nuclear receptor subfamily 1 group D member 1	17	40092787-40100725	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007935	Uncertain		Supported	Nuclear bodies	Melanoma:1.36e-4 (favourable), Colorectal cancer:1.94e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 37.4	Expressed in all		
FRMD8	FKSG44, FLJ90369	ENSG00000126391	FERM domain containing 8	11	65386599-65413525	Predicted intracellular proteins	Evidence at protein level	HPA002861, HPA005506	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:9.94e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 24.9	Expressed in all		
PRDX5	ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10	ENSG00000126432	Peroxiredoxin 5	11	64318088-64321811	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008661, HPA037915, HPA037916	Enhanced		Enhanced	Mitochondria<br>Cytosol	Renal cancer:1.24e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 606.1	Expressed in all		
BCL2L12		ENSG00000126453	BCL2 like 12	19	49665142-49673916	Predicted intracellular proteins	Evidence at protein level	HPA020856	Approved		Approved	Cytosol	Renal cancer:8.75e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.6	Expressed in all		
IRF3		ENSG00000126456	Interferon regulatory factor 3	19	49659569-49665875	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004895, CAB013018	Approved		Supported	Cytosol	Renal cancer:1.56e-7 (unfavourable), Urothelial cancer:3.61e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 47.2	Expressed in all		
PRMT1	ANM1, HCP1, HRMT1L2	ENSG00000126457	Protein arginine methyltransferase 1	19	49675786-49689029	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022550, HPA069769, HPA072136	Enhanced		Supported	Nucleoplasm	Liver cancer:8.04e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 181.1	Expressed in all		
RRAS		ENSG00000126458	Related RAS viral (r-ras) oncogene homolog	19	49635292-49640201	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010160, HPA060364, CAB069439	Uncertain		Approved	Vesicles	Renal cancer:1.54e-9 (unfavourable), Glioma:6.03e-5 (unfavourable), Lung cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 209.2	Mixed		
PRRG2	PRGP2	ENSG00000126460	Proline rich and Gla domain 2	19	49580646-49591015	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010702	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.82e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.5	Cell line enhanced		CAPAN-2: 13.1;T-47d: 13.6;U-266/84: 12.9
SCAF1	FLJ00034, SR-A1	ENSG00000126461	SR-related CTD associated factor 1	19	49642125-49658642	Predicted intracellular proteins	Evidence at protein level	HPA046828, HPA054593	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:9.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
PRR12	KIAA1205	ENSG00000126464	Proline rich 12	19	49591643-49626439	Predicted intracellular proteins	Evidence at protein level	HPA011959	Approved		Approved	Cytosol		Expressed in all	Mixed			skin: 15.3	Expressed in all		
TSKS	PPP1R161, TSSKS	ENSG00000126467	Testis specific serine kinase substrate	19	49739753-49763330	Predicted intracellular proteins	Evidence at protein level	HPA045729	Enhanced					Tissue enhanced	Tissue enriched	43	testis: 72.4	skin: 1.6	Cell line enhanced		K-562: 1.7;NB-4: 7.2;THP-1: 1.6
FLRT1	MGC21624, SPG68	ENSG00000126500	Fibronectin leucine rich transmembrane protein 1	11	64103188-64119173	Predicted membrane proteins	Evidence at protein level	HPA054589	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 12.5	cervix, uterine: 4.0	Cell line enhanced		SCLC-21H: 6.4;SH-SY5Y: 14.3;THP-1: 7.6
ASL		ENSG00000126522	Argininosuccinate lyase	7	66075798-66093558	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003696, HPA016646	Supported		Approved	Cytosol	Cervical cancer:4.05e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 97.5	Expressed in all		
SBDS	CGI-97, FLJ10917, SDS, SWDS	ENSG00000126524	SBDS ribosome assembly guanine nucleotide exchange factor	7	66987677-66995601	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028891	Approved		Supported	Nucleus<br>Cytosol	Breast cancer:1.49e-4 (unfavourable), Head and neck cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 243.3	Expressed in all		
CSN1S1	CASA, CSN1	ENSG00000126545	Casein alpha s1	4	69931081-69946574	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035659, HPA057031	Enhanced					Tissue enriched	Tissue enriched	85	breast: 1600.9	adipose tissue: 18.9	Not detected		
STATH	STR	ENSG00000126549	Statherin	4	69995930-70002570	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA044569	Enhanced					Group enriched	Tissue enriched	1719	salivary gland: 44726.6	ovary: 26.0	Not detected		
HTN1	HIS1	ENSG00000126550	Histatin 1	4	70050402-70058845	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1777	salivary gland: 24297.5	ovary: 13.6	Not detected		
STAT5A	MGF, STAT5	ENSG00000126561	Signal transducer and activator of transcription 5A	17	42287547-42311943	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003860, HPA027873, HPA042128, HPA049883, HPA051156	Approved		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 90.3	Cell line enhanced		HDLM-2: 100.4;HEL: 145.8;K-562: 246.3;MOLT-4: 160.1
WNK4	PRKWNK4	ENSG00000126562	WNK lysine deficient protein kinase 4	17	42780678-42796936	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016500	Approved					Mixed	Tissue enhanced		kidney: 19.0;prostate: 15.4;rectum: 12.0	colon: 8.8	Cell line enhanced		fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
BECN1	ATG6, VPS30	ENSG00000126581	Beclin 1	17	42810134-42833350	Predicted intracellular proteins	Evidence at protein level	CAB010143, HPA028949	Enhanced					Expressed in all	Expressed in all			rectum: 71.3	Expressed in all		
PRKCG	MGC57564, PKCC, PKCG, SCA14	ENSG00000126583	Protein kinase C gamma	19	53879190-53907652	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013051, HPA047870, HPA054560	Supported					Mixed	Tissue enriched	9	cerebral cortex: 40.9	testis: 4.7	Cell line enhanced		A549: 2.0;SH-SY5Y: 1.5
TRAP1	HSP75, HSP90L	ENSG00000126602	TNF receptor associated protein 1	16	3651639-3717597	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041082, HPA044227	Enhanced		Enhanced	Mitochondria	Colorectal cancer:1.80e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 95.4	Expressed in all		
GLIS2	NPHP7	ENSG00000126603	GLIS family zinc finger 2	16	4314761-4339597	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056976			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.06e-6 (favourable), Endometrial cancer:1.59e-5 (unfavourable)	Expressed in all	Mixed			gallbladder: 9.7	Cell line enhanced		U-2197: 35.6
NSRP1	CCDC55, DKFZP434K1421, NSrp70	ENSG00000126653	Nuclear speckle splicing regulatory protein 1	17	30115521-30186475	Predicted intracellular proteins	Evidence at protein level	HPA015593, HPA015603	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 44.6	Expressed in all		
DNAJC8	SPF31	ENSG00000126698	DnaJ heat shock protein family (Hsp40) member C8	1	28199456-28233025	Predicted intracellular proteins	Evidence at protein level	HPA026275, HPA026283	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.95e-5 (favourable), Thyroid cancer:2.39e-4 (favourable), Liver cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 93.5	Expressed in all		
AHDC1	DJ159A19.3, RP1-159A19.1	ENSG00000126705	AT-hook DNA binding motif containing 1	1	27534035-27604431	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028648, HPA028691	Approved		Supported	Nucleus	Endometrial cancer:1.20e-4 (unfavourable), Head and neck cancer:2.68e-4 (favourable), Ovarian cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 16.0	Mixed		
IFI6	6-16, FAM14C, G1P3, IFI-6-16, IFI616	ENSG00000126709	Interferon alpha inducible protein 6	1	27666061-27672218	Predicted membrane proteins	Evidence at transcript level	HPA005543	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			placenta: 413.9	Group enriched	6	BJ hTERT+ SV40 Large T+: 1217.0;BJ hTERT+ SV40 Large T+ RasG12V: 1476.2;EFO-21: 494.2;SK-MEL-30: 747.5
DACH2		ENSG00000126733	Dachshund family transcription factor 2	X	86148458-86832604	Predicted intracellular proteins	Evidence at transcript level	HPA000258	Approved					Not detected	Group enriched	8	cerebral cortex: 11.9;epididymis: 4.4;fallopian tube: 5.0	kidney: 0.8	Cell line enriched	8	HAP1: 6.1
ZNF384	CAGH1A, CIZ, NMP4, NP, TNRC1	ENSG00000126746	Zinc finger protein 384	12	6666477-6689572	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004051	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 66.0	Expressed in all		
EMG1	C2F, Grcc2f, NEP1	ENSG00000126749	EMG1, N1-specific pseudouridine methyltransferase	12	6970893-6979941	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039304, HPA039666	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.83e-6 (unfavourable), Liver cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 21.0	Expressed in all		
SSX1	CT5.1	ENSG00000126752	SSX family member 1	X	48255317-48267444	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683	Supported		Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enriched	26	testis: 12.7	epididymis: 0.4	Group enriched	9	Daudi: 47.0;Karpas-707: 66.3;U-2197: 20.0
UXT	ART-27, STAP1	ENSG00000126756	Ubiquitously expressed prefoldin like chaperone	X	47651798-47659161	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050499, HPA058400	Approved		Supported	Nucleus<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			ovary: 184.1	Expressed in all		
CFP	PFC	ENSG00000126759	Complement factor properdin	X	47623172-47630305	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 58.1;spleen: 76.6	appendix: 29.9	Cell line enhanced		EFO-21: 21.2;HEL: 4.6;HMC-1: 4.9;NB-4: 7.2;U-937: 6.1
ELK1		ENSG00000126767	ELK1, ETS transcription factor	X	47635521-47650604	Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB003808, HPA036084, HPA064381	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.25e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 50.9	Expressed in all		
TIMM17B	DXS9822, JM3	ENSG00000126768	Translocase of inner mitochondrial membrane 17B	X	48893447-48898143	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029093	Approved		Approved	Microtubules<br>Mitochondria	Cervical cancer:6.63e-4 (favourable), Urothelial cancer:7.88e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 43.9	Expressed in all		
PCNX4	C14orf135, PCNXL4	ENSG00000126773	Pecanex homolog 4 (Drosophila)	14	60091911-60169133	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002076, HPA003390	Uncertain		Approved	Cytosol	Renal cancer:6.84e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.2	Expressed in all		
ATG14	ATG14L, KIAA0831	ENSG00000126775	Autophagy related 14	14	55366392-55411858	Predicted intracellular proteins	Evidence at protein level	CAB037242	Uncertain				Liver cancer:1.63e-4 (unfavourable), Renal cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 17.1	Expressed in all		
KTN1	CG1, KIAA0004, KNT	ENSG00000126777	Kinectin 1	14	55559072-55701526	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003178, CAB015331, HPA017876	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 268.4	Expressed in all		
SIX1	DFNA23	ENSG00000126778	SIX homeobox 1	14	60643415-60658259	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001893, CAB058690	Enhanced		Supported	Nucleus<br>Nucleoli	Endometrial cancer:8.92e-6 (unfavourable), Lung cancer:3.94e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 21.9;parathyroid gland: 53.5;prostate: 21.2;salivary gland: 21.6;skeletal muscle: 41.5	adipose tissue: 5.6	Cell line enhanced		LHCN-M2: 118.6;RH-30: 69.5
RHOJ	ARHJ, FLJ14445, RASL7B, TCL	ENSG00000126785	Ras homolog family member J	14	63204114-63293219	Predicted intracellular proteins	Evidence at protein level	HPA003050	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 48.3	Cell line enhanced		AF22: 64.5;HUVEC TERT2: 319.9;TIME: 83.9;WM-115: 109.1
DLGAP5	DLG1, DLG7, HURP, KIAA0008	ENSG00000126787	DLG associated protein 5	14	55148112-55191678	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005546	Enhanced		Supported	Microtubule organizing center<br>Cytosol	Liver cancer:1.52e-6 (unfavourable), Pancreatic cancer:9.94e-6 (unfavourable), Endometrial cancer:4.59e-4 (unfavourable), Lung cancer:7.85e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 29.8	lymph node: 20.4	Mixed		
L3HYPDH	C14orf149, FLJ25436	ENSG00000126790	Trans-L-3-hydroxyproline dehydratase	14	59460363-59484430	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056694	Approved		Uncertain	Vesicles	Renal cancer:1.72e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
HSPA2		ENSG00000126803	Heat shock protein family A (Hsp70) member 2	14	64535905-64546173	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000798, HPA052504	Enhanced	Approved	Approved	Nucleoplasm<br>Vesicles	Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 188.6	cerebral cortex: 96.4	Cell line enhanced		A549: 67.9;BEWO: 110.2;BJ hTERT+: 80.5;SCLC-21H: 119.3
ZBTB1	KIAA0997, ZNF909	ENSG00000126804	Zinc finger and BTB domain containing 1	14	64503712-64533690	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050516	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Head and neck cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.5	Expressed in all		
TRMT5	KIAA1393, TRM5	ENSG00000126814	TRNA methyltransferase 5	14	60971451-60981358	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000943	Supported		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
SGPP1		ENSG00000126821	Sphingosine-1-phosphate phosphatase 1	14	63684214-63728039	Predicted membrane proteins	Evidence at protein level	HPA053149, HPA064908	Approved		Supported	Nucleus		Expressed in all	Expressed in all			placenta: 34.7	Mixed		
PLEKHG3	ARHGEF43, KIAA0599	ENSG00000126822	Pleckstrin homology and RhoGEF domain containing G3	14	64704102-64750247	Predicted intracellular proteins	Evidence at protein level	HPA063455, HPA065323, HPA073702, HPA074734	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Centrosome<br>Cytosol	Renal cancer:7.39e-8 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 53.5	Mixed		
PZP	CPAMD6	ENSG00000126838	PZP, alpha-2-macroglobulin like	12	9148840-9208370	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA041403, HPA041471	Supported					Tissue enhanced	Tissue enriched	12	liver: 45.9	testis: 3.8	Group enriched	7	HeLa: 3.2;SiHa: 2.6
PRDM7	ZNF910	ENSG00000126856	PR/SET domain 7	16	90056566-90092072	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059944	Approved		Uncertain	Nuclear speckles		Tissue enriched	Tissue enriched	11	testis: 1.1	all non-specific tissues: 0.0	Group enriched	30	REH: 3.8;SK-MEL-30: 2.1
RHOT1	ARHT1, FLJ11040, MIRO-1	ENSG00000126858	Ras homolog family member T1	17	32142454-32253374	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010687, CAB068223, CAB068224	Enhanced					Expressed in all	Expressed in all			parathyroid gland: 48.8	Expressed in all		
EVI2A	EVDA, EVI2	ENSG00000126860	Ecotropic viral integration site 2A	17	31317560-31321884	Predicted membrane proteins	Evidence at protein level	HPA045033, HPA057051	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.63e-6 (unfavourable), Melanoma:7.55e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 83.0	Cell line enhanced		Karpas-707: 71.2;RPMI-8226: 110.1
OMG	OMGP	ENSG00000126861	Oligodendrocyte myelin glycoprotein	17	31272013-31297539	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008206, HPA012693	Enhanced					Group enriched	Tissue enriched	318	cerebral cortex: 137.4	bone marrow: 0.4	Not detected		
WDR60	FAP163, FLJ10300	ENSG00000126870	WD repeat domain 60	7	158856578-158956747	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020607, HPA021316	Approved		Approved	Microtubule organizing center		Expressed in all	Expressed in all			testis: 75.5	Expressed in all		
AIF1L	C9orf58, FLJ12783, IBA2	ENSG00000126878	Allograft inflammatory factor 1 like	9	131096476-131123152	Predicted intracellular proteins	Evidence at protein level	HPA020522, HPA056852	Enhanced				Renal cancer:5.54e-6 (favourable)	Expressed in all	Tissue enhanced		kidney: 287.5;spleen: 288.1	thyroid gland: 155.2	Cell line enhanced		AF22: 139.6;NTERA-2: 106.7;RPTEC TERT1: 230.5
FAM78A	C9orf59, FLJ00024	ENSG00000126882	Family with sequence similarity 78 member A	9	131258076-131276547	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021472, HPA023914	Uncertain		Uncertain	Nucleus<br>Vesicles	Head and neck cancer:2.00e-4 (favourable), Cervical cancer:3.67e-4 (favourable)	Expressed in all	Mixed			lymph node: 27.4	Cell line enhanced		BEWO: 37.7;HEL: 34.3;HL-60: 30.4;NB-4: 37.9;THP-1: 35.7;U-937: 27.8
NUP214	CAIN, CAN, D9S46E, N214	ENSG00000126883	Nucleoporin 214	9	131125561-131234670	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA048789			Supported	Nucleus<br>Vesicles<br>Focal adhesion sites	Renal cancer:2.39e-5 (favourable)	Expressed in all	Expressed in all			testis: 123.0	Expressed in all		
CTAG2	CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803	ENSG00000126890	Cancer/testis antigen 2	X	154651972-154653579	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA071467	Enhanced				Liver cancer:2.35e-4 (unfavourable)	Mixed	Group enriched	8	fallopian tube: 2.6;heart muscle: 3.2;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0	pancreas: 0.4	Group enriched	29	K-562: 126.4;RPMI-8226: 215.0;SK-BR-3: 146.5;U-266/84: 251.9
AVPR2	DIR, DIR3, V2R	ENSG00000126895	Arginine vasopressin receptor 2	X	153902531-153907166	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046678	Approved					Mixed	Tissue enhanced		adipose tissue: 5.8	kidney: 2.8	Cell line enhanced		EFO-21: 3.0;SCLC-21H: 4.6;U-266/84: 2.7;U-698: 2.8
SLC10A3	DXS253E, P3	ENSG00000126903	Solute carrier family 10 member 3	X	154487306-154490690	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA021656	Approved		Approved	Intermediate filaments	Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.0	Expressed in all		
MAP2K2	MEK2, PRKMK2	ENSG00000126934	Mitogen-activated protein kinase kinase 2	19	4090321-4124129	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003835, HPA051993	Supported		Supported	Cytosol	Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 135.0	Expressed in all		
HNRNPH2	FTP3, hnRNPH', HNRPH', HNRPH2	ENSG00000126945	Heterogeneous nuclear ribonucleoprotein H2	X	101408295-101414133	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000914, HPA001359, CAB004436, HPA016884	Supported		Enhanced	Nucleoplasm	Renal cancer:7.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 216.1	Expressed in all		
ARMCX1	ALEX1, GASP7	ENSG00000126947	Armadillo repeat containing, X-linked 1	X	101550531-101554700	Predicted membrane proteins	Evidence at protein level	HPA005685, CAB020695	Supported		Approved	Nucleus<br>Mitochondria<br>Cytosol	Pancreatic cancer:7.32e-5 (favourable), Cervical cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 59.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 75.6;RH-30: 84.3
TMEM35A	FLJ14084, TMEM35	ENSG00000126950	Transmembrane protein 35A	X	101078720-101096364	Predicted membrane proteins	Evidence at protein level	HPA048583	Enhanced		Supported	Vesicles<br>Focal adhesion sites<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 42.4;seminal vesicle: 65.5	prostate: 33.7	Cell line enhanced		HUVEC TERT2: 40.2;SH-SY5Y: 12.9
NXF5		ENSG00000126952	Nuclear RNA export factor 5	X	101832112-101857577	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA002079	Uncertain					Not detected	Not detected			cerebral cortex,epididymis,spleen: 0.1	Not detected		
TIMM8A	DDP, DFN1, MTS	ENSG00000126953	Translocase of inner mitochondrial membrane 8A	X	101345661-101349196	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003628	Supported		Enhanced	Mitochondria	Breast cancer:7.89e-5 (unfavourable), Endometrial cancer:8.87e-5 (unfavourable), Renal cancer:1.69e-4 (favourable)	Expressed in all	Mixed			liver: 8.9	Expressed in all		
ZC4H2	HCA127, KIAA1166, WWS	ENSG00000126970	Zinc finger C4H2-type containing	X	64915802-65034713	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049584	Approved		Approved	Vesicles<br>Microtubules	Thyroid cancer:3.51e-5 (unfavourable)	Mixed	Mixed			parathyroid gland: 17.5	Cell line enhanced		NTERA-2: 51.9;REH: 36.2
CANX	CNX, IP90, P90	ENSG00000127022	Calnexin	5	179678628-179730925	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004738, HPA009433, HPA009696	Enhanced		Enhanced	Endoplasmic reticulum	Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 294.4	Expressed in all		
INTS11	CPSF3L, CPSF73L, FLJ20542, INT11, RC-68	ENSG00000127054	Integrator complex subunit 11	1	1311585-1324691	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028379, HPA029025	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 77.0	Expressed in all		
RGS13		ENSG00000127074	Regulator of G-protein signaling 13	1	192636138-192660306	Predicted intracellular proteins	Evidence at protein level	HPA044952	Uncertain					Mixed	Group enriched	6	appendix: 14.3;lymph node: 68.4;tonsil: 36.9	small intestine: 7.1	Cell line enriched	12	Daudi: 37.3
IPPK	C9orf12, FLJ13163, INSP5K2, IP5K, IPK1	ENSG00000127080	Inositol-pentakisphosphate 2-kinase	9	92613184-92670265	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020603	Uncertain		Approved	Cytosol	Urothelial cancer:1.28e-4 (unfavourable)	Mixed	Mixed			skin: 34.2	Expressed in all		
ZNF484	BA526D8.4, FLJ33884	ENSG00000127081	Zinc finger protein 484	9	92845031-92878038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028973	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 6.9	Mixed		
OMD	osteoadherin, SLRR2C	ENSG00000127083	Osteomodulin	9	92414245-92424461	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA005731, HPA069948		Approved	Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Mixed	Mixed			cervix, uterine: 36.4	Group enriched	13	ASC diff: 6.2;ASC TERT1: 5.9
FGD3	FLJ00004, ZFYVE5	ENSG00000127084	FYVE, RhoGEF and PH domain containing 3	9	92947451-93036236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020963, HPA021018	Approved		Approved	Nucleus<br>Cytosol	Head and neck cancer:2.23e-7 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	spleen: 29.0	Cell line enhanced		HMC-1: 35.3;Karpas-707: 40.4;RT4: 25.9
HIVEP3	FLJ16752, KBP-1, KBP1, KIAA1555, KRC, Schnurri-3, SHN3, ZAS3, ZNF40C	ENSG00000127124	Human immunodeficiency virus type I enhancer binding protein 3	1	41506365-42035925	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005728	Approved		Supported	Nucleoplasm		Mixed	Mixed			skin: 5.6	Cell line enhanced		HDLM-2: 17.9
PPCS	FLJ11838	ENSG00000127125	Phosphopantothenoylcysteine synthetase	1	42456117-42473385	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031361, HPA031363	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Liver cancer:5.96e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 110.6	Expressed in all		
EDN2	ET2	ENSG00000127129	Endothelin 2	1	41478775-41484673	Predicted secreted proteins	Evidence at protein level	HPA028459	Uncertain		Approved	Cytosol	Endometrial cancer:2.85e-4 (unfavourable), Pancreatic cancer:5.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 10.6;small intestine: 18.1	epididymis: 5.5	Cell line enhanced		CAPAN-2: 12.3;EFO-21: 32.7;SCLC-21H: 19.7;SK-BR-3: 31.2;U-2 OS: 16.7
BCL11B	CTIP-2, CTIP2, hRIT1-alpha, ZNF856B	ENSG00000127152	B-cell CLL/lymphoma 11B	14	99169287-99271524	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049117	Enhanced	Supported	Approved	Nucleus<br>Nucleoli fibrillar center	Urothelial cancer:7.48e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 12.2;skin: 18.7	tonsil: 7.4	Cell line enriched	6	MOLT-4: 41.1
COX7C		ENSG00000127184	Cytochrome c oxidase subunit 7C	5	86617904-86620962	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046647	Approved				Renal cancer:1.23e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 821.9	Expressed in all		
TRAF2	TRAP3	ENSG00000127191	TNF receptor associated factor 2	9	136881912-136926607	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004603, HPA009972, HPA010634	Uncertain		Enhanced	Cytosol	Renal cancer:2.09e-4 (unfavourable), Liver cancer:3.06e-4 (unfavourable), Colorectal cancer:9.32e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 22.5	Expressed in all		
ABHD8	FLJ11743, MGC14280, MGC2512	ENSG00000127220	Abhydrolase domain containing 8	19	17292131-17310236	Predicted intracellular proteins	Evidence at protein level	HPA037658, HPA058209	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.04e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 28.5	Cell line enhanced		PC-3: 48.7
MASP1	CRARF, MASP, PRSS5	ENSG00000127241	Mannan binding lectin serine peptidase 1	3	187217285-187292022	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001617, HPA009641	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.20e-4 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 135.4	endometrium: 94.8	Group enriched	8	BJ: 107.2;BJ hTERT+: 389.0
ATP13A4	DKFZp761I1011, FLJ37958	ENSG00000127249	ATPase 13A4	3	193402077-193593111	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA051932			Approved	Nucleoplasm	Head and neck cancer:3.91e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 87.9;parathyroid gland: 131.5;thyroid gland: 68.5	lung: 53.7	Cell line enriched	7	SCLC-21H: 4.6
HRASLS	H-REV107, HRASLS1	ENSG00000127252	HRAS like suppressor	3	193241125-193277738	Predicted membrane proteins	Evidence at transcript level	HPA051179	Uncertain		Approved	Focal adhesion sites<br>Cytosol	Testis cancer:4.36e-4 (favourable)	Mixed	Group enriched	6	skeletal muscle: 27.2;testis: 95.8	thyroid gland: 10.0	Cell line enhanced		HAP1: 11.5;PC-3: 20.0;SCLC-21H: 22.9;U-2 OS: 12.2;U-251 MG: 12.7
HELB		ENSG00000127311	DNA helicase B	12	66302545-66347645	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			lymph node: 3.5	Mixed		
RAP1B	DKFZp586H0723, K-REV, RAL1B	ENSG00000127314	RAP1B, member of RAS oncogene family	12	68610839-68671901	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 243.9	Expressed in all		
IL22	IL-21, IL-22, IL-D110, IL-TIF, ILTIF, MGC79382, MGC79384, TIFa, TIFIL-23, zcyto18	ENSG00000127318	Interleukin 22	12	68248242-68253607	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			appendix,urinary bladder: 0.8	Not detected		
TSPAN8	CO-029, TM4SF3	ENSG00000127324	Tetraspanin 8	12	71125085-71441898	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB026009, HPA044337	Enhanced		Approved	Nucleoplasm	Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 910.6;duodenum: 905.9;rectum: 911.5;small intestine: 909.2	stomach: 573.4	Cell line enhanced		CACO-2: 36.0;HeLa: 34.8;PC-3: 151.7;RT4: 30.6
BEST3	MGC13168, MGC40411, VMD2L3	ENSG00000127325	Bestrophin 3	12	69643360-69699476	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA054582	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 16.3;skeletal muscle: 12.2	testis: 5.6	Group enriched	13	REH: 32.4;RPMI-8226: 26.4;U-698: 43.2
RAB3IP	FLJ22548, RABIN3, RABIN8	ENSG00000127328	RAB3A interacting protein	12	69738681-69823204	Predicted intracellular proteins	Evidence at protein level	HPA039794	Uncertain		Approved	Intermediate filaments	Renal cancer:5.68e-13 (favourable)	Mixed	Tissue enhanced		testis: 134.1	epididymis: 53.2	Expressed in all		
PTPRB	PTPB	ENSG00000127329	Protein tyrosine phosphatase, receptor type B	12	70515866-70637440	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004782, HPA067868	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)	Expressed in all	Mixed			lung: 54.0	Cell line enhanced		EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
DYRK2		ENSG00000127334	Dual specificity tyrosine phosphorylation regulated kinase 2	12	67648338-67665406	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027230, HPA056902	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 31.0	Expressed in all		
YEATS4	GAS41, NuBI-1, YAF9	ENSG00000127337	YEATS domain containing 4	12	69359703-69390796	Predicted intracellular proteins	Evidence at protein level	HPA072532			Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:3.52e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 69.3	Expressed in all		
TAS2R3	T2R3	ENSG00000127362	Taste 2 receptor member 3	7	141764097-141765197	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			ovary: 0.5	Not detected		
TAS2R4	T2R4	ENSG00000127364	Taste 2 receptor member 4	7	141778442-141780819	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			skin: 1.7	Not detected		
TAS2R5	T2R5	ENSG00000127366	Taste 2 receptor member 5	7	141790217-141791367	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 5.0	epididymis: 3.4	Cell line enhanced		hTCEpi: 3.8
CRYGN		ENSG00000127377	Crystallin gamma N	7	151428835-151440813	Predicted intracellular proteins	Evidence at transcript level	HPA050788	Uncertain					Tissue enriched	Group enriched	6	seminal vesicle: 10.2;thyroid gland: 32.3	parathyroid gland: 3.4	Cell line enhanced		CACO-2: 1.1;HHSteC: 1.4;SCLC-21H: 2.0
LRRC61	FLJ31392, HSPC295, MGC3036	ENSG00000127399	Leucine rich repeat containing 61	7	150322639-150338150	Predicted intracellular proteins	Evidence at transcript level	HPA019355	Approved		Approved	Nucleoplasm	Glioma:2.15e-5 (unfavourable), Stomach cancer:2.85e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 22.6	Cell line enhanced		HDLM-2: 71.3;NTERA-2: 64.8
TRPV5	CaT2, ECAC1	ENSG00000127412	Transient receptor potential cation channel subfamily V member 5	7	142908101-142933808	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA063175	Approved					Not detected	Not detected			kidney: 0.5	Not detected		
IDUA	MPS1	ENSG00000127415	Iduronidase, alpha-L-	4	986997-1004506	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025901, HPA046979, HPA054254	Enhanced		Supported	Vesicles	Renal cancer:7.87e-5 (unfavourable), Urothelial cancer:8.04e-5 (favourable), Colorectal cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.5	Cell line enhanced		U-266/70: 43.1
FGFRL1		ENSG00000127418	Fibroblast growth factor receptor-like 1	4	1009936-1026897	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB026019, HPA068828	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 67.6	Mixed		
TMEM175	MGC4618	ENSG00000127419	Transmembrane protein 175	4	932387-958656	Predicted membrane proteins, Transporters	Evidence at protein level	HPA057160	Approved		Approved	Nucleus<br>Nuclear membrane	Pancreatic cancer:9.85e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 20.7	Expressed in all		
AUNIP	AIBp, C1orf135, MGC2603	ENSG00000127423	Aurora kinase A and ninein interacting protein	1	25831913-25859458	Predicted intracellular proteins	Evidence at protein level	HPA028730	Uncertain		Enhanced	Centrosome	Endometrial cancer:3.94e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 29.0	bone marrow: 3.8	Mixed		
PIN1	dod	ENSG00000127445	Peptidylprolyl cis/trans isomerase, NIMA-interacting 1	19	9835257-9849682	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004528, CAB009326, HPA068650	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.80e-5 (favourable), Pancreatic cancer:3.25e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.9	Expressed in all		
FBXL12	Fbl12, FLJ20188	ENSG00000127452	F-box and leucine rich repeat protein 12	19	9810267-9827816	Predicted intracellular proteins	Evidence at protein level	HPA002843			Approved	Mitochondria	Liver cancer:1.41e-4 (unfavourable), Head and neck cancer:3.21e-4 (favourable), Melanoma:4.96e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 21.7	Expressed in all		
EMC1	KIAA0090	ENSG00000127463	ER membrane protein complex subunit 1	1	19215664-19251552	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048904	Approved		Approved	Microtubules<br>Cytokinetic bridge	Liver cancer:8.56e-6 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.4	Expressed in all		
PLA2G5		ENSG00000127472	Phospholipase A2 group V	1	20028179-20091190	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA053361	Approved					Group enriched	Tissue enhanced		heart muscle: 48.6	seminal vesicle: 19.8	Cell line enhanced		U-138 MG: 1.0;U-2197: 2.1
UBR4	KIAA0462, KIAA1307, RBAF600, ZUBR1	ENSG00000127481	Ubiquitin protein ligase E3 component n-recognin 4	1	19074506-19210276	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013394, HPA021046	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			skin: 90.3	Expressed in all		
HP1BP3	HP1-BP74	ENSG00000127483	Heterochromatin protein 1 binding protein 3	1	20742661-20787323	Predicted intracellular proteins	Evidence at protein level	HPA028215, HPA054295	Supported		Supported	Nuclear speckles	Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 192.4	Expressed in all		
ADGRE2	CD312, EMR2	ENSG00000127507	Adhesion G protein-coupled receptor E2	19	14732393-14778541	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA055200			Uncertain	Vesicles	Renal cancer:4.35e-6 (unfavourable)	Mixed	Tissue enhanced		appendix: 27.0;spleen: 15.4	adipose tissue: 6.0	Cell line enhanced		HEL: 10.6;HMC-1: 16.0;U-937: 11.8
SIN3B	KIAA0700	ENSG00000127511	SIN3 transcription regulator family member B	19	16829400-16880353	Predicted intracellular proteins	Evidence at protein level	HPA050329	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Prostate cancer:3.58e-4 (unfavourable), Pancreatic cancer:4.37e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.3	Expressed in all		
OR7A10		ENSG00000127515	Olfactory receptor family 7 subfamily A member 10	19	14840948-14841877	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SLC35E1	FLJ14251	ENSG00000127526	Solute carrier family 35 member E1	19	16549831-16572382	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016570, HPA062214	Approved		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 28.5	Expressed in all		
EPS15L1	eps15R	ENSG00000127527	Epidermal growth factor receptor pathway substrate 15 like 1	19	16355239-16472085	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019237, HPA055309	Uncertain		Approved	Vesicles	Renal cancer:8.10e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.0	Expressed in all		
KLF2	LKLF	ENSG00000127528	Kruppel like factor 2	19	16324817-16327874	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055964	Approved		Approved	Nucleoplasm	Liver cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 115.9	Cell line enhanced		TIME: 57.5;U-266/70: 36.1;U-266/84: 34.1
OR7C2	OR19-18, OR7C3	ENSG00000127529	Olfactory receptor family 7 subfamily C member 2	19	14941489-14942448	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047295	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR7C1	OR19-5, OR7C4	ENSG00000127530	Olfactory receptor family 7 subfamily C member 1	19	14799146-14800211	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047127	Uncertain					Tissue enriched	Tissue enhanced		epididymis: 3.5;parathyroid gland: 5.0;testis: 3.9	seminal vesicle: 1.5	Not detected		
F2RL3	PAR4	ENSG00000127533	F2R like thrombin/trypsin receptor 3	19	16888860-16892606	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:6.25e-4 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Group enriched	8	HEL: 26.3;HMC-1: 10.0
UQCR11	QCR10, UQCR	ENSG00000127540	Ubiquinol-cytochrome c reductase, complex III subunit XI	19	1597172-1605490	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.23e-4 (favourable), Renal cancer:1.65e-4 (favourable), Pancreatic cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 111.9	Expressed in all		
GFER	ALR, ERV1, HERV1, HPO1, HPO2, HSS	ENSG00000127554	Growth factor, augmenter of liver regeneration	16	1984207-1987749	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041227, HPA063553	Approved		Enhanced	Mitochondria<br>Cytosol	Renal cancer:4.06e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 50.0	Expressed in all		
SYNGR3		ENSG00000127561	Synaptogyrin 3	16	1989660-1994275	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB034278, HPA042842	Enhanced		Approved	Plasma membrane	Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable)	Mixed	Tissue enriched	7	cerebral cortex: 82.6	parathyroid gland: 12.6	Cell line enhanced		HDLM-2: 45.7;HMC-1: 26.7;U-266/70: 30.7
PKMYT1	MYT1, PPP1R126	ENSG00000127564	Protein kinase, membrane associated tyrosine/threonine 1	16	2968024-2980539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068860			Supported	Nucleus<br>Nucleoli<br>Golgi apparatus	Lung cancer:3.37e-4 (unfavourable), Liver cancer:8.33e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 17.0;testis: 27.7	lymph node: 9.7	Mixed		
WFIKKN1	C16orf12, RJD2, WFDC20A, WFIKKN	ENSG00000127578	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 1	16	629239-634116	Predicted secreted proteins	Evidence at protein level	CAB025858, HPA043362, HPA044237	Uncertain					Mixed	Not detected			cerebral cortex,endometrium,lung,spleen: 0.1	Cell line enhanced		EFO-21: 4.2;NTERA-2: 1.3
WDR24	C16orf21, DKFZp434F054, JFP7	ENSG00000127580	WD repeat domain 24	16	684622-690444	Predicted intracellular proteins	Evidence at protein level	HPA039506	Approved				Renal cancer:3.75e-6 (favourable)	Expressed in all	Expressed in all			testis: 11.8	Expressed in all		
FBXL16	C16orf22, Fbl16, MGC33974	ENSG00000127585	F-box and leucine rich repeat protein 16	16	692498-705829	Predicted intracellular proteins	Evidence at protein level	HPA039504, HPA056354	Enhanced				Endometrial cancer:6.24e-5 (unfavourable), Pancreatic cancer:7.34e-5 (favourable), Renal cancer:1.87e-4 (favourable)	Expressed in all	Tissue enriched	23	cerebral cortex: 186.4	testis: 8.0	Cell line enhanced		AN3-CA: 16.9;SCLC-21H: 35.4;SH-SY5Y: 23.8
CHTF18	C16orf41, C321D2.4, CHL12, Ctf18	ENSG00000127586	Chromosome transmission fidelity factor 18	16	788046-800737	Predicted intracellular proteins	Evidence at protein level	HPA040976, HPA056209			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.43e-8 (unfavourable), Urothelial cancer:2.78e-4 (favourable)	Expressed in all	Mixed			testis: 4.7	Cell line enhanced		BEWO: 46.5
GNG13	G(gamma)13, h2-35	ENSG00000127588	G protein subunit gamma 13	16	798041-800733	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA046272	Approved					Mixed	Tissue enhanced		cerebral cortex: 2.5;duodenum: 1.4;small intestine: 1.4	colon: 0.7	Cell line enhanced		CACO-2: 8.6;HEK 293: 8.3;MCF7: 10.0
MACF1	ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF	ENSG00000127603	Microtubule-actin crosslinking factor 1	1	39081316-39487177	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013713, HPA068064, HPA068103	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Actin filaments	Renal cancer:2.77e-5 (favourable)	Expressed in all	Expressed in all			lung: 137.2	Expressed in all		
SMARCA4	BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2	ENSG00000127616	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	19	10961001-11065395	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004208	Supported		Supported	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
KDM4B	JMJD2B, KIAA0876, TDRD14B	ENSG00000127663	Lysine demethylase 4B	19	4969113-5153595	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062872			Supported	Nucleus<br>Cytosol	Endometrial cancer:4.25e-7 (favourable), Melanoma:2.13e-4 (unfavourable), Colorectal cancer:2.74e-4 (unfavourable), Breast cancer:7.39e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 19.9	Expressed in all		
TICAM1	MGC35334, PRVTIRB, TICAM-1, TRIF	ENSG00000127666	Toll like receptor adaptor molecule 1	19	4815932-4831704	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042460	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Lung cancer:3.48e-4 (unfavourable), Endometrial cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 22.0	Mixed		
METTL25	C12orf26, FLJ22789	ENSG00000127720	Methyltransferase like 25	12	82358497-82479236	Predicted intracellular proteins	Evidence at protein level	HPA039534, HPA041207	Uncertain		Uncertain	Plasma membrane<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			testis: 10.9	Mixed		
IL17B	IL-17B, IL-20, MGC138900, MGC138901, NIRF, ZCYTO7	ENSG00000127743	Interleukin 17B	5	149371324-149404202	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA042441	Uncertain					Mixed	Tissue enhanced		breast: 4.0	smooth muscle: 3.3	Cell line enhanced		HEL: 1.2
EMC6	MGC2963, TMEM93	ENSG00000127774	ER membrane protein complex subunit 6	17	3668815-3669668	Predicted membrane proteins	Evidence at protein level	HPA062681	Uncertain		Approved	Nucleus<br>Centrosome	Lung cancer:9.39e-5 (unfavourable), Cervical cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 49.2	Expressed in all		
OR1E2	OR17-135, OR17-93, OR1E4	ENSG00000127780	Olfactory receptor family 1 subfamily E member 2	17	3432870-3433841	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
METTL16	METT10D, MGC3329	ENSG00000127804	Methyltransferase like 16	17	2405562-2511891	Predicted intracellular proteins	Evidence at protein level	HPA020352, HPA059798	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.06e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
TUBA4A	FLJ30169, H2-ALPHA, TUBA1	ENSG00000127824	Tubulin alpha 4a	2	219249711-219278170	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004621, CAB005887, HPA039247, HPA043684, HPA063394	Approved		Enhanced	Microtubules	Liver cancer:4.54e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 181.8	Cell line enhanced		HBEC3-KT: 297.7
VIL1	D2S1471, VIL	ENSG00000127831	Villin 1	2	218419092-218453295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002452, HPA006884, HPA006885	Enhanced		Enhanced	Plasma membrane		Tissue enhanced	Group enriched	7	colon: 173.7;duodenum: 398.5;rectum: 199.6;small intestine: 480.0	gallbladder: 44.7	Group enriched	91	CACO-2: 628.4;Hep G2: 245.1
AAMP		ENSG00000127837	Angio associated migratory cell protein	2	218264123-218270257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017717, HPA031868	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:4.94e-7 (unfavourable), Endometrial cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 115.1	Expressed in all		
PNKD	BRP17, DKFZp564N1362, DYT8, FKSG19, FPD1, KIAA1184, KIPP1184, MGC31943, MR-1, PDC, PKND1, TAHCCP2	ENSG00000127838	Paroxysmal nonkinesigenic dyskinesia	2	218270392-218346793	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010134, HPA017068	Approved		Enhanced	Mitochondria	Renal cancer:5.13e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 119.5	Expressed in all		
TNFRSF19	TAJ, TAJ-alpha, TRADE, TROY	ENSG00000127863	TNF receptor superfamily member 19	13	23570370-23676104	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010135			Approved	Nucleoplasm<br>Mitochondria	Renal cancer:9.13e-7 (favourable), Lung cancer:3.87e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 128.9	fallopian tube: 50.5	Cell line enhanced		BJ hTERT+: 65.9;fHDF/TERT166: 48.4;Hep G2: 58.9;SK-MEL-30: 111.1;WM-115: 86.3
RNF6	DKFZp686P0776	ENSG00000127870	Ring finger protein 6	13	26132115-26222493	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039343, HPA040048	Approved		Supported	Nuclear membrane	Cervical cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.0	Mixed		
ECHS1	SCEH	ENSG00000127884	Enoyl-CoA hydratase, short chain 1	10	133362480-133373689	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003783, HPA021995, HPA022476	Enhanced		Enhanced	Mitochondria	Renal cancer:8.57e-5 (favourable)	Expressed in all	Expressed in all			liver: 438.0	Expressed in all		
ZNF835	BC37295_3	ENSG00000127903	Zinc finger protein 835	19	56661981-56671783	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA051136	Uncertain		Approved	Microtubules		Mixed	Mixed			ovary: 5.3	Cell line enhanced		BEWO: 2.3;EFO-21: 1.9;NTERA-2: 4.7;SH-SY5Y: 2.6;U-266/84: 2.8
AKAP9	AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO	ENSG00000127914	A-kinase anchoring protein 9	7	91940867-92110673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008548, CAB012909, HPA026109	Enhanced		Enhanced	Golgi apparatus<br>Vesicles<br>Centrosome	Renal cancer:2.10e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
GNG11	GNGT11	ENSG00000127920	G protein subunit gamma 11	7	93921699-93928610	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA045255	Uncertain					Expressed in all	Expressed in all			placenta: 123.2	Cell line enhanced		EFO-21: 204.6;HUVEC TERT2: 287.9;U-87 MG: 180.8
SEM1	DSS1, ECD, SHFD1, Shfdg1, SHFM1, SHSF1	ENSG00000127922	SEM1, 26S proteasome complex subunit	7	96481626-96709891	Predicted intracellular proteins	Evidence at protein level	HPA020429, HPA072648	Uncertain		Approved	Cytosol	Urothelial cancer:8.00e-5 (favourable), Ovarian cancer:2.52e-4 (favourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 223.1	Expressed in all		
GNGT1	GNG1	ENSG00000127928	G protein subunit gamma transducin 1	7	93591573-93911265	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042721	Supported					Mixed	Tissue enriched	6	placenta: 3.9	urinary bladder: 0.6	Cell line enhanced		EFO-21: 8.7;SCLC-21H: 3.1;T-47d: 4.8
HIP1	ILWEQ	ENSG00000127946	Huntingtin interacting protein 1	7	75533300-75738962	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA013606, CAB015334, CAB016402, HPA017964	Enhanced		Enhanced	Vesicles		Expressed in all	Mixed			testis: 35.2	Mixed		
PTPN12	PTP-PEST, PTPG1	ENSG00000127947	Protein tyrosine phosphatase, non-receptor type 12	7	77537275-77640071	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007097	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.27e-6 (unfavourable), Cervical cancer:1.15e-4 (unfavourable), Pancreatic cancer:2.01e-4 (unfavourable), Liver cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.2	Expressed in all		
POR	CYPOR, FLJ26468	ENSG00000127948	Cytochrome p450 oxidoreductase	7	75899200-75986855	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004372, HPA010136	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 220.8	Expressed in all		
FGL2	pT49, T49	ENSG00000127951	Fibrinogen like 2	7	77193371-77199848	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA021011, HPA026682	Enhanced					Expressed in all	Expressed in all			spleen: 232.5	Cell line enhanced		RPTEC TERT1: 4.2;U-937: 4.7;WM-115: 6.3
STYXL1	DUSP24, MK-STYX	ENSG00000127952	Serine/threonine/tyrosine interacting like 1	7	75996338-76048004	Predicted intracellular proteins	Evidence at transcript level	HPA050261	Uncertain		Approved	Nuclear speckles	Urothelial cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 46.0	Expressed in all		
STEAP4	FLJ23153, STAMP2, TIARP, TNFAIP9	ENSG00000127954	STEAP4 metalloreductase	7	88270892-88306891	Predicted membrane proteins, Transporters	Evidence at protein level	HPA075871			Supported	Golgi apparatus	Liver cancer:2.97e-4 (favourable), Stomach cancer:5.77e-4 (unfavourable)	Tissue enhanced	Expressed in all			adipose tissue: 130.7	Group enriched	6	HSkMC: 88.7;SiHa: 126.7;U-2197: 154.7
GNAI1		ENSG00000127955	G protein subunit alpha i1	7	80133955-80219402	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022449, HPA042141	Approved		Supported	Nucleus<br>Nucleoli<br>Centrosome	Melanoma:5.09e-4 (unfavourable), Stomach cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 94.5	Mixed		
PEX1	ZWS, ZWS1	ENSG00000127980	Peroxisomal biogenesis factor 1	7	92487020-92528531	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA020235	Approved		Supported	Peroxisomes		Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
MTERF1	MTERF	ENSG00000127989	Mitochondrial transcription termination factor 1	7	91692008-91880720	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044894, HPA069560	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			lymph node: 16.4	Expressed in all		
SGCE	DYT11	ENSG00000127990	Sarcoglycan epsilon	7	94585230-94656209	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA074790			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Plasma membrane	Head and neck cancer:1.61e-5 (unfavourable), Stomach cancer:1.35e-4 (unfavourable)	Expressed in all	Mixed			ovary: 133.2	Mixed		
RBM48	C7orf64, DKFZp564O0523, HSPC304	ENSG00000127993	RNA binding motif protein 48	7	92528773-92538005	Predicted intracellular proteins	Evidence at protein level	HPA021777, HPA025306	Uncertain		Enhanced	Nucleoplasm	Liver cancer:3.17e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.8	Expressed in all		
CASD1	C7orf12, FLJ21213, FLJ21879	ENSG00000127995	CAS1 domain containing 1	7	94509219-94557019	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044404	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 38.8	Mixed		
ZNF780B	ZNF779	ENSG00000128000	Zinc finger protein 780B	19	40028260-40056209	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003311	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			thyroid gland: 8.0	Mixed		
LRFN1	KIAA1484, SALM2	ENSG00000128011	Leucine rich repeat and fibronectin type III domain containing 1	19	39306568-39315336	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.31e-5 (unfavourable), Ovarian cancer:3.13e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 5.5	spleen: 2.2	Cell line enhanced		CACO-2: 14.4;HEK 293: 19.2
ZFP36	G0S24, NUP475, RNF162A, TIS11, TTP	ENSG00000128016	ZFP36 ring finger protein	19	39406813-39409412	Predicted intracellular proteins	Evidence at transcript level	HPA006009	Approved		Approved	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			gallbladder: 928.0	Expressed in all		
SRD5A3	FLJ13352, SRD5A2L, SRD5A2L1	ENSG00000128039	Steroid 5 alpha-reductase 3	4	55346109-55373096	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027006	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 28.2	Expressed in all		
SPINK2	HUSI-II	ENSG00000128040	Serine peptidase inhibitor, Kazal type 2	4	56809860-56821742	Predicted secreted proteins	Evidence at protein level	CAB020824, HPA026813	Enhanced				Lung cancer:2.82e-4 (favourable)	Group enriched	Tissue enriched	15	epididymis: 6416.1	testis: 428.6	Cell line enhanced		Daudi: 15.0;NB-4: 11.4;U-266/70: 67.9
RASL11B		ENSG00000128045	RAS like family 11 member B	4	52862290-52866835	Predicted intracellular proteins	Evidence at transcript level	HPA057803	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		ovary: 26.0;parathyroid gland: 30.1	cerebral cortex: 13.5	Cell line enhanced		BEWO: 13.0;NTERA-2: 14.5;SH-SY5Y: 38.8
PAICS	ADE2H1, AIRC, PAIS	ENSG00000128050	Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase	4	56435741-56464579	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035895, HPA041538	Uncertain		Approved	Cytosol	Renal cancer:5.85e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable), Thyroid cancer:2.41e-4 (unfavourable), Ovarian cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.0	Expressed in all		
KDR	CD309, FLK1, VEGFR, VEGFR2	ENSG00000128052	Kinase insert domain receptor	4	55078477-55125589	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB004028	Enhanced		Supported	Plasma membrane	Renal cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 119.2	thyroid gland: 54.7	Group enriched	9	HUVEC TERT2: 178.6;TIME: 148.0
PPAT	GPAT, PRAT	ENSG00000128059	Phosphoribosyl pyrophosphate amidotransferase	4	56393362-56435615	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036091, HPA036092	Approved		Approved	Midbody ring	Liver cancer:1.14e-8 (unfavourable), Endometrial cancer:5.15e-5 (unfavourable), Thyroid cancer:1.95e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.1	Expressed in all		
TUBGCP6	DJ402G11.6, GCP6, KIAA1669	ENSG00000128159	Tubulin gamma complex associated protein 6	22	50217689-50244992	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043928	Approved				Urothelial cancer:3.18e-5 (favourable), Pancreatic cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.2	Expressed in all		
ADM2	AM2, FLJ21135	ENSG00000128165	Adrenomedullin 2	22	50481556-50486440	Predicted secreted proteins	Evidence at transcript level						Thyroid cancer:2.72e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 19.2	kidney: 5.8	Cell line enhanced		HHSteC: 30.8;Karpas-707: 27.1
DGCR6L	FLJ10666	ENSG00000128185	DiGeorge syndrome critical region gene 6-like	22	20314276-20320080	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:3.82e-5 (favourable), Lung cancer:5.37e-4 (favourable)	Expressed in all	Expressed in all			testis: 97.0	Expressed in all		
DGCR8	C22orf12, DGCRK6, Gy1, pasha	ENSG00000128191	DGCR8, microprocessor complex subunit	22	20080232-20111877	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.08e-4 (unfavourable), Renal cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
ASPHD2	FLJ39838	ENSG00000128203	Aspartate beta-hydroxylase domain containing 2	22	26429273-26445015	Predicted membrane proteins	Evidence at protein level	HPA000820	Uncertain				Renal cancer:4.06e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 12.8	stomach: 7.8	Cell line enhanced		Karpas-707: 15.8
VPREB3	8HS20	ENSG00000128218	Pre-B lymphocyte 3	22	23752743-23754468	Predicted secreted proteins	Evidence at protein level	HPA003041	Supported					Expressed in all	Tissue enhanced		lymph node: 117.3;tonsil: 95.8	spleen: 61.1	Cell line enhanced		Daudi: 168.5;REH: 255.6;U-698: 50.4
SDF2L1	AP000553.C22.4, OTTHUMT00000075032	ENSG00000128228	Stromal cell derived factor 2 like 1	22	21642261-21644298	Predicted secreted proteins	Evidence at protein level	HPA005638	Approved				Endometrial cancer:4.98e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 45.4	Expressed in all		
GAL3ST1	CST	ENSG00000128242	Galactose-3-O-sulfotransferase 1	22	30554635-30574587	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA001220	Approved		Approved	Vesicles	Renal cancer:1.79e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 18.0;duodenum: 23.2;small intestine: 27.0	kidney: 10.1	Cell line enhanced		A549: 25.1;EFO-21: 13.7
YWHAH	YWHA1	ENSG00000128245	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	22	31944461-31957603	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025918	Uncertain				Liver cancer:1.59e-5 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 896.7	lung: 137.7	Expressed in all		
RFPL1	RNF78	ENSG00000128250	Ret finger protein like 1	22	29438583-29442455	Predicted intracellular proteins	Evidence at transcript level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane		Not detected	Tissue enriched	8	cerebral cortex: 27.8	adrenal gland: 3.6	Cell line enhanced		HDLM-2: 6.6;HMC-1: 2.3;Karpas-707: 2.0;SH-SY5Y: 3.5;THP-1: 2.2
RFPL2	RNF79	ENSG00000128253	Ret finger protein like 2	22	32190435-32203477	Predicted intracellular proteins	Evidence at transcript level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane	Prostate cancer:4.16e-4 (favourable)	Tissue enriched	Tissue enriched	7	prostate: 5.8	cerebral cortex: 0.8	Not detected		
GNAZ		ENSG00000128266	G protein subunit alpha z	22	23070361-23125037	Predicted intracellular proteins	Evidence at protein level	HPA003011	Enhanced		Approved	Vesicles	Endometrial cancer:4.85e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 49.7	seminal vesicle: 23.0	Cell line enhanced		SCLC-21H: 44.4;SH-SY5Y: 24.7
MGAT3	GNT-III	ENSG00000128268	Mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase	22	39457344-39492194	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017598	Approved				Renal cancer:5.04e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 38.6	small intestine: 32.5	Cell line enhanced		BEWO: 65.1;HMC-1: 51.2;U-266/70: 57.7
ADORA2A	ADORA2, RDC8	ENSG00000128271	Adenosine A2a receptor	22	24417879-24442360	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001943, HPA065566, HPA075997	Enhanced	Supported				Not detected	Tissue enhanced		bone marrow: 24.6;lymph node: 22.7	appendix: 17.8	Cell line enhanced		Karpas-707: 36.8;SK-BR-3: 55.0;U-266/70: 38.8;U-266/84: 50.0;U-698: 37.2
ATF4	CREB-2, TAXREB67, TXREB	ENSG00000128272	Activating transcription factor 4	22	39519695-39522685	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011596	Approved		Supported	Microtubule organizing center<br>Cytosol	Renal cancer:9.77e-5 (unfavourable), Liver cancer:4.07e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 530.2	Expressed in all		
A4GALT	A14GALT, Gb3S, P(k), P1	ENSG00000128274	Alpha 1,4-galactosyltransferase	22	42692121-42721298	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA001141, HPA076542			Supported	Mitochondria	Cervical cancer:2.48e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 30.5	Mixed		
RFPL3		ENSG00000128276	Ret finger protein like 3	22	32354885-32361161	Predicted intracellular proteins	Evidence at protein level	HPA048320, HPA072380			Approved	Nuclear speckles<br>Plasma membrane		Not detected	Tissue enriched	13	testis: 3.6	prostate: 0.2	Not detected		
CDC42EP1	Borg5, CEP1, MSE55	ENSG00000128283	CDC42 effector protein 1	22	37560447-37569405	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006379	Approved		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			stomach: 106.6	Mixed		
APOL3	APOLIII, CG12-1	ENSG00000128284	Apolipoprotein L3	22	36140330-36166177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036228			Approved	Nuclear bodies<br>Mitochondria	Renal cancer:1.23e-5 (unfavourable), Breast cancer:6.82e-4 (favourable)	Expressed in all	Mixed			spleen: 64.0	Cell line enhanced		ASC TERT1: 38.5;Karpas-707: 42.5
MCHR1	GPR24, MCH1R, SLC1	ENSG00000128285	Melanin concentrating hormone receptor 1	22	40678750-40682814	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.49e-6 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 8.6	ovary: 2.1	Cell line enhanced		NTERA-2: 1.2;RH-30: 1.6;T-47d: 1.3;U-87 MG: 1.5
TPST2	TANGO13B	ENSG00000128294	Tyrosylprotein sulfotransferase 2	22	26521983-26596717	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021054	Approved				Renal cancer:2.34e-6 (unfavourable), Endometrial cancer:8.08e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 135.8	Expressed in all		
BAIAP2L2	FLJ22582, pinkbar	ENSG00000128298	BAI1 associated protein 2 like 2	22	38084889-38110670	Predicted intracellular proteins	Evidence at protein level	HPA003043	Approved					Expressed in all	Tissue enhanced		duodenum: 107.2;small intestine: 97.5	gallbladder: 27.4	Cell line enhanced		RPTEC TERT1: 22.3;SK-MEL-30: 29.5;WM-115: 29.0
MPST	MST, TST2, TUM1	ENSG00000128309	Mercaptopyruvate sulfurtransferase	22	37019635-37029822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001240	Enhanced		Approved	Mitochondria<br>Cytosol	Urothelial cancer:5.89e-4 (favourable)	Expressed in all	Mixed			duodenum: 108.8	Expressed in all		
GALR3		ENSG00000128310	Galanin receptor 3	22	37823382-37825495	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex,testis: 0.2	Not detected		
TST	RDS	ENSG00000128311	Thiosulfate sulfurtransferase	22	37010859-37020183	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003044, HPA003643, CAB009546	Enhanced		Supported	Mitochondria	Renal cancer:7.59e-6 (favourable), Urothelial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			colon: 143.5	Mixed		
APOL5	APOLV	ENSG00000128313	Apolipoprotein L5	22	35717872-35729483	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA040968	Uncertain					Tissue enriched	Not detected			skeletal muscle,testis: 0.5	Cell line enriched	12	U-698: 1.2
IGLL1	14.1, CD179B, IGL5, IGLL, IGVPB	ENSG00000128322	Immunoglobulin lambda like polypeptide 1	22	23573125-23580308	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051134, HPA071406	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	18	bone marrow: 44.2;testis: 15.8	tonsil: 1.6	Cell line enriched	39	REH: 687.9
APOL2	APOL-II	ENSG00000128335	Apolipoprotein L2	22	36226203-36239954	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001078	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:5.06e-6 (favourable)	Expressed in all	Expressed in all			gallbladder: 64.8	Expressed in all		
RAC2	EN-7	ENSG00000128340	Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)	22	37225261-37244448	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB022946, HPA047820	Approved				Renal cancer:1.06e-6 (unfavourable), Breast cancer:1.03e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 443.7	Cell line enhanced		HL-60: 579.7;HMC-1: 1246.3;U-87 MG: 600.7
LIF	CDF, DIA, HILDA	ENSG00000128342	Leukemia inhibitory factor	22	30240447-30246851	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018844, CAB025985	Approved		Enhanced	Cytosol	Renal cancer:6.78e-8 (unfavourable), Cervical cancer:9.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 75.6	urinary bladder: 42.0	Cell line enhanced		hTEC/SVTERT24-B: 111.9;U-138 MG: 121.7;U-251 MG: 77.3;U-87 MG: 95.4
C22orf23	EVG1, FLJ32787, LOC84645	ENSG00000128346	Chromosome 22 open reading frame 23	22	37943050-37953669	Predicted intracellular proteins	Evidence at protein level	HPA000650			Approved	Nucleus		Mixed	Tissue enhanced		testis: 145.1	skin: 31.0	Cell line enhanced		U-87 MG: 46.8
APOBEC3A	ARP3, PHRBN	ENSG00000128383	Apolipoprotein B mRNA editing enzyme catalytic subunit 3A	22	38952741-38992778	Predicted intracellular proteins	Evidence at protein level	HPA043237, HPA056980, HPA066719	Approved		Uncertain	Nucleoplasm		Tissue enhanced	Tissue enhanced		appendix: 29.8;bone marrow: 59.0	spleen: 19.5	Not detected		
APOBEC3F	ARP8, BK150C2.4.MRNA, KA6	ENSG00000128394	Apolipoprotein B mRNA editing enzyme catalytic subunit 3F	22	39040604-39053910	Predicted intracellular proteins	Evidence at protein level	HPA073637			Uncertain	Nucleoplasm<br>Cytosol	Urothelial cancer:8.28e-4 (favourable)	Expressed in all	Mixed			lymph node: 18.5	Mixed		
RIBC2	C22orf11, DKFZp566F0546, FLJ25720	ENSG00000128408	RIB43A domain with coiled-coils 2	22	45413691-45432496	Predicted intracellular proteins	Evidence at transcript level	HPA003210	Uncertain				Cervical cancer:7.08e-8 (favourable)	Mixed	Group enriched	8	fallopian tube: 15.9;testis: 37.3	parathyroid gland: 3.1	Cell line enhanced		SiHa: 13.9
KRT17	PCHC1	ENSG00000128422	Keratin 17	17	41619437-41624842	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000029, HPA000452, HPA000453, HPA000539, HPA045062	Enhanced		Enhanced	Intermediate filaments	Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 222.3;seminal vesicle: 226.0;urinary bladder: 322.8	prostate: 115.6	Group enriched	6	hTCEpi: 14378.7;SiHa: 8960.6
EMC4	FLJ90746, MGC24415, PIG17, TMEM85	ENSG00000128463	ER membrane protein complex subunit 4	15	34224999-34230156	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026868, HPA053440	Approved		Approved	Cell Junctions<br>Focal adhesion sites		Expressed in all	Expressed in all			epididymis: 122.1	Expressed in all		
RNF112	BFP, ZNF179	ENSG00000128482	Ring finger protein 112	17	19411125-19417276	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015970	Approved		Approved	Nuclear speckles		Tissue enriched	Tissue enhanced		cerebral cortex: 33.0	prostate: 11.0	Cell line enhanced		SCLC-21H: 7.1;SH-SY5Y: 11.1;U-87 MG: 33.6
SPECC1	CYTSB, FLJ36955, HCMOGT-1, NSP	ENSG00000128487	Sperm antigen with calponin homology and coiled-coil domains 1	17	20009344-20319026	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021421, HPA021430	Enhanced				Lung cancer:1.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.2	Cell line enhanced		SiHa: 107.9
CPA4	CPA3	ENSG00000128510	Carboxypeptidase A4	7	130293134-130324180	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021030	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Urothelial cancer:1.31e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	skin: 67.8	esophagus: 10.0	Cell line enhanced		LHCN-M2: 238.0;U-2 OS: 159.5;U-87 MG: 268.2
DOCK4	FLJ34238, KIAA0716	ENSG00000128512	Dedicator of cytokinesis 4	7	111726110-112206411	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071516			Approved	Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 31.9	lung: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 42.1;HUVEC TERT2: 67.4;TIME: 57.4
POT1	DKFZp586D211, hPot1	ENSG00000128513	Protection of telomeres 1	7	124822386-124929983	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068538			Supported	Nucleus		Expressed in all	Mixed			thyroid gland: 21.6	Expressed in all		
TAS2R16	T2R16	ENSG00000128519	Taste 2 receptor member 16	7	122994704-122995700	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ATP6V1F	ATP6S14, VATF, Vma7	ENSG00000128524	ATPase H+ transporting V1 subunit F	7	128862826-128865844	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009529, HPA048700, HPA062011	Enhanced				Renal cancer:2.49e-5 (favourable), Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 288.0	Expressed in all		
LSM8	YJR022W	ENSG00000128534	LSM8 homolog, U6 small nuclear RNA associated	7	118184032-118192824	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020116	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.46e-6 (unfavourable), Endometrial cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 52.4	Expressed in all		
CDHR3	CDH28, FLJ23834, FLJ44366	ENSG00000128536	Cadherin related family member 3	7	105876796-106033773	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011218	Uncertain		Approved	Nucleoli fibrillar center		Mixed	Tissue enriched	8	fallopian tube: 147.1	lung: 19.1	Cell line enhanced		AF22: 4.9;Daudi: 4.7;WM-115: 4.3
PRKRIP1	C114, FLJ13902, KRBOX3	ENSG00000128563	PRKR interacting protein 1 (IL11 inducible)	7	102363872-102426676	Predicted intracellular proteins	Evidence at protein level	HPA051146	Uncertain		Supported	Actin filaments<br>Cytosol	Urothelial cancer:1.94e-4 (favourable), Colorectal cancer:3.65e-4 (unfavourable), Renal cancer:4.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.7	Expressed in all		
VGF	SCG7, SgVII	ENSG00000128564	VGF nerve growth factor inducible	7	101162509-101165593	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA055177, HPA072505	Enhanced		Supported	Golgi apparatus<br>Vesicles	Endometrial cancer:4.25e-4 (unfavourable), Glioma:4.43e-4 (unfavourable)	Tissue enriched	Tissue enriched	22	cerebral cortex: 46.1	adipose tissue: 2.0	Group enriched	11	SH-SY5Y: 182.3;SK-MEL-30: 372.7;U-2 OS: 87.3;WM-115: 139.3
PODXL	Gp200, PC, PCLP	ENSG00000128567	Podocalyxin like	7	131500262-131558217	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Renal cancer:2.89e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 29.6	Cell line enhanced		fHDF/TERT166: 106.7;NTERA-2: 181.6;TIME: 168.8
FOXP2	CAGH44, SPCH1, TNRC10	ENSG00000128573	Forkhead box P2	7	114086327-114693772	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000382, HPA000383, HPA001679	Enhanced		Enhanced	Nucleoplasm		Mixed	Mixed			endometrium: 13.7	Cell line enhanced		AF22: 20.9;RH-30: 37.7
STRIP2	FAM40B, FAR11B, KIAA1170	ENSG00000128578	Striatin interacting protein 2	7	129434433-129488399	Predicted intracellular proteins	Evidence at protein level	HPA019657	Uncertain		Supported	Cytosol	Stomach cancer:5.41e-4 (favourable), Lung cancer:6.78e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 13.9;testis: 23.5	skeletal muscle: 9.7	Mixed		
IFT22	DKFZp761N0823, FLJ13225, FLJ14117, RABL5	ENSG00000128581	Intraflagellar transport 22	7	101313367-101321823	Predicted intracellular proteins	Evidence at protein level	HPA042930	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 139.6	Expressed in all		
MKLN1	TWA2	ENSG00000128585	Muskelin 1	7	131110096-131496636	Predicted intracellular proteins	Evidence at protein level	HPA022817, HPA041810	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			prostate: 26.0	Expressed in all		
DNAJB9	MDG1	ENSG00000128590	DnaJ heat shock protein family (Hsp40) member B9	7	108569568-108574850	Predicted secreted proteins	Evidence at protein level	HPA040967, HPA041553	Supported		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 113.5	Expressed in all		
FLNC	ABP-280, ABPL, FLN2	ENSG00000128591	Filamin C	7	128830377-128859274	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA006135	Enhanced		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.17e-5 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Glioma:2.14e-4 (unfavourable), Renal cancer:5.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 384.7	smooth muscle: 160.7	Cell line enhanced		BJ: 331.0;hTEC/SVTERT24-B: 190.2;U-2 OS: 169.5
LRRC4	NAG14	ENSG00000128594	Leucine rich repeat containing 4	7	128027071-128032107	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051100			Approved	Golgi apparatus	Renal cancer:6.98e-4 (favourable), Endometrial cancer:8.19e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 52.8	parathyroid gland: 13.1	Group enriched	9	AF22: 16.3;NTERA-2: 36.7;REH: 32.0;SCLC-21H: 22.0;SH-SY5Y: 12.3
CALU		ENSG00000128595	Calumenin	7	128739292-128771807	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006018	Supported		Supported	Endoplasmic reticulum	Renal cancer:1.30e-11 (unfavourable), Urothelial cancer:4.60e-5 (unfavourable), Liver cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 444.9	Expressed in all		
CCDC136	DKFZP434G156, KIAA1793, NAG6	ENSG00000128596	Coiled-coil domain containing 136	7	128790757-128822132	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010647, HPA071015	Enhanced		Approved	Nucleoli		Mixed	Tissue enriched	7	testis: 308.5	cerebral cortex: 44.2	Cell line enhanced		U-87 MG: 29.4;U-937: 36.3
SMO	FZD11, SMOH	ENSG00000128602	Smoothened, frizzled class receptor	7	129188872-129213545	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011446	Approved					Expressed in all	Mixed			ovary: 30.4	Cell line enhanced		AN3-CA: 84.8;NTERA-2: 69.7
IRF5		ENSG00000128604	Interferon regulatory factor 5	7	128937612-128950035	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046700	Enhanced					Expressed in all	Mixed			spleen: 23.9	Cell line enhanced		HDLM-2: 121.5;RPMI-8226: 65.7;U-937: 50.3
LRRC17	H_RG318M05.3, P37NB	ENSG00000128606	Leucine rich repeat containing 17	7	102912991-102944949	Predicted secreted proteins	Evidence at protein level	HPA030139			Approved	Nucleoplasm<br>Nuclear speckles<br>Plasma membrane	Renal cancer:4.12e-6 (unfavourable), Urothelial cancer:6.30e-4 (unfavourable)	Mixed	Tissue enhanced		ovary: 99.1	gallbladder: 46.8	Group enriched	5	LHCN-M2: 1100.6;RH-30: 248.7
KLHDC10	KIAA0265, slim	ENSG00000128607	Kelch domain containing 10	7	130070510-130135720	Predicted intracellular proteins	Evidence at protein level	HPA020119	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 69.5	Expressed in all		
NDUFA5	B13, CI-13kB, CI-13KD-B, NUFM, UQOR13	ENSG00000128609	NADH:ubiquinone oxidoreductase subunit A5	7	123536997-123558255	Predicted intracellular proteins	Evidence at protein level	HPA043175	Supported				Renal cancer:3.99e-9 (favourable), Breast cancer:8.47e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 250.6	Expressed in all		
FEZF1	ZNF312B	ENSG00000128610	FEZ family zinc finger 1	7	122301394-122310691	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064639, HPA073693	Approved		Supported	Nucleus<br>Cytosol		Mixed	Tissue enriched	44	testis: 7.0	adipose tissue,cerebral cortex: 0.1	Group enriched	10	NTERA-2: 161.5;SCLC-21H: 82.6
OPN1SW	BCP, BOP, CBT	ENSG00000128617	Opsin 1, short wave sensitive	7	128772491-128775790	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013562, HPA014083	Enhanced				Renal cancer:2.26e-8 (unfavourable), Stomach cancer:5.98e-8 (unfavourable), Liver cancer:8.50e-5 (unfavourable), Urothelial cancer:9.33e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 6.7	Cell line enhanced		U-87 MG: 64.7
MRPS12	RPMS12, RPS12, RPSM12	ENSG00000128626	Mitochondrial ribosomal protein S12	19	38930548-38933162	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046775, HPA050633	Uncertain					Expressed in all	Expressed in all			duodenum: 12.0	Expressed in all		
MYO1B	myr1	ENSG00000128641	Myosin IB	2	191245185-191425389	Predicted intracellular proteins	Evidence at protein level	HPA013607, HPA060144	Approved		Enhanced	Plasma membrane	Renal cancer:2.36e-5 (unfavourable)	Expressed in all	Mixed			liver: 130.2	Cell line enhanced		hTERT-HME1: 276.9
HOXD1	HOX4, HOX4G	ENSG00000128645	Homeobox D1	2	176188579-176190907	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040062, HPA056900			Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		epididymis: 8.7;fallopian tube: 7.3	lung: 4.5	Cell line enhanced		EFO-21: 5.9;RPTEC TERT1: 15.3;RT4: 12.7;SCLC-21H: 6.3
HOXD3	HOX1D, HOX4, HOX4A	ENSG00000128652	Homeobox D3	2	176136612-176173102	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051831, HPA063671			Enhanced	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Tissue enriched	6	epididymis: 46.7	fallopian tube: 8.0	Cell line enhanced		EFO-21: 7.4;HSkMC: 6.6;RPTEC TERT1: 7.3;SCLC-21H: 16.3;SH-SY5Y: 9.8
MTX2		ENSG00000128654	Metaxin 2	2	176269395-176338025	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031550, HPA031551, HPA031552	Approved	Approved	Supported	Nucleoli<br>Mitochondria	Endometrial cancer:5.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 116.5	Mixed		
PDE11A		ENSG00000128655	Phosphodiesterase 11A	2	177623252-178108339	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034560	Approved					Tissue enhanced	Tissue enhanced		parathyroid gland: 10.5;prostate: 8.8	testis: 6.4	Cell line enhanced		fHDF/TERT166: 2.2;Hep G2: 2.0
CHN1	ARHGAP2, CHN, DURS2, n-chimerin, RhoGAP2	ENSG00000128656	Chimerin 1	2	174799363-175005369	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036111			Approved	Cytosol	Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Group enriched	7	cerebral cortex: 639.0;parathyroid gland: 133.3	placenta: 56.0	Cell line enhanced		BJ hTERT+: 172.5
GAD1	GAD	ENSG00000128683	Glutamate decarboxylase 1	2	170813213-170861151	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004415, HPA031949, HPA058412, CAB078176	Enhanced	Supported	Approved	Vesicles	Cervical cancer:7.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)	Tissue enhanced	Tissue enriched	6	cerebral cortex: 75.3	parathyroid gland: 11.8	Cell line enhanced		HEL: 55.7
OSGEPL1	OSGEPL, Qri7	ENSG00000128694	O-sialoglycoprotein endopeptidase like 1	2	189746660-189763227	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030693	Uncertain		Enhanced	Mitochondria	Ovarian cancer:3.19e-4 (favourable), Liver cancer:3.71e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
ORMDL1		ENSG00000128699	ORMDL sphingolipid biosynthesis regulator 1	2	189770323-189784371	Predicted membrane proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Renal cancer:5.84e-9 (unfavourable), Urothelial cancer:1.49e-5 (favourable), Ovarian cancer:3.04e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 155.0	Expressed in all		
HAT1	KAT1	ENSG00000128708	Histone acetyltransferase 1	2	171922448-171983682	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036788, CAB037191	Enhanced		Enhanced	Nucleoplasm	Liver cancer:5.72e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 56.3	Expressed in all		
HOXD9	HOX4, HOX4C	ENSG00000128709	Homeobox D9	2	176122720-176124937	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068683			Supported	Nucleus<br>Nucleoli	Liver cancer:1.08e-5 (unfavourable), Colorectal cancer:8.25e-4 (unfavourable), Head and neck cancer:9.58e-4 (favourable)	Expressed in all	Tissue enhanced		endometrium: 45.4	smooth muscle: 23.7	Cell line enhanced		HEK 293: 14.8;RPTEC TERT1: 14.2;SH-SY5Y: 23.1;TIME: 13.8
HOXD10	HOX4, HOX4D	ENSG00000128710	Homeobox D10	2	176108790-176119942	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065871			Approved	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:1.92e-6 (unfavourable)	Mixed	Tissue enhanced		endometrium: 48.3;smooth muscle: 25.2	kidney: 12.7	Cell line enhanced		HEK 293: 36.4;RPTEC TERT1: 21.3;SCLC-21H: 12.9;SiHa: 17.8;U-251 MG: 11.0
HOXD11	HOX4, HOX4F	ENSG00000128713	Homeobox D11	2	176104216-176109754	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055155			Approved	Nucleoplasm		Mixed	Tissue enhanced		endometrium: 4.2	seminal vesicle: 1.3	Cell line enhanced		HEK 293: 18.4;SCLC-21H: 7.0;U-251 MG: 3.8
HOXD13	HOX4I, SPD	ENSG00000128714	Homeobox D13	2	176092891-176095938	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064064			Supported	Nucleus	Colorectal cancer:6.95e-5 (unfavourable)	Mixed	Group enriched	8	cervix, uterine: 7.9;colon: 4.9;prostate: 16.9;rectum: 9.5;seminal vesicle: 24.5	urinary bladder: 1.5	Cell line enhanced		HAP1: 20.6;HEK 293: 52.3;HL-60: 52.4;NB-4: 24.7;SCLC-21H: 19.3
HERC2	D15F37S1, jdf2, p528	ENSG00000128731	HECT and RLD domain containing E3 ubiquitin protein ligase 2	15	28111040-28322152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017188, HPA048389	Approved		Approved	Vesicles	Renal cancer:1.41e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Cell line enhanced		HEL: 48.6
SNRPN	HCERN3, PWCR, RT-LI, SM-D, SMN, SNRNP-N, SNURF-SNRPN	ENSG00000128739	Small nuclear ribonucleoprotein polypeptide N	15	24823637-24978723	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003482, HPA067842	Approved		Supported	Nucleoplasm	Renal cancer:8.93e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 515.1	Cell line enhanced		NTERA-2: 762.8
PSMG2	CLAST3, HCCA3, HsT1707, MDS003, MGC15092, PAC2, TNFSF5IP1	ENSG00000128789	Proteasome assembly chaperone 2	18	12658043-12725740	Predicted intracellular proteins	Evidence at protein level	HPA041517, HPA046741	Uncertain		Approved	Nucleus<br>Nuclear bodies	Ovarian cancer:3.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 172.4	Expressed in all		
TWSG1	TSG	ENSG00000128791	Twisted gastrulation BMP signaling modulator 1	18	9334767-9402420	Predicted secreted proteins	Evidence at protein level	HPA014898	Uncertain		Supported	Centrosome<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 116.3	Expressed in all		
ARHGAP22	RhoGAP2	ENSG00000128805	Rho GTPase activating protein 22	10	48446034-48656265	Predicted intracellular proteins	Evidence at protein level	CAB020696, HPA040391, HPA064439	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.16e-8 (unfavourable)	Mixed	Mixed			cerebral cortex: 8.0	Cell line enhanced		LHCN-M2: 53.6;TIME: 56.1;U-87 MG: 81.1
WDFY4	C10orf64, Em:AC060234.3, FLJ45748, KIAA1607	ENSG00000128815	WDFY family member 4	10	48684876-48982956	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040634	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		lymph node: 33.0;spleen: 23.8	tonsil: 22.1	Cell line enhanced		Daudi: 43.5;HDLM-2: 52.1;HL-60: 17.1;U-698: 17.8;U-937: 19.6
EIF2AK4	GCN2, KIAA1338	ENSG00000128829	Eukaryotic translation initiation factor 2 alpha kinase 4	15	39934146-40035591	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011811	Approved		Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 54.3	Expressed in all		
MYO5C	MGC74969	ENSG00000128833	Myosin VC	15	52192322-52295798	Predicted intracellular proteins	Evidence at protein level	CAB020790, HPA032115, HPA032116	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:2.47e-5 (favourable), Endometrial cancer:5.18e-5 (favourable), Stomach cancer:5.82e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Cell line enhanced		MCF7: 35.3;SK-BR-3: 25.4;T-47d: 38.5
CGNL1	FLJ14957, JACOP, KIAA1749, PCING	ENSG00000128849	Cingulin like 1	15	57375967-57550727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB013500, HPA056911, HPA069214	Enhanced		Approved	Cell Junctions	Renal cancer:1.37e-6 (favourable), Endometrial cancer:3.55e-4 (favourable), Liver cancer:5.58e-4 (favourable)	Expressed in all	Mixed			kidney: 73.1	Cell line enhanced		AF22: 12.9;HUVEC TERT2: 43.8;TIME: 26.5
TMOD2	NTMOD	ENSG00000128872	Tropomodulin 2	15	51751561-51816368	Predicted intracellular proteins	Evidence at protein level	HPA041365	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Pancreatic cancer:4.53e-4 (favourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 111.0	seminal vesicle: 11.7	Cell line enhanced		SCLC-21H: 43.4
TTBK2	KIAA0847, SCA11	ENSG00000128881	Tau tubulin kinase 2	15	42738734-42920809	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018113, HPA049866	Approved		Uncertain	Intermediate filaments		Mixed	Tissue enhanced		testis: 61.5	cerebral cortex: 16.6	Mixed		
ELL3	FLJ22637	ENSG00000128886	Elongation factor for RNA polymerase II 3	15	43772600-43777543	Predicted intracellular proteins	Evidence at protein level	HPA028938	Approved		Supported	Nucleoplasm<br>Nucleoli		Mixed	Tissue enhanced		testis: 9.9	lymph node: 4.3	Cell line enhanced		Daudi: 5.3;SCLC-21H: 3.8;U-698: 12.4
C15orf57	CCDC32, MGC20481	ENSG00000128891	Chromosome 15 open reading frame 57	15	40528683-40565057	Predicted intracellular proteins	Evidence at protein level	HPA041688	Uncertain		Approved	Nuclear speckles<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 35.2	Expressed in all		
INO80	hINO80, Ino80, INO80A, INOC1, KIAA1259	ENSG00000128908	INO80 complex subunit	15	40978880-41116354	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041417, HPA041484			Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
ICE2	BRCC1, FLJ11896, NARG2	ENSG00000128915	Interactor of little elongation complex ELL subunit 2	15	60419609-60479160	Predicted intracellular proteins	Evidence at protein level	HPA040058			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.0	Expressed in all		
DLL4		ENSG00000128917	Delta like canonical Notch ligand 4	15	40929340-40939072	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA023392	Uncertain				Cervical cancer:3.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 28.6	lung: 16.4	Group enriched	14	BJ hTERT+: 48.7;HUVEC TERT2: 13.2;SCLC-21H: 37.4
ALDH1A2	RALDH2	ENSG00000128918	Aldehyde dehydrogenase 1 family member A2	15	57953424-58497866	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010022	Approved					Mixed	Tissue enhanced		endometrium: 118.1;fallopian tube: 108.9	testis: 96.9	Group enriched	6	AN3-CA: 352.0;HEK 293: 116.8;K-562: 305.3;MOLT-4: 330.5
MINDY2	FAM63B, KIAA1164	ENSG00000128923	MINDY lysine 48 deubiquitinase 2	15	58771192-58861900	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051103, HPA063669	Approved		Enhanced	Nucleoplasm	Renal cancer:3.00e-8 (favourable)	Expressed in all	Mixed			thyroid gland: 16.3	Expressed in all		
IVD	ACAD2	ENSG00000128928	Isovaleryl-CoA dehydrogenase	15	40405795-40435947	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041391, HPA044250	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.91e-9 (favourable), Liver cancer:1.95e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.7	Mixed		
KNSTRN	C15orf23, FLJ14502, kinastrin, SKAP, TRAF4AF1	ENSG00000128944	Kinetochore localized astrin/SPAG5 binding protein	15	40382721-40394246	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042027	Enhanced		Supported	Microtubules<br>Mitotic spindle<br>Cytosol	Renal cancer:7.88e-9 (unfavourable), Pancreatic cancer:3.43e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 113.9	thyroid gland: 64.1	Expressed in all		
DUT	dUTPase	ENSG00000128951	Deoxyuridine triphosphatase	15	48331011-48343373	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054422, HPA060360	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 114.3	Expressed in all		
CHAC1	MGC4504	ENSG00000128965	ChaC glutathione specific gamma-glutamylcyclotransferase 1	15	40952962-40956519	Predicted intracellular proteins	Evidence at protein level	HPA042708, HPA043505	Approved				Renal cancer:2.23e-7 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 25.5	pancreas: 14.5	Cell line enhanced		BJ hTERT+: 88.7;HHSteC: 67.5;hTCEpi: 94.1;SK-MEL-30: 73.8
CLN6	FLJ20561, HsT18960, nclf	ENSG00000128973	Ceroid-lipofuscinosis, neuronal 6, late infantile, variant	15	68206992-68257211	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066046, HPA074162	Approved		Approved	Vesicles	Renal cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			appendix: 19.8	Expressed in all		
ARPP19	ARPP-16, ARPP-19, ARPP16, ENSAL	ENSG00000128989	CAMP regulated phosphoprotein 19	15	52547045-52569883	Predicted intracellular proteins	Evidence at protein level	HPA056851	Approved				Renal cancer:1.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 510.5	Expressed in all		
VPS13C	FLJ10381, FLJ20136, KIAA1421	ENSG00000129003	Vacuolar protein sorting 13 homolog C	15	61852389-62060473	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043507	Uncertain		Approved	Microtubules		Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
CALML4	MGC4809, NY-BR-20	ENSG00000129007	Calmodulin like 4	15	68190705-68206110	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA051109	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		duodenum: 79.8;small intestine: 74.4	colon: 58.5	Mixed		
ISLR	HsT17563	ENSG00000129009	Immunoglobulin superfamily containing leucine rich repeat	15	74173671-74176872	Predicted secreted proteins	Evidence at protein level	HPA040326, HPA050811	Approved		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:4.89e-8 (unfavourable)	Expressed in all	Mixed			endometrium: 198.8	Cell line enhanced		ASC diff: 85.5;ASC TERT1: 46.5;fHDF/TERT166: 227.9;RPMI-8226: 63.5
THAP10		ENSG00000129028	THAP domain containing 10	15	70881342-70892785	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041416	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.05e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.0	Cell line enhanced		U-2197: 36.6
LOXL1	LOL, LOXL	ENSG00000129038	Lysyl oxidase like 1	15	73925989-73952137	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042111, HPA063583	Approved		Approved	Endoplasmic reticulum	Glioma:1.33e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 16.8	Cell line enhanced		BJ hTERT+: 61.2
ACKR4	CCBP2, CCR11, CCRL1, CCX-CKR, PPR1, VSHK1	ENSG00000129048	Atypical chemokine receptor 4	3	132597237-132618967	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA054926			Approved	Vesicles<br>Mitochondria		Mixed	Mixed			duodenum: 19.1	Cell line enriched	6	BJ hTERT+: 281.6
ANAPC13	APC13, DKFZP566D193, SWM1	ENSG00000129055	Anaphase promoting complex subunit 13	3	134477706-134486716	Predicted intracellular proteins	Evidence at protein level	HPA046114	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:2.66e-7 (favourable), Cervical cancer:1.66e-4 (favourable), Liver cancer:1.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 155.1	Expressed in all		
MBD4	MED1	ENSG00000129071	Methyl-CpG binding domain 4, DNA glycosylase	3	129430944-129440179	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002031	Supported		Supported	Nuclear speckles	Renal cancer:2.73e-6 (unfavourable), Pancreatic cancer:2.18e-4 (unfavourable), Prostate cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 76.6	Expressed in all		
COPB1	COPB	ENSG00000129083	Coatomer protein complex subunit beta 1	11	14443440-14500027	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012338, HPA043954, HPA064403	Supported		Enhanced	Golgi apparatus<br>Vesicles<br>Cytosol	Liver cancer:5.63e-7 (unfavourable), Head and neck cancer:6.91e-4 (unfavourable), Pancreatic cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 132.5	Expressed in all		
PSMA1	HC2, MGC14542, MGC14575, MGC14751, MGC1667, MGC21459, MGC22853, MGC23915, NU, PROS30	ENSG00000129084	Proteasome subunit alpha 1	11	14504874-14643635	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB033765, HPA037646, HPA043891	Supported		Enhanced	Nucleoplasm	Renal cancer:4.03e-11 (unfavourable), Liver cancer:3.79e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 120.9	Expressed in all		
SUMF2	DKFZp566I1024	ENSG00000129103	Sulfatase modifying factor 2	7	56064002-56080670	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024040, CAB025743, HPA074892	Enhanced		Uncertain	Vesicles<br>Plasma membrane	Cervical cancer:6.58e-6 (unfavourable), Endometrial cancer:3.96e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 160.7	Expressed in all		
PALLD	CGI-151, KIAA0992, SIH002	ENSG00000129116	Palladin, cytoskeletal associated protein	4	168497066-168928457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035905, CAB070159	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Urothelial cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 444.9	Cell line enhanced		LHCN-M2: 240.0
SPCS3	FLJ22649, PRO3567, SPC22/23, SPC3, YLR066W	ENSG00000129128	Signal peptidase complex subunit 3	4	176319964-176332245	Predicted intracellular proteins	Evidence at protein level	HPA053180	Approved				Endometrial cancer:8.89e-6 (favourable), Pancreatic cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 104.1	Expressed in all		
BBOX1	BBH, BBOX, G-BBH, gamma-BBH	ENSG00000129151	Gamma-butyrobetaine hydroxylase 1	11	27040725-27127809	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007600, HPA027823	Enhanced	Approved			Renal cancer:1.45e-5 (favourable), Endometrial cancer:6.65e-4 (unfavourable)	Group enriched	Tissue enriched	7	kidney: 473.0	liver: 66.1	Cell line enhanced		hTCEpi: 9.6;RPTEC TERT1: 6.3
MYOD1	bHLHc1, MYF3, MYOD, PUM	ENSG00000129152	Myogenic differentiation 1	11	17719568-17722131	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051362			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Tissue enhanced	Tissue enriched	10	skeletal muscle: 9.0	prostate: 0.9	Cell line enriched	17	RH-30: 447.0
SERGEF	DelGEF, Gnefr	ENSG00000129158	Secretion regulating guanine nucleotide exchange factor	11	17788048-18013162	Predicted intracellular proteins	Evidence at protein level	HPA037811, HPA037812, HPA074086	Supported		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:7.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 52.9	Expressed in all		
KCNC1	Kv3.1	ENSG00000129159	Potassium voltage-gated channel subfamily C member 1	11	17734774-17856804	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA047634, HPA048249	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 18.6	testis: 2.2	Cell line enhanced		RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
TPH1	TPH, TPRH	ENSG00000129167	Tryptophan hydroxylase 1	11	18017564-18042426	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010767, HPA022483	Enhanced		Uncertain	Cytosol		Mixed	Group enriched	6	colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5	prostate: 2.4	Mixed		
CSRP3	CLP, CMD1M, MLP	ENSG00000129170	Cysteine and glycine rich protein 3	11	19182030-19210573	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042581	Enhanced					Tissue enriched	Group enriched	25	heart muscle: 1501.4;skeletal muscle: 467.9	prostate: 40.1	Not detected		
E2F8	FLJ23311	ENSG00000129173	E2F transcription factor 8	11	19224063-19241620	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064882			Supported	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Mixed			bone marrow: 9.2	Mixed		
DCTD		ENSG00000129187	DCMP deaminase	4	182890060-182917936	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035894	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.81e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 167.0	Expressed in all		
SOX15	SOX20, SOX26, SOX27	ENSG00000129194	SRY-box 15	17	7588178-7590170	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067196, HPA074049	Enhanced		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		skin: 40.5	esophagus: 17.5	Group enriched	8	A-431: 108.6;HaCaT: 120.2;HBEC3-KT: 39.0;hTCEpi: 38.2
FAM64A	CATS, FLJ10156, FLJ10491, RCS1	ENSG00000129195	Family with sequence similarity 64 member A	17	6444415-6451469	Predicted intracellular proteins	Evidence at protein level	HPA043783, HPA049934	Uncertain		Enhanced	Nucleus		Mixed	Mixed			spleen: 6.2	Cell line enhanced		AF22: 158.0
RPAIN	hRIP, MGC4189, RIP	ENSG00000129197	RPA interacting protein	17	5419641-5432876	Predicted intracellular proteins	Evidence at protein level	HPA023924, HPA031526	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Prostate cancer:4.41e-5 (unfavourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.7	Expressed in all		
USP6	HRP1, Tre-2, TRE17, Tre2, TRESMCR	ENSG00000129204	Ubiquitin specific peptidase 6	17	5116438-5175034	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Tissue enriched	Group enriched	5	ovary: 3.5;skeletal muscle: 7.5;testis: 17.1	smooth muscle: 1.8	Mixed		
SHBG	ABP, MGC126834, MGC138391, TEBG	ENSG00000129214	Sex hormone binding globulin	17	7613946-7633383	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		liver: 33.0;testis: 13.7	small intestine: 7.4	Cell line enhanced		ASC diff: 3.0;HSkMC: 3.1
PLD2		ENSG00000129219	Phospholipase D2	17	4807096-4823434	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA013397	Approved					Expressed in all	Expressed in all			esophagus: 42.5	Mixed		
AIPL1	LCA4	ENSG00000129221	Aryl hydrocarbon receptor interacting protein like 1	17	6393693-6435199	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026578	Supported		Uncertain	Nucleoplasm<br>Cytosol		Tissue enriched	Not detected			testis: 0.8	Cell line enhanced		HaCaT: 1.3
CD68	DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1	ENSG00000129226	CD68 molecule	17	7579467-7582113	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000051, CAB000066, HPA048982, CAB072861, CAB072862	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (unfavourable)	Mixed	Expressed in all			lung: 532.4	Expressed in all		
TXNDC17	MGC14353, TRP14, TXNL5	ENSG00000129235	Thioredoxin domain containing 17	17	6640758-6644541	Predicted intracellular proteins	Evidence at protein level	HPA022931	Approved				Renal cancer:1.15e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 70.0	Expressed in all		
ATP1B2	AMOG	ENSG00000129244	ATPase Na+/K+ transporting subunit beta 2	17	7646627-7657768	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010698	Enhanced				Pancreatic cancer:1.05e-4 (favourable), Renal cancer:4.17e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 339.2	ovary: 36.7	Cell line enhanced		AF22: 9.7;HAP1: 3.1;K-562: 4.2
FXR2	FMR1L2	ENSG00000129245	FMR1 autosomal homolog 2	17	7591230-7614871	Predicted intracellular proteins	Evidence at protein level	CAB011205, HPA022997	Supported		Supported	Cytosol	Pancreatic cancer:3.49e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.4	Mixed		
KIF1C	SAX2, SPAX2, SPG58	ENSG00000129250	Kinesin family member 1C	17	4997948-5028401	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024602, HPA045020	Approved				Renal cancer:2.26e-9 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 193.6	Expressed in all		
MPDU1	CDGIf, Lec35, PQLC5, SL15	ENSG00000129255	Mannose-P-dolichol utilization defect 1	17	7583529-7592789	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014845	Uncertain		Supported	Endoplasmic reticulum<br>Mitochondria		Expressed in all	Expressed in all			rectum: 67.3	Expressed in all		
PHF20L1	CGI-72, FLJ13649, FLJ21615, MGC64923, TDRD20B	ENSG00000129292	PHD finger protein 20-like 1	8	132775358-132848807	Predicted intracellular proteins	Evidence at protein level	HPA025060, HPA028417	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
LRRC6	CILD19, LRTP, TSLRP	ENSG00000129295	Leucine rich repeat containing 6	8	132571953-132675617	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028058	Approved				Thyroid cancer:5.98e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 31.3;testis: 46.9	kidney: 12.6	Cell line enhanced		RPTEC TERT1: 12.0
CCNT1	CCNT, CYCT1, HIVE1	ENSG00000129315	Cyclin T1	12	48688458-48716998	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004892, CAB009016	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 20.1	Expressed in all		
PUS7L	DKFZP434G1415	ENSG00000129317	Pseudouridylate synthase 7 like	12	43718993-43758817	Predicted intracellular proteins	Evidence at protein level	HPA056203, HPA058750	Uncertain		Supported	Nuclear speckles		Expressed in all	Mixed			parathyroid gland: 9.8	Expressed in all		
KRI1	FLJ12949	ENSG00000129347	KRI1 homolog	19	10553078-10566037	Predicted intracellular proteins	Evidence at protein level	HPA043110, HPA043574	Approved		Enhanced	Nucleoli	Renal cancer:4.89e-10 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Colorectal cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 26.6	Expressed in all		
ILF3	DRBP76, MPHOSPH4, MPP4, NF90, NFAR-1	ENSG00000129351	Interleukin enhancer binding factor 3	19	10654261-10692417	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001897	Supported		Supported	Nucleoplasm<br>Nucleoli<br>Mitochondria	Melanoma:1.57e-4 (unfavourable), Renal cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.4	Expressed in all		
SLC44A2	CTL2	ENSG00000129353	Solute carrier family 44 member 2	19	10602457-10644559	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003228, HPA070799	Approved		Approved	Vesicles<br>Cell Junctions	Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 226.1	Mixed		
AP1M2	AP1-mu2, HSMU1B, mu2	ENSG00000129354	Adaptor related protein complex 1 mu 2 subunit	19	10572671-10587315	Predicted intracellular proteins	Evidence at protein level	HPA054999			Supported	Vesicles	Renal cancer:3.73e-6 (favourable), Endometrial cancer:2.07e-4 (favourable)	Mixed	Mixed			thyroid gland: 98.3	Cell line enhanced		Hep G2: 212.3;MCF7: 206.6;U-2 OS: 174.7
CDKN2D	INK4D, p19	ENSG00000129355	Cyclin dependent kinase inhibitor 2D	19	10566462-10569059	Predicted intracellular proteins	Evidence at protein level	CAB011201, HPA043546	Enhanced		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:1.02e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 181.1	cerebral cortex: 61.3	Expressed in all		
MTUS1	ATBP, ATIP1, DKFZp586D1519, FLJ14295, ICIS, KIAA1288, MP44, MTSG1	ENSG00000129422	Microtubule associated tumor suppressor 1	8	17643795-17800917	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067903, HPA069795			Enhanced	Nucleoli<br>Microtubules	Colorectal cancer:1.05e-4 (favourable), Renal cancer:2.76e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 128.1	Cell line enhanced		A549: 104.4;AN3-CA: 92.7;HUVEC TERT2: 247.3
KLK14	KLK-L6	ENSG00000129437	Kallikrein related peptidase 14	19	51077495-51084245	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026228	Uncertain					Tissue enhanced	Tissue enriched	5	skin: 10.4	breast: 2.0	Cell line enhanced		HaCaT: 8.7;U-266/84: 3.7
SIGLEC9	CD329	ENSG00000129450	Sialic acid binding Ig like lectin 9	19	51124908-51136651	Predicted membrane proteins	Evidence at protein level	HPA010682	Uncertain				Renal cancer:6.17e-5 (unfavourable)	Mixed	Tissue enhanced		appendix: 24.7;spleen: 23.5	lung: 12.2	Group enriched	7	Karpas-707: 16.8;RPMI-8226: 11.4
KLK10	NES1, PRSSL1	ENSG00000129451	Kallikrein related peptidase 10	19	51012739-51020175	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA017195			Uncertain	Plasma membrane<br>Cytosol	Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 138.2;skin: 52.7	tonsil: 45.8	Group enriched	5	CAPAN-2: 200.9;HaCaT: 307.2
KLK8	HNP, neuropsin, ovasin, PRSS19, TADG14	ENSG00000129455	Kallikrein related peptidase 8	19	50996007-51002711	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB019393, HPA035761	Enhanced		Approved	Vesicles	Pancreatic cancer:1.10e-4 (unfavourable), Endometrial cancer:2.31e-4 (unfavourable), Lung cancer:5.72e-4 (unfavourable), Urothelial cancer:6.17e-4 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 77.9;fallopian tube: 20.9;skin: 96.8	breast: 11.0	Group enriched	7	A-431: 76.9;CAPAN-2: 98.5;HaCaT: 73.3
NGDN	C14orf120, CANu1, DKFZP564O092, LCP5, lpd-2, NGD	ENSG00000129460	Neuroguidin	14	23469688-23509862	Predicted intracellular proteins	Evidence at protein level	HPA000944	Approved		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			endometrium: 55.2	Expressed in all		
RIPK3	RIP3	ENSG00000129465	Receptor interacting serine/threonine kinase 3	14	24336021-24340045	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055087	Uncertain					Mixed	Mixed			small intestine: 25.1	Cell line enhanced		CAPAN-2: 11.3;HDLM-2: 6.9;SK-BR-3: 15.6
ADCY4	AC4	ENSG00000129467	Adenylate cyclase 4	14	24318349-24335093	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB005070, HPA048344	Approved				Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 21.1	lung: 11.6	Group enriched	6	HUVEC TERT2: 7.8;TIME: 3.1
RAB2B	FLJ14824	ENSG00000129472	RAB2B, member RAS oncogene family	14	21459020-21476973	Predicted intracellular proteins	Evidence at protein level	HPA050292	Uncertain					Expressed in all	Expressed in all			prostate: 19.1	Expressed in all		
BCL2L2	BCL-W, KIAA0271, PPP1R51	ENSG00000129473	BCL2 like 2	14	23298790-23311759	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB040539	Approved				Renal cancer:1.99e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 88.8	Expressed in all		
AJUBA	JUB, MGC15563	ENSG00000129474	Ajuba LIM protein	14	22971174-22982642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006171	Approved		Approved	Nucleus<br>Golgi apparatus	Pancreatic cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 73.7	placenta: 28.0	Mixed		
DTD2	C14orf126, MGC9912	ENSG00000129480	D-tyrosyl-tRNA deacylase 2 (putative)	14	31446036-31457510	Predicted intracellular proteins	Evidence at protein level	HPA001117	Approved		Approved	Vesicles	Urothelial cancer:5.74e-6 (unfavourable), Head and neck cancer:9.33e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.8	Expressed in all		
PARP2	ADPRTL2	ENSG00000129484	Poly(ADP-ribose) polymerase 2	14	20343582-20357905	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA052003	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 46.3	Expressed in all		
HEATR5A	C14orf125, DKFZP434I1735	ENSG00000129493	HEAT repeat containing 5A	14	31291791-31420582	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049539	Uncertain				Renal cancer:1.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.2	Expressed in all		
FOXA1	HNF3A	ENSG00000129514	Forkhead box A1	14	37589984-37596059	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011595, HPA050505	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Urothelial cancer:1.00e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 146.0	breast: 36.3	Cell line enhanced		MCF7: 98.8;PC-3: 81.2;RT4: 94.9;SK-BR-3: 88.5;T-47d: 157.4
SNX6		ENSG00000129515	Sorting nexin 6	14	34561094-34630183	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049374	Approved		Supported	Endosomes<br>Lysosomes	Liver cancer:1.25e-4 (unfavourable), Pancreatic cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 220.7	Expressed in all		
EAPP	BM036, C14orf11, FLJ20578	ENSG00000129518	E2F associated phosphoprotein	14	34515929-34539711	Predicted intracellular proteins	Evidence at protein level	HPA002916	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:2.23e-6 (favourable), Thyroid cancer:2.96e-4 (favourable), Lung cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 75.0	Expressed in all		
EGLN3	HIFPH3, PHD3	ENSG00000129521	Egl-9 family hypoxia inducible factor 3	14	33924231-34462774	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA064895			Approved	Cytosol	Liver cancer:2.14e-5 (unfavourable), Renal cancer:2.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 98.0	heart muscle: 62.0	Cell line enhanced		RH-30: 43.2;RT4: 97.7
MIS18BP1	C14orf106, FLJ11186, KIAA1903, KNL2, M18BP1	ENSG00000129534	MIS18 binding protein 1	14	45203190-45253540	Predicted intracellular proteins	Evidence at protein level	HPA006504	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:3.83e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 25.9	Expressed in all		
NRL	D14S46E, NRL-MAF, RP27	ENSG00000129535	Neural retina leucine zipper	14	24080107-24115014	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026066, HPA064599	Supported		Supported	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 4.6	Mixed		
RNASE1	RAC1, RNS1	ENSG00000129538	Ribonuclease A family member 1, pancreatic	14	20801228-20803278	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001140	Supported		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			pancreas: 1946.8	Group enriched	6	HUVEC TERT2: 239.6;RT4: 91.0;TIME: 122.8
NEDD8	Nedd-8	ENSG00000129559	Neural precursor cell expressed, developmentally down-regulated 8	14	24216852-24232454	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004082, HPA027583, HPA060254	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 559.0	Expressed in all		
DAD1	OST2	ENSG00000129562	Defender against cell death 1	14	22564905-22589269	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA028882	Uncertain		Approved	Cytosol	Liver cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 516.1	Expressed in all		
TEP1	p240, TLP1, TP1, TROVE1, VAULT2	ENSG00000129566	Telomerase associated protein 1	14	20365667-20413429	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029206			Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:9.58e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 46.9	Expressed in all		
EPB41L4A	NBL4	ENSG00000129595	Erythrocyte membrane protein band 4.1 like 4A	5	112142441-112419316	Predicted intracellular proteins	Evidence at protein level	HPA036580	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:3.65e-5 (favourable)	Mixed	Expressed in all			parathyroid gland: 25.6	Cell line enhanced		EFO-21: 28.6;HeLa: 23.8
CDO1		ENSG00000129596	Cysteine dioxygenase type 1	5	115804733-115816954	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036573, HPA057503	Enhanced		Uncertain	Nucleoplasm	Liver cancer:1.91e-5 (favourable)	Group enriched	Tissue enhanced		epididymis: 137.5;liver: 209.9	adipose tissue: 104.0	Cell line enhanced		AF22: 38.7;ASC diff: 32.4;HAP1: 14.4;NTERA-2: 14.5
REEP5	C5orf18, D5S346, DP1, TB2, Yip2e	ENSG00000129625	Receptor accessory protein 5	5	112876379-112922539	Predicted membrane proteins	Evidence at protein level	HPA003895, HPA069960	Approved		Approved	Endoplasmic reticulum	Endometrial cancer:5.23e-6 (favourable), Renal cancer:2.05e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 343.0	Expressed in all		
ITFG1	CDA08, LNKN-1, TIP	ENSG00000129636	Integrin alpha FG-GAP repeat containing 1	16	47154387-47464149	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015590, HPA019728	Approved		Approved	Intermediate filaments<br>Aggresome	Renal cancer:1.95e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 110.1	Expressed in all		
QRICH2	DKFZP434P0316	ENSG00000129646	Glutamine rich 2	17	76274049-76307998	Predicted intracellular proteins	Evidence at protein level	HPA052219	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Expressed in all	Tissue enriched	11	testis: 22.2	thyroid gland: 1.9	Mixed		
FOXJ1	FKHL13, HFH-4, HFH4	ENSG00000129654	Forkhead box J1	17	76136333-76141299	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005714	Enhanced				Renal cancer:2.03e-5 (unfavourable), Breast cancer:9.39e-4 (favourable)	Tissue enhanced	Tissue enriched	8	fallopian tube: 83.6	lung: 10.3	Group enriched	10	BEWO: 28.2;CAPAN-2: 21.8
SEC14L1	PRELID4A, SEC14L	ENSG00000129657	SEC14 like lipid binding 1	17	77086716-77217101	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021463, HPA028703	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			placenta: 119.5	Expressed in all		
RHBDF2	FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG	ENSG00000129667	Rhomboid 5 homolog 2	17	76470891-76501790	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018080	Uncertain				Renal cancer:3.96e-11 (unfavourable)	Expressed in all	Expressed in all			appendix: 49.4	Mixed		
AANAT	SNAT	ENSG00000129673	Aralkylamine N-acetyltransferase	17	76453351-76470117	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054321			Supported	Cytosol		Not detected	Tissue enhanced		testis: 4.5	appendix: 2.2	Cell line enhanced		A549: 2.2;SCLC-21H: 3.5;U-698: 2.5
ARHGEF6	alpha-PIX, alphaPIX, Cool-2, Cool2, KIAA0006, MRX46	ENSG00000129675	Rac/Cdc42 guanine nucleotide exchange factor 6	X	136665547-136782088	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003578	Approved		Approved	Cytosol		Expressed in all	Mixed			placenta: 63.3	Cell line enhanced		HL-60: 113.2;HMC-1: 452.5;U-937: 117.5
MAP7D3	FLJ12649	ENSG00000129680	MAP7 domain containing 3	X	136213220-136256482	Predicted intracellular proteins	Evidence at protein level	HPA035598, HPA058101	Approved		Enhanced	Centrosome	Urothelial cancer:5.38e-5 (unfavourable), Endometrial cancer:9.00e-5 (unfavourable), Stomach cancer:7.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 30.0	Mixed		
FGF13	FGF2, FHF2	ENSG00000129682	Fibroblast growth factor 13	X	138614731-139222777	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002809			Supported	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 108.4	cerebral cortex: 47.9	Cell line enhanced		AF22: 42.4;HAP1: 40.9;U-2197: 64.4;WM-115: 37.0
ASH2L	ASH2, ASH2L1, ASH2L2, Bre2	ENSG00000129691	ASH2 like histone lysine methyltransferase complex subunit	8	38105242-38144076	Predicted intracellular proteins	Evidence at protein level	HPA042289	Approved		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:4.25e-4 (favourable)	Expressed in all	Expressed in all			testis: 74.9	Expressed in all		
TTI2	C8orf41, FLJ23263	ENSG00000129696	TELO2 interacting protein 2	8	33473386-33513601	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023523, HPA029823	Approved		Enhanced	Centrosome		Expressed in all	Mixed			testis: 22.1	Expressed in all		
ART1	ART2, CD296	ENSG00000129744	ADP-ribosyltransferase 1	11	3645128-3664416	CD markers, Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA051148	Uncertain					Not detected	Tissue enriched	21	skeletal muscle: 16.4	esophagus: 0.7	Not detected		
CHRNA10		ENSG00000129749	Cholinergic receptor nicotinic alpha 10 subunit	11	3665587-3671384	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	21	skeletal muscle: 16.6	appendix,lung: 0.7	Mixed		
CDKN1C	BWCR, BWS, KIP2, P57	ENSG00000129757	Cyclin dependent kinase inhibitor 1C	11	2883213-2885881	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002924	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Tissue enhanced		placenta: 202.5	adipose tissue: 62.5	Cell line enhanced		HeLa: 21.7;SH-SY5Y: 31.6;SiHa: 21.0
SGO1	NY-BR-85, SGOL1	ENSG00000129810	Shugoshin 1	3	20160593-20186292	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035501, HPA069857	Enhanced		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 13.2	lymph node: 8.1	Mixed		
RPS4Y1	MGC119100, MGC5070, RPS4Y, S4	ENSG00000129824	Ribosomal protein S4, Y-linked 1	Y	2841486-2932000	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Approved					Mixed	Mixed			prostate: 403.7	Cell line enhanced		U-698: 1166.0
VCY1B	BPY1B	ENSG00000129862	Variable charge, Y-linked 1B	Y	14056217-14056958	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Not detected	Tissue enriched	85	testis: 27.1	placenta: 0.3	Cell line enriched	6	U-266/70: 1.0
VCY	BPY1, VCY1, VCY1A	ENSG00000129864	Variable charge, Y-linked	Y	13985772-13986513	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Not detected	Tissue enriched	85	testis: 27.1	placenta: 0.3	Cell line enriched	6	U-266/70: 1.0
CDY2B	CDY	ENSG00000129873	Chromodomain Y-linked 2B	Y	17877410-17880220	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
CDH15	CDH14, CDH3	ENSG00000129910	Cadherin 15	16	89171767-89195492	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA009139, HPA070961	Enhanced		Supported	Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	11	skeletal muscle: 13.0	placenta: 1.1	Cell line enriched	5	RH-30: 142.1
KLF16	BTEB4, DRRF, NSLP2	ENSG00000129911	Kruppel like factor 16	19	1852399-1863568	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052481	Approved		Supported	Nucleus	Renal cancer:2.93e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 17.5	Expressed in all		
TMEM8A	M83, TMEM6, TMEM8	ENSG00000129925	Transmembrane protein 8A	16	370773-387113	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051281, HPA064673	Approved		Supported	Nucleoplasm<br>Cytokinetic bridge	Renal cancer:1.29e-5 (favourable)	Expressed in all	Expressed in all			testis: 57.1	Expressed in all		
DOHH	HLRC1, MGC4293	ENSG00000129932	Deoxyhypusine hydroxylase	19	3490821-3500940	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041953	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)	Expressed in all	Mixed			duodenum: 17.8	Expressed in all		
MAU2	KIAA0892, mau-2, MAU2L, MGC75361, SCC4	ENSG00000129933	MAU2 sister chromatid cohesion factor	19	19320681-19358755	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059897			Supported	Nucleoplasm	Head and neck cancer:3.90e-5 (favourable)	Expressed in all	Expressed in all			testis: 25.6	Expressed in all		
SHC2	SCK, SHCB, SLI	ENSG00000129946	SHC adaptor protein 2	19	416583-460996	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA006136	Approved		Approved	Cytosol	Colorectal cancer:4.58e-4 (unfavourable), Pancreatic cancer:8.53e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 18.7	Cell line enhanced		SCLC-21H: 14.8;SH-SY5Y: 12.0
PLPPR3	FLJ11535, LPPR3, PRG-2, PRG2	ENSG00000129951	Phospholipid phosphatase related 3	19	812488-821977	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052293, HPA057034	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Tissue enhanced		bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.9	testis: 2.1	Cell line enhanced		NB-4: 38.6;THP-1: 86.0
INS-IGF2		ENSG00000129965	INS-IGF2 readthrough	11	2132538-2161209	Predicted secreted proteins	Evidence at protein level	CAB019430	Enhanced					Not detected	Tissue enhanced		pancreas: 1.6;placenta: 3.3	adrenal gland,endometrium: 0.5	Cell line enhanced		SH-SY5Y: 1.3
ABHD17A	C19orf27, FAM108A1, MGC5244	ENSG00000129968	Abhydrolase domain containing 17A	19	1876810-1885547	Predicted intracellular proteins	Evidence at protein level	HPA043270, HPA047226	Uncertain		Approved	Vesicles	Pancreatic cancer:1.76e-5 (favourable), Endometrial cancer:1.73e-4 (favourable), Head and neck cancer:6.46e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 31.4	Mixed		
LBP	BPIFD2	ENSG00000129988	Lipopolysaccharide binding protein	20	38346356-38377023	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001508, CAB025905	Approved				Renal cancer:3.62e-12 (unfavourable), Cervical cancer:5.56e-4 (unfavourable), Stomach cancer:5.76e-4 (unfavourable)	Tissue enriched	Group enriched	5	adipose tissue: 69.3;liver: 264.7	appendix: 31.3	Group enriched	7	ASC diff: 6.7;HSkMC: 8.5
SYT5		ENSG00000129990	Synaptotagmin 5	19	55171199-55180441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA078390	Enhanced				Pancreatic cancer:5.54e-4 (favourable), Glioma:8.26e-4 (unfavourable)	Mixed	Tissue enriched	10	cerebral cortex: 131.4	adrenal gland: 12.7	Cell line enhanced		EFO-21: 25.6;HMC-1: 53.1;K-562: 20.2;SCLC-21H: 18.7
TNNI3	CMD2A, CMH7, TNNC1	ENSG00000129991	Troponin I3, cardiac type	19	55151767-55157773	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009349, HPA046428	Enhanced		Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	174	heart muscle: 3607.1	breast: 20.7	Cell line enhanced		HEK 293: 11.1;HMC-1: 17.7;K-562: 34.7
CBFA2T3	ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4	ENSG00000129993	CBFA2/RUNX1 translocation partner 3	16	88874858-88977204	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059931, HPA062423, HPA065890	Approved		Enhanced	Nucleoplasm	Head and neck cancer:3.95e-4 (favourable)	Mixed	Tissue enhanced		spleen: 18.7	lymph node: 10.4	Cell line enhanced		HEL: 57.7;K-562: 102.3;MOLT-4: 46.5;REH: 103.4;T-47d: 47.0
GAMT	PIG2, TP53I2	ENSG00000130005	Guanidinoacetate N-methyltransferase	19	1397026-1401570	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051806	Approved				Stomach cancer:6.57e-4 (unfavourable)	Tissue enriched	Group enriched	5	epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6	pancreas: 48.1	Mixed		
PUDP	DXF68S1E, FAM16AX, GS1, HDHD1, HDHD1A	ENSG00000130021	Pseudouridine 5'-phosphatase	X	7048920-7148190	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072672	Approved				Thyroid cancer:4.80e-4 (favourable), Pancreatic cancer:7.27e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 31.3	Mixed		
ERMARD	C6orf70, dJ266L20.3, FLJ11152	ENSG00000130023	ER membrane associated RNA degradation	6	169751622-169781584	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041741	Approved		Approved	Cytosol		Expressed in all	Expressed in all			testis: 33.2	Expressed in all		
PHF10	BAF45a, FLJ10975, XAP135	ENSG00000130024	PHD finger protein 10	6	169703905-169725566	Predicted intracellular proteins	Evidence at protein level	HPA055649	Supported		Supported	Nucleus	Pancreatic cancer:1.12e-5 (favourable), Renal cancer:1.56e-5 (unfavourable), Liver cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 103.6	Expressed in all		
PRRG3	TMG3	ENSG00000130032	Proline rich and Gla domain 3	X	151695124-151705924	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060566	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 8.9	cervix, uterine: 7.5	Cell line enhanced		NTERA-2: 1.0
GALNT8	GALNAC-T8	ENSG00000130035	Polypeptide N-acetylgalactosaminyltransferase 8	12	4720341-4851927	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012638, HPA014418, HPA073461	Approved		Approved	Vesicles		Tissue enhanced	Group enriched	7	cerebral cortex: 19.4;colon: 17.6;duodenum: 8.1;rectum: 40.6;small intestine: 18.9;testis: 26.5	appendix: 3.2	Cell line enhanced		Karpas-707: 24.5;NTERA-2: 12.1;U-2 OS: 4.6;U-266/84: 7.3
KCNA5	HK2, HPCN1, Kv1.5	ENSG00000130037	Potassium voltage-gated channel subfamily A member 5	12	5043989-5046788	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA021516, CAB022562	Approved					Mixed	Tissue enhanced		heart muscle: 16.1	esophagus: 5.6	Cell line enriched	20	NTERA-2: 4.3
CRACR2A	EFCAB4B, MGC4266	ENSG00000130038	Calcium release activated channel regulator 2A	12	3606633-3764819	Predicted intracellular proteins	Evidence at protein level	HPA038686	Enhanced				Prostate cancer:2.85e-6 (favourable)	Mixed	Mixed			salivary gland: 15.1	Mixed		
NXNL2	C9orf121	ENSG00000130045	Nucleoredoxin-like 2	9	88535101-88584274	Predicted intracellular proteins	Evidence at transcript level	HPA045526	Uncertain		Approved	Cytosol	Endometrial cancer:3.83e-8 (favourable), Breast cancer:6.53e-4 (favourable), Renal cancer:9.60e-4 (favourable)	Group enriched	Mixed			adipose tissue: 7.7	Cell line enhanced		RPTEC TERT1: 7.9
STARD8	ARHGAP38, KIAA0189	ENSG00000130052	StAR related lipid transfer domain containing 8	X	68647666-68725842	Predicted intracellular proteins	Evidence at protein level	HPA060788	Uncertain					Expressed in all	Mixed			adipose tissue: 14.9	Cell line enhanced		HEL: 14.3;K-562: 18.2
FAM155B	CXorf63, TED, TMEM28	ENSG00000130054	Family with sequence similarity 155 member B	X	69505241-69532508	Predicted membrane proteins	Evidence at transcript level	HPA036093	Uncertain				Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable)	Mixed	Tissue enhanced		heart muscle: 10.8;seminal vesicle: 8.5;thyroid gland: 16.7	cerebral cortex: 2.5	Cell line enhanced		AN3-CA: 8.3;HAP1: 20.7;NTERA-2: 27.5;SCLC-21H: 15.3
GDPD2	FLJ20207, GDE3, OBDPF	ENSG00000130055	Glycerophosphodiester phosphodiesterase domain containing 2	X	70423031-70433390	Enzymes, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skin: 50.8;spleen: 60.0	small intestine: 20.0	Group enriched	8	AF22: 8.8;NTERA-2: 19.3
SAT1	SAT, SSAT	ENSG00000130066	Spermidine/spermine N1-acetyltransferase 1	X	23783173-23786226	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047343, HPA055312, CAB069914	Supported				Endometrial cancer:2.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1269.5	Expressed in all		
GNL3L	FLJ10613, GNL3B	ENSG00000130119	G protein nucleolar 3 like	X	54530211-54561071	Predicted intracellular proteins	Evidence at protein level	HPA036314, HPA036315	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 16.4	Expressed in all		
SH3BP4		ENSG00000130147	SH3 domain binding protein 4	2	234951973-235055714	Predicted intracellular proteins	Evidence at protein level	HPA037533, HPA037534	Uncertain				Renal cancer:2.07e-6 (favourable)	Expressed in all	Mixed			breast: 42.6	Mixed		
MOSPD2	MGC26706	ENSG00000130150	Motile sperm domain containing 2	X	14873441-14922327	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003334	Uncertain		Approved	Endoplasmic reticulum	Liver cancer:8.91e-4 (unfavourable)	Expressed in all	Mixed			skin: 28.6	Expressed in all		
DOCK6	KIAA1395, ZIR1	ENSG00000130158	Dedicator of cytokinesis 6	19	11199295-11262481	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049423, HPA049424	Approved		Supported	Cytosol	Head and neck cancer:9.09e-4 (favourable)	Expressed in all	Mixed			skin: 29.4	Cell line enhanced		HUVEC TERT2: 57.1;TIME: 56.1
ECSIT	SITPEC	ENSG00000130159	ECSIT signalling integrator	19	11505916-11529174	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042979	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.48e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 54.2	Expressed in all		
LDLR	LDLCQ2	ENSG00000130164	Low density lipoprotein receptor	19	11089362-11133816	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA009647, HPA013159	Approved				Pancreatic cancer:6.60e-5 (unfavourable), Urothelial cancer:3.43e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 87.6	Expressed in all		
ELOF1	ELF1, MGC4549	ENSG00000130165	Elongation factor 1 homolog	19	11551147-11559236	Predicted intracellular proteins	Evidence at protein level	HPA045606	Uncertain		Approved	Cytosol	Cervical cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 163.7	Expressed in all		
TSPAN16	TM-8, TM4-B, TM4SF16	ENSG00000130167	Tetraspanin 16	19	11296139-11326996	Predicted membrane proteins	Evidence at protein level	HPA041579	Approved					Not detected	Tissue enriched	46	testis: 154.0	bone marrow: 3.3	Not detected		
ANGPTL8	C19orf80, RIFL, TD26	ENSG00000130173	Angiopoietin like 8	19	11237450-11241943	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042131			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.84e-6 (unfavourable)	Tissue enriched	Group enriched	20	adipose tissue: 13.7;liver: 63.8	epididymis: 1.9	Group enriched	28	Hep G2: 24.9;MCF7: 16.3
PRKCSH	G19P1, GIIB, PCLD, PLD1, VASAP-60	ENSG00000130175	Protein kinase C substrate 80K-H	19	11435288-11450968	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004465, HPA041940, HPA043560	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:7.69e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 237.6	Expressed in all		
CNN1	Sm-Calp, SMCC	ENSG00000130176	Calponin 1	19	11538717-11550323	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000007, HPA014263	Enhanced		Approved	Actin filaments	Renal cancer:5.43e-6 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 2110.1;smooth muscle: 3106.1	endometrium: 1736.7	Cell line enhanced		BJ: 76.7;BJ hTERT+ SV40 Large T+: 43.2;BJ hTERT+ SV40 Large T+ RasG12V: 62.2;HBF TERT88: 68.9
CDC16	ANAPC6, APC6, CUT9	ENSG00000130177	Cell division cycle 16	13	114234887-114272723	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042826	Approved					Expressed in all	Expressed in all			testis: 83.8	Expressed in all		
ZSCAN10	ZNF206	ENSG00000130182	Zinc finger and SCAN domain containing 10	16	3088890-3099317	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			skin: 0.6	Cell line enriched	123	NTERA-2: 56.8
THEM6	C8orf55, DSCD75	ENSG00000130193	Thioesterase superfamily member 6	8	142727203-142736927	Predicted intracellular proteins	Evidence at protein level	HPA023255	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:6.66e-7 (favourable), Urothelial cancer:4.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 18.5	Cell line enhanced		RT4: 89.6
NECTIN2	CD112, HVEB, PRR2, PVRL2, PVRR2	ENSG00000130202	Nectin cell adhesion molecule 2	19	44846175-44889228	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012759, CAB026138, HPA073459	Enhanced		Approved	Nucleoli fibrillar center<br>Cell Junctions		Expressed in all	Expressed in all			placenta: 111.4	Mixed		
APOE	AD2	ENSG00000130203	Apolipoprotein E	19	44905754-44909393	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB008363, HPA065539, HPA068768, CAB069921	Enhanced		Approved	Vesicles		Expressed in all	Expressed in all			adrenal gland: 1801.1	Cell line enhanced		ASC diff: 1276.1;Hep G2: 626.6;HSkMC: 991.4;SK-MEL-30: 1417.0
TOMM40	C19orf1, D19S1177E, PER-EC1, PEREC1, TOM40	ENSG00000130204	Translocase of outer mitochondrial membrane 40	19	44890569-44903689	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036231, HPA036232	Supported		Enhanced	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
APOC1		ENSG00000130208	Apolipoprotein C1	19	44914247-44919349	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA051518	Supported				Liver cancer:1.15e-7 (favourable)	Tissue enriched	Tissue enriched	7	liver: 7257.2	adrenal gland: 1113.0	Cell line enhanced		Hep G2: 389.1;HSkMC: 242.1;SK-MEL-30: 203.2
GADD45G	CR6, DDIT2, GADD45gamma, GRP17	ENSG00000130222	Growth arrest and DNA damage inducible gamma	9	89605013-89606555	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023606	Approved		Approved	Nucleus	Pancreatic cancer:3.80e-5 (favourable), Endometrial cancer:7.06e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 47.2	Cell line enhanced		HDLM-2: 108.4;SCLC-21H: 69.0
LRCH2	KIAA1495	ENSG00000130224	Leucine rich repeats and calponin homology domain containing 2	X	115110616-115234072	Predicted intracellular proteins	Evidence at protein level	HPA003233	Approved		Approved	Nucleoli<br>Plasma membrane		Mixed	Mixed			prostate: 13.8	Cell line enhanced		HAP1: 22.2
DPP6	DPL1, DPPX	ENSG00000130226	Dipeptidyl peptidase like 6	7	153887097-154894285	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050509	Enhanced	Supported				Tissue enriched	Tissue enhanced		cerebral cortex: 51.1;endometrium: 27.6	smooth muscle: 15.4	Cell line enriched	9	NTERA-2: 5.5
XPO7	KIAA0745, RANBP16	ENSG00000130227	Exportin 7	8	21919671-22006585	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043727, HPA048153	Uncertain		Approved	Nucleus	Colorectal cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 78.8	Expressed in all		
ACE2		ENSG00000130234	Angiotensin I converting enzyme 2	X	15561033-15602148	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA000288, CAB026174	Enhanced				Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable)	Tissue enhanced	Group enriched	5	duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0	heart muscle: 27.9	Cell line enhanced		HaCaT: 1.1
FAM98C	FLJ44669	ENSG00000130244	Family with sequence similarity 98 member C	19	38403135-38409088	Predicted intracellular proteins	Evidence at protein level	HPA040930, HPA041730	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:8.51e-5 (unfavourable), Urothelial cancer:5.53e-4 (favourable)	Expressed in all	Mixed			small intestine: 15.2	Expressed in all		
SAFB2	KIAA0138	ENSG00000130254	Scaffold attachment factor B2	19	5586999-5624046	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050894	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Urothelial cancer:2.12e-4 (favourable), Pancreatic cancer:2.53e-4 (favourable), Endometrial cancer:7.10e-4 (favourable)	Expressed in all	Expressed in all			ovary: 40.0	Expressed in all		
RPL36	DKFZp566B023, L36	ENSG00000130255	Ribosomal protein L36	19	5674947-5691876	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047153	Supported		Uncertain	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2363.0	Expressed in all		
ATP8B3	ATPIK	ENSG00000130270	ATPase phospholipid transporting 8B3	19	1782075-1812276	Enzymes, Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.80e-9 (unfavourable)	Mixed	Tissue enriched	7	testis: 28.7	bone marrow: 4.0	Cell line enhanced		Karpas-707: 16.1;U-266/70: 14.2
GDF1		ENSG00000130283	Growth differentiation factor 1	19	18868545-18896096	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	7	cerebral cortex: 12.2	testis: 1.7	Cell line enhanced		EFO-21: 2.8;HEK 293: 3.3;NB-4: 3.1;NTERA-2: 2.4;SCLC-21H: 2.4
NCAN	CSPG3	ENSG00000130287	Neurocan	19	19211973-19252233	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036814	Enhanced		Uncertain	Vesicles<br>Centrosome		Tissue enriched	Tissue enriched	101	cerebral cortex: 183.5	testis: 1.8	Cell line enhanced		AF22: 1.0;SCLC-21H: 2.7;SH-SY5Y: 1.7
KIF1A	ATSV, C2orf20, SPG30, UNC104	ENSG00000130294	Kinesin family member 1A	2	240713764-240820308	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005442			Approved	Microtubule organizing center<br>Cytosol	Endometrial cancer:4.97e-4 (unfavourable)	Tissue enhanced	Tissue enriched	13	cerebral cortex: 308.3	adrenal gland: 23.0	Cell line enhanced		AN3-CA: 79.8;HAP1: 157.5;K-562: 125.1;SCLC-21H: 477.1
GTPBP3	FLJ14700, GTPBG3, MSS1, MTGP1, THDF1	ENSG00000130299	GTP binding protein 3 (mitochondrial)	19	17334920-17342735	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042158	Approved		Supported	Mitochondria	Renal cancer:1.64e-4 (unfavourable), Liver cancer:1.86e-4 (unfavourable), Prostate cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 12.3	Expressed in all		
PLVAP	FELS, gp68, PV-1, PV1	ENSG00000130300	Plasmalemma vesicle associated protein	19	17351448-17377350	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002279	Supported					Expressed in all	Expressed in all			thyroid gland: 329.1	Cell line enriched	31	EFO-21: 506.3
BST2	CD317, tetherin	ENSG00000130303	Bone marrow stromal cell antigen 2	19	17402939-17405648	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017060	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 586.7	Mixed		
SLC27A1	ACSVL5, FATP, FATP1, FLJ00336, MGC71751	ENSG00000130304	Solute carrier family 27 member 1	19	17468769-17506168	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076520			Approved	Plasma membrane<br>Mitochondria<br>Cytosol	Renal cancer:4.70e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 34.5	Cell line enhanced		SK-MEL-30: 36.4
NSUN5	FLJ10267, NOL1R, NSUN5A, p120(NOL1), WBSCR20, WBSCR20A, Ynl022cL	ENSG00000130305	NOP2/Sun RNA methyltransferase family member 5	7	73302517-73308867	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020536, HPA045590, HPA046867	Approved		Enhanced	Nucleus<br>Nucleoli	Glioma:2.11e-4 (unfavourable), Liver cancer:3.96e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.0	Mixed		
USHBP1	AIEBP, FLJ38709, MCC2	ENSG00000130307	USH1 protein network component harmonin binding protein 1	19	17249176-17282786	Predicted intracellular proteins	Evidence at protein level	HPA052471	Uncertain					Mixed	Mixed			placenta: 8.2	Cell line enhanced		BEWO: 10.6
COLGALT1	FLJ22329, GLT25D1	ENSG00000130309	Collagen beta(1-O)galactosyltransferase 1	19	17555594-17583162	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047821	Approved		Approved	Vesicles	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.65e-5 (unfavourable), Pancreatic cancer:1.92e-4 (unfavourable), Urothelial cancer:3.83e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 58.0	Expressed in all		
DDA1	C19orf58, MGC2594, PCIA1	ENSG00000130311	DET1 and DDB1 associated 1	19	17309518-17323301	Predicted intracellular proteins	Evidence at protein level	HPA042134, HPA055272	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 11.6	Expressed in all		
MRPL34	L34mt, MGC24974, MGC2633	ENSG00000130312	Mitochondrial ribosomal protein L34	19	17292609-17306843	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA049276	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:4.29e-6 (favourable), Pancreatic cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			kidney: 76.6	Expressed in all		
PGLS	6PGL	ENSG00000130313	6-phosphogluconolactonase	19	17511629-17521288	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040744, HPA042032	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 46.7	Expressed in all		
LSM7	YNL147W	ENSG00000130332	LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated	19	2321517-2328620	Predicted intracellular proteins	Evidence at protein level	HPA041850	Uncertain		Approved	Nucleoli fibrillar center	Endometrial cancer:4.19e-5 (favourable), Cervical cancer:3.28e-4 (favourable), Urothelial cancer:6.96e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 70.9	Expressed in all		
TULP4	KIAA1397, TUSP	ENSG00000130338	Tubby like protein 4	6	158232236-158511828	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005445	Approved					Expressed in all	Mixed			cerebral cortex: 12.6	Expressed in all		
SNX9	SDP1, SH3PX1, SH3PXD3A	ENSG00000130340	Sorting nexin 9	6	157700387-157945077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031410, HPA057203	Approved		Enhanced	Plasma membrane<br>Cytosol	Lung cancer:3.77e-4 (unfavourable), Cervical cancer:5.95e-4 (unfavourable), Renal cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.2	Mixed		
RTN4IP1	NIMP	ENSG00000130347	Reticulon 4 interacting protein 1	6	106571971-106629487	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036357	Approved				Renal cancer:8.55e-6 (favourable), Breast cancer:9.18e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.4	Expressed in all		
QRSL1	DKFZP564C1278, FLJ10989, FLJ12189, FLJ13447, GatA	ENSG00000130348	Glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1	6	106629578-106668417	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029585, HPA029587	Approved		Approved	Vesicles<br>Centrosome	Liver cancer:7.97e-5 (unfavourable), Renal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 18.6	Expressed in all		
C6orf203	HSPC230, PRED31	ENSG00000130349	Chromosome 6 open reading frame 203	6	107028213-107051342	Predicted intracellular proteins	Evidence at protein level	HPA049535	Approved				Urothelial cancer:2.11e-5 (favourable), Renal cancer:4.09e-5 (favourable), Pancreatic cancer:3.29e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 47.6	Expressed in all		
RSPH3	dJ111C20.1, RSHL2, RSP3	ENSG00000130363	Radial spoke 3 homolog	6	158972871-159000187	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039109, HPA040230	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:2.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 26.4	Mixed		
MAS1		ENSG00000130368	MAS1 proto-oncogene, G protein-coupled receptor	6	159906690-159916530	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.8	cervix, uterine: 0.7	Cell line enriched	9	HMC-1: 6.7
ACSBG2	BGR, DKFZp434K1635, PRTD-NY3	ENSG00000130377	Acyl-CoA synthetase bubblegum family member 2	19	6135247-6193094	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043421, HPA051013	Enhanced		Uncertain	Cytosol		Not detected	Tissue enriched	716	testis: 294.0	cerebral cortex: 0.4	Not detected		
MLLT1	ENL, LTG19, YEATS1	ENSG00000130382	MLLT1, super elongation complex subunit	19	6210379-6279948	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031166	Approved		Supported	Nucleoplasm	Head and neck cancer:6.03e-5 (favourable)	Expressed in all	Expressed in all			placenta: 61.5	Expressed in all		
FUT5	FUC-TV	ENSG00000130383	Fucosyltransferase 5	19	5865826-5870540	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA046966	Uncertain					Not detected	Not detected			bone marrow,testis: 0.3	Not detected		
BMP15	GDF9B	ENSG00000130385	Bone morphogenetic protein 15	X	50910784-50916607	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.3	Not detected		
AFDN	AF-6, AF6, MLLT4	ENSG00000130396	Afadin, adherens junction formation factor	6	167826922-167972023	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868	Approved		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Breast cancer:7.43e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 110.7	Mixed		
ACTN4	FSGS1	ENSG00000130402	Actinin alpha 4	19	38647649-38731583	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001873, HPA006035	Supported		Approved	Nuclear bodies<br>Cytosol	Renal cancer:5.25e-5 (favourable), Pancreatic cancer:5.65e-4 (unfavourable), Lung cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 118.4	Expressed in all		
STK33		ENSG00000130413	Serine/threonine kinase 33	11	8391868-8594289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015742, HPA056855	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:4.89e-6 (favourable)	Mixed	Tissue enhanced		fallopian tube: 67.1;testis: 93.1	parathyroid gland: 43.4	Cell line enhanced		SCLC-21H: 26.8
NDUFA10	CI-42k	ENSG00000130414	NADH:ubiquinone oxidoreductase subunit A10	2	239892450-240025402	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059529, HPA067045, CAB070846	Approved		Supported	Mitochondria	Renal cancer:2.09e-7 (favourable), Melanoma:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 63.8	Expressed in all		
EPO	EP	ENSG00000130427	Erythropoietin	7	100720800-100723700	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB010336	Supported				Renal cancer:2.18e-6 (unfavourable), Liver cancer:5.67e-5 (unfavourable)	Group enriched	Tissue enhanced		cervix, uterine: 2.0;endometrium: 1.7;liver: 1.7	prostate: 1.1	Group enriched	6	BEWO: 2.0;Hep G2: 5.5
ARPC1B	ARC41, p40-ARC, p41-ARC	ENSG00000130429	Actin related protein 2/3 complex subunit 1B	7	99374249-99394801	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004832	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.62e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 251.5	Expressed in all		
CACNG6		ENSG00000130433	Calcium voltage-gated channel auxiliary subunit gamma 6	19	53992288-54012669	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA056615			Approved	Nucleoli fibrillar center<br>Cytosol		Mixed	Group enriched	11	fallopian tube: 18.0;skeletal muscle: 33.9	lung: 2.3	Cell line enhanced		A549: 13.3;EFO-21: 23.7;HHSteC: 5.4
ZSWIM6	KIAA1577	ENSG00000130449	Zinc finger SWIM-type containing 6	5	61332273-61546170	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035938	Uncertain		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 17.0	Mixed		
FCHO1	KIAA0290	ENSG00000130475	FCH domain only 1	19	17747718-17788568	Predicted intracellular proteins	Evidence at protein level	HPA041653, HPA062981	Approved		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		lymph node: 28.8	spleen: 19.9	Cell line enhanced		Daudi: 44.6
UNC13A	KIAA1032, Munc13-1	ENSG00000130477	Unc-13 homolog A	19	17601328-17688365	Predicted intracellular proteins	Evidence at protein level	HPA041418, HPA077242	Uncertain		Uncertain	Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol		Tissue enhanced	Tissue enriched	16	cerebral cortex: 53.5	adrenal gland: 3.4	Group enriched	7	HMC-1: 14.3;NTERA-2: 23.7;SCLC-21H: 45.8;SH-SY5Y: 9.8
MAP1S	BPY2IP1, C19orf5, FLJ10669, MAP8, VCY2IP1	ENSG00000130479	Microtubule associated protein 1S	19	17719242-17734516	Predicted intracellular proteins	Evidence at protein level	HPA050934, HPA054637	Approved		Enhanced	Cytosol	Pancreatic cancer:2.65e-4 (favourable), Liver cancer:5.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.5	Expressed in all		
KLHDC7B	MGC16635	ENSG00000130487	Kelch domain containing 7B	22	50548033-50551023	Predicted intracellular proteins	Evidence at protein level	HPA000518	Uncertain				Breast cancer:1.30e-4 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 12.7	thyroid gland: 3.4	Group enriched	6	HHSteC: 18.6;HMC-1: 87.0
SCO2	MYP6, SCO1L	ENSG00000130489	SCO2, cytochrome c oxidase assembly protein	22	50523568-50525606	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046943, HPA056254	Approved		Approved	Mitochondria	Renal cancer:1.67e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 47.1	Expressed in all		
PXDN	D2S448, D2S448E, KIAA0230, MG50, PRG2, PXN	ENSG00000130508	Peroxidasin	2	1631887-1744852	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012375	Approved				Endometrial cancer:2.75e-4 (unfavourable), Cervical cancer:6.28e-4 (unfavourable), Stomach cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 87.2	adipose tissue: 66.9	Mixed		
SSBP4		ENSG00000130511	Single stranded DNA binding protein 4	19	18418864-18434562	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.04e-10 (unfavourable), Pancreatic cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			spleen: 51.1	Expressed in all		
GDF15	MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB	ENSG00000130513	Growth differentiation factor 15	19	18374731-18389176	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011191, CAB062554, HPA070957	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Tissue enhanced		placenta: 122.1;prostate: 74.5	kidney: 41.6	Cell line enhanced		BEWO: 401.5;HHSteC: 474.6
PGPEP1	Pcp, PGP, PGP-I, PGPI	ENSG00000130517	Pyroglutamyl-peptidase I	19	18340587-18369950	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035368, HPA055277	Approved		Approved	Golgi apparatus	Renal cancer:3.71e-8 (favourable), Pancreatic cancer:1.71e-4 (favourable), Melanoma:6.80e-4 (favourable)	Expressed in all	Expressed in all			kidney: 29.3	Cell line enhanced		HMC-1: 51.6
KIAA1683		ENSG00000130518	KIAA1683	19	18257097-18274509	Predicted intracellular proteins	Evidence at protein level	HPA042409	Enhanced					Mixed	Tissue enriched	6	testis: 34.3	endometrium: 5.3	Cell line enhanced		A549: 2.3
LSM4	YER112W	ENSG00000130520	LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated	19	18306230-18323274	Predicted intracellular proteins	Evidence at protein level	HPA040932	Uncertain		Approved	Vesicles	Ovarian cancer:1.34e-4 (favourable), Renal cancer:2.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 102.4	Expressed in all		
JUND	AP-1	ENSG00000130522	JunD proto-oncogene, AP-1 transcription factor subunit	19	18279760-18281622	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005268, HPA063029	Supported		Supported	Nucleus	Breast cancer:6.15e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 277.7	Expressed in all		
HRC	MGC133236	ENSG00000130528	Histidine rich calcium binding protein	19	49151198-49155424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA004833	Enhanced					Mixed	Group enriched	39	heart muscle: 351.8;skeletal muscle: 155.5	epididymis,prostate: 6.5	Group enriched	6	Hep G2: 3.9;HSkMC: 4.0;K-562: 7.1;THP-1: 9.3;U-266/84: 3.0
TRPM4	FLJ20041	ENSG00000130529	Transient receptor potential cation channel subfamily M member 4	19	49157741-49211836	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA041169	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable)	Expressed in all	Mixed			prostate: 29.4	Cell line enhanced		RT4: 47.8
OR11H1	OR22-1	ENSG00000130538	Olfactory receptor family 11 subfamily H member 1	22	15528158-15529139	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SULT4A1	hBR-STL-1, SULTX3	ENSG00000130540	Sulfotransferase family 4A member 1	22	43824509-43862503	Predicted intracellular proteins	Evidence at protein level	HPA003129	Enhanced					Tissue enhanced	Tissue enriched	35	cerebral cortex: 143.6	adrenal gland: 4.0	Not detected		
ZNF557	MGC4054	ENSG00000130544	Zinc finger protein 557	19	7069444-7087968	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003151, HPA029291	Uncertain		Approved	Nucleus<br>Intermediate filaments<br>Cytosol	Head and neck cancer:3.67e-6 (favourable), Pancreatic cancer:1.51e-4 (favourable), Lung cancer:2.62e-4 (favourable), Endometrial cancer:5.70e-4 (favourable)	Expressed in all	Mixed			testis: 5.4	Expressed in all		
CRB3	MGC17303	ENSG00000130545	Crumbs 3, cell polarity complex component	19	6463777-6467221	Predicted membrane proteins	Evidence at protein level	HPA013835	Enhanced		Supported	Cell Junctions	Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable)	Mixed	Mixed			duodenum: 37.4	Cell line enhanced		A-431: 50.4;BEWO: 34.1;CACO-2: 31.7;HaCaT: 32.6
OLFM1	AMY, NOE1, NOELIN, OlfA	ENSG00000130558	Olfactomedin 1	9	135075422-135121179	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057444			Approved	Nucleus<br>Nucleoli<br>Cytosol	Cervical cancer:7.14e-4 (favourable), Glioma:9.38e-4 (unfavourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 729.9	epididymis: 86.4	Cell line enhanced		NTERA-2: 108.6;SCLC-21H: 182.9;SiHa: 139.8;T-47d: 189.5;U-2197: 81.2
CAMSAP1	DKFZp434F195, FLJ31228	ENSG00000130559	Calmodulin regulated spectrin associated protein 1	9	135808487-135907228	Predicted intracellular proteins	Evidence at protein level	HPA020527, HPA024161	Approved		Supported	Mitotic spindle<br>Cytosol	Renal cancer:3.09e-5 (favourable)	Expressed in all	Expressed in all			testis: 34.2	Expressed in all		
UBAC1	GBDR1, KPC2, UBADC1	ENSG00000130560	UBA domain containing 1	9	135932969-135961380	Predicted intracellular proteins	Evidence at protein level	HPA005651	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.58e-7 (favourable), Cervical cancer:4.34e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 88.7	Expressed in all		
SAG	ARRESTIN, RP47	ENSG00000130561	S-antigen visual arrestin	2	233307816-233347055	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004946	Supported					Not detected	Group enriched	8	epididymis: 1.1;testis: 1.9	endometrium: 0.1	Not detected		
ZBTB46	BTBD4, BZEL, FLJ13502, RINZF, ZNF340	ENSG00000130584	Zinc finger and BTB domain containing 46	20	63743666-63831244	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA013997	Uncertain		Approved	Nucleus	Pancreatic cancer:2.17e-4 (favourable)	Expressed in all	Mixed			spleen: 13.3	Mixed		
HELZ2	KIAA1769, PDIP1, PRIC285	ENSG00000130589	Helicase with zinc finger 2	20	63558086-63574239	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051267	Uncertain				Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 15.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 55.4
SAMD10	C20orf136	ENSG00000130590	Sterile alpha motif domain containing 10	20	63974113-63980008	Predicted intracellular proteins	Evidence at protein level	HPA040973	Approved		Approved	Nucleoplasm	Liver cancer:4.60e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 7.6	Mixed		
LSP1	WP34	ENSG00000130592	Lymphocyte-specific protein 1	11	1852970-1892267	Predicted intracellular proteins	Evidence at protein level	CAB017781, HPA019693, HPA071843	Enhanced		Supported	Plasma membrane	Endometrial cancer:2.54e-4 (favourable), Cervical cancer:3.56e-4 (favourable), Glioma:9.00e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 279.2	Cell line enhanced		Daudi: 229.4;HDLM-2: 1037.0;RPMI-8226: 322.1
TNNT3	AMCD2B, DA2B, DKFZp779M2348, FSSV	ENSG00000130595	Troponin T3, fast skeletal type	11	1919562-1938706	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB002451, HPA037810, HPA056909	Enhanced				Cervical cancer:7.37e-4 (favourable)	Group enriched	Tissue enriched	72	skeletal muscle: 9522.9	esophagus: 132.2	Cell line enriched	15	HSkMC: 34.3
TNNI2	AMCD2B, DA2B, FSSV	ENSG00000130598	Troponin I2, fast skeletal type	11	1838989-1841680	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB018697, HPA055938	Enhanced		Approved	Plasma membrane<br>Intermediate filaments		Group enriched	Tissue enriched	38	skeletal muscle: 5537.1	esophagus: 144.6	Cell line enhanced		CAPAN-2: 62.9;hTCEpi: 145.7;T-47d: 23.3
COL5A1		ENSG00000130635	Collagen type V alpha 1 chain	9	134641774-134844843	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030769	Approved		Approved	Vesicles	Renal cancer:2.07e-12 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 157.8	Cell line enhanced		BJ: 370.0;fHDF/TERT166: 317.6;SiHa: 305.8
ATXN10	E46L, FLJ37990, SCA10	ENSG00000130638	Ataxin 10	22	45671798-45845307	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049531	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 133.9	Expressed in all		
TUBGCP2	GCP2, SPBC97, Spc97p	ENSG00000130640	Tubulin gamma complex associated protein 2	10	133278630-133312337	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037885	Approved		Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			fallopian tube: 34.3	Expressed in all		
CALY	CALCYON, DRD1IP, NSG3	ENSG00000130643	Calcyon neuron specific vesicular protein	10	133324072-133336935	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042283	Enhanced				Pancreatic cancer:3.54e-4 (favourable)	Group enriched	Group enriched	13	adrenal gland: 23.5;cerebral cortex: 77.1	testis: 3.8	Not detected		
CYP2E1	CYP2E	ENSG00000130649	Cytochrome P450 family 2 subfamily E member 1	10	133520406-133561220	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009128, HPA029564	Enhanced					Tissue enriched	Tissue enriched	177	liver: 5332.2	tonsil: 30.1	Cell line enhanced		HaCaT: 9.7;NB-4: 15.1
PNPLA7	C9orf111, FLJ31318, FLJ43070, FLJ44279, NTE-R1, NTEL1, RP11-48C7.2	ENSG00000130653	Patatin like phospholipase domain containing 7	9	137459953-137550534	Predicted membrane proteins	Evidence at protein level	HPA009130	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol	Pancreatic cancer:2.24e-5 (favourable)	Tissue enhanced	Mixed			prostate: 17.6	Cell line enriched	21	HMC-1: 72.0
HBZ	HBZ-T1, HBZ1	ENSG00000130656	Hemoglobin subunit zeta	16	152687-154503	Predicted intracellular proteins	Evidence at protein level	HPA071726	Approved					Not detected	Group enriched	12	bone marrow: 2.3;placenta: 1.0;testis: 3.9	skin: 0.2	Cell line enriched	80	K-562: 2107.5
PAK4		ENSG00000130669	P21 (RAC1) activated kinase 4	19	39125770-39182816	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB025747, CAB044670, HPA070175, HPA072220	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:5.29e-5 (favourable), Prostate cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 47.8	Expressed in all		
MNX1	HB9, HLXB9, HOXHB9, SCRA1	ENSG00000130675	Motor neuron and pancreas homeobox 1	7	156994051-157010651	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071717			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enhanced		duodenum: 7.3;small intestine: 6.7	colon: 3.7	Cell line enhanced		AN3-CA: 16.0;EFO-21: 15.3;RPMI-8226: 25.9;SCLC-21H: 22.6
ZNF337	dJ694B14.1	ENSG00000130684	Zinc finger protein 337	20	25674215-25696841	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044303, HPA064219	Approved		Approved	Nuclear speckles<br>Plasma membrane	Renal cancer:2.87e-6 (unfavourable)	Mixed	Expressed in all			parathyroid gland: 27.9	Expressed in all		
CEP85	CCDC21, DKFZP434L0117	ENSG00000130695	Centrosomal protein 85	1	26234153-26279038	Predicted intracellular proteins	Evidence at protein level	HPA028252	Approved		Supported	Nucleoli<br>Golgi apparatus<br>Microtubule organizing center<br>Cytosol	Liver cancer:4.39e-6 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 48.1;testis: 52.4	heart muscle: 17.5	Expressed in all		
TAF4	TAF2C, TAF2C1, TAF4A, TAFII130, TAFII135	ENSG00000130699	TATA-box binding protein associated factor 4	20	61953469-62065810	Predicted intracellular proteins	Evidence at protein level	HPA008599, CAB031484	Supported		Enhanced	Nucleoplasm	Liver cancer:3.31e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.6	Mixed		
GATA5	bB379O24.1, GATAS	ENSG00000130700	GATA binding protein 5	20	62463497-62475970	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067583			Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		duodenum: 11.4;small intestine: 11.0;testis: 8.7	stomach: 7.5	Cell line enhanced		HEL: 2.6;K-562: 4.2;SiHa: 2.1;T-47d: 4.4
RBBP8NL	C20orf151, dJ908M14.3	ENSG00000130701	RBBP8 N-terminal like	20	62410237-62427533	Predicted intracellular proteins	Evidence at protein level	HPA042627	Uncertain				Urothelial cancer:6.91e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 5.2	duodenum: 4.5	Cell line enhanced		BEWO: 17.9;CACO-2: 22.7;MCF7: 8.7;SK-BR-3: 9.3
LAMA5		ENSG00000130702	Laminin subunit alpha 5	20	62307955-62367312	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054609, CAB078157	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		skin: 42.1	placenta: 28.9	Cell line enhanced		CACO-2: 131.3
OSBPL2	DFNA67, KIAA0772, ORP-2	ENSG00000130703	Oxysterol binding protein like 2	20	62231922-62296213	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041127, HPA042659	Uncertain		Approved	Cytosol	Renal cancer:4.20e-5 (favourable)	Expressed in all	Expressed in all			skin: 49.7	Expressed in all		
ADRM1	ARM1, GP110, Rpn13	ENSG00000130706	Adhesion regulating molecule 1	20	62302093-62308862	Predicted intracellular proteins	Evidence at protein level	HPA042266	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.02e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 108.5	Expressed in all		
ASS1	ASS, CTLN1	ENSG00000130707	Argininosuccinate synthase 1	9	130444929-130501274	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020896, HPA020934	Enhanced		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:8.14e-9 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 1259.9;liver: 1027.3	fallopian tube: 261.5	Cell line enhanced		BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
PRDM12		ENSG00000130711	PR/SET domain 12	9	130664594-130682981	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA043143	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.3	Cell line enriched	16	RH-30: 15.6
EXOSC2	hRrp4p, p7, RRP4, Rrp4p	ENSG00000130713	Exosome component 2	9	130693721-130704894	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021756, HPA021790	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:4.36e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 21.4	Expressed in all		
POMT1	LGMD2K	ENSG00000130714	Protein O-mannosyltransferase 1	9	131502902-131523806	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA065252			Approved	Golgi apparatus	Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.7	Expressed in all		
UCK1	FLJ12255, URK1	ENSG00000130717	Uridine-cytidine kinase 1	9	131523801-131531268	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050969	Approved		Approved	Nucleus	Renal cancer:2.21e-7 (favourable), Cervical cancer:3.19e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.2	Expressed in all		
FIBCD1	FLJ14810	ENSG00000130720	Fibrinogen C domain containing 1	9	130902438-130939286	Predicted intracellular proteins	Evidence at protein level	HPA053898, HPA055353	Uncertain		Supported	Cell Junctions		Mixed	Tissue enhanced		adrenal gland: 4.7;parathyroid gland: 8.6;testis: 5.3	cerebral cortex: 2.5	Cell line enhanced		MCF7: 25.2;RPTEC TERT1: 18.5;U-2 OS: 17.4;U-251 MG: 11.7
PRRC2B	BAT2L, BAT2L1, KIAA0515, LQFBS-1, MGC10526	ENSG00000130723	Proline rich coiled-coil 2B	9	131394093-131500197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021022, HPA064301	Uncertain		Approved	Nuclear bodies<br>Cytosol	Renal cancer:5.42e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 153.7	Expressed in all		
CHMP2A	BC-2, CHMP2, VPS2, VPS2A	ENSG00000130724	Charged multivesicular body protein 2A	19	58551566-58555124	Predicted intracellular proteins	Evidence at protein level	HPA041153, HPA042031	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 191.7	Expressed in all		
UBE2M	hUbc12, UBC12	ENSG00000130725	Ubiquitin conjugating enzyme E2 M	19	58555712-58558960	Predicted intracellular proteins	Evidence at protein level	CAB004993, HPA054551, HPA057800	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 108.0	Expressed in all		
TRIM28	KAP1, PPP1R157, RNF96, TF1B, TIF1B	ENSG00000130726	Tripartite motif containing 28	19	58544091-58550722	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010066, HPA064033	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.85e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 215.8	Expressed in all		
METTL26	C16orf13, MGC13114	ENSG00000130731	Methyltransferase like 26	16	634427-636366	Predicted intracellular proteins	Evidence at protein level	HPA044004	Uncertain				Renal cancer:1.73e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
YIPF2	FinGER2, MGC3262	ENSG00000130733	Yip1 domain family member 2	19	10922185-10928681	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019902	Approved		Approved	Golgi apparatus<br>Mitochondria		Expressed in all	Expressed in all			testis: 72.9	Expressed in all		
ATG4D	APG4-D, APG4D, AUTL4	ENSG00000130734	Autophagy related 4D cysteine peptidase	19	10543895-10553418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067683	Approved				Renal cancer:2.39e-7 (favourable), Cervical cancer:3.18e-5 (favourable), Stomach cancer:5.03e-4 (favourable), Pancreatic cancer:9.95e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 25.2	Mixed		
EIF2S3	EIF2, EIF2G, EIF2gamma	ENSG00000130741	Eukaryotic translation initiation factor 2 subunit gamma	X	24054716-24077971	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012471	Approved				Renal cancer:5.44e-6 (unfavourable), Liver cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 179.5	Expressed in all		
TMEM160	FLJ20512	ENSG00000130748	Transmembrane protein 160	19	47045907-47048630	Predicted membrane proteins	Evidence at protein level	HPA055904	Uncertain					Expressed in all	Mixed			cerebral cortex: 21.0	Expressed in all		
ZC3H4	C19orf7, KIAA1064	ENSG00000130749	Zinc finger CCCH-type containing 4	19	47064187-47113752	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA040934, HPA041068	Supported		Enhanced	Nucleoplasm<br>Cytosol	Urothelial cancer:2.23e-4 (favourable)	Expressed in all	Expressed in all			spleen: 13.5	Expressed in all		
NPAS1	bHLHe11, MOP5, PASD5	ENSG00000130751	Neuronal PAS domain protein 1	19	47019820-47045775	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043364, HPA072259		Approved	Approved	Nucleoplasm		Tissue enhanced	Group enriched	5	cerebral cortex: 3.9;skin: 4.4;spleen: 1.8;stomach: 2.6	lymph node: 0.6	Cell line enhanced		HEK 293: 10.1;NB-4: 11.4
GMFG		ENSG00000130755	Glia maturation factor gamma	19	39328353-39342372	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002954	Uncertain	Approved	Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:9.11e-6 (unfavourable), Cervical cancer:7.35e-4 (favourable)	Expressed in all	Expressed in all			spleen: 308.1	Cell line enhanced		HMC-1: 476.8;Karpas-707: 305.6;REH: 329.6;THP-1: 378.5;U-937: 301.7
MAP3K10	MEKK10, MLK2, MST	ENSG00000130758	Mitogen-activated protein kinase kinase kinase 10	19	40191744-40215575	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007039	Approved		Approved	Nucleus<br>Actin filaments<br>Cytosol	Urothelial cancer:2.13e-4 (favourable), Head and neck cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 31.1	testis: 7.1	Mixed		
ARHGEF16	GEF16, NBR	ENSG00000130762	Rho guanine nucleotide exchange factor 16	1	3454426-3481113	Predicted intracellular proteins	Evidence at protein level	HPA010609	Approved				Renal cancer:1.24e-10 (favourable), Liver cancer:1.82e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 42.1	small intestine: 35.9	Cell line enhanced		CAPAN-2: 48.8;MCF7: 24.6;SK-BR-3: 25.6
LRRC47	KIAA1185, RP1-286D6.3	ENSG00000130764	Leucine rich repeat containing 47	1	3778558-3796504	Predicted intracellular proteins	Evidence at protein level	HPA008512, HPA012018	Enhanced		Supported	Nucleoli fibrillar center	Renal cancer:2.75e-4 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 19.7	Expressed in all		
SESN2	DKFZp761M0212, HI95, SES2, SEST2	ENSG00000130766	Sestrin 2	1	28259527-28282491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018191	Uncertain		Approved	Cytosol	Liver cancer:4.78e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 25.6	Expressed in all		
SMPDL3B	ASML3B	ENSG00000130768	Sphingomyelin phosphodiesterase acid like 3B	1	27934993-27959157	Predicted secreted proteins	Evidence at protein level	HPA030561			Approved	Golgi apparatus<br>Cytosol		Mixed	Mixed			rectum: 25.6	Cell line enhanced		BEWO: 44.0;CAPAN-2: 31.4;SK-BR-3: 34.4;T-47d: 31.2
ATPIF1	ATPI, ATPIP, IP, MGC1167, MGC8898	ENSG00000130770	ATPase inhibitory factor 1	1	28236109-28246906	Predicted intracellular proteins	Evidence at protein level	HPA027999	Supported		Enhanced	Mitochondria	Endometrial cancer:6.38e-8 (favourable), Ovarian cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 388.7	Expressed in all		
MED18	FLJ20045, p28b	ENSG00000130772	Mediator complex subunit 18	1	28329002-28335967	Predicted intracellular proteins	Evidence at protein level	HPA027429	Uncertain		Approved	Nucleoplasm	Renal cancer:8.38e-5 (favourable), Liver cancer:1.52e-4 (unfavourable), Endometrial cancer:3.93e-4 (favourable), Stomach cancer:6.72e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 13.2	Expressed in all		
THEMIS2	C1orf38, ICB-1	ENSG00000130775	Thymocyte selection associated family member 2	1	27872543-27886685	Predicted intracellular proteins	Evidence at protein level	HPA031096, HPA031097	Uncertain		Approved	Golgi apparatus		Expressed in all	Tissue enhanced		bone marrow: 137.5	spleen: 117.3	Cell line enhanced		Karpas-707: 98.1;U-266/70: 80.2
CLIP1	CLIP, CLIP-170, CLIP170, CYLN1, RSN	ENSG00000130779	CAP-Gly domain containing linker protein 1	12	122271432-122422632	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004399, HPA026678	Approved		Supported	Microtubule ends<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 158.6	Expressed in all		
CCDC62	CT109, ERAP75, FLJ40344, TSP-NY	ENSG00000130783	Coiled-coil domain containing 62	12	122774327-122827528	Predicted intracellular proteins	Evidence at protein level	HPA039021, HPA058741	Approved		Approved	Nucleoplasm<br>Plasma membrane		Not detected	Tissue enriched	146	testis: 116.0	spleen: 0.7	Cell line enhanced		U-2 OS: 3.0
HIP1R	FLJ14000, HIP12, HIP3, ILWEQ, KIAA0655	ENSG00000130787	Huntingtin interacting protein 1 related	12	122834453-122862960	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017187, HPA038135, HPA038136	Enhanced		Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:6.50e-7 (favourable), Urothelial cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 53.1	Mixed		
ZNF317		ENSG00000130803	Zinc finger protein 317	19	9140380-9163424	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042075, HPA048625	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 20.7	Expressed in all		
PPAN	BXDC3, SSF, SSF1, SSF2	ENSG00000130810	Peter pan homolog (Drosophila)	19	10106289-10111634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043265	Approved					Expressed in all	Expressed in all			lymph node: 20.2	Expressed in all		
EIF3G	eIF3-delta, eIF3-p44, eIF3g, EIF3S4	ENSG00000130811	Eukaryotic translation initiation factor 3 subunit G	19	10115017-10119918	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041997	Approved		Enhanced	Cytosol	Ovarian cancer:3.94e-4 (favourable)	Expressed in all	Expressed in all			ovary: 217.8	Expressed in all		
ANGPTL6	AGF, ARP5	ENSG00000130812	Angiopoietin like 6	19	10092338-10102796	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		liver: 11.0	lymph node: 3.9	Cell line enriched	9	HMC-1: 51.7
C19orf66	FLJ11286, RyDEN	ENSG00000130813	Chromosome 19 open reading frame 66	19	10086122-10093252	Predicted intracellular proteins	Evidence at protein level	HPA042001	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.96e-11 (unfavourable), Urothelial cancer:1.35e-4 (favourable), Breast cancer:4.04e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 20.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 44.2;BJ hTERT+ SV40 Large T+ RasG12V: 48.5
DNMT1	CXXC9, DNMT, MCMT	ENSG00000130816	DNA methyltransferase 1	19	10133345-10231286	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002694, CAB005876	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.2	Expressed in all		
ZNF426	MGC2663	ENSG00000130818	Zinc finger protein 426	19	9523224-9538645	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029342	Approved		Approved	Nucleoplasm	Renal cancer:2.57e-6 (favourable), Urothelial cancer:1.81e-4 (favourable), Head and neck cancer:3.74e-4 (favourable)	Expressed in all	Mixed			esophagus: 22.7	Mixed		
SLC6A8	CRTR, CT1	ENSG00000130821	Solute carrier family 6 member 8	X	153688099-153696593	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 89.2	Mixed		
PNCK	CaMK1b, MGC45419	ENSG00000130822	Pregnancy up-regulated nonubiquitous CaM kinase	X	153669730-153689010	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007458	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.04e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 40.5;seminal vesicle: 52.3	smooth muscle: 22.4	Cell line enriched	7	AN3-CA: 29.8
DKC1	Cbf5, DKC, dyskerin, NAP57, NOLA4, XAP101	ENSG00000130826	Dyskerin pseudouridine synthase 1	X	154762742-154777689	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000166, HPA000447, HPA001022, CAB033086	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.46e-9 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:2.66e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable), Melanoma:9.13e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.5	Expressed in all		
PLXNA3	6.3, Plxn3, PLXN4, SEX, XAP-6	ENSG00000130827	Plexin A3	X	154458281-154477779	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA058989			Supported	Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			skin: 12.0	Mixed		
DUSP9	MKP-4, MKP4	ENSG00000130829	Dual specificity phosphatase 9	X	153642492-153651326	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003336	Enhanced		Approved	Endoplasmic reticulum	Endometrial cancer:1.60e-4 (unfavourable)	Mixed	Group enriched	35	kidney: 29.0;placenta: 103.3	testis: 1.8	Cell line enriched	6	Hep G2: 251.7
MPP1	DXS552E, PEMP	ENSG00000130830	Membrane palmitoylated protein 1	X	154778684-154821007	Predicted intracellular proteins	Evidence at protein level	HPA000167			Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Renal cancer:4.60e-6 (favourable)	Expressed in all	Expressed in all			placenta: 119.5	Cell line enhanced		HEL: 191.8
ZNF331	RITA, ZNF361, ZNF463	ENSG00000130844	Zinc finger protein 331	19	53520981-53580269	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063157			Approved	Nucleoplasm	Stomach cancer:4.79e-4 (unfavourable), Thyroid cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 208.6	Cell line enhanced		HEK 293: 73.6
ZNF236		ENSG00000130856	Zinc finger protein 236	18	76822607-76970727	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008600	Uncertain					Expressed in all	Mixed			testis: 13.3	Mixed		
SLC7A10	asc-1	ENSG00000130876	Solute carrier family 7 member 10	19	33208664-33225850	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA041884, HPA057036	Uncertain		Uncertain	Nucleus<br>Nucleoli		Mixed	Group enriched	24	adipose tissue: 31.6;cerebral cortex: 6.5	breast: 0.8	Cell line enhanced		BEWO: 1.8;HSkMC: 1.2;THP-1: 2.6;U-2 OS: 1.1
LRP3	hLRp105, LRP-3	ENSG00000130881	LDL receptor related protein 3	19	33177603-33208867	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:6.12e-7 (favourable)	Expressed in all	Mixed			ovary: 63.4	Mixed		
C12orf65	FLJ38663, SPG55	ENSG00000130921	Chromosome 12 open reading frame 65	12	123232916-123257959	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038194, HPA057595	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol	Liver cancer:4.29e-9 (unfavourable), Urothelial cancer:7.82e-5 (favourable)	Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
NOL11	DKFZP586L0724	ENSG00000130935	Nucleolar protein 11	17	67717833-67744531	Predicted intracellular proteins	Evidence at protein level	HPA022010	Supported		Enhanced	Nucleoli	Colorectal cancer:1.00e-6 (favourable), Liver cancer:2.59e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.5	Expressed in all		
UBE4B	E4, KIAA0684, UBOX3, UFD2	ENSG00000130939	Ubiquitination factor E4B	1	10032832-10181239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019219	Approved				Liver cancer:3.69e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 43.4	Expressed in all		
CASZ1	castor, cst, FLJ20321, SRG, ZNF693	ENSG00000130940	Castor zinc finger 1	1	10636604-10796650	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028222, HPA029927	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		skin: 26.9	prostate: 15.9	Cell line enhanced		HDLM-2: 12.4;SCLC-21H: 23.3;SK-BR-3: 14.1
PKDREJ		ENSG00000130943	Polycystin (PKD) family receptor for egg jelly	22	46255663-46263355	Predicted membrane proteins	Evidence at protein level	HPA034587	Enhanced					Not detected	Tissue enriched	9	testis: 6.2	skin: 0.7	Not detected		
HSD17B3	SDR12C2	ENSG00000130948	Hydroxysteroid 17-beta dehydrogenase 3	9	96235306-96302152	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056833	Enhanced		Supported	Vesicles		Mixed	Tissue enriched	15	testis: 74.9	thyroid gland: 4.8	Cell line enhanced		HBEC3-KT: 2.6;HEL: 3.2;U-2 OS: 5.8
NUTM2F	DKFZp434I1117, FAM22F	ENSG00000130950	NUT family member 2F	9	94318196-94328644	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Cell line enriched	13	NTERA-2: 1.3
HABP4	IHABP4, SERBP1L	ENSG00000130956	Hyaluronan binding protein 4	9	96450201-96491336	Predicted intracellular proteins	Evidence at protein level	HPA055969	Approved				Renal cancer:1.10e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 73.8	Mixed		
FBP2		ENSG00000130957	Fructose-bisphosphatase 2	9	94558720-94593793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012513, HPA055286	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	8	skeletal muscle: 266.1	stomach: 32.7	Cell line enhanced		BEWO: 3.9;MCF7: 2.4;SiHa: 3.0
SLC35D2	SQV7L, UGTrel8	ENSG00000130958	Solute carrier family 35 member D2	9	96320706-96383710	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064047	Approved		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			small intestine: 72.4	Mixed		
PRRG1	PRGP1	ENSG00000130962	Proline rich and Gla domain 1	X	37349275-37457295	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056029, HPA078129	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.6	Cell line enhanced		RPTEC TERT1: 59.3
UBA1	A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X	ENSG00000130985	Ubiquitin like modifier activating enzyme 1	X	47190861-47215128	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000289, HPA001506, CAB019435, CAB073410	Approved		Enhanced	Nucleoplasm	Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 239.4	Expressed in all		
RGN	RC, SMP30	ENSG00000130988	Regucalcin	X	47078355-47093314	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029102, HPA029103	Enhanced		Approved	Nucleus	Renal cancer:5.10e-10 (favourable), Liver cancer:7.55e-4 (favourable)	Tissue enriched	Tissue enhanced		adrenal gland: 202.7;liver: 196.4	kidney: 57.0	Group enriched	6	CACO-2: 17.9;fHDF/TERT166: 5.3;Hep G2: 22.3
POLN		ENSG00000130997	DNA polymerase nu	4	2071918-2242121	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035939, HPA035940			Enhanced	Nucleoplasm		Mixed	Tissue enhanced		adipose tissue: 3.0;testis: 4.4	epididymis,prostate: 1.0	Mixed		
PPIL4		ENSG00000131013	Peptidylprolyl isomerase like 4	6	149504733-149546038	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031599, HPA031600	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 48.0	Expressed in all		
ULBP2	RAET1H	ENSG00000131015	UL16 binding protein 2	6	149942000-149949235	Predicted membrane proteins	Evidence at protein level	CAB018974	Approved		Supported	Vesicles<br>Plasma membrane	Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,esophagus: 3.0	Cell line enhanced		SiHa: 69.8
AKAP12	AKAP250, SSeCKS	ENSG00000131016	A-kinase anchoring protein 12	6	151239999-151358557	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006344, CAB026379, HPA056230	Enhanced		Supported	Plasma membrane<br>Cytosol	Lung cancer:6.34e-5 (unfavourable), Endometrial cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 184.5	Cell line enhanced		REH: 175.6
SYNE1	8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B	ENSG00000131018	Spectrin repeat containing nuclear envelope protein 1	6	152121684-152637801	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019113	Approved		Supported	Nucleoplasm<br>Nuclear membrane		Mixed	Expressed in all			parathyroid gland: 59.2	Mixed		
ULBP3	RAET1N	ENSG00000131019	UL16 binding protein 3	6	150063150-150069095	Predicted secreted proteins	Evidence at protein level	HPA056541, HPA063007	Approved		Uncertain	Vesicles<br>Microtubule organizing center		Mixed	Tissue enhanced		testis: 11.9;thyroid gland: 8.8	fallopian tube: 3.9	Mixed		
LATS1	WARTS	ENSG00000131023	Large tumor suppressor kinase 1	6	149658153-149718256	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031804	Approved		Uncertain	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 23.6	Expressed in all		
EPS8L1	DRC3, FLJ20258, MGC23164, MGC4642	ENSG00000131037	EPS8 like 1	19	55072020-55087923	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041851, HPA043545	Uncertain		Supported	Cytosol	Colorectal cancer:4.44e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 18.4;stomach: 23.5	esophagus: 9.0	Cell line enhanced		BEWO: 51.9;T-47d: 24.8
LILRB2	CD85d, ILT4, LIR-2, LIR2, MIR-10, MIR10	ENSG00000131042	Leukocyte immunoglobulin like receptor B2	19	54273821-54281184	CD markers, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.45e-7 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 8.7;bone marrow: 20.5;spleen: 10.4	lung: 3.9	Not detected		
AAR2	bA234K24.2, C20orf4	ENSG00000131043	AAR2 splicing factor homolog	20	36236459-36270918	Predicted intracellular proteins	Evidence at protein level	CAB034220, HPA048645	Uncertain		Approved	Cytosol	Liver cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.9	Expressed in all		
TTLL9	C20orf125, dJ310O13.1	ENSG00000131044	Tubulin tyrosine ligase like 9	20	31870702-31944963	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA041772, HPA055676	Uncertain		Uncertain	Nucleoplasm<br>Microtubules		Tissue enhanced	Tissue enhanced		fallopian tube: 7.1;testis: 6.3	epididymis: 3.2	Not detected		
BPIFA2	bA49G10.1, C20orf70, PSP, SPLUNC2	ENSG00000131050	BPI fold containing family A member 2	20	33161768-33181412	Predicted secreted proteins	Evidence at protein level	HPA044006	Enhanced					Tissue enhanced	Tissue enriched	520	salivary gland: 2662.8	epididymis: 5.1	Not detected		
RBM39	CAPER, CAPERalpha, CC1.3, fSAP59, HCC1, RNPC2	ENSG00000131051	RNA binding motif protein 39	20	35701347-35742312	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001591	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Microtubules<br>Microtubule organizing center	Renal cancer:2.78e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 123.0	Expressed in all		
COX4I2	COX4-2, COX4B, COX4L2, COXIV-2, dJ857M17.2	ENSG00000131055	Cytochrome c oxidase subunit 4I2	20	31637888-31645006	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Head and neck cancer:6.04e-5 (favourable), Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Group enriched	5	lung: 42.8;placenta: 157.5	thyroid gland: 19.3	Cell line enriched	5	SH-SY5Y: 1.8
BPIFA3	bA49G10.4, C20orf71, SPLUNC3	ENSG00000131059	BPI fold containing family A member 3	20	33217310-33227758	Predicted secreted proteins	Evidence at protein level	HPA062708	Enhanced					Not detected	Tissue enriched	534	testis: 53.4	all non-specific tissues: 0.0	Not detected		
ZNF341	dJ553F4.3	ENSG00000131061	Zinc finger protein 341	20	33731657-33792269	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023240, HPA024607, HPA067108	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:1.87e-4 (unfavourable), Head and neck cancer:3.93e-4 (favourable)	Expressed in all	Mixed			testis: 2.3	Mixed		
GGT7	D20S101, dJ18C9.2, GGTL3, GGTL5	ENSG00000131067	Gamma-glutamyltransferase 7	20	34844720-34872860	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013204, HPA013339	Approved		Approved	Nucleus<br>Vesicles	Endometrial cancer:1.26e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex,parathyroid gland: 50.0	Mixed		
DEFB118	C20orf63, DEFB-18, dJ1018D12.3, ESC42	ENSG00000131068	Defensin beta 118	20	31368618-31373923	Predicted secreted proteins	Evidence at protein level	HPA042634	Enhanced					Not detected	Tissue enriched	12295	epididymis: 1229.5	all non-specific tissues: 0.0	Not detected		
ACSS2	ACAS2, AceCS, ACS, ACSA, dJ1161H23.1	ENSG00000131069	Acyl-CoA synthetase short-chain family member 2	20	34872146-34927962	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004141	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.04e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 55.9	Mixed		
EDA2R	EDA-A2R, EDAA2R, TNFRSF27, XEDAR	ENSG00000131080	Ectodysplasin A2 receptor	X	66595637-66639298	Predicted membrane proteins	Evidence at protein level	HPA054522			Approved	Cell Junctions		Mixed	Mixed			thyroid gland: 9.5	Cell line enhanced		HSkMC: 24.5;LHCN-M2: 26.7
ARHGEF9	KIAA0424, PEM-2	ENSG00000131089	Cdc42 guanine nucleotide exchange factor 9	X	63634967-63809274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035419, HPA055291	Approved		Supported	Cytosol	Renal cancer:1.02e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 80.1	Mixed		
C1QL1	C1QRF, C1QTNF14, CRF	ENSG00000131094	Complement C1q like 1	17	44959693-44968071	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.31e-8 (unfavourable)	Tissue enriched	Tissue enriched	14	cerebral cortex: 38.4	prostate: 2.6	Cell line enhanced		SCLC-21H: 49.2;SH-SY5Y: 31.5;U-2 OS: 108.2;U-87 MG: 32.8
GFAP	FLJ45472	ENSG00000131095	Glial fibrillary acidic protein	17	44903161-44916937	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000039, HPA056030, HPA063513	Enhanced	Supported	Supported	Intermediate filaments		Tissue enriched	Tissue enriched	398	cerebral cortex: 3768.4	bone marrow: 9.4	Mixed		
PYY	PYY1	ENSG00000131096	Peptide YY	17	43952738-44004469	Predicted secreted proteins	Evidence at protein level	HPA010973, CAB016734	Enhanced					Group enriched	Group enriched	15	colon: 52.6;rectum: 39.2;small intestine: 27.4	duodenum: 2.5	Cell line enhanced		HMC-1: 2.6
HIGD1B	CLST11240, CLST11240-15	ENSG00000131097	HIG1 hypoxia inducible domain family member 1B	17	44846353-44850480	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Group enriched	6	lung: 55.4;placenta: 153.8	gallbladder: 18.2	Mixed		
ATP6V1E1	ATP6E, ATP6E2, ATP6V1E, P31, Vma4	ENSG00000131100	ATPase H+ transporting V1 subunit E1	22	17592136-17628818	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009528, CAB018699, HPA029196	Enhanced		Approved	Nucleoplasm	Renal cancer:7.66e-8 (favourable), Liver cancer:1.56e-5 (unfavourable), Prostate cancer:4.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 301.3	Expressed in all		
ZNF227		ENSG00000131115	Zinc finger protein 227	19	44207547-44237268	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030573	Uncertain		Approved	Plasma membrane	Urothelial cancer:2.64e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.7	Mixed		
ZNF428	C19orf37, MGC51082, Zfp428	ENSG00000131116	Zinc finger protein 428	19	43607219-43619874	Predicted intracellular proteins	Evidence at protein level	HPA042596, HPA048072	Uncertain		Approved	Nucleoli<br>Mitochondria	Pancreatic cancer:3.60e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
TEX101	CT131, MGC4766, SGRG, SPATA44	ENSG00000131126	Testis expressed 101	19	43401496-43418597	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041915, HPA042513	Enhanced					Mixed	Tissue enriched	108	testis: 173.9	skin: 1.6	Not detected		
ZNF141	D4S90, pHZ-44	ENSG00000131127	Zinc finger protein 141	4	337814-384864	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:4.76e-4 (favourable)	Expressed in all	Mixed			adrenal gland,thyroid gland: 14.9	Mixed		
CCL25	Ckb15, SCYA25, TECK	ENSG00000131142	C-C motif chemokine ligand 25	19	8052767-8062650	Predicted secreted proteins	Evidence at protein level	HPA055883	Uncertain					Group enriched	Group enriched	317	duodenum: 529.5;small intestine: 653.7	lymph node: 1.8	Cell line enhanced		BEWO: 2.7;HEL: 2.7;REH: 5.6;SH-SY5Y: 2.0
COX4I1	COX4, COX4-1	ENSG00000131143	Cytochrome c oxidase subunit 4I1	16	85798633-85807044	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002485, CAB004080	Supported		Supported	Mitochondria	Renal cancer:2.56e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 1085.8	Expressed in all		
EMC8	C16orf2, C16orf4, COX4NB, FAM158B, NOC4	ENSG00000131148	ER membrane protein complex subunit 8	16	85771758-85799608	Predicted intracellular proteins	Evidence at protein level	HPA049476	Approved		Supported	Cytosol	Renal cancer:6.39e-4 (favourable), Liver cancer:8.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.4	Expressed in all		
GSE1	KIAA0182	ENSG00000131149	Gse1 coiled-coil protein	16	85169525-85676204	Predicted intracellular proteins	Evidence at protein level	HPA036365	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 83.4	Expressed in all		
RP11-178L8.4		ENSG00000131152		16	87302876-87334273	Predicted intracellular proteins	Evidence at transcript level	HPA040850	Uncertain					Not detected	Not detected			duodenum,endometrium,lymph node,skeletal muscle: 0.6	Mixed		
GINS2	Pfs2, PSF2	ENSG00000131153	GINS complex subunit 2	16	85676198-85690073	Predicted intracellular proteins	Evidence at protein level	HPA057285	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 12.2	Cell line enhanced		U-698: 182.9
CHMP1A	CHMP1, KIAA0047, PCOLN3, PRSM1, Vps46A	ENSG00000131165	Charged multivesicular body protein 1A	16	89644431-89657845	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 53.1	Expressed in all		
SH3BGRL	MGC117402	ENSG00000131171	SH3 domain binding glutamate rich protein like	X	81201943-81298547	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051248	Approved		Approved	Vesicles	Stomach cancer:4.08e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 360.6	Mixed		
COX7B		ENSG00000131174	Cytochrome c oxidase subunit 7B	X	77899438-77907373	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058041	Uncertain				Renal cancer:6.80e-6 (favourable), Urothelial cancer:2.43e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 65.4	Expressed in all		
SLC34A1	NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2	ENSG00000131183	Solute carrier family 34 member 1	5	177379235-177398848	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051255	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Mitotic spindle		Tissue enriched	Tissue enriched	164	kidney: 161.7	liver: 0.9	Group enriched	12	HEL: 2.1;U-937: 1.2
F12		ENSG00000131187	Coagulation factor XII	5	177402140-177409576	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003825	Approved				Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable)	Tissue enriched	Tissue enriched	78	liver: 141.6	bone marrow: 1.8	Cell line enhanced		HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5
PRR7	MGC10772	ENSG00000131188	Proline rich 7, synaptic	5	177446445-177456286	Predicted intracellular proteins	Evidence at transcript level	HPA046636	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.1	bone marrow: 3.7	Mixed		
NFATC1	NF-ATC, NFAT2, NFATc	ENSG00000131196	Nuclear factor of activated T-cells 1	18	79395856-79529325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004513, HPA071732	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 24.7	Cell line enhanced		U-698: 42.3
IDO1	IDO, INDO	ENSG00000131203	Indoleamine 2,3-dioxygenase 1	8	39902275-39928444	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023072, HPA023149, HPA027772, CAB072820	Enhanced				Renal cancer:1.12e-7 (unfavourable), Ovarian cancer:3.32e-4 (favourable), Melanoma:5.27e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 149.4	lymph node: 57.3	Cell line enriched	7	EFO-21: 54.8
GJA9	CX58, CX59, GJA10	ENSG00000131233	Gap junction protein alpha 9	1	38874451-38881587	Predicted membrane proteins	Evidence at transcript level	HPA067850	Uncertain					Not detected	Tissue enhanced		testis: 2.0	skin: 0.5	Not detected		
CAP1	CAP	ENSG00000131236	Adenylate cyclase associated protein 1	1	40040233-40072649	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030124	Approved		Supported	Cytosol	Liver cancer:1.44e-6 (unfavourable)	Expressed in all	Expressed in all			appendix: 417.0	Expressed in all		
PPT1	CLN1, INCL, PPT	ENSG00000131238	Palmitoyl-protein thioesterase 1	1	40072705-40097703	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021546	Supported				Liver cancer:6.98e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 193.0	Expressed in all		
RAB11FIP4	FLJ00131, KIAA1821, MGC11316, RAB11-FIP4	ENSG00000131242	RAB11 family interacting protein 4	17	31391624-31538217	Predicted intracellular proteins	Evidence at protein level	HPA021595	Approved				Renal cancer:7.74e-8 (favourable), Stomach cancer:1.22e-4 (favourable), Colorectal cancer:2.70e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 67.9	testis: 42.4	Cell line enhanced		BEWO: 62.0;HMC-1: 36.4
RLIM	MGC15161, NY-REN-43, RNF12	ENSG00000131263	Ring finger protein, LIM domain interacting	X	74585217-74614617	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018895	Approved		Supported	Nucleoplasm<br>Cytosol	Thyroid cancer:6.04e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
CDX4		ENSG00000131264	Caudal type homeobox 4	X	73447254-73455245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056528	Uncertain					Tissue enriched	Tissue enriched	8	skin: 1.3	seminal vesicle,testis: 0.1	Not detected		
ABCB7	ABC7, ASAT, Atm1p, EST140535	ENSG00000131269	ATP binding cassette subfamily B member 7	X	75053172-75156732	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034982	Approved		Supported	Mitochondria	Renal cancer:5.31e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
TRAF3	CAP-1, CD40bp, CRAF1, LAP1	ENSG00000131323	TNF receptor associated factor 3	14	102777476-102911500	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002933	Uncertain				Liver cancer:1.02e-5 (unfavourable), Pancreatic cancer:2.42e-5 (favourable)	Expressed in all	Mixed			appendix: 25.7	Expressed in all		
HAUS8	HICE1, MGC20533, NY-SAR-48	ENSG00000131351	HAUS augmin like complex subunit 8	19	17049729-17075625	Predicted intracellular proteins	Evidence at protein level	HPA039406	Uncertain				Cervical cancer:9.54e-4 (favourable)	Expressed in all	Mixed			testis: 16.7	Mixed		
ADGRE3	EMR3	ENSG00000131355	Adhesion G protein-coupled receptor E3	19	14619117-14690027	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA015638	Uncertain					Not detected	Tissue enhanced		appendix: 8.7;spleen: 8.6	lung: 3.9	Cell line enriched	50	HMC-1: 39.7
MRPS25	DKFZp313H0817, FLJ00023, MRP-S25, RPMS25	ENSG00000131368	Mitochondrial ribosomal protein S25	3	15042460-15065335	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043490	Approved		Enhanced	Mitochondria	Renal cancer:3.60e-7 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
SH3BP5	Sab	ENSG00000131370	SH3 domain binding protein 5	3	15254853-15341368	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036445, HPA057988	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 221.2	Expressed in all		
HACL1	2-HPCL, HPCL, PHYH2	ENSG00000131373	2-hydroxyacyl-CoA lyase 1	3	15560704-15601852	Predicted intracellular proteins	Evidence at protein level	HPA035496, HPA035497	Approved				Renal cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 50.9	Expressed in all		
TBC1D5	KIAA0210	ENSG00000131374	TBC1 domain family member 5	3	17157162-18444817	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035125, HPA035126	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.75e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Expressed in all		
CAPN7	PalBH	ENSG00000131375	Calpain 7	3	15206152-15252918	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046617	Uncertain				Colorectal cancer:4.85e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.4	Expressed in all		
RFTN1	FLJ23866, KIAA0084, MIG2, Raftlin	ENSG00000131378	Raftlin, lipid raft linker 1	3	16313574-16514026	Predicted intracellular proteins	Evidence at protein level	HPA048725	Approved				Renal cancer:1.29e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 135.3	Cell line enhanced		HDLM-2: 165.3;SH-SY5Y: 142.4
C3orf20	DKFZP434N1817	ENSG00000131379	Chromosome 3 open reading frame 20	3	14675099-14773034	Predicted intracellular proteins	Evidence at protein level	HPA039584	Uncertain					Not detected	Tissue enriched	29	testis: 10.4	lymph node,tonsil: 0.3	Cell line enhanced		Daudi: 2.9;HEL: 7.7;U-698: 4.4
RBSN	ZFYVE20	ENSG00000131381	Rabenosyn, RAB effector	3	15070073-15099163	Predicted intracellular proteins	Evidence at protein level	HPA044878	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 30.7	Expressed in all		
GALNT15	GALNT7, GALNTL2, pp-GalNAc-T15	ENSG00000131386	Polypeptide N-acetylgalactosaminyltransferase 15	3	16174649-16231992	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017076	Uncertain		Approved	Golgi apparatus<br>Cytosol		Tissue enriched	Tissue enhanced		adipose tissue: 36.3;cerebral cortex: 41.2;placenta: 43.0	breast: 18.3	Group enriched	11	ASC diff: 91.0;ASC TERT1: 90.9;HSkMC: 72.4;U-2197: 22.3
SLC6A6	TAUT	ENSG00000131389	Solute carrier family 6 member 6	3	14402576-14489349	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015028, HPA016488	Enhanced		Approved	Cell Junctions<br>Cytosol	Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable)	Expressed in all	Mixed			ovary: 50.8	Mixed		
KCNC3	Kv3.3, SCA13	ENSG00000131398	Potassium voltage-gated channel subfamily C member 3	19	50311937-50333515	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA018041	Approved				Renal cancer:1.23e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 39.9	cerebral cortex: 19.8	Cell line enhanced		HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8
NAPSA	KAP, Kdap, NAP1, NAPA	ENSG00000131400	Napsin A aspartic peptidase	19	50358477-50365830	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009591, HPA045280, HPA047236, HPA047744	Enhanced				Renal cancer:1.21e-4 (favourable)	Tissue enriched	Tissue enriched	14	lung: 1412.2	kidney: 101.4	Cell line enriched	23	U-698: 27.1
NR1H2	LXR-b, NER, NER-I, RIP15, UNR	ENSG00000131408	Nuclear receptor subfamily 1 group H member 2	19	50329653-50382982	Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056838, HPA070212	Uncertain		Approved	Nucleoplasm	Colorectal cancer:9.86e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 87.6	Expressed in all		
LRRC4B	DKFZp761A179, HSM, LRIG4	ENSG00000131409	Leucine rich repeat containing 4B	19	50516892-50568045	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA058986	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 61.4	cervix, uterine: 12.9	Cell line enhanced		HMC-1: 29.7;SH-SY5Y: 31.3;U-2 OS: 28.7
PDLIM4	RIL	ENSG00000131435	PDZ and LIM domain 4	5	132257671-132273454	Predicted intracellular proteins	Evidence at protein level	HPA011912	Uncertain		Approved	Actin filaments<br>Cytosol		Mixed	Mixed			smooth muscle: 61.9	Cell line enhanced		hTEC/SVTERT24-B: 117.7
KIF3A	FLA10, KLP-20	ENSG00000131437	Kinesin family member 3A	5	132692628-132737638	Predicted intracellular proteins	Evidence at protein level	CAB037085	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 82.8	testis: 43.9	Expressed in all		
MGAT1	GLCNAC-TI, GLYT1, GNT-1, GnTI, MGAT	ENSG00000131446	Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase	5	180784782-180815652	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017432	Approved				Renal cancer:8.65e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 118.4	Expressed in all		
GFPT2	GFAT2	ENSG00000131459	Glutamine-fructose-6-phosphate transaminase 2	5	180300690-180353387	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056892, HPA059910	Uncertain		Supported	Vesicles	Renal cancer:2.58e-14 (unfavourable), Lung cancer:2.95e-4 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable), Cervical cancer:9.09e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 90.9	appendix: 25.7	Cell line enhanced		ASC TERT1: 138.7;hTEC/SVTERT24-B: 242.9;U-87 MG: 409.1
TUBG1	TUBG, TUBGCP1	ENSG00000131462	Tubulin gamma 1	17	42609676-42615234	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004608	Enhanced				Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 242.8	smooth muscle: 40.2	Expressed in all		
PSME3	Ki, PA28-gamma, PA28G, REG-GAMMA	ENSG00000131467	Proteasome activator subunit 3	17	42824385-42843758	Predicted intracellular proteins	Evidence at protein level	CAB008388, HPA012510	Supported		Enhanced	Nucleoplasm	Liver cancer:5.41e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 106.3	Expressed in all		
RPL27	L27	ENSG00000131469	Ribosomal protein L27	17	42998273-43002959	Cancer-related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002649	Approved				Renal cancer:7.80e-8 (unfavourable)	Expressed in all	Expressed in all			breast: 2437.8	Expressed in all		
PSMC3IP	GT198, Hop2, HUMGT198A, TBPIP	ENSG00000131470	PSMC3 interacting protein	17	42572315-42577831	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044439	Enhanced		Supported	Nucleoplasm	Renal cancer:9.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 32.2	fallopian tube: 9.6	Expressed in all		
AOC3	HPAO, VAP-1, VAP1	ENSG00000131471	Amine oxidase, copper containing 3	17	42851184-42858130	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000980, CAB025797	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 450.1	smooth muscle: 205.7	Cell line enriched	17	ASC diff: 210.1
ACLY	ACL, ATPCL, CLATP	ENSG00000131473	ATP citrate lyase	17	41866908-41930542	Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007783, HPA022434, HPA022953, HPA022959, HPA028758	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Cervical cancer:1.79e-4 (unfavourable), Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 100.5	Expressed in all		
VPS25	DERP9, EAP20, MGC10540	ENSG00000131475	Vacuolar protein sorting 25 homolog	17	42773436-42779599	Predicted intracellular proteins	Evidence at protein level	CAB004978, HPA052217, HPA057284	Uncertain		Approved	Centrosome	Colorectal cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 93.3	Expressed in all		
RAMP2		ENSG00000131477	Receptor activity modifying protein 2	17	42758447-42763041	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052020			Approved	Vesicles		Expressed in all	Mixed			lung: 178.6	Cell line enhanced		ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
AOC2	DAO2, RAO	ENSG00000131480	Amine oxidase, copper containing 2	17	42844600-42850707	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA057779	Uncertain				Urothelial cancer:2.47e-4 (favourable)	Tissue enhanced	Group enriched	5	adipose tissue: 6.2;testis: 5.8	spleen: 1.2	Cell line enhanced		ASC diff: 7.7
G6PC	G6PT, GSD1a	ENSG00000131482	Glucose-6-phosphatase catalytic subunit	17	42900797-42913369	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052324	Enhanced				Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)	Tissue enriched	Tissue enhanced		kidney: 89.1;liver: 147.3	small intestine: 33.2	Not detected		
NDUFA2	B8	ENSG00000131495	NADH:ubiquinone oxidoreductase subunit A2	5	140638740-140647785	Predicted intracellular proteins	Evidence at protein level	HPA035933	Uncertain				Cervical cancer:6.53e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 117.4	Expressed in all		
ANKHD1	FLJ10042, FLJ11979, FLJ14127, FLJ20288, KIAA1085, MASK, MASK1	ENSG00000131503	Ankyrin repeat and KH domain containing 1	5	140401814-140539856	Predicted intracellular proteins	Evidence at protein level	HPA008718	Approved					Mixed	Expressed in all			parathyroid gland: 74.5	Expressed in all		
DIAPH1	DFNA1, hDIA1, LFHL1	ENSG00000131504	Diaphanous related formin 1	5	141515016-141619055	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004916, HPA076913	Approved		Approved	Plasma membrane	Renal cancer:1.29e-5 (favourable), Pancreatic cancer:7.81e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.6	Expressed in all		
NDFIP1	MGC10924, N4WBP5	ENSG00000131507	Nedd4 family interacting protein 1	5	142108505-142154443	Predicted membrane proteins	Evidence at protein level	HPA009682	Approved				Head and neck cancer:2.33e-7 (unfavourable), Renal cancer:2.39e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 246.0	Expressed in all		
UBE2D2	UBC4, UbcH5B	ENSG00000131508	Ubiquitin conjugating enzyme E2 D2	5	139526431-139628433	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003920	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:9.63e-7 (unfavourable), Renal cancer:2.09e-5 (unfavourable), Colorectal cancer:5.09e-5 (favourable), Endometrial cancer:5.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 239.4	Expressed in all		
EXOC4	KIAA1699, MGC27170, SEC8, SEC8L1, Sec8p	ENSG00000131558	Exocyst complex component 4	7	133253073-134066589	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA031443, HPA031444	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:6.85e-5 (favourable), Pancreatic cancer:6.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.9	Expressed in all		
ACAP3	CENTB5, KIAA1716	ENSG00000131584	ArfGAP with coiled-coil, ankyrin repeat and PH domains 3	1	1292376-1309609	Predicted intracellular proteins	Evidence at protein level	HPA049317, HPA058381	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 26.5	Expressed in all		
C1orf159	FLJ20584	ENSG00000131591	Chromosome 1 open reading frame 159	1	1081818-1116361	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010019	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 15.3	Expressed in all		
ANO1	DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A	ENSG00000131620	Anoctamin 1	11	70078302-70189528	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032148, HPA057356	Enhanced				Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 220.9;seminal vesicle: 298.5	skin: 115.8	Group enriched	5	A-431: 121.8;CAPAN-2: 182.7;HaCaT: 224.5
PPFIA1	LIP.1, LIPRIN	ENSG00000131626	PTPRF interacting protein alpha 1	11	70270700-70384403	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008272, CAB017032, HPA042271	Uncertain		Enhanced	Focal adhesion sites<br>Cytosol	Renal cancer:3.76e-4 (favourable), Head and neck cancer:5.58e-4 (unfavourable), Pancreatic cancer:8.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.2	Expressed in all		
TMEM204	C16orf30, CLP24, FLJ20898	ENSG00000131634	Transmembrane protein 204	16	1528688-1555580	Predicted membrane proteins	Evidence at transcript level	HPA014028	Approved				Liver cancer:4.76e-4 (favourable), Melanoma:7.89e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 40.6	Cell line enhanced		BJ: 13.1;BJ hTERT+: 17.0;fHDF/TERT166: 11.0;HHSteC: 30.6;HSkMC: 10.6
KREMEN2	KRM2, MGC10791	ENSG00000131650	Kringle containing transmembrane protein 2	16	2963944-2968383	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA003223	Uncertain		Approved	Nucleoli	Lung cancer:8.98e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 6.9	cerebral cortex: 2.1	Cell line enhanced		HMC-1: 24.6;RPMI-8226: 19.1
THOC6	fSAP35, MGC2655, WDR58	ENSG00000131652	THO complex 6	16	3024027-3027755	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052953	Uncertain		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:4.40e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 29.2	Expressed in all		
TRAF7	DKFZp586I021, MGC7807, RFWD1, RNF119	ENSG00000131653	TNF receptor associated factor 7	16	2155698-2178129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041229	Approved		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			skin: 40.6	Expressed in all		
BARX1		ENSG00000131668	BARX homeobox 1	9	93951622-93955372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055858			Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:8.16e-6 (unfavourable), Head and neck cancer:1.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	stomach: 11.1	testis: 1.5	Group enriched	6	AN3-CA: 27.2;HMC-1: 61.1;NTERA-2: 20.7;THP-1: 19.2
NINJ1	NIN1	ENSG00000131669	Ninjurin 1	9	93121489-93134288	Predicted membrane proteins	Evidence at protein level	HPA045063	Uncertain					Expressed in all	Expressed in all			bone marrow: 158.2	Mixed		
CA6		ENSG00000131686	Carbonic anhydrase 6	1	8945867-8975092	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA028550, HPA028692	Enhanced					Mixed	Tissue enriched	154	salivary gland: 3805.4	breast: 24.7	Mixed		
NPHP4	KIAA0673, POC10, SLSN4	ENSG00000131697	Nephrocystin 4	1	5862811-5992473	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065526	Approved					Mixed	Mixed			fallopian tube: 12.5	Mixed		
MAP1B	MAP5, PPP1R102	ENSG00000131711	Microtubule associated protein 1B	5	72107234-72209570	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009792, HPA022275	Enhanced		Enhanced	Cytosol	Urothelial cancer:8.22e-5 (unfavourable)	Tissue enriched	Tissue enriched	5	cerebral cortex: 187.6	smooth muscle: 36.8	Cell line enhanced		TIME: 228.1
RHOXF2	CT107, PEPP-2, PEPP2, THG1	ENSG00000131721	Rhox homeobox family member 2	X	120158561-120165630	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003314, CAB020794	Enhanced					Tissue enhanced	Tissue enriched	184	testis: 20.8	skin: 0.1	Cell line enhanced		K-562: 209.3;NB-4: 108.3;THP-1: 42.9;U-266/84: 73.5
IL13RA1	CD213a1, IL-13Ra, NR4	ENSG00000131724	Interleukin 13 receptor subunit alpha 1	X	118727572-118794539	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA000293			Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.19e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 72.0	Mixed		
WDR44	DKFZp686L20145, RAB11BP, RPH11	ENSG00000131725	WD repeat domain 44	X	118346073-118449961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038084, HPA046719	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 23.2	Expressed in all		
CKMT2	SMTCK	ENSG00000131730	Creatine kinase, mitochondrial 2	5	81233285-81266397	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051880	Enhanced					Mixed	Group enriched	22	heart muscle: 710.7;skeletal muscle: 505.3	adrenal gland: 27.9	Cell line enhanced		BEWO: 3.3;T-47d: 5.1
ZCCHC9	DKFZp761J139, PPP1R41	ENSG00000131732	Zinc finger CCHC-type containing 9	5	81301590-81313297	Predicted intracellular proteins	Evidence at protein level	HPA038404, HPA057521	Uncertain		Approved	Intermediate filaments		Expressed in all	Expressed in all			placenta: 27.4	Expressed in all		
KRT34	Ha-4, KRTHA4	ENSG00000131737	Keratin 34	17	41377650-41382403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055194, HPA072208	Supported		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	8	cervix, uterine: 4.2	testis: 0.5	Cell line enhanced		BJ: 170.4;BJ hTERT+ SV40 Large T+ RasG12V: 45.2;HBF TERT88: 41.4
KRT33B	Ha-3II, KRTHA3B	ENSG00000131738	Keratin 33B	17	41363494-41369800	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055194	Supported					Tissue enhanced	Not detected			testis: 0.1	Cell line enhanced		BJ: 3.4;hTEC/SVTERT24-B: 1.5;U-2197: 1.0
TNS4	CTEN	ENSG00000131746	Tensin 4	17	40475828-40501597	Predicted intracellular proteins	Evidence at protein level						Lung cancer:5.16e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 66.6	esophagus: 31.6	Cell line enhanced		HaCaT: 123.8;HBEC3-KT: 447.5;hTCEpi: 328.7;hTERT-HME1: 108.8
TOP2A	TOP2	ENSG00000131747	Topoisomerase (DNA) II alpha	17	40388516-40417950	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002448, HPA006458, HPA026773	Enhanced	Approved	Supported	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 108.5	lymph node: 47.7	Expressed in all		
STARD3	es64, MLN64	ENSG00000131748	StAR related lipid transfer domain containing 3	17	39637065-39663484	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	CAB017021	Uncertain				Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.3	Expressed in all		
RARA	NR1B1, RAR	ENSG00000131759	Retinoic acid receptor alpha	17	40309192-40357643	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058282			Supported	Nucleus<br>Cytosol	Endometrial cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.6	Expressed in all		
PPP1R1B	DARPP-32, FLJ20940	ENSG00000131771	Protein phosphatase 1 regulatory inhibitor subunit 1B	17	39626740-39636626	Predicted intracellular proteins	Evidence at protein level	CAB004026, HPA048630, HPA061142	Approved	Approved				Mixed	Tissue enhanced		rectum: 219.9	colon: 209.5	Cell line enhanced		CAPAN-2: 11.0;HSkMC: 23.1;SCLC-21H: 31.9
KHDRBS3	Etle, etoile, SALP, SLM-2, SLM2, T-STAR	ENSG00000131773	KH RNA binding domain containing, signal transduction associated 3	8	135457457-135656722	Predicted intracellular proteins	Evidence at protein level	HPA000275, HPA000500, HPA000981	Enhanced		Supported	Nucleoplasm	Renal cancer:7.16e-6 (favourable)	Expressed in all	Group enriched	7	cerebral cortex: 89.1;testis: 285.9	epididymis: 27.8	Cell line enhanced		WM-115: 83.8
CHD1L	ALC1	ENSG00000131778	Chromodomain helicase DNA binding protein 1 like	1	147242641-147295766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027789, HPA028670	Enhanced		Supported	Nucleoplasm	Renal cancer:1.31e-9 (unfavourable), Liver cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
PEX11B		ENSG00000131779	Peroxisomal biogenesis factor 11 beta	1	145911350-145918837	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA050104	Supported				Liver cancer:2.67e-4 (unfavourable), Lung cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 44.8	Expressed in all		
FMO5		ENSG00000131781	Flavin containing monooxygenase 5	1	147175351-147243050	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012373	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.34e-6 (favourable)	Tissue enriched	Tissue enhanced		liver: 324.7	small intestine: 75.4	Cell line enhanced		Hep G2: 26.6;HMC-1: 7.7;THP-1: 6.7
PIAS3	FLJ14651, ZMIZ5	ENSG00000131788	Protein inhibitor of activated STAT 3	1	145848522-145859836	Predicted intracellular proteins	Evidence at protein level	HPA006389, HPA067383	Approved		Supported	Nucleoplasm	Renal cancer:1.21e-7 (unfavourable), Liver cancer:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 60.1	Expressed in all		
PRKAB2		ENSG00000131791	Protein kinase AMP-activated non-catalytic subunit beta 2	1	147155106-147172550	Predicted intracellular proteins	Evidence at protein level	HPA044342	Approved		Approved	Nucleoplasm	Thyroid cancer:6.78e-7 (unfavourable), Breast cancer:4.55e-4 (unfavourable), Head and neck cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.5	Expressed in all		
FSHB		ENSG00000131808	Follicle stimulating hormone beta subunit	11	30231016-30235261	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB023410, HPA069703	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PDHA1	PDHA	ENSG00000131828	Pyruvate dehydrogenase (lipoamide) alpha 1	X	19343893-19361705	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047487, HPA047864, HPA063053	Approved		Supported	Mitochondria	Renal cancer:1.13e-7 (favourable)	Expressed in all	Expressed in all			heart muscle: 222.0	Expressed in all		
RAI2		ENSG00000131831	Retinoic acid induced 2	X	17800049-17861337	Predicted intracellular proteins	Evidence at protein level	HPA051054	Uncertain		Approved	Plasma membrane	Renal cancer:3.39e-14 (favourable), Pancreatic cancer:2.77e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 79.1	Cell line enriched	9	ASC diff: 71.0
MCCC2	MCCB	ENSG00000131844	Methylcrotonoyl-CoA carboxylase 2	5	71587288-71658704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038300, HPA038301, HPA061546	Enhanced		Enhanced	Mitochondria	Renal cancer:6.43e-8 (favourable), Liver cancer:1.70e-4 (favourable), Colorectal cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			prostate: 77.2	Mixed		
ZNF304		ENSG00000131845	Zinc finger protein 304	19	57351307-57359898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050531	Approved		Approved	Nuclear speckles	Renal cancer:1.52e-7 (favourable), Melanoma:4.95e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.9	Mixed		
ZSCAN5A	MGC4161, ZNF495, ZSCAN5	ENSG00000131848	Zinc finger and SCAN domain containing 5A	19	56219670-56368383	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041263, HPA043123, HPA046836, HPA060667	Uncertain		Uncertain	Nuclear speckles		Mixed	Tissue enhanced		testis: 34.6	fallopian tube: 11.4	Expressed in all		
ZNF132	pHZ-12	ENSG00000131849	Zinc finger protein 132	19	58432814-58440222	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA008726	Uncertain		Approved	Vesicles<br>Intermediate filaments	Renal cancer:7.26e-13 (favourable), Pancreatic cancer:1.92e-4 (favourable)	Mixed	Mixed			parathyroid gland: 11.6	Mixed		
USP29		ENSG00000131864	Ubiquitin specific peptidase 29	19	57119138-57131926	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021064	Uncertain					Not detected	Tissue enriched	5	testis: 9.0	skin: 1.7	Not detected		
SELENOS	AD-015, MGC2553, SBBI8, SELS, SEPS1, VIMP	ENSG00000131871	Selenoprotein S	15	101270817-101277500	Predicted membrane proteins	Evidence at protein level	HPA010025	Approved		Enhanced	Endoplasmic reticulum	Endometrial cancer:1.33e-4 (favourable), Ovarian cancer:5.19e-4 (favourable)	Expressed in all	Expressed in all			testis: 141.8	Expressed in all		
CHSY1	CSS1, KIAA0990	ENSG00000131873	Chondroitin sulfate synthase 1	15	101175723-101251932	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048902	Uncertain				Renal cancer:6.33e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 64.8	Expressed in all		
SNRPA1	Lea1	ENSG00000131876	Small nuclear ribonucleoprotein polypeptide A'	15	101281510-101295282	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045622, HPA048499	Supported		Supported	Nucleoplasm<br>Nuclear speckles<br>Nuclear bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.56e-5 (unfavourable), Ovarian cancer:8.83e-5 (favourable)	Expressed in all	Expressed in all			testis: 68.6	Expressed in all		
LLGL1	DLG4, HUGL, HUGL-1, Lgl1, LLGL, Mgl1	ENSG00000131899	LLGL1, scribble cell polarity complex component	17	18225587-18244875	Predicted intracellular proteins	Evidence at protein level	HPA022924, HPA023569	Enhanced				Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 21.1	endometrium: 7.0	Expressed in all		
NR0B2	SHP	ENSG00000131910	Nuclear receptor subfamily 0 group B member 2	1	26911489-26913966	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Tissue enhanced		duodenum: 78.6;liver: 48.8	small intestine: 28.9	Cell line enriched	19	Hep G2: 53.5
LIN28A	CSDD1, FLJ12457, LIN-28, LIN28, ZCCHC1	ENSG00000131914	Lin-28 homolog A	1	26410778-26429722	Predicted intracellular proteins	Evidence at protein level	CAB020785	Enhanced		Uncertain	Nucleoplasm		Tissue enriched	Tissue enriched	12	testis: 4.3	skin: 0.3	Cell line enriched	10	NTERA-2: 860.9
THAP1	4833431A01Rik, DYT6, FLJ10477	ENSG00000131931	THAP domain containing 1	8	42836674-42843325	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071310			Supported	Nucleus		Expressed in all	Mixed			testis: 17.6	Expressed in all		
RHPN2		ENSG00000131941	Rhophilin Rho GTPase binding protein 2	19	32978593-33064888	Predicted intracellular proteins	Evidence at protein level	HPA051749	Uncertain				Renal cancer:1.22e-8 (favourable), Head and neck cancer:1.58e-4 (unfavourable)	Expressed in all	Mixed			prostate: 43.6	Mixed		
C19orf12	DKFZP762D096, MGC10922, MPAN, NBIA4, SPG43	ENSG00000131943	Chromosome 19 open reading frame 12	19	29698886-29715789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046930	Approved					Expressed in all	Expressed in all			adipose tissue: 122.7	Expressed in all		
FAAP24	C19orf40, FLJ46828, MGC32020	ENSG00000131944	Fanconi anemia core complex associated protein 24	19	32972209-32978222	Predicted intracellular proteins	Evidence at protein level	HPA041168	Uncertain		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.00e-7 (unfavourable), Endometrial cancer:4.38e-4 (unfavourable)	Expressed in all	Mixed			testis: 11.9	Expressed in all		
LRRC9	FLJ46156	ENSG00000131951	Leucine rich repeat containing 9	14	59919713-60063559	Predicted intracellular proteins	Evidence at transcript level	HPA040965, HPA041381	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 3.5;testis: 10.8	fallopian tube: 1.9	Cell line enhanced		NTERA-2: 1.0
ACTR10	ACTR11, Arp10, Arp11, HARP11	ENSG00000131966	Actin-related protein 10 homolog	14	58200080-58235636	Predicted intracellular proteins	Evidence at protein level	HPA071251			Supported	Nucleoli	Renal cancer:8.48e-8 (favourable), Liver cancer:2.71e-5 (unfavourable), Breast cancer:3.24e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 11.7	Expressed in all		
ABHD12B	BEM46L3, C14orf29	ENSG00000131969	Abhydrolase domain containing 12B	14	50872160-50904970	Predicted intracellular proteins	Evidence at transcript level	HPA002873	Uncertain		Uncertain	Nucleus		Tissue enriched	Tissue enriched	8	skin: 16.3	cerebral cortex: 2.1	Not detected		
GCH1	DYT14, DYT5, DYT5a, GCH, GTPCH1	ENSG00000131979	GTP cyclohydrolase 1	14	54842008-54902852	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028612	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Pancreatic cancer:1.41e-4 (favourable), Urothelial cancer:6.67e-4 (favourable), Ovarian cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 22.6	liver: 18.8	Cell line enhanced		SH-SY5Y: 48.2
LGALS3	GALIG, LGALS2, MAC-2	ENSG00000131981	Galectin 3	14	55124110-55145413	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003162, CAB005191	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			colon: 871.1	Cell line enhanced		SK-MEL-30: 1368.8
PODNL1	FLJ23447, SLRR5B	ENSG00000132000	Podocan like 1	19	13931187-13953392	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042807	Approved				Glioma:2.06e-8 (unfavourable), Urothelial cancer:4.49e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 12.3	skin: 8.5	Cell line enhanced		HSkMC: 17.5;SiHa: 21.2;U-2 OS: 16.8
DNAJB1	Hsp40, HSPF1, RSPH16B, Sis1	ENSG00000132002	DnaJ heat shock protein family (Hsp40) member B1	19	14514770-14529770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017450, HPA063247	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 348.8	Expressed in all		
ZSWIM4	FLJ12221	ENSG00000132003	Zinc finger SWIM-type containing 4	19	13795460-13832230	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA042084	Uncertain				Renal cancer:7.85e-5 (unfavourable)	Expressed in all	Mixed			appendix: 5.7	Mixed		
FBXW9	Fbw9, MGC10870	ENSG00000132004	F-box and WD repeat domain containing 9	19	12688053-12696643	Predicted intracellular proteins	Evidence at protein level	HPA042087	Approved		Approved	Cytosol		Expressed in all	Mixed			fallopian tube: 21.0	Expressed in all		
RFX1	EF-C	ENSG00000132005	Regulatory factor X1	19	13961538-14007039	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048722	Approved		Supported	Nucleoplasm	Head and neck cancer:2.42e-4 (favourable), Pancreatic cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			testis: 16.8	Expressed in all		
ZNF20	KOX13	ENSG00000132010	Zinc finger protein 20	19	12092843-12140407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020887	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Not detected	Mixed			testis: 9.3	Mixed		
C19orf57	MGC11271	ENSG00000132016	Chromosome 19 open reading frame 57	19	13882348-13906452	Predicted intracellular proteins	Evidence at protein level	HPA044012, HPA054615	Enhanced		Approved	Nucleoplasm	Endometrial cancer:3.38e-4 (unfavourable), Head and neck cancer:5.14e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.7	skin: 13.9	Mixed		
DCAF15	C19orf72, MGC99481	ENSG00000132017	DDB1 and CUL4 associated factor 15	19	13952492-13961449	Predicted intracellular proteins	Evidence at protein level	HPA068351			Approved	Vesicles<br>Mitochondria	Renal cancer:1.34e-5 (unfavourable), Pancreatic cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 59.9	Expressed in all		
CC2D1A	FLJ20241, MRT3	ENSG00000132024	Coiled-coil and C2 domain containing 1A	19	13906201-13930879	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005436, CAB015220	Supported		Supported	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Head and neck cancer:7.02e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 35.6	Expressed in all		
RTBDN	FLJ36353	ENSG00000132026	Retbindin	19	12825478-12835428	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052511			Approved	Endoplasmic reticulum		Mixed	Group enriched	6	adrenal gland: 4.6;cerebral cortex: 14.6;testis: 3.5	stomach: 1.2	Cell line enhanced		SCLC-21H: 9.8;SH-SY5Y: 5.8;U-266/84: 16.0
MATN3	EDM5, HOA	ENSG00000132031	Matrilin 3	2	19992111-20012694	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA051250			Approved	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:4.74e-5 (unfavourable), Liver cancer:8.62e-5 (unfavourable), Cervical cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 20.2;placenta: 16.5	seminal vesicle: 6.2	Cell line enriched	5	Hep G2: 98.9
TRIM21	RNF81, Ro/SSA, RO52, SSA1	ENSG00000132109	Tripartite motif containing 21	11	4384897-4393696	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004566, HPA005673	Approved		Approved	Nucleoplasm	Thyroid cancer:2.26e-6 (favourable), Breast cancer:4.83e-5 (favourable), Liver cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.2	Mixed		
SPATA6	FLJ10007, SRF-1, SRF1	ENSG00000132122	Spermatogenesis associated 6	1	48295372-48472208	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028234			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		testis: 89.0	fallopian tube: 24.6	Cell line enhanced		ASC TERT1: 14.7
LRRC41	MUF1	ENSG00000132128	Leucine rich repeat containing 41	1	46261196-46303608	Predicted intracellular proteins	Evidence at protein level	HPA051941	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.66e-9 (unfavourable), Cervical cancer:5.50e-4 (unfavourable), Renal cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.8	Expressed in all		
CCT6B	Cctz2, TSA303	ENSG00000132141	Chaperonin containing TCP1 subunit 6B	17	34927859-34981078	Predicted intracellular proteins	Evidence at protein level	HPA042996, HPA045576, HPA049949	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	33	testis: 225.1	breast: 6.9	Cell line enhanced		RPMI-8226: 8.3
DHX30	DDX30, FLJ11214, KIAA0890	ENSG00000132153	DExH-box helicase 30	3	47802909-47850195	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034806	Supported		Supported	Mitochondria<br>Cytosol	Renal cancer:1.37e-6 (favourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
RAF1	c-Raf, CRAF, Raf-1	ENSG00000132155	Raf-1 proto-oncogene, serine/threonine kinase	3	12583601-12664226	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002640, CAB019291	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Expressed in all		
SLC6A11	GAT3	ENSG00000132164	Solute carrier family 6 member 11	3	10816200-10940733	Predicted membrane proteins, Transporters	Evidence at protein level	HPA037981	Supported	Supported				Tissue enhanced	Tissue enhanced		cerebral cortex: 18.1;skin: 6.7	esophagus: 5.5	Cell line enhanced		HaCaT: 11.8;Hep G2: 10.7;hTCEpi: 8.5;NTERA-2: 6.6
PPARG	NR1C3, PPARG1, PPARG2, PPARgamma	ENSG00000132170	Peroxisome proliferator activated receptor gamma	3	12287368-12434356	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004282, HPA051239, HPA063663	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 173.3	placenta: 59.2	Cell line enhanced		ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
NUP210	FLJ22389, GP210, KIAA0906, POM210	ENSG00000132182	Nucleoporin 210	3	13316235-13420309	Predicted membrane proteins, Transporters	Evidence at protein level	HPA066888	Approved				Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 48.6	Mixed		
FCRLA	FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595	ENSG00000132185	Fc receptor like A	1	161706972-161714352	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016545	Enhanced					Tissue enriched	Group enriched	10	appendix: 31.2;lymph node: 80.5;spleen: 56.4;tonsil: 86.7	urinary bladder: 6.2	Cell line enhanced		Daudi: 338.0;SK-MEL-30: 150.5;U-698: 179.6
HSD17B7	PRAP, SDR37C1	ENSG00000132196	Hydroxysteroid 17-beta dehydrogenase 7	1	162790702-162812817	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047496	Approved				Renal cancer:8.47e-5 (unfavourable)	Expressed in all	Mixed			liver: 16.9	Expressed in all		
ENOSF1	HSRTSBETA, rTS, TYMSAS	ENSG00000132199	Enolase superfamily member 1	18	670324-712676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047829	Enhanced				Breast cancer:2.27e-4 (favourable)	Expressed in all	Mixed			kidney: 38.9	Expressed in all		
EMILIN2	FLJ33200, FOAP-10	ENSG00000132205	Elastin microfibril interfacer 2	18	2847030-2915993	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA064576	Supported				Renal cancer:1.62e-4 (unfavourable), Liver cancer:6.30e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 269.3	placenta: 31.4	Cell line enhanced		ASC diff: 33.3;BEWO: 36.7;HL-60: 30.1;HMC-1: 53.5;U-2197: 43.7
SLX1A	GIYD1	ENSG00000132207	SLX1 homolog A, structure-specific endonuclease subunit	16	30193887-30197561	Predicted intracellular proteins	Evidence at protein level	HPA047038	Uncertain		Approved	Nucleoplasm		Not detected	Expressed in all			duodenum: 50.3	Mixed		
ARFIP2	POR1	ENSG00000132254	ADP ribosylation factor interacting protein 2	11	6474683-6481479	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB032985, HPA038156	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Golgi apparatus	Endometrial cancer:2.00e-5 (favourable), Renal cancer:9.53e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.5	Expressed in all		
TRIM5	RNF88, TRIM5alpha	ENSG00000132256	Tripartite motif containing 5	11	5663557-5938619	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013497, HPA023420, HPA023422	Approved		Supported	Cytosol		Expressed in all	Mixed			epididymis: 26.9	Expressed in all		
CNGA4	CNCA2, CNG5, CNGB2, OCNC2, OCNCb	ENSG00000132259	Cyclic nucleotide gated channel alpha 4	11	6234765-6244429	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Endometrial cancer:1.48e-4 (favourable)	Tissue enriched	Group enriched	9	fallopian tube: 27.9;testis: 10.5	lung: 2.1	Not detected		
TRIM22	GPSTAF50, RNF94, STAF50	ENSG00000132274	Tripartite motif containing 22	11	5689689-5737089	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003307, HPA003575	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			spleen: 174.9	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 183.3
RRP8	KIAA0409, NML	ENSG00000132275	Ribosomal RNA processing 8, methyltransferase, homolog (yeast)	11	6595075-6603620	Predicted intracellular proteins	Evidence at protein level	HPA038487, HPA057562	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.10e-7 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 12.4	Expressed in all		
TIMM10B	FXC1, TIM10B, Tim9b	ENSG00000132286	Translocase of inner mitochondrial membrane 10B	11	6481447-6484679	Predicted intracellular proteins	Evidence at protein level	HPA052265	Approved				Renal cancer:3.19e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.8	Expressed in all		
EFR3A	KIAA0143	ENSG00000132294	EFR3 homolog A	8	131904088-132013642	Predicted intracellular proteins	Evidence at protein level	HPA022859, HPA023092, HPA023402	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.4	Expressed in all		
HHLA1	PLA2L	ENSG00000132297	HERV-H LTR-associating 1	8	132061486-132111159	Predicted secreted proteins	Evidence at transcript level	HPA059051	Uncertain					Not detected	Not detected			placenta: 0.1	Cell line enriched	12	NTERA-2: 1.1
PTCD3	DKFZp666K071, FLJ20758	ENSG00000132300	Pentatricopeptide repeat domain 3	2	86106182-86142157	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA041154, HPA041382	Supported		Enhanced	Mitochondria	Stomach cancer:6.77e-4 (favourable), Urothelial cancer:6.86e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.2	Expressed in all		
IMMT	HMP, Mic60, MINOS2, P87, P89	ENSG00000132305	Inner membrane mitochondrial protein	2	86143932-86195770	Predicted intracellular proteins	Evidence at protein level	CAB022439, HPA036164, HPA036165	Enhanced		Enhanced	Mitochondria	Renal cancer:3.51e-6 (favourable), Endometrial cancer:1.06e-4 (unfavourable), Liver cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 107.3	Expressed in all		
MRPL35		ENSG00000132313	Mitochondrial ribosomal protein L35	2	86199355-86213794	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA043482	Uncertain				Renal cancer:9.96e-6 (favourable), Liver cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 64.6	Expressed in all		
IQCA1	DRC11, FLJ22527, IQCA	ENSG00000132321	IQ motif containing with AAA domain 1	2	236324147-236507542	Predicted intracellular proteins	Evidence at transcript level	HPA057320			Uncertain	Nucleus	Renal cancer:2.54e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 17.9;thyroid gland: 32.3	cerebral cortex: 11.4	Cell line enhanced		EFO-21: 3.1;HBEC3-KT: 2.2;HeLa: 2.5;U-2 OS: 12.9
ILKAP	DKFZP434J2031, FLJ10181, PPM1O	ENSG00000132323	ILK associated serine/threonine phosphatase	2	238170401-238203729	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004752, HPA056099	Uncertain		Approved	Nucleoplasm	Renal cancer:9.89e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.0	Expressed in all		
PER2	KIAA0347	ENSG00000132326	Period circadian clock 2	2	238244038-238290102	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060510	Enhanced				Head and neck cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.2	Mixed		
RAMP1		ENSG00000132329	Receptor activity modifying protein 1	2	237858893-237912114	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA057814			Supported	Nucleoplasm<br>Nuclear membrane	Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable)	Expressed in all	Tissue enhanced		endometrium: 234.1	smooth muscle: 171.5	Cell line enhanced		HDLM-2: 126.9;PC-3: 142.8;SH-SY5Y: 202.6
SCLY	SCL	ENSG00000132330	Selenocysteine lyase	2	238060889-238099413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055760	Uncertain		Approved	Golgi apparatus		Not detected	Expressed in all			testis: 12.9	Expressed in all		
PTPRE	PTPE	ENSG00000132334	Protein tyrosine phosphatase, receptor type E	10	127907061-128085855	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015870, HPA021872	Supported		Approved	Intermediate filaments	Renal cancer:4.08e-5 (unfavourable)	Expressed in all	Mixed			appendix: 34.8	Cell line enhanced		HUVEC TERT2: 34.9;TIME: 64.9
RAN	ARA24, Gsp1, TC4	ENSG00000132341	RAN, member RAS oncogene family	12	130871879-130877678	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA063353			Uncertain	Nucleus	Liver cancer:9.99e-8 (unfavourable), Renal cancer:1.46e-7 (unfavourable), Prostate cancer:7.86e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 559.9	Expressed in all		
PRKAA1	AMPKa1	ENSG00000132356	Protein kinase AMP-activated catalytic subunit alpha 1	5	40759379-40798374	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005050, HPA035409, HPA064946	Supported		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 74.4	Expressed in all		
CARD6	CINCIN1	ENSG00000132357	Caspase recruitment domain family member 6	5	40841184-40860175	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036438	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Expressed in all	Mixed			spleen: 17.0	Cell line enhanced		HUVEC TERT2: 26.1;TIME: 27.4
RAP1GAP2	GARNL4, KIAA1039	ENSG00000132359	RAP1 GTPase activating protein 2	17	2755705-3037739	Predicted intracellular proteins	Evidence at protein level	HPA022148, HPA022896	Approved		Supported	Nuclear membrane<br>Cytosol	Renal cancer:1.36e-6 (favourable)	Expressed in all	Mixed			cerebral cortex: 35.2	Cell line enhanced		SH-SY5Y: 55.4
CLUH	CLU1, KIAA0664	ENSG00000132361	Clustered mitochondria homolog	17	2689386-2712663	Predicted intracellular proteins	Evidence at protein level	HPA031505, HPA044346	Uncertain		Supported	Nuclear bodies<br>Vesicles	Renal cancer:1.92e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 50.7	Expressed in all		
INPP5K	SKIP	ENSG00000132376	Inositol polyphosphate-5-phosphatase K	17	1494571-1516888	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031044	Uncertain				Pancreatic cancer:1.47e-6 (favourable), Endometrial cancer:2.33e-5 (favourable), Cervical cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 32.2	Expressed in all		
MYBBP1A	FLJ37886, P160, PAP2	ENSG00000132382	MYB binding protein 1a	17	4538897-4555631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005466	Supported		Supported	Nucleoli<br>Vesicles	Pancreatic cancer:1.61e-4 (favourable), Renal cancer:5.95e-4 (unfavourable), Thyroid cancer:8.12e-4 (unfavourable), Melanoma:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 21.6	Expressed in all		
RPA1	HSSB, REPA1, RF-A, RP-A, RPA70	ENSG00000132383	Replication protein A1	17	1829702-1900082	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004563, HPA006914, HPA046497	Supported		Enhanced	Nucleoplasm	Liver cancer:9.00e-9 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 44.7	Expressed in all		
SERPINF1	EPC-1, PEDF, PIG35	ENSG00000132386	Serpin family F member 1	17	1761959-1777574	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005825	Approved				Renal cancer:1.40e-8 (unfavourable), Cervical cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 739.1	Cell line enhanced		ASC diff: 752.1;ASC TERT1: 594.5;Hep G2: 362.7;HHSteC: 306.9;HSkMC: 845.8
UBE2G1	UBC7, UBE2G	ENSG00000132388	Ubiquitin conjugating enzyme E2 G1	17	4269259-4366628	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045681, HPA050551	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 73.2	Expressed in all		
EEFSEC	eEFSec, EFSEC, SELB	ENSG00000132394	Eukaryotic elongation factor, selenocysteine-tRNA specific	3	128153454-128408646	Predicted intracellular proteins	Evidence at protein level	HPA035795	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Cervical cancer:2.98e-5 (favourable)	Expressed in all	Expressed in all			testis: 18.8	Expressed in all		
TBC1D14	KIAA1322	ENSG00000132405	TBC1 domain family member 14	4	6909242-7033118	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036930, HPA067398	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.28e-10 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 67.5	Expressed in all		
TMEM128	MGC13159	ENSG00000132406	Transmembrane protein 128	4	4235542-4248212	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044809	Uncertain					Expressed in all	Expressed in all			thyroid gland: 63.9	Expressed in all		
COQ3	bA9819.1	ENSG00000132423	Coenzyme Q3, methyltransferase	6	99369400-99394204	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031273, HPA031274	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:6.86e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 20.8	Expressed in all		
PNISR	bA98I9.2, C6orf111, DKFZp564B0769, FLJ14752, SFRS18, SRrp130	ENSG00000132424	PNN interacting serine and arginine rich protein	6	99398051-99425331	Predicted intracellular proteins	Evidence at protein level	HPA038796	Uncertain		Supported	Nuclear speckles<br>Cytosol	Urothelial cancer:1.09e-4 (favourable), Renal cancer:1.41e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 127.1	Expressed in all		
POPDC3	bA355M14.1, MGC22671, POP3	ENSG00000132429	Popeye domain containing 3	6	105158280-105179995	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012514			Approved	Nucleoli<br>Cytosol	Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 8.8;heart muscle: 19.8;skeletal muscle: 41.8;testis: 9.1	epididymis: 2.9	Cell line enhanced		RH-30: 20.5
SEC61G	SSS1	ENSG00000132432	Sec61 translocon gamma subunit	7	54752250-54759974	Predicted membrane proteins, Transporters	Evidence at protein level	HPA053196	Uncertain				Renal cancer:6.60e-8 (unfavourable), Head and neck cancer:4.64e-7 (unfavourable), Liver cancer:3.85e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 408.8	Expressed in all		
LANCL2	GPR69B, TASP	ENSG00000132434	LanC like 2	7	55365448-55433742	Predicted intracellular proteins	Evidence at protein level	HPA019711, HPA029535	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:1.03e-6 (favourable), Ovarian cancer:1.89e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 41.2	parathyroid gland: 16.5	Cell line enriched	6	A-431: 130.0
FIGNL1		ENSG00000132436	Fidgetin like 1	7	50444128-50542535	Predicted intracellular proteins	Evidence at protein level	HPA055542	Approved				Renal cancer:9.54e-7 (unfavourable), Liver cancer:1.01e-4 (unfavourable), Melanoma:4.82e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 14.7	Mixed		
DDC	AADC	ENSG00000132437	Dopa decarboxylase	7	50458436-50565457	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017742	Enhanced		Approved	Actin filaments		Mixed	Tissue enhanced		duodenum: 155.2;kidney: 320.9;small intestine: 180.5	adrenal gland: 63.8	Group enriched	9	CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
FTHL17	CT38	ENSG00000132446	Ferritin heavy chain like 17	X	31071241-31072053	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	14	testis: 3.4	skin: 0.2	Not detected		
GRSF1		ENSG00000132463	G-rich RNA sequence binding factor 1	4	70815782-70839945	Predicted intracellular proteins	Evidence at protein level	HPA036984, HPA036985	Enhanced		Enhanced	Mitochondria	Renal cancer:2.72e-9 (favourable), Colorectal cancer:1.47e-5 (favourable), Liver cancer:8.29e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 95.7	Expressed in all		
ENAM	AIH2	ENSG00000132464	Enamelin	4	70628744-70686816	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.81e-14 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 8.3;kidney: 5.9	heart muscle: 2.4	Not detected		
JCHAIN	IGCJ, IGJ, JCH	ENSG00000132465	Joining chain of multimeric IgA and IgM	4	70655541-70681817	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB034436, HPA044132	Enhanced				Head and neck cancer:7.56e-7 (favourable), Breast cancer:1.81e-6 (favourable), Renal cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 6965.1	Group enriched	205	Daudi: 2569.0;Karpas-707: 1336.5;RPMI-8226: 2653.0;U-266/70: 5934.2;U-266/84: 2263.1;U-698: 3199.2
ANKRD17	FLJ22206, GTAR, KIAA0697, MASK2, NY-BR-16	ENSG00000132466	Ankyrin repeat domain 17	4	73073376-73258798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045024, HPA063731	Approved		Supported	Nucleus<br>Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 49.7	Expressed in all		
UTP3	CRLZ1, DKFZp761F222, FLJ23256, SAS10	ENSG00000132467	UTP3, small subunit processome component homolog (S. cerevisiae)	4	70688479-70690551	Predicted intracellular proteins	Evidence at protein level	HPA035655, HPA041453	Approved		Supported	Nucleoli<br>Vesicles	Renal cancer:3.16e-4 (favourable)	Expressed in all	Expressed in all			spleen: 43.2	Expressed in all		
ITGB4	CD104	ENSG00000132470	Integrin subunit beta 4	17	75721328-75757818	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002422, CAB005258, HPA036348, HPA036349	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable)	Expressed in all	Mixed			skin: 84.3	Cell line enhanced		CAPAN-2: 787.0;HaCaT: 304.0;HBEC3-KT: 550.4
WBP2	GRAMD6, WBP-2	ENSG00000132471	WW domain binding protein 2	17	75845699-75856507	Predicted intracellular proteins	Evidence at protein level	HPA065682, HPA068819	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 360.8	Expressed in all		
H3F3B	H3.3B	ENSG00000132475	H3 histone family member 3B	17	75776434-75785893	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037166, CAB037187, CAB037221, HPA042570	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 2832.4	Expressed in all		
UNK	KIAA1753, ZC3H5, ZC3HDC5	ENSG00000132478	Unkempt family zinc finger	17	75784771-75825799	Predicted intracellular proteins	Evidence at protein level	HPA023636, HPA027962	Uncertain		Supported	Cytosol<br>Cytoplasmic bodies	Pancreatic cancer:6.58e-5 (favourable), Head and neck cancer:2.02e-4 (favourable)	Expressed in all	Expressed in all			skin: 16.4	Expressed in all		
TRIM47	GOA, RNF100	ENSG00000132481	Tripartite motif containing 47	17	75874161-75878575	Predicted intracellular proteins	Evidence at protein level	HPA014933	Uncertain		Supported	Cytosol	Liver cancer:5.59e-5 (unfavourable), Renal cancer:9.69e-5 (unfavourable), Breast cancer:6.54e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 23.8	Mixed		
ZRANB2	ZIS, ZIS1, ZIS2, ZNF265	ENSG00000132485	Zinc finger RANBP2-type containing 2	1	71063291-71081297	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053960, HPA061949, HPA063298	Supported		Enhanced	Nucleus	Renal cancer:1.57e-8 (unfavourable), Liver cancer:7.29e-5 (unfavourable), Prostate cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 116.1	Expressed in all		
EIF5A	EIF-5A, EIF5A1, MGC104255, MGC99547	ENSG00000132507	Eukaryotic translation initiation factor 5A	17	7306999-7312463	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB005042, HPA061298	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.63e-5 (unfavourable), Lung cancer:9.04e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 435.8	Expressed in all		
KDM6B	JMJD3, KIAA0346	ENSG00000132510	Lysine demethylase 6B	17	7839904-7854796	Predicted intracellular proteins	Evidence at protein level	HPA037988	Enhanced		Approved	Nuclear speckles	Thyroid cancer:3.37e-4 (unfavourable), Renal cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			appendix: 28.8	Mixed		
CLEC10A	CD301, CLECSF13, CLECSF14, HML, HML2	ENSG00000132514	C-type lectin domain family 10 member A	17	7074537-7080307	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA021937	Approved				Head and neck cancer:1.26e-5 (favourable), Testis cancer:4.22e-4 (unfavourable), Lung cancer:9.24e-4 (favourable)	Expressed in all	Mixed			appendix: 38.9	Not detected		
SLC52A1	FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1	ENSG00000132517	Solute carrier family 52 member 1	17	5032600-5052009	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB011449	Uncertain				Cervical cancer:9.54e-4 (favourable)	Mixed	Group enriched	10	duodenum: 36.1;placenta: 26.1;skin: 13.2;small intestine: 26.3	parathyroid gland: 2.6	Cell line enhanced		A549: 2.1;BEWO: 1.9;HMC-1: 4.1;SK-BR-3: 2.0
GUCY2D	CORD6, CYGD, GUC1A4, GUC2D, LCA, LCA1, retGC, RETGC-1, ROS-GC1	ENSG00000132518	Guanylate cyclase 2D, retinal	17	8002594-8020339	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		testis: 1.4	lymph node: 0.3	Cell line enriched	6	HMC-1: 1.1
GPS2		ENSG00000132522	G protein pathway suppressor 2	17	7311324-7315564	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA067540	Approved		Supported	Nucleoplasm	Renal cancer:3.42e-5 (unfavourable), Pancreatic cancer:7.50e-5 (favourable)	Expressed in all	Expressed in all			testis: 97.4	Expressed in all		
XAF1	BIRC4BP, HSXIAPAF1, XIAPAF1	ENSG00000132530	XIAP associated factor 1	17	6755447-6775647	Predicted intracellular proteins	Evidence at protein level	HPA057302	Approved		Supported	Nucleus<br>Mitochondria<br>Rods & Rings	Renal cancer:2.73e-7 (unfavourable)	Expressed in all	Mixed			spleen: 81.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 69.2;BJ hTERT+ SV40 Large T+ RasG12V: 74.2
DLG4	PSD-95, PSD95, SAP-90, SAP90	ENSG00000132535	Discs large MAGUK scaffold protein 4	17	7189890-7219702	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001999, CAB002000, HPA010122	Enhanced		Approved	Vesicles	Pancreatic cancer:8.82e-6 (favourable), Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 178.6	endometrium: 28.9	Cell line enhanced		HMC-1: 57.4
RIDA	HRSP12, P14.5, PSP, UK114	ENSG00000132541	Reactive intermediate imine deaminase A homolog	8	98102344-98117241	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022856, HPA023489	Enhanced				Liver cancer:9.61e-6 (favourable)	Expressed in all	Group enriched	9	kidney: 454.6;liver: 698.7	cerebral cortex: 62.3	Expressed in all		
VPS13B	CHS1, COH1	ENSG00000132549	Vacuolar protein sorting 13 homolog B	8	99013266-99877580	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043865			Approved	Cell Junctions		Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
RGS22	CT145, DKFZP434I092, PRTD-NY2	ENSG00000132554	Regulator of G-protein signaling 22	8	99960936-100131268	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	testis: 108.9	fallopian tube: 16.7	Not detected		
MATN2		ENSG00000132561	Matrilin 2	8	97868840-98036716	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033879	Approved				Thyroid cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 456.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 73.2;BJ hTERT+ SV40 Large T+ RasG12V: 104.0;HaCaT: 101.1;HBF TERT88: 97.3
REEP2	C5orf19, SGC32445, SPG72, Yip2d	ENSG00000132563	Receptor accessory protein 2	5	138439017-138446969	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA031813	Enhanced				Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 90.1	smooth muscle: 18.0	Cell line enhanced		AN3-CA: 89.1;SCLC-21H: 46.8;SH-SY5Y: 47.6
PCBD2	DCOH2, DCOHM	ENSG00000132570	Pterin-4 alpha-carbinolamine dehydratase 2	5	134904906-135007959	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036428	Uncertain		Approved	Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
SDF2		ENSG00000132581	Stromal cell derived factor 2	17	28648356-28662189	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042799			Approved	Vesicles	Liver cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 27.8	Expressed in all		
FLOT2	ECS-1, ECS1, ESA, ESA1, M17S1	ENSG00000132589	Flotillin 2	17	28879335-28897679	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001396, CAB004395	Enhanced					Expressed in all	Expressed in all			spleen: 93.7	Expressed in all		
ERAL1	HERA-B	ENSG00000132591	Era like 12S mitochondrial rRNA chaperone 1	17	28854938-28861067	Predicted intracellular proteins	Evidence at protein level	HPA021425, HPA024423	Supported		Enhanced	Mitochondria<br>Cytosol	Liver cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.2	Expressed in all		
PRMT7	FLJ10640, KIAA1933	ENSG00000132600	Protein arginine methyltransferase 7	16	68310974-68358563	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044241	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Endometrial cancer:2.31e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.0	Expressed in all		
NIP7	CGI-37, FLJ10296, HSPC031, KD93	ENSG00000132603	NIP7, nucleolar pre-rRNA processing protein	16	69339430-69343111	Predicted intracellular proteins	Evidence at protein level	HPA040856, HPA059850	Enhanced		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:6.69e-5 (unfavourable), Head and neck cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
TERF2	TRBF2, TRF2	ENSG00000132604	Telomeric repeat binding factor 2	16	69355561-69408571	Predicted intracellular proteins	Evidence at protein level	HPA001907, HPA002735, CAB010451	Enhanced		Supported	Nuclear bodies		Expressed in all	Expressed in all			lymph node: 42.2	Expressed in all		
VPS4A	FLJ22197, SKD1, SKD1A, SKD2, VPS4, VPS4-1	ENSG00000132612	Vacuolar protein sorting 4 homolog A	16	69311356-69326939	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018751, CAB034411, HPA060092	Approved				Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 31.9	Expressed in all		
MTSS1L	ABBA, ABBA-1, LOC92154	ENSG00000132613	MTSS1L, I-BAR domain containing	16	70661204-70686066	Predicted intracellular proteins	Evidence at protein level	HPA048531, HPA066469	Approved		Supported	Focal adhesion sites	Breast cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 320.2	Mixed		
HSPA12B	C20orf60, dJ1009E24.2	ENSG00000132622	Heat shock protein family A (Hsp70) member 12B	20	3732667-3753111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013659, HPA015639	Uncertain					Expressed in all	Mixed			spleen: 25.4	Cell line enhanced		CACO-2: 4.0;EFO-21: 4.6;HUVEC TERT2: 7.9;TIME: 4.3
ANKEF1	ANKRD5, dJ839B4.6, FLJ21669	ENSG00000132623	Ankyrin repeat and EF-hand domain containing 1	20	9986126-10058303	Predicted intracellular proteins	Evidence at protein level	HPA041151	Approved		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Thyroid cancer:1.58e-4 (unfavourable), Lung cancer:1.81e-4 (unfavourable), Renal cancer:4.44e-4 (favourable)	Mixed	Tissue enhanced		testis: 33.7	thyroid gland: 11.3	Mixed		
SCP2D1	C20orf79, dJ1068E13.2, HSD22	ENSG00000132631	SCP2 sterol binding domain containing 1	20	18813726-18814392	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	593	testis: 59.2	all non-specific tissues: 0.0	Not detected		
PCED1A	bA12M19.1, C20orf81, FAM113A, FLJ22376	ENSG00000132635	PC-esterase domain containing 1A	20	2835314-2841190	Predicted intracellular proteins	Evidence at protein level	HPA050816	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.96e-5 (favourable), Liver cancer:7.31e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 81.5	Expressed in all		
SNAP25	bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25	ENSG00000132639	Synaptosome associated protein 25	20	10218830-10307418	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000360, HPA001830	Enhanced	Supported				Group enriched	Tissue enriched	31	cerebral cortex: 1759.0	adrenal gland: 57.2	Cell line enhanced		SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7
BTBD3	dJ742J24.1, KIAA0952	ENSG00000132640	BTB domain containing 3	20	11890723-11926609	Predicted intracellular proteins	Evidence at protein level	HPA041424, HPA042048	Uncertain		Supported	Vesicles	Liver cancer:2.51e-5 (unfavourable), Lung cancer:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 60.1	Cell line enhanced		AN3-CA: 223.4;HeLa: 128.7
PCNA		ENSG00000132646	Proliferating cell nuclear antigen	20	5114953-5126626	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000148, HPA030521, HPA030522, HPA030523	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.03e-6 (unfavourable), Cervical cancer:1.86e-5 (favourable), Liver cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 223.2	Expressed in all		
NXT1	MTR2, P15	ENSG00000132661	Nuclear transport factor 2 like export factor 1	20	23350736-23354777	Predicted intracellular proteins	Evidence at protein level	HPA047471			Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.15e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.6	Expressed in all		
POLR3F	RPC39, RPC6	ENSG00000132664	RNA polymerase III subunit F	20	18467127-18484643	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA049441, HPA050173, HPA072298	Uncertain		Approved	Nucleus	Liver cancer:8.87e-9 (unfavourable), Pancreatic cancer:6.48e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 11.6	Expressed in all		
RIN2	RASSF4	ENSG00000132669	Ras and Rab interactor 2	20	19886521-20002457	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034641	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:8.34e-6 (favourable)	Expressed in all	Expressed in all			gallbladder: 28.9	Cell line enhanced		PC-3: 44.5
PTPRA	HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA	ENSG00000132670	Protein tyrosine phosphatase, receptor type A	20	2864184-3039076	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029412, CAB034366, HPA069480	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.29e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 167.4	Expressed in all		
SSTR4		ENSG00000132671	Somatostatin receptor 4	20	23035386-23036812	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA064252	Uncertain					Not detected	Not detected			cerebral cortex: 0.8	Not detected		
DAP3	bMRP-10, DAP-3, DKFZp686G12159, MGC126058, MGC126059, MRP-S29, MRPS29	ENSG00000132676	Death associated protein 3	1	155687960-155739010	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023687	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:4.14e-6 (unfavourable), Liver cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 82.0	Expressed in all		
RHBG	SLC42A2	ENSG00000132677	Rh family B glycoprotein (gene/pseudogene)	1	156369212-156385219	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042726, HPA048489	Enhanced		Approved	Nucleoplasm	Urothelial cancer:8.06e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 3.5;ovary: 2.1	esophagus,liver: 0.6	Group enriched	28	CACO-2: 2.1;Hep G2: 2.0;RT4: 4.3
KIAA0907	BLOM7, SNORA80EHG	ENSG00000132680	KIAA0907	1	155913043-155934400	Predicted intracellular proteins	Evidence at protein level	HPA008796	Approved		Approved	Nucleoplasm	Renal cancer:2.78e-10 (unfavourable), Liver cancer:1.01e-6 (unfavourable), Urothelial cancer:4.36e-5 (favourable), Prostate cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 55.3	Expressed in all		
ATP1A4	ATP1AL2	ENSG00000132681	ATPase Na+/K+ transporting subunit alpha 4	1	160151570-160186977	Enzymes, Predicted membrane proteins	Evidence at protein level						Urothelial cancer:2.20e-4 (favourable)	Group enriched	Tissue enhanced		placenta: 10.2;testis: 18.2;urinary bladder: 8.6	lymph node: 4.1	Group enriched	11	BEWO: 19.2;HDLM-2: 48.0;RT4: 49.0
NES	FLJ21841	ENSG00000132688	Nestin	1	156668763-156677397	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005889, HPA006286, HPA007007, HPA026111, CAB058692	Enhanced		Enhanced	Intermediate filaments	Renal cancer:8.02e-7 (unfavourable)	Group enriched	Mixed			heart muscle: 103.1	Cell line enhanced		AF22: 620.1;HUVEC TERT2: 268.3;LHCN-M2: 427.4;RH-30: 502.3
BCAN	BEHAB, CSPG7, MGC13038	ENSG00000132692	Brevican	1	156641390-156659532	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA007865, CAB025862	Enhanced	Supported				Group enriched	Tissue enriched	24	cerebral cortex: 428.3	epididymis: 18.0	Cell line enhanced		HDLM-2: 67.3;K-562: 92.6;U-266/84: 84.7
CRP	PTX1	ENSG00000132693	C-reactive protein	1	159712289-159714589	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB005036, HPA027367, HPA027396	Supported				Renal cancer:4.17e-10 (unfavourable)	Tissue enriched	Group enriched	67	gallbladder: 172.9;liver: 532.1	endometrium: 5.2	Cell line enhanced		EFO-21: 5.9;HDLM-2: 5.8;U-2 OS: 4.4;U-266/84: 7.5
ARHGEF11	GTRAP48, KIAA0380, PDZ-RHOGEF	ENSG00000132694	Rho guanine nucleotide exchange factor 11	1	156934840-157045370	Predicted intracellular proteins	Evidence at protein level	HPA011026, HPA012037, HPA014658	Enhanced		Approved	Golgi apparatus<br>Plasma membrane	Pancreatic cancer:1.72e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Mixed		
RAB25	CATX-8	ENSG00000132698	RAB25, member RAS oncogene family	1	156061160-156070514	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA010872, CAB033645	Enhanced		Uncertain	Cell Junctions<br>Cytosol	Renal cancer:1.38e-6 (favourable)	Mixed	Tissue enhanced		esophagus: 297.5	skin: 169.0	Cell line enhanced		BEWO: 114.9;CAPAN-2: 103.6;MCF7: 128.3;RT4: 119.8;SK-BR-3: 179.2;T-47d: 210.8
HAPLN2	BRAL1	ENSG00000132702	Hyaluronan and proteoglycan link protein 2	1	156619294-156625725	Predicted secreted proteins	Evidence at protein level	HPA045765	Enhanced					Tissue enriched	Tissue enriched	47	cerebral cortex: 42.1	duodenum: 0.8	Not detected		
APCS	MGC88159, PTX2, SAP	ENSG00000132703	Amyloid P component, serum	1	159587825-159588865	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB007817, HPA053294	Supported					Tissue enriched	Tissue enriched	25	liver: 1851.8	gallbladder: 73.5	Cell line enhanced		RH-30: 1.1
FCRL2	CD307b, FCRH2, IRTA4, SPAP1	ENSG00000132704	Fc receptor like 2	1	157745733-157777132	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	8	appendix: 16.3;lymph node: 28.4;spleen: 25.9;tonsil: 23.7	rectum: 3.0	Group enriched	27	Daudi: 9.2;U-266/70: 2.0;U-698: 7.2
DCAF8	FLJ35857, H326, WDR42A	ENSG00000132716	DDB1 and CUL4 associated factor 8	1	160215715-160262531	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027218, HPA027381	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.74e-5 (unfavourable), Pancreatic cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 155.7	Expressed in all		
SYT11	DKFZp781D015, KIAA0080, MGC10881, MGC17226	ENSG00000132718	Synaptotagmin 11	1	155859509-155885199	Predicted intracellular proteins	Evidence at protein level	HPA064091	Enhanced				Endometrial cancer:2.93e-5 (unfavourable)	Tissue enriched	Tissue enriched	14	cerebral cortex: 402.2	endometrium: 28.4	Cell line enhanced		Karpas-707: 130.6;SCLC-21H: 84.6;SH-SY5Y: 83.1;U-87 MG: 84.4
IGHMBP2	CATF1, CMT2S, HCSA, HMN6, SMARD1, SMUBP2, ZFAND7	ENSG00000132740	Immunoglobulin mu binding protein 2	11	68903842-68940602	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060994			Approved	Nucleus	Renal cancer:1.29e-8 (unfavourable), Pancreatic cancer:5.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 27.9	Expressed in all		
ACY3	ACY-3, HCBP1, MGC9740	ENSG00000132744	Aminoacylase 3	11	67642555-67650659	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039219, HPA048187	Enhanced				Endometrial cancer:4.80e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 80.6;kidney: 53.3;small intestine: 78.6	cervix, uterine: 16.1	Cell line enhanced		CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
ALDH3B2	ALDH8	ENSG00000132746	Aldehyde dehydrogenase 3 family member B2	11	67662162-67681200	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045132	Enhanced					Mixed	Group enriched	6	breast: 89.9;esophagus: 103.4;skin: 122.2	tonsil: 19.0	Cell line enhanced		MCF7: 49.6;SK-BR-3: 48.3;T-47d: 12.2
TESMIN	CXCDC2, MTL5	ENSG00000132749	Testis expressed metallothionein like protein	11	68707440-68751564	Predicted intracellular proteins	Evidence at protein level	HPA018539			Supported	Nucleoplasm	Endometrial cancer:1.75e-5 (unfavourable)	Mixed	Tissue enriched	17	testis: 95.3	breast: 5.5	Cell line enhanced		T-47d: 22.3
MMACHC	cblC, DKFZP564I122	ENSG00000132763	Methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria	1	45500053-45513382	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027394, HPA027399, HPA027402	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			liver: 8.9	Expressed in all		
DPH2	DPH2L2	ENSG00000132768	DPH2 homolog	1	43970000-43973369	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045796	Uncertain		Approved	Nucleus	Liver cancer:1.17e-8 (unfavourable), Stomach cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 14.3	Expressed in all		
TOE1	hCaf1z	ENSG00000132773	Target of EGR1, member 1 (nuclear)	1	45339670-45343975	Predicted intracellular proteins	Evidence at protein level	HPA053775, HPA069119	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.12e-9 (unfavourable), Renal cancer:2.71e-4 (unfavourable), Head and neck cancer:9.05e-4 (favourable), Stomach cancer:9.98e-4 (favourable)	Expressed in all	Mixed			testis: 11.8	Expressed in all		
NASP	DKFZp547F162, FLB7527, FLJ31599, FLJ35510, MGC19722, MGC20372, MGC2297, PRO1999	ENSG00000132780	Nuclear autoantigenic sperm protein	1	45583846-45618904	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028136, HPA030518, HPA030520	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.91e-8 (unfavourable), Liver cancer:4.96e-6 (unfavourable), Melanoma:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.6	Expressed in all		
MUTYH	MYH	ENSG00000132781	MutY DNA glycosylase	1	45329163-45340470	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008732	Uncertain		Supported	Nucleus	Liver cancer:4.76e-8 (unfavourable), Renal cancer:7.25e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 10.7	Expressed in all		
CTNNBL1	C20orf33, FLJ21108, NAP, NYD-SP19, P14, P14L	ENSG00000132792	Catenin beta like 1	20	37693955-37872129	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004742, HPA027907	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 75.3	Expressed in all		
LPIN3	LIPN3L, SMP2	ENSG00000132793	Lipin 3	20	41340920-41360582	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051466, HPA052667, HPA070640	Approved		Supported	Cytosol	Renal cancer:1.14e-5 (unfavourable), Ovarian cancer:1.74e-4 (unfavourable), Endometrial cancer:9.74e-4 (unfavourable)	Expressed in all	Mixed			skin: 48.5	Mixed		
ZSWIM3	C20orf164, dJ337O18.7, PPP1R174	ENSG00000132801	Zinc finger SWIM-type containing 3	20	45857617-45879122	Predicted intracellular proteins	Evidence at protein level	HPA055692, HPA060508	Uncertain		Approved	Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Breast cancer:9.32e-5 (unfavourable), Endometrial cancer:4.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.2	Mixed		
RBM38	dJ800J21.2, HSRNASEB, RNPC1, seb4B, SEB4D	ENSG00000132819	RNA binding motif protein 38	20	57391407-57409333	Predicted intracellular proteins	Evidence at protein level	CAB017036	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:3.64e-7 (favourable), Renal cancer:1.05e-5 (unfavourable), Thyroid cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 86.8	Mixed		
VSTM2L	C20orf102, dJ1118M15.2	ENSG00000132821	V-set and transmembrane domain containing 2 like	20	37903104-37945350	Predicted secreted proteins	Evidence at protein level	HPA043832	Uncertain				Endometrial cancer:1.63e-5 (unfavourable), Urothelial cancer:8.14e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 55.1	gallbladder: 26.8	Cell line enhanced		CAPAN-2: 58.1;HDLM-2: 86.5;SK-BR-3: 59.9
OSER1	C20orf111, dJ1183I21.1, HSPC207, Osr1, Perit1	ENSG00000132823	Oxidative stress responsive serine rich 1	20	44196496-44210791	Predicted intracellular proteins	Evidence at protein level	HPA045125	Approved		Approved	Nucleoli<br>Nuclear speckles	Endometrial cancer:2.58e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 184.6	Expressed in all		
SERINC3	AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1	ENSG00000132824	Serine incorporator 3	20	44496221-44522109	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048116	Uncertain				Cervical cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 201.7	Expressed in all		
PPP1R3D	PPP1R6	ENSG00000132825	Protein phosphatase 1 regulatory subunit 3D	20	59936668-59940297	Predicted intracellular proteins	Evidence at protein level	HPA041146	Approved		Approved	Nucleoli<br>Vesicles<br>Mitochondria	Stomach cancer:9.14e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.1	Mixed		
DMGDH		ENSG00000132837	Dimethylglycine dehydrogenase	5	78997606-79236038	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036441, HPA036442, HPA077849	Enhanced		Supported	Mitochondria	Renal cancer:1.17e-5 (favourable), Liver cancer:5.32e-5 (favourable)	Group enriched	Group enriched	11	kidney: 179.1;liver: 146.2	epididymis: 14.9	Cell line enhanced		BJ hTERT+: 2.9;Hep G2: 5.2
BHMT2		ENSG00000132840	Betaine--homocysteine S-methyltransferase 2	5	79069717-79089466	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044573	Enhanced					Group enriched	Group enriched	6	kidney: 362.7;liver: 238.5	epididymis: 46.2	Cell line enhanced		Hep G2: 53.5;hTEC/SVTERT24-B: 46.4;U-87 MG: 18.9
AP3B1	ADTB3A, HPS2	ENSG00000132842	Adaptor related protein complex 3 beta 1 subunit	5	78000525-78294755	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038737, HPA045458	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.97e-6 (favourable), Colorectal cancer:1.37e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 65.5	Expressed in all		
ZBED3	MGC15435	ENSG00000132846	Zinc finger BED-type containing 3	5	77072072-77087323	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055995	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.68e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 18.8	Mixed		
PATJ	Cipp, INADL	ENSG00000132849	PATJ, crumbs cell polarity complex component	1	61742477-62178675	Predicted intracellular proteins	Evidence at protein level	HPA066352, HPA066960, HPA069079	Approved		Supported	Cell Junctions<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.6	Cell line enhanced		A-431: 31.4
KANK4	ANKRD38, KIAA0172	ENSG00000132854	KN motif and ankyrin repeat domains 4	1	62236979-62319414	Predicted intracellular proteins	Evidence at protein level	HPA014030	Uncertain		Uncertain	Microtubules<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 29.5;placenta: 16.4	adipose tissue: 11.8	Cell line enhanced		BEWO: 32.2;Hep G2: 9.9;SCLC-21H: 7.5
ANGPTL3	ANGPT5	ENSG00000132855	Angiopoietin like 3	1	62597487-62606159	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038097	Approved					Tissue enriched	Tissue enriched	6	liver: 356.4	kidney: 55.7	Not detected		
SYT4	HsT1192, KIAA1342	ENSG00000132872	Synaptotagmin 4	18	43267878-43277650	Predicted intracellular proteins	Evidence at protein level	HPA010574	Approved		Supported	Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		adrenal gland: 20.4;cerebral cortex: 82.5	seminal vesicle: 11.3	Cell line enriched	10	SH-SY5Y: 251.0
SLC14A2	HUT2, UT2	ENSG00000132874	Solute carrier family 14 member 2	18	45212995-45683686	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 4.0	adipose tissue: 1.6	Cell line enriched	5	U-266/70: 3.4
FBXO44	FBG3, FBX30, Fbx44, Fbxo6a, MGC14140	ENSG00000132879	F-box protein 44	1	11654375-11663327	Predicted intracellular proteins	Evidence at protein level	HPA003363	Approved		Approved	Nucleoplasm	Renal cancer:6.29e-5 (favourable), Pancreatic cancer:2.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 98.1	Mixed		
RSG1	C1orf89, MGC10731	ENSG00000132881	REM2 and RAB like small GTPase 1	1	16231700-16237162	Predicted intracellular proteins	Evidence at protein level	HPA028453, HPA041672	Approved		Enhanced	Nucleoplasm	Renal cancer:1.36e-10 (favourable)	Expressed in all	Mixed			fallopian tube: 11.0	Mixed		
CASP9	APAF-3, ICE-LAP6, MCH6, PPP1R56	ENSG00000132906	Caspase 9	1	15490832-15526534	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001473, CAB004348, HPA046488	Approved		Approved	Mitochondria	Urothelial cancer:1.67e-5 (favourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 37.1	Expressed in all		
NMUR2	NMU2R	ENSG00000132911	Neuromedin U receptor 2	5	152391532-152433368	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA045836	Enhanced					Group enriched	Tissue enhanced		stomach: 1.1;testis: 2.2	thyroid gland: 0.9	Cell line enriched	10	EFO-21: 8.9
DCTN4		ENSG00000132912	Dynactin subunit 4	5	150708440-150759109	Predicted intracellular proteins	Evidence at protein level	CAB017532, HPA038026	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Expressed in all			cerebral cortex: 67.3	Expressed in all		
PDE6A	PDEA, RP43	ENSG00000132915	Phosphodiesterase 6A	5	149857955-149944793	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016970, HPA074677	Enhanced					Not detected	Tissue enriched	8	epididymis: 20.2	testis: 2.4	Cell line enhanced		CACO-2: 2.1
ATP8A2	ATPIB, ML-1	ENSG00000132932	ATPase phospholipid transporting 8A2	13	25372071-26025851	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039926, HPA040033	Approved		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Group enriched	6	cerebral cortex: 26.4;testis: 10.7	adrenal gland: 2.9	Cell line enhanced		HMC-1: 19.3;SCLC-21H: 3.9
MTUS2	CAZIP, ICIS, KIAA0774, TIP150	ENSG00000132938	Microtubule associated tumor suppressor candidate 2	13	28820348-29505947	Predicted intracellular proteins	Evidence at protein level	HPA031473, HPA031474, HPA031475	Enhanced		Supported	Microtubules<br>Cytokinetic bridge		Mixed	Group enriched	5	heart muscle: 33.4;ovary: 9.5	cerebral cortex: 4.2	Cell line enhanced		HaCaT: 11.7;HeLa: 3.7
ZMYM5	MYM, ZNF198L1, ZNF237	ENSG00000132950	Zinc finger MYM-type containing 5	13	19823482-19863636	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020879	Uncertain					Expressed in all	Expressed in all			testis: 44.5	Expressed in all		
USPL1	bA121O19.1, C13orf22, D13S106E	ENSG00000132952	Ubiquitin specific peptidase like 1	13	30617693-30660770	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039342, HPA040172	Uncertain					Expressed in all	Expressed in all			testis: 40.5	Expressed in all		
XPO4	FLJ13046, KIAA1721	ENSG00000132953	Exportin 4	13	20777329-20903048	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053768			Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.63e-4 (unfavourable), Endometrial cancer:8.25e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 15.7	Expressed in all		
TPTE2	TPIP	ENSG00000132958	Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2	13	19422877-19536762	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA068342			Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	35	testis: 11.9	tonsil: 0.3	Cell line enhanced		HDLM-2: 4.4
POMP	C13orf12, HSPC014, UMP1	ENSG00000132963	Proteasome maturation protein	13	28659104-28678925	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026995	Approved		Supported	Nuclear speckles	Head and neck cancer:2.05e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 146.5	Expressed in all		
CDK8	K35	ENSG00000132964	Cyclin dependent kinase 8	13	26254104-26405238	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044721			Approved	Nucleus	Stomach cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			testis: 17.7	Mixed		
ALOX5AP	FLAP	ENSG00000132965	Arachidonate 5-lipoxygenase activating protein	13	30713478-30764426	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026592	Enhanced				Renal cancer:5.68e-4 (unfavourable), Ovarian cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 301.7	Cell line enhanced		HDLM-2: 579.8;HL-60: 265.4;HMC-1: 899.6;THP-1: 279.0;U-937: 238.0
WASF3	KIAA0900, SCAR3, WAVE3	ENSG00000132970	WAS protein family member 3	13	26557703-26688948	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037086	Approved				Pancreatic cancer:2.21e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 86.4	thyroid gland: 28.1	Cell line enhanced		ASC diff: 56.8
RNF17	FLJ11045, Mmip-2, SPATA23, TDRD4	ENSG00000132972	Ring finger protein 17	13	24764152-24879921	Predicted intracellular proteins	Evidence at protein level	HPA039699, HPA040111	Approved					Tissue enriched	Tissue enriched	19	testis: 44.0	placenta: 2.3	Not detected		
GPR12	GPCR21, PPP1R84	ENSG00000132975	G protein-coupled receptor 12	13	26755200-26760785	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050972	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 7.9	breast: 1.7	Cell line enriched	8	SCLC-21H: 16.7
CHRM3		ENSG00000133019	Cholinergic receptor muscarinic 3	1	239386565-239915452	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA024106, HPA048036	Approved		Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 15.7	esophagus: 8.4	Cell line enhanced		RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
MYH8	MyHC-peri, MyHC-pn	ENSG00000133020	Myosin heavy chain 8	17	10390322-10421950	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349, CAB016527	Enhanced					Tissue enhanced	Group enriched	5	esophagus: 16.9;skeletal muscle: 5.5	prostate: 2.2	Cell line enriched	10	HSkMC: 5.2
MYH10	NMMHCB	ENSG00000133026	Myosin heavy chain 10	17	8474205-8630761	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017180, HPA047541, HPA057198	Enhanced		Enhanced	Actin filaments<br>Mitochondria<br>Cytosol	Renal cancer:1.38e-4 (favourable), Urothelial cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 81.0	Cell line enhanced		AF22: 213.4
PEMT	PEMPT, PEMT2	ENSG00000133027	Phosphatidylethanolamine N-methyltransferase	17	17505563-17591708	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042375	Approved		Approved	Cytosol	Endometrial cancer:6.77e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 208.8	Expressed in all		
SCO1	SCOD1	ENSG00000133028	SCO1, cytochrome c oxidase assembly protein	17	10672474-10698375	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA021565, HPA021579	Enhanced				Renal cancer:9.69e-7 (favourable), Thyroid cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.5	Expressed in all		
MPRIP	M-RIP, p116Rip, RHOIP3	ENSG00000133030	Myosin phosphatase Rho interacting protein	17	17042545-17217679	Predicted intracellular proteins	Evidence at protein level	HPA022034, HPA022901	Enhanced		Supported	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 197.8	Expressed in all		
CHI3L1	GP39, YKL40	ENSG00000133048	Chitinase 3 like 1	1	203178931-203186749	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		appendix: 186.7;cerebral cortex: 267.1;urinary bladder: 179.4	bone marrow: 146.9	Group enriched	7	ASC diff: 215.1;ASC TERT1: 484.9;HSkMC: 450.3;THP-1: 704.0;U-138 MG: 292.3;U-87 MG: 289.1
MYBPH		ENSG00000133055	Myosin binding protein H	1	203167811-203175813	Predicted intracellular proteins	Evidence at protein level	HPA061383	Enhanced		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Group enriched	Group enriched	5	prostate: 5.1;skeletal muscle: 7.9	esophagus: 1.2	Cell line enhanced		CACO-2: 25.5;HSkMC: 41.6;THP-1: 10.2
PIK3C2B	C2-PI3K, PI3K-C2beta	ENSG00000133056	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta	1	204422628-204494724	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030515, HPA050360	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.16e-4 (favourable), Liver cancer:5.42e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 28.2	Cell line enhanced		BEWO: 67.8;RT4: 60.2
DSTYK	DustyPK, KIAA0472, RIP5, RIPK5	ENSG00000133059	Dual serine/threonine and tyrosine protein kinase	1	205142505-205211566	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044140	Uncertain		Uncertain	Nuclear speckles<br>Intermediate filaments	Urothelial cancer:8.73e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 28.8	Expressed in all		
CHIT1	CHI3, CHIT	ENSG00000133063	Chitinase 1	1	203212827-203273641	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010575	Approved				Cervical cancer:2.02e-4 (favourable)	Tissue enhanced	Group enriched	14	bone marrow: 31.3;breast: 10.9;cervix, uterine: 13.5;lung: 53.2;lymph node: 21.0	prostate,thyroid gland: 1.8	Not detected		
SLC41A1	MgtE	ENSG00000133065	Solute carrier family 41 member 1	1	205789093-205813748	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014721, HPA015138	Uncertain		Approved	Mitochondria	Cervical cancer:1.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 66.8	testis: 37.3	Mixed		
LGR6	FLJ14471	ENSG00000133067	Leucine rich repeat containing G protein-coupled receptor 6	1	202193901-202319781	G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008556	Approved		Approved	Nucleoplasm<br>Plasma membrane	Glioma:2.00e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 14.3	gallbladder: 9.6	Cell line enhanced		A549: 15.6;CAPAN-2: 13.4;HaCaT: 7.3
TMCC2	FLJ38497, HUCEP11	ENSG00000133069	Transmembrane and coiled-coil domain family 2	1	205228176-205273343	Predicted membrane proteins	Evidence at protein level	HPA014254	Approved					Mixed	Tissue enhanced		bone marrow: 52.4;cerebral cortex: 15.1	placenta: 7.8	Cell line enhanced		SCLC-21H: 41.5
DCLK1	DCAMKL1, DCDC3A, DCLK, KIAA0369	ENSG00000133083	Doublecortin like kinase 1	13	35768652-36131306	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012405, HPA015040, HPA015655	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.42e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 140.5	smooth muscle: 27.3	Cell line enhanced		ASC diff: 19.8;ASC TERT1: 19.0;fHDF/TERT166: 18.2;HAP1: 18.4;HSkMC: 18.4;NTERA-2: 36.7
CCNA1	CT146	ENSG00000133101	Cyclin A1	13	36431520-36442882	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA060646			Approved	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:1.70e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 59.6;testis: 144.6	fallopian tube: 27.9	Cell line enhanced		HMC-1: 300.4;THP-1: 46.6;U-937: 68.5
COG6	COD2, KIAA1134	ENSG00000133103	Component of oligomeric golgi complex 6	13	39655627-39791665	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040410, HPA040441	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus	Stomach cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.6	Expressed in all		
SPG20	KIAA0610, TAHCCP1	ENSG00000133104	Spastic paraplegia 20 (Troyer syndrome)	13	36301638-36370180	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039053, HPA039054	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			epididymis: 81.4	Mixed		
RXFP2	GPR106, GREAT, INSL3R, LGR8, RXFPR2	ENSG00000133105	Relaxin/insulin like family peptide receptor 2	13	31739542-31803388	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			endometrium: 0.8	Not detected		
EPSTI1	BRESI1, MGC29634	ENSG00000133106	Epithelial stromal interaction 1	13	42886388-42992271	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017362	Approved		Approved	Cytosol	Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			spleen: 42.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 97.1;HDLM-2: 68.7
TRPC4	HTRP4, TRP4	ENSG00000133107	Transient receptor potential cation channel subfamily C member 4	13	37636636-37870425	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 18.6;seminal vesicle: 12.1;smooth muscle: 18.5	prostate: 10.8	Cell line enhanced		AF22: 8.0;BJ: 16.3;BJ hTERT+ SV40 Large T+: 7.5;fHDF/TERT166: 14.3;U-2197: 8.0
POSTN	OSF-2, periostin, PN	ENSG00000133110	Periostin	13	37562583-37598844	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA012306	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.83e-7 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Stomach cancer:4.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 246.4	Group enriched	7	hTEC/SVTERT24-B: 490.4;U-138 MG: 610.6;U-2197: 396.9
RFXAP		ENSG00000133111	Regulatory factor X associated protein	13	36819224-36829104	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032035			Approved	Nuclear speckles	Lung cancer:2.26e-5 (favourable), Pancreatic cancer:4.18e-4 (favourable), Stomach cancer:4.91e-4 (favourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
TPT1	fortilin, TCTP	ENSG00000133112	Tumor protein, translationally-controlled 1	13	45333471-45341370	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008364, HPA039437	Approved		Supported	Cytosol	Renal cancer:2.54e-5 (unfavourable), Thyroid cancer:4.31e-5 (favourable), Breast cancer:5.90e-5 (favourable), Endometrial cancer:2.35e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 8103.8	Expressed in all		
GPALPP1	AD029, bA245H20.2, KIAA1704, LSR7	ENSG00000133114	GPALPP motifs containing 1	13	44989529-45037669	Predicted intracellular proteins	Evidence at protein level	HPA038966, HPA058739	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 15.4	Expressed in all		
STOML3	Epb7.2l, SRO	ENSG00000133115	Stomatin like 3	13	38965925-38991066	Predicted membrane proteins, Transporters	Evidence at protein level	HPA012892, HPA071011	Enhanced		Enhanced	Plasma membrane	Endometrial cancer:1.49e-4 (favourable)	Tissue enhanced	Tissue enriched	18	fallopian tube: 50.3	lung: 2.8	Cell line enriched	33	AF22: 15.4
KL		ENSG00000133116	Klotho	13	33016433-33066145	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.29e-9 (favourable), Pancreatic cancer:4.44e-4 (favourable)	Group enriched	Group enriched	5	kidney: 136.6;parathyroid gland: 346.4	placenta: 44.1	Cell line enhanced		HMC-1: 2.1;SK-BR-3: 3.4
RFC3	MGC5276, RFC38	ENSG00000133119	Replication factor C subunit 3	13	33818049-33966558	Predicted intracellular proteins	Evidence at protein level	HPA030149	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			lymph node: 26.8	Expressed in all		
STARD13	ARHGAP37, DLC2, GT650, LINC00464	ENSG00000133121	StAR related lipid transfer domain containing 13	13	33103135-33350630	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039535, HPA058867	Enhanced		Approved	Nuclear membrane<br>Nucleoli<br>Cytosol	Renal cancer:1.23e-4 (unfavourable)	Expressed in all	Mixed			placenta: 35.3	Cell line enhanced		LHCN-M2: 41.8;WM-115: 40.0
IRS4	IRS-4, PY160	ENSG00000133124	Insulin receptor substrate 4	X	108732482-108736409	Predicted secreted proteins	Evidence at protein level	HPA017372	Uncertain					Mixed	Tissue enhanced		endometrium: 1.6;ovary: 4.3;thyroid gland: 2.1	cervix, uterine: 1.0	Cell line enhanced		HEK 293: 8.2;RT4: 2.1;WM-115: 1.9
MORC4	FLJ11565, ZCW4, ZCWCC2	ENSG00000133131	MORC family CW-type zinc finger 4	X	106813871-107000244	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000395, HPA015547, HPA050250	Enhanced		Enhanced	Nucleoplasm	Breast cancer:3.56e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 114.4	Expressed in all		
BEX2	DJ79P11.1	ENSG00000133134	Brain expressed X-linked 2	X	103309346-103311046	Predicted intracellular proteins	Evidence at protein level	HPA045384	Uncertain				Renal cancer:3.05e-13 (favourable), Endometrial cancer:8.54e-7 (unfavourable), Lung cancer:1.52e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 226.5	thyroid gland: 156.9	Cell line enhanced		hTCEpi: 64.4;NTERA-2: 86.5;SCLC-21H: 148.6;SH-SY5Y: 61.1
RNF128	FLJ23516, GRAIL	ENSG00000133135	Ring finger protein 128, E3 ubiquitin protein ligase	X	106693794-106796993	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019675	Uncertain				Renal cancer:1.07e-7 (unfavourable)	Mixed	Mixed			small intestine: 66.9	Cell line enhanced		BEWO: 40.1;CAPAN-2: 30.6;RT4: 70.6;WM-115: 52.6
TBC1D8B	FLJ20298, GRAMD8B, RP11-321G1.1	ENSG00000133138	TBC1 domain family member 8B	X	106802680-106876145	Predicted intracellular proteins	Evidence at protein level	HPA023883, HPA027527	Enhanced	Supported	Approved	Cytosol		Mixed	Mixed			adrenal gland: 25.7	Mixed		
TCEAL4	FLJ21174, WEX7	ENSG00000133142	Transcription elongation factor A like 4	X	103576231-103587736	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:3.11e-5 (unfavourable), Lung cancer:2.75e-4 (favourable)	Expressed in all	Expressed in all			ovary: 555.7	Mixed		
BEX1		ENSG00000133169	Brain expressed X-linked 1	X	103062651-103064240	Predicted intracellular proteins	Evidence at protein level	HPA045384	Approved				Renal cancer:8.16e-8 (favourable), Breast cancer:6.43e-4 (favourable), Thyroid cancer:6.88e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 505.2	parathyroid gland: 154.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 525.2;HBF TERT88: 582.7;HL-60: 1113.6;SCLC-21H: 490.1
FAM104A	FLJ14775	ENSG00000133193	Family with sequence similarity 104 member A	17	73207353-73236753	Predicted intracellular proteins	Evidence at protein level	HPA021459			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.26e-10 (unfavourable), Liver cancer:2.12e-7 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 163.8	bone marrow: 27.0	Expressed in all		
SLC39A11	C17orf26	ENSG00000133195	Solute carrier family 39 member 11	17	72645949-73092712	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021455			Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 60.1	Expressed in all		
EPHB2	DRT, EPHT3, ERK, Hek5, Tyro5	ENSG00000133216	EPH receptor B2	1	22710839-22921500	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013647, HPA071200	Approved		Supported	Nucleus<br>Plasma membrane	Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable)	Tissue enhanced	Mixed			rectum: 27.3	Cell line enhanced		HUVEC TERT2: 71.2;TIME: 69.5
SRRM1	MGC39488, POP101, SRM160	ENSG00000133226	Serine and arginine repetitive matrix 1	1	24631716-24673267	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049941, HPA058612	Supported		Enhanced	Nuclear speckles	Liver cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 96.3	Expressed in all		
BTBD2		ENSG00000133243	BTB domain containing 2	19	1985438-2034881	Predicted intracellular proteins	Evidence at protein level						Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.9	Expressed in all		
PRAM1	PML-RAR	ENSG00000133246	PML-RARA regulated adaptor molecule 1	19	8490056-8503112	Predicted intracellular proteins	Evidence at protein level	HPA045236, HPA050161	Approved		Approved	Golgi apparatus	Renal cancer:8.08e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 65.1	appendix: 15.2	Cell line enhanced		HL-60: 18.4;THP-1: 26.7;U-937: 99.1
KMT5C	MGC2705, SUV420H2	ENSG00000133247	Lysine methyltransferase 5C	19	55339853-55348120	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052294	Uncertain		Approved	Nucleoplasm	Renal cancer:1.05e-8 (unfavourable)	Expressed in all	Mixed			skin: 4.8	Cell line enhanced		SCLC-21H: 21.9
ZNF414	MGC15716, Zfp414	ENSG00000133250	Zinc finger protein 414	19	8509678-8514164	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053769	Approved		Approved	Nucleus<br>Cytosol	Head and neck cancer:1.67e-6 (favourable), Endometrial cancer:4.17e-4 (favourable), Pancreatic cancer:4.59e-4 (favourable), Urothelial cancer:8.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 12.3	Mixed		
PDE6B	CSNB3, CSNBAD2, PDEB, rd1, RP40	ENSG00000133256	Phosphodiesterase 6B	4	625584-670782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054148, HPA059929	Supported		Approved	Cytosol	Lung cancer:5.34e-4 (favourable)	Mixed	Mixed			cerebral cortex: 22.3	Cell line enhanced		MOLT-4: 25.1;REH: 15.3;SCLC-21H: 23.8;SH-SY5Y: 12.6;U-266/84: 16.5
HSPBP1	FES1, HspBP1	ENSG00000133265	HSPA (Hsp70) binding protein 1	19	55262231-55280381	Predicted intracellular proteins	Evidence at protein level	CAB005865, HPA071444	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 40.1	Expressed in all		
CSNK1G2	CK1g2	ENSG00000133275	Casein kinase 1 gamma 2	19	1941149-1981338	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034868, HPA056572	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			testis: 76.8	Expressed in all		
SLF1	ANKRD32, BRCTD1, BRCTx, DKFZp564C0469, DKFZp761C121	ENSG00000133302	SMC5-SMC6 complex localization factor 1	5	94618347-94739436	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040793, HPA054213	Uncertain		Approved	Nucleus		Expressed in all	Tissue enhanced		testis: 12.9	cerebral cortex: 4.4	Cell line enhanced		HeLa: 34.7
CNDP2	CN2, CPGL, FLJ10830, HsT2298, PEPA	ENSG00000133313	CNDP dipeptidase 2 (metallopeptidase M20 family)	18	74495816-74523454	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026196, HPA036898, HPA036899	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.50e-6 (favourable)	Expressed in all	Expressed in all			kidney: 342.2	Expressed in all		
MACROD1	LRP16	ENSG00000133315	MACRO domain containing 1	11	63998558-64166106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041031, HPA071075	Uncertain		Supported	Nucleoplasm	Renal cancer:4.68e-6 (favourable), Pancreatic cancer:2.90e-4 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 106.6	kidney: 17.4	Cell line enhanced		RPMI-8226: 99.7
WDR74	FLJ10439	ENSG00000133316	WD repeat domain 74	11	62832342-62841809	Predicted intracellular proteins	Evidence at protein level	HPA037795, HPA038419	Uncertain		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			bone marrow: 82.7	Expressed in all		
LGALS12	GRIP1	ENSG00000133317	Galectin 12	11	63506084-63516774	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.60e-7 (unfavourable)	Mixed	Tissue enriched	7	adipose tissue: 89.9	bone marrow: 12.5	Group enriched	15	ASC diff: 21.2;HL-60: 45.6;NB-4: 70.9;U-937: 93.2
RTN3	ASYIP, HAP, NSPL2, NSPLII, RTN3-A1	ENSG00000133318	Reticulon 3	11	63681446-63759891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015649, HPA015650	Enhanced		Supported	Endoplasmic reticulum	Liver cancer:1.30e-6 (unfavourable), Renal cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1030.6	Expressed in all		
RARRES3	HRASLS4, TIG3	ENSG00000133321	Retinoic acid receptor responder 3	11	63536809-63546462	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:6.26e-6 (unfavourable), Breast cancer:1.35e-5 (favourable), Cervical cancer:4.00e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 166.5	Cell line enhanced		CAPAN-2: 203.5;RPTEC TERT1: 87.4;SK-BR-3: 131.4
HRASLS2	FLJ20556	ENSG00000133328	HRAS like suppressor 2	11	63552770-63563383	Predicted membrane proteins	Evidence at protein level	HPA058997	Approved		Approved	Mitochondria	Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 67.6;small intestine: 46.5	rectum: 14.4	Cell line enriched	7	U-266/70: 97.6
MYH11	SMHC, SMMHC	ENSG00000133392	Myosin heavy chain 11	16	15703172-15857033	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002302, HPA014539, HPA015310	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.10e-5 (favourable)	Tissue enhanced	Tissue enhanced		seminal vesicle: 1381.0;smooth muscle: 1022.0	prostate: 899.8	Cell line enhanced		BEWO: 1.7;NB-4: 1.2;U-698: 3.4
FOPNL	C16orf63, DKFZp686N1651, FLJ31153, FOR20, PHSECRG2	ENSG00000133393	FGFR1OP N-terminal like	16	15865720-15888625	Predicted intracellular proteins	Evidence at protein level	HPA040599	Supported		Supported	Centrosome		Expressed in all	Expressed in all			thyroid gland: 53.9	Expressed in all		
MED10	L6, MGC5309, NUT2, TRG20	ENSG00000133398	Mediator complex subunit 10	5	6371881-6378594	Predicted intracellular proteins	Evidence at protein level	HPA042795, HPA054188			Supported	Nucleoplasm	Liver cancer:1.62e-6 (unfavourable), Renal cancer:2.19e-5 (unfavourable), Glioma:4.81e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.7	Expressed in all		
PDZD2	KIAA0300, PDZK3	ENSG00000133401	PDZ domain containing 2	5	31639410-32110931	Predicted intracellular proteins	Evidence at protein level	CAB020784, HPA036503, HPA036504, HPA064387	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			ovary: 18.3	Cell line enhanced		BEWO: 8.1;SiHa: 12.6;SK-BR-3: 8.1
MORC2	AC004542.C22.1, KIAA0852, ZCW3, ZCWCC1	ENSG00000133422	MORC family CW-type zinc finger 2	22	30925130-30968298	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000436	Enhanced		Supported	Nucleus<br>Cytosol	Renal cancer:6.54e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 55.5	Expressed in all		
LARGE1	KIAA0609, LARGE	ENSG00000133424	LARGE xylosyl- and glucuronyltransferase 1	22	33162226-33922841	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 43.2	Mixed		
GSTT2B	GSTT2P	ENSG00000133433	Glutathione S-transferase theta 2B (gene/pseudogene)	22	23957414-23961186	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000750	Uncertain		Supported	Nucleoplasm<br>Cytosol	Breast cancer:5.06e-4 (favourable)	Expressed in all	Tissue enriched	7	breast: 411.1	adrenal gland: 60.8	Cell line enhanced		AN3-CA: 53.0;HHSteC: 68.3;T-47d: 60.4
MYO18B	BK125H2.1	ENSG00000133454	Myosin XVIIIB	22	25742144-26031041	Predicted intracellular proteins	Evidence at protein level	HPA000953	Uncertain		Supported	Nucleoplasm<br>Centrosome		Mixed	Group enriched	8	heart muscle: 47.3;skeletal muscle: 52.5	testis: 5.8	Cell line enhanced		HDLM-2: 9.7;REH: 13.6;RH-30: 29.4;U-2 OS: 13.9;U-266/70: 7.2
SLC2A11	GLUT10, GLUT11	ENSG00000133460	Solute carrier family 2 member 11	22	23856703-23886309	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042960, HPA071184	Uncertain		Uncertain	Nucleus<br>Cell Junctions	Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable)	Mixed	Mixed			parathyroid gland: 10.9	Mixed		
C1QTNF6	CTRP6, ZACRP6	ENSG00000133466	C1q and tumor necrosis factor related protein 6	22	37180167-37199385	Predicted intracellular proteins	Evidence at protein level	HPA002042	Enhanced		Approved	Nucleus	Renal cancer:0.00e+0 (unfavourable), Lung cancer:9.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 52.3;placenta: 41.4	gallbladder: 13.5	Cell line enhanced		MCF7: 83.4;RT4: 39.7
GGT2	GGT	ENSG00000133475	Gamma-glutamyltransferase 2	22	21207973-21227637	Predicted membrane proteins	Evidence at protein level	HPA045635, HPA047534, HPA065444	Supported		Approved	Vesicles		Tissue enhanced	Tissue enhanced		lung: 1.3;thyroid gland: 1.5	breast,salivary gland: 0.9	Cell line enhanced		HDLM-2: 1.5;HeLa: 2.0;U-2197: 8.2
FAM83F		ENSG00000133477	Family with sequence similarity 83 member F	22	39994949-40043529	Predicted intracellular proteins	Evidence at protein level	HPA051207, HPA064657	Enhanced		Approved	Nucleus<br>Mitochondria	Colorectal cancer:1.73e-4 (favourable), Pancreatic cancer:9.40e-4 (favourable)	Mixed	Tissue enhanced		testis: 21.6	skin: 16.5	Cell line enhanced		hTCEpi: 27.3;RT4: 14.8;SCLC-21H: 46.9
SEC14L4	dJ130H16.5, TAP3	ENSG00000133488	SEC14 like lipid binding 4	22	30488913-30505711	Predicted intracellular proteins	Evidence at protein level	HPA069748			Approved	Centrosome		Tissue enhanced	Group enriched	8	bone marrow: 5.0;liver: 10.3;lung: 6.9;parathyroid gland: 10.5;testis: 7.1	adrenal gland: 0.9	Cell line enhanced		A549: 6.7;BEWO: 36.9;SiHa: 9.8
GIMAP6	FLJ22690, IAN6	ENSG00000133561	GTPase, IMAP family member 6	7	150625375-150632648	Predicted intracellular proteins	Evidence at protein level	HPA026715, HPA050740	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:1.56e-4 (favourable), Head and neck cancer:2.91e-4 (favourable), Endometrial cancer:3.12e-4 (favourable), Renal cancer:5.27e-4 (unfavourable)	Expressed in all	Mixed			spleen: 88.1	Cell line enhanced		HUVEC TERT2: 104.1;MOLT-4: 34.5;TIME: 29.3
GIMAP4	FLJ11110, HIMAP4, IAN1, IMAP4	ENSG00000133574	GTPase, IMAP family member 4	7	150567277-150573955	Predicted intracellular proteins	Evidence at protein level	HPA019135, HPA019137, HPA027198	Enhanced				Renal cancer:1.13e-4 (unfavourable), Endometrial cancer:7.63e-4 (favourable)	Expressed in all	Expressed in all			spleen: 147.7	Cell line enriched	23	HUVEC TERT2: 253.7
ADCK2	MGC20727	ENSG00000133597	AarF domain containing kinase 2	7	140673153-140696261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036036	Approved		Uncertain	Centrosome<br>Cytosol	Renal cancer:9.75e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.2	Mixed		
MKRN1	RNF61	ENSG00000133606	Makorin ring finger protein 1	7	140453040-140479569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000567			Approved	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 224.7	Expressed in all		
AGAP3	CENTG3	ENSG00000133612	ArfGAP with GTPase domain, ankyrin repeat and PH domain 3	7	151085831-151144436	Predicted intracellular proteins	Evidence at protein level	HPA012883	Approved				Renal cancer:8.58e-5 (unfavourable), Liver cancer:6.21e-4 (unfavourable), Colorectal cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 92.5	Mixed		
KRBA1	KIAA1862	ENSG00000133619	KRAB-A domain containing 1	7	149714781-149734575	Predicted intracellular proteins	Evidence at protein level	HPA021237, HPA050448	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.77e-4 (favourable)	Mixed	Mixed			heart muscle: 12.1	Mixed		
ACTR3B	ARP11, ARP3beta	ENSG00000133627	ARP3 actin related protein 3 homolog B	7	152759749-152855378	Predicted intracellular proteins	Evidence at protein level	HPA047016, HPA051683	Uncertain				Renal cancer:1.66e-4 (favourable), Stomach cancer:4.53e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.9	Mixed		
NTS		ENSG00000133636	Neurotensin	12	85874295-85882992	Predicted secreted proteins	Evidence at protein level	HPA026664	Enhanced				Cervical cancer:9.94e-5 (favourable), Endometrial cancer:5.10e-4 (unfavourable)	Tissue enhanced	Group enriched	9	small intestine: 189.6;stomach: 43.5	lymph node: 13.4	Cell line enhanced		HEL: 45.5;NTERA-2: 10.8
BTG1	APRO2	ENSG00000133639	BTG anti-proliferation factor 1	12	92140278-92145897	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005972			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.95e-7 (unfavourable), Breast cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 261.0	Expressed in all		
LRRIQ1	FLJ12303, KIAA1801	ENSG00000133640	Leucine rich repeats and IQ motif containing 1	12	85036314-85263224	Predicted intracellular proteins	Evidence at protein level	HPA046162	Uncertain					Mixed	Group enriched	7	fallopian tube: 13.7;testis: 25.7	parathyroid gland: 2.9	Cell line enhanced		RPTEC TERT1: 2.2;SH-SY5Y: 2.1
C12orf29	DKFZp434N2030	ENSG00000133641	Chromosome 12 open reading frame 29	12	88033846-88050160	Predicted intracellular proteins	Evidence at protein level	HPA039663	Uncertain		Approved	Vesicles	Renal cancer:3.44e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 17.1	Expressed in all		
ATP13A3	AFURS1	ENSG00000133657	ATPase 13A3	3	194402672-194498364	Predicted membrane proteins	Evidence at protein level	HPA029471	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 149.3	Expressed in all		
SFTPD	COLEC7, SFTP4, SP-D	ENSG00000133661	Surfactant protein D	10	79937740-79982614	Predicted secreted proteins	Evidence at protein level	CAB004578, HPA044582, HPA056768	Enhanced					Tissue enriched	Tissue enriched	56	lung: 782.5	bone marrow: 13.8	Cell line enhanced		BEWO: 1.3;hTCEpi: 2.3;MCF7: 1.1
DYDC2	bA36D19.6, MGC16186	ENSG00000133665	DPY30 domain containing 2	10	80344745-80368073	Predicted intracellular proteins	Evidence at protein level	HPA038006, HPA038007	Enhanced				Ovarian cancer:3.54e-4 (favourable)	Tissue enhanced	Tissue enriched	10	fallopian tube: 153.3	testis: 15.0	Cell line enhanced		AF22: 2.1;NTERA-2: 3.4;SCLC-21H: 3.4;SH-SY5Y: 2.1;U-2197: 2.0
TMEM254	bA369J21.6, C10orf57, FLJ13263	ENSG00000133678	Transmembrane protein 254	10	80078646-80092557	Predicted membrane proteins	Evidence at protein level	HPA029105, HPA072613	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			skin: 85.7	Mixed		
TMTC1	ARG99, FLJ31400, FLJ41625, OLF	ENSG00000133687	Transmembrane and tetratricopeptide repeat containing 1	12	29500840-29784759	Predicted membrane proteins	Evidence at protein level	HPA016720	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.90e-4 (unfavourable), Renal cancer:5.49e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 60.8	adipose tissue: 41.7	Cell line enhanced		HHSteC: 71.4;hTERT-HME1: 81.2;RH-30: 120.9
KRAS	KRAS1, KRAS2	ENSG00000133703	KRAS proto-oncogene, GTPase	12	25204789-25250936	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA049830	Approved				Renal cancer:2.75e-5 (favourable), Pancreatic cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 32.6	Expressed in all		
IPO8	IMP8, RANBP8	ENSG00000133704	Importin 8	12	30628988-30695986	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018439, HPA023765	Uncertain		Supported	Nucleus	Renal cancer:8.62e-5 (favourable), Liver cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.8	Expressed in all		
LARS	FLJ10595, FLJ21788, HSPC192, LARS1, LEUS, RNTLS	ENSG00000133706	Leucyl-tRNA synthetase	5	146113038-146182660	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036424, HPA040881	Supported		Supported	Nuclear bodies<br>Cytosol	Liver cancer:3.78e-5 (unfavourable), Thyroid cancer:2.98e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 70.8	Expressed in all		
SPINK5	DKFZp686K19184, FLJ21544, FLJ97536, FLJ97596, FLJ99794, LEKTI, LETKI, NETS, NS, VAKTI	ENSG00000133710	Serine peptidase inhibitor, Kazal type 5	5	148025683-148137289	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA009067, HPA011351, CAB015347	Enhanced		Enhanced	Vesicles		Tissue enhanced	Group enriched	26	esophagus: 1130.0;skin: 383.9;tonsil: 270.0	breast: 22.9	Cell line enhanced		HaCaT: 13.2;HeLa: 14.7;Karpas-707: 13.8
IMPA1	IMPA	ENSG00000133731	Inositol monophosphatase 1	8	81657961-81686693	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037489	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 72.0	Expressed in all		
LRRCC1	CLERC, KIAA1764, VFL1	ENSG00000133739	Leucine rich repeat and coiled-coil centrosomal protein 1	8	85107147-85146076	Predicted intracellular proteins	Evidence at protein level	HPA012893	Uncertain					Expressed in all	Tissue enhanced		testis: 57.8	thyroid gland: 14.2	Cell line enhanced		HDLM-2: 38.0
E2F5		ENSG00000133740	E2F transcription factor 5	8	85177225-85217158	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA055723			Supported	Nucleus<br>Nucleoli	Renal cancer:1.89e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 30.9	Cell line enhanced		AF22: 76.4;Daudi: 112.8
CA1	Car1	ENSG00000133742	Carbonic anhydrase 1	8	85327608-85379014	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006558, CAB025790	Enhanced					Group enriched	Group enriched	30	bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0	smooth muscle: 49.9	Cell line enriched	1560	HEL: 1145.7
CCDC59	BR22, HSPC128, TAP26	ENSG00000133773	Coiled-coil domain containing 59	12	82223681-82358805	Predicted intracellular proteins	Evidence at protein level	HPA038555	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.39e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.4	Expressed in all		
SWAP70	KIAA0640, SWAP-70	ENSG00000133789	SWAP switching B-cell complex subunit 70	11	9664077-9752991	Predicted intracellular proteins	Evidence at protein level	HPA006810	Supported					Expressed in all	Expressed in all			spleen: 82.2	Mixed		
ARNTL	bHLHe5, BMAL1, JAP3, MOP3, PASD3	ENSG00000133794	Aryl hydrocarbon receptor nuclear translocator like	11	13276652-13387266	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB045962, HPA050938	Supported		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			adrenal gland: 26.3	Mixed		
LYVE1	LYVE-1, XLKD1	ENSG00000133800	Lymphatic vessel endothelial hyaluronan receptor 1	11	10556966-10611689	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025860, HPA042953	Supported				Renal cancer:6.98e-5 (unfavourable), Ovarian cancer:1.07e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 157.5;placenta: 213.1	smooth muscle: 95.3	Cell line enriched	11	HUVEC TERT2: 67.8
AMPD3		ENSG00000133805	Adenosine monophosphate deaminase 3	11	10308313-10507579	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038662, HPA047408	Uncertain		Enhanced	Nuclear membrane	Endometrial cancer:2.37e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 54.4	bone marrow: 41.4	Cell line enhanced		BJ hTERT+: 35.8
MICALCL	FLJ14966	ENSG00000133808	MICAL C-terminal like	11	12276080-12359144	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039895, HPA040438	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		skin: 17.3;testis: 13.4	lung: 10.3	Cell line enhanced		HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9
SBF2	CMT4B2, DENND7B, KIAA1766, MTMR13	ENSG00000133812	SET binding factor 2	11	9778667-10294207	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050933	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Renal cancer:3.66e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
MICAL2	KIAA0750	ENSG00000133816	Microtubule associated monooxygenase, calponin and LIM domain containing 2	11	12094008-12263789	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030437	Approved		Approved	Golgi apparatus	Renal cancer:3.63e-5 (unfavourable)	Expressed in all	Mixed			testis: 79.8	Cell line enhanced		U-138 MG: 131.4
RRAS2	TC21	ENSG00000133818	Related RAS viral (r-ras) oncogene homolog 2	11	14277926-14364506	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010420, HPA050942	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.44e-4 (unfavourable), Liver cancer:3.31e-4 (unfavourable), Head and neck cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.3	Mixed		
HSD17B4	DBP, MFE-2, SDR8C1	ENSG00000133835	Hydroxysteroid 17-beta dehydrogenase 4	5	119452443-119637199	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021302, HPA021311, HPA021479	Enhanced		Enhanced	Peroxisomes	Renal cancer:6.31e-6 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 229.7	Expressed in all		
ZFC3H1	CCDC131, CSRC2, KIAA0546, MGC23401, PSRC2	ENSG00000133858	Zinc finger C3H1-type containing	12	71609472-71667725	Predicted intracellular proteins	Evidence at protein level	HPA007072, HPA007151	Enhanced		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:1.48e-5 (unfavourable), Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Mixed			testis: 19.1	Expressed in all		
TEX15	CT42	ENSG00000133863	Testis expressed 15, meiosis and synapsis associated	8	30831544-30890606	Predicted intracellular proteins	Evidence at protein level	HPA036799, HPA036800	Enhanced		Approved	Nuclear speckles		Not detected	Group enriched	32	endometrium: 11.0;smooth muscle: 8.3;testis: 22.3	cerebral cortex,gallbladder: 0.4	Cell line enhanced		HAP1: 8.7;HEL: 17.3;K-562: 4.9;SCLC-21H: 4.9
SARAF	MGC8721, TMEM66	ENSG00000133872	Store-operated calcium entry associated regulatory factor	8	30063012-30083208	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040400			Supported	Endoplasmic reticulum<br>Rods & Rings	Lung cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 287.0	Expressed in all		
RNF122	FLJ12526	ENSG00000133874	Ring finger protein 122	8	33547755-33567125	Predicted membrane proteins	Evidence at transcript level	HPA003888	Uncertain				Renal cancer:4.50e-7 (unfavourable), Thyroid cancer:1.88e-4 (unfavourable), Prostate cancer:5.37e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.6	Cell line enhanced		HEK 293: 76.9;Karpas-707: 38.8
DUSP26	DUSP24, MGC1136	ENSG00000133878	Dual specificity phosphatase 26	8	33591332-33600106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018221	Approved		Supported	Nucleus		Tissue enhanced	Tissue enhanced		cerebral cortex: 47.1;skeletal muscle: 138.7	ovary: 39.6	Group enriched	29	SCLC-21H: 110.0;SH-SY5Y: 23.6
DPF2	BAF45d, REQ, ubi-d4	ENSG00000133884	Double PHD fingers 2	11	65333754-65353249	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020880, HPA056786	Approved		Supported	Nucleoplasm	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 52.1	Expressed in all		
MEN1		ENSG00000133895	Menin 1	11	64803510-64811294	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030342	Uncertain		Supported	Nucleoplasm<br>Cytosol	Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.3	Expressed in all		
C14orf1	ERG28, NET51	ENSG00000133935	Chromosome 14 open reading frame 1	14	75649791-75661189	Predicted membrane proteins	Evidence at protein level	HPA043172, HPA063568	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.30e-5 (favourable)	Expressed in all	Expressed in all			testis: 77.2	Expressed in all		
GSC		ENSG00000133937	Goosecoid homeobox	14	94768216-94770230	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075650			Approved	Nucleus<br>Nuclear bodies		Mixed	Tissue enhanced		adipose tissue: 2.1	breast: 1.1	Cell line enhanced		HEK 293: 1.7;MCF7: 2.1;REH: 2.6;SH-SY5Y: 3.3;T-47d: 2.1;U-251 MG: 1.8
C14orf159	FLJ39975	ENSG00000133943	Chromosome 14 open reading frame 159	14	91060333-91225632	Predicted intracellular proteins	Evidence at protein level	HPA041423, HPA052932	Approved		Supported	Cytosol	Renal cancer:3.77e-15 (favourable), Lung cancer:9.48e-5 (favourable), Endometrial cancer:4.28e-4 (favourable), Ovarian cancer:7.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.6	Expressed in all		
UNC79	KIAA1409	ENSG00000133958	Unc-79 homolog (C. elegans)	14	93333219-93707876	Predicted membrane proteins	Evidence at protein level	HPA071881			Approved	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 5.2;testis: 3.0	adrenal gland: 1.0	Cell line enhanced		REH: 3.9;SCLC-21H: 3.6;SH-SY5Y: 2.0;U-937: 1.2
NUMB	C14orf41	ENSG00000133961	NUMB, endocytic adaptor protein	14	73275107-73463642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002874, CAB011478	Approved		Enhanced	Cell Junctions<br>Cytosol	Renal cancer:2.32e-6 (favourable)	Expressed in all	Expressed in all			lung: 78.0	Expressed in all		
CATSPERB	C14orf161, FLJ14298	ENSG00000133962	Cation channel sperm associated auxiliary subunit beta	14	91580696-91780707	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035134	Uncertain		Uncertain	Vesicles		Mixed	Mixed			skin: 2.7	Cell line enhanced		CAPAN-2: 1.1
VRTN	C14orf115, FLJ10811, vertnin	ENSG00000133980	Vertebrae development associated	14	74303069-74360008	Predicted intracellular proteins	Evidence at protein level	HPA001460	Uncertain		Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 1.8;testis: 2.9	lymph node: 0.5	Cell line enriched	10	NTERA-2: 49.5
COX16	C14orf112, HSPC203	ENSG00000133983	COX16, cytochrome c oxidase assembly homolog	14	70325081-70359731	Predicted intracellular proteins	Evidence at protein level	HPA062659	Uncertain		Supported	Mitochondria	Renal cancer:1.03e-12 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
TTC9	KIAA0227, TTC9A	ENSG00000133985	Tetratricopeptide repeat domain 9	14	70641787-70675360	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.10e-8 (favourable), Endometrial cancer:1.82e-5 (favourable)	Expressed in all	Tissue enhanced		esophagus: 44.6	fallopian tube: 15.9	Cell line enhanced		A-431: 15.5;RH-30: 20.2;SK-BR-3: 26.6
MED6	NY-REN-28	ENSG00000133997	Mediator complex subunit 6	14	70581257-70600690	Predicted intracellular proteins	Evidence at protein level	HPA030764, HPA069039	Approved		Enhanced	Nucleoplasm	Liver cancer:1.04e-4 (unfavourable), Melanoma:2.75e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 28.6	Expressed in all		
EIF2S1	EIF-2alpha, EIF2, EIF2A	ENSG00000134001	Eukaryotic translation initiation factor 2 subunit alpha	14	67359997-67386516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011663, HPA064885	Supported		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:4.73e-7 (unfavourable), Pancreatic cancer:4.97e-4 (unfavourable), Urothelial cancer:7.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 61.1	Expressed in all		
ADAM20		ENSG00000134007	ADAM metallopeptidase domain 20	14	70522358-70535015	Predicted membrane proteins	Evidence at protein level	HPA059377	Enhanced					Not detected	Tissue enriched	77	testis: 9.2	cerebral cortex,endometrium,epididymis,skin: 0.1	Not detected		
LOXL2	WS9-14	ENSG00000134013	Lysyl oxidase like 2	8	23297189-23425328	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025848, HPA036257, HPA056542	Approved		Approved	Nucleoplasm	Lung cancer:1.46e-7 (unfavourable), Renal cancer:2.91e-7 (unfavourable), Cervical cancer:9.83e-6 (unfavourable), Glioma:1.78e-4 (unfavourable), Pancreatic cancer:9.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 59.8	placenta: 53.3	Cell line enhanced		BJ: 809.1;U-87 MG: 911.1
ELP3	FLJ10422, KAT9	ENSG00000134014	Elongator acetyltransferase complex subunit 3	8	28089673-28191156	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA025812	Uncertain				Renal cancer:1.31e-5 (favourable), Colorectal cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 37.6	Expressed in all		
PEBP4	CORK1, hPEBP4, MGC22776	ENSG00000134020	Phosphatidylethanolamine binding protein 4	8	22713251-23000000	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025064	Uncertain					Group enriched	Tissue enhanced		epididymis: 470.5;lung: 173.6;skeletal muscle: 233.0	thyroid gland: 96.3	Cell line enriched	7	U-266/70: 3.0
ADAMDEC1	M12.219	ENSG00000134028	ADAM like decysin 1	8	24384285-24406013	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		colon: 210.9;rectum: 339.7;small intestine: 476.3	duodenum: 189.1	Group enriched	7	U-266/70: 8.1;U-266/84: 1.9
CTIF	KIAA0427	ENSG00000134030	Cap binding complex dependent translation initiation factor	18	48539046-48863217	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA016865, HPA024801	Uncertain		Supported	Cytosol	Renal cancer:3.18e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 24.9	Mixed		
MRO	B29, C18orf3, FLJ30140	ENSG00000134042	Maestro	18	50795120-50825402	Predicted intracellular proteins	Evidence at transcript level	HPA022011	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 27.5;kidney: 25.5;testis: 54.7	thyroid gland: 10.4	Cell line enhanced		ASC diff: 1.9;ASC TERT1: 6.0
MBD2		ENSG00000134046	Methyl-CpG binding domain protein 2	18	54151601-54224788	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037282, HPA067582, HPA067615	Approved		Enhanced	Nucleoplasm	Colorectal cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.6	Expressed in all		
IER3IP1		ENSG00000134049	Immediate early response 3 interacting protein 1	18	47152834-47176374	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010027	Supported		Supported	Endoplasmic reticulum	Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.8	Expressed in all		
MRPS36	DC47, MRP-S36	ENSG00000134056	Mitochondrial ribosomal protein S36	5	69217760-69230129	Predicted intracellular proteins	Evidence at protein level	HPA035802, HPA056795	Supported		Enhanced	Mitochondria	Renal cancer:5.02e-6 (favourable)	Expressed in all	Expressed in all			kidney: 52.2	Expressed in all		
CCNB1	CCNB	ENSG00000134057	Cyclin B1	5	69167010-69178245	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000115, CAB003804, HPA030741, HPA061448	Enhanced		Enhanced	Cytosol	Renal cancer:1.11e-16 (unfavourable), Liver cancer:1.54e-7 (unfavourable), Lung cancer:3.38e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 65.5	Expressed in all		
CDK7	CAK, CAK1, CDKN7, MO15, STK1	ENSG00000134058	Cyclin dependent kinase 7	5	69234795-69277430	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004364, HPA007932	Enhanced				Renal cancer:9.42e-7 (unfavourable), Pancreatic cancer:3.09e-4 (unfavourable)	Expressed in all	Mixed			testis: 23.7	Mixed		
CD180	LY64, Ly78, RP105	ENSG00000134061	CD180 molecule	5	67179613-67196799	CD markers, Predicted membrane proteins	Evidence at protein level	HPA003740	Enhanced					Mixed	Tissue enhanced		lymph node: 27.4;tonsil: 21.3	spleen: 17.8	Group enriched	11	Daudi: 32.2;Karpas-707: 29.5;U-266/70: 25.3;U-266/84: 34.5;U-698: 8.6
IRAK2		ENSG00000134070	Interleukin 1 receptor associated kinase 2	3	10164865-10243743	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB013483, HPA050520	Uncertain		Approved	Vesicles	Urothelial cancer:6.60e-5 (favourable), Pancreatic cancer:2.26e-4 (unfavourable), Liver cancer:8.35e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 14.6	Cell line enhanced		BEWO: 31.5;BJ hTERT+: 28.0;CAPAN-2: 30.8;RT4: 38.6
CAMK1	CaMKI	ENSG00000134072	Calcium/calmodulin dependent protein kinase I	3	9757342-9769992	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB031904, HPA051409	Approved		Approved	Cytosol	Liver cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 107.7	Cell line enhanced		HMC-1: 344.4
THUMPD3	DKFZP434F091	ENSG00000134077	THUMP domain containing 3	3	9362842-9386791	Predicted intracellular proteins	Evidence at protein level	HPA036170, HPA036171	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:1.25e-7 (unfavourable), Renal cancer:1.03e-4 (favourable)	Expressed in all	Expressed in all			testis: 107.5	Expressed in all		
VHL	VHL1	ENSG00000134086	Von Hippel-Lindau tumor suppressor	3	10141008-10152220	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB005430, HPA031631, HPA031632	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.32e-5 (unfavourable), Breast cancer:9.02e-5 (unfavourable), Stomach cancer:7.84e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 34.7	Expressed in all		
BHLHE40	BHLHB2, bHLHe40, Clast5, DEC1, SHARP2, STRA13	ENSG00000134107	Basic helix-loop-helix family member e40	3	4979116-4985323	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028922	Uncertain		Supported	Nuclear bodies	Pancreatic cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 230.0	Cell line enhanced		HDLM-2: 406.6;U-87 MG: 191.8
ARL8B	ARL10C, FLJ10702, Gie1	ENSG00000134108	ADP ribosylation factor like GTPase 8B	3	5122220-5180912	Predicted intracellular proteins	Evidence at protein level	HPA038759, HPA040515, HPA045924	Approved				Liver cancer:3.68e-6 (unfavourable), Renal cancer:4.84e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.6	Expressed in all		
EDEM1	EDEM, KIAA0212	ENSG00000134109	ER degradation enhancing alpha-mannosidase like protein 1	3	5187646-5219957	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029565	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			lymph node: 47.7	Expressed in all		
CNTN6	NB-3	ENSG00000134115	Contactin 6	3	1092576-1404217	Predicted membrane proteins	Evidence at protein level	HPA016645	Uncertain					Group enriched	Tissue enhanced		lung: 4.6;thyroid gland: 17.4	cerebral cortex: 4.0	Group enriched	22	AF22: 2.0;SH-SY5Y: 2.4
CHL1	CALL, FLJ44930, L1CAM2, MGC132578	ENSG00000134121	Cell adhesion molecule L1 like	3	196596-409417	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003345, CAB026120	Enhanced				Renal cancer:1.21e-6 (favourable)	Tissue enhanced	Tissue enriched	5	cerebral cortex: 111.8	ovary: 20.9	Group enriched	6	SK-MEL-30: 73.7;WM-115: 29.2
MEIS2	HsT18361, MRG1	ENSG00000134138	Meis homeobox 2	15	36889204-37101299	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003256, CAB004999	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.64e-7 (unfavourable)	Mixed	Mixed			endometrium: 63.5	Cell line enhanced		fHDF/TERT166: 89.3;SH-SY5Y: 111.8
DPH6	ATPBD4, MGC14798	ENSG00000134146	Diphthamine biosynthesis 6	15	35217345-35546193	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042976, HPA055496	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 18.1	Expressed in all		
KATNBL1	C15orf29, FLJ22557	ENSG00000134152	Katanin regulatory subunit B1 like 1	15	34140674-34210096	Predicted intracellular proteins	Evidence at protein level	HPA062573	Approved		Approved	Nucleus<br>Midbody<br>Mitotic spindle	Renal cancer:4.60e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 46.7	Expressed in all		
EMC7	C11orf3, C15orf24	ENSG00000134153	ER membrane protein complex subunit 7	15	34084017-34101948	Predicted membrane proteins	Evidence at protein level	HPA010029, HPA047572	Approved		Approved	Nucleoplasm	Endometrial cancer:4.68e-5 (favourable), Head and neck cancer:9.25e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 129.8	Expressed in all		
TRPM1	CSNB1C, LTRPC1, MLSN1	ENSG00000134160	Transient receptor potential cation channel subfamily M member 1	15	31001061-31161273	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA014779, HPA014785	Supported		Uncertain	Nucleoplasm<br>Cytosol		Tissue enriched	Group enriched	26	skin: 4.8;testis: 2.1	kidney: 0.1	Cell line enriched	91	SK-MEL-30: 9.1
GNAT2	ACHM4	ENSG00000134183	G protein subunit alpha transducin 2	1	109603267-109619929	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	testis: 3.9	placenta: 0.6	Cell line enhanced		HAP1: 2.0
GSTM1	GST1, H-B, MU	ENSG00000134184	Glutathione S-transferase mu 1	1	109687814-109709039	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022669, CAB047357, HPA048652, HPA055972, HPA055973	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		liver: 317.1	parathyroid gland: 233.1	Cell line enhanced		HEL: 78.7;HeLa: 68.9;HHSteC: 66.1;hTEC/SVTERT24-B: 72.9;MOLT-4: 92.2
PRPF38B	FLJ10330, NET1	ENSG00000134186	Pre-mRNA processing factor 38B	1	108692323-108701803	Predicted intracellular proteins	Evidence at protein level	HPA053255	Approved				Renal cancer:2.03e-4 (unfavourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.7	Expressed in all		
REG4	GISP, REG-IV, RELP	ENSG00000134193	Regenerating family member 4	1	119794018-119811660	Predicted secreted proteins	Evidence at protein level	CAB025867, HPA046555	Enhanced					Group enriched	Group enriched	9	colon: 215.7;duodenum: 239.5;rectum: 299.4;small intestine: 664.5	appendix: 39.6	Group enriched	24	PC-3: 85.3;RT4: 20.5
TSPAN2	FLJ12082, TSN2, TSPAN-2	ENSG00000134198	Tetraspanin 2	1	115048011-115089500	Predicted membrane proteins	Evidence at protein level	HPA015640	Uncertain		Approved	Nucleoplasm	Renal cancer:8.48e-7 (unfavourable), Endometrial cancer:8.89e-4 (unfavourable)	Mixed	Tissue enhanced		endometrium: 71.7;smooth muscle: 64.6	seminal vesicle: 40.5	Cell line enhanced		EFO-21: 58.1;U-937: 21.9
TSHB		ENSG00000134200	Thyroid stimulating hormone beta	1	115029824-115034309	Predicted secreted proteins	Evidence at protein level	CAB022202, HPA042681	Supported					Not detected	Not detected			gallbladder: 0.5	Not detected		
GSTM5		ENSG00000134201	Glutathione S-transferase mu 5	1	109712255-109775428	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved		Approved	Cytokinetic bridge<br>Cytosol		Mixed	Group enriched	6	breast: 845.2;ovary: 221.0	fallopian tube: 84.6	Group enriched	8	fHDF/TERT166: 12.9;HHSteC: 5.7;HSkMC: 5.3
GSTM3	GST5	ENSG00000134202	Glutathione S-transferase mu 3	1	109733932-109741038	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017130, HPA035190, CAB040583, HPA055972	Enhanced		Supported	Cytosol	Melanoma:1.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 722.1	Cell line enhanced		T-47d: 462.4
SYT6		ENSG00000134207	Synaptotagmin 6	1	114089291-114153919	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058362			Uncertain	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.5	kidney: 1.5	Group enriched	7	NTERA-2: 23.0;WM-115: 16.3
VAV3		ENSG00000134215	Vav guanine nucleotide exchange factor 3	1	107571160-107965144	Predicted intracellular proteins	Evidence at protein level	CAB002012	Uncertain				Renal cancer:4.60e-8 (favourable)	Expressed in all	Tissue enhanced		kidney: 90.9	skin: 58.7	Cell line enhanced		REH: 48.1;RH-30: 60.2;RPTEC TERT1: 66.0;T-47d: 100.9
CHIA	AMCase, CHIT2, TSA1902	ENSG00000134216	Chitinase, acidic	1	111290862-111320566	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059193	Approved					Tissue enhanced	Group enriched	11	lung: 15.6;stomach: 8.2	endometrium: 1.1	Cell line enhanced		ASC diff: 1.1
PSRC1	DDA3	ENSG00000134222	Proline and serine rich coiled-coil 1	1	109279556-109283186	Predicted intracellular proteins	Evidence at protein level	HPA049315, HPA056561	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.36e-9 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.6	testis: 14.0	Expressed in all		
HMGCS2		ENSG00000134240	3-hydroxy-3-methylglutaryl-CoA synthase 2	1	119747996-119768905	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027423, HPA027442, CAB032906	Enhanced		Supported	Mitochondria	Liver cancer:2.43e-7 (favourable), Renal cancer:3.43e-5 (favourable), Ovarian cancer:2.17e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 1270.5	colon: 363.4	Cell line enriched	15	RT4: 161.6
PTPN22	Lyp, Lyp1, Lyp2, PTPN8	ENSG00000134242	Protein tyrosine phosphatase, non-receptor type 22	1	113813811-113871759	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004912, CAB012209, HPA013350	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		bone marrow: 24.8	lymph node: 23.3	Cell line enhanced		Daudi: 49.5;U-698: 25.4
SORT1	Gp95, NT3	ENSG00000134243	Sortilin 1	1	109309568-109397951	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006889, CAB011498	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 169.5	Mixed		
WNT2B	WNT13, XWNT2	ENSG00000134245	Wnt family member 2B	1	112466541-112530165	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047274, HPA060696, HPA066368	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Mixed			seminal vesicle: 20.0	Cell line enhanced		HSkMC: 6.3
PTGFRN	CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6	ENSG00000134247	Prostaglandin F2 receptor inhibitor	1	116910057-116990358	CD markers, Predicted membrane proteins	Evidence at protein level	HPA017074	Approved				Renal cancer:3.98e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 69.3	Cell line enhanced		U-87 MG: 146.9
LAMTOR5	HBXIP, MGC71071, XIP	ENSG00000134248	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 5	1	110401249-110407942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006812	Approved		Supported	Cytosol	Liver cancer:2.60e-4 (unfavourable), Thyroid cancer:5.52e-4 (favourable), Ovarian cancer:7.23e-4 (favourable)	Expressed in all	Expressed in all			kidney: 431.6	Expressed in all		
ADAM30	svph4	ENSG00000134249	ADAM metallopeptidase domain 30	1	119893533-119896495	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA026080	Uncertain					Not detected	Tissue enriched	471	testis: 47.0	all non-specific tissues: 0.0	Not detected		
NOTCH2		ENSG00000134250	Notch 2	1	119911553-120069626	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048743	Approved		Supported	Nucleoplasm<br>Plasma membrane	Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 46.7	Mixed		
TRIM45	FLJ13181, RNF99	ENSG00000134253	Tripartite motif containing 45	1	117111060-117122587	Predicted intracellular proteins	Evidence at protein level	HPA030266, HPA054308	Uncertain		Supported	Cytokinetic bridge<br>Cytosol	Breast cancer:1.58e-4 (favourable), Thyroid cancer:2.92e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 14.4	Cell line enhanced		RH-30: 30.6
CEPT1		ENSG00000134255	Choline/ethanolamine phosphotransferase 1	1	111139627-111185102	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level						Glioma:6.43e-4 (favourable)	Expressed in all	Expressed in all			spleen: 37.1	Expressed in all		
CD101	IGSF2, V7	ENSG00000134256	CD101 molecule	1	117001750-117036476	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049527, HPA057763	Approved		Uncertain	Mitochondria		Mixed	Tissue enhanced		lung: 9.6	small intestine: 6.8	Cell line enriched	8	HMC-1: 24.0
VTCN1	B7-H4, B7H4, B7S1, B7X, FLJ22418	ENSG00000134258	V-set domain containing T-cell activation inhibitor 1	1	117143587-117210960	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054200	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites		Group enriched	Tissue enhanced		breast: 129.4;fallopian tube: 51.3	cervix, uterine: 22.0	Group enriched	8	BEWO: 43.1;SK-BR-3: 182.1
NGF	NGFB	ENSG00000134259	Nerve growth factor	1	115285918-115338236	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:8.08e-7 (unfavourable), Head and neck cancer:1.80e-4 (unfavourable)	Mixed	Tissue enhanced		ovary: 12.3	smooth muscle: 5.9	Cell line enhanced		BJ: 73.7;BJ hTERT+ SV40 Large T+: 28.4;hTEC/SVTERT24-B: 29.7;U-2197: 55.6
AP4B1	BETA-4, SPG47	ENSG00000134262	Adaptor related protein complex 4 beta 1 subunit	1	113894748-113905201	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028162, HPA028652	Approved		Approved	Vesicles	Liver cancer:8.60e-7 (unfavourable), Renal cancer:3.73e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.2	Expressed in all		
NAPG		ENSG00000134265	NSF attachment protein gamma	18	10525905-10552761	Predicted intracellular proteins	Evidence at protein level	HPA008208, HPA011389	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.5	Expressed in all		
SPIRE1	KIAA1135, spir-1	ENSG00000134278	Spire type actin nucleation factor 1	18	12446512-12658134	Predicted intracellular proteins	Evidence at protein level	HPA040737, HPA040942	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:2.07e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 61.3	cerebral cortex: 50.4	Mixed		
PPHLN1		ENSG00000134283	Periphilin 1	12	42238447-42459715	Predicted intracellular proteins	Evidence at protein level	HPA038902, HPA038903	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Liver cancer:1.28e-7 (unfavourable), Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
FKBP11	FKBP19	ENSG00000134285	FK506 binding protein 11	12	48921518-48926474	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041709	Enhanced		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable)	Expressed in all	Mixed			pancreas: 60.7	Mixed		
ARF3		ENSG00000134287	ADP ribosylation factor 3	12	48935723-48957551	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 402.7	Expressed in all		
TMEM106C	MGC5576	ENSG00000134291	Transmembrane protein 106C	12	47963569-47968878	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047204	Enhanced				Liver cancer:5.27e-8 (unfavourable), Renal cancer:4.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 169.3	Expressed in all		
SLC38A2	ATA2, KIAA1382, SAT2, SNAT2	ENSG00000134294	Solute carrier family 38 member 2	12	46358189-46372867	Predicted membrane proteins	Evidence at protein level	HPA035180	Approved		Approved	Vesicles		Expressed in all	Expressed in all			skin: 238.8	Mixed		
YWHAQ	14-3-3, HS1	ENSG00000134308	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta	2	9583972-9631014	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007925, CAB010286	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.83e-6 (unfavourable), Endometrial cancer:8.20e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 398.1	Expressed in all		
KIDINS220	ARMS	ENSG00000134313	Kinase D interacting substrate 220	2	8721081-8837630	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014790	Supported		Approved	Nucleoplasm	Renal cancer:9.29e-6 (favourable), Lung cancer:9.64e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 101.6	Expressed in all		
GRHL1	LBP-32, MGR, TFCP2L2	ENSG00000134317	Grainyhead like transcription factor 1	2	9951693-10002277	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005798, HPA006420	Enhanced		Enhanced	Nucleus<br>Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		esophagus: 111.4;skin: 106.8	parathyroid gland: 50.3	Cell line enhanced		BEWO: 205.8;SK-BR-3: 84.4
ROCK2		ENSG00000134318	Rho associated coiled-coil containing protein kinase 2	2	11179761-11348330	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007459, CAB008666, HPA044109	Approved		Supported	Cytosol	Renal cancer:1.57e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 41.0	Expressed in all		
RSAD2	cig5, vig1, viperin	ENSG00000134321	Radical S-adenosyl methionine domain containing 2	2	6865806-6898239	Predicted intracellular proteins	Evidence at protein level	HPA041160, HPA049409	Approved		Supported	Nucleoli fibrillar center<br>Endoplasmic reticulum	Endometrial cancer:4.60e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 75.1;BJ hTERT+ SV40 Large T+ RasG12V: 120.3;HMC-1: 51.2
MYCN	bHLHe37, MYCNOT, N-myc, NMYC	ENSG00000134323	V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog	2	15940564-15947007	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057420			Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enhanced		placenta: 13.7	cerebral cortex: 7.2	Cell line enhanced		AF22: 43.5;BEWO: 230.1;HMC-1: 50.4;NTERA-2: 91.1;RH-30: 61.3
LPIN1	KIAA0188	ENSG00000134324	Lipin 1	2	11677595-11827409	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038021	Approved		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			testis: 102.1	Expressed in all		
CMPK2	NDK, TYKi, UMP-CMPK2	ENSG00000134326	Cytidine/uridine monophosphate kinase 2	2	6840570-6866635	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041430	Approved		Approved	Mitochondria	Endometrial cancer:4.71e-4 (unfavourable)	Expressed in all	Mixed			spleen: 5.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 16.8;BJ hTERT+ SV40 Large T+ RasG12V: 15.8;HEL: 23.9;MOLT-4: 11.9
IAH1		ENSG00000134330	Isoamyl acetate-hydrolyzing esterase 1 homolog	2	9473658-9496543	Predicted intracellular proteins	Evidence at protein level	HPA040523			Supported	Nucleoplasm	Renal cancer:3.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 121.2	Mixed		
LDHA		ENSG00000134333	Lactate dehydrogenase A	11	18394388-18408425	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015336, CAB069404	Uncertain		Supported	Vesicles<br>Cytosol	Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 503.4	Expressed in all		
SAA2		ENSG00000134339	Serum amyloid A2	11	18239223-18248643	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.30e-8 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 713.3;cervix, uterine: 414.7;liver: 581.2	appendix: 211.6	Cell line enhanced		A-431: 25.4;EFO-21: 20.0;HaCaT: 23.6;HBEC3-KT: 41.5
ANO3	C11orf25, DYT23, GENX-3947, TMEM16C	ENSG00000134343	Anoctamin 3	11	26309599-26663288	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041629	Uncertain					Not detected	Tissue enriched	6	epididymis: 62.2	cerebral cortex: 10.5	Cell line enhanced		HDLM-2: 5.9;U-2 OS: 1.7;U-2197: 4.2
IL6ST	CD130, GP130	ENSG00000134352	Interleukin 6 signal transducer	5	55935095-55994993	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010558, CAB025784	Uncertain		Supported	Golgi apparatus<br>Plasma membrane	Renal cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.8	Expressed in all		
FST	FS	ENSG00000134363	Follistatin	5	53480409-53487134	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026025	Approved				Renal cancer:4.44e-5 (unfavourable)	Expressed in all	Mixed			liver: 33.0	Cell line enhanced		BJ hTERT+: 272.8;HaCaT: 253.0;PC-3: 509.0
CFHR4	CFHL4, FHR-4, FHR4	ENSG00000134365	Complement factor H related 4	1	196850241-196918972	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.57e-6 (favourable)	Tissue enriched	Tissue enriched	373	liver: 78.3	testis: 0.2	Cell line enhanced		U-266/70: 1.1
NAV1	DKFZp781D0314, FLJ12560, FLJ14203, KIAA1151, MGC14961, POMFIL3, steerin-1	ENSG00000134369	Neuron navigator 1	1	201622885-201826969	Predicted intracellular proteins	Evidence at protein level	CAB012302, HPA018127, HPA027887	Enhanced		Approved	Microtubules	Renal cancer:3.10e-6 (unfavourable)	Mixed	Mixed			cerebral cortex: 31.8	Cell line enhanced		TIME: 153.0
CDC73	C1orf28, FIHP, HRPT1, HRPT2, parafibromin	ENSG00000134371	Cell division cycle 73	1	193122017-193253901	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016359, HPA030772	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 32.2	Expressed in all		
TIMM17A	TIM17, TIM17A	ENSG00000134375	Translocase of inner mitochondrial membrane 17A	1	201955491-201970661	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA010083	Approved		Supported	Nucleoplasm<br>Mitochondria	Breast cancer:1.98e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 63.2	Expressed in all		
CRB1	LCA8, RP12	ENSG00000134376	Crumbs 1, cell polarity complex component	1	197268204-197478455	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA061250, HPA063127	Approved		Uncertain	Vesicles		Tissue enriched	Group enriched	10	cerebral cortex: 12.2;testis: 5.0	ovary: 0.8	Cell line enriched	5	HeLa: 9.0
CFHR5	CFHL5, FHR-5, FHR5	ENSG00000134389	Complement factor H related 5	1	196977556-197009674	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726	Supported					Tissue enriched	Tissue enriched	500	liver: 88.0	testis: 0.1	Not detected		
ERN2	IRE1b	ENSG00000134398	Endoplasmic reticulum to nucleus signaling 2	16	23690326-23713500	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016558	Uncertain					Mixed	Group enriched	7	cervix, uterine: 27.6;colon: 27.5;duodenum: 12.3;gallbladder: 25.1;rectum: 23.2;small intestine: 9.9;stomach: 49.1	appendix: 3.8	Cell line enriched	8	CAPAN-2: 5.9
RPS15A	S15A	ENSG00000134419	Ribosomal protein S15a	16	18781295-18790383	Predicted intracellular proteins, Predicted membrane proteins, Ribosomal proteins	Evidence at protein level	HPA047103	Supported				Renal cancer:7.29e-7 (unfavourable)	Expressed in all	Expressed in all			breast: 4784.5	Expressed in all		
RAX	RX	ENSG00000134438	Retina and anterior neural fold homeobox	18	59267035-59274086	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			prostate: 0.2	Cell line enhanced		HMC-1: 1.6;SH-SY5Y: 1.0
NARS	NARS1	ENSG00000134440	Asparaginyl-tRNA synthetase	18	57600656-57622213	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034257, HPA040017	Enhanced		Approved	Cytosol	Liver cancer:1.23e-7 (unfavourable), Renal cancer:1.73e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 154.1	Expressed in all		
GRP		ENSG00000134443	Gastrin releasing peptide	18	59220168-59230774	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lung: 13.4;thyroid gland: 10.4	parathyroid gland: 3.9	Group enriched	8	BJ hTERT+: 4.2;fHDF/TERT166: 5.1
KIAA1468	FLJ33841, HsT3308, HsT885	ENSG00000134444	KIAA1468	18	62187258-62307829	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039708, HPA040038	Approved		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			skin: 24.6	Expressed in all		
FBXO18	FBH1, Fbx18, FLJ14590	ENSG00000134452	F-box protein, helicase, 18	10	5890203-5937594	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA002844	Supported				Liver cancer:7.73e-7 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 46.8	Expressed in all		
RBM17	MGC14439, SPF45	ENSG00000134453	RNA binding motif protein 17	10	6088987-6117457	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037477, HPA037478	Supported		Supported	Nucleoplasm	Liver cancer:4.57e-8 (unfavourable), Renal cancer:4.31e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 104.6	Expressed in all		
IL2RA	CD25, IDDM10, IL2R	ENSG00000134460	Interleukin 2 receptor subunit alpha	10	6010689-6062325	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002419, HPA054622	Enhanced				Renal cancer:2.08e-9 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4	tonsil: 12.0	Cell line enriched	80	HDLM-2: 1041.6
ANKRD16	DKFZP434N1511	ENSG00000134461	Ankyrin repeat domain 16	10	5861617-5889906	Predicted intracellular proteins	Evidence at protein level	HPA037920, HPA037921	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.31e-7 (unfavourable), Pancreatic cancer:1.98e-4 (favourable)	Expressed in all	Mixed			testis: 9.9	Expressed in all		
ECHDC3	FLJ20909	ENSG00000134463	Enoyl-CoA hydratase domain containing 3	10	11742366-11764070	Predicted intracellular proteins	Evidence at protein level	HPA038306	Enhanced		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Renal cancer:3.43e-4 (favourable), Urothelial cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 76.6	Cell line enhanced		A-431: 46.0;BEWO: 27.7
IL15RA	CD215, IL-15RA	ENSG00000134470	Interleukin 15 receptor subunit alpha	10	5943639-5978187	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026215	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 33.5	Cell line enhanced		CAPAN-2: 59.4;HDLM-2: 70.4
CCNH	CycH, p34, p37	ENSG00000134480	Cyclin H	5	87391494-87413019	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB019416, HPA044138	Approved		Supported	Nucleoplasm	Renal cancer:3.92e-5 (unfavourable), Ovarian cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 88.4	Expressed in all		
HRH4	AXOR35, GPCR105, GPRv53, H4R, HH4R	ENSG00000134489	Histamine receptor H4	18	24460629-24479957	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA035009	Uncertain					Not detected	Not detected			skin: 0.7	Cell line enhanced		HL-60: 1.1
TMEM241	C18orf45, FLJ44259, MGC11386	ENSG00000134490	Transmembrane protein 241	18	23197144-23437961	Predicted membrane proteins	Evidence at protein level	HPA029489, HPA059922	Uncertain		Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:5.80e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.2	Mixed		
KCTD1	C18orf5	ENSG00000134504	Potassium channel tetramerization domain containing 1	18	26454910-26657401	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.60e-8 (favourable), Endometrial cancer:2.22e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 72.7	Cell line enhanced		AF22: 101.7;HaCaT: 97.2
CABLES1	FLJ35924, HsT2563	ENSG00000134508	Cdk5 and Abl enzyme substrate 1	18	23134564-23260467	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA073649			Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.71e-6 (favourable)	Tissue enriched	Tissue enhanced		parathyroid gland: 60.1	lung: 32.2	Cell line enhanced		SK-MEL-30: 120.1;U-266/70: 164.7
DOCK2	KIAA0209	ENSG00000134516	Dedicator of cytokinesis 2	5	169637247-170083382	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036469	Enhanced					Expressed in all	Mixed			lymph node: 52.1	Cell line enhanced		Daudi: 87.0;HDLM-2: 143.2;HL-60: 97.8;HMC-1: 119.0
EMP1	CL-20, TMP	ENSG00000134531	Epithelial membrane protein 1	12	13196716-13219939	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051931, HPA056250			Approved	Nucleoplasm	Ovarian cancer:2.26e-8 (unfavourable), Urothelial cancer:9.69e-8 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 2199.3	Cell line enhanced		ASC TERT1: 819.4
SOX5	L-SOX5, MGC35153	ENSG00000134532	SRY-box 5	12	23529500-23951032	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060499			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 58.4	cerebral cortex: 11.7	Cell line enhanced		AF22: 14.4;HDLM-2: 25.3;K-562: 15.1;WM-115: 13.9
RERG	MGC15754	ENSG00000134533	RAS like estrogen regulated growth inhibitor	12	15107783-15348675	Predicted intracellular proteins	Evidence at protein level	HPA041387	Approved				Endometrial cancer:7.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 141.5	smooth muscle: 125.5	Group enriched	5	AN3-CA: 14.0;BEWO: 32.9;T-47d: 62.0;U-2 OS: 22.6
SLCO1B1	LST-1, OATP-C, OATP1B1, SLC21A6	ENSG00000134538	Solute carrier organic anion transporter family member 1B1	12	21131202-21239246	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050892	Supported					Tissue enriched	Tissue enriched	248	liver: 308.0	breast: 1.2	Not detected		
KLRD1	CD94	ENSG00000134539	Killer cell lectin like receptor D1	12	10226058-10329600	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069688	Uncertain					Mixed	Tissue enhanced		spleen: 18.8	lymph node: 6.7	Mixed		
KLRC1	CD159a, NKG2, NKG2-A, NKG2-B	ENSG00000134545	Killer cell lectin like receptor C1	12	10442264-10454685	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058052			Approved	Plasma membrane		Mixed	Mixed			spleen: 9.9	Cell line enhanced		HeLa: 3.5
SPX	C12orf39, MGC10946, NPQ, spexin	ENSG00000134548	Spexin hormone	12	21526307-21537377	Predicted secreted proteins	Evidence at protein level						Renal cancer:1.31e-6 (favourable)	Tissue enhanced	Group enriched	6	adipose tissue: 53.7;placenta: 13.5	thyroid gland: 6.1	Cell line enhanced		CACO-2: 11.2;HBEC3-KT: 4.9;hTERT-HME1: 6.9;U-2 OS: 4.4
PRH2	Pr	ENSG00000134551	Proline rich protein HaeIII subfamily 2	12	10929236-10932341	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1858	salivary gland: 16591.4	ovary: 8.9	Not detected		
LRP4	CLSS, LRP-4, MEGF7, SOST2	ENSG00000134569	LDL receptor related protein 4	11	46856868-46918642	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011934, HPA012300	Approved		Uncertain	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		cerebral cortex: 35.4;skin: 37.9	parathyroid gland: 13.1	Cell line enhanced		AF22: 21.2
MYBPC3	CMH4, FHC, MYBP-C	ENSG00000134571	Myosin binding protein C, cardiac	11	47331397-47352702	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040147, HPA043898	Enhanced					Not detected	Tissue enriched	496	heart muscle: 711.2	testis: 1.4	Cell line enriched	15	U-937: 4.9
DDB2	DDBB, FLJ34321, UV-DDB2, XPE	ENSG00000134574	Damage specific DNA binding protein 2	11	47214465-47239240	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB025912, HPA058406	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Endometrial cancer:1.20e-4 (favourable), Cervical cancer:1.58e-4 (favourable), Breast cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			skin: 53.7	Expressed in all		
ACP2	LAP	ENSG00000134575	Acid phosphatase 2, lysosomal	11	47239302-47248906	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 41.2	Expressed in all		
USP26		ENSG00000134588	Ubiquitin specific peptidase 26	X	133024631-133097109	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 1.1	bone marrow,breast,endometrium,epididymis,gallbladder,lymph node,prostate,skin,spleen,thyroid gland: 0.1	Not detected		
FAM127A	CXX1, Mar8, MAR8C, Mart8	ENSG00000134590	Family with sequence similarity 127 member A	X	135032366-135033546	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.97e-4 (favourable), Endometrial cancer:2.69e-4 (unfavourable), Liver cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 240.4	Mixed		
RAB33A	RabS10	ENSG00000134594	RAB33A, member RAS oncogene family	X	130171649-130184870	Predicted intracellular proteins	Evidence at protein level	HPA059737	Uncertain		Approved	Vesicles		Group enriched	Tissue enhanced		cerebral cortex: 31.9	lymph node: 9.1	Cell line enhanced		HMC-1: 70.4;Karpas-707: 65.9;U-266/70: 50.9
SOX3	PHP	ENSG00000134595	SRY-box 3	X	140502985-140505116	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054720, HPA075003			Enhanced	Nucleoplasm		Tissue enhanced	Tissue enriched	7	fallopian tube: 14.2	testis: 2.0	Group enriched	11	AF22: 7.2;HEK 293: 7.2;NTERA-2: 17.4
RBMX2	CGI-79, Snu17	ENSG00000134597	RNA binding motif protein, X-linked 2	X	130401969-130413343	Predicted intracellular proteins	Evidence at protein level	HPA026609	Approved		Approved	Nuclear membrane<br>Nucleoli	Renal cancer:8.44e-9 (unfavourable), Liver cancer:7.04e-4 (unfavourable), Lung cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 29.4	Expressed in all		
STK26	MASK, MST4	ENSG00000134602	Serine/threonine kinase 26	X	132023265-132075943	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059921	Approved		Approved	Nucleus<br>Golgi apparatus<br>Centrosome<br>Cytosol	Renal cancer:6.87e-5 (unfavourable), Liver cancer:6.82e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 68.5	Mixed		
PIWIL4	FLJ36156, HIWI2, Miwi2	ENSG00000134627	Piwi like RNA-mediated gene silencing 4	11	94543840-94621421	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036587, HPA036588, HPA057508	Enhanced		Approved	Nucleus<br>Mitochondria		Mixed	Tissue enhanced		testis: 24.3	bone marrow: 15.5	Cell line enhanced		NB-4: 58.5;THP-1: 13.6
MTNR1B		ENSG00000134640	Melatonin receptor 1B	11	92969720-92985066	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		placenta: 1.4	testis: 0.8	Not detected		
PUM1	KIAA0099, PUMH1	ENSG00000134644	Pumilio RNA binding family member 1	1	30931506-31065991	Predicted intracellular proteins	Evidence at protein level	HPA027424, HPA027449	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:7.62e-8 (favourable), Liver cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 73.0	Expressed in all		
SPOCD1	FLJ25348, PPP1R146	ENSG00000134668	SPOC domain containing 1	1	31790422-31816051	Predicted intracellular proteins	Evidence at protein level	HPA031713, HPA031714, HPA031715	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Urothelial cancer:4.05e-5 (favourable)	Group enriched	Tissue enhanced		testis: 14.1;urinary bladder: 10.0	appendix: 4.4	Cell line enhanced		hTEC/SVTERT24-B: 51.5;RT4: 71.0;U-87 MG: 82.7
YARS	tyrRS, YRS, YTS	ENSG00000134684	Tyrosyl-tRNA synthetase	1	32775237-32818153	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017936, HPA018950, HPA018954	Enhanced		Enhanced	Cytosol	Renal cancer:1.02e-11 (unfavourable), Liver cancer:6.97e-11 (unfavourable), Urothelial cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 81.5	Expressed in all		
PHC2	EDR2, HPH2	ENSG00000134686	Polyhomeotic homolog 2	1	33323623-33431052	Predicted intracellular proteins	Evidence at protein level	HPA047403	Supported		Supported	Nucleoplasm	Liver cancer:2.28e-6 (unfavourable), Renal cancer:2.35e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 88.1	Expressed in all		
CDCA8	BOR, DasraB, FLJ12042, MESRGP	ENSG00000134690	Cell division cycle associated 8	1	37692418-37709719	Predicted intracellular proteins	Evidence at protein level	HPA028120, HPA028258, HPA028783, CAB040294	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytokinetic bridge	Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.93e-10 (unfavourable), Melanoma:6.04e-4 (unfavourable), Pancreatic cancer:8.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.5	lymph node: 23.0	Mixed		
GNL2	HUMAUANTIG, Ngp-1, Nog2, Nug2	ENSG00000134697	G protein nucleolar 2	1	37566816-37595935	Predicted intracellular proteins	Evidence at protein level	HPA027163, HPA060026	Approved		Enhanced	Nucleoli	Renal cancer:2.90e-11 (unfavourable), Liver cancer:5.86e-9 (unfavourable), Ovarian cancer:7.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 55.6	Expressed in all		
AGO4	EIF2C4, FLJ20033, hAGO4, KIAA1567	ENSG00000134698	Argonaute 4, RISC catalytic component	1	35808172-35857890	Predicted intracellular proteins	Evidence at protein level	CAB012179, HPA068896	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Head and neck cancer:5.70e-5 (favourable)	Expressed in all	Expressed in all			skin: 24.4	Mixed		
HOOK1	HK1	ENSG00000134709	Hook microtubule tethering protein 1	1	59814786-59876378	Predicted intracellular proteins	Evidence at protein level	HPA018537, HPA018820	Enhanced				Colorectal cancer:4.53e-6 (favourable), Head and neck cancer:4.42e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 55.2	testis: 30.1	Cell line enhanced		EFO-21: 32.6;RPTEC TERT1: 24.3
CYP2J2		ENSG00000134716	Cytochrome P450 family 2 subfamily J member 2	1	59893308-59926790	Enzymes, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.54e-7 (unfavourable)	Mixed	Tissue enhanced		liver: 74.4;small intestine: 92.3	heart muscle: 57.5	Cell line enhanced		RT4: 48.3;SK-BR-3: 12.0
BTF3L4	MGC23908	ENSG00000134717	Basic transcription factor 3 like 4	1	52056125-52090716	Predicted intracellular proteins	Evidence at protein level	HPA067026	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.73e-8 (unfavourable), Renal cancer:4.43e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 72.6	Expressed in all		
ZCCHC11	KIAA0191, PAPD3, TUT4	ENSG00000134744	Zinc finger CCHC-type containing 11	1	52408282-52553487	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027412, HPA027973	Supported		Supported	Nucleoli<br>Cytosol	Liver cancer:9.00e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.8	Mixed		
PRPF38A	FLJ14936, Prp38	ENSG00000134748	Pre-mRNA processing factor 38A	1	52404564-52420839	Predicted intracellular proteins	Evidence at protein level	HPA053099, HPA058407	Uncertain		Enhanced	Nucleus	Liver cancer:3.83e-5 (unfavourable), Renal cancer:7.41e-5 (unfavourable), Colorectal cancer:7.16e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.0	Expressed in all		
DSC2	CDHF2, DSC3	ENSG00000134755	Desmocollin 2	18	31058840-31102415	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011911, HPA012615	Enhanced				Urothelial cancer:3.01e-4 (unfavourable), Lung cancer:5.80e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 186.7	parathyroid gland: 62.0	Cell line enhanced		BEWO: 36.6;CAPAN-2: 44.0;HaCaT: 63.9;hTCEpi: 55.4;SK-BR-3: 33.9
DSG3	CDHF6	ENSG00000134757	Desmoglein 3	18	31447795-31478702	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA046864, HPA056863, CAB069880	Enhanced				Pancreatic cancer:1.43e-5 (unfavourable), Urothelial cancer:9.90e-4 (unfavourable)	Group enriched	Tissue enriched	5	esophagus: 349.5	tonsil: 66.0	Group enriched	7	HaCaT: 182.7;hTCEpi: 362.3
RNF138	NARF, STRIN	ENSG00000134758	Ring finger protein 138	18	32091855-32131561	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041101			Approved	Mitochondria		Expressed in all	Expressed in all			testis: 167.7	Expressed in all		
ELP2	FLJ10879, STATIP1, StIP	ENSG00000134759	Elongator acetyltransferase complex subunit 2	18	36129444-36180556	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002996, CAB020835	Approved		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Colorectal cancer:5.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 59.6	Expressed in all		
DSG1	CDHF4, DSG	ENSG00000134760	Desmoglein 1	18	31318089-31357029	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009394, HPA022128	Enhanced				Urothelial cancer:2.99e-4 (unfavourable)	Group enriched	Tissue enriched	20	skin: 725.7	esophagus: 36.4	Cell line enriched	17	hTCEpi: 6.6
DSC3	CDHF3, DSC, DSC1, DSC2, DSC4	ENSG00000134762	Desmocollin 3	18	30990008-31042815	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037328, HPA049265, HPA073937	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Urothelial cancer:1.04e-5 (unfavourable)	Tissue enhanced	Group enriched	12	esophagus: 119.1;skin: 454.8	tonsil: 24.8	Cell line enhanced		HaCaT: 242.4;hTCEpi: 115.0;hTERT-HME1: 89.5
DSC1	CDHF1	ENSG00000134765	Desmocollin 1	18	31129236-31162856	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA075379	Enhanced					Group enriched	Tissue enriched	15	skin: 273.0	heart muscle: 17.8	Not detected		
DTNA	D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3	ENSG00000134769	Dystrobrevin alpha	18	34493290-34891844	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015196, HPA071177	Enhanced		Approved	Nucleoplasm<br>Cell Junctions<br>Intermediate filaments	Renal cancer:2.64e-7 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 197.2	heart muscle: 101.8	Cell line enhanced		NTERA-2: 42.7;SCLC-21H: 70.5;U-87 MG: 59.2
FHOD3	FHOS2, FLJ22297, FLJ22717, KIAA1695	ENSG00000134775	Formin homology 2 domain containing 3	18	36297714-36780055	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021827, HPA024696	Uncertain				Renal cancer:1.19e-5 (favourable)	Mixed	Tissue enhanced		heart muscle: 96.5;seminal vesicle: 88.0	epididymis: 51.4	Cell line enhanced		BJ hTERT+: 58.7;HDLM-2: 74.2
TPGS2	C18orf10, DKFZP586M1523, HsT3006	ENSG00000134779	Tubulin polyglutamylase complex subunit 2	18	36777647-36829216	Predicted intracellular proteins	Evidence at protein level	HPA040596, HPA040617, HPA061753	Uncertain		Supported	Nucleoli	Liver cancer:1.24e-5 (unfavourable), Ovarian cancer:1.93e-5 (favourable), Cervical cancer:4.09e-4 (favourable), Testis cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 367.2	Expressed in all		
DAGLA	C11orf11, DAGLALPHA, KIAA0659, NSDDR	ENSG00000134780	Diacylglycerol lipase alpha	11	61680433-61747001	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA062497	Approved				Endometrial cancer:1.13e-7 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 18.6	colon,testis: 3.0	Mixed		
SLC43A3	DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1	ENSG00000134802	Solute carrier family 43 member 3	11	57406954-57427580	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030551, HPA077244	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:3.97e-13 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 122.3	Cell line enhanced		WM-115: 524.5
TIMM10	TIM10, TIM10A, TIMM10A	ENSG00000134809	Translocase of inner mitochondrial membrane 10	11	57528463-57530803	Predicted intracellular proteins	Evidence at protein level	HPA039946	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			epididymis: 52.6	Expressed in all		
GIF	IF, IFMH, INF, TCN3	ENSG00000134812	Gastric intrinsic factor	11	59829268-59845501	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039908, HPA040774	Enhanced					Tissue enriched	Tissue enriched	1701	stomach: 1311.7	cerebral cortex: 0.7	Not detected		
DHX34	DDX34, KIAA0134	ENSG00000134815	DExH-box helicase 34	19	47349281-47382704	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042159, HPA043558	Uncertain		Uncertain	Nucleus<br>Intermediate filaments	Renal cancer:3.16e-6 (unfavourable), Liver cancer:8.63e-6 (unfavourable)	Expressed in all	Mixed			testis: 20.8	Expressed in all		
APLNR	AGTRL1, APJ, APJR, FLJ90771	ENSG00000134817	Apelin receptor	11	57233577-57237314	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB025842	Approved					Expressed in all	Group enriched	5	cerebral cortex: 82.7;placenta: 146.8;spleen: 161.6	adipose tissue: 24.9	Group enriched	22	AF22: 6.2;HEL: 5.0;K-562: 1.5;NTERA-2: 1.8
FADS2	D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13	ENSG00000134824	Fatty acid desaturase 2	11	61792980-61867354	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006741	Approved				Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 414.3	Expressed in all		
TMEM258	C11orf10	ENSG00000134825	Transmembrane protein 258	11	61768501-61792802	Predicted membrane proteins	Evidence at protein level	HPA044602	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:4.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 437.6	Expressed in all		
TCN1	TC1, TCI	ENSG00000134827	Transcobalamin 1	11	59852800-59866575	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.56e-8 (unfavourable), Breast cancer:1.90e-4 (favourable)	Tissue enhanced	Tissue enhanced		bone marrow: 123.8;gallbladder: 254.4;salivary gland: 315.5	stomach: 75.5	Cell line enhanced		CAPAN-2: 4.7;HaCaT: 4.6;PC-3: 6.4;SiHa: 7.7
C5AR2	C5L2, GPR77	ENSG00000134830	Complement component 5a receptor 2	19	47332147-47347327	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA016629	Uncertain					Tissue enhanced	Tissue enhanced		spleen: 9.7	appendix: 5.9	Group enriched	6	MCF7: 15.8;T-47d: 23.3
TMEM165	GDT1, TMPT27, TPARL	ENSG00000134851	Transmembrane protein 165	4	55395957-55453397	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038299, HPA062424	Supported		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 87.1	Expressed in all		
CLOCK	bHLHe8, KAT13D, KIAA0334	ENSG00000134852	Clock circadian regulator	4	55427903-55547138	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001867, HPA027565	Supported		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 26.4	Expressed in all		
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
GGACT	A2LD1	ENSG00000134864	Gamma-glutamylamine cyclotransferase	13	100530164-100589528	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065320	Enhanced					Expressed in all	Tissue enriched	6	kidney: 75.9	testis: 11.8	Cell line enriched	8	SCLC-21H: 157.1
COL4A2	DKFZp686I14213, FLJ22259	ENSG00000134871	Collagen type IV alpha 2 chain	13	110305812-110513027	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010751, HPA029118	Enhanced		Supported	Vesicles	Renal cancer:3.49e-5 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 829.9	smooth muscle: 401.0	Cell line enhanced		EFO-21: 1032.9;WM-115: 470.6
CLDN10	CPETRL3, OSP-L	ENSG00000134873	Claudin 10	13	95433604-95579759	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012969, HPA042348	Enhanced				Renal cancer:7.46e-5 (favourable), Thyroid cancer:2.13e-4 (favourable)	Mixed	Tissue enhanced		kidney: 163.5	cervix, uterine: 112.6	Cell line enhanced		EFO-21: 10.0;HUVEC TERT2: 11.9;NTERA-2: 28.0;RPTEC TERT1: 43.5
DZIP1	DZIP, KIAA0996	ENSG00000134874	DAZ interacting zinc finger protein 1	13	95578202-95644703	Predicted intracellular proteins	Evidence at protein level	HPA054891, HPA057272, HPA070194	Uncertain		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		testis: 57.5	ovary: 30.4	Mixed		
UBAC2	FLJ30548, PHGDHL1, RP11-178C10.1	ENSG00000134882	UBA domain containing 2	13	99200774-99386434	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013448	Approved		Approved	Cytosol	Pancreatic cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.8	Expressed in all		
ARGLU1	FLJ10154	ENSG00000134884	Arginine and glutamate rich 1	13	106541673-106568164	Predicted intracellular proteins	Evidence at protein level	HPA034962, HPA056792	Supported		Enhanced	Nucleoplasm<br>Mitochondria	Pancreatic cancer:3.92e-5 (favourable), Urothelial cancer:7.34e-5 (favourable), Renal cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 328.3	Expressed in all		
BIVM	FLJ20159	ENSG00000134897	Basic, immunoglobulin-like variable motif containing	13	102799049-102841535	Predicted intracellular proteins	Evidence at transcript level	HPA050126	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			kidney: 15.1	Mixed		
ERCC5	ERCM2, XPGC	ENSG00000134899	ERCC excision repair 5, endonuclease	13	102844844-102876001	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045845, HPA050374	Supported		Supported	Nucleoplasm	Renal cancer:2.96e-6 (unfavourable), Urothelial cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 16.4	Expressed in all		
TPP2	TPPII	ENSG00000134900	Tripeptidyl peptidase 2	13	102597003-102679958	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021069, HPA049630	Approved		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 66.8	Expressed in all		
KDELC1	EP58, MGC5302	ENSG00000134901	KDEL motif containing 1	13	102784281-102799007	Predicted secreted proteins	Evidence at protein level	CAB020780, HPA043946, HPA064398	Approved		Supported	Nucleus	Head and neck cancer:2.24e-4 (unfavourable), Renal cancer:4.73e-4 (unfavourable), Lung cancer:4.81e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 17.7	Mixed		
CARS2	FLJ12118	ENSG00000134905	Cysteinyl-tRNA synthetase 2, mitochondrial (putative)	13	110641412-110713603	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041776	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:2.49e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Endometrial cancer:1.84e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 28.4	Expressed in all		
ARHGAP32	GC-GAP, GRIT, KIAA0712, MGC1892, RICS	ENSG00000134909	Rho GTPase activating protein 32	11	128965060-129279324	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038382, HPA038389, HPA061505	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Pancreatic cancer:6.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 44.0	Mixed		
STT3A	ITM1, MGC9042, STT3-A, TMC	ENSG00000134910	STT3A, catalytic subunit of the oligosaccharyltransferase complex	11	125591712-125625215	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030735	Approved		Uncertain	Nucleoplasm<br>Vesicles<br>Cytosol	Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 1131.8	epididymis: 173.0	Expressed in all		
ADAMTS8	ADAM-TS8, FLJ41712, METH2	ENSG00000134917	ADAM metallopeptidase with thrombospondin type 1 motif 8	11	130404925-130428993	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at transcript level	HPA066349	Approved				Endometrial cancer:1.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 10.9;lung: 15.5	seminal vesicle: 5.5	Cell line enhanced		HMC-1: 3.2;NTERA-2: 1.8;U-2 OS: 8.7
ACRV1	D11S4365, SP-10, SPACA2	ENSG00000134940	Acrosomal vesicle protein 1	11	125671522-125681123	Predicted secreted proteins	Evidence at protein level	HPA038718, HPA038719	Enhanced					Mixed	Tissue enriched	40	testis: 153.6	epididymis: 3.8	Mixed		
ETS1	ETS-1, EWSR2, FLJ10768	ENSG00000134954	ETS proto-oncogene 1, transcription factor	11	128458761-128587558	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB002575, HPA063230	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.30e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 320.7	Cell line enhanced		U-698: 322.0
SLC37A2	FLJ00171	ENSG00000134955	Solute carrier family 37 member 2	11	125063067-125090312	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014948	Uncertain					Expressed in all	Mixed			adrenal gland: 24.7	Cell line enhanced		A-431: 23.5;CAPAN-2: 49.0;hTERT-HME1: 45.0;U-138 MG: 41.2
KLB		ENSG00000134962	Klotho beta	4	39406853-39451536	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021136	Uncertain					Tissue enriched	Tissue enhanced		adipose tissue: 20.6;liver: 9.1	testis: 5.0	Group enriched	19	ASC diff: 4.5;Hep G2: 17.2
TMED7	CGI-109, FLJ90481, p24g3, p24gamma3	ENSG00000134970	Transmembrane p24 trafficking protein 7	5	115613508-115632992	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008960, CAB025883	Supported					Expressed in all	Expressed in all			thyroid gland: 138.8	Expressed in all		
APC	DP2, DP2.5, DP3, PPP1R46	ENSG00000134982	APC, WNT signaling pathway regulator	5	112707498-112846239	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013349	Supported					Expressed in all	Tissue enhanced		cerebral cortex: 60.1	parathyroid gland: 19.9	Expressed in all		
NREP	C5orf13, D4S114, P311, PRO1873, PTZ17, SEZ17	ENSG00000134986	Neuronal regeneration related protein	5	111662621-111997464	Predicted intracellular proteins	Evidence at protein level	HPA000545	Approved		Approved	Vesicles	Stomach cancer:3.09e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 175.0	Cell line enhanced		AF22: 411.4;SH-SY5Y: 475.7
WDR36	GLC1G, TA-WDRP, UTP21	ENSG00000134987	WD repeat domain 36	5	111091716-111130502	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037796, HPA037797	Supported		Supported	Nucleoli	Thyroid cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 17.2	Expressed in all		
OSTF1	bA235O14.1, OSF, SH3P2	ENSG00000134996	Osteoclast stimulating factor 1	9	75088543-75147265	Predicted intracellular proteins	Evidence at protein level	HPA020514	Approved		Supported	Cytosol	Endometrial cancer:3.67e-5 (favourable)	Expressed in all	Expressed in all			spleen: 122.7	Cell line enhanced		HDLM-2: 286.9
RFK	FLJ11149, RIFK	ENSG00000135002	Riboflavin kinase	9	76385517-76394517	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023259, CAB033887, HPA057163	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 37.8	Expressed in all		
UBQLN1	DA41, DSK2, PLIC-1, XDRP1	ENSG00000135018	Ubiquilin 1	9	83659963-83708203	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037256, HPA054143	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.07e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 113.8	Expressed in all		
NAA35	bA379P1.1, FLJ21613, FLJ22643, MAK10	ENSG00000135040	N(alpha)-acetyltransferase 35, NatC auxiliary subunit	9	85941146-86022298	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021547, HPA051586	Approved		Supported	Vesicles	Liver cancer:1.16e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 37.9	Expressed in all		
C9orf40	FLJ10110	ENSG00000135045	Chromosome 9 open reading frame 40	9	74946581-74952886	Predicted intracellular proteins	Evidence at protein level	HPA042167	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:3.43e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
ANXA1	ANX1, LPC1	ENSG00000135046	Annexin A1	9	73151757-73170393	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011271, HPA011272, CAB013023, CAB035987, CAB058693	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable)	Expressed in all	Tissue enriched	6	esophagus: 7548.8	tonsil: 1217.6	Mixed		
CTSL	CTSL1, FLJ31037	ENSG00000135047	Cathepsin L	9	87725519-87731393	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000459	Enhanced				Lung cancer:5.15e-5 (unfavourable), Renal cancer:4.34e-4 (favourable), Glioma:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 748.5	Cell line enhanced		ASC TERT1: 1401.5
TMEM2		ENSG00000135048	Transmembrane protein 2	9	71683366-71816690	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044889	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 94.6	Cell line enhanced		AF22: 107.2
AGTPBP1	CCP1, KIAA1035, Nna1	ENSG00000135049	ATP/GTP binding protein 1	9	85546539-85742029	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057208	Approved		Approved	Nucleoli<br>Vesicles		Expressed in all	Expressed in all			bone marrow: 39.2	Expressed in all		
GOLM1	bA379P1.3, C9orf155, FLJ23608, GOLPH2, GP73	ENSG00000135052	Golgi membrane protein 1	9	86026146-86100173	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA010638, HPA011929, CAB015341	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:8.14e-5 (favourable), Liver cancer:1.30e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 402.2	Mixed		
FAM189A2	C9orf61, X123	ENSG00000135063	Family with sequence similarity 189 member A2	9	69324572-69392455	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029411, HPA057207	Approved				Endometrial cancer:1.16e-6 (favourable), Renal cancer:1.75e-5 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 101.0	cervix, uterine: 64.4	Cell line enhanced		BEWO: 4.9;NTERA-2: 7.3;SK-MEL-30: 5.2
PSAT1	PSA	ENSG00000135069	Phosphoserine aminotransferase 1	9	78297143-78330093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB014882, CAB040567, HPA042924	Enhanced		Enhanced	Cytosol	Renal cancer:6.00e-7 (unfavourable), Endometrial cancer:5.62e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 186.0	liver: 138.7	Cell line enhanced		hTCEpi: 853.3
ISCA1	HBLD2, hIscA, ISA1, MGC4276	ENSG00000135070	Iron-sulfur cluster assembly 1	9	86264546-86283102	Predicted intracellular proteins	Evidence at protein level	HPA042789	Uncertain				Renal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 74.4	Expressed in all		
ADAM19	MLTNB	ENSG00000135074	ADAM metallopeptidase domain 19	5	157395534-157575775	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA055537			Approved	Vesicles	Renal cancer:3.90e-12 (unfavourable)	Expressed in all	Mixed			lymph node: 34.4	Cell line enhanced		HDLM-2: 101.7;U-251 MG: 170.3
HAVCR2	CD366, FLJ14428, Tim-3, TIM3, TIMD3	ENSG00000135077	Hepatitis A virus cellular receptor 2	5	157085832-157142869	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026003	Enhanced					Expressed in all	Mixed			lung: 24.0	Cell line enhanced		HDLM-2: 16.9;RPMI-8226: 10.3
CCNJL	FLJ14166	ENSG00000135083	Cyclin J like	5	160251652-160345396	Predicted intracellular proteins	Evidence at protein level	HPA049970	Approved		Approved	Nuclear speckles	Thyroid cancer:7.10e-4 (favourable), Colorectal cancer:7.31e-4 (favourable), Urothelial cancer:8.02e-4 (favourable)	Mixed	Tissue enhanced		testis: 19.4	lung: 10.3	Cell line enhanced		HBEC3-KT: 46.5;WM-115: 45.6
TAOK3	DPK, JIK, MAP3K18	ENSG00000135090	TAO kinase 3	12	118149801-118372945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017160	Approved		Uncertain	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 48.8	Expressed in all		
USP30	FLJ40511, MGC10702	ENSG00000135093	Ubiquitin specific peptidase 30	12	109023089-109088026	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016952	Approved				Renal cancer:5.23e-6 (favourable)	Expressed in all	Expressed in all			testis: 25.4	Expressed in all		
SDS	SDH	ENSG00000135094	Serine dehydratase	12	113392445-113426301	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039230	Uncertain		Approved	Mitochondria<br>Cytosol	Cervical cancer:5.24e-4 (favourable)	Tissue enriched	Tissue enriched	18	liver: 189.8	cerebral cortex: 10.5	Cell line enhanced		HMC-1: 1.5
MSI1		ENSG00000135097	Musashi RNA binding protein 1	12	120341330-120369180	Predicted intracellular proteins	Evidence at protein level	HPA064401			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Pancreatic cancer:5.99e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 17.5;testis: 14.6	skeletal muscle: 7.2	Cell line enhanced		AF22: 118.2;HAP1: 57.0;NTERA-2: 62.4;SCLC-21H: 104.1;SH-SY5Y: 45.6
HNF1A	HNF1, LFB1, MODY3, TCF1	ENSG00000135100	HNF1 homeobox A	12	120978543-121002512	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010430, HPA035231	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		duodenum: 15.5;kidney: 10.6;small intestine: 15.7	liver: 6.3	Group enriched	7	A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
FBXO21	FBX21, KIAA0875	ENSG00000135108	F-box protein 21	12	117141988-117190531	Predicted intracellular proteins	Evidence at protein level	HPA062411, HPA071452	Approved		Approved	Mitochondria	Renal cancer:2.05e-8 (favourable)	Expressed in all	Expressed in all			fallopian tube: 204.6	Expressed in all		
TBX3	TBX3-ISO, UMS, XHL	ENSG00000135111	T-box 3	12	114670254-114684164	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005799			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 200.0	prostate: 119.8	Cell line enhanced		BJ: 87.5;BJ hTERT+: 80.2;RT4: 103.3
OASL	p59OASL, TRIP14	ENSG00000135114	2'-5'-oligoadenylate synthetase like	12	121019111-121039242	Predicted intracellular proteins	Evidence at protein level	HPA001474	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.70e-9 (unfavourable), Pancreatic cancer:9.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 35.4;stomach: 22.1	lung: 19.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 131.5;BJ hTERT+ SV40 Large T+ RasG12V: 70.4;hTEC/SVTERT24-B: 56.8
HRK	DP5	ENSG00000135116	Harakiri, BCL2 interacting protein	12	116856144-116881441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025973	Uncertain					Mixed	Group enriched	9	cerebral cortex: 13.3;thyroid gland: 6.4	testis: 1.1	Cell line enhanced		Daudi: 7.9;SCLC-21H: 10.7;SH-SY5Y: 8.3;SK-MEL-30: 16.7;U-698: 25.7
RNFT2	FLJ14627, TMEM118	ENSG00000135119	Ring finger protein, transmembrane 2	12	116738178-116853631	Predicted membrane proteins	Evidence at protein level	HPA064161	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 15.3	testis: 6.0	Mixed		
P2RX4	P2X4	ENSG00000135124	Purinergic receptor P2X 4	12	121209857-121234106	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039494	Enhanced		Approved	Actin filaments<br>Cytosol	Endometrial cancer:6.30e-10 (favourable)	Expressed in all	Mixed			placenta: 33.8	Mixed		
BICDL1	BICDR-1, CCDC64, FLJ26450	ENSG00000135127	BICD family like cargo adaptor 1	12	119989869-120094494	Predicted intracellular proteins	Evidence at protein level	HPA061116	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:1.21e-5 (favourable), Renal cancer:3.93e-5 (favourable), Head and neck cancer:3.15e-4 (favourable), Cervical cancer:6.50e-4 (favourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 73.9;skin: 58.6	epididymis: 45.6	Cell line enhanced		hTCEpi: 35.3;SCLC-21H: 36.3
DTX1	hDx-1	ENSG00000135144	Deltex E3 ubiquitin ligase 1	12	113056709-113098028	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051249, HPA055275	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.02e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 13.4	spleen: 11.4	Group enriched	9	Daudi: 77.9;REH: 41.0;U-698: 75.9
TRAFD1	FLN29	ENSG00000135148	TRAF-type zinc finger domain containing 1	12	112125501-112153609	Predicted intracellular proteins	Evidence at protein level	HPA039254, HPA039266	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.26e-6 (unfavourable), Urothelial cancer:3.92e-5 (favourable), Liver cancer:4.87e-4 (unfavourable), Cervical cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			testis: 53.7	Expressed in all		
DMTF1	DMP1, DMTF, hDMP1, MRUL	ENSG00000135164	Cyclin D binding myb like transcription factor 1	7	87152361-87196337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023846	Supported		Supported	Nucleoplasm	Renal cancer:4.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 84.1	Expressed in all		
OCM2		ENSG00000135175	Oncomodulin 2	7	97984684-97991169	Predicted intracellular proteins	No evidence	HPA046422	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
TMEM243	C7orf23, MGC4175, MM-TRAG	ENSG00000135185	Transmembrane protein 243	7	87196160-87220587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014918	Uncertain				Lung cancer:5.45e-4 (favourable), Melanoma:6.84e-4 (unfavourable), Urothelial cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 103.9	Expressed in all		
CCDC146	KIAA1505	ENSG00000135205	Coiled-coil domain containing 146	7	77122434-77329533	Predicted intracellular proteins	Evidence at protein level	HPA020082, HPA020105	Uncertain		Approved	Golgi apparatus<br>Vesicles	Head and neck cancer:7.37e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 57.6;testis: 39.3	thyroid gland: 13.8	Mixed		
TMEM60	C7orf35, DC32	ENSG00000135211	Transmembrane protein 60	7	77793728-77798580	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA062625	Approved				Breast cancer:3.09e-4 (favourable), Glioma:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.4	Expressed in all		
CD36	FAT, GP3B, GP4, GPIV, SCARB3	ENSG00000135218	CD36 molecule	7	80369575-80679277	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA002018, CAB025866, HPA071026	Enhanced		Enhanced	Golgi apparatus	Stomach cancer:4.47e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1617.9	Cell line enhanced		ASC diff: 218.9;HEL: 144.7
UGT2A3	FLJ21934	ENSG00000135220	UDP glucuronosyltransferase family 2 member A3	4	68928463-68951791	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported				Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9	rectum: 23.9	Cell line enriched	8	Hep G2: 13.5
CSN2	CASB	ENSG00000135222	Casein beta	4	69955256-69961007	Predicted secreted proteins	Evidence at protein level	HPA041036	Supported					Tissue enriched	Tissue enriched	348	breast: 347.6	salivary gland: 0.9	Not detected		
UGT2B28		ENSG00000135226	UDP glucuronosyltransferase family 2 member B28	4	69280499-69295050	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain					Tissue enriched	Tissue enriched	12	breast: 267.2	gallbladder: 21.5	Group enriched	9	Daudi: 2.1;NB-4: 1.7
PNPLA8	IPLA2-2, IPLA2G, iPLA2gamma	ENSG00000135241	Patatin like phospholipase domain containing 8	7	108470422-108569666	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020083	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.86e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 63.1	Expressed in all		
HILPDA	C7orf68, FLJ21076, HIG-2, HIG2	ENSG00000135245	Hypoxia inducible lipid droplet associated	7	128455849-128458418	Predicted membrane proteins	Evidence at protein level	HPA010515	Approved		Supported	Nucleoplasm<br>Lipid droplets	Liver cancer:4.30e-11 (unfavourable), Renal cancer:2.05e-7 (unfavourable)	Expressed in all	Expressed in all			esophagus: 107.8	Expressed in all		
FAM71F1	FAM137A, NYD-SP18	ENSG00000135248	Family with sequence similarity 71 member F1	7	128709061-128731743	Predicted intracellular proteins	Evidence at transcript level	HPA020636			Uncertain	Cytosol		Tissue enriched	Tissue enriched	145	testis: 82.6	epididymis: 0.5	Cell line enriched	16	NTERA-2: 16.3
RINT1	FLJ11785, RINT-1	ENSG00000135249	RAD50 interactor 1	7	105532085-105567677	Predicted intracellular proteins	Evidence at protein level	HPA019875, HPA031646	Approved		Approved	Golgi apparatus	Thyroid cancer:2.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 19.0	Expressed in all		
SRPK2	SFRSK2	ENSG00000135250	SRSF protein kinase 2	7	105110704-105399308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015522, HPA020876	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 197.4	Expressed in all		
KCP	CRIM2, FLJ33365, NET67	ENSG00000135253	Kielin/chordin-like protein	7	128862451-128910719	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		kidney: 2.7;seminal vesicle: 3.3	gallbladder: 1.5	Cell line enhanced		CAPAN-2: 8.4;HMC-1: 4.7;U-87 MG: 2.3
TES	DKFZP586B2022, TESS-2, TESTIN	ENSG00000135269	Testin LIM domain protein	7	116210493-116258783	Predicted intracellular proteins	Evidence at protein level	HPA015269, HPA018123	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:1.20e-5 (unfavourable), Renal cancer:8.71e-5 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 271.7	Cell line enhanced		EFO-21: 215.5
MDFIC	HIC	ENSG00000135272	MyoD family inhibitor domain containing	7	114922154-115019202	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030716	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 48.0	Cell line enhanced		U-2197: 101.4
MTO1		ENSG00000135297	Mitochondrial tRNA translation optimization 1	6	73461578-73509236	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030230, HPA030232	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 24.9	Expressed in all		
ADGRB3	BAI3, KIAA0550	ENSG00000135298	Adhesion G protein-coupled receptor B3	6	68635367-69389511	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	cerebral cortex: 53.1	adrenal gland: 5.1	Group enriched	5	SCLC-21H: 10.4;SH-SY5Y: 20.2
ANKRD6	KIAA0957	ENSG00000135299	Ankyrin repeat domain 6	6	89433170-89633834	Predicted intracellular proteins	Evidence at protein level	CAB020693, HPA035694, HPA064642	Enhanced		Supported	Vesicles		Mixed	Mixed			cerebral cortex: 23.7	Cell line enhanced		AF22: 15.3;BEWO: 45.7;HAP1: 14.8
HTR1B	5-HT1B, 5-HT1DB, HTR1D2, S12	ENSG00000135312	5-hydroxytryptamine receptor 1B	6	77461753-77463773	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028808	Enhanced		Uncertain	Plasma membrane		Mixed	Tissue enhanced		placenta: 10.0;stomach: 4.7	cerebral cortex: 2.4	Group enriched	16	HUVEC TERT2: 68.8;TIME: 29.9
KHDC1	bA257K9.4, C6orf147, C6orf148, Em:AC019205.8, MGC10818, NDG1	ENSG00000135314	KH homology domain containing 1	6	73241314-73310365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029032			Approved	Mitochondria<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 9.9	testis: 6.8	Mixed		
CEP162	C6orf84, KIAA1009, QN1	ENSG00000135315	Centrosomal protein 162	6	84124241-84227635	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030170, HPA030171, HPA030172, HPA030173	Supported		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 15.7	Mixed		
SYNCRIP	dJ3J17.2, GRY-RBP, hnRNP-Q, HNRNPQ, HNRPQ1, NSAP1	ENSG00000135316	Synaptotagmin binding cytoplasmic RNA interacting protein	6	85607785-85643792	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010895, HPA041275	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:6.28e-5 (unfavourable), Ovarian cancer:5.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 132.3	Expressed in all		
SNX14	RGS-PX2	ENSG00000135317	Sorting nexin 14	6	85505496-85594156	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017639	Approved		Supported	Cytosol	Head and neck cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 156.6	Expressed in all		
NT5E	CALJA, CD73, eN, eNT, NT5	ENSG00000135318	5'-nucleotidase ecto	6	85449584-85495791	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017357	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 172.7	smooth muscle: 106.3	Cell line enhanced		LHCN-M2: 772.3;U-87 MG: 800.0
MRAP2	bA51G5.2, C6orf117	ENSG00000135324	Melanocortin 2 receptor accessory protein 2	6	84033756-84090881	Disease related genes, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.66e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 21.0	fallopian tube: 13.4	Group enriched	5	K-562: 81.0;SCLC-21H: 35.1
EPHA7	Hek11	ENSG00000135333	EPH receptor A7	6	93240020-93419547	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010496	Approved					Tissue enhanced	Tissue enriched	13	parathyroid gland: 253.5	prostate: 20.2	Cell line enhanced		AF22: 15.6;HEK 293: 41.9;RH-30: 41.8;THP-1: 25.7
AKIRIN2	C6orf166, dJ486L4.2, FLJ10342	ENSG00000135334	Akirin 2	6	87675072-87702209	Predicted intracellular proteins	Evidence at protein level	HPA064239			Supported	Nucleoplasm		Expressed in all	Expressed in all			spleen: 58.2	Expressed in all		
ORC3	IMAGE50150, LATHEO, ORC3L	ENSG00000135336	Origin recognition complex subunit 3	6	87590067-87667453	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039553, HPA053748	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:2.89e-5 (unfavourable), Renal cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.9	Expressed in all		
LCA5	C6orf152	ENSG00000135338	LCA5, lebercilin	6	79484991-79537458	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029053, HPA029055	Supported				Renal cancer:4.69e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 48.1	fallopian tube: 15.6	Cell line enhanced		HEL: 13.2
MAP3K7	MEKK7, TAK1	ENSG00000135341	Mitogen-activated protein kinase kinase kinase 7	6	90513573-90587045	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007633	Approved		Approved	Nuclear speckles<br>Cytosol	Liver cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.0	Expressed in all		
CGA	FSHA, GPHa, GPHA1, HCG, LHA, TSHA	ENSG00000135346	Glycoprotein hormones, alpha polypeptide	6	87085498-87095406	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023350, HPA029698	Enhanced					Tissue enhanced	Tissue enriched	22	placenta: 654.5	stomach: 29.1	Cell line enriched	26	BEWO: 481.2
GJA10	CX62	ENSG00000135355	Gap junction protein alpha 10	6	89894469-89921760	Predicted membrane proteins	Evidence at protein level	HPA021145	Uncertain					Tissue enriched	Not detected			testis: 0.4	Not detected		
PRR5L	FLJ14213, PROTOR-2	ENSG00000135362	Proline rich 5 like	11	36296288-36465204	Predicted intracellular proteins	Evidence at protein level	HPA070174			Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:7.71e-8 (unfavourable), Endometrial cancer:7.30e-5 (favourable), Stomach cancer:4.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 51.1	colon: 35.0	Cell line enhanced		HMC-1: 51.8;hTERT-HME1: 46.7;SiHa: 43.9
LMO2	RBTN2, RBTNL1, RHOM2, TTG2	ENSG00000135363	LIM domain only 2	11	33858576-33892289	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016258, HPA029285	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.12e-4 (favourable)	Expressed in all	Mixed			spleen: 25.7	Cell line enhanced		HEL: 48.0;HL-60: 42.9;K-562: 49.4;THP-1: 47.5
PHF21A	BHC80, BM-006, KIAA1696	ENSG00000135365	PHD finger protein 21A	11	45929323-46121178	Predicted intracellular proteins	Evidence at protein level	HPA023580	Uncertain				Renal cancer:2.59e-8 (unfavourable), Liver cancer:1.66e-6 (unfavourable), Colorectal cancer:6.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.7	Expressed in all		
NAT10	FLJ10774, FLJ12179, hALP, KIAA1709, NET43	ENSG00000135372	N-acetyltransferase 10	11	34105602-34147670	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB035546, HPA057576, HPA071628	Enhanced		Enhanced	Nucleoli<br>Midbody	Liver cancer:9.61e-8 (unfavourable), Renal cancer:8.83e-5 (unfavourable), Head and neck cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
EHF	ESE3, ESEJ	ENSG00000135373	ETS homologous factor	11	34621093-34661057	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA050923, HPA060734	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Colorectal cancer:5.81e-4 (favourable), Pancreatic cancer:6.94e-4 (unfavourable)	Mixed	Mixed			esophagus: 228.3	Cell line enhanced		CAPAN-2: 122.7;HaCaT: 85.2;HBEC3-KT: 76.2;RT4: 172.3;T-47d: 201.8
ELF5		ENSG00000135374	E74 like ETS transcription factor 5	11	34478793-34513805	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062706			Supported	Nucleoplasm	Lung cancer:3.64e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 172.6;salivary gland: 64.2	seminal vesicle: 42.2	Group enriched	10	RT4: 24.0;T-47d: 53.3
PRRG4	TMG4	ENSG00000135378	Proline rich and Gla domain 4	11	32829943-32858123	Predicted membrane proteins	Evidence at protein level	HPA009040, HPA024566	Uncertain		Approved	Golgi apparatus		Expressed in all	Mixed			skin: 25.1	Cell line enhanced		HaCaT: 47.2;hTCEpi: 20.5
CAPRIN1	caprin-1, GPIAP1, M11S1, RNG105	ENSG00000135387	Cell cycle associated protein 1	11	34051683-34101156	Predicted intracellular proteins	Evidence at protein level	HPA018126, HPA063617	Approved				Liver cancer:8.67e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 248.9	Expressed in all		
ATP5G2		ENSG00000135390	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C2 (subunit 9)	12	53632726-53677408	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051469	Approved					Expressed in all	Expressed in all			fallopian tube: 779.5	Expressed in all		
DNAJC14	DNAJ, DRIP78, FLJ32792, HDJ3, LIP6	ENSG00000135392	DnaJ heat shock protein family (Hsp40) member C14	12	55820960-55830824	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017653	Approved					Expressed in all	Expressed in all			parathyroid gland: 49.4	Expressed in all		
CD63	ME491, MLA1, TSPAN30	ENSG00000135404	CD63 molecule	12	55725323-55729707	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010088, CAB026356	Supported		Supported	Vesicles	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 1743.5	Expressed in all		
PRPH	NEF4, PRPH1	ENSG00000135406	Peripherin	12	49293252-49298686	Predicted intracellular proteins	Evidence at protein level	CAB002437, HPA039277, HPA063887	Enhanced					Mixed	Tissue enhanced		adrenal gland: 20.5	testis: 11.6	Group enriched	93	AN3-CA: 342.0;SCLC-21H: 92.7
AVIL	ADVIL, DOC6, FLJ12386, p92	ENSG00000135407	Advillin	12	57797376-57818704	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058864	Approved				Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			skin: 6.7	Cell line enhanced		RH-30: 8.3
AMHR2	MISR2, MISRII	ENSG00000135409	Anti-Mullerian hormone receptor type 2	12	53423855-53431534	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 32.1;ovary: 40.9	testis: 10.1	Group enriched	19	HEL: 36.1;K-562: 19.9
LACRT	LACRITIN	ENSG00000135413	Lacritin	12	54630811-54634895	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	6	salivary gland: 4.6	breast: 0.7	Not detected		
GDF11	BMP-11	ENSG00000135414	Growth differentiation factor 11	12	55743280-55757278	Predicted secreted proteins	Evidence at protein level	HPA060985, HPA069609	Enhanced		Approved	Vesicles	Pancreatic cancer:1.08e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,seminal vesicle: 13.3	Cell line enhanced		HMC-1: 112.3
GLS2	GA, GLS, hLGA, LGA	ENSG00000135423	Glutaminase 2	12	56470944-56488414	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038608	Uncertain					Tissue enhanced	Tissue enriched	11	liver: 80.4	cerebral cortex: 7.2	Cell line enhanced		Daudi: 22.6;SCLC-21H: 10.1
ITGA7		ENSG00000135424	Integrin subunit alpha 7	12	55684568-55716043	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008427	Uncertain		Approved	Plasma membrane<br>Cytosol	Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 154.7	smooth muscle: 136.8	Cell line enhanced		ASC diff: 46.9;hTEC/SVTERT24-B: 66.1;SK-MEL-30: 38.6;U-87 MG: 57.9
TESPA1	KIAA0748	ENSG00000135426	Thymocyte expressed, positive selection associated 1	12	54948018-54984746	Predicted intracellular proteins	Evidence at protein level	HPA058823	Approved					Mixed	Tissue enhanced		lymph node: 46.7	cerebral cortex: 34.7	Group enriched	6	HEL: 238.5;HMC-1: 184.2
FAM186B	C12orf25, DKFZP434J0113	ENSG00000135436	Family with sequence similarity 186 member B	12	49582885-49605639	Predicted intracellular proteins	Evidence at protein level	HPA039736, HPA040028	Uncertain					Not detected	Tissue enriched	32	testis: 76.1	parathyroid gland: 2.3	Mixed		
RDH5	HSD17B9, RDH1, SDR9C5	ENSG00000135437	Retinol dehydrogenase 5	12	55720367-55724705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063345			Approved	Vesicles		Mixed	Tissue enhanced		adipose tissue: 97.7	liver: 30.0	Cell line enhanced		ASC diff: 19.5;ASC TERT1: 17.1;hTEC/SVTERT24-B: 15.2;LHCN-M2: 12.8;U-87 MG: 26.2
AGAP2	CENTG1	ENSG00000135439	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	12	57723761-57742157	Predicted intracellular proteins	Evidence at protein level	HPA023474	Approved		Supported	Nucleus<br>Nucleoli<br>Mitochondria		Tissue enriched	Tissue enriched	7	cerebral cortex: 144.5	lymph node: 19.8	Cell line enhanced		RH-30: 95.5
BLOC1S1	BLOS1, BORCS1, GCN5L1	ENSG00000135441	Biogenesis of lysosomal organelles complex 1 subunit 1	12	55716037-55720087	Predicted intracellular proteins	Evidence at protein level	HPA021381	Approved				Ovarian cancer:2.19e-4 (favourable), Cervical cancer:2.77e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 214.5	Expressed in all		
KRT85	Hb-5, KRTHB5	ENSG00000135443	Keratin 85	12	52360006-52367481	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Not detected	Not detected			testis: 0.8	Cell line enhanced		A549: 2.0
CDK4	PSK-J3	ENSG00000135446	Cyclin dependent kinase 4	12	57747727-57756013	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006024, CAB013116, CAB069405	Enhanced		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol	Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 121.7	Group enriched	9	HBEC3-KT: 1874.1;LHCN-M2: 2370.6;RH-30: 8554.0
PPP1R1A		ENSG00000135447	Protein phosphatase 1 regulatory inhibitor subunit 1A	12	54575387-54588659	Predicted intracellular proteins	Evidence at protein level	CAB007811, HPA041542	Approved				Endometrial cancer:2.36e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 252.9;skeletal muscle: 291.2	kidney: 74.4	Cell line enhanced		ASC diff: 6.1;NTERA-2: 29.5;RPTEC TERT1: 24.5
TROAP	TASTIN	ENSG00000135451	Trophinin associated protein	12	49323236-49331731	Predicted intracellular proteins	Evidence at protein level	HPA044102	Uncertain				Liver cancer:1.39e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 32.0;testis: 44.1	tonsil: 13.7	Expressed in all		
TSPAN31	SAS	ENSG00000135452	Tetraspanin 31	12	57738013-57750211	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057489	Approved				Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.5	Expressed in all		
B4GALNT1	beta1-4GalNAc-T, GALGT, SPG26	ENSG00000135454	Beta-1,4-N-acetyl-galactosaminyltransferase 1	12	57623410-57633355	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008968, HPA015128	Enhanced				Renal cancer:3.18e-14 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 26.2	seminal vesicle: 4.0	Cell line enhanced		EFO-21: 33.8;HDLM-2: 29.7
TFCP2	CP2, LBP-1C, LSF, TFCP2C	ENSG00000135457	Transcription factor CP2	12	51093663-51173134	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA070247			Supported	Nucleoplasm<br>Cytosol	Melanoma:1.18e-4 (unfavourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Mixed		
COQ10A	FLJ32452	ENSG00000135469	Coenzyme Q10A	12	56266858-56270966	Predicted intracellular proteins	Evidence at protein level	HPA068931			Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:2.06e-4 (favourable), Renal cancer:3.44e-4 (favourable), Colorectal cancer:5.46e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 97.2	Expressed in all		
FAIM2	KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2	ENSG00000135472	Fas apoptotic inhibitory molecule 2	12	49866896-49904217	Predicted membrane proteins	Evidence at protein level	HPA018790, HPA048800	Enhanced		Approved	Intermediate filaments		Tissue enriched	Tissue enriched	7	cerebral cortex: 369.7	adrenal gland: 55.7	Cell line enhanced		HHSteC: 10.2;U-87 MG: 37.7
PAN2	hPAN2, KIAA0710, USP52	ENSG00000135473	PAN2 poly(A) specific ribonuclease subunit	12	56316223-56334053	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.0	Expressed in all		
ESPL1	ESP1, KIAA0165, SEPA	ENSG00000135476	Extra spindle pole bodies like 1, separase	12	53268299-53293643	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012185	Uncertain		Supported	Nucleoplasm<br>Vesicles	Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 11.4;testis: 10.6	lymph node: 4.8	Mixed		
KRT7	CK7, K2C7, K7, SCL	ENSG00000135480	Keratin 7	12	52232520-52252186	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000028, HPA007272	Enhanced				Renal cancer:2.77e-9 (favourable), Pancreatic cancer:7.78e-5 (unfavourable), Ovarian cancer:9.42e-5 (unfavourable), Endometrial cancer:1.99e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 984.0	urinary bladder: 454.0	Cell line enhanced		HBEC3-KT: 4461.4;RT4: 5973.0;SiHa: 6200.7
ZC3H10	FLJ14451, ZC3HDC10	ENSG00000135482	Zinc finger CCCH-type containing 10	12	56118159-56127514	Predicted intracellular proteins	Evidence at protein level	HPA039236, HPA062265	Uncertain		Approved	Vesicles		Expressed in all	Mixed			testis: 10.3	Expressed in all		
HNRNPA1	ALS20, hnRNP-A1, hnRNPA1, HNRPA1	ENSG00000135486	Heterogeneous nuclear ribonucleoprotein A1	12	54280193-54287088	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001609, HPA001666, HPA005812, HPA007185, CAB010894	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 1919.7	Expressed in all		
SLC26A10		ENSG00000135502	Solute carrier family 26 member 10	12	57619527-57626151	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044719	Uncertain					Tissue enhanced	Mixed			endometrium: 1.7	Cell line enhanced		NTERA-2: 3.0;RH-30: 2.2;SH-SY5Y: 4.4;U-266/70: 2.2
ACVR1B	ActRIB, ACVRLK4, ALK4, SKR2	ENSG00000135503	Activin A receptor type 1B	12	51951667-51997078	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026126, HPA063761	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 54.6	Expressed in all		
OS9	ERLEC2, OS-9	ENSG00000135506	OS9, endoplasmic reticulum lectin	12	57693955-57721557	Predicted secreted proteins, Transporters	Evidence at protein level	CAB011518, HPA013694	Supported		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 295.8	Cell line enriched	11	RH-30: 3430.4
MIP	AQP0, LIM1, MP26	ENSG00000135517	Major intrinsic protein of lens fiber	12	56449502-56469166	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014940	Supported					Not detected	Tissue enhanced		testis: 1.2	cerebral cortex,liver: 0.2	Not detected		
KCNH3	BEC1, elk2, Kv12.2	ENSG00000135519	Potassium voltage-gated channel subfamily H member 3	12	49539157-49558308	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051088	Uncertain		Approved	Nucleus<br>Mitochondria		Tissue enhanced	Group enriched	5	cerebral cortex: 24.2;fallopian tube: 7.1;parathyroid gland: 4.9	adrenal gland: 2.2	Cell line enhanced		A549: 7.6;RPTEC TERT1: 7.7;U-2 OS: 11.2
LTV1	C6orf93, dJ468K18.4, FLJ14909	ENSG00000135521	LTV1 ribosome biogenesis factor	6	143843344-143863812	Predicted intracellular proteins	Evidence at protein level	HPA030159, HPA030160, HPA030161	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:6.01e-13 (unfavourable), Liver cancer:4.95e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
MAP7	E-MAP-115	ENSG00000135525	Microtubule associated protein 7	6	136342281-136550819	Predicted intracellular proteins	Evidence at protein level	HPA029712, HPA029713	Enhanced		Supported	Microtubules<br>Cytosol	Renal cancer:5.07e-7 (favourable), Cervical cancer:9.70e-5 (unfavourable), Liver cancer:9.22e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 52.9	Cell line enhanced		MCF7: 67.4
CD164	DFNA66, MGC-24, MUC-24	ENSG00000135535	CD164 molecule	6	109366514-109382457	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010636	Uncertain					Expressed in all	Expressed in all			thyroid gland: 613.1	Expressed in all		
LACE1	AFG1	ENSG00000135537	Lactation elevated 1	6	108294894-108526796	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030154, HPA030155, HPA030659	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		testis: 17.3	parathyroid gland: 8.5	Mixed		
NHSL1	bA43P8.1, C6orf63, KIAA1357	ENSG00000135540	NHS like 1	6	138422043-138692571	Predicted intracellular proteins	Evidence at protein level	HPA029966, HPA029967, HPA029968	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			small intestine: 25.8	Cell line enhanced		TIME: 52.4
AHI1	FLJ20069, JBTS3, ORF1	ENSG00000135541	Abelson helper integration site 1	6	135283532-135497776	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031698, HPA046684	Approved		Approved	Centrosome	Renal cancer:4.07e-9 (unfavourable), Pancreatic cancer:7.51e-5 (favourable)	Expressed in all	Mixed			testis: 51.3	Mixed		
HEY2	bHLHb32, HERP1, HESR2	ENSG00000135547	Hes related family bHLH transcription factor with YRPW motif 2	6	125747664-125761269	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030205, HPA074851	Approved		Approved	Nuclear bodies<br>Aggresome		Expressed in all	Mixed			fallopian tube: 21.6	Cell line enhanced		HEK 293: 6.3;SK-MEL-30: 5.0;TIME: 11.9;U-266/70: 13.2
PKIB	PRKACN2	ENSG00000135549	CAMP-dependent protein kinase inhibitor beta	6	122471917-122726373	Predicted intracellular proteins	Evidence at protein level	HPA030156	Approved				Renal cancer:2.47e-7 (favourable), Liver cancer:4.72e-7 (unfavourable)	Expressed in all	Tissue enhanced		colon: 89.1;placenta: 85.4	parathyroid gland: 78.0	Cell line enhanced		AF22: 71.0;PC-3: 106.9;RPTEC TERT1: 141.0;SCLC-21H: 186.3
TAAR5	PNR	ENSG00000135569	Trace amine associated receptor 5	6	132588673-132589686	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA051703	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NMBR	BB1, BB1R	ENSG00000135577	Neuromedin B receptor	6	142058330-142088799	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA026665			Supported	Plasma membrane<br>Cytosol		Not detected	Group enriched	5	fallopian tube: 1.4;testis: 2.6	cerebral cortex: 0.3	Not detected		
SMPD2	ISC1, nSMase	ENSG00000135587	Sphingomyelin phosphodiesterase 2	6	109440763-109443919	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018110, HPA018125	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable)	Expressed in all	Mixed			testis: 55.8	Expressed in all		
MICAL1	DKFZp434B1517, FLJ11937, FLJ21739, MICAL, NICAL	ENSG00000135596	Microtubule associated monooxygenase, calponin and LIM domain containing 1	6	109444062-109465968	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030175, HPA030176, HPA030178	Approved				Pancreatic cancer:2.63e-7 (favourable), Renal cancer:6.71e-7 (unfavourable)	Expressed in all	Mixed			bone marrow: 39.5	Cell line enhanced		THP-1: 95.6
REPS1		ENSG00000135597	RALBP1 associated Eps domain containing 1	6	138903493-138988261	Predicted intracellular proteins	Evidence at protein level	HPA029961, HPA029962	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.1	Expressed in all		
STX11		ENSG00000135604	Syntaxin 11	6	144150526-144188370	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA007992, HPA076253	Approved		Supported	Nuclear bodies<br>Mitochondria		Expressed in all	Tissue enhanced		bone marrow: 100.8	adipose tissue: 32.1	Cell line enhanced		HDLM-2: 37.8;Karpas-707: 15.3;TIME: 14.2;U-266/70: 19.0
TEC	PSCTK4	ENSG00000135605	Tec protein tyrosine kinase	4	48135783-48269864	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005733, HPA024657	Approved		Supported	Plasma membrane	Ovarian cancer:7.12e-4 (favourable)	Mixed	Mixed			epididymis: 5.0	Cell line enhanced		HEL: 11.8;HMC-1: 17.4;U-266/70: 15.1;U-266/84: 10.6
PRADC1	C2orf7, hPAP21, MGC13004, PAP21	ENSG00000135617	Protease associated domain containing 1	2	73228006-73233238	Predicted secreted proteins	Evidence at protein level	HPA051066	Approved					Expressed in all	Expressed in all			heart muscle: 46.8	Expressed in all		
SEMA4F	SEMAM, SEMAW	ENSG00000135622	Ssemaphorin 4F	2	74654228-74683853	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064095, HPA065969	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome	Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.1	Mixed		
CCT7	Ccth, Nip7-1	ENSG00000135624	Chaperonin containing TCP1 subunit 7	2	73233420-73253021	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008425	Approved		Approved	Cytosol	Liver cancer:1.84e-5 (unfavourable), Endometrial cancer:2.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 286.8	Expressed in all		
EGR4	NGFI-C, PAT133	ENSG00000135625	Early growth response 4	2	73290929-73293705	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028983	Enhanced					Mixed	Group enriched	29	cerebral cortex: 9.7;testis: 3.2	adipose tissue,appendix: 0.2	Cell line enriched	6	HMC-1: 1.4
RAB11FIP5	GAF1, KIAA0857, pp75, RIP11	ENSG00000135631	RAB11 family interacting protein 5	2	73073382-73156721	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036406, HPA036407	Enhanced		Enhanced	Vesicles<br>Microtubule organizing center	Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 73.1	parathyroid gland: 26.9	Mixed		
SMYD5	NN8-4AG, RAI15, RRG1, ZMYND23	ENSG00000135632	SMYD family member 5	2	73214222-73227237	Predicted intracellular proteins	Evidence at protein level	HPA015514, HPA049002	Uncertain		Approved	Mitochondria	Liver cancer:6.58e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 34.2	Expressed in all		
DYSF	FER1L1, LGMD2B	ENSG00000135636	Dysferlin	2	71453722-71686768	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002510, HPA017071, HPA021945	Enhanced		Supported	Plasma membrane<br>Microtubule organizing center		Expressed in all	Mixed			skeletal muscle: 32.8	Group enriched	6	HUVEC TERT2: 69.0;LHCN-M2: 62.5;RH-30: 75.9;TIME: 44.6
CCDC142	FLJ14397	ENSG00000135637	Coiled-coil domain containing 142	2	74471986-74483408	Predicted intracellular proteins	Evidence at transcript level	HPA056946	Approved				Renal cancer:3.71e-7 (unfavourable), Endometrial cancer:1.87e-4 (unfavourable), Liver cancer:4.46e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 5.8	Mixed		
EMX1		ENSG00000135638	Empty spiracles homeobox 1	2	72916260-72936071	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006230, HPA006421	Approved		Approved	Nucleoli	Renal cancer:1.54e-6 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0	testis: 2.6	Cell line enhanced		BEWO: 2.2;CACO-2: 3.1;HEK 293: 7.5
KCNMB4		ENSG00000135643	Potassium calcium-activated channel subfamily M regulatory beta subunit 4	12	70366276-70434292	Predicted membrane proteins	Evidence at protein level	HPA072287	Enhanced		Approved	Cytosol		Mixed	Group enriched	8	adrenal gland: 19.5;cerebral cortex: 38.1	placenta: 3.7	Cell line enhanced		NTERA-2: 7.7;RH-30: 8.0;RT4: 7.4
USP15	KIAA0529, UNPH4	ENSG00000135655	Ubiquitin specific peptidase 15	12	62260338-62417431	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006237, HPA006428, HPA071014	Approved		Enhanced	Cytosol	Renal cancer:1.58e-5 (unfavourable), Liver cancer:8.04e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 121.6	Expressed in all		
GNS		ENSG00000135677	Glucosamine (N-acetyl)-6-sulfatase	12	64713445-64759447	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013695, CAB026011, HPA048508	Enhanced				Liver cancer:1.94e-5 (unfavourable), Glioma:4.17e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 172.9	Expressed in all		
CPM		ENSG00000135678	Carboxypeptidase M	12	68842197-68971570	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002657, HPA077243	Uncertain		Uncertain	Vesicles	Endometrial cancer:1.00e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 164.0	placenta: 101.2	Cell line enhanced		ASC diff: 48.8;ASC TERT1: 35.1;HSkMC: 66.3;SiHa: 73.7
MDM2	HDM2, MGC5370	ENSG00000135679	MDM2 proto-oncogene	12	68808176-68850686	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000086, CAB016303	Supported		Supported	Nucleus	Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable)	Expressed in all	Expressed in all			rectum: 33.9	Expressed in all		
KLHL36	C16orf44, FLJ12543	ENSG00000135686	Kelch like family member 36	16	84648525-84667686	Predicted intracellular proteins	Evidence at protein level	HPA023423	Approved		Approved	Cytosol	Renal cancer:5.52e-10 (favourable), Pancreatic cancer:9.81e-5 (favourable)	Expressed in all	Expressed in all			testis: 20.1	Mixed		
BCO1	BCDO, BCDO1, BCMO, BCMO1, FLJ10730	ENSG00000135697	Beta-carotene oxygenase 1	16	81238448-81291142	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043811			Uncertain	Actin filaments<br>Microtubule organizing center		Mixed	Tissue enhanced		duodenum: 8.7;small intestine: 14.8	kidney: 3.3	Cell line enhanced		A549: 9.9;EFO-21: 7.6;HAP1: 3.2;NTERA-2: 4.4;RPTEC TERT1: 6.2
MPHOSPH6	MPP6	ENSG00000135698	M-phase phosphoprotein 6	16	82147798-82170226	Predicted intracellular proteins	Evidence at protein level	CAB003674, HPA026948	Approved		Supported	Nucleus<br>Nucleoli	Ovarian cancer:3.41e-5 (favourable), Liver cancer:4.36e-5 (unfavourable), Prostate cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 91.8	Expressed in all		
CHST5	FLJ22167, I-GLCNAC-6-ST	ENSG00000135702	Carbohydrate sulfotransferase 5	16	75528535-75535247	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043804	Enhanced					Group enriched	Group enriched	14	colon: 45.6;duodenum: 85.9;rectum: 59.7;small intestine: 83.5	stomach: 4.8	Mixed		
KIAA0513		ENSG00000135709	KIAA0513	16	85027751-85094230	Predicted intracellular proteins	Evidence at protein level	HPA012866, HPA014431	Enhanced		Uncertain	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.72e-5 (favourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 102.6	adrenal gland: 14.9	Mixed		
DYNC1LI2	DNCLI2	ENSG00000135720	Dynein cytoplasmic 1 light intermediate chain 2	16	66720893-66751798	Predicted intracellular proteins	Evidence at protein level	HPA057201			Approved	Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 141.9	Expressed in all		
FBXL8	Fbl8	ENSG00000135722	F-box and leucine rich repeat protein 8	16	67159931-67164570	Predicted intracellular proteins	Evidence at protein level	HPA035587, HPA035588	Uncertain		Approved	Golgi apparatus	Endometrial cancer:5.39e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.2	Mixed		
FHOD1	FHOS	ENSG00000135723	Formin homology 2 domain containing 1	16	67229387-67247658	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024468	Approved		Supported	Cytosol	Renal cancer:1.90e-8 (unfavourable), Cervical cancer:9.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 62.3	skeletal muscle: 40.4	Expressed in all		
CCDC102A	MGC10992	ENSG00000135736	Coiled-coil domain containing 102A	16	57512178-57536599	Predicted intracellular proteins	Evidence at protein level	HPA040598, HPA040958	Supported		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			prostate: 5.5	Mixed		
SLC9A5	NHE5	ENSG00000135740	Solute carrier family 9 member A5	16	67237683-67272190	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041004, HPA041329	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		spleen: 7.8	cerebral cortex: 2.5	Cell line enhanced		U-138 MG: 5.9
AGT	SERPINA8	ENSG00000135744	Angiotensinogen	1	230702523-230714297	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001557, CAB025798	Supported					Group enriched	Tissue enhanced		cerebral cortex: 226.5;liver: 649.6	gallbladder: 133.7	Cell line enhanced		CACO-2: 60.4;Hep G2: 401.1;THP-1: 150.6
PCNX2	FLJ11383, KIAA0435, PCNXL2	ENSG00000135749	Pecanex homolog 2 (Drosophila)	1	232983435-233295713	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013815, HPA014427	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:2.27e-5 (unfavourable)	Mixed	Mixed			cerebral cortex: 14.0	Mixed		
KCNK1	DPK, K2p1.1, TWIK-1	ENSG00000135750	Potassium two pore domain channel subfamily K member 1	1	233614004-233672512	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016049, CAB022588	Approved		Approved	Vesicles	Renal cancer:8.69e-8 (unfavourable), Liver cancer:3.84e-4 (favourable), Pancreatic cancer:7.29e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 46.4	Cell line enhanced		SCLC-21H: 70.2;U-266/70: 104.5;U-266/84: 92.8
URB2	KIAA0133, NET10, NPA2	ENSG00000135763	URB2 ribosome biogenesis 2 homolog (S. cerevisiae)	1	229626234-229660199	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008902, HPA046788	Uncertain		Enhanced	Nucleoli		Expressed in all	Mixed			testis: 10.6	Expressed in all		
EGLN1	C1orf12, HIFPH2, PHD2, SM-20, ZMYND6	ENSG00000135766	Egl-9 family hypoxia inducible factor 1	1	231363751-231425044	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022129	Approved		Approved	Cytosol	Cervical cancer:2.99e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.9	Expressed in all		
CAPN9	GC36, nCL-4	ENSG00000135773	Calpain 9	1	230747384-230802003	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020398, CAB033483	Enhanced					Mixed	Tissue enhanced		rectum: 25.2;stomach: 58.9	colon: 14.4	Cell line enriched	9	SCLC-21H: 17.8
COG2	LDLC	ENSG00000135775	Component of oligomeric golgi complex 2	1	230642489-230693982	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA076994			Approved	Golgi apparatus	Colorectal cancer:9.76e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.2	Expressed in all		
ABCB10	EST20237, M-ABC2, MTABC2	ENSG00000135776	ATP binding cassette subfamily B member 10	1	229516582-229558695	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB044063, CAB044065, HPA055175	Uncertain					Expressed in all	Expressed in all			bone marrow: 36.5	Expressed in all		
NTPCR	C1orf57, HCR-NTPase, MGC13186	ENSG00000135778	Nucleoside-triphosphatase, cancer-related	1	232950605-232983882	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028125, HPA054304	Uncertain		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 11.4	Mixed		
TAF5L	PAF65B	ENSG00000135801	TATA-box binding protein associated factor 5 like	1	229593111-229626047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067941			Enhanced	Nuclear speckles<br>Cytoplasmic bodies		Expressed in all	Expressed in all			placenta: 20.6	Expressed in all		
GLUL	GLNS	ENSG00000135821	Glutamate-ammonia ligase	1	182381704-182392206	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007316, HPA007571, CAB008636	Approved		Supported	Mitochondria<br>Cytosol	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 851.0	Cell line enhanced		ASC diff: 791.8;ASC TERT1: 567.1;HSkMC: 512.4
STX6		ENSG00000135823	Syntaxin 6	1	180972712-181023121	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA038557, HPA038558	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.93e-8 (unfavourable), Liver cancer:6.24e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 30.2	Expressed in all		
RGS8	MGC119067, MGC119068, MGC119069	ENSG00000135824	Regulator of G-protein signaling 8	1	182641816-182684576	Predicted intracellular proteins	Evidence at protein level	HPA076764	Supported					Group enriched	Group enriched	5	cerebral cortex: 5.3;testis: 4.9;thyroid gland: 11.3	adrenal gland: 1.3	Group enriched	5	AF22: 5.6;SCLC-21H: 18.7
RNASEL	PRCA1, RNS4	ENSG00000135828	Ribonuclease L	1	182573634-182589256	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002633, CAB010906	Approved		Supported	Cytosol		Expressed in all	Mixed			parathyroid gland: 17.6	Mixed		
DHX9	DDX9, LKP, RHA	ENSG00000135829	DExH-box helicase 9	1	182839369-182887751	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011819, HPA028050, HPA055684	Supported		Enhanced	Nucleus	Liver cancer:3.17e-4 (unfavourable), Melanoma:6.04e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 137.9	Expressed in all		
KIAA1614		ENSG00000135835	KIAA1614	1	180913154-180951614	Predicted intracellular proteins	Evidence at protein level	HPA028227, HPA061684	Approved		Approved	Nuclear membrane<br>Vesicles		Mixed	Mixed			thyroid gland: 9.2	Cell line enhanced		RH-30: 17.2;SH-SY5Y: 47.3
CEP350	CAP350, KIAA0480	ENSG00000135837	Centrosomal protein 350	1	179954738-180114880	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028355, HPA028357, HPA030845	Enhanced		Supported	Centrosome	Renal cancer:1.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.7	Expressed in all		
NPL	C1orf13, DHDPS1, NPL1	ENSG00000135838	N-acetylneuraminate pyruvate lyase	1	182789293-182830384	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028345			Approved	Vesicles<br>Plasma membrane	Renal cancer:6.63e-4 (unfavourable), Liver cancer:8.05e-4 (unfavourable)	Expressed in all	Mixed			placenta: 63.8	Mixed		
FAM129A	C1orf24, GIG39, NIBAN	ENSG00000135842	Family with sequence similarity 129 member A	1	184790724-184974550	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA028172, HPA028231, HPA028657	Approved		Supported	Plasma membrane<br>Cytosol	Urothelial cancer:4.52e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 104.1	Mixed		
PIGC		ENSG00000135845	Phosphatidylinositol glycan anchor biosynthesis class C	1	172370189-172444086	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036663	Uncertain				Renal cancer:1.43e-8 (unfavourable), Liver cancer:4.49e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.7	Expressed in all		
LAMC1	LAMB2	ENSG00000135862	Laminin subunit gamma 1	1	183023460-183145592	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001908, HPA001909, CAB004486, CAB078163	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane	Urothelial cancer:8.85e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 332.9	smooth muscle: 147.5	Cell line enhanced		ASC diff: 1091.5;HSkMC: 716.3
RC3H1	KIAA2025, RNF198, roquin, RP5-1198E17.5	ENSG00000135870	Ring finger and CCCH-type domains 1	1	173931214-174022297	Predicted intracellular proteins	Evidence at protein level	HPA027428, HPA027434, HPA027448	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.96e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 12.9	Mixed		
GPR55		ENSG00000135898	G protein-coupled receptor 55	2	230907318-230961066	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 5.8;testis: 9.0	tonsil: 4.4	Cell line enhanced		HDLM-2: 6.0;Karpas-707: 23.3;SK-MEL-30: 4.7
SP110	IFI41, IFI75	ENSG00000135899	SP110 nuclear body protein	2	230167293-230225729	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047036, HPA058554	Approved		Supported	Nucleus	Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 66.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 94.0
MRPL44	FLJ12701, FLJ13990	ENSG00000135900	Mitochondrial ribosomal protein L44	2	223957404-223967714	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038147, HPA038148	Approved		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Liver cancer:1.29e-4 (unfavourable), Renal cancer:2.02e-4 (favourable)	Expressed in all	Expressed in all			kidney: 37.5	Expressed in all		
CHRND	ACHRD	ENSG00000135902	Cholinergic receptor nicotinic delta subunit	2	232525993-232536667	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA056404, HPA065404			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	12	skeletal muscle: 9.6	prostate: 0.8	Cell line enriched	76	RH-30: 79.9
PAX3	HUP2, WS1	ENSG00000135903	Paired box 3	2	222199888-222298996	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063659, HPA069000	Approved		Supported	Nucleoplasm		Tissue enriched	Group enriched	8	breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4	prostate: 0.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6
DOCK10	KIAA0694, ZIZ3	ENSG00000135905	Dedicator of cytokinesis 10	2	224765090-225042445	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058106	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			spleen: 46.6	Cell line enhanced		HDLM-2: 50.8
TTLL4	KIAA0173	ENSG00000135912	Tubulin tyrosine ligase like 4	2	218710845-218755416	Predicted intracellular proteins	Evidence at protein level	HPA027091, HPA050252	Approved		Approved	Mitochondria	Renal cancer:6.63e-12 (unfavourable), Liver cancer:2.95e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
USP37	KIAA1594	ENSG00000135913	Ubiquitin specific peptidase 37	2	218450251-218568361	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045160	Approved		Approved	Nucleus<br>Nucleoli	Head and neck cancer:2.85e-4 (favourable)	Mixed	Mixed			testis: 23.2	Expressed in all		
HTR2B	5-HT(2B), 5-HT2B	ENSG00000135914	5-hydroxytryptamine receptor 2B	2	231108230-231125118	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012867, HPA063658	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cervix, uterine: 31.2;endometrium: 30.1;smooth muscle: 23.2	adrenal gland: 19.1	Cell line enhanced		HHSteC: 7.0;HSkMC: 11.5;SK-MEL-30: 23.9
ITM2C	BRI3, BRICD2C, E25, hRPC.1050_D_4, ITM3	ENSG00000135916	Integral membrane protein 2C	2	230864639-230879248	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 852.3	Mixed		
SLC19A3	THTR2	ENSG00000135917	Solute carrier family 19 member 3	2	227685210-227718012	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038898	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		adipose tissue: 50.2;placenta: 35.3	duodenum: 12.3	Cell line enhanced		ASC diff: 6.9;BEWO: 6.1;CACO-2: 12.7
SERPINE2	GDN, nexin, PI7, PN1, PNI	ENSG00000135919	Serpin family E member 2	2	223975112-224039319	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:6.48e-5 (unfavourable)	Tissue enriched	Tissue enriched	7	placenta: 1628.0	cerebral cortex: 235.8	Cell line enhanced		fHDF/TERT166: 5130.1;SK-MEL-30: 2298.5;WM-115: 2211.8
DNAJB2	CMT2T, HSJ1, HSPF3	ENSG00000135924	DnaJ heat shock protein family (Hsp40) member B2	2	219279267-219286900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036268	Approved		Enhanced	Nuclear membrane	Colorectal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 161.8	Expressed in all		
WNT10A		ENSG00000135925	Wnt family member 10A	2	218880363-218899581	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013898	Uncertain					Tissue enhanced	Tissue enhanced		skin: 8.3	placenta: 3.9	Cell line enhanced		CAPAN-2: 36.8;HaCaT: 106.8;HDLM-2: 47.5;U-266/70: 47.5
TMBIM1	LFG3, PP1201, RECS1	ENSG00000135926	Transmembrane BAX inhibitor motif containing 1	2	218274192-218292586	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012093, HPA070824	Approved		Supported	Vesicles	Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 269.0	Expressed in all		
CYP27A1	CP27, CTX, CYP27	ENSG00000135929	Cytochrome P450 family 27 subfamily A member 1	2	218781749-218815293	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059155	Enhanced		Enhanced	Mitochondria	Liver cancer:8.62e-6 (favourable), Breast cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 279.5	lung: 98.4	Cell line enhanced		Hep G2: 187.0;RPTEC TERT1: 50.8;SK-MEL-30: 86.7;WM-115: 42.3
EIF4E2	4EHP, EIF4EL3, IF4e	ENSG00000135930	Eukaryotic translation initiation factor 4E family member 2	2	232550052-232583644	Predicted intracellular proteins	Evidence at protein level	HPA019253			Approved	Mitochondria<br>Cytosol	Liver cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 75.2	Expressed in all		
ARMC9	ARM, FLJ12584, KIAA1868, KU-MEL-1	ENSG00000135931	Armadillo repeat containing 9	2	231198546-231374837	Predicted intracellular proteins	Evidence at protein level	HPA019041, HPA026671	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:7.66e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 34.0	Cell line enhanced		BJ hTERT+: 223.1;SK-MEL-30: 176.9
CAB39	CGI-66, MO25	ENSG00000135932	Calcium binding protein 39	2	230712845-230821075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037112	Supported		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:9.05e-6 (favourable), Pancreatic cancer:8.33e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 78.9	Expressed in all		
COX5B		ENSG00000135940	Cytochrome c oxidase subunit 5B	2	97646040-97648383	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034517	Supported		Enhanced	Mitochondria	Urothelial cancer:2.73e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 447.7	Expressed in all		
REV1	REV1L	ENSG00000135945	REV1, DNA directed polymerase	2	99400475-99490035	Predicted intracellular proteins	Evidence at protein level	HPA044534, HPA051036	Uncertain		Approved	Cytosol	Prostate cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 23.2	Expressed in all		
TSGA10	CEP4L, CT79	ENSG00000135951	Testis specific 10	2	98997261-99154964	Predicted intracellular proteins	Evidence at protein level	HPA036879			Approved	Cytosol		Mixed	Group enriched	11	fallopian tube: 19.2;testis: 92.9	thyroid gland: 4.8	Cell line enhanced		RPTEC TERT1: 3.1
MFSD9	MGC11332	ENSG00000135953	Major facilitator superfamily domain containing 9	2	102715840-102736888	Predicted membrane proteins	Evidence at protein level	HPA055293, HPA061859	Approved		Approved	Nucleoli	Glioma:7.48e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 9.8	Expressed in all		
TMEM127	FLJ20507, FLJ22257	ENSG00000135956	Transmembrane protein 127	2	96248516-96265994	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:6.69e-5 (favourable), Liver cancer:6.59e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 112.5	Expressed in all		
EDAR	DL, ED1R, ED3, ED5, EDA1R, EDA3, Edar	ENSG00000135960	Ectodysplasin A receptor	2	108894471-108989372	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA042292	Approved					Mixed	Mixed			esophagus: 2.8	Group enriched	7	CAPAN-2: 4.0;HaCaT: 8.7
TGFBRAP1	TRAP-1, TRAP1, VPS3	ENSG00000135966	Transforming growth factor beta receptor associated protein 1	2	105264391-105330034	Predicted intracellular proteins	Evidence at protein level	HPA037672, HPA038397	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 20.9	Expressed in all		
GCC2	GCC185, KIAA0336	ENSG00000135968	GRIP and coiled-coil domain containing 2	2	108448561-108509415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035849, HPA035850	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Liver cancer:4.24e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 34.0	Expressed in all		
MRPS9	MRP-S9, RPMS9, S9mt	ENSG00000135972	Mitochondrial ribosomal protein S9	2	105037983-105099960	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043476, HPA048479	Enhanced		Enhanced	Nucleoli<br>Mitochondria	Liver cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.4	Expressed in all		
GPR45	PSP24, PSP24A	ENSG00000135973	G protein-coupled receptor 45	2	105241743-105243049	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055940	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.8	testis: 0.4	Group enriched	14	BEWO: 1.3;U-2 OS: 4.5
C2orf49	asw, MGC5509	ENSG00000135974	Chromosome 2 open reading frame 49	2	105337359-105349211	Predicted intracellular proteins	Evidence at protein level	HPA043846, HPA060814	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 24.2	Expressed in all		
ANKRD36	UNQ2430	ENSG00000135976	Ankyrin repeat domain 36	2	97113496-97264521	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Mixed			testis: 13.4	Mixed		
EPC2	DKFZP566F2124	ENSG00000135999	Enhancer of polycomb homolog 2	2	148644440-148787568	Predicted intracellular proteins	Evidence at protein level	HPA036759	Uncertain		Approved	Nuclear speckles		Expressed in all	Expressed in all			endometrium: 44.3	Expressed in all		
ARHGEF4	ASEF, KIAA1112, STM6	ENSG00000136002	Rho guanine nucleotide exchange factor 4	2	130836916-131047263	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018267	Approved				Testis cancer:7.00e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 61.6;skin: 44.1	esophagus: 14.5	Cell line enhanced		HaCaT: 31.5;hTCEpi: 52.8;SCLC-21H: 52.6
ISCU	hnifU, IscU, ISU2, NIFUN	ENSG00000136003	Iron-sulfur cluster assembly enzyme	12	108562582-108569384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB006329, HPA038602, HPA057592	Approved		Supported	Cytosol	Renal cancer:2.73e-7 (favourable), Cervical cancer:4.90e-7 (favourable), Urothelial cancer:6.12e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 399.3	Expressed in all		
ALDH1L2	FLJ38508, mtFDH	ENSG00000136010	Aldehyde dehydrogenase 1 family member L2	12	105019784-105084577	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039481, HPA059282	Uncertain		Enhanced	Mitochondria		Mixed	Mixed			cervix, uterine: 8.4	Cell line enhanced		ASC TERT1: 58.5;fHDF/TERT166: 77.9
STAB2	DKFZP434E0321, FEEL-2, FELL, HARE, SCARH1, STAB-2	ENSG00000136011	Stabilin 2	12	103587273-103766727	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026871	Enhanced		Uncertain	Cytosol		Not detected	Tissue enriched	6	spleen: 48.3	liver: 7.8	Cell line enhanced		BEWO: 11.1;HaCaT: 2.8
USP44	FLJ14528	ENSG00000136014	Ubiquitin specific peptidase 44	12	95516560-95551490	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026543			Approved	Nucleoli fibrillar center<br>Microtubules		Tissue enhanced	Tissue enriched	7	testis: 43.6	parathyroid gland: 6.0	Cell line enriched	6	NTERA-2: 137.8
SCYL2	CVAK104, KIAA1360	ENSG00000136021	SCY1 like pseudokinase 2	12	100267140-100341724	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021050	Approved					Expressed in all	Expressed in all			parathyroid gland: 41.8	Expressed in all		
CKAP4	CLIMP-63, ERGIC-63, P63	ENSG00000136026	Cytoskeleton associated protein 4	12	106237877-106304279	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000278, HPA000792, HPA001225	Enhanced		Uncertain	Nuclear speckles<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-5 (unfavourable), Lung cancer:5.61e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 78.5	Cell line enhanced		BJ hTERT+: 563.9;fHDF/TERT166: 652.4
PLXNC1	CD232, VESPR	ENSG00000136040	Plexin C1	12	94148723-94307675	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026155, HPA066899	Uncertain		Approved	Mitochondria		Expressed in all	Mixed			testis: 28.5	Cell line enhanced		HAP1: 34.3;SK-MEL-30: 32.7;U-266/70: 49.2;U-266/84: 50.5
APPL2	DIP13B, FLJ10659	ENSG00000136044	Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2	12	105173296-105236238	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039688, HPA043925	Approved				Renal cancer:7.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 78.0	Expressed in all		
PWP1	IEF-SSP-9502	ENSG00000136045	PWP1 homolog, endonuclein	12	107685732-107713167	Predicted intracellular proteins	Evidence at protein level	HPA038708			Approved	Nucleoli<br>Golgi apparatus	Liver cancer:1.40e-5 (unfavourable), Renal cancer:2.26e-4 (unfavourable), Head and neck cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.0	Expressed in all		
DRAM1	DRAM, FLJ11259	ENSG00000136048	DNA damage regulated autophagy modulator 1	12	101877351-102012130	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:6.52e-8 (favourable), Renal cancer:3.91e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 130.5	Cell line enhanced		BJ hTERT+: 400.1
WASHC4	KIAA1033, SWIP	ENSG00000136051	WASH complex subunit 4	12	105107324-105169134	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045666, HPA046737	Uncertain		Enhanced	Nucleoplasm	Cervical cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 51.1	Expressed in all		
SLC41A2	DKFZP434K0427	ENSG00000136052	Solute carrier family 41 member 2	12	104802553-104958744	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038658	Approved				Renal cancer:3.35e-4 (unfavourable), Liver cancer:9.94e-4 (favourable)	Expressed in all	Mixed			liver: 60.0	Cell line enhanced		HDLM-2: 52.1
VILL		ENSG00000136059	Villin like	3	37988059-38007188	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035675	Enhanced				Glioma:1.16e-4 (unfavourable), Head and neck cancer:1.75e-4 (favourable)	Tissue enhanced	Tissue enhanced		stomach: 93.8	small intestine: 67.6	Cell line enhanced		CAPAN-2: 21.9
FLNB	ABP-278, FH1, FLN1L, LRS1, TABP, TAP	ENSG00000136068	Filamin B	3	58008400-58172251	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA004747, HPA004886, CAB019322	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:3.45e-6 (favourable), Pancreatic cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 148.3	Expressed in all		
NEK3	HSPK36, MGC29949	ENSG00000136098	NIMA related kinase 3	13	52132639-52159861	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019062, HPA043230	Enhanced		Approved	Microtubules		Expressed in all	Expressed in all			testis: 29.6	Mixed		
PCDH8	ARCADLIN, PAPC	ENSG00000136099	Protocadherin 8	13	52842889-52848641	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010509	Uncertain		Uncertain	Golgi apparatus<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 5.7	testis: 0.7	Group enriched	7	AF22: 23.5;NTERA-2: 4.9;SCLC-21H: 6.4
VPS36	C13orf9, CGI-145, Eap45	ENSG00000136100	Vacuolar protein sorting 36 homolog	13	52412602-52450628	Predicted intracellular proteins	Evidence at protein level	HPA039734, HPA043947	Approved		Supported	Vesicles<br>Lysosomes<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.91e-6 (favourable)	Expressed in all	Expressed in all			skin: 62.4	Expressed in all		
RNASEH2B	AGS2, DLEU8, FLJ11712	ENSG00000136104	Ribonuclease H2 subunit B	13	50909678-50973745	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040084, HPA041469	Approved		Enhanced	Nucleus	Renal cancer:2.54e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 29.9	Expressed in all		
CKAP2	FLJ10749, LB1, se20-10, TMAP	ENSG00000136108	Cytoskeleton associated protein 2	13	52455429-52476628	Predicted intracellular proteins	Evidence at protein level	HPA008410, HPA027821	Enhanced		Enhanced	Microtubules<br>Cytosol	Renal cancer:1.90e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 58.5	bone marrow: 42.4	Expressed in all		
CNMD	BRICD3, CHM-I, CHM1, LECT1, MYETS1	ENSG00000136110	Chondromodulin	13	52703264-52739812	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010510	Uncertain					Group enriched	Tissue enhanced		salivary gland: 3.0;testis: 3.5;thyroid gland: 5.8	lung: 2.5	Cell line enriched	125	NTERA-2: 47.4
TBC1D4	AS160, DKFZp779C0666, KIAA0603	ENSG00000136111	TBC1 domain family member 4	13	75284665-75482114	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA040145, HPA059885	Approved		Supported	Cytosol	Renal cancer:1.07e-11 (favourable)	Expressed in all	Expressed in all			adrenal gland: 82.8	Cell line enhanced		CACO-2: 70.0
THSD1	TMTSP	ENSG00000136114	Thrombospondin type 1 domain containing 1	13	52377167-52406494	Predicted membrane proteins	Evidence at protein level	HPA012611, CAB020796	Uncertain		Enhanced	Cytosol		Expressed in all	Mixed			lung: 16.6	Cell line enhanced		HUVEC TERT2: 34.0
BORA	C13orf34, FLJ22624	ENSG00000136122	Bora, aurora kinase A activator	13	72727749-72756198	Predicted intracellular proteins	Evidence at protein level	HPA040866	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			lymph node: 10.4	Expressed in all		
LRCH1	CHDC1, KIAA1016	ENSG00000136141	Leucine rich repeats and calponin homology domain containing 1	13	46553168-46753040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021536	Uncertain		Approved	Nucleoli<br>Actin filaments<br>Cytosol	Renal cancer:1.04e-4 (favourable), Ovarian cancer:5.75e-4 (unfavourable), Cervical cancer:6.24e-4 (unfavourable), Lung cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 26.8	Expressed in all		
SUCLA2		ENSG00000136143	Succinate-CoA ligase ADP-forming beta subunit	13	47936491-48001354	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039435, HPA039536, HPA061528	Enhanced	Supported	Enhanced	Mitochondria	Renal cancer:7.59e-14 (favourable), Urothelial cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 78.7	Expressed in all		
RCBTB1	CLLD7, CLLL7, FLJ10716	ENSG00000136144	RCC1 and BTB domain containing protein 1	13	49531946-49585583	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056783			Approved	Nucleoplasm	Ovarian cancer:1.21e-5 (unfavourable), Lung cancer:5.51e-5 (favourable), Renal cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 74.0	Expressed in all		
MED4	DRIP36, HSPC126, TRAP36, VDRIP	ENSG00000136146	Mediator complex subunit 4	13	48053323-48095131	Predicted intracellular proteins	Evidence at protein level	HPA006232	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 103.5	Expressed in all		
PHF11	BCAP, IGER, NY-REN-34	ENSG00000136147	PHD finger protein 11	13	49495610-49528987	Predicted intracellular proteins	Evidence at protein level	HPA016566, HPA016708	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:4.46e-7 (unfavourable), Endometrial cancer:7.98e-6 (favourable), Urothelial cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 57.6	Mixed		
COG3	SEC34	ENSG00000136152	Component of oligomeric golgi complex 3	13	45464898-45536630	Predicted secreted proteins	Evidence at protein level	HPA040353, HPA054470	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	Ovarian cancer:9.53e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 30.7	Expressed in all		
LMO7	FBX20, FBXO20, KIAA0858	ENSG00000136153	LIM domain 7	13	75620434-75859870	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020923, HPA050184	Approved		Supported	Actin filaments<br>Cytosol	Renal cancer:7.75e-12 (favourable), Pancreatic cancer:3.51e-4 (unfavourable), Endometrial cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 269.4	Cell line enhanced		fHDF/TERT166: 440.3;LHCN-M2: 438.5
SCEL	FLJ21667, MGC22531	ENSG00000136155	Sciellin	13	77535674-77645263	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039737, HPA040154	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 476.6;skin: 397.0	lung: 98.9	Cell line enhanced		CAPAN-2: 28.9;HaCaT: 54.8;HBEC3-KT: 21.3;RPTEC TERT1: 89.6
ITM2B	BRI, BRI2, BRICD2B, E25B, E3-16	ENSG00000136156	Integral membrane protein 2B	13	48233158-48270357	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029292, HPA071992	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.73e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 1855.0	Expressed in all		
SPRY2	hSPRY2	ENSG00000136158	Sprouty RTK signaling antagonist 2	13	80335976-80340951	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB037205, HPA042198	Approved		Supported	Microtubules		Expressed in all	Expressed in all			adipose tissue: 69.7	Cell line enhanced		AN3-CA: 269.3
NUDT15	FLJ10956, MTH2	ENSG00000136159	Nudix hydrolase 15	13	48037567-48047222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038968, HPA038969	Approved		Supported	Nucleoplasm	Melanoma:1.25e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 22.8	Expressed in all		
EDNRB	ETB, HSCR, HSCR2	ENSG00000136160	Endothelin receptor type B	13	77895481-77919768	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB017842, HPA027546	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.20e-5 (favourable)	Group enriched	Tissue enhanced		placenta: 180.2	cerebral cortex: 88.8	Cell line enhanced		AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
RCBTB2	CHC1L	ENSG00000136161	RCC1 and BTB domain containing protein 2	13	48488959-48533256	Predicted intracellular proteins	Evidence at protein level	HPA040242	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 45.0	Cell line enriched	10	MOLT-4: 221.7
LCP1	CP64, L-PLASTIN, LC64P, PLS2	ENSG00000136167	Lymphocyte cytosolic protein 1	13	46125920-46211871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019493, CAB020673	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			lymph node: 614.4	Cell line enhanced		HDLM-2: 728.6;HL-60: 666.2;HMC-1: 741.0;U-698: 751.3
SETDB2	C13orf4, CLLD8, CLLL8, KMT1F	ENSG00000136169	SET domain bifurcated 2	13	49444374-49495003	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012190, HPA071677	Approved		Approved	Nucleoplasm	Renal cancer:1.92e-7 (favourable)	Expressed in all	Mixed			testis: 28.2	Expressed in all		
SCRN1	KIAA0193	ENSG00000136193	Secernin 1	7	29920103-29990289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024517	Enhanced		Approved	Cytosol	Renal cancer:1.15e-5 (favourable), Endometrial cancer:4.00e-5 (unfavourable), Urothelial cancer:2.60e-4 (unfavourable), Ovarian cancer:7.27e-4 (unfavourable), Breast cancer:8.32e-4 (unfavourable), Cervical cancer:8.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 172.0	parathyroid gland: 129.1	Mixed		
C7orf25	MGC2821	ENSG00000136197	Chromosome 7 open reading frame 25	7	42908726-42912305	Predicted intracellular proteins	Evidence at protein level	HPA020120, HPA049635	Approved		Supported	Nucleoplasm<br>Cytosol		Not detected	Mixed			testis: 7.9	Expressed in all		
TNS3	FLJ13732, H_NH0549I23.2, TEM6, TENS1	ENSG00000136205	Tensin 3	7	47275154-47582558	Predicted intracellular proteins	Evidence at protein level	HPA055338, HPA056015	Approved		Enhanced	Focal adhesion sites	Renal cancer:5.21e-4 (favourable)	Expressed in all	Expressed in all			placenta: 81.5	Cell line enhanced		A549: 240.1
SPDYE1	Ringo1, SPDYE, WBSCR19	ENSG00000136206	Speedy/RINGO cell cycle regulator family member E1	7	44000889-44010122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Mixed	Tissue enriched	6	testis: 8.2	skin: 1.3	Mixed		
CHST12	C4S-2, C4ST2	ENSG00000136213	Carbohydrate sulfotransferase 12	7	2403560-2448483	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA041680	Approved		Approved	Golgi apparatus	Pancreatic cancer:1.32e-5 (favourable)	Expressed in all	Expressed in all			spleen: 16.1	Cell line enhanced		U-266/70: 68.5
IGF2BP3	CT98, IMP-3, IMP3	ENSG00000136231	Insulin like growth factor 2 mRNA binding protein 3	7	23310209-23470467	Predicted intracellular proteins	Evidence at protein level	HPA002037	Approved		Enhanced	Cytosol		Mixed	Tissue enhanced		placenta: 41.6	testis: 9.3	Mixed		
GPNMB	HGFIN, NMB	ENSG00000136235	Glycoprotein nmb	7	23235967-23275108	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 654.6	Cell line enriched	5	ASC diff: 3230.9
RAPGEF5	GFR, KIAA0277, MR-GEF	ENSG00000136237	Rap guanine nucleotide exchange factor 5	7	22118238-22357144	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA057821, HPA076772	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:3.52e-5 (favourable), Endometrial cancer:9.44e-4 (unfavourable)	Expressed in all	Tissue enriched	12	parathyroid gland: 1205.9	placenta: 97.1	Cell line enhanced		HUVEC TERT2: 37.6;SCLC-21H: 40.3;TIME: 21.0;U-698: 26.6
RAC1	p21-Rac1, Rac-1, TC-25	ENSG00000136238	Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)	7	6374523-6403977	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB035994, HPA047820	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:1.74e-5 (unfavourable), Pancreatic cancer:4.57e-5 (unfavourable), Renal cancer:2.11e-4 (unfavourable), Lung cancer:4.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 281.6	Expressed in all		
KDELR2	ELP-1, ERD2.2	ENSG00000136240	KDEL endoplasmic reticulum protein retention receptor 2	7	6445953-6484242	Predicted membrane proteins	Evidence at protein level	HPA016459	Approved				Renal cancer:6.79e-8 (unfavourable), Head and neck cancer:1.03e-5 (unfavourable), Glioma:8.16e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 204.0	Expressed in all		
NUPL2	CG1, H_RG271G13.9, hCG1, NLP_1	ENSG00000136243	Nucleoporin like 2	7	23181827-23201011	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA049036, HPA057251			Enhanced	Nucleus		Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
IL6	BSF2, HGF, HSF, IFNB2, IL-6	ENSG00000136244	Interleukin 6	7	22725884-22732002	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB023406, CAB072821	Supported		Approved	Vesicles	Renal cancer:1.10e-11 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 136.4	urinary bladder: 73.6	Group enriched	7	BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5
ZDHHC4	FLJ10479, ZNF374	ENSG00000136247	Zinc finger DHHC-type containing 4	7	6577434-6589374	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA032124, HPA064358	Approved		Approved	Nuclear bodies	Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 77.7	Mixed		
AOAH		ENSG00000136250	Acyloxyacyl hydrolase	7	36512949-36724549	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021666, HPA026716	Uncertain					Expressed in all	Tissue enhanced		spleen: 88.9	appendix: 45.9	Group enriched	6	HDLM-2: 3.4;NB-4: 16.7;THP-1: 13.5;U-937: 6.8
BZW2	HSPC028, MST017, MSTP017	ENSG00000136261	Basic leucine zipper and W2 domains 2	7	16646131-16706523	Predicted intracellular proteins	Evidence at protein level	HPA022813, HPA026709	Approved		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Liver cancer:7.86e-8 (unfavourable), Renal cancer:6.01e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 173.5	Expressed in all		
DGKB	DAGK2, DGK, DGK-BETA, KIAA0718	ENSG00000136267	Diacylglycerol kinase beta	7	14145049-14974777	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020321		Supported				Tissue enriched	Tissue enriched	6	cerebral cortex: 34.2	endometrium: 5.6	Cell line enhanced		AF22: 1.2;fHDF/TERT166: 2.0;SCLC-21H: 1.5;U-266/70: 2.5
TBRG4	Cpr2, FASTKD4, H_TD2522F11.8, KIAA0948	ENSG00000136270	Transforming growth factor beta regulator 4	7	45100100-45112047	Predicted intracellular proteins	Evidence at protein level	HPA020582, HPA050430	Approved		Enhanced	Mitochondria	Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
DDX56	NOH61	ENSG00000136271	DEAD-box helicase 56	7	44565417-44575051	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019749, CAB037320	Uncertain				Renal cancer:8.41e-7 (unfavourable), Liver cancer:1.38e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland,skin: 5.6	Expressed in all		
HUS1		ENSG00000136273	HUS1 checkpoint clamp component	7	47695730-47979581	Predicted intracellular proteins	Evidence at protein level	HPA026787	Approved				Cervical cancer:4.25e-5 (unfavourable), Liver cancer:9.54e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 12.3	Expressed in all		
NACAD	KIAA0363	ENSG00000136274	NAC alpha domain containing	7	45080438-45088914	Predicted intracellular proteins	Evidence at protein level	HPA020981	Enhanced		Approved	Nucleus<br>Cytosol	Glioma:2.23e-4 (unfavourable)	Group enriched	Tissue enriched	6	cerebral cortex: 48.7	ovary: 7.6	Cell line enhanced		SCLC-21H: 30.5;SH-SY5Y: 19.0
DBNL	ABP1, HIP-55, SH3P7	ENSG00000136279	Drebrin like	7	44044640-44069456	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020265, HPA027735	Enhanced		Supported	Nucleoplasm<br>Cytosol	Glioma:3.20e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 141.9	Expressed in all		
CCM2	C7orf22, MGC4607, OSM	ENSG00000136280	CCM2 scaffolding protein	7	44999475-45076469	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020273, HPA021669, HPA065815	Enhanced		Enhanced	Mitochondria	Renal cancer:5.06e-7 (unfavourable), Pancreatic cancer:1.16e-4 (favourable), Colorectal cancer:1.79e-4 (unfavourable), Glioma:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.1	Expressed in all		
MYO1G	HA-2	ENSG00000136286	Myosin IG	7	44962662-44979098	Predicted intracellular proteins	Evidence at protein level	HPA021252	Enhanced				Renal cancer:8.71e-8 (unfavourable), Cervical cancer:8.26e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 27.7;lymph node: 27.7;spleen: 24.6	appendix: 21.9	Cell line enhanced		HDLM-2: 53.6;HEL: 62.4;HL-60: 31.8;MOLT-4: 71.7;THP-1: 52.2;U-937: 44.7
TTYH3	KIAA1691	ENSG00000136295	Tweety family member 3	7	2631951-2664802	Predicted membrane proteins	Evidence at protein level	HPA053520	Uncertain				Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 62.2	Expressed in all		
MMD2	PAQR10	ENSG00000136297	Monocyte to macrophage differentiation associated 2	7	4905989-4959213	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	83	cerebral cortex: 41.2;testis: 12.4	adrenal gland: 0.3	Not detected		
CIDEB		ENSG00000136305	Cell death-inducing DFFA-like effector b	14	24305096-24311430	Predicted intracellular proteins	Evidence at protein level	HPA001272	Uncertain					Mixed	Expressed in all			liver: 184.0	Cell line enhanced		HDLM-2: 39.8;Hep G2: 32.5;HL-60: 24.6;U-937: 28.0
TTC5	Strap	ENSG00000136319	Tetratricopeptide repeat domain 5	14	20256558-20305994	Predicted intracellular proteins	Evidence at protein level	HPA045008, HPA054198	Approved		Supported	Nucleoplasm	Renal cancer:8.54e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.5	Mixed		
NKX2-8	Nkx2-9, NKX2.8, NKX2H	ENSG00000136327	NK2 homeobox 8	14	36580579-36582607	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062879	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		testis: 3.1	lung: 0.6	Cell line enhanced		HaCaT: 4.6;PC-3: 2.8;SiHa: 1.3
NKX2-1	BCH, NKX2A, TITF1, TTF-1, TTF1	ENSG00000136352	NK2 homeobox 1	14	36516392-36521149	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000078, CAB053633, HPA074316	Enhanced		Uncertain	Golgi apparatus<br>Vesicles		Group enriched	Group enriched	177	lung: 101.3;thyroid gland: 103.5	stomach: 0.5	Cell line enriched	36	SCLC-21H: 119.8
ZFHX2	KIAA1056, KIAA1762, ZFH-5, ZNF409	ENSG00000136367	Zinc finger homeobox 2	14	23520855-23556192	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000720, HPA005146	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		testis: 13.0	parathyroid gland: 4.0	Cell line enhanced		AN3-CA: 4.5
MTHFS	HsT19268	ENSG00000136371	Methenyltetrahydrofolate synthetase	15	79833585-79897379	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008067, HPA054177	Approved		Supported	Cytosol	Liver cancer:1.29e-6 (favourable), Renal cancer:2.04e-4 (favourable), Glioma:6.94e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 116.1	Expressed in all		
ADAMTS7	ADAM-TS7, DKFZp434H204	ENSG00000136378	ADAM metallopeptidase with thrombospondin type 1 motif 7	15	78759203-78811431	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045284, HPA048453	Uncertain		Supported	Vesicles	Stomach cancer:9.53e-4 (unfavourable)	Mixed	Tissue enhanced		endometrium: 7.2	heart muscle: 4.3	Cell line enriched	9	HMC-1: 229.5
ABHD17C	FAM108C1	ENSG00000136379	Abhydrolase domain containing 17C	15	80679684-80755621	Predicted intracellular proteins	Evidence at protein level	HPA048890	Uncertain					Expressed in all	Mixed			colon: 64.0	Mixed		
IREB2	IRP2	ENSG00000136381	Iron responsive element binding protein 2	15	78437431-78501456	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032885, HPA040371, HPA068982	Uncertain		Approved	Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 48.0	Expressed in all		
ALPK3	KIAA1330, MAK, Midori	ENSG00000136383	Alpha kinase 3	15	84816680-84873482	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026558	Uncertain		Approved	Nucleus	Renal cancer:3.95e-7 (favourable)	Mixed	Tissue enhanced		heart muscle: 32.8;parathyroid gland: 36.2;skeletal muscle: 47.6	adipose tissue: 12.3	Cell line enhanced		BEWO: 12.8;HUVEC TERT2: 12.1;LHCN-M2: 16.5;NTERA-2: 12.1;RH-30: 34.1
TM6SF1		ENSG00000136404	Transmembrane 6 superfamily member 1	15	83107407-83144854	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016051, HPA056857	Uncertain				Renal cancer:6.79e-4 (favourable)	Mixed	Mixed			thyroid gland: 13.3	Cell line enhanced		HEL: 16.0;HHSteC: 33.2;HUVEC TERT2: 18.1;TIME: 46.3
CIB2	DFNB48, KIP2, USH1J	ENSG00000136425	Calcium and integrin binding family member 2	15	78104606-78131544	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036697	Approved	Supported			Renal cancer:6.16e-4 (favourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 31.4	Cell line enhanced		AN3-CA: 39.7;HAP1: 43.8;SCLC-21H: 46.7;SH-SY5Y: 48.9
CALCOCO2	MGC17318, NDP52	ENSG00000136436	Calcium binding and coiled-coil domain 2	17	48830988-48866522	Predicted intracellular proteins	Evidence at protein level	HPA022989, HPA023019, HPA023195	Enhanced		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 249.4	Expressed in all		
RSAD1	FLJ11164	ENSG00000136444	Radical S-adenosyl methionine domain containing 1	17	50478800-50485975	Predicted intracellular proteins	Evidence at protein level	HPA022436, HPA022967	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.7	Expressed in all		
NMT1	NMT	ENSG00000136448	N-myristoyltransferase 1	17	45051610-45109016	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022949, HPA022963	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.6	Expressed in all		
MYCBPAP	AMAP-1, DKFZp434N1415	ENSG00000136449	MYCBP associated protein	17	50508384-50531501	Predicted intracellular proteins	Evidence at protein level	HPA023257, HPA024405	Enhanced		Approved	Vesicles		Mixed	Tissue enriched	12	testis: 91.5	fallopian tube: 7.5	Cell line enhanced		HDLM-2: 3.7
SRSF1	ASF, MGC5228, SF2, SF2p33, SFRS1, SRp30a	ENSG00000136450	Serine and arginine rich splicing factor 1	17	58003360-58007346	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013073, HPA061301	Supported		Enhanced	Nucleoplasm	Liver cancer:1.64e-6 (unfavourable), Renal cancer:2.95e-5 (unfavourable), Colorectal cancer:4.56e-5 (favourable), Cervical cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 156.5	Expressed in all		
VEZF1	DB1, ZNF161	ENSG00000136451	Vascular endothelial zinc finger 1	17	57971547-57988259	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027520, HPA048315	Uncertain		Enhanced	Nucleoplasm	Colorectal cancer:6.14e-5 (favourable), Liver cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.1	Expressed in all		
CHAD	SLRR4A	ENSG00000136457	Chondroadherin	17	50464496-50468966	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018241	Enhanced				Liver cancer:1.59e-4 (favourable), Breast cancer:7.68e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 31.8	adrenal gland: 13.4	Cell line enhanced		RT4: 3.4;SCLC-21H: 10.1
TACO1	CCDC44	ENSG00000136463	Translational activator of cytochrome c oxidase I	17	63600872-63608365	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021626, HPA021643, HPA024294	Enhanced		Enhanced	Mitochondria	Pancreatic cancer:3.73e-4 (favourable)	Expressed in all	Expressed in all			kidney: 30.7	Expressed in all		
TEX2	HT008, KIAA1738, TMEM96	ENSG00000136478	Testis expressed 2	17	64147227-64263301	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020648, HPA057116	Approved		Approved	Nucleus	Colorectal cancer:3.90e-6 (favourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
DCAF7	HAN11, SWAN-1, WDR68	ENSG00000136485	DDB1 and CUL4 associated factor 7	17	63550461-63594266	Predicted intracellular proteins	Evidence at protein level	HPA022948, HPA022962	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.42e-4 (unfavourable), Renal cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 61.4	Expressed in all		
GH2	GH-V, GHL, GHV, hGH-V	ENSG00000136487	Growth hormone 2	17	63880215-63881935	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Not detected	Tissue enriched	199	placenta: 189.1	smooth muscle: 0.9	Cell line enriched	21	BEWO: 7.8
CSH1	CSA, CSMT, FLJ75407, hCS-A, PL	ENSG00000136488	Chorionic somatomammotropin hormone 1	17	63894909-63896661	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026374, HPA043715	Enhanced					Tissue enriched	Tissue enriched	211	placenta: 13487.0	smooth muscle: 63.9	Cell line enriched	6	BEWO: 11.1
LIMD2	MGC10986	ENSG00000136490	LIM domain containing 2	17	63695902-63701172	Predicted intracellular proteins	Evidence at protein level	HPA062867			Approved	Vesicles	Renal cancer:5.36e-11 (unfavourable)	Expressed in all	Group enriched	5	appendix: 140.1;bone marrow: 71.2;lymph node: 255.5;spleen: 191.0;tonsil: 138.2	urinary bladder: 30.2	Cell line enhanced		Daudi: 173.9;SH-SY5Y: 172.7;U-698: 174.0
BRIP1	BACH1, FANCJ, OF	ENSG00000136492	BRCA1 interacting protein C-terminal helicase 1	17	61681266-61863521	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005474	Approved		Supported	Nucleus<br>Nuclear membrane	Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable)	Mixed	Tissue enhanced		testis: 14.4	bone marrow: 5.0	Cell line enhanced		MCF7: 77.7
KAT7	HBO1, HBOA, MYST2, ZC2HC7	ENSG00000136504	Lysine acetyltransferase 7	17	49788555-49835030	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044470	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
RTP4	IFRG28, Z3CXXC4	ENSG00000136514	Receptor transporter protein 4	3	187368332-187372076	Predicted membrane proteins	Evidence at protein level	HPA064887, HPA071189	Uncertain		Supported	Nucleus	Urothelial cancer:1.45e-4 (favourable), Thyroid cancer:4.35e-4 (favourable), Pancreatic cancer:6.83e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 16.7	Cell line enhanced		CAPAN-2: 9.2;HDLM-2: 11.0;SK-MEL-30: 14.0
ACTL6A	Actl6, Arp4, BAF53A, INO80K	ENSG00000136518	Actin like 6A	3	179562880-179588408	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012188, HPA018671	Supported		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.89e-5 (unfavourable), Renal cancer:4.80e-5 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 112.6	Expressed in all		
NDUFB5	CI-SGDH, MGC12314, SGDH	ENSG00000136521	NADH:ubiquinone oxidoreductase subunit B5	3	179604690-179627647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005640	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 136.7	Expressed in all		
MRPL47	CGI-204, NCM1	ENSG00000136522	Mitochondrial ribosomal protein L47	3	179588285-179604654	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA037553, HPA047779	Approved		Enhanced	Mitochondria	Endometrial cancer:3.15e-4 (unfavourable), Cervical cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
TRA2B	Htra2-beta, PPP1R156, SFRS10	ENSG00000136527	Transformer 2 beta homolog (Drosophila)	3	185915906-185938136	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011692, HPA063597, HPA064972	Supported		Enhanced	Nucleoplasm	Ovarian cancer:2.15e-4 (favourable), Liver cancer:8.51e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 56.6	Expressed in all		
SCN2A	HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2	ENSG00000136531	Sodium voltage-gated channel alpha subunit 2	2	165194993-165392310	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB022567	Enhanced					Tissue enhanced	Tissue enriched	26	cerebral cortex: 56.6	kidney: 2.1	Cell line enhanced		U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2
TBR1		ENSG00000136535	T-box, brain 1	2	161416094-161425870	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051256, HPA078644, HPA078657	Enhanced	Approved				Not detected	Tissue enriched	30	cerebral cortex: 30.6	testis: 1.0	Not detected		
MARCH7	AXOT, MARCH-VII, RNF177	ENSG00000136536	Membrane associated ring-CH-type finger 7	2	159712457-159771027	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA014275, HPA022152	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.84e-4 (unfavourable), Liver cancer:2.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
ERMN	ERMIN, JN, KIAA1189	ENSG00000136541	Ermin	2	157318625-157327713	Predicted intracellular proteins	Evidence at protein level	HPA038295, HPA038296	Enhanced				Endometrial cancer:6.93e-6 (favourable)	Group enriched	Tissue enriched	27	cerebral cortex: 227.8	bone marrow: 8.3	Cell line enriched	8	HAP1: 20.7
GALNT5	GalNAc-T5	ENSG00000136542	Polypeptide N-acetylgalactosaminyltransferase 5	2	157257598-157314211	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008963, HPA009035	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lung: 18.4;rectum: 19.7;stomach: 16.8	colon: 13.9	Cell line enhanced		A-431: 60.2;BJ hTERT+: 63.9;fHDF/TERT166: 72.0;HaCaT: 69.5;LHCN-M2: 65.2
SCN7A	NaG, Nav2.1, Nav2.2, SCN6A	ENSG00000136546	Sodium voltage-gated channel alpha subunit 7	2	166403573-166494247	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004879	Uncertain					Mixed	Tissue enhanced		ovary: 63.2	lung: 41.1	Not detected		
TANK	I-TRAF, TRAF2	ENSG00000136560	TRAF family member associated NFKB activator	2	161136908-161236221	Predicted intracellular proteins	Evidence at protein level	CAB010345, HPA037675, HPA037676	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:2.78e-6 (unfavourable), Liver cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 68.2	Expressed in all		
BLK	MGC10442	ENSG00000136573	BLK proto-oncogene, Src family tyrosine kinase	8	11494001-11564604	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005093, HPA069571	Approved		Approved	Nucleoplasm		Mixed	Group enriched	10	appendix: 22.0;lymph node: 61.2;spleen: 40.6;tonsil: 51.4	urinary bladder: 4.3	Group enriched	6	Daudi: 99.9;REH: 39.4;RPMI-8226: 47.4;U-698: 55.4;U-87 MG: 29.9
GATA4		ENSG00000136574	GATA binding protein 4	8	11676959-11760002	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013125, HPA073899	Uncertain		Supported	Nuclear bodies		Tissue enhanced	Tissue enhanced		duodenum: 72.5;heart muscle: 59.0;ovary: 111.8	testis: 51.5	Cell line enhanced		HEK 293: 11.9;Hep G2: 21.2;HHSteC: 31.6;SH-SY5Y: 45.2
SKIL	SNO, SnoA, SnoN	ENSG00000136603	SKI like proto-oncogene	3	170357678-170396835	Predicted intracellular proteins	Evidence at protein level	HPA008472	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.19e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 36.9	Expressed in all		
EPRS	EARS, GLUPRORS, PARS, QARS, QPRS	ENSG00000136628	Glutamyl-prolyl-tRNA synthetase	1	219968601-220046658	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026490, HPA030052	Enhanced		Enhanced	Cytosol	Urothelial cancer:2.62e-4 (unfavourable), Breast cancer:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.4	Expressed in all		
HLX	HB24, HLX1	ENSG00000136630	H2.0 like homeobox	1	220879400-220885059	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005968	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 60.3	lung: 27.1	Cell line enhanced		THP-1: 72.2
VPS45	h-vps45, H1, VPS45A, VPS45B	ENSG00000136631	Vacuolar protein sorting 45 homolog	1	150067293-150145327	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027425, HPA027441	Uncertain		Approved	Microtubules	Liver cancer:6.57e-6 (unfavourable), Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 37.6	Expressed in all		
IL10	CSIF, IL-10, IL10A, TGIF	ENSG00000136634	Interleukin 10	1	206767602-206772494	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB013120	Uncertain					Mixed	Tissue enhanced		appendix: 8.7	adipose tissue: 7.4	Group enriched	7	HMC-1: 5.2;U-266/70: 6.5
KCTD3	NY-REN-45	ENSG00000136636	Potassium channel tetramerization domain containing 3	1	215567392-215621807	Predicted intracellular proteins	Evidence at protein level	HPA015142	Approved		Approved	Cytosol	Renal cancer:8.94e-6 (unfavourable), Pancreatic cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 103.7	Expressed in all		
RPS6KC1	humS6PKh1	ENSG00000136643	Ribosomal protein S6 kinase C1	1	213051233-213274773	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026531, HPA031565	Approved		Enhanced	Endosomes<br>Lysosomes<br>Cytosol	Renal cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.4	Expressed in all		
CBWD2		ENSG00000136682	COBW domain containing 2	2	113437691-113496189	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane	Endometrial cancer:3.22e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 18.9	Expressed in all		
IL36G	IL-1F9, IL-1H1, IL-1RP2, IL1E, IL1F9, IL1H1	ENSG00000136688	Interleukin 36, gamma	2	112973203-112985665	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	skin: 15.8;tonsil: 39.2	esophagus: 2.7	Not detected		
IL1RN	ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430	ENSG00000136689	Interleukin 1 receptor antagonist	2	113107214-113134016	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001482, CAB009633	Enhanced				Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1243.9	tonsil: 290.5	Cell line enhanced		A-431: 51.8;HaCaT: 100.6;RT4: 89.4
IL36A	FIL1, FIL1E, IL-1F6, IL1(EPSILON), IL1F6, MGC129552, MGC129553	ENSG00000136694	Interleukin 36, alpha	2	113005461-113008044	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	1237	esophagus: 459.4;tonsil: 105.4	endometrium: 0.2	Cell line enhanced		MOLT-4: 1.0
IL36RN	FIL1, FIL1(DELTA), FIL1D, IL-1F5, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, MGC29840	ENSG00000136695	Interleukin 36 receptor antagonist	2	113058638-113065382	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034542	Uncertain					Tissue enriched	Group enriched	7	esophagus: 17.2;skin: 40.7;tonsil: 38.1	placenta: 4.7	Group enriched	18	BEWO: 25.1;U-87 MG: 19.4
IL36B	FIL1, FILI-(ETA), IL-1F8, IL-1H2, IL1-ETA, IL1F8, IL1H2, MGC126880, MGC126882	ENSG00000136696	Interleukin 36, beta	2	113022091-113052867	Predicted intracellular proteins	Evidence at transcript level	HPA035664	Uncertain					Tissue enhanced	Tissue enhanced		esophagus: 2.2;skin: 7.3;tonsil: 3.4	breast: 1.2	Cell line enriched	21	U-87 MG: 71.9
IL1F10	FKSG75, IL-1F10, IL-1HY2, IL1-theta, MGC11983, MGC119832, MGC119833	ENSG00000136697	Interleukin 1 family member 10 (theta)	2	113067970-113075850	Predicted intracellular proteins	Evidence at protein level	HPA059813	Approved					Tissue enhanced	Group enriched	5	skin: 4.8;tonsil: 2.5	breast: 0.7	Not detected		
CFC1	CRYPTIC, HTX2	ENSG00000136698	Cripto, FRL-1, cryptic family 1	2	130592168-130599575	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA041773	Uncertain					Tissue enriched	Tissue enhanced		pancreas: 4.1;prostate: 10.4;stomach: 8.0	fallopian tube: 1.6	Group enriched	18	RPMI-8226: 13.6;SCLC-21H: 12.6
SMPD4	FLJ20297, FLJ20756, KIAA1418, NET13, nSMase-3, NSMASE3	ENSG00000136699	Sphingomyelin phosphodiesterase 4	2	130151392-130182750	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046279, HPA049426	Approved		Approved	Nuclear membrane<br>Cytosol	Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.37e-6 (unfavourable), Endometrial cancer:7.47e-5 (unfavourable), Prostate cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
WDR33	FLJ11294, NET14, WDC146	ENSG00000136709	WD repeat domain 33	2	127701022-127811187	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026897, HPA046527	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 38.2	Expressed in all		
CCDC115	ccp1, FLJ30131, MGC12981	ENSG00000136710	Coiled-coil domain containing 115	2	130338241-130342349	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034598	Approved		Supported	Vesicles<br>Plasma membrane	Breast cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			ovary: 55.5	Expressed in all		
SAP130	FLJ12761	ENSG00000136715	Sin3A associated protein 130	2	127941217-128028120	Predicted intracellular proteins	Evidence at protein level	HPA034664			Supported	Nuclear speckles	Liver cancer:7.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.9	Expressed in all		
BIN1	AMPH2, AMPHL, SH3P9	ENSG00000136717	Bridging integrator 1	2	127048027-127107355	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB001945, HPA003894, HPA005437	Enhanced		Supported	Cytosol		Expressed in all	Group enriched	7	cerebral cortex: 156.4;skeletal muscle: 724.1	adrenal gland: 61.4	Mixed		
IMP4	BXDC4, MGC19606	ENSG00000136718	IMP4 homolog, U3 small nucleolar ribonucleoprotein	2	130342225-130347810	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066222, HPA066673			Enhanced	Nucleoli	Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 22.7	Expressed in all		
HS6ST1	HS6ST	ENSG00000136720	Heparan sulfate 6-O-sulfotransferase 1	2	128236716-128318577	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA044586			Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 40.8	Expressed in all		
UGGT1	HUGT1, UGCGL1	ENSG00000136731	UDP-glucose glycoprotein glucosyltransferase 1	2	128091200-128195677	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012761, HPA015127	Enhanced		Uncertain	Cytosol	Renal cancer:6.37e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
GYPC	CD236, CD236R, Ge, GPC, GYPD	ENSG00000136732	Glycophorin C (Gerbich blood group)	2	126655933-126696675	Blood group antigen proteins, CD markers, Predicted membrane proteins	Evidence at protein level	HPA008965, CAB009445	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 229.7	Cell line enhanced		HHSteC: 315.4;SK-MEL-30: 452.6
STAM	STAM1	ENSG00000136738	Signal transducing adaptor molecule	10	17644125-17715914	Predicted intracellular proteins	Evidence at protein level	CAB034399, HPA043882	Supported		Supported	Vesicles	Liver cancer:3.44e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 41.9	Expressed in all		
GAD2	GAD65	ENSG00000136750	Glutamate decarboxylase 2	10	26216307-26304558	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044637, CAB078177	Enhanced					Group enriched	Tissue enriched	17	cerebral cortex: 22.9	pancreas: 1.3	Group enriched	13	MOLT-4: 2.4;SCLC-21H: 7.4
ABI1	ABI-1, E3B1, SSH3BP1	ENSG00000136754	Abl interactor 1	10	26746593-26861087	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008375, HPA029973, HPA068407	Approved		Supported	Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 87.4	Expressed in all		
YME1L1		ENSG00000136758	YME1 like 1 ATPase	10	27110112-27155266	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066953	Approved		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:8.25e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 105.7	Expressed in all		
DNAJC1	DNAJL1, ERdj1, MTJ1	ENSG00000136770	DnaJ heat shock protein family (Hsp40) member C1	10	21756537-22003769	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA013432	Approved		Approved	Endoplasmic reticulum	Liver cancer:1.96e-5 (unfavourable), Renal cancer:2.33e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.8	Expressed in all		
NIPSNAP3A	DKFZp564D177, FLJ13953, HSPC299, MGC14553	ENSG00000136783	Nipsnap homolog 3A	9	104747688-104760122	Predicted intracellular proteins	Evidence at protein level	HPA042491	Approved					Expressed in all	Expressed in all			adrenal gland: 50.9	Expressed in all		
LRRC8A	FLJ10337, KIAA1437, LRRC8, SWELL1	ENSG00000136802	Leucine rich repeat containing 8 family member A	9	128882112-128918039	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:5.27e-5 (favourable), Pancreatic cancer:3.83e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.7	Expressed in all		
CDK9	C-2k, CDC2L4, PITALRE, TAK	ENSG00000136807	Cyclin dependent kinase 9	9	127785679-127790787	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004216, HPA006738	Supported		Approved	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 60.5	Expressed in all		
TXN	TRX	ENSG00000136810	Thioredoxin	9	110243811-110256640	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008678, HPA047478, HPA055752	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:3.40e-6 (favourable)	Expressed in all	Expressed in all			esophagus: 702.9	Expressed in all		
ODF2	CT134, ODF84	ENSG00000136811	Outer dense fiber of sperm tails 2	9	128455186-128501292	Predicted intracellular proteins	Evidence at protein level	HPA001874, HPA048841	Enhanced		Supported	Centrosome	Liver cancer:1.58e-4 (unfavourable), Prostate cancer:1.72e-4 (unfavourable)	Expressed in all	Tissue enriched	15	testis: 535.2	fallopian tube: 36.6	Expressed in all		
KIAA0368	ECM29, FLJ22036	ENSG00000136813	KIAA0368	9	111360692-111484745	Predicted intracellular proteins	Evidence at protein level	HPA021646, HPA059795	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 80.8	Mixed		
TOR1B	DQ1, MGC4386	ENSG00000136816	Torsin family 1 member B	9	129803153-129811281	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013403, HPA013697, CAB022709	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			rectum: 24.4	Expressed in all		
C9orf78	HCA59, HSPC220	ENSG00000136819	Chromosome 9 open reading frame 78	9	129827290-129835863	Predicted intracellular proteins	Evidence at protein level	HPA021216, HPA021232, HPA021242	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.49e-7 (favourable)	Expressed in all	Expressed in all			bone marrow: 71.1	Expressed in all		
SMC2	CAP-E, hCAP-E, SMC2L1	ENSG00000136824	Structural maintenance of chromosomes 2	9	104094260-104141417	Predicted intracellular proteins	Evidence at protein level	HPA071309	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 22.2	Expressed in all		
KLF4	EZF, GKLF	ENSG00000136826	Kruppel like factor 4	9	107484852-107490482	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002926	Enhanced		Supported	Nucleoplasm	Renal cancer:3.93e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 128.5	Cell line enhanced		hTCEpi: 66.2;U-2197: 130.0
TOR1A	DQ2, DYT1	ENSG00000136827	Torsin family 1 member A	9	129812944-129824134	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB012473, HPA051195	Approved		Supported	Nuclear membrane<br>Vesicles	Lung cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
RALGPS1	KIAA0351, RALGEF2, RALGPS1A	ENSG00000136828	Ral GEF with PH domain and SH3 binding motif 1	9	126914774-127223166	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.20e-11 (favourable)	Expressed in all	Expressed in all			small intestine: 32.0	Mixed		
FAM129B	bA356B19.6, C9orf88, DKFZP434H0820, FLJ13518, FLJ22151, FLJ22298, MINERVA	ENSG00000136830	Family with sequence similarity 129 member B	9	127505339-127578989	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021284, HPA021417, HPA023261, HPA024312	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			esophagus: 362.3	Mixed		
OR1J1	hg32	ENSG00000136834	Olfactory receptor family 1 subfamily J member 1	9	122476958-122477926	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13C9		ENSG00000136839	Olfactory receptor family 13 subfamily C member 9	9	104617248-104618204	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ST6GALNAC4	SIAT3C, SIAT7D, ST6GALNACIV	ENSG00000136840	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4	9	127907886-127917038	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009042			Approved	Nucleus<br>Golgi apparatus	Liver cancer:8.63e-7 (unfavourable), Ovarian cancer:5.12e-4 (unfavourable), Renal cancer:8.39e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 24.4	Cell line enhanced		HDLM-2: 98.1;RPMI-8226: 103.5
TMOD1	D9S57E, ETMOD, TMOD	ENSG00000136842	Tropomodulin 1	9	97501180-97601748	Predicted intracellular proteins	Evidence at protein level	HPA051202	Enhanced		Approved	Cytosol		Tissue enhanced	Mixed			heart muscle: 93.4	Group enriched	7	EFO-21: 35.5;HDLM-2: 143.0;K-562: 47.3;SH-SY5Y: 166.4
DAB2IP	AF9Q34, AIP1, DIP1/2, KIAA1743	ENSG00000136848	DAB2 interacting protein	9	121567057-121785530	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.00e-15 (favourable)	Expressed in all	Mixed			testis: 33.8	Cell line enhanced		HaCaT: 72.1
STXBP1	hUNC18, MUNC18-1, rbSec1, UNC18	ENSG00000136854	Syntaxin binding protein 1	9	127579370-127696027	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008209, HPA023483, CAB034434	Enhanced		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:1.47e-4 (unfavourable), Endometrial cancer:4.78e-4 (unfavourable), Liver cancer:5.73e-4 (unfavourable), Pancreatic cancer:9.81e-4 (favourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 396.3	fallopian tube: 52.6	Cell line enhanced		SCLC-21H: 169.1
SLC2A8	GLUT8, GLUTX1	ENSG00000136856	Solute carrier family 2 member 8	9	127397138-127408424	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011935	Uncertain		Approved	Vesicles	Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable)	Expressed in all	Expressed in all			testis: 50.0	Cell line enhanced		CACO-2: 101.8
ANGPTL2	ARP2, HARP	ENSG00000136859	Angiopoietin like 2	9	127087332-127122883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040933, HPA041299	Approved		Approved	Golgi apparatus	Renal cancer:3.32e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 114.9	Cell line enhanced		ASC diff: 96.3;ASC TERT1: 66.5;BJ hTERT+: 165.9;HSkMC: 70.1
CDK5RAP2	C48, CEP215, FLJ10867, MCPH3	ENSG00000136861	CDK5 regulatory subunit associated protein 2	9	120388869-120580170	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035820, HPA046529	Approved		Enhanced	Cell Junctions<br>Centrosome		Expressed in all	Expressed in all			testis: 37.4	Expressed in all		
ZFP37	ZNF906	ENSG00000136866	ZFP37 zinc finger protein	9	113038380-113056759	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA049112	Uncertain		Approved	Nucleus<br>Vesicles	Glioma:9.22e-5 (favourable)	Mixed	Mixed			ovary: 8.8	Mixed		
SLC31A2	COPT2, CTR2, hCTR2	ENSG00000136867	Solute carrier family 31 member 2	9	113150942-113164137	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014861	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Intermediate filaments		Mixed	Expressed in all			salivary gland: 169.9	Cell line enhanced		hTCEpi: 59.3
SLC31A1	COPT1, CTR1, hCTR1	ENSG00000136868	Solute carrier family 31 member 1	9	113221562-113264492	Predicted membrane proteins, Transporters	Evidence at protein level	HPA013810	Approved				Renal cancer:2.20e-6 (favourable), Thyroid cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 56.5	Expressed in all		
TLR4	ARMD10, CD284, hToll, TLR-4	ENSG00000136869	Toll like receptor 4	9	117704332-117716871	CD markers, Predicted membrane proteins	Evidence at protein level	CAB004025, HPA049174	Approved		Supported	Golgi apparatus<br>Cytosol	Testis cancer:3.79e-4 (unfavourable), Endometrial cancer:6.29e-4 (favourable)	Expressed in all	Mixed			spleen: 48.3	Cell line enhanced		Karpas-707: 40.8;TIME: 38.1
ZNF189		ENSG00000136870	Zinc finger protein 189	9	101398873-101410660	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034814	Uncertain		Approved	Intermediate filaments	Renal cancer:5.32e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 104.7	Expressed in all		
ALDOB		ENSG00000136872	Aldolase, fructose-bisphosphate B	9	101420578-101435823	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002198, CAB020827	Enhanced					Tissue enriched	Group enriched	23	duodenum: 3705.7;kidney: 6574.8;liver: 5092.2;small intestine: 5611.2	gallbladder: 231.1	Cell line enhanced		BEWO: 16.8;NB-4: 10.8;RPMI-8226: 13.6;SH-SY5Y: 17.3
STX17	FLJ20651	ENSG00000136874	Syntaxin 17	9	99906633-99970341	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001204	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:1.62e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.7	Expressed in all		
PRPF4	HPRP4, HPRP4P, PRP4, Prp4p, SNRNP60	ENSG00000136875	Pre-mRNA processing factor 4	9	113275343-113292905	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021794, HPA022248	Enhanced		Enhanced	Nuclear speckles	Liver cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.3	Expressed in all		
FPGS		ENSG00000136877	Folylpolyglutamate synthase	9	127794597-127814327	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050488	Approved				Endometrial cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube,ovary: 26.1	Expressed in all		
USP20	KIAA1003	ENSG00000136878	Ubiquitin specific peptidase 20	9	129834698-129881838	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006287, HPA007008	Uncertain	Approved	Approved	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.54e-7 (favourable), Renal cancer:5.65e-5 (favourable), Colorectal cancer:2.48e-4 (unfavourable), Endometrial cancer:4.01e-4 (favourable), Cervical cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 22.1	Expressed in all		
BAAT	BAT	ENSG00000136881	Bile acid-CoA:amino acid N-acyltransferase	9	101360417-101383519	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021251, HPA021330	Supported		Uncertain	Vesicles	Renal cancer:4.24e-7 (unfavourable), Liver cancer:4.97e-4 (favourable)	Tissue enriched	Tissue enriched	16	liver: 340.4	gallbladder: 21.1	Cell line enhanced		A549: 1.8
KIF12		ENSG00000136883	Kinesin family member 12	9	114086126-114099291	Predicted intracellular proteins	Evidence at protein level	HPA020192, HPA024127	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 36.6;kidney: 46.9	thyroid gland: 33.0	Cell line enhanced		CACO-2: 6.3;RPTEC TERT1: 31.9;SCLC-21H: 7.6
ATP6V1G1	ATP6G, ATP6G1, ATP6GL, ATP6J, DKFZp547P234, Vma10	ENSG00000136888	ATPase H+ transporting V1 subunit G1	9	114587746-114598373	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004615, HPA042898	Supported		Supported	Nucleus<br>Nucleoli	Renal cancer:1.73e-7 (favourable)	Expressed in all	Expressed in all			epididymis: 301.0	Expressed in all		
TEX10	bA208F1.2, FLJ20287, Ipi1	ENSG00000136891	Testis expressed 10	9	100302077-100352939	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:4.46e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
GARNL3	bA356B19.1, DKFZp761J1523	ENSG00000136895	GTPase activating Rap/RanGAP domain like 3	9	127224265-127393660	Predicted intracellular proteins	Evidence at protein level	HPA022433, HPA028757, HPA074886	Uncertain		Approved	Vesicles		Mixed	Mixed			parathyroid gland: 15.5	Cell line enhanced		SH-SY5Y: 3.7
MRPL50	FLJ20493, MRP-L50	ENSG00000136897	Mitochondrial ribosomal protein L50	9	101387633-101398614	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022925, HPA056854	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.21e-10 (favourable)	Expressed in all	Expressed in all			adrenal gland: 20.8	Expressed in all		
DPM2	MGC111193, MGC21559	ENSG00000136908	Dolichyl-phosphate mannosyltransferase subunit 2, regulatory	9	127935099-127938484	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA064623	Approved				Endometrial cancer:2.20e-4 (favourable), Liver cancer:7.08e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube,stomach: 24.8	Expressed in all		
WDR38		ENSG00000136918	WD repeat domain 38	9	124853417-124857890	Predicted intracellular proteins	Evidence at transcript level	HPA056607	Uncertain				Endometrial cancer:3.97e-4 (favourable)	Tissue enhanced	Tissue enriched	17	fallopian tube: 125.2	lung: 7.3	Not detected		
TSTD2	C9orf97, PP4189	ENSG00000136925	Thiosulfate sulfurtransferase like domain containing 2	9	97600080-97633575	Predicted intracellular proteins	Evidence at protein level	HPA022537, HPA024241, HPA064304	Uncertain		Approved	Nucleoplasm	Renal cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.9	Expressed in all		
GABBR2	GABABR2, GPR51, GPRC3B, HG20	ENSG00000136928	Gamma-aminobutyric acid type B receptor subunit 2	9	98288082-98709197	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013820, HPA031684, CAB079065	Enhanced	Approved				Group enriched	Tissue enriched	18	cerebral cortex: 77.9	adrenal gland: 4.3	Cell line enhanced		BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3
HEMGN	CT155, EDAG, NDR	ENSG00000136929	Hemogen	9	97926791-97944856	Predicted intracellular proteins	Evidence at protein level	HPA019572, HPA019604, HPA019606	Enhanced					Not detected	Group enriched	14	bone marrow: 141.7;testis: 88.2	placenta: 8.1	Group enriched	7	HEL: 54.8;K-562: 247.2
PSMB7		ENSG00000136930	Proteasome subunit beta 7	9	124353466-124415444	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052408, HPA054902	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 236.9	Expressed in all		
NR5A1	AD4BP, ELP, FTZ1, FTZF1, hSF-1, SF-1	ENSG00000136931	Nuclear receptor subfamily 5 group A member 1	9	124481236-124507430	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	6	adrenal gland: 137.7;ovary: 36.3;spleen: 151.6	testis: 19.6	Group enriched	31	HEL: 73.5;Hep G2: 36.2;K-562: 17.7
TRMO	C9orf156, HSPC219	ENSG00000136932	TRNA methyltransferase O	9	97904489-97922570	Predicted intracellular proteins	Evidence at protein level	HPA021281, HPA052197	Approved		Approved	Nucleoplasm	Renal cancer:4.81e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 29.7	Expressed in all		
RABEPK	bA65N13.1, RAB9P40	ENSG00000136933	Rab9 effector protein with kelch motifs	9	125200542-125234158	Predicted intracellular proteins	Evidence at protein level	HPA023920, HPA067106	Enhanced		Uncertain	Plasma membrane		Expressed in all	Expressed in all			liver: 30.6	Expressed in all		
GOLGA1	golgin-97, MGC33154	ENSG00000136935	Golgin A1	9	124878357-124948492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013065, HPA044329, HPA050555	Enhanced		Enhanced	Golgi apparatus	Endometrial cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
XPA	XP1, XPAC	ENSG00000136936	XPA, DNA damage recognition and repair factor	9	97674909-97697357	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB000155, HPA056856	Supported		Approved	Nucleus<br>Cytokinetic bridge	Renal cancer:4.28e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 38.9	Expressed in all		
NCBP1	CBP80, NCBP, Sto1	ENSG00000136937	Nuclear cap binding protein subunit 1	9	97633626-97673748	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042411, HPA049031	Enhanced		Supported	Nucleoplasm<br>Cytosol	Prostate cancer:4.17e-4 (unfavourable), Colorectal cancer:5.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.5	Expressed in all		
ANP32B	APRIL, PHAPI2, SSP29	ENSG00000136938	Acidic nuclear phosphoprotein 32 family member B	9	97983361-98015943	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063133, HPA067561	Supported		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:1.98e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 264.3	Expressed in all		
OR1L4	OR1L5, OR9-E	ENSG00000136939	Olfactory receptor family 1 subfamily L member 4	9	122723990-122724925	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PDCL	DKFZp564M1863, PhLP	ENSG00000136940	Phosducin like	9	122798389-122828631	Predicted intracellular proteins	Evidence at protein level	HPA021571, HPA021647, CAB026473	Uncertain		Supported	Cytosol	Renal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.9	Mixed		
RPL35	L35	ENSG00000136942	Ribosomal protein L35	9	124857880-124861981	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006047	Approved		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 2747.0	Expressed in all		
CTSV	CTSL2, CTSU	ENSG00000136943	Cathepsin V	9	97029679-97039643	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB017112	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 69.3;skin: 64.2;testis: 131.8	placenta: 25.9	Cell line enriched	7	BEWO: 563.7
LMX1B	NPS1	ENSG00000136944	LIM homeobox transcription factor 1 beta	9	126614443-126701032	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073716			Approved	Nucleus		Tissue enriched	Tissue enhanced		breast: 5.8;salivary gland: 11.2	testis: 2.2	Cell line enhanced		MCF7: 13.7;T-47d: 10.1
ARPC5L	ARC16-2, MGC3038	ENSG00000136950	Actin related protein 2/3 complex subunit 5 like	9	124862130-124877733	Predicted intracellular proteins	Evidence at protein level	HPA022013	Approved					Expressed in all	Expressed in all			testis: 75.7	Expressed in all		
ENPP2	ATX, PD-IALPHA, PDNP2	ENSG00000136960	Ectonucleotide pyrophosphatase/phosphodiesterase 2	8	119557086-119673453	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023700, HPA053652	Approved		Approved	Nucleus<br>Golgi apparatus<br>Actin filaments	Pancreatic cancer:2.07e-5 (favourable)	Expressed in all	Expressed in all			placenta: 376.2	Cell line enhanced		ASC TERT1: 231.1;BJ hTERT+: 160.8
DSCC1	DCC1, hDCC1, MGC5528	ENSG00000136982	DNA replication and sister chromatid cohesion 1	8	119833976-119856010	Predicted intracellular proteins	Evidence at protein level	HPA023780, HPA024401	Uncertain		Approved	Nucleoplasm	Liver cancer:3.92e-6 (unfavourable), Lung cancer:3.93e-4 (unfavourable), Melanoma:5.73e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 7.9	Expressed in all		
DERL1	DER-1, DER1, derlin-1, FLJ13784, MGC3067, PRO2577	ENSG00000136986	Derlin 1	8	123013164-123042423	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016562, CAB037269	Enhanced		Enhanced	Endoplasmic reticulum	Endometrial cancer:5.66e-5 (unfavourable), Renal cancer:1.58e-4 (unfavourable), Breast cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 76.8	Expressed in all		
MYC	bHLHe39, c-Myc, MYCC	ENSG00000136997	V-myc avian myelocytomatosis viral oncogene homolog	8	127735434-127741434	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000084, CAB010307, HPA055893, HPA066556	Supported		Enhanced	Nucleoplasm	Renal cancer:5.49e-8 (unfavourable), Urothelial cancer:4.96e-5 (unfavourable), Ovarian cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 151.6	Expressed in all		
NOV	CCN3, IGFBP9	ENSG00000136999	Nephroblastoma overexpressed	8	119416306-119424353	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018449, HPA019684, CAB034423	Enhanced		Supported	Vesicles		Expressed in all	Tissue enriched	39	adrenal gland: 1392.1	prostate: 35.4	Cell line enhanced		BJ hTERT+: 99.0;U-2197: 116.0
IL33	C9orf26, DKFZp586H0523, DVS27, IL1F11, NF-HEV	ENSG00000137033	Interleukin 33	9	6215786-6257983	Predicted intracellular proteins	Evidence at protein level	CAB007057, HPA024426	Supported				Breast cancer:4.42e-4 (favourable)	Expressed in all	Mixed			placenta: 87.7	Cell line enriched	10	U-2197: 151.4
TMEM261	C9orf123, MGC4730	ENSG00000137038	Transmembrane protein 261	9	7796490-7888380	Predicted membrane proteins	Evidence at protein level	HPA014585	Approved				Renal cancer:1.96e-11 (favourable), Endometrial cancer:4.15e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.3	Expressed in all		
RANBP6		ENSG00000137040	RAN binding protein 6	9	6011043-6015625	Predicted intracellular proteins	Evidence at protein level	HPA043748, HPA052684	Approved		Supported	Vesicles	Renal cancer:1.34e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.2	Expressed in all		
POLR1E	FLJ13390, FLJ13970, PAF53, PRAF1	ENSG00000137054	RNA polymerase I subunit E	9	37485935-37503697	Predicted intracellular proteins, Predicted membrane proteins, RNA polymerase related proteins	Evidence at protein level	HPA022527, HPA052400	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Breast cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			ovary: 51.5	Expressed in all		
PLAA	DOA1, FLJ11281, FLJ12699, PLA2P, PLAP	ENSG00000137055	Phospholipase A2 activating protein	9	26904083-26947463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005035, HPA020994, HPA020996	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.9	Mixed		
IL11RA		ENSG00000137070	Interleukin 11 receptor subunit alpha	9	34650702-34661892	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013162, CAB032830, HPA036652	Supported				Renal cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Mixed		
UBAP2	bA176F3.5, FLJ22435, KIAA1491	ENSG00000137073	Ubiquitin associated protein 2	9	33921693-34048949	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021684	Approved		Approved	Cytosol	Liver cancer:3.45e-6 (unfavourable), Renal cancer:1.95e-4 (favourable), Ovarian cancer:8.59e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.6	Expressed in all		
APTX	AOA, AOA1, AXA1, EAOH, EOAHA, FLJ20157	ENSG00000137074	Aprataxin	9	32972606-33025168	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064930	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:6.01e-5 (favourable)	Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
RNF38		ENSG00000137075	Ring finger protein 38	9	36336396-36487548	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015853	Approved		Supported	Nucleoplasm	Renal cancer:2.90e-6 (favourable)	Expressed in all	Expressed in all			testis: 116.8	Expressed in all		
TLN1	ILWEQ, TLN	ENSG00000137076	Talin 1	9	35696948-35732395	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002006, HPA004748	Supported		Supported	Plasma membrane<br>Focal adhesion sites<br>Microtubule organizing center<br>Cytosol	Colorectal cancer:5.56e-4 (unfavourable), Renal cancer:7.21e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 204.8	Expressed in all		
CCL21	6Ckine, CKb9, ECL, exodus-2, SCYA21, SLC, TCA4	ENSG00000137077	C-C motif chemokine ligand 21	9	34709005-34710124	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB005067, HPA051210	Enhanced					Mixed	Tissue enhanced		lymph node: 3155.9	tonsil: 946.7	Cell line enhanced		K-562: 1.0
SIT1	SIT	ENSG00000137078	Signaling threshold regulating transmembrane adaptor 1	9	35649295-35650950	Predicted membrane proteins	Evidence at protein level	HPA018506	Enhanced				Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable)	Mixed	Group enriched	5	appendix: 24.6;lymph node: 56.1;spleen: 21.9;tonsil: 29.6	urinary bladder: 6.0	Cell line enhanced		Daudi: 80.3;HDLM-2: 65.0;U-698: 70.1
IFNA21	IFN-alphaI	ENSG00000137080	Interferon alpha 21	9	21165637-21166660	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			lymph node: 0.1	Not detected		
DMRT1	CT154, DMT1	ENSG00000137090	Doublesex and mab-3 related transcription factor 1	9	841690-969090	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027850	Enhanced					Tissue enriched	Tissue enriched	107	testis: 50.7	thyroid gland: 0.4	Cell line enriched	8	SCLC-21H: 3.8
DNAJB5	Hsc40	ENSG00000137094	DnaJ heat shock protein family (Hsp40) member B5	9	34989641-34998900	Predicted intracellular proteins	Evidence at protein level	HPA023818, HPA050794	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			smooth muscle: 92.2	Mixed		
SPAG8	BS-84, CT142, HSD-1, hSMP-1, SPAG3	ENSG00000137098	Sperm associated antigen 8	9	35808045-35812272	Predicted intracellular proteins	Evidence at protein level	HPA068012	Enhanced				Endometrial cancer:2.15e-4 (favourable)	Mixed	Group enriched	10	fallopian tube: 28.6;testis: 16.3	thyroid gland: 2.2	Not detected		
DCTN3	DCTN-22	ENSG00000137100	Dynactin subunit 3	9	34613545-34620523	Predicted intracellular proteins	Evidence at protein level	HPA044905	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:5.76e-11 (favourable), Ovarian cancer:2.10e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 129.7	Expressed in all		
CD72	CD72b, LYB2	ENSG00000137101	CD72 molecule	9	35609533-35646810	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002505, HPA044658	Enhanced		Approved	Nucleus<br>Mitochondria	Renal cancer:2.49e-8 (unfavourable)	Expressed in all	Group enriched	8	appendix: 25.1;lymph node: 71.1;spleen: 64.7;tonsil: 42.6	gallbladder: 6.2	Cell line enhanced		Daudi: 13.0;Karpas-707: 8.1;REH: 7.0;U-698: 27.7
TMEM8B	C9orf127, NAG-5, NGX6	ENSG00000137103	Transmembrane protein 8B	9	35814451-35854847	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052130, HPA062701	Approved		Approved	Vesicles	Renal cancer:1.89e-15 (favourable), Pancreatic cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Mixed		
GRHPR	GLXR, PH2	ENSG00000137106	Glyoxylate and hydroxypyruvate reductase	9	37422666-37436990	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022971	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.39e-9 (favourable), Breast cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			liver: 323.3	Expressed in all		
ALDH1B1	ALDH5, ALDHX	ENSG00000137124	Aldehyde dehydrogenase 1 family member B1	9	38392664-38398661	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021037	Approved		Supported	Nucleoplasm<br>Vesicles<br>Mitochondria	Thyroid cancer:1.17e-5 (unfavourable), Renal cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 178.4	Mixed		
HINT2		ENSG00000137133	Histidine triad nucleotide binding protein 2	9	35812960-35815354	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA020961, HPA059109	Enhanced		Enhanced	Mitochondria	Renal cancer:2.97e-9 (favourable), Ovarian cancer:1.66e-4 (favourable)	Expressed in all	Expressed in all			kidney: 83.2	Expressed in all		
ARHGEF39	C9orf100, FLJ14642	ENSG00000137135	Rho guanine nucleotide exchange factor 39	9	35658875-35675866	Predicted intracellular proteins	Evidence at protein level	HPA061299	Uncertain				Ovarian cancer:4.48e-4 (favourable)	Mixed	Mixed			lymph node: 2.3	Mixed		
IGFBPL1	bA113O24.1	ENSG00000137142	Insulin like growth factor binding protein like 1	9	38408994-38424447	Predicted secreted proteins	Evidence at protein level	HPA051354	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	8	thyroid gland: 31.5	cerebral cortex: 3.9	Group enriched	6	AF22: 359.4;NTERA-2: 100.5;RH-30: 101.1;SCLC-21H: 438.6;SH-SY5Y: 383.3
DENND4C	bA513M16.3, C9orf55, C9orf55B, FLJ20686, RAB10GEF	ENSG00000137145	DENN domain containing 4C	9	19230435-19373545	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014917, HPA015096	Approved		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:3.51e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.6	Expressed in all		
RPS6	S6	ENSG00000137154	Ribosomal protein S6	9	19375715-19380254	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB004027, HPA031153	Supported		Enhanced	Endoplasmic reticulum<br>Cytosol	Endometrial cancer:4.12e-4 (favourable)	Expressed in all	Expressed in all			ovary: 4805.4	Expressed in all		
CNPY3	CAG4A, TNRC5	ENSG00000137161	Canopy FGF signaling regulator 3	6	42929192-42939287	Predicted secreted proteins	Evidence at protein level	HPA016560	Uncertain				Renal cancer:9.85e-6 (unfavourable), Colorectal cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 103.1	Expressed in all		
FOXP4	FLJ40908	ENSG00000137166	Forkhead box P4	6	41546426-41602384	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007176	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.17e-6 (unfavourable), Liver cancer:9.72e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 36.9	Expressed in all		
PPIL1	CYPL1	ENSG00000137168	Peptidylprolyl isomerase like 1	6	36854827-36875024	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062916			Approved	Nucleoli	Liver cancer:1.28e-5 (unfavourable), Ovarian cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.0	Expressed in all		
KLC4	bA387M24.3, KNSL8	ENSG00000137171	Kinesin light chain 4	6	43040777-43075099	Predicted intracellular proteins	Evidence at protein level	HPA030168, HPA030169	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:6.99e-6 (favourable)	Expressed in all	Expressed in all			duodenum: 70.0	Expressed in all		
KIF13A	bA500C11.2	ENSG00000137177	Kinesin family member 13A	6	17759183-17987623	Predicted intracellular proteins	Evidence at protein level	HPA029253, HPA029254	Uncertain				Liver cancer:5.06e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.3	Mixed		
ZSCAN9	PRD51, ZNF193	ENSG00000137185	Zinc finger and SCAN domain containing 9	6	28224886-28233482	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054512, HPA059951	Uncertain		Approved	Nucleoplasm	Renal cancer:1.21e-6 (unfavourable), Urothelial cancer:1.16e-5 (favourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.8	Mixed		
PIM1	PIM	ENSG00000137193	Pim-1 proto-oncogene, serine/threonine kinase	6	37170203-37175426	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003941, CAB017040	Uncertain		Supported	Nucleoli<br>Cytosol	Endometrial cancer:9.73e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 133.9	Expressed in all		
GMPR		ENSG00000137198	Guanosine monophosphate reductase	6	16238580-16295549	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000904, HPA021476	Uncertain				Renal cancer:2.94e-5 (favourable), Ovarian cancer:2.06e-4 (favourable), Lung cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 105.7	Cell line enhanced		HEL: 171.8;HMC-1: 275.3
CMTR1	FTSJD2, ISG95, KIAA0082, MTr1	ENSG00000137200	Cap methyltransferase 1	6	37433219-37482827	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029954, HPA029979, HPA029980	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 85.5	Expressed in all		
TFAP2A	AP-2, AP2TF, TFAP2	ENSG00000137203	Transcription factor AP-2 alpha	6	10393186-10419659	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000326, HPA028850, HPA056871	Enhanced		Enhanced	Nucleoplasm	Lung cancer:1.09e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		breast: 40.0;placenta: 42.3;skin: 76.1	epididymis: 24.9	Cell line enhanced		HDLM-2: 103.3
SLC22A7	NLT, OAT2	ENSG00000137204	Solute carrier family 22 member 7	6	43295694-43305538	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030220	Approved				Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable)	Tissue enriched	Group enriched	73	kidney: 50.3;liver: 167.8	testis: 1.4	Cell line enriched	14	Hep G2: 6.7
YIPF3	C6orf109, dJ337H4.3, DKFZp566C243, FinGER3, KLIP1	ENSG00000137207	Yip1 domain family member 3	6	43511827-43516990	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014859, HPA063699	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 142.8	Expressed in all		
TMEM14B	MGC1223	ENSG00000137210	Transmembrane protein 14B	6	10747759-10852753	Predicted membrane proteins	Evidence at protein level						Liver cancer:9.35e-5 (unfavourable), Endometrial cancer:6.51e-4 (unfavourable), Ovarian cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 205.0	Expressed in all		
TMEM63B	C6orf110, dJ421H19.2, DKFZp434P0531	ENSG00000137216	Transmembrane protein 63B	6	44126914-44155519	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029249, HPA029250, HPA029251	Uncertain		Enhanced	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			lung: 59.0	Expressed in all		
FRS3	FRS2B, FRS2beta, SNT-2	ENSG00000137218	Fibroblast growth factor receptor substrate 3	6	41770176-41786542	Predicted intracellular proteins	Evidence at protein level	HPA030162, HPA030174	Enhanced		Uncertain	Nucleoplasm	Pancreatic cancer:3.87e-4 (favourable)	Expressed in all	Mixed			testis: 22.0	Expressed in all		
TJAP1	PILT, TJP4	ENSG00000137221	Tight junction associated protein 1	6	43477523-43506556	Predicted intracellular proteins	Evidence at protein level	HPA030164, HPA030165, HPA030166	Supported		Approved	Golgi apparatus	Liver cancer:9.02e-6 (unfavourable), Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 33.8	Expressed in all		
CAPN11		ENSG00000137225	Calpain 11	6	44158811-44184402	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018070, HPA030955	Enhanced					Not detected	Tissue enriched	33	testis: 54.8	adipose tissue,breast: 1.6	Group enriched	5	NTERA-2: 2.2;TIME: 4.7
TINAG		ENSG00000137251	Tubulointerstitial nephritis antigen	6	54307859-54390152	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035427	Approved				Liver cancer:2.05e-5 (unfavourable), Renal cancer:8.75e-5 (favourable)	Tissue enhanced	Tissue enriched	7	kidney: 113.9	small intestine: 15.7	Cell line enriched	36	RPTEC TERT1: 69.3
HCRTR2	OX2R	ENSG00000137252	Hypocretin receptor 2	6	55106460-55282620	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA054516	Supported					Not detected	Not detected			kidney: 0.6	Cell line enriched	7	AF22: 1.0
KIAA0319	NMIG	ENSG00000137261	KIAA0319	6	24544104-24646155	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015607, HPA076313	Enhanced		Uncertain	Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 15.8	fallopian tube: 2.8	Cell line enhanced		HDLM-2: 2.6;SCLC-21H: 5.1;U-266/84: 2.6
IRF4	LSIRF, MUM1	ENSG00000137265	Interferon regulatory factor 4	6	391739-411447	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002038, HPA002698, CAB013508	Enhanced		Supported	Nucleoplasm	Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 27.1	tonsil: 24.1	Group enriched	5	HDLM-2: 204.2;Karpas-707: 141.1;RPMI-8226: 136.6;U-266/70: 134.4;U-266/84: 98.3;U-698: 40.9;WM-115: 106.9
SLC22A23	C6orf85, FLJ22174	ENSG00000137266	Solute carrier family 22 member 23	6	3268962-3457022	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014697	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			stomach: 27.9	Mixed		
TUBB2A	dJ40E16.7, TUBB, TUBB2	ENSG00000137267	Tubulin beta 2A class IIa	6	3153669-3157526	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015339, HPA043640, HPA046280	Supported		Supported	Microtubules	Urothelial cancer:1.61e-4 (unfavourable), Renal cancer:4.65e-4 (favourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 622.8	skin: 72.0	Expressed in all		
LRRC1	dJ523E19.1, FLJ10775, FLJ11834, LANO	ENSG00000137269	Leucine rich repeat containing 1	6	53794497-53924121	Predicted intracellular proteins	Evidence at protein level	HPA031603, HPA031604	Enhanced		Supported	Cytosol	Renal cancer:2.21e-7 (favourable), Pancreatic cancer:1.18e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 41.9	Mixed		
GCM1	GCMA, hGCMa	ENSG00000137270	Glial cells missing homolog 1	6	53126964-53148829	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA011343	Enhanced		Approved	Vesicles		Not detected	Tissue enriched	21	placenta: 29.1	kidney: 1.3	Cell line enriched	25	BEWO: 38.0
FOXF2	FKHL6, FREAC2	ENSG00000137273	Forkhead box F2	6	1389834-1395597	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			lung: 18.4	Cell line enhanced		BJ hTERT+: 64.9;HEK 293: 24.6;U-2197: 30.0
BPHL	Bph-rp, MCNAA, VACVase	ENSG00000137274	Biphenyl hydrolase like	6	3118374-3153578	Predicted intracellular proteins	Evidence at protein level	HPA036752, HPA036753	Enhanced		Supported	Mitochondria	Renal cancer:5.16e-7 (favourable), Ovarian cancer:5.97e-4 (favourable)	Expressed in all	Expressed in all			kidney: 112.2	Expressed in all		
RIPK1	RIP	ENSG00000137275	Receptor interacting serine/threonine kinase 1	6	3063991-3115187	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010302, HPA015257	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			skin: 26.1	Expressed in all		
TUBB2B	bA506K6.1, DKFZp566F223, MGC8685	ENSG00000137285	Tubulin beta 2B class IIb	6	3224261-3231730	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Supported				Endometrial cancer:1.94e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 308.7	epididymis: 51.8	Cell line enhanced		AF22: 504.0;CACO-2: 319.1;SCLC-21H: 896.6;SH-SY5Y: 392.2
UQCC2	bA6B20.2, C6orf125, Cbp6, M19, MGC14833, MNF1	ENSG00000137288	Ubiquinol-cytochrome c reductase complex assembly factor 2	6	33694293-33711727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039111	Uncertain		Supported	Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			testis: 131.3	Expressed in all		
HMGA1	HMGIY	ENSG00000137309	High mobility group AT-hook 1	6	34236873-34246231	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032200	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:1.29e-6 (unfavourable), Lung cancer:3.36e-4 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable), Pancreatic cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 163.8	Expressed in all		
TCF19	SC1	ENSG00000137310	Transcription factor 19	6	31158542-31167159	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.54e-10 (unfavourable), Liver cancer:5.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 11.3	skin: 6.7	Cell line enhanced		A-431: 72.1;HEK 293: 41.2;SCLC-21H: 57.4;U-138 MG: 47.7
FLOT1		ENSG00000137312	Flotillin 1	6	30727709-30742733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001393, CAB007766	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:1.49e-4 (unfavourable), Ovarian cancer:3.06e-4 (favourable), Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 18.9	Expressed in all		
IER3	DIF-2, IEX-1, IEX-1L, PRG1	ENSG00000137331	Immediate early response 3	6	30743199-30744554	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043847	Approved				Renal cancer:3.10e-7 (unfavourable), Liver cancer:6.36e-5 (unfavourable), Head and neck cancer:5.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 20.7	adipose tissue: 11.4	Group enriched	6	A-431: 133.8;EFO-21: 51.6;HBEC3-KT: 133.4;RPTEC TERT1: 150.4
MDC1	Em:AB023051.5, KIAA0170, NFBD1	ENSG00000137337	Mediator of DNA damage checkpoint 1	6	30699807-30717889	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006915	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Tissue enhanced		testis: 9.6	skin: 3.3	Cell line enhanced		A-431: 21.4;HEK 293: 41.5
PGBD1	dJ874C20.4, HUCEP-4, SCAND4	ENSG00000137338	PiggyBac transposable element derived 1	6	28281572-28302549	Predicted intracellular proteins	Evidence at protein level	HPA007267	Uncertain		Approved	Nucleoplasm<br>Cytosol	Melanoma:1.71e-4 (unfavourable), Liver cancer:3.77e-4 (unfavourable), Renal cancer:4.97e-4 (unfavourable), Pancreatic cancer:6.79e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 7.9	Mixed		
ATAT1	C6orf134, Em:AB023049.7, FLJ13158, MEC17	ENSG00000137343	Alpha tubulin acetyltransferase 1	6	30626842-30646823	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046816, HPA050999	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:1.03e-5 (unfavourable), Renal cancer:7.78e-5 (unfavourable), Urothelial cancer:1.35e-4 (favourable)	Expressed in all	Mixed			epididymis: 4.4	Cell line enhanced		AF22: 7.3
TPMT		ENSG00000137364	Thiopurine S-methyltransferase	6	18128311-18155074	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019851	Approved				Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 129.8	Expressed in all		
CLPS		ENSG00000137392	Colipase	6	35794982-35797344	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010512	Enhanced					Tissue enriched	Tissue enriched	264	pancreas: 56632.1	ovary: 214.3	Not detected		
RNF144B	bA528A10.3, IBRDC2	ENSG00000137393	Ring finger protein 144B	6	18387350-18468874	Predicted membrane proteins	Evidence at protein level	CAB046013, HPA054127, HPA072469	Uncertain		Approved	Nucleoli<br>Mitochondria		Expressed in all	Tissue enhanced		thyroid gland: 68.1	breast: 35.0	Cell line enhanced		Daudi: 137.5;U-698: 110.9
NRM	NRM29	ENSG00000137404	Nurim (nuclear envelope membrane protein)	6	30688047-30691420	Predicted membrane proteins	Evidence at protein level	HPA072545, HPA073982			Enhanced	Nuclear membrane	Renal cancer:3.52e-8 (unfavourable)	Expressed in all	Mixed			skin,smooth muscle: 1.6	Mixed		
MTCH1	CGI-64, PSAP, SLC25A49	ENSG00000137409	Mitochondrial carrier 1	6	36968141-36986298	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015971	Approved				Renal cancer:1.16e-7 (favourable), Liver cancer:1.17e-4 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 569.1	Expressed in all		
VARS2	DKFZP434L1435, G7a, KIAA1885, VARS2L, VARSL	ENSG00000137411	Valyl-tRNA synthetase 2, mitochondrial	6	30908242-30926459	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA062449, HPA070267	Approved		Approved	Mitochondria		Expressed in all	Mixed			esophagus: 5.2	Mixed		
TAF8	FLJ32821, TAF(II)43, TBN	ENSG00000137413	TATA-box binding protein associated factor 8	6	42050513-42087461	Predicted intracellular proteins	Evidence at protein level	HPA031730, HPA031731, HPA031734	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 24.3	Expressed in all		
FAM8A1	AHCP	ENSG00000137414	Family with sequence similarity 8 member A1	6	17600355-17611719	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044698, HPA073675	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			endometrium: 45.5	Expressed in all		
C6orf52		ENSG00000137434	Chromosome 6 open reading frame 52	6	10671418-10694797	Predicted intracellular proteins	Evidence at transcript level	HPA051142	Uncertain		Approved	Nuclear speckles	Endometrial cancer:6.50e-5 (favourable)	Mixed	Tissue enhanced		testis: 18.0	fallopian tube: 10.5	Mixed		
FGFBP1	FGFBP, HBP17	ENSG00000137440	Fibroblast growth factor binding protein 1	4	15935569-15938740	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA004332	Enhanced				Pancreatic cancer:5.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 297.8	skin: 40.2	Cell line enhanced		CAPAN-2: 164.8;HaCaT: 489.2;HBEC3-KT: 688.5
FGFBP2	KSP37	ENSG00000137441	Fibroblast growth factor binding protein 2	4	15960243-15969309	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA039180	Uncertain					Group enriched	Tissue enhanced		bone marrow: 29.0	spleen: 18.0	Cell line enhanced		SK-MEL-30: 4.8;T-47d: 2.8;WM-115: 1.2
CPEB2		ENSG00000137449	Cytoplasmic polyadenylation element binding protein 2	4	15002674-15070153	Predicted intracellular proteins	Evidence at protein level	HPA072513			Approved	Cytosol		Expressed in all	Tissue enhanced		testis: 41.7	parathyroid gland: 20.5	Cell line enhanced		RPTEC TERT1: 26.5
FHDC1	KIAA1727	ENSG00000137460	FH2 domain containing 1	4	152936352-152979696	Predicted intracellular proteins	Evidence at protein level	HPA008527	Uncertain				Renal cancer:1.33e-5 (favourable)	Mixed	Tissue enhanced		thyroid gland: 26.8	lung: 12.9	Cell line enhanced		BEWO: 29.6;SK-BR-3: 10.8;WM-115: 10.5
TLR2	CD282, TIL4	ENSG00000137462	Toll like receptor 2	4	153701500-153705699	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA060231, HPA071546			Supported	Nucleus<br>Mitochondria	Renal cancer:1.11e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 52.7	bone marrow: 34.8	Cell line enhanced		RT4: 8.5;THP-1: 25.3
MGARP	C4orf49, CESP-1, HUMMR, OSAP	ENSG00000137463	Mitochondria localized glutamic acid rich protein	4	139266163-139280338	Predicted membrane proteins	Evidence at protein level	HPA015994	Enhanced		Supported	Mitochondria		Tissue enhanced	Tissue enriched	10	adrenal gland: 267.2	ovary: 27.1	Cell line enhanced		BJ: 15.5;fHDF/TERT166: 21.3;HHSteC: 17.8;HUVEC TERT2: 46.0
TTC29	NYD-SP14	ENSG00000137473	Tetratricopeptide repeat domain 29	4	146706638-146945882	Predicted intracellular proteins	Evidence at protein level	HPA037006, HPA061473	Uncertain					Tissue enhanced	Group enriched	27	fallopian tube: 34.2;testis: 151.1	lung: 3.4	Cell line enhanced		ASC TERT1: 3.4;hTERT-HME1: 1.2;U-266/70: 1.6;U-87 MG: 1.0
MYO7A	DFNA11, DFNB2, NSRD2, USH1B	ENSG00000137474	Myosin VIIA	11	77128264-77215239	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028918, CAB034059	Uncertain		Approved	Cytosol	Renal cancer:3.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 26.8;placenta: 20.8	testis: 17.2	Cell line enhanced		BEWO: 11.1;RH-30: 20.1;RPMI-8226: 9.7;SK-BR-3: 8.1;U-937: 11.1
FCHSD2	KIAA0769, SH3MD3	ENSG00000137478	FCH and double SH3 domains 2	11	72836745-73142261	Predicted intracellular proteins	Evidence at protein level	HPA038545, HPA038546	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 64.1	Expressed in all		
ARRB1	ARR1	ENSG00000137486	Arrestin beta 1	11	75264182-75351705	Predicted intracellular proteins	Evidence at protein level	CAB003763, HPA049318, HPA070249	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			lung: 80.4	Cell line enhanced		HEL: 151.4;RH-30: 109.6
SLCO2B1	OATP-B, OATP2B1, SLC21A9	ENSG00000137491	Solute carrier organic anion transporter family member 2B1	11	75100563-75206549	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020659	Uncertain					Expressed in all	Expressed in all			liver: 123.1	Cell line enhanced		CACO-2: 75.7;HEL: 13.5;Hep G2: 14.2;HMC-1: 23.5
THAP12	DAP4, P52rIPK, PRKRIR, THAP0	ENSG00000137492	THAP domain containing 12	11	76349956-76380971	Plasma proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA008758	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 42.8	Expressed in all		
ANKRD42	FLJ37874, PPP1R79, SARP	ENSG00000137494	Ankyrin repeat domain 42	11	83193739-83260694	Predicted intracellular proteins	Evidence at protein level	HPA039917	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		testis: 71.5	fallopian tube: 26.2	Expressed in all		
IL18BP	IL18BPa	ENSG00000137496	Interleukin 18 binding protein	11	71998541-72005715	Predicted secreted proteins	Evidence at protein level	CAB025980, HPA041061	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:2.93e-6 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 56.2	appendix: 32.8	Mixed		
NUMA1		ENSG00000137497	Nuclear mitotic apparatus protein 1	11	72002864-72080693	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019841, HPA019859, HPA029912	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 247.9	Expressed in all		
CCDC90B	MDS011, MDS025	ENSG00000137500	Coiled-coil domain containing 90B	11	83259097-83286407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011130, HPA011931	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			testis: 97.8	Expressed in all		
SYTL2	CHR11SYT, exophilin-4, FLJ20163, FLJ21219, KIAA1597, MGC102768, PPP1R151, SGA72M, SLP2	ENSG00000137501	Synaptotagmin like 2	11	85694224-85811159	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039651	Approved		Approved	Nucleus<br>Golgi apparatus<br>Plasma membrane	Colorectal cancer:2.67e-4 (favourable), Urothelial cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		stomach: 120.5	rectum: 81.4	Cell line enhanced		RH-30: 170.2;RPTEC TERT1: 95.1
RAB30		ENSG00000137502	RAB30, member RAS oncogene family	11	82973133-83071923	Predicted intracellular proteins	Evidence at protein level	HPA054514, HPA060565	Approved		Enhanced	Vesicles		Expressed in all	Expressed in all			cerebral cortex,tonsil: 28.4	Cell line enhanced		U-698: 116.4
CREBZF	ZF	ENSG00000137504	CREB/ATF bZIP transcription factor	11	85659708-85682908	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021526, HPA063652	Uncertain		Approved	Nucleus<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 31.7	Expressed in all		
LRRC32	D11S833E, GARP	ENSG00000137507	Leucine rich repeat containing 32	11	76657524-76670747	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055775, HPA058434			Supported	Nucleoplasm	Renal cancer:3.93e-5 (unfavourable), Urothelial cancer:2.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 76.4	Group enriched	5	ASC diff: 78.8;ASC TERT1: 49.2;HSkMC: 32.0;HUVEC TERT2: 43.0;U-2197: 100.6
PRCP	HUMPCP, PCP	ENSG00000137509	Prolylcarboxypeptidase	11	82823502-82970584	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017065	Approved				Renal cancer:2.65e-6 (favourable)	Expressed in all	Expressed in all			placenta: 222.7	Expressed in all		
NARS2	DFNB94, FLJ23441, SLM5	ENSG00000137513	Asparaginyl-tRNA synthetase 2, mitochondrial (putative)	11	78435961-78574874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026793	Supported		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:1.22e-6 (favourable), Ovarian cancer:1.39e-5 (favourable)	Expressed in all	Expressed in all			kidney: 19.8	Expressed in all		
RNF121	FLJ11099	ENSG00000137522	Ring finger protein 121	11	71928701-71997597	Predicted membrane proteins	Evidence at protein level	HPA046041	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.72e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.5	Expressed in all		
MRPL15	HSPC145, L15mt, MRP-L15, MRP-L7, RPML7	ENSG00000137547	Mitochondrial ribosomal protein L15	8	54135210-54147901	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA044425	Enhanced				Endometrial cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 84.8	Expressed in all		
PI15	P25TI	ENSG00000137558	Peptidase inhibitor 15	8	74824537-74855029	Predicted secreted proteins	Evidence at protein level	HPA006593, HPA030057	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		appendix: 73.2;prostate: 50.5;smooth muscle: 67.8	endometrium: 33.0	Group enriched	9	AF22: 21.0;SH-SY5Y: 22.2;SK-MEL-30: 22.4;U-266/70: 5.5
TTPA	AVED	ENSG00000137561	Alpha tocopherol transfer protein	8	63048553-63086053	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	17	liver: 82.7	rectum: 4.8	Cell line enhanced		SK-BR-3: 4.7;U-2 OS: 3.3;U-2197: 3.6
GGH		ENSG00000137563	Gamma-glutamyl hydrolase	8	63015079-63039171	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019296, HPA025226	Approved				Endometrial cancer:3.99e-7 (unfavourable), Lung cancer:1.65e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 90.0	liver: 63.2	Mixed		
SLCO5A1	OATP-J, OATP5A1, OATPRP4, SLC21A15	ENSG00000137571	Solute carrier organic anion transporter family member 5A1	8	69667047-69835064	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA025062	Uncertain					Mixed	Tissue enhanced		prostate: 3.6	skeletal muscle: 2.6	Cell line enhanced		HAP1: 5.7;NTERA-2: 3.6;RPMI-8226: 2.5;SCLC-21H: 4.6
SULF1	hSulf-1, KIAA1077, SULF-1	ENSG00000137573	Sulfatase 1	8	69466624-69660915	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054728	Supported				Renal cancer:1.06e-7 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 105.4	prostate: 85.8	Cell line enhanced		BJ: 265.6;BJ hTERT+: 341.5;fHDF/TERT166: 405.6;WM-115: 176.0
TGS1	NCOA6IP, PIMT	ENSG00000137574	Trimethylguanosine synthase 1	8	55773142-55825448	Predicted intracellular proteins	Evidence at protein level	HPA025024, HPA029824	Supported		Enhanced	Nucleus<br>Cytosol	Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.3	Expressed in all		
SDCBP	MDA-9, SYCL	ENSG00000137575	Syndecan binding protein	8	58552924-58582860	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012245, HPA023840	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			placenta: 365.1	Mixed		
NEK1	KIAA1901, NY-REN-55	ENSG00000137601	NIMA related kinase 1	4	169392857-169612629	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020873, HPA040413	Approved		Approved	Nuclear membrane<br>Nucleoli	Renal cancer:1.42e-4 (favourable)	Expressed in all	Mixed			testis: 21.8	Expressed in all		
DDX60	FLJ20035	ENSG00000137628	DExD/H-box helicase 60	4	168216293-168318807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046952	Approved		Supported	Intermediate filaments<br>Cytosol	Pancreatic cancer:3.35e-4 (unfavourable)	Expressed in all	Mixed			stomach: 45.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 35.0;BJ hTERT+ SV40 Large T+ RasG12V: 35.2
NXPE4	C11orf33, FAM55D, FLJ20127	ENSG00000137634	Neurexophilin and PC-esterase domain family member 4	11	114570591-114595762	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042801	Approved					Tissue enriched	Group enriched	9	colon: 139.6;rectum: 158.4;salivary gland: 38.2	appendix: 11.9	Not detected		
SORL1	C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1	ENSG00000137642	Sortilin related receptor 1	11	121452203-121633693	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011500, HPA031321	Uncertain		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:1.80e-7 (favourable)	Expressed in all	Mixed			cervix, uterine: 67.8	Cell line enhanced		CAPAN-2: 125.3;RT4: 81.2;U-698: 97.2
TMPRSS4	MT-SP2, TMPRSS3	ENSG00000137648	Transmembrane protease, serine 4	11	118077012-118121890	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006238	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.14e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 77.1;urinary bladder: 77.3	esophagus: 73.8	Group enriched	9	A-431: 25.3;CAPAN-2: 123.9;HaCaT: 53.5;RPTEC TERT1: 73.7;RT4: 99.4
BUD13	Cwc26, fSAP71, MGC13125	ENSG00000137656	BUD13 homolog	11	116748170-116772988	Predicted intracellular proteins	Evidence at protein level	HPA038340, HPA038341	Enhanced		Enhanced	Nucleus	Liver cancer:5.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
TRPC6	FSGS2, TRP6	ENSG00000137672	Transient receptor potential cation channel subfamily C member 6	11	101451564-101872562	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA045098, HPA062164	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		placenta: 30.1	lung: 20.0	Cell line enhanced		A549: 4.4;ASC diff: 6.0;BJ hTERT+: 3.9;HEL: 4.3;RPTEC TERT1: 16.5
MMP7	MPSL1, PUMP-1	ENSG00000137673	Matrix metallopeptidase 7	11	102520508-102530753	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025869, HPA051358	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 820.8	breast: 201.7	Cell line enhanced		A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMP20		ENSG00000137674	Matrix metallopeptidase 20	11	102576835-102625332	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.1	appendix,breast,kidney,tonsil: 0.1	Not detected		
MMP27		ENSG00000137675	Matrix metallopeptidase 27	11	102691487-102705806	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA069097	Approved					Not detected	Group enriched	5	breast: 6.0;skin: 2.8	bone marrow: 0.8	Not detected		
C11orf70	MGC13040	ENSG00000137691	Chromosome 11 open reading frame 70	11	102047443-102084560	Predicted intracellular proteins	Evidence at protein level	HPA038585	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		fallopian tube: 46.5;testis: 54.7	epididymis: 13.1	Mixed		
DCUN1D5	FLJ32431, MGC2714	ENSG00000137692	Defective in cullin neddylation 1 domain containing 5	11	103062076-103092215	Predicted intracellular proteins	Evidence at protein level	HPA050863	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:2.01e-7 (unfavourable), Ovarian cancer:9.52e-5 (favourable), Prostate cancer:4.12e-4 (unfavourable), Head and neck cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.6	Mixed		
YAP1	YAP65	ENSG00000137693	Yes associated protein 1	11	102110461-102233423	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009370, HPA038885, CAB069915, HPA070359	Enhanced		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 147.1	Mixed		
TRIM29	ATDC, FLJ36085	ENSG00000137699	Tripartite motif containing 29	11	120111275-120185529	Predicted intracellular proteins	Evidence at protein level	HPA020053	Enhanced		Supported	Nucleoplasm<br>Intermediate filaments	Endometrial cancer:2.88e-4 (unfavourable), Pancreatic cancer:4.46e-4 (unfavourable), Stomach cancer:4.93e-4 (favourable)	Tissue enhanced	Group enriched	6	esophagus: 400.3;skin: 455.7	tonsil: 68.3	Cell line enhanced		HaCaT: 211.2;hTCEpi: 225.5;RT4: 101.2;SiHa: 190.1
SLC37A4	G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d	ENSG00000137700	Solute carrier family 37 member 4	11	119024114-119030906	Predicted membrane proteins	Evidence at protein level	HPA038939, HPA038940	Enhanced		Approved	Mitochondria		Expressed in all	Tissue enhanced		kidney: 36.6	duodenum: 30.8	Cell line enhanced		HEK 293: 24.3
BTG4	APRO3, PC3B	ENSG00000137707	BTG anti-proliferation factor 4	11	111467526-111512354	Predicted intracellular proteins	Evidence at transcript level	HPA057157			Approved	Endoplasmic reticulum<br>Golgi apparatus		Not detected	Tissue enriched	18	testis: 47.5	fallopian tube: 2.6	Cell line enhanced		CACO-2: 2.8;Karpas-707: 3.2;U-266/70: 2.3
POU2F3	Epoc-1, OCT11, PLA-1, Skn-1a	ENSG00000137709	POU class 2 homeobox 3	11	120236640-120319944	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019652	Enhanced				Thyroid cancer:8.14e-4 (favourable)	Mixed	Group enriched	11	parathyroid gland: 15.5;skin: 72.3	seminal vesicle: 3.8	Cell line enhanced		CAPAN-2: 3.7;SK-BR-3: 2.2;T-47d: 5.2
RDX	DFNB24	ENSG00000137710	Radixin	11	110174880-110296722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000263, HPA000763, CAB037312	Enhanced		Enhanced	Plasma membrane		Expressed in all	Expressed in all			adrenal gland: 198.2	Mixed		
PPP2R1B	PP2A-Abeta, PR65B	ENSG00000137713	Protein phosphatase 2 scaffold subunit Abeta	11	111726908-111766427	Predicted intracellular proteins	Evidence at protein level	CAB004034, HPA018908	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 98.6	Expressed in all		
FDX1	ADX, FDX	ENSG00000137714	Ferredoxin 1	11	110429883-110464881	Predicted intracellular proteins	Evidence at protein level	HPA041630, HPA062087	Enhanced		Enhanced	Mitochondria	Renal cancer:3.58e-7 (favourable), Stomach cancer:2.53e-4 (favourable)	Expressed in all	Tissue enriched	11	adrenal gland: 387.5	seminal vesicle: 36.5	Expressed in all		
C11orf1	FLJ23499	ENSG00000137720	Chromosome 11 open reading frame 1	11	111878935-111885975	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038410, HPA057519	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.39e-4 (favourable), Endometrial cancer:9.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 104.9	Expressed in all		
FXYD6		ENSG00000137726	FXYD domain containing ion transport regulator 6	11	117836976-117877486	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041334, HPA042284	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.05e-5 (unfavourable), Renal cancer:4.38e-5 (favourable), Urothelial cancer:1.60e-4 (unfavourable), Liver cancer:5.87e-4 (favourable), Pancreatic cancer:5.97e-4 (favourable)	Tissue enriched	Expressed in all			cerebral cortex: 696.9	Cell line enhanced		AF22: 128.6;HAP1: 89.7;SCLC-21H: 231.1;SH-SY5Y: 118.8
ARHGAP20	KIAA1391	ENSG00000137727	Rho GTPase activating protein 20	11	110577042-110713189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038458, HPA038459, HPA076303	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 15.4	Cell line enhanced		ASC diff: 16.9;ASC TERT1: 5.7;SiHa: 7.6
FXYD2	ATP1G1, HOMG2, MGC12372	ENSG00000137731	FXYD domain containing ion transport regulator 2	11	117800844-117828698	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064218, HPA068838	Supported		Approved	Mitochondria	Renal cancer:3.23e-9 (favourable)	Tissue enriched	Group enriched	6	gallbladder: 571.3;kidney: 1433.1;salivary gland: 380.4	pancreas: 134.6	Group enriched	24	MOLT-4: 1801.2;RPTEC TERT1: 3683.4
MMP13	CLG3	ENSG00000137745	Matrix metallopeptidase 13	11	102942995-102955734	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		lung: 1.5;urinary bladder: 1.3	appendix: 0.3	Cell line enhanced		HaCaT: 15.8;PC-3: 6.2
TMPRSS13	MSPL, TMPRSS11	ENSG00000137747	Transmembrane protease, serine 13	11	117900643-117929459	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 36.4	cervix, uterine,esophagus: 10.5	Cell line enhanced		BEWO: 32.1;MCF7: 22.3;SK-BR-3: 36.2;T-47d: 46.4
CASP1	ICE, IL1BC	ENSG00000137752	Caspase 1	11	105025443-105035250	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002685, HPA003056	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.11e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 139.8	Cell line enhanced		BJ hTERT+: 91.3;U-937: 106.2
CASP5	ICE(rel)III	ENSG00000137757	Caspase 5	11	104994235-105023168	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040937	Uncertain					Group enriched	Group enriched	6	appendix: 20.2;colon: 15.9;duodenum: 10.1;rectum: 14.5;small intestine: 18.9	smooth muscle: 2.7	Cell line enriched	8	HHSteC: 3.1
ALKBH8	MGC10235, TRM9, TRMT9	ENSG00000137760	AlkB homolog 8, tRNA methyltransferase	11	107502726-107565746	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038724, HPA038725, HPA061514	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			parathyroid gland: 9.6	Expressed in all		
MAP2K5	HsT17454, MAPKK5, MEK5, PRKMK5	ENSG00000137764	Mitogen-activated protein kinase kinase 5	15	67542709-67807123	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB022094, HPA027347, HPA027755	Supported		Approved	Nucleoli<br>Microtubules	Renal cancer:8.03e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.7	Expressed in all		
UNC13C	DKFZp547H074, Munc13-3	ENSG00000137766	Unc-13 homolog C	15	54012904-54633414	Predicted intracellular proteins	Evidence at protein level	HPA041516	Uncertain					Not detected	Group enriched	15	cerebral cortex: 17.4;testis: 15.3	ovary,thyroid gland: 1.1	Group enriched	9	Karpas-707: 52.9;U-266/70: 74.2
SQRDL	CGI-44	ENSG00000137767	Sulfide quinone reductase-like (yeast)	15	45631148-45691294	Predicted intracellular proteins	Evidence at protein level	HPA017079, HPA041589	Enhanced		Enhanced	Mitochondria	Endometrial cancer:2.57e-4 (favourable), Lung cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			colon: 193.5	Cell line enhanced		HBEC3-KT: 198.5
CTDSPL2	FLJ10523, HSPC129	ENSG00000137770	CTD small phosphatase like 2	15	44427234-44529038	Predicted intracellular proteins	Evidence at protein level	HPA040763, HPA062198	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
SLTM	FLJ13213, Met	ENSG00000137776	SAFB like transcription modulator	15	58879045-58933653	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040256, HPA040381	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 66.5	Expressed in all		
THBS1	THBS, THBS-1, TSP, TSP-1, TSP1	ENSG00000137801	Thrombospondin 1	15	39581079-39599466	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB033678, HPA059756	Approved		Approved	Plasma membrane	Renal cancer:8.47e-5 (unfavourable), Stomach cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 573.9	Cell line enhanced		fHDF/TERT166: 2033.2;HUVEC TERT2: 2095.4;TIME: 3015.4
MAPKBP1	KIAA0596	ENSG00000137802	Mitogen-activated protein kinase binding protein 1	15	41774434-41827855	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030832, HPA030833	Enhanced		Approved	Nucleoli	Endometrial cancer:1.47e-4 (favourable), Ovarian cancer:6.80e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.0	Mixed		
NUSAP1	ANKT, BM037, FLJ13421, LNP, NuSAP1, PRO0310p1, Q0310, SAPL	ENSG00000137804	Nucleolar and spindle associated protein 1	15	41332694-41381050	Predicted intracellular proteins	Evidence at protein level	HPA042904, HPA074847	Enhanced		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:6.82e-14 (unfavourable), Pancreatic cancer:6.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 75.3	lymph node: 57.2	Expressed in all		
NDUFAF1	CGI-65, CIA30	ENSG00000137806	NADH:ubiquinone oxidoreductase complex assembly factor 1	15	41387349-41402519	Predicted intracellular proteins	Evidence at protein level	HPA039933, HPA040064	Supported		Enhanced	Cytosol	Renal cancer:3.34e-6 (favourable), Liver cancer:2.88e-5 (favourable)	Expressed in all	Expressed in all			testis: 45.5	Expressed in all		
KIF23	KNSL5, MKLP-1, MKLP1	ENSG00000137807	Kinesin family member 23	15	69414246-69448427	Predicted intracellular proteins	Evidence at protein level	CAB010414, HPA045208, HPA068831	Approved		Enhanced	Nucleoplasm	Liver cancer:3.18e-5 (unfavourable), Pancreatic cancer:3.69e-5 (unfavourable), Endometrial cancer:8.62e-4 (unfavourable)	Mixed	Mixed			testis: 19.7	Expressed in all		
ITGA11	HsT18964	ENSG00000137809	Integrin subunit alpha 11	15	68296533-68432162	Predicted membrane proteins	Evidence at protein level	HPA051813	Uncertain				Renal cancer:3.22e-7 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 54.7;endometrium: 52.4;smooth muscle: 75.7	epididymis: 22.9	Cell line enhanced		fHDF/TERT166: 203.4;U-138 MG: 173.0;WM-115: 98.4
KNL1	AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7	ENSG00000137812	Kinetochore scaffold 1	15	40594020-40664342	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026624, HPA049647	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Lung cancer:2.11e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 31.7	lymph node: 4.4	Mixed		
HAUS2	C15orf25, CEP27, FLJ10460, HsT17025	ENSG00000137814	HAUS augmin like complex subunit 2	15	42548810-42569994	Predicted intracellular proteins	Evidence at protein level	HPA039965	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 22.5	Expressed in all		
RTF1	KIAA0252	ENSG00000137815	RTF1 homolog, Paf1/RNA polymerase II complex component	15	41408408-41483563	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006714	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 63.5	Expressed in all		
PARP6	pART17	ENSG00000137817	Poly(ADP-ribose) polymerase family member 6	15	72241181-72272999	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026991	Approved		Approved	Plasma membrane	Renal cancer:8.02e-8 (unfavourable), Cervical cancer:3.17e-5 (favourable), Colorectal cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.9	Mixed		
RPLP1	LP1	ENSG00000137818	Ribosomal protein lateral stalk subunit P1	15	69452784-69456194	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003368			Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.30e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 1840.0	Expressed in all		
PAQR5	FLJ20190, MPRG	ENSG00000137819	Progestin and adipoQ receptor family member 5	15	69298947-69407780	Predicted membrane proteins	Evidence at protein level	HPA076729			Approved	Vesicles	Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable)	Mixed	Tissue enhanced		kidney: 55.8	adrenal gland: 20.8	Cell line enhanced		A549: 34.9;CAPAN-2: 40.4;HMC-1: 69.7
LRRC49	FLJ20156	ENSG00000137821	Leucine rich repeat containing 49	15	70853239-71053657	Predicted intracellular proteins	Evidence at protein level	HPA015596	Uncertain					Mixed	Mixed			heart muscle: 36.4	Cell line enhanced		HHSteC: 28.0
TUBGCP4	76P, FLJ14797	ENSG00000137822	Tubulin gamma complex associated protein 4	15	43369221-43409771	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043212	Approved		Supported	Centrosome		Expressed in all	Expressed in all			parathyroid gland: 13.1	Expressed in all		
RMDN3	FAM82A2, FAM82C, FLJ10579, PTPIP51, RMD3	ENSG00000137824	Regulator of microtubule dynamics 3	15	40735884-40755851	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009975	Supported		Enhanced	Mitochondria	Renal cancer:6.70e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 58.1	Expressed in all		
ITPKA	IP3-3KA, IP3KA	ENSG00000137825	Inositol-trisphosphate 3-kinase A	15	41493393-41503551	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040454	Enhanced	Approved	Approved	Vesicles	Renal cancer:3.76e-9 (unfavourable), Glioma:5.08e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 25.7;duodenum: 17.7;small intestine: 19.8	stomach: 8.9	Cell line enhanced		Hep G2: 22.6
UACA	FLJ10128, KIAA1561	ENSG00000137831	Uveal autoantigen with coiled-coil domains and ankyrin repeats	15	70654554-70763593	Predicted intracellular proteins	Evidence at protein level	HPA041412, HPA043503	Uncertain		Supported	Nucleus<br>Cytosol	Pancreatic cancer:7.01e-5 (unfavourable), Urothelial cancer:1.03e-4 (unfavourable), Renal cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 59.6	Cell line enhanced		BJ: 206.5
SMAD6	HsT17432, MADH6, MADH7	ENSG00000137834	SMAD family member 6	15	66702228-66782848	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061917			Supported	Nucleus<br>Nuclear bodies<br>Golgi apparatus	Urothelial cancer:5.45e-5 (favourable)	Expressed in all	Tissue enhanced		lung: 16.8	placenta: 10.7	Cell line enhanced		EFO-21: 28.0
PLCB2	FLJ38135	ENSG00000137841	Phospholipase C beta 2	15	40278176-40307935	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009443, HPA041298	Approved		Approved	Cytosol	Renal cancer:7.20e-5 (unfavourable), Head and neck cancer:3.00e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 55.9	appendix: 38.2	Cell line enhanced		HEL: 70.2;HMC-1: 82.2;U-937: 41.8
TMEM62	FLJ23375	ENSG00000137842	Transmembrane protein 62	15	43123279-43185146	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044461, HPA062359	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies<br>Cytoplasmic bodies	Endometrial cancer:9.72e-7 (favourable)	Expressed in all	Expressed in all			breast: 28.7	Mixed		
PAK6	PAK5	ENSG00000137843	P21 (RAC1) activated kinase 6	15	40238759-40277487	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031124	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions		Not detected	Mixed			cerebral cortex: 28.6	Cell line enhanced		CACO-2: 17.4;HaCaT: 28.5;hTCEpi: 13.9
ADAM10	CD156c, HsT18717, kuz, MADM	ENSG00000137845	ADAM metallopeptidase domain 10	15	58588807-58749978	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB001709, HPA050670	Approved		Supported	Vesicles<br>Plasma membrane	Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 47.9	Expressed in all		
DUOX1	LNOX1, NOXEF1, THOX1	ENSG00000137857	Dual oxidase 1	15	45129933-45165576	Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA023544	Approved				Cervical cancer:4.31e-6 (favourable)	Tissue enhanced	Tissue enhanced		skin: 96.9;thyroid gland: 92.6	esophagus: 73.2	Cell line enhanced		HaCaT: 56.9;hTCEpi: 22.1;RT4: 29.0
SLC28A2	CNT2, HCNT2, HsT17153, SPNT1	ENSG00000137860	Solute carrier family 28 member 2	15	45252230-45277845	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046068, HPA055623	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 64.9;rectum: 37.1;small intestine: 97.9	stomach: 21.0	Not detected		
STRA6	FLJ12541	ENSG00000137868	Stimulated by retinoic acid 6	15	74179466-74212267	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040839	Approved		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cervix, uterine: 37.0;placenta: 20.4	endometrium: 13.2	Cell line enhanced		CAPAN-2: 162.1;SH-SY5Y: 119.5;WM-115: 273.5
CYP19A1	ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM	ENSG00000137869	Cytochrome P450 family 19 subfamily A member 1	15	51208057-51338610	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000355, HPA051194	Enhanced		Approved	Mitochondria		Mixed	Tissue enriched	15	placenta: 174.5	adrenal gland: 11.9	Group enriched	6	ASC TERT1: 65.0;HDLM-2: 16.2;HSkMC: 22.8
ZNF280D	FLJ20086, SUHW4, ZNF634	ENSG00000137871	Zinc finger protein 280D	15	56630181-56918571	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030233	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			endometrium: 31.8	Mixed		
SEMA6D	FLJ11598, KIAA1479	ENSG00000137872	Semaphorin 6D	15	47184101-47774223	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043109			Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:5.96e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 63.6	small intestine: 44.3	Cell line enhanced		BJ hTERT+: 12.7;SCLC-21H: 16.1;SH-SY5Y: 13.4
BCL2L10	BCL-B, Boo, Diva	ENSG00000137875	BCL2 like 10	15	52109263-52112775	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042222	Approved					Mixed	Tissue enhanced		skin: 6.1	kidney: 3.3	Group enriched	8	NB-4: 21.5;SiHa: 4.5
RSL24D1	C15orf15, HRP-L30-iso, L30, RPL24, RPL24L	ENSG00000137876	Ribosomal L24 domain containing 1	15	55180806-55197067	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA062724, HPA063392	Enhanced		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 124.4	Expressed in all		
SPTBN5	BSPECV, HUBSPECV, HUSPECV	ENSG00000137877	Spectrin beta, non-erythrocytic 5	15	41848144-41894077	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			gallbladder,heart muscle,thyroid gland: 1.3	Cell line enhanced		SCLC-21H: 6.0;TIME: 11.0;WM-115: 4.2
GCOM1	FLJ30973, GRINL1A, MYZAP-POLR2M	ENSG00000137878	GRINL1A complex locus 1	15	57591908-57714745	Predicted intracellular proteins	Evidence at protein level	HPA039827, HPA068141	Approved		Approved	Nucleoplasm		Not detected	Mixed			heart muscle: 6.2	Cell line enhanced		HEL: 29.8;RH-30: 8.7;TIME: 11.5
GCHFR	GFRP, HsT16933	ENSG00000137880	GTP cyclohydrolase I feedback regulator	15	40764020-40767710	Predicted intracellular proteins	Evidence at protein level	HPA046258	Approved		Supported	Nucleoplasm	Lung cancer:5.62e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 62.4	Cell line enhanced		RPTEC TERT1: 101.8;SCLC-21H: 141.5
BCAR3	NSP2, SH2D3B	ENSG00000137936	Breast cancer anti-estrogen resistance 3	1	93561786-93847150	Predicted intracellular proteins	Evidence at protein level	HPA014858	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:3.08e-7 (favourable), Lung cancer:8.92e-7 (unfavourable), Pancreatic cancer:4.38e-4 (unfavourable), Liver cancer:5.42e-4 (unfavourable), Head and neck cancer:8.41e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 32.6	Mixed		
TTLL7	FLJ23033	ENSG00000137941	Tubulin tyrosine ligase like 7	1	83865028-83999150	Predicted intracellular proteins	Evidence at protein level	HPA052249, HPA059321	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 46.8	smooth muscle: 10.8	Cell line enhanced		HDLM-2: 26.3;RH-30: 21.3;SCLC-21H: 16.4
FNBP1L	C1orf39, FLJ20275, TOCA1	ENSG00000137942	Formin binding protein 1 like	1	93448131-93554661	Predicted intracellular proteins	Evidence at protein level	HPA065273	Approved		Supported	Cytosol	Renal cancer:4.72e-7 (favourable), Liver cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 53.8	Mixed		
KYAT3	CCBL2, KAT3, KATIII, RBM1, RP11-82K18.3	ENSG00000137944	Kynurenine aminotransferase 3	1	88935773-88992953	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026538, HPA027168	Enhanced		Approved	Nucleoli<br>Cytosol	Renal cancer:5.02e-6 (favourable), Breast cancer:3.19e-5 (favourable), Head and neck cancer:1.86e-4 (favourable), Ovarian cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.8	Expressed in all		
GTF2B	TFIIB	ENSG00000137947	General transcription factor IIB	1	88852932-88891944	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061626	Enhanced		Supported	Nucleus<br>Nuclear bodies	Breast cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 47.6	Expressed in all		
BRDT	BRD6, CT9	ENSG00000137948	Bromodomain testis associated	1	91949371-92014426	Predicted intracellular proteins	Evidence at protein level	CAB012237	Approved					Group enriched	Tissue enriched	124	testis: 235.9	bone marrow: 1.9	Cell line enriched	33	BEWO: 19.0
RABGGTB		ENSG00000137955	Rab geranylgeranyltransferase beta subunit	1	75786197-75795079	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026585, HPA027167, HPA030793	Approved	Approved	Supported	Vesicles	Renal cancer:1.12e-5 (unfavourable), Liver cancer:9.80e-5 (unfavourable)	Expressed in all	Expressed in all			kidney: 69.4	Expressed in all		
IFI44L	C1orf29, GS3686	ENSG00000137959	Interferon induced protein 44 like	1	78619922-78646145	Predicted intracellular proteins	Evidence at protein level	HPA053247, HPA060372	Enhanced		Approved	Nucleoplasm	Renal cancer:1.06e-4 (unfavourable), Endometrial cancer:2.95e-4 (unfavourable), Glioma:5.08e-4 (favourable)	Expressed in all	Mixed			spleen: 32.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 43.7;BJ hTERT+ SV40 Large T+ RasG12V: 49.2;HSkMC: 19.4;SK-MEL-30: 17.2
GIPC2	FLJ20075, SEMCAP-2	ENSG00000137960	GIPC PDZ domain containing family member 2	1	77979542-78138449	Predicted intracellular proteins	Evidence at protein level	HPA051212, HPA062684	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.11e-6 (favourable), Colorectal cancer:5.49e-4 (favourable)	Mixed	Mixed			kidney: 41.6	Cell line enhanced		Hep G2: 15.3;HUVEC TERT2: 19.2
ARHGAP29	PARG1	ENSG00000137962	Rho GTPase activating protein 29	1	94148988-94275068	Predicted intracellular proteins	Evidence at protein level	HPA026534	Approved		Approved	Nucleus<br>Plasma membrane<br>Centrosome<br>Cytosol	Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:9.63e-4 (unfavourable)	Expressed in all	Mixed			spleen: 49.9	Cell line enhanced		A-431: 194.8
IFI44	MTAP44, p44, TLDC5	ENSG00000137965	Interferon induced protein 44	1	78649796-78664078	Predicted intracellular proteins	Evidence at protein level	HPA027148, HPA043858	Approved		Approved	Nucleoplasm	Renal cancer:1.37e-8 (unfavourable)	Expressed in all	Expressed in all			spleen: 88.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 163.8;BJ hTERT+ SV40 Large T+ RasG12V: 210.0
SLC44A5	CTL5, MGC34032	ENSG00000137968	Solute carrier family 44 member 5	1	75202131-75611116	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047455, HPA051011	Uncertain		Approved	Cytosol	Renal cancer:6.52e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 12.6	parathyroid gland: 8.1	Cell line enhanced		SH-SY5Y: 12.2;TIME: 11.9
CLCA2	CLCRG2	ENSG00000137975	Chloride channel accessory 2	1	86424086-86456558	Predicted membrane proteins	Evidence at protein level	HPA047192	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions		Group enriched	Group enriched	5	esophagus: 126.4;skin: 102.7	tonsil: 22.5	Cell line enhanced		BEWO: 36.7;HBEC3-KT: 23.7;hTCEpi: 148.8
DNASE2B	DLAD	ENSG00000137976	Deoxyribonuclease 2 beta	1	84398532-84415018	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	salivary gland: 73.0	prostate: 10.5	Not detected		
DBT		ENSG00000137992	Dihydrolipoamide branched chain transacylase E2	1	100186919-100249834	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026481, HPA026485, HPA026533	Enhanced		Supported	Mitochondria	Renal cancer:8.79e-12 (favourable)	Expressed in all	Expressed in all			kidney: 19.7	Expressed in all		
RTCA	RPC, RTC1, RTCD1	ENSG00000137996	RNA 3'-terminal phosphate cyclase	1	100266207-100292769	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027982, HPA027990, HPA028151	Uncertain		Enhanced	Nucleus	Liver cancer:2.76e-5 (unfavourable)	Expressed in all	Expressed in all			kidney: 35.8	Expressed in all		
IFT172	BBS20, NPHP17, osm-1, SLB, wim	ENSG00000138002	Intraflagellar transport 172	2	27444371-27489789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044893	Uncertain		Approved	Vesicles	Liver cancer:6.05e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.5	Mixed		
SELENOI	EPT1, KIAA1724, SELI, SEPI	ENSG00000138018	Selenoprotein I	2	26308547-26395891	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 33.7	Expressed in all		
CGREF1	CGR11	ENSG00000138028	Cell growth regulator with EF-hand domain 1	2	27098889-27119115	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008241	Uncertain				Endometrial cancer:3.18e-4 (unfavourable), Liver cancer:7.57e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 44.7	stomach: 11.5	Cell line enhanced		SK-BR-3: 58.9
HADHB	MTPB	ENSG00000138029	Hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit	2	26243170-26290468	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037539, HPA037540, HPA066099	Enhanced		Supported	Mitochondria	Renal cancer:1.37e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 300.8	Expressed in all		
KHK		ENSG00000138030	Ketohexokinase	2	27086747-27100772	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007040	Enhanced		Approved	Cytosol	Endometrial cancer:7.62e-8 (unfavourable)	Group enriched	Group enriched	11	duodenum: 113.1;kidney: 111.2;liver: 97.3;small intestine: 133.2	cerebral cortex: 10.1	Cell line enhanced		Hep G2: 32.5
ADCY3	AC3	ENSG00000138031	Adenylate cyclase 3	2	24819169-24919839	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB010223	Approved				Renal cancer:1.32e-9 (unfavourable)	Expressed in all	Expressed in all			placenta: 122.5	Expressed in all		
PPM1B	PP2CB, PP2CBETA, PPC2BETAX	ENSG00000138032	Protein phosphatase, Mg2+/Mn2+ dependent 1B	2	44167969-44244384	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016745	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 82.3	Expressed in all		
PNPT1	DFNB70, old-35, OLD35, PNPase	ENSG00000138035	Polyribonucleotide nucleotidyltransferase 1	2	55634265-55693910	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033424, HPA034602, HPA034603	Supported		Enhanced	Mitochondria	Liver cancer:1.95e-7 (unfavourable), Pancreatic cancer:5.44e-5 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 9.9	Expressed in all		
DYNC2LI1	CGI-60, D2LIC, DKFZP564A033, LIC3	ENSG00000138036	Dynein cytoplasmic 2 light intermediate chain 1	2	43774039-43810010	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062905	Approved		Approved	Cytosol	Renal cancer:2.73e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 86.1	Expressed in all		
LHCGR	HHG, LCGR, LGR2, LHR, ULG5	ENSG00000138039	Luteinizing hormone/choriogonadotropin receptor	2	48686775-48755730	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009814	Uncertain					Not detected	Tissue enhanced		ovary: 1.6;testis: 4.3	adipose tissue: 1.3	Not detected		
THUMPD2	C2orf8, MGC2454	ENSG00000138050	THUMP domain containing 2	2	39736060-39779267	Predicted intracellular proteins	Evidence at protein level	HPA043042, HPA058025	Approved		Uncertain	Nucleoplasm	Renal cancer:7.27e-5 (unfavourable), Liver cancer:6.05e-4 (unfavourable)	Expressed in all	Mixed			ovary,thyroid gland: 3.8	Mixed		
CYP1B1	CP1B, GLC3A	ENSG00000138061	Cytochrome P450 family 1 subfamily B member 1	2	38066973-38109902	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011705, HPA026863	Approved		Uncertain	Mitochondria	Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 76.1	Cell line enhanced		HSkMC: 400.2;SiHa: 283.9;U-87 MG: 138.5
SULT6B1		ENSG00000138068	Sulfotransferase family 6B member 1	2	37167820-37196598	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	11	fallopian tube: 1.0;testis: 4.3	bone marrow: 0.2	Cell line enriched	6	WM-115: 2.2
RAB1A	RAB1, YPT1	ENSG00000138069	RAB1A, member RAS oncogene family	2	65070701-65130106	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005331, HPA056141	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Head and neck cancer:4.19e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 219.2	Expressed in all		
ACTR2	ARP2	ENSG00000138071	ARP2 actin related protein 2 homolog	2	65227753-65271253	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005083, HPA015050	Approved		Approved	Cytosol	Liver cancer:4.50e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 292.2	Expressed in all		
PREB	SEC12	ENSG00000138073	Prolactin regulatory element binding	2	27130756-27134675	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013582, HPA014133	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			epididymis: 107.6	Expressed in all		
SLC5A6	SMVT	ENSG00000138074	Solute carrier family 5 member 6	2	27199587-27212958	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036958	Approved		Approved	Cell Junctions	Renal cancer:3.60e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 81.3	Expressed in all		
ABCG5	STSL	ENSG00000138075	ATP binding cassette subfamily G member 5	2	43812472-43838865	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016514			Approved	Nucleus	Liver cancer:2.60e-5 (favourable)	Tissue enriched	Group enriched	32	duodenum: 56.5;liver: 28.4;small intestine: 56.2	gallbladder: 1.4	Cell line enriched	37	Hep G2: 6.3
PREPL	KIAA0436	ENSG00000138078	Prolyl endopeptidase-like	2	44316281-44361862	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063238	Approved					Expressed in all	Expressed in all			cerebral cortex: 257.4	Expressed in all		
SLC3A1	ATR1, CSNU1, D2H, NBAT, RBAT	ENSG00000138079	Solute carrier family 3 member 1	2	44275458-44321494	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA038360, HPA071102	Enhanced		Approved	Nuclear bodies<br>Mitochondria	Renal cancer:3.67e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 688.2	small intestine: 148.9	Cell line enriched	14	RPTEC TERT1: 80.7
EMILIN1	DKFZp586M121, gp115	ENSG00000138080	Elastin microfibril interfacer 1	2	27078567-27086408	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002822	Supported				Renal cancer:8.13e-9 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 73.7	Cell line enhanced		BJ: 81.8;HHSteC: 82.2;HSkMC: 78.7;SH-SY5Y: 135.3
FBXO11	FBX11, UBR6	ENSG00000138081	F-box protein 11	2	47789316-47905793	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002690			Supported	Nucleus		Expressed in all	Expressed in all			testis: 75.4	Expressed in all		
SIX3	HPE2	ENSG00000138083	SIX homeobox 3	2	44941898-44946077	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067988			Approved	Nucleoplasm		Mixed	Tissue enriched	31	parathyroid gland: 39.3	cervix, uterine: 1.2	Cell line enhanced		HAP1: 12.7;SCLC-21H: 77.1;SH-SY5Y: 27.8
ATRAID	APR3, C2orf28, HSPC013, p18	ENSG00000138085	All-trans retinoic acid induced differentiation factor	2	27212027-27217178	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051353	Uncertain					Expressed in all	Expressed in all			epididymis: 521.0	Expressed in all		
CENPO	CENP-O, MGC11266	ENSG00000138092	Centromere protein O	2	24793136-24822376	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.71e-13 (unfavourable), Liver cancer:1.73e-6 (unfavourable), Endometrial cancer:3.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 13.0	Expressed in all		
LRPPRC	GP130, LRP130, LSFC	ENSG00000138095	Leucine rich pentatricopeptide repeat containing	2	43886508-43996005	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB033786, HPA036408, HPA036409	Enhanced		Enhanced	Mitochondria	Liver cancer:2.31e-7 (unfavourable), Renal cancer:6.65e-6 (favourable), Endometrial cancer:1.72e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.1	Expressed in all		
TRIM54	MURF, MURF-3, RNF30	ENSG00000138100	Tripartite motif containing 54	2	27282392-27307439	Predicted intracellular proteins	Evidence at protein level	HPA019690	Uncertain				Renal cancer:6.46e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 63.9;skeletal muscle: 181.1	epididymis: 30.7	Group enriched	13	HAP1: 7.4;NTERA-2: 15.3
DTNB		ENSG00000138101	Dystrobrevin beta	2	25377198-25673647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061357	Uncertain		Approved	Mitochondria	Liver cancer:2.54e-4 (unfavourable), Renal cancer:3.47e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 23.8	Mixed		
ACTR1A	ARP1, Arp1A	ENSG00000138107	ARP1 actin-related protein 1 homolog A, centractin alpha	10	102461881-102502711	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037193, HPA047443	Approved		Approved	Microtubules		Expressed in all	Expressed in all			cerebral cortex: 114.3	Expressed in all		
CYP2C9	CYP2C10, P450IIC9	ENSG00000138109	Cytochrome P450 family 2 subfamily C member 9	10	94938658-94989390	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA015066, CAB016123	Enhanced				Liver cancer:2.83e-6 (favourable)	Tissue enriched	Tissue enriched	7	liver: 963.1	duodenum: 136.8	Not detected		
MFSD13A	bA18I14.8, C10orf77, FLJ22529, TMEM180	ENSG00000138111	Major facilitator superfamily domain containing 13A	10	102461395-102477045	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018031	Uncertain		Approved	Golgi apparatus<br>Cytosol	Cervical cancer:8.29e-4 (favourable), Renal cancer:8.51e-4 (unfavourable)	Expressed in all	Mixed			lung: 11.5	Mixed		
CYP2C8	CPC8	ENSG00000138115	Cytochrome P450 family 2 subfamily C member 8	10	95036772-95069497	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013547, HPA013970, HPA015066	Enhanced				Pancreatic cancer:9.82e-4 (favourable)	Tissue enriched	Tissue enriched	154	liver: 1124.1	gallbladder: 7.3	Not detected		
MYOF	FER1L3, KIAA1207	ENSG00000138119	Myoferlin	10	93306429-93482317	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014245	Enhanced		Supported	Vesicles<br>Plasma membrane	Pancreatic cancer:1.40e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 101.2	Mixed		
LOXL4	FLJ21889, LOXC	ENSG00000138131	Lysyl oxidase like 4	10	98247690-98268250	Predicted secreted proteins	Evidence at protein level	CAB033876, HPA037609	Approved		Approved	Vesicles	Glioma:5.36e-4 (unfavourable), Ovarian cancer:9.57e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.8	Cell line enhanced		BJ hTERT+: 199.7;CAPAN-2: 260.1;U-2 OS: 57.0
STAMBPL1	ALMalpha, AMSH-FP, AMSH-LP, bA399O19.2, FLJ31524, KIAA1373	ENSG00000138134	STAM binding protein like 1	10	88879734-88975153	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040202	Uncertain		Approved	Plasma membrane	Renal cancer:1.08e-5 (unfavourable)	Mixed	Mixed			adrenal gland,testis: 29.7	Mixed		
CH25H		ENSG00000138135	Cholesterol 25-hydroxylase	10	89205629-89207314	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			gallbladder: 23.0	Cell line enhanced		ASC diff: 6.0;fHDF/TERT166: 25.5;HSkMC: 6.0
LBX1	HPX6, LBX1H	ENSG00000138136	Ladybird homeobox 1	10	101226195-101229794	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA002016, HPA002086	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enriched	67	skeletal muscle: 9.1	lung: 0.1	Group enriched	8	HEK 293: 3.1;RH-30: 4.1;SCLC-21H: 10.7
ATAD1	FLJ14600	ENSG00000138138	ATPase family, AAA domain containing 1	10	87751512-87841343	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA037569	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Renal cancer:3.98e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.0	Expressed in all		
BTBD16	C10orf87, Em:AC061711.1, FLJ25359	ENSG00000138152	BTB domain containing 16	10	122271306-122338162	Predicted intracellular proteins	Evidence at protein level	HPA040529, HPA057638	Uncertain		Uncertain	Nucleoli<br>Cytosol	Renal cancer:1.50e-4 (unfavourable)	Tissue enriched	Group enriched	7	skin: 9.9;testis: 14.2;urinary bladder: 19.0	liver: 2.1	Cell line enriched	9	RT4: 26.9
KIF11	Eg5, HKSP, KNSL1, TRIP5	ENSG00000138160	Kinesin family member 11	10	92593286-92655395	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006916, HPA010093, HPA010568, CAB017617	Enhanced		Supported	Mitotic spindle<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.19e-7 (unfavourable), Pancreatic cancer:2.30e-4 (unfavourable), Lung cancer:3.27e-4 (unfavourable)	Expressed in all	Mixed			testis: 21.8	Expressed in all		
CUZD1	ERG-1, UO-44	ENSG00000138161	CUB and zona pellucida like domains 1	10	122832149-122850793	Predicted membrane proteins	Evidence at protein level	HPA068479, HPA068660, HPA074117	Enhanced		Approved	Nucleoli<br>Vesicles		Tissue enriched	Tissue enriched	173	pancreas: 380.6	testis: 2.1	Mixed		
TACC2	AZU-1	ENSG00000138162	Transforming acidic coiled-coil containing protein 2	10	121989174-122254545	Predicted intracellular proteins	Evidence at protein level	HPA031020, HPA031021, HPA061394	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.50e-10 (favourable), Thyroid cancer:8.45e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 112.7	Mixed		
DUSP5	HVH3	ENSG00000138166	Dual specificity phosphatase 5	10	110497838-110511544	Enzymes, Predicted intracellular proteins	Evidence at protein level						Lung cancer:8.30e-6 (unfavourable)	Expressed in all	Mixed			esophagus: 100.1	Cell line enhanced		hTERT-HME1: 303.0;U-266/70: 167.5
CALHM2	FAM26B	ENSG00000138172	Calcium homeostasis modulator 2	10	103446786-103452402	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014706	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:3.03e-6 (unfavourable)	Expressed in all	Mixed			ovary: 44.8	Mixed		
ARL3	ARFL3	ENSG00000138175	ADP ribosylation factor like GTPase 3	10	102673731-102714407	Predicted intracellular proteins	Evidence at protein level	HPA036292, HPA063596	Approved		Supported	Nucleus<br>Centrosome	Renal cancer:1.71e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 35.8	Expressed in all		
CEP55	C10orf3, CT111, FLJ10540	ENSG00000138180	Centrosomal protein 55	10	93496632-93529092	Predicted intracellular proteins	Evidence at protein level	HPA023430	Approved		Supported	Plasma membrane<br>Midbody<br>Microtubule organizing center	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 39.4	lymph node: 17.6	Mixed		
KIF20B	CT90, KRMP1, MPHOSPH1, MPP1	ENSG00000138182	Kinesin family member 20B	10	89701610-89774939	Predicted intracellular proteins	Evidence at protein level	HPA031263	Uncertain				Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.8	Expressed in all		
ENTPD1	ATPDase, CD39, NTPDase-1, SPG64	ENSG00000138185	Ectonucleoside triphosphate diphosphohydrolase 1	10	95711779-95869695	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB002494, HPA014067	Enhanced		Uncertain	Microtubules	Renal cancer:5.33e-5 (unfavourable), Thyroid cancer:7.89e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 98.8	Group enriched	7	HDLM-2: 179.7;Karpas-707: 112.9
EXOC6	DKFZp761I2124, EXOC6A, FLJ1125, MGC33397, SEC15L, SEC15L1, Sec15p	ENSG00000138190	Exocyst complex component 6	10	92834713-93059493	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036285, HPA059111	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			placenta: 49.7	Cell line enhanced		HUVEC TERT2: 87.5
PLCE1	KIAA1516, NPHS3, PLCE	ENSG00000138193	Phospholipase C epsilon 1	10	94030812-94332823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA015597, HPA015598	Enhanced		Supported	Cytosol		Expressed in all	Mixed			endometrium: 21.6	Cell line enhanced		RT4: 17.8;U-2 OS: 13.5
RBP4		ENSG00000138207	Retinol binding protein 4	10	93591687-93601744	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001641, CAB004555	Supported				Liver cancer:1.74e-8 (favourable), Endometrial cancer:1.50e-4 (unfavourable)	Tissue enriched	Tissue enriched	10	liver: 6109.2	adipose tissue: 630.9	Cell line enhanced		CACO-2: 219.3;Hep G2: 755.1;PC-3: 113.0
DBR1		ENSG00000138231	Debranching RNA lariats 1	3	138161012-138174949	Predicted intracellular proteins	Evidence at protein level	HPA035365	Supported		Supported	Nucleoplasm	Liver cancer:1.36e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 13.7	Expressed in all		
DNAJC13	KIAA0678, RME8	ENSG00000138246	DnaJ heat shock protein family (Hsp40) member C13	3	132417526-132539032	Predicted membrane proteins	Evidence at protein level	HPA036923, HPA036924	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:7.49e-4 (unfavourable), Pancreatic cancer:8.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.9	Expressed in all		
GPR87	GPR95	ENSG00000138271	G protein-coupled receptor 87	3	151294086-151316952	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA066313			Approved	Nucleoplasm<br>Lipid droplets<br>Mitochondria	Pancreatic cancer:4.62e-6 (unfavourable)	Group enriched	Tissue enhanced		esophagus: 29.3;skin: 29.8	placenta: 12.0	Cell line enhanced		A-431: 87.7;HaCaT: 68.9;HBEC3-KT: 74.5;hTCEpi: 98.3;hTERT-HME1: 43.6
ANXA7	ANX7	ENSG00000138279	Annexin A7	10	73375101-73414076	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004312, HPA064290	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 473.1	Expressed in all		
FAM149B1	KIAA0974	ENSG00000138286	Family with sequence similarity 149 member B1	10	73168166-73244504	Predicted intracellular proteins	Evidence at transcript level	HPA039189, HPA039859	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:7.81e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.4	Expressed in all		
ASCC1	ASC1p50, CGI-18, Em:AC022392.3	ENSG00000138303	Activating signal cointegrator 1 complex subunit 1	10	72096032-72217134	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038038, HPA057567	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.00e-4 (unfavourable), Liver cancer:3.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.7	Expressed in all		
PLA2G12B	PLA2G13	ENSG00000138308	Phospholipase A2 group XIIB	10	72935170-72954778	Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA057745, HPA059562	Approved		Approved	Vesicles		Tissue enriched	Group enriched	10	duodenum: 35.2;kidney: 19.0;liver: 49.9;small intestine: 45.9	lung: 3.9	Group enriched	6	CACO-2: 10.3;Hep G2: 14.2
ZNF365	KIAA0844, UAN	ENSG00000138311	Zinc finger protein 365	10	62374192-62672011	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052446	Enhanced		Supported	Vesicles<br>Microtubule organizing center		Mixed	Tissue enhanced		cerebral cortex: 54.5	parathyroid gland: 10.9	Cell line enhanced		HaCaT: 18.7;PC-3: 12.7;U-251 MG: 14.7
OIT3	FLJ39116, LZP	ENSG00000138315	Oncoprotein induced transcript 3	10	72893581-72933033	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	8	liver: 53.4	spleen: 6.5	Cell line enhanced		CACO-2: 1.7;Hep G2: 1.5
ADAMTS14		ENSG00000138316	ADAM metallopeptidase with thrombospondin type 1 motif 14	10	70672803-70762441	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA034605			Uncertain	Cytosol		Mixed	Tissue enhanced		gallbladder: 10.9;placenta: 11.1	urinary bladder: 4.4	Cell line enhanced		CAPAN-2: 8.0;K-562: 9.5;RH-30: 5.3;U-138 MG: 8.8
RPS24	S24	ENSG00000138326	Ribosomal protein S24	10	78033760-78056812	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003364	Approved		Approved	Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.10e-10 (unfavourable), Breast cancer:1.50e-4 (favourable)	Expressed in all	Expressed in all			ovary: 6825.3	Expressed in all		
TET1	bA119F7.1, CXXC6, KIAA1676, LCX	ENSG00000138336	Tet methylcytosine dioxygenase 1	10	68560656-68694482	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019032, HPA057273			Supported	Nucleus<br>Nuclear membrane		Tissue enriched	Mixed			parathyroid gland: 2.4	Cell line enhanced		BEWO: 17.6;HAP1: 21.7;K-562: 11.0;NTERA-2: 12.2
DNA2	DNA2L, KIAA0083	ENSG00000138346	DNA replication helicase/nuclease 2	10	68414064-68472121	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037487, HPA057526	Approved		Supported	Mitochondria		Mixed	Mixed			lymph node: 6.3	Mixed		
MYPN	MYOP	ENSG00000138347	Myopalladin	10	68106117-68212017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036299, HPA061494	Enhanced		Approved	Nucleus<br>Vesicles<br>Cytosol		Tissue enriched	Group enriched	27	heart muscle: 41.6;skeletal muscle: 99.9	prostate: 2.6	Cell line enhanced		BJ: 33.6;fHDF/TERT166: 87.0;HBF TERT88: 24.6;LHCN-M2: 39.6
AOX1	AO, AOH1	ENSG00000138356	Aldehyde oxidase 1	2	200585868-200677064	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040199, HPA040215	Enhanced				Renal cancer:6.05e-5 (favourable)	Tissue enriched	Group enriched	5	adrenal gland: 368.8;kidney: 97.5;liver: 432.3	ovary: 56.8	Cell line enhanced		ASC diff: 241.4;ASC TERT1: 125.7;hTERT-HME1: 56.6
ATIC	AICARFT, IMPCHASE, PURH	ENSG00000138363	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	2	215311817-215349773	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013462, HPA021012	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 44.8	Expressed in all		
SMARCAL1	HARP, HHARP	ENSG00000138375	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a like 1	2	216412414-216483053	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020337	Uncertain		Supported	Nucleoplasm	Liver cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 19.8	Expressed in all		
BARD1		ENSG00000138376	BRCA1 associated RING domain 1	2	214725646-214809711	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034106, HPA035354, HPA044864	Enhanced		Supported	Nuclear speckles		Expressed in all	Mixed			testis: 11.1	Mixed		
STAT4		ENSG00000138378	Signal transducer and activator of transcription 4	2	191029576-191151596	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001860, CAB013108	Enhanced				Renal cancer:1.07e-8 (unfavourable), Pancreatic cancer:5.88e-4 (favourable)	Mixed	Tissue enhanced		testis: 50.5	spleen: 18.5	Group enriched	7	Karpas-707: 34.1;U-266/70: 20.1;U-266/84: 6.9
MSTN	GDF8	ENSG00000138379	Myostatin	2	190055697-190062729	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB009963	Approved				Glioma:3.98e-4 (favourable)	Tissue enriched	Tissue enhanced		skeletal muscle: 3.4	cerebral cortex,endometrium: 1.3	Group enriched	13	LHCN-M2: 21.5;RH-30: 50.3
CARF	ALS2CR8, CaRF, FLJ21579, NYD-SP24	ENSG00000138380	Calcium responsive transcription factor	2	202912214-202987063	Predicted intracellular proteins	Evidence at protein level	HPA034557, HPA043191	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Cytosol		Mixed	Mixed			testis: 37.0	Expressed in all		
ASNSD1	FLJ20752, NBLA00058, NS3TP1	ENSG00000138381	Asparagine synthetase domain containing 1	2	189661385-189670831	Predicted intracellular proteins	Evidence at protein level	HPA036132, HPA036133, HPA075042	Uncertain		Approved	Cytosol	Glioma:5.68e-4 (favourable), Liver cancer:8.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 51.4	Expressed in all		
METTL5	HSPC133	ENSG00000138382	Methyltransferase like 5	2	169810081-169824931	Predicted intracellular proteins	Evidence at protein level	HPA038223	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.06e-8 (unfavourable), Liver cancer:6.64e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 76.8	Expressed in all		
SSB	La, La/SSB, LARP3	ENSG00000138385	Sjogren syndrome antigen B	2	169791933-169812064	Predicted intracellular proteins	Evidence at protein level	CAB004643, HPA017287	Supported		Approved	Nucleoplasm	Liver cancer:8.30e-8 (unfavourable), Renal cancer:6.17e-6 (unfavourable), Head and neck cancer:5.99e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 131.2	Expressed in all		
NAB1		ENSG00000138386	NGFI-A binding protein 1	2	190646746-190692766	Predicted intracellular proteins	Evidence at protein level	HPA002738	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Pancreatic cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 80.6	Expressed in all		
CDK15	ALS2CR7, PFTAIRE2, PFTK2	ENSG00000138395	Cyclin dependent kinase 15	2	201790461-201895550	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015786	Uncertain		Approved	Nucleus<br>Golgi apparatus		Not detected	Tissue enhanced		epididymis: 21.2;ovary: 8.4	testis: 4.0	Cell line enhanced		BJ hTERT+: 23.4;BJ hTERT+ SV40 Large T+ RasG12V: 22.4;HBF TERT88: 33.8;HMC-1: 58.6;LHCN-M2: 16.8
PPIG	CARS-Cyp, SCAF10, SRCyp	ENSG00000138398	Peptidylprolyl isomerase G	2	169584340-169641406	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021788, HPA057469	Supported		Supported	Nuclear speckles<br>Cytosol	Renal cancer:4.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
FASTKD1	FLJ21901	ENSG00000138399	FAST kinase domains 1	2	169529749-169573875	Predicted intracellular proteins	Evidence at protein level	HPA043719	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			rectum: 26.5	Expressed in all		
MDH1B	FLJ25341, RP11-95H11	ENSG00000138400	Malate dehydrogenase 1B	2	206737763-206765547	Predicted intracellular proteins	Evidence at transcript level	HPA073761	Approved					Mixed	Group enriched	5	fallopian tube: 35.3;testis: 43.8	parathyroid gland: 7.5	Cell line enhanced		SCLC-21H: 4.0
HECW2	KIAA1301, NEDL2	ENSG00000138411	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2	2	196194370-196593692	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034609	Uncertain		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum	Renal cancer:5.18e-5 (unfavourable)	Mixed	Mixed			placenta: 15.8	Cell line enhanced		HDLM-2: 59.6;HUVEC TERT2: 24.5;SCLC-21H: 45.1;TIME: 32.0
IDH1		ENSG00000138413	Isocitrate dehydrogenase (NADP(+)) 1, cytosolic	2	208236227-208266074	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033218, HPA035248, HPA057936, CAB062556	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 338.1	Expressed in all		
OLA1	GTPBP9, PTD004	ENSG00000138430	Obg like ATPase 1	2	174072447-174248698	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035790, HPA041443	Approved		Enhanced	Cytosol	Liver cancer:9.73e-8 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 99.7	Expressed in all		
CIR1	CIR	ENSG00000138433	Corepressor interacting with RBPJ, 1	2	174348022-174395715	Predicted intracellular proteins	Evidence at protein level	HPA015784, HPA061442	Approved		Supported	Nuclear speckles	Renal cancer:1.04e-7 (unfavourable), Urothelial cancer:2.04e-5 (favourable), Liver cancer:2.52e-4 (unfavourable), Endometrial cancer:9.56e-4 (unfavourable), Ovarian cancer:9.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.1	Expressed in all		
SSFA2	CS-1, KIAA1927, KRAP, SPAG13	ENSG00000138434	Sperm specific antigen 2	2	181891833-181930738	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034665, HPA039989	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.91e-5 (favourable), Urothelial cancer:5.79e-5 (unfavourable), Pancreatic cancer:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 137.2	Mixed		
CHRNA1	CHRNA	ENSG00000138435	Cholinergic receptor nicotinic alpha 1 subunit	2	174747592-174787935	Disease related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071554	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		prostate: 3.2;skeletal muscle: 7.2	colon: 1.5	Group enriched	23	LHCN-M2: 370.9;RH-30: 348.5
FAM117B	ALS2CR13, FLJ38771	ENSG00000138439	Family with sequence similarity 117 member B	2	202635188-202769757	Predicted intracellular proteins	Evidence at protein level	HPA003229, HPA028746	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			parathyroid gland: 24.4	Mixed		
WDR12	FLJ10881, YTM1	ENSG00000138442	WD repeat domain 12	2	202874782-203014798	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036389	Uncertain		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:2.57e-6 (unfavourable)	Expressed in all	Mixed			testis: 7.3	Expressed in all		
ABI2	ABI-2, ABI2B, AblBP3, AIP-1, argBPIA, SSH3BP2	ENSG00000138443	Abl interactor 2	2	203328219-203447723	Predicted intracellular proteins	Evidence at protein level	HPA062433, HPA070567	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 98.8	Mixed		
ITGAV	CD51, MSK8, VNRA, VTNR	ENSG00000138448	Integrin subunit alpha V	2	186590065-186680901	Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002499, HPA004856	Supported		Approved	Focal adhesion sites<br>Cytosol	Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 191.2	Cell line enhanced		RT4: 294.1
SLC40A1	FPN1, HFE4, IREG1, MTP1, SLC11A3	ENSG00000138449	Solute carrier family 40 member 1	2	189560579-189583758	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065634	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.55e-5 (favourable)	Expressed in all	Expressed in all			spleen: 489.1	Group enriched	6	ASC diff: 336.9;CACO-2: 97.8;HEL: 380.0;HMC-1: 94.0;T-47d: 188.1
SLC35A5	FLJ20730	ENSG00000138459	Solute carrier family 35 member A5	3	112561709-112585577	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035519, HPA057964	Uncertain		Approved	Golgi apparatus	Renal cancer:4.10e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.9	Expressed in all		
DIRC2	FLJ14784, RCC4	ENSG00000138463	Disrupted in renal carcinoma 2	3	122794795-122881139	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072579			Supported	Vesicles	Renal cancer:8.81e-11 (favourable), Pancreatic cancer:5.81e-5 (unfavourable), Liver cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 16.2	Mixed		
SENP7		ENSG00000138468	SUMO1/sentrin specific peptidase 7	3	101324205-101513241	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027259	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 44.4	Expressed in all		
GUCA1C	GCAP3	ENSG00000138472	Guanylate cyclase activator 1C	3	108907792-108953895	Predicted intracellular proteins	Evidence at protein level	HPA041597	Approved		Approved	Focal adhesion sites		Tissue enriched	Tissue enhanced		heart muscle: 8.9;pancreas: 8.4;stomach: 5.3	testis: 1.7	Cell line enriched	83	RPTEC TERT1: 10.6
CCDC54	FLJ25362, NYD-SP17, SP17	ENSG00000138483	Coiled-coil domain containing 54	3	107377194-107378637	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	137	testis: 165.4	placenta: 1.2	Not detected		
COX17		ENSG00000138495	COX17, cytochrome c oxidase copper chaperone	3	119654513-119677454	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042226, HPA048158	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 114.8	Expressed in all		
PARP9	BAL, BAL1	ENSG00000138496	Poly(ADP-ribose) polymerase family member 9	3	122527924-122564577	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066708			Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Ovarian cancer:6.65e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 89.2;BJ hTERT+ SV40 Large T+ RasG12V: 110.6
MNS1	FLJ11222, SPATA40	ENSG00000138587	Meiosis specific nuclear structural 1	15	56421544-56465137	Predicted intracellular proteins	Evidence at protein level	HPA039975, HPA040382	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Group enriched	6	fallopian tube: 33.7;testis: 86.9	kidney: 9.7	Mixed		
USP8	HumORF8, KIAA0055, SPG59, UBPY	ENSG00000138592	Ubiquitin specific peptidase 8	15	50424380-50514419	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050215	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.29e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.0	Expressed in all		
SECISBP2L	KIAA0256	ENSG00000138593	SECIS binding protein 2 like	15	48988476-49046563	Predicted intracellular proteins	Evidence at protein level	HPA039875	Approved		Approved	Nucleoplasm	Renal cancer:5.65e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
TMOD3	UTMOD	ENSG00000138594	Tropomodulin 3	15	51829628-51947295	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001849	Approved		Approved	Actin filaments<br>Cytosol	Pancreatic cancer:3.38e-5 (unfavourable), Cervical cancer:3.25e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 47.7	Expressed in all		
SPPL2A	IMP3, PSL2	ENSG00000138600	Signal peptide peptidase like 2A	15	50702266-50765808	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036062, HPA067304	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 291.5	Expressed in all		
GLCE	HSEPI, KIAA0836	ENSG00000138604	Glucuronic acid epimerase	15	69160584-69272217	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040481, HPA048216	Uncertain		Approved	Mitochondria		Expressed in all	Mixed			placenta: 19.1	Cell line enhanced		HUVEC TERT2: 99.7
SHF		ENSG00000138606	Src homology 2 domain containing F	15	45167214-45201175	Predicted intracellular proteins	Evidence at protein level	HPA057381			Approved	Nucleus		Expressed in all	Mixed			adrenal gland: 29.9	Cell line enhanced		SCLC-21H: 142.5;SH-SY5Y: 57.3
APH1B	APH-1B, DKFZp564D0372, PSFL	ENSG00000138613	Aph-1 homolog B, gamma-secretase subunit	15	63276018-63309126	Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:1.05e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 153.4	thyroid gland: 32.1	Mixed		
INTS14	C15orf44, DKFZP564O1664, VWA9	ENSG00000138614	Integrator complex subunit 14	15	65578753-65611289	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040255, HPA040651	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			fallopian tube: 39.1	Expressed in all		
CILP	HsT18872	ENSG00000138615	Cartilage intermediate layer protein	15	65194758-65211488	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003195	Uncertain				Thyroid cancer:2.24e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 67.0;smooth muscle: 70.8	gallbladder: 54.9	Cell line enhanced		ASC diff: 2.9;ASC TERT1: 1.7;EFO-21: 1.0;HSkMC: 4.7
PARP16	C15orf30, FLJ20509, FLJ25281, pART15	ENSG00000138617	Poly(ADP-ribose) polymerase family member 16	15	65234460-65300618	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017081	Approved					Expressed in all	Expressed in all			ovary: 13.0	Expressed in all		
PPCDC	FLJ14585, MDS018	ENSG00000138621	Phosphopantothenoylcysteine decarboxylase	15	75023555-75117462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045667	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 22.4	Expressed in all		
HCN4		ENSG00000138622	Hyperpolarization activated cyclic nucleotide gated potassium channel 4	15	73319859-73369264	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Group enriched	Group enriched	6	cerebral cortex: 1.4;heart muscle: 1.5;testis: 6.7	adrenal gland: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.3;NTERA-2: 4.7;U-2 OS: 2.1
SEMA7A	CD108, H-Sema-L, SEMAL	ENSG00000138623	Semaphorin 7A (John Milton Hagen blood group)	15	74409289-74434467	Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008210, HPA042273	Uncertain		Uncertain	Vesicles	Renal cancer:2.45e-11 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 59.6;testis: 56.9	placenta: 44.8	Cell line enhanced		HMC-1: 510.6;hTEC/SVTERT24-B: 213.0;U-251 MG: 310.7
UBL7	BMSC-UbP, MGC14421	ENSG00000138629	Ubiquitin like 7	15	74445977-74461182	Predicted intracellular proteins	Evidence at protein level	HPA040423, HPA041897	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:6.37e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.4	Expressed in all		
ARHGAP24	DKFZP564B1162, FilGAP, FLJ33877	ENSG00000138639	Rho GTPase activating protein 24	4	85475114-86002670	Predicted intracellular proteins	Evidence at protein level	HPA014288	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.67e-11 (favourable)	Expressed in all	Expressed in all			kidney: 106.3	Cell line enhanced		ASC diff: 75.0;HUVEC TERT2: 101.5;TIME: 70.7
FAM13A	ARHGAP48, FAM13A1, KIAA0914	ENSG00000138640	Family with sequence similarity 13 member A	4	88725955-89111398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038108, HPA038109	Uncertain		Approved	Nucleoli<br>Cell Junctions<br>Cytosol	Urothelial cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 114.4	Cell line enhanced		ASC diff: 38.0
HERC3	KIAA0032	ENSG00000138641	HECT and RLD domain containing E3 ubiquitin protein ligase 3	4	88521048-88708542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039170	Approved		Approved	Cytosol	Renal cancer:5.65e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 61.0	Mixed		
HERC6	FLJ20637	ENSG00000138642	HECT and RLD domain containing E3 ubiquitin protein ligase family member 6	4	88378739-88443111	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035846	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:7.14e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 22.8	Group enriched	5	BJ hTERT+ SV40 Large T+: 108.0;BJ hTERT+ SV40 Large T+ RasG12V: 83.5
HERC5	CEB1	ENSG00000138646	HECT and RLD domain containing E3 ubiquitin protein ligase 5	4	88457117-88506163	Predicted membrane proteins	Evidence at protein level	HPA043929	Supported				Endometrial cancer:4.46e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 106.5	endometrium: 25.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 83.8;BJ hTERT+ SV40 Large T+ RasG12V: 120.3
PCDH10	KIAA1400, OL-PCDH	ENSG00000138650	Protocadherin 10	4	133149315-133208606	Predicted membrane proteins	Evidence at protein level	HPA011220, HPA073462	Approved		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Group enriched	5	cerebral cortex: 62.0;placenta: 36.7;prostate: 17.6;seminal vesicle: 24.5	adrenal gland: 6.8	Cell line enhanced		HUVEC TERT2: 23.1;MOLT-4: 19.4;TIME: 45.4;U-138 MG: 14.3
NDST4		ENSG00000138653	N-deacetylase and N-sulfotransferase 4	4	114827763-115113876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011129	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.4;ovary: 1.8	spleen: 1.0	Cell line enhanced		AF22: 2.8;CACO-2: 2.4;RH-30: 14.2;T-47d: 3.1
ZGRF1	C4orf21, FLJ11331	ENSG00000138658	Zinc finger GRF-type containing 1	4	112539333-112636995	Predicted intracellular proteins	Evidence at protein level	HPA030704, HPA030706	Uncertain		Approved	Cytosol		Mixed	Mixed			testis: 6.7	Mixed		
AP1AR	2C18, C4orf16, gamma-BAR, PRO0971	ENSG00000138660	Adaptor related protein complex 1 associated regulatory protein	4	112231737-112270047	Predicted intracellular proteins	Evidence at protein level	HPA035863, HPA058115	Approved		Supported	Golgi apparatus	Renal cancer:4.05e-7 (favourable), Urothelial cancer:7.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.7	Expressed in all		
COPS4	CSN4	ENSG00000138663	COP9 signalosome subunit 4	4	83034447-83075818	Predicted intracellular proteins	Evidence at protein level	HPA036894, HPA042828	Uncertain		Supported	Nuclear speckles	Renal cancer:5.21e-6 (favourable), Colorectal cancer:4.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
HNRNPD	AUF1, HNRPD	ENSG00000138668	Heterogeneous nuclear ribonucleoprotein D	4	82352498-82374503	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004911	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 341.0	Expressed in all		
PRKG2	cGKII, PRKGR2	ENSG00000138669	Protein kinase, cGMP-dependent, type II	4	81087370-81215117	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007386, CAB018739	Approved					Tissue enhanced	Tissue enhanced		prostate: 15.3;small intestine: 14.4	duodenum: 9.7	Cell line enhanced		HEL: 18.8;SCLC-21H: 7.3
RASGEF1B	FLJ31695, GPIG4	ENSG00000138670	RasGEF domain family member 1B	4	81426393-82044244	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044574	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.21e-6 (favourable), Head and neck cancer:1.49e-5 (favourable), Cervical cancer:6.40e-4 (favourable)	Expressed in all	Mixed			skin: 31.6	Cell line enhanced		CACO-2: 12.9;Daudi: 13.1;Karpas-707: 9.0;NTERA-2: 11.1;SCLC-21H: 10.7
SEC31A	ABP125, ABP130, KIAA0905, SEC31L1	ENSG00000138674	SEC31 homolog A, COPII coat complex component	4	82818661-82901166	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005457	Approved		Supported	Vesicles<br>Cytosol	Urothelial cancer:2.69e-4 (unfavourable), Liver cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 281.0	Expressed in all		
FGF5		ENSG00000138675	Fibroblast growth factor 5	4	80266599-80336680	Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010313, HPA042442			Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Not detected	Tissue enhanced		gallbladder: 5.6	smooth muscle: 1.4	Cell line enhanced		BJ hTERT+: 97.8;fHDF/TERT166: 68.3;HBF TERT88: 85.6;LHCN-M2: 67.6;U-138 MG: 108.3
GPAT3	AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324	ENSG00000138678	Glycerol-3-phosphate acyltransferase 3	4	83535914-83605875	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA029414, CAB033749	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable)	Mixed	Tissue enhanced		kidney: 89.9	duodenum: 40.7	Cell line enhanced		CAPAN-2: 141.3;U-87 MG: 67.1;WM-115: 52.9
IL21	IL-21, Za11	ENSG00000138684	Interleukin 21	4	122612628-122621069	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 18.1;tonsil: 6.3	testis: 4.1	Not detected		
FGF2	FGFB	ENSG00000138685	Fibroblast growth factor 2	4	122826708-122898236	Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB000125	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:9.85e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 26.1	Cell line enhanced		BJ: 206.0;fHDF/TERT166: 215.4
BBS7	BBS2L1, FLJ10715	ENSG00000138686	Bardet-Biedl syndrome 7	4	121824440-121870497	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044592	Approved					Expressed in all	Mixed			cerebral cortex: 25.7	Expressed in all		
KIAA1109	FLJ21404, FSA, KIAA1371, Tweek	ENSG00000138688	KIAA1109	4	122152333-122362758	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038076	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:4.33e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 130.9	Expressed in all		
BMPR1B	ALK6, CDw293	ENSG00000138696	Bone morphogenetic protein receptor type 1B	4	94757968-95158448	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 37.2;prostate: 37.0	seminal vesicle: 21.0	Cell line enhanced		A549: 21.1;SH-SY5Y: 20.1
RAP1GDS1	SmgGDS	ENSG00000138698	Rap1 GTPase-GDP dissociation stimulator 1	4	98261384-98443861	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019060	Approved		Supported	Cytosol	Renal cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 93.9	Expressed in all		
LARP1B	DKFZp434K245, DKFZp686E0316, FLJ10378, LARP2	ENSG00000138709	La ribonucleoprotein domain family member 1B	4	128061268-128222931	Predicted intracellular proteins	Evidence at protein level	HPA036280	Approved		Approved	Cytosol	Renal cancer:5.13e-5 (favourable)	Expressed in all	Expressed in all			testis: 103.0	Expressed in all		
MMRN1	ECM, EMILIN4, GPIa*, MMRN	ENSG00000138722	Multimerin 1	4	89879532-89954629	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035769	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.77e-4 (unfavourable), Stomach cancer:5.46e-4 (unfavourable)	Mixed	Mixed			placenta: 57.5	Cell line enriched	11	HUVEC TERT2: 1035.6
PDE5A		ENSG00000138735	Phosphodiesterase 5A	4	119494395-119628991	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004729, HPA012873	Approved		Approved	Cytosol	Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable)	Expressed in all	Mixed			prostate: 97.7	Cell line enhanced		BJ hTERT+: 38.5;HHSteC: 55.3
PRDM5	PFM2	ENSG00000138738	PR/SET domain 5	4	120684919-120922870	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051406	Enhanced		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 20.7	Mixed		
TRPC3		ENSG00000138741	Transient receptor potential cation channel subfamily C member 3	4	121879027-121951754	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA037969	Uncertain					Not detected	Tissue enhanced		smooth muscle: 4.1	cerebral cortex: 2.1	Cell line enhanced		HEK 293: 1.6;HEL: 2.4;Karpas-707: 1.9;U-2 OS: 1.8
NAAA	ASAHL	ENSG00000138744	N-acylethanolamine acid amidase	4	75913657-75941051	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026135	Approved				Endometrial cancer:1.93e-4 (favourable), Pancreatic cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			prostate: 114.9	Mixed		
NUP54		ENSG00000138750	Nucleoporin 54	4	76114659-76148515	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035929, HPA058122	Approved		Approved	Nucleoplasm	Liver cancer:4.64e-4 (unfavourable), Colorectal cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
CXCL9	CMK, crg-10, Humig, MIG, SCYB9	ENSG00000138755	C-X-C motif chemokine ligand 9	4	76001275-76007488	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.15e-6 (unfavourable), Endometrial cancer:2.07e-4 (favourable), Breast cancer:6.36e-4 (favourable), Ovarian cancer:8.06e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 327.4	appendix: 86.2	Not detected		
BMP2K	BIKe, DKFZp434K0614	ENSG00000138756	BMP2 inducible kinase	4	78776342-78916372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026436, HPA026451, HPA026501	Approved		Supported	Nuclear speckles	Colorectal cancer:1.74e-4 (favourable)	Mixed	Mixed			testis: 32.8	Expressed in all		
G3BP2	KIAA0660	ENSG00000138757	G3BP stress granule assembly factor 2	4	75642782-75724525	Predicted intracellular proteins	Evidence at protein level	HPA018304, HPA018425	Enhanced		Enhanced	Cytosol	Renal cancer:6.65e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 178.5	Expressed in all		
SEPT11	FLJ10849	ENSG00000138758	Septin 11	4	76949703-77040384	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003459, HPA005665	Approved		Approved	Cytosol	Liver cancer:1.70e-5 (unfavourable), Renal cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			placenta: 120.1	Mixed		
FRAS1	FLJ14927, FLJ22031, KIAA1500	ENSG00000138759	Fraser extracellular matrix complex subunit 1	4	78057570-78544269	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011281, HPA051601	Approved		Approved	Nucleoli fibrillar center	Renal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 20.2	kidney,placenta: 8.2	Cell line enhanced		fHDF/TERT166: 28.1;RH-30: 19.7;SiHa: 23.0
SCARB2	CD36L2, HLGP85, LIMP-2, LIMPII, SR-BII	ENSG00000138760	Scavenger receptor class B member 2	4	76158733-76234536	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB015415, HPA018014	Supported		Approved	Cytosol	Breast cancer:2.82e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 112.1	Mixed		
CCNG2		ENSG00000138764	Cyclin G2	4	77157151-77433388	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA034684	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.47e-5 (favourable), Pancreatic cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 150.2	Expressed in all		
CNOT6L	Ccr4b, DKFZp434K098	ENSG00000138767	CCR4-NOT transcription complex subunit 6 like	4	77713387-77819615	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042688	Uncertain		Supported	Cytosol	Renal cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 43.7	Expressed in all		
USO1	p115, TAP, VDP	ENSG00000138768	USO1 vesicle transport factor	4	75724593-75814286	Predicted intracellular proteins	Evidence at protein level	CAB010108, HPA038282, HPA038283	Supported		Enhanced	Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 91.1	Expressed in all		
CDKL2	KKIAMRE, P56	ENSG00000138769	Cyclin dependent kinase like 2	4	75578005-75630716	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040672			Approved	Nucleus<br>Centrosome	Renal cancer:6.88e-15 (favourable)	Mixed	Tissue enhanced		testis: 33.1	cerebral cortex: 9.8	Cell line enhanced		A-431: 2.7;RPTEC TERT1: 3.3
SHROOM3	APXL3, KIAA1481, SHRM, ShrmL	ENSG00000138771	Shroom family member 3	4	76435100-76783253	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047784	Enhanced				Renal cancer:1.64e-13 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.6	Cell line enhanced		AF22: 30.8
ANXA3	ANX3	ENSG00000138772	Annexin A3	4	78551519-78610451	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013398, HPA013431	Enhanced		Supported	Cytosol	Renal cancer:8.48e-6 (favourable), Pancreatic cancer:1.28e-4 (unfavourable)	Mixed	Expressed in all			bone marrow: 198.3	Cell line enhanced		A-431: 316.4;CACO-2: 302.6;CAPAN-2: 428.5;EFO-21: 275.3;hTERT-HME1: 372.7;RPTEC TERT1: 312.0
PPA2	FLJ20459	ENSG00000138777	Pyrophosphatase (inorganic) 2	4	105369077-105474081	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030888, HPA031671, HPA031672	Supported		Approved	Nucleus<br>Mitochondria	Renal cancer:1.27e-11 (favourable), Breast cancer:2.98e-4 (unfavourable), Colorectal cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			prostate: 21.3	Expressed in all		
CENPE	KIF10, PPP1R61	ENSG00000138778	Centromere protein E	4	103105806-103198409	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042294	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytosol		Mixed	Mixed			testis: 7.7	Mixed		
GSTCD	FLJ13273	ENSG00000138780	Glutathione S-transferase C-terminal domain containing	4	105708778-105847728	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046160, HPA061782	Approved		Supported	Nucleus		Expressed in all	Mixed			testis: 19.5	Expressed in all		
INTS12	INT12, PHF22, SBBI22	ENSG00000138785	Integrator complex subunit 12	4	105682627-105895986	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035772, HPA041814	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Liver cancer:2.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.5	Expressed in all		
ENPEP	CD249, gp160	ENSG00000138792	Glutamyl aminopeptidase	4	110365733-110565285	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002821, HPA005128	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Group enriched	5	duodenum: 36.5;kidney: 94.3;parathyroid gland: 160.7;small intestine: 180.3	placenta: 21.5	Cell line enhanced		BEWO: 2.6;HEK 293: 6.8;MOLT-4: 1.4
CASP6	MCH2	ENSG00000138794	Caspase 6	4	109688622-109703583	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003775, HPA011337, HPA024303	Enhanced		Supported	Nucleus<br>Cytosol	Colorectal cancer:2.64e-5 (favourable), Urothelial cancer:9.93e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 46.1	Expressed in all		
LEF1	TCF10, TCF1ALPHA, TCF7L3	ENSG00000138795	Lymphoid enhancer binding factor 1	4	108047545-108168956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002087, CAB019405	Enhanced		Approved	Nucleoplasm	Renal cancer:2.47e-6 (unfavourable), Endometrial cancer:1.37e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 41.7	tonsil: 28.3	Group enriched	6	MOLT-4: 512.4;REH: 443.8
HADH	HADH1, HADHSC, SCHAD	ENSG00000138796	Hydroxyacyl-CoA dehydrogenase	4	107989714-108035175	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039588, HPA043888	Supported		Supported	Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			adipose tissue: 154.5	Expressed in all		
EGF		ENSG00000138798	Epidermal growth factor	4	109912884-110012266	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Tissue enriched	7	kidney: 122.1	pancreas: 18.5	Cell line enhanced		EFO-21: 5.9;SK-BR-3: 8.5;U-251 MG: 3.0
PAPSS1	ATPSK1, PAPSS	ENSG00000138801	3'-phosphoadenosine 5'-phosphosulfate synthase 1	4	107590276-107720452	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049781	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:2.70e-5 (unfavourable), Endometrial cancer:8.58e-4 (favourable), Colorectal cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 73.7	Expressed in all		
SEC24B		ENSG00000138802	SEC24 homolog B, COPII coat complex component	4	109433772-109540896	Predicted intracellular proteins	Evidence at protein level	HPA038181	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:2.33e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.8	Expressed in all		
C4orf17	DKFZP434G072	ENSG00000138813	Chromosome 4 open reading frame 17	4	99511004-99542303	Predicted intracellular proteins	Evidence at protein level	HPA060374, HPA060564	Uncertain					Not detected	Tissue enriched	352	testis: 35.2	all non-specific tissues: 0.0	Not detected		
PPP3CA	CALN, CALNA, CNA1, PPP2B	ENSG00000138814	Protein phosphatase 3 catalytic subunit alpha	4	101023409-101348278	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012778, CAB018581	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.82e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 164.3	Expressed in all		
SLC39A8	BIGM103	ENSG00000138821	Solute carrier family 39 member 8	4	102251041-102431258	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038832, HPA038833	Approved				Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 257.0	cervix, uterine: 129.4	Cell line enhanced		BJ hTERT+: 128.9;Karpas-707: 123.0
MTTP	ABL, MTP	ENSG00000138823	Microsomal triglyceride transfer protein	4	99563761-99623999	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051170, HPA054862	Uncertain		Approved	Cytosol		Tissue enriched	Group enriched	16	duodenum: 236.3;liver: 133.9;small intestine: 292.6	testis: 13.5	Cell line enhanced		AF22: 10.2;Hep G2: 8.0
FBN2	CCA, DA9	ENSG00000138829	Fibrillin 2	5	128257909-128659185	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012853, CAB026401	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:7.41e-5 (unfavourable)	Mixed	Tissue enriched	9	placenta: 118.4	testis: 13.8	Cell line enhanced		HHSteC: 116.8;hTERT-HME1: 171.2;HUVEC TERT2: 107.0
MAPK8IP3	JIP3, JSAP1, KIAA1066, syd	ENSG00000138834	Mitogen-activated protein kinase 8 interacting protein 3	16	1706183-1770317	Predicted intracellular proteins	Evidence at protein level	CAB005580, HPA041785, HPA069311	Approved		Approved	Vesicles	Renal cancer:5.25e-5 (unfavourable), Urothelial cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.9	Expressed in all		
RGS3	C2PA, FLJ20370, PDZ-RGS3	ENSG00000138835	Regulator of G-protein signaling 3	9	113444731-113597743	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032507, HPA041109			Enhanced	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:6.62e-4 (unfavourable), Breast cancer:9.93e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 66.4	Cell line enhanced		BJ hTERT+: 201.8;HDLM-2: 382.8
GUCD1	C22orf13, LLN4, MGC1842	ENSG00000138867	Guanylyl cyclase domain containing 1	22	24540423-24555935	Predicted intracellular proteins	Evidence at protein level	HPA022786			Approved	Nucleoplasm	Cervical cancer:6.84e-4 (favourable), Ovarian cancer:7.26e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 63.0	Expressed in all		
TTLL8		ENSG00000138892	Tubulin tyrosine ligase like 8	22	50015123-50056935	Predicted intracellular proteins	Evidence at transcript level	HPA016882	Uncertain					Not detected	Tissue enriched	42	testis: 4.2	all non-specific tissues: 0.0	Not detected		
RNF185	FLJ38628	ENSG00000138942	Ring finger protein 185	22	31160183-31207019	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.82e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 86.7	Expressed in all		
KIAA1644		ENSG00000138944	KIAA1644	22	44243667-44312851	Predicted membrane proteins	Evidence at transcript level	HPA051178	Uncertain		Approved	Vesicles<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 27.6;endometrium: 42.8;smooth muscle: 44.6	cervix, uterine: 19.2	Cell line enhanced		SiHa: 38.9;U-2197: 76.1;U-87 MG: 46.0;WM-115: 27.3
PARVG		ENSG00000138964	Parvin gamma	22	44172956-44219533	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031833, HPA031834	Uncertain				Renal cancer:3.43e-6 (unfavourable), Endometrial cancer:4.44e-6 (favourable)	Expressed in all	Tissue enhanced		spleen: 38.4	appendix: 35.4	Cell line enhanced		HL-60: 92.2;NB-4: 28.2;THP-1: 43.6;U-937: 42.1
B4GALNT3	B4GalNac-T3, FLJ16224, FLJ40362	ENSG00000139044	Beta-1,4-N-acetyl-galactosaminyltransferase 3	12	460364-563509	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011404	Enhanced				Endometrial cancer:1.69e-10 (favourable)	Mixed	Tissue enhanced		stomach: 69.3	colon: 21.5	Cell line enhanced		BEWO: 37.3;NTERA-2: 17.2
PDE6H		ENSG00000139053	Phosphodiesterase 6H	12	14973022-14981865	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Not detected	Tissue enhanced		bone marrow: 2.4;placenta: 1.3	adrenal gland: 0.5	Not detected		
ERP27	C12orf46, ERp27, FLJ32115, PDIA8	ENSG00000139055	Endoplasmic reticulum protein 27	12	14914035-14939082	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039636, HPA052851	Enhanced					Expressed in all	Group enriched	10	fallopian tube: 104.4;pancreas: 282.3	kidney: 20.0	Cell line enhanced		CAPAN-2: 16.3;RT4: 74.3
ETV6	TEL	ENSG00000139083	ETS variant 6	12	11649854-11895402	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000264	Enhanced		Enhanced	Nucleoli<br>Cytosol	Renal cancer:4.66e-8 (unfavourable), Urothelial cancer:1.54e-5 (favourable), Pancreatic cancer:9.38e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.4	Cell line enhanced		HDLM-2: 80.8
GABARAPL1	APG8L, ATG8B, ATG8L, gec1	ENSG00000139112	GABA type A receptor associated protein like 1	12	10212458-10223130	Predicted intracellular proteins	Evidence at protein level	HPA051386, HPA065883	Approved		Approved	Vesicles	Renal cancer:8.19e-8 (favourable), Liver cancer:2.36e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 432.0	Cell line enhanced		HHSteC: 208.2;SiHa: 253.0
KIF21A	FEOM1, FLJ20052	ENSG00000139116	Kinesin family member 21A	12	39293228-39443390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB022079, HPA058432	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.07e-8 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.0	fallopian tube: 54.6	Cell line enhanced		SH-SY5Y: 199.8
CPNE8		ENSG00000139117	Copine 8	12	38646822-38907430	Predicted intracellular proteins	Evidence at protein level	HPA038600	Approved				Stomach cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			placenta: 17.2	Cell line enhanced		RPTEC TERT1: 49.5
YARS2	CGI-04, FLJ13995, mt-TyrRS	ENSG00000139131	Tyrosyl-tRNA synthetase 2	12	32727490-32755902	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038721, HPA057610, HPA074097	Uncertain		Supported	Nuclear bodies<br>Mitochondria	Liver cancer:3.19e-5 (unfavourable)	Expressed in all	Mixed			placenta: 11.1	Expressed in all		
FGD4	CMT4H, frabin, FRABP, ZFYVE6	ENSG00000139132	FYVE, RhoGEF and PH domain containing 4	12	32399529-32646050	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039235	Approved		Supported	Actin filaments	Renal cancer:7.16e-5 (favourable)	Expressed in all	Expressed in all			ovary: 30.2	Mixed		
ALG10	ALG10A, DIE2, FLJ14751	ENSG00000139133	ALG10, alpha-1,2-glucosyltransferase	12	34022281-34029694	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043329, HPA063387	Approved		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 4.6	Expressed in all		
PIK3C2G		ENSG00000139144	Phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma	12	18247614-18648416	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:3.50e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.4;stomach: 20.0	parathyroid gland: 17.3	Group enriched	6	BEWO: 1.2;HaCaT: 1.8;hTERT-HME1: 2.9
FAM60A	C12orf14, TERA	ENSG00000139146	Family with sequence similarity 60 member A	12	31280584-31327058	Predicted intracellular proteins	Evidence at protein level	HPA038167, HPA057585	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.57e-4 (unfavourable), Liver cancer:5.78e-4 (unfavourable), Renal cancer:7.89e-4 (favourable)	Expressed in all	Mixed			endometrium: 44.5	Expressed in all		
PLCZ1	NYD-SP27, PLCzeta	ENSG00000139151	Phospholipase C zeta 1	12	18683169-18738057	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	23	testis: 48.5	skin: 2.1	Not detected		
AEBP2	MGC17922	ENSG00000139154	AE binding protein 2	12	19404045-19720801	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020893, HPA022282	Uncertain		Supported	Nucleus	Liver cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 57.5	Expressed in all		
SLCO1C1	OATP-F, OATP1, OATP1C1, SLC21A14	ENSG00000139155	Solute carrier organic anion transporter family member 1C1	12	20695355-20753386	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 27.5	testis: 2.6	Cell line enriched	9	HeLa: 2.7
ETFBKMT	C12orf72, DKFZp451L235, METTL20, MGC50559	ENSG00000139160	Electron transfer flavoprotein beta subunit lysine methyltransferase	12	31647160-31673114	Predicted intracellular proteins	Evidence at protein level	HPA039024	Uncertain					Mixed	Mixed			parathyroid gland: 8.8	Mixed		
ETNK1	EKI, EKI1	ENSG00000139163	Ethanolamine kinase 1	12	22625075-22690665	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010712, HPA029407	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 45.6	Expressed in all		
ZCRB1	MADP-1, MADP1, RBM36, SNRNP31, ZCCHC19	ENSG00000139168	Zinc finger CCHC-type and RNA binding motif containing 1	12	42312078-42326118	Predicted intracellular proteins	Evidence at protein level						Liver cancer:5.33e-7 (unfavourable), Renal cancer:1.37e-6 (unfavourable), Ovarian cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 153.7	Expressed in all		
TMEM117	DKFZp434K2435	ENSG00000139173	Transmembrane protein 117	12	43835967-44389762	Predicted membrane proteins	Evidence at transcript level	HPA039899, HPA046223	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge	Melanoma:3.94e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 7.3	Mixed		
PRICKLE1	EPM1B, FLJ31937, RILP	ENSG00000139174	Prickle planar cell polarity protein 1	12	42456757-42590355	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001379, HPA050037	Enhanced		Approved	Nucleoplasm	Glioma:5.56e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 21.2	Cell line enriched	13	HBEC3-KT: 727.1
C1RL	C1r-LP, C1RL1	ENSG00000139178	Complement C1r subcomponent like	12	7089587-7109273	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011338, CAB026172	Supported		Approved	Microtubules<br>Cytosol	Renal cancer:1.52e-7 (unfavourable), Breast cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			liver: 83.7	Cell line enhanced		HSkMC: 60.9
NDUFA9	CI-39k, NDUFS2L, SDR22E1	ENSG00000139180	NADH:ubiquinone oxidoreductase subunit A9	12	4649095-4694317	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042268, HPA073212	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.57e-7 (favourable), Urothelial cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.4	Expressed in all		
CLSTN3	CDHR14, CSTN3, KIAA0726	ENSG00000139182	Calsyntenin 3	12	7129698-7158945	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.19e-5 (favourable), Renal cancer:4.49e-5 (unfavourable), Breast cancer:5.08e-4 (favourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 126.6	parathyroid gland: 40.3	Mixed		
KLRG1	2F1, CLEC15A, MAFA, MAFA-L	ENSG00000139187	Killer cell lectin like receptor G1	12	8950044-9010760	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051403, HPA076494			Supported	Vesicles		Mixed	Tissue enhanced		spleen: 15.8	lymph node: 13.5	Cell line enhanced		HEL: 29.9;NTERA-2: 22.2;U-937: 16.1
VAMP1	SYB1, VAMP-1	ENSG00000139190	Vesicle associated membrane protein 1	12	6462237-6470987	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002779, CAB016119, CAB079000	Approved	Approved			Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 43.5	Cell line enriched	5	U-698: 140.4
TAPBPL	FLJ10143, TAPBP-R, TAPBPR	ENSG00000139192	TAP binding protein like	12	6451690-6466517	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039545	Uncertain				Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.2	Cell line enhanced		CAPAN-2: 58.5
CD27	S152, TNFRSF7, Tp55	ENSG00000139193	CD27 molecule	12	6444867-6451718	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002420, HPA038936	Enhanced				Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 140.5;tonsil: 85.8	spleen: 67.8	Group enriched	122	Daudi: 153.8;U-698: 81.7
RBP5	CRBPIII	ENSG00000139194	Retinol binding protein 5	12	7123684-7128942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038723	Enhanced		Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 455.7;liver: 204.9	spleen: 102.0	Cell line enhanced		Hep G2: 17.0;K-562: 46.6
PEX5	PTS1R, PXR1	ENSG00000139197	Peroxisomal biogenesis factor 5	12	7188685-7218574	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039259, HPA039260	Enhanced		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			testis: 81.3	Expressed in all		
PIANP	C12orf53, DKFZp547D2210, PANP	ENSG00000139200	PILR alpha associated neural protein	12	6693792-6700800	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010631	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 64.3	endometrium: 13.4	Cell line enhanced		NTERA-2: 20.8;SH-SY5Y: 20.6;U-2 OS: 11.2
SLC38A4	ATA3, NAT3, PAAT	ENSG00000139209	Solute carrier family 38 member 4	12	46764761-46832408	Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:5.37e-4 (favourable)	Tissue enriched	Tissue enriched	40	liver: 346.9	smooth muscle: 8.7	Cell line enhanced		LHCN-M2: 37.9;RH-30: 14.5;RT4: 71.7
AMIGO2	ALI1, DEGA	ENSG00000139211	Adhesion molecule with Ig like domain 2	12	47075707-47079951	Predicted membrane proteins	Evidence at protein level	HPA054004, HPA059601	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.80e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Cell line enhanced		CAPAN-2: 184.4;fHDF/TERT166: 158.6;LHCN-M2: 167.5;RT4: 222.6;U-2 OS: 170.3
SCAF11	CASP11, SFRS2IP, SIP1, SRRP129, SRSF2IP	ENSG00000139218	SR-related CTD associated factor 11	12	45919131-45992120	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038862, HPA045456, HPA046345	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 84.9	Expressed in all		
COL2A1	AOM, SEDC, STL1	ENSG00000139219	Collagen type II alpha 1 chain	12	47972965-48004486	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002214, HPA055753	Supported		Approved	Nucleoplasm		Mixed	Group enriched	9	epididymis: 23.0;stomach: 6.2	prostate: 1.6	Group enriched	23	AF22: 154.1;HAP1: 101.9;HEK 293: 33.7
PPFIA2		ENSG00000139220	PTPRF interacting protein alpha 2	12	81257975-81759553	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 61.0	testis: 11.4	Group enriched	9	HAP1: 30.3;SCLC-21H: 11.7
ANP32D	PP32R2	ENSG00000139223	Acidic nuclear phosphoprotein 32 family member D	12	48472665-48473624	Predicted intracellular proteins	Evidence at protein level	HPA063133, HPA067561	Uncertain		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol		Not detected	Not detected			testis,thyroid gland: 0.1	Not detected		
LLPH	C12orf31, hLLP, MGC14817	ENSG00000139233	LLP homolog, long-term synaptic facilitation	12	66116555-66130768	Predicted intracellular proteins	Evidence at protein level	HPA048920, HPA058786			Enhanced	Nucleoli	Liver cancer:6.44e-7 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 42.5	Expressed in all		
LRIG3	FLJ90440, KIAA3016	ENSG00000139263	Leucine rich repeats and immunoglobulin like domains 3	12	58872149-58920522	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010773	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		thyroid gland: 97.8	skin: 33.0	Mixed		
MARCH9	FLJ36578, RNF179	ENSG00000139266	Membrane associated ring-CH-type finger 9	12	57755098-57760407	Enzymes, Predicted membrane proteins	Evidence at protein level						Lung cancer:1.54e-5 (favourable), Renal cancer:2.98e-5 (favourable), Ovarian cancer:1.59e-4 (favourable), Endometrial cancer:3.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Cell line enriched	16	RH-30: 498.8
INHBE	activin, MGC4638	ENSG00000139269	Inhibin beta E subunit	12	57452323-57459280	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016843, CAB034017	Enhanced		Approved	Vesicles	Renal cancer:5.66e-8 (unfavourable)	Tissue enriched	Tissue enriched	28	liver: 68.1	thyroid gland: 2.4	Cell line enhanced		HHSteC: 43.4;Karpas-707: 57.3;U-266/70: 203.5
GLIPR1	GliPR, RTVP1	ENSG00000139278	GLI pathogenesis related 1	12	75480680-75503853	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011014	Approved				Renal cancer:8.69e-9 (unfavourable)	Expressed in all	Mixed			appendix: 64.9	Cell line enhanced		hTEC/SVTERT24-B: 189.5;U-138 MG: 359.6
TPH2	FLJ37295, NTPH	ENSG00000139287	Tryptophan hydroxylase 2	12	71938846-72186618	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046274, CAB078198	Enhanced	Supported				Not detected	Tissue enhanced		cerebral cortex: 1.0	testis: 0.2	Not detected		
PHLDA1	DT1P1B11, PHRIP, TDAG51	ENSG00000139289	Pleckstrin homology like domain family A member 1	12	76025447-76033932	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB016160, HPA019000, HPA063520	Approved		Supported	Nucleoli		Expressed in all	Mixed			salivary gland: 68.6	Mixed		
TMEM19	FLJ10936	ENSG00000139291	Transmembrane protein 19	12	71686087-71705046	Predicted membrane proteins	Evidence at protein level	HPA016830	Approved					Expressed in all	Expressed in all			kidney: 40.8	Expressed in all		
LGR5	FEX, GPR49, GPR67, HG38	ENSG00000139292	Leucine rich repeat containing G protein-coupled receptor 5	12	71439770-71586310	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA012530	Approved				Lung cancer:5.09e-4 (favourable)	Group enriched	Tissue enhanced		fallopian tube: 26.6;placenta: 26.9	seminal vesicle: 9.8	Group enriched	6	Hep G2: 25.0;SH-SY5Y: 110.2
PTPRQ	DFNB84	ENSG00000139304	Protein tyrosine phosphatase, receptor type Q	12	80402178-80680234	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053245	Uncertain		Approved	Cytosol		Not detected	Tissue enhanced		testis: 4.9	lung: 3.4	Cell line enhanced		ASC TERT1: 3.4;BJ: 3.3;HBF TERT88: 2.6;RH-30: 2.8;RT4: 2.7;U-2197: 2.9
DUSP6	MKP-3, PYST1	ENSG00000139318	Dual specificity phosphatase 6	12	89347232-89353271	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017566, HPA053188	Approved		Uncertain	Nucleoplasm<br>Cytosol	Endometrial cancer:7.21e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 141.2	Cell line enhanced		AN3-CA: 428.0
POC1B	FLJ14923, TUWD12, WDR51B	ENSG00000139323	POC1 centriolar protein B	12	89419718-89526024	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.45e-6 (favourable), Endometrial cancer:9.59e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 19.8	Expressed in all		
TMTC3	FLJ90492, SMILE	ENSG00000139324	Transmembrane and tetratricopeptide repeat containing 3	12	88142296-88199887	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA038550	Approved					Expressed in all	Mixed			skin: 14.9	Expressed in all		
LUM	LDC, SLRR2D	ENSG00000139329	Lumican	12	91102629-91111831	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001522, CAB025783	Supported				Renal cancer:1.75e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 929.5	placenta: 602.2	Cell line enhanced		BJ: 269.9;BJ hTERT+: 1272.0;fHDF/TERT166: 208.2
KERA	CNA2, SLRR2B	ENSG00000139330	Keratocan	12	91050491-91057983	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039321	Uncertain					Mixed	Tissue enhanced		gallbladder: 1.5	breast,fallopian tube: 0.8	Not detected		
SNRPF	Sm-F	ENSG00000139343	Small nuclear ribonucleoprotein polypeptide F	12	95858928-95903828	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.11e-6 (unfavourable)	Expressed in all	Expressed in all			appendix: 36.8	Expressed in all		
AMDHD1	MGC35366	ENSG00000139344	Amidohydrolase domain containing 1	12	95943293-95968716	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039720	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enhanced		testis: 25.8	liver: 22.0	Cell line enhanced		HMC-1: 57.9;Karpas-707: 44.7;SiHa: 44.1;U-266/84: 42.8
NEDD1	GCP-WD, TUBGCP7	ENSG00000139350	Neural precursor cell expressed, developmentally down-regulated 1	12	96907223-96953777	Predicted intracellular proteins	Evidence at protein level	HPA038591	Approved				Liver cancer:1.94e-4 (unfavourable), Lung cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.9	Expressed in all		
SYCP3		ENSG00000139351	Synaptonemal complex protein 3	12	101728648-101739472	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB032978, HPA039635, HPA043938	Enhanced					Tissue enriched	Tissue enriched	265	testis: 172.2	lung: 0.6	Cell line enhanced		Karpas-707: 1.0
ASCL1	ASH1, bHLHa46, HASH1	ENSG00000139352	Achaete-scute family bHLH transcription factor 1	12	102957686-102960516	Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA029217	Enhanced					Group enriched	Group enriched	8	cerebral cortex: 16.2;liver: 6.4	adrenal gland: 1.4	Group enriched	23	SCLC-21H: 63.4;SH-SY5Y: 30.9
GAS2L3		ENSG00000139354	Growth arrest specific 2 like 3	12	100573683-100628286	Predicted intracellular proteins	Evidence at protein level	HPA048593	Approved				Renal cancer:3.58e-7 (unfavourable)	Mixed	Mixed			gallbladder: 7.0	Mixed		
TMEM132B	KIAA1786, KIAA1906	ENSG00000139364	Transmembrane protein 132B	12	125186836-125662377	Predicted membrane proteins	Evidence at protein level	HPA035661, HPA035662	Uncertain					Tissue enriched	Tissue enriched	7	cerebral cortex: 21.8	thyroid gland: 3.1	Cell line enhanced		HSkMC: 4.8;NTERA-2: 7.7;U-138 MG: 11.6
SLC15A4	PHT1, PTR4	ENSG00000139370	Solute carrier family 15 member 4	12	128793191-128823983	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016713	Approved		Supported	Nucleoplasm	Renal cancer:7.56e-6 (unfavourable), Liver cancer:6.78e-4 (unfavourable), Head and neck cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,testis: 20.2	Mixed		
TDG		ENSG00000139372	Thymine DNA glycosylase	12	103965804-103988874	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052263	Supported		Supported	Nucleoplasm	Renal cancer:1.90e-10 (unfavourable), Liver cancer:6.27e-5 (unfavourable), Melanoma:6.90e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 23.8	Expressed in all		
RITA1	C12orf52, FLJ14827, RITA	ENSG00000139405	RBPJ interacting and tubulin associated 1	12	113185526-113192368	Predicted intracellular proteins	Evidence at protein level	HPA039094, HPA039095, HPA061531	Supported		Supported	Nucleus	Liver cancer:9.79e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 20.4	Expressed in all		
SDSL	cSDH, SDS-RS1	ENSG00000139410	Serine dehydratase like	12	113422237-113438276	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005740	Approved		Approved	Cytosol	Renal cancer:3.09e-5 (favourable), Pancreatic cancer:8.58e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 35.2	Cell line enhanced		MCF7: 64.8
MMAB	cblB, CFAP23	ENSG00000139428	Methylmalonic aciduria (cobalamin deficiency) cblB type	12	109553737-109573874	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039017	Approved		Approved	Mitochondria	Renal cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 32.5	Expressed in all		
GLTP		ENSG00000139433	Glycolipid transfer protein	12	109850943-109880488	Predicted intracellular proteins	Evidence at protein level	HPA056461	Approved		Supported	Cytosol	Thyroid cancer:4.17e-6 (favourable), Cervical cancer:2.01e-5 (favourable), Liver cancer:7.68e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 293.8	Expressed in all		
GIT2	KIAA0148, PKL	ENSG00000139436	GIT ArfGAP 2	12	109929792-109996389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004681	Approved		Approved	Microtubules	Renal cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 47.9	Expressed in all		
TCHP	MGC10854, TpMs	ENSG00000139437	Trichoplein keratin filament binding	12	109900264-109983841	Predicted intracellular proteins	Evidence at protein level	HPA038638, HPA061543	Supported		Supported	Plasma membrane<br>Centrosome<br>Cytosol	Stomach cancer:5.52e-4 (favourable)	Expressed in all	Expressed in all			skin: 32.6	Expressed in all		
FAM222A	C12orf34, FLJ14721	ENSG00000139438	Family with sequence similarity 222 member A	12	109714228-109770507	Predicted intracellular proteins	Evidence at protein level	HPA040181	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites<br>Mitochondria	Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.0;testis: 16.5	adrenal gland: 9.8	Cell line enriched	5	SH-SY5Y: 122.9
FOXN4		ENSG00000139445	Forkhead box N4	12	109277979-109309220	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050018	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enriched	13	testis: 10.7	cervix, uterine: 0.8	Cell line enhanced		SCLC-21H: 4.2;SH-SY5Y: 3.9;U-266/70: 3.9
NUP58	KIAA0410, NUP45, NUPL1	ENSG00000139496	Nucleoporin 58	13	25301524-25349800	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039360	Approved		Approved	Plasma membrane<br>Mitochondria<br>Cytosol	Cervical cancer:2.57e-4 (unfavourable), Liver cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.0	Expressed in all		
MTMR6		ENSG00000139505	Myotubularin related protein 6	13	25246201-25288009	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 30.6	Expressed in all		
SLC46A3	DKFZp686A1775, FLJ42613	ENSG00000139508	Solute carrier family 46 member 3	13	28700064-28718970	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039930	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Lung cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 87.7	Cell line enhanced		RPTEC TERT1: 22.1
SLC7A1	ATRC1, CAT-1, ERR, HCAT1, REC1L	ENSG00000139514	Solute carrier family 7 member 1	13	29509410-29595688	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039721	Approved				Renal cancer:1.32e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 41.8	Expressed in all		
PDX1	IDX-1, IPF1, MODY4, PDX-1, STF-1	ENSG00000139515	Pancreatic and duodenal homeobox 1	13	27920020-27926231	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025873, HPA059146	Enhanced		Supported	Nucleoplasm		Group enriched	Tissue enriched	7	duodenum: 43.6	stomach: 6.2	Group enriched	6	AN3-CA: 1.2;CACO-2: 1.0;CAPAN-2: 1.2;HDLM-2: 3.9;HEK 293: 2.2;HeLa: 4.1
LNX2	MGC46315, PDZRN1	ENSG00000139517	Ligand of numb-protein X 2	13	27545911-27620404	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040698	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:7.09e-13 (favourable)	Expressed in all	Expressed in all			testis: 23.3	Expressed in all		
SUOX		ENSG00000139531	Sulfite oxidase	12	55997180-56006641	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038208, HPA038209	Approved				Renal cancer:4.77e-7 (favourable), Urothelial cancer:8.32e-5 (favourable), Pancreatic cancer:6.28e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 108.9	Mixed		
CCDC65	CFAP250, CILD27, DRC2, FAP250, FLJ35732, NYD-SP28	ENSG00000139537	Coiled-coil domain containing 65	12	48904110-48931840	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038520, HPA057573	Uncertain		Approved	Vesicles<br>Microtubule organizing center		Mixed	Group enriched	12	fallopian tube: 42.8;testis: 67.9	lung: 4.4	Mixed		
SLC39A5		ENSG00000139540	Solute carrier family 39 member 5	12	56230049-56237846	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA018423			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.05e-4 (favourable)	Tissue enhanced	Group enriched	12	colon: 73.2;duodenum: 240.2;kidney: 115.0;liver: 86.0;pancreas: 53.1;rectum: 48.9;small intestine: 240.4	gallbladder: 10.0	Group enriched	62	CACO-2: 33.1;Hep G2: 39.7
TARBP2	Trbp	ENSG00000139546	TARBP2, RISC loading complex RNA binding subunit	12	53500921-53506431	Predicted intracellular proteins	Evidence at protein level	HPA051181, HPA061454, CAB069406	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.75e-6 (unfavourable), Liver cancer:3.09e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 18.9	Expressed in all		
RDH16	RODH-4, SDR9C8	ENSG00000139547	Retinol dehydrogenase 16 (all-trans)	12	56951431-56959374	Predicted membrane proteins	Evidence at protein level	HPA038518	Enhanced				Liver cancer:2.16e-5 (favourable)	Tissue enriched	Tissue enriched	85	liver: 278.6	prostate: 3.2	Cell line enhanced		HaCaT: 1.1;hTCEpi: 2.0
DHH	HHG-3, MGC35145	ENSG00000139549	Desert hedgehog	12	49089421-49094819	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	21	testis: 20.7	appendix,placenta: 0.9	Group enriched	8	AN3-CA: 2.1;EFO-21: 4.6;HUVEC TERT2: 1.7;K-562: 7.8;TIME: 3.7
ACVRL1	ACVRLK1, ALK1, HHT, HHT2, ORW2	ENSG00000139567	Activin A receptor like type 1	12	51906908-51923361	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007041	Approved					Expressed in all	Tissue enhanced		placenta: 126.4	lung: 76.4	Cell line enhanced		ASC diff: 42.2;EFO-21: 52.0;HUVEC TERT2: 171.4;TIME: 130.8
GPR84	EX33	ENSG00000139572	G protein-coupled receptor 84	12	54362445-54364487	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027603	Enhanced					Mixed	Tissue enhanced		appendix: 11.6;bone marrow: 14.7	adipose tissue: 6.0	Cell line enhanced		HL-60: 10.3;NB-4: 25.5;U-937: 4.0
NPFF	FMRFAL	ENSG00000139574	Neuropeptide FF-amide peptide precursor	12	53506690-53507638	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	1231	epididymis: 1000.1	duodenum: 0.8	Cell line enriched	6	HHSteC: 11.2
NABP2	hSSB1, MGC2731, OBFC2B, SOSS-B1, SSB1	ENSG00000139579	Nucleic acid binding protein 2	12	56222015-56229854	Predicted intracellular proteins	Evidence at protein level	HPA044615, HPA057213	Supported		Enhanced	Nucleoplasm	Liver cancer:7.44e-6 (unfavourable), Cervical cancer:8.35e-6 (favourable), Renal cancer:2.69e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.0	Expressed in all		
N4BP2L1	CG018	ENSG00000139597	NEDD4 binding protein 2 like 1	13	32400723-32428311	Predicted intracellular proteins	Evidence at protein level	HPA038971	Approved		Uncertain	Nucleoplasm<br>Cytosol	Liver cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			ovary: 47.8	Cell line enhanced		HEL: 21.3;NB-4: 38.0
CELA1	ELA1	ENSG00000139610	Chymotrypsin like elastase family member 1	12	51328443-51346679	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		adrenal gland: 2.5;pancreas: 1.3	lymph node: 0.9	Cell line enriched	6	BEWO: 5.2
SMARCC2	BAF170, CRACC2, Rsc8	ENSG00000139613	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 2	12	56162983-56189567	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004321, HPA021213, HPA061788	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 76.8	Expressed in all		
BRCA2	BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11	ENSG00000139618	BRCA2, DNA repair associated	13	32315474-32400266	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026815	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 5.2	bone marrow: 4.1	Mixed		
KANSL2	C12orf41, FLJ20436, NSL2	ENSG00000139620	KAT8 regulatory NSL complex subunit 2	12	48653401-48682238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038497, HPA038498	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:4.32e-4 (favourable), Liver cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 31.9	Expressed in all		
CERS5	FLJ25304, LASS5, MGC45411, Trh4	ENSG00000139624	Ceramide synthase 5	12	50129306-50167533	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026589	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:9.33e-11 (unfavourable), Liver cancer:4.63e-5 (unfavourable), Thyroid cancer:5.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
MAP3K12	DLK, MEKK12, MUK, ZPK, ZPKP1	ENSG00000139625	Mitogen-activated protein kinase kinase kinase 12	12	53479669-53500063	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039936, HPA071996	Approved		Approved	Nucleus<br>Cell Junctions	Renal cancer:5.43e-10 (unfavourable), Pancreatic cancer:1.51e-4 (favourable)	Mixed	Mixed			gallbladder: 23.9	Cell line enhanced		HHSteC: 46.6
ITGB7		ENSG00000139626	Integrin subunit beta 7	12	53191318-53207307	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042277			Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			spleen: 32.5	Group enriched	97	Karpas-707: 3399.5;RPMI-8226: 2658.1
GALNT6	GalNAc-T6	ENSG00000139629	Polypeptide N-acetylgalactosaminyltransferase 6	12	51351247-51392867	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011762, HPA017086	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Ovarian cancer:5.40e-4 (favourable), Endometrial cancer:9.85e-4 (favourable)	Mixed	Tissue enhanced		stomach: 61.5	cervix, uterine: 49.5	Mixed		
CSAD	CSD, PCAP	ENSG00000139631	Cysteine sulfinic acid decarboxylase	12	53157663-53180909	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039487	Approved				Renal cancer:1.93e-6 (unfavourable), Urothelial cancer:6.81e-6 (favourable), Liver cancer:1.37e-4 (favourable), Pancreatic cancer:3.39e-4 (favourable), Head and neck cancer:6.33e-4 (favourable), Colorectal cancer:9.50e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 70.7	Cell line enhanced		ASC diff: 57.9;T-47d: 49.5
LMBR1L	FLJ10494, KIAA1174	ENSG00000139636	Limb development membrane protein 1 like	12	49096551-49110900	Predicted membrane proteins	Evidence at protein level						Renal cancer:4.45e-7 (unfavourable), Colorectal cancer:1.04e-4 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 27.9	endometrium: 9.1	Expressed in all		
C12orf10	Gamm1, MYG, MYG1	ENSG00000139637	Chromosome 12 open reading frame 10	12	53299686-53307177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038626, HPA038627	Approved	Supported	Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 114.3	Expressed in all		
ESYT1	FAM62A, KIAA0747, MBC2	ENSG00000139641	Extended synaptotagmin 1	12	56118250-56144671	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016858, HPA076926	Approved		Supported	Endoplasmic reticulum	Renal cancer:3.86e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 114.6	Expressed in all		
TMBIM6	BAXI1, BI-1, TEGT	ENSG00000139644	Transmembrane BAX inhibitor motif containing 6	12	49707725-49764934	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017378	Approved				Renal cancer:1.00e-5 (favourable), Head and neck cancer:1.91e-4 (unfavourable), Breast cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 1188.4	Expressed in all		
ANKRD52	FLJ34236, PP6-ARS-C	ENSG00000139645	Ankyrin repeat domain 52	12	56237807-56258391	Predicted intracellular proteins	Evidence at protein level	HPA043815	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
KRT71	K6IRS1, KRT6IRS, KRT6IRS1	ENSG00000139648	Keratin 71	12	52543909-52553147	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049404	Supported					Tissue enhanced	Group enriched	34	breast: 1.4;epididymis: 5.3	all non-specific tissues: 0.0	Cell line enriched	11	CACO-2: 5.1
ZNF740	Zfp740	ENSG00000139651	Zinc finger protein 740	12	53180700-53195141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035691	Approved		Approved	Nucleus	Melanoma:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.3	Expressed in all		
SMIM2	C13orf44, MGC5590	ENSG00000139656	Small integral membrane protein 2	13	44143543-44161257	Predicted membrane proteins	Evidence at protein level	HPA026891	Enhanced					Not detected	Tissue enriched	8	testis: 30.0	epididymis: 3.6	Cell line enhanced		BJ hTERT+: 2.1;SiHa: 2.1
WDFY2	ZFYVE22	ENSG00000139668	WD repeat and FYVE domain containing 2	13	51584455-51767707	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			skin: 21.3	Expressed in all		
HNRNPA1L2	LOC144983	ENSG00000139675	Heterogeneous nuclear ribonucleoprotein A1-like 2	13	52640786-52643796	Predicted intracellular proteins	Evidence at protein level						Breast cancer:2.58e-4 (favourable), Pancreatic cancer:4.26e-4 (favourable)	Expressed in all	Mixed			ovary: 6.0	Expressed in all		
LPAR6	P2RY5, P2Y5	ENSG00000139679	Lysophosphatidic acid receptor 6	13	48389567-48444704	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028934, HPA076273	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable)	Expressed in all	Expressed in all			placenta: 100.9	Cell line enhanced		AF22: 19.1;HUVEC TERT2: 26.4
ESD		ENSG00000139684	Esterase D	13	46771256-46797232	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039700	Approved		Approved	Golgi apparatus<br>Cytosol	Head and neck cancer:2.16e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 245.7	Expressed in all		
RB1	OSRC, PPP1R130, RB	ENSG00000139687	RB transcriptional corepressor 1	13	48303751-48481986	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000095, CAB016687, HPA050082	Supported		Enhanced	Nucleoplasm	Ovarian cancer:6.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 36.1	Mixed		
SBNO1	FLJ10701, FLJ10833, MOP3, Sno	ENSG00000139697	Strawberry notch homolog 1	12	123289109-123364843	Predicted intracellular proteins	Evidence at protein level	HPA042388	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 126.2	Expressed in all		
MORN3		ENSG00000139714	MORN repeat containing 3	12	121648742-121672631	Predicted intracellular proteins	Evidence at protein level	HPA038709, HPA038710	Uncertain		Approved	Nucleoplasm	Breast cancer:1.16e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 6.7	testis: 5.1	Group enriched	7	BEWO: 14.7;CACO-2: 7.0
SETD1B	KIAA1076, KMT2G, Set1B	ENSG00000139718	SET domain containing 1B	12	121804180-121832584	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021667, HPA059412	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 19.0	Expressed in all		
VPS33A		ENSG00000139719	VPS33A, CORVET/HOPS core subunit	12	122229564-122266521	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038701			Approved	Nucleoplasm	Liver cancer:9.11e-5 (unfavourable), Thyroid cancer:2.41e-4 (favourable), Renal cancer:5.29e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.8	Expressed in all		
VPS37B	FLJ12750	ENSG00000139722	VPS37B, ESCRT-I subunit	12	122865328-122896444	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038217, HPA038218	Enhanced				Renal cancer:1.35e-6 (favourable)	Expressed in all	Expressed in all			esophagus: 34.8	Mixed		
RHOF	ARHF, FLJ20247, RIF	ENSG00000139725	Ras homolog family member F, filopodia associated	12	121777754-121803403	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045912, HPA076019	Enhanced		Uncertain	Nucleus<br>Golgi apparatus		Mixed	Expressed in all			lymph node: 46.0	Cell line enhanced		CAPAN-2: 112.6;HDLM-2: 171.6;PC-3: 116.5
DENR	DRP, DRP1, SMAP-3	ENSG00000139726	Density regulated re-initiation and release factor	12	122752774-122771064	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021783	Approved		Approved	Cytosol	Liver cancer:1.58e-7 (unfavourable), Renal cancer:8.57e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 108.3	Expressed in all		
DIAPH3	AN, AUNA1, DRF3, FLJ34705, NSDAN	ENSG00000139734	Diaphanous related formin 3	13	59665583-60163987	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032151			Supported	Plasma membrane<br>Microtubules	Lung cancer:3.72e-4 (unfavourable), Endometrial cancer:4.18e-4 (unfavourable), Colorectal cancer:9.04e-4 (favourable)	Mixed	Tissue enriched	7	testis: 34.0	placenta: 5.0	Mixed		
SLAIN1	C13orf32, FLJ30046	ENSG00000139737	SLAIN motif family member 1	13	77697854-77764242	Predicted intracellular proteins	Evidence at protein level	HPA040798			Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Ovarian cancer:9.07e-4 (favourable)	Tissue enhanced	Expressed in all			cerebral cortex: 217.1	Cell line enhanced		HL-60: 61.7;MOLT-4: 72.0;SCLC-21H: 69.0
RBM26	ARRS2, C13orf10, FLJ20957, PPP1R132, PRO1777, SE70-2, ZC3H17	ENSG00000139746	RNA binding motif protein 26	13	79311824-79406477	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040252	Approved		Approved	Nuclear speckles	Renal cancer:5.87e-6 (unfavourable), Prostate cancer:3.46e-4 (unfavourable), Urothelial cancer:8.20e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.0	Expressed in all		
SRRM4	KIAA1853, nSR100	ENSG00000139767	Serine/arginine repetitive matrix 4	12	118981495-119163051	Predicted intracellular proteins	Evidence at protein level	HPA052783	Uncertain					Tissue enriched	Tissue enriched	9	cerebral cortex: 13.5	adrenal gland: 1.5	Group enriched	5	HeLa: 2.3;SCLC-21H: 4.6;SH-SY5Y: 3.3
METTL21C	C13orf39, LOC196541	ENSG00000139780	Methyltransferase like 21C	13	102685744-102694504	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	13	epididymis: 42.2	seminal vesicle: 3.1	Not detected		
MBNL2	MBLL, MBLL39	ENSG00000139793	Muscleblind like splicing regulator 2	13	97221434-97394120	Predicted intracellular proteins	Evidence at protein level	HPA062685			Supported	Nucleoplasm	Pancreatic cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 84.1	Mixed		
RNF113B	RNF161, ZNF183L1	ENSG00000139797	Ring finger protein 113B	13	98175785-98177265	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	588	testis: 58.8	all non-specific tissues: 0.0	Not detected		
ZIC5		ENSG00000139800	Zic family member 5	13	99962964-99971909	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074045			Uncertain	Nucleoplasm<br>Vesicles		Mixed	Group enriched	45	cerebral cortex: 2.3;testis: 6.6	all non-specific tissues: 0.0	Cell line enhanced		AF22: 21.7;NTERA-2: 15.0;SCLC-21H: 100.6
ABHD13	bA153I24.2, BEM46L1, C13orf6, FLJ14906	ENSG00000139826	Abhydrolase domain containing 13	13	108218379-108234255	Predicted membrane proteins	Evidence at protein level	HPA032143, HPA032144	Approved		Approved	Cytosol		Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
RAB20	FLJ20429	ENSG00000139832	RAB20, member RAS oncogene family	13	110523066-110561733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052111, HPA068647	Uncertain		Supported	Golgi apparatus<br>Vesicles	Urothelial cancer:4.48e-4 (favourable), Renal cancer:8.57e-4 (favourable)	Expressed in all	Mixed			spleen: 42.0	Cell line enhanced		SK-BR-3: 63.7;T-47d: 50.6
GRTP1	FLJ22474, TBC1D6	ENSG00000139835	Growth hormone regulated TBC protein 1	13	113324164-113364148	Predicted intracellular proteins	Evidence at protein level	HPA046201	Approved				Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 47.1	Cell line enhanced		T-47d: 52.1
CUL4A		ENSG00000139842	Cullin 4A	13	113208193-113267108	Predicted intracellular proteins	Evidence at protein level	HPA058979			Approved	Nucleoplasm	Stomach cancer:2.84e-4 (favourable)	Expressed in all	Expressed in all			testis: 90.1	Expressed in all		
TTC6	C14orf25, NCRNA00291	ENSG00000139865	Tetratricopeptide repeat domain 6	14	37595847-38041442	Predicted intracellular proteins	Evidence at protein level	HPA069293			Approved	Centrosome		Group enriched	Group enriched	6	breast: 10.5;prostate: 28.3;testis: 10.4	stomach: 2.6	Cell line enhanced		Hep G2: 5.7;MCF7: 9.4;RT4: 6.7;T-47d: 21.4
SSTR1		ENSG00000139874	Somatostatin receptor 1	14	38207999-38213067	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031506	Approved				Renal cancer:4.28e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4	small intestine: 9.1	Cell line enhanced		BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
CDH24	CDH11L	ENSG00000139880	Cadherin 24	14	23047062-23057538	Predicted membrane proteins	Evidence at protein level	HPA065233			Approved	Nucleoplasm<br>Cell Junctions<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.15e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 8.5	Cell line enhanced		SCLC-21H: 62.2
REM2	FLJ38964	ENSG00000139890	RRAD and GEM like GTPase 2	14	22883165-22887686	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 6.0;parathyroid gland: 4.6	testis: 2.9	Cell line enhanced		AF22: 3.0
CBLN3		ENSG00000139899	Cerebellin 3 precursor	14	24426532-24430954	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041266	Supported	Supported	Approved	Nucleus	Renal cancer:6.20e-6 (unfavourable), Endometrial cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.4	Cell line enhanced		HDLM-2: 16.0;HSkMC: 17.3;Karpas-707: 13.3
TSSK4	C14orf20, STK22E	ENSG00000139908	Testis specific serine kinase 4	14	24205697-24208362	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060660, HPA077103	Enhanced		Approved	Cell Junctions		Mixed	Tissue enhanced		testis: 42.2	skin: 10.1	Mixed		
NOVA1		ENSG00000139910	NOVA alternative splicing regulator 1	14	26443093-26597754	Predicted intracellular proteins	Evidence at protein level	HPA004155	Uncertain		Supported	Nucleus<br>Nucleoli		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	breast: 31.8	Cell line enhanced		AF22: 40.2;HAP1: 20.8
FITM1	FIT1	ENSG00000139914	Fat storage inducing transmembrane protein 1	14	24131275-24132849	Predicted membrane proteins	Evidence at protein level	HPA019842	Uncertain				Liver cancer:1.00e-3 (favourable)	Mixed	Group enriched	15	heart muscle: 45.8;skeletal muscle: 113.0	spleen: 5.4	Cell line enriched	23	RH-30: 60.8
MDGA2	MAMDC1	ENSG00000139915	MAM domain containing glycosylphosphatidylinositol anchor 2	14	46839629-47674954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003084	Uncertain					Tissue enhanced	Group enriched	15	cerebral cortex: 6.2;testis: 6.9	skin: 0.4	Cell line enhanced		AF22: 5.0;T-47d: 2.4;U-138 MG: 5.6;U-2 OS: 4.3;WM-115: 3.4
TMX1	PDIA11, TMX, TXNDC, TXNDC1	ENSG00000139921	Thioredoxin related transmembrane protein 1	14	51240162-51257546	Predicted membrane proteins	Evidence at protein level	HPA003085	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Liver cancer:1.29e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.8	Expressed in all		
FRMD6	C14orf31, EX1, MGC17921, willin	ENSG00000139926	FERM domain containing 6	14	51489100-51730727	Predicted intracellular proteins	Evidence at protein level	HPA001297	Uncertain	Approved	Approved	Mitochondria	Renal cancer:1.28e-4 (unfavourable), Pancreatic cancer:2.66e-4 (unfavourable), Stomach cancer:3.50e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 126.3	Cell line enhanced		fHDF/TERT166: 644.4
PELI2		ENSG00000139946	Pellino E3 ubiquitin protein ligase family member 2	14	56117814-56301526	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053182	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:1.53e-6 (favourable)	Mixed	Mixed			testis: 18.8	Cell line enhanced		HMC-1: 29.1;MOLT-4: 31.6;SCLC-21H: 20.6
RTN1	NSP	ENSG00000139970	Reticulon 1	14	59595976-59870966	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002745, HPA040945, HPA044249	Enhanced		Enhanced	Endoplasmic reticulum	Pancreatic cancer:3.69e-4 (favourable)	Tissue enhanced	Tissue enriched	8	cerebral cortex: 411.6	parathyroid gland: 49.6	Cell line enhanced		HEL: 54.3;SCLC-21H: 84.4;SH-SY5Y: 121.8
C14orf37	UT2	ENSG00000139971	Chromosome 14 open reading frame 37	14	57999735-58298139	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001580, HPA001789	Enhanced		Approved	Plasma membrane		Mixed	Mixed			kidney: 8.8	Cell line enhanced		AF22: 9.6;fHDF/TERT166: 8.4
SYT16	CHR14SYT, Strep14, SYT14L, yt14r	ENSG00000139973	Synaptotagmin 16	14	61811974-62112550	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004199, HPA076871	Uncertain		Approved	Cytosol		Mixed	Group enriched	8	cerebral cortex: 18.0;prostate: 3.6;testis: 6.9	stomach: 1.2	Cell line enhanced		A-431: 9.4;PC-3: 5.0;RPTEC TERT1: 4.7;RT4: 13.5;U-2 OS: 6.9
SLC38A6	NAT-1	ENSG00000139974	Solute carrier family 38 member 6	14	60981114-61083733	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018508	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Microtubules	Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Mixed		
NAA30	C14orf35, FLJ35355, MAK3, Mak3p, NAT12	ENSG00000139977	N(alpha)-acetyltransferase 30, NatC catalytic subunit	14	57390544-57415917	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057824	Uncertain		Supported	Cytosol	Renal cancer:1.25e-8 (favourable)	Expressed in all	Expressed in all			testis: 34.2	Expressed in all		
ADAM21	ADAM31	ENSG00000139985	ADAM metallopeptidase domain 21	14	70452157-70459899	Predicted membrane proteins	Evidence at protein level	HPA059016	Uncertain					Not detected	Tissue enriched	31	testis: 15.5	cerebral cortex: 0.5	Cell line enhanced		U-138 MG: 1.4;U-251 MG: 1.1
RDH12	FLJ30273, LCA13, RP53, SDR7C2	ENSG00000139988	Retinol dehydrogenase 12 (all-trans/9-cis/11-cis)	14	67701886-67734452	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		gallbladder: 27.7;skin: 58.2	kidney: 13.6	Not detected		
DCAF5	BCRG2, BCRP2, D14S1461E, KIAA1824, WDR22	ENSG00000139990	DDB1 and CUL4 associated factor 5	14	69050881-69153150	Predicted intracellular proteins	Evidence at protein level	HPA041575, HPA048098	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 111.5	Expressed in all		
RAB15		ENSG00000139998	RAB15, member RAS oncogene family	14	64945814-64972776	Predicted intracellular proteins	Evidence at protein level	HPA041177	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 62.9	Cell line enhanced		HAP1: 153.9;RH-30: 186.0;RT4: 173.7
WDR89	C14orf150, MGC9907	ENSG00000140006	WD repeat domain 89	14	63597039-63641861	Predicted intracellular proteins	Evidence at protein level	HPA000813	Uncertain		Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.26e-4 (unfavourable), Breast cancer:3.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.6	Expressed in all		
ESR2	Erb, NR3A2	ENSG00000140009	Estrogen receptor 2	14	64084232-64338112	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB065126	Enhanced					Not detected	Tissue enhanced		testis: 10.4	adrenal gland: 6.3	Cell line enhanced		U-266/70: 7.3;U-698: 11.3
KCNH5	eag2, H-EAG2, Kv10.2	ENSG00000140015	Potassium voltage-gated channel subfamily H member 5	14	62699454-63102037	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA030487	Uncertain		Uncertain	Microtubules<br>Mitotic spindle		Not detected	Tissue enhanced		adrenal gland: 1.4;cerebral cortex: 3.6	testis: 0.7	Cell line enhanced		BEWO: 1.5;HeLa: 5.0;RT4: 7.9
STON2	STN2, STNB2	ENSG00000140022	Stonin 2	14	81260656-81436465	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003086	Enhanced		Supported	Nucleoli<br>Cytosol	Endometrial cancer:4.96e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 34.2	Cell line enhanced		HEL: 130.5;HMC-1: 63.9
EFCAB11	C14orf143	ENSG00000140025	EF-hand calcium binding domain 11	14	89794669-89954777	Predicted intracellular proteins	Evidence at transcript level	HPA051209			Approved	Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 60.1	fallopian tube: 17.2	Expressed in all		
GPR65	hTDAG8, TDAG8	ENSG00000140030	G protein-coupled receptor 65	14	88005124-88014811	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA054454			Approved	Cytosol	Renal cancer:4.99e-4 (unfavourable)	Mixed	Mixed			spleen: 13.3	Cell line enhanced		Daudi: 4.0;HEL: 5.5;HL-60: 5.9;HMC-1: 7.9;RH-30: 11.1
PTGR2	FLJ39091, ZADH1	ENSG00000140043	Prostaglandin reductase 2	14	73851844-73886827	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001125	Approved		Approved	Vesicles	Renal cancer:4.55e-12 (favourable)	Expressed in all	Mixed			thyroid gland: 21.2	Cell line enhanced		T-47d: 39.4
JDP2	JUNDM2	ENSG00000140044	Jun dimerization protein 2	14	75427716-75474111	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059511	Supported		Approved	Nucleoplasm<br>Nuclear speckles	Colorectal cancer:8.58e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 85.7	Cell line enhanced		HHSteC: 140.4
AK7	FLJ32864	ENSG00000140057	Adenylate kinase 7	14	96392111-96489427	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003543	Enhanced				Renal cancer:1.14e-4 (favourable), Endometrial cancer:3.18e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 38.8	parathyroid gland: 14.9	Cell line enhanced		BEWO: 16.6;CAPAN-2: 13.2;MCF7: 37.9;REH: 32.2
FAM181A	C14orf152	ENSG00000140067	Family with sequence similarity 181 member A	14	93918894-93929608	Predicted intracellular proteins	Evidence at protein level	HPA001603	Enhanced					Group enriched	Tissue enhanced		cerebral cortex: 3.4;testis: 13.7	fallopian tube: 2.9	Cell line enriched	10	AF22: 4.2
SLC24A4	NCKX4	ENSG00000140090	Solute carrier family 24 member 4	14	92322581-92501483	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 7.1	spleen: 2.7	Cell line enhanced		SCLC-21H: 1.5
FBLN5	ARMD3, DANCE, EVEC, UP50	ENSG00000140092	Fibulin 5	14	91869412-91947987	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA000848, HPA000868, CAB025843	Supported		Supported	Plasma membrane	Liver cancer:6.75e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 221.0	Group enriched	6	ASC diff: 345.3;ASC TERT1: 182.9;BJ: 207.7;BJ hTERT+: 185.8;fHDF/TERT166: 343.2;HHSteC: 70.5;HSkMC: 175.5
SERPINA10	PZI, ZPI	ENSG00000140093	Serpin family A member 10	14	94280455-94293271	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048739			Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.00e-4 (favourable)	Tissue enriched	Tissue enriched	89	liver: 193.7	bone marrow: 2.1	Cell line enriched	6	Hep G2: 13.4
C14orf79		ENSG00000140104	Chromosome 14 open reading frame 79	14	104985775-105010482	Predicted intracellular proteins	Evidence at transcript level	HPA042052, HPA061117	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			fallopian tube: 24.1	Mixed		
WARS	IFI53, IFP53	ENSG00000140105	Tryptophanyl-tRNA synthetase	14	100333788-100376805	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005573, HPA018944			Enhanced	Cytosol	Ovarian cancer:1.94e-4 (favourable), Liver cancer:7.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 473.2	Expressed in all		
SLC25A47	C14orf68	ENSG00000140107	Solute carrier family 25 member 47	14	100323337-100330378	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	171	liver: 101.0	duodenum,small intestine: 0.5	Cell line enhanced		Hep G2: 1.1
WDR20	DMR, FLJ33659, MGC33177	ENSG00000140153	WD repeat domain 20	14	102139503-102224847	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.26e-9 (favourable)	Expressed in all	Expressed in all			testis: 40.6	Expressed in all		
NIPA2		ENSG00000140157	Non imprinted in Prader-Willi/Angelman syndrome 2	15	22838641-22868384	Predicted membrane proteins, Transporters	Evidence at protein level	HPA067160, HPA071342	Approved		Approved	Golgi apparatus		Expressed in all	Expressed in all			appendix: 44.4	Expressed in all		
SLC12A6	ACCPN, KCC3	ENSG00000140199	Solute carrier family 12 member 6	15	34229996-34338060	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA034563	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:3.33e-6 (favourable)	Expressed in all	Mixed			testis: 46.4	Cell line enhanced		HaCaT: 38.6
DUOXA1	FLJ32334, mol, NIP, NUMBIP	ENSG00000140254	Dual oxidase maturation factor 1	15	45117367-45129938	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041578	Approved					Tissue enhanced	Tissue enhanced		esophagus: 122.2;skin: 107.9;thyroid gland: 112.0	epididymis: 60.3	Cell line enriched	9	HaCaT: 92.0
MFAP1		ENSG00000140259	Microfibrillar associated protein 1	15	43804492-43824802	Predicted intracellular proteins	Evidence at protein level	HPA042370	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.04e-9 (favourable), Liver cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.2	Expressed in all		
TCF12	bHLHb20, HEB, HsT17266, HTF4	ENSG00000140262	Transcription factor 12	15	56918623-57299281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB004432, HPA065827	Approved		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:5.24e-5 (unfavourable), Melanoma:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 116.2	Expressed in all		
SORD		ENSG00000140263	Sorbitol dehydrogenase	15	45023104-45077185	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040260, HPA040621	Enhanced		Approved	Cytosol	Liver cancer:6.14e-5 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 404.7	Mixed		
SERF2	4F5REL, FAM2C, H4F5rel, HsT17089	ENSG00000140264	Small EDRK-rich factor 2	15	43777087-43802589	Predicted intracellular proteins	Evidence at protein level	HPA056613			Uncertain	Nucleus<br>Nucleoli	Endometrial cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 911.3	Expressed in all		
ZSCAN29	FLJ35867, Zfp690, ZNF690	ENSG00000140265	Zinc finger and SCAN domain containing 29	15	43358172-43371025	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA007241, HPA011109	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			testis: 27.3	Expressed in all		
DUOXA2		ENSG00000140274	Dual oxidase maturation factor 2	15	45114321-45118421	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA063548	Enhanced					Group enriched	Tissue enhanced		gallbladder: 97.3;urinary bladder: 24.7	thyroid gland: 13.6	Cell line enhanced		U-2 OS: 1.0
DUOX2	LNOX2, P138-TOX, P138(TOX), THOX2	ENSG00000140279	Dual oxidase 2	15	45092650-45114344	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		gallbladder: 446.7;thyroid gland: 124.8	urinary bladder: 87.1	Cell line enriched	8	HaCaT: 5.5
LYSMD2	MGC35274	ENSG00000140280	LysM domain containing 2	15	51723011-51751585	Predicted intracellular proteins	Evidence at protein level	HPA040460	Approved		Approved	Nuclear bodies<br>Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 38.2	Mixed		
SLC27A2	ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS	ENSG00000140284	Solute carrier family 27 member 2	15	50182196-50236395	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026089	Enhanced				Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable)	Tissue enhanced	Group enriched	5	epididymis: 80.1;kidney: 162.3;liver: 145.5	placenta: 24.7	Cell line enhanced		HaCaT: 78.4;HL-60: 52.3;SCLC-21H: 47.4
FGF7	KGF	ENSG00000140285	Fibroblast growth factor 7	15	49423096-49488775	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA043605	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		gallbladder: 55.0	endometrium: 31.1	Cell line enhanced		ASC diff: 31.5;ASC TERT1: 29.3;HSkMC: 31.1;RH-30: 33.7;U-138 MG: 23.1
HDC		ENSG00000140287	Histidine decarboxylase	15	50241947-50266026	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038891	Approved					Mixed	Tissue enhanced		epididymis: 53.2	gallbladder: 17.3	Group enriched	6	HEL: 392.3;HMC-1: 885.1
GCNT3	C2/4GnT, C2GnT-M, C2GnT2	ENSG00000140297	Glucosaminyl (N-acetyl) transferase 3, mucin type	15	59594875-59640239	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011154	Enhanced		Approved	Golgi apparatus<br>Vesicles	Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 142.2;gallbladder: 118.0;rectum: 134.6;small intestine: 138.4	duodenum: 97.7	Cell line enriched	6	A549: 133.3
BNIP2	BNIP-2, Nip2	ENSG00000140299	BCL2 interacting protein 2	15	59659146-59689534	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026843	Approved				Renal cancer:2.19e-5 (unfavourable), Endometrial cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 84.4	Expressed in all		
GTF2A2	HsT18745, TFIIA	ENSG00000140307	General transcription factor IIA subunit 2	15	59638062-59657541	Predicted intracellular proteins	Evidence at protein level	HPA056239			Supported	Nucleoplasm		Expressed in all	Tissue enriched	5	testis: 369.2	adrenal gland: 73.5	Expressed in all		
SRP14	ALURBP, MGC14326	ENSG00000140319	Signal recognition particle 14	15	40035739-40039188	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA053738, HPA065118			Enhanced	Nucleus<br>Nucleoli	Renal cancer:5.31e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 373.9	Expressed in all		
BAHD1	KIAA0945	ENSG00000140320	Bromo adjacent homology domain containing 1	15	40439721-40468242	Predicted intracellular proteins	Evidence at protein level	HPA041196			Supported	Nucleoplasm	Renal cancer:1.29e-10 (favourable), Breast cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.3	Expressed in all		
DISP2	C15orf36, DISPB, HsT16908, KIAA1742, LINC00594	ENSG00000140323	Dispatched RND transporter family member 2	15	40358235-40378639	Predicted membrane proteins	Evidence at protein level	HPA059903	Uncertain		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 7.4	thyroid gland: 1.8	Group enriched	5	HaCaT: 5.9;SCLC-21H: 15.8
CDAN1	CDA-I, CDAI	ENSG00000140326	Codanin 1	15	42723559-42737126	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039404, HPA040787	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.07e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 15.2	Expressed in all		
TLE3	ESG, ESG3, GRG3, HsT18976, KIAA1547	ENSG00000140332	Transducin like enhancer of split 3	15	70047790-70098176	Predicted intracellular proteins	Evidence at protein level	HPA054116	Approved		Supported	Nucleoplasm	Cervical cancer:2.09e-5 (favourable)	Expressed in all	Mixed			bone marrow: 48.7	Expressed in all		
ANP32A	C15orf1, I1PP2A, LANP, MAPM, mapmodulin, PHAPI, PP32	ENSG00000140350	Acidic nuclear phosphoprotein 32 family member A	15	68778535-68820897	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005231, HPA063133, HPA067561	Supported		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			lymph node: 181.3	Expressed in all		
COMMD4	FLJ20452	ENSG00000140365	COMM domain containing 4	15	75335891-75343224	Predicted intracellular proteins	Evidence at protein level	HPA066957	Uncertain		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 76.2	Expressed in all		
UBE2Q2	DKFZp762C143	ENSG00000140367	Ubiquitin conjugating enzyme E2 Q2	15	75843285-75901078	Enzymes, Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.5	Expressed in all		
PSTPIP1	CD2BP1, CD2BP1L, CD2BP1S, H-PIP, PAPAS, PSTPIP	ENSG00000140368	Proline-serine-threonine phosphatase interacting protein 1	15	76993359-77037332	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010600	Enhanced				Renal cancer:7.36e-9 (unfavourable), Endometrial cancer:4.74e-5 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 37.6	appendix: 16.2	Cell line enhanced		HDLM-2: 55.7;NB-4: 15.1;U-937: 50.2
ETFA	EMA, GA2, MADD	ENSG00000140374	Electron transfer flavoprotein alpha subunit	15	76215355-76311472	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018990, HPA018993, HPA018996, HPA024089	Enhanced		Enhanced	Mitochondria	Renal cancer:5.04e-8 (favourable)	Expressed in all	Expressed in all			liver: 197.8	Expressed in all		
BCL2A1	ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1, GRS, HBPA1	ENSG00000140379	BCL2 related protein A1	15	79960889-79971446	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.77e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 115.2;bone marrow: 277.0	lymph node: 62.1	Cell line enhanced		HMC-1: 76.7;SK-MEL-30: 329.3;U-138 MG: 43.6
HMG20A	FLJ10739, HMGX1, HMGXB1	ENSG00000140382	High mobility group 20A	15	77420412-77485607	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008126	Supported		Approved	Nucleus		Expressed in all	Expressed in all			spleen: 49.0	Expressed in all		
SCAPER	Zfp291, ZNF291	ENSG00000140386	S-phase cyclin A associated protein in the ER	15	76347904-76905444	Predicted intracellular proteins	Evidence at protein level	HPA046253, HPA061180	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:2.69e-9 (favourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
TSPAN3	TM4-A, TM4SF8, TSPAN-3	ENSG00000140391	Tetraspanin 3	15	77041404-77083984	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA015996	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			epididymis: 527.2	Expressed in all		
WDR61	REC14	ENSG00000140395	WD repeat domain 61	15	78277835-78299794	Predicted intracellular proteins	Evidence at protein level	HPA039932, HPA040065	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.03e-10 (favourable)	Expressed in all	Expressed in all			epididymis: 126.8	Expressed in all		
NCOA2	bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2	ENSG00000140396	Nuclear receptor coactivator 2	8	70109762-70403805	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060243			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.0	Expressed in all		
NEIL1	FLJ22402, FPG1, hFPG1, NEI1	ENSG00000140398	Nei like DNA glycosylase 1	15	75346955-75357114	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054084	Approved		Supported	Nucleoplasm	Pancreatic cancer:2.09e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 10.6	Mixed		
MAN2C1	MANA, MANA1	ENSG00000140400	Mannosidase alpha class 2C member 1	15	75355207-75368630	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040627, HPA067407	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
DNAJA4	PRO1472	ENSG00000140403	DnaJ heat shock protein family (Hsp40) member A4	15	78264086-78282196	Predicted intracellular proteins	Evidence at protein level	CAB004646, HPA041790	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.08e-7 (favourable), Glioma:8.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 95.4	Cell line enhanced		CAPAN-2: 38.0;RT4: 67.8;SCLC-21H: 62.7;SiHa: 45.2
MESDC1	MGC99595	ENSG00000140406	Mesoderm development candidate 1	15	81000944-81005788	Predicted intracellular proteins	Evidence at protein level	HPA071716			Approved	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:1.87e-7 (unfavourable), Lung cancer:1.47e-5 (unfavourable)	Expressed in all	Mixed			spleen: 14.3	Expressed in all		
TPM1	C15orf13, CMH3	ENSG00000140416	Tropomyosin 1 (alpha)	15	63042632-63071915	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000261, HPA009066, CAB017698, HPA047089, HPA053624	Supported		Approved	Actin filaments<br>Cytosol	Urothelial cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 7139.0	Expressed in all		
IGF1R	CD221, IGFIR, IGFR, JTK13, MGC18216	ENSG00000140443	Insulin like growth factor 1 receptor	15	98648971-98964530	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010268, HPA045563	Uncertain		Uncertain	Vesicles	Renal cancer:3.75e-7 (favourable)	Expressed in all	Mixed			prostate: 25.0	Mixed		
ARRDC4	FLJ36045	ENSG00000140450	Arrestin domain containing 4	15	97960698-97973838	Predicted intracellular proteins	Evidence at protein level	HPA042109	Approved					Expressed in all	Expressed in all			skin: 42.0	Cell line enhanced		BJ: 86.9;hTCEpi: 62.8
PIF1	C15orf20, FLJ22692	ENSG00000140451	PIF1 5'-to-3' DNA helicase	15	64815632-64825668	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB018701	Supported		Supported	Nucleoplasm	Melanoma:5.22e-4 (unfavourable)	Tissue enhanced	Mixed			lymph node: 5.3	Mixed		
USP3		ENSG00000140455	Ubiquitin specific peptidase 3	15	63504511-63594640	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053275, HPA060513, HPA077975			Supported	Nucleoplasm	Urothelial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 32.1	Expressed in all		
CYP11A1	CYP11A, P450SCC	ENSG00000140459	Cytochrome P450 family 11 subfamily A member 1	15	74337759-74367740	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016436	Enhanced					Mixed	Tissue enriched	11	adrenal gland: 748.5	testis: 68.5	Group enriched	25	BEWO: 102.7;HEL: 79.0;SiHa: 23.2
BBS4		ENSG00000140463	Bardet-Biedl syndrome 4	15	72686179-72738476	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039418	Approved		Supported	Cytosol	Endometrial cancer:2.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.0	Expressed in all		
PML	MYL, RNF71, TRIM19	ENSG00000140464	Promyelocytic leukemia	15	73994673-74047812	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008312, CAB010194, CAB016304	Supported		Enhanced	Nuclear bodies	Renal cancer:6.27e-8 (unfavourable), Breast cancer:3.24e-4 (favourable), Pancreatic cancer:3.29e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 45.1	Expressed in all		
CYP1A1	CP11, CYP1, P1-450, P450-C, P450DX	ENSG00000140465	Cytochrome P450 family 1 subfamily A member 1	15	74719542-74725610	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018654	Uncertain					Group enriched	Group enriched	8	liver: 33.9;small intestine: 20.5;urinary bladder: 80.8	breast: 5.7	Cell line enhanced		CACO-2: 30.3;hTCEpi: 14.0;HUVEC TERT2: 15.7
ADAMTS17	FLJ16363, FLJ32769	ENSG00000140470	ADAM metallopeptidase with thrombospondin type 1 motif 17	15	99971589-100342005	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062487			Approved	Nucleus		Mixed	Mixed			endometrium: 3.4	Cell line enhanced		HEK 293: 8.0;SK-MEL-30: 3.4;WM-115: 4.0
LINS1	LINS, WINS1	ENSG00000140471	Lines homolog 1	15	100559369-100603230	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038578, HPA038579	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 14.0	Expressed in all		
ULK3	DKFZP434C131, FLJ90566	ENSG00000140474	Unc-51 like kinase 3	15	74836116-74843346	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040474	Approved				Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 28.4	Expressed in all		
GOLGA6D		ENSG00000140478	Golgin A6 family member D	15	75282835-75295807	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	16	testis: 17.8	liver: 1.1	Not detected		
PCSK6	PACE4, SPC4	ENSG00000140479	Proprotein convertase subtilisin/kexin type 6	15	101297142-101525202	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004774	Uncertain				Renal cancer:7.06e-7 (unfavourable), Breast cancer:9.99e-4 (favourable)	Mixed	Tissue enhanced		liver: 90.3;spleen: 124.6	placenta: 53.9	Cell line enhanced		BEWO: 57.8;HEK 293: 58.5;Hep G2: 39.9
CCDC33	CT61, FLJ32855	ENSG00000140481	Coiled-coil domain containing 33	15	74202705-74336472	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	17	fallopian tube: 75.4;testis: 22.5	lung: 2.8	Group enriched	5	CAPAN-2: 7.8;SCLC-21H: 5.8;SH-SY5Y: 6.3
CELF6	BRUNOL6	ENSG00000140488	CUGBP Elav-like family member 6	15	72284727-72320129	Predicted intracellular proteins	Evidence at protein level	HPA046985, HPA053526	Uncertain		Approved	Cytosol		Not detected	Mixed			cerebral cortex: 11.1	Cell line enhanced		U-266/70: 2.7
SCAMP2		ENSG00000140497	Secretory carrier membrane protein 2	15	74843730-74873365	Predicted membrane proteins	Evidence at protein level	HPA014699, HPA019194	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.12e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 128.7	Expressed in all		
CYP1A2	CP12, P3-450	ENSG00000140505	Cytochrome P450 family 1 subfamily A member 2	15	74748844-74756202	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB016531	Enhanced					Group enriched	Tissue enriched	170	liver: 268.6	thyroid gland: 1.5	Mixed		
LMAN1L	ERGIC-53L, ERGL	ENSG00000140506	Lectin, mannose binding 1 like	15	74812716-74825758	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		prostate: 91.3;spleen: 31.7	heart muscle: 12.7	Not detected		
HAPLN3	EXLD1, HsT19883	ENSG00000140511	Hyaluronan and proteoglycan link protein 3	15	88877288-88895626	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039237	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.18e-13 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.8;lymph node: 10.8	spleen: 4.0	Cell line enhanced		HDLM-2: 29.8;U-2 OS: 31.7
RHCG	C15orf6, PDRC2, RHGK, SLC42A3	ENSG00000140519	Rh family C glycoprotein	15	89471398-89496613	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041874, HPA043317	Enhanced				Lung cancer:3.80e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 2901.8	tonsil: 420.3	Cell line enhanced		A549: 3.3;hTCEpi: 1.4;RT4: 1.6;SK-MEL-30: 1.0
POLG	POLG1, POLGA	ENSG00000140521	DNA polymerase gamma, catalytic subunit	15	89305198-89334861	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056821	Approved				Prostate cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 19.7	Expressed in all		
RLBP1	CRALBP	ENSG00000140522	Retinaldehyde binding protein 1	15	89209869-89221751	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042051, HPA044083	Supported	Approved	Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Group enriched	Tissue enriched	9	cerebral cortex: 6.1	testis: 0.6	Cell line enriched	53	SK-MEL-30: 16.5
FANCI	FLJ10719, KIAA1794	ENSG00000140525	Fanconi anemia complementation group I	15	89243949-89317261	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039972, HPA040379	Approved		Enhanced	Nucleoplasm	Renal cancer:2.71e-13 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 60.4	lymph node: 28.6	Expressed in all		
ABHD2	LABH2	ENSG00000140526	Abhydrolase domain containing 2	15	89087459-89202360	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA005999	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.18e-7 (favourable)	Expressed in all	Expressed in all			testis: 93.8	Expressed in all		
WDR93		ENSG00000140527	WD repeat domain 93	15	89690797-89743638	Predicted intracellular proteins	Evidence at transcript level	HPA046196, HPA048112	Uncertain		Uncertain	Actin filaments		Mixed	Tissue enhanced		fallopian tube: 14.2;testis: 21.1	epididymis: 6.1	Mixed		
TICRR	C15orf42, FLJ41618, MGC45866, SLD3, Treslin	ENSG00000140534	TOPBP1 interacting checkpoint and replication regulator	15	89575482-89631056	Predicted intracellular proteins	Evidence at protein level	HPA046746, HPA049454			Enhanced	Nucleoplasm	Melanoma:2.87e-6 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable)	Mixed	Mixed			testis: 2.7	Mixed		
NTRK3	TRKC	ENSG00000140538	Neurotrophic receptor tyrosine kinase 3	15	87859751-88256768	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009233, HPA027484, HPA048065	Enhanced		Supported	Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enhanced		cerebral cortex: 39.6	testis: 15.2	Cell line enriched	8	U-138 MG: 99.2
DET1	FLJ10103	ENSG00000140543	De-etiolated homolog 1 (Arabidopsis)	15	88494440-88546675	Predicted intracellular proteins	Evidence at protein level	HPA048873	Uncertain		Approved	Nucleoplasm<br>Microtubules		Expressed in all	Mixed			ovary: 14.1	Mixed		
MFGE8	BA46, EDIL1, hP47, HsT19888, MFG-E8, OAcGD3S, SED1, SPAG10	ENSG00000140545	Milk fat globule-EGF factor 8 protein	15	88898683-88913411	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB002753, HPA002807	Uncertain		Approved	Cytosol	Renal cancer:6.06e-9 (unfavourable), Stomach cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 319.8	Cell line enhanced		ASC diff: 1212.9;ASC TERT1: 638.2;HSkMC: 676.6
ZNF710	DKFZp547K1113, FLJ00306, FLJ37393	ENSG00000140548	Zinc finger protein 710	15	90001392-90082206	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030226, HPA030227, HPA030228	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			appendix: 20.4	Expressed in all		
UNC45A	GC-UNC45, SMAP-1	ENSG00000140553	Unc-45 myosin chaperone A	15	90930180-90954093	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039228	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:7.46e-7 (favourable), Liver cancer:7.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.3	Expressed in all		
ST8SIA2	HsT19690, SIAT8B, ST8SIA-II, STX	ENSG00000140557	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2	15	92393828-92468728	Predicted secreted proteins	Evidence at protein level	HPA054518	Approved		Approved	Microtubule organizing center		Mixed	Tissue enhanced		cerebral cortex: 2.1;heart muscle: 2.4	cervix, uterine: 1.2	Cell line enhanced		AF22: 25.4;LHCN-M2: 6.4;RH-30: 11.3;RPMI-8226: 6.1;WM-115: 7.1
MCTP2	FLJ11175, FLJ33303	ENSG00000140563	Multiple C2 and transmembrane domain containing 2	15	94231538-94483952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051176, HPA070541	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.18e-5 (unfavourable)	Mixed	Mixed			placenta: 28.6	Cell line enhanced		HEL: 19.0;U-698: 15.8;U-87 MG: 24.4
FURIN	FUR, PACE, PCSK3, SPC1	ENSG00000140564	Furin, paired basic amino acid cleaving enzyme	15	90868592-90883458	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009499	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Lung cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 92.8	Expressed in all		
IQGAP1	HUMORFA01, KIAA0051, p195, SAR1	ENSG00000140575	IQ motif containing GTPase activating protein 1	15	90388218-90502243	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013302, HPA014055	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Pancreatic cancer:5.67e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 120.4	Expressed in all		
CRTC3	FLJ21868	ENSG00000140577	CREB regulated transcription coactivator 3	15	90529925-90645345	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043735, HPA063691	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 50.7	Mixed		
EFL1	EFTUD1, FAM42A, FLJ13119, HsT19294, RIA1	ENSG00000140598	Elongation factor like GTPase 1	15	82130230-82262763	Predicted intracellular proteins	Evidence at protein level	HPA039654, HPA047110, HPA052345	Uncertain		Approved	Cytosol	Renal cancer:1.50e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.4	Expressed in all		
SH3GL3	CNSA3, EEN-B2, HsT19371, SH3D2C, SH3P13	ENSG00000140600	SH3 domain containing GRB2 like 3, endophilin A3	15	83447228-83618743	Predicted intracellular proteins	Evidence at protein level	HPA039381	Enhanced					Mixed	Group enriched	12	cerebral cortex: 29.9;testis: 38.5	lung: 2.9	Cell line enhanced		HAP1: 30.3;HEK 293: 13.3;K-562: 21.4;RH-30: 8.7
SEC11A	SEC11L1, sid2895, SPC18, SPCS4A	ENSG00000140612	SEC11 homolog A, signal peptidase complex subunit	15	84669538-84716716	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047533			Approved	Nuclear membrane<br>Golgi apparatus	Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 211.1	Expressed in all		
SEPT12	FLJ25410	ENSG00000140623	Septin 12	16	4777669-4788521	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041128			Uncertain	Microtubules		Tissue enhanced	Tissue enriched	668	testis: 107.9	bone marrow: 0.1	Not detected		
GLYR1	BM045, HIBDL, N-PAC, NP60	ENSG00000140632	Glyoxylate reductase 1 homolog	16	4803203-4847342	Predicted intracellular proteins	Evidence at protein level	CAB017022, HPA048226, HPA050136	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Renal cancer:8.74e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 111.5	Expressed in all		
PMM2	CDG1, CDG1a, CDGS, PMI, PMI1	ENSG00000140650	Phosphomannomutase 2	16	8788823-8849331	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040852, HPA063649	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:8.97e-6 (unfavourable), Colorectal cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			rectum: 28.3	Expressed in all		
SLC5A2	SGLT2	ENSG00000140675	Solute carrier family 5 member 2	16	31483002-31490860	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041603	Enhanced					Not detected	Tissue enriched	10	kidney: 26.5	testis: 2.7	Not detected		
ITGAX	CD11C	ENSG00000140678	Integrin subunit alpha X	16	31355134-31382997	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004458, HPA004723, CAB072871	Enhanced				Renal cancer:1.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 58.3;spleen: 59.0	bone marrow: 30.4	Cell line enriched	5	HMC-1: 92.2
TGFB1I1	ARA55, Hic-5, TSC-5	ENSG00000140682	Transforming growth factor beta 1 induced transcript 1	16	31471585-31477960	Predicted intracellular proteins	Evidence at protein level	CAB020844	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:6.06e-8 (unfavourable), Urothelial cancer:7.73e-5 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 137.4;smooth muscle: 150.3	seminal vesicle: 104.2	Mixed		
C16orf58	FLJ13868	ENSG00000140688	Chromosome 16 open reading frame 58	16	31489471-31509309	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024406	Uncertain		Approved	Nucleoplasm<br>Nucleoli<br>Golgi apparatus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 77.4	Expressed in all		
ARMC5	FLJ13063	ENSG00000140691	Armadillo repeat containing 5	16	31458080-31467166	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041524, HPA063706	Approved		Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:1.97e-6 (favourable)	Expressed in all	Mixed			bone marrow: 13.2	Cell line enhanced		NB-4: 37.4
PARN	DAN	ENSG00000140694	Poly(A)-specific ribonuclease	16	14435701-14632728	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006314, CAB011673, HPA012010	Enhanced		Approved	Nucleoli<br>Nuclear speckles	Head and neck cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.0	Expressed in all		
FTO	ALKBH9, KIAA1752, MGC5149	ENSG00000140718	FTO, alpha-ketoglutarate dependent dioxygenase	16	53701692-54158512	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017123, HPA041086, HPA068695	Enhanced		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 87.0	Expressed in all		
UQCRC2	QCR2, UQCR2	ENSG00000140740	Ubiquinol-cytochrome c reductase core protein II	16	21952660-21983660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007998, HPA019146	Enhanced		Enhanced	Mitochondria	Renal cancer:6.58e-9 (favourable)	Expressed in all	Expressed in all			heart muscle: 151.1	Expressed in all		
CDR2	CDR62, Yo	ENSG00000140743	Cerebellar degeneration related protein 2	16	22345936-22437165	Predicted intracellular proteins	Evidence at protein level	HPA018151, HPA023870	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 108.5	Expressed in all		
IGSF6	DORA	ENSG00000140749	Immunoglobulin superfamily member 6	16	21639537-21652660	Predicted membrane proteins	Evidence at protein level	HPA041023, HPA041072	Uncertain				Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 15.2;spleen: 18.1	lung: 8.0	Not detected		
ARHGAP17	FLJ10308, FLJ13219, NADRIN, RICH1, WBP15	ENSG00000140750	Rho GTPase activating protein 17	16	24919385-25015666	Predicted intracellular proteins	Evidence at protein level	HPA041703	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.59e-4 (favourable), Urothelial cancer:3.76e-4 (unfavourable), Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 70.5	Mixed		
MYLK3	caMLCK, MLCK	ENSG00000140795	Myosin light chain kinase 3	16	46703369-46790407	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA073447	Enhanced					Not detected	Tissue enhanced		heart muscle: 69.4;skeletal muscle: 16.9	testis: 11.7	Cell line enhanced		BEWO: 12.5;HEL: 36.3;K-562: 5.8;SK-BR-3: 6.2
ABCC12	MRP9	ENSG00000140798	ATP binding cassette subfamily C member 12	16	48082973-48156018	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043100	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.9	breast: 0.6	Not detected		
NKD1		ENSG00000140807	Naked cuticle homolog 1	16	50548330-50649249	Predicted intracellular proteins	Evidence at protein level	HPA041352, HPA049413	Uncertain		Approved	Nucleoli fibrillar center		Tissue enhanced	Mixed			smooth muscle: 8.1	Group enriched	6	AF22: 6.2;CACO-2: 11.1;Hep G2: 24.6
DHX38	DDX38, hPrp16, KIAA0224, PRP16, PRPF16	ENSG00000140829	DEAH-box helicase 38	16	72093562-72112912	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041347, HPA041604	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 50.0	Expressed in all		
TXNL4B	Dim2, DLP, FLJ20511	ENSG00000140830	Thioredoxin like 4B	16	72044289-72094431	Predicted intracellular proteins	Evidence at protein level	HPA065865			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
MARVELD3	MRVLDC3	ENSG00000140832	MARVEL domain containing 3	16	71626161-71642114	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043514, HPA045471			Approved	Vesicles<br>Intermediate filaments	Renal cancer:6.80e-10 (favourable)	Mixed	Tissue enhanced		small intestine: 37.1	duodenum: 31.5	Cell line enhanced		BEWO: 29.9;CAPAN-2: 19.9;MCF7: 31.1;T-47d: 24.8
CHST4	HEC-GLCNAC-6-ST, LSST	ENSG00000140835	Carbohydrate sulfotransferase 4	16	71525233-71538746	Predicted secreted proteins	Evidence at protein level	HPA021955	Enhanced				Liver cancer:9.24e-4 (unfavourable)	Tissue enriched	Tissue enriched	13	gallbladder: 102.5	fallopian tube: 8.0	Cell line enhanced		CAPAN-2: 7.3;NB-4: 3.0;NTERA-2: 7.1;SCLC-21H: 4.0
ZFHX3	ATBF1, ZNF927	ENSG00000140836	Zinc finger homeobox 3	16	72782885-73059698	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059353	Uncertain				Renal cancer:1.37e-5 (favourable), Breast cancer:1.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 28.3	thyroid gland: 12.4	Mixed		
CLEC18B		ENSG00000140839	C-type lectin domain family 18 member B	16	74408270-74421953	Predicted secreted proteins	Evidence at transcript level	HPA048976	Uncertain				Glioma:1.55e-4 (unfavourable)	Group enriched	Group enriched	10	kidney: 30.9;testis: 8.1	cerebral cortex: 2.0	Cell line enhanced		AF22: 1.1;K-562: 2.7
CPNE2	CPN2	ENSG00000140848	Copine 2	16	57092537-57148367	Predicted intracellular proteins	Evidence at protein level	HPA041132	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			lung: 55.6	Mixed		
NLRC5	CLR16.1, FLJ21709, NOD27	ENSG00000140853	NLR family CARD domain containing 5	16	56989485-57083531	Predicted intracellular proteins	Evidence at protein level	HPA059120, HPA060405			Supported	Centrosome	Ovarian cancer:2.30e-4 (favourable), Renal cancer:2.44e-4 (unfavourable), Cervical cancer:9.69e-4 (favourable)	Expressed in all	Mixed			spleen: 45.1	Cell line enhanced		HEL: 84.3
KATNB1		ENSG00000140854	Katanin regulatory subunit B1	16	57735730-57757250	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041165, HPA041839	Enhanced		Supported	Plasma membrane<br>Microtubules<br>Cytosol	Liver cancer:3.93e-4 (unfavourable), Pancreatic cancer:8.44e-4 (favourable), Endometrial cancer:9.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 45.3	Expressed in all		
KIFC3		ENSG00000140859	Kinesin family member C3	16	57758217-57863053	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021240	Uncertain					Expressed in all	Expressed in all			skin: 98.4	Expressed in all		
ADAMTS18	ADAMTS21	ENSG00000140873	ADAM metallopeptidase with thrombospondin type 1 motif 18	16	77247813-77435114	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044326	Uncertain					Mixed	Tissue enriched	16	placenta: 29.1	cervix, uterine: 1.8	Group enriched	7	HUVEC TERT2: 6.7;TIME: 2.0;U-87 MG: 4.7
NUDT7		ENSG00000140876	Nudix hydrolase 7	16	77722492-77742260	Predicted intracellular proteins	Evidence at protein level	HPA042042	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.36e-11 (favourable), Head and neck cancer:1.84e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 35.7	Cell line enhanced		THP-1: 33.4
GCSH		ENSG00000140905	Glycine cleavage system protein H	16	81081938-81096425	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041368	Approved		Approved	Vesicles	Renal cancer:6.26e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 157.3	Expressed in all		
CMTM3	BNAS2, CKLFSF3, FLJ31762	ENSG00000140931	CKLF like MARVEL transmembrane domain containing 3	16	66603874-66613892	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013870, HPA072695	Approved		Approved	Nucleoplasm	Renal cancer:4.42e-6 (unfavourable), Stomach cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.6	Mixed		
CMTM2	CKLFSF2, FLJ25732, MGC39436	ENSG00000140932	CKLF like MARVEL transmembrane domain containing 2	16	66579448-66588275	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	1018	testis: 712.6	appendix,bone marrow: 0.6	Cell line enriched	23	REH: 29.0
CDH11	CAD11, OB	ENSG00000140937	Cadherin 11	16	64943753-65126112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013072	Enhanced				Renal cancer:2.48e-9 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 223.4	placenta: 173.7	Cell line enhanced		BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5
NOL3	ARC, CARD2, MYP, NOP30	ENSG00000140939	Nucleolar protein 3	16	67170154-67175735	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009208	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:6.43e-5 (unfavourable), Renal cancer:2.41e-4 (unfavourable)	Expressed in all	Mixed			skin: 69.2	Mixed		
MAP1LC3B	ATG8F	ENSG00000140941	Microtubule associated protein 1 light chain 3 beta	16	87383995-87404779	Predicted intracellular proteins	Evidence at protein level	CAB037216, HPA052474, HPA052484, HPA053767	Uncertain				Renal cancer:2.77e-7 (favourable), Stomach cancer:8.97e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 122.4	Expressed in all		
MBTPS1	KIAA0091, PCSK8, S1P, SKI-1	ENSG00000140943	Membrane bound transcription factor peptidase, site 1	16	84053761-84116906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056109	Supported				Renal cancer:2.21e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 118.5	Expressed in all		
CDH13	CDHH	ENSG00000140945	Cadherin 13	16	82626803-83800640	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001380, CAB025863	Enhanced		Supported	Plasma membrane	Renal cancer:1.73e-6 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 70.0	cervix, uterine: 66.4	Cell line enhanced		LHCN-M2: 185.2;U-138 MG: 276.1;U-87 MG: 239.0
ZCCHC14	BDG29, MGC14139	ENSG00000140948	Zinc finger CCHC-type containing 14	16	87406246-87492045	Predicted intracellular proteins	Evidence at protein level	HPA014122			Uncertain	Nuclear membrane	Renal cancer:1.47e-14 (favourable)	Expressed in all	Expressed in all			testis: 61.6	Mixed		
TLDC1	KIAA1609	ENSG00000140950	TBC/LysM-associated domain containing 1	16	84476421-84554033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041020	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Lung cancer:1.03e-5 (unfavourable), Pancreatic cancer:7.05e-5 (unfavourable)	Expressed in all	Mixed			placenta: 15.5	Mixed		
ADAD2	FLJ00337, TENRL	ENSG00000140955	Adenosine deaminase domain containing 2	16	84191138-84197168	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	43	testis: 32.3	cerebral cortex,skin: 0.7	Cell line enriched	10	SCLC-21H: 3.2
OSGIN1	BDGI, OKL38	ENSG00000140961	Oxidative stress induced growth inhibitor 1	16	83948282-83966332	Predicted intracellular proteins	Evidence at protein level	HPA019239			Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.89e-5 (favourable)	Tissue enriched	Tissue enhanced		liver: 57.3	duodenum: 31.3	Cell line enhanced		A549: 60.9;Hep G2: 69.5;T-47d: 69.3;WM-115: 61.3
IRF8	ICSBP, ICSBP1, IRF-8	ENSG00000140968	Interferon regulatory factor 8	16	85898803-85922609	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002267, HPA002531, CAB013480	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Tissue enhanced		lymph node: 297.7;spleen: 205.7;tonsil: 232.5	appendix: 118.0	Cell line enhanced		Daudi: 177.0;THP-1: 280.9;U-698: 672.1;U-937: 108.3
RHOT2	ARHT2, C16orf39, MIRO-2	ENSG00000140983	Ras homolog family member T2	16	668086-674174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012624, HPA012895	Approved		Supported	Cytosol	Head and neck cancer:5.01e-4 (favourable), Renal cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			spleen: 31.2	Expressed in all		
RPL3L		ENSG00000140986	Ribosomal protein L3 like	16	1943974-1957606	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA049136	Enhanced		Approved	Nuclear speckles		Mixed	Tissue enriched	5	skeletal muscle: 323.9	heart muscle: 61.3	Cell line enhanced		CACO-2: 3.3
ZSCAN32	FLJ20417, ZNF434	ENSG00000140987	Zinc finger and SCAN domain containing 32	16	3382081-3401065	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005758	Uncertain		Approved	Nucleoplasm		Mixed	Expressed in all			parathyroid gland: 13.6	Expressed in all		
RPS2	LLREP3, S2	ENSG00000140988	Ribosomal protein S2	16	1962052-1964860	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055133	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.04e-7 (unfavourable), Liver cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3063.2	Expressed in all		
NDUFB10	PDSW	ENSG00000140990	NADH:ubiquinone oxidoreductase subunit B10	16	1959508-1961975	Predicted intracellular proteins	Evidence at protein level	HPA073189	Enhanced				Renal cancer:9.43e-6 (favourable), Cervical cancer:7.38e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 449.6	Expressed in all		
PDPK1	PDK1	ENSG00000140992	3-phosphoinositide dependent protein kinase 1	16	2537964-2603188	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004272, HPA035199, HPA068961	Supported		Approved	Vesicles	Renal cancer:1.29e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.0	Expressed in all		
TIGD7	Sancho	ENSG00000140993	Tigger transposable element derived 7	16	3298832-3305729	Predicted intracellular proteins	Evidence at protein level	HPA041357, HPA041474	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 14.7	Mixed		
DEF8	FLJ20186	ENSG00000140995	Differentially expressed in FDCP 8 homolog	16	89947925-89968060	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041745, HPA049434	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.95e-8 (favourable), Pancreatic cancer:1.35e-7 (favourable)	Expressed in all	Expressed in all			lymph node: 89.1	Expressed in all		
TCF25	KIAA1049, Nulp1	ENSG00000141002	Transcription factor 25	16	89873570-89913627	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041699, HPA041786	Enhanced				Endometrial cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 123.7	Expressed in all		
GALNS	GALNAC6S, GAS	ENSG00000141012	Galactosamine (N-acetyl)-6-sulfatase	16	88813734-88856970	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026404, HPA042433	Enhanced		Approved	Cytosol	Liver cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.7	Expressed in all		
GAS8	DRC4, GAS11	ENSG00000141013	Growth arrest specific 8	16	90019629-90044975	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041311, HPA048238	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.09e-7 (favourable), Endometrial cancer:3.01e-4 (favourable), Pancreatic cancer:7.67e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 30.0	Mixed		
MED9	FLJ10193, MED25	ENSG00000141026	Mediator complex subunit 9	17	17476986-17493226	Predicted intracellular proteins	Evidence at protein level	HPA056415	Uncertain		Approved	Nucleoplasm<br>Midbody	Renal cancer:2.83e-9 (favourable), Pancreatic cancer:4.18e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
NCOR1	hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1	ENSG00000141027	Nuclear receptor corepressor 1	17	16029157-16218185	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043246, HPA050288, HPA051168, CAB072830	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.7	Expressed in all		
COPS3	CSN3, SGN3	ENSG00000141030	COP9 signalosome subunit 3	17	17246820-17281293	Predicted intracellular proteins	Evidence at protein level	HPA021997, HPA050557	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.65e-5 (unfavourable), Prostate cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.6	Expressed in all		
GID4	C17orf39, VID24	ENSG00000141034	GID complex subunit 4 homolog	17	18039292-18068404	Predicted intracellular proteins	Evidence at protein level	HPA044348	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			testis: 62.9	Expressed in all		
ZNF287	ZKSCAN13, ZSCAN45	ENSG00000141040	Zinc finger protein 287	17	16551387-16569206	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029290	Uncertain		Approved	Golgi apparatus	Renal cancer:5.28e-5 (favourable)	Mixed	Mixed			parathyroid gland: 13.0	Mixed		
MYOCD	MYCD	ENSG00000141052	Myocardin	17	12665890-12768949	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB046485	Approved					Mixed	Tissue enhanced		seminal vesicle: 28.9	smooth muscle: 22.9	Cell line enhanced		BJ: 5.5;BJ hTERT+: 5.2;HBF TERT88: 10.1;hTEC/SVTERT24-B: 11.7;REH: 7.6
KSR1	KSR, RSU2	ENSG00000141068	Kinase suppressor of ras 1	17	27456714-27626438	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB009623, HPA011215	Uncertain				Renal cancer:6.54e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 75.6	Cell line enhanced		HDLM-2: 562.3;HEL: 176.9
UTP4	CIRH1A, CIRHIN, FLJ14728, KIAA1988, NAIC, TEX292	ENSG00000141076	UTP4, small subunit processome component	16	69131291-69231130	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041139, HPA043542	Approved		Supported	Nucleoli fibrillar center	Liver cancer:8.18e-7 (unfavourable), Ovarian cancer:2.88e-5 (favourable), Head and neck cancer:9.05e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 51.0	Expressed in all		
RANBP10	KIAA1464	ENSG00000141084	RAN binding protein 10	16	67723066-67806652	Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.52e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 26.7	Expressed in all		
CTRL		ENSG00000141086	Chymotrypsin like	16	67927640-67932414	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA034504, HPA034505	Enhanced		Uncertain	Nucleoplasm		Not detected	Tissue enriched	209	pancreas: 1629.9	ovary: 7.8	Mixed		
DPEP3		ENSG00000141096	Dipeptidase 3	16	67975663-67980829	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA031870, HPA058607	Enhanced					Group enriched	Tissue enriched	25	testis: 56.9	spleen: 2.3	Not detected		
GFOD2	FLJ23802, MGC11335	ENSG00000141098	Glucose-fructose oxidoreductase domain containing 2	16	67674531-67719421	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040939, HPA041112	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.95e-4 (favourable), Renal cancer:8.66e-4 (favourable)	Expressed in all	Expressed in all			esophagus,parathyroid gland: 22.7	Expressed in all		
NOB1	ART-4, MST158, NOB1P, PSMD8BP1	ENSG00000141101	NIN1/PSMD8 binding protein 1 homolog	16	69741867-69754940	Predicted intracellular proteins	Evidence at protein level	HPA041522, HPA049430, HPA067411	Approved		Approved	Focal adhesion sites<br>Cytosol	Head and neck cancer:4.21e-5 (unfavourable), Liver cancer:8.16e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 69.4	Expressed in all		
PRPSAP2	PAP41	ENSG00000141127	Phosphoribosyl pyrophosphate synthetase associated protein 2	17	18840085-18931287	Predicted intracellular proteins	Evidence at protein level	HPA021881	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 61.1	Expressed in all		
UNC45B	CMYA4, UNC45	ENSG00000141161	Unc-45 myosin chaperone B	17	35147817-35189345	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017861	Uncertain		Supported	Cytosol		Group enriched	Group enriched	21	heart muscle: 65.8;skeletal muscle: 68.0	prostate: 3.1	Group enriched	9	BEWO: 1.6;HSkMC: 1.8
PCTP	STARD2	ENSG00000141179	Phosphatidylcholine transfer protein	17	55750979-55842830	Predicted intracellular proteins	Evidence at protein level	HPA022979	Approved		Approved	Nucleus<br>Nucleoli	Head and neck cancer:3.43e-6 (unfavourable)	Expressed in all	Expressed in all			liver: 49.3	Expressed in all		
OR4D1	OR4D3, TPCR16	ENSG00000141194	Olfactory receptor family 4 subfamily D member 1	17	58155133-58156156	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node,testis: 0.1	Not detected		
TOM1L1	SRCASM	ENSG00000141198	Target of myb1 like 1 membrane trafficking protein	17	54899387-54968646	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022916	Uncertain				Renal cancer:3.81e-6 (favourable), Colorectal cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.9	Mixed		
KIF2B		ENSG00000141200	Kinesin family member 2B	17	53822901-53825213	Predicted intracellular proteins	Evidence at protein level	HPA023081, HPA023103, HPA024795	Uncertain		Uncertain	Nucleoli<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle		Not detected	Tissue enriched	1329	testis: 132.9	all non-specific tissues: 0.0	Not detected		
C17orf80	FLJ20721, HLC-8, MIG3, SPEP1	ENSG00000141219	Chromosome 17 open reading frame 80	17	73232233-73248947	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012896	Uncertain		Approved	Nucleoplasm<br>Vesicles	Liver cancer:9.02e-6 (unfavourable), Colorectal cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Expressed in all		
TOB1	APRO5, TOB, TROB, TROB1	ENSG00000141232	Transducer of ERBB2, 1	17	50862223-50867978	Predicted intracellular proteins	Evidence at protein level	HPA047839	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.04e-5 (unfavourable), Prostate cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 278.7	Expressed in all		
VPS53	FLJ10979, HCCS1	ENSG00000141252	VPS53, GARP complex subunit	17	508668-721717	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022988, HPA024446	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.08e-5 (favourable), Pancreatic cancer:1.56e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.3	Expressed in all		
SPATA22	NYD-SP20	ENSG00000141255	Spermatogenesis associated 22	17	3440019-3513852	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	80	testis: 415.6	placenta: 5.1	Group enriched	8	K-562: 6.9;TIME: 8.9
SGSM2	KIAA0397, RUTBC1	ENSG00000141258	Small G protein signaling modulator 2	17	2337498-2381058	Predicted intracellular proteins	Evidence at protein level	HPA021641, HPA024553	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:9.00e-6 (favourable), Head and neck cancer:3.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 78.0	Expressed in all		
NPEPPS	MP100, PSA	ENSG00000141279	Aminopeptidase puromycin sensitive	17	47522942-47623276	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021453, HPA045649	Uncertain		Supported	Cytosol	Colorectal cancer:3.39e-5 (favourable), Liver cancer:3.67e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 106.9	Expressed in all		
SKAP1	SCAP1, SKAP55	ENSG00000141293	Src kinase associated phosphoprotein 1	17	48133440-48430275	Predicted intracellular proteins	Evidence at protein level	HPA002969, CAB025882, CAB055513	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:3.14e-4 (favourable), Breast cancer:5.07e-4 (favourable)	Mixed	Mixed			lymph node: 33.6	Cell line enhanced		CAPAN-2: 26.1;HDLM-2: 14.7;HMC-1: 11.3;Karpas-707: 11.5;RPMI-8226: 13.6;RPTEC TERT1: 17.6;U-266/70: 11.0
LRRC46	MGC16309	ENSG00000141294	Leucine rich repeat containing 46	17	47831627-47837713	Predicted intracellular proteins	Evidence at protein level	HPA021882, HPA074893	Enhanced		Approved	Cytosol	Endometrial cancer:2.11e-4 (favourable)	Tissue enhanced	Group enriched	13	fallopian tube: 120.7;testis: 55.6	lung: 6.5	Mixed		
SCRN2		ENSG00000141295	Secernin 2	17	47837692-47841333	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022934, HPA023434	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:3.86e-4 (favourable), Urothelial cancer:5.83e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 84.3	Expressed in all		
SSH2	KIAA1725	ENSG00000141298	Slingshot protein phosphatase 2	17	29625938-29930276	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017189, HPA057099	Uncertain					Expressed in all	Expressed in all			bone marrow: 35.7	Expressed in all		
RHBDL3	RHBDL4, VRHO	ENSG00000141314	Rhomboid like 3	17	32266176-32324661	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA059607	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.7	adrenal gland: 5.5	Cell line enhanced		A549: 4.0;AF22: 4.3;HDLM-2: 5.7;NTERA-2: 6.4;U-2 OS: 4.6
SPACA3	ALLP17, CT54, LYC3, LYZL3, SLLP1	ENSG00000141316	Sperm acrosome associated 3	17	32970376-32997877	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023633	Enhanced					Tissue enhanced	Tissue enriched	17	testis: 77.5	pancreas: 4.5	Cell line enriched	17	U-266/70: 72.1
ARSG	KIAA1001	ENSG00000141337	Arylsulfatase G	17	68259182-68422731	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023245, HPA023285	Enhanced				Renal cancer:7.04e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 48.6	thyroid gland: 18.9	Mixed		
ABCA8	KIAA0822	ENSG00000141338	ATP binding cassette subfamily A member 8	17	68867292-68955392	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044914	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 67.5	Group enriched	6	ASC diff: 23.3;ASC TERT1: 52.5;HHSteC: 10.6;HSkMC: 41.5
G6PC3	UGRP	ENSG00000141349	Glucose-6-phosphatase catalytic subunit 3	17	44070735-44076344	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067052			Supported	Endoplasmic reticulum	Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.3	Expressed in all		
CLTC	CLTCL2, Hc	ENSG00000141367	Clathrin heavy chain	17	59619689-59696956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010389, CAB011571, CAB017155, HPA059143	Approved		Enhanced	Vesicles<br>Mitotic spindle<br>Cytosol	Urothelial cancer:2.02e-4 (unfavourable), Liver cancer:5.54e-4 (unfavourable), Cervical cancer:7.35e-4 (unfavourable), Colorectal cancer:7.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 365.5	Expressed in all		
C17orf64		ENSG00000141371	Chromosome 17 open reading frame 64	17	60392429-60431421	Predicted intracellular proteins	Evidence at protein level	HPA044415	Enhanced		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	233	testis: 185.6	spleen: 0.7	Cell line enhanced		MCF7: 4.4
BCAS3	FLJ20128	ENSG00000141376	BCAS3, microtubule associated cell migration factor	17	60677453-61392838	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA052409, HPA057289	Approved		Supported	Nucleoli	Pancreatic cancer:1.23e-5 (favourable), Renal cancer:1.73e-5 (favourable), Cervical cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.8	Expressed in all		
PTRH2	BIT1, CFAP37, CGI-147, PTH2	ENSG00000141378	Peptidyl-tRNA hydrolase 2	17	59674636-59707626	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA012897	Supported		Supported	Mitochondria	Renal cancer:1.01e-8 (unfavourable), Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 43.9	Expressed in all		
SS18	SSXT, SYT	ENSG00000141380	SS18, nBAF chromatin remodeling complex subunit	18	26016253-26091217	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055741, HPA059539	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 75.7	Expressed in all		
TAF4B	TAF2C2, TAFII105	ENSG00000141384	TATA-box binding protein associated factor 4b	18	26225936-26391685	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028937	Uncertain		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Urothelial cancer:1.72e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Mixed	Mixed			testis: 4.2	Cell line enhanced		Daudi: 24.6
AFG3L2	SCA28, SPAX5	ENSG00000141385	AFG3 like matrix AAA peptidase subunit 2	18	12328944-12377314	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA004479, HPA004480	Enhanced		Enhanced	Mitochondria	Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 123.6	Expressed in all		
PRELID3A	C18orf43, FLJ31484, HFL-EDDG1, SLMO1	ENSG00000141391	PRELI domain containing 3A	18	12407896-12432238	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.89e-7 (unfavourable)	Mixed	Mixed			seminal vesicle: 16.6	Mixed		
IMPA2		ENSG00000141401	Inositol monophosphatase 2	18	11981025-12030883	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029561	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			skin: 129.8	Cell line enhanced		BEWO: 240.8;SiHa: 163.4
GNAL		ENSG00000141404	G protein subunit alpha L	18	11688956-11885685	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015464, HPA051160	Supported		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 28.8	Cell line enhanced		Daudi: 18.9;HeLa: 17.7
SLC39A6	LIV-1	ENSG00000141424	Solute carrier family 39 member 6	18	36108532-36129385	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042377	Approved				Liver cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 209.2	Expressed in all		
RPRD1A	FLJ10656, HsT3101, P15RS	ENSG00000141425	Regulation of nuclear pre-mRNA domain containing 1A	18	35984387-36067576	Predicted intracellular proteins	Evidence at protein level	HPA040602	Supported		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			epididymis: 140.2	Expressed in all		
C18orf21	HsT3108, PNAS-124, PNAS-131	ENSG00000141428	Chromosome 18 open reading frame 21	18	35972083-35979286	Predicted intracellular proteins	Evidence at protein level	HPA065505, HPA067322	Uncertain		Approved	Nucleoli<br>Plasma membrane	Liver cancer:1.38e-6 (unfavourable), Ovarian cancer:1.81e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.6	Expressed in all		
GALNT1	GalNAc-T1	ENSG00000141429	Polypeptide N-acetylgalactosaminyltransferase 1	18	35581117-35711834	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012628	Uncertain					Expressed in all	Expressed in all			urinary bladder: 85.6	Expressed in all		
ASXL3	KIAA1713	ENSG00000141431	Additional sex combs like 3, transcriptional regulator	18	33578577-33751192	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA039539, HPA040034	Uncertain					Not detected	Tissue enhanced		ovary: 2.9	testis: 2.7	Group enriched	11	AF22: 2.4;HEK 293: 1.2;RPMI-8226: 5.8;SCLC-21H: 3.3;SH-SY5Y: 1.5
ADCYAP1	PACAP	ENSG00000141433	Adenylate cyclase activating polypeptide 1	18	904943-912172	Predicted secreted proteins	Evidence at protein level	HPA065887		Approved			Renal cancer:2.91e-6 (favourable)	Tissue enhanced	Tissue enhanced		appendix: 19.3;cerebral cortex: 16.0;gallbladder: 15.7	testis: 5.6	Cell line enriched	17	SCLC-21H: 20.8
MEP1B		ENSG00000141434	Meprin A subunit beta	18	32185069-32220404	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029119	Enhanced					Group enriched	Group enriched	37	duodenum: 251.4;small intestine: 402.2	colon: 8.7	Cell line enhanced		SCLC-21H: 6.6
SLC25A52	MCART2	ENSG00000141437	Solute carrier family 25 member 52	18	31759562-31760880	Predicted membrane proteins	Evidence at transcript level	HPA046388, HPA058261	Uncertain		Approved	Mitochondria		Not detected	Tissue enriched	64	testis: 15.4	adipose tissue,skin: 0.2	Not detected		
GAREM1	C18orf11, FAM59A, FLJ21610, GAREM	ENSG00000141441	GRB2 associated regulator of MAPK1 subtype 1	18	32124877-32470484	Predicted intracellular proteins	Evidence at protein level	HPA040709, HPA042046	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.49e-6 (favourable), Pancreatic cancer:6.73e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 13.7	Cell line enhanced		hTERT-HME1: 23.0;RT4: 21.0;SH-SY5Y: 22.6
ESCO1	EFO1, ESO1, KIAA1911	ENSG00000141446	Establishment of sister chromatid cohesion N-acetyltransferase 1	18	21529281-21600884	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042497	Approved					Expressed in all	Expressed in all			testis: 36.6	Expressed in all		
OSBPL1A	ORP-1, ORP1, OSBPL1B	ENSG00000141447	Oxysterol binding protein like 1A	18	24162044-24397880	Predicted intracellular proteins	Evidence at protein level	HPA040959, HPA043401	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.98e-13 (favourable), Stomach cancer:1.86e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 131.1	Mixed		
GATA6		ENSG00000141448	GATA binding protein 6	18	22169443-22202528	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011581, HPA066629	Uncertain		Supported	Nucleus	Renal cancer:1.92e-9 (unfavourable)	Tissue enhanced	Mixed			adrenal gland: 50.8	Cell line enhanced		BEWO: 51.6;CACO-2: 55.5
GREB1L	C18orf6, FLJ13687, KIAA1772	ENSG00000141449	Growth regulation by estrogen in breast cancer 1 like	18	21242242-21525417	Predicted intracellular proteins	Evidence at protein level	HPA041647, HPA044218	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 11.5	thyroid gland: 5.8	Cell line enhanced		AF22: 50.3;BEWO: 99.4;CACO-2: 39.5
C18orf8	HsT2591, MIC-1, MIC1	ENSG00000141452	Chromosome 18 open reading frame 8	18	23503470-23531807	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043589	Uncertain		Uncertain	Nucleus	Liver cancer:3.94e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.0	Expressed in all		
PELP1	MNAR	ENSG00000141456	Proline, glutamate and leucine rich protein 1	17	4669774-4704337	Predicted intracellular proteins	Evidence at protein level	HPA053966, HPA056028, HPA060760	Supported		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:4.07e-5 (favourable), Liver cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.2	Expressed in all		
NPC1		ENSG00000141458	NPC intracellular cholesterol transporter 1	18	23506184-23586898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026618, CAB070132, HPA077445	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:2.26e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 110.1	Expressed in all		
SLC14A1	HsT1341, JK, RACH1, RACH2	ENSG00000141469	Solute carrier family 14 member 1 (Kidd blood group)	18	45724127-45752520	Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058353, HPA059570	Supported		Supported	Vesicles		Group enriched	Group enriched	5	prostate: 137.8;urinary bladder: 49.9	cerebral cortex: 18.1	Cell line enriched	14	RT4: 97.7
ARRB2	ARR2, BARR2, DKFZp686L0365	ENSG00000141480	Arrestin beta 2	17	4710489-4721499	Predicted intracellular proteins	Evidence at protein level	HPA065681			Supported	Vesicles	Prostate cancer:2.61e-5 (unfavourable), Cervical cancer:2.93e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 171.5	Expressed in all		
SLC13A5	NACT	ENSG00000141485	Solute carrier family 13 member 5	17	6684713-6713567	Predicted membrane proteins, Transporters	Evidence at protein level	HPA044343, HPA057088	Approved		Uncertain	Nucleoplasm		Tissue enriched	Tissue enriched	9	liver: 118.4	salivary gland: 12.8	Cell line enriched	65	Hep G2: 39.1
ZMYND15	DKFZp434N127	ENSG00000141497	Zinc finger MYND-type containing 15	17	4740015-4746119	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023286			Uncertain	Nuclear speckles<br>Cytosol		Expressed in all	Tissue enhanced		parathyroid gland: 15.7;testis: 29.5	lung: 7.5	Cell line enhanced		A-431: 1.9;CAPAN-2: 1.8
WRAP53	FLJ10385, TCAB1, WDR79	ENSG00000141499	WD repeat containing antisense to TP53	17	7686071-7703502	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023026, HPA028130, HPA029928	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.70e-4 (unfavourable), Pancreatic cancer:8.26e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 21.8	Mixed		
MINK1	B55, MAP4K6, MINK, YSK2, ZC3	ENSG00000141503	Misshapen like kinase 1	17	4833388-4898061	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056296	Approved				Pancreatic cancer:2.77e-4 (favourable), Liver cancer:3.00e-4 (unfavourable), Prostate cancer:9.27e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.5	Expressed in all		
SAT2	SSAT2	ENSG00000141504	Spermidine/spermine N1-acetyltransferase family member 2	17	7626234-7627876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022136, HPA057096	Enhanced				Endometrial cancer:8.76e-6 (favourable), Pancreatic cancer:6.05e-5 (favourable), Lung cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.0	Mixed		
ASGR1	CLEC4H1	ENSG00000141505	Asialoglycoprotein receptor 1	17	7173431-7179564	Predicted intracellular proteins	Evidence at protein level	HPA011954, HPA012852	Enhanced		Supported	Vesicles<br>Cell Junctions		Tissue enriched	Tissue enriched	13	liver: 236.1	testis: 17.6	Cell line enriched	25	Hep G2: 331.3
PIK3R5	p101, P101-PI3K	ENSG00000141506	Phosphoinositide-3-kinase regulatory subunit 5	17	8878911-8965712	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044505, HPA052247, HPA052412	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 55.2	spleen: 27.9	Cell line enhanced		HDLM-2: 36.3;U-937: 8.8
TP53	LFS1, p53	ENSG00000141510	Tumor protein p53	17	7661779-7687550	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB002973, CAB039238, CAB039239, HPA051244, CAB072876	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.3	Expressed in all		
CCDC40	CILD15, FAP172, FLJ20753, FLJ32021, KIAA1640	ENSG00000141519	Coiled-coil domain containing 40	17	80036632-80100613	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022974	Enhanced		Approved	Microtubules	Renal cancer:2.45e-4 (unfavourable), Endometrial cancer:2.95e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.7	testis: 12.8	Cell line enhanced		SCLC-21H: 14.2
ARHGDIA	GDIA1, RHOGDI	ENSG00000141522	Rho GDP dissociation inhibitor alpha	17	81867721-81871406	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010005, HPA021407	Approved		Enhanced	Cytosol	Lung cancer:7.63e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 206.6	Expressed in all		
TMC6	EVER1, EVIN1, LAK-4P	ENSG00000141524	Transmembrane channel like 6	17	78110458-78132407	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051430	Uncertain				Stomach cancer:1.82e-4 (favourable), Urothelial cancer:3.20e-4 (favourable)	Expressed in all	Expressed in all			spleen: 82.8	Cell line enhanced		K-562: 99.9;SK-BR-3: 90.6
SLC16A3	MCT3, MCT4	ENSG00000141526	Solute carrier family 16 member 3	17	82228397-82261129	Predicted membrane proteins, Transporters	Evidence at protein level	CAB017490, HPA021451	Approved		Supported	Nuclear membrane<br>Plasma membrane	Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 74.3	Mixed		
CARD14	BIMP2, CARMA2, PSORS2	ENSG00000141527	Caspase recruitment domain family member 14	17	80169992-80209331	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 17.8	esophagus: 7.0	Cell line enhanced		MCF7: 6.3;SK-BR-3: 8.0;T-47d: 22.6
TTYH2	C17orf29	ENSG00000141540	Tweety family member 2	17	74213514-74262020	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.74e-5 (unfavourable)	Group enriched	Tissue enriched	6	cerebral cortex: 129.2	testis: 21.8	Cell line enhanced		SK-MEL-30: 62.2
RAB40B	RAR, SEC4L	ENSG00000141542	RAB40B, member RAS oncogene family	17	82654973-82698728	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:2.95e-6 (favourable), Lung cancer:9.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 56.8	epididymis: 18.0	Mixed		
EIF4A3	DDX48, EIF4AIII, KIAA0111	ENSG00000141543	Eukaryotic translation initiation factor 4A3	17	80135214-80147183	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021878	Enhanced		Supported	Nucleoplasm	Liver cancer:1.68e-5 (unfavourable), Colorectal cancer:3.57e-5 (favourable), Lung cancer:1.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 112.1	Expressed in all		
CSNK1D	CKID, CKIdelta, HCKID	ENSG00000141551	Casein kinase 1 delta	17	82239023-82273731	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB015410	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.38e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable), Endometrial cancer:7.04e-4 (unfavourable), Renal cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.9	Expressed in all		
ANAPC11	APC11, Apc11p, HSPC214, MGC882	ENSG00000141552	Anaphase promoting complex subunit 11	17	81890790-81900991	Predicted intracellular proteins	Evidence at protein level	HPA021989, HPA027838	Approved		Enhanced	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			testis: 109.9	Expressed in all		
TBCD		ENSG00000141556	Tubulin folding cofactor D	17	82752064-82945922	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045200	Approved				Liver cancer:2.39e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.6	Expressed in all		
FN3KRP	FLJ12171, FN3KL	ENSG00000141560	Fructosamine 3 kinase related protein	17	82716683-82730328	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056172, HPA065831	Approved		Approved	Nucleoplasm	Glioma:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 48.8	Expressed in all		
NARF	DKFZp434G0420, FLJ10067, IOP2	ENSG00000141562	Nuclear prelamin A recognition factor	17	82458180-82490537	Predicted intracellular proteins	Evidence at protein level	HPA053006			Supported	Nucleus<br>Nucleoli	Renal cancer:1.48e-10 (unfavourable), Cervical cancer:1.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.3	Expressed in all		
RPTOR	KIAA1303, KOG1, Mip1, raptor	ENSG00000141564	Regulatory associated protein of MTOR complex 1	17	80544819-80966371	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013514, HPA064306	Approved		Enhanced	Nucleoplasm<br>Lysosomes<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 11.2	Expressed in all		
FOXK2	ILF, ILF1	ENSG00000141568	Forkhead box K2	17	82519713-82644662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027523	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.24e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 53.2	Expressed in all		
TRIM65		ENSG00000141569	Tripartite motif containing 65	17	75880335-75897003	Predicted intracellular proteins	Evidence at protein level	HPA021575, HPA021578, HPA064820	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:4.74e-6 (unfavourable), Renal cancer:1.82e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 20.4	Expressed in all		
CBX8	HPC3, PC3, RC1	ENSG00000141570	Chromobox 8	17	79792132-79801683	Predicted intracellular proteins	Evidence at protein level	HPA031462	Enhanced		Enhanced	Nucleoplasm	Renal cancer:5.39e-7 (unfavourable), Liver cancer:3.94e-6 (unfavourable), Pancreatic cancer:3.84e-5 (favourable)	Expressed in all	Mixed			epididymis: 13.2	Mixed		
SECTM1	K12	ENSG00000141574	Secreted and transmembrane 1	17	82321024-82334074	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051214	Approved					Expressed in all	Tissue enhanced		small intestine: 96.6	duodenum: 64.4	Cell line enhanced		SiHa: 125.5;U-2197: 82.3
RNF157	KIAA1917	ENSG00000141576	Ring finger protein 157	17	76142453-76240373	Predicted intracellular proteins	Evidence at protein level	HPA021854, HPA021991, HPA023922	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 60.6;testis: 57.3	skeletal muscle: 24.9	Cell line enhanced		HDLM-2: 92.0;U-266/70: 38.2
CEP131	AZ1, AZI1, KIAA1118	ENSG00000141577	Centrosomal protein 131	17	81189593-81222999	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024019	Approved		Supported	Microtubules<br>Cytokinetic bridge<br>Microtubule organizing center	Liver cancer:9.68e-5 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Expressed in all		
ZNF750	FLJ13841, Zfp750	ENSG00000141579	Zinc finger protein 750	17	82829435-82840578	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021573, HPA023012	Enhanced					Mixed	Tissue enhanced		esophagus: 60.5;skin: 54.4	salivary gland: 13.0	Cell line enhanced		BEWO: 16.4;hTCEpi: 4.5;MCF7: 3.6;SK-BR-3: 9.5
WDR45B	WDR45L, WIPI3	ENSG00000141580	WD repeat domain 45B	17	82614562-82648553	Predicted intracellular proteins	Evidence at protein level	HPA017886			Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Liver cancer:2.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 82.9	Expressed in all		
CBX4	hPC2, NBP16, PC2	ENSG00000141582	Chromobox 4	17	79833156-79839429	Predicted intracellular proteins	Evidence at protein level	HPA008228, HPA012021	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:8.72e-8 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 85.1	cerebral cortex: 25.6	Expressed in all		
RNF165	ARKL2, RNF111L2	ENSG00000141622	Ring finger protein 165	18	46326809-46463140	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041615, HPA047798	Uncertain		Approved	Nucleus<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 9.3;parathyroid gland: 9.8	thyroid gland: 7.0	Cell line enhanced		AF22: 13.9;SCLC-21H: 17.1;SH-SY5Y: 17.5
DYM	DMC, FLJ20071, SMC	ENSG00000141627	Dymeclin	18	49041474-49461347	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043551, HPA049187	Approved		Supported	Golgi apparatus	Renal cancer:2.76e-5 (favourable), Urothelial cancer:5.26e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
MAPK4	Erk3-related, Erk4, PRKM4	ENSG00000141639	Mitogen-activated protein kinase 4	18	50560078-50731824	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		adrenal gland: 29.7;cerebral cortex: 33.4;parathyroid gland: 60.1	seminal vesicle: 13.9	Cell line enhanced		SCLC-21H: 13.6;SH-SY5Y: 3.0
ELAC1	D29	ENSG00000141642	ElaC ribonuclease Z 1	18	50967991-50988121	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040867, HPA066483	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.43e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.8	Expressed in all		
MBD1	CXXC3, PCM1	ENSG00000141644	Methyl-CpG binding domain protein 1	18	50266882-50281774	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009017, CAB036003, HPA068850	Approved		Enhanced	Nucleoplasm<br>Vesicles	Prostate cancer:1.70e-6 (unfavourable), Liver cancer:5.08e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 109.0	Expressed in all		
SMAD4	DPC4, MADH4	ENSG00000141646	SMAD family member 4	18	51028394-51085045	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019154	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:1.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.3	Expressed in all		
TNFRSF11A	CD265, FEO, LOH18CR1, PDB2, RANK	ENSG00000141655	TNF receptor superfamily member 11a	18	62325287-62391292	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010391, HPA027728, HPA047976	Uncertain		Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 30.6	small intestine: 20.5	Cell line enhanced		HDLM-2: 116.8;PC-3: 18.0;SCLC-21H: 24.0
ZCCHC2	C18orf49, FLJ20222, FLJ20281, KIAA1744	ENSG00000141664	Zinc finger CCHC-type containing 2	18	62523007-62587709	Predicted intracellular proteins	Evidence at protein level	HPA040943	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 22.4	Mixed		
FBXO15	FBX15, MGC39671	ENSG00000141665	F-box protein 15	18	74073353-74147865	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 4.9;testis: 6.6	cerebral cortex,epididymis: 2.0	Cell line enhanced		SCLC-21H: 2.6
CBLN2		ENSG00000141668	Cerebellin 2 precursor	18	72536680-72638521	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	7	cerebral cortex: 30.2;seminal vesicle: 7.3	small intestine: 2.8	Cell line enriched	8	SH-SY5Y: 57.5
PMAIP1	APR, NOXA	ENSG00000141682	Phorbol-12-myristate-13-acetate-induced protein 1	18	59899948-59904306	Predicted intracellular proteins	Evidence at protein level	HPA051063	Uncertain		Approved	Vesicles	Renal cancer:3.15e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 55.8	placenta: 18.4	Cell line enhanced		U-138 MG: 194.4
P3H4	LEPREL4, NO55, SC65	ENSG00000141696	Prolyl 3-hydroxylase family member 4 (non-enzymatic)	17	41801947-41812604	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.48e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 18.3	Mixed		
NT5C3B	cN-IIIB, MGC20781, NT5C3L	ENSG00000141698	5'-nucleotidase, cytosolic IIIB	17	41825181-41836263	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030786, HPA057095	Approved				Liver cancer:8.11e-5 (unfavourable), Pancreatic cancer:2.67e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.2	Mixed		
FAM134C	DKFZp686B1036, FLJ33806	ENSG00000141699	Family with sequence similarity 134 member C	17	42579513-42610623	Predicted membrane proteins	Evidence at protein level	HPA016492	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 48.2	Expressed in all		
ERBB2	CD340, HER-2, HER2, NEU, NGL	ENSG00000141736	Erb-b2 receptor tyrosine kinase 2	17	39687914-39730426	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.5	Cell line enriched	22	SK-BR-3: 2343.7
GRB7		ENSG00000141738	Growth factor receptor bound protein 7	17	39737927-39747291	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005226, HPA057084, CAB073538	Approved		Supported	Plasma membrane	Endometrial cancer:6.60e-7 (unfavourable), Renal cancer:8.23e-5 (favourable), Ovarian cancer:3.10e-4 (unfavourable), Pancreatic cancer:6.90e-4 (unfavourable)	Mixed	Mixed			fallopian tube: 35.1	Cell line enriched	8	SK-BR-3: 272.9
MIEN1	C17orf37, C35, MGC14832, ORB3, Rdx12, XTP4	ENSG00000141741	Migration and invasion enhancer 1	17	39728496-39730787	Predicted intracellular proteins	Evidence at protein level	HPA061344	Approved					Expressed in all	Expressed in all			prostate: 41.0	Cell line enriched	5	SK-BR-3: 451.5
PNMT	PENT	ENSG00000141744	Phenylethanolamine N-methyltransferase	17	39667981-39670475	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017029, HPA043412, HPA051005	Enhanced				Endometrial cancer:3.95e-5 (unfavourable)	Tissue enhanced	Tissue enriched	8	adrenal gland: 226.6	seminal vesicle: 29.2	Cell line enhanced		HEL: 4.8;K-562: 10.4;NB-4: 14.5;SCLC-21H: 7.0;SH-SY5Y: 5.8
ARL5C	ARL12	ENSG00000141748	ADP ribosylation factor like GTPase 5C	17	39156894-39167484	Predicted intracellular proteins	No evidence	HPA069849	Uncertain					Not detected	Not detected			lymph node: 0.4	Not detected		
STAC2	24b2	ENSG00000141750	SH3 and cysteine rich domain 2	17	39210536-39225872	Predicted intracellular proteins	Evidence at protein level	HPA017288			Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.05e-5 (unfavourable), Glioma:5.04e-4 (unfavourable), Ovarian cancer:6.66e-4 (unfavourable)	Group enriched	Group enriched	6	breast: 32.0;cerebral cortex: 30.1;epididymis: 13.8;seminal vesicle: 35.6	skin: 4.5	Cell line enhanced		HeLa: 22.2;hTEC/SVTERT24-B: 4.8;U-87 MG: 14.4
IGFBP4	BP-4, HT29-IGFBP, IBP4, IGFBP-4	ENSG00000141753	Insulin like growth factor binding protein 4	17	40443461-40457731	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA066240	Supported				Renal cancer:2.72e-5 (unfavourable), Endometrial cancer:3.54e-4 (favourable), Liver cancer:5.49e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 932.6	Cell line enhanced		A549: 1206.8;HSkMC: 1458.4
FKBP10	FKBP6, FLJ20683, FLJ22041, FLJ23833, hFKBP65	ENSG00000141756	FK506 binding protein 10	17	41812680-41823217	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051171, HPA057021	Enhanced		Approved	Vesicles	Renal cancer:0.00e+0 (unfavourable), Thyroid cancer:3.43e-5 (unfavourable), Cervical cancer:4.16e-4 (unfavourable), Urothelial cancer:4.99e-4 (unfavourable)	Expressed in all	Mixed			placenta: 84.7	Mixed		
TXNL4A	DIB1, DIM1, HsT161, SNRNP15, TXNL4, U5-15kD	ENSG00000141759	Thioredoxin like 4A	18	79970811-80033949	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041324			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Liver cancer:3.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 82.5	Expressed in all		
CACNA1A	APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6	ENSG00000141837	Calcium voltage-gated channel subunit alpha1 A	19	13206442-13633025	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA064258, HPA071902	Enhanced		Uncertain	Endoplasmic reticulum	Pancreatic cancer:4.32e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 15.1	stomach: 3.5	Group enriched	7	SCLC-21H: 56.1;U-87 MG: 26.1
MISP3		ENSG00000141854	MISP family member 3	19	14072536-14075062	Predicted intracellular proteins	Evidence at protein level	HPA042225	Uncertain				Stomach cancer:3.11e-5 (favourable), Renal cancer:9.52e-4 (favourable)	Expressed in all	Mixed			small intestine: 8.5	Cell line enhanced		Karpas-707: 7.7;RPMI-8226: 8.7
SAMD1		ENSG00000141858	Sterile alpha motif domain containing 1	19	14087840-14091036	Predicted intracellular proteins	Evidence at protein level	HPA041662, HPA049059	Uncertain		Approved	Mitochondria<br>Cytosol	Liver cancer:1.96e-5 (unfavourable), Renal cancer:7.98e-5 (unfavourable), Cervical cancer:7.41e-4 (favourable), Stomach cancer:8.31e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.2	Expressed in all		
BRD4	CAP, HUNK1, HUNKI, MCAP	ENSG00000141867	Bromodomain containing 4	19	15235519-15332545	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015055, HPA061646, CAB068177, CAB068178	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 41.9	Expressed in all		
SLC39A3	ZIP3	ENSG00000141873	Solute carrier family 39 member 3	19	2732204-2740152	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042139, HPA058526	Uncertain		Approved	Vesicles	Endometrial cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			testis: 110.2	Cell line enhanced		U-937: 326.0
NFIC	CTF, CTF5, NF-I, NFI	ENSG00000141905	Nuclear factor I C	19	3359563-3469217	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004300, CAB004674, HPA052625	Supported		Enhanced	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:1.52e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 68.9	Cell line enhanced		SiHa: 191.4
TPGS1	C19orf20, GTRGEO22, PGs1	ENSG00000141933	Tubulin polyglutamylase complex subunit 1	19	507497-519654	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.24e-4 (favourable), Pancreatic cancer:8.82e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 6.6	Cell line enhanced		HEK 293: 32.8;SH-SY5Y: 38.0
PLPP2	LPP2, PAP-2c, PPAP2C	ENSG00000141934	Phospholipid phosphatase 2	19	281040-291504	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055540	Uncertain		Approved	Mitochondria	Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 128.6	cervix, uterine: 92.0	Cell line enhanced		A549: 122.2;CAPAN-2: 128.0
ZIM3	ZNF657	ENSG00000141946	Zinc finger imprinted 3	19	57134096-57145202	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034575	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
PRDM15	C21orf83, ZNF298	ENSG00000141956	PR/SET domain 15	21	41798225-41879482	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024268, HPA029255, HPA029256	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 8.8	Cell line enhanced		Daudi: 21.6;U-698: 37.6
PFKL		ENSG00000141959	Phosphofructokinase, liver type	21	44300051-44327376	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030047	Approved		Approved	Nucleoli<br>Mitochondria	Ovarian cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 101.7	Expressed in all		
FEM1A		ENSG00000141965	Fem-1 homolog A	19	4791681-4801273	Predicted intracellular proteins	Evidence at protein level	HPA016565, HPA063622			Supported	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	7	skeletal muscle: 94.0	parathyroid gland: 13.6	Expressed in all		
VAV1	VAV	ENSG00000141968	Vav guanine nucleotide exchange factor 1	19	6772714-6857366	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001864	Enhanced		Approved	Cytosol	Renal cancer:1.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 57.6	appendix: 53.0	Cell line enhanced		HMC-1: 96.0;Karpas-707: 90.4;MOLT-4: 100.9;U-937: 80.7
MVB12A	FAM125A, FLJ32495	ENSG00000141971	Multivesicular body subunit 12A	19	17405722-17433724	Predicted intracellular proteins	Evidence at protein level	HPA041885, HPA042231	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Cervical cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			ovary: 38.1	Expressed in all		
CIB3	KIP3	ENSG00000141977	Calcium and integrin binding family member 3	19	16161368-16173525	Predicted intracellular proteins	Evidence at protein level	HPA043553	Uncertain					Tissue enriched	Not detected			bone marrow: 0.8	Cell line enhanced		HMC-1: 3.9;MCF7: 1.7;U-937: 1.6
SH3GL1	CNSA1, EEN, MGC111371, SH3D2B, SH3P8	ENSG00000141985	SH3 domain containing GRB2 like 1, endophilin A2	19	4360370-4400547	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021485	Approved		Enhanced	Cytosol	Renal cancer:9.36e-8 (unfavourable), Liver cancer:1.10e-4 (unfavourable), Cervical cancer:1.50e-4 (favourable), Endometrial cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 114.5	Expressed in all		
DUS3L	DUS3, FLJ13896	ENSG00000141994	Dihydrouridine synthase 3 like	19	5784832-5791238	Predicted intracellular proteins	Evidence at protein level	HPA041854, HPA041944, HPA062846	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 26.7	Mixed		
DPP9		ENSG00000142002	Dipeptidyl peptidase 9	19	4675224-4724673	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036059	Approved		Supported	Cytosol	Renal cancer:3.38e-8 (unfavourable), Endometrial cancer:6.21e-5 (favourable), Stomach cancer:7.72e-5 (favourable), Breast cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			appendix: 33.1	Expressed in all		
DMRTC2		ENSG00000142025	DMRT like family C2	19	41844743-41852333	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045016	Uncertain					Not detected	Tissue enriched	128	testis: 48.6	lymph node,parathyroid gland,thyroid gland: 0.3	Not detected		
CCDC97	FLJ40267, MGC20255	ENSG00000142039	Coiled-coil domain containing 97	19	41310189-41324883	Predicted intracellular proteins	Evidence at protein level	HPA043320, HPA043572	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
TMEM91	FLJ27310, IFITMD6	ENSG00000142046	Transmembrane protein 91	19	41350911-41384083	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA053240	Uncertain				Renal cancer:3.52e-7 (unfavourable), Pancreatic cancer:3.54e-5 (favourable)	Expressed in all	Expressed in all			skin: 31.1	Mixed		
ZFP14	KIAA1559, ZNF531	ENSG00000142065	ZFP14 zinc finger protein	19	36334453-36379199	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030637	Uncertain		Approved	Nuclear speckles	Urothelial cancer:2.75e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Mixed		
SIRT3	SIR2L3	ENSG00000142082	Sirtuin 3	11	215458-236931	Predicted intracellular proteins	Evidence at protein level	HPA026809, CAB037142	Approved				Renal cancer:4.85e-9 (favourable), Endometrial cancer:8.51e-5 (favourable), Pancreatic cancer:4.45e-4 (favourable), Glioma:9.21e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 50.7	Expressed in all		
IFITM3	1-8U	ENSG00000142089	Interferon induced transmembrane protein 3	11	319669-327537	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004337	Uncertain				Renal cancer:5.78e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1037.8	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1986.9;BJ hTERT+ SV40 Large T+ RasG12V: 2628.1;HHSteC: 2049.3
PGGHG	ATHL1, FLJ22635	ENSG00000142102	Protein-glucosylgalactosylhydroxylysine glucosidase	11	289135-296107	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039383, HPA058829	Uncertain		Enhanced	Cytosol	Urothelial cancer:5.12e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 73.6	Mixed		
HUNK		ENSG00000142149	Hormonally up-regulated Neu-associated kinase	21	31873315-32044633	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027295, HPA027372	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.48e-5 (favourable)	Mixed	Mixed			placenta: 6.8	Cell line enhanced		AF22: 13.3;BEWO: 15.9;RH-30: 17.7;SCLC-21H: 17.5;SiHa: 14.1
COL6A1		ENSG00000142156	Collagen type VI alpha 1 chain	21	45981737-46005050	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019142, HPA029401	Enhanced		Approved	Cytosol	Renal cancer:1.07e-8 (unfavourable), Urothelial cancer:4.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 401.2	Cell line enhanced		ASC TERT1: 1614.9;HHSteC: 849.5;HSkMC: 1234.5;U-138 MG: 1268.9
IFNAR1	IFNAR, IFRC	ENSG00000142166	Interferon alpha and beta receptor subunit 1	21	33324477-33359862	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018015, HPA029226	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
SOD1	ALS, ALS1, IPOA	ENSG00000142168	Superoxide dismutase 1	21	31659622-31668931	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001401, CAB008670	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			liver: 768.9	Expressed in all		
COL6A2		ENSG00000142173	Collagen type VI alpha 2 chain	21	46098097-46132849	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007029, HPA030920, HPA038799	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:8.72e-14 (unfavourable)	Expressed in all	Expressed in all			placenta: 472.0	Cell line enhanced		ASC TERT1: 1480.1;BJ: 903.2;HHSteC: 946.3;HSkMC: 1105.7;U-138 MG: 1108.3
SIK1	msk, SNF1LK	ENSG00000142178	Salt inducible kinase 1	21	43414515-43427128	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB023801, HPA038211	Approved		Supported	Cytosol		Mixed	Mixed			seminal vesicle: 13.9	Cell line enhanced		HaCaT: 18.5;HBEC3-KT: 22.7;HeLa: 32.3;hTCEpi: 25.9;SiHa: 16.7;U-266/84: 20.5
DNMT3L	MGC1090	ENSG00000142182	DNA methyltransferase 3 like	21	44246339-44262216	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055234, HPA066780	Uncertain		Approved	Nuclear speckles		Tissue enriched	Group enriched	6	kidney: 7.2;liver: 10.4;lymph node: 2.3	spleen: 1.1	Cell line enriched	7	BEWO: 40.9
TRPM2	EREG1, KNP3, LTRPC2, NUDT9H, NUDT9L1, TRPC7	ENSG00000142185	Transient receptor potential cation channel subfamily M member 2	21	44350163-44443081	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030976, HPA035260	Enhanced		Approved	Nuclear membrane	Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:7.59e-4 (favourable), Endometrial cancer:9.28e-4 (favourable)	Expressed in all	Mixed			bone marrow: 18.8	Cell line enhanced		HL-60: 33.1;NB-4: 37.1;THP-1: 48.2;U-937: 52.8
SCYL1	GKLP, HT019, MGC78454, NKTL, NTKL, P105, TAPK, TEIF, TRAP	ENSG00000142186	SCY1 like pseudokinase 1	11	65525077-65538704	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015015	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 55.2	Expressed in all		
TMEM50B	C21orf4	ENSG00000142188	Transmembrane protein 50B	21	33432485-33480011	Predicted membrane proteins, Transporters	Evidence at protein level	CAB034199, HPA068995	Approved		Approved	Nucleoli fibrillar center	Head and neck cancer:3.00e-4 (favourable), Lung cancer:3.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 74.6	Expressed in all		
APP	AD1	ENSG00000142192	Amyloid beta precursor protein	21	25880550-26171128	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000157, HPA001462	Enhanced		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.79e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1203.4	Mixed		
DOPEY2	C21orf5, KIAA0933	ENSG00000142197	Dopey family member 2	21	36156782-36294274	Predicted intracellular proteins	Evidence at protein level	CAB034922, HPA072065	Approved		Approved	Nucleoplasm<br>Mitochondria	Breast cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 85.6	Mixed		
URB1	C21orf108, KIAA0539, NPA1	ENSG00000142207	URB1 ribosome biogenesis 1 homolog (S. cerevisiae)	21	32311018-32393026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018334	Supported		Supported	Nucleoli fibrillar center	Liver cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 12.0	Expressed in all		
AKT1	AKT, PKB, PRKBA, RAC	ENSG00000142208	AKT serine/threonine kinase 1	14	104769349-104795751	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002891, CAB003765	Enhanced		Supported	Nucleus<br>Microtubules	Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			prostate: 106.4	Expressed in all		
IL19	IL-10C, IL-19, MDA1, NG.1, ZMDA1	ENSG00000142224	Interleukin 19	1	206798870-206842981	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cervix, uterine: 21.0	salivary gland: 2.3	Cell line enriched	11	BJ hTERT+: 4.9
EMP3	YMP	ENSG00000142227	Epithelial membrane protein 3	19	48321509-48330553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.31e-7 (unfavourable), Stomach cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 200.5	Mixed		
SAE1	AOS1, FLJ3091, Sua1	ENSG00000142230	SUMO1 activating enzyme subunit 1	19	47113274-47210636	Predicted intracellular proteins	Evidence at protein level	HPA041906, HPA043552	Enhanced				Liver cancer:5.49e-8 (unfavourable), Renal cancer:8.15e-5 (unfavourable), Thyroid cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 145.7	Expressed in all		
NTN5		ENSG00000142233	Netrin 5	19	48661407-48673081	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Mixed			endometrium,fallopian tube,ovary: 1.5	Not detected		
LMTK3	KIAA1883, LMR3, PPP1R101, TYKLM3	ENSG00000142235	Lemur tyrosine kinase 3	19	48485271-48513189	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040203, HPA077070	Enhanced		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.18e-8 (favourable)	Mixed	Group enriched	6	cerebral cortex: 20.3;parathyroid gland: 4.9	duodenum: 2.2	Cell line enhanced		HMC-1: 6.1;SK-BR-3: 6.2;U-266/70: 5.9
GEMIN7	FLJ13956	ENSG00000142252	Gem nuclear organelle associated protein 7	19	45079195-45091524	Predicted intracellular proteins	Evidence at protein level	HPA052075			Supported	Nucleus<br>Cytosol	Renal cancer:9.64e-11 (unfavourable), Liver cancer:5.86e-5 (unfavourable), Urothelial cancer:8.00e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 30.3	Expressed in all		
CBLC	CBL-3, CBL-SL, RNF57	ENSG00000142273	Cbl proto-oncogene C	19	44777869-44800634	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008087, HPA035266	Approved		Approved	Nucleoplasm	Renal cancer:3.11e-6 (favourable)	Mixed	Tissue enhanced		duodenum: 52.5;skin: 41.9;small intestine: 44.0	colon: 21.4	Cell line enhanced		A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
WTIP		ENSG00000142279	Wilms tumor 1 interacting protein	19	34481638-34512304	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			ovary: 34.3	Mixed		
ADAMTS10	ADAM-TS10	ENSG00000142303	ADAM metallopeptidase with thrombospondin type 1 motif 10	19	8580242-8610735	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040223	Uncertain		Uncertain	Cytosol	Renal cancer:4.55e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 5.9	Cell line enhanced		NB-4: 24.4;REH: 9.3
SLC6A3	DAT, DAT1	ENSG00000142319	Solute carrier family 6 member 3	5	1392790-1445430	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012763, HPA013602, CAB016249, CAB078172	Supported	Supported	Approved	Vesicles	Renal cancer:3.40e-7 (unfavourable)	Tissue enriched	Not detected			thyroid gland: 0.3	Not detected		
RNPEPL1		ENSG00000142327	Arginyl aminopeptidase like 1	2	240565804-240581372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036772	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:5.06e-4 (unfavourable), Head and neck cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			skin: 29.2	Mixed		
CAPN10		ENSG00000142330	Calpain 10	2	240586716-240617705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004170, HPA056098	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.78e-6 (unfavourable), Pancreatic cancer:7.94e-5 (favourable), Head and neck cancer:8.47e-5 (favourable)	Expressed in all	Mixed			skin,spleen: 14.5	Expressed in all		
MYO1F		ENSG00000142347	Myosin IF	19	8520790-8577577	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055242	Enhanced				Renal cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 50.4;bone marrow: 59.7;spleen: 63.3	lung: 23.4	Cell line enhanced		HDLM-2: 45.8;HMC-1: 73.1;NB-4: 127.9;THP-1: 99.8;U-937: 61.8
ERVK3-1	HERV-K(HML6-1)	ENSG00000142396	Endogenous retrovirus group K3 member 1	19	58305319-58315663	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.38e-4 (unfavourable), Liver cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 46.6	Expressed in all		
NLRP12	CLR19.3, Monarch1, NALP12, PAN6, PYPAF7, RNO2	ENSG00000142405	NLR family pyrin domain containing 12	19	53793603-53824394	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042981	Approved					Tissue enriched	Tissue enhanced		appendix: 3.1;bone marrow: 4.1	spleen: 2.2	Cell line enhanced		HMC-1: 3.9;THP-1: 2.7;U-87 MG: 4.2;U-937: 2.9
CACNG8		ENSG00000142408	Calcium voltage-gated channel auxiliary subunit gamma 8	19	53963040-53990215	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041351	Enhanced					Tissue enriched	Tissue enriched	34	cerebral cortex: 23.7	testis: 0.6	Cell line enhanced		AF22: 7.2;HMC-1: 21.1;TIME: 12.3
ZNF787		ENSG00000142409	Zinc finger protein 787	19	56087366-56121280	Predicted intracellular proteins	Evidence at protein level	HPA035140	Supported		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Expressed in all			spleen: 19.3	Expressed in all		
TIMM29	C19orf52	ENSG00000142444	Translocase of inner mitochondrial membrane 29	19	10928733-10933535	Predicted intracellular proteins	Evidence at protein level	HPA041858	Approved		Approved	Nucleoplasm<br>Mitochondria	Stomach cancer:7.03e-7 (favourable), Cervical cancer:9.93e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex,testis: 7.5	Expressed in all		
FBN3		ENSG00000142449	Fibrillin 3	19	8065402-8149846	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049482	Uncertain				Endometrial cancer:5.15e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 2.1;thyroid gland: 1.8	cerebral cortex,salivary gland: 1.1	Cell line enhanced		CACO-2: 3.1;NTERA-2: 12.3;REH: 16.9
CARM1	PRMT4	ENSG00000142453	Coactivator associated arginine methyltransferase 1	19	10871513-10923070	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB032961, HPA043561, HPA048073	Supported		Enhanced	Nucleoplasm	Renal cancer:7.88e-6 (unfavourable), Urothelial cancer:8.37e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 37.1	Expressed in all		
EVI5L		ENSG00000142459	Ecotropic viral integration site 5 like	19	7830233-7864976	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043099, HPA043563	Approved		Approved	Nuclear bodies	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 41.6	Mixed		
TM4SF5		ENSG00000142484	Transmembrane 4 L six family member 5	17	4771884-4783213	Predicted membrane proteins	Evidence at protein level	HPA055674			Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions		Tissue enriched	Group enriched	5	duodenum: 176.7;small intestine: 168.8	liver: 33.3	Group enriched	13	CACO-2: 45.1;Hep G2: 64.9
SLC47A1	FLJ10847, MATE1	ENSG00000142494	Solute carrier family 47 member 1	17	19495385-19579034	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021987	Enhanced				Endometrial cancer:5.54e-8 (favourable), Renal cancer:1.06e-5 (favourable), Lung cancer:1.88e-5 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 138.3;kidney: 105.1	liver: 53.8	Cell line enhanced		A549: 19.2;AN3-CA: 15.5;Hep G2: 28.2;U-266/70: 23.7
PSMB6	DELTA, Y	ENSG00000142507	Proteasome subunit beta 6	17	4796144-4798503	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023312, HPA063656	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 200.1	Expressed in all		
GPR32	RVDR1	ENSG00000142511	G protein-coupled receptor 32	19	50770464-50771732	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	99	parathyroid gland: 260.1	placenta: 2.6	Cell line enriched	361	BEWO: 36.0
SIGLEC10	MGC126774, PRO940, SIGLEC-10, SLG2	ENSG00000142512	Sialic acid binding Ig like lectin 10	19	51410021-51417803	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025807, HPA027093	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 48.4;spleen: 36.9	lymph node: 22.1	Cell line enhanced		Daudi: 21.0;HEL: 13.5;HMC-1: 10.2;U-698: 14.8;U-937: 9.7
ACPT		ENSG00000142513	Acid phosphatase, testicular	19	50790415-50795224	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 1.4;testis: 2.2	parathyroid gland: 0.5	Cell line enhanced		HEK 293: 1.3;U-266/84: 1.3
KLK3	APS, PSA	ENSG00000142515	Kallikrein related peptidase 3	19	50854915-50860764	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000070, HPA000764	Enhanced					Tissue enriched	Tissue enriched	365	prostate: 12913.0	seminal vesicle: 35.3	Group enriched	165	BEWO: 30.5;NB-4: 17.7;RPMI-8226: 12.8;SH-SY5Y: 11.1;U-2197: 10.1
ZNF473	DKFZP434N043, HZFP100, KIAA1141	ENSG00000142528	Zinc finger protein 473	19	50025714-50053414	Predicted intracellular proteins	Evidence at protein level	HPA004191, HPA073309	Uncertain		Supported	Nucleoplasm	Liver cancer:3.72e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 76.4	fallopian tube: 11.1	Expressed in all		
FAM71E1		ENSG00000142530	Family with sequence similarity 71 member E1	19	50466785-50476753	Predicted intracellular proteins	Evidence at transcript level	HPA048111			Approved	Nucleoli fibrillar center	Renal cancer:5.35e-7 (favourable)	Expressed in all	Tissue enriched	11	testis: 38.4	cerebral cortex: 3.3	Cell line enhanced		HEK 293: 13.1
RPS11	S11	ENSG00000142534	Ribosomal protein S11	19	49496365-49499689	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA049719	Uncertain		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:3.50e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 6662.2	Expressed in all		
PTH2	TIP39	ENSG00000142538	Parathyroid hormone 2	19	49422414-49423441	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
CTD-2545M3.6		ENSG00000142539		19	50415799-50428409	Predicted intracellular proteins	Evidence at transcript level	HPA018523	Uncertain					Not detected	Tissue enhanced		appendix: 1.3;spleen: 1.8	duodenum,lymph node: 0.6	Cell line enhanced		REH: 2.7;U-2 OS: 1.1;U-266/70: 1.2;U-698: 1.3
RPL13A	L13A, TSTA1	ENSG00000142541	Ribosomal protein L13a	19	49487554-49492308	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038751	Approved		Approved	Nucleoli<br>Cytosol	Renal cancer:1.44e-5 (unfavourable), Liver cancer:9.97e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4609.7	Expressed in all		
CTU1	ATPBD3, MGC17332, NCS6	ENSG00000142544	Cytosolic thiouridylase subunit 1	19	51097606-51108370	Predicted intracellular proteins	Evidence at protein level	HPA053797	Uncertain				Urothelial cancer:5.73e-5 (favourable)	Expressed in all	Mixed			spleen: 2.8	Cell line enhanced		HEK 293: 40.6
NOSIP	CGI-25	ENSG00000142546	Nitric oxide synthase interacting protein	19	49555711-49590262	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043464, HPA062132	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
IGLON5	LOC402665	ENSG00000142549	IgLON family member 5	19	51311848-51330354	Predicted secreted proteins	Evidence at protein level	HPA041994	Approved		Uncertain	Nucleus	Renal cancer:5.62e-7 (unfavourable)	Tissue enhanced	Group enriched	7	adrenal gland: 2.3;cerebral cortex: 11.1;testis: 9.5	esophagus,seminal vesicle: 1.0	Group enriched	8	HMC-1: 30.8;NTERA-2: 16.0;SH-SY5Y: 24.3;U-2 OS: 6.9
RCN3	RLP49	ENSG00000142552	Reticulocalbin 3	19	49527618-49546962	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043134, HPA050402	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:5.80e-12 (unfavourable)	Expressed in all	Expressed in all			small intestine: 45.0	Cell line enhanced		ASC diff: 170.1;BJ: 238.6;fHDF/TERT166: 192.6
ZNF614	FLJ21941	ENSG00000142556	Zinc finger protein 614	19	52012765-52030240	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021197	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Mixed			prostate: 14.0	Expressed in all		
SLC2A5	GLUT5	ENSG00000142583	Solute carrier family 2 member 5	1	9035107-9088478	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005449	Enhanced				Renal cancer:5.44e-5 (unfavourable)	Group enriched	Tissue enhanced		duodenum: 109.0;small intestine: 92.6;testis: 139.9	bone marrow: 64.4	Cell line enhanced		Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
RERE	ARG, ARP, ATN1L, DNB1, KIAA0458	ENSG00000142599	Arginine-glutamic acid dipeptide repeats	1	8352397-8817643	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024093	Uncertain					Expressed in all	Expressed in all			endometrium: 93.2	Expressed in all		
MMEL1	MMEL2, NEPII, NL1, NL2, SEP	ENSG00000142606	Membrane metalloendopeptidase like 1	1	2590639-2632990	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007876, HPA008205, CAB020786	Uncertain					Mixed	Tissue enhanced		testis: 5.4	stomach: 2.5	Cell line enhanced		CAPAN-2: 2.1;EFO-21: 2.4;MCF7: 1.9;SK-BR-3: 10.6
CFAP74	C1orf222, FLJ45476, KIAA1751	ENSG00000142609	Cilia and flagella associated protein 74	1	1921951-2003837	Predicted intracellular proteins	Evidence at protein level	HPA028521, HPA029274, HPA030240	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 9.6;testis: 8.5	skin: 4.0	Mixed		
PRDM16	KIAA1675, KMT8F, MEL1, MGC166915, PFM13	ENSG00000142611	PR/SET domain 16	1	3069168-3438621	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050343, HPA060467			Enhanced	Nucleoplasm	Thyroid cancer:4.70e-5 (unfavourable)	Mixed	Mixed			thyroid gland: 7.6	Cell line enhanced		AN3-CA: 1.4;CACO-2: 1.2;HAP1: 1.4;HEK 293: 1.6;HHSteC: 1.7;MCF7: 1.2
CELA2A	ELA2A	ENSG00000142615	Chymotrypsin like elastase family member 2A	1	15456728-15472091	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	371	pancreas: 34335.1	ovary: 92.5	Cell line enhanced		HMC-1: 1.1
PADI3	PDI3	ENSG00000142619	Peptidyl arginine deiminase 3	1	17249098-17284233	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043739	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.55e-11 (unfavourable), Endometrial cancer:3.22e-4 (unfavourable)	Tissue enhanced	Group enriched	10	esophagus: 3.7;seminal vesicle: 4.9;urinary bladder: 10.2	epididymis: 0.6	Cell line enhanced		EFO-21: 13.2;RT4: 13.9;T-47d: 12.0
FHAD1	KIAA1937	ENSG00000142621	Forkhead associated phosphopeptide binding domain 1	1	15247272-15400283	Predicted intracellular proteins	Evidence at protein level	HPA054284	Enhanced					Mixed	Group enriched	6	fallopian tube: 24.1;lung: 5.2;testis: 24.7	cervix, uterine: 3.1	Group enriched	5	HDLM-2: 27.2;HMC-1: 70.7;K-562: 16.4;U-87 MG: 42.0
PADI1	HPAD10, PAD1, PDI, PDI1	ENSG00000142623	Peptidyl arginine deiminase 1	1	17205126-17246005	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062294	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.34e-11 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 37.1	skin: 5.4	Cell line enhanced		CAPAN-2: 4.5;EFO-21: 2.3;HaCaT: 1.3;LHCN-M2: 1.6;RPTEC TERT1: 1.9
EPHA2	ECK	ENSG00000142627	EPH receptor A2	1	16124337-16156087	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010464			Supported	Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		esophagus: 86.8	gallbladder: 44.5	Cell line enhanced		PC-3: 211.2;WM-115: 253.0
ARHGEF19	FLJ33962, WGEF	ENSG00000142632	Rho guanine nucleotide exchange factor 19	1	16197854-16212609	Predicted intracellular proteins	Evidence at protein level	HPA068108			Approved	Nuclear bodies	Renal cancer:8.88e-5 (unfavourable), Lung cancer:6.53e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 20.9	thyroid gland: 11.5	Cell line enhanced		T-47d: 23.8
EFHD2	MGC4342	ENSG00000142634	EF-hand domain family member D2	1	15409895-15430343	Predicted intracellular proteins	Evidence at protein level	HPA048961	Enhanced		Approved	Cytosol	Renal cancer:6.31e-9 (unfavourable), Urothelial cancer:3.60e-5 (favourable), Thyroid cancer:2.70e-4 (favourable), Lung cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 111.1	Expressed in all		
PEX14		ENSG00000142655	Peroxisomal biogenesis factor 14	1	10472288-10630758	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046104, HPA049231	Supported		Supported	Nucleoli fibrillar center<br>Peroxisomes		Expressed in all	Expressed in all			seminal vesicle: 32.7	Expressed in all		
PGD		ENSG00000142657	Phosphogluconate dehydrogenase	1	10398592-10420144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031314, HPA031315	Enhanced	Supported	Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 486.8	Expressed in all		
MYOM3	FLJ35961	ENSG00000142661	Myomesin 3	1	24056035-24112175	Predicted intracellular proteins	Evidence at protein level	HPA028132, HPA029752	Uncertain		Approved	Vesicles	Renal cancer:4.28e-6 (favourable)	Tissue enhanced	Group enriched	5	heart muscle: 69.9;kidney: 31.8;skeletal muscle: 86.5	testis: 12.1	Cell line enhanced		A549: 4.2;Hep G2: 12.2
SH3BGRL3		ENSG00000142669	SH3 domain binding glutamate rich protein like 3	1	26279176-26281522	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030848, HPA076219	Approved		Approved	Nuclear bodies	Renal cancer:2.17e-10 (unfavourable)	Expressed in all	Expressed in all			epididymis: 448.9	Expressed in all		
CNKSR1	CNK, CNK1, KSR	ENSG00000142675	Connector enhancer of kinase suppressor of Ras 1	1	26177403-26189886	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA030847	Uncertain		Approved	Cytosol	Urothelial cancer:5.91e-4 (favourable)	Mixed	Mixed			parathyroid gland: 20.6	Cell line enhanced		A-431: 15.5;CAPAN-2: 23.4;HaCaT: 17.4
RPL11	L11	ENSG00000142676	Ribosomal protein L11	1	23691779-23696425	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002734, HPA074839	Approved		Approved	Vesicles	Renal cancer:5.93e-6 (unfavourable), Breast cancer:2.55e-4 (favourable)	Expressed in all	Expressed in all			ovary: 4915.9	Expressed in all		
IL22RA1	CRF2-9, IL22R	ENSG00000142677	Interleukin 22 receptor subunit alpha 1	1	24119771-24143121	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	5	colon: 11.3;duodenum: 20.2;esophagus: 10.1;pancreas: 26.1;rectum: 10.9;skin: 38.7;small intestine: 31.3	gallbladder: 4.0	Cell line enhanced		CACO-2: 9.3;HaCaT: 4.5;Hep G2: 5.5
ZNF593	ZT86	ENSG00000142684	Zinc finger protein 593	1	26169871-26170873	Predicted intracellular proteins	Evidence at protein level	HPA054363, HPA059387	Supported		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			breast: 16.4	Expressed in all		
C1orf216	FLJ38984	ENSG00000142686	Chromosome 1 open reading frame 216	1	35713875-35719472	Predicted intracellular proteins	Evidence at protein level	HPA028299, HPA031343	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.68e-10 (unfavourable), Liver cancer:2.15e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 60.6	smooth muscle: 18.6	Expressed in all		
KIAA0319L	KIAA1837	ENSG00000142687	KIAA0319 like	1	35433490-35557950	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072692			Approved	Nucleoli<br>Golgi apparatus	Liver cancer:5.92e-5 (unfavourable), Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.6	Expressed in all		
EVA1B	C1orf78, FAM176B, FLJ10647	ENSG00000142694	Eva-1 homolog B	1	36322031-36324154	Predicted intracellular proteins	Evidence at protein level	HPA041928, HPA043537	Approved		Approved	Cytosol	Renal cancer:4.79e-5 (unfavourable), Breast cancer:4.58e-4 (favourable), Liver cancer:4.82e-4 (unfavourable)	Expressed in all	Mixed			placenta: 14.6	Cell line enhanced		BJ: 28.4
C1orf94	MGC15882	ENSG00000142698	Chromosome 1 open reading frame 94	1	34166883-34219131	Predicted intracellular proteins	Evidence at protein level	HPA045805			Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	32	testis: 42.4	cerebral cortex: 1.3	Group enriched	7	NTERA-2: 17.2;U-87 MG: 47.7
DMRTA2		ENSG00000142700	DMRT like family A2	1	50417550-50423500	Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA043098, HPA062958	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Tissue enhanced	Not detected			testis: 0.7	Cell line enhanced		BEWO: 3.0;HBEC3-KT: 2.3;RH-30: 11.1;SH-SY5Y: 2.6;SiHa: 2.5
PLK4	Sak, STK18	ENSG00000142731	Polo like kinase 4	4	127880861-127899195	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017327, HPA035026, HPA043198	Approved		Supported	Centrosome<br>Cytosol	Colorectal cancer:7.46e-5 (favourable), Lung cancer:5.13e-4 (unfavourable), Pancreatic cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.9	bone marrow: 13.9	Mixed		
MAP3K6	ASK2, MAPKKK6, MEKK6	ENSG00000142733	Mitogen-activated protein kinase kinase kinase 6	1	27355184-27366892	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051192	Approved		Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Cytosol	Glioma:1.73e-4 (unfavourable), Head and neck cancer:7.26e-4 (favourable), Liver cancer:8.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 114.9	esophagus: 41.2	Mixed		
FCN3	FCNH, HAKA1	ENSG00000142748	Ficolin 3	1	27369112-27374824	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025945	Approved					Mixed	Group enriched	6	liver: 144.1;lung: 266.5	placenta: 33.0	Not detected		
GPN2	ATPBD1B, FLJ10349	ENSG00000142751	GPN-loop GTPase 2	1	26876133-26890297	Predicted intracellular proteins	Evidence at protein level	HPA028059	Uncertain				Liver cancer:3.56e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.3	Expressed in all		
SYTL1	exophilin-7, FLJ14996, JFC1, SLP1	ENSG00000142765	Synaptotagmin like 1	1	27342020-27353937	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037825	Enhanced				Endometrial cancer:6.83e-7 (favourable), Renal cancer:1.12e-5 (unfavourable)	Mixed	Mixed			skin: 69.0	Cell line enhanced		BEWO: 46.5;CAPAN-2: 49.3;NB-4: 51.8
WDTC1	ADP, DCAF9, KIAA1037	ENSG00000142784	WD and tetratricopeptide repeats 1	1	27234516-27308633	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028177, HPA028180, HPA028182	Uncertain		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.84e-8 (favourable), Cervical cancer:4.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 73.7	Expressed in all		
CELA3A	ELA3, ELA3A	ENSG00000142789	Chymotrypsin like elastase family member 3A	1	22001656-22012539	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028086, HPA045650	Supported		Approved	Cytosol		Tissue enriched	Tissue enriched	352	pancreas: 56987.6	ovary: 161.9	Cell line enriched	24	MOLT-4: 20.6
NBPF3	AE2	ENSG00000142794	Neuroblastoma breakpoint family member 3	1	21440128-21485005	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043692, HPA044023, HPA046971, HPA058050	Supported					Mixed	Tissue enriched	6	testis: 20.4	breast,placenta: 3.4	Cell line enhanced		BJ hTERT+: 12.6
HSPG2	perlecan, PRCAN, SJS1	ENSG00000142798	Heparan sulfate proteoglycan 2	1	21822245-21937297	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009820, HPA018892, CAB020718	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 135.6	Cell line enhanced		EFO-21: 257.0;HUVEC TERT2: 511.1;TIME: 402.8
ITGB3BP	CENPR, HSU37139, NRIF3, TAP20	ENSG00000142856	Integrin subunit beta 3 binding protein	1	63440770-63593721	Predicted intracellular proteins	Evidence at protein level	HPA028463	Approved		Supported	Nucleoplasm	Renal cancer:8.45e-6 (unfavourable), Liver cancer:7.24e-5 (unfavourable), Head and neck cancer:4.32e-4 (favourable)	Expressed in all	Mixed			testis: 36.4	Expressed in all		
SERBP1	CGI-55, CHD3IP, DKFZP564M2423, HABP4L, PAI-RBP1, PAIRBP1	ENSG00000142864	SERPINE1 mRNA binding protein 1	1	67407810-67430415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020559, CAB026297	Enhanced		Enhanced	Cytosol	Liver cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 293.4	Expressed in all		
BCL10	c-E10, CARMEN, CIPER, CLAP, mE10	ENSG00000142867	B-cell CLL/lymphoma 10	1	85266248-85277090	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB001944, HPA017925	Approved		Approved	Nucleoplasm	Liver cancer:7.21e-7 (unfavourable), Colorectal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 30.5	Expressed in all		
CYR61	CCN1, GIG1, IGFBP10	ENSG00000142871	Cysteine rich angiogenic inducer 61	1	85580761-85583962	Predicted secreted proteins	Evidence at protein level	HPA029853	Uncertain				Renal cancer:1.39e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 1095.9	Mixed		
PRKACB	PKACb	ENSG00000142875	Protein kinase cAMP-activated catalytic subunit beta	1	84078062-84238498	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010363, HPA029754, HPA071185	Approved		Approved	Cytosol	Renal cancer:1.89e-6 (favourable), Liver cancer:9.49e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 316.3	adrenal gland: 63.1	Mixed		
PIGK	GPI8, hGPI8	ENSG00000142892	Phosphatidylinositol glycan anchor biosynthesis class K	1	77088990-77219430	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA056383, HPA057040	Uncertain				Liver cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.4	Expressed in all		
TINAGL1	ARG1, LCN7, LIECG3, P3ECSL, TINAGRP	ENSG00000142910	Tubulointerstitial nephritis antigen like 1	1	31576485-31587686	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048695	Approved				Renal cancer:3.65e-6 (favourable), Thyroid cancer:9.64e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 268.9	adipose tissue: 102.6	Cell line enhanced		BEWO: 313.9;EFO-21: 383.9;TIME: 309.9
AZIN2	ADC, KIAA1945, ODC-p, ODC1L, ODCp	ENSG00000142920	Antizyme inhibitor 2	1	33081104-33120530	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 30.1	cerebral cortex: 17.0	Cell line enhanced		SK-MEL-30: 15.1
RPS8	S8	ENSG00000142937	Ribosomal protein S8	1	44775251-44778779	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA029266			Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:9.05e-9 (unfavourable), Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 5543.6	Expressed in all		
KIF2C	CT139, KNSL6, MCAK	ENSG00000142945	Kinesin family member 2C	1	44739818-44767767	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006219			Supported	Nucleoplasm<br>Midbody<br>Centrosome	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.07e-7 (unfavourable), Pancreatic cancer:6.86e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 135.0	bone marrow: 20.4	Mixed		
PTPRF	LAR	ENSG00000142949	Protein tyrosine phosphatase, receptor type F	1	43525187-43623666	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012710	Uncertain		Approved	Golgi apparatus	Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable)	Expressed in all	Mixed			skin: 128.2	Mixed		
BEST4	VMD2L2	ENSG00000142959	Bestrophin 4	1	44783585-44787705	Predicted membrane proteins	Evidence at protein level	HPA058564	Uncertain					Mixed	Tissue enhanced		colon: 26.2;rectum: 21.3	duodenum: 11.3	Cell line enhanced		Hep G2: 2.1
MOB3C	MOB1E, MOBKL2C	ENSG00000142961	MOB kinase activator 3C	1	46607715-46616891	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Cervical cancer:3.16e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 20.7	Mixed		
CYP4B1		ENSG00000142973	Cytochrome P450 family 4 subfamily B member 1	1	46757838-46819413	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004331	Approved		Supported	Vesicles	Cervical cancer:5.99e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 382.2	fallopian tube: 79.0	Cell line enriched	9	RT4: 234.9
TMEM61		ENSG00000143001	Transmembrane protein 61	1	54980792-54992293	Predicted membrane proteins	Evidence at transcript level	HPA030614	Uncertain				Renal cancer:1.78e-7 (favourable), Colorectal cancer:1.07e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 11.2;salivary gland: 10.1	seminal vesicle: 8.2	Cell line enriched	7	RPMI-8226: 16.2
DMRTB1		ENSG00000143006	DMRT like family B with proline rich C-terminal 1	1	53459399-53467488	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036490, HPA058553	Enhanced					Tissue enhanced	Tissue enriched	67	testis: 69.6	epididymis: 1.0	Not detected		
LMO4		ENSG00000143013	LIM domain only 4	1	87328468-87348923	Predicted intracellular proteins	Evidence at protein level	CAB022345, HPA045877, HPA061638	Approved		Supported	Nucleoplasm<br>Midbody ring	Thyroid cancer:1.42e-4 (favourable), Ovarian cancer:1.47e-4 (favourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 217.4	Expressed in all		
SYPL2	Mg29	ENSG00000143028	Synaptophysin like 2	1	109466628-109482137	Predicted membrane proteins	Evidence at protein level	HPA018032			Approved	Nucleoplasm	Renal cancer:3.05e-4 (favourable)	Mixed	Tissue enriched	7	skeletal muscle: 129.4	parathyroid gland: 17.4	Cell line enhanced		ASC diff: 22.2;BJ: 12.2;BJ hTERT+: 36.7;fHDF/TERT166: 18.3;HAP1: 12.5
BARHL2		ENSG00000143032	BarH like homeobox 2	1	90711539-90717237	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	37	testis: 3.6	all non-specific tissues: 0.0	Cell line enhanced		HAP1: 1.1;HEK 293: 3.4
MTF2	M96, PCL2, TDRD19A	ENSG00000143033	Metal response element binding transcription factor 2	1	93079235-93139081	Predicted intracellular proteins	Evidence at protein level	HPA069047, HPA069066			Enhanced	Nucleoplasm	Renal cancer:2.47e-7 (unfavourable), Liver cancer:8.90e-7 (unfavourable), Prostate cancer:1.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 30.7	Expressed in all		
SLC44A3	CTL3, MGC45474	ENSG00000143036	Solute carrier family 44 member 3	1	94820342-94895246	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047433	Enhanced				Renal cancer:7.63e-5 (favourable)	Expressed in all	Mixed			rectum: 38.5	Cell line enhanced		RPTEC TERT1: 76.8;RT4: 55.4
IGSF3	EWI-3, MGC117164, V8	ENSG00000143061	Immunoglobulin superfamily member 3	1	116574399-116667755	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036305, HPA036306	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.87e-6 (favourable), Liver cancer:4.03e-6 (unfavourable), Endometrial cancer:1.98e-4 (unfavourable), Pancreatic cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			skin: 21.5	Cell line enhanced		HDLM-2: 237.0;WM-115: 235.3
ZNF697	MGC45731	ENSG00000143067	Zinc finger protein 697	1	119619422-119647773	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049933	Uncertain		Approved	Nucleoplasm	Renal cancer:6.20e-5 (favourable)	Expressed in all	Mixed			placenta: 10.9	Cell line enhanced		SK-MEL-30: 35.9;WM-115: 45.9
CTTNBP2NL	DKFZp547A023	ENSG00000143079	CTTNBP2 N-terminal like	1	112396181-112463456	Predicted intracellular proteins	Evidence at protein level	HPA007301	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Colorectal cancer:1.14e-4 (favourable), Renal cancer:8.08e-4 (favourable)	Expressed in all	Mixed			placenta: 29.0	Mixed		
STRIP1	FAM40A, FAR11A, FLJ14743, KIAA1761	ENSG00000143093	Striatin interacting protein 1	1	110031577-110074641	Predicted intracellular proteins	Evidence at protein level	HPA060302, HPA060498	Approved		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.8	Expressed in all		
KCNA10	Kv1.8	ENSG00000143105	Potassium voltage-gated channel subfamily A member 10	1	110517217-110519175	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA015061, CAB022564			Uncertain	Nucleoplasm<br>Cytosol		Not detected	Not detected			testis: 0.8	Not detected		
PSMA5	ZETA	ENSG00000143106	Proteasome subunit alpha 5	1	109399031-109426427	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028392, HPA028398, HPA028441	Approved		Approved	Cytosol	Colorectal cancer:1.45e-5 (favourable), Liver cancer:2.28e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 14.9	Cell line enhanced		MOLT-4: 36.7
FNDC7	FLJ35838	ENSG00000143107	Fibronectin type III domain containing 7	1	108712657-108742740	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028079, HPA054297	Enhanced		Approved	Nucleoplasm<br>Actin filaments		Not detected	Tissue enriched	12	testis: 2.0	bone marrow,cerebral cortex: 0.1	Not detected		
C1orf162	MGC24133	ENSG00000143110	Chromosome 1 open reading frame 162	1	111473792-111478512	Predicted membrane proteins	Evidence at protein level	HPA026988	Approved				Renal cancer:3.14e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.3	Cell line enhanced		HDLM-2: 121.3;HL-60: 50.8;THP-1: 33.7;U-937: 81.9
CD53	MOX44, TSPAN25	ENSG00000143119	CD53 molecule	1	110873154-110899928	CD markers, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047216	Approved				Renal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 462.7	Cell line enhanced		Daudi: 353.2;HDLM-2: 199.1;HMC-1: 262.4;U-266/70: 196.6
PROK1	EGVEGF, PK1, PRK1	ENSG00000143125	Prokineticin 1	1	110451200-110457354	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	ovary: 239.3;placenta: 75.8;testis: 119.4	seminal vesicle: 15.2	Cell line enriched	9	ASC diff: 16.3
CELSR2	ADGRC2, CDHF10, EGFL2, Flamingo1, KIAA0279, MEGF3	ENSG00000143126	Cadherin EGF LAG seven-pass G-type receptor 2	1	109250019-109275750	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013952	Uncertain		Approved	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 45.1	skin: 31.0	Cell line enhanced		AF22: 49.6;HaCaT: 44.6;MCF7: 45.4
ITGA10		ENSG00000143127	Integrin subunit alpha 10	1	145891208-145910189	Plasma proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:7.18e-4 (favourable)	Tissue enhanced	Mixed			cervix, uterine: 8.1	Cell line enhanced		ASC TERT1: 35.3;HSkMC: 33.5;hTERT-HME1: 31.5;LHCN-M2: 60.2;TIME: 100.9
GPR161	RE2	ENSG00000143147	G protein-coupled receptor 161	1	168079543-168137667	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA015576, HPA072047	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		smooth muscle: 40.3	endometrium: 28.6	Mixed		
ALDH9A1	ALDH4, ALDH7, ALDH9, E3	ENSG00000143149	Aldehyde dehydrogenase 9 family member A1	1	165662216-165698863	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA006077, HPA010873	Approved		Approved	Cytosol	Pancreatic cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 206.0	Mixed		
ATP1B1	ATP1B	ENSG00000143153	ATPase Na+/K+ transporting subunit beta 1	1	169105697-169132722	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012911	Enhanced				Renal cancer:7.08e-7 (favourable)	Expressed in all	Expressed in all			kidney: 1337.2	Cell line enhanced		RPTEC TERT1: 355.3;SH-SY5Y: 411.9
TIPRL	dJ69E11.3, MGC3794, TIP41, TIPRL1	ENSG00000143155	TOR signaling pathway regulator	1	168178933-168202114	Predicted intracellular proteins	Evidence at protein level	HPA027995, HPA054282	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.45e-8 (unfavourable), Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 38.5	Expressed in all		
NME7	CFAP67, FLJ37194, NM23-H7	ENSG00000143156	NME/NM23 family member 7	1	169132531-169367967	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038014, HPA054289	Uncertain		Approved	Mitochondria	Liver cancer:3.24e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 39.0	Expressed in all		
POGK	BASS2, KIAA15131, KRBOX2, LST003	ENSG00000143157	Pogo transposable element with KRAB domain	1	166839447-166856344	Predicted intracellular proteins	Evidence at protein level	HPA007838, HPA031630	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:5.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
MPC2	BRP44, DKFZP564B167	ENSG00000143158	Mitochondrial pyruvate carrier 2	1	167916729-167937040	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056091	Uncertain					Expressed in all	Expressed in all			testis: 355.9	Expressed in all		
CREG1	CREG	ENSG00000143162	Cellular repressor of E1A stimulated genes 1	1	167529677-167553767	Predicted secreted proteins	Evidence at protein level	HPA056390			Approved	Vesicles<br>Microtubules		Expressed in all	Expressed in all			thyroid gland: 209.5	Expressed in all		
DCAF6	IQWD1, PC326	ENSG00000143164	DDB1 and CUL4 associated factor 6	1	167935783-168075843	Predicted intracellular proteins	Evidence at protein level	HPA054305			Supported	Nucleus<br>Focal adhesion sites		Expressed in all	Expressed in all			skeletal muscle: 223.5	Expressed in all		
GPA33	A33	ENSG00000143167	Glycoprotein A33	1	167052836-167166479	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018858, CAB025943	Enhanced					Tissue enriched	Group enriched	8	colon: 183.6;duodenum: 130.8;rectum: 188.7;small intestine: 131.3	appendix: 19.0	Cell line enhanced		NTERA-2: 1.0
RXRG	NR2B3	ENSG00000143171	Retinoid X receptor gamma	1	165400917-165445355	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002615, HPA012933	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Thyroid cancer:9.40e-5 (favourable)	Group enriched	Tissue enhanced		skeletal muscle: 16.7	cervix, uterine: 4.7	Cell line enriched	6	SK-MEL-30: 29.1
TBX19	dj747L4.1, TPIT	ENSG00000143178	T-box 19	1	168281040-168314426	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005800, HPA072686	Supported		Approved	Nuclear speckles	Renal cancer:4.55e-9 (unfavourable)	Expressed in all	Mixed			endometrium: 5.4	Cell line enhanced		HaCaT: 4.8
UCK2	UMPK	ENSG00000143179	Uridine-cytidine kinase 2	1	165827531-165911618	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057128			Approved	Nucleus	Renal cancer:5.12e-13 (unfavourable), Liver cancer:9.22e-8 (unfavourable), Lung cancer:4.98e-4 (unfavourable), Melanoma:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 41.1	Expressed in all		
TMCO1	HP10122, TMCC4	ENSG00000143183	Transmembrane and coiled-coil domains 1	1	165724293-165827755	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054768			Supported	Endoplasmic reticulum	Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 157.4	Expressed in all		
XCL1	ATAC, LPTN, LTN, SCM-1, SCM-1a, SCYC1	ENSG00000143184	X-C motif chemokine ligand 1	1	168576473-168582077	Predicted secreted proteins	Evidence at protein level	HPA057725	Approved					Mixed	Tissue enhanced		spleen: 5.7	endometrium: 3.3	Cell line enhanced		CACO-2: 2.4;Hep G2: 2.5;SCLC-21H: 4.0;U-266/70: 3.7
XCL2	SCM-1b, SCYC2	ENSG00000143185	X-C motif chemokine ligand 2	1	168540765-168543997	Predicted secreted proteins	Evidence at protein level	HPA057725	Approved				Renal cancer:8.36e-9 (unfavourable), Lung cancer:3.17e-4 (favourable)	Mixed	Tissue enhanced		spleen: 14.1	bone marrow: 8.4	Cell line enhanced		CACO-2: 2.1
POU2F1	OCT1, OTF1	ENSG00000143190	POU class 2 homeobox 1	1	167220829-167427345	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002608, HPA058559, HPA064323	Supported		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:2.98e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.0	Mixed		
MAEL	CT128, FLJ14904, SPATA35	ENSG00000143194	Maelstrom spermatogenic transposon silencer	1	166975582-167022214	Predicted intracellular proteins	Evidence at protein level	HPA078602	Approved					Tissue enhanced	Tissue enriched	30	testis: 282.8	placenta: 9.3	Cell line enriched	11	NTERA-2: 3.3
ILDR2	C1orf32	ENSG00000143195	Immunoglobulin like domain containing receptor 2	1	166895711-166975482	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012545	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 11.3;testis: 17.4	kidney: 3.1	Cell line enhanced		AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
DPT		ENSG00000143196	Dermatopontin	1	168695459-168729264	Predicted secreted proteins	Evidence at protein level	HPA065548			Approved	Vesicles	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 330.3	Group enriched	10	ASC diff: 94.1;fHDF/TERT166: 44.4
MGST3	GST-III	ENSG00000143198	Microsomal glutathione S-transferase 3	1	165630861-165661796	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA053311			Approved	Nucleus		Expressed in all	Expressed in all			epididymis: 629.7	Expressed in all		
ADCY10	HCA2, RP1-313L4.2, SAC, SACI, Sacy	ENSG00000143199	Adenylate cyclase 10, soluble	1	167809388-167914215	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015243, HPA017749	Approved					Tissue enhanced	Tissue enriched	11	testis: 33.1	liver: 3.1	Cell line enhanced		T-47d: 1.3
RFWD2	COP1, FLJ10416, RNF200	ENSG00000143207	Ring finger and WD repeat domain 2	1	175944831-176207493	Enzymes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.96e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 42.2	Expressed in all		
NECTIN4	LNIR, nectin-4, PRR4, PVRL4	ENSG00000143217	Nectin cell adhesion molecule 4	1	161070995-161089599	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010775	Enhanced		Supported	Plasma membrane		Mixed	Tissue enhanced		esophagus: 45.9;skin: 79.5	breast,placenta: 17.1	Cell line enhanced		BEWO: 53.8;HaCaT: 32.5;SK-BR-3: 35.3;T-47d: 28.8
UFC1	HSPC155	ENSG00000143222	Ubiquitin-fold modifier conjugating enzyme 1	1	161152776-161158856	Predicted intracellular proteins	Evidence at protein level	HPA027481, HPA028722	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.62e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 253.4	Expressed in all		
PPOX	PPO, VP	ENSG00000143224	Protoporphyrinogen oxidase	1	161166410-161178013	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030123	Uncertain		Approved	Mitochondria<br>Cytosol	Renal cancer:9.89e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 38.9	Expressed in all		
FCGR2A	CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2	ENSG00000143226	Fc fragment of IgG receptor IIa	1	161505430-161524013	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010718, HPA014730	Enhanced				Renal cancer:6.49e-7 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 160.6	appendix: 148.6	Cell line enhanced		HEL: 26.6;HMC-1: 50.4;K-562: 16.0;THP-1: 42.6;U-937: 21.3
NUF2	CDCA1, CT106, NUF2R	ENSG00000143228	NUF2, NDC80 kinetochore complex component	1	163266576-163355764	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059692			Supported	Nucleus	Liver cancer:1.04e-5 (unfavourable), Melanoma:4.83e-4 (unfavourable), Lung cancer:9.16e-4 (unfavourable), Pancreatic cancer:9.75e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 95.1	lymph node: 21.8	Mixed		
RGS5		ENSG00000143248	Regulator of G-protein signaling 5	1	163111121-163321791	Predicted intracellular proteins	Evidence at protein level	HPA001821		Approved	Supported	Cytosol	Renal cancer:9.17e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 406.2	Group enriched	45	HUVEC TERT2: 1084.9;SH-SY5Y: 4496.0
SDHC	CYB560, cybL, PGL3	ENSG00000143252	Succinate dehydrogenase complex subunit C	1	161314257-161375340	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.20e-4 (favourable)	Expressed in all	Expressed in all			kidney: 188.8	Expressed in all		
PFDN2		ENSG00000143256	Prefoldin subunit 2	1	161100556-161118111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028700, HPA058304	Approved		Enhanced	Cytosol	Renal cancer:4.39e-8 (unfavourable), Head and neck cancer:9.10e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.6	Expressed in all		
NR1I3	CAR, CAR1, MB67	ENSG00000143257	Nuclear receptor subfamily 1 group I member 3	1	161229666-161238302	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051365			Approved	Nucleoplasm		Tissue enriched	Tissue enriched	9	liver: 82.5	kidney: 9.4	Cell line enhanced		CACO-2: 3.7
USP21	USP16, USP23	ENSG00000143258	Ubiquitin specific peptidase 21	1	161159450-161165723	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028397	Uncertain	Supported	Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.50e-6 (unfavourable), Urothelial cancer:3.35e-5 (favourable), Liver cancer:1.68e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 45.7	Expressed in all		
F13B	FXIIIB	ENSG00000143278	Coagulation factor XIII B chain	1	197039191-197067267	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA003827, HPA052139	Supported				Liver cancer:6.78e-5 (favourable)	Tissue enriched	Tissue enriched	111	liver: 122.1	duodenum: 1.1	Not detected		
PRCC	RCCP1	ENSG00000143294	Papillary renal cell carcinoma (translocation-associated)	1	156750610-156800817	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017151, HPA019463, HPA019481	Supported		Enhanced	Nuclear speckles	Renal cancer:8.99e-15 (unfavourable), Thyroid cancer:3.72e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable), Liver cancer:8.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 54.5	Expressed in all		
FCRL5	BXMAS1, CD307e, FCRH5, IRTA2	ENSG00000143297	Fc receptor like 5	1	157513377-157552520	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 20.5;tonsil: 32.8	appendix: 17.9	Cell line enhanced		U-266/70: 2.5;U-698: 5.1
RRNAD1	C1orf66, CGI-41, METTL25B	ENSG00000143303	Ribosomal RNA adenine dimethylase domain containing 1	1	156728442-156736960	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA047426	Approved		Approved	Nucleoli<br>Cytosol	Colorectal cancer:5.60e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.2	Expressed in all		
MRPL24	MRP-L18	ENSG00000143314	Mitochondrial ribosomal protein L24	1	156737303-156741590	Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA030295, HPA054323	Approved				Renal cancer:3.99e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 117.5	Expressed in all		
PIGM	GPI-MT-I	ENSG00000143315	Phosphatidylinositol glycan anchor biosynthesis class M	1	160027673-160031991	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA047418	Uncertain				Ovarian cancer:3.27e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.3	Mixed		
CASQ1	CASQ, PDIB1	ENSG00000143318	Calsequestrin 1	1	160190556-160201886	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA007845, CAB015170, HPA026823	Enhanced		Uncertain	Nucleoplasm<br>Mitochondria	Urothelial cancer:8.93e-5 (favourable)	Mixed	Tissue enriched	33	skeletal muscle: 1514.0	esophagus: 45.3	Group enriched	9	BEWO: 18.6;HDLM-2: 35.6;RT4: 53.5
ISG20L2	FLJ12671	ENSG00000143319	Interferon stimulated exonuclease gene 20 like 2	1	156721891-156728799	Predicted intracellular proteins	Evidence at protein level	HPA028005, HPA054285	Approved		Supported	Nucleoplasm	Renal cancer:4.80e-5 (unfavourable), Liver cancer:6.15e-5 (unfavourable), Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
CRABP2	CRABP-II	ENSG00000143320	Cellular retinoic acid binding protein 2	1	156699606-156705816	Predicted intracellular proteins	Evidence at protein level	HPA004135	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.19e-13 (unfavourable), Endometrial cancer:2.11e-5 (unfavourable)	Expressed in all	Tissue enriched	5	esophagus: 1042.5	skin: 193.5	Cell line enhanced		BJ hTERT+: 1263.6;MCF7: 468.2;T-47d: 1127.9
HDGF	HMG1L2	ENSG00000143321	Hepatoma derived growth factor	1	156742107-156766925	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026035, HPA048728, HPA053422	Enhanced		Enhanced	Nucleoplasm	Liver cancer:2.43e-8 (unfavourable), Endometrial cancer:6.02e-4 (unfavourable), Ovarian cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 190.4	Expressed in all		
ABL2	ABLL, ARG	ENSG00000143322	ABL proto-oncogene 2, non-receptor tyrosine kinase	1	179099327-179229684	Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001866, CAB017106, HPA072754	Uncertain		Supported	Nucleoplasm	Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 20.3	Expressed in all		
XPR1	SYG1, X3	ENSG00000143324	Xenotropic and polytropic retrovirus receptor 1	1	180632004-180890251	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA016557	Enhanced				Liver cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
RGS16	A28-RGS14, RGS-r	ENSG00000143333	Regulator of G-protein signaling 16	1	182598623-182604408	Predicted intracellular proteins	Evidence at protein level	HPA053250, HPA055824	Uncertain		Approved	Cytosol	Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enriched	7	thyroid gland: 171.8	gallbladder: 25.1	Cell line enhanced		Daudi: 77.3;SCLC-21H: 127.9;U-266/70: 93.7;U-698: 109.4
TOR1AIP1	FLJ13142, LAP1B	ENSG00000143337	Torsin 1A interacting protein 1	1	179882042-179925000	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047151, HPA050546	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			thyroid gland: 79.3	Expressed in all		
FAM163A	C1orf76, MGC16664, NDSP	ENSG00000143340	Family with sequence similarity 163 member A	1	179743163-179816198	Predicted membrane proteins	Evidence at transcript level	HPA010778	Uncertain					Mixed	Tissue enhanced		adrenal gland: 7.6;testis: 8.7	gallbladder: 1.8	Cell line enriched	38	SH-SY5Y: 118.8
HMCN1	ARMD1, FBLN6, FIBL-6, FIBL6	ENSG00000143341	Hemicentin 1	1	185734551-186190949	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051677	Uncertain				Renal cancer:3.59e-7 (unfavourable)	Tissue enriched	Tissue enhanced		lung: 22.3	prostate: 12.6	Group enriched	6	fHDF/TERT166: 17.3;MCF7: 58.7;SK-MEL-30: 38.8;U-138 MG: 13.5;WM-115: 43.4
RGL1	RGL	ENSG00000143344	Ral guanine nucleotide dissociation stimulator like 1	1	183636085-183928531	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA019788	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.49e-5 (unfavourable), Lung cancer:4.32e-4 (favourable)	Expressed in all	Mixed			spleen: 62.6	Cell line enhanced		HSkMC: 39.9
LYPLAL1	Q96AV0	ENSG00000143353	Lysophospholipase like 1	1	219173844-219212865	Predicted intracellular proteins	Evidence at protein level	HPA045806	Approved		Supported	Cytosol	Renal cancer:1.31e-4 (favourable)	Expressed in all	Mixed			kidney: 43.0	Mixed		
LHX9		ENSG00000143355	LIM homeobox 9	1	197911902-197935478	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009695	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		ovary: 11.5;testis: 4.5	lung: 2.2	Cell line enriched	9	fHDF/TERT166: 213.5
PRUNE1	DRES-17, H-PRUNE, HTCD37, PRUNE	ENSG00000143363	Prune exopolyphosphatase	1	151008420-151035713	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028411	Uncertain		Supported	Cytosol	Renal cancer:3.48e-4 (unfavourable), Endometrial cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 53.9	Expressed in all		
RORC	NR1F3, RORG, RZRG, TOR	ENSG00000143365	RAR related orphan receptor C	1	151806071-151831872	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065620			Supported	Nuclear bodies	Renal cancer:2.94e-5 (favourable), Colorectal cancer:1.83e-4 (favourable)	Mixed	Mixed			thyroid gland: 50.4	Cell line enhanced		HDLM-2: 24.3;Karpas-707: 9.4;MOLT-4: 5.6;T-47d: 10.0
TUFT1		ENSG00000143367	Tuftelin 1	1	151540305-151583583	Predicted intracellular proteins	Evidence at protein level	HPA028112, HPA054301	Approved	Approved	Approved	Vesicles	Endometrial cancer:4.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 92.8	esophagus: 25.8	Mixed		
SF3B4	Hsh49, SAP49, SF3b49	ENSG00000143368	Splicing factor 3b subunit 4	1	149923317-149928344	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028578, HPA064660	Approved		Approved	Nuclear speckles	Renal cancer:1.74e-7 (unfavourable), Liver cancer:1.54e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
ECM1		ENSG00000143369	Extracellular matrix protein 1	1	150508062-150513789	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA027241	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.51e-9 (unfavourable), Urothelial cancer:1.20e-5 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable)	Expressed in all	Group enriched	6	epididymis: 581.9;esophagus: 989.7	tonsil: 122.7	Cell line enhanced		ASC TERT1: 277.2;BJ hTERT+: 233.5;fHDF/TERT166: 213.1;hTEC/SVTERT24-B: 192.3
ZNF687	KIAA1441	ENSG00000143373	Zinc finger protein 687	1	151281618-151292180	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021193, HPA023948	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 26.0	Expressed in all		
TARS2	FLJ12528, TARSL1	ENSG00000143374	Threonyl-tRNA synthetase 2, mitochondrial (putative)	1	150487364-150507609	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028626	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 29.2	Expressed in all		
CGN	KIAA1319	ENSG00000143375	Cingulin	1	151510510-151538692	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017193, HPA027586, HPA027587, HPA027657	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:5.84e-10 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 73.4	small intestine: 61.9	Cell line enhanced		CACO-2: 75.4;CAPAN-2: 52.0
SNX27	KIAA0488, MGC20471, MY014	ENSG00000143376	Sorting nexin family member 27	1	151612065-151699091	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045816			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.1	Expressed in all		
SETDB1	ESET, KG1T, KIAA0067, KMT1E, TDRD21	ENSG00000143379	SET domain bifurcated 1	1	150926263-150964744	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018142, HPA058484	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:4.25e-4 (unfavourable), Liver cancer:8.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.3	Expressed in all		
ADAMTSL4	DKFZP434K1772, TSRC1	ENSG00000143382	ADAMTS like 4	1	150549369-150560937	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA006279	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.35e-7 (unfavourable), Glioma:1.63e-4 (unfavourable), Colorectal cancer:1.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 88.9	lung: 32.3	Cell line enhanced		ASC TERT1: 64.0;BEWO: 191.0;K-562: 60.1
MCL1	BCL2L3, Mcl-1	ENSG00000143384	BCL2 family apoptosis regulator	1	150574551-150579738	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002781, HPA008455, HPA031125, CAB068195	Approved		Enhanced	Mitochondria	Renal cancer:7.16e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 661.4	Cell line enriched	11	U-698: 3345.2
CTSK	CTSO, CTSO2, PKND, PYCD	ENSG00000143387	Cathepsin K	1	150796208-150808323	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050346			Supported	Vesicles	Renal cancer:7.12e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 575.0	Group enriched	6	ASC diff: 1592.3;ASC TERT1: 590.6;BJ hTERT+: 1576.7
RFX5		ENSG00000143390	Regulatory factor X5	1	151340640-151347357	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018519	Supported					Expressed in all	Expressed in all			lymph node: 85.6	Expressed in all		
PI4KB	PI4K-BETA, pi4K92, PIK4CB	ENSG00000143393	Phosphatidylinositol 4-kinase beta	1	151291797-151327715	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006280, HPA006281, CAB022071	Approved		Supported	Golgi apparatus	Pancreatic cancer:1.25e-5 (favourable), Liver cancer:2.97e-4 (unfavourable), Renal cancer:3.23e-4 (unfavourable), Thyroid cancer:6.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
PIP5K1A		ENSG00000143398	Phosphatidylinositol-4-phosphate 5-kinase type 1 alpha	1	151197949-151249536	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029366	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:4.16e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 67.8	Expressed in all		
ANP32E	LANP-L, LANPL, MGC5350	ENSG00000143401	Acidic nuclear phosphoprotein 32 family member E	1	150218417-150236156	Predicted intracellular proteins	Evidence at protein level	CAB021114, HPA063133, HPA067561	Supported		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:3.82e-8 (unfavourable), Liver cancer:4.50e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 84.1	Expressed in all		
MINDY1	FAM63A, FLJ11280, MINDY-1	ENSG00000143409	MINDY lysine 48 deubiquitinase 1	1	150996086-151008375	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028351, HPA028358, HPA061086	Approved		Supported	Nucleoplasm	Renal cancer:3.43e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.1	Cell line enhanced		T-47d: 46.6
ANXA9	ANX31	ENSG00000143412	Annexin A9	1	150982017-150995634	Predicted intracellular proteins	Evidence at protein level	HPA028404, HPA028698	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:8.74e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 35.3	Cell line enhanced		CAPAN-2: 31.9;MCF7: 38.4;T-47d: 113.2
SELENBP1	hSBP, hSP56, LPSB	ENSG00000143416	Selenium binding protein 1	1	151364302-151372733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005741, CAB008366, HPA011731	Enhanced		Supported	Nucleoli	Head and neck cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			rectum: 488.9	Cell line enhanced		ASC diff: 97.2;HEL: 100.3;SK-BR-3: 194.4
CERS2	FLJ10243, LASS2, SP260	ENSG00000143418	Ceramide synthase 2	1	150960583-150975004	Predicted membrane proteins	Evidence at protein level	HPA027262	Approved		Supported	Nuclear membrane<br>Endoplasmic reticulum		Expressed in all	Expressed in all			liver: 410.7	Expressed in all		
ENSA	ARPP-19e, MGC4319, MGC78563, MGC8394	ENSG00000143420	Endosulfine alpha	1	150600851-150629612	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051294	Uncertain		Approved	Nucleus<br>Nucleoli<br>Microtubules<br>Cytosol	Cervical cancer:8.24e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 267.3	Cell line enriched	12	U-698: 5502.7
SEMA6C	KIAA1869	ENSG00000143434	Semaphorin 6C	1	151131685-151146664	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA076150, HPA077625			Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol	Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 111.3	testis: 33.8	Cell line enhanced		AF22: 13.8;HUVEC TERT2: 20.6
MRPL9		ENSG00000143436	Mitochondrial ribosomal protein L9	1	151759643-151763564	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA008579	Approved		Supported	Mitochondria	Liver cancer:1.04e-7 (unfavourable), Renal cancer:1.44e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.5	Expressed in all		
ARNT	bHLHe2, HIF-1beta	ENSG00000143437	Aryl hydrocarbon receptor nuclear translocator	1	150809705-150876768	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001759, CAB004318	Enhanced		Supported	Nucleus<br>Nuclear bodies		Expressed in all	Expressed in all			ovary: 46.7	Cell line enriched	7	U-698: 274.9
POGZ	KIAA0461, ZNF280E, ZNF635m	ENSG00000143442	Pogo transposable element with ZNF domain	1	151402724-151459465	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006800, HPA008781	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.92e-5 (unfavourable), Urothelial cancer:4.40e-4 (favourable), Endometrial cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.7	Expressed in all		
C1orf56	FLJ20519, MENT	ENSG00000143443	Chromosome 1 open reading frame 56	1	151047740-151051986	Predicted secreted proteins	Evidence at protein level	HPA037429, HPA037430	Enhanced					Expressed in all	Tissue enriched	7	testis: 48.5	thyroid gland: 6.8	Mixed		
OAZ3		ENSG00000143450	Ornithine decarboxylase antizyme 3	1	151762899-151771334	Predicted intracellular proteins	Evidence at protein level	HPA030136			Supported	Nucleoplasm		Mixed	Tissue enriched	13	testis: 197.6	prostate: 14.7	Mixed		
HORMAD1	CT46, DKFZP434A1315	ENSG00000143452	HORMA domain containing 1	1	150698060-150720888	Predicted intracellular proteins	Evidence at protein level	HPA028346, HPA037850	Enhanced		Approved	Nucleoplasm<br>Nucleoli		Tissue enhanced	Tissue enriched	26	testis: 224.9	skin: 8.8	Cell line enhanced		A549: 5.6;hTCEpi: 14.9;SiHa: 6.8;THP-1: 8.3;U-2 OS: 4.1
GOLPH3L	GPP34R	ENSG00000143457	Golgi phosphoprotein 3 like	1	150646225-150697144	Predicted intracellular proteins	Evidence at protein level	HPA028558			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 51.4	Cell line enriched	6	U-698: 294.2
GABPB2	MGC29891	ENSG00000143458	GA binding protein transcription factor beta subunit 2	1	151070578-151125542	Predicted intracellular proteins	Evidence at protein level	HPA028471, HPA058483	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 20.1	Mixed		
SYT14	FLJ34198, sytXIV	ENSG00000143469	Synaptotagmin 14	1	209938174-210171389	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036963			Supported	Vesicles		Tissue enhanced	Group enriched	5	cerebral cortex: 3.0;testis: 6.7;thyroid gland: 9.8	adrenal gland: 1.3	Cell line enhanced		BJ hTERT+: 10.5;SCLC-21H: 7.8;TIME: 8.9;U-138 MG: 7.9
KCNH1	eag, eag1, h-eag, Kv10.1	ENSG00000143473	Potassium voltage-gated channel subfamily H member 1	1	210676823-211134180	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014551, HPA019445	Enhanced		Approved	Vesicles		Not detected	Tissue enriched	6	cerebral cortex: 6.2	testis: 1.0	Cell line enhanced		RH-30: 4.9;SH-SY5Y: 6.8;SK-MEL-30: 4.8;T-47d: 4.3
DTL	CDT2, DCAF2, L2DTL, RAMP	ENSG00000143476	Denticleless E3 ubiquitin protein ligase homolog	1	212035553-212107400	Predicted intracellular proteins	Evidence at protein level	HPA028016, HPA032023, HPA032031	Uncertain		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.71e-9 (unfavourable), Liver cancer:4.41e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 23.8	bone marrow: 8.2	Mixed		
DYRK3	hYAK3-2, RED, REDK	ENSG00000143479	Dual specificity tyrosine phosphorylation regulated kinase 3	1	206635536-206684419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA075041			Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.41e-7 (unfavourable)	Expressed in all	Tissue enhanced		testis: 86.7	gallbladder: 23.2	Cell line enhanced		hTERT-HME1: 56.1
EIF2D	LGTN	ENSG00000143486	Eukaryotic translation initiation factor 2D	1	206571292-206612463	Predicted intracellular proteins	Evidence at protein level	HPA028220	Approved		Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 74.1	Expressed in all		
INTS7	C1orf73, DKFZP434B168, INT7	ENSG00000143493	Integrator complex subunit 7	1	211940399-212035542	Predicted intracellular proteins	Evidence at protein level	HPA072611			Supported	Nuclear bodies	Renal cancer:1.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 38.8	thyroid gland: 11.2	Expressed in all		
VASH2	FLJ12505	ENSG00000143494	Vasohibin 2	1	212950520-212992037	Predicted intracellular proteins	Evidence at protein level	HPA045820			Approved	Cytosol		Tissue enhanced	Tissue enhanced		testis: 11.3	appendix,esophagus,prostate: 4.5	Cell line enhanced		AN3-CA: 27.4;NTERA-2: 46.2;RH-30: 131.2
TAF1A	SL1, TAFI48	ENSG00000143498	TATA-box binding protein associated factor, RNA polymerase I subunit A	1	222557902-222589933	Predicted intracellular proteins	Evidence at protein level	HPA054334	Approved		Supported	Nucleoplasm	Cervical cancer:9.26e-6 (unfavourable)	Expressed in all	Mixed			testis: 12.0	Expressed in all		
SMYD2	HSKM-B, KMT3C, ZMYND14	ENSG00000143499	SET and MYND domain containing 2	1	214281102-214337131	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029023	Uncertain		Approved	Intermediate filaments<br>Mitochondria<br>Cytosol	Cervical cancer:1.53e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 153.5	Expressed in all		
SUSD4	FLJ10052	ENSG00000143502	Sushi domain containing 4	1	223220819-223364202	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058296	Uncertain		Approved	Vesicles	Endometrial cancer:4.28e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 42.4	cerebral cortex: 38.5	Cell line enriched	5	SCLC-21H: 46.1
DUSP10	MKP-5, MKP5	ENSG00000143507	Dual specificity phosphatase 10	1	221701424-221742176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016758	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.69e-4 (unfavourable), Liver cancer:5.42e-4 (favourable)	Expressed in all	Mixed			liver: 16.7	Cell line enhanced		HaCaT: 86.1
HHIPL2	FLJ13840, KIAA1822L	ENSG00000143512	HHIP like 2	1	222522258-222548103	Predicted secreted proteins	Evidence at protein level	HPA059673	Enhanced		Uncertain	Mitochondria<br>Cytosol	Lung cancer:4.64e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 9.0;thyroid gland: 3.4	prostate: 1.4	Cell line enhanced		A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5
TP53BP2	53BP2, ASPP2, PPP1R13A	ENSG00000143514	Tumor protein p53 binding protein 2	1	223779899-223845972	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021603, HPA050429	Supported		Enhanced	Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 34.6	Mixed		
ATP8B2	ATPID, KIAA1137	ENSG00000143515	ATPase phospholipid transporting 8B2	1	154325553-154351307	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046680	Approved				Urothelial cancer:5.29e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 61.1	Mixed		
FLG2	IFPS	ENSG00000143520	Filaggrin family member 2	1	152348735-152360006	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028699	Approved					Tissue enriched	Tissue enriched	14	skin: 578.9	breast: 42.8	Not detected		
CRNN	C1orf10, SEP53	ENSG00000143536	Cornulin	1	152409243-152414263	Predicted intracellular proteins	Evidence at protein level	HPA024343, CAB026182	Enhanced					Group enriched	Tissue enriched	20	esophagus: 4518.8	tonsil: 225.3	Not detected		
ADAM15	MDC15	ENSG00000143537	ADAM metallopeptidase domain 15	1	155050566-155062775	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011633, HPA072878	Uncertain		Uncertain	Vesicles	Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 72.6	Cell line enhanced		PC-3: 305.3
JTB	hJT, PAR	ENSG00000143543	Jumping translocation breakpoint	1	153974269-153977688	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006514	Approved		Approved	Vesicles<br>Actin filaments	Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 116.4	Expressed in all		
RAB13		ENSG00000143545	RAB13, member RAS oncogene family	1	153981617-153986358	Predicted intracellular proteins	Evidence at protein level	HPA003996	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			prostate: 150.3	Mixed		
S100A8	60B8AG, CAGA, CFAG, CGLA, MRP8, P8	ENSG00000143546	S100 calcium binding protein A8	1	153390032-153391188	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002791, HPA024372	Enhanced		Supported	Intermediate filaments	Renal cancer:8.94e-7 (unfavourable)	Expressed in all	Group enriched	9	bone marrow: 14915.7;esophagus: 12755.4;tonsil: 4867.3	appendix: 1232.5	Group enriched	28	hTCEpi: 103.6;SK-BR-3: 396.8;THP-1: 195.3
TPM3	NEM1, TRK	ENSG00000143549	Tropomyosin 3	1	154155304-154194648	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000261, HPA009066, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Liver cancer:6.73e-6 (unfavourable), Ovarian cancer:2.39e-5 (favourable), Renal cancer:3.12e-5 (unfavourable), Pancreatic cancer:3.65e-4 (unfavourable), Lung cancer:4.01e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 2869.3	bone marrow: 428.4	Expressed in all		
NUP210L		ENSG00000143552	Nucleoporin 210 like	1	153992685-154155116	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA047195, HPA064245, HPA066707	Enhanced		Approved	Nuclear bodies		Not detected	Tissue enriched	100	testis: 47.8	seminal vesicle,smooth muscle,thyroid gland: 0.4	Cell line enriched	42	MCF7: 12.0
SNAPIN	BLOC1S7, BORCS3, SNAPAP	ENSG00000143553	SNAP associated protein	1	153658654-153661830	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA046974	Approved		Approved	Nucleoli<br>Golgi apparatus	Renal cancer:5.42e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 42.3	Expressed in all		
SLC27A3	ACSVL3, FATP3, MGC4365	ENSG00000143554	Solute carrier family 27 member 3	1	153774354-153780157	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006935, HPA067508	Uncertain		Supported	Endoplasmic reticulum	Pancreatic cancer:5.23e-4 (favourable), Renal cancer:6.33e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 43.9	lung: 20.9	Cell line enhanced		ASC diff: 42.9;MCF7: 27.0
S100A7	PSOR1, S100A7c	ENSG00000143556	S100 calcium binding protein A7	1	153457744-153460701	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001453, HPA006997, CAB033766	Enhanced					Group enriched	Group enriched	6	skin: 326.2;tonsil: 885.9	esophagus: 95.9	Cell line enhanced		HaCaT: 5.4;SK-BR-3: 10.6
UBAP2L	KIAA0144, NICE-4	ENSG00000143569	Ubiquitin associated protein 2 like	1	154220179-154271510	Predicted intracellular proteins	Evidence at protein level	HPA035068	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.89e-5 (unfavourable), Liver cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 122.8	Expressed in all		
SLC39A1	ZIP1, ZIRTL	ENSG00000143570	Solute carrier family 39 member 1	1	153959099-153968184	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016506			Uncertain	Cytosol	Liver cancer:4.12e-7 (unfavourable), Head and neck cancer:5.26e-5 (unfavourable), Cervical cancer:4.83e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 134.2	Expressed in all		
HAX1	HCLSBP1, HS1BP1	ENSG00000143575	HCLS1 associated protein X-1	1	154272511-154275875	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055141, HPA075289	Approved		Supported	Mitochondria	Renal cancer:1.34e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 114.9	Expressed in all		
CREB3L4	AIbZIP, ATCE1, CREB3, CREB4, hJAL	ENSG00000143578	CAMP responsive element binding protein 3 like 4	1	153967534-153974363	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA038122	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Mitochondria	Endometrial cancer:7.21e-4 (favourable)	Group enriched	Expressed in all			prostate: 170.5	Expressed in all		
EFNA3	Ehk1-L, EPLG3, LERK3	ENSG00000143590	Ephrin A3	1	155078872-155087538	Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB010494	Uncertain				Renal cancer:9.66e-10 (unfavourable), Liver cancer:2.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 51.3	cerebral cortex: 17.0	Cell line enhanced		HAP1: 19.5;SCLC-21H: 32.5;T-47d: 24.4
AQP10		ENSG00000143595	Aquaporin 10	1	154321090-154325325	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065947	Enhanced					Not detected	Group enriched	8	duodenum: 68.4;small intestine: 48.7	fallopian tube: 7.2	Group enriched	27	HEL: 16.1;HMC-1: 6.3;K-562: 18.7;SH-SY5Y: 5.0
KCNN3	hSK3, KCa2.3, SKCA3	ENSG00000143603	Potassium calcium-activated channel subfamily N member 3	1	154697455-154870280	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA017990, HPA057127	Uncertain		Approved	Nucleoplasm	Renal cancer:1.97e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 25.4	fallopian tube: 9.4	Cell line enhanced		Daudi: 28.1;HMC-1: 23.0;Karpas-707: 46.9;U-266/70: 47.5
C1orf43	DKFZp586G1722, NICE-3	ENSG00000143612	Chromosome 1 open reading frame 43	1	154206706-154220637	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010725	Approved				Liver cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 194.9	Expressed in all		
GATAD2B	P66beta	ENSG00000143614	GATA zinc finger domain containing 2B	1	153789030-153923360	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017015	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.30e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 19.7	Expressed in all		
ILF2	NF45	ENSG00000143621	Interleukin enhancer binding factor 2	1	153661788-153671048	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007484	Supported		Enhanced	Nucleus<br>Nucleoli	Liver cancer:5.71e-8 (unfavourable), Renal cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 211.7	Expressed in all		
RIT1	MGC125864, MGC125865, RIBB, RIT, ROC1	ENSG00000143622	Ras like without CAAX 1	1	155897808-155911404	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053249	Approved				Liver cancer:8.64e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.5	Expressed in all		
INTS3	C1orf60, FLJ21919, INT3, SOSS-A	ENSG00000143624	Integrator complex subunit 3	1	153728067-153774808	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA074391	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.34e-6 (unfavourable), Pancreatic cancer:5.42e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 16.5	Expressed in all		
PKLR		ENSG00000143627	Pyruvate kinase, liver and RBC	1	155289839-155301434	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006653, CAB034376, CAB034378	Enhanced		Approved	Endoplasmic reticulum<br>Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 14.0;liver: 26.4	bone marrow: 7.8	Cell line enriched	16	K-562: 72.0
HCN3	KIAA1535	ENSG00000143630	Hyperpolarization activated cyclic nucleotide gated potassium channel 3	1	155277583-155289848	Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA026584	Approved				Urothelial cancer:6.93e-4 (favourable), Renal cancer:7.49e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,skin: 2.9	Cell line enhanced		K-562: 5.7
FLG		ENSG00000143631	Filaggrin	1	152302175-152325203	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002210, HPA027505, HPA030188, HPA030189	Enhanced		Supported	Vesicles		Tissue enriched	Tissue enriched	26	skin: 548.3	breast: 21.1	Cell line enhanced		HaCaT: 8.9;NTERA-2: 3.1;U-2 OS: 2.5;U-2197: 2.4
ACTA1	ACTA, NEM3	ENSG00000143632	Actin, alpha 1, skeletal muscle	1	229431245-229434098	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000045, HPA041264, HPA041271	Enhanced					Group enriched	Tissue enriched	14	skeletal muscle: 45978.0	heart muscle: 3193.1	Cell line enriched	30	BEWO: 452.7
C1orf131	DKFZp547B1713	ENSG00000143633	Chromosome 1 open reading frame 131	1	231223763-231241187	Predicted intracellular proteins	Evidence at protein level	HPA028452, HPA029920	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.64e-9 (unfavourable), Urothelial cancer:9.84e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 21.6	Expressed in all		
GALNT2	GalNAc-T2	ENSG00000143641	Polypeptide N-acetylgalactosaminyltransferase 2	1	230057990-230282124	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011222	Supported		Enhanced	Golgi apparatus	Renal cancer:2.79e-13 (unfavourable), Lung cancer:8.48e-8 (unfavourable), Cervical cancer:1.22e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 48.5	Expressed in all		
TTC13	FLJ22584	ENSG00000143643	Tetratricopeptide repeat domain 13	1	230906243-230978875	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018022, HPA051558	Uncertain		Approved	Nucleoplasm	Renal cancer:1.60e-11 (unfavourable), Pancreatic cancer:4.59e-5 (favourable), Head and neck cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 23.0	Expressed in all		
SCCPDH	CGI-49, NET11	ENSG00000143653	Saccharopine dehydrogenase (putative)	1	246724047-246768137	Predicted membrane proteins	Evidence at protein level	HPA050775	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			testis: 241.5	Mixed		
LYST	CHS, CHS1	ENSG00000143669	Lysosomal trafficking regulator	1	235661041-235883640	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053366, HPA055725			Approved	Nucleoplasm<br>Plasma membrane<br>Microtubule organizing center	Renal cancer:5.27e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 20.9	Cell line enhanced		HDLM-2: 28.5;THP-1: 66.9;U-937: 29.8
MAP3K21	KIAA1804, MLK4	ENSG00000143674	Mitogen-activated protein kinase kinase kinase 21	1	233327768-233385148	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007636	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 17.8	Cell line enhanced		HEK 293: 25.2
CEP170	FAM68A, KAB, KIAA0470	ENSG00000143702	Centrosomal protein 170	1	243124428-243255348	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042151, HPA045597, HPA045787	Uncertain		Enhanced	Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:1.30e-9 (unfavourable)	Expressed in all	Tissue enhanced		testis: 130.5	cerebral cortex: 44.7	Expressed in all		
ACP1	HAAP, LMW-PTP, LMWPTP	ENSG00000143727	Acid phosphatase 1, soluble	2	264140-278283	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016754	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:6.67e-6 (unfavourable), Melanoma:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 128.8	Expressed in all		
SNAP47	C1orf142, SNAP-47, SVAP1	ENSG00000143740	Synaptosome associated protein 47	1	227728539-227781231	Predicted intracellular proteins	Evidence at protein level	HPA028167	Enhanced		Approved	Cytosol		Expressed in all	Expressed in all			testis: 56.6	Expressed in all		
SRP9		ENSG00000143742	Signal recognition particle 9	1	225777813-225790466	Predicted intracellular proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 340.2	Expressed in all		
NVL	NVL2	ENSG00000143748	Nuclear VCP-like	1	224227334-224330387	Predicted intracellular proteins	Evidence at protein level	HPA028207, HPA028219, HPA028224, HPA028654	Enhanced		Enhanced	Nucleoli	Renal cancer:4.10e-11 (unfavourable), Liver cancer:5.77e-5 (unfavourable), Lung cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			skin: 18.7	Expressed in all		
SDE2	C1orf55, FLJ35382	ENSG00000143751	SDE2 telomere maintenance homolog	1	225982702-225999331	Predicted intracellular proteins	Evidence at protein level	HPA028467, HPA031255, HPA031256	Approved		Approved	Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.1	Expressed in all		
DEGS1	DEGS-1, Des-1, DES1, FADS7, MLD	ENSG00000143753	Delta 4-desaturase, sphingolipid 1	1	224175756-224193441	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA076422			Supported	Mitochondria	Renal cancer:6.83e-7 (unfavourable), Liver cancer:4.29e-5 (unfavourable), Endometrial cancer:7.74e-5 (unfavourable), Urothelial cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 616.3	Expressed in all		
FBXO28	CENP-30, Fbx28, FLJ10766, KIAA0483	ENSG00000143756	F-box protein 28	1	224114087-224162047	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003289			Supported	Nucleus<br>Focal adhesion sites		Expressed in all	Expressed in all			parathyroid gland,skin: 25.0	Expressed in all		
ARF1		ENSG00000143761	ADP ribosylation factor 1	1	228082660-228099212	Predicted intracellular proteins	Evidence at protein level	CAB007742	Uncertain		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 384.2	Expressed in all		
LEFTY2	EBAF, LEFTA, LEFTYA, TGFB4	ENSG00000143768	Left-right determination factor 2	1	225936598-225941489	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025801, HPA047883, HPA056210	Approved					Tissue enriched	Group enriched	6	endometrium: 264.3;smooth muscle: 57.0	ovary: 26.0	Group enriched	12	HDLM-2: 8.7;NTERA-2: 40.5;RPMI-8226: 31.4
CNIH4	HSPC163	ENSG00000143771	Cornichon family AMPA receptor auxiliary protein 4	1	224356850-224379459	Predicted membrane proteins	Evidence at protein level	HPA044268	Approved				Renal cancer:4.27e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable), Pancreatic cancer:4.61e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 27.4	Expressed in all		
ITPKB	IP3-3KB, IP3KB	ENSG00000143772	Inositol-trisphosphate 3-kinase B	1	226631690-226739323	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030273, HPA072923	Uncertain		Approved	Nucleus	Head and neck cancer:1.72e-5 (favourable), Lung cancer:6.65e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.6	Cell line enhanced		SK-MEL-30: 36.3
GUK1		ENSG00000143774	Guanylate kinase 1	1	228139962-228148984	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028118, HPA048587	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:8.85e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 264.8	Expressed in all		
CDC42BPA	FLJ23347, KIAA0451, MRCK, MRCKA, PK428	ENSG00000143776	CDC42 binding protein kinase alpha	1	226989865-227318474	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB070414, HPA071252	Approved		Approved	Intermediate filaments		Expressed in all	Expressed in all			testis: 45.2	Mixed		
CNIH3	CNIH-3, FLJ38993	ENSG00000143786	Cornichon family AMPA receptor auxiliary protein 3	1	224434660-224740549	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 14.7	testis: 4.2	Cell line enhanced		hTEC/SVTERT24-B: 46.6;NTERA-2: 17.2;U-266/70: 18.9;U-87 MG: 53.6
C1orf35	MGC4174, MMTAG2	ENSG00000143793	Chromosome 1 open reading frame 35	1	228100726-228105411	Predicted intracellular proteins	Evidence at protein level	HPA046175	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:1.79e-6 (unfavourable), Ovarian cancer:7.38e-4 (favourable), Colorectal cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 14.3	Expressed in all		
MBOAT2	FLJ14415, FLJ90298, OACT2	ENSG00000143797	Membrane bound O-acyltransferase domain containing 2	2	8852690-9003813	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014836	Uncertain		Approved	Vesicles	Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 50.1	cerebral cortex: 29.7	Mixed		
PARP1	ADPRT, PARP, PPOL	ENSG00000143799	Poly(ADP-ribose) polymerase 1	1	226360691-226408079	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727	Supported	Supported	Enhanced	Nucleus	Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 198.4	Expressed in all		
PSEN2	AD3L, AD4, PS2, STM2	ENSG00000143801	Presenilin 2	1	226870184-226896105	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013634, HPA038005			Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 28.8	Mixed		
PYCR2	P5CR2	ENSG00000143811	Pyrroline-5-carboxylate reductase family member 2	1	225919877-225924340	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA056873	Approved		Approved	Mitochondria	Renal cancer:1.42e-6 (unfavourable), Colorectal cancer:5.02e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 71.9	Expressed in all		
LBR	DHCR14B, TDRD18	ENSG00000143815	Lamin B receptor	1	225401502-225428925	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049840, HPA062236	Enhanced		Enhanced	Nuclear membrane	Liver cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 98.6	Expressed in all		
WNT9A	WNT14	ENSG00000143816	Wnt family member 9A	1	227918656-227947898	Plasma proteins, Predicted secreted proteins	Evidence at transcript level						Ovarian cancer:1.06e-4 (unfavourable)	Mixed	Mixed			heart muscle: 7.2	Cell line enhanced		HaCaT: 14.4;RH-30: 16.0;SCLC-21H: 17.7;SiHa: 15.7
EPHX1	EPHX	ENSG00000143819	Epoxide hydrolase 1	1	225810092-225845563	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020593, HPA048847	Enhanced				Lung cancer:7.02e-5 (favourable), Prostate cancer:1.32e-4 (favourable)	Tissue enriched	Expressed in all			adrenal gland: 1085.6	Cell line enhanced		ASC diff: 821.1;SiHa: 629.7
REN		ENSG00000143839	Renin	1	204154819-204190324	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005131, CAB025903	Approved				Renal cancer:6.45e-5 (unfavourable)	Tissue enriched	Tissue enhanced		kidney: 51.2;placenta: 21.0	endometrium: 8.9	Cell line enhanced		BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
SOX13	ICA12, MGC117216, Sox-13	ENSG00000143842	SRY-box 13	1	204073115-204127743	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051790, HPA054843			Enhanced	Nucleoplasm	Colorectal cancer:6.49e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 53.8	Cell line enhanced		SK-BR-3: 103.3
ETNK2	EKI2, FLJ10761	ENSG00000143845	Ethanolamine kinase 2	1	204131062-204152003	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057167	Enhanced				Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 110.6;liver: 120.7;testis: 143.1	ovary: 43.4	Mixed		
PPFIA4		ENSG00000143847	PTPRF interacting protein alpha 4	1	203026498-203078740	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053419, HPA054132	Enhanced				Renal cancer:1.73e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 24.8;heart muscle: 14.5	skeletal muscle: 6.5	Cell line enhanced		RH-30: 13.1;U-87 MG: 12.1
PLEKHA6	KIAA0969, PEPP3	ENSG00000143850	Pleckstrin homology domain containing A6	1	204218851-204377665	Predicted intracellular proteins	Evidence at protein level	HPA028152, HPA054311	Approved		Supported	Vesicles<br>Cell Junctions<br>Microtubule organizing center	Urothelial cancer:3.57e-4 (favourable)	Expressed in all	Mixed			stomach: 40.6	Cell line enhanced		BEWO: 88.4;CAPAN-2: 75.9;PC-3: 64.5;RT4: 62.5
PTPN7	HEPTP, LC-PTP	ENSG00000143851	Protein tyrosine phosphatase, non-receptor type 7	1	202147013-202161588	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009530, HPA019118	Approved				Renal cancer:2.42e-8 (unfavourable), Endometrial cancer:1.52e-4 (favourable), Head and neck cancer:1.84e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 25.2;lymph node: 24.3	tonsil: 19.3	Cell line enhanced		HEL: 48.4;HL-60: 93.9;HMC-1: 132.7;U-937: 65.7
SYT2		ENSG00000143858	Synaptotagmin 2	1	202590596-202710417	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA030372, HPA063655	Enhanced	Supported	Approved	Vesicles		Tissue enriched	Tissue enhanced		adrenal gland: 1.8;cerebral cortex: 2.1	epididymis,testis: 1.0	Cell line enhanced		AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
ARL8A	ARL10B, FLJ45195, Gie2	ENSG00000143862	ADP ribosylation factor like GTPase 8A	1	202133404-202144743	Predicted intracellular proteins	Evidence at protein level	HPA038759, HPA040515, HPA045924	Approved				Colorectal cancer:3.08e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 113.6	Expressed in all		
OSR1	ODD	ENSG00000143867	Odd-skipped related transciption factor 1	2	19351485-19358653	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA015525	Uncertain					Mixed	Mixed			adipose tissue: 22.1	Cell line enriched	14	U-2197: 92.8
GDF7	BMP12	ENSG00000143869	Growth differentiation factor 7	2	20666664-20679245	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		seminal vesicle: 29.5	endometrium: 11.5	Cell line enhanced		HAP1: 1.7;Hep G2: 2.8;RT4: 6.2;SH-SY5Y: 3.3
PDIA6	ERp5, P5, TXNDC7	ENSG00000143870	Protein disulfide isomerase family A member 6	2	10783391-10837977	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034347, HPA034652, HPA034653	Enhanced		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.51e-6 (unfavourable), Liver cancer:3.63e-5 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable), Cervical cancer:1.80e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 591.9	Expressed in all		
RHOB	ARH6, ARHB, MST081, RhoB, RHOH6	ENSG00000143878	Ras homolog family member B	2	20447074-20449445	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 710.5	Cell line enhanced		RPTEC TERT1: 344.8;SK-BR-3: 419.9
ATP6V1C2	ATP6C2, VMA5	ENSG00000143882	ATPase H+ transporting V1 subunit C2	2	10721649-10785110	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034734, HPA067305	Approved		Uncertain	Mitochondria	Renal cancer:1.12e-11 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 83.9;epididymis: 99.0;skin: 123.7	placenta: 55.1	Group enriched	9	BEWO: 71.4;SK-BR-3: 20.0
HNRNPLL	HNRPLL	ENSG00000143889	Heterogeneous nuclear ribonucleoprotein L like	2	38561978-38603586	Predicted intracellular proteins	Evidence at protein level	HPA046084	Approved		Approved	Nucleus<br>Mitochondria<br>Cytosol	Liver cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.5	Mixed		
GALM		ENSG00000143891	Galactose mutarotase	2	38665910-38741237	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035472, HPA035473, HPA064835	Enhanced		Approved	Nucleoplasm	Renal cancer:9.06e-5 (favourable), Urothelial cancer:1.32e-4 (favourable)	Expressed in all	Expressed in all			kidney: 118.1	Mixed		
CAMKMT	C2orf34, CLNMT	ENSG00000143919	Calmodulin-lysine N-methyltransferase	2	44361950-44772592	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067912			Supported	Nucleus	Glioma:5.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
ABCG8	GBD4	ENSG00000143921	ATP binding cassette subfamily G member 8	2	43838964-43878466	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019556	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	25	duodenum: 50.0;liver: 34.0;small intestine: 55.5	gallbladder: 1.8	Cell line enriched	44	Hep G2: 6.9
EML4	C2orf2, ELP120, ROPP120	ENSG00000143924	Echinoderm microtubule associated protein like 4	2	42169350-42332548	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA036687, HPA036688, HPA065337	Enhanced		Supported	Intermediate filaments<br>Microtubules<br>Cytosol		Expressed in all	Mixed			placenta: 50.5	Expressed in all		
CALM2	CAMII, PHKD	ENSG00000143933	Calmodulin 2	2	47160082-47176601	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB007790, HPA044999	Approved				Thyroid cancer:1.94e-5 (favourable), Liver cancer:8.35e-5 (unfavourable), Endometrial cancer:4.84e-4 (unfavourable), Breast cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1533.3	Expressed in all		
CHAC2		ENSG00000143942	ChaC cation transport regulator homolog 2	2	53767792-53775196	Predicted intracellular proteins	Evidence at protein level	HPA049235	Approved		Approved	Cytosol	Liver cancer:3.80e-7 (unfavourable)	Expressed in all	Mixed			testis: 9.8	Expressed in all		
RPS27A	S27A, Uba80, UBCEP80	ENSG00000143947	Ribosomal protein S27a	2	55231903-55235853	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB033319, HPA041344, HPA049132, HPA054087	Supported		Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:2.60e-6 (unfavourable), Liver cancer:2.26e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3413.3	Expressed in all		
WDPCP	BBS15, C2orf86, fritz, hFrtz	ENSG00000143951	WD repeat containing planar cell polarity effector	2	63121383-63827843	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044144	Uncertain		Approved	Cell Junctions		Mixed	Mixed			testis: 11.4	Expressed in all		
VPS54	HCC8, PPP1R164	ENSG00000143952	VPS54, GARP complex subunit	2	63892146-64019072	Predicted intracellular proteins	Evidence at protein level	HPA055894, HPA067981, HPA070582			Enhanced	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:2.03e-4 (favourable), Liver cancer:2.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.8	Expressed in all		
REG3G	LPPM429, PAP1B, UNQ429	ENSG00000143954	Regenerating family member 3 gamma	2	79025686-79028505	Predicted secreted proteins	Evidence at protein level	HPA047894, HPA048334, HPA060705	Uncertain		Approved	Cytosol		Tissue enriched	Group enriched	15	epididymis: 201.5;testis: 107.2	pancreas: 10.0	Not detected		
ASXL2	ASXH2, FLJ10898, KIAA1685	ENSG00000143970	Additional sex combs like 2, transcriptional regulator	2	25733753-25878516	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034646, HPA058040			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 26.6	Expressed in all		
ETAA1	ETAA16	ENSG00000143971	Ewing tumor associated antigen 1	2	67397319-67410545	Predicted intracellular proteins	Evidence at protein level	HPA035048, HPA035049	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland,thyroid gland: 15.7	Expressed in all		
SNRPG	Sm-G	ENSG00000143977	Small nuclear ribonucleoprotein polypeptide G	2	70281362-70293771	Predicted intracellular proteins	Evidence at protein level	HPA064152, HPA067814	Enhanced		Approved	Nucleoplasm	Renal cancer:1.08e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 114.2	Expressed in all		
ABHD1	FLJ36128, LABH1	ENSG00000143994	Abhydrolase domain containing 1	2	27123789-27130812	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044390	Uncertain					Mixed	Tissue enriched	17	testis: 30.0	liver: 1.7	Cell line enhanced		RPMI-8226: 1.1;T-47d: 3.0;U-266/70: 2.4;U-266/84: 1.9
MEIS1		ENSG00000143995	Meis homeobox 1	2	66433452-66573869	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB011521, HPA056000, HPA058641	Approved		Supported	Nucleoplasm	Head and neck cancer:2.70e-5 (favourable), Renal cancer:1.69e-4 (unfavourable)	Tissue enhanced	Expressed in all			endometrium: 92.6	Cell line enhanced		BJ hTERT+: 37.0;SH-SY5Y: 30.4
TRIM43B		ENSG00000144010	Tripartite motif containing 43B	2	95476967-95484731	Predicted intracellular proteins	No evidence	HPA042223, HPA042772	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
TRIM43	TRIM43A	ENSG00000144015	Tripartite motif containing 43	2	95592018-95599778	Predicted intracellular proteins	Evidence at protein level	HPA042223, HPA042772	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
CIAO1	CIA1, WDR39	ENSG00000144021	Cytosolic iron-sulfur assembly component 1	2	96266132-96273349	Predicted intracellular proteins	Evidence at protein level	HPA017882	Uncertain		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.13e-5 (unfavourable), Liver cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
ZNF514	FLJ14457	ENSG00000144026	Zinc finger protein 514	2	95147330-95165413	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028974	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			epididymis: 32.8	Expressed in all		
SNRNP200	ASCC3L1, BRR2, HELIC2, KIAA0788, RP33, U5-200KD	ENSG00000144028	Small nuclear ribonucleoprotein U5 subunit 200	2	96274336-96305515	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029321	Approved		Supported	Nucleoplasm	Endometrial cancer:3.89e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 116.4	Expressed in all		
MRPS5	MRP-S5, S5mt	ENSG00000144029	Mitochondrial ribosomal protein S5	2	95087207-95149434	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055765	Approved		Supported	Mitochondria	Endometrial cancer:7.98e-7 (unfavourable), Liver cancer:7.73e-5 (unfavourable), Thyroid cancer:6.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.9	Expressed in all		
ANKRD53	FLJ12056, FLJ36160	ENSG00000144031	Ankyrin repeat domain 53	2	70978380-70985499	Predicted intracellular proteins	Evidence at protein level	HPA049574	Approved					Mixed	Tissue enhanced		testis: 17.5	adipose tissue: 4.3	Cell line enhanced		HHSteC: 1.3;HSkMC: 1.2
TPRKB	CGI-121, CGI121	ENSG00000144034	TP53RK binding protein	2	73729104-73737400	Predicted intracellular proteins	Evidence at protein level	HPA035712	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 79.9	Expressed in all		
NAT8	ATase2, GLA, Hcml1, TSC501	ENSG00000144035	N-acetyltransferase 8 (putative)	2	73640832-73642393	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA067855, HPA074519	Enhanced		Approved	Endoplasmic reticulum		Tissue enriched	Tissue enriched	18	kidney: 891.8	liver: 49.4	Cell line enriched	12	Hep G2: 8.7
EXOC6B	KIAA0919, SEC15B, SEC15L2	ENSG00000144036	Exocyst complex component 6B	2	72175984-72826041	Predicted intracellular proteins	Evidence at protein level	HPA034546, HPA063991	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 33.6	Mixed		
SFXN5	BBG-TCC	ENSG00000144040	Sideroflexin 5	2	72942036-73075619	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015473, HPA056866	Approved		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:2.26e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 39.4	epididymis: 18.6	Mixed		
TEX261	MGC32043, TEG-261	ENSG00000144043	Testis expressed 261	2	70985938-70994945	Predicted membrane proteins	Evidence at transcript level	HPA016631	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:4.23e-4 (unfavourable), Endometrial cancer:6.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 93.1	Expressed in all		
DQX1	FLJ23757	ENSG00000144045	DEAQ-box RNA dependent ATPase 1	2	74518131-74526336	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039158	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		duodenum: 14.4;small intestine: 13.5	colon: 5.5	Cell line enhanced		HBEC3-KT: 4.2;Hep G2: 11.5;hTCEpi: 4.3
DUSP11	PIR1	ENSG00000144048	Dual specificity phosphatase 11	2	73762184-73780157	Predicted intracellular proteins	Evidence at protein level	HPA021052			Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytokinetic bridge	Liver cancer:2.10e-7 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 62.4	Expressed in all		
ST6GAL2	KIAA1877, SIAT2, St6gal2, St6GalII	ENSG00000144057	ST6 beta-galactoside alpha-2,6-sialyltransferase 2	2	106801600-106887108	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014459	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Tissue enriched	Tissue enhanced		cerebral cortex: 22.1;thyroid gland: 47.9	testis: 9.8	Cell line enhanced		A549: 4.8;PC-3: 5.5;RPMI-8226: 6.7;SCLC-21H: 7.2;U-138 MG: 7.4;U-266/70: 7.5
NPHP1	JBTS4, NPH1, SLSN1	ENSG00000144061	Nephrocystin 1	2	110122311-110205066	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046093, HPA074071	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		testis: 46.0	fallopian tube: 28.4	Mixed		
MALL	BENE	ENSG00000144063	Mal, T-cell differentiation protein like	2	110083870-110116566	Predicted membrane proteins	Evidence at protein level	HPA051410	Uncertain				Pancreatic cancer:1.23e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 222.2;parathyroid gland: 321.0	small intestine: 182.4	Cell line enhanced		A-431: 176.6;A549: 174.8;CAPAN-2: 233.6;fHDF/TERT166: 228.9;HaCaT: 183.5
THNSL2	FLJ10916, SOFAT, TSH2	ENSG00000144115	Threonine synthase like 2	2	88170295-88186636	Predicted intracellular proteins	Evidence at protein level	HPA035395	Approved					Expressed in all	Tissue enhanced		parathyroid gland: 74.4	thyroid gland: 38.2	Cell line enhanced		HHSteC: 19.8;T-47d: 21.4
RALB		ENSG00000144118	RAS like proto-oncogene B	2	120240064-120294713	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB026010, HPA065232	Enhanced				Pancreatic cancer:1.67e-4 (unfavourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 664.6	placenta: 82.8	Expressed in all		
C1QL2	C1QTNF10, CTRP10	ENSG00000144119	Complement C1q like 2	2	119156243-119158889	Predicted secreted proteins	Evidence at protein level	HPA057934	Uncertain					Mixed	Tissue enriched	17	cerebral cortex: 2.5	lymph node,testis: 0.1	Cell line enhanced		SCLC-21H: 2.8
TMEM177	MGC10993	ENSG00000144120	Transmembrane protein 177	2	119679167-119686507	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036689, HPA053816	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Mixed			fallopian tube: 16.9	Expressed in all		
NT5DC4		ENSG00000144130	5'-nucleotidase domain containing 4	2	112721486-112742879	Predicted intracellular proteins	Evidence at transcript level	HPA046856	Uncertain					Tissue enhanced	Tissue enriched	7	testis: 3.4	lymph node: 0.5	Cell line enriched	10	K-562: 14.2
RABL2A		ENSG00000144134	RAB, member of RAS oncogene family-like 2A	2	113627229-113643396	Predicted intracellular proteins	Evidence at protein level	HPA042642, HPA042700, HPA044007	Approved		Approved	Vesicles<br>Centrosome	Renal cancer:1.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 31.5	cerebral cortex: 8.1	Mixed		
SLC20A1	Glvr-1, GLVR1, PiT-1	ENSG00000144136	Solute carrier family 20 member 1	2	112645857-112663827	Predicted membrane proteins, Transporters	Evidence at protein level	CAB019279, HPA035834	Approved		Approved	Vesicles	Renal cancer:3.44e-5 (unfavourable), Head and neck cancer:6.56e-5 (unfavourable)	Expressed in all	Expressed in all			colon: 51.1	Expressed in all		
FBLN7	FLJ37440, TM14	ENSG00000144152	Fibulin 7	2	112138385-112188216	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034992			Approved	Plasma membrane<br>Cell Junctions		Mixed	Mixed			parathyroid gland: 18.7	Cell line enhanced		AF22: 24.3;BJ hTERT+: 14.4;SCLC-21H: 18.6;SH-SY5Y: 13.4;U-2197: 23.6
ZC3H8	Fliz1, ZC3HDC8	ENSG00000144161	Zinc finger CCCH-type containing 8	2	112211525-112255136	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034803, HPA034804	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:1.12e-6 (unfavourable), Renal cancer:1.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
LIPT1	MGC12290, MGC13378	ENSG00000144182	Lipoyltransferase 1	2	99154955-99163157	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034802	Approved				Urothelial cancer:9.60e-8 (favourable), Lung cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 24.3	Expressed in all		
CNGA3	ACHM2, CCNC1, CCNCa, CNCG3, CNG3	ENSG00000144191	Cyclic nucleotide gated channel alpha 3	2	98346155-98398601	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA049378, CAB079025	Approved	Approved				Tissue enriched	Mixed			esophagus: 1.9	Cell line enriched	7	U-87 MG: 6.9
FAHD2B	DKFZp434N062	ENSG00000144199	Fumarylacetoacetate hydrolase domain containing 2B	2	97083583-97094882	Predicted intracellular proteins	Evidence at protein level	HPA042145, HPA044987	Approved				Glioma:2.81e-4 (unfavourable)	Mixed	Expressed in all			epididymis: 48.4	Mixed		
LYG1	SALW1939	ENSG00000144214	Lysozyme g1	2	99284238-99304742	Predicted secreted proteins	Evidence at transcript level						Renal cancer:8.44e-4 (favourable)	Tissue enriched	Group enriched	5	kidney: 22.0;testis: 4.8	breast: 2.5	Mixed		
AFF3	LAF4, MLLT2-like	ENSG00000144218	AF4/FMR2 family member 3	2	99545419-100142739	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA044512, HPA053379	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.64e-4 (unfavourable)	Tissue enhanced	Mixed			prostate: 29.7	Cell line enhanced		Daudi: 35.6;U-698: 50.7
UBXN4	KIAA0242, UBXD2, UBXDC1	ENSG00000144224	UBX domain protein 4	2	135741619-135785055	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036325	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 105.0	Expressed in all		
NXPH2	NPH2	ENSG00000144227	Neurexophilin 2	2	138670772-138780348	Predicted secreted proteins	Evidence at transcript level	HPA034759	Approved					Mixed	Group enriched	9	cerebral cortex: 5.7;kidney: 5.0;ovary: 14.0	endometrium: 0.9	Cell line enhanced		AF22: 3.8;SCLC-21H: 1.7;SiHa: 4.0;U-2 OS: 6.3;U-251 MG: 1.7
SPOPL	BTBD33	ENSG00000144228	Speckle type BTB/POZ protein like	2	138501801-138573547	Predicted intracellular proteins	Evidence at protein level	HPA034687	Uncertain		Approved	Vesicles	Renal cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			breast: 16.2	Mixed		
THSD7B	KIAA1679	ENSG00000144229	Thrombospondin type 1 domain containing 7B	2	136765545-137677717	Predicted membrane proteins	Evidence at transcript level	HPA051416, HPA056745	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		epididymis: 5.1	adipose tissue: 2.0	Group enriched	8	Daudi: 7.8;SCLC-21H: 25.8
GPR17		ENSG00000144230	G protein-coupled receptor 17	2	127645864-127652639	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029766	Enhanced	Supported	Approved	Vesicles		Tissue enriched	Mixed			spleen: 9.6	Cell line enhanced		HeLa: 1.7;REH: 4.0;TIME: 3.5;U-2 OS: 1.8;U-2197: 1.8;U-251 MG: 2.1
POLR2D	RBP4	ENSG00000144231	RNA polymerase II subunit D	2	127843551-127858157	Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA034694, HPA046092	Approved		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:2.79e-4 (unfavourable), Liver cancer:8.91e-4 (unfavourable)	Expressed in all	Tissue enriched	5	testis: 134.0	tonsil: 24.4	Expressed in all		
AMMECR1L	MGC4268	ENSG00000144233	AMMECR1 like	2	127861630-127885922	Predicted intracellular proteins	Evidence at protein level	HPA000590, HPA057234	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.3	Expressed in all		
GALNT13	GalNAc-T13, KIAA1918	ENSG00000144278	Polypeptide N-acetylgalactosaminyltransferase 13	2	153871913-154453849	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060775	Approved					Tissue enriched	Group enriched	6	adrenal gland: 6.6;cerebral cortex: 32.7	prostate: 3.5	Cell line enhanced		SH-SY5Y: 46.7;WM-115: 33.1
PKP4	p0071	ENSG00000144283	Plakophilin 4	2	158456964-158682879	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037334, HPA066647, HPA070648	Approved		Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:3.29e-7 (favourable), Endometrial cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			kidney: 65.6	Expressed in all		
SCN1A	FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI	ENSG00000144285	Sodium voltage-gated channel alpha subunit 1	2	165989160-166149214	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078664			Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Tissue enriched	Group enriched	41	cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2	adrenal gland,placenta,testis: 0.1	Cell line enhanced		AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
SLC4A10	NBCn2, NCBE	ENSG00000144290	Solute carrier family 4 member 10	2	161424332-161985282	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034755	Supported					Tissue enhanced	Tissue enriched	22	cerebral cortex: 57.5	adrenal gland: 2.6	Cell line enriched	10	Karpas-707: 6.1
SCRN3	FLJ23142	ENSG00000144306	Secernin 3	2	174395730-174429575	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034689, HPA034690	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 48.4	Mixed		
LNPK	KIAA1715, LNP, LNP1, Ul	ENSG00000144320	Lunapark, ER junction formation factor	2	175923892-176002839	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014205	Approved		Supported	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 44.7	Expressed in all		
ZNF385B	FLJ25270, ZNF533	ENSG00000144331	Zinc finger protein 385B	2	179441982-179861505	Predicted intracellular proteins	Evidence at protein level	HPA046086			Supported	Nucleoli fibrillar center	Renal cancer:1.04e-9 (favourable), Breast cancer:4.86e-8 (favourable)	Group enriched	Tissue enhanced		lung: 27.5	prostate: 20.0	Cell line enhanced		Daudi: 12.3;HAP1: 32.8;U-698: 60.0
TMEFF2	CT120.2, HPP1, TENB2, TPEF, TR	ENSG00000144339	Transmembrane protein with EGF like and two follistatin like domains 2	2	191949043-192195709	Predicted membrane proteins	Evidence at protein level	HPA015587	Uncertain		Uncertain	Microtubules<br>Cytokinetic bridge		Tissue enriched	Tissue enhanced		cerebral cortex: 41.0;prostate: 64.1	seminal vesicle: 19.6	Group enriched	6	AF22: 38.8;LHCN-M2: 94.7
CDCA7	FLJ14736, JPO1	ENSG00000144354	Cell division cycle associated 7	2	173354820-173368997	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005565	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.20e-4 (unfavourable), Melanoma:5.50e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 44.7	Mixed		
DLX1		ENSG00000144355	Distal-less homeobox 1	2	172084740-172089677	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035666, HPA045884	Approved		Approved	Nucleus<br>Vesicles<br>Cell Junctions		Tissue enhanced	Tissue enhanced		adrenal gland: 1.6;cerebral cortex: 5.0	prostate: 0.8	Cell line enhanced		AN3-CA: 103.9
UBR3	DKFZp434P117, FLJ37422, KIAA2024, ZNF650	ENSG00000144357	Ubiquitin protein ligase E3 component n-recognin 3 (putative)	2	169827458-170084131	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035390	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
PHOSPHO2	MGC22679	ENSG00000144362	Phosphatase, orphan 2	2	169694454-169701708	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034726, HPA034727	Uncertain		Approved	Vesicles	Liver cancer:3.82e-6 (unfavourable), Renal cancer:9.53e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
GULP1	CED-6, CED6, GULP	ENSG00000144366	GULP, engulfment adaptor PTB domain containing 1	2	188291669-188595931	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020587	Enhanced		Approved	Vesicles	Renal cancer:4.25e-6 (favourable), Stomach cancer:6.17e-4 (unfavourable)	Mixed	Mixed			epididymis: 99.9	Cell line enhanced		AF22: 114.8;WM-115: 252.9
FAM171B	FLJ34104, KIAA1946	ENSG00000144369	Family with sequence similarity 171 member B	2	186693971-186765965	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010639, HPA013434	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable)	Tissue enriched	Tissue enriched	6	cerebral cortex: 114.5	parathyroid gland: 19.3	Mixed		
HSPD1	GroEL, HSP60, SPG13	ENSG00000144381	Heat shock protein family D (Hsp60) member 1	2	197486581-197516737	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001523, CAB002775, HPA050025, CAB072816	Supported		Enhanced	Mitochondria	Endometrial cancer:1.61e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 834.1	Expressed in all		
CCDC150	FLJ39660	ENSG00000144395	Coiled-coil domain containing 150	2	196639554-196763490	Predicted intracellular proteins	Evidence at protein level	HPA043968, HPA048104	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	9	kidney: 2.6;testis: 8.8	liver: 0.6	Cell line enhanced		SCLC-21H: 5.2
METTL21A	FAM119A, HCA557b, HSPA-KMT, LOC151194	ENSG00000144401	Methyltransferase like 21A	2	207580631-207625928	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034712	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:1.87e-5 (unfavourable), Renal cancer:5.43e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.3	Expressed in all		
UNC80	C2orf21, FLJ33496, KIAA1843, UNC-80	ENSG00000144406	Unc-80 homolog, NALCN activator	2	209771993-209999300	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042472	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2	gallbladder: 1.9	Cell line enhanced		AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4
PTH2R	PTHR2	ENSG00000144407	Parathyroid hormone 2 receptor	2	208359714-208854503	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA010655	Approved					Tissue enhanced	Mixed			bone marrow: 2.9	Group enriched	9	EFO-21: 10.1;HEL: 14.3;HL-60: 3.1;SH-SY5Y: 6.7
CPO		ENSG00000144410	Carboxypeptidase O	2	206939554-206969474	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	14	small intestine: 131.5	epididymis: 9.3	Not detected		
NBEAL1	ALS2CR16, ALS2CR17, MGC164581	ENSG00000144426	Neurobeachin like 1	2	203014879-203226378	Predicted intracellular proteins	Evidence at protein level	HPA049189, HPA049447	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			thyroid gland: 7.7	Mixed		
KANSL1L	C2orf67, FLJ23861, FLJ32349, KIAA1267L, MSL1v2	ENSG00000144445	KAT8 regulatory NSL complex subunit 1 like	2	210021423-210171383	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043102, HPA046790	Uncertain		Approved	Cytosol		Expressed in all	Tissue enriched	13	parathyroid gland: 585.1	testis: 46.0	Expressed in all		
SPAG16	DKFZp666P1710, FLJ22724, PF20, WDR29	ENSG00000144451	Sperm associated antigen 16	2	213284379-214410501	Predicted intracellular proteins	Evidence at protein level	HPA037542	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.82e-4 (favourable), Prostate cancer:4.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 84.3	Mixed		
ABCA12	DKFZP434G232, ICR2B, LI2	ENSG00000144452	ATP binding cassette subfamily A member 12	2	214931542-215138428	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA078239			Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Group enriched	6	breast: 7.7;skin: 25.2	tonsil: 2.5	Group enriched	6	hTCEpi: 28.4;SK-BR-3: 13.8;T-47d: 9.1
SUMF1	FGE, UNQ3037	ENSG00000144455	Sulfatase modifying factor 1	3	3700814-4467281	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA038025	Uncertain				Renal cancer:4.79e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 72.6	Expressed in all		
NYAP2	KIAA1486	ENSG00000144460	Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2	2	225399710-225654018	Predicted intracellular proteins	Evidence at protein level	HPA045531	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Not detected	Tissue enriched	6	cerebral cortex: 1.8	lung: 0.3	Cell line enhanced		SiHa: 2.0
RHBDD1	DKFZp547E052	ENSG00000144468	Rhomboid domain containing 1	2	226835581-226999215	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013972, HPA057125	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 32.2	Mixed		
ACKR3	CMKOR1, CXCR7, GPR159, RDC1	ENSG00000144476	Atypical chemokine receptor 3	2	236567787-236582358	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA032003, HPA049718	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 176.7	Cell line enhanced		RT4: 248.8;SiHa: 100.8;U-2197: 297.4
TRPM8		ENSG00000144481	Transient receptor potential cation channel subfamily M member 8	2	233917398-234019522	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level						Liver cancer:7.15e-4 (favourable)	Tissue enriched	Tissue enriched	8	prostate: 127.3	liver: 16.2	Cell line enhanced		Karpas-707: 3.9;RPTEC TERT1: 6.2;SK-MEL-30: 6.6;WM-115: 5.0
HES6	bHLHb41	ENSG00000144485	Hes family bHLH transcription factor 6	2	238238267-238240662	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061763			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Lung cancer:9.18e-5 (favourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 76.8	fallopian tube: 22.3	Cell line enhanced		NB-4: 122.5;SCLC-21H: 144.1;SK-MEL-30: 141.7
ESPNL	FLJ42568	ENSG00000144488	Espin-like	2	238100157-238133287	Predicted intracellular proteins	Evidence at protein level	HPA055103	Uncertain					Mixed	Mixed			seminal vesicle: 1.2	Cell line enhanced		Daudi: 1.8;HHSteC: 2.1;U-87 MG: 2.0
ANKMY1	FLJ20499, ZMYND13	ENSG00000144504	Ankyrin repeat and MYND domain containing 1	2	240479422-240569209	Predicted intracellular proteins	Evidence at protein level	HPA026620	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Urothelial cancer:3.20e-4 (favourable)	Expressed in all	Group enriched	6	fallopian tube: 39.5;testis: 94.2	parathyroid gland: 11.4	Mixed		
COPS7B	CSN7B	ENSG00000144524	COP9 signalosome subunit 7B	2	231781671-231809254	Predicted intracellular proteins	Evidence at protein level	HPA034675, HPA034676	Uncertain		Supported	Nucleoplasm	Renal cancer:1.50e-6 (unfavourable), Liver cancer:8.37e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
DIS3L2	FAM6A, FLJ36974, MGC42174	ENSG00000144535	DIS3 like 3'-5' exoribonuclease 2	2	231961245-232344350	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035796, HPA035797	Approved				Liver cancer:3.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.4	Expressed in all		
CPNE9	KIAA4217	ENSG00000144550	Copine family member 9	3	9703807-9729908	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 12.6	testis: 2.3	Cell line enhanced		Daudi: 1.6;U-937: 1.6
FANCD2	FA-D2, FACD, FAD, FANCD	ENSG00000144554	Fanconi anemia complementation group D2	3	10026414-10101930	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016117, HPA063742	Approved		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Ovarian cancer:5.00e-5 (unfavourable)	Expressed in all	Mixed			testis: 21.7	Mixed		
TAMM41	C3orf31, DKFZp434E0519, MGC16471	ENSG00000144559	TAM41 mitochondrial translocator assembly and maintenance homolog	3	11790442-11846919	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036834, HPA044861	Uncertain		Approved	Cytosol	Colorectal cancer:1.23e-4 (favourable)	Expressed in all	Mixed			epididymis: 11.8	Expressed in all		
VGLL4	KIAA0121	ENSG00000144560	Vestigial like family member 4	3	11556070-11771350	Predicted intracellular proteins	Evidence at protein level	HPA038225, HPA038614	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.32e-5 (favourable)	Expressed in all	Expressed in all			ovary: 111.1	Expressed in all		
RAB5A	RAB5	ENSG00000144566	RAB5A, member RAS oncogene family	3	19947079-19985175	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004567, HPA049354	Approved					Expressed in all	Expressed in all			parathyroid gland: 79.4	Expressed in all		
FAM134A	C2orf17, MAG-2, MGC3035	ENSG00000144567	Family with sequence similarity 134 member A	2	219176225-219185479	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011170, HPA011844	Approved		Approved	Cytosol	Liver cancer:1.49e-4 (unfavourable), Colorectal cancer:7.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 143.4	Expressed in all		
CTDSP1	NLIIF, SCP1	ENSG00000144579	CTD small phosphatase 1	2	218398256-218405941	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062654			Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 106.8	Expressed in all		
CNOT9	CAF40, CT129, RCD1, RCD1+, RQCD1	ENSG00000144580	CCR4-NOT transcription complex subunit 9	2	218568580-218597080	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046622	Approved				Renal cancer:4.69e-9 (unfavourable), Liver cancer:8.41e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 48.9	Expressed in all		
MARCH4	KIAA1399, MARCH-IV, RNF174	ENSG00000144583	Membrane associated ring-CH-type finger 4	2	216257865-216372027	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014348	Approved					Mixed	Tissue enriched	6	cerebral cortex: 9.1	stomach: 1.6	Cell line enhanced		BJ: 63.3;fHDF/TERT166: 37.3
STK11IP	KIAA1898, LIP1, LKB1IP, STK11IP1	ENSG00000144589	Serine/threonine kinase 11 interacting protein	2	219597860-219616451	Predicted intracellular proteins	Evidence at protein level	HPA036837, HPA036838, HPA053192	Approved		Enhanced	Vesicles	Pancreatic cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
GMPPA		ENSG00000144591	GDP-mannose pyrophosphorylase A	2	219498867-219506989	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035512, HPA035513	Approved		Approved	Nucleoplasm	Renal cancer:1.90e-10 (unfavourable), Liver cancer:1.62e-4 (unfavourable), Stomach cancer:5.24e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 84.1	Expressed in all		
GRIP2	KIAA1719	ENSG00000144596	Glutamate receptor interacting protein 2	3	14489111-14556075	Predicted intracellular proteins	Evidence at transcript level	HPA035673			Approved	Cytosol		Mixed	Tissue enhanced		skeletal muscle: 12.4	heart muscle: 8.6	Cell line enhanced		BJ hTERT+: 2.5;NTERA-2: 2.1;PC-3: 5.7;SCLC-21H: 4.0;U-2 OS: 2.4
EAF1		ENSG00000144597	ELL associated factor 1	3	15427355-15450635	Predicted intracellular proteins	Evidence at protein level	HPA059516, HPA060569, HPA069538	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles<br>Cytokinetic bridge	Lung cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 33.7	Expressed in all		
CNTN4	BIG-2	ENSG00000144619	Contactin 4	3	2098813-3057956	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 48.7	testis: 24.3	Group enriched	6	BEWO: 8.1;CACO-2: 7.6;HEK 293: 5.1;SH-SY5Y: 18.0;WM-115: 5.6
DYNC1LI1	DNCLI1	ENSG00000144635	Dynein cytoplasmic 1 light intermediate chain 1	3	32525971-32570874	Predicted intracellular proteins	Evidence at protein level	HPA035013	Approved		Supported	Centrosome<br>Cytosol	Liver cancer:9.19e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 74.3	Expressed in all		
RBMS3		ENSG00000144642	RNA binding motif single stranded interacting protein 3	3	28574791-30010391	Predicted intracellular proteins	Evidence at protein level	HPA034719	Uncertain		Approved	Vesicles	Renal cancer:1.85e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 28.0	Mixed		
GADL1		ENSG00000144644	Glutamate decarboxylase like 1	3	30726200-30894765	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039160, HPA040229	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		skeletal muscle: 9.0	thyroid gland: 2.5	Cell line enhanced		HAP1: 5.0
OSBPL10		ENSG00000144645	Oxysterol binding protein like 10	3	31657890-32077580	Predicted intracellular proteins	Evidence at protein level	HPA003636			Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.51e-4 (favourable), Pancreatic cancer:3.14e-4 (unfavourable), Urothelial cancer:4.85e-4 (unfavourable)	Mixed	Mixed			testis: 32.1	Cell line enhanced		hTERT-HME1: 61.7;RPTEC TERT1: 64.6
POMGNT2	AGO61, C3orf39, FLJ14566, GTDC2	ENSG00000144647	Protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-)	3	43079232-43106076	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA034870, HPA040989	Uncertain				Renal cancer:4.00e-7 (favourable), Liver cancer:1.26e-5 (unfavourable), Colorectal cancer:8.13e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 35.7	Mixed		
ACKR2	CCBP2, CCR10, CCR9, CMKBR9, D6	ENSG00000144648	Atypical chemokine receptor 2	3	42804752-42887974	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013819, HPA073493	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		placenta: 22.9	adipose tissue: 5.3	Cell line enhanced		BEWO: 50.1;HEL: 15.5;SK-BR-3: 21.0
FAM198A	C3orf41, DKFZP434B172	ENSG00000144649	Family with sequence similarity 198 member A	3	42979267-43060211	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047726	Approved		Supported	Vesicles		Mixed	Mixed			fallopian tube: 15.7	Cell line enhanced		AN3-CA: 3.7;RPMI-8226: 3.0;T-47d: 7.5
CSRNP1	AXUD1, DKFZp566F164, FAM130B, TAIP-3, URAX1	ENSG00000144655	Cysteine and serine rich nuclear protein 1	3	39141855-39154562	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045207, HPA058463			Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.07e-4 (favourable), Stomach cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 123.5	Cell line enhanced		SK-BR-3: 48.5
SLC25A38	FLJ20551	ENSG00000144659	Solute carrier family 25 member 38	3	39383348-39397351	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041027	Approved				Renal cancer:1.58e-5 (favourable), Urothelial cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 65.9	Expressed in all		
ITGA9	ALPHA-RLC, ITGA4L, RLC	ENSG00000144668	Integrin subunit alpha 9	3	37452115-37823514	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030609	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 34.7	Cell line enhanced		CACO-2: 8.3;HEL: 7.3;SH-SY5Y: 12.3;WM-115: 6.1
SLC22A14	OCTL2, ORCTL4	ENSG00000144671	Solute carrier family 22 member 14	3	38282294-38318575	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	20	testis: 13.5	kidney: 0.6	Not detected		
GOLGA4	GCP2, GOLG, golgin-240, p230	ENSG00000144674	Golgin A4	3	37243177-37366751	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035102	Supported		Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Renal cancer:3.62e-6 (favourable)	Expressed in all	Expressed in all			testis: 81.0	Expressed in all		
CTDSPL	C3orf8, HYA22, PSR1, RBSP3, SCP3	ENSG00000144677	CTD small phosphatase like	3	37861960-37984469	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048325	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.22e-14 (favourable)	Expressed in all	Expressed in all			skin: 65.7	Mixed		
STAC	STAC1	ENSG00000144681	SH3 and cysteine rich domain	3	36380344-36548007	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035143	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 23.4;prostate: 21.7	lung: 15.8	Cell line enhanced		fHDF/TERT166: 34.6;HaCaT: 28.9;SH-SY5Y: 48.5;U-87 MG: 45.7
IQSEC1	ARF-GEP100, BRAG2, GEP100, KIAA0763	ENSG00000144711	IQ motif and Sec7 domain 1	3	12897220-13073117	Predicted intracellular proteins	Evidence at protein level	HPA038143, HPA038144	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:3.58e-6 (favourable), Breast cancer:3.03e-5 (unfavourable), Pancreatic cancer:9.07e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 83.3	Cell line enhanced		BEWO: 75.1
CAND2	KIAA0667, TIP120B, Tp120b	ENSG00000144712	Cullin associated and neddylation dissociated 2 (putative)	3	12796472-12871916	Predicted intracellular proteins	Evidence at protein level	HPA005777	Approved		Approved	Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		skeletal muscle: 42.3;testis: 29.3	heart muscle: 16.3	Cell line enhanced		HEK 293: 18.6;REH: 11.8
RPL32	L32	ENSG00000144713	Ribosomal protein L32	3	12834485-12841588	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047501, HPA051994	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 4513.7	Expressed in all		
PTPRG	PTPG, RPTPG	ENSG00000144724	Protein tyrosine phosphatase, receptor type G	3	61561569-62297613	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA064237	Uncertain				Renal cancer:3.10e-6 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 73.5	thyroid gland: 22.8	Mixed		
IL17RD	FLJ35755, IL-17RD, IL17RLM, SEF	ENSG00000144730	Interleukin 17 receptor D	3	57089982-57170306	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039577, HPA043550	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.92e-9 (favourable)	Mixed	Mixed			parathyroid gland: 26.8	Group enriched	7	AF22: 24.6;AN3-CA: 62.9;NTERA-2: 39.0;SH-SY5Y: 108.1
SHQ1	FLJ10539, Shq1p	ENSG00000144736	SHQ1, H/ACA ribonucleoprotein assembly factor	3	72749277-72861914	Predicted intracellular proteins	Evidence at protein level	HPA042792	Uncertain		Supported	Nucleoplasm	Colorectal cancer:2.83e-4 (favourable), Endometrial cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			testis: 18.0	Expressed in all		
SLC25A26		ENSG00000144741	Solute carrier family 25 member 26	3	66133610-66388116	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026887	Enhanced		Supported	Mitochondria	Renal cancer:1.73e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.5	Expressed in all		
UBA3	hUba3, NAE2, UBE1C	ENSG00000144744	Ubiquitin like modifier activating enzyme 3	3	69054730-69080408	Predicted intracellular proteins	Evidence at protein level	HPA034873, HPA034874, HPA065335	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 66.8	Expressed in all		
ARL6IP5	DERP11, GTRAP3-18, HSPC127, JWA, PRAF3, Yip6b	ENSG00000144746	ADP ribosylation factor like GTPase 6 interacting protein 5	3	69084944-69106066	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015540, CAB019321	Supported		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			prostate: 214.1	Expressed in all		
TMF1	ARA160, TMF	ENSG00000144747	TATA element modulatory factor 1	3	69019827-69052303	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008729	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 28.1	Expressed in all		
LRIG1	DKFZP586O1624, LIG-1, LIG1	ENSG00000144749	Leucine rich repeats and immunoglobulin like domains 1	3	66378797-66501263	Predicted membrane proteins	Evidence at protein level	HPA011846	Approved		Approved	Cytosol	Lung cancer:3.01e-5 (favourable), Urothelial cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 59.6	Cell line enhanced		Daudi: 28.6;hTEC/SVTERT24-B: 30.3
LRTM1	HT017	ENSG00000144771	Leucine rich repeats and transmembrane domains 1	3	54918237-54967088	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skeletal muscle: 9.3;spleen: 8.9	esophagus: 4.3	Cell line enhanced		HEL: 1.0
RP11-977G19.10		ENSG00000144785		12	56285916-56316059	Predicted secreted proteins	Evidence at protein level	HPA038466	Uncertain					Not detected	Mixed			cerebral cortex: 7.9	Mixed		
LIMD1		ENSG00000144791	LIM domains containing 1	3	45555394-45686338	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064220			Supported	Nucleus<br>Focal adhesion sites	Renal cancer:6.73e-5 (favourable)	Expressed in all	Expressed in all			lung: 26.6	Expressed in all		
ZNF660	FLJ36870	ENSG00000144792	Zinc finger protein 660	3	44578223-44599694	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029705	Uncertain		Uncertain	Nucleoli fibrillar center<br>Cytosol		Mixed	Mixed			ovary: 3.1	Cell line enhanced		AF22: 3.3;HEL: 3.1;NTERA-2: 5.2;RH-30: 3.3
NFKBIZ	FLJ34463, INAP, MAIL	ENSG00000144802	NFKB inhibitor zeta	3	101827991-101861022	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA010547, HPA075363	Enhanced		Supported	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:4.30e-8 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 268.5	Cell line enhanced		BJ hTERT+: 58.3
COL8A1	C3orf7, MGC9568	ENSG00000144810	Collagen type VIII alpha 1 chain	3	99638475-99799226	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA053107	Enhanced		Supported	Vesicles	Renal cancer:9.39e-8 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 87.4	lung: 56.9	Cell line enhanced		fHDF/TERT166: 930.0;LHCN-M2: 289.1;TIME: 423.8
NXPE3	FAM55C, MGC15606	ENSG00000144815	Neurexophilin and PC-esterase domain family member 3	3	101779202-101827392	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA036259	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.76e-6 (unfavourable)	Mixed	Mixed			parathyroid gland: 34.5	Expressed in all		
ADGRG7	FLJ14454, GPR128	ENSG00000144820	Adhesion G protein-coupled receptor G7	3	100609589-100695479	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	duodenum: 42.8;liver: 12.5;small intestine: 42.9	colon: 5.3	Not detected		
MYH15	KIAA1000	ENSG00000144821	Myosin heavy chain 15	3	108380369-108529322	Predicted intracellular proteins	Evidence at protein level	HPA034871	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria		Not detected	Tissue enhanced		cerebral cortex: 1.9	testis: 0.8	Cell line enhanced		Karpas-707: 1.7;PC-3: 4.7;SH-SY5Y: 1.9;U-87 MG: 1.9
PHLDB2	FLJ21791, LL5b, LL5beta	ENSG00000144824	Pleckstrin homology like domain family B member 2	3	111732497-111976517	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035146, HPA035147	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable)	Expressed in all	Mixed			placenta: 59.0	Mixed		
ABHD10	FLJ11342	ENSG00000144827	Abhydrolase domain containing 10	3	111979010-111993363	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA036991, HPA036992, HPA066081	Supported		Approved	Mitochondria	Renal cancer:4.72e-9 (favourable), Cervical cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 62.1	Expressed in all		
TAGLN3	NP22, NP25	ENSG00000144834	Transgelin 3	3	111998664-112013887	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062620	Enhanced					Tissue enhanced	Tissue enriched	8	cerebral cortex: 356.0	adrenal gland: 42.3	Group enriched	6	AF22: 98.0;RPTEC TERT1: 30.7;SCLC-21H: 63.4;SH-SY5Y: 96.4
PLA1A	ps-PLA1	ENSG00000144837	Phospholipase A1 member A	3	119597842-119629811	Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA059740			Approved	Nuclear speckles	Cervical cancer:2.81e-7 (favourable)	Group enriched	Group enriched	5	epididymis: 164.9;parathyroid gland: 38.9;seminal vesicle: 93.1	liver: 19.6	Cell line enriched	15	SK-MEL-30: 19.7
RABL3	MGC23920	ENSG00000144840	RAB, member of RAS oncogene family like 3	3	120686681-120742993	Predicted intracellular proteins	Evidence at protein level	HPA035150, HPA035151	Uncertain		Approved	Nucleoplasm	Renal cancer:2.79e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.1	Expressed in all		
ADPRH	ARH1	ENSG00000144843	ADP-ribosylarginine hydrolase	3	119579268-119589945	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB001701, HPA036961	Approved		Approved	Nucleus<br>Nuclear membrane	Breast cancer:2.42e-4 (favourable)	Expressed in all	Mixed			lung: 20.1	Cell line enhanced		HDLM-2: 22.2;HMC-1: 16.3;Karpas-707: 18.2;U-266/70: 18.7
IGSF11	BT-IgSF, CT119, Igsf13, MGC35227, VSIG3	ENSG00000144847	Immunoglobulin superfamily member 11	3	118900557-119146068	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046377	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 31.0;testis: 64.9	ovary: 20.1	Cell line enhanced		A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
ATG3	APG3L, DKFZp564M1178, FLJ22125, MGC15201, PC3-96	ENSG00000144848	Autophagy related 3	3	112532509-112562046	Predicted intracellular proteins	Evidence at protein level	CAB037260, HPA040471	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:9.35e-6 (unfavourable), Prostate cancer:1.59e-4 (unfavourable), Cervical cancer:6.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 154.8	Expressed in all		
NR1I2	BXR, ONR1, PAR2, PXR, SXR	ENSG00000144852	Nuclear receptor subfamily 1 group I member 2	3	119780484-119818485	FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029309, HPA055121, HPA073926			Enhanced	Nucleoplasm		Group enriched	Group enriched	10	colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0	stomach: 1.7	Group enriched	7	Hep G2: 9.8;RH-30: 3.3
BOC	CDON2	ENSG00000144857	BOC cell adhesion associated, oncogene regulated	3	113211003-113287459	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025806, HPA060778, HPA061787	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable)	Mixed	Mixed			fallopian tube: 51.7	Cell line enhanced		AN3-CA: 73.4;ASC diff: 77.9;BJ hTERT+: 34.1
SRPRB	APMCF1, SR-beta	ENSG00000144867	SRP receptor beta subunit	3	133784033-133825772	Predicted membrane proteins	Evidence at protein level	HPA011173	Approved		Approved	Plasma membrane	Liver cancer:3.12e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 52.0	Expressed in all		
TMEM108	CT124, MGC3040	ENSG00000144868	Transmembrane protein 108	3	133038391-133397792	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063350	Uncertain		Approved	Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.9;testis: 25.8	adrenal gland: 15.0	Cell line enhanced		HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
AGTR1	AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R	ENSG00000144891	Angiotensin II receptor type 1	3	148697784-148743008	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003596	Enhanced		Uncertain	Vesicles		Group enriched	Tissue enhanced		placenta: 214.0	liver: 50.9	Cell line enhanced		ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
MED12L	KIAA1635, TNRC11L, TRALP, TRALPUSH	ENSG00000144893	Mediator complex subunit 12 like	3	151085697-151437072	Predicted intracellular proteins	Evidence at protein level	HPA036807	Uncertain		Approved	Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 26.6	testis: 8.5	Cell line enhanced		BEWO: 17.8;HEL: 18.7
EIF2A	EIF-2A	ENSG00000144895	Eukaryotic translation initiation factor 2A	3	150546678-150584242	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036256	Approved		Approved	Mitochondria<br>Cytosol	Pancreatic cancer:6.57e-6 (unfavourable), Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 139.1	Expressed in all		
ALDH1L1	10-fTHF, FTHFD	ENSG00000144908	Aldehyde dehydrogenase 1 family member L1	3	126103562-126197994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036900, HPA050139	Enhanced	Supported	Supported	Cytosol	Renal cancer:2.42e-8 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 121.2;liver: 190.4	adipose tissue: 80.9	Cell line enhanced		Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8
OSBPL11	FLJ13012, FLJ13164, ORP-11, ORP11	ENSG00000144909	Oxysterol binding protein like 11	3	125528858-125595090	Predicted intracellular proteins	Evidence at protein level	HPA039144			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			spleen: 22.9	Expressed in all		
TRPC1	HTRP-1	ENSG00000144935	Transient receptor potential cation channel subfamily C member 1	3	142724074-142807888	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB009387, HPA021130	Supported		Approved	Vesicles	Renal cancer:2.72e-5 (unfavourable)	Mixed	Mixed			endometrium: 18.6	Mixed		
NCEH1	AADACL1, KIAA1363, NCEH	ENSG00000144959	Neutral cholesterol ester hydrolase 1	3	172630249-172711218	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026888	Supported		Approved	Endoplasmic reticulum	Pancreatic cancer:8.25e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 35.0	Cell line enhanced		CAPAN-2: 250.8
SPATA16	NYD-SP12	ENSG00000144962	Spermatogenesis associated 16	3	172889358-173141268	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037884	Enhanced					Not detected	Tissue enriched	606	testis: 105.7	kidney: 0.1	Not detected		
FAM86B2		ENSG00000145002	Family with sequence similarity 86 member B2	8	12425614-12436343	Predicted intracellular proteins	Evidence at protein level	HPA041610, HPA055718	Uncertain		Uncertain	Vesicles		Not detected	Tissue enhanced		fallopian tube: 4.3	thyroid gland: 2.3	Cell line enhanced		hTERT-HME1: 5.2;RPMI-8226: 11.6;SCLC-21H: 5.5
LPP		ENSG00000145012	LIM domain containing preferred translocation partner in lipoma	3	188153284-188890671	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011133, HPA017342	Enhanced		Enhanced	Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 117.9	Cell line enhanced		EFO-21: 109.0;U-698: 138.0
TMEM44	DKFZp686O18124	ENSG00000145014	Transmembrane protein 44	3	194587673-194633689	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043718	Uncertain		Approved	Cytosol	Renal cancer:6.55e-13 (unfavourable)	Expressed in all	Mixed			epididymis: 16.7	Mixed		
RUBCN	KIAA0226, rubicon, rundataxin	ENSG00000145016	RUN and cysteine rich domain containing beclin 1 interacting protein	3	197671393-197749727	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050908, HPA054497	Approved		Supported	Vesicles<br>Cytosol	Liver cancer:9.91e-5 (unfavourable), Prostate cancer:1.62e-4 (unfavourable), Colorectal cancer:6.65e-4 (unfavourable)	Expressed in all	Expressed in all			spleen,testis: 24.3	Expressed in all		
AMT	GCST, NKH	ENSG00000145020	Aminomethyltransferase	3	49416775-49422753	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005566	Supported		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.90e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.2	Group enriched	12	BEWO: 14.2;Hep G2: 30.0;NTERA-2: 7.6;SH-SY5Y: 11.8
TCTA		ENSG00000145022	T-cell leukemia translocation altered	3	49412206-49416475	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA007342	Approved		Approved	Cytosol	Renal cancer:5.00e-15 (favourable), Lung cancer:6.76e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 76.2	Expressed in all		
NICN1	MGC12936	ENSG00000145029	Nicolin 1	3	49422946-49429326	Predicted intracellular proteins	Evidence at protein level	HPA058014			Supported	Nucleoplasm	Renal cancer:8.81e-7 (favourable), Pancreatic cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.5	Mixed		
UCN2	SRP, UCN-II, UCNI, URP	ENSG00000145040	Urocortin 2	3	48561727-48563773	Predicted secreted proteins	Evidence at protein level	HPA066841	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enriched	8	skin: 15.5	endometrium: 2.0	Cell line enhanced		hTCEpi: 19.9;hTEC/SVTERT24-B: 21.7;SiHa: 20.5;WM-115: 55.5
DCAF1	KIAA0800, MGC102804, VPRBP	ENSG00000145041	DDB1 and CUL4 associated factor 1	3	51395867-51500002	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036142, HPA052445, HPA053203	Approved		Enhanced	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			testis: 96.8	Expressed in all		
MANF	ARMET, ARP	ENSG00000145050	Mesencephalic astrocyte derived neurotrophic factor	3	51385047-51389397	Predicted secreted proteins	Evidence at protein level	HPA011175	Approved		Supported	Endoplasmic reticulum	Head and neck cancer:9.58e-6 (unfavourable), Liver cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 125.4	Expressed in all		
CCDC39	CILD14, DKFZp434A128, FAP59	ENSG00000145075	Coiled-coil domain containing 39	3	180602858-180871005	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035363, HPA035364	Enhanced					Mixed	Mixed			lymph node: 23.7	Mixed		
STXBP5L	KIAA1006, LLGL4	ENSG00000145087	Syntaxin binding protein 5 like	3	120908072-121424761	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 15.7;ovary: 12.3;thyroid gland: 14.1	seminal vesicle: 4.8	Cell line enhanced		AF22: 6.5;MOLT-4: 5.3;SCLC-21H: 10.6;SH-SY5Y: 4.2
EAF2	BM040, TRAITS, U19	ENSG00000145088	ELL associated factor 2	3	121835183-121886526	Predicted intracellular proteins	Evidence at protein level	HPA008411	Enhanced				Cervical cancer:2.25e-9 (favourable), Endometrial cancer:2.66e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 63.7	bone marrow: 47.8	Cell line enhanced		Daudi: 52.5;HL-60: 90.7;U-698: 63.7;U-937: 50.3
ILDR1	DFNB42, MGC50831	ENSG00000145103	Immunoglobulin like domain containing receptor 1	3	121987323-122022204	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018207	Approved				Renal cancer:5.79e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	cervix, uterine: 20.0	Cell line enhanced		CAPAN-2: 6.5;HDLM-2: 10.3;MCF7: 5.7;RT4: 7.7;T-47d: 6.4;U-266/70: 5.6
TM4SF19		ENSG00000145107	Transmembrane 4 L six family member 19	3	196319342-196338503	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 9.0	esophagus: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 18.9;hTERT-HME1: 24.3;PC-3: 34.0;U-138 MG: 18.7;U-87 MG: 19.9
MUC4		ENSG00000145113	Mucin 4, cell surface associated	3	195746765-195812277	Predicted membrane proteins	Evidence at protein level	HPA005895, CAB013536	Approved					Tissue enhanced	Tissue enhanced		colon: 1.0	esophagus: 0.4	Not detected		
SLIT2	SLIL3, Slit-2	ENSG00000145147	Slit guidance ligand 2	4	20253260-20620561	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB007590, HPA019511, HPA023088	Uncertain				Renal cancer:6.51e-4 (favourable)	Mixed	Mixed			lung: 49.5	Cell line enhanced		BJ hTERT+: 175.8;BJ hTERT+ SV40 Large T+: 96.6;fHDF/TERT166: 96.4;HBF TERT88: 115.2
EIF2B5	EIF-2B, EIF2Bepsilon	ENSG00000145191	Eukaryotic translation initiation factor 2B subunit epsilon	3	184135038-184145311	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015412, HPA064370, HPA069303	Uncertain		Enhanced	Cytosol	Liver cancer:3.38e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.0	Expressed in all		
AHSG	A2HS, FETUA, HSGA	ENSG00000145192	Alpha 2-HS glycoprotein	3	186612923-186621318	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001524, HPA001525, CAB026209	Enhanced		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	1903	liver: 2823.4	testis: 1.4	Cell line enriched	64	Hep G2: 1410.0
ECE2	KIAA0604, MGC2408	ENSG00000145194	Endothelin converting enzyme 2	3	184249650-184293031	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043346, HPA062215	Enhanced		Approved	Nucleus<br>Cytosol	Endometrial cancer:8.41e-5 (unfavourable), Liver cancer:5.80e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 15.4	Expressed in all		
VWA5B2	DKFZp761K032, LOC90113	ENSG00000145198	Von Willebrand factor A domain containing 5B2	3	184230429-184242329	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036823, HPA036824, HPA061412	Enhanced		Approved	Nucleus<br>Golgi apparatus		Mixed	Tissue enriched	10	adrenal gland: 53.4	cerebral cortex: 5.4	Cell line enriched	11	SCLC-21H: 37.2
DGKQ	DAGK, DAGK4, DAGK7	ENSG00000145214	Diacylglycerol kinase theta	4	958887-986895	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026797, CAB033835	Uncertain					Expressed in all	Expressed in all			small intestine: 26.0	Mixed		
FIP1L1	DKFZp586K0717, FIP1	ENSG00000145216	Factor interacting with PAPOLA and CPSF1	4	53377643-53460861	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037475, HPA058202	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.8	Expressed in all		
SLC26A1	EDM4, SAT-1	ENSG00000145217	Solute carrier family 26 member 1	4	979073-993440	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041654	Uncertain		Approved	Microtubules	Renal cancer:1.19e-4 (favourable)	Mixed	Mixed			adrenal gland,kidney: 6.0	Mixed		
LYAR	ZC2HC2, ZLYAR	ENSG00000145220	Ly1 antibody reactive	4	4267701-4290169	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035881	Enhanced		Supported	Nucleus<br>Nucleoli	Renal cancer:4.36e-10 (unfavourable), Liver cancer:3.20e-5 (unfavourable), Ovarian cancer:8.82e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 185.7	lymph node: 27.6	Expressed in all		
CENPC	CENP-C, CENPC1, hcp-4, MIF2	ENSG00000145241	Centromere protein C	4	67468748-67545606	Predicted intracellular proteins	Evidence at protein level	HPA049740, HPA058252			Enhanced	Nuclear bodies	Renal cancer:5.63e-4 (favourable), Lung cancer:9.67e-4 (favourable)	Expressed in all	Mixed			ovary: 6.2	Mixed		
EPHA5	CEK7, EHK1, Hek7, TYRO4	ENSG00000145242	EPH receptor A5	4	65319563-65670495	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	5	cerebral cortex: 18.0	cervix, uterine: 3.3	Cell line enhanced		PC-3: 8.7;TIME: 10.3;U-138 MG: 25.1;U-2197: 14.6;U-251 MG: 17.0
CORIN	ATC2, CRN, Lrp4, PRSC, TMPRSS10	ENSG00000145244	Corin, serine peptidase	4	47593998-47838106	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070941			Approved	Nuclear bodies<br>Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		heart muscle: 38.6	skin: 9.4	Group enriched	6	ASC diff: 7.2;ASC TERT1: 31.6
ATP10D	ATPVD, KIAA1487	ENSG00000145246	ATPase phospholipid transporting 10D (putative)	4	47485288-47593486	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA050808	Approved		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:5.00e-8 (favourable)	Expressed in all	Mixed			parathyroid gland: 22.5	Cell line enhanced		HAP1: 43.0
OCIAD2	MGC45416	ENSG00000145247	OCIA domain containing 2	4	48885019-48906937	Predicted intracellular proteins	Evidence at protein level	HPA040979, HPA041090	Enhanced		Enhanced	Mitochondria	Renal cancer:2.67e-5 (favourable), Urothelial cancer:2.34e-4 (favourable), Ovarian cancer:6.56e-4 (favourable), Pancreatic cancer:6.89e-4 (unfavourable), Endometrial cancer:7.37e-4 (favourable)	Expressed in all	Expressed in all			kidney: 151.5	Cell line enhanced		U-251 MG: 320.9
SLC10A4	MGC29802	ENSG00000145248	Solute carrier family 10 member 4	4	48483343-48489196	Predicted membrane proteins, Transporters	Evidence at protein level	HPA028835	Uncertain	Supported				Tissue enhanced	Tissue enhanced		adrenal gland: 6.2;cerebral cortex: 4.0	cervix, uterine: 1.5	Cell line enhanced		HAP1: 15.2;K-562: 13.9;SH-SY5Y: 41.0
SLC10A6	SOAT	ENSG00000145283	Solute carrier family 10 member 6	4	86823468-86849263	Predicted membrane proteins	Evidence at protein level	HPA016662	Enhanced					Group enriched	Tissue enhanced		esophagus: 11.0;skin: 17.3	adipose tissue: 6.2	Cell line enhanced		BJ: 1.4;BJ hTERT+: 1.0;HaCaT: 1.1
SCD5	ACOD4, FADS4, FLJ21032, HSCD5, SCD4	ENSG00000145284	Stearoyl-CoA desaturase 5	4	82629539-82798857	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042380	Uncertain				Renal cancer:2.32e-5 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 200.6;cerebral cortex: 500.3	epididymis: 117.0	Mixed		
PLAC8	C15, onzin	ENSG00000145287	Placenta specific 8	4	83090048-83137075	Predicted intracellular proteins	Evidence at protein level	HPA040465, HPA077912	Supported		Approved	Cytosol	Cervical cancer:3.03e-4 (favourable)	Mixed	Mixed			bone marrow: 235.8	Cell line enhanced		A-431: 158.5;CAPAN-2: 447.2;HL-60: 259.1;RPMI-8226: 161.8
ENOPH1	E1, MASA, mtnC	ENSG00000145293	Enolase-phosphatase 1	4	82430562-82461091	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004985, HPA044607	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.74e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 98.3	Expressed in all		
CABS1	C4orf35, CLPH, FLJ32897, NYD-SP26	ENSG00000145309	Calcium binding protein, spermatid associated 1	4	70334966-70337116	Predicted intracellular proteins	Evidence at protein level	HPA044016, HPA055352	Enhanced					Not detected	Tissue enriched	601	testis: 151.7	salivary gland: 0.2	Not detected		
GC	DBP, hDBP, VDBP	ENSG00000145321	GC, vitamin D binding protein	4	71741693-71804041	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001526, CAB008596, HPA019855	Supported				Renal cancer:5.81e-5 (unfavourable), Liver cancer:8.08e-4 (favourable)	Tissue enriched	Tissue enriched	5	liver: 3875.6	gallbladder: 712.5	Cell line enhanced		HL-60: 1.4;RH-30: 2.5;SiHa: 1.3
TRMT10A	MGC27034, RG9MTD2, TRM10	ENSG00000145331	TRNA methyltransferase 10A	4	99546709-99564032	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047601, HPA058241	Uncertain		Approved	Nucleoplasm<br>Nucleoli<br>Actin filaments<br>Cytosol	Thyroid cancer:2.14e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.2	Expressed in all		
KLHL8	KIAA1378	ENSG00000145332	Kelch like family member 8	4	87160103-87240314	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013856, HPA017762	Approved		Enhanced	Nucleoplasm	Renal cancer:1.53e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 73.6	Expressed in all		
SNCA	alpha-synuclein, NACP, PARK1, PARK4, PD1	ENSG00000145335	Synuclein alpha	4	89724099-89838315	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005459, CAB010877	Enhanced					Tissue enriched	Group enriched	5	bone marrow: 160.8;cerebral cortex: 459.2	endometrium: 57.1	Cell line enhanced		HEL: 198.4;HUVEC TERT2: 218.9;SK-MEL-30: 203.3;TIME: 246.6
PYURF	PreY	ENSG00000145337	PIGY upstream reading frame	4	88520985-88523813	Predicted intracellular proteins	Evidence at protein level	HPA036455	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			breast: 113.4	Mixed		
TBCK	HSPC302, MGC16169	ENSG00000145348	TBC1 domain containing kinase	4	106041599-106321495	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039951, HPA051611	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:3.20e-4 (favourable)	Expressed in all	Mixed			testis: 16.0	Expressed in all		
CAMK2D	CAMKD	ENSG00000145349	Calcium/calmodulin dependent protein kinase II delta	4	113451032-113761927	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026281, HPA051783, HPA051785, HPA053973	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 110.3	Mixed		
CISD2	ERIS, Miner1, NAF-1, WFS2, ZCD2	ENSG00000145354	CDGSH iron sulfur domain 2	4	102868978-102889242	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015914	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			thyroid gland: 61.9	Expressed in all		
DDIT4L	REDD2, Rtp801L	ENSG00000145358	DNA damage inducible transcript 4 like	4	100185870-100190782	Predicted intracellular proteins	Evidence at protein level	HPA050903			Uncertain	Nucleoplasm<br>Plasma membrane<br>Actin filaments	Endometrial cancer:5.77e-4 (favourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 113.3	cervix, uterine: 33.2	Cell line enhanced		ASC TERT1: 13.5;BJ: 25.0;fHDF/TERT166: 12.5;HSkMC: 10.7;RPTEC TERT1: 15.6
ANK2	LQT4	ENSG00000145362	Ankyrin 2	4	112818109-113383740	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008007, CAB015178, HPA035970	Enhanced		Supported	Plasma membrane	Renal cancer:2.41e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 184.4	kidney: 125.1	Cell line enhanced		RH-30: 60.5;SH-SY5Y: 33.1
TIFA	MGC20791, T2BP, T6BP, TIFAA	ENSG00000145365	TRAF interacting protein with forkhead associated domain	4	112274542-112285903	Predicted intracellular proteins	Evidence at protein level	HPA045889	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 37.6	Expressed in all		
SPATA5	AFG2, SPAF	ENSG00000145375	Spermatogenesis associated 5	4	122923074-123319450	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036450, HPA036451	Approved		Approved	Cytosol		Expressed in all	Mixed			testis: 4.2	Mixed		
FABP2	I-FABP	ENSG00000145384	Fatty acid binding protein 2	4	119317250-119322390	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034607, CAB047325, CAB047326	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Group enriched	Group enriched	12	duodenum: 261.4;small intestine: 554.5	rectum: 33.8	Not detected		
CCNA2	CCN1, CCNA	ENSG00000145386	Cyclin A2	4	121816444-121823933	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000114, HPA020626	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:4.43e-6 (unfavourable), Liver cancer:9.17e-5 (unfavourable), Lung cancer:4.27e-4 (unfavourable), Endometrial cancer:8.78e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 29.3	Expressed in all		
METTL14	KIAA1627	ENSG00000145388	Methyltransferase like 14	4	118685368-118715433	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038002	Supported		Supported	Nucleoplasm	Renal cancer:1.46e-5 (favourable)	Expressed in all	Expressed in all			testis: 23.5	Expressed in all		
USP53	KIAA1350	ENSG00000145390	Ubiquitin specific peptidase 53	4	119212587-119295517	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035844, HPA035845	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.58e-8 (favourable), Colorectal cancer:3.15e-6 (favourable), Prostate cancer:7.54e-6 (unfavourable)	Expressed in all	Mixed			fallopian tube: 48.8	Cell line enhanced		BJ hTERT+: 265.8;SK-MEL-30: 79.9
SETD7	KIAA1717, KMT7, SET7, SET7/9, Set9	ENSG00000145391	SET domain containing lysine methyltransferase 7	4	139495941-139606699	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058111	Approved		Supported	Nucleoli	Breast cancer:8.28e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.7	Mixed		
NAF1		ENSG00000145414	Nuclear assembly factor 1 ribonucleoprotein	4	163110073-163166921	Predicted intracellular proteins	Evidence at protein level	HPA036241, HPA036242, HPA066090	Approved		Enhanced	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 24.4	Expressed in all		
MARCH1	FLJ20668, MARCH-I, RNF171	ENSG00000145416	Membrane associated ring-CH-type finger 1	4	163524298-164384050	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014600	Uncertain		Supported	Mitochondria		Mixed	Mixed			lymph node: 36.0	Mixed		
SFRP2	FRP-2, SARP1, SDF-5	ENSG00000145423	Secreted frizzled related protein 2	4	153780592-153789120	Predicted secreted proteins	Evidence at protein level	HPA002652			Approved	Intermediate filaments	Renal cancer:8.56e-6 (unfavourable), Urothelial cancer:4.39e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 489.6;urinary bladder: 512.1	esophagus: 234.0	Cell line enhanced		AF22: 221.7;ASC diff: 57.2;HSkMC: 100.0;NTERA-2: 312.3
RPS3A	MFTL, S3A	ENSG00000145425	Ribosomal protein S3A	4	151099573-151104652	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047100, HPA053454	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 5260.9	Expressed in all		
RNF175	FLJ34190	ENSG00000145428	Ring finger protein 175	4	153710125-153760235	Predicted membrane proteins	Evidence at protein level	HPA035837	Uncertain				Glioma:4.15e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 13.2	seminal vesicle: 4.1	Cell line enhanced		AF22: 6.9;REH: 5.6;SH-SY5Y: 6.3;THP-1: 10.0;U-87 MG: 3.4
PDGFC	fallotein, SCDGF	ENSG00000145431	Platelet derived growth factor C	4	156760454-156971394	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA009134	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.35e-5 (favourable), Stomach cancer:3.05e-4 (unfavourable), Urothelial cancer:3.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 40.6	endometrium: 16.8	Cell line enhanced		fHDF/TERT166: 47.4;U-138 MG: 41.4
CBR4	FLJ14431, SDR45C1	ENSG00000145439	Carbonyl reductase 4	4	168863770-169010275	Predicted intracellular proteins	Evidence at protein level	HPA037499	Supported				Renal cancer:3.64e-14 (favourable)	Expressed in all	Expressed in all			kidney: 28.7	Expressed in all		
GLRA3		ENSG00000145451	Glycine receptor alpha 3	4	174636914-174829314	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	6	breast: 2.6;cerebral cortex: 9.1	adrenal gland: 1.0	Cell line enhanced		Karpas-707: 1.4
CYP4V2	CYP4AH1	ENSG00000145476	Cytochrome P450 family 4 subfamily V member 2	4	186191520-186213456	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029122	Approved		Approved	Nuclear speckles	Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 65.1	liver: 47.4	Cell line enhanced		SK-MEL-30: 19.3
ROPN1L	ASP, FLJ25776, RSPH11	ENSG00000145491	Rhophilin associated tail protein 1 like	5	10441524-10472029	Predicted intracellular proteins	Evidence at protein level	HPA039193, HPA041830	Enhanced					Group enriched	Tissue enriched	7	testis: 298.1	fallopian tube: 43.4	Cell line enhanced		HMC-1: 2.3;NB-4: 8.4
NDUFS6	CI-13kA	ENSG00000145494	NADH:ubiquinone oxidoreductase subunit S6	5	1801400-1816605	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064221	Supported					Expressed in all	Expressed in all			skeletal muscle: 112.0	Expressed in all		
MARCH6	MARCH-VI, RNF176, TEB4	ENSG00000145495	Membrane associated ring-CH-type finger 6	5	10353703-10440388	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040841, HPA063246	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 96.8	Expressed in all		
NKD2	Naked2	ENSG00000145506	Naked cuticle homolog 2	5	1008829-1038943	Predicted intracellular proteins	Evidence at protein level	HPA049463	Uncertain				Renal cancer:2.66e-5 (unfavourable), Melanoma:9.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 5.5;skin: 3.8	spleen: 2.9	Cell line enhanced		BEWO: 17.2;NB-4: 11.0;RPMI-8226: 29.0
CDH18	CDH14, EY-CADHERIN	ENSG00000145526	Cadherin 18	5	19472951-20575873	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014416	Uncertain					Mixed	Tissue enhanced		adrenal gland: 5.9;cerebral cortex: 19.0	testis: 3.2	Cell line enhanced		EFO-21: 4.1;U-2 OS: 7.1;U-2197: 5.6
ADAMTS16	ADAMTS16s	ENSG00000145536	ADAM metallopeptidase with thrombospondin type 1 motif 16	5	5140330-5320304	Predicted secreted proteins	Evidence at protein level						Renal cancer:3.29e-5 (favourable)	Mixed	Tissue enhanced		gallbladder: 9.9;ovary: 11.2	adipose tissue: 6.3	Cell line enhanced		hTEC/SVTERT24-B: 3.9;U-2197: 5.3
SRD5A1		ENSG00000145545	Steroid 5 alpha-reductase 1	5	6633343-6674386	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA051402	Approved				Endometrial cancer:8.73e-6 (unfavourable)	Expressed in all	Mixed			skin: 16.8	Mixed		
MYO10	KIAA0799	ENSG00000145555	Myosin X	5	16661914-16936276	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015224, HPA024223	Enhanced		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.75e-4 (favourable), Cervical cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 68.3	Mixed		
FAM105A	FLJ11127, NET20	ENSG00000145569	Family with sequence similarity 105 member A	5	14581775-14615007	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046638	Uncertain		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:1.02e-4 (favourable), Testis cancer:7.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 35.5	Cell line enhanced		HMC-1: 87.0;U-937: 38.0
RPL37	L37	ENSG00000145592	Ribosomal protein L37	5	40825262-40835335	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level						Renal cancer:2.67e-6 (unfavourable), Urothelial cancer:6.34e-4 (favourable)	Expressed in all	Expressed in all			breast: 925.8	Expressed in all		
SKP2	FBL1, FBXL1, p45	ENSG00000145604	S-phase kinase associated protein 2	5	36151989-36184319	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB013491, CAB013533, HPA051196, HPA054633	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:4.77e-15 (unfavourable), Melanoma:3.72e-7 (unfavourable), Ovarian cancer:8.57e-4 (favourable)	Expressed in all	Tissue enriched	6	placenta: 84.6	lymph node: 13.7	Expressed in all		
OSMR	OSMRB	ENSG00000145623	Oncostatin M receptor	5	38845858-38945596	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017278	Approved		Approved	Nucleoli	Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 55.1	Mixed		
UGT3A1	FLJ34658	ENSG00000145626	UDP glycosyltransferase family 3 member A1	5	35951010-36001028	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047697, HPA056290	Uncertain		Approved	Vesicles<br>Cytosol		Group enriched	Tissue enhanced		kidney: 53.4;liver: 29.2	duodenum: 9.5	Cell line enriched	51	RH-30: 26.5
PLK2	SNK	ENSG00000145632	Polo like kinase 2	5	58453982-58460260	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009624, HPA069329	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.0	Cell line enhanced		T-47d: 343.8
FAM159B		ENSG00000145642	Family with sequence similarity 159 member B	5	64690308-64718090	Predicted membrane proteins	Evidence at protein level	HPA011778	Enhanced					Tissue enriched	Group enriched	8	pancreas: 1.0;stomach: 3.4	cerebral cortex,duodenum: 0.2	Group enriched	17	NTERA-2: 3.5;RPTEC TERT1: 5.5;SCLC-21H: 1.5
GZMA	CTLA3, HFSP	ENSG00000145649	Granzyme A	5	55102648-55110252	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA054134	Uncertain				Renal cancer:1.26e-6 (unfavourable), Endometrial cancer:6.44e-6 (favourable), Breast cancer:7.27e-4 (favourable)	Expressed in all	Mixed			spleen: 70.9	Cell line enhanced		HL-60: 3.2
PIK3R1	GRB1, p85, p85-ALPHA	ENSG00000145675	Phosphoinositide-3-kinase regulatory subunit 1	5	68215720-68301821	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001216, CAB004268	Approved		Approved	Cytosol	Liver cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 132.9	Expressed in all		
HAPLN1	CRTL1	ENSG00000145681	Hyaluronan and proteoglycan link protein 1	5	83637805-83721613	Predicted secreted proteins	Evidence at protein level	HPA019105, HPA019482, HPA025238	Enhanced	Approved	Supported	Vesicles	Renal cancer:4.81e-9 (unfavourable)	Mixed	Tissue enriched	8	placenta: 103.4	cerebral cortex: 12.8	Group enriched	35	PC-3: 130.7;TIME: 73.5;U-2 OS: 149.3
LHFPL2	KIAA0206	ENSG00000145685	Lipoma HMGIC fusion partner-like 2	5	78485215-78770021	Predicted membrane proteins	Evidence at protein level	HPA042402	Uncertain		Approved	Vesicles<br>Actin filaments	Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 36.4	Mixed		
SSBP2	HSPC116	ENSG00000145687	Single stranded DNA binding protein 2	5	81413021-81751797	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020834, HPA068605	Approved		Supported	Nucleoplasm		Mixed	Expressed in all			parathyroid gland: 76.2	Cell line enhanced		REH: 178.5
BHMT	BHMT1	ENSG00000145692	Betaine--homocysteine S-methyltransferase	5	79111779-79132290	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038285, HPA058310	Enhanced		Supported	Cytosol	Liver cancer:7.32e-4 (favourable)	Tissue enhanced	Group enriched	225	kidney: 788.8;liver: 563.6	urinary bladder: 3.0	Cell line enhanced		Hep G2: 2.4;NTERA-2: 1.4;SCLC-21H: 1.1
ANKRD31	FLJ40191	ENSG00000145700	Ankyrin repeat domain 31	5	75068275-75236878	Predicted intracellular proteins	Evidence at protein level	HPA057566	Enhanced					Not detected	Tissue enriched	12	testis: 9.9	esophagus: 0.8	Not detected		
IQGAP2		ENSG00000145703	IQ motif containing GTPase activating protein 2	5	76403249-76708132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004241, HPA037403, HPA037404	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:9.44e-12 (favourable), Liver cancer:5.65e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 126.8	testis: 92.1	Cell line enhanced		CACO-2: 61.1;HMC-1: 186.1;RPMI-8226: 56.3
CRHBP	CRF-BP, CRFBP	ENSG00000145708	Corticotropin releasing hormone binding protein	5	76952713-76981158	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046120	Approved					Tissue enhanced	Tissue enhanced		liver: 69.9;spleen: 42.2	kidney: 30.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 3.2;BJ hTERT+ SV40 Large T+ RasG12V: 3.3;HBF TERT88: 6.0;U-698: 4.8;U-87 MG: 3.6;WM-115: 3.2
RASA1	CM-AVM, GAP, p120, p120GAP, p120RASGAP, RASA	ENSG00000145715	RAS p21 protein activator 1	5	87267888-87391931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB007789, HPA036393, HPA064556	Enhanced					Expressed in all	Expressed in all			placenta: 136.4	Expressed in all		
LIX1	C5orf11, Lft	ENSG00000145721	Limb and CNS expressed 1	5	97091867-97142872	Predicted intracellular proteins	Evidence at transcript level	HPA058426	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:2.48e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	cerebral cortex: 32.8	seminal vesicle: 5.7	Cell line enriched	9	RPTEC TERT1: 24.5
GIN1	FLJ20125, GIN-1, TGIN1, ZH2C2	ENSG00000145723	Gypsy retrotransposon integrase 1	5	103086000-103120151	Predicted intracellular proteins	Evidence at protein level	HPA037402, HPA061362	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:1.63e-4 (favourable)	Expressed in all	Mixed			testis: 8.3	Expressed in all		
PPIP5K2	CFAP160, HISPPD1, KIAA0433, VIP2	ENSG00000145725	Diphosphoinositol pentakisphosphate kinase 2	5	103120149-103212799	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037895, HPA038442	Approved		Approved	Vesicles	Thyroid cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.3	Expressed in all		
PAM	PAL, PHM	ENSG00000145730	Peptidylglycine alpha-amidating monooxygenase	5	102753981-103031105	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB026119, HPA042260	Enhanced		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 947.8	Cell line enhanced		fHDF/TERT166: 553.5
BDP1	HSA238520, KIAA1241, KIAA1689, TAF3B1, TFC5, TFIIIB150, TFIIIB90, TFNR	ENSG00000145734	B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB	5	71455615-71567820	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Mixed			thyroid gland: 1.6	Cell line enhanced		TIME: 6.5
GTF2H2	BTF2, BTF2P44, p44, T-BTF2P44, TFIIH	ENSG00000145736	General transcription factor IIH subunit 2	5	71032670-71067689	Predicted intracellular proteins	Evidence at protein level	HPA047001			Supported	Nuclear speckles		Mixed	Mixed			smooth muscle: 7.6	Mixed		
SLC30A5	FLJ12496, FLJ12756, MGC5499, ZnT-5, ZNT5, ZNTL1, ZTL1	ENSG00000145740	Solute carrier family 30 member 5	5	69093646-69131069	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035373	Approved		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 61.7	Expressed in all		
BTF3	BTF3a, BTF3b, NACB	ENSG00000145741	Basic transcription factor 3	5	73498408-73505635	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013007, HPA056420	Approved		Supported	Cytosol		Expressed in all	Expressed in all			ovary: 1442.8	Expressed in all		
FBXL17	DKFZP434C1715, Fbl17, Fbx13, FBXO13	ENSG00000145743	F-box and leucine rich repeat protein 17	5	107859035-108382098	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036410, HPA036411	Uncertain		Approved	Nucleus	Renal cancer:4.60e-8 (favourable), Thyroid cancer:3.27e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
SPATA9	FLJ35906, NYD-SP16	ENSG00000145757	Spermatogenesis associated 9	5	95652181-95698711	Predicted membrane proteins	Evidence at protein level	HPA010848	Uncertain		Approved	Mitochondria		Not detected	Tissue enriched	39	testis: 53.6	adipose tissue: 1.3	Not detected		
TSLP		ENSG00000145777	Thymic stromal lymphopoietin	5	111070062-111078024	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		gallbladder: 15.0	prostate: 10.4	Cell line enhanced		ASC TERT1: 10.5;HHSteC: 14.4;hTEC/SVTERT24-B: 22.1;hTERT-HME1: 9.6;U-87 MG: 13.8
TNFAIP8	GG2-1, MDC-3.13, SCC-S2	ENSG00000145779	TNF alpha induced protein 8	5	119268692-119399688	Predicted intracellular proteins	Evidence at protein level	HPA054434, HPA057089	Uncertain		Approved	Nucleoplasm	Breast cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 134.4	Expressed in all		
FEM1C	EUROIMAGE686608, EUROIMAGE783647, FEM1A, KIAA1785	ENSG00000145780	Fem-1 homolog C	5	115520908-115544894	Predicted intracellular proteins	Evidence at protein level	HPA059919, HPA060977	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-4 (unfavourable), Colorectal cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.2	Expressed in all		
COMMD10	PTD002	ENSG00000145781	COMM domain containing 10	5	116084991-116412762	Predicted intracellular proteins	Evidence at protein level	HPA045441, HPA075641	Approved		Uncertain	Plasma membrane<br>Cytosol	Stomach cancer:2.99e-4 (unfavourable), Thyroid cancer:6.93e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 46.8	Expressed in all		
ATG12	APG12, APG12L	ENSG00000145782	Autophagy related 12	5	115828200-115841858	Predicted intracellular proteins	Evidence at protein level	CAB013272	Uncertain				Renal cancer:1.54e-7 (unfavourable), Liver cancer:1.36e-4 (unfavourable), Thyroid cancer:4.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.1	Expressed in all		
MEGF10	KIAA1780	ENSG00000145794	Multiple EGF like domains 10	5	127290831-127465737	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 15.8	adrenal gland: 2.2	Cell line enhanced		AF22: 31.3;RH-30: 37.5
ADAMTS19		ENSG00000145808	ADAM metallopeptidase with thrombospondin type 1 motif 19	5	129460265-129738683	Predicted secreted proteins	Evidence at transcript level	HPA056171, HPA058438	Uncertain		Approved	Vesicles<br>Midbody		Tissue enhanced	Group enriched	13	cervix, uterine: 16.8;endometrium: 16.9;placenta: 5.4;smooth muscle: 9.2	adrenal gland: 0.9	Group enriched	7	MCF7: 12.3;SH-SY5Y: 37.6
YIPF5	FinGER5, SMAP-5	ENSG00000145817	Yip1 domain family member 5	5	144158159-144170714	Predicted membrane proteins	Evidence at protein level	HPA042338, HPA073622	Enhanced		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles	Head and neck cancer:1.12e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable), Breast cancer:7.83e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 43.2	Expressed in all		
ARHGAP26	GRAF, KIAA0621, OPHN1L, OPHN1L1	ENSG00000145819	Rho GTPase activating protein 26	5	142770384-143229011	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035106, HPA035107	Enhanced		Approved	Cytosol	Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		Karpas-707: 61.5
CXCL14	BMAC, bolekine, BRAK, Kec, KS1, MIP-2g, NJAC, SCYB14	ENSG00000145824	C-X-C motif chemokine ligand 14	5	135570679-135579279	Predicted secreted proteins	Evidence at protein level	CAB029996	Uncertain				Cervical cancer:1.71e-4 (favourable), Colorectal cancer:4.52e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 874.5	kidney: 335.8	Group enriched	12	HAP1: 60.3;hTCEpi: 55.4;RPTEC TERT1: 157.5;U-2 OS: 88.6
LECT2	chm-II, chm2	ENSG00000145826	Leukocyte cell derived chemotaxin 2	5	135922279-135955034	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043883	Enhanced				Liver cancer:4.16e-5 (favourable)	Tissue enriched	Tissue enriched	16	liver: 230.9	testis: 14.6	Mixed		
SLC25A48	FLJ44862, HDMCP	ENSG00000145832	Solute carrier family 25 member 48	5	135834649-135888637	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014674	Uncertain		Approved	Intermediate filaments<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 17.7;kidney: 7.3	skeletal muscle: 2.7	Cell line enhanced		HAP1: 2.4;HEK 293: 1.6;SCLC-21H: 2.0;U-2 OS: 2.3
DDX46	FLJ25329, KIAA0801, Prp5, PRPF5	ENSG00000145833	DEAD-box helicase 46	5	134758771-134855133	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036554, HPA057501	Supported		Enhanced	Nuclear speckles	Colorectal cancer:9.01e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
IL9	HP40, IL-9, P40	ENSG00000145839	Interleukin 9	5	135892246-135895827	Cancer-related genes, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.7	skin: 0.5	Cell line enriched	235	HDLM-2: 41.4
TIMD4		ENSG00000145850	T-cell immunoglobulin and mucin domain containing 4	5	156919282-156963255	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015625, CAB026027	Approved				Renal cancer:3.37e-4 (favourable)	Tissue enriched	Group enriched	6	lymph node: 63.6;testis: 163.0	adipose tissue: 17.9	Group enriched	16	U-266/70: 73.7;U-266/84: 19.8
RNF145	FLJ31951	ENSG00000145860	Ring finger protein 145	5	159157409-159210053	Predicted membrane proteins	Evidence at protein level	HPA036562	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.64e-6 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Expressed in all		
C1QTNF2	CTRP2	ENSG00000145861	C1q and tumor necrosis factor related protein 2	5	160347751-160370641	Predicted secreted proteins	Evidence at protein level	HPA061290	Approved		Approved	Golgi apparatus<br>Centrosome		Mixed	Mixed			cervix, uterine: 4.5	Cell line enhanced		RH-30: 33.1;U-138 MG: 14.8;U-2 OS: 8.6
GABRA6		ENSG00000145863	Gamma-aminobutyric acid type A receptor alpha6 subunit	5	161547063-161702593	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	CAB022462	Approved					Not detected	Tissue enhanced		testis: 1.1	cerebral cortex: 0.3	Not detected		
GABRB2		ENSG00000145864	Gamma-aminobutyric acid type A receptor beta2 subunit	5	161288429-161549044	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001964, HPA067632	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 62.8	epididymis: 5.2	Cell line enriched	17	SCLC-21H: 27.6
FBXO38	Fbx38, FLJ13962, MOKA, SP329	ENSG00000145868	F-box protein 38	5	148383935-148442836	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034821, HPA041444	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 30.8	Expressed in all		
SPINK7	ECG2, ECRG2	ENSG00000145879	Serine peptidase inhibitor, Kazal type 7 (putative)	5	148312419-148315922	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036294	Enhanced					Group enriched	Group enriched	25	esophagus: 416.8;tonsil: 106.3	cervix, uterine: 10.5	Not detected		
PCYOX1L	MGC3265	ENSG00000145882	Prenylcysteine oxidase 1 like	5	149358007-149369653	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037463, HPA038402	Approved		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enhanced		parathyroid gland: 21.4	cerebral cortex: 12.5	Mixed		
GLRA1	STHE	ENSG00000145888	Glycine receptor alpha 1	5	151822513-151924842	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016502, CAB079042	Uncertain	Supported				Not detected	Not detected			adrenal gland: 0.4	Not detected		
TNIP1	ABIN-1, KIAA0113, NAF1, VAN	ENSG00000145901	TNFAIP3 interacting protein 1	5	151029945-151093577	Predicted intracellular proteins	Evidence at protein level	HPA037893, HPA037894, HPA071950	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:6.86e-5 (favourable), Breast cancer:5.69e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 132.2	Expressed in all		
G3BP1	G3BP, HDH-VIII	ENSG00000145907	G3BP stress granule assembly factor 1	5	151771045-151812785	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004052, CAB037068	Supported		Enhanced	Cytosol	Renal cancer:3.33e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 91.0	Expressed in all		
ZNF300		ENSG00000145908	Zinc finger protein 300	5	150894392-150904983	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028975, HPA051777	Uncertain		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			ovary: 12.4	Mixed		
N4BP3	LZTS4	ENSG00000145911	NEDD4 binding protein 3	5	178113443-178126087	Predicted intracellular proteins	Evidence at protein level	HPA030972, HPA030973, HPA061387	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:2.38e-4 (favourable)	Mixed	Tissue enhanced		placenta: 11.8	parathyroid gland: 10.2	Cell line enhanced		MCF7: 15.8;RH-30: 19.3;SK-BR-3: 53.2
NHP2	FLJ20479, NOLA2	ENSG00000145912	NHP2 ribonucleoprotein	5	178149460-178153967	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA044171, HPA050400	Enhanced		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.97e-4 (unfavourable), Liver cancer:5.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.9	Expressed in all		
RMND5B	FLJ22318, GID2, GID2B	ENSG00000145916	Required for meiotic nuclear division 5 homolog B	5	178130996-178150565	Predicted intracellular proteins	Evidence at protein level	HPA047778	Uncertain		Approved	Nucleoplasm	Renal cancer:7.22e-8 (favourable), Pancreatic cancer:7.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 94.7	Expressed in all		
BOD1	FAM44B	ENSG00000145919	Biorientation of chromosomes in cell division 1	5	173607514-173616660	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036293	Uncertain				Liver cancer:2.49e-6 (unfavourable), Head and neck cancer:2.02e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.5	Expressed in all		
CPLX2	CPX-2, DKFZp547D155	ENSG00000145920	Complexin 2	5	175796310-175884020	Predicted intracellular proteins	Evidence at protein level	HPA071191			Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 236.4;epididymis: 145.5	adrenal gland: 44.3	Group enriched	19	A549: 549.3;Hep G2: 253.5;SCLC-21H: 296.3
TENM2	KIAA1127, ODZ2, Ten-M2	ENSG00000145934	Teneurin transmembrane protein 2	5	167284799-168264157	Predicted membrane proteins	Evidence at protein level	HPA038018, HPA038420, HPA068691	Uncertain		Approved	Nucleoli	Urothelial cancer:7.52e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 9.0;heart muscle: 17.1	prostate: 3.6	Cell line enhanced		fHDF/TERT166: 51.2;HBEC3-KT: 30.8;HDLM-2: 40.1;U-138 MG: 73.5;U-2 OS: 67.5;U-251 MG: 41.3
KCNMB1	hslo-beta	ENSG00000145936	Potassium calcium-activated channel subfamily M regulatory beta subunit 1	5	170374671-170389677	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:4.13e-6 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 64.2;smooth muscle: 69.7	endometrium: 42.0	Cell line enhanced		REH: 7.4;U-937: 2.6
FAM50B	D6S2654E, X5L	ENSG00000145945	Family with sequence similarity 50 member B	6	3849386-3851317	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064111, HPA067817	Approved		Enhanced	Nucleoplasm<br>Cytokinetic bridge	Renal cancer:4.01e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.0	Cell line enhanced		HDLM-2: 81.7
MYLK4	SgK085	ENSG00000145949	Myosin light chain kinase family member 4	6	2663629-2750966	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA015860	Uncertain					Mixed	Tissue enhanced		skeletal muscle: 9.8	kidney: 3.1	Cell line enriched	7	HEL: 6.4
FAM217A	C6orf146, MGC43581	ENSG00000145975	Family with sequence similarity 217 member A	6	4049434-4087344	Predicted intracellular proteins	Evidence at transcript level	HPA035455	Uncertain					Not detected	Tissue enriched	33	testis: 22.8	epididymis: 0.6	Not detected		
TBC1D7	dJ257A7.3, FLJ32666	ENSG00000145979	TBC1 domain family member 7	6	13266542-13328583	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034748	Approved				Renal cancer:2.03e-7 (unfavourable), Ovarian cancer:4.98e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 24.4	Expressed in all		
FARS2	dJ236A3.1, FARS1	ENSG00000145982	Phenylalanyl-tRNA synthetase 2, mitochondrial	6	5261044-5771580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018148, HPA028836	Approved		Approved	Plasma membrane	Renal cancer:1.24e-6 (favourable), Colorectal cancer:5.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 24.5	Expressed in all		
GFOD1	ADG-90, C6orf114, FLJ20330	ENSG00000145990	Glucose-fructose oxidoreductase domain containing 1	6	13357830-13487662	Predicted intracellular proteins	Evidence at protein level	HPA029096	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.29e-5 (unfavourable), Renal cancer:6.72e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 22.3	Cell line enhanced		HEL: 28.5;HMC-1: 41.5
CDKAL1	FLJ20342	ENSG00000145996	CDK5 regulatory subunit associated protein 1 like 1	6	20534457-21232404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057474			Uncertain	Vesicles	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 16.0	Cell line enriched	6	SCLC-21H: 222.3
PSD2	DKFZp761B0514, EFA6C	ENSG00000146005	Pleckstrin and Sec7 domain containing 2	5	139795821-139844466	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	29	cerebral cortex: 58.5	epididymis: 2.0	Cell line enhanced		SH-SY5Y: 1.0
LRRTM2	KIAA0416	ENSG00000146006	Leucine rich repeat transmembrane neuronal 2	5	138868923-138875368	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	cerebral cortex: 29.0	placenta: 3.0	Group enriched	7	HDLM-2: 14.6;SCLC-21H: 5.8
ZMAT2	FLJ31121, hSNU23, Snu23	ENSG00000146007	Zinc finger matrin-type 2	5	140698680-140706676	Predicted intracellular proteins	Evidence at protein level	HPA036518	Approved		Approved	Nucleus<br>Mitochondria	Colorectal cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 103.3	Expressed in all		
GFRA3	GFRa-3	ENSG00000146013	GDNF family receptor alpha 3	5	138252379-138274671	Predicted membrane proteins	Evidence at protein level	HPA020731	Approved		Uncertain	Plasma membrane<br>Cytosol		Mixed	Mixed			seminal vesicle: 8.1	Cell line enriched	21	SH-SY5Y: 33.1
KLHL3	KIAA1129	ENSG00000146021	Kelch like family member 3	5	137617500-137736090	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051291	Approved					Mixed	Mixed			thyroid gland: 13.7	Cell line enhanced		TIME: 10.9;U-266/70: 6.0
DCDC2	DCDC2A, DFNB66, KIAA1154, NPHP19, RU2	ENSG00000146038	Doublecortin domain containing 2	6	24171756-24358052	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031582, HPA031583, HPA031584	Enhanced		Enhanced	Microtubules<br>Mitotic spindle<br>Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		kidney: 23.2	parathyroid gland: 15.3	Group enriched	8	CACO-2: 59.2;EFO-21: 45.6;Hep G2: 55.9;RPTEC TERT1: 193.3
SLC17A4	KIAA2138	ENSG00000146039	Solute carrier family 17 member 4	6	25754699-25781191	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA055564	Approved					Group enriched	Group enriched	6	colon: 20.4;duodenum: 28.6;gallbladder: 25.4;liver: 22.3;rectum: 28.9;small intestine: 35.0	pancreas: 4.2	Cell line enriched	5	RPTEC TERT1: 1.1
HIST1H2BA	bA317E16.3, H2BFU, STBP, TSH2B	ENSG00000146047	Histone cluster 1 H2B family member a	6	25726777-25727292	Predicted intracellular proteins	Evidence at protein level	CAB011603, HPA042205, HPA043013	Enhanced					Tissue enriched	Tissue enriched	112	testis: 11.1	all non-specific tissues: 0.0	Not detected		
KAAG1	RU2, RU2AS	ENSG00000146049	Kidney associated antigen 1	6	24356903-24358284	Predicted intracellular proteins	Evidence at transcript level	HPA036021	Approved					Mixed	Not detected			thyroid gland: 0.5	Group enriched	6	CACO-2: 4.4;EFO-21: 3.9;HEK 293: 1.0;Hep G2: 3.6
TRIM7	GNIP, RNF90	ENSG00000146054	Tripartite motif containing 7	5	181193924-181205293	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039213	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Group enriched	5	skeletal muscle: 67.7;skin: 22.1	esophagus: 8.6	Cell line enhanced		HDLM-2: 34.1;PC-3: 18.2
TRIM41	MGC1127, RINCK	ENSG00000146063	Tripartite motif containing 41	5	181222499-181235809	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024204	Approved		Supported	Nucleoli<br>Nuclear bodies	Thyroid cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
HIGD2A	MGC2198, RCF1B	ENSG00000146066	HIG1 hypoxia inducible domain family member 2A	5	176388747-176389771	Predicted membrane proteins	Evidence at protein level	HPA042715	Uncertain		Supported	Mitochondria<br>Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 170.9	Expressed in all		
FAM193B	FLJ10404, IRIZIO, KIAA1931	ENSG00000146067	Family with sequence similarity 193 member B	5	177519788-177554541	Predicted intracellular proteins	Evidence at protein level	HPA035848, HPA058112	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:3.71e-8 (unfavourable), Urothelial cancer:1.30e-5 (favourable)	Expressed in all	Expressed in all			skin: 60.2	Expressed in all		
PLA2G7	LDL-PLA2, PAFAH	ENSG00000146070	Phospholipase A2 group VII	6	46704201-46735693	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035916			Uncertain	Vesicles		Expressed in all	Mixed			spleen: 37.5	Cell line enhanced		NTERA-2: 1.7;PC-3: 3.2;RT4: 1.3;U-2 OS: 1.7
TNFRSF21	CD358, DR6	ENSG00000146072	TNF receptor superfamily member 21	6	47231532-47309905	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006746, CAB009805	Approved				Renal cancer:7.23e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 105.2	Cell line enhanced		RT4: 416.8
RNF44	KIAA1100	ENSG00000146083	Ring finger protein 44	5	176526697-176538025	Predicted intracellular proteins	Evidence at protein level	HPA038981	Uncertain		Approved	Nucleoplasm	Endometrial cancer:2.57e-7 (unfavourable), Liver cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 50.1	Expressed in all		
MUT		ENSG00000146085	Methylmalonyl-CoA mutase	6	49430360-49463191	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035971, HPA035972	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:8.71e-13 (favourable)	Expressed in all	Expressed in all			liver: 104.1	Expressed in all		
RASGEF1C	FLJ35841	ENSG00000146090	RasGEF domain family member 1C	5	180100791-180209153	Predicted intracellular proteins	Evidence at transcript level	HPA028242	Uncertain		Approved	Mitochondria		Tissue enhanced	Group enriched	8	cerebral cortex: 16.4;testis: 6.1	seminal vesicle: 1.3	Cell line enhanced		BEWO: 2.2;MCF7: 1.9;SCLC-21H: 9.1;U-2 OS: 2.5
DOK3	FLJ22570	ENSG00000146094	Docking protein 3	5	177501907-177511274	Predicted intracellular proteins	Evidence at protein level	HPA077312	Enhanced				Renal cancer:3.82e-11 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 92.0	spleen: 63.6	Cell line enhanced		Daudi: 120.7;HMC-1: 116.5;REH: 193.3;U-698: 118.3
ABT1		ENSG00000146109	Activator of basal transcription 1	6	26596952-26600744	Predicted intracellular proteins	Evidence at protein level	HPA077039			Approved	Vesicles	Ovarian cancer:1.89e-4 (favourable), Urothelial cancer:3.80e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 17.9	Expressed in all		
PPP1R18	KIAA1949, phostensin	ENSG00000146112	Protein phosphatase 1 regulatory subunit 18	6	30676389-30687895	Predicted intracellular proteins	Evidence at protein level	HPA044745, HPA051000	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:1.11e-16 (unfavourable), Colorectal cancer:4.71e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 53.3	spleen: 35.1	Mixed		
DAAM2	KIAA0381	ENSG00000146122	Dishevelled associated activator of morphogenesis 2	6	39792298-39904877	Predicted intracellular proteins	Evidence at protein level	HPA051300, HPA054630	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.8	Cell line enhanced		HSkMC: 39.9;LHCN-M2: 46.3;SK-MEL-30: 54.3;WM-115: 26.5
PRIM2	PRIM2A	ENSG00000146143	Primase (DNA) subunit 2	6	57314805-57646849	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046566			Supported	Nucleoplasm	Renal cancer:7.34e-6 (unfavourable), Ovarian cancer:3.00e-5 (favourable), Liver cancer:3.44e-5 (unfavourable), Pancreatic cancer:5.25e-4 (unfavourable), Endometrial cancer:6.98e-4 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 51.6	testis: 11.5	Expressed in all		
MLIP	C6orf142, CIP, MGC18257	ENSG00000146147	Muscular LMNA interacting protein	6	53929982-54266280	Predicted intracellular proteins	Evidence at protein level	HPA029252, HPA046654	Approved		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		heart muscle: 112.5;liver: 67.0;skeletal muscle: 45.7	skin: 20.6	Group enriched	7	HUVEC TERT2: 16.4;SK-MEL-30: 14.9
HMGCLL1	bA418P12.1, DKFZP434G1411	ENSG00000146151	3-hydroxymethyl-3-methylglutaryl-CoA lyase like 1	6	55434369-55579214	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 14.5;placenta: 9.0	prostate: 5.2	Cell line enriched	11	SCLC-21H: 7.1
LGSN	GLULD1, LGS	ENSG00000146166	Lengsin, lens protein with glutamine synthetase domain	6	63275951-63319977	Predicted intracellular proteins	Evidence at protein level	HPA030957, HPA039983	Enhanced		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enhanced		kidney: 2.8;liver: 2.4;placenta: 1.8	testis: 0.7	Cell line enhanced		A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
FGD2	ZFYVE4	ENSG00000146192	FYVE, RhoGEF and PH domain containing 2	6	37005646-37029070	Predicted intracellular proteins	Evidence at protein level	HPA029145, HPA049692	Approved					Mixed	Tissue enhanced		spleen: 42.4	lymph node: 25.0	Group enriched	6	CAPAN-2: 2.4;Daudi: 8.2;HDLM-2: 10.5;U-698: 6.3
SCUBE3	CEGF3, FLJ34743	ENSG00000146197	Signal peptide, CUB domain and EGF like domain containing 3	6	35214419-35253079	Predicted secreted proteins	Evidence at protein level	HPA040606	Uncertain		Supported	Plasma membrane	Thyroid cancer:1.38e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	thyroid gland: 49.4	seminal vesicle: 6.8	Cell line enhanced		AF22: 27.2;ASC diff: 56.0;ASC TERT1: 76.2;HSkMC: 37.2;hTEC/SVTERT24-B: 32.0;U-138 MG: 30.4;WM-115: 26.3
ANO7	IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G	ENSG00000146205	Anoctamin 7	2	241188509-241225377	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035730	Uncertain					Tissue enriched	Tissue enhanced		prostate: 100.6;stomach: 26.0	small intestine: 15.4	Cell line enhanced		BEWO: 2.1;Hep G2: 1.5
CRIP3	bA480N24.2, TLP, TLP-A	ENSG00000146215	Cysteine rich protein 3	6	43299710-43308797	Predicted intracellular proteins	Evidence at protein level	HPA036198	Uncertain		Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		heart muscle: 15.9;testis: 15.5	seminal vesicle: 11.8	Cell line enhanced		HAP1: 2.9;HEK 293: 3.1;HeLa: 2.4;Hep G2: 4.5;NTERA-2: 5.8;RPMI-8226: 3.4
TTBK1	KIAA1855	ENSG00000146216	Tau tubulin kinase 1	6	43243680-43288259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031735, HPA031736	Enhanced		Supported	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 18.9	small intestine: 3.1	Group enriched	13	SCLC-21H: 24.9;SH-SY5Y: 8.7
TCTE1	D6S46, DRC5, FAP155, MGC33600	ENSG00000146221	T-complex-associated-testis-expressed 1	6	44278743-44297688	Predicted intracellular proteins	Evidence at transcript level	HPA031739			Uncertain	Vesicles		Tissue enhanced	Group enriched	13	fallopian tube: 23.1;testis: 35.3	lung: 2.2	Cell line enhanced		SCLC-21H: 1.0
RPL7L1	dJ475N16.4	ENSG00000146223	Ribosomal protein L7 like 1	6	42879618-42889925	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046049, HPA050478			Approved	Nucleoli<br>Mitochondria	Liver cancer:8.53e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 71.5	Expressed in all		
NFKBIE	IKBE	ENSG00000146232	NFKB inhibitor epsilon	6	44258166-44265788	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002692, HPA005941, CAB010272	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.37e-6 (unfavourable), Breast cancer:1.72e-5 (favourable), Liver cancer:3.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Mixed			spleen: 26.1	Expressed in all		
CYP39A1		ENSG00000146233	Cytochrome P450 family 39 subfamily A member 1	6	46549580-46652830	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.86e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 56.8	epididymis: 28.9	Cell line enhanced		hTCEpi: 11.0;SiHa: 9.9;U-698: 7.7
TPBG	5T4, 5T4-AG	ENSG00000146242	Trophoblast glycoprotein	6	82363206-82370828	Predicted membrane proteins	Evidence at protein level	HPA010554	Enhanced		Approved	Nucleoplasm	Colorectal cancer:6.68e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.4	Cell line enhanced		hTEC/SVTERT24-B: 64.9
IRAK1BP1	AIP70, SIMPL	ENSG00000146243	Interleukin 1 receptor associated kinase 1 binding protein 1	6	78867472-78946440	Predicted intracellular proteins	Evidence at protein level	HPA035742, HPA035743	Uncertain		Approved	Vesicles		Mixed	Tissue enriched	8	bone marrow: 59.8	testis,thyroid gland: 7.0	Mixed		
PHIP	BRWD2, DCAF14, FLJ20705, ndrp, WDR11	ENSG00000146247	Pleckstrin homology domain interacting protein	6	78935867-79078236	Predicted intracellular proteins	Evidence at protein level	HPA019140, HPA019838	Approved		Supported	Nucleoplasm	Renal cancer:1.71e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
PRSS35	C6orf158, dJ223E3.1, MGC46520	ENSG00000146250	Protease, serine 35	6	83512538-83525704	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA038787, HPA038788	Uncertain					Tissue enhanced	Tissue enhanced		ovary: 12.9	cerebral cortex: 9.9	Cell line enhanced		CACO-2: 71.2;HAP1: 13.2;RPTEC TERT1: 18.6
MMS22L	C6orf167, dJ39B17.2	ENSG00000146263	MMS22 like, DNA repair protein	6	97142161-97283217	Predicted intracellular proteins	Evidence at protein level	HPA067042			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 12.4	bone marrow: 4.5	Expressed in all		
FAXC	C6orf168, dJ273F20, MGC2817	ENSG00000146267	Failed axon connections homolog	6	99271169-99350062	Predicted intracellular proteins	Evidence at protein level	HPA039106	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 23.5	seminal vesicle: 14.9	Cell line enhanced		HAP1: 24.5;SCLC-21H: 40.3;SH-SY5Y: 25.2
GABRR1		ENSG00000146276	Gamma-aminobutyric acid type A receptor rho1 subunit	6	89177501-89231278	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.8	placenta: 0.3	Cell line enhanced		NTERA-2: 1.2
PNRC1	B4-2, PROL2, PRR2	ENSG00000146278	Proline rich nuclear receptor coactivator 1	6	89080751-89085160	Predicted intracellular proteins	Evidence at protein level	HPA029839, HPA066513	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.88e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 272.4	Expressed in all		
PM20D2	ACY1L2, bA63L7.3	ENSG00000146281	Peptidase M20 domain containing 2	6	89146050-89165565	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030325, HPA030326, HPA030327	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			prostate: 41.1	Mixed		
RARS2	DALRD2, dJ382I10.6, MGC14993, MGC23778, PRO1992, RARSL	ENSG00000146282	Arginyl-tRNA synthetase 2, mitochondrial	6	87514378-87590003	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039987, HPA042645	Uncertain		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 56.9	Expressed in all		
SCML4	dJ47M23.1	ENSG00000146285	Sex comb on midleg-like 4 (Drosophila)	6	107704104-107824317	Predicted intracellular proteins	Evidence at protein level	HPA063326, HPA065958	Approved		Enhanced	Nucleoplasm		Mixed	Tissue enhanced		lymph node: 16.1	spleen: 11.1	Cell line enriched	6	HDLM-2: 60.8
TBC1D32	bA57L9.1, BROMI, C6orf170, C6orf171, dJ310J6.1, FLJ30899, FLJ34235	ENSG00000146350	TBC1 domain family member 32	6	121079494-121334745	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013413	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 6.1	Cell line enhanced		HDLM-2: 20.6
CLVS2	bA160A10.4, C6orf212, C6orf213, RLBP1L2	ENSG00000146352	Clavesin 2	6	122995971-123072927	Predicted intracellular proteins	Evidence at protein level	HPA043764	Uncertain					Tissue enhanced	Group enriched	6	cerebral cortex: 15.4;prostate: 5.0	endometrium: 1.7	Group enriched	8	HEL: 10.9;SCLC-21H: 10.7
GPR6		ENSG00000146360	G protein-coupled receptor 6	6	109978256-109980718	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	16	cerebral cortex: 1.5	all non-specific tissues: 0.0	Cell line enriched	11	SCLC-21H: 1.1
RNF217	C6orf172, dJ84N20.1, IBRDC1, MGC26996	ENSG00000146373	Ring finger protein 217	6	124962545-125092633	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029598	Uncertain				Renal cancer:4.60e-5 (unfavourable), Urothelial cancer:1.92e-4 (unfavourable)	Expressed in all	Tissue enriched	8	parathyroid gland: 95.7	testis: 12.5	Mixed		
RSPO3	FLJ14440, THSD2	ENSG00000146374	R-spondin 3	6	127118604-127197765	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA029957	Approved					Mixed	Tissue enhanced		endometrium: 103.2;smooth muscle: 102.9	placenta: 73.2	Cell line enhanced		A549: 24.0;U-138 MG: 5.6;U-87 MG: 5.4
ARHGAP18	bA307O14.2, MacGAP	ENSG00000146376	Rho GTPase activating protein 18	6	129576132-129710225	Predicted intracellular proteins	Evidence at protein level	HPA031595	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.54e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 48.0	Cell line enhanced		HMC-1: 344.1
TAAR2	GPR58	ENSG00000146378	Trace amine associated receptor 2 (gene/pseudogene)	6	132617022-132624275	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
TAAR6	TA4, TRAR4	ENSG00000146383	Trace amine associated receptor 6	6	132570322-132571359	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			kidney: 0.1	Not detected		
TAAR8	GPR102, TA5, TAR5, TRAR5	ENSG00000146385	Trace amine associated receptor 8	6	132552693-132553721	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ABRACL	C6orf115, Costars, HSPC280, PRO2013	ENSG00000146386	ABRA C-terminal like	6	139028682-139043302	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030217	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.65e-6 (favourable)	Expressed in all	Mixed			epididymis: 147.3	Mixed		
TAAR1	TA1, TAR1, TRAR1	ENSG00000146399	Trace amine associated receptor 1	6	132644984-132646003	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055614	Approved					Tissue enhanced	Group enriched	17	fallopian tube: 2.2;stomach: 7.8	duodenum,endometrium,prostate,urinary bladder: 0.2	Not detected		
SLC18B1	C6orf192, dJ55C23.6	ENSG00000146409	Solute carrier family 18 member B1	6	132769370-132798553	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029747, HPA049659	Approved		Supported	Golgi apparatus<br>Cytosol	Head and neck cancer:3.55e-4 (favourable), Liver cancer:7.90e-4 (unfavourable), Renal cancer:9.24e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 37.5	Mixed		
MTFR2	DUFD1, FAM54A	ENSG00000146410	Mitochondrial fission regulator 2	6	136231024-136250335	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029792, HPA029794	Approved		Uncertain	Vesicles	Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 12.7	bone marrow: 10.2	Mixed		
SLC2A12	GLUT12, GLUT8	ENSG00000146411	Solute carrier family 2 member 12	6	133988697-134052636	Predicted membrane proteins, Transporters	Evidence at protein level	HPA031593, HPA031594	Approved		Enhanced	Plasma membrane<br>Cell Junctions		Tissue enriched	Tissue enhanced		prostate: 43.3	endometrium: 16.1	Cell line enhanced		CAPAN-2: 8.0;HaCaT: 6.1;U-2 OS: 10.1
SHPRH	bA545I5.2, FLJ90837, KIAA2023	ENSG00000146414	SNF2 histone linker PHD RING helicase	6	145864245-145964423	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034854, HPA034950	Approved		Approved	Mitochondria		Mixed	Mixed			ovary: 15.1	Expressed in all		
AIG1	AIG-1, dJ95L4.1, FLJ10485	ENSG00000146416	Androgen induced 1	6	143060496-143340304	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA060766	Approved		Approved	Golgi apparatus	Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 153.1	Expressed in all		
DYNLT1	TCTEL1	ENSG00000146425	Dynein light chain Tctex-type 1	6	158636474-158644739	Predicted intracellular proteins	Evidence at protein level	HPA046559			Supported	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 273.3	Expressed in all		
TIAM2	STEF	ENSG00000146426	T-cell lymphoma invasion and metastasis 2	6	154832697-155257723	Predicted intracellular proteins	Evidence at protein level	HPA011134, HPA013903	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 18.0;testis: 24.4	thyroid gland: 10.2	Cell line enhanced		AF22: 62.0;HDLM-2: 27.3;RH-30: 39.8
TMEM181	GPR178, KIAA1423	ENSG00000146433	Transmembrane protein 181	6	158536436-158635428	Predicted membrane proteins	Evidence at protein level	HPA040189	Approved		Approved	Golgi apparatus<br>Vesicles	Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 41.5	Expressed in all		
PNLDC1	dJ195P10.2, FLJ40240	ENSG00000146453	PARN like, ribonuclease domain containing 1	6	159800249-159820704	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052026	Uncertain					Mixed	Tissue enriched	5	testis: 12.2	fallopian tube: 2.4	Not detected		
WTAP	KIAA0105, MGC3925, Mum2	ENSG00000146457	Wilms tumor 1 associated protein	6	159725585-159756319	Predicted intracellular proteins	Evidence at protein level	HPA010549, HPA010550	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles	Liver cancer:6.57e-6 (unfavourable), Renal cancer:3.01e-5 (unfavourable), Ovarian cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 177.1	Expressed in all		
ZMYM4	KIAA0425, MYM, ZNF198L3, ZNF262	ENSG00000146463	Zinc finger MYM-type containing 4	1	35268967-35422058	Predicted intracellular proteins	Evidence at protein level	HPA051301, HPA054802	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.75e-9 (unfavourable), Renal cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.9	Expressed in all		
VIP		ENSG00000146469	Vasoactive intestinal peptide	6	152750798-152759765	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017324, CAB018649, HPA072701	Supported		Approved	Endoplasmic reticulum		Group enriched	Group enriched	5	appendix: 209.4;colon: 71.4;rectum: 68.3;small intestine: 52.7;smooth muscle: 58.1	duodenum: 16.8	Cell line enhanced		SH-SY5Y: 2.8;TIME: 1.6
ARMT1	C6orf211, FLJ12910	ENSG00000146476	Acidic residue methyltransferase 1	6	151452258-151470101	Predicted intracellular proteins	Evidence at protein level	HPA003004, HPA005819	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cytosol	Colorectal cancer:4.14e-4 (favourable), Cervical cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.6	Expressed in all		
SLC22A3	EMT, OCT3	ENSG00000146477	Solute carrier family 22 member 3	6	160348268-160452581	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029750	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Cervical cancer:7.19e-5 (unfavourable), Urothelial cancer:7.26e-4 (unfavourable)	Mixed	Mixed			seminal vesicle: 70.8	Cell line enhanced		A549: 24.2;HeLa: 24.0;Hep G2: 15.5;RPTEC TERT1: 10.1
VWDE	FLJ14712	ENSG00000146530	Von Willebrand factor D and EGF domains	7	12330885-12403941	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026619, HPA036044	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 3.9	breast,epididymis,heart muscle: 1.1	Cell line enhanced		K-562: 7.1;NTERA-2: 3.7;SCLC-21H: 7.1
GNA12	gep	ENSG00000146535	G protein subunit alpha 12	7	2728112-2844324	Predicted intracellular proteins	Evidence at protein level	CAB010046	Approved		Supported	Cytosol	Liver cancer:1.20e-6 (unfavourable), Renal cancer:4.71e-5 (unfavourable), Urothelial cancer:2.27e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.5	Expressed in all		
C7orf50	MGC11257, YCR016W	ENSG00000146540	Chromosome 7 open reading frame 50	7	996986-1138260	Predicted intracellular proteins	Evidence at protein level	HPA052281	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:6.20e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 55.8	Expressed in all		
SDK1	FLJ31425	ENSG00000146555	Sidekick cell adhesion molecule 1	7	3301448-4269000	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011392	Approved		Approved	Cytosol	Pancreatic cancer:4.08e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 15.0	spleen: 6.0	Cell line enhanced		BEWO: 10.1;RT4: 8.9;U-2 OS: 13.6
CCZ1B	C7orf28B, DKFZP586I1023, H_NH0577018.2, MGC19819	ENSG00000146574	CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated	7	6794134-6826770	Predicted intracellular proteins	Evidence at protein level	HPA045114, HPA050006	Uncertain		Enhanced	Vesicles		Mixed	Expressed in all			parathyroid gland: 48.7	Expressed in all		
C7orf26	MGC2718	ENSG00000146576	Chromosome 7 open reading frame 26	7	6590017-6608726	Predicted intracellular proteins	Evidence at protein level	HPA042899, HPA052175	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments<br>Cytosol	Pancreatic cancer:6.95e-5 (favourable)	Expressed in all	Expressed in all			spleen: 25.7	Expressed in all		
RBAK	ZNF769	ENSG00000146587	RB associated KRAB zinc finger	7	5045821-5069488	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071231			Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 14.8	Expressed in all		
CREB5	CRE-BPA, H_GS165L15.1	ENSG00000146592	CAMP responsive element binding protein 5	7	28299321-28825894	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050020, HPA061622			Approved	Nucleus<br>Vesicles<br>Plasma membrane		Mixed	Mixed			gallbladder: 18.6	Cell line enhanced		HL-60: 49.5
FERD3L	bHLHa31, N-TWIST, NATO3	ENSG00000146618	Fer3 like bHLH transcription factor	7	19144782-19145421	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043494	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Cell line enriched	129	SCLC-21H: 12.8
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
CDCA5		ENSG00000146670	Cell division cycle associated 5	11	65066300-65084164	Predicted intracellular proteins	Evidence at protein level	HPA023691	Approved		Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.21e-6 (unfavourable), Pancreatic cancer:8.72e-6 (unfavourable), Endometrial cancer:2.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 31.0;testis: 46.5	lymph node: 18.9	Mixed		
IGFBP3	BP-53, IBP3	ENSG00000146674	Insulin like growth factor binding protein 3	7	45912245-45921874	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010360			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:5.07e-7 (unfavourable), Colorectal cancer:1.08e-4 (unfavourable), Liver cancer:1.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 2671.0	endometrium: 886.0	Cell line enhanced		fHDF/TERT166: 6647.1;U-2197: 3223.6;U-87 MG: 1735.3
PURB	PURBETA	ENSG00000146676	Purine rich element binding protein B	7	44876293-44885361	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048766			Supported	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 24.5	Expressed in all		
IGFBP1	AFBP, hIGFBP-1, IBP1, IGF-BP25, PP12	ENSG00000146678	Insulin like growth factor binding protein 1	7	45888357-45893668	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004445, HPA046972, HPA050640	Enhanced		Approved	Golgi apparatus	Renal cancer:6.90e-11 (unfavourable), Lung cancer:1.03e-4 (unfavourable), Stomach cancer:6.64e-4 (unfavourable)	Tissue enriched	Group enriched	52	endometrium: 120.4;liver: 563.0;placenta: 265.8	fallopian tube: 6.0	Group enriched	8	Hep G2: 33.4;U-2197: 71.7;U-87 MG: 128.8
SSC4D	S4D-SRCRB, SRCRB-S4D, SRCRB4D	ENSG00000146700	Scavenger receptor cysteine rich family member with 4 domains	7	76389334-76409695	Predicted secreted proteins	Evidence at transcript level	HPA062611	Uncertain				Endometrial cancer:2.83e-6 (unfavourable), Renal cancer:4.71e-4 (unfavourable), Glioma:6.31e-4 (unfavourable)	Mixed	Group enriched	5	kidney: 1.4;parathyroid gland: 4.2;thyroid gland: 2.0	cervix, uterine: 0.5	Group enriched	12	EFO-21: 6.3;Hep G2: 6.5;U-2 OS: 27.2
MDH2		ENSG00000146701	Malate dehydrogenase 2	7	76048051-76067508	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA019714, HPA019716, HPA019848, HPA026720	Enhanced		Enhanced	Mitochondria	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 233.2	Expressed in all		
POMZP3	POM-ZP3, POM121	ENSG00000146707	POM121 and ZP3 fusion	7	76609986-76627261	Predicted intracellular proteins	Evidence at transcript level	HPA049817	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:3.78e-4 (unfavourable), Cervical cancer:4.34e-4 (favourable), Ovarian cancer:9.31e-4 (favourable)	Expressed in all	Mixed			testis: 13.7	Expressed in all		
GBAS	NIPSNAP2	ENSG00000146729	Glioblastoma amplified sequence	7	55951793-56000181	Predicted intracellular proteins	Evidence at protein level	HPA063084	Enhanced		Supported	Mitochondria	Renal cancer:3.02e-8 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 224.4	Expressed in all		
CCT6A	CCT6, Cctz, HTR3, TCP20, TCPZ, TTCP20	ENSG00000146731	Chaperonin containing TCP1 subunit 6A	7	56051630-56063989	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042996, HPA045576, HPA049949	Supported		Approved	Cytosol	Liver cancer:9.00e-10 (unfavourable), Renal cancer:2.19e-4 (unfavourable), Breast cancer:4.04e-4 (unfavourable), Head and neck cancer:8.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 120.3	Expressed in all		
PSPH	PSP	ENSG00000146733	Phosphoserine phosphatase	7	56011051-56051604	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020376, HPA029515	Approved		Approved	Cytosol	Liver cancer:2.75e-5 (unfavourable), Breast cancer:2.30e-4 (unfavourable), Pancreatic cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 25.3	Expressed in all		
TRIM50	FLJ32804, TRIM50A	ENSG00000146755	Tripartite motif containing 50	7	73312539-73328082	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019862, HPA047843	Uncertain		Approved	Cytosol	Renal cancer:9.36e-7 (favourable)	Group enriched	Tissue enhanced		stomach: 10.4;testis: 4.6	kidney: 1.7	Cell line enriched	25	Hep G2: 4.6
ZNF92	HPF12, TF12	ENSG00000146757	Zinc finger protein 92	7	65373799-65401135	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003173			Approved	Nucleus	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Mixed			breast: 13.2	Expressed in all		
ATXN7L1	ATXN7L4, KIAA1218, MGC33190	ENSG00000146776	Ataxin 7 like 1	7	105605067-105876604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021448	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 16.4	Mixed		
TMEM168	DKFZp564C012, FLJ13576	ENSG00000146802	Transmembrane protein 168	7	112762382-112790592	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA020389	Approved				Lung cancer:4.07e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Expressed in all		
ASB15	FLJ43370	ENSG00000146809	Ankyrin repeat and SOCS box containing 15	7	123567010-123639481	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 19.2;skeletal muscle: 43.9	kidney: 7.5	Not detected		
C7orf43	FLJ10925	ENSG00000146826	Chromosome 7 open reading frame 43	7	100154420-100158715	Predicted intracellular proteins	Evidence at protein level	HPA019359, HPA029463, HPA029464	Approved		Enhanced	Vesicles<br>Plasma membrane<br>Microtubule organizing center	Pancreatic cancer:6.19e-5 (favourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
SLC12A9	CIP1	ENSG00000146828	Solute carrier family 12 member 9	7	100826820-100867009	Predicted membrane proteins, Transporters	Evidence at protein level	HPA067536	Approved				Ovarian cancer:4.00e-4 (unfavourable), Renal cancer:4.92e-4 (unfavourable), Lung cancer:5.97e-4 (favourable)	Expressed in all	Mixed			placenta: 20.2	Expressed in all		
GIGYF1	GYF1, PERQ1	ENSG00000146830	GRB10 interacting GYF protein 1	7	100679507-100689448	Predicted intracellular proteins	Evidence at protein level	HPA020999, HPA023995	Enhanced		Approved	Vesicles<br>Microtubules	Pancreatic cancer:1.35e-5 (favourable), Liver cancer:2.30e-4 (unfavourable), Head and neck cancer:7.42e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 35.8	Expressed in all		
TRIM4	RNF87	ENSG00000146833	Tripartite motif containing 4	7	99876958-99919600	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019356, HPA029461	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.36e-6 (favourable)	Expressed in all	Expressed in all			ovary: 50.6	Mixed		
MEPCE	BCDIN3, FLJ20257, MePCE	ENSG00000146834	Methylphosphate capping enzyme	7	100428790-100434126	Predicted intracellular proteins	Evidence at protein level	CAB026384, HPA051587	Supported		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:1.01e-10 (favourable), Endometrial cancer:6.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 87.8	Expressed in all		
ZAN		ENSG00000146839	Zonadhesin (gene/pseudogene)	7	100733626-100797797	Predicted membrane proteins	No evidence							Tissue enriched	Not detected			testis: 0.5	Not detected		
TMEM209	FLJ14803, NET31	ENSG00000146842	Transmembrane protein 209	7	130164715-130207770	Predicted membrane proteins	Evidence at protein level	HPA031678	Uncertain		Approved	Nuclear membrane<br>Nuclear speckles<br>Vesicles		Expressed in all	Expressed in all			testis: 27.5	Expressed in all		
AGBL3	CCP3, MGC32955	ENSG00000146856	ATP/GTP binding protein like 3	7	134986508-135147963	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020397, HPA024150	Uncertain		Uncertain	Nuclear speckles<br>Mitochondria<br>Cytosol	Renal cancer:4.02e-4 (unfavourable)	Mixed	Mixed			epididymis: 9.6	Cell line enhanced		HEK 293: 5.1
STRA8		ENSG00000146857	Stimulated by retinoic acid 8	7	135231979-135258492	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 1.6	skin: 0.6	Cell line enhanced		BEWO: 1.2;THP-1: 1.7
ZC3HAV1L	C7orf39, MGC14289	ENSG00000146858	Zinc finger CCCH-type containing, antiviral 1 like	7	139025706-139036029	Predicted intracellular proteins	Evidence at protein level	HPA020386, HPA050741	Uncertain		Enhanced	Cytosol	Cervical cancer:7.35e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 14.2	Mixed		
TMEM140	FLJ11000	ENSG00000146859	Transmembrane protein 140	7	135148072-135166215	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			spleen: 38.1	Mixed		
TLK2	MGC44450, PKU-ALPHA	ENSG00000146872	Tousled like kinase 2	17	62458658-62615481	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:9.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 96.2	Expressed in all		
EPHA1	EPH, EPHT, EPHT1	ENSG00000146904	EPH receptor A1	7	143390289-143408892	Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB026144	Uncertain				Renal cancer:1.14e-6 (favourable)	Mixed	Tissue enriched	24	parathyroid gland: 877.3	esophagus: 36.2	Cell line enhanced		CACO-2: 29.0;HaCaT: 28.6;NTERA-2: 106.2
NOM1	C7orf3, PPP1R113, SGD1	ENSG00000146909	Nucleolar protein with MIF4G domain 1	7	156949723-156973182	Predicted intracellular proteins	Evidence at protein level	HPA019866, HPA051624	Approved		Enhanced	Nucleoli		Expressed in all	Mixed			testis: 7.5	Expressed in all		
CNPY1		ENSG00000146910	Canopy FGF signaling regulator 1	7	155474206-155555450	Predicted intracellular proteins	Evidence at transcript level	HPA047400	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.8	pancreas: 0.7	Cell line enriched	11	AF22: 30.3
NCAPG2	CAP-G2, FLJ20311, hCAP-G2, LUZP5, MTB	ENSG00000146918	Non-SMC condensin II complex subunit G2	7	158631311-158704829	Predicted intracellular proteins	Evidence at protein level	HPA026631	Approved		Supported	Nuclear speckles	Liver cancer:3.00e-5 (unfavourable), Renal cancer:4.06e-5 (unfavourable), Head and neck cancer:1.91e-4 (favourable), Melanoma:3.21e-4 (unfavourable), Endometrial cancer:7.94e-4 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)	Expressed in all	Mixed			testis: 27.7	Expressed in all		
ASB10	GLC1F	ENSG00000146926	Ankyrin repeat and SOCS box containing 10	7	151175698-151187832	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	8	skeletal muscle: 27.9	heart muscle: 3.3	Not detected		
NLGN4X	HLNX, KIAA1260, NLGN, NLGN4	ENSG00000146938	Neuroligin 4, X-linked	X	5840637-6228863	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA001651	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.1	ovary: 12.9	Group enriched	5	AF22: 51.1;NTERA-2: 42.7
SHROOM2	APXL	ENSG00000146950	Shroom family member 2	X	9786456-9949443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051646, HPA061435	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.35e-7 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.8	Cell line enhanced		WM-115: 22.8
RAB19	RAB19B	ENSG00000146955	RAB19, member RAS oncogene family	7	140404043-140426250	Predicted intracellular proteins	Evidence at protein level	HPA051077	Uncertain				Renal cancer:2.36e-8 (favourable)	Mixed	Mixed			parathyroid gland: 6.2	Cell line enhanced		CAPAN-2: 4.4;HDLM-2: 10.4;MCF7: 3.8;RT4: 5.6;SK-BR-3: 4.1;T-47d: 5.7
LUC7L2	CGI-59, CGI-74, FLJ10657, H_NH0792N18.3, hLuc7B2, LUC7B2	ENSG00000146963	LUC7 like 2, pre-mRNA splicing factor	7	139340359-139423457	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051631	Approved		Approved	Nucleus	Renal cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 100.7	Expressed in all		
DENND2A	FAM31D, KIAA1277	ENSG00000146966	DENN domain containing 2A	7	140518420-140673993	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.05e-6 (unfavourable), Glioma:4.97e-4 (unfavourable), Colorectal cancer:9.35e-4 (favourable)	Tissue enriched	Mixed			endometrium: 31.6	Cell line enhanced		AF22: 53.5;BJ hTERT+: 42.3;RPTEC TERT1: 51.1;U-2197: 29.5
TMEM27	NX17	ENSG00000147003	Transmembrane protein 27	X	15627318-15665031	Predicted membrane proteins, Transporters	Evidence at protein level	HPA048543	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:6.78e-9 (favourable), Ovarian cancer:5.65e-4 (favourable)	Tissue enriched	Tissue enriched	16	kidney: 422.0	parathyroid gland: 26.6	Cell line enhanced		HaCaT: 6.8;RPTEC TERT1: 5.3
SH3KBP1	CIN85	ENSG00000147010	SH3 domain containing kinase binding protein 1	X	19533975-19887601	Predicted intracellular proteins	Evidence at protein level	HPA003351, HPA003355, CAB021892	Enhanced		Supported	Cytosol	Renal cancer:2.10e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 79.5	Expressed in all		
TMEM47	BCMP1, DKFZp564E153, DKFZP761J17121, TM4SF10, VAB-9	ENSG00000147027	Transmembrane protein 47	X	34627064-34657288	Predicted membrane proteins	Evidence at protein level	HPA046658	Approved		Approved	Nuclear membrane	Renal cancer:4.05e-6 (favourable), Melanoma:2.10e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 75.5	Cell line enhanced		BJ: 94.7;fHDF/TERT166: 268.6
LANCL3	FLJ42925	ENSG00000147036	LanC like 3	X	37571569-37684463	Predicted intracellular proteins	Evidence at protein level	HPA005470, HPA076575	Approved		Approved	Mitochondria		Not detected	Mixed			esophagus: 1.3	Cell line enhanced		HEL: 12.8;HMC-1: 3.9;K-562: 3.0
SYTL5		ENSG00000147041	Synaptotagmin like 5	X	38006582-38128819	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026074	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytosol		Mixed	Tissue enhanced		stomach: 11.8	placenta: 10.6	Cell line enhanced		CACO-2: 5.1;MCF7: 4.4;SK-MEL-30: 11.6;U-2 OS: 5.0
CASK	CAGH39, FGS4, LIN2, TNRC8	ENSG00000147044	Calcium/calmodulin dependent serine protein kinase	X	41514934-41923463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001949, HPA023857	Enhanced		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:6.11e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 34.5	Mixed		
KDM6A	UTX	ENSG00000147050	Lysine demethylase 6A	X	44873177-45112602	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000568, HPA001165, HPA002111	Enhanced		Approved	Nucleoli		Expressed in all	Expressed in all			bone marrow: 41.0	Mixed		
SPIN2A	DXF34, SPIN2, TDRD25	ENSG00000147059	Spindlin family member 2A	X	57134530-57137625	Predicted intracellular proteins	Evidence at protein level	HPA000162, HPA069835	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			cerebral cortex: 1.6	Mixed		
MSN		ENSG00000147065	Moesin	X	65588377-65741931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338	Enhanced		Enhanced	Plasma membrane	Renal cancer:1.60e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 420.9	Mixed		
AKAP4	AKAP82, CT99, Fsc1, hAKAP82, HI, p82	ENSG00000147081	A-kinase anchoring protein 4	X	50190768-50201013	Predicted intracellular proteins	Evidence at protein level	HPA005949, HPA020046	Enhanced					Not detected	Tissue enriched	2796	testis: 279.5	all non-specific tissues: 0.0	Not detected		
CCNB3		ENSG00000147082	Cyclin B3	X	50202713-50351910	Predicted intracellular proteins	Evidence at protein level	HPA000496	Enhanced		Supported	Nuclear speckles		Not detected	Group enriched	9	epididymis: 5.8;testis: 7.9	cerebral cortex: 0.7	Cell line enhanced		CAPAN-2: 1.5
HDAC8	HDACL1, MRXS6, RPD3, WTS	ENSG00000147099	Histone deacetylase 8	X	72329516-72573103	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048560	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			epididymis: 27.1	Expressed in all		
SLC16A2	AHDS, DXS128, MCT7, MCT8, MRX22, XPCT	ENSG00000147100	Solute carrier family 16 member 2	X	74421461-74533917	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA072719			Approved	Plasma membrane	Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 24.0	Cell line enhanced		BJ: 73.2
CXorf36	DIA1R, FLJ14103	ENSG00000147113	Chromosome X open reading frame 36	X	45148374-45200901	Disease related genes, Predicted secreted proteins	Evidence at transcript level	HPA002806	Uncertain					Expressed in all	Tissue enhanced		placenta: 58.4	adipose tissue: 36.3	Cell line enriched	145	HUVEC TERT2: 67.8
ZNF157	HZF22	ENSG00000147117	Zinc finger protein 157	X	47370583-47414305	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003319	Uncertain					Tissue enhanced	Mixed			fallopian tube: 2.1	Cell line enhanced		U-266/84: 1.6
ZNF182	HHZ150, KOX14, Zfp182, ZNF21	ENSG00000147118	Zinc finger protein 182	X	47974851-48003978	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059574	Uncertain		Approved	Nucleus	Urothelial cancer:1.55e-7 (favourable), Renal cancer:2.42e-5 (unfavourable), Liver cancer:3.73e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.2	Expressed in all		
CHST7	C6ST-2, C6ST2	ENSG00000147119	Carbohydrate sulfotransferase 7	X	46573784-46598408	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA003919	Approved				Cervical cancer:7.20e-4 (favourable)	Expressed in all	Mixed			spleen: 12.8	Cell line enhanced		EFO-21: 22.4;NTERA-2: 21.4
KRBOX4	FLJ20344, ZNF673	ENSG00000147121	KRAB box domain containing 4	X	46446857-46497422	Predicted intracellular proteins	Evidence at protein level	HPA065295			Approved	Nucleoplasm	Renal cancer:1.98e-7 (unfavourable), Liver cancer:2.87e-6 (unfavourable), Lung cancer:4.67e-5 (favourable), Urothelial cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 29.3	Mixed		
NDUFB11	ESSS, Np15, NP17.3	ENSG00000147123	NADH:ubiquinone oxidoreductase subunit B11	X	47142216-47145504	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA030367	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 129.1	Expressed in all		
ZNF41	MGC8941, MRX89	ENSG00000147124	Zinc finger protein 41	X	47445879-47482946	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069102	Enhanced		Approved	Nucleoplasm	Renal cancer:6.95e-4 (favourable), Head and neck cancer:8.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Expressed in all		
RAB41		ENSG00000147127	RAB41, member RAS oncogene family	X	70282093-70285002	Predicted intracellular proteins	Evidence at protein level	HPA001510	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.0;testis: 7.0	skin: 1.6	Cell line enhanced		U-2197: 3.5;U-87 MG: 4.5
ZMYM3	DXS6673E, KIAA0385, MYM, ZNF198L2, ZNF261	ENSG00000147130	Zinc finger MYM-type containing 3	X	71239624-71255146	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003211, HPA075255	Approved		Enhanced	Nucleoplasm	Liver cancer:5.18e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 44.0	Expressed in all		
TAF1	BA2R, CCG1, CCGS, DYT3, DYT3/TAF1, KAT4, NSCL2, TAF2A, TAFII250	ENSG00000147133	TATA-box binding protein associated factor 1	X	71366239-71532374	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001075, CAB016283	Supported		Enhanced	Nucleoplasm	Renal cancer:6.03e-4 (unfavourable), Lung cancer:6.54e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
GPR174	FKSG79	ENSG00000147138	G protein-coupled receptor 174	X	79170972-79172229	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA041025	Enhanced		Uncertain	Vesicles		Mixed	Tissue enhanced		lymph node: 29.8;spleen: 16.7;tonsil: 17.2	appendix: 12.6	Cell line enriched	8	MOLT-4: 85.1
NONO	NMT55, NRB54, P54, P54NRB, PPP1R114	ENSG00000147140	Non-POU domain containing, octamer-binding	X	71283192-71301168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022069, HPA054094, HPA054559	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:9.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 245.9	Expressed in all		
CCDC120	JM11	ENSG00000147144	Coiled-coil domain containing 120	X	49053572-49069857	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000561			Uncertain	Mitochondria		Expressed in all	Mixed			skin: 17.9	Cell line enhanced		BEWO: 28.0
LPAR4	GPR23, LPA4, P2RY9, P2Y5-LIKE, P2Y9	ENSG00000147145	Lysophosphatidic acid receptor 4	X	78747709-78757094	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046563, HPA054951, HPA055571	Uncertain		Supported	Nuclear bodies<br>Vesicles<br>Plasma membrane		Tissue enhanced	Tissue enhanced		ovary: 4.5	cerebral cortex: 2.2	Cell line enhanced		AF22: 9.2;NTERA-2: 15.2;RH-30: 6.2
EBP	CDPX2, CHO2, CPX, CPXD	ENSG00000147155	Emopamil binding protein (sterol isomerase)	X	48521158-48528716	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003130	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			liver: 91.3	Expressed in all		
AWAT2	DGAT2L4, MFAT	ENSG00000147160	Acyl-CoA wax alcohol acyltransferase 2	X	70040542-70049938	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA062748	Approved					Tissue enriched	Tissue enhanced		breast: 2.0;skin: 1.2	testis: 0.5	Not detected		
OGT	FLJ23071, HRNT1, MGC22921, O-GLCNAC	ENSG00000147162	O-linked N-acetylglucosamine (GlcNAc) transferase	X	71533083-71575897	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030751, HPA030752, HPA030753, HPA030754, CAB034099	Approved		Supported	Nucleoplasm<br>Plasma membrane	Urothelial cancer:6.85e-7 (favourable), Renal cancer:2.36e-6 (unfavourable), Head and neck cancer:1.97e-4 (favourable), Endometrial cancer:8.33e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 83.2	Expressed in all		
SNX12		ENSG00000147164	Sorting nexin 12	X	71056332-71073426	Predicted intracellular proteins	Evidence at protein level	CAB070423	Approved				Renal cancer:1.51e-7 (favourable), Endometrial cancer:1.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
ITGB1BP2	CHORDC3	ENSG00000147166	Integrin subunit beta 1 binding protein 2	X	71301734-71305371	Predicted intracellular proteins	Evidence at protein level	HPA040721			Approved	Cytosol		Mixed	Tissue enhanced		heart muscle: 52.9;smooth muscle: 23.1	skeletal muscle: 16.0	Cell line enhanced		HMC-1: 8.1
IL2RG	CD132, CIDX, IMD4, SCIDX1	ENSG00000147168	Interleukin 2 receptor subunit gamma	X	71107404-71112108	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046641, HPA049691	Enhanced		Approved	Vesicles	Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 273.3;tonsil: 279.4	appendix: 182.3	Cell line enriched	5	Karpas-707: 1646.4
GCNA	ACRC, NAAR1	ENSG00000147174	Germ cell nuclear acidic peptidase	X	71578411-71613583	Predicted intracellular proteins	Evidence at protein level	HPA023476	Enhanced		Approved	Vesicles		Mixed	Group enriched	5	adrenal gland: 5.9;testis: 20.6	spleen: 2.4	Mixed		
ZNF711	CMPX1, dJ75N13.1, MRX97, Zfp711, ZNF4, ZNF5, ZNF6	ENSG00000147180	Zinc finger protein 711	X	85244032-85273362	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030654	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 69.8	cerebral cortex: 32.7	Cell line enhanced		AF22: 34.0;HAP1: 51.8;HEK 293: 42.5;RH-30: 40.6
CPXCR1	CT77	ENSG00000147183	CPX chromosome region, candidate 1	X	88747225-88754785	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	57	testis: 11.5	fallopian tube: 0.2	Not detected		
DIAPH2	DIA, DIA2, POF, POF2	ENSG00000147202	Diaphanous related formin 2	X	96684663-97604997	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005647, CAB015461, CAB068183, CAB068184	Enhanced		Supported	Nucleoli<br>Endoplasmic reticulum<br>Vesicles	Endometrial cancer:2.16e-5 (unfavourable), Pancreatic cancer:2.12e-4 (unfavourable), Renal cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 17.8	Mixed		
NXF3		ENSG00000147206	Nuclear RNA export factor 3	X	103075810-103093125	Predicted intracellular proteins	Evidence at protein level	HPA003132, HPA046757	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 39.8;testis: 71.8	epididymis: 13.5	Cell line enhanced		HEL: 44.1;HL-60: 37.4;U-2197: 127.8;U-937: 80.9
RIPPLY1		ENSG00000147223	Ripply transcriptional repressor 1	X	106900063-106903335	Predicted secreted proteins	Evidence at protein level	HPA052284	Uncertain					Group enriched	Tissue enhanced		kidney: 2.3;liver: 3.0	seminal vesicle: 1.2	Cell line enriched	11	RH-30: 6.3
PRPS1	CMTX5, DFN2, DFNX1	ENSG00000147224	Phosphoribosyl pyrophosphate synthetase 1	X	107628424-107651026	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043760	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			thyroid gland: 73.9	Expressed in all		
CXorf57	FLJ10178, FLJ14191	ENSG00000147231	Chromosome X open reading frame 57	X	106611930-106679442	Predicted intracellular proteins	Evidence at protein level	HPA000896, HPA001374	Uncertain		Approved	Intermediate filaments		Mixed	Mixed			adrenal gland: 9.4	Cell line enhanced		HEK 293: 34.2;RT4: 31.7
FRMPD3	KIAA1817, RP5-1070B1.1	ENSG00000147234	FERM and PDZ domain containing 3	X	107522450-107605251	Predicted intracellular proteins	Evidence at transcript level	HPA003164	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.9;ovary: 6.7;thyroid gland: 5.5	seminal vesicle: 1.9	Cell line enhanced		Daudi: 4.2;SCLC-21H: 2.1;WM-115: 2.1
HTR2C	5-HT2C, 5HTR2C, HTR1C	ENSG00000147246	5-hydroxytryptamine receptor 2C	X	114584078-114910061	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	cerebral cortex: 3.1	cervix, uterine: 0.5	Cell line enhanced		EFO-21: 2.5;U-266/70: 3.6;U-266/84: 2.8
DOCK11	ACG, FLJ32122, FLJ43653, ZIZ2	ENSG00000147251	Dedicator of cytokinesis 11	X	118495898-118686163	Predicted intracellular proteins	Evidence at protein level	HPA059695	Uncertain		Approved	Nuclear membrane<br>Nucleoli	Head and neck cancer:4.87e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 34.0	Cell line enhanced		HMC-1: 81.5
IGSF1	IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2	ENSG00000147255	Immunoglobulin superfamily member 1	X	131273506-131578899	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012732, HPA035582	Enhanced		Approved	Cytosol	Endometrial cancer:4.25e-8 (unfavourable)	Tissue enriched	Tissue enhanced		testis: 20.0	adrenal gland: 13.1	Cell line enhanced		Hep G2: 22.7;SH-SY5Y: 30.6
ARHGAP36	FLJ30058	ENSG00000147256	Rho GTPase activating protein 36	X	131058242-131089883	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002064	Enhanced		Approved	Nucleus<br>Vesicles<br>Plasma membrane		Tissue enriched	Tissue enriched	19	adrenal gland: 137.8	cerebral cortex: 7.4	Cell line enriched	173	SH-SY5Y: 188.2
GPC3	DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1	ENSG00000147257	Glypican 3	X	133535745-133985895	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006316			Approved	Plasma membrane	Stomach cancer:4.83e-4 (unfavourable)	Expressed in all	Tissue enriched	6	placenta: 845.0	lung: 130.6	Group enriched	6	HAP1: 539.0;Hep G2: 1445.8
GPR119	GPCR2, hGPCR2	ENSG00000147262	G protein-coupled receptor 119	X	130384440-130385447	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:6.93e-4 (favourable)	Tissue enriched	Not detected			pancreas: 0.6	Cell line enhanced		Hep G2: 1.1
RBMX	hnRNP-G, HNRNPG, RNMX	ENSG00000147274	RNA binding motif protein, X-linked	X	136848004-136880764	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057707	Supported		Approved	Nucleoplasm	Liver cancer:5.16e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 296.7	Expressed in all		
MCPH1	BRIT1, FLJ12847	ENSG00000147316	Microcephalin 1	8	6406592-6648504	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008238, CAB012177	Supported		Uncertain	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:8.52e-4 (favourable)	Expressed in all	Expressed in all			testis: 19.5	Expressed in all		
MFHAS1	LRRC65, MASL1	ENSG00000147324	Malignant fibrous histiocytoma amplified sequence 1	8	8783354-8893645	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051213, HPA054471	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			spleen: 16.6	Cell line enhanced		MOLT-4: 111.7
FBXO25	FBX25	ENSG00000147364	F-box protein 25	8	406428-477967	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Cervical cancer:5.38e-5 (favourable), Renal cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 151.3	Mixed		
FATE1	CT43, FATE	ENSG00000147378	Fetal and adult testis expressed 1	X	151716035-151723194	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034604	Enhanced				Renal cancer:2.88e-4 (unfavourable)	Group enriched	Tissue enriched	314	testis: 308.4	cerebral cortex: 0.9	Not detected		
MAGEA4	CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MGC21336	ENSG00000147381	MAGE family member A4	X	151912509-151925170	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021942, CAB040535	Enhanced		Approved	Nuclear speckles<br>Cytosol		Mixed	Tissue enriched	7	testis: 44.7	placenta: 6.3	Cell line enhanced		A-431: 382.3;AN3-CA: 243.7;HMC-1: 436.2;U-266/84: 580.0
NSDHL	H105e3, SDR31E1, XAP104	ENSG00000147383	NAD(P) dependent steroid dehydrogenase-like	X	152830967-152869729	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000248, HPA000571	Enhanced		Enhanced	Endoplasmic reticulum<br>Lipid droplets	Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 54.1	Expressed in all		
ZNF185	SCELL	ENSG00000147394	Zinc finger protein 185 (LIM domain)	X	152914442-152973480	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000400, HPA016438	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol	Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 400.1;esophagus: 278.4;seminal vesicle: 202.3	cervix, uterine: 105.3	Cell line enhanced		A-431: 108.1;EFO-21: 131.6;TIME: 192.3
CETN2	CALT, CEN2	ENSG00000147400	Centrin 2	X	152826973-152830777	Predicted intracellular proteins	Evidence at protein level	HPA028956	Uncertain				Cervical cancer:7.54e-6 (favourable), Ovarian cancer:9.97e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 374.6	Expressed in all		
RPL10	DXS648, DXS648E, FLJ23544, L10, NOV, QM	ENSG00000147403	Ribosomal protein L10	X	154389955-154409168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB010339, HPA011311	Enhanced		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.67e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 9682.7	Expressed in all		
CSGALNACT1	ChGn, CSGalNAcT-1, FLJ11264	ENSG00000147408	Chondroitin sulfate N-acetylgalactosaminyltransferase 1	8	19404161-19758029	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA061336			Supported	Actin filaments		Expressed in all	Expressed in all			thyroid gland: 145.2	Cell line enhanced		A549: 52.2;BJ hTERT+: 26.0;RPTEC TERT1: 29.9;U-2197: 33.6;U-87 MG: 25.2
ATP6V1B2	ATP6B2, HO57, VATB, Vma2, VPP3	ENSG00000147416	ATPase H+ transporting V1 subunit B2	8	20197367-20226819	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008147	Enhanced		Supported	Vesicles	Renal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 304.2	Expressed in all		
CCDC25	FLJ10853	ENSG00000147419	Coiled-coil domain containing 25	8	27733311-27772653	Predicted intracellular proteins	Evidence at protein level	HPA023256	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.11e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 35.6	Expressed in all		
HMBOX1	FLJ21616, HNF1LA, HOT1, PBHNF	ENSG00000147421	Homeobox containing 1	8	28890394-29064764	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055855, HPA058586, CAB070418	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			testis: 13.9	Expressed in all		
CHRNB3		ENSG00000147432	Cholinergic receptor nicotinic beta 3 subunit	8	42697376-42737407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045555	Enhanced					Tissue enriched	Tissue enhanced		testis: 2.6	cerebral cortex: 0.6	Cell line enhanced		NTERA-2: 1.1;U-266/84: 1.8
CHRNA6		ENSG00000147434	Cholinergic receptor nicotinic alpha 6 subunit	8	42752620-42796392	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			adrenal gland,fallopian tube: 0.5	Cell line enhanced		Daudi: 3.0;HDLM-2: 2.5;HMC-1: 1.1;U-698: 2.5
GNRH1	GNRH, GRH, LHRH	ENSG00000147437	Gonadotropin releasing hormone 1	8	25419260-25424654	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA027532	Supported				Renal cancer:8.08e-9 (unfavourable)	Mixed	Mixed			skin: 10.4	Cell line enriched	5	SCLC-21H: 23.9
BIN3		ENSG00000147439	Bridging integrator 3	8	22620418-22669148	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023769	Approved					Expressed in all	Mixed			bone marrow: 25.5	Expressed in all		
DOK2	Dok-2, p56dok-2	ENSG00000147443	Docking protein 2	8	21908873-21913860	Predicted intracellular proteins	Evidence at protein level	CAB004379, HPA066571	Enhanced				Renal cancer:2.20e-4 (unfavourable), Melanoma:4.31e-4 (favourable)	Expressed in all	Mixed			spleen: 35.0	Group enriched	9	HDLM-2: 23.7;HEL: 48.6;HMC-1: 98.0;THP-1: 28.2;U-937: 31.6
SLC25A37	HT015, MFRN, MFRN1, MSCP	ENSG00000147454	Solute carrier family 25 member 37	8	23528805-23575463	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045680	Uncertain				Renal cancer:4.37e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 80.1	Expressed in all		
CHMP7	MGC29816	ENSG00000147457	Charged multivesicular body protein 7	8	23243637-23262000	Predicted intracellular proteins	Evidence at protein level	HPA036119	Uncertain		Supported	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		lymph node: 38.5	tonsil: 25.3	Expressed in all		
DOCK5	FLJ21034	ENSG00000147459	Dedicator of cytokinesis 5	8	25184723-25418082	Predicted intracellular proteins	Evidence at protein level	HPA017719, HPA056837	Approved		Enhanced	Cytosol	Renal cancer:1.18e-6 (unfavourable), Endometrial cancer:1.91e-4 (favourable)	Expressed in all	Mixed			spleen: 18.6	Mixed		
STAR	StAR, STARD1	ENSG00000147465	Steroidogenic acute regulatory protein	8	38143649-38151265	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023644, HPA027318, CAB032598	Enhanced					Tissue enhanced	Tissue enriched	12	adrenal gland: 2879.8	ovary: 245.8	Group enriched	7	HEL: 92.1;K-562: 433.7
PROSC		ENSG00000147471	Proline synthetase cotranscribed homolog (bacterial)	8	37762593-37779767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017033, HPA023646, HPA023733	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.4	Expressed in all		
ERLIN2	C8orf2, Erlin-2, NET32, SPFH2, SPG18	ENSG00000147475	ER lipid raft associated 2	8	37736599-37759101	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA002025, CAB014894	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:6.67e-6 (favourable), Glioma:1.96e-4 (unfavourable), Colorectal cancer:5.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 80.9	Expressed in all		
SNTG1	G1SYN, SYN4	ENSG00000147481	Syntrophin gamma 1	8	49909789-50794118	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA072282	Supported					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.6;spleen: 3.8	testis: 1.2	Not detected		
PXDNL	FLJ25471, PMR1	ENSG00000147485	Peroxidasin like	8	51319578-51809445	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007919			Approved	Nucleoplasm<br>Cytosol	Breast cancer:3.27e-5 (unfavourable)	Mixed	Group enriched	8	epididymis: 11.5;heart muscle: 24.1;testis: 9.0	adipose tissue: 1.8	Group enriched	7	AF22: 7.6;Daudi: 4.2;SH-SY5Y: 6.5
ST18	KIAA0535, NZF3, ZC2H2C3, ZC2HC10, ZNF387	ENSG00000147488	ST18, C2H2C-type zinc finger	8	52110839-52460959	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044919	Uncertain					Tissue enhanced	Tissue enriched	7	cerebral cortex: 11.6	stomach: 1.5	Cell line enhanced		HAP1: 2.8;SCLC-21H: 11.3;U-87 MG: 1.5
RGS20	RGSZ1, ZGAP1	ENSG00000147509	Regulator of G-protein signaling 20	8	53851808-53959303	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA070193	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	thyroid gland: 2.1	Cell line enhanced		SK-MEL-30: 23.4;U-87 MG: 28.2
TACC1		ENSG00000147526	Transforming acidic coiled-coil containing protein 1	8	38728186-38853028	Predicted intracellular proteins	Evidence at protein level	CAB017041, HPA024702	Approved				Renal cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 166.8	Expressed in all		
GOLGA7	GCP16, GOLGA3AP1, GOLGA7A, HSPC041	ENSG00000147533	Golgin A7	8	41490396-41510980	Predicted intracellular proteins	Evidence at protein level	HPA046878	Uncertain				Endometrial cancer:1.36e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 96.4	Expressed in all		
PLPP5	DPPL1, HTPAP, PPAPDC1B	ENSG00000147535	Phospholipid phosphatase 5	8	38263130-38269243	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055777			Approved	Vesicles	Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable)	Expressed in all	Expressed in all			prostate: 120.8	Mixed		
GINS4	MGC14799, SLD5	ENSG00000147536	GINS complex subunit 4	8	41529206-41545046	Predicted intracellular proteins	Evidence at protein level	HPA024663, HPA026580	Uncertain		Supported	Nucleoplasm<br>Centrosome	Endometrial cancer:2.30e-5 (unfavourable)	Mixed	Mixed			lymph node: 6.2	Mixed		
NSD3	FLJ20353, KMT3F, WHISTLE, WHSC1L1	ENSG00000147548	Nuclear receptor binding SET domain protein 3	8	38269697-38382272	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005659, CAB013721, HPA018893	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
DNAJC5B	CSP-beta, MGC26226	ENSG00000147570	DnaJ heat shock protein family (Hsp40) member C5 beta	8	66021560-66100526	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077389			Approved	Vesicles		Mixed	Tissue enriched	13	testis: 114.3	lung: 9.1	Group enriched	6	HDLM-2: 17.3;RPTEC TERT1: 15.6;THP-1: 8.8;U-266/70: 8.7;U-937: 8.8
CRH	CRF, CRH1	ENSG00000147571	Corticotropin releasing hormone	8	66176382-66178725	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046846, HPA062111	Uncertain	Supported				Tissue enriched	Tissue enhanced		cerebral cortex: 2.1;placenta: 8.0	adipose tissue: 1.2	Not detected		
TRIM55	MURF-2, RNF29	ENSG00000147573	Tripartite motif containing 55	8	66126896-66175487	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038793, HPA053691	Approved		Approved	Golgi apparatus<br>Cytosol		Group enriched	Tissue enhanced		heart muscle: 40.0;liver: 19.7	testis: 13.2	Cell line enriched	17	LHCN-M2: 356.6
ADHFE1	ADHFe1, FLJ32430	ENSG00000147576	Alcohol dehydrogenase, iron containing 1	8	66430185-66471601	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023062	Enhanced		Approved	Vesicles	Renal cancer:4.55e-5 (favourable), Breast cancer:5.76e-5 (favourable), Liver cancer:9.90e-5 (favourable)	Mixed	Mixed			liver: 14.3	Cell line enhanced		ASC diff: 1.1;RPTEC TERT1: 1.2
MRPS28	HSPC007, MRP-S28, MRPS35	ENSG00000147586	Mitochondrial ribosomal protein S28	8	79918717-80030289	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA027202	Approved		Enhanced	Mitochondria	Renal cancer:1.20e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 114.1	Expressed in all		
PMP2	FABP8, M-FABP, MP2	ENSG00000147588	Peripheral myelin protein 2	8	81440326-81447523	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	55	cerebral cortex: 288.6	seminal vesicle: 5.2	Cell line enhanced		WM-115: 1.3
LACTB2	CGI-83	ENSG00000147592	Lactamase beta 2	8	70635318-70669174	Predicted intracellular proteins	Evidence at protein level	HPA044391, HPA053040	Approved		Supported	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 119.4	Cell line enhanced		SK-BR-3: 329.9
PRDM14		ENSG00000147596	PR/SET domain 14	8	70051651-70071693	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019094, HPA057070	Uncertain		Uncertain	Nucleoplasm		Tissue enriched	Tissue enhanced		testis: 1.7	skin: 0.5	Cell line enriched	101	NTERA-2: 50.3
TERF1	PIN2, TRBF1, TRF, TRF1	ENSG00000147601	Telomeric repeat binding factor 1	8	73008864-73048122	Predicted intracellular proteins	Evidence at protein level	HPA048379			Supported	Nucleoli fibrillar center<br>Nuclear bodies	Renal cancer:6.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 45.8	Expressed in all		
RPL7	humL7-1, L7	ENSG00000147604	Ribosomal protein L7	8	73290267-73295789	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA058373	Approved		Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 5525.6	Expressed in all		
SLC26A7	SUT2	ENSG00000147606	Solute carrier family 26 member 7	8	91209494-91398152	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	21	thyroid gland: 550.6	kidney: 26.3	Not detected		
PSKH2		ENSG00000147613	Protein serine kinase H2	8	86048373-86088621	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA015095	Uncertain					Tissue enhanced	Not detected			testis: 0.4	Cell line enriched	21	HEL: 8.2
ATP6V0D2	ATP6D2, FLJ38708, VMA6	ENSG00000147614	ATPase H+ transporting V0 subunit d2	8	85987323-86154228	Predicted intracellular proteins	Evidence at protein level	HPA055327, HPA058496	Enhanced		Approved	Vesicles	Renal cancer:2.20e-6 (favourable)	Tissue enriched	Tissue enriched	15	kidney: 59.4	rectum: 3.9	Cell line enhanced		SCLC-21H: 2.3;SK-MEL-30: 2.6;U-87 MG: 4.8
SYBU	FLJ20366, GOLSYN, KIAA1472, OCSYN, SNPHL	ENSG00000147642	Syntabulin	8	109573978-109691791	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053057	Uncertain		Supported	Vesicles	Liver cancer:7.74e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 76.0	adrenal gland: 40.7	Cell line enhanced		HaCaT: 20.2;PC-3: 23.7;SCLC-21H: 20.0;SK-BR-3: 38.8
DPYS	DHPase	ENSG00000147647	Dihydropyrimidinase	8	104330324-104467053	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024785	Enhanced					Group enriched	Group enriched	22	kidney: 200.4;liver: 246.2	gallbladder: 10.1	Not detected		
MTDH	3D3, AEG-1, LYRIC	ENSG00000147649	Metadherin	8	97644179-97728770	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010932, HPA015104, CAB068204, CAB068205	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:3.82e-4 (unfavourable), Pancreatic cancer:5.36e-4 (unfavourable), Lung cancer:7.76e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 104.4	Expressed in all		
LRP12	FLJ12929, ST7	ENSG00000147650	LDL receptor related protein 12	8	104489231-104589024	Predicted membrane proteins	Evidence at protein level	HPA017245	Uncertain		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Mitochondria	Endometrial cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 27.8	Mixed		
EBAG9	EB9, RCAS1	ENSG00000147654	Estrogen receptor binding site associated, antigen, 9	8	109539711-109565996	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021153, HPA021154, CAB072810, CAB072811, CAB072812	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 96.5	Expressed in all		
RSPO2	MGC35555	ENSG00000147655	R-spondin 2	8	107899316-108083648	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024764, CAB025900, HPA053068	Approved					Mixed	Tissue enhanced		cerebral cortex: 20.2;placenta: 25.7	prostate: 15.8	Cell line enhanced		HEK 293: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2
POLR2K	RPB10alpha	ENSG00000147669	RNA polymerase II subunit K	8	100150584-100154002	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA063185			Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 98.4	Expressed in all		
MAL2		ENSG00000147676	Mal, T-cell differentiation protein 2 (gene/pseudogene)	8	119165034-119245673	Predicted membrane proteins	Evidence at protein level	HPA043831	Uncertain				Breast cancer:4.57e-6 (unfavourable), Renal cancer:2.39e-5 (favourable), Endometrial cancer:8.44e-5 (unfavourable), Pancreatic cancer:3.98e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 266.5	Cell line enhanced		A-431: 909.7;HaCaT: 399.9;SK-BR-3: 1080.1
EIF3H	eIF3-gamma, eIF3-p40, eIF3h, EIF3S3	ENSG00000147677	Eukaryotic translation initiation factor 3 subunit H	8	116642130-116766925	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023117, HPA023553	Approved		Approved	Cytosol	Breast cancer:5.26e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable), Liver cancer:8.34e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 480.9	Expressed in all		
UTP23	C8orf53, MGC14595	ENSG00000147679	UTP23, small subunit processome component	8	116766503-116849463	Predicted intracellular proteins	Evidence at protein level	HPA044418	Uncertain		Approved	Nucleoli	Breast cancer:5.18e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.2	Expressed in all		
NDUFB9	B22, LYRM3, UQOR22	ENSG00000147684	NADH:ubiquinone oxidoreductase subunit B9	8	124539103-124568510	Predicted intracellular proteins	Evidence at protein level	HPA042768	Approved		Supported	Mitochondria	Renal cancer:3.42e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 443.1	Expressed in all		
TATDN1	CDA11	ENSG00000147687	TatD DNase domain containing 1	8	124488485-124539458	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023634, HPA053045	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 62.1	Expressed in all		
FAM83A	BJ-TSA-9, MGC14128	ENSG00000147689	Family with sequence similarity 83 member A	8	123178960-123210079	Predicted intracellular proteins	Evidence at protein level	HPA052615			Approved	Nucleoplasm	Lung cancer:2.98e-9 (unfavourable), Pancreatic cancer:4.99e-6 (unfavourable), Endometrial cancer:3.85e-4 (unfavourable)	Tissue enhanced	Tissue enriched	8	esophagus: 77.9	seminal vesicle: 9.3	Cell line enhanced		A-431: 72.5;HBEC3-KT: 90.5;hTCEpi: 47.9;K-562: 183.8
GSDMC	MLZE	ENSG00000147697	Gasdermin C	8	129748196-129786888	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023670, HPA024767, HPA026317	Supported		Enhanced	Mitochondria		Group enriched	Tissue enhanced		esophagus: 20.0;skin: 44.3;spleen: 21.6	tonsil: 6.5	Cell line enhanced		A-431: 13.0;HaCaT: 3.1;hTCEpi: 4.5;HUVEC TERT2: 5.2;TIME: 4.3
FAM135B	C8ORFK32	ENSG00000147724	Family with sequence similarity 135 member B	8	138130023-138496822	Predicted intracellular proteins	Evidence at transcript level	HPA023911, HPA023950, HPA024815	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Tissue enhanced	Group enriched	8	adrenal gland: 3.6;cerebral cortex: 8.3;testis: 7.3	colon: 0.8	Cell line enriched	11	RH-30: 8.5
ZNF7	HF.16, KOX4	ENSG00000147789	Zinc finger protein 7	8	144827464-144847509	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030296, HPA059090	Uncertain		Approved	Mitochondria	Renal cancer:8.46e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
ARHGAP39	CrGAP, KIAA1688, Vilse	ENSG00000147799	Rho GTPase activating protein 39	8	144529179-144605816	Predicted intracellular proteins	Evidence at protein level	HPA044491			Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Tissue enhanced		testis: 16.4	cerebral cortex,fallopian tube: 7.3	Mixed		
SLC39A4	AEZ, AWMS2, ZIP4	ENSG00000147804	Solute carrier family 39 member 4	8	144409742-144416895	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:9.04e-4 (favourable)	Expressed in all	Group enriched	8	duodenum: 134.2;small intestine: 95.7	kidney: 14.3	Group enriched	9	CAPAN-2: 50.5;Hep G2: 102.1
NAPRT	NAPRT1, PP3856	ENSG00000147813	Nicotinate phosphoribosyltransferase	8	143574785-143578649	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023739, HPA024017, CAB068206, CAB068207	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:6.28e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 21.4;small intestine: 20.7	bone marrow: 9.6	Cell line enhanced		CAPAN-2: 33.3;SK-BR-3: 30.1
VLDLR	CARMQ1, CHRMQ1, VLDLRCH	ENSG00000147852	Very low density lipoprotein receptor	9	2621834-2660053	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032462, HPA051312	Uncertain		Approved	Vesicles<br>Cytokinetic bridge<br>Microtubule organizing center	Endometrial cancer:5.95e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 110.0;parathyroid gland: 124.0	fallopian tube: 43.7	Cell line enhanced		BEWO: 60.5
AK3	AK3L1, AK6, AKL3L1	ENSG00000147853	Adenylate kinase 3	9	4709559-4742043	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063324	Enhanced		Supported	Mitochondria	Renal cancer:6.07e-9 (favourable)	Expressed in all	Expressed in all			kidney: 106.2	Expressed in all		
UHRF2	MGC33463, NIRF, RNF107, TDRD23, URF2	ENSG00000147854	Ubiquitin like with PHD and ring finger domains 2	9	6413151-6507054	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026633, HPA026697			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 32.8	Expressed in all		
NFIB	NFI-RED, NFIB2, NFIB3	ENSG00000147862	Nuclear factor I B	9	14081843-14398983	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003956	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:3.53e-4 (favourable)	Expressed in all	Mixed			breast: 44.5	Cell line enhanced		AN3-CA: 151.3
CER1	DAND4	ENSG00000147869	Cerberus 1, DAN family BMP antagonist	9	14719724-14722717	Predicted secreted proteins	Evidence at protein level	HPA019917	Uncertain					Tissue enriched	Tissue enriched	6	epididymis: 1.3	endometrium: 0.2	Group enriched	10	HEL: 3.6;NTERA-2: 7.1;SCLC-21H: 3.2
PLIN2	ADFP, ADRP	ENSG00000147872	Perilipin 2	9	19108375-19149290	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016607, CAB037331	Supported		Supported	Lipid droplets	Thyroid cancer:2.16e-4 (favourable), Renal cancer:3.32e-4 (unfavourable)	Group enriched	Expressed in all			liver: 450.7	Cell line enhanced		ASC diff: 1543.1;HHSteC: 1631.5
IFNA5	IFN-alphaG	ENSG00000147873	Interferon alpha 5	9	21304326-21305312	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			epididymis: 0.2	Not detected		
HAUS6	dgt6, FAM29A, FLJ20060, KIAA1574	ENSG00000147874	HAUS augmin like complex subunit 6	9	19053143-19103119	Predicted intracellular proteins	Evidence at protein level	HPA020960, HPA020965	Approved		Supported	Nuclear speckles<br>Microtubule organizing center<br>Cytosol	Renal cancer:3.13e-5 (unfavourable), Liver cancer:3.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 43.2	lymph node: 13.3	Expressed in all		
CDKN2B	CDK4I, INK4B, MTS2, P15, p15INK4b, TP15	ENSG00000147883	Cyclin dependent kinase inhibitor 2B	9	22002903-22009363	Predicted intracellular proteins	Evidence at protein level	CAB000349, HPA052838, HPA063327	Uncertain		Approved	Nucleoplasm	Endometrial cancer:4.47e-6 (unfavourable), Renal cancer:1.03e-4 (unfavourable), Liver cancer:1.49e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 32.6	Cell line enhanced		HaCaT: 30.4;SiHa: 46.3
IFNA16	IFN-alphaO	ENSG00000147885	Interferon alpha 16	9	21216373-21217311	Predicted secreted proteins	Evidence at transcript level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CDKN2A	ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf	ENSG00000147889	Cyclin dependent kinase inhibitor 2A	9	21967753-21995301	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000093, CAB000445, CAB018232, HPA047838	Uncertain		Enhanced	Nucleoli	Endometrial cancer:1.82e-7 (unfavourable), Renal cancer:5.76e-7 (unfavourable), Liver cancer:2.17e-4 (unfavourable), Head and neck cancer:5.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 7.5	Cell line enhanced		HEK 293: 297.6
C9orf72	DENNL72, MGC23980	ENSG00000147894	Chromosome 9 open reading frame 72	9	27546545-27573866	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023873	Uncertain					Expressed in all	Expressed in all			testis: 32.1	Mixed		
IFNK		ENSG00000147896	Interferon kappa	9	27524314-27526498	Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			skin: 0.1	Not detected		
ZCCHC7	AIR1, FLJ22611	ENSG00000147905	Zinc finger CCHC-type containing 7	9	37120539-37358149	Predicted intracellular proteins	Evidence at protein level	HPA020600, HPA021088, HPA029522	Uncertain		Enhanced	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.4	Expressed in all		
FBXO10	FBX10	ENSG00000147912	F-box protein 10	9	37510892-37576349	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002863, HPA072721	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 16.4	Cell line enhanced		HHSteC: 29.5
SIGMAR1	OPRS1, SR-BP1	ENSG00000147955	Sigma non-opioid intracellular receptor 1	9	34634722-34637809	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013470, HPA018002, HPA024071	Approved				Urothelial cancer:3.42e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 67.8	Expressed in all		
CBWD5		ENSG00000147996	COBW domain containing 5	9	65668805-65734041	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Mixed	Expressed in all			breast: 22.0	Expressed in all		
CEP78	C9orf81, FLJ12643	ENSG00000148019	Centrosomal protein 78	9	78236062-78279690	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048846	Approved					Expressed in all	Tissue enhanced		testis: 30.7	endometrium,parathyroid gland: 9.9	Expressed in all		
NTRK2	TRKB	ENSG00000148053	Neurotrophic receptor tyrosine kinase 2	9	84668551-85027070	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007637, CAB010346	Enhanced		Approved	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 439.6;thyroid gland: 215.7	breast: 82.1	Group enriched	5	AF22: 9.4;HaCaT: 3.1;RPTEC TERT1: 8.1;SH-SY5Y: 12.9;WM-115: 2.8
IDNK	bA522I20.2, C9orf103, hGntK	ENSG00000148057	IDNK, gluconokinase	9	83623049-83644130	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020378, HPA058429	Enhanced		Approved	Mitochondria<br>Cytosol	Endometrial cancer:1.10e-6 (favourable)	Expressed in all	Mixed			kidney: 50.5	Mixed		
SHC3	N-Shc, NSHC, SHCC	ENSG00000148082	SHC adaptor protein 3	9	89005771-89178767	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031427, HPA046656, HPA072448	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 45.3	parathyroid gland: 12.6	Cell line enhanced		AF22: 20.5;SH-SY5Y: 8.1;U-87 MG: 11.2
AUH		ENSG00000148090	AU RNA binding methylglutaconyl-CoA hydratase	9	91213815-91361913	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA004171	Enhanced				Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			kidney: 65.4	Expressed in all		
MFSD14B	FLJ14753, HIATL1	ENSG00000148110	Major facilitator superfamily domain containing 14B	9	94374551-94461042	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017978			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enriched	5	parathyroid gland: 255.7	skin: 50.6	Expressed in all		
C9orf3	AOPEP, AP-O, APO, C90RF3, FLJ14675	ENSG00000148120	Chromosome 9 open reading frame 3	9	94726701-95087218	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004633, HPA072729	Approved		Approved	Cell Junctions	Renal cancer:6.33e-5 (favourable)	Expressed in all	Expressed in all			skin: 50.0	Mixed		
PLPPR1	FLJ20300, LPPR1, MGC26189, PRG-3	ENSG00000148123	Phospholipid phosphatase related 1	9	101028709-101325135	Predicted membrane proteins	Evidence at protein level	HPA014760, HPA014968, HPA014979	Supported		Supported	Nucleoplasm	Lung cancer:1.37e-4 (favourable)	Group enriched	Group enriched	6	cerebral cortex: 23.8;kidney: 15.8	epididymis: 3.3	Cell line enhanced		Hep G2: 2.1;SCLC-21H: 6.4
OR13C4		ENSG00000148136	Olfactory receptor family 13 subfamily C member 4	9	104526253-104527209	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF462	DKFZP762N2316, KIAA1803, Zfp462	ENSG00000148143	Zinc finger protein 462	9	106863097-107013634	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA022283	Uncertain		Approved	Nucleoplasm	Renal cancer:6.19e-4 (favourable)	Mixed	Mixed			parathyroid gland: 15.9	Mixed		
INIP	C9orf80, HSPC043, hSSBIP1, MISE, SOSS-C	ENSG00000148153	INTS3 and NABP interacting protein	9	112683926-112718236	Predicted intracellular proteins	Evidence at protein level	HPA020382	Approved		Supported	Nucleoplasm	Renal cancer:2.00e-8 (favourable), Stomach cancer:2.53e-4 (favourable), Breast cancer:7.08e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 17.5	Expressed in all		
UGCG	GCS	ENSG00000148154	UDP-glucose ceramide glucosyltransferase	9	111896766-111935369	Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024124	Approved				Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 84.1	Expressed in all		
ACTL7B	Tact1	ENSG00000148156	Actin like 7B	9	108854589-108856967	Predicted intracellular proteins	Evidence at protein level	HPA021803, HPA024664	Enhanced					Not detected	Tissue enriched	589	testis: 58.9	all non-specific tissues: 0.0	Not detected		
SNX30	ATG24A	ENSG00000148158	Sorting nexin family member 30	9	112750838-112881671	Predicted intracellular proteins	Evidence at protein level	HPA019346	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.01e-7 (favourable)	Expressed in all	Mixed			lung: 32.2	Expressed in all		
STOM	BND7, EPB7, EPB72	ENSG00000148175	Stomatin	9	121338988-121370304	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010961, HPA011419	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 463.6	Cell line enhanced		ASC diff: 468.5;hTCEpi: 411.2
GSN	DKFZp313L0718	ENSG00000148180	Gelsolin	9	121207794-121332843	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010823, CAB016728, CAB036009, HPA054026	Supported		Supported	Actin filaments	Urothelial cancer:1.79e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 1354.2	Cell line enhanced		ASC diff: 964.0;HaCaT: 513.8
MRRF	RRF	ENSG00000148187	Mitochondrial ribosome recycling factor	9	122264603-122331343	Predicted intracellular proteins	Evidence at protein level	HPA047177, HPA049987	Enhanced		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:2.14e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Expressed in all		
NR6A1	CT150, GCNF, GCNF1, RTR	ENSG00000148200	Nuclear receptor subfamily 6 group A member 1	9	124517275-124771310	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031461, HPA045145			Supported	Nucleus		Tissue enriched	Tissue enriched	8	testis: 42.7	thyroid gland: 5.1	Cell line enhanced		BEWO: 107.1;K-562: 31.0;NTERA-2: 39.7
CRB2	FLJ16786, FLJ38464	ENSG00000148204	Crumbs 2, cell polarity complex component	9	123356170-123380324	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043674	Supported					Group enriched	Tissue enhanced		cerebral cortex: 9.4	kidney: 2.0	Cell line enriched	7	AF22: 32.2
OR5C1	hRPK-465_F_21, OR5C2P, OR9-F	ENSG00000148215	Olfactory receptor family 5 subfamily C member 1	9	122788933-122789895	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ALAD	ALADH, PBGS	ENSG00000148218	Aminolevulinate dehydratase	9	113386317-113401333	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021023, HPA022124	Enhanced				Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 147.1	Expressed in all		
ASTN2	KIAA0634	ENSG00000148219	Astrotactin 2	9	116425225-117415070	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027035	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-16 (favourable)	Expressed in all	Expressed in all			prostate: 40.5	Cell line enhanced		SH-SY5Y: 39.4
WDR31	FLJ35921	ENSG00000148225	WD repeat domain 31	9	113313222-113340298	Predicted intracellular proteins	Evidence at transcript level	HPA019340, HPA019347	Approved		Approved	Nuclear bodies<br>Cytosol	Renal cancer:1.90e-9 (favourable), Endometrial cancer:1.85e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 16.3	testis: 9.2	Mixed		
POLE3	CHARAC17, CHRAC17, p17, Ybl1	ENSG00000148229	DNA polymerase epsilon 3, accessory subunit	9	113407235-113410672	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047945	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:8.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.4	Expressed in all		
SURF4	ERV29, FLJ22993, MGC102753	ENSG00000148248	Surfeit 4	9	133361449-133376166	Predicted membrane proteins, Transporters	Evidence at protein level	HPA064613	Approved				Head and neck cancer:1.47e-5 (unfavourable), Breast cancer:5.85e-4 (unfavourable), Liver cancer:8.11e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 82.7	Expressed in all		
GBGT1	A3GALNT, FS, MGC44848, UDP-GalNAc	ENSG00000148288	Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1	9	133152948-133163945	Predicted secreted proteins	Evidence at protein level	HPA051298	Approved				Renal cancer:3.46e-5 (unfavourable), Colorectal cancer:6.22e-4 (unfavourable)	Expressed in all	Mixed			placenta: 15.6	Cell line enhanced		HEL: 53.1;HMC-1: 47.0
SURF1		ENSG00000148290	SURF1, cytochrome c oxidase assembly factor	9	133351755-133356676	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB033946	Uncertain				Renal cancer:6.92e-9 (favourable)	Expressed in all	Expressed in all			epididymis: 46.8	Expressed in all		
SURF2		ENSG00000148291	Surfeit 2	9	133356552-133361169	Predicted intracellular proteins	Evidence at protein level	HPA044340, HPA052213	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 39.1	Expressed in all		
SURF6	FLJ30322, RRP14	ENSG00000148296	Surfeit 6	9	133328774-133336398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023608, HPA074622	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.31e-5 (favourable)	Expressed in all	Mixed			ovary: 8.8	Expressed in all		
MED22	Med24, SURF5	ENSG00000148297	Mediator complex subunit 22	9	133338323-133348131	Predicted intracellular proteins	Evidence at protein level	HPA020391, HPA063694	Uncertain		Approved	Nucleoplasm	Renal cancer:3.76e-11 (favourable), Liver cancer:5.16e-6 (unfavourable), Pancreatic cancer:6.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 10.9	Expressed in all		
REXO4	hPMC2, XPMC2H	ENSG00000148300	REX4 homolog, 3'-5' exonuclease	9	133406059-133418096	Predicted intracellular proteins	Evidence at protein level	HPA047006	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:4.76e-6 (unfavourable), Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 11.2	Expressed in all		
RPL7A	L7A, SURF3, TRUP	ENSG00000148303	Ribosomal protein L7a	9	133348214-133351426	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046794			Approved	Nucleoli<br>Vesicles	Ovarian cancer:3.60e-5 (unfavourable), Liver cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2618.0	Expressed in all		
GTF3C5	TFiiiC2-63, TFIIIC63, TFIIICepsilon	ENSG00000148308	General transcription factor IIIC subunit 5	9	133030675-133058503	Predicted intracellular proteins	Evidence at protein level	HPA067063, HPA069805	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 48.2	Expressed in all		
ASB6		ENSG00000148331	Ankyrin repeat and SOCS box containing 6	9	129634604-129642169	Predicted intracellular proteins	Evidence at protein level	HPA004341	Approved				Colorectal cancer:1.06e-5 (unfavourable), Liver cancer:2.40e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 22.7	Expressed in all		
PTGES2	C9orf15, FLJ14038	ENSG00000148334	Prostaglandin E synthase 2	9	128120693-128128462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020631, HPA020733	Approved		Approved	Mitochondria	Renal cancer:5.83e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 35.1	Expressed in all		
NTMT1	AD-003, C9orf32, HOMT1A, METTL11A, NRMT, NRMT1	ENSG00000148335	N-terminal Xaa-Pro-Lys N-methyltransferase 1	9	129608884-129636131	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020092, HPA058420	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 90.5	Expressed in all		
CIZ1	LSFR1, ZNF356	ENSG00000148337	CDKN1A interacting zinc finger protein 1	9	128166064-128204383	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020380, HPA020387	Uncertain		Enhanced	Nucleoplasm	Liver cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 87.1	Expressed in all		
SLC25A25	KIAA1896, MCSC, PCSCL	ENSG00000148339	Solute carrier family 25 member 25	9	128068201-128109245	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020381	Uncertain		Supported	Vesicles<br>Mitochondria	Renal cancer:4.65e-6 (favourable), Liver cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 62.9	Expressed in all		
SH3GLB2	KIAA1848	ENSG00000148341	SH3 domain containing GRB2 like endophilin B2	9	129007036-129028303	Predicted intracellular proteins	Evidence at protein level	HPA021438, HPA024734	Approved		Supported	Nucleoplasm<br>Cytosol	Cervical cancer:1.56e-6 (favourable), Renal cancer:2.32e-4 (favourable), Urothelial cancer:4.28e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 92.1	Expressed in all		
MIGA2	C9orf54, FAM73B, FLJ00199, FLJ14596	ENSG00000148343	Mitoguardin 2	9	129036621-129072082	Predicted membrane proteins	Evidence at protein level	HPA041363	Approved		Approved	Cell Junctions<br>Cytosol	Pancreatic cancer:3.04e-6 (favourable)	Expressed in all	Mixed			small intestine: 15.5	Expressed in all		
PTGES	MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12	ENSG00000148344	Prostaglandin E synthase	9	129738331-129753047	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045064	Enhanced		Supported	Endoplasmic reticulum	Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 82.9;seminal vesicle: 119.5	urinary bladder: 36.3	Cell line enhanced		BEWO: 155.0;HaCaT: 189.3;U-2197: 372.3
LCN2	24p3, NGAL	ENSG00000148346	Lipocalin 2	9	128149071-128153455	Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002695, CAB016549, CAB016550	Enhanced		Supported	Endoplasmic reticulum	Breast cancer:9.61e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 1852.1;gallbladder: 3419.4	cervix, uterine: 1163.5	Group enriched	11	CAPAN-2: 3169.5;EFO-21: 1362.3
LRSAM1	CMT2P, FLJ31641	ENSG00000148356	Leucine rich repeat and sterile alpha motif containing 1	9	127451486-127503501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021403, HPA021844, CAB037304	Supported		Approved	Cytosol	Pancreatic cancer:6.78e-6 (favourable), Renal cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 20.8	Expressed in all		
HMCN2	DKFZp434P0216, FLJ23816	ENSG00000148357	Hemicentin 2	9	130265882-130434123	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053903, HPA070647	Enhanced		Approved	Vesicles		Mixed	Mixed			small intestine: 11.4	Cell line enhanced		HaCaT: 6.9;RH-30: 17.3;SH-SY5Y: 4.4;U-87 MG: 4.0
GPR107	FLJ20998, KIAA1624, LUSTR1, RP11-88G17	ENSG00000148358	G protein-coupled receptor 107	9	130053426-130140169	Predicted membrane proteins	Evidence at protein level	HPA031704	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.87e-5 (favourable), Breast cancer:3.56e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 55.3	Expressed in all		
C9orf142	PAXX, XLS	ENSG00000148362	Chromosome 9 open reading frame 142	9	136992418-136993984	Predicted intracellular proteins	Evidence at protein level	HPA045268	Uncertain		Supported	Nucleus	Cervical cancer:2.06e-4 (favourable), Pancreatic cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			spleen: 21.9	Expressed in all		
IDI2	IPPI2	ENSG00000148377	Isopentenyl-diphosphate delta isomerase 2	10	1018907-1025859	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	skeletal muscle: 76.3	heart muscle: 1.8	Not detected		
INPP5E	CORS1, JBTS1, pharbin, PPI5PIV	ENSG00000148384	Inositol polyphosphate-5-phosphatase E	9	136428619-136439823	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA065758	Approved				Pancreatic cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.9	Expressed in all		
LCN9		ENSG00000148386	Lipocalin 9	9	135663322-135666422	Predicted secreted proteins	Evidence at protein level	HPA060941	Enhanced					Not detected	Tissue enhanced		epididymis: 1.1	cerebral cortex: 0.6	Cell line enriched	19	BEWO: 16.2
SEC16A	KIAA0310, p250, Sec16L	ENSG00000148396	SEC16 homolog A, endoplasmic reticulum export factor	9	136440096-136483759	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005684	Supported		Supported	Endoplasmic reticulum<br>Golgi apparatus	Endometrial cancer:1.30e-6 (favourable), Renal cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			prostate: 29.6	Expressed in all		
DPH7	C9orf112, FLJ90634, RRT2, WDR85	ENSG00000148399	Diphthamide biosynthesis 7	9	137554904-137578935	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022911	Uncertain		Approved	Nuclear bodies	Renal cancer:1.52e-5 (unfavourable), Urothelial cancer:3.23e-4 (favourable), Pancreatic cancer:6.52e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 18.1	Expressed in all		
NOTCH1	TAN1	ENSG00000148400	Notch 1	9	136494444-136545862	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB008112, CAB022466, HPA067168	Supported		Approved	Nucleoplasm	Renal cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 24.0	Cell line enhanced		MOLT-4: 77.4
CACNA1B	CACNL1A5, CACNN, Cav2.2	ENSG00000148408	Calcium voltage-gated channel subunit alpha1 B	9	137877789-138124624	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044347	Uncertain					Tissue enhanced	Group enriched	8	adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6	prostate: 0.9	Cell line enriched	6	SCLC-21H: 23.0
NACC2	BEND9, BTBD14A, BTBD31, MGC23427	ENSG00000148411	NACC family member 2	9	136006537-136095285	Predicted intracellular proteins	Evidence at protein level	HPA047924, HPA052962	Approved		Approved	Nucleoli<br>Mitochondria	Renal cancer:8.28e-5 (favourable), Stomach cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 46.8	Mixed		
PROSER2	C10orf47, MGC35403	ENSG00000148426	Proline and serine rich 2	10	11823339-11872277	Predicted intracellular proteins	Evidence at protein level	HPA041337	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Mixed	Mixed			placenta: 10.3	Cell line enhanced		A-431: 74.3;CAPAN-2: 87.1
USP6NL	KIAA0019, RN-tre, RNTRE, TRE2NL, USP6NL-IT1	ENSG00000148429	USP6 N-terminal like	10	11453946-11611754	Predicted intracellular proteins	Evidence at protein level	HPA039196	Approved				Head and neck cancer:8.06e-4 (favourable)	Expressed in all	Mixed			testis: 45.0	Mixed		
COMMD3	BUP, C10orf8	ENSG00000148444	COMM domain containing 3	10	22315974-22320308	Predicted intracellular proteins	Evidence at protein level	HPA036584	Approved				Liver cancer:5.46e-7 (unfavourable)	Expressed in all	Expressed in all			breast: 53.1	Expressed in all		
MSRB2	CBS-1, CBS1, CGI-131, MSRB, PILB	ENSG00000148450	Methionine sulfoxide reductase B2	10	23095506-23122013	Predicted secreted proteins	Evidence at protein level	HPA027933	Enhanced					Expressed in all	Mixed			heart muscle: 28.1	Mixed		
PDSS1	COQ1, TPRT, TPT	ENSG00000148459	Decaprenyl diphosphate synthase subunit 1	10	26697659-26746798	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038032, HPA042741	Uncertain		Approved	Cytosol	Liver cancer:1.25e-5 (unfavourable), Endometrial cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 18.4	Expressed in all		
FAM171A1	C10orf38, FLJ12884	ENSG00000148468	Family with sequence similarity 171 member A1	10	15211643-15371062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051345	Approved		Approved	Nucleoplasm<br>Plasma membrane	Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 73.2	Cell line enhanced		TIME: 95.9
MINDY3	C10orf97, CARP, DERP5, FAM188A, FLJ13397, my042	ENSG00000148481	MINDY lysine 48 deubiquitinase 3	10	15778170-15860520	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038400, HPA038406	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			testis: 39.2	Expressed in all		
SLC39A12	FLJ30499	ENSG00000148482	Solute carrier family 39 member 12	10	17951839-18043292	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	28	cerebral cortex: 25.3	breast: 0.8	Not detected		
TMEM236	bA162I21.2, bA16O1.2, FAM23A, FAM23B	ENSG00000148483	Transmembrane protein 236	10	17752252-17800868	Predicted membrane proteins	Evidence at protein level	HPA045096	Enhanced					Tissue enhanced	Group enriched	9	colon: 14.4;duodenum: 22.1;rectum: 15.5;small intestine: 37.7	appendix: 2.3	Cell line enriched	9	MOLT-4: 8.4
RSU1	FLJ31034, RSP-1	ENSG00000148484	Ras suppressor protein 1	10	16590611-16817528	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025927	Uncertain		Approved	Vesicles	Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 58.8	Expressed in all		
ST8SIA6	SIAT8F	ENSG00000148488	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6	10	17318383-17454330	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011635, HPA072708	Uncertain		Uncertain	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		breast: 13.4;lung: 18.1	epididymis: 9.1	Cell line enriched	8	HMC-1: 442.5
PARD3	ASIP, Baz, Bazooka, PAR3, PARD3A, PPP1R118	ENSG00000148498	Par-3 family cell polarity regulator	10	34109560-34815325	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030443	Approved		Enhanced	Cell Junctions	Liver cancer:1.73e-5 (unfavourable), Urothelial cancer:4.41e-4 (unfavourable)	Expressed in all	Mixed			skin: 68.7	Mixed		
ANKRD30A	NY-BR-1	ENSG00000148513	Ankyrin repeat domain 30A	10	37125788-37384111	Predicted intracellular proteins	Evidence at protein level	HPA071849						Tissue enriched	Tissue enriched	15	breast: 49.8	testis: 3.3	Group enriched	34	A549: 2.4;U-266/70: 8.1
ZEB1	AREB6, BZP, FECD6, NIL-2-A, PPCD3, TCF8, ZEB, Zfhep, Zfhx1a	ENSG00000148516	Zinc finger E-box binding homeobox 1	10	31318495-31529814	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027524, CAB058686	Enhanced		Supported	Nucleoplasm	Renal cancer:7.34e-6 (unfavourable)	Expressed in all	Mixed			smooth muscle: 79.9	Cell line enhanced		ASC TERT1: 102.9
FAM13C	FAM13C1	ENSG00000148541	Family with sequence similarity 13 member C	10	59246129-59363181	Predicted intracellular proteins	Evidence at protein level	HPA037888	Approved		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 39.4	Cell line enhanced		NTERA-2: 4.3;SCLC-21H: 10.0;SH-SY5Y: 5.3
NRBF2	COPR1, COPR2, DKFZp564C1664, FLJ30395	ENSG00000148572	Nuclear receptor binding factor 2	10	63133247-63155031	Predicted intracellular proteins	Evidence at protein level	HPA021670, HPA059477	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.36e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 30.7	Expressed in all		
A1CF	ACF, ACF64, ACF65, APOBEC1CF, ASP	ENSG00000148584	APOBEC1 complementation factor	10	50799409-50885675	Predicted intracellular proteins	Evidence at protein level	HPA037779, HPA044079	Enhanced		Supported	Nucleoplasm		Tissue enriched	Tissue enhanced		liver: 76.0;small intestine: 29.8	duodenum: 23.5	Group enriched	18	CACO-2: 19.3;Hep G2: 41.7
CDHR1	CORD15, KIAA1775, PCDH21, RP65	ENSG00000148600	Cadherin related family member 1	10	84194635-84219621	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036819	Supported					Tissue enhanced	Group enriched	5	rectum: 57.9;skin: 252.1	colon: 29.2	Cell line enhanced		HAP1: 10.5;HEK 293: 4.8;HEL: 5.7;RPTEC TERT1: 12.5
LRIT1	DKFZP434K091, FIGLER9, LRRC21, PAL	ENSG00000148602	Leucine rich repeat, Ig-like and transmembrane domains 1	10	84231593-84241461	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	69	testis: 6.8	all non-specific tissues: 0.0	Not detected		
RGR	RP44	ENSG00000148604	Retinal G protein coupled receptor	10	84245053-84259960	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	13	cerebral cortex: 16.1	testis: 1.2	Not detected		
POLR3A	hRPC155, RPC1, RPC155	ENSG00000148606	RNA polymerase III subunit A	10	77969251-78029545	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037926	Uncertain		Supported	Nucleoplasm	Liver cancer:3.64e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 17.9	Expressed in all		
HERC4	DKFZP564G092, KIAA1593	ENSG00000148634	HECT and RLD domain containing E3 ubiquitin protein ligase 4	10	67921899-68075348	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045453, HPA070301	Uncertain		Supported	Nucleoli fibrillar center<br>Cytosol	Renal cancer:3.86e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 32.5	Expressed in all		
C10orf11	CDA017, OCA7	ENSG00000148655	Chromosome 10 open reading frame 11	10	75431453-76560167	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047446, HPA050419	Approved		Supported	Nucleus<br>Cytosol		Mixed	Mixed			epididymis: 73.4	Cell line enhanced		Hep G2: 31.4;NB-4: 42.2;SK-MEL-30: 71.9;THP-1: 33.2;U-937: 34.6
CAMK2G	CAMKG	ENSG00000148660	Calcium/calmodulin dependent protein kinase II gamma	10	73812501-73874591	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040656, HPA051783, HPA051785, HPA053973	Approved		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 119.0	Expressed in all		
ADIRF	AFRO, APM2, C10orf116	ENSG00000148671	Adipogenesis regulatory factor	10	86968192-86983934	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026810	Approved		Supported	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		adipose tissue: 265.8	small intestine: 144.5	Cell line enhanced		A-431: 92.8;HaCaT: 235.9;PC-3: 133.9;RT4: 150.3
GLUD1	GDH, GLUD	ENSG00000148672	Glutamate dehydrogenase 1	10	87050486-87094866	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA042492, HPA044839, HPA061369	Approved		Supported	Mitochondria	Renal cancer:1.44e-6 (favourable), Pancreatic cancer:1.76e-5 (unfavourable), Glioma:5.08e-4 (favourable)	Expressed in all	Expressed in all			liver: 457.9	Expressed in all		
ANKRD1	ALRP, C-193, CARP, CVARP, MCARP	ENSG00000148677	Ankyrin repeat domain 1	10	90912096-90921276	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038736	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Head and neck cancer:1.95e-4 (unfavourable)	Tissue enhanced	Tissue enriched	108	heart muscle: 3714.2	lung: 34.4	Group enriched	6	CACO-2: 348.0;EFO-21: 1053.3;HUVEC TERT2: 325.0;LHCN-M2: 1166.6;TIME: 1606.3
HTR7	5-HT7	ENSG00000148680	5-hydroxytryptamine receptor 7	10	90740823-90857698	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022708, HPA073617	Approved		Supported	Nuclear speckles<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	8	parathyroid gland: 44.8;testis: 16.1	urinary bladder: 3.8	Cell line enhanced		hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
RPP30	TSG15	ENSG00000148688	Ribonuclease P/MRP subunit p30	10	90871716-90908553	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037578	Enhanced		Approved	Nucleus<br>Nucleoli<br>Microtubule ends<br>Cytosol	Renal cancer:1.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 50.5	Expressed in all		
FRA10AC1	C10orf4	ENSG00000148690	FRA10A associated CGG repeat 1	10	93667883-93702572	Predicted intracellular proteins	Evidence at protein level	HPA039204	Approved					Expressed in all	Expressed in all			cerebral cortex: 21.3	Expressed in all		
ADD3	ADDL	ENSG00000148700	Adducin 3	10	109996368-110135565	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009797, HPA035696	Supported		Supported	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 168.6	Cell line enhanced		ASC diff: 215.0;ASC TERT1: 204.7
HABP2	FSAP, HABP, HGFAL, PHBP	ENSG00000148702	Hyaluronan binding protein 2	10	113550837-113589602	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019518	Approved					Tissue enriched	Group enriched	12	gallbladder: 55.8;liver: 225.6	stomach: 11.3	Cell line enriched	5	RPTEC TERT1: 38.3
VAX1		ENSG00000148704	Ventral anterior homeobox 1	10	117128521-117138301	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028946	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		cerebral cortex: 1.4	testis: 0.4	Group enriched	8	A-431: 2.9;WM-115: 2.4
DNAJB12	DJ10, FLJ20027	ENSG00000148719	DnaJ heat shock protein family (Hsp40) member B12	10	72332830-72355230	Predicted membrane proteins	Evidence at protein level	HPA010642	Approved		Supported	Endoplasmic reticulum	Colorectal cancer:4.79e-4 (unfavourable), Head and neck cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 48.0	Expressed in all		
EIF4EBP2		ENSG00000148730	Eukaryotic translation initiation factor 4E binding protein 2	10	70404379-70428618	Predicted intracellular proteins	Evidence at protein level	CAB019415, HPA037410, HPA061665	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:6.69e-6 (favourable)	Expressed in all	Expressed in all			adipose tissue: 74.3	Expressed in all		
NPFFR1	GPR147, NPFF1R1, OT7T022	ENSG00000148734	Neuropeptide FF receptor 1	10	70247329-70283676	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA037521	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.1	cerebral cortex,lymph node: 0.8	Cell line enhanced		U-2 OS: 1.0
PLEKHS1	bA211N11.2, C10orf81, FLJ23537	ENSG00000148735	Pleckstrin homology domain containing S1	10	113751454-113783429	Predicted intracellular proteins	Evidence at protein level	HPA037583			Supported	Centrosome	Urothelial cancer:1.03e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 88.6	duodenum: 41.1	Cell line enhanced		CAPAN-2: 7.3;RH-30: 3.8;RT4: 12.5;T-47d: 4.9
TCF7L2	TCF-4, TCF4	ENSG00000148737	Transcription factor 7 like 2	10	112950250-113167678	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013535, HPA038800	Supported	Approved	Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 30.9	Mixed		
MKI67	MIB-, PPP1R105	ENSG00000148773	Marker of proliferation Ki-67	10	128096659-128126385	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000058, HPA000451, HPA001164, CAB068198	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Nuclear bodies	Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.61e-6 (unfavourable), Pancreatic cancer:9.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 28.8	lymph node: 17.9	Mixed		
CYP17A1	CPT7, CYP17, P450C17, S17AH	ENSG00000148795	Cytochrome P450 family 17 subfamily A member 1	10	102830531-102837533	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA048533	Enhanced				Renal cancer:5.43e-7 (favourable)	Tissue enriched	Tissue enriched	25	adrenal gland: 3751.4	testis: 152.4	Cell line enhanced		HMC-1: 2.6;SCLC-21H: 1.3
INA	NEF5, NF-66	ENSG00000148798	Internexin neuronal intermediate filament protein alpha	10	103277163-103290351	Predicted intracellular proteins	Evidence at protein level	CAB002059, HPA008057	Enhanced	Supported	Supported	Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments		Tissue enhanced	Tissue enriched	6	cerebral cortex: 89.0	adrenal gland: 16.0	Cell line enhanced		NTERA-2: 53.4;SCLC-21H: 122.4;SH-SY5Y: 62.7;SiHa: 76.3
FUOM	C10orf125, FLJ26016, FucM, FucU	ENSG00000148803	Fucose mutarotase	10	133355154-133358035	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039207	Uncertain					Expressed in all	Tissue enhanced		liver: 74.9	duodenum: 50.9	Mixed		
LRRC27	KIAA1674	ENSG00000148814	Leucine rich repeat containing 27	10	132332154-132379918	Predicted intracellular proteins	Evidence at protein level	HPA037595, HPA067395	Enhanced		Approved	Nucleus<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 100.8	fallopian tube: 21.1	Mixed		
MTG1	GTPBP7	ENSG00000148824	Mitochondrial ribosome associated GTPase 1	10	133394094-133421307	Predicted intracellular proteins	Evidence at protein level	HPA037826, HPA037827	Approved		Supported	Mitochondria	Renal cancer:6.79e-7 (unfavourable), Urothelial cancer:1.03e-5 (favourable), Pancreatic cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.5	Expressed in all		
NKX6-2	GTX, NKX6.1, NKX6B	ENSG00000148826	NK6 homeobox 2	10	132783179-132786052	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Group enriched	25	cerebral cortex: 15.7;stomach: 16.7	testis: 0.6	Not detected		
PAOX	PAO	ENSG00000148832	Polyamine oxidase	10	133379234-133391694	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047782			Uncertain	Nucleoplasm<br>Centrosome	Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 7.6	cerebral cortex: 3.2	Cell line enhanced		A-431: 5.2;U-266/70: 12.5
GSTO1	GSTTLp28, P28	ENSG00000148834	Glutathione S-transferase omega 1	10	104235356-104267459	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037603, HPA037604	Enhanced				Renal cancer:2.11e-4 (unfavourable), Breast cancer:6.95e-4 (favourable), Head and neck cancer:8.83e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 266.3	Expressed in all		
TAF5	TAF2D, TAFII100	ENSG00000148835	TATA-box binding protein associated factor 5	10	103367967-103389065	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006195, HPA006474	Supported		Supported	Nucleoplasm	Renal cancer:1.36e-9 (unfavourable), Stomach cancer:7.39e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 20.7	lymph node,placenta: 5.1	Expressed in all		
PPRC1	KIAA0595, MGC74642, PRC	ENSG00000148840	Peroxisome proliferator-activated receptor gamma, coactivator-related 1	10	102132994-102150331	Predicted intracellular proteins	Evidence at protein level	HPA038511, HPA057571	Approved		Enhanced	Nucleoplasm	Renal cancer:6.71e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 20.8	Expressed in all		
ITPRIP	bA127L20.2, DANGER, KIAA1754	ENSG00000148841	Inositol 1,4,5-trisphosphate receptor interacting protein	10	104309698-104338404	Predicted membrane proteins	Evidence at protein level	HPA043626			Uncertain	Vesicles	Lung cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 135.2	Mixed		
CNNM2	ACDP2	ENSG00000148842	Cyclin and CBS domain divalent metal cation transport mediator 2	10	102918293-103090221	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059954, HPA071631			Enhanced	Vesicles	Renal cancer:2.39e-8 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 33.6	placenta: 12.4	Expressed in all		
PDCD11	ALG-4, KIAA0185, RRP5	ENSG00000148843	Programmed cell death 11	10	103396648-103446292	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017924, CAB026472	Approved		Supported	Nucleoli<br>Vesicles	Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 27.9	Expressed in all		
ADAM12	MCMPMltna, MLTN	ENSG00000148848	ADAM metallopeptidase domain 12	10	126012381-126388455	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA030866, HPA030867, HPA030868	Enhanced		Supported	Plasma membrane	Renal cancer:2.39e-14 (unfavourable)	Mixed	Tissue enriched	8	placenta: 237.2	cervix, uterine: 29.7	Cell line enhanced		fHDF/TERT166: 119.5;hTEC/SVTERT24-B: 94.3;U-2197: 86.6;U-251 MG: 71.0
RGS10		ENSG00000148908	Regulator of G-protein signaling 10	10	119499828-119542708	Predicted intracellular proteins	Evidence at protein level	CAB004559, HPA021305, HPA058485	Enhanced	Supported	Supported	Nucleus<br>Plasma membrane	Renal cancer:4.20e-10 (unfavourable), Endometrial cancer:6.32e-4 (favourable), Cervical cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 137.6	Cell line enhanced		HMC-1: 456.7
BTBD10	GMRP-1, GMRP1, MGC13007	ENSG00000148925	BTB domain containing 10	11	13388001-13463297	Predicted intracellular proteins	Evidence at protein level	HPA046777	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 67.8	Expressed in all		
ADM	AM	ENSG00000148926	Adrenomedullin	11	10304680-10307397	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016075	Approved				Renal cancer:6.33e-4 (unfavourable), Liver cancer:7.56e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 158.5	Cell line enhanced		ASC diff: 519.0;U-138 MG: 397.2
GAS2		ENSG00000148935	Growth arrest specific 2	11	22625642-22813055	Predicted intracellular proteins	Evidence at protein level	HPA058904	Enhanced		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:6.13e-4 (favourable)	Tissue enhanced	Tissue enhanced		liver: 20.4	kidney: 5.5	Group enriched	11	Hep G2: 29.5;Karpas-707: 61.6;SCLC-21H: 29.3;U-266/84: 21.3
SLC5A12	MGC52019, SMCT2	ENSG00000148942	Solute carrier family 5 member 12	11	26667019-26723427	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060904	Enhanced					Tissue enriched	Tissue enhanced		epididymis: 58.2;kidney: 173.7	small intestine: 33.4	Cell line enhanced		Karpas-707: 1.6;NTERA-2: 1.7;T-47d: 1.1
LIN7C	FLJ11215, LIN-7-C, LIN-7C, Lin7c, MALS-3, VELI3	ENSG00000148943	Lin-7 homolog C, crumbs cell polarity complex component	11	27494576-27506773	Predicted intracellular proteins	Evidence at protein level	HPA051118	Approved				Renal cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 24.3	Expressed in all		
LRRC4C	KIAA1580, NGL-1	ENSG00000148948	Leucine rich repeat containing 4C	11	40114203-41459773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051335, HPA054800	Approved		Approved	Cytosol		Tissue enhanced	Tissue enriched	7	cerebral cortex: 34.4	cervix, uterine: 4.7	Group enriched	9	AF22: 18.9;U-2 OS: 21.7
IMMP1L	FLJ25059, IMMP1	ENSG00000148950	Inner mitochondrial membrane peptidase subunit 1	11	31432401-31509645	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058308	Approved				Pancreatic cancer:6.72e-4 (favourable), Liver cancer:7.97e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 39.2	Expressed in all		
SAA4	C-SAA, CSAA	ENSG00000148965	Serum amyloid A4, constitutive	11	18231349-18236893	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026061, HPA060139	Supported					Tissue enriched	Tissue enriched	42	liver: 776.2	cervix, uterine: 18.6	Cell line enriched	14	Hep G2: 15.6
PGAP2	CWH43-N, FRAG1, MRT21	ENSG00000148985	Post-GPI attachment to proteins 2	11	3797724-3826371	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063099	Approved		Approved	Microtubules	Liver cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 263.3	Expressed in all		
TUT1	FLJ21850, FLJ22267, FLJ22347, PAPD2, RBM21, TUTase	ENSG00000149016	Terminal uridylyl transferase 1, U6 snRNA-specific	11	62575045-62592177	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069055, HPA071838			Supported	Nucleus<br>Cytosol	Colorectal cancer:9.51e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 17.8	Expressed in all		
SCGB1A1	CC10, CC16, CCSP, UGB	ENSG00000149021	Secretoglobin family 1A member 1	11	62405103-62423195	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025686, HPA031828	Supported					Tissue enriched	Tissue enriched	9	lung: 4742.5	fallopian tube: 521.2	Cell line enriched	70	HaCaT: 1741.2
SYT8	DKFZp434K0322	ENSG00000149043	Synaptotagmin 8	11	1828307-1837521	Predicted membrane proteins	Evidence at transcript level	HPA052700	Uncertain		Approved	Nucleoplasm<br>Cell Junctions		Tissue enhanced	Group enriched	5	gallbladder: 26.5;skin: 80.2;urinary bladder: 24.5	seminal vesicle: 8.6	Group enriched	6	CAPAN-2: 56.5;hTCEpi: 72.7;T-47d: 25.8
ZNF214		ENSG00000149050	Zinc finger protein 214	11	6999318-7020368	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055391	Uncertain					Mixed	Mixed			fallopian tube: 6.9	Mixed		
ZNF215	ZKSCAN11, ZSCAN43	ENSG00000149054	Zinc finger protein 215	11	6926404-7001004	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047243, HPA051010	Enhanced		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			lymph node: 4.5	Cell line enhanced		U-698: 14.5
HSD17B12	KAR, SDR12C1	ENSG00000149084	Hydroxysteroid 17-beta dehydrogenase 12	11	43680558-43856617	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016427	Approved				Renal cancer:2.10e-8 (favourable), Liver cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 196.5	Expressed in all		
APIP	APIP2, CGI-29, Mmrp19	ENSG00000149089	APAF1 interacting protein	11	34853094-34916499	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021188, HPA024131	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.99e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.2	Expressed in all		
PAMR1	DKFZP586H2123, RAMP	ENSG00000149090	Peptidase domain containing associated with muscle regeneration 1	11	35431823-35530300	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.08e-5 (unfavourable), Stomach cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 87.0;endometrium: 92.2	placenta: 76.1	Cell line enhanced		ASC TERT1: 233.7;BJ hTERT+: 274.9;HSkMC: 84.2;U-87 MG: 78.6
DGKZ	DAGK5, DAGK6, DGK-ZETA, hDGKzeta	ENSG00000149091	Diacylglycerol kinase zeta	11	46332905-46380554	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051336	Supported		Supported	Nuclear speckles	Renal cancer:4.74e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.6	Expressed in all		
EIF3M	eIF3m, FLJ29030, GA17, hfl-B5, PCID1, TANGO7	ENSG00000149100	Eukaryotic translation initiation factor 3 subunit M	11	32583798-32606262	Predicted intracellular proteins	Evidence at protein level	HPA031063	Approved		Supported	Cytosol	Liver cancer:1.28e-9 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 235.1	Expressed in all		
TNKS1BP1	FLJ45975, KIAA1741, TAB182	ENSG00000149115	Tankyrase 1 binding protein 1	11	57299638-57324952	Predicted intracellular proteins	Evidence at protein level	HPA037929, HPA037930	Enhanced				Renal cancer:2.11e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 79.1	Expressed in all		
GLYAT	ACGNAT, GAT	ENSG00000149124	Glycine-N-acyltransferase	11	58640426-58731974	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040251, HPA044094	Enhanced				Renal cancer:1.31e-6 (favourable)	Group enriched	Group enriched	10	kidney: 584.9;liver: 355.3	adipose tissue: 47.4	Mixed		
SERPING1	C1-INH, C1IN, C1NH, HAE1, HAE2	ENSG00000149131	Serpin family G member 1	11	57597387-57614853	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026161, HPA048738	Supported				Renal cancer:1.55e-4 (unfavourable), Ovarian cancer:8.03e-4 (favourable), Colorectal cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 1365.0	Group enriched	5	ASC diff: 881.8;ASC TERT1: 462.5;HSkMC: 802.1
OR5F1	OR11-10	ENSG00000149133	Olfactory receptor family 5 subfamily F member 1	11	55993681-55994625	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059360	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SSRP1	FACT80	ENSG00000149136	Structure specific recognition protein 1	11	57325985-57335877	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002697	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:4.03e-7 (unfavourable), Pancreatic cancer:1.40e-4 (unfavourable), Renal cancer:5.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.9	Expressed in all		
SLC43A1	PB39, POV1, R00504	ENSG00000149150	Solute carrier family 43 member 1	11	57484534-57515786	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018813, HPA018826	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 50.0	Mixed		
PTPRJ	CD148, DEP1, HPTPeta	ENSG00000149177	Protein tyrosine phosphatase, receptor type J	11	47980558-48170841	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006026	Approved				Renal cancer:1.13e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.6	Mixed		
C11orf49	FLJ22210, MGC4707	ENSG00000149179	Chromosome 11 open reading frame 49	11	46936689-47164385	Predicted intracellular proteins	Evidence at protein level	HPA040051, HPA040280	Uncertain		Approved	Nuclear speckles	Liver cancer:2.18e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.2	Expressed in all		
ARFGAP2	FLJ14576, IRZ, Zfp289, ZNF289	ENSG00000149182	ADP ribosylation factor GTPase activating protein 2	11	47164299-47177125	Predicted intracellular proteins	Evidence at protein level	HPA016649, HPA018152	Enhanced		Supported	Golgi apparatus	Renal cancer:7.65e-7 (favourable)	Expressed in all	Expressed in all			skin: 90.1	Expressed in all		
CELF1	BRUNOL2, CUG-BP, CUGBP, CUGBP1, EDEN-BP, hNab50, NAB50, NAPOR	ENSG00000149187	CUGBP Elav-like family member 1	11	47465944-47565569	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016114, HPA044597, CAB069989	Supported		Enhanced	Nucleoplasm	Liver cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 133.1	Expressed in all		
HIKESHI	C11orf73, HSPC138, HSPC179, OPI10	ENSG00000149196	Hikeshi, heat shock protein nuclear import factor	11	86302211-86345931	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035063, HPA035064	Approved				Renal cancer:4.01e-12 (unfavourable), Liver cancer:8.81e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 46.6	Expressed in all		
CCDC81	FLJ16339, FLJ23514	ENSG00000149201	Coiled-coil domain containing 81	11	86374736-86423109	Predicted intracellular proteins	Evidence at protein level	HPA040745, HPA040827	Uncertain		Uncertain	Plasma membrane		Tissue enhanced	Group enriched	10	fallopian tube: 46.1;testis: 11.0	endometrium: 2.7	Cell line enhanced		BJ: 2.9;HBF TERT88: 1.8
SESN3	MGC29667, SEST3	ENSG00000149212	Sestrin 3	11	95165513-95232541	Predicted intracellular proteins	Evidence at protein level	HPA037935			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		testis: 104.8	parathyroid gland: 54.5	Cell line enhanced		AF22: 27.8;ASC diff: 32.0;ASC TERT1: 35.5
ENDOD1	KIAA0830	ENSG00000149218	Endonuclease domain containing 1	11	95089810-95132645	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008932, HPA010517	Enhanced		Approved	Nuclear membrane	Renal cancer:6.64e-7 (favourable), Urothelial cancer:3.27e-4 (unfavourable), Pancreatic cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 99.6	Cell line enhanced		ASC diff: 132.3
CCDC82	FLJ23518	ENSG00000149231	Coiled-coil domain containing 82	11	96352769-96389923	Predicted intracellular proteins	Evidence at protein level	HPA038704	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 55.5	Mixed		
KLHL35	FLJ33790	ENSG00000149243	Kelch like family member 35	11	75422394-75430629	Predicted intracellular proteins	Evidence at protein level	HPA039232, HPA039864	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Centrosome	Cervical cancer:4.63e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 3.6;testis: 6.2	cervix, uterine: 1.1	Cell line enhanced		CACO-2: 13.0;HMC-1: 8.9;PC-3: 8.3;SiHa: 19.5
TENM4	KIAA1302, ODZ4, Ten-M4	ENSG00000149256	Teneurin transmembrane protein 4	11	78652831-79440948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019521, HPA065961	Approved					Mixed	Tissue enhanced		ovary: 20.8;parathyroid gland: 54.0	thyroid gland: 9.7	Cell line enhanced		PC-3: 9.9;SH-SY5Y: 18.6
SERPINH1	CBP1, CBP2, colligen, HSP47, SERPINH2	ENSG00000149257	Serpin family H member 1	11	75562056-75572783	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004441, HPA029198	Supported		Enhanced	Endoplasmic reticulum	Renal cancer:3.22e-15 (unfavourable), Head and neck cancer:1.85e-4 (unfavourable), Cervical cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.1	Mixed		
CAPN5	ADNIV, HTRA3, nCL-3, VRNI	ENSG00000149260	Calpain 5	11	77066932-77126155	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033237	Uncertain				Endometrial cancer:2.16e-6 (unfavourable)	Expressed in all	Mixed			colon: 61.0	Mixed		
INTS4	INT4, MGC16733, MST093	ENSG00000149262	Integrator complex subunit 4	11	77878720-77994678	Predicted intracellular proteins	Evidence at protein level	HPA042378	Uncertain		Approved	Nucleoli	Liver cancer:9.44e-6 (unfavourable), Thyroid cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Expressed in all		
PAK1		ENSG00000149269	P21 (RAC1) activated kinase 1	11	77321707-77474635	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003565, CAB005312	Enhanced	Supported	Enhanced	Plasma membrane<br>Cytosol	Glioma:9.48e-5 (unfavourable), Colorectal cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 184.2	Mixed		
RPS3	FLJ26283, FLJ27450, MGC87870, S3	ENSG00000149273	Ribosomal protein S3	11	75399486-75422280	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063339	Uncertain		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.92e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 3537.9	Expressed in all		
ZC3H12C	KIAA1726, MCPIP3	ENSG00000149289	Zinc finger CCCH-type containing 12C	11	110093361-110171841	Predicted intracellular proteins	Evidence at protein level	HPA038836, HPA038837	Approved		Approved	Nuclear membrane<br>Golgi apparatus	Renal cancer:9.90e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 13.6	Mixed		
TTC12	FLJ13859, FLJ20535, TPARM	ENSG00000149292	Tetratricopeptide repeat domain 12	11	113314529-113383544	Predicted intracellular proteins	Evidence at protein level	HPA038542, HPA038543, HPA061364	Approved		Approved	Nucleoplasm	Endometrial cancer:2.48e-5 (favourable), Renal cancer:5.95e-5 (favourable), Colorectal cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.4	Cell line enhanced		SiHa: 27.4
NCAM1	CD56, NCAM	ENSG00000149294	Neural cell adhesion molecule 1	11	112961247-113278436	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000142, CAB018071, HPA039835	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 334.9	heart muscle: 87.5	Cell line enhanced		RH-30: 128.0;SCLC-21H: 126.2;U-138 MG: 71.8;WM-115: 77.9
DRD2		ENSG00000149295	Dopamine receptor D2	11	113409615-113475691	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015139, HPA015691	Supported	Supported				Mixed	Tissue enhanced		adrenal gland: 11.2	smooth muscle: 2.2	Cell line enriched	10	SCLC-21H: 104.3
C11orf52	FLJ25219, MGC14839	ENSG00000149300	Chromosome 11 open reading frame 52	11	111918032-111926872	Predicted intracellular proteins	Evidence at protein level	HPA038387, HPA038388	Uncertain		Enhanced	Cell Junctions		Not detected	Mixed			kidney: 44.9	Cell line enhanced		CAPAN-2: 19.2;RPTEC TERT1: 20.1;T-47d: 70.7
HTR3B	5-HT3B	ENSG00000149305	5-hydroxytryptamine receptor 3B	11	113904677-113946565	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039559	Approved					Not detected	Tissue enhanced		cerebral cortex: 2.7	testis: 1.1	Not detected		
NPAT	E14, p220	ENSG00000149308	Nuclear protein, coactivator of histone transcription	11	108157215-108222642	Predicted intracellular proteins	Evidence at protein level	HPA045908, HPA066370			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			lymph node: 17.5	Expressed in all		
ATM	ATA, ATC, ATD, ATDC, TEL1, TELO1	ENSG00000149311	ATM serine/threonine kinase	11	108222484-108369102	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000102, HPA067142	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 40.8	Expressed in all		
AASDHPPT	AASD-PPT, ACPS, CGI-80, LYS5	ENSG00000149313	Aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase	11	106075501-106098710	Predicted intracellular proteins	Evidence at protein level	HPA026687	Approved				Renal cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 81.9	Expressed in all		
GLB1L2		ENSG00000149328	Galactosidase beta 1 like 2	11	134331874-134378341	Predicted secreted proteins	Evidence at protein level	HPA054808, HPA059955	Uncertain		Supported	Nucleus		Mixed	Tissue enhanced		parathyroid gland: 53.2;prostate: 56.1	fallopian tube: 41.3	Cell line enhanced		CAPAN-2: 43.7;HaCaT: 46.4;SCLC-21H: 41.1
SLX4IP	C20orf94, dJ1099D15.3	ENSG00000149346	SLX4 interacting protein	20	10435303-10636829	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046372	Approved		Approved	Cytosol	Renal cancer:9.51e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.1	Mixed		
LAMTOR1	C11orf59, FLJ20625, p18, p27RF-Rho, Pdro, Ragulator1	ENSG00000149357	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 1	11	72085895-72103387	Predicted intracellular proteins	Evidence at protein level	HPA002997	Approved		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 143.2	Expressed in all		
P4HA3	C-P4Halpha(III)	ENSG00000149380	Prolyl 4-hydroxylase subunit alpha 3	11	74235801-74311657	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA007897	Approved				Renal cancer:3.34e-9 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)	Mixed	Tissue enhanced		smooth muscle: 14.5	gallbladder: 8.9	Cell line enhanced		BJ: 16.3;HUVEC TERT2: 31.5;TIME: 22.1
GRIK4	GluK4, GRIK, KA1	ENSG00000149403	Glutamate ionotropic receptor kainate type subunit 4	11	120511700-120988904	Predicted membrane proteins, Transporters	Evidence at protein level	HPA074453	Enhanced					Tissue enriched	Tissue enhanced		cerebral cortex: 11.3	ovary,thyroid gland: 3.5	Group enriched	5	HDLM-2: 5.7;HEL: 16.7;T-47d: 4.4
ST14	HAI, MT-SP1, PRSS14, SNC19, TMPRSS14	ENSG00000149418	Suppression of tumorigenicity 14	11	130159562-130210376	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA047014			Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.03e-11 (favourable)	Expressed in all	Mixed			small intestine: 149.0	Cell line enhanced		CAPAN-2: 361.3;HaCaT: 255.1;RPMI-8226: 192.2;T-47d: 268.8
HYOU1	Grp170, HSP12A, ORP150	ENSG00000149428	Hypoxia up-regulated 1	11	119044189-119057202	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA049296	Approved				Renal cancer:5.10e-5 (unfavourable), Endometrial cancer:2.58e-4 (favourable), Thyroid cancer:5.00e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 111.7	Expressed in all		
GGTLC1	dJ831C21.1, dJ831C21.2, GGTLA3, GGTLA4	ENSG00000149435	Gamma-glutamyltransferase light chain 1	20	23985050-23988779	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Tissue enriched	Group enriched	14	lung: 38.7;testis: 15.8	thyroid gland: 1.9	Not detected		
ADAM33	C20orf153, dJ964F7.1, DKFZp434K0521	ENSG00000149451	ADAM metallopeptidase domain 33	20	3667965-3682246	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA067152, HPA071758	Approved		Uncertain	Nuclear speckles<br>Plasma membrane		Mixed	Mixed			endometrium: 103.3	Cell line enhanced		ASC diff: 55.2;ASC TERT1: 72.4;BJ: 31.3;BJ hTERT+: 51.1;fHDF/TERT166: 29.6;U-2197: 46.1
SLC22A8	OAT3	ENSG00000149452	Solute carrier family 22 member 8	11	62989154-63015839	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044174	Enhanced					Tissue enhanced	Tissue enriched	395	kidney: 339.8	cerebral cortex: 0.8	Not detected		
KAT14	ATAC2, CRP2BP, CSRP2BP, dJ717M23.1, PRO1194	ENSG00000149474	Lysine acetyltransferase 14	20	18138118-18188387	Predicted intracellular proteins	Evidence at protein level	CAB034224, HPA068443	Uncertain		Approved	Vesicles	Renal cancer:4.64e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
TKFC	DAK, DKFZP586B1621, NET45	ENSG00000149476	Triokinase and FMN cyclase	11	61333210-61353295	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039486, HPA048186	Enhanced		Approved	Nucleus<br>Cytosol	Endometrial cancer:1.32e-5 (favourable), Renal cancer:8.38e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 194.2	Expressed in all		
MTA2	MTA1-L1, MTA1L1	ENSG00000149480	Metastasis associated 1 family member 2	11	62593214-62601840	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005315, HPA006214, CAB017522	Enhanced		Enhanced	Nucleoplasm	Liver cancer:4.82e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 88.3	Expressed in all		
TMEM138	HSPC196, JBTS16	ENSG00000149483	Transmembrane protein 138	11	61362001-61369509	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042373	Approved		Approved	Microtubules	Renal cancer:4.12e-6 (unfavourable), Liver cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 24.9	Expressed in all		
FADS1	D5D, FADS6, FADSD5, LLCDL1, TU12	ENSG00000149485	Fatty acid desaturase 1	11	61799625-61829318	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042705	Approved				Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 89.1	Expressed in all		
TMC2	C20orf145, dJ686C3.3	ENSG00000149488	Transmembrane channel like 2	20	2536607-2641784	Predicted membrane proteins	Evidence at transcript level	HPA046350	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
ROM1	ROM, TSPAN23	ENSG00000149489	Retinal outer segment membrane protein 1	11	62611722-62615120	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028910	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 25.4	ovary: 13.3	Mixed		
EML3	ELP95, FLJ35827	ENSG00000149499	Echinoderm microtubule associated protein like 3	11	62602218-62612765	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.13e-8 (unfavourable)	Expressed in all	Expressed in all			appendix: 37.6	Expressed in all		
INCENP	FLJ31633	ENSG00000149503	Inner centromere protein	11	62123973-62153163	Predicted intracellular proteins	Evidence at protein level	CAB013292, HPA051339, HPA070550	Enhanced		Supported	Nucleus<br>Nuclear bodies<br>Midbody	Pancreatic cancer:5.76e-5 (unfavourable), Liver cancer:1.25e-4 (unfavourable), Lung cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 12.7	Expressed in all		
ZP1		ENSG00000149506	Zona pellucida glycoprotein 1	11	60867562-60875693	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			epididymis,prostate: 0.2	Group enriched	37	RPMI-8226: 8.4;SK-BR-3: 2.5
OOSP2	FLJ36198, PLAC1L, TMEM122	ENSG00000149507	Oocyte secreted protein 2	11	60040275-60048044	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050914	Enhanced					Not detected	Tissue enriched	487	testis: 48.6	all non-specific tissues: 0.0	Not detected		
MS4A3	CD20L, HTM4	ENSG00000149516	Membrane spanning 4-domains A3	11	60056587-60071128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019210	Supported					Not detected	Tissue enriched	256	bone marrow: 305.3	skin,spleen: 1.1	Cell line enhanced		HEL: 172.0;K-562: 132.6;NB-4: 69.9;THP-1: 214.5;U-937: 98.3
PLCH2	KIAA0450, PLC-eta2, PLCeta2, PLCL4, RP3-395M20.1	ENSG00000149527	Phospholipase C eta 2	1	2425980-2505530	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072705	Approved					Mixed	Tissue enhanced		skin: 58.5	esophagus: 14.0	Cell line enhanced		HBEC3-KT: 91.6;hTCEpi: 42.6;hTERT-HME1: 26.9
CPSF7	FLJ12529	ENSG00000149532	Cleavage and polyadenylation specific factor 7	11	61402641-61430031	Predicted intracellular proteins	Evidence at protein level	HPA041094	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 76.2	Expressed in all		
MS4A2	APY, FCER1B, IGER, MS4A1	ENSG00000149534	Membrane spanning 4-domains A2	11	60088261-60098466	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA059967	Enhanced					Mixed	Tissue enhanced		lung: 24.8	gallbladder: 18.4	Cell line enhanced		HEL: 2.4;THP-1: 1.0
B3GAT3	GlcAT-I	ENSG00000149541	Beta-1,3-glucuronyltransferase 3	11	62615296-62622175	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051328	Approved				Liver cancer:5.11e-6 (unfavourable), Glioma:5.96e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.9	Expressed in all		
EI24	EPG4, PIG8, TP53I8	ENSG00000149547	EI24, autophagy associated transmembrane protein	11	125569216-125584687	Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047165, HPA051029	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:9.28e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 1120.1	liver: 125.1	Expressed in all		
CCDC15	FLJ13215	ENSG00000149548	Coiled-coil domain containing 15	11	124954121-125041489	Predicted intracellular proteins	Evidence at transcript level	HPA040450, HPA041738	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	5	testis: 18.9	breast: 3.5	Mixed		
CHEK1	CHK1	ENSG00000149554	Checkpoint kinase 1	11	125625136-125676255	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044364			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 62.5;seminal vesicle: 52.6	testis: 22.1	Expressed in all		
FEZ1	UNC-76	ENSG00000149557	Fasciculation and elongation protein zeta 1	11	125445745-125496317	Predicted intracellular proteins	Evidence at protein level	HPA038490			Supported	Microtubules<br>Cytosol	Renal cancer:2.16e-6 (unfavourable), Cervical cancer:9.06e-5 (unfavourable)	Tissue enriched	Tissue enriched	10	cerebral cortex: 410.9	urinary bladder: 41.3	Cell line enhanced		AF22: 156.1;NTERA-2: 145.3;SCLC-21H: 181.1
ESAM	W117m	ENSG00000149564	Endothelial cell adhesion molecule	11	124752583-124762290	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA051043, HPA056293	Uncertain		Approved	Microtubules		Expressed in all	Expressed in all			placenta: 157.9	Group enriched	15	HEL: 198.2;HUVEC TERT2: 233.4;TIME: 115.5
KIRREL3	KIAA1867, KIRRE, NEPH2	ENSG00000149571	Kin of IRRE like 3 (Drosophila)	11	126423359-127003460	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA053324, HPA056320	Enhanced					Tissue enhanced	Tissue enriched	11	cerebral cortex: 20.4	adrenal gland: 1.9	Cell line enhanced		BJ: 21.4;BJ hTERT+: 12.0;fHDF/TERT166: 14.2;U-138 MG: 11.2;U-251 MG: 11.6
MPZL2	EVA, EVA1	ENSG00000149573	Myelin protein zero like 2	11	118253403-118264536	Predicted membrane proteins	Evidence at protein level	HPA060740	Approved		Approved	Cell Junctions	Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable)	Expressed in all	Tissue enhanced		esophagus: 209.1	urinary bladder: 118.1	Cell line enhanced		CAPAN-2: 107.3;EFO-21: 123.8;HaCaT: 149.0;RT4: 257.4;TIME: 288.5
SCN2B		ENSG00000149575	Sodium voltage-gated channel beta subunit 2	11	118161951-118176673	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Group enriched	9	cerebral cortex: 34.7;heart muscle: 7.1	smooth muscle: 2.4	Cell line enhanced		U-2197: 1.6
SIDT2	CGI-40	ENSG00000149577	SID1 transmembrane family member 2	11	117178733-117197445	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052352	Approved				Renal cancer:4.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 60.8	Expressed in all		
TMEM25	FLJ14399	ENSG00000149582	Transmembrane protein 25	11	118531041-118547280	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012163, HPA051562	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			duodenum: 47.0	Cell line enhanced		T-47d: 41.7
TAGLN	DKFZp686P11128, SM22, SMCC, TAGLN1, WS3-10	ENSG00000149591	Transgelin	11	117199321-117204782	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001447, HPA019467	Enhanced		Approved	Microtubules<br>Mitochondria<br>Cytosol	Renal cancer:2.12e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 11975.2	Expressed in all		
JPH2	JP-2	ENSG00000149596	Junctophilin 2	20	44111695-44187578	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052646	Approved					Mixed	Tissue enhanced		skeletal muscle: 72.1;smooth muscle: 56.0	seminal vesicle: 47.8	Cell line enhanced		EFO-21: 21.6;fHDF/TERT166: 18.5;SiHa: 16.8
DUSP15	bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY	ENSG00000149599	Dual specificity phosphatase 15	20	31847637-31870747	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA076649	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:5.40e-7 (favourable)	Mixed	Tissue enhanced		testis: 77.1	parathyroid gland: 16.1	Cell line enhanced		REH: 14.6;SH-SY5Y: 4.6
COMMD7	C20orf92, dJ1085F17.3	ENSG00000149600	COMM domain containing 7	20	32702691-32743997	Predicted intracellular proteins	Evidence at protein level	HPA054119			Supported	Vesicles	Liver cancer:1.46e-4 (unfavourable), Urothelial cancer:3.53e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 80.3	Expressed in all		
C20orf144	bclt, dJ63M2.6	ENSG00000149609	Chromosome 20 open reading frame 144	20	33662284-33665619	Predicted intracellular proteins	Evidence at protein level	HPA019029	Enhanced					Not detected	Tissue enriched	435	testis: 43.4	all non-specific tissues: 0.0	Not detected		
KIAA1755	RP5-1054A22.3	ENSG00000149633	KIAA1755	20	38210488-38260772	Predicted intracellular proteins	Evidence at protein level	HPA051064	Approved		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 33.6	Cell line enhanced		AF22: 74.8;ASC TERT1: 11.9;WM-115: 19.1
SPATA25	C20orf165, dJ337O18.8, TSG23	ENSG00000149634	Spermatogenesis associated 25	20	45886489-45887635	Predicted intracellular proteins	Evidence at protein level	HPA041386			Approved	Golgi apparatus		Mixed	Mixed			testis: 15.4	Mixed		
OCSTAMP	C20orf123, dJ257E24.3	ENSG00000149635	Osteoclast stimulatory transmembrane protein	20	46540946-46550574	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA031116	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enhanced		AF22: 1.1;HMC-1: 2.0;NB-4: 1.6;U-266/84: 1.7
DSN1	C20orf172, dJ469A13.2, hKNL-3, KNL3, MIS13	ENSG00000149636	DSN1 homolog, MIS12 kinetochore complex component	20	36751791-36773818	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002813, HPA030627	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center<br>Nuclear bodies<br>Cytosol	Renal cancer:1.54e-5 (unfavourable), Liver cancer:4.16e-5 (unfavourable), Cervical cancer:4.49e-4 (favourable)	Expressed in all	Mixed			testis: 40.2	Expressed in all		
SOGA1	C20orf117, dJ132F21.1, FLJ44670, KIAA0889, SOGA	ENSG00000149639	Suppressor of glucose, autophagy associated 1	20	36777442-36863686	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043992	Approved		Approved	Nucleoli<br>Cytosol	Ovarian cancer:8.28e-5 (unfavourable), Renal cancer:4.49e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 20.2	Mixed		
CNBD2	C20orf152, CNMPD1, dJ954P9.1	ENSG00000149646	Cyclic nucleotide binding domain containing 2	20	35954564-36030700	Predicted intracellular proteins	Evidence at protein level	HPA043182	Uncertain					Not detected	Tissue enhanced		testis: 38.0	epididymis: 15.3	Mixed		
SPINT4	C20orf137, dJ601O1.1	ENSG00000149651	Serine peptidase inhibitor, Kunitz type 4	20	45722351-45725830	Predicted secreted proteins	Evidence at protein level	HPA046703	Enhanced					Not detected	Tissue enriched	1619	epididymis: 347.0	seminal vesicle: 0.2	Not detected		
CDH22	C20orf25, dJ998H6.1	ENSG00000149654	Cadherin 22	20	46173733-46308498	Predicted membrane proteins	Evidence at transcript level	HPA012164	Uncertain					Mixed	Group enriched	6	adrenal gland: 2.0;cerebral cortex: 10.2;fallopian tube: 2.3;skin: 5.1	prostate,seminal vesicle,testis: 0.7	Cell line enriched	23	SCLC-21H: 3.7
LSM14B	bA11M20.3, C20orf40, FAM61B, FLJ25473, FT005, LSM13, RAP55B	ENSG00000149657	LSM family member 14B	20	62122461-62135378	Predicted intracellular proteins	Evidence at protein level	HPA041274, HPA061189	Approved		Supported	Nucleoli fibrillar center<br>Vesicles	Liver cancer:3.61e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 78.8	Expressed in all		
YTHDF1	C20orf21, FLJ20391	ENSG00000149658	YTH N6-methyladenosine RNA binding protein 1	20	63195429-63216234	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.65e-5 (unfavourable), Breast cancer:7.96e-4 (unfavourable), Thyroid cancer:9.60e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 42.4	Expressed in all		
CABLES2	C20orf150, dJ908M14.2, ik3-2	ENSG00000149679	Cdk5 and Abl enzyme substrate 2	20	62388632-62407285	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052138			Approved	Nuclear bodies<br>Cell Junctions	Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 58.3	cerebral cortex: 9.0	Expressed in all		
ORAOV1	TAOS1	ENSG00000149716	Oral cancer overexpressed 1	11	69653076-69675416	Predicted intracellular proteins	Evidence at protein level	HPA062696			Approved	Nucleoplasm	Renal cancer:1.51e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 21.9	Expressed in all		
GPHA2	A2, GPA2, MGC126572, ZSIG51	ENSG00000149735	Glycoprotein hormone alpha 2	11	64934471-64935888	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	6	gallbladder: 26.3;pancreas: 76.9	testis: 7.9	Cell line enriched	6	Hep G2: 14.4
SLC22A9	FLJ23666, OAT4, OAT7, UST3	ENSG00000149742	Solute carrier family 22 member 9	11	63369789-63410294	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	30	liver: 22.8	skeletal muscle: 0.7	Not detected		
TRPT1	MGC11134	ENSG00000149743	TRNA phosphotransferase 1	11	64223799-64226254	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038705, HPA038706	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 44.9	Expressed in all		
NUDT22	MGC13045	ENSG00000149761	Nudix hydrolase 22	11	64225941-64230686	Predicted intracellular proteins	Evidence at protein level	HPA039334, HPA053464	Approved		Enhanced	Nucleoplasm	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			duodenum: 31.1	Expressed in all		
FERMT3	KIND3, MGC10966, MIG-2, MIG2B, UNC112C, URP2	ENSG00000149781	Fermitin family member 3	11	64206678-64223886	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065231			Approved	Vesicles	Renal cancer:2.12e-5 (unfavourable), Endometrial cancer:9.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 114.2	lymph node: 101.2	Cell line enhanced		HEL: 276.6;HMC-1: 277.8
PLCB3		ENSG00000149782	Phospholipase C beta 3	11	64251523-64269150	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009257, HPA039279, HPA043907	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.31e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 114.9	Expressed in all		
MRPL49	C11orf4, L49mt, NOF, NOF1	ENSG00000149792	Mitochondrial ribosomal protein L49	11	65122183-65127371	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA046778	Approved				Renal cancer:4.22e-15 (favourable), Breast cancer:3.79e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 83.4	Expressed in all		
CDC42EP2	BORG1, CEP2	ENSG00000149798	CDC42 effector protein 2	11	65314818-65322429	Predicted intracellular proteins	Evidence at protein level	HPA038562	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:2.89e-5 (unfavourable), Lung cancer:6.66e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 46.1	Cell line enhanced		U-2197: 69.2
FAU	asr1, FLJ22986, Fub1, Fubi, MNSFbeta, RPS30, S30	ENSG00000149806	FAU, ubiquitin like and ribosomal protein S30 fusion	11	65120628-65122473	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA059015	Supported		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 1268.8	Expressed in all		
TM7SF2	ANG1, DHCR14A, NET47	ENSG00000149809	Transmembrane 7 superfamily member 2	11	65111845-65116384	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030691, HPA072704	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Renal cancer:8.49e-8 (favourable)	Expressed in all	Expressed in all			adrenal gland: 160.5	Cell line enhanced		T-47d: 122.6
VPS51	ANG2, ANG3, C11orf2, C11orf3, FFR	ENSG00000149823	VPS51, GARP complex subunit	11	65089324-65111860	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039650, HPA061447	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Vesicles	Renal cancer:2.41e-9 (favourable)	Expressed in all	Expressed in all			ovary: 101.9	Expressed in all		
TBX6		ENSG00000149922	T-box 6	16	30085793-30091887	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062498			Approved	Nucleus		Mixed	Mixed			stomach: 4.4	Cell line enhanced		RT4: 5.5;U-266/70: 5.4
PPP4C	PP4, PPX	ENSG00000149923	Protein phosphatase 4 catalytic subunit	16	30075978-30085377	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043837	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 78.0	Expressed in all		
ALDOA		ENSG00000149925	Aldolase, fructose-bisphosphate A	16	30053090-30070457	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004177, CAB006252	Enhanced		Supported	Cytosol	Liver cancer:5.79e-5 (unfavourable), Lung cancer:7.32e-5 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 9377.0	esophagus: 1428.8	Expressed in all		
FAM57B	DKFZP434I2117	ENSG00000149926	Family with sequence similarity 57 member B	16	30024427-30052978	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030837	Uncertain					Tissue enriched	Group enriched	12	cerebral cortex: 18.6;testis: 77.0	skeletal muscle: 3.9	Cell line enhanced		NTERA-2: 16.7;SCLC-21H: 105.0;SH-SY5Y: 35.9
DOC2A		ENSG00000149927	Double C2 domain alpha	16	30005509-30023270	Predicted intracellular proteins	Evidence at protein level	HPA065676			Uncertain	Nucleus<br>Nucleoli<br>Cell Junctions		Tissue enhanced	Group enriched	9	cerebral cortex: 69.7;testis: 21.0	ovary: 5.2	Cell line enhanced		BEWO: 12.9;SCLC-21H: 42.7;U-937: 14.1
HIRIP3		ENSG00000149929	HIRA interacting protein 3	16	29992321-29996436	Predicted intracellular proteins	Evidence at protein level	HPA051897, HPA063205	Approved		Enhanced	Nucleus	Cervical cancer:2.74e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.5	Expressed in all		
TAOK2	KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2	ENSG00000149930	TAO kinase 2	16	29973641-29992261	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010650	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.9	Expressed in all		
TMEM219		ENSG00000149932	Transmembrane protein 219	16	29940885-29973052	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059185	Approved				Endometrial cancer:5.79e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 198.4	Expressed in all		
HMGA2	BABL, HMGIC, LIPO	ENSG00000149948	High mobility group AT-hook 2	12	65824131-65966295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017809, HPA039076	Approved		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.86e-4 (unfavourable), Head and neck cancer:4.79e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 3.7	bone marrow: 2.9	Cell line enhanced		AF22: 292.5
MMP3	STMY, STMY1	ENSG00000149968	Matrix metallopeptidase 3	11	102835801-102843803	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007875	Uncertain		Supported	Vesicles	Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 26.5;endometrium: 58.6	urinary bladder: 9.0	Group enriched	15	BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
CNKSR2	CNK2, KIAA0902, KSR2	ENSG00000149970	Connector enhancer of kinase suppressor of Ras 2	X	21374418-21654695	Predicted intracellular proteins	Evidence at protein level	HPA001502			Approved	Golgi apparatus<br>Plasma membrane		Tissue enhanced	Tissue enriched	9	cerebral cortex: 53.9	adrenal gland: 5.8	Cell line enhanced		A549: 6.4;NTERA-2: 10.9;RH-30: 9.6
CNTN5	hNB-2, NB-2	ENSG00000149972	Contactin 5	11	99020953-100358885	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039492, HPA041223	Approved		Supported	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 2.6;placenta: 3.4;thyroid gland: 3.0	fallopian tube: 1.8	Not detected		
KLRF1	CLEC5C, NKp80	ENSG00000150045	Killer cell lectin like receptor F1	12	9827481-9845007	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 24.9	bone marrow: 7.2	Cell line enhanced		BJ hTERT+: 1.2;HAP1: 1.4;U-937: 3.5
CLEC1A	CLEC1, MGC34328	ENSG00000150048	C-type lectin domain family 1 member A	12	10069554-10111627	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	5	placenta: 71.1	smooth muscle: 12.9	Cell line enhanced		BEWO: 20.5;HUVEC TERT2: 15.2;U-266/84: 8.0
MKX	C10orf48, IRXL1, MGC39616	ENSG00000150051	Mohawk homeobox	10	27672875-27746060	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006927	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles		Mixed	Tissue enhanced		ovary: 13.6;prostate: 26.0	fallopian tube: 8.2	Cell line enhanced		BJ: 43.3;BJ hTERT+: 23.7;BJ hTERT+ SV40 Large T+: 30.7;fHDF/TERT166: 114.3
MPP7	FLJ32798	ENSG00000150054	Membrane palmitoylated protein 7	10	28050993-28334486	Predicted intracellular proteins	Evidence at protein level	HPA037597, HPA037598	Enhanced		Supported	Cell Junctions	Renal cancer:2.79e-14 (favourable), Lung cancer:5.88e-4 (favourable)	Mixed	Expressed in all			esophagus: 41.2	Cell line enhanced		CACO-2: 37.3;T-47d: 83.8
ITGB1	CD29, FNRB, GPIIA, MDF2, MSK12	ENSG00000150093	Integrin subunit beta 1	10	32900319-33005792	Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB003434, HPA059297, HPA069003	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites	Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1069.5	Expressed in all		
FXYD4	CHIF	ENSG00000150201	FXYD domain containing ion transport regulator 4	10	43371642-43376335	Predicted membrane proteins	Evidence at protein level	HPA058421	Enhanced					Group enriched	Tissue enriched	26	kidney: 127.4	stomach: 4.8	Not detected		
TRIM48	RNF101	ENSG00000150244	Tripartite motif containing 48	11	55262182-55271119	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Not detected			skin: 0.3	Not detected		
OR8K1		ENSG00000150261	Olfactory receptor family 8 subfamily K member 1	11	56346039-56346998	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055233	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M9		ENSG00000150269	Olfactory receptor family 5 subfamily M member 9	11	56462469-56463401	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PCDH15	CDHR15, DFNB23, USH1F	ENSG00000150275	Protocadherin related 15	10	53802771-55627942	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074437		Supported				Tissue enriched	Tissue enhanced		adrenal gland: 25.0;cerebral cortex: 12.2	kidney: 8.1	Cell line enhanced		U-2 OS: 1.1;U-266/70: 2.5
CTF1	CT-1, CT1	ENSG00000150281	Cardiotrophin 1	16	30896607-30903560	Predicted intracellular proteins	Evidence at protein level	CAB025853	Uncertain				Glioma:5.72e-5 (unfavourable), Lung cancer:9.87e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.7	Mixed		
CWC15	AD002, C11orf5, Cwf15, HSPC148	ENSG00000150316	CWC15 spliceosome associated protein homolog	11	94962622-94973612	Predicted intracellular proteins	Evidence at protein level	HPA039878	Supported		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:1.91e-5 (unfavourable), Thyroid cancer:7.17e-4 (favourable), Ovarian cancer:9.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.2	Expressed in all		
FCGR1A	CD64, CD64A	ENSG00000150337	Fc fragment of IgG receptor Ia	1	149782671-149792518	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.83e-8 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 91.1	appendix: 48.9	Cell line enriched	5	THP-1: 113.9
ARID5B	FLJ21150, MRF2	ENSG00000150347	AT-rich interaction domain 5B	10	61901300-62096944	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015037	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 62.1	Cell line enhanced		BJ hTERT+: 91.0
KLHL1	FLJ30047, KIAA1490, MRP2	ENSG00000150361	Kelch like family member 1	13	69700594-70108493	Predicted intracellular proteins	Evidence at transcript level	HPA021196	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 1.9	prostate: 0.5	Cell line enriched	8	HeLa: 1.6
CDH8		ENSG00000150394	Cadherin 8	16	61647242-62037035	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014908	Approved					Tissue enhanced	Group enriched	8	cerebral cortex: 27.8;seminal vesicle: 6.9	ovary: 2.1	Cell line enhanced		AF22: 6.9;fHDF/TERT166: 4.9;HaCaT: 12.6;LHCN-M2: 14.1
DCUN1D2	C13orf17, FLJ10704, FLJ20092	ENSG00000150401	Defective in cullin neddylation 1 domain containing 2	13	113455819-113490952	Predicted intracellular proteins	Evidence at protein level	HPA039349	Uncertain		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:5.65e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 66.6	Expressed in all		
TMCO3	C13orf11, FLJ20623	ENSG00000150403	Transmembrane and coiled-coil domains 3	13	113490995-113554590	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039561, HPA048126	Uncertain		Approved	Cytosol	Liver cancer:1.14e-5 (unfavourable), Urothelial cancer:4.10e-4 (unfavourable), Cervical cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 48.6	Expressed in all		
TMEM218		ENSG00000150433	Transmembrane protein 218	11	125096545-125111763	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038489	Uncertain		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.9	Expressed in all		
TIRAP	Mal, wyatt	ENSG00000150455	TIR domain containing adaptor protein	11	126283065-126298845	Predicted intracellular proteins	Evidence at protein level	HPA054431	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:1.24e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Mixed		
EEF1AKMT1	N6AMT2	ENSG00000150456	Eukaryotic translation elongation factor 1 alpha lysine methyltransferase 1	13	20728731-20773958	Predicted intracellular proteins	Evidence at protein level	HPA040417, HPA042543	Uncertain		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.82e-4 (favourable)	Expressed in all	Expressed in all			endometrium,fallopian tube: 18.1	Mixed		
LATS2		ENSG00000150457	Large tumor suppressor kinase 2	13	20973032-21061547	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039191, HPA049037	Approved		Supported	Microtubule organizing center<br>Cytosol	Cervical cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Mixed		
SAP18	2HOR0202, MGC27131, SAP18p	ENSG00000150459	Sin3A associated protein 18	13	21140514-21149084	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA011352, CAB012273	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 257.2	Expressed in all		
ADGRL3	KIAA0768, LEC3, LPHN3	ENSG00000150471	Adhesion G protein-coupled receptor L3	4	61201258-62078335	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015027, HPA015762, CAB022698	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 42.0;parathyroid gland: 30.6	cervix, uterine: 8.5	Cell line enhanced		AF22: 41.2;EFO-21: 10.2
KIAA1328		ENSG00000150477	KIAA1328	18	36829106-37232172	Predicted intracellular proteins	Evidence at protein level	HPA040946	Approved		Approved	Nuclear speckles<br>Vesicles<br>Lipid droplets		Mixed	Expressed in all			testis: 35.8	Expressed in all		
FAM124A	FLJ30707	ENSG00000150510	Family with sequence similarity 124 member A	13	51222334-51284241	Predicted intracellular proteins	Evidence at protein level	HPA048182	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 13.9	Group enriched	5	HAP1: 18.4;HUVEC TERT2: 8.8;NTERA-2: 34.8;SH-SY5Y: 14.1
MIA2	FLJ22404, TALI	ENSG00000150526	Melanoma inhibitory activity 2	14	39230231-39253639	Predicted secreted proteins	Evidence at protein level	HPA054066, HPA055459	Supported		Supported	Endoplasmic reticulum		Not detected	Tissue enhanced		epididymis: 3.7	parathyroid gland: 2.5	Cell line enhanced		CAPAN-2: 3.0
CTAGE5	cTAGE-5A, cTAGE-5B, cTAGE-5C, cTAGE-5D, MEA6, MGEA, MGEA11, MGEA6	ENSG00000150527	CTAGE family member 5, ER export factor	14	39265284-39388513	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain				Renal cancer:2.81e-4 (favourable)	Mixed	Expressed in all			thyroid gland: 77.4	Expressed in all		
HNMT		ENSG00000150540	Histamine N-methyltransferase	2	137964020-138016364	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035480, HPA035481	Approved				Pancreatic cancer:3.41e-4 (unfavourable), Urothelial cancer:4.68e-4 (favourable)	Expressed in all	Expressed in all			liver: 124.0	Cell line enhanced		Hep G2: 152.7;RT4: 91.6
LYPD1	LYPDC1, MGC29643	ENSG00000150551	LY6/PLAUR domain containing 1	2	132644853-132671579	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Group enriched	17	cerebral cortex: 27.2;fallopian tube: 127.3	salivary gland: 4.5	Cell line enhanced		hTEC/SVTERT24-B: 56.7;U-251 MG: 88.0;WM-115: 207.2
LYPD6B	CT116, LYPD7	ENSG00000150556	LY6/PLAUR domain containing 6B	2	149038107-149215262	Predicted secreted proteins, Transporters	Evidence at transcript level	HPA049239	Uncertain					Mixed	Tissue enhanced		gallbladder: 58.6;skin: 56.5	testis: 42.4	Cell line enhanced		fHDF/TERT166: 50.2;LHCN-M2: 85.2;RT4: 43.6
PDCD4	H731	ENSG00000150593	Programmed cell death 4	10	110871795-110900006	Predicted intracellular proteins	Evidence at protein level	HPA001032, HPA027214, CAB037024	Supported		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 461.7	Expressed in all		
ADRA2A	ADRA2, ADRA2R, ADRAR	ENSG00000150594	Adrenoceptor alpha 2A	10	111077163-111080907	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:8.06e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 33.2	Cell line enhanced		ASC diff: 7.4;ASC TERT1: 9.3;HEL: 18.7;HeLa: 7.4;HSkMC: 23.3
GPM6A	GPM6	ENSG00000150625	Glycoprotein M6A	4	175632934-176002664	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017338	Supported					Tissue enriched	Tissue enriched	36	cerebral cortex: 1104.1	lung: 30.7	Group enriched	9	AF22: 49.3;Daudi: 30.7;HAP1: 18.0;U-251 MG: 42.1
WDR17		ENSG00000150627	WD repeat domain 17	4	176065834-176182818	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042766, HPA054501	Approved		Approved	Nuclear speckles		Mixed	Tissue enhanced		cerebral cortex: 25.2;parathyroid gland: 19.3	thyroid gland: 11.0	Cell line enhanced		AF22: 7.7;SCLC-21H: 10.5
SPATA4	SPEF1B, TSARG2	ENSG00000150628	Spermatogenesis associated 4	4	176184638-176195671	Predicted intracellular proteins	Evidence at protein level	HPA019220	Enhanced					Not detected	Tissue enriched	18	testis: 243.1	fallopian tube: 13.5	Cell line enhanced		U-87 MG: 2.4
VEGFC	VRP	ENSG00000150630	Vascular endothelial growth factor C	4	176683538-176792727	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, RAS pathway related proteins, Transporters	Evidence at protein level						Lung cancer:7.88e-5 (unfavourable), Renal cancer:1.17e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 51.7	placenta: 30.7	Cell line enhanced		BJ: 135.8;HBF TERT88: 122.6;hTEC/SVTERT24-B: 129.0;LHCN-M2: 120.0
CCDC102B	ACY1L, AN, C18orf14, FLJ23594, HsT1731	ENSG00000150636	Coiled-coil domain containing 102B	18	68715209-69055189	Predicted intracellular proteins	Evidence at protein level	HPA040623, HPA048194	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.90e-6 (unfavourable)	Mixed	Tissue enhanced		placenta: 41.0	gallbladder: 21.6	Cell line enhanced		ASC TERT1: 10.0;BJ hTERT+: 23.3;fHDF/TERT166: 20.3;HSkMC: 11.2
CD226	DNAM-1, DNAM1, PTA1, TLiSA1	ENSG00000150637	CD226 molecule	18	69831158-69961803	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015715, HPA050348	Supported		Approved	Midbody		Not detected	Tissue enriched	11	parathyroid gland: 318.5	spleen: 28.4	Group enriched	7	HEL: 89.9;HMC-1: 37.6
CNDP1	CN1, CPGL2, HsT2308, MGC10825	ENSG00000150656	Carnosine dipeptidase 1	18	74534440-74587212	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008933	Enhanced					Group enriched	Group enriched	12	cerebral cortex: 101.7;liver: 23.0	duodenum: 5.1	Cell line enriched	68	U-266/84: 57.1
FSIP1	FLJ35989	ENSG00000150667	Fibrous sheath interacting protein 1	15	39600031-39782830	Predicted intracellular proteins	Evidence at protein level	HPA041002	Uncertain		Uncertain	Nucleoplasm		Tissue enriched	Group enriched	7	colon: 11.2;rectum: 18.4;testis: 13.6	breast: 2.2	Mixed		
DLG2	chapsyn-110, PPP1R58, PSD-93, PSD93	ENSG00000150672	Discs large MAGUK scaffold protein 2	11	83455012-85627922	Predicted intracellular proteins	Evidence at protein level	HPA021307, HPA023896, CAB072341	Enhanced		Approved	Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 72.8	thyroid gland: 25.8	Cell line enhanced		BEWO: 7.6;NTERA-2: 5.5;SCLC-21H: 6.4;SH-SY5Y: 8.7;T-47d: 19.2
CCDC83	CT148, FLJ42119, MGC34732	ENSG00000150676	Coiled-coil domain containing 83	11	85855101-85920021	Predicted intracellular proteins	Evidence at transcript level	HPA039707, HPA039882			Uncertain	Nucleus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	148	testis: 63.5	cerebral cortex,endometrium: 0.4	Cell line enriched	8	MCF7: 2.1
RGS18	RGS13	ENSG00000150681	Regulator of G-protein signaling 18	1	192158457-192185815	Predicted intracellular proteins	Evidence at protein level	HPA028727, HPA045780	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		spleen: 35.0	appendix: 19.2	Group enriched	6	HEL: 53.8;HL-60: 36.8;NB-4: 27.4;U-937: 31.1
PRSS23	SIG13, SPUVE	ENSG00000150687	Protease, serine 23	11	86791059-86952910	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030591	Uncertain				Head and neck cancer:2.12e-4 (unfavourable), Renal cancer:3.06e-4 (unfavourable), Pancreatic cancer:5.56e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 397.1	Cell line enhanced		HUVEC TERT2: 503.9;TIME: 926.9
MTMR12	3-PAP, 3PAP, FLJ20476, KIAA1682, PIP3AP	ENSG00000150712	Myotubularin related protein 12	5	32226994-32313009	Predicted intracellular proteins	Evidence at protein level	HPA051333	Supported				Renal cancer:1.29e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
PPP1R1C	Inhibitor-1-like	ENSG00000150722	Protein phosphatase 1 regulatory inhibitor subunit 1C	2	181954241-182131398	Predicted intracellular proteins	Evidence at protein level	HPA055043			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enriched	9	heart muscle: 14.1	prostate: 1.6	Not detected		
C11orf53	MGC50104	ENSG00000150750	Chromosome 11 open reading frame 53	11	111245805-111286401	Predicted intracellular proteins	Evidence at transcript level	HPA056128	Uncertain					Mixed	Tissue enhanced		testis: 4.7	gallbladder: 2.2	Not detected		
CCT5	KIAA0098	ENSG00000150753	Chaperonin containing TCP1 subunit 5	5	10249921-10266412	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002238, HPA005958, CAB006271	Enhanced		Supported	Nucleoli<br>Cytosol	Liver cancer:6.57e-11 (unfavourable), Renal cancer:8.23e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 190.8	Expressed in all		
FAM173B	JS-2	ENSG00000150756	Family with sequence similarity 173 member B	5	10226330-10249897	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA074513			Approved	Nucleus<br>Vesicles	Breast cancer:1.32e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
DOCK1	ced5, DOCK180	ENSG00000150760	Dedicator of cytokinesis 1	10	126905409-127452517	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004378, HPA048692, HPA053277	Approved		Enhanced	Nucleus		Expressed in all	Mixed			parathyroid gland: 65.9	Mixed		
DIXDC1	Dixin, KIAA1735	ENSG00000150764	DIX domain containing 1	11	111927144-112022584	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039658			Supported	Cytosol	Urothelial cancer:4.19e-5 (unfavourable), Renal cancer:6.89e-5 (favourable)	Expressed in all	Mixed			seminal vesicle: 49.5	Cell line enhanced		TIME: 40.5
DLAT	DLTA, PDC-E2	ENSG00000150768	Dihydrolipoamide S-acetyltransferase	11	112024814-112064390	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003782, HPA040786, HPA062766	Enhanced		Enhanced	Mitochondria	Renal cancer:1.95e-14 (favourable), Colorectal cancer:6.19e-6 (favourable), Liver cancer:7.49e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
PIH1D2		ENSG00000150773	PIH1 domain containing 2	11	112064010-112074274	Predicted intracellular proteins	Evidence at protein level	HPA039496			Uncertain	Nucleoplasm<br>Cytosol		Mixed	Group enriched	7	fallopian tube: 35.4;testis: 126.7	thyroid gland: 11.6	Mixed		
C11orf57	FLJ10726	ENSG00000150776	Chromosome 11 open reading frame 57	11	112074086-112085150	Predicted intracellular proteins	Evidence at protein level	HPA039493, HPA039892	Approved		Supported	Cytosol	Liver cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 26.7	Expressed in all		
TIMM8B	DDP2, FLJ21744, MGC102866, MGC117373, TIM8B	ENSG00000150779	Translocase of inner mitochondrial membrane 8 homolog B	11	112084800-112086798	Predicted intracellular proteins	Evidence at protein level	HPA041173	Approved					Expressed in all	Expressed in all			adrenal gland: 39.3	Expressed in all		
IL18	IGIF, IL-18, IL-1g, IL1F4	ENSG00000150782	Interleukin 18	11	112143251-112164117	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003980, CAB007772	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Colorectal cancer:2.78e-4 (favourable)	Expressed in all	Tissue enhanced		esophagus: 133.0;skin: 171.5	lymph node: 71.9	Cell line enhanced		CAPAN-2: 155.6;HaCaT: 143.7;hTCEpi: 132.7;U-2 OS: 214.0
TEX12		ENSG00000150783	Testis expressed 12	11	112167372-112172559	Predicted intracellular proteins	Evidence at protein level	HPA038289, HPA038290	Enhanced					Not detected	Tissue enriched	38	testis: 32.7	skin: 0.8	Cell line enhanced		U-698: 1.0
PTS	PTPS	ENSG00000150787	6-pyruvoyltetrahydropterin synthase	11	112226365-112269955	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001481	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 66.9	Expressed in all		
PIP4K2A	PIP5K2A, PIP5KIIA, PIP5KIIalpha	ENSG00000150867	Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha	10	22534849-22714555	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065440, HPA068771	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.46e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.3	Expressed in all		
C2orf50	FLJ25143	ENSG00000150873	Chromosome 2 open reading frame 50	2	11133053-11146790	Predicted intracellular proteins	Evidence at protein level	HPA062894	Enhanced					Mixed	Tissue enriched	10	fallopian tube: 22.7	cerebral cortex: 2.3	Cell line enhanced		CAPAN-2: 1.0;T-47d: 1.0
FREM2	DKFZp686J0811	ENSG00000150893	FRAS1 related extracellular matrix protein 2	13	38687129-38887131	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA028831	Uncertain		Approved	Cytosol	Renal cancer:2.23e-7 (favourable)	Mixed	Tissue enhanced		kidney: 8.2;thyroid gland: 8.3	lung: 3.3	Cell line enhanced		AF22: 15.4;HAP1: 10.9;MCF7: 6.0;RT4: 5.7;WM-115: 5.8
FOXO1	FKH1, FKHR, FOXO1A	ENSG00000150907	Forkhead box O1	13	40469953-40666597	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001252, CAB022326	Approved	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.33e-5 (favourable), Liver cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 80.7	Cell line enhanced		HSkMC: 39.2;U-698: 40.3
CRIM1	S52	ENSG00000150938	Cysteine rich transmembrane BMP regulator 1	2	36355926-36551135	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000556	Enhanced				Renal cancer:9.51e-4 (favourable)	Expressed in all	Expressed in all			placenta: 239.7	Cell line enhanced		TIME: 540.0
SEC24D	KIAA0755	ENSG00000150961	SEC24 homolog D, COPII coat complex component	4	118722823-118838683	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041626, HPA053486	Approved		Approved	Vesicles	Renal cancer:3.42e-6 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 76.6	Expressed in all		
ABCB9	EST122234	ENSG00000150967	ATP binding cassette subfamily B member 9	12	122920951-122981649	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033052, HPA035113, HPA035114	Approved		Supported	Vesicles	Glioma:4.62e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 23.8	cerebral cortex: 12.0	Mixed		
RILPL2	FLJ30380, FLJ32372, MGC7036	ENSG00000150977	Rab interacting lysosomal protein like 2	12	123410683-123436717	Predicted intracellular proteins	Evidence at protein level	HPA028958	Uncertain		Supported	Cytosol	Endometrial cancer:5.24e-7 (favourable)	Expressed in all	Mixed			bone marrow: 21.6	Expressed in all		
DHX37	DDX37, KIAA1517, MGC2695, MGC4322	ENSG00000150990	DEAH-box helicase 37	12	124946825-124989122	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047607	Enhanced		Approved	Nuclear membrane	Liver cancer:9.54e-10 (unfavourable)	Expressed in all	Mixed			bone marrow: 10.0	Expressed in all		
UBC		ENSG00000150991	Ubiquitin C	12	124911604-124917368	Predicted intracellular proteins	Evidence at protein level	CAB000362, CAB005419, HPA041344, HPA049132	Supported				Renal cancer:7.90e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 1965.2	Expressed in all		
ITPR1	ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29	ENSG00000150995	Inositol 1,4,5-trisphosphate receptor type 1	3	4493348-4847840	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014765, HPA016487	Approved		Approved	Vesicles	Thyroid cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 106.8	thyroid gland: 47.4	Cell line enhanced		HDLM-2: 75.1;HeLa: 38.4;U-87 MG: 44.6
TKTL2	DKFZP434L1717, FLJ32975	ENSG00000151005	Transketolase like 2	4	163471093-163473746	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	495	testis: 103.8	spleen: 0.2	Not detected		
PRSS53	POL3S	ENSG00000151006	Protease, serine 53	16	31083425-31089628	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA034955, HPA034956	Uncertain					Mixed	Tissue enhanced		skin: 1.1	prostate: 0.5	Cell line enhanced		SCLC-21H: 5.5
SLC7A11	xCT	ENSG00000151012	Solute carrier family 7 member 11	4	138164097-138242349	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064215			Supported	Vesicles	Ovarian cancer:1.77e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.4	epididymis: 8.2	Expressed in all		
NOCT	Ccr4c, CCR4L, CCRN4L, NOC	ENSG00000151014	Nocturnin	4	139015789-139045939	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012287, HPA053714	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.05e-5 (unfavourable), Lung cancer:5.28e-5 (unfavourable), Urothelial cancer:6.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 21.2	gallbladder: 8.4	Expressed in all		
ENKUR	C10orf63, CFAP106, enkurin, MGC26778	ENSG00000151023	Enkurin, TRPC channel interacting protein	10	24981979-25062279	Predicted intracellular proteins	Evidence at protein level	HPA037593, HPA037594, HPA061503	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 69.4	cerebral cortex: 15.2	Cell line enhanced		AN3-CA: 1.4;CAPAN-2: 2.3
GPR158	KIAA1136	ENSG00000151025	G protein-coupled receptor 158	10	25175062-25602226	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013185	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	17	cerebral cortex: 17.9	testis: 1.0	Cell line enhanced		HEL: 18.7;T-47d: 5.2
LYZL2		ENSG00000151033	Lysozyme like 2	10	30611779-30629762	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	670	testis: 67.0	all non-specific tissues: 0.0	Cell line enriched	6	SK-BR-3: 2.2
CACNA2D4		ENSG00000151062	Calcium voltage-gated channel auxiliary subunit alpha2delta 4	12	1791957-1918836	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031952	Uncertain					Mixed	Not detected			placenta,testis: 0.8	Cell line enhanced		Hep G2: 6.4;HL-60: 4.5;HMC-1: 24.8;NB-4: 8.3
DCP1B	FLJ31638	ENSG00000151065	Decapping mRNA 1B	12	1946054-2004535	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039709, HPA058778	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 36.7	Mixed		
CACNA1C	CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS	ENSG00000151067	Calcium voltage-gated channel subunit alpha1 C	12	1970786-2697950	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039796, CAB079031	Enhanced	Approved				Mixed	Tissue enhanced		smooth muscle: 30.9	endometrium: 26.2	Cell line enriched	17	HDLM-2: 188.9
KCNA6	HBK2, Kv1.6, PPP1R96	ENSG00000151079	Potassium voltage-gated channel subfamily A member 6	12	4809176-4813412	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	CAB011539, HPA014418	Approved					Not detected	Not detected			appendix,duodenum,lymph node: 0.1	Not detected		
THRB	ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2	ENSG00000151090	Thyroid hormone receptor beta	3	24117160-24495282	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002008, CAB002009, HPA061035	Approved		Supported	Nuclear bodies	Renal cancer:9.46e-8 (favourable)	Mixed	Mixed			cerebral cortex: 36.3	Cell line enhanced		K-562: 43.8;RT4: 28.1
NGLY1	FLJ11005, PNG1	ENSG00000151092	N-glycanase 1	3	25718944-25790039	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036825	Approved				Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable)	Expressed in all	Expressed in all			testis: 116.0	Expressed in all		
OXSM	CEM1, FASN2D, FLJ20604, KS	ENSG00000151093	3-oxoacyl-ACP synthase, mitochondrial	3	25782917-25794534	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021293, HPA021300, HPA021337	Enhanced		Approved	Mitochondria<br>Cytosol	Renal cancer:4.18e-9 (favourable), Colorectal cancer:1.35e-4 (favourable), Endometrial cancer:5.51e-4 (favourable)	Expressed in all	Expressed in all			testis: 17.4	Mixed		
UEVLD	Attp, UEV3	ENSG00000151116	UEV and lactate/malate dehyrogenase domains	11	18529609-18588747	Predicted intracellular proteins	Evidence at protein level	HPA047134	Approved		Approved	Nucleus<br>Cytosol	Colorectal cancer:7.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.8	Mixed		
TMEM86A	FLJ90119	ENSG00000151117	Transmembrane protein 86A	11	18693122-18704785	Predicted membrane proteins	Evidence at transcript level	HPA057119	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			skin: 13.3	Cell line enhanced		RPTEC TERT1: 13.2
C12orf45	MGC40397	ENSG00000151131	Chromosome 12 open reading frame 45	12	104986310-105074197	Predicted intracellular proteins	Evidence at protein level	HPA038722	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:4.58e-10 (unfavourable)	Expressed in all	Expressed in all			appendix: 14.0	Expressed in all		
TMEM263	C12orf23, MGC17943	ENSG00000151135	Transmembrane protein 263	12	106955719-106978778	Predicted intracellular proteins	Evidence at protein level	HPA042339	Uncertain				Thyroid cancer:1.83e-4 (unfavourable), Liver cancer:7.84e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 63.7	Expressed in all		
BTBD11	ABTB2B, FLJ33957	ENSG00000151136	BTB domain containing 11	12	107318413-107659642	Predicted intracellular proteins	Evidence at protein level	HPA055898			Approved	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 130.5	thyroid gland: 31.7	Cell line enhanced		A549: 22.8;MOLT-4: 14.0
UBE3B		ENSG00000151148	Ubiquitin protein ligase E3B	12	109477402-109536705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041012	Approved		Approved	Nuclear speckles<br>Mitochondria	Renal cancer:2.49e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 34.1	Expressed in all		
ANK3		ENSG00000151150	Ankyrin 3	10	60026298-60733490	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013249, CAB015179, HPA038455, HPA055643	Approved		Approved	Plasma membrane	Renal cancer:8.88e-16 (favourable)	Mixed	Expressed in all			parathyroid gland: 283.9	Cell line enhanced		RT4: 40.1
IPMK		ENSG00000151151	Inositol polyphosphate multikinase	10	58191517-58267934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037837, HPA057542	Uncertain		Enhanced	Nucleus	Renal cancer:9.96e-7 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 28.3	Mixed		
RAD9B	FLJ40346	ENSG00000151164	RAD9 checkpoint clamp component B	12	110501655-110532086	Predicted intracellular proteins	Evidence at protein level	HPA040643	Approved					Mixed	Tissue enriched	30	testis: 20.5	ovary: 0.6	Cell line enhanced		SiHa: 2.6
PLBD2	p76	ENSG00000151176	Phospholipase B domain containing 2	12	113358566-113391625	Predicted secreted proteins	Evidence at protein level	HPA017163	Approved				Renal cancer:3.58e-11 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 109.2	Expressed in all		
DLG5	KIAA0583, P-dlg	ENSG00000151208	Discs large MAGUK scaffold protein 5	10	77790791-77926526	Predicted intracellular proteins	Evidence at protein level	HPA001746			Supported	Cell Junctions	Liver cancer:5.38e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 33.8	Mixed		
MAT1A	MAT, MATA1, SAMS, SAMS1	ENSG00000151224	Methionine adenosyltransferase 1A	10	80271820-80289684	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048627	Supported					Tissue enriched	Tissue enriched	10	liver: 689.6	epididymis: 68.4	Cell line enriched	11	Hep G2: 64.0
SLC2A13	HMIT	ENSG00000151229	Solute carrier family 2 member 13	12	39755021-40106089	Predicted membrane proteins, Transporters	Evidence at protein level	HPA006584	Approved		Approved	Nuclear membrane		Mixed	Tissue enhanced		cerebral cortex: 49.3;parathyroid gland: 74.7	cervix, uterine: 20.4	Mixed		
GXYLT1	FLJ43151, GLT8D3	ENSG00000151233	Glucoside xylosyltransferase 1	12	42081845-42144879	Enzymes, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:3.91e-4 (favourable)	Expressed in all	Mixed			testis: 17.8	Expressed in all		
TWF1	A6, PTK9	ENSG00000151239	Twinfilin actin binding protein 1	12	43793723-43806375	Predicted intracellular proteins	Evidence at protein level	HPA018116	Approved		Enhanced	Cytosol	Liver cancer:1.53e-4 (unfavourable), Colorectal cancer:8.29e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 119.5	Expressed in all		
DIP2C	KIAA0934	ENSG00000151240	Disco interacting protein 2 homolog C	10	274190-689668	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030264, HPA059325	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.46e-6 (favourable), Endometrial cancer:8.92e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 23.4	Cell line enhanced		U-2197: 30.9
EIF4E	EIF4E1, EIF4EL1, EIF4F	ENSG00000151247	Eukaryotic translation initiation factor 4E	4	98871684-98930637	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004077, CAB016316, HPA051311	Supported		Enhanced	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 103.5	Expressed in all		
MAGI1	AIP3, BAIAP1, BAP1, MAGI-1, TNRC19, WWP3	ENSG00000151276	Membrane associated guanylate kinase, WW and PDZ domain containing 1	3	65353525-66038834	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031851, HPA031852, HPA031853	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions	Renal cancer:4.55e-8 (favourable)	Expressed in all	Mixed			thyroid gland: 18.9	Cell line enhanced		HEL: 32.4
TEX30	C13orf27	ENSG00000151287	Testis expressed 30	13	102765990-102773811	Predicted intracellular proteins	Evidence at protein level	HPA053545	Enhanced				Prostate cancer:2.10e-6 (unfavourable), Cervical cancer:2.09e-5 (favourable)	Expressed in all	Group enriched	7	epididymis: 87.8;testis: 223.6	placenta: 22.3	Cell line enhanced		NB-4: 184.1
CSNK1G3		ENSG00000151292	Casein kinase 1 gamma 3	5	123512099-123617045	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027010	Approved				Colorectal cancer:9.90e-5 (favourable)	Expressed in all	Expressed in all			testis: 28.4	Mixed		
SRFBP1	BUD22, FLJ25286, p49, Rlb1, STRAP	ENSG00000151304	Serum response factor binding protein 1	5	121961961-122075570	Predicted intracellular proteins	Evidence at protein level	HPA042737, HPA058150	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Pancreatic cancer:5.31e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.8	Expressed in all		
AKAP6	ADAP6, AKAP100, KIAA0311, mAKAP, PRKA6	ENSG00000151320	A-kinase anchoring protein 6	14	32329273-32837681	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB001983, HPA048741	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 49.0;heart muscle: 36.0	skeletal muscle: 16.6	Cell line enhanced		fHDF/TERT166: 12.2
NPAS3	bHLHe12, MOP6, PASD6	ENSG00000151322	Neuronal PAS domain protein 3	14	32934933-33804176	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002892	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 24.9	cervix, uterine: 10.1	Group enriched	8	AF22: 9.3;U-266/70: 17.8;U-266/84: 5.0
FAM177A1	C14orf24	ENSG00000151327	Family with sequence similarity 177 member A1	14	35044907-35113130	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053222, HPA055440	Uncertain		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:8.51e-5 (favourable), Head and neck cancer:9.70e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 103.2	Expressed in all		
MBIP		ENSG00000151332	MAP3K12 binding inhibitory protein 1	14	36298558-36320676	Predicted intracellular proteins	Evidence at protein level	HPA003388	Supported		Supported	Nucleus<br>Nucleoli<br>Cytosol	Ovarian cancer:1.14e-4 (favourable), Renal cancer:1.25e-4 (favourable), Lung cancer:1.52e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 136.4	Expressed in all		
MIPOL1	CCDC193	ENSG00000151338	Mirror-image polydactyly 1	14	37197913-37552361	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002893, HPA050179	Enhanced		Approved	Cytosol		Mixed	Mixed			testis: 13.9	Cell line enhanced		HUVEC TERT2: 20.9
EXT2	SOTV	ENSG00000151348	Exostosin glycosyltransferase 2	11	44095549-44245429	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA078409			Supported	Golgi apparatus	Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 90.7	Expressed in all		
TMEM18	DKFZp434C1714	ENSG00000151353	Transmembrane protein 18	2	667335-677439	Predicted membrane proteins	Evidence at protein level	HPA040233	Approved		Approved	Mitochondria	Melanoma:3.21e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 43.8	Expressed in all		
ALLC	ALC	ENSG00000151360	Allantoicase	2	3658195-3702671	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	21	testis: 23.9	gallbladder: 1.1	Cell line enriched	12	U-266/84: 4.2
KCTD14	MGC2376	ENSG00000151364	Potassium channel tetramerization domain containing 14	11	78015715-78046191	Predicted intracellular proteins	Evidence at protein level	HPA041118, HPA042181	Enhanced				Melanoma:3.96e-5 (unfavourable), Renal cancer:6.92e-5 (favourable), Pancreatic cancer:1.05e-4 (unfavourable), Thyroid cancer:5.93e-4 (favourable), Ovarian cancer:8.01e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 27.0	Cell line enhanced		HBEC3-KT: 18.6;Hep G2: 19.7;RPTEC TERT1: 34.1;U-2 OS: 21.2
THRSP	Lpgp, LPGP1, S14, SPOT14, THRP	ENSG00000151365	Thyroid hormone responsive	11	78063861-78068351	Predicted intracellular proteins	Evidence at protein level	HPA040642	Approved		Approved	Nucleoplasm	Renal cancer:1.16e-4 (unfavourable), Thyroid cancer:3.28e-4 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 231.2;liver: 182.9	breast: 43.6	Cell line enriched	12	ASC diff: 52.2
NDUFC2	B14.5b, HLC-1	ENSG00000151366	NADH:ubiquinone oxidoreductase subunit C2	11	78068304-78080219	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038873, HPA056195	Approved		Supported	Mitochondria	Renal cancer:5.00e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 370.1	Expressed in all		
ME3		ENSG00000151376	Malic enzyme 3	11	86441108-86672636	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038473	Approved				Urothelial cancer:3.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.7	Cell line enhanced		CAPAN-2: 44.6;TIME: 30.7
MSGN1	pMesogenin1	ENSG00000151379	Mesogenin 1	2	17816496-17817101	Predicted intracellular proteins, Transcription factors	No evidence							Not detected	Not detected			esophagus: 0.4	Not detected		
ADAMTS12		ENSG00000151388	ADAM metallopeptidase with thrombospondin type 1 motif 12	5	33523535-33892192	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA035973, HPA075079	Uncertain		Approved	Nucleoli<br>Mitochondria	Urothelial cancer:6.78e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 9.8	Cell line enhanced		hTEC/SVTERT24-B: 48.2;U-2 OS: 38.4
NUBPL	C14orf127, FLJ12660, huInd1, IND1	ENSG00000151413	Nucleotide binding protein like	14	31489956-31861224	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029203	Approved		Approved	Mitochondria	Renal cancer:3.64e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.0	Expressed in all		
NEK7		ENSG00000151414	NIMA related kinase 7	1	198156963-198322420	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA015520, HPA018193	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 93.3	Expressed in all		
ATP6V1G3	ATP6G3, Vma10	ENSG00000151418	ATPase H+ transporting V1 subunit G3	1	198523222-198540945	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA028701	Enhanced					Tissue enriched	Tissue enriched	11	kidney: 21.3	epididymis: 2.0	Cell line enhanced		fHDF/TERT166: 1.9
FER	PPP1R74, TYK3	ENSG00000151422	FER tyrosine kinase	5	108747822-109196841	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007641, CAB022464	Approved		Supported	Cytosol	Renal cancer:5.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.4	Cell line enhanced		RPMI-8226: 62.9
VIPAS39	C14orf133, hSPE-39, SPE-39, SPE39, VIPAR, VPS16B	ENSG00000151445	VPS33B interacting protein, apical-basolateral polarity regulator, spe-39 homolog	14	77426675-77457952	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003589, HPA003593	Approved				Liver cancer:1.06e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
ANKRD50	KIAA1223	ENSG00000151458	Ankyrin repeat domain 50	4	124664052-124712732	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044008	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			testis: 27.7	Cell line enhanced		TIME: 120.1
UPF2	DKFZP434D222, KIAA1408, RENT2, smg-3	ENSG00000151461	UPF2 regulator of nonsense transcripts homolog (yeast)	10	11920022-12043170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA067008			Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.0	Expressed in all		
CDC123	C10orf7, D123	ENSG00000151465	Cell division cycle 123	10	12195965-12250589	Predicted intracellular proteins	Evidence at protein level	HPA037830, HPA057540	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:3.16e-7 (unfavourable), Renal cancer:2.42e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 65.3	Expressed in all		
SCLT1	FLJ30655, hCAP-1A	ENSG00000151466	Sodium channel and clathrin linker 1	4	128864921-129093607	Predicted intracellular proteins	Evidence at protein level	HPA036560, HPA036561	Approved		Supported	Microtubules<br>Cytosol		Mixed	Mixed			spleen: 11.3	Expressed in all		
CCDC3	DKFZp761F241	ENSG00000151468	Coiled-coil domain containing 3	10	12896625-13099652	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA062425			Approved	Nucleus<br>Cytosol	Renal cancer:1.38e-5 (unfavourable)	Expressed in all	Mixed			skin: 158.4	Cell line enhanced		HAP1: 19.8;HDLM-2: 30.2;U-2 OS: 21.3
C4orf33	FLJ33703	ENSG00000151470	Chromosome 4 open reading frame 33	4	129093317-129116640	Predicted intracellular proteins	Evidence at protein level	HPA061199	Uncertain		Approved	Nuclear bodies<br>Golgi apparatus	Urothelial cancer:2.49e-5 (favourable), Renal cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
FRMD4A	bA295P9.4, FLJ10210, FRMD4, KIAA1294	ENSG00000151474	FERM domain containing 4A	10	13643706-14462142	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038449	Uncertain		Approved	Nucleus<br>Golgi apparatus	Head and neck cancer:2.63e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 38.0	Cell line enhanced		hTEC/SVTERT24-B: 89.3;TIME: 90.6;WM-115: 154.1
SLC25A31	ANT4, DKFZP434N1235	ENSG00000151475	Solute carrier family 25 member 31	4	127730378-127774299	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015064, HPA016841, HPA046835, HPA071684	Uncertain		Enhanced	Mitochondria		Not detected	Tissue enriched	852	testis: 85.1	all non-specific tissues: 0.0	Not detected		
PTPRO	GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2	ENSG00000151490	Protein tyrosine phosphatase, receptor type O	12	15322397-15597399	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034525	Enhanced					Tissue enhanced	Tissue enhanced		rectum: 33.0	cerebral cortex: 21.7	Cell line enhanced		NTERA-2: 6.6;SCLC-21H: 4.7;SH-SY5Y: 8.4
EPS8		ENSG00000151491	Epidermal growth factor receptor pathway substrate 8	12	15620158-15882329	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003897	Approved		Approved	Golgi apparatus	Renal cancer:1.45e-7 (favourable), Pancreatic cancer:3.33e-7 (unfavourable), Thyroid cancer:5.11e-4 (favourable)	Expressed in all	Mixed			gallbladder: 88.1	Mixed		
ACAD8		ENSG00000151498	Acyl-CoA dehydrogenase family member 8	11	134253495-134265855	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040689, HPA043903	Enhanced				Renal cancer:6.42e-10 (favourable), Lung cancer:2.38e-4 (favourable), Head and neck cancer:6.19e-4 (favourable), Colorectal cancer:7.62e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.2	Expressed in all		
THYN1	THY28	ENSG00000151500	Thymocyte nuclear protein 1	11	134248279-134253370	Predicted intracellular proteins	Evidence at protein level	HPA038732, HPA038733	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Lung cancer:1.01e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 92.2	Expressed in all		
VPS26B	MGC10485, Pep8b	ENSG00000151502	VPS26, retromer complex component B	11	134224645-134247792	Predicted intracellular proteins	Evidence at protein level	HPA038172	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 60.4	Expressed in all		
NCAPD3	CAP-D3, FLJ42888, hCAP-D3, hcp-6, hHCP-6, KIAA0056	ENSG00000151503	Non-SMC condensin II complex subunit D3	11	134150119-134225454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040286			Supported	Nucleoplasm		Tissue enriched	Tissue enriched	11	prostate: 194.2	testis: 17.2	Expressed in all		
VTI1A	MVti1, Vti1-rp2, Vti1a	ENSG00000151532	Vesicle transport through interaction with t-SNAREs 1A	10	112446998-112818744	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054108	Supported		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Expressed in all		
QDPR	DHPR, PKU2, SDR33C1	ENSG00000151552	Quinoid dihydropteridine reductase	4	17460261-17512234	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA058951, HPA065649	Enhanced		Approved	Mitochondria	Renal cancer:7.84e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 226.3	Expressed in all		
FAM160B1	bA106M7.3, KIAA1600	ENSG00000151553	Family with sequence similarity 160 member B1	10	114821744-114899832	Predicted intracellular proteins	Evidence at protein level	HPA043624	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:4.02e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
ANO4	FLJ34221, FLJ34272, FLJ35277, TMEM16D	ENSG00000151572	Anoctamin 4	12	100717526-101128641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA053412	Uncertain				Renal cancer:5.48e-5 (favourable)	Mixed	Group enriched	6	adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.6;endometrium: 8.4;ovary: 10.9;prostate: 11.7;seminal vesicle: 11.4	testis: 2.0	Cell line enhanced		fHDF/TERT166: 14.2;SK-MEL-30: 13.3;TIME: 26.1;WM-115: 10.6
TEX9		ENSG00000151575	Testis expressed 9	15	56244009-56445997	Predicted intracellular proteins	Evidence at protein level	HPA039415	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			fallopian tube: 44.5	Mixed		
QTRT2	FLJ12960, QTRTD1	ENSG00000151576	Queuine tRNA-ribosyltransferase accessory subunit 2	3	114005833-114088422	Predicted intracellular proteins	Evidence at protein level	HPA036827, HPA036828	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments	Prostate cancer:6.95e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.3	Expressed in all		
DRD3		ENSG00000151577	Dopamine receptor D3	3	114128652-114199407	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Not detected		
MMAA	cblA	ENSG00000151611	Methylmalonic aciduria (cobalamin deficiency) cblA type	4	145618263-145660035	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037361	Approved		Approved	Cytosol	Renal cancer:2.23e-5 (favourable), Urothelial cancer:3.21e-4 (favourable), Colorectal cancer:3.38e-4 (favourable)	Expressed in all	Mixed			liver: 12.3	Mixed		
ZNF827		ENSG00000151612	Zinc finger protein 827	4	145757627-145938635	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021166	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			prostate: 37.4	Cell line enhanced		WM-115: 67.4
POU4F2	Brn-3b, BRN3B	ENSG00000151615	POU class 4 homeobox 2	4	146638893-146642474	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 2.1
EDNRA		ENSG00000151617	Endothelin receptor type A	4	147480917-147544954	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013774, CAB018957	Uncertain				Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 146.8	cervix, uterine: 83.0	Cell line enhanced		ASC TERT1: 11.8;LHCN-M2: 17.3;SH-SY5Y: 16.4
NR3C2	MLR, MR	ENSG00000151623	Nuclear receptor subfamily 3 group C member 2	4	148078762-148444698	Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009155, HPA074979	Enhanced		Supported	Nucleoplasm	Renal cancer:3.10e-11 (favourable)	Mixed	Mixed			thyroid gland: 32.3	Cell line enhanced		HUVEC TERT2: 4.9;Karpas-707: 4.5;PC-3: 5.4;RPTEC TERT1: 5.9;TIME: 6.4
AKR1C2	BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD	ENSG00000151632	Aldo-keto reductase family 1 member C2	10	4987400-5018031	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB047304, HPA068265	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Group enriched	Group enriched	5	adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0	duodenum: 29.8	Cell line enhanced		A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
DPYSL4	DRP-4, ULIP4	ENSG00000151640	Dihydropyrimidinase like 4	10	132186900-132205776	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049066	Approved		Approved	Vesicles<br>Mitochondria	Urothelial cancer:3.11e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 30.0	heart muscle: 7.5	Cell line enhanced		AF22: 51.3;AN3-CA: 63.4;SH-SY5Y: 74.6
VENTX	HPX42B, VENTX2	ENSG00000151650	VENT homeobox	10	133237404-133241929	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050955	Uncertain		Uncertain	Nucleoli fibrillar center<br>Cytosol		Tissue enriched	Mixed			appendix: 4.7	Group enriched	22	NB-4: 10.5;NTERA-2: 9.2
ADAM8	CD156, CD156a, MS2	ENSG00000151651	ADAM metallopeptidase domain 8	10	133262403-133276868	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064637	Approved				Renal cancer:3.99e-10 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 43.8;spleen: 32.9	appendix: 30.1	Cell line enhanced		A-431: 51.7;BEWO: 78.4;CAPAN-2: 61.7;HaCaT: 61.1;HDLM-2: 42.3;U-87 MG: 33.6
ITIH2	H2P	ENSG00000151655	Inter-alpha-trypsin inhibitor heavy chain 2	10	7703269-7749520	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059150	Supported		Approved	Golgi apparatus	Liver cancer:1.48e-4 (favourable)	Tissue enriched	Tissue enriched	208	liver: 1093.4	cerebral cortex: 5.2	Cell line enriched	896	Hep G2: 735.5
KIN	KIN17, Rts2	ENSG00000151657	Kin17 DNA and RNA binding protein	10	7750962-7787981	Predicted intracellular proteins	Evidence at protein level	CAB016339, HPA038700			Enhanced	Nucleus	Renal cancer:1.44e-7 (unfavourable), Urothelial cancer:3.23e-5 (favourable)	Expressed in all	Mixed			endometrium: 5.6	Expressed in all		
PIGF		ENSG00000151665	Phosphatidylinositol glycan anchor biosynthesis class F	2	46580937-46617119	Predicted membrane proteins	Evidence at protein level	HPA051389	Uncertain				Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
ANKAR	FLJ25415	ENSG00000151687	Ankyrin and armadillo repeat containing	2	189674290-189761193	Predicted intracellular proteins	Evidence at transcript level	HPA036168	Uncertain		Approved	Nucleus<br>Microtubule organizing center		Mixed	Tissue enriched	7	testis: 10.3	parathyroid gland: 1.4	Not detected		
INPP1		ENSG00000151689	Inositol polyphosphate-1-phosphatase	2	190343470-190371665	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036698, HPA036699	Supported		Approved	Vesicles	Thyroid cancer:1.12e-5 (favourable), Urothelial cancer:5.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 73.6	Mixed		
MFSD6	FLJ20160	ENSG00000151690	Major facilitator superfamily domain containing 6	2	190408355-190509205	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022274	Approved		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 79.0	Cell line enhanced		HDLM-2: 73.8
RNF144A	KIAA0161, RNF144, UBCE7IP4	ENSG00000151692	Ring finger protein 144A	2	6917392-7068286	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049939	Approved		Approved	Vesicles	Stomach cancer:7.32e-5 (unfavourable), Endometrial cancer:6.00e-4 (unfavourable), Head and neck cancer:6.96e-4 (favourable)	Expressed in all	Mixed			endometrium: 43.1	Cell line enhanced		HMC-1: 112.4
ASAP2	CENTB3, DDEF2, KIAA0400, PAP, SHAG1	ENSG00000151693	ArfGAP with SH3 domain, ankyrin repeat and PH domain 2	2	9206765-9405683	Predicted intracellular proteins	Evidence at protein level	CAB018615	Approved		Supported	Cytosol	Endometrial cancer:1.61e-4 (unfavourable), Pancreatic cancer:4.68e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 73.6	thyroid gland: 32.6	Mixed		
ADAM17	CD156B, cSVP, TACE	ENSG00000151694	ADAM metallopeptidase domain 17	2	9488486-9555792	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010738, CAB025906, HPA051575	Approved		Supported	Cytosol	Urothelial cancer:4.23e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.8	Expressed in all		
FLI1	EWSR2, SIC-1	ENSG00000151702	Fli-1 proto-oncogene, ETS transcription factor	11	128686535-128813267	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073099			Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 46.1	placenta: 15.6	Cell line enhanced		HEL: 93.0;HUVEC TERT2: 46.8;REH: 44.4;TIME: 47.8
KCNJ1	Kir1.1, ROMK1	ENSG00000151704	Potassium voltage-gated channel subfamily J member 1	11	128836315-128867373	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA026962	Enhanced					Tissue enriched	Tissue enriched	117	kidney: 210.8	epididymis: 1.7	Cell line enriched	42	RPTEC TERT1: 87.0
TMEM45B	BC016153, FLJ40787	ENSG00000151715	Transmembrane protein 45B	11	129815819-129860003	Predicted membrane proteins	Evidence at protein level	HPA015878	Approved		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		duodenum: 136.2;small intestine: 139.1	rectum: 103.3	Cell line enhanced		CACO-2: 32.2;Hep G2: 27.4;PC-3: 45.6;RT4: 105.7;T-47d: 34.7
WWC2	BOMB, FLJ22029	ENSG00000151718	WW and C2 domain containing 2	4	183099293-183320777	Predicted intracellular proteins	Evidence at protein level	HPA044005	Uncertain		Approved	Microtubules	Cervical cancer:8.61e-4 (unfavourable), Renal cancer:9.29e-4 (favourable)	Expressed in all	Mixed			lung: 42.5	Mixed		
CENPU	CENP-50, CENP-U, KLIP1, MLF1IP, PBIP1	ENSG00000151725	Centromere protein U	4	184694618-184734133	Predicted intracellular proteins	Evidence at protein level	HPA022048	Approved		Supported	Nucleus<br>Microtubule organizing center	Renal cancer:1.11e-9 (unfavourable), Pancreatic cancer:2.09e-4 (unfavourable), Lung cancer:7.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 45.6;testis: 67.6	lymph node: 25.3	Mixed		
ACSL1	ACS1, FACL1, FACL2, LACS, LACS1, LACS2	ENSG00000151726	Acyl-CoA synthetase long-chain family member 1	4	184755595-184826818	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011316, HPA011964	Enhanced		Supported	Nucleus<br>Mitochondria	Renal cancer:1.25e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 824.0	Expressed in all		
SLC25A4	ANT1, PEO2, PEO3, T1	ENSG00000151729	Solute carrier family 25 member 4	4	185143241-185150382	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Enhanced	Mitochondria	Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 122.1;skeletal muscle: 66.2	cerebral cortex: 38.1	Mixed		
AMN1		ENSG00000151743	Antagonist of mitotic exit network 1 homolog	12	31671137-31729174	Predicted intracellular proteins	Evidence at protein level	HPA046157, HPA062290	Uncertain		Approved	Centrosome		Expressed in all	Expressed in all			testis: 99.8	Mixed		
BICD1		ENSG00000151746	BICD cargo adaptor 1	12	32106835-32383633	Predicted intracellular proteins	Evidence at protein level	HPA041309	Approved		Approved	Vesicles	Renal cancer:2.33e-7 (unfavourable)	Mixed	Mixed			ovary: 29.0	Mixed		
SAV1	salvador, WW45, WWP4	ENSG00000151748	Salvador family WW domain containing protein 1	14	50632058-50668331	Predicted intracellular proteins	Evidence at protein level	HPA001808	Approved		Supported	Cytosol	Renal cancer:3.83e-6 (favourable), Breast cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.3	Expressed in all		
CCDC122	FLJ31846	ENSG00000151773	Coiled-coil domain containing 122	13	43823909-43879727	Predicted intracellular proteins	Evidence at protein level	CAB034233, HPA054995, HPA061456	Approved		Approved	Nucleus<br>Vesicles		Mixed	Mixed			prostate,thyroid gland: 7.9	Mixed		
SERP2	bA269C23.1, C13orf21	ENSG00000151778	Stress associated endoplasmic reticulum protein family member 2	13	44373665-44397714	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038970	Uncertain				Renal cancer:1.94e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 52.7;testis: 23.7	epididymis: 11.3	Cell line enhanced		LHCN-M2: 3.2;SH-SY5Y: 5.6;U-2197: 4.5
NBAS	NAG	ENSG00000151779	Neuroblastoma amplified sequence	2	15166909-15561330	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036817	Approved		Approved	Nuclear membrane<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:5.84e-5 (unfavourable), Liver cancer:1.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
ZNF385D	FLJ22419, ZNF659	ENSG00000151789	Zinc finger protein 385D	3	21412222-22373321	Predicted intracellular proteins	Evidence at protein level	HPA036190	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.8	adipose tissue: 3.1	Cell line enhanced		ASC TERT1: 2.2;RPTEC TERT1: 3.3;U-87 MG: 8.1
TDO2	TDO, TPH2	ENSG00000151790	Tryptophan 2,3-dioxygenase	4	155854738-155920406	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039611	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	18	liver: 278.3	appendix: 15.7	Group enriched	5	EFO-21: 7.3;HDLM-2: 14.7;U-87 MG: 8.6
GUF1	FLJ13220	ENSG00000151806	GUF1 homolog, GTPase	4	44678427-44700926	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003934, HPA024222	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:2.66e-6 (favourable), Thyroid cancer:1.65e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 13.4	Expressed in all		
SLC35F4	C14orf36, FLJ37712	ENSG00000151812	Solute carrier family 35 member F4	14	57563922-57982194	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043853	Uncertain		Approved	Nucleoli fibrillar center		Not detected	Tissue enhanced		prostate: 1.9;seminal vesicle: 4.9;testis: 1.8	thyroid gland: 1.1	Cell line enhanced		RPMI-8226: 1.0;U-87 MG: 2.0
GABRA2		ENSG00000151834	Gamma-aminobutyric acid type A receptor alpha2 subunit	4	46248427-46475230	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB079061		Supported				Tissue enhanced	Tissue enriched	7	cerebral cortex: 74.3	epididymis: 11.3	Cell line enhanced		U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
SACS	ARSACS, DKFZp686B15167, DNAJC29, KIAA0730, PPP1R138, SPAX6	ENSG00000151835	Sacsin molecular chaperone	13	23328826-23411513	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017714	Uncertain				Renal cancer:6.21e-6 (unfavourable), Endometrial cancer:9.04e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 32.5	cerebral cortex: 16.0	Mixed		
CCDC175	C14orf38	ENSG00000151838	Coiled-coil domain containing 175	14	59504539-59576831	Predicted intracellular proteins	Evidence at protein level	HPA004200	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Not detected	Tissue enriched	8	testis: 4.0	fallopian tube,rectum: 0.4	Not detected		
PABPC3	PABP3, PABPL3, tPABP	ENSG00000151846	Poly(A) binding protein cytoplasmic 3	13	25095868-25099254	Predicted intracellular proteins	Evidence at protein level	HPA045423, HPA067156	Approved		Approved	Cytosol	Ovarian cancer:8.00e-4 (unfavourable)	Mixed	Tissue enriched	151	testis: 60.6	cerebral cortex: 0.4	Cell line enriched	9	U-266/84: 4.3
CENPJ	BM032, CPAP, LAP, LIP1, MCPH6, Sas-4, SASS4, SCKL4	ENSG00000151849	Centromere protein J	13	24882284-24922889	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA060426			Approved	Nucleoplasm<br>Plasma membrane<br>Centrosome	Renal cancer:1.75e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 42.8	thyroid gland: 20.5	Expressed in all		
FBXO4	FBX4	ENSG00000151876	F-box protein 4	5	41925254-41941743	Predicted intracellular proteins	Evidence at protein level	HPA003362			Approved	Nucleus	Renal cancer:1.28e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 21.0	Mixed		
TMEM267	C5orf28, FLJ21657	ENSG00000151881	Transmembrane protein 267	5	43444252-43483893	Predicted membrane proteins	Evidence at protein level	HPA059946			Approved	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable), Renal cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.0	Expressed in all		
CCL28	CCK1, MEC, SCYA28	ENSG00000151882	C-C motif chemokine ligand 28	5	43376645-43412391	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077434	Supported				Pancreatic cancer:1.43e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 71.1;salivary gland: 126.0	thyroid gland: 38.0	Cell line enhanced		EFO-21: 12.1;SiHa: 31.8;SK-MEL-30: 12.9;T-47d: 37.8
PARP8	FLJ21308, pART16	ENSG00000151883	Poly(ADP-ribose) polymerase family member 8	5	50665899-50846522	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049183	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Midbody ring<br>Cytosol	Urothelial cancer:1.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 72.9	Cell line enhanced		THP-1: 65.6
GFRA1	GDNFR, GDNFRA, GFR-ALPHA-1, RET1L, RETL1, TRNR1	ENSG00000151892	GDNF family receptor alpha 1	10	116056925-116273467	Predicted membrane proteins	Evidence at protein level	HPA043829	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Tissue enriched	Mixed			breast: 30.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 41.6;BJ hTERT+ SV40 Large T+ RasG12V: 75.3;EFO-21: 44.6;fHDF/TERT166: 68.9;HBF TERT88: 62.5;MCF7: 45.6;U-251 MG: 45.6
CACUL1	C10orf46, CAC1, FLJ40409, MGC33215	ENSG00000151893	CDK2 associated cullin domain 1	10	118674167-118755249	Predicted intracellular proteins	Evidence at protein level	HPA050611			Approved	Nucleoplasm	Liver cancer:1.34e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.2	Expressed in all		
DST	BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2	ENSG00000151914	Dystonin	6	56457987-56954628	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030200	Uncertain		Approved	Nucleus<br>Microtubules<br>Cytosol		Expressed in all	Expressed in all			skin: 192.1	Cell line enhanced		hTCEpi: 351.4;hTERT-HME1: 274.7
BEND6	bA203B9.1, C6orf65, FLJ30162	ENSG00000151917	BEN domain containing 6	6	56955126-57027342	Predicted intracellular proteins	Evidence at protein level	HPA031605, HPA052973	Enhanced		Approved	Nucleus<br>Plasma membrane		Tissue enriched	Tissue enriched	6	cerebral cortex: 39.2	cervix, uterine: 6.6	Mixed		
TIAL1	TIAR	ENSG00000151923	TIA1 cytotoxic granule associated RNA binding protein like 1	10	119571802-119597029	Predicted intracellular proteins	Evidence at protein level	HPA060962			Approved	Nucleus<br>Vesicles	Liver cancer:7.81e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.8	Expressed in all		
BAG3		ENSG00000151929	BCL2 associated athanogene 3	10	119651370-119677819	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018493, HPA020586	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 98.2	Mixed		
GLT1D1	FLJ31978	ENSG00000151948	Glycosyltransferase 1 domain containing 1	12	128853427-128984968	Predicted intracellular proteins	Evidence at protein level	HPA039051, HPA039052			Enhanced	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 22.4;testis: 28.2	bone marrow: 18.6	Group enriched	7	MOLT-4: 10.5;NTERA-2: 18.0;SCLC-21H: 9.9
TMEM132D	KIAA1944, MOLT, PPP1R153	ENSG00000151952	Transmembrane protein 132D	12	129071725-129903666	Predicted membrane proteins	Evidence at protein level	HPA010739	Approved					Mixed	Tissue enriched	12	cerebral cortex: 12.3	testis: 1.0	Cell line enhanced		AF22: 2.6;MOLT-4: 3.9;NTERA-2: 1.8
RBM46	CT68, MGC27016	ENSG00000151962	RNA binding motif protein 46	4	154781213-154828813	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	59	testis: 50.2	thyroid gland: 0.8	Not detected		
SCHIP1	SCHIP-1	ENSG00000151967	Schwannomin interacting protein 1	3	159839861-159897360	Predicted intracellular proteins	Evidence at protein level	HPA003243, HPA069824	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Glioma:3.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 102.8;heart muscle: 53.1	skeletal muscle: 25.5	Cell line enhanced		AN3-CA: 45.4;HUVEC TERT2: 48.7;NTERA-2: 29.7;SH-SY5Y: 177.1
MCHR2	GPR145, MCH2, MCH2R, SLT	ENSG00000152034	Melanin concentrating hormone receptor 2	6	99919910-99994247	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	47	cerebral cortex: 8.6;testis: 4.3	colon,small intestine: 0.1	Not detected		
KCNE4	MiRP3	ENSG00000152049	Potassium voltage-gated channel subfamily E regulatory subunit 4	2	223051814-223198399	Predicted membrane proteins	Evidence at protein level	HPA011420	Approved		Approved	Nuclear bodies<br>Microtubules	Renal cancer:2.02e-7 (unfavourable), Colorectal cancer:9.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 54.0	endometrium: 33.5	Cell line enriched	6	AN3-CA: 152.4
AP1S3		ENSG00000152056	Adaptor related protein complex 1 sigma 3 subunit	2	223751686-223838027	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA066782	Approved		Supported	Vesicles	Pancreatic cancer:2.08e-5 (unfavourable), Lung cancer:3.36e-5 (unfavourable)	Mixed	Tissue enhanced		epididymis: 54.2	thyroid gland: 23.6	Cell line enhanced		CACO-2: 130.6
RABGAP1L	FLJ38519, HHL, KIAA0471, TBC1D18	ENSG00000152061	RAB GTPase activating protein 1 like	1	174159410-174995308	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054695	Uncertain		Approved	Nucleoli<br>Cytosol	Lung cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 76.6	Expressed in all		
CCDC74B	DKFZp434E2321	ENSG00000152076	Coiled-coil domain containing 74B	2	130139287-130145134	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.55e-4 (unfavourable), Breast cancer:4.46e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 23.1;testis: 52.0	cervix, uterine: 13.9	Cell line enhanced		SCLC-21H: 12.3;SH-SY5Y: 15.8
TMEM56	FLJ31842	ENSG00000152078	Transmembrane protein 56	1	95117338-95197607	Predicted membrane proteins	Evidence at protein level	HPA046762	Uncertain		Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		liver: 66.1	heart muscle: 16.7	Cell line enhanced		RH-30: 34.4
MZT2B	FAM128B, FLJ14346, MOZART2B	ENSG00000152082	Mitotic spindle organizing protein 2B	2	130181737-130190729	Predicted intracellular proteins	Evidence at protein level	HPA051758, HPA052623	Approved		Supported	Centrosome<br>Cytosol	Renal cancer:9.37e-8 (unfavourable), Liver cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.3	Expressed in all		
TUBA3E		ENSG00000152086	Tubulin alpha 3e	2	130191743-130198461	Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules		Mixed	Tissue enriched	26	testis: 74.6	heart muscle: 2.9	Group enriched	11	BEWO: 4.0;U-2 OS: 2.7
ASTN1	ASTN	ENSG00000152092	Astrotactin 1	1	176857302-177164973	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074112			Approved	Golgi apparatus<br>Vesicles		Tissue enriched	Group enriched	6	adrenal gland: 19.6;cerebral cortex: 66.8	ovary: 7.4	Cell line enhanced		Karpas-707: 4.1;NTERA-2: 4.4;SCLC-21H: 3.2;U-2 OS: 3.6;U-266/84: 14.7
CFC1B		ENSG00000152093	Cripto, FRL-1, cryptic family 1B	2	130521197-130528604	Predicted secreted proteins	No evidence	HPA041773	Uncertain					Not detected	Not detected			pancreas,prostate,rectum: 0.1	Not detected		
FAM168B	KIAA0280L, MANI	ENSG00000152102	Family with sequence similarity 168 member B	2	131047876-131093460	Predicted intracellular proteins	Evidence at protein level	HPA043778, HPA061659	Enhanced				Renal cancer:5.30e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 112.6	Expressed in all		
PTPN14	PEZ	ENSG00000152104	Protein tyrosine phosphatase, non-receptor type 14	1	214348696-214552449	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011469, HPA053864, CAB069441	Uncertain		Enhanced	Nucleoplasm	Pancreatic cancer:2.29e-4 (unfavourable), Stomach cancer:5.16e-4 (unfavourable)	Expressed in all	Mixed			skin: 19.9	Mixed		
MGAT5	GNT-V	ENSG00000152127	Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase	2	134119983-134454621	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010919	Approved					Expressed in all	Mixed			parathyroid gland: 32.6	Expressed in all		
TMEM163	DKFZP566N034, SV31	ENSG00000152128	Transmembrane protein 163	2	134455759-134719000	Predicted membrane proteins, Transporters	Evidence at protein level	HPA007224	Uncertain				Urothelial cancer:3.15e-4 (favourable), Lung cancer:7.94e-4 (favourable)	Mixed	Mixed			lung: 21.5	Cell line enhanced		HEL: 18.1;RPTEC TERT1: 50.5;SCLC-21H: 35.5
GPATCH11	CCDC75, CENP-Y, CENPY, FLJ38348	ENSG00000152133	G-patch domain containing 11	2	37084451-37099244	Predicted intracellular proteins	Evidence at protein level	HPA038231, HPA038232	Enhanced		Supported	Nucleus		Expressed in all	Mixed			adipose tissue: 23.8	Expressed in all		
HSPB8	CMT2L, E2IG1, H11, HSP22, HspB8	ENSG00000152137	Heat shock protein family B (small) member 8	12	119178642-119221131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015876	Approved		Supported	Cytosol	Liver cancer:2.98e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 426.6	Cell line enhanced		EFO-21: 74.9;MCF7: 83.7
GEMIN6	FLJ23459	ENSG00000152147	Gem nuclear organelle associated protein 6	2	38751534-38785000	Predicted intracellular proteins	Evidence at protein level	HPA035726, HPA035727	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			testis: 28.9	Expressed in all		
TMEM178A	MGC33926, TMEM178	ENSG00000152154	Transmembrane protein 178A	2	39664982-39717963	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA052128	Uncertain		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 55.4	kidney: 19.3	Cell line enhanced		AF22: 137.1;NTERA-2: 17.7;SCLC-21H: 30.2
POU4F1	BRN3A, RDC-1	ENSG00000152192	POU class 4 homeobox 1	13	78598362-78603560	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068024	Enhanced					Mixed	Tissue enhanced		testis: 1.8	tonsil: 0.7	Cell line enhanced		HEK 293: 12.9;HEL: 13.8;RH-30: 17.3;SCLC-21H: 20.1;U-266/70: 12.2
RNF219	C13orf7, FLJ13449	ENSG00000152193	Ring finger protein 219	13	78614291-78659179	Predicted intracellular proteins	Evidence at protein level	HPA034785, HPA034786	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:4.99e-6 (unfavourable)	Expressed in all	Mixed			testis: 27.3	Mixed		
CYSLTR2	CysLT(2), CYSLT2R	ENSG00000152207	Cysteinyl leukotriene receptor 2	13	48653711-48711226	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046528	Uncertain					Group enriched	Tissue enhanced		placenta: 36.7;seminal vesicle: 25.0	spleen: 11.4	Cell line enriched	64	HDLM-2: 83.3
GRID2	GluD2, GluR-delta-2	ENSG00000152208	Glutamate ionotropic receptor delta type subunit 2	4	92303622-93810157	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056253, HPA058538	Enhanced					Tissue enriched	Tissue enriched	10	testis: 60.4	cerebral cortex: 6.2	Cell line enhanced		SCLC-21H: 1.4;U-2 OS: 8.2;U-266/70: 2.7;WM-115: 1.3
ARL11	ARLTS1, FLJ33930	ENSG00000152213	ADP ribosylation factor like GTPase 11	13	49628299-49633872	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040855, HPA040887	Uncertain					Mixed	Tissue enhanced		lymph node: 7.6	spleen: 6.3	Cell line enhanced		Daudi: 5.3;HMC-1: 8.9;NB-4: 6.7;THP-1: 9.3
RIT2	RIBA, RIN	ENSG00000152214	Ras like without CAAX 2	18	42743227-43115691	Predicted intracellular proteins	Evidence at protein level	HPA072174	Supported					Tissue enriched	Tissue enriched	6	cerebral cortex: 18.3	adrenal gland: 2.8	Not detected		
SETBP1	KIAA0437, SEB	ENSG00000152217	SET binding protein 1	18	44680173-45068510	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049022, HPA057259	Uncertain		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Renal cancer:6.34e-8 (favourable)	Mixed	Expressed in all			seminal vesicle: 13.8	Cell line enhanced		AF22: 15.8;Karpas-707: 45.8
ARL14EP	ARF7EP, C11orf46, FLJ38968	ENSG00000152219	ADP ribosylation factor like GTPase 14 effector protein	11	30323051-30338227	Predicted intracellular proteins	Evidence at protein level	HPA039634, HPA048127	Approved		Approved	Nucleus<br>Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:2.50e-5 (favourable), Liver cancer:5.26e-4 (unfavourable), Urothelial cancer:7.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.5	Expressed in all		
EPG5	hEPG5, KIAA1632	ENSG00000152223	Ectopic P-granules autophagy protein 5 homolog	18	45847609-45967274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031689	Uncertain		Approved	Nuclear speckles	Renal cancer:4.04e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.3	Expressed in all		
PSTPIP2		ENSG00000152229	Proline-serine-threonine phosphatase interacting protein 2	18	45983536-46072272	Predicted intracellular proteins	Evidence at protein level	HPA040923, HPA040944	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Mitochondria	Renal cancer:2.39e-7 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 47.2;spleen: 69.7	placenta: 17.3	Cell line enhanced		HEL: 91.3;HMC-1: 95.2
ATP5A1	ATP5A, ATP5AL2, ATPM, hATP1, OMR, ORM	ENSG00000152234	ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle	18	46080248-46104334	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013067, HPA040622, HPA044202	Enhanced		Supported	Mitochondria	Renal cancer:1.22e-15 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 869.9	Expressed in all		
HAUS1	CCDC5, FLJ40084, HEI-C, HsT1461	ENSG00000152240	HAUS augmin like complex subunit 1	18	46104332-46128333	Predicted intracellular proteins	Evidence at protein level	HPA040601, HPA040652	Supported		Supported	Centrosome<br>Cytosol	Ovarian cancer:1.55e-4 (favourable), Liver cancer:2.45e-4 (unfavourable), Prostate cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 41.4	Expressed in all		
C18orf25	ARKL1, MGC12909, RNF111L1	ENSG00000152242	Chromosome 18 open reading frame 25	18	46173553-46266991	Predicted intracellular proteins	Evidence at protein level	HPA051314, HPA065021	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 38.8	Expressed in all		
SPC25	AD024, MGC22228, SPBC25	ENSG00000152253	SPC25, NDC80 kinetochore complex component	2	168834132-168913371	Predicted intracellular proteins	Evidence at protein level	HPA047144, HPA050544	Approved		Enhanced	Cytosol	Liver cancer:4.74e-6 (unfavourable), Endometrial cancer:8.61e-5 (unfavourable), Lung cancer:9.44e-5 (unfavourable)	Mixed	Mixed			lymph node: 4.9	Mixed		
G6PC2	IGRP	ENSG00000152254	Glucose-6-phosphatase catalytic subunit 2	2	168901240-168910000	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	12	pancreas: 2.9	testis: 0.2	Not detected		
PDK1		ENSG00000152256	Pyruvate dehydrogenase kinase 1	2	172555373-172608669	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017554, HPA027376, HPA059083	Approved		Approved	Nucleoli<br>Mitochondria	Renal cancer:1.10e-8 (unfavourable), Cervical cancer:7.30e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
PTH	PTH1	ENSG00000152266	Parathyroid hormone	11	13492055-13496181	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000072, CAB023409, CAB026363, HPA048540	Enhanced					Not detected	Tissue enriched	109145	parathyroid gland: 59340.8	thyroid gland: 0.5	Not detected		
PDE3B	HcGIP1	ENSG00000152270	Phosphodiesterase 3B	11	14643723-14872044	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056111			Approved	Endoplasmic reticulum	Pancreatic cancer:7.91e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 65.4	testis: 17.4	Mixed		
TCF7L1	TCF3	ENSG00000152284	Transcription factor 7 like 1	2	85133410-85310388	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071298			Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.16e-5 (unfavourable), Endometrial cancer:1.70e-4 (unfavourable), Renal cancer:2.06e-4 (unfavourable), Stomach cancer:2.72e-4 (unfavourable), Urothelial cancer:5.38e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue,endometrium,thyroid gland: 22.5	Cell line enhanced		NTERA-2: 99.6;RH-30: 43.7;T-47d: 41.9
TGOLN2	TGN38, TGN46, TGN48, TGN51, TTGN2	ENSG00000152291	Trans-golgi network protein 2	2	85318020-85328425	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011489, HPA012609, HPA012723	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 146.3	Expressed in all		
SH2D6	FLJ35993	ENSG00000152292	SH2 domain containing 6	2	85418721-85437029	Predicted intracellular proteins	Evidence at transcript level	HPA053873	Uncertain					Mixed	Tissue enhanced		duodenum: 1.5;testis: 3.1;thyroid gland: 1.4	small intestine: 1.1	Cell line enhanced		LHCN-M2: 1.7
KCNK13	K2p13.1, THIK-1, THIK1	ENSG00000152315	Potassium two pore domain channel subfamily K member 13	14	90061765-90185857	Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level	HPA003514	Approved		Approved	Nuclear speckles<br>Cell Junctions		Mixed	Tissue enhanced		parathyroid gland: 14.6;testis: 14.4	kidney: 3.3	Cell line enhanced		RT4: 1.4
UHMK1	KIS, Kist	ENSG00000152332	U2AF homology motif kinase 1	1	162497251-162529629	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071190			Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
ATG10	APG10L, DKFZP586I0418, FLJ13954	ENSG00000152348	Autophagy related 10	5	81972025-82276857	Predicted intracellular proteins	Evidence at protein level	HPA044163	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 22.2	Expressed in all		
POC5	C5orf37, FLJ35779, hPOC5, MGC120442, MGC120443, MGC120444	ENSG00000152359	POC5 centriolar protein	5	75674124-75717481	Predicted intracellular proteins	Evidence at protein level	HPA037509, HPA037510, HPA061521	Approved		Approved	Nucleus	Liver cancer:1.60e-7 (unfavourable), Renal cancer:6.74e-5 (unfavourable), Urothelial cancer:1.09e-4 (favourable)	Expressed in all	Mixed			testis: 36.2	Expressed in all		
SPOCK1	SPOCK, testican-1, TIC1	ENSG00000152377	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 1	5	136975298-137598379	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007450, HPA026770	Uncertain		Approved	Vesicles	Head and neck cancer:1.93e-5 (unfavourable), Renal cancer:3.77e-5 (unfavourable), Colorectal cancer:1.93e-4 (unfavourable), Ovarian cancer:4.72e-4 (unfavourable), Lung cancer:9.08e-4 (unfavourable), Stomach cancer:9.40e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 209.2	prostate: 108.0	Cell line enhanced		AF22: 299.3;ASC diff: 403.2;HUVEC TERT2: 508.1;U-138 MG: 298.1
FAM151B	UNQ9217	ENSG00000152380	Family with sequence similarity 151 member B	5	80487969-80542563	Predicted intracellular proteins	Evidence at protein level	HPA043805	Uncertain		Approved	Cytosol		Mixed	Mixed			bone marrow: 2.8	Mixed		
TADA1	ADA1, hADA1, HFI1, STAF42, TADA1L	ENSG00000152382	Transcriptional adaptor 1	1	166856510-166876327	Predicted intracellular proteins	Evidence at protein level	HPA028651	Approved		Supported	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 23.9	Expressed in all		
GUCY1A2	GC-SA2, GUC1A2	ENSG00000152402	Guanylate cyclase 1 soluble subunit alpha 2	11	106674012-107018524	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009534	Uncertain				Renal cancer:3.02e-5 (unfavourable)	Mixed	Tissue enhanced		placenta: 25.6	endometrium: 21.1	Cell line enhanced		BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
CWF19L2	FLJ32343	ENSG00000152404	CWF19-like 2, cell cycle control (S. pombe)	11	107326345-107457844	Predicted intracellular proteins	Evidence at protein level	HPA038166	Uncertain		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			endometrium: 18.0	Expressed in all		
JMY	FLJ37870, WHAMM2	ENSG00000152409	Junction mediating and regulatory protein, p53 cofactor	5	79236189-79327215	Predicted intracellular proteins	Evidence at protein level	HPA037508, HPA043308	Uncertain		Uncertain	Nucleoplasm	Renal cancer:3.03e-5 (favourable), Ovarian cancer:1.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.6	Cell line enhanced		Karpas-707: 31.6
HOMER1	HOMER-1B, SYN47, Ves-1	ENSG00000152413	Homer scaffolding protein 1	5	79372636-79514217	Predicted intracellular proteins	Evidence at protein level	CAB004437, HPA036521, HPA036522	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 48.9	thyroid gland: 25.2	Mixed		
XRCC4		ENSG00000152422	X-ray repair cross complementing 4	5	83077498-83353787	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006801, HPA051538	Enhanced		Supported	Nucleus	Breast cancer:1.80e-5 (unfavourable)	Expressed in all	Mixed			testis: 16.1	Expressed in all		
BOLL	BOULE	ENSG00000152430	Boule homolog, RNA binding protein	2	197726879-197786762	Predicted intracellular proteins	Evidence at protein level	HPA018678, HPA048813	Enhanced					Not detected	Tissue enriched	67	testis: 87.9	skeletal muscle: 1.3	Not detected		
ZNF547	FLJ31100	ENSG00000152433	Zinc finger protein 547	19	57363477-57379565	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056001	Uncertain					Mixed	Mixed			thyroid gland: 5.2	Mixed		
ZNF773	MGC4728, ZNF419B	ENSG00000152439	Zinc finger protein 773	19	57499915-57518404	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003152	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Mixed			parathyroid gland: 13.1	Mixed		
ZNF776	FLJ38288	ENSG00000152443	Zinc finger protein 776	19	57746796-57758159	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046653, HPA068553	Uncertain		Approved	Nucleus<br>Cytosol	Cervical cancer:9.74e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 26.3	Mixed		
ZNF256	BMZF-3	ENSG00000152454	Zinc finger protein 256	19	57940833-57947675	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055390	Uncertain		Supported	Nucleus		Expressed in all	Mixed			testis: 7.9	Cell line enhanced		HEK 293: 30.4
SUV39H2	FLJ23414, KMT1B	ENSG00000152455	Suppressor of variegation 3-9 homolog 2	10	14878820-14904315	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045901, HPA057554	Enhanced		Approved	Mitochondria	Liver cancer:2.01e-6 (unfavourable), Renal cancer:5.71e-5 (unfavourable), Breast cancer:5.55e-4 (unfavourable)	Expressed in all	Tissue enriched	12	testis: 73.2	placenta: 6.1	Expressed in all		
DCLRE1C	A-SCID, ARTEMIS, FLJ11360, SCIDA, SNM1C	ENSG00000152457	DNA cross-link repair 1C	10	14897359-14954432	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA069295			Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:9.03e-8 (unfavourable), Head and neck cancer:1.30e-4 (favourable), Ovarian cancer:7.98e-4 (favourable)	Expressed in all	Mixed			lymph node: 16.4	Expressed in all		
OLAH	FLJ11106, SAST, THEDC1	ENSG00000152463	Oleoyl-ACP hydrolase	10	15032227-15073852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037947, HPA037948	Enhanced					Group enriched	Tissue enriched	7	testis: 46.0	breast: 6.2	Cell line enhanced		hTCEpi: 3.3;LHCN-M2: 3.0;SK-BR-3: 4.2
RPP38		ENSG00000152464	Ribonuclease P/MRP subunit p38	10	15097180-15139818	Enzymes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045128, HPA050398	Approved		Supported	Nucleoli	Urothelial cancer:2.89e-6 (favourable), Liver cancer:1.46e-4 (unfavourable), Renal cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 76.3	Expressed in all		
NMT2		ENSG00000152465	N-myristoyltransferase 2	10	15102584-15168693	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001303	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 39.4	Cell line enhanced		TIME: 123.2
ZSCAN1	FLJ33779, ZNF915	ENSG00000152467	Zinc finger and SCAN domain containing 1	19	58034032-58054631	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007938	Uncertain		Approved	Nucleoli	Ovarian cancer:7.36e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 7.4	cerebral cortex: 5.3	Cell line enhanced		EFO-21: 2.8;HMC-1: 1.8;NTERA-2: 2.1;T-47d: 2.9
ZNF837		ENSG00000152475	Zinc finger protein 837	19	58367618-58381060	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042833	Uncertain		Approved	Nucleoli	Renal cancer:1.76e-5 (favourable), Endometrial cancer:1.27e-4 (favourable)	Expressed in all	Mixed			skin,spleen: 1.4	Cell line enhanced		HEK 293: 8.6
USP12	USP12L1	ENSG00000152484	Ubiquitin specific peptidase 12	13	27066142-27171896	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007288	Uncertain					Expressed in all	Expressed in all			bone marrow: 45.6	Expressed in all		
CCDC50	C3orf6, DFNA44, Ymer	ENSG00000152492	Coiled-coil domain containing 50	3	191329077-191398670	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001336	Approved		Supported	Cytosol	Liver cancer:2.48e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 49.2	Mixed		
CAMK4	CaMK-GR	ENSG00000152495	Calcium/calmodulin dependent protein kinase IV	5	111223653-111494886	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB004347, HPA011753, HPA017206	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		cerebral cortex: 16.5;testis: 17.0	lymph node: 9.7	Cell line enhanced		HDLM-2: 83.9;SH-SY5Y: 35.7
TRIM36	HAPRIN, RBCC728, RNF98	ENSG00000152503	Tripartite motif containing 36	5	115124762-115180546	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061321			Approved	Nucleus<br>Cytosol		Tissue enhanced	Tissue enriched	16	testis: 313.5	cerebral cortex: 19.9	Cell line enhanced		RH-30: 23.2;SCLC-21H: 31.3;SH-SY5Y: 20.6
ZFP36L2	BRF2, ERF2, RNF162C, TIS11D	ENSG00000152518	ZFP36 ring finger protein like 2	2	43222402-43226609	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047428	Approved					Expressed in all	Expressed in all			thyroid gland: 274.7	Expressed in all		
PAN3		ENSG00000152520	PAN3 poly(A) specific ribonuclease subunit	13	28138506-28295335	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028817	Approved					Expressed in all	Expressed in all			spleen: 28.7	Expressed in all		
PLEKHH2	KIAA2028, PLEKHH1L	ENSG00000152527	Pleckstrin homology, MyTH4 and FERM domain containing H2	2	43637273-43767987	Predicted intracellular proteins	Evidence at protein level	HPA077225			Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			endometrium: 32.1	Mixed		
PFKM	PFK-1, PFKX, PPP1R122	ENSG00000152556	Phosphofructokinase, muscle	12	48105139-48146404	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002117	Approved		Approved	Endoplasmic reticulum	Renal cancer:2.28e-7 (favourable), Endometrial cancer:5.85e-6 (unfavourable), Head and neck cancer:7.91e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 549.3	Expressed in all		
TMEM123	KCT3, PORIMIN	ENSG00000152558	Transmembrane protein 123	11	102396332-102470384	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026001, HPA062862			Supported	Golgi apparatus<br>Vesicles<br>Cytosol	Pancreatic cancer:2.66e-4 (unfavourable), Melanoma:5.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 575.8	Mixed		
GRIA4	GluA4, GLUR4, GLURD	ENSG00000152578	Glutamate ionotropic receptor AMPA type subunit 4	11	105609994-105982092	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	10	cerebral cortex: 73.2	adrenal gland: 7.3	Cell line enhanced		AF22: 11.9;NTERA-2: 4.0;SCLC-21H: 5.1
IGSF10	CMF608, FLJ25972	ENSG00000152580	Immunoglobulin superfamily member 10	3	151425384-151458709	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012921	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Mixed	Tissue enhanced		ovary: 18.1	gallbladder: 14.7	Cell line enhanced		HeLa: 31.1;HL-60: 18.4;REH: 15.7;RPMI-8226: 38.1
SPEF2	CT122, FLJ23577, KPL2	ENSG00000152582	Sperm flagellar 2	5	35617844-35814611	Predicted intracellular proteins	Evidence at protein level	HPA039606, HPA040343	Enhanced					Mixed	Mixed			fallopian tube: 25.5	Cell line enhanced		HDLM-2: 12.3
SPARCL1	MAST9	ENSG00000152583	SPARC like 1	4	87473335-87531061	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026225	Enhanced				Urothelial cancer:3.33e-4 (unfavourable), Colorectal cancer:4.06e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2035.8	Cell line enhanced		AF22: 23.6;U-266/70: 7.1
DSPP	DFNA39, DGI1, DMP3	ENSG00000152591	Dentin sialophosphoprotein	4	87608529-87616910	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA036230	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DMP1		ENSG00000152592	Dentin matrix acidic phosphoprotein 1	4	87650307-87664361	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA037465	Approved					Not detected	Not detected			testis: 0.8	Not detected		
MEPE		ENSG00000152595	Matrix extracellular phosphoglycoprotein	4	87821411-87846817	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038003, HPA038004	Uncertain					Not detected	Tissue enriched	41	cerebral cortex: 4.0	all non-specific tissues: 0.0	Not detected		
MBNL1	EXP, EXP35, EXP40, EXP42, KIAA0428, MBNL	ENSG00000152601	Muscleblind like splicing regulator 1	3	152243828-152465780	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016398, HPA035098	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.90e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 169.7	Expressed in all		
CAPSL	MGC26610	ENSG00000152611	Calcyphosine like	5	35904295-35938779	Predicted intracellular proteins	Evidence at protein level	HPA046811, HPA058495	Enhanced		Approved	Nucleus<br>Microtubules		Group enriched	Tissue enriched	10	fallopian tube: 175.4	testis: 17.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 6.8;BJ hTERT+ SV40 Large T+ RasG12V: 6.0;HBF TERT88: 4.6;REH: 7.2;U-698: 13.2
NADK2	C5orf33, FLJ30596, MNADK, NADKD1	ENSG00000152620	NAD kinase 2, mitochondrial	5	36192592-36242279	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038366, HPA038367, HPA061492	Enhanced					Expressed in all	Expressed in all			liver: 173.0	Expressed in all		
GPD1L	KIAA0089	ENSG00000152642	Glycerol-3-phosphate dehydrogenase 1-like	3	32105689-32168713	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.33e-15 (favourable), Liver cancer:1.35e-5 (unfavourable), Lung cancer:5.71e-5 (favourable), Colorectal cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			prostate: 92.5	Expressed in all		
GJA1	CX43, GJAL, ODD, ODDD, ODOD, SDTY3	ENSG00000152661	Gap junction protein alpha 1	6	121435692-121449727	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB010753, HPA035097, HPA047551, HPA069245	Enhanced	Supported	Supported	Nucleoplasm<br>Vesicles<br>Cell Junctions	Stomach cancer:4.99e-5 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 651.5	skin: 469.0	Cell line enhanced		HUVEC TERT2: 306.6;NTERA-2: 370.8;U-87 MG: 348.4
CCNO	CCNU, FLJ22422, UDG2, UNG2	ENSG00000152669	Cyclin O	5	55231152-55233680	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050090	Uncertain				Stomach cancer:5.10e-4 (favourable), Endometrial cancer:6.78e-4 (favourable), Lung cancer:7.60e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 6.9	fallopian tube,seminal vesicle: 1.6	Cell line enhanced		BEWO: 4.2;T-47d: 5.6
DDX4	VASA	ENSG00000152670	DEAD-box helicase 4	5	55738017-55817157	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB026170, HPA037763, HPA037764	Enhanced					Tissue enriched	Tissue enriched	526	testis: 270.5	tonsil: 0.5	Cell line enhanced		BEWO: 1.8
CLEC4F	CLECSF13, FLJ39110, KCLR	ENSG00000152672	C-type lectin domain family 4 member F	2	70808643-70820600	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			small intestine: 4.9	Cell line enhanced		AN3-CA: 1.7
SLC30A6	FLJ31101, ZNT6	ENSG00000152683	Solute carrier family 30 member 6	2	32165841-32224379	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055032, HPA057328	Uncertain		Enhanced	Golgi apparatus	Liver cancer:9.58e-6 (unfavourable), Endometrial cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 19.8	Expressed in all		
PELO		ENSG00000152684	Pelota homolog (Drosophila)	5	52787940-52804046	Predicted intracellular proteins	Evidence at protein level	HPA031458	Approved		Approved	Nucleoli fibrillar center	Breast cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 20.0	Expressed in all		
RASGRP3	CalDAG-GEFIII, GRP3, KIAA0846	ENSG00000152689	RAS guanyl releasing protein 3	2	33436324-33564750	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA058937			Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Mixed			lymph node: 33.8	Group enriched	5	Daudi: 64.5;HEL: 85.5;U-266/70: 109.3;U-266/84: 41.0;U-698: 27.2
SAR1B	SARA2	ENSG00000152700	Secretion associated Ras related GTPase 1B	5	134601144-134649271	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006923, HPA048368	Supported		Approved	Endoplasmic reticulum	Liver cancer:6.59e-4 (favourable), Endometrial cancer:7.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 118.6	Expressed in all		
CATSPER3	CACRC	ENSG00000152705	Cation channel sperm associated 3	5	134967906-135011707	Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Tissue enriched	26	testis: 38.6	fallopian tube: 1.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 2.5
GPR180	ITR	ENSG00000152749	G protein-coupled receptor 180	13	94601903-94634645	Predicted membrane proteins	Evidence at protein level	HPA047250	Approved		Approved	Vesicles	Renal cancer:3.18e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 6.3	Mixed		
TCTEX1D1	FLJ40873	ENSG00000152760	Tctex1 domain containing 1	1	66752459-66778787	Predicted intracellular proteins	Evidence at protein level	HPA028420	Uncertain					Tissue enriched	Tissue enhanced		fallopian tube: 16.6;placenta: 9.6	liver: 4.0	Group enriched	6	HEL: 14.3;HUVEC TERT2: 13.0;THP-1: 12.0
WDR78	DIC4, FLJ23129	ENSG00000152763	WD repeat domain 78	1	66812885-66924887	Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.60e-5 (favourable)	Mixed	Group enriched	5	fallopian tube: 43.8;testis: 62.9	parathyroid gland: 10.2	Cell line enhanced		RPTEC TERT1: 8.6
ANKRD22	MGC22805	ENSG00000152766	Ankyrin repeat domain 22	10	88822132-88851818	Predicted intracellular proteins	Evidence at protein level	HPA012922	Approved		Approved	Nucleus	Endometrial cancer:8.73e-6 (favourable), Pancreatic cancer:6.15e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 38.6;stomach: 49.2	esophagus: 27.0	Cell line enhanced		A-431: 13.9;CAPAN-2: 43.6;RT4: 27.0;T-47d: 21.2
FARP1	CDEP, MGC87400, PLEKHC2, PPP1R75	ENSG00000152767	FERM, ARH/RhoGEF and pleckstrin domain protein 1	13	98142562-98455176	Predicted intracellular proteins	Evidence at protein level	HPA000760			Supported	Cytosol	Renal cancer:1.39e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 58.8	Mixed		
IFIT5	RI58	ENSG00000152778	Interferon induced protein with tetratricopeptide repeats 5	10	89414586-89421001	Predicted intracellular proteins	Evidence at protein level	HPA037957, HPA062180	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Mixed			parathyroid gland: 36.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 66.6;BJ hTERT+ SV40 Large T+ RasG12V: 82.7
SLC16A12	MCT12	ENSG00000152779	Solute carrier family 16 member 12	10	89430299-89556641	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037587			Approved	Mitochondria	Renal cancer:4.50e-12 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 63.5;kidney: 93.5	seminal vesicle: 20.2	Cell line enhanced		ASC TERT1: 16.2;HSkMC: 6.0
PANK1	MGC24596, PANK, PANK1a, PANK1b	ENSG00000152782	Pantothenate kinase 1	10	89579497-89645572	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.55e-10 (favourable), Liver cancer:1.50e-4 (favourable)	Mixed	Tissue enhanced		kidney: 46.6;liver: 55.1	duodenum: 20.6	Mixed		
PRDM8	KMT8D	ENSG00000152784	PR/SET domain 8	4	80183879-80204329	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057253			Approved	Nuclear bodies		Tissue enhanced	Tissue enhanced		prostate: 40.8;seminal vesicle: 37.7	cerebral cortex: 23.2	Cell line enhanced		LHCN-M2: 34.7;NB-4: 30.5;SCLC-21H: 116.7
BMP3		ENSG00000152785	Bone morphogenetic protein 3	4	81030965-81057531	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		urinary bladder: 20.6	lung: 8.7	Cell line enhanced		AF22: 10.7;Daudi: 12.2;RT4: 11.3;SK-BR-3: 4.6
HNRNPDL	HNRPDL, JKTBP, laAUF1	ENSG00000152795	Heterogeneous nuclear ribonucleoprotein D like	4	82422564-82430408	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056820, HPA063147	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 422.5	Expressed in all		
HHEX	HEX, HOX11L-PEN, PRHX	ENSG00000152804	Hematopoietically expressed homeobox	10	92689951-92695646	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051894, HPA055460	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:3.25e-5 (unfavourable), Cervical cancer:3.91e-5 (favourable), Liver cancer:6.23e-4 (unfavourable), Breast cancer:8.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 164.8	Cell line enhanced		HEL: 89.2;HMC-1: 92.9;HUVEC TERT2: 88.4;K-562: 137.7
UTRN	DMDL, DRP, DRP1	ENSG00000152818	Utrophin	6	144285701-144853034	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016348, HPA018894	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.61e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 174.0	Cell line enhanced		HAP1: 226.1
GRM1	GPRC1A, mGlu1, MGLUR1, PPP1R85	ENSG00000152822	Glutamate metabotropic receptor 1	6	146027646-146437598	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015701	Approved		Approved	Vesicles		Not detected	Group enriched	5	cerebral cortex: 7.0;heart muscle: 1.7	kidney: 0.8	Not detected		
PTPRK	R-PTP-kappa	ENSG00000152894	Protein tyrosine phosphatase, receptor type K	6	127968779-128520674	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054056, HPA054822	Uncertain		Supported	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 27.8	Mixed		
GGPS1	GGPPS1	ENSG00000152904	Geranylgeranyl diphosphate synthase 1	1	235327350-235344532	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029472	Enhanced				Liver cancer:6.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 90.1	Expressed in all		
CNTNAP4	CASPR4, KIAA1763	ENSG00000152910	Contactin associated protein like 4	16	76277278-76559238	Predicted membrane proteins	Evidence at protein level	HPA031859, HPA057342	Enhanced					Tissue enriched	Tissue enriched	21	cerebral cortex: 35.9	testis: 1.6	Group enriched	6	Daudi: 7.9;HSkMC: 3.0;Karpas-707: 2.6;RPMI-8226: 4.9
ZNF117	H-plk, HPF9	ENSG00000152926	Zinc finger protein 117	7	64971776-65006684	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031148			Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.17e-11 (unfavourable)	Expressed in all	Mixed			adrenal gland: 25.2	Mixed		
RAB3C		ENSG00000152932	RAB3C, member RAS oncogene family	5	58582221-58859394	Predicted intracellular proteins	Evidence at protein level	HPA003160, HPA048156	Enhanced		Approved	Cytosol		Mixed	Group enriched	17	adrenal gland: 12.0;cerebral cortex: 55.3	small intestine: 2.0	Cell line enhanced		HEL: 2.2;SCLC-21H: 11.9;SH-SY5Y: 3.9
LMNTD1	FLJ36004, IFLTD1, Pas1c1	ENSG00000152936	Lamin tail domain containing 1	12	25409307-25648579	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA038640, HPA045911	Uncertain		Approved	Nucleoplasm<br>Centrosome		Tissue enhanced	Group enriched	7	fallopian tube: 27.1;testis: 26.6	rectum: 3.7	Cell line enhanced		SH-SY5Y: 8.1;U-2197: 24.9
MARVELD2	DFNB49, FLJ30532, MRVLDC2, TRIC	ENSG00000152939	MARVEL domain containing 2	5	69415112-69444330	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018119, HPA061726	Uncertain		Supported	Cell Junctions	Renal cancer:2.84e-13 (favourable)	Mixed	Tissue enhanced		thyroid gland: 19.7	small intestine: 8.7	Cell line enhanced		BEWO: 30.0;CAPAN-2: 22.9;HaCaT: 17.6;RT4: 17.7;SCLC-21H: 32.0;T-47d: 18.4
RAD17	CCYC, RAD17Sp, Rad24	ENSG00000152942	RAD17 checkpoint clamp loader component	5	69369293-69414801	Predicted intracellular proteins	Evidence at protein level	CAB004551, HPA005448	Approved		Enhanced	Nucleoplasm	Renal cancer:5.79e-6 (favourable)	Expressed in all	Expressed in all			testis: 39.3	Mixed		
MED21	SRB7, SURB7	ENSG00000152944	Mediator complex subunit 21	12	27022546-27066343	Predicted intracellular proteins	Evidence at protein level	HPA017177	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.74e-8 (favourable)	Expressed in all	Expressed in all			testis: 69.4	Expressed in all		
PLOD2	LH2	ENSG00000152952	Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2	3	146069440-146163653	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025898, HPA069126	Approved		Uncertain	Nucleoli<br>Cytosol	Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 150.8	Cell line enhanced		HBF TERT88: 615.2;U-87 MG: 554.9
STK32B	HSA250839, STK32, STKG6, YANK2	ENSG00000152953	Serine/threonine kinase 32B	4	5051442-5500998	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058536			Approved	Microtubules	Renal cancer:1.63e-8 (favourable)	Mixed	Tissue enhanced		kidney: 15.8	testis: 8.6	Cell line enhanced		HUVEC TERT2: 22.9;REH: 22.7;U-2197: 40.5;WM-115: 110.5
NRSN1	p24, VMP	ENSG00000152954	Neurensin 1	6	24126122-24154900	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA061006	Approved		Approved	Nucleus<br>Vesicles		Tissue enriched	Tissue enriched	14	cerebral cortex: 96.3	adrenal gland: 6.6	Cell line enhanced		SCLC-21H: 14.0;SH-SY5Y: 10.0
JAKMIP1	FLJ31564, Gababrbp, JAMIP1, MARLIN1	ENSG00000152969	Janus kinase and microtubule interacting protein 1	4	6026199-6200591	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044570	Uncertain					Mixed	Tissue enriched	6	cerebral cortex: 38.7	prostate: 6.9	Cell line enhanced		Daudi: 11.3;MOLT-4: 36.1;SCLC-21H: 22.4;U-266/70: 20.1
ZIC1	ZIC, ZNF201	ENSG00000152977	Zic family member 1	3	147393422-147510293	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004098	Supported		Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	9	cerebral cortex: 23.8	skin: 2.5	Cell line enriched	5	AF22: 171.9
ADGRA3	FLJ38547, GPR125, PGR21	ENSG00000152990	Adhesion G protein-coupled receptor A3	4	22345071-22516054	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008904	Uncertain					Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
CPB1		ENSG00000153002	Carboxypeptidase B1	3	148791102-148860187	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026158, HPA038069, HPA046340	Enhanced					Group enriched	Tissue enriched	312	pancreas: 47292.1	ovary: 151.6	Cell line enhanced		HDLM-2: 1.0;U-2 OS: 1.7
SREK1IP1	FLJ36754, P18SRP, SFRS12IP1	ENSG00000153006	SREK1 interacting protein 1	5	64718144-64768685	Predicted intracellular proteins	Evidence at protein level	HPA045677, HPA062853	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:9.03e-4 (unfavourable), Renal cancer:9.68e-4 (unfavourable)	Expressed in all	Mixed			placenta: 12.4	Expressed in all		
LGI2	FLJ10675, KIAA1916	ENSG00000153012	Leucine rich repeat LGI family member 2	4	24998847-25030879	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017140	Approved		Approved	Centrosome		Mixed	Tissue enriched	19	parathyroid gland: 371.4	smooth muscle: 19.6	Cell line enhanced		AF22: 27.8;RPMI-8226: 9.3;SCLC-21H: 21.4
CWC27	NY-CO-10, SDCCAG-10, SDCCAG10	ENSG00000153015	CWC27 spliceosome associated protein homolog	5	64768930-65018763	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020344, HPA024149, HPA065809	Approved		Enhanced	Nucleoplasm	Liver cancer:5.27e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
MR1	HLALS	ENSG00000153029	Major histocompatibility complex, class I-related	1	181033425-181061938	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048304			Supported	Plasma membrane		Expressed in all	Mixed			thyroid gland: 28.2	Mixed		
SRP19		ENSG00000153037	Signal recognition particle 19	5	112861222-112869788	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029272	Approved				Renal cancer:3.72e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 64.7	Expressed in all		
CENPH		ENSG00000153044	Centromere protein H	5	69189548-69210357	Predicted intracellular proteins	Evidence at protein level	HPA036494	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:5.11e-15 (unfavourable), Liver cancer:5.22e-5 (unfavourable), Ovarian cancer:2.50e-4 (favourable), Cervical cancer:6.86e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 53.9	lymph node: 20.6	Expressed in all		
CDYL	CDYL1, DKFZP586C1622	ENSG00000153046	Chromodomain Y-like	6	4706159-4955551	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012249, HPA035578	Enhanced		Supported	Nuclear speckles	Glioma:2.10e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Melanoma:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 27.7	Expressed in all		
CARHSP1	CRHSP-24, CSDC1	ENSG00000153048	Calcium regulated heat stable protein 1	16	8852942-8869012	Predicted intracellular proteins	Evidence at protein level	HPA051911	Approved				Urothelial cancer:7.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 260.3	Expressed in all		
TEKT5	CT149, FLJ32871	ENSG00000153060	Tektin 5	16	10627501-10694945	Predicted intracellular proteins	Evidence at protein level	HPA043578			Supported	Actin filaments		Mixed	Tissue enriched	48	testis: 45.6	stomach: 0.9	Cell line enriched	16	BEWO: 12.0
BANK1	BANK, FLJ20706	ENSG00000153064	B-cell scaffold protein with ankyrin repeats 1	4	101411286-102074812	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037002	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Group enriched	5	appendix: 45.9;lymph node: 96.8;spleen: 77.4;thyroid gland: 21.6;tonsil: 87.2	urinary bladder: 12.9	Cell line enhanced		Daudi: 9.7;HEL: 9.5;HL-60: 7.6;U-266/70: 23.8
TXNDC11	EFP1	ENSG00000153066	Thioredoxin domain containing 11	16	11679080-11742878	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041174, HPA041390	Supported		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.5	Expressed in all		
DAB2	DOC-2	ENSG00000153071	DAB2, clathrin adaptor protein	5	39371675-39462300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009314, HPA028888	Enhanced		Enhanced	Nucleoli fibrillar center<br>Vesicles<br>Plasma membrane	Liver cancer:7.38e-6 (unfavourable), Stomach cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 321.8	Cell line enhanced		fHDF/TERT166: 273.0;U-138 MG: 234.0
ACMSD		ENSG00000153086	Aminocarboxymuconate semialdehyde decarboxylase	2	134838547-134902034	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010533, HPA011179	Enhanced				Renal cancer:2.39e-4 (favourable)	Group enriched	Group enriched	10	kidney: 137.3;liver: 80.2	gallbladder: 10.8	Cell line enriched	16	RPTEC TERT1: 19.7
ACOXL	FLJ11042	ENSG00000153093	Acyl-CoA oxidase-like	2	110732573-111118222	Predicted intracellular proteins	Evidence at protein level	HPA035392, HPA035393			Supported	Nucleoli<br>Cytosol	Urothelial cancer:6.48e-4 (favourable)	Group enriched	Group enriched	6	epididymis: 9.2;lung: 14.5;parathyroid gland: 6.9;prostate: 5.2;testis: 5.2;urinary bladder: 7.6	thyroid gland: 1.3	Cell line enhanced		A-431: 11.1;RPMI-8226: 15.9;RT4: 23.3;U-266/70: 14.6
BCL2L11	BIM, BimEL, BimL, BimS, BOD	ENSG00000153094	BCL2 like 11	2	111119378-111168447	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB026332	Approved					Expressed in all	Expressed in all			thyroid gland: 33.2	Cell line enhanced		U-266/70: 73.4
ANAPC1	APC1, MCPR, TSG24	ENSG00000153107	Anaphase promoting complex subunit 1	2	111766271-111884690	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036329, HPA036330, HPA042998	Approved		Approved	Vesicles	Endometrial cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.6	Expressed in all		
CAST		ENSG00000153113	Calpastatin	5	96525267-96779595	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009491, HPA036881, HPA036882	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Stomach cancer:1.20e-5 (unfavourable), Pancreatic cancer:9.27e-5 (unfavourable), Urothelial cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 401.9	Mixed		
SCOC	HRIHFB2072, SCOCO, UNC-69	ENSG00000153130	Short coiled-coil protein	4	140257286-140385726	Predicted intracellular proteins	Evidence at protein level	HPA061198, HPA070321	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.82e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 187.9	Expressed in all		
CLGN		ENSG00000153132	Calmegin	4	140388455-140427968	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB020709, HPA048761, HPA058627	Enhanced		Enhanced	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	5	testis: 186.4	heart muscle: 35.6	Cell line enhanced		U-251 MG: 54.9
CETN3	CEN3	ENSG00000153140	Centrin 3	5	90392261-90409786	Predicted intracellular proteins	Evidence at protein level	HPA035608, HPA063704	Approved		Supported	Centrosome	Liver cancer:2.22e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 225.8	ovary: 36.5	Expressed in all		
SMARCA5	hISWI, hSNF2H, ISWI	ENSG00000153147	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5	4	143513463-143557486	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005227, HPA008751	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
SYCP2L	C6orf177, dJ62D2.1, NO145	ENSG00000153157	Synaptonemal complex protein 2 like	6	10886831-10979320	Predicted intracellular proteins	Evidence at protein level	HPA034679			Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	20	parathyroid gland: 122.5	testis: 5.9	Cell line enhanced		HL-60: 10.7;HMC-1: 35.1;K-562: 9.5;NB-4: 9.1
BMP6	VGR, VGR1	ENSG00000153162	Bone morphogenetic protein 6	6	7726797-7881422	Predicted secreted proteins	Evidence at protein level	CAB002773, HPA062683	Approved		Approved	Mitochondria	Breast cancer:6.45e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 33.4	lung: 10.4	Cell line enhanced		HUVEC TERT2: 162.0;Karpas-707: 72.0;SiHa: 90.3;TIME: 73.2
RGPD3	RGP3	ENSG00000153165	RANBP2-like and GRIP domain containing 3	2	106391290-106468376	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	13	testis: 11.7	cerebral cortex,kidney: 0.8	Cell line enhanced		HEL: 1.4;MOLT-4: 4.1
RASSF3		ENSG00000153179	Ras association domain family member 3	12	64507001-64697567	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022664, CAB034035, HPA038469	Supported		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 86.2	Expressed in all		
HNRNPU	C1orf199, FLJ30202, FLJ37978, hnRNPU, HNRNPU-AS1, HNRPU, NCRNA00201, SAF-A	ENSG00000153187	Heterogeneous nuclear ribonucleoprotein U	1	244840638-244864560	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011532, HPA041057, HPA058707	Supported		Supported	Nucleoplasm	Liver cancer:8.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 225.2	Expressed in all		
RANBP2	ADANE, ANE1, NUP358	ENSG00000153201	RAN binding protein 2	2	108719481-108785811	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564	Supported					Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
AHCTF1	ELYS	ENSG00000153207	AT-hook containing transcription factor 1	1	246839098-246931978	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA031658	Uncertain		Supported	Nuclear membrane	Renal cancer:3.49e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 61.5	Expressed in all		
MERTK	c-Eyk, mer, RP38, Tyro12	ENSG00000153208	MER proto-oncogene, tyrosine kinase	2	111898479-112029561	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036196, HPA075622	Approved		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 77.2	Cell line enhanced		CACO-2: 31.5;Hep G2: 27.2;HUVEC TERT2: 32.3
TMEM87B	FLJ14681	ENSG00000153214	Transmembrane protein 87B	2	112055223-112119318	Predicted membrane proteins	Evidence at protein level	HPA035183	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.52e-7 (unfavourable), Cervical cancer:3.78e-4 (unfavourable), Head and neck cancer:4.28e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Mixed			prostate: 44.5	Expressed in all		
OR14K1	OR5AY1	ENSG00000153230	Olfactory receptor family 14 subfamily K member 1	1	247738615-247739559	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA016643	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
PTPRR	EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ	ENSG00000153233	Protein tyrosine phosphatase, receptor type R	12	70638073-70920843	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB011461, HPA011851, HPA071067	Uncertain		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Urothelial cancer:1.40e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.8	endometrium: 9.0	Group enriched	11	HDLM-2: 18.5;RT4: 29.7;SH-SY5Y: 6.2
NR4A2	HZF-3, NOT, NURR1, RNR1, TINUR	ENSG00000153234	Nuclear receptor subfamily 4 group A member 2	2	156324432-156342348	Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000543, CAB010481	Uncertain		Supported	Nuclear speckles		Expressed in all	Tissue enhanced		adrenal gland: 174.3	ovary: 95.8	Cell line enhanced		HeLa: 10.1;HMC-1: 9.6;U-266/70: 11.3
CCDC148	MGC125588	ENSG00000153237	Coiled-coil domain containing 148	2	158171081-158456753	Predicted intracellular proteins	Evidence at protein level	HPA042626	Uncertain		Approved	Nucleus<br>Nucleoli	Thyroid cancer:2.54e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 4.2;testis: 5.8	fallopian tube: 2.4	Cell line enhanced		CAPAN-2: 2.2;HBF TERT88: 1.7;SCLC-21H: 2.0
PLA2R1	CLEC13C, PLA2-R, PLA2G1R, PLA2IR	ENSG00000153246	Phospholipase A2 receptor 1	2	159932006-160062610	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB068217, CAB068218	Approved		Approved	Cytosol	Stomach cancer:3.08e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 70.6	parathyroid gland: 34.5	Cell line enhanced		ASC TERT1: 13.7;BJ hTERT+: 13.1;SiHa: 12.5;TIME: 38.6
RBMS1	C2orf12, DKFZp564H0764, HCC-4, MSSP-1, MSSP-2, MSSP-3, SCR2, YC1	ENSG00000153250	RNA binding motif single stranded interacting protein 1	2	160272151-160493794	Predicted intracellular proteins	Evidence at protein level	HPA047943, HPA061791			Supported	Cytosol	Renal cancer:1.33e-7 (unfavourable), Liver cancer:4.45e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 119.9	Mixed		
SCN3A	Nav1.3	ENSG00000153253	Sodium voltage-gated channel alpha subunit 3	2	165087522-165204067	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA035396	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 13.6	adrenal gland: 1.9	Cell line enhanced		Karpas-707: 7.8;MOLT-4: 26.0;RPTEC TERT1: 11.6;SH-SY5Y: 7.3
FEZF2	FEZL, FKSG36, FLJ10142, TOF, Zfp312, ZNF312	ENSG00000153266	FEZ family zinc finger 2	3	62369681-62374324	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	30	cerebral cortex: 11.7	colon: 0.3	Cell line enhanced		AF22: 1.4;NTERA-2: 1.0
CD96	TACTILE	ENSG00000153283	CD96 molecule	3	111292719-111665750	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066754	Enhanced				Renal cancer:2.02e-6 (unfavourable), Urothelial cancer:5.23e-5 (favourable), Head and neck cancer:5.52e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 28.0	urinary bladder: 16.7	Group enriched	8	HEL: 13.0;MOLT-4: 51.4;RT4: 46.0;U-937: 40.7;WM-115: 10.8
SLC25A27	FLJ33552, UCP4	ENSG00000153291	Solute carrier family 25 member 27	6	46652915-46678193	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA069732			Supported	Mitochondria	Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Mixed			epididymis: 85.3	Cell line enhanced		HeLa: 29.3
ADGRF1	GPR110, hGPCR36, PGR19	ENSG00000153292	Adhesion G protein-coupled receptor F1	6	46997703-47042363	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038438	Approved				Renal cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9	gallbladder: 9.4	Group enriched	9	A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
ADGRF4	FLJ38076, GPR115, PGR18	ENSG00000153294	Adhesion G protein-coupled receptor F4	6	47685864-47722021	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007131, HPA007158	Enhanced		Uncertain	Mitochondria	Pancreatic cancer:5.52e-4 (unfavourable)	Mixed	Group enriched	8	esophagus: 12.1;skin: 45.8	tonsil: 3.7	Cell line enhanced		HaCaT: 11.5;HBEC3-KT: 14.9;hTCEpi: 22.8;U-87 MG: 25.8
FRMD1	bA164L23.1, DKFZp434O0117, FLJ00181, FLJ22615, FLJ40260	ENSG00000153303	FERM domain containing 1	6	168055745-168081557	Predicted intracellular proteins	Evidence at protein level	HPA030347	Supported		Approved	Actin filaments		Tissue enriched	Tissue enhanced		colon: 5.8;stomach: 6.4;testis: 5.9	rectum: 4.6	Cell line enhanced		K-562: 2.8
FAM49B	BM-009	ENSG00000153310	Family with sequence similarity 49 member B	8	129839593-130017129	Predicted intracellular proteins	Evidence at protein level	HPA009076	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:3.09e-10 (unfavourable), Liver cancer:3.02e-6 (unfavourable), Endometrial cancer:1.24e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 137.4	Expressed in all		
ASAP1	CENTB4, DDEF1, KIAA1249, PAP, ZG14P	ENSG00000153317	ArfGAP with SH3 domain, ankyrin repeat and PH domain 1	8	130052104-130443660	Predicted intracellular proteins	Evidence at protein level	HPA011136, CAB037292, HPA048565	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol	Liver cancer:5.63e-8 (unfavourable), Renal cancer:1.50e-7 (unfavourable), Lung cancer:3.56e-5 (unfavourable), Endometrial cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 56.0	Expressed in all		
TRAPPC8	GSG1, HsT2706, KIAA1012, TRS85	ENSG00000153339	Trafficking protein particle complex 8	18	31829173-31953136	Predicted intracellular proteins	Evidence at protein level	HPA041107	Approved		Approved	Microtubules<br>Cytosol	Renal cancer:1.85e-9 (favourable)	Expressed in all	Expressed in all			testis: 54.2	Expressed in all		
FAM81B	FLJ25333	ENSG00000153347	Family with sequence similarity 81 member B	5	95391344-95450454	Predicted intracellular proteins	Evidence at protein level	HPA072554	Approved					Mixed	Group enriched	13	fallopian tube: 78.9;testis: 121.2	parathyroid gland: 7.5	Cell line enhanced		CAPAN-2: 1.1
INO80C	C18orf37, FLJ38183, hIes6, IES6	ENSG00000153391	INO80 complex subunit C	18	35452230-35497991	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049060	Approved		Supported	Nucleoli fibrillar center	Endometrial cancer:2.62e-5 (unfavourable), Cervical cancer:3.58e-4 (favourable)	Expressed in all	Expressed in all			testis: 166.3	Expressed in all		
LPCAT1	AGPAT10, AGPAT9, AYTL2, FLJ12443	ENSG00000153395	Lysophosphatidylcholine acyltransferase 1	5	1456480-1523977	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA012501, HPA022268	Enhanced		Supported	Endoplasmic reticulum<br>Lipid droplets	Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 19.0;spleen: 14.7	cerebral cortex: 4.4	Cell line enhanced		BEWO: 80.0;EFO-21: 74.7;PC-3: 52.0
PLEKHG4B	KIAA1909	ENSG00000153404	Pleckstrin homology and RhoGEF domain containing G4B	5	92151-189972	Predicted intracellular proteins	Evidence at protein level	HPA036274, HPA058157	Uncertain		Approved	Nucleoplasm	Lung cancer:3.47e-4 (favourable)	Mixed	Tissue enhanced		thyroid gland: 5.2	testis: 3.2	Cell line enhanced		REH: 30.0;SCLC-21H: 16.5;T-47d: 17.9
NMRAL1	FLJ25918, HSCARG, SDR48A1	ENSG00000153406	NmrA like redox sensor 1	16	4461680-4495763	Predicted intracellular proteins	Evidence at protein level	HPA041353, HPA062287	Uncertain		Enhanced	Nucleus	Cervical cancer:3.33e-7 (favourable)	Expressed in all	Mixed			fallopian tube: 21.5	Mixed		
UBALD1	FAM100A	ENSG00000153443	UBA like domain containing 1	16	4608883-4615027	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066771	Approved		Approved	Nucleus<br>Cell Junctions<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 23.8	Expressed in all		
C16orf89	MGC45438	ENSG00000153446	Chromosome 16 open reading frame 89	16	5044122-5066110	Predicted secreted proteins	Evidence at protein level	HPA013613, HPA016934	Enhanced					Group enriched	Tissue enhanced		lung: 145.4;thyroid gland: 352.5	epididymis: 94.3	Cell line enhanced		ASC diff: 1.4;Hep G2: 1.7;NTERA-2: 1.5;U-2197: 2.0
TMEM251	C14orf109, DKFZP564F1123	ENSG00000153485	Transmembrane protein 251	14	93184951-93187089	Predicted membrane proteins	Evidence at transcript level	HPA048559	Uncertain		Approved	Golgi apparatus<br>Cell Junctions	Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			prostate: 27.0	Expressed in all		
ING1	p24ING1c, p33, p33ING1, p33ING1b, p47, p47ING1a	ENSG00000153487	Inhibitor of growth family member 1	13	110712736-110723339	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016136, CAB017773, HPA052591	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.81e-4 (favourable)	Expressed in all	Expressed in all			ovary: 20.9	Expressed in all		
TEX29	bA474D23.1, C13orf16, MGC35169	ENSG00000153495	Testis expressed 29	13	111316184-111344249	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 46.8	cerebral cortex: 3.0	Cell line enriched	42	U-698: 15.3
SPACA7	C13orf28	ENSG00000153498	Sperm acrosome associated 7	13	112376319-112434689	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048349	Enhanced					Not detected	Tissue enriched	73	testis: 50.2	bone marrow,skin: 0.6	Not detected		
ADPRHL1	ARH2	ENSG00000153531	ADP-ribosylhydrolase like 1	13	113399610-113453524	Predicted intracellular proteins	Evidence at protein level	HPA066478	Enhanced		Approved	Nucleoplasm	Liver cancer:2.55e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable)	Mixed	Group enriched	14	heart muscle: 258.3;skeletal muscle: 114.3	fallopian tube: 13.2	Cell line enhanced		SCLC-21H: 24.5;T-47d: 35.4
CMTM7	CKLFSF7, FLJ30992	ENSG00000153551	CKLF like MARVEL transmembrane domain containing 7	3	32391671-32483067	Predicted membrane proteins, Transporters	Evidence at protein level	HPA077409			Approved	Plasma membrane	Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 61.7	Mixed		
FBXL2	FBL2, FBL3	ENSG00000153558	F-box and leucine rich repeat protein 2	3	33277025-33403662	Predicted intracellular proteins	Evidence at protein level	HPA061783			Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Renal cancer:3.35e-4 (favourable)	Mixed	Mixed			cerebral cortex: 5.8	Cell line enhanced		CAPAN-2: 6.7
UBP1	LBP-1a	ENSG00000153560	Upstream binding protein 1 (LBP-1a)	3	33388336-33441371	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003967			Supported	Nucleoplasm	Colorectal cancer:1.81e-4 (favourable), Liver cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 54.5	Expressed in all		
RMND5A	FLJ13910, GID2, GID2A, p44CTLH, RMD5	ENSG00000153561	Required for meiotic nuclear division 5 homolog A	2	86720173-86778041	Predicted intracellular proteins	Evidence at protein level	HPA046795, HPA060843	Uncertain		Approved	Nucleoplasm	Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.1	Expressed in all		
CD8A	CD8	ENSG00000153563	CD8a molecule	2	86784610-86808396	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000012, HPA037756, CAB075722	Enhanced				Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 161.9	lymph node: 46.9	Cell line enriched	5	MOLT-4: 11.7
RPIA		ENSG00000153574	Ribose 5-phosphate isomerase A	2	88691644-88750935	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042620	Approved				Renal cancer:8.53e-6 (unfavourable), Liver cancer:1.46e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.2	Expressed in all		
GOLGA8F	DKFZp434P162	ENSG00000153684	Golgin A8 family member F	15	28378621-28392018	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	51	testis: 5.1	all non-specific tissues: 0.0	Cell line enriched	14	NB-4: 1.3
PTPRD	HPTP, PTPD	ENSG00000153707	Protein tyrosine phosphatase, receptor type D	9	8314246-10612723	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054829	Uncertain		Approved	Vesicles	Renal cancer:7.45e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 32.7;parathyroid gland: 47.0	ovary: 11.7	Cell line enhanced		AF22: 27.3;RH-30: 9.9
LURAP1L	bA3L8.2, C9orf150, FLJ38505, MGC46502	ENSG00000153714	Leucine rich adaptor protein 1 like	9	12775021-12822131	Predicted intracellular proteins	Evidence at protein level	HPA024407	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			placenta: 43.0	Cell line enhanced		HHSteC: 122.7;hTERT-HME1: 91.2;T-47d: 162.8
CNKSR3	FLJ31349, MAGI1	ENSG00000153721	CNKSR family member 3	6	154387504-154510659	Predicted intracellular proteins	Evidence at protein level	CAB037133, HPA049651	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:6.00e-4 (favourable)	Mixed	Mixed			esophagus: 15.6	Mixed		
GTF2E1	FE, TFIIE-A	ENSG00000153767	General transcription factor IIE subunit 1	3	120742637-120783069	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009884, HPA056359, HPA066881	Enhanced		Enhanced	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 18.4	Expressed in all		
CFDP1	BCNT, CENP-29, CP27, p97, SWC5, Yeti	ENSG00000153774	Craniofacial development protein 1	16	75293698-75433485	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041316, HPA048242	Approved		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:9.63e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 111.6	Expressed in all		
TGIF2LX		ENSG00000153779	TGFB induced factor homeobox 2 like, X-linked	X	89921882-89922883	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034543	Supported		Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	134	testis: 13.3	all non-specific tissues: 0.0	Group enriched	10	SH-SY5Y: 11.2;U-2 OS: 12.7;U-266/84: 14.3
ZDHHC7	FLJ10792, FLJ20279, SERZ-B, SERZ1, ZNF370	ENSG00000153786	Zinc finger DHHC-type containing 7	16	84974181-85011535	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019215, HPA059054, HPA059642	Uncertain		Enhanced	Golgi apparatus	Renal cancer:1.12e-5 (favourable), Liver cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 64.8	Expressed in all		
FAM92B	FLJ44299	ENSG00000153789	Family with sequence similarity 92 member B	16	85098358-85112508	Predicted intracellular proteins	Evidence at protein level	HPA041022	Enhanced					Group enriched	Tissue enriched	10	fallopian tube: 136.1	lung: 14.1	Cell line enhanced		SCLC-21H: 3.0
C7orf31		ENSG00000153790	Chromosome 7 open reading frame 31	7	25134697-25180356	Predicted intracellular proteins	Evidence at protein level	HPA020346			Approved	Nucleoplasm<br>Mitochondria	Glioma:1.52e-4 (unfavourable)	Expressed in all	Tissue enriched	14	testis: 131.4	parathyroid gland: 9.5	Mixed		
TMPRSS11D		ENSG00000153802	Transmembrane protease, serine 11D	4	67820876-67884032	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052834	Uncertain					Group enriched	Group enriched	39	esophagus: 70.5;tonsil: 30.6	cervix, uterine: 1.3	Not detected		
JAZF1	DKFZp761K2222, TIP27, ZNF802	ENSG00000153814	JAZF zinc finger 1	7	27830573-28180743	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB019271, HPA066967	Approved		Supported	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			adrenal gland: 112.8	Mixed		
CMIP		ENSG00000153815	C-Maf inducing protein	16	81445170-81711762	Predicted intracellular proteins	Evidence at protein level	HPA054424, HPA066710	Approved		Supported	Nucleoplasm<br>Cytosol	Lung cancer:9.47e-7 (unfavourable), Thyroid cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 87.4	Expressed in all		
SPHKAP	SKIP	ENSG00000153820	SPHK1 interactor, AKAP domain containing	2	227979950-228181645	Predicted intracellular proteins	Evidence at protein level	HPA042499, HPA048168	Enhanced					Not detected	Group enriched	7	cerebral cortex: 19.4;heart muscle: 19.0	ovary: 2.7	Cell line enriched	17	BJ hTERT+: 37.3
KCNJ16	BIR9, Kir5.1	ENSG00000153822	Potassium voltage-gated channel subfamily J member 16	17	70053429-70135608	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059563	Approved		Uncertain	Vesicles	Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable)	Group enriched	Group enriched	8	kidney: 209.1;parathyroid gland: 269.7;thyroid gland: 235.1	seminal vesicle: 31.5	Cell line enriched	18	RPTEC TERT1: 211.8
PID1	FLJ20701, NYGGF4	ENSG00000153823	Phosphotyrosine interaction domain containing 1	2	228850526-229271285	Predicted intracellular proteins	Evidence at protein level	HPA036103	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 67.2	Cell line enhanced		hTEC/SVTERT24-B: 86.1;LHCN-M2: 48.1;REH: 56.9;RH-30: 88.5
TRIP12	KIAA0045	ENSG00000153827	Thyroid hormone receptor interactor 12	2	229763838-229923239	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036835, HPA045893	Enhanced		Approved	Nuclear speckles	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 270.8	Expressed in all		
FBXO36	Fbx36, FLJ37592	ENSG00000153832	F-box protein 36	2	229922302-230013109	Predicted intracellular proteins	Evidence at transcript level	HPA053865			Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.28e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 17.6	thyroid gland: 12.5	Mixed		
CEBPG	GPE1BP, IG/EBP-1	ENSG00000153879	CCAAT/enhancer binding protein gamma	19	33373330-33382686	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA012024	Enhanced		Supported	Nucleoplasm	Endometrial cancer:7.97e-5 (unfavourable), Renal cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.3	Expressed in all		
KCTD15	MGC25497	ENSG00000153885	Potassium channel tetramerization domain containing 15	19	33795933-33815763	Predicted intracellular proteins	Evidence at protein level	HPA050822	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.65e-8 (unfavourable)	Expressed in all	Expressed in all			skin: 86.3	Mixed		
ZNF599	FLJ30663	ENSG00000153896	Zinc finger protein 599	19	34758076-34773229	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA014701	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Mixed			epididymis: 14.6	Mixed		
MCOLN2	FLJ36691, TRP-ML2, TRPML2	ENSG00000153898	Mucolipin 2	1	84925583-84997113	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA019114, HPA048999	Uncertain		Supported	Intermediate filaments	Lung cancer:2.56e-4 (favourable)	Mixed	Mixed			rectum: 17.2	Cell line enhanced		Daudi: 14.8;HAP1: 14.9;HDLM-2: 23.0;THP-1: 19.8;U-698: 12.6
LGI4		ENSG00000153902	Leucine rich repeat LGI family member 4	19	35124513-35142451	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042116, HPA043556	Approved		Approved	Golgi apparatus	Renal cancer:2.84e-7 (unfavourable)	Group enriched	Mixed			cerebral cortex: 26.2	Cell line enriched	36	WM-115: 29.6
DDAH1	DDAH	ENSG00000153904	Dimethylarginine dimethylaminohydrolase 1	1	85318481-85578363	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006308	Enhanced		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:5.21e-6 (favourable), Colorectal cancer:5.99e-4 (favourable)	Expressed in all	Mixed			kidney: 121.4	Cell line enhanced		SH-SY5Y: 122.6
SREK1	DKFZp564B176, SFRS12, SRrp508, SRrp86	ENSG00000153914	Splicing regulatory glutamic acid and lysine rich protein 1	5	66139971-66183615	Predicted intracellular proteins	Evidence at protein level	HPA037673, HPA037674, HPA059332	Enhanced		Enhanced	Nucleoplasm<br>Nuclear speckles	Head and neck cancer:2.54e-4 (favourable), Renal cancer:5.77e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.0	Expressed in all		
CHD1		ENSG00000153922	Chromodomain helicase DNA binding protein 1	5	98853985-98928957	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA022236	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:7.25e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 44.3	Expressed in all		
ANKFN1	FLJ38335	ENSG00000153930	Ankyrin repeat and fibronectin type III domain containing 1	17	55882301-56511659	Predicted intracellular proteins	Evidence at protein level	HPA021566, HPA022538	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 14.3;fallopian tube: 8.5	cerebral cortex,testis: 3.2	Cell line enhanced		HeLa: 4.8;MOLT-4: 12.3;T-47d: 4.7;U-2197: 4.5
DGKE	DAGK6, DGK	ENSG00000153933	Diacylglycerol kinase epsilon	17	56834099-56869567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017167	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.92e-5 (favourable)	Mixed	Mixed			testis: 12.1	Cell line enhanced		Karpas-707: 61.4
HS2ST1	KIAA0448	ENSG00000153936	Heparan sulfate 2-O-sulfotransferase 1	1	86914648-87109998	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043069, HPA043603, HPA075001	Supported		Approved	Mitochondria	Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 34.0	Expressed in all		
MSI2		ENSG00000153944	Musashi RNA binding protein 2	17	57255851-57684685	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB022300	Approved		Supported	Cytosol	Renal cancer:9.22e-8 (favourable), Stomach cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 119.2	Expressed in all		
CACNA2D1	CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3	ENSG00000153956	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	7	81946444-82443798	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA008213, HPA008621	Enhanced				Renal cancer:1.16e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 35.4	Cell line enhanced		HUVEC TERT2: 45.6;SH-SY5Y: 66.1
ZUFSP	C6orf113, dJ412I7.3	ENSG00000153975	Zinc finger with UFM1 specific peptidase domain	6	116635618-116668794	Predicted intracellular proteins	Evidence at protein level	HPA044426	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.8	Expressed in all		
HS3ST3A1	30ST3A1, 3OST3A1	ENSG00000153976	Heparan sulfate-glucosamine 3-sulfotransferase 3A1	17	13495689-13601927	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062518, HPA071530	Uncertain		Approved	Microtubules		Mixed	Tissue enhanced		spleen: 9.1	seminal vesicle: 6.8	Cell line enhanced		PC-3: 40.6;U-251 MG: 103.1;U-87 MG: 72.4
GDPD1	FLJ37451, GDE4	ENSG00000153982	Glycerophosphodiester phosphodiesterase domain containing 1	17	59220467-59275967	Predicted membrane proteins	Evidence at protein level						Lung cancer:2.98e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 27.9	testis: 20.0	Cell line enhanced		HEL: 27.1;SCLC-21H: 21.6
NUS1	C6orf68, MGC7199, NgBR, TANGO14	ENSG00000153989	NUS1 dehydrodolichyl diphosphate synthase subunit	6	117675502-117710640	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA027504	Supported		Approved	Vesicles<br>Plasma membrane	Cervical cancer:6.99e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 92.2	Expressed in all		
SEMA3D	coll-2, Sema-Z2	ENSG00000153993	Semaphorin 3D	7	84995553-85186855	Predicted intracellular proteins	Evidence at protein level	HPA037522	Uncertain		Approved	Golgi apparatus<br>Plasma membrane		Mixed	Group enriched	5	spleen: 66.2;thyroid gland: 76.6	prostate: 13.4	Cell line enhanced		fHDF/TERT166: 22.0;HaCaT: 25.4;TIME: 36.0
PPP2R5E		ENSG00000154001	Protein phosphatase 2 regulatory subunit B'epsilon	14	63371357-63543374	Predicted intracellular proteins	Evidence at protein level	HPA006034, CAB072342	Approved		Supported	Cytosol	Liver cancer:1.95e-4 (unfavourable), Renal cancer:4.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.9	Expressed in all		
ASB17		ENSG00000154007	Ankyrin repeat and SOCS box containing 17	1	75918873-75932431	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	380	testis: 84.7	kidney: 0.2	Not detected		
GRAP		ENSG00000154016	GRB2-related adaptor protein	17	19020673-19047637	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046595, HPA066654	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		lymph node: 30.9;spleen: 25.4	tonsil: 20.7	Group enriched	5	Daudi: 52.5;HUVEC TERT2: 24.8;MOLT-4: 12.3;REH: 35.4;TIME: 47.9;U-698: 35.4
SLC5A10	SGLT5	ENSG00000154025	Solute carrier family 5 member 10	17	18950345-19022595	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052014	Uncertain					Tissue enriched	Tissue enriched	25	kidney: 43.9	bone marrow: 1.7	Cell line enhanced		U-937: 4.4
AK5		ENSG00000154027	Adenylate kinase 5	1	77282051-77559969	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019128, HPA057255	Enhanced		Supported	Microtubule organizing center<br>Cytosol	Prostate cancer:3.88e-4 (favourable)	Group enriched	Tissue enriched	9	cerebral cortex: 220.7	breast: 23.6	Cell line enhanced		ASC TERT1: 65.9;BJ: 57.0;fHDF/TERT166: 60.0;LHCN-M2: 159.8;U-2 OS: 61.3
CABYR	CBP86, CT88, FSP-2	ENSG00000154040	Calcium binding tyrosine phosphorylation regulated	18	24138956-24161603	Predicted intracellular proteins	Evidence at protein level	HPA040703, HPA047801	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:4.75e-4 (unfavourable)	Mixed	Tissue enriched	39	testis: 445.1	cerebral cortex: 11.3	Cell line enhanced		SiHa: 25.8
IMPACT	RWDD5	ENSG00000154059	Impact RWD domain protein	18	24426616-24453535	Predicted intracellular proteins	Evidence at protein level	HPA041045, HPA041968	Approved		Approved	Nucleoplasm	Renal cancer:7.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Mixed		
ANKRD29	FLJ25053	ENSG00000154065	Ankyrin repeat domain 29	18	23598926-23662885	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041272, HPA049419	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Head and neck cancer:1.92e-5 (favourable), Lung cancer:5.98e-5 (favourable), Renal cancer:7.20e-5 (favourable)	Mixed	Mixed			lung: 47.4	Cell line enhanced		U-2197: 19.0;U-87 MG: 20.5
SDHAF4	C6orf57, Sdh8	ENSG00000154079	Succinate dehydrogenase complex assembly factor 4	6	70566917-70589569	Predicted secreted proteins	Evidence at protein level	HPA031824	Supported		Approved	Nucleus<br>Mitochondria	Renal cancer:1.95e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 17.2	Expressed in all		
CHST9	GALNAC-4-ST2, GALNAC4ST-2	ENSG00000154080	Carbohydrate sulfotransferase 9	18	26906481-27185317	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011393	Uncertain					Mixed	Tissue enhanced		fallopian tube: 16.5;testis: 12.7	spleen: 7.8	Group enriched	7	CACO-2: 7.6;Hep G2: 9.4;RPTEC TERT1: 31.6;SCLC-21H: 10.6
THY1	CD90	ENSG00000154096	Thy-1 cell surface antigen	11	119417378-119424985	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003733, CAB068243, CAB068244	Enhanced		Approved	Nucleus<br>Plasma membrane	Renal cancer:2.40e-6 (unfavourable), Glioma:9.64e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 421.8;smooth muscle: 434.2	gallbladder: 161.0	Cell line enhanced		BJ: 643.3;BJ hTERT+: 686.4;fHDF/TERT166: 1040.5
DNAAF1	CILD13, FLJ25330, LRRC50, ODA7, swt	ENSG00000154099	Dynein axonemal assembly factor 1	16	84145287-84178767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041166, HPA074239	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.14e-4 (favourable)	Tissue enhanced	Group enriched	19	fallopian tube: 36.3;testis: 82.6	lung: 3.0	Cell line enhanced		Hep G2: 1.4;Karpas-707: 3.6;PC-3: 1.4;U-266/70: 3.1;U-266/84: 2.0
C16orf74	MGC17624	ENSG00000154102	Chromosome 16 open reading frame 74	16	85690084-85751129	Predicted intracellular proteins	Evidence at protein level	HPA049367	Uncertain		Approved	Plasma membrane<br>Centrosome	Pancreatic cancer:1.54e-5 (unfavourable), Head and neck cancer:1.71e-4 (unfavourable), Melanoma:4.08e-4 (unfavourable)	Mixed	Mixed			urinary bladder: 13.3	Cell line enhanced		HBEC3-KT: 68.8;T-47d: 79.3
TBCEL	LRRC35, MGC10233	ENSG00000154114	Tubulin folding cofactor E like	11	121024072-121090775	Predicted intracellular proteins	Evidence at protein level	HPA038593, HPA038594	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 35.7	Mixed		
JPH3	CAGL237, HDL2, JP-3, JP3, TNRC22	ENSG00000154118	Junctophilin 3	16	87601835-87698156	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA076304			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	22	cerebral cortex: 43.3	adrenal gland: 2.0	Cell line enhanced		MCF7: 5.8;NTERA-2: 6.6;SH-SY5Y: 8.9;SiHa: 5.9;U-2 OS: 27.3
ANKH	ANK, CCAL2, CMDJ, CPPDD, HANK	ENSG00000154122	ANKH inorganic pyrophosphate transport regulator	5	14704804-14871778	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA068104			Approved	Cytosol	Glioma:7.64e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 49.4	Mixed		
OTULIN	FAM105B, FLJ34884	ENSG00000154124	OTU deubiquitinase with linear linkage specificity	5	14664664-14699711	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051074	Uncertain		Approved	Plasma membrane<br>Mitochondria	Renal cancer:2.59e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 17.1	Expressed in all		
UBASH3B	KIAA1959, STS-1, TULA2	ENSG00000154127	Ubiquitin associated and SH3 domain containing B	11	122655675-122814473	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038605, HPA038607	Approved		Approved	Plasma membrane		Mixed	Tissue enhanced		placenta: 19.6;spleen: 21.3	lung: 6.7	Cell line enhanced		HEL: 108.5;HMC-1: 77.6
ROBO4	ECSM4, FLJ20798, MRB	ENSG00000154133	Roundabout guidance receptor 4	11	124883691-124898500	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA065212			Approved	Plasma membrane	Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 58.2	adipose tissue: 45.1	Group enriched	9	HUVEC TERT2: 203.4;TIME: 180.3
ROBO3	FLJ21044, HGPPS, HGPS, RBIG1	ENSG00000154134	Roundabout guidance receptor 3	11	124865386-124881470	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		smooth muscle: 1.2	cerebral cortex: 0.8	Cell line enriched	11	AF22: 17.9
PANX3	Px3	ENSG00000154143	Pannexin 3	11	124611490-124620356	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
TBRG1	FLJ14621, NIAM, TB-5	ENSG00000154144	Transforming growth factor beta regulator 1	11	124622836-124635398	Predicted intracellular proteins	Evidence at protein level	HPA055645, HPA068022			Enhanced	Nucleus		Expressed in all	Expressed in all			spleen: 16.0	Expressed in all		
NRGN	RC3	ENSG00000154146	Neurogranin	11	124739846-124747210	Predicted intracellular proteins	Evidence at protein level	CAB006908, HPA038171	Enhanced				Renal cancer:1.52e-5 (unfavourable)	Expressed in all	Tissue enriched	17	cerebral cortex: 961.5	lung: 56.2	Cell line enhanced		HEL: 133.6;PC-3: 108.8
FAM134B	FLJ20152, JK1	ENSG00000154153	Family with sequence similarity 134 member B	5	16473038-16617058	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA012077			Supported	Endoplasmic reticulum	Renal cancer:5.25e-10 (favourable)	Expressed in all	Expressed in all			kidney: 62.2	Cell line enhanced		HSkMC: 20.3;RPTEC TERT1: 19.9;SCLC-21H: 20.1
CDH12	Br-cadherin, CDHB	ENSG00000154162	Cadherin 12	5	21750673-22853622	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA029325	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 3.6;cervix, uterine: 4.5;fallopian tube: 3.5	adrenal gland: 2.2	Group enriched	5	PC-3: 2.0;SCLC-21H: 3.7;U-2 OS: 1.3
GPR15		ENSG00000154165	G protein-coupled receptor 15	3	98531899-98533150	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA013775	Approved					Mixed	Tissue enhanced		colon: 25.0;rectum: 46.8	urinary bladder: 18.4	Group enriched	22	HDLM-2: 5.6;U-266/70: 1.9
TOMM70	KIAA0719, Tom70, TOMM70A	ENSG00000154174	Translocase of outer mitochondrial membrane 70	3	100363431-100401398	Predicted membrane proteins	Evidence at protein level	HPA014589, CAB017156, HPA048020	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 52.8	Expressed in all		
ABI3BP	DKFZP586L2024, NESHBP, TARSH	ENSG00000154175	ABI family member 3 binding protein	3	100749156-100993515	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044127	Uncertain				Renal cancer:6.14e-4 (favourable)	Mixed	Mixed			gallbladder: 158.4	Cell line enhanced		hTEC/SVTERT24-B: 841.3;hTERT-HME1: 650.5;TIME: 1525.7
ANGPT1	Ang1, KIAA0003	ENSG00000154188	Angiopoietin 1	8	107249482-107498055	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB017815, HPA018793, HPA018816	Enhanced				Renal cancer:4.40e-4 (favourable)	Mixed	Tissue enhanced		seminal vesicle: 46.2	lung: 32.9	Cell line enhanced		ASC diff: 60.0;HEL: 46.9;HSkMC: 105.6;U-138 MG: 70.1;WM-115: 46.8
PITPNC1	RDGB-BETA, RDGBB, RDGBB1	ENSG00000154217	Phosphatidylinositol transfer protein, cytoplasmic 1	17	67377281-67697261	Predicted intracellular proteins	Evidence at protein level	HPA026563, HPA031250	Uncertain		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.85e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 46.6	Mixed		
CC2D1B	KIAA1836	ENSG00000154222	Coiled-coil and C2 domain containing 1B	1	52345723-52366193	Predicted intracellular proteins	Evidence at protein level	HPA027500, HPA031426	Uncertain		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.45e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 18.7	Expressed in all		
CERS3	LASS3, MGC27091	ENSG00000154227	Ceramide synthase 3	15	100400395-100544995	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006092, HPA024356	Approved		Approved	Nucleoplasm		Tissue enhanced	Group enriched	9	esophagus: 48.1;skin: 60.5;testis: 32.3;tonsil: 14.3	breast: 4.3	Cell line enriched	6	hTCEpi: 47.1
PRKCA	PKCA	ENSG00000154229	Protein kinase C alpha	17	66302636-66810743	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003844, HPA006563, HPA006564, CAB016290	Enhanced	Approved	Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 45.0	Cell line enhanced		U-87 MG: 157.3
LRRK1	FLJ23119, KIAA1790, RIPK6, Roco1	ENSG00000154237	Leucine rich repeat kinase 1	15	100919215-101078254	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010537	Uncertain		Supported	Mitochondria<br>Cytosol	Renal cancer:5.71e-5 (unfavourable)	Mixed	Mixed			lymph node: 12.6	Cell line enhanced		Daudi: 27.9
CEP112	CCDC46, MGC33887	ENSG00000154240	Centrosomal protein 112	17	65635538-66192084	Predicted intracellular proteins	Evidence at protein level	HPA024481			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Tissue enriched	6	testis: 86.4	endometrium: 14.2	Cell line enhanced		LHCN-M2: 27.2;RH-30: 73.5
GAL3ST2	GP3ST	ENSG00000154252	Galactose-3-O-sulfotransferase 2	2	241776825-241804208	Predicted secreted proteins	Evidence at protein level	HPA071809	Enhanced					Group enriched	Group enriched	8	colon: 9.3;rectum: 4.0	appendix,fallopian tube: 0.8	Cell line enhanced		Hep G2: 1.4
ABCA9	EST640918	ENSG00000154258	ATP binding cassette subfamily A member 9	17	68974488-69061064	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052113, HPA054823	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			ovary: 32.5	Cell line enhanced		ASC diff: 14.7;ASC TERT1: 31.9;HSkMC: 11.9
ABCA6	EST155051	ENSG00000154262	ATP binding cassette subfamily A member 6	17	69078702-69141888	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064878, HPA067180			Approved	Nucleoplasm	Liver cancer:3.29e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 41.4	ovary: 37.4	Cell line enhanced		ASC diff: 28.1;ASC TERT1: 41.4;HSkMC: 18.8;HUVEC TERT2: 47.8
ABCA10	EST698739	ENSG00000154263	ATP binding cassette subfamily A member 10	17	69147214-69244846	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014535	Uncertain					Mixed	Mixed			ovary: 13.8	Cell line enhanced		HUVEC TERT2: 1.1;RT4: 1.0;U-2197: 1.8
ABCA5	EST90625	ENSG00000154265	ATP binding cassette subfamily A member 5	17	69244311-69327244	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022032, HPA062904	Approved		Approved	Nucleus	Pancreatic cancer:9.97e-5 (favourable)	Expressed in all	Expressed in all			skin: 28.0	Cell line enhanced		SiHa: 19.6
ENPP3	B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3	ENSG00000154269	Ectonucleotide pyrophosphatase/phosphodiesterase 3	6	131628442-131747418	CD markers, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043772	Enhanced				Renal cancer:1.96e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cervix, uterine: 45.4;small intestine: 49.9	seminal vesicle: 22.0	Group enriched	15	HEL: 3.9;Hep G2: 9.9;HMC-1: 5.4
C4orf19	FLJ11017	ENSG00000154274	Chromosome 4 open reading frame 19	4	37453941-37623495	Predicted intracellular proteins	Evidence at protein level	HPA043458, HPA052894	Enhanced		Supported	Cell Junctions	Renal cancer:1.49e-11 (favourable)	Mixed	Mixed			rectum: 26.9	Group enriched	6	RT4: 70.0;SK-BR-3: 25.9;T-47d: 116.1
UCHL1	PARK5, PGP9.5, Uch-L1	ENSG00000154277	Ubiquitin C-terminal hydrolase L1	4	41256413-41268455	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002580, HPA005993, CAB079024	Enhanced	Supported	Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.08e-5 (unfavourable), Urothelial cancer:1.93e-4 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 785.9	adrenal gland: 107.9	Cell line enhanced		EFO-21: 912.4;SCLC-21H: 1141.2;U-87 MG: 916.2
MIA3	FLJ39207, KIAA0268, TANGO, TANGO1, UNQ6077	ENSG00000154305	MIA family member 3, ER export factor	1	222618086-222668012	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055922, HPA056816	Enhanced		Enhanced	Vesicles	Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 81.5	Expressed in all		
DISP1	DISPA, DKFZP434I0428, MGC13130, MGC16796	ENSG00000154309	Dispatched RND transporter family member 1	1	222872271-223005995	Predicted membrane proteins	Evidence at protein level	HPA051411	Uncertain		Approved	Nuclear bodies	Renal cancer:3.86e-5 (favourable), Thyroid cancer:4.16e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable)	Expressed in all	Mixed			lung: 15.8	Cell line enhanced		RH-30: 15.5
TNIK	KIAA0551	ENSG00000154310	TRAF2 and NCK interacting kinase	3	171061339-171460408	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012128, HPA012297	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 35.5	Cell line enhanced		HEL: 58.9;HMC-1: 63.1;WM-115: 53.8
FAM167A	C8orf13	ENSG00000154319	Family with sequence similarity 167 member A	8	11421463-11474715	Predicted intracellular proteins	Evidence at protein level	HPA023915, HPA030426	Approved		Approved	Mitochondria	Endometrial cancer:5.96e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 32.4;thyroid gland: 88.0	lung: 15.8	Cell line enhanced		Daudi: 41.5;RPMI-8226: 43.0;SH-SY5Y: 48.2
NEIL2	FLJ31644, MGC2832, MGC4505, NEH2	ENSG00000154328	Nei like DNA glycosylase 2	8	11769639-11787346	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073029, HPA073916			Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 45.4	Mixed		
PGM5	PGMRP	ENSG00000154330	Phosphoglucomutase 5	9	68328308-68531061	Predicted intracellular proteins	Evidence at protein level	CAB034397, HPA046329, HPA067102	Enhanced				Renal cancer:1.83e-5 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 283.6;seminal vesicle: 327.6	smooth muscle: 217.9	Cell line enhanced		PC-3: 55.9;RH-30: 40.1;SK-BR-3: 38.8
WNT3A		ENSG00000154342	Wnt family member 3A	1	228007051-228061260	Predicted secreted proteins	Evidence at protein level						Cervical cancer:6.11e-5 (favourable)	Mixed	Tissue enriched	6	placenta: 23.2	lung: 3.8	Group enriched	9	HEK 293: 1.1;U-2 OS: 3.9
OBSCN	ARHGEF30, KIAA1556, KIAA1639, UNC89	ENSG00000154358	Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	1	228208130-228378874	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021186	Enhanced		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:1.64e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 301.1	heart muscle: 45.7	Mixed		
LONRF1	FLJ23749, RNF191	ENSG00000154359	LON peptidase N-terminal domain and ring finger 1	8	12721894-12756073	Predicted intracellular proteins	Evidence at protein level	HPA023584, HPA024814	Uncertain		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			skin: 30.8	Cell line enhanced		Karpas-707: 47.8;SCLC-21H: 45.0
TRIM11	BIA1, RNF92	ENSG00000154370	Tripartite motif containing 11	1	228393673-228406840	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028541, HPA043879	Approved		Enhanced	Nucleus<br>Cytosol	Liver cancer:7.42e-5 (unfavourable), Renal cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 18.8	Expressed in all		
ENAH	FLJ10773, MENA, NDPP1	ENSG00000154380	Enabled homolog (Drosophila)	1	225486835-225653142	Predicted intracellular proteins	Evidence at protein level	HPA028448, HPA028696	Enhanced		Enhanced	Plasma membrane<br>Focal adhesion sites<br>Cytosol		Expressed in all	Mixed			smooth muscle: 81.3	Mixed		
PPP1R3A	GM, PPP1R3	ENSG00000154415	Protein phosphatase 1 regulatory subunit 3A	7	113876777-114075920	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Group enriched	18	heart muscle: 26.6;skeletal muscle: 53.1	prostate: 2.2	Cell line enriched	59	THP-1: 9.8
CCSAP	C1orf96, CSAP, FLJ41471	ENSG00000154429	Centriole, cilia and spindle associated protein	1	229321005-229343294	Predicted intracellular proteins	Evidence at protein level	HPA028402, HPA043443	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Microtubule ends	Renal cancer:4.50e-13 (unfavourable), Liver cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 54.0	placenta: 18.6	Expressed in all		
ASZ1	ALP1, ANKL1, C7orf7, CT1.19, GASZ, Orf3	ENSG00000154438	Ankyrin repeat, SAM and basic leucine zipper domain containing 1	7	117363222-117428123	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA020558	Enhanced		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	188	testis: 18.7	all non-specific tissues: 0.0	Not detected		
SH3RF1	KIAA1494, POSH, RNF142, SH3MD2	ENSG00000154447	SH3 domain containing ring finger 1	4	169094256-169271105	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA074783			Supported	Vesicles<br>Intermediate filaments	Renal cancer:5.51e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 32.1	Mixed		
GBP5		ENSG00000154451	Guanylate binding protein 5	1	89258950-89272804	Predicted intracellular proteins	Evidence at protein level	HPA028656	Approved		Approved	Endoplasmic reticulum	Renal cancer:5.53e-8 (unfavourable), Endometrial cancer:3.73e-6 (favourable), Ovarian cancer:1.24e-4 (favourable), Colorectal cancer:9.54e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 100.5	lymph node: 60.4	Cell line enhanced		NB-4: 6.3;U-266/70: 15.8;U-937: 24.8
BUB3	BUB3L	ENSG00000154473	BUB3, mitotic checkpoint protein	10	123154277-123170467	Predicted intracellular proteins	Evidence at protein level	HPA003601, CAB037075	Supported		Enhanced	Nucleoplasm	Renal cancer:3.81e-7 (unfavourable), Liver cancer:4.45e-5 (unfavourable), Cervical cancer:2.04e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 112.0	Expressed in all		
GPR26		ENSG00000154478	G protein-coupled receptor 26	10	123666355-123694607	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA062736	Enhanced					Tissue enriched	Tissue enriched	16	cerebral cortex: 4.3	testis: 0.2	Cell line enriched	15	SCLC-21H: 1.4
CCDC173	C2orf77, LOC129881	ENSG00000154479	Coiled-coil domain containing 173	2	169645425-169694433	Predicted intracellular proteins	Evidence at protein level	HPA042995, HPA048454	Uncertain					Mixed	Tissue enriched	6	testis: 143.7	fallopian tube: 23.4	Cell line enhanced		HEL: 9.8;SCLC-21H: 3.1
MMP21		ENSG00000154485	Matrix metallopeptidase 21	10	125766453-125775821	Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	27	epididymis: 59.2	ovary: 2.1	Not detected		
C10orf90	bA422P15.2, FATS, FLJ32938	ENSG00000154493	Chromosome 10 open reading frame 90	10	126424997-126670446	Predicted intracellular proteins	Evidence at protein level	HPA038648, HPA057599	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enriched	Group enriched	12	breast: 5.6;cerebral cortex: 15.3;salivary gland: 4.3;testis: 12.1	adipose tissue,skin: 0.7	Group enriched	9	SK-MEL-30: 94.3;U-2197: 33.5;U-266/84: 18.9;U-87 MG: 36.2;WM-115: 29.4
FAM69A	FLJ23493	ENSG00000154511	Family with sequence similarity 69 member A	1	92832737-92961522	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015718, HPA017281	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:1.45e-7 (unfavourable), Breast cancer:8.96e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 44.7	Mixed		
ATP5G3		ENSG00000154518	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 (subunit 9)	2	175176258-175184607	Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.31e-6 (favourable), Head and neck cancer:6.01e-4 (unfavourable), Colorectal cancer:9.90e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 534.0	Expressed in all		
CNTNAP3B		ENSG00000154529	Contactin associated protein-like 3B	9	41890314-42129510	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA047731	Uncertain					Not detected	Mixed			esophagus,skin: 10.4	Cell line enhanced		A549: 27.0;AF22: 41.2;WM-115: 28.0
MAGED4	KIAA1859, MAGE-E1, MAGE1, MGC3210	ENSG00000154545	MAGE family member D4	X	52184823-52192268	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003554	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		A549: 2.7;ASC TERT1: 1.8;Hep G2: 5.3
SRSF12	SFRS13B, SFRS19, SRrp35	ENSG00000154548	Serine and arginine rich splicing factor 12	6	89095959-89118081	Predicted intracellular proteins	Evidence at protein level	HPA049782	Approved					Mixed	Group enriched	6	cerebral cortex: 6.9;testis: 20.9	parathyroid gland,thyroid gland: 2.1	Cell line enhanced		AF22: 9.1;AN3-CA: 8.8;HAP1: 7.7;HEK 293: 7.0;REH: 6.9;SCLC-21H: 9.5;SH-SY5Y: 8.4
PDLIM3	ALP	ENSG00000154553	PDZ and LIM domain 3	4	185500660-185535612	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004749	Enhanced				Renal cancer:4.97e-7 (unfavourable), Thyroid cancer:2.13e-6 (unfavourable), Liver cancer:7.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 1097.6	seminal vesicle: 292.1	Cell line enhanced		LHCN-M2: 125.9;RH-30: 35.3;U-266/70: 91.6
SORBS2	ARGBP2, KIAA0777	ENSG00000154556	Sorbin and SH3 domain containing 2	4	185585444-185956652	Predicted intracellular proteins	Evidence at protein level	HPA036754, HPA036755	Supported		Supported	Nucleoplasm	Renal cancer:3.10e-6 (favourable), Liver cancer:1.47e-5 (favourable), Endometrial cancer:6.07e-5 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 378.9;thyroid gland: 462.8	parathyroid gland: 282.5	Cell line enhanced		AF22: 235.7;TIME: 107.2;WM-115: 71.3
ELOC	SIII, TCEB1	ENSG00000154582	Elongin C	8	73939169-73972287	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA078113			Approved	Cell Junctions	Breast cancer:6.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.4	Expressed in all		
LY96	MD-2	ENSG00000154589	Lymphocyte antigen 96	8	73991352-74029087	Predicted secreted proteins	Evidence at protein level	HPA053060			Approved	Vesicles	Renal cancer:6.38e-11 (unfavourable)	Expressed in all	Mixed			spleen: 61.2	Cell line enhanced		Karpas-707: 119.4;U-87 MG: 82.4
PSMA8	MGC26605, PSMA7L	ENSG00000154611	Proteasome subunit alpha 8	18	26133852-26193355	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	20	testis: 39.0	lymph node,tonsil: 1.9	Group enriched	73	Daudi: 24.2;U-266/70: 15.3;U-266/84: 15.8
TMSB4Y	TB4Y	ENSG00000154620	Thymosin beta 4, Y-linked	Y	13703567-13706024	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 5.7	Cell line enhanced		BEWO: 13.6;HEL: 10.6;RPTEC TERT1: 13.5;SCLC-21H: 6.1
CXADR	CAR	ENSG00000154639	Coxsackie virus and adenovirus receptor	21	17512382-17593579	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003342, CAB005103, HPA030411, HPA030412	Enhanced		Enhanced	Plasma membrane<br>Cell Junctions	Head and neck cancer:3.50e-4 (favourable)	Expressed in all	Mixed			skin: 59.1	Cell line enhanced		CACO-2: 77.2;NTERA-2: 105.2;RT4: 82.7
BTG3	ANA, APRO4, tob55	ENSG00000154640	BTG anti-proliferation factor 3	21	17593653-17612947	Predicted intracellular proteins	Evidence at protein level	HPA018400	Approved				Liver cancer:1.16e-4 (unfavourable), Renal cancer:7.37e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 129.1	Mixed		
C21orf91	C21orf14, C21orf38, CSSG1, EURL, YG81	ENSG00000154642	Chromosome 21 open reading frame 91	21	17788967-17819386	Predicted intracellular proteins	Evidence at protein level	HPA018288, HPA049030	Approved		Approved	Microtubules<br>Cytokinetic bridge		Expressed in all	Mixed			testis: 44.4	Cell line enhanced		Karpas-707: 77.6
CHODL	C21orf68, FLJ12627, MT75, PRED12	ENSG00000154645	Chondrolectin	21	17901263-18267373	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017282	Enhanced	Supported			Endometrial cancer:1.18e-6 (unfavourable)	Mixed	Tissue enhanced		spleen: 19.5;testis: 57.6	prostate: 9.3	Cell line enhanced		U-266/70: 2.1;U-266/84: 5.1;U-87 MG: 7.6
TMPRSS15	ENTK, MGC133046, PRSS7	ENSG00000154646	Transmembrane protease, serine 15	21	18269116-18485879	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015611, HPA072934	Enhanced					Group enriched	Tissue enriched	44	duodenum: 1010.9	small intestine: 22.7	Group enriched	22	U-138 MG: 50.9;U-87 MG: 140.8
NCAM2	MGC51008, NCAM21	ENSG00000154654	Neural cell adhesion molecule 2	21	20998315-21543329	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA030900, HPA030901	Supported		Supported	Nuclear bodies<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 68.8	adrenal gland: 15.8	Cell line enhanced		T-47d: 86.4;WM-115: 22.5
L3MBTL4	FLJ35936, HsT1031	ENSG00000154655	L(3)mbt-like 4 (Drosophila)	18	5954706-6415237	Predicted intracellular proteins	Evidence at protein level	HPA064194, HPA069042	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			testis: 23.4	Cell line enhanced		RPMI-8226: 8.0;SCLC-21H: 6.3;SH-SY5Y: 6.2
PDE1C	Hcam3	ENSG00000154678	Phosphodiesterase 1C	7	31751179-32299329	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021751, HPA052375	Uncertain		Approved	Nucleus		Tissue enhanced	Tissue enhanced		heart muscle: 37.2	cerebral cortex: 20.8	Cell line enhanced		fHDF/TERT166: 114.5;U-251 MG: 66.4;WM-115: 102.6
RABGEF1	rabex-5, RABEX5	ENSG00000154710	RAB guanine nucleotide exchange factor 1	7	66682164-66811464	Predicted intracellular proteins	Evidence at protein level	HPA001407			Supported	Nucleoli<br>Cytosol	Glioma:2.90e-5 (unfavourable), Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 49.5	Expressed in all		
MRPL39	C21orf92, FLJ20451, L39mt, MGC104174, MGC3400, MRP-L5, MSTP003, PRED22, PRED66, RPML5	ENSG00000154719	Mitochondrial ribosomal protein L39	21	25585656-25607517	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018331	Approved				Pancreatic cancer:5.84e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.7	Expressed in all		
JAM2	C21orf43, CD322, JAM-B, JAMB, VE-JAM	ENSG00000154721	Junctional adhesion molecule 2	21	25639272-25717562	CD markers, Predicted membrane proteins	Evidence at protein level	HPA028789, HPA077346			Supported	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enhanced		placenta: 92.9	cerebral cortex: 34.2	Cell line enhanced		AF22: 25.3;BJ hTERT+: 13.4;HDLM-2: 15.5;U-138 MG: 18.0;U-87 MG: 13.2
ATP5J	ATP5, ATP5A, ATPM, CF6	ENSG00000154723	ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6	21	25716503-25735673	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031069	Supported		Supported	Mitochondria	Renal cancer:2.37e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 528.8	Expressed in all		
GABPA	E4TF1-60, E4TF1A, NFT2, NRF2, NRF2A	ENSG00000154727	GA binding protein transcription factor alpha subunit	21	25734570-25772460	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003258, CAB004411, HPA028791	Supported		Enhanced	Nucleoplasm	Renal cancer:3.97e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.1	Expressed in all		
ADAMTS1	C3-C5, KIAA1346, METH1	ENSG00000154734	ADAM metallopeptidase with thrombospondin type 1 motif 1	21	26835747-26845409	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016394	Uncertain				Head and neck cancer:5.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 412.9	adipose tissue: 279.9	Cell line enhanced		BJ: 346.6;hTEC/SVTERT24-B: 277.6
ADAMTS5	ADAMTS11, ADMP-2	ENSG00000154736	ADAM metallopeptidase with thrombospondin type 1 motif 5	21	26917912-26966513	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA005661, CAB025996, HPA030906, HPA030908	Approved		Supported	Nucleoplasm	Renal cancer:2.46e-4 (unfavourable), Thyroid cancer:8.54e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 42.4	ovary: 24.3	Cell line enhanced		ASC diff: 26.2;fHDF/TERT166: 12.4;RH-30: 40.0;U-87 MG: 14.5
TSEN2	MGC2776, SEN2, SEN2L	ENSG00000154743	TRNA splicing endonuclease subunit 2	3	12484432-12539623	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA027120, HPA027125, HPA027268	Approved		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.13e-5 (unfavourable), Urothelial cancer:3.49e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.7	Expressed in all		
SLFN13	FLJ31952	ENSG00000154760	Schlafen family member 13	17	35435096-35448837	Predicted intracellular proteins	Evidence at protein level	HPA022532, HPA023064	Uncertain		Approved	Cytokinetic bridge	Cervical cancer:3.82e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 41.2	fallopian tube: 26.9	Cell line enhanced		HL-60: 104.7;REH: 68.4;U-266/70: 48.2
WNT7A		ENSG00000154764	Wnt family member 7A	3	13816258-13880121	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015719, CAB025894	Approved				Pancreatic cancer:3.03e-6 (unfavourable), Endometrial cancer:2.96e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 6.7;gallbladder: 3.6;placenta: 3.9	lung: 3.0	Group enriched	5	BEWO: 56.9;EFO-21: 52.0;PC-3: 18.2;RPTEC TERT1: 74.6
XPC	RAD4, XPCC	ENSG00000154767	XPC complex subunit, DNA damage recognition and repair factor	3	14145147-14178783	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009932, HPA035707, HPA069673	Supported		Enhanced	Nucleus<br>Plasma membrane	Renal cancer:4.14e-7 (favourable), Urothelial cancer:2.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.4	Expressed in all		
CCDC174	C3orf19, FLJ33839	ENSG00000154781	Coiled-coil domain containing 174	3	14651746-14672659	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043468, HPA060129	Approved		Enhanced	Nucleoplasm	Urothelial cancer:3.81e-5 (favourable), Prostate cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 18.0	Expressed in all		
FGD5	FLJ00274, FLJ39957, ZFYVE23	ENSG00000154783	FYVE, RhoGEF and PH domain containing 5	3	14810853-14934565	Predicted intracellular proteins	Evidence at protein level	HPA014536, HPA019191	Uncertain				Urothelial cancer:7.50e-4 (favourable)	Expressed in all	Mixed			spleen: 35.0	Group enriched	8	HUVEC TERT2: 80.3;TIME: 64.8;U-2197: 19.8
FLCN	BHD, MGC17998, MGC23445	ENSG00000154803	Folliculin	17	17212212-17237188	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015158, HPA028760	Supported		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:4.49e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 30.8	Expressed in all		
DPH3	DELGIP, DELGIP1, DESR1, DPH3A, KTI11, MGC20197, ZCSL2	ENSG00000154813	Diphthamide biosynthesis 3	3	16257978-16264972	Predicted intracellular proteins	Evidence at protein level	HPA035287	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 23.2	Expressed in all		
OXNAD1	MGC15763	ENSG00000154814	Oxidoreductase NAD binding domain containing 1	3	16265160-16350299	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036830, HPA059160	Approved		Approved	Nucleus	Renal cancer:1.00e-7 (favourable), Urothelial cancer:7.63e-4 (favourable)	Expressed in all	Mixed			lymph node: 19.7	Expressed in all		
PLCL2	KIAA1092, PLCE2	ENSG00000154822	Phospholipase C like 2	3	16802651-17090594	Predicted intracellular proteins	Evidence at protein level	HPA047616	Uncertain				Renal cancer:2.98e-10 (favourable)	Expressed in all	Mixed			ovary: 15.2	Cell line enhanced		Daudi: 17.6;HAP1: 25.5
CXXC1	CFP1, CGBP, hCGBP, HsT2645, PCCX1, PHF18, SPP1, ZCGPC1	ENSG00000154832	CXXC finger protein 1	18	50282343-50288304	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044511	Supported		Enhanced	Nucleus	Liver cancer:4.18e-6 (unfavourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 28.8	Expressed in all		
SKA1	C18orf24, MGC10200	ENSG00000154839	Spindle and kinetochore associated complex subunit 1	18	50374995-50394173	Predicted intracellular proteins	Evidence at protein level	HPA045495	Approved		Supported	Microtubules	Liver cancer:9.60e-8 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 5.5;testis: 5.9	lymph node: 4.1	Mixed		
PPP4R1	PP4R1	ENSG00000154845	Protein phosphatase 4 regulatory subunit 1	18	9546791-9615240	Predicted intracellular proteins	Evidence at protein level	HPA040905, HPA041089	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			esophagus: 78.2	Expressed in all		
APCDD1	B7323	ENSG00000154856	APC down-regulated 1	18	10454628-10489948	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.39e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 153.1	cerebral cortex: 60.6	Cell line enhanced		AF22: 31.6;BJ hTERT+: 56.8;HaCaT: 37.9;HSkMC: 28.6
PIEZO2	C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771	ENSG00000154864	Piezo type mechanosensitive ion channel component 2	18	10666483-11148762	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015986, HPA031974, HPA031975, HPA040616	Enhanced		Approved	Vesicles	Renal cancer:9.57e-7 (unfavourable)	Mixed	Mixed			lung: 12.8	Cell line enhanced		AF22: 17.1;BJ hTERT+ SV40 Large T+ RasG12V: 24.8;HeLa: 26.7;U-266/70: 19.5
MPPE1		ENSG00000154889	Metallophosphoesterase 1	18	11882622-11909223	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012639	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:6.45e-7 (favourable), Melanoma:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 78.0	Expressed in all		
USP43	FLJ30626	ENSG00000154914	Ubiquitin specific peptidase 43	17	9644698-9729691	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023389, HPA027762	Uncertain				Stomach cancer:5.39e-4 (favourable)	Mixed	Mixed			placenta: 11.9	Cell line enhanced		BEWO: 11.2;T-47d: 9.2
RAB6B		ENSG00000154917	RAB6B, member RAS oncogene family	3	133824239-133895836	Predicted intracellular proteins	Evidence at protein level	CAB017713, HPA059131	Uncertain		Approved	Golgi apparatus	Pancreatic cancer:3.97e-6 (favourable), Endometrial cancer:9.01e-4 (unfavourable)	Expressed in all	Group enriched	5	cerebral cortex: 211.3;parathyroid gland: 77.1	fallopian tube: 26.2	Cell line enhanced		HEL: 207.7;K-562: 49.3;SCLC-21H: 56.7
EME1	FLJ31364, MMS4L, SLX2A	ENSG00000154920	Essential meiotic structure-specific endonuclease 1	17	50373220-50381483	Predicted intracellular proteins	Evidence at protein level	CAB016127, HPA052188	Supported		Approved	Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		epididymis: 7.7;testis: 9.8	bone marrow,lymph node: 2.8	Mixed		
EPHB1	EPHT2, Hek6	ENSG00000154928	EPH receptor B1	3	134597801-135260467	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067740	Enhanced		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 23.7;testis: 20.5	thyroid gland: 11.9	Cell line enhanced		HDLM-2: 59.3;HMC-1: 31.7
ACSS1	ACAS2L, AceCS2L, dJ568C11.3, MGC33843	ENSG00000154930	Acyl-CoA synthetase short-chain family member 1	20	25006230-25058980	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041014, HPA043228	Enhanced				Lung cancer:8.33e-5 (favourable), Cervical cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			placenta: 166.2	Cell line enhanced		RPMI-8226: 51.0
ANKRD40	MGC15396	ENSG00000154945	Ankyrin repeat domain 40	17	50693190-50707924	Predicted intracellular proteins	Evidence at protein level	HPA021668, HPA021759	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 58.1	Expressed in all		
ZNF18	HDSG1, KOX11, Zfp535, ZKSCAN6, ZNF535, ZSCAN38	ENSG00000154957	Zinc finger protein 18	17	11977439-11997510	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006144	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:3.06e-6 (unfavourable), Pancreatic cancer:5.12e-6 (favourable), Cervical cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 22.3	Expressed in all		
CA10	CA-RPX, CARPX, HUCEP-15	ENSG00000154975	Carbonic anhydrase 10	17	51630313-52160017	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054825, HPA057837	Supported		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 56.7;cervix, uterine: 32.1	testis: 10.7	Cell line enhanced		RT4: 1.6;SCLC-21H: 7.3
VOPP1	DKFZp564K0822, ECop, FLJ20532, GASP	ENSG00000154978	Vesicular, overexpressed in cancer, prosurvival protein 1	7	55436056-55572988	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.99e-8 (unfavourable), Liver cancer:4.35e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 110.2	Mixed		
SEPT14	FLJ44060	ENSG00000154997	Septin 14	7	55793544-55862789	Predicted intracellular proteins	Evidence at protein level	HPA073255	Enhanced					Tissue enriched	Tissue enriched	15	testis: 41.7	parathyroid gland: 2.7	Cell line enhanced		BEWO: 6.0
APOOL	AAIR8193, CXorf33, FAM121A, Mic27, UNQ8193	ENSG00000155008	Apolipoprotein O like	X	85003826-85093316	Predicted secreted proteins	Evidence at protein level	HPA000612	Enhanced		Approved	Mitochondria	Renal cancer:1.35e-12 (favourable), Breast cancer:2.68e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.2	Expressed in all		
DKK2		ENSG00000155011	Dickkopf WNT signaling pathway inhibitor 2	4	106921802-107283806	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009727, HPA052611	Uncertain		Supported	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 24.1	lung: 8.2	Cell line enriched	7	SH-SY5Y: 23.5
CYP2U1	SPG49	ENSG00000155016	Cytochrome P450 family 2 subfamily U member 1	4	107931369-107953457	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041622, HPA046754, HPA064827	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			prostate: 15.7	Mixed		
RSPH10B		ENSG00000155026	Radial spoke head 10 homolog B	7	5925550-5970683	Predicted intracellular proteins	Evidence at protein level	HPA049182	Supported					Not detected	Group enriched	8	fallopian tube: 13.4;testis: 35.8	parathyroid gland: 3.0	Not detected		
FBXL18	Fbl18, FLJ11467	ENSG00000155034	F-box and leucine rich repeat protein 18	7	5431335-5513798	Predicted intracellular proteins	Evidence at protein level	HPA036049			Approved	Nucleoplasm<br>Cytosol	Cervical cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 9.5	Expressed in all		
CNTNAP5	caspr5, FLJ31966	ENSG00000155052	Contactin associated protein like 5	2	124025287-124915287	Predicted membrane proteins	Evidence at protein level	HPA069095, HPA069356			Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 5.8;gallbladder: 1.6	adrenal gland: 0.7	Cell line enhanced		AF22: 1.1;SH-SY5Y: 2.8
PROM2		ENSG00000155066	Prominin 2	2	95274453-95291308	Predicted membrane proteins	Evidence at protein level	CAB046005, HPA063728	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 71.1	esophagus: 44.6	Cell line enhanced		A-431: 69.3;CAPAN-2: 119.5;HaCaT: 65.0;hTCEpi: 56.7;RT4: 66.9;SK-BR-3: 88.2
AK9	AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954	ENSG00000155085	Adenylate kinase 9	6	109492856-109691217	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 31.2	parathyroid gland: 17.1	Expressed in all		
ODF1	CT133, HSPB10, ODF27, ODFPG, RT7	ENSG00000155087	Outer dense fiber of sperm tails 1	8	102551572-102561017	Predicted intracellular proteins	Evidence at protein level	HPA064295	Approved					Not detected	Tissue enriched	1426	testis: 418.3	cerebral cortex: 0.2	Not detected		
KLF10	EGRA, TIEG, TIEG1	ENSG00000155090	Kruppel like factor 10	8	102648779-102655902	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Lung cancer:2.61e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 100.0	Expressed in all		
PTPRN2	IA-2beta, ICAAR, KIAA0387, phogrin	ENSG00000155093	Protein tyrosine phosphatase, receptor type N2	7	157539056-158587788	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006900, HPA026656	Approved		Supported	Vesicles	Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.3	stomach: 38.9	Cell line enhanced		AF22: 28.0;HDLM-2: 38.8;NB-4: 27.1;SCLC-21H: 26.6;SH-SY5Y: 24.3;U-87 MG: 27.1
AZIN1	OAZI, OAZIN, ODC1L	ENSG00000155096	Antizyme inhibitor 1	8	102826357-102893864	Predicted intracellular proteins	Evidence at protein level	HPA027948	Approved		Approved	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 133.4	Expressed in all		
ATP6V1C1	ATP6C, ATP6D, VATC, Vma5	ENSG00000155097	ATPase H+ transporting V1 subunit C1	8	103021063-103073051	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023943, HPA057297	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.82e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 123.1	Expressed in all		
TMEM55A	DKFZp762O076	ENSG00000155099	Transmembrane protein 55A	8	90993796-91041064	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014591	Approved				Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.7	Mixed		
OTUD6B	CGI-77, DUBA5	ENSG00000155100	OTU domain containing 6B	8	91070196-91087095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024046, HPA024503, HPA024772	Enhanced	Approved	Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:7.50e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 17.2	Expressed in all		
CDK19	bA346C16.3, CDC2L6, CDK11, KIAA1028	ENSG00000155111	Cyclin dependent kinase 19	6	110609978-110815958	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007053	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:4.72e-5 (unfavourable), Liver cancer:3.56e-4 (unfavourable)	Expressed in all	Mixed			prostate: 42.4	Expressed in all		
GTF3C6	bA397G5.3, C6orf51, TFIIIC35	ENSG00000155115	General transcription factor IIIC subunit 6	6	110958560-110967890	Predicted intracellular proteins	Evidence at protein level	HPA056179, HPA061345	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:7.27e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 101.0	Expressed in all		
TTC39B	C9orf52, FLJ33868	ENSG00000155158	Tetratricopeptide repeat domain 39B	9	15163622-15307360	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054804, HPA063162	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.08e-7 (favourable), Lung cancer:9.64e-6 (favourable)	Expressed in all	Mixed			gallbladder: 11.0	Cell line enhanced		HEL: 36.6
AGPAT5	FLJ11210, LPAAT-e, LPAAT-epsilon	ENSG00000155189	1-acylglycerol-3-phosphate O-acyltransferase 5	8	6708357-6759666	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010644, HPA010950	Approved				Liver cancer:4.57e-4 (unfavourable), Colorectal cancer:8.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.9	Expressed in all		
MMS19	hMMS19, MET18, MMS19L	ENSG00000155229	MMS19 homolog, cytosolic iron-sulfur assembly component	10	97458324-97498794	Predicted intracellular proteins	Evidence at protein level	HPA051936, HPA056299	Approved		Enhanced	Nucleoplasm	Urothelial cancer:3.39e-4 (unfavourable), Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.6	Expressed in all		
OR4K1		ENSG00000155249	Olfactory receptor family 4 subfamily K member 1	14	19935608-19936683	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028877	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
PI4K2A	DKFZP761G1923, PI4KII, PIK42A	ENSG00000155252	Phosphatidylinositol 4-kinase type 2 alpha	10	97640686-97676434	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB030649	Approved				Colorectal cancer:4.21e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.3	Expressed in all		
MARVELD1	bA548K23.8, FLJ22343, FLJ23440, GB14, MGC4415, MRVLDC1	ENSG00000155254	MARVEL domain containing 1	10	97713173-97718152	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.89e-7 (unfavourable), Lung cancer:5.85e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 69.3	Mixed		
ZFYVE27	FLJ32919, SPG33	ENSG00000155256	Zinc finger FYVE-type containing 27	10	97737121-97760907	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA037523, HPA069876	Approved		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:6.91e-4 (unfavourable), Stomach cancer:7.54e-4 (favourable), Urothelial cancer:7.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 33.3	Expressed in all		
GOLGA7B	bA451M19.3, bA459F3.4, C10orf132, C10orf133	ENSG00000155265	Golgin A7 family member B	10	97850239-97871580	Predicted intracellular proteins	Evidence at protein level	HPA046878	Uncertain					Mixed	Group enriched	7	cerebral cortex: 18.3;epididymis: 28.5;skin: 17.4	adrenal gland: 3.1	Cell line enhanced		A-431: 4.7;HDLM-2: 5.4;SK-MEL-30: 17.6
GPR78		ENSG00000155269	G protein-coupled receptor 78	4	8558725-8619761	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013209	Uncertain					Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	194	BEWO: 19.5
TRMT44	C4orf23, FLJ35725, METTL19, TRM44	ENSG00000155275	TRNA methyltransferase 44 homolog (S. cerevisiae)	4	8436140-8493531	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045461	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			endometrium: 10.0	Expressed in all		
SLC25A28	MRS3/4, MRS4L	ENSG00000155287	Solute carrier family 25 member 28	10	99610522-99620609	Predicted intracellular proteins, Transporters	Evidence at protein level						Cervical cancer:2.18e-6 (favourable), Renal cancer:7.28e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 93.6	Expressed in all		
HSPA13	STCH	ENSG00000155304	Heat shock protein family A (Hsp70) member 13	21	14371115-14383484	Predicted secreted proteins	Evidence at protein level	HPA014797	Approved					Expressed in all	Expressed in all			cerebral cortex: 55.7	Expressed in all		
SAMSN1	HACS1, NASH1, SASH2, SH3D6B, SLy2	ENSG00000155307	SAM domain, SH3 domain and nuclear localization signals 1	21	14485228-14583402	Predicted intracellular proteins	Evidence at protein level	HPA010645, HPA017055	Approved		Enhanced	Plasma membrane	Renal cancer:4.52e-6 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 110.1;bone marrow: 123.6	spleen: 43.6	Cell line enhanced		HEL: 244.0;K-562: 292.8;Karpas-707: 97.1
USP25	USP21	ENSG00000155313	Ubiquitin specific peptidase 25	21	15730025-15880069	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018297, HPA024142	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 97.6	Expressed in all		
GRAMD3	FLJ21313, NS3TP2	ENSG00000155324	GRAM domain containing 3	5	126360132-126496494	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009678, HPA010095	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Mixed			thyroid gland: 69.1	Cell line enhanced		BJ hTERT+: 93.5
ZCCHC10	FLJ20094	ENSG00000155329	Zinc finger CCHC-type containing 10	5	132996985-133026604	Predicted intracellular proteins	Evidence at protein level	HPA038944	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
C16orf87		ENSG00000155330	Chromosome 16 open reading frame 87	16	46796607-46831411	Predicted intracellular proteins	Evidence at protein level	HPA041179	Uncertain		Approved	Nucleoplasm	Head and neck cancer:7.95e-5 (unfavourable), Pancreatic cancer:6.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 56.9	parathyroid gland: 34.3	Expressed in all		
MOV10	fSAP113, gb110, MGC2948	ENSG00000155363	Mov10 RISC complex RNA helicase	1	112673141-112700746	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031627			Approved	Cytosol	Renal cancer:1.48e-11 (unfavourable), Liver cancer:3.44e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.9	Mixed		
RHOC	ARH9, ARHC, RhoC	ENSG00000155366	Ras homolog family member C	1	112701106-112707434	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA051461	Uncertain				Renal cancer:3.65e-5 (unfavourable), Liver cancer:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 699.4	Expressed in all		
PPM1J	DKFZp434P1514, FLJ35951, MGC19531, PP2Czeta, PPP2CZ	ENSG00000155367	Protein phosphatase, Mg2+/Mn2+ dependent 1J	1	112709994-112715477	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046045	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	epididymis: 22.8;skeletal muscle: 24.1;skin: 21.4;testis: 46.5	heart muscle: 4.7	Cell line enhanced		T-47d: 18.2
DBI	ACBD1, ACBP	ENSG00000155368	Diazepam binding inhibitor, acyl-CoA binding protein	2	119366921-119372560	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051428	Approved				Renal cancer:3.73e-5 (unfavourable), Cervical cancer:5.77e-5 (favourable)	Expressed in all	Expressed in all			breast: 907.6	Expressed in all		
SLC16A1	MCT, MCT1	ENSG00000155380	Solute carrier family 16 member 1	1	112911847-112957013	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003324, CAB017489, HPA071055, CAB079035	Enhanced	Supported	Enhanced	Plasma membrane<br>Cell Junctions	Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable)	Expressed in all	Mixed			testis: 31.4	Mixed		
HEATR3	FLJ20718	ENSG00000155393	HEAT repeat containing 3	16	50065941-50106387	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041990, HPA058579	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:5.16e-6 (unfavourable), Liver cancer:4.11e-5 (unfavourable)	Expressed in all	Mixed			appendix: 15.6	Expressed in all		
TRIM74	MGC45440, TRIM50C	ENSG00000155428	Tripartite motif containing 74	7	72959485-72969466	Predicted intracellular proteins	Evidence at protein level	HPA047843			Approved	Cytosol		Not detected	Tissue enhanced		stomach: 5.3	testis: 3.9	Cell line enhanced		HEK 293: 3.5
NIFK	hNIFK, MKI67IP, Nopp34	ENSG00000155438	Nucleolar protein interacting with the FHA domain of MKI67	2	121726945-121736923	Predicted intracellular proteins	Evidence at protein level	CAB015382, HPA035735, HPA035736, CAB075728, CAB075729	Supported		Enhanced	Nucleoli	Renal cancer:5.01e-11 (unfavourable), Liver cancer:2.92e-6 (unfavourable), Endometrial cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 49.6	Expressed in all		
OXA1L	MGC133129, OXA1	ENSG00000155463	OXA1L, mitochondrial inner membrane protein	14	22766522-22773041	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003531	Approved		Supported	Mitochondria	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 142.6	Expressed in all		
SLC7A7	LPI, y+LAT-1	ENSG00000155465	Solute carrier family 7 member 7	14	22773222-22829820	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA036227	Enhanced				Renal cancer:6.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 281.9	parathyroid gland: 162.5	Group enriched	5	BEWO: 191.5;CACO-2: 274.5;EFO-21: 65.6
MAGEC1	CT7, CT7.1, MAGE-C1, MGC39366	ENSG00000155495	MAGE family member C1	X	141903894-141909388	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004622, CAB015452	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enriched	134	testis: 13.3	all non-specific tissues: 0.0	Group enriched	8	K-562: 48.3;Karpas-707: 36.9;U-2 OS: 35.6;U-2197: 60.6;U-266/70: 35.4;U-266/84: 30.8
LARP1	KIAA0731, LARP, MGC19556	ENSG00000155506	La ribonucleoprotein domain family member 1	5	154712902-154817607	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015222, HPA051397, HPA054819	Supported		Supported	Nucleus<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 152.1	Expressed in all		
CNOT8	CAF1, CALIF, hCAF1, POP2	ENSG00000155508	CCR4-NOT transcription complex subunit 8	5	154857553-154876793	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051398	Approved				Liver cancer:5.33e-4 (unfavourable), Urothelial cancer:6.41e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 74.6	Expressed in all		
GRIA1	GluA1, GLUR1, GLURA	ENSG00000155511	Glutamate ionotropic receptor AMPA type subunit 1	5	153489615-153813869	FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB001965, HPA035202	Supported					Tissue enriched	Tissue enriched	6	cerebral cortex: 67.1	lung: 10.6	Cell line enhanced		AF22: 11.5;BJ: 4.7;LHCN-M2: 6.9;U-266/70: 4.4
LRGUK	CFAP246, FLJ32786	ENSG00000155530	Leucine rich repeats and guanylate kinase domain containing	7	134127299-134264591	Predicted intracellular proteins	Evidence at protein level	HPA029505, HPA029506	Uncertain					Mixed	Group enriched	8	epididymis: 1.7;fallopian tube: 5.4;testis: 8.4	lung,thyroid gland: 0.6	Cell line enhanced		NTERA-2: 1.4;SH-SY5Y: 1.3;SK-MEL-30: 1.4
SETD9	C5orf35, MGC33648	ENSG00000155542	SET domain containing 9	5	56909260-56925532	Predicted intracellular proteins	Evidence at protein level	HPA049936			Approved	Nucleoplasm		Expressed in all	Tissue enriched	6	testis: 27.1	thyroid gland: 4.3	Mixed		
MIER3	DKFZp686L09111, DKFZp781I1119, FLJ35954	ENSG00000155545	MIER family member 3	5	56919602-56971675	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058349, HPA065946	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			colon: 30.2	Expressed in all		
NUP205	C7orf14, KIAA0225	ENSG00000155561	Nucleoporin 205	7	135557919-135648757	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Liver cancer:1.90e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
ZKSCAN2	FLJ23199, ZNF694, ZSCAN34	ENSG00000155592	Zinc finger with KRAB and SCAN domains 2	16	25236001-25257931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049141	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus	Renal cancer:1.70e-6 (favourable)	Expressed in all	Mixed			testis: 7.6	Mixed		
C9orf85	MGC61599	ENSG00000155621	Chromosome 9 open reading frame 85	9	71911510-71986054	Predicted intracellular proteins	Evidence at protein level	HPA050767			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 13.9	Mixed		
XAGE2	CT12.2, GAGED3, XAGE-2, XAGE2B	ENSG00000155622	X antigen family member 2	X	52369030-52375680	Predicted intracellular proteins	Evidence at protein level	HPA052507, HPA060900	Supported					Mixed	Tissue enriched	35	placenta: 294.4	lung: 8.4	Cell line enhanced		BEWO: 95.0;SK-BR-3: 17.4;T-47d: 19.2
PIK3AP1	BCAP, FLJ35564	ENSG00000155629	Phosphoinositide-3-kinase adaptor protein 1	10	96593312-96720514	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026136, HPA038452	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		spleen: 85.6	lymph node: 72.0	Cell line enhanced		Daudi: 60.8;REH: 166.9;THP-1: 62.4;U-698: 79.5;U-937: 74.4
RBM45	DRB1, FLJ44612	ENSG00000155636	RNA binding motif protein 45	2	178112424-178139011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020448	Approved		Supported	Nucleus	Renal cancer:5.34e-9 (unfavourable), Liver cancer:5.74e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 12.4	Expressed in all		
TTN	CMD1G, CMH9, CMPD4, FLJ32040, LGMD2J, MYLK5, TMD	ENSG00000155657	Titin	2	178525989-178830802	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007042, CAB022682, HPA030048	Enhanced					Tissue enhanced	Tissue enriched	7	skeletal muscle: 322.5	heart muscle: 46.7	Mixed		
VSIG4	Z39IG	ENSG00000155659	V-set and immunoglobulin domain containing 4	X	66021738-66040125	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003903, CAB026000	Approved		Uncertain	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.95e-6 (unfavourable), Colorectal cancer:1.34e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 243.4	Not detected		
PDIA4	ERP70, ERP72	ENSG00000155660	Protein disulfide isomerase family A member 4	7	149003062-149028641	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA006139, HPA006140, CAB017368	Supported		Supported	Endoplasmic reticulum	Renal cancer:5.20e-9 (unfavourable), Glioma:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 372.1	Expressed in all		
KDM8	FLJ13798, JMJD5	ENSG00000155666	Lysine demethylase 8	16	27203495-27221768	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026545	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 24.2	small intestine: 13.8	Mixed		
PDZD9	C16orf65, MGC50721	ENSG00000155714	PDZ domain containing 9	16	21983865-22001110	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 10.3	cerebral cortex: 0.2	Not detected		
OTOA	CT108, DFNB22	ENSG00000155719	Otoancorin	16	21678514-21760729	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041405	Uncertain					Not detected	Group enriched	13	spleen: 2.6;testis: 6.0	epididymis: 0.3	Not detected		
KCTD18	6530404F10Rik, FLJ31322, FLJ37818	ENSG00000155729	Potassium channel tetramerization domain containing 18	2	200488952-200519784	Predicted intracellular proteins	Evidence at protein level	HPA045498, HPA058028	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 23.2	Expressed in all		
FAM126B	HYCC2, MGC39518	ENSG00000155744	Family with sequence similarity 126 member B	2	200973718-201071671	Predicted intracellular proteins	Evidence at protein level	HPA036166, HPA036167, HPA067307	Uncertain		Supported	Nucleus<br>Cell Junctions		Expressed in all	Mixed			cerebral cortex: 14.7	Expressed in all		
ALS2CR12		ENSG00000155749	Amyotrophic lateral sclerosis 2 chromosome region 12	2	201288271-201357398	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035793			Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	5	fallopian tube: 15.0;testis: 31.8	lung: 4.2	Cell line enhanced		U-2197: 4.3
ALS2CR11	FLJ25351	ENSG00000155754	Amyotrophic lateral sclerosis 2 chromosome region candidate 11	2	201487425-201619178	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	78	testis: 74.2	ovary: 0.9	Cell line enhanced		hTEC/SVTERT24-B: 2.0;SCLC-21H: 2.8;U-2197: 7.1
TMEM237	ALS2CR4, JBTS14	ENSG00000155755	Transmembrane protein 237	2	201620184-201643570	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA052596, HPA054732	Enhanced				Renal cancer:7.96e-6 (unfavourable), Melanoma:1.33e-4 (unfavourable), Endometrial cancer:2.51e-4 (unfavourable)	Expressed in all	Mixed			skin: 21.9	Expressed in all		
FZD7	FzE3	ENSG00000155760	Frizzled class receptor 7	2	202034587-202038445	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA069165	Approved		Approved	Nucleoplasm	Liver cancer:7.71e-5 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 39.1	Cell line enhanced		CAPAN-2: 63.3
SPAG17	CT143, FLJ34497, PF6, RP4-776P7.2	ENSG00000155761	Sperm associated antigen 17	1	117953861-118185223	Predicted intracellular proteins	Evidence at protein level	HPA028597, HPA028666	Enhanced					Mixed	Tissue enhanced		fallopian tube: 13.6;testis: 27.9	esophagus: 6.8	Not detected		
DEPTOR	DEP.6, DEPDC6, FLJ12428	ENSG00000155792	DEP domain containing MTOR interacting protein	8	119873717-120050913	Predicted intracellular proteins	Evidence at protein level	CAB020841, HPA023938, HPA023945, HPA024011	Enhanced		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 163.8	Cell line enhanced		Daudi: 74.2;RPMI-8226: 128.8;RPTEC TERT1: 111.5
FMN2		ENSG00000155816	Formin 2	1	240014348-240475189	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050649			Approved	Plasma membrane<br>Actin filaments		Group enriched	Group enriched	6	cerebral cortex: 53.8;parathyroid gland: 33.5	adrenal gland: 7.0	Cell line enhanced		BJ: 60.2;fHDF/TERT166: 54.7;LHCN-M2: 63.8;U-138 MG: 48.9;WM-115: 77.8
RNF20	BRE1, BRE1A, FLJ11189, FLJ20382, hBRE1, KAIA2779	ENSG00000155827	Ring finger protein 20	9	101533851-101563344	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012478, HPA051773	Supported		Enhanced	Nucleoplasm	Renal cancer:1.64e-6 (favourable)	Expressed in all	Expressed in all			testis: 59.3	Expressed in all		
CYLC2		ENSG00000155833	Cylicin 2	9	102995311-103018488	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	532	testis: 80.1	urinary bladder: 0.1	Not detected		
PPARGC1B	PERC, PGC1B	ENSG00000155846	PPARG coactivator 1 beta	5	149730298-149855022	Predicted intracellular proteins	Evidence at protein level	HPA050543			Supported	Nucleus		Mixed	Mixed			parathyroid gland: 14.6	Mixed		
ELMO1	CED-12, CED12, ELMO-1, KIAA0281	ENSG00000155849	Engulfment and cell motility 1	7	36854361-37449249	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.27e-5 (unfavourable), Pancreatic cancer:4.62e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.9	Cell line enhanced		U-698: 82.2
SLC26A2	DTD, DTDST	ENSG00000155850	Solute carrier family 26 member 2	5	149960737-149993455	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041957, HPA058090	Enhanced		Approved	Vesicles	Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 213.0;rectum: 207.1	parathyroid gland: 82.7	Expressed in all		
LSM11	FLJ38273	ENSG00000155858	LSM11, U7 small nuclear RNA associated	5	157743695-157760709	Predicted intracellular proteins	Evidence at protein level	HPA039587	Uncertain		Supported	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			cerebral cortex: 8.5	Mixed		
MED7	CRSP33, CRSP9	ENSG00000155868	Mediator complex subunit 7	5	157137412-157159019	Predicted intracellular proteins	Evidence at protein level	HPA067181			Supported	Nuclear bodies	Liver cancer:2.37e-5 (unfavourable), Renal cancer:8.69e-5 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
SAXO1	C9orf138, FAM154A, MGC35182	ENSG00000155875	Stabilizer of axonemal microtubules 1	9	18927658-19049354	Predicted intracellular proteins	Evidence at protein level	HPA023899	Enhanced					Not detected	Tissue enriched	112	testis: 58.4	epididymis: 0.5	Not detected		
RRAGA	FIP-1, RAGA	ENSG00000155876	Ras related GTP binding A	9	19049395-19050983	Predicted intracellular proteins	Evidence at protein level	HPA003734	Supported		Approved	Golgi apparatus<br>Vesicles	Head and neck cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 128.1	Expressed in all		
SLC24A2	NCKX2	ENSG00000155886	Solute carrier family 24 member 2	9	19507452-19786928	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	7	cerebral cortex: 51.6	adrenal gland: 7.9	Cell line enhanced		K-562: 2.3;SCLC-21H: 2.6;U-87 MG: 2.9
TRIM42	FLJ40097, PPP1R40, T4A1	ENSG00000155890	Tripartite motif containing 42	3	140678039-140701150	Predicted intracellular proteins	Evidence at protein level	HPA003581, HPA022481			Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Tissue enriched	293	testis: 29.2	all non-specific tissues: 0.0	Not detected		
PXYLP1	ACPL2, FLJ23751	ENSG00000155893	2-phosphoxylose phosphatase 1	3	141228726-141367753	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017243	Approved					Expressed in all	Expressed in all			epididymis: 180.6	Mixed		
ADCY8	AC8, ADCY3, HBAC1	ENSG00000155897	Adenylate cyclase 8	8	130780301-131042426	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018652, HPA024291	Supported					Group enriched	Group enriched	8	cerebral cortex: 12.9;epididymis: 27.8;fallopian tube: 6.2	seminal vesicle: 2.0	Group enriched	7	U-138 MG: 17.5;U-87 MG: 33.7
RASA2	GAP1M	ENSG00000155903	RAS p21 protein activator 2	3	141487047-141615342	Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA035374, HPA035375	Approved		Approved	Vesicles	Renal cancer:7.62e-7 (unfavourable), Urothelial cancer:4.34e-5 (favourable)	Expressed in all	Mixed			lymph node: 25.0	Expressed in all		
RMND1	bA351K16.3, C6orf96, FLJ20627, RMD1	ENSG00000155906	Required for meiotic nuclear division 1 homolog	6	151404763-151452181	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031397, HPA031398, HPA031399	Approved		Supported	Mitochondria	Head and neck cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 44.1	Expressed in all		
RAET1L		ENSG00000155918	Retinoic acid early transcript 1L	6	150018334-150025532	Predicted membrane proteins	Evidence at protein level						Lung cancer:4.09e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	esophagus: 38.9	tonsil: 5.9	Cell line enriched	6	HaCaT: 15.6
SLA	hSLAP, SLA1, SLAP, SLAP-1	ENSG00000155926	Src like adaptor	8	133036724-133103054	Predicted intracellular proteins	Evidence at protein level	HPA012296, HPA074192	Approved		Approved	Nuclear membrane		Expressed in all	Tissue enhanced		appendix: 104.2	lymph node: 79.7	Cell line enhanced		HMC-1: 39.6;Karpas-707: 88.0;MOLT-4: 27.3;U-266/84: 51.3;U-937: 38.7
TMBIM4	CGI-119, GAAP, LFG4, S1R, ZPRO	ENSG00000155957	Transmembrane BAX inhibitor motif containing 4	12	66135846-66170072	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA077642			Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 164.3	Expressed in all		
VBP1	PFD3, PFDN3	ENSG00000155959	VHL binding protein 1	X	155197007-155239817	Predicted intracellular proteins	Evidence at protein level	CAB006260, HPA023230	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 85.3	Expressed in all		
RAB39B	MRX72	ENSG00000155961	RAB39B, member RAS oncogene family	X	155258241-155264589	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001114, HPA042505	Approved				Breast cancer:8.95e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 19.4	epididymis: 7.5	Cell line enhanced		Daudi: 19.2;Karpas-707: 24.8;SCLC-21H: 15.4;U-266/70: 26.3;U-266/84: 17.9
CLIC2	XAP121	ENSG00000155962	Chloride intracellular channel 2	X	155276211-155334657	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047381, HPA060101	Uncertain		Approved	Plasma membrane	Renal cancer:1.74e-5 (unfavourable)	Expressed in all	Mixed			spleen: 62.8	Cell line enhanced		HDLM-2: 85.0;K-562: 44.8;Karpas-707: 31.6;RPMI-8226: 54.1
AFF2	FMR2, FRAXE	ENSG00000155966	AF4/FMR2 family member 2	X	148500619-149000663	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003139	Approved					Mixed	Tissue enhanced		epididymis: 14.5;placenta: 21.1	bone marrow: 8.3	Cell line enhanced		Daudi: 52.9;HL-60: 25.2;U-698: 74.2;U-937: 18.0
MICU3	DKFZp313A0139, EFHA2	ENSG00000155970	Mitochondrial calcium uptake family member 3	8	17027238-17122644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024048, HPA024771, HPA024779	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 34.8	parathyroid gland: 14.2	Cell line enhanced		HBF TERT88: 12.3
GRIP1		ENSG00000155974	Glutamate receptor interacting protein 1	12	66347431-66804186	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038856	Uncertain					Mixed	Mixed			seminal vesicle: 11.6	Cell line enhanced		BEWO: 22.7;HaCaT: 17.8;RT4: 17.2
VPS37A	FLJ32642, HCRP1, PQBP2, SPG53	ENSG00000155975	VPS37A, ESCRT-I subunit	8	17246571-17302427	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024705, HPA024781	Enhanced		Approved	Vesicles<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 57.3	Expressed in all		
KIF5A	D12S1889, MY050, NKHC, SPG10	ENSG00000155980	Kinesin family member 5A	12	57549998-57586632	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004469, HPA073448	Enhanced	Approved	Approved	Nucleoplasm<br>Mitotic spindle<br>Cytosol	Pancreatic cancer:5.23e-4 (favourable)	Tissue enriched	Tissue enriched	28	cerebral cortex: 325.7	adrenal gland: 11.4	Cell line enhanced		HDLM-2: 28.1;NTERA-2: 15.0;SCLC-21H: 36.2
NAT2	AAC2	ENSG00000156006	N-acetyltransferase 2	8	18391245-18401218	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043704	Uncertain				Colorectal cancer:4.61e-5 (favourable)	Tissue enhanced	Group enriched	13	colon: 14.4;duodenum: 32.7;liver: 62.4;rectum: 14.0;small intestine: 27.1	smooth muscle: 2.3	Cell line enhanced		RT4: 1.2;SCLC-21H: 2.5;SK-BR-3: 1.0
MAGEA8	CT1.8, MAGE8, MGC2182	ENSG00000156009	MAGE family member A8	X	149881141-149885835	Predicted intracellular proteins	Evidence at protein level	HPA003998	Enhanced					Mixed	Tissue enriched	9	placenta: 19.0	testis: 2.0	Group enriched	27	U-2 OS: 35.5;U-266/70: 48.5
PSD3	DKFZp761K1423, EFA6D, EFA6R, HCA67, KIAA0942	ENSG00000156011	Pleckstrin and Sec7 domain containing 3	8	18527301-19084730	Predicted intracellular proteins	Evidence at protein level	HPA002455	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.76e-5 (unfavourable), Colorectal cancer:7.55e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 83.3	testis: 29.6	Cell line enhanced		U-87 MG: 48.5
CARNMT1	C9orf41, FLJ25795	ENSG00000156017	Carnosine N-methyltransferase 1	9	74981020-75028423	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026756	Uncertain					Expressed in all	Expressed in all			testis: 30.0	Expressed in all		
MCU	C10orf42, CCDC109A, FLJ46135	ENSG00000156026	Mitochondrial calcium uniporter	10	72692131-72887694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016480	Approved		Supported	Mitochondria	Liver cancer:6.06e-5 (unfavourable), Renal cancer:5.07e-4 (favourable)	Expressed in all	Expressed in all			stomach: 40.7	Expressed in all		
ELMSAN1	C14orf117, C14orf43, LSR68	ENSG00000156030	ELM2 and Myb/SANT domain containing 1	14	73715122-73790285	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003111	Approved		Enhanced	Nucleoplasm	Ovarian cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
CFAP70	FLJ25765, TTC18	ENSG00000156042	Cilia and flagella associated protein 70	10	73253759-73358859	Predicted intracellular proteins	Evidence at protein level	HPA037582, HPA070304	Enhanced					Mixed	Tissue enhanced		fallopian tube: 23.4;testis: 37.6	epididymis: 13.8	Mixed		
GNA14		ENSG00000156049	G protein subunit alpha 14	9	77423079-77648307	Predicted intracellular proteins	Evidence at protein level	HPA048886	Approved					Mixed	Mixed			thyroid gland: 29.8	Cell line enhanced		BJ hTERT+: 1.9;PC-3: 3.0;U-2197: 2.0
FAM161B	C14orf44, FLJ31697	ENSG00000156050	Family with sequence similarity 161 member B	14	73931501-73950414	Predicted intracellular proteins	Evidence at protein level	HPA019125	Approved				Renal cancer:6.78e-4 (favourable)	Expressed in all	Mixed			testis: 18.8	Mixed		
GNAQ	G-ALPHA-q, GAQ	ENSG00000156052	G protein subunit alpha q	9	77716087-78031458	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010036, HPA048886	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:1.11e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 84.9	Mixed		
WIF1		ENSG00000156076	WNT inhibitory factor 1	12	65050626-65121566	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039104	Approved					Tissue enhanced	Tissue enriched	6	lung: 159.4	cerebral cortex: 26.4	Cell line enhanced		HEK 293: 1.9;NTERA-2: 2.7
UGT2B4	UGT2B11	ENSG00000156096	UDP glucuronosyltransferase family 2 member B4	4	69480165-69526014	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033260, HPA045108	Enhanced					Tissue enriched	Tissue enriched	78	liver: 655.5	heart muscle: 8.3	Cell line enriched	11	RH-30: 4.5
GPR61	BALGR	ENSG00000156097	G protein-coupled receptor 61	1	109539872-109548406	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007326, HPA026088	Approved					Not detected	Tissue enhanced		adrenal gland: 1.0;cerebral cortex: 3.4;thyroid gland: 1.2	testis: 0.5	Not detected		
MMP16	C8orf57, DKFZp761D112, MT3-MMP	ENSG00000156103	Matrix metallopeptidase 16	8	88032009-88328025	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023693	Uncertain		Approved	Vesicles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 9.6	gallbladder: 4.2	Cell line enhanced		AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
ADK	AK	ENSG00000156110	Adenosine kinase	10	74151185-74709303	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB032876, HPA038391, HPA038409	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable)	Expressed in all	Expressed in all			liver: 77.6	Expressed in all		
KCNMA1	KCa1.1, mSLO1, SLO	ENSG00000156113	Potassium calcium-activated channel subfamily M alpha 1	10	76869601-77638369	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA054648	Approved					Mixed	Tissue enhanced		smooth muscle: 137.0	endometrium: 109.5	Cell line enhanced		PC-3: 148.0;U-138 MG: 111.0;U-87 MG: 107.5
BATF	B-ATF, BATF1, SFA-2	ENSG00000156127	Basic leucine zipper ATF-like transcription factor	14	75522425-75547015	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059588, HPA064962	Approved		Enhanced	Nucleoplasm	Renal cancer:3.74e-9 (unfavourable), Endometrial cancer:5.35e-6 (favourable), Head and neck cancer:7.91e-5 (favourable), Urothelial cancer:4.30e-4 (favourable), Colorectal cancer:8.30e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	appendix: 26.5	Cell line enhanced		HDLM-2: 321.9;MCF7: 99.6;RT4: 64.2;U-937: 74.7
DCK		ENSG00000156136	Deoxycytidine kinase	4	70992538-71030914	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059609, HPA062773	Approved		Supported	Nucleus	Liver cancer:6.90e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 93.9	Expressed in all		
ADAMTS3	ADAMTS-4, KIAA0366	ENSG00000156140	ADAM metallopeptidase with thrombospondin type 1 motif 3	4	72280969-72569386	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA021368, HPA021369	Uncertain		Approved	Intermediate filaments		Mixed	Tissue enhanced		parathyroid gland: 7.3	testis: 3.5	Cell line enhanced		AF22: 13.0;HEL: 12.6;K-562: 10.9;U-2 OS: 8.7
ALX3	FND	ENSG00000156150	ALX homeobox 3	1	110059994-110070700	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Mixed			skin: 7.7	Mixed		
DPY19L4		ENSG00000156162	Dpy-19 like 4 (C. elegans)	8	94719703-94793836	Predicted membrane proteins	Evidence at protein level	HPA024780	Approved		Approved	Vesicles	Endometrial cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.9	Expressed in all		
NDUFAF6	C8orf38, MGC40214	ENSG00000156170	NADH:ubiquinone oxidoreductase complex assembly factor 6	8	94895767-95116455	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047148, HPA050545	Approved					Expressed in all	Mixed			thyroid gland: 10.5	Expressed in all		
DRAM2	MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154	ENSG00000156171	DNA damage regulated autophagy modulator 2	1	111117333-111140216	Predicted membrane proteins	Evidence at protein level	HPA018036, HPA061701	Enhanced		Enhanced	Golgi apparatus<br>Vesicles	Liver cancer:3.45e-5 (unfavourable), Melanoma:6.43e-4 (unfavourable), Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Mixed			spleen: 19.3	Mixed		
C8orf37	BBS21, CORD16, FLJ30600, RP64	ENSG00000156172	Chromosome 8 open reading frame 37	8	95244919-95269201	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024198	Approved		Approved	Plasma membrane<br>Cell Junctions<br>Cytosol	Endometrial cancer:4.63e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 6.3	Mixed		
PPEF2	PPP7CB	ENSG00000156194	Protein phosphatase with EF-hand domain 2	4	75859864-75902571	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.4	Not detected		
CFAP161	C15orf26, FLJ38615	ENSG00000156206	Cilia and flagella associated protein 161	15	81007033-81149175	Predicted intracellular proteins	Evidence at protein level	HPA041807	Uncertain				Endometrial cancer:3.05e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 24.8;testis: 11.5	lung: 4.1	Group enriched	5	HEL: 75.9;K-562: 25.9
ADAMTSL3	KIAA1233, punctin-2	ENSG00000156218	ADAMTS like 3	15	83654086-84039842	Predicted secreted proteins	Evidence at protein level	HPA034773, HPA034774	Approved		Approved	Vesicles		Mixed	Mixed			placenta: 14.9	Group enriched	6	EFO-21: 11.2;RPTEC TERT1: 10.6;TIME: 10.7;U-2 OS: 2.4
ART3		ENSG00000156219	ADP-ribosyltransferase 3	4	76011184-76112802	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011268	Enhanced					Tissue enhanced	Tissue enhanced		skeletal muscle: 77.0;testis: 174.4	heart muscle: 29.1	Group enriched	7	NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
SLC28A1	CNT1	ENSG00000156222	Solute carrier family 28 member 1	15	84884654-84945796	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019551	Enhanced					Group enriched	Group enriched	26	duodenum: 37.9;kidney: 49.4;liver: 35.4;small intestine: 53.6	placenta: 1.7	Not detected		
WHAMM	KIAA1971, WHAMM1, WHDC1	ENSG00000156232	WAS protein homolog associated with actin, golgi membranes and microtubules	15	82809628-82836108	Predicted intracellular proteins	Evidence at protein level	HPA039690, HPA040231	Supported		Supported	Cytosol	Prostate cancer:2.31e-4 (unfavourable), Cervical cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 18.8	Expressed in all		
CXCL13	ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13	ENSG00000156234	C-X-C motif chemokine ligand 13	4	77511753-77611834	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA052613	Uncertain				Renal cancer:1.16e-10 (unfavourable), Ovarian cancer:5.41e-4 (favourable), Endometrial cancer:5.52e-4 (favourable), Colorectal cancer:9.12e-4 (favourable)	Expressed in all	Group enriched	7	appendix: 163.3;lymph node: 599.9;spleen: 423.8;tonsil: 395.7	urinary bladder: 57.9	Cell line enhanced		U-266/70: 1.0
N6AMT1	C21orf127, HEMK2, MTQ2, N6AMT, PRED28	ENSG00000156239	N-6 adenine-specific DNA methyltransferase 1 (putative)	21	28872191-28885371	Predicted intracellular proteins	Evidence at protein level	CAB034133, CAB034135, HPA059242	Approved		Approved	Nucleoplasm<br>Centrosome		Expressed in all	Mixed			parathyroid gland: 10.8	Expressed in all		
RWDD2B	C21orf6, GL011	ENSG00000156253	RWD domain containing 2B	21	29004384-29019378	Predicted intracellular proteins	Evidence at protein level	HPA018316	Uncertain					Expressed in all	Mixed			testis,thyroid gland: 1.8	Mixed		
USP16	Ubp-M	ENSG00000156256	Ubiquitin specific peptidase 16	21	29024629-29054488	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021140	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 57.2	Expressed in all		
CCT8	C21orf112, Cctq, PRED71	ENSG00000156261	Chaperonin containing TCP1 subunit 8	21	29055805-29073797	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018520, HPA021051, HPA029426	Enhanced		Approved	Nucleus<br>Intermediate filaments<br>Cytosol	Liver cancer:1.56e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 135.9	Expressed in all		
MAP3K7CL	C21orf7, TAK1L, TAKL, TAKL-1, TAKL-2, TAKL-4	ENSG00000156265	MAP3K7 C-terminal like	21	29077471-29175889	Predicted intracellular proteins	Evidence at protein level	HPA030079, HPA042439	Uncertain		Approved	Nucleoplasm	Renal cancer:8.31e-6 (unfavourable)	Expressed in all	Mixed			heart muscle: 17.9	Cell line enhanced		HBF TERT88: 56.2;RH-30: 242.2
NAA11	ARD1B, ARD2, hARD2	ENSG00000156269	N(alpha)-acetyltransferase 11, NatA catalytic subunit	4	79225694-79326050	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035922	Approved					Tissue enhanced	Group enriched	37	placenta: 6.1;testis: 11.4	cerebral cortex,endometrium,parathyroid gland,smooth muscle,thyroid gland: 0.2	Cell line enhanced		K-562: 11.1;U-266/70: 25.3;U-266/84: 8.0
BACH1	BACH-1, BTBD24	ENSG00000156273	BTB domain and CNC homolog 1	21	29194071-29630751	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034949	Approved		Approved	Nucleus<br>Cytosol	Pancreatic cancer:3.11e-5 (unfavourable), Renal cancer:7.14e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.9	Expressed in all		
CLDN17	MGC126552, MGC126554	ENSG00000156282	Claudin 17	21	30165564-30166756	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045903	Enhanced					Tissue enhanced	Tissue enriched	5	esophagus: 6.6	tonsil: 1.2	Not detected		
CLDN8		ENSG00000156284	Claudin 8	21	30214006-30216073	Predicted membrane proteins, Transporters	Evidence at protein level	HPA060605	Supported				Renal cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 84.9;kidney: 76.1;rectum: 56.0	thyroid gland: 37.3	Cell line enriched	17	HaCaT: 30.1
TSPAN7	A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2	ENSG00000156298	Tetraspanin 7	X	38561370-38688920	CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003140, CAB062566, CAB068245	Enhanced				Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 574.4	adrenal gland: 99.2	Cell line enhanced		HDLM-2: 39.2;MOLT-4: 141.6;SCLC-21H: 109.6;U-266/70: 47.0
TIAM1		ENSG00000156299	T-cell lymphoma invasion and metastasis 1	21	31118416-31559977	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010416, HPA034853	Uncertain		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cell Junctions<br>Cytokinetic bridge<br>Cytosol		Mixed	Mixed			skin: 28.0	Cell line enhanced		BEWO: 33.2;SCLC-21H: 38.3
SCAF4	DKFZp434E098, KIAA1172, SFRS15, SRA4	ENSG00000156304	SR-related CTD associated factor 4	21	31671033-31732075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018319, HPA018668, HPA021504, HPA028807	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 28.4	Expressed in all		
RPGR	COD1, CORDX1, CRD, RP15, RP3	ENSG00000156313	Retinitis pigmentosa GTPase regulator	X	38269163-38327564	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001593, HPA073455	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			fallopian tube: 22.9	Mixed		
CDK20	CCRK, p42	ENSG00000156345	Cyclin dependent kinase 20	9	87966441-87974753	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007666, HPA027379, HPA027401	Enhanced		Supported	Nucleoplasm	Renal cancer:2.12e-5 (favourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 20.7	Cell line enhanced		SCLC-21H: 21.7;THP-1: 19.4
PCGF6	MBLR, RNF134	ENSG00000156374	Polycomb group ring finger 6	10	103302796-103351134	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.54e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
ANKRD9		ENSG00000156381	Ankyrin repeat domain 9	14	102501760-102509799	Predicted intracellular proteins	Evidence at protein level	HPA055985	Uncertain				Renal cancer:1.17e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 50.3	Mixed		
SFR1	bA373N18.1, C10orf78, FLJ41960, MEI5, MEIR5	ENSG00000156384	SWI5 dependent homologous recombination repair protein 1	10	104122058-104126385	Predicted intracellular proteins	Evidence at protein level	HPA039617	Uncertain				Liver cancer:2.59e-5 (unfavourable), Renal cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 33.1	Expressed in all		
SORCS3	KIAA1059, SORCS	ENSG00000156395	Sortilin related VPS10 domain containing receptor 3	10	104641101-105265235	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:5.72e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 11.9	adrenal gland: 2.6	Not detected		
SFXN2		ENSG00000156398	Sideroflexin 2	10	102714538-102743492	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018150, HPA026834	Enhanced		Approved	Mitochondria	Renal cancer:2.28e-5 (favourable), Cervical cancer:2.28e-4 (favourable), Urothelial cancer:6.52e-4 (favourable), Liver cancer:9.95e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 18.7	parathyroid gland: 12.4	Cell line enhanced		T-47d: 35.9
C14orf2	MP68	ENSG00000156411	Chromosome 14 open reading frame 2	14	103912288-103928269	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058978, HPA060520	Enhanced		Supported	Nucleoli fibrillar center<br>Mitochondria	Ovarian cancer:6.80e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 209.1	Expressed in all		
FUT6	FCT3A, FLJ40754, FT1A, FucT-VI	ENSG00000156413	Fucosyltransferase 6	19	5830610-5839731	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043707, HPA046966	Approved		Supported	Golgi apparatus	Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 49.8;kidney: 34.5	small intestine: 30.6	Group enriched	5	Hep G2: 7.2;RPMI-8226: 2.7
TDRD9	C14orf75, DKFZp434N0820, FLJ36164, NET54	ENSG00000156414	Tudor domain containing 9	14	103928462-104052667	Enzymes, Predicted intracellular proteins	Evidence at protein level						Thyroid cancer:5.52e-4 (unfavourable)	Mixed	Group enriched	6	parathyroid gland: 39.7;testis: 75.0	thyroid gland: 9.1	Cell line enhanced		HDLM-2: 22.6;HeLa: 13.9;HMC-1: 82.8;RPTEC TERT1: 19.5
FGF18	FGF-18, ZFGF5	ENSG00000156427	Fibroblast growth factor 18	5	171419656-171457623	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA018795	Uncertain					Group enriched	Tissue enhanced		heart muscle: 6.6	adipose tissue: 1.9	Cell line enriched	61	EFO-21: 178.4
PCDH1	pc42	ENSG00000156453	Protocadherin 1	5	141853111-141879246	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047720, HPA050538	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 40.3	Cell line enhanced		CAPAN-2: 75.4;HaCaT: 95.1;RT4: 59.1;TIME: 60.2;WM-115: 51.1
SH3RF2	FLJ23654, Hepp1, POSHER, PPP1R39, RNF158	ENSG00000156463	SH3 domain containing ring finger 2	5	145936579-146081791	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035903, HPA058119	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		skin: 67.3	heart muscle: 26.1	Cell line enhanced		CACO-2: 57.4
GDF6	BMP13, KFS, KFS1, SGM1	ENSG00000156466	Growth differentiation factor 6	8	96142330-96160792	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045206	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Renal cancer:2.17e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		placenta: 15.1	gallbladder: 3.8	Cell line enriched	7	LHCN-M2: 27.7
UQCRB	QCR7, QP-C, UQBP, UQCR6	ENSG00000156467	Ubiquinol-cytochrome c reductase binding protein	8	96225920-96235634	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043060	Approved				Renal cancer:2.90e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 520.9	Expressed in all		
MTERF3	CGI-12, FLJ10939, MTERFD1	ENSG00000156469	Mitochondrial transcription termination factor 3	8	96239398-96261610	Predicted intracellular proteins	Evidence at protein level	HPA002966			Supported	Nucleoplasm<br>Mitochondria	Renal cancer:5.88e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.4	Expressed in all		
PTDSS1	KIAA0024, PSS1, PSSA	ENSG00000156471	Phosphatidylserine synthase 1	8	96261715-96336995	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA016852	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum	Liver cancer:1.08e-5 (unfavourable), Lung cancer:9.83e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.1	Expressed in all		
PPP2R2B	PR52B, PR55-BETA, SCA12	ENSG00000156475	Protein phosphatase 2 regulatory subunit Bbeta	5	146581146-147084784	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038118, HPA042122, HPA042770	Approved		Approved	Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 135.2	testis: 33.9	Cell line enhanced		HaCaT: 19.5;HDLM-2: 97.5;RT4: 19.0
RPL30	L30	ENSG00000156482	Ribosomal protein L30	8	98024851-98046469	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA002651	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.41e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 5911.7	Expressed in all		
KCNS2	Kv9.2	ENSG00000156486	Potassium voltage-gated channel modifier subfamily S member 2	8	98427022-98432848	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051417	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 7.2	placenta: 2.2	Group enriched	9	HSkMC: 1.5;SCLC-21H: 7.5
FAM122C	RP3-473B4.1	ENSG00000156500	Family with sequence similarity 122C	X	134796789-134854610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059961	Approved		Uncertain	Nucleoplasm		Mixed	Mixed			testis: 7.9	Mixed		
SUPV3L1	SUV3	ENSG00000156502	Suv3 like RNA helicase	10	69180232-69209099	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038380, HPA038405	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			testis: 29.0	Expressed in all		
FAM122B	DKFZp686L20116, RP11-308B5.5	ENSG00000156504	Family with sequence similarity 122B	X	134769566-134797232	Predicted intracellular proteins	Evidence at protein level	HPA000266	Enhanced		Approved	Nucleoplasm	Endometrial cancer:7.19e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
EEF1A1	EE1A1, EEF1A, EF1A, LENG7	ENSG00000156508	Eukaryotic translation elongation factor 1 alpha 1	6	73515750-73523797	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051759, HPA053862, HPA056990	Supported		Supported	Cytosol	Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 14741.4	Expressed in all		
FBXO43	Fbx43	ENSG00000156509	F-box protein 43	8	100133360-100145800	Predicted intracellular proteins	Evidence at protein level	HPA024292, HPA024295, HPA024824	Uncertain					Mixed	Tissue enriched	18	testis: 9.8	tonsil: 0.5	Mixed		
HKDC1	FLJ22761, FLJ37767	ENSG00000156510	Hexokinase domain containing 1	10	69220303-69267559	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011956, HPA064198, HPA064230	Approved		Enhanced	Mitochondria		Mixed	Tissue enhanced		duodenum: 53.1;small intestine: 52.3	thyroid gland: 15.2	Group enriched	6	A549: 35.7;CACO-2: 46.7;CAPAN-2: 96.8;EFO-21: 31.5;Hep G2: 22.5;RPTEC TERT1: 61.4
HK1		ENSG00000156515	Hexokinase 1	10	69269984-69401882	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007043, HPA007044, CAB010052, HPA011956	Supported		Enhanced	Mitochondria	Head and neck cancer:3.39e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 153.6	Cell line enhanced		K-562: 491.8
TYSND1	MGC34695, NET41	ENSG00000156521	Trypsin domain containing 1	10	70137981-70146676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030304	Uncertain		Uncertain	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Mixed			adipose tissue: 5.8	Cell line enhanced		HaCaT: 24.4;PC-3: 39.1
PHF6	BFLS, BORJ, CENP-31, KIAA1823, MGC14797	ENSG00000156531	PHD finger protein 6	X	134373253-134428791	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001023	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:3.38e-4 (unfavourable), Pancreatic cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 41.7	Expressed in all		
CD109	CPAMD7, DKFZp762L1111, FLJ38569	ENSG00000156535	CD109 molecule	6	73695785-73828316	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015723	Enhanced				Stomach cancer:7.96e-5 (unfavourable), Renal cancer:2.65e-4 (unfavourable), Urothelial cancer:4.68e-4 (unfavourable)	Expressed in all	Tissue enriched	43	parathyroid gland: 967.3	skin: 22.4	Cell line enhanced		ASC TERT1: 162.5
LRFN2	FIGLER2, KIAA1246, SALM1	ENSG00000156564	Leucine rich repeat and fibronectin type III domain containing 2	6	40391586-40587465	Predicted membrane proteins	Evidence at protein level	HPA076660	Enhanced		Supported	Vesicles		Not detected	Tissue enriched	5	cerebral cortex: 6.8	testis: 1.3	Cell line enhanced		REH: 1.5;SH-SY5Y: 5.0
NODAL		ENSG00000156574	Nodal growth differentiation factor	10	70432315-70447951	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045201	Uncertain					Tissue enriched	Tissue enhanced		testis: 2.9	skin: 1.2	Cell line enhanced		CACO-2: 1.6;SH-SY5Y: 1.5
PRG3	MBP2, MBPH	ENSG00000156575	Proteoglycan 3, pro eosinophil major basic protein 2	11	57376769-57381150	Predicted secreted proteins	Evidence at protein level	HPA064183	Enhanced					Not detected	Tissue enriched	45	bone marrow: 29.3	liver,spleen: 0.6	Cell line enriched	64	HMC-1: 174.6
UBE2L6	UBCH8	ENSG00000156587	Ubiquitin conjugating enzyme E2 L6	11	57551656-57568284	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003328, CAB073407	Enhanced		Approved	Cytosol	Pancreatic cancer:4.88e-4 (unfavourable), Breast cancer:6.75e-4 (favourable)	Expressed in all	Expressed in all			spleen: 148.0	Mixed		
ZDHHC5	KIAA1748, ZNF375	ENSG00000156599	Zinc finger DHHC-type containing 5	11	57667747-57701187	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014670	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Pancreatic cancer:6.74e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 87.5	Expressed in all		
MED19	LCMR1	ENSG00000156603	Mediator complex subunit 19	11	57703714-57712323	Predicted intracellular proteins	Evidence at protein level	HPA039912, HPA040860	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:1.34e-6 (unfavourable), Ovarian cancer:1.76e-6 (favourable)	Expressed in all	Expressed in all			testis: 28.6	Expressed in all		
ZFAND3	FLJ13222, TEX27	ENSG00000156639	Zinc finger AN1-type containing 3	6	37819499-38154624	Predicted intracellular proteins	Evidence at protein level	HPA016755	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 185.0	Expressed in all		
NPTN	GP55, GP65, np55, np65, SDFR1, SDR1	ENSG00000156642	Neuroplastin	15	73560014-73634134	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051497, HPA072453	Approved		Approved	Cytokinetic bridge<br>Mitochondria		Expressed in all	Expressed in all			smooth muscle: 433.8	Expressed in all		
KAT6B	Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B	ENSG00000156650	Lysine acetyltransferase 6B	10	74825582-75032622	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006104	Supported		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
SAMD8	FLJ25082, SMSr	ENSG00000156671	Sterile alpha motif domain containing 8	10	75099586-75182123	Predicted membrane proteins	Evidence at protein level	HPA044402			Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
RAB11FIP1	FLJ22524, FLJ22622, Rab11-FIP1, RCP	ENSG00000156675	RAB11 family interacting protein 1	8	37858618-37899467	Predicted intracellular proteins	Evidence at protein level	CAB017037, HPA023904, HPA024010, HPA025960	Enhanced		Enhanced	Vesicles	Renal cancer:1.14e-6 (favourable), Head and neck cancer:6.61e-4 (favourable)	Mixed	Expressed in all			lung: 111.7	Cell line enhanced		K-562: 65.6
UNC5D	KIAA1777, Unc5h4	ENSG00000156687	Unc-5 netrin receptor D	8	35235457-35796550	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042940	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 9.2;duodenum: 6.1;prostate: 8.3	cervix, uterine: 3.4	Cell line enhanced		HEK 293: 2.7;NTERA-2: 9.6;SH-SY5Y: 3.5;U-251 MG: 2.5
GLYATL2	BXMAS2-10, MGC24009	ENSG00000156689	Glycine-N-acyltransferase like 2	11	58834065-58904215	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060292, HPA065454	Uncertain		Approved	Mitochondria	Endometrial cancer:9.05e-7 (favourable)	Tissue enhanced	Group enriched	6	breast: 14.3;cervix, uterine: 27.5;gallbladder: 11.0	salivary gland: 3.0	Cell line enhanced		BJ hTERT+: 4.1;HAP1: 5.9;SK-BR-3: 10.2;U-2197: 6.0
UTP14A	NY-CO-16, SDCCAG16	ENSG00000156697	UTP14A small subunit processome component	X	129906121-129929761	Predicted intracellular proteins	Evidence at protein level	HPA047217, HPA054023	Uncertain		Supported	Nucleoli<br>Cytosol	Renal cancer:8.12e-8 (unfavourable), Head and neck cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 18.5	Expressed in all		
AIFM1	AIF, CMTX4, NAMSD, PDCD8	ENSG00000156709	Apoptosis inducing factor mitochondria associated 1	X	130129362-130165887	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB003764, HPA030611	Enhanced				Renal cancer:4.42e-10 (favourable)	Expressed in all	Expressed in all			kidney: 158.1	Expressed in all		
MAPK13	p38delta, PRKM13, SAPK4	ENSG00000156711	Mitogen-activated protein kinase 13	6	36127809-36144524	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007667, CAB025854	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:9.00e-4 (favourable)	Expressed in all	Mixed			skin: 93.7	Cell line enhanced		HBEC3-KT: 107.0
BAG4	SODD	ENSG00000156735	BCL2 associated athanogene 4	8	38176533-38213301	Predicted intracellular proteins	Evidence at protein level	CAB013716, HPA018951	Approved					Expressed in all	Expressed in all			cerebral cortex: 27.1	Expressed in all		
MS4A1	B1, Bp35, CD20, MS4A2	ENSG00000156738	Membrane spanning 4-domains A1	11	60455752-60470760	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000015, HPA014341, HPA014391	Enhanced		Supported	Plasma membrane	Breast cancer:4.34e-5 (favourable)	Mixed	Group enriched	15	appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8	urinary bladder: 38.3	Group enriched	19	Daudi: 534.8;U-698: 258.0
TBC1D31	Gm85, MGC21654, WDR67	ENSG00000156787	TBC1 domain family member 31	8	123041968-123152153	Predicted intracellular proteins	Evidence at protein level	HPA023710	Approved		Approved	Centrosome	Lung cancer:2.91e-4 (unfavourable)	Mixed	Mixed			testis: 8.4	Expressed in all		
WDYHV1	C8orf32, FLJ10204	ENSG00000156795	WDYHV motif containing 1	8	123416725-123467230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024823, HPA053680	Approved		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:4.93e-5 (unfavourable), Liver cancer:3.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 18.5	Expressed in all		
ATAD2	CT137, DKFZp667N1320, MGC29843, MGC5254, PRO2000	ENSG00000156802	ATPase family, AAA domain containing 2	8	123319850-123416350	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029424, CAB056158	Enhanced		Enhanced	Nucleoplasm	Renal cancer:8.33e-15 (unfavourable), Endometrial cancer:2.04e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.4	Expressed in all		
FBXO32	ATROGIN1, Fbx32, MAFbx	ENSG00000156804	F-box protein 32	8	123497889-123541206	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065209			Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.73e-4 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 146.8	skeletal muscle: 88.6	Group enriched	6	HDLM-2: 163.0;U-251 MG: 43.0
NSMCE2	C8orf36, FLJ32440, MMS21, NSE2, ZMIZ7	ENSG00000156831	NSE2/MMS21 homolog, SMC5-SMC6 complex SUMO ligase	8	125091679-125367120	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051614, HPA065734	Supported		Supported	Nucleus<br>Nuclear bodies	Liver cancer:7.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 30.0	Expressed in all		
ZNF689	FLJ90415	ENSG00000156853	Zinc finger protein 689	16	30602558-30624012	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054095, HPA055385	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Pancreatic cancer:9.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.4	Expressed in all		
PRR14	MGC3121	ENSG00000156858	Proline rich 14	16	30650717-30656440	Predicted intracellular proteins	Evidence at protein level	HPA052022, HPA060265	Uncertain		Approved	Nucleoplasm	Cervical cancer:8.19e-5 (favourable)	Expressed in all	Expressed in all			spleen: 20.0	Expressed in all		
FBRS	FBS, FBS1, FLJ11618	ENSG00000156860	Fibrosin	16	30658431-30670814	Predicted intracellular proteins	Evidence at protein level	HPA044117	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 78.0	Expressed in all		
FRRS1	SDFR2, SDR2	ENSG00000156869	Ferric chelate reductase 1	1	99708703-99766631	Predicted membrane proteins	Evidence at protein level	HPA017883	Approved				Renal cancer:6.53e-4 (unfavourable)	Expressed in all	Mixed			placenta: 15.8	Cell line enhanced		HEL: 33.4
PHKG2		ENSG00000156873	Phosphorylase kinase catalytic subunit gamma 2	16	30748270-30761176	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065618, HPA068751			Supported	Cytosol	Lung cancer:1.90e-4 (favourable), Cervical cancer:7.90e-4 (favourable), Pancreatic cancer:8.02e-4 (favourable), Colorectal cancer:9.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 149.4	Expressed in all		
MFSD14A	DKFZP564L0864, HIAT1	ENSG00000156875	Major facilitator superfamily domain containing 14A	1	100038097-100083377	Predicted membrane proteins	Evidence at protein level	HPA073681			Approved	Vesicles	Liver cancer:2.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 195.0	Expressed in all		
SASS6	DKFZp761A078, FLJ22097, SAS-6, SAS6	ENSG00000156876	SAS-6 centriolar assembly protein	1	100083563-100132955	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028187	Uncertain		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			testis: 13.3	Mixed		
COX6A2		ENSG00000156885	Cytochrome c oxidase subunit 6A2	16	31427731-31428428	Predicted intracellular proteins, Transporters	Evidence at protein level							Group enriched	Group enriched	23	heart muscle: 687.3;skeletal muscle: 1846.8	esophagus: 54.9	Cell line enhanced		HSkMC: 1.6;SiHa: 1.0;U-266/84: 7.0
ITGAD	ADB2, CD11d	ENSG00000156886	Integrin subunit alpha D	16	31393312-31426505	CD markers, Predicted membrane proteins	Evidence at protein level	HPA026786	Uncertain					Mixed	Tissue enriched	5	spleen: 27.9	lymph node: 5.1	Not detected		
ADGRG4	GPR112, PGR17, RP1-299I16	ENSG00000156920	Adhesion G protein-coupled receptor G4	X	136300963-136416888	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035324	Uncertain					Not detected	Tissue enhanced		duodenum: 2.5;small intestine: 1.7	fallopian tube: 0.5	Not detected		
ZIC3	HTX, HTX1, ZNF203	ENSG00000156925	Zic family member 3	X	137566142-137577691	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052936, HPA069523	Approved		Supported	Nucleoplasm		Tissue enriched	Group enriched	12	cerebral cortex: 1.6;testis: 1.3	bone marrow,skin: 0.1	Group enriched	38	AF22: 39.4;NTERA-2: 44.7
MALSU1	C7orf30, mtRsfA	ENSG00000156928	Mitochondrial assembly of ribosomal large subunit 1	7	23298739-23311729	Predicted secreted proteins	Evidence at protein level	HPA020487, HPA052210	Approved		Enhanced	Mitochondria	Head and neck cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 5.2	Expressed in all		
VPS8	FLJ32099, KIAA0804	ENSG00000156931	VPS8, CORVET complex subunit	3	184812143-185052614	Predicted intracellular proteins	Evidence at protein level	HPA036871	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 31.2	Expressed in all		
GALK2	GK2	ENSG00000156958	Galactokinase 2	15	49155656-49367869	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043564, HPA048267	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.88e-5 (favourable), Endometrial cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			kidney: 31.8	Expressed in all		
LHFPL4		ENSG00000156959	Lipoma HMGIC fusion partner-like 4	3	9498361-9553802	Predicted membrane proteins	Evidence at protein level	HPA041421	Uncertain		Approved	Nucleus<br>Golgi apparatus		Group enriched	Tissue enriched	9	cerebral cortex: 23.1	adrenal gland: 2.6	Cell line enhanced		NTERA-2: 4.4;SCLC-21H: 11.9;SH-SY5Y: 13.4;U-266/84: 7.9;WM-115: 3.9
B3GNT7	beta3GnT7	ENSG00000156966	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7	2	231395543-231401164	Predicted secreted proteins	Evidence at protein level	HPA035625, HPA035626	Enhanced				Thyroid cancer:6.00e-4 (favourable)	Expressed in all	Tissue enhanced		rectum: 72.7	colon: 54.1	Cell line enhanced		CAPAN-2: 16.3;HEL: 13.4;THP-1: 8.9;WM-115: 22.2
MPV17L	FLJ39599, MLPH1, MLPH2, MPV17L1	ENSG00000156968	MPV17 mitochondrial inner membrane protein like	16	15395754-15413268	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041180	Uncertain		Supported	Vesicles	Renal cancer:1.48e-11 (favourable)	Mixed	Mixed			breast: 10.3	Cell line enhanced		HMC-1: 35.5
BUB1B	Bub1A, BUBR1, MAD3L, SSK1	ENSG00000156970	BUB1 mitotic checkpoint serine/threonine kinase B	15	40161023-40221136	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008419			Supported	Cytosol	Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.3	lymph node: 14.9	Mixed		
PDE6D	JBTS22	ENSG00000156973	Phosphodiesterase 6D	2	231732425-231786272	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037433, HPA037434	Uncertain				Renal cancer:4.02e-5 (unfavourable), Urothelial cancer:4.97e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.3	Expressed in all		
EIF4A2	BM-010, DDX2B, EIF4A, EIF4F	ENSG00000156976	Eukaryotic translation initiation factor 4A2	3	186783205-186789900	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011690, HPA068286	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			ovary: 726.0	Expressed in all		
BRPF1	BR140	ENSG00000156983	Bromodomain and PHD finger containing 1	3	9731729-9748018	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003359	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.20e-5 (unfavourable), Prostate cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.3	Expressed in all		
RPUSD3	MGC29784	ENSG00000156990	RNA pseudouridylate synthase domain containing 3	3	9837849-9844602	Predicted intracellular proteins	Evidence at protein level	HPA037551, HPA037552	Uncertain		Approved	Nucleus	Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 54.0	Expressed in all		
SST	SMST	ENSG00000157005	Somatostatin	3	187668906-187670399	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000075, HPA019472, CAB034105	Enhanced	Supported			Endometrial cancer:1.93e-5 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 211.9;duodenum: 376.3;stomach: 305.7	small intestine: 142.4	Group enriched	5	EFO-21: 20.9;U-2 OS: 42.8
TATDN2	KIAA0218	ENSG00000157014	TatD DNase domain containing 2	3	10248023-10281218	Predicted intracellular proteins	Evidence at protein level	HPA036822, HPA058001	Approved		Supported	Nucleus<br>Nuclear speckles<br>Cytosol	Pancreatic cancer:4.66e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.3	Expressed in all		
GHRL	ghrelin, MTLRP, obestatin	ENSG00000157017	Ghrelin and obestatin prepropeptide	3	10285675-10292947	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014246, CAB022731	Enhanced					Mixed	Tissue enriched	8	stomach: 156.2	duodenum: 19.0	Cell line enhanced		Karpas-707: 10.4
SEC13	D3S1231E, npp-20, SEC13L1, SEC13R	ENSG00000157020	SEC13 homolog, nuclear pore and COPII coat complex component	3	10293131-10321178	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035292, HPA057943	Approved		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 120.0	Expressed in all		
EXOG	ENDOGL1, ENDOGL2, ENGL, ENGL-a, ENGL-b	ENSG00000157036	Exo/endonuclease G	3	38496127-38542161	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012531	Enhanced				Pancreatic cancer:1.92e-5 (favourable), Prostate cancer:4.90e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.4	Expressed in all		
NTAN1		ENSG00000157045	N-terminal asparagine amidase	16	15037853-15056079	Predicted intracellular proteins	Evidence at protein level	HPA051418			Approved	Nucleoplasm<br>Golgi apparatus	Glioma:8.85e-4 (unfavourable), Stomach cancer:9.07e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 20.4	Expressed in all		
SHCBP1L	C1orf14	ENSG00000157060	SHC binding and spindle associated 1 like	1	182899865-182953525	Predicted intracellular proteins	Evidence at protein level	HPA036124, HPA036125, HPA064821	Enhanced					Tissue enhanced	Tissue enriched	989	testis: 98.9	all non-specific tissues: 0.0	Not detected		
NMNAT2	C1orf15, KIAA0479, PNAT2	ENSG00000157064	Nicotinamide nucleotide adenylyltransferase 2	1	183248237-183418602	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061714	Enhanced					Mixed	Tissue enriched	6	cerebral cortex: 73.5	testis: 13.3	Cell line enhanced		SCLC-21H: 91.4;U-2197: 42.4;U-87 MG: 34.4
ZFYVE9	MADHIP, PPP1R173, SARA, SMADIP	ENSG00000157077	Zinc finger FYVE-type containing 9	1	52142094-52346686	Predicted intracellular proteins	Evidence at protein level	CAB017702, HPA065852, HPA065862	Approved		Enhanced	Vesicles<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 45.2	Mixed		
ATP2B2	PMCA2	ENSG00000157087	ATPase plasma membrane Ca2+ transporting 2	3	10324023-10708031	Enzymes, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005606	Enhanced					Tissue enhanced	Tissue enriched	7	cerebral cortex: 64.7	salivary gland: 9.7	Group enriched	7	EFO-21: 3.0;RPMI-8226: 5.4;SCLC-21H: 4.2;SH-SY5Y: 1.2
LYZL4	LYC4, MGC26768	ENSG00000157093	Lysozyme like 4	3	42397078-42410600	Predicted secreted proteins	Evidence at protein level	HPA038806	Approved					Not detected	Tissue enriched	58	testis: 43.8	cerebral cortex: 0.7	Not detected		
SLC6A1	GABATHG, GABATR, GAT1	ENSG00000157103	Solute carrier family 6 member 1	3	10992724-11039247	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013341, CAB022293	Enhanced		Uncertain	Mitochondria	Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable)	Group enriched	Group enriched	5	cerebral cortex: 119.4;liver: 50.4	parathyroid gland: 16.0	Not detected		
SMG1	ATX, KIAA0421, LIP	ENSG00000157106	SMG1, nonsense mediated mRNA decay associated PI3K related kinase	16	18804853-18926454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006870, HPA031623, HPA073972	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			skin: 50.1	Expressed in all		
FCHO2		ENSG00000157107	FCH domain only 2	5	72955981-73090522	Predicted intracellular proteins	Evidence at protein level	HPA037685, HPA037686, HPA077850	Enhanced		Approved	Vesicles<br>Centrosome<br>Cytosol	Renal cancer:7.00e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Mixed		
RBPMS	HERMES	ENSG00000157110	RNA binding protein with multiple splicing	8	30384479-30572261	Predicted intracellular proteins	Evidence at protein level	HPA056999	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			seminal vesicle: 267.6	Cell line enhanced		ASC diff: 222.6
TMEM171	PRP2	ENSG00000157111	Transmembrane protein 171	5	73120292-73131817	Predicted membrane proteins	Evidence at protein level	HPA042308	Approved				Renal cancer:3.93e-10 (favourable)	Mixed	Tissue enhanced		colon: 32.4;rectum: 32.3;thyroid gland: 47.1	duodenum: 26.3	Cell line enhanced		LHCN-M2: 48.9;WM-115: 161.7
KLHL40	KBTBD5, NEM8, SRYP	ENSG00000157119	Kelch like family member 40	3	42685519-42692544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024463, HPA052201	Enhanced					Tissue enhanced	Tissue enriched	14	skeletal muscle: 61.0	prostate: 4.3	Not detected		
C8A		ENSG00000157131	Complement C8 alpha chain	1	56854806-56918221	Disease related genes, Plasma proteins, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	63	liver: 328.8	gallbladder: 5.2	Not detected		
TIMP4		ENSG00000157150	TIMP metallopeptidase inhibitor 4	3	12153051-12159351	Plasma proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	5	adipose tissue: 138.8	cerebral cortex: 27.5	Cell line enhanced		ASC diff: 99.5;HSkMC: 45.7;NTERA-2: 37.0;U-87 MG: 36.7
SYN2	SYNII, SYNIIa, SYNIIb	ENSG00000157152	Synapsin II	3	12004402-12191400	Predicted intracellular proteins	Evidence at protein level	HPA037012, CAB079005		Supported	Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	29	cerebral cortex: 200.0	testis: 6.8	Cell line enhanced		HMC-1: 4.4;NTERA-2: 4.3;SCLC-21H: 4.0;SH-SY5Y: 14.4
NRG1	GGF, HGL, HRG, NDF, NRG1-IT2	ENSG00000157168	Neuregulin 1	8	31639386-32767959	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010964	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 20.0	Cell line enhanced		A549: 130.4;hTEC/SVTERT24-B: 101.2
C1orf27	FLJ20505, odr-4, TTG1	ENSG00000157181	Chromosome 1 open reading frame 27	1	186375838-186421378	Predicted membrane proteins	Evidence at protein level	HPA015988, HPA031352	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Ovarian cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.3	Expressed in all		
CPT2	CPT1, CPTASE	ENSG00000157184	Carnitine palmitoyltransferase 2	1	53196429-53214197	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028201, HPA028202, HPA028214	Enhanced		Supported	Nucleoplasm<br>Nucleoli<br>Mitochondria	Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			liver: 25.9	Expressed in all		
NECAP2	FLJ10420	ENSG00000157191	NECAP endocytosis associated 2	1	16440672-16460078	Predicted intracellular proteins	Evidence at protein level	HPA028077	Approved		Approved	Endoplasmic reticulum	Liver cancer:6.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 86.0	Expressed in all		
LRP8	APOER2, HSZ75190, LRP-8, MCI1	ENSG00000157193	LDL receptor related protein 8	1	53242364-53328070	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073031	Enhanced				Endometrial cancer:3.46e-6 (unfavourable), Lung cancer:7.02e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 25.2;testis: 46.9;thyroid gland: 87.5	appendix: 7.7	Expressed in all		
CDCP2		ENSG00000157211	CUB domain containing protein 2	1	54132968-54153770	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA031143	Uncertain					Not detected	Not detected			breast,cervix, uterine,spleen: 0.1	Not detected		
PAXIP1	CAGF28, CAGF29, PAXIP1L, PTIP, TNRC2	ENSG00000157212	PAX interacting protein 1	7	154943687-155003084	Predicted intracellular proteins	Evidence at protein level	HPA006694, HPA016950	Enhanced		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			testis: 16.2	Expressed in all		
STEAP2	IPCA-1, PCANAP1, STAMP1, STMP	ENSG00000157214	STEAP2 metalloreductase	7	90167590-90238137	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029115, HPA055603	Uncertain		Supported	Vesicles		Tissue enriched	Tissue enriched	11	prostate: 208.0	parathyroid gland: 18.7	Cell line enhanced		A549: 20.3;CAPAN-2: 42.2;U-138 MG: 26.9
SSBP3	CSDP, FLJ10355, SSDP, SSDP1	ENSG00000157216	Single stranded DNA binding protein 3	1	54225432-54413479	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:2.48e-9 (favourable), Endometrial cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 117.5	Expressed in all		
HTR5A	5-HT5A	ENSG00000157219	5-hydroxytryptamine receptor 5A	7	155070324-155085749	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB017467	Approved					Not detected	Tissue enriched	11	cerebral cortex: 8.6	testis: 0.7	Not detected		
CLDN12		ENSG00000157224	Claudin 12	7	90383721-90513402	Predicted membrane proteins	Evidence at protein level	HPA026945	Approved				Cervical cancer:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 40.5	Mixed		
MMP14	MT1-MMP	ENSG00000157227	Matrix metallopeptidase 14	14	22836557-22849027	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009918, HPA051432	Approved		Approved	Intermediate filaments<br>Cytosol	Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 236.6	Cell line enhanced		HHSteC: 664.7
FZD1	DKFZp564G072	ENSG00000157240	Frizzled class receptor 1	7	91264364-91271326	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013008	Approved		Supported	Plasma membrane	Renal cancer:8.87e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 32.4	Mixed		
GATAD1	FLJ22489, ODAG, RG083M05.2	ENSG00000157259	GATA zinc finger domain containing 1	7	92447453-92458836	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006105, HPA072785			Supported	Nucleus		Expressed in all	Expressed in all			thyroid gland: 42.3	Expressed in all		
SUSD3	MGC26847	ENSG00000157303	Sushi domain containing 3	9	93058688-93085138	Predicted membrane proteins	Evidence at protein level	HPA042310	Uncertain		Approved	Nucleus	Breast cancer:5.13e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 91.6	lymph node: 66.4	Cell line enhanced		Daudi: 107.9;NB-4: 49.1;RPMI-8226: 56.9
TMED6	MGC23911, p24g5, p24gamma5	ENSG00000157315	Transmembrane p24 trafficking protein 6	16	69343248-69351809	Predicted membrane proteins	Evidence at protein level	HPA012532	Approved				Endometrial cancer:7.74e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 35.3;pancreas: 61.2;stomach: 37.5	epididymis: 21.3	Cell line enhanced		Hep G2: 10.1
CLEC18A	MRCL	ENSG00000157322	C-type lectin domain family 18 member A	16	69950705-69964452	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048976	Uncertain					Tissue enriched	Group enriched	7	kidney: 15.7;testis: 3.7	adrenal gland: 1.3	Not detected		
DHRS4	FLJ11008, humNRDR, SCAD-SRL, SDR-SRL, SDR25C2	ENSG00000157326	Dehydrogenase/reductase 4	14	23953586-23969279	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023972	Uncertain		Approved	Nuclear membrane<br>Vesicles	Renal cancer:4.55e-6 (favourable)	Expressed in all	Expressed in all			kidney: 149.0	Mixed		
C1orf158	MGC35194	ENSG00000157330	Chromosome 1 open reading frame 158	1	12746215-12763699	Predicted intracellular proteins	Evidence at transcript level	HPA028396			Uncertain	Cytosol		Group enriched	Group enriched	15	fallopian tube: 42.6;testis: 47.5	lung: 2.9	Not detected		
CLEC18C	MGC34761	ENSG00000157335	C-type lectin domain family 18 member C	16	70173322-70187361	Predicted secreted proteins	Evidence at transcript level	HPA048976	Uncertain					Tissue enriched	Group enriched	23	kidney: 11.4;testis: 3.6	duodenum: 0.3	Not detected		
ARMC12	C6orf81, FLJ25390	ENSG00000157343	Armadillo repeat containing 12	6	35737032-35749079	Predicted intracellular proteins	Evidence at protein level	HPA030895			Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	8	testis: 63.2	epididymis: 7.5	Cell line enhanced		HSkMC: 4.9;MOLT-4: 4.0
DDX19B	DBP5, DDX19	ENSG00000157349	DEAD-box helicase 19B	16	70289663-70335283	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB037229, CAB037284, HPA046380, HPA066668	Approved		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			testis: 82.8	Mixed		
ST3GAL2	SIAT4B, ST3GalA.2, ST3GALII	ENSG00000157350	ST3 beta-galactoside alpha-2,3-sialyltransferase 2	16	70375978-70439237	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017270	Approved		Approved	Vesicles	Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable)	Expressed in all	Mixed			appendix: 15.2	Mixed		
FUK	FLJ39408	ENSG00000157353	Fucokinase	16	70454421-70480274	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041971	Approved		Approved	Vesicles	Urothelial cancer:8.38e-4 (favourable), Renal cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.9	Mixed		
IL34	C16orf77, IL-34, MGC34647	ENSG00000157368	Interleukin 34	16	70579895-70660682	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.52e-8 (unfavourable), Cervical cancer:7.41e-4 (favourable), Head and neck cancer:9.69e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 58.0;spleen: 145.6	cerebral cortex: 20.8	Cell line enhanced		NTERA-2: 5.5;U-138 MG: 3.5
DHRS1	FLJ25430, MGC20204, SDR19C1	ENSG00000157379	Dehydrogenase/reductase 1	14	24290598-24299833	Predicted intracellular proteins	Evidence at protein level	HPA000599	Approved		Approved	Nucleus<br>Centrosome<br>Cytosol	Liver cancer:1.18e-5 (favourable), Lung cancer:6.83e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 78.3	Expressed in all		
CACNA1D	CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2	ENSG00000157388	Calcium voltage-gated channel subunit alpha1 D	3	53328963-53813733	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA020215	Uncertain		Approved	Nuclear membrane	Renal cancer:8.34e-8 (favourable)	Mixed	Mixed			fallopian tube: 13.5	Cell line enhanced		HMC-1: 19.6;RPMI-8226: 38.4;SK-BR-3: 7.4
ARSE	CDPX, CDPX1	ENSG00000157399	Arylsulfatase E (chondrodysplasia punctata 1)	X	2934632-2968310	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA060518, HPA070651	Approved		Supported	Golgi apparatus	Colorectal cancer:8.95e-4 (favourable)	Mixed	Tissue enhanced		kidney: 41.3;liver: 49.3	pancreas: 23.9	Cell line enhanced		A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
KIT	C-Kit, CD117, PBT, SCFR	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	4	54657918-54740715	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB003288, HPA004471, CAB068253, CAB072867, HPA073252	Enhanced	Supported	Supported	Plasma membrane	Renal cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		breast: 133.6	thyroid gland: 78.7	Group enriched	14	HEL: 220.1;HMC-1: 434.1
HYDIN	CILD5, DKFZp434D0513, KIAA1864, PPP1R31	ENSG00000157423	HYDIN, axonemal central pair apparatus protein	16	70807378-71230722	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067155, HPA074129	Enhanced		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		fallopian tube: 9.1;parathyroid gland: 5.4;testis: 6.4	epididymis: 2.6	Cell line enhanced		RPTEC TERT1: 2.1;SiHa: 6.4
AASDH	ACSF4, LYS2, NRPS998	ENSG00000157426	Aminoadipate-semialdehyde dehydrogenase	4	56338287-56387508	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036472, HPA036473	Approved					Expressed in all	Mixed			parathyroid gland: 15.1	Expressed in all		
ZNF19	KOX12, MGC51021	ENSG00000157429	Zinc finger protein 19	16	71464555-71565089	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063685	Approved		Approved	Mitochondria		Mixed	Expressed in all			testis: 29.2	Mixed		
CACNA2D3	HSA272268	ENSG00000157445	Calcium voltage-gated channel auxiliary subunit alpha2delta 3	3	54122547-55074557	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030849, HPA030850			Uncertain	Nucleus<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 16.2	adrenal gland: 5.4	Cell line enhanced		BJ hTERT+: 3.3;HAP1: 1.9;HeLa: 6.3
RNF111	ARK, Arkadia, DKFZP761D081, FLJ38008	ENSG00000157450	Ring finger protein 111	15	58865175-59097419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038576, HPA038577	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 22.9	Expressed in all		
CCNB2	HsT17299	ENSG00000157456	Cyclin B2	15	59105078-59125045	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008873, CAB009575	Enhanced		Enhanced	Golgi apparatus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.74e-5 (unfavourable), Melanoma:3.21e-5 (unfavourable), Liver cancer:2.83e-4 (unfavourable), Lung cancer:4.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 122.6	bone marrow: 44.7	Expressed in all		
FAM81A	MGC26690	ENSG00000157470	Family with sequence similarity 81 member A	15	59372693-59523549	Predicted intracellular proteins	Evidence at protein level	HPA001847, HPA065797	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 33.3	fallopian tube: 9.9	Cell line enhanced		Daudi: 47.3
MYO1E	HuncM-IC, MGC104638, MYO1C	ENSG00000157483	Myosin IE	15	59132434-59372900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023886	Approved				Lung cancer:1.57e-6 (unfavourable), Endometrial cancer:4.19e-4 (favourable), Pancreatic cancer:7.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 67.0	Mixed		
APPL1	APPL	ENSG00000157500	Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1	3	57227737-57273468	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011138, HPA073477	Approved		Uncertain	Mitotic spindle<br>Centrosome	Renal cancer:7.26e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Expressed in all		
MUM1L1	FLJ33516	ENSG00000157502	MUM1 like 1	X	106168305-106208956	Predicted intracellular proteins	Evidence at protein level	HPA000168, HPA020464	Enhanced				Thyroid cancer:5.95e-4 (unfavourable)	Mixed	Tissue enriched	7	ovary: 226.8	testis: 33.9	Cell line enhanced		AF22: 2.9;HSkMC: 2.1;LHCN-M2: 4.6;NTERA-2: 2.1;T-47d: 1.7
AFAP1L1	FLJ36748	ENSG00000157510	Actin filament associated protein 1 like 1	5	149271871-149341802	Predicted intracellular proteins	Evidence at protein level						Colorectal cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 29.8	Cell line enhanced		BEWO: 57.1;TIME: 37.4;WM-115: 105.1
TSC22D3	DIP, DSIPI, GILZ, hDIP, TSC-22R	ENSG00000157514	TSC22 domain family member 3	X	107713221-107777342	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001916, CAB034364	Approved		Approved	Nuclear speckles<br>Golgi apparatus<br>Cytosol	Endometrial cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 548.3	Cell line enhanced		ASC diff: 261.1;HHSteC: 527.6;hTCEpi: 413.6;Karpas-707: 261.7
DSCR3	DCRA	ENSG00000157538	DSCR3 arrestin fold containing	21	37223420-37267919	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023288	Uncertain		Approved	Mitochondria	Renal cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			kidney: 32.2	Expressed in all		
DYRK1A	DYRK, DYRK1, MNBH	ENSG00000157540	Dual specificity tyrosine phosphorylation regulated kinase 1A	21	37365790-37517450	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015323, HPA015810	Approved		Approved	Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
KCNJ6	BIR1, GIRK2, hiGIRK2, KATP2, KCNJ7, Kir3.2	ENSG00000157542	Potassium voltage-gated channel subfamily J member 6	21	37607376-37916446	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enriched	9	cerebral cortex: 2.6	spleen,stomach,testis: 0.2	Cell line enhanced		LHCN-M2: 7.1;TIME: 1.8
KCNJ15	IRKK, Kir1.3, Kir4.2	ENSG00000157551	Potassium voltage-gated channel subfamily J member 15	21	38157034-38307357	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016702	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 261.3;thyroid gland: 216.3	lung: 63.4	Cell line enhanced		ASC TERT1: 48.4;HBEC3-KT: 50.0;RPTEC TERT1: 51.4;RT4: 65.6
ERG	erg-3, p55	ENSG00000157554	ERG, ETS transcription factor	21	38380027-38661780	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018377, HPA046598	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:6.18e-6 (unfavourable), Renal cancer:3.94e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.8	Cell line enhanced		HUVEC TERT2: 115.5;MOLT-4: 38.1;REH: 138.0;TIME: 92.4
ETS2		ENSG00000157557	ETS proto-oncogene 2, transcription factor	21	38805307-38824955	Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	HPA003176			Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 252.7	Cell line enhanced		HEL: 249.9
TSPAN18	TSPAN	ENSG00000157570	Tetraspanin 18	11	44726465-44932421	Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			smooth muscle: 69.3	Cell line enhanced		AF22: 36.4;CAPAN-2: 54.1;HDLM-2: 47.8;NTERA-2: 34.7;RH-30: 37.3;SCLC-21H: 38.6;SH-SY5Y: 39.5
LCA5L	C21orf13, MGC33295	ENSG00000157578	LCA5L, lebercilin like	21	39405844-39445805	Predicted intracellular proteins	Evidence at protein level	HPA019790, HPA032010	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	17	testis: 201.6	fallopian tube: 12.2	Mixed		
SLC35B2	UGTrel4	ENSG00000157593	Solute carrier family 35 member B2	6	44254096-44257890	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029638	Approved		Approved	Vesicles	Liver cancer:8.59e-5 (unfavourable), Prostate cancer:6.07e-4 (favourable), Breast cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 59.2	Expressed in all		
TMEM164	FLJ22679, RP13-360B22.2	ENSG00000157600	Transmembrane protein 164	X	110002631-110182734	Predicted membrane proteins	Evidence at protein level	HPA038784	Approved		Approved	Vesicles<br>Cell Junctions	Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable)	Expressed in all	Expressed in all			lung: 26.7	Expressed in all		
MX1	IFI-78K, MxA	ENSG00000157601	MX dynamin like GTPase 1	21	41420304-41459214	Predicted intracellular proteins	Evidence at protein level	HPA030917, HPA030918, HPA049724	Approved	Approved	Supported	Nuclear membrane<br>Cytosol	Renal cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 114.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 786.8;BJ hTERT+ SV40 Large T+ RasG12V: 735.0;SK-MEL-30: 205.0
CREB3L1	OASIS	ENSG00000157613	CAMP responsive element binding protein 3 like 1	11	46277661-46321422	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA024069, CAB026151	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 66.0	Cell line enhanced		fHDF/TERT166: 248.2
C2CD2	C21orf25, C21orf258, DKFZP586F0422, TMEM24L	ENSG00000157617	C2 calcium dependent domain containing 2	21	41885112-41953890	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030922, HPA030924	Enhanced		Approved	Nucleoplasm	Renal cancer:7.68e-5 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 110.0	spleen: 46.2	Cell line enhanced		ASC diff: 54.3
TAB3	MAP3K7IP3	ENSG00000157625	TGF-beta activated kinase 1 and MAP3K7 binding protein 3	X	30827442-30975084	Predicted intracellular proteins	Evidence at protein level	HPA034980, HPA034981	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:8.45e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.6	Expressed in all		
SLC38A10	MGC15523, PP1744	ENSG00000157637	Solute carrier family 38 member 10	17	81245000-81295547	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA021374, HPA023161, HPA024631	Enhanced		Enhanced	Golgi apparatus	Renal cancer:5.34e-7 (unfavourable), Pancreatic cancer:2.92e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 44.6	Expressed in all		
C9orf43	MGC17358	ENSG00000157653	Chromosome 9 open reading frame 43	9	113410054-113429684	Predicted intracellular proteins	Evidence at protein level	HPA021310			Approved	Cytosol		Mixed	Tissue enriched	43	testis: 73.9	parathyroid gland: 1.7	Mixed		
PALM2-AKAP2		ENSG00000157654	PALM2-AKAP2 readthrough	9	109780309-110172512	Predicted intracellular proteins	Evidence at protein level	HPA058905, HPA074153	Uncertain					Not detected	Tissue enhanced		adipose tissue: 23.4	heart muscle: 19.7	Cell line enhanced		hTEC/SVTERT24-B: 27.6;RH-30: 52.6;WM-115: 31.6
ZNF618	KIAA1952, NEDD10	ENSG00000157657	Zinc finger protein 618	9	113876282-114056591	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023116, HPA061732	Uncertain		Approved	Nucleoplasm	Renal cancer:5.22e-7 (favourable), Glioma:8.34e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.5	Mixed		
DGKI	DGK-IOTA	ENSG00000157680	Diacylglycerol kinase iota	7	137381037-137847092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021924			Approved	Nucleoplasm		Mixed	Group enriched	11	cerebral cortex: 9.3;thyroid gland: 33.0	heart muscle,smooth muscle: 1.8	Cell line enhanced		SCLC-21H: 7.5;U-2197: 16.4;U-87 MG: 6.3
TMEM268	C9orf91, DKFZp547P234, FLJ38045	ENSG00000157693	Transmembrane protein 268	9	114611206-114646422	Predicted membrane proteins	Evidence at transcript level	HPA017199	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:3.61e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.3	Expressed in all		
SVOPL	MGC46715	ENSG00000157703	SVOP like	7	138594285-138701352	Predicted membrane proteins	Evidence at transcript level	HPA018035	Uncertain					Mixed	Tissue enriched	5	parathyroid gland: 14.3	fallopian tube: 2.6	Cell line enhanced		HMC-1: 3.7;NTERA-2: 1.2;T-47d: 4.1
SNX22	FLJ13952	ENSG00000157734	Sorting nexin 22	15	64151715-64157481	Predicted intracellular proteins	Evidence at protein level	HPA038470	Approved		Approved	Nucleoplasm<br>Vesicles	Breast cancer:2.89e-5 (favourable), Thyroid cancer:2.19e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 16.2;thyroid gland: 14.4	lymph node: 9.0	Cell line enhanced		Daudi: 13.5;SCLC-21H: 4.9
UBN2	FLJ25778, KIAA2030	ENSG00000157741	Ubinuclein 2	7	139230356-139308236	Predicted intracellular proteins	Evidence at protein level	HPA019743, HPA020122, HPA020124	Uncertain		Supported	Nucleoplasm	Head and neck cancer:4.49e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 26.4	skin: 11.8	Expressed in all		
BRAF	BRAF1	ENSG00000157764	B-Raf proto-oncogene, serine/threonine kinase	7	140719327-140924764	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001328, CAB004552, HPA071048	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
SLC34A2	NAPI-3B	ENSG00000157765	Solute carrier family 34 member 2	4	25655301-25678748	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037989	Enhanced					Tissue enhanced	Tissue enriched	10	lung: 1121.1	fallopian tube: 111.8	Group enriched	76	BEWO: 31.0;EFO-21: 114.1;RPTEC TERT1: 66.5
ACAN	AGC1, CSPG1, CSPGCP, MSK16	ENSG00000157766	Aggrecan	15	88803443-88875354	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016377, HPA038241, HPA038242	Enhanced				Renal cancer:1.47e-6 (unfavourable)	Mixed	Tissue enhanced		seminal vesicle: 5.0	testis: 3.3	Cell line enriched	5	WM-115: 28.1
PSMG3	C7orf48, MGC10911, PAC3	ENSG00000157778	Proteasome assembly chaperone 3	7	1567330-1571005	Predicted intracellular proteins	Evidence at protein level	HPA023876	Approved				Liver cancer:2.40e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 46.6	Expressed in all		
CABP1		ENSG00000157782	Calcium binding protein 1	12	120640552-120667324	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051438	Uncertain					Tissue enhanced	Tissue enriched	7	cerebral cortex: 77.4	adipose tissue: 11.2	Cell line enhanced		NTERA-2: 6.8;SCLC-21H: 3.8;U-87 MG: 8.4
WDR19	DYF-2, FLJ23127, IFT144, KIAA1638, NPHP13, ORF26, Oseg6, Pwdmp	ENSG00000157796	WD repeat domain 19	4	39182404-39285810	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039616, HPA058847	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.70e-4 (favourable), Liver cancer:4.43e-4 (unfavourable), Prostate cancer:8.58e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 30.7	Mixed		
SLC37A3	DKFZp761N0624	ENSG00000157800	Solute carrier family 37 member 3	7	140293693-140404433	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014713, HPA061841			Supported	Cytosol	Liver cancer:4.78e-5 (unfavourable), Cervical cancer:9.54e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 73.0	Mixed		
AP3S2	sigma3b	ENSG00000157823	Adaptor related protein complex 3 sigma 2 subunit	15	89830599-89894638	Predicted intracellular proteins	Evidence at transcript level	HPA049270	Uncertain		Approved	Vesicles	Renal cancer:5.55e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.7	Expressed in all		
FMNL2	FHOD2, KIAA1902	ENSG00000157827	Formin like 2	2	152335237-152649834	Predicted intracellular proteins	Evidence at protein level	HPA005464	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Liver cancer:9.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 137.8	placenta: 82.9	Cell line enhanced		BEWO: 184.8
GAREM2	FAM59B, FLJ00375, GAREML, KIAA2038	ENSG00000157833	GRB2 associated regulator of MAPK1 subtype 2	2	26173091-26189663	Predicted intracellular proteins	Evidence at protein level	HPA071575			Approved	Cytosol		Mixed	Group enriched	6	cerebral cortex: 23.0;parathyroid gland: 17.8	smooth muscle: 3.4	Cell line enhanced		HAP1: 17.3;U-2 OS: 14.6
SPPL3	DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4	ENSG00000157837	Signal peptide peptidase like 3	12	120762510-120904371	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA004194, HPA059958	Uncertain		Supported	Vesicles<br>Plasma membrane	Liver cancer:1.29e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 84.1	Mixed		
DPYSL5	CRAM, CRMP-5, CRMP5, Ulip6	ENSG00000157851	Dihydropyrimidinase like 5	2	26847747-26950351	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034544, HPA072387	Enhanced		Approved	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	8	cerebral cortex: 31.3;testis: 10.0	adrenal gland: 2.5	Cell line enhanced		AF22: 139.1;HAP1: 122.4;SCLC-21H: 196.8;SH-SY5Y: 105.0
DRC1	C2orf39, CCDC164, CILD21, FLJ32660, MGC16372	ENSG00000157856	Dynein regulatory complex subunit 1	2	26401916-26456711	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	fallopian tube: 62.4;testis: 36.8	lung: 4.7	Not detected		
RAB28		ENSG00000157869	RAB28, member RAS oncogene family	4	13361354-13484365	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044575	Approved				Urothelial cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
FAM213B	C1orf93, MGC26818	ENSG00000157870	Family with sequence similarity 213 member B	1	2586491-2591469	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006403	Approved	Approved	Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.28e-4 (favourable), Liver cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 14.6	Mixed		
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
PANK4	FLJ10782	ENSG00000157881	Pantothenate kinase 4	1	2508533-2526628	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011723, HPA012036, HPA027961	Uncertain		Approved	Cytosol	Renal cancer:1.57e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 3.2	skin: 2.9	Mixed		
CIB4		ENSG00000157884	Calcium and integrin binding family member 4	2	26581202-26641368	Predicted intracellular proteins	Evidence at protein level	HPA036130, HPA036131	Uncertain					Tissue enhanced	Group enriched	10	testis: 20.1;thyroid gland: 4.2	placenta: 1.1	Not detected		
MEGF11	DKFZp434L121, KIAA1781	ENSG00000157890	Multiple EGF like domains 11	15	65895079-66253747	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA017982	Uncertain					Tissue enhanced	Group enriched	6	cerebral cortex: 13.0;fallopian tube: 12.3	testis: 1.9	Cell line enhanced		AN3-CA: 3.1;HEK 293: 2.4;RPTEC TERT1: 7.0;SCLC-21H: 8.5
C12orf43	FLJ12448	ENSG00000157895	Chromosome 12 open reading frame 43	12	121000486-121016502	Predicted intracellular proteins	Evidence at protein level	HPA046148, HPA061739	Uncertain		Enhanced	Nucleoli<br>Golgi apparatus	Liver cancer:1.29e-6 (unfavourable), Lung cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 20.8	Expressed in all		
PEX10	RNF69	ENSG00000157911	Peroxisomal biogenesis factor 10	1	2403964-2413797	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA049458, HPA049755	Approved		Approved	Nucleoplasm	Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.2	Expressed in all		
RER1		ENSG00000157916	Retention in endoplasmic reticulum sorting receptor 1	1	2391775-2405444	Predicted membrane proteins, Transporters	Evidence at protein level	CAB037240, HPA051400	Supported		Enhanced	Golgi apparatus	Renal cancer:8.23e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 186.8	Expressed in all		
RADIL	FLJ10324, KIAA1849, RASIP2	ENSG00000157927	Rap associating with DIL domain	7	4797055-4883719	Predicted intracellular proteins	Evidence at protein level	HPA051776	Approved		Approved	Nucleus<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 9.5	lung: 4.3	Cell line enhanced		AN3-CA: 8.1;SCLC-21H: 12.4;SH-SY5Y: 24.2
SKI		ENSG00000157933	SKI proto-oncogene	1	2228695-2310119	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010449, HPA066567	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 36.2	Expressed in all		
WIPI2	ATG18B, ATG21, CGI-50, DKFZP434J154, DKFZp686P02188, FLJ12979, FLJ14217, FLJ42984	ENSG00000157954	WD repeat domain, phosphoinositide interacting 2	7	5190188-5233826	Predicted intracellular proteins	Evidence at protein level	HPA019852, HPA021488	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.05e-6 (favourable), Endometrial cancer:7.69e-5 (unfavourable), Pancreatic cancer:9.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.7	Expressed in all		
LDLRAP1	ARH, ARH2, DKFZp586D0624, FHCB1, FHCB2, MGC34705	ENSG00000157978	Low density lipoprotein receptor adaptor protein 1	1	25543580-25568886	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB003705, HPA050358	Approved		Approved	Microtubules		Expressed in all	Expressed in all			spleen: 50.9	Mixed		
AGAP1	CENTG2, GGAP1, KIAA1099	ENSG00000157985	ArfGAP with GTPase domain, ankyrin repeat and PH domain 1	2	235494089-236131800	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051405	Uncertain				Liver cancer:2.60e-5 (unfavourable), Renal cancer:6.52e-5 (favourable), Ovarian cancer:9.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.5	Cell line enhanced		SCLC-21H: 93.8
KRTCAP3	KCP3	ENSG00000157992	Keratinocyte associated protein 3	2	27442366-27446481	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047136, HPA060203	Enhanced		Approved	Nucleus<br>Cytosol	Breast cancer:2.67e-5 (favourable)	Expressed in all	Mixed			small intestine: 34.8	Cell line enhanced		A-431: 53.9;CAPAN-2: 60.3;SCLC-21H: 37.2
ANKRD61		ENSG00000157999	Ankyrin repeat domain 61	7	6031376-6036386	Predicted intracellular proteins	Evidence at transcript level	HPA029511	Uncertain					Mixed	Tissue enhanced		testis: 11.0	bone marrow: 4.0	Cell line enhanced		HeLa: 5.6
PAFAH2	HSD-PLA2	ENSG00000158006	Platelet activating factor acetylhydrolase 2	1	25959767-25998157	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018157	Approved				Renal cancer:0.00e+0 (favourable), Endometrial cancer:3.28e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 29.1	Expressed in all		
EXTL1	EXTL, MGC70794	ENSG00000158008	Exostosin like glycosyltransferase 1	1	26019884-26036464	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA037749	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 11.2	skeletal muscle: 4.3	Cell line enriched	10	WM-115: 148.7
SLC30A2	ZNT2	ENSG00000158014	Solute carrier family 30 member 2	1	26037252-26046133	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017979			Approved	Vesicles	Renal cancer:2.86e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 22.0;thyroid gland: 42.4	pancreas: 16.5	Group enriched	5	BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
BRE	BRCC4, BRCC45	ENSG00000158019	Brain and reproductive organ-expressed (TNFRSF1A modulator)	2	27889941-28338901	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017926	Approved		Supported	Cytosol	Liver cancer:6.33e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 189.5	Expressed in all		
TRIM63	IRF, MURF-1, RNF28, SMRZ	ENSG00000158022	Tripartite motif containing 63	1	26051304-26068436	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	16	heart muscle: 101.2;skeletal muscle: 139.3	esophagus: 7.6	Group enriched	35	ASC diff: 11.0;SK-MEL-30: 42.2
WDR66	CaM-IP4, MGC33630	ENSG00000158023	WD repeat domain 66	12	121917862-122003927	Predicted intracellular proteins	Evidence at protein level	HPA039902, HPA040005	Supported		Uncertain	Plasma membrane<br>Cytosol	Endometrial cancer:3.11e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 32.6;testis: 30.7	thyroid gland: 7.4	Cell line enhanced		HBEC3-KT: 22.5;hTCEpi: 21.0;hTERT-HME1: 15.0
MRPL17	MRP-L26, RPML26	ENSG00000158042	Mitochondrial ribosomal protein L17	11	6680782-6683401	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043666, HPA050552	Uncertain		Uncertain	Nucleoli<br>Golgi apparatus<br>Vesicles	Renal cancer:3.15e-7 (unfavourable), Liver cancer:2.59e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 37.0	Expressed in all		
DUSP2	PAC-1	ENSG00000158050	Dual specificity phosphatase 2	2	96143166-96145440	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA071920			Supported	Nucleus<br>Nuclear membrane	Renal cancer:4.97e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 78.9;seminal vesicle: 86.2	lymph node: 50.7	Cell line enhanced		RT4: 27.2;SCLC-21H: 34.8;U-698: 28.6
GRHL3	SOM, TFCP2L4	ENSG00000158055	Grainyhead like transcription factor 3	1	24319322-24364482	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA059960	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Group enriched	11	esophagus: 85.1;skin: 50.1;tonsil: 22.6;urinary bladder: 28.1	testis: 4.3	Cell line enhanced		BEWO: 43.8;HaCaT: 32.1;MCF7: 43.8;RT4: 51.5
UBXN11	SOC, SOCI, UBXD5	ENSG00000158062	UBX domain protein 11	1	26281328-26318363	Predicted intracellular proteins	Evidence at protein level	HPA028600, HPA031357	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:5.90e-6 (unfavourable), Cervical cancer:2.54e-5 (favourable), Endometrial cancer:1.90e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 50.2	Expressed in all		
NLRP14	CLR11.2, GC-LRR, Nalp-iota, NALP14, NOD5, PAN8	ENSG00000158077	NLR family pyrin domain containing 14	11	7020446-7071308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039477	Uncertain		Uncertain	Cytosol		Not detected	Tissue enhanced		testis: 1.6	parathyroid gland: 0.6	Not detected		
PTPDC1	FLJ37312, PTP9Q22	ENSG00000158079	Protein tyrosine phosphatase domain containing 1	9	94030794-94109856	Predicted intracellular proteins	Evidence at protein level	HPA016747, HPA026832	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 14.2	Mixed		
GALNT14	FLJ12691, GalNac-T10, GalNac-T14	ENSG00000158089	Polypeptide N-acetylgalactosaminyltransferase 14	2	30910467-31155202	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030138			Approved	Nucleus<br>Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 40.3	parathyroid gland: 12.8	Cell line enhanced		RPTEC TERT1: 29.5;RT4: 23.6;SCLC-21H: 25.2
NCK1	NCK, NCKalpha	ENSG00000158092	NCK adaptor protein 1	3	136862208-136949823	Predicted intracellular proteins	Evidence at protein level	CAB005063, HPA030766	Supported		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:9.14e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 48.8	Expressed in all		
HPD	4-HPPD, 4HPPD, GLOD3, PPD	ENSG00000158104	4-hydroxyphenylpyruvate dioxygenase	12	121839527-121863596	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038321, HPA038322	Enhanced		Uncertain	Nuclear speckles		Tissue enriched	Group enriched	86	kidney: 529.9;liver: 1293.2	seminal vesicle: 10.5	Cell line enriched	24	Hep G2: 349.1
RHPN1	KIAA1929, ODF5, RHPN	ENSG00000158106	Rhophilin Rho GTPase binding protein 1	8	143368887-143384220	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024288, HPA024671	Approved		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		cerebral cortex: 7.1	parathyroid gland: 4.8	Cell line enhanced		MCF7: 21.9;MOLT-4: 21.1;T-47d: 42.5
TPRG1L	FAM79A, FLJ21811, RP11-46F15.3	ENSG00000158109	Tumor protein p63 regulated 1 like	1	3625002-3630127	Predicted intracellular proteins	Evidence at protein level	HPA063163, CAB079051		Supported	Approved	Vesicles<br>Cytosol	Renal cancer:1.76e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 102.1	Expressed in all		
LRRC43	MGC35140	ENSG00000158113	Leucine rich repeat containing 43	12	122167738-122203471	Predicted intracellular proteins	Evidence at transcript level	HPA039425, HPA047606	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Group enriched	5	fallopian tube: 30.3;testis: 8.5	parathyroid gland: 3.6	Cell line enhanced		HUVEC TERT2: 2.2;SCLC-21H: 2.5
AAED1	C9orf21	ENSG00000158122	AhpC/TSA antioxidant enzyme domain containing 1	9	96639577-96655303	Predicted intracellular proteins	Evidence at protein level	HPA021294	Approved				Renal cancer:3.26e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 15.9	Mixed		
XDH	XO, XOR	ENSG00000158125	Xanthine dehydrogenase	2	31334321-31414715	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062641, HPA069323	Supported		Supported	Nucleus	Urothelial cancer:8.73e-6 (favourable)	Mixed	Tissue enhanced		breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6	colon: 11.2	Cell line enhanced		HBEC3-KT: 14.4;hTERT-HME1: 23.9
XKR8	FLJ10307	ENSG00000158156	XK related 8	1	27959462-27968096	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049984, HPA053529	Uncertain		Approved	Golgi apparatus	Breast cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 13.7	Mixed		
CNNM4	ACDP4, KIAA1592	ENSG00000158158	Cyclin and CBS domain divalent metal cation transport mediator 4	2	96760902-96811891	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017732	Enhanced		Uncertain	Plasma membrane<br>Actin filaments	Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 36.9	Expressed in all		
EYA3	DKFZp686C132	ENSG00000158161	EYA transcriptional coactivator and phosphatase 3	1	27970344-28088696	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052432, HPA062889	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.15e-6 (favourable), Head and neck cancer:5.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
DZIP1L	DZIP2, FLJ32844	ENSG00000158163	DAZ interacting zinc finger protein 1 like	3	138061990-138115818	Predicted intracellular proteins	Evidence at protein level	HPA030404	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge		Mixed	Mixed			fallopian tube: 16.6	Mixed		
TMSB15A	TMSL8, TMSNB	ENSG00000158164	Thymosin beta 15a	X	102513676-102516784	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		prostate: 22.5	thyroid gland: 8.5	Cell line enhanced		AF22: 507.9;NTERA-2: 133.4;RH-30: 226.1;SH-SY5Y: 141.1
FANCC	FA3, FAC, FACC	ENSG00000158169	Fanconi anemia complementation group C	9	95099054-95426796	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017793, HPA030771	Approved		Supported	Nucleoplasm	Renal cancer:6.03e-6 (favourable)	Expressed in all	Mixed			testis: 17.6	Expressed in all		
MRAS	M-RAs, R-RAS3, RRAS3	ENSG00000158186	Muscle RAS oncogene homolog	3	138347648-138405534	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042728	Approved				Endometrial cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 114.0	Cell line enhanced		EFO-21: 110.3
WASF2	SCAR2, WAVE2	ENSG00000158195	WAS protein family member 2	1	27404226-27490158	Predicted intracellular proteins	Evidence at protein level	CAB022632, HPA045288	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:5.29e-8 (unfavourable), Ovarian cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 88.1	Expressed in all		
ABHD3	LABH3	ENSG00000158201	Abhydrolase domain containing 3	18	21650897-21704805	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010729	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane	Melanoma:8.52e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 71.5	Cell line enhanced		REH: 188.5;RPMI-8226: 159.6
ESYT3	CHR3SYT, FAM62C	ENSG00000158220	Extended synaptotagmin 3	3	138434586-138481686	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039200	Approved				Lung cancer:8.30e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 8.4;skin: 7.5;thyroid gland: 8.5	endometrium: 3.7	Cell line enhanced		NTERA-2: 4.1;SCLC-21H: 5.2;SiHa: 1.9
FAIM	FAIM1, FLJ10582	ENSG00000158234	Fas apoptotic inhibitory molecule	3	138608606-138633376	Predicted intracellular proteins	Evidence at protein level	HPA042440, HPA052209	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:3.96e-5 (unfavourable), Renal cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 61.0	Mixed		
FAM46B	MGC16491	ENSG00000158246	Family with sequence similarity 46 member B	1	27005020-27012836	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		esophagus: 59.9;skin: 39.4	seminal vesicle: 22.1	Cell line enhanced		hTCEpi: 45.0;NTERA-2: 32.9
CLSTN2	CDHR13, CS2, CSTN2, FLJ39113	ENSG00000158258	Calsyntenin 2	3	139935185-140577397	Predicted membrane proteins	Evidence at protein level	HPA031342	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 34.6;ovary: 81.6	adipose tissue: 18.8	Cell line enhanced		AF22: 5.2;SCLC-21H: 17.0;THP-1: 6.3
COLEC12	CL-P1, SCARA4, SRCL	ENSG00000158270	Collectin subfamily member 12	18	316740-500722	Predicted membrane proteins	Evidence at protein level	HPA047917, HPA071056	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Cell Junctions	Thyroid cancer:8.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 28.2	lung: 16.7	Cell line enhanced		ASC TERT1: 16.8;BJ: 10.3;HSkMC: 14.5;U-2197: 29.2
RNF207	C1orf188, FLJ32096, FLJ46380	ENSG00000158286	Ring finger protein 207	1	6205475-6221299	Predicted intracellular proteins	Evidence at protein level	HPA028378, HPA042535	Uncertain		Approved	Cytosol	Renal cancer:1.92e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 11.1	seminal vesicle: 5.2	Cell line enhanced		CAPAN-2: 14.3
CUL4B		ENSG00000158290	Cullin 4B	X	120524609-120575794	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003046, HPA011880, CAB017786, HPA058979	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 68.3	Expressed in all		
GPR153	PGR1	ENSG00000158292	G protein-coupled receptor 153	1	6247346-6260975	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA007159	Approved				Endometrial cancer:3.07e-4 (unfavourable), Lung cancer:3.75e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 17.4	Cell line enhanced		PC-3: 65.6;RH-30: 32.1;SCLC-21H: 39.5
SLC13A3	NADC3, SDCT2	ENSG00000158296	Solute carrier family 13 member 3	20	46557823-46684467	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014333, HPA014353, HPA014736	Enhanced		Supported	Plasma membrane		Mixed	Tissue enriched	7	kidney: 431.7	placenta: 60.9	Cell line enhanced		EFO-21: 17.7;Hep G2: 38.2
GPRASP2	FLJ37327, GASP2	ENSG00000158301	G protein-coupled receptor associated sorting protein 2	X	102712176-102717733	Predicted intracellular proteins	Evidence at protein level	HPA017438	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.60e-6 (favourable), Urothelial cancer:6.63e-5 (unfavourable), Pancreatic cancer:5.71e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 41.6	Mixed		
RHBDL2	FLJ20435	ENSG00000158315	Rhomboid like 2	1	38885807-38941799	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043807	Approved					Mixed	Mixed			skin: 22.1	Cell line enhanced		CAPAN-2: 40.9;HaCaT: 21.4;RT4: 37.8
AUTS2	FBRSL2, KIAA0442	ENSG00000158321	AUTS2, activator of transcription and developmental regulator	7	69598919-70793068	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000390	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 21.7	Cell line enhanced		NTERA-2: 68.0;SCLC-21H: 136.5
SHROOM4	KIAA1202	ENSG00000158352	Shroom family member 4	X	50591647-50814302	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010565	Uncertain				Renal cancer:4.66e-4 (unfavourable), Endometrial cancer:8.37e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 19.2	placenta: 13.1	Cell line enhanced		EFO-21: 6.5;HUVEC TERT2: 22.2;TIME: 8.3
HIST1H2BD	H2B/b, H2BFB	ENSG00000158373	Histone cluster 1 H2B family member d	6	26158146-26171349	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671, CAB062336	Supported		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 90.2	Expressed in all		
CDC25C	CDC25, PPP1R60	ENSG00000158402	Cell division cycle 25C	5	138285265-138338355	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB003800, HPA066991	Approved		Supported	Nuclear speckles	Liver cancer:3.03e-6 (unfavourable), Colorectal cancer:2.49e-4 (favourable), Lung cancer:4.38e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 31.8	rectum: 4.4	Mixed		
HIST1H4H	H4/h, H4FH	ENSG00000158406	Histone cluster 1 H4 family member h	6	26277609-26285638	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:6.18e-6 (unfavourable), Liver cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 9.9	prostate: 6.3	Cell line enhanced		U-266/84: 49.1
MITD1	LOC129531	ENSG00000158411	Microtubule interacting and trafficking domain containing 1	2	99161427-99181058	Predicted intracellular proteins	Evidence at protein level	HPA036162, HPA036163	Approved		Enhanced	Vesicles	Renal cancer:1.32e-11 (unfavourable), Urothelial cancer:5.46e-8 (favourable), Liver cancer:1.47e-6 (unfavourable), Breast cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 42.2	Expressed in all		
EIF5B	DKFZp434I036, FLJ10524, IF2, KIAA0741	ENSG00000158417	Eukaryotic translation initiation factor 5B	2	99337353-99401326	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034648, HPA040095	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:7.15e-10 (unfavourable), Renal cancer:1.42e-6 (unfavourable), Ovarian cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.5	Expressed in all		
RIBC1	FLJ32783	ENSG00000158423	RIB43A domain with coiled-coils 1	X	53422690-53431120	Predicted intracellular proteins	Evidence at protein level	HPA001150, HPA021613	Uncertain		Approved	Nuclear bodies	Cervical cancer:1.90e-5 (favourable), Endometrial cancer:9.66e-4 (favourable)	Mixed	Group enriched	7	fallopian tube: 45.0;testis: 41.7	thyroid gland: 6.1	Cell line enhanced		T-47d: 7.4
TMSB15B	MGC39900	ENSG00000158427	Thymosin beta 15B	X	103918896-103966712	Predicted intracellular proteins	Evidence at protein level	HPA064607	Uncertain					Not detected	Mixed			endometrium: 18.6	Cell line enhanced		AF22: 73.0;REH: 52.5
CATIP	C2orf62, MGC50811	ENSG00000158428	Ciliogenesis associated TTC17 interacting protein	2	218356856-218368099	Predicted intracellular proteins	Evidence at protein level	HPA044818	Supported					Mixed	Tissue enhanced		fallopian tube: 31.9	testis: 7.3	Cell line enriched	14	BEWO: 3.7
CNOT11	C2orf29, C40	ENSG00000158435	CCR4-NOT transcription complex subunit 11	2	101252802-101270316	Predicted intracellular proteins	Evidence at protein level	HPA069823			Supported	Nucleoplasm	Renal cancer:8.33e-6 (unfavourable), Liver cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.0	Expressed in all		
KCNB1	Kv2.1	ENSG00000158445	Potassium voltage-gated channel subfamily B member 1	20	49293394-49484297	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001979, HPA042434	Enhanced					Mixed	Tissue enhanced		adipose tissue: 10.9;cerebral cortex: 21.6	fallopian tube,smooth muscle: 7.4	Cell line enhanced		CACO-2: 1.8;U-2 OS: 1.8
TSPAN33	MGC50844, Penumbra	ENSG00000158457	Tetraspanin 33	7	129144892-129169697	Predicted membrane proteins, Transporters	Evidence at protein level	HPA020357	Approved		Approved	Microtubules	Renal cancer:8.74e-5 (favourable), Pancreatic cancer:8.88e-4 (favourable)	Expressed in all	Expressed in all			kidney: 127.3	Cell line enhanced		AN3-CA: 48.8;HEL: 76.0;U-266/70: 73.4
NRG2	Don-1, HRG2, NTAK	ENSG00000158458	Neuregulin 2	5	139846779-140043299	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA038935, HPA047973	Uncertain		Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		parathyroid gland: 13.3	ovary: 10.2	Cell line enhanced		AN3-CA: 7.0;PC-3: 12.4;SCLC-21H: 5.8
AHCYL2	KIAA0828	ENSG00000158467	Adenosylhomocysteinase like 2	7	129225023-129430211	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053128	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.08e-7 (favourable), Head and neck cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			rectum: 194.5	Cell line enriched	9	HDLM-2: 218.4
B4GALT5	beta4GalT-V	ENSG00000158470	Beta-1,4-galactosyltransferase 5	20	49632945-49713878	Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.87e-5 (unfavourable), Liver cancer:2.69e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 59.8	Expressed in all		
CD1D		ENSG00000158473	CD1d molecule	1	158179947-158184896	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	CAB016107, HPA072662	Uncertain		Supported	Endoplasmic reticulum	Renal cancer:2.12e-5 (unfavourable)	Mixed	Mixed			spleen: 20.6	Cell line enhanced		HBEC3-KT: 8.3;HHSteC: 14.4;MOLT-4: 19.6;THP-1: 9.9
CD1A	CD1	ENSG00000158477	CD1a molecule	1	158254137-158258269	CD markers, Predicted membrane proteins	Evidence at protein level	CAB000009, HPA010734	Enhanced				Cervical cancer:6.37e-4 (favourable)	Mixed	Group enriched	6	esophagus: 9.5;skin: 27.0	lymph node,tonsil: 2.9	Cell line enriched	122	MOLT-4: 48.8
SPATA2	KIAA0757, PD1, PPP1R145, tamo	ENSG00000158480	Spermatogenesis associated 2	20	49903391-49915508	Predicted intracellular proteins	Evidence at protein level	HPA048581, HPA052224	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:1.87e-4 (unfavourable), Thyroid cancer:4.53e-4 (unfavourable), Melanoma:9.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.4	Expressed in all		
CD1C	CD1	ENSG00000158481	CD1c molecule	1	158289786-158293630	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Cervical cancer:1.79e-5 (favourable)	Mixed	Tissue enhanced		spleen: 40.6;tonsil: 45.1	lymph node: 39.8	Cell line enriched	16	MOLT-4: 46.0
FAM86C1	FAM86C, FLJ10661, FLJ27199	ENSG00000158483	Family with sequence similarity 86 member C1	11	71787510-71801236	Predicted intracellular proteins	Evidence at protein level						Liver cancer:5.79e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.8	Expressed in all		
CD1B	CD1	ENSG00000158485	CD1b molecule	1	158327951-158331531	CD markers, Predicted membrane proteins	Evidence at protein level	HPA021824	Approved					Mixed	Tissue enhanced		rectum: 3.1;skin: 3.9	lymph node: 2.7	Cell line enriched	1556	MOLT-4: 465.4
DNAH3	DKFZp434N074, DLP3, Dnahc3b, Hsadhc3	ENSG00000158486	Dynein axonemal heavy chain 3	16	20933111-21159441	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA062493			Approved	Nuclear membrane<br>Intermediate filaments		Mixed	Group enriched	5	fallopian tube: 8.1;testis: 6.0	lung: 1.3	Not detected		
CD1E		ENSG00000158488	CD1e molecule	1	158353696-158357553	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057769	Uncertain					Mixed	Tissue enhanced		skin: 18.3	tonsil: 10.4	Cell line enriched	980	MOLT-4: 1075.1
HMHB1	HB-1, HB-1Y	ENSG00000158497	Histocompatibility minor HB-1	5	143812161-143820719	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 1.3;testis: 2.4	bone marrow: 0.6	Cell line enhanced		Karpas-707: 2.3;REH: 4.1
CPA2		ENSG00000158516	Carboxypeptidase A2	7	130266827-130289798	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA020342, HPA021317	Enhanced					Tissue enriched	Tissue enriched	104	pancreas: 9283.9	stomach: 89.6	Cell line enhanced		AN3-CA: 2.0;CACO-2: 3.0;RH-30: 2.8;SCLC-21H: 1.9
NCF1	NCF1A, NOXO2, p47phox, SH3PXD1A	ENSG00000158517	Neutrophil cytosolic factor 1	7	74773962-74789315	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004524, HPA047836, HPA052095	Enhanced					Mixed	Tissue enhanced		lymph node: 71.2;spleen: 74.1	bone marrow: 60.9	Group enriched	6	Daudi: 72.6;HMC-1: 122.5
CPA5		ENSG00000158525	Carboxypeptidase A5	7	130344816-130368730	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020322			Approved	Nucleus		Not detected	Tissue enriched	18	testis: 47.4	spleen: 2.6	Cell line enhanced		RH-30: 7.1;RT4: 2.7;U-266/84: 4.1
TSR2	DT1P1A10, RP1-112K5.2, WGG1	ENSG00000158526	TSR2, ribosome maturation factor	X	54440401-54445487	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030514	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol	Renal cancer:1.21e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 88.4	Expressed in all		
PPP1R9A	FLJ20068, KIAA1222, Neurabin-I	ENSG00000158528	Protein phosphatase 1 regulatory subunit 9A	7	94907202-95296415	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027726, HPA075591	Uncertain		Approved	Plasma membrane	Renal cancer:8.63e-6 (favourable), Ovarian cancer:7.17e-4 (favourable)	Mixed	Mixed			cerebral cortex: 20.6	Mixed		
ZC3H18	NHN1	ENSG00000158545	Zinc finger CCCH-type containing 18	16	88570381-88631966	Predicted intracellular proteins	Evidence at protein level	HPA040847, HPA041327	Enhanced		Enhanced	Nuclear speckles	Renal cancer:3.68e-4 (favourable), Liver cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.8	Expressed in all		
ZFAND2B	AIRAPL	ENSG00000158552	Zinc finger AN1-type containing 2B	2	219195237-219209651	Predicted intracellular proteins	Evidence at protein level	HPA035159, HPA035160	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Pancreatic cancer:9.38e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 68.0	Expressed in all		
POM121L2	POM121-L	ENSG00000158553	POM121 transmembrane nucleoporin like 2	6	27285903-27312170	Predicted intracellular proteins	Evidence at transcript level	HPA046150	Uncertain					Not detected	Tissue enriched	152	testis: 15.1	all non-specific tissues: 0.0	Not detected		
GDPD5	GDE2, PP1665	ENSG00000158555	Glycerophosphodiester phosphodiesterase domain containing 5	11	75434640-75525903	Predicted membrane proteins	Evidence at protein level	HPA065257, HPA066762, HPA069281	Uncertain		Approved	Golgi apparatus	Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 67.0	testis: 31.2	Cell line enhanced		HDLM-2: 62.5
DYNC1I1	DNCI1, DNCIC1	ENSG00000158560	Dynein cytoplasmic 1 intermediate chain 1	7	95772506-96110322	Predicted intracellular proteins	Evidence at protein level	HPA061689	Enhanced				Endometrial cancer:3.79e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 83.9	adrenal gland: 16.8	Cell line enhanced		EFO-21: 13.2;SH-SY5Y: 11.0;WM-115: 9.0
PFKFB1	PFRX	ENSG00000158571	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1	X	54932961-54998534	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	8	adipose tissue: 30.1;liver: 18.7;skeletal muscle: 39.3	breast: 3.8	Cell line enhanced		ASC diff: 5.9;Hep G2: 2.4
ALAS2	ASB	ENSG00000158578	5'-aminolevulinate synthase 2	X	55009055-55031064	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001638	Approved					Mixed	Tissue enriched	7	bone marrow: 335.6	placenta: 51.0	Group enriched	173	HEL: 42.0;K-562: 61.5
TMED4	HNLF, p24a3, p24alpha3	ENSG00000158604	Transmembrane p24 trafficking protein 4	7	44577894-44582287	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 190.7	Expressed in all		
PPP1R15B	FLJ14744	ENSG00000158615	Protein phosphatase 1 regulatory subunit 15B	1	204403387-204411791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061088			Approved	Golgi apparatus	Renal cancer:8.74e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 81.6	Expressed in all		
COPG2	2-COP	ENSG00000158623	Coatomer protein complex subunit gamma 2	7	130506238-130668748	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045712	Approved					Expressed in all	Expressed in all			ovary: 48.2	Expressed in all		
EMSY	C11orf30	ENSG00000158636	EMSY, BRCA2 interacting transcriptional repressor	11	76444923-76553025	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012234, HPA050777	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 20.4	Expressed in all		
PAGE5	CT16.1, CT16.2, PAGE-5	ENSG00000158639	PAGE family member 5	X	55220355-55224108	Predicted intracellular proteins	Evidence at protein level	HPA052619, HPA055869	Supported		Uncertain	Mitochondria		Group enriched	Tissue enriched	74	testis: 41.0	fallopian tube,liver: 0.5	Group enriched	160	Karpas-707: 324.6;U-266/84: 709.6
GPAT4	AGPAT6, DKFZp586M1819, LPAAT-zeta, TSARG7	ENSG00000158669	Glycerol-3-phosphate acyltransferase 4	8	41577187-41625001	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016471	Approved				Ovarian cancer:2.20e-4 (unfavourable), Prostate cancer:4.15e-4 (favourable), Urothelial cancer:5.65e-4 (favourable), Endometrial cancer:9.37e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.3	Expressed in all		
PKD1L1	PRO19563	ENSG00000158683	Polycystin 1 like 1, transient receptor potential channel interacting	7	47774652-47948491	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020422, HPA022424	Uncertain					Tissue enhanced	Tissue enhanced		testis: 2.4	adipose tissue: 1.8	Group enriched	8	T-47d: 5.0;U-266/70: 10.5;U-266/84: 3.7
ZSCAN12	dJ29K1.2, KIAA0426, ZFP96, ZNF29K1, ZNF305, ZNF96	ENSG00000158691	Zinc finger and SCAN domain containing 12	6	28378955-28399734	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006637	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Mixed			thyroid gland: 8.7	Mixed		
TAGLN2	HA1756, KIAA0120	ENSG00000158710	Transgelin 2	1	159918107-159925732	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001925	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.92e-10 (unfavourable), Breast cancer:2.06e-5 (unfavourable), Liver cancer:7.07e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 902.5	Expressed in all		
ELK4	SAP1	ENSG00000158711	ELK4, ETS transcription factor	1	205597556-205631962	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028863	Uncertain		Supported	Nucleoplasm	Renal cancer:2.94e-6 (unfavourable), Head and neck cancer:4.65e-4 (favourable)	Expressed in all	Expressed in all			prostate: 42.8	Expressed in all		
SLAMF8	BLAME, CD353, SBBI42	ENSG00000158714	SLAM family member 8	1	159826750-159837249	CD markers, Predicted membrane proteins	Evidence at protein level	HPA067601	Enhanced				Renal cancer:5.42e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 39.3	lymph node: 36.1	Cell line enhanced		ASC TERT1: 1.1;HL-60: 1.0;U-138 MG: 2.0;U-87 MG: 1.3
SLC45A3	IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein	ENSG00000158715	Solute carrier family 45 member 3	1	205657851-205680459	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019073, HPA019075	Enhanced		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable)	Tissue enriched	Tissue enriched	30	prostate: 505.2	stomach: 16.5	Cell line enriched	28	HMC-1: 749.2
DUSP23	DUSP25, FLJ20442	ENSG00000158716	Dual specificity phosphatase 23	1	159780932-159782543	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028211, HPA045792	Approved		Supported	Nucleoplasm	Renal cancer:2.59e-5 (unfavourable), Liver cancer:3.06e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 40.4	Mixed		
RNF166	MGC14381, MGC2647	ENSG00000158717	Ring finger protein 166	16	88696495-88706421	Predicted intracellular proteins	Evidence at protein level	HPA042970			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:9.45e-6 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 57.1	Expressed in all		
NBL1	D1S1733E, DAN, DAND1, NB, NO3	ENSG00000158747	Neuroblastoma 1, DAN family BMP antagonist	1	19640554-19658456	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007394, CAB026132	Uncertain					Expressed in all	Expressed in all			ovary: 552.0	Cell line enhanced		SK-MEL-30: 357.2
HTR6	5-HT6, 5-HT6R	ENSG00000158748	5-hydroxytryptamine receptor 6	1	19665287-19679562	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Not detected			cerebral cortex: 0.8	Cell line enhanced		SH-SY5Y: 2.1
ITLN2	HL-2	ENSG00000158764	Intelectin 2	1	160945025-160954799	Predicted secreted proteins	Evidence at protein level	HPA006683, HPA067326	Enhanced					Tissue enhanced	Group enriched	19	duodenum: 244.7;small intestine: 454.0	lung: 18.2	Cell line enhanced		HEL: 10.8;HMC-1: 3.0;SK-MEL-30: 3.0
F11R	CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1	ENSG00000158769	F11 receptor	1	160995211-161021348	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB004671, HPA043616, HPA061700	Enhanced		Supported	Cell Junctions<br>Microtubules		Expressed in all	Expressed in all			lung: 95.0	Cell line enhanced		HaCaT: 179.6
USF1	bHLHb11, MLTFI, UEF	ENSG00000158773	Upstream transcription factor 1	1	161039251-161045977	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB001480, HPA036233, HPA036535	Supported		Enhanced	Nucleoplasm	Renal cancer:6.01e-12 (unfavourable), Urothelial cancer:1.95e-5 (favourable), Head and neck cancer:8.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.8	Expressed in all		
PLA2G2F		ENSG00000158786	Phospholipase A2 group IIF	1	20139326-20150386	Enzymes, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level						Urothelial cancer:3.86e-4 (favourable)	Tissue enriched	Group enriched	11	skin: 11.3;tonsil: 7.2;urinary bladder: 3.9	gallbladder: 0.6	Cell line enriched	57	RT4: 110.7
SPATA2L	C16orf76, MGC26885, tamo	ENSG00000158792	Spermatogenesis associated 2 like	16	89696343-89701705	Predicted intracellular proteins	Evidence at protein level	HPA041182, HPA042453	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 9.1	Cell line enhanced		MCF7: 25.9
NIT1		ENSG00000158793	Nitrilase 1	1	161118086-161125445	Predicted intracellular proteins	Evidence at protein level	HPA006657	Approved				Renal cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 49.9	Expressed in all		
DEDD	CASP8IP1, DEDD1, DEFT, FLDED1, KE05	ENSG00000158796	Death effector domain containing	1	161120974-161132688	Predicted intracellular proteins	Evidence at protein level	HPA030681, HPA073628	Approved		Approved	Nucleoplasm	Renal cancer:4.98e-7 (unfavourable), Liver cancer:8.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 47.2	Expressed in all		
ZNF276	CENP-Z, CENPZ, MGC45417, ZADT, ZFP276, ZNF477	ENSG00000158805	Zinc finger protein 276	16	89720400-89740903	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021309, HPA022255	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.9	Expressed in all		
NPM2		ENSG00000158806	Nucleophosmin/nucleoplasmin 2	8	22024125-22036897	Predicted intracellular proteins	Evidence at protein level	HPA041070	Enhanced		Approved	Nucleus<br>Nucleoli	Renal cancer:3.18e-6 (favourable), Pancreatic cancer:9.02e-4 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 69.7;thyroid gland: 42.7	cerebral cortex: 31.8	Cell line enhanced		HaCaT: 15.6;HEL: 13.0;Hep G2: 21.9
EDA	ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED	ENSG00000158813	Ectodysplasin A	X	69616067-70039469	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037972, HPA037973			Supported	Vesicles<br>Lipid droplets	Renal cancer:1.04e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 19.4	thyroid gland: 10.0	Cell line enhanced		EFO-21: 5.0;Hep G2: 12.2
FGF17	FGF-13	ENSG00000158815	Fibroblast growth factor 17	8	22042398-22048809	Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA052600	Approved					Tissue enhanced	Mixed			cerebral cortex: 1.8	Not detected		
VWA5B1	FLJ32784	ENSG00000158816	Von Willebrand factor A domain containing 5B1	1	20290919-20354894	Predicted intracellular proteins	Evidence at protein level	HPA027496, HPA028405, HPA064829	Enhanced		Approved	Plasma membrane<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 5.0	epididymis: 1.6	Cell line enriched	10	SCLC-21H: 1.4
CDA	CDD	ENSG00000158825	Cytidine deaminase	1	20588948-20618908	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064202	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:8.56e-5 (unfavourable), Cervical cancer:5.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 104.6;esophagus: 56.7	liver: 33.3	Cell line enhanced		A-431: 142.3;CAPAN-2: 92.8;HeLa: 100.6;SiHa: 200.2
PINK1	PARK6	ENSG00000158828	PTEN induced putative kinase 1	1	20633455-20651511	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001931, CAB026191	Uncertain				Renal cancer:1.11e-16 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 145.5	Expressed in all		
B4GALT3	beta4Gal-T3	ENSG00000158850	Beta-1,4-galactosyltransferase 3	1	161171310-161177968	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010793	Approved		Supported	Golgi apparatus	Renal cancer:7.12e-7 (unfavourable), Liver cancer:5.87e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 31.1	Expressed in all		
DMTN	DMT, EPB49	ENSG00000158856	Dematin actin binding protein	8	22048995-22082527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024290	Uncertain				Renal cancer:3.85e-9 (favourable), Glioma:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 221.5	Cell line enhanced		HEL: 202.5
ADAMTS4	ADAMTS-2, ADMP-1, KIAA0688	ENSG00000158859	ADAM metallopeptidase with thrombospondin type 1 motif 4	1	161184308-161199056	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025876, HPA051296, HPA068374	Uncertain		Approved	Nuclear speckles	Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 62.8	appendix: 22.9	Cell line enhanced		hTEC/SVTERT24-B: 11.8;HUVEC TERT2: 12.0;SH-SY5Y: 8.4;TIME: 9.9;U-251 MG: 9.0
FAM160B2	FLJ21801, RAI16	ENSG00000158863	Family with sequence similarity 160 member B2	8	22089159-22104898	Predicted intracellular proteins	Evidence at protein level	HPA025040	Approved		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 17.7	Mixed		
NDUFS2	CI-49	ENSG00000158864	NADH:ubiquinone oxidoreductase core subunit S2	1	161197104-161214395	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055140, HPA061953	Enhanced		Enhanced	Nucleoplasm<br>Mitochondria	Renal cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 124.0	Expressed in all		
SLC5A11	KST1, SGLT6, SMIT2	ENSG00000158865	Solute carrier family 5 member 11	16	24845841-24911628	Predicted membrane proteins	Evidence at protein level	HPA035331	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Group enriched	5	cerebral cortex: 10.5;duodenum: 6.6;kidney: 6.1;small intestine: 15.2	breast: 1.7	Cell line enhanced		BEWO: 1.7;Hep G2: 11.2;Karpas-707: 3.2
FCER1G		ENSG00000158869	Fc fragment of IgE receptor Ig	1	161215234-161220699	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022108, HPA026872	Supported				Renal cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 462.9	Group enriched	5	HEL: 69.1;HMC-1: 265.2;THP-1: 185.7;U-266/84: 61.5;U-937: 67.6
APOA2		ENSG00000158874	Apolipoprotein A2	1	161222292-161223631	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025885	Supported					Tissue enriched	Tissue enriched	1068	liver: 18325.0	bone marrow: 17.1	Cell line enriched	8	Hep G2: 11388.0
TOMM40L	FLJ12770, TOMM40B	ENSG00000158882	Translocase of outer mitochondrial membrane 40 like	1	161225939-161230744	Predicted intracellular proteins	Evidence at protein level	HPA051304	Approved				Liver cancer:1.36e-4 (unfavourable), Endometrial cancer:1.44e-4 (unfavourable), Renal cancer:7.80e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.3	Expressed in all		
MPZ	CMT1, CMT1B, CMT2I, CMT2J, HMSNIB	ENSG00000158887	Myelin protein zero	1	161304735-161309972	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068925	Supported					Tissue enriched	Mixed			seminal vesicle: 16.7	Cell line enriched	8	WM-115: 201.9
WFDC8	C20orf170, dJ461P17.1, WAP8	ENSG00000158901	WAP four-disulfide core domain 8	20	45551153-45579326	Predicted secreted proteins	Evidence at protein level	HPA042710, HPA071119	Enhanced					Not detected	Tissue enriched	436	epididymis: 487.6	seminal vesicle: 1.1	Cell line enriched	6	U-87 MG: 2.6
CCAR2	DBC-1, DBC1, KIAA1967, NET35	ENSG00000158941	Cell cycle and apoptosis regulator 2	8	22604632-22621514	Predicted intracellular proteins	Evidence at protein level	HPA019907, HPA019943, CAB072827, CAB072828	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 135.8	Expressed in all		
WNT9B	WNT14B, WNT15	ENSG00000158955	Wnt family member 9B	17	46833201-46886730	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058361, HPA059572	Approved					Not detected	Tissue enhanced		parathyroid gland: 3.1;seminal vesicle: 9.4	skin: 1.4	Not detected		
CACHD1	KIAA1573, VWCD1	ENSG00000158966	Cache domain containing 1	1	64470792-64693058	Predicted membrane proteins	Evidence at protein level	HPA017202	Uncertain		Uncertain	Nucleus<br>Nucleoli		Expressed in all	Mixed			ovary: 28.1	Cell line enhanced		AF22: 40.8;NTERA-2: 56.8
CDC42SE2	FLJ21967, SPEC2	ENSG00000158985	CDC42 small effector 2	5	131245493-131398447	Predicted intracellular proteins	Evidence at protein level	HPA038624	Enhanced				Colorectal cancer:4.50e-5 (favourable), Urothelial cancer:7.50e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 92.9	Expressed in all		
RAPGEF6	PDZ-GEF2, PDZGEF2, RA-GEF-2	ENSG00000158987	Rap guanine nucleotide exchange factor 6	5	131423921-131635236	Predicted intracellular proteins	Evidence at protein level	HPA037982, HPA037983	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:3.87e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 21.9	Expressed in all		
EPB41	4.1R, EL1	ENSG00000159023	Erythrocyte membrane protein band 4.1	1	28887091-29120046	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028076, HPA028412, HPA028414	Supported		Supported	Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.75e-6 (unfavourable), Endometrial cancer:4.58e-4 (unfavourable), Head and neck cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 50.6	Mixed		
MIS18A	B28, C21orf45, C21orf46, FASP1, hMis18alpha	ENSG00000159055	MIS18 kinetochore protein A	21	32268219-32279069	Predicted intracellular proteins	Evidence at protein level	HPA018286, HPA020585	Enhanced		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 38.8	Expressed in all		
ALG8	MGC2840	ENSG00000159063	ALG8, alpha-1,3-glucosyltransferase	11	78100936-78139660	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA051898	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 86.2	Expressed in all		
FBXW5	DKFZP434B205, Fbw5, MGC20962	ENSG00000159069	F-box and WD repeat domain containing 5	9	136940435-136944696	Predicted intracellular proteins	Evidence at protein level	HPA046615	Approved		Approved	Mitochondria	Endometrial cancer:1.02e-4 (favourable), Renal cancer:4.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 163.1	Expressed in all		
C21orf59	C21orf48, CILD26, FBB18, FLJ20467, Kur	ENSG00000159079	Chromosome 21 open reading frame 59	21	32592079-32612866	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018453, HPA019055, HPA028849, CAB034170	Enhanced	Supported	Approved	Rods & Rings	Renal cancer:1.54e-5 (unfavourable), Endometrial cancer:8.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.6	Expressed in all		
SYNJ1	INPP5G, PARK20	ENSG00000159082	Synaptojanin 1	21	32628759-32728048	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA011916	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.9	testis: 18.4	Expressed in all		
PAXBP1	C21orf66, fSAP105, GCFC, GCFC1	ENSG00000159086	PAX3 and PAX7 binding protein 1	21	32733899-32771858	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003757	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.50e-5 (unfavourable), Prostate cancer:9.43e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 18.7	Expressed in all		
IFNAR2	IFNABR	ENSG00000159110	Interferon alpha and beta receptor subunit 2	21	33229901-33265675	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.54e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 58.7	Expressed in all		
MRPL10	L10MT, MGC17973, MRP-L10, MRP-L8, MRPL8, RPML8	ENSG00000159111	Mitochondrial ribosomal protein L10	17	47823272-47831534	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA021234, HPA029885	Enhanced		Enhanced	Mitochondria	Liver cancer:6.67e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 61.1	Expressed in all		
IFNGR2	AF-1, IFNGT1	ENSG00000159128	Interferon gamma receptor 2	21	33402896-33479348	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA001535	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Mixed			spleen: 10.0	Mixed		
GART	PGFT, PRGS	ENSG00000159131	Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase	21	33503931-33543491	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002119, HPA005779	Approved		Uncertain	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
SON	BASS1, C21orf50, DBP-5, FLJ21099, FLJ33914, KIAA1019, NREBP	ENSG00000159140	SON DNA binding protein	21	33542618-33577481	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023535, HPA031755, HPA031756	Supported		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 223.1	Expressed in all		
DONSON	B17, C21orf60, C2TA, DKFZP434M035	ENSG00000159147	Downstream neighbor of SON	21	33559542-33588708	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039558, HPA049033	Uncertain		Approved	Nucleoplasm<br>Cell Junctions<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 40.3	parathyroid gland: 15.4	Expressed in all		
SV2A	KIAA0736, SV2	ENSG00000159164	Synaptic vesicle glycoprotein 2A	1	149903318-149917882	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB002226, HPA007863	Enhanced		Approved	Cytosol	Renal cancer:3.22e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 166.9;parathyroid gland: 72.0	epididymis: 28.2	Cell line enhanced		NTERA-2: 65.6;SCLC-21H: 63.2
LAD1		ENSG00000159166	Ladinin 1	1	201373244-201399915	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007256, HPA028732	Enhanced		Enhanced	Actin filaments	Lung cancer:6.73e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 291.7;skin: 236.6	small intestine: 93.9	Cell line enhanced		A-431: 173.4;CAPAN-2: 150.1;HaCaT: 219.8;MCF7: 165.3;RT4: 146.2;SK-BR-3: 220.4
STC1	STC	ENSG00000159167	Stanniocalcin 1	8	23841915-23854807	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018625, HPA023918	Approved				Renal cancer:1.23e-6 (unfavourable), Glioma:9.44e-5 (unfavourable), Lung cancer:1.53e-4 (unfavourable), Stomach cancer:5.55e-4 (unfavourable), Head and neck cancer:6.32e-4 (unfavourable), Cervical cancer:8.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 78.0	endometrium: 53.9	Cell line enhanced		BJ hTERT+: 280.7;hTEC/SVTERT24-B: 201.5;U-87 MG: 608.6
TNNI1		ENSG00000159173	Troponin I1, slow skeletal type	1	201403768-201429866	Predicted intracellular proteins	Evidence at protein level	HPA028190	Approved		Uncertain	Nucleus<br>Nucleoli	Head and neck cancer:9.27e-4 (unfavourable)	Group enriched	Tissue enriched	21	skeletal muscle: 4420.6	esophagus: 206.1	Cell line enriched	12	RH-30: 471.8
CSRP1	CSRP, CYRP, D1S181E	ENSG00000159176	Cysteine and glycine rich protein 1	1	201483530-201509456	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045617	Uncertain				Renal cancer:2.11e-4 (unfavourable), Head and neck cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 3310.4	Mixed		
PRAC1	C17orf92, PRAC	ENSG00000159182	Prostate cancer susceptibility candidate 1	17	48721719-48722522	Predicted intracellular proteins	Evidence at transcript level	HPA047871	Approved					Tissue enriched	Group enriched	38	colon: 102.9;prostate: 171.7;rectum: 220.8	urinary bladder: 4.3	Cell line enriched	32	PC-3: 343.9
HOXB13		ENSG00000159184	Homeobox B13	17	48724763-48729178	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004438, HPA062852, HPA065019	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Tissue enhanced		prostate: 115.1;rectum: 39.0	colon: 21.4	Cell line enriched	13	PC-3: 139.6
C1QC	C1QG	ENSG00000159189	Complement C1q C chain	1	22643630-22648110	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001471, CAB009828	Supported		Uncertain	Vesicles	Renal cancer:1.17e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 1285.6	Cell line enhanced		RPMI-8226: 1.7
KCNE2	LQT6, MiRP1	ENSG00000159197	Potassium voltage-gated channel subfamily E regulatory subunit 2	21	34364024-34371389	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA029706, HPA051553	Enhanced					Tissue enriched	Tissue enriched	25	stomach: 175.3	duodenum: 7.0	Cell line enhanced		SCLC-21H: 2.3
ATP5G1	ATP5G	ENSG00000159199	ATP synthase, H+ transporting, mitochondrial Fo complex subunit C1 (subunit 9)	17	48892765-48895871	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.24e-6 (favourable), Cervical cancer:3.88e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 388.5	Expressed in all		
RCAN1	DSCR1	ENSG00000159200	Regulator of calcineurin 1	21	34513142-34615142	Predicted intracellular proteins	Evidence at protein level	CAB037218	Uncertain		Approved	Cytosol		Expressed in all	Tissue enriched	8	parathyroid gland: 1116.7	placenta: 137.4	Cell line enhanced		SK-MEL-30: 987.4;WM-115: 803.4
UBE2Z	FLJ13855, USE1	ENSG00000159202	Ubiquitin conjugating enzyme E2 Z	17	48908369-48929056	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007922	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.05e-4 (unfavourable), Colorectal cancer:4.62e-4 (favourable), Liver cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.7	Expressed in all		
CIART	BC017397, C1orf51	ENSG00000159208	Circadian associated repressor of transcription	1	150282543-150287093	Predicted intracellular proteins	Evidence at protein level	HPA027515, HPA054349	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			seminal vesicle: 33.9	Cell line enhanced		Karpas-707: 28.2
SNF8	Dot3, EAP30, VPS22	ENSG00000159210	SNF8, ESCRT-II complex subunit	17	48929316-48945117	Predicted intracellular proteins	Evidence at protein level	HPA059320	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.81e-7 (unfavourable), Liver cancer:7.64e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.0	Expressed in all		
CLIC6	CLIC1L, CLIC5	ENSG00000159212	Chloride intracellular channel 6	21	34669389-34718227	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA055123, HPA065285	Enhanced				Lung cancer:3.15e-5 (favourable), Breast cancer:6.11e-5 (favourable)	Mixed	Tissue enhanced		stomach: 79.1	cervix, uterine: 24.4	Cell line enhanced		HMC-1: 2.4;NTERA-2: 3.8;T-47d: 7.2;THP-1: 2.3
CCDC24	MGC45441	ENSG00000159214	Coiled-coil domain containing 24	1	43991359-43996528	Predicted intracellular proteins	Evidence at protein level	HPA035424, HPA061710	Uncertain		Enhanced	Plasma membrane<br>Cytosol	Breast cancer:3.06e-5 (favourable), Liver cancer:1.70e-4 (unfavourable), Head and neck cancer:3.18e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 18.3	testis: 15.2	Cell line enhanced		CAPAN-2: 11.7
RUNX1	AML1, AMLCR1, CBFA2, PEBP2A2	ENSG00000159216	Runt related transcription factor 1	21	34787801-36004667	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004176, HPA037912	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:3.44e-15 (unfavourable)	Expressed in all	Mixed			breast: 34.0	Cell line enhanced		HEL: 225.2
IGF2BP1	IMP-1	ENSG00000159217	Insulin like growth factor 2 mRNA binding protein 1	17	48997412-49055650	Predicted intracellular proteins	Evidence at protein level	HPA021367, HPA062273	Enhanced		Supported	Cytosol		Tissue enriched	Group enriched	6	placenta: 8.0;testis: 9.1	kidney: 1.4	Cell line enhanced		AF22: 145.0;CACO-2: 196.9;REH: 127.4
GIP		ENSG00000159224	Gastric inhibitory polypeptide	17	48958554-48968596	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016729, HPA021612	Enhanced					Tissue enriched	Group enriched	156	duodenum: 261.3;small intestine: 93.9	stomach: 1.1	Cell line enhanced		A549: 6.0;BEWO: 5.7;Hep G2: 6.5
CBR1	CBR, SDR21C1	ENSG00000159228	Carbonyl reductase 1	21	36069941-36073166	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018433	Approved		Approved	Nucleus<br>Cytosol	Breast cancer:2.18e-4 (favourable), Renal cancer:4.75e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 544.9	Mixed		
CBR3	SDR21C2	ENSG00000159231	Carbonyl reductase 3	21	36134912-36146566	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018434	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-6 (unfavourable)	Expressed in all	Mixed			skin: 20.7	Mixed		
GJD2	CX36, GJA9	ENSG00000159248	Gap junction protein delta 2	15	34751032-34754965	Predicted membrane proteins	Evidence at protein level	HPA014355	Uncertain					Tissue enriched	Group enriched	6	adrenal gland: 7.9;cerebral cortex: 1.9	pancreas: 0.8	Not detected		
ACTC1	ACTC, CMD1R	ENSG00000159251	Actin, alpha, cardiac muscle 1	15	34788096-34796139	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037330, HPA041264, HPA041271	Enhanced				Head and neck cancer:3.72e-5 (unfavourable), Urothelial cancer:9.32e-4 (unfavourable)	Group enriched	Tissue enriched	10	heart muscle: 1903.0	seminal vesicle: 191.9	Group enriched	7	fHDF/TERT166: 217.0;LHCN-M2: 930.7;RH-30: 512.0
MORC3	KIAA0136, NXP2, ZCW5, ZCWCC3	ENSG00000159256	MORC family CW-type zinc finger 3	21	36320189-36386148	Predicted intracellular proteins	Evidence at protein level	HPA018406, HPA034848	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			endometrium: 30.9	Expressed in all		
CHAF1B	CAF-1, CAF1, CAF1A, CAF1P60, MPHOSPH7, MPP7	ENSG00000159259	Chromatin assembly factor 1 subunit B	21	36385378-36419015	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021679, CAB033604	Enhanced		Supported	Nucleoplasm	Liver cancer:6.14e-6 (unfavourable), Cervical cancer:5.44e-5 (favourable), Colorectal cancer:7.92e-4 (favourable)	Expressed in all	Mixed			testis: 5.4	Expressed in all		
CLDN14	DFNB29	ENSG00000159261	Claudin 14	21	36460621-36576569	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA054707			Uncertain	Vesicles	Liver cancer:1.53e-4 (favourable)	Tissue enriched	Group enriched	11	kidney: 3.6;liver: 9.5	gallbladder: 0.6	Cell line enriched	18	HDLM-2: 205.9
SIM2	bHLHe15, MGC119447, SIM	ENSG00000159263	Single-minded family bHLH transcription factor 2	21	36699133-36749917	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029295	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 22.8;kidney: 13.0;prostate: 10.3	stomach: 5.1	Cell line enhanced		PC-3: 40.7;RPTEC TERT1: 41.3;RT4: 26.9
HLCS	HCS	ENSG00000159267	Holocarboxylase synthetase	21	36750888-36990236	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017379	Approved		Supported	Cytosol	Breast cancer:7.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.7	Expressed in all		
GOLGA6A	GLP, GOLGA6	ENSG00000159289	Golgin A6 family member A	15	74069857-74082550	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	9	testis: 19.6	liver: 2.1	Cell line enhanced		U-266/70: 1.0
SCUBE1		ENSG00000159307	Signal peptide, CUB domain and EGF like domain containing 1	22	43197283-43343388	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003190	Approved					Mixed	Tissue enhanced		ovary: 24.9	testis: 13.8	Cell line enhanced		AN3-CA: 7.2;HMC-1: 43.8;THP-1: 13.8
ARHGAP27	CAMGAP1, FLJ43547, SH3D20, SH3P20	ENSG00000159314	Rho GTPase activating protein 27	17	45393902-45434421	Predicted intracellular proteins	Evidence at protein level	HPA023919, HPA053053	Approved		Supported	Nucleus<br>Cytosol	Urothelial cancer:3.21e-4 (favourable)	Expressed in all	Mixed			esophagus: 14.0	Cell line enhanced		BEWO: 16.1;RT4: 20.7
ADPGK	ADP-GK, DKFZp434B195	ENSG00000159322	ADP dependent glucokinase	15	72751369-72785846	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045194, HPA058525	Approved		Approved	Centrosome	Renal cancer:4.52e-7 (unfavourable), Prostate cancer:2.22e-4 (unfavourable)	Expressed in all	Mixed			lung: 25.1	Expressed in all		
PTMS	ParaT	ENSG00000159335	Parathymosin	12	6765516-6770952	Predicted intracellular proteins	Evidence at protein level	HPA038186	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:6.18e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 136.1	Expressed in all		
PLA2G4D	cPLA2delta	ENSG00000159337	Phospholipase A2 group IVD	15	42067009-42094554	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Group enriched	29	prostate: 34.2;skin: 16.5	esophagus: 0.8	Cell line enriched	30	RPMI-8226: 12.2
PADI4	PAD, PADI5, PDI4, PDI5	ENSG00000159339	Peptidyl arginine deiminase 4	1	17308195-17364004	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017007, HPA042825	Enhanced					Not detected	Tissue enriched	12	bone marrow: 71.8	spleen: 5.9	Cell line enhanced		HEL: 1.1;RPMI-8226: 1.0
ADIPOR1	ACDCR1, PAQR1	ENSG00000159346	Adiponectin receptor 1	1	202940823-202958572	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Ovarian cancer:5.27e-4 (favourable), Pancreatic cancer:5.50e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 136.6	Expressed in all		
CYB5R1	humb5R2, NQO3A2	ENSG00000159348	Cytochrome b5 reductase 1	1	202961869-202967280	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010641, HPA014147	Enhanced		Uncertain	Nucleoli<br>Mitochondria<br>Cytosol	Endometrial cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 183.8	Expressed in all		
PSMD4	AF, AF-1, Rpn10, S5A	ENSG00000159352	Proteasome 26S subunit, non-ATPase 4	1	151254703-151267479	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038807, HPA039252, CAB047300	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-10 (unfavourable)	Expressed in all	Expressed in all			testis: 174.0	Expressed in all		
ATP13A2	CLN12, HSA9947, PARK9	ENSG00000159363	ATPase 13A2	1	16985958-17011928	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037038, CAB037111, HPA050910, HPA054717	Approved				Liver cancer:3.33e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 74.8	Expressed in all		
M1AP	C2orf65, D6Mm5e, SPATA37	ENSG00000159374	Meiosis 1 associated protein	2	74557883-74648338	Predicted intracellular proteins	Evidence at protein level	HPA045420, HPA059302	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 14.8	fallopian tube: 4.2	Group enriched	10	NTERA-2: 2.1;RT4: 1.6
PSMB4	HN3, PROS26	ENSG00000159377	Proteasome subunit beta 4	1	151399534-151401944	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006700	Approved		Approved	Intermediate filaments<br>Centrosome<br>Cytosol	Renal cancer:2.90e-10 (unfavourable), Liver cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 275.5	Expressed in all		
IRX6	IRX-3, IRX7	ENSG00000159387	Iroquois homeobox 6	16	55323760-55330760	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA018332	Uncertain		Approved	Nucleus<br>Mitochondria	Lung cancer:3.34e-4 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 8.6;heart muscle: 4.9	skin: 3.3	Cell line enhanced		AF22: 1.3;HEK 293: 1.5;RPTEC TERT1: 4.5;SK-MEL-30: 3.0
BTG2	APRO1, MGC126063, MGC126064, PC3, TIS21	ENSG00000159388	BTG anti-proliferation factor 2	1	203305491-203309602	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002355	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:8.53e-4 (favourable)	Expressed in all	Expressed in all			ovary: 666.8	Cell line enhanced		HMC-1: 140.5;U-266/70: 189.1
CES5A	CAUXIN, CES4C1, CES5, CES7, FLJ31547	ENSG00000159398	Carboxylesterase 5A	16	55846154-55956031	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047635	Uncertain					Tissue enhanced	Tissue enriched	40	epididymis: 79.9	liver: 1.9	Cell line enriched	29	U-266/70: 5.8
HK2		ENSG00000159399	Hexokinase 2	2	74833981-74893359	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028587	Enhanced				Renal cancer:1.37e-4 (unfavourable), Liver cancer:3.65e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 80.4	Cell line enhanced		U-87 MG: 168.5
C1R		ENSG00000159403	Complement C1r	12	7080209-7092607	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001251, HPA001551	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:1.94e-14 (unfavourable)	Expressed in all	Expressed in all			liver: 1226.4	Cell line enhanced		ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4
CELF3	BRUNOL1, CAGH4, ERDA4, MGC57297, TNRC4	ENSG00000159409	CUGBP Elav-like family member 3	1	151702404-151716814	Predicted intracellular proteins	Evidence at protein level	HPA006292	Uncertain		Approved	Nucleoplasm		Group enriched	Group enriched	6	adrenal gland: 15.2;cerebral cortex: 51.7	stomach: 5.5	Group enriched	10	SCLC-21H: 50.0;SH-SY5Y: 31.5
ALDH4A1	ALDH4, P5CDh	ENSG00000159423	Aldehyde dehydrogenase 4 family member A1	1	18871430-18902781	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004645, HPA006401	Enhanced				Cervical cancer:5.06e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 185.7;liver: 108.1	adipose tissue: 63.8	Expressed in all		
STARD9	KIAA1300, KIF16A	ENSG00000159433	StAR related lipid transfer domain containing 9	15	42575659-42720981	Predicted intracellular proteins	Evidence at protein level	HPA014562, HPA038631	Uncertain		Supported	Microtubules		Mixed	Mixed			testis: 14.4	Mixed		
THEM4	CTMP	ENSG00000159445	Thioesterase superfamily member 4	1	151873584-151909808	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028161	Approved				Liver cancer:1.38e-4 (unfavourable), Pancreatic cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			epididymis,kidney: 11.6	Mixed		
TCHH	THH	ENSG00000159450	Trichohyalin	1	152106317-152115454	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028375	Uncertain					Tissue enhanced	Tissue enhanced		placenta: 1.6;spleen: 2.1	testis: 1.2	Cell line enhanced		HaCaT: 3.2;SCLC-21H: 1.3;THP-1: 1.3
LCE2B	LEP10, SPRL1B, XP5	ENSG00000159455	Late cornified envelope 2B	1	152686123-152687401	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	skin: 564.7	breast: 56.0	Not detected		
UBR1		ENSG00000159459	Ubiquitin protein ligase E3 component n-recognin 1	15	42942897-43106113	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038838	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 27.4	Expressed in all		
AMFR	gp78, RNF45	ENSG00000159461	Autocrine motility factor receptor	16	56361452-56425538	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB026381, HPA029018, HPA077835	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 154.7	Expressed in all		
MED8	ARC32, MGC17544, MGC19641	ENSG00000159479	Mediator complex subunit 8	1	43383917-43389808	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028377, HPA028438	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.11e-7 (unfavourable), Liver cancer:2.04e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 41.6	Expressed in all		
TGM7	TGMZ	ENSG00000159495	Transglutaminase 7	15	43276280-43302255	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Group enriched	5	testis: 1.5;tonsil: 1.5	esophagus: 0.2	Cell line enriched	33	EFO-21: 3.3
RGL4	Rgr	ENSG00000159496	Ral guanine nucleotide dissociation stimulator like 4	22	23688136-23699176	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035979	Uncertain		Approved	Centrosome		Not detected	Tissue enriched	8	bone marrow: 107.4	lymph node: 12.9	Cell line enhanced		MOLT-4: 21.0;U-937: 47.3
SPRR2G		ENSG00000159516	Small proline rich protein 2G	1	153149582-153150869	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	10	skin: 271.7	tonsil: 27.2	Cell line enriched	12	hTCEpi: 2.5
PGLYRP3	PGLYRPIalpha, PGRP-Ialpha, PGRPIA	ENSG00000159527	Peptidoglycan recognition protein 3	1	153297862-153310718	Predicted secreted proteins	Evidence at protein level	HPA030369	Uncertain					Tissue enhanced	Group enriched	9	esophagus: 42.8;skin: 87.1	tonsil: 6.8	Group enriched	15	HaCaT: 3.4;HDLM-2: 1.4;hTCEpi: 1.0
ISL2	FLJ10160	ENSG00000159556	ISL LIM homeobox 2	15	76336724-76342476	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075192			Approved	Rods & Rings		Mixed	Not detected			prostate: 0.9	Cell line enhanced		HEK 293: 13.3
RSPRY1	KIAA1972	ENSG00000159579	Ring finger and SPRY domain containing 1	16	57186137-57240475	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003729	Approved				Head and neck cancer:8.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
CCDC17	FLJ33084	ENSG00000159588	Coiled-coil domain containing 17	1	45620044-45624057	Predicted intracellular proteins	Evidence at protein level	HPA028338	Enhanced					Tissue enhanced	Tissue enriched	17	fallopian tube: 54.5	lung: 3.2	Not detected		
GPBP1L1	SP192	ENSG00000159592	GC-rich promoter binding protein 1 like 1	1	45627304-45688113	Predicted intracellular proteins	Evidence at protein level	HPA028593	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Expressed in all			testis: 107.1	Expressed in all		
NAE1	APP-BP1, APPBP1, ula-1	ENSG00000159593	NEDD8 activating enzyme E1 subunit 1	16	66802875-66873256	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041178, HPA042041	Enhanced		Approved	Nucleus<br>Microtubules<br>Centrosome	Liver cancer:3.92e-8 (unfavourable), Thyroid cancer:9.44e-5 (favourable)	Expressed in all	Expressed in all			testis: 86.4	Expressed in all		
TMEM69	C1orf154, FLJ21029	ENSG00000159596	Transmembrane protein 69	1	45687214-45694443	Predicted membrane proteins	Evidence at transcript level	HPA026993	Approved		Approved	Nucleoplasm	Liver cancer:3.66e-8 (unfavourable), Breast cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
ADGRG5	GPR114, PGR27	ENSG00000159618	Adhesion G protein-coupled receptor G5	16	57542421-57591681	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007133	Enhanced		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Cervical cancer:4.25e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 11.2;tonsil: 8.8	appendix,spleen: 5.9	Cell line enriched	8	HMC-1: 31.8
DRC7	C16orf50, CCDC135, CFAP50, DKFZp434I099, FAP50	ENSG00000159625	Dynein regulatory complex subunit 7	16	57694793-57731805	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.61e-4 (favourable)	Tissue enhanced	Group enriched	18	fallopian tube: 32.4;testis: 81.2	parathyroid gland: 3.2	Cell line enhanced		Hep G2: 2.0
ACE	ACE1, CD143, DCP1	ENSG00000159640	Angiotensin I converting enzyme	17	63477061-63498380	Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002426, CAB002921, HPA029298, HPA069790	Enhanced		Approved	Vesicles		Expressed in all	Tissue enhanced		duodenum: 178.9;small intestine: 291.6	testis: 83.7	Cell line enhanced		ASC TERT1: 44.4;HUVEC TERT2: 28.2
TEPP		ENSG00000159648	Testis, prostate and placenta expressed	16	57976435-57988116	Predicted secreted proteins	Evidence at protein level	HPA062092	Enhanced					Tissue enhanced	Tissue enriched	9	testis: 7.3	thyroid gland: 0.8	Not detected		
UROC1	FLJ31300, HMFN0320	ENSG00000159650	Urocanate hydratase 1	3	126481281-126517773	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA069863	Enhanced					Tissue enriched	Tissue enriched	126	liver: 43.0	fallopian tube: 0.3	Cell line enriched	7	NB-4: 2.6
EFCAB14	KIAA0494	ENSG00000159658	EF-hand calcium binding domain 14	1	46675159-46719064	Predicted membrane proteins	Evidence at protein level	HPA011224, HPA011938	Supported		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 305.3	Expressed in all		
SPON2	DIL1	ENSG00000159674	Spondin 2	4	1166932-1208962	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040170, HPA066095	Uncertain		Approved	Vesicles	Endometrial cancer:2.03e-4 (favourable), Urothelial cancer:9.22e-4 (unfavourable)	Tissue enriched	Tissue enhanced		endometrium: 105.2;prostate: 113.0	cervix, uterine: 53.6	Group enriched	6	HHSteC: 216.0;HSkMC: 330.1
CHCHD6	CHCM1, MGC13016, Mic25, PPP1R23	ENSG00000159685	Coiled-coil-helix-coiled-coil-helix domain containing 6	3	126704220-126960406	Predicted intracellular proteins	Evidence at protein level	HPA047673, HPA051975	Approved		Supported	Mitochondria	Renal cancer:6.76e-4 (favourable), Cervical cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.8	Expressed in all		
CTBP1	BARS	ENSG00000159692	C-terminal binding protein 1	4	1211448-1249953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004217, HPA018987, HPA044971	Approved		Enhanced	Nucleoplasm	Endometrial cancer:4.03e-4 (favourable), Urothelial cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 141.8	Expressed in all		
LRRC36	FLJ11004	ENSG00000159708	Leucine rich repeat containing 36	16	67326798-67385203	Predicted intracellular proteins	Evidence at protein level	HPA055237, HPA058479	Enhanced					Mixed	Tissue enriched	7	testis: 62.5	placenta: 8.8	Cell line enhanced		hTEC/SVTERT24-B: 1.4
TPPP3	CGI-38, p20, p25gamma	ENSG00000159713	Tubulin polymerization promoting protein family member 3	16	67389809-67393535	Predicted intracellular proteins	Evidence at protein level	HPA047629	Approved		Approved	Nucleoli fibrillar center	Renal cancer:8.84e-4 (unfavourable)	Expressed in all	Tissue enriched	6	fallopian tube: 1311.7	lung: 213.8	Cell line enhanced		A549: 51.8;RH-30: 29.0;SCLC-21H: 54.1;SH-SY5Y: 21.0
ZDHHC1	C16orf1, HSU90653, ZNF377	ENSG00000159714	Zinc finger DHHC-type containing 1	16	67394419-67416833	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA042531, HPA048659	Uncertain		Approved	Cytosol	Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 31.8	Mixed		
ATP6V0D1	ATP6D, ATP6DV, P39, VATX, Vma6, VPATPD	ENSG00000159720	ATPase H+ transporting V0 subunit d1	16	67438014-67481237	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA016938	Uncertain				Renal cancer:1.76e-8 (favourable), Pancreatic cancer:1.20e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 187.1	Expressed in all		
AGRP	Agrt, ART, ASIP2	ENSG00000159723	Agouti related neuropeptide	16	67482571-67483813	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA041017	Uncertain	Supported				Mixed	Group enriched	5	adrenal gland: 5.8;epididymis: 24.7	lung: 3.0	Not detected		
ZFYVE28	KIAA1643	ENSG00000159733	Zinc finger FYVE-type containing 28	4	2269582-2418663	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038175, HPA057587	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.35e-6 (favourable)	Mixed	Mixed			cerebral cortex: 9.9	Mixed		
CARMIL2	LRRC16C, RLTPR	ENSG00000159753	Capping protein regulator and myosin 1 linker 2	16	67644919-67657569	Predicted intracellular proteins	Evidence at protein level	HPA041402	Approved					Mixed	Tissue enhanced		appendix: 16.2;lymph node: 25.0;spleen: 15.1	tonsil: 10.1	Cell line enhanced		Daudi: 45.8;MOLT-4: 51.3;REH: 96.9;RPMI-8226: 40.2;U-698: 73.2
C16orf86	FLJ41802	ENSG00000159761	Chromosome 16 open reading frame 86	16	67666816-67668758	Predicted intracellular proteins	Evidence at protein level	HPA073475	Enhanced				Renal cancer:2.12e-7 (favourable), Pancreatic cancer:1.47e-4 (favourable)	Expressed in all	Tissue enriched	7	testis: 27.5	parathyroid gland: 3.9	Cell line enhanced		HSkMC: 2.4
PIP	GCDFP-15, GCDFP15, GPIP4	ENSG00000159763	Prolactin induced protein	7	143132077-143139746	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002661, HPA009177	Enhanced				Renal cancer:5.96e-5 (favourable)	Tissue enriched	Group enriched	618	breast: 4504.1;salivary gland: 6904.2;seminal vesicle: 4198.4	cervix, uterine: 8.4	Cell line enriched	415	T-47d: 649.3
FAM131B	KIAA0773	ENSG00000159784	Family with sequence similarity 131 member B	7	143353400-143362770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021371, HPA029992			Enhanced	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	8	cerebral cortex: 63.8	parathyroid gland: 7.5	Cell line enhanced		CACO-2: 11.5;NTERA-2: 22.2;PC-3: 19.9;SCLC-21H: 25.4
RGS12		ENSG00000159788	Regulator of G-protein signaling 12	4	3293028-3439913	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054646, HPA067421			Supported	Nucleus<br>Nucleoli	Head and neck cancer:7.03e-4 (favourable), Renal cancer:8.43e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.7	Mixed		
PSKH1		ENSG00000159792	Protein serine kinase H1	16	67893272-67929678	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA053927	Approved		Approved	Nucleoplasm	Renal cancer:4.28e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.5	Expressed in all		
ZYX		ENSG00000159840	Zyxin	7	143381080-143391111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004835, CAB009321, HPA073497, CAB075747	Approved		Supported	Focal adhesion sites	Renal cancer:7.92e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 391.0	Expressed in all		
ABR	MDB	ENSG00000159842	Active BCR-related	17	1003518-1229021	Predicted intracellular proteins	Evidence at protein level	HPA053618, HPA054824	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.21e-4 (favourable), Cervical cancer:4.03e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 12.6	Cell line enhanced		Daudi: 26.9;LHCN-M2: 20.5;TIME: 33.6;U-251 MG: 34.7;U-698: 21.1
LYPD5	FLJ30469	ENSG00000159871	LY6/PLAUR domain containing 5	19	43795929-43827206	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042511, HPA054670	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:5.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 43.7	testis: 12.3	Cell line enhanced		A-431: 3.3;BEWO: 5.5;HaCaT: 5.3
CCDC117	FLJ33814	ENSG00000159873	Coiled-coil domain containing 117	22	28772674-28789301	Predicted intracellular proteins	Evidence at protein level	HPA000826	Uncertain		Approved	Nucleus<br>Microtubules<br>Cytosol		Mixed	Expressed in all			testis: 67.8	Expressed in all		
ZNF230	FDZF2	ENSG00000159882	Zinc finger protein 230	19	44002948-44013926	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006172			Approved	Mitochondria		Mixed	Mixed			ovary: 5.2	Mixed		
CCDC107	MGC31967	ENSG00000159884	Coiled-coil domain containing 107	9	35658290-35661511	Predicted membrane proteins	Evidence at protein level	HPA016857, HPA050442			Enhanced	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 63.7	Expressed in all		
ZNF222		ENSG00000159885	Zinc finger protein 222	19	44025342-44033112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004086	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:5.56e-7 (favourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
NPR2	AMDM, ANPb, ANPRB, GUCY2B, NPRB	ENSG00000159899	Natriuretic peptide receptor 2	9	35792154-35809732	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Mixed			endometrium: 31.1	Cell line enhanced		ASC diff: 37.7
ZNF221		ENSG00000159905	Zinc finger protein 221	19	43951223-43967709	Predicted intracellular proteins	Evidence at transcript level	HPA059435	Uncertain		Approved	Nuclear bodies		Mixed	Mixed			parathyroid gland: 5.1	Mixed		
ZNF233	FLJ38032	ENSG00000159915	Zinc finger protein 233	19	44259880-44275317	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA020975	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 26.1	cerebral cortex: 5.8	Mixed		
ZNF235	ANF270, HZF6, ZFP93, ZNF270	ENSG00000159917	Zinc finger protein 235	19	44228729-44305046	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045582	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			parathyroid gland: 5.1	Mixed		
GNE	IBM2, Uae1	ENSG00000159921	Glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase	9	36214441-36277056	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007045, HPA027258	Approved		Supported	Cytosol	Renal cancer:9.28e-11 (favourable)	Expressed in all	Expressed in all			rectum: 53.4	Cell line enhanced		RPTEC TERT1: 82.9
TNFRSF13C	BAFFR, CD268	ENSG00000159958	TNF receptor superfamily member 13C	22	41922023-41926818	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA003246, CAB008380	Enhanced		Uncertain	Nucleus	Cervical cancer:4.44e-7 (favourable)	Mixed	Group enriched	10	appendix: 22.9;lymph node: 46.1;spleen: 43.5;tonsil: 49.9	bone marrow: 4.0	Cell line enhanced		REH: 19.1;U-698: 7.7
OR3A3	OR17-137, OR17-16, OR17-201, OR3A6, OR3A7, OR3A8P	ENSG00000159961	Olfactory receptor family 3 subfamily A member 3	17	3420568-3421533	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			gallbladder,lymph node,tonsil: 0.1	Cell line enriched	10	HDLM-2: 1.5
ARHGAP35	GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP	ENSG00000160007	Rho GTPase activating protein 35	19	46918676-47005077	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037311, HPA055184, HPA056470	Approved		Supported	Nuclear bodies<br>Aggresome	Renal cancer:5.55e-8 (favourable)	Expressed in all	Expressed in all			testis: 76.2	Expressed in all		
PTGIR	IP	ENSG00000160013	Prostaglandin I2 (prostacyclin) receptor (IP)	19	46620468-46625118	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 13.9	appendix: 8.2	Cell line enhanced		BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
CALM3	PHKD	ENSG00000160014	Calmodulin 3	19	46601074-46610793	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA044999	Approved				Lung cancer:2.07e-4 (unfavourable), Thyroid cancer:9.10e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1313.4	Expressed in all		
DFFA	DFF-45, DFF1, DFF45, ICAD	ENSG00000160049	DNA fragmentation factor subunit alpha	1	10456522-10472526	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002679, HPA018859, HPA019938, HPA025230	Supported		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.57e-9 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 28.8	Expressed in all		
CCDC28B	MGC1203, RP4-622L5.5	ENSG00000160050	Coiled-coil domain containing 28B	1	32200386-32205387	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028589	Uncertain				Pancreatic cancer:1.10e-5 (favourable), Breast cancer:2.92e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 40.8	testis: 22.7	Mixed		
IQCC	FLJ10547	ENSG00000160051	IQ motif containing C	1	32205661-32208687	Predicted intracellular proteins	Evidence at protein level	HPA028602, HPA028686	Approved		Supported	Vesicles	Pancreatic cancer:8.23e-5 (favourable), Testis cancer:3.79e-4 (favourable), Lung cancer:5.65e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 11.6	thyroid gland: 6.0	Mixed		
TMEM234	C1orf91, dJ622L5.7, FLJ90779, RP4-622L5	ENSG00000160055	Transmembrane protein 234	1	32214472-32222359	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015049	Uncertain		Approved	Vesicles	Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable)	Expressed in all	Mixed			epididymis: 12.8	Expressed in all		
BSDC1	FLJ10276, RP4-811H24.7	ENSG00000160058	BSD domain containing 1	1	32365103-32394731	Predicted intracellular proteins	Evidence at protein level	HPA031358, HPA031360	Approved		Enhanced	Golgi apparatus	Head and neck cancer:8.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 113.4	Expressed in all		
ZBTB8A	BOZF1, FLJ90065, ZBTB8, ZNF916A	ENSG00000160062	Zinc finger and BTB domain containing 8A	1	32539427-32605939	Predicted intracellular proteins	Evidence at protein level	HPA031768, HPA031769, HPA031770	Approved		Approved	Nuclear speckles<br>Focal adhesion sites		Expressed in all	Mixed			endometrium: 10.3	Mixed		
ATAD3B	KIAA1273, TOB3	ENSG00000160072	ATPase family, AAA domain containing 3B	1	1471769-1497848	Predicted intracellular proteins	Evidence at protein level	HPA058968, HPA064867, HPA065305	Approved		Supported	Mitochondria	Renal cancer:5.48e-9 (unfavourable), Liver cancer:1.81e-5 (unfavourable)	Expressed in all	Mixed			appendix: 7.5	Mixed		
SSU72	HSPC182	ENSG00000160075	SSU72 homolog, RNA polymerase II CTD phosphatase	1	1541673-1574869	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069290, HPA070604	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 149.3	Expressed in all		
UBE2J2	NCUBE2, Ubc6p	ENSG00000160087	Ubiquitin conjugating enzyme E2 J2	1	1253909-1273885	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.00e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 115.2	Expressed in all		
ZNF362	FLJ25476, lin-29, RN	ENSG00000160094	Zinc finger protein 362	1	33256545-33300719	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059239	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			spleen: 22.1	Expressed in all		
FNDC5	FRCP2	ENSG00000160097	Fibronectin type III domain containing 5	1	32862268-32872482	Predicted membrane proteins	Evidence at protein level	HPA051290	Approved					Group enriched	Tissue enhanced		skeletal muscle: 110.2	heart muscle: 26.5	Cell line enhanced		RH-30: 45.0;SCLC-21H: 9.3
CPAMD8	K-CAP, KIAA1283, VIP	ENSG00000160111	C3 and PZP like, alpha-2-macroglobulin domain containing 8	19	16892947-17026815	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031327, HPA031328, HPA031330	Uncertain					Mixed	Tissue enhanced		prostate: 25.1;seminal vesicle: 52.1	lung: 22.8	Group enriched	10	BEWO: 18.7;EFO-21: 11.7;T-47d: 32.2
NR2F6	EAR-2, ERBAL2	ENSG00000160113	Nuclear receptor subfamily 2 group F member 6	19	17231883-17245940	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:4.36e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 30.9	Expressed in all		
ANKLE1	ANKRD41, FLJ39369, LEMD6	ENSG00000160117	Ankyrin repeat and LEM domain containing 1	19	17281645-17287646	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026789, HPA073498	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:4.86e-5 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 13.7	lymph node: 3.6	Cell line enhanced		Daudi: 47.2;U-937: 40.1
CCDC58	FLJ33273	ENSG00000160124	Coiled-coil domain containing 58	3	122359591-122383231	Predicted intracellular proteins	Evidence at protein level	HPA047777, HPA051965	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.94e-5 (unfavourable), Endometrial cancer:1.53e-4 (unfavourable), Urothelial cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			kidney: 47.4	Expressed in all		
VMA21	MEAX, XMEA	ENSG00000160131	VMA21, vacuolar ATPase assembly factor	X	151396515-151409364	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA010972	Uncertain				Cervical cancer:2.30e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.0	Expressed in all		
KALRN	ARHGEF24, DUET, duo, HAPIP, Hs.8004, Kalirin, TRAD	ENSG00000160145	Kalirin, RhoGEF kinase	3	124080023-124726325	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011913, CAB026456	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 51.3	spleen: 11.8	Cell line enhanced		CACO-2: 47.6;HEL: 31.9;SH-SY5Y: 16.9
CILP2	MGC45771	ENSG00000160161	Cartilage intermediate layer protein 2	19	19538248-19546659	Predicted secreted proteins	Evidence at protein level	HPA041847	Uncertain				Endometrial cancer:3.22e-6 (unfavourable), Ovarian cancer:2.50e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 2.5;testis: 4.2	adipose tissue: 0.8	Cell line enhanced		ASC diff: 3.2;HEK 293: 2.6
ABCG1	ABC8	ENSG00000160179	ATP binding cassette subfamily G member 1	21	42199689-42297244	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA031470, HPA031471	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:7.16e-6 (favourable)	Expressed in all	Expressed in all			lung: 43.5	Cell line enhanced		MCF7: 25.3;MOLT-4: 25.1;SCLC-21H: 26.2
TFF3	HITF, ITF	ENSG00000160180	Trefoil factor 3	21	42311667-42315651	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020681, HPA035464	Enhanced		Approved	Nucleus<br>Nucleoli	Endometrial cancer:5.60e-6 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 470.7;colon: 496.2;rectum: 504.3;thyroid gland: 620.1	small intestine: 457.0	Cell line enhanced		MCF7: 63.2;SCLC-21H: 28.3;T-47d: 35.0;TIME: 85.5
TFF2	SML1	ENSG00000160181	Trefoil factor 2	21	42346357-42351128	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB025834, HPA036705	Enhanced				Liver cancer:1.99e-4 (unfavourable)	Group enriched	Group enriched	29	duodenum: 1027.1;stomach: 5110.7	gallbladder: 107.1	Group enriched	20	CAPAN-2: 32.8;PC-3: 124.0
TFF1	BCEI, D21S21, HP1.A, HPS2, pNR-2, pS2	ENSG00000160182	Trefoil factor 1	21	42362282-42366594	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002170, HPA003425	Enhanced				Breast cancer:5.00e-4 (favourable), Endometrial cancer:5.67e-4 (favourable)	Group enriched	Tissue enriched	32	stomach: 6419.9	gallbladder: 203.1	Cell line enriched	49	MCF7: 8447.1
TMPRSS3	DFNB10, DFNB8	ENSG00000160183	Transmembrane protease, serine 3	21	42371890-42396846	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Colorectal cancer:3.64e-4 (unfavourable), Renal cancer:8.24e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 35.2	stomach: 13.7	Cell line enhanced		HEL: 58.2;SiHa: 35.3;U-266/84: 182.5
UBASH3A	CLIP4, STS-2, TULA	ENSG00000160185	Ubiquitin associated and SH3 domain containing A	21	42403447-42447681	Predicted intracellular proteins	Evidence at protein level	HPA035367			Supported	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		lymph node: 12.5	appendix: 6.7	Group enriched	6	HEL: 20.6;MOLT-4: 38.2
RSPH1	CILD24, FLJ32753, RSP44, RSPH10A, TSGA2	ENSG00000160188	Radial spoke head 1 homolog	21	42472486-42496354	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016816, HPA017382	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	6	fallopian tube: 251.8	testis: 42.3	Cell line enhanced		HEL: 4.8;MCF7: 8.1;RPTEC TERT1: 11.5
SLC37A1		ENSG00000160190	Solute carrier family 37 member 1	21	42496008-42581440	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030418, CAB034154	Approved				Thyroid cancer:3.43e-5 (favourable), Endometrial cancer:9.22e-5 (favourable)	Expressed in all	Mixed			duodenum: 45.6	Cell line enhanced		HEL: 112.3
PDE9A		ENSG00000160191	Phosphodiesterase 9A	21	42653636-42775509	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011380	Enhanced		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		prostate: 56.8	spleen: 25.5	Cell line enhanced		AF22: 29.5;EFO-21: 28.2;NTERA-2: 41.2;SCLC-21H: 26.8
WDR4	TRM82, TRMT82	ENSG00000160193	WD repeat domain 4	21	42843094-42879568	Predicted intracellular proteins	Evidence at protein level	HPA017381	Uncertain		Supported	Nucleus<br>Cytosol	Liver cancer:5.48e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 10.9	Expressed in all		
NDUFV3	CI-10k	ENSG00000160194	NADH:ubiquinone oxidoreductase subunit V3	21	42879644-42913304	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019791, HPA020463, HPA030427, CAB034142	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 29.0	Expressed in all		
PKNOX1	PREP1	ENSG00000160199	PBX/knotted 1 homeobox 1	21	42974510-43033931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004285, HPA057215, HPA065017	Approved		Enhanced	Nucleoplasm	Liver cancer:4.54e-8 (unfavourable), Pancreatic cancer:6.71e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 16.8	Expressed in all		
CBS	HIP4	ENSG00000160200	Cystathionine-beta-synthase	21	43053191-43076943	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001223	Supported		Approved	Nucleoli<br>Vesicles		Mixed	Tissue enhanced		liver: 56.6;ovary: 31.1	cerebral cortex: 19.8	Cell line enhanced		HAP1: 171.2;HHSteC: 181.6
U2AF1	RN, RNU2AF1, U2AF35, U2AFBP	ENSG00000160201	U2 small nuclear RNA auxiliary factor 1	21	43092956-43107587	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044833, HPA052083	Supported		Enhanced	Nucleoplasm		Not detected	Expressed in all			thyroid gland: 70.1	Expressed in all		
CRYAA	CRYA1, HSPB4	ENSG00000160202	Crystallin alpha A	21	43169008-43172805	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037737, HPA038430	Supported		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	8	kidney: 12.3	liver: 1.5	Cell line enriched	95	Hep G2: 25.4
HSF2BP		ENSG00000160207	Heat shock transcription factor 2 binding protein	21	43529192-43659493	Predicted intracellular proteins	Evidence at protein level	HPA031724			Approved	Nucleus<br>Cytosol		Mixed	Tissue enriched	9	testis: 40.8	cerebral cortex: 4.4	Cell line enhanced		HBEC3-KT: 9.1
RRP1B	KIAA0179, Nnp1, PPP1R136, RRP1	ENSG00000160208	Ribosomal RNA processing 1B	21	43659548-43696079	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017893, HPA020324	Supported		Enhanced	Nucleoli	Renal cancer:2.95e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 21.7	Expressed in all		
PDXK	C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79	ENSG00000160209	Pyridoxal kinase	21	43719094-43762307	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030196, HPA030197, HPA030198, CAB033918	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 47.5	Expressed in all		
G6PD	G6PD1	ENSG00000160211	Glucose-6-phosphate dehydrogenase	X	154531391-154547572	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000247, HPA000834	Enhanced		Approved	Vesicles<br>Microtubule organizing center<br>Cytosol	Liver cancer:9.45e-13 (unfavourable)	Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
CSTB	CST6, EPM1, PME, STFB	ENSG00000160213	Cystatin B	21	43772511-43776445	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA017380, CAB047320, HPA058557	Enhanced		Supported	Nucleoli<br>Cytosol	Liver cancer:6.66e-5 (unfavourable), Renal cancer:2.10e-4 (unfavourable)	Expressed in all	Tissue enriched	8	esophagus: 1822.8	tonsil: 228.0	Expressed in all		
RRP1	D21S2056E, NNP-1, Nop52, RRP1A	ENSG00000160214	Ribosomal RNA processing 1	21	43789513-43805293	Predicted intracellular proteins	Evidence at protein level	HPA016818, HPA018166	Approved		Enhanced	Nucleoli	Renal cancer:6.29e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 12.1	Expressed in all		
AGPAT3	LPAAT-gamma	ENSG00000160216	1-acylglycerol-3-phosphate O-acyltransferase 3	21	43865186-43986536	Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.29e-4 (favourable), Cervical cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 57.5	Mixed		
TRAPPC10	EHOC-1, TMEM1, TRS130	ENSG00000160218	Trafficking protein particle complex 10	21	44012319-44106552	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA050423	Supported					Expressed in all	Expressed in all			parathyroid gland: 14.4	Expressed in all		
GAB3		ENSG00000160219	GRB2 associated binding protein 3	X	154675249-154751583	Predicted intracellular proteins	Evidence at protein level	HPA010090	Approved				Renal cancer:5.07e-4 (unfavourable)	Mixed	Mixed			spleen: 17.6	Cell line enhanced		HEL: 21.1;HMC-1: 22.6
C21orf33	D21S2048E, ES1, GT335, HES1, KNP-I, KNP-Ia, KNPH, KNPI	ENSG00000160221	Chromosome 21 open reading frame 33	21	44133605-44145723	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018517	Supported		Approved	Centrosome<br>Mitochondria		Mixed	Expressed in all			kidney: 35.4	Cell line enhanced		Daudi: 101.9
ICOSLG	B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653	ENSG00000160223	Inducible T-cell costimulator ligand	21	44222991-44240966	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB026037, HPA029179	Uncertain		Supported	Plasma membrane<br>Cytoplasmic bodies		Not detected	Mixed			bone marrow: 10.3	Mixed		
AIRE	APECED, APS1, PGA1	ENSG00000160224	Autoimmune regulator	21	44285838-44298648	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038267	Uncertain					Tissue enriched	Not detected			lymph node: 0.3	Not detected		
C21orf2	A2, LRRC76, YF5	ENSG00000160226	Chromosome 21 open reading frame 2	21	44328944-44339402	Predicted intracellular proteins	Evidence at protein level	HPA030284, CAB034126, CAB034128	Supported		Approved	Nucleoplasm	Pancreatic cancer:1.32e-4 (favourable), Renal cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 17.9	Mixed		
ZNF66	FLJ16537, ZNF66P	ENSG00000160229	Zinc finger protein 66	19	20776304-20807322	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		ovary: 9.5	thyroid gland: 4.2	Cell line enhanced		RT4: 11.8
LRRC3	C21orf102	ENSG00000160233	Leucine rich repeat containing 3	21	44455486-44462196	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017975	Uncertain					Mixed	Mixed			liver: 4.1	Cell line enhanced		BEWO: 8.4;U-2 OS: 6.7
ITGB2	CD18, LFA-1, MAC-1, MFI7	ENSG00000160255	Integrin subunit beta 2	21	44885953-44931989	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008877, HPA016894	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			appendix: 239.2	Cell line enhanced		EFO-21: 120.5;THP-1: 518.6;U-937: 447.2
FAM207A	C21orf70, PRED56	ENSG00000160256	Family with sequence similarity 207 member A	21	44940010-44976989	Predicted intracellular proteins	Evidence at protein level	CAB034178, HPA036354	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:7.04e-4 (unfavourable), Renal cancer:7.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
RALGDS	RalGEF, RGDS, RGF	ENSG00000160271	Ral guanine nucleotide dissociation stimulator	9	133097720-133149334	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA025961, CAB032582	Approved		Approved	Nucleus	Cervical cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
FTCD		ENSG00000160282	Formimidoyltransferase cyclodeaminase	21	46136262-46155567	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020073, HPA030928, HPA030929, HPA036114	Enhanced		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable)	Tissue enriched	Group enriched	18	kidney: 100.2;liver: 184.7	testis: 7.7	Cell line enriched	24	Hep G2: 62.7
SPATC1L	C21orf56	ENSG00000160284	Spermatogenesis and centriole associated 1 like	21	46161148-46184476	Predicted intracellular proteins	Evidence at protein level	HPA018979, HPA019165, HPA029394	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.16e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 11.7	prostate: 7.4	Cell line enhanced		K-562: 33.7
LSS	OSC	ENSG00000160285	Lanosterol synthase	21	46188141-46228824	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA032060, HPA032062, CAB034116	Supported		Approved	Cytosol	Urothelial cancer:3.07e-4 (unfavourable), Stomach cancer:6.80e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 38.7	Expressed in all		
VAV2		ENSG00000160293	Vav guanine nucleotide exchange factor 2	9	133761894-133992604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003224	Uncertain		Approved	Vesicles	Renal cancer:7.39e-7 (favourable), Thyroid cancer:4.33e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 32.2	Mixed		
MCM3AP	GANP, KIAA0572, Map80, SAC3	ENSG00000160294	Minichromosome maintenance complex component 3 associated protein	21	46235126-46286297	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021527, HPA032103	Approved		Supported	Nucleus<br>Nuclear membrane<br>Cytosol	Pancreatic cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.8	Expressed in all		
C21orf58		ENSG00000160298	Chromosome 21 open reading frame 58	21	46300181-46323875	Predicted intracellular proteins	Evidence at protein level	HPA035110, HPA035111	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:4.20e-4 (favourable), Head and neck cancer:7.00e-4 (favourable), Melanoma:7.48e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 42.4	testis: 9.0	Mixed		
PCNT	KEN, KIAA0402, PCN, PCNT2, PCNTB, SCKL4	ENSG00000160299	Pericentrin	21	46324122-46445769	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016820, HPA019887, HPA032101	Enhanced		Enhanced	Centrosome		Expressed in all	Mixed			skeletal muscle: 24.3	Expressed in all		
DIP2A	C21orf106, Dip2, KIAA0184	ENSG00000160305	Disco interacting protein 2 homolog A	21	46458899-46569852	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052516	Uncertain		Approved	Nucleus	Head and neck cancer:9.35e-5 (favourable)	Expressed in all	Expressed in all			testis: 13.9	Expressed in all		
S100B	S100beta	ENSG00000160307	S100 calcium binding protein B	21	46598962-46605208	Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000073, HPA015768, CAB078196	Enhanced		Approved	Nucleus<br>Vesicles		Group enriched	Group enriched	8	adipose tissue: 208.2;cerebral cortex: 626.3	seminal vesicle: 49.5	Group enriched	6	SK-MEL-30: 519.7;WM-115: 1274.2
PRMT2	HRMT1L1, MGC111373	ENSG00000160310	Protein arginine methyltransferase 2	21	46635167-46665124	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018976, HPA029591	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 98.6	Expressed in all		
CLDND2	MGC33839	ENSG00000160318	Claudin domain containing 2	19	51367098-51369003	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA056971	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.3	spleen: 6.2	Mixed		
ZNF208	PMIDP, ZNF95	ENSG00000160321	Zinc finger protein 208	19	21932958-22010949	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Mixed			testis: 16.5	Group enriched	10	NTERA-2: 33.9;U-266/84: 7.7
ADAMTS13	C9orf8, DKFZp434C2322, FLJ42993, MGC118899, MGC118900, TTP, vWF-CP, VWFCP	ENSG00000160323	ADAM metallopeptidase with thrombospondin type 1 motif 13	9	133414358-133459402	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042014, HPA042844	Uncertain					Mixed	Mixed			liver: 6.2	Mixed		
CACFD1	C9orf7, D9S2135, flower	ENSG00000160325	Calcium channel flower domain containing 1	9	133459965-133470848	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015280			Approved	Nucleoplasm	Renal cancer:2.83e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.6	Mixed		
SLC2A6	GLUT6, GLUT9, HSA011372	ENSG00000160326	Solute carrier family 2 member 6	9	133471095-133479137	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042272, CAB046014	Uncertain				Renal cancer:1.02e-11 (unfavourable), Glioma:1.94e-4 (unfavourable), Liver cancer:8.82e-4 (unfavourable)	Expressed in all	Mixed			appendix: 6.1	Cell line enhanced		HMC-1: 57.7
ZNF761	FLJ16231, FLJ35333, KIAA2033	ENSG00000160336	Zinc finger protein 761	19	53431993-53458261	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:2.04e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 91.8	Mixed		
FCN2	EBP-37, FCNL, ficolin-2, P35	ENSG00000160339	Ficolin 2	9	134880812-134887520	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	5	liver: 55.0	breast: 10.4	Not detected		
C9orf116	MGC29761, PIERCE1, RbEST47	ENSG00000160345	Chromosome 9 open reading frame 116	9	135495181-135501734	Predicted intracellular proteins	Evidence at protein level	HPA021439, HPA065287	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:3.53e-5 (favourable)	Expressed in all	Group enriched	6	epididymis: 31.1;fallopian tube: 154.4;testis: 63.3	thyroid gland: 13.6	Cell line enhanced		T-47d: 39.2;U-2197: 39.8
LCN1	MGC71975, PMFA, TLC, TP, VEGP	ENSG00000160349	Lipocalin 1	9	135521438-135526532	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	11	fallopian tube: 3.1;seminal vesicle: 12.2	testis: 0.6	Not detected		
ZNF714		ENSG00000160352	Zinc finger protein 714	19	21082159-21125270	Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:4.27e-5 (favourable), Endometrial cancer:5.47e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 25.9	ovary: 21.9	Mixed		
GPSM1	AGS3, DKFZP727I051	ENSG00000160360	G-protein signaling modulator 1	9	136327476-136359605	Predicted intracellular proteins	Evidence at protein level	HPA042199	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:3.30e-4 (unfavourable), Colorectal cancer:6.07e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 28.4	Cell line enhanced		REH: 73.8
C19orf47	FLJ36888	ENSG00000160392	Chromosome 19 open reading frame 47	19	40319536-40348527	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041843, HPA046309	Uncertain		Enhanced	Nucleoplasm	Endometrial cancer:7.10e-5 (unfavourable), Liver cancer:1.41e-4 (unfavourable), Breast cancer:6.50e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.7	Expressed in all		
HIPK4	FLJ32818	ENSG00000160396	Homeodomain interacting protein kinase 4	19	40379271-40390187	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027733	Uncertain					Not detected	Group enriched	29	cerebral cortex: 4.7;testis: 14.6	endometrium: 0.3	Not detected		
CFAP157	C9orf117	ENSG00000160401	Cilia and flagella associated protein 157	9	127706989-127716002	Predicted intracellular proteins	Evidence at protein level	HPA021474, HPA021786	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.45e-4 (favourable)	Mixed	Tissue enriched	8	fallopian tube: 94.5	lung: 12.0	Cell line enhanced		A549: 5.9;SCLC-21H: 5.2
TOR2A	FLJ14771, TORP1	ENSG00000160404	Torsin family 2 member A	9	127731524-127735317	Predicted secreted proteins	Evidence at protein level	HPA071229	Approved				Stomach cancer:7.51e-4 (favourable)	Expressed in all	Mixed			bone marrow: 16.5	Expressed in all		
ST6GALNAC6	SIAT7F, ST6GALNACVI	ENSG00000160408	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 6	9	127885321-127905408	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA018890	Approved		Approved	Nucleus		Expressed in all	Expressed in all			rectum: 154.1	Expressed in all		
SHKBP1	PP203, Sb1	ENSG00000160410	SH3KBP1 binding protein 1	19	40576851-40591399	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041887	Uncertain		Approved	Cell Junctions		Expressed in all	Expressed in all			spleen: 53.4	Expressed in all		
RDH13	SDR7C3	ENSG00000160439	Retinol dehydrogenase 13	19	55039108-55071291	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042006	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:2.09e-4 (favourable)	Expressed in all	Mixed			placenta: 3.5	Mixed		
ZER1	C9orf60, Hzyg, ZYG, ZYG11BL	ENSG00000160445	Zyg-11 related cell cycle regulator	9	128729786-128772414	Predicted intracellular proteins	Evidence at protein level	HPA048464			Approved	Cytosol	Renal cancer:5.15e-11 (favourable), Cervical cancer:1.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 71.5	Expressed in all		
ZDHHC12	FLJ14524, ZNF400	ENSG00000160446	Zinc finger DHHC-type containing 12	9	128720869-128724127	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA059339	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			small intestine: 35.8	Mixed		
PKN3	PKNbeta, UTDP4-1	ENSG00000160447	Protein kinase N3	9	128702523-128720918	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045390, HPA058305	Uncertain		Approved	Vesicles		Expressed in all	Mixed			adipose tissue: 7.6	Cell line enhanced		HeLa: 45.8
SPTBN4	KIAA1642, SPTBN3	ENSG00000160460	Spectrin beta, non-erythrocytic 4	19	40466241-40576464	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054481	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	6	cerebral cortex: 18.6	adrenal gland: 2.8	Cell line enhanced		K-562: 1.6;Karpas-707: 1.8;SCLC-21H: 4.6;SH-SY5Y: 2.5
BRSK1	KIAA1811	ENSG00000160469	BR serine/threonine kinase 1	19	55282072-55312533	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021212, HPA061719	Supported		Supported	Nucleoplasm	Renal cancer:7.98e-6 (unfavourable), Pancreatic cancer:1.02e-4 (favourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 137.8	parathyroid gland: 24.6	Cell line enhanced		SCLC-21H: 65.8;SH-SY5Y: 53.1
COX6B2	COXVIB2, CT59, FLJ32865	ENSG00000160471	Cytochrome c oxidase subunit 6B2	19	55349306-55354814	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035014			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:9.70e-5 (unfavourable)	Mixed	Tissue enriched	14	testis: 74.5	rectum: 5.2	Group enriched	6	CAPAN-2: 21.1;SCLC-21H: 11.9
TMEM190	MDAC1	ENSG00000160472	Transmembrane protein 190	19	55376836-55378244	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enriched	9	fallopian tube: 231.3	testis: 26.4	Cell line enhanced		Hep G2: 7.3;SCLC-21H: 6.1
NLRP4	CLR19.5, CT58, FLJ32126, NALP4, PAN2, PYPAF4, RNH2	ENSG00000160505	NLR family pyrin domain containing 4	19	55836578-55881854	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		testis: 12.8;tonsil: 4.6	lymph node: 1.9	Cell line enriched	6	Daudi: 58.8
PLPP7	C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3	ENSG00000160539	Phospholipid phosphatase 7 (inactive)	9	131289694-131309262	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA070252	Uncertain		Approved	Nucleus<br>Vesicles		Mixed	Group enriched	5	heart muscle: 32.6;skeletal muscle: 72.2	cerebral cortex: 10.1	Cell line enhanced		AN3-CA: 10.2;ASC diff: 7.8;SCLC-21H: 13.4;SH-SY5Y: 9.1
TAOK1	FLJ14314, KIAA1361, MAP3K16, MARKK, PSK2, TAO1	ENSG00000160551	TAO kinase 1	17	29390464-29551904	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007669	Approved		Approved	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 41.5	Expressed in all		
MED27	CRSP34, CRSP8, MED3, TRAP37	ENSG00000160563	Mediator complex subunit 27	9	131860107-132079908	Predicted intracellular proteins	Evidence at protein level	HPA007002	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Cervical cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
DEDD2	FLAME-3	ENSG00000160570	Death effector domain containing 2	19	42198598-42220140	Predicted intracellular proteins	Evidence at protein level	HPA043419			Approved	Nucleoplasm	Urothelial cancer:3.26e-6 (favourable)	Expressed in all	Mixed			spleen: 11.8	Mixed		
SIK3	FLJ12240, KIAA0999, L19, QSK	ENSG00000160584	SIK family kinase 3	11	116843402-117098437	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045245, HPA048161	Enhanced		Approved	Nucleoplasm	Renal cancer:1.12e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.9	Expressed in all		
MPZL3		ENSG00000160588	Myelin protein zero like 3	11	118226690-118252350	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029116			Approved	Golgi apparatus	Thyroid cancer:3.64e-4 (favourable), Pancreatic cancer:4.98e-4 (unfavourable)	Expressed in all	Mixed			skin: 25.8	Cell line enhanced		CAPAN-2: 23.2;HMC-1: 25.7
JAML	AMICA, AMICA1, Gm638	ENSG00000160593	Junction adhesion molecule like	11	118193740-118225094	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047919	Approved				Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		appendix: 82.3	spleen: 67.0	Cell line enhanced		CACO-2: 4.8;HMC-1: 24.2
NEK8	NPHP9	ENSG00000160602	NIMA related kinase 8	17	28725897-28743455	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040661, HPA040679	Approved				Lung cancer:4.52e-4 (favourable), Colorectal cancer:6.98e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.7	Mixed		
TLCD1		ENSG00000160606	TLC domain containing 1	17	28724348-28727935	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042366	Enhanced				Renal cancer:9.05e-5 (unfavourable), Liver cancer:3.28e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 23.4	Cell line enhanced		SK-BR-3: 86.3
PCSK7	LPC, PC7, PC8, SPC7	ENSG00000160613	Proprotein convertase subtilisin/kexin type 7	11	117204337-117232525	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043181, HPA052957			Uncertain	Nucleus<br>Nuclear membrane<br>Nucleoli		Expressed in all	Expressed in all			endometrium: 75.4	Expressed in all		
SAFB	HET, SAFB1	ENSG00000160633	Scaffold attachment factor B	19	5623035-5668478	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001969, HPA016832, HPA020076	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:9.75e-5 (favourable), Urothelial cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 53.9	Expressed in all		
CD3G		ENSG00000160654	CD3g molecule	11	118344344-118355161	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017520, HPA038494	Enhanced				Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.4;tonsil: 18.8	spleen: 16.1	Cell line enriched	69	MOLT-4: 160.9
S100A1	S100-alpha, S100A	ENSG00000160678	S100 calcium binding protein A1	1	153627926-153632039	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB002599, HPA006462	Enhanced				Endometrial cancer:1.12e-4 (unfavourable), Renal cancer:3.08e-4 (unfavourable)	Group enriched	Group enriched	5	heart muscle: 1882.3;skeletal muscle: 995.9	thyroid gland: 267.2	Cell line enhanced		EFO-21: 122.7;Hep G2: 207.0;SK-MEL-30: 802.9
CHTOP	C1orf77, DKFZP547E1010, FOP, SRAG	ENSG00000160679	Chromatin target of PRMT1	1	153633982-153646306	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028647, HPA030540	Approved		Enhanced	Nuclear speckles	Renal cancer:2.02e-4 (unfavourable), Urothelial cancer:2.69e-4 (favourable), Melanoma:4.08e-4 (unfavourable), Liver cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.2	Expressed in all		
CXCR5	BLR1, CD185, MDR15	ENSG00000160683	C-X-C motif chemokine receptor 5	11	118883766-118897799	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB026149, HPA042432	Enhanced					Not detected	Tissue enhanced		appendix: 14.5;lymph node: 32.5;spleen: 21.0;tonsil: 14.3	bone marrow: 6.4	Group enriched	8	Daudi: 12.9;U-698: 43.3
ZBTB7B	c-Krox, hcKrox, ZBTB15, ZFP67, ZNF857B	ENSG00000160685	Zinc finger and BTB domain containing 7B	1	155002630-155018522	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006811, HPA025820	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			skin: 89.4	Mixed		
FLAD1	FAD1, PP591	ENSG00000160688	Flavin adenine dinucleotide synthetase 1	1	154983338-154993111	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028476, HPA028486, HPA028563	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.55e-6 (unfavourable), Liver cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 28.5	Expressed in all		
SHC1	p66, SHC, ShcA	ENSG00000160691	SHC adaptor protein 1	1	154962298-154974395	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001844, CAB005374, CAB016305	Supported		Enhanced	Cytosol	Renal cancer:2.22e-16 (unfavourable), Lung cancer:1.92e-4 (unfavourable), Cervical cancer:6.74e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 162.2	Expressed in all		
VPS11	PEP5, RNF108	ENSG00000160695	VPS11, CORVET/HOPS core subunit	11	119067692-119081978	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039020	Approved		Approved	Cytosol	Renal cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.5	Expressed in all		
NLRX1	CLR11.3, NOD9	ENSG00000160703	NLR family member X1	11	119166568-119184016	Predicted intracellular proteins	Evidence at protein level	HPA061516	Supported		Supported	Plasma membrane<br>Cell Junctions<br>Mitochondria	Renal cancer:2.59e-6 (favourable), Endometrial cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 37.8	Mixed		
ADAR	ADAR1, G1P1, IFI4	ENSG00000160710	Adenosine deaminase, RNA specific	1	154582062-154627999	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003890, HPA051519, CAB056157	Enhanced		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 121.4	Expressed in all		
IL6R	CD126	ENSG00000160712	Interleukin 6 receptor	1	154405193-154469450	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.65e-4 (favourable)	Expressed in all	Mixed			appendix: 33.4	Cell line enhanced		THP-1: 147.4;U-266/84: 186.8
UBE2Q1	NICE-5, PRO3094, UBE2Q	ENSG00000160714	Ubiquitin conjugating enzyme E2 Q1	1	154548577-154559028	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063368	Approved		Approved	Nucleoplasm<br>Centrosome	Renal cancer:4.84e-7 (unfavourable), Thyroid cancer:1.86e-5 (favourable), Liver cancer:8.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
CHRNB2		ENSG00000160716	Cholinergic receptor nicotinic beta 2 subunit	1	154567781-154580026	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	15	cerebral cortex: 21.2	adrenal gland: 1.4	Group enriched	7	SCLC-21H: 30.2;SH-SY5Y: 27.0
CRTC2	TORC2	ENSG00000160741	CREB regulated transcription coactivator 2	1	153947669-153958625	Predicted intracellular proteins	Evidence at protein level	HPA028454, HPA028465	Supported		Enhanced	Nucleoplasm	Renal cancer:1.35e-7 (unfavourable), Urothelial cancer:6.12e-5 (favourable), Colorectal cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.0	Expressed in all		
ANO10	FLJ10375, MGC47890, SCAR10, TMEM16K	ENSG00000160746	Anoctamin 10	3	43354859-43691594	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051569	Approved				Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 62.5	Mixed		
FDPS		ENSG00000160752	Farnesyl diphosphate synthase	1	155308748-155320666	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028200	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 186.4	Expressed in all		
RUSC1	NESCA	ENSG00000160753	RUN and SH3 domain containing 1	1	155320896-155331114	Predicted intracellular proteins	Evidence at protein level	HPA028510, HPA029922, HPA029923	Approved		Supported	Cytosol	Liver cancer:7.78e-6 (unfavourable), Renal cancer:9.24e-6 (unfavourable), Prostate cancer:2.65e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 38.5	Expressed in all		
FAM189B	C1orf2, cote1	ENSG00000160767	Family with sequence similarity 189 member B	1	155247205-155255483	Predicted membrane proteins	Evidence at protein level	HPA006659, HPA050674	Uncertain		Supported	Nucleoplasm	Renal cancer:3.43e-7 (unfavourable), Endometrial cancer:9.59e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Cervical cancer:4.98e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 6.8	Expressed in all		
PAQR6	FLJ22672, PRdelta	ENSG00000160781	Progestin and adipoQ receptor family member 6	1	156243321-156248117	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073505			Approved	Nucleus<br>Nucleoli	Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable)	Tissue enriched	Tissue enriched	9	cerebral cortex: 97.5	skin: 10.7	Cell line enhanced		U-266/70: 19.6
PMF1		ENSG00000160783	Polyamine modulated factor 1	1	156212993-156240042	Predicted intracellular proteins	Evidence at protein level	HPA034583, HPA071854			Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 68.6	Expressed in all		
SLC25A44	FLJ90431, KIAA0446	ENSG00000160785	Solute carrier family 25 member 44	1	156193932-156212796	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065411			Approved	Nucleus<br>Mitochondria	Pancreatic cancer:2.49e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 43.0	Expressed in all		
LMNA	CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1	ENSG00000160789	Lamin A/C	1	156082573-156140089	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004022, HPA006660	Supported					Expressed in all	Expressed in all			gallbladder: 343.4	Expressed in all		
CCR5	CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22	ENSG00000160791	C-C motif chemokine receptor 5 (gene/pseudogene)	3	46370854-46376206	CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable)	Expressed in all	Mixed			appendix: 20.4	Group enriched	17	Karpas-707: 4.9;U-266/84: 2.1
NBEAL2	KIAA0540	ENSG00000160796	Neurobeachin like 2	3	46979683-47009703	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051969	Approved				Head and neck cancer:4.60e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 76.6	Cell line enhanced		HEL: 69.8
CCDC12	MGC23918	ENSG00000160799	Coiled-coil domain containing 12	3	46921726-46982010	Predicted intracellular proteins	Evidence at protein level	HPA056814, HPA060530	Approved		Supported	Nucleoplasm	Renal cancer:1.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 58.1	Expressed in all		
PTH1R	PTHR, PTHR1	ENSG00000160801	Parathyroid hormone 1 receptor	3	46877746-46903799	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007978	Approved				Renal cancer:6.79e-6 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 158.9	adrenal gland: 36.7	Cell line enriched	8	RPTEC TERT1: 88.0
UBQLN4	A1U, C1orf6, UBIN	ENSG00000160803	Ubiquilin 4	1	156035301-156053794	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA061797	Approved		Supported	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 41.1	Expressed in all		
MYL3	CMH8, MLC1SB, MLC1V, VLC1	ENSG00000160808	Myosin light chain 3	3	46857872-46882169	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016564, CAB018662, HPA046859, HPA063034	Enhanced		Approved	Nucleoli<br>Mitochondria	Renal cancer:1.22e-8 (favourable)	Tissue enhanced	Group enriched	11	heart muscle: 1578.0;skeletal muscle: 1730.1	esophagus: 157.4	Cell line enhanced		CACO-2: 6.4;HSkMC: 5.6;RPTEC TERT1: 27.5
PPP1R35	C7orf47, MGC22793	ENSG00000160813	Protein phosphatase 1 regulatory subunit 35	7	100435282-100436565	Predicted intracellular proteins	Evidence at protein level	HPA021604, HPA051607	Enhanced		Approved	Nucleoplasm	Urothelial cancer:4.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 34.2	spleen: 17.9	Expressed in all		
GPATCH4	DKFZP434F1735, FLJ20249, GPATC4	ENSG00000160818	G-patch domain containing 4	1	156594487-156601496	Predicted intracellular proteins	Evidence at protein level	HPA028323, HPA054319	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:3.17e-5 (unfavourable), Renal cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
LRRC71	C1orf92, FLJ32884	ENSG00000160838	Leucine rich repeat containing 71	1	156920650-156933094	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	9	fallopian tube: 20.1;testis: 22.2	lung: 2.3	Cell line enhanced		HBEC3-KT: 2.6;PC-3: 1.5;TIME: 1.2
FCRL3	CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e	ENSG00000160856	Fc receptor like 3	1	157674321-157700857	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA048022	Enhanced					Mixed	Group enriched	13	appendix: 18.1;lymph node: 55.9;spleen: 36.7;tonsil: 32.3	urinary bladder: 2.8	Cell line enriched	7	Daudi: 6.9
AZGP1	ZA2G, ZAG	ENSG00000160862	Alpha-2-glycoprotein 1, zinc-binding	7	99966720-99976157	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012582, CAB016087, CAB032276	Enhanced				Renal cancer:1.53e-4 (favourable), Liver cancer:2.90e-4 (favourable)	Group enriched	Tissue enhanced		breast: 1201.5;liver: 1272.1;prostate: 1490.2;salivary gland: 1423.5	kidney: 294.4	Cell line enhanced		Hep G2: 33.7;RPMI-8226: 79.5;T-47d: 35.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
CYP3A4	CYP3A3	ENSG00000160868	Cytochrome P450 family 3 subfamily A member 4	7	99756960-99784265	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033671, HPA072245	Enhanced		Uncertain	Cytosol		Tissue enriched	Group enriched	199	duodenum: 826.8;liver: 2451.8;small intestine: 971.1	adrenal gland: 7.1	Cell line enhanced		BEWO: 1.8;NB-4: 1.3;RPMI-8226: 2.2;SCLC-21H: 1.4;SH-SY5Y: 2.4
CYP3A7	CP37, P450-HFLA	ENSG00000160870	Cytochrome P450 family 3 subfamily A member 7	7	99705037-99735196	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol		Tissue enriched	Tissue enriched	15	liver: 143.3	kidney: 9.8	Cell line enhanced		Hep G2: 1.6;HHSteC: 1.0
NACC1	BEND8, BTBD14B, BTBD30, NAC-1, NAC1	ENSG00000160877	Nucleus accumbens associated 1	19	13118103-13141141	Predicted intracellular proteins	Evidence at protein level	HPA021238, HPA062245, CAB069927	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 37.1	Expressed in all		
CYP11B1	CPN1, CYP11B, FHI, P450C11	ENSG00000160882	Cytochrome P450 family 11 subfamily B member 1	8	142872356-142879846	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	916	adrenal gland: 1871.2	testis: 2.0	Not detected		
HK3		ENSG00000160883	Hexokinase 3	5	176880869-176899332	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056743	Enhanced				Renal cancer:3.84e-8 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 87.9	spleen: 27.9	Cell line enhanced		SCLC-21H: 5.3;THP-1: 2.5;U-937: 16.3
LY6K	CT97, FLJ35226, HSJ001348	ENSG00000160886	Lymphocyte antigen 6 family member K	8	142700111-142705127	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017770, CAB075742, CAB075743	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Lung cancer:9.17e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 29.0	adipose tissue: 5.9	Cell line enhanced		A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
IER2	ETR101	ENSG00000160888	Immediate early response 2	19	13150415-13154908	Predicted intracellular proteins	Evidence at protein level	HPA055387, HPA060574			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 161.2	Expressed in all		
ZNF394	FLJ12298, ZKSCAN14, ZSCAN46	ENSG00000160908	Zinc finger protein 394	7	99486519-99500324	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051421, HPA054639	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.09e-4 (favourable), Lung cancer:2.11e-4 (favourable), Breast cancer:3.56e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 62.0	Expressed in all		
CPSF4	CPSF30, NAR	ENSG00000160917	Cleavage and polyadenylation specific factor 4	7	99438922-99457371	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049094, HPA066470	Uncertain		Supported	Nucleoplasm	Renal cancer:1.68e-4 (unfavourable), Liver cancer:5.87e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.8	Expressed in all		
LY6E	RIG-E, SCA-2, TSA-1	ENSG00000160932	Lymphocyte antigen 6 family member E	8	143017982-143023832	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level						Renal cancer:6.74e-8 (unfavourable)	Expressed in all	Expressed in all			lung: 109.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 564.1;MCF7: 492.5
VPS28		ENSG00000160948	VPS28, ESCRT-I subunit	8	144423601-144428563	Predicted intracellular proteins	Evidence at protein level	HPA024688, HPA024745	Enhanced				Endometrial cancer:9.93e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 237.0	Expressed in all		
TONSL	IKBR, NFKBIL2	ENSG00000160949	Tonsoku-like, DNA repair protein	8	144428775-144444444	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024679, HPA046494	Uncertain		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.62e-7 (unfavourable), Liver cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 5.4	Mixed		
PTGER1	EP1	ENSG00000160951	Prostaglandin E receptor 1	19	14472466-14475362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		kidney: 2.9;spleen: 2.5	lung: 0.7	Cell line enhanced		HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
MUM1	EXPAND1, MUM-1	ENSG00000160953	Melanoma associated antigen (mutated) 1	19	1354711-1378431	Predicted intracellular proteins	Evidence at protein level	HPA048063	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:2.25e-6 (favourable), Endometrial cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			testis: 51.0	Expressed in all		
RECQL4	RecQ4	ENSG00000160957	RecQ like helicase 4	8	144511288-144517845	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017800, HPA025821	Supported		Enhanced	Nucleus	Liver cancer:1.91e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Mixed		
LRRC14	KIAA0014, LRRC14A	ENSG00000160959	Leucine rich repeat containing 14	8	144517992-144525178	Predicted intracellular proteins	Evidence at protein level	HPA021047	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.6	Expressed in all		
ZNF333	KIAA1806	ENSG00000160961	Zinc finger protein 333	19	14689801-14733746	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA043973, HPA054680	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			endometrium: 11.1	Mixed		
COL26A1	EMI6, EMID2, Emu2	ENSG00000160963	Collagen type XXVI alpha 1 chain	7	101362820-101559024	Predicted secreted proteins	Evidence at protein level	HPA027059	Approved		Approved	Vesicles	Liver cancer:2.32e-5 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 10.2;parathyroid gland: 5.4	prostate: 3.1	Cell line enhanced		AF22: 29.3;BEWO: 22.8;HAP1: 10.9;NTERA-2: 25.1
PPP1R16A	MGC14333, MYPT3	ENSG00000160972	Protein phosphatase 1 regulatory subunit 16A	8	144477969-144502121	Predicted intracellular proteins	Evidence at protein level	HPA023755	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			duodenum: 27.2	Mixed		
FOXH1	FAST1	ENSG00000160973	Forkhead box H1	8	144473412-144476335	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			small intestine: 0.9	Cell line enriched	21	NTERA-2: 20.6
ORAI2	C7orf19, CBCIP2, FLJ12474, FLJ14733, H_NH0514P08.8, TMEM142B	ENSG00000160991	ORAI calcium release-activated calcium modulator 2	7	102433106-102456821	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055137, HPA065937	Uncertain		Approved	Nucleus	Pancreatic cancer:8.49e-5 (favourable), Thyroid cancer:6.65e-4 (favourable)	Expressed in all	Mixed			appendix: 41.9	Expressed in all		
ALKBH4	FLJ20013	ENSG00000160993	AlkB homolog 4, lysine demethylase	7	102456238-102464876	Predicted intracellular proteins	Evidence at protein level	HPA051422	Approved				Renal cancer:3.09e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.0	Expressed in all		
CCDC105	FLJ40365	ENSG00000160994	Coiled-coil domain containing 105	19	15010744-15023269	Predicted intracellular proteins	Evidence at protein level	HPA058585	Approved					Not detected	Tissue enriched	104	testis: 11.7	skin: 0.1	Not detected		
SH2B2	APS	ENSG00000160999	SH2B adaptor protein 2	7	102285091-102321711	Predicted intracellular proteins	Evidence at protein level	HPA051131	Uncertain		Enhanced	Cytosol	Renal cancer:6.99e-7 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 12.9	Cell line enhanced		Daudi: 46.0;Karpas-707: 43.6;U-266/70: 42.7;U-266/84: 73.5;U-698: 59.4
MRNIP	C5orf45, DKFZp686L2452, LOC51149, MGC65027, MGC78537	ENSG00000161010	MRN complex interacting protein	5	179835133-179862173	Predicted intracellular proteins	Evidence at protein level	HPA043975	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.64e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube: 13.8	Mixed		
SQSTM1	A170, OSIL, p60, p62, p62B, PDB3	ENSG00000161011	Sequestosome 1	5	179806398-179838078	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004587, HPA064165, HPA068843	Supported		Enhanced	Vesicles<br>Cytosol	Liver cancer:2.31e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 371.5	Expressed in all		
MGAT4B	GnT-Ivb	ENSG00000161013	Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme B	5	179797597-179806952	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052134	Uncertain				Glioma:8.53e-5 (unfavourable), Renal cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 153.7	Expressed in all		
RPL8	L8	ENSG00000161016	Ribosomal protein L8	8	144789765-144792587	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA045095, HPA050165	Enhanced		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Liver cancer:7.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 954.7	Expressed in all		
MAML1	KIAA0200, Mam-1	ENSG00000161021	Mastermind like transcriptional coactivator 1	5	179732850-179796511	Predicted intracellular proteins	Evidence at protein level	HPA037687, HPA057531	Approved		Enhanced	Nucleoplasm	Renal cancer:1.84e-5 (unfavourable), Melanoma:9.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 15.3	small intestine: 8.5	Cell line enhanced		SK-MEL-30: 15.6
PGLYRP2	PGLYRPL, PGRP-L, PGRPL, tagL, tagL-alpha, tagl-beta, TAGL-like	ENSG00000161031	Peptidoglycan recognition protein 2	19	15468645-15498956	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB033468, HPA043568, HPA046311, HPA075237	Approved		Approved	Cell Junctions		Tissue enriched	Tissue enriched	17	liver: 133.2	testis: 7.8	Group enriched	8	MCF7: 5.7;T-47d: 6.8
LRWD1	CENP-33, DKFZp434K1815, ORCA	ENSG00000161036	Leucine rich repeats and WD repeat domain containing 1	7	102464929-102473168	Predicted intracellular proteins	Evidence at protein level	HPA021320	Enhanced		Supported	Nucleus<br>Nucleoli<br>Vesicles	Pancreatic cancer:8.71e-5 (favourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Tissue enriched	11	testis: 209.0	fallopian tube: 18.8	Expressed in all		
FBXL13	DRC6, Fbl13, MGC21636	ENSG00000161040	F-box and leucine rich repeat protein 13	7	102813230-103074843	Predicted intracellular proteins	Evidence at protein level	HPA057232	Uncertain					Mixed	Group enriched	5	fallopian tube: 7.9;testis: 37.4	stomach: 4.5	Cell line enhanced		HUVEC TERT2: 11.6;U-266/84: 12.5;U-87 MG: 9.3;U-937: 9.5
NAPEPLD	C7orf18, FMP30, NAPE-PLD	ENSG00000161048	N-acyl phosphatidylethanolamine phospholipase D	7	103099776-103149560	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019832, HPA024338	Approved		Enhanced	Cytosol	Renal cancer:7.32e-6 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.2	Mixed		
SCGB3A1	HIN-1, HIN1, LU105, PnSP-2, UGRP2	ENSG00000161055	Secretoglobin family 3A member 1	5	180590103-180591540	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	6	breast: 125.3;cervix, uterine: 345.8;lung: 301.1;salivary gland: 193.1	stomach: 40.9	Cell line enhanced		NB-4: 1.3
PSMC2	MSS1, Nbla10058, S7	ENSG00000161057	Proteasome 26S subunit, ATPase 2	7	103344254-103369395	Predicted intracellular proteins	Evidence at protein level	HPA019238, HPA049621	Supported		Supported	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			testis: 105.0	Expressed in all		
CELF5	BRUNOL5	ENSG00000161082	CUGBP Elav-like family member 5	19	3224703-3297076	Predicted intracellular proteins	Evidence at protein level	HPA042012, HPA060336	Enhanced					Tissue enhanced	Tissue enriched	7	cerebral cortex: 38.1	ovary: 5.1	Cell line enhanced		NTERA-2: 3.5;REH: 4.0;SCLC-21H: 5.2;SH-SY5Y: 2.8
MFSD12	C19orf28, MGC20700, PP3501	ENSG00000161091	Major facilitator superfamily domain containing 12	19	3538261-3574290	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042149, HPA043088	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable)	Tissue enriched	Expressed in all			skin: 64.2	Expressed in all		
USP41		ENSG00000161133	Ubiquitin specific peptidase 41	22	20350578-20390758	Enzymes, Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Cell line enhanced		RH-30: 1.2;SCLC-21H: 1.8
YDJC		ENSG00000161179	YdjC homolog (bacterial)	22	21628089-21630064	Predicted intracellular proteins	Evidence at protein level	HPA061005			Approved	Nucleoplasm	Urothelial cancer:8.98e-5 (favourable), Liver cancer:9.84e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 2.8	Cell line enhanced		K-562: 71.0
CCDC116	FLJ36046	ENSG00000161180	Coiled-coil domain containing 116	22	21632716-21637327	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	testis: 23.1	placenta: 0.7	Cell line enhanced		HMC-1: 2.7
DVL3	KIAA0208	ENSG00000161202	Dishevelled segment polarity protein 3	3	184155388-184173610	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB046486, HPA058265	Approved		Approved	Intermediate filaments<br>Midbody ring<br>Centrosome	Renal cancer:1.53e-8 (unfavourable), Prostate cancer:4.77e-5 (unfavourable), Colorectal cancer:1.90e-4 (unfavourable), Liver cancer:8.41e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 55.3	Expressed in all		
AP2M1	AP50, CLAPM1, mu2	ENSG00000161203	Adaptor related protein complex 2 mu 1 subunit	3	184174689-184184091	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036849, HPA069870	Uncertain		Supported	Plasma membrane	Renal cancer:7.45e-6 (unfavourable), Liver cancer:9.12e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 557.6	Expressed in all		
ABCF3	EST201864	ENSG00000161204	ATP binding cassette subfamily F member 3	3	184186023-184194012	Predicted intracellular proteins	Evidence at protein level	HPA036332	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:4.16e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.2	Expressed in all		
PCYT1A	CT, CTPCT, PCYT1	ENSG00000161217	Phosphate cytidylyltransferase 1, choline, alpha	3	196214222-196287957	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035428	Approved		Approved	Nucleus	Liver cancer:8.65e-5 (unfavourable)	Expressed in all	Expressed in all			duodenum: 66.9	Expressed in all		
FBXO27	Fbg5, Fbx27	ENSG00000161243	F-box protein 27	19	38990714-39032785	Predicted intracellular proteins	Evidence at protein level	HPA046800, HPA062242	Approved		Approved	Nucleoplasm	Endometrial cancer:3.53e-5 (unfavourable), Breast cancer:2.15e-4 (favourable), Glioma:7.83e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 22.7	esophagus: 8.4	Cell line enhanced		RT4: 14.1
DMKN	ZD52F10	ENSG00000161249	Dermokine	19	35497220-35513658	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029406	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.37e-6 (favourable)	Mixed	Tissue enriched	15	skin: 3991.5	breast: 259.8	Cell line enhanced		CACO-2: 150.9;HBEC3-KT: 169.4;RPTEC TERT1: 173.1
U2AF1L4	MGC33901, U2AF1L3, U2af26	ENSG00000161265	U2 small nuclear RNA auxiliary factor 1 like 4	19	35742464-35745445	Predicted intracellular proteins	Evidence at protein level	HPA052083, HPA061644	Supported		Approved	Nucleoplasm	Head and neck cancer:2.58e-5 (favourable), Pancreatic cancer:8.58e-5 (favourable), Renal cancer:9.73e-5 (unfavourable), Breast cancer:2.44e-4 (favourable), Urothelial cancer:7.05e-4 (favourable)	Expressed in all	Mixed			testis: 7.7	Mixed		
BDH1	BDH, SDR9C1	ENSG00000161267	3-hydroxybutyrate dehydrogenase 1	3	197509783-197573323	Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030947, HPA058709	Enhanced		Enhanced	Mitochondria	Renal cancer:7.12e-8 (favourable), Liver cancer:9.86e-7 (favourable), Cervical cancer:1.09e-4 (favourable)	Expressed in all	Tissue enriched	6	liver: 170.2	colon: 27.0	Cell line enhanced		U-937: 60.1
NPHS1	CNF, NPHN	ENSG00000161270	NPHS1, nephrin	19	35825964-35869287	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB035555	Enhanced					Mixed	Tissue enhanced		kidney: 17.7;lymph node: 5.4;pancreas: 5.5	tonsil: 2.3	Cell line enhanced		HMC-1: 1.1
THAP8	FLJ32891	ENSG00000161277	THAP domain containing 8	19	36034985-36054762	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064056, HPA070139			Enhanced	Nucleoplasm	Liver cancer:1.32e-4 (unfavourable), Pancreatic cancer:3.19e-4 (favourable)	Expressed in all	Mixed			testis: 9.0	Mixed		
COX7A1	COX7A, COX7AH	ENSG00000161281	Cytochrome c oxidase subunit 7A1	19	36150922-36152869	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Group enriched	6	heart muscle: 357.0;skeletal muscle: 1077.7	adipose tissue: 117.8	Cell line enhanced		ASC diff: 34.1;ASC TERT1: 25.4;BJ: 29.4;BJ hTERT+: 23.3;fHDF/TERT166: 41.5;HHSteC: 27.7;HSkMC: 24.9
ZNF382	FLJ14686, KS1	ENSG00000161298	Zinc finger protein 382	19	36604817-36634113	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049259	Approved		Approved	Nuclear speckles		Mixed	Mixed			cerebral cortex: 10.9	Mixed		
LRRC56	DKFZp761L1518, FLJ00101	ENSG00000161328	Leucine rich repeat containing 56	11	537527-554916	Predicted intracellular proteins	Evidence at transcript level	HPA038728	Uncertain				Lung cancer:6.19e-4 (favourable), Pancreatic cancer:6.32e-4 (favourable), Endometrial cancer:7.39e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 3.9	epididymis,fallopian tube: 1.5	Cell line enhanced		AN3-CA: 1.7;Karpas-707: 1.8;T-47d: 1.8
PLXDC1	TEM3, TEM7	ENSG00000161381	Plexin domain containing 1	17	39063303-39154394	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012805	Approved				Renal cancer:9.15e-8 (unfavourable)	Expressed in all	Mixed			gallbladder: 22.8	Cell line enhanced		BJ hTERT+: 7.5;U-87 MG: 5.7
PGAP3	CAB2, MGC9753, PER1, PERLD1, PP1498	ENSG00000161395	Post-GPI attachment to proteins 3	17	39671122-39696797	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016591	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 35.6	Cell line enhanced		SK-BR-3: 99.2
IKZF3	Aiolos, ZNFN1A3	ENSG00000161405	IKAROS family zinc finger 3	17	39757715-39864188	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017105, HPA024377	Enhanced		Uncertain	Plasma membrane<br>Cytosol	Cervical cancer:6.85e-6 (favourable), Head and neck cancer:4.16e-4 (favourable), Melanoma:5.42e-4 (favourable), Renal cancer:7.38e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 44.7;spleen: 31.7;tonsil: 39.2	appendix: 25.5	Cell line enhanced		Daudi: 50.3;Karpas-707: 25.9;U-266/70: 32.8;U-266/84: 35.9;U-698: 78.2
GRIN2C	GluN2C, NMDAR2C	ENSG00000161509	Glutamate ionotropic receptor NMDA type subunit 2C	17	74842023-74861504	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 9.5;thyroid gland: 14.1	heart muscle: 6.1	Cell line enhanced		BEWO: 6.1;SCLC-21H: 3.3
FDXR	ADXR	ENSG00000161513	Ferredoxin reductase	17	74862497-74873031	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008597, CAB009818, HPA044393, HPA053673	Enhanced		Enhanced	Mitochondria	Endometrial cancer:2.38e-4 (favourable)	Expressed in all	Tissue enriched	6	adrenal gland: 232.0	testis: 39.1	Expressed in all		
SAP30BP	HCNGP, HTRG, HTRP	ENSG00000161526	SAP30 binding protein	17	75667116-75708062	Predicted intracellular proteins	Evidence at protein level	HPA042382, HPA052943	Supported		Enhanced	Nucleoplasm	Liver cancer:4.71e-5 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
ACOX1	PALMCOX	ENSG00000161533	Acyl-CoA oxidase 1	17	75941507-75979363	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB021094, HPA021192, HPA021195, HPA028759	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:5.25e-7 (favourable)	Expressed in all	Expressed in all			liver: 98.4	Expressed in all		
PRPSAP1	PAP39	ENSG00000161542	Phosphoribosyl pyrophosphate synthetase associated protein 1	17	76309486-76384521	Predicted intracellular proteins	Evidence at protein level	HPA062396			Approved	Cytosol	Colorectal cancer:1.39e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 82.4	Expressed in all		
CYGB	HGB, STAP	ENSG00000161544	Cytoglobin	17	76527356-76551175	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA017757, HPA061642	Approved	Approved	Enhanced	Nuclear speckles	Endometrial cancer:2.55e-5 (favourable), Glioma:1.63e-4 (unfavourable), Renal cancer:2.13e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 46.4	Cell line enhanced		ASC diff: 50.4;Hep G2: 40.6;HHSteC: 93.4;HSkMC: 66.1;SH-SY5Y: 131.4
SRSF2	PR264, SC-35, SC35, SFRS2, SFRS2A	ENSG00000161547	Serine and arginine rich splicing factor 2	17	76734115-76737374	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049905	Supported		Approved	Nucleus<br>Cytosol	Liver cancer:3.53e-8 (unfavourable), Renal cancer:1.05e-7 (unfavourable), Endometrial cancer:8.73e-4 (unfavourable), Urothelial cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 127.2	Expressed in all		
ZNF577	MGC4400	ENSG00000161551	Zinc finger protein 577	19	51804816-51890950	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041499, HPA046761	Uncertain		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.03e-4 (favourable)	Mixed	Mixed			ovary: 28.9	Mixed		
TMEM143	FLJ10922	ENSG00000161558	Transmembrane protein 143	19	48332356-48364237	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014476	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.53e-7 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 32.5	heart muscle: 15.5	Expressed in all		
KLHL10	FLJ32662	ENSG00000161594	Kelch like family member 10	17	41835685-41848384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067538	Enhanced					Not detected	Tissue enriched	48	testis: 90.0	epididymis: 1.8	Not detected		
CCDC155	FLJ32658, KASH5	ENSG00000161609	Coiled-coil domain containing 155	19	49388218-49417994	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019937, HPA019940	Enhanced					Tissue enhanced	Tissue enriched	135	testis: 56.9	pancreas: 0.4	Cell line enhanced		SCLC-21H: 1.5;U-266/70: 2.7
HCRT	OX, PPOX	ENSG00000161610	Hypocretin neuropeptide precursor	17	42184060-42185452	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB004758	Uncertain					Tissue enhanced	Not detected			adipose tissue,appendix,cerebral cortex,duodenum: 0.1	Not detected		
ALDH16A1	MGC10204	ENSG00000161618	Aldehyde dehydrogenase 16 family member A1	19	49453169-49471048	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA059488	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			spleen: 17.6	Mixed		
DCD	AIDD, DCD-1, DSEP, HCAP, PIF	ENSG00000161634	Dermcidin	12	54644591-54648493	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063967	Supported					Tissue enriched	Tissue enriched	96	breast: 336.4	skeletal muscle: 3.5	Not detected		
ITGA5	CD49e, FNRA	ENSG00000161638	Integrin subunit alpha 5	12	54395261-54419460	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002642, CAB009008	Enhanced				Renal cancer:1.32e-8 (unfavourable), Cervical cancer:4.07e-6 (unfavourable), Liver cancer:2.23e-5 (unfavourable), Lung cancer:2.44e-4 (unfavourable), Head and neck cancer:2.91e-4 (unfavourable), Colorectal cancer:8.43e-4 (unfavourable), Thyroid cancer:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 489.0	Cell line enhanced		HUVEC TERT2: 1106.4;TIME: 1039.6;U-87 MG: 602.5
SIGLEC11		ENSG00000161640	Sialic acid binding Ig like lectin 11	19	49948985-49961172	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA060278	Approved					Mixed	Group enriched	7	ovary: 80.0;spleen: 31.7	adrenal gland: 8.1	Cell line enriched	15	HEL: 9.4
ZNF385A	DKFZp586G1122, Hzf, ZFP385, ZNF385	ENSG00000161642	Zinc finger protein 385A	12	54369133-54391298	Predicted intracellular proteins	Evidence at protein level	HPA039799			Supported	Nucleus<br>Cytosol	Renal cancer:9.75e-5 (unfavourable), Colorectal cancer:5.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 170.0	cerebral cortex: 66.1	Cell line enhanced		HEL: 98.3
MPP3	DLG3	ENSG00000161647	Membrane palmitoylated protein 3	17	43800799-43833170	Predicted intracellular proteins	Evidence at protein level	HPA021818, HPA024742	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 2.9	Cell line enhanced		SCLC-21H: 11.2
CD300LG	CLM9, Trem4	ENSG00000161649	CD300 molecule like family member g	17	43847148-43863629	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Group enriched	5	adipose tissue: 143.0;placenta: 86.4;testis: 33.9	lung: 17.3	Not detected		
IZUMO2	C19orf41, MGC33947, SCRL	ENSG00000161652	IZUMO family member 2	19	50152548-50163195	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042143	Uncertain					Not detected	Tissue enriched	250	testis: 56.1	prostate,skin,thyroid gland: 0.2	Not detected		
NAGS	AGAS, ARGA, NAT7	ENSG00000161653	N-acetylglutamate synthase	17	44004546-44009063	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027300			Supported	Mitochondria		Expressed in all	Tissue enhanced		duodenum: 14.8;small intestine: 13.6	liver: 5.0	Cell line enhanced		HHSteC: 4.0;TIME: 5.0;U-87 MG: 8.7
LSM12	FLJ30656	ENSG00000161654	LSM12 homolog	17	44034635-44067619	Predicted intracellular proteins	Evidence at protein level	HPA051934	Approved		Approved	Cytosol	Renal cancer:1.18e-7 (unfavourable), Pancreatic cancer:7.49e-5 (unfavourable), Liver cancer:1.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.1	Expressed in all		
ASB16	FLJ30165	ENSG00000161664	Ankyrin repeat and SOCS box containing 16	17	44170447-44179083	Predicted intracellular proteins	Evidence at protein level	HPA066834	Approved		Approved	Focal adhesion sites		Mixed	Tissue enriched	5	skeletal muscle: 23.2	spleen: 4.2	Mixed		
EMC10	C19orf63, HSM1, HSS1, INM02	ENSG00000161671	ER membrane protein complex subunit 10	19	50476400-50490870	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053905	Uncertain				Renal cancer:6.64e-6 (favourable), Pancreatic cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 63.8	Cell line enhanced		HEK 293: 176.7
JOSD2	SBBI54	ENSG00000161677	Josephin domain containing 2	19	50505998-50511353	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.04e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 16.8	Mixed		
SHANK1	SPANK-1, SSTRIP, synamon	ENSG00000161681	SH3 and multiple ankyrin repeat domains 1	19	50661827-50719450	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032129, HPA032130	Uncertain		Supported	Plasma membrane		Tissue enhanced	Tissue enriched	24	cerebral cortex: 35.8	adrenal gland: 1.5	Cell line enhanced		REH: 4.6;U-138 MG: 2.6;U-2 OS: 7.1
FAM171A2	MGC34829	ENSG00000161682	Family with sequence similarity 171 member A2	17	44353215-44363875	Predicted membrane proteins	Evidence at protein level	HPA019770	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 13.3	epididymis: 3.3	Cell line enhanced		REH: 20.9;SCLC-21H: 18.5
DBF4B	ASKL1, chifb, DRF1, FLJ13087, ZDBF1B	ENSG00000161692	DBF4 zinc finger B	17	44708608-44752264	Predicted intracellular proteins	Evidence at protein level	HPA048465	Uncertain		Supported	Nucleus		Expressed in all	Mixed			testis: 5.6	Mixed		
PLCD3		ENSG00000161714	Phospholipase C delta 3	17	45108967-45133354	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025711, HPA053665	Approved		Approved	Plasma membrane	Lung cancer:2.89e-6 (unfavourable), Thyroid cancer:4.28e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 29.7	Mixed		
FMNL3	DKFZp762B245, MGC45819, WBP3	ENSG00000161791	Formin like 3	12	49636499-49708165	Predicted intracellular proteins	Evidence at protein level	HPA002552, HPA023201	Uncertain		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Mixed			lymph node: 28.0	Mixed		
AQP5		ENSG00000161798	Aquaporin 5	12	49961870-49965681	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065008	Enhanced		Approved	Plasma membrane	Head and neck cancer:1.75e-5 (favourable)	Tissue enhanced	Group enriched	8	salivary gland: 255.6;stomach: 53.3;testis: 176.4	breast: 21.1	Group enriched	9	CAPAN-2: 7.6;REH: 9.2
RACGAP1	MgcRacGAP	ENSG00000161800	Rac GTPase activating protein 1	12	49976923-50033136	Predicted intracellular proteins	Evidence at protein level	CAB025859, HPA039427, HPA043912	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.98e-8 (unfavourable), Liver cancer:1.86e-6 (unfavourable), Pancreatic cancer:4.12e-6 (unfavourable), Breast cancer:1.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 84.3	lymph node: 28.6	Expressed in all		
OR7G1	OR19-15, OR7G1P	ENSG00000161807	Olfactory receptor family 7 subfamily G member 1	19	9114828-9115763	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LARP4	PP13296	ENSG00000161813	La ribonucleoprotein domain family member 4	12	50392383-50480004	Predicted intracellular proteins	Evidence at protein level	HPA039306, HPA039673	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			adrenal gland: 36.6	Expressed in all		
GRASP	Tamalin	ENSG00000161835	General receptor for phosphoinositides 1 associated scaffold protein	12	52006940-52015889	Predicted intracellular proteins	Evidence at protein level	HPA040664, HPA062028	Approved		Approved	Nuclear bodies<br>Vesicles		Expressed in all	Mixed			adipose tissue: 21.6	Cell line enhanced		HUVEC TERT2: 27.8;TIME: 19.7;WM-115: 43.6
RAVER1	KIAA1978	ENSG00000161847	Ribonucleoprotein, PTB binding 1	19	10316212-10333640	Predicted intracellular proteins	Evidence at protein level	HPA043575, HPA049457	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			small intestine: 20.2	Expressed in all		
KRT84	Hb-4, KRTHB4	ENSG00000161849	Keratin 84	12	52377812-52385652	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039714	Supported					Tissue enhanced	Not detected			tonsil: 0.5	Not detected		
KRT82	Hb-2, KRTHB2	ENSG00000161850	Keratin 82	12	52393931-52406355	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058715, HPA067230	Enhanced					Not detected	Not detected			placenta,testis: 0.1	Not detected		
SYCE2	CESC1	ENSG00000161860	Synaptonemal complex central element protein 2	19	12898786-12919276	Predicted intracellular proteins	Evidence at protein level	HPA042080, HPA062919	Enhanced		Supported	Nucleus	Cervical cancer:3.85e-5 (favourable), Endometrial cancer:9.91e-4 (unfavourable)	Mixed	Tissue enriched	15	testis: 38.9	cerebral cortex: 2.5	Cell line enhanced		EFO-21: 11.1;SiHa: 12.6
SPC24	FLJ90806, SPBC24	ENSG00000161888	SPC24, NDC80 kinetochore complex component	19	11131520-11155808	Predicted intracellular proteins	Evidence at protein level	HPA051234	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:1.46e-4 (unfavourable), Cervical cancer:3.59e-4 (favourable)	Expressed in all	Mixed			bone marrow: 16.6	Mixed		
IP6K3	IHPK3, INSP6K3	ENSG00000161896	Inositol hexakisphosphate kinase 3	6	33721670-33746905	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053644	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.09e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 32.4;thyroid gland: 21.9	heart muscle: 9.1	Cell line enhanced		HHSteC: 18.4;LHCN-M2: 30.1;RH-30: 15.3
LEMD2	dJ482C21.1, NET25	ENSG00000161904	LEM domain containing 2	6	33771202-33789136	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017340	Supported		Enhanced	Nuclear membrane	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.8	Expressed in all		
ALOX15	15-LOX-1	ENSG00000161905	Arachidonate 15-lipoxygenase	17	4630902-4642294	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004962, CAB004963, HPA013859	Approved					Mixed	Tissue enhanced		fallopian tube: 19.6;lung: 9.8	breast: 4.7	Group enriched	7	HMC-1: 13.6;MCF7: 10.8;T-47d: 3.9
TREML1	dJ238O23.3, TLT1	ENSG00000161911	Triggering receptor expressed on myeloid cells like 1	6	41149342-41154337	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA016700, HPA017860	Enhanced					Mixed	Tissue enhanced		bone marrow: 5.0;lymph node: 6.5	tonsil: 4.4	Cell line enriched	176	HEL: 59.6
ZNF653	Zip67	ENSG00000161914	Zinc finger protein 653	19	11483427-11505923	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023631, HPA023635	Uncertain		Supported	Nucleus	Endometrial cancer:4.15e-4 (favourable), Colorectal cancer:8.37e-4 (unfavourable), Urothelial cancer:8.74e-4 (favourable)	Expressed in all	Mixed			testis: 19.0	Expressed in all		
MED11	HSPC296, MGC88387	ENSG00000161920	Mediator complex subunit 11	17	4731428-4733610	Predicted intracellular proteins	Evidence at protein level	HPA056669	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:1.86e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
CXCL16	CXCLG16, SR-PSOX, SRPSOX	ENSG00000161921	C-X-C motif chemokine ligand 16	17	4733526-4739922	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053253, HPA066315	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			lung: 106.0	Cell line enhanced		A-431: 84.5;CACO-2: 54.2;HaCaT: 93.1
SCIMP	C17orf87, DTFT5783, FLJ32580, MGC163426, MGC163428, UNQ5783	ENSG00000161929	SLP adaptor and CSK interacting membrane protein	17	5208961-5234860	Predicted membrane proteins	Evidence at protein level	HPA006117	Enhanced					Mixed	Tissue enhanced		spleen: 68.5	lymph node: 45.9	Cell line enhanced		U-698: 7.7
RNASEK-C17orf49		ENSG00000161939	RNASEK-C17orf49 readthrough	17	7012635-7017520	Predicted membrane proteins	Evidence at protein level	HPA022961, HPA024457	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Not detected	Not detected			endometrium,small intestine,testis: 0.6	Cell line enhanced		U-87 MG: 3.6
BCL6B	BAZF, ZBTB28, ZNF62	ENSG00000161940	B-cell CLL/lymphoma 6B	17	7023020-7030290	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059147, HPA075112	Uncertain		Approved	Vesicles	Head and neck cancer:8.56e-5 (favourable), Renal cancer:4.04e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 34.6	Group enriched	14	HEL: 16.2;HMC-1: 46.5;HUVEC TERT2: 79.9;TIME: 30.9
ASGR2	CLEC4H2	ENSG00000161944	Asialoglycoprotein receptor 2	17	7101322-7115700	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014899, HPA015998	Enhanced		Supported	Endoplasmic reticulum<br>Plasma membrane		Tissue enriched	Tissue enriched	11	liver: 317.7	gallbladder: 28.1	Cell line enriched	7	Hep G2: 356.8
TNFSF13	APRIL, CD256	ENSG00000161955	Tumor necrosis factor superfamily member 13	17	7558292-7561608	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004863	Uncertain				Renal cancer:1.30e-9 (favourable), Glioma:8.28e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 149.6	Cell line enhanced		EFO-21: 41.1;RPTEC TERT1: 83.9
SENP3	DKFZP586K0919, DKFZp762A152, SMT3IP1, SSP3, Ulp1	ENSG00000161956	SUMO1/sentrin/SMT3 specific peptidase 3	17	7561875-7571969	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060290	Supported		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:6.22e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.4	Expressed in all		
FGF11	FHF3, FLJ16061, MGC102953, MGC45269	ENSG00000161958	Fibroblast growth factor 11	17	7438273-7444937	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA066605, HPA075188	Enhanced		Approved	Centrosome		Mixed	Tissue enhanced		adrenal gland: 17.3;skin: 13.7	cerebral cortex: 10.3	Cell line enhanced		HaCaT: 16.3
EIF4A1	DDX2A, EIF-4A, EIF4A	ENSG00000161960	Eukaryotic translation initiation factor 4A1	17	7572706-7579005	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011689, HPA068286	Uncertain		Approved	Cytosol	Renal cancer:1.76e-8 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 458.2	Expressed in all		
RPL26	L26	ENSG00000161970	Ribosomal protein L26	17	8377520-8383213	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA030449, CAB037301	Supported		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			breast: 5194.8	Expressed in all		
CCDC42	CCDC42A, FLJ32734	ENSG00000161973	Coiled-coil domain containing 42	17	8729934-8745219	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	364	testis: 128.6	lung,spleen: 0.3	Not detected		
POLR3K	RPC11	ENSG00000161980	RNA polymerase III subunit K	16	46407-53628	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA005891	Approved		Uncertain	Nucleus<br>Cytosol		Expressed in all	Expressed in all			lymph node: 20.5	Expressed in all		
SNRNP25	C16orf33, U11/U12-25K	ENSG00000161981	Small nuclear ribonucleoprotein U11/U12 subunit 25	16	53010-57669	Predicted intracellular proteins	Evidence at protein level	HPA041183, HPA044248	Uncertain		Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.16e-5 (favourable), Cervical cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 55.4	Expressed in all		
PRR35	C16orf11	ENSG00000161992	Proline rich 35	16	560422-565528	Predicted intracellular proteins	Evidence at transcript level	HPA069297	Uncertain					Not detected	Tissue enhanced		kidney: 2.9	testis: 0.8	Not detected		
WDR90	C16orf15, C16orf16, C16orf17, C16orf18, C16orf19, FLJ36483, KIAA1924	ENSG00000161996	WD repeat domain 90	16	649311-667833	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049362, HPA061785	Approved		Approved	Nuclear speckles	Head and neck cancer:2.70e-4 (favourable)	Expressed in all	Mixed			testis: 28.1	Mixed		
JMJD8	C16orf20	ENSG00000161999	Jumonji domain containing 8	16	681671-684528	Predicted secreted proteins	Evidence at transcript level							Expressed in all	Expressed in all			parathyroid gland: 59.8	Mixed		
CCDC78	C16orf25, FLJ34512	ENSG00000162004	Coiled-coil domain containing 78	16	722582-726954	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	11	fallopian tube: 97.7	lung: 8.5	Cell line enhanced		SCLC-21H: 13.2
MSLNL	C16orf37, MPFL	ENSG00000162006	Mesothelin-like	16	769428-783370	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Not detected			epididymis: 0.8	Group enriched	5	CAPAN-2: 9.8;HeLa: 4.3
SSTR5		ENSG00000162009	Somatostatin receptor 5	16	1078781-1080142	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA066503			Supported	Plasma membrane		Mixed	Tissue enhanced		adrenal gland: 1.2	kidney: 0.5	Group enriched	15	Hep G2: 10.4;PC-3: 50.7
SPSB3	C16orf31, SSB-3	ENSG00000162032	SplA/ryanodine receptor domain and SOCS box containing 3	16	1776712-1793700	Predicted intracellular proteins	Evidence at protein level	HPA046602	Approved		Approved	Mitochondria		Mixed	Expressed in all			adrenal gland: 29.1	Mixed		
MEIOB	C16orf73, MGC35212	ENSG00000162039	Meiosis specific with OB domains	16	1833983-1884294	Predicted intracellular proteins	Evidence at protein level	HPA042547			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	61	testis: 71.4	kidney: 1.1	Group enriched	5	HMC-1: 24.7;K-562: 85.3;THP-1: 55.0
HS3ST6	HS3ST5	ENSG00000162040	Heparan sulfate-glucosamine 3-sulfotransferase 6	16	1911463-1918440	Enzymes, Predicted intracellular proteins	Evidence at protein level						Cervical cancer:3.73e-4 (favourable)	Tissue enhanced	Tissue enriched	10	skin: 9.5	fallopian tube: 0.9	Not detected		
C16orf59	FLJ13909	ENSG00000162062	Chromosome 16 open reading frame 59	16	2460080-2464963	Predicted intracellular proteins	Evidence at protein level	HPA051394, HPA055389	Approved		Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 5.5	bone marrow,lymph node: 2.5	Mixed		
CCNF	FBX1, FBXO1	ENSG00000162063	Cyclin F	16	2429394-2458854	Predicted intracellular proteins	Evidence at protein level	HPA060596, HPA070495, HPA071600	Enhanced		Supported	Centrosome	Liver cancer:7.46e-7 (unfavourable)	Expressed in all	Mixed			lymph node,tonsil: 8.6	Expressed in all		
TBC1D24	DFNA65, DFNB86, KIAA1171, TLDC6	ENSG00000162065	TBC1 domain family member 24	16	2475051-2509560	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044712, HPA068080	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Breast cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 23.0	Expressed in all		
AMDHD2	CGI-14	ENSG00000162066	Amidohydrolase domain containing 2	16	2520357-2531422	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041184, HPA041321	Enhanced		Approved	Nucleoli<br>Cytosol	Cervical cancer:5.19e-4 (favourable)	Expressed in all	Mixed			testis: 15.9	Mixed		
NTN3	NTN2L	ENSG00000162068	Netrin 3	16	2471499-2474145	Predicted secreted proteins	Evidence at protein level	HPA050817	Uncertain					Mixed	Not detected			testis: 0.6	Group enriched	5	REH: 4.8;SCLC-21H: 7.6;SH-SY5Y: 3.8
BICDL2	CCDC64B	ENSG00000162069	BICD family like cargo adaptor 2	16	3027682-3036926	Predicted intracellular proteins	Evidence at protein level	HPA043251	Uncertain		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol	Urothelial cancer:9.04e-4 (favourable)	Mixed	Tissue enhanced		skin: 28.5	stomach: 17.2	Cell line enhanced		BEWO: 14.7;CAPAN-2: 12.6;HaCaT: 19.6;MCF7: 17.2;T-47d: 13.1
PAQR4	FLJ30002	ENSG00000162073	Progestin and adipoQ receptor family member 4	16	2969245-2973489	Predicted membrane proteins	Evidence at protein level	HPA068394			Approved	Vesicles	Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 54.0;parathyroid gland: 65.2	prostate,skin: 19.2	Mixed		
FLYWCH2		ENSG00000162076	FLYWCH family member 2	16	2883186-2899382	Predicted intracellular proteins	Evidence at protein level	HPA041354	Uncertain		Approved	Nucleus	Pancreatic cancer:1.87e-5 (favourable), Cervical cancer:9.38e-4 (favourable)	Expressed in all	Expressed in all			spleen: 35.1	Expressed in all		
ZG16B	HRPE773, JCLN2, PRO1567	ENSG00000162078	Zymogen granule protein 16B	16	2830169-2839585	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041125, HPA053549	Enhanced		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:3.48e-6 (favourable)	Tissue enhanced	Tissue enriched	225	salivary gland: 19471.0	prostate: 86.7	Cell line enhanced		MCF7: 20.7;SK-BR-3: 18.1;T-47d: 20.8
ZNF75A	FLJ31529	ENSG00000162086	Zinc finger protein 75a	16	3305406-3318852	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001665	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 46.7	Mixed		
ADCY9	AC9	ENSG00000162104	Adenylate cyclase 9	16	3953387-4116185	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041328, HPA044225	Approved		Approved	Cytosol	Renal cancer:5.24e-8 (favourable), Endometrial cancer:2.55e-5 (unfavourable)	Expressed in all	Mixed			thyroid gland: 31.9	Mixed		
SHANK2	CORTBP1, CTTNBP1, ProSAP1, SHANK, SPANK-3	ENSG00000162105	SH3 and multiple ankyrin repeat domains 2	11	70467856-71252577	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008174	Approved				Renal cancer:1.94e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.9	thyroid gland: 11.6	Cell line enhanced		Karpas-707: 16.4;RT4: 16.7;T-47d: 15.1
CLPB	ANKCLB, FLJ13152, HSP78, SKD3	ENSG00000162129	ClpB homolog, mitochondrial AAA ATPase chaperonin	11	72292425-72434680	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039005, HPA039006, HPA064571	Enhanced				Renal cancer:8.36e-8 (favourable)	Expressed in all	Tissue enriched	10	testis: 176.6	parathyroid gland: 18.5	Expressed in all		
NEU3		ENSG00000162139	Neuraminidase 3	11	74988134-75018893	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038729, HPA038730, HPA070381	Uncertain		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:5.98e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.4	Expressed in all		
CYB561A3	CYBASC3	ENSG00000162144	Cytochrome b561 family member A3	11	61348745-61362299	Predicted membrane proteins	Evidence at protein level	HPA052548	Approved					Expressed in all	Expressed in all			adrenal gland: 187.1	Expressed in all		
PPP1R32	C11orf66, FLJ32771, IIIG9	ENSG00000162148	Protein phosphatase 1 regulatory subunit 32	11	61481120-61490931	Predicted intracellular proteins	Evidence at protein level	HPA039068	Enhanced				Endometrial cancer:4.13e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 64.8;testis: 87.5	epididymis: 15.5	Mixed		
ASRGL1	ALP, ALP1, FLJ22316	ENSG00000162174	Asparaginase like 1	11	62337448-62393412	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029725, HPA055572, CAB070192	Enhanced		Approved	Nucleoplasm<br>Microtubules	Renal cancer:4.32e-7 (favourable), Endometrial cancer:1.56e-5 (favourable), Colorectal cancer:6.14e-4 (favourable), Liver cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 181.6	Cell line enhanced		HAP1: 86.4;SCLC-21H: 132.5
GNG3		ENSG00000162188	G protein subunit gamma 3	11	62707658-62709201	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enriched	Tissue enriched	17	cerebral cortex: 315.2	adrenal gland: 19.0	Group enriched	7	Karpas-707: 104.6;SCLC-21H: 335.7
UBXN1	2B28, LOC51035, SAKS1, UBXD10	ENSG00000162191	UBX domain protein 1	11	62676498-62679117	Predicted intracellular proteins	Evidence at protein level	HPA012669	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			ovary: 145.9	Expressed in all		
LBHD1	C11orf48, MGC2477	ENSG00000162194	LBH domain containing 1	11	62662817-62672255	Predicted intracellular proteins	Evidence at protein level	HPA012127, HPA023592	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 9.3	Mixed		
TTC9C	MGC29649	ENSG00000162222	Tetratricopeptide repeat domain 9C	11	62728069-62740293	Predicted intracellular proteins	Evidence at protein level	HPA055169	Approved		Approved	Nucleoplasm	Renal cancer:4.67e-7 (unfavourable), Stomach cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.0	Expressed in all		
TAF6L	PAF65A	ENSG00000162227	TATA-box binding protein associated factor 6 like	11	62771303-62787342	Predicted intracellular proteins	Evidence at protein level	HPA067239	Approved		Supported	Nucleoplasm	Head and neck cancer:8.98e-5 (favourable)	Expressed in all	Expressed in all			skin: 11.9	Expressed in all		
NXF1	DKFZp667O0311, Mex67, TAP	ENSG00000162231	Nuclear RNA export factor 1	11	62792123-62806302	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB016327, HPA061593	Supported		Supported	Nucleoplasm	Pancreatic cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 147.7	Expressed in all		
STX5	SED5, STX5A	ENSG00000162236	Syntaxin 5	11	62806897-62832088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001358	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 59.1	Expressed in all		
SLC25A45		ENSG00000162241	Solute carrier family 25 member 45	11	65375192-65383701	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA050821	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			spleen: 12.4	Cell line enhanced		HDLM-2: 16.2;Karpas-707: 16.4
RPL29	HIP, HUMRPL29, L29, RPL29P10	ENSG00000162244	Ribosomal protein L29	3	51993600-51995942	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA069064	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			ovary: 2738.5	Expressed in all		
ITIH3	H3P	ENSG00000162267	Inter-alpha-trypsin inhibitor heavy chain 3	3	52794768-52809009	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017373	Approved	Approved			Renal cancer:4.49e-8 (unfavourable)	Tissue enriched	Tissue enriched	51	liver: 413.6	spleen: 8.0	Cell line enriched	18	Hep G2: 11.7
SYVN1	DER3, HRD1	ENSG00000162298	Synoviolin 1	11	65121780-65134533	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA005480, HPA024300, CAB037030	Enhanced		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane	Head and neck cancer:6.88e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 73.8	Expressed in all		
ZFPL1	D11S750, MCG4	ENSG00000162300	Zinc finger protein like 1	11	65084223-65088400	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014909, HPA017347	Enhanced		Enhanced	Golgi apparatus	Liver cancer:9.12e-6 (unfavourable), Renal cancer:2.73e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 31.7	Expressed in all		
RPS6KA4	MSK2, RSK-B	ENSG00000162302	Ribosomal protein S6 kinase A4	11	64359148-64372215	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008649, HPA023225	Approved		Supported	Nucleus<br>Cytosol	Liver cancer:8.17e-4 (unfavourable), Lung cancer:9.27e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 23.1	Expressed in all		
LRP5	BMND1, EVR1, EVR4, HBM, LR3, LRP7, OPPG, OPS, OPTA1, VBCH2	ENSG00000162337	LDL receptor related protein 5	11	68312609-68449275	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013001, HPA030505	Approved				Renal cancer:3.55e-10 (favourable)	Expressed in all	Expressed in all			small intestine: 49.8	Mixed		
TPCN2	TPC2	ENSG00000162341	Two pore segment channel 2	11	69048897-69162440	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016561, HPA027080	Enhanced		Approved	Nucleoli	Ovarian cancer:1.49e-4 (unfavourable), Head and neck cancer:2.96e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 10.2	Expressed in all		
FGF19		ENSG00000162344	Fibroblast growth factor 19	11	69698232-69704642	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA036082	Approved					Mixed	Tissue enriched	28	gallbladder: 262.2	small intestine: 9.4	Cell line enriched	14	CAPAN-2: 87.6
CYP4A22		ENSG00000162365	Cytochrome P450 family 4 subfamily A member 22	1	47137435-47149741	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	16	kidney: 33.5;liver: 109.1	epididymis: 4.5	Cell line enriched	5	RH-30: 1.2
PDZK1IP1	DD96, MAP17, SPAP	ENSG00000162366	PDZK1 interacting protein 1	1	47183593-47191044	Predicted membrane proteins	Evidence at protein level	HPA014907	Enhanced		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:3.45e-4 (unfavourable), Glioma:9.46e-4 (unfavourable)	Expressed in all	Group enriched	6	gallbladder: 297.8;kidney: 1052.9	esophagus: 121.2	Group enriched	5	EFO-21: 138.3;RPTEC TERT1: 370.1
TAL1	bHLHa17, SCL, TCL5	ENSG00000162367	TAL bHLH transcription factor 1, erythroid differentiation factor	1	47216290-47232220	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017805, HPA047866, HPA073983	Approved		Supported	Nucleus		Mixed	Tissue enhanced		bone marrow: 17.7	placenta: 10.0	Cell line enhanced		HEL: 137.6;HMC-1: 62.0;K-562: 43.6;TIME: 28.0
CMPK1	CMPK, UMP-CMPK	ENSG00000162368	Cytidine/uridine monophosphate kinase 1	1	47333797-47378839	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA053730, HPA058604	Approved		Supported	Nucleus	Glioma:8.67e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 169.1	Expressed in all		
BEND5	C1orf165, FLJ11588	ENSG00000162373	BEN domain containing 5	1	48727523-48776969	Predicted intracellular proteins	Evidence at protein level	HPA054347, HPA058007	Uncertain				Urothelial cancer:8.30e-6 (favourable), Breast cancer:2.50e-5 (favourable), Pancreatic cancer:1.29e-4 (favourable), Lung cancer:1.29e-4 (favourable)	Mixed	Mixed			cerebral cortex: 6.0	Cell line enhanced		AF22: 3.2;HDLM-2: 10.2;MOLT-4: 3.6;REH: 5.7;SH-SY5Y: 3.1
ELAVL4	HUD, PNEM	ENSG00000162374	ELAV like RNA binding protein 4	1	50048014-50203786	Predicted intracellular proteins	Evidence at protein level	CAB004442, HPA043047	Enhanced		Approved	Nucleoplasm<br>Vesicles		Group enriched	Group enriched	9	adrenal gland: 10.7;cerebral cortex: 53.3;testis: 10.9	appendix: 2.9	Cell line enriched	21	SH-SY5Y: 131.1
COA7	C1orf163, FLJ12439, RESA1, SELRC1	ENSG00000162377	Cytochrome c oxidase assembly factor 7 (putative)	1	52684451-52698366	Predicted intracellular proteins	Evidence at protein level	HPA028154, HPA029926	Approved		Approved	Nucleus<br>Mitochondria	Liver cancer:7.01e-5 (unfavourable), Stomach cancer:4.35e-4 (favourable), Endometrial cancer:8.55e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
ZYG11B	FLJ13456, ZYG11	ENSG00000162378	Zyg-11 family member B, cell cycle regulator	1	52726467-52827342	Predicted intracellular proteins	Evidence at protein level	HPA028156	Uncertain		Approved	Golgi apparatus<br>Intermediate filaments	Renal cancer:9.80e-7 (favourable), Colorectal cancer:5.42e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.0	Expressed in all		
SLC1A7	EAAT5	ENSG00000162383	Solute carrier family 1 member 7	1	53087179-53142632	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049124	Supported					Tissue enhanced	Tissue enhanced		gallbladder: 8.5	small intestine: 3.5	Cell line enriched	8	HHSteC: 21.0
C1orf123	FLJ20580	ENSG00000162384	Chromosome 1 open reading frame 123	1	53214099-53220617	Predicted intracellular proteins	Evidence at protein level	HPA043835	Uncertain		Approved	Cytosol	Renal cancer:1.53e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 89.3	Expressed in all		
MAGOH	MAGOH1, MAGOHA	ENSG00000162385	Mago homolog, exon junction complex core component	1	53226892-53238610	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB015425, HPA043036, HPA047754	Approved		Supported	Nucleus	Renal cancer:1.45e-5 (unfavourable), Breast cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 82.2	Expressed in all		
ACOT11	BFIT, BFIT1, KIAA0707, STARD14, THEA, THEM1	ENSG00000162390	Acyl-CoA thioesterase 11	1	54542257-54639192	Predicted intracellular proteins	Evidence at protein level	HPA041047	Enhanced		Supported	Cytosol	Renal cancer:3.07e-8 (favourable), Colorectal cancer:9.37e-4 (favourable)	Mixed	Mixed			duodenum: 36.4	Cell line enhanced		RT4: 32.0
FAM151A	C1orf179, MGC27169	ENSG00000162391	Family with sequence similarity 151 member A	1	54609182-54623556	Predicted intracellular proteins	Evidence at protein level	HPA016840	Approved		Uncertain	Nucleoplasm	Renal cancer:4.09e-5 (favourable)	Group enriched	Group enriched	14	kidney: 175.3;small intestine: 66.8	liver: 8.5	Cell line enriched	41	CACO-2: 63.5
PARS2	DKFZp727A071	ENSG00000162396	Prolyl-tRNA synthetase 2, mitochondrial (putative)	1	54756898-54764514	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028308, HPA028314, HPA028518	Uncertain		Approved	Nucleoli fibrillar center<br>Mitochondria	Renal cancer:1.24e-6 (favourable), Colorectal cancer:1.26e-5 (favourable), Liver cancer:2.34e-4 (unfavourable)	Expressed in all	Mixed			testis: 8.0	Mixed		
LEXM	C1orf177, FLJ40201, LEM	ENSG00000162398	Lymphocyte expansion molecule	1	54806063-54842252	Predicted intracellular proteins	Evidence at protein level	HPA035889, HPA035890	Uncertain					Mixed	Group enriched	5	esophagus: 10.5;testis: 7.0	duodenum: 1.6	Not detected		
BSND	BART, DFNB73	ENSG00000162399	Barttin CLCNK type accessory beta subunit	1	54998933-55010883	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053836, HPA060617	Enhanced					Tissue enriched	Tissue enriched	7	kidney: 10.2	salivary gland: 1.5	Cell line enriched	15	RPMI-8226: 8.0
USP24	KIAA1057	ENSG00000162402	Ubiquitin specific peptidase 24	1	55066359-55215113	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026723, HPA028428, HPA067124	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.34e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
PLPP3	LPP3, PAP-2b, PPAP2B	ENSG00000162407	Phospholipid phosphatase 3	1	56494747-56645301	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA028892, HPA072751	Uncertain		Supported	Golgi apparatus	Renal cancer:4.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 546.5	Group enriched	8	ASC diff: 484.3;ASC TERT1: 245.1;HSkMC: 316.7;U-138 MG: 173.1;U-2197: 610.0
NOL9	FLJ23323, Grc3, NET6	ENSG00000162408	Nucleolar protein 9	1	6521347-6554535	Predicted intracellular proteins	Evidence at protein level	HPA036347			Supported	Nucleoli<br>Intermediate filaments	Liver cancer:3.69e-5 (unfavourable)	Expressed in all	Mixed			spleen: 8.4	Expressed in all		
PRKAA2	AMPK, AMPKa2, PRKAA	ENSG00000162409	Protein kinase AMP-activated catalytic subunit alpha 2	1	56645322-56715335	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA044540	Approved		Supported	Nuclear speckles<br>Golgi apparatus	Renal cancer:4.95e-5 (favourable), Endometrial cancer:4.80e-4 (unfavourable), Liver cancer:5.30e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 26.5	parathyroid gland: 15.0	Cell line enhanced		RPTEC TERT1: 10.7
KLHL21	KIAA0469	ENSG00000162413	Kelch like family member 21	1	6590724-6614607	Predicted intracellular proteins	Evidence at protein level	HPA051364, HPA059307	Uncertain		Supported	Centrosome	Renal cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 39.8	Mixed		
ZSWIM5	KIAA1511	ENSG00000162415	Zinc finger SWIM-type containing 5	1	45016399-45306209	Predicted intracellular proteins	Evidence at transcript level	HPA018211	Uncertain		Approved	Nuclear speckles		Expressed in all	Mixed			parathyroid gland: 15.8	Cell line enhanced		SCLC-21H: 8.6
GMEB1	P96PIF, PIF96	ENSG00000162419	Glucocorticoid modulatory element binding protein 1	1	28668732-28719353	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044811, HPA052975	Supported		Enhanced	Nucleoplasm	Liver cancer:8.91e-7 (unfavourable), Endometrial cancer:1.94e-4 (favourable)	Expressed in all	Mixed			bone marrow: 8.5	Expressed in all		
SLC45A1	DNB5	ENSG00000162426	Solute carrier family 45 member 1	1	8317826-8344167	Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 11.7	endometrium: 3.2	Cell line enhanced		HHSteC: 4.1;U-87 MG: 6.3
SELENON	MDRS1, RSMD1, RSS, SELN, SEPN1	ENSG00000162430	Selenoprotein N	1	25800176-25818224	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058076	Approved		Supported	Cytosol	Liver cancer:3.40e-5 (unfavourable), Endometrial cancer:2.23e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 81.2	Mixed		
AK4	AK3, AK3L1	ENSG00000162433	Adenylate kinase 4	1	65147549-65232145	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042753, HPA049461	Enhanced		Supported	Mitochondria	Pancreatic cancer:4.34e-5 (unfavourable), Cervical cancer:4.17e-4 (unfavourable), Renal cancer:4.36e-4 (unfavourable), Stomach cancer:4.87e-4 (unfavourable), Head and neck cancer:8.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 190.7	liver: 53.7	Cell line enhanced		Hep G2: 141.9
JAK1	JAK1A, JAK1B, JTK3	ENSG00000162434	Janus kinase 1	1	64833229-64966504	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013088	Approved				Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 115.6	Expressed in all		
RAVER2	FLJ10770, KIAA1579	ENSG00000162437	Ribonucleoprotein, PTB binding 2	1	64745095-64833232	Predicted intracellular proteins	Evidence at protein level	HPA045785	Approved		Approved	Nucleoplasm	Renal cancer:5.14e-6 (favourable)	Expressed in all	Mixed			rectum: 29.4	Mixed		
CTRC	CLCR, ELA4	ENSG00000162438	Chymotrypsin C	1	15438439-15449242	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046920	Enhanced					Tissue enriched	Tissue enriched	361	pancreas: 18186.4	ovary: 50.3	Not detected		
LZIC	MGC15436	ENSG00000162441	Leucine zipper and CTNNBIP1 domain containing	1	9922113-9943407	Predicted intracellular proteins	Evidence at protein level	HPA028184, HPA058614	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:2.47e-5 (unfavourable), Renal cancer:3.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 120.1	Expressed in all		
RBP7	CRBPIV	ENSG00000162444	Retinol binding protein 7	1	9997206-10016020	Predicted intracellular proteins	Evidence at protein level	HPA034749	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Colorectal cancer:2.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 260.1	breast: 82.2	Cell line enhanced		EFO-21: 12.5;SK-MEL-30: 7.2;T-47d: 32.2
KNCN	FLJ32011, KINO, L5	ENSG00000162456	Kinocilin	1	46545644-46551527	Predicted membrane proteins	Evidence at transcript level	HPA046357	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
FBLIM1	CAL, FBLP-1, migfilin	ENSG00000162458	Filamin binding LIM protein 1	1	15756607-15786594	Predicted intracellular proteins	Evidence at protein level	HPA025287, HPA072750	Approved		Enhanced	Nucleoli fibrillar center<br>Cell Junctions<br>Focal adhesion sites	Cervical cancer:4.07e-4 (unfavourable), Melanoma:6.15e-4 (unfavourable), Renal cancer:8.64e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 101.8	Cell line enhanced		HUVEC TERT2: 210.1;TIME: 323.6
TMEM82		ENSG00000162460	Transmembrane protein 82	1	15742422-15747982	Predicted membrane proteins	Evidence at protein level	HPA060282	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:3.80e-7 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 23.0;liver: 9.0;small intestine: 19.4	kidney: 7.6	Cell line enriched	5	CACO-2: 2.6
SLC25A34	DKFZp781A10161	ENSG00000162461	Solute carrier family 25 member 34	1	15736405-15741396	Predicted membrane proteins, Transporters	Evidence at protein level	HPA069806			Supported	Mitochondria		Mixed	Tissue enhanced		duodenum: 14.5;small intestine: 15.2	skeletal muscle: 8.2	Mixed		
AKR7A3		ENSG00000162482	Aldo-keto reductase family 7 member A3	1	19282558-19289250	Predicted intracellular proteins	Evidence at protein level	HPA064638			Approved	Cytosol	Renal cancer:8.80e-7 (favourable)	Group enriched	Group enriched	5	duodenum: 170.4;gallbladder: 38.7;kidney: 49.0;liver: 44.8;small intestine: 106.8;stomach: 70.3	colon: 15.9	Cell line enhanced		SK-BR-3: 12.6
DRAXIN	C1orf187, Draxin, FLJ34999, Neucrin	ENSG00000162490	Dorsal inhibitory axon guidance protein	1	11691729-11725857	Predicted secreted proteins	Evidence at protein level	HPA014302	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 1.5	testis: 0.6	Group enriched	5	NTERA-2: 28.2;REH: 5.8
PDPN	aggrus, Gp38, GP40, PA2.26, T1A-2	ENSG00000162493	Podoplanin	1	13583465-13617957	Predicted membrane proteins	Evidence at protein level	HPA007534, CAB008376	Enhanced					Tissue enhanced	Tissue enhanced		placenta: 194.0	appendix: 78.6	Cell line enhanced		AF22: 148.2;EFO-21: 336.7;HAP1: 260.6;HHSteC: 181.4;TIME: 199.2
LRRC38		ENSG00000162494	Leucine rich repeat containing 38	1	13474977-13514048	Predicted membrane proteins	Evidence at protein level	HPA038778	Approved					Mixed	Group enriched	19	adrenal gland: 19.9;skeletal muscle: 10.5	placenta: 0.8	Cell line enhanced		MOLT-4: 13.0;PC-3: 10.4;U-138 MG: 17.5
DHRS3	RDH17, retSDR1, Rsdr1, SDR1, SDR16C1	ENSG00000162496	Dehydrogenase/reductase 3	1	12567910-12617731	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010844	Supported		Approved	Nucleoli<br>Mitochondria	Thyroid cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 99.9	Cell line enhanced		CAPAN-2: 219.3;WM-115: 228.2
MATN1	CMP, CRTM	ENSG00000162510	Matrilin 1, cartilage matrix protein	1	30711277-30723587	Predicted secreted proteins	Evidence at protein level	HPA028580	Supported					Tissue enhanced	Not detected			ovary: 0.8	Not detected		
LAPTM5		ENSG00000162511	Lysosomal protein transmembrane 5	1	30732469-30757820	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051293	Approved		Approved	Cytosol	Renal cancer:5.89e-5 (unfavourable), Cervical cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 799.7	Cell line enhanced		HEL: 921.8;HMC-1: 2049.8;REH: 698.6;U-698: 604.9
SDC3	N-syndecan, SYND3	ENSG00000162512	Syndecan 3	1	30869467-30908761	Predicted membrane proteins	Evidence at protein level	HPA017087, CAB025786, HPA048085	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.71e-4 (unfavourable), Melanoma:2.36e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 136.4	Cell line enhanced		SK-MEL-30: 167.1;WM-115: 290.3
PEF1	PEF1A	ENSG00000162517	Penta-EF-hand domain containing 1	1	31629862-31644896	Predicted intracellular proteins	Evidence at protein level	HPA061608			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:2.88e-4 (unfavourable), Cervical cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 183.0	Expressed in all		
SYNC	SYNC1, SYNCOILIN	ENSG00000162520	Syncoilin, intermediate filament protein	1	32680360-32703596	Predicted intracellular proteins	Evidence at protein level	HPA028311	Approved		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		smooth muscle: 74.1	skeletal muscle: 36.1	Cell line enhanced		BJ hTERT+: 65.1;fHDF/TERT166: 91.5;U-138 MG: 98.1;WM-115: 67.5
RBBP4	lin-53, NURF55, RbAp48	ENSG00000162521	RB binding protein 4, chromatin remodeling factor	1	32651142-32686211	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006264, HPA060710, HPA060724	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.89e-6 (unfavourable), Melanoma:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
KIAA1522		ENSG00000162522	KIAA1522	1	32741885-32774970	Predicted intracellular proteins	Evidence at protein level	HPA032050, HPA032051, HPA064839	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Liver cancer:6.29e-7 (unfavourable), Renal cancer:1.29e-5 (favourable), Pancreatic cancer:8.25e-5 (unfavourable)	Expressed in all	Mixed			skin: 72.8	Cell line enhanced		CAPAN-2: 110.4
TSSK3	SPOGA3, STK22C	ENSG00000162526	Testis specific serine kinase 3	1	32351521-32364312	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037516	Uncertain		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Not detected	Tissue enhanced		testis: 25.5	bone marrow: 5.5	Mixed		
TMCO4	DKFZp686C23231	ENSG00000162542	Transmembrane and coiled-coil domains 4	1	19682213-19799945	Predicted membrane proteins	Evidence at protein level	HPA014601, HPA014620	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:4.12e-11 (favourable), Liver cancer:1.12e-4 (unfavourable), Urothelial cancer:3.64e-4 (favourable), Endometrial cancer:3.71e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 37.0	Cell line enhanced		CAPAN-2: 36.6
UBXN10	FLJ25429, UBXD3	ENSG00000162543	UBX domain protein 10	1	20186085-20196048	Predicted intracellular proteins	Evidence at protein level	HPA028555, HPA028564	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Glioma:1.64e-4 (unfavourable), Endometrial cancer:2.02e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 79.1	testis: 25.5	Group enriched	6	HEL: 2.5;HMC-1: 6.3;K-562: 7.6;SCLC-21H: 6.6
CAMK2N1	CaMKIINalpha	ENSG00000162545	Calcium/calmodulin dependent protein kinase II inhibitor 1	1	20482391-20486220	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.37e-7 (unfavourable), Lung cancer:1.66e-4 (unfavourable), Liver cancer:5.49e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 321.1	small intestine: 95.6	Cell line enhanced		AN3-CA: 195.3;CAPAN-2: 173.9
ALPL	HOPS, TNSALP	ENSG00000162551	Alkaline phosphatase, liver/bone/kidney	1	21509372-21578412	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007105, HPA008765, CAB020829	Enhanced		Approved	Cytosol	Melanoma:7.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 78.8	kidney: 47.2	Group enriched	8	HAP1: 31.9;HSkMC: 126.3;hTEC/SVTERT24-B: 139.0;LHCN-M2: 85.3;NTERA-2: 40.7;SCLC-21H: 103.8
WNT4	WNT-4	ENSG00000162552	Wnt family member 4	1	22117305-22143969	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011397	Uncertain		Approved	Vesicles	Pancreatic cancer:4.90e-4 (favourable), Melanoma:5.34e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 49.2	ovary: 15.3	Cell line enhanced		HaCaT: 7.6;SCLC-21H: 12.2;SK-BR-3: 6.6
TTLL10	FLJ36119, TTLL5	ENSG00000162571	Tubulin tyrosine ligase like 10	1	1173884-1197935	Predicted intracellular proteins	Evidence at protein level	HPA042712	Uncertain				Endometrial cancer:1.61e-5 (favourable)	Mixed	Group enriched	8	fallopian tube: 14.2;testis: 27.9	lung: 2.7	Cell line enriched	31	SCLC-21H: 27.2
SCNN1D	dNaCh, ENaCdelta	ENSG00000162572	Sodium channel epithelial 1 delta subunit	1	1280436-1292029	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026884	Enhanced		Supported	Plasma membrane<br>Actin filaments	Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable)	Mixed	Tissue enhanced		testis: 13.8	cerebral cortex: 7.3	Mixed		
MXRA8	DKFZp586E2023	ENSG00000162576	Matrix remodeling associated 8	1	1352689-1361777	Predicted membrane proteins	Evidence at protein level	HPA053958, HPA055780	Uncertain		Approved	Nucleoli	Renal cancer:3.43e-6 (unfavourable), Urothelial cancer:9.87e-4 (unfavourable), Stomach cancer:9.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 57.4	endometrium: 44.5	Cell line enhanced		BJ: 122.4;BJ hTERT+: 55.0;fHDF/TERT166: 56.2
FAAP20	C1orf86, FLJ31031	ENSG00000162585	Fanconi anemia core complex associated protein 20	1	2184461-2212720	Predicted intracellular proteins	Evidence at protein level	HPA038829	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cell Junctions	Pancreatic cancer:2.88e-4 (favourable), Liver cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 13.0	Expressed in all		
MEGF6	EGFL3	ENSG00000162591	Multiple EGF like domains 6	1	3489920-3611495	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052129	Uncertain		Approved	Microtubules<br>Cytokinetic bridge	Colorectal cancer:3.08e-4 (unfavourable), Head and neck cancer:6.57e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 48.2	gallbladder: 17.0	Cell line enhanced		BJ: 37.3;HeLa: 26.6;U-2197: 36.2
CCDC27	FLJ32825	ENSG00000162592	Coiled-coil domain containing 27	1	3746460-3771645	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	92	testis: 14.8	endometrium,prostate: 0.1	Cell line enriched	6	THP-1: 1.1
IL23R	IL-23R	ENSG00000162594	Interleukin 23 receptor	1	67138907-67259979	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056427	Uncertain					Not detected	Tissue enhanced		adrenal gland: 2.1;testis: 2.8	rectum: 1.0	Cell line enhanced		HMC-1: 8.0;K-562: 3.2;U-2197: 12.8
DIRAS3	ARHI, NOEY2	ENSG00000162595	DIRAS family GTPase 3	1	68045962-68051631	Predicted intracellular proteins	Evidence at protein level	HPA028483, HPA028557, HPA029384	Approved		Approved	Nuclear membrane<br>Cytosol	Breast cancer:9.21e-4 (favourable), Renal cancer:9.21e-4 (favourable)	Mixed	Tissue enhanced		ovary: 57.2	parathyroid gland: 20.5	Cell line enhanced		HSkMC: 9.3;TIME: 7.1;U-251 MG: 5.6;U-87 MG: 12.2
C1orf87	CREF, MGC34837	ENSG00000162598	Chromosome 1 open reading frame 87	1	59987269-60073770	Predicted intracellular proteins	Evidence at protein level	HPA031366, HPA031368	Enhanced					Tissue enhanced	Tissue enriched	10	fallopian tube: 47.9	lung: 4.9	Not detected		
NFIA	KIAA1439, NFI-L	ENSG00000162599	Nuclear factor I A	1	60865259-61462793	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006111, HPA008884	Enhanced		Enhanced	Nucleoplasm	Urothelial cancer:2.03e-4 (unfavourable), Renal cancer:7.01e-4 (favourable), Head and neck cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.8	Cell line enhanced		AN3-CA: 77.5
OMA1	FLJ33782, MPRP-1, YKR087C, ZMPOMA1	ENSG00000162600	OMA1 zinc metallopeptidase	1	58415384-58546802	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055120	Approved		Approved	Nucleoplasm<br>Mitochondria	Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable)	Expressed in all	Expressed in all			prostate: 31.9	Expressed in all		
MYSM1	KIAA1915	ENSG00000162601	Myb like, SWIRM and MPN domains 1	1	58654739-58700092	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054291, HPA067133	Approved		Supported	Nucleoplasm<br>Plasma membrane	Head and neck cancer:5.09e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.2	Mixed		
TM2D1	BBP	ENSG00000162604	TM2 domain containing 1	1	61681046-61725423	Predicted membrane proteins	Evidence at protein level	HPA046058, HPA055621	Approved		Enhanced	Nucleoplasm	Liver cancer:2.02e-7 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 68.0	Expressed in all		
USP1		ENSG00000162607	Ubiquitin specific peptidase 1	1	62436297-62451804	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028387, HPA028440	Approved		Supported	Nucleoplasm	Liver cancer:5.81e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 92.3	Expressed in all		
FUBP1	FBP, FUBP	ENSG00000162613	Far upstream element binding protein 1	1	77944055-77979110	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006149	Enhanced		Enhanced	Nucleoplasm	Liver cancer:9.83e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Expressed in all		
NEXN	NELIN, nexilin	ENSG00000162614	Nexilin F-actin binding protein	1	77888513-77943895	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011185	Approved				Colorectal cancer:5.60e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 298.6;skeletal muscle: 248.9	prostate: 109.6	Cell line enhanced		BJ: 129.6;LHCN-M2: 116.4;RH-30: 106.0
DNAJB4	HLJ1	ENSG00000162616	DnaJ heat shock protein family (Hsp40) member B4	1	77979175-78017964	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004995, HPA028383, HPA028385	Approved		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:2.28e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.4	Cell line enhanced		HUVEC TERT2: 150.2;LHCN-M2: 254.4
ADGRL4	ELTD1, ETL	ENSG00000162618	Adhesion G protein-coupled receptor L4	1	78889764-79006718	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA025229	Supported				Renal cancer:1.60e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 67.7	Group enriched	5	HUVEC TERT2: 239.6;TIME: 288.6
LRRIQ3	LRRC44, MGC22773	ENSG00000162620	Leucine rich repeats and IQ motif containing 3	1	74026015-74198187	Predicted intracellular proteins	Evidence at protein level	HPA030799	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	11	testis: 37.1	fallopian tube: 3.5	Mixed		
LRRC53		ENSG00000162621	Leucine rich repeat containing 53	1	74469878-74512614	Predicted membrane proteins	No evidence	HPA054062	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Not detected		
TYW3	C1orf171, FLJ40918	ENSG00000162623	TRNA-yW synthesizing protein 3 homolog	1	74733152-74766678	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029641	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.49e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 32.6	Expressed in all		
LHX8	Lhx7	ENSG00000162624	LIM homeobox 8	1	75128434-75161533	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071806			Approved	Nucleus<br>Nucleoli<br>Cytosol		Not detected	Tissue enhanced		placenta: 1.8;testis: 1.3;tonsil: 1.5	gallbladder,urinary bladder: 1.0	Group enriched	6	SCLC-21H: 30.2;U-266/70: 6.6
SNX7		ENSG00000162627	Sorting nexin 7	1	98661701-98760500	Predicted intracellular proteins	Evidence at protein level	HPA037419, HPA054338	Enhanced		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:9.59e-7 (unfavourable), Colorectal cancer:5.10e-5 (favourable)	Expressed in all	Mixed			smooth muscle: 37.7	Mixed		
B3GALT2	beta3Gal-T2	ENSG00000162630	Beta-1,3-galactosyltransferase 2	1	193179045-193186654	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 29.0;gallbladder: 26.0	heart muscle: 14.9	Group enriched	5	AF22: 19.6;ASC TERT1: 6.1;LHCN-M2: 11.4;WM-115: 23.5
NTNG1	KIAA0976, Lmnt1	ENSG00000162631	Netrin G1	1	107140007-107483458	Predicted secreted proteins	Evidence at protein level	HPA065954			Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 8.6	seminal vesicle: 6.7	Cell line enhanced		ASC TERT1: 34.3;fHDF/TERT166: 19.6;RPTEC TERT1: 20.8;U-138 MG: 22.6;U-87 MG: 25.0
FAM102B	DKFZp779B126, SYM-3B	ENSG00000162636	Family with sequence similarity 102 member B	1	108560089-108644900	Predicted intracellular proteins	Evidence at protein level	HPA028451	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.47e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.9	Mixed		
HENMT1	C1orf59, FLJ30525, HEN1	ENSG00000162639	HEN1 methyltransferase homolog 1	1	108648290-108661526	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028464, HPA028497	Uncertain		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:2.48e-5 (unfavourable), Cervical cancer:2.56e-4 (favourable), Colorectal cancer:9.95e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 128.3	lymph node: 14.8	Cell line enhanced		U-937: 75.4
AKNAD1	C1orf62, MGC26989	ENSG00000162641	AKNA domain containing 1	1	108815898-108858228	Predicted intracellular proteins	Evidence at transcript level	HPA030270, HPA030271, HPA030272	Uncertain					Tissue enhanced	Tissue enriched	63	testis: 6.4	skin: 0.1	Not detected		
C1orf52	FLJ44982, gm117	ENSG00000162642	Chromosome 1 open reading frame 52	1	85249953-85259672	Predicted intracellular proteins	Evidence at protein level	HPA036072, HPA061790	Approved		Enhanced	Nucleus	Renal cancer:1.17e-7 (unfavourable), Liver cancer:5.37e-5 (unfavourable), Prostate cancer:4.93e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 31.8	Expressed in all		
WDR63	DIC3, FLJ30067, NYD-SP29	ENSG00000162643	WD repeat domain 63	1	84999147-85133138	Predicted intracellular proteins	Evidence at protein level	HPA038526	Enhanced					Tissue enhanced	Tissue enhanced		adrenal gland: 28.3;fallopian tube: 23.1;testis: 33.6	parathyroid gland: 6.2	Cell line enhanced		ASC TERT1: 5.9;HSkMC: 4.1;hTCEpi: 5.0;LHCN-M2: 5.2
GBP2		ENSG00000162645	Guanylate binding protein 2	1	89106132-89150456	Predicted intracellular proteins	Evidence at protein level	HPA042682, CAB045975	Supported		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:2.14e-10 (unfavourable), Urothelial cancer:1.10e-5 (favourable), Pancreatic cancer:5.73e-5 (unfavourable), Breast cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 195.5	Cell line enhanced		EFO-21: 57.2;HDLM-2: 65.6;RT4: 69.0
ATXN7L2	FLJ00381, MGC46534	ENSG00000162650	Ataxin 7 like 2	1	109483479-109492804	Predicted intracellular proteins	Evidence at protein level	HPA029827, HPA054952	Uncertain		Approved	Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:1.19e-8 (unfavourable), Endometrial cancer:7.65e-4 (unfavourable)	Expressed in all	Mixed			testis: 4.4	Mixed		
GBP4	Mpa2	ENSG00000162654	Guanylate binding protein 4	1	89181148-89198932	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030101, HPA062039	Enhanced		Approved	Plasma membrane	Renal cancer:1.30e-5 (unfavourable), Ovarian cancer:9.29e-5 (favourable)	Expressed in all	Mixed			lung: 46.9	Cell line enhanced		CAPAN-2: 10.6;HEL: 11.8;REH: 10.2;RT4: 14.7;U-266/70: 12.3
ZNF326	FLJ20403, ZAN75, Zfp326, ZIRD	ENSG00000162664	Zinc finger protein 326	1	89995112-90035531	Predicted intracellular proteins	Evidence at protein level	HPA028450, HPA028461, HPA028466	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Urothelial cancer:2.84e-4 (favourable), Breast cancer:9.46e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 29.5	Expressed in all		
HFM1	FLJ36760, FLJ39011, MER3, SEC63D1	ENSG00000162669	HFM1, ATP dependent DNA helicase homolog	1	91260766-91404869	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035036, HPA035557			Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enriched	5	testis: 25.0	ovary: 4.7	Cell line enhanced		AF22: 5.1;AN3-CA: 2.6;K-562: 2.6;SCLC-21H: 2.1;SH-SY5Y: 2.3
BRINP3	DBCCR1L, DBCCR1L1, FAM5C	ENSG00000162670	BMP/retinoic acid inducible neural specific 3	1	190097662-190478404	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054693	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 44.5;small intestine: 19.6	prostate: 10.9	Cell line enriched	6	SCLC-21H: 17.0
GFI1	GFI-1, GFI1A, ZNF163	ENSG00000162676	Growth factor independent 1 transcriptional repressor	1	92474762-92486876	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011197	Uncertain				Colorectal cancer:5.68e-5 (favourable)	Mixed	Tissue enhanced		bone marrow: 34.8	lymph node: 8.1	Cell line enhanced		HL-60: 49.8;HMC-1: 42.0;THP-1: 86.5;U-937: 207.4
KCNT2	KCa4.2, SLICK, SLO2.1	ENSG00000162687	Potassium sodium-activated channel subfamily T member 2	1	196225779-196609225	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA051218	Uncertain		Approved	Vesicles	Renal cancer:1.67e-5 (unfavourable)	Mixed	Tissue enhanced		ovary: 6.0	cerebral cortex: 3.5	Cell line enhanced		HHSteC: 2.7;NTERA-2: 2.6;SCLC-21H: 8.5;SH-SY5Y: 6.9
AGL		ENSG00000162688	Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase	1	99850084-99924023	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA028498, HPA054340	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.73e-10 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 90.3	parathyroid gland: 35.1	Mixed		
VCAM1	CD106	ENSG00000162692	Vascular cell adhesion molecule 1	1	100719742-100739045	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000154, HPA034796, HPA069867	Enhanced		Approved	Cell Junctions	Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable)	Tissue enriched	Tissue enriched	5	spleen: 549.1	lymph node: 109.7	Cell line enhanced		HHSteC: 144.7;HSkMC: 83.9;hTEC/SVTERT24-B: 31.1;U-138 MG: 25.9
EXTL2		ENSG00000162694	Exostosin like glycosyltransferase 2	1	100872372-100895998	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB020716, HPA068921	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:1.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.1	Expressed in all		
SLC30A7	ZNT7, ZnTL2	ENSG00000162695	Solute carrier family 30 member 7	1	100896076-100981753	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018034	Uncertain		Supported	Golgi apparatus		Expressed in all	Mixed			parathyroid gland: 20.9	Expressed in all		
ZNF281	ZBP-99	ENSG00000162702	Zinc finger protein 281	1	200404940-200410056	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051228	Uncertain		Enhanced	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Cervical cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.5	Expressed in all		
ARPC5	ARC16, dJ127C7.3, p16-Arc	ENSG00000162704	Actin related protein 2/3 complex subunit 5	1	183620846-183635757	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022013, HPA031972	Approved		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.21e-10 (unfavourable), Liver cancer:3.63e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 201.3	Expressed in all		
CADM3	BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1	ENSG00000162706	Cell adhesion molecule 3	1	159171609-159203313	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002981, CAB025746	Enhanced				Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 278.5;placenta: 113.9	cervix, uterine: 44.7	Group enriched	7	HHSteC: 54.6;HSkMC: 158.9;hTERT-HME1: 91.2;U-2 OS: 34.5;WM-115: 59.5
NLRP3	AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1	ENSG00000162711	NLR family pyrin domain containing 3	1	247416156-247449108	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012878	Uncertain					Mixed	Tissue enhanced		bone marrow: 34.4	appendix: 14.5	Cell line enhanced		NB-4: 9.6;THP-1: 54.1;U-937: 15.5
ZNF496	MGC15548, ZKSCAN17, ZSCAN49	ENSG00000162714	Zinc finger protein 496	1	247297412-247331846	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055834			Uncertain	Golgi apparatus		Expressed in all	Expressed in all			fallopian tube: 24.2	Expressed in all		
TRIM58	BIA2	ENSG00000162722	Tripartite motif containing 58	1	247857199-247878205	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023637	Uncertain					Mixed	Group enriched	6	bone marrow: 16.1;placenta: 6.8;testis: 5.4;thyroid gland: 22.0	prostate: 2.1	Group enriched	5	HAP1: 15.0;HEL: 35.6;K-562: 19.9;PC-3: 34.5;U-2 OS: 31.0;U-937: 8.8;WM-115: 38.8
SLAMF9	CD2F-10, CD84-H1, SF2001	ENSG00000162723	SLAM family member 9	1	159951492-159954254	Predicted membrane proteins	Evidence at transcript level	HPA035153	Uncertain					Mixed	Tissue enhanced		testis: 1.1	appendix: 0.6	Cell line enhanced		HBEC3-KT: 2.6;HEL: 4.6;PC-3: 1.9;SK-MEL-30: 1.7
OR2M5	OR2M5P	ENSG00000162727	Olfactory receptor family 2 subfamily M member 5	1	248145148-248146086	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KCNJ9	GIRK3, Kir3.3	ENSG00000162728	Potassium voltage-gated channel subfamily J member 9	1	160081570-160090563	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA070478	Enhanced					Tissue enriched	Tissue enriched	113	cerebral cortex: 52.3	adrenal gland,testis: 0.4	Not detected		
IGSF8	CD316, CD81P3, EWI2, PGRL	ENSG00000162729	Immunoglobulin superfamily member 8	1	160091340-160098943	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011917	Uncertain				Cervical cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 107.8	Expressed in all		
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
PEA15	HMAT1, HUMMAT1H, MAT1, MAT1H, PEA-15, PED	ENSG00000162734	Phosphoprotein enriched in astrocytes 15	1	160205337-160215376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028356, HPA070820	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:6.53e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1087.0	Expressed in all		
PEX19	D1S2223E, HK33, PMP1, PMPI, PXF, PXMP1	ENSG00000162735	Peroxisomal biogenesis factor 19	1	160276812-160286348	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044837, HPA051966	Supported		Enhanced	Peroxisomes	Renal cancer:2.92e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 86.2	Expressed in all		
NCSTN	APH2, KIAA0253	ENSG00000162736	Nicastrin	1	160343272-160358952	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021982, HPA054846, HPA070642	Approved		Approved	Cytosol	Renal cancer:7.75e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 143.2	Expressed in all		
VANGL2	KIAA1215, LPP1, LTAP, MGC119403, MGC119404, STB1, STBM, STBM1	ENSG00000162738	VANGL planar cell polarity protein 2	1	160400586-160428678	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA027043	Uncertain					Expressed in all	Tissue enhanced		skin: 44.6	cerebral cortex: 18.1	Cell line enhanced		AF22: 105.2;NTERA-2: 43.1;SH-SY5Y: 30.7
SLAMF6	CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000	ENSG00000162739	SLAM family member 6	1	160485030-160523262	CD markers, Predicted membrane proteins	Evidence at protein level	HPA051363, HPA051903	Uncertain				Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 70.8;spleen: 43.3;tonsil: 44.6	appendix: 27.2	Cell line enhanced		Daudi: 63.2;MOLT-4: 17.4;U-698: 89.3
OLFML2B	DKFZP586L151	ENSG00000162745	Olfactomedin like 2B	1	161983192-162023854	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054136, HPA062739	Approved		Approved	Cytosol	Renal cancer:1.01e-12 (unfavourable), Liver cancer:4.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 76.9	placenta: 58.7	Cell line enhanced		HSkMC: 82.6;RH-30: 85.9
FCRLB	FCRL2, FCRLM2, FCRLY, FLJ31052, FREB-2	ENSG00000162746	Fc receptor like B	1	161721563-161728143	Predicted secreted proteins	Evidence at protein level	CAB026139	Uncertain		Supported	Cytosol		Tissue enhanced	Tissue enhanced		tonsil: 1.6	seminal vesicle: 1.2	Cell line enhanced		fHDF/TERT166: 6.8;HMC-1: 6.5
FCGR3B	CD16, CD16b, FCG3, FCGR3	ENSG00000162747	Fc fragment of IgG receptor IIIb	1	161623196-161631963	CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 118.1;spleen: 115.2	urinary bladder: 36.3	Not detected		
SLC9C2	MGC43026, SLC9A11	ENSG00000162753	Solute carrier family 9 member C2 (putative)	1	173500464-173603094	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 10.6	fallopian tube: 0.8	Not detected		
KLHDC9	KARCA1	ENSG00000162755	Kelch domain containing 9	1	161098361-161100346	Predicted intracellular proteins	Evidence at protein level	HPA032058, HPA043197	Uncertain		Uncertain	Nucleoplasm	Ovarian cancer:4.20e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 9.5	fallopian tube: 2.3	Cell line enhanced		EFO-21: 2.0
C1orf74	FLJ25078, URLC4	ENSG00000162757	Chromosome 1 open reading frame 74	1	209779208-209784559	Predicted intracellular proteins	Evidence at protein level	HPA028496	Uncertain		Approved	Plasma membrane<br>Cytosol	Cervical cancer:8.52e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 5.0	Mixed		
LMX1A	LMX1, LMX1.1	ENSG00000162761	LIM homeobox transcription factor 1 alpha	1	165201867-165356715	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028051, HPA030088			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Not detected	Tissue enhanced		duodenum: 1.0;testis: 2.2	adipose tissue,rectum,small intestine: 0.6	Cell line enriched	11	SCLC-21H: 1.0
LRRC52	FLJ25811	ENSG00000162763	Leucine rich repeat containing 52	1	165544007-165563961	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	26	testis: 18.6	parathyroid gland: 0.7	Not detected		
FLVCR1	AXPC1, FLVCR, MFSD7B, PCA	ENSG00000162769	Feline leukemia virus subgroup C cellular receptor 1	1	212858255-212899363	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046646	Approved		Approved	Cell Junctions	Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 21.4	duodenum: 9.8	Expressed in all		
FAM71A	FLJ32796	ENSG00000162771	Family with sequence similarity 71 member A	1	212624474-212626778	Predicted intracellular proteins	Evidence at protein level	HPA028462	Enhanced					Not detected	Tissue enriched	95	testis: 78.3	fallopian tube: 0.8	Not detected		
ATF3		ENSG00000162772	Activating transcription factor 3	1	212565334-212620777	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001562	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			smooth muscle: 450.5	Cell line enhanced		BEWO: 126.9
RBM15	OTT, OTT1	ENSG00000162775	RNA binding motif protein 15	1	110338506-110346681	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015201, HPA019824, HPA049642	Supported		Enhanced	Nucleoplasm	Renal cancer:1.37e-4 (unfavourable), Liver cancer:7.61e-4 (unfavourable), Stomach cancer:7.97e-4 (favourable)	Expressed in all	Mixed			bone marrow: 27.9	Expressed in all		
DENND2D	FLJ22457, RP5-1180E21.2	ENSG00000162777	DENN domain containing 2D	1	111187174-111204535	Predicted intracellular proteins	Evidence at protein level	HPA043630, HPA048642	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:8.66e-5 (favourable), Cervical cancer:1.67e-4 (favourable), Head and neck cancer:2.70e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 110.8	tonsil: 77.1	Cell line enhanced		HDLM-2: 60.3;MOLT-4: 132.4;SK-BR-3: 76.3
AXDND1	C1orf125, FLJ32940	ENSG00000162779	Axonemal dynein light chain domain containing 1	1	179365720-179554735	Predicted intracellular proteins	Evidence at protein level	HPA071114	Enhanced					Not detected	Tissue enriched	51	testis: 24.5	epididymis,fallopian tube: 0.4	Not detected		
TDRD5	FLJ34823, TUDOR3	ENSG00000162782	Tudor domain containing 5	1	179591613-179691272	Predicted intracellular proteins	Evidence at protein level	HPA029418	Enhanced					Mixed	Tissue enriched	5	testis: 42.6	epididymis: 8.0	Cell line enhanced		SK-BR-3: 4.4;T-47d: 9.6;U-266/70: 10.9;U-266/84: 9.0
IER5		ENSG00000162783	Immediate early response 5	1	181088712-181092899	Predicted intracellular proteins	Evidence at protein level	HPA029894	Uncertain	Approved	Supported	Nucleus<br>Nucleoli	Endometrial cancer:2.42e-7 (favourable), Lung cancer:1.18e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 31.1	Expressed in all		
SNED1	FLJ00133, Snep, SST3	ENSG00000162804	Sushi, nidogen and EGF like domains 1	2	240998838-241095568	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036414, HPA036415	Uncertain					Mixed	Mixed			endometrium: 29.8	Cell line enhanced		ASC TERT1: 290.9;HSkMC: 154.1
BPNT1		ENSG00000162813	3'(2'), 5'-bisphosphate nucleotidase 1	1	220057482-220090462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048461	Approved		Approved	Nuclear speckles	Renal cancer:6.38e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 48.6	Expressed in all		
SPATA17	IQCH	ENSG00000162814	Spermatogenesis associated 17	1	217631324-217871696	Predicted intracellular proteins	Evidence at protein level	HPA030099	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		fallopian tube: 6.5;testis: 18.2	epididymis: 4.1	Cell line enhanced		SCLC-21H: 1.5
C1orf115	FLJ14146	ENSG00000162817	Chromosome 1 open reading frame 115	1	220689845-220699157	Predicted intracellular proteins	Evidence at transcript level						Ovarian cancer:5.12e-5 (favourable), Endometrial cancer:6.52e-4 (favourable)	Expressed in all	Mixed			small intestine: 110.8	Cell line enhanced		Hep G2: 35.3;HUVEC TERT2: 34.6;TIME: 63.7
BROX	C1orf58, FLJ32421	ENSG00000162819	BRO1 domain and CAAX motif containing	1	222712553-222735196	Predicted intracellular proteins	Evidence at protein level	HPA031445	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.7	Expressed in all		
NBPF20		ENSG00000162825	Neuroblastoma breakpoint family member 20	1	145289900-145405778	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Not detected	Mixed			parathyroid gland: 17.1	Mixed		
ACP6	ACPL1, LPAP	ENSG00000162836	Acid phosphatase 6, lysophosphatidic	1	147629652-147670496	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028560	Uncertain				Urothelial cancer:6.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Cell line enhanced		RPTEC TERT1: 90.7
WDR64	FLJ32978	ENSG00000162843	WD repeat domain 64	1	241652278-241802133	Predicted intracellular proteins	Evidence at protein level	HPA046186	Uncertain					Not detected	Tissue enriched	10	testis: 5.5	placenta: 0.5	Not detected		
KIF26B	FLJ10157	ENSG00000162849	Kinesin family member 26B	1	245154985-245709431	Predicted intracellular proteins	Evidence at protein level	HPA027709, HPA028478, HPA028561, HPA028562	Enhanced		Approved	Plasma membrane<br>Microtubules	Ovarian cancer:1.24e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 2.3	Cell line enhanced		HSkMC: 8.1;REH: 19.4;SH-SY5Y: 11.8;U-937: 8.1
TFB2M	FLJ22661, FLJ23182, Hkp1	ENSG00000162851	Transcription factor B2, mitochondrial	1	246540560-246566324	Predicted intracellular proteins	Evidence at protein level	HPA028482, HPA028554, HPA030265	Approved		Enhanced	Mitochondria		Expressed in all	Expressed in all			adrenal gland: 29.5	Expressed in all		
CNST	C1orf71, FLJ32001, PPP1R64	ENSG00000162852	Consortin, connexin sorting protein	1	246566444-246668584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007225, HPA007226	Approved		Supported	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 26.3	Expressed in all		
PPP1R21	CCDC128, FLJ16566, KLRAQ1	ENSG00000162869	Protein phosphatase 1 regulatory subunit 21	2	48440598-48515391	Predicted intracellular proteins	Evidence at protein level	HPA036791, HPA036792	Approved		Approved	Vesicles	Renal cancer:4.59e-6 (favourable), Endometrial cancer:6.83e-4 (unfavourable), Pancreatic cancer:8.05e-4 (favourable), Thyroid cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.3	Expressed in all		
KLHDC8A	FLJ10748	ENSG00000162873	Kelch domain containing 8A	1	205336065-205357090	Predicted intracellular proteins	Evidence at transcript level						Thyroid cancer:8.01e-4 (favourable)	Tissue enhanced	Tissue enriched	11	ovary: 288.4	adrenal gland: 26.0	Group enriched	7	AF22: 4.1;HAP1: 8.9;NTERA-2: 2.1;SCLC-21H: 10.2
PM20D1	Cps1, FLJ32569	ENSG00000162877	Peptidase M20 domain containing 1	1	205828022-205850132	Enzymes, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		kidney: 6.0;pancreas: 16.6	skin: 3.9	Cell line enriched	10	Karpas-707: 1.3
PKDCC	SgK493, Vlk	ENSG00000162878	Protein kinase domain containing, cytoplasmic	2	42048020-42058528	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA026427, HPA026442, HPA026526	Uncertain					Expressed in all	Mixed			adipose tissue: 27.4	Cell line enhanced		AN3-CA: 72.7;ASC diff: 41.5;CACO-2: 78.1;HHSteC: 43.5
OXER1	GPCR, GPR170, TG1019	ENSG00000162881	Oxoeicosanoid receptor 1	2	42762481-42764261	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA051433	Uncertain					Expressed in all	Mixed			small intestine: 9.2	Cell line enhanced		CACO-2: 5.4;Hep G2: 5.1;HMC-1: 5.4;REH: 2.9
HAAO		ENSG00000162882	3-hydroxyanthranilate 3,4-dioxygenase	2	42767089-42792593	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036394, HPA042024	Enhanced				Liver cancer:5.77e-4 (favourable)	Group enriched	Tissue enhanced		liver: 152.2	small intestine: 45.5	Cell line enhanced		CACO-2: 11.2;Hep G2: 32.9;REH: 9.2
B3GALNT2	MGC39558	ENSG00000162885	Beta-1,3-N-acetylgalactosaminyltransferase 2	1	235449923-235504481	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA012502, HPA050662	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			smooth muscle: 15.9	Expressed in all		
MAPKAPK2		ENSG00000162889	Mitogen-activated protein kinase-activated protein kinase 2	1	206684944-206734283	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB010297, HPA045556, HPA063708, HPA064435	Approved		Supported	Nucleoplasm<br>Centrosome	Renal cancer:4.58e-6 (unfavourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 113.0	Expressed in all		
IL20	IL-20, IL10D, ZCYTO10	ENSG00000162891	Interleukin 20	1	206865354-206869223	Predicted secreted proteins	Evidence at protein level	CAB025802	Uncertain					Tissue enhanced	Tissue enhanced		smooth muscle: 1.0	seminal vesicle: 0.8	Cell line enhanced		SiHa: 1.9
IL24	C49A, FISP, IL-24, IL10B, mda-7, Mob-5, ST16	ENSG00000162892	Interleukin 24	1	206897443-206904139	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025972	Uncertain				Breast cancer:5.09e-4 (favourable)	Mixed	Tissue enhanced		appendix: 17.3;lymph node: 37.1;spleen: 23.4	urinary bladder: 5.4	Cell line enriched	10	BJ hTERT+: 144.5
FCMR	FAIM3, TOSO	ENSG00000162894	Fc fragment of IgM receptor	1	206904386-206923247	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003910	Approved		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Breast cancer:4.23e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 175.8;spleen: 148.0;tonsil: 146.7	appendix: 88.1	Group enriched	5	RPMI-8226: 97.7;U-266/70: 51.8
PIGR		ENSG00000162896	Polymeric immunoglobulin receptor	1	206928518-206946466	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA006154, CAB009454, HPA012012	Enhanced				Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 1688.0;duodenum: 2659.3	rectum: 1335.9	Cell line enriched	7	EFO-21: 33.8
FCAMR	CD351, FCA/MR, FKSG87	ENSG00000162897	Fc fragment of IgA and IgM receptor	1	206957965-206970625	CD markers, Predicted membrane proteins	Evidence at protein level	HPA056505	Enhanced					Tissue enhanced	Tissue enhanced		kidney: 32.1;lymph node: 14.0;tonsil: 11.3	appendix: 5.2	Not detected		
CAPN2	CANPL2, CANPml, mCANP	ENSG00000162909	Calpain 2	1	223701593-223776018	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024470	Approved	Approved	Supported	Cytosol	Renal cancer:2.19e-4 (favourable), Pancreatic cancer:2.50e-4 (unfavourable), Urothelial cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 267.0	Mixed		
MRPL55		ENSG00000162910	Mitochondrial ribosomal protein L55	1	228106679-228109312	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA027641	Supported		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.62e-6 (unfavourable), Ovarian cancer:6.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.9	Expressed in all		
C1orf145	FLJ31994	ENSG00000162913	Chromosome 1 open reading frame 145	1	228203506-228213664	Predicted intracellular proteins	Evidence at transcript level	HPA046612	Uncertain					Mixed	Mixed			thyroid gland: 1.1	Cell line enhanced		HeLa: 1.4;RPTEC TERT1: 1.2
WDR26	FLJ21016, GID7	ENSG00000162923	WD repeat domain 26	1	224385143-224437033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028539, HPA061094	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.31e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 53.9	Expressed in all		
REL	c-Rel, I-Rel	ENSG00000162924	REL proto-oncogene, NF-kB subunit	2	60881521-60931610	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004404	Uncertain					Mixed	Mixed			bone marrow: 29.8	Expressed in all		
PUS10	CCDC139, FLJ32312	ENSG00000162927	Pseudouridylate synthase 10	2	60940222-61018259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044736, HPA049582	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Mitochondria		Expressed in all	Mixed			thyroid gland: 10.3	Expressed in all		
PEX13		ENSG00000162928	Peroxisomal biogenesis factor 13	2	61017225-61051990	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA032141, HPA032142, CAB032689	Enhanced		Supported	Vesicles	Pancreatic cancer:8.07e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 27.5	Expressed in all		
KIAA1841		ENSG00000162929	KIAA1841	2	61065871-61138034	Predicted intracellular proteins	Evidence at transcript level	HPA051240	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			prostate: 6.9	Mixed		
TRIM17	RBCC, RNF16, terf	ENSG00000162931	Tripartite motif containing 17	1	228407940-228416861	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054908	Uncertain		Approved	Vesicles	Breast cancer:1.86e-4 (favourable)	Mixed	Tissue enhanced		testis: 27.8	cerebral cortex: 6.1	Cell line enhanced		BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
RFTN2	C2orf11, FLJ30574, Raftlin-2	ENSG00000162944	Raftlin family member 2	2	197568224-197676045	Predicted intracellular proteins	Evidence at protein level	HPA035232	Approved					Group enriched	Tissue enhanced		cerebral cortex: 31.4	ovary: 8.7	Cell line enhanced		AF22: 17.0;ASC diff: 8.0;WM-115: 7.5
DISC1		ENSG00000162946	Disrupted in schizophrenia 1	1	231626815-232041272	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048911			Approved	Intermediate filaments		Mixed	Mixed			placenta: 10.5	Mixed		
CAPN13	FLJ23523	ENSG00000162949	Calpain 13	2	30722771-30820542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029496, HPA029497, HPA030034	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		rectum: 26.8;small intestine: 32.4;stomach: 26.5	duodenum: 20.8	Cell line enhanced		RT4: 7.4;SK-BR-3: 16.4;T-47d: 2.8
LRRTM1	FLJ32082	ENSG00000162951	Leucine rich repeat transmembrane neuronal 1	2	80288351-80304749	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062660	Approved					Group enriched	Tissue enhanced		cerebral cortex: 13.3;salivary gland: 4.9	thyroid gland: 2.2	Cell line enhanced		SH-SY5Y: 1.4
MEMO1	C2orf4, CGI-27, MEMO	ENSG00000162959	Mediator of cell motility 1	2	31865060-32011230	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042603, HPA057952	Approved		Approved	Vesicles		Mixed	Expressed in all			testis: 116.1	Expressed in all		
DPY30	Cps25, HDPY-30, Saf19	ENSG00000162961	Dpy-30, histone methyltransferase complex regulatory subunit	2	31867809-32039812	Predicted intracellular proteins	Evidence at protein level	HPA043761	Supported		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:4.26e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 138.5	Expressed in all		
TYW5	C2orf60, FLJ37953	ENSG00000162971	TRNA-yW synthesizing protein 5	2	199929975-199955736	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028294, HPA045803	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			appendix: 1.6	Mixed		
MAIP1	C2orf47, DKFZp666A212, FLJ22555	ENSG00000162972	Matrix AAA peptidase interacting protein 1	2	199955317-200008540	Predicted intracellular proteins	Evidence at protein level	HPA064013, HPA072231	Approved		Approved	Mitochondria	Melanoma:1.87e-4 (unfavourable), Endometrial cancer:2.14e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 31.9	Expressed in all		
KCNF1	IK8, KCNF, kH1, Kv5.1	ENSG00000162975	Potassium voltage-gated channel modifier subfamily F member 1	2	10911937-10914225	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014738, HPA062278	Enhanced		Approved	Golgi apparatus		Tissue enriched	Tissue enriched	32	cerebral cortex: 37.5	endometrium: 1.1	Cell line enhanced		A549: 12.9;MCF7: 3.9;T-47d: 5.7
PQLC3	C2orf22, MGC33602	ENSG00000162976	PQ loop repeat containing 3	2	11155198-11178874	Predicted membrane proteins	Evidence at protein level	HPA061607			Approved	Cytosol		Expressed in all	Expressed in all			cervix, uterine,epididymis: 54.6	Mixed		
ARL5A	ARL5	ENSG00000162980	ADP ribosylation factor like GTPase 5A	2	151788984-151828492	Predicted intracellular proteins	Evidence at protein level	HPA027002	Approved					Expressed in all	Expressed in all			thyroid gland: 48.9	Expressed in all		
FAM84A	FLJ35392, NSE1	ENSG00000162981	Family with sequence similarity 84 member A	2	14632686-14650814	Predicted intracellular proteins	Evidence at protein level	HPA047703	Uncertain		Approved	Nucleus		Mixed	Mixed			colon: 40.3	Cell line enhanced		hTCEpi: 13.1;RT4: 39.2
KCNJ3	GIRK1, KGA, Kir3.1	ENSG00000162989	Potassium voltage-gated channel subfamily J member 3	2	154698299-154858352	Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA024231	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 25.4;parathyroid gland: 39.8	seminal vesicle: 14.1	Cell line enhanced		BJ: 1.2
NEUROD1	BETA2, BHF-1, bHLHa3, MODY6, NEUROD	ENSG00000162992	Neuronal differentiation 1	2	181673088-181680876	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003278, CAB022450	Approved				Glioma:6.83e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 5.9;duodenum: 6.0;small intestine: 4.4;stomach: 4.9	pancreas: 1.8	Cell line enriched	79	SCLC-21H: 331.4
CLHC1	C2orf63, FLJ31438	ENSG00000162994	Clathrin heavy chain linker domain containing 1	2	55174791-55232563	Predicted intracellular proteins	Evidence at protein level	HPA045418, HPA053557	Uncertain		Approved	Nucleoli fibrillar center<br>Centrosome	Urothelial cancer:2.15e-4 (favourable)	Mixed	Tissue enhanced		testis: 23.1	endometrium: 6.8	Mixed		
FRZB	FRE, FRITZ, FRP-3, FRZB-1, FRZB-PEN, FRZB1, FZRB, hFIZ, SFRP3, SRFP3	ENSG00000162998	Frizzled-related protein	2	182833275-182867162	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:8.97e-6 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 101.2	gallbladder: 50.3	Cell line enhanced		AF22: 16.2;ASC diff: 5.3;NTERA-2: 6.7;SH-SY5Y: 6.0
DUSP19	DUSP17, SKRP1	ENSG00000162999	Dual specificity phosphatase 19	2	183078559-183100005	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021501	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 5.5	Mixed		
CFAP36	BARTL1, CCDC104, MGC15407	ENSG00000163001	Cilia and flagella associated protein 36	2	55519604-55545879	Predicted intracellular proteins	Evidence at protein level	HPA008994, HPA017061	Approved					Expressed in all	Expressed in all			testis: 239.2	Expressed in all		
NUP35	MP44	ENSG00000163002	Nucleoporin 35	2	183117513-183161680	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018401, HPA018410, HPA018441	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane<br>Plasma membrane	Ovarian cancer:3.45e-4 (favourable), Liver cancer:5.02e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 44.4	Expressed in all		
CCDC138	FLJ32745	ENSG00000163006	Coiled-coil domain containing 138	2	108786757-108885477	Predicted intracellular proteins	Evidence at protein level	HPA049899, HPA054223	Enhanced		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 19.6	fallopian tube: 6.9	Expressed in all		
ZSWIM2	MGC33890, ZZZ2	ENSG00000163012	Zinc finger SWIM-type containing 2	2	186827835-186849208	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	133	testis: 18.4	cerebral cortex,placenta: 0.1	Not detected		
FBXO41	Fbx41, KIAA1940	ENSG00000163013	F-box protein 41	2	73254682-73284431	Predicted intracellular proteins	Evidence at protein level	HPA055246, HPA058386			Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:5.76e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 38.3	parathyroid gland: 11.1	Cell line enhanced		Daudi: 33.9
ACTG2	ACTA3, ACTL3, ACTSG	ENSG00000163017	Actin, gamma 2, smooth muscle, enteric	2	73892314-73919865	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Supported				Renal cancer:3.95e-7 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 8158.9;smooth muscle: 11634.7	prostate: 3438.5	Cell line enhanced		BEWO: 57.4;BJ hTERT+ SV40 Large T+: 177.9;U-251 MG: 176.7
WDCP	C2orf44, FLJ21945	ENSG00000163026	WD repeat and coiled coil containing	2	24029340-24049575	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041054	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:5.14e-8 (unfavourable), Endometrial cancer:6.53e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.3	Expressed in all		
SMC6	FLJ22116, SMC6L1	ENSG00000163029	Structural maintenance of chromosomes 6	2	17663812-17800242	Predicted intracellular proteins	Evidence at protein level	HPA035057, CAB037186, HPA042733	Uncertain		Supported	Nucleoplasm	Renal cancer:3.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.7	Expressed in all		
VSNL1	HLP3, HPCAL3, HUVISL1, VILIP, VILIP-1	ENSG00000163032	Visinin like 1	2	17539126-17657018	Predicted intracellular proteins	Evidence at protein level	HPA053808					Glioma:9.39e-4 (unfavourable)	Mixed	Tissue enriched	14	cerebral cortex: 624.2	esophagus: 44.0	Cell line enhanced		HaCaT: 107.2;Hep G2: 85.4
CCDC74A	FLJ40345	ENSG00000163040	Coiled-coil domain containing 74A	2	131527675-131533666	Predicted intracellular proteins	Evidence at transcript level	HPA060727			Uncertain	Vesicles	Renal cancer:1.70e-7 (unfavourable), Glioma:1.82e-4 (unfavourable), Testis cancer:4.92e-4 (favourable), Breast cancer:5.11e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 55.2;testis: 79.2	parathyroid gland: 27.2	Cell line enhanced		NTERA-2: 28.4;SCLC-21H: 27.2
H3F3A	H3.3A, H3F3	ENSG00000163041	H3 histone family member 3A	1	226061851-226072001	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011481, CAB037178, HPA042570	Supported		Supported	Nucleoplasm	Renal cancer:1.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 1215.4	Expressed in all		
ANKRD30BL	ANKRD30BP3, NCRNA00164	ENSG00000163046	Ankyrin repeat domain 30B like	2	132147591-132257969	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	31	testis: 3.0	appendix: 0.1	Not detected		
COQ8A	ADCK3, CABC1, COQ8, SCAR9	ENSG00000163050	Coenzyme Q8A	1	226897536-226987545	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA061662			Supported	Mitochondria		Expressed in all	Tissue enriched	6	skeletal muscle: 401.8	adrenal gland: 68.1	Cell line enhanced		HEK 293: 75.6
SLC16A14	FLJ30794, MCT14	ENSG00000163053	Solute carrier family 16 member 14	2	230034974-230068999	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040518	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 14.7	Cell line enhanced		HL-60: 16.9;Karpas-707: 10.1;REH: 16.6;RPMI-8226: 11.3
TEKT4	MGC27019	ENSG00000163060	Tektin 4	2	94871433-94876829	Predicted intracellular proteins	Evidence at protein level	HPA048600, HPA053929	Uncertain		Uncertain	Intermediate filaments	Endometrial cancer:1.29e-4 (favourable)	Tissue enriched	Group enriched	15	fallopian tube: 4.2;testis: 5.2	lung: 0.3	Not detected		
EN1		ENSG00000163064	Engrailed homeobox 1	2	118842171-118847678	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014884, HPA073141	Approved		Supported	Nucleus<br>Nucleoli		Tissue enhanced	Group enriched	13	adipose tissue: 1.3;breast: 1.0;lymph node: 1.9;skeletal muscle: 4.7;skin: 2.2	testis: 0.1	Cell line enhanced		ASC diff: 10.8;fHDF/TERT166: 10.2;HSkMC: 9.7;PC-3: 7.1;U-138 MG: 9.6;U-2197: 10.2
SGCB	A3b, LGMD2E, SGC	ENSG00000163069	Sarcoglycan beta	4	52020706-52038482	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011422, HPA058656	Enhanced		Approved	Cytosol	Renal cancer:5.53e-6 (favourable), Urothelial cancer:7.61e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 75.4	Mixed		
SPATA18	FLJ32906	ENSG00000163071	Spermatogenesis associated 18	4	52051331-52097292	Predicted intracellular proteins	Evidence at protein level	HPA036854, HPA036855	Enhanced				Renal cancer:3.73e-9 (favourable), Endometrial cancer:1.32e-5 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 109.4;testis: 42.6	cervix, uterine: 16.2	Cell line enhanced		ASC TERT1: 22.1;BEWO: 23.6;HSkMC: 21.4;hTCEpi: 20.9
NOSTRIN	MGC20702	ENSG00000163072	Nitric oxide synthase trafficking	2	168786539-168865514	Predicted intracellular proteins	Evidence at protein level	HPA044384	Approved		Supported	Nuclear speckles		Mixed	Mixed			placenta: 36.4	Cell line enhanced		BEWO: 9.8;HEL: 35.7;K-562: 27.4
CFAP221	FAP221, PCDP1	ENSG00000163075	Cilia and flagella associated protein 221	2	119544432-119662251	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 41.9;testis: 44.7	lung: 11.5	Cell line enhanced		RPTEC TERT1: 4.1
CCDC140	FLJ32447	ENSG00000163081	Coiled-coil domain containing 140	2	222298147-222305217	Predicted intracellular proteins	Evidence at transcript level	HPA042500, HPA048166	Uncertain					Tissue enriched	Not detected			skin: 0.3	Not detected		
SGPP2	FLJ39004, SPP2	ENSG00000163082	Sphingosine-1-phosphate phosphatase 2	2	222424517-222560948	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.28e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 59.2	thyroid gland: 33.7	Cell line enhanced		CAPAN-2: 13.9;EFO-21: 12.7;hTCEpi: 31.0;RPTEC TERT1: 32.2;SCLC-21H: 20.4
INHBB		ENSG00000163083	Inhibin beta B subunit	2	120346143-120351808	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:1.02e-4 (favourable), Colorectal cancer:1.44e-4 (unfavourable), Renal cancer:3.02e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 27.1	adipose tissue: 24.9	Cell line enhanced		A549: 42.9;ASC diff: 43.3;MCF7: 44.4;PC-3: 85.1;SK-BR-3: 122.2
XIRP2	CMYA3	ENSG00000163092	Xin actin binding repeat containing 2	2	166888487-167259753	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034813, HPA074599	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Tissue enriched	Group enriched	22	heart muscle: 84.0;skeletal muscle: 301.6	prostate: 8.8	Cell line enhanced		AN3-CA: 1.4;HUVEC TERT2: 3.5;U-2197: 2.7
BBS5	DKFZp762I194	ENSG00000163093	Bardet-Biedl syndrome 5	2	169479178-169506655	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046125	Uncertain				Pancreatic cancer:1.02e-4 (favourable)	Mixed	Mixed			testis: 12.6	Mixed		
BIRC8	hILP2, ILP-2	ENSG00000163098	Baculoviral IAP repeat containing 8	19	53289601-53291626	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	179	testis: 17.8	all non-specific tissues: 0.0	Not detected		
SMARCAD1	DKFZP762K2015, ETL1, KIAA1122	ENSG00000163104	SWI/SNF-related, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1	4	94207611-94291292	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016737	Approved		Enhanced	Nucleoplasm	Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
HPGDS	GSTS, GSTS1, GSTS1-1, H-PGDS, PGD2, PGDS	ENSG00000163106	Hematopoietic prostaglandin D synthase	4	94298535-94342876	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024035	Enhanced					Mixed	Tissue enhanced		placenta: 28.1	lung: 14.5	Group enriched	9	HEL: 43.7;HMC-1: 12.2
PDLIM5	Enh, LIM	ENSG00000163110	PDZ and LIM domain 5	4	94451857-94668227	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013511, HPA016740, HPA020026	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Tissue enriched	Expressed in all			heart muscle: 424.8	Expressed in all		
PDHA2	PDHAL	ENSG00000163114	Pyruvate dehydrogenase (lipoamide) alpha 2	4	95840019-95841474	Citric acid cycle related proteins, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047487, HPA047864, HPA063053	Approved		Supported	Mitochondria		Not detected	Tissue enriched	1010	testis: 101.0	all non-specific tissues: 0.0	Not detected		
STPG2	C4orf37, MGC46496	ENSG00000163116	Sperm tail PG-rich repeat containing 2	4	97184093-98143240	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 3.9	thyroid gland: 0.9	Not detected		
NEURL3	Lincr, LOC93082	ENSG00000163121	Neuralized E3 ubiquitin protein ligase 3	2	96497643-96508109	Enzymes, Predicted intracellular proteins	Evidence at transcript level						Liver cancer:6.46e-4 (unfavourable)	Mixed	Tissue enhanced		salivary gland: 13.9	pancreas: 4.2	Cell line enhanced		BEWO: 3.6;CAPAN-2: 13.6;RPMI-8226: 6.9;RT4: 3.7
RPRD2	FLJ32145, HSPC099, KIAA0460	ENSG00000163125	Regulation of nuclear pre-mRNA domain containing 2	1	150363091-150476566	Predicted intracellular proteins	Evidence at protein level	HPA061693	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
ANKRD23	DARP, FLJ32449, MARP3	ENSG00000163126	Ankyrin repeat domain 23	2	96824526-96857934	Predicted intracellular proteins	Evidence at protein level	HPA036201	Approved		Supported	Nucleoplasm<br>Actin filaments		Not detected	Tissue enriched	64	skeletal muscle: 495.5	prostate: 7.7	Cell line enriched	8	Karpas-707: 27.1
CTSS		ENSG00000163131	Cathepsin S	1	150730196-150765957	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000460, HPA002988	Supported		Approved	Vesicles		Expressed in all	Expressed in all			spleen: 374.8	Cell line enhanced		HMC-1: 238.0;U-698: 410.8
MSX1	HOX7, HYD1, OFC5	ENSG00000163132	Msh homeobox 1	4	4859666-4863936	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026198, HPA063895, HPA073604	Enhanced		Supported	Nucleoplasm	Endometrial cancer:1.64e-7 (favourable), Renal cancer:1.18e-5 (unfavourable)	Tissue enriched	Group enriched	6	cervix, uterine: 61.1;endometrium: 23.7	adipose tissue: 6.6	Cell line enhanced		CACO-2: 39.5
PACRGL	C4orf28, MGC29898	ENSG00000163138	PARK2 coregulated like	4	20696282-20752907	Predicted intracellular proteins	Evidence at protein level	HPA054666			Approved	Nucleoplasm<br>Vesicles	Urothelial cancer:4.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.3	Expressed in all		
BNIPL	BNIP-S, BNIP-Salpha, BNIP-Sbeta, BNIPl-1, BNIPL-2, PP753	ENSG00000163141	BCL2 interacting protein like	1	151036570-151047600	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019946			Approved	Cytosol	Thyroid cancer:4.32e-4 (favourable), Endometrial cancer:6.50e-4 (unfavourable)	Mixed	Group enriched	7	esophagus: 88.9;skin: 227.0	breast: 21.6	Cell line enriched	14	T-47d: 44.3
C1QTNF7	CTRP7	ENSG00000163145	C1q and tumor necrosis factor related protein 7	4	15339818-15446166	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB007055, HPA051797, HPA055392	Uncertain		Approved	Vesicles		Mixed	Mixed			cervix, uterine: 36.4	Cell line enhanced		ASC diff: 3.0;ASC TERT1: 2.1;HSkMC: 1.2
TNFAIP8L2	FLJ23467	ENSG00000163154	TNF alpha induced protein 8 like 2	1	151156629-151159749	Predicted intracellular proteins	Evidence at protein level	HPA062742			Uncertain	Vesicles	Renal cancer:3.53e-7 (unfavourable), Melanoma:3.64e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 34.7;spleen: 39.1	appendix: 25.8	Group enriched	6	HEL: 26.1;HL-60: 13.6;HMC-1: 38.0;NB-4: 15.6;THP-1: 62.9;U-937: 28.8
LYSMD1	MGC35223, RP11-68I18.5, SB145	ENSG00000163155	LysM domain containing 1	1	151159748-151165948	Predicted intracellular proteins	Evidence at protein level	HPA028055, HPA064537	Uncertain		Enhanced	Nucleus		Expressed in all	Mixed			ovary: 13.3	Expressed in all		
SCNM1	MGC3180	ENSG00000163156	Sodium channel modifier 1	1	151156664-151170297	Predicted intracellular proteins	Evidence at protein level	HPA052439, HPA054324	Uncertain		Approved	Nucleus	Renal cancer:2.17e-13 (unfavourable), Ovarian cancer:1.23e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 45.2	Expressed in all		
TMOD4	Sk-Tmod	ENSG00000163157	Tropomodulin 4	1	151169986-151176284	Predicted intracellular proteins	Evidence at protein level	HPA028203	Enhanced					Not detected	Tissue enriched	29	skeletal muscle: 378.9	prostate: 13.0	Mixed		
VPS72	Swc2, TCFL1, YL-1, YL1	ENSG00000163159	Vacuolar protein sorting 72 homolog	1	151169987-151195321	Predicted intracellular proteins	Evidence at protein level	HPA065709			Supported	Nuclear speckles	Liver cancer:4.41e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
ERCC3	BTF2, GTF2H, RAD25, TFIIH, XPB	ENSG00000163161	ERCC excision repair 3, TFIIH core complex helicase subunit	2	127257290-127294176	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037153, HPA046077	Approved		Enhanced	Nucleoplasm	Liver cancer:1.62e-7 (unfavourable), Renal cancer:4.30e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 55.1	Expressed in all		
RNF149	FLJ90504	ENSG00000163162	Ring finger protein 149	2	101271219-101308701	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA011424	Approved		Approved	Vesicles<br>Plasma membrane	Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable)	Expressed in all	Expressed in all			appendix: 67.8	Mixed		
IWS1	DKFZp761G0123, FLJ10006, FLJ14655, FLJ32319	ENSG00000163166	IWS1, SUPT6H interacting protein	2	127436207-127526886	Predicted intracellular proteins	Evidence at protein level	HPA035719, HPA061866	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 44.2	Expressed in all		
BOLA3		ENSG00000163170	BolA family member 3	2	74135398-74147994	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053162	Uncertain				Renal cancer:9.90e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 49.5	Expressed in all		
CDC42EP3	BORG2, CEP3, UB1	ENSG00000163171	CDC42 effector protein 3	2	37641882-37738468	Predicted intracellular proteins	Evidence at protein level	HPA034986, HPA061792	Approved		Supported	Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			prostate: 153.3	Cell line enhanced		LHCN-M2: 504.9
S100A11	S100C	ENSG00000163191	S100 calcium binding protein A11	1	152032506-152047907	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034320, HPA042745	Enhanced				Renal cancer:3.24e-6 (unfavourable), Liver cancer:3.64e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 2721.4	Expressed in all		
LCE3D	LEP16, SPRL6A, SPRL6B	ENSG00000163202	Late cornified envelope 3D	1	152579381-152580504	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		skin: 26.5;tonsil: 79.8	esophagus: 11.6	Group enriched	5	hTCEpi: 3.2;hTERT-HME1: 3.1
SMCP	MCSP	ENSG00000163206	Sperm mitochondria associated cysteine rich protein	1	152878317-152885047	Predicted intracellular proteins	Evidence at protein level	HPA035105	Supported					Tissue enhanced	Tissue enriched	480	testis: 797.7	cerebral cortex: 1.6	Not detected		
IVL		ENSG00000163207	Involucrin	1	152908545-152911886	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002243, HPA055211	Enhanced		Supported	Nuclear bodies<br>Centrosome<br>Cytosol		Group enriched	Group enriched	7	esophagus: 308.3;skin: 131.2	tonsil: 32.9	Group enriched	24	HaCaT: 256.2;RT4: 61.2;SK-BR-3: 64.8
SPRR3		ENSG00000163209	Small proline rich protein 3	1	153001747-153003856	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA044467	Enhanced				Pancreatic cancer:6.27e-5 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 22075.5	tonsil: 2218.1	Cell line enhanced		CAPAN-2: 5.2;hTCEpi: 6.9;RT4: 10.0
DHX57	DDX57	ENSG00000163214	DExH-box helicase 57	2	38797729-38875934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036160	Uncertain		Approved	Nucleoli<br>Intermediate filaments<br>Microtubules<br>Cytosol	Liver cancer:3.32e-6 (unfavourable)	Expressed in all	Mixed			testis: 30.8	Expressed in all		
SPRR2D		ENSG00000163216	Small proline rich protein 2D	1	153039725-153041931	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.62e-4 (unfavourable)	Group enriched	Tissue enriched	7	esophagus: 2272.9	tonsil: 348.0	Group enriched	10	hTCEpi: 29.4;hTERT-HME1: 27.2;SK-MEL-30: 14.0;U-87 MG: 6.4
BMP10		ENSG00000163217	Bone morphogenetic protein 10	2	68865481-68871517	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	91	heart muscle: 327.8	liver: 3.5	Not detected		
PGLYRP4	PGLYRPIbeta, PGRP-Ibeta, PGRPIB, SBBI67	ENSG00000163218	Peptidoglycan recognition protein 4	1	153330120-153348840	Predicted secreted proteins	Evidence at protein level	CAB025879			Approved	Vesicles<br>Plasma membrane		Group enriched	Group enriched	6	esophagus: 5.8;skin: 18.2	tonsil: 2.1	Cell line enhanced		HaCaT: 3.4;HDLM-2: 2.4;Karpas-707: 1.4
ARHGAP25	KIAA0053	ENSG00000163219	Rho GTPase activating protein 25	2	68679601-68826833	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035346, HPA061395	Enhanced		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.93e-4 (unfavourable), Cervical cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 89.6	lymph node: 81.2	Cell line enhanced		HEL: 59.7;HMC-1: 225.1
S100A9	60B8AG, CAGB, CFAG, CGLB, LIAG, MAC387, MIF, MRP14, NIF, P14	ENSG00000163220	S100 calcium binding protein A9	1	153357854-153361027	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004193, CAB009441	Enhanced		Supported	Nucleoplasm<br>Cell Junctions<br>Cytosol	Liver cancer:1.13e-6 (unfavourable), Renal cancer:8.10e-4 (unfavourable)	Expressed in all	Group enriched	6	bone marrow: 20959.3;esophagus: 24239.1	tonsil: 3911.6	Cell line enriched	5	SK-BR-3: 1782.7
S100A12	CAAF1, CAGC, CGRP, ENRAGE, MRP6, p6	ENSG00000163221	S100 calcium binding protein A12	1	153373706-153375649	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002881, CAB025872	Enhanced				Renal cancer:5.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	19	bone marrow: 2045.4	spleen: 107.1	Cell line enhanced		hTCEpi: 1.6;THP-1: 1.0
TGFA		ENSG00000163235	Transforming growth factor alpha	2	70447280-70554193	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA042297	Approved		Approved	Vesicles	Pancreatic cancer:1.20e-5 (unfavourable), Thyroid cancer:1.52e-4 (favourable)	Expressed in all	Mixed			esophagus: 27.2	Cell line enhanced		A-431: 58.1;CAPAN-2: 69.9;HBEC3-KT: 50.1;RPTEC TERT1: 52.1;U-87 MG: 63.0
TDRD10	DKFZp434M202	ENSG00000163239	Tudor domain containing 10	1	154502219-154548147	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA054327			Approved	Vesicles	Thyroid cancer:8.04e-5 (favourable)	Tissue enhanced	Tissue enriched	12	testis: 77.3	lung: 6.3	Cell line enhanced		HUVEC TERT2: 2.5;TIME: 1.3
CCNYL1	FLJ40432	ENSG00000163249	Cyclin Y like 1	2	207711540-207761839	Predicted intracellular proteins	Evidence at protein level	HPA046825	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			testis: 30.4	Expressed in all		
FZD5	C2orf31, DKFZP434E2135, HFZ5	ENSG00000163251	Frizzled class receptor 5	2	207762586-207769563	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA052361	Approved					Expressed in all	Mixed			duodenum: 19.6	Cell line enhanced		BEWO: 105.1;NTERA-2: 32.1
CRYGC	CRYG3	ENSG00000163254	Crystallin gamma C	2	208128137-208129830	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	testis: 2.6	epididymis: 0.3	Not detected		
DCAF16	C4orf30, FLJ20280	ENSG00000163257	DDB1 and CUL4 associated factor 16	4	17800655-17810758	Predicted intracellular proteins	Evidence at protein level	HPA042487	Uncertain		Approved	Plasma membrane<br>Cytosol	Lung cancer:5.78e-4 (favourable), Liver cancer:6.40e-4 (unfavourable), Urothelial cancer:7.67e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 23.0	Expressed in all		
C1orf189		ENSG00000163263	Chromosome 1 open reading frame 189	1	154199372-154206333	Predicted intracellular proteins	Evidence at protein level	HPA045779	Uncertain					Tissue enhanced	Group enriched	16	fallopian tube: 127.5;testis: 69.2	cervix, uterine: 6.0	Mixed		
NPPC	CNP	ENSG00000163273	Natriuretic peptide C	2	231921820-231926403	Predicted secreted proteins, Transporters	Evidence at protein level	HPA035362	Uncertain					Mixed	Tissue enhanced		prostate: 6.9	cerebral cortex: 3.0	Cell line enhanced		HEK 293: 7.7;NTERA-2: 3.9;SCLC-21H: 6.4;SK-MEL-30: 18.9
GNPDA2	SB52	ENSG00000163281	Glucosamine-6-phosphate deaminase 2	4	44682200-44726595	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000499, HPA046891	Uncertain		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			thyroid gland: 32.4	Mixed		
ALPP		ENSG00000163283	Alkaline phosphatase, placental	2	232378534-232382889	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026327, HPA038764, HPA038765, HPA051699	Enhanced		Approved	Plasma membrane	Pancreatic cancer:4.33e-4 (unfavourable)	Tissue enhanced	Group enriched	14	cervix, uterine: 25.5;placenta: 45.5	fallopian tube: 2.5	Group enriched	6	HaCaT: 311.4;SiHa: 103.4
GABRG1		ENSG00000163285	Gamma-aminobutyric acid type A receptor gamma1 subunit	4	46035769-46124081	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level	HPA035622	Approved					Tissue enriched	Tissue enriched	17	cerebral cortex: 26.0	ovary: 1.5	Cell line enhanced		U-266/70: 1.1
ALPPL2		ENSG00000163286	Alkaline phosphatase, placental like 2	2	232406843-232410714	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB020698, HPA038764, HPA038765, HPA051699	Supported		Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		fallopian tube: 1.5	lung: 0.7	Group enriched	29	BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
GABRB1		ENSG00000163288	Gamma-aminobutyric acid type A receptor beta1 subunit	4	46993723-47426444	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051297	Uncertain					Tissue enhanced	Tissue enriched	12	cerebral cortex: 19.7	heart muscle: 1.5	Cell line enhanced		REH: 1.4;U-87 MG: 2.4
PAQR3		ENSG00000163291	Progestin and adipoQ receptor family member 3	4	78887127-78939438	Predicted membrane proteins	Evidence at protein level	HPA058453	Uncertain					Expressed in all	Not detected			testis: 0.7	Not detected		
NIPAL1	DKFZp686A06115, NPAL1	ENSG00000163293	NIPA like domain containing 1	4	47914142-48040173	Predicted membrane proteins	Evidence at transcript level	HPA036765	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		esophagus: 24.0;skin: 30.8	rectum: 14.6	Cell line enhanced		A-431: 11.6;HaCaT: 13.6;RT4: 14.3
ALPI		ENSG00000163295	Alkaline phosphatase, intestinal	2	232456123-232460032	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA038764, HPA038765, HPA051699	Supported		Approved	Plasma membrane		Tissue enhanced	Group enriched	31	duodenum: 203.2;small intestine: 212.1	colon: 6.6	Cell line enriched	10	CACO-2: 5.9
ANTXR2	CMG-2, CMG2, FLJ31074	ENSG00000163297	Anthrax toxin receptor 2	4	79901149-80125454	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:1.33e-4 (unfavourable)	Expressed in all	Mixed			prostate: 139.5	Cell line enhanced		LHCN-M2: 147.2
HELQ	Hel308	ENSG00000163312	Helicase, POLQ-like	4	83407343-83455856	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036852, HPA036853	Approved		Approved	Nucleoplasm<br>Nuclear speckles	Renal cancer:2.76e-4 (favourable), Pancreatic cancer:9.07e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 11.9	Expressed in all		
MRPS18C	CGI-134, FLJ11146, FLJ22967, MRPS18-1	ENSG00000163319	Mitochondrial ribosomal protein S18C	4	83455932-83469735	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050404	Approved				Renal cancer:2.90e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 39.7	Expressed in all		
CGGBP1	CGGBP, p20-CGGBP	ENSG00000163320	CGG triplet repeat binding protein 1	3	88051944-88149885	Predicted intracellular proteins	Evidence at protein level	HPA035568, HPA037017	Supported		Enhanced	Nucleus	Urothelial cancer:7.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 93.6	Expressed in all		
FAM175A	ABRA1, ABRAXAS, CCDC98, FLJ13614	ENSG00000163322	Family with sequence similarity 175 member A	4	83459517-83523348	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037654	Uncertain		Supported	Nuclear bodies	Renal cancer:1.53e-4 (favourable)	Mixed	Mixed			testis: 22.1	Expressed in all		
GPR155	DEP.7, DEPDC3, FLJ31819, PGR22	ENSG00000163328	G protein-coupled receptor 155	2	174431571-174487094	Predicted membrane proteins	Evidence at protein level	HPA036159, HPA057384	Approved		Approved	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			stomach: 45.4	Cell line enhanced		U-266/70: 11.3;WM-115: 9.8
DAPL1		ENSG00000163331	Death associated protein like 1	2	158795317-158862781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046937, HPA058635	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Microtubules	Cervical cancer:8.43e-4 (favourable)	Group enriched	Tissue enhanced		epididymis: 238.2;esophagus: 243.7;skin: 219.0	fallopian tube: 128.4	Group enriched	5	HaCaT: 3.5;hTCEpi: 16.6;SCLC-21H: 6.9;U-87 MG: 8.2
PMVK	HUMPMKI, PMK, PMKA	ENSG00000163344	Phosphomevalonate kinase	1	154924734-154936991	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029900	Approved				Renal cancer:4.96e-4 (favourable), Ovarian cancer:9.70e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.5	Expressed in all		
PBXIP1	HPIP	ENSG00000163346	PBX homeobox interacting protein 1	1	154944076-154956123	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006949	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:9.22e-6 (favourable), Pancreatic cancer:2.64e-4 (favourable), Colorectal cancer:2.73e-4 (unfavourable), Head and neck cancer:7.19e-4 (favourable), Lung cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 138.8	Cell line enriched	7	Karpas-707: 788.8
CLDN1	ILVASC, SEMP1	ENSG00000163347	Claudin 1	3	190305701-190322475	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002602, HPA048319	Enhanced				Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 306.2;smooth muscle: 186.0	liver: 158.4	Cell line enhanced		EFO-21: 613.4;HaCaT: 206.6;hTCEpi: 206.7;RPTEC TERT1: 310.7;RT4: 210.1
PYGO2		ENSG00000163348	Pygopus family PHD finger 2	1	154957026-154963853	Predicted intracellular proteins	Evidence at protein level	HPA023689	Supported		Approved	Nucleoplasm	Liver cancer:3.88e-6 (unfavourable), Urothelial cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.7	Expressed in all		
HIPK1	KIAA0630, MGC26642, MGC33446, MGC33548, Myak, Nbak2	ENSG00000163349	Homeodomain interacting protein kinase 1	1	113929192-113977869	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016664	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 89.7	Expressed in all		
LENEP	LEP503	ENSG00000163352	Lens epithelial protein	1	154993586-154994315	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.2	Not detected		
DCST2	FLJ32934	ENSG00000163354	DC-STAMP domain containing 2	1	155018520-155033781	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		skin: 5.0;testis: 4.2	duodenum,fallopian tube: 1.3	Cell line enhanced		U-266/70: 1.1
DCST1	FLJ32785	ENSG00000163357	DC-STAMP domain containing 1	1	155033824-155050930	Predicted membrane proteins	Evidence at protein level	HPA060314	Uncertain					Not detected	Group enriched	5	skin: 3.7;testis: 6.1	small intestine: 0.9	Cell line enhanced		HaCaT: 1.8;RPMI-8226: 1.7
COL6A3		ENSG00000163359	Collagen type VI alpha 3 chain	2	237324003-237414375	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010080	Supported				Renal cancer:5.57e-11 (unfavourable)	Expressed in all	Tissue enhanced		smooth muscle: 557.1	gallbladder: 375.3	Cell line enhanced		ASC diff: 2271.2;ASC TERT1: 2960.3;BJ hTERT+: 1039.3;HSkMC: 1966.4
C1orf106	FLJ10901	ENSG00000163362	Chromosome 1 open reading frame 106	1	200891048-200915735	Predicted intracellular proteins	Evidence at transcript level	HPA027499, HPA027511	Uncertain				Endometrial cancer:1.78e-5 (unfavourable)	Expressed in all	Tissue enhanced		small intestine: 69.7	duodenum: 54.3	Cell line enhanced		BEWO: 60.4;HaCaT: 66.8
YY1AP1	HCCA2, YAP, YY1AP	ENSG00000163374	YY1 associated protein 1	1	155659443-155689000	Predicted intracellular proteins	Evidence at protein level	HPA006986, HPA064249	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:2.01e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 130.2	Expressed in all		
KBTBD8	KIAA1842, TA-KRP	ENSG00000163376	Kelch repeat and BTB domain containing 8	3	66998307-67011210	Predicted intracellular proteins	Evidence at protein level	HPA041285, HPA069190	Approved					Mixed	Tissue enhanced		lymph node: 24.3;tonsil: 18.9	testis: 14.5	Cell line enhanced		Daudi: 44.8;U-698: 29.8
FAM19A4	TAFA-4	ENSG00000163377	Family with sequence similarity 19 member A4, C-C motif chemokine like	3	68731766-68953297	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	10	adrenal gland: 18.5	gallbladder: 1.9	Cell line enhanced		HAP1: 1.8;NTERA-2: 8.8;SCLC-21H: 1.1
EOGT	AER61, C3orf64, FLJ33770	ENSG00000163378	EGF domain specific O-linked N-acetylglucosamine transferase	3	68975214-69013961	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019460	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol	Renal cancer:8.97e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 50.3	Mixed		
LMOD3		ENSG00000163380	Leiomodin 3	3	69106872-69123032	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036034	Uncertain					Tissue enriched	Group enriched	17	heart muscle: 73.7;skeletal muscle: 162.2	esophagus: 6.9	Cell line enhanced		HSkMC: 2.1
NAXE	AIBP, APOA1BP, MGC119143, MGC119144, MGC119145, YJEFN1	ENSG00000163382	NAD(P)HX epimerase	1	156591762-156594299	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043766, HPA048164	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.94e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 112.2	Expressed in all		
POGLUT1	9630046K23Rik, C3orf9, hCLP46, KDELCL1, KTELC1, MDS010, MDSRP, MGC32995, Rumi	ENSG00000163389	Protein O-glucosyltransferase 1	3	119468938-119494708	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037855, HPA037856	Approved				Renal cancer:7.02e-7 (unfavourable), Urothelial cancer:2.23e-4 (favourable)	Expressed in all	Mixed			seminal vesicle: 16.5	Expressed in all		
SLC22A15	FLIPT1	ENSG00000163393	Solute carrier family 22 member 15	1	115976498-116070054	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019785	Approved					Expressed in all	Tissue enhanced		bone marrow: 20.5	skin: 11.1	Cell line enhanced		hTCEpi: 26.0;hTERT-HME1: 36.4
CCKAR		ENSG00000163394	Cholecystokinin A receptor	4	26481400-26490462	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	10	gallbladder: 47.2;stomach: 15.2	tonsil: 3.1	Not detected		
IGFN1	DKFZp434B1231, EEF1A2BP1	ENSG00000163395	Immunoglobulin-like and fibronectin type III domain containing 1	1	201190825-201228952	Predicted intracellular proteins	Evidence at protein level	HPA050415	Enhanced		Approved	Midbody ring	Renal cancer:1.27e-8 (unfavourable)	Group enriched	Group enriched	6	endometrium: 17.1;epididymis: 18.4;skeletal muscle: 60.1	cerebral cortex: 5.6	Cell line enriched	6	HeLa: 41.8
ATP1A1		ENSG00000163399	ATPase Na+/K+ transporting subunit alpha 1	1	116372668-116410261	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB018702, CAB069993	Enhanced				Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 2487.1	Expressed in all		
SLC15A2	PEPT2	ENSG00000163406	Solute carrier family 15 member 2	3	121894089-121944102	Predicted membrane proteins, Transporters	Evidence at protein level						Cervical cancer:2.37e-4 (favourable), Lung cancer:6.74e-4 (favourable), Endometrial cancer:6.96e-4 (favourable)	Mixed	Tissue enhanced		cervix, uterine: 78.5;prostate: 64.9	epididymis: 47.8	Mixed		
EIF4E3	MGC39820	ENSG00000163412	Eukaryotic translation initiation factor 4E family member 3	3	71675416-71754773	Predicted intracellular proteins	Evidence at protein level	HPA058649			Approved	Nucleoli fibrillar center	Ovarian cancer:4.64e-5 (favourable), Renal cancer:6.99e-5 (favourable), Lung cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.7	Cell line enhanced		U-937: 39.6
PROK2	BV8, KAL4, MIT1, PK2	ENSG00000163421	Prokineticin 2	3	71771656-71785206	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA041408	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 30.3;bone marrow: 52.7;testis: 24.1	adipose tissue: 11.2	Group enriched	5	HL-60: 8.9;NB-4: 6.1;NTERA-2: 6.5;U-266/70: 11.1;U-266/84: 17.7;U-937: 7.9
C3orf30	FLJ32859, TSCPA	ENSG00000163424	Chromosome 3 open reading frame 30	3	119146150-119160042	Predicted intracellular proteins	Evidence at protein level	HPA062468	Enhanced					Not detected	Tissue enriched	438	testis: 94.4	kidney: 0.2	Not detected		
LRRC58		ENSG00000163428	Leucine rich repeat containing 58	3	120324509-120349339	Predicted intracellular proteins	Evidence at protein level	HPA057574	Uncertain		Approved	Nucleus<br>Cytosol	Liver cancer:4.98e-4 (unfavourable), Thyroid cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 30.1	Expressed in all		
FSTL1	FRP, FSL1, OCC-1, OCC1, tsc36	ENSG00000163430	Follistatin like 1	3	120392293-120451253	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035251, HPA040815	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 656.3	Cell line enhanced		BJ: 1888.8;fHDF/TERT166: 2153.3;HBF TERT88: 1729.6
LMOD1	1D, 64kD, D1	ENSG00000163431	Leiomodin 1	1	201896452-201946588	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028325, HPA028435, HPA030097	Enhanced		Approved	Cytosol	Liver cancer:2.52e-5 (favourable), Renal cancer:1.05e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 331.2	Group enriched	10	ASC diff: 10.7;BJ: 17.8;BJ hTERT+: 27.6;fHDF/TERT166: 13.3;HSkMC: 10.4
ELF3	EPR-1, ERT, ESE-1, ESX	ENSG00000163435	E74 like ETS transcription factor 3	1	202007945-202017188	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003316, HPA003479	Enhanced		Enhanced	Nucleoplasm		Mixed	Mixed			small intestine: 161.7	Cell line enhanced		A549: 188.9;CAPAN-2: 259.7;RT4: 171.2;SK-BR-3: 304.2
PDCL2	GCPHLP	ENSG00000163440	Phosducin like 2	4	55556525-55592212	Predicted intracellular proteins	Evidence at protein level	HPA048260	Enhanced					Group enriched	Tissue enriched	306	testis: 110.4	skin: 0.3	Cell line enhanced		HaCaT: 1.7
TMEM183A	C1orf37	ENSG00000163444	Transmembrane protein 183A	1	203007386-203024848	Predicted membrane proteins	Evidence at protein level	HPA072607			Approved	Nucleus<br>Plasma membrane<br>Cell Junctions	Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
TMEM169	FLJ34263	ENSG00000163449	Transmembrane protein 169	2	216081866-216102783	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA062462, HPA062797, HPA070657	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 12.0	thyroid gland: 4.8	Cell line enhanced		AF22: 8.9;RPTEC TERT1: 10.0;SCLC-21H: 13.4;SH-SY5Y: 17.3
IGFBP7	FSTL2, IGFBP-7, MAC25, PSF	ENSG00000163453	Insulin like growth factor binding protein 7	4	57030773-57110385	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002196, CAB020668	Approved		Uncertain	Golgi apparatus		Expressed in all	Expressed in all			seminal vesicle: 916.3	Cell line enhanced		BJ: 585.7;BJ hTERT+: 522.8;EFO-21: 407.8;RPTEC TERT1: 516.3;TIME: 821.5
TRIM46	FLJ23229, TRIFIC	ENSG00000163462	Tripartite motif containing 46	1	155173787-155184971	Predicted intracellular proteins	Evidence at protein level	HPA030389, HPA055583	Enhanced		Approved	Intermediate filaments<br>Cytosol	Endometrial cancer:2.61e-7 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 7.9;epididymis: 4.0	smooth muscle: 1.5	Cell line enhanced		SH-SY5Y: 11.1
KRTCAP2	KCP2	ENSG00000163463	Keratinocyte associated protein 2	1	155169408-155173475	Predicted membrane proteins	Evidence at protein level						Renal cancer:9.70e-11 (unfavourable)	Expressed in all	Expressed in all			epididymis: 241.8	Expressed in all		
CXCR1	CD181, CDw128a, CKR-1, CMKAR1, IL8RA	ENSG00000163464	C-X-C motif chemokine receptor 1	2	218162845-218166995	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031991	Uncertain					Mixed	Tissue enhanced		appendix: 35.1;spleen: 25.0	adipose tissue: 15.7	Cell line enriched	32	HMC-1: 5.0
ARPC2	ARC34, p34-Arc	ENSG00000163466	Actin related protein 2/3 complex subunit 2	2	218217094-218254356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001994, HPA008352	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.07e-7 (unfavourable), Liver cancer:3.63e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 537.0	Expressed in all		
TSACC	C1orf182, SIP, SSTK-IP	ENSG00000163467	TSSK6 activating cochaperone	1	156337314-156346995	Predicted intracellular proteins	Evidence at protein level	HPA029897			Approved	Nucleus<br>Nuclear bodies		Tissue enhanced	Tissue enriched	506	testis: 1514.6	epididymis: 2.9	Mixed		
CCT3	Cctg, TRIC5	ENSG00000163468	Chaperonin containing TCP1 subunit 3	1	156308968-156367873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006543	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.87e-7 (unfavourable), Renal cancer:6.34e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 206.2	Expressed in all		
TMEM79	FLJ16057, FLJ32254, MATT, MGC13102	ENSG00000163472	Transmembrane protein 79	1	156282935-156293185	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055214	Enhanced		Approved	Nucleoli fibrillar center	Renal cancer:4.31e-7 (unfavourable), Liver cancer:2.61e-5 (unfavourable)	Expressed in all	Group enriched	6	esophagus: 61.6;prostate: 45.5;skin: 66.8	tonsil: 10.3	Mixed		
SSR2	TLAP, TRAPB	ENSG00000163479	Signal sequence receptor subunit 2	1	156009048-156020959	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.00e-7 (unfavourable), Liver cancer:2.86e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 551.1	Expressed in all		
RNF25	AO7, FLJ13906	ENSG00000163481	Ring finger protein 25	2	218663864-218672411	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036420, HPA036421	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:6.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 14.6	Expressed in all		
STK36	FU, KIAA1278	ENSG00000163482	Serine/threonine kinase 36	2	218672026-218702716	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027409, HPA027453, HPA030058	Approved		Supported	Cytosol	Liver cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
ADORA1	RDC7	ENSG00000163485	Adenosine A1 receptor	1	203090654-203167405	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044383			Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 50.2;testis: 25.4	parathyroid gland: 18.9	Cell line enhanced		CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
NEK10	FLJ32685	ENSG00000163491	NIMA related kinase 10	3	27110085-27369460	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038941	Uncertain		Approved	Nucleoplasm<br>Vesicles	Breast cancer:4.20e-4 (favourable)	Tissue enriched	Tissue enhanced		testis: 65.9	breast: 18.6	Cell line enhanced		LHCN-M2: 6.8;U-2 OS: 7.1
CCDC141	CAMDI, FLJ39502	ENSG00000163492	Coiled-coil domain containing 141	2	178830269-179050086	Predicted intracellular proteins	Evidence at protein level	HPA012718			Approved	Nucleoplasm		Not detected	Tissue enriched	13	heart muscle: 50.2	lung: 3.9	Cell line enhanced		CACO-2: 4.0;HEL: 6.8;RH-30: 3.7;U-266/70: 3.7;U-698: 4.4
FEV	Pet-1	ENSG00000163497	FEV, ETS transcription factor	2	218981087-218985657	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067679		Supported	Supported	Nuclear speckles	Pancreatic cancer:4.85e-4 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 2.1;duodenum: 2.9;prostate: 1.9;stomach: 2.4	small intestine: 1.6	Group enriched	6	HMC-1: 22.4;SH-SY5Y: 34.6
CRYBA2		ENSG00000163499	Crystallin beta A2	2	218990189-218993421	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062293	Supported				Pancreatic cancer:7.62e-4 (favourable)	Tissue enriched	Tissue enhanced		adrenal gland: 4.6;stomach: 4.6	small intestine: 3.0	Cell line enriched	6	BEWO: 69.8
IHH	BDA1, HHG2	ENSG00000163501	Indian hedgehog	2	219054420-219060467	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.67e-6 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 8.9;colon: 21.0;duodenum: 14.9;endometrium: 31.4;rectum: 16.7;small intestine: 16.5;stomach: 15.3	prostate: 3.2	Cell line enriched	11	CACO-2: 16.8
KIAA1524	CIP2A	ENSG00000163507	KIAA1524	3	108549869-108589644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039570	Approved		Supported	Plasma membrane<br>Cytosol	Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.3	Mixed		
EOMES	TBR2	ENSG00000163508	Eomesodermin	3	27715949-27722711	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028896	Uncertain				Renal cancer:9.45e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		lymph node: 18.2;spleen: 19.4	tonsil: 5.3	Cell line enhanced		HDLM-2: 7.3;SCLC-21H: 4.9
CWC22	EIF4GL, fSAPb, KIAA1604, NCM	ENSG00000163510	CWC22 spliceosome associated protein homolog	2	179944876-180007113	Predicted intracellular proteins	Evidence at protein level	HPA036748	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:7.76e-5 (unfavourable), Liver cancer:7.42e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 28.9	Expressed in all		
AZI2	AZ2, FLJ21939, NAP1	ENSG00000163512	5-azacytidine induced 2	3	28315003-28349127	Predicted intracellular proteins	Evidence at protein level	HPA035258	Approved				Liver cancer:1.95e-4 (unfavourable), Urothelial cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.7	Expressed in all		
TGFBR2	MFS2	ENSG00000163513	Transforming growth factor beta receptor 2	3	30606502-30694142	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB073537			Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 292.3	Cell line enhanced		ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
RETNLB	FIZZ2, HXCP2, RELMb	ENSG00000163515	Resistin like beta	3	108743424-108757384	Predicted secreted proteins	Evidence at transcript level	HPA049152	Approved				Colorectal cancer:6.86e-5 (favourable)	Tissue enriched	Tissue enhanced		colon: 73.5;rectum: 270.7	small intestine: 36.9	Not detected		
ANKZF1	FLJ10415, ZNF744	ENSG00000163516	Ankyrin repeat and zinc finger domain containing 1	2	219229757-219236669	Predicted intracellular proteins	Evidence at protein level	HPA035208	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.01e-6 (unfavourable), Liver cancer:3.09e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 16.8	Expressed in all		
HDAC11		ENSG00000163517	Histone deacetylase 11	3	13479724-13506424	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.88e-10 (favourable), Liver cancer:1.20e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 66.7	Cell line enhanced		T-47d: 39.9
FCRL4	CD307d, FCRH4, IGFP2, IRTA1	ENSG00000163518	Fc receptor like 4	1	157573749-157598080	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA054030	Approved					Not detected	Tissue enhanced		appendix: 3.6;lymph node: 4.4;tonsil: 9.6	spleen: 1.1	Cell line enriched	36	U-266/70: 3.5
TRAT1	HSPC062, TCRIM, TRIM	ENSG00000163519	T-cell receptor associated transmembrane adaptor 1	3	108822698-108855005	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002356, CAB026130	Enhanced					Mixed	Tissue enhanced		appendix: 14.0;lymph node: 26.4	spleen: 11.5	Cell line enriched	39	MOLT-4: 58.7
FBLN2		ENSG00000163520	Fibulin 2	3	13549131-13638422	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001934, CAB018622	Enhanced		Supported	Plasma membrane	Liver cancer:3.17e-4 (favourable), Endometrial cancer:9.48e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 142.2	Cell line enhanced		ASC diff: 262.8;fHDF/TERT166: 204.8;HMC-1: 273.5;HSkMC: 161.5
GLB1L	MGC10771	ENSG00000163521	Galactosidase beta 1 like	2	219236606-219245478	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043058	Enhanced					Expressed in all	Tissue enhanced		testis: 95.4	fallopian tube: 37.3	Mixed		
STT3B	FLJ90106, SIMP, STT3-B	ENSG00000163527	STT3B, catalytic subunit of the oligosaccharyltransferase complex	3	31532638-31637622	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA036448, HPA036646	Approved		Supported	Endoplasmic reticulum	Colorectal cancer:7.91e-5 (favourable)	Expressed in all	Expressed in all			testis: 165.5	Expressed in all		
CHCHD4	FLJ31709, MIA40, TIMM40	ENSG00000163528	Coiled-coil-helix-coiled-coil-helix domain containing 4	3	14112077-14124870	Predicted intracellular proteins	Evidence at protein level	HPA034688, HPA063727	Uncertain		Supported	Mitochondria	Renal cancer:8.63e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
DPPA2	CT100, PESCRG1	ENSG00000163530	Developmental pluripotency associated 2	3	109293788-109316517	Predicted intracellular proteins	Evidence at protein level	HPA036134	Uncertain		Approved	Nucleus		Tissue enriched	Tissue enriched	11	testis: 6.5	placenta: 0.5	Cell line enhanced		BEWO: 5.8;EFO-21: 10.7
NFASC	FLJ46866, KIAA0756, NF, NRCAML	ENSG00000163531	Neurofascin	1	204828651-205022822	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008832	Enhanced				Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.7	seminal vesicle: 22.4	Cell line enhanced		BJ: 23.3;fHDF/TERT166: 39.1;SCLC-21H: 26.9;U-138 MG: 62.0;U-87 MG: 30.5
FCRL1	CD307a, FCRH1, IFGP1, IRTA5	ENSG00000163534	Fc receptor like 1	1	157794403-157820105	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013323	Enhanced					Mixed	Tissue enhanced		lymph node: 30.3;spleen: 23.5;tonsil: 20.0	appendix: 12.5	Group enriched	31	Daudi: 3.7;U-698: 11.9
SGO2	FLJ25211, SGOL2, TRIPIN	ENSG00000163535	Shugoshin 2	2	200510008-200583782	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035163, HPA040817	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enriched	6	testis: 59.6	lymph node: 9.2	Expressed in all		
SERPINI1	neuroserpin, PI12	ENSG00000163536	Serpin family I member 1	3	167735243-167825568	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001565, CAB026059, HPA056092	Enhanced		Approved	Cytosol	Liver cancer:4.25e-4 (unfavourable)	Expressed in all	Tissue enriched	10	cerebral cortex: 322.1	kidney: 31.3	Mixed		
CLASP2	KIAA0627	ENSG00000163539	Cytoplasmic linker associated protein 2	3	33496245-33718356	Predicted intracellular proteins	Evidence at protein level	HPA067071			Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.48e-6 (favourable)	Expressed in all	Tissue enriched	6	cerebral cortex: 193.2	endometrium: 34.2	Expressed in all		
SUCLG1		ENSG00000163541	Succinate-CoA ligase alpha subunit	2	84423523-84460045	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA036683, HPA036684	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:2.21e-8 (favourable), Endometrial cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 471.2	Expressed in all		
NUAK2	FLJ90349, SNARK	ENSG00000163545	NUAK family kinase 2	1	205302059-205321791	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA008958	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Endometrial cancer:3.01e-7 (unfavourable), Pancreatic cancer:7.94e-6 (favourable)	Expressed in all	Mixed			esophagus: 22.0	Cell line enhanced		BEWO: 42.0;RPTEC TERT1: 30.2
SPTA1	EL2	ENSG00000163554	Spectrin alpha, erythrocytic 1	1	158610706-158686698	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016193, HPA028048, HPA028253, CAB037246	Supported					Not detected	Tissue enriched	19	bone marrow: 47.1	placenta: 2.5	Group enriched	7	HEL: 7.6;K-562: 34.1
PRKCI	DXS1179E, PKCI	ENSG00000163558	Protein kinase C iota	3	170222365-170305981	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026574, HPA038635	Approved		Enhanced	Microtubules<br>Cytokinetic bridge<br>Cytosol	Endometrial cancer:3.93e-6 (unfavourable), Pancreatic cancer:1.22e-4 (unfavourable), Liver cancer:3.02e-4 (unfavourable), Renal cancer:3.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
MNDA	PYHIN3	ENSG00000163563	Myeloid cell nuclear differentiation antigen	1	158831317-158849506	Predicted intracellular proteins	Evidence at protein level	HPA034532, HPA073215	Enhanced		Supported	Nucleoplasm<br>Nucleoli		Expressed in all	Tissue enhanced		bone marrow: 194.8;spleen: 144.9	appendix: 111.3	Group enriched	13	NB-4: 93.3;THP-1: 185.6;U-937: 141.2
PYHIN1	IFIX, MGC23885	ENSG00000163564	Pyrin and HIN domain family member 1	1	158930796-158977054	Predicted intracellular proteins	Evidence at protein level	HPA051224	Enhanced					Mixed	Tissue enhanced		lymph node: 26.3;spleen: 19.2	tonsil: 11.3	Cell line enriched	6	U-698: 33.8
IFI16	IFNGIP1, PYHIN2	ENSG00000163565	Interferon gamma inducible protein 16	1	158999968-159055155	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002134, CAB016293	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.11e-16 (unfavourable)	Expressed in all	Expressed in all			lymph node: 163.5	Mixed		
AIM2	PYHIN4	ENSG00000163568	Absent in melanoma 2	1	159062484-159147096	Predicted intracellular proteins	Evidence at protein level	HPA031365, HPA040309	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		lymph node: 52.5;spleen: 30.9;tonsil: 40.1	appendix: 26.0	Cell line enhanced		Daudi: 60.6;HDLM-2: 110.5;Karpas-707: 32.8;U-266/70: 28.9;U-87 MG: 34.1
EFHB	CFAP21, FLJ25200	ENSG00000163576	EF-hand domain family member B	3	19879472-19947025	Predicted intracellular proteins	Evidence at protein level	HPA078067			Approved	Nucleoli		Mixed	Group enriched	6	fallopian tube: 25.5;testis: 25.8	cerebral cortex: 4.3	Cell line enriched	30	RPTEC TERT1: 14.9
EIF5A2		ENSG00000163577	Eukaryotic translation initiation factor 5A2	3	170888415-170908693	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029090	Approved		Supported	Vesicles	Head and neck cancer:7.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 36.7	smooth muscle: 10.4	Mixed		
SLC2A2	GLUT2	ENSG00000163581	Solute carrier family 2 member 2	3	170996348-171026750	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010444, HPA028997, HPA028998	Enhanced		Approved	Nucleoplasm	Liver cancer:2.63e-5 (favourable)	Tissue enriched	Tissue enriched	7	liver: 433.0	duodenum: 65.7	Group enriched	61	CACO-2: 6.7;Hep G2: 18.6
RPL22L1		ENSG00000163584	Ribosomal protein L22 like 1	3	170864875-170870483	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA048060, HPA056207, HPA068294	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.13e-12 (unfavourable), Ovarian cancer:8.60e-5 (favourable)	Expressed in all	Expressed in all			appendix: 87.1	Expressed in all		
FABP1	L-FABP	ENSG00000163586	Fatty acid binding protein 1	2	88122982-88128116	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002305, HPA028275	Enhanced		Approved	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	7	colon: 4552.0;duodenum: 4123.5;liver: 5672.8;rectum: 3081.5;small intestine: 4506.9	kidney: 602.3	Group enriched	6	CACO-2: 84.1;Hep G2: 221.3
PPM1L	PP2CE	ENSG00000163590	Protein phosphatase, Mg2+/Mn2+ dependent 1L	3	160755602-161078907	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019891, HPA019953	Approved		Approved	Nucleoplasm<br>Cytosol	Breast cancer:4.90e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 39.6	cerebral cortex: 27.9	Group enriched	5	HDLM-2: 73.7;U-266/70: 57.7
ICA1L	ALS2CR14, ALS2CR15	ENSG00000163596	Islet cell autoantigen 1 like	2	202773150-202871985	Predicted intracellular proteins	Evidence at protein level	HPA042507	Approved		Supported	Mitochondria		Mixed	Mixed			cerebral cortex: 22.4	Cell line enhanced		BEWO: 21.1
CTLA4	CD, CD152, CELIAC3, GSE, IDDM12	ENSG00000163599	Cytotoxic T-lymphocyte associated protein 4	2	203867786-203873960	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:4.48e-5 (favourable)	Mixed	Tissue enhanced		appendix: 23.5;lymph node: 31.9	tonsil: 15.3	Group enriched	5	SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
ICOS	AILIM, CD278	ENSG00000163600	Inducible T-cell costimulator	2	203936748-203961577	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032575	Approved				Head and neck cancer:1.80e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 10.9;lymph node: 16.9;tonsil: 14.8	appendix: 10.2	Group enriched	69	HEL: 4.0;MOLT-4: 9.6
RYBP	AAP1, DEDAF, YEAF1	ENSG00000163602	RING1 and YY1 binding protein	3	72371825-72446621	Predicted intracellular proteins	Evidence at protein level	HPA053357	Approved		Supported	Nucleoplasm	Renal cancer:2.50e-5 (favourable)	Expressed in all	Mixed			endometrium: 30.7	Expressed in all		
PPP4R2		ENSG00000163605	Protein phosphatase 4 regulatory subunit 2	3	72996785-73069199	Predicted intracellular proteins	Evidence at protein level	HPA034695, HPA039837, HPA073758	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 66.7	Expressed in all		
CD200R1	CD200R, HCRTR2, MOX2R, OX2R	ENSG00000163606	CD200 receptor 1	3	112921209-112975122	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA068512			Supported	Plasma membrane		Mixed	Tissue enhanced		spleen: 14.5	placenta: 10.2	Cell line enriched	8	HEL: 26.4
GTPBP8	HSPC135	ENSG00000163607	GTP binding protein 8 (putative)	3	112990918-113015060	Predicted intracellular proteins	Evidence at protein level	HPA034831, HPA058631	Approved		Enhanced	Mitochondria	Renal cancer:3.07e-5 (favourable)	Expressed in all	Expressed in all			testis: 33.0	Expressed in all		
NEPRO	C3orf17, DKFZP434F2021, NET17	ENSG00000163608	Nucleolus and neural progenitor protein	3	113002440-113019861	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069654			Supported	Nucleus<br>Nucleoli	Endometrial cancer:1.13e-4 (unfavourable), Liver cancer:4.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
SPICE1	CCDC52, SPICE	ENSG00000163611	Spindle and centriole associated protein 1	3	113442718-113515187	Predicted intracellular proteins	Evidence at protein level	HPA064843	Approved		Supported	Centrosome		Expressed in all	Mixed			endometrium: 17.7	Expressed in all		
CCDC191	KIAA1407	ENSG00000163617	Coiled-coil domain containing 191	3	113964137-114056613	Predicted intracellular proteins	Evidence at protein level	HPA047833	Approved		Approved	Mitochondria	Urothelial cancer:3.45e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 18.8	Mixed		
CADPS	CAPS, CAPS1, KIAA1121, UNC-31	ENSG00000163618	Calcium dependent secretion activator	3	62398346-62875389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059328	Enhanced		Approved	Vesicles		Mixed	Group enriched	8	adrenal gland: 21.6;cerebral cortex: 94.1	heart muscle: 7.5	Cell line enhanced		SCLC-21H: 23.2;SK-MEL-30: 7.0;U-698: 8.9;U-87 MG: 20.1
NKX6-1	Nkx6.1, NKX6A	ENSG00000163623	NK6 homeobox 1	4	84491987-84498450	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036774, CAB070169	Supported		Supported	Nucleoplasm		Mixed	Tissue enhanced		esophagus: 6.9;thyroid gland: 2.9	testis: 1.4	Cell line enhanced		AF22: 4.0;HAP1: 6.0;HEK 293: 4.7;HMC-1: 3.4;U-2197: 5.9
CDS1		ENSG00000163624	CDP-diacylglycerol synthase 1	4	84582979-84651338	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036187, HPA064546	Enhanced		Approved	Nucleus<br>Nuclear membrane	Renal cancer:0.00e+0 (favourable), Colorectal cancer:5.22e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 49.6	Cell line enhanced		CAPAN-2: 39.2;hTCEpi: 39.6;SK-BR-3: 44.9
WDFY3	ALFY, KIAA0993, ZFYVE25	ENSG00000163625	WD repeat and FYVE domain containing 3	4	84669610-84966391	Predicted intracellular proteins	Evidence at protein level	HPA042734, HPA048572	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.2	Mixed		
COX18	FLJ38991	ENSG00000163626	COX18, cytochrome c oxidase assembly factor	4	73052362-73069755	Predicted membrane proteins	Evidence at protein level	HPA046772, HPA049489	Enhanced				Renal cancer:8.22e-7 (favourable), Colorectal cancer:6.31e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 5.4	Expressed in all		
PTPN13	PTP-BAS, PTP-BL, PTP1E, PTPL1	ENSG00000163629	Protein tyrosine phosphatase, non-receptor type 13	4	86594315-86815171	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002213, HPA048888, HPA065290	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			skin: 65.9	Cell line enhanced		AF22: 114.7
SYNPR	MGC26651, SPO	ENSG00000163630	Synaptoporin	3	63228315-63616921	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051368, HPA061671	Enhanced					Tissue enhanced	Tissue enriched	27	cerebral cortex: 78.2	heart muscle: 2.9	Cell line enhanced		SCLC-21H: 1.2
ALB		ENSG00000163631	Albumin	4	73397114-73421412	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB006262, HPA031024, HPA031025	Supported		Enhanced	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:7.87e-4 (unfavourable)	Tissue enriched	Tissue enriched	220	liver: 105947.0	kidney: 482.5	Cell line enriched	33	Hep G2: 3030.6
C3orf49		ENSG00000163632	Chromosome 3 open reading frame 49	3	63819362-63848636	Predicted intracellular proteins	Evidence at transcript level	HPA053582	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.2;testis: 2.1	skin: 0.5	Not detected		
C4orf36	MGC26744	ENSG00000163633	Chromosome 4 open reading frame 36	4	86876205-86936202	Predicted intracellular proteins	Evidence at protein level	HPA057434	Uncertain		Approved	Focal adhesion sites<br>Cytosol	Renal cancer:7.69e-5 (favourable)	Mixed	Tissue enhanced		testis: 10.6	skin: 5.7	Mixed		
THOC7	FLJ23445, fSAP24, NIF3L1BP1	ENSG00000163634	THO complex 7	3	63833870-63863903	Predicted intracellular proteins	Evidence at protein level	HPA044143	Approved		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			breast: 84.4	Expressed in all		
ATXN7	ADCAII, OPCA3, SCA7	ENSG00000163635	Ataxin 7	3	63864557-64003462	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034989			Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.7	Expressed in all		
PSMD6	KIAA0107, p44S10, Rpn7, S10	ENSG00000163636	Proteasome 26S subunit, non-ATPase 6	3	64010549-64024010	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036921, HPA036922	Uncertain		Supported	Golgi apparatus<br>Vesicles	Liver cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 216.4	Cell line enriched	5	MCF7: 1051.2
PRICKLE2	DKFZp686D143	ENSG00000163637	Prickle planar cell polarity protein 2	3	64092242-64445476	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035493			Approved	Golgi apparatus<br>Vesicles		Mixed	Mixed			endometrium: 29.7	Cell line enhanced		ASC diff: 16.5;HSkMC: 16.1;U-87 MG: 15.2
ADAMTS9	KIAA1312	ENSG00000163638	ADAM metallopeptidase with thrombospondin type 1 motif 9	3	64515654-64688000	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028567, HPA028577, HPA028601	Approved		Approved	Endoplasmic reticulum<br>Vesicles		Expressed in all	Tissue enhanced		placenta: 45.1	adipose tissue: 32.1	Cell line enhanced		RPTEC TERT1: 20.9;SH-SY5Y: 136.2;WM-115: 27.9
PPM1K	BDP, DKFZp761G058, hPTMP, PP2Ckappa, PP2Cm	ENSG00000163644	Protein phosphatase, Mg2+/Mn2+ dependent 1K	4	88257620-88284769	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020066, HPA020862, HPA023891	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 61.4	Mixed		
ERICH6	C3orf44, ERICH6A, FAM194A, MGC39662	ENSG00000163645	Glutamate rich 6	3	150659885-150703971	Predicted intracellular proteins	Evidence at protein level	HPA048373	Enhanced					Not detected	Tissue enriched	24	testis: 51.6	epididymis: 2.1	Cell line enhanced		SH-SY5Y: 1.7;U-266/84: 1.9
CLRN1	RP61, USH3, USH3A	ENSG00000163646	Clarin 1	3	150926163-150972999	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054636	Uncertain					Not detected	Group enriched	5	adrenal gland: 6.7;duodenum: 1.5	testis: 0.7	Cell line enriched	31	NTERA-2: 3.5
GMPS		ENSG00000163655	Guanine monophosphate synthase	3	155870536-155944026	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046630			Approved	Cytosol	Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 181.7	Expressed in all		
TIPARP	DDF1, DKFZP434J214, DKFZp686N0351, PARP-1, PARP-7, PARP7, pART14, RM1	ENSG00000163659	TCDD inducible poly(ADP-ribose) polymerase	3	156673235-156706770	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036796	Uncertain		Approved	Microtubules	Breast cancer:2.00e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 232.4	Expressed in all		
CCNL1	ania-6a	ENSG00000163660	Cyclin L1	3	157146508-157160760	Predicted secreted proteins	Evidence at protein level	HPA057911			Supported	Nucleoplasm<br>Nuclear bodies	Urothelial cancer:6.96e-7 (favourable), Renal cancer:1.01e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 28.8	Expressed in all		
PTX3	TNFAIP5, TSG-14	ENSG00000163661	Pentraxin 3	3	157436789-157443628	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA069320	Approved				Endometrial cancer:8.35e-9 (unfavourable), Lung cancer:8.75e-6 (unfavourable), Head and neck cancer:6.36e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 164.6;appendix: 54.2	bone marrow: 52.6	Cell line enhanced		ASC TERT1: 1187.1;HHSteC: 1837.3;HSkMC: 1660.2;hTEC/SVTERT24-B: 1235.3;TIME: 1387.2;U-2197: 1444.5
HESX1	ANF, RPX	ENSG00000163666	HESX homeobox 1	3	57197843-57226521	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024187	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		testis: 12.4	skin: 5.4	Cell line enhanced		NTERA-2: 73.5;U-266/84: 17.0
DCLK3	DCAMKL3, DCDC3C, KIAA1765	ENSG00000163673	Doublecortin like kinase 3	3	36712422-36764349	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040685	Approved					Tissue enhanced	Tissue enhanced		testis: 4.9	cerebral cortex: 1.1	Cell line enhanced		SCLC-21H: 1.0
SLMAP	KIAA1601, SLAP	ENSG00000163681	Sarcolemma associated protein	3	57755450-57929168	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002357, HPA002358	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.58e-6 (favourable), Lung cancer:7.98e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 265.6	Expressed in all		
RPL9	L9	ENSG00000163682	Ribosomal protein L9	4	39454124-39458948	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003372	Approved	Approved	Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:7.34e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 2710.2	Expressed in all		
SMIM14	C4orf34, FLJ13289	ENSG00000163683	Small integral membrane protein 14	4	39546330-39639090	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051299	Uncertain				Head and neck cancer:3.00e-6 (favourable), Renal cancer:2.07e-4 (favourable), Endometrial cancer:2.63e-4 (favourable), Liver cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			liver: 54.3	Cell line enhanced		Daudi: 189.5
RPP14	P14	ENSG00000163684	Ribonuclease P/MRP subunit p14	3	58306247-58324695	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036194	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.07e-10 (favourable), Thyroid cancer:2.96e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 21.1	Expressed in all		
ABHD6		ENSG00000163686	Abhydrolase domain containing 6	3	58237506-58295693	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017283, HPA073225	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable)	Expressed in all	Mixed			small intestine: 50.9	Mixed		
DNASE1L3	DNAS1L3, LSD	ENSG00000163687	Deoxyribonuclease 1 like 3	3	58192257-58214697	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019955	Approved				Renal cancer:1.06e-7 (favourable), Liver cancer:1.20e-6 (favourable)	Mixed	Tissue enhanced		liver: 136.7;spleen: 316.5	tonsil: 51.2	Cell line enhanced		BEWO: 1.8;RPMI-8226: 1.4
C3orf67	FLJ42117, FLJ42930	ENSG00000163689	Chromosome 3 open reading frame 67	3	58717365-59050084	Predicted intracellular proteins	Evidence at protein level	HPA069696			Approved	Golgi apparatus		Mixed	Tissue enhanced		esophagus: 13.2;testis: 47.0	fallopian tube: 6.3	Mixed		
RBM47	FLJ20273, NET18	ENSG00000163694	RNA binding motif protein 47	4	40423267-40630875	Predicted intracellular proteins	Evidence at protein level	HPA006347	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.33e-16 (favourable)	Expressed in all	Mixed			small intestine: 71.5	Cell line enhanced		BEWO: 135.3;CAPAN-2: 55.4
APBB2	FE65L, FE65L1, MGC35575	ENSG00000163697	Amyloid beta precursor protein binding family B member 2	4	40810027-41216714	Predicted intracellular proteins	Evidence at protein level	HPA023542	Approved		Approved	Mitochondria	Endometrial cancer:1.97e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.5	Cell line enhanced		TIME: 151.9
IL17RE	FLJ23658	ENSG00000163701	Interleukin 17 receptor E	3	9902612-9916402	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019011	Uncertain					Expressed in all	Mixed			small intestine: 22.6	Cell line enhanced		ASC TERT1: 27.7;BEWO: 14.7;T-47d: 18.4
IL17RC	IL17-RL	ENSG00000163702	Interleukin 17 receptor C	3	9917074-9933630	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA019885, CAB026255	Approved				Endometrial cancer:1.38e-4 (favourable)	Expressed in all	Expressed in all			prostate: 24.2	Mixed		
CRELD1	AVSD2	ENSG00000163703	Cysteine rich with EGF like domains 1	3	9933822-9945413	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026964	Uncertain		Approved	Nucleoli<br>Cytosol	Glioma:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 65.6	Expressed in all		
PRRT3	FLJ33674	ENSG00000163704	Proline rich transmembrane protein 3	3	9945542-9952394	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035127, HPA035128	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 19.4;parathyroid gland: 27.8	fallopian tube: 12.2	Cell line enhanced		MCF7: 17.7;SK-BR-3: 25.1
FANCD2OS	C3orf24, MGC40179	ENSG00000163705	FANCD2 opposite strand	3	10081317-10108231	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	96	testis: 54.7	bone marrow: 0.5	Cell line enhanced		CACO-2: 1.1
PCOLCE2	PCPE2	ENSG00000163710	Procollagen C-endopeptidase enhancer 2	3	142815922-142889203	Predicted secreted proteins	Evidence at protein level	HPA013203	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.96e-5 (unfavourable), Urothelial cancer:1.08e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 81.7;placenta: 57.9	heart muscle: 42.3	Cell line enhanced		ASC diff: 37.5;U-2197: 58.5;U-266/70: 47.2
U2SURP	fSAPa, SR140	ENSG00000163714	U2 snRNP associated SURP domain containing	3	142964497-143060546	Predicted intracellular proteins	Evidence at protein level	HPA037545, HPA037546, HPA061407	Enhanced		Supported	Nucleoplasm	Renal cancer:8.86e-7 (unfavourable), Liver cancer:3.15e-5 (unfavourable), Urothelial cancer:6.78e-4 (favourable), Endometrial cancer:8.44e-4 (unfavourable), Pancreatic cancer:8.92e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
MTMR14	C3orf29, FLJ22405, FLJ90311, hEDTP, hJumpy	ENSG00000163719	Myotubularin related protein 14	3	9649433-9702393	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA054063	Approved				Renal cancer:2.74e-4 (favourable), Liver cancer:3.95e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 41.8	Expressed in all		
TTC14	FLJ00166, KIAA1980	ENSG00000163728	Tetratricopeptide repeat domain 14	3	180602130-180617828	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009295	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 60.8	Expressed in all		
CXCL3	CINC-2b, GRO3, GROg, MIP-2b, SCYB3	ENSG00000163734	C-X-C motif chemokine ligand 3	4	74036589-74038807	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Cervical cancer:2.33e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 26.9;cervix, uterine: 33.6	appendix: 20.3	Cell line enhanced		BJ hTERT+: 39.2;hTEC/SVTERT24-B: 75.0;RPTEC TERT1: 32.7
CXCL5	ENA-78, SCYB5	ENSG00000163735	C-X-C motif chemokine ligand 5	4	73995642-73998779	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA065474	Approved				Renal cancer:2.45e-5 (unfavourable), Liver cancer:1.39e-4 (unfavourable), Pancreatic cancer:2.23e-4 (unfavourable), Cervical cancer:3.43e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 47.7	urinary bladder: 15.5	Cell line enhanced		A549: 165.3;EFO-21: 141.1;HSkMC: 77.3;hTEC/SVTERT24-B: 78.0;RPTEC TERT1: 436.4
PPBP	b-TG1, Beta-TG, CTAP3, CTAPIII, CXCL7, LA-PF4, LDGF, MDGF, NAP-2, NAP-2-L1, PBP, SCYB7, TGB, TGB1, THBGB1	ENSG00000163736	Pro-platelet basic protein	4	73987038-73988197	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008354, CAB017624	Supported				Cervical cancer:6.17e-4 (unfavourable)	Tissue enriched	Tissue enhanced		bone marrow: 110.6	spleen: 24.3	Cell line enhanced		HBEC3-KT: 1.6;HEL: 6.2;RPTEC TERT1: 1.1
PF4	CXCL4, SCYB4	ENSG00000163737	Platelet factor 4	4	73981077-73982124	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026008, HPA052485	Enhanced					Tissue enhanced	Group enriched	5	bone marrow: 53.7;spleen: 13.4	placenta: 6.5	Cell line enriched	13	HEL: 37.2
MTHFD2L	MGC72244	ENSG00000163738	Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like	4	74114174-74303099	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035434	Uncertain					Mixed	Mixed			adrenal gland: 4.8	Mixed		
CXCL1	FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3, SCYB1	ENSG00000163739	C-X-C motif chemokine ligand 1	4	73869393-73871242	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.60e-4 (unfavourable), Liver cancer:2.91e-4 (unfavourable), Cervical cancer:7.23e-4 (unfavourable), Breast cancer:7.83e-4 (favourable)	Expressed in all	Tissue enhanced		cervix, uterine: 178.6;spleen: 112.8	urinary bladder: 92.0	Group enriched	7	BJ hTERT+: 658.8;EFO-21: 1914.4;RPTEC TERT1: 559.0
RCHY1	ARNIP, CHIMP, DKFZp586C1620, PIRH2, PRO1996, RNF199, ZCHY, ZNF363	ENSG00000163743	Ring finger and CHY zinc finger domain containing 1	4	75479037-75514764	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030339	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.62e-5 (favourable), Urothelial cancer:7.89e-5 (favourable), Colorectal cancer:9.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.7	Expressed in all		
PLSCR2		ENSG00000163746	Phospholipid scramblase 2	3	146391421-146495991	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	10	testis: 23.5	epididymis: 2.2	Not detected		
CCDC158	FLJ25770	ENSG00000163749	Coiled-coil domain containing 158	4	76312997-76421868	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	27	testis: 60.4	thyroid gland: 2.2	Not detected		
CPA3		ENSG00000163751	Carboxypeptidase A3	3	148865256-148897196	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA006479, HPA008689, CAB020712	Enhanced					Mixed	Tissue enhanced		gallbladder: 173.9	lung: 126.9	Cell line enriched	46	HEL: 265.9
GYG1	GYG	ENSG00000163754	Glycogenin 1	3	148991341-149027668	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030497	Approved		Supported	Vesicles	Liver cancer:6.15e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 210.0	Mixed		
HPS3	BLOC2S1, SUTAL	ENSG00000163755	HPS3, biogenesis of lysosomal organelles complex 2 subunit 1	3	149129584-149173732	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046281, HPA052778	Approved		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable)	Expressed in all	Mixed			spleen: 22.0	Expressed in all		
TM4SF18	L6D	ENSG00000163762	Transmembrane 4 L six family member 18	3	149318498-149334414	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA053639, HPA069378	Approved		Uncertain	Nucleoli<br>Vesicles	Liver cancer:8.63e-4 (favourable)	Expressed in all	Mixed			spleen: 47.0	Group enriched	6	A549: 86.7;EFO-21: 184.5;HUVEC TERT2: 55.1;NTERA-2: 47.1
TOPBP1	KIAA0259, TOP2BP1	ENSG00000163781	Topoisomerase (DNA) II binding protein 1	3	133598175-133661893	Predicted intracellular proteins	Evidence at protein level	CAB022451, HPA036738, HPA036739	Approved		Enhanced	Nucleus	Liver cancer:4.66e-5 (unfavourable), Endometrial cancer:5.76e-5 (unfavourable), Pancreatic cancer:1.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 54.2	Expressed in all		
RYK	D3S3195, JTK5, JTK5A, RYK1	ENSG00000163785	Receptor-like tyrosine kinase	3	134065303-134250744	Predicted membrane proteins	Evidence at protein level	CAB034117, HPA045503, HPA075430	Uncertain		Approved	Golgi apparatus<br>Cytosol	Liver cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 101.1	Expressed in all		
SNRK	FLJ20224, HSNFRK, KIAA0096	ENSG00000163788	SNF related kinase	3	43286512-43424764	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042163	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.41e-5 (favourable), Breast cancer:9.28e-4 (favourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
TCF23	bHLHa24, OUT	ENSG00000163792	Transcription factor 23	2	27149004-27156974	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		endometrium: 33.8;ovary: 22.7;smooth muscle: 30.8	fallopian tube: 13.9	Cell line enriched	7	THP-1: 2.3
DNAJC5G	CSP-gamma, FLJ40417	ENSG00000163793	DnaJ heat shock protein family (Hsp40) member C5 gamma	2	27275421-27281499	Predicted membrane proteins	Evidence at transcript level	HPA041445	Approved					Not detected	Group enriched	41	epididymis: 65.0;testis: 42.7	cerebral cortex: 1.3	Cell line enhanced		HAP1: 1.0
UCN	UI, UROC	ENSG00000163794	Urocortin	2	27307400-27308445	Predicted secreted proteins	Evidence at protein level	CAB010911	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.84e-7 (unfavourable), Colorectal cancer:8.10e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2.8	Cell line enhanced		U-266/70: 14.8
ZNF513	FLJ32203, RP58	ENSG00000163795	Zinc finger protein 513	2	27377231-27380790	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051493	Uncertain				Liver cancer:6.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
SLC4A1AP	HLC3, kanadaptin	ENSG00000163798	Solute carrier family 4 member 1 adaptor protein	2	27663471-27694976	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036679	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Liver cancer:3.76e-7 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Urothelial cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 62.0	Expressed in all		
PLB1	FLJ30866, PLB	ENSG00000163803	Phospholipase B1	2	28457145-28643788	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014045			Approved	Cytosol		Mixed	Group enriched	7	skin: 9.4;small intestine: 45.7	testis: 4.2	Cell line enhanced		BEWO: 3.5
SPDYA	Ringo3, SPDY1, SPY1	ENSG00000163806	Speedy/RINGO cell cycle regulator family member A	2	28782517-28850611	Predicted intracellular proteins	Evidence at protein level	HPA035162, HPA066214	Enhanced		Supported	Nucleoplasm		Not detected	Tissue enriched	30	testis: 58.6	skin: 1.9	Mixed		
KIAA1143		ENSG00000163807	KIAA1143	3	44737661-44761662	Predicted intracellular proteins	Evidence at protein level	HPA045018, HPA061799	Approved		Approved	Nucleus<br>Cytokinetic bridge	Renal cancer:3.26e-6 (favourable), Colorectal cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 15.0	Expressed in all		
KIF15	HKLP2, KNSL7, NY-BR-62	ENSG00000163808	Kinesin family member 15	3	44761717-44873376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035516, HPA035517	Approved				Colorectal cancer:3.12e-4 (favourable)	Mixed	Tissue enhanced		testis: 14.2	bone marrow: 3.1	Mixed		
TGM4	TGP	ENSG00000163810	Transglutaminase 4	3	44874608-44914990	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032072, CAB033571	Enhanced					Tissue enriched	Tissue enriched	465	prostate: 689.9	adrenal gland: 1.4	Cell line enhanced		BEWO: 4.7;NB-4: 1.7;RPMI-8226: 1.3;SH-SY5Y: 1.5
WDR43	KIAA0007, NET12, UTP5	ENSG00000163811	WD repeat domain 43	2	28894643-28948222	Predicted intracellular proteins	Evidence at protein level	HPA044733	Uncertain				Liver cancer:3.66e-5 (unfavourable), Endometrial cancer:5.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.5	Expressed in all		
ZDHHC3	GODZ, ZNF373	ENSG00000163812	Zinc finger DHHC-type containing 3	3	44915257-44976185	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB012465, HPA016616	Approved		Approved	Golgi apparatus	Renal cancer:1.81e-8 (favourable), Liver cancer:1.37e-4 (unfavourable), Colorectal cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			skin,testis: 65.5	Expressed in all		
CDCP1	CD318, SIMA135	ENSG00000163814	CUB domain containing protein 1	3	45082278-45146422	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010978, HPA010979, CAB025637	Enhanced				Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable)	Expressed in all	Mixed			skin: 27.7	Cell line enhanced		hTEC/SVTERT24-B: 263.4;hTERT-HME1: 135.9
CLEC3B	TN, TNA	ENSG00000163815	C-type lectin domain family 3 member B	3	45001548-45036071	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002582, HPA034794	Approved				Liver cancer:9.99e-9 (favourable), Head and neck cancer:1.53e-4 (favourable), Pancreatic cancer:5.68e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 303.3	adipose tissue: 203.9	Cell line enhanced		ASC diff: 169.4;ASC TERT1: 341.9;U-2197: 94.5
SLC6A20	XT3, Xtrp3	ENSG00000163817	Solute carrier family 6 member 20	3	45755450-45796535	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029873	Uncertain				Renal cancer:1.55e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 24.4;small intestine: 19.3	gallbladder: 10.9	Cell line enhanced		HaCaT: 1.5
LZTFL1	BBS17	ENSG00000163818	Leucine zipper transcription factor like 1	3	45823316-45916042	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043466, HPA048447	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 35.9	Mixed		
FYCO1	FLJ13335, ZFYVE7	ENSG00000163820	FYVE and coiled-coil domain containing 1	3	45917899-45995824	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035526, HPA057966	Uncertain		Enhanced	Vesicles	Renal cancer:3.33e-11 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 91.9	Expressed in all		
CCR1	CD191, CKR-1, CMKBR1, MIP1aR, SCYAR1	ENSG00000163823	C-C motif chemokine receptor 1	3	46201709-46208396	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 57.5	spleen: 41.1	Cell line enhanced		Karpas-707: 230.1;RPMI-8226: 105.8;U-266/84: 123.3
RTP3	LTM1, TMEM7, Z3CXXC3	ENSG00000163825	Receptor transporter protein 3	3	46497491-46500949	Predicted membrane proteins	Evidence at protein level	HPA075932			Uncertain	Mitochondria	Liver cancer:3.11e-6 (favourable)	Group enriched	Tissue enriched	24	liver: 33.8	testis: 1.4	Cell line enriched	11	SiHa: 10.7
LRRC2		ENSG00000163827	Leucine rich repeat containing 2	3	46515423-46580099	Predicted intracellular proteins	Evidence at protein level	HPA039138, HPA040096	Approved					Tissue enhanced	Group enriched	5	heart muscle: 30.0;skeletal muscle: 55.9;thyroid gland: 37.0	endometrium: 7.8	Cell line enhanced		fHDF/TERT166: 5.6;HEL: 3.8;LHCN-M2: 3.4
ELP6	C3orf75, FLJ20211, TMEM103	ENSG00000163832	Elongator acetyltransferase complex subunit 6	3	47495640-47513761	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046358, HPA064545	Uncertain		Approved	Nucleus<br>Centrosome<br>Cytosol	Renal cancer:3.42e-6 (favourable)	Expressed in all	Expressed in all			testis: 32.0	Expressed in all		
FBXO40	Fbx40, KIAA1195	ENSG00000163833	F-box protein 40	3	121593119-121630295	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	36	heart muscle: 56.2;skeletal muscle: 54.0	prostate: 1.5	Not detected		
DTX3L	BBAP	ENSG00000163840	Deltex E3 ubiquitin ligase 3L	3	122564238-122575203	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010570	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.99e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 83.9;BJ hTERT+ SV40 Large T+ RasG12V: 107.7
ZNF148	BERF-1, BFCOL1, HT-BETA, pHZ-52, ZBP-89, ZFP148	ENSG00000163848	Zinc finger protein 148	3	125225561-125375354	Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001656, CAB017486	Supported		Supported	Nucleus<br>Golgi apparatus	Pancreatic cancer:2.88e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.4	Expressed in all		
NMNAT3	PNAT3	ENSG00000163864	Nicotinamide nucleotide adenylyltransferase 3	3	139560180-139678017	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039077, HPA057402	Approved		Supported	Mitochondria	Renal cancer:1.95e-5 (favourable), Pancreatic cancer:7.29e-5 (favourable), Cervical cancer:9.67e-4 (favourable)	Mixed	Mixed			ovary: 20.5	Cell line enhanced		HEL: 22.9;THP-1: 8.5;U-266/70: 11.9
SMIM12	C1orf212, FLJ90372	ENSG00000163866	Small integral membrane protein 12	1	34712737-34859816	Predicted membrane proteins	Evidence at protein level	HPA065331	Approved		Approved	Mitochondria	Renal cancer:1.15e-5 (favourable), Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 45.3	Expressed in all		
ZMYM6	Buster2, MYM, ZBED7, ZNF198L4, ZNF258	ENSG00000163867	Zinc finger MYM-type containing 6	1	34986165-35031968	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011004, HPA071865	Approved		Supported	Nucleoplasm	Breast cancer:1.30e-5 (favourable)	Expressed in all	Mixed			testis: 19.0	Expressed in all		
TPRA1	FLJ32197, GPR175, TMEM227, TPRA40	ENSG00000163870	Transmembrane protein adipocyte associated 1	3	127573069-127598251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019784	Approved		Approved	Vesicles	Liver cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
YEATS2	FLJ10201, FLJ12841, FLJ13308, KIAA1197	ENSG00000163872	YEATS domain containing 2	3	183697818-183812625	Predicted intracellular proteins	Evidence at protein level	HPA045891	Uncertain		Approved	Nucleoplasm	Renal cancer:6.90e-9 (unfavourable), Liver cancer:4.82e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 19.5	Expressed in all		
GRIK3	GluK3, GLUR7	ENSG00000163873	Glutamate ionotropic receptor kainate type subunit 3	1	36795527-37034129	Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	cerebral cortex: 19.8	seminal vesicle: 3.5	Group enriched	5	SCLC-21H: 11.4;T-47d: 37.2
ZC3H12A	FLJ23231, MCPIP1	ENSG00000163874	Zinc finger CCCH-type containing 12A	1	37474552-37484379	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032052, HPA032053	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:5.95e-5 (unfavourable), Endometrial cancer:9.67e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 84.3	gallbladder: 55.5	Cell line enhanced		RT4: 48.1
MEAF6	C1orf149, CENP-28, Eaf6, FLJ11730, NY-SAR-91	ENSG00000163875	MYST/Esa1 associated factor 6	1	37492575-37514774	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			prostate: 139.9	Expressed in all		
SNIP1		ENSG00000163877	Smad nuclear interacting protein 1	1	37534449-37554344	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036896	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 7.6	Expressed in all		
DNALI1	dJ423B22.5, hp28, P28	ENSG00000163879	Dynein axonemal light intermediate chain 1	1	37556919-37566857	Predicted intracellular proteins	Evidence at protein level	HPA028305	Approved				Lung cancer:6.02e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 86.2	testis: 38.3	Cell line enhanced		AF22: 13.9;RPTEC TERT1: 12.6;SH-SY5Y: 12.3;T-47d: 28.1
POLR2H	RPB8	ENSG00000163882	RNA polymerase II subunit H	3	184361718-184368596	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA037745, HPA055813	Enhanced		Supported	Nucleus	Renal cancer:1.65e-10 (unfavourable), Liver cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 71.8	Expressed in all		
KLF15	KKLF	ENSG00000163884	Kruppel like factor 15	3	126342635-126357442	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028866	Uncertain				Renal cancer:3.27e-7 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 42.8	adipose tissue: 37.0	Cell line enhanced		ASC diff: 38.8;HHSteC: 28.8
CFAP100	CCDC37, FLJ40083, MIA1	ENSG00000163885	Cilia and flagella associated protein 100	3	126394939-126436556	Predicted intracellular proteins	Evidence at protein level	HPA046354	Enhanced					Tissue enhanced	Group enriched	5	fallopian tube: 43.4;testis: 34.5	lung: 7.4	Not detected		
CAMK2N2	CaM-KIIN	ENSG00000163888	Calcium/calmodulin dependent protein kinase II inhibitor 2	3	184259213-184261463	Predicted intracellular proteins	Evidence at protein level	HPA050835			Supported	Nucleus<br>Centrosome	Cervical cancer:9.77e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 12.2;cerebral cortex: 40.4	pancreas: 5.6	Cell line enhanced		REH: 28.6;SCLC-21H: 37.1;U-138 MG: 32.1
LIPH	LPDLR, mPA-PLA1, mPA-PLA1alpha, PLA1B	ENSG00000163898	Lipase H	3	185506262-185552613	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049079	Approved				Renal cancer:9.20e-5 (favourable), Thyroid cancer:4.21e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Endometrial cancer:9.40e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 40.8;stomach: 45.0	colon: 35.7	Cell line enhanced		CAPAN-2: 65.0;RPTEC TERT1: 28.0;T-47d: 16.5
TMEM41A	MGC15397	ENSG00000163900	Transmembrane protein 41A	3	185476496-185499057	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059101, HPA059790	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:6.70e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable), Pancreatic cancer:4.72e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 28.2	Expressed in all		
RPN1	OST1	ENSG00000163902	Ribophorin I	3	128619970-128681075	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009748, HPA026828, HPA051520	Enhanced		Enhanced	Endoplasmic reticulum	Liver cancer:4.80e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 422.3	Expressed in all		
SENP2	AXAM2, DKFZp762A2316, KIAA1331, SMT3IP2	ENSG00000163904	SUMO1/sentrin/SMT3 specific peptidase 2	3	185582496-185633551	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA029247, HPA029248	Approved		Supported	Cytosol	Endometrial cancer:7.98e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 26.9	Expressed in all		
HEYL	bHLHb33, HESR3, HEY3	ENSG00000163909	Hes related family bHLH transcription factor with YRPW motif-like	1	39624153-39639945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001438, HPA076960	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.26e-6 (unfavourable), Urothelial cancer:2.63e-5 (unfavourable), Stomach cancer:3.57e-4 (unfavourable)	Expressed in all	Mixed			placenta: 44.4	Cell line enhanced		LHCN-M2: 18.5;RH-30: 26.3
IFT122	SPG, WDR10, WDR10p, WDR140	ENSG00000163913	Intraflagellar transport 122	3	129440036-129520507	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041815	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 147.4	Expressed in all		
RHO	CSNBAD1, OPN2, RP4	ENSG00000163914	Rhodopsin	3	129528640-129535169	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013440, CAB022486, CAB034887, CAB034888	Supported					Not detected	Not detected			cerebral cortex: 0.3	Not detected		
RFC4	A1, RFC37	ENSG00000163918	Replication factor C subunit 4	3	186789880-186807058	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004557, HPA049123, HPA058507	Enhanced		Enhanced	Nucleoplasm	Renal cancer:2.22e-16 (unfavourable), Liver cancer:6.75e-7 (unfavourable), Cervical cancer:7.41e-5 (favourable), Pancreatic cancer:7.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
RPL39L	RPL39L1	ENSG00000163923	Ribosomal protein L39 like	3	187120948-187180908	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047105	Approved				Glioma:9.50e-7 (unfavourable), Ovarian cancer:1.94e-4 (favourable), Endometrial cancer:6.05e-4 (unfavourable)	Expressed in all	Tissue enriched	15	testis: 220.3	breast: 14.6	Mixed		
BAP1	hucep-6, KIAA0272, UCHL2	ENSG00000163930	BRCA1 associated protein 1	3	52401013-52410350	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004322, HPA028814, HPA028815, HPA055560	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.29e-7 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
TKT		ENSG00000163931	Transketolase	3	53224707-53256052	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029480, HPA029481	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 431.3	Expressed in all		
PRKCD		ENSG00000163932	Protein kinase C delta	3	53156009-53192717	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001863, HPA001890, CAB010469, CAB013225	Enhanced		Enhanced	Endoplasmic reticulum<br>Golgi apparatus<br>Cytosol	Liver cancer:2.24e-4 (unfavourable), Lung cancer:9.01e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 70.4	Expressed in all		
RFT1	CDG1N	ENSG00000163933	RFT1 homolog	3	53088483-53130462	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA060327, HPA069022	Approved		Approved	Vesicles	Liver cancer:1.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.8	Expressed in all		
SFMBT1	DKFZp434L243, RU1, SFMBT	ENSG00000163935	Scm-like with four mbt domains 1	3	52903572-53046750	Predicted intracellular proteins	Evidence at protein level	HPA036152, HPA064564			Enhanced	Nucleoplasm	Endometrial cancer:3.86e-4 (unfavourable)	Expressed in all	Group enriched	6	parathyroid gland: 32.9;testis: 83.1	thyroid gland: 9.9	Expressed in all		
GNL3	C77032, E2IG3, MGC800, NS	ENSG00000163938	G protein nucleolar 3	3	52681156-52694492	Predicted intracellular proteins	Evidence at protein level	CAB020770, HPA036742, HPA036743	Enhanced		Enhanced	Nucleoli<br>Nuclear bodies	Renal cancer:5.69e-5 (unfavourable), Liver cancer:2.93e-4 (unfavourable), Prostate cancer:6.11e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 78.5	Expressed in all		
PBRM1	BAF180, PB1	ENSG00000163939	Polybromo 1	3	52545352-52685917	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015629, HPA059373	Uncertain		Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 44.7	Expressed in all		
UVSSA	KIAA1530	ENSG00000163945	UV stimulated scaffold protein A	4	1347266-1388049	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050824, HPA053496	Approved		Approved	Nucleoplasm	Renal cancer:1.90e-4 (unfavourable), Urothelial cancer:6.87e-4 (favourable)	Expressed in all	Mixed			testis: 12.2	Expressed in all		
FAM208A	C3orf63, KIAA1105, RAP140, se89-1, TASOR	ENSG00000163946	Family with sequence similarity 208 member A	3	56620133-56683237	Predicted intracellular proteins	Evidence at protein level	HPA006735, HPA017142	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 53.5	Expressed in all		
ARHGEF3	DKFZP434F2429, GEF3, STA3, XPLN	ENSG00000163947	Rho guanine nucleotide exchange factor 3	3	56727418-57079329	Predicted intracellular proteins	Evidence at protein level	HPA034715, HPA064945	Uncertain		Approved	Cytosol	Renal cancer:1.96e-7 (favourable), Endometrial cancer:2.17e-4 (favourable), Head and neck cancer:2.61e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 64.9	Cell line enhanced		Hep G2: 60.0;RPMI-8226: 63.7
SLBP	HBP	ENSG00000163950	Stem-loop binding protein	4	1692800-1712555	Predicted intracellular proteins	Evidence at protein level	HPA019254, HPA061670	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.29e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 130.6	Expressed in all		
LRPAP1	A2MRAP, HBP44	ENSG00000163956	LDL receptor related protein associated protein 1	4	3506376-3532559	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA008001, CAB025518	Enhanced	Supported	Enhanced	Endoplasmic reticulum	Renal cancer:4.67e-11 (favourable)	Expressed in all	Expressed in all			placenta: 13.7	Expressed in all		
ZDHHC19	MGC33345	ENSG00000163958	Zinc finger DHHC-type containing 19	3	196197449-196211437	Enzymes, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	44	testis: 29.2	adrenal gland: 0.6	Not detected		
SLC51A	OSTalpha	ENSG00000163959	Solute carrier family 51 alpha subunit	3	196211487-196243178	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA039123	Enhanced				Liver cancer:7.54e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 29.3;liver: 35.1;small intestine: 71.3	colon: 9.9	Cell line enhanced		REH: 3.4
UBXN7	KIAA0794, UBXD7	ENSG00000163960	UBX domain protein 7	3	196347662-196432474	Predicted intracellular proteins	Evidence at protein level	HPA048441, HPA049442	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 22.2	Expressed in all		
RNF168	FLJ35794	ENSG00000163961	Ring finger protein 168	3	196468783-196503768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046109			Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:2.29e-4 (unfavourable), Cervical cancer:8.21e-4 (favourable), Pancreatic cancer:8.31e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.0	Expressed in all		
PIGX	FLJ20522	ENSG00000163964	Phosphatidylinositol glycan anchor biosynthesis class X	3	196639775-196736007	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029409	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:7.45e-5 (unfavourable), Cervical cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.5	Expressed in all		
MELTF	CD228, FLJ38863, MAP97, MFI2, MGC4856, MTf, MTF1	ENSG00000163975	Melanotransferrin	3	196988621-197029816	CD markers, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004880	Approved				Renal cancer:6.99e-11 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 32.3;salivary gland: 28.2	small intestine: 9.6	Cell line enhanced		A-431: 140.8;SK-MEL-30: 152.3
OTOP1		ENSG00000163982	Otopetrin 1	4	4188803-4226889	Predicted membrane proteins	Evidence at transcript level	HPA035599	Uncertain					Not detected	Not detected			skin: 0.2	Not detected		
S100P		ENSG00000163993	S100 calcium binding protein P	4	6693069-6697170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019502	Enhanced		Supported	Nuclear bodies	Pancreatic cancer:2.00e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		bone marrow: 169.5;stomach: 363.3;urinary bladder: 178.9	placenta: 130.7	Cell line enhanced		BEWO: 180.4;Hep G2: 139.7;hTCEpi: 158.3;RT4: 329.6;SK-BR-3: 170.0
ABLIM2	KIAA1808	ENSG00000163995	Actin binding LIM protein family member 2	4	7965310-8158832	Predicted intracellular proteins	Evidence at protein level	HPA035808	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enhanced		skeletal muscle: 37.5;spleen: 28.4	cerebral cortex: 22.1	Group enriched	6	SCLC-21H: 16.3;SiHa: 6.6;U-2197: 19.7
EXO5	C1orf176, DEM1, FLJ21144	ENSG00000164002	Exonuclease 5	1	40508741-40516556	Predicted intracellular proteins	Evidence at protein level	HPA028429			Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.16e-6 (unfavourable), Prostate cancer:2.93e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 11.3	Cell line enhanced		THP-1: 101.0
CLDN19		ENSG00000164007	Claudin 19	1	42733093-42740254	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Group enriched	12	kidney: 19.7;placenta: 14.5	breast: 1.4	Cell line enhanced		CACO-2: 2.4;Hep G2: 4.3
C1orf50	MGC955	ENSG00000164008	Chromosome 1 open reading frame 50	1	42767269-42775747	Predicted intracellular proteins	Evidence at protein level	HPA030236	Uncertain				Melanoma:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.6	Expressed in all		
ERMAP	BTN5, RD, SC	ENSG00000164010	Erythroblast membrane associated protein (Scianna blood group)	1	42817124-42844989	Blood group antigen proteins, Predicted membrane proteins	Evidence at protein level	HPA042573	Uncertain					Expressed in all	Mixed			thyroid gland: 18.7	Cell line enhanced		HEL: 31.0
ZNF691	Zfp691	ENSG00000164011	Zinc finger protein 691	1	42846573-42852477	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA062527	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:7.33e-6 (unfavourable), Pancreatic cancer:6.25e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.5	Expressed in all		
AIMP1	EMAP-2, EMAPII, p43, SCYE1	ENSG00000164022	Aminoacyl tRNA synthetase complex interacting multifunctional protein 1	4	106315544-106349226	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017618, HPA018476	Supported		Enhanced	Cytosol	Head and neck cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 63.2	Expressed in all		
SGMS2	MGC26963, SMS2	ENSG00000164023	Sphingomyelin synthase 2	4	107824563-107915047	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015076	Enhanced				Renal cancer:1.37e-4 (favourable)	Expressed in all	Mixed			gallbladder: 64.4	Mixed		
METAP1	KIAA0094, MAP1A, MetAP1A	ENSG00000164024	Methionyl aminopeptidase 1	4	98995620-99062813	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025485, HPA037997, HPA037998	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.28e-5 (unfavourable), Liver cancer:3.08e-5 (unfavourable), Renal cancer:1.72e-4 (favourable), Colorectal cancer:7.22e-4 (favourable), Urothelial cancer:9.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.3	Expressed in all		
DNAJB14	FLJ14281	ENSG00000164031	DnaJ heat shock protein family (Hsp40) member B14	4	99896248-99946726	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036016	Approved				Renal cancer:2.12e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 34.7	Expressed in all		
H2AFZ	H2A.Z, H2AZ	ENSG00000164032	H2A histone family member Z	4	99948086-99950388	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022549, HPA057236	Supported		Supported	Nucleoplasm	Renal cancer:2.16e-6 (unfavourable), Liver cancer:1.02e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 349.5	Expressed in all		
EMCN	MUC14	ENSG00000164035	Endomucin	4	100395341-100880126	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005928	Approved				Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable)	Expressed in all	Mixed			kidney: 83.7	Cell line enriched	6	HUVEC TERT2: 25.7
SLC9B1	NHA1, NHEDC1	ENSG00000164037	Solute carrier family 9 member B1	4	102885048-103019739	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058971, HPA065520			Supported	Microtubule organizing center<br>Mitochondria		Mixed	Tissue enriched	28	testis: 72.9	epididymis: 2.6	Mixed		
SLC9B2	FLJ23984, NHA2, NHEDC2	ENSG00000164038	Solute carrier family 9 member B2	4	103019868-103085829	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047008	Uncertain		Approved	Nucleoplasm<br>Cell Junctions		Expressed in all	Tissue enhanced		cerebral cortex: 32.5	liver: 20.4	Mixed		
BDH2	DHRS6, FLJ13261, PRO20933, SDR15C1, UCPA-OR, UNQ6308	ENSG00000164039	3-hydroxybutyrate dehydrogenase 2	4	103079435-103099883	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036028, HPA036029	Enhanced		Supported	Cytosol	Renal cancer:4.45e-13 (favourable), Lung cancer:1.20e-4 (favourable), Endometrial cancer:5.21e-4 (favourable), Thyroid cancer:7.75e-4 (favourable)	Expressed in all	Expressed in all			kidney: 456.2	Expressed in all		
PGRMC2	DG6, PMBP	ENSG00000164040	Progesterone receptor membrane component 2	4	128269237-128288829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041172, HPA058652	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol	Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 133.4	Expressed in all		
CDC25A		ENSG00000164045	Cell division cycle 25A	3	48157146-48188402	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005855			Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		testis: 24.4	bone marrow: 9.3	Expressed in all		
CAMP	CAP18, FALL-39, FALL39, LL37	ENSG00000164047	Cathelicidin antimicrobial peptide	3	48223347-48225491	Predicted secreted proteins	Evidence at protein level	CAB015949, CAB016522, HPA029874	Enhanced				Cervical cancer:5.73e-4 (favourable)	Tissue enhanced	Group enriched	101	bone marrow: 1341.0;epididymis: 330.5	lymph node: 8.2	Group enriched	12	Daudi: 18.4;hTCEpi: 12.5;U-698: 50.9
ZNF589	SZF1	ENSG00000164048	Zinc finger protein 589	3	48241100-48299253	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003145	Uncertain		Approved	Nucleoplasm	Lung cancer:6.45e-5 (favourable), Pancreatic cancer:1.21e-4 (favourable), Head and neck cancer:1.71e-4 (favourable), Cervical cancer:2.50e-4 (favourable)	Expressed in all	Mixed			prostate: 28.0	Expressed in all		
FBXW12	Fbw12, FBXO35	ENSG00000164049	F-box and WD repeat domain containing 12	3	48372219-48401259	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037491, HPA037492	Uncertain					Not detected	Tissue enhanced		pancreas: 1.2;testis: 1.0	cerebral cortex: 0.2	Not detected		
PLXNB1	KIAA0407, PLXN5, SEP	ENSG00000164050	Plexin B1	3	48403854-48430051	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA040586	Enhanced				Renal cancer:2.77e-5 (favourable), Head and neck cancer:5.03e-4 (favourable), Urothelial cancer:7.60e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 36.7	Mixed		
CCDC51	FLJ12436	ENSG00000164051	Coiled-coil domain containing 51	3	48432164-48440456	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010980, HPA011408	Supported		Supported	Nucleoplasm<br>Centrosome<br>Mitochondria		Expressed in all	Mixed			thyroid gland: 17.3	Expressed in all		
ATRIP	FLJ12343, MGC20625, MGC21482, MGC26740	ENSG00000164053	ATR interacting protein	3	48446710-48465716	Predicted intracellular proteins	Evidence at protein level	CAB033109, HPA047590	Approved		Supported	Nucleus		Not detected	Tissue enhanced		testis: 30.8	thyroid gland: 10.5	Expressed in all		
SHISA5	hShisa5, SCOTIN	ENSG00000164054	Shisa family member 5	3	48467798-48504826	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042295	Approved				Liver cancer:3.72e-6 (unfavourable), Renal cancer:8.64e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 199.1	Expressed in all		
SPRY1	hSPRY1	ENSG00000164056	Sprouty RTK signaling antagonist 1	4	123396795-123403760	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013538, HPA051369, HPA070554	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			gallbladder: 132.0	Cell line enhanced		AF22: 94.2;AN3-CA: 180.0
BSN	ZNF231	ENSG00000164061	Bassoon presynaptic cytomatrix protein	3	49554489-49671545	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034757	Approved					Mixed	Tissue enriched	7	cerebral cortex: 28.2	testis: 4.2	Cell line enhanced		K-562: 1.7;SCLC-21H: 5.1;SH-SY5Y: 2.9
APEH	D3F15S2, D3S48E, DNF15S2	ENSG00000164062	Acylaminoacyl-peptide hydrolase	3	49674002-49683963	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029700, HPA029701, HPA029702, HPA029703	Enhanced		Enhanced	Cytosol	Renal cancer:3.32e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 101.6	Expressed in all		
INTU	KIAA1284, PDZD6, PDZK6	ENSG00000164066	Inturned planar cell polarity protein	4	127623271-127726737	Predicted intracellular proteins	Evidence at protein level	HPA036714, HPA036715	Enhanced		Approved	Vesicles		Mixed	Mixed			epididymis: 6.4	Mixed		
RNF123	FLJ12565, KPC1	ENSG00000164068	Ring finger protein 123	3	49689499-49721529	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA065983, HPA071879	Approved		Approved	Cytosol	Renal cancer:1.33e-8 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 53.1	Expressed in all		
HSPA4L	APG-1, HSPH3, Osp94	ENSG00000164070	Heat shock protein family A (Hsp70) member 4 like	4	127781821-127840733	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034450, HPA039149, HPA061446	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:3.80e-9 (favourable), Urothelial cancer:6.78e-4 (unfavourable)	Mixed	Tissue enriched	8	testis: 193.3	parathyroid gland: 24.0	Cell line enhanced		HAP1: 84.6
MFSD8	CLN7, MGC33302	ENSG00000164073	Major facilitator superfamily domain containing 8	4	127917805-127965995	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044802	Approved		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:2.21e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 12.5	Mixed		
ABHD18	C4orf29, FLJ21106	ENSG00000164074	Abhydrolase domain containing 18	4	127965306-128039711	Predicted intracellular proteins	Evidence at protein level	HPA050168, HPA051676	Approved		Approved	Nuclear membrane	Colorectal cancer:5.35e-4 (favourable), Urothelial cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 11.0	Expressed in all		
CAMKV	MGC8407, VACAMKL	ENSG00000164076	CaM kinase like vesicle associated	3	49857988-49870222	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007656, CAB034931	Enhanced		Approved	Nucleoplasm<br>Cytokinetic bridge		Group enriched	Tissue enriched	55	cerebral cortex: 86.2	testis: 1.5	Cell line enhanced		AF22: 6.4;HAP1: 8.9;NTERA-2: 30.7;SCLC-21H: 12.2;SH-SY5Y: 7.1
MON1A	MGC13272, SAND1	ENSG00000164077	MON1 homolog A, secretory trafficking associated	3	49908862-49930173	Predicted intracellular proteins	Evidence at protein level	HPA053752, HPA058032	Uncertain		Approved	Cytosol	Pancreatic cancer:3.30e-4 (favourable)	Expressed in all	Mixed			duodenum: 14.5	Expressed in all		
MST1R	CD136, CDw136, PTK8, RON	ENSG00000164078	Macrophage stimulating 1 receptor	3	49887002-49903873	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007657, HPA008180, CAB008972	Enhanced		Approved	Cytosol	Urothelial cancer:2.33e-5 (favourable)	Mixed	Tissue enhanced		skin: 69.4	stomach: 37.2	Cell line enhanced		CAPAN-2: 84.1;HaCaT: 46.9;HBEC3-KT: 41.5;hTCEpi: 57.4;RT4: 49.8
RAD54L2	ARIP4, KIAA0809, SRISNF2L	ENSG00000164080	RAD54-like 2 (S. cerevisiae)	3	51541144-51668667	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035004, HPA039992			Supported	Nucleus<br>Cytosol	Renal cancer:1.71e-5 (favourable)	Expressed in all	Expressed in all			testis: 8.8	Expressed in all		
TEX264	FLJ13935, ZSIG11	ENSG00000164081	Testis expressed 264	3	51662693-51704323	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005002, HPA017739	Enhanced		Supported	Nucleoli<br>Cytosol	Renal cancer:7.95e-9 (favourable), Pancreatic cancer:5.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
GRM2	GPRC1B, mGlu2, MGLUR2	ENSG00000164082	Glutamate metabotropic receptor 2	3	51707070-51718613	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027868, HPA065166	Approved	Supported				Tissue enhanced	Tissue enriched	10	cerebral cortex: 4.4	testis: 0.4	Cell line enriched	7	SCLC-21H: 7.3
DUSP7	MKP-X, PYST2	ENSG00000164086	Dual specificity phosphatase 7	3	52048919-52056550	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.84e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 45.1	Expressed in all		
POC1A	DKFZP434C245, WDR51A	ENSG00000164087	POC1 centriolar protein A	3	52075253-52154690	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040600	Approved				Renal cancer:9.43e-7 (unfavourable), Pancreatic cancer:1.76e-4 (unfavourable), Colorectal cancer:1.78e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 23.1	bone marrow: 7.0	Expressed in all		
PPM1M	FLJ32332, PP2Ceta	ENSG00000164088	Protein phosphatase, Mg2+/Mn2+ dependent 1M	3	52245793-52250597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036905, HPA062291	Uncertain		Approved	Nuclear bodies	Renal cancer:1.61e-5 (unfavourable), Lung cancer:6.69e-4 (favourable), Cervical cancer:7.73e-4 (favourable)	Expressed in all	Expressed in all			lung: 35.0	Mixed		
ETNPPL	AGXT2L1	ENSG00000164089	Ethanolamine-phosphate phospho-lyase	4	108742040-108763054	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044546, HPA072938	Approved		Approved	Nucleus	Glioma:1.31e-4 (favourable)	Group enriched	Group enriched	8	cerebral cortex: 141.2;liver: 98.6	stomach: 15.2	Cell line enhanced		HeLa: 3.8;Hep G2: 1.5;NTERA-2: 1.1
WDR82	MST107, MSTP107, PRO2730, PRO34047, SWD2, TMEM113, WDR82A	ENSG00000164091	WD repeat domain 82	3	52254421-52288020	Predicted intracellular proteins	Evidence at protein level	HPA040427			Approved	Nucleoli		Expressed in all	Expressed in all			endometrium: 93.6	Expressed in all		
PITX2	ARP1, Brx1, IGDS, IHG2, IRID2, Otlx2, RGS, RIEG, RIEG1, RS	ENSG00000164093	Paired like homeodomain 2	4	110617423-110642123	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050074, HPA062728			Enhanced	Nucleus		Mixed	Tissue enhanced		placenta: 72.2	skeletal muscle: 18.3	Cell line enhanced		CACO-2: 23.3;LHCN-M2: 25.4;RH-30: 24.6
C4orf3	HCVFTP1	ENSG00000164096	Chromosome 4 open reading frame 3	4	119296419-119304445	Predicted membrane proteins	Evidence at protein level	HPA026907	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.46e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 150.6	Expressed in all		
PRSS12	BSSP-3, MRT1	ENSG00000164099	Protease, serine 12	4	118280038-118353003	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA035054, HPA035055	Uncertain		Approved	Nucleus<br>Actin filaments	Head and neck cancer:1.03e-4 (favourable), Glioma:1.53e-4 (favourable)	Mixed	Mixed			cervix, uterine: 22.4	Cell line enhanced		SH-SY5Y: 228.5;THP-1: 67.4
NDST3	HSST3	ENSG00000164100	N-deacetylase and N-sulfotransferase 3	4	118033618-118258648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056189	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.0;spleen: 2.8	cervix, uterine: 0.7	Cell line enriched	16	MOLT-4: 13.3
HMGB2	HMG2	ENSG00000164104	High mobility group box 2	4	173331695-173335125	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003506, CAB037206, HPA053314	Enhanced		Supported	Nucleus<br>Nucleoli	Renal cancer:7.60e-12 (unfavourable), Liver cancer:3.76e-5 (unfavourable), Melanoma:3.13e-4 (unfavourable), Pancreatic cancer:7.04e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 1464.0	Expressed in all		
SAP30		ENSG00000164105	Sin3A associated protein 30	4	173369969-173377532	Predicted secreted proteins	Evidence at protein level	CAB022627, HPA059012	Enhanced		Supported	Nucleoplasm	Renal cancer:1.54e-7 (unfavourable), Liver cancer:1.24e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 34.8	Expressed in all		
SCRG1	SCRG-1	ENSG00000164106	Stimulator of chondrogenesis 1	4	173384701-173406380	Predicted secreted proteins	Evidence at protein level	HPA012882	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 24.4;testis: 15.5	smooth muscle: 11.0	Group enriched	13	HSkMC: 4.3;WM-115: 17.6
HAND2	bHLHa26, dHand, Hed, Thing2	ENSG00000164107	Heart and neural crest derivatives expressed 2	4	173524969-173530229	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019591, CAB025576	Approved		Supported	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enhanced		endometrium: 83.9	smooth muscle: 77.9	Cell line enriched	21	SH-SY5Y: 660.2
MAD2L1	HSMAD2, MAD2	ENSG00000164109	MAD2 mitotic arrest deficient-like 1 (yeast)	4	120055608-120067074	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003348	Uncertain		Approved	Nucleoplasm	Renal cancer:3.07e-11 (unfavourable), Liver cancer:5.15e-5 (unfavourable), Lung cancer:2.17e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 4.6	Mixed		
ANXA5	ANX5, ENX2	ENSG00000164111	Annexin A5	4	121667955-121697113	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB003677, HPA035330	Approved		Approved	Nuclear membrane	Renal cancer:9.29e-7 (unfavourable), Liver cancer:1.64e-5 (unfavourable), Head and neck cancer:3.01e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable), Endometrial cancer:3.64e-4 (favourable), Stomach cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 616.2	Expressed in all		
TMEM155	FLJ30834	ENSG00000164112	Transmembrane protein 155	4	121758933-121765427	Predicted secreted proteins	Evidence at transcript level	HPA077585	Approved					Mixed	Group enriched	6	cerebral cortex: 27.6;placenta: 5.7	lymph node: 3.0	Cell line enhanced		fHDF/TERT166: 4.0;HAP1: 2.2;LHCN-M2: 5.5;MOLT-4: 5.1
ADAD1	Tenr	ENSG00000164113	Adenosine deaminase domain containing 1	4	122378966-122429802	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	2122	testis: 212.1	all non-specific tissues: 0.0	Not detected		
MAP9	ASAP, FLJ21159	ENSG00000164114	Microtubule associated protein 9	4	155342658-155376970	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		parathyroid gland: 79.9	cerebral cortex: 27.1	Cell line enhanced		SH-SY5Y: 44.7
GUCY1A3	GC-SA3, GUC1A3	ENSG00000164116	Guanylate cyclase 1 soluble subunit alpha	4	155666711-155732349	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010887, HPA056004, HPA058617	Uncertain		Supported	Nucleus	Lung cancer:2.38e-4 (favourable), Testis cancer:3.59e-4 (unfavourable), Renal cancer:7.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 136.7	smooth muscle: 43.8	Cell line enhanced		HAP1: 7.2;Karpas-707: 7.1;MOLT-4: 15.2;RPTEC TERT1: 9.3;RT4: 11.7;SH-SY5Y: 9.5
FBXO8	FBS, FBX8	ENSG00000164117	F-box protein 8	4	174236658-174284264	Predicted intracellular proteins	Evidence at transcript level	HPA002885	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.29e-7 (favourable)	Expressed in all	Expressed in all			placenta: 45.0	Expressed in all		
CEP44	KIAA1712	ENSG00000164118	Centrosomal protein 44	4	174283677-174333380	Predicted intracellular proteins	Evidence at protein level	HPA041515, HPA041835	Approved					Expressed in all	Mixed			testis: 23.6	Expressed in all		
HPGD	SDR36C1	ENSG00000164120	Hydroxyprostaglandin dehydrogenase 15-(NAD)	4	174490177-174523154	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004919, HPA005679	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.20e-4 (favourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 375.7	stomach: 181.5	Cell line enhanced		A549: 128.2;HEL: 282.4;RT4: 385.2
ASB5		ENSG00000164122	Ankyrin repeat and SOCS box containing 5	4	176213673-176277571	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA028870			Approved	Plasma membrane	Head and neck cancer:5.67e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 75.7	prostate: 20.8	Cell line enriched	14	LHCN-M2: 986.5
C4orf45	FLJ25371	ENSG00000164123	Chromosome 4 open reading frame 45	4	158893134-159038760	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	50	testis: 20.1	bone marrow: 0.4	Not detected		
TMEM144	FLJ11155	ENSG00000164124	Transmembrane protein 144	4	158201604-158255411	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA063554			Approved	Mitochondria	Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 90.5	testis: 46.9	Cell line enhanced		BEWO: 32.7
FAM198B	C4orf18, DKFZp434L142, ENED, FLJ38155	ENSG00000164125	Family with sequence similarity 198 member B	4	158124474-158173318	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007227	Uncertain		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Expressed in all			adrenal gland: 271.5	Cell line enhanced		ASC TERT1: 100.6;HSkMC: 120.9;HUVEC TERT2: 160.0
NPY1R	NPYR	ENSG00000164128	Neuropeptide Y receptor Y1	4	163323961-163344832	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029903			Approved	Nucleus<br>Mitochondria<br>Cytosol	Breast cancer:7.68e-5 (favourable)	Tissue enriched	Tissue enhanced		spleen: 151.8	breast: 39.6	Cell line enriched	16	HEL: 105.6
NPY5R	NPYR5	ENSG00000164129	Neuropeptide Y receptor Y5	4	163343939-163351934	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		spleen: 12.3;testis: 9.7	adipose tissue: 7.7	Not detected		
NAA15	FLJ13340, NARG1, NATH, TBDN100	ENSG00000164134	N(alpha)-acetyltransferase 15, NatA auxiliary subunit	4	139301455-139420033	Predicted intracellular proteins	Evidence at protein level	HPA023589, HPA050661	Approved		Enhanced	Cytosol	Liver cancer:2.03e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.1	Expressed in all		
IL15	IL-15, MGC9721	ENSG00000164136	Interleukin 15	4	141636599-141733987	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004457, HPA037738	Approved		Supported	Nucleoplasm<br>Nuclear speckles		Mixed	Mixed			spleen: 18.8	Mixed		
FAM160A1	FLJ43373	ENSG00000164142	Family with sequence similarity 160 member A1	4	151409216-151663632	Predicted intracellular proteins	Evidence at protein level	HPA046348	Enhanced		Approved	Cytosol		Mixed	Mixed			parathyroid gland: 16.7	Cell line enhanced		SiHa: 9.2
ARFIP1	HSU52521	ENSG00000164144	ADP ribosylation factor interacting protein 1	4	152779937-152918463	Predicted intracellular proteins	Evidence at protein level	CAB005080, HPA037375, HPA063759	Enhanced		Supported	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.83e-10 (favourable), Colorectal cancer:5.75e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 39.4	Expressed in all		
ICE1	KIAA0947	ENSG00000164151	Interactor of little elongation complex ELL subunit 1	5	5420664-5490234	Predicted intracellular proteins	Evidence at protein level	HPA054452, HPA061934	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.2	Expressed in all		
HHIP	FLJ20992, HIP	ENSG00000164161	Hedgehog interacting protein	4	144646021-144745271	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012616	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		lung: 24.2	cerebral cortex: 10.8	Group enriched	6	HUVEC TERT2: 269.0;RH-30: 62.9;TIME: 306.5
ANAPC10	APC10, DKFZP564L0562, DOC1	ENSG00000164162	Anaphase promoting complex subunit 10	4	144967112-145098541	Predicted intracellular proteins	Evidence at protein level	HPA044547	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Melanoma:8.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.7	Expressed in all		
ABCE1	OABP, RLI, RLI1, RNASEL1, RNASELI, RNS4I	ENSG00000164163	ATP binding cassette subfamily E member 1	4	145097932-145129179	Predicted intracellular proteins	Evidence at protein level	CAB012476, HPA036846	Approved		Enhanced	Cytosol	Pancreatic cancer:1.88e-4 (unfavourable), Liver cancer:6.29e-4 (unfavourable), Colorectal cancer:8.69e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
OTUD4	DUBA6, HSHIN1, KIAA1046	ENSG00000164164	OTU deubiquitinase 4	4	145110838-145180161	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036623	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			testis: 72.7	Expressed in all		
LSM6	YDR378C	ENSG00000164167	LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated	4	146175685-146200000	Predicted intracellular proteins	Evidence at protein level	HPA045079	Approved		Approved	Actin filaments	Melanoma:3.88e-4 (unfavourable), Renal cancer:6.65e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 11.1	Expressed in all		
TMEM184C	FLJ10846, TMEM34	ENSG00000164168	Transmembrane protein 184C	4	147617383-147672044	Predicted membrane proteins	Evidence at protein level	HPA054013	Uncertain		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable)	Expressed in all	Group enriched	6	parathyroid gland: 253.9;thyroid gland: 53.2	placenta: 27.6	Expressed in all		
PRMT9	FLJ46629, PRMT10	ENSG00000164169	Protein arginine methyltransferase 9	4	147637785-147684230	Predicted intracellular proteins	Evidence at protein level	HPA036844, HPA042537	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:3.58e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.2	Expressed in all		
ITGA2	CD49B	ENSG00000164171	Integrin subunit alpha 2	5	52989326-53094779	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB017690, HPA060991, HPA063556	Enhanced		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.02e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.5	Cell line enhanced		BJ hTERT+: 74.4;HaCaT: 82.1
MOCS2	MOCO1	ENSG00000164172	Molybdenum cofactor synthesis 2	5	53095679-53110063	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037679, HPA037680	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			kidney: 106.4	Expressed in all		
SLC45A2	AIM-1, MATP, OCA4	ENSG00000164175	Solute carrier family 45 member 2	5	33944616-33984730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		skin: 1.2;testis: 1.2	prostate,rectum: 0.3	Cell line enriched	43	SK-MEL-30: 48.5
EDIL3	DEL1	ENSG00000164176	EGF like repeats and discoidin domains 3	5	83940554-84384793	Predicted secreted proteins	Evidence at protein level	HPA020415	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 131.5	epididymis: 54.6	Cell line enhanced		LHCN-M2: 141.8;TIME: 165.9;U-2 OS: 174.3;U-87 MG: 110.4
TMEM161B	MGC33214	ENSG00000164180	Transmembrane protein 161B	5	88189633-88269476	Predicted membrane proteins	Evidence at protein level	HPA044562	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 59.9	Expressed in all		
ELOVL7	FLJ23563	ENSG00000164181	ELOVL fatty acid elongase 7	5	60751791-60844389	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036337	Approved				Renal cancer:1.54e-9 (favourable), Endometrial cancer:3.87e-5 (unfavourable)	Expressed in all	Mixed			prostate: 35.8	Cell line enhanced		HEL: 33.1
NDUFAF2	B17.2L, mimitin, MMTN, NDUFA12L	ENSG00000164182	NADH:ubiquinone oxidoreductase complex assembly factor 2	5	60945129-61153037	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048082, HPA054776	Supported		Enhanced	Mitochondria	Renal cancer:2.49e-4 (unfavourable), Liver cancer:2.56e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 48.0	Expressed in all		
ZNF474	4933409D10Rik, FLJ32921	ENSG00000164185	Zinc finger protein 474	5	122129513-122153571	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	8	fallopian tube: 26.7;testis: 13.4	lung: 2.5	Mixed		
LMBRD2	DKFZp434H2226	ENSG00000164187	LMBR1 domain containing 2	5	36098412-36151961	Predicted membrane proteins	Evidence at protein level	HPA012165	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 25.4	Mixed		
RANBP3L	FLJ25422	ENSG00000164188	RAN binding protein 3 like	5	36248434-36302114	Predicted intracellular proteins	Evidence at protein level	HPA037471, HPA037472, HPA061526	Approved		Uncertain	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 31.0;kidney: 28.7;prostate: 23.0	breast: 10.0	Cell line enhanced		ASC diff: 8.5;HSkMC: 1.8;T-47d: 2.0
NIPBL	DKFZp434L1319, FLJ11203, FLJ12597, FLJ13354, FLJ13648, IDN3, Scc2	ENSG00000164190	NIPBL, cohesin loading factor	5	36876759-37066413	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040834, HPA058239	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 43.0	Expressed in all		
RNF180		ENSG00000164197	Ring finger protein 180	5	64165844-64372869	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006897	Approved		Approved	Cytosol	Renal cancer:6.81e-5 (favourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 62.4	thyroid gland: 24.8	Cell line enriched	5	RPMI-8226: 20.6
ADGRV1	DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1	ENSG00000164199	Adhesion G protein-coupled receptor V1	5	90529344-91164437	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA067503	Approved		Approved	Lipid droplets		Mixed	Tissue enriched	11	adrenal gland: 261.4	kidney: 22.9	Cell line enhanced		AF22: 15.3;HAP1: 23.8;NTERA-2: 11.7;SCLC-21H: 13.1
SLC25A46		ENSG00000164209	Solute carrier family 25 member 46	5	110738136-110765161	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA039601, HPA071582	Approved		Supported	Mitochondria	Thyroid cancer:2.52e-4 (unfavourable), Colorectal cancer:8.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
STARD4		ENSG00000164211	StAR related lipid transfer domain containing 4	5	111496033-111512590	Predicted intracellular proteins	Evidence at protein level	HPA046177, HPA048081	Approved		Approved	Plasma membrane	Liver cancer:4.80e-5 (unfavourable), Renal cancer:5.89e-5 (unfavourable), Urothelial cancer:2.84e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 41.4	Mixed		
PGGT1B	BGGI, GGTI	ENSG00000164219	Protein geranylgeranyltransferase type I subunit beta	5	115204012-115262872	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030646	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.0	Expressed in all		
F2RL2	PAR3	ENSG00000164220	Coagulation factor II thrombin receptor like 2	5	76615482-76623434	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Colorectal cancer:4.69e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 10.9	smooth muscle: 5.6	Cell line enhanced		BJ hTERT+: 43.2;HEL: 65.9;hTEC/SVTERT24-B: 34.7;U-138 MG: 52.8;WM-115: 67.6
CCDC112	MGC39633	ENSG00000164221	Coiled-coil domain containing 112	5	115267188-115296831	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045120, HPA050621	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.51e-6 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 73.7	cerebral cortex: 13.1	Expressed in all		
ANKRD33B		ENSG00000164236	Ankyrin repeat domain 33B	5	10564330-10657816	Predicted intracellular proteins	Evidence at protein level	HPA056974	Uncertain		Approved	Mitochondria	Renal cancer:4.16e-5 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 12.9	Cell line enhanced		HDLM-2: 44.9;HMC-1: 27.3
CMBL	FLJ23617	ENSG00000164237	Carboxymethylenebutenolidase homolog	5	10275875-10308026	Predicted intracellular proteins	Evidence at protein level	HPA036571	Uncertain				Ovarian cancer:1.99e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 315.7	duodenum: 177.0	Mixed		
C5orf63	FLJ44606, YDR286C	ENSG00000164241	Chromosome 5 open reading frame 63	5	127042558-127073492	Predicted intracellular proteins	Evidence at transcript level	HPA043240	Approved		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 36.8	Cell line enhanced		U-87 MG: 49.1
PRRC1	FLJ32875	ENSG00000164244	Proline rich coiled-coil 1	5	127517609-127555089	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039212	Supported		Approved	Vesicles	Breast cancer:9.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 54.1	Expressed in all		
F2RL1	GPR11, PAR2	ENSG00000164251	F2R like trypsin receptor 1	5	76818933-76835315	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB012989, HPA014091	Approved		Approved	Plasma membrane	Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable)	Expressed in all	Mixed			colon: 58.9	Cell line enhanced		PC-3: 113.9;RPTEC TERT1: 152.3
AGGF1	FLJ10283, GPATC7, GPATCH7, HSU84971, VG5Q	ENSG00000164252	Angiogenic factor with G-patch and FHA domains 1	5	77029251-77065234	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Colorectal cancer:2.87e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.8	Mixed		
WDR41	FLJ10904	ENSG00000164253	WD repeat domain 41	5	77425970-77620611	Predicted intracellular proteins	Evidence at protein level	HPA043124	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Liver cancer:4.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.6	Expressed in all		
PRDM9	KMT8B, MSBP3, PFM6, ZNF899	ENSG00000164256	PR/SET domain 9	5	23443586-23528597	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059555	Uncertain					Not detected	Group enriched	7	epididymis: 1.7;testis: 7.1	bone marrow: 0.6	Cell line enriched	7	U-266/70: 5.0
NDUFS4	AQDQ, CI-18	ENSG00000164258	NADH:ubiquinone oxidoreductase subunit S4	5	53560633-53683340	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003884	Supported		Supported	Mitochondria	Renal cancer:3.85e-6 (favourable)	Expressed in all	Expressed in all			kidney: 139.9	Expressed in all		
SCGB3A2	LU103, PNSP1, UGRP1	ENSG00000164265	Secretoglobin family 3A member 2	5	147870682-147882191	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	188	lung: 1867.1	thyroid gland: 9.9	Cell line enhanced		A-431: 76.2;EFO-21: 49.6;NTERA-2: 60.1;PC-3: 279.6
SPINK1	PCTT, PSTI, Spink3, TATI	ENSG00000164266	Serine peptidase inhibitor, Kazal type 1	5	147824568-147831786	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026366, HPA027498	Enhanced				Renal cancer:5.44e-7 (unfavourable), Urothelial cancer:2.15e-5 (favourable)	Tissue enhanced	Tissue enriched	8	pancreas: 7127.3	stomach: 927.5	Group enriched	9	CACO-2: 208.3;RT4: 548.2
HTR4	5-HT4	ENSG00000164270	5-hydroxytryptamine receptor 4	5	148451032-148677235	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040591	Approved					Not detected	Tissue enhanced		duodenum: 4.8;small intestine: 10.0	rectum: 3.1	Not detected		
ESM1		ENSG00000164283	Endothelial cell specific molecule 1	5	54977864-55022671	Predicted secreted proteins	Evidence at protein level						Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)	Tissue enriched	Tissue enhanced		kidney: 19.2;thyroid gland: 27.2	endometrium: 5.8	Group enriched	5	HUVEC TERT2: 236.2;TIME: 434.9
GRPEL2	DKFZp451C205, FLJ23713, Mt-GrpE#2	ENSG00000164284	GrpE like 2, mitochondrial	5	149345430-149354583	Predicted intracellular proteins	Evidence at protein level	HPA018173, HPA023211	Uncertain		Enhanced	Mitochondria	Liver cancer:6.16e-8 (unfavourable), Colorectal cancer:3.87e-5 (favourable), Endometrial cancer:2.21e-4 (unfavourable), Renal cancer:4.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 30.4	thyroid gland: 9.7	Expressed in all		
CDC20B	FLJ37927	ENSG00000164287	Cell division cycle 20B	5	55112995-55173175	Predicted intracellular proteins	Evidence at protein level	HPA053900	Uncertain					Tissue enhanced	Group enriched	6	endometrium: 1.2;fallopian tube: 3.4;kidney: 1.2;testis: 4.9	lung: 0.4	Not detected		
ARSK	DKFZp313G1735, TSULF	ENSG00000164291	Arylsulfatase family member K	5	95555074-95605064	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042384	Approved		Approved	Nucleus<br>Vesicles	Liver cancer:2.59e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 22.7	thyroid gland: 8.5	Expressed in all		
RHOBTB3	KIAA0878	ENSG00000164292	Rho related BTB domain containing 3	5	95713522-95824383	Predicted intracellular proteins	Evidence at protein level	HPA000265			Uncertain	Vesicles		Expressed in all	Expressed in all			ovary: 99.0	Cell line enhanced		HaCaT: 281.3
GPX8	EPLA847, UNQ847	ENSG00000164294	Glutathione peroxidase 8 (putative)	5	55160118-55167071	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036720	Enhanced		Supported	Actin filaments<br>Cytosol	Renal cancer:5.13e-9 (unfavourable), Stomach cancer:7.96e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 48.0	Mixed		
TIGD6	DKFZp761E2110	ENSG00000164296	Tigger transposable element derived 6	5	149993118-150001167	Predicted intracellular proteins	Evidence at protein level	HPA044599	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Actin filaments	Colorectal cancer:5.35e-4 (favourable), Pancreatic cancer:5.88e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 21.4	testis: 6.7	Mixed		
SPZ1	FLJ25709, NYD-TSP1, PPP1R148	ENSG00000164299	Spermatogenic leucine zipper 1	5	80319625-80321842	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	453	testis: 45.2	all non-specific tissues: 0.0	Not detected		
SERINC5	C5orf12, TPO1	ENSG00000164300	Serine incorporator 5	5	80111651-80256079	Predicted membrane proteins	Evidence at protein level	HPA037898, HPA037899	Supported		Uncertain	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 55.4	Mixed		
ENPP6	MGC33971	ENSG00000164303	Ectonucleotide pyrophosphatase/phosphodiesterase 6	4	184088706-184221230	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042740	Approved		Approved	Golgi apparatus		Tissue enriched	Tissue enhanced		kidney: 30.6;ovary: 15.0	cerebral cortex: 8.6	Cell line enhanced		Karpas-707: 2.3;SH-SY5Y: 3.8;U-266/70: 2.2;U-266/84: 1.1
CAGE1	bA69L16.7, CT95, CTAG3	ENSG00000164304	Cancer antigen 1	6	7326656-7389743	Predicted intracellular proteins	Evidence at protein level	HPA029832	Uncertain					Not detected	Tissue enriched	77	testis: 8.3	endometrium: 0.1	Not detected		
CASP3	apopain, CPP32, CPP32B, Yama	ENSG00000164305	Caspase 3	4	184627696-184649509	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000091, HPA002643, CAB008381	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.30e-5 (unfavourable), Endometrial cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 54.4	Expressed in all		
PRIMPOL	CCDC111, FLJ33167	ENSG00000164306	Primase and DNA directed polymerase	4	184649613-184694963	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054372	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			endometrium: 17.2	Expressed in all		
ERAP1	A-LAP, ARTS-1, ERAAP1, KIAA0525, PILS-AP	ENSG00000164307	Endoplasmic reticulum aminopeptidase 1	5	96760810-96808100	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025095, HPA042317	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			placenta: 68.0	Expressed in all		
ERAP2	L-RAP, LRAP	ENSG00000164308	Endoplasmic reticulum aminopeptidase 2	5	96875939-96919716	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025618, HPA034498, HPA064360	Enhanced		Approved	Golgi apparatus	Pancreatic cancer:1.20e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 49.3	Cell line enhanced		CAPAN-2: 155.3;hTEC/SVTERT24-B: 83.9;TIME: 152.1
CMYA5	C5orf10, DKFZp451G223, myospryn, SPRYD2, TRIM76	ENSG00000164309	Cardiomyopathy associated 5	5	79689877-79800240	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	8	heart muscle: 102.2;skeletal muscle: 172.4	ovary: 18.2	Cell line enhanced		RT4: 1.2;THP-1: 3.6
EGFLAM	AGRINL, AGRNL, FLJ39155, PIKA	ENSG00000164318	EGF like, fibronectin type III and laminin G domains	5	38258409-38465021	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 73.4	adipose tissue: 43.0	Cell line enhanced		hTERT-HME1: 12.6;HUVEC TERT2: 13.4;LHCN-M2: 30.8;U-2 OS: 16.5
CFAP97	DKFZp434F1728, hmw, KIAA1430	ENSG00000164323	Cilia and flagella associated protein 97	4	185159665-185209504	Predicted intracellular proteins	Evidence at protein level	HPA049446, HPA053335	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
TMEM174	FLJ31268, MGC13034	ENSG00000164325	Transmembrane protein 174	5	73173195-73175143	Predicted membrane proteins	Evidence at protein level	HPA037975	Enhanced				Renal cancer:3.30e-6 (favourable)	Tissue enriched	Tissue enriched	685	kidney: 159.4	thyroid gland: 0.2	Not detected		
CARTPT	CART	ENSG00000164326	CART prepropeptide	5	71719163-71721048	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB025515, HPA046278	Enhanced				Stomach cancer:4.36e-4 (unfavourable)	Tissue enriched	Tissue enriched	8	adrenal gland: 132.5	cerebral cortex: 17.4	Not detected		
RICTOR	AVO3, KIAA1999, MGC39830, PIA	ENSG00000164327	RPTOR independent companion of MTOR complex 2	5	38937919-39074408	Predicted intracellular proteins	Evidence at protein level	HPA037802, HPA037803	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			testis: 17.2	Expressed in all		
PAPD4	FLJ38499, GLD2, TUT2	ENSG00000164329	Poly(A) RNA polymerase D4, non-canonical	5	79612120-79686648	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054468			Approved	Cytosol		Expressed in all	Expressed in all			spleen: 38.4	Expressed in all		
EBF1	EBF, OLF1	ENSG00000164330	Early B-cell factor 1	5	158695916-159099761	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061169			Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 41.6	placenta: 16.2	Cell line enhanced		ASC diff: 27.3;HSkMC: 22.6;REH: 81.2
ANKRA2		ENSG00000164331	Ankyrin repeat family A member 2	5	73552335-73565686	Predicted intracellular proteins	Evidence at protein level	HPA065263			Approved	Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
UBLCP1	CPUB1, MGC10067	ENSG00000164332	Ubiquitin like domain containing CTD phosphatase 1	5	159263081-159286040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039615	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:4.46e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 49.9	Expressed in all		
FAM170A	ZNFD	ENSG00000164334	Family with sequence similarity 170 member A	5	119629559-119635822	Predicted intracellular proteins	Evidence at protein level	HPA037900, HPA037902	Enhanced					Not detected	Tissue enriched	104	testis: 21.0	skin: 0.2	Not detected		
UTP15	FLJ12787, FLJ23637, NET21	ENSG00000164338	UTP15, small subunit processome component	5	73565443-73583377	Predicted intracellular proteins	Evidence at protein level	HPA044697			Supported	Nucleoli<br>Endoplasmic reticulum		Expressed in all	Expressed in all			bone marrow: 23.2	Expressed in all		
TLR3	CD283	ENSG00000164342	Toll like receptor 3	4	186069152-186088069	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025658	Enhanced				Pancreatic cancer:3.09e-4 (unfavourable)	Mixed	Mixed			placenta: 24.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.4;CAPAN-2: 42.4
KLKB1	KLK3	ENSG00000164344	Kallikrein B1	4	186208979-186258471	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	45	liver: 155.0	gallbladder,kidney: 3.4	Cell line enhanced		NTERA-2: 2.9;SCLC-21H: 2.3
NSA2	FLJ94393, HCLG1, HUSSY-29, TINP1	ENSG00000164346	NSA2, ribosome biogenesis homolog	5	74766991-74780113	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043487	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 73.8	Expressed in all		
GFM2	EFG2, FLJ21661	ENSG00000164347	G elongation factor mitochondrial 2	5	74721204-74767371	Predicted intracellular proteins	Evidence at protein level	HPA036863	Uncertain				Renal cancer:1.33e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 36.6	Expressed in all		
TERT	EST2, hEST2, TCS1, TP2, TRT	ENSG00000164362	Telomerase reverse transcriptase	5	1253147-1295069	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA054641, HPA065897	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Not detected			lymph node,testis: 0.5	Cell line enhanced		ASC TERT1: 349.5;fHDF/TERT166: 388.9;HBEC3-KT: 725.5;hTEC/SVTERT24-B: 626.8;TIME: 672.9
SLC6A18	FLJ31236, Xtrp2	ENSG00000164363	Solute carrier family 6 member 18	5	1225355-1246189	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011885	Enhanced					Tissue enriched	Tissue enriched	83	kidney: 8.2	all non-specific tissues: 0.0	Not detected		
CCDC127	FLJ25701	ENSG00000164366	Coiled-coil domain containing 127	5	196871-218215	Predicted intracellular proteins	Evidence at protein level	HPA045052	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:4.04e-6 (unfavourable), Renal cancer:5.95e-5 (unfavourable), Breast cancer:7.01e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 23.0	Expressed in all		
FOXQ1	HFH1	ENSG00000164379	Forkhead box Q1	6	1312440-1314748	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059700			Supported	Nucleus	Prostate cancer:6.68e-4 (favourable)	Expressed in all	Tissue enhanced		stomach: 105.8;urinary bladder: 43.8	skin: 33.1	Cell line enhanced		CACO-2: 32.2;HaCaT: 39.8;Hep G2: 65.9;RT4: 32.0
ADGRF2	GPR111, hGPCR35, PGR20	ENSG00000164393	Adhesion G protein-coupled receptor F2	6	47656436-47697797	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035507	Uncertain					Not detected	Tissue enhanced		fallopian tube: 1.5;skin: 1.4	esophagus: 0.3	Not detected		
ACSL6	ACS2, FACL6, KIAA0837, LACS2, LACS5	ENSG00000164398	Acyl-CoA synthetase long-chain family member 6	5	131949973-132012243	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040470	Enhanced					Group enriched	Group enriched	6	bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4	adrenal gland: 6.4	Group enriched	6	SCLC-21H: 13.0;U-937: 5.2
IL3	IL-3, MCGF, MGC79398, MGC79399, MULTI-CSF	ENSG00000164399	Interleukin 3	5	132060529-132063204	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			bone marrow,epididymis,parathyroid gland,testis: 0.1	Cell line enriched	15	HMC-1: 2.2
CSF2	GM-CSF, GMCSF	ENSG00000164400	Colony stimulating factor 2	5	132073790-132076170	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA057404, HPA062006			Enhanced	Vesicles		Mixed	Tissue enhanced		lung: 3.0	urinary bladder: 0.9	Cell line enhanced		BJ hTERT+: 74.1;hTEC/SVTERT24-B: 20.9
SEPT8	KIAA0202, SEP2	ENSG00000164402	Septin 8	5	132750817-132807241	Predicted intracellular proteins	Evidence at protein level	HPA005665, HPA036534	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:6.98e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 280.3	Mixed		
SHROOM1	APXL2, KIAA1960	ENSG00000164403	Shroom family member 1	5	132822141-132830898	Predicted intracellular proteins	Evidence at protein level	HPA037690, HPA037691	Uncertain		Approved	Vesicles	Renal cancer:5.72e-6 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 54.5	seminal vesicle: 21.3	Mixed		
GDF9		ENSG00000164404	Growth differentiation factor 9	5	132861181-132866884	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069146	Supported					Tissue enriched	Group enriched	5	epididymis: 5.0;testis: 14.1	thyroid gland: 1.8	Mixed		
UQCRQ	QCR8, QP-C, UQCR7	ENSG00000164405	Ubiquinol-cytochrome c reductase complex III subunit VII	5	132866560-132868031	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046693, HPA053323	Approved		Enhanced	Mitochondria	Endometrial cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 376.0	Expressed in all		
LEAP2	LEAP-2	ENSG00000164406	Liver enriched antimicrobial peptide 2	5	132872322-132875046	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.68e-4 (favourable)	Tissue enriched	Tissue enriched	9	liver: 66.1	small intestine: 7.7	Mixed		
GJB7	bA136M9.1, CX25	ENSG00000164411	Gap junction protein beta 7	6	87282978-87329278	Predicted membrane proteins	Evidence at transcript level							Mixed	Group enriched	7	fallopian tube: 11.1;placenta: 3.8	lung: 1.0	Cell line enhanced		BEWO: 4.3;HDLM-2: 7.0;MCF7: 3.1;RT4: 2.9
SLC35A1	CMPST, hCST	ENSG00000164414	Solute carrier family 35 member A1	6	87470623-87512336	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.70e-6 (unfavourable)	Expressed in all	Expressed in all			prostate: 59.5	Expressed in all		
GRIK2	GluK2, GLUR6, MRT6	ENSG00000164418	Glutamate ionotropic receptor kainate type subunit 2	6	101398788-102070083	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014395, HPA014623, CAB022463	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 22.5	thyroid gland: 6.3	Cell line enhanced		BJ: 14.3;BJ hTERT+: 22.6;fHDF/TERT166: 16.5;WM-115: 25.2
MB21D1	C6orf150, cGAS	ENSG00000164430	Mab-21 domain containing 1	6	73413515-73452276	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031700, HPA031702	Enhanced		Approved	Microtubule organizing center<br>Cytosol	Renal cancer:2.27e-7 (unfavourable)	Expressed in all	Mixed			bone marrow: 8.7	Cell line enhanced		RH-30: 40.2
FABP7	B-FABP, BLBP	ENSG00000164434	Fatty acid binding protein 7	6	122779475-122784074	Predicted intracellular proteins	Evidence at protein level	CAB025488, HPA028825, CAB058697	Enhanced				Renal cancer:1.65e-6 (unfavourable), Breast cancer:2.49e-4 (favourable)	Group enriched	Group enriched	13	breast: 33.1;cerebral cortex: 102.3	skin: 5.2	Group enriched	8	AF22: 75.1;U-251 MG: 17.6;WM-115: 45.7
TLX3	HOX11L2, RNX	ENSG00000164438	T-cell leukemia homeobox 3	5	171309284-171312134	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030504, HPA060957, HPA069359	Approved		Supported	Nucleoplasm		Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	6	SH-SY5Y: 28.2
TXLNB	C6orf198, dJ522B19.2, DKFZp451A175, MDP77	ENSG00000164440	Taxilin beta	6	139240061-139292139	Predicted intracellular proteins	Evidence at protein level	HPA030401, HPA030402, HPA030403	Enhanced					Mixed	Group enriched	6	heart muscle: 52.2;skeletal muscle: 102.3	ovary: 13.7	Cell line enhanced		Daudi: 3.4;RPMI-8226: 2.5;U-698: 4.7
CITED2	MRG1	ENSG00000164442	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2	6	139371807-139374620	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016157, CAB069879	Supported		Supported	Nucleoplasm	Stomach cancer:3.33e-4 (unfavourable), Renal cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 379.3	Cell line enhanced		fHDF/TERT166: 828.8
FAM26D	C6orf78, FLJ32239	ENSG00000164451	Family with sequence similarity 26 member D	6	116529013-116558868	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	46	placenta: 33.8	testis: 0.7	Not detected		
T		ENSG00000164458	T brachyury transcription factor	6	166157656-166168700	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003322	Uncertain		Supported	Nucleus		Tissue enriched	Tissue enriched	20	parathyroid gland: 8.7	testis: 0.4	Group enriched	6	HeLa: 10.3;SCLC-21H: 4.2
CREBRF	C5orf41, LRF	ENSG00000164463	CREB3 regulatory factor	5	173056352-173139284	Predicted intracellular proteins	Evidence at protein level	HPA015329			Supported	Nucleus	Renal cancer:3.20e-7 (favourable), Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 43.6	Mixed		
DCBLD1	dJ94G16.1, MGC46341	ENSG00000164465	Discoidin, CUB and LCCL domain containing 1	6	117453817-117569858	Predicted membrane proteins	Evidence at protein level	HPA059667	Approved				Renal cancer:8.57e-8 (unfavourable), Cervical cancer:6.44e-5 (unfavourable)	Expressed in all	Mixed			gallbladder: 14.3	Mixed		
SFXN1	FLJ12876	ENSG00000164466	Sideroflexin 1	5	175477062-175529742	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019543, HPA063745	Uncertain		Enhanced	Mitochondria		Expressed in all	Expressed in all			liver: 51.7	Expressed in all		
SAMD3	bA73O6.2, FLJ34032	ENSG00000164483	Sterile alpha motif domain containing 3	6	130144315-130365425	Predicted intracellular proteins	Evidence at protein level	HPA028992, HPA028993	Uncertain					Not detected	Tissue enhanced		spleen: 13.0	lymph node: 11.5	Group enriched	5	HBF TERT88: 1.7;HDLM-2: 3.1;hTEC/SVTERT24-B: 2.2;NTERA-2: 1.7;PC-3: 1.1
TMEM200A	KIAA1913, TTMC	ENSG00000164484	Transmembrane protein 200A	6	130365734-130443063	Predicted membrane proteins	Evidence at protein level	HPA014396	Uncertain				Renal cancer:3.92e-4 (favourable)	Mixed	Tissue enhanced		endometrium: 65.1	smooth muscle: 29.4	Cell line enhanced		HBF TERT88: 39.5;hTEC/SVTERT24-B: 66.8
IL22RA2	CRF2-S1, IL-22BP	ENSG00000164485	Interleukin 22 receptor subunit alpha 2	6	137143820-137173648	Predicted secreted proteins	Evidence at protein level	HPA030582, CAB034906	Uncertain					Mixed	Tissue enhanced		breast: 4.1;tonsil: 2.9	appendix: 1.9	Cell line enhanced		U-937: 1.0
DACT2	bA503C24.7, C6orf116, DAPPER2	ENSG00000164488	Dishevelled binding antagonist of beta catenin 2	6	168292830-168319754	Predicted intracellular proteins	Evidence at transcript level	HPA030251, HPA030252	Approved				Endometrial cancer:1.07e-5 (favourable), Renal cancer:5.76e-5 (favourable)	Tissue enhanced	Tissue enhanced		placenta: 18.8	prostate: 7.3	Group enriched	6	A549: 3.0;CACO-2: 2.2;EFO-21: 1.4;Hep G2: 1.0;hTCEpi: 1.3;NTERA-2: 2.3;SCLC-21H: 3.0
PDSS2	bA59I9.3, C6orf210	ENSG00000164494	Decaprenyl diphosphate synthase subunit 2	6	107152557-107459564	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029685, HPA029686	Approved		Enhanced	Cytosol	Renal cancer:3.75e-7 (favourable), Breast cancer:1.34e-5 (unfavourable), Colorectal cancer:5.74e-5 (favourable)	Expressed in all	Expressed in all			prostate: 23.4	Expressed in all		
C7orf72		ENSG00000164500	Chromosome 7 open reading frame 72	7	50096036-50159830	Predicted intracellular proteins	Evidence at transcript level	HPA026094	Uncertain					Not detected	Tissue enriched	31	testis: 5.9	lymph node,tonsil: 0.1	Cell line enriched	9	U-698: 7.2
STXBP5	LLGL3, tomosyn	ENSG00000164506	Syntaxin binding protein 5	6	147204425-147390476	Predicted intracellular proteins	Evidence at protein level	HPA039991, HPA049727, CAB079016	Enhanced	Supported	Enhanced	Cytosol	Renal cancer:2.74e-7 (unfavourable), Breast cancer:4.48e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 278.8	testis: 40.2	Cell line enhanced		HEL: 188.3;HMC-1: 193.3
HIST1H2AA	bA317E16.2, H2AFR	ENSG00000164508	Histone cluster 1 H2A family member a	6	25726132-25726527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Not detected	Tissue enriched	90	testis: 17.1	kidney,pancreas: 0.1	Not detected		
IL31RA	CRL, CRL3, GLM-R, Glmr, IL-31RA	ENSG00000164509	Interleukin 31 receptor A	5	55851379-55922853	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051532, HPA068114	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 3.6	bone marrow: 1.2	Cell line enhanced		hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
ANKRD55	FLJ11795	ENSG00000164512	Ankyrin repeat domain 55	5	56099678-56233359	Predicted intracellular proteins	Evidence at protein level	HPA051049	Approved					Tissue enriched	Group enriched	6	lymph node: 4.1;testis: 17.3	tonsil: 1.8	Group enriched	6	HEL: 30.8;HMC-1: 15.0;NB-4: 14.3
RAET1E	bA350J20.7, LETAL, ULBP4	ENSG00000164520	Retinoic acid early transcript 1E	6	149883375-149898102	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054022			Approved	Focal adhesion sites<br>Cytosol		Tissue enhanced	Tissue enhanced		esophagus: 70.8;skin: 29.0	tonsil: 10.3	Cell line enhanced		HBEC3-KT: 15.9;HeLa: 20.3;hTCEpi: 15.6;SiHa: 11.2;U-87 MG: 9.0
PI16	CD364, dJ90K10.5, MGC45378, MSMBBP	ENSG00000164530	Peptidase inhibitor 16	6	36948263-36964837	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA076574	Approved					Tissue enhanced	Tissue enhanced		cervix, uterine: 199.5	urinary bladder: 78.6	Cell line enhanced		Daudi: 3.7;fHDF/TERT166: 3.6;U-2197: 1.0
TBX20		ENSG00000164532	T-box 20	7	35202430-35254147	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enhanced		adrenal gland: 5.6;heart muscle: 22.2	placenta: 5.0	Cell line enhanced		SH-SY5Y: 7.5;WM-115: 4.2
DAGLB	DAGLBETA, KCCR13L	ENSG00000164535	Diacylglycerol lipase beta	7	6409126-6484190	Predicted membrane proteins	Evidence at protein level	HPA069377			Supported	Plasma membrane	Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 20.6	Expressed in all		
KIAA0895		ENSG00000164542	KIAA0895	7	36324221-36390125	Predicted intracellular proteins	Evidence at transcript level	HPA021036, HPA061066	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 44.5	parathyroid gland: 23.9	Cell line enhanced		SCLC-21H: 51.4
STK17A	DRAK1	ENSG00000164543	Serine/threonine kinase 17a	7	43582758-43626786	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA018138, HPA037979	Uncertain		Approved	Nuclear speckles<br>Plasma membrane		Expressed in all	Expressed in all			lymph node: 49.2	Expressed in all		
TRA2A	AWMS1, htra-2-alpha, tra2a	ENSG00000164548	Transformer 2 alpha homolog	7	23504780-23532041	Predicted intracellular proteins	Evidence at protein level	HPA054018	Uncertain		Supported	Nucleoli<br>Vesicles	Renal cancer:1.79e-6 (unfavourable), Liver cancer:2.07e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 67.7	Expressed in all		
GALNT10	GalNAc-T10	ENSG00000164574	Polypeptide N-acetylgalactosaminyltransferase 10	5	154190730-154420984	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA007525	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Endometrial cancer:3.33e-6 (favourable), Ovarian cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 81.7	Mixed		
SAP30L	FLJ11526, NS4ATP2	ENSG00000164576	SAP30 like	5	154445957-154461054	Predicted intracellular proteins	Evidence at protein level	HPA048665			Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.06e-5 (favourable), Renal cancer:1.71e-4 (favourable), Urothelial cancer:2.69e-4 (favourable), Head and neck cancer:9.09e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 25.2	Expressed in all		
RPS14	EMTB, S14	ENSG00000164587	Ribosomal protein S14	5	150443190-150449756	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA018504	Uncertain		Enhanced	Endoplasmic reticulum<br>Cytosol	Liver cancer:7.73e-4 (unfavourable), Renal cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 1992.0	Expressed in all		
HCN1	BCNG-1, BCNG1, HAC-2	ENSG00000164588	Hyperpolarization activated cyclic nucleotide gated potassium channel 1	5	45254950-45696498	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019195	Enhanced					Not detected	Tissue enriched	8	cerebral cortex: 4.9	heart muscle: 0.6	Cell line enhanced		WM-115: 1.0
MYOZ3	CS-3, CS3, FRP3	ENSG00000164591	Myozenin 3	5	150660874-150679365	Predicted intracellular proteins	Evidence at protein level	HPA039166	Enhanced					Mixed	Tissue enriched	11	skeletal muscle: 87.7	testis: 7.8	Cell line enhanced		HAP1: 5.3;NTERA-2: 9.1;REH: 13.2
COG5	GOLTC1, GTC90	ENSG00000164597	Component of oligomeric golgi complex 5	7	107201555-107564514	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020300, HPA041583	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Thyroid cancer:1.48e-4 (unfavourable), Liver cancer:3.77e-4 (unfavourable), Endometrial cancer:9.72e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 36.8	Mixed		
NEUROD6	Atoh2, bHLHa2, Math-2, Nex1, NEX1M	ENSG00000164600	Neuronal differentiation 6	7	31337461-31340894	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027046, HPA074530	Enhanced	Approved				Not detected	Tissue enriched	180	cerebral cortex: 18.0	all non-specific tissues: 0.0	Cell line enriched	71	SCLC-21H: 7.0
BMT2	C7orf60, DKFZp762M126, FLJ31818	ENSG00000164603	Base methyltransferase of 25S rRNA 2 homolog	7	112819147-112939916	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044405, HPA050733	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 14.9	Expressed in all		
GPR85	SREB2	ENSG00000164604	G protein-coupled receptor 85	7	113078331-113087778	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 16.7	skeletal muscle: 11.4	Cell line enriched	6	HEL: 99.3
SLU7	9G8	ENSG00000164609	SLU7 homolog, splicing factor	5	160401641-160421711	Predicted intracellular proteins	Evidence at protein level	HPA035907, HPA058120	Uncertain		Enhanced	Nucleoplasm<br>Nuclear speckles	Renal cancer:1.98e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.1	Expressed in all		
RP9	PAP-1	ENSG00000164610	Retinitis pigmentosa 9 (autosomal dominant)	7	33094797-33109401	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031523, HPA050778	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:2.65e-5 (unfavourable), Liver cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.9	Expressed in all		
PTTG1	EAP1, HPTTG, PTTG, securin, TUTR1	ENSG00000164611	Pituitary tumor-transforming 1	5	160421822-160428744	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB008373, HPA008890, HPA045034	Enhanced		Supported	Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.62e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 286.7	thyroid gland: 121.5	Expressed in all		
CAMLG	CAML, GET2	ENSG00000164615	Calcium modulating ligand	5	134738501-134752160	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA052636, HPA056472	Approved		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:1.09e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 99.6	Expressed in all		
BMPER	CRIM3, Cv2	ENSG00000164619	BMP binding endothelial regulator	7	33904911-34155872	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018083		Supported				Tissue enhanced	Mixed			placenta: 9.5	Cell line enhanced		fHDF/TERT166: 17.5;HBF TERT88: 23.1;hTEC/SVTERT24-B: 16.0;U-138 MG: 24.5
RELL2	C5orf16, FLJ90583	ENSG00000164620	RELT like 2	5	141636950-141641077	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077928			Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 13.2;parathyroid gland: 23.3	testis: 4.3	Mixed		
KCNK5	K2p5.1, TASK-2	ENSG00000164626	Potassium two pore domain channel subfamily K member 5	6	39188973-39229450	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA059148	Uncertain		Approved	Nucleus	Renal cancer:4.98e-7 (favourable), Cervical cancer:3.29e-4 (favourable), Urothelial cancer:4.45e-4 (favourable), Pancreatic cancer:5.85e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 39.3	gallbladder: 29.5	Cell line enhanced		CACO-2: 28.9;HEL: 32.6;HMC-1: 28.2;K-562: 30.8
KIF6	C6orf102, dJ1043E3.1, dJ137F1.4, dJ188D3.1, DKFZp451I2418, MGC33317	ENSG00000164627	Kinesin family member 6	6	39329990-39725405	Predicted intracellular proteins	Evidence at protein level	HPA038811, HPA058624	Enhanced		Approved	Centrosome		Mixed	Group enriched	6	cerebral cortex: 7.0;fallopian tube: 6.0;testis: 9.6	lung: 1.2	Cell line enhanced		RPMI-8226: 6.3;SCLC-21H: 14.3;SK-MEL-30: 4.0
ZNF12	GIOT-3, KOX3, ZNF325	ENSG00000164631	Zinc finger protein 12	7	6688433-6706923	Predicted intracellular proteins	Evidence at protein level	HPA063402			Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			parathyroid gland: 31.2	Expressed in all		
SLC29A4	ENT4, FLJ34923	ENSG00000164638	Solute carrier family 29 member 4	7	5274369-5306870	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052829			Supported	Microtubules<br>Cytokinetic bridge	Pancreatic cancer:4.52e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 44.2	cerebral cortex: 12.0	Cell line enhanced		AN3-CA: 45.6;SH-SY5Y: 74.8
C7orf62	MGC26647	ENSG00000164645	Chromosome 7 open reading frame 62	7	88794106-88795721	Predicted intracellular proteins	Evidence at transcript level	HPA023817, HPA024163			Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Tissue enriched	519	testis: 51.9	all non-specific tissues: 0.0	Not detected		
STEAP1	PRSS24, STEAP	ENSG00000164647	STEAP family member 1	7	90154375-90164829	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030985	Uncertain					Tissue enriched	Tissue enhanced		prostate: 119.0	appendix: 40.6	Cell line enhanced		CAPAN-2: 106.6;U-138 MG: 147.9
CDCA7L	JPO2, R1, RAM2	ENSG00000164649	Cell division cycle associated 7 like	7	21900900-21946084	Predicted intracellular proteins	Evidence at protein level	HPA027169	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.36e-6 (unfavourable), Renal cancer:1.98e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.7	Mixed		
SP8		ENSG00000164651	Sp8 transcription factor	7	20782283-20786886	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054006	Uncertain		Approved	Nucleus		Tissue enhanced	Tissue enriched	12	prostate: 10.5	skin: 0.8	Cell line enhanced		HUVEC TERT2: 5.3;NTERA-2: 13.0;PC-3: 20.5
MIOS	FLJ20323, MIO, Sea4	ENSG00000164654	Meiosis regulator for oocyte development	7	7566872-7608929	Predicted intracellular proteins	Evidence at protein level	HPA042928, HPA052223	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.28e-6 (favourable), Endometrial cancer:6.51e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 54.8	Expressed in all		
KIAA1324L	EIG121L, FLJ31340	ENSG00000164659	KIAA1324 like	7	86876906-87059699	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044527, HPA076093	Uncertain		Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		lung: 32.2	cerebral cortex: 21.7	Cell line enhanced		K-562: 44.1;SCLC-21H: 45.6
USP49	MGC20741	ENSG00000164663	Ubiquitin specific peptidase 49	6	41789896-41895361	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030254, HPA030255	Uncertain					Mixed	Mixed			testis: 9.1	Cell line enhanced		REH: 42.8;U-698: 45.4
SYTL3	exophilin-6, SLP3	ENSG00000164674	Synaptotagmin like 3	6	158650014-158764876	Predicted intracellular proteins	Evidence at protein level	HPA030584, HPA030585, HPA030586	Approved		Approved	Nucleoli fibrillar center<br>Vesicles	Cervical cancer:8.84e-5 (favourable)	Mixed	Tissue enhanced		thyroid gland: 44.5	fallopian tube: 22.9	Cell line enhanced		HMC-1: 21.4;SCLC-21H: 19.1;U-2 OS: 20.9;U-266/70: 21.7
IQUB	FLJ35834	ENSG00000164675	IQ motif and ubiquitin domain containing	7	123452400-123535077	Predicted intracellular proteins	Evidence at protein level	HPA049626			Approved	Nuclear speckles<br>Intermediate filaments<br>Cytosol		Mixed	Tissue enriched	8	testis: 66.3	fallopian tube: 8.2	Cell line enhanced		RPTEC TERT1: 1.8
HEY1	bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1	ENSG00000164683	Hes related family bHLH transcription factor with YRPW motif 1	8	79764010-79767863	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055599, HPA063472	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 96.4	placenta: 28.8	Cell line enhanced		HEK 293: 120.1;SK-MEL-30: 70.9
ZNF704	FLJ16218, Gig1	ENSG00000164684	Zinc finger protein 704	8	80628451-80874781	Predicted intracellular proteins	Evidence at protein level	HPA024285, HPA024302	Uncertain		Approved	Nucleoplasm	Renal cancer:4.02e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 35.3	Cell line enhanced		HaCaT: 63.8;RH-30: 44.5;SH-SY5Y: 61.9;SK-BR-3: 54.1
FABP5	E-FABP, KFABP, PA-FABP	ENSG00000164687	Fatty acid binding protein 5	8	81280363-81284777	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB017831, CAB040577, HPA051895	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.69e-10 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1664.2	Mixed		
SHH	HHG1, HLP3, HPE3, MCOPCB5, SMMCI, TPT, TPTPS	ENSG00000164690	Sonic hedgehog	7	155799986-155812273	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:8.62e-5 (favourable)	Mixed	Tissue enhanced		adrenal gland: 12.0;stomach: 10.5;urinary bladder: 13.5	cervix, uterine: 6.8	Cell line enhanced		CAPAN-2: 4.7;EFO-21: 8.5;PC-3: 3.8;RT4: 21.2
TAGAP	ARHGAP47, FLJ32631, IDDM21	ENSG00000164691	T-cell activation RhoGTPase activating protein	6	159034468-159045152	Predicted intracellular proteins	Evidence at protein level	HPA031000	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 129.8	lymph node: 55.5	Cell line enhanced		Daudi: 27.0;HMC-1: 50.5;Karpas-707: 41.7;U-698: 34.9;U-937: 30.4
COL1A2	OI4	ENSG00000164692	Collagen type I alpha 2 chain	7	94394561-94431232	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB032650, HPA059738	Approved		Supported	Endoplasmic reticulum	Renal cancer:1.51e-9 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 2950.1	Cell line enhanced		ASC diff: 2673.1;ASC TERT1: 3247.5;BJ: 3371.1;fHDF/TERT166: 10547.5;HSkMC: 2949.4
FNDC1	bA243O10.1, dJ322A24.1, FNDC2, KIAA1866	ENSG00000164694	Fibronectin type III domain containing 1	6	159169397-159272109	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030962, HPA030963	Approved		Supported	Nuclear speckles	Renal cancer:1.93e-6 (unfavourable), Endometrial cancer:6.10e-5 (favourable)	Tissue enhanced	Tissue enhanced		gallbladder: 22.9;thyroid gland: 34.1	smooth muscle: 16.5	Cell line enhanced		fHDF/TERT166: 2.3
CHMP4C	MGC22825, Shax3, VPS32C	ENSG00000164695	Charged multivesicular body protein 4C	8	81732434-81759515	Predicted intracellular proteins	Evidence at protein level	HPA023799	Enhanced				Renal cancer:1.96e-6 (favourable), Pancreatic cancer:6.99e-5 (unfavourable), Lung cancer:9.33e-5 (unfavourable), Urothelial cancer:6.45e-4 (favourable)	Mixed	Mixed			duodenum: 41.8	Cell line enhanced		CAPAN-2: 36.2;hTCEpi: 36.8
SLC13A4	SUT-1, SUT1	ENSG00000164707	Solute carrier family 13 member 4	7	135681237-135729258	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA048582	Approved					Mixed	Tissue enriched	10	placenta: 76.8	testis: 7.4	Cell line enriched	6	HDLM-2: 28.0
PGAM2	PGAM-M	ENSG00000164708	Phosphoglycerate mutase 2	7	44062727-44065587	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA050314, HPA060173	Enhanced		Approved	Nucleoplasm<br>Cytosol		Not detected	Group enriched	8	heart muscle: 521.3;skeletal muscle: 1459.5	testis: 126.6	Cell line enriched	10	SCLC-21H: 77.0
BRI3		ENSG00000164713	Brain protein I3	7	98252379-98310441	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042215	Uncertain				Head and neck cancer:3.35e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 119.1	Expressed in all		
LMTK2	AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100	ENSG00000164715	Lemur tyrosine kinase 2	7	98106885-98209633	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA010657, HPA041836	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 27.9	Expressed in all		
SLC35G3	AMAC1, FLJ40154, TMEM21A	ENSG00000164729	Solute carrier family 35 member G3	17	35192520-35194523	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	15	testis: 1.6	lymph node,skeletal muscle,spleen: 0.1	Not detected		
CTSB		ENSG00000164733	Cathepsin B	8	11842524-11869448	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB000457, HPA018156	Uncertain		Supported	Nucleoli<br>Vesicles	Thyroid cancer:5.76e-4 (favourable), Urothelial cancer:9.02e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 2894.5	Expressed in all		
SOX17		ENSG00000164736	SRY-box 17	8	54457935-54460888	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025594, HPA068399	Enhanced		Approved	Nucleoplasm	Endometrial cancer:2.76e-4 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 30.2;endometrium: 32.2;fallopian tube: 30.1	adipose tissue: 14.7	Cell line enriched	8	EFO-21: 102.6
DLC1	ARHGAP7, DLC-1, HP, p122-RhoGAP, STARD12	ENSG00000164741	DLC1 Rho GTPase activating protein	8	13083361-13604610	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017753	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Endometrial cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			lung: 78.7	Cell line enhanced		U-2197: 120.6
ADCY1	AC1, DFNB44	ENSG00000164742	Adenylate cyclase 1	7	45574140-45723116	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018364, HPA068274	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 35.0	cervix, uterine: 8.2	Cell line enhanced		hTERT-HME1: 17.5;SCLC-21H: 16.1;SH-SY5Y: 27.5;SK-MEL-30: 23.8;WM-115: 17.1
C8orf48	FLJ25402	ENSG00000164743	Chromosome 8 open reading frame 48	8	13566843-13568287	Predicted intracellular proteins	Evidence at protein level	HPA025068, HPA026107, HPA027431, HPA027440	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 12.4	thyroid gland: 7.3	Cell line enhanced		U-87 MG: 11.0;WM-115: 8.6
SUN3	MGC33329, SUNC1	ENSG00000164744	Sad1 and UNC84 domain containing 3	7	47987148-48029119	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008344			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	156	testis: 74.6	placenta: 0.4	Cell line enriched	8	U-2 OS: 21.7
C7orf57		ENSG00000164746	Chromosome 7 open reading frame 57	7	48035511-48061304	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021286	Enhanced					Mixed	Tissue enhanced		fallopian tube: 22.0;testis: 6.8	lung: 3.4	Cell line enhanced		hTERT-HME1: 4.2;U-266/70: 2.4
HNF4G	NR2A2	ENSG00000164749	Hepatocyte nuclear factor 4 gamma	8	75407914-75566843	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005438	Enhanced					Mixed	Group enriched	5	duodenum: 100.2;small intestine: 125.6	rectum: 21.0	Cell line enhanced		A549: 3.8;CAPAN-2: 13.9;PC-3: 4.4
PEX2	PAF-1, PMP35, PXMP3, RNF72, ZWS3	ENSG00000164751	Peroxisomal biogenesis factor 2	8	76980258-77001044	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010983, HPA011410, HPA027729	Approved		Supported	Vesicles		Expressed in all	Expressed in all			seminal vesicle: 111.5	Expressed in all		
RAD21	hHR21, KIAA0078, SCC1	ENSG00000164754	RAD21 cohesin complex component	8	116845935-116874866	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020044, CAB022065	Supported		Enhanced	Nucleoplasm	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.4	Expressed in all		
SLC30A8	ZnT-8, ZNT8	ENSG00000164756	Solute carrier family 30 member 8	8	116950273-117176714	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA076165	Enhanced					Group enriched	Tissue enhanced		pancreas: 13.2	salivary gland: 4.9	Group enriched	27	U-266/70: 36.7;U-266/84: 25.2
MED30	THRAP6, TRAP25	ENSG00000164758	Mediator complex subunit 30	8	117520713-117540262	Predicted intracellular proteins	Evidence at protein level	HPA045767			Approved	Nucleoplasm	Renal cancer:1.70e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 27.8	Expressed in all		
TNFRSF11B	OCIF, OPG, TR1	ENSG00000164761	TNF receptor superfamily member 11b	8	118923557-118952200	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB034939	Approved				Urothelial cancer:3.88e-4 (unfavourable), Cervical cancer:6.22e-4 (unfavourable), Renal cancer:6.79e-4 (favourable)	Expressed in all	Tissue enriched	5	thyroid gland: 140.4	kidney: 25.7	Cell line enhanced		BJ: 369.9;BJ hTERT+: 1312.6;fHDF/TERT166: 188.6
SBSPON	C8orf84, RPESP	ENSG00000164764	Somatomedin B and thrombospondin type 1 domain containing	8	73064540-73124088	Predicted secreted proteins	Evidence at protein level	HPA029595, CAB034214, CAB034332	Uncertain		Approved	Vesicles	Breast cancer:7.18e-4 (favourable), Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enhanced		prostate: 23.8	urinary bladder: 16.2	Group enriched	6	BJ: 7.6;RPTEC TERT1: 12.1
PHKG1	PHKG	ENSG00000164776	Phosphorylase kinase catalytic subunit gamma 1	7	56080283-56092996	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012057	Enhanced					Tissue enriched	Tissue enriched	7	skeletal muscle: 100.5	cerebral cortex: 14.2	Mixed		
EN2		ENSG00000164778	Engrailed homeobox 2	7	155458129-155464831	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045646, HPA069809			Supported	Nucleus<br>Nucleoli fibrillar center	Glioma:2.82e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		parathyroid gland: 2.0;testis: 1.1	endometrium: 0.6	Cell line enhanced		AF22: 40.5;AN3-CA: 14.1;HEK 293: 23.0
KCNV1	Kv8.1	ENSG00000164794	Potassium voltage-gated channel modifier subfamily V member 1	8	109963645-109975847	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enriched	32	cerebral cortex: 21.8	epididymis,skin,thyroid gland: 0.6	Not detected		
CSMD3		ENSG00000164796	CUB and Sushi multiple domains 3	8	112222928-113437099	Predicted membrane proteins	Evidence at transcript level	HPA029007	Uncertain					Not detected	Group enriched	7	cerebral cortex: 4.9;testis: 1.8	fallopian tube,prostate,spleen: 0.4	Not detected		
SPIDR	KIAA0146	ENSG00000164808	Scaffolding protein involved in DNA repair	8	47260575-47736306	Predicted intracellular proteins	Evidence at protein level	HPA027201, HPA041582	Approved		Supported	Nucleoplasm	Renal cancer:2.04e-6 (unfavourable), Ovarian cancer:8.91e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 30.7	Expressed in all		
ORC5	ORC5L, Orc5p, ORC5T, PPP1R117	ENSG00000164815	Origin recognition complex subunit 5	7	104126341-104208047	Predicted intracellular proteins	Evidence at protein level	HPA019730	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 34.4	Expressed in all		
DEFA5	DEF5, HD-5	ENSG00000164816	Defensin alpha 5	8	7055304-7056734	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015775, CAB069919	Enhanced				Colorectal cancer:9.44e-5 (favourable)	Tissue enhanced	Group enriched	480	duodenum: 10677.9;small intestine: 19102.0	appendix: 31.0	Group enriched	6	BEWO: 55.6;NB-4: 31.4;RPMI-8226: 35.9;SH-SY5Y: 42.9;U-2197: 16.2
DNAAF5	CILD18, FLJ20397, FLJ25564, FLJ31671, FLJ39381, HEATR2	ENSG00000164818	Dynein axonemal assembly factor 5	7	726701-786475	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020243	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.83e-4 (unfavourable), Head and neck cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 22.8	Expressed in all		
DEFA4	DEF4, HP-4	ENSG00000164821	Defensin alpha 4	8	6935822-6938338	Predicted secreted proteins	Evidence at protein level	HPA051266	Enhanced					Not detected	Tissue enriched	640	bone marrow: 3105.2	spleen: 4.8	Cell line enriched	8	THP-1: 8.6
DEFA6	DEF6, HD-6	ENSG00000164822	Defensin alpha 6	8	6924693-6926076	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA019462	Enhanced					Tissue enhanced	Group enriched	525	duodenum: 5743.0;small intestine: 10524.2	colon: 15.4	Group enriched	9	BEWO: 28.1;NB-4: 20.0;RPMI-8226: 25.8;SH-SY5Y: 26.0;U-2197: 10.6
OSGIN2	C8orf1, hT41	ENSG00000164823	Oxidative stress induced growth inhibitor family member 2	8	89901859-89927888	Predicted intracellular proteins	Evidence at transcript level	HPA028515, HPA050595	Approved		Approved	Nucleoli	Liver cancer:3.91e-6 (unfavourable), Lung cancer:2.93e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
DEFB1	BD1, DEFB-1, DEFB101, HBD-1, HBD1, MGC51822	ENSG00000164825	Defensin beta 1	8	6870575-6878022	Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:1.90e-5 (favourable), Lung cancer:5.62e-4 (unfavourable), Pancreatic cancer:5.94e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 618.9;kidney: 1500.2	salivary gland: 232.3	Cell line enhanced		NB-4: 34.9;SCLC-21H: 45.7;THP-1: 129.4
SUN1	FLJ12407, KIAA0810, UNC84A	ENSG00000164828	Sad1 and UNC84 domain containing 1	7	816615-896435	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA008346, HPA008461	Enhanced		Enhanced	Nuclear membrane		Expressed in all	Expressed in all			endometrium: 120.7	Expressed in all		
OXR1	TLDC3	ENSG00000164830	Oxidation resistance 1	8	106359476-106752694	Predicted intracellular proteins	Evidence at protein level	HPA027375, HPA027380, HPA027395	Enhanced		Supported	Vesicles	Renal cancer:5.82e-5 (favourable), Pancreatic cancer:3.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.7	Expressed in all		
TMEM74	FLJ30668, NET36	ENSG00000164841	Transmembrane protein 74	8	108606850-108787615	Predicted membrane proteins	Evidence at protein level	HPA015672	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 6.2	heart muscle: 1.6	Cell line enhanced		HEK 293: 3.6;NTERA-2: 4.9;SCLC-21H: 12.4
GPR146	PGR8	ENSG00000164849	G protein-coupled receptor 146	7	1044576-1059261	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Expressed in all			adipose tissue: 33.6	Cell line enhanced		BEWO: 22.4
GPER1	CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR	ENSG00000164850	G protein-coupled estrogen receptor 1	7	1082208-1093815	G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027052	Approved				Endometrial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			placenta: 9.1	Cell line enhanced		AN3-CA: 10.6;Hep G2: 15.3
UNCX	Uncx4.1	ENSG00000164853	UNC homeobox	7	1232907-1237318	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063294			Approved	Nucleoplasm		Not detected	Not detected			kidney: 0.4	Cell line enriched	16	NB-4: 63.3
TMEM184A	MGC9712, SDMG1	ENSG00000164855	Transmembrane protein 184A	7	1542235-1560821	Predicted membrane proteins	Evidence at protein level	HPA053790, HPA071312	Uncertain		Approved	Nucleoplasm	Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 33.5	esophagus: 26.5	Cell line enhanced		SCLC-21H: 43.0;SK-BR-3: 42.7;T-47d: 47.5
NOS3	ECNOS, eNOS	ENSG00000164867	Nitric oxide synthase 3	7	150990995-151014588	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002168	Enhanced				Renal cancer:3.63e-4 (unfavourable)	Expressed in all	Tissue enriched	7	spleen: 71.8	adipose tissue: 10.6	Cell line enhanced		BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7
SPAG11B	EDDM2B, EP2, EP2C, EP2D, HE2	ENSG00000164871	Sperm associated antigen 11B	8	7442684-7463674	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023842	Supported					Not detected	Tissue enriched	5739	epididymis: 6744.6	seminal vesicle: 1.1	Group enriched	7	BEWO: 3.9;NB-4: 5.5;RPMI-8226: 2.2;SH-SY5Y: 3.8
MICALL2	FLJ23471, JRAB, MGC46023, MICAL-L2	ENSG00000164877	MICAL like 2	7	1428465-1459502	Predicted intracellular proteins	Evidence at protein level	HPA025695	Enhanced				Renal cancer:6.53e-9 (unfavourable)	Expressed in all	Mixed			small intestine: 17.5	Cell line enhanced		HMC-1: 23.3
CA3	CAIII, Car3	ENSG00000164879	Carbonic anhydrase 3	8	85373436-85449040	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004967, HPA021775, HPA026700	Enhanced				Breast cancer:4.24e-6 (favourable)	Group enriched	Tissue enriched	13	skeletal muscle: 1838.7	prostate: 138.3	Group enriched	34	HEL: 44.2;RH-30: 77.2
INTS1	DKFZp586J0619, INT1, KIAA1440, NET28	ENSG00000164880	Integrator complex subunit 1	7	1470277-1504367	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021658, HPA053009	Approved		Approved	Nucleoplasm	Liver cancer:1.66e-4 (unfavourable), Pancreatic cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
CDK5	PSSALRE	ENSG00000164885	Cyclin dependent kinase 5	7	151053812-151058530	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008909, HPA064535	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 49.9	Expressed in all		
SLC4A2	AE2, BND3L, EPB3L1, HKB3, NBND3	ENSG00000164889	Solute carrier family 4 member 2	7	151057210-151076527	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019339	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Liver cancer:9.04e-6 (unfavourable), Renal cancer:1.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.3	Expressed in all		
SLC7A13	AGT-1, XAT2	ENSG00000164893	Solute carrier family 7 member 13	8	86214052-86321146	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	170	kidney: 42.9	breast,testis: 0.2	Not detected		
FASTK	FAST	ENSG00000164896	Fas activated serine/threonine kinase	7	151076593-151080866	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031621, CAB032539	Approved		Approved	Nuclear speckles<br>Mitochondria	Pancreatic cancer:3.99e-4 (favourable), Colorectal cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 41.7	Expressed in all		
TMUB1	C7orf21, SB144	ENSG00000164897	Transmembrane and ubiquitin like domain containing 1	7	151081080-151083546	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA029429	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			small intestine: 52.2	Expressed in all		
FMC1	C7orf55, HSPC268	ENSG00000164898	Formation of mitochondrial complex V assembly factor 1 homolog	7	139339457-139346319	Predicted intracellular proteins	Evidence at protein level	HPA045663, HPA050553	Approved		Approved	Mitochondria	Ovarian cancer:5.63e-6 (favourable), Renal cancer:2.05e-5 (favourable), Lung cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			prostate: 12.8	Expressed in all		
GBX1		ENSG00000164900	Gastrulation brain homeobox 1	7	151148589-151174745	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055783	Uncertain					Tissue enhanced	Group enriched	57	skeletal muscle: 4.4;testis: 6.9	all non-specific tissues: 0.0	Cell line enhanced		HMC-1: 1.4
PHAX	FLJ13193, RNUXA	ENSG00000164902	Phosphorylated adaptor for RNA export	5	126600268-126627252	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059630, HPA070326	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 17.8	Expressed in all		
ALDH7A1	ATQ1, EPD, PDE	ENSG00000164904	Aldehyde dehydrogenase 7 family member A1	5	126531200-126595418	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023296	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:3.08e-4 (favourable)	Expressed in all	Expressed in all			kidney: 120.6	Mixed		
FOXK1	IMAGE:5164497	ENSG00000164916	Forkhead box K1	7	4682309-4771443	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017998, HPA018864	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 12.4	Expressed in all		
COX6C		ENSG00000164919	Cytochrome c oxidase subunit 6C	8	99873200-99894062	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA014295, CAB016244	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			duodenum: 339.6	Expressed in all		
OSR2	FLJ90037	ENSG00000164920	Odd-skipped related transciption factor 2	8	98944403-98952104	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052425, HPA063486	Uncertain		Approved	Nucleus<br>Plasma membrane	Head and neck cancer:2.44e-5 (favourable)	Mixed	Tissue enhanced		endometrium: 205.3;fallopian tube: 144.6	ovary: 102.9	Cell line enriched	13	ASC diff: 372.1
YWHAZ	14-3-3-zeta, KCIP-1, YWHAD	ENSG00000164924	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	8	100916525-100953388	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005065	Approved				Renal cancer:2.03e-6 (unfavourable), Pancreatic cancer:1.20e-5 (unfavourable), Liver cancer:2.28e-5 (unfavourable), Endometrial cancer:3.91e-4 (unfavourable), Lung cancer:3.93e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 925.0	Expressed in all		
BAALC		ENSG00000164929	Brain and acute leukemia, cytoplasmic	8	103140710-103230305	Predicted intracellular proteins	Evidence at protein level	HPA027132, HPA068307	Approved		Supported	Nucleus<br>Cytosol		Tissue enriched	Tissue enriched	16	cerebral cortex: 247.7	adrenal gland: 15.6	Cell line enhanced		AF22: 50.6;SCLC-21H: 32.7;SH-SY5Y: 21.7;U-87 MG: 73.6
FZD6	Hfz6	ENSG00000164930	Frizzled class receptor 6	8	103298433-103332866	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017991	Approved		Approved	Plasma membrane	Pancreatic cancer:1.20e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 45.5	Mixed		
CTHRC1		ENSG00000164932	Collagen triple helix repeat containing 1	8	103371515-103382997	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059806, HPA061896	Approved		Approved	Nucleoplasm	Renal cancer:1.22e-14 (unfavourable), Liver cancer:1.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 137.8;placenta: 125.5;urinary bladder: 100.0	breast: 49.2	Cell line enhanced		ASC TERT1: 202.9;HHSteC: 162.6;HSkMC: 291.0;WM-115: 375.8
SLC25A32	MFTC	ENSG00000164933	Solute carrier family 25 member 32	8	103398635-103415189	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024763, HPA047402	Uncertain		Supported	Mitochondria	Renal cancer:1.53e-6 (unfavourable), Lung cancer:2.09e-4 (unfavourable), Endometrial cancer:7.23e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder,lymph node: 21.0	Expressed in all		
DCAF13	DKFZP564O0463, Gm83, HSPC064, WDSOF1	ENSG00000164934	DDB1 and CUL4 associated factor 13	8	103414714-103443453	Predicted intracellular proteins	Evidence at protein level	HPA044504	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cell Junctions<br>Centrosome<br>Cytosol	Liver cancer:8.05e-6 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Breast cancer:4.06e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 58.8	Expressed in all		
DCSTAMP	DC-STAMP, FIND, TM7SF4	ENSG00000164935	Dendrocyte expressed seven transmembrane protein	8	104339087-104356689	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	10	epididymis: 2.4;lung: 5.6	cerebral cortex,cervix, uterine,lymph node,urinary bladder: 0.3	Not detected		
TP53INP1	DKFZp434M1317, FLJ22139, P53DINP1, SIP, Teap, TP53INP1A, TP53INP1B	ENSG00000164938	Tumor protein p53 inducible nuclear protein 1	8	94925972-94949411	Predicted intracellular proteins	Evidence at protein level	HPA005856	Uncertain		Supported	Cytosol	Urothelial cancer:5.45e-5 (favourable), Head and neck cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 52.8	Cell line enhanced		Karpas-707: 57.1;U-266/70: 65.0
INTS8	C8orf52, FLJ20530, INT8, MGC131633	ENSG00000164941	Integrator complex subunit 8	8	94813311-94881746	Predicted intracellular proteins	Evidence at protein level	HPA057299	Approved		Approved	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 57.3	Expressed in all		
KIAA1429	DKFZP434I116, fSAP121	ENSG00000164944	KIAA1429	8	94487693-94553529	Predicted intracellular proteins	Evidence at protein level	HPA031530	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 30.2	Expressed in all		
FREM1	C9orf143, C9orf145, C9orf154, DKFZp686M16108, FLJ25461, TILRR	ENSG00000164946	FRAS1 related extracellular matrix 1	9	14734666-14910995	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		endometrium: 34.0;epididymis: 44.5	smooth muscle: 23.2	Cell line enriched	8	HEL: 162.3
GEM	KIR	ENSG00000164949	GTP binding protein overexpressed in skeletal muscle	8	94249253-94262350	Predicted intracellular proteins	Evidence at protein level	HPA024798	Approved				Renal cancer:1.56e-5 (unfavourable), Thyroid cancer:4.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 364.8	endometrium: 157.2	Cell line enhanced		BJ hTERT+: 67.0;U-266/70: 106.3;U-87 MG: 102.0
PDP1	PDH, PDP, PPM2A, PPM2C	ENSG00000164951	Pyruvate dehyrogenase phosphatase catalytic subunit 1	8	93857807-93926066	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA018483, HPA019081, HPA021152	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Renal cancer:8.42e-9 (favourable), Breast cancer:8.61e-5 (unfavourable), Ovarian cancer:5.60e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 82.3	Expressed in all		
TMEM67	JBTS6, MGC26979, MKS3, NPHP11	ENSG00000164953	Transmembrane protein 67	8	93754844-93819234	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:7.62e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.5	testis: 12.5	Mixed		
WASHC5	KIAA0196, SPG8	ENSG00000164961	WASH complex subunit 5	8	125024260-125091840	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034216, CAB034219, HPA064649, HPA070916	Enhanced		Supported	Nucleoplasm	Liver cancer:6.74e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 39.6	Expressed in all		
RPP25L	bA296L22.5, C9orf23, MGC29635	ENSG00000164967	Ribonuclease P/MRP subunit p25 like	9	34610486-34612104	Predicted intracellular proteins	Evidence at protein level	HPA052187, HPA059698	Uncertain		Supported	Nucleus	Renal cancer:3.01e-9 (favourable), Urothelial cancer:8.21e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.7	Expressed in all		
FAM219A	bA573M23.5, C9orf25, FLJ39031	ENSG00000164970	Family with sequence similarity 219 member A	9	34398184-34458570	Predicted intracellular proteins	Evidence at protein level	HPA019338, HPA052909	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.98e-5 (unfavourable), Renal cancer:5.54e-5 (unfavourable), Pancreatic cancer:2.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.1	Expressed in all		
C9orf24	bA573M23.4, CBE1, MGC32921, MGC33614, NYD-SP22, SMRP1	ENSG00000164972	Chromosome 9 open reading frame 24	9	34379019-34397832	Predicted intracellular proteins	Evidence at protein level	HPA053008	Enhanced				Endometrial cancer:3.23e-5 (favourable), Pancreatic cancer:1.75e-4 (favourable)	Tissue enhanced	Group enriched	11	fallopian tube: 173.9;testis: 65.3	lung: 10.9	Not detected		
SNAPC3	MGC132011, MGC33124, PTFbeta, SNAP50	ENSG00000164975	Small nuclear RNA activating complex polypeptide 3	9	15422704-15465953	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053145, HPA066031			Supported	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Mixed			cerebral cortex: 11.9	Expressed in all		
KIAA1161	NET37	ENSG00000164976	KIAA1161	9	34366670-34376853	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060533, HPA067487	Approved		Approved	Mitochondria	Renal cancer:1.20e-13 (favourable), Endometrial cancer:6.96e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 29.4	Cell line enhanced		SK-BR-3: 43.1;T-47d: 50.4
NUDT2	APAH1	ENSG00000164978	Nudix hydrolase 2	9	34329506-34343713	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004684, HPA044903, HPA058623, HPA067639	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			epididymis: 43.6	Expressed in all		
TMEM65		ENSG00000164983	Transmembrane protein 65	8	124306189-124372692	Predicted membrane proteins	Evidence at protein level	HPA025020	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.05e-4 (unfavourable), Breast cancer:2.17e-4 (unfavourable), Liver cancer:2.56e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.6	Mixed		
PSIP1	LEDGF, p52, p75, PSIP2	ENSG00000164985	PC4 and SFRS1 interacting protein 1	9	15464066-15511019	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013718, HPA019697	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 161.3	Expressed in all		
CCDC171	bA536D16.1, bA778P13.1, C9orf93, Em:AL513423.1, FLJ39267, FLJ46740	ENSG00000164989	Coiled-coil domain containing 171	9	15553086-16061663	Predicted intracellular proteins	Evidence at protein level	HPA019803, HPA019806, HPA024133	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 20.7	endometrium: 9.7	Cell line enhanced		HEL: 10.5
UBAP1	UBAP	ENSG00000165006	Ubiquitin associated protein 1	9	34179005-34252523	Predicted intracellular proteins	Evidence at protein level	HPA019804, HPA041590	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:7.49e-6 (favourable)	Expressed in all	Expressed in all			testis: 88.6	Expressed in all		
DIRAS2	Di-Ras2, DKFZp761C07121	ENSG00000165023	DIRAS family GTPase 2	9	90609832-90643105	Predicted intracellular proteins	Evidence at protein level	HPA043758	Uncertain					Tissue enhanced	Tissue enriched	9	cerebral cortex: 128.3	cervix, uterine: 13.9	Cell line enhanced		AF22: 7.0;EFO-21: 1.9;SCLC-21H: 1.5
SYK		ENSG00000165025	Spleen associated tyrosine kinase	9	90801787-90898549	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001384, CAB007773	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 96.0	Cell line enhanced		Daudi: 89.3;HEL: 64.8;HL-60: 80.0;REH: 76.3
NIPSNAP3B	FLJ11275	ENSG00000165028	Nipsnap homolog 3B	9	104764157-104777457	Predicted intracellular proteins	Evidence at protein level	HPA042491	Uncertain					Mixed	Mixed			adipose tissue: 15.6	Cell line enhanced		REH: 3.9
ABCA1	ABC1, HDLDT1, TGD	ENSG00000165029	ATP binding cassette subfamily A member 1	9	104781002-104928237	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057283, CAB069889	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			adrenal gland: 38.0	Cell line enhanced		U-87 MG: 76.7
NFIL3	E4BP4, IL3BP1, NF-IL3A, NFIL3A	ENSG00000165030	Nuclear factor, interleukin 3 regulated	9	91409045-91423862	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003261	Approved		Approved	Nuclear bodies	Renal cancer:3.23e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 137.2	Expressed in all		
LETM2	FLJ25409	ENSG00000165046	Leucine zipper and EF-hand containing transmembrane protein 2	8	38386207-38409527	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA025032	Approved		Approved	Nucleus<br>Nuclear bodies<br>Cytosol		Mixed	Tissue enriched	9	testis: 39.5	cerebral cortex: 4.2	Mixed		
METTL2B	FLJ11350, METL, METTL2	ENSG00000165055	Methyltransferase like 2B	7	128476729-128506602	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			skin: 12.9	Expressed in all		
PRKACG	PKACg	ENSG00000165059	Protein kinase cAMP-activated catalytic subunit gamma	9	69012529-69014113	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004530, HPA071185	Supported		Approved	Cytosol		Not detected	Tissue enriched	302	testis: 30.1	all non-specific tissues: 0.0	Not detected		
FXN	CyaY, FA, FARR, FRDA, X25	ENSG00000165060	Frataxin	9	69035259-69100178	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022164, HPA068304	Supported		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.1	Expressed in all		
ZMAT4	FLJ13842	ENSG00000165061	Zinc finger matrin-type 4	8	40530590-40897833	Predicted intracellular proteins	Evidence at protein level	HPA056671, HPA069813	Enhanced		Approved	Intermediate filaments	Thyroid cancer:3.51e-4 (unfavourable)	Tissue enhanced	Group enriched	8	cerebral cortex: 10.1;thyroid gland: 27.6	testis: 2.4	Group enriched	5	AF22: 22.3;U-2197: 13.1
NKX6-3	FLJ25169	ENSG00000165066	NK6 homeobox 3	8	41645178-41650669	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA042790	Uncertain					Group enriched	Tissue enhanced		duodenum: 17.3;stomach: 50.6	parathyroid gland: 7.3	Group enriched	7	Daudi: 4.2;THP-1: 1.8
TMEM71	FLJ33069	ENSG00000165071	Transmembrane protein 71	8	132685007-132760712	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058401, HPA070655	Uncertain		Enhanced	Mitochondria		Mixed	Mixed			heart muscle: 27.1	Cell line enhanced		HDLM-2: 53.9;U-937: 26.7
MAMDC2	MGC21981	ENSG00000165072	MAM domain containing 2	9	70043581-70226970	Predicted secreted proteins	Evidence at protein level	HPA021814, HPA022249	Uncertain		Approved	Nuclear speckles<br>Plasma membrane	Thyroid cancer:7.78e-4 (unfavourable)	Mixed	Mixed			endometrium: 60.6	Cell line enhanced		ASC diff: 35.3;HHSteC: 44.9;LHCN-M2: 57.7;TIME: 54.7
PRSS37		ENSG00000165076	Protease, serine 37	7	141836286-141841487	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA020541	Enhanced					Not detected	Tissue enriched	162	testis: 55.3	skin: 0.3	Not detected		
CPA6	CPAH	ENSG00000165078	Carboxypeptidase A6	8	67422038-67746385	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		prostate: 4.9;rectum: 2.9	colon: 1.7	Cell line enhanced		CACO-2: 2.9;EFO-21: 1.8;Hep G2: 3.6
C8orf34	vest-1, VEST1	ENSG00000165084	Chromosome 8 open reading frame 34	8	68330722-68819022	Predicted intracellular proteins	Evidence at protein level	HPA044420, HPA053065	Uncertain		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		fallopian tube: 14.7;parathyroid gland: 18.7	cerebral cortex: 6.1	Cell line enhanced		HEK 293: 2.4;LHCN-M2: 1.9;RH-30: 2.3
TMC1	DFNA36, DFNB11, DFNB7	ENSG00000165091	Transmembrane channel like 1	9	72521801-72836351	Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		cervix, uterine: 1.6	placenta: 1.0	Cell line enhanced		BEWO: 3.1;HAP1: 6.7;NTERA-2: 3.0;U-266/70: 1.6;U-266/84: 1.5
ALDH1A1	ALDH1, PUMB1, RALDH1	ENSG00000165092	Aldehyde dehydrogenase 1 family member A1	9	72900662-73080442	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002123, CAB020690	Approved	Approved	Enhanced	Cytosol	Cervical cancer:7.77e-5 (favourable)	Expressed in all	Expressed in all			liver: 760.0	Cell line enhanced		A549: 3635.1;Hep G2: 855.5;RPTEC TERT1: 528.6
KDM1B	AOF1, bA204B7.3, C6orf193, dJ298J15.2, FLJ33898, FLJ34109, FLJ43328, LSD2	ENSG00000165097	Lysine demethylase 1B	6	18155329-18223853	Predicted intracellular proteins	Evidence at protein level	HPA031269	Uncertain		Approved	Nucleus	Colorectal cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 65.1	Expressed in all		
HGSNAT	FLJ32731, HGNAT, TMEM76	ENSG00000165102	Heparan-alpha-glucosaminide N-acetyltransferase	8	43140455-43202855	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA029578	Approved				Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 49.2	Expressed in all		
RASEF	FLJ31614, RAB45	ENSG00000165105	RAS and EF-hand domain containing	9	82979585-83063177	Predicted intracellular proteins	Evidence at protein level	HPA021431			Approved	Microtubules		Mixed	Expressed in all			thyroid gland: 44.6	Mixed		
GKAP1	FKSG21, GKAP42	ENSG00000165113	G kinase anchoring protein 1	9	83739421-83829516	Predicted intracellular proteins	Evidence at protein level	HPA035117, HPA035118, HPA066173	Enhanced	Approved	Approved	Microtubule organizing center<br>Cytosol	Renal cancer:1.05e-6 (favourable), Pancreatic cancer:6.96e-5 (favourable)	Mixed	Tissue enriched	21	testis: 363.1	skeletal muscle: 17.6	Mixed		
KIF27	DKFZp434D0917	ENSG00000165115	Kinesin family member 27	9	83836698-83921465	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		testis: 46.6	thyroid gland: 14.0	Mixed		
C9orf64	MGC10999	ENSG00000165118	Chromosome 9 open reading frame 64	9	83938311-83956986	Predicted intracellular proteins	Evidence at protein level	HPA054903, HPA066190	Uncertain		Approved	Golgi apparatus	Renal cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.4	Mixed		
HNRNPK	CSBP, HNRPK, TUNP	ENSG00000165119	Heterogeneous nuclear ribonucleoprotein K	9	83968083-83980616	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004435, HPA007644, CAB016225, HPA044105	Supported		Enhanced	Nucleoplasm	Liver cancer:6.68e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 528.1	Expressed in all		
SSMEM1	C7orf45, FLJ40316	ENSG00000165120	Serine rich single-pass membrane protein 1	7	130207860-130216843	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	199	testis: 57.1	lung,placenta: 0.2	Not detected		
SVEP1	bA427L11.3, C9orf13, FLJ13529, POLYDOM	ENSG00000165124	Sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1	9	110365251-110579880	Predicted secreted proteins	Evidence at protein level	HPA020610, HPA021520	Uncertain				Stomach cancer:8.33e-4 (unfavourable)	Mixed	Tissue enhanced		placenta: 87.2	adipose tissue: 36.7	Cell line enhanced		ASC diff: 101.0;ASC TERT1: 59.3;BJ hTERT+: 50.6;HHSteC: 45.2;HSkMC: 48.5
TRPV6	CaT1, ECAC2	ENSG00000165125	Transient receptor potential cation channel subfamily V member 6	7	142871203-142885762	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA062864	Approved					Tissue enriched	Tissue enhanced		prostate: 37.4;salivary gland: 28.9	placenta: 16.7	Cell line enhanced		HaCaT: 16.0;RT4: 26.0;SK-BR-3: 17.7;T-47d: 49.5
C7orf34	CTM-1	ENSG00000165131	Chromosome 7 open reading frame 34	7	142939343-142940868	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	40	testis: 41.5	bone marrow: 1.0	Not detected		
ANKS6	ANKRD14, FLJ36928, NPHP16, SAMD6	ENSG00000165138	Ankyrin repeat and sterile alpha motif domain containing 6	9	98731329-98796965	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008355	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.44e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 15.3	Mixed		
FBP1	FBP	ENSG00000165140	Fructose-bisphosphatase 1	9	94603133-94640249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005857, HPA012513, CAB033869	Enhanced		Uncertain	Mitochondria	Renal cancer:6.86e-7 (favourable), Urothelial cancer:1.64e-5 (favourable), Liver cancer:1.79e-4 (favourable), Endometrial cancer:5.16e-4 (favourable)	Expressed in all	Tissue enhanced		liver: 443.9	duodenum: 329.6	Cell line enhanced		HaCaT: 66.7;MCF7: 184.8;RT4: 124.5;U-698: 78.4
TMEM246	C9orf125, MGC12992	ENSG00000165152	Transmembrane protein 246	9	101473171-101533537	Predicted membrane proteins	Evidence at protein level	HPA011318, HPA054041	Uncertain		Approved	Mitochondria	Renal cancer:1.55e-8 (favourable)	Mixed	Mixed			cerebral cortex: 46.5	Mixed		
ZHX1		ENSG00000165156	Zinc fingers and homeoboxes 1	8	123248451-123275541	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055357, HPA060251			Enhanced	Nucleoplasm	Endometrial cancer:6.09e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 62.9	Expressed in all		
CFAP47	CHDC2, CXorf22, CXorf30, CXorf59, FLJ36601, MGC34831, RP13-11B7.1	ENSG00000165164	Cilia and flagella associated protein 47	X	35919734-36385319	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA044633, HPA054859	Uncertain					Tissue enhanced	Tissue enriched	5	fallopian tube: 7.5	testis: 1.3	Group enriched	6	Karpas-707: 1.1;U-266/70: 2.2
CYBB	CGD, GP91-PHOX, NOX2	ENSG00000165168	Cytochrome b-245 beta chain	X	37780011-37813461	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051227	Enhanced					Expressed in all	Tissue enhanced		appendix: 215.6	lung: 132.2	Group enriched	5	Daudi: 37.3;NB-4: 40.0;REH: 49.1;RPMI-8226: 143.6
DYNLT3	TCTE1L, TCTEX1L	ENSG00000165169	Dynein light chain Tctex-type 3	X	37836757-37847637	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003938	Approved				Glioma:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 77.2	Mixed		
WBSCR27		ENSG00000165171	Williams Beuren syndrome chromosome region 27	7	73834590-73842535	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022420	Uncertain		Supported	Focal adhesion sites	Renal cancer:1.10e-6 (favourable), Colorectal cancer:1.73e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Cell line enhanced		RPMI-8226: 54.9;T-47d: 21.0
MID1IP1	FLJ10386, G12-like, MIG12, STRAIT11499, THRSPL	ENSG00000165175	MID1 interacting protein 1	X	38801432-38806537	Predicted intracellular proteins	Evidence at protein level	HPA038816	Uncertain				Renal cancer:1.15e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Urothelial cancer:8.06e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 66.2	Expressed in all		
C9orf84	FLJ32779	ENSG00000165181	Chromosome 9 open reading frame 84	9	111686173-111795008	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA032108			Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	10	testis: 31.0	adrenal gland: 3.1	Cell line enhanced		A-431: 4.3;SiHa: 5.3;U-2 OS: 23.4;U-266/84: 3.3
CXorf58	FLJ25444	ENSG00000165182	Chromosome X open reading frame 58	X	23907801-23939507	Predicted intracellular proteins	Evidence at protein level	HPA031542, HPA031543, HPA031544	Uncertain					Not detected	Tissue enriched	9	testis: 6.2	fallopian tube: 0.6	Not detected		
KIAA1958	FLJ39294	ENSG00000165185	KIAA1958	9	112486847-112669397	Predicted intracellular proteins	Evidence at protein level	HPA020625	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			ovary: 12.2	Mixed		
PTCHD1	FLJ30296	ENSG00000165186	Patched domain containing 1	X	23334016-23404372	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA046110	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.6;seminal vesicle: 5.1	endometrium: 2.6	Cell line enhanced		HEK 293: 1.5;RT4: 1.3;WM-115: 5.3
RNF183	MGC4734	ENSG00000165188	Ring finger protein 183	9	113297093-113303376	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057675	Uncertain				Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 20.0;gallbladder: 9.0	kidney: 4.3	Cell line enriched	10	SCLC-21H: 22.2
ASB11	DKFZp779E2460	ENSG00000165192	Ankyrin repeat and SOCS box containing 11	X	15281697-15315656	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000238	Uncertain					Tissue enriched	Group enriched	6	heart muscle: 30.6;skeletal muscle: 42.1	stomach: 5.8	Not detected		
PCDH19	EFMR, EIEE9, KIAA1313	ENSG00000165194	Protocadherin 19	X	100291644-100410273	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027533	Approved		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 11.3	cervix, uterine: 2.6	Cell line enriched	7	AF22: 17.7
PIGA	GPI3	ENSG00000165195	Phosphatidylinositol glycan anchor biosynthesis class A	X	15319451-15335580	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001174	Approved				Pancreatic cancer:7.64e-4 (unfavourable)	Expressed in all	Mixed			lung: 9.8	Expressed in all		
VEGFD	FIGF, VEGF-D	ENSG00000165197	Vascular endothelial growth factor D	X	15345591-15384376	Cancer-related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA027342	Uncertain					Mixed	Tissue enhanced		breast: 25.0;lung: 59.3	adipose tissue: 13.2	Cell line enhanced		ASC diff: 2.3;ASC TERT1: 2.0;HSkMC: 2.1
OR1Q1	HSTPCR106, OR1Q2, OR1Q3, OR9-A, OST226, OST226OR9-A, TPCR106	ENSG00000165202	Olfactory receptor family 1 subfamily Q member 1	9	122614738-122615682	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044828	Uncertain					Not detected	Not detected			epididymis: 0.9	Not detected		
OR1K1	hg99, MNAB	ENSG00000165204	Olfactory receptor family 1 subfamily K member 1	9	122800123-122801073	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
STRBP	FLJ11307, ILF3L, SPNR	ENSG00000165209	Spermatid perinuclear RNA binding protein	9	123109500-123268576	Predicted intracellular proteins	Evidence at protein level	HPA020651	Approved				Renal cancer:1.70e-10 (favourable), Liver cancer:8.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 79.0	Mixed		
CLDN3	C7orf1, CPE-R2, CPETR2, HRVP1, RVP1	ENSG00000165215	Claudin 3	7	73768997-73770270	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002702, HPA014361	Supported		Supported	Cell Junctions	Renal cancer:3.39e-5 (favourable)	Mixed	Tissue enhanced		colon: 87.7;small intestine: 119.5	duodenum: 55.0	Cell line enhanced		MCF7: 175.3;PC-3: 44.1;SCLC-21H: 68.2;T-47d: 98.9
GAPVD1	DKFZP434C212, KIAA1521	ENSG00000165219	GTPase activating protein and VPS9 domains 1	9	125261794-125367207	Predicted intracellular proteins	Evidence at protein level	HPA029386, HPA029387	Uncertain		Supported	Cytosol		Expressed in all	Expressed in all			testis: 49.2	Expressed in all		
CARD19	bA370F5.1, BinCARD, C9orf89, MGC11115	ENSG00000165233	Caspase recruitment domain family member 19	9	93096218-93113283	Predicted membrane proteins	Evidence at protein level	HPA010921, HPA010990, HPA038297	Approved		Supported	Mitochondria	Liver cancer:1.32e-5 (unfavourable), Glioma:6.41e-5 (unfavourable)	Expressed in all	Mixed			testis: 11.1	Expressed in all		
WNK2	KIAA1760, NY-CO-43, PRKWNK2, SDCCAG43	ENSG00000165238	WNK lysine deficient protein kinase 2	9	93184916-93320572	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015555, HPA016519, CAB017813	Enhanced		Approved	Cytosol		Mixed	Mixed			heart muscle: 29.1	Cell line enhanced		Hep G2: 21.0;SCLC-21H: 44.2
ATP7A	MNK	ENSG00000165240	ATPase copper transporting alpha	X	77910656-78050395	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA012887, HPA048107	Approved		Supported	Golgi apparatus<br>Vesicles	Renal cancer:8.38e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.3	Mixed		
ZNF367	FLJ33970	ENSG00000165244	Zinc finger protein 367	9	96385941-96418329	Predicted intracellular proteins	Evidence at protein level	HPA015319, HPA015785	Uncertain		Supported	Nucleoplasm	Thyroid cancer:2.34e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 16.0	testis: 11.2	Mixed		
NLGN4Y	KIAA0951	ENSG00000165246	Neuroligin 4, Y-linked	Y	14522638-14845650	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA001651	Approved					Mixed	Tissue enhanced		prostate: 11.4;seminal vesicle: 12.5	cerebral cortex: 7.5	Cell line enhanced		BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
HDX	CXorf43, FLJ30678	ENSG00000165259	Highly divergent homeobox	X	84317874-84502479	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047189	Uncertain		Approved	Cytosol		Mixed	Mixed			cerebral cortex,endometrium: 3.8	Mixed		
NDUFB6	B17, CI	ENSG00000165264	NADH:ubiquinone oxidoreductase subunit B6	9	32552999-32573184	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044001, HPA053334	Supported		Enhanced	Mitochondria	Renal cancer:7.47e-10 (favourable), Cervical cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 70.2	Expressed in all		
AQP7	AQP7L, AQP9, AQPap	ENSG00000165269	Aquaporin 7	9	33383179-33402682	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.21e-8 (favourable)	Mixed	Tissue enriched	5	adipose tissue: 355.1	parathyroid gland: 66.5	Cell line enriched	49	ASC diff: 181.4
NOL6	bA311H10.1, FLJ21959, MGC14896, MGC14921, MGC20838, Nrap, UTP22	ENSG00000165271	Nucleolar protein 6	9	33461441-33473930	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055891, HPA061002	Supported		Enhanced	Nucleus<br>Nucleoli<br>Mitochondria	Liver cancer:4.83e-5 (unfavourable), Thyroid cancer:9.49e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
AQP3	GIL	ENSG00000165272	Aquaporin 3 (Gill blood group)	9	33441154-33447611	Blood group antigen proteins, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014924	Enhanced		Supported	Nucleus<br>Plasma membrane	Cervical cancer:5.31e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 971.6	Cell line enhanced		HaCaT: 113.2;HeLa: 108.6;RT4: 167.6;SK-BR-3: 112.0;U-266/70: 114.3;U-266/84: 148.6
TRMT10B	bA3J10.9, FLJ31455, RG9MTD3	ENSG00000165275	TRNA methyltransferase 10B	9	37753803-37778972	Predicted intracellular proteins	Evidence at transcript level	HPA021800	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Lung cancer:3.91e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable)	Expressed in all	Mixed			skin: 12.9	Expressed in all		
VCP	IBMPFD, p97	ENSG00000165280	Valosin containing protein	9	35056064-35073249	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB005593, HPA012728, HPA012814	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:9.63e-7 (favourable), Endometrial cancer:7.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 94.2	Expressed in all		
PIGO	DKFZp434M222, FLJ00135	ENSG00000165282	Phosphatidylinositol glycan anchor biosynthesis class O	9	35088688-35096601	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014905			Approved	Nucleus<br>Nucleoli	Renal cancer:3.05e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 74.6	Expressed in all		
STOML2	HSPC108, SLP-2	ENSG00000165283	Stomatin like 2	9	35099776-35103195	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB015944, HPA062016	Supported		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.00e-5 (favourable), Liver cancer:4.77e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 98.6	Expressed in all		
BRWD3	FLJ38568, MRX93	ENSG00000165288	Bromodomain and WD repeat domain containing 3	X	80670854-80809688	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA012802	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 8.6	Mixed		
SLITRK5	bA364G4.2, KIAA0918, LRRC11	ENSG00000165300	SLIT and NTRK like family member 5	13	87672615-87696272	Predicted membrane proteins	Evidence at protein level	HPA013843	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus		Not detected	Tissue enhanced		cerebral cortex: 4.9;fallopian tube: 4.7	seminal vesicle: 1.8	Cell line enhanced		AF22: 6.9
MELK	KIAA0175	ENSG00000165304	Maternal embryonic leucine zipper kinase	9	36572862-36677683	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017214	Uncertain				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 16.9	lymph node: 11.7	Expressed in all		
ARMC3	CT81, FLJ32827	ENSG00000165309	Armadillo repeat containing 3	10	22928024-23038523	Predicted intracellular proteins	Evidence at protein level	HPA037823, HPA037824	Enhanced					Tissue enhanced	Group enriched	12	fallopian tube: 74.2;testis: 61.0	lung: 5.5	Cell line enriched	10	CAPAN-2: 5.3
OTUD1	DUBA7, OTDC1	ENSG00000165312	OTU deubiquitinase 1	10	23439458-23442390	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038503, HPA038504	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus	Renal cancer:6.61e-7 (favourable), Endometrial cancer:4.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 43.3	Cell line enhanced		CAPAN-2: 37.8;HaCaT: 36.0;SiHa: 28.0
ARHGAP12	FLJ10971, FLJ20737, FLJ21785	ENSG00000165322	Rho GTPase activating protein 12	10	31805404-31928876	Predicted intracellular proteins	Evidence at protein level	HPA000412	Enhanced				Renal cancer:4.64e-5 (favourable), Glioma:1.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.2	Mixed		
FAT3	CDHF15, CDHR10, KIAA1989	ENSG00000165323	FAT atypical cadherin 3	11	92352096-92896470	Predicted membrane proteins	Evidence at protein level	HPA026878	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 3.9;seminal vesicle: 2.6	prostate: 1.6	Cell line enhanced		AF22: 3.6;NTERA-2: 1.2;U-2 OS: 1.1;U-251 MG: 1.8
DEUP1	CCDC67, FLJ25393	ENSG00000165325	Deuterosome assembly protein 1	11	93329971-93438487	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010986	Uncertain					Not detected	Group enriched	11	fallopian tube: 7.6;testis: 29.8	thyroid gland: 1.6	Not detected		
HECTD2	FLJ37306	ENSG00000165338	HECT domain E3 ubiquitin protein ligase 2	10	91409280-91514829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037767	Approved		Approved	Nucleoplasm	Renal cancer:1.67e-5 (unfavourable)	Mixed	Mixed			prostate: 28.1	Mixed		
SLC7A3	ATRC3, CAT-3, FLJ14541	ENSG00000165349	Solute carrier family 7 member 3	X	70925582-70931125	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003629	Approved					Tissue enriched	Tissue enhanced		endometrium: 7.8;prostate: 9.9;seminal vesicle: 7.5	smooth muscle: 4.1	Cell line enhanced		HAP1: 66.1;NTERA-2: 130.6;REH: 25.9
FBXO33	Fbx33	ENSG00000165355	F-box protein 33	14	39397669-39432500	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046657	Approved		Approved	Nucleoplasm	Renal cancer:4.58e-4 (favourable), Lung cancer:4.94e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 33.3	Expressed in all		
INTS6L	DDX26B, FLJ41215	ENSG00000165359	Integrator complex subunit 6 like	X	135520643-135582510	Predicted intracellular proteins	Evidence at protein level	HPA001552, HPA013200, HPA013335, HPA030747	Uncertain		Supported	Centrosome<br>Mitochondria	Renal cancer:4.28e-8 (unfavourable), Urothelial cancer:2.94e-4 (favourable), Cervical cancer:5.39e-4 (favourable), Pancreatic cancer:5.54e-4 (favourable)	Mixed	Mixed			lymph node: 14.6	Mixed		
GPR101		ENSG00000165370	G protein-coupled receptor 101	X	137030148-137031674	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001084	Uncertain					Not detected	Not detected			cerebral cortex: 0.1	Not detected		
CLDN2		ENSG00000165376	Claudin 2	X	106900164-106930861	Predicted membrane proteins	Evidence at protein level	CAB002609, HPA051548	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Thyroid cancer:1.70e-4 (favourable)	Group enriched	Tissue enhanced		gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3	epididymis: 41.1	Group enriched	23	A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
LRFN5	C14orf146, FIGLER8, SALM5	ENSG00000165379	Leucine rich repeat and fibronectin type III domain containing 5	14	41607570-41904549	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001177	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 52.3	cervix, uterine: 16.8	Cell line enhanced		AN3-CA: 16.8;RPTEC TERT1: 4.6;SCLC-21H: 11.1;U-138 MG: 11.4
LRRC18	MGC34773, UNQ933, UNQ9338, VKGE9338	ENSG00000165383	Leucine rich repeat containing 18	10	48909483-48914232	Predicted intracellular proteins	Evidence at protein level	HPA039256	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 12.1;testis: 25.3	lung: 2.3	Not detected		
SPTSSA	C14orf147, ssSPTa	ENSG00000165389	Serine palmitoyltransferase small subunit A	14	34432789-34462356	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			adrenal gland: 90.1	Expressed in all		
WRN	RECQ3, RECQL2	ENSG00000165392	Werner syndrome RecQ like helicase	8	31033801-31173769	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028661	Approved		Supported	Nuclear speckles		Expressed in all	Mixed			endometrium: 14.8	Expressed in all		
MARCH8	c-MIR, CMIR, MARCH-VIII, MIR, RNF178	ENSG00000165406	Membrane associated ring-CH-type finger 8	10	45454585-45594906	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014597	Approved				Pancreatic cancer:2.71e-4 (favourable), Renal cancer:6.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 104.6	Expressed in all		
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
CFL2	NEM7	ENSG00000165410	Cofilin 2	14	34706769-34714823	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037078, HPA045599	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.16e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 242.7	Expressed in all		
SUGT1	SGT1	ENSG00000165416	SGT1 homolog, MIS12 kinetochore complex assembly cochaperone	13	52652709-52700909	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015942, HPA043949	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:8.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.4	Expressed in all		
GTF2A1	TFIIA	ENSG00000165417	General transcription factor IIA subunit 1	14	81175452-81221377	Predicted intracellular proteins	Evidence at protein level	HPA000869	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 38.9	Expressed in all		
ZCCHC24	C10orf56, FLJ90798, Z3CXXC8	ENSG00000165424	Zinc finger CCHC-type containing 24	10	79382325-79445627	Predicted intracellular proteins	Evidence at protein level	HPA038348	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:5.35e-6 (unfavourable), Ovarian cancer:3.76e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 70.6	Cell line enhanced		ASC diff: 92.6;ASC TERT1: 80.6;BJ hTERT+: 74.4;HSkMC: 87.6
PGM2L1	BM32A, FLJ32029	ENSG00000165434	Phosphoglucomutase 2 like 1	11	74330318-74398473	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056995, HPA060948	Enhanced		Approved	Mitochondria		Mixed	Tissue enriched	9	cerebral cortex: 64.1	endometrium: 7.3	Cell line enhanced		RH-30: 18.2
PHYHIPL	Em:AC025038.1, KIAA1796	ENSG00000165443	Phytanoyl-CoA 2-hydroxylase interacting protein like	10	59176590-59247774	Predicted intracellular proteins	Evidence at protein level	HPA038746	Uncertain		Approved	Cytosol	Renal cancer:1.60e-7 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 89.4	adrenal gland: 22.4	Cell line enhanced		Hep G2: 22.4;SCLC-21H: 6.7;SH-SY5Y: 20.0;SK-BR-3: 6.0
SLC16A9	C10orf36, FLJ43803, MCT9	ENSG00000165449	Solute carrier family 16 member 9	10	59650761-59736002	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049286	Approved		Approved	Nucleus<br>Cell Junctions	Renal cancer:2.56e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 198.5;kidney: 201.0	spleen: 56.3	Cell line enhanced		HAP1: 11.1;NTERA-2: 20.0;U-937: 14.6
FOLR2		ENSG00000165457	Folate receptor beta	11	72216601-72221950	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Thyroid cancer:8.41e-4 (favourable), Colorectal cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 235.4	Group enriched	6	Daudi: 2.6;U-698: 12.5
INPPL1	SHIP2	ENSG00000165458	Inositol polyphosphate phosphatase like 1	11	72223701-72239105	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037601	Approved		Supported	Golgi apparatus<br>Cytosol	Liver cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 64.3	Expressed in all		
PHOX2A	ARIX, CFEOM2, FEOM2, PMX2A	ENSG00000165462	Paired like homeobox 2a	11	72239077-72245664	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065621, HPA078004	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Vesicles		Tissue enriched	Tissue enriched	14	adrenal gland: 26.4	appendix: 1.8	Cell line enriched	240	SH-SY5Y: 603.9
MBL2	COLEC1, MBL	ENSG00000165471	Mannose binding lectin 2	10	52765380-52771700	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002027, CAB016782	Enhanced					Tissue enriched	Tissue enriched	1414	liver: 141.4	all non-specific tissues: 0.0	Cell line enriched	9	Hep G2: 1.5
GJB2	CX26, DFNA3, DFNB1, NSRD1	ENSG00000165474	Gap junction protein beta 2	13	20187470-20192898	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB013093, HPA014362	Uncertain		Approved	Mitochondria	Renal cancer:2.53e-6 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable), Glioma:5.98e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable)	Expressed in all	Tissue enriched	9	esophagus: 725.5	tonsil: 81.3	Cell line enhanced		CAPAN-2: 129.4;hTCEpi: 78.0;RT4: 137.8
CRYL1	GDH, lambda-CRY, MGC149525, MGC149526	ENSG00000165475	Crystallin lambda 1	13	20403667-20525857	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040403	Enhanced		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane	Renal cancer:2.30e-9 (favourable), Endometrial cancer:1.76e-5 (favourable)	Expressed in all	Expressed in all			kidney: 338.1	Mixed		
REEP3	C10orf74, Yip2b	ENSG00000165476	Receptor accessory protein 3	10	63521363-63625123	Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:1.32e-4 (unfavourable), Liver cancer:3.19e-4 (unfavourable), Head and neck cancer:7.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 56.9	Mixed		
HEPACAM	FLJ25530, GLIALCAM, hepaCAM	ENSG00000165478	Hepatic and glial cell adhesion molecule	11	124919193-124936412	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017613, CAB025486	Enhanced		Approved	Vesicles		Tissue enriched	Tissue enriched	5	cerebral cortex: 80.7	adipose tissue: 15.1	Cell line enriched	27	Hep G2: 18.8
SKA3	C13orf3, MGC4832, RAMA1	ENSG00000165480	Spindle and kinetochore associated complex subunit 3	13	21153595-21176602	Predicted intracellular proteins	Evidence at protein level	HPA039272	Approved		Uncertain	Plasma membrane<br>Cytosol	Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 10.1	lymph node: 5.0	Mixed		
MICU2	EFHA1	ENSG00000165487	Mitochondrial calcium uptake 2	13	21492691-21604214	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045511, HPA058790	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:1.40e-7 (favourable)	Expressed in all	Expressed in all			kidney: 78.5	Expressed in all		
DDIAS	C11orf82, FLJ25416, FLJ38838, noxin	ENSG00000165490	DNA damage induced apoptosis suppressor	11	82899975-82958277	Predicted secreted proteins	Evidence at protein level	HPA038540, HPA038541	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		testis: 20.0	skeletal muscle: 6.4	Mixed		
PCF11	KIAA0824	ENSG00000165494	PCF11 cleavage and polyadenylation factor subunit	11	83156988-83187451	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040779			Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:2.03e-5 (favourable), Head and neck cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.8	Expressed in all		
PKNOX2		ENSG00000165495	PBX/knotted 1 homeobox 2	11	125164687-125433389	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028867, CAB034342, HPA055368, HPA066962	Supported		Enhanced	Nucleus<br>Cytokinetic bridge		Tissue enhanced	Mixed			thyroid gland: 20.1	Cell line enhanced		AF22: 38.2;AN3-CA: 9.0;LHCN-M2: 9.6;WM-115: 21.0
RPL10L		ENSG00000165496	Ribosomal protein L10 like	14	46651010-46651821	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA011311	Uncertain		Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	45	testis: 127.0	rectum: 2.8	Cell line enriched	54	U-2 OS: 40.6
LRR1	LRR-1, MGC20689, PPIL5	ENSG00000165501	Leucine rich repeat protein 1	14	49598697-49614672	Predicted intracellular proteins	Evidence at protein level	HPA065703, HPA069364	Approved		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles	Renal cancer:4.90e-7 (unfavourable), Liver cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 33.6	lymph node: 12.1	Expressed in all		
RPL36AL	RPL36A	ENSG00000165502	Ribosomal protein L36a like	14	49618519-49620685	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA077586			Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Thyroid cancer:2.83e-4 (favourable)	Expressed in all	Expressed in all			ovary: 529.4	Expressed in all		
DNAAF2	C14orf104, CILD10, FLJ10563, KTU, PF13	ENSG00000165506	Dynein axonemal assembly factor 2	14	49625174-49635230	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA002894, HPA004113	Enhanced		Supported	Cytosol	Renal cancer:6.74e-7 (favourable)	Expressed in all	Expressed in all			fallopian tube: 13.9	Expressed in all		
C10orf10	DEPP, FIG, Fseg	ENSG00000165507	Chromosome 10 open reading frame 10	10	44970981-44978810	Predicted secreted proteins	Evidence at protein level	CAB013687, HPA037819	Uncertain		Approved	Nucleus<br>Vesicles	Renal cancer:2.29e-6 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 238.0	Cell line enhanced		ASC diff: 98.2;HDLM-2: 98.9;HHSteC: 216.9;HSkMC: 146.6;HUVEC TERT2: 137.8
MAGEC3	CT7.2, HCA2, MAGE-C3	ENSG00000165509	MAGE family member C3	X	141838316-141897832	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA052067	Approved					Tissue enriched	Tissue enhanced		testis: 1.0	cerebral cortex: 0.6	Cell line enhanced		U-266/84: 1.5
ZNF22	HKR-T1, KOX15, Zfp422, ZNF422	ENSG00000165512	Zinc finger protein 22	10	45000475-45005326	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016736, HPA054893	Approved		Enhanced	Nucleus	Renal cancer:1.11e-5 (unfavourable), Stomach cancer:8.06e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 46.7	Mixed		
KLHDC2	HCLP-1, LCP	ENSG00000165516	Kelch domain containing 2	14	49767608-49786385	Predicted intracellular proteins	Evidence at protein level	HPA000628	Approved		Supported	Nucleoplasm<br>Nuclear membrane<br>Nuclear bodies	Renal cancer:2.75e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.1	Expressed in all		
EML5	EMAP-2, HuEMAP-2	ENSG00000165521	Echinoderm microtubule associated protein like 5	14	88612431-88792752	Predicted intracellular proteins	Evidence at protein level	HPA054019, HPA055379	Uncertain					Not detected	Tissue enhanced		ovary: 23.7	prostate: 8.7	Cell line enhanced		SH-SY5Y: 26.6
NEMF	FLJ10051, NY-CO-1, SDCCAG1	ENSG00000165525	Nuclear export mediator factor	14	49782083-49853203	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004160	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.3	Expressed in all		
RPUSD4	FLJ14494	ENSG00000165526	RNA pseudouridylate synthase domain containing 4	11	126202094-126211692	Predicted intracellular proteins	Evidence at protein level	HPA039689	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:1.24e-4 (unfavourable), Colorectal cancer:6.14e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 44.9	Expressed in all		
ARF6		ENSG00000165527	ADP ribosylation factor 6	14	49893092-49897054	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002778	Approved				Pancreatic cancer:3.10e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 96.6	Expressed in all		
TTC8	BBS8, RP51	ENSG00000165533	Tetratricopeptide repeat domain 8	14	88824153-88881078	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:1.69e-5 (favourable), Renal cancer:4.89e-4 (favourable), Ovarian cancer:7.77e-4 (favourable)	Expressed in all	Expressed in all			ovary: 91.0	Expressed in all		
TMEM63C	C14orf171, CSC1, DKFZp434P0111, hsCSC1	ENSG00000165548	Transmembrane protein 63C	14	77116568-77259495	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA030657	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		adrenal gland: 12.9;cerebral cortex: 18.5;testis: 13.8	epididymis: 5.6	Cell line enhanced		Daudi: 13.3;Karpas-707: 17.4;SCLC-21H: 38.5;SK-BR-3: 21.9
NGB		ENSG00000165553	Neuroglobin	14	77265483-77271312	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042615, HPA058596	Enhanced					Tissue enhanced	Group enriched	5	adrenal gland: 10.1;cerebral cortex: 4.8;fallopian tube: 2.2	pancreas: 1.0	Group enriched	30	RPMI-8226: 4.3;SCLC-21H: 14.4
NOXRED1	C14orf148, FLJ32809	ENSG00000165555	NADP dependent oxidoreductase domain containing 1	14	77394021-77423517	Predicted intracellular proteins	Evidence at transcript level	HPA055658	Approved					Mixed	Tissue enriched	7	testis: 11.7	thyroid gland: 1.6	Not detected		
CDX2	CDX3	ENSG00000165556	Caudal type homeobox 2	13	27962137-27971139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002221, HPA045669, HPA049580	Enhanced		Supported	Nucleoplasm		Tissue enriched	Group enriched	6	colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2	appendix: 4.7	Cell line enhanced		CACO-2: 9.4;CAPAN-2: 3.3;HEK 293: 5.6
AMER2	FAM123A, FLJ25477	ENSG00000165566	APC membrane recruitment protein 2	13	25161684-25172288	Predicted intracellular proteins	Evidence at protein level	HPA039458	Enhanced					Tissue enriched	Tissue enriched	53	cerebral cortex: 72.4	fallopian tube,testis: 1.3	Group enriched	5	AF22: 3.6;SCLC-21H: 3.5;U-266/70: 5.2
AKR1E2	AKR1CL2, AKRDC1, MGC10612	ENSG00000165568	Aldo-keto reductase family 1 member E2	10	4786629-4848062	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037821, HPA037822	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	5	testis: 29.8	thyroid gland: 5.6	Cell line enhanced		U-2197: 19.2
KBTBD6	DKFZp547E1912	ENSG00000165572	Kelch repeat and BTB domain containing 6	13	41127569-41132746	Predicted intracellular proteins	Evidence at protein level	HPA046861, HPA048914	Uncertain					Expressed in all	Mixed			cerebral cortex: 23.6	Expressed in all		
SSX5		ENSG00000165583	SSX family member 5	X	48186220-48196763	Predicted intracellular proteins	Evidence at protein level	HPA045683	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		thyroid gland: 1.0	testis: 0.9	Cell line enriched	6	BEWO: 4.8
SSX3	CT5.3	ENSG00000165584	SSX family member 3	X	48346428-48356707	Predicted intracellular proteins	Evidence at protein level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	70	testis: 25.3	thyroid gland: 0.3	Cell line enhanced		Karpas-707: 1.5
OTX2		ENSG00000165588	Orthodenticle homeobox 2	14	56799905-56810479	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000633	Approved					Tissue enriched	Not detected			testis: 0.5	Group enriched	735	HAP1: 239.3;NTERA-2: 192.9
FAAH2	AMDD, FAAH-2, FLJ31204, RP11-479E16.1	ENSG00000165591	Fatty acid amide hydrolase 2	X	57286706-57489196	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.47e-13 (favourable), Urothelial cancer:6.83e-5 (favourable), Thyroid cancer:2.66e-4 (favourable), Ovarian cancer:5.99e-4 (favourable)	Mixed	Mixed			parathyroid gland: 20.2	Cell line enhanced		CAPAN-2: 12.2;HDLM-2: 12.0;RPMI-8226: 18.0;U-266/70: 15.9
DRGX	DRG11, PRRXL1	ENSG00000165606	Dorsal root ganglia homeobox	10	49364181-49396016	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043978	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enriched	11	adrenal gland: 8.9	skin: 0.8	Group enriched	16	RH-30: 13.8;SH-SY5Y: 68.3;U-2197: 21.7
NUDT5	hYSAH1, YSA1H	ENSG00000165609	Nudix hydrolase 5	10	12165325-12196144	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019827	Approved		Approved	Nucleus<br>Vesicles<br>Centrosome	Renal cancer:7.14e-12 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 45.6	Expressed in all		
DACT1	DAPPER, DAPPER1, FRODO, HDPR1, THYEX3	ENSG00000165617	Dishevelled binding antagonist of beta catenin 1	14	58633967-58648321	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003016	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			gallbladder: 40.2	Cell line enhanced		U-138 MG: 31.7
OXGR1	aKGR, GPR80, GPR99, P2RY15, P2Y15	ENSG00000165621	Oxoglutarate receptor 1	13	96985719-96994730	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA067673			Supported	Plasma membrane		Mixed	Tissue enhanced		breast: 5.1	kidney: 4.6	Cell line enhanced		RT4: 2.6;SK-BR-3: 1.1;U-2 OS: 1.7
UCMA	C10orf49	ENSG00000165623	Upper zone of growth plate and cartilage matrix associated	10	13221767-13234334	Predicted secreted proteins	Evidence at transcript level	HPA046718	Uncertain					Tissue enhanced	Tissue enhanced		ovary: 1.4	heart muscle: 0.4	Not detected		
BEND7	C10orf30, FLJ40283	ENSG00000165626	BEN domain containing 7	10	13438484-13528974	Predicted intracellular proteins	Evidence at protein level	HPA037835	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles		Mixed	Mixed			thyroid gland: 40.9	Mixed		
ATP5C1	ATP5C, ATP5CL1	ENSG00000165629	ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1	10	7788129-7807815	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA060949	Approved				Renal cancer:9.26e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 463.5	Expressed in all		
PRPF18	hPrp18	ENSG00000165630	Pre-mRNA processing factor 18	10	13586927-13630868	Predicted intracellular proteins	Evidence at protein level	HPA037599, HPA047950	Supported		Approved	Nuclear speckles<br>Cytosol	Liver cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 38.5	Expressed in all		
TAF3	TAF140, TAFII140	ENSG00000165632	TATA-box binding protein associated factor 3	10	7818504-8016627	Predicted intracellular proteins	Evidence at protein level	HPA066184			Supported	Nucleoplasm<br>Nuclear membrane	Liver cancer:2.14e-7 (unfavourable), Renal cancer:5.01e-4 (unfavourable)	Expressed in all	Mixed			testis: 14.1	Expressed in all		
VSTM4	C10orf72, FLJ31737	ENSG00000165633	V-set and transmembrane domain containing 4	10	49014245-49115509	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA017279	Uncertain		Approved	Nucleus<br>Vesicles	Urothelial cancer:4.25e-4 (unfavourable)	Tissue enriched	Mixed			adrenal gland: 54.8	Cell line enhanced		RH-30: 9.1;U-138 MG: 10.5;U-2197: 22.4;U-87 MG: 11.4
VDAC2		ENSG00000165637	Voltage dependent anion channel 2	10	75210154-75231448	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA043475	Enhanced		Enhanced	Mitochondria	Head and neck cancer:4.51e-4 (unfavourable), Liver cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 269.4	Expressed in all		
SOHLH1	bA100C15.3, bHLHe80, C9orf157, NOHLH, SPATA27, TEB2	ENSG00000165643	Spermatogenesis and oogenesis specific basic helix-loop-helix 1	9	135693407-135699528	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059439			Approved	Nuclear speckles		Mixed	Group enriched	27	cerebral cortex: 6.3;testis: 13.4	skin: 0.3	Group enriched	36	CACO-2: 14.6;U-266/84: 19.8
COMTD1	FLJ23841	ENSG00000165644	Catechol-O-methyltransferase domain containing 1	10	75233969-75236030	Predicted intracellular proteins	Evidence at protein level	HPA042165	Approved		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.88e-4 (favourable)	Expressed in all	Mixed			duodenum: 13.6	Cell line enhanced		HEK 293: 43.6;PC-3: 61.2
SLC18A2	SVAT, SVMT, VMAT2	ENSG00000165646	Solute carrier family 18 member A2	10	117241093-117279430	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA073224	Approved					Mixed	Tissue enhanced		cervix, uterine: 47.6	adrenal gland: 19.0	Cell line enriched	18	HMC-1: 308.7
PDZD8	bA129M16.2, FLJ34427, PDZK8	ENSG00000165650	PDZ domain containing 8	10	117277274-117375467	Predicted secreted proteins	Evidence at protein level	HPA015716, HPA051610	Uncertain		Approved	Nucleoli fibrillar center<br>Plasma membrane	Pancreatic cancer:6.10e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 46.5	Expressed in all		
ZNF503	FLJ45745, MGC2555, Nlz2	ENSG00000165655	Zinc finger protein 503	10	75397830-75401906	Predicted intracellular proteins	Evidence at protein level	HPA026848	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.97e-4 (favourable), Prostate cancer:3.50e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 25.7	Cell line enhanced		HEK 293: 100.8;PC-3: 132.2
FAM175B	ABRO1, Em:AC068896.4, KIAA0157	ENSG00000165660	Family with sequence similarity 175 member B	10	124801785-124836670	Predicted intracellular proteins	Evidence at protein level	HPA037591, HPA037592, HPA074089	Approved		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 21.0	Expressed in all		
QSOX2	DKFZp762A2013, QSCN6L1, SOXN	ENSG00000165661	Quiescin sulfhydryl oxidase 2	9	136206333-136245841	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012716, HPA017280	Uncertain		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:9.64e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 20.7	Expressed in all		
FAM204A	bA319I23.1, C10orf84, FLJ13188	ENSG00000165669	Family with sequence similarity 204 member A	10	118297930-118342328	Predicted intracellular proteins	Evidence at protein level	HPA038182, HPA062025	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 89.3	Expressed in all		
NSD1	ARA267, FLJ22263, KMT3B, STO	ENSG00000165671	Nuclear receptor binding SET domain protein 1	5	177133025-177300215	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048431, HPA070333, HPA073705	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 43.2	Mixed		
PRDX3	AOP-1, AOP1, MER5, SP-22	ENSG00000165672	Peroxiredoxin 3	10	119167703-119178833	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008656, HPA041488	Enhanced					Expressed in all	Expressed in all			adrenal gland: 429.1	Expressed in all		
ENOX2	APK1, COVA1, tNOX	ENSG00000165675	Ecto-NOX disulfide-thiol exchanger 2	X	130623369-130903317	Predicted intracellular proteins	Evidence at protein level	HPA000514	Uncertain		Approved	Nucleus<br>Actin filaments	Renal cancer:1.09e-5 (favourable)	Expressed in all	Expressed in all			endometrium: 20.0	Expressed in all		
GHITM	DERP2, HSPC282, My021, PTD010, TMBIM5	ENSG00000165678	Growth hormone inducible transmembrane protein	10	84139440-84153245	Predicted membrane proteins	Evidence at protein level	HPA016464, HPA061664	Approved		Supported	Mitochondria	Renal cancer:2.32e-10 (favourable), Head and neck cancer:1.76e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 352.9	Expressed in all		
CLEC1B	CLEC2	ENSG00000165682	C-type lectin domain family 1 member B	12	9985642-10013424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	liver: 33.7	bone marrow: 5.6	Group enriched	5	Karpas-707: 8.1;U-266/84: 19.9
SNAPC4	FLJ13451, PTFalpha, SNAP190	ENSG00000165684	Small nuclear RNA activating complex polypeptide 4	9	136375577-136400168	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046627, HPA073243	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Pancreatic cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			testis: 20.6	Expressed in all		
TMEM52B	C12orf59, FLJ31166	ENSG00000165685	Transmembrane protein 52B	12	10170542-10191801	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058096	Enhanced		Approved	Focal adhesion sites		Tissue enriched	Tissue enriched	21	kidney: 183.5	placenta: 8.6	Cell line enriched	8	CACO-2: 79.4
PMPCA	Alpha-MPP, INPP5E, KIAA0123	ENSG00000165688	Peptidase, mitochondrial processing alpha subunit	9	136410570-136423761	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021648, HPA063735	Enhanced		Enhanced	Mitochondria	Renal cancer:2.14e-6 (favourable), Pancreatic cancer:8.00e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 38.6	Expressed in all		
SDCCAG3	NY-CO-3	ENSG00000165689	Serologically defined colon cancer antigen 3	9	136401922-136410609	Predicted intracellular proteins	Evidence at protein level	HPA029303	Approved				Renal cancer:8.50e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 36.4	Expressed in all		
FRMD7	FLJ43346, NYS, NYS1	ENSG00000165694	FERM domain containing 7	X	132076993-132128020	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000886	Uncertain					Not detected	Tissue enhanced		endometrium: 2.8;kidney: 3.0;smooth muscle: 3.5	seminal vesicle: 0.7	Cell line enhanced		U-87 MG: 1.5
AK8	C9orf98, FLJ32704	ENSG00000165695	Adenylate kinase 8	9	132725578-132878777	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021443, HPA021445, HPA023894	Enhanced				Renal cancer:1.61e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 16.0;fallopian tube: 30.0;testis: 21.7	thyroid gland: 5.8	Cell line enhanced		MCF7: 1.8;RPTEC TERT1: 2.0;T-47d: 1.6
SPACA9	C9orf9, Mast	ENSG00000165698	Sperm acrosome associated 9	9	132878027-132890201	Predicted intracellular proteins	Evidence at protein level	HPA022243, HPA051600	Enhanced		Approved	Mitochondria	Renal cancer:8.31e-4 (favourable), Endometrial cancer:8.61e-4 (favourable)	Expressed in all	Group enriched	5	epididymis: 90.3;fallopian tube: 63.1;testis: 130.1	thyroid gland: 18.0	Mixed		
TSC1	hamartin, KIAA0243, LAM, TSC	ENSG00000165699	Tuberous sclerosis 1	9	132891348-132944633	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011568, CAB012481, HPA074132	Supported		Enhanced	Cytosol	Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.7	Expressed in all		
GFI1B	ZNF163B	ENSG00000165702	Growth factor independent 1B transcriptional repressor	9	132944000-132991687	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004420	Enhanced					Not detected	Tissue enriched	15	bone marrow: 23.8	testis: 1.5	Group enriched	6	HEL: 151.4;HMC-1: 92.4;K-562: 47.5
HPRT1	HGPRT, HPRT	ENSG00000165704	Hypoxanthine phosphoribosyltransferase 1	X	134460153-134520513	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006360, CAB012200	Enhanced		Supported	Cytosol	Head and neck cancer:1.35e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Mixed		
BORCS5	LOH12CR1, LOH1CR12	ENSG00000165714	BLOC-1 related complex subunit 5	12	12357079-12469694	Predicted intracellular proteins	Evidence at protein level	HPA039509, HPA043627	Approved		Supported	Cytosol	Liver cancer:3.47e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex,epididymis: 7.4	Expressed in all		
FAM69B	C9orf136, MGC20262	ENSG00000165716	Family with sequence similarity 69 member B	9	136712570-136724050	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046812, HPA054443	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Vesicles	Colorectal cancer:1.77e-5 (unfavourable), Pancreatic cancer:9.48e-5 (favourable)	Expressed in all	Mixed			placenta: 29.6	Cell line enhanced		EFO-21: 67.2;HEK 293: 59.7;HUVEC TERT2: 67.6
ZMYND19	MIZIP	ENSG00000165724	Zinc finger MYND-type containing 19	9	137582079-137590490	Predicted intracellular proteins	Evidence at protein level	HPA020642, HPA050761	Supported		Approved	Golgi apparatus<br>Vesicles	Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 46.1	Expressed in all		
STOX1	C10orf24, FLJ25162	ENSG00000165730	Storkhead box 1	10	68827541-68895432	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA037844, HPA037845	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol	Breast cancer:3.37e-5 (favourable), Lung cancer:2.08e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 20.0	cerebral cortex: 14.0	Cell line enhanced		AN3-CA: 8.0;HAP1: 8.3
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
DDX21	GURDB, RH-II/GU	ENSG00000165732	DExD-box helicase 21	10	68956128-68985073	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036592, HPA036593	Enhanced		Enhanced	Nucleus<br>Nucleoli	Pancreatic cancer:3.12e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 71.2	Expressed in all		
BMS1	BMS1L, KIAA0187	ENSG00000165733	BMS1, ribosome biogenesis factor	10	42782801-42834937	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036589, HPA043081	Uncertain		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.06e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.3	Expressed in all		
STK32C	MGC23665, PKE, YANK3	ENSG00000165752	Serine/threonine kinase 32C	10	132207492-132331847	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017894	Uncertain				Liver cancer:1.68e-6 (unfavourable), Renal cancer:5.31e-6 (unfavourable), Endometrial cancer:1.09e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 52.6	Expressed in all		
KIAA1462	JCAD	ENSG00000165757	KIAA1462	10	30012800-30115494	Predicted intracellular proteins	Evidence at protein level	HPA017956	Enhanced		Supported	Vesicles<br>Cell Junctions	Stomach cancer:2.01e-4 (unfavourable), Renal cancer:2.54e-4 (unfavourable)	Expressed in all	Mixed			placenta: 48.7	Cell line enhanced		HUVEC TERT2: 25.1;TIME: 55.5
OR4K2		ENSG00000165762	Olfactory receptor family 4 subfamily K member 2	14	19876232-19877309	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FUNDC2	DC44, HCBP6	ENSG00000165775	FUN14 domain containing 2	X	155025980-155060303	Predicted intracellular proteins	Evidence at protein level	HPA059129	Approved				Liver cancer:3.78e-5 (unfavourable), Endometrial cancer:7.26e-4 (unfavourable), Cervical cancer:9.20e-4 (favourable)	Expressed in all	Expressed in all			ovary: 7.8	Expressed in all		
TMEM55B	C14orf9, MGC26684	ENSG00000165782	Transmembrane protein 55B	14	20457719-20461612	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048528	Approved				Renal cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 42.0	Expressed in all		
METTL17	FLJ20859, METT11D1	ENSG00000165792	Methyltransferase like 17	14	20989770-20997035	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002955, HPA059802	Uncertain		Enhanced	Nucleus		Expressed in all	Expressed in all			adrenal gland: 23.7	Expressed in all		
SLC39A2	ZIP2	ENSG00000165794	Solute carrier family 39 member 2	14	20999255-21001871	Predicted membrane proteins	Evidence at protein level	HPA030489	Uncertain					Mixed	Group enriched	11	esophagus: 19.0;prostate: 19.2;seminal vesicle: 46.9;skin: 34.1	breast: 2.6	Cell line enriched	67	HaCaT: 20.5
NDRG2	KIAA1248, SYLD	ENSG00000165795	NDRG family member 2	14	21016763-21070872	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002896, HPA003590, CAB017491	Enhanced		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.43e-12 (favourable), Liver cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1029.5	Cell line enhanced		Hep G2: 38.7
RNASE7	RAE1	ENSG00000165799	Ribonuclease A family member 7	14	21042226-21044234	Predicted secreted proteins	Evidence at protein level	HPA005690, CAB062560, CAB068225	Enhanced					Tissue enhanced	Tissue enhanced		esophagus: 72.0;skin: 29.2;tonsil: 19.6	gallbladder: 11.1	Cell line enhanced		HBEC3-KT: 17.9;hTCEpi: 7.6;hTERT-HME1: 40.4
ARHGEF40	FLJ10357, solo	ENSG00000165801	Rho guanine nucleotide exchange factor 40	14	21070270-21090240	Predicted intracellular proteins	Evidence at protein level	HPA030746, HPA030757	Uncertain					Expressed in all	Expressed in all			adrenal gland: 32.5	Mixed		
NSMF	NELF	ENSG00000165802	NMDA receptor synaptonuclear signaling and neuronal migration factor	9	137447570-137459334	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044316	Enhanced		Supported	Nucleoplasm	Renal cancer:1.85e-6 (favourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 189.6	duodenum: 36.2	Mixed		
ZNF219		ENSG00000165804	Zinc finger protein 219	14	21090046-21104722	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030761, HPA056168	Approved		Supported	Nucleus		Expressed in all	Expressed in all			skin: 44.0	Expressed in all		
C12orf50	FLJ35821	ENSG00000165805	Chromosome 12 open reading frame 50	12	87980035-88034037	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	880	testis: 87.9	all non-specific tissues: 0.0	Not detected		
CASP7	CMH-1, ICE-LAP3, MCH3	ENSG00000165806	Caspase 7	10	113679162-113730907	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025563	Approved				Breast cancer:2.11e-4 (favourable), Renal cancer:5.90e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 74.4	Mixed		
PPP1R36	C14orf50	ENSG00000165807	Protein phosphatase 1 regulatory subunit 36	14	64549902-64589380	Predicted intracellular proteins	Evidence at protein level	HPA077492	Enhanced					Mixed	Group enriched	6	fallopian tube: 17.4;testis: 58.9	duodenum: 6.6	Group enriched	6	CAPAN-2: 12.6;SCLC-21H: 3.4
BTNL9	BTN8, FLJ32535	ENSG00000165810	Butyrophilin like 9	5	181040225-181061523	Predicted membrane proteins	Evidence at protein level	HPA043429			Approved	Nuclear membrane<br>Vesicles	Liver cancer:1.55e-9 (favourable), Endometrial cancer:7.51e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 166.9	lung: 55.8	Cell line enhanced		U-2 OS: 5.7;U-698: 25.5
CCDC186	C10orf118, FLJ10188, FLJ35301	ENSG00000165813	Coiled-coil domain containing 186	10	114120862-114174220	Predicted intracellular proteins	Evidence at protein level	HPA014569, HPA018019	Approved		Approved	Golgi apparatus	Renal cancer:7.65e-8 (favourable)	Expressed in all	Expressed in all			testis: 32.3	Mixed		
VWA2	AMACO, CCSP-2, FLJ16213, FLJ45857, NET42	ENSG00000165816	Von Willebrand factor A domain containing 2	10	114239330-114291513	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037847	Uncertain					Mixed	Tissue enhanced		fallopian tube: 11.0	stomach: 7.8	Group enriched	6	CAPAN-2: 5.9;HaCaT: 2.7;SCLC-21H: 2.1
METTL3	M6A, MT-A70, Spo8	ENSG00000165819	Methyltransferase like 3	14	21498133-21511375	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.19e-5 (unfavourable), Pancreatic cancer:2.72e-4 (favourable), Ovarian cancer:2.78e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.5	Expressed in all		
SALL2	Hsal2, KIAA0360, ZNF795	ENSG00000165821	Spalt like transcription factor 2	14	21521081-21537216	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004162	Approved		Approved	Nucleus<br>Vesicles	Pancreatic cancer:1.23e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 67.9	cerebral cortex: 42.4	Cell line enhanced		AF22: 123.9;NTERA-2: 95.1;SCLC-21H: 50.0
PRAP1	UPA	ENSG00000165828	Proline rich acidic protein 1	10	133347146-133352683	Predicted secreted proteins	Evidence at protein level	HPA038713, HPA052451	Supported		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane		Group enriched	Group enriched	6	duodenum: 928.6;liver: 297.4;small intestine: 1097.7	kidney: 125.6	Group enriched	5	CACO-2: 18.2;Hep G2: 64.2
TRUB1	PUS4	ENSG00000165832	TruB pseudouridine synthase family member 1	10	114938193-114977676	Predicted intracellular proteins	Evidence at protein level	HPA037914, HPA057552	Approved		Supported	Vesicles<br>Actin filaments		Expressed in all	Expressed in all			adrenal gland: 38.5	Expressed in all		
ERICH6B	FAM194B, FLJ32682	ENSG00000165837	Glutamate rich 6B	13	45534522-45615739	Predicted intracellular proteins	Evidence at transcript level	HPA043559	Uncertain					Not detected	Tissue enriched	35	testis: 3.4	all non-specific tissues: 0.0	Not detected		
CYP2C19	CPCJ, CYP2C, P450IIC19	ENSG00000165841	Cytochrome P450 family 2 subfamily C member 19	10	94762624-94853260	Cancer-related genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015066	Supported					Not detected	Tissue enhanced		duodenum: 48.3;liver: 125.6	small intestine: 20.7	Not detected		
ZFYVE1	DFCP1, KIAA1589, PPP1R172, TAFF1, ZNFN2A1	ENSG00000165861	Zinc finger FYVE-type containing 1	14	72969451-73027212	Predicted intracellular proteins	Evidence at protein level	HPA002898	Approved		Supported	Endoplasmic reticulum	Renal cancer:5.07e-12 (favourable)	Expressed in all	Expressed in all			testis: 22.6	Expressed in all		
C10orf82	Em:AC016825.4, MGC33547	ENSG00000165863	Chromosome 10 open reading frame 82	10	116663696-116670264	Predicted intracellular proteins	Evidence at transcript level	HPA043022			Approved	Mitochondria		Mixed	Tissue enriched	25	testis: 111.7	ovary: 4.4	Cell line enhanced		Hep G2: 1.7;NTERA-2: 1.3;T-47d: 3.5
HSPA12A	FLJ13874, KIAA0417	ENSG00000165868	Heat shock protein family A (Hsp70) member 12A	10	116671192-116849741	Predicted intracellular proteins	Evidence at protein level	HPA011273, HPA073244	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.61e-7 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.0	adrenal gland: 26.7	Cell line enhanced		RPTEC TERT1: 46.5
FRAT1		ENSG00000165879	FRAT1, WNT signaling pathway regulator	10	97319267-97321915	Predicted intracellular proteins	Evidence at protein level	CAB046472, HPA055258	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:6.36e-5 (favourable), Head and neck cancer:2.75e-4 (favourable), Cervical cancer:5.92e-4 (favourable)	Expressed in all	Mixed			spleen: 9.2	Mixed		
UBTD1	FLJ11807	ENSG00000165886	Ubiquitin domain containing 1	10	97498868-97571209	Predicted intracellular proteins	Evidence at protein level	HPA034825	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Colorectal cancer:5.54e-4 (unfavourable)	Expressed in all	Mixed			testis: 34.0	Mixed		
ANKRD2	ARPP	ENSG00000165887	Ankyrin repeat domain 2	10	97572499-97583884	Predicted intracellular proteins	Evidence at protein level	HPA040842, HPA040884	Enhanced		Enhanced	Vesicles		Tissue enhanced	Group enriched	14	heart muscle: 35.9;skeletal muscle: 119.4	kidney: 5.6	Cell line enhanced		A-431: 14.1;HaCaT: 11.0;RPTEC TERT1: 10.3
E2F7		ENSG00000165891	E2F transcription factor 7	12	77021247-77065580	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064866			Supported	Nuclear speckles		Mixed	Tissue enhanced		testis: 5.1	bone marrow: 3.0	Mixed		
ARHGAP42	FLJ32810, GRAF3	ENSG00000165895	Rho GTPase activating protein 42	11	100687653-100991937	Predicted intracellular proteins	Evidence at protein level	HPA039924	Enhanced		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			placenta: 23.7	Cell line enhanced		CAPAN-2: 27.8
ISCA2	HBLD1, ISA2	ENSG00000165898	Iron-sulfur cluster assembly 2	14	74493720-74497106	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030492	Approved				Renal cancer:1.68e-7 (favourable), Thyroid cancer:8.98e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 56.6	Expressed in all		
OTOGL	C12orf64, FLJ90579	ENSG00000165899	Otogelin like	12	80209453-80379090	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040364, HPA053392	Uncertain		Approved	Cytosol		Tissue enhanced	Tissue enriched	5	kidney: 6.2	heart muscle: 1.1	Cell line enhanced		SCLC-21H: 1.6;U-2 OS: 1.0;U-87 MG: 2.6
LARGE2	FLJ35207, GYLTL1B, PP5656	ENSG00000165905	LARGE xylosyl- and glucuronyltransferase 2	11	45921621-45929096	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056621	Approved				Renal cancer:3.04e-12 (favourable)	Mixed	Tissue enhanced		placenta: 52.7	parathyroid gland: 21.6	Cell line enhanced		BEWO: 33.3;NTERA-2: 32.6;T-47d: 67.1
PACSIN3	SDPIII	ENSG00000165912	Protein kinase C and casein kinase substrate in neurons 3	11	47177525-47186443	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039480, HPA043904	Approved	Approved	Supported	Plasma membrane<br>Cytosol	Ovarian cancer:2.09e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 164.2	heart muscle: 93.6	Mixed		
TTC7B	TTC7L1	ENSG00000165914	Tetratricopeptide repeat domain 7B	14	90524564-90816479	Predicted intracellular proteins	Evidence at protein level	HPA058363, HPA059577	Enhanced		Supported	Plasma membrane	Renal cancer:3.20e-6 (favourable)	Mixed	Expressed in all			cerebral cortex: 72.6	Mixed		
SLC39A13	FLJ25785	ENSG00000165915	Solute carrier family 39 member 13	11	47407132-47416501	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043971	Approved		Uncertain	Cytosol	Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 58.3	Expressed in all		
PSMC3	TBP-1, TBP1	ENSG00000165916	Proteasome 26S subunit, ATPase 3	11	47418769-47426473	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006065	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.6	Expressed in all		
RAPSN	CMS1D, CMS1E, RNF205	ENSG00000165917	Receptor associated protein of the synapse	11	47437757-47449178	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039475	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Mixed	Tissue enriched	10	skeletal muscle: 30.0	placenta: 2.9	Group enriched	40	LHCN-M2: 47.4;RH-30: 226.0
AGBL2	CCP2, FLJ23598	ENSG00000165923	ATP/GTP binding protein like 2	11	47659591-47715389	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007718	Uncertain					Mixed	Group enriched	7	fallopian tube: 15.3;testis: 22.6	epididymis: 2.8	Cell line enhanced		CAPAN-2: 4.0
TC2N	C14orf47, C2CD1, FLJ36557, MTAC2D1, Tac2-N	ENSG00000165929	Tandem C2 domains, nuclear	14	91779751-91867536	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027549	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:4.13e-5 (favourable), Pancreatic cancer:9.86e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 40.3	Cell line enhanced		CAPAN-2: 16.8;RT4: 29.2;SK-BR-3: 32.5;T-47d: 20.0
CPSF2	KIAA1367	ENSG00000165934	Cleavage and polyadenylation specific factor 2	14	92121937-92172145	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024238	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:4.35e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 47.7	Expressed in all		
SMCO2	C12orf70, LOC341346	ENSG00000165935	Single-pass membrane protein with coiled-coil domains 2	12	27466810-27502185	Predicted membrane proteins	Evidence at protein level	HPA014366	Uncertain					Mixed	Tissue enhanced		testis: 1.3	skin: 0.6	Cell line enhanced		HDLM-2: 2.0
MOAP1	MAP-1, PNMA4	ENSG00000165943	Modulator of apoptosis 1	14	93182196-93184928	Predicted intracellular proteins	Evidence at protein level	HPA000939	Uncertain		Approved	Nucleus<br>Cell Junctions	Lung cancer:7.37e-9 (favourable), Renal cancer:3.15e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 86.1	Expressed in all		
IFI27L1	FAM14B	ENSG00000165948	Interferon alpha inducible protein 27 like 1	14	94081282-94103846	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enhanced		testis: 71.9	ovary: 27.5	Expressed in all		
IFI27	FAM14D, ISG12, P27	ENSG00000165949	Interferon alpha inducible protein 27	14	94104836-94116698	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028875	Uncertain				Ovarian cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			spleen: 729.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1891.1;BJ hTERT+ SV40 Large T+ RasG12V: 1737.9;EFO-21: 516.8
SERPINA12	OL-64, Vaspin	ENSG00000165953	Serpin family A member 12	14	94487274-94517844	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	skin: 349.1	breast: 35.5	Cell line enhanced		Hep G2: 1.5
CLMN	FLJ12383, KIAA0500, KIAA1188	ENSG00000165959	Calmin	14	95181940-95319906	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012634	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.68e-7 (favourable)	Expressed in all	Tissue enhanced		testis: 48.9	kidney: 14.5	Cell line enhanced		WM-115: 15.3
PDZRN4	DKFZp434B0417, FLJ33777, IMAGE5767589, LNX4	ENSG00000165966	PDZ domain containing ring finger 4	12	41188448-41574590	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042101	Enhanced					Tissue enhanced	Tissue enhanced		seminal vesicle: 19.6	prostate: 9.3	Cell line enriched	6	U-266/70: 2.7
SLC6A5	GLYT2, NET1	ENSG00000165970	Solute carrier family 6 member 5	11	20599400-20659285	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.4	testis: 0.6	Not detected		
CCDC38	FLJ40089	ENSG00000165972	Coiled-coil domain containing 38	12	95867048-95942974	Predicted intracellular proteins	Evidence at protein level	HPA039726			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	18	testis: 26.3	liver: 1.4	Not detected		
NELL1	FLJ45906, IDH3GL	ENSG00000165973	Neural EGFL like 1	11	20669551-21575681	Predicted secreted proteins	Evidence at protein level	HPA051535	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 22.9;kidney: 18.8	prostate: 8.8	Cell line enhanced		HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2
PTER		ENSG00000165983	Phosphotriesterase related	10	16436943-16513745	Predicted intracellular proteins	Evidence at protein level	HPA038044, HPA038045	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.52e-6 (favourable), Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 42.7	Mixed		
C1QL3	C1ql, C1QTNF13, CTRP13, K100	ENSG00000165985	Complement C1q like 3	10	16513743-16522005	Predicted secreted proteins	Evidence at protein level						Renal cancer:6.29e-5 (favourable)	Mixed	Tissue enriched	24	cerebral cortex: 43.3	duodenum: 1.8	Group enriched	10	HDLM-2: 29.9;SCLC-21H: 22.4
CACNB2	CACNLB2, MYSB	ENSG00000165995	Calcium voltage-gated channel auxiliary subunit beta 2	10	18140677-18541869	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA035325, HPA035326	Uncertain				Renal cancer:3.56e-5 (favourable)	Mixed	Mixed			cerebral cortex: 26.3	Cell line enhanced		HAP1: 8.3;HSkMC: 7.1
HACD1	CAP, PTPLA	ENSG00000165996	3-hydroxyacyl-CoA dehydratase 1	10	17589032-17617377	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 42.0	smooth muscle: 36.3	Mixed		
ARL5B	ARL8	ENSG00000165997	ADP ribosylation factor like GTPase 5B	10	18659405-18681639	Predicted intracellular proteins	Evidence at protein level	HPA027002	Approved				Liver cancer:1.15e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 27.9	Expressed in all		
SMCO4	C11orf75, FN5	ENSG00000166002	Single-pass membrane protein with coiled-coil domains 4	11	93478472-93543508	Predicted membrane proteins	Evidence at protein level	HPA041120	Uncertain				Renal cancer:5.81e-7 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 97.5	Cell line enhanced		Karpas-707: 102.3
CEP295	KIAA1731	ENSG00000166004	Centrosomal protein 295	11	93661639-93730358	Predicted intracellular proteins	Evidence at protein level	HPA038595, HPA038596, HPA038597	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 22.2	Expressed in all		
KCNC2	Kv3.2	ENSG00000166006	Potassium voltage-gated channel subfamily C member 2	12	75040077-75209868	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA019664, CAB022571	Uncertain		Supported	Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	11	cerebral cortex: 46.4	prostate: 4.3	Not detected		
TAF1D	JOSD3, MGC5306, TAF(I)41	ENSG00000166012	TATA-box binding protein associated factor, RNA polymerase I subunit D	11	93729948-93784391	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055935, HPA060385	Uncertain		Supported	Nucleoplasm<br>Microtubule organizing center	Renal cancer:3.17e-7 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 13.8	Expressed in all		
ABTB2	ABTB2A, BTBD22, DKFZP586C1619	ENSG00000166016	Ankyrin repeat and BTB domain containing 2	11	34150988-34358008	Predicted intracellular proteins	Evidence at protein level	HPA020065, HPA030699	Approved		Supported	Nucleus	Renal cancer:3.51e-5 (favourable), Cervical cancer:5.70e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 13.0	Mixed		
R3HCC1L	C10orf28, GIDRP86, PSORT	ENSG00000166024	R3H domain and coiled-coil containing 1 like	10	98134624-98244897	Predicted intracellular proteins	Evidence at protein level	HPA037367	Approved		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Expressed in all			testis: 38.9	Expressed in all		
AMOTL1	JEAP	ENSG00000166025	Angiomotin like 1	11	94706431-94876753	Predicted intracellular proteins	Evidence at protein level	HPA001196	Approved		Supported	Cell Junctions<br>Cytosol	Renal cancer:5.03e-6 (favourable)	Expressed in all	Expressed in all			prostate: 52.5	Mixed		
HTRA1	ARMD7, HtrA, IGFBP5-protease, PRSS11	ENSG00000166033	HtrA serine peptidase 1	10	122461525-122514908	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036655	Enhanced		Supported	Plasma membrane	Renal cancer:7.90e-7 (unfavourable), Urothelial cancer:5.62e-6 (unfavourable), Glioma:8.66e-4 (unfavourable)	Expressed in all	Mixed			ovary: 503.4	Cell line enhanced		ASC diff: 1649.0;HSkMC: 1139.5;LHCN-M2: 1027.1;U-87 MG: 974.2
LIPC	HL, HTGL	ENSG00000166035	Lipase C, hepatic type	15	58410569-58569843	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	14	liver: 86.4	kidney: 6.3	Cell line enhanced		CACO-2: 6.9;EFO-21: 5.7;Hep G2: 16.4;HMC-1: 6.0;U-2197: 17.2
CEP57	KIAA0092, Translokin, TSP57	ENSG00000166037	Centrosomal protein 57	11	95789965-95832693	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018315	Approved		Supported	Microtubules<br>Cytosol	Glioma:3.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 53.9	Expressed in all		
TCP11L2	MGC40368	ENSG00000166046	T-complex 11 like 2	12	106301929-106347015	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039483, HPA042188	Uncertain		Supported	Nuclear speckles	Head and neck cancer:9.52e-4 (favourable)	Mixed	Expressed in all			lung: 25.9	Mixed		
PASD1	CT63	ENSG00000166049	PAS domain containing repressor 1	X	151563622-151676739	Predicted intracellular proteins	Evidence at protein level	HPA011122, HPA011152	Enhanced		Supported	Nuclear speckles		Mixed	Tissue enriched	298	testis: 29.8	all non-specific tissues: 0.0	Group enriched	7	BEWO: 33.0;HMC-1: 47.7;U-266/84: 19.0
SPRED1	FLJ33903, PPP1R147	ENSG00000166068	Sprouty related EVH1 domain containing 1	15	38252326-38357249	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042193, HPA061805	Approved		Supported	Nucleus	Renal cancer:7.37e-5 (unfavourable), Stomach cancer:8.29e-5 (unfavourable), Endometrial cancer:7.08e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 48.2	Mixed		
TMCO5A	MGC35118, TMCO5	ENSG00000166069	Transmembrane and coiled-coil domains 5A	15	37921939-37967724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056530	Enhanced					Not detected	Tissue enriched	195	testis: 123.0	fallopian tube: 0.6	Not detected		
GPR176	Gm1012	ENSG00000166073	G protein-coupled receptor 176	15	39799032-39920892	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA039943, HPA039979	Approved				Renal cancer:9.38e-7 (unfavourable), Stomach cancer:6.84e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 18.4	Cell line enhanced		BJ hTERT+: 243.3;fHDF/TERT166: 159.0
JAM3	JAM-C, JAMC	ENSG00000166086	Junctional adhesion molecule 3	11	134068925-134152001	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003417, HPA050434	Uncertain		Enhanced	Golgi apparatus	Urothelial cancer:2.68e-4 (unfavourable), Renal cancer:3.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 144.4	Cell line enhanced		RH-30: 119.8
IL25	IL-17E, IL-25, IL17E	ENSG00000166090	Interleukin 25	14	23372809-23376403	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024864	Approved					Not detected	Not detected			testis: 0.3	Not detected		
CMTM5	CKLFSF5, FLJ37521	ENSG00000166091	CKLF like MARVEL transmembrane domain containing 5	14	23376808-23379772	Predicted membrane proteins	Evidence at protein level	HPA052338	Enhanced		Approved	Golgi apparatus<br>Vesicles		Group enriched	Tissue enriched	20	cerebral cortex: 81.3	seminal vesicle: 4.1	Cell line enriched	6	HEL: 73.9
GLB1L3	FLJ90231	ENSG00000166105	Galactosidase beta 1 like 3	11	134274245-134319564	Predicted intracellular proteins	Evidence at protein level	HPA039916	Uncertain				Lung cancer:1.97e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 14.5;seminal vesicle: 7.0	cerebral cortex: 4.0	Cell line enhanced		HEK 293: 5.2;NTERA-2: 3.5;PC-3: 4.3;SCLC-21H: 8.6
ADAMTS15		ENSG00000166106	ADAM metallopeptidase with thrombospondin type 1 motif 15	11	130448974-130476641	Predicted secreted proteins	Evidence at transcript level	HPA042867	Uncertain		Approved	Cytosol	Urothelial cancer:5.63e-5 (unfavourable), Glioma:9.00e-4 (favourable), Lung cancer:9.72e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 30.3;placenta: 23.7	breast: 11.0	Cell line enhanced		ASC diff: 49.3;ASC TERT1: 30.1;EFO-21: 34.5
SVOP	DKFZp761H039	ENSG00000166111	SV2 related protein	12	108907741-109021240	Predicted membrane proteins	Evidence at protein level	HPA016573	Uncertain					Group enriched	Tissue enriched	15	cerebral cortex: 32.2	adrenal gland: 2.0	Cell line enhanced		Karpas-707: 2.0;RPMI-8226: 2.0;SCLC-21H: 1.8;SH-SY5Y: 1.4
SPATA19	CT132, FLJ25851, SPAS1, spergen1	ENSG00000166118	Spermatogenesis associated 19	11	133840631-133845538	Predicted intracellular proteins	Evidence at protein level	HPA040082	Enhanced					Not detected	Tissue enriched	509	testis: 142.8	esophagus: 0.2	Not detected		
GPT2	ALT2	ENSG00000166123	Glutamic--pyruvic transaminase 2	16	46884378-46931297	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051514	Approved		Approved	Mitochondria	Ovarian cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 85.0	Mixed		
AMN	amnionless	ENSG00000166126	Amnion associated transmembrane protein	14	102922656-102933596	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000817	Approved				Renal cancer:9.62e-5 (favourable)	Mixed	Group enriched	6	colon: 20.0;duodenum: 34.2;kidney: 29.0;small intestine: 70.6	liver: 6.7	Cell line enhanced		CACO-2: 6.8;Hep G2: 5.6;U-698: 3.0
RAB8B		ENSG00000166128	RAB8B, member RAS oncogene family	15	63189469-63267782	Predicted intracellular proteins	Evidence at protein level	HPA074534			Supported	Nucleoplasm<br>Vesicles	Renal cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.6	Expressed in all		
IKBIP	FLJ31051, IKIP	ENSG00000166130	IKBKB interacting protein	12	98613405-98645113	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038677, HPA038678, HPA061541	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:4.60e-9 (unfavourable), Liver cancer:4.00e-5 (unfavourable)	Expressed in all	Mixed			placenta: 36.6	Expressed in all		
RPUSD2	C15orf19, C18B11, FLJ31409	ENSG00000166133	RNA pseudouridylate synthase domain containing 2	15	40569300-40574943	Predicted intracellular proteins	Evidence at protein level	HPA042079, HPA042194	Approved		Approved	Nucleoplasm<br>Microtubules	Renal cancer:7.63e-7 (favourable)	Expressed in all	Mixed			lymph node: 7.7	Expressed in all		
HIF1AN	DKFZp762F1811, FIH1, FLJ20615, FLJ22027	ENSG00000166135	Hypoxia inducible factor 1 alpha subunit inhibitor	10	100529072-100559998	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048742, HPA065302, CAB069903	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 25.7	Expressed in all		
NDUFB8	ASHI, CI-ASHI	ENSG00000166136	NADH:ubiquinone oxidoreductase subunit B8	10	100523740-100530000	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA003886	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 306.4	Expressed in all		
ZFYVE19	ANCHR, FLJ14840	ENSG00000166140	Zinc finger FYVE-type containing 19	15	40807086-40815084	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040283, HPA041946	Uncertain				Endometrial cancer:7.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.3	Expressed in all		
PPP1R14D	CPI17-like, FLJ20251, GBPI-1, MGC119014, MGC119016	ENSG00000166143	Protein phosphatase 1 regulatory inhibitor subunit 14D	15	40815445-40828709	Predicted intracellular proteins	Evidence at protein level	HPA041846	Uncertain				Renal cancer:3.07e-4 (unfavourable)	Tissue enhanced	Group enriched	7	colon: 105.5;duodenum: 111.1;gallbladder: 24.2;rectum: 100.0;small intestine: 89.8	appendix: 12.4	Cell line enhanced		RPMI-8226: 2.1;RT4: 1.5;U-266/84: 1.4
SPINT1	HAI, MANSC2	ENSG00000166145	Serine peptidase inhibitor, Kunitz type 1	15	40844018-40858207	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006903, HPA031178	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 217.3	Cell line enhanced		BEWO: 311.8;HaCaT: 333.0;RT4: 245.6;SK-BR-3: 418.2;T-47d: 251.3
FBN1	FBN, MASS, MFS1, OCTD, SGS, WMS	ENSG00000166147	Fibrillin 1	15	48408306-48645849	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002670, HPA017759, HPA021057, CAB058696, CAB068188	Enhanced		Approved	Cytosol	Renal cancer:7.44e-5 (unfavourable), Urothelial cancer:5.11e-4 (unfavourable), Stomach cancer:6.57e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 107.5	adipose tissue: 70.8	Cell line enhanced		ASC TERT1: 315.9;fHDF/TERT166: 318.3;U-138 MG: 199.6;U-2197: 276.9
AVPR1A	AVPR1	ENSG00000166148	Arginine vasopressin receptor 1A	12	63142759-63150942	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 77.8	adipose tissue: 20.0	Group enriched	8	ASC diff: 3.9;Karpas-707: 9.4;U-266/84: 6.8
C16orf78	MGC33367	ENSG00000166152	Chromosome 16 open reading frame 78	16	49373823-49399431	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	516	testis: 71.0	spleen: 0.1	Not detected		
DEPDC4	DEP.4, FLJ33505	ENSG00000166153	DEP domain containing 4	12	100203669-100267079	Predicted intracellular proteins	Evidence at protein level	HPA039323	Uncertain		Approved	Microtubules		Mixed	Tissue enhanced		testis: 7.2	kidney: 1.8	Mixed		
LRTM2		ENSG00000166159	Leucine rich repeats and transmembrane domains 2	12	1820267-1836752	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055094	Uncertain					Not detected	Tissue enriched	47	cerebral cortex: 8.3	testis: 0.1	Group enriched	12	HEL: 7.7;SCLC-21H: 5.2
OPN1MW2		ENSG00000166160	Opsin 1, medium wave sensitive 2	X	154219756-154233286	Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BRD7	BP75, CELTIX1	ENSG00000166164	Bromodomain containing 7	16	50313487-50368934	Predicted intracellular proteins	Evidence at protein level	HPA042389, CAB046458, HPA060171	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-4 (favourable), Melanoma:5.38e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 106.6	Expressed in all		
CKB	CKBB	ENSG00000166165	Creatine kinase B	14	103519659-103523111	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001254, CAB047313	Enhanced		Supported	Cytosol	Renal cancer:4.02e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 475.1	Cell line enhanced		CACO-2: 340.9;HEK 293: 940.9;SCLC-21H: 678.1
TRMT61A	C14orf172, FLJ40452, GCD14, Gcd14p, hTRM61	ENSG00000166166	TRNA methyltransferase 61A	14	103529184-103537073	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.60e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 10.1	Expressed in all		
BTRC	beta-TrCP1, betaTrCP, bTrCP, bTrCP1, FBXW1A, Fwd1	ENSG00000166167	Beta-transducin repeat containing E3 ubiquitin protein ligase	10	101354033-101557321	Predicted intracellular proteins	Evidence at protein level	HPA031156, CAB032986	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 34.0	Expressed in all		
POLL		ENSG00000166169	DNA polymerase lambda	10	101578882-101588270	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066704			Enhanced	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 49.9	Mixed		
BAG5		ENSG00000166170	BCL2 associated athanogene 5	14	103556544-103562831	Predicted intracellular proteins	Evidence at protein level	HPA016429	Enhanced		Supported	Vesicles	Renal cancer:1.58e-8 (favourable)	Expressed in all	Tissue enriched	6	testis: 241.5	thyroid gland: 38.5	Expressed in all		
DPCD	DKFZP566F084, RP11-529I10.4	ENSG00000166171	Deleted in primary ciliary dyskinesia homolog (mouse)	10	101570560-101609668	Predicted intracellular proteins	Evidence at protein level	HPA036603, HPA036604	Enhanced		Approved	Nuclear speckles	Endometrial cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 153.2	Mixed		
LARP6	acheron, FLJ11196	ENSG00000166173	La ribonucleoprotein domain family member 6	15	70829130-70854159	Predicted intracellular proteins	Evidence at protein level	HPA020338, HPA049029	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:9.90e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 84.7	thyroid gland: 40.7	Cell line enhanced		U-2197: 216.0
API5	AAC-11, AAC11, API5L1	ENSG00000166181	Apoptosis inhibitor 5	11	43311963-43344529	Predicted intracellular proteins	Evidence at protein level	HPA026598	Approved		Enhanced	Nuclear speckles	Renal cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 95.8	Expressed in all		
ASPG	C14orf76	ENSG00000166183	Asparaginase	14	104085679-104115581	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069761	Enhanced					Tissue enhanced	Tissue enhanced		liver: 29.5	esophagus: 13.9	Not detected		
ZNF319	KIAA1388, Zfp319	ENSG00000166188	Zinc finger protein 319	16	57994668-58000453	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052584	Uncertain		Approved	Nucleus	Pancreatic cancer:5.87e-5 (favourable), Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.9	Expressed in all		
HPS6	BLOC2S3, FLJ22501	ENSG00000166189	HPS6, biogenesis of lysosomal organelles complex 2 subunit 3	10	102065390-102068038	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040687	Approved					Expressed in all	Expressed in all			fallopian tube: 12.0	Expressed in all		
SENP8	DEN1, HsT17512, NEDP1, PRSC2	ENSG00000166192	SUMO/sentrin peptidase family member, NEDD8 specific	15	72114258-72143688	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036273	Approved		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		testis: 27.7	thyroid gland: 8.3	Expressed in all		
NOLC1	KIAA0035, NOPP130, NOPP140, P130	ENSG00000166197	Nucleolar and coiled-body phosphoprotein 1	10	102152176-102163871	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032654, HPA037366, HPA050388	Supported		Enhanced	Nucleoli	Thyroid cancer:8.25e-5 (unfavourable), Renal cancer:9.19e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.2	Expressed in all		
ALKBH3	DEPC-1	ENSG00000166199	AlkB homolog 3, alpha-ketoglutaratedependent dioxygenase	11	43880811-43920266	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA009674, HPA046489	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			epididymis: 32.4	Mixed		
COPS2	ALIEN, CSN2, TRIP15	ENSG00000166200	COP9 signalosome subunit 2	15	49106068-49155661	Predicted intracellular proteins	Evidence at protein level	HPA016867, HPA018271, HPA061071	Approved		Enhanced	Vesicles<br>Cytokinetic bridge		Expressed in all	Expressed in all			thyroid gland: 103.5	Expressed in all		
GABRB3		ENSG00000166206	Gamma-aminobutyric acid type A receptor beta3 subunit	15	26543546-26939539	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 78.3	gallbladder: 21.5	Cell line enhanced		A549: 61.5;HAP1: 28.7;NTERA-2: 48.0;SCLC-21H: 51.8
SPIC	MGC40611, SPI-C	ENSG00000166211	Spi-C transcription factor	12	101475421-101486997	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	12	spleen: 46.7	lymph node: 3.9	Not detected		
TBATA	C10orf27, FLJ32820, spatial	ENSG00000166220	Thymus, brain and testes associated	10	70771239-70785401	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 32.0	spleen: 1.1	Cell line enriched	28	SK-BR-3: 3.0
SGPL1	SPL	ENSG00000166224	Sphingosine-1-phosphate lyase 1	10	70815961-70881173	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA021125, HPA023086	Enhanced		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			skin: 34.5	Expressed in all		
FRS2	FRS2A, FRS2alpha, SNT-1, SNT1	ENSG00000166225	Fibroblast growth factor receptor substrate 2	12	69470349-69579789	Predicted intracellular proteins	Evidence at protein level	HPA038323			Approved	Cell Junctions		Expressed in all	Expressed in all			parathyroid gland: 27.6	Expressed in all		
CCT2	Cctb	ENSG00000166226	Chaperonin containing TCP1 subunit 2	12	69585334-69601570	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003197, HPA003198	Enhanced		Supported	Cytosol	Liver cancer:3.61e-9 (unfavourable), Prostate cancer:3.67e-4 (unfavourable), Head and neck cancer:8.38e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 367.6	Expressed in all		
PCBD1	DCOH, PCBD, PCD	ENSG00000166228	Pterin-4 alpha-carbinolamine dehydratase 1	10	70882280-70888784	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037575, HPA061723	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 157.7	Mixed		
ARIH1	ARI, HARI, HHARI, UBCH7BP	ENSG00000166233	Ariadne RBR E3 ubiquitin protein ligase 1	15	72474326-72602985	Predicted intracellular proteins	Evidence at protein level	HPA003295, HPA073245	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
C16orf71	DKFZp686H2240, FLJ43261	ENSG00000166246	Chromosome 16 open reading frame 71	16	4734272-4749396	Predicted intracellular proteins	Evidence at protein level	HPA049468	Enhanced		Uncertain	Nuclear speckles	Endometrial cancer:7.49e-4 (favourable)	Mixed	Group enriched	17	fallopian tube: 35.8;testis: 113.1	lung: 4.3	Mixed		
CLMP	ACAM, ASAM, FLJ22415	ENSG00000166250	CXADR like membrane protein	11	123069865-123195281	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			adipose tissue: 65.1	Cell line enhanced		BJ: 143.8;U-138 MG: 227.7
SCN3B	HSA243396	ENSG00000166257	Sodium voltage-gated channel beta subunit 3	11	123629187-123655244	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA041707			Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enriched	11	cerebral cortex: 132.1	adrenal gland: 11.5	Cell line enhanced		hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
COX11	COX11P	ENSG00000166260	COX11, cytochrome c oxidase copper chaperone	17	54951902-54968785	Predicted membrane proteins	Evidence at protein level	HPA044020	Approved				Colorectal cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 60.8	Expressed in all		
ZNF202	ZKSCAN10, ZSCAN42	ENSG00000166261	Zinc finger protein 202	11	123724177-123741675	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:9.93e-7 (unfavourable), Liver cancer:2.52e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 16.7	Expressed in all		
FAM227B	C15orf33, FLJ32800	ENSG00000166262	Family with sequence similarity 227 member B	15	49326962-49620931	Predicted intracellular proteins	Evidence at protein level	HPA049774, HPA061695	Uncertain		Approved	Nuclear speckles		Mixed	Expressed in all			testis: 21.4	Mixed		
STXBP4	MGC50337, Synip	ENSG00000166263	Syntaxin binding protein 4	17	54968727-55173632	Predicted intracellular proteins	Evidence at protein level	CAB007760, HPA022138, HPA022888, HPA024227	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			parathyroid gland: 12.5	Mixed		
CYYR1	C21orf95	ENSG00000166265	Cysteine and tyrosine rich 1	21	26466209-26573284	Predicted membrane proteins	Evidence at transcript level	CAB034921, HPA067685	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			adrenal gland: 60.2	Cell line enhanced		AF22: 13.8;NTERA-2: 39.4;RH-30: 16.1;SCLC-21H: 39.7
CUL5	VACM-1	ENSG00000166266	Cullin 5	11	108008733-108107776	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA002185, CAB017787	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 25.9	Expressed in all		
MYRFL	bcm1377, C12orf15, C12orf28, FLJ25056	ENSG00000166268	Myelin regulatory factor-like	12	69825304-69959097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049340	Approved		Approved	Nucleoli		Mixed	Group enriched	5	duodenum: 23.7;small intestine: 24.0	testis: 4.3	Cell line enhanced		NTERA-2: 5.2;T-47d: 11.1
WBP1L	C10orf26, FLJ20154, OPAL1	ENSG00000166272	WW domain binding protein 1-like	10	102743970-102816267	Predicted membrane proteins	Evidence at protein level	HPA037635, HPA038371	Uncertain		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.56e-6 (favourable), Endometrial cancer:4.03e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 69.9	Expressed in all		
BORCS7	C10orf32, FLJ40752	ENSG00000166275	BLOC-1 related complex subunit 7	10	102854223-102864961	Predicted intracellular proteins	Evidence at protein level	HPA037648	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:9.08e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
C2		ENSG00000166278	Complement C2	6	31897785-31945672	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016775	Supported				Renal cancer:2.64e-7 (unfavourable)	Tissue enriched	Tissue enhanced		liver: 86.3;lung: 42.6	placenta: 21.9	Group enriched	5	Hep G2: 30.0;Karpas-707: 94.7
PLEKHF1	APPD, MGC4090, PHAFIN1, ZFYVE15	ENSG00000166289	Pleckstrin homology and FYVE domain containing 1	19	29665056-29675457	Predicted intracellular proteins	Evidence at protein level	HPA025925	Uncertain				Renal cancer:1.54e-5 (unfavourable), Urothelial cancer:4.54e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 18.6	Cell line enhanced		BEWO: 33.0
TMEM100	FLJ10970, FLJ37856	ENSG00000166292	Transmembrane protein 100	17	55719627-55732121	Predicted membrane proteins	Evidence at protein level	HPA055936	Approved		Uncertain	Nucleoplasm	Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 131.2;placenta: 78.3	epididymis: 44.5	Cell line enhanced		ASC diff: 19.9;ASC TERT1: 13.7;HHSteC: 37.7;HSkMC: 15.0;U-87 MG: 13.6;WM-115: 11.8
ANAPC16	APC16, bA570G20.3, C10orf104, CENP-27, FLJ33728	ENSG00000166295	Anaphase promoting complex subunit 16	10	72216000-72235860	Predicted intracellular proteins	Evidence at protein level	HPA037815	Approved		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 40.2	Expressed in all		
SMPD1	ASM	ENSG00000166311	Sphingomyelin phosphodiesterase 1	11	6390431-6394998	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.57e-6 (favourable), Glioma:1.09e-4 (unfavourable), Pancreatic cancer:7.47e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.5	Mixed		
APBB1	Fe65, RIR	ENSG00000166313	Amyloid beta precursor protein binding family B member 1	11	6395124-6419414	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022104, HPA038521, HPA038522	Approved		Enhanced	Plasma membrane	Renal cancer:7.44e-13 (favourable), Pancreatic cancer:1.86e-5 (favourable), Liver cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 236.5	Cell line enhanced		SCLC-21H: 81.4
SYNPO2L	FLJ12921	ENSG00000166317	Synaptopodin 2 like	10	73644881-73663803	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055192, HPA057142	Enhanced		Approved	Nuclear speckles<br>Cell Junctions<br>Cytosol		Group enriched	Group enriched	12	heart muscle: 168.4;skeletal muscle: 95.9	esophagus: 11.1	Cell line enhanced		CACO-2: 3.4;HSkMC: 2.3;RH-30: 3.0;SK-BR-3: 2.5
NUDT13	DKFZp586P2219	ENSG00000166321	Nudix hydrolase 13	10	73110375-73131828	Predicted intracellular proteins	Evidence at transcript level	HPA040636	Approved		Approved	Nucleus		Mixed	Mixed			epididymis,parathyroid gland: 4.7	Mixed		
C11orf65	MGC33948	ENSG00000166323	Chromosome 11 open reading frame 65	11	108308519-108467531	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	26	testis: 94.0	epididymis: 3.6	Mixed		
TRIM44	DIPB, MC7	ENSG00000166326	Tripartite motif containing 44	11	35662805-35818007	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049053, HPA057633	Approved		Approved	Vesicles<br>Plasma membrane	Liver cancer:5.24e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.7	Mixed		
CCDC182		ENSG00000166329	Coiled-coil domain containing 182	17	57744481-57745312	Predicted intracellular proteins	Evidence at transcript level	HPA023446	Uncertain					Not detected	Tissue enriched	211	testis: 21.0	all non-specific tissues: 0.0	Not detected		
ILK		ENSG00000166333	Integrin linked kinase	11	6603708-6610874	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004041, HPA048437	Enhanced		Enhanced	Cell Junctions<br>Focal adhesion sites	Renal cancer:2.44e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 558.8	Expressed in all		
TAF10	TAF2A, TAF2H, TAFII30	ENSG00000166337	TATA-box binding protein associated factor 10	11	6606296-6612667	Predicted intracellular proteins	Evidence at protein level	HPA004148, CAB022405	Supported		Supported	Nucleoplasm	Renal cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 133.2	Expressed in all		
TPP1	CLN2, SCAR7	ENSG00000166340	Tripeptidyl peptidase 1	11	6612763-6619461	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037709, HPA044868	Enhanced				Liver cancer:1.11e-4 (unfavourable), Head and neck cancer:4.31e-4 (unfavourable), Stomach cancer:4.46e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 206.9	Expressed in all		
DCHS1	CDH25, CDHR6, FIB1, FLJ11790, KIAA1773, PCDH16	ENSG00000166341	Dachsous cadherin-related 1	11	6621323-6655854	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA017970, HPA050246	Approved		Approved	Plasma membrane	Renal cancer:9.32e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 29.6	Cell line enhanced		AF22: 32.9;HUVEC TERT2: 39.1;REH: 21.3;SH-SY5Y: 34.2
NETO1	BCTL1, BTCL1	ENSG00000166342	Neuropilin and tolloid like 1	18	72742314-72868146	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA064630			Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	16	cerebral cortex: 64.0	spleen: 4.1	Cell line enhanced		MOLT-4: 22.4;REH: 24.8;RPMI-8226: 30.0;RT4: 22.5;SCLC-21H: 43.0
MSS51	FLJ39565, ZMYND17	ENSG00000166343	MSS51 mitochondrial translational activator	10	73423579-73433561	Predicted intracellular proteins	Evidence at protein level	HPA038564			Uncertain	Vesicles<br>Cytosol		Mixed	Group enriched	15	parathyroid gland: 162.6;skeletal muscle: 81.4	heart muscle: 8.3	Mixed		
CYB5A	CYB5	ENSG00000166347	Cytochrome b5 type A	18	74250847-74292016	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006333, HPA047548, HPA058547	Enhanced		Approved	Vesicles<br>Cytosol	Liver cancer:4.15e-4 (favourable), Colorectal cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			liver: 1260.1	Cell line enhanced		ASC diff: 766.9
USP54	bA137L10.3, bA137L10.4, C10orf29, FLJ37318	ENSG00000166348	Ubiquitin specific peptidase 54	10	73497538-73625953	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047663	Approved		Approved	Mitochondria	Lung cancer:7.00e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 59.6	cerebral cortex: 30.7	Cell line enhanced		PC-3: 29.7
RAG1	MGC43321, RNF74	ENSG00000166349	Recombination activating 1	11	36510709-36593156	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043939			Supported	Nucleus		Mixed	Tissue enhanced		thyroid gland: 4.2	spleen: 3.6	Group enriched	102	MOLT-4: 227.0;REH: 243.3
POTED	A26B3, ANKRD21, CT104.1, POTE, POTE-21, POTE21	ENSG00000166351	POTE ankyrin domain family member D	21	13609858-13641585	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Not detected		
C11orf74	FLJ38678, HEPIS, NWC	ENSG00000166352	Chromosome 11 open reading frame 74	11	36594493-36659290	Predicted intracellular proteins	Evidence at protein level	HPA044880	Uncertain		Approved	Aggresome<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 177.5	Mixed		
WDR88	PQWD	ENSG00000166359	WD repeat domain 88	19	33132090-33175795	Predicted intracellular proteins	Evidence at protein level	HPA041916, HPA050336	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	7	testis: 11.1	cerebral cortex,thyroid gland: 1.6	Mixed		
OR10A5	JCG6, OR10A1, OR11-403	ENSG00000166363	Olfactory receptor family 10 subfamily A member 5	11	6845652-6846705	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2D2	hg27, OR11-610, OR2D1	ENSG00000166368	Olfactory receptor family 2 subfamily D member 2	11	6891490-6892599	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ATP9B	ATPIIB	ENSG00000166377	ATPase phospholipid transporting 9B (putative)	18	79069285-79378283	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029364	Approved					Expressed in all	Expressed in all			testis: 39.0	Expressed in all		
PPFIBP2	Cclp1	ENSG00000166387	PPFIA binding protein 2	11	7513298-7657127	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001935, HPA003911	Approved		Approved	Mitochondria	Renal cancer:5.39e-8 (favourable), Urothelial cancer:1.34e-5 (favourable), Lung cancer:2.26e-5 (favourable), Head and neck cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 184.8	Cell line enhanced		BEWO: 77.4;RT4: 91.3
MOGAT2	DGAT2L5, FLJ22644, MGAT2	ENSG00000166391	Monoacylglycerol O-acyltransferase 2	11	75717819-75732958	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028834	Uncertain					Tissue enhanced	Group enriched	12	colon: 12.5;duodenum: 37.2;liver: 12.1;rectum: 12.5;small intestine: 43.6	appendix: 1.9	Group enriched	6	Hep G2: 2.7;RPMI-8226: 1.8
CYB5R2		ENSG00000166394	Cytochrome b5 reductase 2	11	7665100-7677222	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038962, HPA061707	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 227.5	parathyroid gland: 72.2	Cell line enhanced		BJ hTERT+: 101.1;BJ hTERT+ SV40 Large T+: 61.1;BJ hTERT+ SV40 Large T+ RasG12V: 57.7;NTERA-2: 69.5;WM-115: 94.6
SERPINB7	MEGSIN	ENSG00000166396	Serpin family B member 7	18	63752935-63805376	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024200	Enhanced		Approved	Endoplasmic reticulum<br>Mitochondria	Pancreatic cancer:3.03e-5 (unfavourable)	Mixed	Tissue enhanced		skin: 123.7;tonsil: 34.1	breast: 17.4	Cell line enhanced		BJ: 202.3;fHDF/TERT166: 131.6;HaCaT: 363.6;HBF TERT88: 215.1;U-138 MG: 215.5
KIAA0355		ENSG00000166398	KIAA0355	19	34254537-34355586	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014570	Uncertain		Approved	Nucleoplasm	Melanoma:2.82e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 33.2	Mixed		
SERPINB8	CAP2, PI8	ENSG00000166401	Serpin family B member 8	18	63969925-64019779	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034300	Enhanced		Approved	Nucleus<br>Cytosol	Renal cancer:3.31e-5 (unfavourable)	Expressed in all	Mixed			skin: 48.9	Mixed		
TUB	rd5	ENSG00000166402	Tubby bipartite transcription factor	11	8019244-8106112	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017997, HPA049019	Uncertain		Approved	Nucleoli<br>Microtubule organizing center<br>Centrosome	Renal cancer:2.35e-5 (favourable), Pancreatic cancer:2.85e-4 (favourable)	Mixed	Mixed			cerebral cortex: 51.4	Cell line enhanced		HEK 293: 34.0;HeLa: 33.4;SCLC-21H: 65.2;SH-SY5Y: 43.8
RIC3	AYST720, FLJ11608, PRO1385	ENSG00000166405	RIC3 acetylcholine receptor chaperone	11	8106093-8169055	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA065016	Approved					Mixed	Mixed			parathyroid gland: 28.2	Cell line enhanced		NTERA-2: 5.0;SCLC-21H: 9.9;SH-SY5Y: 6.2
LMO1	RBTN1, RHOM1, TTG1	ENSG00000166407	LIM domain only 1	11	8224304-8268716	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		skeletal muscle: 10.1;skin: 5.9	epididymis: 2.0	Group enriched	6	HeLa: 22.0;SCLC-21H: 14.8;SH-SY5Y: 41.0;SiHa: 8.4
IDH3A		ENSG00000166411	Isocitrate dehydrogenase 3 (NAD(+)) alpha	15	78131498-78171949	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041465, HPA062971	Supported		Enhanced	Mitochondria	Renal cancer:6.49e-8 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 44.1	Expressed in all		
WDR72	FLJ38736	ENSG00000166415	WD repeat domain 72	15	53513741-53762878	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048212, HPA057410, HPA059819	Uncertain		Approved	Vesicles	Renal cancer:3.33e-16 (favourable), Thyroid cancer:1.80e-4 (unfavourable)	Mixed	Group enriched	6	kidney: 104.7;thyroid gland: 92.1	liver: 16.9	Cell line enhanced		A549: 8.9;EFO-21: 5.9;NTERA-2: 5.9;RPMI-8226: 11.9;RPTEC TERT1: 8.1;U-266/70: 5.7
CRABP1	CRABP, CRABP-I, CRABPI, RBP5	ENSG00000166426	Cellular retinoic acid binding protein 1	15	78340324-78348230	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017203	Approved	Supported			Endometrial cancer:4.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 269.2	seminal vesicle: 64.5	Group enriched	7	AF22: 952.0;NTERA-2: 289.5
PLD4	C14orf175	ENSG00000166428	Phospholipase D family member 4	14	104924816-104937790	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051512	Approved					Mixed	Mixed			lymph node: 13.9	Cell line enhanced		HMC-1: 99.3;RPMI-8226: 58.9;THP-1: 143.6
ZMAT1	KIAA1789	ENSG00000166432	Zinc finger matrin-type 1	X	101882288-101932031	Predicted intracellular proteins	Evidence at protein level	HPA012827	Enhanced		Approved	Nucleoplasm	Pancreatic cancer:1.72e-5 (favourable)	Mixed	Tissue enhanced		epididymis: 25.8	parathyroid gland: 12.2	Cell line enhanced		Karpas-707: 5.9;U-266/70: 3.1
XRRA1	FLJ00225	ENSG00000166435	X-ray radiation resistance associated 1	11	74807739-74949200	Predicted intracellular proteins	Evidence at protein level	HPA039263			Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Tissue enhanced		testis: 35.5	thyroid gland: 11.8	Cell line enhanced		hTERT-HME1: 27.8
TRIM66	C11orf29, KIAA0298, TIF1D	ENSG00000166436	Tripartite motif containing 66	11	8612037-8671866	Predicted intracellular proteins	Evidence at protein level	HPA027420	Approved		Supported	Nucleoplasm	Renal cancer:3.96e-4 (unfavourable), Pancreatic cancer:8.89e-4 (favourable)	Expressed in all	Mixed			testis: 14.0	Mixed		
RNF169	KIAA1991	ENSG00000166439	Ring finger protein 169	11	74748868-74842413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046138, HPA058368	Uncertain		Supported	Nuclear speckles	Pancreatic cancer:8.04e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.8	Expressed in all		
RPL27A	L27A	ENSG00000166441	Ribosomal protein L27a	11	8682411-8714759	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060776, HPA063379	Supported		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.83e-10 (unfavourable), Breast cancer:7.84e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 2813.8	Expressed in all		
ST5	DENND2B, HTS1, p126	ENSG00000166444	Suppression of tumorigenicity 5	11	8693351-8910951	Predicted intracellular proteins	Evidence at protein level	HPA046796	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 194.5	Mixed		
CDYL2	FLJ38866	ENSG00000166446	Chromodomain Y-like 2	16	80597906-80804329	Predicted intracellular proteins	Evidence at protein level	HPA041016	Approved				Endometrial cancer:6.13e-4 (favourable)	Expressed in all	Mixed			testis: 21.3	Cell line enhanced		HDLM-2: 14.7;HUVEC TERT2: 19.5;MCF7: 15.7;TIME: 28.5
TMEM130	DKFZp761L1417, FLJ42643	ENSG00000166448	Transmembrane protein 130	7	98846488-98870771	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012928	Uncertain		Supported	Golgi apparatus	Lung cancer:7.84e-4 (favourable)	Tissue enhanced	Group enriched	9	adrenal gland: 49.1;cerebral cortex: 183.0;testis: 70.7	epididymis: 11.5	Cell line enhanced		BJ hTERT+: 5.4;EFO-21: 6.0;NTERA-2: 3.8;SH-SY5Y: 8.3
PRTG	FLJ25756, IGDCC5	ENSG00000166450	Protogenin	15	55611546-55743090	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA032138	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		thyroid gland: 18.2	testis: 6.7	Cell line enriched	6	AF22: 148.8
CENPN	BM039, C16orf60, FLJ13607, FLJ22660	ENSG00000166451	Centromere protein N	16	81006498-81033114	Predicted intracellular proteins	Evidence at protein level	HPA052870			Supported	Nucleus	Pancreatic cancer:1.46e-5 (unfavourable), Renal cancer:4.86e-4 (unfavourable), Lung cancer:6.49e-4 (unfavourable)	Expressed in all	Mixed			prostate: 24.5	Expressed in all		
AKIP1	BCA3, C11orf17	ENSG00000166452	A-kinase interacting protein 1	11	8911139-8920084	Predicted intracellular proteins	Evidence at protein level	HPA061391			Supported	Nucleoplasm	Liver cancer:6.24e-9 (unfavourable), Endometrial cancer:5.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 30.5	Expressed in all		
ATMIN	ASCIZ, KIAA0431, ZNF822	ENSG00000166454	ATM interactor	16	81035847-81047358	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054967, HPA066900	Approved		Supported	Nuclear bodies	Renal cancer:6.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 61.3	Expressed in all		
C16orf46	FLJ32702	ENSG00000166455	Chromosome 16 open reading frame 46	16	81053497-81077267	Predicted intracellular proteins	Evidence at protein level	HPA041136, HPA041379	Uncertain		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 10.0	thyroid gland: 4.7	Mixed		
TMEM41B	KIAA0033	ENSG00000166471	Transmembrane protein 41B	11	9280654-9314780	Predicted membrane proteins	Evidence at protein level	HPA014946	Uncertain		Approved	Peroxisomes	Liver cancer:9.18e-6 (unfavourable)	Expressed in all	Mixed			thyroid gland: 22.3	Expressed in all		
LEO1		ENSG00000166477	LEO1 homolog, Paf1/RNA polymerase II complex component	15	51938025-51971806	Predicted intracellular proteins	Evidence at protein level	HPA040741, HPA040941	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			parathyroid gland: 35.6	Expressed in all		
ZNF143	pHZ-1, SBF, STAF	ENSG00000166478	Zinc finger protein 143	11	9460319-9528524	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003263, HPA074818	Supported		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Liver cancer:1.76e-5 (unfavourable), Renal cancer:6.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.1	Expressed in all		
TMX3	FLJ20793, KIAA1830, PDIA13, TXNDC10	ENSG00000166479	Thioredoxin related transmembrane protein 3	18	68673688-68715298	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014157	Uncertain				Renal cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 31.4	Expressed in all		
MFAP4		ENSG00000166482	Microfibrillar associated protein 4	17	19383442-19387240	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA054097	Supported		Approved	Endoplasmic reticulum	Renal cancer:6.83e-7 (unfavourable), Head and neck cancer:3.51e-4 (favourable), Ovarian cancer:4.64e-4 (unfavourable), Urothelial cancer:7.12e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 972.0	Cell line enhanced		ASC diff: 262.3;ASC TERT1: 405.8;fHDF/TERT166: 213.0;HHSteC: 224.2;HSkMC: 294.1;MOLT-4: 290.1;SH-SY5Y: 360.1
WEE1	WEE1A	ENSG00000166483	WEE1 G2 checkpoint kinase	11	9573681-9593457	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004619, HPA068845	Approved		Approved	Nucleoli	Renal cancer:5.19e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 90.6	Expressed in all		
MAPK7	BMK1, ERK5, PRKM7	ENSG00000166484	Mitogen-activated protein kinase 7	17	19377721-19383544	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018561, HPA031031	Uncertain		Enhanced	Nucleus<br>Cytosol	Liver cancer:1.86e-4 (unfavourable)	Expressed in all	Mixed			testis: 10.6	Mixed		
PRKCB	PKCB, PRKCB1, PRKCB2	ENSG00000166501	Protein kinase C beta	16	23836001-24220611	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003843, HPA048321, HPA054203	Approved		Supported	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 125.4	spleen: 64.5	Cell line enhanced		HEL: 145.7;HMC-1: 137.9;K-562: 211.8
RP11-382A20.3		ENSG00000166503	Hepatoma-derived growth factor-related protein 3 	15	83112738-83208018	Predicted intracellular proteins	Evidence at protein level	HPA040719	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 33.0	cerebral cortex: 19.5	Mixed		
NDST2	HSST2, NST2	ENSG00000166507	N-deacetylase and N-sulfotransferase 2	10	73801911-73811798	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051515	Approved		Approved	Cytosol		Mixed	Expressed in all			spleen: 44.9	Expressed in all		
MCM7	CDC47, MCM2, PPP1R104	ENSG00000166508	Minichromosome maintenance complex component 7	7	100092728-100101940	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002163, HPA003898, CAB016312	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:1.28e-4 (favourable), Liver cancer:2.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.9	Expressed in all		
CLEC3A	CLECSF1	ENSG00000166509	C-type lectin domain family 3 member A	16	78022515-78066761	Predicted secreted proteins	Evidence at protein level	HPA051511	Uncertain				Breast cancer:1.61e-4 (unfavourable)	Tissue enriched	Tissue enhanced		breast: 12.4;urinary bladder: 8.3	prostate: 3.3	Cell line enhanced		MCF7: 2.5;SK-BR-3: 5.5;T-47d: 19.7
CCDC68	SE57-1	ENSG00000166510	Coiled-coil domain containing 68	18	54901509-54959508	Predicted intracellular proteins	Evidence at protein level	HPA040865, HPA048197	Supported		Approved	Golgi apparatus<br>Cytosol	Cervical cancer:4.50e-4 (unfavourable), Renal cancer:5.28e-4 (favourable)	Mixed	Tissue enhanced		placenta: 46.2	small intestine: 27.3	Cell line enhanced		HHSteC: 11.3;HSkMC: 10.8;TIME: 22.8
CLEC4E	CLECSF9, mincle	ENSG00000166523	C-type lectin domain family 4 member E	12	8533305-8540963	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004935	Uncertain		Uncertain	Cytosol		Mixed	Tissue enhanced		appendix: 53.9;bone marrow: 49.6;spleen: 44.0	gallbladder: 18.9	Cell line enhanced		NB-4: 2.8;RPTEC TERT1: 9.2
ZNF3	A8-51, FLJ20216, HF.12, KOX25, PP838, Zfp113	ENSG00000166526	Zinc finger protein 3	7	100064033-100082548	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003719	Supported	Approved	Approved	Nucleoplasm	Melanoma:1.59e-4 (unfavourable), Urothelial cancer:2.20e-4 (favourable), Lung cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 56.8	Expressed in all		
CLEC4D	CD368, CLECSF8, Mpcl	ENSG00000166527	C-type lectin domain family 4 member D	12	8509475-8522366	Predicted intracellular proteins	Evidence at protein level	HPA004906	Approved					Tissue enriched	Group enriched	6	appendix: 10.5;bone marrow: 42.8	cervix, uterine: 4.8	Cell line enhanced		NB-4: 1.5;NTERA-2: 9.1;U-937: 4.2
ZSCAN21	DKFZp434L134, NY-REN-21, Zipro1, ZNF38	ENSG00000166529	Zinc finger and SCAN domain containing 21	7	100049774-100065038	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016948, HPA023591	Uncertain		Approved	Endoplasmic reticulum	Thyroid cancer:4.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
RIMKLB	FAM80B, KIAA1238, NAAGS, NAAGS-I	ENSG00000166532	Ribosomal modification protein rimK like family member B	12	8681600-8783095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059552			Approved	Nucleoplasm<br>Microtubule organizing center		Mixed	Expressed in all			endometrium: 74.7	Cell line enhanced		U-698: 113.0
A2ML1	CPAMD9, FLJ25179, p170	ENSG00000166535	Alpha-2-macroglobulin like 1	12	8822472-8887001	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038847, HPA038848	Enhanced					Tissue enhanced	Tissue enriched	6	esophagus: 479.2	skin: 85.5	Cell line enhanced		HMC-1: 9.6;hTCEpi: 3.9;SK-BR-3: 10.3
BEAN1	SCA31	ENSG00000166546	Brain expressed, associated with NEDD4, 1	16	66427297-66493529	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA053851	Uncertain		Uncertain	Nucleoplasm<br>Centrosome		Mixed	Mixed			cerebral cortex: 2.2	Cell line enhanced		AN3-CA: 5.5;BEWO: 2.9;RPTEC TERT1: 4.0;U-87 MG: 3.3
TK2	SCA31	ENSG00000166548	Thymidine kinase 2, mitochondrial	16	66508003-66552544	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041162	Uncertain				Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 89.9	Mixed		
TMED3	C15orf22, p24B, p24g4, p24gamma4	ENSG00000166557	Transmembrane p24 trafficking protein 3	15	79311062-79427432	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA049314, HPA076949	Approved		Supported	Golgi apparatus	Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 163.2	Mixed		
SLC38A8		ENSG00000166558	Solute carrier family 38 member 8	16	84009667-84042636	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Not detected			testis: 0.9	Cell line enriched	5	SCLC-21H: 4.0
SEC11C	SEC11L3, SPC21, SPCS4C	ENSG00000166562	SEC11 homolog C, signal peptidase complex subunit	18	59139477-59158836	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA026816, HPA047533	Approved		Approved	Nuclear membrane<br>Golgi apparatus		Expressed in all	Expressed in all			prostate: 271.8	Expressed in all		
CPLX4	CPX-IV	ENSG00000166569	Complexin 4	18	59275156-59318649	Predicted intracellular proteins	Evidence at protein level	HPA047627	Supported					Not detected	Not detected			skin,testis: 0.4	Not detected		
GALR1	GALNR, GALNR1	ENSG00000166573	Galanin receptor 1	18	77250549-77277896	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		adrenal gland: 2.1;cerebral cortex: 1.7	prostate,seminal vesicle,testis: 0.4	Not detected		
TMEM135	FLJ22104	ENSG00000166575	Transmembrane protein 135	11	87037844-87323758	Predicted membrane proteins	Evidence at protein level	HPA056685, HPA069473	Uncertain		Supported	Vesicles	Renal cancer:9.02e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 31.7	Expressed in all		
IQCD	CFAP84, DRC10	ENSG00000166578	IQ motif containing D	12	113195441-113221094	Predicted intracellular proteins	Evidence at protein level	HPA046810, HPA048782	Supported		Approved	Nucleus	Pancreatic cancer:3.90e-4 (favourable)	Mixed	Group enriched	6	fallopian tube: 34.8;testis: 65.4	parathyroid gland: 7.7	Cell line enhanced		BJ hTERT+: 22.7
NDEL1	MITAP1, NDE1L1, NDE2, NUDEL	ENSG00000166579	NudE neurodevelopment protein 1 like 1	17	8413131-8490411	Predicted intracellular proteins	Evidence at protein level	HPA017916	Approved					Expressed in all	Expressed in all			adrenal gland: 81.4	Expressed in all		
CENPV	CENP-V, p30, PRR6	ENSG00000166582	Centromere protein V	17	16342534-16353656	Predicted intracellular proteins	Evidence at protein level	HPA042529, HPA042616	Enhanced					Expressed in all	Mixed			testis: 13.6	Cell line enhanced		AF22: 98.5;NTERA-2: 98.2
CDH16		ENSG00000166589	Cadherin 16	16	66908122-66918984	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013526, HPA036260	Enhanced				Renal cancer:1.02e-7 (favourable)	Tissue enriched	Group enriched	8	kidney: 231.3;thyroid gland: 58.0	fallopian tube: 17.2	Cell line enriched	78	RPTEC TERT1: 163.7
RRAD	RAD, REM3	ENSG00000166592	RRAD, Ras related glycolysis inhibitor and calcium channel regulator	16	66921679-66925644	Predicted intracellular proteins	Evidence at protein level	HPA041755	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Expressed in all	Tissue enhanced		heart muscle: 98.8;skeletal muscle: 67.5	esophagus: 62.8	Group enriched	8	HDLM-2: 166.9;U-87 MG: 48.4
FAM96B	CGI-128, CIA2B, MIP18	ENSG00000166595	Family with sequence similarity 96 member B	16	66932055-66934423	Predicted intracellular proteins	Evidence at protein level	HPA041501, HPA041736	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 120.8	Expressed in all		
CFAP52	FLJ37528, WDR16, WDRPUH	ENSG00000166596	Cilia and flagella associated protein 52	17	9576627-9643459	Predicted intracellular proteins	Evidence at protein level	HPA023247	Enhanced					Mixed	Group enriched	9	fallopian tube: 91.8;testis: 22.0	lung: 6.6	Cell line enhanced		CAPAN-2: 1.5;MCF7: 1.6;REH: 1.3;T-47d: 1.1
HSP90B1	GP96, GRP94, TRA1	ENSG00000166598	Heat shock protein 90 beta family member 1	12	103930107-103953645	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003901, CAB005224, HPA008424	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.03e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 2386.1	Expressed in all		
MC4R		ENSG00000166603	Melanocortin 4 receptor	18	60371110-60372775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016719	Uncertain					Tissue enhanced	Group enriched	10	cerebral cortex: 2.9;fallopian tube: 5.0	epididymis: 0.4	Cell line enriched	64	fHDF/TERT166: 75.8
BLCAP	BC10	ENSG00000166619	Bladder cancer associated protein	20	37492472-37527931	Predicted intracellular proteins	Evidence at protein level	HPA047390			Approved	Nucleoli	Urothelial cancer:7.28e-5 (favourable), Endometrial cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 224.4	Expressed in all		
SERPINB12	YUKOPIN	ENSG00000166634	Serpin family B member 12	18	63556160-63567011	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.76e-4 (favourable)	Group enriched	Tissue enriched	5	skin: 78.3	esophagus: 15.2	Not detected		
CHRFAM7A	CHRNA7-DR1, D-10	ENSG00000166664	CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion	15	30357766-30393849	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 5.0;testis: 5.4	thyroid gland: 2.5	Cell line enhanced		HAP1: 3.9;HEL: 3.3;RH-30: 2.7;SH-SY5Y: 3.8;U-937: 3.1
ATF7IP2	FLJ12668	ENSG00000166669	Activating transcription factor 7 interacting protein 2	16	10326434-10483638	Predicted intracellular proteins	Evidence at protein level	HPA041156, HPA041228	Enhanced				Liver cancer:5.68e-5 (favourable), Urothelial cancer:8.57e-5 (favourable), Breast cancer:4.98e-4 (favourable)	Mixed	Tissue enhanced		testis: 35.7	lymph node: 10.3	Mixed		
MMP10	STMY2	ENSG00000166670	Matrix metallopeptidase 10	11	102770503-102780628	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	CAB002159	Uncertain		Approved	Plasma membrane<br>Cytosol	Urothelial cancer:7.12e-4 (favourable)	Tissue enhanced	Tissue enriched	40	endometrium: 443.1	appendix: 11.1	Cell line enhanced		BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
TVP23A	FAM18A, YDR084C	ENSG00000166676	Trans-golgi network vesicle protein 23 homolog A	16	10760919-10818794	Predicted membrane proteins	Evidence at transcript level	HPA060582	Uncertain		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.3	ovary: 3.2	Cell line enhanced		SH-SY5Y: 2.2
BEX3	Bex, DXS6984E, HGR74, NADE, NGFRAP1	ENSG00000166681	Brain expressed X-linked 3	X	103376340-103378077	Predicted intracellular proteins	Evidence at protein level	HPA018886	Approved		Supported	Cytosol	Endometrial cancer:7.23e-5 (unfavourable), Renal cancer:1.28e-4 (favourable), Stomach cancer:3.48e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 605.0	Mixed		
TMPRSS5	MGC141886, MGC148044	ENSG00000166682	Transmembrane protease, serine 5	11	113687550-113706373	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010992			Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 10.1	salivary gland: 3.0	Cell line enhanced		CAPAN-2: 2.9;WM-115: 2.6
COG1	KIAA1381, LDLB	ENSG00000166685	Component of oligomeric golgi complex 1	17	73192632-73208507	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029224	Supported				Liver cancer:2.91e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.8	Expressed in all		
PLEKHA7	DKFZp686M22243	ENSG00000166689	Pleckstrin homology domain containing A7	11	16777317-17014443	Predicted intracellular proteins	Evidence at protein level	HPA038610, HPA066103	Approved		Supported	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:1.89e-15 (favourable)	Mixed	Mixed			parathyroid gland: 50.8	Cell line enhanced		CAPAN-2: 113.7;HaCaT: 75.7;RT4: 94.4
ZNF606	FLJ14260, KIAA1852, ZNF328	ENSG00000166704	Zinc finger protein 606	19	57977053-58003349	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041712, HPA043584	Uncertain		Supported	Nucleoplasm	Urothelial cancer:4.75e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 18.9	Cell line enhanced		HEK 293: 21.5
ZCCHC18	PNMA7B, SIZN2	ENSG00000166707	Zinc finger CCHC-type containing 18	X	104112131-104115846	Predicted intracellular proteins	Evidence at transcript level	HPA034940	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 5.6	ovary: 4.2	Cell line enhanced		Karpas-707: 3.3;SH-SY5Y: 3.2
B2M		ENSG00000166710	Beta-2-microglobulin	15	44711477-44718877	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB002572, HPA006361	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			lymph node: 5119.8	Expressed in all		
ZNF592	CAMOS, KIAA0211, SCAR5	ENSG00000166716	Zinc finger protein 592	15	84748635-84806432	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020332, HPA021600	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 16.7	Expressed in all		
CASC4	DKFZp459F1927, H63	ENSG00000166734	Cancer susceptibility 4	15	44288729-44415758	Predicted intracellular proteins	Evidence at protein level	HPA043015, HPA049488	Enhanced		Supported	Golgi apparatus	Renal cancer:1.45e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 141.6	Expressed in all		
HTR3A	5-HT3A, 5-HT3R, HTR3	ENSG00000166736	5-hydroxytryptamine receptor 3A	11	113974881-113990313	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA069442	Supported				Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable)	Tissue enriched	Group enriched	5	appendix: 2.8;lymph node: 7.8;tonsil: 7.2	small intestine: 1.1	Cell line enhanced		CAPAN-2: 5.3;Daudi: 4.2;NTERA-2: 3.6;SCLC-21H: 22.1
NNMT		ENSG00000166741	Nicotinamide N-methyltransferase	11	114257787-114313285	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059180	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 197.2	adipose tissue: 107.8	Cell line enhanced		HSkMC: 300.0;RPTEC TERT1: 491.7
ACSM1	BUCS1, MACS1	ENSG00000166743	Acyl-CoA synthetase medium-chain family member 1	16	20623237-20698890	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046291	Uncertain					Group enriched	Tissue enriched	49	breast: 298.7	prostate: 6.0	Group enriched	11	K-562: 3.2;NTERA-2: 15.6
AP1G1	ADTG, CLAPG1	ENSG00000166747	Adaptor related protein complex 1 gamma 1 subunit	16	71729000-71809201	Predicted intracellular proteins	Evidence at protein level	CAB009049, HPA041224	Approved		Enhanced	Vesicles<br>Cytosol	Renal cancer:2.96e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.8	Expressed in all		
SLFN5	MGC19764	ENSG00000166750	Schlafen family member 5	17	35243036-35273655	Predicted intracellular proteins	Evidence at protein level	HPA017760	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			lymph node: 37.4	Cell line enhanced		hTERT-HME1: 113.0
CATSPER2		ENSG00000166762	Cation channel sperm associated 2	15	43628503-43668118	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enhanced		testis: 30.8	parathyroid gland: 6.5	Mixed		
C16orf45	FLJ32618	ENSG00000166780	Chromosome 16 open reading frame 45	16	15434295-15625028	Predicted intracellular proteins	Evidence at protein level	HPA041114	Uncertain		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.53e-4 (favourable), Renal cancer:1.75e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 171.9	cervix, uterine: 59.6	Cell line enhanced		fHDF/TERT166: 72.2;U-87 MG: 109.4
KIAA0430	LKAP, Marf1, PPP1R34	ENSG00000166783	KIAA0430	16	15594386-15643166	Predicted intracellular proteins	Evidence at protein level	HPA017992	Approved		Supported	Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 20.6	Expressed in all		
SAAL1	FLJ41463	ENSG00000166788	Serum amyloid A like 1	11	18069935-18106091	Predicted intracellular proteins	Evidence at protein level	HPA039003, HPA039004	Approved		Supported	Nucleoplasm	Renal cancer:5.78e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 23.2	Expressed in all		
YPEL4	FLJ30213	ENSG00000166793	Yippee like 4	11	57645087-57649944	Predicted intracellular proteins	Evidence at transcript level	HPA045621	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 19.0	ovary: 4.3	Cell line enhanced		AF22: 3.2;SK-MEL-30: 3.1
PPIB	CYPB, OI9	ENSG00000166794	Peptidylprolyl isomerase B	15	64155812-64163205	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	CAB011487, HPA012720	Enhanced		Supported	Nucleus<br>Endoplasmic reticulum	Renal cancer:2.02e-11 (unfavourable), Endometrial cancer:1.56e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 855.2	Expressed in all		
LDHC	CT32	ENSG00000166796	Lactate dehydrogenase C	11	18412307-18452058	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045442	Enhanced					Mixed	Tissue enriched	402	testis: 472.9	thyroid gland: 1.1	Cell line enhanced		U-2197: 4.8;U-266/70: 3.5;U-266/84: 3.0
FAM96A	CIA2A, FLJ22875	ENSG00000166797	Family with sequence similarity 96 member A	15	64072559-64094018	Predicted secreted proteins	Evidence at protein level	HPA040459, HPA063729	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			liver: 106.1	Expressed in all		
LDHAL6A	LDH6A, MGC23940	ENSG00000166800	Lactate dehydrogenase A like 6A	11	18455824-18479600	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	13	testis: 17.5	skin: 1.3	Cell line enriched	6	HL-60: 8.8
FAM111A	FLJ22794, KIAA1895	ENSG00000166801	Family with sequence similarity 111 member A	11	59142748-59155039	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039529, HPA040176	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.15e-5 (unfavourable), Urothelial cancer:4.39e-4 (favourable)	Expressed in all	Expressed in all			prostate,spleen: 45.6	Mixed		
PCLAF	KIAA0101, NS5ATP9, OEATC-1, p15(PAF), PAF15	ENSG00000166803	PCNA clamp associated factor	15	64364311-64387687	Predicted intracellular proteins	Evidence at protein level	HPA047929			Supported	Centrosome	Renal cancer:9.77e-15 (unfavourable), Liver cancer:3.26e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 76.2;lymph node: 50.8	tonsil: 36.9	Mixed		
KIF7	JBTS12	ENSG00000166813	Kinesin family member 7	15	89608789-89655451	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043145	Approved				Endometrial cancer:3.80e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 5.3	Cell line enhanced		U-2197: 36.1
LDHD		ENSG00000166816	Lactate dehydrogenase D	16	75111860-75116771	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041766, HPA048639, HPA066148	Enhanced		Approved	Cytosol	Renal cancer:2.95e-14 (favourable), Liver cancer:5.61e-4 (favourable)	Expressed in all	Mixed			kidney: 34.0	Cell line enhanced		HMC-1: 13.2;T-47d: 27.8;U-266/70: 8.9
PLIN1	PLIN	ENSG00000166819	Perilipin 1	15	89664365-89679427	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024299, CAB033821, CAB037333	Enhanced		Uncertain	Peroxisomes		Tissue enhanced	Tissue enriched	10	adipose tissue: 1012.5	breast: 100.6	Cell line enriched	157	ASC diff: 142.8
PEX11A	MGC119947, MGC138534, PEX11-ALPHA	ENSG00000166821	Peroxisomal biogenesis factor 11 alpha	15	89677764-89690783	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Head and neck cancer:2.57e-4 (unfavourable)	Expressed in all	Mixed			prostate: 29.3	Cell line enhanced		SK-BR-3: 40.6
TMEM170A	FLJ37611, TMEM170	ENSG00000166822	Transmembrane protein 170A	16	75443054-75465497	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055071	Uncertain				Renal cancer:2.36e-9 (favourable)	Expressed in all	Expressed in all			testis: 32.4	Expressed in all		
MESP1	bHLHc5, MGC10676	ENSG00000166823	Mesoderm posterior bHLH transcription factor 1	15	89748661-89751310	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069981			Supported	Nucleus<br>Nucleoli		Group enriched	Tissue enhanced		adipose tissue: 4.8;prostate: 4.8	cerebral cortex: 1.4	Cell line enhanced		A-431: 3.1;HDLM-2: 2.9;HEK 293: 2.7;PC-3: 5.2;SCLC-21H: 3.0
ANPEP	CD13, gp150, LAP1, p150, PEPN	ENSG00000166825	Alanyl aminopeptidase, membrane	15	89784889-89815401	CD markers, Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002417, HPA004625	Enhanced		Supported	Plasma membrane		Expressed in all	Group enriched	9	duodenum: 2386.4;small intestine: 2133.7	kidney: 263.2	Cell line enhanced		BJ hTERT+: 958.3;HUVEC TERT2: 770.8;TIME: 760.6;U-2197: 926.0
SCNN1G	ENaCgamma, SCNEG	ENSG00000166828	Sodium channel epithelial 1 gamma subunit	16	23182715-23216883	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071194			Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:3.20e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 24.6;kidney: 46.7	thyroid gland: 9.5	Group enriched	5	hTCEpi: 33.4;RT4: 17.1
RBPMS2		ENSG00000166831	RNA binding protein with multiple splicing 2	15	64739892-64775587	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.48e-4 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 134.9	seminal vesicle: 63.9	Cell line enhanced		AF22: 38.7;AN3-CA: 51.6;HEL: 77.7;NTERA-2: 76.7
NAV2	FLJ10633, FLJ11030, FLJ23707, HELAD1, KIAA1419, POMFIL2, RAINB1	ENSG00000166833	Neuron navigator 2	11	19350724-20121598	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA011755, HPA011891	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			heart muscle: 39.2	Cell line enhanced		hTERT-HME1: 69.3;SH-SY5Y: 87.7
ANKDD1A	FLJ25870	ENSG00000166839	Ankyrin repeat and death domain containing 1A	15	64911902-64958700	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040757	Approved		Approved	Nucleoplasm		Mixed	Mixed			spleen: 15.0	Cell line enhanced		Karpas-707: 17.4;RT4: 14.8;U-266/84: 17.5
GLYATL1	FLJ34646, MGC15397	ENSG00000166840	Glycine-N-acyltransferase like 1	11	58905398-59043527	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039501	Supported		Uncertain	Golgi apparatus<br>Cytosol	Renal cancer:3.03e-5 (favourable), Liver cancer:3.69e-4 (favourable)	Group enriched	Group enriched	13	kidney: 145.2;liver: 298.1	prostate: 17.4	Cell line enhanced		CACO-2: 1.6;Daudi: 3.5;RPTEC TERT1: 1.2;U-2197: 1.1
C18orf54	LAS2, MGC33382	ENSG00000166845	Chromosome 18 open reading frame 54	18	54357917-54385218	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040704			Approved	Nucleoplasm		Mixed	Tissue enriched	8	testis: 30.4	placenta: 3.8	Mixed		
DCTN5	MGC3248, p25	ENSG00000166847	Dynactin subunit 5	16	23641392-23677455	Predicted intracellular proteins	Evidence at protein level	HPA042003, HPA063710	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:4.02e-4 (unfavourable), Renal cancer:4.48e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex,testis: 38.1	Expressed in all		
TERF2IP	RAP1	ENSG00000166848	TERF2 interacting protein	16	75647786-75761872	Predicted intracellular proteins	Evidence at protein level	HPA006719, CAB018660, CAB018749	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.15e-5 (favourable), Ovarian cancer:6.14e-5 (favourable), Pancreatic cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 221.2	Expressed in all		
PLK1	PLK	ENSG00000166851	Polo like kinase 1	16	23677656-23690367	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051638, HPA053229	Approved				Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 44.2	lymph node: 32.8	Expressed in all		
CLPX		ENSG00000166855	Caseinolytic mitochondrial matrix peptidase chaperone subunit	15	65148219-65185342	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040262, HPA048199	Approved		Enhanced	Mitochondria	Renal cancer:1.93e-9 (favourable)	Expressed in all	Expressed in all			skin: 17.7	Expressed in all		
GPR182	ADMR, AM-R, G10D, hrhAMR	ENSG00000166856	G protein-coupled receptor 182	12	56994446-56998441	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027037	Enhanced					Not detected	Tissue enhanced		spleen: 12.2;testis: 6.7	liver: 2.0	Cell line enhanced		RH-30: 1.8
ZBTB39	KIAA0352, ZNF922	ENSG00000166860	Zinc finger and BTB domain containing 39	12	56998834-57006446	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016866, HPA020306	Uncertain		Approved	Vesicles		Expressed in all	Mixed			testis: 13.4	Expressed in all		
CACNG2	MGC138502, MGC138504, stargazin	ENSG00000166862	Calcium voltage-gated channel auxiliary subunit gamma 2	22	36563921-36703558	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	13	cerebral cortex: 15.3	adrenal gland: 1.2	Group enriched	11	SCLC-21H: 3.3;SH-SY5Y: 1.3
TAC3	NKB, NKNB, ZNEUROK1	ENSG00000166863	Tachykinin 3	12	57010000-57028883	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045919	Supported	Approved	Approved	Vesicles		Tissue enriched	Tissue enriched	23	placenta: 617.0	cerebral cortex: 27.2	Cell line enhanced		K-562: 13.1;SCLC-21H: 2.7
MYO1A	DFNA48, MYHL	ENSG00000166866	Myosin IA	12	57028517-57051198	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053490	Enhanced					Group enriched	Group enriched	13	colon: 67.8;duodenum: 333.2;rectum: 71.8;small intestine: 338.4	stomach: 16.1	Cell line enhanced		BEWO: 1.9;CACO-2: 6.6;Hep G2: 3.7
CHP2		ENSG00000166869	Calcineurin like EF-hand protein 2	16	23754627-23758951	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB072806	Approved					Tissue enhanced	Group enriched	10	colon: 119.1;duodenum: 252.0;rectum: 127.6;skin: 143.8;small intestine: 227.3	cervix, uterine: 17.1	Cell line enhanced		hTERT-HME1: 4.5;NB-4: 4.6
NEMP1	KIAA0286, TMEM194, TMEM194A	ENSG00000166881	Nuclear envelope integral membrane protein 1	12	57055643-57088063	Predicted membrane proteins	Evidence at protein level	HPA014394	Uncertain		Approved	Nucleoplasm	Renal cancer:1.09e-5 (unfavourable), Liver cancer:1.93e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.5	Expressed in all		
OR4D6		ENSG00000166884	Olfactory receptor family 4 subfamily D member 6	11	59456938-59457991	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
NAB2	MADER	ENSG00000166886	NGFI-A binding protein 2	12	57088894-57095476	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004510, HPA027464	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Breast cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 39.3	Expressed in all		
VPS39	KIAA0770, VAM6	ENSG00000166887	VPS39, HOPS complex subunit	15	42158701-42208316	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.21e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.7	Expressed in all		
STAT6	D12S1644, IL-4-STAT	ENSG00000166888	Signal transducer and activator of transcription 6	12	57095408-57132139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001861	Approved		Enhanced	Nucleoplasm<br>Cytosol	Urothelial cancer:1.14e-4 (favourable), Endometrial cancer:1.69e-4 (favourable), Thyroid cancer:7.76e-4 (favourable)	Expressed in all	Expressed in all			skin: 163.9	Mixed		
PATL1	FLJ36874, Pat1b	ENSG00000166889	PAT1 homolog 1, processing body mRNA decay factor	11	59636716-59668980	Predicted intracellular proteins	Evidence at protein level	HPA039030	Uncertain		Supported	Cytoplasmic bodies	Pancreatic cancer:2.04e-4 (unfavourable), Colorectal cancer:4.56e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 37.0	Expressed in all		
ATP23	KUB3, XRCC6BP1	ENSG00000166896	ATP23 metallopeptidase and ATP synthase assembly factor homolog	12	57941541-57957269	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035804, HPA043204	Uncertain		Enhanced	Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol	Renal cancer:1.44e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 26.8	rectum: 5.5	Expressed in all		
ELFN2	dJ63G5.3, KIAA1904, LRRC62, PPP1R29	ENSG00000166897	Extracellular leucine rich repeat and fibronectin type III domain containing 2	22	37367960-37427470	Predicted membrane proteins	Evidence at protein level	HPA000781	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.21e-4 (unfavourable)	Mixed	Tissue enriched	7	cerebral cortex: 24.3	testis: 3.4	Cell line enhanced		RPTEC TERT1: 16.3;U-2 OS: 25.4
STX3	STX3A	ENSG00000166900	Syntaxin 3	11	59755059-59805882	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002191, HPA069176	Approved		Approved	Nucleus<br>Nuclear bodies<br>Golgi apparatus<br>Cytosol	Liver cancer:8.41e-7 (unfavourable), Renal cancer:1.14e-6 (favourable)	Expressed in all	Expressed in all			placenta: 72.4	Mixed		
MRPL16	FLJ20484, PNAS-111	ENSG00000166902	Mitochondrial ribosomal protein L16	11	59806135-59810872	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054133	Supported				Breast cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 71.6	Expressed in all		
PIP4K2C	FLJ22055, PIP5K2C	ENSG00000166908	Phosphatidylinositol-5-phosphate 4-kinase type 2 gamma	12	57591174-57603418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028658, HPA058551	Approved		Approved	Vesicles	Renal cancer:2.06e-6 (favourable), Liver cancer:7.98e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 109.1	Mixed		
MTMR10	FLJ20313	ENSG00000166912	Myotubularin related protein 10	15	30938941-30991607	Predicted intracellular proteins	Evidence at protein level	HPA006081	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:7.77e-12 (favourable)	Expressed in all	Expressed in all			placenta: 36.9	Expressed in all		
YWHAB	YWHAA	ENSG00000166913	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta	20	44885676-44908532	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003759, HPA007925, HPA011212	Enhanced		Supported	Cytosol	Liver cancer:1.91e-6 (unfavourable), Renal cancer:2.52e-5 (favourable), Endometrial cancer:5.46e-4 (unfavourable), Lung cancer:6.01e-4 (unfavourable), Head and neck cancer:6.14e-4 (unfavourable), Breast cancer:9.18e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 445.0	Expressed in all		
C15orf48	NMES1	ENSG00000166920	Chromosome 15 open reading frame 48	15	45430529-45448761	Predicted intracellular proteins	Evidence at protein level	HPA012943	Enhanced					Expressed in all	Tissue enhanced		colon: 716.6;rectum: 832.9	small intestine: 330.3	Cell line enhanced		A-431: 52.4;CAPAN-2: 96.3
SCG5	7B2, SGNE1, SgV	ENSG00000166922	Secretogranin V	15	32641676-32697098	Predicted secreted proteins	Evidence at protein level	HPA013136, HPA074618	Enhanced				Renal cancer:4.51e-9 (unfavourable), Head and neck cancer:9.64e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 233.7;parathyroid gland: 192.7	adrenal gland: 80.4	Group enriched	6	HHSteC: 22.6;HSkMC: 24.3;NTERA-2: 15.6;SCLC-21H: 37.1;SH-SY5Y: 38.6;U-87 MG: 46.3
GREM1	CKTSF1B1, CRAC1, DAND2, DRM, gremlin, HMPS	ENSG00000166923	Gremlin 1, DAN family BMP antagonist	15	32717974-32745107	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA007526	Uncertain				Lung cancer:4.46e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		gallbladder: 92.4;smooth muscle: 67.3	urinary bladder: 22.4	Cell line enhanced		BJ: 150.1;BJ hTERT+: 219.5;BJ hTERT+ SV40 Large T+ RasG12V: 161.4;fHDF/TERT166: 426.8;hTEC/SVTERT24-B: 168.1
NYAP1	C7orf51, FLJ37538, KIAA1486L	ENSG00000166924	Neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1	7	100483927-100494799	Predicted intracellular proteins	Evidence at protein level	HPA022251	Uncertain		Supported	Golgi apparatus<br>Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 25.1;testis: 7.7	adrenal gland: 3.3	Cell line enhanced		HUVEC TERT2: 3.2;SH-SY5Y: 9.9
TSC22D4	THG-1, TILZ2	ENSG00000166925	TSC22 domain family member 4	7	100463359-100479279	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA006757	Uncertain		Approved	Cytosol	Colorectal cancer:2.66e-4 (unfavourable), Liver cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 278.2	Expressed in all		
MS4A6E		ENSG00000166926	Membrane spanning 4-domains A6E	11	60334831-60396596	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	37	testis: 61.9	appendix: 1.6	Not detected		
MS4A7	CD20L4, CFFM4, MS4A8	ENSG00000166927	Membrane spanning 4-domains A7	11	60378482-60395951	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017418, CAB026387	Approved					Expressed in all	Tissue enhanced		spleen: 316.0	lung: 125.0	Cell line enriched	25	THP-1: 78.2
MS4A14	DKFZp434H092, FLJ32856, MS4A16, NYD-SP21	ENSG00000166928	Membrane spanning 4-domains A14	11	60378530-60417756	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level							Mixed	Tissue enriched	12	testis: 91.8	spleen: 7.6	Cell line enriched	23	THP-1: 6.3
MS4A5	CD20L2	ENSG00000166930	Membrane spanning 4-domains A5	11	60429589-60455214	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA043732	Uncertain					Not detected	Tissue enriched	280	testis: 73.1	duodenum: 0.2	Not detected		
DIS3L	DIS3L1, FLJ38088, KIAA1955, MGC4562	ENSG00000166938	DIS3 like exosome 3'-5' exoribonuclease	15	66293217-66333898	Predicted intracellular proteins	Evidence at protein level	HPA041805	Approved		Approved	Plasma membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 25.6	Expressed in all		
CCNDBP1	DIP1, GCIP, HHM	ENSG00000166946	Cyclin D1 binding protein 1	15	43185118-43197176	Predicted intracellular proteins	Evidence at protein level	CAB020664, HPA041065	Supported		Enhanced	Nucleoplasm	Renal cancer:2.06e-4 (favourable)	Expressed in all	Mixed			bone marrow: 7.6	Cell line enhanced		HEL: 4.6
EPB42	MGC116735, MGC116737, PA	ENSG00000166947	Erythrocyte membrane protein band 4.2	15	43106225-43221283	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040261	Supported					Not detected	Tissue enriched	13	bone marrow: 57.6	placenta: 4.5	Cell line enriched	96	HEL: 74.7
TGM6	dJ734P14.3, SCA35, TGM3L, TGY	ENSG00000166948	Transglutaminase 6	20	2380908-2432753	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059196	Uncertain					Not detected	Not detected			tonsil: 0.4	Not detected		
SMAD3	HsT17436, JV15-2, MADH3	ENSG00000166949	SMAD family member 3	15	67063763-67195195	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008094, HPA046386, HPA067203, CAB069409	Approved		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 54.2	Expressed in all		
MS4A8	CD20L5, MS4A4, MS4A8B	ENSG00000166959	Membrane spanning 4-domains A8	11	60699574-60715811	Predicted membrane proteins	Evidence at protein level	HPA007318, HPA007319	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 186.5;fallopian tube: 226.5;small intestine: 210.9	stomach: 49.1	Cell line enhanced		SCLC-21H: 1.1
CCDC178	C18orf34, FLJ44050	ENSG00000166960	Coiled-coil domain containing 178	18	32937402-33441101	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 27.7	spleen: 10.6	Group enriched	15	HUVEC TERT2: 4.2;U-87 MG: 4.3
MS4A15		ENSG00000166961	Membrane spanning 4-domains A15	11	60756953-60776732	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	lung: 71.4	endometrium: 6.2	Cell line enhanced		HEL: 6.6;MOLT-4: 2.7;U-266/70: 7.9;U-266/84: 3.3
MAP1A	MAP1L	ENSG00000166963	Microtubule associated protein 1A	15	43510958-43531620	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039063, HPA039064, HPA066488	Enhanced		Approved	Cytosol	Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable)	Tissue enhanced	Tissue enriched	9	cerebral cortex: 165.6	smooth muscle: 18.9	Cell line enhanced		fHDF/TERT166: 72.9;U-87 MG: 119.0
RCCD1	MGC14386	ENSG00000166965	RCC1 domain containing 1	15	90954870-90963125	Predicted intracellular proteins	Evidence at protein level	HPA039683, HPA040776	Enhanced		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 8.9	Mixed		
AKTIP	FLJ13258, FTS	ENSG00000166971	AKT interacting protein	16	53491040-53504411	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041794, HPA046300	Approved				Renal cancer:1.18e-14 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.4	Expressed in all		
MAPRE2	EB1, EB2, RP1	ENSG00000166974	Microtubule associated protein RP/EB family member 2	18	34976928-35143470	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016738, HPA016739	Enhanced		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 174.6	Mixed		
EVA1C	B18, B19, C21orf63, C21orf64, FAM176C, PRED34	ENSG00000166979	Eva-1 homolog C	21	32412006-32515397	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015720, HPA029944, CAB034174	Enhanced				Head and neck cancer:5.06e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 25.5	Cell line enhanced		A549: 16.5;CAPAN-2: 16.0;U-87 MG: 14.9
TCP10L2	bA517H2.3	ENSG00000166984	T-complex 10-like 2	6	167146414-167196913	Predicted intracellular proteins	Evidence at transcript level	CAB034197, HPA044709	Uncertain					Not detected	Tissue enhanced		epididymis: 1.6;testis: 1.5	small intestine: 0.3	Not detected		
MARS	CMT2U, MetRS, SPG70	ENSG00000166986	Methionyl-tRNA synthetase	12	57475445-57517569	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004125, CAB017097	Supported	Approved	Enhanced	Cytosol	Liver cancer:4.55e-7 (unfavourable), Renal cancer:1.59e-4 (unfavourable), Breast cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.7	Expressed in all		
MBD6	KIAA1887	ENSG00000166987	Methyl-CpG binding domain protein 6	12	57520710-57530148	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038948, HPA038949	Uncertain		Enhanced	Nucleus		Expressed in all	Expressed in all			testis: 65.8	Expressed in all		
CNPY4	MGC40499, PRAT4B	ENSG00000166997	Canopy FGF signaling regulator 4	7	100119613-100125511	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014166, HPA025240	Uncertain		Approved	Vesicles	Renal cancer:3.59e-5 (unfavourable), Liver cancer:3.99e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 34.8	Expressed in all		
PDIA3	ERp57, ERp60, ERp61, GRP57, GRP58, HsT17083, P58, PI-PLC	ENSG00000167004	Protein disulfide isomerase family A member 3	15	43746392-43773279	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002645, HPA003230, CAB011199, CAB075744	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:2.11e-8 (unfavourable), Head and neck cancer:8.95e-5 (unfavourable), Endometrial cancer:2.05e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
NUDT21	CFIM25, CPSF5	ENSG00000167005	Nudix hydrolase 21	16	56429133-56452199	Predicted intracellular proteins	Evidence at protein level	HPA019863, HPA074228	Uncertain		Supported	Nuclear bodies<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 128.9	Expressed in all		
NAT16	C7orf52, FLJ39237	ENSG00000167011	N-acetyltransferase 16 (putative)	7	101170493-101180276	Predicted intracellular proteins	Evidence at transcript level	HPA021918	Uncertain		Approved	Nucleus		Tissue enhanced	Group enriched	8	cerebral cortex: 5.1;thyroid gland: 3.0	pancreas: 0.5	Cell line enhanced		RPMI-8226: 1.6;SH-SY5Y: 3.6;SK-MEL-30: 2.0;U-2 OS: 3.1;U-87 MG: 1.6
TERB2	C15orf43, MGC33951	ENSG00000167014	Telomere repeat binding bouquet formation protein 2	15	44956702-44979229	Predicted intracellular proteins	Evidence at protein level	HPA041780, HPA041941			Uncertain	Nucleus<br>Nucleoli<br>Centrosome		Not detected	Tissue enriched	25	testis: 40.1	breast: 1.6	Not detected		
NKX3-1	BAPX2, NKX3.1, NKX3A	ENSG00000167034	NK3 homeobox 1	8	23678693-23682927	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA078571	Enhanced					Tissue enriched	Tissue enriched	11	prostate: 485.5	testis: 45.0	Cell line enhanced		SiHa: 27.8;U-138 MG: 25.5
SGSM1	KIAA1941, RUTBC2	ENSG00000167037	Small G protein signaling modulator 1	22	24806169-24927578	Predicted intracellular proteins	Evidence at protein level	HPA003986	Approved					Mixed	Tissue enhanced		cerebral cortex: 14.8;parathyroid gland: 19.0	fallopian tube: 7.6	Cell line enhanced		RPMI-8226: 1.5;SCLC-21H: 2.4;SH-SY5Y: 1.4
DUSP18	DUSP20	ENSG00000167065	Dual specificity phosphatase 18	22	30652051-30667890	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034070, HPA051349	Approved		Supported	Nucleoplasm		Mixed	Mixed			testis: 22.3	Expressed in all		
TEF	KIAA1655	ENSG00000167074	TEF, PAR bZIP transcription factor	22	41367333-41399326	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.47e-11 (favourable)	Expressed in all	Mixed			parathyroid gland: 58.6	Expressed in all		
MEI1	MGC40042, SPATA38	ENSG00000167077	Meiotic double-stranded break formation protein 1	22	41699499-41799456	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049240	Approved		Uncertain	Nucleoplasm<br>Plasma membrane	Cervical cancer:1.59e-6 (favourable)	Tissue enhanced	Tissue enhanced		testis: 18.6	spleen: 10.7	Cell line enhanced		HMC-1: 7.9;Karpas-707: 21.6;U-266/70: 24.1
B4GALNT2	Cad, GALGT2, Sda	ENSG00000167080	Beta-1,4-N-acetyl-galactosaminyltransferase 2	17	49132460-49176840	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015721	Approved				Renal cancer:1.29e-5 (favourable)	Mixed	Tissue enhanced		colon: 33.3	rectum: 14.9	Mixed		
PBX3		ENSG00000167081	PBX homeobox 3	9	125747345-125967377	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003881	Supported		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 340.6	Mixed		
GNGT2	GNG9	ENSG00000167083	G protein subunit gamma transducin 2	17	49202791-49210574	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA043381	Supported				Renal cancer:3.11e-4 (unfavourable)	Mixed	Mixed			spleen: 26.3	Cell line enhanced		Daudi: 59.2;HDLM-2: 66.4;RH-30: 24.6
PHB	PHB1	ENSG00000167085	Prohibitin	17	49404049-49414905	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003280	Supported		Supported	Vesicles<br>Mitochondria	Head and neck cancer:1.58e-4 (unfavourable), Renal cancer:3.77e-4 (favourable), Liver cancer:9.91e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 202.4	Expressed in all		
SNRPD1	HsT2456, Sm-D1, SNRPD	ENSG00000167088	Small nuclear ribonucleoprotein D1 polypeptide	18	21612267-21633524	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040516	Supported				Ovarian cancer:7.90e-6 (favourable), Liver cancer:1.82e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 81.2	Expressed in all		
TTC16	FLJ32780	ENSG00000167094	Tetratricopeptide repeat domain 16	9	127716066-127731600	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	12	fallopian tube: 10.9;testis: 18.3	lung: 1.1	Not detected		
SUN5	dJ726C3.1, SPAG4L, TSARG4	ENSG00000167098	Sad1 and UNC84 domain containing 5	20	32983773-33004433	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048529	Enhanced					Not detected	Tissue enriched	411	testis: 41.0	all non-specific tissues: 0.0	Not detected		
SAMD14	FLJ36890	ENSG00000167100	Sterile alpha motif domain containing 14	17	50110040-50129882	Predicted intracellular proteins	Evidence at protein level	HPA051916	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.2	testis: 1.8	Cell line enhanced		HDLM-2: 12.8;HEL: 7.8;HMC-1: 24.7;SH-SY5Y: 14.0
PIP5KL1	bA203J24.5, MGC46424	ENSG00000167103	Phosphatidylinositol-4-phosphate 5-kinase like 1	9	127920879-127930797	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056240	Uncertain		Supported	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 3.8	skin: 2.2	Cell line enhanced		Karpas-707: 32.1;RPMI-8226: 21.0
BPIFB6	BPIL3, LPLUNC6	ENSG00000167104	BPI fold containing family B member 6	20	33031648-33044047	Predicted secreted proteins	Evidence at protein level	HPA043057	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM92	FLJ33318	ENSG00000167105	Transmembrane protein 92	17	50271406-50281485	Predicted membrane proteins	Evidence at protein level	HPA063009, HPA069820	Approved		Supported	Nucleoplasm	Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 40.2;small intestine: 50.6	gallbladder: 21.8	Cell line enhanced		A549: 16.5;CACO-2: 25.7;CAPAN-2: 25.7;EFO-21: 56.2
FAM102A	bA203J24.7, C9orf132, Eeig1, SYM-3A	ENSG00000167106	Family with sequence similarity 102 member A	9	127940579-127980513	Predicted intracellular proteins	Evidence at protein level	HPA036030			Approved	Cytosol		Expressed in all	Mixed			stomach: 100.1	Expressed in all		
ACSF2	ACSMW, FLJ20920	ENSG00000167107	Acyl-CoA synthetase family member 2	17	50426158-50474845	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA024693	Enhanced		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 136.9	thyroid gland: 68.6	Expressed in all		
GOLGA2	GM130, golgin-95	ENSG00000167110	Golgin A2	9	128255829-128275995	Predicted intracellular proteins	Evidence at protein level	CAB015421, HPA021178, HPA021230, HPA021799	Enhanced		Enhanced	Golgi apparatus	Renal cancer:9.77e-5 (favourable), Colorectal cancer:1.64e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 161.0	Expressed in all		
TRUB2	CLONE24922	ENSG00000167112	TruB pseudouridine synthase family member 2	9	128305161-128322742	Predicted intracellular proteins	Evidence at protein level	HPA021211, HPA052190	Uncertain		Supported	Cytosol	Renal cancer:5.57e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.0	Expressed in all		
COQ4	CGI-92	ENSG00000167113	Coenzyme Q4	9	128322536-128334072	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021406, HPA042945	Supported		Supported	Mitochondria	Endometrial cancer:4.93e-6 (favourable), Renal cancer:5.76e-6 (favourable), Cervical cancer:2.97e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 64.9	Expressed in all		
SLC27A4	ACSVL4, FATP4	ENSG00000167114	Solute carrier family 27 member 4	9	128340646-128361470	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007293, CAB009771	Approved		Supported	Vesicles	Renal cancer:2.61e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 72.1	Expressed in all		
URM1	C9orf74, MGC2668	ENSG00000167118	Ubiquitin related modifier 1	9	128371319-128392016	Predicted intracellular proteins	Evidence at protein level	HPA053645, HPA065160	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.43e-6 (favourable), Liver cancer:6.91e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 25.1	Expressed in all		
CERCAM	CEECAM1, CerCAM, GLT25D3	ENSG00000167123	Cerebral endothelial cell adhesion molecule	9	128411751-128437351	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021657, HPA051595	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Renal cancer:3.33e-16 (unfavourable), Urothelial cancer:3.30e-5 (unfavourable), Ovarian cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 155.6	Mixed		
DOLPP1	LSFR2	ENSG00000167130	Dolichyldiphosphatase 1	9	129081100-129090438	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA019179	Approved		Approved	Vesicles<br>Intermediate filaments		Expressed in all	Expressed in all			duodenum: 25.8	Expressed in all		
CCDC103	CILD17, FLJ13094, FLJ34211, PR46b	ENSG00000167131	Coiled-coil domain containing 103	17	44899142-44905390	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043131			Approved	Cytosol		Not detected	Group enriched	7	fallopian tube: 24.5;testis: 27.0	thyroid gland: 3.6	Cell line enhanced		A549: 10.3;U-87 MG: 9.5
ENDOG		ENSG00000167136	Endonuclease G	9	128818474-128822677	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA021335, HPA021830	Approved				Renal cancer:1.06e-7 (favourable), Endometrial cancer:5.12e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 45.8	Expressed in all		
TBC1D21	MGC34741, MgcRabGAP	ENSG00000167139	TBC1 domain family member 21	15	73873608-73889214	Predicted intracellular proteins	Evidence at protein level	HPA043319	Enhanced	Supported				Not detected	Tissue enriched	621	testis: 62.0	all non-specific tissues: 0.0	Not detected		
PRRX2	PMX2, PRX2	ENSG00000167157	Paired related homeobox 2	9	129665641-129722674	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006607, HPA026808	Approved		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		cervix, uterine: 9.9;skin: 10.7	testis: 6.3	Cell line enhanced		BJ: 24.1;BJ hTERT+: 16.5;fHDF/TERT166: 32.1;U-2197: 31.5
UGT1A6	GNT1, HLUGP, UGT1F	ENSG00000167165	UDP glucuronosyltransferase family 1 member A6	2	233691607-233773300	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009819, HPA054065	Enhanced				Liver cancer:2.89e-6 (unfavourable)	Tissue enhanced	Group enriched	6	kidney: 75.4;liver: 72.4;urinary bladder: 107.9	esophagus: 15.2	Cell line enhanced		CACO-2: 44.4;EFO-21: 75.2;HaCaT: 258.5;RT4: 119.0
C15orf39	DKFZP434H132, FLJ46337	ENSG00000167173	Chromosome 15 open reading frame 39	15	75195643-75212169	Predicted intracellular proteins	Evidence at protein level	HPA039961, HPA041907	Uncertain		Enhanced	Cytosol	Renal cancer:3.05e-4 (unfavourable), Testis cancer:6.02e-4 (unfavourable), Melanoma:7.94e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 123.7	bone marrow: 39.1	Expressed in all		
ISLR2	KIAA1465	ENSG00000167178	Immunoglobulin superfamily containing leucine rich repeat 2	15	74100311-74138540	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012930, HPA067333	Uncertain					Mixed	Group enriched	5	cerebral cortex: 31.1;testis: 14.8	endometrium: 4.5	Group enriched	13	SCLC-21H: 68.2;SH-SY5Y: 91.6
SP2	KIAA0048	ENSG00000167182	Sp2 transcription factor	17	47896150-47928957	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003357, CAB010245	Supported		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:1.82e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.3	Expressed in all		
PRR15L	ATAD4, MGC11242	ENSG00000167183	Proline rich 15 like	17	47951967-47957878	Predicted intracellular proteins	Evidence at protein level	HPA022918	Approved		Approved	Cytosol	Renal cancer:6.29e-13 (favourable), Stomach cancer:1.69e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 180.5	small intestine: 141.6	Cell line enhanced		HaCaT: 18.3;MCF7: 15.0;SCLC-21H: 13.8;SK-BR-3: 26.8;T-47d: 22.7
COQ7	CAT5, CLK-1	ENSG00000167186	Coenzyme Q7, hydroxylase	16	19067599-19080095	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067252, HPA071922	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:8.23e-12 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.2	Expressed in all		
GPRC5B	RAIG-2	ENSG00000167191	G protein-coupled receptor class C group 5 member B	16	19856691-19886167	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015247	Enhanced		Supported	Nucleus<br>Nucleoli<br>Vesicles	Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 308.3	testis: 66.2	Cell line enhanced		EFO-21: 84.6;HHSteC: 50.7
CRK		ENSG00000167193	CRK proto-oncogene, adaptor protein	17	1420689-1463162	Predicted intracellular proteins	Evidence at protein level	CAB010485, HPA068087	Approved		Approved	Plasma membrane		Expressed in all	Expressed in all			thyroid gland: 61.0	Expressed in all		
C16orf92	FLJ25404	ENSG00000167194	Chromosome 16 open reading frame 92	16	30023334-30027736	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 22.9	cerebral cortex: 3.4	Cell line enhanced		RPMI-8226: 1.7;SCLC-21H: 9.5;SH-SY5Y: 1.9
GOLGA6C		ENSG00000167195	Golgin A6 family member C	15	75258599-75270199	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Tissue enriched	55	testis: 10.5	epididymis,liver,skeletal muscle: 0.1	Not detected		
FBXO22	FBX22, FISTC1	ENSG00000167196	F-box protein 22	15	75903859-75942510	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
TBC1D2B	KIAA1055	ENSG00000167202	TBC1 domain family member 2B	15	77984036-78077724	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041833, HPA048174, HPA052663	Approved		Supported	Cytosol		Expressed in all	Expressed in all			ovary: 57.3	Expressed in all		
NOD2	BLAU, CARD15, CD, CLR16.3, IBD1, NLRC2, PSORAS1	ENSG00000167207	Nucleotide binding oligomerization domain containing 2	16	50693603-50733077	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041985, HPA054494	Enhanced		Approved	Golgi apparatus<br>Cytosol		Mixed	Mixed			skin: 11.2	Cell line enhanced		HMC-1: 10.3;T-47d: 5.3;THP-1: 4.8;U-266/70: 12.4;U-266/84: 5.1
SNX20	SLIC-1, SLIC1	ENSG00000167208	Sorting nexin 20	16	50666300-50681353	Predicted intracellular proteins	Evidence at protein level	HPA043649	Uncertain		Uncertain	Nucleoplasm	Renal cancer:6.00e-6 (unfavourable), Head and neck cancer:6.56e-4 (favourable), Cervical cancer:9.07e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 31.5	appendix: 26.4	Cell line enhanced		HDLM-2: 27.0;HMC-1: 67.9;NB-4: 29.9;U-266/70: 19.2;U-937: 21.8
LOXHD1	DFNB77, FLJ32670, LH2D1	ENSG00000167210	Lipoxygenase homology domains 1	18	46476972-46657033	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	epididymis: 8.3;testis: 41.3	fallopian tube: 2.6	Not detected		
KATNAL2	DKFZP667C165, MGC33211	ENSG00000167216	Katanin catalytic subunit A1 like 2	18	46917492-47102243	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040712, HPA042029	Approved		Approved	Nucleoplasm<br>Intermediate filaments	Renal cancer:1.24e-7 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 45.1;testis: 32.6	thyroid gland: 24.4	Mixed		
HDHD2	DKFZP564D1378	ENSG00000167220	Haloacid dehalogenase like hydrolase domain containing 2	18	47107403-47150520	Predicted intracellular proteins	Evidence at protein level	HPA040697, CAB045978, HPA059818	Approved		Approved	Vesicles	Renal cancer:3.52e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.9	Expressed in all		
ZNF91	HPF7, HTF10	ENSG00000167232	Zinc finger protein 91	19	23304991-23395560	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Urothelial cancer:3.48e-4 (favourable), Renal cancer:7.58e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 17.6	Mixed		
IGF2	C11orf43, FLJ44734, IGF-II	ENSG00000167244	Insulin like growth factor 2	11	2129112-2141238	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007556, HPA007993	Enhanced		Approved	Nucleoplasm<br>Vesicles	Liver cancer:7.12e-4 (favourable)	Group enriched	Tissue enriched	18	placenta: 3962.9	fallopian tube: 217.6	Cell line enhanced		CACO-2: 711.5;Hep G2: 406.1;LHCN-M2: 277.7;RH-30: 396.9;SH-SY5Y: 525.9
RNF214	DKFZp547C195	ENSG00000167257	Ring finger protein 214	11	117232625-117286445	Predicted intracellular proteins	Evidence at protein level	HPA039332	Approved		Approved	Golgi apparatus<br>Cytosol	Liver cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 33.4	Expressed in all		
CDK12	CRK7, CRKR, CRKRS, KIAA0904	ENSG00000167258	Cyclin dependent kinase 12	17	39461511-39564907	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008038	Supported		Supported	Nucleus		Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
DPEP2		ENSG00000167261	Dipeptidase 2	16	67987394-68000586	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035644	Approved				Testis cancer:8.47e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 38.7	lung: 27.9	Cell line enhanced		HEL: 3.7;HMC-1: 16.1;U-937: 4.9
DUS2	DUS2L, FLJ20399, SMM1	ENSG00000167264	Dihydrouridine synthase 2	16	67987746-68079320	Predicted intracellular proteins	Evidence at protein level	HPA042560, HPA043528	Enhanced		Enhanced	Cytosol	Renal cancer:3.50e-5 (favourable)	Expressed in all	Mixed			testis: 39.2	Expressed in all		
POP5		ENSG00000167272	POP5 homolog, ribonuclease P/MRP subunit	12	120578764-120581398	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047598, HPA069204	Approved		Approved	Nucleus<br>Nucleoli	Cervical cancer:2.68e-5 (favourable), Renal cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.8	Expressed in all		
ENGASE	FLJ21865	ENSG00000167280	Endo-beta-N-acetylglucosaminidase	17	79074939-79088599	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021551	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:8.97e-6 (unfavourable), Urothelial cancer:8.73e-5 (favourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			spleen: 28.1	Mixed		
RBFOX3	FOX-3, HRNBP3, NeuN	ENSG00000167281	RNA binding protein, fox-1 homolog 3	17	79089345-79516148	Predicted intracellular proteins	Evidence at protein level	HPA030790, CAB078782	Enhanced	Approved	Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		cerebral cortex: 62.3;seminal vesicle: 33.2	prostate: 24.1	Group enriched	7	A549: 14.1;NTERA-2: 13.9;SCLC-21H: 26.0;U-2 OS: 10.8
ATP5L	ATP5JG	ENSG00000167283	ATP synthase, H+ transporting, mitochondrial Fo complex subunit G	11	118401154-118431496	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044629	Approved		Supported	Mitochondria	Renal cancer:4.09e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 117.0	Expressed in all		
CD3D	T3D	ENSG00000167286	CD3d molecule	11	118338954-118342744	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013055	Enhanced				Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 199.3;tonsil: 119.1	appendix: 86.9	Cell line enriched	7	MOLT-4: 903.0
TBC1D16	FLJ20748, MGC25062	ENSG00000167291	TBC1 domain family member 16	17	79932343-80035848	Predicted intracellular proteins	Evidence at protein level	HPA024482, HPA065839	Approved		Approved	Intermediate filaments		Expressed in all	Mixed			adipose tissue: 40.7	Cell line enhanced		SK-MEL-30: 155.6
TEPSIN	C17orf56, ENTHD2, FLJ31528	ENSG00000167302	TEPSIN, adaptor related protein complex 4 accessory protein	17	81228277-81239091	Predicted intracellular proteins	Evidence at protein level	HPA063410			Supported	Nuclear membrane<br>Nuclear speckles<br>Golgi apparatus	Renal cancer:7.31e-8 (unfavourable), Pancreatic cancer:6.95e-4 (favourable), Head and neck cancer:9.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 15.8	Expressed in all		
MYO5B	KIAA1119	ENSG00000167306	Myosin VB	18	49822813-50195093	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040593, HPA040902, HPA069773	Enhanced		Approved	Plasma membrane	Renal cancer:1.45e-11 (favourable), Pancreatic cancer:2.26e-5 (unfavourable)	Expressed in all	Mixed			small intestine: 67.6	Cell line enhanced		HaCaT: 88.6;RH-30: 147.5
ART5		ENSG00000167311	ADP-ribosyltransferase 5	11	3638503-3642316	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA041637, HPA044099	Uncertain				Renal cancer:1.85e-4 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 10.2;testis: 22.6	endometrium: 5.1	Cell line enhanced		BEWO: 2.9;HEK 293: 1.9;U-2 OS: 2.1
ACAA2	DSAEC	ENSG00000167315	Acetyl-CoA acyltransferase 2	18	49782167-49813960	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042303	Enhanced		Supported	Mitochondria	Renal cancer:1.36e-10 (favourable), Endometrial cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 509.5	Mixed		
STIM1	D11S4896E, GOK	ENSG00000167323	Stromal interaction molecule 1	11	3854527-4093210	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011088, HPA012123, CAB037128, CAB037288	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 86.8	Expressed in all		
RRM1		ENSG00000167325	Ribonucleotide reductase catalytic subunit M1	11	4094707-4138876	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022093, HPA057265, HPA064297	Enhanced		Enhanced	Cytosol	Liver cancer:1.53e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 60.4	Expressed in all		
OR51E2	PSGR	ENSG00000167332	Olfactory receptor family 51 subfamily E member 2	11	4680171-4697854	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	8	prostate: 45.9	placenta: 5.8	Cell line enhanced		ASC TERT1: 1.3
TRIM68	FLJ10369, RNF137, SS-56	ENSG00000167333	Tripartite motif containing 68	11	4598672-4608259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023455	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:4.14e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.0	Mixed		
MMP26	endometase, MGC126590, MGC126592	ENSG00000167346	Matrix metallopeptidase 26	11	4704927-4992429	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	63	endometrium: 23.9	prostate,testis: 0.3	Not detected		
OR51I1		ENSG00000167359	Olfactory receptor family 51 subfamily I member 1	11	5440570-5441514	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
OR51Q1		ENSG00000167360	Olfactory receptor family 51 subfamily Q member 1 (gene/pseudogene)	11	5422111-5423206	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044998	Uncertain					Not detected	Not detected			epididymis: 0.1	Cell line enriched	23	RT4: 2.2
FN3K		ENSG00000167363	Fructosamine 3 kinase	17	82735575-82751197	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059151, HPA061358	Enhanced		Approved	Mitochondria	Renal cancer:1.39e-6 (favourable), Endometrial cancer:1.10e-4 (favourable), Pancreatic cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.8	Cell line enhanced		HAP1: 34.0;Hep G2: 42.8
PRRT2	DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC	ENSG00000167371	Proline rich transmembrane protein 2	16	29811382-29815892	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014447, HPA019203	Enhanced		Supported	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 98.1	ovary: 54.6	Cell line enhanced		AF22: 26.4;REH: 19.4;U-138 MG: 18.0
ZNF23	KOX16, Zfp612, ZNF359, ZNF612	ENSG00000167377	Zinc finger protein 23	16	71447597-71463095	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023534	Uncertain		Approved	Cytosol		Not detected	Mixed			cerebral cortex: 12.0	Expressed in all		
IRGQ	FKSG27, IRGQ1	ENSG00000167378	Immunity related GTPase Q	19	43584369-43596135	Predicted intracellular proteins	Evidence at protein level	HPA043254, HPA050338	Enhanced		Supported	Vesicles	Pancreatic cancer:3.57e-5 (favourable), Renal cancer:3.92e-4 (favourable), Cervical cancer:5.17e-4 (favourable), Liver cancer:9.60e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.2	Mixed		
ZNF226		ENSG00000167380	Zinc finger protein 226	19	44165073-44178381	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006145, CAB034353	Uncertain		Approved	Nuclear bodies	Urothelial cancer:2.37e-5 (favourable), Pancreatic cancer:8.34e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
ZNF180	HHZ168	ENSG00000167384	Zinc finger protein 180	19	44474428-44500524	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028979, HPA028980	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 12.3	Mixed		
PPP2R3B	PPP2R3L, PPP2R3LY, PR48	ENSG00000167393	Protein phosphatase 2 regulatory subunit B''beta	X	333963-386955	Predicted intracellular proteins	Evidence at protein level	HPA074545			Uncertain	Endoplasmic reticulum	Urothelial cancer:1.90e-5 (favourable), Pancreatic cancer:2.92e-5 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 14.7	heart muscle: 4.6	Cell line enhanced		PC-3: 20.0;U-698: 23.8
ZNF668	FLJ13479	ENSG00000167394	Zinc finger protein 668	16	31060843-31074320	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043048	Uncertain		Approved	Nucleus<br>Nucleoli	Prostate cancer:6.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 6.9	Expressed in all		
ZNF646	KIAA0296	ENSG00000167395	Zinc finger protein 646	16	31074422-31084196	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042364, HPA066468	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.28e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.3	spleen: 10.8	Expressed in all		
VKORC1	VKCFD2	ENSG00000167397	Vitamin K epoxide reductase complex subunit 1	16	31090842-31095980	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA042720	Approved		Supported	Endoplasmic reticulum	Renal cancer:2.09e-10 (unfavourable)	Expressed in all	Expressed in all			liver: 141.4	Expressed in all		
GNG8		ENSG00000167414	G protein subunit gamma 8	19	46634076-46634685	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Head and neck cancer:2.14e-5 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 29.3	cerebral cortex: 10.2	Group enriched	10	SCLC-21H: 310.9;SH-SY5Y: 1226.5
LPO	SPO	ENSG00000167419	Lactoperoxidase	17	58218548-58268518	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028688	Enhanced	Supported				Not detected	Tissue enriched	221	salivary gland: 372.8	testis: 1.6	Cell line enriched	7	THP-1: 6.2
CA4	CAIV, Car4, RP17	ENSG00000167434	Carbonic anhydrase 4	17	60149936-60170899	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011089, HPA017258	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		colon: 253.5;rectum: 180.9	adipose tissue: 88.7	Not detected		
SMG8	C17orf71, FLJ10587, FLJ23205	ENSG00000167447	SMG8, nonsense mediated mRNA decay factor	17	59209400-59215247	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024841	Approved		Approved	Nucleoplasm	Liver cancer:3.72e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 13.9	Expressed in all		
TPM4		ENSG00000167460	Tropomyosin 4	19	16067021-16103005	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004685, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.26e-10 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 814.8	Expressed in all		
RAB8A	MEL, RAB8	ENSG00000167461	RAB8A, member RAS oncogene family	19	16111629-16134234	Predicted intracellular proteins	Evidence at protein level	HPA041945			Supported	Nucleus<br>Plasma membrane	Renal cancer:6.56e-5 (unfavourable), Thyroid cancer:1.71e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 64.5	Expressed in all		
GPX4	MCSP, PHGPx	ENSG00000167468	Glutathione peroxidase 4	19	1103926-1106791	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008630, HPA047224, HPA058546	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Endometrial cancer:1.84e-5 (favourable), Cervical cancer:7.18e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable), Renal cancer:8.61e-4 (favourable)	Expressed in all	Expressed in all			testis: 1140.7	Expressed in all		
MIDN		ENSG00000167470	Midnolin	19	1248553-1259140	Predicted intracellular proteins	Evidence at protein level	HPA042018, HPA049432	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 51.5	Expressed in all		
JSRP1	FLJ32416, JP-45	ENSG00000167476	Junctional sarcoplasmic reticulum protein 1	19	2252252-2269759	Predicted intracellular proteins	Evidence at protein level	HPA044741	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	39	skeletal muscle: 116.2	duodenum: 2.9	Cell line enhanced		Karpas-707: 117.9;RPMI-8226: 73.9;U-266/70: 338.6
FAM129C	BCNP1, FLJ39802	ENSG00000167483	Family with sequence similarity 129 member C	19	17523301-17553839	Predicted intracellular proteins	Evidence at protein level	HPA043277	Approved					Mixed	Group enriched	15	appendix: 13.9;bone marrow: 11.3;lymph node: 28.2;spleen: 36.9;tonsil: 9.4	gallbladder: 1.3	Group enriched	20	Daudi: 35.8;REH: 23.1;U-698: 21.5
KLHL26		ENSG00000167487	Kelch like family member 26	19	18636965-18671714	Predicted intracellular proteins	Evidence at protein level	HPA023074	Uncertain				Renal cancer:1.25e-6 (favourable), Breast cancer:5.01e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.2	Mixed		
GATAD2A	p66alpha	ENSG00000167491	GATA zinc finger domain containing 2A	19	19385826-19508931	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006759, HPA024373	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 64.1	Expressed in all		
MVD	MPD	ENSG00000167508	Mevalonate diphosphate decarboxylase	16	88651935-88663161	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041404, HPA048250	Uncertain		Approved	Cell Junctions<br>Cytosol	Endometrial cancer:2.17e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 33.9	Expressed in all		
CDT1	DUP, RIS2	ENSG00000167513	Chromatin licensing and DNA replication factor 1	16	88803213-88809258	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017224	Approved		Supported	Nucleus<br>Nuclear bodies	Liver cancer:2.12e-6 (unfavourable), Renal cancer:2.69e-6 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 20.4	lymph node: 4.7	Mixed		
TRAPPC2L	HSPC176	ENSG00000167515	Trafficking protein particle complex 2 like	16	88856220-88862686	Predicted intracellular proteins	Evidence at protein level	HPA041714	Approved		Supported	Vesicles<br>Cytosol	Endometrial cancer:3.75e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 91.5	Expressed in all		
ANKRD11	LZ16, T13	ENSG00000167522	Ankyrin repeat domain 11	16	89267627-89490561	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB019288, HPA041593, HPA049470	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.39e-4 (unfavourable), Prostate cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 24.4	Expressed in all		
SPATA33	C16orf55, FLJ31606	ENSG00000167523	Spermatogenesis associated 33	16	89657802-89671272	Predicted intracellular proteins	Evidence at protein level	HPA045648, HPA073096	Enhanced		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:1.06e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 77.2	fallopian tube: 25.6	Expressed in all		
SGK494		ENSG00000167524	Uncharacterized serine/threonine-protein kinase SgK494	17	28607964-28614200	Predicted intracellular proteins	Evidence at protein level	HPA046590	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Mixed			testis: 10.5	Mixed		
PROCA1	MGC39650	ENSG00000167525	Protein interacting with cyclin A1	17	28703197-28711854	Predicted intracellular proteins	Evidence at transcript level	HPA023648	Approved					Mixed	Tissue enriched	20	testis: 139.5	spleen: 6.9	Cell line enhanced		REH: 11.1
RPL13	BBC1, D16S444E, L13	ENSG00000167526	Ribosomal protein L13	16	89560657-89566828	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051702	Approved		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:6.26e-4 (favourable), Renal cancer:6.64e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3872.9	Expressed in all		
ZNF641	FLJ31295	ENSG00000167528	Zinc finger protein 641	12	48337180-48351414	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035189	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:8.30e-5 (favourable), Ovarian cancer:3.91e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 28.8	Expressed in all		
LALBA	LYZL7	ENSG00000167531	Lactalbumin alpha	12	48567684-48570066	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB026343, HPA029855, HPA029856	Supported					Tissue enriched	Tissue enriched	566	breast: 2476.8	testis: 4.3	Not detected		
CACNB3	CACNLB3	ENSG00000167535	Calcium voltage-gated channel auxiliary subunit beta 3	12	48813794-48828941	FDA approved drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA059515			Approved	Golgi apparatus<br>Vesicles		Mixed	Mixed			endometrium: 40.0	Cell line enhanced		U-937: 85.2
DHRS13	MGC23280, SDR7C5	ENSG00000167536	Dehydrogenase/reductase 13	17	28897781-28903071	Predicted intracellular proteins	Evidence at protein level	HPA022991	Uncertain		Approved	Vesicles	Liver cancer:3.39e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 25.2	Mixed		
TP53I13	DSCP1	ENSG00000167543	Tumor protein p53 inducible protein 13	17	29566052-29573157	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.10e-6 (unfavourable), Pancreatic cancer:3.13e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 53.3	Expressed in all		
KMT2D	ALR, CAGL114, MLL2, MLL4, TNRC21	ENSG00000167548	Lysine methyltransferase 2D	12	49018975-49059774	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035977	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
CORO6	FLJ14871	ENSG00000167549	Coronin 6	17	29614756-29622907	Predicted intracellular proteins	Evidence at protein level	HPA021556			Supported	Golgi apparatus	Renal cancer:9.61e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		skeletal muscle: 127.5	heart muscle: 46.5	Cell line enhanced		REH: 15.0;RH-30: 17.3;SH-SY5Y: 23.2
RHEBL1	FLJ25797, MGC34869	ENSG00000167550	Ras homolog enriched in brain like 1	12	49064685-49070025	Predicted intracellular proteins	Evidence at protein level	HPA053111, HPA061001	Uncertain		Uncertain	Nucleus<br>Centrosome		Mixed	Mixed			fallopian tube,lymph node: 3.8	Cell line enhanced		HDLM-2: 26.3;U-266/84: 40.4
TUBA1A	B-ALPHA-1, FLJ25113, TUBA3	ENSG00000167552	Tubulin alpha 1a	12	49184796-49189324	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB008686, HPA039247, HPA043684, HPA063394	Enhanced		Enhanced	Microtubules	Renal cancer:2.90e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 1373.1	Expressed in all		
TUBA1C	bcm948, MGC10851, MGC14580, TUBA6	ENSG00000167553	Tubulin alpha 1c	12	49188736-49274603	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Supported		Supported	Microtubules	Liver cancer:8.48e-8 (unfavourable), Renal cancer:6.26e-7 (unfavourable), Pancreatic cancer:5.64e-6 (unfavourable), Colorectal cancer:7.37e-5 (favourable), Breast cancer:2.90e-4 (unfavourable), Lung cancer:6.85e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 311.2	Expressed in all		
ZNF610	FLJ36040	ENSG00000167554	Zinc finger protein 610	19	52336245-52367778	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055771, HPA078134	Enhanced		Approved	Nucleus	Renal cancer:1.05e-7 (favourable), Ovarian cancer:3.38e-4 (favourable)	Mixed	Tissue enhanced		testis: 22.0	ovary: 10.4	Mixed		
ZNF528	KIAA1827	ENSG00000167555	Zinc finger protein 528	19	52397849-52418412	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065435			Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 31.1	Mixed		
ZNF701	FLJ10891	ENSG00000167562	Zinc finger protein 701	19	52555457-52587174	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005532	Uncertain		Approved	Nucleoplasm<br>Microtubule organizing center	Urothelial cancer:4.89e-5 (favourable)	Mixed	Expressed in all			thyroid gland: 16.2	Mixed		
SERTAD3	RBT1	ENSG00000167565	SERTA domain containing 3	19	40440844-40444705	Predicted intracellular proteins	Evidence at protein level	HPA068262			Supported	Nucleoli		Expressed in all	Expressed in all			prostate: 40.4	Expressed in all		
NCKAP5L	KIAA1602	ENSG00000167566	NCK associated protein 5 like	12	49791146-49828750	Predicted intracellular proteins	Evidence at protein level	HPA041034	Approved		Approved	Golgi apparatus	Renal cancer:1.16e-5 (unfavourable), Liver cancer:2.07e-4 (unfavourable), Pancreatic cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			placenta: 12.9	Mixed		
RAB4B	FLJ78649, MGC52123	ENSG00000167578	RAB4B, member RAS oncogene family	19	40778216-40796938	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.99e-5 (favourable), Renal cancer:1.28e-4 (unfavourable), Pancreatic cancer:2.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 56.1	Expressed in all		
AQP2		ENSG00000167580	Aquaporin 2	12	49950741-49958881	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046834	Enhanced					Group enriched	Group enriched	132	kidney: 435.9;seminal vesicle: 302.5	testis: 2.8	Cell line enhanced		EFO-21: 3.0;HMC-1: 1.7
GPD1		ENSG00000167588	Glycerol-3-phosphate dehydrogenase 1	12	50103819-50111319	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044620	Enhanced					Mixed	Tissue enhanced		adipose tissue: 636.1;skeletal muscle: 195.7	kidney: 148.1	Cell line enhanced		ASC diff: 86.3;CACO-2: 22.1;Hep G2: 17.0;RPMI-8226: 20.7
PROSER3	C19orf55, FLJ30657	ENSG00000167595	Proline and serine rich 3	19	35758143-35771028	Predicted intracellular proteins	Evidence at protein level	HPA058492	Approved		Approved	Golgi apparatus	Renal cancer:3.74e-7 (unfavourable)	Expressed in all	Mixed			testis: 14.1	Mixed		
CYP2S1		ENSG00000167600	Cytochrome P450 family 2 subfamily S member 1	19	41193049-41207539	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA049227, HPA069248	Approved		Approved	Endoplasmic reticulum	Renal cancer:1.60e-6 (unfavourable)	Expressed in all	Tissue enhanced		duodenum: 96.7;small intestine: 68.6;stomach: 111.7	colon: 25.9	Cell line enhanced		A549: 83.4;CACO-2: 39.6;HaCaT: 43.5;NTERA-2: 68.5
AXL	ARK, JTK11, Tyro7, UFO	ENSG00000167601	AXL receptor tyrosine kinase	19	41219203-41261766	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032501, HPA037422, HPA037423	Uncertain				Renal cancer:2.53e-7 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 54.6	Mixed		
NFKBID	IkappaBNS, TA-NFKBH	ENSG00000167604	NFKB inhibitor delta	19	35887653-35902303	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043573			Approved	Mitochondria	Urothelial cancer:8.34e-6 (favourable), Head and neck cancer:5.43e-4 (favourable), Breast cancer:6.01e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 9.8	appendix: 5.9	Mixed		
TMC4		ENSG00000167608	Transmembrane channel like 4	19	54160108-54173250	Predicted membrane proteins	Evidence at protein level	HPA048635	Approved				Renal cancer:1.54e-8 (favourable)	Expressed in all	Tissue enhanced		duodenum: 30.8	small intestine: 22.1	Cell line enriched	7	T-47d: 27.9
ANKRD33	C12orf7, DKFZp686O1689, PANKY	ENSG00000167612	Ankyrin repeat domain 33	12	51887960-51891664	Predicted intracellular proteins	Evidence at transcript level	HPA040013, HPA058753	Uncertain					Not detected	Not detected			placenta: 0.5	Not detected		
LAIR1	CD305	ENSG00000167613	Leukocyte associated immunoglobulin like receptor 1	19	54351384-54370558	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011155	Enhanced		Supported	Plasma membrane	Renal cancer:5.01e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 7.1	appendix: 4.2	Cell line enhanced		HMC-1: 6.6;Karpas-707: 14.1;THP-1: 15.4
TTYH1		ENSG00000167614	Tweety family member 1	19	54415219-54436900	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023617, HPA050655	Approved				Breast cancer:3.64e-4 (favourable)	Tissue enriched	Tissue enriched	27	cerebral cortex: 57.7	fallopian tube,testis: 2.1	Group enriched	6	AF22: 5.8;AN3-CA: 17.4;U-2 OS: 7.0
LENG8	KIAA1932, MGC40108, pp13842	ENSG00000167615	Leukocyte receptor cluster member 8	19	54448887-54462037	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042004, HPA042056, HPA061571	Uncertain		Supported	Nucleus	Renal cancer:3.30e-7 (unfavourable), Urothelial cancer:2.73e-6 (favourable), Head and neck cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			spleen: 165.7	Expressed in all		
CDC42EP5	Borg3, CEP5	ENSG00000167617	CDC42 effector protein 5	19	54465026-54473264	Predicted intracellular proteins	Evidence at protein level	HPA043449	Approved				Renal cancer:2.79e-5 (unfavourable), Urothelial cancer:1.36e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 3.1;prostate: 2.4	adipose tissue: 0.9	Not detected		
LAIR2	CD306	ENSG00000167618	Leukocyte associated immunoglobulin like receptor 2	19	54497879-54510687	CD markers, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 1.4	spleen: 0.8	Cell line enhanced		BEWO: 2.2
TMEM145	FLJ90805	ENSG00000167619	Transmembrane protein 145	19	42313325-42325062	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060462	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	6	cerebral cortex: 38.3	adrenal gland: 5.9	Cell line enhanced		SCLC-21H: 32.9;SH-SY5Y: 14.2
ZNF526	KIAA1951, MGC4267	ENSG00000167625	Zinc finger protein 526	19	42220271-42228201	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023070, HPA056609	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			skin: 6.2	Expressed in all		
TRAPPC9	IKBKBBP, KIAA1882, MRT13, NIBP, T1, TRS120	ENSG00000167632	Trafficking protein particle complex 9	8	139730343-140458579	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026579			Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:5.11e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 49.7	Expressed in all		
KIR3DL1	AMB11, CD158E1, CD158e1/2, CD158e2, cl-11, cl-2, KIR, nkat3, NKB1, NKB1B	ENSG00000167633	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1	19	54816468-54830778	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			bone marrow: 0.1	Not detected		
NLRP7	CLR19.4, NALP7, NOD12, PAN7, PYPAF3	ENSG00000167634	NLR family pyrin domain containing 7	19	54923509-54966312	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051382	Uncertain		Uncertain	Golgi apparatus		Tissue enriched	Tissue enriched	14	testis: 2.8	duodenum: 0.2	Cell line enhanced		BEWO: 1.8;U-266/84: 3.4
ZNF146	OZF	ENSG00000167635	Zinc finger protein 146	19	36214602-36238774	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003358	Supported		Supported	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 63.2	Expressed in all		
ZNF283		ENSG00000167637	Zinc finger protein 283	19	43827292-43852017	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072977			Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 10.2	Cell line enhanced		U-2 OS: 25.1
PPP1R14A	CPI-17, PPP1INL	ENSG00000167641	Protein phosphatase 1 regulatory inhibitor subunit 14A	19	38251237-38256591	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005044, CAB009803, HPA042097, HPA054534	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.25e-5 (unfavourable), Stomach cancer:7.12e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 110.8	Cell line enhanced		A549: 89.9;EFO-21: 78.3;K-562: 38.3
SPINT2	HAI-2, Kop	ENSG00000167642	Serine peptidase inhibitor, Kunitz type 2	19	38244035-38292614	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011101, CAB018969	Approved		Uncertain	Plasma membrane<br>Intermediate filaments<br>Cytosol	Renal cancer:3.41e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 539.2	Cell line enhanced		A-431: 736.5;CAPAN-2: 1060.7
C19orf33	H2RSP, IMUP, IMUP-1, IMUP-2	ENSG00000167644	Chromosome 19 open reading frame 33	19	38304161-38305009	Predicted intracellular proteins	Evidence at protein level	HPA054406, HPA059696	Uncertain		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.05e-4 (unfavourable), Lung cancer:5.42e-4 (unfavourable)	Mixed	Mixed			esophagus: 177.8	Cell line enhanced		A-431: 535.8;A549: 841.0;CAPAN-2: 498.9;PC-3: 484.7
YIF1B	FinGER8	ENSG00000167645	Yip1 interacting factor homolog B, membrane trafficking protein	19	38305104-38317273	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039328, HPA055257, HPA062675	Approved		Approved	Golgi apparatus<br>Vesicles	Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.5	Expressed in all		
DNAAF3	C19orf51, CILD2, FLJ36139, FLJ40069, PCD, PF22	ENSG00000167646	Dynein axonemal assembly factor 3	19	55158661-55166722	Predicted intracellular proteins	Evidence at protein level	HPA056220			Approved	Nuclear bodies<br>Mitochondria	Renal cancer:1.83e-5 (unfavourable)	Mixed	Group enriched	12	fallopian tube: 69.1;testis: 67.9	lung: 5.9	Cell line enhanced		HEK 293: 24.3;HEL: 28.5;K-562: 22.5
PSCA		ENSG00000167653	Prostate stem cell antigen	8	142670308-142682724	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030783, HPA056418	Approved		Supported	Plasma membrane	Pancreatic cancer:5.60e-5 (unfavourable)	Tissue enriched	Group enriched	8	prostate: 344.6;stomach: 1648.5;urinary bladder: 343.4	esophagus: 101.7	Cell line enhanced		CAPAN-2: 18.6;HeLa: 27.5;RT4: 47.1
ATCAY	BNIP-H	ENSG00000167654	ATCAY, caytaxin	19	3879864-3928079	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA017755	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 108.9	adrenal gland: 8.8	Cell line enhanced		NTERA-2: 7.2;SCLC-21H: 15.5;SH-SY5Y: 9.8
LY6D	E48	ENSG00000167656	Lymphocyte antigen 6 family member D	8	142784880-142786592	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA024755, HPA064317	Enhanced				Pancreatic cancer:1.94e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)	Group enriched	Group enriched	11	esophagus: 631.6;skin: 717.0	tonsil: 61.0	Cell line enriched	26	A-431: 128.0
DAPK3	ZIP, ZIPK	ENSG00000167657	Death associated protein kinase 3	19	3958453-3971123	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028569, HPA064809	Approved		Approved	Nucleus	Endometrial cancer:2.01e-5 (favourable), Renal cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 76.3	Expressed in all		
EEF2	EEF-2, EF2	ENSG00000167658	Eukaryotic translation elongation factor 2	19	3976056-3985469	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007795, HPA040534, HPA057351	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.81e-6 (favourable), Renal cancer:1.25e-5 (favourable)	Expressed in all	Expressed in all			ovary: 1621.6	Expressed in all		
TMIGD2	CD28H, IGPR-1, MGC23244	ENSG00000167664	Transmembrane and immunoglobulin domain containing 2	19	4292232-4302431	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011081	Approved					Mixed	Tissue enhanced		lymph node: 7.4	appendix: 5.5	Cell line enhanced		BEWO: 12.1;HEL: 26.9;MOLT-4: 21.9
CHAF1A	CAF-1, CAF1, CAF1B, CAF1P150, MGC71229, P150	ENSG00000167670	Chromatin assembly factor 1 subunit A	19	4402662-4445018	Predicted intracellular proteins	Evidence at protein level	CAB015186	Enhanced		Supported	Nucleus<br>Cytosol	Stomach cancer:4.15e-6 (favourable), Cervical cancer:8.22e-5 (favourable)	Expressed in all	Mixed			testis: 21.9	Expressed in all		
UBXN6	UBXD1, UBXDC2	ENSG00000167671	UBX domain protein 6	19	4444999-4457822	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040906, HPA041313, HPA061872	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.78e-5 (favourable), Endometrial cancer:5.68e-5 (favourable), Pancreatic cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			testis: 138.8	Expressed in all		
CTB-50L17.10		ENSG00000167674	Hepatoma-derived growth factor-related protein 2 	19	4472287-4502211	Predicted intracellular proteins	Evidence at protein level	HPA042559, HPA044208	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:6.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
PLIN4	KIAA1881, S3-12	ENSG00000167676	Perilipin 4	19	4502180-4518465	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044682, HPA054657	Enhanced		Supported	Vesicles<br>Lipid droplets<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.31e-4 (unfavourable), Colorectal cancer:8.31e-4 (unfavourable)	Mixed	Tissue enriched	14	adipose tissue: 812.2	skeletal muscle: 59.1	Cell line enriched	7	ASC diff: 171.0
SEMA6B	SEM-SEMA-Y, SEMA-VIB, SEMAN, semaZ	ENSG00000167680	Semaphorin 6B	19	4542593-4559808	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB025157, HPA055778, HPA058523	Enhanced				Renal cancer:3.29e-5 (unfavourable), Thyroid cancer:1.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 65.5	spleen: 24.5	Cell line enhanced		Hep G2: 88.4;HMC-1: 180.6;HUVEC TERT2: 71.3;TIME: 88.7
ZNF444	EZF2, FLJ11137, ZSCAN17	ENSG00000167685	Zinc finger protein 444	19	56132599-56160893	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056895, HPA065203	Approved		Supported	Nucleus<br>Nucleoli	Urothelial cancer:1.87e-4 (favourable), Renal cancer:2.61e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 27.8	Expressed in all		
NXN	FLJ12614, NRX	ENSG00000167693	Nucleoredoxin	17	799313-979770	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023566	Approved		Supported	Golgi apparatus<br>Cytosol		Expressed in all	Mixed			endometrium: 42.7	Mixed		
FAM57A	CT120, FLJ22282	ENSG00000167695	Family with sequence similarity 57 member A	17	732412-742972	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.53e-6 (favourable), Renal cancer:1.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 82.7	esophagus: 25.9	Expressed in all		
GLOD4	C17orf25, CGI-150, HC71	ENSG00000167699	Glyoxalase domain containing 4	17	757097-783390	Predicted intracellular proteins	Evidence at protein level	HPA021623, HPA023246, HPA023248	Enhanced		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.18e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 82.7	Expressed in all		
MFSD3		ENSG00000167700	Major facilitator superfamily domain containing 3	8	144509074-144511213	Predicted membrane proteins	Evidence at protein level	HPA056013	Uncertain		Approved	Vesicles	Renal cancer:5.44e-7 (favourable), Cervical cancer:5.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 14.5	Mixed		
GPT	ALT1, GPT1	ENSG00000167701	Glutamic--pyruvic transaminase	8	144502973-144507174	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031059, HPA031060, CAB032997, CAB032999	Enhanced				Liver cancer:1.47e-5 (favourable), Renal cancer:2.19e-4 (favourable)	Tissue enriched	Mixed			liver: 25.0	Mixed		
KIFC2		ENSG00000167702	Kinesin family member C2	8	144466043-144474202	Predicted secreted proteins	Evidence at protein level	HPA029264	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 73.1	Mixed		
SLC43A2	MGC34680	ENSG00000167703	Solute carrier family 43 member 2	17	1569267-1628886	Predicted membrane proteins, Transporters	Evidence at protein level	HPA021564	Enhanced				Pancreatic cancer:1.05e-6 (favourable), Renal cancer:5.40e-5 (favourable)	Expressed in all	Tissue enhanced		placenta: 31.7	appendix: 17.0	Cell line enhanced		CACO-2: 14.8
RILP	FLJ31193	ENSG00000167705	Rab interacting lysosomal protein	17	1646145-1650077	Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.51e-5 (favourable), Urothelial cancer:7.12e-4 (favourable), Breast cancer:7.97e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 8.7	Cell line enhanced		HEL: 16.7;HMC-1: 8.2
SERPINF2	A2AP, AAP, ALPHA-2-PI, API, PLI	ENSG00000167711	Serpin family F member 2	17	1742836-1755268	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001885, CAB024863	Approved		Uncertain	Nucleoplasm<br>Vesicles	Liver cancer:2.26e-5 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 117.4;liver: 452.5	kidney: 63.3	Cell line enriched	24	Hep G2: 99.1
WDR81	CAMRQ2, FLJ33817, PPP1R166, SORF-2	ENSG00000167716	WD repeat domain 81	17	1716523-1738599	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023044	Uncertain		Approved	Nucleoplasm	Pancreatic cancer:3.30e-4 (favourable)	Expressed in all	Mixed			ovary,spleen: 10.4	Mixed		
SRR	ILV1, ISO1	ENSG00000167720	Serine racemase	17	2303383-2325260	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007529, CAB015343	Approved		Approved	Vesicles	Renal cancer:2.45e-6 (favourable), Endometrial cancer:6.20e-5 (favourable), Pancreatic cancer:8.16e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 25.5	Expressed in all		
TSR1	FLJ10534	ENSG00000167721	TSR1, ribosome maturation factor	17	2322503-2337507	Predicted intracellular proteins	Evidence at protein level	HPA024434, HPA053087	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
TRPV3	VRL3	ENSG00000167723	Transient receptor potential cation channel subfamily V member 3	17	3510502-3557995	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA069550			Approved	Plasma membrane<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		skin: 5.1;small intestine: 4.5	duodenum: 1.7	Cell line enhanced		BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
HSD11B1L	SCDR10, SDR26C2	ENSG00000167733	Hydroxysteroid 11-beta dehydrogenase 1 like	19	5680604-5688523	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA049078			Approved	Vesicles	Head and neck cancer:4.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.6	fallopian tube: 7.9	Cell line enhanced		SH-SY5Y: 20.1
CYB5D2	MGC32124	ENSG00000167740	Cytochrome b5 domain containing 2	17	4143168-4187310	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042299	Approved		Approved	Nuclear membrane<br>Nucleoli<br>Centrosome	Renal cancer:2.03e-10 (favourable), Liver cancer:4.98e-6 (favourable), Pancreatic cancer:7.76e-5 (favourable), Endometrial cancer:6.19e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 51.8	Expressed in all		
GGT6	FLJ90165	ENSG00000167741	Gamma-glutamyltransferase 6	17	4556927-4560818	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023362, HPA027213	Approved				Renal cancer:9.42e-7 (favourable), Lung cancer:4.35e-4 (favourable)	Mixed	Mixed			colon: 54.8	Group enriched	8	RT4: 48.3;SK-BR-3: 15.2;T-47d: 59.4
C19orf48	MGC13170	ENSG00000167747	Chromosome 19 open reading frame 48	19	50797704-50804929	Predicted intracellular proteins	Evidence at transcript level	HPA042000	Uncertain		Approved	Plasma membrane	Liver cancer:8.80e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 84.5	Expressed in all		
KLK1	Klk6	ENSG00000167748	Kallikrein 1	19	50819148-50823787	Enzymes, Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	36	pancreas: 1994.7;salivary gland: 2549.9	colon: 63.5	Cell line enriched	18	RPMI-8226: 26.9
KLK4	EMSP, EMSP1, KLK-L1, PRSS17, PSTS	ENSG00000167749	Kallikrein related peptidase 4	19	50906352-50910738	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051839	Enhanced					Tissue enriched	Tissue enriched	37	prostate: 406.5	skin: 10.8	Cell line enhanced		CAPAN-2: 5.7;HaCaT: 7.0
KLK2		ENSG00000167751	Kallikrein related peptidase 2	19	50861568-50880567	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000764	Supported					Tissue enriched	Tissue enriched	192	prostate: 867.2	testis: 4.5	Cell line enhanced		NB-4: 3.6
KLK5	KLK-L2, SCTE	ENSG00000167754	Kallikrein related peptidase 5	19	50943303-50953093	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA014343, CAB025503, CAB026341	Enhanced				Urothelial cancer:3.85e-6 (unfavourable), Endometrial cancer:2.33e-4 (unfavourable), Lung cancer:9.79e-4 (unfavourable)	Tissue enhanced	Tissue enriched	6	skin: 213.5	breast: 37.8	Group enriched	41	A-431: 414.4;HaCaT: 396.7
KLK6	Bssp, Klk7, neurosin, PRSS18, PRSS9	ENSG00000167755	Kallikrein related peptidase 6	19	50958631-50969673	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051837			Supported	Nucleoplasm<br>Nuclear membrane<br>Cytokinetic bridge	Endometrial cancer:1.38e-5 (unfavourable), Urothelial cancer:1.27e-4 (unfavourable), Pancreatic cancer:7.82e-4 (unfavourable), Lung cancer:8.85e-4 (unfavourable)	Tissue enhanced	Group enriched	5	cerebral cortex: 78.6;esophagus: 63.0;fallopian tube: 44.9;tonsil: 31.3	kidney: 10.2	Group enriched	15	A-431: 496.5;CAPAN-2: 1158.9
KLK11	PRSS20, TLSP	ENSG00000167757	Kallikrein related peptidase 11	19	51022216-51028039	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026340	Approved				Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 225.7;skin: 214.5	prostate: 104.9	Cell line enhanced		CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6
KLK13	KLK-L4	ENSG00000167759	Kallikrein related peptidase 13	19	51056206-51065114	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at protein level	HPA062136	Enhanced					Tissue enhanced	Tissue enriched	9	esophagus: 402.2	tonsil: 45.0	Cell line enriched	10	HaCaT: 16.8
ZNF83	FLJ11015, HPF1, ZNF816B	ENSG00000167766	Zinc finger protein 83	19	52594060-52690496	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA025970	Approved		Approved	Nucleoplasm	Urothelial cancer:6.92e-6 (favourable), Renal cancer:3.13e-5 (unfavourable), Head and neck cancer:3.83e-4 (favourable), Ovarian cancer:9.06e-4 (favourable), Melanoma:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 111.9	Mixed		
KRT80	KB20	ENSG00000167767	Keratin 80	12	52168996-52192000	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA077836, HPA077918			Enhanced	Intermediate filaments	Breast cancer:1.05e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 125.0	tonsil: 37.7	Cell line enhanced		A-431: 176.4;MCF7: 219.4;U-2 OS: 184.3
KRT1	EHK1, KRT1A	ENSG00000167768	Keratin 1	12	52674736-52680407	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002153, HPA017917, HPA062908	Enhanced					Group enriched	Tissue enriched	25	skin: 15454.7	breast: 622.4	Group enriched	36	HaCaT: 84.1;hTCEpi: 28.5
ACER1	ASAH3	ENSG00000167769	Alkaline ceramidase 1	19	6306142-6333629	Enzymes, Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	6	skin: 67.8	esophagus: 11.4	Cell line enhanced		T-47d: 2.7
OTUB1	FLJ20113, FLJ40710	ENSG00000167770	OTU deubiquitinase, ubiquitin aldehyde binding 1	11	63985853-64001811	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039176, CAB072836	Approved	Supported	Approved	Nucleus<br>Cytosol	Head and neck cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.0	Expressed in all		
RCOR2		ENSG00000167771	REST corepressor 2	11	63911221-63916844	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021638	Uncertain		Approved	Nucleus<br>Vesicles<br>Midbody		Mixed	Tissue enhanced		cerebral cortex: 13.2	testis: 3.7	Cell line enhanced		AF22: 39.9;NTERA-2: 52.3;SCLC-21H: 95.8;SH-SY5Y: 57.5
ANGPTL4	ARP4, FIAF, HFARP, NL2, PGAR, pp1158	ENSG00000167772	Angiopoietin like 4	19	8363289-8374373	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007879, CAB033770	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.34e-5 (unfavourable), Colorectal cancer:7.53e-4 (unfavourable), Lung cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 78.7	liver: 43.2	Cell line enhanced		HBEC3-KT: 161.5;TIME: 92.8;U-138 MG: 64.0
CD320	8D6, 8D6A	ENSG00000167775	CD320 molecule	19	8302127-8308356	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014500, HPA073489	Approved		Approved	Cytosol	Liver cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 77.2	Mixed		
SPRYD3	FLJ14800	ENSG00000167778	SPRY domain containing 3	12	53064316-53079420	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039426, HPA039685	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:1.78e-15 (favourable), Head and neck cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.9	Expressed in all		
IGFBP6		ENSG00000167779	Insulin like growth factor binding protein 6	12	53097436-53102345	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008005	Uncertain				Glioma:6.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 72.2	cervix, uterine: 47.7	Cell line enhanced		BJ: 290.6;HaCaT: 180.1;U-87 MG: 136.0
SOAT2	ACAT2	ENSG00000167780	Sterol O-acyltransferase 2	12	53103518-53124538	Enzymes, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	5	duodenum: 12.1;small intestine: 22.0	spleen: 3.2	Cell line enhanced		CACO-2: 8.8;Hep G2: 15.8;U-266/70: 5.6
ZNF558	FLJ30932	ENSG00000167785	Zinc finger protein 558	19	8806170-8832328	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003151	Uncertain				Renal cancer:1.23e-6 (unfavourable), Urothelial cancer:9.30e-5 (favourable), Head and neck cancer:1.04e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 19.0	Mixed		
CABP2		ENSG00000167791	Calcium binding protein 2	11	67518912-67524517	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
NDUFV1	CI-51K	ENSG00000167792	NADH:ubiquinone oxidoreductase core subunit V1	11	67606852-67612535	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045211, HPA075051	Approved		Supported	Mitochondria<br>Cytosol	Renal cancer:7.49e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 222.1	Expressed in all		
CDK2AP2	DOC-1R, p14	ENSG00000167797	Cyclin dependent kinase 2 associated protein 2	11	67506497-67508649	Predicted intracellular proteins	Evidence at protein level	HPA047599	Uncertain		Approved	Nucleoplasm	Renal cancer:5.20e-4 (unfavourable), Endometrial cancer:8.80e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 50.5	Expressed in all		
NUDT8	FLJ41567	ENSG00000167799	Nudix hydrolase 8	11	67627938-67629930	Predicted intracellular proteins	Evidence at protein level	HPA041252, HPA041466	Enhanced		Approved	Nucleoli<br>Cytosol	Renal cancer:3.70e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 20.8	Cell line enhanced		RPMI-8226: 155.8
TBX10	TBX13, TBX7	ENSG00000167800	T-box 10	11	67631303-67639560	Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA047881	Uncertain					Group enriched	Group enriched	27	colon: 8.8;duodenum: 5.8;rectum: 8.6;small intestine: 10.6	appendix: 0.3	Cell line enhanced		NTERA-2: 5.3;RPMI-8226: 2.5;SK-BR-3: 9.3;U-2 OS: 2.7
PRDX2	MGC4104, NKEFB, PRP, PRX2, PRXII, TDPX1, TSA	ENSG00000167815	Peroxiredoxin 2	19	12796820-12801859	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008713	Approved				Renal cancer:5.66e-11 (favourable)	Expressed in all	Expressed in all			adrenal gland: 468.9	Mixed		
OR8J3		ENSG00000167822	Olfactory receptor family 8 subfamily J member 3	11	56136771-56137718	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5I1	HSOlf1, OLF1	ENSG00000167825	Olfactory receptor family 5 subfamily I member 1	11	55935456-55936400	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF232	ZSCAN11	ENSG00000167840	Zinc finger protein 232	17	5105541-5123116	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027309, HPA028611	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Liver cancer:4.66e-4 (unfavourable), Pancreatic cancer:6.55e-4 (favourable)	Expressed in all	Mixed			ovary: 4.3	Mixed		
MIS12	hMIS12, KNTC2AP, MGC2488, MTW1	ENSG00000167842	MIS12, kinetochore complex component	17	5486285-5490814	Predicted intracellular proteins	Evidence at protein level	HPA044482	Approved				Pancreatic cancer:8.00e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 38.6	Expressed in all		
CD300C	CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR	ENSG00000167850	CD300c molecule	17	74541108-74546143	CD markers, Predicted membrane proteins	Evidence at transcript level	HPA014523	Approved				Testis cancer:8.53e-5 (unfavourable)	Mixed	Tissue enhanced		lung: 12.4	appendix: 9.5	Cell line enhanced		HEL: 6.4;HMC-1: 29.3;U-937: 12.8
CD300A	CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60	ENSG00000167851	CD300a molecule	17	74466416-74484796	CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011645	Approved				Renal cancer:1.91e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 85.8	appendix: 40.0	Cell line enhanced		HMC-1: 88.9;NB-4: 27.4;RPMI-8226: 57.9
TEKT1		ENSG00000167858	Tektin 1	17	6789133-6831761	Predicted intracellular proteins	Evidence at protein level	HPA044444, HPA062285	Approved				Endometrial cancer:6.08e-4 (favourable)	Group enriched	Group enriched	7	fallopian tube: 79.5;testis: 16.7	lung: 6.9	Not detected		
HID1	C17orf28, DMC1, HID-1	ENSG00000167861	HID1 domain containing	17	74950743-74973166	Predicted intracellular proteins	Evidence at protein level	HPA023095, HPA031406	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:3.13e-5 (favourable), Urothelial cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			prostate: 54.2	Cell line enhanced		MCF7: 89.3;SH-SY5Y: 61.4;SK-BR-3: 129.5;T-47d: 96.0
MRPL58	DS-1, ICT1	ENSG00000167862	Mitochondrial ribosomal protein L58	17	75012670-75021261	Enzymes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003634	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 36.1	Expressed in all		
ATP5H	ATP5JD, ATPQ	ENSG00000167863	ATP synthase, H+ transporting, mitochondrial Fo complex subunit D	17	75038863-75046985	Predicted intracellular proteins	Evidence at protein level	HPA042777, HPA048459	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			heart muscle: 616.6	Expressed in all		
TMEM88	FLJ20025, MGC71744	ENSG00000167874	Transmembrane protein 88	17	7855065-7856099	Predicted membrane proteins	Evidence at protein level	HPA052991	Approved				Liver cancer:4.43e-6 (favourable), Colorectal cancer:1.16e-4 (unfavourable)	Expressed in all	Mixed			placenta: 34.2	Group enriched	5	AN3-CA: 60.4;HHSteC: 35.4;HUVEC TERT2: 42.7;NTERA-2: 26.4
EVPL	EVPK	ENSG00000167880	Envoplakin	17	76004502-76027452	Predicted intracellular proteins	Evidence at protein level	CAB002220, HPA053969	Enhanced		Supported	Intermediate filaments<br>Cytosol		Mixed	Group enriched	9	esophagus: 77.5;skin: 111.0	duodenum: 10.7	Cell line enhanced		HaCaT: 51.8;RT4: 68.1;T-47d: 50.1
SRP68		ENSG00000167881	Signal recognition particle 68	17	76038775-76072653	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023303, HPA055617	Approved		Enhanced	Focal adhesion sites<br>Cytosol	Liver cancer:4.28e-5 (unfavourable), Head and neck cancer:2.18e-4 (unfavourable), Thyroid cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 71.8	Expressed in all		
MGAT5B	FLJ25132, GnT-IX, GnT-VB	ENSG00000167889	Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B	17	76868456-76950393	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011082			Approved	Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle		Group enriched	Tissue enriched	14	cerebral cortex: 23.1	testis: 1.6	Cell line enhanced		A549: 28.7;SCLC-21H: 18.6;U-138 MG: 18.3;U-2 OS: 21.0
TMC8	EVER2, EVIN2	ENSG00000167895	Transmembrane channel like 8	17	78130770-78142968	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047387, HPA054429	Uncertain		Uncertain	Golgi apparatus	Renal cancer:1.96e-7 (unfavourable), Cervical cancer:8.45e-6 (favourable), Head and neck cancer:4.19e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 118.8;spleen: 104.5	appendix: 72.5	Cell line enhanced		HL-60: 50.1;HMC-1: 106.6;Karpas-707: 74.8;RPMI-8226: 46.3;U-266/70: 38.2;U-937: 41.2
TK1		ENSG00000167900	Thymidine kinase 1	17	78174075-78187233	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004683	Enhanced				Renal cancer:6.50e-11 (unfavourable), Lung cancer:3.03e-5 (unfavourable), Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 45.7	Expressed in all		
TMEM68	FLJ32370	ENSG00000167904	Transmembrane protein 68	8	55696424-55773407	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018216, HPA019173	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			fallopian tube: 36.8	Expressed in all		
CYP7A1	CYP7	ENSG00000167910	Cytochrome P450 family 7 subfamily A member 1	8	58490178-58500236	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.19e-4 (favourable)	Tissue enriched	Tissue enriched	61	liver: 26.0	duodenum: 0.4	Not detected		
GSDMA	FLJ39120, GSDM, GSDM1	ENSG00000167914	Gasdermin A	17	39953263-39977766	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023313, HPA064826	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	7	skin: 58.4	epididymis: 7.9	Cell line enhanced		HBEC3-KT: 2.9;hTCEpi: 2.0;hTERT-HME1: 4.1
KRT24	FLJ20261, MGC138169, MGC138173	ENSG00000167916	Keratin 24	17	40697991-40703750	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022978	Uncertain		Approved	Intermediate filaments<br>Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 20.3;esophagus: 28.4;tonsil: 67.0	placenta: 10.6	Cell line enriched	11	SK-BR-3: 5.3
TMEM99	MGC21518	ENSG00000167920	Transmembrane protein 99	17	40819106-40836274	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Tissue enhanced		testis: 177.0	epididymis: 53.1	Mixed		
GHDC	LGP1	ENSG00000167925	GH3 domain containing	17	42188799-42194532	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA031650	Uncertain				Renal cancer:2.00e-6 (favourable), Glioma:5.91e-5 (unfavourable), Endometrial cancer:3.21e-4 (favourable), Ovarian cancer:5.20e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.2	Mixed		
FAM234A	C16orf9, DKFZP761D0211, FLJ32603, ITFG3	ENSG00000167930	Family with sequence similarity 234 member A	16	234546-268971	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011651, HPA071871	Uncertain		Uncertain	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 111.8	Expressed in all		
SOST	DAND6, VBCH	ENSG00000167941	Sclerostin	17	43753731-43758788	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025660	Approved					Group enriched	Tissue enriched	16	kidney: 10.3	lung: 0.6	Cell line enriched	37	HaCaT: 4.6
PRR25	gs64	ENSG00000167945	Proline rich 25	16	805443-813861	Predicted intracellular proteins	No evidence	HPA042974	Uncertain					Not detected	Not detected			adipose tissue,appendix,cerebral cortex: 0.1	Not detected		
ZNF598	FLJ00086	ENSG00000167962	Zinc finger protein 598	16	1997654-2009823	Predicted intracellular proteins	Evidence at protein level	HPA041760, HPA041896	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			spleen: 11.5	Expressed in all		
RAB26		ENSG00000167964	RAB26, member RAS oncogene family	16	2140803-2154165	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA075624			Uncertain	Vesicles<br>Plasma membrane<br>Centrosome	Cervical cancer:8.20e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 21.1	liver: 11.4	Cell line enhanced		A549: 18.3;HeLa: 14.7;SCLC-21H: 32.1;SK-BR-3: 18.7
MLST8	GbetaL, GBL, Lst8, Pop3	ENSG00000167965	MTOR associated protein, LST8 homolog	16	2204248-2209416	Predicted intracellular proteins	Evidence at protein level	CAB019935, HPA041841	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cell Junctions	Renal cancer:7.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.6	Expressed in all		
E4F1	E4F	ENSG00000167967	E4F transcription factor 1	16	2223566-2235742	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052042, HPA071325			Enhanced	Nucleoplasm	Head and neck cancer:1.10e-4 (favourable), Renal cancer:5.50e-4 (unfavourable), Cervical cancer:9.13e-4 (favourable)	Expressed in all	Expressed in all			skin: 12.8	Expressed in all		
DNASE1L2	DNAS1L2	ENSG00000167968	Deoxyribonuclease 1 like 2	16	2235816-2238711	Predicted secreted proteins	Evidence at protein level	HPA044714			Approved	Mitochondria		Mixed	Tissue enriched	6	skin: 11.9	cerebral cortex: 1.9	Mixed		
ECI1	DCI	ENSG00000167969	Enoyl-CoA delta isomerase 1	16	2239395-2252300	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041746, HPA043227	Enhanced				Renal cancer:8.99e-8 (favourable), Cervical cancer:3.04e-5 (favourable), Liver cancer:1.07e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 69.3	Expressed in all		
CASKIN1	ANKS5A, KIAA1306	ENSG00000167971	CASK interacting protein 1	16	2177180-2196525	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055990, CAB079050	Enhanced	Supported	Approved	Nucleus<br>Cytosol		Mixed	Tissue enriched	33	cerebral cortex: 20.3	testis: 0.6	Cell line enhanced		HDLM-2: 13.8;SCLC-21H: 7.7
ABCA3	ABC-C, ABC3, EST111653, LBM180	ENSG00000167972	ATP binding cassette subfamily A member 3	16	2275881-2340746	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007884	Enhanced		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		lung: 135.5	cerebral cortex: 51.5	Cell line enhanced		SCLC-21H: 53.9;T-47d: 71.7
KCTD5	FLJ20040	ENSG00000167977	Potassium channel tetramerization domain containing 5	16	2682475-2709030	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			lymph node: 23.1	Expressed in all		
SRRM2	Cwc21, KIAA0324, SRL300, SRm300	ENSG00000167978	Serine/arginine repetitive matrix 2	16	2752329-2772538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041411, HPA066181	Supported		Enhanced	Nuclear speckles	Renal cancer:4.82e-4 (unfavourable), Liver cancer:5.08e-4 (unfavourable), Head and neck cancer:6.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 288.8	Expressed in all		
ZNF597	FLJ33071, HIT-4	ENSG00000167981	Zinc finger protein 597	16	3432422-3443542	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001556	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			testis: 7.2	Mixed		
NLRC3	CLR16.2, FLJ00348, NOD3	ENSG00000167984	NLR family CARD domain containing 3	16	3539033-3577400	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048062			Supported	Microtubule organizing center<br>Cytosol		Mixed	Tissue enhanced		lymph node: 15.7	spleen: 11.1	Cell line enhanced		HEL: 7.8;HL-60: 14.5;HMC-1: 7.7;NB-4: 12.3;U-698: 19.1;U-937: 10.6
SDHAF2	C11orf79, FLJ20487, PGL2, SDH5	ENSG00000167985	Succinate dehydrogenase complex assembly factor 2	11	61430042-61447529	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039464, HPA039732	Supported		Supported	Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 35.5	Expressed in all		
DDB1		ENSG00000167986	Damage specific DNA binding protein 1	11	61299451-61342596	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032821, HPA045174, HPA068456	Approved		Enhanced	Nucleoplasm	Renal cancer:1.51e-8 (favourable), Colorectal cancer:7.09e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 490.0	Expressed in all		
VPS37C	FLJ20847	ENSG00000167987	VPS37C, ESCRT-I subunit	11	61130256-61161617	Predicted intracellular proteins	Evidence at protein level	HPA043348	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:2.37e-7 (favourable), Liver cancer:5.85e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 25.2	Expressed in all		
VWCE	FLJ32009, URG11, VWC1	ENSG00000167992	Von Willebrand factor C and EGF domains	11	61258286-61295424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040401, HPA043921	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Tissue enhanced		fallopian tube: 5.1;ovary: 5.8	liver: 3.7	Cell line enhanced		Hep G2: 14.6;HSkMC: 8.6;REH: 11.0
RAB3IL1	GRAB	ENSG00000167994	RAB3A interacting protein like 1	11	61897301-61920269	Predicted intracellular proteins	Evidence at protein level	HPA039723	Uncertain		Approved	Cytosol	Liver cancer:1.61e-7 (unfavourable), Renal cancer:1.49e-4 (unfavourable), Thyroid cancer:3.30e-4 (unfavourable), Colorectal cancer:6.08e-4 (unfavourable)	Expressed in all	Mixed			testis: 48.7	Cell line enhanced		K-562: 39.5;U-2197: 52.9
BEST1	BEST, BMD, RP50, VMD2	ENSG00000167995	Bestrophin 1	11	61949821-61965515	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA057464	Supported					Group enriched	Mixed			cerebral cortex: 17.0	Cell line enhanced		SK-MEL-30: 40.9;U-266/70: 10.4
FTH1	FHC, FTH, FTHL6, PIG15, PLIF	ENSG00000167996	Ferritin heavy chain 1	11	61959718-61967660	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008623	Approved		Approved	Microtubules	Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 4962.3	Expressed in all		
BSCL2	GNG3LG, SPG17	ENSG00000168000	BSCL2, seipin lipid droplet biogenesis associated	11	62690275-62709845	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042394	Approved				Renal cancer:7.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 250.5	Expressed in all		
POLR2G	hRPB19, hsRPB7, RPB7	ENSG00000168002	RNA polymerase II subunit G	11	62761544-62766710	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA053000	Approved		Supported	Nucleoplasm	Liver cancer:6.02e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 100.0	Expressed in all		
SLC3A2	4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE	ENSG00000168003	Solute carrier family 3 member 2	11	62856102-62888875	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010455, HPA017980	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 431.9	Expressed in all		
HRASLS5	HRLP5	ENSG00000168004	HRAS like suppressor family member 5	11	63461404-63491194	Predicted intracellular proteins	Evidence at protein level						Glioma:9.80e-5 (unfavourable)	Mixed	Tissue enriched	5	testis: 96.2	adipose tissue: 17.8	Group enriched	6	HAP1: 11.7;NB-4: 2.4
C11orf84		ENSG00000168005	Chromosome 11 open reading frame 84	11	63813388-63827718	Predicted intracellular proteins	Evidence at protein level	HPA040128, HPA050313	Uncertain		Approved	Nuclear speckles	Liver cancer:1.53e-5 (unfavourable), Renal cancer:5.42e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 42.6	Expressed in all		
ATG16L2	ATG16B, FLJ00012, WDR80	ENSG00000168010	Autophagy related 16 like 2	11	72814308-72843674	Predicted intracellular proteins	Evidence at protein level	HPA045444, HPA050312	Approved		Enhanced	Nucleoplasm	Renal cancer:3.39e-4 (unfavourable), Pancreatic cancer:7.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 99.0	Expressed in all		
C2CD3	DKFZP586P0123	ENSG00000168014	C2 calcium dependent domain containing 3	11	74012714-74171210	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038552, HPA038553, HPA040433	Approved		Approved	Nucleus<br>Microtubule organizing center		Expressed in all	Mixed			testis: 30.0	Expressed in all		
TRANK1	KIAA0342, LBA1	ENSG00000168016	Tetratricopeptide repeat and ankyrin repeat containing 1	3	36826820-36945057	Predicted intracellular proteins	Evidence at protein level	HPA035508	Approved		Approved	Nucleoplasm	Renal cancer:2.52e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 39.1	Cell line enhanced		Daudi: 68.8;HMC-1: 33.4
TTC21A	IFT139A, STI2	ENSG00000168026	Tetratricopeptide repeat domain 21A	3	39107704-39138903	Predicted intracellular proteins	Evidence at protein level	HPA035510, HPA035511	Enhanced		Supported	Nucleoplasm	Endometrial cancer:1.79e-4 (favourable)	Mixed	Tissue enriched	25	testis: 39.4	fallopian tube: 1.5	Not detected		
RPSA	37LRP, LAMR1, LRP, p40, SA	ENSG00000168028	Ribosomal protein SA	3	39406689-39412542	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB009561	Approved		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 2084.6	Expressed in all		
ENTPD3	CD39L3, HB6, NTPDase-3	ENSG00000168032	Ectonucleoside triphosphate diphosphohydrolase 3	3	40387156-40428619	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA071802			Approved	Cytosol		Mixed	Tissue enhanced		cervix, uterine: 33.6	urinary bladder: 14.7	Cell line enhanced		HBEC3-KT: 9.3;hTCEpi: 6.3;RT4: 15.1
CTNNB1	armadillo, beta-catenin, CTNNB	ENSG00000168036	Catenin beta 1	3	41194837-41260096	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000108, CAB001950, HPA029159, HPA029160	Enhanced		Enhanced	Plasma membrane	Colorectal cancer:7.54e-4 (favourable)	Expressed in all	Expressed in all			placenta: 285.6	Expressed in all		
ULK4	FAM7C1, FLJ20574, REC01035	ENSG00000168038	Unc-51 like kinase 4	3	41246599-41962430	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017930	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Mixed	Tissue enhanced		testis: 38.1	parathyroid gland: 14.4	Mixed		
FADD	GIG3, MORT1	ENSG00000168040	Fas associated via death domain	11	70203163-70207390	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001464, CAB010209	Supported		Supported	Nucleoplasm<br>Cytosol	Lung cancer:2.21e-5 (unfavourable), Head and neck cancer:8.22e-5 (unfavourable), Thyroid cancer:3.45e-4 (favourable), Cervical cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.3	Expressed in all		
LTBP3	LTBP2	ENSG00000168056	Latent transforming growth factor beta binding protein 3	11	65538805-65558930	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA073170			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 104.2	Cell line enhanced		U-87 MG: 154.3
NAALADL1		ENSG00000168060	N-acetylated alpha-linked acidic dipeptidase like 1	11	65044818-65058549	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047123	Enhanced		Uncertain	Cytosol		Expressed in all	Tissue enriched	5	small intestine: 104.2	duodenum: 20.1	Cell line enhanced		fHDF/TERT166: 6.0;HHSteC: 17.2;HSkMC: 9.8;SCLC-21H: 12.7
SAC3D1	HSU79266, SHD1	ENSG00000168061	SAC3 domain containing 1	11	65040901-65044828	Predicted intracellular proteins	Evidence at protein level	HPA042677	Uncertain		Approved	Cytosol	Liver cancer:9.67e-6 (unfavourable), Renal cancer:5.66e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 11.6	cerebral cortex: 2.9	Mixed		
BATF2	MGC20410	ENSG00000168062	Basic leucine zipper ATF-like transcription factor 2	11	64987943-64997045	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062496	Approved		Approved	Nucleoli	Ovarian cancer:9.39e-5 (favourable), Pancreatic cancer:2.12e-4 (unfavourable)	Expressed in all	Mixed			spleen: 17.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 12.0;BJ hTERT+ SV40 Large T+ RasG12V: 19.1
SLC22A11	OAT4	ENSG00000168065	Solute carrier family 22 member 11	11	64555626-64572875	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026076	Approved				Renal cancer:3.68e-5 (favourable)	Group enriched	Group enriched	114	epididymis: 10.0;kidney: 26.0;placenta: 44.8	seminal vesicle: 0.2	Cell line enhanced		BEWO: 1.2
SF1	ZCCHC25, ZFM1, ZNF162	ENSG00000168066	Splicing factor 1	11	64764606-64778786	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018883	Supported		Enhanced	Nucleoplasm	Liver cancer:4.85e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 145.9	Expressed in all		
MAP4K2	BL44, GCK, RAB8IP	ENSG00000168067	Mitogen-activated protein kinase kinase kinase kinase 2	11	64784914-64803241	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007330	Enhanced		Approved	Vesicles	Liver cancer:3.10e-5 (unfavourable)	Expressed in all	Mixed			spleen: 22.9	Mixed		
MAJIN	C11orf85	ENSG00000168070	Membrane anchored junction protein	11	64937517-64972085	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	9	testis: 41.6	gallbladder: 4.5	Group enriched	9	CAPAN-2: 6.4;SiHa: 3.3
CCDC88B	BRLZ, CCDC88, FLJ00354, FLJ37970, GIPIE, HkRP3	ENSG00000168071	Coiled-coil domain containing 88B	11	64340223-64357534	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026652	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:7.65e-5 (unfavourable), Head and neck cancer:1.48e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 36.2	bone marrow: 31.3	Cell line enhanced		HMC-1: 73.4;THP-1: 23.2
SCARA3	APC7, CSR, CSR1, MSLR1, MSRL1	ENSG00000168077	Scavenger receptor class A member 3	8	27633868-27676776	Predicted membrane proteins	Evidence at protein level	HPA029861, HPA047386	Uncertain		Supported	Endoplasmic reticulum		Expressed in all	Tissue enhanced		fallopian tube: 151.9	smooth muscle: 108.4	Cell line enhanced		ASC TERT1: 137.0;HeLa: 151.4;HUVEC TERT2: 130.0;U-2 OS: 147.0
PBK	CT84, FLJ14385, Nori-3, SPK, TOPK	ENSG00000168078	PDZ binding kinase	8	27809620-27838095	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005753, HPA050656	Enhanced	Supported	Approved	Cytosol	Renal cancer:1.18e-12 (unfavourable), Liver cancer:8.29e-5 (unfavourable), Pancreatic cancer:6.56e-4 (unfavourable)	Expressed in all	Tissue enriched	8	testis: 108.8	lymph node: 13.3	Mixed		
SCARA5	FLJ23907, MGC45780, NET33	ENSG00000168079	Scavenger receptor class A member 5	8	27869882-27992727	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024661	Approved					Mixed	Mixed			adipose tissue: 66.0	Cell line enriched	19	ASC diff: 157.1
PNOC	N/OFQ, NOP, PPNOC	ENSG00000168081	Prepronociceptin	8	28316986-28343355	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044507, HPA056724	Enhanced				Endometrial cancer:2.94e-6 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 44.2;fallopian tube: 26.3;lymph node: 28.9	tonsil: 21.4	Group enriched	6	Daudi: 27.2;Karpas-707: 20.9;RPMI-8226: 7.7;U-698: 15.7
COPS6	CSN6, MOV34-34KD	ENSG00000168090	COP9 signalosome subunit 6	7	100088954-100092200	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044315	Approved		Supported	Nucleoplasm	Renal cancer:6.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.6	Expressed in all		
PAFAH1B2		ENSG00000168092	Platelet activating factor acetylhydrolase 1b catalytic subunit 2	11	117144267-117176894	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051836	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 68.2	Expressed in all		
ANKS3	FLJ32345, FLJ32767, KIAA1977	ENSG00000168096	Ankyrin repeat and sterile alpha motif domain containing 3	16	4696510-4734378	Predicted intracellular proteins	Evidence at protein level	HPA041409, HPA041482	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			ovary: 8.1	Expressed in all		
NUDT16L1	SDOS	ENSG00000168101	Nudix hydrolase 16 like 1	16	4693694-4695859	Predicted intracellular proteins	Evidence at protein level	HPA044186, HPA063605	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.02e-6 (favourable), Lung cancer:2.79e-4 (favourable)	Expressed in all	Expressed in all			prostate: 30.1	Expressed in all		
KIAA1586		ENSG00000168116	KIAA1586	6	57046532-57055239	Predicted intracellular proteins	Evidence at protein level	HPA036370	Enhanced		Approved	Nucleus<br>Nuclear membrane		Expressed in all	Mixed			testis: 14.0	Expressed in all		
RAB4A	HRES-1/RAB4, RAB4	ENSG00000168118	RAB4A, member RAS oncogene family	1	229271062-229305894	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			prostate: 56.2	Mixed		
OR1F1	Olfmf, OR16-36, OR16-37, OR16-88, OR16-89, OR16-90, OR1F10, OR1F13P, OR1F4, OR1F5, OR1F6, OR1F7, OR1F8, OR1F9, OR3-145	ENSG00000168124	Olfactory receptor family 1 subfamily F member 1	16	3204247-3205188	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.7	Not detected		
OR2B2	hs6M1-10, OR2B2Q, OR2B9, OR6-1	ENSG00000168131	Olfactory receptor family 2 subfamily B member 2	6	27911185-27912396	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KCNJ4	HIR, hIRK2, HRK1, IRK3, Kir2.3	ENSG00000168135	Potassium voltage-gated channel subfamily J member 4	22	38426327-38455199	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Group enriched	25	cerebral cortex: 40.9;heart muscle: 11.4	gallbladder: 1.0	Cell line enriched	8	SCLC-21H: 13.4
SETD5	FLJ10707	ENSG00000168137	SET domain containing 5	3	9397615-9479240	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB017093, HPA035574	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:4.27e-4 (unfavourable), Liver cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.7	Expressed in all		
VASN	SLITL2	ENSG00000168140	Vasorin	16	4371848-4383528	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011246, HPA016992	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Endometrial cancer:6.24e-5 (unfavourable)	Expressed in all	Mixed			placenta: 16.1	Cell line enriched	14	U-2197: 640.8
FAM83B	C6orf143, FLJ30642	ENSG00000168143	Family with sequence similarity 83 member B	6	54846771-54942022	Predicted intracellular proteins	Evidence at protein level	HPA031464, HPA031465	Enhanced				Urothelial cancer:1.86e-5 (unfavourable), Lung cancer:1.48e-4 (unfavourable), Pancreatic cancer:7.60e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		skin: 27.3	esophagus: 17.7	Cell line enhanced		A-431: 17.1;HaCaT: 18.9;hTCEpi: 15.2;hTERT-HME1: 21.2;RT4: 19.6
HIST3H3	H3.4, H3/g, H3FT, H3t	ENSG00000168148	Histone cluster 3 H3	1	228424845-228425325	Predicted intracellular proteins	Evidence at protein level	CAB001386, CAB003812, HPA042570	Supported		Supported	Nucleoplasm		Not detected	Tissue enriched	11	testis: 2.1	adrenal gland,fallopian tube,gallbladder,skin: 0.1	Not detected		
THAP9	FLJ34093	ENSG00000168152	THAP domain containing 9	4	82900684-82919969	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037420, HPA037421	Uncertain		Approved	Mitochondria	Renal cancer:3.50e-5 (favourable)	Expressed in all	Mixed			testis: 11.4	Mixed		
OR2C1	OLFmf3, OR2C2P	ENSG00000168158	Olfactory receptor family 2 subfamily C member 1	16	3355889-3357294	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.1	parathyroid gland: 0.4	Not detected		
RNF187		ENSG00000168159	Ring finger protein 187	1	228487061-228495766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030098	Approved		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 143.2	Expressed in all		
HOOK3	HK3	ENSG00000168172	Hook microtubule tethering protein 3	8	42896932-43030539	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA024756	Approved		Supported	Golgi apparatus<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.32e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 36.6	Expressed in all		
MAPK1IP1L	C14orf32	ENSG00000168175	Mitogen-activated protein kinase 1 interacting protein 1 like	14	55051631-55070192	Predicted intracellular proteins	Evidence at protein level	HPA034506	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.82e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 53.2	Expressed in all		
DDIT4	Dig2, FLJ20500, REDD-1, REDD1, RTP801	ENSG00000168209	DNA damage inducible transcript 4	10	72273920-72276036	Predicted intracellular proteins	Evidence at protein level	HPA034507, HPA034508	Approved		Supported	Cytosol	Renal cancer:2.54e-6 (unfavourable), Pancreatic cancer:2.78e-4 (unfavourable), Head and neck cancer:5.42e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 220.9	Expressed in all		
RBPJ	CBF1, IGKJRB, IGKJRB1, KBF2, RBP-J, RBPJK, RBPSUH, SUH	ENSG00000168214	Recombination signal binding protein for immunoglobulin kappa J region	4	26163455-26435131	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060647			Supported	Nucleoplasm	Endometrial cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			placenta: 77.2	Expressed in all		
LMBRD1	bA810I22.1, C6orf209, cblF, FLJ11240	ENSG00000168216	LMBR1 domain containing 1	6	69675802-69797111	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019547	Uncertain				Renal cancer:1.07e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 173.4	Expressed in all		
ZCCHC4	FLJ23024, HSPC052, ZGRF4	ENSG00000168228	Zinc finger CCHC-type containing 4	4	25312785-25370383	Predicted intracellular proteins	Evidence at protein level	HPA035575, HPA035576	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Mixed			testis: 8.2	Expressed in all		
PTGDR	DP, DP1, PTGDR1	ENSG00000168229	Prostaglandin D2 receptor	14	52267713-52276724	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		rectum: 8.6;spleen: 8.7	colon: 5.6	Not detected		
TTC39C	C18orf17, FLJ33761, HsT2697	ENSG00000168234	Tetratricopeptide repeat domain 39C	18	23992773-24135610	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065705, HPA065713	Approved		Approved	Nucleoplasm	Renal cancer:2.60e-5 (unfavourable), Breast cancer:1.48e-4 (favourable)	Expressed in all	Expressed in all			liver: 47.8	Mixed		
GLYCTK	HBEBP2, HBEBP4	ENSG00000168237	Glycerate kinase	3	52287089-52293476	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006913	Approved		Approved	Golgi apparatus<br>Cytosol<br>Rods & Rings	Head and neck cancer:1.64e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 38.3;liver: 60.6	small intestine: 31.8	Expressed in all		
GNG4		ENSG00000168243	G protein subunit gamma 4	1	235547687-235650754	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 25.3;ovary: 18.4;prostate: 17.5	endometrium: 8.4	Cell line enhanced		NTERA-2: 75.6;SCLC-21H: 93.5;SH-SY5Y: 118.5
UBTD2	DC-UbP, MGC30022	ENSG00000168246	Ubiquitin domain containing 2	5	172209640-172284071	Predicted intracellular proteins	Evidence at protein level	HPA035891, HPA035892	Uncertain				Liver cancer:1.44e-5 (unfavourable), Colorectal cancer:5.92e-5 (favourable)	Expressed in all	Mixed			testis: 53.4	Expressed in all		
POLR2J3		ENSG00000168255	RNA polymerase II subunit J3	7	102537918-102572656	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at transcript level	HPA011403, HPA042997, HPA044010, HPA046970	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			cerebral cortex: 56.5	Expressed in all		
NKIRAS2	DKFZP434N1526, kappaB-Ras2, KBRAS2	ENSG00000168256	NFKB inhibitor interacting Ras like 2	17	42011382-42025644	Predicted intracellular proteins	Evidence at protein level	HPA062861			Approved	Nucleus<br>Nucleoli	Renal cancer:1.23e-4 (unfavourable), Liver cancer:5.56e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 49.2	Expressed in all		
DNAJC7	TPR2, TTC2	ENSG00000168259	DnaJ heat shock protein family (Hsp40) member C7	17	41976433-42021376	Predicted intracellular proteins	Evidence at protein level	HPA023015, HPA052395	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.35e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
KCNV2	Kv8.2	ENSG00000168263	Potassium voltage-gated channel modifier subfamily V member 2	9	2717502-2730037	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA031131	Supported					Tissue enriched	Tissue enriched	44	testis: 6.6	skin: 0.1	Not detected		
IRF2BP2	IRF-2BP2	ENSG00000168264	Interferon regulatory factor 2 binding protein 2	1	234604269-234609525	Predicted intracellular proteins	Evidence at protein level	HPA027815, HPA062269	Approved		Enhanced	Nucleoplasm	Renal cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 98.7	Cell line enhanced		THP-1: 189.9
PTF1A	bHLHa29, PTF1-p48	ENSG00000168267	Pancreas specific transcription factor, 1a	10	23192327-23194252	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022612			Approved	Nucleoplasm		Tissue enhanced	Tissue enriched	6	pancreas: 18.2	testis: 3.1	Cell line enriched	10	U-2 OS: 2.6
NT5DC2	FLJ12442	ENSG00000168268	5'-nucleotidase domain containing 2	3	52524385-52535054	Predicted intracellular proteins	Evidence at protein level	HPA050683	Approved				Liver cancer:2.16e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 96.1	Mixed		
FOXI1	FKHL10, FREAC6	ENSG00000168269	Forkhead box I1	5	170105897-170109725	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071469	Enhanced		Uncertain	Nucleoli<br>Vesicles		Group enriched	Tissue enhanced		breast: 10.4;kidney: 20.0	salivary gland: 6.2	Cell line enhanced		MCF7: 1.2
SMIM4	C3orf78	ENSG00000168273	Small integral membrane protein 4	3	52534013-52579237	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047771	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Lung cancer:1.78e-5 (favourable), Renal cancer:1.63e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 102.2	Expressed in all		
COA6	C1orf31	ENSG00000168275	Cytochrome c oxidase assembly factor 6	1	234373456-234384049	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028588	Approved		Supported	Mitochondria	Renal cancer:1.12e-5 (unfavourable), Urothelial cancer:7.12e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 45.4	Expressed in all		
KIF5C		ENSG00000168280	Kinesin family member 5C	2	148875250-149026759	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035210, HPA062272	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 205.3	prostate: 44.3	Cell line enhanced		AF22: 38.5;NTERA-2: 39.3;SCLC-21H: 236.2;SH-SY5Y: 49.2
MGAT2	GNT-II	ENSG00000168282	Mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase	14	49620795-49623481	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043721, HPA056824	Approved		Supported	Golgi apparatus	Cervical cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.0	Expressed in all		
BMI1	PCGF4, RNF51	ENSG00000168283	BMI1 proto-oncogene, polycomb ring finger	10	22321211-22331484	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011120, HPA030471, HPA030472	Supported		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol	Liver cancer:2.60e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.3	Expressed in all		
THAP11	CTG-B43a, CTG-B45d, HRIHFB2206	ENSG00000168286	THAP domain containing 11	16	67842082-67844195	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041434, HPA042189	Supported		Enhanced	Nucleoplasm<br>Cytokinetic bridge		Expressed in all	Expressed in all			fallopian tube: 25.4	Expressed in all		
MMADHC	C2orf25, cblD, CL25022	ENSG00000168288	Methylmalonic aciduria and homocystinuria, cblD type	2	149569634-149587816	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037531, HPA037532	Supported				Pancreatic cancer:2.73e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 123.1	Expressed in all		
PDHB		ENSG00000168291	Pyruvate dehydrogenase (lipoamide) beta	3	58427630-58433857	Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033794, HPA036744, HPA036745	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.79e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 112.0	Expressed in all		
PXK	FLJ20335	ENSG00000168297	PX domain containing serine/threonine kinase like	3	58332880-58426126	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024068	Supported		Supported	Plasma membrane<br>Microtubule organizing center<br>Cytosol	Lung cancer:5.68e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 124.5	Expressed in all		
HIST1H1E	H1.4, H1e, H1F4, H1s-4	ENSG00000168298	Histone cluster 1 H1 family member e	6	26156354-26157107	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011506, HPA055907	Supported		Supported	Nuclear speckles		Mixed	Tissue enriched	11	bone marrow: 36.2	lymph node: 3.3	Cell line enhanced		U-266/84: 11.0;U-87 MG: 13.1
PCMTD1	FLJ10883	ENSG00000168300	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1	8	51817575-51899186	Predicted intracellular proteins	Evidence at protein level	HPA025696, HPA061444	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 186.8	Expressed in all		
KCTD6	KCASH3, MGC27385	ENSG00000168301	Potassium channel tetramerization domain containing 6	3	58492114-58502360	Predicted intracellular proteins	Evidence at protein level	HPA036100, HPA036101	Uncertain		Approved	Nucleoli<br>Mitochondria	Liver cancer:4.57e-4 (unfavourable), Renal cancer:8.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.2	Expressed in all		
MPLKIP	C7orf11, ORF20, TTDN1	ENSG00000168303	M-phase specific PLK1 interacting protein	7	40126023-40134659	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058457, HPA065463	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			liver: 4.3	Expressed in all		
ACOX2	BRCACOX, BRCOX, THCCox	ENSG00000168306	Acyl-CoA oxidase 2	3	58505136-58537319	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038280, HPA064845	Enhanced		Supported	Vesicles<br>Cytosol		Tissue enhanced	Tissue enhanced		liver: 87.9	kidney: 42.5	Cell line enhanced		ASC diff: 10.4;ASC TERT1: 17.4;fHDF/TERT166: 6.6;Hep G2: 7.0;HSkMC: 11.8
FAM107A	DRR1, TU3A	ENSG00000168309	Family with sequence similarity 107 member A	3	58564117-58627610	Predicted intracellular proteins	Evidence at protein level	HPA055888	Enhanced		Supported	Nuclear speckles	Liver cancer:3.38e-4 (favourable), Endometrial cancer:3.56e-4 (unfavourable)	Tissue enriched	Group enriched	5	cerebral cortex: 485.7;fallopian tube: 125.1	epididymis: 57.5	Group enriched	6	ASC diff: 12.6;HUVEC TERT2: 48.1
IRF2		ENSG00000168310	Interferon regulatory factor 2	4	184387713-184474580	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030813, CAB032306, HPA057327	Supported		Enhanced	Nucleoplasm<br>Cytosol	Breast cancer:6.95e-5 (favourable), Thyroid cancer:8.34e-5 (favourable)	Expressed in all	Expressed in all			spleen: 74.2	Expressed in all		
MOBP		ENSG00000168314	Myelin-associated oligodendrocyte basic protein	3	39467198-39529479	Predicted intracellular proteins	Evidence at protein level	HPA035152	Supported					Tissue enriched	Tissue enriched	23	cerebral cortex: 175.9	parathyroid gland: 7.5	Cell line enriched	56	HAP1: 19.1
CX3CR1	CCRL1, CMKBRL1, CMKDR1, GPR13, V28	ENSG00000168329	C-X3-C motif chemokine receptor 1	3	39263494-39281735	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA030311, CAB032478, HPA046587, HPA077743	Approved		Approved	Nucleus		Tissue enhanced	Tissue enhanced		cerebral cortex: 59.2	spleen: 16.6	Cell line enriched	18	RPMI-8226: 409.2
C8orf22		ENSG00000168333	Chromosome 8 open reading frame 22	8	49054311-49076090	Predicted intracellular proteins	Evidence at transcript level	HPA060329	Uncertain				Renal cancer:2.06e-10 (unfavourable)	Group enriched	Tissue enriched	79	skeletal muscle: 362.1	prostate: 4.5	Cell line enriched	13	HEL: 1.3
XIRP1	CMYA1, DKFZp451D042, Xin	ENSG00000168334	Xin actin binding repeat containing 1	3	39183210-39192596	Predicted intracellular proteins	Evidence at protein level	HPA016750, HPA018458, CAB026391	Enhanced		Approved	Nucleus<br>Actin filaments		Tissue enhanced	Group enriched	14	heart muscle: 113.0;skeletal muscle: 58.4	esophagus: 5.9	Cell line enhanced		HSkMC: 3.2;RH-30: 2.9
INSM2	IA-6, Mlt1	ENSG00000168348	INSM transcriptional repressor 2	14	35534042-35537054	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044885, HPA051925	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		cerebral cortex: 1.3	testis: 0.7	Cell line enriched	121	SH-SY5Y: 115.7
DEGS2	C14orf66, DES2, FADS8	ENSG00000168350	Delta 4-desaturase, sphingolipid 2	14	100143957-100160163	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046644			Approved	Nucleus<br>Nucleoli	Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable)	Mixed	Tissue enhanced		skin: 31.4;small intestine: 38.7	duodenum: 24.8	Cell line enriched	16	T-47d: 98.2
SCN11A	NaN, Nav1.9, SCN12A, SNS-2	ENSG00000168356	Sodium voltage-gated channel alpha subunit 11	3	38845769-38950561	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA036746, HPA036747	Uncertain					Not detected	Tissue enhanced		placenta: 3.7;spleen: 5.3	testis: 2.0	Cell line enhanced		HDLM-2: 1.1
ARF4	ARF2	ENSG00000168374	ADP ribosylation factor 4	3	57571363-57598220	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:7.29e-7 (unfavourable), Thyroid cancer:9.30e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 325.8	Expressed in all		
SEPT2	DIFF6, hNedd5, KIAA0158, NEDD5, Pnutl3	ENSG00000168385	Septin 2	2	241315100-241354027	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017190, HPA018481	Supported		Supported	Nucleus<br>Actin filaments	Liver cancer:3.66e-4 (unfavourable), Glioma:4.32e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 369.5	Expressed in all		
FILIP1L	DOC-1, GIP130	ENSG00000168386	Filamin A interacting protein 1 like	3	99830141-100114513	Predicted intracellular proteins	Evidence at protein level	HPA043133	Approved		Approved	Plasma membrane	Renal cancer:9.40e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 217.1	Cell line enhanced		HDLM-2: 74.0;TIME: 118.7
MFSD2A	FLJ14490, MFSD2	ENSG00000168389	Major facilitator superfamily domain containing 2A	1	39955112-39969968	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043107	Uncertain		Approved	Plasma membrane<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 116.7;seminal vesicle: 110.9	testis: 63.4	Cell line enhanced		THP-1: 112.5
DTYMK	CDC8, TMPK, TYMK	ENSG00000168393	Deoxythymidylate kinase	2	241675742-241686991	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042593, HPA042719	Approved		Approved	Mitochondria	Liver cancer:1.73e-5 (unfavourable), Renal cancer:1.22e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 24.0	Expressed in all		
TAP1	ABCB2, D6S114E, PSF1, RING4	ENSG00000168394	Transporter 1, ATP binding cassette subfamily B member	6	32845209-32853978	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009516, HPA072354	Approved		Supported	Endoplasmic reticulum<br>Microtubule organizing center	Renal cancer:6.58e-5 (unfavourable), Ovarian cancer:4.07e-4 (favourable), Colorectal cancer:9.01e-4 (favourable)	Expressed in all	Mixed			appendix: 19.9	Mixed		
ING5	FLJ23842, p28ING5	ENSG00000168395	Inhibitor of growth family member 5	2	241687085-241729478	Predicted intracellular proteins	Evidence at protein level	HPA042685	Approved				Liver cancer:2.86e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.7	Expressed in all		
ATG4B	APG4B, AUTL1, DKFZp586D1822, KIAA0943	ENSG00000168397	Autophagy related 4B cysteine peptidase	2	241637213-241673857	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB037195, HPA069803	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.79e-4 (unfavourable), Colorectal cancer:6.85e-4 (unfavourable), Urothelial cancer:9.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.0	Expressed in all		
BDKRB2	BK-2	ENSG00000168398	Bradykinin receptor B2	14	96204679-96244166	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050841	Approved					Mixed	Mixed			gallbladder: 32.5	Cell line enhanced		ASC TERT1: 34.0;BJ hTERT+: 75.7;U-87 MG: 38.4
MLKL	FLJ34389	ENSG00000168404	Mixed lineage kinase domain like pseudokinase	16	74671855-74700960	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level						Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Mixed			spleen: 28.9	Mixed		
RFWD3	FLJ10520, RNF201	ENSG00000168411	Ring finger and WD repeat domain 3	16	74621394-74666881	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048258, HPA075649			Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 46.9	Expressed in all		
MTNR1A	MEL-1A-R	ENSG00000168412	Melatonin receptor 1A	4	186533655-186555567	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		kidney: 2.2;testis: 1.9	colon: 1.2	Not detected		
KCNG4	Kv6.4	ENSG00000168418	Potassium voltage-gated channel modifier subfamily G member 4	16	84218667-84239750	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.6	Not detected		
RHOH	ARHH, RhoH, TTF	ENSG00000168421	Ras homolog family member H	4	40191053-40246967	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030345	Uncertain					Mixed	Tissue enhanced		lymph node: 98.3;tonsil: 77.5	appendix: 47.7	Cell line enhanced		Daudi: 89.6;HMC-1: 81.4;MOLT-4: 142.8;U-266/70: 49.6;U-698: 79.5
KLHL30	FLJ43374	ENSG00000168427	Kelch like family member 30	2	238138722-238152947	Predicted intracellular proteins	Evidence at transcript level	HPA062095			Approved	Microtubule organizing center		Mixed	Tissue enhanced		skeletal muscle: 22.1	heart muscle: 5.6	Cell line enhanced		BEWO: 3.1;RH-30: 4.4;THP-1: 1.5
COG7		ENSG00000168434	Component of oligomeric golgi complex 7	16	23388493-23453180	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040758, HPA064645	Uncertain		Enhanced	Golgi apparatus	Renal cancer:3.14e-4 (favourable), Endometrial cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.8	Expressed in all		
CDC40	EHB3, FLJ10564, PRP17, PRPF17	ENSG00000168438	Cell division cycle 40	6	110180141-110254275	Predicted secreted proteins	Evidence at protein level	HPA046620			Supported	Nucleus		Expressed in all	Expressed in all			thyroid gland: 27.1	Expressed in all		
STIP1	HOP, STI1	ENSG00000168439	Stress induced phosphoprotein 1	11	64185272-64204543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017448, HPA039291, HPA044062	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:6.18e-8 (unfavourable), Head and neck cancer:1.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 220.4	Expressed in all		
SCNN1B	ENaCbeta	ENSG00000168447	Sodium channel epithelial 1 beta subunit	16	23278231-23381299	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015612	Uncertain				Renal cancer:2.09e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 72.0	esophagus: 44.8	Cell line enhanced		hTCEpi: 24.0;RT4: 14.6;U-266/70: 41.7;U-266/84: 14.3
HR	ALUNC, AU	ENSG00000168453	HR, lysine demethylase and nuclear receptor corepressor	8	22114415-22133384	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054888			Supported	Nucleoplasm		Mixed	Tissue enhanced		skin: 58.9	cerebral cortex: 11.9	Cell line enhanced		HaCaT: 70.7;SiHa: 29.4;T-47d: 27.6
TXNDC2	SPTRX1	ENSG00000168454	Thioredoxin domain containing 2	18	9885726-9889275	Predicted intracellular proteins	Evidence at protein level	CAB016414, HPA018817	Enhanced		Enhanced	Nucleus<br>Cytosol		Not detected	Tissue enriched	473	testis: 143.7	smooth muscle: 0.3	Cell line enhanced		K-562: 1.3;U-2 OS: 1.2
RAB31	Rab22B	ENSG00000168461	RAB31, member RAS oncogene family	18	9708165-9862551	Predicted intracellular proteins	Evidence at protein level	HPA019717	Approved					Expressed in all	Expressed in all			cerebral cortex: 169.8	Mixed		
REEP4	C8orf20, FLJ22246, FLJ22277, PP432, Yip2c	ENSG00000168476	Receptor accessory protein 4	8	22138020-22141951	Predicted membrane proteins	Evidence at protein level	HPA042683	Approved		Approved	Cytosol	Renal cancer:2.88e-5 (unfavourable), Liver cancer:4.14e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 66.4	Expressed in all		
TNXB	TNXB1, TNXB2, TNXBS, XB, XBS	ENSG00000168477	Tenascin XB	6	32041154-32115334	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 91.6	endometrium: 18.6	Cell line enhanced		ASC diff: 8.6;ASC TERT1: 14.3;U-2197: 15.6;U-87 MG: 8.2
LGI3		ENSG00000168481	Leucine rich repeat LGI family member 3	8	22146825-22157084	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024826			Approved	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 76.0;lung: 23.9;skin: 17.3;thyroid gland: 21.6	esophagus: 5.2	Cell line enhanced		A549: 1.0;SCLC-21H: 1.9;SK-MEL-30: 1.3;WM-115: 1.0
SFTPC	BRICD6, PSP-C, SFTP2, SMDP2, SP-C	ENSG00000168484	Surfactant protein C	8	22156913-22164479	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA010928	Enhanced					Tissue enriched	Tissue enriched	832	lung: 25269.5	adrenal gland: 30.3	Group enriched	9	BEWO: 9.2;NB-4: 8.0;SCLC-21H: 6.1;U-2197: 24.0
BMP1	PCOLC	ENSG00000168487	Bone morphogenetic protein 1	8	22164736-22212326	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA014572	Enhanced				Renal cancer:3.37e-9 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 21.1	smooth muscle: 10.5	Mixed		
ATXN2L	A2D, A2lp	ENSG00000168488	Ataxin 2 like	16	28823035-28837237	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041506, HPA043391, HPA071955	Approved		Enhanced	Cytosol	Renal cancer:7.99e-7 (unfavourable), Liver cancer:9.85e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 187.6	Expressed in all		
PHYHIP	DYRK1AP3, KIAA0273, PAHX-AP	ENSG00000168490	Phytanoyl-CoA 2-hydroxylase interacting protein	8	22219704-22232341	Predicted intracellular proteins	Evidence at protein level	HPA068030, HPA069318	Approved		Enhanced	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 182.7;skin: 58.2	adrenal gland: 28.8	Cell line enhanced		RPMI-8226: 6.4;SH-SY5Y: 3.6
CCDC110	CT52, KM-HN-1, MGC33607	ENSG00000168491	Coiled-coil domain containing 110	4	185445182-185471759	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-5 (favourable)	Mixed	Tissue enriched	14	testis: 188.3	thyroid gland: 13.2	Cell line enhanced		SCLC-21H: 10.4;U-266/70: 5.6;U-266/84: 6.4
POLR3D	BN51T, RPC4, TSBN51	ENSG00000168495	RNA polymerase III subunit D	8	22245104-22254600	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA061331, HPA067875, HPA068461, HPA069089	Enhanced		Enhanced	Nucleoplasm	Renal cancer:9.15e-6 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Urothelial cancer:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 24.6	Expressed in all		
FEN1	FEN-1, MF1, RAD2	ENSG00000168496	Flap structure-specific endonuclease 1	11	61792637-61797244	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002262, HPA006748	Enhanced		Enhanced	Nucleoplasm<br>Nucleoli	Liver cancer:3.39e-6 (unfavourable), Renal cancer:5.73e-6 (unfavourable), Ovarian cancer:7.85e-4 (favourable), Stomach cancer:9.46e-4 (favourable)	Expressed in all	Mixed			lymph node: 34.8	Expressed in all		
SDPR	cavin-2, CAVIN2, PS-p68, SDR	ENSG00000168497	Serum deprivation response	2	191834302-191847255	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039325, HPA062122	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:8.45e-5 (favourable), Stomach cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 165.9	Group enriched	6	fHDF/TERT166: 118.5;HEL: 101.3;HUVEC TERT2: 284.6;LHCN-M2: 440.0;TIME: 114.4
MTCL1	CCDC165, KIAA0802, SOGA2	ENSG00000168502	Microtubule crosslinking factor 1	18	8705661-8832778	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046245	Uncertain				Renal cancer:5.19e-4 (unfavourable), Cervical cancer:6.45e-4 (unfavourable)	Mixed	Mixed			gallbladder: 12.8	Mixed		
GBX2		ENSG00000168505	Gastrulation brain homeobox 2	2	236165236-236168369	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067809			Approved	Nucleoplasm		Group enriched	Not detected			cerebral cortex: 0.6	Cell line enhanced		AF22: 47.4;PC-3: 13.2
HFE2	haemojuvelin, hemojuvelin, HFE2A, HJV, JH, RGMC	ENSG00000168509	Hemochromatosis type 2 (juvenile)	1	146017468-146036746	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	15	heart muscle: 45.4;liver: 123.4;skeletal muscle: 212.6	esophagus: 8.6	Cell line enhanced		HSkMC: 1.1;K-562: 1.4
SCGB1D1	LIPA, LPHA, MGC71958	ENSG00000168515	Secretoglobin family 1D member 1	11	62190216-62193539	Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enhanced		cervix, uterine: 2.0;fallopian tube: 1.3	endometrium: 0.5	Cell line enriched	43	SCLC-21H: 7.1
HEXIM2	FLJ32384	ENSG00000168517	Hexamethylene bisacetamide inducible 2	17	45160700-45170040	Predicted intracellular proteins	Evidence at protein level	HPA023323, HPA028455	Enhanced		Supported	Nucleoplasm<br>Nuclear speckles	Endometrial cancer:2.53e-4 (favourable), Ovarian cancer:9.85e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.8	Expressed in all		
FNTA	FPTA, PGGT1A, PTAR2	ENSG00000168522	Farnesyltransferase, CAAX box, alpha	8	43034194-43085788	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010149, HPA018830	Approved		Approved	Cytosol	Renal cancer:2.94e-12 (unfavourable)	Expressed in all	Expressed in all			placenta: 63.4	Expressed in all		
SERINC2	FKSG84, PRO0899, TDE2, TDE2L	ENSG00000168528	Serine incorporator 2	1	31409565-31434680	Predicted membrane proteins	Evidence at protein level	HPA005974	Enhanced				Endometrial cancer:1.69e-7 (favourable), Liver cancer:2.11e-4 (unfavourable), Lung cancer:5.70e-4 (unfavourable)	Expressed in all	Mixed			urinary bladder: 133.9	Cell line enhanced		HaCaT: 290.8;HBEC3-KT: 373.3;RT4: 285.7
MYL1		ENSG00000168530	Myosin light chain 1	2	210290150-210315190	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046859, HPA063034	Uncertain				Head and neck cancer:6.59e-4 (unfavourable)	Group enriched	Tissue enriched	31	skeletal muscle: 7521.5	prostate: 242.5	Group enriched	11	HSkMC: 37.4;RH-30: 11.2
TRAPPC11	C4orf41, FLJ12716, foigr, gry	ENSG00000168538	Trafficking protein particle complex 11	4	183659267-183713594	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045427			Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:2.66e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.2	Expressed in all		
CHRM1		ENSG00000168539	Cholinergic receptor muscarinic 1	11	62908679-62921807	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014101, CAB022366	Enhanced		Approved	Nucleus<br>Cytosol		Tissue enriched	Group enriched	8	cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0	adrenal gland: 3.8	Cell line enhanced		MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0
COL3A1	EDS4A	ENSG00000168542	Collagen type III alpha 1 chain	2	188974320-189012746	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA007583, CAB016766, CAB059993	Approved				Renal cancer:3.59e-10 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 3796.7;gallbladder: 3334.2;smooth muscle: 3029.8	placenta: 2768.0	Cell line enhanced		AF22: 1344.2;ASC diff: 1690.4;ASC TERT1: 2979.5;fHDF/TERT166: 1406.5;HHSteC: 1419.6;HSkMC: 2318.4
GFRA2	GDNFRB, NTNRA, RETL2, TRNR2	ENSG00000168546	GDNF family receptor alpha 2	8	21690403-21812357	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024704, CAB032791	Uncertain		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		thyroid gland: 13.4	spleen: 9.5	Group enriched	12	HEL: 8.1;HMC-1: 17.5;WM-115: 3.6
ING2	ING1L, p33ING2	ENSG00000168556	Inhibitor of growth family member 2	4	183504994-183511096	Predicted intracellular proteins	Evidence at protein level	HPA019486, HPA021517	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:5.43e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 63.3	Expressed in all		
CDKN2AIP	CARF, FLJ20036	ENSG00000168564	CDKN2A interacting protein	4	183444591-183448198	Predicted intracellular proteins	Evidence at protein level	HPA041397, HPA062142	Approved		Enhanced	Nucleoplasm	Renal cancer:3.00e-5 (favourable)	Expressed in all	Expressed in all			testis: 37.6	Expressed in all		
SNRNP48	C6orf151, dJ336K20B.1, dJ512B11.2, FLJ32234	ENSG00000168566	Small nuclear ribonucleoprotein U11/U12 subunit 48	6	7590199-7611967	Predicted intracellular proteins	Evidence at protein level	HPA029234	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.16e-4 (unfavourable), Breast cancer:8.30e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 10.7	Expressed in all		
TMEM223	MGC3196	ENSG00000168569	Transmembrane protein 223	11	62771629-62792021	Predicted membrane proteins	Evidence at protein level	HPA014504	Approved		Approved	Nucleus<br>Nuclear membrane<br>Mitochondria		Expressed in all	Expressed in all			spleen: 15.1	Expressed in all		
SLC20A2	Glvr-2, GLVR2, MLVAR, PiT-2, Ram-1	ENSG00000168575	Solute carrier family 20 member 2	8	42416475-42541926	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA026540	Approved				Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 138.4	Expressed in all		
CRYGA	CRY-g-A, CRYG1, CRYG5	ENSG00000168582	Crystallin gamma A	2	208160740-208163576	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex,testis: 0.1	Not detected		
DYNLRB2	DNCL2B, DNLC2B, ROBLD2	ENSG00000168589	Dynein light chain roadblock-type 2	16	80540734-80550760	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.91e-5 (favourable)	Mixed	Group enriched	8	fallopian tube: 134.8;testis: 325.7	epididymis: 27.5	Cell line enhanced		MCF7: 4.4;RPTEC TERT1: 2.8;SCLC-21H: 2.2
TMUB2	MGC3123	ENSG00000168591	Transmembrane and ubiquitin like domain containing 2	17	44186970-44191731	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043137	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 48.4	Expressed in all		
ADAM29	CT73, svph1	ENSG00000168594	ADAM metallopeptidase domain 29	4	174829668-174978180	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	145	testis: 73.3	endometrium: 0.5	Not detected		
STAT3	APRF	ENSG00000168610	Signal transducer and activator of transcription 3	17	42313324-42388568	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001671, CAB003859, HPA058603, CAB068241, CAB068242	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			gallbladder: 127.5	Mixed		
ZSWIM1	C20orf162, dJ337O18.5	ENSG00000168612	Zinc finger SWIM-type containing 1	20	45881227-45885266	Predicted intracellular proteins	Evidence at protein level	HPA041147, HPA046751	Uncertain		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 9.3	Expressed in all		
ADAM9	CORD9, KIAA0021, MCMP, MDC9, Mltng	ENSG00000168615	ADAM metallopeptidase domain 9	8	38996869-39105144	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004000			Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.7	Expressed in all		
ADAM18	ADAM27, tMDCIII	ENSG00000168619	ADAM metallopeptidase domain 18	8	39584489-39730064	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	85	testis: 8.4	all non-specific tissues: 0.0	Not detected		
GDNF	ATF1, ATF2, HFB1-GDNF	ENSG00000168621	Glial cell derived neurotrophic factor	5	37812677-37839686	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB005210, HPA070283	Supported		Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			placenta: 7.0	Cell line enhanced		hTEC/SVTERT24-B: 41.1;U-87 MG: 12.1;WM-115: 45.1
DPCR1	bCX105N19.6, PBLT	ENSG00000168631	Diffuse panbronchiolitis critical region 1	6	30934523-30954221	Predicted membrane proteins	Evidence at protein level	HPA014036	Enhanced				Pancreatic cancer:6.58e-4 (unfavourable)	Group enriched	Tissue enriched	12	stomach: 191.3	gallbladder: 16.0	Not detected		
WFDC13	C20orf138, dJ601O1.3, WAP13	ENSG00000168634	WAP four-disulfide core domain 13	20	45702016-45708817	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	319	epididymis: 106.6	seminal vesicle: 0.3	Not detected		
AXIN2	DKFZp781B0869, MGC126582	ENSG00000168646	Axin 2	17	65528563-65561647	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012283, CAB017783	Approved		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.58e-4 (favourable)	Expressed in all	Mixed			endometrium: 31.1	Cell line enhanced		AF22: 26.9;CACO-2: 43.2;Hep G2: 53.5
NDUFS5	CI-15k	ENSG00000168653	NADH:ubiquinone oxidoreductase subunit S5	1	39026318-39034636	Predicted intracellular proteins	Evidence at protein level	HPA042582	Supported				Ovarian cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 642.7	Expressed in all		
VWA3B	DKFZp686F2227, MGC26733	ENSG00000168658	Von Willebrand factor A domain containing 3B	2	98087116-98313299	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036700, HPA036701	Approved		Approved	Nucleus		Tissue enhanced	Group enriched	9	fallopian tube: 41.2;testis: 36.2	lung: 4.3	Not detected		
ZNF30	DKFZp686N19164, FLJ20562, KOX28	ENSG00000168661	Zinc finger protein 30	19	34926903-34945170	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030400	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.16e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 5.0	Mixed		
UGT3A2		ENSG00000168671	UDP glycosyltransferase family 3 member A2	5	36035017-36071358	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059475	Uncertain		Approved	Nucleus<br>Cytosol		Tissue enriched	Tissue enhanced		skin: 11.9;testis: 4.6	bone marrow: 3.2	Cell line enhanced		HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
FAM84B	BCMP101, NSE2	ENSG00000168672	Family with sequence similarity 84 member B	8	126552442-126558393	Predicted intracellular proteins	Evidence at protein level	HPA050782, HPA062115	Approved		Approved	Nucleoplasm	Renal cancer:1.96e-8 (favourable), Urothelial cancer:1.75e-5 (favourable), Endometrial cancer:9.71e-4 (unfavourable)	Expressed in all	Mixed			kidney: 29.6	Cell line enhanced		A-431: 65.0;AN3-CA: 96.5;MCF7: 83.0;PC-3: 66.5
LDLRAD4	C18orf1	ENSG00000168675	Low density lipoprotein receptor class A domain containing 4	18	13217498-13652755	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047633, HPA054556, HPA065246	Approved		Supported	Nucleoplasm<br>Vesicles	Renal cancer:4.58e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.5	Cell line enhanced		HEL: 34.2;MOLT-4: 94.8;REH: 32.0
KCTD19	FLJ40162	ENSG00000168676	Potassium channel tetramerization domain containing 19	16	67289428-67326763	Predicted intracellular proteins	Evidence at protein level	HPA049310, HPA053321	Uncertain					Not detected	Tissue enriched	15	testis: 39.2	bone marrow: 2.6	Cell line enhanced		HBF TERT88: 2.0;U-266/70: 4.4
SLC16A4	MCT4, MCT5	ENSG00000168679	Solute carrier family 16 member 4	1	110362848-110391082	Predicted membrane proteins	Evidence at transcript level	HPA046986, HPA060163	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.69e-4 (favourable)	Expressed in all	Tissue enhanced		kidney: 125.2	placenta: 39.9	Cell line enhanced		BEWO: 19.0;CAPAN-2: 26.1;SK-MEL-30: 24.1
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	5	35852695-35879603	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010215	Approved		Approved	Plasma membrane<br>Microtubule organizing center		Expressed in all	Tissue enhanced		appendix: 182.9;lymph node: 158.5	tonsil: 112.9	Cell line enhanced		fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
TMEM208	HSPC171	ENSG00000168701	Transmembrane protein 208	16	67227103-67229278	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041868, HPA041949	Supported				Head and neck cancer:9.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 89.7	Expressed in all		
LRP1B	LRP-DIT, LRPDIT	ENSG00000168702	LDL receptor related protein 1B	2	140231423-142131701	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069094, HPA074788	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 16.4;thyroid gland: 9.6	epididymis: 2.7	Cell line enhanced		ASC diff: 1.0;HEK 293: 1.5;U-138 MG: 1.8
WFDC12	C20orf122, dJ211D12.4, WAP2	ENSG00000168703	WAP four-disulfide core domain 12	20	45123425-45124465	Predicted secreted proteins	Evidence at protein level						Renal cancer:5.65e-4 (unfavourable)	Group enriched	Tissue enriched	12	skin: 49.7	seminal vesicle: 4.3	Not detected		
AHCYL1	IRBIT, PPP1R78, XPVKONA	ENSG00000168710	Adenosylhomocysteinase like 1	1	109984686-110023741	Predicted intracellular proteins	Evidence at protein level	HPA042589	Approved		Supported	Cytosol	Colorectal cancer:7.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 253.8	Expressed in all		
DNAJC21	DNAJA5, GS3, JJJ1	ENSG00000168724	DnaJ heat shock protein family (Hsp40) member C21	5	34929593-34958964	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040789, HPA049208	Approved		Approved	Vesicles	Liver cancer:2.36e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 101.6	Expressed in all		
PKIG		ENSG00000168734	CAMP-dependent protein kinase inhibitor gamma	20	44531785-44624247	Predicted intracellular proteins	Evidence at protein level	HPA042703, HPA063690	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:4.90e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 177.2	Cell line enhanced		BJ hTERT+: 425.9
NPNT	EGFL6L, POEM	ENSG00000168743	Nephronectin	4	105894775-106004027	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003711, HPA050203	Supported		Approved	Nucleus<br>Cell Junctions<br>Cytosol	Renal cancer:8.28e-8 (favourable)	Expressed in all	Tissue enhanced		lung: 168.4;thyroid gland: 276.0	prostate: 136.5	Cell line enhanced		BEWO: 27.8;HeLa: 22.2;RPTEC TERT1: 28.6;T-47d: 48.1
CA7		ENSG00000168748	Carbonic anhydrase 7	16	66844379-66854153	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047237	Uncertain					Tissue enhanced	Tissue enhanced		colon: 54.6;rectum: 49.8	small intestine: 10.7	Cell line enhanced		REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
FAM178B	LOC51252	ENSG00000168754	Family with sequence similarity 178 member B	2	96875882-96986592	Predicted intracellular proteins	Evidence at transcript level	HPA042516, HPA062110	Uncertain		Uncertain	Nuclear speckles<br>Golgi apparatus		Tissue enriched	Group enriched	5	bone marrow: 11.4;epididymis: 6.7;spleen: 16.7;testis: 7.4	fallopian tube: 2.0	Cell line enhanced		K-562: 23.0;RPMI-8226: 19.2;WM-115: 26.6
TSPY2	TSPYQ1	ENSG00000168757	Testis specific protein, Y-linked 2	Y	6246223-6249019	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	132	testis: 14.1	adipose tissue: 0.1	Group enriched	484	U-266/70: 81.8;U-266/84: 82.9
SEMA4C	Semacl1, Semaf, SEMAI	ENSG00000168758	Semaphorin 4C	2	96859716-96870757	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA011090	Approved				Renal cancer:9.50e-7 (unfavourable), Colorectal cancer:3.53e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.9	Cell line enriched	6	BEWO: 298.1
CNNM3	ACDP3	ENSG00000168763	Cyclin and CBS domain divalent metal cation transport mediator 3	2	96816245-96833911	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016711	Supported		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 45.6	Expressed in all		
GSTM4		ENSG00000168765	Glutathione S-transferase mu 4	1	109656081-109674836	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048652, HPA055972, HPA055973	Approved		Approved	Cytokinetic bridge<br>Cytosol	Breast cancer:9.96e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 149.7	Mixed		
TET2	FLJ20032, KIAA1546	ENSG00000168769	Tet methylcytosine dioxygenase 2	4	105145875-105279816	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043135	Supported		Approved	Nucleoplasm		Mixed	Mixed			bone marrow: 15.7	Mixed		
CXXC4	IDAX	ENSG00000168772	CXXC finger protein 4	4	104468312-104494901	Predicted intracellular proteins	Evidence at protein level	HPA036600, HPA036925	Uncertain		Uncertain	Nucleus<br>Golgi apparatus	Pancreatic cancer:2.19e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 8.9	thyroid gland: 4.1	Cell line enhanced		AF22: 6.9;AN3-CA: 9.0;Karpas-707: 6.4;SCLC-21H: 14.1;U-266/70: 7.4
TCTN2	C12orf38, FLJ12975, JBTS24, MKS8, TECT2	ENSG00000168778	Tectonic family member 2	12	123671113-123708403	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA039900	Enhanced		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			fallopian tube: 46.6	Mixed		
SHOX2	OG12, OG12X, SHOT	ENSG00000168779	Short stature homeobox 2	3	158095954-158106503	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		adipose tissue: 4.1;testis: 3.3	cervix, uterine: 2.8	Cell line enhanced		SH-SY5Y: 26.1;THP-1: 28.6
PPIP5K1	HISPPD2A, IPS1, KIAA0377, VIP1	ENSG00000168781	Diphosphoinositol pentakisphosphate kinase 1	15	43533462-43590253	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039380	Approved		Supported	Cytosol	Renal cancer:7.14e-8 (favourable), Ovarian cancer:8.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 53.1	Expressed in all		
TSPAN5	NET-4, TM4SF9, Tspan-5	ENSG00000168785	Tetraspanin 5	4	98470367-98658629	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.83e-5 (unfavourable), Stomach cancer:8.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 75.9	ovary: 57.2	Mixed		
ABHD15		ENSG00000168792	Abhydrolase domain containing 15	17	29560547-29567137	Predicted secreted proteins	Evidence at protein level	HPA014470	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			adipose tissue: 20.5	Mixed		
ZBTB5	KIAA0354	ENSG00000168795	Zinc finger and BTB domain containing 5	9	37438114-37465399	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021521	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 17.6	Expressed in all		
CHTF8	CTF8, DERPC, FLJ20400	ENSG00000168802	Chromosome transmission fidelity factor 8	16	69118010-69132584	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051872, HPA065522	Approved		Enhanced	Nucleoplasm	Renal cancer:3.59e-9 (favourable)	Expressed in all	Expressed in all			fallopian tube: 112.9	Expressed in all		
ADAL		ENSG00000168803	Adenosine deaminase like	15	43330674-43354555	Predicted intracellular proteins	Evidence at protein level	HPA046215, HPA048175	Approved		Approved	Microtubules	Renal cancer:7.64e-9 (favourable)	Expressed in all	Mixed			testis: 24.8	Mixed		
LCMT2	KIAA0547, MGC9534, PPM2, TYW4	ENSG00000168806	Leucine carboxyl methyltransferase 2	15	43323649-43330605	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039401, HPA048176	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:5.69e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.2	Mixed		
SNTB2	D16S2531E, EST25263, SNT2B2, SNT3, SNTL	ENSG00000168807	Syntrophin beta 2	16	69187129-69309052	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			parathyroid gland: 35.4	Mixed		
IL12A	CLMF, IL-12A, NFSK, NKSF1, p35	ENSG00000168811	Interleukin 12A	3	159988750-159996019	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA001886	Uncertain					Mixed	Tissue enhanced		esophagus: 4.0	fallopian tube: 3.2	Cell line enhanced		HDLM-2: 11.1;SK-BR-3: 12.8
ZNF507	KIAA1084	ENSG00000168813	Zinc finger protein 507	19	32345594-32387667	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030964, HPA049728	Uncertain		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 35.0	Expressed in all		
STX18	Ufe1	ENSG00000168818	Syntaxin 18	4	4415742-4542346	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003019	Approved		Approved	Plasma membrane	Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 180.1	Expressed in all		
NSG1		ENSG00000168824	Neuron-specific protein family member 1 	4	4348140-4419058	Predicted membrane proteins	Evidence at protein level	HPA035775			Approved	Mitochondria	Pancreatic cancer:9.49e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 143.1	cerebral cortex: 68.6	Group enriched	8	HAP1: 87.0;SCLC-21H: 199.6;SH-SY5Y: 87.5;SK-MEL-30: 63.7;TIME: 166.8;U-698: 51.3
ZBTB49	FLJ38559, ZNF509	ENSG00000168826	Zinc finger and BTB domain containing 49	4	4290251-4321786	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024450	Approved		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Urothelial cancer:2.88e-5 (favourable), Pancreatic cancer:1.76e-4 (favourable), Head and neck cancer:5.24e-4 (favourable)	Expressed in all	Mixed			testis: 7.4	Expressed in all		
GFM1	EFGM, EGF1, GFM	ENSG00000168827	G elongation factor mitochondrial 1	3	158644278-158692575	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034764, HPA034765, HPA061405	Enhanced		Approved	Nucleus<br>Mitochondria	Renal cancer:1.16e-7 (favourable), Pancreatic cancer:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.5	Expressed in all		
OR13J1		ENSG00000168828	Olfactory receptor family 13 subfamily J member 1	9	35869263-35870601	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Not detected		
HTR1E	5-HT1E	ENSG00000168830	5-hydroxytryptamine receptor 1E	6	86937306-87016683	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004931	Approved					Not detected	Tissue enhanced		endometrium: 2.4;ovary: 4.9	cerebral cortex: 1.8	Group enriched	19	PC-3: 1.4;SH-SY5Y: 6.2
FSTL5	DKFZp566D234, KIAA1263	ENSG00000168843	Follistatin like 5	4	161383897-162164035	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	11	adrenal gland: 7.8;cerebral cortex: 16.2	testis: 1.1	Cell line enhanced		HL-60: 9.8;HUVEC TERT2: 9.0;Karpas-707: 53.8;SH-SY5Y: 11.3;U-2197: 15.1
DDX19A	DDX19L, FLJ11126	ENSG00000168872	DEAD-box helicase 19A	16	70346829-70373383	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045252, HPA066668	Approved		Uncertain	Nucleoplasm	Liver cancer:8.05e-5 (unfavourable), Head and neck cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 51.3	Expressed in all		
ATOH8	bHLHa21, FLJ14708, HATH6	ENSG00000168874	Atonal bHLH transcription factor 8	2	85751344-85788066	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028406			Supported	Nucleoplasm	Pancreatic cancer:8.98e-6 (favourable), Renal cancer:3.80e-5 (favourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 31.6	lung: 17.0	Cell line enhanced		RH-30: 29.0;TIME: 23.5
SOX14	SOX28	ENSG00000168875	SRY-box 14	3	137764284-137766338	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Group enriched	19	placenta: 2.4;prostate: 1.2	all non-specific tissues: 0.0	Not detected		
ANKRD49	FGIF, FLJ20189, GBIF	ENSG00000168876	Ankyrin repeat domain 49	11	94493629-94499583	Predicted intracellular proteins	Evidence at protein level	HPA040273, HPA048137	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:6.16e-4 (favourable), Renal cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.4	Expressed in all		
SFTPB	SFTP3, SP-B	ENSG00000168878	Surfactant protein B	2	85657314-85668741	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002440, HPA034820, HPA062148	Enhanced				Endometrial cancer:1.71e-6 (unfavourable), Renal cancer:2.99e-6 (unfavourable)	Group enriched	Tissue enriched	912	lung: 5318.7	adrenal gland: 5.8	Cell line enhanced		BEWO: 2.8;U-2197: 6.3
USP39	CGI-21, SAD1, SNRNP65	ENSG00000168883	Ubiquitin specific peptidase 39	2	85602856-85649282	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034823		Approved	Supported	Nucleoplasm	Renal cancer:4.05e-7 (unfavourable), Liver cancer:2.84e-6 (unfavourable), Endometrial cancer:5.52e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.4	Expressed in all		
TNIP2	ABIN-2, FLIP1, KLIP, MGC4289	ENSG00000168884	TNFAIP3 interacting protein 2	4	2741648-2756376	Predicted intracellular proteins	Evidence at protein level	CAB020818, HPA049886, HPA063197	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.94e-5 (unfavourable), Endometrial cancer:1.13e-4 (favourable), Lung cancer:5.73e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.1	Expressed in all		
C2orf68		ENSG00000168887	Chromosome 2 open reading frame 68	2	85606654-85612066	Predicted intracellular proteins	Evidence at protein level	HPA051143	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Mitochondria	Renal cancer:1.11e-6 (unfavourable), Endometrial cancer:1.12e-6 (unfavourable), Liver cancer:6.76e-6 (unfavourable)	Expressed in all	Expressed in all			endometrium: 26.2	Expressed in all		
TMEM150A	FLJ90024, TM6P1, TMEM150, TTN1	ENSG00000168890	Transmembrane protein 150A	2	85598548-85603196	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019015	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			placenta: 33.4	Mixed		
RNF181	HSPC238	ENSG00000168894	Ring finger protein 181	2	85595725-85597613	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046112, HPA062121	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.06e-6 (unfavourable), Thyroid cancer:4.59e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 171.6	Expressed in all		
VAMP5		ENSG00000168899	Vesicle associated membrane protein 5	2	85584408-85593412	Predicted membrane proteins	Evidence at protein level	HPA035082	Supported				Renal cancer:1.28e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 119.8	Cell line enhanced		HUVEC TERT2: 284.0;LHCN-M2: 332.6;TIME: 191.2
BTNL3	BTN9.1, BTNLR	ENSG00000168903	Butyrophilin like 3	5	180988845-181006727	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	25	colon: 24.5;duodenum: 115.1;rectum: 26.3;small intestine: 89.1	gallbladder: 2.5	Not detected		
LRRC28	FLJ34269, FLJ45242, MGC24976	ENSG00000168904	Leucine rich repeat containing 28	15	99251362-99390729	Predicted intracellular proteins	Evidence at transcript level	HPA039378, HPA040784, HPA066130	Approved		Approved	Nucleus<br>Golgi apparatus<br>Mitochondria	Ovarian cancer:9.97e-5 (favourable), Cervical cancer:1.41e-4 (favourable)	Expressed in all	Expressed in all			testis: 50.3	Expressed in all		
MAT2A	MATA2, MATII, SAMS2	ENSG00000168906	Methionine adenosyltransferase 2A	2	85539165-85545280	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009968, HPA043028	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.29e-5 (unfavourable), Melanoma:5.94e-5 (unfavourable), Liver cancer:4.87e-4 (unfavourable), Lung cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 644.9	Expressed in all		
PLA2G4F	PLA2G4F/Z	ENSG00000168907	Phospholipase A2 group IVF	15	42139034-42156636	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA042713, HPA056752	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:2.00e-4 (unfavourable)	Mixed	Tissue enriched	5	skin: 92.5	lung: 18.4	Cell line enhanced		hTCEpi: 1.4;RT4: 6.6
ENHO	C9orf165, UNQ470	ENSG00000168913	Energy homeostasis associated	9	34521040-34523041	Predicted secreted proteins	Evidence at transcript level	HPA042575	Approved				Endometrial cancer:3.71e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	cerebral cortex: 140.3	testis: 11.5	Cell line enhanced		AN3-CA: 14.6;NTERA-2: 21.5;SCLC-21H: 12.8;SH-SY5Y: 10.9
ZNF608	DKFZp434M098, KIAA1281, NY-REN-36	ENSG00000168916	Zinc finger protein 608	5	124636913-124748807	Predicted intracellular proteins	Evidence at protein level	HPA005545	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.28e-5 (unfavourable), Endometrial cancer:5.47e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 18.2	Cell line enhanced		AF22: 60.2;REH: 100.7
SLC35G2	DKFZp564K2464, MGC3295, TMEM22	ENSG00000168917	Solute carrier family 35 member G2	3	136818647-136855892	Predicted membrane proteins, Transporters	Evidence at protein level	HPA052054, HPA064728	Approved		Supported	Plasma membrane	Renal cancer:1.16e-7 (unfavourable)	Mixed	Mixed			testis: 21.3	Cell line enhanced		BJ hTERT+: 59.1
INPP5D	hp51CN, SHIP, SHIP1	ENSG00000168918	Inositol polyphosphate-5-phosphatase D	2	233059967-233207903	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016300, HPA070455	Uncertain		Approved	Cytosol	Head and neck cancer:2.03e-5 (favourable)	Expressed in all	Mixed			lymph node: 39.3	Cell line enhanced		HEL: 84.8;HMC-1: 83.7;hTCEpi: 63.0;NB-4: 56.4
LETM1		ENSG00000168924	Leucine zipper and EF-hand containing transmembrane protein 1	4	1811479-1856247	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011029, HPA011100	Enhanced		Enhanced	Mitochondria	Prostate cancer:1.77e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable), Renal cancer:8.90e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.3	Expressed in all		
CTRB1	CTRB	ENSG00000168925	Chymotrypsinogen B1	16	75219000-75224924	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	376	pancreas: 48923.8	ovary: 130.0	Cell line enhanced		EFO-21: 2.9;HDLM-2: 2.3;U-2 OS: 2.4;U-266/84: 1.0
CTRB2		ENSG00000168928	Chymotrypsinogen B2	16	75204096-75207185	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	392	pancreas: 29060.0	ovary: 74.0	Cell line enhanced		EFO-21: 3.0;U-2 OS: 6.8;U-251 MG: 1.5;U-266/84: 1.9
TRIM49	RNF18, TRIM49A	ENSG00000168930	Tripartite motif containing 49	11	89797655-89808575	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
TMEM129	D4S2561E	ENSG00000168936	Transmembrane protein 129	4	1715952-1721358	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA060920			Approved	Vesicles	Renal cancer:9.64e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.1	Expressed in all		
PPIC	CYPC	ENSG00000168938	Peptidylprolyl isomerase C	5	123023250-123036741	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA039163	Approved				Liver cancer:4.78e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 77.6	Mixed		
SPRY3	HSPRY3	ENSG00000168939	Sprouty RTK signaling antagonist 3	X	155767812-155782459	Predicted membrane proteins	Evidence at transcript level	CAB013505	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			epididymis: 2.6	Cell line enhanced		AN3-CA: 3.4
CEP120	CCDC100, FLJ36090	ENSG00000168944	Centrosomal protein 120	5	123344885-123423592	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028823, HPA051556	Uncertain		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 29.7	Expressed in all		
STXBP6	amisyn, HSPC156	ENSG00000168952	Syntaxin binding protein 6	14	24809656-25050297	Predicted intracellular proteins	Evidence at protein level	HPA003552	Approved					Mixed	Mixed			placenta: 61.2	Cell line enhanced		HBF TERT88: 62.1
TM4SF20	FLJ22800, TCCE518	ENSG00000168955	Transmembrane 4 L six family member 20	2	227362156-227381995	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051838, HPA063184, HPA065531	Uncertain		Supported	Plasma membrane<br>Focal adhesion sites		Group enriched	Group enriched	35	duodenum: 277.2;small intestine: 163.8	testis: 6.3	Cell line enhanced		A549: 2.5;RPMI-8226: 1.2
MFF	C2orf33, GL004	ENSG00000168958	Mitochondrial fission factor	2	227325151-227357836	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010968, HPA074625	Approved		Supported	Mitochondria	Liver cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 353.8	Expressed in all		
GRM5	GPRC1E, mGlu5, MGLUR5, PPP1R86	ENSG00000168959	Glutamate metabotropic receptor 5	11	88504576-89065945	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	8	cerebral cortex: 27.2	testis: 3.2	Not detected		
LGALS9	LGALS9A	ENSG00000168961	Galectin 9	17	27629798-27649560	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Approved	Cytosol	Renal cancer:1.52e-5 (unfavourable), Cervical cancer:2.35e-5 (favourable)	Expressed in all	Mixed			rectum: 42.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 23.0;HMC-1: 54.5;MOLT-4: 26.1;THP-1: 38.7;U-937: 38.5
JMJD7-PLA2G4B		ENSG00000168970	JMJD7-PLA2G4B readthrough	15	41828095-41848155	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA005726	Uncertain		Approved	Cytosol		Mixed	Mixed			lung: 1.6	Mixed		
CPLX1	CPX-I	ENSG00000168993	Complexin 1	4	784957-826198	Predicted intracellular proteins	Evidence at protein level	HPA071191			Uncertain	Vesicles	Cervical cancer:4.20e-4 (unfavourable), Pancreatic cancer:5.05e-4 (favourable)	Expressed in all	Tissue enriched	11	cerebral cortex: 60.2	adipose tissue: 5.3	Cell line enriched	7	SCLC-21H: 95.0
PXDC1	C6orf145	ENSG00000168994	PX domain containing 1	6	3722614-3752026	Predicted intracellular proteins	Evidence at protein level	HPA019246			Approved	Plasma membrane	Endometrial cancer:1.14e-4 (unfavourable), Colorectal cancer:3.64e-4 (unfavourable)	Expressed in all	Mixed			placenta: 82.7	Mixed		
SIGLEC7	CD328, p75/AIRM1, QA79, SIGLEC-7, SIGLEC19P, SIGLECP2	ENSG00000168995	Sialic acid binding Ig like lectin 7	19	51142299-51153526	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 21.0	appendix: 14.4	Group enriched	10	Karpas-707: 39.7;RPMI-8226: 23.1;U-937: 27.4
NTSR2	NTR2	ENSG00000169006	Neurotensin receptor 2	2	11658178-11670164	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	25	cerebral cortex: 25.0	ovary: 0.9	Not detected		
E2F6	E2F-6	ENSG00000169016	E2F transcription factor 6	2	11444375-11466177	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075185			Supported	Nucleoplasm	Liver cancer:1.20e-5 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 7.2	Expressed in all		
FEM1B		ENSG00000169018	Fem-1 homolog B	15	68277803-68295865	Predicted intracellular proteins	Evidence at protein level	HPA041920, HPA042192	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 105.4	Expressed in all		
COMMD8	FLJ20502	ENSG00000169019	COMM domain containing 8	4	47450796-47463719	Predicted intracellular proteins	Evidence at protein level	HPA035887	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.71e-5 (favourable), Liver cancer:1.40e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 46.4	Expressed in all		
ATP5I		ENSG00000169020	ATP synthase, H+ transporting, mitochondrial Fo complex subunit E	4	672436-674338	Predicted intracellular proteins	Evidence at protein level	HPA035010	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 541.4	Expressed in all		
UQCRFS1	RIP1, RIS1, RISP, UQCR5	ENSG00000169021	Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1	19	29205321-29213541	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041863, HPA050339	Enhanced		Enhanced	Mitochondria	Renal cancer:3.92e-9 (favourable), Colorectal cancer:3.29e-4 (favourable), Ovarian cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 70.9	Expressed in all		
MFSD7	FLJ22269, LP2561	ENSG00000169026	Major facilitator superfamily domain containing 7	4	681829-689441	Predicted membrane proteins	Evidence at transcript level	HPA043593	Uncertain				Renal cancer:2.66e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.0	Cell line enhanced		BEWO: 7.9;T-47d: 24.0
COL4A3		ENSG00000169031	Collagen type IV alpha 3 chain	2	227164565-227314792	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042064	Approved		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:2.51e-7 (favourable)	Group enriched	Tissue enhanced		thyroid gland: 26.8	lung: 22.4	Cell line enhanced		HeLa: 10.8;Karpas-707: 7.1;RPTEC TERT1: 8.3;U-266/70: 6.7
MAP2K1	MAPKK1, MEK1, PRKMK1	ENSG00000169032	Mitogen-activated protein kinase kinase 1	15	66386817-66492312	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003834, HPA026430	Approved		Enhanced	Plasma membrane<br>Cytosol	Glioma:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.4	Expressed in all		
KLK7	PRSS6, SCCE	ENSG00000169035	Kallikrein related peptidase 7	19	50976482-50984099	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018994, CAB026342, HPA062126	Enhanced		Supported	Nuclear membrane<br>Plasma membrane	Endometrial cancer:8.06e-5 (unfavourable), Pancreatic cancer:1.16e-4 (unfavourable)	Tissue enhanced	Group enriched	5	esophagus: 68.7;skin: 219.6	fallopian tube: 27.9	Group enriched	6	CAPAN-2: 7.1;HaCaT: 28.1
HNRNPH1	hnRNPH, HNRPH1	ENSG00000169045	Heterogeneous nuclear ribonucleoprotein H1	5	179614178-179634784	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000914, HPA001359, HPA016884, CAB032820	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:3.29e-7 (unfavourable), Renal cancer:3.46e-4 (unfavourable), Head and neck cancer:7.85e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 203.6	Expressed in all		
IRS1	HIRS-1	ENSG00000169047	Insulin receptor substrate 1	2	226731317-226799759	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005261, HPA046433	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			thyroid gland: 33.9	Mixed		
MECP2	MRX16, MRX79, RTT	ENSG00000169057	Methyl-CpG binding protein 2	X	154021573-154137103	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000593, HPA001341, CAB037264	Enhanced		Supported	Nucleus	Renal cancer:7.32e-9 (favourable), Endometrial cancer:8.35e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.7	Expressed in all		
VCX3A	VCX-8r, VCX-A, VCX3	ENSG00000169059	Variable charge, X-linked 3A	X	6533618-6535118	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Mixed	Tissue enriched	205	testis: 27.5	placenta: 0.1	Cell line enhanced		HMC-1: 4.3;PC-3: 2.3;U-138 MG: 7.3;U-266/70: 3.5
UPF3A	HUPF3A, RENT3A, UPF3	ENSG00000169062	UPF3 regulator of nonsense transcripts homolog A (yeast)	13	114281584-114305817	Predicted intracellular proteins	Evidence at protein level	HPA018325, HPA061316	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Pancreatic cancer:7.09e-5 (favourable), Urothelial cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 84.4	Expressed in all		
ZBBX	FLJ23049	ENSG00000169064	Zinc finger B-box domain containing	3	167240287-167381346	Predicted intracellular proteins	Evidence at protein level	HPA036327, HPA036328	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 38.1;testis: 67.6	lung: 5.5	Not detected		
ACTBL2	DKFZp686D0972	ENSG00000169067	Actin, beta like 2	5	57480016-57482809	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Uncertain					Not detected	Not detected			cervix, uterine: 0.3	Cell line enhanced		RPTEC TERT1: 1.2;SiHa: 3.0;U-2 OS: 1.8
ROR2	BDB, BDB1, NTRKR2	ENSG00000169071	Receptor tyrosine kinase like orphan receptor 2	9	91563091-91950162	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA021868	Uncertain				Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 35.1	endometrium: 21.4	Cell line enhanced		AF22: 25.3;HHSteC: 55.3;HSkMC: 39.9;U-266/70: 29.6
AR	AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1	ENSG00000169083	Androgen receptor	X	67544032-67730619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000001, HPA065701, CAB065764	Enhanced		Approved	Mitochondria	Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable)	Mixed	Mixed			fallopian tube: 42.3	Cell line enhanced		AF22: 15.6;HAP1: 21.1;LHCN-M2: 14.9;RH-30: 28.3
DHRSX	DHRS5X, DHRS5Y, DHRSXY, DHRSY, SDR46C1, SDR7C6	ENSG00000169084	Dehydrogenase/reductase X-linked	X	2219516-2502805	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003035	Approved		Approved	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 17.1	Mixed		
C8orf46	MGC33510	ENSG00000169085	Chromosome 8 open reading frame 46	8	66460003-66518524	Predicted intracellular proteins	Evidence at protein level	HPA075134			Approved	Nuclear speckles		Tissue enriched	Tissue enriched	14	cerebral cortex: 65.1	seminal vesicle: 4.5	Cell line enhanced		LHCN-M2: 1.8;SK-MEL-30: 1.9;T-47d: 2.8;WM-115: 2.9
HSPBAP1	FLJ22623, PASS1	ENSG00000169087	HSPB1 associated protein 1	3	122740003-122793824	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044930	Approved		Approved	Mitochondria		Expressed in all	Mixed			testis: 19.3	Expressed in all		
ASMTL		ENSG00000169093	Acetylserotonin O-methyltransferase-like	X	1403139-1453762	Predicted intracellular proteins	Evidence at protein level	HPA003630, HPA021865	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			thyroid gland: 34.4	Expressed in all		
SLC25A6	ANT3, ANT3Y, MGC17525	ENSG00000169100	Solute carrier family 25 member 6	X	1386152-1392724	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046835, HPA071684	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			ovary: 291.7	Expressed in all		
CHST14	D4ST-1, D4ST1, HD4ST	ENSG00000169105	Carbohydrate sulfotransferase 14	15	40470998-40474571	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA057697, HPA071601	Approved		Approved	Vesicles		Expressed in all	Expressed in all			placenta: 38.8	Expressed in all		
PARM1	Cipar1, DKFZP564O0823, WSC4	ENSG00000169116	Prostate androgen-regulated mucin-like protein 1	4	74933095-75050115	Predicted membrane proteins	Evidence at protein level	HPA038236	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Thyroid cancer:1.78e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 206.6	Cell line enhanced		ASC diff: 30.6;Karpas-707: 32.2;U-266/70: 37.9
CSNK1G1	CK1gamma1	ENSG00000169118	Casein kinase 1 gamma 1	15	64165517-64356259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018209			Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 59.9	thyroid gland: 13.9	Expressed in all		
FAM110B	C8orf72, MGC39325	ENSG00000169122	Family with sequence similarity 110 member B	8	57994509-58204279	Predicted intracellular proteins	Evidence at protein level	HPA008318, HPA011781	Uncertain		Supported	Mitochondria<br>Cytosol	Endometrial cancer:3.88e-8 (unfavourable), Renal cancer:4.31e-8 (favourable), Pancreatic cancer:1.44e-4 (favourable)	Mixed	Tissue enhanced		spleen: 28.2	cerebral cortex: 17.7	Cell line enhanced		RPTEC TERT1: 9.6
ARMC4	CILD23, DKFZP434P1735, FLJ10376, FLJ10817	ENSG00000169126	Armadillo repeat containing 4	10	27812164-27999048	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037829	Enhanced					Mixed	Group enriched	11	fallopian tube: 28.9;testis: 40.2	prostate: 3.2	Cell line enhanced		AF22: 6.0;RH-30: 14.9
AFAP1L2	Em:AC005383.4, FLJ14564, KIAA1914, XB130	ENSG00000169129	Actin filament associated protein 1 like 2	10	114294824-114404756	Predicted intracellular proteins	Evidence at protein level	HPA037843	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.55e-5 (unfavourable), Pancreatic cancer:3.76e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 138.0	parathyroid gland: 94.7	Cell line enhanced		A-431: 64.5;CAPAN-2: 68.1;EFO-21: 53.1;HaCaT: 87.3;RPMI-8226: 36.0;RPTEC TERT1: 45.2
ZNF354A	EZNF, HKL1, KID-1, KID1, TCF17	ENSG00000169131	Zinc finger protein 354A	5	178694605-178730702	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052043	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:3.45e-6 (unfavourable), Ovarian cancer:8.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.7	Mixed		
ATF5		ENSG00000169136	Activating transcription factor 5	19	49928702-49933935	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030187	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.39e-7 (unfavourable), Cervical cancer:1.14e-4 (favourable), Endometrial cancer:1.16e-4 (unfavourable)	Tissue enriched	Group enriched	7	liver: 387.6;thyroid gland: 190.2	appendix: 42.4	Expressed in all		
UBE2V2	DDVit-1, DDVIT1, EDAF-1, EDPF-1, EDPF1, MMS2, UEV-2, UEV2	ENSG00000169139	Ubiquitin conjugating enzyme E2 V2	8	48008400-48064708	Predicted intracellular proteins	Evidence at protein level	HPA052535, HPA053186			Supported	Nucleoplasm	Renal cancer:4.96e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 97.6	Expressed in all		
GOT1L1	MGC33309	ENSG00000169154	Glutamic-oxaloacetic transaminase 1-like 1	8	37934281-37940129	Predicted intracellular proteins	Evidence at transcript level	HPA028778	Uncertain					Not detected	Tissue enriched	26	testis: 21.5	ovary: 0.8	Not detected		
ZBTB43	FLJ22470, KIAA0414, ZBTB22B, ZNF-X, ZNF297B	ENSG00000169155	Zinc finger and BTB domain containing 43	9	126805006-126838210	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016825	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:8.73e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 38.8	Expressed in all		
CPT1C	CPT1P, CPTIC, FLJ23809	ENSG00000169169	Carnitine palmitoyltransferase 1C	19	49690898-49713731	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014529, HPA063621	Approved		Approved	Centrosome	Pancreatic cancer:1.84e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 34.2	adrenal gland: 7.0	Cell line enhanced		AF22: 39.0;SH-SY5Y: 74.9
PCSK9	FH3, HCHOLA3, NARC-1	ENSG00000169174	Proprotein convertase subtilisin/kexin type 9	1	55039548-55064852	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Urothelial cancer:2.40e-4 (unfavourable)	Mixed	Tissue enhanced		liver: 6.1;lung: 11.1	colon: 3.4	Cell line enhanced		A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
XPO6	FLJ22519, KIAA0370, RANBP20	ENSG00000169180	Exportin 6	16	28097979-28211920	Predicted intracellular proteins	Evidence at protein level	HPA038246	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 93.8	Expressed in all		
GSG1L	KTSR5831, MGC18079, PRO19651	ENSG00000169181	GSG1 like	16	27787535-28063509	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014479	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 11.7;heart muscle: 7.3	fallopian tube: 2.7	Group enriched	7	HMC-1: 7.3;THP-1: 2.1
MN1	MGCR, MGCR1, MGCR1-PEN	ENSG00000169184	MN1 proto-oncogene, transcriptional regulator	22	27748277-27801498	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003072	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		skeletal muscle: 22.0	cerebral cortex: 6.4	Cell line enhanced		AF22: 31.4;RH-30: 12.4;TIME: 16.8;U-2 OS: 17.9;U-2197: 17.1
APEX2	APE2, APEXL2, XTH2, ZGRF2	ENSG00000169188	Apurinic/apyrimidinic endodeoxyribonuclease 2	X	55000357-55009057	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048577			Supported	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Liver cancer:6.13e-7 (unfavourable), Ovarian cancer:5.21e-4 (favourable), Cervical cancer:6.17e-4 (favourable), Urothelial cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			skin: 14.3	Expressed in all		
NSMCE1	NSE1	ENSG00000169189	NSE1 homolog, SMC5-SMC6 complex component	16	27224991-27268794	Predicted intracellular proteins	Evidence at protein level	HPA041567, HPA043091	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 122.9	Expressed in all		
CCDC126	FLJ23031	ENSG00000169193	Coiled-coil domain containing 126	7	23597379-23644708	Predicted intracellular proteins	Evidence at protein level	HPA026883	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
IL13	ALRH, BHR1, IL-13, MGC116786, MGC116788, MGC116789, P600	ENSG00000169194	Interleukin 13	5	132656263-132661110	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042421			Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	10	testis: 19.9	gallbladder: 2.0	Cell line enriched	226	HDLM-2: 38.1
NPIPB12		ENSG00000169203	Nuclear pore complex interacting protein family, member B12	16	29483642-29505999	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			skin: 133.9	Expressed in all		
OR10G3		ENSG00000169208	Olfactory receptor family 10 subfamily G member 3	14	21569803-21570744	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA019766	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RAB3B		ENSG00000169213	RAB3B, member RAS oncogene family	1	51907956-51990764	Predicted intracellular proteins	Evidence at protein level	HPA003159, CAB023293	Enhanced		Approved	Cell Junctions		Group enriched	Tissue enhanced		cerebral cortex: 8.2;prostate: 17.8	adrenal gland: 4.0	Cell line enhanced		BJ: 105.7;TIME: 79.3
OR6F1	OST731	ENSG00000169214	Olfactory receptor family 6 subfamily F member 1	1	247711829-247712755	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	21	testis: 2.1	all non-specific tissues: 0.0	Not detected		
CD2BP2	LIN1, PPP1R59, Snu40	ENSG00000169217	CD2 cytoplasmic tail binding protein 2	16	30350766-30355361	Predicted intracellular proteins	Evidence at protein level	HPA041508, HPA061309	Enhanced		Enhanced	Nuclear speckles<br>Cytosol	Liver cancer:1.84e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 80.8	Expressed in all		
RSPO1	FLJ40906, RSPONDIN	ENSG00000169218	R-spondin 1	1	37611350-37634923	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046154	Uncertain					Tissue enriched	Tissue enhanced		endometrium: 43.4;fallopian tube: 33.1	smooth muscle: 21.2	Cell line enhanced		NTERA-2: 1.3
RGS14		ENSG00000169220	Regulator of G-protein signaling 14	5	177357837-177372601	Predicted intracellular proteins	Evidence at protein level	HPA046847, HPA061819	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Liver cancer:1.84e-6 (unfavourable), Glioma:9.11e-4 (unfavourable)	Expressed in all	Mixed			spleen: 21.7	Cell line enhanced		HDLM-2: 101.9;HMC-1: 82.1;RPMI-8226: 39.1
TBC1D10B	DKFZP434P1750, EPI64B, FLJ13130, Rab27A-GAPbeta	ENSG00000169221	TBC1 domain family member 10B	16	30357102-30370264	Predicted intracellular proteins	Evidence at protein level	HPA048894	Uncertain				Liver cancer:8.94e-5 (unfavourable), Colorectal cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
LMAN2	C5orf8, GP36B, VIP36	ENSG00000169223	Lectin, mannose binding 2	5	177331562-177351852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003927	Approved				Renal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 164.8	Expressed in all		
GCSAML	C1orf150, FLJ44728	ENSG00000169224	Germinal center associated signaling and motility like	1	247507058-247577690	Predicted intracellular proteins	Evidence at protein level	HPA027507, HPA027510	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enhanced		prostate: 9.1;testis: 7.3	lung: 3.3	Group enriched	98	HEL: 133.3;HMC-1: 495.5
RAB24		ENSG00000169228	RAB24, member RAS oncogene family	5	177301198-177303744	Predicted intracellular proteins	Evidence at protein level	HPA034945			Uncertain	Focal adhesion sites	Renal cancer:2.54e-7 (unfavourable), Liver cancer:7.56e-5 (unfavourable), Head and neck cancer:6.22e-4 (favourable)	Expressed in all	Expressed in all			spleen: 40.1	Expressed in all		
PRELID1	CGI-106, PRELI, PX19	ENSG00000169230	PRELI domain containing 1	5	177303774-177306959	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005701	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:2.89e-7 (unfavourable), Liver cancer:5.46e-5 (unfavourable)	Expressed in all	Expressed in all			small intestine: 130.3	Expressed in all		
THBS3		ENSG00000169231	Thrombospondin 3	1	155195588-155209051	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006293, HPA073242	Approved		Approved	Vesicles	Renal cancer:2.38e-12 (unfavourable), Endometrial cancer:1.44e-4 (unfavourable), Colorectal cancer:2.43e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.6	Cell line enhanced		SCLC-21H: 49.1
CA5B		ENSG00000169239	Carbonic anhydrase 5B	X	15688830-15788409	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012618	Uncertain		Supported	Mitochondria	Renal cancer:6.66e-6 (favourable)	Expressed in all	Mixed			cervix, uterine: 34.1	Cell line enhanced		hTERT-HME1: 26.3
SLC50A1	HsSWEET1, RAG1AP1, RP11-540D14.5, RZPDo834D038D, SCP, slv, SWEET1	ENSG00000169241	Solute carrier family 50 member 1	1	155135344-155138857	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018095	Approved				Renal cancer:3.88e-7 (unfavourable)	Expressed in all	Expressed in all			epididymis: 135.2	Expressed in all		
EFNA1	ECKLG, EPLG1, LERK1, TNFAIP4	ENSG00000169242	Ephrin A1	1	155127460-155134857	Cancer-related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB032498	Uncertain					Expressed in all	Mixed			placenta: 123.9	Cell line enhanced		BEWO: 211.4;SiHa: 136.8;SK-BR-3: 146.1
CXCL10	C7, crg-2, gIP-10, IFI10, INP10, IP-10, mob-1, SCYB10	ENSG00000169245	C-X-C motif chemokine ligand 10	4	76021117-76023497	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.16e-6 (unfavourable), Ovarian cancer:1.12e-5 (favourable), Pancreatic cancer:4.61e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 129.4	lymph node: 72.5	Cell line enhanced		BJ hTERT+: 4.9;BJ hTERT+ SV40 Large T+: 2.0;BJ hTERT+ SV40 Large T+ RasG12V: 2.1;RPMI-8226: 2.9;THP-1: 2.0
NPIPB3	KIAA0220, NPIPL3	ENSG00000169246	Nuclear pore complex interacting protein family member B3	16	21402237-21448567	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 189.3	Expressed in all		
SH3TC2	CMT4C, KIAA1985	ENSG00000169247	SH3 domain and tetratricopeptide repeats 2	5	148923639-149063163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037683, HPA037684	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	6	cerebral cortex: 3.0;placenta: 2.8;testis: 8.8	cervix, uterine,heart muscle: 0.7	Cell line enhanced		RT4: 6.6;SK-MEL-30: 5.9;WM-115: 8.2
CXCL11	b-R1, H174, I-TAC, IP-9, SCYB11, SCYB9B	ENSG00000169248	C-X-C motif chemokine ligand 11	4	76033682-76041415	Predicted secreted proteins	Evidence at protein level	CAB009921	Uncertain				Ovarian cancer:4.31e-7 (favourable), Renal cancer:3.29e-6 (unfavourable), Pancreatic cancer:8.18e-5 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 13.5	lymph node: 11.5	Group enriched	6	BJ hTERT+: 2.4;BJ hTERT+ SV40 Large T+: 4.3;BJ hTERT+ SV40 Large T+ RasG12V: 4.7
ZRSR2	U2AF1-RS2, U2AF1L2, URP, ZC3H22	ENSG00000169249	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2	X	15790472-15823260	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.1	Expressed in all		
NMD3	CGI-07	ENSG00000169251	NMD3 ribosome export adaptor	3	161104696-161253532	Predicted intracellular proteins	Evidence at protein level	HPA035019			Supported	Nucleus<br>Nucleoli	Pancreatic cancer:2.03e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 44.8	Expressed in all		
ADRB2	ADRB2R, ADRBR, B2AR, BAR	ENSG00000169252	Adrenoceptor beta 2	5	148825245-148828687	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003431, HPA075322	Uncertain		Uncertain	Cytosol	Renal cancer:3.15e-9 (favourable)	Mixed	Mixed			lung: 16.3	Cell line enhanced		hTCEpi: 28.8;hTERT-HME1: 31.6
B3GALNT1	B3GALT3, beta3Gal-T3, galT3, GLOB, P1	ENSG00000169255	Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)	3	161083883-161105384	Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041204			Approved	Vesicles		Expressed in all	Mixed			thyroid gland: 47.9	Cell line enhanced		RT4: 111.0
GPRIN1	GRIN1, KIAA1893	ENSG00000169258	G protein regulated inducer of neurite outgrowth 1	5	176595802-176610133	Predicted intracellular proteins	Evidence at protein level	HPA036478, HPA070892	Enhanced		Supported	Vesicles<br>Plasma membrane	Renal cancer:2.79e-7 (unfavourable), Lung cancer:6.83e-6 (unfavourable)	Expressed in all	Tissue enriched	7	cerebral cortex: 27.8	duodenum: 3.8	Cell line enhanced		HDLM-2: 52.6;SCLC-21H: 70.4
HSPB3	HSPL27	ENSG00000169271	Heat shock protein family B (small) member 3	5	54455601-54456384	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	10	heart muscle: 212.2;skeletal muscle: 64.3	esophagus: 14.0	Cell line enhanced		BJ hTERT+: 56.3;fHDF/TERT166: 24.5;HSkMC: 9.6
KCNAB1	AKR6A3, hKvb3, hKvBeta3, KCNA1B, Kvb1.3	ENSG00000169282	Potassium voltage-gated channel subfamily A member regulatory beta subunit 1	3	156037701-156539138	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044550	Approved					Tissue enhanced	Tissue enhanced		prostate: 37.4;thyroid gland: 48.4	seminal vesicle: 26.6	Cell line enhanced		hTEC/SVTERT24-B: 5.2
MRPL1	BM022	ENSG00000169288	Mitochondrial ribosomal protein L1	4	77862520-77952790	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043656	Supported		Supported	Mitochondria	Renal cancer:3.35e-5 (favourable)	Expressed in all	Expressed in all			kidney: 29.5	Expressed in all		
SHE		ENSG00000169291	Src homology 2 domain containing E	1	154469772-154502113	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037417	Approved					Tissue enhanced	Mixed			testis: 31.9	Group enriched	6	HUVEC TERT2: 42.7;TIME: 11.5
NR0B1	AHC, AHCH, DAX1, DSS	ENSG00000169297	Nuclear receptor subfamily 0 group B member 1	X	30304206-30309598	Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061948, HPA067207			Supported	Nuclear speckles<br>Vesicles<br>Microtubule organizing center		Tissue enhanced	Group enriched	8	adrenal gland: 27.8;testis: 35.0	ovary: 4.1	Cell line enhanced		A549: 51.8;RT4: 14.5;U-87 MG: 7.9
PGM2	FLJ10983	ENSG00000169299	Phosphoglucomutase 2	4	37826633-37862937	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040676	Uncertain		Approved	Intermediate filaments	Colorectal cancer:2.14e-5 (favourable)	Expressed in all	Mixed			esophagus: 36.5	Expressed in all		
STK32A	MGC22688, YANK1	ENSG00000169302	Serine/threonine kinase 32A	5	147234963-147387852	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040236	Uncertain		Approved	Centrosome		Tissue enhanced	Tissue enhanced		adrenal gland: 15.6;thyroid gland: 16.1	cerebral cortex: 7.3	Group enriched	6	RT4: 12.4;SK-MEL-30: 43.0
IL1RAPL1	IL1R8, IL1RAPL, MRX10, MRX21, MRX34, OPHN4, TIGIRR-2	ENSG00000169306	Interleukin 1 receptor accessory protein like 1	X	28587399-29956723	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	11	cerebral cortex: 5.1	ovary,prostate,seminal vesicle: 0.4	Cell line enhanced		WM-115: 2.5
P2RY12	HORK3, P2Y12, SP1999	ENSG00000169313	Purinergic receptor P2Y12	3	151337380-151384812	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013796, HPA014518	Enhanced					Tissue enriched	Tissue enriched	6	cerebral cortex: 83.8	lymph node: 13.1	Not detected		
C22orf15	FLJ36561, N27C7-3	ENSG00000169314	Chromosome 22 open reading frame 15	22	23763021-23765861	Predicted secreted proteins	Evidence at transcript level						Endometrial cancer:8.53e-5 (favourable)	Tissue enhanced	Tissue enriched	15	fallopian tube: 29.3	testis: 1.9	Cell line enhanced		AF22: 1.1;BJ hTERT+: 1.5;MOLT-4: 1.0
OR5AU1		ENSG00000169327	Olfactory receptor family 5 subfamily AU member 1	14	21154865-21156063	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			seminal vesicle: 0.2	Not detected		
KIAA1024		ENSG00000169330	KIAA1024	15	79432516-79472290	Predicted membrane proteins	Evidence at protein level	HPA011545	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enriched	11	adrenal gland: 14.0	prostate,salivary gland: 1.2	Cell line enhanced		U-138 MG: 9.2
PDILT	PDIA7	ENSG00000169340	Protein disulfide isomerase like, testis expressed	16	20359170-20404737	Predicted secreted proteins	Evidence at protein level	HPA041913	Approved					Not detected	Tissue enriched	5	testis: 31.2	stomach: 6.1	Group enriched	6	HBEC3-KT: 9.1;hTCEpi: 7.4;hTERT-HME1: 2.4
UMOD		ENSG00000169344	Uromodulin	16	20333052-20356301	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009446, HPA043420, HPA054721	Enhanced					Tissue enriched	Tissue enriched	726	kidney: 2392.4	cerebral cortex: 3.2	Not detected		
GP2	ZAP75	ENSG00000169347	Glycoprotein 2	16	20309572-20327808	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015739, HPA016668	Enhanced					Tissue enriched	Tissue enriched	206	pancreas: 7530.3	duodenum: 36.5	Not detected		
SLC33A1	ACATN, AT-1, AT1, SPG42	ENSG00000169359	Solute carrier family 33 member 1	3	155821024-155854429	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042430, HPA060345	Uncertain		Approved	Nucleus		Expressed in all	Expressed in all			thyroid gland: 67.3	Expressed in all		
SNUPN	RNUT1, SNURPORTIN-1, Snurportin1	ENSG00000169371	Snurportin 1	15	75598083-75626469	Predicted intracellular proteins	Evidence at protein level	CAB005004	Approved		Supported	Nuclear membrane		Expressed in all	Expressed in all			testis: 54.1	Expressed in all		
CRADD	RAIDD	ENSG00000169372	CASP2 and RIPK1 domain containing adaptor with death domain	12	93677375-93894840	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB005337	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:4.04e-9 (favourable), Cervical cancer:9.06e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 32.8	Expressed in all		
SIN3A	DKFZP434K2235, KIAA0700	ENSG00000169375	SIN3 transcription regulator family member A	15	75369379-75455842	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004506, HPA047213, HPA062123	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 55.3	Expressed in all		
ARL13B	ARL2L1, DKFZp761H079, JBTS8	ENSG00000169379	ADP ribosylation factor like GTPase 13B	3	93980139-94055668	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048926	Enhanced		Uncertain	Microtubules<br>Cytosol		Expressed in all	Mixed			thyroid gland: 9.3	Mixed		
RNASE2	EDN, RAF3, RNS2	ENSG00000169385	Ribonuclease A family member 2	14	20955452-20956436	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA044983	Enhanced				Renal cancer:3.28e-13 (unfavourable)	Tissue enriched	Tissue enriched	73	bone marrow: 995.8	smooth muscle: 13.6	Group enriched	286	HL-60: 411.9;NB-4: 325.9;THP-1: 920.7;U-937: 968.9
ELSPBP1	E12, EDDM12, HE12	ENSG00000169393	Epididymal sperm binding protein 1	19	47994651-48025153	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044256, HPA050341	Enhanced					Tissue enhanced	Tissue enriched	2038	epididymis: 3638.2	testis: 1.7	Cell line enhanced		BEWO: 1.5;HMC-1: 9.1;NB-4: 3.7
RNASE3	ECP, RAF1, RNS3	ENSG00000169397	Ribonuclease A family member 3	14	20891399-20892348	Predicted secreted proteins	Evidence at protein level	HPA056183	Enhanced					Tissue enriched	Tissue enriched	300	bone marrow: 572.3	skin: 1.9	Cell line enhanced		HL-60: 114.0;THP-1: 41.0;U-937: 225.8
PTK2	FADK, FAK, FAK1, PPP1R71	ENSG00000169398	Protein tyrosine kinase 2	8	140657900-141002216	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001842, CAB004036, HPA029671	Approved		Supported	Vesicles<br>Focal adhesion sites<br>Cytosol	Breast cancer:3.21e-4 (unfavourable), Endometrial cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 107.1	Mixed		
RSPH10B2		ENSG00000169402	Radial spoke head 10 homolog B2	7	6754109-6799365	Predicted intracellular proteins	Evidence at protein level	HPA049182	Supported					Not detected	Group enriched	7	fallopian tube: 16.1;testis: 35.8	parathyroid gland: 3.6	Not detected		
PTAFR		ENSG00000169403	Platelet activating factor receptor	1	28147166-28193936	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA027543	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		appendix: 41.1	bone marrow: 26.2	Cell line enhanced		HBEC3-KT: 26.0;HMC-1: 113.4
PTPN9	MEG2	ENSG00000169410	Protein tyrosine phosphatase, non-receptor type 9	15	75463251-75579289	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041922	Approved		Approved	Vesicles	Renal cancer:2.49e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.8	Expressed in all		
RNASE6	RAD1, RNaseK6, RNS6	ENSG00000169413	Ribonuclease A family member k6	14	20781051-20782467	Predicted secreted proteins	Evidence at protein level	HPA000698	Approved					Expressed in all	Mixed			lymph node: 90.2	Cell line enriched	6	RPMI-8226: 36.0
NPR1	ANPa, ANPRA, GUCY2A, NPRA	ENSG00000169418	Natriuretic peptide receptor 1	1	153678637-153693992	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA031087			Approved	Nucleus<br>Nucleoli<br>Plasma membrane	Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 72.0;fallopian tube: 58.2	placenta: 25.4	Cell line enriched	6	ASC diff: 107.2
KCNK9	K2p9.1, TASK-3, TASK3	ENSG00000169427	Potassium two pore domain channel subfamily K member 9	8	139600838-139703056	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Group enriched	7	adrenal gland: 4.7;cerebral cortex: 4.8	cervix, uterine: 0.7	Cell line enhanced		PC-3: 2.0;SCLC-21H: 1.1
CXCL8	3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1	ENSG00000169429	C-X-C motif chemokine ligand 8	4	73740506-73743716	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA057179	Supported				Renal cancer:3.13e-6 (unfavourable), Cervical cancer:1.18e-5 (unfavourable), Liver cancer:1.19e-5 (unfavourable)	Expressed in all	Tissue enriched	7	bone marrow: 2076.0	appendix: 293.4	Cell line enriched	6	BJ hTERT+: 3127.1
SCN9A	ETHA, Nav1.7, NE-NA, NENA, PN1	ENSG00000169432	Sodium voltage-gated channel alpha subunit 9	2	166195185-166375993	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB013679, HPA061843	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:2.30e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 9.1	placenta: 5.9	Cell line enhanced		BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
RASSF6		ENSG00000169435	Ras association domain family member 6	4	73571550-73620631	Predicted intracellular proteins	Evidence at protein level	HPA037712	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		stomach: 33.0	rectum: 13.8	Cell line enhanced		Daudi: 53.8;RT4: 55.3;U-698: 42.2
COL22A1		ENSG00000169436	Collagen type XXII alpha 1 chain	8	138588235-138914006	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024830	Supported		Supported	Endoplasmic reticulum<br>Vesicles	Lung cancer:2.13e-6 (unfavourable), Glioma:3.62e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 9.7	prostate: 4.8	Group enriched	5	HDLM-2: 27.1;RT4: 9.7;SCLC-21H: 9.4;U-2 OS: 6.9
SDC2	CD362, fibroglycan, HSPG, HSPG1, SYND2	ENSG00000169439	Syndecan 2	8	96493351-96611780	CD markers, Predicted membrane proteins	Evidence at protein level	CAB025123, HPA044416	Uncertain		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 712.7	Cell line enhanced		AF22: 646.8;U-138 MG: 309.2
CD52	CDW52	ENSG00000169442	CD52 molecule	1	26317957-26320523	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level						Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable)	Expressed in all	Tissue enriched	35	epididymis: 43887.5	lymph node: 1251.0	Group enriched	8	Daudi: 505.6;REH: 946.6;U-266/84: 745.1;U-698: 783.6
MMGT1	EMC5, TMEM32	ENSG00000169446	Membrane magnesium transporter 1	X	135962070-135974063	Predicted membrane proteins	Evidence at protein level	HPA032037	Approved				Renal cancer:1.94e-5 (favourable), Breast cancer:8.54e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 34.5	Expressed in all		
SPRR1B	GADD33, SPRR1	ENSG00000169469	Small proline rich protein 1B	1	153031202-153032900	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:7.64e-5 (unfavourable), Lung cancer:7.66e-5 (unfavourable), Urothelial cancer:7.28e-4 (unfavourable)	Group enriched	Tissue enriched	6	esophagus: 2454.9	tonsil: 406.1	Cell line enriched	8	hTCEpi: 263.1
SPRR1A		ENSG00000169474	Small proline rich protein 1A	1	152985231-152985500	Predicted intracellular proteins	Evidence at protein level	CAB011237	Enhanced				Pancreatic cancer:1.03e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 9968.1	tonsil: 835.5	Group enriched	6	HaCaT: 21.3;hTCEpi: 49.9;RT4: 21.6
OR4K14		ENSG00000169484	Olfactory receptor family 4 subfamily K member 14	14	20014260-20015193	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4K15	OR4K15Q	ENSG00000169488	Olfactory receptor family 4 subfamily K member 15	14	19975444-19976659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055732	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TM2D2	BLP1	ENSG00000169490	TM2 domain containing 2	8	38988808-38996824	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA047152, HPA050547	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane	Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.3	Expressed in all		
HTRA4	FLJ90724	ENSG00000169495	HtrA serine peptidase 4	8	38974164-38988662	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045402	Enhanced					Tissue enhanced	Tissue enriched	20	placenta: 94.9	bone marrow: 4.7	Cell line enriched	160	BEWO: 219.1
PLEKHA2	TAPP2	ENSG00000169499	Pleckstrin homology domain containing A2	8	38901235-38973909	Predicted intracellular proteins	Evidence at protein level	HPA004706	Approved		Uncertain	Nucleus<br>Nuclear bodies<br>Cytosol	Renal cancer:1.95e-6 (unfavourable)	Expressed in all	Expressed in all			lymph node: 91.8	Cell line enhanced		Daudi: 113.1
CLIC4	CLIC4L, DKFZP566G223, H1, huH1, P64H1	ENSG00000169504	Chloride intracellular channel 4	1	24745357-24844324	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA008019, HPA060804	Enhanced		Supported	Cytosol	Renal cancer:1.48e-5 (favourable), Cervical cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 398.9	Expressed in all		
SLC38A11	AVT2, FLJ39822	ENSG00000169507	Solute carrier family 38 member 11	2	164896186-164955525	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043432	Uncertain				Renal cancer:2.00e-8 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 47.1;gallbladder: 28.2	seminal vesicle: 23.5	Cell line enriched	8	BJ hTERT+: 202.7
GPR183	EBI2	ENSG00000169508	G protein-coupled receptor 183	13	99294530-99307405	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028847, CAB033690	Uncertain		Approved	Nuclear membrane<br>Vesicles	Cervical cancer:9.77e-4 (favourable)	Expressed in all	Mixed			appendix: 114.8	Group enriched	49	HDLM-2: 144.6;HL-60: 85.1
CRCT1	C1orf42, NICE-1	ENSG00000169509	Cysteine rich C-terminal 1	1	152514502-152516010	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:7.03e-4 (unfavourable)	Tissue enhanced	Group enriched	11	esophagus: 84.0;skin: 82.8;tonsil: 17.6	breast: 5.6	Cell line enriched	14	CAPAN-2: 4.5
CCDC8	3M3, DKFZp564K0322, PPP1R20	ENSG00000169515	Coiled-coil domain containing 8	19	46410372-46413584	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041993	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:1.72e-5 (favourable)	Mixed	Tissue enhanced		ovary: 45.3	fallopian tube: 37.6	Cell line enhanced		AN3-CA: 20.7;RH-30: 24.3
METTL15	FLJ33979, METT5D1	ENSG00000169519	Methyltransferase like 15	11	28108248-28527041	Predicted intracellular proteins	Evidence at protein level	HPA039885			Approved	Golgi apparatus<br>Plasma membrane<br>Actin filaments	Renal cancer:7.95e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 14.7	Expressed in all		
ZNF280A	3'OY11.1, SUHW1, ZNF280, ZNF636	ENSG00000169548	Zinc finger protein 280A	22	22513736-22520270	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044475	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Not detected			adrenal gland: 0.3	Cell line enhanced		BEWO: 1.8;K-562: 7.3;SK-MEL-30: 1.6
MUC15		ENSG00000169550	Mucin 15, cell surface associated	11	26559033-26572233	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA026110	Approved					Tissue enriched	Tissue enriched	18	epididymis: 2826.7	thyroid gland: 159.3	Cell line enhanced		BEWO: 9.4;K-562: 11.5;SK-BR-3: 15.6;U-266/70: 6.2;U-266/84: 16.2
CT55	CXorf48, FLJ20527	ENSG00000169551	Cancer/testis antigen 55	X	135156536-135171398	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	31	testis: 6.5	cerebral cortex: 0.2	Cell line enriched	18	K-562: 6.7
ZEB2	KIAA0569, SIP-1, SIP1, ZFHX1B	ENSG00000169554	Zinc finger E-box binding homeobox 2	2	144364364-144524583	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003456	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:6.04e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 99.9	Mixed		
GJB1	CMTX, CMTX1, CX32	ENSG00000169562	Gap junction protein beta 1	X	71215194-71225516	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB012994	Uncertain				Renal cancer:2.85e-6 (favourable)	Tissue enhanced	Tissue enhanced		liver: 159.4	gallbladder: 59.2	Group enriched	6	Hep G2: 94.2;SK-MEL-30: 123.7
PCBP1	hnRNP-E1, hnRNP-X, HNRPE1, HNRPX	ENSG00000169564	Poly(rC) binding protein 1	2	70087454-70089203	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB037113, HPA043803, HPA068497	Supported		Enhanced	Nuclear speckles<br>Cytoplasmic bodies	Renal cancer:1.71e-5 (favourable)	Expressed in all	Expressed in all			spleen: 284.0	Expressed in all		
HINT1	HINT, PKCI-1, PRKCNH1	ENSG00000169567	Histidine triad nucleotide binding protein 1	5	131159027-131171735	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044577	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 173.9	Expressed in all		
DTWD2	FLJ33977	ENSG00000169570	DTW domain containing 2	5	118837322-118988545	Predicted intracellular proteins	Evidence at protein level	HPA053173, HPA054864	Approved		Supported	Nuclear bodies	Renal cancer:6.09e-5 (favourable), Colorectal cancer:3.16e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 18.7	Mixed		
VPREB1	CD179A, VpreB	ENSG00000169575	Pre-B lymphocyte 1	22	22244675-22245515	CD markers, Predicted secreted proteins	Evidence at protein level	HPA055886	Uncertain					Not detected	Tissue enriched	15	bone marrow: 17.1	tonsil: 1.1	Group enriched	13	Daudi: 5.6;MOLT-4: 13.7;RPMI-8226: 3.1
CLIC3		ENSG00000169583	Chloride intracellular channel 3	9	136994635-136996803	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005963	Enhanced		Supported	Nuclear bodies	Renal cancer:1.12e-4 (unfavourable), Urothelial cancer:7.74e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 86.8;thyroid gland: 85.7	skin: 43.5	Cell line enhanced		BEWO: 234.7;MCF7: 88.6;T-47d: 100.2;TIME: 70.2
INO80E	CCDC95, FLJ90652	ENSG00000169592	INO80 complex subunit E	16	29995294-30005793	Predicted intracellular proteins	Evidence at protein level	HPA043146	Approved		Supported	Nucleoplasm<br>Nucleoli		Expressed in all	Expressed in all			fallopian tube: 64.2	Expressed in all		
BNC1	BNC, HsT19447	ENSG00000169594	Basonuclin 1	15	83255903-83284714	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA063183, HPA066947, HPA077428			Enhanced	Nucleoplasm		Tissue enhanced	Tissue enhanced		testis: 56.0	esophagus: 11.8	Cell line enhanced		HBEC3-KT: 83.5;hTCEpi: 92.6;hTERT-HME1: 95.2
DFFB	CAD, CPAN, DFF-40, DFF40	ENSG00000169598	DNA fragmentation factor subunit beta	1	3857267-3885429	Predicted intracellular proteins	Evidence at protein level	CAB004328, HPA052904	Approved		Approved	Nucleus<br>Nucleoli	Urothelial cancer:6.29e-5 (favourable)	Expressed in all	Mixed			duodenum: 2.9	Mixed		
NFU1	CGI-33, HIRIP5, NifU, NIFUC	ENSG00000169599	NFU1 iron-sulfur cluster scaffold	2	69395750-69437628	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035826	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 71.2	Expressed in all		
ANTXR1	ATR, FLJ10601, FLJ21776, TEM8	ENSG00000169604	Anthrax toxin receptor 1	2	69013178-69249327	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054785			Uncertain	Vesicles	Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 180.5	Cell line enhanced		LHCN-M2: 286.7
GKN1	AMP18, BRICD1, CA11	ENSG00000169605	Gastrokine 1	2	68974573-68980974	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA047684	Enhanced				Pancreatic cancer:1.54e-4 (unfavourable), Urothelial cancer:4.53e-4 (favourable)	Tissue enriched	Tissue enriched	1189	stomach: 31769.6	placenta: 26.7	Group enriched	11	HaCaT: 5.1;HMC-1: 13.6;MOLT-4: 9.1;NTERA-2: 14.8;REH: 6.0;U-2 OS: 9.9;U-266/70: 7.3
CKAP2L	FLJ40629, radmis	ENSG00000169607	Cytoskeleton associated protein 2 like	2	112736607-112764677	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039407, HPA040057, HPA070737	Uncertain		Enhanced	Mitotic spindle<br>Cytosol	Lung cancer:7.63e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 8.7;testis: 9.6	lymph node: 6.3	Mixed		
C15orf40	MGC29937	ENSG00000169609	Chromosome 15 open reading frame 40	15	82988441-83011641	Predicted intracellular proteins	Evidence at protein level	HPA042980	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:4.35e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 23.6	Expressed in all		
FAM103A1	C15orf18, HsT19360, MGC2560, RAM	ENSG00000169612	Family with sequence similarity 103 member A1	15	82986207-82991057	Predicted intracellular proteins	Evidence at protein level	HPA041923, HPA041948	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 37.0	Expressed in all		
PROKR1	GPR73, GPR73a, PKR1, ZAQ	ENSG00000169618	Prokineticin receptor 1	2	68643589-68658247	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029396	Uncertain					Not detected	Group enriched	8	adipose tissue: 1.7;adrenal gland: 1.4;epididymis: 4.3	testis: 0.3	Cell line enhanced		NTERA-2: 2.0
APLF	C2orf13, MGC47799, Xip1, ZCCHH1	ENSG00000169621	Aprataxin and PNKP like factor	2	68467561-68655862	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029396, HPA034642, HPA034643	Uncertain		Supported	Nucleoplasm		Mixed	Mixed			skin: 3.3	Mixed		
BOLA2B		ENSG00000169627	BolA family member 2B	16	30192934-30194306	Predicted intracellular proteins	Evidence at protein level	HPA045380, HPA046696	Supported		Uncertain	Nucleus		Mixed	Expressed in all			lymph node: 32.5	Expressed in all		
RGPD8	RanBP2alpha, RANBP2L1	ENSG00000169629	RANBP2-like and GRIP domain containing 8	2	112370092-112434488	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	5	testis: 31.7	cerebral cortex: 5.8	Cell line enhanced		HEL: 14.4
HIC2	HRG22, KIAA1020, ZBTB30, ZNF907	ENSG00000169635	HIC ZBTB transcriptional repressor 2	22	21417404-21451463	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031884, HPA059399	Uncertain		Supported	Nucleus	Endometrial cancer:7.42e-5 (unfavourable)	Tissue enriched	Mixed			placenta: 8.4	Cell line enhanced		BEWO: 66.9;K-562: 113.3
LUZP1	LUZP	ENSG00000169641	Leucine zipper protein 1	1	23084023-23177808	Predicted intracellular proteins	Evidence at protein level	HPA028506, HPA028542	Enhanced		Uncertain	Vesicles<br>Actin filaments<br>Cytosol	Renal cancer:1.46e-7 (favourable), Cervical cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 47.1	Mixed		
HEXDC	FLJ23825	ENSG00000169660	Hexosaminidase D	17	82418318-82442645	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022834, HPA023379, HPA027844	Uncertain		Approved	Nucleoli fibrillar center<br>Mitochondria	Urothelial cancer:2.52e-5 (favourable), Head and neck cancer:2.71e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable), Cervical cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.4	Expressed in all		
DRD5	DRD1B, DRD1L2	ENSG00000169676	Dopamine receptor D5	4	9781680-9784009	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA048930	Supported					Not detected	Tissue enhanced		appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8	testis: 0.8	Not detected		
BUB1	BUB1A, BUB1L, hBUB1	ENSG00000169679	BUB1 mitotic checkpoint serine/threonine kinase	2	110637698-110678114	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006123			Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.03e-5 (unfavourable), Pancreatic cancer:2.37e-5 (unfavourable), Endometrial cancer:3.65e-4 (unfavourable), Lung cancer:3.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 69.5	lymph node: 24.1	Mixed		
SPNS1	HSpin1, LAT, nrs, PP2030, SPIN1, SPINL	ENSG00000169682	Sphingolipid transporter 1 (putative)	16	28974221-28984548	Predicted membrane proteins, Transporters	Evidence at protein level	HPA041995, HPA042988	Enhanced		Approved	Nucleoli fibrillar center<br>Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Expressed in all			parathyroid gland: 37.1	Expressed in all		
LRRC45	MGC20806	ENSG00000169683	Leucine rich repeat containing 45	17	82023302-82031151	Predicted intracellular proteins	Evidence at protein level	HPA023372, HPA023382, HPA024768	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 8.3	Mixed		
CHRNA5		ENSG00000169684	Cholinergic receptor nicotinic alpha 5 subunit	15	78565520-78595269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054381	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Lung cancer:3.64e-5 (unfavourable)	Mixed	Mixed			gallbladder: 6.9	Mixed		
MT1B	MT1, MT1Q	ENSG00000169688	Metallothionein 1B	16	56651899-56653204	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		duodenum: 1.3;liver: 3.2	appendix: 0.5	Not detected		
CENPX	CENP-X, FAAP10, MGC14480, MHF2, STRA13	ENSG00000169689	Centromere protein X	17	82018702-82024107	Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 70.2	Expressed in all		
AGPAT2	BSCL, LPAAT-beta	ENSG00000169692	1-acylglycerol-3-phosphate O-acyltransferase 2	9	136673143-136687423	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA019544	Uncertain		Approved	Centrosome		Expressed in all	Expressed in all			adipose tissue: 300.1	Mixed		
ASPSCR1	ASPL, ASPS, TUG, UBXD9, UBXN9	ENSG00000169696	ASPSCR1, UBX domain containing tether for SLC2A4	17	81976807-82017406	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026749	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.3	Expressed in all		
GP9	CD42a, GPIX	ENSG00000169704	Glycoprotein IX platelet	3	129060767-129062406	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA063182	Enhanced					Not detected	Tissue enhanced		bone marrow: 2.9;spleen: 2.7	testis: 1.2	Cell line enriched	19	HEL: 75.1
FASN	FAS, SDR27X1	ENSG00000169710	Fatty acid synthase	17	82078333-82098332	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005192, HPA006461, CAB015417, HPA056108	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 290.7	Expressed in all		
CNBP	CNBP1, DM2, RNF163, ZCCHC22, ZNF9	ENSG00000169714	CCHC-type zinc finger nucleic acid binding protein	3	129169484-129183922	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063097			Supported	Nucleus<br>Cytosol	Pancreatic cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 474.6	Expressed in all		
MT1E	MT1, MTD	ENSG00000169715	Metallothionein 1E	16	56625475-56627112	Predicted intracellular proteins	Evidence at protein level	HPA041152	Approved		Approved	Nucleoplasm	Renal cancer:5.06e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 419.6	Cell line enhanced		HBEC3-KT: 785.4;LHCN-M2: 689.5;RPTEC TERT1: 700.7;U-2 OS: 539.7
ACTRT2	Arp-T2, ARPM2, FLJ25424	ENSG00000169717	Actin related protein T2	1	3021483-3022903	Predicted intracellular proteins	Evidence at protein level	HPA006480, HPA025079	Enhanced					Not detected	Tissue enriched	1022	testis: 102.2	all non-specific tissues: 0.0	Not detected		
DUS1L	DUS1, PP3111	ENSG00000169718	Dihydrouridine synthase 1 like	17	82057506-82065887	Predicted intracellular proteins	Evidence at protein level	HPA023384	Uncertain		Approved	Plasma membrane	Renal cancer:5.89e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 99.0	Expressed in all		
GPS1	COPS1, CSN1	ENSG00000169727	G protein pathway suppressor 1	17	82050691-82057470	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:3.06e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.0	Expressed in all		
RFNG		ENSG00000169733	RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase	17	82047902-82051831	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA011564, HPA031673	Uncertain		Supported	Nucleus	Pancreatic cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 19.7	Expressed in all		
DCXR	DCR, KIDCR, SDR20C1	ENSG00000169738	Dicarbonyl and L-xylulose reductase	17	82035136-82037732	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023371, HPA023863	Enhanced		Uncertain	Nucleoli<br>Microtubules	Renal cancer:2.13e-4 (favourable), Pancreatic cancer:4.70e-4 (favourable)	Expressed in all	Group enriched	6	epididymis: 297.5;kidney: 217.3;liver: 640.9;prostate: 137.5	adipose tissue: 56.7	Expressed in all		
ZNF32	KOX30	ENSG00000169740	Zinc finger protein 32	10	43643859-43648856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039148, HPA059640			Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.02e-4 (favourable), Liver cancer:7.08e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 71.8	Mixed		
LDB2	CLIM1, LDB1	ENSG00000169744	LIM domain binding 2	4	16501541-16898809	Predicted intracellular proteins	Evidence at protein level	CAB017544, HPA068634	Supported		Supported	Nucleus<br>Nucleoli<br>Plasma membrane		Expressed in all	Mixed			endometrium: 108.3	Cell line enhanced		HAP1: 35.5;HUVEC TERT2: 54.3;U-138 MG: 25.3
RAC3		ENSG00000169750	Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)	17	82031624-82034204	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA047820	Uncertain				Endometrial cancer:6.21e-5 (unfavourable), Thyroid cancer:4.69e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.7	Expressed in all		
NRG4	HRG4	ENSG00000169752	Neuregulin 4	15	75935969-76059795	Predicted membrane proteins	Evidence at protein level	HPA010957	Uncertain					Mixed	Tissue enhanced		fallopian tube: 1.0;testis: 1.3	stomach: 0.8	Cell line enhanced		HeLa: 2.9;HL-60: 1.3;SiHa: 1.2;U-937: 2.1
LIMS1	PINCH, PINCH1	ENSG00000169756	LIM zinc finger domain containing 1	2	108534355-108687246	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058455, HPA061230	Approved		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:7.88e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 61.1	Expressed in all		
TMEM266	C15orf27, FLJ38190	ENSG00000169758	Transmembrane protein 266	15	76059837-76229121	Predicted membrane proteins	Evidence at protein level	HPA041921, HPA049425	Enhanced		Supported	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 1.9;skeletal muscle: 1.5	placenta: 1.2	Cell line enhanced		NTERA-2: 1.0
NLGN1	KIAA1070	ENSG00000169760	Neuroligin 1	3	173396284-174286644	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006572, HPA006680	Approved		Uncertain	Nuclear bodies<br>Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 25.4	testis: 12.5	Cell line enhanced		fHDF/TERT166: 20.1;HUVEC TERT2: 20.7;RH-30: 25.4;WM-115: 26.7
TAPT1	FLJ90013	ENSG00000169762	Transmembrane anterior posterior transformation 1	4	16160505-16227410	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042567, HPA048658	Approved		Approved	Vesicles	Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 21.5	Expressed in all		
UGP2	UGP1, UGPP1	ENSG00000169764	UDP-glucose pyrophosphorylase 2	2	63840940-63891562	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA034696, HPA034697, HPA064836	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Mitochondria	Liver cancer:2.50e-5 (favourable)	Expressed in all	Expressed in all			liver: 593.9	Expressed in all		
TAS2R1	T2R1, TRB7	ENSG00000169777	Taste 2 receptor member 1	5	9628997-9712378	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA051879	Uncertain					Not detected	Tissue enriched	40	testis: 13.1	fallopian tube: 0.3	Not detected		
LINGO1	FLJ14594, LERN1, LRRN6A	ENSG00000169783	Leucine rich repeat and Ig domain containing 1	15	77613027-77820900	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA074653	Enhanced		Approved	Plasma membrane	Renal cancer:3.23e-7 (unfavourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 130.8	placenta: 9.8	Cell line enhanced		AF22: 23.6;AN3-CA: 18.6;HAP1: 31.4;HEK 293: 19.6;NTERA-2: 56.8
PRY	PRY1, PTPN13LY	ENSG00000169789	PTPN13-like, Y-linked	Y	22490397-22514637	Predicted intracellular proteins	Evidence at protein level	HPA046366	Uncertain					Not detected	Not detected			epididymis,testis: 0.2	Not detected		
RBMY1F	MGC33094	ENSG00000169800	RNA binding motif protein, Y-linked, family 1, member F	Y	22168542-22182982	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Group enriched	244	U-266/70: 23.8;U-266/84: 24.9
PRY2	PTPN13LY2	ENSG00000169807	PTPN13-like, Y-linked 2	Y	22071756-22096007	Predicted intracellular proteins	Evidence at protein level	HPA046366	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
HNRNPF	HNRPF	ENSG00000169813	Heterogeneous nuclear ribonucleoprotein F	10	43385617-43409166	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016884, HPA069667	Supported		Enhanced	Nucleoplasm	Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 209.6	Expressed in all		
BTD		ENSG00000169814	Biotinidase	3	15601341-15645822	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052275	Uncertain				Renal cancer:2.60e-9 (favourable)	Expressed in all	Expressed in all			epididymis: 53.0	Mixed		
CSGALNACT2	GALNACT-2, GALNACT2, MGC40204, PRO0082	ENSG00000169826	Chondroitin sulfate N-acetylgalactosaminyltransferase 2	10	43138486-43185308	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031540	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.53e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 87.2	Expressed in all		
TACR3	NK3R	ENSG00000169836	Tachykinin receptor 3	4	103586031-103719816	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA009418	Uncertain					Not detected	Not detected			cerebral cortex: 0.5	Cell line enriched	13	BEWO: 6.9
GSX1	Gsh-1, GSH1	ENSG00000169840	GS homeobox 1	13	27792643-27794768	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			cerebral cortex: 0.7	Not detected		
PCDH7	BH-Pcdh, PPP1R120	ENSG00000169851	Protocadherin 7	4	30720415-31146805	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011866, HPA046521	Uncertain		Enhanced	Plasma membrane<br>Cell Junctions	Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 46.0	Cell line enhanced		RH-30: 116.4;RT4: 51.9
ROBO1	DUTT1, FLJ21882, SAX3	ENSG00000169855	Roundabout guidance receptor 1	3	78597240-79767815	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013524, HPA052968, HPA074461	Uncertain		Enhanced	Plasma membrane	Liver cancer:9.88e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 32.9	Mixed		
ONECUT1	HNF-6, HNF6, HNF6A	ENSG00000169856	One cut homeobox 1	15	52756989-52791078	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003457	Enhanced					Group enriched	Group enriched	6	gallbladder: 8.4;liver: 5.9;pancreas: 2.3;testis: 1.8	bone marrow: 0.7	Cell line enhanced		MCF7: 1.7;WM-115: 1.5
AVEN	PDCD12	ENSG00000169857	Apoptosis and caspase activation inhibitor	15	33866227-34039176	Predicted intracellular proteins	Evidence at protein level	HPA020863	Approved		Approved	Plasma membrane<br>Actin filaments<br>Centrosome	Renal cancer:5.29e-10 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 19.1	Expressed in all		
P2RY1	P2Y1	ENSG00000169860	Purinergic receptor P2Y1	3	152834693-152841439	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA015577	Enhanced				Renal cancer:2.04e-7 (unfavourable)	Mixed	Tissue enhanced		placenta: 34.0	esophagus: 19.9	Cell line enriched	6	HEL: 38.5
CTNND2	GT24, NPRAP	ENSG00000169862	Catenin delta 2	5	10971840-11904043	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015077, CAB037339	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enriched	18	cerebral cortex: 103.2	spleen: 5.6	Cell line enhanced		AF22: 19.5;MCF7: 7.1;SK-BR-3: 4.4;U-266/84: 12.6
TRIM56	RNF109	ENSG00000169871	Tripartite motif containing 56	7	101085439-101097967	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024358	Approved		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:2.13e-4 (favourable), Liver cancer:3.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 29.5	Mixed		
MUC17		ENSG00000169876	Mucin 17, cell surface associated	7	101020072-101058745	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA031634	Enhanced					Group enriched	Group enriched	8	duodenum: 21.8;small intestine: 42.5	rectum: 3.8	Not detected		
AHSP	EDRF, ERAF	ENSG00000169877	Alpha hemoglobin stabilizing protein	16	31527864-31528803	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040940	Enhanced					Not detected	Tissue enriched	26	bone marrow: 881.3	placenta: 34.3	Cell line enhanced		hTCEpi: 2.0;K-562: 1.1
WNT10B	SHFM6, WNT-12	ENSG00000169884	Wnt family member 10B	12	48965340-48971763	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA055048, HPA062539	Enhanced		Approved	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 11.6	skin: 3.0	Cell line enhanced		T-47d: 7.6
CALML6	CAGLP	ENSG00000169885	Calmodulin like 6	1	1914827-1917296	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enriched	9	skeletal muscle: 37.6	esophagus: 4.2	Cell line enhanced		AN3-CA: 1.6
REPS2	POB1	ENSG00000169891	RALBP1 associated Eps domain containing 2	X	16946691-17153280	Predicted secreted proteins	Evidence at protein level	HPA000565, HPA026073	Uncertain				Pancreatic cancer:3.24e-4 (unfavourable), Renal cancer:4.08e-4 (favourable), Urothelial cancer:4.56e-4 (favourable), Liver cancer:5.36e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 28.8	Cell line enhanced		HDLM-2: 27.9;Karpas-707: 8.4;RH-30: 8.1
MUC3A	MUC3	ENSG00000169894	Mucin 3A, cell surface associated	7	100949555-100968346	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010871	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 41.6;gallbladder: 21.8;small intestine: 37.1	rectum: 13.1	Cell line enhanced		CACO-2: 6.0;CAPAN-2: 2.1;U-2 OS: 1.4
SYAP1	FLJ14495, PRO3113	ENSG00000169895	Synapse associated protein 1	X	16719632-16765336	Predicted secreted proteins	Evidence at protein level	HPA000175, HPA000882, HPA048047	Approved		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Ovarian cancer:3.18e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 33.5	Expressed in all		
ITGAM	CD11B, CR3A, MAC-1	ENSG00000169896	Integrin subunit alpha M	16	31259990-31332892	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002274, CAB025091, CAB072870	Enhanced				Renal cancer:6.93e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 130.2	appendix: 36.3	Cell line enhanced		HMC-1: 47.6;NB-4: 12.7;U-937: 18.8
PYDC1	ASC2, POP1	ENSG00000169900	Pyrin domain containing 1	16	31215962-31217359	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	8	skin: 4.3	cerebral cortex: 0.5	Not detected		
TPST1	TANGO13A	ENSG00000169902	Tyrosylprotein sulfotransferase 1	7	66205199-66420543	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA047415, HPA061837	Approved		Approved	Golgi apparatus	Renal cancer:8.16e-6 (unfavourable), Urothelial cancer:3.73e-5 (unfavourable), Stomach cancer:8.78e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 55.7	Mixed		
TM4SF4	il-TMP	ENSG00000169903	Transmembrane 4 L six family member 4	3	149473974-149503281	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046430	Enhanced		Approved	Plasma membrane<br>Cytosol		Group enriched	Group enriched	34	duodenum: 579.6;gallbladder: 1319.6;liver: 346.9;small intestine: 504.0	stomach: 20.2	Group enriched	6	A549: 19.4;RPTEC TERT1: 24.4
TOR1AIP2	IFRG15, LULL1, NET9	ENSG00000169905	Torsin 1A interacting protein 2	1	179839967-179877803	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051849, HPA058348, HPA070542	Uncertain		Enhanced	Endoplasmic reticulum	Renal cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 34.1	Expressed in all		
S100G	CABP1, CABP9K, CALB3	ENSG00000169906	S100 calcium binding protein G	X	16650158-16654670	Predicted intracellular proteins	Evidence at protein level	CAB017688, HPA055873	Enhanced					Group enriched	Tissue enriched	11	duodenum: 240.6	small intestine: 22.6	Cell line enhanced		RPMI-8226: 1.6
TM4SF1	L6, M3S1	ENSG00000169908	Transmembrane 4 L six family member 1	3	149369022-149377865	Predicted membrane proteins	Evidence at protein level	CAB002760, HPA002823	Uncertain				Urothelial cancer:3.43e-6 (unfavourable), Renal cancer:2.24e-4 (unfavourable), Pancreatic cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 327.5	Cell line enhanced		CAPAN-2: 539.1;LHCN-M2: 495.4
OTUD3	DUBA4, KIAA0459	ENSG00000169914	OTU deubiquitinase 3	1	19882513-19912945	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028543, HPA028544	Approved		Approved	Nucleoplasm<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			testis: 19.4	Expressed in all		
OTUD7A	C15orf16, CEZANNE2, OTUD7	ENSG00000169918	OTU deubiquitinase 7A	15	31475398-31870789	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044554	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 13.5	testis: 5.1	Cell line enhanced		SCLC-21H: 6.3;SH-SY5Y: 2.7
GUSB		ENSG00000169919	Glucuronidase beta	7	65960684-65982314	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA036322, HPA036323	Approved		Supported	Vesicles		Expressed in all	Expressed in all			breast: 95.9	Expressed in all		
BRD3	KIAA0043, ORFX, RING3L	ENSG00000169925	Bromodomain containing 3	9	134030305-134068535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051830	Approved		Approved	Nuclear bodies	Renal cancer:2.71e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.6	Expressed in all		
KLF13	BTEB3, FKLF-2, NSLP1, RFLAT-1	ENSG00000169926	Kruppel like factor 13	15	31326855-31435665	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:2.37e-9 (favourable)	Expressed in all	Expressed in all			bone marrow: 37.8	Mixed		
FRMPD4	KIAA0316, PDZD10, PDZK10	ENSG00000169933	FERM and PDZ domain containing 4	X	12138466-12724523	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	31	cerebral cortex: 17.7;parathyroid gland: 30.1	heart muscle: 0.7	Cell line enhanced		LHCN-M2: 3.5;U-2197: 6.0;U-266/70: 4.5
ZFPM2	FOG2, hFOG-2, ZC2HC11B, ZNF89B	ENSG00000169946	Zinc finger protein, FOG family member 2	8	104590733-105804532	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004094	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		ovary: 41.0	smooth muscle: 26.3	Cell line enhanced		AF22: 6.4;BJ hTERT+: 11.5;HHSteC: 8.3;HUVEC TERT2: 9.0
ZNF764	MGC13138	ENSG00000169951	Zinc finger protein 764	16	30553764-30558498	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003203	Uncertain		Approved	Cytosol	Endometrial cancer:6.84e-4 (favourable)	Expressed in all	Mixed			testis: 6.0	Expressed in all		
HSFY2	FLJ25453	ENSG00000169953	Heat shock transcription factor, Y-linked 2	Y	18731440-18828662	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	200	testis: 24.7	kidney: 0.1	Not detected		
ZNF747	MGC2474	ENSG00000169955	Zinc finger protein 747	16	30530367-30535347	Predicted intracellular proteins	Evidence at protein level	HPA003203, HPA069173	Uncertain		Approved	Centrosome<br>Cytosol	Pancreatic cancer:4.46e-4 (favourable), Cervical cancer:6.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.6	Mixed		
ZNF768	FLJ23436	ENSG00000169957	Zinc finger protein 768	16	30524001-30526821	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024630, HPA066512	Supported		Approved	Nucleus<br>Vesicles	Renal cancer:9.30e-6 (favourable), Urothelial cancer:6.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
TAS1R3	T1R3	ENSG00000169962	Taste 1 receptor member 3	1	1331314-1335306	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA053439	Uncertain					Mixed	Group enriched	5	epididymis: 14.9;salivary gland: 3.3	appendix: 1.7	Cell line enhanced		Karpas-707: 1.8
TMEM42	MGC29956	ENSG00000169964	Transmembrane protein 42	3	44861869-44865670	Predicted membrane proteins	Evidence at transcript level	HPA052569	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli	Renal cancer:1.10e-5 (favourable), Breast cancer:5.23e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 12.8	Mixed		
MAP3K2	MEKK2, MEKK2B	ENSG00000169967	Mitogen-activated protein kinase kinase kinase 2	2	127298730-127388465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021540	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 29.8	Expressed in all		
PUSL1	FLJ90811	ENSG00000169972	Pseudouridylate synthase-like 1	1	1308567-1311677	Predicted intracellular proteins	Evidence at protein level	HPA032057, HPA039999	Uncertain		Enhanced	Vesicles	Renal cancer:1.62e-5 (unfavourable), Liver cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 9.1	Expressed in all		
SF3B5	MGC3133, SF3b10, Ysf3	ENSG00000169976	Splicing factor 3b subunit 5	6	144094881-144095573	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054408	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			fallopian tube: 204.2	Expressed in all		
ZNF35	HF.10, HF10, Zfp105	ENSG00000169981	Zinc finger protein 35	3	44648727-44660791	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051859, HPA054738	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 9.2	Mixed		
TIGD4		ENSG00000169989	Tigger transposable element derived 4	4	152769354-152779764	Predicted intracellular proteins	Evidence at protein level	HPA035649	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 8.6	fallopian tube: 3.2	Cell line enhanced		U-266/70: 3.4;U-266/84: 6.5
IFFO2		ENSG00000169991	Intermediate filament family orphan 2	1	18904281-18956686	Predicted intracellular proteins	Evidence at transcript level	HPA015987, HPA064603	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			skin: 72.4	Cell line enhanced		HDLM-2: 129.1
NLGN2	KIAA1366	ENSG00000169992	Neuroligin 2	17	7404874-7419860	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055321, HPA069278	Enhanced		Approved	Mitochondria	Renal cancer:3.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 40.7	endometrium: 21.8	Cell line enhanced		AF22: 43.3
MYO7B		ENSG00000169994	Myosin VIIB	2	127535802-127637729	Predicted intracellular proteins	Evidence at protein level	HPA039131	Enhanced				Renal cancer:1.25e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 113.9;small intestine: 92.1	colon: 35.2	Cell line enriched	17	MOLT-4: 228.8
CHD3	Mi-2a, Mi2-ALPHA, ZFH	ENSG00000170004	Chromodomain helicase DNA binding protein 3	17	7884806-7912760	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043368, HPA076524	Supported		Approved	Nucleus<br>Nucleoli<br>Microtubule organizing center	Endometrial cancer:7.68e-5 (favourable), Colorectal cancer:2.43e-4 (unfavourable), Pancreatic cancer:8.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 85.1	Expressed in all		
TMEM154	FLJ32028	ENSG00000170006	Transmembrane protein 154	4	152618632-152680165	Predicted membrane proteins	Evidence at protein level	HPA019184, HPA055411	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		esophagus: 64.3;skin: 69.5	tonsil: 24.1	Cell line enhanced		HMC-1: 62.0
MYRIP	DKFZp586F1018, exophilin-8, MyRIP, SLAC2-C, SLAC2C	ENSG00000170011	Myosin VIIA and Rab interacting protein	3	39808914-40260321	Predicted intracellular proteins	Evidence at protein level	HPA006433			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:3.96e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 20.6	spleen: 9.9	Cell line enhanced		HAP1: 4.2;HUVEC TERT2: 13.0;SCLC-21H: 3.8;SH-SY5Y: 10.0
ALCAM	CD166, MEMD	ENSG00000170017	Activated leukocyte cell adhesion molecule	3	105366909-105576900	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002148, HPA010926	Approved				Renal cancer:3.15e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 471.5	lung: 111.2	Cell line enhanced		U-138 MG: 467.1
YWHAG	PPP1R170	ENSG00000170027	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	7	76326794-76359031	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013274, CAB018389, HPA026918	Approved	Supported			Renal cancer:4.01e-4 (unfavourable), Cervical cancer:4.53e-4 (unfavourable), Lung cancer:5.34e-4 (unfavourable), Pancreatic cancer:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 611.5	Expressed in all		
UBE2E3	UbcH9	ENSG00000170035	Ubiquitin conjugating enzyme E2 E3	2	180967248-181076585	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003303, HPA030445	Approved				Pancreatic cancer:1.78e-5 (unfavourable), Head and neck cancer:8.08e-5 (unfavourable), Liver cancer:9.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 131.8	Expressed in all		
CNTROB	LIP8, PP1221	ENSG00000170037	Centrobin, centriole duplication and spindle assembly protein	17	7932101-7949918	Predicted intracellular proteins	Evidence at protein level	HPA023319, HPA023320, HPA023321, HPA023325	Approved		Supported	Centrosome<br>Cytosol	Liver cancer:9.88e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 91.4	Expressed in all		
TRAPPC1	BET5, MUM2	ENSG00000170043	Trafficking protein particle complex 1	17	7930345-7932123	Predicted intracellular proteins	Evidence at protein level	HPA052398	Approved					Expressed in all	Expressed in all			placenta: 165.1	Expressed in all		
ZPLD1		ENSG00000170044	Zona pellucida like domain containing 1	3	102099244-102479841	Predicted membrane proteins	Evidence at transcript level	HPA077519			Approved	Nucleoplasm		Mixed	Tissue enhanced		gallbladder: 3.5;testis: 1.3	duodenum: 0.9	Cell line enriched	8	RPTEC TERT1: 5.0
KCNAB3	AKR6A9, KCNA3B	ENSG00000170049	Potassium voltage-gated channel subfamily A regulatory beta subunit 3	17	7921859-7929803	Predicted intracellular proteins	Evidence at protein level	HPA077993			Approved	Mitochondria		Mixed	Tissue enhanced		endometrium: 14.6;smooth muscle: 8.6	cerebral cortex: 4.7	Cell line enhanced		REH: 11.9
SERPINA9	CENTERIN, GCET1, SERPINA11b	ENSG00000170054	Serpin family A member 9	14	94462717-94479689	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	10	appendix: 17.1;lymph node: 50.4;tonsil: 66.3	epididymis: 4.5	Cell line enriched	49	Daudi: 50.2
FAM153A	NY-REN-7	ENSG00000170074	Family with sequence similarity 153 member A	5	177707981-177783398	Predicted intracellular proteins	Evidence at transcript level	HPA042585, HPA044022, HPA046691, HPA052337, HPA055498	Uncertain					Not detected	Tissue enhanced		testis: 13.8	ovary: 2.8	Not detected		
GPR37L1	ETBR-LP-2	ENSG00000170075	G protein-coupled receptor 37 like 1	1	202122858-202133592	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA064454	Enhanced					Tissue enriched	Tissue enriched	65	cerebral cortex: 34.1	seminal vesicle: 0.5	Cell line enhanced		HaCaT: 1.1;MCF7: 1.1;T-47d: 3.6
SIMC1	C5orf25, FLJ44216, OOMA1, PLEIAD	ENSG00000170085	SUMO interacting motifs containing 1	5	176238367-176345991	Predicted intracellular proteins	Evidence at protein level	HPA037889, HPA037890	Uncertain		Supported	Nucleus<br>Nucleoli fibrillar center	Endometrial cancer:2.32e-6 (unfavourable), Glioma:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 71.8	ovary: 58.7	Mixed		
TMEM192	FLJ38482	ENSG00000170088	Transmembrane protein 192	4	165070608-165208549	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014717, HPA024110	Enhanced		Enhanced	Nucleoplasm<br>Endosomes<br>Lysosomes	Renal cancer:2.33e-14 (favourable), Breast cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 51.0	Expressed in all		
HMP19		ENSG00000170091	HMP19 protein	5	174045604-174243501	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046531, HPA056191	Enhanced		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	7	cerebral cortex: 288.5	adrenal gland: 42.0	Group enriched	84	SCLC-21H: 45.2;SH-SY5Y: 65.3
SPDYE5		ENSG00000170092	Speedy/RINGO cell cycle regulator family member E5	7	75493625-75504304	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 4.8	skin: 2.3	Mixed		
SERPINA6	CBG	ENSG00000170099	Serpin family A member 6	14	94304248-94323394	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017864	Approved				Endometrial cancer:6.96e-5 (favourable)	Tissue enriched	Tissue enriched	6	liver: 217.2	gallbladder: 33.9	Cell line enriched	15	T-47d: 583.2
ZNF778	FLJ31875	ENSG00000170100	Zinc finger protein 778	16	89217703-89237071	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052057, HPA057151	Uncertain		Supported	Nucleus<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 15.1	Mixed		
NIPA1	MGC35570, SPG6	ENSG00000170113	Non imprinted in Prader-Willi/Angelman syndrome 1	15	22773063-22829791	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023269	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 38.2	parathyroid gland: 16.8	Mixed		
FOXD4	FKHL9, FOXD4a, FREAC5	ENSG00000170122	Forkhead box D4	9	116231-118204	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Mixed	Not detected			testis: 0.8	Cell line enhanced		THP-1: 2.9
GPR25		ENSG00000170128	G protein-coupled receptor 25	1	200872955-200874178	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		stomach: 1.7	appendix,lung: 0.6	Cell line enriched	6	U-266/70: 1.0
UBE2E1	UbcH6	ENSG00000170142	Ubiquitin conjugating enzyme E2 E1	3	23805903-23891316	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030445, CAB073413	Approved		Approved	Nucleoplasm	Liver cancer:9.97e-7 (unfavourable)	Expressed in all	Expressed in all			placenta: 119.1	Expressed in all		
HNRNPA3	HNRPA3	ENSG00000170144	Heterogeneous nuclear ribonucleoprotein A3	2	177212563-177223958	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001666, HPA005812, HPA066381	Supported		Enhanced	Nucleoplasm	Renal cancer:9.57e-7 (unfavourable), Liver cancer:2.95e-5 (unfavourable), Cervical cancer:4.87e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 309.7	Expressed in all		
SIK2	DKFZp434K1115, KIAA0781, LOH11CR1I, QIK, SNF1LK2	ENSG00000170145	Salt inducible kinase 2	11	111602391-111730853	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016026	Approved		Approved	Golgi apparatus	Renal cancer:1.17e-9 (favourable), Liver cancer:4.93e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 32.1	Expressed in all		
RNF150	KIAA1214	ENSG00000170153	Ring finger protein 150	4	140859807-141212877	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA037987	Uncertain				Breast cancer:1.41e-4 (favourable)	Mixed	Mixed			endometrium,fallopian tube: 21.3	Cell line enhanced		fHDF/TERT166: 21.9;SH-SY5Y: 42.3
CCDC144A	FLJ43983, KIAA0565	ENSG00000170160	Coiled-coil domain containing 144A	17	16689537-16777881	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022996, HPA047220, HPA047851	Approved		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enhanced		testis: 16.6	endometrium: 6.1	Mixed		
VGLL2		ENSG00000170162	Vestigial like family member 2	6	117265558-117273565	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	13	skeletal muscle: 45.1	heart muscle: 3.5	Group enriched	6	RH-30: 13.5;U-2 OS: 5.0
HOXD4	HOX4, HOX4B	ENSG00000170166	Homeobox D4	2	176151222-176153226	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054383, HPA070349	Approved		Enhanced	Nucleus<br>Cell Junctions		Tissue enhanced	Tissue enhanced		endometrium: 23.6;epididymis: 22.9	fallopian tube: 15.5	Cell line enhanced		EFO-21: 11.0;HEK 293: 25.9;RPTEC TERT1: 15.6
CHRNB1	CHRNB	ENSG00000170175	Cholinergic receptor nicotinic beta 1 subunit	17	7445061-7457707	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005822, CAB011200	Approved					Expressed in all	Expressed in all			skeletal muscle: 21.9	Cell line enhanced		LHCN-M2: 28.7;RH-30: 68.7
HOXD12	HOX4H	ENSG00000170178	Homeobox D12	2	176099730-176101193	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059444	Uncertain					Not detected	Tissue enhanced		colon: 1.0;rectum: 1.1;seminal vesicle: 1.8	prostate: 0.8	Cell line enhanced		REH: 2.3
GYPA	CD235a, GPA, MN, MNS	ENSG00000170180	Glycophorin A (MNS blood group)	4	144109303-144140751	Blood group antigen proteins, CD markers, Predicted membrane proteins	Evidence at protein level	CAB002658, HPA014811	Enhanced					Not detected	Tissue enriched	16	bone marrow: 84.6	placenta: 5.4	Group enriched	264	HEL: 127.3;K-562: 31.3
USP38	HP43.8KD, KIAA1891	ENSG00000170185	Ubiquitin specific peptidase 38	4	143184917-143223830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036990, HPA047948	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.1	Expressed in all		
SLC16A5	MCT5, MCT6	ENSG00000170190	Solute carrier family 16 member 5	17	75087727-75106162	Predicted membrane proteins, Transporters	Evidence at transcript level							Expressed in all	Mixed			duodenum: 34.5	Cell line enhanced		A549: 59.5;RPTEC TERT1: 52.1;RT4: 111.4
NANP	C20orf147, dJ694B14.3, HDHD4, MGC26833	ENSG00000170191	N-acetylneuraminic acid phosphatase	20	25612935-25624175	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050342	Uncertain		Approved	Nuclear membrane	Liver cancer:9.01e-6 (unfavourable)	Expressed in all	Mixed			testis: 4.9	Expressed in all		
ANKK1	X-kinase	ENSG00000170209	Ankyrin repeat and kinase domain containing 1	11	113387791-113400418	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012813	Uncertain					Mixed	Tissue enhanced		skin: 4.2	fallopian tube: 1.3	Cell line enhanced		hTCEpi: 1.5
ADRA1B		ENSG00000170214	Adrenoceptor alpha 1B	5	159916783-159972544	Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA074416			Supported	Plasma membrane	Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.8;spleen: 17.0	ovary: 4.8	Cell line enhanced		EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
ADPRM	C17orf48, MDS006	ENSG00000170222	ADP-ribose/CDP-alcohol diphosphatase, manganese dependent	17	10697594-10711233	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023265, HPA023820	Approved				Endometrial cancer:2.38e-5 (favourable), Cervical cancer:1.69e-4 (favourable)	Expressed in all	Expressed in all			prostate: 16.0	Expressed in all		
FABP6	I-15P, I-BABP, I-BALB, I-BAP, ILBP, ILBP3, ILLBP	ENSG00000170231	Fatty acid binding protein 6	5	160187367-160238735	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012601, CAB024713	Enhanced				Renal cancer:4.35e-9 (unfavourable)	Mixed	Tissue enriched	49	small intestine: 4217.5	fallopian tube: 86.2	Cell line enhanced		Daudi: 22.1;EFO-21: 26.9;HDLM-2: 12.3;U-2197: 11.6
PWWP2A	KIAA1935	ENSG00000170234	PWWP domain containing 2A	5	160061801-160119423	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA046733, HPA058233	Uncertain		Supported	Nucleoplasm<br>Focal adhesion sites	Urothelial cancer:3.51e-4 (favourable), Renal cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 15.4	Expressed in all		
USP50		ENSG00000170236	Ubiquitin specific peptidase 50	15	50500562-50546708	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA039470	Uncertain					Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
USP47		ENSG00000170242	Ubiquitin specific peptidase 47	11	11841423-11959323	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA029286, HPA029289	Supported		Approved	Intermediate filaments		Expressed in all	Expressed in all			parathyroid gland: 75.4	Expressed in all		
PDCD6IP	AIP1, Alix, Hp95	ENSG00000170248	Programmed cell death 6 interacting protein	3	33798352-33869707	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011905, CAB016212	Approved		Enhanced	Cytosol	Renal cancer:3.90e-9 (favourable), Colorectal cancer:1.16e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 64.1	Expressed in all		
MRGPRX1	MRGX1	ENSG00000170255	MAS related GPR family member X1	11	18933813-18939507	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF212	C2H2-150	ENSG00000170260	Zinc finger protein 212	7	149239651-149255609	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049807, HPA054178	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
MRAP	B27, C21orf61, FALP	ENSG00000170262	Melanocortin 2 receptor accessory protein	21	32291813-32314784	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA011024	Uncertain					Not detected	Group enriched	8	adipose tissue: 52.7;adrenal gland: 65.2	breast: 7.5	Cell line enhanced		Hep G2: 1.0;HSkMC: 1.2
FAM161A	FLJ13305, RP28	ENSG00000170264	Family with sequence similarity 161 member A	2	61824854-61854143	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032119	Enhanced				Endometrial cancer:9.02e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 10.0	fallopian tube: 6.4	Mixed		
ZNF282	HUB1	ENSG00000170265	Zinc finger protein 282	7	149195485-149226248	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024374	Supported		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine,fallopian tube: 14.9	Expressed in all		
GLB1	EBP, ELNR1	ENSG00000170266	Galactosidase beta 1	3	32996608-33097230	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB008382, HPA040610, HPA069503	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 122.5	Cell line enriched	5	BEWO: 804.9
GON7	C14orf142	ENSG00000170270	GON7, KEOPS complex subunit homolog	14	93202894-93207094	Predicted intracellular proteins	Evidence at protein level	HPA051832	Approved		Approved	Nucleus<br>Nucleoli	Liver cancer:1.53e-5 (unfavourable), Renal cancer:3.08e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 31.2	Expressed in all		
FAXDC2	C5orf4, FLJ13758	ENSG00000170271	Fatty acid hydroxylase domain containing 2	5	154818491-154859252	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Renal cancer:9.71e-10 (favourable), Liver cancer:3.87e-5 (favourable)	Expressed in all	Tissue enriched	6	parathyroid gland: 388.2	ovary: 66.6	Cell line enhanced		ASC diff: 22.0
CRTAP	CASP, LEPREL3, P3H5	ENSG00000170275	Cartilage associated protein	3	33113979-33147773	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA043598, HPA044150	Approved		Approved	Intermediate filaments<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cervix, uterine: 197.9	Expressed in all		
HSPB2	Hs.78846, MKBP	ENSG00000170276	Heat shock protein family B (small) member 2	11	111912242-111914093	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 36.6	skeletal muscle: 25.0	Cell line enhanced		ASC diff: 13.8;fHDF/TERT166: 21.7;HSkMC: 6.9;LHCN-M2: 13.3;U-138 MG: 11.8
C7orf33		ENSG00000170279	Chromosome 7 open reading frame 33	7	148590565-148615860	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Cell line enriched	26	SCLC-21H: 2.6
CNGB3	ACHM1, ACHM3, RMCH	ENSG00000170289	Cyclic nucleotide gated channel beta 3	8	86553977-86743675	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA057244	Enhanced					Not detected	Tissue enhanced		bone marrow: 2.7;testis: 3.9	fallopian tube: 2.1	Cell line enriched	19	SCLC-21H: 23.7
SLN	MGC12301, MGC125854, MGC125855	ENSG00000170290	Sarcolipin	11	107707378-107719693	Predicted membrane proteins, Transporters	Evidence at protein level	CAB011628			Approved	Microtubules	Renal cancer:3.52e-9 (unfavourable)	Group enriched	Tissue enriched	17	skeletal muscle: 2802.0	heart muscle: 162.9	Cell line enhanced		BEWO: 1.1;HSkMC: 1.8;PC-3: 1.0;U-2 OS: 1.2
ELP5	C17orf81, DERP6	ENSG00000170291	Elongator acetyltransferase complex subunit 5	17	7251416-7259940	Predicted intracellular proteins	Evidence at protein level	HPA023279	Uncertain		Supported	Cytosol	Pancreatic cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			testis: 173.3	Expressed in all		
CMTM8	CKLFSF8	ENSG00000170293	CKLF like MARVEL transmembrane domain containing 8	3	32238679-32370325	Predicted membrane proteins	Evidence at protein level	HPA055077, HPA073258	Approved		Approved	Nucleoplasm	Renal cancer:2.80e-4 (favourable)	Expressed in all	Mixed			placenta: 24.8	Cell line enhanced		BEWO: 199.8
GABARAP	ATG8A, MM46	ENSG00000170296	GABA type A receptor-associated protein	17	7240014-7242770	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA065883			Approved	Vesicles	Pancreatic cancer:9.52e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 763.1	Expressed in all		
LGALS9B		ENSG00000170298	Galectin 9B	17	20449395-20467539	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Uncertain	Cytosol		Mixed	Tissue enhanced		gallbladder: 11.7;rectum: 11.8;stomach: 28.8	colon: 7.5	Group enriched	7	CAPAN-2: 7.5;U-937: 2.2
STX8	CARB	ENSG00000170310	Syntaxin 8	17	9250471-9576591	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001540	Approved		Uncertain	Nuclear bodies<br>Golgi apparatus<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			testis: 96.6	Expressed in all		
CDK1	CDC2, CDC28A	ENSG00000170312	Cyclin dependent kinase 1	10	60778331-60794852	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA003387, CAB003799	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.10e-6 (unfavourable), Pancreatic cancer:4.15e-6 (unfavourable), Lung cancer:7.88e-4 (unfavourable), Cervical cancer:8.81e-4 (favourable)	Expressed in all	Mixed			lymph node: 47.5	Expressed in all		
UBB	FLJ25987, MGC8385	ENSG00000170315	Ubiquitin B	17	16380798-16382745	Predicted intracellular proteins	Evidence at protein level	CAB013048, HPA041344, HPA049132	Supported				Renal cancer:1.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 2234.2	Mixed		
NFRKB	DKFZp547B2013, INO80G	ENSG00000170322	Nuclear factor related to kappaB binding protein	11	129863636-129895590	Predicted intracellular proteins	Evidence at protein level	HPA007082, HPA007128	Approved		Enhanced	Nucleus	Liver cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 38.1	Expressed in all		
FABP4	A-FABP, aP2	ENSG00000170323	Fatty acid binding protein 4	8	81478419-81483263	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002188, CAB024961	Enhanced					Group enriched	Tissue enriched	7	adipose tissue: 3652.0	breast: 559.1	Group enriched	277	ASC diff: 2538.9;RT4: 1531.5
FRMPD2	MGC35285, PDZD5C, PDZK5C	ENSG00000170324	FERM and PDZ domain containing 2	10	48153088-48274870	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.6;fallopian tube: 4.6	thyroid gland: 0.8	Cell line enhanced		BEWO: 2.3;SCLC-21H: 1.2
PRDM10	KIAA1231, MGC131802, PFM7	ENSG00000170325	PR/SET domain 10	11	129899706-130002835	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026997	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Vesicles		Expressed in all	Mixed			parathyroid gland: 7.6	Expressed in all		
B3GNT2	B3GN-T1, B3GN-T2, B3GNT-2, B3GNT1, BETA3GNT	ENSG00000170340	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2	2	62196113-62224731	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA005997	Approved		Approved	Vesicles	Pancreatic cancer:1.62e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 51.0	Expressed in all		
FOS	AP-1, c-fos	ENSG00000170345	Fos proto-oncogene, AP-1 transcription factor subunit	14	75278774-75282230	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018531	Approved		Supported	Nucleoplasm	Prostate cancer:7.81e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 1853.4	Cell line enriched	5	hTCEpi: 324.8
TMED10	p23, P24(DELTA), p24d1, p24delta1, TMP21	ENSG00000170348	Transmembrane p24 trafficking protein 10	14	75131470-75176631	Predicted membrane proteins	Evidence at protein level	CAB034442, CAB037251, HPA047139, HPA050539	Enhanced		Supported	Golgi apparatus	Thyroid cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 244.2	Expressed in all		
SETMAR	metnase	ENSG00000170364	SET domain and mariner transposase fusion gene	3	4303304-4317567	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA057999			Supported	Nucleoli	Renal cancer:6.61e-6 (favourable), Liver cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 16.0	Mixed		
SMAD1	JV4-1, MADH1, MADR1	ENSG00000170365	SMAD family member 1	4	145481194-145558079	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB005389	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 67.4	Cell line enhanced		HUVEC TERT2: 94.6
CST5		ENSG00000170367	Cystatin D	20	23875935-23879750	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB024944, HPA061449	Enhanced					Tissue enriched	Tissue enriched	363	salivary gland: 756.2	lung,smooth muscle: 2.0	Not detected		
CST2		ENSG00000170369	Cystatin SA	20	23823769-23826731	Predicted secreted proteins	Evidence at protein level	CAB024963, HPA043706, HPA044763	Enhanced					Mixed	Tissue enriched	281	salivary gland: 2052.3	gallbladder: 7.3	Cell line enriched	13	RT4: 53.8
EMX2		ENSG00000170370	Empty spiracles homeobox 2	10	117542444-117549546	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003497, HPA065294	Enhanced	Supported	Approved	Nucleus	Renal cancer:2.28e-13 (favourable), Cervical cancer:2.80e-4 (favourable)	Group enriched	Group enriched	5	cervix, uterine: 59.5;endometrium: 114.9;epididymis: 115.2;fallopian tube: 73.0;kidney: 38.4;seminal vesicle: 65.3;smooth muscle: 59.8	cerebral cortex: 14.0	Cell line enhanced		EFO-21: 22.1;fHDF/TERT166: 20.9;RPTEC TERT1: 19.9
CST1		ENSG00000170373	Cystatin SN	20	23747553-23751268	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB026769, HPA043706, HPA044763	Enhanced				Breast cancer:4.00e-4 (favourable)	Mixed	Tissue enriched	27	salivary gland: 9590.6	gallbladder: 352.0	Cell line enhanced		CACO-2: 139.8;RT4: 891.2;TIME: 178.3
SP7	osterix, OSX	ENSG00000170374	Sp7 transcription factor	12	53326575-53345315	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029964, HPA063202	Enhanced	Approved				Not detected	Tissue enhanced		testis: 1.3	parathyroid gland,thyroid gland: 0.4	Not detected		
TCAF2	FAM115C, FAM139A, FLJ40722	ENSG00000170379	TRPM8 channel associated factor 2	7	143620950-143730409	Predicted intracellular proteins	Evidence at protein level	HPA038756, HPA038758	Uncertain		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:4.17e-6 (unfavourable), Glioma:6.78e-5 (unfavourable)	Mixed	Mixed			placenta: 8.1	Cell line enhanced		HDLM-2: 11.0;TIME: 15.8;U-87 MG: 14.1
SEMA3E	coll-5, KIAA0331, M-SemaK, SEMAH	ENSG00000170381	Semaphorin 3E	7	83363906-83649010	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029419, HPA063804	Uncertain	Supported	Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			prostate: 8.7	Cell line enhanced		SK-BR-3: 29.4;U-2 OS: 21.3
LRRN2	FIGLER7, GAC1, LRANK1, LRRN5	ENSG00000170382	Leucine rich repeat neuronal 2	1	204617170-204685733	Predicted membrane proteins	Evidence at transcript level	HPA029124	Uncertain		Approved	Endoplasmic reticulum	Endometrial cancer:2.59e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 23.4;parathyroid gland: 21.2	fallopian tube: 11.5	Cell line enhanced		HEL: 8.3;NTERA-2: 17.9;RPMI-8226: 20.1;T-47d: 9.4
SLC30A1	ZNT1, ZRC1	ENSG00000170385	Solute carrier family 30 member 1	1	211571568-211578742	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015275, HPA049000	Uncertain		Supported	Vesicles<br>Plasma membrane		Expressed in all	Mixed			liver: 47.3	Expressed in all		
DCLK2	DCAMKL2, DCDC3, DCDC3B, DCK2, MGC45428	ENSG00000170390	Doublecortin like kinase 2	4	150078274-150257457	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015770	Enhanced				Pancreatic cancer:2.48e-4 (favourable), Ovarian cancer:3.25e-4 (favourable)	Tissue enriched	Tissue enriched	10	cerebral cortex: 82.6	heart muscle: 7.9	Cell line enhanced		AF22: 23.3;BJ hTERT+: 20.2
ZNF804A	C2orf10	ENSG00000170396	Zinc finger protein 804A	2	184598366-184939492	Predicted intracellular proteins	Evidence at protein level	HPA029195	Uncertain		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.4	thyroid gland: 2.7	Cell line enhanced		Daudi: 21.5;RH-30: 19.3;U-698: 15.3
GPRC5C	RAIG-3	ENSG00000170412	G protein-coupled receptor class C group 5 member C	17	74424851-74451653	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029776	Enhanced		Uncertain	Nucleus<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.58e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 104.0	Cell line enhanced		HMC-1: 144.5;RPTEC TERT1: 168.2;T-47d: 118.6
TMEM182	FLJ30294	ENSG00000170417	Transmembrane protein 182	2	102736905-103019900	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045861	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Group enriched	9	heart muscle: 56.8;skeletal muscle: 44.4	prostate: 5.8	Mixed		
VSTM2A	MGC33530, VSTM2	ENSG00000170419	V-set and transmembrane domain containing 2A	7	54542325-54571080	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA021404, HPA024134	Uncertain				Renal cancer:5.34e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 12.7;cerebral cortex: 40.8;prostate: 15.5	stomach: 4.8	Cell line enhanced		Karpas-707: 1.3;SCLC-21H: 6.9;SH-SY5Y: 4.3
KRT8	CARD2, CK8, CYK8, K2C8, K8, KO	ENSG00000170421	Keratin 8	12	52897187-52949954	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000131, CAB001696, HPA049866	Enhanced		Supported	Intermediate filaments	Pancreatic cancer:1.51e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 1475.5	duodenum: 1118.4	Cell line enhanced		A549: 5518.3;BEWO: 3855.6;CACO-2: 6334.4;CAPAN-2: 4191.3;MCF7: 7987.2;SK-BR-3: 3839.1;T-47d: 4059.8
KRT78	K5B	ENSG00000170423	Keratin 78	12	52837804-52849092	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039724	Enhanced					Tissue enhanced	Tissue enriched	8	esophagus: 1055.1	tonsil: 127.1	Group enriched	7	EFO-21: 5.3;RT4: 1.3;SK-BR-3: 3.0;U-87 MG: 3.0
ADORA2B		ENSG00000170425	Adenosine A2b receptor	17	15944917-15975746	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA073747			Uncertain	Cytosol		Mixed	Mixed			colon: 8.5	Cell line enhanced		HMC-1: 142.9
SDR9C7	RDHS, SDR-O	ENSG00000170426	Short chain dehydrogenase/reductase family 9C member 7	12	56923154-56934405	Predicted intracellular proteins	Evidence at protein level	HPA039059			Approved	Nucleoli<br>Cytosol		Group enriched	Tissue enhanced		esophagus: 10.7;skin: 46.1	tonsil: 6.8	Not detected		
MGMT		ENSG00000170430	O-6-methylguanine-DNA methyltransferase	10	129467184-129768007	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002786, HPA032135, HPA032136, HPA069497, CAB069881	Supported		Enhanced	Nucleoplasm	Liver cancer:1.54e-4 (favourable), Cervical cancer:9.42e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 26.1	Mixed		
METTL7B	ALDI, MGC17301	ENSG00000170439	Methyltransferase like 7B	12	55681546-55684611	Predicted secreted proteins	Evidence at protein level	HPA038644	Enhanced		Supported	Vesicles<br>Microtubules	Thyroid cancer:2.37e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 137.1;liver: 122.2	small intestine: 52.1	Cell line enhanced		CAPAN-2: 42.8;EFO-21: 33.6;LHCN-M2: 33.5;U-87 MG: 35.3
KRT86	Hb6, KRTHB6, MNX	ENSG00000170442	Keratin 86	12	52249300-52309163	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039798, HPA049778	Supported		Approved	Cytosol		Mixed	Tissue enhanced		thyroid gland: 6.9	testis: 2.4	Cell line enhanced		A-431: 21.8;A549: 23.3;MCF7: 39.4;RPMI-8226: 22.5
HARS		ENSG00000170445	Histidyl-tRNA synthetase	5	140673173-140692024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036539	Approved		Enhanced	Cytosol	Liver cancer:1.96e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
NFXL1	HOZFP	ENSG00000170448	Nuclear transcription factor, X-box binding like 1	4	47847233-47914667	Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA059132	Approved		Approved	Nucleoplasm	Liver cancer:9.28e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.9	Expressed in all		
KRT75	K6HF	ENSG00000170454	Keratin 75	12	52424070-52434525	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019367, HPA076201	Supported		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Not detected			breast: 0.9	Group enriched	8	PC-3: 33.1;U-2 OS: 48.9
DENND5B	MGC24039	ENSG00000170456	DENN domain containing 5B	12	31382223-31591097	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038865	Approved		Approved	Nucleoli<br>Microtubules		Expressed in all	Mixed			testis: 29.6	Mixed		
CD14		ENSG00000170458	CD14 molecule	5	140631728-140633701	Cancer-related genes, CD markers, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001887, HPA002127, CAB033631, CAB072865, CAB072866	Enhanced		Supported	Vesicles	Renal cancer:6.80e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 267.3	Cell line enhanced		A549: 8.6;CACO-2: 12.0;SiHa: 18.3
DNAJC18	MGC29463	ENSG00000170464	DnaJ heat shock protein family (Hsp40) member C18	5	139408588-139444491	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036538, HPA060154	Approved		Supported	Cell Junctions	Pancreatic cancer:5.89e-4 (favourable)	Mixed	Group enriched	5	cerebral cortex: 30.2;testis: 115.6	ovary: 13.8	Mixed		
KRT6C	KRT6E	ENSG00000170465	Keratin 6C	12	52468516-52473785	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045697, HPA061168	Supported		Supported	Intermediate filaments	Lung cancer:1.23e-5 (unfavourable)	Tissue enhanced	Tissue enriched	50	esophagus: 525.3	cervix, uterine: 10.6	Cell line enriched	6	RPMI-8226: 66.4
RIOX1	C14orf169, FLJ21802, JMJD9, MAPJD, NO66	ENSG00000170468	Ribosomal oxygenase 1	14	73490964-73493392	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003730			Supported	Nucleoli		Expressed in all	Expressed in all			testis: 17.7	Mixed		
SPATA24	CCDC161, T6441	ENSG00000170469	Spermatogenesis associated 24	5	139396563-139404088	Predicted intracellular proteins	Evidence at protein level	HPA044000	Enhanced		Supported	Nucleus<br>Cytosol	Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 177.4	epididymis: 25.6	Expressed in all		
RALGAPB	DKFZp781M2411, KIAA1219, RalGAPbeta	ENSG00000170471	Ral GTPase activating protein non-catalytic beta subunit	20	38472816-38578861	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051454	Approved		Approved	Nuclear speckles	Renal cancer:7.25e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
PYM1	PYM, WIBG	ENSG00000170473	PYM homolog 1, exon junction complex associated factor	12	55901413-55932618	Predicted intracellular proteins	Evidence at protein level	CAB012803, HPA039717, HPA046200	Supported		Supported	Nucleus<br>Nucleoli<br>Cell Junctions<br>Cytosol	Urothelial cancer:1.34e-4 (favourable), Liver cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 50.6	Expressed in all		
MZB1	HSPC190, MEDA-7, MGC29506, PACAP, pERp1	ENSG00000170476	Marginal zone B and B1 cell specific protein	5	139387480-139390081	Predicted secreted proteins	Evidence at protein level	HPA043745, HPA052694	Enhanced				Renal cancer:1.15e-8 (unfavourable), Head and neck cancer:4.60e-5 (favourable), Endometrial cancer:7.27e-4 (favourable)	Mixed	Mixed			lymph node: 160.4	Cell line enhanced		Karpas-707: 505.9;RPMI-8226: 1791.3
KRT4	CK4, CYK4, K4	ENSG00000170477	Keratin 4	12	52806549-52814551	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002154, HPA034881	Supported		Enhanced	Intermediate filaments	Ovarian cancer:3.26e-4 (unfavourable), Urothelial cancer:6.26e-4 (unfavourable)	Group enriched	Tissue enriched	25	esophagus: 14861.9	tonsil: 599.4	Group enriched	28	HaCaT: 385.2;SK-BR-3: 130.9
SLC23A1	SLC23A2, SVCT1, YSPL3	ENSG00000170482	Solute carrier family 23 member 1	5	139367196-139384553	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047612	Enhanced					Group enriched	Group enriched	5	duodenum: 26.7;fallopian tube: 86.2;kidney: 41.9;small intestine: 72.0	liver: 10.7	Cell line enhanced		CACO-2: 7.7;HDLM-2: 7.6;Hep G2: 9.2;Karpas-707: 7.8;RPMI-8226: 7.6;U-266/70: 12.7
KRT74	K6IRS4, KRT5C, KRT6IRS4	ENSG00000170484	Keratin 74	12	52565782-52573825	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048596	Supported					Not detected	Tissue enriched	6	epididymis: 6.9	breast: 1.1	Not detected		
NPAS2	bHLHe9, MOP4, PASD4	ENSG00000170485	Neuronal PAS domain protein 2	2	100820152-100996829	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019674	Uncertain	Supported	Approved	Nucleoplasm	Renal cancer:3.55e-7 (unfavourable), Liver cancer:2.07e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 27.5	Cell line enhanced		PC-3: 102.3
KRT72	K6irs, K6IRS2, KRT6, KRT6IRS2	ENSG00000170486	Keratin 72	12	52585589-52601538	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065523	Supported					Not detected	Tissue enriched	5	testis: 26.8	skin: 5.2	Not detected		
KISS1		ENSG00000170498	KiSS-1 metastasis-suppressor	1	204190341-204196486	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB017775, HPA035542	Enhanced		Approved	Vesicles	Urothelial cancer:6.29e-6 (favourable)	Tissue enhanced	Tissue enriched	87	placenta: 328.1	stomach: 3.7	Group enriched	21	BJ: 123.9;U-2 OS: 60.5
LONRF2	FLJ45273, RNF192	ENSG00000170500	LON peptidase N-terminal domain and ring finger 2	2	100273291-100322733	Predicted intracellular proteins	Evidence at protein level	HPA057366	Approved		Supported	Nucleus	Pancreatic cancer:6.42e-5 (favourable)	Tissue enhanced	Tissue enhanced		epididymis: 55.6	endometrium: 45.2	Cell line enhanced		HAP1: 6.0;HEK 293: 5.7;SCLC-21H: 14.7
NUDT9	MGC3037	ENSG00000170502	Nudix hydrolase 9	4	87422582-87459454	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036917, HPA044866	Approved				Renal cancer:8.00e-11 (favourable), Endometrial cancer:7.43e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 85.9	Expressed in all		
HSD17B13	SCDR9, SDR16C3	ENSG00000170509	Hydroxysteroid 17-beta dehydrogenase 13	4	87303789-87322906	Predicted intracellular proteins	Evidence at protein level	HPA029125	Uncertain		Approved	Golgi apparatus<br>Vesicles	Liver cancer:2.94e-4 (favourable), Lung cancer:7.80e-4 (favourable)	Tissue enriched	Tissue enriched	29	liver: 294.1	adipose tissue: 10.2	Not detected		
PA2G4		ENSG00000170515	Proliferation-associated 2G4	12	56104319-56113907	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011711, CAB012428, HPA016484	Supported		Approved	Cytosol	Renal cancer:4.59e-7 (unfavourable), Liver cancer:6.31e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 138.1	Expressed in all		
COX7B2		ENSG00000170516	Cytochrome c oxidase subunit 7B2	4	46734827-46909235	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enriched	100	testis: 148.8	placenta: 1.4	Cell line enriched	12	Karpas-707: 25.2
ELOVL6	FLJ23378, LCE, MGC5487	ENSG00000170522	ELOVL fatty acid elongase 6	4	110045846-110199199	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA042355	Uncertain				Colorectal cancer:6.74e-4 (favourable)	Expressed in all	Mixed			liver: 27.9	Mixed		
KRT83	Hb-3, KRTHB3	ENSG00000170523	Keratin 83	12	52314301-52321398	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Tissue enhanced	Tissue enhanced		thyroid gland: 1.7	breast,testis: 0.3	Cell line enhanced		A549: 2.9;MCF7: 2.0;RPMI-8226: 9.3
PFKFB3		ENSG00000170525	6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3	10	6144934-6254644	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008266, CAB020795, HPA043889	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.87e-7 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 345.8	Expressed in all		
TMC7	FLJ21240	ENSG00000170537	Transmembrane channel like 7	16	18983934-19063942	Predicted membrane proteins	Evidence at protein level	HPA029465	Uncertain		Approved	Vesicles	Lung cancer:3.20e-4 (unfavourable), Pancreatic cancer:7.64e-4 (unfavourable), Urothelial cancer:9.20e-4 (favourable)	Mixed	Tissue enhanced		testis: 17.8	cerebral cortex: 10.7	Mixed		
ARL6IP1	AIP1, ARL6IP, ARMER, KIAA0069, SPG61	ENSG00000170540	ADP ribosylation factor like GTPase 6 interacting protein 1	16	18791667-18801678	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045307	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			cerebral cortex: 386.9	Expressed in all		
SERPINB9	CAP3, PI9	ENSG00000170542	Serpin family B member 9	6	2887266-2903280	Predicted intracellular proteins	Evidence at protein level	HPA030067	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.66e-6 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 74.8	appendix: 48.4	Cell line enhanced		BEWO: 219.1;U-698: 69.6
SMAGP	hSMAGP, MGC149453, MGC149454	ENSG00000170545	Small cell adhesion glycoprotein	12	51244558-51270890	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039711	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 145.7	esophagus: 83.3	Cell line enhanced		BEWO: 126.2
IRX1	IRX-5	ENSG00000170549	Iroquois homeobox 1	5	3596054-3601403	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043160	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Tissue enhanced		breast: 7.7;kidney: 5.3;salivary gland: 5.7	lung: 3.6	Cell line enhanced		AF22: 9.8;REH: 38.0;U-251 MG: 13.8
CDH2	CD325, CDHN, NCAD	ENSG00000170558	Cadherin 2	18	27950966-28177446	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000141, CAB018580, HPA058574, CAB078686	Enhanced		Supported	Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		heart muscle: 123.5;parathyroid gland: 126.2	adrenal gland: 87.3	Cell line enhanced		AF22: 306.2;fHDF/TERT166: 367.9
IRX2		ENSG00000170561	Iroquois homeobox 2	5	2745845-2751662	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050895, HPA054669	Approved		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:8.84e-4 (favourable)	Mixed	Tissue enhanced		breast: 29.6;lung: 28.0	skin: 19.5	Cell line enhanced		AF22: 100.0;BEWO: 58.5;hTCEpi: 47.9
EMB	MGC71745	ENSG00000170571	Embigin	5	50396192-50443248	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.76e-5 (unfavourable)	Expressed in all	Mixed			bone marrow: 94.7	Cell line enhanced		THP-1: 182.2
SIX2		ENSG00000170577	SIX homeobox 2	2	45005161-45009430	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056958			Supported	Nucleoplasm<br>Nuclear membrane		Mixed	Group enriched	5	cervix, uterine: 18.7;parathyroid gland: 8.6;prostate: 6.3;salivary gland: 9.4;skeletal muscle: 6.7	adipose tissue: 1.9	Cell line enhanced		ASC TERT1: 34.1;LHCN-M2: 39.0;RH-30: 30.9;SCLC-21H: 63.8;U-2197: 32.8;U-698: 29.5
DLGAP1	DAP-1, GKAP, SAPAP1	ENSG00000170579	DLG associated protein 1	18	3496032-4455335	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	cerebral cortex: 91.2	seminal vesicle: 14.6	Cell line enhanced		Daudi: 7.6;HAP1: 3.8;U-2197: 3.0
STAT2	STAT113	ENSG00000170581	Signal transducer and activator of transcription 2	12	56341597-56360155	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003858, HPA018888	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.78e-13 (unfavourable), Endometrial cancer:4.75e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 47.9	Expressed in all		
NUDCD2	DKFZp686E10109, NudCL2	ENSG00000170584	NudC domain containing 2	5	163446526-163460140	Predicted intracellular proteins	Evidence at protein level	HPA037384, HPA037385	Uncertain				Colorectal cancer:2.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.6	Expressed in all		
IRF2BP1	DKFZP434M154, IRF-2BP1	ENSG00000170604	Interferon regulatory factor 2 binding protein 1	19	45883607-45886170	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042164, HPA049480	Approved		Supported	Nucleoplasm	Renal cancer:3.85e-5 (favourable), Pancreatic cancer:2.32e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 13.2	Expressed in all		
OR9K2		ENSG00000170605	Olfactory receptor family 9 subfamily K member 2	12	55129681-55130802	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA015808	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HSPA4	HS24/P52, HSPH2	ENSG00000170606	Heat shock protein family A (Hsp70) member 4	5	133051962-133106449	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA010023, CAB025529	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.13e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 116.7	Expressed in all		
FOXA3	HNF3G	ENSG00000170608	Forkhead box A3	19	45863989-45873797	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB015154, HPA054034	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	5	colon: 16.7;duodenum: 10.3;liver: 32.5;pancreas: 9.8;rectum: 17.9;small intestine: 13.9;stomach: 33.8	gallbladder: 3.6	Cell line enhanced		CACO-2: 8.4;HDLM-2: 11.2;Hep G2: 18.9;K-562: 20.1;NTERA-2: 10.8
FAM71B	MGC26988	ENSG00000170613	Family with sequence similarity 71 member B	5	157161846-157166264	Predicted intracellular proteins	Evidence at protein level	HPA039478, HPA040771	Enhanced					Not detected	Tissue enriched	372	testis: 37.2	all non-specific tissues: 0.0	Not detected		
SLC26A5	DFNB61, PRES	ENSG00000170615	Solute carrier family 26 member 5	7	103352730-103446177	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level							Mixed	Not detected			breast,parathyroid gland: 0.9	Not detected		
COMMD5	FLJ13008, HCaRG, HT002	ENSG00000170619	COMM domain containing 5	8	144841042-144853736	Predicted intracellular proteins	Evidence at protein level	HPA046905			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 18.2	Expressed in all		
SGCD	CMD1L, DAGD, LGMD2F	ENSG00000170624	Sarcoglycan delta	5	155870344-156767788	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA026969	Uncertain					Tissue enhanced	Mixed			thyroid gland: 37.4	Cell line enhanced		BJ: 19.4;fHDF/TERT166: 28.5;RH-30: 26.8;SK-MEL-30: 28.7;U-138 MG: 34.9
GTSF1	FAM112B, FLJ32942	ENSG00000170627	Gametocyte specific factor 1	12	54455950-54473602	Predicted intracellular proteins	Evidence at protein level	HPA038876, HPA038877	Approved		Approved	Nucleoplasm		Tissue enriched	Tissue enriched	16	testis: 333.8	placenta: 20.9	Cell line enhanced		HL-60: 233.8;K-562: 259.6;NB-4: 280.4;THP-1: 272.7;U-266/84: 235.1
ZNF16	KOX9	ENSG00000170631	Zinc finger protein 16	8	144930358-144950888	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035782, HPA061835	Uncertain		Supported	Nucleus<br>Nucleoli	Head and neck cancer:2.39e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 16.1	Expressed in all		
ARMC10	MGC3195, SVH	ENSG00000170632	Armadillo repeat containing 10	7	103074881-103099764	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011036, HPA011057	Enhanced		Supported	Mitochondria	Pancreatic cancer:2.49e-6 (unfavourable), Glioma:6.98e-6 (unfavourable), Liver cancer:3.58e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
RNF34	FLJ21786, RIF, RIFF	ENSG00000170633	Ring finger protein 34	12	121400041-121430623	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA074151			Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.72e-8 (unfavourable), Urothelial cancer:3.02e-4 (favourable), Renal cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 45.8	Expressed in all		
ACYP2		ENSG00000170634	Acylphosphatase 2	2	53970838-54305300	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035301	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 73.7	Expressed in all		
TRABD	PP2447	ENSG00000170638	TraB domain containing	22	50185915-50199598	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA000822	Approved		Approved	Nucleus<br>Mitochondria	Endometrial cancer:1.19e-5 (favourable), Renal cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 38.5	Expressed in all		
TMEM133	AD031	ENSG00000170647	Transmembrane protein 133	11	100991989-100993941	Predicted membrane proteins	Evidence at protein level	HPA060528, HPA065742	Uncertain		Approved	Endoplasmic reticulum<br>Golgi apparatus	Pancreatic cancer:1.76e-4 (unfavourable)	Expressed in all	Mixed			placenta: 18.3	Cell line enhanced		CAPAN-2: 12.4
ATF7	ATFA	ENSG00000170653	Activating transcription factor 7	12	53507856-53626410	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA003384	Approved		Approved	Nucleus<br>Cytosol	Stomach cancer:2.10e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 40.3	Expressed in all		
RASA4B		ENSG00000170667	RAS p21 protein activator 4B	7	102482445-102517781	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA043010	Uncertain		Uncertain	Vesicles<br>Cell Junctions		Not detected	Tissue enhanced		skeletal muscle: 39.7	cerebral cortex: 15.7	Cell line enhanced		SH-SY5Y: 14.3;U-138 MG: 18.0;U-2 OS: 16.6
SOCS6	CIS4, Cish4, HSPC060, SOCS4, SSI4, STAI4, STATI4	ENSG00000170677	Suppressor of cytokine signaling 6	18	70288901-70330200	Predicted intracellular proteins	Evidence at protein level	CAB010189	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:1.02e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.0	Mixed		
MURC	cavin-4, CAVIN4	ENSG00000170681	Muscle related coiled-coil protein	9	100578079-100587906	Predicted intracellular proteins	Evidence at protein level	HPA020973, HPA020987, HPA021021	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Tissue enhanced	Group enriched	9	heart muscle: 34.8;skeletal muscle: 103.8	prostate: 7.4	Cell line enhanced		NTERA-2: 9.6;SCLC-21H: 17.1
OR10A3	HSHTPCRX12, HTPCRX12	ENSG00000170683	Olfactory receptor family 10 subfamily A member 3	11	7938534-7939594	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF296	ZNF342	ENSG00000170684	Zinc finger protein 296	19	45071500-45076588	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046940, HPA049576	Uncertain		Approved	Nucleoplasm<br>Centrosome	Head and neck cancer:5.24e-4 (favourable)	Expressed in all	Mixed			spleen: 3.7	Cell line enhanced		Daudi: 16.2;U-698: 18.2
HOXB9	HOX2, HOX2E	ENSG00000170689	Homeobox B9	17	48621159-48626356	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031463			Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:6.64e-5 (unfavourable), Endometrial cancer:4.47e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 107.2	colon: 26.1	Cell line enhanced		HDLM-2: 315.3;HEK 293: 116.2;HMC-1: 112.5;K-562: 130.4
TTLL6	FLJ35808	ENSG00000170703	Tubulin tyrosine ligase like 6	17	48762235-48817214	Predicted intracellular proteins	Evidence at protein level	HPA052397	Enhanced		Approved	Vesicles<br>Microtubules		Mixed	Tissue enhanced		testis: 26.0	fallopian tube: 5.8	Cell line enriched	5	HDLM-2: 4.1
POLH	RAD30A, XP-V	ENSG00000170734	DNA polymerase eta	6	43576150-43615660	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006721, HPA026762	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
SYT9		ENSG00000170743	Synaptotagmin 9	11	7238778-7469042	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 6.1;seminal vesicle: 5.1	adrenal gland: 2.7	Cell line enhanced		HEK 293: 9.6;RT4: 14.7;SH-SY5Y: 14.3;TIME: 16.8
KCNS3	Kv9.3	ENSG00000170745	Potassium voltage-gated channel modifier subfamily S member 3	2	17877847-18361616	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014864	Approved		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 35.5	skeletal muscle: 29.6	Cell line enhanced		RH-30: 66.9;RT4: 38.5
RBMXL2	HNRNPG-T, HNRPGT	ENSG00000170748	RNA binding motif protein, X-linked like 2	11	7089027-7090900	Predicted intracellular proteins	Evidence at protein level	HPA038912, HPA051842	Enhanced					Tissue enriched	Tissue enriched	499	testis: 49.8	all non-specific tissues: 0.0	Not detected		
KIF5B	KNS, KNS1	ENSG00000170759	Kinesin family member 5B	10	32009010-32056431	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009846, HPA037589, HPA037590	Approved		Enhanced	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 187.6	Expressed in all		
GPR37	EDNRBL, hET(B)R-LP, PAELR	ENSG00000170775	G protein-coupled receptor 37	7	124745997-124765627	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042903, HPA068009	Approved		Approved	Nuclear membrane<br>Cytosol	Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 78.7;testis: 27.6	placenta: 12.8	Cell line enhanced		AF22: 12.8;fHDF/TERT166: 24.0;TIME: 17.5
AKAP13	AKAP-Lbc, ARHGEF13, BRX, c-lbc, HA-3, Ht31, LBC, PROTO-LB	ENSG00000170776	A-kinase anchoring protein 13	15	85380571-85749358	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019773	Approved		Supported	Cytosol		Expressed in all	Expressed in all			endometrium: 74.5	Expressed in all		
TPD52L3	NYD-SP25	ENSG00000170777	Tumor protein D52 like 3	9	6328375-6331900	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	2754	testis: 275.3	all non-specific tissues: 0.0	Cell line enriched	12	BEWO: 1.2
CDCA4	FLJ20764, Hepp	ENSG00000170779	Cell division cycle associated 4	14	105009573-105021148	Predicted intracellular proteins	Evidence at protein level	HPA059416, HPA064971	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.47e-6 (unfavourable), Liver cancer:4.19e-4 (unfavourable), Pancreatic cancer:6.67e-4 (unfavourable), Lung cancer:7.94e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 32.9	testis: 13.8	Expressed in all		
OR10A4	OR10A4P	ENSG00000170782	Olfactory receptor family 10 subfamily A member 4	11	6876625-6877619	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SDR16C5	EPHD-2, RDH-E2, RDHE2	ENSG00000170786	Short chain dehydrogenase/reductase family 16C member 5	8	56300010-56320776	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025224	Enhanced				Head and neck cancer:7.88e-4 (favourable)	Mixed	Group enriched	6	breast: 15.2;esophagus: 36.3;lung: 40.3;skin: 72.9;small intestine: 21.7;stomach: 21.0;tonsil: 25.3	cervix, uterine: 5.6	Cell line enhanced		CAPAN-2: 22.6;HaCaT: 11.3;hTCEpi: 15.1;T-47d: 9.2
DYDC1	bA36D19.5, DPY30D1	ENSG00000170788	DPY30 domain containing 1	10	80336105-80356755	Predicted intracellular proteins	Evidence at protein level	HPA037790, HPA037791	Uncertain					Tissue enhanced	Tissue enriched	21	testis: 200.6	fallopian tube: 9.5	Not detected		
OR10A2	OR10A2P, OST363	ENSG00000170790	Olfactory receptor family 10 subfamily A member 2	11	6869693-6870745	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CHCHD7	COX23, MGC2217	ENSG00000170791	Coiled-coil-helix-coiled-coil-helix domain containing 7	8	56211686-56218798	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050783	Approved		Approved	Cell Junctions<br>Aggresome	Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable)	Expressed in all	Expressed in all			ovary: 61.6	Expressed in all		
HTRA3	Prsp, Tasp	ENSG00000170801	HtrA serine peptidase 3	4	8269765-8307111	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021187, HPA063810	Approved		Approved	Vesicles	Renal cancer:1.61e-9 (unfavourable), Thyroid cancer:1.29e-4 (unfavourable)	Expressed in all	Mixed			ovary: 60.9	Cell line enriched	6	U-2197: 168.9
FOXN2	HTLF	ENSG00000170802	Forkhead box N2	2	48314637-48379294	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003485	Supported		Supported	Nucleus<br>Vesicles	Renal cancer:2.81e-5 (unfavourable), Glioma:5.14e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 36.4	Expressed in all		
LMOD2		ENSG00000170807	Leiomodin 2	7	123655807-123664290	Predicted intracellular proteins	Evidence at protein level	HPA051039	Enhanced					Group enriched	Group enriched	19	heart muscle: 506.5;skeletal muscle: 316.7	esophagus: 21.9	Cell line enriched	8	HSkMC: 1.0
BFSP2	CP47, CP49, LIFL-L, phakinin	ENSG00000170819	Beaded filament structural protein 2	3	133399995-133475222	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038464, HPA062959	Enhanced		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Not detected			lymph node: 0.4	Group enriched	7	Daudi: 1.5;U-698: 1.7
FSHR	FSHRO, LGR1, ODG1	ENSG00000170820	Follicle stimulating hormone receptor	2	48962157-49154537	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Group enriched	9	ovary: 2.5;testis: 4.3	gallbladder: 0.3	Not detected		
USP32	NY-REN-60, USP10	ENSG00000170832	Ubiquitin specific peptidase 32	17	60179094-60422470	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044365	Approved		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 155.0	Expressed in all		
CEL	BSSL, MODY8	ENSG00000170835	Carboxyl ester lipase	9	133061978-133071861	Predicted secreted proteins	Evidence at protein level	HPA008023, HPA052701	Enhanced				Breast cancer:4.14e-4 (unfavourable)	Tissue enriched	Tissue enriched	95	pancreas: 23233.0	epididymis: 244.0	Mixed		
PPM1D	PP2C-DELTA, Wip1	ENSG00000170836	Protein phosphatase, Mg2+/Mn2+ dependent 1D	17	60600183-60666280	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022277	Uncertain		Approved	Endoplasmic reticulum	Colorectal cancer:3.52e-4 (favourable), Liver cancer:4.27e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.6	Expressed in all		
GPR27	SREB1	ENSG00000170837	G protein-coupled receptor 27	3	71754050-71756496	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029395	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Actin filaments<br>Cytosol	Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 46.5	cerebral cortex: 24.9	Cell line enhanced		EFO-21: 17.2;HL-60: 14.7;NTERA-2: 30.5;SH-SY5Y: 12.3
PSG6		ENSG00000170848	Pregnancy specific beta-1-glycoprotein 6	19	42902079-42919563	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	75	placenta: 70.2	bone marrow: 0.9	Cell line enriched	18	U-2197: 134.3
KBTBD2	BKLHD1, DKFZP566C134	ENSG00000170852	Kelch repeat and BTB domain containing 2	7	32868172-32894131	Predicted intracellular proteins	Evidence at protein level	HPA021133	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center	Cervical cancer:1.89e-4 (unfavourable), Liver cancer:5.69e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 38.6	Expressed in all		
RIOX2	FLJ14393, JMJD10, mdig, MINA, MINA53, NO52	ENSG00000170854	Ribosomal oxygenase 2	3	97941818-97972457	Predicted intracellular proteins	Evidence at protein level	HPA007603, HPA008080, CAB013458	Supported		Enhanced	Nucleus<br>Nucleoli	Breast cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 100.7	Mixed		
TRIAP1	HSPC132, MDM35, P53CSV, WF-1	ENSG00000170855	TP53 regulated inhibitor of apoptosis 1	12	120443961-120446412	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA053640	Approved		Approved	Nucleoplasm<br>Mitochondria	Melanoma:2.22e-4 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 40.3	Expressed in all		
LSM3	SMX4, USS2, YLR438C	ENSG00000170860	LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated	3	14178358-14201119	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044966	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			kidney: 21.1	Expressed in all		
KIAA0232		ENSG00000170871	KIAA0232	4	6781375-6884170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036891, HPA036892, HPA061498	Approved		Approved	Cytosol	Renal cancer:3.91e-10 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.8	Expressed in all		
MTSS1	KIAA0429, MIM, MIMA, MIMB	ENSG00000170873	MTSS1, I-BAR domain containing	8	124550790-124728429	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075540	Approved				Renal cancer:2.11e-7 (favourable)	Expressed in all	Expressed in all			placenta: 51.6	Cell line enhanced		HDLM-2: 92.3;HEL: 304.1
TMEM43	ARVD5, DKFZp586G1919, LUMA, MGC3222	ENSG00000170876	Transmembrane protein 43	3	14124940-14143679	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA019198	Approved				Pancreatic cancer:4.38e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 124.4	Expressed in all		
RNF139	HRCA1, RCA1, TRC8	ENSG00000170881	Ring finger protein 139	8	124474738-124487914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001202	Approved				Pancreatic cancer:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 114.8	Expressed in all		
RPS9	S9	ENSG00000170889	Ribosomal protein S9	19	54200742-54249003	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA048746	Approved				Renal cancer:1.63e-4 (unfavourable), Breast cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			ovary: 112.4	Expressed in all		
PLA2G1B	PLA2, PLA2A, PPLA2	ENSG00000170890	Phospholipase A2 group IB	12	120322111-120327789	Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB022329, HPA047822, HPA060803	Enhanced		Enhanced	Cytosol		Tissue enriched	Tissue enriched	246	pancreas: 23843.3	ovary: 96.9	Cell line enhanced		Hep G2: 1.7;U-2 OS: 1.8
CYTL1	C17, C4orf4	ENSG00000170891	Cytokine like 1	4	5014586-5019472	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA067201			Supported	Nuclear membrane<br>Endoplasmic reticulum	Stomach cancer:3.00e-5 (unfavourable), Urothelial cancer:1.25e-4 (unfavourable), Renal cancer:7.43e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		placenta: 64.9	seminal vesicle: 19.1	Cell line enhanced		HEL: 171.3;HUVEC TERT2: 124.6;NB-4: 237.3;WM-115: 86.9
TSEN34	LENG5, SEN34, SEN34L	ENSG00000170892	TRNA splicing endonuclease subunit 34	19	54189938-54194536	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041111, HPA048208	Approved		Supported	Nucleus	Liver cancer:1.44e-7 (unfavourable)	Expressed in all	Mixed			fallopian tube: 37.2	Mixed		
TRH		ENSG00000170893	Thyrotropin releasing hormone	3	129974305-129977938	Predicted secreted proteins	Evidence at protein level	HPA035596	Enhanced					Tissue enhanced	Group enriched	9	cervix, uterine: 32.1;endometrium: 27.4	fallopian tube: 3.4	Not detected		
GSTA4		ENSG00000170899	Glutathione S-transferase alpha 4	6	52977948-52995378	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048934	Approved					Expressed in all	Expressed in all			adrenal gland: 390.0	Cell line enhanced		AF22: 92.3
MSANTD4	KIAA1826	ENSG00000170903	Myb/SANT DNA binding domain containing 4 with coiled-coils	11	105995623-106022403	Predicted intracellular proteins	Evidence at protein level	HPA014411	Approved		Approved	Nucleus	Renal cancer:1.26e-5 (favourable), Breast cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 27.4	Mixed		
NDUFA3	B9	ENSG00000170906	NADH:ubiquinone oxidoreductase subunit A3	19	54102728-54109257	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046976	Supported				Urothelial cancer:4.80e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 16.0	Expressed in all		
OSCAR		ENSG00000170909	Osteoclast associated, immunoglobulin-like receptor	19	54094668-54102692	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:2.71e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 9.0;lung: 14.1	appendix: 3.3	Cell line enhanced		EFO-21: 13.1;HHSteC: 7.9;U-937: 14.0
PAQR8	C6orf33, LMPB1, MPRB	ENSG00000170915	Progestin and adipoQ receptor family member 8	6	52361421-52407777	Predicted membrane proteins	Evidence at protein level	HPA064625			Supported	Golgi apparatus<br>Plasma membrane	Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 64.9	Cell line enhanced		Hep G2: 28.4
NUDT6	FGF-AS, FGF2AS, gfg, gfg-1	ENSG00000170917	Nudix hydrolase 6	4	122888697-122922968	Predicted intracellular proteins	Evidence at protein level	HPA039202, HPA066115	Uncertain		Approved	Microtubules		Mixed	Mixed			kidney: 20.0	Expressed in all		
OR7G3	OST085	ENSG00000170920	Olfactory receptor family 7 subfamily G member 3	19	9126012-9126950	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TANC2	DKFZP564D166, FLJ10215, FLJ11824, KIAA1148, KIAA1636, rols, ROLSA	ENSG00000170921	Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2	17	63009556-63427699	Predicted intracellular proteins	Evidence at protein level	HPA023274	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		parathyroid gland: 78.0	testis: 34.9	Mixed		
OR7G2	OST260	ENSG00000170923	Olfactory receptor family 7 subfamily G member 2	19	9102269-9103306	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TEX13B	TGC3B, TSGA5	ENSG00000170925	Testis expressed 13B	X	107980864-107982370	Predicted intracellular proteins	Evidence at protein level	HPA011283	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
PKHD1	ARPKD, FCYT, TIGM1	ENSG00000170927	Polycystic kidney and hepatic disease 1 (autosomal recessive)	6	51615300-52087625	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031227	Approved				Renal cancer:9.74e-8 (favourable)	Group enriched	Group enriched	5	epididymis: 5.7;kidney: 15.3	pancreas: 1.9	Cell line enriched	7	RPTEC TERT1: 8.1
OR1M1	OR19-6	ENSG00000170929	Olfactory receptor family 1 subfamily M member 1	19	9093179-9094213	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.1	Not detected		
NCBP2L		ENSG00000170935	Nuclear cap binding protein subunit 2-like	X	107774899-107795829	Predicted intracellular proteins	Evidence at transcript level	HPA010664	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.4;testis: 3.9	fallopian tube: 1.2	Not detected		
DNAJC24	DPH4, JJJ3, ZCSL3	ENSG00000170946	DnaJ heat shock protein family (Hsp40) member C24	11	31369840-31431849	Predicted intracellular proteins	Evidence at protein level	HPA020025, HPA025237	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex,thyroid gland: 11.3	Expressed in all		
MBD3L1	MBD3L	ENSG00000170948	Methyl-CpG binding domain protein 3 like 1	19	8832398-8843340	Predicted intracellular proteins	Evidence at protein level	HPA043121, HPA046753	Supported					Not detected	Tissue enriched	5	testis: 34.5	fallopian tube: 6.4	Not detected		
ZNF160	F11, FLJ00032, HKr18, HZF5, KIAA1611, KR18	ENSG00000170949	Zinc finger protein 160	19	53066606-53103436	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023599	Uncertain		Approved	Nuclear speckles<br>Cytosol	Urothelial cancer:2.67e-5 (favourable)	Expressed in all	Expressed in all			spleen: 37.4	Mixed		
PGK2	PGK-2, PGKPS	ENSG00000170950	Phosphoglycerate kinase 2	6	49785651-49787307	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045385, HPA073644, HPA073656	Supported					Not detected	Tissue enriched	774	testis: 346.1	epididymis: 0.4	Not detected		
OR8B12		ENSG00000170953	Olfactory receptor family 8 subfamily B member 12	11	124542682-124543679	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
ZNF415		ENSG00000170954	Zinc finger protein 415	19	53107879-53133077	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005553	Approved		Approved	Nucleoli fibrillar center<br>Microtubules		Mixed	Mixed			testis: 39.6	Cell line enhanced		RT4: 17.7
PRKCDBP	cavin-3, CAVIN3, HSRBC, MGC20400, SRBC	ENSG00000170955	Protein kinase C delta binding protein	11	6318946-6320647	Predicted intracellular proteins	Evidence at protein level	HPA055136, HPA073327	Approved		Approved	Plasma membrane	Renal cancer:5.21e-6 (unfavourable), Cervical cancer:3.75e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 30.4	Cell line enhanced		A-431: 88.2;BJ: 80.0;TIME: 91.9;U-87 MG: 101.1;WM-115: 110.6
CEACAM3	CD66d, CGM1	ENSG00000170956	Carcinoembryonic antigen related cell adhesion molecule 3	19	41796437-41811553	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011041	Approved					Not detected	Tissue enriched	5	bone marrow: 28.5	appendix: 5.3	Not detected		
DCDC1		ENSG00000170959	Doublecortin domain containing 1	11	30830369-31369810	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 6.6;testis: 4.2	gallbladder: 2.8	Cell line enhanced		U-266/70: 1.1
HAS2		ENSG00000170961	Hyaluronan synthase 2	8	121612116-121641390	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA052060			Approved	Nuclear speckles		Mixed	Tissue enhanced		adipose tissue: 27.9	gallbladder: 12.7	Cell line enhanced		HBF TERT88: 154.7;hTEC/SVTERT24-B: 155.8;LHCN-M2: 174.3;U-138 MG: 396.2;U-251 MG: 103.0
PDGFD	IEGF, MSTP036, SCDGF-B	ENSG00000170962	Platelet derived growth factor D	11	103907186-104164379	Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA046183, HPA066271	Approved		Approved	Golgi apparatus<br>Vesicles	Stomach cancer:9.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		adrenal gland: 140.5;ovary: 96.6	gallbladder: 53.7	Group enriched	6	ASC diff: 96.8;HHSteC: 36.1
PLAC1	CT92, OOSP2L	ENSG00000170965	Placenta specific 1	X	134565838-134764322	Predicted secreted proteins	Evidence at protein level	HPA063425	Enhanced					Mixed	Tissue enriched	21	placenta: 37.7	testis: 1.7	Cell line enhanced		HEK 293: 18.2;hTCEpi: 11.1
DDI1	FLJ36017	ENSG00000170967	DNA damage inducible 1 homolog 1	11	104036580-104039188	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	283	testis: 28.2	all non-specific tissues: 0.0	Not detected		
S1PR1	CD363, D1S3362, edg-1, EDG1	ENSG00000170989	Sphingosine-1-phosphate receptor 1	1	101236888-101241518	Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB010104, HPA075568	Supported		Supported	Vesicles	Urothelial cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 86.8	Cell line enhanced		BJ: 53.9;HUVEC TERT2: 149.1;TIME: 81.9;U-251 MG: 103.4
HS6ST2		ENSG00000171004	Heparan sulfate 6-O-sulfotransferase 2	X	132626016-132961395	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA034625, HPA034626	Uncertain		Supported	Nucleoplasm	Urothelial cancer:6.03e-4 (favourable)	Mixed	Tissue enhanced		kidney: 15.0;ovary: 17.6	placenta: 11.9	Cell line enhanced		HEK 293: 42.3;RH-30: 63.9;SH-SY5Y: 87.0
OR4D5		ENSG00000171014	Olfactory receptor family 4 subfamily D member 5	11	123939543-123940637	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045005	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PYGO1		ENSG00000171016	Pygopus family PHD finger 1	15	55538890-55588947	Predicted intracellular proteins	Evidence at protein level	HPA042248	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 29.9	thyroid gland: 12.0	Cell line enhanced		U-698: 23.4
LRRC8E	FLJ23420	ENSG00000171017	Leucine rich repeat containing 8 family member E	19	7888505-7902021	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020466	Uncertain					Mixed	Mixed			skin: 11.0	Cell line enhanced		U-87 MG: 35.6
PKIA	PRKACN1	ENSG00000171033	CAMP-dependent protein kinase inhibitor alpha	8	78516139-78605267	Predicted intracellular proteins	Evidence at protein level	HPA042791	Uncertain				Stomach cancer:5.41e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 407.4	heart muscle,parathyroid gland: 123.6	Cell line enhanced		HUVEC TERT2: 86.5;RT4: 79.9
XKR6	C8orf21, C8orf5, C8orf7	ENSG00000171044	XK related 6	8	10896045-11201366	Predicted membrane proteins	Evidence at protein level	HPA024828, HPA064769	Uncertain		Approved	Actin filaments		Mixed	Mixed			testis: 1.8	Cell line enhanced		U-266/84: 4.8
TSNARE1	FLJ31164	ENSG00000171045	T-SNARE domain containing 1	8	142212080-142403240	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015890			Approved	Nucleus	Urothelial cancer:7.33e-4 (favourable)	Expressed in all	Expressed in all			skin: 29.2	Mixed		
FPR2	ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R	ENSG00000171049	Formyl peptide receptor 2	19	51752026-51770526	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA029154	Approved					Mixed	Tissue enhanced		appendix: 69.7	spleen: 19.7	Cell line enriched	21	U-937: 23.5
FPR1	FMLP, FPR	ENSG00000171051	Formyl peptide receptor 1	19	51745172-51804110	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA046550, HPA061744	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:2.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 177.8	bone marrow: 95.0	Cell line enriched	6	U-87 MG: 51.5
PATE1	PATE	ENSG00000171053	Prostate and testis expressed 1	11	125746293-125749867	Predicted secreted proteins	Evidence at protein level	HPA076587	Uncertain					Not detected	Tissue enriched	8	epididymis: 2299.3	seminal vesicle: 297.8	Cell line enhanced		BEWO: 1.3;NB-4: 1.5
OR13H1		ENSG00000171054	Olfactory receptor family 13 subfamily H member 1	X	131544074-131545000	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FEZ2		ENSG00000171055	Fasciculation and elongation protein zeta 2	2	36531805-36646087	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035978	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Liver cancer:7.79e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 78.6	Expressed in all		
SOX7		ENSG00000171056	SRY-box 7	8	10723768-10730512	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009065	Approved		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Tissue enhanced		placenta: 49.6	lung: 18.7	Cell line enhanced		HaCaT: 21.1;HUVEC TERT2: 46.6;TIME: 36.3
C8orf74		ENSG00000171060	Chromosome 8 open reading frame 74	8	10672637-10700593	Predicted intracellular proteins	Evidence at protein level	HPA027986	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enriched	42	testis: 12.4	skin: 0.2	Not detected		
C11orf24	DM4E3	ENSG00000171067	Chromosome 11 open reading frame 24	11	68261335-68272001	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012748	Uncertain		Uncertain	Nucleoplasm<br>Vesicles	Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 65.9	Expressed in all		
ALK	CD246	ENSG00000171094	Anaplastic lymphoma receptor tyrosine kinase	2	29192774-29921566	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010694	Approved		Supported	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 2.7;testis: 2.0	adrenal gland: 0.5	Cell line enriched	6	SH-SY5Y: 28.3
KYAT1	CCBL1, GTK, KATI	ENSG00000171097	Kynurenine aminotransferase 1	9	128832942-128882494	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021176, HPA021177, HPA027736	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			cerebral cortex: 17.0	Expressed in all		
MTM1		ENSG00000171100	Myotubularin 1	X	150568619-150673322	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA010008, HPA010665	Approved		Supported	Plasma membrane	Renal cancer:7.40e-7 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.3	Expressed in all		
OBP2B	hOBPIIb, LCN14	ENSG00000171102	Odorant binding protein 2B	9	133205277-133209250	Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enhanced		breast: 1.8;testis: 6.8	fallopian tube: 1.4	Not detected		
TRMT61B	FLJ20628	ENSG00000171103	TRNA methyltransferase 61B	2	28849821-28870301	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026747, HPA026751	Enhanced		Uncertain	Cytosol	Renal cancer:9.61e-5 (favourable), Liver cancer:3.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.5	Expressed in all		
INSR	CD220	ENSG00000171105	Insulin receptor	19	7112255-7294034	CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA036302, HPA036303	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			ovary: 35.5	Cell line enhanced		Karpas-707: 42.9
MFN1	FLJ20693	ENSG00000171109	Mitofusin 1	3	179347692-179394931	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB033437, HPA059230	Approved		Supported	Mitochondria	Liver cancer:8.08e-5 (unfavourable), Endometrial cancer:6.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.4	Expressed in all		
GIMAP8	DKFZp667I133, hIAN6, IAN9	ENSG00000171115	GTPase, IMAP family member 8	7	150450630-150479392	Predicted intracellular proteins	Evidence at protein level	HPA014474, HPA017765	Supported				Testis cancer:8.47e-4 (unfavourable)	Expressed in all	Mixed			spleen: 55.9	Cell line enriched	8	HUVEC TERT2: 49.3
HSFX1	LW-1	ENSG00000171116	Heat shock transcription factor family, X-linked 1	X	149774068-149776867	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063040	Approved					Not detected	Mixed			ovary: 4.6	Mixed		
NRTN	NTN	ENSG00000171119	Neurturin	19	5823802-5828324	Disease related genes, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:3.86e-4 (favourable), Head and neck cancer:7.23e-4 (favourable), Melanoma:9.92e-4 (favourable)	Mixed	Mixed			heart muscle: 3.1	Cell line enhanced		REH: 19.1;SH-SY5Y: 11.4;U-266/70: 8.7
KCNMB3	KCNMB2, KCNMBL	ENSG00000171121	Potassium calcium-activated channel subfamily M regulatory beta subunit 3	3	179236691-179267002	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015665, HPA019185	Approved		Approved	Nucleus<br>Mitochondria		Not detected	Mixed			placenta: 6.1	Cell line enhanced		HEL: 7.2
FUT3	CD174, LE	ENSG00000171124	Fucosyltransferase 3 (Lewis blood group)	19	5842888-5851474	Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046966	Supported				Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 68.0;esophagus: 83.0;small intestine: 63.1	rectum: 49.4	Group enriched	5	A-431: 40.5;RH-30: 14.4
KCNG3	Kv6.3	ENSG00000171126	Potassium voltage-gated channel modifier subfamily G member 3	2	42442017-42494097	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA041625			Approved	Cytoplasmic bodies		Mixed	Tissue enhanced		adrenal gland: 1.2;cerebral cortex: 1.3;testis: 1.1	colon,endometrium: 0.4	Cell line enhanced		HAP1: 4.9;HMC-1: 14.2;NTERA-2: 10.3
ATP6V0E2	ATP6V0E2L, C7orf32	ENSG00000171130	ATPase H+ transporting V0 subunit e2	7	149872968-149880698	Predicted membrane proteins	Evidence at transcript level						Renal cancer:8.26e-7 (favourable), Pancreatic cancer:5.80e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 261.0	Expressed in all		
PRKCE		ENSG00000171132	Protein kinase C epsilon	2	45651345-46187990	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB001948, HPA044496, HPA054252	Enhanced		Approved	Vesicles	Renal cancer:2.63e-7 (favourable), Endometrial cancer:2.42e-4 (unfavourable), Lung cancer:9.62e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 48.3	parathyroid gland: 20.5	Mixed		
OR2K2	HSHTPCRH06, HTPCRH06, OR2AR1P	ENSG00000171133	Olfactory receptor family 2 subfamily K member 2	9	111327483-111328520	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA024261	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
JAGN1	FLJ14602, GL009	ENSG00000171135	Jagunal homolog 1	3	9890554-9894349	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA067610			Approved	Vesicles		Expressed in all	Expressed in all			epididymis: 37.9	Expressed in all		
RLN3	H3, RXN3, ZINS4	ENSG00000171136	Relaxin 3	19	14028148-14031042	Predicted secreted proteins	Evidence at protein level	HPA043731	Uncertain					Not detected	Group enriched	6	parathyroid gland: 2.9;testis: 3.3	spleen: 0.5	Not detected		
TADA3	ADA3, FLJ20221, FLJ21329, hADA3, NGG1, TADA3L	ENSG00000171148	Transcriptional adaptor 3	3	9779860-9793011	Predicted intracellular proteins	Evidence at protein level	HPA042250	Approved		Supported	Nucleoplasm	Renal cancer:5.47e-5 (favourable)	Expressed in all	Expressed in all			testis: 71.9	Expressed in all		
SOCS5	CIS6, Cish5, CISH6, KIAA0671, SOCS-5	ENSG00000171150	Suppressor of cytokine signaling 5	2	46698952-46763129	Predicted intracellular proteins	Evidence at protein level	HPA020884, CAB025510	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:7.28e-4 (unfavourable), Ovarian cancer:7.53e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 31.1	Expressed in all		
C1GALT1C1	C1GALT2, COSMC	ENSG00000171155	C1GALT1 specific chaperone 1	X	120625793-120630150	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015632	Approved		Approved	Cytosol	Breast cancer:5.66e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 44.5	Expressed in all		
C9orf16	EST00098, FLJ12823, MGC4639	ENSG00000171159	Chromosome 9 open reading frame 16	9	128160260-128163928	Predicted intracellular proteins	Evidence at protein level	HPA020725	Uncertain		Approved	Microtubules	Liver cancer:3.13e-5 (unfavourable), Cervical cancer:7.60e-4 (favourable), Colorectal cancer:9.91e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 151.4	Expressed in all		
MORN4	bA548K23.4, C10orf83, FLJ25925, rtp	ENSG00000171160	MORN repeat containing 4	10	97614553-97633500	Predicted intracellular proteins	Evidence at protein level	HPA052718	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 32.1	Mixed		
ZNF672	FLJ22301	ENSG00000171161	Zinc finger protein 672	1	248838210-248849517	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055779, HPA062506	Approved		Enhanced	Nucleoplasm	Urothelial cancer:1.79e-5 (favourable), Pancreatic cancer:7.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.8	Expressed in all		
ZNF692	AREBP, FLJ20531, Zfp692	ENSG00000171163	Zinc finger protein 692	1	248850006-248859144	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059337, HPA062792	Uncertain		Enhanced	Nucleus<br>Nucleoli	Renal cancer:7.72e-9 (unfavourable), Urothelial cancer:8.35e-5 (favourable), Pancreatic cancer:4.09e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.8	Expressed in all		
NAIF1	bA379C10.2, C9orf90, DKFZp762G199	ENSG00000171169	Nuclear apoptosis inducing factor 1	9	128061233-128068206	Predicted intracellular proteins	Evidence at protein level	HPA054898, HPA064931			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.02e-5 (favourable), Renal cancer:8.30e-5 (favourable), Liver cancer:1.61e-4 (unfavourable)	Expressed in all	Mixed			testis: 4.6	Expressed in all		
RBKS	DKFZp686G13268, RBSK	ENSG00000171174	Ribokinase	2	27781364-27891098	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019725, HPA028285	Enhanced		Approved	Cytosol		Expressed in all	Tissue enhanced		adrenal gland: 34.7	kidney: 19.5	Cell line enhanced		EFO-21: 10.8;RPTEC TERT1: 18.4
OR2M4	HSHTPCRX18, HTPCRX18, OST710, TPCR100	ENSG00000171180	Olfactory receptor family 2 subfamily M member 4	1	248238929-248239864	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA051308	Uncertain					Not detected	Not detected			cerebral cortex: 0.2	Not detected		
GRIK1	GluK1, GLUR5	ENSG00000171189	Glutamate ionotropic receptor kainate type subunit 1	21	29536933-29940033	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA014623	Uncertain				Glioma:9.12e-4 (unfavourable)	Group enriched	Tissue enhanced		adrenal gland: 16.3;cerebral cortex: 9.0	prostate: 4.0	Not detected		
MUC7	FLJ27047, MG2	ENSG00000171195	Mucin 7, secreted	4	70430492-70482997	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA006411	Enhanced					Group enriched	Tissue enriched	1464	salivary gland: 11361.9	ovary: 7.7	Not detected		
OPRPN	BPLP, PRL1, PROL1	ENSG00000171199	Opiorphin prepropeptide	4	70397882-70410194	Predicted secreted proteins	Evidence at protein level	HPA065711	Approved					Tissue enhanced	Group enriched	10	breast: 33.1;salivary gland: 18.9	epididymis: 2.5	Not detected		
SMR3B	P-B, PRL3, PROL3	ENSG00000171201	Submaxillary gland androgen regulated protein 3B	4	70370093-70390244	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1608	salivary gland: 85397.1	ovary: 53.0	Cell line enriched	34	EFO-21: 3.9
TMEM126A	DKFZp586C1924, OPA7	ENSG00000171202	Transmembrane protein 126A	11	85647967-85656547	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046648	Approved		Approved	Nucleus<br>Cytosol	Liver cancer:8.60e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.3	Expressed in all		
TMEM126B	HT007	ENSG00000171204	Transmembrane protein 126B	11	85628573-85636539	Predicted membrane proteins	Evidence at protein level	HPA014480, HPA019186	Uncertain		Supported	Mitochondria		Expressed in all	Expressed in all			epididymis: 39.6	Expressed in all		
TRIM8	GERP, RNF27	ENSG00000171206	Tripartite motif containing 8	10	102644496-102658407	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023560, HPA023561	Approved		Enhanced	Nucleoplasm<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 60.9	Expressed in all		
NETO2	FLJ10430, NEOT2	ENSG00000171208	Neuropilin and tolloid like 2	16	47077703-47143997	Predicted membrane proteins, Transporters	Evidence at protein level	HPA013180	Uncertain		Approved	Golgi apparatus	Renal cancer:5.53e-6 (unfavourable)	Mixed	Tissue enhanced		spleen: 31.5	cerebral cortex: 20.9	Mixed		
CSN3	CSN10	ENSG00000171209	Casein kappa	4	70242588-70251428	Predicted secreted proteins	Evidence at protein level	HPA035953, HPA035954	Enhanced					Group enriched	Tissue enriched	13	breast: 428.0	salivary gland: 32.0	Not detected		
CLDN20		ENSG00000171217	Claudin 20	6	155264013-155276548	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			skin: 1.0	Mixed		
CDC42BPG	DMPK2, HSMDPKIN, kappa-200, MRCKgamma	ENSG00000171219	CDC42 binding protein kinase gamma	11	64823387-64844569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027382, HPA061836	Enhanced		Supported	Cytosol	Renal cancer:5.99e-13 (favourable)	Mixed	Tissue enhanced		skin: 35.6	parathyroid gland: 14.5	Cell line enhanced		BEWO: 30.1;HaCaT: 21.0;MCF7: 25.1;SCLC-21H: 19.6
SCAND1	RAZ1, SDP1	ENSG00000171222	SCAN domain containing 1	20	35953617-35959472	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047138			Supported	Nucleus<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			duodenum: 29.4	Expressed in all		
JUNB		ENSG00000171223	JunB proto-oncogene, AP-1 transcription factor subunit	19	12791496-12793315	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004464, HPA019149	Approved		Enhanced	Nucleoplasm	Renal cancer:1.05e-4 (unfavourable), Ovarian cancer:3.65e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 320.7	Expressed in all		
C10orf35		ENSG00000171224	Chromosome 10 open reading frame 35	10	69630251-69633599	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034591	Enhanced		Approved	Nucleus<br>Centrosome<br>Cytosol	Liver cancer:1.03e-4 (unfavourable), Head and neck cancer:8.64e-4 (unfavourable), Urothelial cancer:9.72e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.6	testis: 20.2	Cell line enhanced		PC-3: 53.3
TMEM37	PR, PR1	ENSG00000171227	Transmembrane protein 37	2	119429901-119438520	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053794	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Mixed			kidney: 108.5	Cell line enhanced		EFO-21: 25.4;Hep G2: 50.5;RPTEC TERT1: 45.1
UGT2B7	UGT2B9	ENSG00000171234	UDP glucuronosyltransferase family 2 member B7	4	69051363-69112987	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045108	Uncertain				Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable)	Group enriched	Group enriched	13	kidney: 1326.3;liver: 825.7	fallopian tube: 79.7	Cell line enhanced		EFO-21: 73.2;RPTEC TERT1: 235.7;U-2197: 40.2
LRG1	LRG	ENSG00000171236	Leucine rich alpha-2-glycoprotein 1	19	4536409-4540474	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001888, HPA001889	Enhanced		Approved	Vesicles	Renal cancer:3.66e-6 (unfavourable), Thyroid cancer:3.49e-4 (favourable)	Tissue enriched	Tissue enriched	8	liver: 173.8	appendix,esophagus: 21.1	Cell line enhanced		THP-1: 15.8;U-937: 34.0
SHCBP1	FLJ22009, PAL	ENSG00000171241	SHC binding and spindle associated 1	16	46580554-46621626	Predicted intracellular proteins	Evidence at protein level	HPA048876	Uncertain		Approved	Nuclear bodies<br>Microtubules<br>Cytokinetic bridge	Pancreatic cancer:4.47e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 17.4	bone marrow: 16.7	Mixed		
SOSTDC1	DAND7, DKFZp564D206, USAG1	ENSG00000171243	Sclerostin domain containing 1	7	16461481-16530580	Predicted secreted proteins	Evidence at protein level						Renal cancer:3.22e-5 (favourable), Ovarian cancer:8.69e-4 (favourable), Urothelial cancer:8.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 57.1;stomach: 53.4	kidney: 23.0	Cell line enhanced		AF22: 8.0;EFO-21: 11.2;NTERA-2: 4.7;RPTEC TERT1: 16.9
NPTX1		ENSG00000171246	Neuronal pentraxin 1	17	80467148-80477843	Predicted secreted proteins	Evidence at protein level	HPA077062	Enhanced					Tissue enhanced	Tissue enriched	28	cerebral cortex: 122.5	adrenal gland: 4.3	Cell line enhanced		HAP1: 33.7;SiHa: 44.5;U-138 MG: 85.8;WM-115: 120.6
FAM98B	FLJ38426	ENSG00000171262	Family with sequence similarity 98 member B	15	38454127-38487710	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008320, HPA008502	Enhanced		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 32.1	Expressed in all		
ZNF439	DKFZp571K0837	ENSG00000171291	Zinc finger protein 439	19	11848726-11883750	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus		Mixed	Mixed			parathyroid gland: 25.5	Cell line enhanced		U-138 MG: 15.4
ZNF440	FLJ37933	ENSG00000171295	Zinc finger protein 440	19	11814284-11835201	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus	Renal cancer:1.18e-4 (favourable), Prostate cancer:3.57e-4 (unfavourable), Urothelial cancer:9.88e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 23.2	Mixed		
GAA		ENSG00000171298	Glucosidase alpha, acid	17	80101556-80119879	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026970, HPA029126	Enhanced				Colorectal cancer:7.66e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 69.7	Mixed		
CANT1	SCAN-1, SHAPY	ENSG00000171302	Calcium activated nucleotidase 1	17	78991717-79009867	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019627, HPA019639, HPA022818	Enhanced				Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 115.7	Expressed in all		
KCNK3	K2p3.1, TASK, TASK-1	ENSG00000171303	Potassium two pore domain channel subfamily K member 3	2	26692690-26733420	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level						Renal cancer:2.37e-7 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 111.8;placenta: 35.8	lung: 19.9	Group enriched	6	EFO-21: 10.3;SCLC-21H: 30.6
ZDHHC16	APH2	ENSG00000171307	Zinc finger DHHC-type containing 16	10	97446131-97457370	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA039893, HPA040214	Uncertain		Supported	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland,placenta: 31.5	Expressed in all		
CHST11	C4ST, C4St-1, C4ST1, HSA269537	ENSG00000171310	Carbohydrate sulfotransferase 11	12	104455295-104762014	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA052828	Approved		Approved	Golgi apparatus	Renal cancer:7.59e-11 (unfavourable), Urothelial cancer:8.42e-4 (unfavourable)	Expressed in all	Mixed			appendix: 27.6	Mixed		
EXOSC1	CGI-108, CSL4, Csl4p, hCsl4p, p13, SKI4, Ski4p	ENSG00000171311	Exosome component 1	10	97436142-97446017	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038370	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.88e-9 (unfavourable)	Expressed in all	Expressed in all			epididymis: 54.6	Expressed in all		
PGAM1	PGAM-B, PGAMA	ENSG00000171314	Phosphoglycerate mutase 1	10	97426160-97433441	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042528, HPA060483	Approved		Approved	Nucleoplasm	Breast cancer:2.04e-4 (unfavourable), Cervical cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 421.2	Expressed in all		
CHD7	CRG, FLJ20357, FLJ20361, KIAA1416	ENSG00000171316	Chromodomain helicase DNA binding protein 7	8	60678778-60868028	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA053075			Supported	Nucleoplasm<br>Nucleoli	Endometrial cancer:5.34e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 14.6	Cell line enhanced		AF22: 50.9;SCLC-21H: 55.1
ESCO2	EFO2, RBS	ENSG00000171320	Establishment of sister chromatid cohesion N-acetyltransferase 2	8	27771949-27812640	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027243, HPA053679			Supported	Nucleus<br>Golgi apparatus	Colorectal cancer:1.04e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 11.2	testis: 10.4	Mixed		
KRT19	CK19, K19, K1CS, MGC15366	ENSG00000171345	Keratin 19	17	41523617-41528308	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000031, HPA002465	Enhanced		Supported	Intermediate filaments	Renal cancer:2.98e-5 (unfavourable), Pancreatic cancer:6.82e-5 (unfavourable)	Mixed	Mixed			urinary bladder: 678.5	Cell line enhanced		HBEC3-KT: 2110.1;RT4: 2508.0;SK-BR-3: 4076.0;T-47d: 3451.5
KRT15	CK15, K15, K1CO	ENSG00000171346	Keratin 15	17	41513743-41522529	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023910, HPA024554	Enhanced		Supported	Nucleoplasm<br>Intermediate filaments	Breast cancer:4.50e-4 (favourable)	Tissue enhanced	Group enriched	7	breast: 321.5;esophagus: 784.4;skin: 1010.3	prostate: 94.7	Group enriched	12	HaCaT: 732.6;hTCEpi: 454.1
LURAP1	C1orf190, FLJ25163, LRAP35a	ENSG00000171357	Leucine rich adaptor protein 1	1	46203334-46221261	Predicted intracellular proteins	Evidence at protein level	HPA030060, HPA030061	Uncertain		Approved	Vesicles	Renal cancer:8.81e-8 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 18.1;thyroid gland: 17.6	testis: 9.2	Mixed		
KRT38	KRTHA8	ENSG00000171360	Keratin 38	17	41436446-41440921	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			tonsil: 0.3	Not detected		
CLCN5	ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN	ENSG00000171365	Chloride voltage-gated channel 5	X	49922615-50099235	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000401, HPA003213	Uncertain		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 33.7;kidney: 52.0	placenta: 9.6	Cell line enhanced		CACO-2: 44.1;RH-30: 76.7
TPPP	p25, p25alpha, TPPP/p25, TPPP1	ENSG00000171368	Tubulin polymerization promoting protein	5	659862-693395	Predicted intracellular proteins	Evidence at protein level	HPA036575, HPA036576	Enhanced		Supported	Mitochondria<br>Cytosol	Renal cancer:5.40e-6 (favourable)	Expressed in all	Tissue enriched	10	cerebral cortex: 166.6	fallopian tube: 16.9	Cell line enhanced		A549: 6.6;AN3-CA: 5.0;SCLC-21H: 15.6
KCND3	KSHIVB, Kv4.3, SCA19, SCA22	ENSG00000171385	Potassium voltage-gated channel subfamily D member 3	1	111770662-111989155	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029452	Approved					Mixed	Mixed			cerebral cortex: 26.7	Cell line enhanced		SCLC-21H: 14.0;WM-115: 2.8
APLN	apelin, XNPEP2	ENSG00000171388	Apelin	X	129645259-129654937	Predicted secreted proteins	Evidence at transcript level						Renal cancer:9.61e-5 (unfavourable), Cervical cancer:2.92e-4 (unfavourable), Lung cancer:6.09e-4 (unfavourable), Liver cancer:9.32e-4 (unfavourable)	Group enriched	Tissue enhanced		placenta: 79.6	lung: 20.8	Cell line enriched	6	HUVEC TERT2: 421.2
KRTAP4-4	KAP4.13, KAP4.4, KRTAP4-13	ENSG00000171396	Keratin associated protein 4-4	17	41159651-41160731	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRT13	CK13, K13, MGC161462, MGC3781	ENSG00000171401	Keratin 13	17	41500981-41505705	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000133, HPA030877, HPA069771	Enhanced		Enhanced	Intermediate filaments	Renal cancer:1.45e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable)	Group enriched	Tissue enriched	20	esophagus: 35138.5	tonsil: 1728.2	Group enriched	134	A-431: 2202.2;HaCaT: 1446.9
XAGE3	CT12.3a, CT12.3b, GAGED4, PLAC6, pp9012, XAGE-3	ENSG00000171402	X antigen family member 3	X	52862525-52868068	Predicted intracellular proteins	Evidence at protein level	HPA052507, HPA059045, HPA060900	Approved					Mixed	Tissue enriched	167	placenta: 575.4	adipose tissue: 3.4	Cell line enhanced		BEWO: 1.2;U-266/70: 1.6;U-266/84: 1.4
KRT9	CK-9, EPPK, K9	ENSG00000171403	Keratin 9	17	41565841-41572058	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007261, CAB037322	Supported					Tissue enriched	Tissue enhanced		skin: 2.9	adrenal gland: 0.7	Cell line enhanced		BEWO: 6.7;HaCaT: 14.8;U-937: 4.1
XAGE5	CT12.5, GAGED5, XAGE-5	ENSG00000171405	X antigen family member 5	X	52812204-52818301	Predicted intracellular proteins	Evidence at transcript level	HPA052507, HPA055941, HPA059045	Uncertain		Approved	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enriched	10	testis: 2.1	skin: 0.2	Cell line enriched	47	U-2 OS: 22.9
PDE7B		ENSG00000171408	Phosphodiesterase 7B	6	135851696-136195574	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023967	Uncertain		Approved	Nucleoplasm	Renal cancer:1.59e-4 (favourable)	Mixed	Mixed			ovary: 16.2	Cell line enhanced		EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6
MRPL36	BRIP1, L36mt, MRP-L36, PRPL36, RPMJ	ENSG00000171421	Mitochondrial ribosomal protein L36	5	1798386-1801366	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047238	Approved		Supported	Nuclear bodies<br>Mitochondria	Renal cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 95.6	Expressed in all		
ZNF581	FLJ22550, HSPC189	ENSG00000171425	Zinc finger protein 581	19	55635459-55645622	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059657	Uncertain				Liver cancer:5.74e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 21.7	Expressed in all		
NAT1	AAC1	ENSG00000171428	N-acetyltransferase 1	8	18170477-18223689	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017782, HPA043704	Approved				Colorectal cancer:5.07e-4 (favourable)	Tissue enriched	Mixed			epididymis: 18.4	Mixed		
KRT20	CK20, K20, MGC35423	ENSG00000171431	Keratin 20	17	40875941-40885227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000032, HPA024309, HPA024684, HPA027236	Enhanced		Supported	Cytosol	Renal cancer:1.32e-4 (unfavourable), Liver cancer:7.05e-4 (unfavourable)	Group enriched	Tissue enhanced		colon: 356.1;duodenum: 252.4;rectum: 295.3;small intestine: 499.6	stomach: 82.3	Cell line enhanced		BEWO: 1.0;RT4: 2.3
GLOD5		ENSG00000171433	Glyoxalase domain containing 5	X	48761750-48773648	Predicted intracellular proteins	Evidence at protein level	HPA010667	Uncertain		Uncertain	Mitochondria		Mixed	Tissue enhanced		duodenum: 10.8;kidney: 11.0;small intestine: 10.7	epididymis: 6.8	Cell line enhanced		MCF7: 1.6
KSR2	FLJ25965	ENSG00000171435	Kinase suppressor of ras 2	12	117453012-117968983	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA035536	Approved					Not detected	Tissue enhanced		cerebral cortex: 4.1	adrenal gland: 1.2	Group enriched	6	HUVEC TERT2: 3.8;SCLC-21H: 3.8;TIME: 5.6
ZNF524	MGC23143	ENSG00000171443	Zinc finger protein 524	19	55600022-55603138	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050981	Uncertain		Approved	Nucleus	Urothelial cancer:4.98e-8 (favourable)	Expressed in all	Expressed in all			spleen: 15.7	Mixed		
MCC		ENSG00000171444	Mutated in colorectal cancers	5	113022099-113488830	Predicted intracellular proteins	Evidence at protein level	HPA037390, HPA037391	Approved	Approved	Supported	Nucleoplasm	Renal cancer:6.19e-4 (favourable)	Expressed in all	Tissue enhanced		ovary: 87.5;parathyroid gland: 66.9	skin: 25.1	Cell line enhanced		HBEC3-KT: 39.0
KRT27	KRT25C	ENSG00000171446	Keratin 27	17	40776808-40782534	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055114	Supported					Tissue enhanced	Tissue enhanced		breast: 1.3	skin,testis: 0.4	Cell line enhanced		EFO-21: 1.3
ZBTB26	ZNF481	ENSG00000171448	Zinc finger and BTB domain containing 26	9	122915566-122931500	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021444	Uncertain					Expressed in all	Mixed			testis: 18.2	Expressed in all		
CDK5R2	NCK5AI, P39, p39nck5ai	ENSG00000171450	Cyclin dependent kinase 5 regulatory subunit 2	2	218959655-218962162	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 52.1	adrenal gland: 5.1	Group enriched	10	SCLC-21H: 21.4;SH-SY5Y: 14.0
DSEL	C18orf4, FLJ11477, NCAG1	ENSG00000171451	Dermatan sulfate epimerase-like	18	67506582-67516980	Predicted membrane proteins	Evidence at protein level	HPA060942			Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Mixed			cerebral cortex: 5.2	Cell line enhanced		BJ: 31.6;LHCN-M2: 38.7;U-138 MG: 46.6
POLR1C	RPA39, RPA40, RPA5, RPAC1	ENSG00000171453	RNA polymerase I subunit C	6	43509702-43529585	Disease related genes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA031010			Supported	Nucleus	Renal cancer:4.17e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.5	Expressed in all		
ASXL1	KIAA0978	ENSG00000171456	Additional sex combs like 1, transcriptional regulator	20	32358344-32439319	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064156			Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.86e-4 (unfavourable), Head and neck cancer:9.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 68.5	Expressed in all		
OR1L6	OR1L7	ENSG00000171459	Olfactory receptor family 1 subfamily L member 6	9	122749740-122750783	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DLK2	EGFL9, MGC2487	ENSG00000171462	Delta like non-canonical Notch ligand 2	6	43450352-43456632	Predicted membrane proteins	Evidence at transcript level	HPA061223, HPA068672	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		prostate: 9.3;skin: 14.5	seminal vesicle: 7.5	Cell line enhanced		HaCaT: 21.0;hTCEpi: 27.7
ZNF562	FLJ20079	ENSG00000171466	Zinc finger protein 562	19	9641808-9675086	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055332, HPA062397	Uncertain		Approved	Nucleoplasm	Head and neck cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 18.7	Expressed in all		
ZNF318	HRIHFB2436, ZFP318	ENSG00000171467	Zinc finger protein 318	6	43307134-43369478	Predicted intracellular proteins	Evidence at protein level	HPA027022, HPA027031	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
ZNF561	MGC45408	ENSG00000171469	Zinc finger protein 561	19	9604680-9621399	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055332, HPA062397	Uncertain		Approved	Nucleoplasm	Renal cancer:1.16e-4 (favourable), Ovarian cancer:1.31e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 38.2	Mixed		
WIPF2	WICH, WIRE	ENSG00000171475	WAS/WASL interacting protein family member 2	17	40219304-40284136	Predicted intracellular proteins	Evidence at protein level	HPA024000, HPA024001, HPA024467	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 32.4	Expressed in all		
HOPX	HOP, LAGY, NECC1, OB1, SMAP31	ENSG00000171476	HOP homeobox	4	56647988-56681899	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018632, HPA030180	Enhanced					Mixed	Tissue enhanced		epididymis: 658.1;skin: 839.4	esophagus: 525.5	Cell line enhanced		HDLM-2: 28.9;HUVEC TERT2: 55.7;RT4: 40.2;TIME: 62.0
SPACA5B	LYZL5B	ENSG00000171478	Sperm acrosome associated 5B	X	48130657-48132613	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA044747, HPA047149	Supported					Not detected	Tissue enriched	149	testis: 16.5	fallopian tube: 0.1	Not detected		
OR1L3	OR9-D	ENSG00000171481	Olfactory receptor family 1 subfamily L member 3	9	122675130-122676104	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058878	Uncertain					Not detected	Not detected			cerebral cortex: 0.1	Not detected		
NLRP5	CLR19.8, MATER, NALP5, PAN11, PYPAF8	ENSG00000171487	NLR family pyrin domain containing 5	19	55999726-56061813	Predicted secreted proteins	Evidence at protein level	HPA056271	Uncertain					Not detected	Tissue enriched	51	parathyroid gland: 22.9	testis: 0.4	Cell line enhanced		U-2 OS: 3.9
LRRC8C	AD158	ENSG00000171488	Leucine rich repeat containing 8 family member C	1	89633072-89769903	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029347	Uncertain		Approved	Golgi apparatus	Renal cancer:3.75e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 22.7	Mixed		
SPACA5	dJ54B20.3, LYC5, LYZL5, PNPK6288, SLLP2, UNQ6288	ENSG00000171489	Sperm acrosome associated 5	X	48004336-48009729	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA044747, HPA047149	Supported					Not detected	Tissue enriched	10	testis: 13.6	thyroid gland: 1.4	Not detected		
RSL1D1	CSIG, DKFZP564M182, L12, PBK1, UTP30	ENSG00000171490	Ribosomal L1 domain containing 1	16	11833850-11851585	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043483	Supported		Enhanced	Nucleoli	Liver cancer:1.38e-4 (unfavourable), Head and neck cancer:2.95e-4 (unfavourable), Renal cancer:3.24e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 145.4	Expressed in all		
LRRC8D	FLJ10470, LRRC5	ENSG00000171492	Leucine rich repeat containing 8 family member D	1	89821014-89936611	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014745			Approved	Nucleoplasm<br>Mitochondria	Endometrial cancer:3.21e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 35.9	Expressed in all		
MROH2B	DKFZp781F0822, FLJ40243, HEATR7B2	ENSG00000171495	Maestro heat like repeat family member 2B	5	40998017-41071342	Predicted intracellular proteins	Evidence at protein level	HPA059457	Supported					Tissue enriched	Tissue enriched	418	testis: 41.8	all non-specific tissues: 0.0	Not detected		
OR1L8		ENSG00000171496	Olfactory receptor family 1 subfamily L member 8	9	122567548-122568477	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		spleen: 1.2	testis: 0.8	Cell line enriched	7	RT4: 5.5
PPID	CYP-40	ENSG00000171497	Peptidylprolyl isomerase D	4	158709134-158723396	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019520, HPA019692	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			duodenum: 50.9	Expressed in all		
OR1N2		ENSG00000171501	Olfactory receptor family 1 subfamily N member 2	9	122553112-122555173	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
COL24A1		ENSG00000171502	Collagen type XXIV alpha 1 chain	1	85729233-86156943	Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			cervix, uterine: 3.5	Cell line enhanced		Karpas-707: 2.7;NTERA-2: 1.9;RH-30: 2.6;U-266/70: 5.3
ETFDH	ETFQO	ENSG00000171503	Electron transfer flavoprotein dehydrogenase	4	158672125-158709623	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041978	Enhanced				Renal cancer:5.76e-10 (favourable)	Expressed in all	Expressed in all			liver: 99.7	Expressed in all		
OR1N1	OR1-26, OR1N3	ENSG00000171505	Olfactory receptor family 1 subfamily N member 1	9	122526358-122527296	G-protein coupled receptors, Predicted membrane proteins	No evidence							Group enriched	Not detected			cervix, uterine,testis: 0.1	Not detected		
RXFP1	LGR7, RXFPR1	ENSG00000171509	Relaxin/insulin like family peptide receptor 1	4	158315311-158653372	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027067	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 21.6;endometrium: 10.1	adrenal gland: 5.7	Group enriched	6	EFO-21: 26.8;HEL: 8.8;RPTEC TERT1: 10.0
LPAR3	Edg-7, EDG7, HOFNH30, LP-A3, LPA3, RP4-678I3	ENSG00000171517	Lysophosphatidic acid receptor 3	1	84811602-84893213	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013421			Supported	Plasma membrane	Ovarian cancer:4.31e-5 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 66.9	prostate: 23.3	Cell line enhanced		HAP1: 22.1;HBEC3-KT: 18.9;hTCEpi: 20.1;NTERA-2: 23.5;PC-3: 24.6;SK-MEL-30: 19.8
PTGER4	EP4	ENSG00000171522	Prostaglandin E receptor 4	5	40679498-40693735	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA011226, HPA012756	Approved				Urothelial cancer:2.48e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 48.1	Cell line enhanced		HDLM-2: 33.9;RT4: 28.7;TIME: 37.0
TBCA		ENSG00000171530	Tubulin folding cofactor A	5	77691166-77868780	Predicted intracellular proteins	Evidence at protein level	HPA036487	Approved		Supported	Nucleoli<br>Microtubules		Expressed in all	Expressed in all			adrenal gland: 305.8	Expressed in all		
NEUROD2	bHLHa1, NDRF	ENSG00000171532	Neuronal differentiation 2	17	39603536-39609777	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enriched	142	cerebral cortex: 14.9	stomach: 0.1	Cell line enriched	302	SCLC-21H: 30.2
MAP6	FLJ41346, KIAA1878, MAP6-N, STOP	ENSG00000171533	Microtubule associated protein 6	11	75586918-75669120	Predicted intracellular proteins	Evidence at protein level	CAB015442, CAB022600, HPA039061, HPA039062	Enhanced		Uncertain	Plasma membrane	Pancreatic cancer:3.41e-4 (favourable), Prostate cancer:9.15e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 68.1;fallopian tube: 65.5	parathyroid gland: 52.6	Group enriched	6	AF22: 37.3;CACO-2: 31.4;HDLM-2: 19.9;SCLC-21H: 73.4;SH-SY5Y: 33.6
OTP		ENSG00000171540	Orthopedia homeobox	5	77628712-77639688	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059342	Supported					Tissue enriched	Not detected			lung,testis: 0.1	Not detected		
ECEL1	DINE, XCE	ENSG00000171551	Endothelin converting enzyme like 1	2	232479827-232487828	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067560, HPA069756		Supported	Approved	Nucleoplasm<br>Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enriched	25	ovary: 111.9	spleen: 4.4	Group enriched	7	AN3-CA: 40.8;HeLa: 15.2
BCL2L1	Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52	ENSG00000171552	BCL2 like 1	20	31664452-31723989	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters	Evidence at protein level	HPA035734, CAB072801	Approved		Approved	Mitochondria	Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 100.5	Expressed in all		
FGG		ENSG00000171557	Fibrinogen gamma chain	4	154604134-154612967	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027529, CAB033120	Supported				Renal cancer:1.00e-6 (unfavourable)	Tissue enriched	Tissue enriched	115	liver: 8699.0	lung: 75.7	Cell line enriched	42	Hep G2: 503.3
FGA		ENSG00000171560	Fibrinogen alpha chain	4	154583126-154590766	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016776, HPA051370, HPA064755	Supported				Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable)	Tissue enriched	Tissue enriched	237	liver: 9265.4	stomach: 39.0	Cell line enriched	11	Hep G2: 285.6
OR2AT4		ENSG00000171561	Olfactory receptor family 2 subfamily AT member 4	11	75088713-75089754	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060357	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	12	K-562: 2.6
FGB		ENSG00000171564	Fibrinogen beta chain	4	154562956-154571086	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001900, HPA001901, CAB008624	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:5.72e-5 (unfavourable)	Tissue enriched	Tissue enriched	556	liver: 10006.0	kidney: 17.9	Cell line enriched	9	Hep G2: 184.1
PLRG1	Cwc1, PRL1, Prp46, PRPF46, TANGO4	ENSG00000171566	Pleiotropic regulator 1	4	154535006-154550435	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035931, HPA035932, HPA061486	Supported		Enhanced	Nuclear membrane<br>Nuclear speckles	Renal cancer:8.20e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.1	Expressed in all		
ZNF584	FLJ39899	ENSG00000171574	Zinc finger protein 584	19	58401504-58418327	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level	HPA043408, HPA048075	Uncertain		Approved	Nuclear speckles		Expressed in all	Mixed			fallopian tube: 10.1	Mixed		
DSCAM	CHD2-42, CHD2-52	ENSG00000171587	DS cell adhesion molecule	21	40010999-40847139	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA019324	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 12.4	placenta,spleen: 1.0	Cell line enhanced		HBEC3-KT: 2.6;MCF7: 6.2;NTERA-2: 2.2;SCLC-21H: 3.9;T-47d: 2.0
DNAI2	CILD9, DIC2	ENSG00000171595	Dynein axonemal intermediate chain 2	17	74274247-74314884	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB006245, HPA050565	Enhanced					Tissue enhanced	Group enriched	8	fallopian tube: 48.0;testis: 27.7	lung: 4.6	Cell line enhanced		HMC-1: 1.6
NMUR1	FM-3, GPC-R, GPR66, NMU1R	ENSG00000171596	Neuromedin U receptor 1	2	231523160-231530495	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA027895	Uncertain					Mixed	Mixed			adipose tissue: 5.5	Not detected		
CLSTN1	CDHR12, CSTN1, KIAA0911	ENSG00000171603	Calsyntenin 1	1	9729026-9824526	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012412	Approved				Renal cancer:4.10e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 381.7	Expressed in all		
CXXC5	HSPC195, RINF, WID	ENSG00000171604	CXXC finger protein 5	5	139647299-139683882	Predicted intracellular proteins	Evidence at protein level	HPA036508, HPA058148	Approved		Enhanced	Nucleoplasm<br>Cytosol	Endometrial cancer:4.10e-7 (unfavourable), Colorectal cancer:2.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 99.3	Expressed in all		
ZNF274	ZKSCAN19, ZSCAN51	ENSG00000171606	Zinc finger protein 274	19	58183029-58213562	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028880	Uncertain		Supported	Nucleus<br>Centrosome	Prostate cancer:1.75e-4 (unfavourable), Glioma:4.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.2	Expressed in all		
PIK3CD	p110D	ENSG00000171608	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	1	9651732-9729114	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB015420, HPA044953	Enhanced		Approved	Vesicles<br>Cytokinetic bridge		Expressed in all	Tissue enhanced		lymph node: 56.4	spleen: 51.2	Cell line enhanced		HDLM-2: 146.7;REH: 64.7;U-937: 63.7
PTCRA	PT-ALPHA, PTA	ENSG00000171611	Pre T-cell antigen receptor alpha	6	42915989-42925835	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 3.2;spleen: 4.8	lung: 2.1	Group enriched	12	MOLT-4: 33.3;SK-MEL-30: 10.7
SLC25A33	BMSC-MCP, MGC4399, PNC1	ENSG00000171612	Solute carrier family 25 member 33	1	9539482-9585179	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049982	Uncertain				Cervical cancer:4.86e-4 (favourable), Lung cancer:7.02e-4 (favourable)	Expressed in all	Mixed			testis: 22.1	Expressed in all		
ENC1	ENC-1, KLHL37, NRPB, PIG10, TP53I10	ENSG00000171617	Ectodermal-neural cortex 1	5	74627406-74641424	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA078061			Uncertain	Plasma membrane	Renal cancer:2.95e-5 (unfavourable), Breast cancer:3.88e-4 (unfavourable)	Expressed in all	Tissue enriched	15	cerebral cortex: 461.4	gallbladder: 30.8	Mixed		
SPSB1	SSB-1	ENSG00000171621	SplA/ryanodine receptor domain and SOCS box containing 1	1	9292880-9369532	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.08e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 62.2	Cell line enhanced		hTEC/SVTERT24-B: 81.5
P2RY6	P2Y6	ENSG00000171631	Pyrimidinergic receptor P2Y6	11	73264505-73298617	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022740	Uncertain				Renal cancer:2.50e-7 (unfavourable)	Mixed	Tissue enhanced		placenta: 16.8;spleen: 35.6	appendix: 10.8	Cell line enhanced		AN3-CA: 64.0;EFO-21: 20.2;MCF7: 25.4;SK-BR-3: 41.5
BPTF	FAC1, FALZ, NURF301	ENSG00000171634	Bromodomain PHD finger transcription factor	17	67825524-67984378	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029069, HPA048289	Approved		Enhanced	Nucleoplasm	Renal cancer:8.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 67.6	Expressed in all		
S100Z	Gm625, S100-zeta	ENSG00000171643	S100 calcium binding protein Z	5	76850001-76921650	Predicted intracellular proteins	Evidence at protein level	HPA051929	Approved					Tissue enhanced	Mixed			spleen: 3.3	Cell line enriched	6	U-698: 55.6
ZIK1	ZNF762	ENSG00000171649	Zinc finger protein interacting with K protein 1	19	57578456-57593777	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059975	Uncertain		Approved	Intermediate filaments		Mixed	Mixed			parathyroid gland: 12.2	Cell line enhanced		HEK 293: 26.5;NTERA-2: 34.3
GPR82		ENSG00000171657	G protein-coupled receptor 82	X	41724155-41730135	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035914	Approved					Mixed	Tissue enhanced		tonsil: 6.3	lymph node: 3.7	Cell line enriched	16	HMC-1: 3.6
GPR34		ENSG00000171659	G protein-coupled receptor 34	X	41688973-41697277	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA010668, CAB025490	Uncertain		Uncertain	Nucleus<br>Cytosol		Expressed in all	Mixed			placenta: 60.9	Cell line enhanced		HMC-1: 1.1
PLEKHG5	GEF720, KIAA0720, Syx, Tech	ENSG00000171680	Pleckstrin homology and RhoGEF domain containing G5	1	6466092-6520061	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049570	Uncertain		Approved	Nucleus	Glioma:8.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 110.9	spleen: 34.6	Mixed		
ATF7IP	FLJ10688, p621	ENSG00000171681	Activating transcription factor 7 interacting protein	12	14365632-14502935	Predicted intracellular proteins	Evidence at protein level	HPA016578, HPA023505	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Glioma:7.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
LKAAEAR1	C20orf201	ENSG00000171695	LKAAEAR motif containing 1	20	64083380-64084359	Predicted intracellular proteins	Evidence at transcript level	HPA056463	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		testis: 2.7	cerebral cortex: 0.8	Cell line enhanced		REH: 5.1;SCLC-21H: 6.5
RGS19	GAIP, RGSGAIP	ENSG00000171700	Regulator of G-protein signaling 19	20	64073181-64079988	Predicted intracellular proteins	Evidence at protein level	HPA056384, HPA069984	Enhanced		Supported	Nucleoli fibrillar center<br>Cell Junctions	Renal cancer:2.06e-9 (unfavourable), Liver cancer:2.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 53.7	lymph node: 39.8	Expressed in all		
TCEA2	TFIIS	ENSG00000171703	Transcription elongation factor A2	20	64049836-64072347	Predicted intracellular proteins	Evidence at protein level	HPA043836	Approved		Supported	Nucleoplasm<br>Centrosome		Expressed in all	Expressed in all			cerebral cortex: 73.8	Expressed in all		
DEFB4A	DEFB-2, DEFB102, DEFB2, DEFB4, HBD-2, SAP1	ENSG00000171711	Defensin beta 4A	8	7894629-7896711	Predicted secreted proteins, Transporters	Evidence at protein level							Group enriched	Group enriched	8	esophagus: 6.0;gallbladder: 10.4;tonsil: 12.3	cervix, uterine: 1.2	Cell line enhanced		EFO-21: 2.4
ANO5	GDD1, LGMD2L, TMEM16E	ENSG00000171714	Anoctamin 5	11	22193176-22283357	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058857	Uncertain				Renal cancer:2.50e-7 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 56.1	skeletal muscle: 23.6	Cell line enhanced		A549: 4.5;HAP1: 5.6;HEK 293: 6.2
HDAC3	HD3, RPD3, RPD3-2	ENSG00000171720	Histone deacetylase 3	5	141620876-141636870	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005583, HPA052052	Supported		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 52.1	Expressed in all		
SPATA46	C1orf111	ENSG00000171722	Spermatogenesis associated 46	1	162373203-162376870	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 28.9	adrenal gland: 4.2	Cell line enhanced		SCLC-21H: 1.1
GPHN	KIAA1385	ENSG00000171723	Gephyrin	14	66507407-67181803	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003116, CAB004419, HPA024694	Enhanced		Uncertain	Cytoplasmic bodies	Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.5	Mixed		
VAT1L	KIAA1576	ENSG00000171724	Vesicle amine transport 1 like	16	77788530-77980107	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044061, CAB046032	Enhanced		Approved	Cytosol	Renal cancer:3.01e-6 (unfavourable)	Tissue enhanced	Group enriched	6	adrenal gland: 90.6;cerebral cortex: 38.8	heart muscle: 10.3	Cell line enhanced		BJ hTERT+: 55.2;fHDF/TERT166: 29.2;NTERA-2: 79.1;U-87 MG: 80.3
TMEM51	C1orf72, FLJ10199	ENSG00000171729	Transmembrane protein 51	1	15152532-15220480	Predicted membrane proteins	Evidence at protein level	HPA014547, HPA019441	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.16e-8 (favourable)	Expressed in all	Mixed			gallbladder: 33.4	Mixed		
CAMTA1	KIAA0833	ENSG00000171735	Calmodulin binding transcription activator 1	1	6785324-7769706	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036342, HPA036343	Approved		Supported	Nucleoli<br>Cytosol	Ovarian cancer:4.10e-4 (favourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 99.9	Expressed in all		
LGALS4	GAL4	ENSG00000171747	Galectin 4	19	38801671-38813364	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025653, HPA031184, HPA031185, HPA031186	Enhanced		Uncertain	Plasma membrane	Renal cancer:2.28e-4 (unfavourable), Urothelial cancer:3.21e-4 (favourable)	Group enriched	Tissue enhanced		colon: 736.0;duodenum: 526.9;rectum: 640.3;small intestine: 493.5	gallbladder: 138.8	Cell line enhanced		CACO-2: 1.0;RT4: 2.2;SH-SY5Y: 1.0
LRRC34	MGC27085	ENSG00000171757	Leucine rich repeat containing 34	3	169793428-169812986	Predicted intracellular proteins	Evidence at protein level	HPA035747	Approved		Approved	Cell Junctions<br>Microtubules<br>Cytokinetic bridge		Mixed	Group enriched	8	fallopian tube: 12.2;testis: 26.8	cerebral cortex: 2.2	Cell line enhanced		HEL: 7.6;HL-60: 7.2;NTERA-2: 8.7
PAH	PH	ENSG00000171759	Phenylalanine hydroxylase	12	102836885-102958410	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA028407, HPA031642	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:4.30e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 504.6;liver: 722.4	gallbladder: 125.9	Cell line enriched	26	Hep G2: 161.3
SPATA5L1	FLJ12286, MGC5347	ENSG00000171763	Spermatogenesis associated 5 like 1	15	45402331-45421419	Predicted intracellular proteins	Evidence at protein level	HPA043679	Uncertain		Approved	Nucleus<br>Nucleoli	Prostate cancer:7.88e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.9	Expressed in all		
GATM	AGAT	ENSG00000171766	Glycine amidinotransferase	15	45361124-45402327	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026077	Enhanced		Supported	Mitochondria	Renal cancer:1.38e-4 (favourable)	Expressed in all	Group enriched	6	kidney: 1904.2;liver: 1291.1;pancreas: 573.9	ovary: 195.7	Cell line enhanced		RH-30: 190.4;U-266/70: 92.4;U-266/84: 115.1
SYCE1	bA108K14.6, C10orf94, CT76	ENSG00000171772	Synaptonemal complex central element protein 1	10	133553901-133569835	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040208	Enhanced		Uncertain	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	6	testis: 81.8	placenta: 13.3	Group enriched	10	K-562: 16.5;U-2 OS: 16.2
NXNL1	RDCVF, TXNL6	ENSG00000171773	Nucleoredoxin-like 1	19	17455425-17460954	Predicted intracellular proteins	Evidence at protein level	HPA042010	Approved					Not detected	Tissue enhanced		adipose tissue: 2.0	skin: 1.0	Not detected		
RASGRP4		ENSG00000171777	RAS guanyl releasing protein 4	19	38409051-38426305	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		bone marrow: 13.1	appendix: 8.7	Group enriched	6	HEL: 21.5;HMC-1: 20.1;U-937: 4.8
NHLH1	bHLHa35, HEN1, NSCL, NSCL1	ENSG00000171786	Nescient helix-loop-helix 1	1	160367067-160372848	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA017943, CAB033854	Uncertain		Approved	Golgi apparatus		Group enriched	Not detected			skin: 0.8	Cell line enriched	12	SCLC-21H: 30.9
SLFNL1	FLJ23878	ENSG00000171790	Schlafen like 1	1	41015597-41023237	Predicted intracellular proteins	Evidence at protein level	HPA054956			Approved	Cytosol		Not detected	Tissue enriched	16	testis: 47.8	lung: 3.0	Cell line enhanced		CACO-2: 4.4
BCL2	Bcl-2, PPP1R50	ENSG00000171791	BCL2, apoptosis regulator	18	63123346-63320128	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000003, HPA055295	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 69.3	parathyroid gland: 35.3	Cell line enhanced		Karpas-707: 59.5;U-266/70: 217.8
RHNO1	C12orf32, HKMT1188, MGC13204, RHINO	ENSG00000171792	RAD9-HUS1-RAD1 interacting nuclear orphan 1	12	2876258-2889523	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.74e-13 (unfavourable), Liver cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.4	Expressed in all		
CTPS1	CTPS	ENSG00000171793	CTP synthase 1	1	40979335-41012565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017111, HPA051322	Enhanced		Supported	Actin filaments<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 80.2	Expressed in all		
UTF1		ENSG00000171794	Undifferentiated embryonic cell transcription factor 1	10	133230274-133231558	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	11	testis: 1.4	spleen: 0.1	Group enriched	18	NTERA-2: 5.7;RPMI-8226: 1.4
KNDC1	bB439H18.3, C10orf23, FLJ25027, KIAA1768, RASGEF2	ENSG00000171798	Kinase non-catalytic C-lobe domain containing 1	10	133160447-133226412	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039624	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 19.4;fallopian tube: 10.4	adrenal gland: 6.4	Cell line enhanced		AN3-CA: 1.5;EFO-21: 1.1;NTERA-2: 1.4;RPMI-8226: 1.4
WDR87	NYD-SP11	ENSG00000171804	WD repeat domain 87	19	37884823-37906677	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	203	testis: 30.5	thyroid gland: 0.1	Not detected		
METTL18	AsTP2, C1orf156, HPM1, MGC9084	ENSG00000171806	Methyltransferase like 18	1	169792529-169794966	Predicted intracellular proteins	Evidence at protein level	HPA035314	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.01e-4 (unfavourable), Urothelial cancer:3.28e-4 (favourable), Renal cancer:4.06e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 44.5	lymph node: 15.3	Expressed in all		
CFAP46	bA288G11.4, bA288G11.5, bB137A17.2, bB137A17.3, C10orf123, C10orf124, C10orf92, C10orf93, DKFZp434A1721, FLJ25954, TTC40	ENSG00000171811	Cilia and flagella associated protein 46	10	132808392-132942823	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037786, HPA038034, HPA038867, HPA038868	Uncertain					Mixed	Tissue enhanced		fallopian tube: 11.7;skeletal muscle: 11.4;testis: 23.8	thyroid gland: 4.5	Cell line enhanced		HAP1: 1.0;SH-SY5Y: 1.0
COL8A2	FECD, FECD1, PPCD, PPCD2	ENSG00000171812	Collagen type VIII alpha 2 chain	1	36095236-36125220	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049788	Uncertain		Uncertain	Golgi apparatus	Renal cancer:9.35e-5 (unfavourable), Ovarian cancer:7.26e-4 (unfavourable), Head and neck cancer:9.44e-4 (favourable)	Expressed in all	Mixed			placenta: 18.2	Cell line enhanced		BJ: 4.9;fHDF/TERT166: 3.3;HHSteC: 11.8
PWWP2B	bA432J24.1, FLJ46823, PWWP2	ENSG00000171813	PWWP domain containing 2B	10	132397168-132417863	Predicted intracellular proteins	Evidence at protein level	HPA038056, HPA038502			Enhanced	Nucleoplasm	Renal cancer:5.75e-4 (favourable)	Expressed in all	Mixed			spleen: 16.4	Cell line enhanced		BEWO: 53.5;MCF7: 33.4
PCDHB1	PCDH-BETA1	ENSG00000171815	Protocadherin beta 1	5	141051135-141059344	Predicted membrane proteins	Evidence at protein level	HPA053921	Uncertain					Not detected	Not detected			fallopian tube,testis: 0.7	Not detected		
ZNF540	DKFZp547B0714	ENSG00000171817	Zinc finger protein 540	19	37551406-37614097	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003444	Supported		Supported	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Mixed			thyroid gland: 13.3	Mixed		
ANGPTL7	AngX, CDT6	ENSG00000171819	Angiopoietin like 7	1	11189341-11195981	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		seminal vesicle: 9.3	gallbladder: 5.8	Cell line enriched	434	SCLC-21H: 48.4
FBXL14	Fbl14, MGC40195	ENSG00000171823	F-box and leucine rich repeat protein 14	12	1565993-1594165	Predicted intracellular proteins	Evidence at protein level	HPA053889	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:9.04e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 15.2	Mixed		
EXOSC10	p2, p3, p4, PM-Scl, PM/Scl-100, PMSCL2, RRP6, Rrp6p	ENSG00000171824	Exosome component 10	1	11066618-11099881	Predicted intracellular proteins	Evidence at protein level	HPA028470, HPA028484, CAB037141	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.49e-6 (unfavourable), Thyroid cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 46.8	Expressed in all		
ZNF570	FLJ30791	ENSG00000171827	Zinc finger protein 570	19	37467585-37488652	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at transcript level	HPA028881	Uncertain		Approved	Nucleoplasm	Renal cancer:4.06e-5 (favourable)	Expressed in all	Mixed			testis: 10.7	Mixed		
NINJ2		ENSG00000171840	Ninjurin 2	12	564296-663779	Predicted membrane proteins	Evidence at protein level	HPA058980			Approved	Endoplasmic reticulum	Head and neck cancer:5.31e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 55.6	bone marrow: 23.9	Cell line enhanced		HEL: 137.2;MOLT-4: 210.8
MLLT3	AF-9, AF9, YEATS3	ENSG00000171843	MLLT3, super elongation complex subunit	9	20341665-20622543	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001824	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.84e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 40.6	Cell line enhanced		HEL: 229.3
FAM90A1	FLJ10408	ENSG00000171847	Family with sequence similarity 90 member A1	12	8221260-8227618	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.92e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 11.6	ovary: 5.3	Cell line enhanced		BEWO: 4.7;HDLM-2: 7.1;NTERA-2: 17.6
RRM2		ENSG00000171848	Ribonucleotide reductase regulatory subunit M2	2	10122328-10131419	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA056994	Enhanced		Supported	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 47.5	Mixed		
TRAPPC12	CGI-87, TTC-15, TTC15	ENSG00000171853	Trafficking protein particle complex 12	2	3379675-3485094	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034799	Uncertain				Breast cancer:1.80e-5 (favourable), Renal cancer:2.44e-4 (unfavourable), Pancreatic cancer:9.15e-4 (favourable)	Expressed in all	Expressed in all			testis: 48.7	Expressed in all		
IFNB1	IFB, IFF, IFNB	ENSG00000171855	Interferon beta 1	9	21077105-21077963	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB009386	Uncertain					Not detected	Not detected			bone marrow: 0.3	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 1.1
RPS21	S21	ENSG00000171858	Ribosomal protein S21	20	62387116-62388520	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003371	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Liver cancer:8.46e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2356.2	Expressed in all		
C3AR1	AZ3B, C3AR	ENSG00000171860	Complement C3a receptor 1	12	8058302-8066471	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB009405	Enhanced					Expressed in all	Tissue enhanced		appendix: 86.6	placenta: 49.5	Cell line enriched	9	HMC-1: 172.5
MRM3	FLJ10581, HC90, RMTL1, RNMTL1	ENSG00000171861	Mitochondrial rRNA methyltransferase 3	17	782273-792509	Predicted intracellular proteins	Evidence at protein level	HPA022534, HPA023031, HPA023292	Enhanced		Supported	Mitochondria	Endometrial cancer:2.81e-4 (favourable), Renal cancer:3.00e-4 (favourable)	Expressed in all	Expressed in all			testis: 31.3	Expressed in all		
PTEN	BZS, MHAM, MMAC1, PTEN1, TEP1	ENSG00000171862	Phosphatase and tensin homolog	10	87863113-87971930	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004076, HPA031335	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 83.6	Expressed in all		
RPS7	S7	ENSG00000171863	Ribosomal protein S7	2	3575205-3580919	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA056586	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.34e-8 (unfavourable), Liver cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2616.2	Expressed in all		
PRND	dJ1068H6.4, DOPPEL, DPL, PrPLP	ENSG00000171864	Prion protein 2 (dublet)	20	4721910-4728460	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043373	Enhanced					Tissue enhanced	Tissue enriched	22	testis: 136.5	endometrium: 6.0	Not detected		
RNASEH1		ENSG00000171865	Ribonuclease H1	2	3544793-3558616	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043037	Uncertain				Liver cancer:7.83e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 10.9	Expressed in all		
PRNP	AltPrP, CD230, CJD, GSS, PRIP, PRP	ENSG00000171867	Prion protein	20	4686236-4701590	CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA042754, HPA043398	Enhanced		Approved	Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 619.4	Cell line enhanced		WM-115: 985.1
KLF17	FLJ40160, Zfp393, ZNF393	ENSG00000171872	Kruppel like factor 17	1	44118850-44135140	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024629	Enhanced					Tissue enriched	Tissue enhanced		testis: 8.1	smooth muscle: 1.7	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1.4;BJ hTERT+ SV40 Large T+ RasG12V: 1.2;HBF TERT88: 1.5;U-138 MG: 2.6
ADRA1D	ADRA1, ADRA1A, ADRA1R	ENSG00000171873	Adrenoceptor alpha 1D	20	4220631-4249074	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA038789	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 4.3;prostate: 4.5	seminal vesicle: 2.6	Cell line enhanced		BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
FRMD5	MGC14161	ENSG00000171877	FERM domain containing 5	15	43870761-44195252	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011746, HPA013961			Uncertain	Golgi apparatus<br>Centrosome	Pancreatic cancer:5.89e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 20.4;heart muscle: 29.4	adrenal gland: 7.2	Cell line enhanced		WM-115: 59.3
AQP4	MIWC	ENSG00000171885	Aquaporin 4	18	26852038-26865818	Predicted membrane proteins, Transporters	Evidence at protein level	CAB005079, HPA014784, CAB058689	Enhanced	Supported	Supported	Plasma membrane<br>Cell Junctions		Tissue enriched	Group enriched	16	cerebral cortex: 630.0;lung: 171.9	thyroid gland: 24.4	Cell line enhanced		AF22: 2.4;RPTEC TERT1: 1.0
CYP4F11		ENSG00000171903	Cytochrome P450 family 4 subfamily F member 11	19	15912367-15934867	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017265, CAB033648, HPA058960	Enhanced				Breast cancer:4.05e-4 (favourable), Pancreatic cancer:9.28e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 29.5;liver: 32.7;small intestine: 26.3	epididymis: 20.0	Cell line enhanced		A-431: 11.4;CAPAN-2: 44.2;EFO-21: 17.4;Hep G2: 17.0;RT4: 12.1
TLN2	ILWEQ, KIAA0320	ENSG00000171914	Talin 2	15	62390526-62844631	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017194, HPA051828, HPA054787	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 41.2;kidney: 41.1	thyroid gland: 21.7	Mixed		
LGALS9C		ENSG00000171916	Galectin 9C	17	18476737-18494945	Predicted intracellular proteins	Evidence at protein level	HPA046876, HPA047218	Approved		Approved	Cytosol		Mixed	Tissue enhanced		gallbladder: 4.9;rectum: 5.0;stomach: 10.0	colon: 2.7	Not detected		
TVP23B	CGI-148, FAM18B, FAM18B1, YDR084C	ENSG00000171928	Trans-golgi network vesicle protein 23 homolog B	17	18780995-18806714	Predicted membrane proteins	Evidence at protein level	HPA019585, HPA065603	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 78.5	Expressed in all		
FBXW10	C17orf1, C17orf1A, Fbw10, HREP, SM2SH2	ENSG00000171931	F-box and WD repeat domain containing 10	17	18744024-18779349	Predicted intracellular proteins	Evidence at transcript level	HPA047457			Approved	Nucleoplasm		Not detected	Tissue enriched	20	testis: 18.3	epididymis: 0.9	Cell line enhanced		A549: 2.0;CAPAN-2: 1.0;HaCaT: 1.4
OR10H3		ENSG00000171936	Olfactory receptor family 10 subfamily H member 3	19	15741393-15742343	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF217	ZABC1	ENSG00000171940	Zinc finger protein 217	20	53567065-53609907	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051857	Approved		Enhanced	Nuclear speckles		Expressed in all	Mixed			testis: 41.2	Expressed in all		
OR10H2		ENSG00000171942	Olfactory receptor family 10 subfamily H member 2	19	15728020-15729060	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SRGAP2C	SRGAP2P1	ENSG00000171943	SLIT-ROBO Rho GTPase activating protein 2C	1	121184810-121392822	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		parathyroid gland: 34.2	skin: 18.1	Cell line enhanced		WM-115: 78.0
OR52A5		ENSG00000171944	Olfactory receptor family 52 subfamily A member 5	11	5131692-5132642	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			bone marrow: 0.1	Not detected		
SCG2	CHGC, SgII, SN	ENSG00000171951	Secretogranin II	2	223596940-223602503	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA011893, HPA075062	Enhanced	Supported			Renal cancer:7.01e-10 (unfavourable), Pancreatic cancer:5.58e-4 (favourable)	Group enriched	Group enriched	8	adrenal gland: 446.7;cerebral cortex: 232.0	duodenum: 45.1	Cell line enhanced		ASC TERT1: 35.0;HSkMC: 31.4;SCLC-21H: 52.8;SH-SY5Y: 20.7;WM-115: 32.8
ATPAF2	ATP12, Atp12p, LP3663, MGC29736	ENSG00000171953	ATP synthase mitochondrial F1 complex assembly factor 2	17	17977409-18039209	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023329, HPA059422	Supported		Enhanced	Cytosol	Renal cancer:6.00e-5 (favourable), Endometrial cancer:4.95e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.5	Expressed in all		
CYP4F22	FLJ39501	ENSG00000171954	Cytochrome P450 family 4 subfamily F member 22	19	15508493-15552317	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058960	Uncertain					Group enriched	Tissue enhanced		esophagus: 14.0;skin: 34.3	seminal vesicle: 9.1	Cell line enhanced		MCF7: 1.3
FOXB1	FKH5, HFKH-5	ENSG00000171956	Forkhead box B1	15	60004222-60061730	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073369			Approved	Nucleoplasm<br>Mitochondria		Tissue enhanced	Not detected			testis: 0.7	Cell line enhanced		AF22: 6.3;HDLM-2: 13.5;HEK 293: 9.8
PPIH	CYP-20, CYPH, MGC5016, SnuCyp-20, USA-CYP	ENSG00000171960	Peptidylprolyl isomerase H	1	42658425-42676758	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059019	Approved				Renal cancer:1.78e-9 (unfavourable), Liver cancer:1.55e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 60.1	Expressed in all		
DRC3	CFAP134, DKFZP586M1120, LRRC48	ENSG00000171962	Dynein regulatory complex subunit 3	17	17972813-18016889	Predicted intracellular proteins	Evidence at transcript level	HPA036040, HPA036041	Approved				Endometrial cancer:4.05e-5 (favourable), Breast cancer:1.51e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 99.2	testis: 21.8	Mixed		
ZNF57	ZNF424	ENSG00000171970	Zinc finger protein 57	19	2900898-2918476	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061915			Approved	Nucleoli	Renal cancer:4.11e-9 (favourable), Lung cancer:6.26e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 47.3	skin: 11.5	Mixed		
C20orf196	FLJ25067	ENSG00000171984	Chromosome 20 open reading frame 196	20	5750393-5863912	Predicted intracellular proteins	Evidence at transcript level	HPA040749	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus<br>Vesicles	Urothelial cancer:4.05e-5 (favourable)	Expressed in all	Mixed			lymph node: 18.6	Expressed in all		
C11orf40	NOV1	ENSG00000171987	Chromosome 11 open reading frame 40	11	4571423-4577820	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.2	Not detected		
JMJD1C	DKFZp761F0118, FLJ14374, KDM3C, KIAA1380, TRIP8	ENSG00000171988	Jumonji domain containing 1C	10	63167221-63521850	Predicted intracellular proteins	Evidence at protein level	HPA056175, HPA066195	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
LDHAL6B	LDH6B, LDHAL6, LDHL	ENSG00000171989	Lactate dehydrogenase A like 6B	15	59206823-59208515	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053962	Enhanced					Not detected	Tissue enriched	166	testis: 76.5	gallbladder: 0.4	Not detected		
SYNPO	KIAA1029	ENSG00000171992	Synaptopodin	5	150601080-150659220	Predicted intracellular proteins	Evidence at protein level	CAB033265, HPA034631, CAB037325, HPA071347	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:1.53e-6 (unfavourable)	Expressed in all	Tissue enhanced		skeletal muscle: 446.6	heart muscle: 226.3	Cell line enhanced		BEWO: 85.1;TIME: 144.5;U-87 MG: 148.8
ZNF556	FLJ11637	ENSG00000172000	Zinc finger protein 556	19	2867335-2883445	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA060593			Approved	Nucleus		Mixed	Tissue enhanced		fallopian tube: 3.3;ovary: 6.5	testis: 1.3	Cell line enhanced		Hep G2: 9.1;RH-30: 18.6
MAL		ENSG00000172005	Mal, T-cell differentiation protein	2	95025677-95053996	Predicted membrane proteins	Evidence at protein level	HPA065691			Approved	Golgi apparatus<br>Centrosome	Renal cancer:3.96e-9 (favourable), Endometrial cancer:5.18e-6 (unfavourable)	Mixed	Tissue enriched	8	esophagus: 2449.8	tonsil: 315.5	Group enriched	6	HDLM-2: 467.4;MOLT-4: 571.7;RPTEC TERT1: 1845.6
ZNF554	FLJ34817	ENSG00000172006	Zinc finger protein 554	19	2819874-2835773	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060247, HPA063358	Uncertain		Supported	Nucleoplasm<br>Nucleoli	Renal cancer:1.99e-5 (favourable), Pancreatic cancer:4.69e-4 (favourable), Urothelial cancer:5.00e-4 (favourable), Lung cancer:9.31e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Mixed		
RAB33B	DKFZP434G099	ENSG00000172007	RAB33B, member RAS oncogene family	4	139453232-139476609	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048367	Uncertain				Urothelial cancer:9.19e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 13.0	Expressed in all		
THOP1		ENSG00000172009	Thimet oligopeptidase 1	19	2785460-2815807	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025497, HPA035262	Uncertain		Supported	Cytosol	Endometrial cancer:2.35e-4 (favourable), Stomach cancer:5.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.1	Mixed		
ANKRD20A4		ENSG00000172014	Ankyrin repeat domain 20 family member A4	9	64369394-64413142	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Mixed			testis: 1.2	Cell line enhanced		HDLM-2: 1.5
REG3A	HIP, PAP, PAP1, PBCGF, REG-III, REG3	ENSG00000172016	Regenerating family member 3 alpha	2	79157003-79159753	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA047894, HPA048334, HPA060705	Supported		Approved	Cytosol		Tissue enhanced	Group enriched	56	duodenum: 5635.7;small intestine: 8081.8	stomach: 122.0	Cell line enhanced		BEWO: 18.5;EFO-21: 17.0;HDLM-2: 16.3;RPMI-8226: 17.5;SH-SY5Y: 16.7;U-2 OS: 30.9
GAP43	B-50, PP46	ENSG00000172020	Growth associated protein 43	3	115623324-115721490	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004417, HPA013392, HPA015600	Enhanced		Enhanced	Plasma membrane		Tissue enriched	Tissue enriched	38	cerebral cortex: 345.9	appendix: 9.1	Group enriched	6	AF22: 34.3;NTERA-2: 74.0;SCLC-21H: 55.5;SH-SY5Y: 37.6;U-87 MG: 16.1
REG1B	PSPS2, REGH, REGI-BETA, REGL	ENSG00000172023	Regenerating family member 1 beta	2	79085030-79088019	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045549, HPA045579	Supported					Tissue enhanced	Tissue enhanced		duodenum: 734.2;small intestine: 435.2	pancreas: 181.6	Cell line enhanced		EFO-21: 6.0;HDLM-2: 3.9;U-2 OS: 15.6;U-251 MG: 3.2
EPHX4	ABHD7, EPHXRP, FLJ90341	ENSG00000172031	Epoxide hydrolase 4	1	92029982-92063536	Predicted intracellular proteins	Evidence at protein level	HPA035067	Uncertain		Approved	Vesicles	Pancreatic cancer:2.00e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.6	thyroid gland: 3.0	Cell line enhanced		A-431: 13.4;CAPAN-2: 11.4;EFO-21: 24.3;RPTEC TERT1: 27.3
LAMB2	LAMS, NPHS5	ENSG00000172037	Laminin subunit beta 2	3	49121114-49133118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000053, HPA001895, HPA050033, CAB078160	Supported		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 207.4	Cell line enhanced		fHDF/TERT166: 231.7
USP19	KIAA0891, ZMYND9	ENSG00000172046	Ubiquitin specific peptidase 19	3	49108046-49120938	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.05e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Expressed in all		
QARS		ENSG00000172053	Glutaminyl-tRNA synthetase	3	49095932-49105135	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036986, HPA036987	Enhanced		Enhanced	Cytosol	Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable)	Expressed in all	Expressed in all			rectum: 117.0	Expressed in all		
ORMDL3		ENSG00000172057	ORMDL sphingolipid biosynthesis regulator 3	17	39921041-39927601	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA065643			Supported	Endoplasmic reticulum	Urothelial cancer:5.18e-4 (favourable), Lung cancer:9.29e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 164.7	Expressed in all		
SERF1A	4F5, FAM2A, H4F5, SERF1, SMAM1	ENSG00000172058	Small EDRK-rich factor 1A	5	70900665-70918530	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075271			Approved	Nuclear bodies		Not detected	Mixed			cerebral cortex: 9.1	Mixed		
KLF11	MODY7, TIEG2, Tieg3	ENSG00000172059	Kruppel like factor 11	2	10042849-10054836	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058276			Approved	Nucleoplasm<br>Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			testis: 56.4	Mixed		
LRRC15	LIB	ENSG00000172061	Leucine rich repeat containing 15	3	194355247-194369743	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA035503	Uncertain		Approved	Vesicles<br>Plasma membrane		Tissue enhanced	Mixed			cervix, uterine: 4.7	Group enriched	8	fHDF/TERT166: 93.4;U-138 MG: 22.2;U-87 MG: 61.4
SMN1	BCD541, GEMIN1, SMA, SMA@, SMA1, SMA2, SMA3, SMNT, TDRD16A	ENSG00000172062	Survival of motor neuron 1, telomeric	5	70925030-70953942	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045271, CAB069888	Enhanced				Renal cancer:6.62e-13 (unfavourable)	Expressed in all	Mixed			lymph node: 17.0	Cell line enhanced		MOLT-4: 95.9;T-47d: 82.9;WM-115: 116.4
EIF2AK3	PEK, PERK	ENSG00000172071	Eukaryotic translation initiation factor 2 alpha kinase 3	2	88556741-88627576	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB009204, HPA015737	Enhanced					Expressed in all	Mixed			parathyroid gland: 37.3	Expressed in all		
TEX37	C2orf51, FLJ25369, TSC21	ENSG00000172073	Testis expressed 37	2	88524651-88529584	Predicted intracellular proteins	Evidence at protein level	HPA043987	Enhanced					Tissue enriched	Tissue enriched	515	testis: 82.4	placenta: 0.1	Cell line enriched	40	BEWO: 48.5
MOB3A	MOB-LAK, MOB1C, MOBKL2A, moblak	ENSG00000172081	MOB kinase activator 3A	19	2071038-2096673	Predicted intracellular proteins	Evidence at protein level	HPA057744			Uncertain	Intermediate filaments<br>Cytosol	Endometrial cancer:1.33e-6 (favourable), Renal cancer:1.93e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 85.3	Expressed in all		
KRCC1	FLJ22333	ENSG00000172086	Lysine rich coiled-coil 1	2	88027205-88055729	Predicted intracellular proteins	Evidence at protein level	HPA045618, HPA052666	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.4	Expressed in all		
NME6	IPIA-ALPHA, NM23-H6	ENSG00000172113	NME/NM23 nucleoside diphosphate kinase 6	3	48293264-48301685	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017909	Approved		Approved	Vesicles	Liver cancer:2.17e-7 (unfavourable), Renal cancer:3.18e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 27.7	Expressed in all		
CYCS	CYC, HCS	ENSG00000172115	Cytochrome c, somatic	7	25120091-25125361	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004222, CAB005126, CAB018597	Enhanced		Supported	Mitochondria	Renal cancer:1.30e-5 (favourable), Head and neck cancer:2.81e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 309.2	Expressed in all		
CD8B	CD8B1	ENSG00000172116	CD8b molecule	2	86815339-86861924	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004353, HPA029164	Enhanced		Supported	Plasma membrane	Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 60.8;lymph node: 39.6	parathyroid gland: 22.7	Cell line enriched	50	RPMI-8226: 837.8
SLFN12	FLJ10260	ENSG00000172123	Schlafen family member 12	17	35411060-35433283	Predicted intracellular proteins	Evidence at protein level	HPA022523	Uncertain				Renal cancer:4.14e-5 (unfavourable)	Mixed	Mixed			spleen: 13.2	Mixed		
CALB2	CAL2	ENSG00000172137	Calbindin 2	16	71358713-71390438	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000106, HPA007305, HPA007306	Enhanced	Supported	Enhanced	Cytosol	Colorectal cancer:5.78e-5 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 54.6;testis: 24.9	adrenal gland: 12.7	Cell line enhanced		HEL: 57.0;HMC-1: 116.3;U-2 OS: 39.2
SLC9C1	NHE, SLC9A10	ENSG00000172139	Solute carrier family 9 member C1	3	112140887-112294258	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Group enriched	10	skin: 2.9;testis: 14.1	thyroid gland: 0.8	Not detected		
OR1A1	OR17-7	ENSG00000172146	Olfactory receptor family 1 subfamily A member 1	17	3215621-3216550	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR1A2	OR17-6	ENSG00000172150	Olfactory receptor family 1 subfamily A member 2	17	3197519-3198448	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8I2		ENSG00000172154	Olfactory receptor family 8 subfamily I member 2	11	56093308-56094240	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LCE1D	LEP4	ENSG00000172155	Late cornified envelope 1D	1	152796751-152798181	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	306	skin: 101.7	skeletal muscle: 0.3	Not detected		
CCL11	eotaxin, MGC22554, SCYA11	ENSG00000172156	C-C motif chemokine ligand 11	17	34285668-34288334	Cancer-related genes, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:1.99e-4 (favourable), Colorectal cancer:8.70e-4 (favourable)	Mixed	Tissue enhanced		appendix: 39.3;small intestine: 37.3	duodenum: 30.8	Cell line enriched	18	BJ hTERT+: 7.2
FRMD3	EPB41L4O, MGC20553	ENSG00000172159	FERM domain containing 3	9	83242990-83538546	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017285	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane	Thyroid cancer:1.79e-4 (favourable), Renal cancer:7.24e-4 (favourable)	Tissue enhanced	Tissue enhanced		heart muscle: 56.5	skeletal muscle: 28.5	Cell line enhanced		HEL: 21.0;RPMI-8226: 54.8;SCLC-21H: 32.9
SNTB1	59-DAP, A1B, BSYN2, SNT2, SNT2B1, TIP-43	ENSG00000172164	Syntrophin beta 1	8	120535745-120813273	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA024659	Uncertain					Expressed in all	Tissue enhanced		adrenal gland: 73.7;thyroid gland: 100.8	liver: 45.3	Cell line enhanced		Hep G2: 61.4;U-266/70: 69.2
MTBP		ENSG00000172167	MDM2 binding protein	8	120445400-120542133	Predicted intracellular proteins	Evidence at protein level	HPA025694, HPA050594	Uncertain		Approved	Nucleus		Mixed	Mixed			testis: 9.1	Mixed		
TEFM	C17orf42, FLJ22729	ENSG00000172171	Transcription elongation factor, mitochondrial	17	30897336-30906820	Predicted intracellular proteins	Evidence at protein level	HPA023788, HPA053044	Approved		Enhanced	Mitochondria	Melanoma:8.64e-4 (unfavourable), Liver cancer:9.20e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 5.6	Expressed in all		
MRPL13	L13, L13A, L13mt, RPL13, RPML13	ENSG00000172172	Mitochondrial ribosomal protein L13	8	120380761-120445402	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060899	Approved				Breast cancer:1.37e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 49.4	Expressed in all		
MALT1	MLT, PCASP1	ENSG00000172175	MALT1 paracaspase	18	58671386-58754477	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004494, HPA048432	Enhanced		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 34.0	Expressed in all		
PRL		ENSG00000172179	Prolactin	6	22287244-22297501	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023353, HPA042416, HPA062017	Enhanced		Uncertain	Cytosol		Not detected	Group enriched	9	endometrium: 10.7;placenta: 27.2	testis: 2.2	Cell line enhanced		Daudi: 11.1;SCLC-21H: 6.5;U-937: 2.1
ISG20	CD25, HEM45	ENSG00000172183	Interferon stimulated exonuclease gene 20	15	88636153-88656483	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.86e-8 (unfavourable), Ovarian cancer:1.85e-5 (favourable), Glioma:3.12e-5 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 221.4	spleen: 136.2	Cell line enhanced		Daudi: 151.0;SK-MEL-30: 543.4
OR4C11	OR4C11P	ENSG00000172188	Olfactory receptor family 4 subfamily C member 11	11	55603354-55604398	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MBOAT1	dJ434O11.1, LPEAT1, MGC44669, OACT1	ENSG00000172197	Membrane bound O-acyltransferase domain containing 1	6	20102145-20212399	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA052996			Approved	Mitochondria	Pancreatic cancer:9.15e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 55.7	Cell line enhanced		HaCaT: 55.4;HEL: 47.2
OR8U1		ENSG00000172199	Olfactory receptor family 8 subfamily U member 1	11	56375624-56376553	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ID4	bHLHb27	ENSG00000172201	Inhibitor of DNA binding 4, HLH protein	6	19837386-19840684	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060800			Supported	Nucleus	Pancreatic cancer:2.49e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 626.0	fallopian tube: 128.5	Cell line enhanced		AF22: 57.9;AN3-CA: 71.8;EFO-21: 163.7;HEK 293: 91.1;SCLC-21H: 185.5
GPR22		ENSG00000172209	G protein-coupled receptor 22	7	107470018-107475659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Group enriched	13	adrenal gland: 1.2;cerebral cortex: 4.7;cervix, uterine: 3.2;endometrium: 2.5;heart muscle: 5.4	smooth muscle: 0.2	Cell line enriched	29	SH-SY5Y: 2.9
CXCR6	BONZO, CD186, STRL33, TYMSTR	ENSG00000172215	C-X-C motif chemokine receptor 6	3	45940933-45948353	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:6.74e-6 (favourable), Renal cancer:2.42e-5 (unfavourable), Head and neck cancer:2.16e-4 (favourable), Cervical cancer:4.92e-4 (favourable)	Mixed	Mixed			lymph node: 17.3	Group enriched	6	BEWO: 2.8;CAPAN-2: 9.8
CEBPB	C/EBP-beta, CRP2, IL6DBP, LAP, NFIL6, TCF5	ENSG00000172216	CCAAT/enhancer binding protein beta	20	50190734-50192689	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004213, HPA061355, HPA062267	Supported		Enhanced	Nucleoplasm	Renal cancer:2.44e-12 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 112.4	Expressed in all		
AZU1	AZAMP, AZU, CAP37, HBP, HUMAZUR, NAZC	ENSG00000172232	Azurocidin 1	19	825097-832018	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055851	Enhanced					Mixed	Tissue enriched	525	bone marrow: 1311.2	skin: 2.4	Cell line enriched	6	THP-1: 722.4
TPSAB1	TPS1, TPS2, TPSB1	ENSG00000172236	Tryptase alpha/beta 1	16	1240696-1242554	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016369, CAB022175, HPA049153, HPA049554	Supported				Head and neck cancer:9.62e-6 (favourable)	Mixed	Tissue enhanced		gallbladder: 211.6	lung: 158.5	Cell line enriched	163	HMC-1: 3406.5
ATOH1	bHLHa14, HATH1, MATH-1, Math1	ENSG00000172238	Atonal bHLH transcription factor 1	4	93828753-93830964	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Colorectal cancer:3.26e-5 (favourable)	Tissue enhanced	Group enriched	9	colon: 17.6;duodenum: 11.1;rectum: 19.7;small intestine: 22.4	appendix: 1.9	Not detected		
PAIP1		ENSG00000172239	Poly(A) binding protein interacting protein 1	5	43526267-43557758	Predicted intracellular proteins	Evidence at protein level	HPA073653, HPA076187	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:4.79e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 153.0	Expressed in all		
CLEC7A	CD369, CLECSF12, dectin-1, hDectin-1, SCARE2	ENSG00000172243	C-type lectin domain family 7 member A	12	10116777-10130258	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043244, HPA050229			Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.31e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 65.6	bone marrow: 53.3	Group enriched	15	Karpas-707: 144.0;U-266/84: 116.1
C5orf34	FLJ32363	ENSG00000172244	Chromosome 5 open reading frame 34	5	43486701-43515145	Predicted intracellular proteins	Evidence at protein level	HPA045386	Approved				Endometrial cancer:2.65e-6 (unfavourable)	Expressed in all	Tissue enhanced		testis: 7.7	prostate: 3.9	Mixed		
C1QTNF4	CTRP4, ZACRP4	ENSG00000172247	C1q and tumor necrosis factor related protein 4	11	47589664-47594659	Predicted secreted proteins	Evidence at protein level	HPA041032	Approved					Mixed	Tissue enriched	5	cerebral cortex: 28.2	parathyroid gland: 5.2	Cell line enriched	6	REH: 10.4
NEGR1	IGLON4, KILON, MGC46680, Ntra	ENSG00000172260	Neuronal growth regulator 1	1	71395940-72282734	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA011894	Uncertain		Approved	Vesicles<br>Actin filaments<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 54.3	gallbladder: 16.9	Mixed		
ZNF131	pHZ-10, ZBTB35	ENSG00000172262	Zinc finger protein 131	5	43065176-43192021	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007023, HPA027748, HPA074630	Approved		Enhanced	Nucleoplasm<br>Intermediate filaments	Liver cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.4	Expressed in all		
MACROD2	C20orf133, dJ631M13.5	ENSG00000172264	MACRO domain containing 2	20	13995369-16053197	Predicted intracellular proteins	Evidence at protein level	HPA049076	Enhanced		Supported	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Mixed			lung: 16.2	Cell line enhanced		EFO-21: 14.4;Karpas-707: 13.4;SCLC-21H: 12.6
DPAGT1	ALG7, CDG-Ij, D11S366, DGPT, DPAGT, DPAGT2, GPT	ENSG00000172269	Dolichyl-phosphate N-acetylglucosaminephosphotransferase 1	11	119096503-119108331	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053878	Approved				Liver cancer:2.03e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 25.5	Expressed in all		
BSG	CD147, EMMPRIN, OK	ENSG00000172270	Basigin (Ok blood group)	19	571277-583493	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002427, HPA036048, HPA074870	Enhanced		Approved	Vesicles	Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 593.5	Expressed in all		
HINFP	DKFZP434F162, HiNF-P, MIZF, ZNF743	ENSG00000172273	Histone H4 transcription factor	11	119121587-119136044	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061008	Uncertain				Liver cancer:4.44e-8 (unfavourable), Thyroid cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			testis: 11.9	Expressed in all		
CDY1	CDY1A	ENSG00000172288	Chromodomain Y-linked 1	Y	25622162-25624902	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 1.0	all non-specific tissues: 0.0	Not detected		
OR10V1		ENSG00000172289	Olfactory receptor family 10 subfamily V member 1	11	59712823-59713864	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA060076	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CERS6	LASS6	ENSG00000172292	Ceramide synthase 6	2	168455862-168775137	Predicted membrane proteins	Evidence at protein level	HPA044683, HPA063527	Approved		Supported	Nucleus	Liver cancer:1.10e-4 (unfavourable), Endometrial cancer:7.31e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 43.5	Mixed		
SPTLC3	C20orf38, FLJ11112, hLCB2b, LCB2B, SPTLC2L	ENSG00000172296	Serine palmitoyltransferase long chain base subunit 3	20	13008979-13169103	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044247, HPA048079	Enhanced		Approved	Microtubules	Renal cancer:4.51e-7 (favourable), Pancreatic cancer:6.02e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 40.8	Cell line enhanced		RPTEC TERT1: 33.2;U-87 MG: 56.0
COPRS	C17orf79, COPR5, HSA272196, TTP1	ENSG00000172301	Coordinator of PRMT5 and differentiation stimulator	17	31851864-31859337	Predicted intracellular proteins	Evidence at protein level	HPA052552	Approved		Supported	Nucleus<br>Plasma membrane<br>Cytosol	Liver cancer:3.69e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 268.0	Expressed in all		
TP53RK	BUD32, C20orf64, dJ101A2.2, Nori-2p, prpk	ENSG00000172315	TP53 regulating kinase	20	46684365-46689779	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004688, HPA015837	Approved				Liver cancer:6.27e-5 (unfavourable), Endometrial cancer:6.70e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 16.6	Expressed in all		
B3GALT1	beta3Gal-T1	ENSG00000172318	Beta-1,3-galactosyltransferase 1	2	167868948-167874041	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 5.2;colon: 3.7;rectum: 4.0	skeletal muscle: 1.8	Cell line enriched	7	AN3-CA: 33.1
OR5A1	OR5A1P, OST181	ENSG00000172320	Olfactory receptor family 5 subfamily A member 1	11	59443144-59444194	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
CLEC12A	CD371, CLL-1, DCAL-2, MICL	ENSG00000172322	C-type lectin domain family 12 member A	12	9951316-9995694	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048515	Enhanced				Urothelial cancer:9.33e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 51.3	spleen: 26.6	Group enriched	7	HL-60: 17.3;U-937: 52.2
OR5A2		ENSG00000172324	Olfactory receptor family 5 subfamily A member 2	11	59421943-59422976	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047135, HPA049575	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BPGM		ENSG00000172331	Bisphosphoglycerate mutase	7	134646808-134679813	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016493, HPA028735	Enhanced		Approved	Nucleoli	Renal cancer:1.54e-8 (favourable), Cervical cancer:7.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 65.1	Expressed in all		
POP7	RPP2, RPP20	ENSG00000172336	POP7 homolog, ribonuclease P/MRP subunit	7	100706053-100707495	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021007	Uncertain		Supported	Nucleoli<br>Vesicles	Liver cancer:4.99e-5 (unfavourable), Renal cancer:6.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 41.1	Expressed in all		
ALG14	MGC19780	ENSG00000172339	ALG14, UDP-N-acetylglucosaminyltransferase subunit	1	94974407-95072945	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA031829	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			thyroid gland: 2.9	Mixed		
SUCLG2		ENSG00000172340	Succinate-CoA ligase GDP-forming beta subunit	3	67360460-67654614	Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046705, HPA051998	Enhanced		Supported	Plasma membrane<br>Mitochondria	Renal cancer:2.79e-10 (favourable), Colorectal cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			colon: 168.2	Expressed in all		
STARD5	MGC10327	ENSG00000172345	StAR related lipid transfer domain containing 5	15	81309053-81324183	Predicted intracellular proteins	Evidence at protein level	HPA040662	Approved		Approved	Vesicles<br>Cytosol		Mixed	Mixed			skin: 9.4	Cell line enhanced		HMC-1: 5.2;U-266/70: 5.5;U-937: 5.4
CSDC2	PIPPin	ENSG00000172346	Cold shock domain containing C2	22	41560763-41577741	Predicted intracellular proteins	Evidence at protein level	HPA003073, HPA076549	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.42e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 62.5;ovary: 72.0	heart muscle: 45.3	Cell line enriched	6	U-2 OS: 40.5
RCAN2	DSCR1L1, ZAKI-4	ENSG00000172348	Regulator of calcineurin 2	6	46220736-46491972	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053880	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.12e-6 (favourable), Pancreatic cancer:2.48e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 145.4	Group enriched	6	fHDF/TERT166: 49.1;HDLM-2: 120.1
IL16	FLJ16806, FLJ42735, HsT19289, IL-16, LCF, prIL-16	ENSG00000172349	Interleukin 16	15	81159575-81314058	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005247, HPA018467	Enhanced		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		lymph node: 154.4;tonsil: 124.0	spleen: 118.2	Cell line enhanced		HEL: 26.3;HMC-1: 44.5;RPMI-8226: 34.9;U-266/70: 45.9;U-937: 27.4
ABCG4	WHITE2	ENSG00000172350	ATP binding cassette subfamily G member 4	11	119149012-119162653	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA040312	Uncertain					Not detected	Group enriched	6	cerebral cortex: 6.6;parathyroid gland: 4.1;testis: 5.1	seminal vesicle: 0.8	Cell line enhanced		AN3-CA: 1.7;HAP1: 1.0
CDY1B		ENSG00000172352	Chromodomain Y-linked 1B	Y	24045229-24048019	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	40	testis: 4.0	all non-specific tissues: 0.0	Not detected		
GNB2		ENSG00000172354	G protein subunit beta 2	7	100673531-100679174	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010032, HPA040736	Approved		Enhanced	Plasma membrane		Expressed in all	Expressed in all			esophagus: 235.4	Expressed in all		
CFAP53	CCDC11, FLJ32743	ENSG00000172361	Cilia and flagella associated protein 53	18	50227193-50266522	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040595, HPA041069, HPA066142	Enhanced		Approved	Midbody	Renal cancer:5.85e-4 (favourable)	Mixed	Group enriched	12	fallopian tube: 44.6;testis: 127.0	epididymis: 6.9	Cell line enhanced		hTERT-HME1: 3.5
OR5B12	OR5B12P, OR5B16, OST743	ENSG00000172362	Olfactory receptor family 5 subfamily B member 12	11	58439120-58440173	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5B2	OST073	ENSG00000172365	Olfactory receptor family 5 subfamily B member 2	11	58422265-58423313	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
MCRIP2	C16orf14, FAM195A, MGC15416	ENSG00000172366	MAPK regulated corepressor interacting protein 2	16	636817-648474	Predicted intracellular proteins	Evidence at protein level	HPA060363	Uncertain				Renal cancer:1.45e-5 (favourable), Urothelial cancer:7.23e-4 (favourable)	Expressed in all	Mixed			colon: 10.8	Mixed		
PDZD3	FLJ22756, IKEPP, PDZK2	ENSG00000172367	PDZ domain containing 3	11	119185457-119190223	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		duodenum: 17.3;kidney: 10.8;small intestine: 21.2	rectum: 6.7	Not detected		
C2CD2L	KIAA0285, TMEM24	ENSG00000172375	C2CD2 like	11	119102198-119118544	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA011044	Approved		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol	Renal cancer:1.75e-4 (unfavourable), Endometrial cancer:4.92e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.6	Expressed in all		
OR9I1		ENSG00000172377	Olfactory receptor family 9 subfamily I member 1	11	58118500-58119444	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ARNT2	bHLHe1, KIAA0307	ENSG00000172379	Aryl hydrocarbon receptor nuclear translocator 2	15	80404350-80597937	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001056, CAB005081	Enhanced		Supported	Nucleus	Pancreatic cancer:1.46e-6 (favourable), Renal cancer:7.51e-4 (favourable)	Expressed in all	Tissue enriched	8	cerebral cortex: 153.7	testis: 18.8	Mixed		
GNG12		ENSG00000172380	G protein subunit gamma 12	1	67701466-67833467	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA057790, HPA062208	Enhanced		Approved	Mitochondria		Expressed in all	Mixed			duodenum: 122.4	Mixed		
PRSS27	CAPH2, MPN	ENSG00000172382	Protease, serine 27	16	2712418-2720551	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB024920	Approved					Tissue enhanced	Tissue enriched	7	esophagus: 210.7	tonsil: 28.1	Cell line enhanced		BEWO: 6.1;SK-BR-3: 18.9;T-47d: 14.0
MYOZ2	C4orf5, CS-1	ENSG00000172399	Myozenin 2	4	119135784-119187789	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035763, HPA035764	Enhanced		Approved	Nucleus<br>Cytosol		Tissue enhanced	Tissue enriched	8	heart muscle: 500.2	skeletal muscle: 63.4	Cell line enhanced		HSkMC: 1.6;SK-MEL-30: 4.7;U-87 MG: 6.0
SYNPO2	MYOPODIN	ENSG00000172403	Synaptopodin 2	4	118850688-119061247	Predicted intracellular proteins	Evidence at protein level	HPA030665, CAB037231, HPA049707, HPA068563	Enhanced		Supported	Vesicles<br>Actin filaments<br>Cytosol	Renal cancer:5.67e-5 (unfavourable), Urothelial cancer:3.91e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 421.3	smooth muscle: 342.7	Cell line enhanced		fHDF/TERT166: 44.3;SH-SY5Y: 89.5
DNAJB7	HSC3	ENSG00000172404	DnaJ heat shock protein family (Hsp40) member B7	22	40859549-40862126	Predicted intracellular proteins	Evidence at transcript level	HPA000534	Approved					Not detected	Tissue enriched	19	testis: 10.9	duodenum,small intestine: 0.5	Not detected		
CLP1	hClp1, HEAB	ENSG00000172409	Cleavage and polyadenylation factor I subunit 1	11	57648992-57661868	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057770	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 17.0	Expressed in all		
INSL5		ENSG00000172410	Insulin like 5	1	66797741-66801256	Predicted secreted proteins	Evidence at protein level	HPA030100, CAB033849	Enhanced					Group enriched	Group enriched	228	colon: 77.7;rectum: 141.9	cerebral cortex: 0.4	Not detected		
EFCAB3	FLJ25818	ENSG00000172421	EF-hand calcium binding domain 3	17	62343941-62416479	Predicted intracellular proteins	Evidence at protein level	HPA046862	Uncertain					Not detected	Tissue enriched	24	testis: 10.5	adipose tissue: 0.4	Not detected		
TTC36	HBP21	ENSG00000172425	Tetratricopeptide repeat domain 36	11	118527472-118531197	Predicted intracellular proteins	Evidence at protein level	HPA038731	Enhanced		Uncertain	Nucleoplasm	Liver cancer:1.81e-5 (favourable)	Group enriched	Tissue enhanced		liver: 64.4	epididymis: 15.5	Cell line enhanced		SK-BR-3: 5.3
RSPH9	C6orf206, CILD12, FLJ30845, MRPS18AL1	ENSG00000172426	Radial spoke head 9 homolog	6	43645046-43672599	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031703	Enhanced					Mixed	Group enriched	6	fallopian tube: 13.4;testis: 12.2	lung: 2.0	Cell line enhanced		U-87 MG: 2.1
COPS9	CSNAP, MYEOV2	ENSG00000172428	COP9 signalosome subunit 9	2	240126563-240136807	Predicted intracellular proteins	Evidence at protein level	HPA044845	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 192.2	Expressed in all		
GTPBP2		ENSG00000172432	GTP binding protein 2	6	43605316-43629162	Predicted intracellular proteins	Evidence at protein level	HPA031418, HPA031419	Approved		Enhanced	Vesicles	Renal cancer:1.44e-15 (unfavourable), Liver cancer:1.08e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 47.4	Expressed in all		
FGGY	FLJ10986	ENSG00000172456	FGGY carbohydrate kinase domain containing	1	59296638-59810647	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA054971			Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			epididymis: 44.3	Cell line enhanced		HDLM-2: 39.7
OR9G4		ENSG00000172457	Olfactory receptor family 9 subfamily G member 4	11	56742827-56743811	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IL17D	FLJ30846, IL-17D, IL-22, IL-27, IL27	ENSG00000172458	Interleukin 17D	13	20702127-20723098	Predicted secreted proteins	Evidence at protein level							Group enriched	Group enriched	7	cerebral cortex: 100.2;skeletal muscle: 45.9	ovary: 10.2	Mixed		
FUT9	Fuc-TIX	ENSG00000172461	Fucosyltransferase 9	6	96015984-96215612	Predicted membrane proteins	Evidence at protein level	HPA070923			Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol		Tissue enhanced	Group enriched	12	cerebral cortex: 28.1;stomach: 22.4	duodenum: 2.0	Cell line enhanced		MCF7: 2.2;RT4: 5.1;SCLC-21H: 7.5;SK-BR-3: 2.7
OR5AP2		ENSG00000172464	Olfactory receptor family 5 subfamily AP member 2	11	56641466-56642471	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TCEAL1	p21, pp21, SIIR, WEX9	ENSG00000172465	Transcription elongation factor A like 1	X	103628704-103630953	Predicted intracellular proteins	Evidence at protein level	HPA057345, HPA060384			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 146.5	Mixed		
ZNF24	KOX17, Zfp191, ZNF191, ZSCAN3	ENSG00000172466	Zinc finger protein 24	18	35332212-35345482	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024062, CAB025642	Supported		Supported	Nucleus	Renal cancer:1.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 56.6	Expressed in all		
HSFY1	HSF2L, HSFY	ENSG00000172468	Heat shock transcription factor, Y-linked 1	Y	18546671-18588963	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	93	testis: 24.8	epididymis,kidney,skin: 0.2	Not detected		
MANEA	FLJ12838, mandaselin	ENSG00000172469	Mannosidase endo-alpha	6	95577543-95609457	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011046, HPA011069	Enhanced		Supported	Golgi apparatus	Colorectal cancer:3.04e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 19.4	Expressed in all		
RAB40A	Rar-2, RAR2A	ENSG00000172476	RAB40A, member RAS oncogene family	X	103499130-103519489	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 9.8;esophagus: 7.8	prostate,testis: 5.9	Cell line enhanced		AF22: 3.3;NTERA-2: 3.7
C2orf54	FLJ22671	ENSG00000172478	Chromosome 2 open reading frame 54	2	240886048-240896889	Predicted intracellular proteins	Evidence at protein level	HPA052722			Approved	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:2.77e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 112.1;skin: 51.5	tonsil: 25.5	Group enriched	7	CACO-2: 49.6;HaCaT: 39.3;SK-BR-3: 116.4
AGXT	AGT, AGT1, AGXT1, PH1, SPAT, SPT	ENSG00000172482	Alanine-glyoxylate aminotransferase	2	240868479-240880502	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035370, HPA035371	Enhanced		Supported	Vesicles	Liver cancer:5.92e-5 (favourable)	Tissue enriched	Tissue enriched	58	liver: 611.6	kidney: 10.4	Cell line enhanced		Hep G2: 5.6;SK-BR-3: 1.1
OR8J1		ENSG00000172487	Olfactory receptor family 8 subfamily J member 1	11	56360215-56361288	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5T3	OR5T3Q	ENSG00000172489	Olfactory receptor family 5 subfamily T member 3	11	56252200-56253222	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA044986	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AFF1	AF-4, AF4, MLLT2, PBM1	ENSG00000172493	AF4/FMR2 family member 1	4	86935002-87141054	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA069947			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 91.6	Expressed in all		
ACOT12	Cach, STARD15, THEAL	ENSG00000172497	Acyl-CoA thioesterase 12	5	81330005-81394179	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037723, HPA037724			Approved	Nucleoplasm<br>Cytosol	Liver cancer:5.30e-4 (favourable)	Tissue enriched	Tissue enriched	19	liver: 51.3	kidney: 2.7	Not detected		
FIBP	FGFIBP	ENSG00000172500	FGF1 intracellular binding protein	11	65883741-65888539	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011729	Approved		Supported	Nuclear speckles	Liver cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
CARNS1	ATPGD1, KIAA1394	ENSG00000172508	Carnosine synthase 1	11	67414968-67425607	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038569	Enhanced					Group enriched	Group enriched	11	cerebral cortex: 37.1;skeletal muscle: 25.9	heart muscle: 2.9	Cell line enriched	10	RPMI-8226: 5.3
OR10H5		ENSG00000172519	Olfactory receptor family 10 subfamily H member 5	19	15793951-15795082	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BANP	BEND1, DKFZp761H172, FLJ10177, FLJ20538, SMAR1, SMARBP1	ENSG00000172530	BTG3 associated nuclear protein	16	87949244-88077318	Predicted intracellular proteins	Evidence at protein level	HPA047164	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 14.1	Expressed in all		
PPP1CA	PP-1A, PP1A, PP1alpha, PPP1A	ENSG00000172531	Protein phosphatase 1 catalytic subunit alpha	11	67398183-67421183	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB004545, HPA046833	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Thyroid cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 166.4	Expressed in all		
HCFC1	CFF, HCF-1, HCF1, HFC1, MGC70925, MRX3, PPP1R89, VCAF	ENSG00000172534	Host cell factor C1	X	153947553-153971807	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018312			Supported	Nucleoplasm<br>Mitochondria	Liver cancer:4.31e-6 (unfavourable), Pancreatic cancer:9.62e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 24.6	Expressed in all		
FAM170B	C10orf73, Em:AC084727.4	ENSG00000172538	Family with sequence similarity 170 member B	10	49131154-49134008	Predicted intracellular proteins	Evidence at protein level	HPA043899, HPA050610	Uncertain					Not detected	Tissue enriched	75	testis: 7.4	all non-specific tissues: 0.0	Not detected		
CTSW		ENSG00000172543	Cathepsin W	11	65879809-65883741	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB016345	Enhanced				Endometrial cancer:8.36e-6 (favourable), Renal cancer:8.84e-6 (unfavourable), Breast cancer:3.06e-4 (favourable), Head and neck cancer:9.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 70.6;spleen: 60.4	lung: 36.5	Group enriched	20	HEL: 149.5;NB-4: 242.5
NIPAL4	ICHYN	ENSG00000172548	NIPA like domain containing 4	5	157460019-157474717	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038259	Approved				Urothelial cancer:6.82e-4 (favourable)	Tissue enhanced	Tissue enhanced		skin: 41.9	esophagus: 10.2	Group enriched	10	hTCEpi: 21.3;RT4: 80.1
MUCL1	SBEM	ENSG00000172551	Mucin like 1	12	54830519-54858393	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039093	Enhanced					Tissue enriched	Tissue enriched	43	breast: 3798.1	salivary gland: 89.1	Cell line enhanced		MCF7: 1.5;SK-BR-3: 3.5
SNTG2	G2SYN, SYN5	ENSG00000172554	Syntrophin gamma 2	2	950868-1367613	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 2.5;testis: 2.4	adipose tissue,endometrium: 2.0	Cell line enhanced		Daudi: 1.1;HAP1: 1.8;NTERA-2: 2.1;SCLC-21H: 2.3
FNDC9	C5orf40, MGC27121	ENSG00000172568	Fibronectin type III domain containing 9	5	157341600-157345721	Predicted membrane proteins	Evidence at transcript level	HPA011115, HPA017291	Approved					Tissue enriched	Group enriched	18	adrenal gland: 6.2;cerebral cortex: 20.7	appendix: 0.7	Not detected		
PDE3A	CGI-PDE	ENSG00000172572	Phosphodiesterase 3A	12	20369245-20684381	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014492	Uncertain		Supported	Cytosol	Renal cancer:1.72e-6 (unfavourable)	Expressed in all	Mixed			heart muscle: 35.4	Group enriched	8	AF22: 15.4;HEL: 26.9;HeLa: 53.3;HUVEC TERT2: 11.9;SH-SY5Y: 31.0;U-138 MG: 22.1
RASGRP1	CalDAG-GEFII, RASGRP	ENSG00000172575	RAS guanyl releasing protein 1	15	38488103-38565575	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA039389			Supported	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 28.4;lymph node: 25.0	tonsil: 15.2	Cell line enhanced		HDLM-2: 50.5;MOLT-4: 41.7
KLHL6	FLJ00029	ENSG00000172578	Kelch like family member 6	3	183487531-183555689	Predicted intracellular proteins	Evidence at protein level	HPA024512	Uncertain				Renal cancer:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		lymph node: 35.1;tonsil: 28.7	appendix: 16.0	Cell line enhanced		Daudi: 29.8;U-266/70: 62.9;U-266/84: 32.1;U-698: 86.1
CHCHD1	C10orf34, FLJ25854	ENSG00000172586	Coiled-coil-helix-coiled-coil-helix domain containing 1	10	73782047-73783652	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039046	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center<br>Mitochondria	Urothelial cancer:5.42e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 62.7	Expressed in all		
MRPL52		ENSG00000172590	Mitochondrial ribosomal protein L52	14	22829879-22835037	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA012319	Approved		Approved	Mitochondria		Expressed in all	Expressed in all			appendix: 72.1	Expressed in all		
SMPDL3A	ASM3A, ASML3a, FLJ20177, yR36GH4.1	ENSG00000172594	Sphingomyelin phosphodiesterase acid like 3A	6	122789049-122809720	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030148	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria	Colorectal cancer:6.11e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 81.9	Mixed		
RND1	ARHS, Rho6, RHOS	ENSG00000172602	Rho family GTPase 1	12	48857145-48865898	Predicted intracellular proteins	Evidence at protein level	HPA077800			Supported	Vesicles<br>Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		cerebral cortex: 39.8;liver: 31.1	gallbladder: 23.6	Cell line enriched	6	SK-BR-3: 51.2
RAD9A	RAD9	ENSG00000172613	RAD9 checkpoint clamp component A	11	67317871-67398410	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006725, HPA048155	Enhanced		Enhanced	Nucleoplasm	Urothelial cancer:7.52e-6 (favourable), Renal cancer:2.82e-5 (unfavourable), Cervical cancer:6.95e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 15.0	Mixed		
EFEMP2	FBLN4, UPH1	ENSG00000172638	EGF containing fibulin like extracellular matrix protein 2	11	65866441-65873592	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023270	Approved				Renal cancer:3.94e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 50.3	Cell line enhanced		BJ hTERT+: 106.7;fHDF/TERT166: 149.3;LHCN-M2: 95.3
OR10AD1	OR10AD1P	ENSG00000172640	Olfactory receptor family 10 subfamily AD member 1	12	48202083-48203387	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049913	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
AGAP5	CTGLF2, Em:AC073389.1	ENSG00000172650	ArfGAP with GTPase domain, ankyrin repeat and PH domain 5	10	73674285-73698159	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain					Not detected	Mixed			testis: 11.6	Expressed in all		
WASHC2C	Em:AC012044.3, FAM21C, KIAA0592	ENSG00000172661	WASH complex subunit 2C	10	45727200-45792961	Predicted intracellular proteins	Evidence at protein level	HPA047844, HPA060975, HPA061022	Supported		Supported	Nucleoli<br>Vesicles<br>Cytosol	Liver cancer:1.35e-5 (unfavourable), Lung cancer:4.69e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 41.9	Expressed in all		
TMEM134	FLJ21749	ENSG00000172663	Transmembrane protein 134	11	67461710-67469272	Predicted membrane proteins	Evidence at protein level	HPA043744	Approved		Supported	Cytosol		Expressed in all	Expressed in all			skin: 38.5	Expressed in all		
ZMAT3	FLJ12296, MGC10613, PAG608, WIG-1, WIG1	ENSG00000172667	Zinc finger matrin-type 3	3	179017223-179072279	Predicted intracellular proteins	Evidence at protein level	HPA027569, HPA028671, HPA054356	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 29.0	Expressed in all		
ZFAND4	ANUBL1, FLJ40185	ENSG00000172671	Zinc finger AN1-type containing 4	10	45615501-45672780	Predicted intracellular proteins	Evidence at transcript level	HPA037839, HPA057543	Uncertain		Approved	Golgi apparatus		Expressed in all	Tissue enriched	13	testis: 95.4	lymph node: 7.5	Cell line enhanced		Daudi: 32.0
THEMIS	bA325O24.3, bA325O24.4, C6orf190, C6orf207, FLJ40584, TSEPA	ENSG00000172673	Thymocyte selection associated	6	127708072-127918631	Predicted intracellular proteins	Evidence at protein level	HPA031422, HPA031425	Enhanced					Mixed	Tissue enhanced		lymph node: 8.4	cerebral cortex,spleen: 4.5	Cell line enhanced		HDLM-2: 30.2;MOLT-4: 41.2;RPMI-8226: 15.0
MOS		ENSG00000172680	MOS proto-oncogene, serine/threonine kinase	8	56112942-56113982	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040424	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
ZNF738		ENSG00000172687	Zinc finger protein 738	19	21358930-21379302	Predicted intracellular proteins	Evidence at protein level	HPA059135	Uncertain				Ovarian cancer:2.27e-4 (favourable)	Mixed	Mixed			ovary: 11.7	Mixed		
MS4A10	CD20L7, MS4A9	ENSG00000172689	Membrane spanning 4-domains A10	11	60785348-60801305	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA014778	Uncertain					Not detected	Group enriched	193	duodenum: 74.2;small intestine: 95.8	kidney: 0.4	Not detected		
SLFN11	FLJ34922	ENSG00000172716	Schlafen family member 11	17	35350305-35373701	Predicted intracellular proteins	Evidence at protein level	HPA023030, HPA062062	Uncertain		Enhanced	Nucleoplasm	Renal cancer:9.93e-10 (unfavourable)	Expressed in all	Expressed in all			lung: 56.0	Mixed		
FAM71D	C14orf54	ENSG00000172717	Family with sequence similarity 71 member D	14	67189393-67228550	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	34	testis: 24.1	skin: 0.7	Cell line enhanced		U-2 OS: 1.1
CCL19	CKb11, ELC, exodus-3, MIP-3b, SCYA19	ENSG00000172724	C-C motif chemokine ligand 19	9	34689567-34691277	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA067758	Enhanced				Renal cancer:8.63e-7 (unfavourable), Cervical cancer:9.91e-6 (favourable), Breast cancer:2.88e-5 (favourable)	Expressed in all	Group enriched	5	adipose tissue: 173.8;appendix: 771.8;lymph node: 703.2;tonsil: 556.0	gallbladder: 107.9	Cell line enhanced		HDLM-2: 2.9;TIME: 1.2
CORO1B	coronin-2	ENSG00000172725	Coronin 1B	11	67435510-67443821	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017616, HPA040113, HPA070456	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:1.65e-4 (favourable)	Expressed in all	Expressed in all			prostate: 85.9	Mixed		
FUT10		ENSG00000172728	Fucosyltransferase 10	8	33370824-33473422	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053970, HPA058655	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Golgi apparatus		Mixed	Mixed			parathyroid gland: 8.7	Mixed		
LRRC20	FLJ10751, FLJ10844	ENSG00000172731	Leucine rich repeat containing 20	10	70298970-70382650	Predicted intracellular proteins	Evidence at protein level	HPA039630			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.41e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 120.5	heart muscle: 28.5	Cell line enhanced		U-2 OS: 83.3
MUS81	FLJ44872, SLX3	ENSG00000172732	MUS81 structure-specific endonuclease subunit	11	65857126-65867653	Predicted intracellular proteins	Evidence at protein level	HPA059530	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.0	Expressed in all		
PURG	PURG-A, PURG-B	ENSG00000172733	Purine rich element binding protein G	8	30995802-31033715	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047746	Uncertain		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;testis: 4.8	endometrium: 2.6	Cell line enhanced		AF22: 6.0;NTERA-2: 4.8;SH-SY5Y: 6.0
TMEM217	C6orf128, dJ355M6.2	ENSG00000172738	Transmembrane protein 217	6	37212180-37258155	Predicted membrane proteins	Evidence at protein level	HPA045432, HPA071187, HPA074578			Supported	Nucleoli		Mixed	Tissue enriched	14	testis: 14.2	adrenal gland: 1.0	Cell line enhanced		HEL: 3.0;HUVEC TERT2: 2.8;TIME: 7.2
OR4D9		ENSG00000172742	Olfactory receptor family 4 subfamily D member 9	11	59514913-59515857	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF596		ENSG00000172748	Zinc finger protein 596	8	232137-264703	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055463	Uncertain		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 27.8	parathyroid gland: 12.9	Mixed		
COL6A5	COL29A1, FLJ35880, VWA4	ENSG00000172752	Collagen type VI alpha 5 chain	3	130345516-130484844	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA043138	Uncertain					Not detected	Group enriched	6	lung: 3.8;skin: 7.4	duodenum,stomach: 0.9	Cell line enriched	73	HDLM-2: 14.7
CFL1	CFL	ENSG00000172757	Cofilin 1	11	65823022-65862026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033687, CAB037077, HPA053761	Approved				Liver cancer:1.73e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 1225.4	Expressed in all		
TMCC1	KIAA0779	ENSG00000172765	Transmembrane and coiled-coil domain family 1	3	129647792-129893576	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053894	Uncertain				Renal cancer:1.77e-6 (unfavourable), Pancreatic cancer:1.87e-4 (unfavourable), Liver cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
NAA16	FLJ22054, MGC40612, NARG1L, PRO2435	ENSG00000172766	N(alpha)-acetyltransferase 16, NatA auxiliary subunit	13	41311205-41377030	Predicted intracellular proteins	Evidence at protein level	HPA039761, HPA040157	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			bone marrow: 14.4	Expressed in all		
OR5B3	OR5B13, OST129	ENSG00000172769	Olfactory receptor family 5 subfamily B member 3	11	58402464-58403409	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
EFCAB12	C3orf25	ENSG00000172771	EF-hand calcium binding domain 12	3	129401321-129428651	Predicted intracellular proteins	Evidence at protein level	HPA037694	Uncertain	Supported				Mixed	Group enriched	5	fallopian tube: 31.3;testis: 6.7	prostate: 3.7	Cell line enhanced		Hep G2: 1.0;SCLC-21H: 1.0
OR10W1	OR10W1P	ENSG00000172772	Olfactory receptor family 10 subfamily W member 1	11	58266792-58268260	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FAM192A	C16orf94, NIP30	ENSG00000172775	Family with sequence similarity 192 member A	16	57152466-57186116	Predicted intracellular proteins	Evidence at protein level	HPA054382, HPA059652	Uncertain		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 175.9	Expressed in all		
RAB43	ISY1, RAB11B, RAB41	ENSG00000172780	RAB43, member RAS oncogene family	3	129087569-129122801	Predicted intracellular proteins	Evidence at protein level	HPA046840, HPA060085	Enhanced		Supported	Plasma membrane		Mixed	Mixed			thyroid gland: 37.3	Mixed		
FADS6		ENSG00000172782	Fatty acid desaturase 6	17	74877299-74893781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA016802	Uncertain					Tissue enhanced	Tissue enhanced		epididymis: 21.9	small intestine: 10.1	Mixed		
CBWD1		ENSG00000172785	COBW domain containing 1	9	121038-179147	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Mixed	Expressed in all			adrenal gland: 44.8	Mixed		
HOXC5	HOX3, HOX3D	ENSG00000172789	Homeobox C5	12	54032853-54035358	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026794	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		fallopian tube: 6.0	ovary: 3.1	Cell line enhanced		AN3-CA: 5.6;SH-SY5Y: 7.0
RAB37		ENSG00000172794	RAB37, member RAS oncogene family	17	74670578-74747335	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:8.80e-6 (unfavourable), Testis cancer:9.27e-4 (unfavourable)	Mixed	Mixed			spleen: 20.9	Cell line enhanced		HEL: 47.0;HMC-1: 48.4;U-266/70: 61.0;U-937: 27.5
DCP2	NUDT20	ENSG00000172795	Decapping mRNA 2	5	112976702-113020970	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011677, HPA057676	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Cytoplasmic bodies	Renal cancer:2.66e-5 (unfavourable), Liver cancer:4.84e-4 (unfavourable)	Expressed in all	Mixed			placenta: 18.9	Expressed in all		
SNX32	FLJ30934, SNX6B	ENSG00000172803	Sorting nexin 32	11	65833641-65856896	Predicted intracellular proteins	Evidence at protein level	HPA041775	Uncertain		Uncertain	Cell Junctions<br>Focal adhesion sites		Mixed	Tissue enhanced		cerebral cortex: 7.7	testis: 1.8	Cell line enhanced		HHSteC: 3.0;HSkMC: 3.4;SH-SY5Y: 1.9;U-266/70: 4.3
RPL38	L38	ENSG00000172809	Ribosomal protein L38	17	74203582-74210655	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA052543	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.17e-8 (unfavourable), Head and neck cancer:2.51e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2584.8	Expressed in all		
CYP7B1	SPG5A	ENSG00000172817	Cytochrome P450 family 7 subfamily B member 1	8	64587763-64798761	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017761	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 40.3	thyroid gland: 22.4	Cell line enhanced		HSkMC: 11.3;SH-SY5Y: 6.2;WM-115: 11.7
OVOL1	HOVO1	ENSG00000172818	Ovo like transcriptional repressor 1	11	65787022-65797219	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003984	Uncertain		Approved	Nucleus	Renal cancer:1.00e-13 (favourable), Endometrial cancer:1.87e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 37.3;skin: 33.4;testis: 35.3	urinary bladder: 15.5	Cell line enhanced		A-431: 16.3;BEWO: 49.5;HaCaT: 27.3;RT4: 24.5;SK-BR-3: 17.8
RARG	NR1B3, RARC	ENSG00000172819	Retinoic acid receptor gamma	12	53210567-53232980	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053883	Supported		Supported	Nucleoplasm	Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable)	Expressed in all	Tissue enhanced		skin: 143.4	esophagus: 77.3	Mixed		
CES4A	CES8, FLJ37464	ENSG00000172824	Carboxylesterase 4A	16	66988589-67009758	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035701	Approved		Approved	Cytosol	Renal cancer:2.35e-6 (unfavourable)	Mixed	Group enriched	7	fallopian tube: 28.9;skin: 9.2	epididymis: 2.7	Cell line enhanced		HDLM-2: 17.6;SiHa: 4.2
CES3	ES31, FLJ21736	ENSG00000172828	Carboxylesterase 3	16	66961237-66975148	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041008, HPA041307	Approved		Approved	Nuclear membrane<br>Endoplasmic reticulum	Liver cancer:7.26e-5 (favourable)	Mixed	Tissue enhanced		colon: 37.2;duodenum: 30.5;rectum: 34.1	small intestine: 26.6	Cell line enhanced		AN3-CA: 7.1
SSH3	FLJ10928, FLJ20515	ENSG00000172830	Slingshot protein phosphatase 3	11	67303448-67312607	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019949, HPA019957	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Actin filaments<br>Cytosol	Pancreatic cancer:2.89e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 37.5	Cell line enhanced		RT4: 69.9
CES2	CE-2, CES2A1, iCE	ENSG00000172831	Carboxylesterase 2	16	66934444-66945096	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018897	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 527.2	Expressed in all		
PDP2	KIAA1348, PPM2B, PPM2C2	ENSG00000172840	Pyruvate dehyrogenase phosphatase catalytic subunit 2	16	66878589-66895754	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019950, HPA062059	Approved		Supported	Mitochondria	Renal cancer:9.75e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 15.5	Expressed in all		
SP3	SPR-2	ENSG00000172845	Sp3 transcription factor	2	173906459-173965702	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004580, HPA032145, HPA032146	Supported	Supported			Renal cancer:2.46e-5 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 91.7	Expressed in all		
KRT2	KRT2A, KRTE	ENSG00000172867	Keratin 2	12	52644558-52652164	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006299, CAB037321	Enhanced		Approved	Golgi apparatus<br>Intermediate filaments<br>Cytosol		Group enriched	Tissue enriched	23	skin: 2600.1	breast: 112.2	Cell line enhanced		HEL: 1.9
DMXL1		ENSG00000172869	Dmx like 1	5	119037772-119249138	Predicted intracellular proteins	Evidence at protein level	HPA036431, HPA036432	Approved		Supported	Nucleoli<br>Cytosol	Renal cancer:5.16e-5 (favourable)	Expressed in all	Mixed			prostate: 43.4	Expressed in all		
METAP1D	MAP1D, Metap1l	ENSG00000172878	Methionyl aminopeptidase type 1D, mitochondrial	2	171999583-172082430	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030298, HPA030299	Uncertain		Supported	Vesicles		Expressed in all	Mixed			ovary: 9.3	Expressed in all		
ZNF621	FLJ45246	ENSG00000172888	Zinc finger protein 621	3	40524878-40574685	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065518, HPA071440			Supported	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 22.6	Expressed in all		
EGFL7	ZNEU1	ENSG00000172889	EGF like domain multiple 7	9	136658856-136672678	Predicted secreted proteins	Evidence at protein level	HPA050716	Approved				Colorectal cancer:4.22e-6 (unfavourable), Renal cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 263.7	Cell line enhanced		EFO-21: 172.9;HUVEC TERT2: 276.0;TIME: 254.4
NADSYN1	FLJ10631	ENSG00000172890	NAD synthetase 1	11	71453109-71524107	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB017798, HPA038523, HPA038524	Approved		Enhanced	Cytosol	Liver cancer:5.17e-6 (unfavourable), Renal cancer:8.72e-5 (unfavourable), Urothelial cancer:5.10e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 41.7	Expressed in all		
DHCR7	SLOS	ENSG00000172893	7-dehydrocholesterol reductase	11	71428193-71452868	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA044280	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 115.2	Expressed in all		
LVRN	APQ, AQPEP, FLJ90650, TAQPEP	ENSG00000172901	Laeverin	5	115962454-116027619	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA053254	Enhanced					Not detected	Group enriched	22	adipose tissue: 11.8;placenta: 31.5	breast: 1.0	Not detected		
NBEA	BCL8B, FLJ10197, KIAA1544, LYST2	ENSG00000172915	Neurobeachin	13	34942287-35673022	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039730, HPA040385	Enhanced		Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:7.86e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 30.3	seminal vesicle: 12.2	Cell line enriched	5	SH-SY5Y: 83.5
RNASEH2C	AGS3, AYP1	ENSG00000172922	Ribonuclease H2 subunit C	11	65714896-65720947	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065375			Approved	Nucleus	Pancreatic cancer:3.68e-5 (favourable), Renal cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.1	Expressed in all		
MYEOV	OCIM	ENSG00000172927	Myeloma overexpressed	11	69294138-69367726	Predicted membrane proteins	Evidence at transcript level	HPA012949	Uncertain		Approved	Nucleus<br>Vesicles	Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable)	Mixed	Group enriched	5	adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 6.8	appendix: 1.0	Cell line enhanced		A-431: 154.1;A549: 74.9;U-2 OS: 38.7
ANKRD13D		ENSG00000172932	Ankyrin repeat domain 13D	11	67288547-67302485	Predicted intracellular proteins	Evidence at protein level	HPA039950	Approved		Approved	Nucleus<br>Mitochondria	Renal cancer:5.73e-10 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 69.4	Expressed in all		
MRGPRF	GPR140, GPR168, MGC21621, mrgF	ENSG00000172935	MAS related GPR family member F	11	69004395-69013409	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA028811	Approved		Supported	Nuclear membrane<br>Plasma membrane		Expressed in all	Mixed			smooth muscle: 78.8	Cell line enhanced		ASC diff: 43.0;BJ: 31.1;BJ hTERT+: 74.9;BJ hTERT+ SV40 Large T+: 31.7;U-2197: 40.5
MYD88		ENSG00000172936	Myeloid differentiation primary response 88	3	38138478-38143022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009104	Approved		Supported	Vesicles<br>Mitochondria<br>Cytosol	Breast cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 57.1	Expressed in all		
MRGPRD	mrgD	ENSG00000172938	MAS related GPR family member D	11	68980021-68980986	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA031346	Uncertain					Not detected	Not detected			seminal vesicle: 0.3	Not detected		
OXSR1	KIAA1101, OSR1	ENSG00000172939	Oxidative stress responsive 1	3	38165089-38255488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008237, CAB017181	Enhanced		Enhanced	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 43.0	Expressed in all		
SLC22A13	OAT10, OCTL1, OCTL3, ORCTL3	ENSG00000172940	Solute carrier family 22 member 13	3	38265812-38278315	Predicted membrane proteins, Transporters	Evidence at protein level	HPA035603, HPA035962	Enhanced					Tissue enriched	Tissue enriched	39	kidney: 10.7	testis: 0.2	Not detected		
PHF8	JHDM1F, KDM7B, KIAA1111, ZNF422	ENSG00000172943	PHD finger protein 8	X	53936676-54048958	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA038779, HPA062015	Approved		Supported	Nucleus	Urothelial cancer:3.74e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 85.8	Expressed in all		
LCLAT1	AGPAT8, ALCAT1, FLJ37965, LYCAT	ENSG00000172954	Lysocardiolipin acyltransferase 1	2	30447226-30644225	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA031880, HPA049217	Uncertain		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 18.8	Expressed in all		
ADH6	ADH-5	ENSG00000172955	Alcohol dehydrogenase 6 (class V)	4	99202638-99219537	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA067946, HPA069081	Enhanced					Tissue enriched	Tissue enriched	7	liver: 359.6	kidney: 53.5	Group enriched	8	Hep G2: 30.3;RPTEC TERT1: 6.8
XKR3	MGC57211, XTES	ENSG00000172967	XK related 3	22	16783412-16821699	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003379, HPA035081	Uncertain					Not detected	Tissue enriched	81	testis: 14.4	cerebral cortex: 0.1	Cell line enriched	12	Karpas-707: 165.9
FRG2C		ENSG00000172969	FSHD region gene 2 family member C	3	75664330-75667220	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Tissue enhanced		testis: 1.0	kidney: 0.6	Cell line enriched	17	HDLM-2: 11.8
KAT5	cPLA2, ESA1, HTATIP, HTATIP1, PLIP, TIP60, ZC2HC5	ENSG00000172977	Lysine acetyltransferase 5	11	65711996-65719604	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016953	Approved		Supported	Nucleoplasm	Renal cancer:1.10e-13 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.4	Expressed in all		
SH3RF3	FLJ00204, POSH2, SH3MD4	ENSG00000172985	SH3 domain containing ring finger 3	2	109129348-109504632	Predicted secreted proteins	Evidence at protein level	HPA044822, HPA048444	Approved		Enhanced	Nucleoplasm<br>Centrosome<br>Cytosol	Ovarian cancer:2.33e-4 (unfavourable)	Expressed in all	Mixed			placenta: 7.6	Cell line enhanced		TIME: 19.3;U-266/84: 20.2
GXYLT2	GLT8D4	ENSG00000172986	Glucoside xylosyltransferase 2	3	72888073-72998138	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA068429	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge<br>Midbody ring	Renal cancer:1.46e-7 (unfavourable), Urothelial cancer:2.42e-5 (unfavourable)	Mixed	Mixed			ovary: 20.6	Cell line enhanced		MOLT-4: 29.2
HPSE2	HPA2, HPR2, UFS	ENSG00000172987	Heparanase 2 (inactive)	10	98457077-99235862	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044603	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 53.4	prostate: 22.8	Group enriched	24	BJ hTERT+: 11.3;HEL: 23.9
DCAKD	FLJ22955	ENSG00000172992	Dephospho-CoA kinase domain containing	17	45023340-45061109	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060997			Approved	Nucleus	Endometrial cancer:7.16e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.1	Expressed in all		
ARPP21	ARPP-21, R3HDM3, TARPP	ENSG00000172995	CAMP regulated phosphoprotein 21	3	35638945-35794496	Predicted intracellular proteins	Evidence at protein level	HPA017303	Enhanced		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	6	cerebral cortex: 127.1	skeletal muscle: 20.2	Group enriched	10	MOLT-4: 54.6;REH: 34.0;RH-30: 19.9
TADA2B	MGC21874	ENSG00000173011	Transcriptional adaptor 2B	4	7041899-7057952	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035770	Approved		Approved	Nuclear speckles	Renal cancer:7.17e-11 (favourable), Urothelial cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
CCDC96	FLJ90575	ENSG00000173013	Coiled-coil domain containing 96	4	7040849-7042939	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047546	Enhanced				Renal cancer:3.80e-5 (favourable), Endometrial cancer:4.05e-4 (favourable), Pancreatic cancer:4.87e-4 (favourable)	Expressed in all	Group enriched	14	fallopian tube: 17.7;testis: 61.7	cerebral cortex,lung: 2.7	Mixed		
GRK2	ADRBK1, BARK1	ENSG00000173020	G protein-coupled receptor kinase 2	11	67266410-67286556	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005021, CAB037248, HPA048330	Approved		Approved	Vesicles	Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 127.3	Expressed in all		
RELA	NFKB3, p65	ENSG00000173039	RELA proto-oncogene, NF-kB subunit	11	65653596-65663094	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004264, CAB005030, HPA063461	Supported		Enhanced	Cytosol	Renal cancer:5.66e-4 (unfavourable), Liver cancer:9.18e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 62.5	Expressed in all		
EVC2	LBN	ENSG00000173040	EvC ciliary complex subunit 2	4	5542772-5709548	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA040910, HPA048122	Uncertain		Approved	Mitochondria	Renal cancer:1.58e-4 (favourable)	Mixed	Mixed			ovary: 8.8	Cell line enhanced		HHSteC: 10.9
ZNF680	FLJ90430	ENSG00000173041	Zinc finger protein 680	7	64519884-64563106	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003173			Approved	Nucleus		Expressed in all	Expressed in all			thyroid gland: 42.5	Mixed		
HECTD4	C12orf51, FLJ34154, KIAA0614	ENSG00000173064	HECT domain E3 ubiquitin protein ligase 4	12	112160188-112382439	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041062, HPA045473	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:2.97e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.4	Expressed in all		
FAM222B	C17orf63, FLJ10700	ENSG00000173065	Family with sequence similarity 222 member B	17	28755978-28855232	Predicted intracellular proteins	Evidence at protein level	HPA051840, HPA062239	Approved		Enhanced	Nucleoplasm	Liver cancer:3.45e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.9	Expressed in all		
BNC2	BSN2, FLJ20043	ENSG00000173068	Basonuclin 2	9	16409503-16870843	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018525, HPA059419	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		endometrium: 44.5;ovary: 39.4;smooth muscle: 48.0	fallopian tube: 19.3	Mixed		
DEC1	CTS9	ENSG00000173077	Deleted in esophageal cancer 1	9	115141818-115402644	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.5	Not detected		
RXFP4	GPCR142, GPR100, RLN3R2, RXFPR4	ENSG00000173080	Relaxin/insulin like family peptide receptor 4	1	155941710-155942949	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 2.0;duodenum: 1.4;rectum: 2.2	small intestine: 1.1	Not detected		
HPSE	HPA, HPSE1, HSE1	ENSG00000173083	Heparanase	4	83292461-83335153	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB009813, HPA055344			Enhanced	Nucleoplasm<br>Vesicles		Mixed	Tissue enhanced		parathyroid gland: 20.0	testis: 10.0	Cell line enhanced		Karpas-707: 27.7
COQ2	CL640, FLJ26072	ENSG00000173085	Coenzyme Q2, polyprenyltransferase	4	83261536-83284914	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA056599, HPA068727	Approved		Approved	Cytosol		Expressed in all	Expressed in all			adrenal gland: 18.4	Expressed in all		
CCDC63	FLJ35843, ODA5	ENSG00000173093	Coiled-coil domain containing 63	12	110846769-110907535	Predicted intracellular proteins	Evidence at protein level	HPA061568			Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Tissue enriched	Tissue enriched	28	testis: 29.6	heart muscle: 1.0	Cell line enriched	14	MCF7: 3.3
HSPA6	HSP70B'	ENSG00000173110	Heat shock protein family A (Hsp70) member 6	1	161524540-161526910	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017452, HPA028549, HPA052504	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.98e-5 (unfavourable), Liver cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 27.8	spleen: 15.1	Cell line enriched	7	Karpas-707: 36.1
TRMT112	HSPC152, HSPC170, hTrm112, TRM112, TRMT11-2	ENSG00000173113	TRNA methyltransferase 11-2 homolog (S. cerevisiae)	11	64316460-64318084	Predicted intracellular proteins	Evidence at protein level	HPA039901, HPA040006	Uncertain		Approved	Nucleus<br>Microtubules	Head and neck cancer:1.62e-4 (unfavourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 306.4	Expressed in all		
LRRN3	FIGLER5, FLJ11129, NLRR3	ENSG00000173114	Leucine rich repeat neuronal 3	7	111091006-111125454	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043820, HPA046792	Uncertain		Approved	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6	lung: 11.6	Cell line enhanced		AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
KDM2A	CXXC8, DKFZP434M1735, FBL11, FBL7, FBXL11, FLJ00115, JHDM1A, KIAA1004, LILINA	ENSG00000173120	Lysine demethylase 2A	11	67119269-67258087	Enzymes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB012272, HPA044251	Supported		Approved	Nucleus		Expressed in all	Expressed in all			testis: 60.0	Expressed in all		
ACSM6	bA310E22.3, C10orf129	ENSG00000173124	Acyl-CoA synthetase medium-chain family member 6	10	95194200-95228928	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA044593	Uncertain				Urothelial cancer:7.71e-4 (favourable)	Tissue enriched	Tissue enhanced		stomach: 1.7	urinary bladder: 0.6	Cell line enriched	27	RT4: 3.0
ADCK5	FLJ35454	ENSG00000173137	AarF domain containing kinase 5	8	144373101-144393242	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA025692, HPA028679	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			duodenum: 9.6	Mixed		
MRPL57	MRP63	ENSG00000173141	Mitochondrial ribosomal protein L57	13	21176645-21179084	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039779, HPA059370	Enhanced		Supported	Mitochondria	Pancreatic cancer:8.35e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 21.8	Expressed in all		
NOC3L	AD24, C10orf117, FAD24, FLJ12820	ENSG00000173145	NOC3 like DNA replication regulator	10	94333226-94362959	Predicted intracellular proteins	Evidence at protein level	HPA063958, HPA067638, HPA070981			Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 19.2	Expressed in all		
ESRRA	ERR1, ERRa, ERRalpha, ESRL1, NR3B1	ENSG00000173153	Estrogen related receptor alpha	11	64305572-64316743	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053785			Supported	Nucleus<br>Nucleoli fibrillar center<br>Microtubules<br>Cytokinetic bridge	Renal cancer:1.34e-7 (favourable)	Expressed in all	Expressed in all			duodenum: 86.6	Expressed in all		
RHOD	ARHD, Rho, RhoD, RhoHP1	ENSG00000173156	Ras homolog family member D	11	67056818-67072013	Predicted intracellular proteins	Evidence at protein level						Lung cancer:3.10e-4 (unfavourable), Cervical cancer:9.17e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 37.0	Cell line enhanced		A-431: 131.9;HaCaT: 116.3;HBEC3-KT: 125.2;hTCEpi: 146.2;T-47d: 136.0
ADAMTS20	GON-1	ENSG00000173157	ADAM metallopeptidase with thrombospondin type 1 motif 20	12	43353866-43551921	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027608, HPA027609	Uncertain					Not detected	Not detected			placenta: 0.8	Cell line enhanced		Karpas-707: 2.6;NTERA-2: 2.8;U-266/70: 3.1;U-266/84: 1.5
COMMD1	C2orf5, MGC27155, MURR1	ENSG00000173163	Copper metabolism domain containing 1	2	61888724-62147247	Predicted intracellular proteins	Evidence at protein level	HPA034633, HPA049223	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 47.8	Expressed in all		
RAPH1	ALS2CR18, ALS2CR9, KIAA1681	ENSG00000173166	Ras association (RalGDS/AF-6) and pleckstrin homology domains 1	2	203394345-203535410	Predicted intracellular proteins	Evidence at protein level	HPA016744, HPA020027	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol		Mixed	Expressed in all			thyroid gland: 50.0	Mixed		
MTX1	MTX, MTXN	ENSG00000173171	Metaxin 1	1	155208699-155213824	Predicted membrane proteins	Evidence at protein level	HPA011543	Uncertain		Supported	Mitochondria	Renal cancer:3.39e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 71.8	Expressed in all		
ADCY5	AC5	ENSG00000173175	Adenylate cyclase 5	3	123282296-123449758	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017730, HPA077682	Uncertain		Enhanced	Intermediate filaments	Renal cancer:7.46e-6 (favourable)	Mixed	Tissue enhanced		heart muscle: 69.1	prostate,seminal vesicle: 30.0	Cell line enhanced		MCF7: 11.9;RPTEC TERT1: 4.0
PARP14	KIAA1268, pART8	ENSG00000173193	Poly(ADP-ribose) polymerase family member 14	3	122680618-122730840	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008846, HPA012063	Supported		Enhanced	Cytosol	Renal cancer:1.79e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.1	Cell line enhanced		BJ hTERT+ SV40 Large T+: 67.0;BJ hTERT+ SV40 Large T+ RasG12V: 107.2
CYSLTR1	CysLT(1), CysLT1, CYSLT1R	ENSG00000173198	Cysteinyl leukotriene receptor 1	X	78271464-78327691	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA010546	Approved					Mixed	Mixed			spleen: 14.8	Cell line enhanced		HL-60: 16.0;NB-4: 17.8;RPMI-8226: 29.5;THP-1: 17.5;U-937: 22.4
PARP15	FLJ40597, pART7	ENSG00000173200	Poly(ADP-ribose) polymerase family member 15	3	122577602-122639047	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035757			Approved	Mitochondria		Mixed	Tissue enhanced		lymph node: 55.0;spleen: 60.4;tonsil: 48.1	appendix: 35.3	Cell line enhanced		HEL: 7.8;TIME: 8.4
CKS1B	CKS1, ckshs1	ENSG00000173207	CDC28 protein kinase regulatory subunit 1B	1	154974653-154979249	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA003424, HPA030762	Approved	Supported	Approved	Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol	Renal cancer:6.03e-7 (unfavourable), Liver cancer:2.94e-5 (unfavourable), Melanoma:3.12e-5 (unfavourable), Thyroid cancer:4.87e-4 (favourable), Pancreatic cancer:6.13e-4 (unfavourable), Endometrial cancer:7.89e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 84.9	Expressed in all		
ABCD2	ALDL1, ALDR, ALDRP	ENSG00000173208	ATP binding cassette subfamily D member 2	12	39550033-39619751	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enhanced		adipose tissue: 16.7	cervix, uterine: 8.5	Group enriched	6	ASC diff: 8.0;HDLM-2: 15.7;Karpas-707: 20.8;SH-SY5Y: 18.5;U-266/70: 7.4
AHSA2	AHA1, DKFZp564C236, Hch1	ENSG00000173209	Activator of HSP90 ATPase homolog 2	2	61177418-61191203	Predicted intracellular proteins	Evidence at protein level	HPA051137	Approved		Approved	Vesicles<br>Microtubules<br>Cytokinetic bridge	Renal cancer:4.11e-6 (unfavourable), Urothelial cancer:1.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.1	Expressed in all		
ABLIM3	KIAA0843	ENSG00000173210	Actin binding LIM protein family member 3	5	149141483-149260542	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003245	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.28e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 79.4	adipose tissue: 63.7	Cell line enhanced		TIME: 84.5
MAB21L3	C1orf161, FLJ38716	ENSG00000173212	Mab-21 like 3	1	116111755-116135240	Predicted intracellular proteins	Evidence at protein level	HPA039551, HPA046187	Uncertain		Approved	Nucleoplasm		Mixed	Group enriched	5	esophagus: 7.5;skin: 7.2	colon,kidney,rectum: 1.3	Cell line enhanced		BEWO: 3.7;EFO-21: 8.0;RT4: 10.4
MFSD4B	KIAA1919, MGC33953	ENSG00000173214	Major facilitator superfamily domain containing 4B	6	111259348-111271167	Predicted membrane proteins	Evidence at protein level	HPA031784	Approved		Uncertain	Intermediate filaments		Expressed in all	Mixed			placenta: 5.0	Mixed		
VANGL1	STB2	ENSG00000173218	VANGL planar cell polarity protein 1	1	115641953-115698224	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA025235, CAB076375	Approved		Approved	Plasma membrane	Colorectal cancer:7.53e-4 (favourable), Pancreatic cancer:7.89e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 19.4	Mixed		
GLRX	GRX, GRX1	ENSG00000173221	Glutaredoxin	5	95751319-95823005	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008634, HPA046431, CAB069419	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			kidney: 218.9	Expressed in all		
IQCB1	KIAA0036, NPHP5, SLSN5	ENSG00000173226	IQ motif containing B1	3	121769763-121835079	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042028	Approved		Supported	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle	Liver cancer:3.08e-5 (unfavourable), Cervical cancer:1.77e-4 (favourable), Lung cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 52.5	Expressed in all		
SYT12	SRG1	ENSG00000173227	Synaptotagmin 12	11	67006778-67050863	Predicted intracellular proteins	Evidence at protein level	HPA011006	Uncertain				Pancreatic cancer:4.13e-4 (unfavourable)	Tissue enhanced	Tissue enriched	7	parathyroid gland: 115.1	cerebral cortex: 17.2	Cell line enhanced		HeLa: 31.9;MCF7: 25.6;SiHa: 44.9;SK-BR-3: 15.2;T-47d: 19.2
GOLGB1	GCP, GCP372, giantin, GOLIM1	ENSG00000173230	Golgin B1	3	121663199-121749767	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011008, HPA011555	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			prostate: 41.9	Expressed in all		
C11orf86	FLJ22675	ENSG00000173237	Chromosome 11 open reading frame 86	11	66975277-66977004	Predicted intracellular proteins	Evidence at transcript level	HPA039348	Uncertain				Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:6.97e-5 (unfavourable), Lung cancer:8.97e-4 (unfavourable)	Mixed	Group enriched	7	duodenum: 68.2;small intestine: 70.9	colon: 10.3	Cell line enriched	5	SiHa: 26.4
LIPM	bA304I5.1, LIPL3	ENSG00000173239	Lipase family member M	10	88802730-88820546	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level						Pancreatic cancer:6.47e-4 (unfavourable)	Mixed	Tissue enriched	14	skin: 51.4	breast: 3.7	Cell line enhanced		CAPAN-2: 3.0;HL-60: 1.6;NB-4: 1.1;RT4: 1.2;T-47d: 1.5;U-937: 1.2
GPR151	GALR4, PGR7	ENSG00000173250	G protein-coupled receptor 151	5	146513103-146516190	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.2	Not detected		
DMRT2		ENSG00000173253	Doublesex and mab-3 related transcription factor 2	9	1049858-1057552	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at transcript level	HPA029297	Uncertain					Tissue enhanced	Tissue enriched	7	parathyroid gland: 108.9	kidney: 16.2	Cell line enhanced		HaCaT: 3.3;RH-30: 4.8;RPMI-8226: 13.4;SCLC-21H: 3.4;SK-MEL-30: 4.0;WM-115: 3.5
ZNF483	KIAA1962, ZKSCAN16, ZSCAN48	ENSG00000173258	Zinc finger protein 483	9	111525159-111577844	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055041	Uncertain		Approved	Nucleoli		Tissue enhanced	Mixed			cerebral cortex: 13.0	Cell line enhanced		NTERA-2: 7.5;SCLC-21H: 5.1
PLAC8L1		ENSG00000173261	PLAC8 like 1	5	146084386-146104369	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	10	testis: 31.1	skin: 3.0	Cell line enhanced		AN3-CA: 5.5
SLC2A14	GLUT14, SLC2A3P3	ENSG00000173262	Solute carrier family 2 member 14	12	7812512-7891148	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006539	Supported		Approved	Plasma membrane		Tissue enriched	Tissue enriched	35	testis: 148.8	ovary: 4.2	Cell line enhanced		BEWO: 17.9;CACO-2: 25.7
GPR137	C11orf4, GPR137A, TM7SF1L1	ENSG00000173264	G protein-coupled receptor 137	11	64270062-64289500	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA062871	Uncertain		Approved	Nucleus<br>Nucleoli<br>Actin filaments	Liver cancer:5.34e-4 (unfavourable), Pancreatic cancer:6.18e-4 (favourable)	Expressed in all	Expressed in all			testis: 146.5	Expressed in all		
SNCG	BCSG1, persyn, SR	ENSG00000173267	Synuclein gamma	10	86958618-86963260	Predicted intracellular proteins	Evidence at protein level	CAB001452, HPA014404, CAB040581	Enhanced	Approved			Renal cancer:2.29e-8 (unfavourable), Stomach cancer:7.15e-4 (unfavourable)	Group enriched	Tissue enhanced		adipose tissue: 174.6;adrenal gland: 198.1;urinary bladder: 183.2	seminal vesicle: 114.9	Cell line enhanced		CAPAN-2: 463.6;RT4: 350.3;T-47d: 106.9
MMRN2	EMILIN3, EndoGlyx-1, FLJ13465	ENSG00000173269	Multimerin 2	10	86935540-86969481	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA020741	Approved		Approved	Vesicles		Expressed in all	Expressed in all			placenta: 101.6	Cell line enhanced		CAPAN-2: 78.1;HUVEC TERT2: 155.0;TIME: 182.9
MZT2A	FAM128A, MOZART2A	ENSG00000173272	Mitotic spindle organizing protein 2A	2	131464900-131492743	Predicted intracellular proteins	Evidence at protein level	HPA051758, HPA052623	Approved		Supported	Centrosome<br>Cytosol	Renal cancer:3.04e-11 (unfavourable), Breast cancer:3.04e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 40.5	Mixed		
TNKS	PARP-5a, PARP5A, pART5, TIN1, TINF1, TNKS1	ENSG00000173273	Tankyrase	8	9555914-9782346	Enzymes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA025690	Approved		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			testis: 52.8	Expressed in all		
ZNF449	FLJ23614, ZSCAN19	ENSG00000173275	Zinc finger protein 449	X	135344796-135363152	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA018079	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 12.3	Mixed		
ZBTB21	KIAA1227, ZNF295	ENSG00000173276	Zinc finger and BTB domain containing 21	21	41986831-42010387	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024655, HPA031757, HPA031758	Enhanced		Enhanced	Nucleus		Expressed in all	Mixed			adrenal gland: 47.6	Expressed in all		
PPP1R3B	FLJ14005, GL, PPP1R4	ENSG00000173281	Protein phosphatase 1 regulatory subunit 3B	8	9136255-9151574	Predicted intracellular proteins	Evidence at protein level	HPA028731	Approved		Approved	Cytosol	Renal cancer:4.08e-7 (unfavourable), Stomach cancer:6.03e-5 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 151.3	Cell line enhanced		HUVEC TERT2: 39.3;RPTEC TERT1: 46.9
OR10K1		ENSG00000173285	Olfactory receptor family 10 subfamily K member 1	1	158465562-158466503	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059125	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPR148	PGR6	ENSG00000173302	G protein-coupled receptor 148	2	130729070-130730336	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060527	Uncertain					Not detected	Not detected			stomach: 0.4	Not detected		
STOX2	DKFZp762K222	ENSG00000173320	Storkhead box 2	4	183797692-184023526	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049776, HPA065002	Uncertain		Uncertain	Nucleoplasm<br>Actin filaments<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 17.4	parathyroid gland: 11.5	Cell line enhanced		AF22: 13.0;NTERA-2: 16.8;SH-SY5Y: 16.8
MAP3K11	MEKK11, MLK3, PTK1, SPRK	ENSG00000173327	Mitogen-activated protein kinase kinase kinase 11	11	65597755-65615382	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB010165	Approved		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			spleen: 54.7	Expressed in all		
TRIB1	C8FW, GIG2, TRB1	ENSG00000173334	Tribbles pseudokinase 1	8	125430321-125438405	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063982			Approved	Plasma membrane		Expressed in all	Expressed in all			bone marrow: 243.6	Cell line enhanced		HEL: 173.6
CST9	CLM, CTES7A	ENSG00000173335	Cystatin 9	20	23602410-23605876	Predicted secreted proteins	Evidence at transcript level	HPA029190	Uncertain					Tissue enriched	Tissue enriched	12	breast: 2.1	kidney: 0.1	Not detected		
KCNK7	K2p7.1	ENSG00000173338	Potassium two pore domain channel subfamily K member 7	11	65592855-65595996	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels	Evidence at transcript level	HPA077577			Approved	Plasma membrane		Tissue enhanced	Tissue enriched	7	skin: 53.2	esophagus: 7.9	Cell line enhanced		SCLC-21H: 8.4
SFT2D3	MGC5391	ENSG00000173349	SFT2 domain containing 3	2	127701508-127705242	Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			parathyroid gland: 7.9	Cell line enhanced		ASC diff: 5.1;hTCEpi: 5.1
RP11-330H6.5		ENSG00000173366		3	52221081-52231190	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		lymph node: 3.7;tonsil: 2.3	appendix,spleen: 1.9	Cell line enhanced		Daudi: 9.9;RPMI-8226: 18.1;U-698: 8.8
C1QB		ENSG00000173369	Complement C1q B chain	1	22652762-22661538	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA052116	Approved				Renal cancer:9.58e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 1435.2	Not detected		
C1QA		ENSG00000173372	Complement C1q A chain	1	22636506-22639608	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002350, CAB009823	Supported		Uncertain	Golgi apparatus<br>Cytosol	Renal cancer:1.58e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 1166.4	Cell line enhanced		HMC-1: 2.0;RPMI-8226: 4.9;SCLC-21H: 3.5
NDNF	C4orf31, FLJ23191	ENSG00000173376	Neuron derived neurotrophic factor	4	121035613-121073021	Predicted secreted proteins	Evidence at protein level	HPA048881			Supported	Vesicles	Renal cancer:3.26e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		lung: 159.9;placenta: 86.6	ovary: 52.7	Cell line enhanced		fHDF/TERT166: 37.8;U-266/70: 16.0;U-266/84: 60.4
IQCF1	MGC39725	ENSG00000173389	IQ motif containing F1	3	51894876-51903335	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	574	testis: 57.4	all non-specific tissues: 0.0	Not detected		
OLR1	CLEC8A, LOX-1, SCARE1	ENSG00000173391	Oxidized low density lipoprotein receptor 1	12	10158301-10172138	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050798			Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Head and neck cancer:8.24e-5 (unfavourable)	Expressed in all	Group enriched	6	appendix: 41.3;cerebral cortex: 32.7;lung: 146.3;placenta: 160.9	bone marrow: 15.8	Cell line enhanced		CACO-2: 102.6;HHSteC: 104.1;SiHa: 261.9;SK-BR-3: 72.4
GLIPR1L1	MGC26856	ENSG00000173401	GLI pathogenesis related 1 like 1	12	75334639-75370560	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042095	Enhanced					Not detected	Tissue enriched	45	testis: 78.3	skin: 1.7	Cell line enriched	100	NTERA-2: 109.3
DAG1	156DAG, A3a, AGRNR, DAG	ENSG00000173402	Dystroglycan 1	3	49468703-49535618	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB001960, CAB016353	Enhanced		Supported	Vesicles	Renal cancer:2.59e-4 (favourable)	Expressed in all	Expressed in all			placenta: 109.3	Expressed in all		
INSM1	IA-1, IA1	ENSG00000173404	INSM transcriptional repressor 1	20	20368121-20370949	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 9.3;stomach: 5.6	duodenum: 3.0	Cell line enriched	32	SCLC-21H: 438.4
DAB1		ENSG00000173406	DAB1, reelin adaptor protein	1	56994778-58546734	Predicted intracellular proteins	Evidence at protein level	CAB032329, HPA052033, HPA067495	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8	prostate: 6.4	Cell line enhanced		fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
ARV1		ENSG00000173409	ARV1 homolog, fatty acid homeostasis modulator	1	230978981-231000595	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA035709	Approved		Approved	Vesicles	Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 61.9	Expressed in all		
NAA20	dJ1002M8.1, NAT3, NAT5	ENSG00000173418	N(alpha)-acetyltransferase 20, NatB catalytic subunit	20	20017116-20033655	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA063344			Supported	Cytosol	Head and neck cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 82.5	Expressed in all		
CCDC36	CT74, FLJ25320	ENSG00000173421	Coiled-coil domain containing 36	3	49198428-49258104	Predicted intracellular proteins	Evidence at protein level	HPA045690, HPA069534	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	14	testis: 48.6	adipose tissue: 3.5	Cell line enhanced		hTEC/SVTERT24-B: 9.9;LHCN-M2: 3.5;U-2197: 5.0
RNASE8	RAE2	ENSG00000173431	Ribonuclease A family member 8	14	21057822-21058455	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	105	salivary gland: 27.2	skin: 0.2	Not detected		
SAA1	PIG4, SAA, TP53I4	ENSG00000173432	Serum amyloid A1	11	18266174-18269977	Disease related genes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.57e-12 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 3976.7;liver: 1183.1	cervix, uterine: 635.0	Group enriched	5	HBEC3-KT: 868.8;HHSteC: 212.1
MINOS1	C1orf151, FLJ36999, Mic10, MIO10, RP5-1056L3.2	ENSG00000173436	Mitochondrial inner membrane organizing system 1	1	19596977-19629821	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059930	Enhanced		Supported	Mitochondria	Liver cancer:7.23e-4 (unfavourable), Urothelial cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			prostate: 13.1	Expressed in all		
EHBP1L1	DKFZp762C186, TANGERIN	ENSG00000173442	EH domain binding protein 1 like 1	11	65576038-65592650	Predicted intracellular proteins	Evidence at protein level	HPA039479	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.45e-4 (unfavourable)	Expressed in all	Mixed			skeletal muscle: 88.6	Mixed		
THAP2	DKFZP564I0422	ENSG00000173451	THAP domain containing 2	12	71663009-71680639	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039790	Approved		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			adrenal gland: 35.2	Expressed in all		
TMEM196	MGC42090	ENSG00000173452	Transmembrane protein 196	7	19719310-19773598	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA043163	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 9.2	endometrium: 2.2	Group enriched	7	ASC diff: 3.1;ASC TERT1: 3.1
RNF26	MGC2642	ENSG00000173456	Ring finger protein 26	11	119334527-119337313	Predicted membrane proteins	Evidence at transcript level	HPA027620	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:3.45e-6 (favourable), Liver cancer:3.19e-4 (unfavourable), Urothelial cancer:7.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.9	Mixed		
PPP1R14B	PHI-1, PLCB3N, PNG, SOM172	ENSG00000173457	Protein phosphatase 1 regulatory inhibitor subunit 14B	11	64244480-64246941	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053882	Approved				Liver cancer:1.75e-6 (unfavourable), Pancreatic cancer:6.77e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 87.3	Expressed in all		
RNASE11	C14orf6, RAJ1	ENSG00000173464	Ribonuclease A family member 11 (inactive)	14	20583559-20609884	Predicted secreted proteins	Evidence at protein level	HPA003724	Uncertain					Not detected	Tissue enriched	7	epididymis: 541.2	testis: 82.0	Not detected		
SSSCA1	p27	ENSG00000173465	Sjogren syndrome/scleroderma autoantigen 1	11	65570430-65573942	Predicted intracellular proteins	Evidence at protein level	HPA039789, HPA064670	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 52.6	Expressed in all		
AGR3	BCMP11, hAG-3, HAG3, PDIA18	ENSG00000173467	Anterior gradient 3, protein disulphide isomerase family member	7	16859405-16881987	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053942	Enhanced		Supported	Endoplasmic reticulum<br>Vesicles		Tissue enhanced	Tissue enhanced		fallopian tube: 354.7;small intestine: 259.5	rectum: 233.8	Cell line enriched	52	T-47d: 316.6
SMARCC1	BAF155, CRACC1, Rsc8, SRG3	ENSG00000173473	SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 1	3	47585272-47782106	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011576, CAB016336, HPA024352, HPA026853	Enhanced		Enhanced	Nucleoplasm	Colorectal cancer:3.34e-4 (favourable), Liver cancer:3.37e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 36.1	Expressed in all		
ZNF417	MGC34079	ENSG00000173480	Zinc finger protein 417	19	57900296-57916610	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042125, HPA043288, HPA056213	Uncertain		Uncertain	Nucleoplasm	Urothelial cancer:3.48e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 59.9	Mixed		
PTPRM	hR-PTPu, PTPRL1, RPTPU	ENSG00000173482	Protein tyrosine phosphatase, receptor type M	18	7566782-8406861	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003891, CAB022442, CAB022443	Supported		Approved	Plasma membrane	Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 91.6	Mixed		
FKBP2	FKBP-13, PPIase	ENSG00000173486	FK506 binding protein 2	11	64241003-64244132	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB025561, HPA049405	Enhanced		Approved	Plasma membrane		Expressed in all	Expressed in all			epididymis: 399.2	Expressed in all		
VEGFB	VEGFL, VRF	ENSG00000173511	Vascular endothelial growth factor B	11	64234538-64238793	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level							Expressed in all	Expressed in all			adipose tissue: 195.0	Expressed in all		
PEAK1	KIAA2002, sgk269	ENSG00000173517	Pseudopodium enriched atypical kinase 1	15	77100656-77420144	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026313, HPA026517	Approved					Expressed in all	Mixed			spleen: 40.6	Expressed in all		
TNFRSF10D	CD264, DcR2, TRAILR4, TRUNDD	ENSG00000173530	TNF receptor superfamily member 10d	8	23135588-23164030	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA070971			Approved	Plasma membrane<br>Actin filaments	Cervical cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 12.7	Cell line enhanced		LHCN-M2: 208.5;WM-115: 234.5
MST1	D3F15S2, DNF15S2, HGFL, MSP, NF15S2	ENSG00000173531	Macrophage stimulating 1	3	49683947-49689501	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024036	Uncertain				Pancreatic cancer:7.14e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 144.2	duodenum: 51.1	Cell line enhanced		Hep G2: 57.1;U-266/70: 16.6
TNFRSF10C	CD263, DcR1, LIT, TRAILR3, TRID	ENSG00000173535	TNF receptor superfamily member 10c	8	23084355-23117437	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB025635	Enhanced					Mixed	Tissue enhanced		appendix: 21.9	spleen: 18.2	Group enriched	5	BEWO: 78.5;HUVEC TERT2: 56.8
GMPPB	KIAA1851	ENSG00000173540	GDP-mannose pyrophosphorylase B	3	49716844-49723951	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014657	Uncertain		Supported	Nucleus	Endometrial cancer:6.19e-6 (favourable), Renal cancer:3.17e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 42.0	Expressed in all		
MOB1B	MOB4A, MOBKL1A	ENSG00000173542	MOB kinase activator 1B	4	70902326-71022449	Predicted intracellular proteins	Evidence at protein level	HPA047088, HPA071690	Supported		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.92e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 24.2	Expressed in all		
ZNF622	MGC17552, MGC2485, ZPR9	ENSG00000173545	Zinc finger protein 622	5	16451519-16465792	Predicted intracellular proteins	Evidence at protein level	HPA036514, HPA036515	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			heart muscle: 28.4	Expressed in all		
CSPG4	HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2	ENSG00000173546	Chondroitin sulfate proteoglycan 4	15	75674322-75712848	Predicted membrane proteins	Evidence at protein level	HPA002951, CAB016189, HPA042785, HPA050008	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable)	Expressed in all	Mixed			smooth muscle: 32.1	Cell line enhanced		SK-MEL-30: 115.3;U-138 MG: 90.7;WM-115: 136.7
SNX33	MGC32065, SH3PX3, SH3PXD3C, SNX30	ENSG00000173548	Sorting nexin 33	15	75647906-75662301	Predicted intracellular proteins	Evidence at protein level	HPA040988	Approved				Ovarian cancer:5.24e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 26.6	Mixed		
C2orf70	LOC339778	ENSG00000173557	Chromosome 2 open reading frame 70	2	26562582-26579532	Predicted intracellular proteins	Evidence at protein level	HPA062453	Enhanced		Approved	Nuclear membrane<br>Vesicles	Pancreatic cancer:6.49e-4 (favourable)	Mixed	Group enriched	6	fallopian tube: 12.0;stomach: 4.9;testis: 17.5	thyroid gland: 1.9	Cell line enhanced		A-431: 3.6;CAPAN-2: 2.7;EFO-21: 1.8;RPTEC TERT1: 2.8
NABP1	DKFZp667M1322, FLJ13624, FLJ22833, hSSB2, MGC111163, OBFC2A, SOSS-B2, SSB2	ENSG00000173559	Nucleic acid binding protein 1	2	191678068-191696659	Predicted intracellular proteins	Evidence at protein level	HPA054978, HPA067802			Supported	Nucleoplasm<br>Cytosol	Renal cancer:8.20e-7 (unfavourable)	Expressed in all	Mixed			appendix: 49.2	Mixed		
ADGRF3	GPR113, hGPCR37, PGR23	ENSG00000173567	Adhesion G protein-coupled receptor F3	2	26308173-26346817	G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA044500	Uncertain					Not detected	Not detected			kidney: 0.8	Mixed		
NLRP13	CLR19.7, NALP13, NOD14, PAN13	ENSG00000173572	NLR family pyrin domain containing 13	19	55891699-55932336	Predicted intracellular proteins	Evidence at protein level	HPA060459	Uncertain					Not detected	Not detected			breast: 0.7	Not detected		
CHD2	DKFZp547I1315, DKFZp686E01200, DKFZp781D1727, FLJ38614	ENSG00000173575	Chromodomain helicase DNA binding protein 2	15	92900189-93028005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060744, HPA060960	Enhanced		Enhanced	Nucleus		Expressed in all	Expressed in all			bone marrow: 48.3	Mixed		
XCR1	CCXCR1, GPR5	ENSG00000173578	X-C motif chemokine receptor 1	3	46017024-46027742	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013169	Uncertain					Mixed	Tissue enhanced		lymph node: 10.8	spleen: 9.1	Cell line enhanced		Karpas-707: 1.8
CCDC106	HSU79303	ENSG00000173581	Coiled-coil domain containing 106	19	55641062-55653161	Predicted intracellular proteins	Evidence at protein level	HPA041925, HPA043219	Uncertain		Supported	Nucleus<br>Cytosol	Renal cancer:7.54e-11 (favourable), Pancreatic cancer:2.23e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 29.8	Cell line enhanced		HEK 293: 77.4
CCR9	CDw199, GPR-9-6, GPR28	ENSG00000173585	C-C motif chemokine receptor 9	3	45886504-45903177	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB006839	Uncertain					Not detected	Group enriched	6	appendix: 1.4;duodenum: 3.8;small intestine: 5.7;spleen: 1.2	lymph node,tonsil: 0.4	Cell line enriched	362	MOLT-4: 90.5
CEP83	CCDC41, NPHP18, NY-REN-58	ENSG00000173588	Centrosomal protein 83	12	94306449-94459988	Predicted intracellular proteins	Evidence at protein level	HPA038161	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.00e-10 (unfavourable), Prostate cancer:4.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.4	Expressed in all		
SULT1B1	ST1B2	ENSG00000173597	Sulfotransferase family 1B member 1	4	69721162-69787961	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002107	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Group enriched	5	colon: 68.9;duodenum: 99.0;rectum: 67.1;small intestine: 103.7;stomach: 41.6	appendix: 13.8	Group enriched	6	HUVEC TERT2: 92.0;TIME: 29.6;U-2197: 29.2
NUDT4	DIPP2, DIPP2alpha, DIPP2beta, HDCMB47P, KIAA0487	ENSG00000173598	Nudix hydrolase 4	12	93377883-93408146	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017593, HPA047027, HPA057684	Approved		Approved	Cytosol	Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			ovary: 184.7	Expressed in all		
PC	PCB	ENSG00000173599	Pyruvate carboxylase	11	66848233-66958376	Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033742, HPA043922, HPA058765	Uncertain		Enhanced	Mitochondria	Ovarian cancer:7.86e-5 (unfavourable), Renal cancer:8.22e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 63.8	Mixed		
UGT2A1		ENSG00000173610	UDP glucuronosyltransferase family 2 member A1 complex locus	4	69588417-69653249	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017261, HPA045108	Uncertain					Tissue enhanced	Group enriched	7	kidney: 8.1;liver: 5.5	skin: 0.9	Not detected		
SCAI	C9orf126, FLJ36664, NET40	ENSG00000173611	Suppressor of cancer cell invasion	9	124942608-125143506	Predicted intracellular proteins	Evidence at protein level	HPA020632	Approved		Supported	Nucleus<br>Nuclear membrane		Mixed	Mixed			cerebral cortex: 11.7	Expressed in all		
GPRC6A	bA86F4.3	ENSG00000173612	G protein-coupled receptor class C group 6 member A	6	116792085-116829037	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Not detected			kidney: 0.7	Cell line enhanced		U-266/70: 1.2
NMNAT1	LCA9, NMNAT, PNAT1	ENSG00000173614	Nicotinamide nucleotide adenylyltransferase 1	1	9943428-9985501	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA059447	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.85e-14 (favourable)	Expressed in all	Mixed			thyroid gland: 12.5	Mixed		
LRFN4	FIGLER6, MGC3103, SALM3.	ENSG00000173621	Leucine rich repeat and fibronectin type III domain containing 4	11	66856647-66860475	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			cerebral cortex: 13.3	Mixed		
TRAPPC3L	bA259P20.2, BET3L, FLJ11180	ENSG00000173626	Trafficking protein particle complex 3 like	6	116494989-116545610	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			spleen: 6.5	Cell line enhanced		Karpas-707: 4.7
APOBEC4	C1orf169, FLJ25691, MGC26594, RP1-127C7.4	ENSG00000173627	Apolipoprotein B mRNA editing enzyme catalytic polypeptide like 4	1	183646404-183653316	Predicted intracellular proteins	Evidence at transcript level	HPA015636, HPA015637	Approved				Endometrial cancer:2.65e-4 (favourable)	Tissue enhanced	Group enriched	10	fallopian tube: 19.6;testis: 18.6	lung: 1.9	Not detected		
SLC19A1	FOLT, RFC1	ENSG00000173638	Solute carrier family 19 member 1	21	45493572-45544411	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024802	Approved		Approved	Plasma membrane	Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 22.0	Expressed in all		
HSPB7	cvHSP	ENSG00000173641	Heat shock protein family B (small) member 7	1	16014028-16019594	Predicted intracellular proteins	Evidence at protein level	HPA027639	Approved		Approved	Nucleoplasm	Urothelial cancer:1.26e-4 (unfavourable), Head and neck cancer:5.29e-4 (unfavourable)	Mixed	Tissue enhanced		heart muscle: 1571.0;skeletal muscle: 639.6	adipose tissue: 342.4	Cell line enriched	5	fHDF/TERT166: 246.0
RCE1	FACE-2, FACE2, hRCE1, RCE1A, RCE1B	ENSG00000173653	Ras converting CAAX endopeptidase 1	11	66842835-66846546	Enzymes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			skin: 23.3	Expressed in all		
UQCRH	QCR6, UQCR8	ENSG00000173660	Ubiquinol-cytochrome c reductase hinge protein	1	46303631-46316776	Predicted intracellular proteins	Evidence at protein level	HPA042574	Supported				Liver cancer:4.63e-5 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 502.5	Expressed in all		
TAS1R1	GPR70, T1R1, TR1	ENSG00000173662	Taste 1 receptor member 1	1	6555181-6579757	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA034579, HPA034580	Approved					Mixed	Tissue enriched	7	testis: 4.1	gallbladder,skin: 0.5	Cell line enhanced		HDLM-2: 1.6;Hep G2: 1.1;LHCN-M2: 1.1
HES3	bHLHb43	ENSG00000173673	Hes family bHLH transcription factor 3	1	6244192-6245578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047927, HPA072697	Uncertain		Uncertain	Nucleus		Tissue enriched	Not detected			testis: 0.1	Cell line enriched	7	NTERA-2: 11.3
EIF1AX	eIF-1A, eIF-4C, EIF1A, EIF4C	ENSG00000173674	Eukaryotic translation initiation factor 1A, X-linked	X	20124518-20141844	Predicted intracellular proteins	Evidence at protein level	HPA002561	Uncertain	Approved	Approved	Cytosol		Expressed in all	Expressed in all			endometrium: 96.3	Expressed in all		
SPDYE2B		ENSG00000173678	Speedy/RINGO cell cycle regulator family member E2B	7	102650325-102661398	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Not detected	Tissue enhanced		testis: 3.9	spleen: 2.0	Cell line enhanced		Karpas-707: 4.2
OR1L1	OR1L2, OR9-C	ENSG00000173679	Olfactory receptor family 1 subfamily L member 1	9	122661566-122662648	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			urinary bladder: 0.1	Not detected		
CXorf23		ENSG00000173681	Chromosome X open reading frame 23	X	19912860-19970298	Predicted intracellular proteins	Evidence at protein level	HPA027215	Approved		Approved	Nucleoplasm	Lung cancer:5.42e-4 (favourable), Urothelial cancer:5.56e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.8	Expressed in all		
PSMD1	P112, Rpn2, S1	ENSG00000173692	Proteasome 26S subunit, non-ATPase 1	2	231056864-231172827	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB021092, HPA036736, HPA036737	Enhanced		Approved	Nucleoplasm<br>Actin filaments	Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 204.0	Expressed in all		
ADGRG2	EDDM6, GPR64, HE6, TM7LN2	ENSG00000173698	Adhesion G protein-coupled receptor G2	X	18989309-19122637	Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001478, HPA050029	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	6	epididymis: 1494.8	parathyroid gland: 240.0	Cell line enhanced		A549: 5.4;BEWO: 7.0;NTERA-2: 6.3;SH-SY5Y: 6.9;U-2197: 13.5
SPATA3	TSARG1	ENSG00000173699	Spermatogenesis associated 3	2	230996121-231025055	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018254	Enhanced					Not detected	Tissue enriched	448	testis: 160.1	cerebral cortex: 0.3	Not detected		
MUC13	DRCC1	ENSG00000173702	Mucin 13, cell surface associated	3	124905442-124953819	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045163	Enhanced				Renal cancer:9.73e-5 (unfavourable)	Tissue enhanced	Group enriched	6	colon: 301.8;duodenum: 614.7;rectum: 330.1;small intestine: 555.7	appendix: 79.5	Cell line enhanced		A549: 6.6;CACO-2: 5.3;CAPAN-2: 11.9;Karpas-707: 5.6
SUSD5	KIAA0527	ENSG00000173705	Sushi domain containing 5	3	33150042-33219215	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA052788	Uncertain		Uncertain	Golgi apparatus<br>Vesicles		Tissue enhanced	Mixed			cerebral cortex: 11.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 26.7;HUVEC TERT2: 60.2;LHCN-M2: 23.3;TIME: 23.4
HEG1	HEG, KIAA1237	ENSG00000173706	Heart development protein with EGF like domains 1	3	124965710-125055958	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA010952, HPA011559	Approved		Approved	Vesicles	Renal cancer:1.93e-5 (unfavourable), Urothelial cancer:1.16e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 65.0	Cell line enhanced		HHSteC: 134.6
WFIKKN2	WFDC20B, WFIKKNRP	ENSG00000173714	WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2	17	50834650-50842348	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	17	ovary: 76.5	testis: 4.4	Not detected		
C11orf80	FLJ22531, TOPOVIBL	ENSG00000173715	Chromosome 11 open reading frame 80	11	66744451-66843328	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038932, HPA038933	Approved		Approved	Centrosome		Expressed in all	Tissue enhanced		skin: 48.2	testis: 26.7	Mixed		
TOMM20	KIAA0016, MAS20, MOM19, TOM20	ENSG00000173726	Translocase of outer mitochondrial membrane 20	1	235109336-235128936	Predicted membrane proteins	Evidence at protein level	CAB005585, HPA011562	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 230.8	Expressed in all		
C1orf100		ENSG00000173728	Chromosome 1 open reading frame 100	1	244352635-244389663	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	51	testis: 71.1	parathyroid gland: 1.3	Cell line enriched	50	K-562: 4.9
AGFG1	HRB, RAB, RIP	ENSG00000173744	ArfGAP with FG repeats 1	2	227472152-227561214	Predicted intracellular proteins	Evidence at protein level	HPA008741	Approved		Supported	Vesicles	Liver cancer:7.31e-6 (unfavourable), Ovarian cancer:3.43e-5 (unfavourable), Lung cancer:1.85e-4 (unfavourable), Renal cancer:6.92e-4 (unfavourable), Cervical cancer:7.13e-4 (unfavourable), Glioma:7.89e-4 (favourable)	Expressed in all	Expressed in all			testis: 169.2	Expressed in all		
STAT5B		ENSG00000173757	Signal transducer and activator of transcription 5B	17	42199168-42276707	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004298, HPA042128, HPA049883, HPA051156	Approved				Renal cancer:2.39e-5 (favourable), Pancreatic cancer:1.63e-4 (favourable), Endometrial cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 71.3	Cell line enhanced		HDLM-2: 112.6
CD7	GP40, LEU-9, Tp40, TP41	ENSG00000173762	CD7 molecule	17	82314868-82317602	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002594, HPA039079	Enhanced				Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 43.1;lymph node: 41.5;spleen: 43.1	small intestine: 17.0	Group enriched	5	Hep G2: 35.2;MOLT-4: 95.7
TOPAZ1	C3orf77, FLJ36157	ENSG00000173769	Testis and ovary specific PAZ domain containing 1	3	44241886-44332098	Predicted intracellular proteins	Evidence at protein level	HPA047431, HPA051034	Uncertain					Not detected	Tissue enriched	65	testis: 6.5	all non-specific tissues: 0.0	Not detected		
CNP		ENSG00000173786	2',3'-cyclic nucleotide 3' phosphodiesterase	17	41966741-41977731	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002672, HPA023266, HPA023278, HPA023280, HPA023338	Enhanced	Supported	Enhanced	Nucleus<br>Cytosol		Expressed in all	Tissue enriched	11	cerebral cortex: 614.8	prostate: 54.9	Expressed in all		
JUP	CTNNG, DP3, DPIII, PDGB, PKGB	ENSG00000173801	Junction plakoglobin	17	41754604-41786931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002139, HPA032047	Supported		Enhanced	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-10 (favourable)	Expressed in all	Group enriched	6	esophagus: 491.8;skin: 785.5	fallopian tube: 113.8	Cell line enhanced		HaCaT: 960.4;RT4: 536.8
HAP1	HAP2, hHLP1, HIP5, HLP	ENSG00000173805	Huntingtin associated protein 1	17	41717742-41734644	Predicted intracellular proteins	Evidence at protein level	HPA023394	Uncertain				Pancreatic cancer:4.26e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 11.5;stomach: 12.8	thyroid gland: 6.4	Cell line enriched	8	REH: 87.3
TDRD12	ECAT8, FLJ13072	ENSG00000173809	Tudor domain containing 12	19	32719753-32829580	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Group enriched	8	epididymis: 10.9;testis: 33.5	ovary: 2.6	Group enriched	34	HDLM-2: 23.6;NTERA-2: 93.5
EIF1	A121, EIF-1, EIF1A, ISO1, SUI1	ENSG00000173812	Eukaryotic translation initiation factor 1	17	41688885-41692668	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.45e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 481.3	Expressed in all		
ENDOV	FLJ35220	ENSG00000173818	Endonuclease V	17	80415165-80438086	Predicted intracellular proteins	Evidence at protein level						Breast cancer:4.24e-5 (favourable), Colorectal cancer:4.40e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.2	Mixed		
RNF213	C17orf27, KIAA1554, KIAA1618, MYMY2, NET57	ENSG00000173821	Ring finger protein 213	17	80260866-80398786	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003347, HPA026790	Approved		Supported	Cytosol	Endometrial cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
TIGD3		ENSG00000173825	Tigger transposable element derived 3	11	65354767-65357613	Predicted intracellular proteins	Evidence at transcript level	HPA040016			Approved	Nucleoplasm<br>Nuclear membrane		Mixed	Tissue enhanced		testis: 3.9	small intestine: 2.3	Cell line enhanced		SCLC-21H: 4.6
KCNH6	erg2, HERG2, Kv11.2	ENSG00000173826	Potassium voltage-gated channel subfamily H member 6	17	63523334-63548977	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Tissue enhanced	Tissue enhanced		kidney: 6.1;prostate: 5.4;small intestine: 5.5	duodenum: 2.2	Group enriched	6	SCLC-21H: 4.0;SH-SY5Y: 1.4
MARCH10	FLJ35757, MARCH-X, RNF190	ENSG00000173838	Membrane associated ring-CH-type finger 10	17	62701314-62808344	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023322	Enhanced		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	7	testis: 144.4	fallopian tube: 20.5	Cell line enhanced		BEWO: 2.5;EFO-21: 4.5;SCLC-21H: 9.7
PLK3	CNK, FNK, PRK	ENSG00000173846	Polo like kinase 3	1	44800225-44805990	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060318	Enhanced				Renal cancer:1.75e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 24.3	Mixed		
NET1	ARHGEF8, NET1A	ENSG00000173848	Neuroepithelial cell transforming 1	10	5412551-5458463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020068	Uncertain		Approved	Nucleus<br>Vesicles	Liver cancer:3.87e-5 (unfavourable), Pancreatic cancer:8.27e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 96.4	Expressed in all		
DPY19L1	KIAA0877	ENSG00000173852	Dpy-19 like 1	7	34928876-35038271	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059139	Uncertain		Approved	Vesicles	Pancreatic cancer:2.99e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.5	Mixed		
PHOSPHO1		ENSG00000173868	Phosphoethanolamine/phosphocholine phosphatase	17	49223362-49230766	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053016, HPA065025	Uncertain		Approved	Plasma membrane<br>Actin filaments		Mixed	Tissue enhanced		spleen: 20.4;testis: 41.1	bone marrow: 12.4	Cell line enhanced		Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
ZNF791	FLJ90396	ENSG00000173875	Zinc finger protein 791	19	12610918-12633840	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021537	Uncertain		Approved	Nucleus	Urothelial cancer:1.39e-5 (favourable), Lung cancer:9.07e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 25.1	Expressed in all		
PHC3	EDR3, FLJ12729, FLJ12967, HPH3	ENSG00000173889	Polyhomeotic homolog 3	3	170086732-170181749	Predicted intracellular proteins	Evidence at protein level	HPA039162, HPA062031	Approved		Supported	Nucleus		Expressed in all	Expressed in all			bone marrow: 33.5	Expressed in all		
GPR160	GPCR1, GPCR150	ENSG00000173890	G protein-coupled receptor 160	3	170037929-170085403	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA006970	Approved		Supported	Plasma membrane	Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 435.1	small intestine: 109.0	Cell line enhanced		THP-1: 130.2;U-266/70: 156.8
CBX2	CDCA6, MGC10561	ENSG00000173894	Chromobox 2	17	79778132-79787983	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023083	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.3	placenta: 3.2	Cell line enhanced		REH: 87.4;SK-BR-3: 100.2
SPTBN2	SCA5	ENSG00000173898	Spectrin beta, non-erythrocytic 2	11	66685248-66729226	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009844, HPA039293, HPA043529	Enhanced		Supported	Cell Junctions<br>Cytosol	Pancreatic cancer:3.14e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 73.0;skin: 59.3;testis: 48.4	parathyroid gland: 24.6	Cell line enhanced		NTERA-2: 49.7;SCLC-21H: 59.4
GOLIM4	GIMPC, GOLPH4, GPP130, P138	ENSG00000173905	Golgi integral membrane protein 4	3	168008677-168095975	Predicted membrane proteins	Evidence at protein level	HPA001677, HPA002315	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			small intestine: 93.8	Mixed		
KRT28	KRT25D	ENSG00000173908	Keratin 28	17	40792203-40799959	Predicted intracellular proteins	Evidence at protein level	HPA066890	Supported					Tissue enhanced	Tissue enhanced		breast: 1.0	testis: 0.4	Not detected		
RBM4B	MGC10871, RBM30, RBM4L, ZCCHC15, ZCCHC21B, ZCRB3B	ENSG00000173914	RNA binding motif protein 4B	11	66664998-66677921	Predicted intracellular proteins	Evidence at protein level	HPA042174, HPA047849	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.02e-4 (unfavourable), Pancreatic cancer:2.10e-4 (favourable), Liver cancer:2.94e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 36.2	Expressed in all		
USMG5	bA792D24.4, DAPIT, MGC14697	ENSG00000173915	Up-regulated during skeletal muscle growth 5 homolog (mouse)	10	103389041-103396466	Predicted membrane proteins	Evidence at protein level	HPA044798			Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 554.9	Expressed in all		
HOXB2	HOX2, HOX2H	ENSG00000173917	Homeobox B2	17	48540894-48544989	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047857			Supported	Nucleus	Glioma:3.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 56.6	cervix, uterine: 24.4	Cell line enhanced		AF22: 58.1;HEK 293: 59.6;HMC-1: 112.4;WM-115: 56.1
C1QTNF1	CTRP1, FLJ90694, GIP, ZSIG37	ENSG00000173918	C1q and tumor necrosis factor related protein 1	17	79022814-79049788	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025429	Approved				Renal cancer:9.09e-9 (unfavourable), Cervical cancer:2.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 155.0	seminal vesicle: 65.5	Cell line enhanced		ASC diff: 229.1;BJ hTERT+: 66.0;HHSteC: 105.8;U-87 MG: 78.1
MARCH3	MARCH-III, MGC48332, RNF173	ENSG00000173926	Membrane associated ring-CH-type finger 3	5	126867714-127030808	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043406	Uncertain		Supported	Vesicles		Mixed	Mixed			testis: 10.9	Cell line enhanced		hTEC/SVTERT24-B: 41.0;TIME: 27.2
SWSAP1	C19orf39, FLJ35119, SWS1AP1, ZSWIM7AP1	ENSG00000173928	SWIM-type zinc finger 7 associated protein 1	19	11374685-11376951	Predicted secreted proteins	Evidence at protein level	HPA052712	Uncertain				Stomach cancer:4.07e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 5.1	Mixed		
SLCO4C1	OATP-H, OATP4C1, OATPX, SLC21A20	ENSG00000173930	Solute carrier organic anion transporter family member 4C1	5	102233986-102296549	Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.12e-4 (favourable)	Tissue enriched	Tissue enhanced		kidney: 42.4	lung: 11.2	Cell line enhanced		Karpas-707: 12.0;RPTEC TERT1: 70.8;U-937: 19.1
RBM4	LARK, RBM4A, ZCCHC21, ZCRB3A	ENSG00000173933	RNA binding motif protein 4	11	66638617-66666682	Predicted intracellular proteins	Evidence at protein level	HPA042174, HPA047849	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 133.6	Expressed in all		
PIFO	C1orf88, FLJ23853, pitchfork	ENSG00000173947	Primary cilia formation	1	111346288-111353013	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.44e-4 (favourable), Pancreatic cancer:2.48e-4 (favourable)	Mixed	Tissue enriched	6	fallopian tube: 272.5	testis: 43.1	Cell line enhanced		RPTEC TERT1: 3.4;RT4: 4.3;T-47d: 3.5;U-87 MG: 3.4
XXYLT1	C3orf21, FLJ35155	ENSG00000173950	Xyloside xylosyltransferase 1	3	195068279-195271167	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.70e-4 (unfavourable)	Expressed in all	Mixed			placenta: 15.0	Expressed in all		
UBXN2A	UBXD4	ENSG00000173960	UBX domain protein 2A	2	23927285-24004909	Predicted intracellular proteins	Evidence at protein level	HPA065482, HPA069096	Supported		Approved	Centrosome	Liver cancer:1.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 12.5	Expressed in all		
RAX2	ARMD6, CORD11, MGC15631, RAXL1	ENSG00000173976	Retina and anterior neural fold homeobox 2	19	3769089-3772221	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052533	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 1.2	fallopian tube: 0.7	Not detected		
LRRC63	RP11-139H14.4	ENSG00000173988	Leucine rich repeat containing 63	13	46211943-46277366	Predicted intracellular proteins	Evidence at transcript level	HPA039318, HPA039763	Uncertain		Approved	Golgi apparatus		Not detected	Group enriched	6	cerebral cortex: 1.1;epididymis: 1.7;testis: 2.4	fallopian tube: 0.3	Cell line enhanced		HDLM-2: 1.1
TCAP	CMD1N, LGMD2G, T-cap, TELE, telethonin	ENSG00000173991	Titin-cap	17	39664187-39666555	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004591, HPA026477	Enhanced				Urothelial cancer:4.55e-4 (favourable)	Group enriched	Group enriched	18	heart muscle: 2132.6;skeletal muscle: 4963.5	esophagus: 195.0	Cell line enhanced		SK-BR-3: 5.6
CCS		ENSG00000173992	Copper chaperone for superoxide dismutase	11	66592821-66606019	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB008672, HPA040026, HPA044090	Approved					Expressed in all	Expressed in all			parathyroid gland: 21.7	Expressed in all		
NRROS	ELLP3030, GARPL1, LRRC33, MGC50789, UNQ3030	ENSG00000174004	Negative regulator of reactive oxygen species	3	196639686-196662004	Predicted membrane proteins	Evidence at protein level	HPA031586	Uncertain				Ovarian cancer:9.63e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 19.8	Cell line enhanced		HMC-1: 93.4;NB-4: 87.0;U-937: 59.2
CEP19	C3orf34, MGC14126	ENSG00000174007	Centrosomal protein 19	3	196706277-196712293	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047614, HPA071138	Enhanced		Supported	Centrosome		Expressed in all	Tissue enhanced		testis: 18.0	fallopian tube: 6.6	Mixed		
KLHL15	KIAA1677	ENSG00000174010	Kelch like family member 15	X	23983720-24027186	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065730	Uncertain		Approved	Aggresome<br>Cytosol		Expressed in all	Mixed			bone marrow: 34.7	Expressed in all		
FBXO45	Fbx45	ENSG00000174013	F-box protein 45	3	196568611-196589059	Predicted intracellular proteins	Evidence at protein level	HPA040730	Uncertain		Approved	Cytosol	Prostate cancer:1.16e-5 (unfavourable), Renal cancer:4.93e-5 (unfavourable), Liver cancer:7.61e-5 (unfavourable), Lung cancer:3.77e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.3	Expressed in all		
SPERT	CBY2, NURIT	ENSG00000174015	Spermatid associated	13	45702311-45714559	Predicted intracellular proteins	Evidence at protein level	HPA039359, HPA040046	Enhanced		Approved	Plasma membrane<br>Cell Junctions		Mixed	Tissue enriched	178	testis: 49.0	fallopian tube,urinary bladder: 0.2	Not detected		
FAM46D	CT1.26, CT112, MGC26999	ENSG00000174016	Family with sequence similarity 46 member D	X	80335504-80445311	Predicted intracellular proteins	Evidence at protein level	HPA059362	Uncertain					Not detected	Tissue enriched	52	testis: 6.2	prostate,thyroid gland: 0.1	Cell line enhanced		AN3-CA: 1.0
GNG5		ENSG00000174021	G protein subunit gamma 5	1	84498325-84506565	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB032623, HPA043651	Approved				Liver cancer:3.23e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 133.5	Expressed in all		
SLC25A30		ENSG00000174032	Solute carrier family 25 member 30	13	45393316-45418455	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045260			Approved	Nucleoplasm	Renal cancer:9.91e-8 (favourable), Ovarian cancer:3.32e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 46.1	Mixed		
C9orf131	MGC41945	ENSG00000174038	Chromosome 9 open reading frame 131	9	35041095-35045991	Predicted intracellular proteins	Evidence at transcript level	HPA022029			Approved	Mitochondria		Not detected	Tissue enriched	12	testis: 62.1	endometrium: 5.1	Cell line enhanced		RT4: 7.4
CD34		ENSG00000174059	CD34 molecule	1	207880972-207911402	CD markers, Predicted membrane proteins	Evidence at protein level	CAB000018, HPA036722, HPA036723	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cell Junctions	Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 316.6	Group enriched	7	HUVEC TERT2: 53.6;MOLT-4: 53.1
CTSF	CATSF, CLN13	ENSG00000174080	Cathepsin F	11	66563463-66568841	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002141, HPA031431, HPA055610	Approved		Approved	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:8.92e-7 (favourable)	Expressed in all	Expressed in all			ovary: 140.6	Cell line enhanced		SK-MEL-30: 123.6
MSRB3	DFNB74, DKFZp686C1178, FLJ36866	ENSG00000174099	Methionine sulfoxide reductase B3	12	65278643-65488244	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA014432	Uncertain				Renal cancer:8.85e-8 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable), Cervical cancer:3.84e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 181.5	Mixed		
LEMD3	MAN1	ENSG00000174106	LEM domain containing 3	12	65169571-65248327	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA025078, HPA076986	Uncertain		Supported	Nuclear membrane	Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.9	Expressed in all		
C16orf91	CCSMST1, gs103, URLC5	ENSG00000174109	Chromosome 16 open reading frame 91	16	1419744-1420800	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 11.9	Expressed in all		
TLR10	CD290	ENSG00000174123	Toll like receptor 10	4	38772239-38782990	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	7	appendix: 21.1;lymph node: 51.7;spleen: 34.7;tonsil: 45.1	urinary bladder: 5.5	Group enriched	65	Daudi: 51.1;REH: 22.0;U-698: 17.6
TLR1	CD281, KIAA0012, rsc786	ENSG00000174125	Toll like receptor 1	4	38790677-38856817	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			appendix: 37.2	Cell line enhanced		Daudi: 8.0;HUVEC TERT2: 10.5;RPMI-8226: 9.8;U-698: 14.4
TLR6	CD286	ENSG00000174130	Toll like receptor 6	4	38823715-38856817	CD markers, Predicted membrane proteins	Evidence at protein level	HPA062733			Approved	Endoplasmic reticulum		Mixed	Mixed			appendix: 14.0	Cell line enhanced		CAPAN-2: 11.7
FAM174A	NS5ATP6, TMEM157, UNQ1912	ENSG00000174132	Family with sequence similarity 174 member A	5	100535305-100586741	Predicted membrane proteins	Evidence at protein level	HPA019539	Approved		Approved	Golgi apparatus<br>Cytosol	Glioma:3.85e-6 (unfavourable), Renal cancer:5.48e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 51.5	Expressed in all		
RGMB	DRAGON, FLJ90406	ENSG00000174136	Repulsive guidance molecule family member b	5	98768650-98798643	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016993			Approved	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 43.6	Cell line enhanced		BJ: 267.0;HBF TERT88: 210.1
FAM53A	DNTNP	ENSG00000174137	Family with sequence similarity 53 member A	4	1617915-1684302	Predicted intracellular proteins	Evidence at protein level	HPA036452, HPA058138	Enhanced		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		testis: 17.5	thyroid gland: 7.8	Cell line enhanced		SCLC-21H: 9.1
NWD2	KIAA1239	ENSG00000174145	NACHT and WD repeat domain containing 2	4	37244220-37449465	Predicted intracellular proteins	Evidence at protein level	HPA046911	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 6.2;thyroid gland: 1.4	adipose tissue: 0.8	Not detected		
CYB561D1	FLJ39035, FLJ44753	ENSG00000174151	Cytochrome b561 family member D1	1	109494052-109502932	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027028	Uncertain				Pancreatic cancer:5.16e-6 (favourable), Renal cancer:2.22e-4 (favourable), Head and neck cancer:4.68e-4 (favourable)	Expressed in all	Mixed			skin: 21.4	Expressed in all		
GSTA3		ENSG00000174156	Glutathione S-transferase alpha 3	6	52896639-52909685	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Approved		Supported	Cytosol		Mixed	Tissue enhanced		adrenal gland: 56.1;fallopian tube: 102.0	placenta: 32.1	Not detected		
ZDHHC24		ENSG00000174165	Zinc finger DHHC-type containing 24	11	66520637-66546238	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA016619	Approved		Approved	Vesicles<br>Cytosol	Glioma:2.39e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 10.9	Expressed in all		
TRMT10C	FLJ20432, MRPP1, RG9MTD1	ENSG00000174173	TRNA methyltransferase 10C, mitochondrial RNase P subunit	3	101561862-101566446	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036671	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.32e-5 (favourable), Liver cancer:6.56e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.8	Expressed in all		
SELP	CD62, CD62P, GMP140, GRMP, PADGEM, PSEL	ENSG00000174175	Selectin P	1	169588849-169630193	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002145, HPA002655, HPA005990	Enhanced				Head and neck cancer:3.12e-4 (favourable)	Mixed	Mixed			smooth muscle: 20.6	Group enriched	46	EFO-21: 34.2;HEL: 30.9
CTU2	C16orf84, NCS2	ENSG00000174177	Cytosolic thiouridylase subunit 2	16	88706463-88715386	Predicted intracellular proteins	Evidence at protein level	HPA041135, HPA041894	Uncertain		Supported	Mitochondria	Liver cancer:5.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 10.3	Expressed in all		
MGA	FLJ12634, KIAA0518, MAD5, MXD5	ENSG00000174197	MGA, MAX dimerization protein	15	41621224-41773081	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA042278, HPA058183	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 16.2	Expressed in all		
C12orf66	FLJ32549	ENSG00000174206	Chromosome 12 open reading frame 66	12	64186316-64222296	Predicted intracellular proteins	Evidence at protein level	HPA046743, HPA052855	Uncertain		Enhanced	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle		Expressed in all	Expressed in all			parathyroid gland: 12.3	Expressed in all		
ARL13A	ARL13	ENSG00000174225	ADP ribosylation factor like GTPase 13A	X	100969708-100990829	Predicted intracellular proteins	Evidence at transcript level	HPA037377, HPA037378	Uncertain					Not detected	Tissue enriched	11	testis: 7.6	skin: 0.7	Cell line enhanced		CACO-2: 1.8
SNX31	MGC39715	ENSG00000174226	Sorting nexin 31	8	100572882-100663415	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA024284, HPA053466	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Testis cancer:1.47e-4 (favourable)	Tissue enriched	Tissue enhanced		urinary bladder: 32.4	esophagus: 7.3	Cell line enriched	51	RT4: 64.7
PIGG	FLJ20265, GPI7, LAS21	ENSG00000174227	Phosphatidylinositol glycan anchor biosynthesis class G	4	499210-540196	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015997	Uncertain		Uncertain	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			parathyroid gland: 35.6	Expressed in all		
PRPF8	hPrp8, Prp8, PRPC8, RP13, SNRNP220	ENSG00000174231	Pre-mRNA processing factor 8	17	1650629-1684882	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009941, CAB015457	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 94.4	Expressed in all		
ADCY6	AC6	ENSG00000174233	Adenylate cyclase 6	12	48766194-48789037	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB018365	Approved		Approved	Golgi apparatus	Liver cancer:8.23e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 44.6	Mixed		
REP15	RAB15EP	ENSG00000174236	RAB15 effector protein	12	27696519-27697596	Predicted intracellular proteins	Evidence at protein level	HPA040448, HPA059868	Approved				Colorectal cancer:9.43e-5 (favourable)	Mixed	Tissue enhanced		colon: 39.7;rectum: 70.4;stomach: 82.2	small intestine: 39.4	Mixed		
PITPNA	PITPN, VIB1A	ENSG00000174238	Phosphatidylinositol transfer protein alpha	17	1517718-1562816	Predicted intracellular proteins	Evidence at protein level	HPA000528	Uncertain		Approved	Vesicles<br>Cytosol	Pancreatic cancer:1.80e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Renal cancer:9.35e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 117.9	Expressed in all		
DDX23	prp28, PRPF28, SNRNP100, U5-100K	ENSG00000174243	DEAD-box helicase 23	12	48829764-48852842	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038680, HPA039037	Approved		Supported	Nucleus<br>Nucleoli	Liver cancer:3.03e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.2	Expressed in all		
ZNF80	pT17	ENSG00000174255	Zinc finger protein 80	3	114234631-114237578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065484	Uncertain					Not detected	Tissue enhanced		breast: 6.4	lymph node: 2.7	Cell line enhanced		MCF7: 1.2
ZNHIT2	C11orf5, FON	ENSG00000174276	Zinc finger HIT-type containing 2	11	65116403-65117708	Predicted intracellular proteins	Evidence at protein level	HPA058066	Uncertain					Expressed in all	Tissue enhanced		testis: 18.9	adrenal gland: 7.7	Mixed		
EVX2		ENSG00000174279	Even-skipped homeobox 2	2	176077472-176083913	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA041576	Uncertain					Not detected	Tissue enhanced		prostate: 2.0;seminal vesicle: 2.2;testis: 2.7	cervix, uterine: 1.1	Not detected		
ZBTB4	KAISO-L1, KIAA1538, ZNF903	ENSG00000174282	Zinc finger and BTB domain containing 4	17	7459366-7484263	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008980, HPA064763	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.65e-9 (favourable), Pancreatic cancer:2.53e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.8	Mixed		
TNK1		ENSG00000174292	Tyrosine kinase non receptor 1	17	7380534-7389774	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012065, HPA056452	Uncertain		Approved	Cell Junctions	Urothelial cancer:1.52e-4 (favourable), Endometrial cancer:4.28e-4 (favourable), Renal cancer:6.40e-4 (favourable)	Mixed	Mixed			skin: 5.1	Cell line enhanced		HaCaT: 8.0;T-47d: 6.9
ZHX3	KIAA0395, TIX1	ENSG00000174306	Zinc fingers and homeoboxes 3	20	41178448-41317672	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046498			Supported	Nucleoplasm	Urothelial cancer:1.84e-5 (unfavourable), Renal cancer:2.53e-5 (favourable), Endometrial cancer:1.62e-4 (unfavourable), Thyroid cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.5	Expressed in all		
PHLDA3	TIH1	ENSG00000174307	Pleckstrin homology like domain family A member 3	1	201464383-201469237	Predicted intracellular proteins	Evidence at protein level	HPA027601	Approved				Endometrial cancer:1.77e-4 (favourable), Renal cancer:3.67e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 61.5	Cell line enhanced		BEWO: 275.2;WM-115: 162.5
DIRC1		ENSG00000174325	Disrupted in renal carcinoma 1	2	188734155-188790104	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA068508			Approved	Nucleoplasm		Not detected	Not detected			gallbladder: 0.4	Cell line enhanced		ASC diff: 2.6;ASC TERT1: 18.9;HSkMC: 7.2
SLC16A11	FLJ90193, MCT11	ENSG00000174326	Solute carrier family 16 member 11	17	7041630-7043923	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:3.19e-7 (favourable), Pancreatic cancer:1.45e-5 (favourable), Liver cancer:2.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 8.9;parathyroid gland: 11.0	seminal vesicle: 3.8	Not detected		
SLC16A13	MCT13	ENSG00000174327	Solute carrier family 16 member 13	17	7036075-7040121	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA065245			Supported	Golgi apparatus	Pancreatic cancer:1.50e-4 (favourable)	Expressed in all	Mixed			liver: 15.4	Cell line enhanced		A549: 21.3
GLIS1	FLJ36155	ENSG00000174332	GLIS family zinc finger 1	1	53506237-53738106	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001409	Uncertain					Tissue enhanced	Tissue enhanced		seminal vesicle: 11.0	prostate: 3.6	Cell line enhanced		BJ hTERT+: 3.7;PC-3: 6.7;U-138 MG: 5.0
OR2Y1		ENSG00000174339	Olfactory receptor family 2 subfamily Y member 1	5	180739042-180740099	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CHRNA9	NACHRA9	ENSG00000174343	Cholinergic receptor nicotinic alpha 9 subunit	4	40335329-40355217	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		fallopian tube: 1.1	cerebral cortex,skin: 0.4	Cell line enriched	10	U-87 MG: 15.6
PODN	MGC24995, PCAN, PODOCAN, SLRR5A	ENSG00000174348	Podocan	1	53062052-53085502	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.02e-5 (unfavourable), Endometrial cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 161.0	ovary: 107.6	Cell line enhanced		BJ: 33.5;fHDF/TERT166: 18.5;HHSteC: 78.9;U-2197: 43.8
SLC6A19		ENSG00000174358	Solute carrier family 6 member 19	5	1201595-1225117	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037415, HPA043207	Enhanced		Approved	Nucleoli	Renal cancer:4.14e-6 (favourable)	Tissue enhanced	Group enriched	21	duodenum: 139.5;kidney: 91.8;small intestine: 156.9	rectum: 6.2	Group enriched	6	BEWO: 13.7;HEL: 16.3
C11orf45	FLJ43646, MGC35558	ENSG00000174370	Chromosome 11 open reading frame 45	11	128899565-128906035	Predicted secreted proteins	Evidence at transcript level	HPA039716	Uncertain		Approved	Cytosol		Mixed	Mixed			skin: 7.5	Cell line enhanced		HBEC3-KT: 8.0
EXO1	HEX1, hExoI	ENSG00000174371	Exonuclease 1	1	241847967-241895148	Predicted intracellular proteins	Evidence at protein level	HPA053079, HPA069738			Enhanced	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.94e-7 (unfavourable), Melanoma:2.04e-4 (unfavourable), Endometrial cancer:8.21e-4 (unfavourable)	Mixed	Mixed			bone marrow: 10.7	Mixed		
RALGAPA1	DKFZp667F074, GARNL1, GRIPE, KIAA0884, RalGAPalpha1, Tulip1	ENSG00000174373	Ral GTPase activating protein catalytic alpha subunit 1	14	35538352-35809304	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000851	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:9.76e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 53.4	Expressed in all		
LIG4		ENSG00000174405	DNA ligase 4	13	108207439-108218368	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001334, HPA057325	Supported		Supported	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 20.2	Expressed in all		
TRHR		ENSG00000174417	Thyrotropin releasing hormone receptor	8	109086621-109119584	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055162	Supported					Not detected	Not detected			thyroid gland: 0.2	Not detected		
GTF2IRD2B		ENSG00000174428	GTF2I repeat domain containing 2B	7	75092573-75149817	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056679, HPA056680			Approved	Nucleoplasm	Breast cancer:3.27e-4 (favourable)	Mixed	Expressed in all			ovary: 40.5	Expressed in all		
ABRA	STARS	ENSG00000174429	Actin binding Rho activating protein	8	106759483-106770245	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	9	heart muscle: 11.0;skeletal muscle: 49.8	esophagus: 3.3	Not detected		
ATP2A2	ATP2B, DAR, SERCA2	ENSG00000174437	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2	12	110280756-110351093	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA062605, HPA067892	Enhanced		Supported	Nucleoplasm		Expressed in all	Expressed in all			skeletal muscle: 1006.4	Expressed in all		
ZWILCH	FLJ10036, KNTC1AP	ENSG00000174442	Zwilch kinetochore protein	15	66504959-66550128	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:2.90e-5 (unfavourable), Renal cancer:2.58e-4 (unfavourable), Prostate cancer:7.34e-4 (unfavourable)	Expressed in all	Tissue enriched	7	testis: 97.0	lymph node: 13.5	Expressed in all		
RPL4	L4	ENSG00000174444	Ribosomal protein L4	15	66498015-66524532	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA034600	Uncertain		Supported	Nucleoli<br>Nuclear bodies<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:5.20e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 3692.5	Expressed in all		
SNAPC5	SNAP19	ENSG00000174446	Small nuclear RNA activating complex polypeptide 5	15	66490135-66497813	Predicted intracellular proteins	Evidence at protein level	HPA024379	Uncertain		Supported	Nucleus		Expressed in all	Expressed in all			testis: 63.7	Expressed in all		
STARD6		ENSG00000174448	StAR related lipid transfer domain containing 6	18	54324358-54357964	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	83	testis: 47.5	cerebral cortex,thyroid gland: 0.5	Cell line enhanced		HDLM-2: 1.9;Karpas-707: 1.9;U-266/70: 2.5
GOLGA6L2	CT105, FLJ36144	ENSG00000174450	Golgin A6 family-like 2	15	23439498-23447234	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	110	testis: 39.3	cerebral cortex: 0.3	Cell line enriched	6	U-266/70: 11.4
VWC2L		ENSG00000174453	Von Willebrand factor C domain containing protein 2-like	2	214411065-214578959	Predicted secreted proteins	Evidence at protein level	HPA044815, HPA059414	Uncertain					Not detected	Tissue enriched	31	cerebral cortex: 3.1	all non-specific tissues: 0.0	Not detected		
C12orf76	FLJ40142	ENSG00000174456	Chromosome 12 open reading frame 76	12	110027028-110073686	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA039713, HPA042013	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
ZCCHC12	FLJ16123, PNMA7A, SIZN, SIZN1	ENSG00000174460	Zinc finger CCHC-type containing 12	X	118823790-118826968	Predicted intracellular proteins	Evidence at protein level	HPA031016, HPA034940	Uncertain		Approved	Nuclear bodies	Thyroid cancer:3.42e-5 (favourable)	Tissue enriched	Group enriched	8	endometrium: 167.0;fallopian tube: 184.1;smooth muscle: 203.5	cerebral cortex: 24.3	Cell line enhanced		HAP1: 4.0;HEK 293: 9.1;NTERA-2: 3.1;SH-SY5Y: 2.6
CNTNAP2	Caspr2, KIAA0868, NRXN4	ENSG00000174469	Contactin associated protein-like 2	7	146116002-148420998	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002739	Enhanced					Tissue enhanced	Group enriched	11	cerebral cortex: 17.9;prostate: 6.0	fallopian tube: 1.0	Cell line enhanced		AF22: 7.9;CACO-2: 5.7;NTERA-2: 11.9;SCLC-21H: 28.5
GALNTL6	GalNAc-T6L, GALNT17	ENSG00000174473	Polypeptide N-acetylgalactosaminyltransferase-like 6	4	171812254-173041559	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031019	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 5.4;testis: 4.5	spleen: 1.9	Not detected		
LINGO2	LERN3, LRRN6C	ENSG00000174482	Leucine rich repeat and Ig domain containing 2	9	27948078-28670286	Predicted membrane proteins	Evidence at transcript level	HPA016633, CAB025361	Approved					Mixed	Tissue enhanced		endometrium: 11.9;smooth muscle: 12.9	thyroid gland: 5.0	Cell line enhanced		AN3-CA: 2.0;SH-SY5Y: 9.6;WM-115: 4.0
BBS1	FLJ23590	ENSG00000174483	Bardet-Biedl syndrome 1	11	66510606-66533627	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058283	Uncertain		Uncertain	Midbody		Mixed	Expressed in all			parathyroid gland: 65.8	Mixed		
DENND4A	IRLB, MYCPBP	ENSG00000174485	DENN domain containing 4A	15	65658046-65792293	Predicted intracellular proteins	Evidence at protein level	HPA065343	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 23.8	Expressed in all		
IGDCC3	HsT18880, PUNC	ENSG00000174498	Immunoglobulin superfamily DCC subclass member 3	15	65327127-65378040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015246	Approved					Tissue enhanced	Group enriched	5	cerebral cortex: 3.3;parathyroid gland: 14.6;placenta: 8.5;testis: 5.0	thyroid gland: 1.5	Cell line enhanced		AF22: 103.7;CACO-2: 22.5;Hep G2: 58.8
GCSAM	GCET2, HGAL, MGC40441	ENSG00000174500	Germinal center associated signaling and motility	3	112120841-112133305	Predicted intracellular proteins	Evidence at protein level	HPA002473	Approved					Mixed	Tissue enhanced		lymph node: 52.0;tonsil: 53.1	skin: 26.2	Group enriched	5	Daudi: 187.5;U-698: 102.8
ANKRD36C	DKFZp667P0924	ENSG00000174501	Ankyrin repeat domain 36C	2	95836919-95991831	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 22.0	bone marrow: 10.7	Cell line enhanced		PC-3: 28.8
SLC26A9		ENSG00000174502	Solute carrier family 26 member 9	1	205913048-205943460	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051485	Enhanced		Approved	Nucleus<br>Cell Junctions	Head and neck cancer:8.55e-5 (favourable)	Tissue enhanced	Group enriched	5	lung: 11.4;salivary gland: 31.5;stomach: 30.8	tonsil: 4.8	Group enriched	12	CAPAN-2: 11.8;Hep G2: 3.4
MFSD4A	DKFZp761N1114, FLJ25004, FLJ34577, MFSD4, UNQ3064	ENSG00000174514	Major facilitator superfamily domain containing 4A	1	205568885-205602918	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.27e-13 (favourable), Lung cancer:4.59e-4 (favourable), Cervical cancer:7.54e-4 (favourable)	Mixed	Tissue enhanced		kidney: 75.4;stomach: 111.7	cerebral cortex: 50.6	Cell line enhanced		HMC-1: 1.3;SCLC-21H: 1.9
PELI3	MGC35521	ENSG00000174516	Pellino E3 ubiquitin protein ligase family member 3	11	66466327-66477337	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033750, HPA038875, HPA062281	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:8.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Mixed		
TTC9B	FLJ30373	ENSG00000174521	Tetratricopeptide repeat domain 9B	19	40216058-40218399	Predicted secreted proteins	Evidence at protein level	HPA042496	Uncertain					Tissue enriched	Tissue enriched	67	cerebral cortex: 57.5	adrenal gland: 0.8	Cell line enriched	21	SCLC-21H: 31.6
MYO1H	FLJ37587	ENSG00000174527	Myosin IH	12	109347903-109455523	Predicted intracellular proteins	Evidence at protein level	HPA039516	Uncertain					Not detected	Tissue enriched	6	testis: 1.7	thyroid gland: 0.3	Not detected		
TMEM81	HC3107, KVLA2788, MGC75217, UNQ2788	ENSG00000174529	Transmembrane protein 81	1	205083129-205084460	Predicted membrane proteins	Evidence at protein level	HPA052515			Approved	Intermediate filaments	Renal cancer:6.65e-9 (unfavourable), Liver cancer:3.25e-6 (unfavourable), Urothelial cancer:2.67e-4 (favourable)	Expressed in all	Mixed			testis: 6.7	Expressed in all		
MRPL11		ENSG00000174547	Mitochondrial ribosomal protein L11	11	66435075-66466738	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA057685	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			fallopian tube: 26.7	Expressed in all		
KLK15	ACO, HSRNASPH, prostinogen	ENSG00000174562	Kallikrein related peptidase 15	19	50825289-50837213	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019802	Uncertain					Tissue enhanced	Tissue enhanced		colon: 3.2;salivary gland: 2.4	adrenal gland: 1.8	Cell line enriched	5	RPMI-8226: 1.7
IL20RB	DIRS1, FNDC6, IL-20R2, MGC34923	ENSG00000174564	Interleukin 20 receptor subunit beta	3	136946230-137011085	Predicted membrane proteins	Evidence at protein level	HPA063914			Approved	Vesicles<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.44e-4 (unfavourable)	Group enriched	Group enriched	9	esophagus: 56.6;skin: 165.5	breast: 12.4	Cell line enhanced		HaCaT: 70.0;HBEC3-KT: 93.7;HHSteC: 70.6;hTCEpi: 372.4;hTERT-HME1: 73.1
GOLT1A	CGI-141, FLJ42654, GOT1, MGC62027, YMR292W	ENSG00000174567	Golgi transport 1A	1	204198160-204214092	Predicted membrane proteins	Evidence at protein level						Renal cancer:6.35e-5 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Glioma:5.49e-4 (unfavourable)	Tissue enriched	Tissue enhanced		duodenum: 40.3;liver: 79.1;small intestine: 42.3	parathyroid gland: 28.1	Cell line enhanced		CACO-2: 12.3;CAPAN-2: 14.9;Hep G2: 14.6;MCF7: 27.7;RT4: 18.6;SK-BR-3: 17.2
AKIRIN1	C1orf108, FLJ12666	ENSG00000174574	Akirin 1	1	38991223-39006059	Predicted intracellular proteins	Evidence at protein level	HPA051871	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Liver cancer:5.39e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 127.9	Expressed in all		
NPAS4	bHLHe79, Le-PAS, NXF, PASD10	ENSG00000174576	Neuronal PAS domain protein 4	11	66421004-66426707	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039255	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.1;endometrium: 1.9	smooth muscle: 1.6	Not detected		
MSL2	FLJ10546, KIAA1585, msl-2, MSL2L1, RNF184	ENSG00000174579	Male-specific lethal 2 homolog (Drosophila)	3	136148922-136197241	Predicted intracellular proteins	Evidence at protein level	HPA003413, HPA048482	Uncertain		Approved	Cytosol	Cervical cancer:4.80e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.9	Expressed in all		
ZNF497	FLJ44773	ENSG00000174586	Zinc finger protein 497	19	58354357-58362848	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047872	Uncertain		Approved	Nucleus<br>Cell Junctions		Mixed	Mixed			fallopian tube: 8.1	Cell line enhanced		HEK 293: 18.3
TRAM1L1	MGC26568	ENSG00000174599	Translocation associated membrane protein 1-like 1	4	117083554-117085576	Predicted membrane proteins	Evidence at transcript level	HPA044560	Uncertain		Approved	Mitochondria		Mixed	Mixed			cerebral cortex: 14.2	Cell line enhanced		SH-SY5Y: 9.5;U-138 MG: 10.8
CMKLR1	RVER1	ENSG00000174600	Chemerin chemokine-like receptor 1	12	108288044-108339341	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA047865	Uncertain					Expressed in all	Mixed			spleen: 48.4	Group enriched	5	ASC diff: 9.6;ASC TERT1: 41.0;BJ hTERT+: 35.4;LHCN-M2: 11.1
ANGEL2	Ccr4d, FLJ12793, KIAA0759L	ENSG00000174606	Angel homolog 2	1	212992182-213015826	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030796	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:8.39e-6 (unfavourable), Urothelial cancer:1.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.0	Expressed in all		
UGT8	CGT	ENSG00000174607	UDP glycosyltransferase 8	4	114598455-114678224	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014405, HPA065785	Approved		Approved	Mitochondria	Renal cancer:8.55e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 101.0	kidney: 29.8	Cell line enhanced		CAPAN-2: 44.4;RPTEC TERT1: 37.0;SCLC-21H: 32.8
KY	FLJ33207	ENSG00000174611	Kyphoscoliosis peptidase	3	134603138-134651636	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036492, HPA036668	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		skin: 11.0	parathyroid gland: 9.3	Cell line enhanced		Karpas-707: 1.6;U-2197: 2.7;U-87 MG: 8.6
IQCK	FLJ36575, MGC35048	ENSG00000174628	IQ motif containing K	16	19716456-19858467	Predicted intracellular proteins	Evidence at transcript level	HPA026792, HPA048786	Approved		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			testis: 33.1	Mixed		
SLCO2A1	MATR1, OATP2A1, PGT, SLC21A2	ENSG00000174640	Solute carrier organic anion transporter family member 2A1	3	133932696-134052184	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA013742	Enhanced				Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable)	Expressed in all	Tissue enhanced		seminal vesicle: 114.6	thyroid gland: 71.3	Group enriched	5	EFO-21: 83.6;TIME: 17.5
ZNF266	HZF1	ENSG00000174652	Zinc finger protein 266	19	9412598-9435578	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026836, HPA054110	Uncertain		Enhanced	Nucleus<br>Vesicles<br>Rods & Rings	Head and neck cancer:3.94e-6 (favourable), Pancreatic cancer:3.03e-5 (favourable), Urothelial cancer:9.15e-5 (favourable), Cervical cancer:1.41e-4 (favourable), Renal cancer:1.82e-4 (unfavourable), Lung cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 117.7	Mixed		
OR7D4	hg105, OR19-B, OR7D4P	ENSG00000174667	Olfactory receptor family 7 subfamily D member 4	19	9213850-9214871	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
SLC29A2	DER12, ENT2, HNP36	ENSG00000174669	Solute carrier family 29 member 2	11	66362521-66372214	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018168	Approved		Uncertain	Nucleoplasm	Endometrial cancer:2.04e-4 (unfavourable), Renal cancer:2.78e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 36.4	parathyroid gland: 21.9	Cell line enhanced		CAPAN-2: 37.2;T-47d: 48.0
BRSK2	C11orf7, PEN11B, STK29	ENSG00000174672	BR serine/threonine kinase 2	11	1389899-1462689	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA073690			Approved	Golgi apparatus		Tissue enhanced	Tissue enhanced		cerebral cortex: 61.7;pancreas: 19.2	testis: 9.5	Cell line enhanced		NTERA-2: 27.4;SCLC-21H: 74.9
B4GAT1	B3GN-T1, B3GNT1, B3GNT6, BETA3GNTI, iGAT, iGNT	ENSG00000174684	Beta-1,4-glucuronyltransferase 1	11	66345372-66347692	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015484	Uncertain				Pancreatic cancer:3.55e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 185.2	adrenal gland: 52.4	Expressed in all		
TMEM167A	FLJ30508, MGC23909, TMEM167	ENSG00000174695	Transmembrane protein 167A	5	83052846-83077863	Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			adrenal gland: 61.9	Expressed in all		
LEP	OB, OBS	ENSG00000174697	Leptin	7	128241284-128257628	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010490, HPA030721	Approved	Approved				Tissue enhanced	Tissue enriched	11	adipose tissue: 322.5	breast: 29.6	Cell line enhanced		BEWO: 2.1
SH3PXD2B	FLJ20831, KIAA1295	ENSG00000174705	SH3 and PX domains 2B	5	172325000-172454523	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036471	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Liver cancer:7.51e-5 (unfavourable), Renal cancer:1.90e-4 (unfavourable), Urothelial cancer:8.45e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 35.7	Mixed		
KIAA1551	C12orf35, FLJ10652, FLJ20696, UTA2-1	ENSG00000174718	KIAA1551	12	31959370-31993107	Predicted intracellular proteins	Evidence at protein level	HPA013816, HPA015622	Approved		Supported	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:5.04e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 90.9	Expressed in all		
LARP7	DKFZP564K112, HDCMA18P, PIP7S	ENSG00000174720	La ribonucleoprotein domain family member 7	4	112636964-112657592	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026842, HPA027930	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:4.33e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 58.5	Expressed in all		
FGFBP3	C10orf13, MGC39320	ENSG00000174721	Fibroblast growth factor binding protein 3	10	91906589-91909483	Predicted secreted proteins	Evidence at protein level	HPA053943	Uncertain					Mixed	Tissue enriched	8	cerebral cortex: 19.5	thyroid gland: 2.5	Cell line enriched	11	AF22: 312.7
NR1D2	BD73, EAR-1r, Hs.37288, HZF2, RVR	ENSG00000174738	Nuclear receptor subfamily 1 group D member 2	3	23945260-23980618	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053868, HPA054798	Approved		Approved	Nucleoplasm	Renal cancer:4.47e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.4	Expressed in all		
PABPC5	PABP5	ENSG00000174740	Poly(A) binding protein cytoplasmic 5	X	91434595-91438584	Predicted intracellular proteins	Evidence at transcript level	HPA000164, HPA000165	Approved					Mixed	Tissue enhanced		ovary: 13.4	adrenal gland: 9.6	Cell line enhanced		AF22: 6.8;RH-30: 8.1
BRMS1	DKFZP564A063	ENSG00000174744	Breast cancer metastasis suppressor 1	11	66337333-66345125	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010824, HPA019637	Approved		Approved	Centrosome	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 36.3	Expressed in all		
RPL15	EC45, L15, RPL10, RPLY10, RPYL10	ENSG00000174748	Ribosomal protein L15	3	23916545-23923692	Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level							Expressed in all	Expressed in all			ovary: 3477.9	Expressed in all		
C4orf32	FLJ39370	ENSG00000174749	Chromosome 4 open reading frame 32	4	112145397-112195256	Predicted membrane proteins	Evidence at protein level	HPA062443, HPA069294	Approved		Supported	Golgi apparatus	Stomach cancer:8.87e-4 (unfavourable)	Mixed	Mixed			adipose tissue: 18.6	Cell line enhanced		Daudi: 29.7
HRAS	HRAS1	ENSG00000174775	HRas proto-oncogene, GTPase	11	532242-537287	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002015, HPA049830	Approved				Liver cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.0	Expressed in all		
WDR49	FLJ33620	ENSG00000174776	WD repeat domain 49	3	167478684-167653983	Predicted intracellular proteins	Evidence at protein level	HPA036225, HPA036226	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 18.4	small intestine: 5.0	Group enriched	17	AF22: 2.8;NTERA-2: 3.2;THP-1: 10.1;U-937: 6.2
SRP72		ENSG00000174780	Signal recognition particle 72	4	56466915-56503680	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA034621	Approved				Liver cancer:3.25e-6 (unfavourable), Colorectal cancer:3.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 89.0	Expressed in all		
PCP2	GPSM4, MGC41903	ENSG00000174788	Purkinje cell protein 2	19	7631611-7633748	Predicted intracellular proteins	Evidence at protein level	HPA057428			Approved	Nuclear speckles<br>Vesicles	Urothelial cancer:2.76e-5 (favourable), Breast cancer:7.93e-4 (favourable)	Mixed	Tissue enriched	9	testis: 72.6	skin: 8.1	Cell line enhanced		HMC-1: 7.2;NB-4: 11.1
RIN1		ENSG00000174791	Ras and Rab interactor 1	11	66330242-66336840	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA035491	Uncertain		Approved	Nucleus<br>Nuclear membrane	Renal cancer:9.34e-7 (unfavourable), Endometrial cancer:2.21e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 19.3	cerebral cortex: 5.2	Cell line enhanced		U-2197: 58.9
C4orf26	AI2A4, FLJ23657	ENSG00000174792	Chromosome 4 open reading frame 26	4	75556048-75565885	Disease related genes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	12	placenta: 5.9	cerebral cortex: 0.5	Cell line enriched	7	HDLM-2: 40.8
THAP6	MGC30052	ENSG00000174796	THAP domain containing 6	4	75513946-75550473	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035767	Uncertain		Approved	Nucleus<br>Centrosome		Expressed in all	Expressed in all			testis: 43.6	Expressed in all		
CEP135	CEP4, FLJ13621, KIAA0635	ENSG00000174799	Centrosomal protein 135	4	55948871-56033363	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073950			Uncertain	Focal adhesion sites	Urothelial cancer:6.11e-5 (favourable)	Mixed	Mixed			endometrium: 13.0	Expressed in all		
FZD4	CD344, EVR1	ENSG00000174804	Frizzled class receptor 4	11	86945679-86955391	CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA042328, HPA074833	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:8.60e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 127.3	seminal vesicle: 42.3	Cell line enhanced		ASC diff: 43.7;Hep G2: 57.9;HUVEC TERT2: 78.0;TIME: 37.7
CD248	CD164L1, TEM1	ENSG00000174807	CD248 molecule	11	66314487-66317044	CD markers, Predicted membrane proteins	Evidence at protein level	HPA051856	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Renal cancer:2.69e-7 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 136.8	placenta: 96.7	Cell line enhanced		ASC diff: 336.6;ASC TERT1: 336.4;BJ hTERT+: 268.5;fHDF/TERT166: 348.4;HSkMC: 374.9;U-2197: 735.8
BTC		ENSG00000174808	Betacellulin	4	74744759-74794686	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:6.10e-5 (favourable)	Mixed	Mixed			skin: 15.4	Cell line enhanced		CAPAN-2: 13.5;RPTEC TERT1: 6.9
PDZK1	NHERF3, PDZD1	ENSG00000174827	PDZ domain containing 1	1	145670852-145708148	Predicted intracellular proteins	Evidence at protein level	HPA005755, HPA006155, CAB008971	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:2.54e-7 (favourable)	Group enriched	Tissue enhanced		kidney: 561.5;small intestine: 127.1	duodenum: 69.0	Cell line enhanced		CACO-2: 83.6;RPTEC TERT1: 168.6;T-47d: 547.9
ADGRE1	EMR1, TM7LN3	ENSG00000174837	Adhesion G protein-coupled receptor E1	19	6887566-6940459	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA052809	Uncertain					Mixed	Tissue enhanced		appendix: 9.9;spleen: 19.7	lung: 6.8	Cell line enhanced		BJ hTERT+: 8.5;HDLM-2: 24.5;HMC-1: 15.9;Karpas-707: 16.0
DENND6A	AFI1A, FAM116A, FLJ34969	ENSG00000174839	DENN domain containing 6A	3	57625457-57693089	Predicted intracellular proteins	Evidence at protein level	HPA062618, HPA069725, HPA071711	Approved		Supported	Vesicles	Renal cancer:7.77e-6 (favourable), Liver cancer:6.36e-4 (unfavourable), Colorectal cancer:9.21e-4 (favourable)	Expressed in all	Expressed in all			ovary: 25.6	Expressed in all		
PDE12	2'-PDE, DKFZp667B1218	ENSG00000174840	Phosphodiesterase 12	3	57556276-57566844	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043171	Approved				Renal cancer:3.63e-8 (favourable), Colorectal cancer:2.85e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 15.9	Expressed in all		
GLMN	FAP48, FKBPAP, GLML, GVM, VMGLOM	ENSG00000174842	Glomulin, FKBP associated protein	1	92246402-92298987	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031446, HPA031448	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.89e-8 (unfavourable), Liver cancer:2.42e-5 (unfavourable), Colorectal cancer:1.71e-4 (favourable)	Expressed in all	Mixed			testis: 15.0	Expressed in all		
DNAH12	DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19	ENSG00000174844	Dynein axonemal heavy chain 12	3	57293699-57544344	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037493, HPA058203, HPA061365	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 16.3;testis: 11.1	lung: 2.7	Not detected		
YIF1A	54TM, FinGER7, YIF1, YIF1P	ENSG00000174851	Yip1 interacting factor homolog A, membrane trafficking protein	11	66284580-66289170	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014840	Approved		Supported	Golgi apparatus<br>Vesicles<br>Microtubule organizing center	Urothelial cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.3	Expressed in all		
CNIH2	CNIH-2, Cnil, MGC50896	ENSG00000174871	Cornichon family AMPA receptor auxiliary protein 2	11	66278190-66285301	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	11	cerebral cortex: 52.9	adrenal gland: 4.6	Cell line enhanced		SCLC-21H: 74.6;SH-SY5Y: 31.1
AMY1B	AMY1	ENSG00000174876	Amylase, alpha 1B (salivary)	1	103687415-103696680	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Tissue enhanced	Tissue enriched	15	salivary gland: 1841.0	cervix, uterine: 126.4	Not detected		
NLRP6	CLR11.4, NALP6, PAN3, PYPAF5	ENSG00000174885	NLR family pyrin domain containing 6	11	278365-285359	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043681, HPA048500	Supported				Liver cancer:4.23e-5 (favourable)	Mixed	Group enriched	13	duodenum: 39.4;small intestine: 40.2	appendix: 3.0	Cell line enhanced		REH: 1.8;U-266/70: 2.8
NDUFA11	B14.7	ENSG00000174886	NADH:ubiquinone oxidoreductase subunit A11	19	5891276-5904006	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072209			Uncertain	Mitochondria	Endometrial cancer:3.38e-5 (favourable), Cervical cancer:4.54e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 309.7	Expressed in all		
RSRC1	BM-011, MGC12197, SFRS21, SRrp53	ENSG00000174891	Arginine and serine rich coiled-coil 1	3	158105855-158545730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044792	Enhanced		Approved	Nuclear speckles	Endometrial cancer:7.40e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.0	Expressed in all		
CATSPERD	MGC39581, TMEM146	ENSG00000174898	Cation channel sperm associated auxiliary subunit delta	19	5720677-5778734	Predicted membrane proteins, Transporters	Evidence at protein level	HPA024056	Supported					Tissue enhanced	Tissue enriched	161	testis: 16.0	all non-specific tissues: 0.0	Cell line enriched	58	HEL: 6.9
PQLC2L	C3orf55	ENSG00000174899	PQ loop repeat containing 2 like	3	157543246-157677749	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054395	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		adipose tissue: 21.6;thyroid gland: 16.0	breast: 6.1	Cell line enhanced		ASC diff: 45.0;ASC TERT1: 25.3;EFO-21: 23.8;LHCN-M2: 28.4
RAB1B		ENSG00000174903	RAB1B, member RAS oncogene family	11	66268533-66277492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010225, HPA056141	Approved		Supported	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:1.09e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 185.0	Expressed in all		
OR9G1	OR9G5	ENSG00000174914	Olfactory receptor family 9 subfamily G member 1	11	56700388-56701305	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PTDSS2	PSS2	ENSG00000174915	Phosphatidylserine synthase 2	11	448268-491399	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA038928, HPA038929	Approved				Liver cancer:5.12e-9 (unfavourable)	Expressed in all	Expressed in all			testis: 25.5	Expressed in all		
C19orf70	MIC13, P117, QIL1	ENSG00000174917	Chromosome 19 open reading frame 70	19	5678421-5680896	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042672	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:7.60e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 79.9	Expressed in all		
C3orf33	AC3-33, FLJ31139	ENSG00000174928	Chromosome 3 open reading frame 33	3	155762617-155806351	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037663	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.48e-7 (favourable)	Expressed in all	Mixed			thyroid gland: 14.4	Mixed		
OR5M3		ENSG00000174937	Olfactory receptor family 5 subfamily M member 3	11	56469574-56470497	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SEZ6L2	FLJ90517, PSK-1	ENSG00000174938	Seizure related 6 homolog like 2	16	29871159-29899547	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA064471	Enhanced				Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 82.4;parathyroid gland: 58.4	adrenal gland: 30.6	Cell line enhanced		EFO-21: 72.2
ASPHD1		ENSG00000174939	Aspartate beta-hydroxylase domain containing 1	16	29900375-29919864	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045175	Uncertain				Pancreatic cancer:7.38e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 53.5	gallbladder: 11.9	Mixed		
KCTD13	FKSG86, PDIP1, POLDIP1	ENSG00000174943	Potassium channel tetramerization domain containing 13	16	29905012-29927035	Predicted intracellular proteins	Evidence at protein level	HPA043524	Enhanced		Supported	Nucleus<br>Nuclear bodies	Renal cancer:8.17e-4 (unfavourable), Colorectal cancer:8.54e-4 (unfavourable), Pancreatic cancer:9.05e-4 (favourable)	Expressed in all	Mixed			testis: 12.5	Mixed		
P2RY14	GPR105, KIAA0001	ENSG00000174944	Purinergic receptor P2Y14	3	151212117-151278467	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB022646	Uncertain				Renal cancer:1.72e-5 (unfavourable)	Mixed	Tissue enhanced		placenta: 45.9	esophagus: 23.3	Cell line enriched	77	HMC-1: 60.0
AMZ1	KIAA1950	ENSG00000174945	Archaelysin family metallopeptidase 1	7	2679522-2775500	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020233	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.0	endometrium: 1.5	Cell line enhanced		BEWO: 6.7;MCF7: 5.8;T-47d: 26.0
GPR171	H963	ENSG00000174946	G protein-coupled receptor 171	3	151197832-151203201	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062429	Approved					Mixed	Tissue enhanced		appendix: 29.8	lymph node: 21.5	Cell line enriched	21	U-266/70: 21.2
GPR149	IEDA, PGR10	ENSG00000174948	G protein-coupled receptor 149	3	154337672-154429715	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA018020	Uncertain					Not detected	Tissue enriched	6	seminal vesicle: 2.9	testis: 0.4	Not detected		
CD164L2		ENSG00000174950	CD164 molecule like 2	1	27379176-27383380	Predicted membrane proteins	Evidence at protein level	HPA062915	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:1.64e-5 (favourable)	Mixed	Tissue enhanced		fallopian tube: 46.3	skin: 10.7	Cell line enhanced		CAPAN-2: 3.5;HaCaT: 1.6;HBEC3-KT: 1.4;hTCEpi: 2.0;SK-BR-3: 1.9
FUT1	H, HSC	ENSG00000174951	Fucosyltransferase 1 (H blood group)	19	48748011-48755390	Blood group antigen proteins, Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:3.99e-4 (favourable)	Mixed	Mixed			stomach: 7.1	Cell line enhanced		HEL: 8.6;SCLC-21H: 8.1
DHX36	DDX36, KIAA1488, MLEL1	ENSG00000174953	DEAH-box helicase 36	3	154272546-154324497	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035399	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 63.3	Expressed in all		
OR5J2		ENSG00000174957	Olfactory receptor family 5 subfamily J member 2	11	56176618-56177556	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059466	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZIC4		ENSG00000174963	Zic family member 4	3	147386046-147406860	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at transcript level	HPA030194	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Group enriched	6	cerebral cortex: 4.3;skin: 1.4	skeletal muscle: 0.5	Cell line enhanced		AF22: 17.0;SH-SY5Y: 5.5
OR10AG1		ENSG00000174970	Olfactory receptor family 10 subfamily AG member 1	11	55967558-55968463	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4S2	OR4S2P, OST725	ENSG00000174982	Olfactory receptor family 4 subfamily S member 2	11	55650904-55651839	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FBXW8	FBW6, FBW8, FBX29, FBXO29	ENSG00000174989	F-box and WD repeat domain containing 8	12	116910956-117031148	Predicted intracellular proteins	Evidence at protein level	HPA038850, HPA038851	Enhanced		Supported	Cytosol		Expressed in all	Expressed in all			thyroid gland: 16.2	Expressed in all		
CA5A	CA5, CAV, CAVA	ENSG00000174990	Carbonic anhydrase 5A	16	87881546-87936529	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		liver: 1.3	bone marrow: 0.8	Cell line enhanced		Hep G2: 1.4
ZG16	hZG16, JCLN, JCLN1, ZG16A	ENSG00000174992	Zymogen granule protein 16	16	29778240-29782973	Predicted secreted proteins	Evidence at protein level	HPA052066, HPA052512	Enhanced					Tissue enriched	Group enriched	6	colon: 363.4;rectum: 502.4;small intestine: 121.4	duodenum: 57.7	Cell line enhanced		SK-BR-3: 1.7
KLC2	FLJ12387	ENSG00000174996	Kinesin light chain 2	11	66257294-66267860	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040416, HPA040434	Enhanced		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:3.16e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 63.8	Expressed in all		
SLC22A1	OCT1	ENSG00000175003	Solute carrier family 22 member 1	6	160121789-160158718	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029846	Approved				Liver cancer:1.35e-5 (favourable)	Tissue enriched	Tissue enriched	253	liver: 286.8	gallbladder: 1.1	Not detected		
TEX36	bA383C5.1, C10orf122	ENSG00000175018	Testis expressed 36	10	125576522-125683144	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	64	testis: 47.4	smooth muscle: 0.7	Cell line enriched	8	U-2197: 7.9
CTBP2	ribeye	ENSG00000175029	C-terminal binding protein 2	10	124984317-125161170	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023559, HPA023564, CAB031916, HPA044971, CAB079018	Approved	Supported	Approved	Cytosol	Renal cancer:1.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 90.2	Mixed		
CHST2	C6ST	ENSG00000175040	Carbohydrate sulfotransferase 2	3	143119331-143124014	Predicted membrane proteins	Evidence at protein level	HPA013620			Supported	Golgi apparatus		Expressed in all	Mixed			spleen: 15.2	Cell line enhanced		HHSteC: 89.5;HMC-1: 44.1
ZDHHC14	FLJ20984, NEW1CP	ENSG00000175048	Zinc finger DHHC-type containing 14	6	157381133-157678146	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046033, HPA063754	Uncertain		Approved	Nucleoli<br>Mitochondria	Pancreatic cancer:6.93e-4 (favourable)	Expressed in all	Mixed			endometrium: 12.3	Cell line enhanced		HDLM-2: 47.1
ATR	FRP1, MEC1, SCKL, SCKL1	ENSG00000175054	ATR serine/threonine kinase	3	142449235-142578826	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054320			Supported	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
UBE2C	UBCH10	ENSG00000175063	Ubiquitin conjugating enzyme E2 C	20	45812576-45816957	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011464, HPA034569, CAB035990, HPA054975	Approved		Enhanced	Plasma membrane<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.24e-6 (unfavourable), Pancreatic cancer:6.91e-4 (unfavourable)	Expressed in all	Mixed			tonsil: 56.9	Mixed		
DSG4	CDHF13, LAH	ENSG00000175065	Desmoglein 4	18	31376777-31414912	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059456	Supported					Not detected	Not detected			testis: 0.8	Cell line enriched	157	HaCaT: 37.3
GK5	MGC40579	ENSG00000175066	Glycerol kinase 5 (putative)	3	142157527-142225607	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042606, HPA057998	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			prostate: 13.6	Expressed in all		
VCPIP1	DUBA3, FLJ23132, KIAA1850, VCIP135	ENSG00000175073	Valosin containing protein interacting protein 1	8	66628487-66667217	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023932	Uncertain		Approved	Plasma membrane		Expressed in all	Mixed			bone marrow: 13.1	Expressed in all		
RTP1	MGC35450, Z3CXXC1	ENSG00000175077	Receptor transporter protein 1	3	187197486-187201465	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.3	testis: 0.7	Cell line enriched	24	T-47d: 2.4
DES	CMD1I, CSM1, CSM2	ENSG00000175084	Desmin	2	219418377-219426739	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000034, HPA018803	Enhanced		Supported	Intermediate filaments	Renal cancer:5.08e-4 (unfavourable)	Expressed in all	Tissue enhanced		heart muscle: 4151.2;skeletal muscle: 5462.0;smooth muscle: 3601.2	seminal vesicle: 3128.9	Cell line enhanced		HSkMC: 50.9;LHCN-M2: 120.4;RH-30: 321.1
PDIK1L	CLIK1L	ENSG00000175087	PDLIM1 interacting kinase 1 like	1	26111165-26125543	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA064157			Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
SPSB4	SSB-4	ENSG00000175093	SplA/ryanodine receptor domain and SOCS box containing 4	3	141051402-141148611	Predicted intracellular proteins	Evidence at protein level	HPA062793			Approved	Nucleoplasm<br>Golgi apparatus	Glioma:2.57e-4 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 1.3;spleen: 1.5;testis: 2.4	pancreas: 1.2	Cell line enhanced		AF22: 12.9;NTERA-2: 3.7;RH-30: 4.3;SH-SY5Y: 3.9;U-2 OS: 3.1
RAG2		ENSG00000175097	Recombination activating 2	11	36575574-36598279	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065704			Approved	Nucleoplasm		Tissue enriched	Tissue enriched	22	thyroid gland: 40.1	testis: 1.8	Group enriched	114	MOLT-4: 37.4;REH: 167.6
TRAF6	RNF85	ENSG00000175104	TNF receptor associated factor 6	11	36487027-36510272	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004605, HPA019805, HPA020599	Approved		Supported	Nucleoli<br>Mitochondria	Renal cancer:1.36e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 16.2	Expressed in all		
ZNF654	FLJ10997, FLJ21142	ENSG00000175105	Zinc finger protein 654	3	88059274-88144665	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036172, HPA036173, HPA049262, HPA077939	Uncertain		Supported	Nucleoplasm<br>Microtubules	Prostate cancer:9.97e-6 (unfavourable)	Expressed in all	Mixed			testis: 11.8	Expressed in all		
TVP23C	FAM18B2, MGC8763	ENSG00000175106	Trans-golgi network vesicle protein 23 homolog C	17	15502264-15563595	Predicted membrane proteins	Evidence at protein level	HPA019585, HPA065603	Uncertain		Enhanced	Golgi apparatus		Mixed	Mixed			thyroid gland: 10.3	Mixed		
MRPS22	C3orf5, GIBT, GK002, MRP-S22	ENSG00000175110	Mitochondrial ribosomal protein S22	3	139005806-139357223	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA006083, HPA007830	Enhanced		Supported	Mitochondria	Endometrial cancer:1.35e-5 (unfavourable), Pancreatic cancer:1.55e-5 (unfavourable), Prostate cancer:1.85e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 69.5	Expressed in all		
PACS1	FLJ10209, KIAA1175	ENSG00000175115	Phosphofurin acidic cluster sorting protein 1	11	66070363-66244747	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038914	Approved		Approved	Microtubules<br>Cytosol		Expressed in all	Expressed in all			testis: 74.1	Expressed in all		
WFDC5	dJ211D12.5, WAP1	ENSG00000175121	WAP four-disulfide core domain 5	20	45109452-45115172	Predicted secreted proteins	Evidence at transcript level						Renal cancer:2.32e-5 (unfavourable)	Tissue enhanced	Tissue enriched	35	skin: 468.5	breast: 13.2	Not detected		
MARCKSL1	F52, MacMARCKS, MLP, MLP1	ENSG00000175130	MARCKS like 1	1	32333832-32336379	Predicted intracellular proteins	Evidence at protein level	CAB020787, HPA030528	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Liver cancer:1.78e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 315.1	Cell line enhanced		AF22: 902.3;NTERA-2: 883.9
SH3BP5L	KIAA1720	ENSG00000175137	SH3 binding domain protein 5 like	1	248810446-248826633	Predicted intracellular proteins	Evidence at protein level	HPA038067, HPA038068	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Expressed in all			cerebral cortex: 19.7	Expressed in all		
OR2T1	OR1-25	ENSG00000175143	Olfactory receptor family 2 subfamily T member 1	1	248405995-248407104	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA063064	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
YPEL2	FKSG4	ENSG00000175155	Yippee like 2	17	59331689-59401729	Predicted intracellular proteins	Evidence at protein level	HPA030501, HPA045621	Uncertain				Endometrial cancer:6.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.2	Cell line enhanced		HDLM-2: 26.2
CADM2	IGSF4D, Necl-3, NECL3, SynCAM2	ENSG00000175161	Cell adhesion molecule 2	3	84958981-86074429	Predicted membrane proteins	Evidence at protein level	HPA010024	Enhanced					Tissue enriched	Tissue enriched	14	cerebral cortex: 86.2	seminal vesicle: 6.2	Cell line enhanced		AF22: 10.8;AN3-CA: 29.1
ABO	A3GALNT, A3GALT1	ENSG00000175164	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	9	133250401-133275214	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		small intestine: 17.9	colon: 7.3	Group enriched	7	A-431: 4.5;CAPAN-2: 18.7;HaCaT: 14.1;K-562: 18.6;RT4: 6.3
PSMD2	MGC14274, P97, Rpn1, S2, TRAP2	ENSG00000175166	Proteasome 26S subunit, non-ATPase 2	3	184298709-184309054	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045192	Approved				Liver cancer:6.63e-7 (unfavourable), Lung cancer:1.55e-4 (unfavourable), Head and neck cancer:9.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 163.6	Expressed in all		
FAM182B		ENSG00000175170	Family with sequence similarity 182 member B	20	25763466-25868225	Predicted intracellular proteins	Evidence at transcript level	HPA050100	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		testis: 11.8	fallopian tube: 6.7	Cell line enriched	5	SCLC-21H: 15.8
PPM1E	CaMKP-N, KIAA1072, POPX1, PP2CH	ENSG00000175175	Protein phosphatase, Mg2+/Mn2+ dependent 1E	17	58755869-58985176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018462, HPA019263	Approved		Approved	Nucleus<br>Nucleoli		Tissue enhanced	Group enriched	5	adrenal gland: 7.3;cerebral cortex: 20.5;testis: 12.1	fallopian tube: 2.4	Cell line enhanced		AF22: 12.1;HAP1: 20.6;SCLC-21H: 10.7;SH-SY5Y: 19.9
FAM131A	C3orf40, MGC21688	ENSG00000175182	Family with sequence similarity 131 member A	3	184335926-184348421	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042800	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 100.5	Mixed		
CSRP2	CRP2, LMO5, SmLIM	ENSG00000175183	Cysteine and glycine rich protein 2	12	76858715-76879060	Predicted intracellular proteins	Evidence at protein level	HPA045617	Uncertain				Renal cancer:4.48e-5 (unfavourable), Prostate cancer:8.52e-4 (favourable)	Expressed in all	Mixed			placenta: 114.6	Cell line enhanced		AF22: 320.2
INHBC		ENSG00000175189	Inhibin beta C subunit	12	57434760-57450828	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	42	liver: 85.9	testis: 2.0	Cell line enhanced		Hep G2: 4.5;Karpas-707: 4.7;RH-30: 3.2;U-266/70: 2.6
PARL	PRO2207, PSARL, PSARL1, RHBDS1	ENSG00000175193	Presenilin associated rhomboid like	3	183829271-183884933	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019545	Approved		Approved	Mitochondria	Urothelial cancer:9.11e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 71.1	Expressed in all		
DDIT3	CHOP, CHOP10, GADD153	ENSG00000175197	DNA damage inducible transcript 3	12	57516588-57520517	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058416, HPA068416	Approved		Supported	Nucleoplasm	Liver cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 263.6	Expressed in all		
PCCA		ENSG00000175198	Propionyl-CoA carboxylase alpha subunit	13	100089015-100530437	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041716, HPA047792	Enhanced				Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			epididymis: 266.0	Cell line enhanced		RPTEC TERT1: 124.8;SCLC-21H: 107.6;U-937: 103.1
HIGD2B	HIGD2BP	ENSG00000175202	HIG1 hypoxia inducible domain family member 2B	15	72675783-72686149	Predicted membrane proteins	Evidence at protein level	HPA019016, HPA042715	Uncertain		Supported	Mitochondria<br>Cytosol		Not detected	Tissue enriched	14	testis: 6.7	epididymis,thyroid gland: 0.4	Not detected		
DCTN2	DCTN-50, RBP50	ENSG00000175203	Dynactin subunit 2	12	57530102-57547331	Predicted intracellular proteins	Evidence at protein level	HPA039715, HPA040040	Enhanced		Enhanced	Centrosome	Liver cancer:1.38e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 163.0	Expressed in all		
NPPA	ANP, PND	ENSG00000175206	Natriuretic peptide A	1	11845709-11848345	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058269	Enhanced	Supported				Tissue enriched	Tissue enriched	1345	heart muscle: 24003.4	epididymis: 17.8	Cell line enhanced		SCLC-21H: 13.6;SH-SY5Y: 11.7
ZNF408	FLJ12827	ENSG00000175213	Zinc finger protein 408	11	46700818-46705912	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017892	Uncertain		Approved	Microtubule organizing center<br>Cytosol	Liver cancer:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 8.3	Expressed in all		
CTDSP2	OS4, PSR2, SCP2	ENSG00000175215	CTD small phosphatase 2	12	57819927-57846739	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052607	Uncertain		Uncertain	Nucleoplasm		Expressed in all	Expressed in all			lung: 170.1	Cell line enriched	7	RH-30: 1169.3
CKAP5	ch-TOG, KIAA0097, TOG, TOGp	ENSG00000175216	Cytoskeleton associated protein 5	11	46743048-46846308	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039377, HPA040375	Enhanced		Supported	Nucleoli<br>Plasma membrane<br>Centrosome	Liver cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 66.2	Expressed in all		
ARHGAP1	CDC42GAP, p50rhoGAP, RhoGAP	ENSG00000175220	Rho GTPase activating protein 1	11	46677080-46700615	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA004689, HPA008285	Approved	Approved	Supported	Vesicles	Liver cancer:2.14e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 116.2	Expressed in all		
MED16	DRIP92, THRAP5, TRAP95	ENSG00000175221	Mediator complex subunit 16	19	867630-893218	Predicted intracellular proteins	Evidence at protein level	HPA030685, HPA046495	Uncertain		Approved	Nucleoli	Renal cancer:1.11e-5 (favourable), Endometrial cancer:5.46e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 28.9	Expressed in all		
ATG13	KIAA0652	ENSG00000175224	Autophagy related 13	11	46617527-46674818	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA039350			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:8.59e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 111.6	Expressed in all		
GAL3ST3	GAL3ST2	ENSG00000175229	Galactose-3-O-sulfotransferase 3	11	66041952-66049180	Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.53e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 4.3;endometrium: 4.3;smooth muscle: 4.8;thyroid gland: 8.2	seminal vesicle: 2.5	Group enriched	5	NTERA-2: 8.8;SH-SY5Y: 7.6
C1orf127	FLJ37118	ENSG00000175262	Chromosome 1 open reading frame 127	1	10946471-10982037	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA027654	Uncertain					Tissue enriched	Tissue enhanced		skeletal muscle: 5.7	stomach: 2.1	Cell line enhanced		THP-1: 1.7
CHST1	C6ST, KSGal6ST	ENSG00000175264	Carbohydrate sulfotransferase 1	11	45648877-45665622	Enzymes, Predicted secreted proteins	Evidence at protein level						Renal cancer:4.64e-7 (unfavourable), Liver cancer:3.95e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 49.0;parathyroid gland: 19.1	thyroid gland: 9.9	Cell line enhanced		HUVEC TERT2: 11.4;TIME: 10.8;WM-115: 35.6
GOLGA8A	GM88, GOLGIN-67	ENSG00000175265	Golgin A8 family member A	15	34379068-34437466	Predicted intracellular proteins	Evidence at transcript level	HPA051808	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.16e-6 (unfavourable), Urothelial cancer:5.68e-6 (favourable), Lung cancer:7.58e-4 (favourable)	Expressed in all	Mixed			skin: 41.0	Mixed		
VWA3A	FLJ40941, FLJ46765	ENSG00000175267	Von Willebrand factor A domain containing 3A	16	22092538-22156966	Predicted intracellular proteins	Evidence at protein level	HPA041696, HPA042044	Uncertain				Endometrial cancer:8.15e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 10.8;testis: 3.3	lung: 2.8	Not detected		
TP53I11	PIG11	ENSG00000175274	Tumor protein p53 inducible protein 11	11	44885903-44951306	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059727, HPA061276	Uncertain		Supported	Endoplasmic reticulum<br>Golgi apparatus	Breast cancer:7.33e-5 (unfavourable), Renal cancer:4.65e-4 (unfavourable), Melanoma:6.12e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 58.4	Cell line enhanced		SCLC-21H: 453.7;T-47d: 206.4
CENPS	APITD1, CENP-S, FAAP16, MHF1	ENSG00000175279	Centromere protein S	1	10430443-10442809	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:1.24e-4 (favourable)	Expressed in all	Expressed in all			testis: 84.5	Expressed in all		
DOLK	DK1, KIAA1094, TMEM15	ENSG00000175283	Dolichol kinase	9	128945530-128947619	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA066767, HPA068706			Supported	Nucleus<br>Nucleoli	Thyroid cancer:6.88e-5 (favourable), Renal cancer:5.53e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 24.7	Expressed in all		
PHYHD1	MGC16638	ENSG00000175287	Phytanoyl-CoA dioxygenase domain containing 1	9	128920895-128942041	Predicted intracellular proteins	Evidence at protein level	HPA012115			Approved	Nuclear speckles	Renal cancer:6.38e-10 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 59.9	Cell line enhanced		ASC diff: 31.7;BEWO: 49.9;RPTEC TERT1: 59.0
CATSPER1	CATSPER	ENSG00000175294	Cation channel sperm associated 1	11	66016752-66026517	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	31	testis: 20.4	lung: 0.6	Cell line enhanced		CAPAN-2: 3.8;EFO-21: 3.7;HEL: 2.4;HMC-1: 4.4
CCNE2	CYCE2	ENSG00000175305	Cyclin E2	8	94879770-94896678	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB007825, CAB019374	Enhanced				Head and neck cancer:5.87e-4 (favourable), Lung cancer:8.77e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 25.6	bone marrow: 22.4	Mixed		
PHYKPL	AGXT2L2, MGC15875	ENSG00000175309	5-phosphohydroxy-L-lysine phospho-lyase	5	178208497-178232791	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036461, HPA063608	Approved		Approved	Mitochondria	Renal cancer:3.82e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 34.5	Expressed in all		
ANKS4B	FLJ38819, HARP	ENSG00000175311	Ankyrin repeat and sterile alpha motif domain containing 4B	16	21233665-21253845	Predicted intracellular proteins	Evidence at protein level	HPA043523	Approved		Approved	Nucleoplasm<br>Cytosol		Group enriched	Tissue enhanced		duodenum: 9.0;rectum: 7.8;small intestine: 12.9	colon: 6.8	Group enriched	10	CACO-2: 1.1;HDLM-2: 3.2;Hep G2: 5.5
CST6		ENSG00000175315	Cystatin E/M	11	66011841-66013505	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB019316, HPA044963	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	9	skin: 213.2	breast: 24.9	Group enriched	6	A-431: 83.9;CAPAN-2: 228.1
GRAMD2		ENSG00000175318	GRAM domain containing 2	15	72159807-72197785	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029435	Uncertain		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol	Thyroid cancer:7.01e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 43.8;placenta: 69.9	lung: 22.8	Group enriched	15	BEWO: 159.8;SK-BR-3: 56.9
ZNF519	FLJ36809, HsT2362	ENSG00000175322	Zinc finger protein 519	18	14057457-14132490	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028982	Uncertain		Approved	Nucleoli		Mixed	Mixed			endometrium: 4.0	Mixed		
LSM1	CASM, YJL124C	ENSG00000175324	LSM1 homolog, mRNA degradation associated	8	38163321-38176730	Predicted intracellular proteins	Evidence at protein level	HPA024601			Supported	Vesicles<br>Cytosol		Expressed in all	Expressed in all			placenta: 35.7	Expressed in all		
PROP1		ENSG00000175325	PROP paired-like homeobox 1	5	177992235-177996242	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049839	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ISX	RAXLX	ENSG00000175329	Intestine specific homeobox	22	35066136-35087387	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060328	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Group enriched	36	colon: 27.4;duodenum: 37.5;rectum: 28.2;small intestine: 29.7	smooth muscle: 0.8	Group enriched	12	CACO-2: 1.3;Hep G2: 3.1
BANF1	BAF	ENSG00000175334	Barrier to autointegration factor 1	11	66002079-66004149	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB032896, HPA039242	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 240.0	Expressed in all		
APOF		ENSG00000175336	Apolipoprotein F	12	56360569-56362823	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	111	liver: 220.1	prostate: 1.9	Cell line enriched	9	Hep G2: 3.0
CHRNA7		ENSG00000175344	Cholinergic receptor nicotinic alpha 7 subunit	15	31923438-32173018	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029422, CAB033624	Enhanced					Mixed	Tissue enhanced		adrenal gland: 9.4;small intestine: 10.4	stomach: 6.2	Cell line enhanced		AN3-CA: 5.8;RT4: 9.8;SH-SY5Y: 7.1;SK-BR-3: 10.0;U-2 OS: 11.2
TMEM9B	C11orf15	ENSG00000175348	TMEM9 domain family member B	11	8947294-8965011	Predicted membrane proteins	Evidence at protein level	HPA037784	Uncertain				Renal cancer:4.26e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 129.7	Expressed in all		
NRIP3	C11orf14	ENSG00000175352	Nuclear receptor interacting protein 3	11	8980576-9004049	Predicted intracellular proteins	Evidence at protein level	HPA040573, HPA058827	Uncertain		Approved	Cytosol		Mixed	Tissue enhanced		cerebral cortex: 36.5;testis: 55.5	adrenal gland: 13.3	Cell line enhanced		HMC-1: 44.7;SiHa: 35.9;U-87 MG: 46.3
PTPN2	PTPT, TC-PTP, TCELLPTP, TCPTP	ENSG00000175354	Protein tyrosine phosphatase, non-receptor type 2	18	12785478-12929643	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015004, HPA046176	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.20e-8 (unfavourable), Ovarian cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 52.5	Expressed in all		
SCUBE2	Cegb1, Cegf1, FLJ16792	ENSG00000175356	Signal peptide, CUB domain and EGF like domain containing 2	11	9020391-9138114	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA006353, HPA029871	Uncertain				Breast cancer:2.41e-4 (favourable)	Expressed in all	Mixed			epididymis: 63.1	Cell line enhanced		HAP1: 6.0;SK-MEL-30: 6.6;T-47d: 26.8
EIF1AD	haponin, MGC11102	ENSG00000175376	Eukaryotic translation initiation factor 1A domain containing	11	65996545-66002176	Predicted intracellular proteins	Evidence at protein level	HPA054991, HPA058735	Uncertain		Supported	Nucleoplasm<br>Vesicles	Endometrial cancer:3.59e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.9	Expressed in all		
SMAD2	JV18-1, MADH2, MADR2	ENSG00000175387	SMAD family member 2	18	47808957-47931146	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB025507, HPA067203, CAB073546	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:9.44e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 126.7	Expressed in all		
EIF3F	eIF3-epsilon, eIF3-p47, eIF3f, EIF3S5	ENSG00000175390	Eukaryotic translation initiation factor 3 subunit F	11	7970251-8001862	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049250	Approved		Uncertain	Nucleoli<br>Cytosol	Liver cancer:6.86e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 178.4	Expressed in all		
ZNF25	FLJ31890, KOX19, Zfp9	ENSG00000175395	Zinc finger protein 25	10	37949572-37976633	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA030190	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			cerebral cortex: 26.9	Mixed		
OR10P1	OR10P1P, OR10P2P, OR10P3P, OST701	ENSG00000175398	Olfactory receptor family 10 subfamily P member 1	12	55636860-55637854	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			heart muscle: 0.2	Not detected		
ARL10	ARL10A	ENSG00000175414	ADP ribosylation factor like GTPase 10	5	176365468-176401865	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047044	Approved					Mixed	Mixed			skin: 17.0	Mixed		
CLTB	Lcb	ENSG00000175416	Clathrin light chain B	5	176392455-176416569	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003692, HPA036458	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Renal cancer:7.89e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 242.7	Expressed in all		
PCSK1	NEC1, PC1, PC3, SPC3	ENSG00000175426	Proprotein convertase subtilisin/kexin type 1	5	96390415-96434143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048564	Approved				Glioma:1.31e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 33.6	adrenal gland: 8.3	Group enriched	6	SCLC-21H: 26.6;U-138 MG: 18.8;U-87 MG: 15.5
LPL	LIPD	ENSG00000175445	Lipoprotein lipase	8	19901717-19967258	Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048749			Supported	Vesicles	Urothelial cancer:6.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 976.8	heart muscle: 239.2	Cell line enriched	7	AF22: 363.8
RFESD		ENSG00000175449	Rieske Fe-S domain containing	5	95646754-95684773	Predicted intracellular proteins	Evidence at protein level	CAB016546	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.1	bone marrow: 16.5	Group enriched	5	HEL: 37.0;K-562: 69.7
CCDC14	DKFZp434L1050, FLJ12892	ENSG00000175455	Coiled-coil domain containing 14	3	123897305-123961408	Predicted intracellular proteins	Evidence at protein level	HPA035278, HPA035279	Uncertain		Enhanced	Centrosome	Renal cancer:3.50e-8 (unfavourable), Urothelial cancer:2.72e-5 (favourable), Prostate cancer:4.76e-4 (unfavourable), Liver cancer:4.82e-4 (unfavourable), Head and neck cancer:5.27e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.5	Expressed in all		
TBC1D10C	Carabin, EPI64C, FLJ00332	ENSG00000175463	TBC1 domain family member 10C	11	67403915-67410089	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069743	Enhanced		Approved	Nuclear bodies	Renal cancer:4.35e-7 (unfavourable), Head and neck cancer:1.86e-5 (favourable), Breast cancer:3.83e-4 (favourable), Cervical cancer:4.20e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 45.6;spleen: 37.9	appendix: 22.0	Cell line enhanced		MOLT-4: 34.1;NB-4: 32.0;U-937: 16.2
SART1	Ara1, SNRNP110, Snu66	ENSG00000175467	Squamous cell carcinoma antigen recognized by T-cells 1	11	65961689-65979828	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031188, HPA031189, HPA031190	Supported		Enhanced	Nuclear speckles<br>Golgi apparatus		Expressed in all	Expressed in all			spleen: 32.3	Expressed in all		
PPP2R2D	MDS026	ENSG00000175470	Protein phosphatase 2 regulatory subunit Bdelta	10	131900644-131959834	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770	Approved		Approved	Cytosol	Colorectal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 6.7	Mixed		
MCTP1	FLJ22344	ENSG00000175471	Multiple C2 and transmembrane domain containing 1	5	94703741-95284575	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019018	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			bone marrow: 29.0	Mixed		
POLD4	p12, POLDS	ENSG00000175482	DNA polymerase delta 4, accessory subunit	11	67350777-67356972	Predicted intracellular proteins	Evidence at protein level	HPA071529			Uncertain	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			small intestine: 120.1	Mixed		
OR52W1	OR52W1P	ENSG00000175485	Olfactory receptor family 52 subfamily W member 1	11	6199146-6200259	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
LRRC25	FLJ38116, MAPA	ENSG00000175489	Leucine rich repeat containing 25	19	18391144-18397617	Predicted membrane proteins	Evidence at protein level	HPA029459	Approved				Testis cancer:6.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 30.4;spleen: 40.6	bone marrow: 20.7	Cell line enhanced		HMC-1: 1.6;THP-1: 1.2;U-937: 1.1
DPP10	DPL2, DPPY, DPRP3	ENSG00000175497	Dipeptidyl peptidase like 10	2	114442299-115845752	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048767	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol		Mixed	Group enriched	7	adrenal gland: 14.1;cerebral cortex: 34.7	pancreas: 3.6	Cell line enhanced		AF22: 4.1;HAP1: 6.4;HMC-1: 3.8;NTERA-2: 3.7;RT4: 5.3;SCLC-21H: 11.4;SH-SY5Y: 4.1
CLCF1	BSF-3, BSF3, CISS2, CLC, NNT-1, NNT1, NR6	ENSG00000175505	Cardiotrophin-like cytokine factor 1	11	67364168-67374177	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA042444	Uncertain		Approved	Nuclear bodies<br>Vesicles		Expressed in all	Tissue enhanced		gallbladder: 26.3	endometrium: 21.4	Cell line enhanced		SiHa: 56.8
TSGA10IP	FAM161C, FLJ32880	ENSG00000175513	Testis specific 10 interacting protein	11	65945445-65959963	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	26	testis: 5.9	thyroid gland: 0.2	Cell line enhanced		NTERA-2: 2.1
GPR152	PGR5	ENSG00000175514	G protein-coupled receptor 152	11	67451301-67452729	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA035078	Uncertain					Not detected	Not detected			spleen: 0.1	Not detected		
UBQLNL	MGC20470, MGC26958	ENSG00000175518	Ubiquilin-like	11	5514393-5516705	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	30	testis: 40.2	epididymis: 1.3	Not detected		
UBQLN3	TUP-1	ENSG00000175520	Ubiquilin 3	11	5507300-5509985	Predicted intracellular proteins	Evidence at protein level	HPA020547, HPA062018	Enhanced					Not detected	Tissue enriched	693	testis: 216.4	epididymis: 0.3	Not detected		
PNLIP	PL	ENSG00000175535	Pancreatic lipase	10	116545931-116567855	Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062430, HPA062494	Enhanced					Tissue enriched	Tissue enriched	325	pancreas: 93703.0	ovary: 288.0	Cell line enhanced		U-2 OS: 1.3
LIPT2		ENSG00000175536	Lipoyl(octanoyl) transferase 2 (putative)	11	74491712-74493733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040249	Approved		Approved	Vesicles<br>Centrosome	Ovarian cancer:1.63e-4 (favourable)	Expressed in all	Mixed			testis: 14.5	Mixed		
KCNE3	HOKPP, MiRP2	ENSG00000175538	Potassium voltage-gated channel subfamily E regulatory subunit 3	11	74454841-74467729	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014849	Approved				Liver cancer:2.28e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 70.1	Cell line enhanced		CACO-2: 18.7;EFO-21: 19.5;HEL: 61.5;NB-4: 27.5;THP-1: 21.7
CABP4	CSNB2B	ENSG00000175544	Calcium binding protein 4	11	67452406-67460313	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 10.0	epididymis,placenta: 2.4	Cell line enhanced		CAPAN-2: 4.4;HMC-1: 18.9
ALG10B	KCR1	ENSG00000175548	ALG10B, alpha-1,2-glucosyltransferase	12	38316578-38329728	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA043329, HPA063387	Approved		Approved	Endoplasmic reticulum		Mixed	Mixed			parathyroid gland: 7.6	Expressed in all		
DRAP1	NC2-alpha	ENSG00000175550	DR1 associated protein 1	11	65919257-65921561	Predicted intracellular proteins	Evidence at protein level	HPA006790	Uncertain		Approved	Cytosol	Renal cancer:3.73e-5 (unfavourable), Thyroid cancer:4.96e-5 (favourable)	Expressed in all	Expressed in all			testis: 140.8	Expressed in all		
LONRF3	FLJ22612, RNF127	ENSG00000175556	LON peptidase N-terminal domain and ring finger 3	X	118974614-119018355	Predicted intracellular proteins	Evidence at protein level	HPA050422, HPA061162	Uncertain		Approved	Nucleus<br>Plasma membrane	Pancreatic cancer:4.32e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 12.6	Cell line enhanced		K-562: 11.8;PC-3: 13.4;SiHa: 14.0
UCP3	SLC25A9	ENSG00000175564	Uncoupling protein 3	11	74000281-74009435	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010771, HPA072225	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	19	skeletal muscle: 71.2	testis: 3.8	Group enriched	5	HDLM-2: 13.8;RH-30: 3.3
UCP2	BMIQ4, SLC25A8	ENSG00000175567	Uncoupling protein 2	11	73974667-73983307	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB025583, HPA075202	Approved		Supported	Mitochondria	Renal cancer:7.80e-6 (unfavourable), Cervical cancer:4.65e-5 (favourable)	Expressed in all	Expressed in all			lymph node: 385.7	Cell line enhanced		SK-BR-3: 390.7
C11orf68	BLES03, P5326	ENSG00000175573	Chromosome 11 open reading frame 68	11	65916808-65919117	Predicted intracellular proteins	Evidence at protein level	HPA045938	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:5.02e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.8	Expressed in all		
PAAF1	FLJ11848, Rpn14, WDR71	ENSG00000175575	Proteasomal ATPase associated factor 1	11	73876699-73931124	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039952, HPA040020	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 53.1	Expressed in all		
MRPL48	CGI-118	ENSG00000175581	Mitochondrial ribosomal protein L48	11	73787316-73865133	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA040241, HPA040864	Approved				Liver cancer:3.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
RAB6A	RAB6	ENSG00000175582	RAB6A, member RAS oncogene family	11	73675638-73761137	Predicted intracellular proteins	Evidence at protein level	CAB009936, HPA059131	Approved		Approved	Golgi apparatus	Endometrial cancer:8.18e-5 (unfavourable), Liver cancer:1.34e-4 (unfavourable), Pancreatic cancer:2.24e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 267.9	Expressed in all		
P2RY2	P2U	ENSG00000175591	Purinergic receptor P2Y2	11	73218298-73236352	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB022642	Uncertain		Uncertain	Cytosol	Pancreatic cancer:2.19e-5 (unfavourable)	Mixed	Tissue enhanced		esophagus: 18.9	skeletal muscle: 14.9	Cell line enhanced		HaCaT: 31.0;HL-60: 27.2;THP-1: 53.1
FOSL1	fra-1	ENSG00000175592	FOS like 1, AP-1 transcription factor subunit	11	65892049-65900573	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004396, HPA066901	Uncertain		Enhanced	Nucleoplasm	Renal cancer:6.40e-6 (unfavourable), Pancreatic cancer:9.26e-5 (unfavourable), Lung cancer:1.95e-4 (unfavourable), Head and neck cancer:2.05e-4 (unfavourable), Glioma:2.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 35.6;gallbladder: 51.7	urinary bladder: 26.8	Cell line enhanced		PC-3: 759.0;WM-115: 1227.8
ERCC4	FANCQ, RAD1, XPF	ENSG00000175595	ERCC excision repair 4, endonuclease catalytic subunit	16	13920157-13952345	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000156, HPA045828	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			testis: 10.4	Expressed in all		
SUGCT	C7orf10, DERP13, FLJ11808, ORF19	ENSG00000175600	Succinyl-CoA:glutarate-CoA transferase	7	40134977-40860763	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026698, HPA026704, HPA026705	Enhanced				Renal cancer:3.93e-7 (favourable), Urothelial cancer:2.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 45.0	liver: 14.6	Cell line enhanced		HBEC3-KT: 30.6;LHCN-M2: 21.2
CCDC85B	DIPA	ENSG00000175602	Coiled-coil domain containing 85B	11	65890112-65891635	Predicted intracellular proteins	Evidence at protein level	HPA054415	Uncertain				Renal cancer:3.78e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.6	adipose tissue: 21.1	Cell line enhanced		WM-115: 340.7
TMEM70	FLJ20533	ENSG00000175606	Transmembrane protein 70	8	73972437-73982783	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA023187, CAB034226	Uncertain		Supported	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 30.2	Expressed in all		
OR4B1	OST208	ENSG00000175619	Olfactory receptor family 4 subfamily B member 1	11	48216792-48217762	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059443	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RPS6KB2	KLS, P70-BETA, p70S6Kb, STK14B	ENSG00000175634	Ribosomal protein S6 kinase B2	11	67428460-67435408	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010010, CAB019404	Approved		Supported	Cytosol	Renal cancer:2.03e-7 (unfavourable)	Expressed in all	Expressed in all			skin: 65.3	Expressed in all		
RMI2	BLAP18, C16orf75, MGC24665	ENSG00000175643	RecQ mediated genome instability 2	16	11249619-11351762	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040995	Uncertain		Supported	Nuclear speckles<br>Cytosol	Liver cancer:2.77e-5 (unfavourable), Cervical cancer:5.69e-5 (favourable)	Expressed in all	Mixed			lymph node: 36.9	Expressed in all		
PRM1	CT94.1	ENSG00000175646	Protamine 1	16	11280836-11281350	Predicted intracellular proteins	Evidence at protein level	HPA055150	Enhanced					Tissue enriched	Tissue enriched	5169	testis: 9195.1	small intestine: 1.7	Cell line enhanced		NB-4: 1.3;U-2197: 1.4
TOM1L2		ENSG00000175662	Target of myb1 like 2 membrane trafficking protein	17	17843511-17972422	Predicted intracellular proteins	Evidence at protein level	HPA022541, HPA023304	Enhanced		Supported	Golgi apparatus<br>Intermediate filaments	Renal cancer:6.21e-9 (favourable), Head and neck cancer:1.24e-4 (favourable), Pancreatic cancer:1.92e-4 (favourable), Ovarian cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 110.6	Expressed in all		
TEX26	C13orf26, MGC40178	ENSG00000175664	Testis expressed 26	13	30932703-30975502	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	30	testis: 40.7	cervix, uterine: 1.3	Not detected		
ZNF77	pT1	ENSG00000175691	Zinc finger protein 77	19	2933218-2944971	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023397	Uncertain		Approved	Nucleus<br>Nucleoli	Lung cancer:6.79e-6 (favourable), Endometrial cancer:6.65e-5 (favourable), Cervical cancer:8.49e-4 (favourable)	Expressed in all	Mixed			breast: 5.8	Mixed		
GPR156	GABABL, PGR28	ENSG00000175697	G protein-coupled receptor 156	3	120164645-120285094	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028642, HPA028644	Uncertain		Supported	Plasma membrane		Mixed	Tissue enhanced		testis: 5.0	fallopian tube: 1.8	Cell line enhanced		SiHa: 3.8;U-2 OS: 2.0
LINC00521	C14orf48	ENSG00000175699	Long intergenic non-protein coding RNA 521	14	93987225-94008863	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 11.9	heart muscle: 0.4	Cell line enhanced		U-266/70: 1.0
LINC00116	NCRNA00116	ENSG00000175701	Long intergenic non-protein coding RNA 116	2	110211529-110245420	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			skeletal muscle: 257.6	Mixed		
KDF1	C1orf172, FLJ34633, RP11-344H11.3	ENSG00000175707	Keratinocyte differentiation factor 1	1	26949562-26960406	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028639, HPA068312	Uncertain		Supported	Nucleoplasm<br>Cell Junctions<br>Mitotic spindle	Renal cancer:3.04e-13 (favourable), Urothelial cancer:4.40e-4 (favourable)	Mixed	Mixed			epididymis: 24.1	Cell line enhanced		A-431: 22.4;BEWO: 20.8;CAPAN-2: 20.7;HaCaT: 19.6;HBEC3-KT: 21.9;hTCEpi: 28.4;SK-BR-3: 19.3
B3GNTL1	B3GNT8	ENSG00000175711	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1	17	82942155-83051810	Predicted intracellular proteins	Evidence at protein level	HPA023585, HPA024547	Supported		Approved	Nucleoli		Mixed	Mixed			bone marrow: 5.0	Mixed		
RBMXL3	CXorf55, FLJ40249	ENSG00000175718	RNA binding motif protein, X-linked like 3	X	115189427-115192868	Predicted intracellular proteins	Evidence at protein level	HPA051842	Supported					Tissue enriched	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
MLXIP	bHLHe36, KIAA0867, MIR, MONDOA	ENSG00000175727	MLX interacting protein	12	122078722-122147347	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA023084	Approved				Liver cancer:2.28e-4 (unfavourable), Renal cancer:2.92e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 24.4	Expressed in all		
NR2F1	COUP-TFI, EAR-3, ERBAL3, SVP44, TCFCOUP1, TFCOUP1	ENSG00000175745	Nuclear receptor subfamily 2 group F member 1	5	93583337-93594615	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019281, HPA058974			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:1.47e-4 (unfavourable), Renal cancer:3.47e-4 (unfavourable)	Expressed in all	Mixed			placenta: 75.6	Cell line enhanced		AF22: 228.5;HHSteC: 146.5;PC-3: 180.1
AURKAIP1	AIP, AKIP, FLJ20608	ENSG00000175756	Aurora kinase A interacting protein 1	1	1373730-1375495	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA031821	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			testis: 148.3	Expressed in all		
TTLL11	bA244O19.1, C9orf20	ENSG00000175764	Tubulin tyrosine ligase like 11	9	121821928-122093606	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021828	Approved					Expressed in all	Mixed			testis: 21.0	Mixed		
EIF4E1B	FLJ36951	ENSG00000175766	Eukaryotic translation initiation factor 4E family member 1B	5	176630682-176646641	Predicted intracellular proteins	Evidence at transcript level	HPA045045	Approved					Not detected	Tissue enhanced		cerebral cortex: 1.6;epididymis: 1.2	testis: 0.3	Cell line enriched	6	T-47d: 3.0
TOMM5	bA613M10.3, C9orf105, Tom5	ENSG00000175768	Translocase of outer mitochondrial membrane 5	9	37582646-37592642	Predicted intracellular proteins	Evidence at protein level	HPA048712	Approved		Supported	Mitochondria	Liver cancer:2.09e-4 (unfavourable), Ovarian cancer:2.37e-4 (favourable), Melanoma:5.49e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 98.5	Expressed in all		
C15orf53	FLJ35695	ENSG00000175779	Chromosome 15 open reading frame 53	15	38696598-38700038	Predicted intracellular proteins	Evidence at transcript level	HPA041914	Uncertain					Not detected	Not detected			lung,urinary bladder: 0.1	Group enriched	12	HEL: 2.5;HMC-1: 1.7
SLC35E3	BLOV1	ENSG00000175782	Solute carrier family 35 member E3	12	68746106-68793964	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA049403	Uncertain				Endometrial cancer:1.78e-4 (favourable)	Expressed in all	Mixed			skin: 6.1	Mixed		
PRIMA1	PRIMA	ENSG00000175785	Proline rich membrane anchor 1	14	93718298-93788481	Predicted membrane proteins	Evidence at protein level	HPA046671, HPA060047	Approved		Approved	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.62e-7 (unfavourable), Endometrial cancer:6.99e-5 (unfavourable)	Mixed	Mixed			smooth muscle: 11.7	Cell line enhanced		HAP1: 5.8;SCLC-21H: 11.6;SH-SY5Y: 5.9
ZNF169	MGC51961	ENSG00000175787	Zinc finger protein 169	9	94259311-94301454	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041769	Uncertain		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			spleen: 7.7	Mixed		
RUVBL1	ECP54, INO80H, NMP238, Pontin52, RVB1, TIH1, TIP49, TIP49a	ENSG00000175792	RuvB like AAA ATPase 1	3	128064778-128153914	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019947, HPA019948	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.21e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 81.6	Expressed in all		
SFN	YWHAS	ENSG00000175793	Stratifin	1	26863138-26864457	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB006268, HPA011105, CAB040552	Enhanced		Supported	Cytosol	Renal cancer:7.45e-6 (unfavourable), Liver cancer:5.68e-5 (unfavourable), Endometrial cancer:1.92e-4 (favourable), Pancreatic cancer:6.01e-4 (unfavourable)	Expressed in all	Group enriched	8	esophagus: 1090.0;skin: 1156.7	tonsil: 132.7	Cell line enhanced		A-431: 663.2;HaCaT: 1030.0;HBEC3-KT: 1288.5;hTCEpi: 852.9
MSRA		ENSG00000175806	Methionine sulfoxide reductase A	8	10054268-10428891	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023804, HPA053069	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			kidney: 113.1	Mixed		
ZNF645	CT138, FLJ25735, HAKAIL	ENSG00000175809	Zinc finger protein 645	X	22272943-22274461	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	141	testis: 14.1	all non-specific tissues: 0.0	Not detected		
CCDC168	C13orf40, FLJ40176	ENSG00000175820	Coiled-coil domain containing 168	13	102729369-102759070	Predicted membrane proteins	Evidence at protein level	HPA048184, HPA058793	Uncertain					Not detected	Tissue enriched	47	testis: 7.6	epididymis: 0.1	Not detected		
CTDNEP1	DULLARD, HSA011916, NET56	ENSG00000175826	CTD nuclear envelope phosphatase 1	17	7243591-7252491	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA037439, HPA066466	Uncertain		Supported	Lipid droplets	Pancreatic cancer:1.81e-4 (favourable), Endometrial cancer:6.45e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 190.1	Expressed in all		
ETV4	E1A-F, E1AF, PEA3	ENSG00000175832	ETS variant 4	17	43527844-43579620	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005768	Approved		Supported	Nucleoli	Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 30.3	cerebral cortex: 13.6	Cell line enhanced		AN3-CA: 164.6;SK-MEL-30: 152.6
SWI5	bA395P17.9, C9orf119, SAE3	ENSG00000175854	SWI5 homologous recombination repair protein	9	128275379-128288990	Predicted intracellular proteins	Evidence at protein level	HPA052032, HPA055472	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:6.78e-4 (unfavourable), Renal cancer:9.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 129.1	Expressed in all		
GAPT	C5orf29, FLJ33641	ENSG00000175857	GRB2 binding adaptor protein, transmembrane	5	58491435-58497090	Predicted intracellular proteins	Evidence at protein level	HPA011070	Uncertain					Mixed	Tissue enhanced		appendix: 38.8;tonsil: 38.8	lymph node: 30.1	Cell line enhanced		HEL: 64.1;HL-60: 33.1;NB-4: 27.3;THP-1: 22.7;U-937: 92.5
BAIAP2	BAP2, IRSp53	ENSG00000175866	BAI1 associated protein 2	17	81035122-81117432	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023310, HPA027421	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:7.58e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 124.7	Mixed		
CALCB	CALC2, CGRP-II, FLJ30166	ENSG00000175868	Calcitonin related polypeptide beta	11	14904997-15082342	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA059886		Supported			Endometrial cancer:3.42e-5 (unfavourable)	Tissue enhanced	Tissue enriched	46	thyroid gland: 32.6	testis: 0.7	Cell line enhanced		HEK 293: 5.4;Karpas-707: 7.5;SH-SY5Y: 3.8;U-266/70: 11.8
CREG2		ENSG00000175874	Cellular repressor of E1A stimulated genes 2	2	101345551-101387595	Predicted secreted proteins	Evidence at protein level	HPA038224	Enhanced					Mixed	Tissue enriched	164	cerebral cortex: 90.9	fallopian tube: 0.5	Cell line enhanced		CACO-2: 2.0;HaCaT: 5.6;HeLa: 1.6;PC-3: 2.3
WBSCR28	MGC26719	ENSG00000175877	Williams-Beuren syndrome chromosome region 28	7	73861159-73865893	Predicted membrane proteins	Evidence at transcript level	HPA077196			Approved	Vesicles		Mixed	Tissue enriched	99	testis: 36.2	duodenum: 0.3	Cell line enhanced		MCF7: 1.2
HOXD8	HOX4, HOX4E	ENSG00000175879	Homeobox D8	2	176129694-176132695	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Lung cancer:3.78e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 122.0;kidney: 83.6	ovary: 43.1	Cell line enhanced		RPTEC TERT1: 56.9
ZDHHC21	DNZ1, HSPC097	ENSG00000175893	Zinc finger DHHC-type containing 21	9	14611071-14693471	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA065254	Approved		Approved	Golgi apparatus<br>Cytosol	Urothelial cancer:9.28e-6 (favourable), Renal cancer:1.29e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 16.0	Cell line enhanced		HEL: 26.6
TSPEAR	C21orf29, DFNB98, MGC11251, TSP-EAR	ENSG00000175894	Thrombospondin type laminin G domain and EAR repeats	21	44497892-44711580	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034203, CAB034204, HPA052995	Approved					Mixed	Tissue enhanced		parathyroid gland: 2.7;testis: 2.6	spleen: 1.9	Cell line enhanced		Karpas-707: 8.0;RPMI-8226: 4.6;SH-SY5Y: 4.0;U-266/70: 4.9;U-266/84: 5.1
PLEKHF2	FLJ13187, PHAFIN2, ZFYVE18	ENSG00000175895	Pleckstrin homology and FYVE domain containing 2	8	95133804-95156684	Predicted intracellular proteins	Evidence at protein level	HPA024829	Uncertain				Renal cancer:1.49e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 62.6	Expressed in all		
A2M	CPAMD5, FWP007, S863-7	ENSG00000175899	Alpha-2-macroglobulin	12	9067664-9116229	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002265, CAB017621	Supported					Expressed in all	Expressed in all			lung: 1920.7	Cell line enhanced		AF22: 726.1;ASC diff: 146.4;Hep G2: 419.1;SK-MEL-30: 170.2
ARL4D	ARF4L	ENSG00000175906	ADP ribosylation factor like GTPase 4D	17	43398959-43401137	Predicted intracellular proteins	Evidence at protein level	HPA060379	Uncertain		Approved	Golgi apparatus<br>Vesicles	Endometrial cancer:1.16e-5 (favourable), Head and neck cancer:6.66e-4 (unfavourable), Urothelial cancer:9.25e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 62.5	Mixed		
DOK7	C4orf25, Dok-7, FLJ33718, FLJ39137	ENSG00000175920	Docking protein 7	4	3463311-3494483	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059449, HPA062780	Approved		Supported	Nucleoplasm<br>Mitochondria	Breast cancer:8.45e-5 (favourable), Urothelial cancer:1.28e-4 (favourable), Endometrial cancer:2.19e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 6.7;heart muscle: 11.1	skeletal muscle: 4.7	Cell line enhanced		MCF7: 27.3;RH-30: 6.5;T-47d: 7.4
LRRN1	FIGLER3	ENSG00000175928	Leucine rich repeat neuronal 1	3	3799437-3847703	Predicted membrane proteins	Evidence at protein level	HPA011071	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 44.3	parathyroid gland: 18.3	Cell line enhanced		AF22: 159.4;CAPAN-2: 50.8;HAP1: 50.2;NTERA-2: 96.1
UBE2O	E2-230K	ENSG00000175931	Ubiquitin conjugating enzyme E2 O	17	76389451-76453206	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023605	Uncertain		Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.34e-9 (unfavourable), Liver cancer:6.84e-8 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 36.0	Expressed in all		
ORAI3	MGC13024, TMEM142C	ENSG00000175938	ORAI calcium release-activated calcium modulator 3	16	30949066-30956461	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015022	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.87e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 27.1	Cell line enhanced		HHSteC: 79.5
KLHL38	C8ORFK36	ENSG00000175946	Kelch like family member 38	8	123645527-123652950	Predicted intracellular proteins	Evidence at protein level	HPA024770, HPA027115	Uncertain		Uncertain	Nucleoplasm<br>Vesicles		Tissue enhanced	Group enriched	15	heart muscle: 35.8;skeletal muscle: 91.2	smooth muscle: 4.3	Cell line enhanced		BJ hTERT+: 1.4;SK-BR-3: 2.1;U-2197: 4.6
UNC119B	MGC5139, POC7B	ENSG00000175970	Unc-119 lipid binding chaperone B	12	120710435-120723640	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.69e-10 (favourable), Pancreatic cancer:1.26e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 75.8	Expressed in all		
DENND2C	dJ1156J9.1, DKFZp686G0351, DKFZp779P1149, FLJ37099, RP5-1156J9.1	ENSG00000175984	DENN domain containing 2C	1	114582848-114670422	Predicted intracellular proteins	Evidence at protein level	HPA054955	Uncertain		Approved	Nucleus		Mixed	Tissue enhanced		esophagus: 19.5;skeletal muscle: 14.3;skin: 14.8	testis: 10.0	Cell line enhanced		U-2197: 10.9;U-266/70: 19.3
PLEKHD1	UPF0639	ENSG00000175985	Pleckstrin homology and coiled-coil domain containing D1	14	69484692-69531551	Predicted intracellular proteins	Evidence at protein level	HPA051875	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 2.8;thyroid gland: 2.7	epididymis: 2.0	Cell line enhanced		SK-BR-3: 1.8;T-47d: 2.1
ASCL3	bHLHa42, HASH3, Sgn1	ENSG00000176009	Achaete-scute family bHLH transcription factor 3	11	8937579-8938211	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA027032	Uncertain					Not detected	Tissue enriched	15	salivary gland: 3.3	spleen,testis: 0.2	Not detected		
TUBB6	HsT1601, MGC4083	ENSG00000176014	Tubulin beta 6 class V	18	12307669-12344320	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Approved				Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:9.69e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 214.3	Mixed		
LYSMD3	FLJ13542	ENSG00000176018	LysM domain containing 3	5	90515611-90529584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018024	Approved		Approved	Cytosol	Colorectal cancer:3.83e-4 (favourable), Renal cancer:9.25e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.7	Expressed in all		
AMIGO3		ENSG00000176020	Adhesion molecule with Ig like domain 3	3	49716834-49719695	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			skeletal muscle: 1.0	Cell line enhanced		CACO-2: 1.7;SH-SY5Y: 1.7
B3GALT6	beta3GalT6	ENSG00000176022	Beta-1,3-galactosyltransferase 6	1	1232265-1235041	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 12.0	Expressed in all		
ZNF613	FLJ13590	ENSG00000176024	Zinc finger protein 613	19	51927147-51948759	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA026833	Uncertain		Approved	Nucleoplasm<br>Vesicles	Urothelial cancer:1.92e-6 (favourable)	Expressed in all	Tissue enhanced		prostate: 32.4	placenta: 9.8	Mixed		
C11orf16		ENSG00000176029	Chromosome 11 open reading frame 16	11	8920076-8933006	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:3.32e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 20.6;lung: 4.1	testis: 2.5	Not detected		
TMPRSS7		ENSG00000176040	Transmembrane protease, serine 7	3	112034843-112081269	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA040630	Uncertain					Not detected	Tissue enhanced		testis: 2.5	fallopian tube: 0.6	Not detected		
NUPR1	COM1, p8	ENSG00000176046	Nuclear protein 1, transcriptional regulator	16	28532708-28539174	Predicted intracellular proteins	Evidence at protein level	HPA053895			Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		thyroid gland: 512.5	pancreas: 235.5	Cell line enhanced		HHSteC: 221.9;hTCEpi: 321.9;SK-MEL-30: 256.2;T-47d: 179.8
JAKMIP2	JAMIP2, KIAA0555	ENSG00000176049	Janus kinase and microtubule interacting protein 2	5	147585439-147782848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046929, HPA065023	Approved		Supported	Golgi apparatus		Tissue enriched	Tissue enriched	6	cerebral cortex: 32.7	testis: 5.3	Cell line enhanced		AF22: 19.7;Karpas-707: 34.1;RH-30: 46.3;SCLC-21H: 26.3
MBLAC2	DKFZp686P15118, MGC46734	ENSG00000176055	Metallo-beta-lactamase domain containing 2	5	90458203-90474768	Predicted intracellular proteins	Evidence at protein level	HPA037757, HPA060264	Uncertain		Approved	Nucleus<br>Nuclear bodies		Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
TPRN	C9orf75, DFNB79, FLJ90254	ENSG00000176058	Taperin	9	137191617-137204193	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020899	Uncertain		Approved	Plasma membrane	Renal cancer:5.16e-9 (favourable), Cervical cancer:2.13e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 28.3	Mixed		
KCNE5	KCNE1L	ENSG00000176076	Potassium voltage-gated channel subfamily E regulatory subunit 5	X	109623700-109625172	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042316	Uncertain		Uncertain	Cytosol		Group enriched	Tissue enhanced		cerebral cortex: 2.1	adipose tissue: 1.1	Cell line enhanced		hTEC/SVTERT24-B: 2.0
ZNF683	Hobit, MGC33414	ENSG00000176083	Zinc finger protein 683	1	26361634-26374522	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023865	Uncertain				Endometrial cancer:2.90e-5 (favourable), Urothelial cancer:3.45e-5 (favourable)	Mixed	Tissue enriched	11	testis: 78.7	lung: 7.1	Cell line enhanced		NB-4: 1.4
SLC35A4		ENSG00000176087	Solute carrier family 35 member A4	5	140564456-140569103	Predicted membrane proteins, Transporters	Evidence at protein level	HPA062210			Approved	Nucleoplasm	Renal cancer:4.56e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 113.2	Mixed		
AIM1L	CRYBG2, FLJ38020	ENSG00000176092	Absent in melanoma 1-like	1	26321859-26360052	Predicted intracellular proteins	Evidence at protein level	HPA029629, HPA029631	Uncertain		Approved	Nucleoplasm	Endometrial cancer:5.11e-6 (unfavourable), Pancreatic cancer:3.53e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 51.2;skin: 21.5	placenta: 13.7	Cell line enhanced		BEWO: 33.9;CACO-2: 36.7;CAPAN-2: 27.8
IP6K1	IHPK1, KIAA0263	ENSG00000176095	Inositol hexakisphosphate kinase 1	3	49724294-49786542	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040825	Approved		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:5.77e-5 (favourable), Head and neck cancer:2.08e-4 (favourable), Pancreatic cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.5	Expressed in all		
SSNA1	N14, NA14	ENSG00000176101	SS nuclear autoantigen 1	9	137188647-137190370	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:8.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 101.1	Expressed in all		
CSTF3	CstF-77	ENSG00000176102	Cleavage stimulation factor subunit 3	11	33077188-33162371	Predicted intracellular proteins	Evidence at protein level	HPA039743, HPA040168	Enhanced		Enhanced	Nucleoplasm	Liver cancer:8.20e-6 (unfavourable), Renal cancer:1.61e-5 (unfavourable), Colorectal cancer:1.63e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 76.3	Expressed in all		
YES1	c-yes, HsT441, Yes	ENSG00000176105	YES proto-oncogene 1, Src family tyrosine kinase	18	721588-812546	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004370, HPA026480	Approved		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 62.0	Mixed		
CHMP6	FLJ11749, VPS20	ENSG00000176108	Charged multivesicular body protein 6	17	80991598-81009517	Predicted intracellular proteins	Evidence at protein level	HPA023001, HPA024460	Approved				Pancreatic cancer:9.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Expressed in all		
DLEU1	BCMS, BCMS1, DLB1, LEU1, LINC00021, NCRNA00021, XTP6	ENSG00000176124	Deleted in lymphocytic leukemia 1	13	50082171-50723236	Predicted intracellular proteins	Evidence at protein level	CAB017848, HPA039465	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			testis: 9.3	Expressed in all		
UFSP1	UFSP	ENSG00000176125	UFM1 specific peptidase 1 (inactive)	7	100888723-100889718	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA027099	Uncertain					Expressed in all	Mixed			adipose tissue: 2.0	Mixed		
MC5R		ENSG00000176136	Melanocortin 5 receptor	18	13824149-13827323	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042365	Approved					Not detected	Tissue enriched	7	epididymis: 3.0	esophagus,testis: 0.4	Cell line enhanced		U-138 MG: 1.8
TMEM39A	FLJ10902	ENSG00000176142	Transmembrane protein 39A	3	119429500-119468830	Predicted membrane proteins	Evidence at protein level	HPA039140	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 32.3	Expressed in all		
TCP11L1	FLJ11336	ENSG00000176148	T-complex 11 like 1	11	33039417-33105943	Predicted intracellular proteins	Evidence at protein level	HPA005769	Approved		Approved	Cytosol	Renal cancer:1.39e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.9	Expressed in all		
GPX2	GSHPX-GI	ENSG00000176153	Glutathione peroxidase 2	14	64939152-64942905	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003545	Enhanced		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:5.10e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 696.1;rectum: 461.1	stomach: 334.9	Group enriched	20	A549: 930.0;HaCaT: 249.8;Hep G2: 659.7;RT4: 543.6;SCLC-21H: 352.2
CCDC57	FLJ00130, FLJ23754	ENSG00000176155	Coiled-coil domain containing 57	17	82101460-82212830	Predicted intracellular proteins	Evidence at protein level	HPA023315, HPA023326, HPA023342, HPA023344	Approved		Approved	Microtubules<br>Microtubule organizing center<br>Cytosol	Renal cancer:2.28e-6 (unfavourable), Pancreatic cancer:5.55e-5 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Mixed		
HSF5	FLJ40311	ENSG00000176160	Heat shock transcription factor 5	17	58420167-58488384	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063613	Enhanced					Not detected	Tissue enriched	64	testis: 88.4	lymph node: 1.3	Not detected		
FOXG1	BF1, FKH2, FKHL1, FKHL2, FKHL3, FKHL4, FOXG1A, FOXG1B, FOXG1C, HBF-3, HFK1, HFK2, HFK3, QIN	ENSG00000176165	Forkhead box G1	14	28760330-28770277	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	6	cerebral cortex: 29.6	testis: 5.2	Cell line enhanced		HEK 293: 10.3;SCLC-21H: 34.2;U-138 MG: 17.5;U-251 MG: 15.3
SPHK1	SPHK	ENSG00000176170	Sphingosine kinase 1	17	76376584-76387860	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022829, HPA028761	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:5.14e-6 (unfavourable)	Expressed in all	Mixed			gallbladder: 19.0	Mixed		
BNIP3	Nip3	ENSG00000176171	BCL2 interacting protein 3	10	131966455-131982013	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003015, CAB011676	Supported		Uncertain	Cytosol	Renal cancer:4.55e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 84.1	Cell line enhanced		A-431: 338.9;U-87 MG: 339.6
ENTHD1	FLJ25421	ENSG00000176177	ENTH domain containing 1	22	39743044-39893864	Predicted intracellular proteins	Evidence at protein level	HPA019800	Uncertain					Tissue enriched	Tissue enriched	25	testis: 19.7	lymph node: 0.7	Cell line enhanced		SK-MEL-30: 1.7
MYPOP	P42pop	ENSG00000176182	Myb related transcription factor, partner of profilin	19	45890020-45902604	Predicted intracellular proteins	Evidence at protein level	HPA065307			Approved	Nucleoplasm	Ovarian cancer:8.67e-5 (unfavourable), Liver cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.2	Expressed in all		
CIDEA	CIDE-A	ENSG00000176194	Cell death-inducing DFFA-like effector a	18	12254319-12277595	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	13	adipose tissue: 221.8	breast: 17.2	Cell line enriched	8	hTEC/SVTERT24-B: 1.4
OR11H4		ENSG00000176198	Olfactory receptor family 11 subfamily H member 4	14	20242739-20243820	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052790	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4D11	OR4D11P	ENSG00000176200	Olfactory receptor family 4 subfamily D member 11	11	59503576-59504511	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LRRTM4	FLJ12568	ENSG00000176204	Leucine rich repeat transmembrane neuronal 4	2	76747719-77593319	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cerebral cortex: 21.3	epididymis: 2.4	Cell line enriched	7	Karpas-707: 91.1
ATAD5	C17orf41, ELG1, FLJ12735, FRAG1	ENSG00000176208	ATPase family, AAA domain containing 5	17	30831970-30895869	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 7.9	lymph node: 4.3	Mixed		
SMIM19	C8orf40	ENSG00000176209	Small integral membrane protein 19	8	42541155-42555193	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011145	Uncertain				Renal cancer:1.74e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 123.2	Expressed in all		
OR11H6		ENSG00000176219	Olfactory receptor family 11 subfamily H member 6	14	20223632-20224805	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF404		ENSG00000176222	Zinc finger protein 404	19	43872363-43901385	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032014, HPA063607	Uncertain		Approved	Nucleoli<br>Intermediate filaments		Mixed	Mixed			epididymis: 11.7	Cell line enriched	6	U-2 OS: 45.7
RTTN	DKFZP434G145	ENSG00000176225	Rotatin	18	70003031-70205945	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041343, HPA041967	Uncertain					Expressed in all	Mixed			testis: 5.2	Mixed		
OR4K17		ENSG00000176230	Olfactory receptor family 4 subfamily K member 17	14	20117407-20118438	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR10H4		ENSG00000176231	Olfactory receptor family 10 subfamily H member 4	19	15949008-15949958	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51B6		ENSG00000176239	Olfactory receptor family 51 subfamily B member 6	11	5351508-5352446	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ACBD7	bA455B2.2, FLJ38219	ENSG00000176244	Acyl-CoA binding domain containing 7	10	15077523-15088776	Predicted intracellular proteins	Evidence at protein level	HPA043326, HPA062478			Approved	Vesicles<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 40.5	testis: 7.7	Cell line enhanced		MOLT-4: 29.4
OR4L1	OR4L2P	ENSG00000176246	Olfactory receptor family 4 subfamily L member 1	14	20060045-20060983	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ANAPC2	APC2, KIAA1406	ENSG00000176248	Anaphase promoting complex subunit 2	9	137174784-137188549	Predicted intracellular proteins	Evidence at protein level	CAB018692, HPA066539	Enhanced		Enhanced	Nucleoplasm	Pancreatic cancer:1.07e-7 (favourable), Endometrial cancer:8.91e-5 (favourable), Stomach cancer:2.87e-4 (favourable), Renal cancer:3.67e-4 (favourable)	Expressed in all	Expressed in all			testis: 27.2	Expressed in all		
OR4K13		ENSG00000176253	Olfactory receptor family 4 subfamily K member 13	14	20033844-20034760	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HMGB4	FLJ40388	ENSG00000176256	High mobility group box 4	1	33860475-33864791	Predicted intracellular proteins	Evidence at protein level	HPA035699	Enhanced					Not detected	Tissue enriched	936	testis: 93.5	all non-specific tissues: 0.0	Not detected		
ZBTB8OS	ARCH	ENSG00000176261	Zinc finger and BTB domain containing 8 opposite strand	1	32600172-32650903	Predicted intracellular proteins	Evidence at protein level	HPA046315	Approved		Approved	Plasma membrane	Renal cancer:7.11e-8 (unfavourable), Liver cancer:4.25e-4 (unfavourable), Melanoma:8.56e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 43.3	Expressed in all		
OR4F21	OR4F21P	ENSG00000176269	Olfactory receptor family 4 subfamily F member 21	8	166049-167043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			testis: 0.2	Cell line enriched	6	BEWO: 1.3
SLC35G1	C10orf60, FLJ33990, TMEM20	ENSG00000176273	Solute carrier family 35 member G1	10	93893973-93956062	Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Group enriched	8	duodenum: 86.0;small intestine: 44.8	rectum,testis: 7.8	Mixed		
OR4K5		ENSG00000176281	Olfactory receptor family 4 subfamily K member 5	14	19920582-19921659	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF135	pHZ-17, ZNF61, ZNF78L1	ENSG00000176293	Zinc finger protein 135	19	58059239-58086310	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006961	Approved		Approved	Cytosol	Renal cancer:3.93e-5 (favourable)	Mixed	Mixed			parathyroid gland: 25.0	Cell line enhanced		T-47d: 6.6
OR4N2		ENSG00000176294	Olfactory receptor family 4 subfamily N member 2	14	19719015-19828372	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 24.3	cerebral cortex: 1.7	Cell line enhanced		U-2 OS: 4.7
OR4M1		ENSG00000176299	Olfactory receptor family 4 subfamily M member 1	14	19780242-19781357	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
FOXR1	DLNB13, FOXN5	ENSG00000176302	Forkhead box R1	11	118971707-118981291	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	14	testis: 3.1	thyroid gland: 0.2	Not detected		
COX8A	COX, COX8, COX8-2, COX8L, VIII, VIII-L	ENSG00000176340	Cytochrome c oxidase subunit 8A	11	63974607-63976543	Predicted membrane proteins, Transporters	Evidence at protein level	HPA055942	Supported				Renal cancer:2.51e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 512.4	Expressed in all		
TAC4	HK-1, PPT-C, Pptc	ENSG00000176358	Tachykinin 4 (hemokinin)	17	49838309-49848017	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 2.0	liver: 1.0	Cell line enhanced		A549: 2.3;BEWO: 5.7;CACO-2: 2.9
ZSCAN2	FLJ20595, ZFP29, ZNF854	ENSG00000176371	Zinc finger and SCAN domain containing 2	15	84600986-84627796	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007296, HPA024331	Supported		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.16e-5 (favourable), Pancreatic cancer:3.52e-4 (favourable), Renal cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 13.8	Expressed in all		
PRR18	MGC35308	ENSG00000176381	Proline rich 18	6	166305300-166308448	Predicted intracellular proteins	Evidence at protein level	HPA077250	Enhanced					Tissue enhanced	Tissue enriched	9	cerebral cortex: 32.6	fallopian tube: 3.4	Group enriched	11	SCLC-21H: 5.0;SH-SY5Y: 2.7
B3GNT4	B3GN-T4, beta3Gn-T4	ENSG00000176383	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4	12	122203543-122208952	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055261	Uncertain		Approved	Nucleoli<br>Mitochondria	Renal cancer:3.52e-6 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 4.3;skin: 2.9	kidney: 1.9	Cell line enhanced		HDLM-2: 4.5;hTCEpi: 4.9;T-47d: 5.0
CDC26	ANAPC12, APC12, C9orf17	ENSG00000176386	Cell division cycle 26	9	113255835-113275589	Predicted intracellular proteins	Evidence at protein level	HPA044130	Approved		Enhanced	Nucleoplasm	Liver cancer:1.72e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.5	Expressed in all		
HSD11B2	SDR9C3	ENSG00000176387	Hydroxysteroid 11-beta dehydrogenase 2	16	67430652-67437553	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032443, HPA042186, HPA056385	Enhanced		Approved	Vesicles	Renal cancer:9.51e-5 (favourable)	Expressed in all	Tissue enhanced		colon: 151.6;kidney: 173.3	salivary gland: 122.5	Cell line enhanced		NTERA-2: 11.4;RPMI-8226: 9.6;RT4: 11.0;SCLC-21H: 17.5;SK-BR-3: 10.0
CRLF3	CREME9, CYTOR4	ENSG00000176390	Cytokine receptor like factor 3	17	30769388-30824776	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007596	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.31e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 39.3	Expressed in all		
RNPEP		ENSG00000176393	Arginyl aminopeptidase	1	201982372-202006147	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036074, HPA036075, HPA061487	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			duodenum: 66.5	Expressed in all		
EID2	CRI2, EID-2, MGC20452	ENSG00000176396	EP300 interacting inhibitor of differentiation 2	19	39538705-39540333	Predicted intracellular proteins	Evidence at protein level	HPA045477	Uncertain		Supported	Nucleoplasm	Prostate cancer:8.74e-4 (unfavourable), Colorectal cancer:9.73e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 26.3	Expressed in all		
DMRTA1		ENSG00000176399	DMRT like family A1	9	22446841-22455740	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044764, HPA062253	Uncertain		Approved	Vesicles	Renal cancer:1.14e-6 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 6.5	liver: 4.3	Cell line enhanced		BJ hTERT+: 5.1
EID2B	EID-3, FLJ38944	ENSG00000176401	EP300 interacting inhibitor of differentiation 2B	19	39530990-39532854	Predicted intracellular proteins	Evidence at protein level	HPA064185	Approved				Pancreatic cancer:2.57e-4 (favourable)	Mixed	Mixed			cerebral cortex: 12.4	Mixed		
GJC3	CX30.2, GJE1	ENSG00000176402	Gap junction protein gamma 3	7	99923269-99929620	Predicted membrane proteins, Transporters	Evidence at protein level	HPA015024	Uncertain					Group enriched	Tissue enhanced		breast: 8.7;prostate: 5.3	testis: 2.7	Cell line enhanced		SK-MEL-30: 1.8;U-2197: 1.7
RIMS2	KIAA0751, OBOE, RAB3IP3, RIM2	ENSG00000176406	Regulating synaptic membrane exocytosis 2	8	103500748-104256094	Predicted intracellular proteins	Evidence at protein level	HPA046538, HPA066498, CAB079049	Enhanced	Supported	Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 67.7;cerebral cortex: 45.0	cervix, uterine: 11.5	Cell line enhanced		Daudi: 10.2;RT4: 8.0;SCLC-21H: 28.6
KCMF1	DEBT91, DKFZP434L1021, PCMF, ZZZ1	ENSG00000176407	Potassium channel modulatory factor 1	2	84971093-85059472	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA030383, HPA030384	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.33e-7 (unfavourable), Renal cancer:4.18e-6 (unfavourable), Pancreatic cancer:6.10e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 124.6	Expressed in all		
DNAJC30	WBSCR18	ENSG00000176410	DnaJ heat shock protein family (Hsp40) member C30	7	73680969-73683453	Predicted membrane proteins	Evidence at protein level	HPA017318	Uncertain	Supported			Renal cancer:4.91e-8 (favourable), Glioma:6.59e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 11.3	Expressed in all		
SPRYD4	DKFZp686N0877	ENSG00000176422	SPRY domain containing 4	12	56468567-56479707	Predicted intracellular proteins	Evidence at protein level	HPA053469	Approved		Approved	Nucleoplasm	Endometrial cancer:8.85e-5 (unfavourable), Lung cancer:4.52e-4 (favourable)	Expressed in all	Mixed			liver: 7.8	Mixed		
VPS37D	MGC35352, WBSCR24	ENSG00000176428	VPS37D, ESCRT-I subunit	7	73667825-73672112	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040978	Uncertain		Approved	Vesicles	Renal cancer:5.80e-9 (favourable), Pancreatic cancer:2.07e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 6.3	Cell line enhanced		SH-SY5Y: 12.4
CLEC14A	C14orf27	ENSG00000176435	C-type lectin domain family 14 member A	14	38254103-38256369	Predicted membrane proteins	Evidence at protein level	HPA039468, HPA048119	Uncertain		Supported	Endoplasmic reticulum<br>Golgi apparatus	Head and neck cancer:4.13e-6 (favourable)	Expressed in all	Tissue enhanced		lung: 76.1	adipose tissue: 40.9	Cell line enhanced		fHDF/TERT166: 60.3;HUVEC TERT2: 345.4;TIME: 121.9
SYNE3	C14orf139, C14orf49, FLJ25605, LINC00341, NCRNA00341, Nesp3, Nesprin-3, NET53	ENSG00000176438	Spectrin repeat containing nuclear envelope family member 3	14	95407266-95475836	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055227, HPA077140	Approved		Enhanced	Nuclear membrane		Mixed	Mixed			adipose tissue: 14.7	Cell line enhanced		ASC diff: 31.9;REH: 31.6
CLK2	clk2	ENSG00000176444	CDC like kinase 2	1	155262868-155278491	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055366, HPA059507	Approved		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.95e-9 (unfavourable), Liver cancer:2.82e-4 (unfavourable), Colorectal cancer:3.77e-4 (unfavourable), Urothelial cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 26.8	Expressed in all		
LPCAT4	AGPAT7, AYTL3, FLJ10257, LPAAT-eta, LPEAT2	ENSG00000176454	Lysophosphatidylcholine acyltransferase 4	15	34358618-34367278	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030719	Uncertain				Liver cancer:9.99e-4 (unfavourable)	Expressed in all	Mixed			rectum: 38.6	Expressed in all		
SLCO3A1	OATP-D, OATP3A1, SLC21A11	ENSG00000176463	Solute carrier organic anion transporter family member 3A1	15	91853695-92172435	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA066327	Approved				Endometrial cancer:6.57e-6 (unfavourable), Cervical cancer:8.61e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.0	Cell line enhanced		CAPAN-2: 55.3;HaCaT: 84.3;HMC-1: 48.5
ZNF575	FLJ32567	ENSG00000176472	Zinc finger protein 575	19	43525497-43536130	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051865	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Expressed in all	Mixed			colon: 4.3	Cell line enhanced		MOLT-4: 6.2
WDR25	C14orf67, MGC4645	ENSG00000176473	WD repeat domain 25	14	100376418-100530303	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003113	Approved		Supported	Nucleoplasm	Renal cancer:3.89e-5 (favourable), Liver cancer:7.36e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 13.6	Mixed		
SGF29	CCDC101, FLJ32446, TDRD29	ENSG00000176476	SAGA complex associated factor 29	16	28553915-28591790	Predicted intracellular proteins	Evidence at protein level	HPA052590, HPA053608	Enhanced		Approved	Nucleus<br>Nucleoli	Pancreatic cancer:2.99e-4 (favourable), Lung cancer:3.37e-4 (favourable), Cervical cancer:4.77e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.6	Expressed in all		
PLA2G16	AdPLA, H-REV107-1, HRASLS3, HREV107, HREV107-3, MGC118754.	ENSG00000176485	Phospholipase A2 group XVI	11	63573195-63616883	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA058997	Uncertain		Approved	Mitochondria	Pancreatic cancer:5.58e-6 (unfavourable), Thyroid cancer:2.54e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 327.7	Cell line enhanced		CAPAN-2: 206.7
DIRAS1	Di-Ras1, GBTS1, RIG	ENSG00000176490	DIRAS family GTPase 1	19	2714567-2721418	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:4.78e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 70.9;heart muscle: 42.5	parathyroid gland: 23.9	Cell line enhanced		HMC-1: 37.7;REH: 44.4
OR5AN1		ENSG00000176495	Olfactory receptor family 5 subfamily AN member 1	11	59364412-59365448	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PHLDB3	FLJ40193	ENSG00000176531	Pleckstrin homology like domain family B member 3	19	43474954-43504935	Predicted intracellular proteins	Evidence at protein level	HPA043425	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.36e-6 (favourable), Renal cancer:4.11e-5 (unfavourable), Stomach cancer:5.77e-4 (unfavourable)	Expressed in all	Mixed			testis: 24.6	Mixed		
PRR15		ENSG00000176532	Proline rich 15	7	29563811-29567295	Predicted intracellular proteins	Evidence at protein level	HPA040996, HPA048121	Enhanced		Uncertain	Vesicles<br>Cell Junctions	Renal cancer:1.83e-6 (favourable), Endometrial cancer:6.37e-4 (favourable), Lung cancer:7.23e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 91.4	colon: 79.1	Cell line enhanced		CAPAN-2: 33.6;HaCaT: 39.3;SK-BR-3: 55.3
GNG7	FLJ00058	ENSG00000176533	G protein subunit gamma 7	19	2511219-2702709	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA057790	Supported				Renal cancer:0.00e+0 (favourable), Lung cancer:1.35e-5 (favourable), Liver cancer:3.05e-4 (favourable), Pancreatic cancer:3.71e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 49.7	Cell line enhanced		REH: 60.2;SK-MEL-30: 23.5;U-266/70: 46.3;U-266/84: 21.0
OR4C5	OR4C5P, OR4C5Q	ENSG00000176540	Olfactory receptor family 4 subfamily C member 5 (gene/pseudogene)	11	48365485-48366465	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049516	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USF3	KIAA2018	ENSG00000176542	Upstream transcription factor family member 3	3	113648385-113696646	Predicted intracellular proteins	Evidence at protein level	HPA029243, HPA029245	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli<br>Centrosome	Renal cancer:1.74e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 13.6	Expressed in all		
OR4C3		ENSG00000176547	Olfactory receptor family 4 subfamily C member 3	11	48324920-48328471	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049116	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4S1		ENSG00000176555	Olfactory receptor family 4 subfamily S member 1	11	48306223-48307152	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CNTD1	CNTD, FLJ40137	ENSG00000176563	Cyclin N-terminal domain containing 1	17	42798792-42811587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA023324			Uncertain	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Mixed	Tissue enriched	25	testis: 73.1	stomach: 2.9	Cell line enhanced		A-431: 2.1;ASC diff: 1.0;SiHa: 1.3
DCAF4L2	WDR21C	ENSG00000176566	DDB1 and CUL4 associated factor 4 like 2	8	87870743-87874068	Predicted intracellular proteins	Evidence at protein level	HPA067584	Uncertain					Tissue enriched	Tissue enriched	389	testis: 38.9	all non-specific tissues: 0.0	Cell line enriched	20	U-266/84: 5.1
OR4X1		ENSG00000176567	Olfactory receptor family 4 subfamily X member 1 (gene/pseudogene)	11	48263861-48264778	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CNBD1	FLJ35802	ENSG00000176571	Cyclic nucleotide binding domain containing 1	8	86866442-87615219	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025037, HPA027469, HPA027786	Uncertain					Not detected	Tissue enriched	13	testis: 11.7	spleen: 0.9	Group enriched	11	Karpas-707: 3.1;U-266/70: 1.9
KBTBD11	KIAA0711, KLHDC7C	ENSG00000176595	Kelch repeat and BTB domain containing 11	8	1973878-2006936	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051159	Uncertain		Approved	Intermediate filaments		Tissue enhanced	Tissue enhanced		cerebral cortex: 21.7	kidney: 8.8	Cell line enhanced		HDLM-2: 12.9;SCLC-21H: 13.6;THP-1: 13.0;U-937: 21.4
B3GNT5	B3GN-T5, beta3Gn-T5	ENSG00000176597	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5	3	183253244-183298504	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017292	Uncertain		Approved	Nucleoli	Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.23e-6 (unfavourable), Liver cancer:5.09e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 49.1	Mixed		
MAP3K19	FLJ23074, RCK, YSK4	ENSG00000176601	Mitogen-activated protein kinase kinase kinase 19	2	134964491-135047468	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA011388			Uncertain	Cytosol		Tissue enhanced	Group enriched	8	fallopian tube: 28.5;testis: 7.8	lung: 2.2	Not detected		
C14orf177	FLJ25773	ENSG00000176605	Chromosome 14 open reading frame 177	14	98711613-98717761	Predicted intracellular proteins	Evidence at transcript level	HPA018091	Uncertain					Not detected	Tissue enriched	23	testis: 2.2	all non-specific tissues: 0.0	Not detected		
LMNB2	LMN2	ENSG00000176619	Lamin B2	19	2427638-2456996	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022593, HPA047863, HPA062477	Enhanced		Supported	Nuclear membrane	Renal cancer:9.34e-5 (unfavourable), Prostate cancer:9.53e-5 (unfavourable), Liver cancer:1.32e-4 (unfavourable), Stomach cancer:3.98e-4 (favourable), Melanoma:5.88e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 21.0	Expressed in all		
RMDN1	CGI-90, FAM82B, FLJ20665, RMD1	ENSG00000176623	Regulator of microtubule dynamics 1	8	86468257-86514357	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026495	Approved		Supported	Actin filaments<br>Centrosome	Renal cancer:8.51e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 83.5	Mixed		
MEX3C	FLJ38871, RKHD2, RNF194	ENSG00000176624	Mex-3 RNA binding family member C	18	51174550-51218304	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040603	Uncertain		Approved	Vesicles	Liver cancer:8.49e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 81.7	Expressed in all		
HORMAD2	CT46.2, MGC26710	ENSG00000176635	HORMA domain containing 2	22	30080174-30177075	Predicted intracellular proteins	Evidence at protein level	HPA003074	Enhanced					Not detected	Tissue enriched	23	testis: 35.2	liver: 1.5	Not detected		
RNF152	FLJ39176	ENSG00000176641	Ring finger protein 152	18	61808063-61894247	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.13e-8 (favourable), Stomach cancer:2.85e-5 (unfavourable)	Expressed in all	Tissue enriched	5	kidney: 56.6	liver: 10.3	Cell line enhanced		HaCaT: 18.4;SH-SY5Y: 13.4;U-138 MG: 20.3
MYO1D	KIAA0727, myr4, PPP1R108	ENSG00000176658	Myosin ID	17	32492522-32877177	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA054744	Uncertain		Approved	Cytosol	Urothelial cancer:4.53e-6 (unfavourable), Renal cancer:5.01e-6 (favourable)	Expressed in all	Mixed			colon: 109.1	Cell line enhanced		CACO-2: 120.9
FOXL1	FKH6, FKHL11, FREAC7	ENSG00000176678	Forkhead box L1	16	86576368-86582160	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		gallbladder: 8.3	duodenum: 3.1	Cell line enhanced		CAPAN-2: 33.6;PC-3: 45.9;U-87 MG: 104.7
TGIF2LY		ENSG00000176679	TGFB induced factor homeobox 2 like, Y-linked	Y	3579041-3580041	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	74	testis: 7.3	all non-specific tissues: 0.0	Not detected		
LRRC37A	KIAA0563	ENSG00000176681	Leucine rich repeat containing 37A	17	46292733-46337794	Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090, HPA049080	Supported		Approved	Vesicles		Not detected	Tissue enriched	8	testis: 13.4	skeletal muscle: 1.6	Cell line enhanced		Daudi: 2.8
FOXC2	FKHL14, MFH-1	ENSG00000176692	Forkhead box C2	16	86567251-86569728	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056302			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:3.57e-7 (unfavourable)	Mixed	Mixed			kidney: 2.8	Cell line enhanced		hTEC/SVTERT24-B: 29.9;LHCN-M2: 30.9;TIME: 34.0;U-2197: 34.2;U-87 MG: 27.6
OR4F17	OR4F11P, OR4F18, OR4F19	ENSG00000176695	Olfactory receptor family 4 subfamily F member 17	19	107461-111696	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BDNF		ENSG00000176697	Brain derived neurotrophic factor	11	27654893-27722058	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009564, HPA031440, HPA056104	Enhanced		Supported	Nuclear speckles<br>Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 11.9	epididymis: 4.9	Cell line enhanced		BJ: 37.3;BJ hTERT+ SV40 Large T+: 30.7;HBF TERT88: 30.4;U-138 MG: 45.3
CCDC121	FLJ13646, FLJ43364	ENSG00000176714	Coiled-coil domain containing 121	2	27625639-27629012	Predicted intracellular proteins	Evidence at protein level	HPA051791	Uncertain		Approved	Actin filaments<br>Cytosol	Renal cancer:1.87e-5 (favourable), Lung cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 46.7	ovary: 12.2	Mixed		
ACSF3		ENSG00000176715	Acyl-CoA synthetase family member 3	16	89088375-89155846	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.97e-6 (favourable), Pancreatic cancer:3.76e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 31.0	Expressed in all		
BOK	BCL2L9, BOKL, MGC4631	ENSG00000176720	BOK, BCL2 family apoptosis regulator	2	241558721-241574138	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.09e-9 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 97.4	endometrium,seminal vesicle: 35.9	Mixed		
ZNF843	MGC46336	ENSG00000176723	Zinc finger protein 843	16	31432593-31443160	Predicted intracellular proteins	Evidence at protein level	HPA030911, HPA030912	Uncertain					Mixed	Mixed			ovary: 3.8	Cell line enhanced		ASC diff: 1.6;EFO-21: 1.7
C8orf59		ENSG00000176731	Chromosome 8 open reading frame 59	8	85214076-85220421	Predicted intracellular proteins	Evidence at protein level	HPA044805, HPA071903			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:0.00e+0 (unfavourable)	Expressed in all	Expressed in all			breast: 119.1	Expressed in all		
PFN4		ENSG00000176732	Profilin family member 4	2	24115371-24123477	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	39	testis: 139.8	thyroid gland: 3.5	Mixed		
OR51V1	OR51A12	ENSG00000176742	Olfactory receptor family 51 subfamily V member 1	11	5199735-5200700	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MAGEB6	CT3.4, FLJ40242, MAGE-B6, MAGEB6A	ENSG00000176746	MAGE family member B6	X	26192440-26195646	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041853	Approved					Tissue enhanced	Tissue enriched	58	testis: 5.7	all non-specific tissues: 0.0	Cell line enriched	13	K-562: 4.1
CDK5R1	Nck5a, p35, p35nck5a	ENSG00000176749	Cyclin dependent kinase 5 regulatory subunit 1	17	32486619-32491256	Predicted intracellular proteins	Evidence at protein level	HPA000252			Supported	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	7	cerebral cortex: 98.4	lymph node: 14.7	Cell line enhanced		SCLC-21H: 62.8;SK-MEL-30: 30.8
TCERG1L	FLJ38950	ENSG00000176769	Transcription elongation regulator 1 like	10	131092391-131311721	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	6	thyroid gland: 25.1	cerebral cortex: 4.1	Cell line enhanced		BEWO: 4.1;U-2 OS: 1.1
NCKAP5	ERIH1, ERIH2, NAP5	ENSG00000176771	NCK associated protein 5	2	132671799-133568463	Predicted intracellular proteins	Evidence at protein level	HPA034639, HPA044859	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lung: 17.3	cerebral cortex,kidney: 4.4	Cell line enriched	7	AF22: 45.7
MAGEB18	MGC33889	ENSG00000176774	MAGE family member B18	X	26138343-26140735	Predicted intracellular proteins	Evidence at protein level	HPA046141	Enhanced					Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Cell line enriched	29	Karpas-707: 3.1
DEFB104A	DEFB-4, DEFB104, DEFB4	ENSG00000176782	Defensin beta 104A	8	7836471-7841242	Predicted secreted proteins	Evidence at protein level	HPA045292	Supported					Not detected	Tissue enriched	609	epididymis: 581.5	esophagus: 0.9	Not detected		
RUFY1	FLJ22251, RABIP4, ZFYVE12	ENSG00000176783	RUN and FYVE domain containing 1	5	179550558-179610026	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038804, HPA057614	Approved		Supported	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			spleen: 20.2	Expressed in all		
OR52E2		ENSG00000176787	Olfactory receptor family 52 subfamily E member 2	11	5058650-5059627	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA045748	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
BASP1	CAP-23, CAP23, NAP-22, NAP22	ENSG00000176788	Brain abundant membrane attached signal protein 1	5	17065598-17276843	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045218, HPA050333	Enhanced		Enhanced	Plasma membrane	Renal cancer:5.25e-11 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 419.0;epididymis: 369.1	placenta: 130.6	Cell line enhanced		HeLa: 555.7;SiHa: 845.8
DEFB103A	DEFB-3, DEFB103, DEFB3, HBD-3, HBD3, HBP-3, HBP3	ENSG00000176797	Defensin beta 103A	8	7881204-7882664	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 2.1	skin: 0.8	Not detected		
OR51L1		ENSG00000176798	Olfactory receptor family 51 subfamily L member 1	11	4998983-4999930	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LRRC37A3	FLJ34306, KIAA0563	ENSG00000176809	Leucine rich repeat containing 37 member A3	17	64854312-64919480	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090	Supported		Approved	Vesicles	Renal cancer:3.25e-6 (unfavourable)	Mixed	Tissue enhanced		testis: 31.6	thyroid gland: 12.5	Mixed		
VSIG10		ENSG00000176834	V-set and immunoglobulin domain containing 10	12	118063593-118136026	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062022			Approved	Microtubule organizing center<br>Cytosol	Liver cancer:1.76e-4 (unfavourable), Melanoma:7.53e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 27.7	Cell line enhanced		HAP1: 35.3
IRX5	IRX-2a	ENSG00000176842	Iroquois homeobox 5	16	54930862-54934485	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047130			Approved	Nuclear speckles<br>Microtubules<br>Cytosol	Lung cancer:4.59e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 17.9;lung: 9.6;skin: 10.1	salivary gland: 4.6	Cell line enhanced		RPTEC TERT1: 20.1;T-47d: 34.4
METRNL		ENSG00000176845	Meteorin like, glial cell differentiation regulator	17	83079691-83095119	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023792	Uncertain					Expressed in all	Mixed			skin: 30.9	Cell line enhanced		U-138 MG: 117.7;U-2197: 151.1
FAM91A1	FLJ23790	ENSG00000176853	Family with sequence similarity 91 member A1	8	123768456-123815452	Predicted intracellular proteins	Evidence at protein level	HPA027978	Approved		Approved	Nucleoplasm<br>Microtubules		Expressed in all	Expressed in all			parathyroid gland: 36.7	Expressed in all		
WSB2	MGC10210, SBA2	ENSG00000176871	WD repeat and SOCS box containing 2	12	118032694-118062430	Predicted intracellular proteins	Evidence at protein level	HPA052606	Uncertain				Liver cancer:2.42e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.2	Expressed in all		
GRIN1	GluN1, NMDAR1	ENSG00000176884	Glutamate ionotropic receptor NMDA type subunit 1	9	137138390-137168762	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB006831	Approved					Mixed	Tissue enriched	208	cerebral cortex: 151.8	prostate: 0.7	Cell line enhanced		RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2
SOX11		ENSG00000176887	SRY-box 11	2	5692667-5701385	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000536, CAB056152, CAB056153	Approved					Group enriched	Tissue enriched	15	cerebral cortex: 5.4	smooth muscle: 0.3	Group enriched	7	AF22: 48.1;NTERA-2: 23.8;REH: 16.5;RH-30: 18.0;SCLC-21H: 35.0;SH-SY5Y: 47.7;WM-115: 11.2
TYMS	HsT422, TMS, TS, Tsase	ENSG00000176890	Thymidylate synthetase	18	657604-673578	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002784	Enhanced				Liver cancer:5.10e-6 (unfavourable)	Expressed in all	Mixed			testis: 59.1	Expressed in all		
OR51G2		ENSG00000176893	Olfactory receptor family 51 subfamily G member 2	11	4914719-4915663	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PXMP2	PMP22	ENSG00000176894	Peroxisomal membrane protein 2	12	132687606-132704991	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:2.75e-4 (favourable), Head and neck cancer:9.84e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 120.3	Expressed in all		
OR51A7		ENSG00000176895	Olfactory receptor family 51 subfamily A member 7	11	4907370-4908308	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA061356	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
TCEANC	MGC17403	ENSG00000176896	Transcription elongation factor A N-terminal and central domain containing	X	13653189-13681964	Predicted intracellular proteins	Evidence at protein level	HPA001013	Uncertain					Mixed	Mixed			epididymis: 3.6	Mixed		
OR51T1		ENSG00000176900	Olfactory receptor family 51 subfamily T member 1	11	4881819-4882883	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046877	Uncertain					Not detected	Not detected			prostate: 0.1	Not detected		
PNMA1	MA1	ENSG00000176903	Paraneoplastic Ma antigen 1	14	73711783-73714372	Predicted intracellular proteins	Evidence at protein level	HPA003817, HPA015007	Enhanced		Supported	Focal adhesion sites<br>Cytosol	Liver cancer:3.00e-5 (unfavourable), Urothelial cancer:4.51e-5 (unfavourable), Head and neck cancer:7.49e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.5	Mixed		
OR51H1	OR51H1P	ENSG00000176904	Olfactory receptor family 51 subfamily H member 1	11	4859656-4860564	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
C8orf4	hTC-1, TC-1, TC1	ENSG00000176907	Chromosome 8 open reading frame 4	8	40153455-40155308	Predicted intracellular proteins	Evidence at protein level	HPA027188	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			placenta: 233.9	Cell line enhanced		AF22: 130.7;BJ hTERT+: 107.2;EFO-21: 81.1;HeLa: 56.7;RPTEC TERT1: 49.9
MAMSTR	FLJ36070, MASTR	ENSG00000176909	MEF2 activating motif and SAP domain containing transcriptional regulator	19	48712742-48719721	Predicted intracellular proteins	Evidence at transcript level	HPA049765			Approved	Nuclear speckles		Expressed in all	Tissue enhanced		adrenal gland: 21.4;skeletal muscle: 31.4	fallopian tube: 10.4	Cell line enhanced		RH-30: 16.1
ANKLE2	KIAA0692, Lem4, LEMD7	ENSG00000176915	Ankyrin repeat and LEM domain containing 2	12	132725503-132761888	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003602, HPA074838	Uncertain		Supported	Endoplasmic reticulum<br>Plasma membrane	Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
C8G		ENSG00000176919	Complement C8 gamma chain	9	136945246-136946974	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046269	Approved		Uncertain	Endoplasmic reticulum	Colorectal cancer:2.99e-4 (unfavourable)	Tissue enriched	Group enriched	6	duodenum: 49.8;liver: 106.5;small intestine: 34.5	gallbladder: 9.8	Cell line enriched	16	HMC-1: 139.2
FUT2	SE, Se2, SEC2, sej	ENSG00000176920	Fucosyltransferase 2	19	48695971-48705950	Blood group antigen proteins, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014402	Uncertain		Uncertain	Plasma membrane<br>Cytosol	Head and neck cancer:5.83e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 51.4	stomach: 32.2	Cell line enriched	6	CAPAN-2: 68.6
OR51S1		ENSG00000176922	Olfactory receptor family 51 subfamily S member 1	11	4848237-4849208	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
OR51F2		ENSG00000176925	Olfactory receptor family 51 subfamily F member 2	11	4821386-4822414	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
EFCAB5	FLJ46247	ENSG00000176927	EF-hand calcium binding domain 5	17	29929200-30108452	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	12	testis: 15.2	rectum: 1.2	Cell line enhanced		RPTEC TERT1: 2.2
GCNT4	C2GNT3	ENSG00000176928	Glucosaminyl (N-acetyl) transferase 4, core 2	5	75025346-75030899	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037431	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.93e-7 (favourable)	Mixed	Mixed			duodenum: 21.4	Cell line enriched	5	RT4: 25.9
MUC20	FLJ14408, KIAA1359	ENSG00000176945	Mucin 20, cell surface associated	3	195720882-195741123	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042249			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:1.57e-4 (favourable)	Mixed	Mixed			colon: 10.4	Cell line enriched	7	SK-BR-3: 20.9
THAP4	CGI-36	ENSG00000176946	THAP domain containing 4	2	241584405-241637449	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA044982, HPA053448	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Renal cancer:1.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 83.1	Expressed in all		
NFATC2IP	ESC2, FLJ14639, NIP45, RAD60	ENSG00000176953	Nuclear factor of activated T-cells 2 interacting protein	16	28950807-28967097	Predicted intracellular proteins	Evidence at protein level	HPA053587			Approved	Nucleus	Renal cancer:1.03e-5 (unfavourable), Prostate cancer:5.23e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.1	Expressed in all		
LY6H	NMLY6	ENSG00000176956	Lymphocyte antigen 6 family member H	8	143157914-143160711	Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	15	cerebral cortex: 38.0	duodenum: 2.5	Cell line enhanced		MOLT-4: 2.0;SCLC-21H: 1.5
FIBIN	MGC24932	ENSG00000176971	Fin bud initiation factor homolog (zebrafish)	11	26994184-26996121	Predicted secreted proteins	Evidence at protein level	HPA040120	Uncertain				Thyroid cancer:1.85e-6 (unfavourable), Renal cancer:1.93e-5 (favourable), Stomach cancer:6.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 124.4	lung: 37.5	Group enriched	9	ASC diff: 67.5;ASC TERT1: 43.5;fHDF/TERT166: 24.9;HHSteC: 106.9;HSkMC: 96.0;hTCEpi: 25.5
FAM89B	LRAP25, MTVR1	ENSG00000176973	Family with sequence similarity 89 member B	11	65572349-65574198	Predicted intracellular proteins	Evidence at protein level	HPA046895	Approved				Renal cancer:9.48e-5 (unfavourable), Liver cancer:2.98e-4 (unfavourable), Ovarian cancer:6.00e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 38.5	Expressed in all		
SHMT1	CSHMT, MGC15229, MGC24556, SHMT	ENSG00000176974	Serine hydroxymethyltransferase 1	17	18327860-18363563	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023314	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable)	Expressed in all	Expressed in all			kidney: 271.5	Expressed in all		
DPP7	DPP2, DPPII	ENSG00000176978	Dipeptidyl peptidase 7	9	137110542-137115177	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021282, CAB025541, HPA059381	Supported		Enhanced	Golgi apparatus<br>Vesicles	Colorectal cancer:6.07e-6 (unfavourable), Pancreatic cancer:8.31e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 70.7	Mixed		
TRIM60	FLJ35882, RNF129, RNF33	ENSG00000176979	Tripartite motif containing 60	4	165031953-165041744	Predicted intracellular proteins	Evidence at transcript level	HPA035809, HPA035810, HPA061496	Uncertain					Tissue enriched	Group enriched	13	placenta: 2.1;testis: 2.7	skin: 0.1	Cell line enriched	17	BEWO: 13.5
SEC24C	KIAA0079	ENSG00000176986	SEC24 homolog C, COPII coat complex component	10	73744384-73772161	Predicted intracellular proteins	Evidence at protein level	HPA040196, HPA040213	Supported		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 85.5	Expressed in all		
FMR1NB	CT37, FLJ25736, NY-SAR-35	ENSG00000176988	Fragile X mental retardation 1 neighbor	X	147981329-148026667	Predicted membrane proteins	Evidence at protein level	HPA011284, CAB026403	Enhanced					Tissue enhanced	Tissue enriched	415	testis: 86.9	epididymis: 0.2	Group enriched	24	U-266/70: 50.9;U-266/84: 39.2
SMCR8	FLJ34716	ENSG00000176994	Smith-Magenis syndrome chromosome region, candidate 8	17	18315310-18328055	Predicted intracellular proteins	Evidence at protein level	HPA021557, HPA024646	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.35e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.0	Expressed in all		
MTHFR		ENSG00000177000	Methylenetetrahydrofolate reductase	1	11785723-11806920	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA063389			Approved	Cell Junctions	Head and neck cancer:3.97e-5 (favourable), Pancreatic cancer:4.81e-5 (favourable), Liver cancer:1.19e-4 (unfavourable), Renal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 64.9	Expressed in all		
DEFB104B		ENSG00000177023	Defensin beta 104B	8	7470308-7475082	Predicted secreted proteins	Evidence at protein level	HPA045292	Supported					Not detected	Tissue enriched	609	epididymis: 581.5	esophagus: 0.9	Not detected		
C19orf18	MGC41906	ENSG00000177025	Chromosome 19 open reading frame 18	19	57958437-57974534	Predicted membrane proteins	Evidence at transcript level	HPA014527	Uncertain		Approved	Golgi apparatus	Endometrial cancer:5.07e-4 (favourable)	Mixed	Tissue enhanced		testis: 17.0	epididymis: 4.9	Cell line enhanced		HEK 293: 2.7
DEAF1	NUDR, SPN, ZMYND5	ENSG00000177030	DEAF1, transcription factor	11	644233-706715	Disease related genes, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA030302	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:1.75e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 40.6	Expressed in all		
MTX3		ENSG00000177034	Metaxin 3	5	79976731-79991262	Predicted intracellular proteins	Evidence at protein level	HPA047858, HPA062061	Approved		Approved	Mitochondria	Liver cancer:5.08e-5 (unfavourable), Ovarian cancer:2.54e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.6	Mixed		
TMEM80	FLJ38216	ENSG00000177042	Transmembrane protein 80	11	695428-705028	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA059592, HPA067046	Uncertain		Approved	Golgi apparatus	Renal cancer:2.47e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 43.5	Expressed in all		
SIX5	DMAHP	ENSG00000177045	SIX homeobox 5	19	45764785-45769226	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042068	Approved					Expressed in all	Mixed			ovary: 33.7	Mixed		
IFNW1		ENSG00000177047	Interferon omega 1	9	21140214-21142145	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			bone marrow,lymph node,skin,testis,thyroid gland: 0.1	Not detected		
FBXO46	20D7-FC4, Fbx46, FBXO34L	ENSG00000177051	F-box protein 46	19	45710629-45730904	Predicted intracellular proteins	Evidence at protein level	HPA049390	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Urothelial cancer:5.09e-6 (favourable), Endometrial cancer:2.13e-5 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Renal cancer:5.33e-4 (unfavourable), Head and neck cancer:5.44e-4 (favourable), Pancreatic cancer:8.11e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 17.7	Expressed in all		
ZDHHC13	FLJ10852, FLJ10941, HIP14L	ENSG00000177054	Zinc finger DHHC-type containing 13	11	19117099-19176422	Enzymes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016759, HPA018791	Uncertain		Enhanced	Vesicles		Expressed in all	Mixed			esophagus: 40.4	Expressed in all		
SLC38A9	FLJ90709	ENSG00000177058	Solute carrier family 38 member 9	5	55625845-55773194	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA043785	Uncertain		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:7.24e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 80.4	Expressed in all		
ACER2	ALKCDase2, ASAH3L, FLJ41587	ENSG00000177076	Alkaline ceramidase 2	9	19409059-19452020	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Group enriched	5	placenta: 14.8;stomach: 62.9;urinary bladder: 44.1	skin: 7.6	Group enriched	5	BEWO: 30.0;RT4: 62.6
WDR73	FLJ14888, HSPC264	ENSG00000177082	WD repeat domain 73	15	84639281-84654343	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039357	Uncertain					Mixed	Mixed			endometrium: 5.7	Expressed in all		
POLE	POLE1	ENSG00000177084	DNA polymerase epsilon, catalytic subunit	12	132623753-132687365	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058210, HPA067385			Enhanced	Nucleus<br>Plasma membrane	Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
FAM109B	DKFZp686J07229, IPIP27B, SES2	ENSG00000177096	Family with sequence similarity 109 member B	22	42074251-42079441	Predicted intracellular proteins	Evidence at protein level	HPA000647	Uncertain					Expressed in all	Mixed			placenta: 22.5	Mixed		
SCN4B	LQT10	ENSG00000177098	Sodium voltage-gated channel beta subunit 4	11	118133377-118152888	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA017293	Approved					Mixed	Tissue enhanced		adipose tissue: 25.0	thyroid gland: 17.0	Cell line enhanced		AN3-CA: 1.2;NTERA-2: 1.4;U-2 OS: 1.4
DSCAML1	KIAA1132	ENSG00000177103	DS cell adhesion molecule like 1	11	117427773-117817525	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035230	Uncertain				Renal cancer:8.37e-4 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 12.1	ovary: 4.4	Cell line enhanced		EFO-21: 6.2;RPTEC TERT1: 3.7;T-47d: 8.5
RHOG	ARHG, MGC125835, MGC125836, RhoG	ENSG00000177105	Ras homolog family member G	11	3826978-3840983	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039871	Enhanced				Renal cancer:9.49e-8 (unfavourable), Colorectal cancer:1.81e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 170.5	Expressed in all		
EPS8L2	FLJ21935, FLJ22171, MGC3088	ENSG00000177106	EPS8 like 2	11	694438-727727	Predicted intracellular proteins	Evidence at protein level	HPA041143	Approved		Supported	Plasma membrane<br>Cytosol	Glioma:1.80e-4 (unfavourable)	Expressed in all	Mixed			small intestine: 110.4	Cell line enhanced		A-431: 186.2;BEWO: 194.1;CAPAN-2: 171.1;SK-BR-3: 177.2
ZDHHC22	C14orf59	ENSG00000177108	Zinc finger DHHC-type containing 22	14	77131270-77142734	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049471, HPA072213			Enhanced	Plasma membrane		Tissue enriched	Tissue enriched	113	cerebral cortex: 64.2	testis: 0.5	Cell line enhanced		AF22: 3.6;NTERA-2: 3.8;RH-30: 6.2;SCLC-21H: 8.2
ANO6	DKFZp313M0720, TMEM16F	ENSG00000177119	Anoctamin 6	12	45215987-45440404	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038958	Approved		Approved	Plasma membrane<br>Cytosol	Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 91.1	Expressed in all		
ZBTB34	KIAA1993, MGC24652, ZNF918	ENSG00000177125	Zinc finger and BTB domain containing 34	9	126860665-126885878	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023893	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			placenta: 9.6	Expressed in all		
FAM9B	TEX39B	ENSG00000177138	Family with sequence similarity 9 member B	X	9024232-9164639	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035135	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enriched	32	testis: 10.3	prostate,skin: 0.3	Group enriched	38	U-266/70: 21.4;U-266/84: 22.5
CETN1	CEN1, CETN	ENSG00000177143	Centrin 1	18	580357-582114	Predicted intracellular proteins	Evidence at protein level	HPA028956, CAB037244	Approved					Tissue enriched	Tissue enriched	1424	testis: 142.4	all non-specific tissues: 0.0	Not detected		
NUDT4P1		ENSG00000177144	Nudix hydrolase 4 pseudogene 1	1	148748894-148750099	Predicted intracellular proteins	Evidence at protein level	HPA017593, HPA047027, HPA057684	Approved		Approved	Cytosol		Not detected	Mixed			gallbladder: 25.4	Cell line enhanced		CACO-2: 28.7;RT4: 24.9
FAM210A	C18orf19, HsT2329, MGC24180	ENSG00000177150	Family with sequence similarity 210 member A	18	13663347-13726663	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014324, HPA051564	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Mitochondria	Head and neck cancer:8.14e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.7	Expressed in all		
OR2T35		ENSG00000177151	Olfactory receptor family 2 subfamily T member 35	1	248638287-248639258	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TALDO1		ENSG00000177156	Transaldolase 1	11	747329-765024	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA040373, HPA048089			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 262.9	Expressed in all		
ULK1	ATG1, ATG1A	ENSG00000177169	Unc-51 like autophagy activating kinase 1	12	131894651-131923167	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063990			Approved	Cytosol		Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
OR14C36	OR5BF1	ENSG00000177174	Olfactory receptor family 14 subfamily C member 36	1	248348775-248349713	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			prostate: 0.1	Not detected		
RIMKLA	FAM80A, MGC47816, NAAGS-II, RP11-157D18.1	ENSG00000177181	Ribosomal modification protein rimK like family member A	1	42380795-42422578	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027826	Uncertain		Uncertain	Nucleoli fibrillar center	Lung cancer:1.43e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.2	parathyroid gland,rectum: 3.8	Cell line enhanced		AN3-CA: 6.7;SCLC-21H: 12.8
CLVS1	C6orf212L, CRALBPL, MGC34646, RLBP1L1	ENSG00000177182	Clavesin 1	8	61057158-61501645	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 10.3	testis: 3.7	Cell line enhanced		SCLC-21H: 4.4;SH-SY5Y: 1.7
OR2M7		ENSG00000177186	Olfactory receptor family 2 subfamily M member 7	1	248323630-248324568	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RPS6KA3	CLS, HU-3, MRX19, RSK, RSK2	ENSG00000177189	Ribosomal protein S6 kinase A3	X	20149911-20267100	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003221, CAB003853, CAB013520	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 92.7	Mixed		
B3GNT8	B3GALT7, beta3Gn-T8, BGALT15	ENSG00000177191	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8	19	41425359-41428730	Predicted secreted proteins	Evidence at protein level	HPA043669	Enhanced				Pancreatic cancer:9.31e-6 (favourable), Endometrial cancer:4.11e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 15.5;small intestine: 16.8	esophagus: 10.7	Cell line enhanced		HMC-1: 5.7;HUVEC TERT2: 2.9;U-937: 4.3
PUS1		ENSG00000177192	Pseudouridylate synthase 1	12	131929200-131945896	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA051636, HPA057593	Approved		Supported	Nucleus<br>Mitochondria	Renal cancer:3.49e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.4	Expressed in all		
CHD9	BC022889, FLJ12178, KIAA0308	ENSG00000177200	Chromodomain helicase DNA binding protein 9	16	53055033-53329150	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042053, HPA049420	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.84e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.2	Expressed in all		
OR2T12		ENSG00000177201	Olfactory receptor family 2 subfamily T member 12	1	248294616-248295578	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPACA4	SAMP14	ENSG00000177202	Sperm acrosome associated 4	19	48606743-48607714	Predicted secreted proteins	Evidence at protein level	HPA041927, HPA061302	Enhanced					Mixed	Tissue enriched	18	testis: 64.9	stomach: 3.5	Not detected		
OR2T33		ENSG00000177212	Olfactory receptor family 2 subfamily T member 33	1	248272852-248273814	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow,testis: 0.2	Not detected		
PDDC1	FLJ34283	ENSG00000177225	Parkinson disease 7 domain containing 1	11	767220-777488	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008812	Uncertain		Supported	Nucleoplasm	Renal cancer:3.79e-5 (favourable), Liver cancer:3.98e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 31.7	Expressed in all		
TRIM72	MG53	ENSG00000177238	Tripartite motif containing 72	16	31214021-31231537	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA023122, HPA054909	Enhanced		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	19	skeletal muscle: 52.4	prostate: 2.8	Cell line enhanced		LHCN-M2: 9.1;RH-30: 27.1;U-266/70: 13.3
MAN1B1	ERManI, MANA-ER, MRT15	ENSG00000177239	Mannosidase alpha class 1B member 1	9	137086927-137109187	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051516	Approved		Uncertain	Vesicles	Liver cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 33.4	Expressed in all		
DEFB103B		ENSG00000177243	Defensin beta 103B	8	7428888-7430348	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		tonsil: 2.1	skin: 0.8	Not detected		
DEFB4B	DEFB4P	ENSG00000177257	Defensin beta 4B	8	7414860-7416863	Predicted secreted proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	19	tonsil: 2.7	lung,skin: 0.1	Not detected		
KCNA3	HLK3, HPCN3, Kv1.3, MK3	ENSG00000177272	Potassium voltage-gated channel subfamily A member 3	1	110672465-110675033	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA016625	Approved					Mixed	Mixed			lymph node: 10.5	Cell line enhanced		HDLM-2: 20.5;Karpas-707: 31.5;U-266/70: 23.9;U-266/84: 21.1
OR2AJ1	OR2AJ1P, OR2AJ1Q	ENSG00000177275	Olfactory receptor family 2 subfamily AJ member 1	1	247933769-247934755	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			spleen: 0.1	Not detected		
FZD8		ENSG00000177283	Frizzled class receptor 8	10	35638249-35642278	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045025, HPA071142	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:8.21e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 15.9	lung: 6.6	Cell line enhanced		PC-3: 37.6;U-138 MG: 14.7
GJD4	CX40.1, FLJ90023	ENSG00000177291	Gap junction protein delta 4	10	35605410-35608935	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA038266	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.7	skin: 1.0	Cell line enhanced		RH-30: 1.6
FBXO39	CT144, Fbx39, MGC35179	ENSG00000177294	F-box protein 39	17	6776223-6797101	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	62	testis: 53.5	ovary: 0.8	Not detected		
CLDN22	CLDN21	ENSG00000177300	Claudin 22	4	183318194-183320774	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.0	endometrium: 0.2	Not detected		
KCNA2	HK4, Kv1.2	ENSG00000177301	Potassium voltage-gated channel subfamily A member 2	1	110519837-110631474	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	CAB001976	Enhanced					Tissue enhanced	Tissue enriched	6	cerebral cortex: 23.2	thyroid gland: 4.1	Cell line enhanced		Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6
TOP3A	TOP3, ZGRF7	ENSG00000177302	Topoisomerase (DNA) III alpha	17	18271428-18315007	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002449	Approved				Pancreatic cancer:1.39e-4 (favourable), Prostate cancer:4.59e-4 (unfavourable)	Expressed in all	Mixed			testis: 12.4	Expressed in all		
CASKIN2	ANKS5B, FLJ21609, KIAA1139	ENSG00000177303	CASK interacting protein 2	17	75500261-75515583	Predicted intracellular proteins	Evidence at protein level	HPA071906, HPA075184	Enhanced		Enhanced	Plasma membrane	Renal cancer:4.83e-8 (favourable), Pancreatic cancer:2.47e-5 (favourable)	Expressed in all	Mixed			lung: 29.0	Mixed		
ZBTB38	CIBZ, FLJ35036, PPP1R171, ZNF921	ENSG00000177311	Zinc finger and BTB domain containing 38	3	141324213-141449792	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA014865, HPA059378			Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 126.8	Cell line enhanced		RPMI-8226: 273.3
BEND2	CXorf20, MGC33653	ENSG00000177324	BEN domain containing 2	X	18162931-18220883	Predicted intracellular proteins	Evidence at protein level	HPA009420, HPA013142	Enhanced					Not detected	Tissue enriched	30	testis: 9.9	spleen: 0.3	Not detected		
CCDC71	FLJ12800	ENSG00000177352	Coiled-coil domain containing 71	3	49162535-49166321	Predicted intracellular proteins	Evidence at protein level	HPA047547	Uncertain		Approved	Nuclear membrane	Renal cancer:9.65e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.2	Expressed in all		
C10orf71	FLJ45913	ENSG00000177354	Chromosome 10 open reading frame 71	10	49299193-49327487	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	34	heart muscle: 28.8;parathyroid gland: 74.8;skeletal muscle: 97.7	prostate: 1.9	Group enriched	17	K-562: 6.2;RH-30: 9.6
OVOS2		ENSG00000177359		12	31111652-31206154	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	8	testis: 2.8	stomach: 0.3	Cell line enhanced		U-266/70: 1.0
LRRN4CL		ENSG00000177363	LRRN4 C-terminal like	11	62686402-62689899	Predicted membrane proteins	Evidence at protein level	HPA050317	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Tissue enriched	Mixed			endometrium: 16.8	Cell line enhanced		ASC TERT1: 15.0;HHSteC: 14.1;HSkMC: 6.6;LHCN-M2: 9.5
TIMM22	TEX4, TIM22	ENSG00000177370	Translocase of inner mitochondrial membrane 22	17	997117-1003671	Predicted membrane proteins	Evidence at protein level	HPA045138	Uncertain				Renal cancer:1.41e-4 (favourable), Pancreatic cancer:3.42e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.4	Expressed in all		
HIC1	ZBTB29, ZNF901	ENSG00000177374	HIC ZBTB transcriptional repressor 1	17	2054154-2063241	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043372	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.36e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 16.3	Cell line enhanced		BJ: 10.1;TIME: 10.1
PPFIA3	KIAA0654, LPNA3, MGC126567, MGC126569	ENSG00000177380	PTPRF interacting protein alpha 3	19	49119389-49151026	Predicted intracellular proteins	Evidence at protein level	HPA043567, HPA050340	Enhanced		Uncertain	Nucleoli fibrillar center<br>Vesicles	Head and neck cancer:6.46e-7 (favourable), Liver cancer:2.24e-5 (unfavourable), Breast cancer:3.09e-4 (unfavourable), Endometrial cancer:8.65e-4 (favourable)	Expressed in all	Group enriched	6	cerebral cortex: 21.5;skin: 20.2	parathyroid gland: 3.6	Cell line enhanced		PC-3: 33.5
MAGEF1		ENSG00000177383	MAGE family member F1	3	184710367-184712002	Predicted intracellular proteins	Evidence at protein level	HPA046899, HPA054190	Uncertain		Approved	Actin filaments	Renal cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 60.1	Expressed in all		
UMODL1		ENSG00000177398	Uromodulin like 1	21	42062959-42143453	Predicted membrane proteins	Evidence at protein level	HPA067245	Uncertain					Group enriched	Group enriched	7	fallopian tube: 1.7;testis: 1.7	small intestine: 0.2	Group enriched	6	SCLC-21H: 1.8;U-266/70: 2.9
SAMD9L	C7orf6, FLJ39885, KIAA2005	ENSG00000177409	Sterile alpha motif domain containing 9 like	7	93130055-93148369	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019461, HPA019465, HPA019488	Enhanced		Approved	Cytosol	Renal cancer:6.63e-5 (unfavourable)	Expressed in all	Mixed			spleen: 52.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 52.6;HDLM-2: 47.0;Karpas-707: 94.3
UBE2U	MGC35130	ENSG00000177414	Ubiquitin conjugating enzyme E2 U (putative)	1	64203627-64267368	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 79.4	stomach: 2.0	Not detected		
PAWR	par-4, PAR4	ENSG00000177425	Pro-apoptotic WT1 regulator	12	79574979-79691097	Predicted intracellular proteins	Evidence at protein level	HPA012640, CAB020779	Approved		Enhanced	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			endometrium: 45.4	Mixed		
TGIF1	HPE4, TGIF	ENSG00000177426	TGFB induced factor homeobox 1	18	3411608-3459978	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062160			Supported	Nucleoplasm	Pancreatic cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 162.4	Mixed		
MIEF2	MGC23130, MiD49, SMCR7	ENSG00000177427	Mitochondrial elongation factor 2	17	18260534-18266552	Predicted membrane proteins	Evidence at protein level	HPA042334	Uncertain				Renal cancer:1.75e-7 (favourable)	Expressed in all	Mixed			skeletal muscle: 7.0	Mixed		
NAP1L5	DRLM	ENSG00000177432	Nucleosome assembly protein 1 like 5	4	88695915-88698235	Predicted intracellular proteins	Evidence at protein level	HPA058227	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 91.1	adrenal gland: 29.5	Cell line enhanced		SH-SY5Y: 42.7
NIM1K	MGC42105, NIM1	ENSG00000177453	NIM1 serine/threonine protein kinase	5	43192071-43280850	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007695	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enriched	8	cerebral cortex: 16.3	lung: 2.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 1.9;HDLM-2: 2.1;PC-3: 2.4;U-87 MG: 2.6
CD19		ENSG00000177455	CD19 molecule	16	28931939-28939346	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB016110	Enhanced					Mixed	Group enriched	11	appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3	urinary bladder: 5.5	Group enriched	40	Daudi: 103.6;REH: 70.5;U-698: 22.6
ERICH5	C8orf47, FLJ39553	ENSG00000177459	Glutamate rich 5	8	98064311-98093610	Predicted intracellular proteins	Evidence at protein level	HPA025070, HPA025293, HPA027233	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.76e-4 (favourable), Urothelial cancer:9.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		fallopian tube: 13.8;gallbladder: 13.7	stomach: 9.2	Cell line enhanced		A549: 6.1;HAP1: 6.4;HEK 293: 8.2;RT4: 12.7
OR2T8	OR2T8P	ENSG00000177462	Olfactory receptor family 2 subfamily T member 8	1	247921018-247921956	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.2	testis: 0.4	Not detected		
NR2C2	hTAK1, TAK1, TR2R1, TR4	ENSG00000177463	Nuclear receptor subfamily 2 group C member 2	3	14947584-15053600	Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006313	Approved		Enhanced	Nucleoplasm	Head and neck cancer:1.51e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.6	Expressed in all		
GPR4		ENSG00000177464	G protein-coupled receptor 4	19	45589764-45602208	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014278	Uncertain				Renal cancer:2.07e-5 (unfavourable), Lung cancer:9.19e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 10.3	Group enriched	11	HUVEC TERT2: 15.6;TIME: 25.6
ACOT4	FLJ31235, PTE-Ib, PTE2B	ENSG00000177465	Acyl-CoA thioesterase 4	14	73591706-73596496	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000779	Enhanced				Renal cancer:8.43e-5 (favourable), Pancreatic cancer:1.77e-4 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 8.9	liver: 4.9	Cell line enhanced		CAPAN-2: 9.1;SK-BR-3: 12.3;T-47d: 38.6
OLIG3	Bhlhb7, bHLHe20	ENSG00000177468	Oligodendrocyte transcription factor 3	6	137492202-137494250	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018303, CAB024865	Uncertain					Not detected	Not detected			esophagus: 0.1	Cell line enhanced		NTERA-2: 1.2
PTRF	cavin-1, CAVIN1	ENSG00000177469	Polymerase I and transcript release factor	17	42402452-42423517	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049838, HPA074213	Supported		Supported	Vesicles<br>Plasma membrane	Urothelial cancer:5.87e-4 (unfavourable), Ovarian cancer:5.92e-4 (unfavourable), Colorectal cancer:6.36e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 343.1	Cell line enhanced		BJ: 868.3;U-138 MG: 835.1
OR2G3		ENSG00000177476	Olfactory receptor family 2 subfamily G member 3	1	247605586-247606515	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ARIH2	TRIAD1	ENSG00000177479	Ariadne RBR E3 ubiquitin protein ligase 2	3	48918821-48986382	Predicted intracellular proteins	Evidence at protein level	HPA067381, HPA069715, HPA070963			Enhanced	Nucleoplasm	Liver cancer:1.70e-4 (unfavourable), Renal cancer:6.60e-4 (favourable), Pancreatic cancer:7.31e-4 (favourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
RBM44	FLJ40411	ENSG00000177483	RNA binding motif protein 44	2	237798389-237842808	Predicted intracellular proteins	Evidence at protein level	HPA003298	Enhanced					Not detected	Tissue enriched	61	testis: 35.7	bone marrow,lung: 0.5	Not detected		
ZBTB33	kaiso, WUGSC:H_DJ525N14.1, ZNF-kaiso, ZNF348	ENSG00000177485	Zinc finger and BTB domain containing 33	X	120250752-120258398	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000755, CAB001980, HPA005732	Approved		Enhanced	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 23.4	Expressed in all		
OR2G2		ENSG00000177489	Olfactory receptor family 2 subfamily G member 2	1	247588360-247589313	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZBED2	MGC10796	ENSG00000177494	Zinc finger BED-type containing 2	3	111592900-111595443	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029786			Approved	Nuclear bodies<br>Mitochondria<br>Cytosol	Pancreatic cancer:8.83e-4 (unfavourable)	Tissue enriched	Tissue enhanced		fallopian tube: 30.3;thyroid gland: 113.1	lung: 14.9	Cell line enhanced		CAPAN-2: 45.9;EFO-21: 33.6;HaCaT: 44.7;HBEC3-KT: 81.4;RPTEC TERT1: 56.1
VCX2	VCX-2r	ENSG00000177504	Variable charge, X-linked 2	X	8169944-8171267	Predicted intracellular proteins	Evidence at protein level	HPA044642, HPA044996, HPA049357	Enhanced					Tissue enhanced	Tissue enriched	32	testis: 3.1	all non-specific tissues: 0.0	Not detected		
IRX3	IRX-1	ENSG00000177508	Iroquois homeobox 3	16	54283304-54286763	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062522			Approved	Vesicles		Expressed in all	Tissue enhanced		breast: 96.6	skin: 70.5	Cell line enhanced		NB-4: 129.5;RPTEC TERT1: 178.7;T-47d: 115.6;THP-1: 136.2
ST8SIA3	SIAT8C	ENSG00000177511	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3	18	57350813-57371731	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063398, HPA066783	Supported		Supported	Golgi apparatus		Group enriched	Tissue enriched	7	cerebral cortex: 31.8	adrenal gland: 4.8	Group enriched	67	NTERA-2: 4.3;SCLC-21H: 8.6;SH-SY5Y: 8.7
RPRM	FLJ90327, REPRIMO	ENSG00000177519	Reprimo, TP53 dependent G2 arrest mediator candidate	2	153477338-153478808	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 21.2;endometrium: 21.8	smooth muscle: 17.4	Group enriched	6	HEK 293: 22.9;MCF7: 21.9;NTERA-2: 19.8;SCLC-21H: 8.5;SH-SY5Y: 8.7
OR2B11		ENSG00000177535	Olfactory receptor family 2 subfamily B member 11	1	247451029-247451982	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047459	Uncertain					Not detected	Not detected			bone marrow: 0.4	Not detected		
SLC25A22	EIEE3, FLJ13044, GC1, NET44	ENSG00000177542	Solute carrier family 25 member 22	11	790475-798333	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA014662	Approved		Enhanced	Nucleoplasm<br>Mitochondria		Expressed in all	Tissue enriched	6	cerebral cortex: 89.6	testis: 15.2	Expressed in all		
RABEP2	FLJ23282, FRA	ENSG00000177548	Rabaptin, RAB GTPase binding effector protein 2	16	28904421-28936526	Predicted intracellular proteins	Evidence at protein level	HPA047641	Approved		Supported	Vesicles<br>Cytosol	Renal cancer:1.24e-6 (favourable), Head and neck cancer:5.84e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 57.1	Expressed in all		
NHLH2	bHLHa34, HEN2, NSCL2	ENSG00000177551	Nescient helix-loop-helix 2	1	115836377-115843917	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055238	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		skin: 3.9	cerebral cortex,testis: 0.8	Cell line enriched	11	SCLC-21H: 68.8
ATOX1	HAH1	ENSG00000177556	Antioxidant 1 copper chaperone	5	151742316-151772532	Predicted intracellular proteins	Evidence at protein level	HPA055036			Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:9.57e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.5	Expressed in all		
FAM187B	FLJ25660, TMEM162	ENSG00000177558	Family with sequence similarity 187 member B	19	35224800-35228729	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	202	testis: 44.2	spleen: 0.2	Not detected		
TBL1XR1	C21, DC42, FLJ12894, IRA1, TBLR1	ENSG00000177565	Transducin beta like 1 X-linked receptor 1	3	177019340-177228000	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019182	Supported		Approved	Nucleoplasm	Liver cancer:1.08e-7 (unfavourable), Renal cancer:4.25e-5 (unfavourable), Glioma:7.23e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 59.4	Expressed in all		
SAMD12	FLJ39458	ENSG00000177570	Sterile alpha motif domain containing 12	8	118189459-118621995	Predicted intracellular proteins	Evidence at protein level	HPA024634	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.52e-6 (favourable), Endometrial cancer:1.11e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 14.1	Cell line enhanced		SK-BR-3: 25.4
CD163	M130, MM130, SCARI1	ENSG00000177575	CD163 molecule	12	7470813-7503893	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002432, HPA046404, HPA051974	Enhanced		Approved	Plasma membrane	Ovarian cancer:7.27e-4 (unfavourable)	Expressed in all	Mixed			appendix: 220.1	Cell line enhanced		HSkMC: 1.2
C18orf32	FLJ23458	ENSG00000177576	Chromosome 18 open reading frame 32	18	49477250-49487252	Predicted membrane proteins	Evidence at protein level	HPA040921	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:8.89e-9 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 119.6	Expressed in all		
PIDD1	DKFZp434D229, LRDD, MGC16925, PIDD	ENSG00000177595	P53-induced death domain protein 1	11	799179-809753	Predicted intracellular proteins	Evidence at protein level	CAB012647, HPA055473	Supported		Approved	Golgi apparatus<br>Cytosol	Endometrial cancer:3.32e-5 (favourable), Cervical cancer:8.19e-5 (favourable), Renal cancer:1.52e-4 (unfavourable), Head and neck cancer:3.91e-4 (favourable)	Expressed in all	Mixed			bone marrow: 4.6	Cell line enhanced		BEWO: 25.3
ZNF491	FLJ34791	ENSG00000177599	Zinc finger protein 491	19	11797667-11809622	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			parathyroid gland: 3.6	Mixed		
RPLP2	D11S2243E, LP2, MGC71408, P2, RPP2	ENSG00000177600	Ribosomal protein lateral stalk subunit P2	11	809647-812880	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA053635	Approved		Approved	Mitochondria	Renal cancer:2.19e-6 (unfavourable), Liver cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1168.6	Expressed in all		
GSG2	haspin	ENSG00000177602	Germ cell associated 2, haspin	17	3723903-3726699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027422, HPA030698	Approved		Supported	Nucleus		Mixed	Tissue enhanced		testis: 13.2	lymph node: 5.0	Mixed		
JUN	AP-1, c-Jun	ENSG00000177606	Jun proto-oncogene, AP-1 transcription factor subunit	1	58780788-58784327	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003801, CAB007780, HPA059474	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 314.6	Cell line enhanced		RH-30: 282.2
CSTF2T	CstF-64T, DKFZp434C1013, KIAA0689, tauCstF-64	ENSG00000177613	Cleavage stimulation factor subunit 2 tau variant	10	51695487-51699591	Predicted intracellular proteins	Evidence at protein level	HPA039216, HPA062021	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 37.6	Expressed in all		
PGBD5	DKFZp761A0620, FLJ11413	ENSG00000177614	PiggyBac transposable element derived 5	1	230314482-230426371	Predicted intracellular proteins	Evidence at protein level	HPA065010			Approved	Nucleoplasm	Glioma:1.20e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 40.1;cervix, uterine: 29.1	adrenal gland: 12.6	Cell line enhanced		Daudi: 21.9;NTERA-2: 30.2;RH-30: 15.9;SCLC-21H: 48.7
C12orf54	MGC35033	ENSG00000177627	Chromosome 12 open reading frame 54	12	48482503-48496512	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	66	testis: 86.6	tonsil: 1.3	Cell line enhanced		HaCaT: 1.2;HBEC3-KT: 3.4;hTERT-HME1: 2.1
GBA	GBA1, GLUC	ENSG00000177628	Glucosylceramidase beta	1	155234452-155244699	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA006667, CAB037171, CAB037289	Supported					Expressed in all	Expressed in all			parathyroid gland: 276.1	Expressed in all		
ACAD9	MGC14452, NPD002	ENSG00000177646	Acyl-CoA dehydrogenase family member 9	3	128879596-128916067	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037716, HPA046720	Supported		Enhanced	Mitochondria	Renal cancer:4.32e-8 (favourable), Liver cancer:3.67e-6 (unfavourable), Endometrial cancer:3.05e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 52.8	Expressed in all		
IL17RA	CD217, CDw217, hIL-17R, IL-17RA, IL17R	ENSG00000177663	Interleukin 17 receptor A	22	17084954-17115694	CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024996	Enhanced		Approved	Nucleoplasm<br>Cytosol	Stomach cancer:8.35e-4 (favourable)	Expressed in all	Mixed			bone marrow: 20.6	Cell line enhanced		HL-60: 47.4;THP-1: 50.1
PNPLA2	ATGL, desnutrin, FP17548, iPLA2zeta, TTS-2.2	ENSG00000177666	Patatin like phospholipase domain containing 2	11	818902-825573	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA055173, HPA062602			Enhanced	Nucleoplasm<br>Lipid droplets		Expressed in all	Tissue enriched	13	adipose tissue: 420.0	skeletal muscle: 33.4	Expressed in all		
MBOAT4	FKSG89, GOAT, OACT4	ENSG00000177669	Membrane bound O-acyltransferase domain containing 4	8	30131824-30144686	Predicted membrane proteins	Evidence at protein level	HPA044509			Supported	Golgi apparatus		Tissue enhanced	Tissue enhanced		fallopian tube: 2.9;stomach: 3.5	gallbladder: 1.6	Cell line enhanced		Hep G2: 2.1
TEX44	C2orf57, MGC35154	ENSG00000177673	Testis expressed 44	2	231592901-231594283	Predicted intracellular proteins	Evidence at protein level	HPA049917, HPA056433	Enhanced					Not detected	Tissue enriched	1204	testis: 120.3	all non-specific tissues: 0.0	Not detected		
AGTRAP	ATRAP	ENSG00000177674	Angiotensin II receptor associated protein	1	11736084-11754802	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044120	Approved		Supported	Vesicles	Liver cancer:6.57e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 92.6	Expressed in all		
CD163L1	CD163B, M160, SCARI2	ENSG00000177675	CD163 molecule like 1	12	7346685-7479897	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015663	Enhanced		Approved	Nucleoplasm<br>Centrosome<br>Cytosol		Mixed	Tissue enhanced		spleen: 43.2	rectum: 24.1	Cell line enhanced		U-87 MG: 22.1
SRRM3	FLJ37078	ENSG00000177679	Serine/arginine repetitive matrix 3	7	76201900-76287288	Predicted intracellular proteins	Evidence at protein level	HPA019337	Uncertain		Approved	Plasma membrane<br>Intermediate filaments<br>Microtubules		Mixed	Group enriched	10	adrenal gland: 2.7;cerebral cortex: 8.5;testis: 1.8	stomach: 0.4	Group enriched	12	SCLC-21H: 12.8;SH-SY5Y: 8.5
THAP5	DKFZp313O1132	ENSG00000177683	THAP domain containing 5	7	108554543-108569750	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043170, HPA051488	Approved		Enhanced	Nucleus	Renal cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
DEFB114	DEFB-14	ENSG00000177684	Defensin beta 114	6	49960249-49964105	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	734	epididymis: 73.3	all non-specific tissues: 0.0	Not detected		
CRACR2B	EFCAB4A, MGC45840	ENSG00000177685	Calcium release activated channel regulator 2B	11	826144-831991	Predicted intracellular proteins	Evidence at protein level	HPA046217	Approved				Colorectal cancer:1.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		salivary gland: 120.0	stomach: 56.6	Cell line enhanced		HDLM-2: 30.7;SK-BR-3: 92.6
SUMO4	dJ281H8.4, IDDM5, SMT3H4	ENSG00000177688	Small ubiquitin-like modifier 4	6	149400227-149401292	Predicted intracellular proteins	Evidence at protein level	HPA042123, HPA048064	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Not detected			liver: 0.6	Not detected		
MAGEB10	FLJ32965	ENSG00000177689	MAGE family member B10	X	27807990-27823014	Predicted intracellular proteins	Evidence at protein level	HPA000611	Uncertain					Not detected	Tissue enriched	10	testis: 4.6	skin: 0.4	Not detected		
DNAJC28	C21orf55, C21orf78	ENSG00000177692	DnaJ heat shock protein family (Hsp40) member C28	21	33485530-33491720	Predicted intracellular proteins	Evidence at protein level	HPA018003, HPA030076	Approved					Mixed	Tissue enhanced		testis: 8.2	thyroid gland: 4.1	Mixed		
OR4F4	OR4F18	ENSG00000177693	Olfactory receptor family 4 subfamily F member 4	15	101922042-101923095	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NAALADL2		ENSG00000177694	N-acetylated alpha-linked acidic dipeptidase like 2	3	174438573-175810552	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012413, HPA017425, CAB025586	Approved		Supported	Nucleoplasm		Mixed	Tissue enhanced		parathyroid gland: 28.0	cervix, uterine: 9.9	Cell line enhanced		ASC TERT1: 10.1;fHDF/TERT166: 5.0;WM-115: 5.8
CD151	PETA-3, RAPH, SFA-1, TSPAN24	ENSG00000177697	CD151 molecule (Raph blood group)	11	832843-839831	Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002428, HPA011906	Supported				Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 361.3	Mixed		
POLR2L	hRPB7.6, hsRPB10b, RBP10, RPABC5, RPB10beta, RPB7.6	ENSG00000177700	RNA polymerase II subunit L	11	837356-842545	Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level						Liver cancer:2.37e-4 (unfavourable), Renal cancer:5.56e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 68.0	Expressed in all		
FAM20C	DKFZp547D065, DMP4, G-CK, IMAGE:4942737	ENSG00000177706	FAM20C, golgi associated secretory pathway kinase	7	192969-260745	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA019823			Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Ovarian cancer:9.40e-6 (unfavourable), Cervical cancer:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 38.3	Cell line enhanced		HSkMC: 118.8;U-87 MG: 99.8
NECTIN3	CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3	ENSG00000177707	Nectin cell adhesion molecule 3	3	111070071-111275563	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009869, HPA011038	Approved		Approved	Microtubule organizing center	Renal cancer:9.82e-7 (favourable)	Expressed in all	Tissue enhanced		testis: 99.5	thyroid gland: 73.7	Cell line enhanced		TIME: 138.4
SLC35G5	AMAC, AMAC1L2	ENSG00000177710	Solute carrier family 35 member G5	8	11330888-11332208	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.4	appendix,skin: 0.4	Not detected		
ANXA2R	AXIIR, C5orf39	ENSG00000177721	Annexin A2 receptor	5	43039081-43043170	Predicted intracellular proteins	Evidence at protein level	HPA051482	Uncertain		Approved	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies	Renal cancer:6.36e-8 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 21.9	spleen: 15.4	Cell line enhanced		REH: 21.2;U-937: 66.7
TMEM94	KIAA0195	ENSG00000177728	Transmembrane protein 94	17	75441159-75500090	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008423, HPA050660	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.2	Expressed in all		
FLII	FLI, Fli1, FLIL, MGC39265	ENSG00000177731	FLII, actin remodeling protein	17	18244836-18258916	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007084, HPA008903, CAB016132	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 41.2	Expressed in all		
SOX12	SOX22	ENSG00000177732	SRY-box 12	20	325595-330224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055052, HPA061627			Supported	Nucleoplasm	Liver cancer:6.64e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.7	Mixed		
HNRNPA0	hnRNPA0, HNRPA0	ENSG00000177733	Heterogeneous nuclear ribonucleoprotein A0	5	137745651-137754376	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036569, HPA059404	Enhanced		Enhanced	Nucleoplasm	Renal cancer:1.99e-4 (favourable), Pancreatic cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 32.8	Expressed in all		
YIPF7	FinGER9, FLJ39576	ENSG00000177752	Yip1 domain family member 7	4	44622065-44678556	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA030642	Uncertain					Not detected	Tissue enriched	42	skeletal muscle: 29.6	esophagus: 0.6	Not detected		
MYOZ1	CS-2, FATZ, MYOZ	ENSG00000177791	Myozenin 1	10	73631654-73641757	Predicted intracellular proteins	Evidence at protein level	HPA037848, HPA038437	Enhanced					Tissue enhanced	Tissue enriched	38	skeletal muscle: 2058.9	esophagus: 54.7	Cell line enriched	25	BEWO: 38.7
TMEM78	FLJ40168	ENSG00000177800	Transmembrane protein 78	1	229249636-229251810	Predicted membrane proteins	Evidence at transcript level	HPA042351	Uncertain					Not detected	Not detected			bone marrow,cerebral cortex,skin,testis: 0.3	Not detected		
KCNJ10	Kir1.2, Kir4.1	ENSG00000177807	Potassium voltage-gated channel subfamily J member 10	1	159998651-160070483	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA078302	Enhanced					Tissue enriched	Group enriched	5	cerebral cortex: 124.7;kidney: 30.6	spleen: 14.5	Cell line enhanced		Hep G2: 4.5;SK-MEL-30: 1.6;U-266/70: 1.6
CHID1	FLJ42707, MGC3234	ENSG00000177830	Chitinase domain containing 1	11	867860-915058	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039374	Uncertain		Uncertain	Nucleoplasm<br>Intermediate filaments	Endometrial cancer:6.76e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 109.0	Expressed in all		
PCDHB9	PCDH-BETA9, PCDH3H	ENSG00000177839	Protocadherin beta 9	5	141187127-141191541	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013445	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 7.9	epididymis,ovary: 2.5	Cell line enhanced		ASC diff: 7.0;SH-SY5Y: 15.3
ZNF620	MGC50836	ENSG00000177842	Zinc finger protein 620	3	40505992-40518736	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031452, HPA059383	Uncertain		Approved	Centrosome		Mixed	Mixed			thyroid gland: 6.0	Mixed		
ZNF518A	KIAA0335, ZNF518	ENSG00000177853	Zinc finger protein 518A	10	96129715-96205288	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029049			Approved	Nucleus		Expressed in all	Mixed			testis: 30.1	Mixed		
TMEM187	CXorf12, DXS9878E, ITBA1	ENSG00000177854	Transmembrane protein 187	X	153972327-153983195	Predicted membrane proteins	Evidence at transcript level	HPA038134	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:9.14e-8 (favourable)	Expressed in all	Expressed in all			fallopian tube: 11.4	Expressed in all		
SVBP	CCDC23, MGC45441	ENSG00000177868	Small vasohibin binding protein	1	42807052-42817252	Predicted intracellular proteins	Evidence at protein level	HPA008507	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:1.18e-4 (unfavourable), Breast cancer:6.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.8	Expressed in all		
ZNF619	FLJ90764	ENSG00000177873	Zinc finger protein 619	3	40477113-40490236	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045094	Uncertain		Approved	Nucleoplasm<br>Intermediate filaments		Expressed in all	Mixed			parathyroid gland: 7.7	Mixed		
CCDC184	C12orf68, LOC387856	ENSG00000177875	Coiled-coil domain containing 184	12	48183584-48185926	Predicted intracellular proteins	Evidence at protein level	HPA039947, HPA041715	Uncertain		Approved	Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 15.3	adrenal gland: 6.7	Cell line enhanced		AF22: 6.1;SH-SY5Y: 4.4;U-2 OS: 2.5;U-87 MG: 3.0
AP3S1	CLAPS3	ENSG00000177879	Adaptor related protein complex 3 sigma 1 subunit	5	115841481-115914081	Predicted intracellular proteins	Evidence at protein level	HPA049270	Uncertain		Approved	Vesicles	Renal cancer:9.57e-8 (unfavourable), Pancreatic cancer:1.13e-5 (unfavourable), Breast cancer:1.22e-4 (unfavourable), Glioma:5.30e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 90.3	Expressed in all		
GRB2	NCKAP2	ENSG00000177885	Growth factor receptor bound protein 2	17	75318076-75405709	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002589, HPA030749, HPA030750	Approved		Supported	Nucleus	Liver cancer:6.04e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 136.5	Expressed in all		
ZBTB41	DKFZp686C06120, FLJ36199, FRBZ1, ZNF924	ENSG00000177888	Zinc finger and BTB domain containing 41	1	197153680-197200542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034841, HPA034842	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Liver cancer:5.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 12.7	Expressed in all		
UBE2N	MGC8489, UBC13, UbcH-ben	ENSG00000177889	Ubiquitin conjugating enzyme E2 N	12	93405673-93442262	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044976	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:2.41e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 253.6	Expressed in all		
ARL6IP6	MGC33864	ENSG00000177917	ADP ribosylation factor like GTPase 6 interacting protein 6	2	152717893-152761253	Predicted membrane proteins	Evidence at protein level	HPA014743	Enhanced		Approved	Nuclear membrane<br>Cytosol	Liver cancer:1.73e-4 (unfavourable), Renal cancer:2.14e-4 (unfavourable)	Expressed in all	Mixed			placenta: 7.5	Expressed in all		
ZNF354C	KID3	ENSG00000177932	Zinc finger protein 354C	5	179060415-179083537	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030904	Uncertain		Supported	Nuclear membrane<br>Cytosol		Mixed	Mixed			ovary: 9.2	Cell line enhanced		AN3-CA: 17.5
CAPZA3	CAPPA3, Gsg3	ENSG00000177938	Capping actin protein of muscle Z-line alpha subunit 3	12	18738101-18739187	Predicted intracellular proteins	Evidence at protein level	HPA038688	Enhanced					Not detected	Tissue enriched	100	testis: 281.4	skin: 2.8	Not detected		
MAMDC4	AEGP, DKFZp434M1411	ENSG00000177943	MAM domain containing 4	9	136850943-136860799	Predicted membrane proteins	Evidence at protein level	CAB026377, HPA059977	Approved		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:1.88e-6 (favourable)	Expressed in all	Mixed			spleen: 5.6	Cell line enhanced		BEWO: 16.2
CENPBD1	MGC16385	ENSG00000177946	CENPB DNA-binding domain containing 1	16	89969791-89972534	Predicted intracellular proteins	Evidence at transcript level	HPA052759, HPA060522	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:5.27e-11 (favourable)	Expressed in all	Mixed			parathyroid gland: 11.1	Expressed in all		
ODF3	CT135, hSHIPPO, SHIPPO1	ENSG00000177947	Outer dense fiber of sperm tails 3	11	196738-200261	Predicted intracellular proteins	Evidence at protein level	HPA038919, HPA039241	Enhanced					Not detected	Tissue enriched	94	testis: 9.4	all non-specific tissues: 0.0	Not detected		
BET1L	GOLIM3, GS15	ENSG00000177951	Bet1 golgi vesicular membrane trafficking protein like	11	167784-207428	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039819	Approved		Approved	Nucleus<br>Golgi apparatus	Liver cancer:2.20e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.0	Expressed in all		
RPS27	MPS-1, MPS1, S27	ENSG00000177954	Ribosomal protein S27	1	153990759-153992150	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA066851			Approved	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:4.86e-7 (unfavourable), Breast cancer:9.69e-4 (favourable)	Expressed in all	Expressed in all			ovary: 12000.9	Expressed in all		
RIC8A	synembryn, synembryn-A	ENSG00000177963	RIC8 guanine nucleotide exchange factor A	11	207511-215113	Predicted intracellular proteins	Evidence at protein level	HPA041491, CAB046012	Approved		Supported	Cytosol	Liver cancer:1.11e-6 (unfavourable), Endometrial cancer:8.60e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 72.1	Expressed in all		
IMP3	BRMS2, C15orf12, FLJ10968, MRPS4	ENSG00000177971	IMP3, U3 small nucleolar ribonucleoprotein	15	75639085-75648706	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA060955, HPA061177			Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			spleen: 47.6	Expressed in all		
ASB8	FLJ21255, MGC5540	ENSG00000177981	Ankyrin repeat and SOCS box containing 8	12	48147788-48181213	Predicted intracellular proteins	Evidence at protein level	HPA003299	Approved				Renal cancer:6.57e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 98.2	Expressed in all		
LCN15	PRO6093, UNQ2541	ENSG00000177984	Lipocalin 15	9	136759634-136766255	Predicted secreted proteins	Evidence at protein level	HPA060584	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0	colon: 2.8	Group enriched	14	Hep G2: 11.9;SCLC-21H: 3.0
ODF3B		ENSG00000177989	Outer dense fiber of sperm tails 3B	22	50529710-50532580	Predicted intracellular proteins	Evidence at protein level	HPA062837	Enhanced				Renal cancer:2.65e-5 (unfavourable), Endometrial cancer:2.84e-4 (favourable), Head and neck cancer:4.89e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 75.0	appendix: 36.7	Cell line enhanced		Karpas-707: 29.6;U-266/70: 44.1
DPY19L2	FLJ32949, SPATA34	ENSG00000177990	Dpy-19 like 2	12	63558913-63668939	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071264			Approved	Nucleus<br>Mitochondria		Mixed	Tissue enriched	8	testis: 112.0	parathyroid gland: 14.4	Mixed		
SPATA31E1	C9orf79, FAM75E1, FLJ35866	ENSG00000177992	SPATA31 subfamily E member 1	9	87882826-87888899	Predicted membrane proteins	Evidence at protein level	HPA024253	Enhanced					Not detected	Tissue enriched	99	testis: 9.9	all non-specific tissues: 0.0	Cell line enhanced		ASC TERT1: 1.1;SCLC-21H: 1.6
C2orf73	FLJ40298	ENSG00000177994	Chromosome 2 open reading frame 73	2	54330034-54383742	Predicted intracellular proteins	Evidence at transcript level	HPA055221, HPA059596	Uncertain					Not detected	Tissue enriched	7	testis: 83.7	fallopian tube: 12.2	Not detected		
GPR150	PGR11	ENSG00000178015	G protein-coupled receptor 150	5	95620078-95622142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA026635	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.3;parathyroid gland: 2.0	pancreas: 1.0	Cell line enhanced		ASC diff: 1.0;SiHa: 1.3;TIME: 2.2
TSPYL6		ENSG00000178021	TSPY like 6	2	54253184-54256272	Predicted intracellular proteins	Evidence at protein level	HPA034699, HPA034700	Enhanced		Approved	Nucleoli<br>Centrosome<br>Cytosol		Tissue enriched	Tissue enriched	390	testis: 39.0	all non-specific tissues: 0.0	Cell line enriched	73	K-562: 7.3
LRRC75B	C22orf36, FAM211B, MGC131773	ENSG00000178026	Leucine rich repeat containing 75B	22	24585620-24593208	Predicted intracellular proteins	Evidence at transcript level	HPA002540	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Tissue enhanced		testis: 2.2	cerebral cortex: 1.3	Cell line enhanced		SH-SY5Y: 4.4
DMAP1	DNMAP1, DNMTAP1, EAF2, FLJ11543, KIAA1425, MEAF2, SWC4	ENSG00000178028	DNA methyltransferase 1 associated protein 1	1	44213455-44220681	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028419, CAB033018	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 40.4	Expressed in all		
ADAMTSL1	ADAMTSR1, C9orf94, FLJ35283	ENSG00000178031	ADAMTS like 1	9	17906563-18910950	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA057437	Uncertain					Mixed	Tissue enhanced		endometrium: 24.1	smooth muscle: 18.7	Cell line enhanced		ASC TERT1: 81.0;hTEC/SVTERT24-B: 62.6;TIME: 164.0;U-138 MG: 93.4
FAM26E	C6orf188, dJ493F7.3, MGC45451	ENSG00000178033	Family with sequence similarity 26 member E	6	116511646-116524792	Predicted membrane proteins	Evidence at protein level	HPA034969, HPA034970	Uncertain		Approved	Golgi apparatus		Mixed	Mixed			placenta: 6.4	Cell line enhanced		TIME: 7.3
IMPDH2		ENSG00000178035	Inosine monophosphate dehydrogenase 2	3	49024325-49029408	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001400, CAB020717	Approved		Enhanced	Cytosol<br>Rods & Rings	Liver cancer:3.22e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 422.5	Expressed in all		
ALS2CL	DKFZp686I0110, FLJ36525, RN49018	ENSG00000178038	ALS2 C-terminal like	3	46668997-46693704	Predicted intracellular proteins	Evidence at protein level	CAB046465, HPA048301	Uncertain				Endometrial cancer:8.10e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 38.8	esophagus: 15.8	Cell line enhanced		CAPAN-2: 30.1;HaCaT: 16.9;HBEC3-KT: 25.9;hTCEpi: 18.1;RT4: 15.4
MLF1		ENSG00000178053	Myeloid leukemia factor 1	3	158571163-158607252	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.15e-5 (unfavourable), Stomach cancer:5.54e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 671.8	fallopian tube: 97.0	Cell line enhanced		A-431: 71.8
PRSS42	TESSP2	ENSG00000178055	Protease, serine 42	3	46829542-46834095	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA046925	Uncertain					Not detected	Group enriched	6	epididymis: 4.8;heart muscle: 8.8;parathyroid gland: 3.1;skeletal muscle: 8.4;testis: 2.0;thyroid gland: 1.9	breast,cervix, uterine,prostate,seminal vesicle: 0.7	Cell line enhanced		NTERA-2: 1.0
NDUFAF3	2P1, C3orf60, DKFZP564J0123, E3-3, MGC10527	ENSG00000178057	NADH:ubiquinone oxidoreductase complex assembly factor 3	3	49020459-49023495	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035376, HPA035377	Enhanced				Renal cancer:1.86e-5 (favourable)	Expressed in all	Expressed in all			testis: 287.5	Expressed in all		
C2orf69	FLJ38973	ENSG00000178074	Chromosome 2 open reading frame 69	2	199911256-199955935	Predicted secreted proteins	Evidence at protein level	HPA045225	Uncertain					Expressed in all	Expressed in all			testis: 26.6	Expressed in all		
GRAMD1C	DKFZp434C0328	ENSG00000178075	GRAM domain containing 1C	3	113828182-113947174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012316	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:4.22e-15 (favourable)	Mixed	Mixed			testis: 28.1	Cell line enhanced		CAPAN-2: 11.4;HUVEC TERT2: 8.3
STAP2	BKS, STAP-2	ENSG00000178078	Signal transducing adaptor family member 2	19	4324043-4342786	Predicted intracellular proteins	Evidence at protein level	HPA002375, HPA027761	Approved				Endometrial cancer:3.03e-5 (favourable), Cervical cancer:2.76e-4 (favourable), Urothelial cancer:4.13e-4 (favourable)	Expressed in all	Mixed			small intestine: 79.8	Cell line enhanced		A-431: 75.0;MCF7: 77.8;RT4: 107.6
HTR3C		ENSG00000178084	5-hydroxytryptamine receptor 3C	3	184053047-184060671	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.9	duodenum: 0.4	Not detected		
TSSK6	CT72, FLJ24002, SSTK	ENSG00000178093	Testis specific serine kinase 6	19	19512418-19515685	Enzymes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enriched	24	testis: 18.6	duodenum,spleen: 0.7	Cell line enhanced		BEWO: 3.9
BOLA1	CGI-143	ENSG00000178096	BolA family member 1	1	149887890-149900798	Predicted secreted proteins	Evidence at protein level	HPA007005	Approved				Liver cancer:5.88e-4 (unfavourable), Ovarian cancer:6.41e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 15.6	Cell line enhanced		MCF7: 42.0
PDE4DIP	CMYA2, KIAA0454, KIAA0477, MMGL	ENSG00000178104	Phosphodiesterase 4D interacting protein	1	148808181-149048286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008162, HPA012678	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			skeletal muscle: 766.6	Expressed in all		
DDX10	HRH-J8	ENSG00000178105	DEAD-box helicase 10	11	108665025-108940930	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004691	Approved		Approved	Nucleoli	Renal cancer:2.14e-5 (favourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
GOLGA8Q		ENSG00000178115	Golgin A8 family member Q	15	30552078-30562501	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	thyroid gland: 20.9	parathyroid gland: 2.8	Group enriched	6	THP-1: 4.4;U-937: 7.0
PPP1R42	dtr, LRRC67, TLLR	ENSG00000178125	Protein phosphatase 1 regulatory subunit 42	8	66964099-67056604	Predicted intracellular proteins	Evidence at transcript level	HPA024313, HPA027983, HPA028628	Uncertain					Mixed	Group enriched	20	fallopian tube: 7.9;testis: 15.6	lung: 0.6	Not detected		
NDUFV2	CI-24k	ENSG00000178127	NADH:ubiquinone oxidoreductase core subunit V2	18	9102630-9134345	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003404, HPA077896	Supported	Approved	Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 190.8	Expressed in all		
DALRD3	FLJ10496	ENSG00000178149	DALR anticodon binding domain containing 3	3	49015488-49022293	Predicted intracellular proteins	Evidence at protein level	HPA036862	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.79e-5 (favourable), Endometrial cancer:9.03e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.2	Expressed in all		
ZNF114	MGC17986	ENSG00000178150	Zinc finger protein 114	19	48270102-48287608	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA025019, HPA029553	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:3.29e-4 (unfavourable)	Mixed	Tissue enhanced		thyroid gland: 10.3	parathyroid gland: 3.6	Cell line enhanced		BEWO: 21.9;Hep G2: 18.9
ZNF518B	KIAA1729	ENSG00000178163	Zinc finger protein 518B	4	10439874-10457410	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031215, HPA031216	Approved		Approved	Nucleus		Mixed	Mixed			testis: 16.9	Mixed		
AMER3	FAM123C, FLJ38377	ENSG00000178171	APC membrane recruitment protein 3	2	130755435-130768134	Predicted intracellular proteins	Evidence at protein level	HPA045593, HPA054230	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Tissue enhanced	Tissue enriched	9	cerebral cortex: 7.0	adrenal gland: 0.8	Cell line enriched	6	SCLC-21H: 12.2
SPINK6	BUSI2, MGC21394, UNQ844	ENSG00000178172	Serine peptidase inhibitor, Kazal type 6	5	148202794-148215137	Predicted secreted proteins	Evidence at protein level	HPA011039	Uncertain				Head and neck cancer:7.16e-4 (favourable)	Group enriched	Not detected			epididymis: 0.9	Group enriched	73	HeLa: 1936.6;SiHa: 1473.3
ZNF366	FLJ39796	ENSG00000178175	Zinc finger protein 366	5	72442652-72507727	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023128, HPA023526	Uncertain					Mixed	Mixed			placenta: 10.2	Cell line enhanced		HUVEC TERT2: 1.0;TIME: 1.1
LCORL	FLJ30696, MLR1	ENSG00000178177	Ligand dependent nuclear receptor corepressor like	4	17841199-18021876	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028794, HPA028795, HPA060033	Uncertain		Supported	Nucleoplasm<br>Nuclear membrane	Colorectal cancer:9.65e-4 (favourable)	Expressed in all	Mixed			testis: 12.1	Expressed in all		
PARD6G	PAR-6G, PAR6gamma	ENSG00000178184	Par-6 family cell polarity regulator gamma	18	80157232-80247546	Predicted intracellular proteins	Evidence at protein level	HPA047017	Uncertain		Approved	Plasma membrane	Liver cancer:3.19e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 44.9	thyroid gland: 30.0	Cell line enhanced		HMC-1: 31.8;U-2 OS: 30.2
ZNF454	FLJ37444	ENSG00000178187	Zinc finger protein 454	5	178941191-178966433	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA024556	Uncertain					Mixed	Mixed			testis: 4.0	Cell line enhanced		AF22: 1.0;EFO-21: 1.9;HHSteC: 1.3;HSkMC: 1.3;NTERA-2: 1.5;SH-SY5Y: 1.1
SH2B1	FLJ30542, SH2B	ENSG00000178188	SH2B adaptor protein 1	16	28846600-28874212	Predicted intracellular proteins	Evidence at protein level	HPA076175			Approved	Vesicles	Renal cancer:2.81e-6 (favourable), Urothelial cancer:1.60e-4 (favourable), Pancreatic cancer:4.38e-4 (favourable), Lung cancer:9.40e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 105.8	Expressed in all		
ZC3H12D	C6orf95, dJ281H8.1, MCPIP4	ENSG00000178199	Zinc finger CCCH-type containing 12D	6	149446795-149485061	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036897	Uncertain		Supported	Nucleoplasm<br>Cytoplasmic bodies		Mixed	Tissue enhanced		appendix: 9.6;lymph node: 11.5;tonsil: 11.6	spleen: 5.9	Cell line enhanced		Daudi: 5.7;HDLM-2: 31.7;REH: 6.4
VN1R1	V1RL1, VNR19I1, ZVNH1, ZVNR1	ENSG00000178201	Vomeronasal 1 receptor 1	19	57454790-57457142	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA062209			Uncertain	Nucleus<br>Vesicles		Mixed	Mixed			epididymis: 2.7	Cell line enhanced		HEK 293: 2.6;U-266/70: 1.9;U-266/84: 2.3
KDELC2	MGC33424	ENSG00000178202	KDEL motif containing 2	11	108472105-108498432	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039315, HPA039817, HPA066134	Uncertain		Supported	Nucleoplasm<br>Vesicles	Urothelial cancer:6.27e-5 (unfavourable), Liver cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.2	Mixed		
PLEC	EBS1, PCN, PLEC1, PLTN	ENSG00000178209	Plectin	8	143915147-143976734	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003847, HPA025967, HPA029906	Enhanced		Enhanced	Intermediate filaments<br>Focal adhesion sites<br>Cytosol	Renal cancer:7.98e-6 (unfavourable), Colorectal cancer:4.29e-4 (unfavourable), Lung cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 94.8	Expressed in all		
SH2D4B		ENSG00000178217	SH2 domain containing 4B	10	80537902-80646560	Predicted intracellular proteins	Evidence at protein level	HPA040022	Uncertain					Not detected	Not detected			epididymis: 0.5	Cell line enriched	64	REH: 17.4
RNF212	FLJ38841, LOC285498	ENSG00000178222	Ring finger protein 212	4	1056250-1113562	Predicted intracellular proteins	Evidence at transcript level	HPA057527	Uncertain				Cervical cancer:1.39e-4 (favourable)	Mixed	Mixed			thyroid gland: 5.8	Cell line enhanced		A-431: 11.1;HeLa: 25.6;SiHa: 24.3
PRSS36	FLJ90661	ENSG00000178226	Protease, serine 36	16	31138925-31150094	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA036079	Uncertain				Cervical cancer:2.97e-7 (favourable)	Mixed	Mixed			skin: 1.2	Cell line enhanced		HeLa: 1.4
ZNF543	DKFZp434H055	ENSG00000178229	Zinc finger protein 543	19	57320509-57330776	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029736, HPA057665	Uncertain		Approved	Nuclear speckles<br>Cytosol	Renal cancer:2.03e-5 (favourable)	Expressed in all	Mixed			ovary: 6.0	Mixed		
TMEM151B	bA444E17.5, C6orf137, TMEM193	ENSG00000178233	Transmembrane protein 151B	6	44270466-44307506	Predicted membrane proteins	Evidence at transcript level	HPA055167	Uncertain					Tissue enhanced	Tissue enriched	10	cerebral cortex: 40.0	adrenal gland: 3.9	Cell line enriched	5	SCLC-21H: 33.6
GALNT11	GalNAc-T11	ENSG00000178234	Polypeptide N-acetylgalactosaminyltransferase 11	7	152025674-152122347	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA039330	Uncertain				Renal cancer:2.24e-6 (favourable), Glioma:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 242.9	Mixed		
SLITRK1	KIAA1910, LRRC12	ENSG00000178235	SLIT and NTRK like family member 1	13	83877205-83882393	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA012414	Enhanced					Tissue enriched	Tissue enriched	81	cerebral cortex: 23.8	adrenal gland,cervix, uterine,pancreas,seminal vesicle: 0.2	Cell line enhanced		A-431: 2.6;AF22: 1.1
WDR6		ENSG00000178252	WD repeat domain 6	3	49007062-49015953	Predicted intracellular proteins	Evidence at protein level	HPA042622	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:2.97e-6 (unfavourable), Renal cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 204.8	Expressed in all		
PRM3		ENSG00000178257	Protamine 3	16	11273218-11273641	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 42.3	bone marrow: 1.8	Cell line enhanced		TIME: 3.0
TNP2	TP2	ENSG00000178279	Transition protein 2	16	11267748-11269533	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	387	testis: 38.6	all non-specific tissues: 0.0	Not detected		
SPAG11A	EDDM2A, HE2	ENSG00000178287	Sperm associated antigen 11A	8	7847876-7868867	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023842	Supported					Not detected	Tissue enriched	12587	epididymis: 6263.0	fallopian tube,seminal vesicle: 0.4	Group enriched	8	BEWO: 1.8;NB-4: 5.5;RPMI-8226: 1.4;SH-SY5Y: 1.3
GEN1	FLJ40869, Gen	ENSG00000178295	GEN1, Holliday junction 5' flap endonuclease	2	17753858-17788941	Predicted intracellular proteins	Evidence at protein level	HPA020078, HPA021141	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.68e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 15.5	Expressed in all		
TMPRSS9		ENSG00000178297	Transmembrane protease, serine 9	19	2389771-2426239	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA051483	Uncertain					Mixed	Tissue enhanced		spleen: 2.3;testis: 1.7	skin: 0.8	Cell line enhanced		Karpas-707: 1.8;U-266/70: 1.7
AQP11		ENSG00000178301	Aquaporin 11	11	77589391-77610355	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042879	Approved		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:9.89e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 24.1;small intestine: 23.1	adrenal gland: 10.0	Cell line enhanced		Hep G2: 7.7
TMEM11	C17orf35, PM1, PMI	ENSG00000178307	Transmembrane protein 11	17	21197280-21214624	Predicted membrane proteins	Evidence at protein level	HPA051795, HPA062854	Uncertain		Supported	Mitochondria		Expressed in all	Mixed			skeletal muscle: 3.6	Mixed		
ZNF354B	FLJ25008, KID2	ENSG00000178338	Zinc finger protein 354B	5	178859953-178888122	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029056	Approved		Approved	Nucleoplasm	Renal cancer:1.30e-5 (unfavourable), Head and neck cancer:9.52e-4 (favourable)	Expressed in all	Expressed in all			placenta: 19.9	Mixed		
KCNG2	KCNF2, Kv6.2	ENSG00000178342	Potassium voltage-gated channel modifier subfamily G member 2	18	79863668-79900184	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA048628	Approved					Not detected	Not detected			cerebral cortex: 0.4	Not detected		
SHISA3	hShisa3	ENSG00000178343	Shisa family member 3	4	42397839-42402487	Predicted membrane proteins	Evidence at protein level	HPA054754			Approved	Lipid droplets<br>Cytosol		Mixed	Tissue enhanced		kidney: 25.1	lymph node: 8.7	Group enriched	6	AN3-CA: 231.0;PC-3: 134.3
OR2D3		ENSG00000178358	Olfactory receptor family 2 subfamily D member 3	11	6920974-6922043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052551	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CALML3	CLP	ENSG00000178363	Calmodulin like 3	10	5524009-5526771	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010070, HPA044999	Approved					Group enriched	Tissue enhanced		esophagus: 165.7;skin: 42.6	tonsil: 22.4	Group enriched	6	A-431: 12.2;hTCEpi: 3.8;RPMI-8226: 2.6
CALML5	CLSP	ENSG00000178372	Calmodulin like 5	10	5498697-5499555	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA040725	Enhanced		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:2.59e-5 (favourable)	Group enriched	Group enriched	8	salivary gland: 260.7;skin: 650.6	breast: 55.6	Cell line enriched	24	A-431: 355.7
ZFAND2A	AIRAP	ENSG00000178381	Zinc finger AN1-type containing 2A	7	1152071-1160759	Predicted intracellular proteins	Evidence at transcript level	HPA019469	Approved				Renal cancer:5.47e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 50.0	Expressed in all		
PLEKHM3	DAPR, PLEKHM1L	ENSG00000178385	Pleckstrin homology domain containing M3	2	207821288-208025560	Predicted intracellular proteins	Evidence at protein level	HPA035046	Uncertain		Approved	Vesicles<br>Cytosol		Mixed	Mixed			parathyroid gland: 18.9	Mixed		
ZNF223		ENSG00000178386	Zinc finger protein 223	19	44051367-44067991	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067823			Approved	Nucleus<br>Mitochondria		Mixed	Mixed			prostate,thyroid gland: 10.6	Cell line enhanced		RT4: 18.6
HTR1A	5-HT1A, ADRB2RL1, ADRBRL1	ENSG00000178394	5-hydroxytryptamine receptor 1A	5	63960356-63962507	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018073	Uncertain					Not detected	Group enriched	10	cerebral cortex: 1.9;ovary: 3.9	testis: 0.2	Group enriched	16	NTERA-2: 1.6;SCLC-21H: 1.5
CCDC185	C1orf65, FLJ35728	ENSG00000178395	Coiled-coil domain containing 185	1	223393417-223395470	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	198	testis: 25.1	cerebral cortex: 0.1	Not detected		
FAM220A	ACPIN1, C7orf70, MGC12966, SIPAR	ENSG00000178397	Family with sequence similarity 220 member A	7	6329409-6348981	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA055050			Approved	Vesicles	Liver cancer:5.17e-6 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 102.3	Expressed in all		
DNAJC22	FLJ13236, wus	ENSG00000178401	DnaJ heat shock protein family (Hsp40) member C22	12	49346917-49357546	Predicted membrane proteins	Evidence at protein level	HPA039953			Approved	Vesicles	Endometrial cancer:4.56e-5 (favourable), Melanoma:7.54e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 17.9	Cell line enhanced		CACO-2: 24.1;EFO-21: 28.4;MCF7: 19.7;T-47d: 21.2
NEUROG2	Atoh4, bHLHa8, Math4A, ngn-2, NGN2	ENSG00000178403	Neurogenin 2	4	112513516-112516172	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	CAB012342	Uncertain					Tissue enhanced	Tissue enhanced		testis: 1.5	cerebral cortex: 0.4	Cell line enriched	8	SH-SY5Y: 216.2
CEP295NL	DDC8, KIAA1731NL	ENSG00000178404	CEP295 N-terminal like	17	78870910-78903217	Predicted intracellular proteins	Evidence at transcript level	HPA023609, HPA024619, HPA025717	Uncertain		Approved	Vesicles		Not detected	Tissue enriched	46	testis: 40.5	bone marrow: 0.8	Cell line enhanced		BEWO: 1.4;U-2 OS: 2.0
BEND3	KIAA1553	ENSG00000178409	BEN domain containing 3	6	107065182-107115269	Predicted intracellular proteins	Evidence at protein level	HPA017891, HPA062067	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			testis: 2.7	Mixed		
NT5DC1	dJ486I3.1, MGC24302, NT5C2L1	ENSG00000178425	5'-nucleotidase domain containing 1	6	116100849-116249497	Predicted intracellular proteins	Evidence at protein level	HPA030352	Uncertain				Renal cancer:7.49e-7 (favourable), Colorectal cancer:2.61e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 47.2	Expressed in all		
GLDC	GCSP, NKH	ENSG00000178445	Glycine decarboxylase	9	6532464-6645783	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002318, HPA052887	Enhanced		Supported	Nucleus<br>Mitochondria	Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 30.3;liver: 19.9;placenta: 20.1	cerebral cortex: 10.6	Cell line enhanced		BEWO: 206.9;RPTEC TERT1: 67.4
COX14	C12orf62, MGC14288	ENSG00000178449	COX14, cytochrome c oxidase assembly factor	12	50111979-50120457	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA044618, HPA062014	Approved		Supported	Mitochondria	Melanoma:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 86.5	Expressed in all		
MCMDC2	C8orf45, FLJ25692	ENSG00000178460	Minichromosome maintenance domain containing 2	8	66870749-66922048	Predicted intracellular proteins	Evidence at protein level	HPA026522			Approved	Actin filaments		Not detected	Tissue enriched	6	testis: 21.6	ovary: 3.7	Mixed		
TUBAL3	FLJ21665	ENSG00000178462	Tubulin alpha like 3	10	5393098-5404830	Predicted intracellular proteins	Evidence at protein level	HPA045900, HPA063394	Uncertain					Tissue enhanced	Tissue enhanced		duodenum: 24.4;small intestine: 31.0	colon: 11.8	Group enriched	6	HEL: 11.9;K-562: 3.8
P4HTM	EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4	ENSG00000178467	Prolyl 4-hydroxylase, transmembrane	3	48989886-49007154	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA007199	Supported		Uncertain	Vesicles<br>Cytosol	Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 50.0	Mixed		
UCN3	SPC, UCNIII	ENSG00000178473	Urocortin 3	10	5365009-5374692	Predicted secreted proteins	Evidence at protein level	HPA038281	Uncertain					Group enriched	Tissue enhanced		duodenum: 9.3;small intestine: 7.5	stomach: 3.6	Cell line enriched	10	SCLC-21H: 1.5
DTX3	FLJ34766, RNF154	ENSG00000178498	Deltex E3 ubiquitin ligase 3	12	57604622-57609804	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059654	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Pancreatic cancer:1.44e-4 (favourable), Lung cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 102.8	Mixed		
KLHL11	FLJ10572	ENSG00000178502	Kelch like family member 11	17	41853545-41865431	Predicted secreted proteins	Evidence at protein level	HPA023021, HPA054269	Uncertain					Mixed	Tissue enhanced		testis: 22.4	cerebral cortex: 10.7	Mixed		
AMBN		ENSG00000178522	Ameloblastin	4	70592256-70607288	Disease related genes, Predicted secreted proteins	Evidence at protein level							Group enriched	Not detected			cerebral cortex: 0.3	Cell line enriched	9	HEK 293: 6.2
CTXN1	FLJ25968	ENSG00000178531	Cortexin 1	19	7924485-7926166	Predicted membrane proteins	Evidence at transcript level	HPA016669	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions		Expressed in all	Tissue enhanced		cerebral cortex: 100.4	endometrium: 22.7	Cell line enhanced		AN3-CA: 86.1;NTERA-2: 70.2;SCLC-21H: 63.8;SH-SY5Y: 96.5
SLC25A20	CAC, CACT	ENSG00000178537	Solute carrier family 25 member 20	3	48856931-48898993	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016862, HPA029863	Approved		Supported	Mitochondria<br>Cytosol		Expressed in all	Expressed in all			liver: 70.9	Cell line enhanced		RPMI-8226: 88.8
CA8	CALS, CARP	ENSG00000178538	Carbonic anhydrase 8	8	60187347-60281412	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024748, CAB025545, CAB047309	Supported				Pancreatic cancer:5.79e-5 (favourable)	Mixed	Tissue enriched	6	parathyroid gland: 105.5	epididymis: 17.4	Cell line enhanced		HEK 293: 15.9;K-562: 29.2;NB-4: 11.8
CD28		ENSG00000178562	CD28 molecule	2	203706475-203738912	CD markers, Predicted membrane proteins	Evidence at protein level	HPA070003	Enhanced					Mixed	Tissue enhanced		lymph node: 32.4;placenta: 20.9	appendix: 18.6	Group enriched	12	Karpas-707: 257.5;RPMI-8226: 118.2;U-266/70: 222.7;U-266/84: 196.1
EPM2AIP1	FLJ11207, KIAA0766	ENSG00000178567	EPM2A interacting protein 1	3	36985043-36993168	Predicted intracellular proteins	Evidence at protein level						Cervical cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 35.7	Mixed		
ERBB4	ALS19, HER4	ENSG00000178568	Erb-b2 receptor tyrosine kinase 4	2	211375717-212538841	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000276, HPA012016, CAB025522	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 17.8	cerebral cortex: 7.6	Group enriched	5	AF22: 6.8;EFO-21: 4.8;HEK 293: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
MAF	c-MAF	ENSG00000178573	MAF bZIP transcription factor	16	79585843-79600714	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010296, HPA028289	Approved				Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 149.6	small intestine: 91.3	Group enriched	9	Karpas-707: 148.6;RPMI-8226: 242.2
CTNNBIP1	ICAT, MGC15093	ENSG00000178585	Catenin beta interacting protein 1	1	9848276-9910336	Predicted intracellular proteins	Evidence at protein level	HPA042617			Approved	Plasma membrane<br>Cell Junctions<br>Mitochondria	Endometrial cancer:5.68e-6 (favourable)	Expressed in all	Expressed in all			skin: 289.6	Expressed in all		
OR6B3	OR6B3P, OR6B3Q	ENSG00000178586	Olfactory receptor family 6 subfamily B member 3	2	240045077-240046072	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047529	Uncertain					Not detected	Tissue enhanced		epididymis: 1.9	testis: 0.7	Not detected		
DEFB125	DEFB-25	ENSG00000178591	Defensin beta 125	20	87250-97094	Predicted secreted proteins	Evidence at transcript level	HPA043095	Uncertain					Not detected	Group enriched	11	epididymis: 1.3;seminal vesicle: 1.5	testis: 0.1	Not detected		
PSAPL1		ENSG00000178597	Prosaposin-like 1 (gene/pseudogene)	4	7430294-7434973	Predicted secreted proteins	Evidence at protein level	HPA038013, HPA038482	Approved		Enhanced	Cytosol		Mixed	Group enriched	7	skin: 52.7;stomach: 36.5	breast: 6.4	Cell line enhanced		CACO-2: 13.5;HaCaT: 3.9;hTCEpi: 3.9;RPMI-8226: 16.8
OTOS	OTOSP	ENSG00000178602	Otospiralin	2	240139026-240144562	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	16	thyroid gland: 74.1	cerebral cortex: 4.6	Not detected		
GTPBP6	FLJ20977, PGPL	ENSG00000178605	GTP binding protein 6 (putative)	X	304529-318819	Predicted intracellular proteins	Evidence at protein level	CAB034924, HPA035467, HPA055418	Approved		Uncertain	Mitochondria	Pancreatic cancer:1.71e-4 (favourable), Liver cancer:8.87e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 26.1	Expressed in all		
ERN1	IRE1, IRE1P	ENSG00000178607	Endoplasmic reticulum to nucleus signaling 1	17	64039142-64130819	Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009495, HPA027730	Supported				Renal cancer:1.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 53.4	Cell line enhanced		Karpas-707: 74.5;U-266/70: 74.0
GPR35		ENSG00000178623	G protein-coupled receptor 35	2	240605431-240631259	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level						Renal cancer:2.59e-5 (unfavourable), Lung cancer:5.86e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 41.4;small intestine: 42.3	colon: 18.4	Cell line enhanced		CACO-2: 17.1;CAPAN-2: 45.0;HDLM-2: 16.3;Hep G2: 22.7;HMC-1: 27.8
C10orf53	Em:AC069546.1	ENSG00000178645	Chromosome 10 open reading frame 53	10	49679651-49710261	Predicted intracellular proteins	Evidence at protein level	HPA037951	Enhanced					Not detected	Tissue enriched	60	testis: 43.5	fallopian tube: 0.7	Not detected		
CSRNP3	FAM130A2, FLJ32093, PPP1R73, TAIP-2	ENSG00000178662	Cysteine and serine rich nuclear protein 3	2	165469647-165689407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA017905	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 16.1	endometrium: 4.6	Group enriched	5	AF22: 9.7;PC-3: 2.2;SCLC-21H: 8.4;SH-SY5Y: 6.2
ZNF713	FLJ39963	ENSG00000178665	Zinc finger protein 713	7	55887475-55942225	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059425, HPA062887	Uncertain		Approved	Nucleoli		Mixed	Mixed			testis: 8.4	Cell line enhanced		SH-SY5Y: 7.3
PARP10	FLJ14464	ENSG00000178685	Poly(ADP-ribose) polymerase family member 10	8	143977153-144012772	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028122, HPA052427	Approved		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			spleen: 56.4	Mixed		
DYNAP	C18orf26, FLJ39106	ENSG00000178690	Dynactin associated protein	18	54587757-54599493	Predicted membrane proteins	Evidence at protein level	HPA011148	Uncertain					Tissue enhanced	Tissue enriched	7	esophagus: 32.1	spleen: 4.3	Cell line enhanced		Karpas-707: 8.9
SUZ12	CHET9, JJAZ1, KIAA0160	ENSG00000178691	SUZ12 polycomb repressive complex 2 subunit	17	31937018-32001045	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057436	Approved		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 50.7	Expressed in all		
NSUN3	FLJ22609	ENSG00000178694	NOP2/Sun RNA methyltransferase family member 3	3	94062916-94128545	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036181, HPA057979	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			testis: 8.0	Expressed in all		
KCTD12	C13orf2, KIAA1778, PFET1	ENSG00000178695	Potassium channel tetramerization domain containing 12	13	76880166-76886390	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056987, HPA077376		Supported	Approved	Mitochondria	Renal cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 122.8	Cell line enhanced		HUVEC TERT2: 191.1;TIME: 151.4
DHFR2	DHFRL1, DHFRP4, FLJ16119	ENSG00000178700	Dihydrofolate reductase 2	3	94047836-94063389	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051465	Uncertain		Supported	Mitochondria	Renal cancer:2.30e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.2	Mixed		
RPP25	FLJ20374	ENSG00000178718	Ribonuclease P and MRP subunit p25	15	74954416-74957464	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046900	Approved		Supported	Nucleoplasm<br>Microtubule organizing center	Glioma:3.67e-5 (unfavourable)	Expressed in all	Mixed			ovary: 12.2	Cell line enhanced		SCLC-21H: 38.4;SK-MEL-30: 39.1
GRINA	HNRGW, LFG1, NMDARA1, TMBIM3	ENSG00000178719	Glutamate ionotropic receptor NMDA type subunit associated protein 1	8	143990058-143993415	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036980, HPA036981	Approved		Approved	Nucleoli fibrillar center<br>Cytosol		Expressed in all	Expressed in all			seminal vesicle: 264.5	Expressed in all		
THBD	CD141	ENSG00000178726	Thrombomodulin	20	23045633-23049741	Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002425, HPA002982	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lung: 73.3	Cell line enhanced		CAPAN-2: 33.8;EFO-21: 30.9;HaCaT: 28.6;hTCEpi: 30.3
GP5	CD42d	ENSG00000178732	Glycoprotein V platelet	3	194394821-194398354	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 1.3	fallopian tube: 1.1	Cell line enriched	10	HEL: 14.6
LMO7DN	C13orf45	ENSG00000178734	LMO7 downstream neighbor	13	75871038-75883811	Predicted intracellular proteins	Evidence at transcript level	HPA052013	Uncertain					Not detected	Tissue enhanced		gallbladder: 1.3	esophagus,lung,testis: 0.7	Cell line enhanced		LHCN-M2: 1.1
COX5A		ENSG00000178741	Cytochrome c oxidase subunit 5A	15	74919791-74938168	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA027526	Supported				Renal cancer:6.06e-7 (favourable), Cervical cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 548.4	Expressed in all		
STX19	MGC21382	ENSG00000178750	Syntaxin 19	3	94014369-94028610	Predicted intracellular proteins	Evidence at protein level	HPA030604	Uncertain		Approved	Intermediate filaments<br>Cytosol		Mixed	Tissue enhanced		epididymis: 19.7	rectum: 14.5	Cell line enhanced		CAPAN-2: 5.2;HaCaT: 1.1;hTCEpi: 2.9
ERFE	C1QTNF15, CTRP15, FAM132B, FLJ37034	ENSG00000178752	Erythroferrone	2	238158982-238168900	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA077259			Approved	Endoplasmic reticulum<br>Microtubule organizing center	Renal cancer:2.46e-4 (unfavourable), Endometrial cancer:3.75e-4 (unfavourable)	Tissue enhanced	Group enriched	8	testis: 17.2;thyroid gland: 40.6	appendix: 3.4	Cell line enhanced		RH-30: 25.5
FAM219B	C15orf17, FLJ00005	ENSG00000178761	Family with sequence similarity 219 member B	15	74899987-74907121	Predicted intracellular proteins	Evidence at protein level	HPA048929, HPA058064	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.29e-4 (favourable), Colorectal cancer:1.75e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.8	Mixed		
ZHX2	KIAA0854	ENSG00000178764	Zinc fingers and homeoboxes 2	8	122781394-122974512	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006769, HPA006996	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 32.8	Cell line enhanced		REH: 47.1
CPN2	ACBP	ENSG00000178772	Carboxypeptidase N subunit 2	3	194339765-194351328	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004732	Uncertain				Liver cancer:2.05e-4 (favourable), Renal cancer:4.59e-4 (unfavourable)	Tissue enriched	Tissue enriched	7	liver: 113.6	kidney: 15.6	Cell line enriched	17	Hep G2: 41.9
CPNE7		ENSG00000178773	Copine 7	16	89575768-89597246	Predicted intracellular proteins	Evidence at protein level	HPA043359	Uncertain				Renal cancer:9.52e-6 (unfavourable), Urothelial cancer:7.22e-4 (favourable)	Mixed	Tissue enhanced		epididymis: 23.6	cerebral cortex: 9.8	Cell line enhanced		HHSteC: 87.2
C5orf46	MGC23985, SSSP1	ENSG00000178776	Chromosome 5 open reading frame 46	5	147880726-147906538	Predicted secreted proteins	Evidence at transcript level	HPA058999			Approved	Nuclear speckles<br>Mitochondria	Renal cancer:1.75e-9 (unfavourable), Cervical cancer:3.98e-4 (unfavourable)	Tissue enhanced	Group enriched	8	breast: 17.6;salivary gland: 77.2;skin: 62.4;testis: 19.9	heart muscle: 5.8	Cell line enhanced		PC-3: 83.2;SiHa: 21.5;U-2 OS: 59.9;U-251 MG: 19.3
CD300LB	CLM7, TREM5	ENSG00000178789	CD300 molecule like family member b	17	74521174-74531474	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 11.4	spleen: 5.2	Cell line enhanced		HL-60: 1.5;NB-4: 1.5;THP-1: 1.3
GDPD4	GDE6	ENSG00000178795	Glycerophosphodiester phosphodiesterase domain containing 4	11	77216558-77301687	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	testis: 4.7	placenta: 0.3	Not detected		
RIIAD1	C1orf230, FLJ36032, NCRNA00166	ENSG00000178796	Regulatory subunit of type II PKA R-subunit (RIIa) domain containing 1	1	151710433-151729805	Predicted intracellular proteins	Evidence at protein level	HPA045703	Enhanced		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:5.46e-4 (favourable)	Tissue enhanced	Group enriched	9	fallopian tube: 70.7;testis: 22.5	cerebral cortex: 5.4	Group enriched	9	CACO-2: 3.6;SCLC-21H: 2.7;SH-SY5Y: 4.8;SK-BR-3: 5.4
MPI		ENSG00000178802	Mannose phosphate isomerase	15	74890005-74902219	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007200	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:2.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 52.3	Expressed in all		
H1FOO		ENSG00000178804	H1 histone family member O, oocyte specific	3	129543214-129551467	Predicted intracellular proteins	Evidence at protein level	HPA037992	Enhanced					Not detected	Tissue enriched	59	testis: 5.8	all non-specific tissues: 0.0	Not detected		
TRIM73	TRIM50B	ENSG00000178809	Tripartite motif containing 73	7	75395063-75410996	Predicted intracellular proteins	Evidence at transcript level	HPA047843, HPA051845	Uncertain		Approved	Cytosol		Not detected	Mixed			stomach: 8.8	Cell line enhanced		Hep G2: 7.1
OPLAH	5-Opase, OPLA	ENSG00000178814	5-oxoprolinase (ATP-hydrolysing)	8	144051266-144063965	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026562, HPA028260, HPA052429	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:1.53e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 58.2	duodenum: 13.8	Cell line enhanced		AN3-CA: 31.2;BEWO: 20.2;PC-3: 24.2
TMEM52		ENSG00000178821	Transmembrane protein 52	1	1917590-1919273	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 38.8;skeletal muscle: 105.7	adrenal gland: 24.4	Cell line enhanced		Hep G2: 13.9;RPMI-8226: 25.7
TMEM139	FLJ90586	ENSG00000178826	Transmembrane protein 139	7	143279957-143288048	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036982, HPA036983	Approved		Approved	Plasma membrane<br>Focal adhesion sites	Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 34.0;kidney: 34.6	small intestine: 20.7	Cell line enhanced		CAPAN-2: 35.7;EFO-21: 26.3;RPTEC TERT1: 53.2;T-47d: 64.1
RNF186	FLJ20225	ENSG00000178828	Ring finger protein 186	1	19814029-19815278	Predicted membrane proteins	Evidence at protein level	HPA034547, HPA035558	Enhanced					Tissue enhanced	Tissue enhanced		duodenum: 132.4;epididymis: 82.2;small intestine: 46.5	kidney: 26.2	Cell line enhanced		RPMI-8226: 1.2
EFCAB13	C17orf57, FLJ40342	ENSG00000178852	EF-hand calcium binding domain 13	17	47323290-47441312	Predicted intracellular proteins	Evidence at protein level	CAB002501, HPA021633, HPA023249, HPA026561	Uncertain		Supported	Nucleus<br>Nuclear speckles<br>Cytosol		Mixed	Tissue enhanced		testis: 37.3	thyroid gland: 23.6	Mixed		
MSC	ABF-1, bHLHa22	ENSG00000178860	Musculin	8	71841549-71844468	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062878			Supported	Nucleoplasm	Renal cancer:1.07e-13 (unfavourable), Liver cancer:4.83e-5 (unfavourable), Glioma:7.15e-4 (unfavourable)	Expressed in all	Mixed			placenta: 22.4	Cell line enriched	14	HDLM-2: 729.2
APOLD1	DKFZP434F0318, FLJ25138	ENSG00000178878	Apolipoprotein L domain containing 1	12	12725917-12829975	Predicted membrane proteins	Evidence at protein level	HPA052462, HPA058882	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		adipose tissue: 142.9	placenta: 123.3	Cell line enhanced		AF22: 35.9;HDLM-2: 17.8
RFLNA	Cfm2, FAM101A, FLJ44614, RefilinA	ENSG00000178882	Refilin A	12	123973241-124316024	Predicted intracellular proteins	Evidence at protein level	HPA058911, HPA078021	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus	Lung cancer:3.16e-5 (unfavourable)	Mixed	Tissue enriched	5	stomach: 90.8	small intestine: 16.8	Cell line enhanced		hTEC/SVTERT24-B: 13.8;HUVEC TERT2: 16.5;LHCN-M2: 28.9;RH-30: 10.8
EXOSC4	FLJ20591, hRrp41p, p12A, RRP41, RRP41A, Rrp41p, SKI6, Ski6p	ENSG00000178896	Exosome component 4	8	144078626-144080647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024792	Approved		Supported	Intermediate filaments<br>Cytosol	Ovarian cancer:2.23e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.1	Expressed in all		
DPY19L3		ENSG00000178904	Dpy-19 like 3 (C. elegans)	19	32405543-32485895	Predicted membrane proteins	Evidence at protein level	HPA008325	Approved		Approved	Microtubules	Pancreatic cancer:1.70e-4 (favourable), Head and neck cancer:5.55e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 20.3	Expressed in all		
TAF7	TAF2F, TAFII55	ENSG00000178913	TATA-box binding protein associated factor 7	5	141260225-141320821	Predicted intracellular proteins	Evidence at protein level	HPA006429	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 138.7	Expressed in all		
ZNF852		ENSG00000178917	Zinc finger protein 852	3	44498970-44510636	Predicted intracellular proteins	Evidence at protein level	HPA048312, HPA049885, HPA071850	Uncertain					Mixed	Mixed			parathyroid gland: 2.8	Mixed		
FOXE1	FKHL15, FOXE2, HFKH4, TITF2, TTF-2	ENSG00000178919	Forkhead box E1	9	97853254-97856715	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enriched	15	thyroid gland: 327.9	tonsil: 22.1	Cell line enhanced		A-431: 12.2;HeLa: 13.5;RPTEC TERT1: 14.9;SiHa: 15.7
PFAS	FGARAT, KIAA0361, PURL	ENSG00000178921	Phosphoribosylformylglycinamidine synthase	17	8247618-8270491	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022140, HPA022886	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Liver cancer:9.19e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 11.6	Expressed in all		
HYI	HT036	ENSG00000178922	Hydroxypyruvate isomerase (putative)	1	43451003-43453989	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040092	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol	Urothelial cancer:2.72e-5 (favourable), Renal cancer:2.75e-5 (unfavourable), Colorectal cancer:4.96e-4 (unfavourable), Liver cancer:5.55e-4 (unfavourable), Breast cancer:9.18e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 81.4	Mixed		
C17orf62	FLJ90469, MGC4368	ENSG00000178927	Chromosome 17 open reading frame 62	17	82442589-82450829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045696	Uncertain		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:6.83e-11 (unfavourable)	Expressed in all	Expressed in all			lymph node: 127.0	Expressed in all		
TPRX1	FLJ40321	ENSG00000178928	Tetrapeptide repeat homeobox 1	19	47801243-47819051	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044922	Uncertain					Not detected	Tissue enriched	13	testis: 1.3	endometrium: 0.1	Not detected		
LGALS7B	GAL7	ENSG00000178934	Galectin 7B	19	38789211-38791749	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB025100	Supported				Endometrial cancer:1.59e-4 (unfavourable)	Group enriched	Tissue enhanced		breast: 10.4;esophagus: 19.3	skeletal muscle: 3.8	Cell line enriched	21	HaCaT: 3.7
ZNF552	FLJ21603	ENSG00000178935	Zinc finger protein 552	19	57803841-57814913	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Uncertain		Uncertain	Nucleus	Colorectal cancer:2.66e-4 (favourable), Breast cancer:4.57e-4 (favourable), Head and neck cancer:9.96e-4 (favourable)	Expressed in all	Mixed			breast: 33.9	Expressed in all		
SMIM10L2A	LED, LINC00086, MGC39606, NCRNA00086	ENSG00000178947	Small integral membrane protein 10 like 2A	X	135421943-135428074	Predicted membrane proteins	Evidence at transcript level						Renal cancer:8.28e-8 (favourable), Endometrial cancer:6.78e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 21.8;cerebral cortex: 22.5	epididymis: 17.6	Cell line enhanced		AN3-CA: 4.8;HAP1: 10.7;hTCEpi: 3.9
GAK	DNAJC26	ENSG00000178950	Cyclin G associated kinase	4	849276-932373	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027405, HPA027459, HPA027463	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:1.70e-6 (favourable), Urothelial cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 51.5	Expressed in all		
ZBTB7A	DKFZp547O146, FBI-1, LRF, pokemon, ZBTB7, ZNF857A	ENSG00000178951	Zinc finger and BTB domain containing 7A	19	4044364-4066945	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB037214, CAB037285, HPA046387	Enhanced		Approved	Nucleoplasm	Renal cancer:1.34e-6 (favourable), Endometrial cancer:6.50e-6 (favourable), Stomach cancer:1.79e-4 (favourable), Pancreatic cancer:2.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 23.9	Expressed in all		
TUFM	EF-TuMT, EFTu	ENSG00000178952	Tu translation elongation factor, mitochondrial	16	28842411-28846408	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018991, HPA024087, CAB075730, CAB075731	Enhanced		Enhanced	Mitochondria	Renal cancer:2.69e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 162.7	Expressed in all		
ERICH3	C1orf173, DKFZp547I048, RP11-653A5.1	ENSG00000178965	Glutamate rich 3	1	74568111-74673738	Predicted intracellular proteins	Evidence at protein level	HPA028655	Approved				Endometrial cancer:1.56e-5 (favourable)	Tissue enhanced	Group enriched	6	cerebral cortex: 18.9;cervix, uterine: 8.6;fallopian tube: 27.7;testis: 43.1	lung: 4.2	Not detected		
RMI1	BLAP75, C9orf76, FLJ12888	ENSG00000178966	RecQ mediated genome instability 1	9	83980711-84004074	Predicted intracellular proteins	Evidence at protein level	HPA021661			Supported	Nucleoplasm<br>Nuclear bodies	Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 21.0	Expressed in all		
CTC1	AAF132, C17orf68, FLJ22170	ENSG00000178971	CST telomere replication complex component 1	17	8224821-8248044	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:6.49e-5 (favourable)	Expressed in all	Expressed in all			spleen: 30.9	Expressed in all		
FBXO34	Fbx34, FLJ20725	ENSG00000178974	F-box protein 34	14	55271303-55361918	Predicted intracellular proteins	Evidence at protein level	HPA052592	Uncertain		Approved	Nuclear speckles	Renal cancer:1.20e-13 (favourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
SELENOW	SELW, SEPW1	ENSG00000178980	Selenoprotein W	19	47778572-47784686	Predicted intracellular proteins	Evidence at protein level						Lung cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 440.9	Mixed		
EIF3K	ARG134, eIF3k, EIF3S12, HSPC029, M9, PLAC-24, PRO1474, PTD001	ENSG00000178982	Eukaryotic translation initiation factor 3 subunit K	19	38619082-38636955	Predicted intracellular proteins	Evidence at protein level	HPA045446, HPA054590	Uncertain		Supported	Cytosol	Cervical cancer:1.31e-4 (favourable), Renal cancer:5.43e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 164.9	Expressed in all		
MRFAP1L1	MGC9651	ENSG00000178988	Morf4 family associated protein 1 like 1	4	6707701-6709880	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.80e-5 (favourable), Urothelial cancer:5.26e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 91.2	Expressed in all		
SNX18	SH3PX2, SH3PXD3B, SNAG1	ENSG00000178996	Sorting nexin 18	5	54517759-54546585	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037800	Approved		Approved	Cytosol	Renal cancer:1.58e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 43.8	Mixed		
EXD1	EXDL1, MGC33637	ENSG00000178997	Exonuclease 3'-5' domain containing 1	15	41182725-41230743	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	72	testis: 29.5	epididymis: 0.4	Not detected		
AURKB	Aik2, AIM-1, ARK2, AurB, IPL1, PPP1R48, STK12, STK5	ENSG00000178999	Aurora kinase B	17	8204733-8210600	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005862, HPA037708	Enhanced		Enhanced	Nucleoplasm<br>Midbody	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.24e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 44.4	tonsil: 33.8	Mixed		
TAS1R2	GPR71, T1R2, TR2	ENSG00000179002	Taste 1 receptor member 2	1	18839599-18859682	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C14orf39	SIX6OS1	ENSG00000179008	Chromosome 14 open reading frame 39	14	60396469-60515543	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059518	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	8	testis: 19.7	adrenal gland: 2.4	Cell line enhanced		HEL: 5.6;MOLT-4: 19.1;RH-30: 6.0;U-2 OS: 13.1
MRFAP1	PAM14, PGR1	ENSG00000179010	Morf4 family associated protein 1	4	6640091-6642745	Predicted intracellular proteins	Evidence at protein level	CAB042447, HPA056367	Approved		Approved	Nucleus	Renal cancer:2.90e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 505.0	Expressed in all		
C3orf38	MGC26717	ENSG00000179021	Chromosome 3 open reading frame 38	3	88149743-88168729	Predicted intracellular proteins	Evidence at protein level	HPA034736, HPA034737	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Ovarian cancer:3.55e-4 (favourable), Prostate cancer:4.12e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.0	Expressed in all		
KLHDC7A	FLJ38753	ENSG00000179023	Kelch domain containing 7A	1	18480982-18486126	Predicted intracellular proteins	Evidence at protein level	HPA056616	Uncertain		Approved	Nuclear speckles	Renal cancer:7.81e-9 (favourable), Urothelial cancer:1.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 20.8	urinary bladder: 6.4	Cell line enhanced		A549: 4.7;CAPAN-2: 8.9;EFO-21: 4.8;NTERA-2: 5.6;RPTEC TERT1: 8.6;RT4: 7.4;T-47d: 9.5
TMEM107	MGC10744	ENSG00000179029	Transmembrane protein 107	17	8173237-8176399	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA052555, HPA059653	Approved		Approved	Nucleoplasm<br>Midbody<br>Midbody ring<br>Cytosol	Endometrial cancer:9.39e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 72.1	Expressed in all		
RRS1	KIAA0112	ENSG00000179041	Ribosome biogenesis regulator homolog	8	66429028-66430733	Predicted intracellular proteins	Evidence at protein level	HPA055549, HPA060937	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			appendix: 16.3	Expressed in all		
EXOC3L1	EXOC3L, FLJ35539, FLJ35587	ENSG00000179044	Exocyst complex component 3 like 1	16	67184366-67190204	Predicted intracellular proteins	Evidence at transcript level	HPA029574	Uncertain		Approved	Vesicles<br>Plasma membrane		Expressed in all	Tissue enhanced		spleen: 30.0	placenta: 8.4	Cell line enhanced		HUVEC TERT2: 2.8;SCLC-21H: 7.6
TRIML2	FLJ25801, SPRYD6	ENSG00000179046	Tripartite motif family like 2	4	188091273-188109603	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043838	Uncertain		Approved	Plasma membrane<br>Cytosol		Tissue enriched	Group enriched	26	placenta: 5.9;testis: 3.4	cerebral cortex,lung: 0.1	Cell line enhanced		A549: 30.5;BEWO: 17.7;hTCEpi: 15.4;NTERA-2: 34.0
RCC2	TD-60	ENSG00000179051	Regulator of chromosome condensation 2	1	17406760-17439724	Predicted intracellular proteins	Evidence at protein level	HPA072281	Approved				Liver cancer:3.42e-8 (unfavourable), Renal cancer:4.03e-8 (unfavourable), Melanoma:1.30e-4 (unfavourable), Cervical cancer:3.31e-4 (favourable)	Expressed in all	Mixed			skin: 35.3	Expressed in all		
OR13D1		ENSG00000179055	Olfactory receptor family 13 subfamily D member 1	9	104694422-104695462	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA055921	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
IGSF22	FLJ37794, IGFN2	ENSG00000179057	Immunoglobulin superfamily member 22	11	18704305-18726230	Predicted intracellular proteins	Evidence at protein level	CAB026459	Uncertain					Mixed	Tissue enhanced		skin: 1.2;testis: 1.0	cerebral cortex: 0.8	Not detected		
C9orf50	FLJ35803	ENSG00000179058	Chromosome 9 open reading frame 50	9	129612225-129620776	Predicted intracellular proteins	Evidence at protein level	HPA026743	Enhanced					Mixed	Tissue enhanced		testis: 8.1	cerebral cortex: 1.8	Cell line enhanced		MCF7: 1.0
ZFP42	REX1, ZNF754	ENSG00000179059	ZFP42 zinc finger protein	4	187995771-188005050	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025557	Uncertain					Tissue enriched	Tissue enhanced		testis: 3.1	placenta: 1.0	Cell line enriched	17	BEWO: 113.6
CCDC89	FLJ38159	ENSG00000179071	Coiled-coil domain containing 89	11	85684866-85686277	Predicted intracellular proteins	Evidence at protein level	HPA040628	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 19.3;testis: 53.4	ovary: 8.1	Cell line enhanced		SCLC-21H: 6.3;U-2197: 5.7
FAM133A	CT115, FLJ37659, RP1-32F7.2	ENSG00000179083	Family with sequence similarity 133 member A	X	93674013-93712274	Predicted intracellular proteins	Evidence at protein level	HPA066175, HPA069513			Approved	Nucleus<br>Nucleoli		Mixed	Group enriched	6	cerebral cortex: 5.3;testis: 14.1	adrenal gland: 1.5	Cell line enhanced		Karpas-707: 33.0;U-2197: 22.2;U-266/70: 27.2;U-266/84: 58.1
DPM3	MGC125904, MGC125905, MGC34275	ENSG00000179085	Dolichyl-phosphate mannosyltransferase subunit 3	1	155139891-155140595	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014667	Approved				Endometrial cancer:7.09e-5 (favourable), Ovarian cancer:8.97e-5 (favourable), Urothelial cancer:8.64e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 78.5	Expressed in all		
C12orf42	FLJ25323	ENSG00000179088	Chromosome 12 open reading frame 42	12	103237591-103496010	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 25.1	spleen: 1.5	Not detected		
CYC1	UQCR4	ENSG00000179091	Cytochrome c1	8	144095027-144097525	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA001247	Supported		Supported	Mitochondria	Renal cancer:5.89e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 242.3	Expressed in all		
PER1	PER, RIGUI	ENSG00000179094	Period circadian clock 1	17	8140472-8156506	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA047947, HPA067064			Supported	Nucleoplasm<br>Cytosol	Stomach cancer:1.94e-4 (unfavourable), Liver cancer:2.56e-4 (favourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 70.3	Expressed in all		
HTR1F	5-HT1F, HTR1EL	ENSG00000179097	5-hydroxytryptamine receptor 1F	3	87990696-87993835	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA005555	Uncertain					Not detected	Tissue enhanced		placenta: 2.7	cerebral cortex: 1.0	Cell line enhanced		K-562: 1.1;LHCN-M2: 1.0
TMTC2	DKFZp762A217	ENSG00000179104	Transmembrane and tetratricopeptide repeat containing 2	12	82686880-83134870	Predicted membrane proteins	Evidence at protein level	HPA026954, HPA026955	Uncertain		Approved	Plasma membrane<br>Actin filaments	Renal cancer:2.84e-5 (favourable)	Mixed	Mixed			cerebral cortex: 16.4	Cell line enhanced		AF22: 31.2;WM-115: 76.7
HES7	bHLHb37	ENSG00000179111	Hes family bHLH transcription factor 7	17	8120590-8124092	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072105	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		placenta: 1.1	testis: 0.9	Cell line enhanced		HAP1: 8.4;HDLM-2: 6.2;HeLa: 8.1
FARSA	CML33, FARSL, FARSLA	ENSG00000179115	Phenylalanyl-tRNA synthetase alpha subunit	19	12922479-12934037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001911	Approved		Supported	Cytosol	Cervical cancer:8.23e-4 (favourable), Stomach cancer:8.32e-4 (favourable), Endometrial cancer:9.22e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 67.2	Expressed in all		
SPTY2D1	DKFZp686I068, FLJ39441, Spt2	ENSG00000179119	SPT2 chromatin protein domain containing 1	11	18606401-18634791	Predicted intracellular proteins	Evidence at protein level	HPA039372, HPA047957	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:2.07e-4 (favourable), Pancreatic cancer:2.59e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 21.3	Expressed in all		
C10orf67	bA215C7.4, C10orf115, LINC01552, MGC46732	ENSG00000179133	Chromosome 10 open reading frame 67	10	23201916-23344845	Predicted intracellular proteins	Evidence at transcript level	HPA038130, HPA038131	Approved		Approved	Nucleoplasm<br>Nucleoli<br>Nuclear speckles		Not detected	Tissue enhanced		fallopian tube: 7.5;testis: 17.4	lung: 4.0	Cell line enhanced		HaCaT: 2.1;SiHa: 4.2
SAMD4B	FLJ10211, hSmaug2, MGC99832, SMGB	ENSG00000179134	Sterile alpha motif domain containing 4B	19	39342396-39385710	Predicted intracellular proteins	Evidence at protein level	HPA016800, HPA059385	Approved		Enhanced	Cytosol	Endometrial cancer:2.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 68.4	Expressed in all		
CYP11B2	ALDOS, CPN2, CYP11B, CYP11BL, P-450C18, P450aldo	ENSG00000179142	Cytochrome P450 family 11 subfamily B member 2	8	142910559-142917843	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049171, HPA056348, HPA057752	Supported					Not detected	Tissue enriched	1057	adrenal gland: 126.3	testis: 0.1	Not detected		
GIMAP7	IAN7, MGC27027	ENSG00000179144	GTPase, IMAP family member 7	7	150514830-150521073	Predicted intracellular proteins	Evidence at protein level	HPA020266, HPA020268	Enhanced		Approved	Vesicles<br>Cytosol	Liver cancer:8.98e-5 (favourable), Head and neck cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 181.4	Group enriched	12	HUVEC TERT2: 74.2;MOLT-4: 60.4
ALOXE3	E-LOX, eLOX3	ENSG00000179148	Arachidonate lipoxygenase 3	17	8095900-8119047	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA023120, HPA078597	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	16	skin: 36.5	breast: 2.2	Cell line enhanced		A-431: 5.5;HBEC3-KT: 7.2;hTCEpi: 5.2;hTERT-HME1: 10.5;T-47d: 4.1
EDC3	FLJ21128, hYjeF_N2-15q23, LSM16, YJDC, YJEFN2	ENSG00000179151	Enhancer of mRNA decapping 3	15	74630558-74696292	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040650, HPA044206, HPA066137	Uncertain		Supported	Cytoplasmic bodies	Liver cancer:7.80e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 65.4	Expressed in all		
TCAIM	C3orf23, DKFZp313N0621, TOAG-1	ENSG00000179152	T-cell activation inhibitor, mitochondrial	3	44338119-44409451	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:2.19e-7 (favourable), Urothelial cancer:2.81e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
FUCA1		ENSG00000179163	Fucosidase, alpha-L- 1, tissue	1	23845077-23868294	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA046542, HPA056371	Enhanced				Renal cancer:5.70e-13 (favourable), Endometrial cancer:2.45e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 185.6	Cell line enhanced		CAPAN-2: 144.5
PXT1	STEPP	ENSG00000179165	Peroxisomal, testis specific 1	6	36390551-36442889	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 3.5	appendix: 0.4	Cell line enhanced		HDLM-2: 2.0
GGN	FLJ35713, MGC33369	ENSG00000179168	Gametogenetin	19	38384265-38388082	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	11	testis: 34.9	small intestine: 3.1	Cell line enhanced		BEWO: 2.5
HNRNPCL1	HNRPCL1	ENSG00000179172	Heterogeneous nuclear ribonucleoprotein C-like 1	1	12847408-12848725	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
TMEM125	MGC17299	ENSG00000179178	Transmembrane protein 125	1	43269994-43274002	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA015796			Approved	Midbody<br>Cytosol	Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable)	Mixed	Tissue enhanced		lung: 113.7	thyroid gland: 51.5	Cell line enhanced		A-431: 23.4;BEWO: 21.1;CAPAN-2: 42.6;SK-BR-3: 31.0;T-47d: 31.2
ZNF664	DKFZp761B128, ZFOC1, ZNF176	ENSG00000179195	Zinc finger protein 664	12	123971845-124015439	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047846			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 236.1	Expressed in all		
SIGLECL1	C19orf75, FLJ40235, SIGLEC23P, SIGLECP7	ENSG00000179213	SIGLEC family like 1	19	51246348-51269330	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	86	testis: 40.1	cervix, uterine: 0.4	Not detected		
CALR	cC1qR, CRT, FLJ26680, RO, SSA	ENSG00000179218	Calreticulin	19	12938578-12944489	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001513, HPA002242, CAB019952	Enhanced				Renal cancer:1.11e-16 (unfavourable), Ovarian cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1652.0	Expressed in all		
MAGED1	DLXIN-1, NRAGE	ENSG00000179222	MAGE family member D1	X	51803007-51902357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043645			Approved	Cytosol	Thyroid cancer:3.25e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 193.9	Mixed		
RP11-111M22.2		ENSG00000179240		11	76381313-76414619	Predicted intracellular proteins	Evidence at transcript level	HPA057405	Uncertain		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Centrosome		Not detected	Mixed			testis: 8.4	Mixed		
LDLRAD3	LRAD3	ENSG00000179241	Low density lipoprotein receptor class A domain containing 3	11	35943981-36232136	Predicted membrane proteins	Evidence at protein level	HPA038251	Approved		Supported	Cell Junctions	Renal cancer:5.05e-8 (unfavourable), Lung cancer:9.34e-6 (unfavourable), Urothelial cancer:2.14e-5 (unfavourable), Cervical cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			breast: 23.0	Mixed		
CDH4		ENSG00000179242	Cadherin 4	20	61252426-61940617	Predicted membrane proteins	Evidence at protein level	HPA015613			Enhanced	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 6.0;spleen: 4.8	seminal vesicle: 1.3	Cell line enhanced		AF22: 11.0;hTERT-HME1: 11.2;U-2 OS: 20.6;U-251 MG: 29.8
SMCO3	C12orf69, LOC440087	ENSG00000179256	Single-pass membrane protein with coiled-coil domains 3	12	14804650-14814182	Predicted membrane proteins	Evidence at protein level	HPA040574, HPA047804	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 5.6	gallbladder,kidney: 3.0	Cell line enhanced		AN3-CA: 1.8
RAD23A	HHR23A, MGC111083	ENSG00000179262	RAD23 homolog A, nucleotide excision repair protein	19	12945855-12953642	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA026418, HPA053901, HPA057003, HPA065599	Supported		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skeletal muscle: 334.1	Expressed in all		
C2orf71	FLJ34931, RP54	ENSG00000179270	Chromosome 2 open reading frame 71	2	29060976-29074261	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051819	Uncertain					Not detected	Not detected			heart muscle,ovary: 0.3	Not detected		
GADD45GIP1	CKBBP2, CKbetaBP2, CRIF1, MGC4667, MGC4758, PLINP-1, Plinp1, PRG6	ENSG00000179271	GADD45G interacting protein 1	19	12953119-12957236	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055205, HPA065048	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			cerebral cortex: 29.7	Expressed in all		
DAND5	CER2, CKTSF1B3, Coco, DANTE, DTE, FLJ38607, GREM3	ENSG00000179284	DAN domain BMP antagonist family member 5	19	12965159-12974762	Predicted secreted proteins	Evidence at transcript level	HPA043493, HPA049472	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		heart muscle: 5.2	bone marrow,cerebral cortex: 1.3	Cell line enriched	16	SH-SY5Y: 19.9
TMEM151A	MGC33486, TMEM151	ENSG00000179292	Transmembrane protein 151A	11	66291870-66296664	Predicted membrane proteins	Evidence at transcript level	HPA041035	Uncertain		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enriched	24	cerebral cortex: 45.2	adrenal gland: 1.8	Group enriched	7	SCLC-21H: 17.8;SH-SY5Y: 3.7
PTPN11	BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2	ENSG00000179295	Protein tyrosine phosphatase, non-receptor type 11	12	112418351-112509913	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005377	Approved		Supported	Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 126.0	Expressed in all		
NSUN7	FLJ14001	ENSG00000179299	NOP2/Sun RNA methyltransferase family member 7	4	40749897-40809985	Predicted intracellular proteins	Evidence at protein level	HPA020653	Uncertain		Supported	Vesicles	Renal cancer:2.76e-8 (favourable)	Mixed	Tissue enhanced		testis: 31.5	fallopian tube: 11.4	Cell line enhanced		CAPAN-2: 5.0;Karpas-707: 2.9;T-47d: 3.9
ZCCHC5	FLJ38865, Mar3, Mart3, ZHC5	ENSG00000179300	Zinc finger CCHC-type containing 5	X	78656069-78659328	Predicted intracellular proteins	Evidence at transcript level	HPA051991, HPA053174, HPA075136	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Plasma membrane		Not detected	Not detected			endometrium: 0.8	Cell line enhanced		fHDF/TERT166: 1.4;HBF TERT88: 2.3;hTEC/SVTERT24-B: 1.7;RH-30: 2.0;U-251 MG: 1.3
FAM156B	TMEM29B	ENSG00000179304	Family with sequence similarity 156 member B	X	52891306-52908560	Predicted intracellular proteins	Evidence at protein level	HPA056640, HPA056643	Uncertain					Not detected	Tissue enhanced		placenta: 46.8	skin: 24.9	Expressed in all		
WSCD1	KIAA0523	ENSG00000179314	WSC domain containing 1	17	5772234-6124427	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA015919	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Group enriched	Tissue enhanced		cerebral cortex: 30.3;spleen: 19.0	testis: 14.9	Cell line enhanced		AF22: 39.4;HUVEC TERT2: 20.9;PC-3: 23.1;RH-30: 61.0;SCLC-21H: 18.5
RAB39A	RAB39	ENSG00000179331	RAB39A, member RAS oncogene family	11	107928503-107963482	Predicted intracellular proteins	Evidence at protein level	HPA042505	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 7.0	spleen: 4.3	Cell line enhanced		RPMI-8226: 11.4;SCLC-21H: 33.8;SH-SY5Y: 18.8
CLK3	clk3	ENSG00000179335	CDC like kinase 3	15	74598500-74645414	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046817	Approved		Supported	Nucleoplasm<br>Intermediate filaments	Colorectal cancer:2.05e-6 (unfavourable), Prostate cancer:5.92e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 71.7	Expressed in all		
HLA-DQB1	CELIAC1, HLA-DQB, IDDM1	ENSG00000179344	Major histocompatibility complex, class II, DQ beta 1	6	32659467-32668383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013667	Uncertain		Supported	Golgi apparatus<br>Rods & Rings		Expressed in all	Tissue enhanced		lymph node: 287.3	lung: 268.5	Cell line enriched	8	HDLM-2: 555.8
GATA2	NFE1B	ENSG00000179348	GATA binding protein 2	3	128479427-128493185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005633, CAB024847	Approved		Supported	Nucleoplasm	Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable)	Expressed in all	Tissue enhanced		prostate: 62.7;seminal vesicle: 74.7	endometrium: 40.5	Cell line enhanced		BEWO: 272.0;HEL: 324.7;HMC-1: 165.0;SH-SY5Y: 347.2
ARID3B	BDP, DRIL2	ENSG00000179361	AT-rich interaction domain 3B	15	74541177-74598131	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050320	Enhanced		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 35.9	placenta: 22.3	Cell line enhanced		NTERA-2: 86.8
TMEM31	MGC39655	ENSG00000179363	Transmembrane protein 31	X	103710909-103714028	Predicted membrane proteins	Evidence at protein level	HPA052760			Approved	Nucleoli fibrillar center		Tissue enhanced	Tissue enriched	64	testis: 85.3	ovary,placenta: 1.3	Cell line enhanced		BEWO: 4.1;MCF7: 4.9;NTERA-2: 1.9
PACS2	KIAA0602, PACS1L	ENSG00000179364	Phosphofurin acidic cluster sorting protein 2	14	105300563-105398147	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001423, HPA077892	Approved		Approved	Mitochondria	Liver cancer:3.11e-5 (unfavourable), Renal cancer:1.56e-4 (favourable), Pancreatic cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 63.3	Expressed in all		
ELMOD2	MGC10084	ENSG00000179387	ELMO domain containing 2	4	140524158-140553770	Predicted intracellular proteins	Evidence at protein level	HPA047600	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.17e-8 (favourable), Thyroid cancer:6.35e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Expressed in all		
EGR3	PILOT	ENSG00000179388	Early growth response 3	8	22687659-22693302	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006206, CAB009373	Uncertain		Uncertain	Nucleus<br>Vesicles	Breast cancer:1.83e-4 (favourable), Melanoma:4.78e-4 (favourable)	Mixed	Mixed			gallbladder: 49.6	Cell line enhanced		HMC-1: 8.5;MCF7: 25.2;SK-MEL-30: 17.0
C1orf101	MGC33370	ENSG00000179397	Chromosome 1 open reading frame 101	1	244454377-244641177	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	12	testis: 38.5	epididymis: 3.3	Not detected		
GPC5		ENSG00000179399	Glypican 5	13	91398607-92873682	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040152, HPA044081	Enhanced		Approved	Nucleus<br>Cytosol	Glioma:5.67e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 15.8;kidney: 8.1;testis: 11.5	lung: 4.9	Group enriched	9	CACO-2: 41.2;HeLa: 18.9
VWA1	FLJ22215, VWA-1, WARP	ENSG00000179403	Von Willebrand factor A domain containing 1	1	1434861-1442882	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		seminal vesicle: 293.3	prostate: 129.1	Cell line enhanced		CAPAN-2: 120.1;Hep G2: 57.0;SCLC-21H: 56.1;T-47d: 57.5
DNAJB8	CT156, MGC33884	ENSG00000179407	DnaJ heat shock protein family (Hsp40) member B8	3	128462439-128467248	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	306	testis: 30.5	all non-specific tissues: 0.0	Not detected		
GEMIN4	DKFZP434B131, DKFZP434D174, HC56, HCAP1, HHRF-1, p97	ENSG00000179409	Gem nuclear organelle associated protein 4	17	744414-753999	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA065699, HPA067891	Uncertain		Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 78.2	Expressed in all		
HNRNPCL4		ENSG00000179412	Heterogeneous nuclear ribonucleoprotein C-like 4	1	13164586-13165467	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FJX1	FLJ22416, FLJ25593	ENSG00000179431	Four jointed box 1	11	35618419-35620868	Predicted secreted proteins	Evidence at protein level	HPA059220	Uncertain		Approved	Vesicles	Renal cancer:9.24e-9 (unfavourable), Urothelial cancer:6.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 22.4	endometrium: 8.8	Mixed		
KLHL28	BTBD5, FLJ20081	ENSG00000179454	Kelch like family member 28	14	44924319-45042322	Predicted intracellular proteins	Evidence at transcript level	HPA000988			Approved	Cytosol		Expressed in all	Mixed			bone marrow: 17.2	Expressed in all		
MKRN3	D15S9, MGC88288, RNF63, ZFP127, ZNF127	ENSG00000179455	Makorin ring finger protein 3	15	23565678-23630075	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029494	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:9.23e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 5.9;placenta: 4.1;testis: 3.6	epididymis: 1.1	Cell line enhanced		K-562: 22.8
ZBTB18	C2H2-171, RP58, TAZ-1, ZNF238	ENSG00000179456	Zinc finger and BTB domain containing 18	1	244048939-244057476	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:6.78e-6 (favourable), Endometrial cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 76.3	Mixed		
OR9A2		ENSG00000179468	Olfactory receptor family 9 subfamily A member 2	7	143026158-143027195	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C14orf28	DRIP-1	ENSG00000179476	Chromosome 14 open reading frame 28	14	44897295-44907257	Predicted intracellular proteins	Evidence at transcript level	HPA059635			Approved	Cytosol		Expressed in all	Mixed			testis: 15.6	Mixed		
ALOX12B	12R-LOX	ENSG00000179477	Arachidonate 12-lipoxygenase, 12R type	17	8072636-8087703	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024002	Supported		Approved	Cytosol		Group enriched	Group enriched	7	skin: 70.0;tonsil: 17.2	esophagus: 6.2	Cell line enhanced		HEK 293: 1.2;hTCEpi: 1.0
SLC17A8	DFNA25, VGLUT3	ENSG00000179520	Solute carrier family 17 member 8	12	100357079-100422059	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB079058		Supported				Tissue enhanced	Tissue enhanced		small intestine: 5.8	cerebral cortex: 1.2	Not detected		
SHARPIN	DKFZP434N1923, SIPL1	ENSG00000179526	SHANK associated RH domain interactor	8	144098633-144108124	Predicted intracellular proteins	Evidence at protein level	HPA044453	Approved		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			testis: 66.1	Expressed in all		
LBX2		ENSG00000179528	Ladybird homeobox 2	2	74497517-74503316	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044257	Uncertain		Approved	Nucleus<br>Midbody		Mixed	Tissue enhanced		duodenum: 5.3;small intestine: 5.3	stomach: 3.0	Cell line enhanced		Hep G2: 14.9
DNHD1	C11orf47, CCDC35, DHCD1, DKFZp686J0796, DNHD1L, FLJ32752, FLJ35709, FLJ46184	ENSG00000179532	Dynein heavy chain domain 1	11	6497260-6593758	Predicted intracellular proteins	Evidence at protein level	HPA039698, HPA040267, HPA057639	Uncertain		Approved	Nucleoplasm<br>Cytokinetic bridge		Mixed	Tissue enriched	6	testis: 19.5	bone marrow: 3.5	Mixed		
SLITRK4	DKFZp547M2010	ENSG00000179542	SLIT and NTRK like family member 4	X	143622790-143635777	Predicted membrane proteins	Evidence at protein level	HPA000431	Enhanced		Uncertain	Microtubules		Tissue enhanced	Tissue enhanced		adrenal gland: 13.9;cerebral cortex: 12.8	cervix, uterine: 8.4	Cell line enhanced		HeLa: 3.9;HHSteC: 2.5;T-47d: 8.3;U-2 OS: 3.5
HTR1D	5-HT1D, HT1DA, HTRL, RDC4	ENSG00000179546	5-hydroxytryptamine receptor 1D	1	23191895-23194729	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable)	Mixed	Group enriched	8	duodenum: 9.4;gallbladder: 2.5;small intestine: 9.1	fallopian tube: 0.9	Cell line enhanced		A549: 9.5;SiHa: 7.5;TIME: 21.6;U-2 OS: 9.0
GCC1	FLJ22035, GCC1P, GCC88, MGC20706	ENSG00000179562	GRIP and coiled-coil domain containing 1	7	127580618-127593611	Predicted intracellular proteins	Evidence at protein level	HPA019369, HPA021323	Enhanced		Enhanced	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 18.7	Expressed in all		
LSMEM2	C3orf45, FLJ38608	ENSG00000179564	Leucine rich single-pass membrane protein 2	3	50279027-50288114	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		heart muscle: 15.4;skeletal muscle: 5.4	testis: 2.8	Not detected		
RNF151		ENSG00000179580	Ring finger protein 151	16	1966823-1968975	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	430	testis: 73.0	appendix,skin,stomach,thyroid gland: 0.1	Not detected		
CIITA	C2TA, MHC2TA, NLRA	ENSG00000179583	Class II major histocompatibility complex transactivator	16	10866222-10932281	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016084	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			lymph node,spleen: 59.2	Cell line enhanced		HDLM-2: 44.9;REH: 81.4
ZFPM1	FOG, FOG1, ZC2HC11A, ZNF89A	ENSG00000179588	Zinc finger protein, FOG family member 1	16	88453317-88537016	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046603	Enhanced		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.24e-4 (favourable)	Expressed in all	Mixed			stomach: 13.7	Cell line enhanced		K-562: 26.0
ALOX15B	15-LOX-2	ENSG00000179593	Arachidonate 15-lipoxygenase, type B	17	8039017-8049134	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010562	Enhanced		Supported	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		breast: 145.0;prostate: 115.3	lung: 26.1	Group enriched	15	HHSteC: 6.5;HSkMC: 11.9;hTCEpi: 25.0
PLD6		ENSG00000179598	Phospholipase D family member 6	17	17200995-17206315	Predicted membrane proteins	Evidence at protein level	HPA049345	Approved				Pancreatic cancer:1.05e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 29.3	ovary: 8.9	Cell line enhanced		HAP1: 42.7
GPHB5	GPB5, ZLUT1	ENSG00000179600	Glycoprotein hormone beta 5	14	63312835-63318879	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
GRM8	GLUR8, GPRC1H, mGlu8, MGLUR8	ENSG00000179603	Glutamate metabotropic receptor 8	7	126438598-127253294	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051481	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 4.1	testis: 3.0	Group enriched	6	HAP1: 3.1;HEK 293: 1.4;NTERA-2: 3.9;RH-30: 2.2;SCLC-21H: 4.1;SH-SY5Y: 2.0;U-2 OS: 1.3
CDC42EP4	BORG4, CEP4, KAIA1777, MGC17125, MGC3740	ENSG00000179604	CDC42 effector protein 4	17	73283624-73312175	Predicted intracellular proteins	Evidence at protein level	HPA023335, HPA024797	Approved	Supported	Enhanced	Plasma membrane<br>Actin filaments<br>Microtubules		Expressed in all	Expressed in all			cerebral cortex: 101.8	Mixed		
OR2AP1	OR2AP1P	ENSG00000179615	Olfactory receptor family 2 subfamily AP member 1	12	55574415-55575344	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C4		ENSG00000179626	Olfactory receptor family 6 subfamily C member 4	12	55551199-55552244	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZBTB42	ZNF925	ENSG00000179627	Zinc finger and BTB domain containing 42	14	104800596-104804712	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000703, HPA066961	Uncertain		Supported	Nucleus	Renal cancer:2.30e-9 (favourable)	Expressed in all	Mixed			prostate: 8.9	Cell line enhanced		HDLM-2: 17.6;MCF7: 24.3;T-47d: 24.0
LACC1	C13orf31, FAMIN, FLJ38725	ENSG00000179630	Laccase domain containing 1	13	43879284-43893932	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB034228, HPA040150, HPA044211	Uncertain					Expressed in all	Mixed			testis: 17.1	Cell line enhanced		TIME: 93.5
MAF1	DKFZp586G1123	ENSG00000179632	MAF1 homolog, negative regulator of RNA polymerase III	8	144104499-144107611	Predicted intracellular proteins	Evidence at protein level	HPA024821, HPA058548	Uncertain		Supported	Nucleus<br>Nucleoli<br>Vesicles	Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 142.6	Expressed in all		
TPPP2	C14orf8, CT152, p18, p25beta	ENSG00000179636	Tubulin polymerization promoting protein family member 2	14	21024109-21036276	Predicted intracellular proteins	Evidence at protein level	HPA004120	Enhanced					Tissue enhanced	Tissue enriched	46	testis: 309.1	liver: 6.7	Not detected		
FCER1A	FCE1A	ENSG00000179639	Fc fragment of IgE receptor Ia	1	159289714-159308224	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB022102, HPA036051, CAB055526	Approved				Renal cancer:1.20e-4 (favourable)	Expressed in all	Mixed			skin: 39.9	Cell line enriched	100	HEL: 401.2
RPRML	MGC43894	ENSG00000179673	Reprimo like	17	46978156-46979248	Predicted membrane proteins	Evidence at transcript level	HPA062668	Uncertain					Tissue enhanced	Tissue enriched	11	cerebral cortex: 8.6	epididymis: 0.7	Cell line enhanced		AF22: 1.9;Daudi: 8.9;HEK 293: 3.5;NTERA-2: 1.9;SCLC-21H: 2.2
ARL14	ARF7, FLJ22595	ENSG00000179674	ADP ribosylation factor like GTPase 14	3	160677159-160678452	Predicted intracellular proteins	Evidence at protein level						Lung cancer:2.64e-5 (unfavourable), Pancreatic cancer:6.71e-4 (unfavourable)	Group enriched	Tissue enhanced		gallbladder: 209.1;stomach: 70.2	duodenum: 50.9	Group enriched	5	A-431: 8.4;CAPAN-2: 31.7;HaCaT: 7.9;RT4: 14.0
OR6C2	OR6C67	ENSG00000179695	Olfactory receptor family 6 subfamily C member 2	12	55452214-55453152	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			epididymis,testis: 0.2	Not detected		
WDR97	KIAA1875	ENSG00000179698	WD repeat domain 97	8	144107726-144118315	Predicted intracellular proteins	Evidence at transcript level	HPA059409	Uncertain					Mixed	Tissue enriched	9	testis: 1.1	adrenal gland: 0.1	Not detected		
NLRP8	CLR19.2, NALP8, NOD16, PAN4	ENSG00000179709	NLR family pyrin domain containing 8	19	55947832-55988629	Predicted intracellular proteins	Evidence at transcript level	HPA056989	Uncertain					Not detected	Not detected			breast,testis: 0.3	Not detected		
PCED1B	FAM113B, MGC16044	ENSG00000179715	PC-esterase domain containing 1B	12	47079603-47236662	Predicted intracellular proteins	Evidence at protein level	HPA043901	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.55e-6 (unfavourable), Urothelial cancer:5.36e-5 (favourable)	Expressed in all	Mixed			lymph node: 42.3	Cell line enhanced		A549: 57.4;K-562: 43.7
APOBEC3B	FLJ21201, PHRBNL	ENSG00000179750	Apolipoprotein B mRNA editing enzyme catalytic subunit 3B	22	38982347-38992804	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA056980, HPA066719			Approved	Nucleoplasm	Cervical cancer:2.58e-5 (favourable), Renal cancer:2.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 18.9	rectum: 13.9	Cell line enhanced		A-431: 241.1;Karpas-707: 215.9
SYCN	FLJ27441, INSSA1, SYL	ENSG00000179751	Syncollin	19	39202831-39204266	Predicted secreted proteins	Evidence at protein level	HPA047654	Enhanced					Tissue enriched	Tissue enriched	401	pancreas: 6057.1	ovary: 15.0	Not detected		
PIPOX	LPIPOX	ENSG00000179761	Pipecolic acid and sarcosine oxidase	17	28950513-29057220	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.49e-4 (favourable)	Group enriched	Group enriched	7	kidney: 137.9;liver: 235.9	epididymis: 26.0	Group enriched	5	AF22: 30.7;Hep G2: 65.9;NTERA-2: 61.7;RH-30: 85.6
FOXS1	FKHL18, FREAC10	ENSG00000179772	Forkhead box S1	20	31844301-31845619	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042475	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.10e-8 (unfavourable)	Expressed in all	Mixed			placenta: 7.0	Cell line enhanced		EFO-21: 3.0;RH-30: 10.5;U-2 OS: 15.0;U-251 MG: 3.6
ATOH7	bHLHa13, Math5	ENSG00000179774	Atonal bHLH transcription factor 7	10	68230624-68232103	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027008	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 2.2	endometrium,kidney,small intestine: 0.3	Cell line enriched	14	SCLC-21H: 9.1
CDH5	7B4, CD144	ENSG00000179776	Cadherin 5	16	66366622-66404786	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB028366	Approved				Renal cancer:5.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 335.1	lung: 120.5	Group enriched	5	HUVEC TERT2: 616.7;TIME: 522.0
LRRC3B	LRP15	ENSG00000179796	Leucine rich repeat containing 3B	3	26622806-26710776	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015568	Approved					Group enriched	Group enriched	7	cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0	endometrium,ovary: 1.6	Cell line enhanced		NTERA-2: 1.6
FAM216B	C13orf30, FLJ40919	ENSG00000179813	Family with sequence similarity 216 member B	13	42781550-42791549	Predicted intracellular proteins	Evidence at transcript level	HPA040118	Uncertain				Endometrial cancer:9.77e-4 (favourable)	Group enriched	Tissue enriched	8	fallopian tube: 122.8	lung: 15.1	Cell line enriched	13	U-87 MG: 1.7
MRGPRX4	MRGX4	ENSG00000179817	MAS related GPR family member X4	11	18172837-18174280	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SK-MEL-30: 1.1;WM-115: 1.8
MYADM		ENSG00000179820	Myeloid associated differentiation marker	19	53866223-53876437	Predicted membrane proteins, Transporters	Evidence at protein level	HPA056301			Approved	Nuclear speckles	Renal cancer:7.71e-7 (unfavourable), Lung cancer:8.15e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 260.7	Mixed		
MRGPRX3	MRGX3	ENSG00000179826	MAS related GPR family member X3	11	18120955-18138480	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		salivary gland: 1.3	breast,testis: 0.7	Cell line enriched	7	HBEC3-KT: 10.4
MROH1	HEATR7A, KIAA1833	ENSG00000179832	Maestro heat like repeat family member 1	8	144148016-144261940	Predicted intracellular proteins	Evidence at protein level	HPA044465	Approved	Supported			Renal cancer:3.65e-6 (favourable), Endometrial cancer:6.74e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 14.9	Mixed		
SERTAD2	KIAA0127, Sei-2, TRIP-Br2	ENSG00000179833	SERTA domain containing 2	2	64631621-64751005	Predicted intracellular proteins	Evidence at protein level	HPA019021, HPA020904	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-4 (unfavourable), Endometrial cancer:4.03e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 54.0	Expressed in all		
AKAP5	AKAP75, AKAP79	ENSG00000179841	A-kinase anchoring protein 5	14	64465499-64474503	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004308, HPA053891	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	5	cerebral cortex: 22.5	rectum: 4.2	Cell line enhanced		CACO-2: 9.0
NKPD1	FLJ33600	ENSG00000179846	NTPase KAP family P-loop domain containing 1	19	45149750-45158737	Predicted membrane proteins	Evidence at protein level	HPA043339	Uncertain					Mixed	Tissue enriched	18	skin: 14.8	seminal vesicle: 0.8	Cell line enhanced		hTCEpi: 1.1;SiHa: 1.5;U-266/70: 2.2
GIPC3	C19orf64, DFNB15, DFNB72, DFNB95	ENSG00000179855	GIPC PDZ domain containing family member 3	19	3585553-3593541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061258, HPA067765	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Mixed	Mixed			smooth muscle: 11.5	Cell line enhanced		HeLa: 12.6;HMC-1: 10.5;THP-1: 15.5;WM-115: 44.4
AC025335.1		ENSG00000179859		17	7913324-7916276	Predicted intracellular proteins	Evidence at transcript level						Cervical cancer:8.89e-5 (favourable)	Expressed in all	Tissue enriched	8	skin: 61.7	fallopian tube: 8.0	Cell line enhanced		SiHa: 14.9
CITED4		ENSG00000179862	Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 4	1	40861051-40862366	Predicted intracellular proteins	Evidence at protein level	HPA056434	Approved		Approved	Vesicles	Endometrial cancer:4.38e-5 (favourable)	Expressed in all	Mixed			breast: 20.5	Cell line enhanced		RPTEC TERT1: 67.0;THP-1: 176.9
ABCA13	FLJ33876, FLJ33951	ENSG00000179869	ATP binding cassette subfamily A member 13	7	48171458-48647496	Predicted membrane proteins	Evidence at transcript level	HPA063601			Approved	Vesicles<br>Centrosome<br>Cytosol		Mixed	Tissue enriched	10	bone marrow: 29.4	testis: 3.0	Cell line enhanced		HDLM-2: 5.3;U-2 OS: 6.8
NLRP11	CLR19.6, NALP11, NOD17, PAN10, PYPAF6	ENSG00000179873	NLR family pyrin domain containing 11	19	55785397-55836800	Predicted intracellular proteins	Evidence at protein level	HPA046402, HPA078027	Uncertain		Supported	Cytosol		Not detected	Tissue enhanced		epididymis: 1.4;testis: 1.3	tonsil: 0.6	Group enriched	18	Daudi: 82.3;Karpas-707: 17.0;RPMI-8226: 44.9;U-266/70: 83.8;U-266/84: 35.2;U-698: 57.1
TIGD5	FLJ14926	ENSG00000179886	Tigger transposable element derived 5	8	143597835-143603224	Predicted intracellular proteins	Evidence at protein level						Renal cancer:9.16e-5 (favourable), Liver cancer:7.68e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 2.2	Mixed		
PDXDC1	KIAA0251	ENSG00000179889	Pyridoxal dependent decarboxylase domain containing 1	16	14974591-15139339	Predicted intracellular proteins	Evidence at protein level	HPA047369, HPA049121, HPA051484	Approved		Enhanced	Golgi apparatus<br>Vesicles	Renal cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 105.7	Expressed in all		
C1orf194		ENSG00000179902	Chromosome 1 open reading frame 194	1	109105951-109113857	Predicted intracellular proteins	Evidence at protein level	HPA031144, HPA049684	Enhanced		Uncertain	Nuclear speckles<br>Cytosol	Endometrial cancer:1.36e-4 (favourable)	Group enriched	Group enriched	31	fallopian tube: 198.1;testis: 199.1	lung: 6.4	Cell line enhanced		AF22: 1.5;SCLC-21H: 2.5
ZNF154	pHZ-92	ENSG00000179909	Zinc finger protein 154	19	57697367-57709194	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			parathyroid gland: 9.5	Cell line enhanced		AF22: 5.2;MOLT-4: 3.6;NTERA-2: 2.9
R3HDM2	KIAA1002	ENSG00000179912	R3H domain containing 2	12	57253762-57431005	Predicted intracellular proteins	Evidence at protein level	HPA038327, HPA038328	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 51.8	Expressed in all		
B3GNT3	B3GN-T3, B3GNT-3, beta3Gn-T3, HP10328, TMEM3	ENSG00000179913	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3	19	17794828-17813082	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA024298	Enhanced				Lung cancer:4.25e-5 (unfavourable), Pancreatic cancer:2.16e-4 (unfavourable)	Mixed	Tissue enhanced		rectum: 50.8	colon: 48.8	Cell line enhanced		A-431: 43.3;BEWO: 45.1;CAPAN-2: 113.3;RT4: 37.2;SK-BR-3: 32.5
ITLN1	FLJ20022, hIntL, HL-1, ITLN, LFR	ENSG00000179914	Intelectin 1	1	160876539-160885170	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB012652, HPA063275, HPA067326	Enhanced					Tissue enhanced	Tissue enhanced		colon: 447.7;rectum: 1428.1;small intestine: 468.9	duodenum: 276.3	Cell line enhanced		HEL: 2.3;HL-60: 1.5;U-937: 5.7
NRXN1	Hs.22998, KIAA0578	ENSG00000179915	Neurexin 1	2	49918505-51225575	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA071400			Approved	Nucleoli<br>Plasma membrane		Tissue enriched	Tissue enriched	12	cerebral cortex: 154.0	seminal vesicle: 12.9	Cell line enriched	9	SCLC-21H: 42.8
SEPHS2	SPS2, SPS2b	ENSG00000179918	Selenophosphate synthetase 2	16	30443631-30446181	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047931	Approved		Approved	Nucleoplasm	Renal cancer:4.35e-8 (favourable)	Expressed in all	Expressed in all			liver: 180.4	Expressed in all		
OR10A7		ENSG00000179919	Olfactory receptor family 10 subfamily A member 7	12	55221025-55221975	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA055111	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPBAR1	BG37, GPCR, GPCR19, GPR131, M-BAR, MGC40597, TGR5	ENSG00000179921	G protein-coupled bile acid receptor 1	2	218259496-218263859	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA062890	Enhanced					Tissue enhanced	Tissue enhanced		gallbladder: 26.9;smooth muscle: 14.0	adipose tissue: 9.9	Cell line enhanced		HHSteC: 1.5;SCLC-21H: 1.1;U-937: 1.4
ZNF784	MGC75238	ENSG00000179922	Zinc finger protein 784	19	55620742-55624601	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059676	Uncertain		Approved	Nucleus	Urothelial cancer:1.02e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 14.7	Expressed in all		
ZNF648	FLJ46813	ENSG00000179930	Zinc finger protein 648	1	182054570-182061712	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA053897	Uncertain					Not detected	Not detected			ovary,testis: 0.6	Cell line enriched	87	HMC-1: 31.7
C14orf119	FLJ20671	ENSG00000179933	Chromosome 14 open reading frame 119	14	23094765-23100462	Predicted intracellular proteins	Evidence at protein level	HPA003638	Uncertain		Supported	Mitochondria<br>Cytosol	Thyroid cancer:3.30e-5 (favourable), Liver cancer:5.42e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.9	Expressed in all		
CCR8	CDw198, CKR-L1, CMKBR8, CMKBRL2, CY6, GPR-CY6, TER1	ENSG00000179934	C-C motif chemokine receptor 8	3	39329706-39333511	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042383	Supported					Mixed	Tissue enhanced		urinary bladder: 2.3	appendix: 1.7	Cell line enriched	22	HDLM-2: 104.4
GOLGA8J		ENSG00000179938	Golgin A8 family member J	15	30083053-30093499	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BBS10	C12orf58, FLJ23560	ENSG00000179941	Bardet-Biedl syndrome 10	12	76344474-76348442	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047954, HPA058743	Approved		Uncertain	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 16.7	Expressed in all		
FIZ1	FLJ14768, ZNF798	ENSG00000179943	FLT3 interacting zinc finger 1	19	55591371-55601970	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074026			Approved	Nucleus	Urothelial cancer:2.02e-4 (favourable), Pancreatic cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.6	Expressed in all		
PUF60	FIR, RoBPI, SIAHBP1	ENSG00000179950	Poly(U) binding splicing factor 60	8	143816344-143829859	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045733, HPA052096, HPA059714	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 26.1	Expressed in all		
SSC5D	FLJ35258, S5D-SRCRB	ENSG00000179954	Scavenger receptor cysteine rich family member with 5 domains	19	55488404-55519098	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042008	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.26e-8 (unfavourable)	Mixed	Mixed			smooth muscle: 32.1	Cell line enhanced		ASC TERT1: 22.1;BJ: 26.4;fHDF/TERT166: 24.8;U-87 MG: 32.1
DCTPP1	CDA03, MGC5627, RS21C6, XTP3TPA	ENSG00000179958	DCTP pyrophosphatase 1	16	30423619-30430075	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002832	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.71e-9 (favourable), Breast cancer:1.64e-5 (unfavourable), Liver cancer:6.28e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 64.1	Expressed in all		
ZNF771	DSC43	ENSG00000179965	Zinc finger protein 771	16	30407297-30431108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030730, HPA046672, HPA059398	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 7.0	Expressed in all		
CRIPAK	FLJ34443	ENSG00000179979	Cysteine rich PAK1 inhibitor	4	1391552-1395989	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:1.55e-4 (favourable), Head and neck cancer:4.37e-4 (favourable)	Expressed in all	Mixed			skin: 15.0	Mixed		
TSHZ1	NY-CO-33, SDCCAG33, TSH1	ENSG00000179981	Teashirt zinc finger homeobox 1	18	75210755-75289950	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006982	Approved		Approved	Nucleoplasm	Thyroid cancer:1.71e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 46.4	Cell line enhanced		HDLM-2: 45.8
PSTK	C10orf89, MGC35392	ENSG00000179988	Phosphoseryl-tRNA kinase	10	122954381-122997513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037780, HPA037781	Approved		Approved	Nucleoli<br>Nuclear bodies<br>Actin filaments		Mixed	Mixed			testis: 5.9	Mixed		
SOCS4	SOCS7	ENSG00000180008	Suppressor of cytokine signaling 4	14	55027230-55049488	Predicted intracellular proteins	Evidence at protein level	CAB013478, HPA057961	Approved		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			thyroid gland: 12.5	Expressed in all		
ZADH2	MGC45594	ENSG00000180011	Zinc binding alcohol dehydrogenase domain containing 2	18	75195108-75209348	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021468, HPA053646	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:1.02e-6 (favourable), Thyroid cancer:1.94e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 52.3	Expressed in all		
OR1E1	HGM071, OR13-66, OR17-2, OR17-32, OR1E5, OR1E6, OR1E9P	ENSG00000180016	Olfactory receptor family 1 subfamily E member 1	17	3397104-3398410	G-protein coupled receptors, Predicted membrane proteins, Transporters	No evidence							Not detected	Not detected			placenta,spleen,testis: 0.1	Not detected		
ZNF48	DKFZp762K013, FLJ31751, MGC43952, ZNF553	ENSG00000180035	Zinc finger protein 48	16	30378106-30400108	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023806	Uncertain		Supported	Mitochondria	Pancreatic cancer:1.20e-6 (favourable), Renal cancer:7.50e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 14.0	Expressed in all		
FAM71E2	C19orf16, DKFZp434G1729	ENSG00000180043	Family with sequence similarity 71 member E2	19	55354908-55363260	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	236	testis: 23.6	all non-specific tissues: 0.0	Cell line enriched	10	SCLC-21H: 1.0
C3orf80		ENSG00000180044	Chromosome 3 open reading frame 80	3	160225496-160228213	Predicted membrane proteins	Evidence at transcript level	HPA047439	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 9.8	esophagus: 2.7	Cell line enriched	6	HMC-1: 126.0
NKX2-6	CSX2, NKX4-2	ENSG00000180053	NK2 homeobox 6	8	23702451-23706598	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		hTEC/SVTERT24-B: 3.6
TMEM150B	TMEM224, TTN2	ENSG00000180061	Transmembrane protein 150B	19	55312801-55334048	Predicted membrane proteins	Evidence at transcript level						Renal cancer:6.14e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 69.8;small intestine: 66.5	lung: 18.9	Cell line enhanced		CACO-2: 7.6;HMC-1: 4.0;U-937: 16.3
ANKRD18A	FLJ35740, KIAA2015	ENSG00000180071	Ankyrin repeat domain 18A	9	38571358-38620660	Predicted intracellular proteins	Evidence at protein level	HPA046346, HPA046695, HPA049923, HPA051288	Uncertain		Supported	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 11.3;testis: 10.2	thyroid gland: 3.5	Cell line enhanced		HL-60: 13.8
WFDC11	WAP11	ENSG00000180083	WAP four-disulfide core domain 11	20	45648563-45670270	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	14	epididymis: 115.8	testis: 8.5	Group enriched	6	HeLa: 5.5;RPMI-8226: 3.6;U-937: 1.1
TMEM86B	MGC30208	ENSG00000180089	Transmembrane protein 86B	19	55226639-55229264	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057689	Uncertain		Approved	Midbody<br>Centrosome	Pancreatic cancer:9.97e-6 (favourable), Liver cancer:3.13e-4 (favourable)	Tissue enriched	Mixed			gallbladder: 6.6	Mixed		
OR3A1	OLFRA03, OR17-40, OR40	ENSG00000180090	Olfactory receptor family 3 subfamily A member 1	17	3291635-3292600	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.7	epididymis: 0.3	Cell line enriched	21	HDLM-2: 20.9
SEPT1	DIFF6, PNUTL3	ENSG00000180096	Septin 1	16	30378133-30395991	Predicted intracellular proteins	Evidence at protein level	HPA041566, HPA060339	Enhanced		Uncertain	Actin filaments	Renal cancer:2.40e-7 (unfavourable), Endometrial cancer:3.04e-5 (favourable), Lung cancer:7.24e-5 (favourable), Cervical cancer:9.72e-5 (favourable), Pancreatic cancer:2.22e-4 (favourable), Head and neck cancer:6.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 16.3;spleen: 11.3	tonsil: 6.0	Cell line enhanced		Daudi: 27.2;MOLT-4: 53.0;REH: 35.4;U-266/84: 23.4
TRNAU1AP	FLJ20503, SECP43, TRSPAP1	ENSG00000180098	TRNA selenocysteine 1 associated protein 1	1	28553085-28578545	Predicted intracellular proteins	Evidence at protein level	HPA032068, HPA032069	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.16e-5 (unfavourable), Liver cancer:8.64e-5 (unfavourable), Endometrial cancer:2.22e-4 (favourable), Thyroid cancer:9.45e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.3	Expressed in all		
EXOC3	SEC6L1, Sec6p	ENSG00000180104	Exocyst complex component 3	5	443158-471937	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA037880			Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:1.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 58.5	Expressed in all		
TDRD6	bA446F17.4, CT41.2, NY-CO-45, SPATA36	ENSG00000180113	Tudor domain containing 6	6	46687875-46704319	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	testis: 42.8;thyroid gland: 10.1	appendix,lymph node: 4.7	Not detected		
C12orf40	FLJ40126	ENSG00000180116	Chromosome 12 open reading frame 40	12	39626167-39908300	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	77	testis: 15.7	tonsil: 0.2	Cell line enriched	7	K-562: 2.4
CSNK1A1L	MGC33182	ENSG00000180138	Casein kinase 1 alpha 1 like	13	37103259-37105664	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA051334			Approved	Cytosol		Not detected	Tissue enriched	16	testis: 6.4	bone marrow: 0.3	Not detected		
LYNX1	SLURP2	ENSG00000180155	Ly6/neurotoxin 1	8	142771197-142777810	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level						Renal cancer:2.82e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 94.6	parathyroid gland: 58.6	Cell line enhanced		BJ: 6.9;fHDF/TERT166: 7.9;HHSteC: 6.9;T-47d: 6.7
TH	DYT5b	ENSG00000180176	Tyrosine hydroxylase	11	2163929-2171877	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002522, HPA013768, HPA061003, CAB072340	Enhanced	Supported				Tissue enhanced	Tissue enriched	81	adrenal gland: 259.8	adipose tissue: 3.2	Group enriched	26	PC-3: 54.8;SK-BR-3: 15.7
MED14	CRSP150, CRSP2, CSRP, CXorf4, EXLM1, RGR1, TRAP170	ENSG00000180182	Mediator complex subunit 14	X	40648306-40735858	Predicted intracellular proteins	Evidence at protein level	HPA064182			Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 32.3	Expressed in all		
FAHD1	C16orf36, DKFZP566J2046	ENSG00000180185	Fumarylacetoacetate hydrolase domain containing 1	16	1826941-1840207	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025530, HPA043226, HPA043534	Enhanced		Enhanced	Nucleus<br>Mitochondria	Renal cancer:2.80e-14 (favourable), Colorectal cancer:8.27e-4 (favourable)	Expressed in all	Expressed in all			kidney: 66.1	Expressed in all		
TDRP	C8orf42, INM01, TDRP1, TDRP2	ENSG00000180190	Testis development related protein	8	489792-545781	Predicted intracellular proteins	Evidence at protein level	HPA008462	Approved		Supported	Vesicles<br>Cytosol	Endometrial cancer:1.52e-4 (unfavourable), Pancreatic cancer:9.37e-4 (favourable)	Expressed in all	Mixed			placenta: 46.8	Cell line enhanced		BEWO: 48.4
RCC1	CHC1	ENSG00000180198	Regulator of chromosome condensation 1	1	28505943-28539300	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015413, HPA027573, HPA027574	Enhanced		Supported	Nucleus<br>Nuclear membrane	Renal cancer:2.43e-11 (unfavourable), Liver cancer:1.91e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 63.8	Expressed in all		
WFDC9	dJ688G8.2, WAP9	ENSG00000180205	WAP four-disulfide core domain 9	20	45607939-45631268	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	405	epididymis: 1257.7	seminal vesicle: 3.1	Not detected		
MYLPF	HUMMLC2B, MRLC2, MYL11	ENSG00000180209	Myosin light chain, phosphorylatable, fast skeletal muscle	16	30370934-30377991	Predicted intracellular proteins	Evidence at protein level	HPA039262, HPA055059	Enhanced					Tissue enhanced	Tissue enriched	95	skeletal muscle: 6541.1	esophagus: 69.1	Group enriched	18	BEWO: 68.9;HSkMC: 114.2
F2		ENSG00000180210	Coagulation factor II, thrombin	11	46719180-46739506	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016780, CAB018650, HPA051476, HPA054698	Enhanced				Renal cancer:6.75e-12 (unfavourable)	Tissue enriched	Tissue enriched	1472	liver: 627.3	testis: 0.4	Cell line enriched	18	Hep G2: 186.7
FAM71C	MGC39520	ENSG00000180219	Family with sequence similarity 71 member C	12	99647753-99650046	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	312	testis: 31.2	all non-specific tissues: 0.0	Not detected		
PRKRA	DYT16, HSD14, PACT, RAX	ENSG00000180228	Protein activator of interferon induced protein kinase EIF2AK2	2	178431414-178451512	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004648, HPA034996, HPA034997	Approved		Supported	Nucleoplasm<br>Cytosol	Liver cancer:8.33e-5 (unfavourable), Testis cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			testis: 56.2	Expressed in all		
ZNRF2	RNF202	ENSG00000180233	Zinc and ring finger 2	7	30284307-30367692	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA072244	Approved				Renal cancer:2.29e-4 (favourable), Endometrial cancer:7.68e-4 (unfavourable), Thyroid cancer:8.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 39.7	Expressed in all		
RRH	peropsin	ENSG00000180245	Retinal pigment epithelium-derived rhodopsin homolog	4	109827994-109844604	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			breast,cerebral cortex,skin: 0.5	Cell line enhanced		U-266/84: 1.0
SLC9A4	NHE4	ENSG00000180251	Solute carrier family 9 member A4	2	102473303-102533972	Predicted membrane proteins, Transporters	Evidence at protein level	HPA036096	Supported		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	5	stomach: 51.3	kidney: 9.5	Cell line enhanced		EFO-21: 1.3;HDLM-2: 2.2;RT4: 3.4
ZNF816	ZNF816A	ENSG00000180257	Zinc finger protein 816	19	52949379-52962911	Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA042466	Uncertain		Uncertain	Nucleoli		Expressed in all	Mixed			prostate: 20.8	Cell line enhanced		RT4: 42.8
PRNT	M8	ENSG00000180259	Prion protein (testis specific)	20	4731282-4740668	Predicted secreted proteins	Evidence at transcript level	HPA045000	Uncertain					Not detected	Tissue enriched	110	testis: 10.9	all non-specific tissues: 0.0	Not detected		
FGD6	FLJ11183, ZFYVE24	ENSG00000180263	FYVE, RhoGEF and PH domain containing 6	12	95076749-95217482	Predicted intracellular proteins	Evidence at protein level	HPA007974	Approved		Approved	Vesicles	Renal cancer:5.46e-6 (unfavourable), Pancreatic cancer:4.62e-5 (unfavourable), Prostate cancer:9.83e-4 (unfavourable)	Expressed in all	Mixed			skin: 9.4	Mixed		
ADGRD2	GPR144, PGR24	ENSG00000180264	Adhesion G protein-coupled receptor D2	9	124451425-124478589	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		seminal vesicle: 1.8	skin: 0.5	Not detected		
GPR139	PGR3	ENSG00000180269	G protein-coupled receptor 139	16	20031485-20073917	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046596	Uncertain					Not detected	Not detected			endometrium: 0.3	Not detected		
PLD5	FLJ40773	ENSG00000180287	Phospholipase D family member 5	1	242082986-242524696	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA028389, HPA050367	Uncertain		Approved	Vesicles<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		seminal vesicle: 4.2	cerebral cortex: 4.1	Cell line enhanced		AF22: 10.2;HDLM-2: 5.0;SH-SY5Y: 3.0;U-2 OS: 3.6
OAZ2		ENSG00000180304	Ornithine decarboxylase antizyme 2	15	64687573-64703281	Predicted intracellular proteins	Evidence at protein level	HPA047694	Uncertain		Approved	Golgi apparatus	Colorectal cancer:9.05e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 118.1	Expressed in all		
WFDC10A	C20orf146, dJ688G8.3, WAP10	ENSG00000180305	WAP four-disulfide core domain 10A	20	45629526-45631196	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	354	epididymis: 175.8	seminal vesicle: 0.4	Not detected		
PNPLA1	dJ50J22.1, FLJ38755	ENSG00000180316	Patatin like phospholipase domain containing 1	6	36243203-36312229	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037853			Uncertain	Intermediate filaments		Mixed	Tissue enriched	6	skin: 35.0	kidney: 5.6	Cell line enriched	5	U-937: 15.5
ALX1	CART1	ENSG00000180318	ALX homeobox 1	12	85280107-85301784	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001598, HPA018905	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus		Tissue enriched	Tissue enhanced		epididymis: 4.3;kidney: 3.1	ovary: 1.8	Cell line enhanced		HEK 293: 19.4;HUVEC TERT2: 13.0;SK-MEL-30: 20.2;THP-1: 11.5;WM-115: 13.3
CCDC43	FLJ31795	ENSG00000180329	Coiled-coil domain containing 43	17	44673069-44689779	Predicted intracellular proteins	Evidence at protein level	HPA023391	Approved		Enhanced	Cytosol	Head and neck cancer:3.42e-5 (unfavourable), Liver cancer:1.33e-4 (unfavourable), Pancreatic cancer:3.19e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 26.1	Expressed in all		
KCTD4	bA321C24.3	ENSG00000180332	Potassium channel tetramerization domain containing 4	13	45192853-45194717	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040734	Uncertain		Approved	Microtubule organizing center		Group enriched	Group enriched	10	cerebral cortex: 17.7;skin: 3.7	gallbladder: 1.1	Cell line enhanced		RPTEC TERT1: 8.8;U-138 MG: 13.7;U-87 MG: 27.1
MEIOC	C17orf104, FLJ35848	ENSG00000180336	Meiosis specific with coiled-coil domain	17	44656404-44690308	Predicted intracellular proteins	Evidence at protein level	HPA027266	Enhanced		Uncertain	Cell Junctions		Not detected	Tissue enriched	52	testis: 86.2	cerebral cortex: 1.6	Cell line enhanced		HAP1: 17.4;HMC-1: 22.4;SiHa: 10.1
FZD2		ENSG00000180340	Frizzled class receptor 2	17	44557459-44559570	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA057667	Uncertain		Approved	Nucleus<br>Nuclear bodies<br>Cell Junctions		Expressed in all	Mixed			placenta: 4.9	Mixed		
TIGD2		ENSG00000180346	Tigger transposable element derived 2	4	89111500-89114899	Predicted intracellular proteins	Evidence at protein level	HPA054844, HPA071168	Uncertain		Approved	Nuclear bodies	Colorectal cancer:4.59e-4 (favourable), Urothelial cancer:7.02e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.0	Expressed in all		
CCDC129	FLJ38344	ENSG00000180347	Coiled-coil domain containing 129	7	31514071-31658720	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024103	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		cervix, uterine: 2.6;salivary gland: 2.4	testis: 2.1	Cell line enhanced		U-2 OS: 1.6
HCLS1	CTTNL, HS1	ENSG00000180353	Hematopoietic cell-specific Lyn substrate 1	3	121631399-121660927	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019143	Supported		Supported	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 271.3	Cell line enhanced		HMC-1: 319.6;U-266/70: 275.0;U-698: 256.8
MTURN	C7orf41, Ells1, FLJ25903	ENSG00000180354	Maturin, neural progenitor differentiation regulator homolog	7	30134810-30162762	Predicted intracellular proteins	Evidence at protein level	HPA029507	Approved		Approved	Cytosol	Renal cancer:7.64e-13 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 351.3	Cell line enhanced		HEL: 86.3;SCLC-21H: 80.0
ZNF609	KIAA0295	ENSG00000180357	Zinc finger protein 609	15	64460742-64686068	Predicted intracellular proteins	Evidence at protein level	HPA040742, HPA040832	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
PAK2	PAK65, PAKgamma	ENSG00000180370	P21 (RAC1) activated kinase 2	3	196739857-196832647	Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB007794	Approved		Enhanced	Nucleus<br>Vesicles	Pancreatic cancer:3.36e-4 (unfavourable), Prostate cancer:9.58e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 60.1	Expressed in all		
CCDC66	DKFZp686C0433	ENSG00000180376	Coiled-coil domain containing 66	3	56557161-56621818	Predicted intracellular proteins	Evidence at protein level	HPA044185	Uncertain		Approved	Cell Junctions<br>Midbody ring<br>Microtubule organizing center		Expressed in all	Mixed			fallopian tube: 9.6	Expressed in all		
DEFB124	DEFB-24	ENSG00000180383	Defensin beta 124	20	31465506-31476757	Predicted secreted proteins	Evidence at transcript level	HPA051046	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 8.9;testis: 5.7	endometrium: 5.4	Group enriched	6	HEL: 2.4;HMC-1: 1.3;U-2 OS: 1.1;WM-115: 5.7
KRTAP9-7	KAP9.7, KRTAP9L1	ENSG00000180386	Keratin associated protein 9-7	17	41275659-41276697	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ATP5EP2		ENSG00000180389	ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit pseudogene 2	13	27945206-27945590	Predicted intracellular proteins	No evidence						Liver cancer:2.36e-4 (unfavourable)	Expressed in all	Not detected			stomach: 0.2	Not detected		
MCFD2	F5F8D, LMAN1IP, SDNSF	ENSG00000180398	Multiple coagulation factor deficiency 2	2	46901870-46941855	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB022410, HPA034593	Supported				Urothelial cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 206.7	Expressed in all		
HARBI1	C11orf77, FLJ32675	ENSG00000180423	Harbinger transposase derived 1	11	46602861-46617909	Predicted intracellular proteins	Evidence at protein level	HPA038671, HPA045457	Uncertain		Enhanced	Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		testis: 21.7	parathyroid gland: 5.4	Expressed in all		
DEFB123	DEFB-23	ENSG00000180424	Defensin beta 123	20	31440519-31450257	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	438	epididymis: 108.1;testis: 178.0	small intestine: 0.3	Not detected		
C11orf71	FLJ20010	ENSG00000180425	Chromosome 11 open reading frame 71	11	114391443-114400511	Predicted intracellular proteins	Evidence at protein level	HPA063943, HPA074787			Supported	Nucleoplasm	Renal cancer:7.01e-9 (favourable), Endometrial cancer:6.94e-4 (favourable)	Expressed in all	Expressed in all			testis: 64.0	Mixed		
CYP8B1	CYP12	ENSG00000180432	Cytochrome P450 family 8 subfamily B member 1	3	42856005-42876165	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	14	liver: 190.6	kidney: 13.7	Cell line enhanced		BEWO: 2.2
OR6K6		ENSG00000180433	Olfactory receptor family 6 subfamily K member 6	1	158754720-158755891	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SERTM1	C13orf36	ENSG00000180440	Serine rich and transmembrane domain containing 1	13	36673912-36697839	Predicted membrane proteins	Evidence at protein level	HPA054814, HPA070485	Uncertain		Supported	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 47.6;endometrium: 37.7;fallopian tube: 29.6	smooth muscle: 24.8	Cell line enhanced		HAP1: 1.2;HEK 293: 1.3;NTERA-2: 3.5;SH-SY5Y: 2.1
GAS1		ENSG00000180447	Growth arrest specific 1	9	86944363-86947189	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB024164, HPA036085, HPA066902	Approved		Approved	Nuclear speckles	Thyroid cancer:1.13e-5 (unfavourable), Renal cancer:1.96e-5 (unfavourable), Colorectal cancer:1.55e-4 (unfavourable), Stomach cancer:8.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 110.8	smooth muscle: 74.4	Cell line enhanced		AN3-CA: 44.7;BJ hTERT+: 53.4;RH-30: 95.7
ARHGAP45	HA-1, HMHA1, KIAA0223	ENSG00000180448	Rho GTPase activating protein 45	19	1065923-1086628	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA019816	Enhanced				Endometrial cancer:6.02e-4 (favourable), Head and neck cancer:7.82e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 56.4;lymph node: 66.6;spleen: 77.8	bone marrow: 44.0	Cell line enhanced		Karpas-707: 72.0;U-266/70: 99.7
OR10Q1		ENSG00000180475	Olfactory receptor family 10 subfamily Q member 1	11	58227882-58228918	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046968	Uncertain					Not detected	Not detected			placenta: 0.1	Not detected		
ZNF571	HSPC059	ENSG00000180479	Zinc finger protein 571	19	37554782-37594790	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA054762			Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Mixed	Tissue enriched	6	thyroid gland: 130.6	parathyroid gland: 21.6	Mixed		
GLIPR1L2	MGC39497	ENSG00000180481	GLI pathogenesis related 1 like 2	12	75391070-75432688	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039795, HPA039866	Enhanced					Mixed	Tissue enriched	8	testis: 84.9	parathyroid gland: 10.9	Cell line enhanced		SK-BR-3: 4.4;U-2 OS: 7.8
DEFB119	DEFB-19, DEFB-20, DEFB120	ENSG00000180483	Defensin beta 119	20	31377164-31390603	Predicted secreted proteins	Evidence at protein level	HPA043059	Supported					Tissue enriched	Group enriched	3499	epididymis: 2335.6;testis: 472.8	duodenum: 0.4	Not detected		
MIGA1	FAM73A, FLJ35093	ENSG00000180488	Mitoguardin 1	1	77779624-77879539	Predicted membrane proteins	Evidence at protein level	HPA017589	Approved		Supported	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 32.7	Expressed in all		
KCNE1	ISK, JLNS2, LQT5, minK	ENSG00000180509	Potassium voltage-gated channel subfamily E regulatory subunit 1	21	34446688-34512275	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 16.6	heart muscle: 3.6	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1.2;CACO-2: 3.3
PRR26	C10orf108, FLJ38681	ENSG00000180525	Proline rich 26	10	649948-669581	Predicted intracellular proteins	Evidence at transcript level	HPA066037	Uncertain					Mixed	Mixed			gallbladder: 7.9	Cell line enhanced		CACO-2: 1.4;CAPAN-2: 1.2;EFO-21: 1.4;RPTEC TERT1: 1.9
NRIP1	RIP140	ENSG00000180530	Nuclear receptor interacting protein 1	21	14961235-15065936	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046571, HPA060036	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 38.9	Cell line enhanced		REH: 87.8
ZSCAN4	FLJ35105, ZNF494	ENSG00000180532	Zinc finger and SCAN domain containing 4	19	57668935-57679152	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA006491	Uncertain					Tissue enhanced	Tissue enhanced		stomach: 2.5	placenta: 1.2	Not detected		
BHLHA15	bHLHa15, BHLHB8, MIST1	ENSG00000180535	Basic helix-loop-helix family member a15	7	98211427-98212979	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB034083, HPA047834	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Tissue enhanced	Group enriched	7	pancreas: 85.5;salivary gland: 54.0	prostate: 9.3	Group enriched	8	Karpas-707: 27.3;RPMI-8226: 50.7;U-266/70: 63.7
RNF182	MGC33993	ENSG00000180537	Ring finger protein 182	6	13924446-13980302	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012309	Approved		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Endometrial cancer:4.66e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 14.6	testis: 6.9	Cell line enhanced		HeLa: 57.3;RPTEC TERT1: 51.0
TSPYL5	KIAA1750	ENSG00000180543	TSPY like 5	8	97273474-97277964	Predicted intracellular proteins	Evidence at protein level	HPA031347	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:1.40e-5 (favourable), Breast cancer:1.21e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 81.4	ovary: 30.4	Cell line enhanced		SCLC-21H: 70.7;SH-SY5Y: 49.4
FUT7		ENSG00000180549	Fucosyltransferase 7	9	137030174-137033010	Predicted intracellular proteins	Evidence at protein level	HPA042780			Approved	Golgi apparatus		Mixed	Tissue enhanced		lymph node: 3.7;spleen: 2.6	bone marrow,tonsil: 2.0	Group enriched	7	NB-4: 10.4;THP-1: 14.0;U-937: 9.1
HIST1H2AC	H2AFL	ENSG00000180573	Histone cluster 1 H2A family member c	6	26124145-26139116	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Expressed in all			prostate: 50.4	Cell line enhanced		SiHa: 77.5;U-2 OS: 74.5
EIF2S3L		ENSG00000180574	Putative eukaryotic translation initiation factor 2 subunit 3-like protein 	12	10505602-10523135	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 4.4	duodenum: 1.0	Cell line enhanced		HaCaT: 2.3;HL-60: 3.9;MOLT-4: 3.4;RH-30: 2.9
SKIDA1	C10orf140, FLJ45187	ENSG00000180592	SKI/DACH domain containing 1	10	21513478-21526368	Predicted intracellular proteins	Evidence at protein level	HPA039208, HPA040439	Uncertain					Mixed	Tissue enhanced		parathyroid gland: 3.9	testis: 3.1	Cell line enhanced		AF22: 25.8;BEWO: 11.6
HIST1H2BC	H2B.1, H2B/l, H2BFL	ENSG00000180596	Histone cluster 1 H2B family member c	6	26114873-26123926	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.75e-5 (unfavourable), Pancreatic cancer:9.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		prostate: 35.5	bone marrow: 16.6	Cell line enhanced		SiHa: 80.4;U-2 OS: 53.7
MB21D2	C3orf59	ENSG00000180611	Mab-21 domain containing 2	3	192796815-192918161	Predicted intracellular proteins	Evidence at protein level	HPA044026	Uncertain		Approved	Cytosol	Endometrial cancer:3.74e-5 (unfavourable), Head and neck cancer:9.94e-4 (unfavourable)	Mixed	Mixed			placenta: 17.1	Cell line enhanced		HDLM-2: 97.0
GSX2	Gsh2	ENSG00000180613	GS homeobox 2	4	54099523-54102505	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.4	Not detected		
SSTR2		ENSG00000180616	Somatostatin receptor 2	17	73165012-73176633	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA007264	Uncertain		Supported	Cytosol	Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.9	spleen: 5.8	Cell line enriched	9	SCLC-21H: 14.9
ZNF594	KIAA1871	ENSG00000180626	Zinc finger protein 594	17	5179536-5191883	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060283, HPA067178, HPA069360			Enhanced	Nucleus		Mixed	Mixed			ovary,parathyroid gland: 13.9	Mixed		
PCGF5	MGC16202, RNF159	ENSG00000180628	Polycomb group ring finger 5	10	91163012-91284331	Predicted intracellular proteins	Evidence at protein level	HPA038349	Approved		Supported	Nucleoli	Renal cancer:4.98e-4 (favourable), Urothelial cancer:6.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 40.5	Expressed in all		
SLC47A2	FLJ31196, MATE2, MATE2-K	ENSG00000180638	Solute carrier family 47 member 2	17	19678288-19718979	Predicted membrane proteins, Transporters	Evidence at protein level						Glioma:7.41e-4 (unfavourable)	Tissue enhanced	Group enriched	5	fallopian tube: 16.5;kidney: 49.3	epididymis: 6.4	Cell line enhanced		hTCEpi: 1.5
PRF1	HPLH2, P1, PFP	ENSG00000180644	Perforin 1	10	70597348-70602775	Cancer-related genes, Disease related genes, Potential drug targets, Predicted secreted proteins, Transporters	Evidence at protein level	CAB002436, HPA037940	Approved		Approved	Cytosol	Renal cancer:1.08e-5 (unfavourable), Endometrial cancer:2.09e-4 (favourable), Head and neck cancer:3.54e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 52.8	lymph node: 20.8	Cell line enriched	16	HDLM-2: 221.2
OR2A4	OR2A10	ENSG00000180658	Olfactory receptor family 2 subfamily A member 4	6	131700469-131701401	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Tissue enriched	Not detected			testis: 0.2	Not detected		
MAB21L1	CAGR1	ENSG00000180660	Mab-21 like 1	13	35474182-35477209	Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864			Enhanced	Nucleus<br>Cytosol		Mixed	Tissue enhanced		adrenal gland: 5.5;breast: 5.2	adipose tissue: 2.4	Cell line enhanced		BJ: 29.7;BJ hTERT+ SV40 Large T+: 36.9;HBF TERT88: 41.4;SH-SY5Y: 135.2
YOD1	DKFZp451J1719, DUBA8, OTUD2	ENSG00000180667	YOD1 deubiquitinase	1	207043849-207052980	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028400, HPA028439	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Tissue enhanced		bone marrow: 37.1	esophagus: 27.8	Cell line enhanced		HEL: 78.5;K-562: 55.5
TMEM64	DKFZp762C1112	ENSG00000180694	Transmembrane protein 64	8	90621995-90791632	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	CAB034221	Uncertain					Expressed in all	Expressed in all			epididymis: 176.0	Mixed		
C3orf22	MGC34728	ENSG00000180697	Chromosome 3 open reading frame 22	3	126526999-126558965	Predicted intracellular proteins	Evidence at protein level	HPA059199	Enhanced					Not detected	Tissue enriched	326	testis: 32.6	all non-specific tissues: 0.0	Not detected		
OR10K2		ENSG00000180708	Olfactory receptor family 10 subfamily K member 2	1	158419928-158420866	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059125	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CHRM4		ENSG00000180720	Cholinergic receptor muscarinic 4	11	46385098-46386608	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022444, HPA072083	Uncertain		Uncertain	Nucleus<br>Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4	testis: 6.9	Cell line enhanced		RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
SHISA2	bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166	ENSG00000180730	Shisa family member 2	13	26044597-26051031	Predicted membrane proteins	Evidence at protein level	HPA049752, HPA050172	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable)	Mixed	Tissue enhanced		breast: 22.3;thyroid gland: 48.3	epididymis: 13.1	Cell line enhanced		LHCN-M2: 21.2;NTERA-2: 18.4;RH-30: 56.6;U-2197: 34.1
S1PR5	Edg-8, EDG8	ENSG00000180739	Sphingosine-1-phosphate receptor 5	19	10512742-10517931	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029683	Enhanced				Renal cancer:6.71e-7 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 14.9;skin: 22.1	spleen: 12.0	Cell line enhanced		HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
CLRN3	MGC32871, TMEM12, USH3AL1	ENSG00000180745	Clarin 3	10	127877841-127892947	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014482	Approved				Stomach cancer:8.98e-4 (favourable)	Group enriched	Group enriched	8	colon: 69.9;duodenum: 73.3;gallbladder: 23.6;kidney: 44.3;liver: 40.4;rectum: 76.3;small intestine: 97.5	appendix: 7.2	Cell line enriched	6	CACO-2: 1.9
GPR157	FLJ12132	ENSG00000180758	G protein-coupled receptor 157	1	9100305-9129170	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028697	Uncertain		Uncertain	Nucleoli<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			parathyroid gland: 24.2	Cell line enhanced		SK-BR-3: 46.8
CHST13	C4ST3	ENSG00000180767	Carbohydrate sulfotransferase 13	3	126524283-126543291	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		liver: 5.9;testis: 6.3	spleen: 2.9	Group enriched	6	CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9
AGTR2	AT2, MRX88	ENSG00000180772	Angiotensin II receptor type 2	X	116170722-116174972	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	6	cervix, uterine: 6.8;endometrium: 13.9;fallopian tube: 3.8;lung: 12.6;smooth muscle: 17.6	adrenal gland: 1.9	Not detected		
SLC36A4	FLJ38932, PAT4	ENSG00000180773	Solute carrier family 36 member 4	11	93144171-93197964	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017887	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			thyroid gland: 14.8	Mixed		
ZDHHC20	FLJ25952	ENSG00000180776	Zinc finger DHHC-type containing 20	13	21372573-21459370	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA014483, HPA014702	Approved		Uncertain	Vesicles<br>Plasma membrane<br>Mitochondria	Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 60.5	Expressed in all		
ANKRD30B	NY-BR-1.1	ENSG00000180777	Ankyrin repeat domain 30B	18	14728272-14852738	Predicted intracellular proteins	Evidence at protein level	HPA060455, HPA071849	Uncertain		Uncertain	Nucleoli		Tissue enhanced	Tissue enriched	11	testis: 14.4	breast: 1.3	Cell line enriched	8	U-2197: 41.6
OR51E1	GPR136, GPR164, OR51E1P, OR52A3P	ENSG00000180785	Olfactory receptor family 51 subfamily E member 1	11	4643420-4655488	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	CAB019995, HPA051439	Approved				Renal cancer:1.23e-6 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 6.4;placenta: 9.6;prostate: 9.0	smooth muscle,urinary bladder: 1.7	Cell line enriched	96	SCLC-21H: 10.5
ZFP3	FLJ30726, ZNF752	ENSG00000180787	ZFP3 zinc finger protein	17	5078248-5096374	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053085, HPA057290	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.69e-7 (favourable), Pancreatic cancer:1.07e-4 (favourable), Lung cancer:1.38e-4 (favourable), Cervical cancer:5.68e-4 (favourable)	Mixed	Mixed			parathyroid gland: 13.1	Cell line enhanced		SH-SY5Y: 6.1
ARSJ	FLJ23548	ENSG00000180801	Arylsulfatase family member J	4	113900284-113979727	Predicted intracellular proteins	Evidence at protein level	HPA036481, HPA036482	Uncertain		Supported	Nucleoli<br>Actin filaments	Renal cancer:2.97e-6 (favourable), Head and neck cancer:6.08e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 12.7	Mixed		
HOXC9	HOX3, HOX3B	ENSG00000180806	Homeobox C9	12	53994895-54003337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063965, HPA072160			Enhanced	Nucleoplasm		Mixed	Tissue enhanced		skeletal muscle: 6.2	adipose tissue: 3.3	Cell line enhanced		AN3-CA: 19.7;HDLM-2: 26.0;HEK 293: 30.3
MAP3K15	ASK3, bA723P2.3, FLJ16518	ENSG00000180815	Mitogen-activated protein kinase kinase kinase 15	X	19360056-19515261	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004006			Approved	Vesicles		Mixed	Tissue enriched	6	adrenal gland: 14.3	spleen: 2.2	Cell line enhanced		A549: 1.8;HAP1: 5.1;HEK 293: 3.8;REH: 2.4
PPA1	IOPPP, PP, PP1, Ppase, SID6-8061	ENSG00000180817	Pyrophosphatase (inorganic) 1	10	70202830-70233911	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019878, HPA020096	Supported		Supported	Vesicles		Expressed in all	Expressed in all			breast: 226.6	Expressed in all		
HOXC10	HOX3I	ENSG00000180818	Homeobox C10	12	53985065-53990279	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053919	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Group enriched	9	kidney: 18.9;skeletal muscle: 40.3;skin: 8.4	breast: 2.5	Cell line enhanced		AN3-CA: 275.9;T-47d: 95.2
PSMG4	C6orf86, PAC4	ENSG00000180822	Proteasome assembly chaperone 4	6	3231403-3303373	Predicted intracellular proteins	Evidence at protein level	HPA067652			Approved	Nucleus<br>Mitochondria	Renal cancer:7.45e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.2	Expressed in all		
BHLHE22	Beta3, BHLHB5, bHLHe22, CAGL85, TNRC20	ENSG00000180828	Basic helix-loop-helix family member e22	8	64580367-64583628	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064128, HPA064872, HPA067500	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 12.2	seminal vesicle: 3.3	Cell line enriched	15	THP-1: 52.6
MAP6D1	FLJ12748, SL21	ENSG00000180834	MAP6 domain containing 1	3	183815876-183825594	Predicted intracellular proteins	Evidence at protein level	HPA037991	Supported		Approved	Cytosol	Prostate cancer:3.37e-4 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 39.7;skeletal muscle: 10.3	skin: 3.6	Cell line enhanced		T-47d: 66.1
ZNF443	ZK1	ENSG00000180855	Zinc finger protein 443	19	12429707-12441112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003150, HPA018683	Supported		Uncertain	Nucleoplasm<br>Microtubule organizing center	Renal cancer:2.74e-7 (favourable), Urothelial cancer:3.91e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 7.0	Mixed		
CXCR2	CD182, CMKAR2, IL8RB	ENSG00000180871	C-X-C motif chemokine receptor 2	2	218125289-218137253	Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB016268, HPA031999, HPA032017	Enhanced					Mixed	Tissue enhanced		appendix: 55.7;spleen: 36.7	esophagus: 29.9	Group enriched	10	BEWO: 13.6;HL-60: 6.5;HMC-1: 14.3;THP-1: 10.4;U-937: 11.8
DEFB112	DEFB-12	ENSG00000180872	Defensin beta 112	6	50043575-50048651	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	53	epididymis: 172.5	seminal vesicle: 3.2	Not detected		
GREM2	CKTSF1B2, DAND3, FLJ21195, Prdc	ENSG00000180875	Gremlin 2, DAN family BMP antagonist	1	240489573-240612149	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB009920	Uncertain					Mixed	Tissue enhanced		gallbladder: 48.8;parathyroid gland: 78.3	rectum: 22.6	Cell line enhanced		BJ: 5.1;BJ hTERT+: 5.2;fHDF/TERT166: 25.0
C11orf42	MGC34805	ENSG00000180878	Chromosome 11 open reading frame 42	11	6205566-6211132	Predicted intracellular proteins	Evidence at protein level	HPA063404	Enhanced					Not detected	Tissue enriched	11	testis: 20.3	skin: 1.8	Cell line enhanced		HEK 293: 1.2;HeLa: 1.0
SSR4	TRAPD	ENSG00000180879	Signal sequence receptor subunit 4	X	153793516-153798505	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA045209	Enhanced				Renal cancer:5.51e-6 (unfavourable), Endometrial cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 979.6	Expressed in all		
CAPS2		ENSG00000180881	Calcyphosine 2	12	75275979-75390928	Predicted intracellular proteins	Evidence at transcript level	HPA040004	Uncertain		Approved	Nucleus<br>Nucleoli<br>Centrosome		Mixed	Tissue enhanced		fallopian tube: 15.9	testis: 6.9	Mixed		
ZNF792	FLJ38451	ENSG00000180884	Zinc finger protein 792	19	34956354-34964049	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035157, HPA035158	Supported		Approved	Nucleoplasm<br>Nuclear bodies	Colorectal cancer:2.72e-4 (favourable)	Expressed in all	Mixed			lung: 6.2	Cell line enhanced		HEL: 11.5;HMC-1: 14.3;SH-SY5Y: 11.1
CUEDC1		ENSG00000180891	CUE domain containing 1	17	57861243-57955323	Predicted intracellular proteins	Evidence at protein level	HPA023050, HPA024836	Approved		Uncertain	Centrosome<br>Mitochondria<br>Cytosol	Liver cancer:2.65e-5 (unfavourable), Renal cancer:8.46e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 52.4	Mixed		
SCRIB	KIAA0147, SCRB1, Vartul	ENSG00000180900	Scribbled planar cell polarity protein	8	143790920-143815379	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB015463, CAB022081, HPA023557, HPA064312	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions<br>Rods & Rings		Expressed in all	Expressed in all			skin: 22.0	Expressed in all		
KCTD2	KIAA0176	ENSG00000180901	Potassium channel tetramerization domain containing 2	17	75032575-75065889	Predicted intracellular proteins	Evidence at protein level						Pancreatic cancer:1.25e-5 (favourable), Liver cancer:1.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 3.4;cerebral cortex: 7.3	kidney: 2.0	Cell line enhanced		HEK 293: 10.4
D2HGDH	D2HGD, FLJ42195, MGC25181	ENSG00000180902	D-2-hydroxyglutarate dehydrogenase	2	241734579-241768816	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA056216, HPA060548	Uncertain		Approved	Mitochondria	Head and neck cancer:9.11e-4 (favourable)	Expressed in all	Expressed in all			skin: 46.5	Expressed in all		
OXTR		ENSG00000180914	Oxytocin receptor	3	8750408-8769628	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	13	breast: 65.4	fallopian tube: 4.9	Cell line enhanced		BJ: 357.1;BJ hTERT+: 104.6;BJ hTERT+ SV40 Large T+: 111.8;fHDF/TERT166: 330.6
CMTR2	AFT, FLJ11171, FTSJD1, MTr2	ENSG00000180917	Cap methyltransferase 2	16	71281389-71289715	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041700, HPA048265	Uncertain		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:4.97e-5 (favourable)	Expressed in all	Expressed in all			testis: 18.9	Expressed in all		
OR56B4		ENSG00000180919	Olfactory receptor family 56 subfamily B member 4	11	6107684-6108835	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix,spleen,thyroid gland: 0.1	Not detected		
FAM83H	FLJ46072	ENSG00000180921	Family with sequence similarity 83 member H	8	143723933-143733801	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024505, HPA024604	Enhanced		Approved	Cytosol	Lung cancer:3.77e-4 (unfavourable), Stomach cancer:4.42e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 17.2	esophagus: 10.3	Cell line enhanced		HaCaT: 37.2;MCF7: 45.2
GPR62		ENSG00000180929	G protein-coupled receptor 62	3	51955314-51957504	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	14	cerebral cortex: 8.0	ovary: 0.5	Cell line enriched	6	SCLC-21H: 2.2
OR56A1		ENSG00000180934	Olfactory receptor family 56 subfamily A member 1	11	6026671-6027741	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
ZNF572	FLJ38002	ENSG00000180938	Zinc finger protein 572	8	124973298-124979389	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066838	Enhanced		Approved	Nuclear speckles		Expressed in all	Mixed			testis: 6.7	Mixed		
ST20	HCCS-1	ENSG00000180953	Suppressor of tumorigenicity 20	15	79898840-79923702	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.69e-8 (unfavourable)	Expressed in all	Mixed			spleen: 11.3	Mixed		
PITPNB	VIB1B	ENSG00000180957	Phosphatidylinositol transfer protein beta	22	27851669-27920134	Predicted intracellular proteins	Evidence at protein level	HPA000528	Uncertain		Approved	Vesicles<br>Cytosol	Head and neck cancer:5.28e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 70.3	Expressed in all		
TCEAL8	MGC45400, WEX3	ENSG00000180964	Transcription elongation factor A like 8	X	103252995-103255203	Predicted intracellular proteins	Evidence at protein level	HPA059115	Uncertain		Approved	Nucleoplasm	Head and neck cancer:8.53e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 149.7	Mixed		
OR52E4		ENSG00000180974	Olfactory receptor family 52 subfamily E member 4	11	5884271-5885300	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
LRRC57	FLJ36812	ENSG00000180979	Leucine rich repeat containing 57	15	42537820-42548802	Predicted intracellular proteins	Evidence at protein level	HPA040894	Approved		Approved	Mitochondria<br>Cytosol	Renal cancer:2.15e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 14.9	Expressed in all		
OR52N2		ENSG00000180988	Olfactory receptor family 52 subfamily N member 2	11	5820314-5821348	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.8	Not detected		
MRPL14	MRP-L32, RPML32	ENSG00000180992	Mitochondrial ribosomal protein L14	6	44113454-44127457	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA038769, HPA076790	Uncertain		Supported	Mitochondria	Renal cancer:7.46e-5 (unfavourable), Thyroid cancer:1.08e-4 (favourable), Ovarian cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			lung: 85.6	Expressed in all		
GPR137C	DKFZp762F0713, TM7SF1L2	ENSG00000180998	G protein-coupled receptor 137C	14	52553148-52637713	Predicted membrane proteins	Evidence at transcript level	HPA003640, HPA030763	Uncertain		Approved	Vesicles		Mixed	Group enriched	6	cerebral cortex: 18.0;epididymis: 10.8;testis: 6.8	gallbladder: 2.1	Mixed		
C1orf105		ENSG00000180999	Chromosome 1 open reading frame 105	1	172420688-172468831	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	testis: 46.2	epididymis: 6.6	Cell line enriched	12	BEWO: 26.1
OR52N1		ENSG00000181001	Olfactory receptor family 52 subfamily N member 1	11	5787854-5788816	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA054028	Uncertain					Not detected	Not detected			adipose tissue: 0.1	Not detected		
BBS12	C4orf24, FLJ35630, FLJ41559	ENSG00000181004	Bardet-Biedl syndrome 12	4	122732702-122744943	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061856	Approved				Renal cancer:9.89e-6 (favourable), Endometrial cancer:5.69e-4 (favourable)	Mixed	Mixed			thyroid gland: 16.0	Mixed		
ZFP82	KIAA1948, MGC45380, ZNF545	ENSG00000181007	ZFP82 zinc finger protein	19	36383120-36418656	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA051669, HPA060470	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			thyroid gland: 8.8	Mixed		
OR52N5	OR52N5Q	ENSG00000181009	Olfactory receptor family 52 subfamily N member 5	11	5777634-5778667	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adipose tissue: 0.1	Not detected		
C17orf47	FLJ40121	ENSG00000181013	Chromosome 17 open reading frame 47	17	58541587-58544368	Predicted intracellular proteins	Evidence at protein level	HPA028424	Uncertain					Not detected	Tissue enriched	32	testis: 16.3	spleen: 0.5	Not detected		
LSMEM1	C7orf53, FLJ39575	ENSG00000181016	Leucine rich single-pass membrane protein 1	7	112480853-112491062	Predicted membrane proteins	Evidence at protein level	HPA013753, HPA047988	Uncertain		Supported	Cytosol		Mixed	Tissue enriched	11	skeletal muscle: 31.8	testis: 2.8	Cell line enhanced		HeLa: 4.9
NQO1	DHQU, DIA4, DTD, NMOR1, QR1	ENSG00000181019	NAD(P)H quinone dehydrogenase 1	16	69706996-69726951	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007308, CAB012421	Enhanced		Enhanced	Cytosol	Head and neck cancer:1.45e-4 (unfavourable)	Expressed in all	Tissue enhanced		breast: 379.3;stomach: 556.0	gallbladder: 320.2	Expressed in all		
OR56B1	OR56B1P	ENSG00000181023	Olfactory receptor family 56 subfamily B member 1	11	5736517-5737491	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045043	Uncertain					Not detected	Not detected			parathyroid gland: 0.3	Not detected		
AEN	FLJ12484, FLJ12562, ISG20L1	ENSG00000181026	Apoptosis enhancing nuclease	15	88621296-88632282	Predicted intracellular proteins	Evidence at protein level	HPA048599			Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Endometrial cancer:1.72e-4 (favourable)	Expressed in all	Mixed			gallbladder: 19.8	Expressed in all		
FKRP	LGMD2I, MDC1C	ENSG00000181027	Fukutin related protein	19	46746046-46776988	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043115, HPA060454	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Pancreatic cancer:8.98e-4 (favourable)	Expressed in all	Expressed in all			placenta: 14.9	Expressed in all		
TRAPPC5	MGC52424, TRS31	ENSG00000181029	Trafficking protein particle complex 5	19	7680843-7687703	Predicted intracellular proteins	Evidence at protein level	HPA042221, HPA049064	Uncertain		Approved	Vesicles		Mixed	Expressed in all			testis: 69.8	Expressed in all		
RPH3AL	Noc2	ENSG00000181031	Rabphilin 3A-like (without C2 domains)	17	212389-386254	Predicted intracellular proteins	Evidence at protein level	HPA024311	Approved				Renal cancer:1.03e-8 (favourable)	Mixed	Mixed			spleen: 11.8	Cell line enhanced		A549: 19.6
SLC25A42	MGC26694	ENSG00000181035	Solute carrier family 25 member 42	19	19063999-19112888	Predicted membrane proteins, Transporters	Evidence at protein level	HPA049449	Approved		Supported	Mitochondria	Lung cancer:4.11e-4 (favourable), Cervical cancer:5.04e-4 (favourable)	Expressed in all	Expressed in all			kidney: 28.8	Mixed		
FCRL6	FcRH6, FLJ16056, IFGP6	ENSG00000181036	Fc receptor like 6	1	159800511-159816251	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 18.4	lung: 8.9	Not detected		
METTL23	C17orf95, LOC124512	ENSG00000181038	Methyltransferase like 23	17	76726830-76733936	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.93e-7 (unfavourable), Liver cancer:4.18e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 86.1	Expressed in all		
SLC26A11		ENSG00000181045	Solute carrier family 26 member 11	17	80219699-80253500	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029893	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 34.4	Mixed		
HIGD1A	DKFZP564K247, HIG1, RCF1A	ENSG00000181061	HIG1 hypoxia inducible domain family member 1A	3	42784298-42804531	Predicted membrane proteins	Evidence at protein level	HPA043336	Approved		Supported	Nucleoplasm<br>Mitochondria	Renal cancer:3.99e-8 (favourable), Colorectal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			rectum: 328.9	Expressed in all		
CHRM2		ENSG00000181072	Cholinergic receptor muscarinic 2	7	136868669-137020255	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022338, HPA029795	Approved					Tissue enhanced	Tissue enhanced		gallbladder: 18.3;heart muscle: 25.8;smooth muscle: 13.7	urinary bladder: 5.9	Cell line enhanced		BJ: 14.1;BJ hTERT+: 15.2;fHDF/TERT166: 71.3;HHSteC: 10.8
OR52N4		ENSG00000181074	Olfactory receptor family 52 subfamily N member 4 (gene/pseudogene)	11	5754693-5755729	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			spleen: 2.4	Not detected		
MAPK15	ERK7, ERK8	ENSG00000181085	Mitogen-activated protein kinase 15	8	143716259-143722458	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA002704			Approved	Nucleoplasm<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 43.7	parathyroid gland: 13.2	Cell line enhanced		CAPAN-2: 6.9;HeLa: 10.4;MCF7: 11.8;T-47d: 12.5
EHMT1	bA188C12.1, Eu-HMTase1, FLJ12879, KIAA1876, KMT1D	ENSG00000181090	Euchromatic histone lysine methyltransferase 1	9	137618963-137870016	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA060022			Supported	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:6.56e-4 (favourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Expressed in all		
ADIPOQ	ACDC, ACRP30, adiponectin, AdipoQ, apM1, GBP28	ENSG00000181092	Adiponectin, C1Q and collagen domain containing	3	186842690-186858463	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB046467, HPA051767	Uncertain					Group enriched	Tissue enriched	17	adipose tissue: 937.7	breast: 56.0	Cell line enriched	475	ASC diff: 213.8
F2R	CF2R, PAR-1, PAR1, TR	ENSG00000181104	Coagulation factor II thrombin receptor	5	76716043-76735781	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB008973, CAB012962	Approved				Renal cancer:2.21e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 94.1	Cell line enhanced		HUVEC TERT2: 297.4;WM-115: 331.7
ZNF707		ENSG00000181135	Zinc finger protein 707	8	143684452-143713898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044991	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.79e-4 (unfavourable)	Expressed in all	Mixed			skin: 4.9	Mixed		
MUC16	CA125, FLJ14303	ENSG00000181143	Mucin 16, cell surface associated	19	8848844-8981342	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB055172, HPA065600	Enhanced					Tissue enhanced	Tissue enhanced		cervix, uterine: 24.0;fallopian tube: 9.4	endometrium: 3.5	Cell line enhanced		A-431: 20.2;CAPAN-2: 7.0;HaCaT: 6.8;HeLa: 26.2
NPM1	B23, NPM	ENSG00000181163	Nucleophosmin	5	171387116-171411137	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011384, CAB012983	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.89e-6 (unfavourable), Liver cancer:4.82e-6 (unfavourable), Head and neck cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1800.2	Expressed in all		
PJA1	FLJ11830, RNF70	ENSG00000181191	Praja ring finger ubiquitin ligase 1	X	69160851-69165793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000595	Enhanced		Approved	Nucleus<br>Nucleoli	Renal cancer:7.44e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 181.5	Cell line enhanced		HAP1: 88.6
DHTKD1	CMT2Q, DKFZP762M115, KIAA1630, MGC3090	ENSG00000181192	Dehydrogenase E1 and transketolase domain containing 1	10	12068972-12123225	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA037949, HPA037950, HPA066098	Approved		Supported	Mitochondria	Renal cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			liver: 66.5	Expressed in all		
PENK		ENSG00000181195	Proenkephalin	8	56436674-56446734	Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013138, CAB016390	Enhanced					Tissue enhanced	Group enriched	9	adrenal gland: 566.0;testis: 208.0	prostate: 41.3	Cell line enhanced		ASC diff: 10.8;ASC TERT1: 6.5;BJ: 7.7;THP-1: 5.8
C4orf50	FLJ46481	ENSG00000181215	Chromosome 4 open reading frame 50	4	5897373-6018507	Predicted intracellular proteins	Evidence at transcript level	HPA058292	Uncertain					Not detected	Not detected			cerebral cortex: 0.9	Not detected		
HIST3H2A	MGC3165	ENSG00000181218	Histone cluster 3 H2A	1	228456979-228457873	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported				Glioma:5.44e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 22.7	cerebral cortex: 10.6	Cell line enhanced		SCLC-21H: 58.3
ZNF746	FLJ31413, PARIS	ENSG00000181220	Zinc finger protein 746	7	149472794-149497817	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020272	Approved				Renal cancer:7.47e-6 (unfavourable), Liver cancer:2.32e-5 (unfavourable), Pancreatic cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
POLR2A	POLR2, POLRA, RPB1	ENSG00000181222	RNA polymerase II subunit A	17	7484366-7514616	Enzymes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	CAB012226, CAB016388, HPA021563, CAB022311, HPA053012	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 117.6	Expressed in all		
TMEM132C	DKFZp761O2018, PPP1R152	ENSG00000181234	Transmembrane protein 132C	12	128267403-128707915	Predicted membrane proteins	Evidence at protein level	HPA015633, HPA015984			Supported	Centrosome<br>Cytosol		Tissue enhanced	Tissue enhanced		adipose tissue: 34.8;cervix, uterine: 24.1	fallopian tube: 15.9	Group enriched	5	AF22: 3.7;ASC diff: 3.5;Daudi: 4.4
SLC25A41	APC4, FLJ40442, MGC34725	ENSG00000181240	Solute carrier family 25 member 41	19	6426037-6433779	Predicted intracellular proteins, Transporters	Evidence at transcript level	HPA043591	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.0;testis: 1.9	esophagus: 0.4	Cell line enhanced		HMC-1: 2.4;U-937: 1.3
TMEM136	MGC17839	ENSG00000181264	Transmembrane protein 136	11	120325129-120333682	Predicted membrane proteins	Evidence at transcript level	HPA074432			Approved	Vesicles<br>Cytosol	Endometrial cancer:6.65e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 12.6	Mixed		
OR5AK2		ENSG00000181273	Olfactory receptor family 5 subfamily AK member 2	11	56988872-56989867	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	68	spleen: 7.2	lung: 0.1	Not detected		
FRAT2		ENSG00000181274	FRAT2, WNT signaling pathway regulator	10	97332497-97334709	Predicted intracellular proteins	Evidence at transcript level	HPA049763	Uncertain		Approved	Nucleus<br>Mitochondria	Renal cancer:2.55e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 25.5	Mixed		
TMEM102	CBAP, FLJ36878	ENSG00000181284	Transmembrane protein 102	17	7435443-7437679	Predicted intracellular proteins	Evidence at protein level	HPA024433	Uncertain		Approved	Vesicles	Renal cancer:9.90e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 3.5	Mixed		
TMEM132E	DFNB99	ENSG00000181291	Transmembrane protein 132E	17	34580749-34639318	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA070608	Approved				Renal cancer:1.55e-4 (unfavourable)	Group enriched	Group enriched	5	cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.0;testis: 1.5	cervix, uterine: 0.4	Cell line enriched	7	RPMI-8226: 31.6
ZNF322	bA457M11.2, bA457M11.3, HCG12, ZNF322A, ZNF388, ZNF489	ENSG00000181315	Zinc finger protein 322	6	26634383-26659752	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043161, HPA046692	Approved		Supported	Nucleus<br>Centrosome<br>Cytosol	Glioma:1.75e-4 (favourable), Lung cancer:8.57e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 29.2	Mixed		
NME9	NM23-H9, TXL-2, TXNDC6	ENSG00000181322	NME/NM23 family member 9	3	138261437-138329886	Predicted intracellular proteins	Evidence at protein level	HPA040000, HPA043881	Enhanced					Mixed	Tissue enhanced		fallopian tube: 30.0	testis: 6.7	Mixed		
SPEM1	C17orf83, FLJ40081	ENSG00000181323	Spermatid maturation 1	17	7420360-7421632	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	321	testis: 32.0	all non-specific tissues: 0.0	Not detected		
HEPHL1	DKFZp686F22190	ENSG00000181333	Hephaestin like 1	11	94021361-94113751	Predicted membrane proteins	Evidence at protein level	HPA031517	Uncertain				Cervical cancer:4.94e-4 (unfavourable)	Tissue enriched	Group enriched	11	esophagus: 3.2;tonsil: 9.4	testis: 0.5	Cell line enhanced		HaCaT: 1.4;HBEC3-KT: 2.0
LRRC75A	C17orf76, FAM211A, FLJ35696	ENSG00000181350	Leucine rich repeat containing 75A	17	16441577-16492153	Predicted intracellular proteins	Evidence at protein level	HPA028528	Uncertain				Pancreatic cancer:7.46e-5 (favourable)	Mixed	Tissue enhanced		duodenum: 11.0	small intestine: 11.0	Cell line enhanced		HEL: 6.2
OFCC1	MRDS1	ENSG00000181355	Orofacial cleft 1 candidate 1	6	9596110-10211608	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035725, HPA050619	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 2.8	cervix, uterine,duodenum,placenta: 0.7	Cell line enhanced		CACO-2: 2.5;K-562: 4.4;SK-MEL-30: 2.7
OR5M8		ENSG00000181371	Olfactory receptor family 5 subfamily M member 8	11	56490435-56491370	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
CCL13	CKb10, MCP-4, MGC17134, NCC-1, SCYA13, SCYL1	ENSG00000181374	C-C motif chemokine ligand 13	17	34356452-34358610	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			lung: 31.6	Cell line enhanced		ASC diff: 1.2;BJ hTERT+: 1.3;BJ hTERT+ SV40 Large T+ RasG12V: 1.0;HMC-1: 1.1;HSkMC: 1.1
CFAP65	CCDC108, DKFZp434O0527, MGC35338	ENSG00000181378	Cilia and flagella associated protein 65	2	219002846-219041527	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA055156	Uncertain				Endometrial cancer:6.08e-5 (favourable)	Tissue enhanced	Group enriched	7	fallopian tube: 41.2;testis: 17.7	lung: 3.9	Cell line enhanced		SH-SY5Y: 1.0
DDX60L	FLJ31033	ENSG00000181381	DEAD-box helicase 60-like	4	168356735-168537786	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043211, HPA055501	Approved		Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:3.04e-5 (unfavourable), Renal cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 33.7	Mixed		
SYNE4	C19orf46, DFNB76, FLJ36445, Nesp4, Nesprin-4	ENSG00000181392	Spectrin repeat containing nuclear envelope family member 4	19	36003307-36008793	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060253	Uncertain				Renal cancer:8.64e-9 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 18.7	prostate: 11.8	Cell line enhanced		CACO-2: 27.6;Hep G2: 20.0;MCF7: 26.0;SK-BR-3: 30.3;T-47d: 29.1
OGFOD3	C17orf101, FLJ22222	ENSG00000181396	2-oxoglutarate and iron dependent oxygenase domain containing 3	17	82389223-82418637	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052099	Uncertain		Approved	Nucleoplasm	Renal cancer:5.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.4	Expressed in all		
WASHC1	FAM39E, FLJ00038, WASH1	ENSG00000181404	WASH complex subunit 1	9	14521-29739	Predicted intracellular proteins	Evidence at protein level	HPA002689	Uncertain		Supported	Vesicles		Expressed in all	Expressed in all			epididymis: 24.5	Expressed in all		
UTS2R	GPR14	ENSG00000181408	Urotensin 2 receptor	17	82374230-82375586	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		testis: 1.1;thyroid gland: 1.3	duodenum: 0.3	Cell line enhanced		Karpas-707: 5.1;SCLC-21H: 2.4;U-266/70: 13.2
AATK	AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77	ENSG00000181409	Apoptosis associated tyrosine kinase	17	81117295-81166077	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009073	Enhanced		Uncertain	Mitochondria		Mixed	Tissue enhanced		cerebral cortex: 36.4;duodenum: 23.4	small intestine: 18.3	Group enriched	5	CACO-2: 35.4;SH-SY5Y: 15.1
DDN	KIAA0749	ENSG00000181418	Dendrin	12	48995149-48999309	Predicted intracellular proteins	Evidence at protein level	HPA060952	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	10	cerebral cortex: 96.0;skeletal muscle: 46.6	kidney: 6.9	Cell line enhanced		HAP1: 12.6;RPMI-8226: 16.5;SCLC-21H: 14.1
SAGE1	CT14, SAGE	ENSG00000181433	Sarcoma antigen 1	X	135889205-135913061	Predicted intracellular proteins	Evidence at protein level	HPA003033, HPA003208	Enhanced		Enhanced	Nucleus		Mixed	Tissue enriched	58	testis: 8.9	cerebral cortex: 0.1	Group enriched	11	AN3-CA: 19.0;K-562: 13.8;Karpas-707: 18.3;U-2 OS: 7.4;U-266/70: 6.7;U-266/84: 16.5
ZNF467	EZI, Zfp467	ENSG00000181444	Zinc finger protein 467	7	149764182-149773479	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042907	Uncertain		Approved	Mitochondria	Pancreatic cancer:4.56e-4 (favourable)	Expressed in all	Mixed			spleen: 14.1	Cell line enhanced		AN3-CA: 30.3;HMC-1: 16.5;T-47d: 17.2
SOX2		ENSG00000181449	SRY-box 2	3	181711924-181714436	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010648, HPA045725, HPA071379	Approved	Supported	Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	8	cerebral cortex: 117.9	esophagus: 14.8	Cell line enhanced		AF22: 273.3;HAP1: 122.7;NTERA-2: 226.0
ZNF678	MGC42493	ENSG00000181450	Zinc finger protein 678	1	227563543-227677443	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA028507	Uncertain		Approved	Nucleoli<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			thyroid gland: 8.9	Expressed in all		
TMEM45A	DERP7, FLJ10134	ENSG00000181458	Transmembrane protein 45A	3	100492619-100577444	Predicted membrane proteins	Evidence at protein level	HPA062101	Uncertain		Approved	Endoplasmic reticulum<br>Vesicles	Renal cancer:6.18e-11 (unfavourable), Lung cancer:7.42e-4 (unfavourable)	Expressed in all	Tissue enriched	10	skin: 563.0	placenta: 58.7	Cell line enhanced		ASC diff: 279.1
RAP2B		ENSG00000181467	RAP2B, member of RAS oncogene family	3	153162270-153170620	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.65e-4 (unfavourable), Ovarian cancer:9.21e-4 (favourable)	Expressed in all	Mixed			placenta: 12.4	Mixed		
ZBTB2	bA351K16.2, KIAA1483, ZNF437	ENSG00000181472	Zinc finger and BTB domain containing 2	6	151364117-151391548	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023136, HPA023137, HPA023458, HPA023487	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:9.36e-6 (unfavourable), Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.0	Expressed in all		
RNF135	MGC13061	ENSG00000181481	Ring finger protein 135	17	30968785-30999911	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021576, HPA052404	Approved		Approved	Vesicles	Renal cancer:7.51e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.7	Mixed		
OR6T1		ENSG00000181499	Olfactory receptor family 6 subfamily T member 1	11	123942785-123943873	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060893	Uncertain					Not detected	Not detected			testis: 0.6	Not detected		
ACBD4	FLJ13322	ENSG00000181513	Acyl-CoA binding domain containing 4	17	45132600-45144181	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051772	Approved		Approved	Nucleus<br>Vesicles	Pancreatic cancer:4.64e-4 (favourable), Liver cancer:4.76e-4 (favourable), Urothelial cancer:6.53e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 30.3	Mixed		
OR8D4		ENSG00000181518	Olfactory receptor family 8 subfamily D member 4	11	123906146-123907476	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SGSH	HSS, MPS3A, SFMD	ENSG00000181523	N-sulfoglucosamine sulfohydrolase	17	80206716-80220923	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023436, HPA023451	Enhanced				Renal cancer:2.66e-4 (unfavourable), Lung cancer:2.72e-4 (favourable), Pancreatic cancer:3.10e-4 (favourable), Testis cancer:5.37e-4 (unfavourable), Liver cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 36.3	Mixed		
MAB21L2		ENSG00000181541	Mab-21 like 2	4	150581922-150584693	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049324, HPA059864			Enhanced	Nucleus<br>Cytosol		Tissue enhanced	Tissue enhanced		colon: 18.3;smooth muscle: 26.2	small intestine: 12.4	Group enriched	20	HHSteC: 4.9;SH-SY5Y: 16.0
FANCB	FAAP95, FAB, FLJ34064	ENSG00000181544	Fanconi anemia complementation group B	X	14843407-14873069	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003124	Uncertain					Mixed	Mixed			bone marrow: 2.4	Mixed		
EDDM3B	FAM12B, HE3-BETA	ENSG00000181552	Epididymal protein 3B	14	20768427-20770948	Predicted secreted proteins	Evidence at protein level	HPA001323	Supported					Not detected	Tissue enriched	234	epididymis: 3239.8	seminal vesicle: 13.8	Cell line enhanced		BEWO: 1.3;NB-4: 1.7
SETD2	FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A	ENSG00000181555	SET domain containing 2	3	47016429-47163967	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042451	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.8	Expressed in all		
EDDM3A	FAM12A, HE3-ALPHA	ENSG00000181562	Epididymal protein 3A	14	20745892-20748380	Predicted secreted proteins	Evidence at protein level	HPA049952	Approved					Not detected	Tissue enriched	15	epididymis: 780.6	seminal vesicle: 50.6	Not detected		
C6orf223	MGC45491	ENSG00000181577	Chromosome 6 open reading frame 223	6	44000580-44005958	Predicted intracellular proteins	Evidence at transcript level	HPA035765, HPA046117	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:9.38e-5 (unfavourable), Liver cancer:4.59e-4 (unfavourable)	Mixed	Group enriched	10	breast: 22.7;lung: 5.6	duodenum: 1.3	Cell line enhanced		A-431: 21.4;RPTEC TERT1: 25.1;THP-1: 9.6
TMIE	DFNB6	ENSG00000181585	Transmembrane inner ear	3	46701333-46710886	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038298	Uncertain		Uncertain	Vesicles<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 7.4;cerebral cortex: 5.2	testis: 1.6	Cell line enhanced		CAPAN-2: 2.2;EFO-21: 2.1;SH-SY5Y: 2.3
MEX3D	KIAA2031, OK/SW-cl.4, RKHD1, RNF193, Tino	ENSG00000181588	Mex-3 RNA binding family member D	19	1554669-1568058	Predicted intracellular proteins	Evidence at protein level	HPA065385	Approved					Expressed in all	Mixed			testis: 17.7	Expressed in all		
OR52D1		ENSG00000181609	Olfactory receptor family 52 subfamily D member 1	11	5488685-5489749	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046965	Uncertain					Not detected	Tissue enriched	13	testis: 1.2	all non-specific tissues: 0.0	Not detected		
MRPS23	CGI-138, HSPC329, MRP-S23	ENSG00000181610	Mitochondrial ribosomal protein S23	17	57834781-57850056	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023453	Supported		Supported	Nuclear membrane<br>Mitochondria	Liver cancer:9.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 61.5	Expressed in all		
OR52H1		ENSG00000181616	Olfactory receptor family 52 subfamily H member 1	11	5544561-5545523	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FDCSP	C4orf7, FDC-SP	ENSG00000181617	Follicular dendritic cell secreted protein	4	70226071-70235252	Predicted secreted proteins	Evidence at protein level	HPA014326, CAB014890	Enhanced				Lung cancer:1.32e-4 (favourable), Head and neck cancer:2.38e-4 (favourable)	Tissue enhanced	Tissue enhanced		lymph node: 1014.2;salivary gland: 1371.2;tonsil: 2458.1	appendix: 359.2	Cell line enhanced		HL-60: 1.0;K-562: 1.0;RH-30: 1.7;U-87 MG: 4.6
GPR135	HUMNPIIY20, PAFR	ENSG00000181619	G protein-coupled receptor 135	14	59429022-59465342	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045337	Uncertain					Mixed	Tissue enhanced		testis: 9.1	fallopian tube,parathyroid gland: 5.0	Mixed		
SLX1B	GIYD2, MGC5178	ENSG00000181625	SLX1 homolog B, structure-specific endonuclease subunit	16	29454501-29458219	Predicted intracellular proteins	Evidence at protein level	HPA047038	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			small intestine: 29.4	Expressed in all		
ANKRD62	DKFZp779B1634	ENSG00000181626	Ankyrin repeat domain 62	18	12093853-12129749	Predicted intracellular proteins	Evidence at protein level	HPA059835	Enhanced					Not detected	Tissue enriched	11	testis: 4.1	pancreas: 0.3	Not detected		
P2RY13	FKSG77, GPR86, GPR94, P2Y13	ENSG00000181631	Purinergic receptor P2Y13	3	151326312-151329548	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA049047	Enhanced					Expressed in all	Tissue enhanced		spleen: 51.2	appendix: 27.9	Not detected		
TNFSF15	MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A	ENSG00000181634	Tumor necrosis factor superfamily member 15	9	114784635-114806126	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012948, HPA046522	Approved		Approved	Nucleus<br>Nuclear membrane<br>Cytosol		Mixed	Mixed			duodenum: 9.5	Cell line enhanced		HaCaT: 11.6;hTEC/SVTERT24-B: 8.5;HUVEC TERT2: 13.6;RT4: 12.9;TIME: 6.2
ZFP41	FLJ00028, FLJ38705, ZNF753	ENSG00000181638	ZFP41 zinc finger protein	8	143246821-143262705	Predicted intracellular proteins	Evidence at transcript level	HPA047232, HPA056268	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Plasma membrane	Liver cancer:3.46e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Mixed		
PHLDA2	BWR1C, HLDA2, IPL, TSSC3	ENSG00000181649	Pleckstrin homology like domain family A member 2	11	2928273-2929455	Predicted intracellular proteins	Evidence at protein level	HPA003994			Uncertain	Nucleoli	Renal cancer:2.63e-6 (unfavourable), Liver cancer:4.22e-5 (unfavourable)	Expressed in all	Tissue enriched	8	placenta: 54.3	stomach: 6.6	Cell line enhanced		HDLM-2: 185.5;PC-3: 149.3;SK-MEL-30: 101.3;WM-115: 170.7
ATG9B	APG9L2, FLJ14885, NOS3AS, SONE	ENSG00000181652	Autophagy related 9B	7	151012209-151024499	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		esophagus: 9.2;placenta: 5.8;skin: 13.5	testis: 3.8	Cell line enhanced		BEWO: 12.5;CAPAN-2: 3.7
GPR88		ENSG00000181656	G protein-coupled receptor 88	1	100538137-100542018	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at transcript level	HPA007488		Approved				Tissue enriched	Group enriched	11	breast: 9.4;cerebral cortex: 3.1;liver: 4.9;ovary: 3.1;parathyroid gland: 4.9;spleen: 14.4	prostate: 0.6	Group enriched	8	HSkMC: 1.1;SCLC-21H: 2.3
HKR1	ZNF875	ENSG00000181666	HKR1, GLI-Kruppel zinc finger family member	19	37312837-37369365	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036126, HPA044855	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Mitochondria	Prostate cancer:5.18e-5 (unfavourable), Pancreatic cancer:4.41e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 54.6	Expressed in all		
PLAG1	ZNF912	ENSG00000181690	PLAG1 zinc finger	8	56160904-56211324	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072290			Supported	Nuclear speckles		Mixed	Mixed			ovary: 5.9	Mixed		
OR8H1		ENSG00000181693	Olfactory receptor family 8 subfamily H member 1	11	56290053-56291090	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5T1	OR5T1P	ENSG00000181698	Olfactory receptor family 5 subfamily T member 1	11	56275639-56276619	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA050952	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
YIPF6	FinGER6, MGC21416	ENSG00000181704	Yip1 domain family member 6	X	68498323-68537285	Predicted membrane proteins	Evidence at protein level	HPA003720	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			thyroid gland: 32.8	Mixed		
OR5T2		ENSG00000181718	Olfactory receptor family 5 subfamily T member 2	11	56232106-56233185	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZBTB20	DKFZp566F123, DPZF, ODA-8S, ZNF288	ENSG00000181722	Zinc finger and BTB domain containing 20	3	114314501-115147271	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015551, HPA016815	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Tissue enhanced	Mixed			testis: 17.4	Mixed		
OR2Z1	OR2Z2	ENSG00000181733	Olfactory receptor family 2 subfamily Z member 1	19	8730954-8732009	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA048760	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C3orf58	DIA1, HASF, MGC33365	ENSG00000181744	Chromosome 3 open reading frame 58	3	143971798-144048719	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048992	Approved				Renal cancer:2.92e-7 (unfavourable)	Expressed in all	Mixed			placenta: 53.9	Cell line enhanced		AN3-CA: 136.9
C5orf30	FLJ25291	ENSG00000181751	Chromosome 5 open reading frame 30	5	103258702-103278660	Predicted intracellular proteins	Evidence at protein level	HPA043434	Uncertain				Liver cancer:1.78e-5 (unfavourable), Endometrial cancer:2.66e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 31.4	Cell line enhanced		BJ: 149.2;U-138 MG: 113.8
OR8K5		ENSG00000181752	Olfactory receptor family 8 subfamily K member 5	11	56159394-56160317	G-protein coupled receptors, Predicted membrane proteins	No evidence							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
AMIGO1	AMIGO, KIAA1163	ENSG00000181754	Adhesion molecule with Ig like domain 1	1	109504175-109509738	Predicted membrane proteins	Evidence at protein level	HPA046152	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 24.6	Cell line enhanced		SCLC-21H: 9.8
OR8H3		ENSG00000181761	Olfactory receptor family 8 subfamily H member 3	11	56122373-56123311	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR8H2		ENSG00000181767	Olfactory receptor family 8 subfamily H member 2	11	56105018-56106055	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPR3	ACCA	ENSG00000181773	G protein-coupled receptor 3	1	27392644-27395814	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB006254	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 5.2	thyroid gland: 1.3	Cell line enhanced		U-2197: 21.6
TMEM252	C9orf71, MGC34760	ENSG00000181778	Transmembrane protein 252	9	68536580-68540867	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.75e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 37.5;small intestine: 25.7	esophagus: 6.8	Cell line enhanced		PC-3: 1.1;RPTEC TERT1: 1.8;SK-BR-3: 1.0
ODF3L2	C19orf19, FLJ40059	ENSG00000181781	Outer dense fiber of sperm tails 3 like 2	19	463346-474983	Predicted intracellular proteins	Evidence at protein level	HPA067973	Uncertain					Not detected	Group enriched	10	skeletal muscle: 2.7;testis: 7.6	spleen: 0.5	Not detected		
OR5AS1		ENSG00000181785	Olfactory receptor family 5 subfamily AS member 1	11	56030419-56031393	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ACTL9	MGC33407	ENSG00000181786	Actin like 9	19	8697397-8698822	Predicted intracellular proteins	Evidence at protein level	HPA019231, HPA026693	Uncertain					Not detected	Tissue enriched	501	testis: 50.0	all non-specific tissues: 0.0	Not detected		
SIAH2		ENSG00000181788	Siah E3 ubiquitin protein ligase 2	3	150741127-150763477	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA061293, CAB069930	Approved		Supported	Nucleoplasm<br>Vesicles	Pancreatic cancer:8.21e-5 (unfavourable), Breast cancer:1.17e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 95.3	Expressed in all		
COPG1	COPG	ENSG00000181789	Coatomer protein complex subunit gamma 1	3	129249606-129277773	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037866, HPA037867, HPA045712	Supported		Supported	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:1.22e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 191.9	Expressed in all		
ADGRB1	BAI1	ENSG00000181790	Adhesion G protein-coupled receptor B1	8	142449430-142545009	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	10	cerebral cortex: 22.0	spleen: 2.2	Cell line enhanced		AN3-CA: 10.7;RPMI-8226: 12.0;U-2 OS: 11.7
OR6S1	OR6S1Q	ENSG00000181803	Olfactory receptor family 6 subfamily S member 1	14	20640696-20641691	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SLC9A9	FLJ35613, NHE9	ENSG00000181804	Solute carrier family 9 member A9	3	143265222-143848531	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA058234	Approved				Renal cancer:5.57e-7 (unfavourable), Lung cancer:8.18e-4 (favourable)	Expressed in all	Mixed			placenta: 22.3	Cell line enhanced		ASC TERT1: 17.2;Karpas-707: 44.4;RPMI-8226: 20.5;U-266/70: 21.8
LSM10	MGC15749	ENSG00000181817	LSM10, U7 small nuclear RNA associated	1	36391238-36397892	Predicted intracellular proteins	Evidence at protein level	HPA048469			Supported	Nucleus<br>Nuclear bodies	Renal cancer:6.40e-6 (unfavourable), Liver cancer:1.83e-4 (unfavourable), Pancreatic cancer:4.89e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 60.3	Expressed in all		
RELL1		ENSG00000181826	RELT like 1	4	37590800-37686376	Predicted membrane proteins	Evidence at protein level	HPA013377	Approved		Supported	Plasma membrane<br>Microtubules		Expressed in all	Mixed			thyroid gland: 27.7	Cell line enhanced		RH-30: 57.4
RFX7	FLJ12994, RFXDC2	ENSG00000181827	Regulatory factor X7	15	56087280-56243266	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035462	Supported		Approved	Nucleus<br>Nuclear membrane	Renal cancer:1.12e-5 (unfavourable)	Expressed in all	Mixed			testis: 8.2	Expressed in all		
SLC35C1	FLJ11320, FUCT1	ENSG00000181830	Solute carrier family 35 member C1	11	45804072-45813015	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064001	Enhanced		Supported	Golgi apparatus	Thyroid cancer:3.64e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 29.4	Expressed in all		
TIGIT	DKFZp667A205, FLJ39873, VSIG9, VSTM3	ENSG00000181847	T-cell immunoreceptor with Ig and ITIM domains	3	114276913-114310288	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.96e-4 (favourable), Cervical cancer:5.43e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 44.3	spleen: 20.5	Cell line enhanced		HDLM-2: 1.2
RNF41	NRDP1, SBBI03	ENSG00000181852	Ring finger protein 41	12	56202175-56221933	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016812	Approved		Approved	Nucleus<br>Nuclear bodies<br>Midbody ring	Renal cancer:2.52e-5 (favourable), Liver cancer:6.49e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 55.3	Expressed in all		
SLC2A4	GLUT4	ENSG00000181856	Solute carrier family 2 member 4	17	7281667-7288257	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016544	Enhanced					Mixed	Tissue enhanced		heart muscle: 32.6;skeletal muscle: 45.0	adipose tissue: 21.8	Cell line enhanced		Hep G2: 3.7
FTMT	MtF	ENSG00000181867	Ferritin mitochondrial	5	121851955-121852833	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	471	testis: 47.1	all non-specific tissues: 0.0	Not detected		
IBA57	C1orf69, FLJ12734	ENSG00000181873	IBA57 homolog, iron-sulfur cluster assembly	1	228165815-228182257	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030555, HPA030556, HPA030557	Approved		Supported	Mitochondria	Renal cancer:1.71e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.1	Mixed		
CLDN7	CEPTRL2, CPETRL2, Hs.84359	ENSG00000181885	Claudin 7	17	7259903-7263983	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB013063, HPA014703, HPA073662	Enhanced		Approved	Vesicles<br>Cell Junctions	Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable)	Expressed in all	Mixed			small intestine: 350.1	Cell line enhanced		BEWO: 162.4;CAPAN-2: 304.6;HaCaT: 644.4;MCF7: 198.9;SK-BR-3: 225.1
ZNF329	FLJ12586	ENSG00000181894	Zinc finger protein 329	19	58126252-58155110	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044373	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:8.58e-9 (favourable)	Expressed in all	Mixed			parathyroid gland: 16.9	Mixed		
ZNF101	DKFZp570I0164, HZF12	ENSG00000181896	Zinc finger protein 101	19	19668796-19683509	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023449, HPA055486	Uncertain				Cervical cancer:5.76e-5 (favourable), Stomach cancer:1.11e-4 (favourable), Head and neck cancer:2.15e-4 (favourable), Ovarian cancer:2.26e-4 (favourable), Urothelial cancer:4.37e-4 (favourable), Lung cancer:6.65e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 31.4	tonsil: 22.3	Expressed in all		
OR4C6		ENSG00000181903	Olfactory receptor family 4 subfamily C member 6	11	55665167-55666096	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node,tonsil: 0.1	Group enriched	7	CAPAN-2: 3.3;Karpas-707: 2.9
C5orf24	FLJ37562	ENSG00000181904	Chromosome 5 open reading frame 24	5	134845680-134859737	Predicted intracellular proteins	Evidence at protein level	HPA057749, HPA062502	Uncertain		Supported	Nucleus	Renal cancer:5.86e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.8	Expressed in all		
ADO	C10orf22, FLJ14547	ENSG00000181915	2-aminoethanethiol dioxygenase	10	62804857-62808483	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039194, HPA040437	Approved				Liver cancer:8.01e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 70.7	Expressed in all		
COA4	CHCHD8, CMC3, E2IG2	ENSG00000181924	Cytochrome c oxidase assembly factor 4 homolog	11	73872667-73876988	Predicted intracellular proteins	Evidence at protein level	HPA040126	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Mitochondria	Renal cancer:2.14e-4 (unfavourable), Ovarian cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 81.4	Expressed in all		
OR4P4	OR4P3P	ENSG00000181927	Olfactory receptor family 4 subfamily P member 4	11	55638358-55639296	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA059458	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRKAG1		ENSG00000181929	Protein kinase AMP-activated non-catalytic subunit gamma 1	12	49002274-49019197	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA077805			Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:2.84e-7 (unfavourable), Renal cancer:1.83e-4 (favourable)	Expressed in all	Expressed in all			breast: 56.9	Expressed in all		
GINS3	FLJ13912, PSF3	ENSG00000181938	GINS complex subunit 3	16	58295080-58406144	Predicted intracellular proteins	Evidence at protein level	HPA041216, HPA048209	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			testis: 10.5	Expressed in all		
OR4C15		ENSG00000181939	Olfactory receptor family 4 subfamily C member 15	11	55554307-55555419	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA061939	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4A15		ENSG00000181958	Olfactory receptor family 4 subfamily A member 15	11	55367884-55368918	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4A16	OR4A16Q	ENSG00000181961	Olfactory receptor family 4 subfamily A member 16	11	55343201-55344187	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
OR52K2		ENSG00000181963	Olfactory receptor family 52 subfamily K member 2	11	4449295-4450361	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
NEUROG1	AKA, bHLHa6, Math4C, NEUROD3, ngn1	ENSG00000181965	Neurogenin 1	5	135534282-135535949	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
CCDC149	DKFZp761B107	ENSG00000181982	Coiled-coil domain containing 149	4	24806117-24980204	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044158, HPA047913	Uncertain		Approved	Nucleoli	Endometrial cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.1	Cell line enhanced		U-87 MG: 30.1
MRPS11	FLJ22512, FLJ23406, HCC-2	ENSG00000181991	Mitochondrial ribosomal protein S11	15	88467453-88480773	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043752, HPA050345	Enhanced		Supported	Mitochondria	Cervical cancer:3.60e-4 (favourable), Ovarian cancer:4.75e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 13.6	Expressed in all		
SNRPE	Sm-E	ENSG00000182004	Small nuclear ribonucleoprotein polypeptide E	1	203861603-203870550	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.38e-5 (unfavourable), Ovarian cancer:3.95e-4 (favourable)	Expressed in all	Expressed in all			breast: 97.4	Expressed in all		
RTKN2	bA531F24.1, Em:AC024597.2, FLJ39352, PLEKHK1	ENSG00000182010	Rhotekin 2	10	62183035-62268707	Predicted intracellular proteins	Evidence at protein level	HPA037946, HPA038446	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enriched	8	lung: 121.3	testis: 14.7	Cell line enhanced		A-431: 40.4
PNMAL1	FLJ10781, KIAA1183L	ENSG00000182013	Paraneoplastic Ma antigen family like 1	19	46466491-46471563	Predicted intracellular proteins	Evidence at protein level	HPA012956	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 133.9	testis: 42.5	Cell line enhanced		HAP1: 33.8;K-562: 32.4;LHCN-M2: 29.9;SH-SY5Y: 33.2
CHST15	BRAG, GALNAC4S-6ST, KIAA0598	ENSG00000182022	Carbohydrate sulfotransferase 15	10	124007666-124093607	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017584	Approved		Approved	Centrosome<br>Cytosol	Renal cancer:2.22e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.6	Cell line enhanced		REH: 82.5
ADIG	MGC39724, RP5-1100H13.2, SMAF1	ENSG00000182035	Adipogenin	20	38581195-38588463	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA041124	Uncertain					Tissue enhanced	Group enriched	10	epididymis: 5.1;testis: 16.1;thyroid gland: 3.4	seminal vesicle: 0.8	Not detected		
USH1G	ANKS4A, FLJ33924, Sans	ENSG00000182040	USH1 protein network component sans	17	74916084-74923256	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA024360	Uncertain					Tissue enhanced	Tissue enhanced		epididymis: 2.3;esophagus: 2.6;skin: 1.8	testis: 1.4	Cell line enhanced		HaCaT: 1.6;hTCEpi: 1.2;K-562: 1.2;MCF7: 1.5;U-2 OS: 1.0
MGAT4C	HGNT-IV-H	ENSG00000182050	MGAT4 family member C	12	85955666-86838904	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA016418	Approved					Tissue enriched	Group enriched	5	cerebral cortex: 5.9;epididymis: 6.7;testis: 5.5;thyroid gland: 15.9	adrenal gland: 1.6	Group enriched	13	NTERA-2: 8.7;SCLC-21H: 4.4
TRIM49B		ENSG00000182053	Tripartite motif containing 49B	11	49027501-49038451	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
IDH2		ENSG00000182054	Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial	15	90083045-90102504	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007831	Enhanced		Supported	Mitochondria	Cervical cancer:5.15e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 450.0	Expressed in all		
OR52A1	HPFH1OR	ENSG00000182070	Olfactory receptor family 52 subfamily A member 1	11	5151009-5186382	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PTCHD3	FLJ44037, PTR	ENSG00000182077	Patched domain containing 3	10	27398187-27414368	Predicted membrane proteins	Evidence at protein level	HPA044613	Enhanced					Not detected	Tissue enriched	9	testis: 4.1	adipose tissue: 0.4	Not detected		
OR6B2	OR6B2P	ENSG00000182083	Olfactory receptor family 6 subfamily B member 2	2	240028965-240030456	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047529	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
TMEM259	ASBABP1, C19orf6, MBRL, MGC4022	ENSG00000182087	Transmembrane protein 259	19	1009648-1021179	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042669, HPA054801	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable)	Expressed in all	Expressed in all			spleen: 129.7	Expressed in all		
WRB	CHD5, GET1	ENSG00000182093	Tryptophan rich basic protein	21	39380244-39428528	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018527	Approved					Expressed in all	Expressed in all			fallopian tube: 109.1	Expressed in all		
TNRC18	CAGL79, KIAA1856, TNRC18A	ENSG00000182095	Trinucleotide repeat containing 18	7	5306790-5425414	Predicted intracellular proteins	Evidence at protein level	HPA020730, HPA024251	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 86.4	Expressed in all		
FAM181B	LOC220382, MGC33846	ENSG00000182103	Family with sequence similarity 181 member B	11	82729941-82733864	Predicted intracellular proteins	Evidence at transcript level	HPA066861	Approved		Approved	Nuclear membrane<br>Mitochondria	Endometrial cancer:8.07e-4 (favourable)	Tissue enriched	Tissue enriched	20	cerebral cortex: 17.5	adrenal gland,fallopian tube: 0.8	Cell line enhanced		RT4: 1.9;SH-SY5Y: 1.3;U-2 OS: 1.3
TMEM30B	CDC50B	ENSG00000182107	Transmembrane protein 30B	14	61277370-61281840	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043162	Uncertain				Renal cancer:5.89e-5 (favourable)	Mixed	Mixed			parathyroid gland: 82.1	Cell line enhanced		A-431: 53.2;CAPAN-2: 42.5;MCF7: 29.9;RT4: 66.7
DEXI	MYLE	ENSG00000182108	Dexi homolog	16	10928891-10942460	Predicted membrane proteins	Evidence at transcript level	HPA041511	Approved		Approved	Nuclear speckles<br>Cytosol	Pancreatic cancer:4.23e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 45.0	Expressed in all		
ZNF716	FLJ46189	ENSG00000182111	Zinc finger protein 716	7	57450177-57473546	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.9	Not detected		
NOP10	MGC70651, NOLA3, NOP10P	ENSG00000182117	NOP10 ribonucleoprotein	15	34341713-34343177	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059198	Supported		Supported	Nuclear bodies	Endometrial cancer:1.48e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 289.4	Expressed in all		
FAM89A	C1orf153, MGC15887	ENSG00000182118	Family with sequence similarity 89 member A	1	231018958-231040246	Predicted intracellular proteins	Evidence at protein level	HPA059052, HPA059578	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.75e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 98.7	Cell line enhanced		BEWO: 141.2
KCNIP1	KCHIP1	ENSG00000182132	Potassium voltage-gated channel interacting protein 1	5	170353487-170736632	Predicted intracellular proteins	Evidence at protein level	HPA022864	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 40.4;epididymis: 26.3	seminal vesicle: 7.9	Cell line enriched	17	RPTEC TERT1: 43.9
TDRKH	TDRD2	ENSG00000182134	Tudor and KH domain containing	1	151770107-151791416	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016419, HPA019625	Approved		Approved	Centrosome<br>Cytosol	Endometrial cancer:1.66e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 76.8;testis: 40.1	cerebral cortex: 13.0	Mixed		
ZNF708	KOX8, ZNF15, ZNF15L1	ENSG00000182141	Zinc finger protein 708	19	21291160-21329425	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Ovarian cancer:3.53e-4 (favourable), Glioma:6.32e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 17.7	Mixed		
IST1	KIAA0174	ENSG00000182149	IST1, ESCRT-III associated factor	16	71845996-71931199	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041802, HPA054532	Approved		Supported	Vesicles	Renal cancer:4.55e-4 (favourable), Urothelial cancer:8.88e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 180.4	Expressed in all		
ERCC6L2	C9orf102, FLJ37706, RAD26L	ENSG00000182150	ERCC excision repair 6 like 2	9	95875701-96014571	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021260	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:8.70e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
MRPL41	BMRP, MRP-L27, MRPL27, PIG3, RPML27	ENSG00000182154	Mitochondrial ribosomal protein L41	9	137551199-137552555	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA024550, HPA027160	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			skeletal muscle: 59.8	Expressed in all		
ENPP7	alk-SMase, NPP7	ENSG00000182156	Ectonucleotide pyrophosphatase/phosphodiesterase 7	17	79730919-79742222	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024603	Approved					Tissue enriched	Group enriched	22	duodenum: 45.7;small intestine: 110.2	kidney: 3.5	Cell line enhanced		Karpas-707: 1.4;U-266/70: 2.1
CREB3L2	BBF2H7, TCAG_1951439	ENSG00000182158	CAMP responsive element binding protein 3 like 2	7	137874979-138002067	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA015068, HPA015534	Uncertain		Supported	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 110.9	Mixed		
P2RY8	P2Y8	ENSG00000182162	Purinergic receptor P2Y8	X	1462572-1537107	Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003631	Enhanced				Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 47.6	tonsil: 31.3	Cell line enhanced		Daudi: 87.1;U-266/70: 75.0;U-698: 136.4
UNC5C		ENSG00000182168	Unc-5 netrin receptor C	4	95162504-95549206	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		thyroid gland: 20.0	adrenal gland: 11.6	Group enriched	6	AF22: 17.6;SH-SY5Y: 82.9
MRGPRG	GPR169, mrgG	ENSG00000182170	MAS related GPR family member G	11	3217944-3218813	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA058909	Uncertain					Not detected	Tissue enriched	15	testis: 1.5	all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 1.0
TSEN54	SEN54, SEN54L	ENSG00000182173	TRNA splicing endonuclease subunit 54	17	75516060-75524739	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA053097	Uncertain				Liver cancer:8.06e-6 (unfavourable), Pancreatic cancer:2.62e-5 (favourable), Stomach cancer:7.78e-5 (favourable), Urothelial cancer:8.54e-4 (favourable)	Expressed in all	Expressed in all			skin: 20.4	Expressed in all		
RGMA	RGM, RGMa	ENSG00000182175	Repulsive guidance molecule family member a	15	93035273-93089204	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012343, HPA039880, HPA044222	Approved		Supported	Nucleoplasm<br>Cytosol	Lung cancer:2.78e-4 (favourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 116.6;smooth muscle: 84.8	skeletal muscle: 42.6	Cell line enhanced		AF22: 49.7;NTERA-2: 22.5
ASB18		ENSG00000182177	Ankyrin repeat and SOCS box containing 18	2	236194872-236264409	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068447	Approved					Not detected	Group enriched	8	heart muscle: 4.3;skeletal muscle: 3.6;testis: 1.0	cerebral cortex: 0.4	Not detected		
UBA7	D8, UBA1B, UBE1L, UBE2	ENSG00000182179	Ubiquitin like modifier activating enzyme 7	3	49805207-49813946	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015444, HPA058182	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:1.48e-4 (favourable), Breast cancer:1.55e-4 (favourable)	Expressed in all	Expressed in all			spleen: 65.5	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 55.3;HMC-1: 91.3
MRPS16	CGI-132	ENSG00000182180	Mitochondrial ribosomal protein S16	10	73248843-73252693	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050081, HPA054538	Supported		Supported	Mitochondria<br>Cytosol	Liver cancer:4.57e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.4	Expressed in all		
FAM159A	MGC52498	ENSG00000182183	Family with sequence similarity 159 member A	1	52633344-52669683	Predicted membrane proteins	Evidence at transcript level	HPA030744	Uncertain					Mixed	Tissue enhanced		lymph node: 8.8;tonsil: 6.6	spleen: 4.5	Cell line enhanced		Daudi: 3.8;Karpas-707: 9.0;RPMI-8226: 11.8
RAD51B	hREC2, R51H2, RAD51L1, REC2	ENSG00000182185	RAD51 paralog B	14	67819779-68730218	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB016191, HPA051869	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			epididymis: 11.0	Expressed in all		
CRYGB	CRYG2	ENSG00000182187	Crystallin gamma B	2	208142573-208146168	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Not detected			testis: 0.5	Not detected		
LDOC1	BCUR1, Mar7, Mart7	ENSG00000182195	LDOC1, regulator of NFKB signaling	X	141175745-141177125	Predicted intracellular proteins	Evidence at protein level	HPA051768, HPA061842	Approved		Supported	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 73.0	Cell line enhanced		MCF7: 106.5;PC-3: 156.8
ARL6IP4	SFRS20, SR-25, SRp25, SRrp37	ENSG00000182196	ADP ribosylation factor like GTPase 6 interacting protein 4	12	122980060-122982913	Predicted intracellular proteins	Evidence at protein level	HPA052098	Approved				Urothelial cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 186.0	Expressed in all		
EXT1	LGCR, LGS, ttv	ENSG00000182197	Exostosin glycosyltransferase 1	8	117794490-118111853	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044394	Uncertain				Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 31.6	Cell line enhanced		BJ hTERT+: 193.5;fHDF/TERT166: 189.8
SHMT2	SHMT	ENSG00000182199	Serine hydroxymethyltransferase 2	12	57229327-57234935	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020543, HPA020549	Enhanced		Enhanced	Microtubules<br>Mitochondria	Renal cancer:4.84e-8 (unfavourable), Breast cancer:8.37e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 74.8	Expressed in all		
MOB2	HCCA2	ENSG00000182208	MOB kinase activator 2	11	1469457-1501247	Predicted intracellular proteins	Evidence at protein level	HPA046313	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:2.02e-4 (favourable), Glioma:7.86e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 70.7	Expressed in all		
HHIPL1	KIAA1822	ENSG00000182218	HHIP like 1	14	99645110-99680569	Predicted secreted proteins	Evidence at transcript level	HPA052767	Approved					Mixed	Tissue enhanced		cerebral cortex: 6.6	smooth muscle: 2.6	Cell line enhanced		EFO-21: 2.9;fHDF/TERT166: 4.3;SiHa: 3.9;THP-1: 2.6
ATP6AP2	APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR	ENSG00000182220	ATPase H+ transporting accessory protein 2	X	40579372-40606848	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA003156	Approved				Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 893.4	Expressed in all		
ZAR1	Z3CXXC6	ENSG00000182223	Zygote arrest 1	4	48490252-48494389	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 1.1	bone marrow: 0.2	Not detected		
CYB5D1	FLJ32499	ENSG00000182224	Cytochrome b5 domain containing 1	17	7857746-7862282	Predicted intracellular proteins	Evidence at protein level	HPA021632	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Expressed in all			fallopian tube: 41.9	Expressed in all		
FAM153B		ENSG00000182230	Family with sequence similarity 153 member B	5	176060689-176132258	Predicted intracellular proteins	Evidence at transcript level	HPA042585, HPA044022, HPA046691, HPA052337, HPA055498	Uncertain					Not detected	Tissue enhanced		ovary: 8.4;testis: 15.4	cerebral cortex: 4.1	Cell line enriched	6	U-2 OS: 1.1
BACE2	AEPLC, ALP56, CEAP1, DRAP	ENSG00000182240	Beta-site APP-cleaving enzyme 2	21	41167801-41282518	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035416	Approved				Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable)	Expressed in all	Mixed			stomach: 30.5	Cell line enhanced		SK-BR-3: 43.8;WM-115: 41.2
UBE2E2	FLJ25157, UbcH8	ENSG00000182247	Ubiquitin conjugating enzyme E2 E2	3	23203020-23591793	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003303, HPA028872, HPA030445, CAB073417	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 40.1	Mixed		
SYNM	DMN, KIAA0353, SYN	ENSG00000182253	Synemin	15	99098217-99135593	Predicted intracellular proteins	Evidence at protein level	CAB017192, HPA040066, HPA044200	Enhanced					Expressed in all	Tissue enhanced		seminal vesicle: 404.4	smooth muscle: 227.4	Cell line enhanced		A549: 33.4;HeLa: 36.9;WM-115: 122.8
KCNA4	HK1, HPCN2, KCNA4L, Kv1.4	ENSG00000182255	Potassium voltage-gated channel subfamily A member 4	11	30009741-30017023	FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	CAB001977, HPA016422	Approved					Not detected	Tissue enhanced		adrenal gland: 7.9;cerebral cortex: 4.3	heart muscle: 1.4	Not detected		
GABRG3		ENSG00000182256	Gamma-aminobutyric acid type A receptor gamma3 subunit	15	26971282-27541991	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054010	Supported					Tissue enhanced	Tissue enhanced		prostate: 10.6;testis: 16.5	cerebral cortex: 4.2	Cell line enhanced		K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
PRR34	C22orf26, FLJ10945	ENSG00000182257	Proline rich 34	22	46049478-46054144	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			skeletal muscle: 1.7	Cell line enhanced		HeLa: 3.9
NLRP10	CLR11.1, NALP10, NOD8, PAN5, Pynod	ENSG00000182261	NLR family pyrin domain containing 10	11	7959424-7965426	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039498, HPA040101	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Tissue enhanced	Tissue enriched	12	skin: 3.2	breast: 0.2	Cell line enhanced		A-431: 14.7;BJ: 4.2;HBF TERT88: 6.6
FIGN		ENSG00000182263	Fidgetin, microtubule severing factor	2	163593396-163736012	Predicted intracellular proteins	Evidence at protein level	HPA034987, HPA057919	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Mixed			ovary: 5.1	Cell line enhanced		AF22: 18.3
IZUMO1	IZUMO, MGC34799, OBF	ENSG00000182264	Izumo sperm-egg fusion 1	19	48740852-48746909	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038104	Enhanced					Not detected	Tissue enriched	22	testis: 19.0	lung: 0.8	Not detected		
TMIGD1	TMIGD, UNQ9372	ENSG00000182271	Transmembrane and immunoglobulin domain containing 1	17	30316333-30334059	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021946			Approved	Mitochondria		Tissue enhanced	Group enriched	23	colon: 81.8;rectum: 109.8;small intestine: 162.9	kidney: 5.1	Not detected		
B4GALNT4	FLJ25045, NGalNAc-T1	ENSG00000182272	Beta-1,4-N-acetyl-galactosaminyltransferase 4	11	369796-382116	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA053126	Uncertain		Approved	Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Mitotic spindle		Mixed	Tissue enhanced		cerebral cortex: 30.9;ovary: 11.7	endometrium,fallopian tube: 6.9	Cell line enhanced		AF22: 38.5;NTERA-2: 34.8;SCLC-21H: 50.7;SH-SY5Y: 55.6
AP1S2	MRX59, MRXS5, PGS, SIGMA1B	ENSG00000182287	Adaptor related protein complex 1 sigma 2 subunit	X	15825806-15855014	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049894, HPA060945	Enhanced		Supported	Golgi apparatus<br>Vesicles	Ovarian cancer:5.53e-6 (favourable), Breast cancer:9.86e-4 (favourable)	Expressed in all	Tissue enriched	7	epididymis: 920.5	smooth muscle: 126.9	Expressed in all		
C8orf33	FLJ20989	ENSG00000182307	Chromosome 8 open reading frame 33	8	145052378-145056030	Predicted intracellular proteins	Evidence at protein level	HPA024812, HPA026104	Approved		Uncertain	Nucleoplasm<br>Plasma membrane	Breast cancer:2.77e-4 (unfavourable), Liver cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 26.2	Expressed in all		
DCAF4L1	WDR21B	ENSG00000182308	DDB1 and CUL4 associated factor 4 like 1	4	41981696-41986467	Predicted intracellular proteins	Evidence at protein level	CAB073535	Enhanced					Tissue enriched	Tissue enriched	122	testis: 45.7	appendix,skin: 0.3	Mixed		
SPACA6	LET7EH, LINC00085, NCRNA00085, SPACA6P	ENSG00000182310	Sperm acrosome associated 6	19	51693340-51712387	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.98e-10 (unfavourable), Endometrial cancer:2.73e-4 (unfavourable)	Mixed	Tissue enriched	19	testis: 4.0	adipose tissue: 0.2	Not detected		
MBD3L3		ENSG00000182315	Methyl-CpG binding domain protein 3 like 3	19	7056209-7058640	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
ZSCAN22	HKR2, ZNF50	ENSG00000182318	Zinc finger and SCAN domain containing 22	19	58327019-58342332	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006471	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 3.3	Cell line enhanced		HEK 293: 13.4
KCNJ14	IRK4, Kir2.4	ENSG00000182324	Potassium voltage-gated channel subfamily J member 14	19	48455509-48466980	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA071765			Approved	Nucleoli		Mixed	Mixed			skin,testis: 2.1	Mixed		
FBXL6	FBL6	ENSG00000182325	F-box and leucine rich repeat protein 6	8	144355431-144359376	Predicted intracellular proteins	Evidence at protein level	HPA008867			Approved	Nucleus	Renal cancer:4.49e-10 (unfavourable)	Expressed in all	Mixed			duodenum: 9.0	Mixed		
C1S		ENSG00000182326	Complement C1s	12	6988259-7071032	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016722, HPA018852	Supported		Approved	Nucleus<br>Cytosol	Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable)	Expressed in all	Expressed in all			liver: 1326.7	Cell line enhanced		ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5
GLTPD2		ENSG00000182327	Glycolipid transfer protein domain containing 2	17	4788959-4790390	Predicted secreted proteins	Evidence at protein level	HPA058295, HPA065267	Uncertain		Approved	Vesicles		Tissue enriched	Tissue enhanced		duodenum: 11.0;kidney: 12.8;liver: 13.8	small intestine: 7.2	Cell line enhanced		CACO-2: 8.6;Hep G2: 9.4
KIAA2012		ENSG00000182329	KIAA2012	2	202073289-202205203	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	9	fallopian tube: 14.7	testis: 1.5	Not detected		
PRAMEF8		ENSG00000182330	PRAME family member 8	1	13281035-13285174	Predicted intracellular proteins	Evidence at transcript level	HPA049887, HPA051704	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LIPF	HGL, HLAL	ENSG00000182333	Lipase F, gastric type	10	88664441-88678814	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045930	Enhanced					Tissue enriched	Tissue enriched	86	stomach: 22415.5	duodenum: 259.5	Cell line enhanced		HMC-1: 3.6;MOLT-4: 2.7;NTERA-2: 3.5;THP-1: 4.5;U-2 OS: 2.4;U-266/70: 2.4
OR5P3	JCG1	ENSG00000182334	Olfactory receptor family 5 subfamily P member 3	11	7825037-7825972	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA060787	Uncertain					Not detected	Not detected			epididymis,skin: 0.1	Not detected		
DAOA	G72	ENSG00000182346	D-amino acid oxidase activator	13	105465867-105491034	Predicted intracellular proteins	Evidence at protein level	HPA053114	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF804B	FLJ32110	ENSG00000182348	Zinc finger protein 804B	7	88759368-89337057	Predicted intracellular proteins	Evidence at protein level	HPA026702	Uncertain					Not detected	Tissue enriched	7	thyroid gland: 7.3	kidney: 0.9	Not detected		
KBTBD3	BKLHD3	ENSG00000182359	Kelch repeat and BTB domain containing 3	11	106051098-106077765	Predicted intracellular proteins	Evidence at protein level	HPA047385	Uncertain				Renal cancer:3.42e-7 (favourable)	Mixed	Mixed			thyroid gland: 7.7	Mixed		
YBEY	C21orf57	ENSG00000182362	YbeY metallopeptidase (putative)	21	46286337-46297751	Predicted intracellular proteins	Evidence at protein level	HPA016593, HPA018162	Uncertain		Enhanced	Nucleoplasm	Breast cancer:5.54e-4 (favourable)	Expressed in all	Expressed in all			testis: 92.0	Mixed		
CLN8	C8orf61, EPMR, FLJ39417	ENSG00000182372	Ceroid-lipofuscinosis, neuronal 8	8	1755778-1801711	Disease related genes, Predicted membrane proteins	Evidence at protein level						Renal cancer:4.36e-8 (favourable)	Expressed in all	Mixed			gallbladder: 7.5	Mixed		
PLCXD1	FLJ11323	ENSG00000182378	Phosphatidylinositol specific phospholipase C X domain containing 1	X	276322-303356	Predicted intracellular proteins	Evidence at protein level	HPA007721	Approved		Approved	Cytosol	Renal cancer:7.82e-14 (unfavourable), Head and neck cancer:2.50e-4 (favourable), Endometrial cancer:8.10e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 25.8	Expressed in all		
NXPH4	NPH4	ENSG00000182379	Neurexophilin 4	12	57216795-57226449	Predicted secreted proteins	Evidence at transcript level						Renal cancer:7.68e-6 (unfavourable), Liver cancer:2.57e-4 (unfavourable), Endometrial cancer:6.21e-4 (unfavourable), Glioma:8.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 8.3;prostate: 7.1;skin: 12.2	placenta: 3.8	Cell line enhanced		AN3-CA: 71.1;RH-30: 60.3
CACNB4	EJM4	ENSG00000182389	Calcium voltage-gated channel auxiliary subunit beta 4	2	151832768-152099475	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA015601	Approved					Mixed	Tissue enhanced		cerebral cortex: 25.9	skin: 8.0	Cell line enhanced		HMC-1: 17.7
IFNL1	IL-29, IL29	ENSG00000182393	Interferon lambda 1	19	39296325-39298673	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			appendix,duodenum,lung,spleen,testis: 0.1	Not detected		
TRAPPC6B		ENSG00000182400	Trafficking protein particle complex 6B	14	39147811-39170532	Predicted intracellular proteins	Evidence at protein level	HPA047928	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.8	Expressed in all		
PGBD4	FLJ32638, FLJ37497	ENSG00000182405	PiggyBac transposable element derived 4	15	34102073-34108684	Predicted intracellular proteins	Evidence at protein level	HPA040896, HPA059823	Uncertain		Approved	Nucleoplasm<br>Centrosome		Mixed	Mixed			testis: 3.5	Mixed		
CDY2A	CDY2	ENSG00000182415	Chromodomain Y-linked 2A	Y	18025787-18028597	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	24	epididymis: 1.3;testis: 3.5	all non-specific tissues: 0.0	Not detected		
NPLOC4	FLJ20657, KIAA1499, NPL4	ENSG00000182446	NPL4 homolog, ubiquitin recognition factor	17	81556887-81648465	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA021560, HPA023295	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.95e-7 (unfavourable), Liver cancer:1.16e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.6	Expressed in all		
OTOL1	C1QTNF15	ENSG00000182447	Otolin 1	3	161496808-161503942	Predicted secreted proteins	No evidence	HPA041030	Uncertain					Not detected	Not detected			cerebral cortex: 0.8	Not detected		
KCNK4	K2p4.1, TRAAK	ENSG00000182450	Potassium two pore domain channel subfamily K member 4	11	64291302-64300031	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Tissue enriched	12	cerebral cortex: 4.3	cervix, uterine: 0.3	Not detected		
TEX19	FLJ35767	ENSG00000182459	Testis expressed 19	17	82359247-82363776	Predicted intracellular proteins	Evidence at protein level	HPA054577	Enhanced					Not detected	Tissue enriched	266	testis: 27.2	cerebral cortex: 0.1	Cell line enhanced		Daudi: 20.1;HMC-1: 20.0;MOLT-4: 16.0;U-266/70: 22.3
TSHZ2	C20orf17, OVC10-2, TSH2, ZABC2, ZNF218	ENSG00000182463	Teashirt zinc finger homeobox 2	20	52972407-53495330	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038123	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Mixed			ovary: 21.7	Cell line enhanced		AN3-CA: 24.7;HeLa: 15.8;SiHa: 16.3;U-2197: 12.7
CAPN12		ENSG00000182472	Calpain 12	19	38730187-38769904	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053322			Approved	Nucleoplasm<br>Focal adhesion sites	Renal cancer:5.90e-6 (unfavourable)	Mixed	Group enriched	6	cervix, uterine: 7.3;gallbladder: 35.5	lung: 3.8	Cell line enriched	16	HMC-1: 34.3
EXOC7	EXO70, Exo70p, KIAA1067, YJL085W	ENSG00000182473	Exocyst complex component 7	17	76081017-76121576	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA022840, HPA022842	Supported		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 102.7	Expressed in all		
KPNA2	IPOA1, QIP2, RCH1, SRP1alpha	ENSG00000182481	Karyopherin subunit alpha 2	17	68035519-68046842	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB015460, HPA041270	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:1.26e-13 (unfavourable), Liver cancer:2.12e-10 (unfavourable), Urothelial cancer:2.19e-4 (unfavourable), Colorectal cancer:3.83e-4 (favourable), Lung cancer:5.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 349.5	Expressed in all		
XKRX	XKR2, XPLAC	ENSG00000182489	XK related, X-linked	X	100913445-100929433	Predicted membrane proteins, Transporters	Evidence at transcript level						Thyroid cancer:3.52e-4 (favourable)	Mixed	Tissue enhanced		skin: 9.4	tonsil: 3.1	Cell line enriched	5	CACO-2: 6.8
BGN	DSPG1, SLRR1A	ENSG00000182492	Biglycan	X	153494939-153509554	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA003157, CAB003678	Enhanced		Approved	Endoplasmic reticulum<br>Golgi apparatus	Renal cancer:6.00e-8 (unfavourable)	Expressed in all	Mixed			gallbladder: 501.3	Cell line enhanced		BJ: 258.4;BJ hTERT+: 318.9;fHDF/TERT166: 430.9;hTEC/SVTERT24-B: 230.0;HUVEC TERT2: 458.3;U-138 MG: 240.7
CEP97	FLJ23047, LRRIQ2	ENSG00000182504	Centrosomal protein 97	3	101723925-101770562	Predicted intracellular proteins	Evidence at protein level	HPA002980	Enhanced		Supported	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			testis: 13.4	Expressed in all		
LHFPL1		ENSG00000182508	Lipoma HMGIC fusion partner-like 1	X	112630648-112680054	Predicted membrane proteins	Evidence at transcript level	HPA003029	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 1.8	seminal vesicle: 1.3	Cell line enhanced		SK-MEL-30: 1.9
FES	FPS	ENSG00000182511	FES proto-oncogene, tyrosine kinase	15	90883695-90895776	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001376	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.5	Cell line enhanced		HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
GLRX5	C14orf87, GRX5, PR01238	ENSG00000182512	Glutaredoxin 5	14	95533503-95544724	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042465, HPA063716	Approved		Supported	Mitochondria	Renal cancer:7.83e-10 (favourable), Ovarian cancer:1.08e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 56.6	Expressed in all		
FAM104B	CXorf44, FLJ20434	ENSG00000182518	Family with sequence similarity 104 member B	X	55143102-55161310	Predicted intracellular proteins	Evidence at transcript level	HPA049082	Approved				Lung cancer:1.22e-4 (favourable), Liver cancer:2.23e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 74.5	Expressed in all		
TBPL2	TBP2, TRF3	ENSG00000182521	TATA-box binding protein like 2	14	55413541-55456726	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056241	Uncertain					Tissue enriched	Mixed			skin: 2.0	Cell line enhanced		HDLM-2: 5.4;U-2 OS: 3.1;U-937: 3.1
CAV3	LGMD1C, LQT9, VIP-21, VIP21	ENSG00000182533	Caveolin 3	3	8733800-8841808	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB017518, CAB018557, HPA054488	Enhanced		Supported	Vesicles<br>Plasma membrane		Tissue enhanced	Group enriched	6	heart muscle: 14.0;skeletal muscle: 63.3	esophagus: 6.0	Group enriched	15	LHCN-M2: 19.0;RH-30: 91.1
MXRA7	FLJ46603, PS1TP1, TMAP1	ENSG00000182534	Matrix remodeling associated 7	17	76672551-76711016	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044819	Uncertain		Approved	Nucleus<br>Endoplasmic reticulum	Urothelial cancer:1.80e-5 (unfavourable), Liver cancer:4.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 456.4	Cell line enhanced		U-87 MG: 650.2
LIMK2		ENSG00000182541	LIM domain kinase 2	22	31212239-31280080	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008183, CAB019313, HPA053882	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.57e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 70.8	Expressed in all		
MFSD5	MGC11308	ENSG00000182544	Major facilitator superfamily domain containing 5	12	53251251-53254405	Predicted membrane proteins	Evidence at protein level	HPA039773	Uncertain				Liver cancer:1.43e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 49.6	Expressed in all		
RNASE10	RAH1, RNASE9	ENSG00000182545	Ribonuclease A family member 10 (inactive)	14	20505537-20511169	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA052593	Uncertain					Group enriched	Mixed			testis: 3.8	Cell line enhanced		SiHa: 7.3;U-2 OS: 11.5
ADI1	APL1, ARD, FLJ10913, HMFT1638, MTCBP-1, mtnD, SIPL	ENSG00000182551	Acireductone dioxygenase 1	2	3497361-3519736	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035403, HPA035404	Approved		Supported	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			liver: 228.3	Expressed in all		
RWDD4	FAM28A, MGC10198, RWDD4A	ENSG00000182552	RWD domain containing 4	4	183639635-183659225	Predicted intracellular proteins	Evidence at protein level	HPA036501, HPA036502	Approved		Approved	Intermediate filaments	Renal cancer:1.01e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 68.2	Expressed in all		
SPNS3	MGC29671	ENSG00000182557	Sphingolipid transporter 3 (putative)	17	4433688-4488208	Predicted membrane proteins	Evidence at protein level	HPA023928	Uncertain				Renal cancer:8.09e-4 (unfavourable)	Mixed	Tissue enriched	6	bone marrow: 12.4	spleen: 2.1	Group enriched	10	HL-60: 3.0;MOLT-4: 4.9;NB-4: 12.9;THP-1: 14.7;U-698: 3.6;U-937: 13.1
CLEC4G	LSECtin, UNQ431	ENSG00000182566	C-type lectin domain family 4 member G	19	7728957-7733906	Predicted membrane proteins	Evidence at protein level	CAB003789, HPA014044	Enhanced					Mixed	Group enriched	6	adipose tissue: 18.7;liver: 27.6;lymph node: 16.8	urinary bladder: 3.4	Not detected		
SATB1		ENSG00000182568	SATB homeobox 1	3	18345387-18445588	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA051769, CAB056144	Supported		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.96e-7 (favourable), Pancreatic cancer:8.97e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 76.6	Cell line enhanced		HDLM-2: 421.9;REH: 115.4;THP-1: 129.6
NXPH3	NPH3	ENSG00000182575	Neurexophilin 3	17	49575858-49583827	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 15.6	seminal vesicle: 9.6	Cell line enhanced		BEWO: 14.1;BJ: 4.0
CSF1R	C-FMS, CD115, CSFR, FMS	ENSG00000182578	Colony stimulating factor 1 receptor	5	150053291-150113372	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB008970, HPA012323	Uncertain		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable)	Expressed in all	Mixed			spleen: 147.7	Group enriched	6	BEWO: 118.6;SK-BR-3: 35.4
EPHB3	ETK2, Hek2, Tyro6	ENSG00000182580	EPH receptor B3	3	184561784-184582409	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA007698, HPA008184, CAB034350	Enhanced				Renal cancer:7.88e-5 (unfavourable)	Expressed in all	Tissue enhanced		skin: 45.4	stomach: 18.1	Cell line enhanced		BEWO: 27.9;HaCaT: 35.7;SK-BR-3: 23.1;T-47d: 19.3
VCX	VCX-10r, VCX-B1, VCX1, VCX10R	ENSG00000182583	Variable charge, X-linked	X	7842262-7844143	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Mixed	Tissue enriched	159	testis: 39.1	duodenum: 0.2	Cell line enhanced		NB-4: 1.0;U-138 MG: 1.4;U-266/70: 2.2
ACTL10	C20orf134	ENSG00000182584	Actin like 10	20	33666498-33668525	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 22.1	prostate: 1.4	Cell line enhanced		RPMI-8226: 3.3;SiHa: 3.6
EPGN	ALGV3072, EPG, epigen, PRO9904	ENSG00000182585	Epithelial mitogen	4	74308473-74315307	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014369			Approved	Nucleus<br>Nuclear membrane<br>Cytosol	Urothelial cancer:2.40e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	esophagus: 63.6	seminal vesicle: 5.4	Group enriched	7	hTCEpi: 132.6;U-2197: 76.6
KRTAP11-1	KAP11.1	ENSG00000182591	Keratin associated protein 11-1	21	30880644-30881555	Predicted intracellular proteins	Evidence at protein level	HPA054008	Supported					Group enriched	Not detected			skin: 0.1	Not detected		
C2orf82	ASCL830, UNQ830	ENSG00000182600	Chromosome 2 open reading frame 82	2	232857270-232878708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA052824	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:3.56e-4 (unfavourable)	Mixed	Tissue enhanced		breast: 5.1;testis: 4.1	cerebral cortex: 2.6	Cell line enriched	13	Hep G2: 40.1
HS3ST4	3OST4	ENSG00000182601	Heparan sulfate-glucosamine 3-sulfotransferase 4	16	25692026-26137688	Enzymes, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	7	cerebral cortex: 18.7	breast: 2.8	Cell line enhanced		NTERA-2: 1.4
TRAK1	KIAA1042, MILT1, OIP106	ENSG00000182606	Trafficking kinesin protein 1	3	42013802-42225889	Predicted intracellular proteins	Evidence at protein level	HPA005853, HPA011367	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum	Renal cancer:4.84e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 110.1	Expressed in all		
TSPAN10	OCSP	ENSG00000182612	Tetraspanin 10	17	81637171-81648749	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		skin: 1.5	lymph node: 1.0	Cell line enhanced		SK-MEL-30: 13.4;U-87 MG: 7.4
OR2V2	OR2V3, OST713	ENSG00000182613	Olfactory receptor family 2 subfamily V member 2	5	181154943-181155890	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049953	Uncertain					Not detected	Not detected			fallopian tube: 0.4	Not detected		
PLCB1	KIAA0581, PLC-I, PLC154	ENSG00000182621	Phospholipase C beta 1	20	8077251-8968360	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004275, CAB005334, HPA034743, HPA057910	Enhanced		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 68.3;parathyroid gland: 121.3	placenta: 28.2	Cell line enhanced		Hep G2: 46.8
SKA2	FAM33A, FLJ12758	ENSG00000182628	Spindle and kinetochore associated complex subunit 2	17	59109951-59155269	Predicted intracellular proteins	Evidence at protein level	HPA059235	Uncertain				Renal cancer:2.90e-7 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 43.1	Expressed in all		
RXFP3	GPCR135, RLN3R1, RXFPR3, SALPR	ENSG00000182631	Relaxin/insulin like family peptide receptor 3	5	33936386-33938237	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA027833	Uncertain					Not detected	Not detected			adrenal gland: 0.3	Not detected		
OR10G7		ENSG00000182634	Olfactory receptor family 10 subfamily G member 7	11	124038066-124039010	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NDN	HsT16328, PWCR	ENSG00000182636	Necdin, MAGE family member	15	23685400-23687330	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA074457			Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.52e-4 (unfavourable)	Expressed in all	Mixed			ovary: 85.0	Cell line enhanced		AF22: 53.6;HSkMC: 51.0;NTERA-2: 43.3;U-2 OS: 83.1
CCDC172	C10orf96, MGC35062	ENSG00000182645	Coiled-coil domain containing 172	10	116324428-116380029	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	14	testis: 22.0	prostate: 1.5	Cell line enriched	177	NTERA-2: 30.9
OR4Q3	C14orf13, OR4Q4	ENSG00000182652	Olfactory receptor family 4 subfamily Q member 3	14	19747428-19748369	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049924	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
NTM	HNT, IGLON2, NTRI	ENSG00000182667	Neurotrimin	11	131370478-132336822	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB024875	Enhanced				Renal cancer:1.10e-8 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 116.0	lung: 39.1	Cell line enhanced		LHCN-M2: 102.1;U-2 OS: 86.6;WM-115: 164.5
TTC3	DCRR1, RNF105, TPRD, TPRDI, TPRDII, TPRDIII	ENSG00000182670	Tetratricopeptide repeat domain 3	21	37073226-37203112	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016810, HPA023964, HPA036304	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 108.0	Expressed in all		
KCNB2	Kv2.2	ENSG00000182674	Potassium voltage-gated channel subfamily B member 2	8	72537391-72938349	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA065970			Approved	Nucleoli<br>Plasma membrane<br>Midbody		Not detected	Tissue enhanced		cerebral cortex: 3.2;spleen: 3.3	fallopian tube,testis: 0.7	Cell line enhanced		HaCaT: 1.3;HDLM-2: 1.4;HEK 293: 3.2;SCLC-21H: 3.4
PPP1R27	DYSFIP1, toonin	ENSG00000182676	Protein phosphatase 1 regulatory subunit 27	17	81833492-81835050	Predicted intracellular proteins	Evidence at protein level	HPA048632	Uncertain					Tissue enriched	Tissue enriched	38	skeletal muscle: 170.9	prostate: 4.5	Group enriched	26	HL-60: 317.1;THP-1: 513.1
BRICD5	C16orf79, MGC21830	ENSG00000182685	BRICHOS domain containing 5	16	2209253-2211950	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019197, HPA063522	Uncertain		Approved	Nucleoplasm<br>Actin filaments	Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:7.01e-4 (favourable), Breast cancer:9.74e-4 (favourable)	Expressed in all	Mixed			testis: 10.6	Mixed		
GALR2	GALNR2	ENSG00000182687	Galanin receptor 2	17	76074794-76077541	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA044513	Approved					Mixed	Tissue enhanced		smooth muscle: 2.4	bone marrow: 0.6	Cell line enhanced		NTERA-2: 2.0;THP-1: 2.0
RESP18		ENSG00000182698	Regulated endocrine specific protein 18	2	219327409-219333177	Predicted intracellular proteins	Evidence at transcript level	HPA045849	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.1	testis: 0.7	Not detected		
IGIP	C5orf53, LOC492311	ENSG00000182700	IgA inducing protein	5	140125935-140129392	Predicted secreted proteins	Evidence at transcript level	HPA041877, HPA048615	Approved		Approved	Vesicles	Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.94e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 28.6	Mixed		
TSKU	E2IG4, LRRC54, TSK	ENSG00000182704	Tsukushi, small leucine rich proteoglycan	11	76782251-76798154	Predicted secreted proteins	Evidence at protein level	HPA008164	Approved		Approved	Nucleus<br>Nuclear bodies	Renal cancer:2.80e-8 (unfavourable), Prostate cancer:1.66e-4 (favourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:3.66e-4 (favourable)	Expressed in all	Expressed in all			liver: 114.4	Cell line enhanced		A549: 150.8;ASC diff: 186.5
CMC4	MTCP1, MTCP1NB, p8, P8MTCP1	ENSG00000182712	C-X9-C motif containing 4	X	155061622-155071362	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045866	Approved		Supported	Mitochondria		Not detected	Expressed in all			heart muscle: 21.4	Expressed in all		
ANXA2	ANX2, ANX2L4, CAL1H, LIP2, LPC2D	ENSG00000182718	Annexin A2	15	60347134-60402883	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004311, HPA046964, HPA061798	Enhanced				Renal cancer:2.11e-6 (unfavourable), Pancreatic cancer:8.47e-6 (unfavourable), Liver cancer:2.54e-5 (unfavourable), Urothelial cancer:6.59e-5 (unfavourable), Endometrial cancer:6.88e-5 (favourable), Lung cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 1488.4	Expressed in all		
RGS6		ENSG00000182732	Regulator of G-protein signaling 6	14	71932439-72566529	Predicted intracellular proteins	Evidence at protein level	HPA003067	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 17.5;testis: 18.7	thyroid gland: 8.8	Group enriched	8	HEL: 10.1;Karpas-707: 24.7
HOXB4	HOX2, HOX2F	ENSG00000182742	Homeobox B4	17	48575513-48580111	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057432	Uncertain		Supported	Nucleus<br>Centrosome	Ovarian cancer:2.23e-4 (unfavourable)	Mixed	Tissue enhanced		epididymis: 16.1	fallopian tube: 12.5	Cell line enhanced		EFO-21: 30.9;HMC-1: 17.8
SLC35D3	FRCL1	ENSG00000182747	Solute carrier family 35 member D3	6	136922264-136925639	Predicted membrane proteins, Transporters	Evidence at protein level	HPA030431, HPA067497	Uncertain		Approved	Microtubule organizing center		Tissue enhanced	Tissue enhanced		adrenal gland: 1.2	lung,stomach: 0.6	Group enriched	16	SCLC-21H: 4.2;SH-SY5Y: 16.3
PAQR7	MPRA, mSR	ENSG00000182749	Progestin and adipoQ receptor family member 7	1	25861210-25871253	Predicted membrane proteins	Evidence at protein level	HPA046936	Approved		Approved	Cytosol	Renal cancer:1.05e-5 (favourable), Liver cancer:1.14e-4 (unfavourable)	Expressed in all	Mixed			testis: 51.0	Cell line enhanced		CAPAN-2: 54.0
PAPPA	ASBABP2, DIPLA1, IGFBP-4ase, PAPA, PAPP-A, PAPPA1	ENSG00000182752	Pappalysin 1	9	116153804-116402322	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001667, CAB016724	Enhanced		Uncertain	Plasma membrane<br>Cytosol		Mixed	Tissue enriched	7	placenta: 104.5	parathyroid gland: 14.8	Cell line enhanced		ASC diff: 34.3;HSkMC: 99.9;U-138 MG: 35.8
MAFA	hMafA, RIPE3b1	ENSG00000182759	MAF bZIP transcription factor A	8	143419182-143430406	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Group enriched	11	skeletal muscle: 8.6;testis: 2.5	placenta: 0.5	Cell line enhanced		MCF7: 1.7;SCLC-21H: 3.7;T-47d: 2.8;U-2 OS: 2.1
NGRN	DSC92	ENSG00000182768	Neugrin, neurite outgrowth associated	15	90265659-90278141	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041367	Approved					Expressed in all	Mixed			thyroid gland: 7.1	Expressed in all		
GRID1	GluD1, KIAA1220	ENSG00000182771	Glutamate ionotropic receptor delta type subunit 1	10	85599555-86366493	Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 7.7	thyroid gland: 3.4	Cell line enhanced		Daudi: 1.8;HEL: 2.3;SH-SY5Y: 1.0
RPS17	MGC72007, RPS17L, RPS17L1, RPS17L2, S17	ENSG00000182774	Ribosomal protein S17	15	82536753-82540564	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA055060	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.78e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1572.3	Expressed in all		
HCAR2	GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG	ENSG00000182782	Hydroxycarboxylic acid receptor 2	12	122701293-122703343	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Group enriched	Tissue enhanced		spleen: 36.0	esophagus: 25.5	Cell line enriched	7	HaCaT: 105.3
OR2T29		ENSG00000182783	Olfactory receptor family 2 subfamily T member 29	1	248558544-248559491	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CCDC87	FLJ10786	ENSG00000182791	Coiled-coil domain containing 87	11	66590176-66593083	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	7	testis: 18.3	parathyroid gland: 2.5	Cell line enhanced		SCLC-21H: 2.7
GSTA5		ENSG00000182793	Glutathione S-transferase alpha 5	6	52831655-52846095	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Uncertain		Approved	Cytosol		Not detected	Not detected			testis: 0.1	Not detected		
C1orf116	FLJ36507, MGC2742, MGC4309, SARG	ENSG00000182795	Chromosome 1 open reading frame 116	1	207018521-207032756	Predicted intracellular proteins	Evidence at protein level	HPA011888, HPA011889	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:1.01e-5 (favourable)	Mixed	Tissue enhanced		esophagus: 112.4;lung: 109.2;prostate: 82.0	stomach: 54.9	Group enriched	5	A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
MAGEB17		ENSG00000182798	MAGE family member B17	X	16167481-16171464	Predicted intracellular proteins	Evidence at transcript level	HPA003756	Uncertain					Mixed	Tissue enriched	6	testis: 2.9	epididymis: 0.4	Cell line enhanced		U-138 MG: 2.7;U-2 OS: 6.2;U-266/70: 11.3
CRIP2	CRP2, ESP1	ENSG00000182809	Cysteine rich protein 2	14	105472962-105480170	Predicted intracellular proteins	Evidence at protein level	HPA042664	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane		Expressed in all	Tissue enhanced		heart muscle: 315.6	fallopian tube: 115.7	Cell line enhanced		MCF7: 206.8
DDX28	FLJ11282, MDDX28	ENSG00000182810	DEAD-box helicase 28	16	68021274-68023442	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA041911, HPA053585	Approved		Supported	Nucleoli<br>Mitochondria<br>Cytosol	Renal cancer:2.07e-10 (favourable)	Expressed in all	Expressed in all			bone marrow: 11.2	Expressed in all		
KRTAP13-2	KAP13-2	ENSG00000182816	Keratin associated protein 13-2	21	30371391-30372257	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	20	colon: 1.9;rectum: 2.0	all non-specific tissues: 0.0	Not detected		
ACBD3	GCP60, GOCAP1, GOLPH1, PAP7	ENSG00000182827	Acyl-CoA binding domain containing 3	1	226144679-226186730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015594	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 48.5	Expressed in all		
C16orf72	FLJ41272, PRO0149	ENSG00000182831	Chromosome 16 open reading frame 72	16	9091648-9121640	Predicted intracellular proteins	Evidence at protein level	HPA041568, HPA067492	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:3.62e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 67.5	Expressed in all		
PLCXD3		ENSG00000182836	Phosphatidylinositol specific phospholipase C X domain containing 3	5	41306954-41510628	Predicted intracellular proteins	Evidence at protein level	HPA046849	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		adrenal gland: 16.7;heart muscle: 22.0;ovary: 28.4	cerebral cortex: 8.3	Cell line enhanced		BJ hTERT+: 6.9;PC-3: 6.9;SH-SY5Y: 36.5;TIME: 15.0
VMO1		ENSG00000182853	Vitelline membrane outer layer 1 homolog	17	4785285-4786433	Predicted secreted proteins	Evidence at protein level	HPA023038	Uncertain				Renal cancer:1.34e-6 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 34.4	spleen: 14.6	Cell line enhanced		A549: 2.7;MCF7: 3.0
OR4F15		ENSG00000182854	Olfactory receptor family 4 subfamily F member 15	15	101818163-101819147	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ALG12	CDG1G, ECM39	ENSG00000182858	ALG12, alpha-1,6-mannosyltransferase	22	49900229-49918458	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA003076, HPA051665	Approved		Approved	Endoplasmic reticulum	Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.2	Expressed in all		
LCK		ENSG00000182866	LCK proto-oncogene, Src family tyrosine kinase	1	32251239-32286165	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003494, CAB003816	Enhanced		Approved	Golgi apparatus	Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 125.9;tonsil: 72.4	appendix: 66.3	Group enriched	7	MOLT-4: 429.5;U-698: 207.6
GALNT9	GALNAC-T9	ENSG00000182870	Polypeptide N-acetylgalactosaminyltransferase 9	12	132196372-132329349	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075016			Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 29.4	thyroid gland: 6.3	Cell line enriched	6	U-87 MG: 30.6
COL18A1	KNO, KNO1, KS	ENSG00000182871	Collagen type XVIII alpha 1 chain	21	45405137-45513720	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001961, HPA011025, HPA036104	Approved		Approved	Golgi apparatus	Liver cancer:6.16e-4 (favourable)	Expressed in all	Expressed in all			cervix, uterine: 144.0	Cell line enhanced		EFO-21: 290.7;NTERA-2: 173.6;TIME: 152.4
RBM10	DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5	ENSG00000182872	RNA binding motif protein 10	X	47144869-47186813	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034972, HPA057372	Approved		Enhanced	Nuclear speckles	Pancreatic cancer:2.86e-6 (favourable), Cervical cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			ovary: 35.1	Expressed in all		
ADGRG3	GPR97, Pb99, PGR26	ENSG00000182885	Adhesion G protein-coupled receptor G3	16	57668187-57689378	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA040469	Uncertain					Mixed	Group enriched	5	appendix: 19.0;bone marrow: 86.6	adipose tissue: 9.8	Cell line enhanced		NB-4: 2.5;SK-MEL-30: 1.6
GLUD2	GLUDP1	ENSG00000182890	Glutamate dehydrogenase 2	X	121047588-121050080	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042492, HPA044839, HPA061369	Uncertain		Supported	Mitochondria	Renal cancer:1.98e-4 (favourable)	Mixed	Tissue enriched	11	testis: 46.5	epididymis: 4.1	Cell line enhanced		HAP1: 7.6;K-562: 7.6;SK-MEL-30: 8.3;WM-115: 11.7
TMEM95	MGC129793, UNQ9390	ENSG00000182896	Transmembrane protein 95	17	7355123-7357219	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	48	testis: 9.9	gallbladder: 0.2	Not detected		
TCHHL1	S100A17, THHL1	ENSG00000182898	Trichohyalin like 1	1	152084144-152089064	Predicted intracellular proteins	Evidence at protein level	HPA042579, HPA063483	Enhanced		Approved	Nuclear membrane<br>Nucleoli		Not detected	Not detected			epididymis: 0.1	Cell line enriched	37	SK-BR-3: 3.7
RPL35A	L35A	ENSG00000182899	Ribosomal protein L35a	3	197949987-197956610	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level						Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.43e-4 (unfavourable), Liver cancer:9.89e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 2041.8	Expressed in all		
RGS7		ENSG00000182901	Regulator of G-protein signaling 7	1	240775515-241357230	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017561	Enhanced		Enhanced	Cytosol		Tissue enhanced	Group enriched	8	adrenal gland: 10.7;cerebral cortex: 46.4;testis: 10.9	stomach: 2.9	Cell line enhanced		U-2 OS: 6.8
SLC25A18		ENSG00000182902	Solute carrier family 25 member 18	22	17563439-17590994	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Group enriched	Tissue enhanced		cerebral cortex: 74.5;liver: 25.2	adipose tissue: 13.8	Cell line enhanced		BEWO: 8.2
ZNF721	KIAA1982	ENSG00000182903	Zinc finger protein 721	4	425815-499156	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA065313			Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:2.76e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 30.8	Expressed in all		
TCEAL7	MGC23947, WEX5	ENSG00000182916	Transcription elongation factor A like 7	X	103330196-103332326	Predicted intracellular proteins	Evidence at protein level	HPA051507, HPA065080	Enhanced		Supported	Nucleus	Stomach cancer:3.53e-4 (unfavourable), Renal cancer:4.31e-4 (unfavourable)	Tissue enriched	Tissue enhanced		cerebral cortex: 145.6	endometrium: 76.7	Cell line enhanced		hTEC/SVTERT24-B: 81.8;SCLC-21H: 242.8
C11orf54	PTD012	ENSG00000182919	Chromosome 11 open reading frame 54	11	93741591-93764749	Predicted intracellular proteins	Evidence at protein level	HPA040088, HPA040511	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.06e-6 (favourable)	Expressed in all	Expressed in all			kidney: 539.3	Expressed in all		
CEP63	FLJ13386	ENSG00000182923	Centrosomal protein 63	3	134485743-134575017	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058154, HPA058313	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 83.9	Expressed in all		
WFDC10B	WAP12	ENSG00000182931	WAP four-disulfide core domain 10B	20	45684653-45705019	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	12	epididymis: 33.3	testis: 2.7	Cell line enhanced		PC-3: 1.8
SRPRA	SR-alpha, Sralpha, SRP-alpha, SRPR	ENSG00000182934	SRP receptor alpha subunit	11	126262919-126269144	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:8.56e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 170.3	Expressed in all		
OTOP3		ENSG00000182938	Otopetrin 3	17	74935719-74949992	Predicted membrane proteins	Evidence at protein level						Head and neck cancer:3.86e-4 (favourable)	Tissue enhanced	Not detected			small intestine: 0.5	Not detected		
EWSR1	EWS	ENSG00000182944	EWS RNA binding protein 1	22	29268009-29300525	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004230, HPA051771, HPA062953	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.27e-6 (unfavourable), Renal cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 213.6	Expressed in all		
ODF3L1	MGC48986	ENSG00000182950	Outer dense fiber of sperm tails 3 like 1	15	75723977-75727688	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	6	testis: 24.0	gallbladder: 3.9	Cell line enhanced		U-87 MG: 1.2
HMGN4	HMG17L3, NHC	ENSG00000182952	High mobility group nucleosomal binding domain 4	6	26538405-26546254	Predicted intracellular proteins	Evidence at protein level	HPA077364			Uncertain	Nucleus		Expressed in all	Expressed in all			thyroid gland: 131.8	Expressed in all		
SPATA13	ARHGEF29, FLJ31208	ENSG00000182957	Spermatogenesis associated 13	13	23979805-24307074	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040185, HPA041208	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:1.16e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 90.2	lymph node: 27.2	Cell line enhanced		HDLM-2: 43.0
GJC1	CX45, GJA7	ENSG00000182963	Gap junction protein gamma 1	17	44798448-44830816	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA071788			Uncertain	Nucleoli<br>Cell Junctions<br>Cytosol	Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 44.3;placenta: 51.5;smooth muscle: 49.2	seminal vesicle: 27.2	Mixed		
SOX1		ENSG00000182968	SRY-box 1	13	112067647-112070488	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	8	cerebral cortex: 3.6;testis: 1.5	skin: 0.3	Group enriched	6	AF22: 44.0;SCLC-21H: 10.1
CNOT10	FLJ12890, FLJ13165	ENSG00000182973	CCR4-NOT transcription complex subunit 10	3	32685145-32773875	Predicted intracellular proteins	Evidence at protein level	HPA035614, HPA041450	Approved		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:1.03e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 72.1	Expressed in all		
RP11-294C11.1		ENSG00000182974		15	21637909-21638992	Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Tissue enriched	24	testis: 2.3	all non-specific tissues: 0.0	Not detected		
MTA1		ENSG00000182979	Metastasis associated 1	14	105419820-105470729	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004508, HPA005544	Supported		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:9.48e-5 (favourable), Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 35.8	Expressed in all		
ZNF662	FLJ45880	ENSG00000182983	Zinc finger protein 662	3	42905731-42917641	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA039116, HPA040377	Uncertain					Mixed	Mixed			skin: 13.3	Cell line enhanced		SH-SY5Y: 3.6;U-2 OS: 4.9
CADM1	BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1	ENSG00000182985	Cell adhesion molecule 1	11	115169218-115504957	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037266	Enhanced		Supported	Cell Junctions	Endometrial cancer:1.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 151.6	Cell line enhanced		CACO-2: 245.0;WM-115: 185.3
ZNF320	DKFZp686G16228, ZFPL	ENSG00000182986	Zinc finger protein 320	19	52863790-52897693	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043696, HPA062474	Uncertain		Approved	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 22.5	Cell line enhanced		RT4: 70.3
C12orf60	MGC47869	ENSG00000182993	Chromosome 12 open reading frame 60	12	14803572-14906586	Predicted intracellular proteins	Evidence at protein level	HPA043911			Approved	Nucleus<br>Cytosol		Mixed	Group enriched	6	adrenal gland: 5.9;testis: 23.9	kidney: 2.5	Mixed		
PYCR1	P5C	ENSG00000183010	Pyrroline-5-carboxylate reductase 1	17	81932384-81942412	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047660	Approved				Renal cancer:7.33e-12 (unfavourable), Liver cancer:2.33e-4 (unfavourable)	Expressed in all	Mixed			salivary gland: 52.3	Mixed		
NAA38	LSMD1, MGC14151, PFAAP2	ENSG00000183011	N(alpha)-acetyltransferase 38, NatC auxiliary subunit	17	7856685-7885238	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA059189			Supported	Nucleus		Expressed in all	Expressed in all			testis: 78.3	Expressed in all		
SPNS2		ENSG00000183018	Sphingolipid transporter 2	17	4498838-4539035	Predicted membrane proteins, Transporters	Evidence at protein level	HPA068717	Uncertain					Expressed in all	Tissue enhanced		esophagus: 46.4	kidney: 30.0	Group enriched	6	BEWO: 29.2;RPTEC TERT1: 120.6;SK-BR-3: 55.8
MCEMP1	C19orf59, MGC132456	ENSG00000183019	Mast cell expressed membrane protein 1	19	7676628-7679826	Predicted membrane proteins	Evidence at protein level	HPA014731	Enhanced					Mixed	Group enriched	9	appendix: 27.9;bone marrow: 43.9;lung: 110.4	smooth muscle: 7.0	Group enriched	5	THP-1: 36.2;U-937: 130.3
AP2A2	ADTAB, CLAPA2, DKFZP564D1864, HIP9, HYPJ, KIAA0899	ENSG00000183020	Adaptor related protein complex 2 alpha 2 subunit	11	924894-1012245	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017514, HPA043040	Enhanced		Supported	Nucleoplasm<br>Vesicles	Liver cancer:9.27e-5 (unfavourable), Pancreatic cancer:4.57e-4 (favourable)	Expressed in all	Mixed			spleen: 16.0	Mixed		
SLC8A1	NCX1	ENSG00000183023	Solute carrier family 8 member A1	2	40097270-40611053	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB022694, HPA070007	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		heart muscle: 78.0	seminal vesicle: 37.6	Cell line enhanced		BJ: 24.4;fHDF/TERT166: 54.5
OR1G1	OR17-209, OR1G2	ENSG00000183024	Olfactory receptor family 1 subfamily G member 1	17	3126584-3127581	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
SLC25A21	ODC, ODC1	ENSG00000183032	Solute carrier family 25 member 21	14	36678431-37172866	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000662	Uncertain					Not detected	Tissue enhanced		testis: 7.6	bone marrow: 3.8	Group enriched	6	HEK 293: 8.7;K-562: 23.4;Karpas-707: 39.1
OTOP2		ENSG00000183034	Otopetrin 2	17	74924275-74933912	Predicted membrane proteins	Evidence at transcript level	HPA024524, HPA053090	Uncertain					Not detected	Tissue enhanced		colon: 20.0;rectum: 11.4	testis: 3.9	Cell line enriched	50	HDLM-2: 9.6
CYLC1		ENSG00000183035	Cylicin 1	X	83861126-83886699	Predicted intracellular proteins	Evidence at protein level	HPA070355	Enhanced					Not detected	Tissue enriched	429	testis: 42.9	all non-specific tissues: 0.0	Not detected		
PCP4	PEP-19	ENSG00000183036	Purkinje cell protein 4	21	39867317-39929397	Predicted intracellular proteins	Evidence at protein level	HPA005792	Enhanced	Supported	Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.85e-7 (favourable), Cervical cancer:9.76e-4 (favourable)	Mixed	Tissue enhanced		seminal vesicle: 1209.1	prostate: 369.5	Cell line enhanced		RPMI-8226: 108.9;SK-BR-3: 19.1;T-47d: 44.5
ABAT	GABAT	ENSG00000183044	4-aminobutyrate aminotransferase	16	8674565-8784575	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041528, HPA041690	Enhanced	Supported	Supported	Mitochondria	Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 164.5;kidney: 135.3;liver: 175.2	thyroid gland: 47.5	Cell line enhanced		Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
SLC25A10	DIC	ENSG00000183048	Solute carrier family 25 member 10	17	81712236-81721016	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023048	Supported		Supported	Nucleoplasm<br>Mitochondria	Urothelial cancer:1.31e-4 (favourable), Head and neck cancer:2.56e-4 (favourable), Ovarian cancer:8.14e-4 (favourable)	Expressed in all	Mixed			kidney: 35.4	Expressed in all		
CAMK1D	CKLiK	ENSG00000183049	Calcium/calmodulin dependent protein kinase ID	10	12349482-12835545	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007266	Enhanced		Approved	Nucleus<br>Cytosol	Lung cancer:1.67e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 52.0	skin,thyroid gland: 21.9	Cell line enhanced		HDLM-2: 105.6;U-266/70: 38.2
RGPD6	RGP6	ENSG00000183054	RANBP2-like and GRIP domain containing 6	2	110513812-110577185	Predicted intracellular proteins	Evidence at protein level	HPA045704, HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Expressed in all			testis: 83.3	Mixed		
LYSMD4	FLJ33008	ENSG00000183060	LysM domain containing 4	15	99715697-99733561	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA029152, HPA059824	Approved		Approved	Actin filaments<br>Cytosol		Expressed in all	Mixed			skin: 18.3	Mixed		
WBP2NL	FLJ26145, GRAMD7, MGC26816, PAWP	ENSG00000183066	WBP2 N-terminal like	22	41998725-42058456	Predicted intracellular proteins	Evidence at protein level	HPA048557	Enhanced					Not detected	Tissue enriched	8	testis: 11.7	epididymis: 1.5	Not detected		
IGSF5	JAM4	ENSG00000183067	Immunoglobulin superfamily member 5	21	39745407-39802096	Predicted membrane proteins	Evidence at transcript level	HPA057282	Uncertain					Tissue enhanced	Mixed			placenta: 3.6	Cell line enhanced		T-47d: 5.4
NKX2-5	CSX, CSX1, NKX2.5, NKX2E, NKX4-1	ENSG00000183072	NK2 homeobox 5	5	173232109-173235357	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065034			Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	126	heart muscle: 32.7;spleen: 14.5	breast,placenta,urinary bladder: 0.1	Cell line enhanced		HEK 293: 27.1;NTERA-2: 10.7;U-2 OS: 24.8;U-251 MG: 15.4
AFMID	DKFZp686F03259, KF	ENSG00000183077	Arylformamidase	17	78187317-78207701	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023861, HPA026536	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			kidney: 87.5	Expressed in all		
GAS6	AXLLG, AXSF, DKFZp666G247, FLJ34709	ENSG00000183087	Growth arrest specific 6	13	113820549-113864067	Predicted secreted proteins	Evidence at protein level	HPA008275, HPA056080	Approved		Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:8.93e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 193.7	Cell line enhanced		BJ: 295.0;BJ hTERT+: 407.1;RPMI-8226: 339.8
FREM3		ENSG00000183090	FRAS1 related extracellular matrix 3	4	143577302-143700675	Predicted secreted proteins	Evidence at protein level	HPA041641	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.6	lung: 0.6	Not detected		
NEB	NEB177D, NEM2	ENSG00000183091	Nebulin	2	151485336-151734487	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016601	Enhanced					Tissue enhanced	Tissue enriched	97	skeletal muscle: 3273.5	prostate: 33.7	Cell line enhanced		RH-30: 33.2;U-266/70: 9.8
BEGAIN	KIAA1446	ENSG00000183092	Brain enriched guanylate kinase associated	14	100537147-100587413	Predicted intracellular proteins	Evidence at protein level	HPA002899	Uncertain		Uncertain	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 20.0	adrenal gland: 3.8	Group enriched	8	HeLa: 36.4;SH-SY5Y: 137.4
GPC6		ENSG00000183098	Glypican 6	13	93226842-94407401	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA017671	Approved		Approved	Golgi apparatus<br>Vesicles		Expressed in all	Mixed			gallbladder: 27.3	Cell line enhanced		ASC diff: 42.9;HSkMC: 51.5;U-87 MG: 51.7
ARHGEF37	FLJ41603	ENSG00000183111	Rho guanine nucleotide exchange factor 37	5	149551947-149634968	Predicted intracellular proteins	Evidence at protein level	HPA043885, HPA053487	Uncertain		Approved	Cytosol	Renal cancer:6.85e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 68.3	Cell line enhanced		EFO-21: 13.0;HaCaT: 22.9;hTCEpi: 24.4
FAM43B	FLJ44952	ENSG00000183114	Family with sequence similarity 43 member B	1	20552439-20555010	Predicted intracellular proteins	Evidence at protein level	HPA050813	Approved		Approved	Cytosol		Tissue enhanced	Tissue enhanced		adrenal gland: 10.3	epididymis: 3.5	Cell line enhanced		AN3-CA: 2.9;fHDF/TERT166: 3.6;SCLC-21H: 4.8;SiHa: 8.3
CSMD1	KIAA1890, PPP1R24	ENSG00000183117	CUB and Sushi multiple domains 1	8	2935353-4994972	Predicted membrane proteins	Evidence at protein level	HPA074707			Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.2;testis: 4.7	fallopian tube: 1.1	Cell line enhanced		K-562: 4.4;U-2 OS: 2.3;U-266/70: 1.7;U-266/84: 1.5;U-698: 1.3
CALHM3	bA225H22.7, FAM26A	ENSG00000183128	Calcium homeostasis modulator 3	10	103472804-103479240	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA018205	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Not detected			testis: 0.4	Cell line enhanced		CAPAN-2: 2.2;U-266/84: 10.0
PTGDR2	CD294, CRTH2, DP2, GPR44	ENSG00000183134	Prostaglandin D2 receptor 2	11	60850940-60855971	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014259	Uncertain					Mixed	Tissue enhanced		small intestine: 7.1;stomach: 7.5	parathyroid gland: 5.0	Cell line enhanced		HEL: 8.5;Hep G2: 3.2;HMC-1: 5.1;K-562: 3.6;NB-4: 8.7
CEP57L1	bA487F23.2, C6orf182, MGC21731	ENSG00000183137	Centrosomal protein 57 like 1	6	109095110-109163932	Predicted intracellular proteins	Evidence at protein level	HPA040378	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			testis: 47.6	Expressed in all		
RIPPLY3	DSCR6	ENSG00000183145	Ripply transcriptional repressor 3	21	37006150-37019659	Predicted intracellular proteins	Evidence at transcript level	HPA055541	Uncertain					Mixed	Not detected			prostate: 0.2	Cell line enhanced		SCLC-21H: 3.2;T-47d: 1.5
PRORY	CYorf17	ENSG00000183146	Proline rich, Y-linked	Y	21382954-21386360	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		small intestine: 1.8	colon,rectum: 0.6	Cell line enhanced		U-266/84: 2.4
ANKRD20A2		ENSG00000183148	Ankyrin repeat domain 20 family member A2	9	40223285-40266392	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Tissue enriched	6	testis: 4.9	spleen: 0.7	Cell line enhanced		Karpas-707: 9.3;U-266/84: 2.9
GPR19		ENSG00000183150	G protein-coupled receptor 19	12	12660891-12696207	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013955	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.4;testis: 7.8	appendix: 2.7	Cell line enhanced		HDLM-2: 37.0;NTERA-2: 39.8
GJD3	Cx30.2, CX31.9, GJA11, GJC1	ENSG00000183153	Gap junction protein delta 3	17	40362931-40363815	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		spleen: 7.0	stomach: 2.7	Cell line enhanced		BEWO: 14.7
RABIF	mss4, RASGRF3	ENSG00000183155	RAB interacting factor	1	202878957-202889135	Predicted intracellular proteins	Evidence at protein level	HPA027715, HPA054936	Approved		Approved	Microtubules<br>Cytokinetic bridge	Renal cancer:2.61e-5 (unfavourable), Ovarian cancer:5.64e-5 (favourable), Liver cancer:1.55e-4 (unfavourable)	Expressed in all	Mixed			testis: 26.1	Expressed in all		
TMEM119		ENSG00000183160	Transmembrane protein 119	12	108589846-108598320	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA051870, HPA052650	Enhanced				Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 93.0	gallbladder: 55.2	Cell line enhanced		ASC diff: 378.8;ASC TERT1: 106.4;BJ hTERT+: 134.8;HSkMC: 171.1
FANCF	FAF	ENSG00000183161	Fanconi anemia complementation group F	11	22622519-22626787	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:2.27e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 10.8	Cell line enhanced		SCLC-21H: 29.4
CALN1		ENSG00000183166	Calneuron 1	7	71779491-72447151	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036278, HPA036708	Approved		Uncertain	Vesicles<br>Plasma membrane		Mixed	Group enriched	5	adrenal gland: 14.7;cerebral cortex: 46.4	testis: 6.0	Cell line enhanced		Karpas-707: 33.8;NTERA-2: 6.0;REH: 6.4;SCLC-21H: 7.8;U-2 OS: 7.6
SMDT1	C22orf32, DDDD, dJ186O1.1, EMRE	ENSG00000183172	Single-pass membrane protein with aspartate rich tail 1	22	42079691-42084284	Predicted membrane proteins, Transporters	Evidence at protein level	HPA032117, HPA060340	Uncertain		Supported	Nucleus<br>Mitochondria	Renal cancer:2.36e-9 (favourable), Endometrial cancer:5.32e-8 (favourable), Pancreatic cancer:5.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 7.8	Mixed		
GABRR3		ENSG00000183185	Gamma-aminobutyric acid type A receptor rho3 subunit (gene/pseudogene)	3	97986673-98035304	FDA approved drug targets, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
C2CD4C	FAM148C, KIAA1957, NLF3	ENSG00000183186	C2 calcium dependent domain containing 4C	19	405438-409170	Predicted intracellular proteins	Evidence at protein level	HPA055915	Uncertain		Approved	Vesicles		Tissue enhanced	Group enriched	6	adipose tissue: 2.6;cerebral cortex: 10.6;gallbladder: 4.4	endometrium: 0.9	Cell line enhanced		HDLM-2: 5.9;NTERA-2: 6.2;SCLC-21H: 13.0;U-2 OS: 6.8
CHST6	MCDC1	ENSG00000183196	Carbohydrate sulfotransferase 6	16	75472052-75495384	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		cervix, uterine: 16.3;duodenum: 10.6;small intestine: 10.9	cerebral cortex: 7.9	Cell line enhanced		AN3-CA: 10.8;CAPAN-2: 11.4;NTERA-2: 6.2;U-2 OS: 8.0;WM-115: 6.7
POTEC	A26B2, CT104.6, DKFZp686J0529, POTE-18, POTE18	ENSG00000183206	POTE ankyrin domain family member C	18	14507339-14543585	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	14	testis: 1.4	prostate: 0.1	Not detected		
RUVBL2	ECP51, INO80J, Reptin52, RVB2, TIH2, TIP48, TIP49b	ENSG00000183207	RuvB like AAA ATPase 2	19	48993448-49015995	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012432, HPA042880, HPA067966	Enhanced		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Liver cancer:9.28e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 72.4	Expressed in all		
GDPGP1	C15orf58	ENSG00000183208	GDP-D-glucose phosphorylase 1	15	90233808-90245811	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA048189, HPA059841	Approved		Approved	Cytosol	Breast cancer:6.32e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.6	Mixed		
CTNNA3	MGC26194, VR22	ENSG00000183230	Catenin alpha 3	10	65912518-67696169	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061818	Enhanced					Tissue enhanced	Tissue enhanced		cerebral cortex: 8.5;heart muscle: 12.4	liver: 4.4	Cell line enhanced		Daudi: 1.7;NTERA-2: 1.7;RPMI-8226: 1.6;SCLC-21H: 1.8;U-266/70: 5.0
RIMBP3C		ENSG00000183246	RIMS binding protein 3C	22	21545357-21551461	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	32	testis: 15.7	spleen: 0.4	Not detected		
PRR36		ENSG00000183248	Proline rich 36	19	7868719-7874379	Predicted intracellular proteins	Evidence at protein level	HPA062741	Uncertain		Approved	Nucleus<br>Golgi apparatus	Testis cancer:7.74e-4 (favourable)	Mixed	Tissue enriched	9	cerebral cortex: 18.0	prostate: 1.9	Cell line enhanced		REH: 26.2;SCLC-21H: 9.4;SH-SY5Y: 19.0
OR51B4		ENSG00000183251	Olfactory receptor family 51 subfamily B member 4	11	5301014-5301996	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Group enriched	8	K-562: 3.2;U-2197: 4.1
PTTG1IP	C21orf1, C21orf3, PBF	ENSG00000183255	Pituitary tumor-transforming 1 interacting protein	21	44849585-44873903	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB034146, HPA061827	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 243.5	Expressed in all		
DDX41	ABS, MGC8828	ENSG00000183258	DEAD-box helicase 41	5	177511577-177517469	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017911, HPA048803	Enhanced		Supported	Nucleus	Renal cancer:2.21e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 52.6	Expressed in all		
ABHD16B	C20orf135, dJ591C20.1	ENSG00000183260	Abhydrolase domain containing 16B	20	63861498-63862988	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA059272	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			testis: 5.7	Cell line enhanced		PC-3: 17.5
OR52E8		ENSG00000183269	Olfactory receptor family 52 subfamily E member 8	11	5856674-5857734	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CCDC60	MGC39827	ENSG00000183273	Coiled-coil domain containing 60	12	119334712-119541047	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 28.0;testis: 19.7	cervix, uterine: 8.2	Not detected		
PLGLB1	PLGL, PRP-B	ENSG00000183281	Plasminogen-like B1	2	87002559-87021852	Predicted secreted proteins	Evidence at transcript level	HPA053770			Approved	Vesicles		Tissue enriched	Tissue enriched	8	liver: 120.5	skin: 15.4	Mixed		
DAZAP2	KIAA0058	ENSG00000183283	DAZ associated protein 2	12	51238292-51271362	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045940			Supported	Nuclear speckles	Renal cancer:3.94e-9 (favourable)	Expressed in all	Expressed in all			bone marrow: 336.1	Expressed in all		
CCBE1	FLJ30681, KIAA1983	ENSG00000183287	Collagen and calcium binding EGF domains 1	18	59430940-59697380	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041361, HPA041374	Uncertain		Enhanced	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		ovary: 40.6	cervix, uterine: 16.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 91.8;HBF TERT88: 109.2;hTERT-HME1: 117.8;LHCN-M2: 146.3
SELENOF	SEP15	ENSG00000183291	Selenoprotein F	1	86862445-86914424	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054937			Approved	Nucleoli<br>Cytosol	Liver cancer:1.98e-5 (unfavourable), Colorectal cancer:6.53e-4 (favourable), Head and neck cancer:8.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 361.7	Expressed in all		
TISP43		ENSG00000183292	Uncharacterized LOC150527	2	130570829-130584161	Predicted intracellular proteins	Evidence at transcript level	HPA044732	Uncertain					Not detected	Tissue enriched	11	testis: 11.5	skin: 1.0	Not detected		
OR5P2	JCG3	ENSG00000183303	Olfactory receptor family 5 subfamily P member 2	11	7795905-7796973	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.1	Not detected		
FAM9A	TEX39A	ENSG00000183304	Family with sequence similarity 9 member A	X	8790795-8801383	Predicted intracellular proteins	Evidence at protein level	HPA056076	Uncertain					Not detected	Tissue enriched	25	testis: 7.2	adrenal gland,cerebral cortex: 0.2	Cell line enriched	16	U-266/84: 6.2
MAGEA2B	MAGE2, MAGEA2, MAGEA2b, MGC16973	ENSG00000183305	MAGE family member A2B	X	152714586-152718607	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	9	testis: 1.9	placenta: 0.2	Cell line enhanced		BEWO: 36.8;HMC-1: 34.9;K-562: 31.7;SH-SY5Y: 56.8;U-266/70: 21.5;U-266/84: 32.0
CECR6		ENSG00000183307	Cat eye syndrome chromosome region, candidate 6	22	17116299-17121367	Predicted membrane proteins	Evidence at protein level	HPA068790	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Tissue enhanced	Group enriched	7	cerebral cortex: 15.0;prostate: 10.8	testis: 1.9	Cell line enhanced		AF22: 5.9;SCLC-21H: 16.7;THP-1: 8.0;U-937: 7.7
ZNF623	KIAA0628	ENSG00000183309	Zinc finger protein 623	8	143636013-143656418	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA044372	Uncertain		Approved	Nucleus	Endometrial cancer:2.94e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 6.2	Cell line enhanced		SiHa: 24.6
OR2T34		ENSG00000183310	Olfactory receptor family 2 subfamily T member 34	1	248573801-248574757	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52L1		ENSG00000183313	Olfactory receptor family 52 subfamily L member 1	11	5985892-5986985	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
EPHA10	FLJ16103, FLJ33655	ENSG00000183317	EPH receptor A10	1	37713880-37765133	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027497	Uncertain					Mixed	Tissue enhanced		testis: 20.4	colon: 7.9	Cell line enhanced		BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
SPDYE4		ENSG00000183318	Speedy/RINGO cell cycle regulator family member E4	17	8753106-8758559	Predicted intracellular proteins	Evidence at protein level	HPA025704, HPA051750	Enhanced					Not detected	Tissue enriched	20	testis: 10.5	bone marrow: 0.5	Cell line enhanced		A549: 1.4;HeLa: 1.1
CCDC125	KENAE	ENSG00000183323	Coiled-coil domain containing 125	5	69280175-69332809	Predicted intracellular proteins	Evidence at protein level	HPA041878	Approved		Uncertain	Nucleoplasm<br>Nuclear membrane<br>Intermediate filaments	Urothelial cancer:2.51e-4 (favourable), Endometrial cancer:4.40e-4 (favourable), Breast cancer:8.06e-4 (unfavourable)	Expressed in all	Mixed			prostate: 11.5	Cell line enhanced		T-47d: 25.4
REC114	C15orf60, CT147, FLJ27520, FLJ36860, FLJ44083, LOC283677	ENSG00000183324	REC114 meiotic recombination protein	15	73443158-73560014	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	96	testis: 63.6	heart muscle: 0.6	Not detected		
BOLA2	BOLA2A, My016	ENSG00000183336	BolA family member 2	16	29443056-29454964	Predicted intracellular proteins	Evidence at protein level	HPA045380, HPA046696	Supported		Uncertain	Nucleus		Not detected	Mixed			duodenum: 12.0	Mixed		
BCOR	FLJ20285, KIAA1575	ENSG00000183337	BCL6 corepressor	X	40049815-40177329	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056308, HPA073591			Enhanced	Nucleus	Liver cancer:1.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.0	Expressed in all		
JRKL	HHMJG	ENSG00000183340	JRK-like	11	96389989-96507574	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046184, HPA060341	Uncertain		Approved	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			parathyroid gland: 19.2	Expressed in all		
C10orf107	bA63A2.1, Em:AC022398.2, MGC44593	ENSG00000183346	Chromosome 10 open reading frame 107	10	61662961-61766766	Predicted intracellular proteins	Evidence at protein level	HPA041398	Enhanced		Uncertain	Nucleoplasm<br>Centrosome<br>Cytosol	Endometrial cancer:1.79e-4 (favourable), Glioma:3.99e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 44.2;testis: 30.5	parathyroid gland: 12.6	Group enriched	6	MOLT-4: 21.5;SH-SY5Y: 6.0
GBP6	DKFZp686G0786	ENSG00000183347	Guanylate binding protein family member 6	1	89364058-89386461	Predicted intracellular proteins	Evidence at protein level	HPA027744	Enhanced					Group enriched	Tissue enriched	7	esophagus: 448.5	tonsil: 65.9	Group enriched	10	A-431: 6.0;HaCaT: 13.1
KIAA2026	FLJ20375	ENSG00000183354	KIAA2026	9	5881596-6007901	Predicted intracellular proteins	Evidence at protein level	HPA002109	Uncertain		Approved	Nucleus<br>Vesicles<br>Cytosol	Renal cancer:8.34e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
OVCH2	OVTN	ENSG00000183378	Ovochymase 2 (gene/pseudogene)	11	7689438-7706421	Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	22	epididymis: 205.6	skin: 9.5	Cell line enriched	7	REH: 20.7
SYNDIG1L	capucin, IFITMD4, TMEM90A	ENSG00000183379	Synapse differentiation inducing 1 like	14	74405893-74426102	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA042594, HPA048487	Uncertain					Mixed	Tissue enriched	10	epididymis: 13.4	lung: 1.3	Not detected		
FHL3	SLIM2	ENSG00000183386	Four and a half LIM domains 3	1	37996770-38005606	Predicted intracellular proteins	Evidence at protein level	HPA045723			Approved	Nucleus	Renal cancer:4.20e-11 (unfavourable), Liver cancer:8.59e-5 (unfavourable), Breast cancer:5.62e-4 (favourable)	Expressed in all	Tissue enriched	13	skeletal muscle: 569.1	smooth muscle: 43.5	Mixed		
OR56A4		ENSG00000183389	Olfactory receptor family 56 subfamily A member 4	11	6001986-6003194	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PMCH	MCH	ENSG00000183395	Pro-melanin concentrating hormone	12	102196459-102197845	Predicted secreted proteins	Evidence at protein level	HPA046055, HPA061884	Enhanced					Tissue enhanced	Tissue enhanced		lymph node: 1.1	appendix: 0.7	Cell line enriched	9	HDLM-2: 40.8
TMEM89		ENSG00000183396	Transmembrane protein 89	3	48620759-48621855	Predicted membrane proteins	Evidence at protein level	HPA053577	Uncertain					Not detected	Tissue enriched	10	testis: 9.4	bone marrow: 0.9	Not detected		
C19orf71	LOC100128569	ENSG00000183397	Chromosome 19 open reading frame 71	19	3539154-3544030	Predicted intracellular proteins	Evidence at protein level	HPA048654	Uncertain		Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:2.02e-5 (favourable), Pancreatic cancer:2.03e-5 (favourable), Head and neck cancer:2.35e-4 (favourable)	Tissue enriched	Mixed			testis: 29.5	Cell line enhanced		HeLa: 52.4;WM-115: 167.8
CCDC159		ENSG00000183401	Coiled-coil domain containing 159	19	11344684-11354944	Predicted intracellular proteins	Evidence at protein level	HPA047126, HPA054655	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Endometrial cancer:1.87e-7 (favourable), Pancreatic cancer:1.42e-4 (favourable), Urothelial cancer:8.62e-4 (favourable), Ovarian cancer:9.46e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.5	Mixed		
RIPK4	ANKK2, ANKRD3, DIK, PKK, RIP4	ENSG00000183421	Receptor interacting serine/threonine kinase 4	21	41739369-41767106	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA030942	Enhanced				Ovarian cancer:6.22e-5 (unfavourable), Pancreatic cancer:3.48e-4 (unfavourable), Renal cancer:6.52e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 31.5	small intestine: 15.0	Cell line enhanced		CAPAN-2: 27.8;HaCaT: 41.4
LRIT3	CSNB1F, FIGLER4, FLJ44691	ENSG00000183423	Leucine rich repeat, Ig-like and transmembrane domains 3	4	109848202-109872315	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA013454	Supported		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Not detected	Not detected			kidney: 0.9	Not detected		
NPIPA1	morpheus, NPIP	ENSG00000183426	Nuclear pore complex interacting protein family member A1	16	14922802-14952060	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA053611	Supported		Approved	Nucleoplasm		Mixed	Mixed			ovary: 68.6	Mixed		
SF3A3	PRP9, PRPF9, SAP61, SF3a60	ENSG00000183431	Splicing factor 3a subunit 3	1	37956975-37990921	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA032054, HPA032055	Enhanced		Enhanced	Nucleoplasm	Liver cancer:2.11e-8 (unfavourable)	Expressed in all	Expressed in all			endometrium: 35.2	Expressed in all		
TFDP3	CT30, E2F-like, HCA661	ENSG00000183434	Transcription factor Dp family member 3	X	133216669-133218348	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	81	testis: 8.0	all non-specific tissues: 0.0	Not detected		
TRIM61	RNF35	ENSG00000183439	Tripartite motif containing 61	4	164954446-164977668	Predicted intracellular proteins	Evidence at transcript level	HPA049109	Uncertain		Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		testis: 10.5	thyroid gland: 4.6	Cell line enhanced		HHSteC: 6.6;U-266/70: 8.1;U-266/84: 4.0
GRIN2A	GluN2A, NMDAR2A	ENSG00000183454	Glutamate ionotropic receptor NMDA type subunit 2A	16	9753404-10182754	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022725	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 25.8	testis: 6.1	Cell line enhanced		fHDF/TERT166: 3.3;U-138 MG: 4.4
URAD	PRHOXNB	ENSG00000183463	Ureidoimidazoline (2-oxo-4-hydroxy-4-carboxy-5-) decarboxylase	13	27977714-27988654	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA038972	Uncertain					Tissue enriched	Group enriched	6	colon: 12.6;duodenum: 8.3;small intestine: 17.9	appendix: 2.3	Group enriched	12	BEWO: 2.6;CACO-2: 2.1
GTF2H2C		ENSG00000183474	GTF2H2 family member C	5	69560208-69594723	Predicted intracellular proteins	Evidence at protein level	HPA047001			Approved	Nuclear speckles		Mixed	Mixed			thyroid gland: 8.3	Mixed		
ASB7		ENSG00000183475	Ankyrin repeat and SOCS box containing 7	15	100602534-100651705	Predicted intracellular proteins	Evidence at protein level	HPA003300	Enhanced		Approved	Nucleus<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			testis: 12.5	Expressed in all		
SH2D7	LOC646892	ENSG00000183476	SH2 domain containing 7	15	78077808-78104909	Predicted intracellular proteins	Evidence at transcript level	HPA051320	Approved					Mixed	Group enriched	7	colon: 1.6;duodenum: 2.1;small intestine: 1.9;testis: 5.7	cerebral cortex: 0.4	Cell line enhanced		SH-SY5Y: 1.4
TREX2		ENSG00000183479	Three prime repair exonuclease 2	X	153444720-153470587	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054060	Uncertain					Mixed	Tissue enriched	8	skin: 28.8	seminal vesicle: 3.4	Cell line enhanced		U-937: 5.4
GPR132	G2A	ENSG00000183484	G protein-coupled receptor 132	14	105049389-105065445	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029694, HPA029695	Supported				Renal cancer:1.71e-5 (unfavourable), Cervical cancer:3.21e-4 (favourable), Head and neck cancer:6.44e-4 (favourable)	Mixed	Mixed			appendix: 9.4	Group enriched	6	HDLM-2: 24.9;Karpas-707: 19.2;THP-1: 5.6
MX2	MXB	ENSG00000183486	MX dynamin like GTPase 2	21	41361943-41409390	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030235	Uncertain				Endometrial cancer:3.71e-5 (unfavourable)	Expressed in all	Mixed			spleen: 45.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 156.9;BJ hTERT+ SV40 Large T+ RasG12V: 158.8;MOLT-4: 89.4;U-266/84: 131.4;U-937: 146.7
EP400	CAGH32, DKFZP434I225, KIAA1498, KIAA1818, P400, TNRC12	ENSG00000183495	E1A binding protein p400	12	131949920-132081102	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA016704, HPA049013	Supported		Supported	Nucleus	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.8	Expressed in all		
MEX3B	DKFZp434J0617, RKHD3, RNF195	ENSG00000183496	Mex-3 RNA binding family member B	15	82041778-82046141	Predicted intracellular proteins	Evidence at protein level	HPA041093	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 41.6	endometrium: 10.1	Cell line enhanced		AN3-CA: 58.8;HEL: 43.1
FAM46C	FLJ20202	ENSG00000183508	Family with sequence similarity 46 member C	1	117605934-117628372	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA054049	Uncertain		Approved	Nucleoplasm	Renal cancer:2.77e-5 (favourable), Endometrial cancer:3.75e-5 (favourable)	Expressed in all	Mixed			testis: 58.7	Cell line enhanced		Karpas-707: 208.6;RPMI-8226: 124.6;U-266/70: 61.2
COA5	C2orf64, FLJ27524, MGC52110, Pet191	ENSG00000183513	Cytochrome c oxidase assembly factor 5	2	98599310-98608515	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA057768	Uncertain		Supported	Mitochondria	Urothelial cancer:1.00e-5 (favourable), Lung cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 42.3	Expressed in all		
UTP11	CGI-94, UTP11L	ENSG00000183520	UTP11, small subunit processome component homolog (S. cerevisiae)	1	38009258-38024824	Predicted intracellular proteins	Evidence at protein level	HPA045830	Approved		Approved	Nucleus	Renal cancer:1.42e-8 (unfavourable), Liver cancer:7.44e-8 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 37.3	Expressed in all		
PSMG1	c21-LRP, DSCR2, LRPC21, PAC1	ENSG00000183527	Proteasome assembly chaperone 1	21	39174769-39183851	Predicted intracellular proteins	Evidence at protein level	HPA057193, HPA070225	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 68.5	Expressed in all		
PRR14L	C22orf30, MGC50372	ENSG00000183530	Proline rich 14 like	22	31676256-31750140	Predicted intracellular proteins	Evidence at protein level	HPA062645	Uncertain		Approved	Nucleoplasm	Renal cancer:3.00e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 15.2	Expressed in all		
KLRC4	NKG2-F	ENSG00000183542	Killer cell lectin like receptor C4	12	10407382-10409757	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		spleen: 13.1	lymph node: 5.6	Cell line enhanced		HeLa: 3.1;U-698: 1.1
ACSM5	FLJ20581	ENSG00000183549	Acyl-CoA synthetase medium-chain family member 5	16	20409534-20441336	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041435	Uncertain					Group enriched	Tissue enriched	5	liver: 142.6	adipose tissue: 26.9	Group enriched	5	ASC diff: 3.6;ASC TERT1: 8.0;HSkMC: 10.0;U-87 MG: 8.4
C10orf120	bA318C4.1	ENSG00000183559	Chromosome 10 open reading frame 120	10	122697709-122699822	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	375	testis: 49.4	epididymis: 0.1	Not detected		
IZUMO1R	Folbp3, FOLR4, JUNO	ENSG00000183560	IZUMO1 receptor, JUNO	11	94305592-94307721	Predicted secreted proteins, Transporters	Evidence at protein level							Not detected	Not detected			adrenal gland: 0.8	Not detected		
SERHL2		ENSG00000183569	Serine hydrolase-like 2	22	42553617-42574382	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	12	breast: 558.7	epididymis: 45.4	Cell line enriched	9	SK-BR-3: 207.3
PCBP3	FLJ44028, PCBP3-OT1, PCBP3OT	ENSG00000183570	Poly(rC) binding protein 3	21	45643694-45942454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030247	Approved					Mixed	Tissue enhanced		testis: 21.6	cerebral cortex: 12.7	Cell line enhanced		HDLM-2: 53.3;HSkMC: 30.0;SH-SY5Y: 50.2;U-87 MG: 24.6;U-937: 24.7
PGPEP1L		ENSG00000183571	Pyroglutamyl-peptidase I-like	15	98968230-99007795	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA041781	Uncertain					Not detected	Group enriched	6	heart muscle: 2.4;skeletal muscle: 10.5;testis: 3.8	breast,esophagus: 0.9	Cell line enhanced		U-2 OS: 1.1
SETD3	C14orf154, FLJ23027	ENSG00000183576	SET domain containing 3	14	99397746-99480889	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003591, HPA003639	Approved		Approved	Mitochondria	Renal cancer:1.89e-15 (favourable), Head and neck cancer:6.46e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 154.4	Expressed in all		
TNFAIP8L3	FLJ41287	ENSG00000183578	TNF alpha induced protein 8 like 3	15	51056598-51105276	Predicted intracellular proteins	Evidence at protein level	HPA048372, HPA077484	Uncertain		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:3.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 137.0;smooth muscle: 122.3	fallopian tube: 38.9	Cell line enhanced		ASC TERT1: 61.0;HUVEC TERT2: 64.8;LHCN-M2: 60.7;TIME: 85.7
ZNRF3	BK747E2.3, FLJ22057, KIAA1133, RNF203	ENSG00000183579	Zinc and ring finger 3	22	28883592-29057487	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA036702, HPA036703	Uncertain		Uncertain	Golgi apparatus		Not detected	Mixed			epididymis: 16.4	Cell line enhanced		Hep G2: 31.1
FBXL7	FBL6, FBL7, KIAA0840	ENSG00000183580	F-box and leucine rich repeat protein 7	5	15500196-15939795	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055464	Uncertain				Liver cancer:1.29e-4 (unfavourable), Thyroid cancer:6.69e-4 (unfavourable)	Expressed in all	Mixed			endometrium,smooth muscle: 36.6	Mixed		
TANGO2	C22orf25, DKFZp761P1121	ENSG00000183597	Transport and golgi organization 2 homolog	22	20017014-20065926	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003080	Approved	Approved			Pancreatic cancer:3.01e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 47.5	Expressed in all		
HIST2H3D		ENSG00000183598	Histone cluster 2 H3 family member d	1	149813271-149813681	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		bone marrow: 2.5	gallbladder: 1.8	Cell line enhanced		U-266/70: 16.7
SFXN4		ENSG00000183605	Sideroflexin 4	10	119140767-119165667	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018028, HPA020872	Approved		Supported	Vesicles		Expressed in all	Expressed in all			thyroid gland: 47.3	Expressed in all		
GKN2	blottin, BRICD1B, GDDR, PRO813, TFIZ1, VLTI465	ENSG00000183607	Gastrokine 2	2	68945232-68952970	Predicted secreted proteins	Evidence at protein level	HPA057765	Enhanced					Tissue enriched	Tissue enriched	37	stomach: 3843.6	lung: 103.7	Cell line enhanced		A549: 1.6;HMC-1: 1.5;NTERA-2: 2.1;PC-3: 3.6;U-2 OS: 1.5;U-266/70: 1.3
FAM167B	C1orf90, MGC10820	ENSG00000183615	Family with sequence similarity 167 member B	1	32247233-32248856	Predicted intracellular proteins	Evidence at protein level	HPA029398, HPA062074	Approved		Approved	Actin filaments	Colorectal cancer:1.11e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 9.4	Cell line enhanced		EFO-21: 11.4;SK-MEL-30: 23.7;U-2197: 28.2
MRPL54		ENSG00000183617	Mitochondrial ribosomal protein L54	19	3762664-3768575	Predicted intracellular proteins	Evidence at protein level	HPA042117, HPA046767	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 90.1	Expressed in all		
ZNF438	bA330O11.1	ENSG00000183621	Zinc finger protein 438	10	30820207-31031937	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA039843	Uncertain		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			thyroid gland: 16.2	Cell line enhanced		U-937: 19.8
HMCES	C3orf37, DC12, SRAPD1	ENSG00000183624	5-hydroxymethylcytosine binding, ES cell specific	3	129278828-129306186	Predicted intracellular proteins	Evidence at protein level	HPA044968	Approved		Approved	Nucleus	Liver cancer:4.41e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 205.0	Expressed in all		
CCR3	CC-CKR-3, CD193, CKR3, CMKBR3	ENSG00000183625	C-C motif chemokine receptor 3	3	46163604-46266706	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB003795	Uncertain					Not detected	Mixed			small intestine: 2.9	Cell line enriched	9	RPMI-8226: 20.3
DGCR6		ENSG00000183628	DiGeorge syndrome critical region gene 6	22	18906028-18914238	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 11.7	thyroid gland: 4.9	Mixed		
GOLGA8G	DKFZp434K052	ENSG00000183629	Golgin A8 family member G	15	28519611-28533014	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	35	testis: 3.5	all non-specific tissues: 0.0	Not detected		
PRR32	CXorf64	ENSG00000183631	Proline rich 32	X	126819764-126821786	Predicted intracellular proteins	No evidence	HPA048386	Uncertain					Tissue enriched	Not detected			fallopian tube: 0.9	Not detected		
TP53TG3	P53TG3, TP53TG3A	ENSG00000183632	TP53 target 3	16	32673528-32676732	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.3	Not detected		
RP1L1	DCDC4B	ENSG00000183638	RP1 like 1	8	10606349-10712187	Predicted intracellular proteins	Evidence at protein level	HPA024686, HPA024744	Enhanced					Not detected	Not detected			skin: 0.2	Not detected		
KRTAP8-1	KAP8.1	ENSG00000183640	Keratin associated protein 8-1	21	30812697-30813252	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Not detected			testis: 0.3	Not detected		
C11orf88	FLJ46266	ENSG00000183644	Chromosome 11 open reading frame 88	11	111514785-111537031	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	5	fallopian tube: 141.7;testis: 39.5	lung: 17.8	Cell line enhanced		CACO-2: 1.3;Karpas-707: 1.2
ZNF530	KIAA1508	ENSG00000183647	Zinc finger protein 530	19	57599885-57612722	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045868	Uncertain		Approved	Vesicles		Mixed	Mixed			spleen: 3.1	Cell line enhanced		HEK 293: 68.7;U-266/84: 40.3
NDUFB1	CI-MNLL, MNLL	ENSG00000183648	NADH:ubiquinone oxidoreductase subunit B1	14	92116122-92121917	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063737			Supported	Nuclear speckles<br>Mitochondria	Renal cancer:1.31e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 278.8	Expressed in all		
MARCH11	MARCH-XI	ENSG00000183654	Membrane associated ring-CH-type finger 11	5	16067139-16180762	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	20	testis: 90.3	cerebral cortex: 4.5	Cell line enriched	13	SH-SY5Y: 89.2
KLHL25	ENC-2, ENC2, FLJ12587	ENSG00000183655	Kelch like family member 25	15	85759323-85795030	Predicted intracellular proteins	Evidence at protein level	HPA023450	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 15.8	testis: 9.9	Mixed		
FAM19A1	TAFA-1, TAFA1	ENSG00000183662	Family with sequence similarity 19 member A1, C-C motif chemokine like	3	68004216-68545625	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013407	Approved					Tissue enhanced	Tissue enriched	6	cerebral cortex: 30.8	seminal vesicle: 5.3	Cell line enriched	9	REH: 1.5
TRMT12	FLJ20772, Trm12, TYW2	ENSG00000183665	TRNA methyltransferase 12 homolog	8	124450820-124462150	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023939	Approved		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:2.99e-5 (unfavourable), Liver cancer:5.10e-4 (unfavourable), Thyroid cancer:9.25e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 14.7	Cell line enhanced		MCF7: 55.6
PSG9	PSG11, PSGII	ENSG00000183668	Pregnancy specific beta-1-glycoprotein 9	19	43211791-43269530	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	118	placenta: 147.0	smooth muscle: 1.2	Cell line enhanced		BJ: 4.4;BJ hTERT+ SV40 Large T+: 4.2;HBF TERT88: 9.0;T-47d: 4.0;U-2197: 9.0
GPR1		ENSG00000183671	G protein-coupled receptor 1	2	206175316-206218047	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010525	Uncertain		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		placenta: 5.6	esophagus: 2.7	Cell line enhanced		HHSteC: 112.4;hTCEpi: 44.7
BMP8A		ENSG00000183682	Bone morphogenetic protein 8a	1	39491646-39525935	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	19	thyroid gland: 82.0	testis: 4.4	Cell line enhanced		U-2197: 12.8;U-266/70: 5.4;U-266/84: 4.6
ALYREF	ALY, ALY/REF, BEF, REF, THOC4	ENSG00000183684	Aly/REF export factor	17	81887844-81891586	Predicted intracellular proteins	Evidence at protein level	CAB016281, HPA019799, HPA061282	Supported		Enhanced	Nuclear speckles	Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 88.5	Expressed in all		
RFLNB	Cfm1, FAM101B, MGC45871, RefilinB	ENSG00000183688	Refilin B	17	439978-445939	Predicted intracellular proteins	Evidence at protein level	HPA030879, HPA060388	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:1.54e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 49.3	placenta: 15.2	Cell line enhanced		fHDF/TERT166: 74.0;HMC-1: 195.7
EFHC2	FLJ22843, MRX74	ENSG00000183690	EF-hand domain containing 2	X	44147882-44343672	Predicted intracellular proteins	Evidence at protein level	HPA034492	Uncertain	Supported				Mixed	Tissue enhanced		fallopian tube: 25.8;testis: 15.4	endometrium: 6.8	Group enriched	5	CAPAN-2: 3.8;HEL: 4.2;HMC-1: 13.1
NOG	SYM1, SYNS1	ENSG00000183691	Noggin	17	56593699-56595590	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA061318	Approved				Pancreatic cancer:6.86e-5 (unfavourable), Endometrial cancer:6.66e-4 (favourable)	Mixed	Group enriched	5	cerebral cortex: 7.3;placenta: 15.8	lymph node: 2.2	Cell line enhanced		EFO-21: 117.5;LHCN-M2: 32.2;PC-3: 35.7;U-2 OS: 40.3
MRGPRX2	MRGX2	ENSG00000183695	MAS related GPR family member X2	11	19054455-19060681	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA055220	Approved					Not detected	Tissue enhanced		breast: 1.2;skin: 1.2	cervix, uterine: 0.6	Not detected		
UPP1	UDRPASE, UP, UPASE, UPP	ENSG00000183696	Uridine phosphorylase 1	7	48088628-48108733	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA054040, HPA055394	Enhanced		Enhanced	Nucleoplasm	Cervical cancer:1.02e-4 (unfavourable), Lung cancer:1.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 35.1	appendix: 17.8	Cell line enhanced		hTERT-HME1: 369.7;WM-115: 110.3
OR4N4		ENSG00000183706	Olfactory receptor family 4 subfamily N member 4	15	22094431-22095556	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome		Not detected	Tissue enriched	103	testis: 10.4	cervix, uterine: 0.1	Not detected		
IFNL2	IL-28A, IL28A	ENSG00000183709	Interferon lambda 2	19	39268514-39270092	Predicted secreted proteins	Evidence at transcript level	CAB025489	Uncertain					Not detected	Not detected			pancreas,testis: 0.1	Cell line enriched	27	HDLM-2: 11.7
OPCML	IGLON1, OBCAM, OPCM	ENSG00000183715	Opioid binding protein/cell adhesion molecule like	11	132414977-133532519	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Group enriched	Tissue enriched	8	cerebral cortex: 63.0	parathyroid gland: 7.5	Cell line enhanced		BJ: 7.9;HDLM-2: 1.8
TRIM52	RNF102	ENSG00000183718	Tripartite motif containing 52	5	181254417-181261139	Predicted intracellular proteins	Evidence at protein level	HPA054565, HPA056819	Uncertain		Supported	Nucleoli<br>Intermediate filaments	Renal cancer:3.46e-4 (unfavourable), Urothelial cancer:4.07e-4 (favourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
LHFP	MGC22429	ENSG00000183722	Lipoma HMGIC fusion partner	13	39342892-39603528	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058975	Approved		Approved	Nucleoli	Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable)	Expressed in all	Mixed			placenta: 196.1	Cell line enhanced		ASC diff: 177.4;HSkMC: 137.4
CMTM4	CKLFSF4	ENSG00000183723	CKLF like MARVEL transmembrane domain containing 4	16	66614750-66696707	Predicted membrane proteins	Evidence at protein level	HPA014704, HPA023890	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:4.72e-9 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 64.1	parathyroid gland: 47.8	Mixed		
TMEM50A	SMP1	ENSG00000183726	Transmembrane protein 50A	1	25337917-25362361	Predicted membrane proteins, Transporters	Evidence at protein level	HPA065192			Approved	Plasma membrane<br>Actin filaments<br>Cytosol	Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 71.2	Expressed in all		
NPBWR1	GPR7	ENSG00000183729	Neuropeptides B and W receptor 1	8	52938431-52941117	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Not detected			cerebral cortex: 0.7	Cell line enhanced		SiHa: 1.2
FIGLA	bHLHc8	ENSG00000183733	Folliculogenesis specific bHLH transcription factor	2	70777310-70790643	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	6	testis: 1.2	cervix, uterine: 0.2	Not detected		
ASCL2	ASH2, bHLHa45, HASH2	ENSG00000183734	Achaete-scute family bHLH transcription factor 2	11	2268495-2270952	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Pancreatic cancer:4.73e-4 (favourable), Cervical cancer:5.11e-4 (favourable)	Group enriched	Mixed			placenta: 6.4	Group enriched	6	BEWO: 19.9;NB-4: 4.0;SCLC-21H: 19.8
TBK1	NAK	ENSG00000183735	TANK binding kinase 1	12	64451880-64502108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA045797, HPA060211	Uncertain		Supported	Nucleoplasm	Renal cancer:4.20e-6 (unfavourable), Liver cancer:3.30e-4 (unfavourable), Melanoma:3.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.3	Expressed in all		
CBX6		ENSG00000183741	Chromobox 6	22	38861450-38872314	Predicted intracellular proteins	Evidence at protein level	HPA048653	Uncertain		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:2.46e-6 (favourable), Liver cancer:8.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 105.8	Expressed in all		
MACC1	7A5, SH3BP4L	ENSG00000183742	MACC1, MET transcriptional regulator	7	20134655-20217404	Predicted intracellular proteins	Evidence at protein level	HPA020081, HPA020103, HPA029476, CAB068194	Supported		Approved	Mitochondria	Renal cancer:5.71e-9 (favourable), Endometrial cancer:1.56e-5 (unfavourable)	Mixed	Mixed			small intestine: 13.0	Cell line enhanced		A-431: 85.3;HaCaT: 59.0
ACSM2A	A-923A4.1, ACSM2, MGC150530	ENSG00000183747	Acyl-CoA synthetase medium-chain family member 2A	16	20451461-20487667	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057699	Supported				Liver cancer:1.41e-5 (favourable)	Group enriched	Group enriched	580	kidney: 285.2;liver: 185.7	cerebral cortex: 0.4	Cell line enhanced		Hep G2: 1.3
TBL3	SAZD, UTP13	ENSG00000183751	Transducin beta like 3	16	1972037-1982933	Predicted intracellular proteins	Evidence at protein level	HPA042562, HPA055695	Enhanced	Supported	Enhanced	Nucleoli	Renal cancer:7.33e-4 (favourable)	Expressed in all	Mixed			testis: 5.6	Expressed in all		
BPY2	BPY2A, VCY2, VCY2A	ENSG00000183753	Basic charge, Y-linked, 2	Y	22973819-23005465	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
ACP7	FLJ16165, PAPL, PAPL1	ENSG00000183760	Acid phosphatase 7, tartrate resistant (putative)	19	39083913-39111493	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042005, HPA042613	Uncertain					Group enriched	Group enriched	6	cerebral cortex: 1.8;skin: 6.9;tonsil: 2.3	epididymis,prostate: 0.5	Cell line enhanced		hTEC/SVTERT24-B: 9.3;U-87 MG: 43.5
KREMEN1	KREMEN, KRM1	ENSG00000183762	Kringle containing transmembrane protein 1	22	29073078-29168333	Predicted membrane proteins	Evidence at protein level	HPA058513			Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Not detected	Mixed			skin: 43.4	Cell line enhanced		U-2197: 55.3
TRAIP	RNF206, TRIP	ENSG00000183763	TRAF interacting protein	3	49828599-49856574	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036261, HPA036262	Enhanced		Supported	Plasma membrane<br>Cytosol	Liver cancer:8.77e-5 (unfavourable)	Expressed in all	Mixed			testis: 11.3	Mixed		
CHEK2	bA444G7, CDS1, CHK2, HuCds1, PP1425, RAD53	ENSG00000183765	Checkpoint kinase 2	22	28687743-28742422	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001878, CAB002030	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:7.80e-9 (unfavourable)	Expressed in all	Mixed			testis: 13.4	Expressed in all		
FOXL2	BPES, BPES1	ENSG00000183770	Forkhead box L2	3	138944224-138947140	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069613	Enhanced		Supported	Nucleus<br>Cytokinetic bridge		Mixed	Tissue enhanced		endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.4	fallopian tube: 7.7	Cell line enhanced		A-431: 4.3;fHDF/TERT166: 4.3;HEL: 7.2;hTCEpi: 5.1;K-562: 7.5;SiHa: 5.9
AIFM3	AIFL, FLJ30473	ENSG00000183773	Apoptosis inducing factor, mitochondria associated 3	22	20965108-20981360	Predicted intracellular proteins	Evidence at protein level	HPA001271			Enhanced	Mitochondria	Urothelial cancer:7.13e-5 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 18.5;colon: 18.7	rectum: 9.0	Cell line enhanced		Hep G2: 5.1;HMC-1: 9.5;T-47d: 5.0;THP-1: 5.1
KCTD16	KIAA1317	ENSG00000183775	Potassium channel tetramerization domain containing 16	5	144170832-144485686	Predicted intracellular proteins	Evidence at protein level	HPA044590, HPA050154	Approved		Approved	Nuclear speckles		Tissue enhanced	Group enriched	7	cerebral cortex: 12.3;testis: 3.0	lung: 1.1	Cell line enhanced		SCLC-21H: 5.4;TIME: 7.3
B3GALT5	B3GalT-V, B3T5, beta3Gal-T5, GLCT5	ENSG00000183778	Beta-1,3-galactosyltransferase 5	21	39556442-39673137	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA054092, HPA054684	Approved				Endometrial cancer:6.36e-4 (favourable)	Mixed	Group enriched	5	colon: 22.7;duodenum: 27.5;gallbladder: 8.6;rectum: 40.5;small intestine: 37.2	stomach: 5.0	Group enriched	5	CAPAN-2: 20.6;NTERA-2: 6.3;RPTEC TERT1: 20.7;SCLC-21H: 5.4
ZNF703	FLJ14299, NLZ1, ZEPPO1, ZNF503L, Zpo1	ENSG00000183779	Zinc finger protein 703	8	37695751-37700021	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023930, CAB068249	Supported				Renal cancer:2.70e-7 (unfavourable)	Expressed in all	Mixed			fallopian tube: 30.7	Cell line enhanced		HEK 293: 142.2
SLC35F3	FLJ37712	ENSG00000183780	Solute carrier family 35 member F3	1	233904933-234324516	Predicted membrane proteins, Transporters	Evidence at protein level	HPA051327, HPA061582	Uncertain		Approved	Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 10.1	breast: 3.0	Cell line enriched	7	HDLM-2: 103.6
KCTD8		ENSG00000183783	Potassium channel tetramerization domain containing 8	4	44173909-44448807	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031562	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 11.5;thyroid gland: 5.2	testis: 2.4	Cell line enhanced		HAP1: 2.2;NTERA-2: 1.5;SCLC-21H: 6.8;U-2 OS: 1.8
C9orf66	FLJ31158	ENSG00000183784	Chromosome 9 open reading frame 66	9	212824-215741	Predicted intracellular proteins	Evidence at transcript level	HPA035652	Uncertain				Renal cancer:1.32e-5 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 17.8	adrenal gland: 4.0	Cell line enhanced		BEWO: 1.5;THP-1: 2.3
TUBA8	TUBAL2	ENSG00000183785	Tubulin alpha 8	22	18110331-18146554	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043684, CAB046031, HPA063394	Approved		Supported	Microtubules		Not detected	Group enriched	6	cerebral cortex: 28.6;heart muscle: 83.0;skeletal muscle: 121.7;testis: 47.4	thyroid gland: 11.2	Group enriched	5	NB-4: 19.8;SCLC-21H: 17.4;TIME: 31.1
ELOA3	ELOA3A, HsT829, TCEB3C, TCEB3L2	ENSG00000183791	Elongin A3	18	47028202-47030078	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NPIPA5		ENSG00000183793	Nuclear pore complex interacting protein family member A5	16	15363624-15381047	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			testis: 17.2	Mixed		
BPY2B	VCY2B	ENSG00000183795	Basic charge, Y-linked, 2B	Y	24607560-24639207	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
EMILIN3	C20orf130, dJ620E11.4, EMILIN5	ENSG00000183798	Elastin microfibril interfacer 3	20	41359966-41366827	Predicted secreted proteins	Evidence at protein level	HPA044034, HPA059912	Approved					Tissue enhanced	Tissue enhanced		epididymis: 65.0	seminal vesicle: 14.0	Group enriched	7	AF22: 6.2;HAP1: 11.4;NTERA-2: 7.0;SCLC-21H: 15.2
OLFML1	UNQ564	ENSG00000183801	Olfactomedin like 1	11	7485388-7511377	Predicted secreted proteins	Evidence at protein level	HPA039735	Uncertain				Renal cancer:4.28e-8 (unfavourable)	Expressed in all	Mixed			ovary: 60.1	Group enriched	7	BEWO: 29.5;U-2197: 19.0
FAM162B	bA86F4.2, C6orf189	ENSG00000183807	Family with sequence similarity 162 member B	6	116752197-116765723	Predicted membrane proteins	Evidence at protein level	HPA036112, HPA060342	Enhanced				Renal cancer:2.48e-4 (unfavourable)	Tissue enriched	Tissue enhanced		placenta: 94.0	lung: 27.0	Cell line enhanced		BJ: 7.3;BJ hTERT+: 19.0;BJ hTERT+ SV40 Large T+ RasG12V: 21.4;HSkMC: 5.6
RBM12B		ENSG00000183808	RNA binding motif protein 12B	8	93729356-93741017	Predicted intracellular proteins	Evidence at protein level	HPA024398, HPA053050	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 33.0	Mixed		
CCR4	CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5	ENSG00000183813	C-C motif chemokine receptor 4	3	32951574-32956349	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA031613	Approved					Mixed	Tissue enhanced		appendix: 11.5	urinary bladder: 8.9	Cell line enriched	17	HDLM-2: 187.8
LIN9	TGS	ENSG00000183814	Lin-9 DREAM MuvB core complex component	1	226231149-226309869	Predicted intracellular proteins	Evidence at protein level	HPA030241	Uncertain		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 16.9	Expressed in all		
BTBD9	dJ322I12.1, KIAA1880	ENSG00000183826	BTB domain containing 9	6	38168451-38640148	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041930	Uncertain		Approved	Nucleoplasm	Renal cancer:4.20e-13 (favourable)	Expressed in all	Mixed			parathyroid gland: 38.3	Expressed in all		
NUDT14	UGPP	ENSG00000183828	Nudix hydrolase 14	14	105172938-105181323	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046755, HPA058759	Approved		Approved	Nucleoli<br>Microtubules	Renal cancer:1.18e-5 (favourable), Ovarian cancer:1.66e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 24.7	Mixed		
ANKRD45	CT117, FLJ45235	ENSG00000183831	Ankyrin repeat domain 45	1	173609561-173669862	Predicted intracellular proteins	Evidence at protein level	HPA031655, HPA031656, HPA031657	Enhanced					Mixed	Tissue enhanced		fallopian tube: 35.0;parathyroid gland: 22.9;testis: 36.3	cerebral cortex: 7.2	Cell line enhanced		AF22: 9.4;BJ hTERT+ SV40 Large T+ RasG12V: 5.0;SH-SY5Y: 9.1
MAATS1	AAT1, AAT1alpha, C3orf15, CaM-IP2, SPATA26	ENSG00000183833	MYCBP associated and testis expressed 1	3	119703022-119767102	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 22.7;testis: 15.8	thyroid gland: 7.8	Cell line enhanced		AF22: 1.7;RPTEC TERT1: 1.8;SCLC-21H: 4.2;SH-SY5Y: 2.7;T-47d: 1.7;U-87 MG: 1.8
PNMA3	MA3, MA5, MGC132756, MGC132758	ENSG00000183837	Paraneoplastic Ma antigen 3	X	153056409-153060467	Predicted intracellular proteins	Evidence at transcript level	HPA047920	Approved				Endometrial cancer:4.14e-5 (unfavourable)	Mixed	Group enriched	13	cerebral cortex: 15.4;epididymis: 45.4;testis: 12.3	fallopian tube: 1.8	Cell line enhanced		NTERA-2: 3.2;SCLC-21H: 1.2
GPR39		ENSG00000183840	G protein-coupled receptor 39	2	132416574-132646559	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA022111	Approved				Pancreatic cancer:7.50e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 18.5	cervix, uterine,colon: 6.0	Cell line enhanced		A-431: 25.5;hTEC/SVTERT24-B: 28.7
FAM3B	2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44	ENSG00000183844	Family with sequence similarity 3 member B	21	41304212-41357431	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015885, HPA029777	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		duodenum: 162.1;small intestine: 166.8	stomach: 124.0	Cell line enhanced		CACO-2: 16.2;CAPAN-2: 10.8;Hep G2: 22.1;RPMI-8226: 62.5
ZNF730		ENSG00000183850	Zinc finger protein 730	19	23075210-23147219	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Tissue enhanced		testis: 9.3	ovary: 3.1	Cell line enhanced		NTERA-2: 23.2;REH: 19.3
KIRREL	NEPH1	ENSG00000183853	Kin of IRRE like (Drosophila)	1	157993273-158100262	Predicted membrane proteins	Evidence at protein level	HPA030458	Approved				Renal cancer:1.12e-8 (unfavourable), Cervical cancer:1.87e-4 (unfavourable), Urothelial cancer:2.85e-4 (unfavourable)	Expressed in all	Mixed			placenta: 47.1	Cell line enhanced		WM-115: 333.0
IQGAP3		ENSG00000183856	IQ motif containing GTPase activating protein 3	1	156525405-156572604	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030142, HPA030143	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.94e-6 (unfavourable)	Expressed in all	Mixed			bone marrow: 9.9	Mixed		
CNGA2	CNCA, CNCA1, CNG2, FLJ46312, OCNC1, OCNCa, OCNCALPHA	ENSG00000183862	Cyclic nucleotide gated channel alpha 2	X	151738451-151745304	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA015065	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
TOB2	APRO5, bK223H9, TOB4, TOBL, TROB2	ENSG00000183864	Transducer of ERBB2, 2	22	41433492-41447023	Predicted intracellular proteins	Evidence at protein level	HPA016603, HPA054112	Approved		Approved	Cytosol	Renal cancer:1.18e-6 (favourable), Endometrial cancer:3.08e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 60.1	Expressed in all		
SCN5A	CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1	ENSG00000183873	Sodium voltage-gated channel alpha subunit 5	3	38548057-38649673	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	18	heart muscle: 27.8	cervix, uterine: 1.5	Cell line enhanced		LHCN-M2: 23.1;RH-30: 22.0
ARSI	FLJ16069, SPG66	ENSG00000183876	Arylsulfatase family member I	5	150296343-150339307	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038386, HPA038398	Uncertain		Approved	Golgi apparatus	Urothelial cancer:1.19e-4 (unfavourable), Lung cancer:9.11e-4 (unfavourable)	Mixed	Mixed			skin: 5.7	Cell line enhanced		HaCaT: 27.7;hTEC/SVTERT24-B: 30.9;U-87 MG: 38.4
UTY	KDM6AL, KDM6C	ENSG00000183878	Ubiquitously transcribed tetratricopeptide repeat containing, Y-linked	Y	13248379-13480673	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000568, HPA001165	Supported		Approved	Nucleoli		Mixed	Mixed			prostate: 13.2	Cell line enhanced		HEL: 18.6
C1orf64	ERRF, MGC24047	ENSG00000183888	Chromosome 1 open reading frame 64	1	16004236-16008807	Predicted intracellular proteins	Evidence at transcript level	HPA026676	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.68e-6 (favourable)	Tissue enhanced	Tissue enhanced		breast: 6.8	cervix, uterine: 3.3	Group enriched	9	Hep G2: 5.3;SK-BR-3: 10.1;T-47d: 4.1
AC138969.4		ENSG00000183889		16	16317444-16350590	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			skin: 116.2	Expressed in all		
TTC32		ENSG00000183891	Tetratricopeptide repeat domain 32	2	19896643-19901986	Predicted intracellular proteins	Evidence at protein level	HPA036024	Approved		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:5.45e-6 (unfavourable), Lung cancer:9.44e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.4	Expressed in all		
LRRC55	FLJ45686	ENSG00000183908	Leucine rich repeat containing 55	11	57181747-57191717	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014053	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 6.6	lymph node: 2.4	Group enriched	33	AF22: 19.1;NTERA-2: 4.6
DNAH2	DNHD3, FLJ46675, KIAA1503	ENSG00000183914	Dynein axonemal heavy chain 2	17	7717354-7833744	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067103	Enhanced		Approved	Microtubules		Mixed	Group enriched	8	fallopian tube: 20.9;parathyroid gland: 28.4;testis: 10.9	placenta: 2.5	Cell line enhanced		A-431: 2.2;CACO-2: 3.2;CAPAN-2: 2.1;SCLC-21H: 2.7;SiHa: 2.4
SH2D1A	DSHP, EBVS, IMD5, LYP, MTCP1, SAP, XLP, XLPD	ENSG00000183918	SH2 domain containing 1A	X	124227868-124373197	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.94e-6 (unfavourable), Breast cancer:2.03e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 36.3;spleen: 17.5	tonsil: 13.2	Group enriched	6	HDLM-2: 89.9;Karpas-707: 148.7;MOLT-4: 209.2
SDR42E2		ENSG00000183921	Short chain dehydrogenase/reductase family 42E, member 2	16	22165583-22191754	Predicted membrane proteins	No evidence	HPA061278	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
PRKX	PKX1	ENSG00000183943	Protein kinase, X-linked	X	3604370-3713608	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015324	Supported		Supported	Nucleus		Expressed in all	Tissue enhanced		thyroid gland: 58.0	fallopian tube: 31.8	Cell line enhanced		HMC-1: 67.0
KMT5A	PR-Set7, SET07, SET8, SETD8	ENSG00000183955	Lysine methyltransferase 5A	12	123383773-123409358	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA064495			Approved	Nucleus<br>Cytosol	Liver cancer:6.21e-7 (unfavourable)	Expressed in all	Expressed in all			prostate: 36.8	Expressed in all		
KCNH8	elk3, Kv12.1	ENSG00000183960	Potassium voltage-gated channel subfamily H member 8	3	19148454-19535646	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016586			Supported	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 4.8	adrenal gland: 2.3	Cell line enhanced		HAP1: 1.0;SH-SY5Y: 4.4
SMTN		ENSG00000183963	Smoothelin	22	31064105-31104757	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB001721, HPA051778, HPA058590	Enhanced		Enhanced	Nucleoplasm<br>Actin filaments	Renal cancer:2.73e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 251.4	Expressed in all		
NPW	PPL8	ENSG00000183971	Neuropeptide W	16	2009926-2020755	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA064874	Approved					Mixed	Tissue enhanced		liver: 5.2;stomach: 2.9	epididymis: 1.7	Cell line enhanced		NB-4: 29.9;RPMI-8226: 57.2;SCLC-21H: 161.6
PP2D1	C3orf48, FLJ25449	ENSG00000183977	Protein phosphatase 2C like domain containing 1	3	19979961-20012330	Predicted intracellular proteins	Evidence at protein level	HPA036870, HPA066083	Supported		Uncertain	Nucleoplasm<br>Intermediate filaments		Not detected	Tissue enriched	11	testis: 12.8	bone marrow: 1.1	Not detected		
COA3	CCDC56, COX25, HSPC009, MITRAC12	ENSG00000183978	Cytochrome c oxidase assembly factor 3	17	42795147-42798704	Predicted membrane proteins	Evidence at protein level	HPA031966	Approved		Supported	Mitochondria	Cervical cancer:3.40e-4 (favourable), Renal cancer:6.62e-4 (favourable), Endometrial cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 213.9	Expressed in all		
NPB	PPL7, PPNPB	ENSG00000183979	Neuropeptide B	17	81900745-81902905	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.6	Cell line enhanced		PC-3: 2.3;RH-30: 1.8;SH-SY5Y: 2.2;U-2 OS: 2.4
ST6GALNAC3	SIAT7C	ENSG00000184005	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3	1	76074719-76634601	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054566, HPA055399	Uncertain		Supported	Nucleoplasm		Mixed	Tissue enhanced		thyroid gland: 22.4	parathyroid gland: 11.1	Cell line enhanced		AF22: 35.4;HUVEC TERT2: 38.4;SK-MEL-30: 49.6;TIME: 16.7
PTP4A2	HU-PP-1, OV-1, PRL-2, ptp-IV1a, PTP4A, PTPCAAX2	ENSG00000184007	Protein tyrosine phosphatase type IVA, member 2	1	31906421-31944856	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281, CAB011204	Uncertain				Renal cancer:5.10e-11 (unfavourable), Liver cancer:2.62e-5 (unfavourable), Urothelial cancer:2.72e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 283.0	Expressed in all		
ACTG1	ACTG, DFNA20, DFNA26	ENSG00000184009	Actin gamma 1	17	81509971-81523847	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271	Approved				Colorectal cancer:2.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 2397.0	Expressed in all		
TMPRSS2	PRSS10	ENSG00000184012	Transmembrane protease, serine 2	21	41464551-41531116	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034493, HPA035787	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)	Tissue enriched	Tissue enhanced		prostate: 489.3	stomach: 142.6	Cell line enhanced		CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
DENND5A	FLJ22354, FLJ33829, FLJ43455, KIAA1091, RAB6IP1	ENSG00000184014	DENN domain containing 5A	11	9138825-9265390	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052923, HPA055009	Uncertain		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.14e-6 (unfavourable), Liver cancer:5.05e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 126.7	Mixed		
OR2T10		ENSG00000184022	Olfactory receptor family 2 subfamily T member 10	1	248592830-248593768	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052019	Uncertain					Tissue enhanced	Tissue enriched	18	kidney: 7.1	prostate: 0.3	Not detected		
DSCR4	DCRB	ENSG00000184029	Down syndrome critical region 4	21	37951425-38121360	Predicted intracellular proteins	Evidence at transcript level	HPA018460	Uncertain					Tissue enriched	Group enriched	18	placenta: 2.0;testis: 1.4	all non-specific tissues: 0.0	Cell line enhanced		BEWO: 5.8;K-562: 9.1;RPMI-8226: 3.0;U-266/70: 5.5;U-266/84: 3.9
KRTAP20-2	KAP20.2	ENSG00000184032	Keratin associated protein 20-2	21	30635236-30635619	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.6	Not detected		
CTAG1B	CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1	ENSG00000184033	Cancer/testis antigen 1B	X	154617609-154619282	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB015453	Enhanced					Not detected	Tissue enriched	55	testis: 5.4	all non-specific tissues: 0.0	Group enriched	1072	U-266/70: 579.6;U-266/84: 139.5
DIABLO	DFNA64, DIABLO-S, FLJ10537, FLJ25049, SMAC	ENSG00000184047	Diablo IAP-binding mitochondrial protein	12	122207662-122227534	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001825, CAB003857, CAB016688	Enhanced		Enhanced	Mitochondria	Renal cancer:5.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 94.9	Expressed in all		
VPS33B	FLJ14848	ENSG00000184056	VPS33B, late endosome and lysosome associated	15	90998416-91022603	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040415	Approved					Expressed in all	Expressed in all			cerebral cortex: 16.1	Expressed in all		
TBX1	CATCH22, VCF	ENSG00000184058	T-box 1	22	19756703-19783593	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029330			Approved	Nuclear bodies<br>Cytoplasmic bodies	Urothelial cancer:8.90e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 23.0	testis: 10.5	Cell line enhanced		K-562: 107.3;TIME: 35.1
ADAP2	CENTA2	ENSG00000184060	ArfGAP with dual PH domains 2	17	30906344-30959322	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.36e-6 (unfavourable), Liver cancer:3.12e-4 (unfavourable), Head and neck cancer:3.97e-4 (favourable), Colorectal cancer:5.62e-4 (unfavourable)	Expressed in all	Mixed			spleen: 29.3	Cell line enhanced		HAP1: 17.5;HEK 293: 9.1;RPMI-8226: 15.4
UQCR10	HSPC051, QCR9, UCCR7.2, UCRC	ENSG00000184076	Ubiquinol-cytochrome c reductase, complex III subunit X	22	29767369-29770413	Predicted membrane proteins	Evidence at protein level						Renal cancer:5.45e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 205.9	Expressed in all		
FAM120C	CXorf17, FLJ20506, ORF34	ENSG00000184083	Family with sequence similarity 120C	X	54068324-54183281	Predicted intracellular proteins	Evidence at protein level	HPA047677	Uncertain		Approved	Nuclear speckles	Head and neck cancer:4.48e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Expressed in all		
TRIML1	FLJ36180, RNF209	ENSG00000184108	Tripartite motif family like 1	4	188139419-188147743	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	147	testis: 14.7	all non-specific tissues: 0.0	Cell line enriched	12	BEWO: 1.5
EIF3C	eIF3-p110, eIF3c, EIF3S8	ENSG00000184110	Eukaryotic translation initiation factor 3 subunit C	16	28688558-28735730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB034045, HPA047097, HPA049495, HPA050112	Supported		Supported	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 571.3	Expressed in all		
CLDN5	AWAL, BEC1, CPETRL1, TMVCF	ENSG00000184113	Claudin 5	22	19523024-19527545	Predicted membrane proteins, Transporters	Evidence at protein level	CAB002607	Approved					Expressed in all	Tissue enhanced		adipose tissue: 128.2	lung: 53.4	Group enriched	12	HUVEC TERT2: 71.6;SCLC-21H: 62.4
NIPSNAP1		ENSG00000184117	Nipsnap homolog 1	22	29554808-29581337	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059227	Uncertain				Renal cancer:8.82e-6 (favourable)	Expressed in all	Expressed in all			liver: 134.2	Expressed in all		
OR4F6	OR4F12	ENSG00000184140	Olfactory receptor family 4 subfamily F member 6	15	101805699-101806686	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CNTN2	AXT, TAG-1, TAX, TAX1	ENSG00000184144	Contactin 2	1	205042937-205078284	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA001397, HPA012497	Approved					Tissue enriched	Tissue enriched	7	cerebral cortex: 81.7	testis: 11.2	Group enriched	7	NTERA-2: 3.8;SCLC-21H: 11.1
SPRR4		ENSG00000184148	Small proline rich protein 4	1	152970666-152972574	Predicted intracellular proteins	Evidence at protein level	HPA055963	Enhanced					Tissue enhanced	Tissue enriched	6	skin: 48.3	breast: 7.8	Not detected		
LRTOMT	CFAP111, COMT2, DFNB63, LRRC51	ENSG00000184154	Leucine rich transmembrane and O-methyltransferase domain containing	11	72080331-72110782	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039949	Approved		Approved	Nucleoli<br>Microtubules	Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			testis: 136.6	Expressed in all		
OR10J5		ENSG00000184155	Olfactory receptor family 10 subfamily J member 5	1	159535078-159536007	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KCNQ3	EBN2, Kv7.3	ENSG00000184156	Potassium voltage-gated channel subfamily Q member 3	8	132120858-132481019	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	14	cerebral cortex: 26.7	adrenal gland: 1.9	Cell line enhanced		hTERT-HME1: 5.1;U-2 OS: 4.5;U-87 MG: 3.5
ADRA2C	ADRA2L2, ADRA2RL2, ADRARL2	ENSG00000184160	Adrenoceptor alpha 2C	4	3766348-3768526	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057688	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8	fallopian tube: 7.9	Cell line enhanced		Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
NR2C2AP	TRA16	ENSG00000184162	Nuclear receptor 2C2 associated protein	19	19201416-19203424	Predicted intracellular proteins	Evidence at protein level	HPA042054, HPA055653	Approved		Enhanced	Nucleoplasm	Liver cancer:5.63e-5 (unfavourable), Thyroid cancer:1.65e-4 (favourable), Colorectal cancer:8.53e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 24.0	Expressed in all		
C1QTNF12	ADIPOLIN, C1QDC2, CTRP12, FAM132A, MGC105127	ENSG00000184163	C1q and tumor necrosis factor related protein 12	1	1242446-1246722	Predicted secreted proteins	Evidence at protein level	HPA024107	Approved		Approved	Vesicles		Mixed	Tissue enhanced		duodenum: 6.9;small intestine: 7.3	colon: 2.1	Group enriched	5	EFO-21: 3.9;U-2 OS: 4.3
CRELD2	MGC11256	ENSG00000184164	Cysteine rich with EGF like domains 2	22	49918167-49927540	Predicted secreted proteins	Evidence at protein level	HPA000603, CAB025604	Approved				Renal cancer:1.34e-9 (unfavourable), Endometrial cancer:2.42e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 94.2	Expressed in all		
OR1D2	OLFR1, OR17-4	ENSG00000184166	Olfactory receptor family 1 subfamily D member 2	17	3092058-3092996	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
SCFD2	FLJ39514, STXBP1L1	ENSG00000184178	Sec1 family domain containing 2	4	52872982-53366075	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036526, HPA036527	Enhanced		Approved	Nucleus	Renal cancer:3.81e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 14.7	Expressed in all		
UBE2F	NCE2	ENSG00000184182	Ubiquitin conjugating enzyme E2 F (putative)	2	237966827-238042782	Predicted intracellular proteins	Evidence at protein level	HPA037444	Approved		Approved	Cytosol	Renal cancer:1.59e-7 (unfavourable), Liver cancer:2.72e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 64.0	Expressed in all		
KCNJ12	hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v	ENSG00000184185	Potassium voltage-gated channel subfamily J member 12	17	21376197-21419872	FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA027021	Approved		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Endometrial cancer:7.84e-5 (unfavourable)	Mixed	Group enriched	5	parathyroid gland: 19.2;skeletal muscle: 23.1	heart muscle: 3.9	Cell line enhanced		HeLa: 2.6;PC-3: 3.9;SCLC-21H: 5.6;SiHa: 2.6;U-2197: 3.9
GPR173	SREB3	ENSG00000184194	G protein-coupled receptor 173	X	53049091-53080615	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA003905			Approved	Plasma membrane<br>Cytosol	Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 19.1	ovary: 8.9	Cell line enhanced		HAP1: 10.2
PPP1R2	IPP2	ENSG00000184203	Protein phosphatase 1 regulatory inhibitor subunit 2	3	195514425-195543386	Predicted intracellular proteins	Evidence at protein level	HPA043729, HPA059420			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 52.4	Expressed in all		
TSPYL2	CDA1, CINAP, CTCL, DENTT, HRIHFB2216, SE20-4, TSPX	ENSG00000184205	TSPY like 2	X	53082367-53088540	Predicted intracellular proteins	Evidence at protein level	HPA044133	Approved				Pancreatic cancer:6.74e-8 (favourable), Renal cancer:8.16e-7 (unfavourable), Colorectal cancer:3.23e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 144.3	Expressed in all		
GOLGA6L4		ENSG00000184206	Golgin A6 family-like 4	15	84235773-84245368	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			ovary: 7.5	Mixed		
PGP		ENSG00000184207	Phosphoglycolate phosphatase	16	2211997-2214807	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043096, HPA046739	Approved		Approved	Nuclear bodies	Urothelial cancer:6.42e-4 (favourable), Renal cancer:7.05e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.1	Expressed in all		
C22orf46	CTA-216E10.6, FLJ23584	ENSG00000184208	Chromosome 22 open reading frame 46	22	41688939-41698136	Predicted secreted proteins	Evidence at transcript level	HPA052741	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:4.70e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 17.3	Expressed in all		
SNRNP35	U1SNRNPBP	ENSG00000184209	Small nuclear ribonucleoprotein U11/U12 subunit 35	12	123457641-123473154	Predicted intracellular proteins	Evidence at protein level	HPA059145, HPA067031	Supported		Supported	Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 34.2	Expressed in all		
DGAT2L6	DC3, FLJ25989	ENSG00000184210	Diacylglycerol O-acyltransferase 2 like 6	X	70177483-70205545	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Group enriched	22	breast: 2.8;skin: 1.6	all non-specific tissues: 0.0	Not detected		
IRAK1	IRAK, pelle	ENSG00000184216	Interleukin 1 receptor associated kinase 1	X	154010500-154019980	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004461, HPA054476	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:2.06e-4 (unfavourable), Liver cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 51.0	Expressed in all		
CMSS1	C3orf26, MGC4308	ENSG00000184220	Cms1 ribosomal small subunit homolog (yeast)	3	99817834-100181732	Predicted intracellular proteins	Evidence at protein level	HPA042820	Uncertain		Approved	Nucleus<br>Nuclear membrane<br>Nucleoli<br>Mitochondria	Liver cancer:5.92e-10 (unfavourable), Endometrial cancer:3.15e-6 (unfavourable), Prostate cancer:3.10e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.1	Expressed in all		
OLIG1	BHLHB6, bHLHe21	ENSG00000184221	Oligodendrocyte transcription factor 1	21	33070144-33072420	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	104	cerebral cortex: 142.6	kidney: 1.3	Cell line enhanced		NB-4: 24.7;RPMI-8226: 14.1;THP-1: 17.1;U-937: 22.7
PCDH9		ENSG00000184226	Protocadherin 9	13	66302834-67230445	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA015581			Approved	Nucleoplasm<br>Centrosome		Tissue enriched	Tissue enriched	11	cerebral cortex: 68.8	seminal vesicle: 6.1	Cell line enhanced		AF22: 24.9;LHCN-M2: 34.9;TIME: 40.1;U-698: 44.9
ACOT1	ACH2, CTE-1, LACH2	ENSG00000184227	Acyl-CoA thioesterase 1	14	73537114-73543794	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043705	Approved		Approved	Mitochondria	Renal cancer:5.09e-8 (favourable)	Expressed in all	Mixed			smooth muscle: 29.4	Cell line enhanced		T-47d: 35.8
OAF	MGC52117	ENSG00000184232	Out at first homolog	11	120210767-120230332	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047412	Uncertain		Approved	Nucleus	Head and neck cancer:5.71e-5 (unfavourable)	Expressed in all	Expressed in all			liver: 80.2	Cell line enhanced		Hep G2: 127.6
ALDH1A3	ALDH6, RALDH3	ENSG00000184254	Aldehyde dehydrogenase 1 family member A3	15	100877714-100916626	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046271, HPA064749	Enhanced		Enhanced	Nucleus<br>Cytosol		Group enriched	Tissue enhanced		prostate: 217.5	adipose tissue: 74.8	Cell line enhanced		HaCaT: 383.6;HBEC3-KT: 772.3;U-2197: 565.6;U-87 MG: 467.6;WM-115: 498.3
CDR1	CDR, CDR34, CDR62A	ENSG00000184258	Cerebellar degeneration related protein 1	X	140782405-140784871	Predicted intracellular proteins	Evidence at protein level	HPA073147			Approved	Nucleoplasm<br>Golgi apparatus<br>Centrosome		Not detected	Group enriched	7	cerebral cortex: 48.4;skin: 12.1	adipose tissue: 4.0	Cell line enhanced		BJ: 6.3;U-87 MG: 26.1
HIST2H2AC	H2A, H2A/q, H2AFQ	ENSG00000184260	Histone cluster 2 H2A family member c	1	149886975-149887364	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported				Renal cancer:1.20e-10 (unfavourable), Urothelial cancer:7.86e-5 (favourable)	Expressed in all	Tissue enriched	10	bone marrow: 23.8	adrenal gland: 2.4	Cell line enhanced		MCF7: 73.2
KCNK12	K2p12.1, THIK-2, THIK2	ENSG00000184261	Potassium two pore domain channel subfamily K member 12	2	47516581-47570939	Predicted membrane proteins, Voltage-gated ion channels	Evidence at transcript level							Tissue enriched	Tissue enriched	17	cerebral cortex: 5.3	placenta,testis: 0.3	Group enriched	6	REH: 21.5;SCLC-21H: 10.5
HIST2H2AB		ENSG00000184270	Histone cluster 2 H2A family member b	1	149887524-149887916	Predicted intracellular proteins	Evidence at protein level	CAB011483, HPA041189	Supported		Approved	Nucleus		Mixed	Tissue enriched	8	bone marrow: 4.0	prostate: 0.5	Cell line enhanced		MOLT-4: 3.4
POU6F1	BRN5, MPOU, TCFB1	ENSG00000184271	POU class 6 homeobox 1	12	51186936-51217708	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047021, HPA050411	Enhanced		Supported	Nuclear bodies<br>Actin filaments	Pancreatic cancer:6.61e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 10.9	Mixed		
DEFB108B		ENSG00000184276	Defensin beta 108B	11	71833200-71837710	Predicted secreted proteins	Evidence at transcript level	HPA042588	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TM2D3	BLP2, FLJ22604	ENSG00000184277	TM2 domain containing 3	15	101621444-101652391	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054064	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 97.2	Expressed in all		
TSSC4		ENSG00000184281	Tumor suppressing subtransferable candidate 4	11	2400488-2403878	Predicted intracellular proteins	Evidence at protein level	HPA041801, HPA058763	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:9.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 56.5	Expressed in all		
TACSTD2	EGP-1, GA733-1, M1S1, TROP2	ENSG00000184292	Tumor-associated calcium signal transducer 2	1	58575423-58577773	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA043104, HPA055067, CAB072852	Enhanced		Supported	Nucleoli<br>Vesicles<br>Plasma membrane	Renal cancer:3.99e-4 (favourable)	Mixed	Tissue enhanced		esophagus: 313.8	skin: 209.6	Cell line enhanced		A-431: 502.8;CAPAN-2: 665.4;HaCaT: 672.0
CLECL1	DCAL1	ENSG00000184293	C-type lectin like 1	12	9715860-9733299	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 28.7;spleen: 22.6;tonsil: 28.3	appendix: 13.3	Group enriched	5	HEL: 44.5;Karpas-707: 47.7;U-698: 120.2;U-937: 75.2
SIX6	OPTX2, Six9	ENSG00000184302	SIX homeobox 6	14	60508951-60512850	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001403	Approved		Approved	Nucleoplasm		Tissue enriched	Not detected			testis: 0.1	Cell line enriched	14	MOLT-4: 33.0
PRKD1	PKC-mu, PKCM, PKD, PRKCM	ENSG00000184304	Protein kinase D1	14	29576479-30191898	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018367, HPA029834	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.44e-5 (favourable), Thyroid cancer:2.91e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 50.3	prostate: 28.5	Mixed		
CCSER1	FAM190A, KIAA1680	ENSG00000184305	Coiled-coil serine rich protein 1	4	90127535-91601913	Predicted intracellular proteins	Evidence at transcript level	HPA041880, HPA054709	Uncertain					Mixed	Tissue enhanced		testis: 4.6	adrenal gland: 1.7	Cell line enhanced		HDLM-2: 1.4;RT4: 1.0;SCLC-21H: 1.5
ZDHHC23	MGC42530	ENSG00000184307	Zinc finger DHHC-type containing 23	3	113947901-113965401	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016808	Uncertain		Approved	Nucleus	Renal cancer:1.48e-7 (favourable), Endometrial cancer:2.85e-4 (unfavourable), Thyroid cancer:5.90e-4 (unfavourable)	Expressed in all	Mixed			testis: 22.5	Mixed		
MROH7	C1orf175, FLJ46354, HEATR8	ENSG00000184313	Maestro heat like repeat family member 7	1	54641754-54710266	Predicted intracellular proteins	Evidence at protein level	HPA071840	Enhanced					Not detected	Tissue enriched	30	testis: 49.5	ovary: 1.6	Not detected		
OR51J1	OR51J1P, OR51J2	ENSG00000184321	Olfactory receptor family 51 subfamily J member 1 (gene/pseudogene)	11	5402597-5403547	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA017605	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
S100A7A	S100A15, S100A7f, S100A7L1	ENSG00000184330	S100 calcium binding protein A7A	1	153416524-153423225	Predicted intracellular proteins	Evidence at protein level	HPA006997	Supported					Tissue enhanced	Group enriched	14	skin: 1.9;tonsil: 5.4	esophagus,testis: 0.2	Not detected		
SRPK3	MSSK1, STK23	ENSG00000184343	SRSF protein kinase 3	X	153776412-153785732	Enzymes, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		heart muscle: 28.7;skeletal muscle: 73.6	prostate: 10.9	Cell line enhanced		RH-30: 45.4
GDF3		ENSG00000184344	Growth differentiation factor 3	12	7689782-7695776	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA018468	Uncertain					Tissue enriched	Tissue enhanced		kidney: 1.1;spleen: 1.1	testis: 0.8	Cell line enriched	14	NTERA-2: 450.4
IQCF2		ENSG00000184345	IQ motif containing F2	3	51861629-51863424	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	96	testis: 9.6	all non-specific tissues: 0.0	Not detected		
SLIT3	MEGF5, SLIL2, Slit-3, SLIT1, slit2	ENSG00000184347	Slit guidance ligand 3	5	168661733-169301129	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051630	Approved		Supported	Cell Junctions	Renal cancer:2.45e-5 (unfavourable)	Mixed	Mixed			parathyroid gland: 99.9	Cell line enhanced		ASC diff: 212.7;fHDF/TERT166: 89.9;RT4: 80.4;SH-SY5Y: 77.7
EFNA5	AF1, EPLG7, LERK7	ENSG00000184349	Ephrin A5	5	107376889-107670895	Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB013282, HPA054047	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 17.1	Cell line enhanced		RPTEC TERT1: 43.4
MRGPRE	GPR167, mrgE	ENSG00000184350	MAS related GPR family member E	11	3227698-3232386	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046556	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 1.0	endometrium: 0.7	Cell line enhanced		RPMI-8226: 1.5;SCLC-21H: 4.1
KRTAP19-1	KAP19.1	ENSG00000184351	Keratin associated protein 19-1	21	30479699-30480344	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Cell line enriched	13	HEK 293: 19.8
HIST1H1B	H1.5, H1b, H1F5, H1s-3	ENSG00000184357	Histone cluster 1 H1 family member b	6	27866849-27867529	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012241, HPA055907	Approved		Supported	Nucleoplasm		Tissue enhanced	Tissue enhanced		bone marrow: 6.2;lymph node: 2.6	urinary bladder: 0.9	Cell line enhanced		MOLT-4: 8.9
SPATA32	AEP2, C17orf46, FLJ25414, TEX34, VAD1.2	ENSG00000184361	Spermatogenesis associated 32	17	45254393-45262112	Predicted intracellular proteins	Evidence at protein level	HPA024549	Approved					Not detected	Tissue enriched	86	testis: 40.7	duodenum: 0.4	Cell line enhanced		A549: 1.1
PKP3		ENSG00000184363	Plakophilin 3	11	392614-404908	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012993, HPA062937	Enhanced		Enhanced	Nucleoplasm<br>Cell Junctions<br>Cytosol	Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 98.2;skin: 148.2	duodenum: 31.4	Cell line enhanced		A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1
MAP7D2	FLJ14503	ENSG00000184368	MAP7 domain containing 2	X	20006713-20116917	Predicted intracellular proteins	Evidence at protein level	HPA051508, HPA059537	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.27e-5 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 49.2;epididymis: 45.6	testis: 18.3	Cell line enhanced		A549: 12.0;CACO-2: 16.0;HEK 293: 23.8;HeLa: 15.1;SCLC-21H: 34.5;SiHa: 13.5
CSF1	M-CSF, MCSF, MGC31930	ENSG00000184371	Colony stimulating factor 1	1	109910242-109930992	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level						Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 66.6	Cell line enhanced		ASC diff: 146.1;HHSteC: 271.2;HSkMC: 150.5
COLEC10	CL-L1	ENSG00000184374	Collectin subfamily member 10	8	118995452-119106582	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:5.79e-4 (favourable)	Mixed	Group enriched	8	liver: 51.2;placenta: 26.0	thyroid gland: 5.0	Group enriched	6	BJ hTERT+: 5.2;HHSteC: 2.1;SK-BR-3: 8.4
ACTRT3	ARPM1	ENSG00000184378	Actin related protein T3	3	169766921-169769895	Predicted intracellular proteins	Evidence at protein level	HPA035817, HPA035818	Approved		Approved	Nucleoplasm	Endometrial cancer:4.11e-4 (unfavourable)	Mixed	Tissue enriched	22	testis: 60.6	fallopian tube: 2.7	Cell line enhanced		ASC diff: 10.2
PLA2G6	iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9	ENSG00000184381	Phospholipase A2 group VI	22	38111495-38205690	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA001171	Approved		Approved	Microtubule organizing center<br>Cytosol	Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable)	Expressed in all	Expressed in all			testis: 60.2	Cell line enhanced		HEL: 55.1
MAML2	KIAA1819, MAM3	ENSG00000184384	Mastermind like transcriptional coactivator 2	11	95976598-96343180	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035223	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.90e-4 (favourable), Pancreatic cancer:3.89e-4 (unfavourable)	Expressed in all	Mixed			placenta: 17.5	Cell line enhanced		HDLM-2: 48.9
PABPC1L2B	RBM32B	ENSG00000184388	Poly(A) binding protein cytoplasmic 1 like 2B	X	73003517-73005713	Predicted intracellular proteins	Evidence at transcript level	HPA041573	Approved					Tissue enriched	Group enriched	5	cerebral cortex: 8.7;prostate: 4.6	testis: 1.2	Cell line enhanced		NTERA-2: 1.6
A3GALT2	A3GALT2P, IGB3S, IGBS3S	ENSG00000184389	Alpha 1,3-galactosyltransferase 2	1	33306766-33321098	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Not detected		
OR4N5		ENSG00000184394	Olfactory receptor family 4 subfamily N member 5	14	20143736-20144662	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	71	HEL: 7.0
SS18L1	CREST, KIAA0693	ENSG00000184402	SS18L1, nBAF chromatin remodeling complex subunit	20	62143795-62182484	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011827, HPA059046	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:8.00e-5 (favourable), Lung cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
KCND2	KIAA1044, Kv4.2, RK5	ENSG00000184408	Potassium voltage-gated channel subfamily D member 2	7	120273668-120750331	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA029068	Approved					Tissue enhanced	Tissue enhanced		cerebral cortex: 20.7	gallbladder: 6.8	Cell line enhanced		ASC TERT1: 3.5;SCLC-21H: 15.6
TOP1MT		ENSG00000184428	Topoisomerase (DNA) I, mitochondrial	8	143304384-143359979	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001915, HPA021542	Approved		Supported	Mitochondria	Renal cancer:1.52e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 41.2	Expressed in all		
COPB2	beta'-COP, betaprime-COP	ENSG00000184432	Coatomer protein complex subunit beta 2	3	139355600-139389732	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036867, HPA058180	Approved		Approved	Cytosol	Liver cancer:2.41e-7 (unfavourable), Pancreatic cancer:1.45e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 173.0	Expressed in all		
LRRC19	FLJ21302	ENSG00000184434	Leucine rich repeat containing 19	9	26993136-27005693	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.08e-8 (favourable)	Group enriched	Group enriched	9	colon: 35.9;duodenum: 23.7;gallbladder: 9.4;kidney: 45.1;rectum: 35.3;small intestine: 34.7	appendix: 3.5	Not detected		
THAP7	MGC10963	ENSG00000184436	THAP domain containing 7	22	20999104-21002196	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003083	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
KNTC1	KIAA0166, ROD	ENSG00000184445	Kinetochore associated 1	12	122527246-122626396	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025241	Approved		Supported	Plasma membrane<br>Cytosol	Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 43.4	bone marrow: 27.1	Expressed in all		
CCR10	GPR2	ENSG00000184451	C-C motif chemokine receptor 10	17	42678889-42683917	Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011684, HPA048007, HPA069188	Uncertain		Supported	Endoplasmic reticulum		Mixed	Mixed			adipose tissue: 4.4	Cell line enhanced		Karpas-707: 6.0;U-266/70: 13.0
NCMAP	C1orf130, FLJ42528, MP11	ENSG00000184454	Non-compact myelin associated protein	1	24556111-24609328	Predicted membrane proteins	Evidence at transcript level	HPA013656	Uncertain				Endometrial cancer:2.83e-6 (favourable)	Mixed	Tissue enhanced		gallbladder: 11.5	thyroid gland: 7.1	Cell line enhanced		A549: 1.8;T-47d: 3.7;U-266/70: 2.3
BPIFC	BPIL2, dJ149A16.7	ENSG00000184459	BPI fold containing family C	22	32413847-32464484	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA037665, HPA043306	Uncertain					Group enriched	Tissue enriched	18	skin: 75.6	breast: 4.1	Cell line enhanced		SCLC-21H: 1.5
WDR27	MGC43690	ENSG00000184465	WD repeat domain 27	6	169457212-169702048	Predicted intracellular proteins	Evidence at protein level	HPA037497, HPA037498	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.78e-5 (unfavourable)	Expressed in all	Mixed			testis: 15.8	Expressed in all		
TXNRD2	TR, TR3, TRXR2	ENSG00000184470	Thioredoxin reductase 2	22	19875517-19941992	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002007, HPA003323	Supported		Supported	Mitochondria<br>Cytosol	Renal cancer:1.10e-7 (favourable)	Expressed in all	Expressed in all			adrenal gland: 34.3	Expressed in all		
C1QTNF8	CTRP8, UNQ5829	ENSG00000184471	C1q and tumor necrosis factor related protein 8	16	1090005-1096244	Predicted secreted proteins	Evidence at protein level	HPA056438	Uncertain					Not detected	Not detected			fallopian tube: 0.7	Not detected		
OR56A3	OR56A3P, OR56A6	ENSG00000184478	Olfactory receptor family 56 subfamily A member 3	11	5947340-5948361	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
FOXO4	AFX1, MLLT7	ENSG00000184481	Forkhead box O4	X	71096197-71103535	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	HPA039560, HPA040232	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:3.46e-4 (favourable), Head and neck cancer:4.61e-4 (favourable)	Expressed in all	Expressed in all			placenta: 172.7	Cell line enriched	8	BEWO: 154.9
POU3F2	BRN2, OCT7, OTF7, POUF3	ENSG00000184486	POU class 3 homeobox 2	6	98834592-98839470	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047081, HPA056261		Approved	Supported	Nucleus		Tissue enriched	Tissue enriched	70	cerebral cortex: 20.4	testis: 0.2	Cell line enhanced		AF22: 123.9;U-251 MG: 32.8;WM-115: 33.3
PTP4A3	PRL-3, PRL-R, PRL3	ENSG00000184489	Protein tyrosine phosphatase type IVA, member 3	8	141391993-141432454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003281	Uncertain				Renal cancer:1.81e-5 (unfavourable)	Expressed in all	Group enriched	6	heart muscle: 69.6;skeletal muscle: 153.1	prostate: 19.1	Cell line enhanced		HDLM-2: 232.0;Karpas-707: 52.7;RPMI-8226: 54.1;U-266/84: 59.5
FOXD4L1	FOXD5	ENSG00000184492	Forkhead box D4-like 1	2	113498665-113501155	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			testis: 0.6	Cell line enhanced		RH-30: 1.6
TMEM255B	FAM70B, MGC20579	ENSG00000184497	Transmembrane protein 255B	13	113759240-113816995	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043334	Approved		Approved	Nucleoplasm	Renal cancer:4.12e-5 (unfavourable)	Expressed in all	Mixed			lung: 8.3	Cell line enhanced		HMC-1: 25.9;HUVEC TERT2: 32.5;PC-3: 36.6;TIME: 30.0;U-87 MG: 39.8
PROS1	PROS	ENSG00000184500	Protein S (alpha)	3	93873033-93974066	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007724, HPA023974	Enhanced				Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 177.6	heart muscle: 78.3	Cell line enhanced		ASC diff: 98.8;SK-MEL-30: 127.4
GAST	GAS	ENSG00000184502	Gastrin	17	41712326-41715969	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB000038	Supported					Group enriched	Tissue enriched	200	stomach: 11203.5	duodenum: 55.9	Group enriched	6	BEWO: 2.6;HaCaT: 4.7;hTCEpi: 2.3
NUTM1	C15orf55, DKFZp434O192, FAM22H, NUT	ENSG00000184507	NUT midline carcinoma family member 1	15	34343315-34357737	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040421	Enhanced					Not detected	Tissue enriched	78	testis: 22.5	duodenum,skin: 0.2	Not detected		
HDDC3	MGC45386	ENSG00000184508	HD domain containing 3	15	90929964-90932569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040895	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			adrenal gland: 16.2	Expressed in all		
BEX5	NGFRAP1L1	ENSG00000184515	Brain expressed X-linked 5	X	102153708-102156057	Predicted intracellular proteins	Evidence at protein level	HPA059058	Enhanced				Renal cancer:1.97e-4 (favourable), Lung cancer:3.09e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 96.0	epididymis: 34.8	Cell line enhanced		HAP1: 14.7;Karpas-707: 39.3
ZFP1	FLJ34243, ZNF475	ENSG00000184517	ZFP1 zinc finger protein	16	75148492-75172236	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044916, HPA062910	Uncertain		Approved	Nucleus	Glioma:5.81e-5 (favourable), Stomach cancer:9.80e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 25.0	Expressed in all		
CEND1	BM88, FLJ90066	ENSG00000184524	Cell cycle exit and neuronal differentiation 1	11	787104-790123	Predicted membrane proteins	Evidence at protein level	HPA042527	Enhanced		Approved	Mitochondria	Glioma:6.10e-5 (unfavourable)	Tissue enriched	Tissue enriched	16	cerebral cortex: 113.9	adrenal gland: 7.0	Cell line enhanced		Karpas-707: 21.5;SCLC-21H: 62.8;SH-SY5Y: 21.2;U-266/70: 15.9;U-87 MG: 27.1
C6orf58	LEG1	ENSG00000184530	Chromosome 6 open reading frame 58	6	127519455-127591817	Predicted secreted proteins	Evidence at protein level	HPA036263, HPA041449	Enhanced					Group enriched	Group enriched	21	duodenum: 603.5;salivary gland: 163.4;stomach: 314.9	esophagus: 17.1	Cell line enhanced		RPMI-8226: 1.8;WM-115: 1.8
DHRS7C	SDR32C2	ENSG00000184544	Dehydrogenase/reductase 7C	17	9771434-9791297	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	16	heart muscle: 62.4;skeletal muscle: 122.7	esophagus: 5.9	Not detected		
DUSP8	C11orf81, FLJ42958, HB5, HVH-5	ENSG00000184545	Dual specificity phosphatase 8	11	1554044-1571920	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020071	Approved		Approved	Cytosol	Renal cancer:2.75e-6 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 5.1	smooth muscle: 2.3	Cell line enhanced		MCF7: 1.9;SH-SY5Y: 2.2
SOCS3	CIS3, Cish3, SOCS-3, SSI-3	ENSG00000184557	Suppressor of cytokine signaling 3	17	78356778-78360077	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012220, HPA068569	Approved		Approved	Cytosol	Renal cancer:9.34e-9 (unfavourable), Breast cancer:4.80e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 321.5	gallbladder: 297.9	Cell line enhanced		HDLM-2: 142.9
C17orf74		ENSG00000184560	Chromosome 17 open reading frame 74	17	7425615-7427568	Predicted membrane proteins	Evidence at transcript level	HPA023649	Uncertain					Not detected	Tissue enriched	308	testis: 30.8	all non-specific tissues: 0.0	Not detected		
SLITRK6	FLJ22774	ENSG00000184564	SLIT and NTRK like family member 6	13	85792790-85799488	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014491, HPA014513	Uncertain		Supported	Plasma membrane	Head and neck cancer:8.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		urinary bladder: 19.6	prostate: 12.1	Group enriched	12	hTCEpi: 19.1;RT4: 76.0;WM-115: 21.9
PIWIL3	HIWI3	ENSG00000184571	Piwi like RNA-mediated gene silencing 3	22	24719034-24774720	Predicted intracellular proteins	Evidence at protein level	HPA061955	Uncertain					Not detected	Tissue enriched	13	testis: 1.7	skin: 0.1	Not detected		
LPAR5	GPR92, GPR93, KPG_010, LPA5	ENSG00000184574	Lysophosphatidic acid receptor 5	12	6618835-6636447	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013170	Approved				Thyroid cancer:6.56e-5 (favourable)	Mixed	Mixed			tonsil: 10.6	Cell line enhanced		HEL: 16.4;HMC-1: 22.4;K-562: 12.4
XPOT	XPO3	ENSG00000184575	Exportin for tRNA	12	64404350-64451127	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA048067, HPA057602			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.41e-12 (unfavourable), Liver cancer:1.81e-7 (unfavourable), Urothelial cancer:5.79e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 83.0	Expressed in all		
TMEM173	ERIS, FLJ38577, MITA, MPYS, NET23, STING	ENSG00000184584	Transmembrane protein 173	5	139475534-139482935	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA038116, HPA038534	Enhanced				Renal cancer:3.59e-8 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 70.7	Cell line enhanced		EFO-21: 150.4;HDLM-2: 331.0
PDE4B	DPDE4	ENSG00000184588	Phosphodiesterase 4B	1	65792514-66374579	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003005	Uncertain		Approved	Golgi apparatus<br>Cytosol	Renal cancer:5.04e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 67.0	Cell line enhanced		AN3-CA: 57.3;HUVEC TERT2: 77.6;NTERA-2: 56.0
FAM19A3	TAFA-3, TAFA3	ENSG00000184599	Family with sequence similarity 19 member A3, C-C motif chemokine like	1	112720419-112727235	Predicted secreted proteins	Evidence at transcript level	HPA055927	Approved				Glioma:8.24e-4 (unfavourable)	Mixed	Group enriched	15	adrenal gland: 19.9;testis: 8.7	epididymis: 0.9	Cell line enhanced		BJ hTERT+: 3.7;HEL: 1.6;U-87 MG: 1.7
C14orf180	C14orf77, NRAC	ENSG00000184601	Chromosome 14 open reading frame 180	14	104579684-104590515	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Group enriched	19	adipose tissue: 34.5;heart muscle: 28.5	adrenal gland: 1.6	Cell line enriched	14	ASC diff: 2.0
SNN		ENSG00000184602	Stannin	16	11668414-11679159	Predicted membrane proteins	Evidence at protein level	HPA011055	Approved		Approved	Cytosol	Liver cancer:1.85e-6 (unfavourable), Renal cancer:1.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 150.6	Expressed in all		
KCNH7	erg3, HERG3, Kv11.3	ENSG00000184611	Potassium voltage-gated channel subfamily H member 7	2	162371407-162838730	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA018039	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 4.7	stomach,testis: 0.6	Group enriched	12	SCLC-21H: 7.7;SK-BR-3: 4.4
NELL2	NRP2	ENSG00000184613	Neural EGFL like 2	12	44508275-44921848	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035714, HPA035715	Uncertain		Approved	Vesicles	Pancreatic cancer:5.56e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 204.1;fallopian tube: 96.7	prostate: 46.5	Cell line enhanced		AF22: 102.5;NTERA-2: 41.0;SCLC-21H: 88.2
KRBA2		ENSG00000184619	KRAB-A domain containing 2	17	8368637-8376711	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA022849	Approved		Approved	Nucleoplasm		Not detected	Mixed			parathyroid gland: 7.3	Mixed		
MED12	CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230	ENSG00000184634	Mediator complex subunit 12	X	71118556-71142454	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003184, HPA003185	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			ovary: 26.8	Expressed in all		
ZNF93	FLJ12488, HPF34, TF34, ZNF505	ENSG00000184635	Zinc finger protein 93	19	19900913-19935575	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Ovarian cancer:9.31e-6 (favourable)	Mixed	Mixed			thyroid gland: 13.9	Cell line enhanced		NTERA-2: 41.8
SEPT9	AF17q25, KIAA0991, MSF, MSF1, PNUTL4, SeptD1	ENSG00000184640	Septin 9	17	77280569-77500596	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042564, HPA050627	Approved		Enhanced	Actin filaments	Liver cancer:1.61e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 268.9	Expressed in all		
PRSS55	CT153, T-SP1, UNQ9391	ENSG00000184647	Protease, serine 55	8	10525546-10554166	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	92	testis: 26.1	epididymis: 0.2	Not detected		
ODF4	CT136, OPPO1	ENSG00000184650	Outer dense fiber of sperm tails 4	17	8339864-8346048	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	172	testis: 17.1	all non-specific tissues: 0.0	Not detected		
FOXD4L4	bA460E7.2, FOXD4L2	ENSG00000184659	Forkhead box D4-like 4	9	65736555-65738784	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.1	Not detected		
CDCA2	PPP1R81, Repo-Man	ENSG00000184661	Cell division cycle associated 2	8	25458997-25507920	Predicted intracellular proteins	Evidence at protein level	HPA026293, HPA030049	Approved		Enhanced	Nucleoplasm	Renal cancer:2.30e-14 (unfavourable), Colorectal cancer:9.62e-4 (favourable)	Mixed	Tissue enriched	6	testis: 31.4	lymph node: 5.4	Mixed		
RALYL	HNRPCL3	ENSG00000184672	RALY RNA binding protein-like	8	84182787-84921844	Predicted intracellular proteins	Evidence at protein level	HPA055868, HPA059112	Enhanced		Approved	Nucleoplasm		Tissue enhanced	Tissue enhanced		adrenal gland: 26.1;cerebral cortex: 49.2;kidney: 19.7	gallbladder: 8.1	Cell line enhanced		AF22: 4.0
AMER1	FAM123B, FLJ39827, RP11-403E24.2, WTX	ENSG00000184675	APC membrane recruitment protein 1	X	64185117-64205744	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065214, HPA065265	Approved		Supported	Nuclear bodies<br>Vesicles<br>Plasma membrane		Expressed in all	Mixed			ovary: 7.7	Mixed		
ZBTB40	KIAA0478, ZNF923	ENSG00000184677	Zinc finger and BTB domain containing 40	1	22451851-22531157	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042386			Approved	Nucleus	Liver cancer:7.78e-8 (unfavourable), Pancreatic cancer:4.12e-5 (favourable), Head and neck cancer:2.01e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 20.8	Mixed		
HIST2H2BE	H2B, H2B.1, H2B/q, H2BFQ	ENSG00000184678	Histone cluster 2 H2B family member e	1	149884459-149886652	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Colorectal cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 113.5	Cell line enhanced		Karpas-707: 40.8;U-266/70: 71.4
CLDN6		ENSG00000184697	Claudin 6	16	3014712-3020071	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.42e-6 (unfavourable), Urothelial cancer:1.78e-4 (unfavourable)	Group enriched	Tissue enhanced		placenta: 1.0;testis: 1.7	cerebral cortex,lung: 0.3	Group enriched	8	BEWO: 460.1;CACO-2: 110.7;NTERA-2: 441.6
OR51M1		ENSG00000184698	Olfactory receptor family 51 subfamily M member 1	11	5389399-5390379	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA056773	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SEPT5	H5, HCDCREL-1, PNUTL1	ENSG00000184702	Septin 5	22	19714464-19724772	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB016120, HPA029095, HPA063885	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:6.87e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 386.8	Cell line enhanced		K-562: 211.0
EIF4ENIF1	2610509L04Rik, 4E-T, Clast4, FLJ21601	ENSG00000184708	Eukaryotic translation initiation factor 4E nuclear import factor 1	22	31436977-31496108	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001619, HPA002078	Enhanced		Enhanced	Vesicles	Renal cancer:1.57e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.0	Expressed in all		
LRRC26	bA350O14.10	ENSG00000184709	Leucine rich repeat containing 26	9	137168758-137170051	Predicted membrane proteins	Evidence at protein level	HPA056312	Approved		Supported	Nucleoli fibrillar center<br>Plasma membrane	Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable)	Tissue enriched	Group enriched	7	colon: 10.2;prostate: 35.5;salivary gland: 26.5	small intestine: 3.5	Group enriched	10	REH: 18.9;RPMI-8226: 87.4
SERINC4	FLJ40363	ENSG00000184716	Serine incorporator 4	15	43794162-43800221	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	10	testis: 2.3	endometrium: 0.2	Not detected		
RNLS	C10orf59, FLJ11218, renalase	ENSG00000184719	Renalase, FAD dependent amine oxidase	10	88273864-88584530	Enzymes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Expressed in all			kidney: 26.5	Mixed		
KRTAP6-1	C21orf103, KAP6.1	ENSG00000184724	Keratin associated protein 6-1	21	30613431-30613930	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
APOBR	APOB100R, APOB48R	ENSG00000184730	Apolipoprotein B receptor	16	28494649-28498970	Predicted intracellular proteins	Evidence at protein level	HPA041667, HPA042093	Enhanced				Endometrial cancer:3.26e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 30.4	appendix: 27.1	Cell line enhanced		HEL: 37.0;HMC-1: 109.0;NB-4: 22.6;U-937: 24.2
FAM110C		ENSG00000184731	Family with sequence similarity 110 member C	2	38814-46870	Predicted intracellular proteins	Evidence at protein level	HPA036144, HPA036145	Uncertain				Glioma:6.77e-4 (unfavourable)	Mixed	Mixed			seminal vesicle: 29.0	Cell line enhanced		HaCaT: 11.8;RPTEC TERT1: 13.6;RT4: 20.1
DDX53	CAGE, CT26	ENSG00000184735	DEAD-box helicase 53	X	22999961-23003589	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	100	testis: 10.0	all non-specific tissues: 0.0	Cell line enhanced		K-562: 4.1;RPMI-8226: 1.6;U-2197: 1.3;U-266/84: 7.3
ATL3	DKFZP564J0863	ENSG00000184743	Atlastin GTPase 3	11	63624087-63671921	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA065702, HPA076616			Enhanced	Endoplasmic reticulum	Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 65.6	Mixed		
NDUFA12	B17.2, DAP13	ENSG00000184752	NADH:ubiquinone oxidoreductase subunit A12	12	94897055-95003770	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039903	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 189.2	Expressed in all		
AC013269.5		ENSG00000184761		2	130539095-130549883	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SMIM10	CXorf69	ENSG00000184785	Small integral membrane protein 10	X	134990938-134992473	Predicted membrane proteins	Evidence at transcript level						Renal cancer:3.69e-6 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 63.4;testis: 50.6	fallopian tube: 17.7	Mixed		
TCTE3	TCTEX1D3	ENSG00000184786	T-complex-associated-testis-expressed 3	6	169740114-169751587	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	173	testis: 17.2	all non-specific tissues: 0.0	Not detected		
UBE2G2	UBC7	ENSG00000184787	Ubiquitin conjugating enzyme E2 G2	21	44768580-44802019	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003332	Approved				Renal cancer:7.02e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 26.5	Expressed in all		
SATL1		ENSG00000184788	Spermidine/spermine N1-acetyl transferase-like 1	X	85092287-85109048	Predicted intracellular proteins	Evidence at transcript level	HPA060369	Uncertain					Not detected	Tissue enhanced		testis: 1.3	cerebral cortex: 0.4	Not detected		
OSBP2	KIAA1664, ORP-4, ORP4, OSBPL1	ENSG00000184792	Oxysterol binding protein 2	22	30693782-30907824	Predicted intracellular proteins	Evidence at protein level	HPA021514	Uncertain		Approved	Cytosol	Renal cancer:3.79e-6 (favourable)	Expressed in all	Tissue enhanced		testis: 34.5	bone marrow: 31.8	Cell line enhanced		HeLa: 98.3;SiHa: 41.6
TUSC5	IFITMD3, LOST1	ENSG00000184811	Tumor suppressor candidate 5	17	1279663-1300987	Predicted membrane proteins	Evidence at protein level	HPA050825	Approved					Tissue enhanced	Tissue enriched	18	adipose tissue: 110.0	breast: 6.1	Cell line enriched	207	ASC diff: 20.6
PRR23B	FLJ46116	ENSG00000184814	Proline rich 23B	3	139019031-139020926	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Not detected	Tissue enriched	16	testis: 1.5	all non-specific tissues: 0.0	Not detected		
ZBTB7C	ZBTB36, ZNF857C	ENSG00000184828	Zinc finger and BTB domain containing 7C	18	48026673-48410752	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Colorectal cancer:1.59e-4 (favourable)	Mixed	Mixed			esophagus: 31.7	Cell line enhanced		RPMI-8226: 6.7;RT4: 34.0;SCLC-21H: 6.5;SH-SY5Y: 7.3
APOO	FAM121B, MGC4825, Mic23, MIC26, My025	ENSG00000184831	Apolipoprotein O	X	23833353-23907934	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003187	Supported		Approved	Mitochondria<br>Cytosol	Renal cancer:2.56e-6 (favourable), Cervical cancer:3.77e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.8	Expressed in all		
PRR16	DSC54	ENSG00000184838	Proline rich 16	5	120464278-120687332	Predicted intracellular proteins	Evidence at protein level	HPA049254	Approved		Approved	Nucleus<br>Midbody<br>Cytosol		Tissue enriched	Mixed			cervix, uterine: 21.7	Cell line enhanced		BJ hTERT+: 67.6;fHDF/TERT166: 78.9;LHCN-M2: 80.9;U-138 MG: 115.3
TMED9	HSGP25L2G, p24a2, p24alpha2	ENSG00000184840	Transmembrane p24 trafficking protein 9	5	177592158-177596124	Predicted membrane proteins	Evidence at protein level	HPA014650	Approved				Renal cancer:5.88e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 212.7	Expressed in all		
DRD1		ENSG00000184845	Dopamine receptor D1	5	175440039-175444208	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA013393		Supported				Mixed	Tissue enhanced		cerebral cortex: 8.0	prostate: 1.7	Group enriched	10	RT4: 20.9;U-2 OS: 5.4
TMEM186	C16orf51, DKFZP564K2062	ENSG00000184857	Transmembrane protein 186	16	8780384-8797648	Predicted membrane proteins	Evidence at protein level	HPA018226, HPA063559	Uncertain		Approved	Cell Junctions	Renal cancer:1.93e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.0	Expressed in all		
SDR42E1	HSPC105	ENSG00000184860	Short chain dehydrogenase/reductase family 42E, member 1	16	81988855-82011488	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA014388	Uncertain					Mixed	Mixed			skin: 10.7	Cell line enhanced		hTCEpi: 8.4;RT4: 15.4;SCLC-21H: 9.5
RBM33	DKFZp434D1319, DKFZp686F102, MGC20460, PRR8	ENSG00000184863	RNA binding motif protein 33	7	155644451-155781485	Predicted intracellular proteins	Evidence at protein level	HPA019232, HPA021497, HPA021768	Approved		Approved	Nucleoplasm	Head and neck cancer:9.63e-5 (favourable), Renal cancer:1.05e-4 (unfavourable), Urothelial cancer:4.29e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 40.8	Expressed in all		
ARMCX2	ALEX2, GASP9, KIAA0512	ENSG00000184867	Armadillo repeat containing, X-linked 2	X	101655281-101659891	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005761	Enhanced		Approved	Nucleus<br>Mitochondria	Pancreatic cancer:3.45e-5 (favourable), Stomach cancer:2.69e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 202.3	thyroid gland: 107.5	Cell line enhanced		LHCN-M2: 146.0;NTERA-2: 125.3
BTBD6	BDPL	ENSG00000184887	BTB domain containing 6	14	105248490-105251093	Predicted intracellular proteins	Evidence at protein level	HPA031355	Approved		Approved	Nucleoplasm	Renal cancer:6.51e-5 (favourable), Breast cancer:1.11e-4 (favourable), Pancreatic cancer:2.25e-4 (favourable)	Expressed in all	Expressed in all			testis: 73.4	Mixed		
SRY	TDF	ENSG00000184895	Sex determining region Y	Y	2786855-2787699	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 1.0;testis: 2.8	esophagus: 0.7	Cell line enhanced		RT4: 1.7
H1FX	H1X, MGC15959, MGC8350	ENSG00000184897	H1 histone family member X	3	129314771-129316277	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012235, HPA040099	Supported		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Tissue enriched	7	bone marrow: 670.4	spleen: 95.9	Expressed in all		
RBM43	C2orf38, FLJ45645	ENSG00000184898	RNA binding motif protein 43	2	151247940-151261879	Predicted intracellular proteins	Evidence at protein level	HPA038204	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			thyroid gland: 20.6	Mixed		
SUMO3	SMT3A, SMT3H1	ENSG00000184900	Small ubiquitin-like modifier 3	21	44805617-44818779	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012180, HPA042123, HPA048064	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Endometrial cancer:7.88e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 80.8	Expressed in all		
IMMP2L	IMMP2L-IT1, IMP2	ENSG00000184903	Inner mitochondrial membrane peptidase subunit 2	7	110663051-111562517	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026711	Approved		Approved	Mitochondria	Head and neck cancer:1.89e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.4	Expressed in all		
TCEAL2	my048, MY0876G05, WEX1	ENSG00000184905	Transcription elongation factor A like 2	X	102125688-102127711	Predicted intracellular proteins	Evidence at protein level	HPA076317			Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 191.7	ovary: 77.7	Cell line enhanced		HAP1: 6.0;SCLC-21H: 7.3;U-2 OS: 11.7
CLCNKB	hClC-Kb	ENSG00000184908	Chloride voltage-gated channel Kb	1	16043736-16057308	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057717	Approved				Renal cancer:1.27e-7 (favourable)	Tissue enriched	Tissue enhanced		kidney: 107.9	salivary gland: 22.0	Cell line enhanced		EFO-21: 1.5
DMRTC1B		ENSG00000184911	DMRT like family C1B	X	72777009-72848802	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA046874, HPA046992	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 16.6	ovary: 10.3	Not detected		
JAG2		ENSG00000184916	Jagged 2	14	105140981-105168824	Predicted membrane proteins	Evidence at protein level	CAB025481, HPA030636, HPA050567	Approved		Supported	Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		skin: 22.5	adipose tissue: 6.5	Cell line enhanced		HaCaT: 54.2;SCLC-21H: 36.3
FMNL1	C17orf1, C17orf1B, FMNL	ENSG00000184922	Formin like 1	17	45221444-45247320	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008129, HPA028288	Enhanced		Approved	Cytosol	Renal cancer:4.23e-8 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 175.0	Cell line enhanced		Karpas-707: 137.1;MOLT-4: 110.5;U-266/70: 120.6
NUTM2A	FAM22A	ENSG00000184923	NUT family member 2A	10	87225448-87236908	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			skin: 1.9	Cell line enhanced		HMC-1: 8.3
PTRHD1	C2orf79, LOC391356	ENSG00000184924	Peptidyl-tRNA hydrolase domain containing 1	2	24789734-24793382	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019951	Approved		Approved	Nucleoplasm	Renal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 14.0	Expressed in all		
LCN12	MGC48935	ENSG00000184925	Lipocalin 12	9	136949551-136955497	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	31	epididymis: 45.4	thyroid gland: 1.4	Not detected		
OR6A2	OR11-55, OR6A1, OR6A2P	ENSG00000184933	Olfactory receptor family 6 subfamily A member 2	11	6794627-6795783	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
WT1	AWT1, GUD, NPHS4, WAGR, WIT-2	ENSG00000184937	Wilms tumor 1	11	32387775-32435630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000327, HPA035717, HPA053848	Enhanced		Supported	Nucleoplasm		Tissue enriched	Tissue enhanced		endometrium: 112.9;fallopian tube: 126.5;smooth muscle: 80.2	testis: 55.1	Cell line enhanced		HEL: 23.8;HMC-1: 28.7;K-562: 21.7;NB-4: 40.6;THP-1: 20.5
ZFP90	KIAA1954, NK10, ZNF756	ENSG00000184939	ZFP90 zinc finger protein	16	68530090-68576072	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029017	Uncertain		Supported	Vesicles<br>Plasma membrane<br>Centrosome	Renal cancer:1.78e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 31.7	Mixed		
AQP12A	AQP12	ENSG00000184945	Aquaporin 12A	2	240691845-240698483	Predicted membrane proteins, Transporters	Evidence at protein level	HPA042216	Supported					Not detected	Tissue enriched	68	pancreas: 27.8	small intestine: 0.4	Not detected		
FAM227A		ENSG00000184949	Family with sequence similarity 227 member A	22	38578120-38656629	Predicted intracellular proteins	Evidence at protein level	HPA003077	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 3.7	testis: 3.5	Group enriched	6	HDLM-2: 11.1;Karpas-707: 14.1
OR6C70		ENSG00000184954	Olfactory receptor family 6 subfamily C member 70	12	55469200-55470138	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	6	Karpas-707: 1.6
MUC6		ENSG00000184956	Mucin 6, oligomeric mucus/gel-forming	11	1012821-1036706	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB002165	Enhanced					Tissue enhanced	Group enriched	24	duodenum: 15.4;seminal vesicle: 40.2;stomach: 24.0	epididymis: 1.1	Not detected		
NOC4L	MGC3162, NET49, UTP19	ENSG00000184967	Nucleolar complex associated 4 homolog	12	132144448-132152473	Predicted intracellular proteins	Evidence at protein level	HPA053424			Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			testis: 24.7	Expressed in all		
USP18		ENSG00000184979	Ubiquitin specific peptidase 18	22	18149899-18177397	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA044768	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 15.4	Cell line enhanced		BJ hTERT+ SV40 Large T+: 144.8;BJ hTERT+ SV40 Large T+ RasG12V: 163.7
NDUFA6	B14, CI-B14, LYRM6, NADHB14	ENSG00000184983	NADH:ubiquinone oxidoreductase subunit A6	22	42085525-42090955	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.05e-6 (favourable), Cervical cancer:3.87e-4 (favourable), Endometrial cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.6	Mixed		
CHRM5		ENSG00000184984	Cholinergic receptor muscarinic 5	15	33968720-34067457	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA013172	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 3.1;testis: 3.4	placenta: 2.3	Group enriched	7	BEWO: 4.5;HMC-1: 14.3
SORCS2	KIAA1329	ENSG00000184985	Sortilin related VPS10 domain containing receptor 2	4	7192538-7742836	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA061916			Approved	Nucleus<br>Cytosol	Renal cancer:3.09e-4 (unfavourable), Ovarian cancer:3.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 19.3	cervix, uterine: 10.4	Cell line enhanced		HaCaT: 17.3;HMC-1: 12.7;SiHa: 15.0
TMEM121	hole, MGC4659	ENSG00000184986	Transmembrane protein 121	14	105526603-105530202	Predicted membrane proteins	Evidence at transcript level	HPA049857	Uncertain		Approved	Cytosol	Thyroid cancer:5.87e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 4.8	spleen: 2.4	Cell line enhanced		EFO-21: 7.7;MCF7: 6.1;PC-3: 9.5;REH: 6.1;SCLC-21H: 6.2
TMEM106A	MGC20235	ENSG00000184988	Transmembrane protein 106A	17	43211835-43220041	Predicted membrane proteins	Evidence at transcript level						Colorectal cancer:9.61e-5 (unfavourable)	Expressed in all	Mixed			kidney: 23.2	Mixed		
SIVA1	CD27BP, SIVA, Siva-1, Siva-2	ENSG00000184990	SIVA1 apoptosis inducing factor	14	104753100-104768494	Predicted intracellular proteins	Evidence at protein level	HPA065398, HPA066693			Supported	Nucleoplasm	Cervical cancer:5.95e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 62.0	Expressed in all		
BRI3BP	BNAS1, HCCR-2, HCCRBP-3, KG19	ENSG00000184992	BRI3 binding protein	12	124993700-125031231	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014957	Approved		Approved	Nucleoplasm<br>Mitochondria	Liver cancer:6.87e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 20.5	Expressed in all		
IFNE	IFNE1	ENSG00000184995	Interferon epsilon	9	21480839-21482313	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 1.1	urinary bladder: 0.8	Cell line enhanced		BJ: 2.7;HeLa: 5.5
SLC22A10	hOAT5, OAT5	ENSG00000184999	Solute carrier family 22 member 10	11	63137867-63369718	Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	106	liver: 36.2	epididymis: 0.3	Not detected		
DGAT1	ARGP1, DGAT	ENSG00000185000	Diacylglycerol O-acyltransferase 1	8	144314584-144326910	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032853	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum		Expressed in all	Tissue enhanced		duodenum: 71.3;small intestine: 75.1	adipose tissue: 20.0	Cell line enhanced		PC-3: 35.6
RFX6	dJ955L16.1, MGC33442, RFXDC1	ENSG00000185002	Regulatory factor X6	6	116877212-116932163	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037696, HPA037697	Approved		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:3.59e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 5.9;stomach: 7.2	duodenum: 2.3	Cell line enhanced		HEK 293: 1.2
ROBO2	KIAA1568	ENSG00000185008	Roundabout guidance receptor 2	3	75906695-77649964	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013371	Approved		Approved	Nucleus<br>Microtubule organizing center		Tissue enhanced	Tissue enhanced		cerebral cortex: 33.8	lung: 15.1	Cell line enhanced		BJ hTERT+: 24.2;HEL: 75.2
AP3M1		ENSG00000185009	Adaptor related protein complex 3 mu 1 subunit	10	74120255-74151063	Predicted intracellular proteins	Evidence at protein level	HPA045591, HPA048380	Uncertain					Expressed in all	Expressed in all			placenta: 46.0	Expressed in all		
F8	DXS1253E, F8C, FVIII, HEMA	ENSG00000185010	Coagulation factor VIII	X	154835788-155026940	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018777	Enhanced					Expressed in all	Expressed in all			lung: 23.4	Mixed		
NT5C1B	AIRP, CN-IB	ENSG00000185013	5'-nucleotidase, cytosolic IB	2	18562872-18589572	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level	HPA056683	Uncertain					Not detected	Tissue enriched	43	testis: 57.5	skin: 1.3	Mixed		
CA13	CAXIII, FLJ37995, MGC59868	ENSG00000185015	Carbonic anhydrase 13	8	85220587-85284073	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA024689, CAB025567	Enhanced		Uncertain	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:9.40e-4 (favourable)	Expressed in all	Mixed			small intestine: 16.5	Cell line enhanced		HEL: 14.2
UBOX5	KIAA0860, RNF37, Ubce7ip5, UIP5	ENSG00000185019	U-box domain containing 5	20	3107573-3160196	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028871	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.80e-5 (favourable), Head and neck cancer:4.52e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 7.1	Expressed in all		
MAFF	hMafF	ENSG00000185022	MAF bZIP transcription factor F	22	38200767-38216511	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025341, HPA055371	Approved		Approved	Nucleus<br>Mitochondria	Breast cancer:4.32e-4 (favourable)	Expressed in all	Mixed			gallbladder: 66.3	Cell line enhanced		hTEC/SVTERT24-B: 79.2;SK-MEL-30: 75.4
BRF1	BRF, GTF3B, hBRF, TAF3B2, TAF3C, TFIIIB90	ENSG00000185024	BRF1, RNA polymerase III transcription initiation factor subunit	14	105209286-105315589	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051918			Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:7.25e-6 (favourable), Renal cancer:1.13e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 21.7	Expressed in all		
LRRC14B		ENSG00000185028	Leucine rich repeat containing 14B	5	191511-195353	Predicted intracellular proteins	Evidence at protein level	HPA038046, HPA038047	Uncertain					Tissue enhanced	Group enriched	26	heart muscle: 13.6;skeletal muscle: 30.1	prostate: 0.8	Cell line enhanced		REH: 6.8;U-266/70: 7.1;U-266/84: 28.6
SEMA4B	KIAA1745, MGC131831, SEMAC, SemC	ENSG00000185033	Semaphorin 4B	15	90160604-90229679	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013372	Approved				Renal cancer:3.33e-8 (unfavourable), Lung cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 49.3	Expressed in all		
MROH2A	HEATR7B1	ENSG00000185038	Maestro heat like repeat family member 2A	2	233775679-233833423	Predicted intracellular proteins	Evidence at transcript level	HPA052107	Uncertain		Uncertain	Cytosol		Tissue enhanced	Group enriched	8	testis: 3.2;thyroid gland: 2.7	liver,stomach: 0.3	Cell line enriched	8	RT4: 4.8
SPDYE16		ENSG00000185040	Speedy/RINGO cell cycle regulator family member E16	7	76531319-76541459	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported					Not detected	Not detected			testis: 0.6	Cell line enhanced		HeLa: 1.9
CIB1	CIB, KIP, SIP2-28	ENSG00000185043	Calcium and integrin binding 1	15	90229975-90234047	Predicted intracellular proteins	Evidence at protein level	CAB012991, HPA042413, HPA048825	Approved		Supported	Nucleoplasm<br>Plasma membrane	Endometrial cancer:2.26e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 207.5	Expressed in all		
ANKS1B	AIDA-1, ANKS2, cajalin-2, EB-1	ENSG00000185046	Ankyrin repeat and sterile alpha motif domain containing 1B	12	98726457-99984654	Predicted intracellular proteins	Evidence at protein level	HPA044628			Approved	Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enriched	8	cerebral cortex: 111.9	testis: 14.0	Cell line enhanced		AF22: 10.0;SCLC-21H: 13.0
NELFA	NELF-A, WHSC2	ENSG00000185049	Negative elongation factor complex member A	4	1982714-2041903	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009960, HPA039858, HPA043931	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:4.35e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 31.7	Expressed in all		
SLC24A3		ENSG00000185052	Solute carrier family 24 member 3	20	19212646-19722937	Predicted membrane proteins, Transporters	Evidence at protein level	HPA043400, HPA045497	Uncertain				Thyroid cancer:6.08e-4 (unfavourable)	Mixed	Mixed			endometrium: 47.7	Cell line enhanced		BJ hTERT+: 10.7;HEL: 16.2;HMC-1: 68.3;T-47d: 15.9
SGCZ	ZSG1	ENSG00000185053	Sarcoglycan zeta	8	14089864-15238339	Predicted membrane proteins	Evidence at transcript level	HPA017585	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.3;ovary: 3.4	breast: 0.7	Not detected		
EFCAB10		ENSG00000185055	EF-hand calcium binding domain 10	7	105565120-105600875	Predicted intracellular proteins	Evidence at transcript level	HPA019751	Uncertain					Mixed	Group enriched	10	fallopian tube: 44.0;testis: 39.9	lung: 4.3	Mixed		
C5orf47	LOC133491	ENSG00000185056	Chromosome 5 open reading frame 47	5	173973779-174006140	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	250	testis: 39.4	cerebral cortex,parathyroid gland: 0.1	Not detected		
KRT76	HUMCYT2A, KRT2B, KRT2P	ENSG00000185069	Keratin 76	12	52768155-52777345	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019656, HPA019696	Approved					Tissue enriched	Tissue enriched	22	tonsil: 2.1	all non-specific tissues: 0.0	Not detected		
FLRT2		ENSG00000185070	Fibronectin leucine rich transmembrane protein 2	14	85530144-85654426	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 36.4	cervix, uterine: 16.7	Cell line enhanced		hTERT-HME1: 46.2;TIME: 45.0;U-138 MG: 57.9;U-2197: 39.9
INTS5	INT5, KIAA1698	ENSG00000185085	Integrator complex subunit 5	11	62646848-62653302	Predicted intracellular proteins	Evidence at protein level	HPA056915	Uncertain		Supported	Nucleus	Renal cancer:8.44e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 21.0	Expressed in all		
RPS27L		ENSG00000185088	Ribosomal protein S27 like	15	63125872-63158021	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA066851			Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Endometrial cancer:9.08e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 222.3	Expressed in all		
MANEAL	FLJ31434	ENSG00000185090	Mannosidase endo-alpha like	1	37793802-37801137	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA063423			Approved	Golgi apparatus	Liver cancer:3.32e-4 (unfavourable), Head and neck cancer:5.28e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 27.2	adrenal gland: 9.5	Cell line enhanced		SCLC-21H: 167.3
ADSSL1	FLJ38602	ENSG00000185100	Adenylosuccinate synthase like 1	14	104724186-104747325	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.99e-4 (unfavourable)	Mixed	Tissue enriched	7	skeletal muscle: 428.0	heart muscle: 63.0	Cell line enhanced		EFO-21: 13.7;MCF7: 10.4;SiHa: 23.7
ANO9	PIG5, TMEM16J, TP53I5	ENSG00000185101	Anoctamin 9	11	417933-442011	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039948, HPA040112	Approved		Uncertain	Golgi apparatus	Urothelial cancer:8.81e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 31.6;small intestine: 30.9	skin: 21.6	Cell line enhanced		BEWO: 8.6;CAPAN-2: 24.1;HaCaT: 14.1;RPMI-8226: 13.6
FAF1	CGI-03, hFAF1, HFAF1s, UBXD12, UBXN3A	ENSG00000185104	Fas associated factor 1	1	50437028-50960263	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018253, CAB072814	Approved		Enhanced	Nucleus	Liver cancer:1.87e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 59.5	Mixed		
MYADML2	LOC255275	ENSG00000185105	Myeloid associated differentiation marker like 2	17	81939645-81947233	Predicted membrane proteins	Evidence at transcript level	HPA041856, HPA048476	Uncertain					Tissue enhanced	Tissue enriched	17	skeletal muscle: 28.8	heart muscle: 1.6	Cell line enriched	8	SCLC-21H: 3.6
FAM43A	FLJ90022	ENSG00000185112	Family with sequence similarity 43 member A	3	194686544-194689037	Predicted intracellular proteins	Evidence at protein level	HPA048345	Uncertain		Approved	Vesicles	Urothelial cancer:9.96e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 34.0	placenta: 18.2	Cell line enhanced		HUVEC TERT2: 113.2;NB-4: 52.7;PC-3: 59.3;TIME: 55.9
NSMCE3	HCA4, MAGEG1, MAGEL3, NDNL2, NSE3	ENSG00000185115	NSE3 homolog, SMC5-SMC6 complex component	15	29264992-29269829	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.94e-4 (unfavourable)	Expressed in all	Not detected			cerebral cortex: 0.8	Not detected		
HSF1	HSTF1	ENSG00000185122	Heat shock transcription factor 1	8	144291591-144314722	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004239, HPA008888	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.95e-4 (unfavourable), Endometrial cancer:8.93e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 127.1	Expressed in all		
C6orf120	bA160E12.4	ENSG00000185127	Chromosome 6 open reading frame 120	6	169702190-169704856	Predicted secreted proteins	Evidence at protein level	HPA039626	Uncertain				Liver cancer:9.52e-5 (unfavourable), Cervical cancer:2.26e-4 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 28.7	Expressed in all		
PURA	PUR-ALPHA, PUR1, PURALPHA	ENSG00000185129	Purine rich element binding protein A	5	140107777-140125619	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:4.77e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 26.9	Expressed in all		
HIST1H2BL	dJ97D16.4, H2B/c, H2BFC	ENSG00000185130	Histone cluster 1 H2B family member l	6	27807444-27807931	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enriched	6	bone marrow: 3.7	lymph node,thyroid gland: 0.6	Cell line enhanced		MOLT-4: 9.8;U-266/84: 8.5
INPP5J	INPP5, PIB5PA, PIPP	ENSG00000185133	Inositol polyphosphate-5-phosphatase J	22	31122731-31134696	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034539			Approved	Nucleoli<br>Cytosol	Renal cancer:1.12e-7 (favourable), Lung cancer:1.47e-5 (favourable)	Tissue enriched	Group enriched	10	parathyroid gland: 215.4;thyroid gland: 242.1	small intestine: 22.4	Cell line enhanced		HL-60: 15.5;SK-BR-3: 30.3;T-47d: 24.0
NPY2R		ENSG00000185149	Neuropeptide Y receptor Y2	4	155208629-155217078	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		breast: 1.0;cerebral cortex: 1.7;testis: 1.0	rectum: 0.6	Cell line enriched	6	SH-SY5Y: 8.0
MIXL1	MILD1, MIXL	ENSG00000185155	Mix paired-like homeobox	1	226223618-226227054	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005662			Approved	Nucleus		Tissue enriched	Tissue enhanced		tonsil: 3.0	lymph node: 2.8	Cell line enhanced		HAP1: 1.7;Hep G2: 5.7;U-698: 1.5
MFSD6L	FLJ35773	ENSG00000185156	Major facilitator superfamily domain containing 6 like	17	8797162-8799349	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA023164	Uncertain				Breast cancer:1.84e-4 (favourable)	Mixed	Tissue enhanced		testis: 29.8	parathyroid gland: 8.4	Cell line enriched	5	HMC-1: 7.5
LRRC37B		ENSG00000185158	Leucine rich repeat containing 37B	17	32007872-32053504	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015135	Approved		Approved	Cytosol		Mixed	Mixed			testis: 32.4	Expressed in all		
DDX51		ENSG00000185163	DEAD-box helicase 51	12	132136594-132144335	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039503	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:4.73e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 11.4	Expressed in all		
NOMO2	NOMO, PM5	ENSG00000185164	NODAL modulator 2	16	18417325-18562211	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046697, HPA061174	Approved					Expressed in all	Expressed in all			parathyroid gland: 157.3	Expressed in all		
AQP12B	INSSA3	ENSG00000185176	Aquaporin 12B	2	240676418-240682906	Predicted membrane proteins	Evidence at protein level	HPA042216	Supported					Not detected	Tissue enriched	57	pancreas: 35.7	duodenum: 0.6	Not detected		
ZNF479	KR19	ENSG00000185177	Zinc finger protein 479	7	57119614-57139864	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enriched	42	testis: 4.1	all non-specific tissues: 0.0	Not detected		
SIGIRR	IL-1R8, TIR8	ENSG00000185187	Single Ig and TIR domain containing	11	405716-417455	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023188	Approved		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:7.61e-6 (favourable), Endometrial cancer:1.34e-5 (favourable), Urothelial cancer:1.54e-5 (favourable), Cervical cancer:7.44e-5 (favourable), Head and neck cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			spleen: 64.7	Cell line enhanced		CAPAN-2: 119.6
NRBP2	DKFZp434P086	ENSG00000185189	Nuclear receptor binding protein 2	8	143833594-143840974	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB020944, HPA029051, HPA029052	Approved		Approved	Cytosol	Renal cancer:2.01e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 55.2	Mixed		
PRSS57	PRSSL1, UNQ782	ENSG00000185198	Protease, serine 57	19	685546-695498	Enzymes, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	173	bone marrow: 103.3	spleen: 0.5	Group enriched	9	NB-4: 239.3;THP-1: 126.5
IFITM2	1-8D	ENSG00000185201	Interferon induced transmembrane protein 2	11	307631-315272	Predicted membrane proteins, Transporters	Evidence at protein level	HPA004337	Uncertain				Renal cancer:2.37e-9 (unfavourable)	Expressed in all	Expressed in all			appendix: 705.4	Cell line enhanced		HMC-1: 1031.9;HSkMC: 907.1
TNFAIP2	B94, EXOC3L3	ENSG00000185215	TNF alpha induced protein 2	14	103123442-103137439	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB004598, HPA030624	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Golgi apparatus<br>Cytosol	Stomach cancer:2.79e-5 (favourable), Urothelial cancer:7.17e-5 (favourable), Renal cancer:4.10e-4 (unfavourable)	Expressed in all	Expressed in all			urinary bladder: 203.5	Cell line enhanced		RT4: 616.3
ZNF445	ZKSCAN15, ZNF168, ZSCAN47	ENSG00000185219	Zinc finger protein 445	3	44431720-44477670	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006678	Uncertain		Approved	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 7.2	Mixed		
PGBD2		ENSG00000185220	PiggyBac transposable element derived 2	1	248906196-248919946	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029888, HPA029889, HPA029890	Uncertain		Supported	Vesicles	Urothelial cancer:2.05e-4 (favourable), Head and neck cancer:6.08e-4 (favourable), Renal cancer:7.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.4	Expressed in all		
TCEAL9	DKFZp313K1940, WBP5, WEX6	ENSG00000185222	Transcription elongation factor A like 9	X	103356452-103358451	Predicted intracellular proteins	Evidence at protein level	HPA011790	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			placenta: 275.0	Mixed		
MC2R	ACTHR	ENSG00000185231	Melanocortin 2 receptor	18	13882044-13915707	Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enriched	23	adrenal gland: 50.6	epididymis: 2.1	Not detected		
RAB11B	H-YPT3	ENSG00000185236	RAB11B, member RAS oncogene family	19	8389981-8404434	Predicted intracellular proteins	Evidence at protein level	HPA054396			Approved	Vesicles<br>Microtubule organizing center	Pancreatic cancer:7.58e-5 (favourable), Renal cancer:2.06e-4 (favourable), Cervical cancer:2.08e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 151.9	Expressed in all		
PRMT3	HRMT1L3	ENSG00000185238	Protein arginine methyltransferase 3	11	20387530-20509294	Predicted intracellular proteins	Evidence at protein level	HPA007832, CAB022083	Uncertain				Liver cancer:2.81e-5 (unfavourable), Pancreatic cancer:3.17e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 27.4	Expressed in all		
GP1BA	CD42b, GP1B, GPIbalpha	ENSG00000185245	Glycoprotein Ib platelet alpha subunit	17	4932297-4935030	CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002496, HPA013316	Supported					Mixed	Tissue enhanced		lymph node: 17.3	tonsil: 7.1	Cell line enriched	23	HEL: 64.4
PRPF39	FLJ11128, FLJ20666	ENSG00000185246	Pre-mRNA processing factor 39	14	45084099-45116282	Predicted intracellular proteins	Evidence at protein level	HPA001176	Approved		Approved	Nucleoplasm	Liver cancer:3.84e-5 (unfavourable), Urothelial cancer:2.99e-4 (favourable), Prostate cancer:4.04e-4 (unfavourable), Melanoma:6.51e-4 (unfavourable), Ovarian cancer:8.48e-4 (favourable)	Expressed in all	Mixed			prostate: 9.8	Expressed in all		
MAGEA11	CT1.11, MAGE-11, MAGE11, MAGEA-11, MGC10511	ENSG00000185247	MAGE family member A11	X	149688228-149717266	Predicted intracellular proteins	Evidence at protein level	HPA052687			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Mixed	Group enriched	15	epididymis: 25.8;testis: 6.9	placenta: 1.0	Cell line enhanced		PC-3: 5.2;U-2 OS: 25.0;U-2197: 3.2
PPIL6	bA425D10.6, dJ919F19.1, MGC41939, RSPH12	ENSG00000185250	Peptidylprolyl isomerase like 6	6	109390215-109441171	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036717	Approved		Approved	Nucleus<br>Golgi apparatus<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 53.2;testis: 32.6	thyroid gland: 17.7	Cell line enhanced		AN3-CA: 5.4;ASC diff: 6.2;ASC TERT1: 7.8
ZNF74	Cos52, Zfp520, ZNF520	ENSG00000185252	Zinc finger protein 74	22	20394115-20408461	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003354	Approved		Supported	Nucleoplasm<br>Actin filaments		Expressed in all	Mixed			ovary: 4.8	Cell line enhanced		K-562: 37.4
KIAA0825	C5orf36, DKFZp686F0372, MGC34713	ENSG00000185261	KIAA0825	5	94152966-94618597	Predicted intracellular proteins	Evidence at protein level	HPA038030, HPA038031	Uncertain					Not detected	Mixed			testis: 5.4	Cell line enhanced		HeLa: 6.1
UBALD2	FAM100B, MGC29814	ENSG00000185262	UBA like domain containing 2	17	76265202-76271299	Predicted intracellular proteins	Evidence at protein level	HPA023046	Uncertain					Expressed in all	Expressed in all			bone marrow: 140.7	Expressed in all		
TEX33	C22orf33, EAN57, MGC35206	ENSG00000185264	Testis expressed 33	22	36991120-37007841	Predicted intracellular proteins	Evidence at protein level	HPA005998	Enhanced					Not detected	Tissue enriched	574	testis: 87.1	cerebral cortex: 0.1	Not detected		
CDNF	ARMETL1	ENSG00000185267	Cerebral dopamine neurotrophic factor	10	14819250-14838575	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044587	Uncertain					Mixed	Tissue enhanced		testis: 20.1	skeletal muscle: 12.5	Cell line enhanced		RPMI-8226: 8.5
NOTUM		ENSG00000185269	NOTUM, palmitoleoyl-protein carboxylesterase	17	81952507-81961840	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enriched	56	placenta: 192.5	liver: 3.4	Cell line enriched	16	Hep G2: 284.8
KLHL33		ENSG00000185271	Kelch like family member 33	14	20425870-20435811	Predicted intracellular proteins	Evidence at transcript level	HPA056560	Uncertain					Not detected	Tissue enriched	10	skeletal muscle: 30.9	endometrium: 3.1	Cell line enriched	9	REH: 4.3
RBM11		ENSG00000185272	RNA binding motif protein 11	21	14216130-14228372	Predicted intracellular proteins	Evidence at protein level	HPA045885			Supported	Nucleoplasm		Mixed	Tissue enriched	17	epididymis: 56.5	cerebral cortex: 3.2	Cell line enhanced		HEL: 1.1
WBSCR17	GalNAc-T5L, GALNTL3	ENSG00000185274	Williams-Beuren syndrome chromosome region 17	7	71132169-71713600	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA013624, HPA047986	Approved		Uncertain	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Golgi apparatus	Testis cancer:3.91e-4 (favourable), Ovarian cancer:4.60e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 76.4	ovary: 29.1	Cell line enhanced		AF22: 14.1;NTERA-2: 10.8;RPMI-8226: 8.6;SK-BR-3: 34.1
ZBTB37	MGC2629, ZNF908	ENSG00000185278	Zinc finger and BTB domain containing 37	1	173868082-173903549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023438	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Mixed	Tissue enhanced		testis: 17.0	spleen: 5.3	Mixed		
NUPR2	NUPR1L	ENSG00000185290	Nuclear protein 2, transcriptional regulator	7	56114681-56116400	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:9.53e-5 (favourable)	Mixed	Tissue enriched	13	testis: 112.4	thyroid gland: 8.7	Mixed		
IL3RA	CD123	ENSG00000185291	Interleukin 3 receptor subunit alpha	X	1336616-1382689	CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003539, CAB018374	Approved				Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable)	Expressed in all	Mixed			lung: 33.2	Cell line enhanced		HDLM-2: 109.2;RPMI-8226: 33.2
SPPL2C	IMP5	ENSG00000185294	Signal peptide peptidase like 2C	17	45844835-45847072	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	21	testis: 2.1	all non-specific tissues: 0.0	Not detected		
CCDC137	MGC16597	ENSG00000185298	Coiled-coil domain containing 137	17	81666364-81673904	Predicted intracellular proteins	Evidence at protein level	HPA052637, HPA053914	Uncertain		Enhanced	Nucleoli	Renal cancer:1.16e-7 (unfavourable), Liver cancer:1.35e-7 (unfavourable), Lung cancer:8.32e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.7	Expressed in all		
SFTPA2	COLEC5, SP-A2	ENSG00000185303	Surfactant protein A2	10	79555852-79560402	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002439, HPA042638, HPA045752, HPA049368	Enhanced					Tissue enriched	Tissue enriched	383	lung: 15972.2	prostate: 41.7	Group enriched	18	BEWO: 7.1;NB-4: 5.1;RPMI-8226: 17.9;U-2197: 13.9
RGPD2	RANBP2L2, RGP2	ENSG00000185304	RANBP2-like and GRIP domain containing 2	2	87755955-87825952	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		placenta: 14.3;testis: 33.3	bone marrow: 6.3	Cell line enhanced		BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7
ARL15	ARFRP2, FLJ20051	ENSG00000185305	ADP ribosylation factor like GTPase 15	5	53883945-54310582	Predicted intracellular proteins	Evidence at protein level	HPA044604, HPA063820	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			placenta: 44.8	Mixed		
C12orf56		ENSG00000185306	Chromosome 12 open reading frame 56	12	64264762-64391192	Predicted intracellular proteins	Evidence at protein level	HPA056986	Enhanced					Mixed	Tissue enriched	21	testis: 15.2	skin: 0.7	Group enriched	13	hTEC/SVTERT24-B: 5.6;SCLC-21H: 5.5
SCN10A	hPN3, Nav1.8, PN3, SNS	ENSG00000185313	Sodium voltage-gated channel alpha subunit 10	3	38696802-38794010	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level							Not detected	Not detected			testis: 0.3	Not detected		
CDK10	PISSLRE	ENSG00000185324	Cyclin dependent kinase 10	16	89680737-89696364	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007451, HPA059634, HPA067060	Uncertain		Supported	Nucleoplasm<br>Midbody<br>Midbody ring	Pancreatic cancer:2.69e-4 (favourable), Urothelial cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.4	Expressed in all		
TMEM105	FLJ38792	ENSG00000185332	Transmembrane protein 105	17	81311270-81330674	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 1.0	kidney,liver: 0.6	Cell line enhanced		CAPAN-2: 2.9;MCF7: 1.1;U-937: 1.8
SOCS1	Cish1, JAB, SOCS-1, SSI-1, TIP3	ENSG00000185338	Suppressor of cytokine signaling 1	16	11254405-11256179	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010355, HPA074108	Approved		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:1.08e-6 (unfavourable), Head and neck cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 19.3	lymph node: 15.7	Cell line enriched	6	HDLM-2: 102.4
TCN2	D22S676, D22S750, TC2	ENSG00000185339	Transcobalamin 2	22	30606838-30627278	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000837			Approved	Cytosol	Liver cancer:2.64e-4 (unfavourable), Cervical cancer:3.47e-4 (favourable)	Expressed in all	Expressed in all			kidney: 122.6	Cell line enhanced		ASC TERT1: 84.6;HUVEC TERT2: 123.3;Karpas-707: 137.2
GAS2L1	GAR22	ENSG00000185340	Growth arrest specific 2 like 1	22	29306582-29312785	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019858	Approved		Approved	Plasma membrane<br>Cell Junctions	Renal cancer:8.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.1	Cell line enhanced		U-138 MG: 75.8
ATP6V0A2	a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1	ENSG00000185344	ATPase H+ transporting V0 subunit a2	12	123712318-123761755	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA044279	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			skin: 15.1	Expressed in all		
PARK2	AR-JP, parkin, PDJ	ENSG00000185345	Parkin RBR E3 ubiquitin protein ligase	6	161347420-162727771	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016257, HPA036012	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:6.75e-12 (favourable)	Mixed	Mixed			cerebral cortex: 13.8	Cell line enhanced		HEL: 4.7;Karpas-707: 2.3;RPMI-8226: 2.3
C14orf80		ENSG00000185347	Chromosome 14 open reading frame 80	14	105489855-105499575	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039049, HPA039050	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:3.54e-4 (unfavourable)	Expressed in all	Mixed			appendix,skin: 6.6	Mixed		
HS6ST3		ENSG00000185352	Heparan sulfate 6-O-sulfotransferase 3	13	96090839-96839562	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA078257			Approved	Nucleoplasm<br>Nuclear membrane<br>Actin filaments	Renal cancer:6.12e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 27.7	urinary bladder: 6.0	Group enriched	8	HAP1: 2.9;RT4: 13.7
HGS	Hrs, Vps27, ZFYVE8	ENSG00000185359	Hepatocyte growth factor-regulated tyrosine kinase substrate	17	81683326-81703138	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004872, HPA007728	Uncertain		Enhanced	Endosomes<br>Lysosomes<br>Cytosol	Renal cancer:4.31e-7 (unfavourable), Liver cancer:5.61e-5 (unfavourable), Cervical cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 85.2	Expressed in all		
TNFAIP8L1	MGC17791	ENSG00000185361	TNF alpha induced protein 8 like 1	19	4639518-4655568	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.28e-7 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 37.1	spleen: 17.5	Expressed in all		
OR2V1	OR2V1P, OST265	ENSG00000185372	Olfactory receptor family 2 subfamily V member 1	5	181124357-181125304	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049953	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RAD51D	HsTRAD, R51H3, RAD51L3, Trad	ENSG00000185379	RAD51 paralog D	17	35092208-35121522	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:7.20e-9 (unfavourable), Pancreatic cancer:3.35e-6 (favourable), Endometrial cancer:5.37e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.6	Expressed in all		
OR7A17	HTPCRX19	ENSG00000185385	Olfactory receptor family 7 subfamily A member 17	19	14880426-14881452	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skin,thyroid gland: 0.4	Not detected		
MAPK11	p38-2, p38Beta, PRKM11, SAPK2	ENSG00000185386	Mitogen-activated protein kinase 11	22	50263713-50270767	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB012961, HPA045069	Approved		Approved	Mitochondria	Renal cancer:6.02e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 27.7	Mixed		
SP140L		ENSG00000185404	SP140 nuclear body protein like	2	230327184-230403732	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055864	Uncertain		Approved	Nucleoplasm	Renal cancer:5.09e-10 (unfavourable)	Expressed in all	Mixed			spleen: 28.7	Mixed		
MRPL30	MRP-L28, RPML28	ENSG00000185414	Mitochondrial ribosomal protein L30	2	99181079-99197626	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047255	Approved					Expressed in all	Expressed in all			thyroid gland: 20.3	Expressed in all		
TARSL2	FLJ25005	ENSG00000185418	Threonyl-tRNA synthetase like 2	15	101653598-101724604	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA066697	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 15.7	Expressed in all		
SMYD3	KMT3E, ZMYND1, ZNFN3A1	ENSG00000185420	SET and MYND domain containing 3	1	245749342-246507312	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB012229, HPA045821, HPA054352	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			epididymis,thyroid gland: 27.0	Expressed in all		
METTL7A	DKFZP586A0522	ENSG00000185432	Methyltransferase like 7A	12	50923472-50932517	Predicted membrane proteins	Evidence at protein level	HPA017434			Supported	Lipid droplets	Renal cancer:0.00e+0 (favourable)	Expressed in all	Expressed in all			thyroid gland: 400.8	Cell line enhanced		ASC diff: 267.0;Karpas-707: 287.8;RPMI-8226: 158.7
IFNLR1	CRF2/12, IFNLR, IL-28R1, IL28RA	ENSG00000185436	Interferon lambda receptor 1	1	24154157-24187959	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017319	Uncertain		Approved	Cytosol	Breast cancer:5.12e-4 (favourable)	Expressed in all	Mixed			small intestine: 10.1	Cell line enhanced		U-266/70: 39.6;U-698: 28.0
SH3BGR	21-GARP	ENSG00000185437	SH3 domain binding glutamate rich protein	21	39445855-39515506	Predicted intracellular proteins	Evidence at protein level	CAB003685, HPA030690	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Group enriched	6	heart muscle: 100.8;skeletal muscle: 435.9	prostate: 41.4	Cell line enhanced		U-87 MG: 100.6
FAM174B	LOC400451, MGC102891	ENSG00000185442	Family with sequence similarity 174 member B	15	92617443-92809884	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015306	Approved		Approved	Intermediate filaments	Endometrial cancer:9.03e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 61.3	Cell line enhanced		CACO-2: 61.8;MCF7: 69.4;RPMI-8226: 73.8;RT4: 176.5
FAM47A	MGC27003	ENSG00000185448	Family with sequence similarity 47 member A	X	34129756-34132314	Predicted intracellular proteins	Evidence at protein level	HPA000610	Uncertain					Not detected	Tissue enriched	56	testis: 5.5	all non-specific tissues: 0.0	Not detected		
C19orf68	LOC374920	ENSG00000185453	Chromosome 19 open reading frame 68	19	48170692-48197620	Predicted intracellular proteins	Evidence at protein level	HPA061028	Uncertain		Approved	Nucleus	Liver cancer:2.35e-5 (unfavourable), Renal cancer:2.44e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.8	Expressed in all		
KPNA7	IPOA8	ENSG00000185467	Karyopherin subunit alpha 7	7	99173574-99207506	Predicted intracellular proteins	Evidence at protein level	HPA031395	Uncertain					Mixed	Tissue enhanced		stomach: 3.1	fallopian tube: 0.9	Cell line enhanced		A-431: 1.7;CAPAN-2: 1.2;SK-BR-3: 1.8
TMEM179B		ENSG00000185475	Transmembrane protein 179B	11	62787415-62790405	Predicted membrane proteins, Transporters	Evidence at protein level	HPA016585, HPA062068			Enhanced	Nuclear speckles		Expressed in all	Expressed in all			epididymis: 89.1	Expressed in all		
GPRIN3	FLJ42625, GRIN3	ENSG00000185477	GPRIN family member 3	4	89236386-89308010	Predicted intracellular proteins	Evidence at protein level	HPA043148, HPA057666, HPA059092	Uncertain		Approved	Nucleus<br>Nucleoli	Colorectal cancer:7.22e-5 (favourable), Renal cancer:8.33e-4 (favourable)	Mixed	Mixed			appendix: 12.0	Cell line enhanced		Karpas-707: 73.5;RPMI-8226: 18.9;SCLC-21H: 31.9
KRT6B	KRTL1	ENSG00000185479	Keratin 6B	12	52446651-52452126	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000130, HPA045697, HPA061168	Supported		Approved	Intermediate filaments	Breast cancer:9.44e-4 (favourable), Urothelial cancer:9.52e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 670.7	tonsil: 67.0	Cell line enhanced		HBEC3-KT: 19.9;hTCEpi: 21.8;RPMI-8226: 9.3
PARPBP	C12orf48, FLJ20641, PARI	ENSG00000185480	PARP1 binding protein	12	102120185-102197520	Predicted intracellular proteins	Evidence at protein level	HPA039677	Approved		Supported	Nucleoplasm	Melanoma:3.17e-4 (unfavourable)	Mixed	Mixed			testis: 7.2	Mixed		
STAC3	MGC2793	ENSG00000185482	SH3 and cysteine rich domain 3	12	57243453-57251193	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039285, HPA039527			Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.11e-6 (unfavourable), Cervical cancer:2.01e-4 (favourable), Colorectal cancer:7.10e-4 (unfavourable)	Expressed in all	Tissue enriched	24	skeletal muscle: 802.4	prostate: 34.1	Cell line enriched	26	RH-30: 2201.5
ROR1	NTRKR1	ENSG00000185483	Receptor tyrosine kinase like orphan receptor 1	1	63774022-64181498	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA057016			Uncertain	Microtubules<br>Cytokinetic bridge		Mixed	Tissue enhanced		parathyroid gland: 52.0	endometrium: 12.1	Cell line enhanced		ASC TERT1: 35.2;NTERA-2: 43.3
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced				Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
FAAP100	C17orf70, FLJ22175	ENSG00000185504	Fanconi anemia core complex associated protein 100	17	81539885-81553961	Predicted intracellular proteins	Evidence at protein level	HPA023954, HPA024626, HPA026532	Uncertain		Enhanced	Nucleoplasm<br>Intermediate filaments<br>Cytosol	Renal cancer:1.00e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 22.3	Expressed in all		
IRF7		ENSG00000185507	Interferon regulatory factor 7	11	612553-615999	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017694, HPA052757	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.71e-10 (unfavourable)	Expressed in all	Mixed			bone marrow: 1.8	Cell line enhanced		EFO-21: 3.4;Karpas-707: 4.6;SCLC-21H: 3.7
L3MBTL1	dJ138B7.3, DKFZp586P1522, KIAA0681, L3MBTL, ZC2HC3	ENSG00000185513	L(3)mbt-like 1 (Drosophila)	20	43507680-43550950	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068051			Supported	Nucleus		Mixed	Mixed			testis: 10.1	Cell line enhanced		BEWO: 7.9
BRCC3	BRCC36, C6.1A, CXorf53	ENSG00000185515	BRCA1/BRCA2-containing complex subunit 3	X	155071420-155123074	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048737			Supported	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 21.2	Expressed in all		
SV2B	HsT19680, KIAA0735	ENSG00000185518	Synaptic vesicle glycoprotein 2B	15	91099950-91301309	Predicted membrane proteins	Evidence at protein level	HPA046247	Approved					Mixed	Tissue enriched	23	cerebral cortex: 47.9	adipose tissue: 2.1	Group enriched	6	RPMI-8226: 1.4;SCLC-21H: 4.6
FAM131C	C1orf117, FLJ36766	ENSG00000185519	Family with sequence similarity 131 member C	1	16057769-16073632	Predicted intracellular proteins	Evidence at protein level	HPA031046	Uncertain		Approved	Nucleoli<br>Intermediate filaments<br>Cytosol	Renal cancer:9.33e-6 (favourable)	Mixed	Tissue enhanced		adrenal gland: 3.3;cerebral cortex: 4.8;kidney: 3.7	heart muscle,skin: 1.1	Cell line enhanced		A549: 7.2;HEK 293: 4.6;PC-3: 5.4
LMNTD2	C11orf35, MGC35138	ENSG00000185522	Lamin tail domain containing 2	11	554855-560779	Predicted intracellular proteins	Evidence at protein level	HPA058474, HPA073912	Uncertain		Approved	Cytoplasmic bodies	Colorectal cancer:3.75e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 9.4	Cell line enhanced		AN3-CA: 4.1;T-47d: 4.6
SPATA45	C1orf227, LOC149643	ENSG00000185523	Spermatogenesis associated 45	1	212830141-212847649	Predicted intracellular proteins	Evidence at transcript level	HPA049921	Uncertain					Not detected	Tissue enriched	11	testis: 13.2	fallopian tube: 1.2	Mixed		
PDE6G	PDEG, RP57	ENSG00000185527	Phosphodiesterase 6G	17	81650459-81663112	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA045118	Supported					Tissue enhanced	Tissue enhanced		lymph node: 26.1;spleen: 33.3	placenta: 18.9	Cell line enhanced		NTERA-2: 10.5;REH: 11.5
PRKG1	PGK, PKG, PRKG1B, PRKGR1B	ENSG00000185532	Protein kinase, cGMP-dependent, type I	10	50991358-52298350	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007699, CAB009629	Enhanced		Approved	Vesicles<br>Cytosol		Mixed	Mixed			smooth muscle: 25.1	Cell line enhanced		AN3-CA: 19.3;BJ hTERT+: 17.6;fHDF/TERT166: 13.4
NR2F2	ARP1, COUP-TFII, COUPTFB, NF-E3, SVP40, TFCOUP2	ENSG00000185551	Nuclear receptor subfamily 2 group F member 2	15	96325938-96340263	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058974			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		ovary: 360.7	endometrium: 187.1	Mixed		
DLK1	Delta1, FA1, pG2, Pref-1, ZOG	ENSG00000185559	Delta like non-canonical Notch ligand 1	14	100725705-100738224	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB005872, HPA053879, HPA062262	Supported		Approved	Golgi apparatus	Endometrial cancer:2.31e-4 (unfavourable)	Tissue enhanced	Group enriched	20	adrenal gland: 1591.0;placenta: 2331.6	ovary: 100.3	Group enriched	6	AF22: 118.4;Hep G2: 282.9;SH-SY5Y: 501.8
TLCD2		ENSG00000185561	TLC domain containing 2	17	1702790-1710438	Predicted membrane proteins	Evidence at transcript level	HPA046063	Uncertain		Approved	Nucleoli<br>Vesicles	Renal cancer:4.36e-5 (unfavourable)	Expressed in all	Mixed			adipose tissue: 6.0	Cell line enhanced		SiHa: 6.2
LSAMP	IGLON3, LAMP	ENSG00000185565	Limbic system-associated membrane protein	3	115802363-117139389	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054051, HPA076122			Approved	Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 102.7	prostate: 43.6	Group enriched	6	AF22: 11.1;SH-SY5Y: 24.0;WM-115: 55.4
AHNAK2	C14orf78	ENSG00000185567	AHNAK nucleoprotein 2	14	104937244-104978357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA000878, HPA002940, HPA004145, HPA020111	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:4.05e-6 (unfavourable), Urothelial cancer:2.23e-5 (unfavourable), Lung cancer:2.79e-5 (unfavourable)	Mixed	Tissue enriched	7	skin: 345.5	smooth muscle: 46.8	Cell line enhanced		hTCEpi: 224.2
OLFML2A	FLJ00237	ENSG00000185585	Olfactomedin like 2A	9	124777158-124814885	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021180, HPA022254	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:3.73e-5 (unfavourable)	Expressed in all	Mixed			spleen: 47.5	Cell line enhanced		ASC TERT1: 112.2;WM-115: 64.5
SP1		ENSG00000185591	Sp1 transcription factor	12	53380176-53416446	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000330, HPA001853, HPA012292	Supported		Enhanced	Nucleoplasm	Pancreatic cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 54.3	Expressed in all		
SPATA8	MGC44294	ENSG00000185594	Spermatogenesis associated 8	15	96783389-96785615	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	1454	testis: 404.5	adrenal gland,gallbladder,placenta: 0.2	Not detected		
MRPL40	MRP-L22, NLVCF	ENSG00000185608	Mitochondrial ribosomal protein L40	22	19431902-19436075	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA006181	Uncertain		Enhanced	Nucleoli<br>Mitochondria	Cervical cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
DBX2	FLJ16139	ENSG00000185610	Developing brain homeobox 2	12	45014672-45051099	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA066053	Uncertain					Tissue enriched	Group enriched	5	cerebral cortex: 4.1;testis: 1.2	skin: 0.5	Not detected		
FAM212A	C3orf54, INKA1	ENSG00000185614	Family with sequence similarity 212 member A	3	49803254-49805030	Predicted intracellular proteins	Evidence at protein level	HPA041879	Uncertain		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 24.4	lung: 7.0	Cell line enhanced		HEL: 60.9;HMC-1: 39.3;THP-1: 28.1;U-937: 27.1
PDIA2	PDA2, PDI, PDIP, PDIR	ENSG00000185615	Protein disulfide isomerase family A member 2	16	283152-287215	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA051692, HPA053492	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	7	pancreas: 523.1	stomach: 71.9	Cell line enhanced		HAP1: 4.0;HEK 293: 7.9;Hep G2: 4.4;MCF7: 3.6;SH-SY5Y: 3.9
PCGF3	DONG1, FLJ36550, MGC40413, RNF3, RNF3A	ENSG00000185619	Polycomb group ring finger 3	4	705748-770640	Predicted intracellular proteins	Evidence at protein level	HPA061879			Supported	Nucleoplasm	Pancreatic cancer:1.44e-4 (favourable), Head and neck cancer:3.73e-4 (favourable), Urothelial cancer:5.25e-4 (favourable)	Expressed in all	Expressed in all			skin: 62.8	Expressed in all		
LMLN	Gp63, Msp	ENSG00000185621	Leishmanolysin like peptidase	3	197960200-198043720	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA016481, HPA028844	Uncertain		Supported	Focal adhesion sites<br>Cytosol	Endometrial cancer:6.77e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 18.6	epididymis: 13.0	Mixed		
P4HB	DSI, ERBA2L, GIT, P4Hbeta, PDI, PDIA1, PO4DB, PO4HB, PROHB	ENSG00000185624	Prolyl 4-hydroxylase subunit beta	17	81843159-81860694	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012463, HPA018884	Enhanced		Supported	Endoplasmic reticulum	Renal cancer:2.30e-11 (unfavourable)	Expressed in all	Expressed in all			small intestine: 504.4	Expressed in all		
PSMD13	p40.5, Rpn9	ENSG00000185627	Proteasome 26S subunit, non-ATPase 13	11	236546-252984	Predicted intracellular proteins	Evidence at protein level	HPA038691, HPA038692	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:1.52e-13 (unfavourable), Liver cancer:4.76e-5 (unfavourable), Endometrial cancer:5.74e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.7	Expressed in all		
PBX1		ENSG00000185630	PBX homeobox 1	1	164555584-164899296	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003505, HPA003881, CAB018768	Supported		Enhanced	Nucleoplasm		Mixed	Expressed in all			endometrium: 248.2	Cell line enhanced		SK-BR-3: 173.0
NDUFA4L2	FLJ26118, NUOMS	ENSG00000185633	NDUFA4, mitochondrial complex associated like 2	12	57234903-57240715	Predicted membrane proteins	Evidence at protein level	HPA055323			Approved	Mitochondria	Renal cancer:1.37e-5 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 152.3;skin: 191.7	placenta: 104.2	Cell line enriched	8	AN3-CA: 123.9
SHC4	RaLP, SHCD	ENSG00000185634	SHC adaptor protein 4	15	48823735-48963444	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA074146			Approved	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 13.1;testis: 20.1	gallbladder: 2.3	Cell line enhanced		AN3-CA: 9.5;SK-MEL-30: 15.2;WM-115: 16.3
KRT79	K6L, KRT6L	ENSG00000185640	Keratin 79	12	52821410-52834295	Predicted intracellular proteins	Evidence at protein level	HPA059347	Enhanced					Group enriched	Group enriched	9	breast: 4.0;skin: 17.1	esophagus: 1.1	Cell line enriched	18	HMC-1: 375.1
ZFP36L1	Berg36, BRF1, cMG1, ERF1, RNF162B, TIS11B	ENSG00000185650	ZFP36 ring finger protein like 1	14	68787660-68796253	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001301	Uncertain					Expressed in all	Expressed in all			endometrium: 583.2	Expressed in all		
UBE2L3	UBCH7	ENSG00000185651	Ubiquitin conjugating enzyme E2 L3	22	21549447-21624034	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045609, HPA062415	Approved		Approved	Nucleus<br>Cytosol	Ovarian cancer:3.82e-6 (favourable), Liver cancer:1.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 67.1	Expressed in all		
NTF3	NGF2	ENSG00000185652	Neurotrophin 3	12	5432112-5521536	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA032001	Approved					Mixed	Tissue enhanced		ovary: 13.5	spleen: 6.2	Cell line enhanced		BJ hTERT+: 9.1;BJ hTERT+ SV40 Large T+: 13.6;BJ hTERT+ SV40 Large T+ RasG12V: 18.8;HBF TERT88: 17.3
BRWD1	C21orf107, DCAF19, FLJ11315, N143, WDR9	ENSG00000185658	Bromodomain and WD repeat domain containing 1	21	39184176-39321559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030943, HPA030944, HPA030945, CAB034184	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 77.7	Expressed in all		
SMIM23	C5orf50, LOC644994	ENSG00000185662	Small integral membrane protein 23	5	171782432-171796126	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	140	testis: 24.9	spleen: 0.1	Not detected		
PMEL	D12S53E, gp100, Pmel17, SI, SIL, SILV	ENSG00000185664	Premelanosome protein	12	55954105-55973317	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA031649	Enhanced				Renal cancer:3.70e-4 (favourable)	Tissue enriched	Tissue enriched	12	skin: 133.4	breast: 10.6	Cell line enriched	55	SK-MEL-30: 6730.3
SYN3		ENSG00000185666	Synapsin III	22	32512552-33058372	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034566	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 9.5;testis: 7.9	placenta: 4.2	Cell line enhanced		HAP1: 5.8;NTERA-2: 3.7;SCLC-21H: 8.6
POU3F1	OCT6, OTF6, SCIP	ENSG00000185668	POU class 3 homeobox 1	1	38044611-38046794	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055980, HPA073824			Enhanced	Nucleoplasm		Mixed	Tissue enriched	14	skin: 23.6	cerebral cortex: 1.6	Group enriched	9	AF22: 12.9;HDLM-2: 22.0;NTERA-2: 6.3;SCLC-21H: 5.3;SK-MEL-30: 15.0
SNAI3	SMUC, Zfp293, ZNF293	ENSG00000185669	Snail family transcriptional repressor 3	16	88677682-88686493	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA071127			Approved	Nucleoplasm	Cervical cancer:1.39e-4 (favourable), Pancreatic cancer:3.58e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 10.9	lymph node: 4.3	Cell line enhanced		NB-4: 11.5;RPMI-8226: 19.9
ZBTB3	FLJ23392	ENSG00000185670	Zinc finger and BTB domain containing 3	11	62748319-62754188	Predicted intracellular proteins	Evidence at protein level	HPA035321, HPA035322	Enhanced		Approved	Mitochondria	Renal cancer:1.65e-5 (favourable), Stomach cancer:9.98e-4 (favourable)	Expressed in all	Mixed			fallopian tube: 7.1	Expressed in all		
LYG2	LYGH	ENSG00000185674	Lysozyme g2	2	99242246-99255282	Predicted secreted proteins	Evidence at protein level	HPA039179	Uncertain					Mixed	Tissue enriched	6	testis: 2.5	skin: 0.4	Cell line enhanced		U-937: 1.9
MORN5	C9orf113, C9orf18, FLJ46909	ENSG00000185681	MORN repeat containing 5	9	122159908-122200088	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:4.86e-4 (favourable)	Tissue enhanced	Group enriched	6	fallopian tube: 175.5;testis: 106.4	smooth muscle: 24.7	Cell line enhanced		NB-4: 1.0;U-87 MG: 1.1
EP400NL	FLJ33915	ENSG00000185684	EP400 N-terminal like	12	132084283-132131639	Predicted intracellular proteins	Evidence at protein level	HPA068417	Enhanced					Expressed in all	Tissue enriched	9	testis: 28.7	spleen: 3.1	Mixed		
PRAME	CT130, MAPE	ENSG00000185686	Preferentially expressed antigen in melanoma	22	22547701-22559361	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045153	Enhanced				Renal cancer:7.48e-9 (unfavourable), Head and neck cancer:3.41e-4 (unfavourable)	Group enriched	Group enriched	8	epididymis: 17.1;testis: 80.5	endometrium: 6.3	Cell line enhanced		HMC-1: 154.1;K-562: 872.4;SH-SY5Y: 199.7;U-2 OS: 171.5
C6orf201	dJ1013A10.5	ENSG00000185689	Chromosome 6 open reading frame 201	6	4079209-4130951	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 30.1	fallopian tube: 1.3	Not detected		
MYBL1	A-myb, AMYB	ENSG00000185697	MYB proto-oncogene like 1	8	66562175-66614247	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008791	Uncertain				Renal cancer:2.03e-8 (unfavourable)	Mixed	Tissue enhanced		lymph node: 24.2;testis: 21.4	tonsil: 14.9	Cell line enhanced		BJ hTERT+ SV40 Large T+: 76.9;HBF TERT88: 109.4
C16orf52		ENSG00000185716	Chromosome 16 open reading frame 52	16	22007638-22087534	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			parathyroid gland: 20.1	Expressed in all		
DRG1	NEDD3	ENSG00000185721	Developmentally regulated GTP binding protein 1	22	31399523-31530634	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001218	Approved		Supported	Nuclear bodies<br>Cytosol	Liver cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 265.1	Expressed in all		
ANKFY1	ANKHZN, BTBD23, KIAA1255, RANK-5, ZFYVE14	ENSG00000185722	Ankyrin repeat and FYVE domain containing 1	17	4163907-4263977	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA024513, HPA024522, HPA065849	Approved		Enhanced	Endosomes		Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
YTHDF3	FLJ31657	ENSG00000185728	YTH N6-methyladenosine RNA binding protein 3	8	63168553-63212786	Predicted intracellular proteins	Evidence at protein level	HPA048703			Approved	Nuclear membrane<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			bone marrow: 59.1	Expressed in all		
ZNF696	FLJ14129	ENSG00000185730	Zinc finger protein 696	8	143289676-143298061	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057855, HPA072473	Uncertain		Approved	Nucleus<br>Nucleoli	Endometrial cancer:3.52e-5 (unfavourable), Cervical cancer:6.63e-5 (unfavourable), Pancreatic cancer:1.41e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 9.8	Mixed		
ADARB2	ADAR3, hRED2, RED2	ENSG00000185736	Adenosine deaminase, RNA specific B2 (inactive)	10	1177318-1737476	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	6	cerebral cortex: 13.1	testis: 2.1	Not detected		
NRG3		ENSG00000185737	Neuregulin 3	10	81875314-82987179	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA075789			Approved	Vesicles		Group enriched	Tissue enhanced		cerebral cortex: 30.3	fallopian tube: 7.3	Cell line enhanced		HEK 293: 1.4;SK-MEL-30: 2.6;U-2 OS: 2.9
SRL		ENSG00000185739	Sarcalumenin	16	4189374-4242080	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA041535, HPA045520	Enhanced					Group enriched	Group enriched	17	heart muscle: 161.0;skeletal muscle: 178.8	esophagus: 10.2	Cell line enriched	11	HSkMC: 2.9
C11orf87	LOC399947, LOH11CR1A, NEURIM1	ENSG00000185742	Chromosome 11 open reading frame 87	11	109422120-109429114	Predicted membrane proteins	Evidence at protein level	HPA034656	Approved					Tissue enhanced	Tissue enriched	20	cerebral cortex: 30.8	endometrium: 1.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 2.7;fHDF/TERT166: 9.0;SCLC-21H: 3.4
IFIT1	G10P1, GARG-16, IFI56, IFNAI1	ENSG00000185745	Interferon induced protein with tetratricopeptide repeats 1	10	89392546-89406486	Predicted intracellular proteins	Evidence at protein level	CAB045980, HPA055380	Approved		Supported	Cytosol		Expressed in all	Expressed in all			spleen: 60.6	Group enriched	5	BJ hTERT+ SV40 Large T+: 746.9;BJ hTERT+ SV40 Large T+ RasG12V: 764.4
CXorf38	MGC39350	ENSG00000185753	Chromosome X open reading frame 38	X	40626921-40647554	Predicted intracellular proteins	Evidence at protein level	HPA050120	Approved		Supported	Cytosol	Urothelial cancer:1.44e-8 (favourable), Pancreatic cancer:7.30e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
CLDN24	CLDN21	ENSG00000185758	Claudin 24	4	183321764-183322426	Predicted membrane proteins	No evidence							Not detected	Not detected			kidney: 0.8	Not detected		
KCNQ5	Kv7.5	ENSG00000185760	Potassium voltage-gated channel subfamily Q member 5	6	72621792-73198851	Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA016655	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 22.3	thyroid gland: 7.9	Cell line enhanced		BJ: 29.6
ADAMTSL5	THSD6	ENSG00000185761	ADAMTS like 5	19	1505018-1513604	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044050			Approved	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 29.0	smooth muscle: 17.4	Mixed		
KCNIP4	CALP, KCHIP4, MGC44947	ENSG00000185774	Potassium voltage-gated channel interacting protein 4	4	20728616-21948799	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA022862		Supported				Mixed	Tissue enhanced		cerebral cortex: 57.3	cervix, uterine: 18.9	Cell line enhanced		RPTEC TERT1: 4.6;SCLC-21H: 5.6
SPATA31A6	FAM75A6	ENSG00000185775	SPATA31 subfamily A member 6	9	42183659-42189882	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 1.5	all non-specific tissues: 0.0	Not detected		
MORF4L1	Eaf3, HsT17725, MEAF3, MORFRG15, MRG15	ENSG00000185787	Mortality factor 4 like 1	15	78810487-78898133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042360, HPA062010	Approved		Supported	Nuclear speckles		Expressed in all	Expressed in all			testis: 1065.7	Expressed in all		
NLRP9	CLR19.1, NALP9, NOD6, PAN12	ENSG00000185792	NLR family pyrin domain containing 9	19	55708432-55738402	Predicted intracellular proteins	Evidence at transcript level	HPA042623	Uncertain					Tissue enriched	Tissue enhanced		prostate: 1.4	testis: 0.6	Not detected		
WDR53	MGC12928, MGC64882	ENSG00000185798	WD repeat domain 53	3	196554177-196568674	Predicted intracellular proteins	Evidence at protein level	HPA016420, HPA019332	Approved		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.57e-6 (unfavourable), Melanoma:3.09e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 112.5	parathyroid gland: 19.9	Expressed in all		
DMWD	D19S593E, DMR-N9, gene59	ENSG00000185800	Dystrophia myotonica, WD repeat containing	19	45782947-45792802	Predicted intracellular proteins	Evidence at protein level	HPA068172, HPA069843	Approved		Approved	Plasma membrane<br>Actin filaments	Liver cancer:1.47e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 39.7	Expressed in all		
SLC52A2	D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2	ENSG00000185803	Solute carrier family 52 member 2	8	144354135-144361272	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA063036	Approved				Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 20.8	Expressed in all		
PIGP	DCRC, DSCR5, DSRC	ENSG00000185808	Phosphatidylinositol glycan anchor biosynthesis class P	21	37059170-37073170	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026921	Uncertain		Approved	Vesicles		Expressed in all	Expressed in all			epididymis: 125.7	Expressed in all		
IKZF1	hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1	ENSG00000185811	IKAROS family zinc finger 1	7	50304124-50405101	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB009247, HPA035221, HPA035222	Enhanced		Supported	Nucleoplasm	Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 83.0	tonsil: 55.9	Cell line enhanced		HDLM-2: 172.0;HMC-1: 152.5;MOLT-4: 116.9;REH: 122.5;U-698: 108.4
PCYT2	ET	ENSG00000185813	Phosphate cytidylyltransferase 2, ethanolamine	17	81900965-81911464	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023033, HPA023034	Enhanced		Supported	Intermediate filaments<br>Centrosome	Renal cancer:4.29e-6 (favourable)	Expressed in all	Expressed in all			testis: 241.6	Expressed in all		
NAT8L	FLJ37478, Hcml3	ENSG00000185818	N-acetyltransferase 8 like	4	2059512-2069089	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040677			Supported	Mitochondria	Endometrial cancer:1.01e-5 (unfavourable)	Group enriched	Group enriched	7	adipose tissue: 48.6;cerebral cortex: 64.9;testis: 19.0	kidney: 6.7	Cell line enhanced		SCLC-21H: 32.4
OR6C76		ENSG00000185821	Olfactory receptor family 6 subfamily C member 76	12	55426254-55427192	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NPAP1	C15orf2	ENSG00000185823	Nuclear pore associated protein 1	15	24675868-24683393	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018828, HPA019562	Uncertain					Not detected	Tissue enriched	11	testis: 5.2	skin: 0.4	Not detected		
BCAP31	6C6-Ag, BAP31, CDM, DXS1357E	ENSG00000185825	B-cell receptor-associated protein 31	X	153700497-153724697	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003906, CAB015350, CAB015424	Enhanced	Approved	Enhanced	Endoplasmic reticulum	Head and neck cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 273.7	Expressed in all		
ARL17A	ARF1P2, ARL17P1	ENSG00000185829	ADP ribosylation factor like GTPase 17A	17	46516702-46579682	Predicted intracellular proteins	Evidence at protein level	HPA046814	Uncertain					Not detected	Expressed in all			endometrium: 14.1	Mixed		
GNB1L	GY2, WDR14	ENSG00000185838	G protein subunit beta 1 like	22	19783224-19854939	Predicted intracellular proteins	Evidence at protein level	HPA034627, HPA034628	Approved		Approved	Cytosol		Expressed in all	Mixed			duodenum: 4.2	Cell line enhanced		K-562: 59.4
DNAH14	C1orf67, DKFZp781B1548, Dnahc14, HL-18, HL18, MGC27277	ENSG00000185842	Dynein axonemal heavy chain 14	1	224896262-225399292	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027718, HPA028545, HPA031379	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		testis: 21.9	thyroid gland: 7.4	Mixed		
CCDC190	C1orf110, MGC48998	ENSG00000185860	Coiled-coil domain containing 190	1	162824458-162868815	Predicted intracellular proteins	Evidence at transcript level	HPA028579, HPA028584, HPA028592	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		esophagus: 3.7;lung: 2.8	fallopian tube: 0.8	Cell line enhanced		hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2
EVI2B	CD361, D17S376, EVDB	ENSG00000185862	Ecotropic viral integration site 2B	17	31303766-31314112	CD markers, Predicted membrane proteins	Evidence at protein level	HPA007436	Enhanced				Renal cancer:2.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 213.7	lymph node: 175.0	Cell line enhanced		HL-60: 77.7;HMC-1: 114.9;Karpas-707: 67.2;RPMI-8226: 98.3;THP-1: 81.9
TMEM210		ENSG00000185863	Transmembrane protein 210	9	137170858-137172409	Predicted membrane proteins	Evidence at protein level	HPA066907	Enhanced					Tissue enhanced	Tissue enriched	11	testis: 10.1	salivary gland: 0.9	Cell line enriched	7	RPMI-8226: 7.9
NPIPB4		ENSG00000185864	Nuclear pore complex interacting protein family member B4	16	21834569-21880827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 124.6	Expressed in all		
ZNF829	DKFZp779O175	ENSG00000185869	Zinc finger protein 829	19	36888124-36916291	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA073073			Approved	Nucleus<br>Nuclear bodies		Mixed	Tissue enriched	5	testis: 18.3	ovary: 3.4	Mixed		
TMPRSS11B		ENSG00000185873	Transmembrane protease, serine 11B	4	68226653-68245720	Enzymes, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:6.91e-4 (favourable)	Group enriched	Group enriched	184	esophagus: 311.6;tonsil: 74.5	cervix, uterine: 1.0	Not detected		
THNSL1	FLJ22002, TSH1	ENSG00000185875	Threonine synthase like 1	10	25016658-25026664	Predicted intracellular proteins	Evidence at protein level	HPA037585	Uncertain		Approved	Nuclear bodies<br>Mitochondria<br>Cytosol		Expressed in all	Mixed			thyroid gland: 14.1	Mixed		
TRIM69	RNF36, Trif, TRIMLESS	ENSG00000185880	Tripartite motif containing 69	15	44728988-44767829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028894	Enhanced				Renal cancer:2.26e-5 (favourable)	Expressed in all	Tissue enriched	17	testis: 57.2	cerebral cortex: 3.4	Cell line enhanced		Karpas-707: 1.8;U-266/70: 6.7
ATP6V0C	ATP6C, ATP6L, ATPL, VATL, Vma3	ENSG00000185883	ATPase H+ transporting V0 subunit c	16	2513870-2520218	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:1.07e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 422.8	Expressed in all		
IFITM1	9-27, CD225, IFI17	ENSG00000185885	Interferon induced transmembrane protein 1	11	313506-315272	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA004810, CAB017615	Enhanced		Supported	Cytosol	Renal cancer:5.77e-9 (unfavourable)	Expressed in all	Expressed in all			epididymis: 918.5	Cell line enhanced		BJ hTERT+ SV40 Large T+: 1313.0;BJ hTERT+ SV40 Large T+ RasG12V: 2441.8
PRSS38	MPN2	ENSG00000185888	Protease, serine 38	1	227815693-227846470	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA028003, HPA055809	Enhanced					Not detected	Tissue enriched	41	testis: 4.2	epididymis: 0.1	Not detected		
BPY2C	VCY2C	ENSG00000185894	Basic charge, Y-linked, 2C	Y	25030901-25062548	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	11	testis: 2.1	gallbladder,kidney: 0.1	Not detected		
LAMP1	CD107a	ENSG00000185896	Lysosomal associated membrane protein 1	13	113297241-113323672	CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB004260, HPA014750	Enhanced				Renal cancer:4.15e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 211.6	Expressed in all		
FFAR3	FFA3R, GPR41	ENSG00000185897	Free fatty acid receptor 3	19	35358460-35360485	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA044681	Uncertain					Not detected	Tissue enhanced		adipose tissue: 2.5;appendix: 3.5;smooth muscle: 2.2	gallbladder: 0.8	Not detected		
TAS2R60	T2R60	ENSG00000185899	Taste 2 receptor member 60	7	143443453-143444409	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA030416	Uncertain					Not detected	Not detected			appendix,bone marrow,liver,parathyroid gland,placenta: 0.1	Not detected		
POMK	FLJ23356, SgK196	ENSG00000185900	Protein-O-mannose kinase	8	43093506-43123434	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA013321	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 6.2	Expressed in all		
C16orf54	FLJ35681	ENSG00000185905	Chromosome 16 open reading frame 54	16	29742463-29746006	Predicted membrane proteins	Evidence at protein level	HPA060546	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 26.0	lymph node: 23.9	Cell line enhanced		HEL: 16.6;HL-60: 15.0;HMC-1: 10.2;MOLT-4: 12.4;THP-1: 14.7
KLHDC8B	MGC35097	ENSG00000185909	Kelch domain containing 8B	3	49171611-49176486	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008463, HPA014467	Supported		Enhanced	Cytosol	Lung cancer:1.47e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 70.0	Mixed		
KLHL34	FLJ34960, RP11-450P7.3	ENSG00000185915	Kelch like family member 34	X	21654690-21658330	Predicted intracellular proteins	Evidence at protein level	HPA060287	Uncertain					Not detected	Tissue enriched	8	skeletal muscle: 8.8	duodenum,heart muscle: 1.1	Not detected		
SETD4	C21orf18, C21orf27	ENSG00000185917	SET domain containing 4	21	36034541-36079389	Predicted intracellular proteins	Evidence at protein level	HPA024073, HPA035405	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			testis: 41.9	Expressed in all		
PTCH1	BCNS, NBCCS, PTCH	ENSG00000185920	Patched 1	9	95442980-95517057	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013717, HPA075072	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 41.7	endometrium: 27.2	Cell line enhanced		WM-115: 70.2
RTN4RL1	DKFZp547J144, NgR3, NGRH2	ENSG00000185924	Reticulon 4 receptor like 1	17	1934677-2025345	Predicted secreted proteins	Evidence at protein level	HPA044428	Uncertain				Renal cancer:7.69e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 12.5	skin: 6.2	Cell line enhanced		fHDF/TERT166: 8.4;HaCaT: 9.4;hTCEpi: 7.2;T-47d: 12.5
OR4C46		ENSG00000185926	Olfactory receptor family 4 subfamily C member 46	11	54603069-54603998	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CALHM1	FAM26C	ENSG00000185933	Calcium homeostasis modulator 1	10	103453387-103458888	Predicted membrane proteins, Transporters	Evidence at protein level	HPA018317	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.8	kidney: 0.6	Cell line enhanced		U-266/70: 1.0;U-266/84: 1.2
KRTAP5-5	KRTAP5-11, KRTAP5.5	ENSG00000185940	Keratin associated protein 5-5	11	1629775-1630707	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
NKAIN3	FAM77D, FLJ39630	ENSG00000185942	Sodium/potassium transporting ATPase interacting 3	8	62248591-62999652	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA018833	Uncertain					Tissue enhanced	Not detected			adrenal gland: 0.4	Cell line enhanced		SCLC-21H: 1.7
RNPC3	FLJ20008, KIAA1839, RBM40, SNRNP65	ENSG00000185946	RNA binding region (RNP1, RRM) containing 3	1	103525691-103555239	Predicted intracellular proteins	Evidence at protein level	HPA052434			Supported	Nucleoplasm	Lung cancer:1.53e-4 (favourable), Urothelial cancer:5.25e-4 (favourable), Prostate cancer:7.70e-4 (unfavourable), Pancreatic cancer:7.82e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 67.0	Expressed in all		
ZNF267	HZF2	ENSG00000185947	Zinc finger protein 267	16	31873758-31917357	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003866	Approved		Approved	Nucleoplasm	Renal cancer:1.58e-6 (unfavourable)	Expressed in all	Mixed			appendix: 24.9	Expressed in all		
IRS2		ENSG00000185950	Insulin receptor substrate 2	13	109752698-109786568	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016944, HPA054664	Approved		Supported	Aggresome<br>Cytosol		Expressed in all	Mixed			bone marrow: 32.9	Cell line enhanced		SH-SY5Y: 42.7;THP-1: 42.3
C7orf61	IMAGE:4839025	ENSG00000185955	Chromosome 7 open reading frame 61	7	100456615-100464271	Predicted intracellular proteins	Evidence at protein level	HPA060395	Enhanced		Approved	Vesicles		Tissue enhanced	Tissue enriched	10	testis: 52.9	cerebral cortex: 5.2	Cell line enhanced		HUVEC TERT2: 20.9;TIME: 12.0
FAM186A	LOC121006	ENSG00000185958	Family with sequence similarity 186 member A	12	50326230-50396622	Predicted intracellular proteins	Evidence at protein level	HPA047128	Uncertain					Not detected	Tissue enriched	19	testis: 10.9	skin: 0.5	Not detected		
SHOX	GCFX, PHOG, SHOXY, SS	ENSG00000185960	Short stature homeobox	X	624344-659411	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035141, HPA060931			Enhanced	Nucleoplasm<br>Vesicles		Not detected	Mixed			spleen: 1.0	Cell line enhanced		BJ: 19.3;BJ hTERT+: 9.5
LCE3A	LEP13	ENSG00000185962	Late cornified envelope 3A	1	152622834-152623103	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	22	tonsil: 99.1	esophagus: 4.5	Cell line enhanced		BJ hTERT+: 2.8;LHCN-M2: 1.2;U-138 MG: 1.7
BICD2	KIAA0699	ENSG00000185963	BICD cargo adaptor 2	9	92711363-92764812	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023013, HPA024452	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.39e-4 (favourable)	Expressed in all	Expressed in all			skin: 69.2	Expressed in all		
LCE3E	LEP17	ENSG00000185966	Late cornified envelope 3E	1	152565654-152566772	Predicted intracellular proteins	Evidence at protein level							Group enriched	Group enriched	35	esophagus: 9.6;skin: 9.0;tonsil: 18.1	breast: 0.3	Not detected		
CCIN	BTBD20, KBTBD14	ENSG00000185972	Calicin	9	36169394-36171334	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	testis: 112.2	smooth muscle: 2.7	Cell line enhanced		BJ: 3.3;fHDF/TERT166: 3.7;hTEC/SVTERT24-B: 5.8;TIME: 6.5
TMLHE	BBOX2, FLJ10727, TMLH, XAP130	ENSG00000185973	Trimethyllysine hydroxylase, epsilon	X	155490115-155669944	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA034589, HPA040331	Approved		Supported	Mitochondria	Renal cancer:3.68e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.7	Mixed		
GRK1	GPRK1, RHOK, RK	ENSG00000185974	G protein-coupled receptor kinase 1	13	113667155-113737735	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035200, HPA059376	Enhanced					Tissue enhanced	Not detected			thyroid gland: 0.8	Not detected		
DEFB128	DEFB-28	ENSG00000185982	Defensin beta 128	20	187853-189681	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	17134	epididymis: 1713.4	all non-specific tissues: 0.0	Not detected		
SLITRK2	CXorf2, KIAA1854, SLITL1	ENSG00000185985	SLIT and NTRK like family member 2	X	145817832-145825842	Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 25.7	seminal vesicle: 7.4	Cell line enriched	39	HAP1: 36.6
PLK5	PLK5P, SgK384ps	ENSG00000185988	Polo like kinase 5	19	1524074-1535456	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035024	Enhanced					Mixed	Tissue enhanced		cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9	epididymis: 3.3	Not detected		
RASA3	GAP1IP4BP, GAPIII	ENSG00000185989	RAS p21 protein activator 3	13	113977783-114132611	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA046759	Uncertain				Renal cancer:1.99e-6 (unfavourable)	Expressed in all	Mixed			lymph node: 17.6	Mixed		
LRCH3	MGC4126	ENSG00000186001	Leucine rich repeats and calponin homology domain containing 3	3	197791226-197888436	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012380, HPA017299	Uncertain		Enhanced	Cytosol	Liver cancer:2.95e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
LEMD1	CT50, LEMP-1	ENSG00000186007	LEM domain containing 1	1	205381378-205457091	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA045425			Approved	Nucleoli<br>Cytosol	Ovarian cancer:1.26e-4 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)	Tissue enhanced	Group enriched	16	epididymis: 18.1;testis: 71.4	fallopian tube: 2.7	Group enriched	6	CAPAN-2: 34.9;NTERA-2: 7.0
ATP4B	ATP6B	ENSG00000186009	ATPase H+/K+ transporting beta subunit	13	113648804-113658186	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045400, HPA052649	Enhanced					Tissue enriched	Tissue enriched	87	stomach: 953.2	fallopian tube: 10.9	Not detected		
NDUFA13	B16.6, CDA016, CGI-39, GRIM-19, GRIM19	ENSG00000186010	NADH:ubiquinone oxidoreductase subunit A13	19	19515736-19529054	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA041213	Supported		Enhanced	Mitochondria		Expressed in all	Expressed in all			heart muscle: 226.3	Expressed in all		
ZNF566	FLJ14779, MGC12515	ENSG00000186017	Zinc finger protein 566	19	36445119-36489902	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023456	Uncertain		Approved	Nucleus	Endometrial cancer:1.86e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 8.0	Mixed		
ZNF529	KIAA1615	ENSG00000186020	Zinc finger protein 529	19	36534774-36605276	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA031311	Uncertain		Approved	Nucleoplasm	Urothelial cancer:1.39e-5 (favourable)	Expressed in all	Mixed			testis: 17.4	Mixed		
ZNF284	DKFZp781F1775	ENSG00000186026	Zinc finger protein 284	19	44072144-44089613	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			skin: 3.6	Mixed		
HTR3E		ENSG00000186038	5-hydroxytryptamine receptor 3E	3	184097064-184106995	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049764	Enhanced					Not detected	Tissue enhanced		duodenum: 1.0	small intestine: 0.8	Cell line enriched	6	RH-30: 1.3
DLEU7	FLJ44882	ENSG00000186047	Deleted in lymphocytic leukemia, 7	13	50711008-50843939	Predicted intracellular proteins	Evidence at transcript level	HPA053750	Uncertain					Mixed	Tissue enriched	7	cerebral cortex: 6.3	epididymis: 0.9	Group enriched	7	NTERA-2: 11.0;U-698: 3.4
KRT73	K6IRS3, KRT6IRS3	ENSG00000186049	Keratin 73	12	52607570-52618559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044031	Enhanced					Not detected	Group enriched	7	lymph node: 2.5;skin: 12.1	appendix: 1.0	Not detected		
TAL2	bHLHa19	ENSG00000186051	TAL bHLH transcription factor 2	9	105662457-105663112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030886	Uncertain		Approved	Cytosol	Renal cancer:2.69e-4 (favourable)	Tissue enhanced	Group enriched	5	kidney: 3.5;skeletal muscle: 4.8	epididymis: 0.8	Cell line enhanced		HAP1: 3.1;K-562: 7.5
AIDA	C1orf80, FLJ12806	ENSG00000186063	Axin interactor, dorsalization associated	1	222668013-222713210	Predicted intracellular proteins	Evidence at protein level	HPA027935	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Cytosol	Cervical cancer:7.08e-5 (unfavourable), Renal cancer:4.37e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.4	Expressed in all		
C15orf41	FLJ22851, HH114, MGC11326	ENSG00000186073	Chromosome 15 open reading frame 41	15	36579611-36810248	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA061023	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enhanced		heart muscle: 63.4	smooth muscle: 14.3	Expressed in all		
CD300LF	CD300f, CLM1, IGSF13, IREM1, NKIR	ENSG00000186074	CD300 molecule like family member f	17	74694311-74712978	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013712	Supported					Expressed in all	Tissue enhanced		lung: 25.6;spleen: 28.0	appendix: 18.2	Group enriched	7	THP-1: 16.6;U-937: 37.2
ZPBP2	MGC41930, ZPBPL	ENSG00000186075	Zona pellucida binding protein 2	17	39868164-39877896	Predicted secreted proteins	Evidence at protein level	HPA027997, HPA053070	Enhanced					Not detected	Tissue enriched	230	testis: 209.2	tonsil: 0.9	Cell line enhanced		U-698: 3.4
KRT5	EBS2, KRT5A	ENSG00000186081	Keratin 5	12	52514575-52520687	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000027, CAB000129, HPA059479	Enhanced		Supported	Intermediate filaments	Breast cancer:1.27e-4 (favourable)	Tissue enhanced	Group enriched	9	esophagus: 3256.1;skin: 5996.8	tonsil: 516.9	Group enriched	6	HaCaT: 2557.9;HBEC3-KT: 3723.5;hTCEpi: 8392.0
NBPF6		ENSG00000186086	Neuroblastoma breakpoint family member 6	1	108450282-108471002	Predicted intracellular proteins	Evidence at transcript level	HPA045044, HPA046411, HPA047447, HPA058050	Uncertain					Tissue enriched	Tissue enriched	6	testis: 4.6	placenta,small intestine: 0.7	Cell line enhanced		BEWO: 6.2;K-562: 9.6
GSAP	LOC54103, PION	ENSG00000186088	Gamma-secretase activating protein	7	77310751-77416400	Predicted intracellular proteins	Evidence at protein level	HPA023994			Supported	Vesicles	Urothelial cancer:4.15e-5 (favourable), Breast cancer:3.36e-4 (favourable), Renal cancer:3.51e-4 (unfavourable)	Expressed in all	Mixed			lung: 26.8	Cell line enhanced		U-937: 13.1
HTR3D		ENSG00000186090	5-hydroxytryptamine receptor 3D	3	184031544-184039369	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR4F5		ENSG00000186092	Olfactory receptor family 4 subfamily F member 5	1	69091-70008	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AGBL4	CCP6, FLJ14442	ENSG00000186094	ATP/GTP binding protein like 4	1	48532855-50023913	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA037994	Approved					Not detected	Tissue enhanced		cerebral cortex: 7.9	fallopian tube: 4.6	Cell line enhanced		NTERA-2: 1.1;SCLC-21H: 1.9
ARGFX		ENSG00000186103	Arginine-fifty homeobox	3	121570704-121586634	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043049	Uncertain					Tissue enriched	Not detected			testis: 0.6	Not detected		
CYP2R1		ENSG00000186104	Cytochrome P450 family 2 subfamily R member 1	11	14877440-14892252	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042949	Approved				Renal cancer:2.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 8.1	Cell line enhanced		Karpas-707: 18.6
LRRC70	LOC100130733, SLRN	ENSG00000186105	Leucine rich repeat containing 70	5	62578735-62581448	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA013409	Uncertain					Mixed	Mixed			thyroid gland: 6.4	Group enriched	16	HUVEC TERT2: 13.7;TIME: 7.3
ANKRD46		ENSG00000186106	Ankyrin repeat domain 46	8	100509752-100559784	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013758	Approved		Approved	Cytosol		Expressed in all	Expressed in all			cerebral cortex: 70.4	Expressed in all		
PIP5K1C	KIAA0589, LCCS3, PIP5Kgamma	ENSG00000186111	Phosphatidylinositol-4-phosphate 5-kinase type 1 gamma	19	3630183-3700479	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA017168	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:7.28e-5 (favourable), Cervical cancer:1.79e-4 (favourable), Pancreatic cancer:2.32e-4 (favourable), Renal cancer:3.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
OR5D14		ENSG00000186113	Olfactory receptor family 5 subfamily D member 14	11	55795556-55796500	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CYP4F2		ENSG00000186115	Cytochrome P450 family 4 subfamily F member 2	19	15878023-15898120	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014048, HPA017265, HPA058960	Supported					Tissue enriched	Group enriched	6	duodenum: 78.2;epididymis: 28.0;kidney: 39.3;liver: 84.6;small intestine: 84.3	prostate: 10.4	Cell line enhanced		Hep G2: 2.5
TEX38	ATPAF1-AS1, C1orf223, LOC374973, THEG4	ENSG00000186118	Testis expressed 38	1	46668855-46673594	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	125	testis: 260.8	parathyroid gland: 2.0	Not detected		
OR5D18		ENSG00000186119	Olfactory receptor family 5 subfamily D member 18	11	55819630-55820571	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZBTB6	ZID, ZNF482	ENSG00000186130	Zinc finger and BTB domain containing 6	9	122908056-122913330	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054111, HPA076894	Approved		Approved	Nucleoplasm<br>Mitochondria	Glioma:9.75e-6 (favourable), Renal cancer:5.08e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 12.6	Expressed in all		
C2orf76	AIM29, LOC130355, MGC104437	ENSG00000186132	Chromosome 2 open reading frame 76	2	119302225-119366828	Predicted intracellular proteins	Evidence at protein level	HPA044977, HPA055362	Uncertain		Approved	Endoplasmic reticulum	Renal cancer:2.16e-8 (unfavourable)	Expressed in all	Expressed in all			epididymis: 53.2	Expressed in all		
TAS2R42	hT2R55, T2R24, T2R55, TAS2R55	ENSG00000186136	Taste 2 receptor member 42	12	11185993-11186937	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA036149	Uncertain		Approved	Nucleoplasm<br>Actin filaments<br>Focal adhesion sites		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
POLR3C	RPC3, RPC62	ENSG00000186141	RNA polymerase III subunit C	1	145824088-145842505	Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA027508, HPA027516	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.85e-5 (unfavourable), Melanoma:1.50e-4 (unfavourable), Endometrial cancer:1.56e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 53.2	Expressed in all		
PRR30	C2orf53, MGC44505	ENSG00000186143	Proline rich 30	2	27136848-27139410	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	1041	testis: 104.0	all non-specific tissues: 0.0	Not detected		
DEFB131	DEFB-31	ENSG00000186146	Defensin beta 131	4	9444534-9450514	Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	epididymis: 207.2	seminal vesicle: 21.0	Cell line enriched	6	TIME: 1.7
UBL4B	FLJ25690	ENSG00000186150	Ubiquitin like 4B	1	110112468-110113945	Predicted intracellular proteins	Evidence at protein level	HPA031364	Enhanced		Uncertain	Intermediate filaments<br>Mitochondria		Tissue enhanced	Tissue enriched	61	testis: 69.3	fallopian tube: 1.1	Cell line enriched	5	BJ hTERT+: 16.6
WWOX	FOR, SDR41C1, WOX1	ENSG00000186153	WW domain containing oxidoreductase	16	78099413-79212667	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050992	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:4.49e-5 (favourable), Breast cancer:9.07e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.6	Cell line enhanced		MCF7: 65.2
CYP4Z1	CYP4A20	ENSG00000186160	Cytochrome P450 family 4 subfamily Z member 1	1	47067488-47118319	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		breast: 6.9	lung: 1.5	Group enriched	43	HDLM-2: 8.5;SK-BR-3: 2.8
CCDC84	DLNB14	ENSG00000186166	Coiled-coil domain containing 84	11	118998142-119015791	Predicted intracellular proteins	Evidence at protein level	HPA039906, HPA071715	Uncertain		Approved	Nucleus	Renal cancer:2.93e-5 (unfavourable)	Expressed in all	Mixed			skin: 4.6	Mixed		
BCL9L	DLNB11	ENSG00000186174	B-cell CLL/lymphoma 9-like	11	118893875-118925608	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA049370, HPA053421	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 35.0	Mixed		
POLR1D	MGC9850, RPA16, RPA9, RPAC2, RPO1-3	ENSG00000186184	RNA polymerase I subunit D	13	27620742-27744237	Disease related genes, Predicted intracellular proteins, RNA polymerase related proteins	Evidence at protein level	HPA039337	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 108.1	Expressed in all		
KIF18B		ENSG00000186185	Kinesin family member 18B	17	44924709-44947711	Predicted intracellular proteins	Evidence at protein level	HPA024205	Enhanced		Supported	Nucleus<br>Microtubule ends<br>Cytosol	Liver cancer:2.44e-6 (unfavourable), Pancreatic cancer:2.16e-4 (unfavourable), Melanoma:6.90e-4 (unfavourable)	Mixed	Tissue enhanced		bone marrow: 8.4	lymph node: 7.3	Mixed		
ZNRF1	DKFZp434E229, FLJ14846, nin283	ENSG00000186187	Zinc and ring finger 1	16	74999030-75110994	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027470	Approved				Cervical cancer:9.90e-4 (favourable)	Expressed in all	Expressed in all			testis: 34.3	Expressed in all		
FFAR4	GPR120, GPR129, O3FAR1, PGR4	ENSG00000186188	Free fatty acid receptor 4	10	93566665-93604480	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042563	Uncertain		Uncertain	Plasma membrane		Tissue enhanced	Tissue enhanced		colon: 8.4;rectum: 12.4	lung: 5.4	Cell line enhanced		A549: 1.2;HaCaT: 2.0;NB-4: 1.6
BPIFB3	C20orf185, dJ726C3.4, LPLUNC3, RYA3	ENSG00000186190	BPI fold containing family B member 3	20	33055424-33073628	Plasma proteins, Predicted secreted proteins	Evidence at transcript level	HPA045741	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.0	salivary gland: 0.2	Group enriched	28	HEL: 3.3;HMC-1: 2.3
BPIFB4	C20orf186, dJ726C3.5, LPLUNC4	ENSG00000186191	BPI fold containing family B member 4	20	33079644-33111751	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		parathyroid gland: 1.3	testis: 0.7	Cell line enhanced		HSkMC: 1.7;U-2 OS: 4.0
SAPCD2	C9orf140, p42.3	ENSG00000186193	Suppressor APC domain containing 2	9	137062124-137070588	Predicted intracellular proteins	Evidence at protein level	HPA044154	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Lung cancer:5.88e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 12.6	small intestine: 4.8	Mixed		
EDARADD		ENSG00000186197	EDAR associated death domain	1	236348257-236484914	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018836	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		urinary bladder: 18.9	seminal vesicle: 11.4	Cell line enhanced		HMC-1: 69.7;RT4: 52.5
SLC51B	OSTbeta	ENSG00000186198	Solute carrier family 51 beta subunit	15	65045370-65053396	Predicted membrane proteins, Transporters	Evidence at protein level	HPA008398, HPA008533	Enhanced		Approved	Vesicles<br>Mitochondria	Renal cancer:8.46e-5 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 59.7;duodenum: 85.4;small intestine: 118.4	colon: 40.7	Group enriched	9	CACO-2: 15.0;EFO-21: 11.0;Hep G2: 10.4
CYP4F12		ENSG00000186204	Cytochrome P450 family 4 subfamily F member 12	19	15672757-15697174	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058960	Approved				Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 36.2;small intestine: 42.3	skin: 22.3	Cell line enhanced		CAPAN-2: 14.8;HaCaT: 26.3;Karpas-707: 14.2;SiHa: 6.0
MARC1	FLJ22390, MOSC1	ENSG00000186205	Mitochondrial amidoxime reducing component 1	1	220786759-220819657	Predicted intracellular proteins	Evidence at protein level	HPA028702	Approved		Supported	Mitochondria	Renal cancer:4.51e-4 (unfavourable)	Mixed	Expressed in all			adipose tissue: 225.9	Cell line enhanced		BEWO: 149.0;NTERA-2: 65.7
LCE5A	LEP18, SPRL5A	ENSG00000186207	Late cornified envelope 5A	1	152510844-152512177	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	6	skin: 94.0	breast: 16.8	Not detected		
SOWAHB	ANKRD56	ENSG00000186212	Sosondowah ankyrin repeat domain family member B	4	76894928-76898147	Predicted intracellular proteins	Evidence at protein level	HPA036809, HPA036810	Approved		Approved	Nucleoli fibrillar center	Renal cancer:1.22e-15 (favourable)	Mixed	Mixed			parathyroid gland: 9.1	Cell line enhanced		BEWO: 8.3;RT4: 15.1;T-47d: 5.0
BLOC1S4	BCAS4L, CNO, FLJ11230	ENSG00000186222	Biogenesis of lysosomal organelles complex 1 subunit 4	4	6716055-6717671	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043840	Approved		Approved	Vesicles<br>Cytosol	Liver cancer:1.06e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.7	Expressed in all		
LCE1E	LEP5	ENSG00000186226	Late cornified envelope 1E	1	152786214-152788426	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	120	skin: 74.0	breast: 0.6	Cell line enhanced		Daudi: 1.3;HaCaT: 8.8;RT4: 1.8
ZNF749	FLJ16360	ENSG00000186230	Zinc finger protein 749	19	57435329-57445485	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042082, HPA042091, HPA056001	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Mixed			parathyroid gland: 4.2	Expressed in all		
KLHL32	BKLHD5, KIAA1900	ENSG00000186231	Kelch like family member 32	6	96924620-97140754	Predicted intracellular proteins	Evidence at protein level	HPA039150	Enhanced					Mixed	Group enriched	6	cerebral cortex: 25.3;fallopian tube: 10.3	testis: 3.1	Cell line enhanced		Daudi: 2.3;HDLM-2: 4.1;SCLC-21H: 2.1;U-266/70: 1.7
MKL2	FLJ31823, MRTF-B	ENSG00000186260	MKL1/myocardin like 2	16	14071321-14266773	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011286	Supported		Supported	Nuclear speckles	Renal cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 50.1	Expressed in all		
BTLA	BTLA1, CD272	ENSG00000186265	B and T lymphocyte associated	3	112463968-112499561	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047211, HPA062029	Enhanced					Mixed	Group enriched	7	appendix: 14.1;lymph node: 29.3;spleen: 14.6;tonsil: 24.7	urinary bladder: 3.0	Cell line enhanced		U-698: 1.3
ZNF17	FLJ40864, FLJ46058, FLJ46615, HPF3, KIAA1947, KOX10	ENSG00000186272	Zinc finger protein 17	19	57411163-57421939	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:6.03e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.3	Expressed in all		
KDM4D	FLJ10251, JMJD2D	ENSG00000186280	Lysine demethylase 4D	11	94973681-94999518	Predicted intracellular proteins	Evidence at protein level	HPA055854, HPA064037	Approved		Approved	Nucleoplasm		Mixed	Tissue enriched	29	testis: 60.7	parathyroid gland: 2.0	Mixed		
GPAT2	CT123	ENSG00000186281	Glycerol-3-phosphate acyltransferase 2, mitochondrial	2	96021946-96039451	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036841	Uncertain		Approved	Mitochondria		Mixed	Mixed			testis: 7.2	Cell line enhanced		BJ: 6.9;BJ hTERT+ SV40 Large T+: 18.2;BJ hTERT+ SV40 Large T+ RasG12V: 11.3;U-2 OS: 11.7
TOR3A	ADIR, ADIR2, FLJ22345	ENSG00000186283	Torsin family 3 member A	1	179081377-179098023	Predicted secreted proteins	Evidence at protein level	HPA028766	Approved				Renal cancer:4.78e-8 (unfavourable)	Expressed in all	Expressed in all			lymph node: 39.6	Expressed in all		
PABPC1L2A	RBM32A	ENSG00000186288	Poly(A) binding protein cytoplasmic 1 like 2A	X	73077276-73079512	Predicted intracellular proteins	Evidence at transcript level	HPA041573	Approved					Tissue enriched	Group enriched	5	adrenal gland: 2.0;cerebral cortex: 6.7;prostate: 3.6;testis: 2.8	epididymis: 0.7	Cell line enhanced		HeLa: 2.6;NTERA-2: 1.4
GABRA5		ENSG00000186297	Gamma-aminobutyric acid type A receptor alpha5 subunit	15	26866363-26949207	FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077031, CAB079022		Supported	Supported	Plasma membrane		Mixed	Tissue enriched	43	cerebral cortex: 81.6	esophagus: 1.8	Group enriched	10	A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
PPP1CC	PP1C, PP1gamma	ENSG00000186298	Protein phosphatase 1 catalytic subunit gamma	12	110719680-110742939	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022645	Uncertain				Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable)	Expressed in all	Expressed in all			testis: 257.5	Expressed in all		
ZNF555	MGC26707	ENSG00000186300	Zinc finger protein 555	19	2841435-2860484	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053956, HPA055430	Uncertain					Mixed	Mixed			testis: 10.4	Mixed		
OR10T2		ENSG00000186306	Olfactory receptor family 10 subfamily T member 2	1	158398522-158399466	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SCLC-21H: 1.0
NAP1L3	MB20, MGC26312, NPL3	ENSG00000186310	Nucleosome assembly protein 1 like 3	X	93670930-93673568	Predicted intracellular proteins	Evidence at protein level	HPA026075			Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 131.3	testis: 31.1	Cell line enhanced		AF22: 13.4;HAP1: 13.7;NTERA-2: 24.0;U-2197: 15.0
PRELID2	FLJ38376, MGC21644	ENSG00000186314	PRELI domain containing 2	5	145471799-145835369	Predicted intracellular proteins	Evidence at transcript level	HPA042486	Uncertain		Approved	Nucleoplasm	Renal cancer:9.65e-6 (unfavourable), Pancreatic cancer:3.78e-4 (unfavourable)	Mixed	Tissue enhanced		small intestine: 28.7	rectum: 19.2	Mixed		
BACE1	BACE	ENSG00000186318	Beta-secretase 1	11	117285207-117316259	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016358	Approved		Supported	Plasma membrane	Urothelial cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			pancreas: 100.7	Mixed		
RGS9BP	FLJ45744, PERRS, R9AP, RGS9	ENSG00000186326	Regulator of G-protein signaling 9 binding protein	19	32675407-32678300	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA049791	Supported					Not detected	Tissue enriched	6	skeletal muscle: 2.6	lung: 0.4	Cell line enhanced		HEL: 4.7
TMEM212	FLJ23172	ENSG00000186329	Transmembrane protein 212	3	171843349-171938715	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045736			Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Not detected	Tissue enriched	6	fallopian tube: 48.3	testis: 8.1	Mixed		
SLC36A3	PAT3, TRAMD2, tramdorin2	ENSG00000186334	Solute carrier family 36 member 3	5	151276762-151303766	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	60	testis: 14.5	epididymis: 0.2	Not detected		
SLC36A2	PAT2, TRAMD1, tramdorin	ENSG00000186335	Solute carrier family 36 member 2	5	151314978-151347590	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044002, HPA062229	Enhanced					Tissue enriched	Group enriched	27	kidney: 67.7;skeletal muscle: 28.0	testis: 1.7	Not detected		
THBS2	TSP2	ENSG00000186340	Thrombospondin 2	6	169215780-169254044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB017716, HPA044304	Approved		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:3.77e-6 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 113.4	endometrium: 71.2	Cell line enhanced		ASC diff: 282.6;ASC TERT1: 196.5;BJ hTERT+ SV40 Large T+ RasG12V: 134.9;hTEC/SVTERT24-B: 150.4
RXRA	NR2B1	ENSG00000186350	Retinoid X receptor alpha	9	134317098-134440585	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004565, CAB005352	Supported		Supported	Nucleus<br>Golgi apparatus	Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable)	Expressed in all	Mixed			esophagus: 25.8	Mixed		
ANKRD37	Lrp2bp	ENSG00000186352	Ankyrin repeat domain 37	4	185396021-185400628	Predicted intracellular proteins	Evidence at protein level	HPA036626, HPA058127	Uncertain		Supported	Nucleus<br>Mitochondria<br>Cytosol		Expressed in all	Expressed in all			esophagus: 31.1	Mixed		
C9orf47	bA791O21.3, C9orf108, FLJ37523	ENSG00000186354	Chromosome 9 open reading frame 47	9	88990863-88996140	Predicted secreted proteins	Evidence at transcript level	CAB009902	Approved					Not detected	Mixed			adrenal gland: 2.1	Cell line enhanced		AF22: 2.7;HeLa: 1.6
NUDT17	FLJ34433	ENSG00000186364	Nudix hydrolase 17	1	145845629-145848953	Predicted intracellular proteins	Evidence at protein level	HPA030145	Enhanced		Approved	Centrosome<br>Cytosol	Renal cancer:1.81e-7 (unfavourable), Liver cancer:8.73e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.2	Cell line enhanced		T-47d: 11.4
KIAA1024L		ENSG00000186367	KIAA1024 like	5	129748079-129766732	Predicted membrane proteins	Evidence at transcript level	HPA013760	Uncertain					Not detected	Tissue enriched	12	skeletal muscle: 11.5	testis: 0.9	Cell line enhanced		SH-SY5Y: 1.5
ZNF75D	D8C6, ZKSCAN24, ZNF75, ZNF82, ZSCAN28	ENSG00000186376	Zinc finger protein 75D	X	135248920-135344087	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004705	Supported		Approved	Nucleoplasm<br>Golgi apparatus	Urothelial cancer:7.42e-5 (favourable), Renal cancer:1.31e-4 (favourable)	Expressed in all	Expressed in all			prostate: 15.8	Mixed		
CYP4X1	MGC40051	ENSG00000186377	Cytochrome P450 family 4 subfamily X member 1	1	47023568-47050751	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA017661	Approved					Mixed	Tissue enhanced		cervix, uterine: 52.7	breast: 18.7	Cell line enhanced		CACO-2: 3.6;NTERA-2: 2.0;SCLC-21H: 3.0;T-47d: 8.7
KRT26	KRT25B	ENSG00000186393	Keratin 26	17	40766238-40772162	Predicted intracellular proteins	Evidence at protein level	HPA026890	Supported					Not detected	Tissue enhanced		testis: 1.0	bone marrow: 0.9	Not detected		
KRT10	CK10, K10, KPP	ENSG00000186395	Keratin 10	17	40818117-40822595	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000132, HPA012014	Enhanced				Renal cancer:9.32e-5 (unfavourable)	Expressed in all	Tissue enriched	31	skin: 18886.8	breast: 612.8	Expressed in all		
GOLGA8R		ENSG00000186399	Golgin A8 family member R	15	30403740-30414162	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 10.5	testis: 5.2	Group enriched	10	HEL: 21.6;THP-1: 5.5;U-937: 7.5
CD300E	CD300LE, CLM2, IREM2	ENSG00000186407	CD300e molecule	17	74609887-74623738	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015570	Uncertain					Mixed	Tissue enhanced		appendix: 52.8;bone marrow: 29.0	adipose tissue: 18.0	Not detected		
CCDC30	FLJ20972, LOC728621, PFD6L	ENSG00000186409	Coiled-coil domain containing 30	1	42463330-42654664	Predicted intracellular proteins	Evidence at protein level	HPA036344, HPA036345	Approved					Mixed	Tissue enhanced		testis: 6.9	fallopian tube: 5.0	Cell line enriched	19	HMC-1: 23.7
NKRF	ITBA4, NRF	ENSG00000186416	NFKB repressing factor	X	119588337-119605895	Predicted intracellular proteins	Evidence at protein level	HPA001476			Supported	Nucleus<br>Nucleoli	Liver cancer:4.92e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 20.3	Expressed in all		
GLDN	CLOM, COLM, colmedin, CRG-L2, UNC-112	ENSG00000186417	Gliomedin	15	51341629-51408013	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059441	Uncertain					Tissue enhanced	Tissue enhanced		cerebral cortex: 23.9	adipose tissue: 12.9	Cell line enhanced		HHSteC: 2.3;U-266/70: 2.5;U-266/84: 2.0
FCAR	CD89	ENSG00000186431	Fc fragment of IgA receptor	19	54874248-54890472	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA014050	Approved		Supported	Plasma membrane		Not detected	Tissue enriched	15	bone marrow: 12.3	appendix: 0.8	Not detected		
KPNA4	IPOA3, MGC12217, MGC26703, QIP1, SRP3	ENSG00000186432	Karyopherin subunit alpha 4	3	160494995-160565588	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB034336, HPA043154, HPA045500	Enhanced		Enhanced	Nucleus	Liver cancer:6.24e-7 (unfavourable), Pancreatic cancer:1.03e-6 (unfavourable), Endometrial cancer:8.59e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 36.6	Expressed in all		
TRDN		ENSG00000186439	Triadin	6	123216339-123637093	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA038226, HPA058226	Enhanced		Approved	Plasma membrane<br>Cytosol		Tissue enhanced	Group enriched	21	heart muscle: 273.5;skeletal muscle: 650.2	prostate: 22.2	Cell line enhanced		MCF7: 1.4
OR6P1		ENSG00000186440	Olfactory receptor family 6 subfamily P member 1	1	158562651-158563604	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047466	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRT3	CK3, K3	ENSG00000186442	Keratin 3	12	52789685-52796117	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	6	esophagus: 1.3;skin: 1.8	tonsil: 0.2	Group enriched	8	HaCaT: 8.3;HMC-1: 4.9
ZNF501	MGC21738, ZNF52	ENSG00000186446	Zinc finger protein 501	3	44729596-44737083	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044161	Uncertain		Approved	Endoplasmic reticulum		Mixed	Mixed			prostate,testis: 2.7	Mixed		
ZNF197	D3S1363E, P18, ZKSCAN9, ZNF166, ZSCAN41	ENSG00000186448	Zinc finger protein 197	3	44584888-44648471	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054567	Uncertain		Approved	Nucleoplasm	Prostate cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 9.2	Mixed		
SPATA12		ENSG00000186451	Spermatogenesis associated 12	3	57060441-57075432	Predicted intracellular proteins	Evidence at transcript level	HPA043323			Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	54	testis: 23.0	fallopian tube,lung: 0.4	Not detected		
TMPRSS12	CT151, MGC57341	ENSG00000186452	Transmembrane protease, serine 12	12	50842920-50887884	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	75	testis: 39.5	epididymis: 0.5	Not detected		
FAM228A	C2orf84, FLJ30851	ENSG00000186453	Family with sequence similarity 228 member A	2	24175069-24200849	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 42.4	cerebral cortex: 2.2	Cell line enhanced		HHSteC: 2.0;TIME: 3.2
DEFB132	DEFB32, RP5-1103G7.6	ENSG00000186458	Defensin beta 132	20	257736-261096	Predicted secreted proteins	Evidence at transcript level	HPA046399	Approved					Tissue enhanced	Tissue enriched	11	epididymis: 332.3	seminal vesicle: 29.0	Not detected		
NAP1L2	BPX, MGC26243	ENSG00000186462	Nucleosome assembly protein 1 like 2	X	73212299-73214848	Predicted intracellular proteins	Evidence at protein level	HPA054050, HPA057065			Enhanced	Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:5.41e-4 (favourable)	Mixed	Tissue enriched	5	cerebral cortex: 90.1	parathyroid gland,prostate: 17.8	Cell line enhanced		EFO-21: 15.7;NTERA-2: 18.1;U-2197: 13.6;U-266/84: 21.9
RPS23	S23	ENSG00000186468	Ribosomal protein S23	5	82273358-82278577	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA054853	Approved		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:2.17e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4322.3	Expressed in all		
GNG2		ENSG00000186469	G protein subunit gamma 2	14	51826195-51979342	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003534, CAB018380	Uncertain	Supported	Approved	Golgi apparatus<br>Vesicles	Renal cancer:3.90e-6 (unfavourable), Pancreatic cancer:1.64e-4 (favourable)	Expressed in all	Expressed in all			testis: 185.4	Cell line enhanced		fHDF/TERT166: 108.6;MOLT-4: 89.8;SH-SY5Y: 94.7;WM-115: 245.1
BTN3A2	BTN3.2	ENSG00000186470	Butyrophilin subfamily 3 member A2	6	26365159-26378320	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB019392	Uncertain				Renal cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 129.4	Mixed		
AKAP14	AKAP28	ENSG00000186471	A-kinase anchoring protein 14	X	119895837-119920716	Predicted intracellular proteins	Evidence at protein level	HPA060999	Enhanced					Tissue enhanced	Group enriched	14	fallopian tube: 67.8;testis: 73.2	lung: 4.8	Cell line enhanced		SCLC-21H: 2.9
PCLO	ACZ, DKFZp779G1236, KIAA0559	ENSG00000186472	Piccolo presynaptic cytomatrix protein	7	82754013-83162930	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015858, HPA029579, CAB079012	Approved	Approved	Approved	Nuclear speckles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 17.4	parathyroid gland: 9.8	Group enriched	36	REH: 239.6;U-2 OS: 298.6
KLK12	KLK-L5	ENSG00000186474	Kallikrein related peptidase 12	19	51029092-51035230	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB025473	Uncertain				Thyroid cancer:8.01e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 32.4	tonsil: 8.1	Not detected		
RGS7BP	R7BP	ENSG00000186479	Regulator of G-protein signaling 7 binding protein	5	64506257-64612312	Predicted intracellular proteins	Evidence at protein level	HPA039600	Approved					Mixed	Tissue enhanced		cerebral cortex: 38.9	fallopian tube: 13.2	Cell line enhanced		HUVEC TERT2: 9.7;NTERA-2: 2.0;SCLC-21H: 1.5
INSIG1	CL-6, MGC1405	ENSG00000186480	Insulin induced gene 1	7	155297776-155310235	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA071524			Approved	Vesicles	Thyroid cancer:9.62e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 281.7	Cell line enhanced		Karpas-707: 871.4
MYT1L	KIAA1106, NZF1, ZC2H2C2, ZC2HC4B	ENSG00000186487	Myelin transcription factor 1 like	2	1789113-2331260	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060245			Approved	Vesicles		Not detected	Tissue enriched	11	cerebral cortex: 60.0	testis: 5.3	Group enriched	12	SCLC-21H: 7.8;SH-SY5Y: 5.2
C5orf38	CEI, IRX2NB	ENSG00000186493	Chromosome 5 open reading frame 38	5	2752131-2755397	Predicted intracellular proteins	Evidence at protein level	HPA073667			Enhanced	Golgi apparatus<br>Vesicles		Mixed	Tissue enhanced		lung: 13.7;salivary gland: 13.0	skin: 8.5	Cell line enhanced		BEWO: 79.2;hTCEpi: 32.4;SiHa: 37.3
ZNF396	FLJ31213, ZSCAN14	ENSG00000186496	Zinc finger protein 396	18	35366697-35377337	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006686	Uncertain					Mixed	Mixed			thyroid gland: 14.3	Mixed		
TMEM222	C1orf160, DKFZP564D0478	ENSG00000186501	Transmembrane protein 222	1	27322145-27336400	Predicted membrane proteins	Evidence at protein level	HPA016579, HPA059374	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			fallopian tube: 47.9	Expressed in all		
OR9Q1		ENSG00000186509	Olfactory receptor family 9 subfamily Q member 1	11	58023881-58181616	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			skeletal muscle,skin,testis: 0.1	Not detected		
CLCNKA	hClC-Ka	ENSG00000186510	Chloride voltage-gated channel Ka	1	16018875-16034050	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA057717	Approved					Group enriched	Group enriched	9	kidney: 64.2;parathyroid gland: 40.4	thyroid gland: 5.5	Group enriched	11	RPMI-8226: 1.3;SK-BR-3: 1.4;U-266/70: 5.7
OR9Q2	OR9Q2P	ENSG00000186513	Olfactory receptor family 9 subfamily Q member 2	11	58190434-58191518	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
ARHGAP30	FLJ00267	ENSG00000186517	Rho GTPase activating protein 30	1	161046946-161069970	Predicted intracellular proteins	Evidence at protein level	HPA036300	Uncertain		Supported	Vesicles	Renal cancer:9.78e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 86.1;spleen: 80.6	appendix: 73.2	Cell line enhanced		Daudi: 82.8;HL-60: 72.0;HMC-1: 106.5;U-266/70: 103.3
SEPT10	FLJ11619	ENSG00000186522	Septin 10	2	109542982-109614206	Predicted intracellular proteins	Evidence at protein level	HPA047860, HPA056304, HPA060310	Enhanced		Enhanced	Actin filaments		Expressed in all	Mixed			testis: 140.8	Mixed		
FAM86B1	MGC16279	ENSG00000186523	Family with sequence similarity 86 member B1	8	12182096-12194133	Predicted intracellular proteins	Evidence at transcript level	HPA041610, HPA055718	Uncertain		Uncertain	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 4.5	endometrium: 2.6	Mixed		
CYP4F8		ENSG00000186526	Cytochrome P450 family 4 subfamily F member 8	19	15615218-15630638	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058960	Approved					Group enriched	Tissue enriched	54	seminal vesicle: 147.7	breast: 2.7	Not detected		
CYP4F3	CYP4F, LTB4H	ENSG00000186529	Cytochrome P450 family 4 subfamily F member 3	19	15640897-15662825	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058960	Approved					Tissue enhanced	Tissue enhanced		bone marrow: 53.1;liver: 98.0	kidney: 29.4	Group enriched	7	A549: 6.6;CAPAN-2: 28.8;HaCaT: 13.3;Hep G2: 12.4
SMYD4	KIAA1936, ZMYND21	ENSG00000186532	SET and MYND domain containing 4	17	1779485-1830634	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030059	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 10.8	Expressed in all		
DEFB105A	DEFB-5, DEFB105	ENSG00000186562	Defensin beta 105A	8	7821966-7823889	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	5851	epididymis: 2275.4	esophagus: 0.3	Cell line enhanced		BEWO: 1.9;NB-4: 5.1;SH-SY5Y: 1.6
FOXD2	FKHL17, FREAC9	ENSG00000186564	Forkhead box D2	1	47436017-47440691	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Tissue enhanced		colon: 3.4;rectum: 2.7	prostate: 1.1	Cell line enhanced		AN3-CA: 11.3;WM-115: 17.4
GPATCH8	GPATC8, KIAA0553	ENSG00000186566	G-patch domain containing 8	17	44395284-44503430	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044380	Approved		Approved	Nuclear speckles<br>Mitochondria		Expressed in all	Mixed			parathyroid gland: 11.7	Mixed		
CEACAM19	CEAL1	ENSG00000186567	Carcinoembryonic antigen related cell adhesion molecule 19	19	44662278-44684359	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA014462, HPA052865	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Expressed in all	Mixed			skin: 12.7	Cell line enhanced		RPTEC TERT1: 11.9;TIME: 16.9
DEFB107A	DEFB-7, DEFB107	ENSG00000186572	Defensin beta 107A	8	7811720-7815716	Predicted secreted proteins	Evidence at transcript level	HPA045626	Approved					Not detected	Tissue enriched	2828	epididymis: 488.6	endometrium: 0.1	Not detected		
NF2	ACN, BANF, merlin, SCH	ENSG00000186575	Neurofibromin 2	22	29603556-29698598	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003097, CAB005385	Supported		Enhanced	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.89e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.7	Expressed in all		
C6orf1	LBH, MGC57858	ENSG00000186577	Chromosome 6 open reading frame 1	6	34246380-34249470	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA037659, HPA037660	Uncertain				Renal cancer:4.38e-4 (unfavourable), Pancreatic cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 57.3	Expressed in all		
DEFB106A	DEFB-6, DEFB106	ENSG00000186579	Defensin beta 106A	8	7825172-7829053	Predicted secreted proteins	Evidence at protein level	HPA045592	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SH-SY5Y: 1.2
SPATC1	MGC61633, SPATA15, SPERIOLIN	ENSG00000186583	Spermatogenesis and centriole associated 1	8	144012414-144047085	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	5	bone marrow: 6.2;testis: 21.7	appendix: 2.5	Cell line enriched	8	U-937: 6.3
UBE2H	GID3, UBC8, UBCH	ENSG00000186591	Ubiquitin conjugating enzyme E2 H	7	129830732-129952949	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003302	Approved		Supported	Mitochondria	Pancreatic cancer:2.33e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 94.5	Expressed in all		
DEFB105B		ENSG00000186599	Defensin beta 105B	8	7487669-7489593	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	18505	epididymis: 1850.5	all non-specific tissues: 0.0	Not detected		
HPDL	4-HPPD-L, GLOXD1, MGC15668	ENSG00000186603	4-hydroxyphenylpyruvate dioxygenase like	1	45326905-45328533	Predicted intracellular proteins	Evidence at protein level	HPA031997, HPA057346	Approved		Supported	Mitochondria	Endometrial cancer:1.60e-5 (unfavourable), Ovarian cancer:1.03e-4 (favourable), Breast cancer:1.81e-4 (favourable)	Mixed	Mixed			colon: 3.8	Cell line enhanced		BEWO: 118.1;SK-BR-3: 58.4
KATNA1		ENSG00000186625	Katanin catalytic subunit A1	6	149594873-149648972	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036207	Approved		Supported	Nucleus<br>Microtubule organizing center	Liver cancer:3.57e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
FSD2	RP11-127F21, SPRYD1	ENSG00000186628	Fibronectin type III and SPRY domain containing 2	15	82755362-82806070	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	21	heart muscle: 34.5;skeletal muscle: 53.5	esophagus: 2.1	Mixed		
ARAP1	CENTD2	ENSG00000186635	ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1	11	72685069-72793599	Predicted intracellular proteins	Evidence at protein level	CAB020703, HPA070383	Approved		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.04e-5 (favourable), Thyroid cancer:6.41e-4 (favourable), Liver cancer:6.45e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 91.3	Expressed in all		
KIF24	bA571F15.4, C9orf48, FLJ10933, FLJ43884	ENSG00000186638	Kinesin family member 24	9	34252381-34311371	Predicted intracellular proteins	Evidence at protein level	HPA020643	Uncertain				Cervical cancer:1.33e-4 (favourable)	Mixed	Tissue enhanced		testis: 20.2	fallopian tube: 5.2	Mixed		
PDE2A		ENSG00000186642	Phosphodiesterase 2A	11	72576141-72674591	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB009752, HPA031192	Enhanced		Supported	Cytosol	Liver cancer:1.76e-6 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 141.8;spleen: 184.3	adipose tissue: 62.1	Cell line enriched	6	HeLa: 340.7
CARMIL3	BC008134, C14orf121, crml-1, LRRC16B	ENSG00000186648	Capping protein regulator and myosin 1 linker 3	14	24052000-24069728	Predicted intracellular proteins	Evidence at protein level	HPA030596	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 6.7;skin: 6.2	testis: 3.0	Cell line enhanced		Daudi: 7.8;HMC-1: 6.5;Karpas-707: 4.8;SCLC-21H: 12.8;SH-SY5Y: 5.6
PRG2	BMPG, MBP, proMBP	ENSG00000186652	Proteoglycan 2, pro eosinophil major basic protein	11	57386794-57390657	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038515	Supported					Not detected	Tissue enriched	30	placenta: 3880.8	bone marrow: 130.2	Group enriched	50	HL-60: 2682.8;HMC-1: 4472.2;NB-4: 6716.6
PRR5	FLJ20185k, PP610, Protor-1	ENSG00000186654	Proline rich 5	22	44668547-44737681	Predicted intracellular proteins	Evidence at protein level	HPA054072	Approved				Endometrial cancer:2.47e-5 (favourable)	Expressed in all	Mixed			spleen: 17.5	Cell line enhanced		U-266/70: 75.3
ZFP91	PZF, ZNF757	ENSG00000186660	ZFP91 zinc finger protein	11	58579111-58621042	Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024037, CAB025417, HPA065325	Approved		Supported	Nucleus<br>Nucleoli	Pancreatic cancer:3.74e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 175.7	Expressed in all		
C17orf58		ENSG00000186665	Chromosome 17 open reading frame 58	17	67991101-67996431	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA023036	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.31e-10 (unfavourable), Liver cancer:8.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 50.5	cervix, uterine: 42.4	Expressed in all		
BCDIN3D		ENSG00000186666	BCDIN3 domain containing RNA methyltransferase	12	49836039-49843129	Predicted intracellular proteins	Evidence at protein level	HPA039911	Approved		Supported	Nucleus<br>Cytosol	Renal cancer:1.03e-5 (favourable), Urothelial cancer:1.06e-4 (favourable), Lung cancer:3.24e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 7.3	Mixed		
MAGEE2	HCA3	ENSG00000186675	MAGE family member E2	X	75782988-75785236	Predicted intracellular proteins	Evidence at transcript level	HPA030625	Uncertain					Tissue enriched	Group enriched	6	adrenal gland: 1.0;cerebral cortex: 3.3	endometrium,ovary,prostate,rectum,smooth muscle: 0.3	Not detected		
CYP27C1	FLJ16008	ENSG00000186684	Cytochrome P450 family 27 subfamily C member 1	2	127184120-127220078	Predicted intracellular proteins	Evidence at protein level	HPA062460, HPA068731			Supported	Vesicles		Mixed	Tissue enhanced		skin: 6.8	cervix, uterine: 2.4	Cell line enhanced		HDLM-2: 13.5;TIME: 11.6;U-138 MG: 13.8
LYRM7	C5orf31, FLJ20796, MZM1L	ENSG00000186687	LYR motif containing 7	5	131170810-131205426	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050053	Approved				Renal cancer:9.84e-6 (favourable)	Expressed in all	Mixed			testis: 29.9	Expressed in all		
CFAP73	CCDC42B, MIA2	ENSG00000186710	Cilia and flagella associated protein 73	12	113149858-113159276	Predicted intracellular proteins	Evidence at protein level	HPA048539	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles	Cervical cancer:1.29e-4 (favourable), Endometrial cancer:5.52e-4 (favourable)	Tissue enhanced	Tissue enriched	9	fallopian tube: 60.1	lung: 6.9	Cell line enhanced		Daudi: 3.1;T-47d: 2.4;U-698: 6.0
CCDC73	NY-SAR-79	ENSG00000186714	Coiled-coil domain containing 73	11	32602246-32794658	Predicted intracellular proteins	Evidence at protein level	HPA038668, HPA038669	Uncertain					Not detected	Tissue enriched	8	testis: 6.7	ovary: 0.8	Cell line enhanced		MOLT-4: 1.4
BCR	ALL, BCR1, CML, D22S11, D22S662, PHL	ENSG00000186716	BCR, RhoGEF and GTPase activating protein	22	23179704-23318037	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010421, CAB018545, HPA038337	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.15e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 47.0	Expressed in all		
OR10H1		ENSG00000186723	Olfactory receptor family 10 subfamily H member 1	19	15807003-15808126	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			urinary bladder: 0.7	Cell line enriched	6	RT4: 2.9
MPPED1	239AB, C22orf1, FAM1A	ENSG00000186732	Metallophosphoesterase domain containing 1	22	43411196-43507848	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	9	cerebral cortex: 39.4	liver: 4.2	Cell line enhanced		HaCaT: 5.9;SCLC-21H: 3.1
FSCN2	RFSN, RP30	ENSG00000186765	Fascin actin-bundling protein 2, retinal	17	81528396-81537130	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		parathyroid gland: 4.3;thyroid gland: 2.9	fallopian tube,stomach: 0.8	Cell line enhanced		EFO-21: 1.8;T-47d: 1.9
FOXI2	FLJ46831	ENSG00000186766	Forkhead box I2	10	127737235-127741186	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:4.23e-7 (favourable)	Tissue enriched	Tissue enhanced		cervix, uterine: 2.6	kidney: 1.6	Not detected		
SPIN4	FLJ44984, TDRD28	ENSG00000186767	Spindlin family member 4	X	63347228-63351344	Predicted intracellular proteins	Evidence at protein level	HPA044559	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:3.56e-6 (unfavourable)	Expressed in all	Mixed			placenta: 6.3	Mixed		
ZNF732	FLJ59067	ENSG00000186777	Zinc finger protein 732	4	270675-305321	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 2.6	skin: 0.8	Cell line enhanced		NTERA-2: 7.2;SH-SY5Y: 1.7
SPIN2B	SPIN-2, TDRD26	ENSG00000186787	Spindlin family member 2B	X	57118551-57121546	Predicted intracellular proteins	Evidence at transcript level	HPA000162, HPA069835	Uncertain		Approved	Nucleoplasm	Renal cancer:1.78e-5 (favourable), Pancreatic cancer:3.39e-4 (favourable), Ovarian cancer:3.43e-4 (favourable)	Expressed in all	Expressed in all			prostate: 18.0	Expressed in all		
SPATA31D3	FAM75D3, FLJ44082	ENSG00000186788	SPATA31 subfamily D member 3	9	81943586-81950038	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	78	testis: 7.8	all non-specific tissues: 0.0	Not detected		
FOXE3	FKHL12, FREAC8	ENSG00000186790	Forkhead box E3	1	47416072-47418052	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Not detected			testis: 0.5	Not detected		
HYAL3	LUCA-3, LUCA14, Minna14	ENSG00000186792	Hyaluronoglucosaminidase 3	3	50292831-50299468	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA049402	Uncertain				Urothelial cancer:2.12e-5 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.7	testis: 14.0	Expressed in all		
KCNK18	K2p18.1, TRESK, TRESK-2, TRESK2, TRIK	ENSG00000186795	Potassium two pore domain channel subfamily K member 18	10	117197489-117210299	Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA044739	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
IFNA10	IFN-alphaC	ENSG00000186803	Interferon alpha 10	9	21206181-21207143	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
VSIG10L		ENSG00000186806	V-set and immunoglobulin domain containing 10 like	19	51331536-51342124	Predicted membrane proteins	Evidence at protein level	HPA060453, HPA066745	Uncertain		Enhanced	Nucleus	Liver cancer:8.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 31.4;salivary gland: 9.2	skin: 5.9	Group enriched	6	Hep G2: 3.2;T-47d: 7.9
CXCR3	CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR	ENSG00000186810	C-X-C motif chemokine receptor 3	X	71615916-71618517	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA045942	Enhanced				Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 17.9	spleen: 8.7	Cell line enriched	13	RPMI-8226: 32.7
ZNF397	MGC13250, ZNF47, ZSCAN15	ENSG00000186812	Zinc finger protein 397	18	35241030-35267133	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026087	Uncertain		Approved	Nucleoli<br>Plasma membrane<br>Microtubules<br>Cytosol	Pancreatic cancer:9.44e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 30.8	Mixed		
ZSCAN30	ZNF397OS, ZNF917	ENSG00000186814	Zinc finger and SCAN domain containing 30	18	35251058-35290245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007289	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 26.4	Expressed in all		
TPCN1	FLJ20612, KIAA1169, TPC1	ENSG00000186815	Two pore segment channel 1	12	113221050-113298585	Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039757	Approved					Expressed in all	Expressed in all			thyroid gland: 53.5	Expressed in all		
LILRB4	CD85k, HM18, ILT3, LIR-5, LIR5	ENSG00000186818	Leukocyte immunoglobulin like receptor B4	19	54643889-54670359	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052807	Approved					Expressed in all	Tissue enhanced		appendix: 14.6;lymph node: 13.4	lung: 8.3	Cell line enriched	33	Karpas-707: 293.0
TNFRSF4	ACT35, CD134, OX40, TXGP1L	ENSG00000186827	TNF receptor superfamily member 4	1	1211326-1214138	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB016128	Enhanced				Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 9.7;appendix: 8.3	lymph node: 7.1	Group enriched	8	MOLT-4: 5.0;NB-4: 7.6
KRT16	NEPPK	ENSG00000186832	Keratin 16	17	41609778-41615899	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000136, HPA000539	Approved		Approved	Intermediate filaments	Pancreatic cancer:1.09e-5 (unfavourable)	Group enriched	Group enriched	6	esophagus: 477.8;tonsil: 102.4	seminal vesicle: 52.5	Cell line enriched	9	hTCEpi: 593.7
HEXIM1	CLP-1, EDG1, HIS1, MAQ1	ENSG00000186834	Hexamethylene bisacetamide inducible 1	17	45148502-45152101	Predicted intracellular proteins	Evidence at protein level	HPA008926, CAB011625	Supported		Enhanced	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			placenta: 36.2	Expressed in all		
SELENOV	SELV	ENSG00000186838	Selenoprotein V	19	39515113-39520686	Predicted intracellular proteins	Evidence at transcript level	HPA059274	Uncertain				Thyroid cancer:7.43e-4 (unfavourable)	Tissue enhanced	Group enriched	13	parathyroid gland: 1.8;testis: 5.5;thyroid gland: 2.1	cerebral cortex: 0.2	Not detected		
LCE1A	LEP1	ENSG00000186844	Late cornified envelope 1A	1	152827473-152827894	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	10	skin: 507.5	breast: 50.5	Not detected		
KRT14	EBS3, EBS4	ENSG00000186847	Keratin 14	17	41582279-41586921	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000134, HPA000452, HPA000539, HPA023040	Enhanced		Enhanced	Intermediate filaments	Breast cancer:2.66e-4 (favourable)	Group enriched	Tissue enriched	19	skin: 7943.3	breast: 421.8	Cell line enhanced		HaCaT: 3480.4;HBEC3-KT: 1395.9;hTCEpi: 1722.3;U-2197: 628.5
TRABD2A	C2orf89, TIKI1	ENSG00000186854	TraB domain containing 2A	2	84821650-84907008	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045817	Approved					Group enriched	Tissue enhanced		colon: 35.4;ovary: 30.7;rectum: 43.1	lymph node: 11.7	Cell line enhanced		BEWO: 38.1;HDLM-2: 29.0;hTEC/SVTERT24-B: 17.5;SiHa: 18.3
KRTAP17-1	KAP17.1	ENSG00000186860	Keratin associated protein 17-1	17	41314917-41315695	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium: 0.1	Group enriched	53	HDLM-2: 8.2;SCLC-21H: 6.3
PDZD7	bA108L7.8, DFNB57, FLJ23209, PDZK7	ENSG00000186862	PDZ domain containing 7	10	101007683-101031157	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		small intestine: 13.2	cerebral cortex: 8.9	Cell line enhanced		SCLC-21H: 16.1;THP-1: 10.8
POFUT2	C21orf80, FUT13, KIAA0958	ENSG00000186866	Protein O-fucosyltransferase 2	21	45263928-45287898	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044297	Uncertain				Renal cancer:8.66e-12 (unfavourable), Colorectal cancer:4.55e-7 (unfavourable), Liver cancer:2.78e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 24.3	Expressed in all		
QRFPR	GPR103	ENSG00000186867	Pyroglutamylated RFamide peptide receptor	4	121329312-121381059	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA014300	Uncertain				Renal cancer:3.09e-4 (favourable)	Tissue enriched	Not detected			heart muscle: 0.6	Cell line enhanced		HL-60: 2.6;hTERT-HME1: 3.2;RPTEC TERT1: 2.0;SCLC-21H: 2.0;U-2 OS: 4.7;WM-115: 2.5
MAPT	DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau	ENSG00000186868	Microtubule associated protein tau	17	45894382-46028334	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000151, HPA048895, HPA069524, HPA069570, CAB072344	Enhanced		Supported	Nuclear speckles<br>Plasma membrane		Group enriched	Tissue enriched	8	cerebral cortex: 116.2	skeletal muscle: 13.7	Cell line enhanced		HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
ERCC6L	FLJ20105, PICH, RAD26L	ENSG00000186871	ERCC excision repair 6 like, spindle assembly checkpoint helicase	X	72204657-72239047	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050492	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Breast cancer:1.80e-4 (unfavourable)	Tissue enhanced	Mixed			lymph node: 2.8	Mixed		
OR13F1		ENSG00000186881	Olfactory receptor family 13 subfamily F member 1	9	104504263-104505222	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM17	FLJ34583	ENSG00000186889	Transmembrane protein 17	2	62500221-62511894	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA018100	Uncertain		Approved	Actin filaments		Expressed in all	Mixed			testis: 8.2	Mixed		
TNFRSF18	AITR, CD357, GITR	ENSG00000186891	TNF receptor superfamily member 18	1	1203508-1206691	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008025	Approved				Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 43.3	parathyroid gland: 18.0	Group enriched	11	RPMI-8226: 148.8;SCLC-21H: 173.4
FGF3	HBGF-3, INT2	ENSG00000186895	Fibroblast growth factor 3	11	69810224-69819024	Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA012692	Approved	Approved				Group enriched	Not detected			all non-specific tissues: 0.0	Cell line enriched	89	CAPAN-2: 8.8
C1QL4	C1QTNF11, CTRP11	ENSG00000186897	Complement C1q like 4	12	49332411-49337188	Predicted secreted proteins	Evidence at transcript level						Renal cancer:3.03e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 2.1;thyroid gland: 1.2	cerebral cortex: 0.7	Cell line enhanced		AN3-CA: 32.7;U-2 OS: 9.6
RTN4RL2	NgR2, NGRH1	ENSG00000186907	Reticulon 4 receptor-like 2	11	57460549-57477534	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.05e-7 (unfavourable)	Expressed in all	Group enriched	6	cerebral cortex: 48.7;thyroid gland: 36.2	liver,parathyroid gland: 6.6	Cell line enhanced		HMC-1: 38.9;Karpas-707: 48.5;REH: 38.5;RPMI-8226: 93.4
ZDHHC17	HIP14, HYPH, KIAA0946	ENSG00000186908	Zinc finger DHHC-type containing 17	12	76763588-76853696	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA016807, HPA058674	Approved		Supported	Golgi apparatus<br>Vesicles<br>Aggresome	Renal cancer:7.11e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 45.2	Expressed in all		
SERPINA11		ENSG00000186910	Serpin family A member 11	14	94442464-94452790	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Endometrial cancer:6.30e-4 (favourable)	Tissue enriched	Tissue enriched	30	liver: 255.9	cervix, uterine: 8.6	Cell line enriched	8	Hep G2: 11.7
P2RY4	NRU, P2P, P2Y4, UNR	ENSG00000186912	Pyrimidinergic receptor P2Y4	X	70258170-70259764	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022644	Uncertain					Not detected	Tissue enriched	5	small intestine: 3.1	rectum,skin: 0.6	Not detected		
ZNF395	DKFZp434K1210, HDBP2, PBF, PRF-1	ENSG00000186918	Zinc finger protein 395	8	28345585-28402701	Predicted intracellular proteins	Evidence at protein level	HPA049382			Approved	Nucleus<br>Cytosol	Renal cancer:5.71e-5 (unfavourable), Liver cancer:1.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 67.0	Expressed in all		
ZACN	L2, LGICZ, LGICZ1, ZAC, ZAC1	ENSG00000186919	Zinc activated ion channel	17	76071961-76083666	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP22-1	KAP22.1	ENSG00000186924	Keratin associated protein 22-1	21	30601087-30601382	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-6	KAP19.6	ENSG00000186925	Keratin associated protein 19-6	21	30541535-30541864	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP6-2	KAP6.2	ENSG00000186930	Keratin associated protein 6-2	21	30598590-30598902	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR13C8		ENSG00000186943	Olfactory receptor family 13 subfamily C member 8	9	104569168-104570130	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PPARA	hPPAR, NR1C1, PPAR	ENSG00000186951	Peroxisome proliferator activated receptor alpha	22	46150521-46243756	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058901, HPA067049, CAB075701	Supported		Enhanced	Nucleus	Renal cancer:4.39e-9 (favourable)	Expressed in all	Expressed in all			kidney: 24.2	Mixed		
TMEM232	FLJ43080	ENSG00000186952	Transmembrane protein 232	5	110289233-110738956	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049386	Uncertain					Not detected	Tissue enhanced		fallopian tube: 26.4;testis: 35.5	thyroid gland: 7.3	Cell line enhanced		U-266/70: 2.1
KRTAP19-2	KAP19.2	ENSG00000186965	Keratin associated protein 19-2	21	30487057-30487436	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP19-4	KAP19.4	ENSG00000186967	Keratin associated protein 19-4	21	30496824-30497133	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP15-1	KAP15.1	ENSG00000186970	Keratin associated protein 15-1	21	30440275-30440945	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP13-4	KAP13.4	ENSG00000186971	Keratin associated protein 13-4	21	30430230-30431026	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			adrenal gland,parathyroid gland: 0.2	Not detected		
FAM183A	hCG23177, LOC440585	ENSG00000186973	Family with sequence similarity 183 member A	1	43145153-43156396	Predicted intracellular proteins	Evidence at transcript level	HPA043382, HPA049120	Approved					Tissue enhanced	Tissue enriched	14	fallopian tube: 154.3	skin: 11.3	Cell line enhanced		CAPAN-2: 3.1;hTCEpi: 1.8;NTERA-2: 3.1;SCLC-21H: 3.1
EFCAB6	dJ185D5.1, DJBP, FLJ23588, HSCBCIP1, KIAA1672	ENSG00000186976	EF-hand calcium binding domain 6	22	43528744-43812337	Predicted intracellular proteins	Evidence at protein level	HPA003098			Uncertain	Nucleoplasm		Mixed	Group enriched	5	fallopian tube: 12.3;testis: 44.2	thyroid gland: 5.1	Mixed		
KRTAP19-5	KAP19.5	ENSG00000186977	Keratin associated protein 19-5	21	30501657-30502117	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	5	HEK 293: 4.3
KRTAP23-1	KAP23.1	ENSG00000186980	Keratin associated protein 23-1	21	30348399-30348609	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KANK3	ANKRD47, FLJ46061	ENSG00000186994	KN motif and ankyrin repeat domains 3	19	8322584-8343262	Predicted intracellular proteins	Evidence at protein level	HPA051153	Approved		Approved	Plasma membrane	Renal cancer:1.69e-5 (favourable)	Expressed in all	Tissue enhanced		spleen: 24.9	adipose tissue: 22.2	Cell line enhanced		HUVEC TERT2: 6.8;TIME: 12.1;U-266/70: 4.5
EMID1	EMI5, EMU1, hEmu1	ENSG00000186998	EMI domain containing 1	22	29205851-29259597	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA000592	Uncertain					Expressed in all	Mixed			spleen: 30.6	Cell line enhanced		HEL: 25.7;NB-4: 63.2
ACTL7A		ENSG00000187003	Actin like 7A	9	108862266-108863759	Predicted intracellular proteins	Evidence at protein level	HPA021624	Enhanced					Not detected	Tissue enriched	1938	testis: 193.7	all non-specific tissues: 0.0	Not detected		
KRTAP21-1	KAP21.1	ENSG00000187005	Keratin associated protein 21-1	21	30754830-30755428	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	breast: 13.5;testis: 6.0	seminal vesicle: 1.3	Cell line enhanced		SK-MEL-30: 1.2
RHD	CD240D, DIIIc, RH, Rh30a, Rh4, RhII, RhPI	ENSG00000187010	Rh blood group D antigen	1	25272393-25330445	Blood group antigen proteins, CD markers, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		bone marrow: 9.2	skin: 2.5	Group enriched	5	HEL: 33.3;K-562: 10.3
ESPN	DFNB36	ENSG00000187017	Espin	1	6424788-6461370	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA028674, HPA060220	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		skin: 96.5;testis: 118.3	small intestine: 77.3	Cell line enhanced		BEWO: 42.8;SK-BR-3: 110.9;T-47d: 47.8
PNLIPRP1	PLRP1	ENSG00000187021	Pancreatic lipase related protein 1	10	116590385-116609175	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	373	pancreas: 2295.1	ovary: 6.1	Not detected		
PTRH1	C9orf115, PTH1	ENSG00000187024	Peptidyl-tRNA hydrolase 1 homolog	9	127692978-127724873	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA021223	Uncertain					Not detected	Expressed in all			adipose tissue: 11.1	Expressed in all		
KRTAP21-2	KAP21.2	ENSG00000187026	Keratin associated protein 21-2	21	30746794-30747233	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	20	skin: 1.1;testis: 2.9	all non-specific tissues: 0.0	Cell line enriched	12	HEK 293: 1.7
SAMD7	DKFZp686E1583	ENSG00000187033	Sterile alpha motif domain containing 7	3	169911572-169939175	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			lymph node,testis: 0.2	Not detected		
GPR141	PGR13	ENSG00000187037	G protein-coupled receptor 141	7	37683796-37833788	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		bone marrow: 18.5	appendix: 5.6	Cell line enhanced		HEL: 11.8;HMC-1: 43.8;NTERA-2: 27.0;U-937: 17.1
TMPRSS6	FLJ30744	ENSG00000187045	Transmembrane protease, serine 6	22	37065436-37109563	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Liver cancer:8.16e-6 (favourable)	Group enriched	Group enriched	6	liver: 40.8;testis: 8.6	stomach: 4.0	Cell line enhanced		Hep G2: 3.6;SCLC-21H: 10.1
CYP4A11	CYP4A2, CYP4AII	ENSG00000187048	Cytochrome P450 family 4 subfamily A member 11	1	46929177-46941484	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	183	kidney: 232.3;liver: 448.3	gallbladder: 1.8	Not detected		
TMEM216	CORS2, HSPC244, JBTS2, MGC13379, MKS2	ENSG00000187049	Transmembrane protein 216	11	61391687-61398863	Disease related genes, Predicted membrane proteins	Evidence at protein level							Expressed in all	Mixed			ovary: 32.4	Mixed		
RPS19BP1	FLJ21770, MGC52010	ENSG00000187051	Ribosomal protein S19 binding protein 1	22	39529093-39532855	Predicted intracellular proteins	Evidence at protein level	HPA042874	Uncertain		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:3.71e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 57.2	Expressed in all		
TMPRSS11A	ECRG1	ENSG00000187054	Transmembrane protease, serine 11A	4	67909385-67964140	Enzymes, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	64	esophagus: 96.0;tonsil: 26.0	cervix, uterine: 0.9	Not detected		
TMEM262		ENSG00000187066	Transmembrane protein 262	11	65084979-65089375	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	57	testis: 13.6	cervix, uterine: 0.2	Not detected		
C3orf70		ENSG00000187068	Chromosome 3 open reading frame 70	3	185078050-185153014	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041861	Uncertain		Approved	Cytosol	Renal cancer:6.40e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		smooth muscle: 26.0	cerebral cortex: 19.1	Cell line enhanced		SCLC-21H: 23.4;SK-BR-3: 6.5;WM-115: 10.7
TEAD1	AA, TCF13, TEF-1	ENSG00000187079	TEA domain transcription factor 1	11	12674591-12944483	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057339, HPA062471			Enhanced	Nucleoplasm		Expressed in all	Mixed			parathyroid gland: 88.3	Mixed		
OR2AK2	OR2AK1P	ENSG00000187080	Olfactory receptor family 2 subfamily AK member 2	1	247965233-247966386	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052544	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
DEFB106B		ENSG00000187082	Defensin beta 106B	8	7482504-7486400	Predicted secreted proteins	Evidence at protein level	HPA045592	Supported					Not detected	Tissue enriched	18221	epididymis: 2094.6	esophagus: 0.1	Cell line enriched	13	NB-4: 1.3
PLCD1		ENSG00000187091	Phospholipase C delta 1	3	38007496-38029762	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009913, HPA020107, HPA021677	Approved		Approved	Microtubules	Renal cancer:9.25e-11 (favourable)	Expressed in all	Mixed			testis: 38.3	Mixed		
CCK		ENSG00000187094	Cholecystokinin	3	42257825-42266207	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045039, HPA069515	Enhanced	Supported				Group enriched	Group enriched	5	cerebral cortex: 133.7;duodenum: 116.2;prostate: 31.6	small intestine: 17.7	Group enriched	6	CAPAN-2: 8.5;RPTEC TERT1: 18.9
ENTPD5	CD39L4, NTPDase-5, PCPH	ENSG00000187097	Ectonucleoside triphosphate diphosphohydrolase 5	14	73958010-74019399	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002927	Enhanced		Approved	Cytosol	Renal cancer:3.95e-5 (favourable)	Expressed in all	Tissue enhanced		liver: 130.4	rectum: 111.3	Expressed in all		
MITF	bHLHe32, MI, WS2, WS2A	ENSG00000187098	Melanogenesis associated transcription factor	3	69739435-69968337	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002578, HPA003259	Enhanced				Renal cancer:8.35e-10 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 80.9;endometrium: 79.3	smooth muscle: 69.5	Cell line enhanced		HMC-1: 78.7;SK-MEL-30: 205.7
HEATR4	MGC48595	ENSG00000187105	HEAT repeat containing 4	14	73478484-73558947	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	7	skin: 4.4;testis: 21.6	duodenum,lymph node: 1.9	Cell line enhanced		SCLC-21H: 2.9
NAP1L1	MGC23410, MGC8688, NAP1, NAP1L, NRP	ENSG00000187109	Nucleosome assembly protein 1 like 1	12	76036587-76085033	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA028861	Approved		Uncertain	Microtubules	Renal cancer:6.14e-13 (unfavourable), Liver cancer:3.29e-9 (unfavourable)	Expressed in all	Expressed in all			ovary: 742.4	Expressed in all		
LILRA5	CD85, CD85f, ILT11, LILRB7, LIR9	ENSG00000187116	Leukocyte immunoglobulin like receptor A5	19	54307070-54313139	CD markers, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.78e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 13.9;bone marrow: 10.3;spleen: 7.5	urinary bladder: 2.4	Not detected		
CMC1	C3orf68, MGC61571	ENSG00000187118	C-X9-C motif containing 1	3	28241584-28325142	Predicted intracellular proteins	Evidence at protein level	HPA043333	Approved				Urothelial cancer:5.52e-4 (favourable), Renal cancer:6.81e-4 (favourable)	Expressed in all	Expressed in all			kidney: 33.5	Expressed in all		
SLIT1	MEGF4, SLIL1, Slit-1, slit1, SLIT3	ENSG00000187122	Slit guidance ligand 1	10	96998038-97185920	Predicted secreted proteins	Evidence at protein level	HPA006879			Approved	Plasma membrane		Group enriched	Tissue enriched	14	cerebral cortex: 60.0	thyroid gland: 4.2	Cell line enriched	11	MOLT-4: 64.7
LYPD6	MGC52057	ENSG00000187123	LY6/PLAUR domain containing 6	2	149329985-149474148	Predicted secreted proteins	Evidence at protein level	HPA042805	Uncertain		Approved	Cytosol	Urothelial cancer:2.72e-4 (favourable), Ovarian cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 17.3;placenta: 22.5	breast: 12.0	Cell line enhanced		AN3-CA: 33.5;fHDF/TERT166: 36.6;LHCN-M2: 38.4;RT4: 30.7
AKR1C1	DD1, DDH, DDH1, HAKRC, MBAB	ENSG00000187134	Aldo-keto reductase family 1 member C1	10	4963253-4983283	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB047303, HPA068265	Uncertain		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:8.03e-9 (favourable), Liver cancer:1.56e-4 (unfavourable), Cervical cancer:3.05e-4 (favourable)	Tissue enhanced	Expressed in all			liver: 322.2	Group enriched	7	ASC diff: 2051.8;Hep G2: 3675.4
VSTM2B		ENSG00000187135	V-set and transmembrane domain containing 2B	19	29526499-29564479	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	20	cerebral cortex: 42.3	cervix, uterine: 2.1	Group enriched	7	SCLC-21H: 1.3;SK-MEL-30: 6.2
FOXD3	Genesis, HFH2	ENSG00000187140	Forkhead box D3	1	63323041-63325126	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022455	Uncertain					Group enriched	Mixed			testis: 1.0	Cell line enhanced		NTERA-2: 14.7;SK-MEL-30: 9.4;WM-115: 18.2
SPATA21	spergen-2, spergen2	ENSG00000187144	Spermatogenesis associated 21	1	16387117-16437424	Predicted intracellular proteins	Evidence at transcript level	HPA032080			Approved	Vesicles<br>Cytosol		Not detected	Tissue enriched	13	testis: 8.0	skin: 0.6	Cell line enriched	7	Hep G2: 3.7
RNF220	C1orf164, FLJ10597	ENSG00000187147	Ring finger protein 220	1	44405194-44651724	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA027577, HPA027578	Uncertain		Approved	Nucleus	Liver cancer:2.35e-6 (unfavourable), Renal cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 47.8	Expressed in all		
ANGPTL5		ENSG00000187151	Angiopoietin like 5	11	101890674-101916522	Predicted secreted proteins	Evidence at protein level	HPA038516	Uncertain					Not detected	Tissue enhanced		ovary: 27.1	breast: 7.2	Cell line enhanced		ASC diff: 1.8
SHTN1	KIAA1598, shootin-1, shootin1	ENSG00000187164	Shootin 1	10	116881482-117126586	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037942, HPA037943	Enhanced	Approved	Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.1	parathyroid gland: 18.7	Mixed		
H1FNT	H1T2, HANP1	ENSG00000187166	H1 histone family member N, testis specific	12	48328980-48330279	Predicted intracellular proteins	Evidence at protein level	HPA046204	Approved					Not detected	Tissue enriched	350	testis: 77.1	cerebral cortex: 0.2	Not detected		
LCE4A	LEP8, SPRL4A	ENSG00000187170	Late cornified envelope 4A	1	152708160-152709491	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	skin: 5.1	breast: 0.8	Not detected		
LCE2A	LEP9	ENSG00000187173	Late cornified envelope 2A	1	152698364-152699442	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	13	skin: 146.6	breast: 11.5	Cell line enhanced		BJ hTERT+: 4.7;SK-MEL-30: 1.6;U-138 MG: 1.0;U-2197: 1.3
KRTAP12-1	KAP12.1, KRTAP12.1	ENSG00000187175	Keratin associated protein 12-1	21	44681576-44682163	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			parathyroid gland,skin: 0.1	Not detected		
LCE2C	LEP11	ENSG00000187180	Late cornified envelope 2C	1	152675295-152676574	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	10	skin: 283.4	breast: 29.7	Not detected		
RP11-195F19.5		ENSG00000187186		9	34664163-34666112	Predicted intracellular proteins	Evidence at protein level	HPA069617	Enhanced		Approved	Nucleoli<br>Endoplasmic reticulum<br>Vesicles	Glioma:5.81e-5 (unfavourable)	Mixed	Tissue enriched	5	testis: 138.9	cerebral cortex: 25.6	Cell line enhanced		HeLa: 31.7
ZNF546	MGC43537, ZNF49	ENSG00000187187	Zinc finger protein 546	19	39984134-40021041	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030838			Approved	Nucleus<br>Cytosol		Mixed	Tissue enhanced		testis: 14.4	parathyroid gland,thyroid gland: 3.2	Mixed		
TSPYL4	dJ486I3.2, KIAA0721	ENSG00000187189	TSPY like 4	6	116249961-116254140	Predicted intracellular proteins	Evidence at protein level	HPA044863	Approved				Renal cancer:5.13e-7 (favourable), Pancreatic cancer:8.46e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 120.8	Mixed		
DAZ3		ENSG00000187191	Deleted in azoospermia 3	Y	24763069-24813492	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Tissue enriched	11	testis: 1.0	all non-specific tissues: 0.0	Not detected		
MT1X	MT-1l, MT1	ENSG00000187193	Metallothionein 1X	16	56682424-56684196	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.82e-10 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 1347.9	Expressed in all		
GCNT1	C2GNT, NACGT2, NAGCT2	ENSG00000187210	Glucosaminyl (N-acetyl) transferase 1, core 2	9	76419850-76507416	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003522, HPA003523, HPA031151	Uncertain		Supported	Nuclear speckles	Urothelial cancer:4.96e-4 (unfavourable), Endometrial cancer:8.44e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 186.4	duodenum: 50.1	Cell line enhanced		HHSteC: 38.9
LCE2D	LEP12, SPRL1A	ENSG00000187223	Late cornified envelope 2D	1	152663396-152664659	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	14	skin: 136.2	breast: 9.9	Not detected		
SESTD1	DKFZp434O0515, Solo	ENSG00000187231	SEC14 and spectrin domain containing 1	2	179101692-179264790	Predicted intracellular proteins	Evidence at protein level	HPA058236, HPA077408			Enhanced	Intermediate filaments	Renal cancer:2.78e-11 (favourable), Liver cancer:1.88e-4 (unfavourable), Stomach cancer:2.67e-4 (unfavourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
LCE3B	LEP14	ENSG00000187238	Late cornified envelope 3B	1	152613811-152614098	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	tonsil: 2.8	all non-specific tissues: 0.0	Not detected		
FNBP1	FBP17, KIAA0554	ENSG00000187239	Formin binding protein 1	9	129887187-130043194	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019635, HPA019691, HPA022119	Enhanced				Renal cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 90.7	Mixed		
DYNC2H1	DHC1b, DHC2, DNCH2, DYH1B, hdhc11	ENSG00000187240	Dynein cytoplasmic 2 heavy chain 1	11	103109431-103479863	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA039015, HPA039016	Approved		Supported	Mitochondria	Renal cancer:8.49e-5 (favourable)	Mixed	Mixed			parathyroid gland: 17.4	Mixed		
KRT12	K12	ENSG00000187242	Keratin 12	17	40861303-40867210	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055217, HPA055835	Enhanced					Mixed	Not detected			small intestine: 0.7	Not detected		
MAGED4B		ENSG00000187243	MAGE family member D4B	X	52061827-52069248	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003554	Approved					Not detected	Tissue enhanced		cerebral cortex: 35.1	endometrium: 13.8	Cell line enhanced		AF22: 48.8;NTERA-2: 40.6
BCAM	CD239, LU	ENSG00000187244	Basal cell adhesion molecule (Lutheran blood group)	19	44809059-44821420	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA005654	Uncertain		Approved	Nucleoli fibrillar center	Renal cancer:5.94e-6 (favourable), Endometrial cancer:1.24e-5 (unfavourable), Colorectal cancer:2.31e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 174.7	Cell line enhanced		HaCaT: 278.4;SK-BR-3: 217.2;T-47d: 152.4
RSBN1L	FLJ42526, FLJ45813, MGC71764	ENSG00000187257	Round spermatid basic protein 1 like	7	77696443-77783022	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA020406, HPA020413	Approved		Supported	Nuclear speckles<br>Plasma membrane	Lung cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
NPSR1	GPR154, GPRA, PGR14	ENSG00000187258	Neuropeptide S receptor 1	7	34658239-34878332	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA007489	Supported					Tissue enhanced	Not detected			stomach: 0.5	Cell line enhanced		HAP1: 1.1
WDR86		ENSG00000187260	WD repeat domain 86	7	151375909-151410727	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		parathyroid gland: 20.9;spleen: 14.3	endometrium: 7.5	Group enriched	5	HSkMC: 9.9;NTERA-2: 2.6;SCLC-21H: 6.9;SH-SY5Y: 4.4
EPOR		ENSG00000187266	Erythropoietin receptor	19	11377205-11384342	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA077613			Supported	Vesicles	Pancreatic cancer:3.17e-5 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 53.1	thyroid gland: 18.0	Mixed		
FAM9C	TEX39C	ENSG00000187268	Family with sequence similarity 9 member C	X	13035618-13044682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	7	spleen: 54.4	testis: 8.1	Cell line enriched	56	AN3-CA: 169.6
KRTAP9-8	KAP9.8	ENSG00000187272	Keratin associated protein 9-8	17	41238045-41239004	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	15	HDLM-2: 1.5
CIDEC	CIDE-3, FLJ20871, Fsp27	ENSG00000187288	Cell death inducing DFFA like effector c	3	9866711-9880254	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018837, HPA020553	Approved					Mixed	Tissue enriched	8	adipose tissue: 761.8	small intestine: 99.2	Cell line enhanced		ASC diff: 1149.6;ASC TERT1: 262.9;HSkMC: 164.2
DCC	IGDCC1, NTN1R1	ENSG00000187323	DCC netrin 1 receptor	18	52340172-53535903	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055376, HPA069552	Supported		Supported	Golgi apparatus		Tissue enhanced	Tissue enhanced		cerebral cortex: 3.7;testis: 13.5	lung: 2.2	Cell line enhanced		AF22: 36.0;U-266/70: 85.8;U-266/84: 39.7
TAF9B	DN-7, DN7, TAF9L, TAFII31L, TFIID-31	ENSG00000187325	TATA-box binding protein associated factor 9b	X	78129748-78139706	Predicted intracellular proteins	Evidence at protein level	HPA045275	Approved				Cervical cancer:5.40e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 43.8	Expressed in all		
PCDHB13	PCDH-BETA13	ENSG00000187372	Protocadherin beta 13	5	141213919-141218979	Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			endometrium,gallbladder: 2.5	Cell line enhanced		EFO-21: 6.9;T-47d: 13.5;U-2197: 10.8
MAGI2	ACVRIP1, AIP1, ARIP1, KIAA0705, MAGI-2	ENSG00000187391	Membrane associated guanylate kinase, WW and PDZ domain containing 2	7	78017057-79453574	Predicted intracellular proteins	Evidence at protein level	HPA013650	Approved				Renal cancer:1.08e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 46.2;parathyroid gland: 38.6	prostate: 14.0	Group enriched	5	AF22: 19.3;Karpas-707: 58.7
LUZP2		ENSG00000187398	Leucine zipper protein 2	11	24496970-25082631	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039007, HPA046161	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	5	adrenal gland: 8.6;cerebral cortex: 33.0	prostate: 3.8	Group enriched	6	HaCaT: 9.2;HAP1: 5.4
LHFPL3	LHFPL4	ENSG00000187416	Lipoma HMGIC fusion partner-like 3	7	104328656-104907232	Predicted membrane proteins	Evidence at transcript level	HPA069691			Approved	Vesicles		Tissue enriched	Tissue enriched	10	cerebral cortex: 48.7	cervix, uterine: 4.6	Cell line enhanced		SCLC-21H: 1.8;SH-SY5Y: 2.1;SK-BR-3: 1.3
CHP1	CHP, p22, p24, Sid470p, SLC9A1BP	ENSG00000187446	Calcineurin like EF-hand protein 1	15	41230839-41281890	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006616	Approved		Approved	Vesicles	Renal cancer:2.79e-6 (favourable), Liver cancer:4.07e-6 (favourable), Endometrial cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			colon: 110.9	Expressed in all		
FPR3	FMLPY, FPRH1, FPRL2, RMLP-R-I	ENSG00000187474	Formyl peptide receptor 3	19	51795163-51826189	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level						Testis cancer:9.13e-4 (unfavourable)	Expressed in all	Mixed			lung: 41.2	Cell line enriched	9	HEL: 9.0
HIST1H1T	H1FT, H1t	ENSG00000187475	Histone cluster 1 H1 family member t	6	26107419-26108136	Predicted intracellular proteins	Evidence at protein level	HPA065718, HPA068266	Enhanced					Not detected	Tissue enriched	8	testis: 1.4	appendix,breast,prostate: 0.1	Not detected		
C11orf96	AG2	ENSG00000187479	Chromosome 11 open reading frame 96	11	43925342-43944338	Predicted intracellular proteins	Evidence at protein level	HPA038843	Uncertain		Approved	Nucleus<br>Focal adhesion sites<br>Cytosol	Renal cancer:2.34e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 163.5	Cell line enriched	12	SH-SY5Y: 199.2
KCNJ11	BIR, Kir6.2	ENSG00000187486	Potassium voltage-gated channel subfamily J member 11	11	17385859-17389331	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA048891	Approved				Renal cancer:1.56e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 32.7	cerebral cortex: 10.2	Cell line enhanced		HEK 293: 12.0;MCF7: 8.2;SCLC-21H: 10.3
CDHR4	CDH29, VLLR9392	ENSG00000187492	Cadherin related family member 4	3	49790732-49799835	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA076277	Enhanced					Tissue enriched	Tissue enriched	9	fallopian tube: 105.0	lung: 11.4	Cell line enhanced		ASC TERT1: 1.0
COL4A1		ENSG00000187498	Collagen type IV alpha 1 chain	13	110148963-110307149	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001695, HPA054039	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:1.30e-7 (unfavourable), Cervical cancer:4.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 1237.0	smooth muscle: 436.3	Cell line enhanced		ASC diff: 355.1;EFO-21: 845.9
PLEKHG7	FLJ46688	ENSG00000187510	Pleckstrin homology and RhoGEF domain containing G7	12	92721462-92772455	Predicted intracellular proteins	Evidence at transcript level	HPA060632	Uncertain					Mixed	Tissue enhanced		epididymis: 3.6;fallopian tube: 4.3	cervix, uterine: 2.6	Cell line enhanced		RPMI-8226: 1.1
GJA4	CX37	ENSG00000187513	Gap junction protein alpha 4	1	34792998-34795747	Predicted membrane proteins, Transporters	Evidence at protein level	HPA047981	Approved				Liver cancer:3.28e-4 (favourable), Renal cancer:7.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 89.3	fallopian tube: 48.2	Cell line enriched	8	EFO-21: 70.4
PTMA	TMSA	ENSG00000187514	Prothymosin, alpha	2	231706895-231713541	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047183, HPA052651	Approved		Enhanced	Nucleus<br>Cytosol	Renal cancer:1.99e-7 (unfavourable), Liver cancer:3.61e-4 (unfavourable), Cervical cancer:6.56e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 1620.2	Expressed in all		
HYPM	CXorf27, HIP17	ENSG00000187516	Huntingtin interacting protein M	X	37990817-37991317	Predicted intracellular proteins	Evidence at protein level	HPA003356	Supported					Not detected	Tissue enriched	153	testis: 50.1	skin: 0.3	Not detected		
HSPA14	HSP70-4, HSP70L1	ENSG00000187522	Heat shock protein family A (Hsp70) member 14	10	14838164-14871741	Predicted intracellular proteins	Evidence at protein level	HPA046180	Approved				Liver cancer:3.70e-8 (unfavourable), Renal cancer:1.09e-5 (unfavourable), Head and neck cancer:5.73e-4 (favourable), Ovarian cancer:9.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.5	Expressed in all		
ATP13A5	FLJ16025	ENSG00000187527	ATPase 13A5	3	193274790-193378843	Predicted membrane proteins	Evidence at transcript level	HPA031771, HPA031774	Uncertain					Tissue enhanced	Tissue enhanced		breast: 17.7	salivary gland: 3.9	Cell line enhanced		SK-BR-3: 1.2
SIRT7		ENSG00000187531	Sirtuin 7	17	81911939-81921323	Predicted intracellular proteins	Evidence at protein level	CAB037261, HPA053669	Enhanced		Supported	Nucleoli fibrillar center<br>Vesicles	Renal cancer:1.69e-7 (unfavourable), Liver cancer:1.97e-5 (unfavourable)	Expressed in all	Mixed			esophagus: 21.6	Expressed in all		
PRR27	C4orf40	ENSG00000187533	Proline rich 27	4	70133616-70176799	Predicted secreted proteins	Evidence at protein level	HPA036150, HPA036151	Enhanced					Tissue enriched	Tissue enriched	1077	salivary gland: 402.8	ovary: 0.3	Not detected		
IFT140	gs114, KIAA0590, WDTC2	ENSG00000187535	Intraflagellar transport 140	16	1510427-1612110	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042197	Approved					Expressed in all	Mixed			fallopian tube: 23.9	Mixed		
POTEG	A26C2, CT104.4, POTE-14, POTE14, POTE14alpha	ENSG00000187537	POTE ankyrin domain family member G	14	19402486-19434341	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Tissue enhanced	Tissue enhanced		prostate: 3.5	testis: 0.7	Not detected		
PRAMEF10		ENSG00000187545	PRAME family member 10	1	12892896-12898270	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	12	liver: 1.1	all non-specific tissues: 0.0	Not detected		
AGMO	FLJ16237, TMEM195	ENSG00000187546	Alkylglycerol monooxygenase	7	15200318-15562015	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057900			Uncertain	Vesicles		Tissue enriched	Tissue enhanced		liver: 63.7	epididymis: 17.6	Cell line enhanced		Karpas-707: 5.6;SCLC-21H: 3.8;WM-115: 15.2
SBK2	SGK069	ENSG00000187550	SH3 domain binding kinase family member 2	19	55529733-55537089	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA030631	Uncertain					Tissue enhanced	Tissue enriched	30	heart muscle: 24.2	testis: 0.8	Group enriched	5	A549: 2.5;Hep G2: 1.4;MCF7: 2.2;NTERA-2: 5.5;RH-30: 4.9;U-2 OS: 3.1
CYP26C1		ENSG00000187553	Cytochrome P450 family 26 subfamily C member 1	10	93060808-93069536	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			spleen: 0.2	Not detected		
TLR5	FLJ10052, MGC126430, MGC126431, SLEB1, TIL3	ENSG00000187554	Toll like receptor 5	1	223109406-223143282	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009013			Approved	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:4.95e-4 (unfavourable)	Mixed	Mixed			ovary: 25.2	Cell line enhanced		A-431: 1.9;HaCaT: 3.3;T-47d: 2.2
USP7	HAUSP	ENSG00000187555	Ubiquitin specific peptidase 7	16	8892094-8964514	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008108, HPA015641	Approved				Renal cancer:8.56e-5 (favourable)	Expressed in all	Expressed in all			testis: 109.1	Expressed in all		
NANOS3	NANOS1L, NOS3, ZC2HC12C	ENSG00000187556	Nanos C2HC-type zinc finger 3	19	13862063-13880757	Predicted intracellular proteins	Evidence at protein level	HPA062989	Enhanced					Tissue enriched	Tissue enriched	6	testis: 7.0	cerebral cortex: 1.1	Not detected		
FOXD4L3	FOXD6	ENSG00000187559	Forkhead box D4-like 3	9	68302867-68304905	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			spleen: 0.3	Not detected		
NHLRC1	bA204B7.2, EPM2B, malin	ENSG00000187566	NHL repeat containing E3 ubiquitin protein ligase 1	6	18120440-18122687	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA066030			Uncertain	Vesicles	Urothelial cancer:5.30e-4 (favourable), Endometrial cancer:9.01e-4 (unfavourable)	Expressed in all	Mixed			skin: 4.5	Cell line enhanced		EFO-21: 6.4;SCLC-21H: 7.2
DPPA3	Stella	ENSG00000187569	Developmental pluripotency associated 3	12	7711454-7717559	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 1.3	lung: 0.6	Group enriched	248	BEWO: 334.2;NTERA-2: 146.4
COX8C	COX8-3	ENSG00000187581	Cytochrome c oxidase subunit 8C	14	93347191-93348356	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003127	Approved					Group enriched	Tissue enriched	51	testis: 29.7	fallopian tube: 0.5	Cell line enriched	7	U-937: 11.3
PLEKHN1	DKFZP434H2010	ENSG00000187583	Pleckstrin homology domain containing N1	1	966497-975865	Predicted intracellular proteins	Evidence at protein level	HPA031742	Uncertain		Approved	Nuclear speckles	Renal cancer:4.97e-5 (unfavourable)	Mixed	Group enriched	11	esophagus: 16.9;skin: 44.0	urinary bladder: 2.7	Cell line enhanced		HaCaT: 22.0
ZNF385C		ENSG00000187595	Zinc finger protein 385C	17	42025576-42098479	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 8.9	ovary: 2.0	Cell line enhanced		HDLM-2: 1.7;MOLT-4: 2.6;SCLC-21H: 3.0
TMEM247		ENSG00000187600	Transmembrane protein 247	2	46429190-46484425	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	26	testis: 35.7	placenta: 1.3	Cell line enriched	13	U-266/84: 1.5
MAGEH1	APR1	ENSG00000187601	MAGE family member H1	X	55452105-55453566	Predicted membrane proteins	Evidence at protein level	HPA011324	Uncertain		Approved	Nucleoli	Endometrial cancer:1.37e-4 (unfavourable), Pancreatic cancer:2.60e-4 (favourable)	Expressed in all	Tissue enriched	5	epididymis: 616.6	cerebral cortex: 115.7	Mixed		
TET3	hCG_40738, MGC22014	ENSG00000187605	Tet methylcytosine dioxygenase 3	2	73986404-74108176	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050845	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:3.58e-5 (unfavourable)	Expressed in all	Mixed			skin: 17.9	Mixed		
ZNF286A	KIAA1874, ZNF286	ENSG00000187607	Zinc finger protein 286A	17	15699577-15720787	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021594			Approved	Nucleoli		Mixed	Mixed			ovary: 21.8	Mixed		
ISG15	G1P2, IFI15, UCRP	ENSG00000187608	ISG15 ubiquitin-like modifier	1	1001138-1014541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004627	Approved				Renal cancer:5.11e-10 (unfavourable)	Expressed in all	Expressed in all			salivary gland: 112.8	Expressed in all		
EXD3	FLJ20433, LOC54932, mut-7	ENSG00000187609	Exonuclease 3'-5' domain containing 3	9	137306896-137423262	Predicted intracellular proteins	Evidence at protein level	HPA047395	Approved		Approved	Actin filaments<br>Focal adhesion sites	Endometrial cancer:4.30e-4 (favourable)	Expressed in all	Mixed			small intestine,spleen: 10.0	Mixed		
OR5W2	OR5W2P, OR5W3P	ENSG00000187612	Olfactory receptor family 5 subfamily W member 2	11	55913650-55914582	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM8C	TMEM226	ENSG00000187616	Transmembrane protein 8C	9	133514586-133528612	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA051846, HPA055785	Uncertain					Not detected	Not detected			cerebral cortex,epididymis: 0.5	Group enriched	29	HSkMC: 11.3;RH-30: 6.9
C17orf97	LIAT1, LOC400566	ENSG00000187624	Chromosome 17 open reading frame 97	17	410327-431062	Predicted intracellular proteins	Evidence at protein level	HPA023583	Approved		Approved	Nucleoli<br>Cytosol		Expressed in all	Tissue enhanced		testis: 28.4	fallopian tube: 10.8	Cell line enhanced		U-2197: 8.4
ZKSCAN4	FLJ32136, P1P373C6, p373c6.1, ZNF307, ZNF427, ZSCAN36	ENSG00000187626	Zinc finger with KRAB and SCAN domains 4	6	28244623-28252224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009637	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.90e-6 (unfavourable), Lung cancer:5.04e-4 (favourable)	Expressed in all	Mixed			testis: 18.3	Expressed in all		
RGPD1	RGP1	ENSG00000187627	RANBP2-like and GRIP domain containing 1	2	86907953-87013981	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Approved	Nuclear membrane<br>Vesicles		Not detected	Group enriched	12	cervix, uterine: 11.8;placenta: 9.0;testis: 24.5	parathyroid gland: 1.2	Cell line enhanced		BEWO: 6.0;MOLT-4: 8.6;NTERA-2: 3.1
DHRS4L2	SDR25C3	ENSG00000187630	Dehydrogenase/reductase 4 like 2	14	23969874-24006408	Predicted intracellular proteins	Evidence at protein level	HPA023972	Uncertain		Uncertain	Nuclear membrane<br>Vesicles	Ovarian cancer:3.21e-4 (favourable)	Expressed in all	Expressed in all			kidney: 123.6	Mixed		
SAMD11	MGC45873	ENSG00000187634	Sterile alpha motif domain containing 11	1	923928-944581	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA030110			Approved	Nucleoplasm<br>Vesicles	Renal cancer:3.35e-5 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 27.6	fallopian tube: 20.4	Cell line enhanced		HEK 293: 98.5;HeLa: 80.1;SCLC-21H: 89.8
PERM1	C1orf170, MGC13275, Perm1, RP11-54O7.8	ENSG00000187642	PPARGC1 and ESRR induced regulator, muscle 1	1	975204-982093	Predicted intracellular proteins	Evidence at protein level	HPA031711, HPA031712	Enhanced				Renal cancer:1.95e-4 (unfavourable)	Mixed	Group enriched	15	heart muscle: 20.7;skeletal muscle: 68.1	esophagus: 3.0	Cell line enhanced		HaCaT: 1.3;SK-BR-3: 1.2
VMAC		ENSG00000187650	Vimentin-type intermediate filament associated coiled-coil protein	19	5904858-5910853	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:5.67e-6 (favourable), Urothelial cancer:7.24e-4 (favourable), Head and neck cancer:8.20e-4 (favourable)	Expressed in all	Mixed			prostate: 7.9	Cell line enhanced		U-266/70: 12.2
C5orf52		ENSG00000187658	Chromosome 5 open reading frame 52	5	157671553-157680143	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	21	testis: 38.7	colon: 1.8	Not detected		
HAPLN4	BRAL2, KIAA1926	ENSG00000187664	Hyaluronan and proteoglycan link protein 4	19	19255641-19262796	Predicted secreted proteins	Evidence at protein level	HPA055856	Approved					Not detected	Group enriched	7	cerebral cortex: 8.4;duodenum: 15.3;small intestine: 21.2	cervix, uterine: 2.1	Cell line enhanced		NB-4: 2.6;NTERA-2: 10.4;SCLC-21H: 2.6
ERC2	CAST, CAST1, ELKSL, KIAA0378, SPBC110, Spc110	ENSG00000187672	ELKS/RAB6-interacting/CAST family member 2	3	55508308-56468363	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073739	Enhanced					Mixed	Tissue enriched	16	cerebral cortex: 24.6	seminal vesicle: 1.5	Cell line enhanced		HAP1: 2.7;Karpas-707: 6.2;SH-SY5Y: 2.2;U-266/70: 4.6
B3GLCT	B3GALTL, B3Glc-T, B3GTL	ENSG00000187676	Beta 3-glucosyltransferase	13	31199936-31332276	Disease related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Mixed			endometrium: 21.1	Cell line enhanced		HDLM-2: 54.9
SPRY4		ENSG00000187678	Sprouty RTK signaling antagonist 4	5	142310427-142326455	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB008086, HPA055471, HPA072661	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.20e-4 (unfavourable), Cervical cancer:7.12e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 26.9	Cell line enhanced		AN3-CA: 111.1;WM-115: 158.0
ERAS	HRAS2, HRASP	ENSG00000187682	ES cell expressed Ras	X	48826513-48830138	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			cerebral cortex: 0.6	Not detected		
TRPV2	VRL, VRL-1, VRL1	ENSG00000187688	Transient receptor potential cation channel subfamily V member 2	17	16415542-16437003	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA044993	Uncertain		Supported	Plasma membrane	Renal cancer:1.19e-6 (unfavourable), Testis cancer:5.53e-4 (unfavourable)	Tissue enriched	Mixed			lung: 44.1	Cell line enhanced		fHDF/TERT166: 83.8;HMC-1: 77.5;SK-MEL-30: 73.0;TIME: 68.5
AMTN	RSTI689, UNQ689	ENSG00000187689	Amelotin	4	70518540-70532742	Predicted secreted proteins	Evidence at protein level	HPA036136, HPA036137	Uncertain					Group enriched	Tissue enhanced		stomach: 6.9;tonsil: 24.9	prostate: 3.3	Cell line enhanced		hTERT-HME1: 3.4;MCF7: 2.6
CXorf67		ENSG00000187690	Chromosome X open reading frame 67	X	51406915-51408843	Predicted intracellular proteins	Evidence at protein level	HPA004003, HPA006128	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Group enriched	21	placenta: 1.3;testis: 4.7	cerebral cortex,epididymis,ovary,prostate,spleen: 0.1	Cell line enriched	63	U-2 OS: 34.0
RP11-723O4.6		ENSG00000187695	Uncharacterized protein FLJ43738 	3	128909874-128971330	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	5	fallopian tube: 10.7;skin: 6.8;testis: 20.3	lung: 2.4	Cell line enhanced		HAP1: 4.6;HL-60: 4.8
C2orf88	MGC13057, smAKAP	ENSG00000187699	Chromosome 2 open reading frame 88	2	189879609-190203484	Predicted intracellular proteins	Evidence at protein level	HPA049549	Approved				Endometrial cancer:4.97e-4 (favourable), Renal cancer:7.79e-4 (favourable), Melanoma:9.39e-4 (unfavourable)	Tissue enhanced	Expressed in all			testis: 92.3	Group enriched	6	HEL: 97.1;K-562: 82.2;RT4: 46.8
OR2T27		ENSG00000187701	Olfactory receptor family 2 subfamily T member 27	1	248649931-248650884	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM203	HBEBP1, MGC14327	ENSG00000187713	Transmembrane protein 203	9	137204082-137205638	Predicted membrane proteins, Transporters	Evidence at protein level						Pancreatic cancer:4.78e-6 (favourable), Renal cancer:1.50e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Expressed in all		
SLC18A3	VACHT	ENSG00000187714	Solute carrier family 18 member A3	10	49610301-49612720	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB037102, CAB079011	Uncertain	Supported				Mixed	Not detected			placenta: 0.6	Group enriched	6	SCLC-21H: 2.0;SH-SY5Y: 7.6
KBTBD12	FLJ46299, KLHDC6	ENSG00000187715	Kelch repeat and BTB domain containing 12	3	127915232-127987671	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	9	heart muscle: 9.2;skeletal muscle: 20.3	stomach: 1.5	Not detected		
THSD4	ADAMTSL6, FLJ13710, FVSY9334, PRO34005	ENSG00000187720	Thrombospondin type 1 domain containing 4	15	71096952-71783383	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026845			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 160.5	fallopian tube: 59.6	Cell line enhanced		BJ hTERT+: 43.1;TIME: 54.2
DNAJB13	RSPH16A, TSARG6	ENSG00000187726	DnaJ heat shock protein family (Hsp40) member B13	11	73950319-73970366	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052465, HPA061330	Enhanced		Approved	Plasma membrane	Renal cancer:2.10e-6 (unfavourable)	Tissue enhanced	Group enriched	7	fallopian tube: 76.0;testis: 19.1	cervix, uterine,epididymis: 6.4	Cell line enhanced		RPTEC TERT1: 3.3
GABRD		ENSG00000187730	Gamma-aminobutyric acid type A receptor delta subunit	1	2019298-2030758	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044371	Enhanced		Uncertain	Golgi apparatus<br>Vesicles	Renal cancer:4.12e-8 (unfavourable)	Expressed in all	Tissue enriched	12	cerebral cortex: 34.0	testis: 2.7	Cell line enhanced		EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
AMY1C	AMY1	ENSG00000187733	Amylase, alpha 1C (salivary)	1	103750406-103758690	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Not detected	Tissue enhanced		cervix, uterine: 33.0;salivary gland: 101.8	pancreas: 26.4	Not detected		
TCEA1	GTF2S, SII, TCEA, TF2S, TFIIS	ENSG00000187735	Transcription elongation factor A1	8	53966552-54022529	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043786	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:3.75e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 199.9	Expressed in all		
NHEJ1	Cernunnos, FLJ12610, XLF	ENSG00000187736	Non-homologous end joining factor 1	2	219075317-219160865	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012334, HPA043869	Approved		Supported	Nucleus<br>Nucleoli fibrillar center		Mixed	Expressed in all			testis: 44.0	Expressed in all		
FANCA	FA-H, FAA, FACA, FAH, FANCH	ENSG00000187741	Fanconi anemia complementation group A	16	89737549-89816657	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063236			Supported	Nucleus		Mixed	Mixed			testis: 19.5	Expressed in all		
SECISBP2		ENSG00000187742	SECIS binding protein 2	9	89318506-89359662	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044314, HPA054905	Approved		Supported	Nucleoplasm	Renal cancer:8.98e-9 (favourable)	Expressed in all	Expressed in all			testis: 127.0	Expressed in all		
OR52B6		ENSG00000187747	Olfactory receptor family 52 subfamily B member 6	11	5580877-5581884	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C9orf153	bA507D14.1	ENSG00000187753	Chromosome 9 open reading frame 153	9	86220265-86259657	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	29	testis: 53.7	bone marrow: 1.8	Mixed		
SSX7		ENSG00000187754	SSX family member 7	X	52644090-52654900	Predicted intracellular proteins	Evidence at transcript level	HPA045683	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			skin: 0.4	Cell line enhanced		HMC-1: 2.8;RT4: 1.4
ADH1A	ADH1	ENSG00000187758	Alcohol dehydrogenase 1A (class I), alpha polypeptide	4	99276367-99291028	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009562, HPA047814, HPA060902	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:2.38e-4 (favourable)	Tissue enriched	Tissue enriched	135	liver: 1367.7	gallbladder: 10.1	Cell line enhanced		ASC diff: 3.7
SEMA4D	C9orf164, CD100, coll-4, FLJ39737, SEMAJ	ENSG00000187764	Semaphorin 4D	9	89360787-89498130	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA015662, HPA023277	Approved		Supported	Endoplasmic reticulum<br>Vesicles	Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 72.4	Cell line enhanced		HDLM-2: 124.4;HMC-1: 86.7;MOLT-4: 98.7
KRTAP10-8	KAP10.8, KRTAP18-8, KRTAP18.8	ENSG00000187766	Keratin associated protein 10-8	21	44612079-44612954	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LIN28B	CSDD2, FLJ16517	ENSG00000187772	Lin-28 homolog B	6	104936616-105083332	Predicted intracellular proteins	Evidence at protein level	HPA036630, HPA061745	Enhanced		Supported	Nucleus<br>Nucleoli<br>Cytosol		Tissue enriched	Tissue enriched	12	placenta: 93.5	testis: 7.7	Cell line enhanced		BEWO: 241.5;K-562: 76.8
FAM69C	C18orf51	ENSG00000187773	Family with sequence similarity 69 member C	18	74434099-74457944	Predicted intracellular proteins	Evidence at protein level	HPA048928	Enhanced					Group enriched	Tissue enhanced		cerebral cortex: 28.8;testis: 8.4	skin: 4.9	Cell line enriched	7	SK-MEL-30: 4.2
DNAH17	DNAHL1, DNEL2, FLJ40457	ENSG00000187775	Dynein axonemal heavy chain 17	17	78423697-78577394	Predicted intracellular proteins	Evidence at protein level	HPA024354, HPA076261	Enhanced		Approved	Nucleoplasm<br>Plasma membrane		Tissue enhanced	Tissue enriched	21	testis: 10.3	skin: 0.4	Group enriched	5	HeLa: 3.2;MOLT-4: 1.9
MCRS1	ICP22BP, INO80Q, MCRS2, MSP58, P78	ENSG00000187778	Microspherule protein 1	12	49556544-49568153	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039057	Supported		Supported	Nucleoplasm	Liver cancer:2.30e-4 (unfavourable), Renal cancer:2.70e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 55.0	Expressed in all		
TMEM72	bA285G1.3, C10orf127, KSP37	ENSG00000187783	Transmembrane protein 72	10	44911200-44937002	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039894, HPA062907	Enhanced				Renal cancer:1.01e-4 (favourable)	Tissue enriched	Tissue enriched	7	kidney: 54.3	rectum: 7.8	Group enriched	105	RPMI-8226: 24.8;U-937: 17.4
FANCM	FAAP250, KIAA1596	ENSG00000187790	Fanconi anemia complementation group M	14	45135940-45200890	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055144			Supported	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.0	endometrium: 4.3	Mixed		
FAM205C	FAM205CP	ENSG00000187791	Family with sequence similarity 205 member C	9	34889064-34895778	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	61	testis: 46.8	kidney: 0.7	Cell line enriched	84	THP-1: 9.8
ZNF70	Cos17, MGC48959	ENSG00000187792	Zinc finger protein 70	22	23738678-23751092	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018821	Uncertain		Supported	Cytosol		Mixed	Mixed			ovary: 4.9	Mixed		
CARD9		ENSG00000187796	Caspase recruitment domain family member 9	9	136361903-136373681	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059502	Enhanced					Mixed	Tissue enhanced		bone marrow: 7.1;spleen: 8.2	appendix: 5.7	Cell line enhanced		HMC-1: 49.3;NB-4: 30.7;THP-1: 30.1
PEAR1	FLJ00193, JEDI, MEGF12	ENSG00000187800	Platelet endothelial aggregation receptor 1	1	156893698-156916434	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035217	Approved		Approved	Nucleoplasm<br>Cell Junctions<br>Centrosome	Renal cancer:4.31e-4 (unfavourable)	Expressed in all	Mixed			placenta: 16.9	Cell line enhanced		HBEC3-KT: 21.4;HUVEC TERT2: 43.6;TIME: 69.3
ZFP69B	FLJ34293, ZKSCAN23B, ZNF643, ZSCAN54B	ENSG00000187801	ZFP69 zinc finger protein B	1	40450102-40463718	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044289	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			cerebral cortex: 3.7	Mixed		
TMEM202	FLJ27523	ENSG00000187806	Transmembrane protein 202	15	72398273-72408029	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enriched	Tissue enriched	230	testis: 23.0	all non-specific tissues: 0.0	Not detected		
SOWAHD	ANKRD58	ENSG00000187808	Sosondowah ankyrin repeat domain family member D	X	119758613-119760164	Predicted intracellular proteins	Evidence at protein level	HPA065955	Uncertain					Tissue enriched	Tissue enhanced		spleen: 5.0	testis: 3.6	Cell line enhanced		BEWO: 4.3;THP-1: 5.8;U-937: 6.0
ZFP69	FLJ16030, ZFP69A, ZKSCAN23A, ZNF642, ZSCAN54A	ENSG00000187815	ZFP69 zinc finger protein	1	40477215-40496343	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027808, HPA054942	Uncertain		Approved	Nucleus	Renal cancer:5.00e-6 (unfavourable), Head and neck cancer:9.31e-4 (favourable)	Expressed in all	Mixed			testis: 6.7	Cell line enhanced		THP-1: 39.0
HELT	bHLHb44, HCM1228, HESL, MEGANE, Mgn	ENSG00000187821	Helt bHLH transcription factor	4	185018841-185020804	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA036188, HPA036189	Uncertain					Not detected	Not detected			lung: 0.5	Cell line enhanced		HAP1: 1.4
ZCCHC16	FLJ46608, Mar4, Mart4	ENSG00000187823	Zinc finger CCHC-type containing 16	X	112454500-112457112	Predicted intracellular proteins	Evidence at transcript level	HPA003272	Uncertain		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Group enriched	Not detected			kidney: 0.8	Not detected		
TMEM220		ENSG00000187824	Transmembrane protein 220	17	10699015-10730316	Predicted membrane proteins	Evidence at protein level	HPA047680			Uncertain	Nucleoplasm	Liver cancer:2.23e-5 (favourable), Pancreatic cancer:1.72e-4 (favourable), Glioma:9.39e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 53.3	Mixed		
C2orf78	COG5373, FLJ43987, hCG1989538	ENSG00000187833	Chromosome 2 open reading frame 78	2	73784189-73817147	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	142	testis: 14.2	all non-specific tissues: 0.0	Not detected		
HIST1H1C	H1.2, H1c, H1F2, H1s-1	ENSG00000187837	Histone cluster 1 H1 family member c	6	26055787-26056428	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011507, HPA055907	Supported		Supported	Nucleus<br>Nucleoli	Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:1.12e-4 (unfavourable), Renal cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 185.2	Cell line enhanced		SiHa: 391.5;U-2 OS: 735.9;U-266/70: 600.9;U-266/84: 562.5
PLSCR3		ENSG00000187838	Phospholipid scramblase 3	17	7389727-7394843	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048387, HPA068609	Supported		Supported	Mitochondria		Mixed	Mixed			smooth muscle: 19.5	Mixed		
EIF4EBP1	4E-BP1, PHAS-I	ENSG00000187840	Eukaryotic translation initiation factor 4E binding protein 1	8	38030341-38060365	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005032, CAB005039, HPA023501	Supported		Supported	Nucleoplasm<br>Cytosol	Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:8.86e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 30.5	Expressed in all		
P2RX2	DFNA41, P2X2	ENSG00000187848	Purinergic receptor P2X 2	12	132618780-132622386	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		epididymis: 26.6;seminal vesicle: 12.7	prostate: 9.7	Cell line enhanced		MCF7: 3.9;T-47d: 10.5
ASCL4	bHLHa44, HASH4	ENSG00000187855	Achaete-scute family bHLH transcription factor 4	12	107774385-107776644	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036116	Uncertain					Tissue enhanced	Not detected			parathyroid gland: 0.7	Not detected		
OR6C75		ENSG00000187857	Olfactory receptor family 6 subfamily C member 75	12	55365111-55366049	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CCDC157		ENSG00000187860	Coiled-coil domain containing 157	22	30356635-30378658	Predicted intracellular proteins	Evidence at protein level	HPA042943	Uncertain					Mixed	Group enriched	5	fallopian tube: 12.0;testis: 28.4	thyroid gland: 3.9	Mixed		
TTC24		ENSG00000187862	Tetratricopeptide repeat domain 24	1	156579727-156586770	Predicted intracellular proteins	Evidence at protein level	HPA029799			Approved	Nucleoplasm		Not detected	Tissue enhanced		lymph node: 6.4;spleen: 3.8;tonsil: 4.2	appendix: 2.4	Cell line enhanced		MOLT-4: 2.5;REH: 10.7;U-698: 1.5
FAM122A	C9orf42, MGC17347	ENSG00000187866	Family with sequence similarity 122A	9	68780034-68784608	Predicted intracellular proteins	Evidence at protein level	HPA056646	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:1.34e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.3	Expressed in all		
PALM3		ENSG00000187867	Paralemmin 3	19	14053365-14059159	Predicted intracellular proteins	Evidence at protein level	HPA052794, HPA056119	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane	Endometrial cancer:7.87e-4 (unfavourable)	Mixed	Mixed			kidney: 15.7	Cell line enhanced		AN3-CA: 35.4;CACO-2: 34.5;HAP1: 35.4;NTERA-2: 24.5
GFRAL	bA360D14.1, C6orf144, GRAL, UNQ9356	ENSG00000187871	GDNF family receptor alpha like	6	55327469-55402493	Predicted membrane proteins	Evidence at protein level	HPA047372	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
C1orf168	FLJ43208, RP4-758N20.2	ENSG00000187889	Chromosome 1 open reading frame 168	1	56718804-56819696	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 21.4;liver: 8.6	cervix, uterine: 5.0	Cell line enriched	22	T-47d: 4.8
SHISA7		ENSG00000187902	Shisa family member 7	19	55428740-55442863	Predicted membrane proteins	Evidence at protein level	HPA058935	Uncertain					Tissue enriched	Tissue enriched	13	cerebral cortex: 18.2	testis: 1.4	Cell line enhanced		HEL: 2.7;HMC-1: 2.7;THP-1: 1.1
LRRC74B		ENSG00000187905	Leucine rich repeat containing 74B	22	21045960-21064168	Predicted intracellular proteins	Evidence at transcript level	HPA049947	Uncertain					Not detected	Tissue enhanced		fallopian tube: 6.0;testis: 1.9	lung: 0.8	Not detected		
DMBT1	GP340, muclin, SALSA	ENSG00000187908	Deleted in malignant brain tumors 1	10	122560665-122643736	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA040778	Enhanced		Approved	Microtubule organizing center	Endometrial cancer:1.43e-4 (favourable)	Group enriched	Tissue enhanced		duodenum: 816.7;small intestine: 277.6	salivary gland: 136.1	Cell line enhanced		hTERT-HME1: 3.5;LHCN-M2: 7.8;RH-30: 20.9
CLEC17A	FLJ45910	ENSG00000187912	C-type lectin domain family 17 member A	19	14583084-14611157	Predicted membrane proteins	Evidence at protein level							Mixed	Group enriched	10	appendix: 16.6;lymph node: 30.4;spleen: 19.2;tonsil: 28.4	urinary bladder: 2.3	Group enriched	11	Daudi: 6.8;U-698: 12.0
OR51I2		ENSG00000187918	Olfactory receptor family 51 subfamily I member 2	11	5453489-5454427	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LCN10		ENSG00000187922	Lipocalin 10	9	136738167-136743356	Predicted secreted proteins	Evidence at protein level	HPA055919	Approved					Tissue enriched	Tissue enriched	6	epididymis: 18.9	endometrium: 3.3	Not detected		
LDLRAD2		ENSG00000187942	Low density lipoprotein receptor class A domain containing 2	1	21812265-21825221	Predicted secreted proteins	Evidence at transcript level	HPA030478	Approved					Mixed	Mixed			adipose tissue: 2.1	Cell line enhanced		REH: 1.1;TIME: 1.8
C2orf66	UNQ6411	ENSG00000187944	Chromosome 2 open reading frame 66	2	196805002-196810276	Predicted secreted proteins	Evidence at transcript level	HPA020869	Uncertain					Mixed	Tissue enhanced		adipose tissue: 2.8;adrenal gland: 1.7;testis: 1.7	skin: 1.1	Cell line enhanced		HEL: 4.0;RT4: 1.3;TIME: 1.5
OVCH1	OVCH	ENSG00000187950	Ovochymase 1	12	29412474-29497686	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA040253	Uncertain					Not detected	Group enriched	5	lung: 6.8;testis: 4.3;thyroid gland: 1.7	spleen: 0.8	Group enriched	6	Daudi: 3.9;HEL: 1.0
ARHGAP11B	B'-T, FAM7B1	ENSG00000187951	Rho GTPase activating protein 11B	15	30624494-30772993	Predicted intracellular proteins	Evidence at protein level	HPA064479	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		bone marrow: 2.0	lymph node,testis: 1.1	Mixed		
CYHR1	CHRP, KIAA0496, MGC13010	ENSG00000187954	Cysteine and histidine rich 1	8	144449582-144465677	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053653, HPA059543	Approved		Enhanced	Nucleoplasm	Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.4	Expressed in all		
COL14A1	UND	ENSG00000187955	Collagen type XIV alpha 1 chain	8	120059780-120372036	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA023781	Uncertain		Approved	Vesicles	Renal cancer:5.79e-5 (unfavourable), Urothelial cancer:1.01e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 278.5	gallbladder: 207.5	Group enriched	7	ASC TERT1: 28.1;RH-30: 106.3
DNER	bet, UNQ26	ENSG00000187957	Delta/notch like EGF repeat containing	2	229357629-229714558	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA017320	Approved				Liver cancer:1.05e-4 (unfavourable), Renal cancer:3.42e-4 (unfavourable)	Tissue enriched	Group enriched	7	adrenal gland: 74.6;cerebral cortex: 176.0	salivary gland: 17.3	Cell line enhanced		hTERT-HME1: 115.0;U-138 MG: 248.6;U-87 MG: 146.3
CPSF4L		ENSG00000187959	Cleavage and polyadenylation specific factor 4 like	17	73248449-73262352	Predicted intracellular proteins	Evidence at transcript level	HPA044047	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	7	Hep G2: 2.0
KLHL17		ENSG00000187961	Kelch like family member 17	1	960587-965715	Predicted intracellular proteins	Evidence at protein level	HPA031251	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:1.89e-6 (unfavourable), Renal cancer:2.70e-6 (unfavourable), Cervical cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			skin: 9.7	Expressed in all		
ZCCHC13	4930513O09RIK, Cnbp2, ZNF9L	ENSG00000187969	Zinc finger CCHC-type containing 13	X	74304190-74305031	Predicted intracellular proteins	Evidence at protein level	HPA003382	Enhanced					Not detected	Tissue enriched	234	testis: 23.3	all non-specific tissues: 0.0	Not detected		
PLA2G2C		ENSG00000187980	Phospholipase A2 group IIC	1	20161253-20177424	Predicted secreted proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enhanced		esophagus: 1.2	testis: 0.6	Cell line enhanced		HL-60: 1.2;U-698: 1.2;U-937: 1.3
ZSCAN23	dJ29K1.3.1, ZNF390, ZNF453	ENSG00000187987	Zinc finger and SCAN domain containing 23	6	28431930-28443502	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA035959, HPA035960	Uncertain					Not detected	Mixed			parathyroid gland: 2.1	Cell line enhanced		SCLC-21H: 2.1
RINL	FLJ45909	ENSG00000187994	Ras and Rab interactor like	19	38867834-38878279	Predicted intracellular proteins	Evidence at protein level	HPA042083, HPA042103	Uncertain		Approved	Nucleoplasm<br>Vesicles	Cervical cancer:6.49e-5 (favourable), Head and neck cancer:1.64e-4 (favourable)	Expressed in all	Mixed			lymph node: 13.9	Cell line enhanced		HMC-1: 20.0;Karpas-707: 19.3
C17orf99	GLPG464, UNQ464	ENSG00000187997	Chromosome 17 open reading frame 99	17	78146353-78166177	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA029655	Uncertain					Not detected	Tissue enriched	6	bone marrow: 5.5	fallopian tube,lymph node: 0.9	Group enriched	14	HaCaT: 3.1;HMC-1: 6.2;K-562: 3.8
OR7D2	FLJ38149, HTPCRH03, OR19-4	ENSG00000188000	Olfactory receptor family 7 subfamily D member 2	19	9185594-9188817	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			testis: 1.8	Cell line enhanced		HEL: 1.6
TPRG1	FAM79B, FLJ41238, FLJ43694	ENSG00000188001	Tumor protein p63 regulated 1	3	188947214-189325304	Predicted intracellular proteins	Evidence at protein level	HPA044751, HPA060187	Uncertain		Supported	Nucleoplasm	Breast cancer:5.43e-4 (favourable)	Tissue enhanced	Tissue enhanced		esophagus: 49.1	breast: 28.4	Cell line enhanced		HDLM-2: 8.9;Karpas-707: 3.3;T-47d: 3.9;U-266/70: 3.5
C1orf204	FLJ39187	ENSG00000188004	Chromosome 1 open reading frame 204	1	159834474-159855347	Predicted intracellular proteins	Evidence at transcript level	HPA045602, HPA051028	Approved		Approved	Nucleoplasm		Mixed	Mixed			ovary,parathyroid gland: 8.3	Mixed		
MORN2	MOPT	ENSG00000188010	MORN repeat containing 2	2	38875962-38929072	Predicted intracellular proteins	Evidence at protein level	HPA057815	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 265.7	Expressed in all		
RTP5	C2orf85, CXXC11, FLJ33590, Z3CXXC5	ENSG00000188011	Receptor transporter protein 5 (putative)	2	241869600-241873823	Predicted membrane proteins	Evidence at protein level	HPA050902	Approved					Tissue enriched	Tissue enriched	9	cerebral cortex: 5.3	lymph node: 0.5	Group enriched	21	MOLT-4: 1.1;SCLC-21H: 3.0
S100A3	S100E	ENSG00000188015	S100 calcium binding protein A3	1	153547329-153549372	Predicted intracellular proteins	Evidence at protein level	HPA042674, HPA056140	Approved		Enhanced	Nucleoli<br>Cytosol	Renal cancer:1.61e-6 (unfavourable)	Expressed in all	Tissue enhanced		lung: 19.9;skin: 17.3	esophagus: 7.5	Cell line enhanced		A549: 71.3;U-2197: 41.8
UBQLN2	Chap1, CHAP1/DSK2, Dsk2, LIC-2, N4BP4, PLIC-2, PLIC2, RIHFB2157	ENSG00000188021	Ubiquilin 2	X	56563639-56567868	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006431, CAB013481	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:2.29e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 53.7	Expressed in all		
RILPL1	FLJ39378	ENSG00000188026	Rab interacting lysosomal protein like 1	12	123470054-123533718	Predicted intracellular proteins	Evidence at protein level	HPA041314	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			heart muscle: 34.5	Mixed		
C19orf67		ENSG00000188032	Chromosome 19 open reading frame 67	19	14081619-14085875	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 5.6	stomach,thyroid gland: 0.4	Not detected		
ZNF490	KIAA1198	ENSG00000188033	Zinc finger protein 490	19	12577961-12640098	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005576	Uncertain					Mixed	Mixed			thyroid gland: 2.8	Mixed		
CLCN1	ClC-1, CLC1	ENSG00000188037	Chloride voltage-gated channel 1	7	143316126-143352083	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	17	skeletal muscle: 22.9	testis: 1.3	Cell line enhanced		HSkMC: 1.1;PC-3: 1.0
NRN1L	MRCC2446, UNQ2446	ENSG00000188038	Neuritin 1 like	16	67884805-67888855	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA041761	Uncertain					Not detected	Mixed			skin: 3.3	Cell line enriched	5	BEWO: 31.0
NWD1		ENSG00000188039	NACHT and WD repeat domain containing 1	19	16719976-16817963	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.55e-4 (favourable)	Tissue enriched	Group enriched	7	cerebral cortex: 1.9;fallopian tube: 7.7;prostate: 5.8;seminal vesicle: 1.6	lung: 0.6	Group enriched	7	MCF7: 1.0;U-937: 2.3
ARL4C	ARL7, LAK	ENSG00000188042	ADP ribosylation factor like GTPase 4C	2	234493041-234497053	Predicted intracellular proteins	Evidence at protein level	HPA028927	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.69e-8 (unfavourable), Endometrial cancer:2.90e-7 (unfavourable), Urothelial cancer:6.99e-5 (unfavourable)	Expressed in all	Mixed			spleen: 72.0	Cell line enhanced		RPTEC TERT1: 234.1;U-2197: 158.1
RNF133		ENSG00000188050	Ring finger protein 133	7	122697712-122699156	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	182	testis: 60.9	lung: 0.3	Not detected		
TMEM221		ENSG00000188051	Transmembrane protein 221	19	17435509-17448567	Predicted membrane proteins	Evidence at protein level	HPA041580	Approved					Tissue enhanced	Tissue enhanced		parathyroid gland: 6.8	fallopian tube: 4.2	Cell line enhanced		AN3-CA: 4.4;PC-3: 6.7;REH: 3.7
TREML4	TLT4	ENSG00000188056	Triggering receptor expressed on myeloid cells like 4	6	41228324-41238882	Predicted membrane proteins	Evidence at transcript level	HPA065044	Uncertain					Not detected	Not detected			spleen: 0.4	Not detected		
RAB42	MGC45806	ENSG00000188060	RAB42, member RAS oncogene family	1	28592200-28595443	Predicted intracellular proteins	Evidence at transcript level	HPA050290			Approved	Endoplasmic reticulum		Mixed	Mixed			lymph node: 9.5	Cell line enhanced		Hep G2: 11.8
WNT7B		ENSG00000188064	Wnt family member 7B	22	45920362-45977129	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 21.4	urinary bladder: 8.0	Cell line enhanced		A549: 108.4;HeLa: 71.0;U-87 MG: 92.0
C11orf95	MGC3032	ENSG00000188070	Chromosome 11 open reading frame 95	11	63759892-63768775	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045002			Approved	Intermediate filaments		Expressed in all	Expressed in all			endometrium: 24.6	Expressed in all		
SCGB1C1	RYD5	ENSG00000188076	Secretoglobin family 1C member 1	11	193080-194573	Predicted secreted proteins	No evidence							Tissue enhanced	Not detected			bone marrow: 0.4	Not detected		
PRSS45	TESSP5	ENSG00000188086	Protease, serine 45	3	46742092-46744755	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA060284	Uncertain					Mixed	Tissue enhanced		epididymis: 9.8;parathyroid gland: 8.6	skeletal muscle: 3.7	Not detected		
PLA2G4E	FLJ45651	ENSG00000188089	Phospholipase A2 group IVE	15	41981582-42051190	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA041105	Enhanced					Tissue enhanced	Tissue enriched	10	skin: 20.4	esophagus,tonsil: 2.0	Not detected		
GPR89B	GPR89, GPR89C, SH120	ENSG00000188092	G protein-coupled receptor 89B	1	147928393-147993521	Predicted membrane proteins	Evidence at protein level	HPA076096			Approved	Endoplasmic reticulum		Mixed	Expressed in all			kidney: 31.2	Expressed in all		
MESP2	bHLHc6, SCDO2	ENSG00000188095	Mesoderm posterior bHLH transcription factor 2	15	89760591-89778754	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Mixed			cervix, uterine: 1.2	Cell line enhanced		U-2197: 4.2
FAM25A	bA96C23.5	ENSG00000188100	Family with sequence similarity 25 member A	10	87020306-87024730	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Tissue enhanced	Tissue enhanced		esophagus: 315.5;skin: 125.9	tonsil: 54.6	Group enriched	6	A-431: 22.6;SK-BR-3: 55.0
EYS	bA166P24.2, bA307F22.3, bA74E24.1, C6orf178, C6orf179, C6orf180, dJ1018A4.2, dJ303F19.1, EGFL10, EGFL11, RP25, SPAM	ENSG00000188107	Eyes shut homolog (Drosophila)	6	63719980-65707225	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA027103	Uncertain					Not detected	Tissue enhanced		testis: 1.4	adipose tissue: 0.8	Cell line enhanced		Karpas-707: 1.1;SCLC-21H: 1.3
C6orf132	bA7K24.2	ENSG00000188112	Chromosome 6 open reading frame 132	6	42101118-42142619	Predicted intracellular proteins	Evidence at protein level	HPA044588	Enhanced		Approved	Golgi apparatus<br>Cytosol	Pancreatic cancer:4.90e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 80.8	skin: 49.9	Cell line enhanced		A-431: 56.9;CACO-2: 48.3;CAPAN-2: 42.1
DAZ1	DAZ, SPGY	ENSG00000188120	Deleted in azoospermia 1	Y	23129355-23199094	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Supported					Not detected	Tissue enhanced		testis: 1.7	stomach: 0.8	Group enriched	15	U-266/70: 11.7;U-266/84: 17.1
OR2AG2	OR2AG2P	ENSG00000188124	Olfactory receptor family 2 subfamily AG member 2	11	6767987-6769055	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.3	Not detected		
MAPK12	ERK6, p38gamma, PRKM12, SAPK-3, SAPK3	ENSG00000188130	Mitogen-activated protein kinase 12	22	50245450-50261825	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB025483, HPA054562	Enhanced		Approved	Nuclear speckles<br>Cytosol	Renal cancer:5.00e-6 (unfavourable)	Mixed	Tissue enriched	6	skeletal muscle: 91.5	cerebral cortex: 15.7	Mixed		
TMEM215		ENSG00000188133	Transmembrane protein 215	9	32783499-32787399	Predicted membrane proteins	Evidence at protein level	HPA052804, HPA063207	Uncertain		Supported	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles		Tissue enriched	Group enriched	5	cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8	cerebral cortex: 0.5	Cell line enhanced		NTERA-2: 1.9
NUTM2G	FAM22G	ENSG00000188152	NUT family member 2G	9	96928310-96940253	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.0	skin: 1.0	Mixed		
COL4A5	ASLN, ATS	ENSG00000188153	Collagen type IV alpha 5 chain	X	108439844-108697545	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA065449			Uncertain	Lipid droplets	Renal cancer:2.41e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 76.4	Cell line enhanced		HHSteC: 80.3;HUVEC TERT2: 76.9;SiHa: 73.2;TIME: 73.5
KRTAP10-6	KAP10.6, KAP18.6, KRTAP18-6, KRTAP18.6	ENSG00000188155	Keratin associated protein 10-6	21	44591268-44592505	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AGRN	AGRIN	ENSG00000188157	Agrin	1	1020123-1056118	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040090	Approved		Supported	Plasma membrane<br>Cytosol	Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 33.2	Cell line enhanced		EFO-21: 223.9
NHS		ENSG00000188158	NHS actin remodeling regulator	X	17375420-17735994	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031497, HPA076257	Uncertain		Supported	Cell Junctions	Endometrial cancer:1.68e-4 (favourable)	Mixed	Mixed			endometrium: 7.9	Cell line enhanced		EFO-21: 12.0;RPTEC TERT1: 14.5
OTOG	FLJ46346, mlemp, OTGN	ENSG00000188162	Otogelin	11	17547373-17647150	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	16	testis: 1.6	all non-specific tissues: 0.0	Cell line enriched	12	CACO-2: 7.7
FAM166A		ENSG00000188163	Family with sequence similarity 166 member A	9	137243584-137247770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023307	Enhanced					Not detected	Tissue enriched	44	testis: 58.6	epididymis: 1.3	Not detected		
TMPPE	FLJ45032	ENSG00000188167	Transmembrane protein with metallophosphoesterase domain	3	33090421-33096801	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027019	Uncertain		Approved	Nucleoplasm<br>Mitochondria		Mixed	Mixed			parathyroid gland: 4.1	Cell line enriched	6	BEWO: 26.4
ZNF626		ENSG00000188171	Zinc finger protein 626	19	20620061-20661596	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045631	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Mixed	Expressed in all			parathyroid gland: 52.8	Mixed		
HEPACAM2	FLJ38683	ENSG00000188175	HEPACAM family member 2	7	93188586-93226524	Predicted membrane proteins	Evidence at protein level						Colorectal cancer:9.73e-5 (favourable)	Mixed	Tissue enhanced		colon: 64.3;rectum: 103.1;small intestine: 53.6	duodenum: 30.2	Cell line enriched	47	SCLC-21H: 202.2
SMTNL2	FLJ42461	ENSG00000188176	Smoothelin like 2	17	4583999-4608319	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.28e-4 (favourable)	Tissue enhanced	Group enriched	9	kidney: 26.8;skeletal muscle: 133.8	fallopian tube: 9.0	Group enriched	7	CACO-2: 40.8;SCLC-21H: 13.5
ZC3H6	FLJ41410, FLJ45877, KIAA2035, ZC3HDC6	ENSG00000188177	Zinc finger CCCH-type containing 6	2	112275594-112340063	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036019, HPA036020, HPA076065	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Mixed			ovary: 7.6	Mixed		
LAMTOR4	C7orf59	ENSG00000188186	Late endosomal/lysosomal adaptor, MAPK and MTOR activator 4	7	100148907-100155944	Predicted intracellular proteins	Evidence at protein level	HPA020998	Enhanced		Enhanced	Vesicles	Breast cancer:2.48e-4 (favourable), Cervical cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			skin: 314.5	Expressed in all		
PRKAR1B		ENSG00000188191	Protein kinase cAMP-dependent type I regulatory subunit beta	7	549197-727650	Predicted intracellular proteins	Evidence at protein level	HPA026719	Approved					Expressed in all	Tissue enriched	9	cerebral cortex: 239.1	ovary: 26.3	Expressed in all		
NUTM2B	bA119F19.1, FAM22B	ENSG00000188199	NUT family member 2B	10	79703227-79714681	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 2.2	Mixed		
NCR3LG1	B7-H6, DKFZp686O24166	ENSG00000188211	Natural killer cell cytotoxicity receptor 3 ligand 1	11	17351726-17377341	Predicted membrane proteins	Evidence at protein level	HPA024137	Uncertain				Renal cancer:4.21e-12 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 12.9	rectum: 5.6	Cell line enhanced		HL-60: 42.1
DCUN1D3	DKFZp686O0290, FLJ41725, MGC48972, SCCRO3	ENSG00000188215	Defective in cullin neddylation 1 domain containing 3	16	20854925-20900384	Predicted intracellular proteins	Evidence at protein level	HPA041983, HPA043511	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.41e-6 (unfavourable)	Expressed in all	Mixed			adipose tissue: 24.0	Expressed in all		
POTEE	A26C1, A26C1A, CT104.2, POTE-2, POTE2, POTE2gamma	ENSG00000188219	POTE ankyrin domain family member E	2	131218067-131265278	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enhanced		testis: 2.1	prostate: 0.7	Cell line enhanced		AN3-CA: 1.0;BEWO: 1.3;K-562: 1.3;U-2 OS: 2.8
ZNF793		ENSG00000188227	Zinc finger protein 793	19	37506939-37548762	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034781	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Mixed			parathyroid gland: 15.7	Cell line enhanced		AN3-CA: 12.6;U-266/70: 15.1
TUBB4B	Beta2, TUBB2C	ENSG00000188229	Tubulin beta 4B class IVb	9	137241213-137243707	FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010880, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 786.8	Expressed in all		
AGAP4	AGAP8, CTGLF1, CTGLF5, Em:AC012044.1, MRIP2	ENSG00000188234	ArfGAP with GTPase domain, ankyrin repeat and PH domain 4	10	45825594-45853875	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain					Mixed	Expressed in all			skin: 24.7	Mixed		
COMMD6	Acrg	ENSG00000188243	COMM domain containing 6	13	75525219-75549439	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			ovary: 288.2	Expressed in all		
PLA2G2A	PLA2B, PLA2L	ENSG00000188257	Phospholipase A2 group IIA	1	19975431-19980416	Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA015236	Enhanced		Uncertain	Nucleus<br>Nucleoli	Melanoma:1.49e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 108.4;rectum: 177.5;small intestine: 233.7	duodenum: 85.7	Group enriched	11	Hep G2: 50.2;RT4: 53.3
IL17REL	FLJ41993	ENSG00000188263	Interleukin 17 receptor E like	22	49994513-50012659	Predicted intracellular proteins	Evidence at protein level	HPA045546	Supported					Mixed	Tissue enhanced		appendix: 3.1;lymph node: 2.4;tonsil: 4.0	stomach: 2.1	Not detected		
HYKK	AGPHD1, LOC123688	ENSG00000188266	Hydroxylysine kinase	15	78507564-78537372	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040706	Approved		Approved	Vesicles<br>Aggresome		Mixed	Mixed			kidney: 12.5	Cell line enhanced		HEK 293: 20.5
OR7A5	HTPCR2	ENSG00000188269	Olfactory receptor family 7 subfamily A member 5	19	14792490-14835376	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053823	Uncertain					Tissue enriched	Tissue enhanced		epididymis: 5.5;parathyroid gland: 5.4;testis: 2.8	breast,seminal vesicle: 0.9	Not detected		
C15orf62	LOC643338	ENSG00000188277	Chromosome 15 open reading frame 62	15	40770080-40772449	Predicted intracellular proteins	Evidence at protein level	HPA044636	Approved					Mixed	Tissue enhanced		esophagus: 14.9;skin: 12.6	tonsil: 4.6	Cell line enhanced		RPTEC TERT1: 13.6
RUFY4	FLJ46536, ZFYVE31	ENSG00000188282	RUN and FYVE domain containing 4	2	218034960-218090581	Predicted intracellular proteins	Evidence at protein level	HPA037980	Uncertain					Mixed	Tissue enhanced		spleen: 2.5	lymph node: 1.3	Cell line enriched	12	Karpas-707: 7.6
ZNF383	FLJ35863	ENSG00000188283	Zinc finger protein 383	19	37217926-37248738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063945	Approved		Supported	Nucleus<br>Nuclear membrane	Urothelial cancer:3.71e-4 (favourable), Pancreatic cancer:9.97e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 9.2	Mixed		
HES4	bHLHb42	ENSG00000188290	Hes family bHLH transcription factor 4	1	998962-1000172	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062465			Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:2.99e-4 (unfavourable), Endometrial cancer:3.85e-4 (favourable), Renal cancer:6.27e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 7.5	Cell line enriched	8	HEK 293: 180.2
IGFL1	UNQ644	ENSG00000188293	IGF like family member 1	19	46229752-46231243	Predicted secreted proteins	Evidence at protein level	HPA014001	Uncertain					Group enriched	Tissue enriched	22	esophagus: 97.7	tonsil: 4.4	Group enriched	8	HaCaT: 6.2;RT4: 20.8;SK-BR-3: 6.6
ZNF669	FLJ12606	ENSG00000188295	Zinc finger protein 669	1	247099962-247104372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044043	Uncertain		Approved	Nucleoli	Renal cancer:4.59e-7 (favourable)	Expressed in all	Mixed			testis: 8.7	Mixed		
C19orf35	FLJ45778	ENSG00000188305	Chromosome 19 open reading frame 35	19	2274622-2282176	Predicted intracellular proteins	Evidence at protein level	HPA057806	Uncertain					Mixed	Mixed			appendix: 1.8	Cell line enriched	13	HMC-1: 10.7
LRRIQ4	LRRC64	ENSG00000188306	Leucine rich repeats and IQ motif containing 4	3	169821922-169837775	Predicted intracellular proteins	Evidence at protein level	HPA036706	Uncertain					Mixed	Tissue enriched	9	testis: 4.3	small intestine: 0.5	Cell line enhanced		RT4: 1.3;T-47d: 1.3
CENPP	CENP-P, RP11-19J3.3	ENSG00000188312	Centromere protein P	9	92325484-92620533	Predicted intracellular proteins	Evidence at protein level	HPA021787, HPA058945	Uncertain		Supported	Nucleus<br>Nucleoli	Head and neck cancer:3.65e-4 (favourable), Cervical cancer:3.91e-4 (favourable)	Mixed	Tissue enhanced		skin: 25.2	parathyroid gland: 8.0	Expressed in all		
PLSCR1	MMTRA1B	ENSG00000188313	Phospholipid scramblase 1	3	146515180-146544864	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA068923, CAB070421	Approved		Supported	Nucleus<br>Golgi apparatus<br>Plasma membrane	Endometrial cancer:1.35e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 114.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 292.9;BJ hTERT+ SV40 Large T+ RasG12V: 404.0;SK-MEL-30: 418.1
C3orf62	FLJ43654	ENSG00000188315	Chromosome 3 open reading frame 62	3	49268602-49277909	Predicted intracellular proteins	Evidence at protein level	HPA043328			Approved	Nuclear speckles	Urothelial cancer:1.62e-5 (favourable), Stomach cancer:3.29e-5 (favourable), Breast cancer:3.93e-4 (favourable), Liver cancer:5.20e-4 (unfavourable), Pancreatic cancer:8.15e-4 (favourable), Lung cancer:8.88e-4 (favourable), Head and neck cancer:9.72e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 28.5	ovary: 8.8	Expressed in all		
ENO4	AC023283.3, C10orf134	ENSG00000188316	Enolase family member 4	10	116849512-116911788	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA037938, HPA061509	Enhanced					Mixed	Tissue enhanced		fallopian tube: 9.2;testis: 6.8	thyroid gland: 3.4	Cell line enhanced		MCF7: 3.0;T-47d: 2.3
ZNF559	MGC13105	ENSG00000188321	Zinc finger protein 559	19	9323772-9351162	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059632, HPA065485	Approved		Supported	Nucleoplasm<br>Cytosol	Ovarian cancer:6.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.8	Mixed		
SBK1	Sbk	ENSG00000188322	SH3 domain binding kinase 1	16	28292519-28323849	Enzymes, Predicted membrane proteins	Evidence at transcript level						Cervical cancer:6.88e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 10.9;skeletal muscle: 12.0	parathyroid gland: 4.1	Cell line enhanced		AF22: 27.9;NTERA-2: 29.2;REH: 29.2;SCLC-21H: 52.5;SH-SY5Y: 44.5
OR6C6		ENSG00000188324	Olfactory receptor family 6 subfamily C member 6	12	55294288-55295232	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA051090	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BSPH1	BSP1, ELSPBP2	ENSG00000188334	Binder of sperm protein homolog 1	19	47968046-47992170	Predicted secreted proteins	Evidence at protein level	HPA048335	Enhanced					Not detected	Tissue enriched	3118	epididymis: 468.2	testis: 0.1	Not detected		
SLC38A3	G17, SN1	ENSG00000188338	Solute carrier family 38 member 3	3	50205246-50221486	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031871			Approved	Microtubules<br>Cytosol		Tissue enriched	Tissue enriched	7	liver: 174.0	cerebral cortex: 25.4	Cell line enhanced		Hep G2: 33.9;SCLC-21H: 18.6
OR6N2		ENSG00000188340	Olfactory receptor family 6 subfamily N member 2	1	158776682-158777635	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA056637	Uncertain					Not detected	Tissue enriched	12	bone marrow: 1.1	all non-specific tissues: 0.0	Not detected		
GTF2F2	BTF4, RAP30, TFIIF	ENSG00000188342	General transcription factor IIF subunit 2	13	45120515-45284909	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA006912	Supported		Supported	Nucleus<br>Microtubules	Head and neck cancer:1.65e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 26.3	Expressed in all		
FAM92A	FAM92A1, FLJ38979	ENSG00000188343	Family with sequence similarity 92 member A	8	93698561-93731527	Predicted intracellular proteins	Evidence at protein level	HPA034760, HPA058942	Enhanced		Approved	Mitochondria		Expressed in all	Tissue enriched	6	testis: 198.8	parathyroid gland: 32.4	Mixed		
FOCAD	FLJ20375, KIAA1797	ENSG00000188352	Focadhesin	9	20658309-20995955	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055015	Uncertain		Uncertain	Mitochondria	Renal cancer:3.09e-8 (favourable), Liver cancer:4.41e-5 (unfavourable), Colorectal cancer:3.25e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.2	Mixed		
PRR19	MGC70924	ENSG00000188368	Proline rich 19	19	42302098-42310821	Predicted intracellular proteins	Evidence at protein level	HPA070350			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Mixed	Tissue enriched	10	testis: 22.5	cerebral cortex: 2.1	Mixed		
ZP3	ZP3-372, ZP3-424, ZP3A, ZP3B, ZPC	ENSG00000188372	Zona pellucida glycoprotein 3	7	76397518-76442071	Predicted membrane proteins	Evidence at protein level	HPA054061	Supported				Renal cancer:1.02e-6 (unfavourable)	Expressed in all	Mixed			fallopian tube: 6.2	Cell line enhanced		A549: 31.8;Karpas-707: 36.7;MCF7: 54.0
C10orf99	AP-57, CSBF, FLJ21763, RLLV1833, UNQ1833	ENSG00000188373	Chromosome 10 open reading frame 99	10	84173738-84185294	Predicted secreted proteins	Evidence at protein level	HPA050920	Enhanced				Renal cancer:1.20e-5 (unfavourable)	Mixed	Group enriched	11	colon: 239.2;esophagus: 185.4;rectum: 264.2	urinary bladder: 20.8	Cell line enriched	6	RT4: 37.2
H3F3C	H3.5	ENSG00000188375	H3 histone family member 3C	12	31791185-31792241	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enriched	15	testis: 33.7	bone marrow: 2.2	Cell line enhanced		SH-SY5Y: 2.6
IFNA2	IFN-alphaA, IFNA	ENSG00000188379	Interferon alpha 2	9	21384254-21385388	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
JAKMIP3	bA140A10.5, C10orf14, C10orf39, FLJ37857, KIAA4091, NECC2	ENSG00000188385	Janus kinase and microtubule interacting protein 3	10	132104671-132184809	Predicted membrane proteins	Evidence at protein level	HPA022872	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 5.8	prostate: 2.2	Cell line enhanced		A549: 2.2;U-266/84: 4.1
PPP3R2	PPP3RL	ENSG00000188386	Protein phosphatase 3 regulatory subunit B, beta	9	101591615-101595021	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA047157	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Tissue enriched	1372	testis: 137.1	all non-specific tissues: 0.0	Not detected		
PDCD1	CD279, hSLE1, PD-1, PD1, SLEB2	ENSG00000188389	Programmed cell death 1	2	241849881-241858908	CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035981, CAB038418, CAB076386	Enhanced				Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable)	Mixed	Tissue enhanced		lymph node: 12.0	appendix: 3.3	Group enriched	13	MOLT-4: 4.6;RPMI-8226: 4.0
CLEC2A	INPE5792, KACL, PILAR, UNQ5792	ENSG00000188393	C-type lectin domain family 2 member A	12	9898673-9932381	Predicted membrane proteins	Evidence at protein level	HPA048530, HPA072407	Approved		Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	14	skin: 67.7	breast: 4.7	Cell line enhanced		BEWO: 5.9;fHDF/TERT166: 16.8;U-937: 42.5
GPR21		ENSG00000188394	G protein-coupled receptor 21	9	123034527-123035696	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA041651	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.1	endometrium: 0.9	Cell line enriched	6	HBEC3-KT: 2.2
TCTEX1D4		ENSG00000188396	Tctex1 domain containing 4	1	44805913-44806675	Predicted intracellular proteins	Evidence at protein level	HPA062652	Enhanced				Endometrial cancer:1.58e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 5.9	epididymis: 1.7	Not detected		
SELL	CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR	ENSG00000188404	Selectin L	1	169690667-169711698	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002144, HPA051972	Enhanced		Approved	Cytosol	Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 254.9;spleen: 219.3;tonsil: 179.1	appendix: 152.7	Cell line enhanced		EFO-21: 9.7;MOLT-4: 16.7;U-266/70: 28.0;U-698: 12.2
MAGEB5	CT3.3, MAGE-B5	ENSG00000188408	MAGE family member B5	X	26216169-26218270	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA052627	Uncertain					Not detected	Not detected			testis: 0.8	Not detected		
CHM	DXS540, REP-1, TCD	ENSG00000188419	CHM, Rab escort protein 1	X	85861180-86047562	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003231, CAB016171	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 21.9	Expressed in all		
NANOS2	NOS2, ZC2HC12B	ENSG00000188425	Nanos C2HC-type zinc finger 2	19	45913214-45914870	Predicted intracellular proteins	Evidence at protein level	HPA014190	Approved					Not detected	Tissue enriched	37	testis: 3.6	all non-specific tissues: 0.0	Not detected		
BLOC1S5	dJ303A1.3, MU, MUTED	ENSG00000188428	Biogenesis of lysosomal organelles complex 1 subunit 5	6	8013567-8064414	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB025613	Uncertain				Liver cancer:8.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.0	Expressed in all		
CERKL	RP26	ENSG00000188452	Ceramide kinase like	2	181536676-181680665	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035443, HPA035444, HPA043203	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.10e-4 (unfavourable), Pancreatic cancer:5.25e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 24.1	spleen: 22.4	Cell line enhanced		HEL: 66.6;MOLT-4: 81.2;NB-4: 55.7;SCLC-21H: 75.7
SLC24A5	JSX, OCA6	ENSG00000188467	Solute carrier family 24 member 5	15	48120972-48142672	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Group enriched	21	skin: 9.6;testis: 2.9	breast: 0.3	Cell line enriched	760	SK-MEL-30: 193.4
IER5L	bA247A12.2	ENSG00000188483	Immediate early response 5 like	9	129175552-129178262	Predicted intracellular proteins	Evidence at transcript level	HPA021327			Approved	Nucleus	Lung cancer:1.48e-6 (unfavourable)	Expressed in all	Mixed			endometrium: 5.9	Cell line enhanced		SiHa: 36.8
H2AFX	H2AX	ENSG00000188486	H2A histone family member X	11	119093854-119095467	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012264, HPA041189, HPA051647	Supported		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:5.47e-9 (unfavourable), Liver cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 18.7	Expressed in all		
INSC		ENSG00000188487	Inscuteable homolog (Drosophila)	11	15112424-15247208	Predicted intracellular proteins	Evidence at protein level	HPA039769	Enhanced					Tissue enhanced	Mixed			small intestine: 2.7	Cell line enhanced		ASC TERT1: 8.1;hTERT-HME1: 4.6;TIME: 10.5
SERPINA5	PAI3, PCI, PLANH3, PROCI	ENSG00000188488	Serpin family A member 5	14	94561442-94593120	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA056919			Approved	Mitochondria	Endometrial cancer:7.72e-4 (favourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 514.2;liver: 405.3;testis: 818.8	gallbladder: 250.7	Cell line enriched	10	Hep G2: 176.3
C19orf54	FLJ41131	ENSG00000188493	Chromosome 19 open reading frame 54	19	40740856-40751553	Predicted intracellular proteins	Evidence at protein level	HPA059043, HPA059628	Approved					Expressed in all	Expressed in all			parathyroid gland: 12.2	Expressed in all		
LCTL	FLJ33279, KLG, KLPH	ENSG00000188501	Lactase like	15	66547179-66565979	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA071640			Approved	Endoplasmic reticulum<br>Plasma membrane		Group enriched	Mixed			cerebral cortex: 1.0	Cell line enhanced		EFO-21: 5.3;NTERA-2: 5.2;U-2 OS: 15.2;U-251 MG: 5.3
NCCRP1	FBXO50, LOC342897, NCCRP-1	ENSG00000188505	Non-specific cytotoxic cell receptor protein 1 homolog (zebrafish)	19	39196961-39201884	Predicted intracellular proteins	Evidence at protein level	HPA052812	Uncertain		Approved	Mitochondria	Endometrial cancer:1.01e-4 (unfavourable)	Mixed	Group enriched	22	esophagus: 263.4;skin: 175.5;tonsil: 113.3	breast: 8.2	Cell line enriched	7	SK-BR-3: 23.1
KRTDAP	KDAP, UNQ467	ENSG00000188508	Keratinocyte differentiation associated protein	19	35487324-35495558	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA063474	Enhanced					Group enriched	Tissue enriched	11	skin: 4647.8	breast: 422.9	Cell line enriched	47	hTCEpi: 55.8
COL25A1		ENSG00000188517	Collagen type XXV alpha 1 chain	4	108810721-109302657	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029107			Approved	Endoplasmic reticulum<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		testis: 20.4	adipose tissue: 7.5	Cell line enriched	6	HeLa: 37.1
FAM83G	FLJ41564, PAWS1	ENSG00000188522	Family with sequence similarity 83 member G	17	18968789-19004804	Predicted intracellular proteins	Evidence at protein level	HPA023369, HPA023940	Enhanced		Supported	Cytosol	Stomach cancer:7.58e-6 (favourable), Liver cancer:8.29e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 64.4	esophagus: 24.2	Mixed		
CFAP77	C9orf171, FLJ46082	ENSG00000188523	Cilia and flagella associated protein 77	9	132410043-132573317	Predicted intracellular proteins	Evidence at protein level	HPA021329, HPA024647, HPA061069	Enhanced		Approved	Cytosol	Endometrial cancer:7.31e-4 (favourable)	Tissue enhanced	Group enriched	10	fallopian tube: 48.8;testis: 22.9	lung: 3.4	Cell line enhanced		SH-SY5Y: 2.1
SRSF10	FUSIP1, FUSIP2, PPP1R149, SFRS13, SFRS13A, SRp38, SRrp40, TASR1, TASR2	ENSG00000188529	Serine and arginine rich splicing factor 10	1	23964804-23980927	Predicted intracellular proteins	Evidence at protein level	HPA053805, HPA053831	Uncertain		Supported	Nucleoplasm	Liver cancer:1.18e-6 (unfavourable), Renal cancer:1.01e-5 (unfavourable), Prostate cancer:1.74e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 100.9	Expressed in all		
HBA2	HBA-T2	ENSG00000188536	Hemoglobin subunit alpha 2	16	172847-173710	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB038417, HPA043780	Enhanced					Expressed in all	Group enriched	27	bone marrow: 18369.0;placenta: 4302.7	spleen: 427.2	Group enriched	18	HEL: 802.0;K-562: 265.1
DUSP28	DUSP26, VHP	ENSG00000188542	Dual specificity phosphatase 28	2	240560054-240564014	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047456, CAB069448	Uncertain		Uncertain	Nuclear speckles<br>Cytosol	Pancreatic cancer:1.84e-4 (favourable)	Expressed in all	Mixed			skeletal muscle: 3.9	Mixed		
C15orf52	FLJ43339	ENSG00000188549	Chromosome 15 open reading frame 52	15	40331452-40340967	Predicted intracellular proteins	Evidence at protein level	HPA040484, HPA041834	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			thyroid gland: 50.4	Cell line enhanced		HaCaT: 108.4;WM-115: 137.0
NBR1	1A1-3B, CA125, KIAA0049, M17S2	ENSG00000188554	NBR1, autophagy cargo receptor	17	43170481-43211689	Predicted intracellular proteins	Evidence at protein level	HPA022944, HPA022999, HPA023999	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Vesicles	Renal cancer:2.00e-5 (favourable)	Expressed in all	Expressed in all			testis: 259.6	Expressed in all		
OR2G6		ENSG00000188558	Olfactory receptor family 2 subfamily G member 6	1	248521647-248522597	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			kidney: 0.1	Not detected		
RALGAPA2	AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2	ENSG00000188559	Ral GTPase activating protein catalytic alpha subunit 2	20	20389552-20712488	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042707, HPA043622	Uncertain		Supported	Plasma membrane<br>Cytosol	Renal cancer:3.77e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.9	Group enriched	5	RT4: 88.7;SCLC-21H: 71.2
NDOR1	bA350O14.9, NR1	ENSG00000188566	NADPH dependent diflavin oxidoreductase 1	9	137205685-137217009	Predicted intracellular proteins	Evidence at protein level	HPA024504	Approved		Approved	Nucleus<br>Intermediate filaments<br>Cytosol		Expressed in all	Mixed			spleen: 14.1	Expressed in all		
FBLL1	LOC345630	ENSG00000188573	Fibrillarin-like 1	5	168529116-168530634	Predicted intracellular proteins	Evidence at transcript level	HPA049546			Approved	Nucleus<br>Nucleoli fibrillar center		Mixed	Tissue enhanced		cerebral cortex: 19.0	testis: 4.3	Group enriched	6	SCLC-21H: 24.5;SH-SY5Y: 18.4
NKAIN2	FAM77B, TCBA1	ENSG00000188580	Sodium/potassium transporting ATPase interacting 2	6	123804141-124825657	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045860			Approved	Cytosol		Mixed	Tissue enriched	44	cerebral cortex: 46.1	adipose tissue,skeletal muscle: 1.0	Cell line enhanced		HEK 293: 4.5;HEL: 5.8;Karpas-707: 7.5
KRTAP1-1	HB2A, KAP1.1, KAP1.1A, KAP1.1B	ENSG00000188581	Keratin associated protein 1-1	17	41040559-41041461	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			pancreas: 0.1	Not detected		
PAQR9	FLJ41938	ENSG00000188582	Progestin and adipoQ receptor family member 9	3	142949164-142963682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052798	Uncertain					Tissue enriched	Tissue enhanced		heart muscle: 5.6;liver: 6.8;testis: 19.3	bone marrow: 3.4	Cell line enhanced		A549: 3.0;AF22: 2.0;HEL: 2.1;NTERA-2: 2.5;U-266/70: 4.6;U-266/84: 2.4
CLEC20A	FLJ44005, LINC00083, NCRNA00083, RP4-593C16.2	ENSG00000188585	C-type lectin domain family 20 member A	1	178479247-178499634	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	6	testis: 3.3	lymph node: 0.5	Not detected		
CFAP54	C12orf55, C12orf63, FLJ31514, FLJ44112	ENSG00000188596	Cilia and flagella associated protein 54	12	96489571-96875555	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039897	Enhanced		Approved	Microtubules<br>Cytosol		Not detected	Tissue enhanced		testis: 11.0	fallopian tube: 8.5	Cell line enhanced		TIME: 8.0
CLN3	BTN1, BTS, JNCL	ENSG00000188603	CLN3, battenin	16	28474111-28495575	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA063280	Uncertain					Expressed in all	Expressed in all			placenta: 46.8	Expressed in all		
FAM72B	RP11-439A17.6	ENSG00000188610	Family with sequence similarity 72 member B	1	121167646-121185539	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 9.7	tonsil: 6.2	Mixed		
ASAH2		ENSG00000188611	N-acylsphingosine amidohydrolase 2	10	50182778-50248610	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA061171	Supported		Approved	Focal adhesion sites		Mixed	Group enriched	17	duodenum: 83.5;small intestine: 71.3	stomach: 4.6	Mixed		
SUMO2	SMT3B, SMT3H2	ENSG00000188612	Small ubiquitin-like modifier 2	17	75165586-75182983	Predicted intracellular proteins	Evidence at protein level	CAB037314, HPA042123, HPA048064	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.23e-6 (unfavourable), Endometrial cancer:1.88e-5 (unfavourable), Liver cancer:2.12e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 342.9	Expressed in all		
NANOS1	NOS1, ZC2HC12A	ENSG00000188613	Nanos C2HC-type zinc finger 1	10	119029716-119033732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB012219	Approved		Supported	Nucleoplasm<br>Cytosol	Breast cancer:1.52e-4 (unfavourable)	Mixed	Tissue enhanced		skeletal muscle: 13.2	thyroid gland: 11.9	Cell line enhanced		SH-SY5Y: 85.4;SK-BR-3: 34.9;SK-MEL-30: 28.2
HMX3	NKX5-1	ENSG00000188620	H6 family homeobox 3	10	123135962-123137741	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069659			Approved	Nucleus<br>Microtubule organizing center		Mixed	Not detected			adipose tissue: 0.3	Cell line enhanced		HEL: 4.7;K-562: 15.8;NB-4: 3.8;SiHa: 5.0
IGFL3	UNQ483	ENSG00000188624	IGF like family member 3	19	46120071-46124674	Predicted secreted proteins	Evidence at protein level	HPA062776	Uncertain					Tissue enhanced	Tissue enriched	7	skin: 16.9	parathyroid gland: 2.5	Cell line enhanced		BJ hTERT+: 3.1;hTEC/SVTERT24-B: 1.3;U-2 OS: 1.4;U-87 MG: 2.5
GOLGA8M		ENSG00000188626	Golgin A8 family member M	15	28701954-28738384	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 3.7;thyroid gland: 11.0	placenta: 2.4	Group enriched	10	HEL: 1.1;U-937: 3.5
ZNF177		ENSG00000188629	Zinc finger protein 177	19	9363020-9382617	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003141	Uncertain					Not detected	Tissue enhanced		testis: 14.3	epididymis: 8.7	Mixed		
LDOC1L	dJ1033E15.2, DKFZp761O17121, Mar6, Mart6	ENSG00000188636	LDOC1 like	22	44492572-44498298	Predicted intracellular proteins	Evidence at protein level	HPA005697	Approved		Approved	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 42.4	Mixed		
DPYD	DPD	ENSG00000188641	Dihydropyrimidine dehydrogenase	1	97077743-97921049	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033241, HPA045210	Uncertain				Pancreatic cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 44.1	Mixed		
S100A16	DT1P1A7, MGC17528, S100F	ENSG00000188643	S100 calcium binding protein A16	1	153606886-153613145	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045841	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1489.4	skin: 394.6	Mixed		
PTAR1		ENSG00000188647	Protein prenyltransferase alpha subunit repeat containing 1	9	69709522-69759959	Predicted intracellular proteins	Evidence at protein level	HPA021248	Uncertain		Approved	Microtubule organizing center<br>Rods & Rings	Renal cancer:4.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 35.5	Expressed in all		
CC2D2B	bA248J23.4, C10orf130	ENSG00000188649	Coiled-coil and C2 domain containing 2B	10	95907603-96032684	Predicted intracellular proteins	Evidence at protein level	HPA044091, HPA072122	Enhanced		Approved	Nucleoli		Not detected	Tissue enhanced		testis: 21.3	thyroid gland: 7.3	Mixed		
RNASE9	h461, RAK1	ENSG00000188655	Ribonuclease A family member 9 (inactive)	14	20556093-20560931	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	1199	epididymis: 119.9	all non-specific tissues: 0.0	Not detected		
SAXO2	DKFZp666G057, FAM154B	ENSG00000188659	Stabilizer of axonemal microtubules 2	15	82262810-82284930	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA040487, HPA040833	Enhanced		Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enhanced		fallopian tube: 95.7	testis: 29.1	Cell line enhanced		HaCaT: 9.3;K-562: 8.9;SCLC-21H: 9.3
RHCE	CD240CE, RH	ENSG00000188672	Rh blood group CcEe antigens	1	25362249-25430192	Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Mixed	Tissue enriched	6	bone marrow: 28.8	epididymis: 5.2	Group enriched	12	HEL: 76.1;K-562: 16.0
C2orf80	GONDA1, LOC389073	ENSG00000188674	Chromosome 2 open reading frame 80	2	208165343-208190073	Predicted intracellular proteins	Evidence at transcript level	HPA042639			Approved	Golgi apparatus		Tissue enriched	Tissue enriched	28	cerebral cortex: 37.5	testis: 1.3	Cell line enhanced		NTERA-2: 1.7
IDO2	INDOL1	ENSG00000188676	Indoleamine 2,3-dioxygenase 2	8	39934614-40016391	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	8	liver: 2.7;placenta: 5.9	appendix,lymph node,testis: 0.5	Not detected		
PARVB	CGI-56	ENSG00000188677	Parvin beta	22	43999211-44172949	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062601			Approved	Cytosol		Expressed in all	Expressed in all			skeletal muscle: 68.6	Mixed		
SLC4A5	NBC4	ENSG00000188687	Solute carrier family 4 member 5	2	74216242-74343414	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036621	Approved					Tissue enriched	Group enriched	6	testis: 30.9;thyroid gland: 44.9	skin: 6.3	Cell line enhanced		U-266/70: 7.2
UROS		ENSG00000188690	Uroporphyrinogen III synthase	10	125784980-125823248	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044038	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.27e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 84.7	Expressed in all		
OR56A5	OR56A5P	ENSG00000188691	Olfactory receptor family 56 subfamily A member 5	11	5967177-5968494	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
KRTAP24-1	KAP24.1	ENSG00000188694	Keratin associated protein 24-1	21	30281309-30282958	Predicted intracellular proteins	Evidence at protein level	HPA017604	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZDHHC9	CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380	ENSG00000188706	Zinc finger DHHC-type containing 9	X	129803288-129843909	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA031814	Uncertain		Supported	Golgi apparatus<br>Cytosol	Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 71.1	Expressed in all		
ZBED6CL	C7orf29	ENSG00000188707	ZBED6 C-terminal like	7	150329789-150332721	Predicted intracellular proteins	Evidence at transcript level	HPA019724, HPA055805	Approved		Approved	Nuclear membrane<br>Vesicles	Renal cancer:1.38e-5 (unfavourable), Pancreatic cancer:2.44e-5 (favourable), Glioma:5.65e-5 (unfavourable), Breast cancer:9.48e-5 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 31.7;parathyroid gland: 30.4	lymph node: 9.8	Cell line enhanced		HDLM-2: 80.9;K-562: 33.8
QRFP	26RFa, P518	ENSG00000188710	Pyroglutamylated RFamide peptide	9	130892702-130896812	Predicted secreted proteins	Evidence at transcript level	HPA043377	Uncertain					Mixed	Tissue enhanced		prostate: 1.3	esophagus: 1.2	Cell line enhanced		U-138 MG: 3.5
DUPD1	DUSP27	ENSG00000188716	Dual specificity phosphatase and pro isomerase domain containing 1	10	75037836-75058514	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042964	Uncertain					Not detected	Tissue enriched	30	skeletal muscle: 24.4	prostate: 0.8	Not detected		
SMIM15	C5orf43, DKFZP686E2158	ENSG00000188725	Small integral membrane protein 15	5	61157709-61162474	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:9.23e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 59.6	Mixed		
OSTN		ENSG00000188729	Osteocrin	3	191199241-191265615	Predicted secreted proteins	Evidence at protein level	CAB024997, CAB025649, HPA030878	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.4	cervix, uterine,epididymis: 2.0	Cell line enriched	30	U-2197: 36.4
VWC2	PSST739, UNQ739	ENSG00000188730	Von Willebrand factor C domain containing 2	7	49773661-49921950	Predicted secreted proteins	Evidence at protein level	HPA055243	Approved					Not detected	Tissue enhanced		heart muscle: 3.2;ovary: 6.1	cerebral cortex: 1.8	Not detected		
FAM221A	C7orf46, DKFZp686F0810, FLJ45875, MGC72075	ENSG00000188732	Family with sequence similarity 221 member A	7	23680130-23703249	Predicted intracellular proteins	Evidence at protein level	HPA019719, HPA026748, HPA026752	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		testis: 34.7	fallopian tube: 14.6	Cell line enhanced		MOLT-4: 20.7;SCLC-21H: 26.9;SH-SY5Y: 41.2
TMEM120B		ENSG00000188735	Transmembrane protein 120B	12	121712752-121783001	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014066	Uncertain		Approved	Nucleoli fibrillar center<br>Cytosol	Liver cancer:1.66e-5 (unfavourable)	Expressed in all	Mixed			endometrium: 11.7	Expressed in all		
FSIP2	FLJ34780	ENSG00000188738	Fibrous sheath interacting protein 2	2	185738895-185833290	Predicted intracellular proteins	Evidence at protein level	HPA036139			Approved	Microtubules<br>Mitochondria		Not detected	Tissue enriched	9	testis: 21.3	stomach: 2.4	Cell line enhanced		RT4: 1.1
RBM34	KIAA0117	ENSG00000188739	RNA binding motif protein 34	1	235131183-235161457	Predicted intracellular proteins	Evidence at protein level	HPA028606	Approved		Supported	Nucleus<br>Nucleoli		Mixed	Expressed in all			testis: 35.5	Expressed in all		
NOXA1	FLJ25475, NY-CO-31, SDCCAG31	ENSG00000188747	NADPH oxidase activator 1	9	137423350-137434406	Predicted intracellular proteins	Evidence at protein level	HPA044781	Uncertain		Approved	Vesicles	Renal cancer:2.65e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.5	Cell line enhanced		CAPAN-2: 11.1;EFO-21: 10.7;MCF7: 15.1;T-47d: 17.6
TMEM198	MGC99813, TMEM198A	ENSG00000188760	Transmembrane protein 198	2	219543663-219550595	Predicted membrane proteins	Evidence at protein level	HPA042385, HPA056598	Uncertain		Approved	Vesicles	Pancreatic cancer:6.89e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 15.7	duodenum: 8.9	Cell line enhanced		SCLC-21H: 23.4;SH-SY5Y: 18.3
BCL2L15	Bfk, C1orf178, FLJ22588	ENSG00000188761	BCL2 like 15	1	113878168-113887547	Predicted intracellular proteins	Evidence at protein level	HPA029732, HPA029733	Enhanced				Endometrial cancer:5.63e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 47.4;duodenum: 66.5;rectum: 52.2;small intestine: 64.3	stomach: 24.0	Cell line enhanced		CAPAN-2: 22.4;EFO-21: 8.1;RPTEC TERT1: 5.6
FZD9	CD349, FZD3	ENSG00000188763	Frizzled class receptor 9	7	73433783-73436120	CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Mixed			skeletal muscle,testis: 1.5	Cell line enhanced		HEK 293: 4.1;NTERA-2: 3.5
SPRED3		ENSG00000188766	Sprouty related EVH1 domain containing 3	19	38388421-38399587	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA071521			Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6	parathyroid gland: 2.6	Cell line enhanced		TIME: 12.9
OPTC		ENSG00000188770	Opticin	1	203494143-203508864	Predicted secreted proteins	Evidence at protein level	HPA034951, HPA034952	Enhanced					Tissue enriched	Not detected			testis: 0.6	Not detected		
PLET1	C11orf34	ENSG00000188771	Placenta expressed transcript 1	11	112248479-112260860	Predicted membrane proteins	Evidence at transcript level	HPA040237	Uncertain					Not detected	Not detected			skin: 0.4	Not detected		
ADRB3		ENSG00000188778	Adrenoceptor beta 3	8	37962991-37966965	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA061969	Uncertain					Not detected	Tissue enhanced		ovary: 8.9;placenta: 3.7	gallbladder: 2.2	Not detected		
SKOR1	CORL1, FUSSEL15, LBXCOR1	ENSG00000188779	SKI family transcriptional corepressor 1	15	67819704-67834561	Predicted intracellular proteins	Evidence at protein level	HPA040673	Approved					Not detected	Not detected			testis: 0.8	Cell line enhanced		U-266/70: 1.8;U-266/84: 1.3;U-698: 1.4
CATSPER4		ENSG00000188782	Cation channel sperm associated 4	1	26190561-26202968	Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA045257	Enhanced					Not detected	Tissue enriched	97	testis: 9.6	all non-specific tissues: 0.0	Not detected		
PRELP	prolargin, SLRR2A	ENSG00000188783	Proline and arginine rich end leucine rich repeat protein	1	203475828-203491352	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.62e-6 (unfavourable), Colorectal cancer:9.70e-5 (unfavourable), Urothelial cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 108.0	Group enriched	7	ASC diff: 12.4;BJ: 6.5;fHDF/TERT166: 9.1
PLA2G2E		ENSG00000188784	Phospholipase A2 group IIE	1	19920009-19923617	Enzymes, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA064085	Uncertain					Not detected	Tissue enriched	11	tonsil: 2.3	small intestine: 0.2	Not detected		
ZNF548	FLJ32932	ENSG00000188785	Zinc finger protein 548	19	57389850-57402992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066042	Uncertain		Approved	Nucleus	Breast cancer:7.85e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 32.6	Mixed		
MTF1		ENSG00000188786	Metal regulatory transcription factor 1	1	37809567-37859620	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028604, HPA028689	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Mixed			bone marrow: 13.1	Expressed in all		
TMCO2	dJ39G22.2	ENSG00000188800	Transmembrane and coiled-coil domains 2	1	40245947-40251691	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	776	testis: 188.7	urinary bladder: 0.2	Not detected		
SHISA6	FLJ45455	ENSG00000188803	Shisa family member 6	17	11241263-11564063	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA023440	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 24.7	seminal vesicle: 10.2	Cell line enriched	8	NTERA-2: 2.2
TMEM201	Ima1, NET5, RP13-15M17.2, SAMP1	ENSG00000188807	Transmembrane protein 201	1	9588922-9614873	Predicted membrane proteins	Evidence at protein level	CAB039039	Approved		Supported	Nucleus<br>Nuclear membrane	Liver cancer:9.61e-8 (unfavourable), Cervical cancer:5.36e-4 (favourable)	Expressed in all	Mixed			testis: 9.9	Expressed in all		
NHLRC3		ENSG00000188811	NHL repeat containing 3	13	39038306-39050109	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA013738	Uncertain					Expressed in all	Expressed in all			thyroid gland: 27.9	Expressed in all		
HMX2	NKX5-2	ENSG00000188816	H6 family homeobox 2	10	123148122-123150672	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043379	Uncertain					Tissue enhanced	Tissue enriched	6	kidney: 1.2	duodenum,prostate,small intestine: 0.1	Cell line enriched	12	REH: 34.4
SNTN	FLJ44379, S100AL	ENSG00000188817	Sentan, cilia apical structure protein	3	63652668-63679020	Predicted intracellular proteins	Evidence at protein level	HPA043322, HPA058399	Enhanced					Group enriched	Tissue enriched	12	fallopian tube: 349.6	thyroid gland: 29.2	Not detected		
ZDHHC11	FLJ13153, ZNF399	ENSG00000188818	Zinc finger DHHC-type containing 11	5	795606-850986	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA057886, HPA069008	Uncertain		Approved	Lipid droplets		Mixed	Mixed			fallopian tube: 10.6	Cell line enhanced		T-47d: 10.8
FAM26F	C6orf187, dJ93H18.5, INAM, OTTHUMP00000017061, OTTHUMP00000017062, RP1-93H18.5	ENSG00000188820	Family with sequence similarity 26 member F	6	116461370-116463779	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:9.31e-10 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 170.6	appendix: 80.5	Cell line enhanced		Karpas-707: 33.4;RPMI-8226: 110.4;U-937: 46.8
CNR2	CB2	ENSG00000188822	Cannabinoid receptor 2	1	23870526-23913362	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	CAB009719	Uncertain					Tissue enriched	Group enriched	6	appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9	bone marrow: 1.0	Group enriched	5	Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
SLX4	BTBD12, FANCP, KIAA1784, KIAA1987	ENSG00000188827	SLX4 structure-specific endonuclease subunit	16	3581181-3611598	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049421, HPA066238	Approved		Supported	Nucleoplasm<br>Cell Junctions<br>Cytosol		Expressed in all	Tissue enhanced		testis: 12.7	lymph node: 4.9	Expressed in all		
GLRA4		ENSG00000188828	Glycine receptor alpha 4	X	103707224-103728655	Predicted membrane proteins	Evidence at transcript level	HPA044759	Uncertain					Not detected	Tissue enhanced		smooth muscle: 2.8	parathyroid gland: 1.0	Cell line enriched	18	SCLC-21H: 2.8
ENTPD8	NTPDase-8, UNQ2492	ENSG00000188833	Ectonucleoside triphosphate diphosphohydrolase 8	9	137434364-137441816	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA021509	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Stomach cancer:7.17e-4 (favourable)	Mixed	Tissue enhanced		colon: 21.7;duodenum: 28.7;small intestine: 31.6	rectum: 12.5	Cell line enhanced		CAPAN-2: 4.8;RPMI-8226: 3.7;T-47d: 2.7
RPL14	CTG-B33, hRL14, L14, RL14	ENSG00000188846	Ribosomal protein L14	3	40457292-40468587	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA004136	Approved		Supported	Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			breast: 312.8	Expressed in all		
BEND4	CCDC4, FLJ35632, FLJ43965	ENSG00000188848	BEN domain containing 4	4	42110938-42152878	Predicted intracellular proteins	Evidence at protein level	HPA036850	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol		Group enriched	Tissue enhanced		prostate: 5.3;testis: 17.7	lymph node: 2.5	Cell line enhanced		HAP1: 35.3;HEL: 19.3;MOLT-4: 10.7;U-698: 9.6
FAM78B		ENSG00000188859	Family with sequence similarity 78 member B	1	166057426-166166969	Predicted intracellular proteins	Evidence at transcript level	HPA052789, HPA073246	Uncertain		Approved	Golgi apparatus<br>Vesicles		Mixed	Not detected			adipose tissue,cerebral cortex,duodenum,stomach,testis: 0.2	Group enriched	7	HDLM-2: 8.8;SK-MEL-30: 6.5;U-2 OS: 2.3;WM-115: 2.2
ZNF563	FLJ34797	ENSG00000188868	Zinc finger protein 563	19	12317477-12333720	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042136	Uncertain					Expressed in all	Tissue enhanced		testis: 25.7	thyroid gland: 8.5	Mixed		
TMC3		ENSG00000188869	Transmembrane channel like 3	15	81331217-81374213	Predicted membrane proteins	Evidence at protein level	HPA040265, HPA040510	Enhanced		Supported	Cytosol		Tissue enhanced	Tissue enriched	137	parathyroid gland: 252.6	epididymis: 1.8	Mixed		
FBF1	ALB, FBF-1, FLJ00103, KIAA1863	ENSG00000188878	Fas binding factor 1	17	75909574-75941140	Predicted intracellular proteins	Evidence at protein level	HPA023677			Supported	Centrosome		Mixed	Tissue enhanced		testis: 32.9	skin: 15.4	Mixed		
KLRG2	CLEC15B, FLJ44186	ENSG00000188883	Killer cell lectin like receptor G2	7	139452690-139483712	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018199	Uncertain				Lung cancer:8.61e-4 (favourable)	Tissue enriched	Tissue enhanced		lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.8	kidney: 2.7	Cell line enhanced		BEWO: 14.0;HAP1: 15.9;SCLC-21H: 8.6;SK-BR-3: 23.3
ASTL	ovastacin, SAS1B	ENSG00000188886	Astacin like metalloendopeptidase	2	96123850-96138436	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA015620	Uncertain					Mixed	Tissue enhanced		bone marrow: 2.4	seminal vesicle: 1.4	Not detected		
MSL1	DKFZp686P24239, hMSL1, MSL-1	ENSG00000188895	Male specific lethal 1 homolog	17	40122298-40136916	Predicted intracellular proteins	Evidence at protein level	HPA022800, HPA023567	Uncertain		Enhanced	Nucleoplasm	Renal cancer:3.06e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 107.0	Expressed in all		
CTD-3088G3.8		ENSG00000188897		16	11359845-11523588	Predicted intracellular proteins	Evidence at transcript level	HPA042154	Uncertain					Not detected	Tissue enhanced		appendix: 5.3;skin: 4.3	testis: 2.8	Cell line enhanced		Daudi: 2.2;HDLM-2: 3.2
LRRK2	DKFZp434H2111, FLJ45829, PARK8, RIPK7, ROCO2	ENSG00000188906	Leucine rich repeat kinase 2	12	40196744-40369285	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA014293, CAB037160	Approved		Approved	Nucleus<br>Vesicles	Renal cancer:3.02e-6 (favourable)	Group enriched	Expressed in all			lung: 95.4	Cell line enhanced		A549: 7.4;ASC TERT1: 5.6;RPTEC TERT1: 6.7
BSX	BSX1	ENSG00000188909	Brain specific homeobox	11	122977570-122981720	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA015654	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
GJB3	CX31, DFNA2, EKV	ENSG00000188910	Gap junction protein beta 3	1	34781189-34786369	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074472			Supported	Vesicles<br>Cell Junctions	Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 33.6;skin: 77.3	tonsil: 11.6	Cell line enhanced		A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
FAM196A	C10orf141, FLJ45557, INSYN2	ENSG00000188916	Family with sequence similarity 196 member A	10	127135426-127196158	Predicted intracellular proteins	Evidence at protein level	HPA035898, HPA035899	Uncertain					Group enriched	Tissue enhanced		cerebral cortex: 3.2	prostate: 1.3	Group enriched	7	SCLC-21H: 3.2;U-87 MG: 5.2
TRMT2B	CXorf34, FLJ12687	ENSG00000188917	TRNA methyltransferase 2 homolog B	X	101009346-101052116	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003745, HPA035120, HPA040814	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.30e-7 (favourable), Breast cancer:1.58e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 21.5	Expressed in all		
HACD4	Em:AL662879.1, PTPLAD2	ENSG00000188921	3-hydroxyacyl-CoA dehydratase 4	9	20999515-21031636	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA058666	Uncertain				Ovarian cancer:3.14e-4 (favourable), Renal cancer:6.77e-4 (unfavourable)	Mixed	Mixed			lung: 12.6	Cell line enhanced		BJ hTERT+: 14.0;HDLM-2: 10.0;U-937: 10.5
CFAP126	C1orf192, Flattop, Fltp	ENSG00000188931	Cilia and flagella associated protein 126	1	161364731-161367874	Predicted intracellular proteins	Evidence at protein level	HPA045904	Enhanced					Not detected	Tissue enriched	9	fallopian tube: 228.1	testis: 25.0	Cell line enhanced		CAPAN-2: 2.3;SCLC-21H: 1.0
NYX	CLRP, CSNB1, CSNB1A, CSNB4	ENSG00000188937	Nyctalopin	X	41447434-41475710	Disease related genes, Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			kidney: 0.3	Cell line enhanced		HDLM-2: 2.3
FAM120AOS	C9orf10OS	ENSG00000188938	Family with sequence similarity 120A opposite strand	9	93446494-93453592	Predicted intracellular proteins	Evidence at transcript level	HPA021475	Approved				Liver cancer:2.95e-5 (unfavourable), Renal cancer:6.04e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 50.3	Expressed in all		
UTS2B	U2B, URP, UTS2D	ENSG00000188958	Urotensin 2B	3	191267168-191330536	Predicted secreted proteins	Evidence at transcript level	HPA026992	Uncertain		Uncertain	Mitochondria		Not detected	Mixed			duodenum: 5.3	Mixed		
C9orf152	bA470J20.2	ENSG00000188959	Chromosome 9 open reading frame 152	9	110190048-110208189	Predicted intracellular proteins	Evidence at protein level	HPA050769	Approved		Supported	Nucleus	Endometrial cancer:7.22e-5 (favourable)	Mixed	Tissue enhanced		rectum: 44.5	colon: 32.5	Group enriched	6	SK-BR-3: 6.9;T-47d: 16.7
NOC2L	DKFZP564C186, NET15, NET7, NIR, PPP1R112	ENSG00000188976	NOC2 like nucleolar associated transcriptional repressor	1	944204-959309	Predicted intracellular proteins	Evidence at protein level	HPA044258, HPA062195	Approved		Enhanced	Nucleoli		Expressed in all	Expressed in all			skin: 42.0	Expressed in all		
MSANTD1	C4orf44, LOC345222	ENSG00000188981	Myb/SANT DNA binding domain containing 1	4	3244369-3271738	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	7	cerebral cortex: 1.9;testis: 2.4	epididymis,lung,spleen: 0.3	Not detected		
AADACL3		ENSG00000188984	Arylacetamide deacetylase like 3	1	12716115-12728759	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		placenta: 1.3	skin: 0.7	Not detected		
NELFB	COBRA1, KIAA1182, NELF-B	ENSG00000188986	Negative elongation factor complex member B	9	137255173-137273546	Predicted intracellular proteins	Evidence at protein level	HPA020259	Enhanced		Enhanced	Nucleoplasm	Renal cancer:4.31e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 47.4	Expressed in all		
SLC15A5		ENSG00000188991	Solute carrier family 15 member 5	12	16188485-16277685	Predicted membrane proteins, Transporters	No evidence	HPA041638	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
LIPI	CT17, LPDL, mPA-PLA1beta, PLA1C, PRED5	ENSG00000188992	Lipase I	21	14108813-14210891	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	120	epididymis: 577.5	thyroid gland: 4.8	Not detected		
LRRC66		ENSG00000188993	Leucine rich repeat containing 66	4	51993702-52017620	Predicted membrane proteins	Evidence at transcript level	HPA014549, HPA027839	Uncertain					Mixed	Tissue enhanced		duodenum: 22.5;small intestine: 20.5	rectum: 6.4	Cell line enhanced		ASC TERT1: 1.0;CAPAN-2: 1.8
ZNF292	bA393I2.3, KIAA0530, ZFP292, Zn-15, Zn-16	ENSG00000188994	Zinc finger protein 292	6	87152833-87264196	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA032154, HPA050618	Uncertain		Approved	Nucleus<br>Nuclear membrane		Expressed in all	Expressed in all			endometrium: 17.1	Expressed in all		
HUS1B		ENSG00000188996	HUS1 checkpoint clamp component B	6	655939-656963	Predicted intracellular proteins	Evidence at protein level	HPA034511, HPA063449			Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 1.2	bone marrow: 0.4	Cell line enhanced		HEK 293: 1.6;U-266/84: 1.5;WM-115: 2.2
KCTD21	KCASH2	ENSG00000188997	Potassium channel tetramerization domain containing 21	11	78171249-78188822	Predicted intracellular proteins	Evidence at protein level	HPA041964	Uncertain		Approved	Cytosol	Thyroid cancer:9.57e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 18.8	Expressed in all		
SBSN	HLAR698, UNQ698	ENSG00000189001	Suprabasin	19	35523367-35528351	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062568, HPA067734	Enhanced		Approved	Vesicles		Group enriched	Group enriched	12	esophagus: 1055.9;skin: 2690.8	tonsil: 151.8	Cell line enhanced		ASC diff: 42.6;ASC TERT1: 75.3;HSkMC: 106.4;U-2197: 48.0;U-87 MG: 117.4
ADAT2	DEADC1, dJ20N2.1, TAD2	ENSG00000189007	Adenosine deaminase, tRNA specific 2	6	143422832-143450673	Predicted intracellular proteins	Evidence at protein level	HPA035479	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Expressed in all	Mixed			skin: 13.0	Expressed in all		
KIR2DL4	103AS, 15.212, CD158D	ENSG00000189013	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 4	19	54803535-54814517	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Not detected			all non-specific tissues: 0.0	Not detected		
MAGEB16		ENSG00000189023	MAGE family member B16	X	35798342-35803735	Predicted intracellular proteins	Evidence at protein level	HPA055743	Uncertain					Tissue enhanced	Tissue enriched	63	testis: 6.2	all non-specific tissues: 0.0	Group enriched	207	K-562: 12.2;U-266/70: 45.6
VHLL	VHLP, VLP	ENSG00000189030	Von Hippel-Lindau tumor suppressor like	1	156298624-156299299	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			esophagus,gallbladder,testis: 0.1	Not detected		
DUSP21		ENSG00000189037	Dual specificity phosphatase 21	X	44844004-44844888	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	41	testis: 9.9	small intestine: 0.2	Not detected		
ZNF567	MGC45586	ENSG00000189042	Zinc finger protein 567	19	36687612-36727701	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023937	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			testis: 16.1	Mixed		
NDUFA4	CI-9k, MLRQ	ENSG00000189043	NDUFA4, mitochondrial complex associated	7	10931951-10940256	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA055323			Supported	Mitochondria	Renal cancer:4.61e-8 (favourable)	Expressed in all	Expressed in all			heart muscle: 251.7	Expressed in all		
ANKDD1B		ENSG00000189045	Ankyrin repeat and death domain containing 1B	5	75611459-75671846	Predicted intracellular proteins	Evidence at transcript level	HPA059722	Uncertain				Renal cancer:2.30e-7 (favourable)	Mixed	Tissue enhanced		fallopian tube: 3.5	rectum: 2.4	Cell line enhanced		RPMI-8226: 1.5
ALKBH2	ABH2, MGC90512	ENSG00000189046	AlkB homolog 2, alpha-ketoglutarate dependent dioxygenase	12	109088188-109093631	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB011198, HPA045392, HPA051976	Approved		Enhanced	Nucleus	Renal cancer:1.41e-5 (unfavourable), Breast cancer:6.67e-5 (favourable), Urothelial cancer:8.67e-4 (favourable)	Expressed in all	Expressed in all			skin: 27.0	Expressed in all		
RNFT1	PTD016	ENSG00000189050	Ring finger protein, transmembrane 1	17	59952240-59964761	Predicted membrane proteins	Evidence at protein level	HPA013739			Approved	Nucleoli	Thyroid cancer:2.57e-4 (favourable), Colorectal cancer:6.57e-4 (favourable), Lung cancer:7.48e-4 (favourable)	Expressed in all	Tissue enriched	9	testis: 114.0	epididymis: 12.6	Expressed in all		
RNF222		ENSG00000189051	Ring finger protein 222	17	8390704-8397826	Predicted membrane proteins	Evidence at transcript level	HPA048916	Uncertain					Tissue enhanced	Group enriched	6	esophagus: 9.7;skin: 4.1;tonsil: 2.0	bone marrow: 0.9	Cell line enriched	7	SK-BR-3: 5.1
CGB5	HCG	ENSG00000189052	Chorionic gonadotropin beta subunit 5	19	49043884-49045311	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol	Stomach cancer:1.18e-5 (unfavourable), Urothelial cancer:9.47e-4 (unfavourable)	Tissue enhanced	Tissue enriched	68	placenta: 31.7	pancreas,skin,testis: 0.4	Group enriched	24	BEWO: 99.4;U-251 MG: 40.1
RELN	PRO1598, RL	ENSG00000189056	Reelin	7	103471784-103989516	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046512			Approved	Plasma membrane<br>Focal adhesion sites		Tissue enhanced	Tissue enhanced		liver: 17.8	cerebral cortex: 7.3	Cell line enhanced		Hep G2: 43.5;PC-3: 11.6;SCLC-21H: 17.5;SH-SY5Y: 17.2;TIME: 29.6
FAM111B	CANP	ENSG00000189057	Family with sequence similarity 111 member B	11	59107185-59127410	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038637	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.17e-5 (unfavourable), Liver cancer:1.76e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 14.9	Mixed		
APOD		ENSG00000189058	Apolipoprotein D	3	195568702-195584205	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA040520	Enhanced		Approved	Plasma membrane	Thyroid cancer:4.12e-4 (unfavourable), Breast cancer:5.51e-4 (favourable), Stomach cancer:6.02e-4 (unfavourable)	Expressed in all	Tissue enriched	7	breast: 4620.2	adipose tissue: 670.2	Cell line enhanced		ASC diff: 1866.1;ASC TERT1: 1018.4;WM-115: 301.1
H1F0	H10, H1FV	ENSG00000189060	H1 histone family member 0	22	37805093-37807436	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000843	Enhanced		Supported	Nucleus<br>Nuclear bodies<br>Golgi apparatus<br>Actin filaments	Renal cancer:7.68e-7 (favourable)	Expressed in all	Expressed in all			bone marrow: 420.2	Cell line enhanced		U-2 OS: 855.8
GAGE2A	CT4.2, GAGE2	ENSG00000189064	G antigen 2A	X	49589529-49596827	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	560	testis: 176.3	cerebral cortex: 0.3	Cell line enhanced		Karpas-707: 62.0;T-47d: 279.0;WM-115: 324.4
LITAF	FLJ38636, PIG7, SIMPLE, TP53I7	ENSG00000189067	Lipopolysaccharide induced TNF factor	16	11547722-11636381	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA006960	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Glioma:1.78e-4 (unfavourable), Testis cancer:6.25e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 225.8	Mixed		
VSTM1	UNQ3033	ENSG00000189068	V-set and transmembrane domain containing 1	19	54040825-54063953	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA059365			Approved	Vesicles		Mixed	Tissue enriched	38	bone marrow: 35.4	urinary bladder: 0.9	Not detected		
TMEM120A	NET29, TMPIT	ENSG00000189077	Transmembrane protein 120A	7	75986837-75994659	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level							Expressed in all	Expressed in all			testis: 72.8	Expressed in all		
ARID2	BAF200, DKFZp686G052, FLJ30619, KIAA1557	ENSG00000189079	AT-rich interaction domain 2	12	45729665-45908040	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063044			Supported	Nucleoplasm<br>Plasma membrane	Head and neck cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.3	Expressed in all		
FAM25G	bA301J7.4	ENSG00000189090	Family with sequence similarity 25 member G	10	47487219-47491693	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Not detected	Tissue enriched	15	skin: 87.4	breast: 5.8	Cell line enriched	25	SK-BR-3: 16.5
SF3B3	KIAA0017, RSE1, SAP130, SF3b130	ENSG00000189091	Splicing factor 3b subunit 3	16	70523788-70577670	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041134, HPA042986	Supported		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 40.9	Expressed in all		
PRSS48	ESSPL	ENSG00000189099	Protease, serine 48	4	151277171-151291453	Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA053801	Uncertain					Not detected	Tissue enhanced		testis: 1.4	skin: 0.4	Not detected		
IL1RAPL2	IL-1R9, IL1R9, IL1RAPL-2, TIGIRR-1	ENSG00000189108	Interleukin 1 receptor accessory protein like 2	X	104566315-105767829	Predicted membrane proteins	Evidence at protein level	HPA036128, HPA036129	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 4.8	adrenal gland: 1.9	Cell line enhanced		fHDF/TERT166: 1.1;hTERT-HME1: 4.3;NTERA-2: 1.0;RT4: 1.6
BLOC1S3	BLOS3, HPS8	ENSG00000189114	Biogenesis of lysosomal organelles complex 1 subunit 3	19	45178745-45181801	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050111			Approved	Golgi apparatus	Renal cancer:3.89e-9 (unfavourable), Urothelial cancer:6.86e-4 (favourable)	Expressed in all	Mixed			skin: 12.1	Expressed in all		
SP6	Epfn, KLF14	ENSG00000189120	Sp6 transcription factor	17	47844908-47855874	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024516, HPA044469			Supported	Nucleoplasm<br>Mitotic spindle<br>Centrosome	Lung cancer:2.11e-6 (unfavourable), Urothelial cancer:5.72e-4 (favourable), Stomach cancer:6.39e-4 (favourable)	Mixed	Tissue enhanced		placenta: 32.5;seminal vesicle: 14.7	skin: 7.2	Cell line enriched	5	BEWO: 88.4
ANKRD34B	DP58	ENSG00000189127	Ankyrin repeat domain 34B	5	80556755-80570488	Predicted intracellular proteins	Evidence at protein level	HPA043327	Uncertain		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol		Tissue enhanced	Tissue enhanced		bone marrow: 1.1;lymph node: 1.0;tonsil: 1.1	kidney: 0.7	Cell line enriched	23	RPTEC TERT1: 71.4
PLAC9		ENSG00000189129	Placenta specific 9	10	80131682-80145359	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043469	Uncertain				Ovarian cancer:6.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 87.5	breast: 68.4	Cell line enhanced		ASC diff: 67.4;ASC TERT1: 59.6;BEWO: 31.0
FAM47B	FLJ35782	ENSG00000189132	Family with sequence similarity 47 member B	X	34942796-34944915	Predicted intracellular proteins	Evidence at protein level	HPA046829, HPA050996	Uncertain					Not detected	Tissue enriched	133	testis: 13.3	all non-specific tissues: 0.0	Not detected		
NKAPL	bA424I5.1, C6orf194	ENSG00000189134	NFKB activating protein like	6	28259320-28260958	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	15	testis: 53.4	seminal vesicle: 3.6	Cell line enhanced		ASC diff: 2.2;BJ: 1.2;fHDF/TERT166: 1.7;HHSteC: 3.9;HSkMC: 2.2
FSCB	C14orf155, DKFZP434F1017	ENSG00000189139	Fibrous sheath CABYR binding protein	14	44504342-44507279	Predicted intracellular proteins	Evidence at protein level	HPA003546	Supported					Not detected	Tissue enriched	520	testis: 51.9	all non-specific tissues: 0.0	Not detected		
CLDN4	CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8	ENSG00000189143	Claudin 4	7	73799542-73832693	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB002610	Enhanced		Supported	Plasma membrane	Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable)	Mixed	Mixed			colon: 208.6	Cell line enhanced		A-431: 285.9;BEWO: 354.2;CAPAN-2: 613.4;MCF7: 279.4;PC-3: 419.8;SK-BR-3: 439.0
ZNF573	FLJ30921	ENSG00000189144	Zinc finger protein 573	19	37735833-37817300	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA042776	Uncertain		Approved	Intermediate filaments<br>Cytosol		Mixed	Mixed			thyroid gland: 4.2	Mixed		
GRAPL		ENSG00000189152	GRB2 related adaptor protein like	17	19127469-19159176	Predicted intracellular proteins	Evidence at transcript level	HPA051796, HPA066654	Uncertain		Approved	Centrosome		Not detected	Tissue enhanced		lymph node: 26.7;spleen: 32.0	tonsil: 21.5	Group enriched	6	Daudi: 27.6;HUVEC TERT2: 13.0;TIME: 34.3;U-698: 24.5
FAM47E	FLJ42946, LOC100129583	ENSG00000189157	Family with sequence similarity 47 member E	4	76214040-76283780	Predicted intracellular proteins	Evidence at transcript level	HPA053331	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 28.1	thyroid gland: 16.3	Mixed		
HN1	ARM2, HN1A	ENSG00000189159	Hematological and neurological expressed 1	17	75135248-75168281	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA059729	Approved		Supported	Nucleus<br>Nuclear membrane<br>Nucleoli	Liver cancer:1.58e-7 (unfavourable), Renal cancer:1.77e-7 (unfavourable), Ovarian cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			testis: 422.3	Expressed in all		
ZNF527	KIAA1829	ENSG00000189164	Zinc finger protein 527	19	37371061-37393066	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA037740, HPA037741	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Mixed	Mixed			parathyroid gland: 4.8	Mixed		
ZAR1L	Z3CXXC7	ENSG00000189167	Zygote arrest 1-like	13	32303700-32315344	Predicted intracellular proteins	Evidence at transcript level	HPA041319	Uncertain					Not detected	Not detected			testis: 0.7	Not detected		
KRTAP10-12	KAP10.12, KRTAP18-12, KRTAP18.12	ENSG00000189169	Keratin associated protein 10-12	21	44697172-44698044	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
S100A13		ENSG00000189171	S100 calcium binding protein A13	1	153618787-153631360	Predicted intracellular proteins	Evidence at protein level	HPA019592, CAB025494	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:1.97e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 331.5	Mixed		
ZNF33A	FLJ23404, KIAA0065, KOX31, KOX5, ZNF11A, ZNF33, ZZAPK	ENSG00000189180	Zinc finger protein 33A	10	38010650-38065088	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056638	Approved					Expressed in all	Expressed in all			parathyroid gland: 35.1	Expressed in all		
OR14I1	OR5BU1, OR5BU1P	ENSG00000189181	Olfactory receptor family 14 subfamily I member 1	1	248681369-248682304	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	5	cerebral cortex: 3.4	prostate: 0.6	Not detected		
KRT77	KRT1B	ENSG00000189182	Keratin 77	12	52689626-52703463	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045934	Enhanced		Approved	Nuclear membrane<br>Plasma membrane		Mixed	Tissue enriched	12	skin: 308.7	breast: 26.2	Cell line enriched	33	HaCaT: 3.2
PCDH18	KIAA1562, PCDH68L	ENSG00000189184	Protocadherin 18	4	137518918-137532494	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017976	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.21e-4 (unfavourable), Urothelial cancer:4.71e-4 (unfavourable)	Mixed	Mixed			placenta: 64.5	Cell line enhanced		AF22: 148.8;ASC diff: 122.0;ASC TERT1: 137.4;fHDF/TERT166: 114.4;HHSteC: 109.9;HSkMC: 146.3
DCAF8L2	WDR42C	ENSG00000189186	DDB1 and CUL4 associated factor 8 like 2	X	27590382-27748821	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	52	testis: 40.5	ovary: 0.7	Cell line enriched	7	U-2 OS: 9.9
ZNF600	DKFZp686F06123, KR-ZNF1	ENSG00000189190	Zinc finger protein 600	19	52764195-52786791	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:4.98e-7 (unfavourable), Urothelial cancer:1.11e-5 (favourable)	Expressed in all	Mixed			spleen: 7.8	Cell line enhanced		RT4: 17.0
BTBD8		ENSG00000189195	BTB domain containing 8	1	92080305-92184725	Predicted intracellular proteins	Evidence at transcript level	HPA024216, HPA035311, HPA035312	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			parathyroid gland: 3.7	Cell line enhanced		ASC TERT1: 2.1;BEWO: 2.4
MAOA		ENSG00000189221	Monoamine oxidase A	X	43654907-43746824	Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB009437, HPA054807, HPA059299	Enhanced		Enhanced	Mitochondria		Expressed in all	Mixed			small intestine: 248.3	Cell line enhanced		ASC diff: 108.7;HHSteC: 249.1;hTCEpi: 61.9;RT4: 102.5
C15orf61	LOC145853	ENSG00000189227	Chromosome 15 open reading frame 61	15	67521068-67530143	Predicted intracellular proteins	Evidence at protein level	HPA062820			Approved	Nucleoli<br>Vesicles<br>Cytosol	Renal cancer:5.31e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.0	Mixed		
NUGGC	C8orf80, HMFN0672, SLIP-GC	ENSG00000189233	Nuclear GTPase, germinal center associated	8	28021964-28083871	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 22.9;tonsil: 21.4	liver: 11.0	Cell line enhanced		Daudi: 84.7;Karpas-707: 28.5;U-698: 59.8
TSPYL1	TSPYL	ENSG00000189241	TSPY like 1	6	116276578-116279903	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031970, HPA031971	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.48e-13 (favourable), Pancreatic cancer:5.40e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 191.9	Expressed in all		
SPANXN3	CT11.8, SPANX-N3	ENSG00000189252	SPANX family member N3	X	143508735-143517475	Predicted intracellular proteins	Evidence at transcript level	HPA045652			Approved	Nucleus<br>Nucleoli fibrillar center		Not detected	Tissue enriched	58	testis: 52.1	duodenum: 0.8	Cell line enriched	6	U-2 OS: 1.9
TRIM64B		ENSG00000189253	Tripartite motif containing 64B	11	89869282-89876017	Predicted intracellular proteins	Evidence at transcript level	HPA045370	Approved					Not detected	Tissue enriched	18	placenta: 3.1	testis,thyroid gland: 0.1	Not detected		
PNRC2		ENSG00000189266	Proline rich nuclear receptor coactivator 2	1	23959109-23963462	Predicted intracellular proteins	Evidence at protein level	HPA027820, HPA045837	Uncertain		Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:7.97e-5 (unfavourable), Melanoma:1.41e-4 (unfavourable), Urothelial cancer:4.05e-4 (favourable), Breast cancer:6.02e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 203.4	Expressed in all		
DRICH1	C22orf43	ENSG00000189269	Aspartate rich 1	22	23608452-23632321	Predicted intracellular proteins	Evidence at protein level	HPA020446			Approved	Nucleus<br>Nucleoli		Mixed	Group enriched	8	epididymis: 20.8;parathyroid gland: 23.9;testis: 81.2	endometrium: 5.4	Cell line enhanced		CACO-2: 9.2
GJB5	CX31.1	ENSG00000189280	Gap junction protein beta 5	1	34755047-34758512	Cancer-related genes, Predicted membrane proteins	Evidence at transcript level	HPA038146	Uncertain				Pancreatic cancer:1.54e-4 (unfavourable)	Group enriched	Group enriched	6	esophagus: 56.4;skin: 77.4	tonsil: 11.4	Cell line enhanced		A-431: 25.3;HaCaT: 80.2;HBEC3-KT: 29.1;hTCEpi: 106.2;RT4: 40.6
FHIT	AP3Aase, FRA3B	ENSG00000189283	Fragile histidine triad	3	59749310-61251459	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002684, HPA018840, HPA018909	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane	Renal cancer:1.36e-4 (favourable)	Mixed	Expressed in all			kidney: 26.8	Cell line enhanced		U-266/70: 27.6
ALKAL2	AUGA, FAM150B	ENSG00000189292	ALK and LTK ligand 2	2	279558-288851	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		adrenal gland: 257.4	ovary: 83.0	Cell line enriched	22	AF22: 137.0
ZKSCAN3	ZF47, Zfp47, ZNF306, ZNF309, ZSCAN35	ENSG00000189298	Zinc finger with KRAB and SCAN domains 3	6	28349914-28369177	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009637, HPA060116	Approved		Enhanced	Nucleoplasm	Glioma:6.55e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.1	Mixed		
FOXR2	FOXN6, MGC21658	ENSG00000189299	Forkhead box R2	X	55623400-55625325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034487, HPA057358	Uncertain		Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	15	testis: 2.8	epididymis: 0.1	Group enriched	107	NTERA-2: 12.2;SH-SY5Y: 11.3;U-266/70: 5.4;U-266/84: 13.9
RRP7A	CGI-96	ENSG00000189306	Ribosomal RNA processing 7 homolog A	22	42509968-42519802	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001586, HPA046768	Approved		Approved	Nucleus<br>Nucleoli<br>Cell Junctions	Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.3	Expressed in all		
LIN54	CXCDC1, DKFZp686L1814, JC8.6, MIP120, TCX1	ENSG00000189308	Lin-54 DREAM MuvB core complex component	4	82909973-83012926	Predicted intracellular proteins	Evidence at protein level	HPA056606	Approved		Approved	Cytosol	Renal cancer:1.06e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 17.2	Expressed in all		
FAM53B	bA12J10.2, KIAA0140, smp	ENSG00000189319	Family with sequence similarity 53 member B	10	124619292-124744269	Predicted intracellular proteins	Evidence at protein level	HPA037751, HPA037752	Approved		Approved	Cytosol	Renal cancer:4.81e-7 (favourable), Pancreatic cancer:7.00e-6 (favourable), Head and neck cancer:1.97e-4 (favourable), Stomach cancer:3.26e-4 (favourable), Cervical cancer:4.96e-4 (favourable)	Expressed in all	Mixed			lymph node: 37.9	Expressed in all		
FAM180A	HWKM1940, UNQ1940	ENSG00000189320	Family with sequence similarity 180 member A	7	135728348-135748846	Predicted secreted proteins	Evidence at protein level	HPA021224	Uncertain					Mixed	Tissue enhanced		gallbladder: 25.5	heart muscle: 10.4	Cell line enhanced		BJ hTERT+: 45.6;fHDF/TERT166: 44.5;U-138 MG: 55.9;U-2197: 239.9
C6orf222	DKFZp779B1540	ENSG00000189325	Chromosome 6 open reading frame 222	6	36315757-36336885	Predicted intracellular proteins	Evidence at protein level	HPA038407, HPA058189	Uncertain					Group enriched	Tissue enhanced		duodenum: 24.7;small intestine: 26.4	rectum: 6.2	Not detected		
SPANXN4	CT11.9, SPANX-N4	ENSG00000189326	SPANX family member N4	X	143025918-143034702	Predicted intracellular proteins	Evidence at transcript level	HPA045730	Uncertain					Not detected	Tissue enriched	227	testis: 22.7	all non-specific tissues: 0.0	Not detected		
S100A14	BCMP84, S100A15	ENSG00000189334	S100 calcium binding protein A14	1	153614255-153616986	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA027613	Enhanced		Supported	Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol		Mixed	Tissue enhanced		esophagus: 2205.9	skin: 591.6	Group enriched	9	A-431: 692.6;HaCaT: 944.8;HBEC3-KT: 1089.8;hTCEpi: 1601.4;SK-BR-3: 1180.8
KAZN	FLJ43806, KAZRIN, KIAA1026	ENSG00000189337	Kazrin, periplakin interacting protein	1	13892792-15118043	Predicted intracellular proteins	Evidence at protein level	HPA032095, HPA032096	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Cytosol	Renal cancer:1.20e-6 (favourable)	Mixed	Tissue enhanced		spleen: 118.3	parathyroid gland: 42.3	Cell line enhanced		AN3-CA: 79.3
SLC35E2B		ENSG00000189339	Solute carrier family 35 member E2B	1	1659529-1692728	Predicted membrane proteins, Transporters	Evidence at protein level	HPA045641, HPA062711	Uncertain		Uncertain	Nucleus	Urothelial cancer:5.15e-4 (favourable), Head and neck cancer:7.64e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 47.2	Expressed in all		
TOGARAM2	Crescerin-2, FAM179A, FLJ43249, LOC165186	ENSG00000189350	TOG array regulator of axonemal microtubules 2	2	28956611-29061373	Predicted intracellular proteins	Evidence at protein level	HPA037561, HPA037562	Uncertain					Not detected	Tissue enriched	5	fallopian tube: 13.7	lung: 2.5	Mixed		
SPATA31D4	FAM75D4, FLJ43859	ENSG00000189357	SPATA31 subfamily D member 4	9	81928514-81934948	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	49	testis: 4.8	all non-specific tissues: 0.0	Not detected		
NEMP2	TMEM194B	ENSG00000189362	Nuclear envelope integral membrane protein 2	2	190504342-190534722	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA057719			Approved	Nucleoplasm	Renal cancer:6.42e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.6	Mixed		
ALG1L	ALG1L1	ENSG00000189366	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase like	3	125929275-125937039	Predicted intracellular proteins	Evidence at transcript level	HPA036108	Uncertain				Glioma:1.82e-4 (favourable), Urothelial cancer:6.24e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 13.1;urinary bladder: 14.8	skin: 6.8	Cell line enhanced		CACO-2: 13.2;CAPAN-2: 12.6;HaCaT: 13.5;MCF7: 23.1;T-47d: 18.5
KIAA0408		ENSG00000189367	KIAA0408	6	127440343-127459391	Predicted intracellular proteins	Evidence at protein level	HPA044035, HPA053341	Uncertain		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 43.8	lung: 30.8	Cell line enhanced		AF22: 21.1;SCLC-21H: 62.8;SH-SY5Y: 28.1
GSPT2	eRF3b, FLJ10441	ENSG00000189369	G1 to S phase transition 2	X	51743431-51746232	Predicted intracellular proteins	Evidence at protein level	HPA044769	Approved		Supported	Cytosol		Expressed in all	Expressed in all			testis: 24.5	Cell line enhanced		NTERA-2: 47.4;PC-3: 49.6
TBC1D28	FLJ40244	ENSG00000189375	TBC1 domain family member 28	17	18635006-18661950	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	70	testis: 18.1	spleen,tonsil: 0.2	Not detected		
C8orf76	FLJ14825	ENSG00000189376	Chromosome 8 open reading frame 76	8	123219957-123241398	Predicted intracellular proteins	Evidence at transcript level	HPA023708	Uncertain		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:5.95e-11 (unfavourable), Endometrial cancer:1.61e-4 (unfavourable), Breast cancer:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 16.1	Expressed in all		
CXCL17	Dcip1, DMC, UNQ473, VCC1	ENSG00000189377	C-X-C motif chemokine ligand 17	19	42428288-42443048	Predicted secreted proteins	Evidence at protein level						Lung cancer:4.92e-5 (favourable), Pancreatic cancer:4.63e-4 (unfavourable)	Mixed	Tissue enhanced		lung: 193.5;stomach: 289.7	esophagus: 83.1	Cell line enhanced		RT4: 1.8
OTUD6A	DUBA2, FLJ25831, HSHIN6	ENSG00000189401	OTU deubiquitinase 6A	X	70062491-70064179	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053304	Enhanced					Tissue enriched	Tissue enriched	14	testis: 9.5	thyroid gland: 0.7	Not detected		
HMGB1	DKFZp686A04236, HMG1, HMG3, SBP-1	ENSG00000189403	High mobility group box 1	13	30456704-30617597	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003506, CAB005873	Supported		Supported	Nucleus		Expressed in all	Expressed in all			lymph node: 781.8	Expressed in all		
MMP23B	MIFR, MIFR-1, MMP22	ENSG00000189409	Matrix metallopeptidase 23B	1	1632095-1635263	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Mixed			gallbladder,placenta: 4.1	Cell line enhanced		HHSteC: 3.5;NTERA-2: 1.8;U-266/70: 2.5
SH2D5		ENSG00000189410	SH2 domain containing 5	1	20719732-20732837	Predicted intracellular proteins	Evidence at protein level	HPA030182			Supported	Cytosol		Tissue enhanced	Group enriched	7	cerebral cortex: 16.6;placenta: 5.1;testis: 9.9	thyroid gland: 1.5	Cell line enhanced		HBEC3-KT: 34.9;hTERT-HME1: 46.6
ZFP92	ZNF897	ENSG00000189420	ZFP92 zinc finger protein	X	153418322-153426481	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA003030	Uncertain					Tissue enhanced	Mixed			fallopian tube: 5.3	Cell line enhanced		HDLM-2: 3.5;HMC-1: 3.1;U-937: 4.8
NCR1	CD335, LY94, NK-p46, NKP46	ENSG00000189430	Natural cytotoxicity triggering receptor 1	19	54906150-54916140	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049311			Approved	Endoplasmic reticulum		Tissue enhanced	Not detected			spleen: 0.6	Not detected		
RASSF10		ENSG00000189431	Ras association domain family member 10	11	13009577-13012106	Predicted intracellular proteins	Evidence at transcript level	HPA040406			Approved	Vesicles<br>Cytosol	Renal cancer:4.12e-5 (favourable), Head and neck cancer:2.76e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 5.4	parathyroid gland: 3.8	Cell line enhanced		A549: 8.6;CAPAN-2: 7.5;HaCaT: 11.6;HMC-1: 5.6;RPTEC TERT1: 9.8
GJB4	CX30.3	ENSG00000189433	Gap junction protein beta 4	1	34759741-34763724	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA055112			Supported	Cell Junctions	Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable)	Group enriched	Tissue enriched	6	skin: 27.7	epididymis: 4.6	Cell line enhanced		A-431: 4.0;HaCaT: 5.8;HBEC3-KT: 3.1;hTCEpi: 2.0;RPTEC TERT1: 1.9;RT4: 2.4
OR2L13	OR2L14	ENSG00000196071	Olfactory receptor family 2 subfamily L member 13	1	248098649-248100922	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 4.0	prostate: 1.0	Not detected		
BLOC1S2	BLOS2, BORCS2, FLJ30135, MGC10120	ENSG00000196072	Biogenesis of lysosomal organelles complex 1 subunit 2	10	100273280-100286712	Predicted intracellular proteins	Evidence at protein level	HPA048088, HPA055010	Approved					Expressed in all	Expressed in all			cerebral cortex: 101.8	Expressed in all		
SYCP2	SCP2	ENSG00000196074	Synaptonemal complex protein 2	20	59863563-59933655	Predicted intracellular proteins	Evidence at protein level	HPA062401, HPA065613			Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol		Group enriched	Group enriched	8	breast: 17.7;testis: 76.9	prostate: 6.0	Cell line enhanced		MOLT-4: 43.5;SiHa: 97.9;T-47d: 77.3
ZNF724	ZNF724P	ENSG00000196081	Zinc finger protein 724	19	23221599-23250390	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			esophagus: 2.9	Mixed		
IL1RAP	C3orf13, IL-1RAcP, IL1R3	ENSG00000196083	Interleukin 1 receptor accessory protein	3	190514051-190659750	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035293	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 113.0;placenta: 53.7	gallbladder: 19.8	Cell line enhanced		SK-MEL-30: 193.6
PTPRT	KIAA0283, RPTPrho	ENSG00000196090	Protein tyrosine phosphatase, receptor type T	20	42072752-43189970	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017336, CAB069423	Approved					Tissue enhanced	Group enriched	5	cerebral cortex: 24.3;fallopian tube: 17.4	placenta: 4.0	Cell line enhanced		BEWO: 1.1
MYBPC1		ENSG00000196091	Myosin binding protein C, slow type	12	101568353-101686018	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021004, HPA027614	Enhanced				Breast cancer:4.76e-5 (favourable)	Tissue enhanced	Tissue enriched	31	skeletal muscle: 3918.4	prostate: 125.8	Not detected		
PAX5	BSAP	ENSG00000196092	Paired box 5	9	36833275-37034185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026269, CAB026869, HPA056394, HPA068498	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lymph node: 48.5;spleen: 26.2;tonsil: 33.2	appendix: 19.5	Group enriched	6	Daudi: 48.5;REH: 181.0;U-698: 61.2
OR5K4		ENSG00000196098	Olfactory receptor family 5 subfamily K member 4	3	98353854-98354819	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6M1		ENSG00000196099	Olfactory receptor family 6 subfamily M member 1	11	123805335-123806387	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA048674	Uncertain					Not detected	Not detected			testis: 0.2	Not detected		
SPOCK3	testican-3	ENSG00000196104	SPARC/osteonectin, cwcv and kazal like domains proteoglycan 3	4	166733384-167234796	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA075020			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Tissue enhanced	Tissue enriched	7	parathyroid gland: 800.5	prostate: 120.0	Cell line enhanced		PC-3: 2.4;RH-30: 6.7;SCLC-21H: 3.5
ZNF676		ENSG00000196109	Zinc finger protein 676	19	22179091-22196951	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enhanced		parathyroid gland: 4.4;testis: 4.0	thyroid gland: 3.0	Cell line enriched	9	NTERA-2: 7.0
ZNF699	FLJ38144, hang	ENSG00000196110	Zinc finger protein 699	19	9294275-9309838	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058287	Uncertain					Mixed	Mixed			parathyroid gland: 4.9	Cell line enhanced		U-138 MG: 14.3
TDRD7	PCTAIRE2BP	ENSG00000196116	Tudor domain containing 7	9	97411950-97496125	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB020800, HPA022250, HPA024529	Approved		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:4.76e-5 (favourable), Liver cancer:5.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 64.1	Cell line enhanced		HDLM-2: 49.4
CCDC189	C16orf93, MGC104706	ENSG00000196118	Coiled-coil domain containing 189	16	30757423-30762710	Predicted intracellular proteins	Evidence at protein level	HPA041806, HPA046289	Approved		Supported	Cytosol		Mixed	Tissue enhanced		fallopian tube: 14.6	testis: 8.6	Mixed		
OR8A1	OST025	ENSG00000196119	Olfactory receptor family 8 subfamily A member 1	11	124569997-124571142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.4	Not detected		
KIAA0895L	LOC653319	ENSG00000196123	KIAA0895 like	16	67175602-67184040	Predicted intracellular proteins	Evidence at transcript level	HPA065996	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:3.16e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 25.4	Expressed in all		
HLA-DRB1	HLA-DR1B	ENSG00000196126	Major histocompatibility complex, class II, DR beta 1	6	32578769-32589848	Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB015400, CAB034021, HPA043151	Enhanced					Expressed in all	Tissue enhanced		lung: 868.4	lymph node: 619.6	Cell line enhanced		HDLM-2: 1095.2;U-87 MG: 302.0
VN1R2	V1RL2	ENSG00000196131	Vomeronasal 1 receptor 2	19	53258292-53261837	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA044551	Uncertain					Not detected	Mixed			small intestine: 2.4	Not detected		
MYT1	MTF1, MYTI, NZF2, PLPB1, ZC2H2C1, ZC2HC4A	ENSG00000196132	Myelin transcription factor 1	20	64151791-64242253	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006303	Uncertain		Supported	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	7	adrenal gland: 2.5;cerebral cortex: 5.7	testis: 0.6	Cell line enhanced		REH: 3.3;SCLC-21H: 16.5;SH-SY5Y: 3.0
SERPINA3	AACT, ACT	ENSG00000196136	Serpin family A member 3	14	94612377-94624055	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000893, HPA002560, CAB016647	Enhanced				Breast cancer:8.92e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 515.4;liver: 2304.3	gallbladder: 228.3	Cell line enriched	6	Hep G2: 302.6
AKR1C3	DDX, HAKRB, HSD17B5, KIAA0119, PGFS	ENSG00000196139	Aldo-keto reductase family 1 member C3	10	5035354-5107686	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010874, HPA068265	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:1.22e-4 (unfavourable), Liver cancer:1.96e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 398.6	Cell line enhanced		A549: 1217.9;AN3-CA: 359.6;ASC diff: 507.5;Hep G2: 391.2;RT4: 424.5
SPATS2L	DNAPTP6, SGNP	ENSG00000196141	Spermatogenesis associated serine rich 2 like	2	200305881-200482263	Predicted intracellular proteins	Evidence at protein level	HPA055427, HPA066310	Uncertain		Enhanced	Nucleoli<br>Cytosol	Pancreatic cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 167.5	Mixed		
ZNF250	MGC9718, ZFP647, ZNF647	ENSG00000196150	Zinc finger protein 250	8	144876497-144902168	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020853	Uncertain		Supported	Nuclear speckles	Renal cancer:2.43e-7 (favourable), Urothelial cancer:8.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.1	Expressed in all		
WDSUB1	FLJ36175, UBOX6, WDSAM1	ENSG00000196151	WD repeat, sterile alpha motif and U-box domain containing 1	2	159235793-159286799	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA036840, HPA058172	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:2.67e-4 (unfavourable), Cervical cancer:3.35e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.9	Expressed in all		
ZNF79	pT7	ENSG00000196152	Zinc finger protein 79	9	127424374-127445372	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028977	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:6.04e-7 (favourable), Pancreatic cancer:5.42e-5 (favourable), Endometrial cancer:6.83e-5 (favourable), Lung cancer:5.96e-4 (favourable)	Expressed in all	Mixed			testis: 11.4	Expressed in all		
S100A4	18A2, 42A, CAPL, FSP1, MTS1, P9KA, PEL98	ENSG00000196154	S100 calcium binding protein A4	1	153543613-153550136	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002618, HPA007973, CAB027387, CAB058698, CAB068227, CAB068228	Enhanced		Enhanced	Plasma membrane	Head and neck cancer:4.03e-5 (favourable), Renal cancer:2.90e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 990.6	Cell line enhanced		BJ hTERT+: 4403.5;fHDF/TERT166: 3054.2
PLEKHG4	ARHGEF44, DKFZP434I216, SCA4	ENSG00000196155	Pleckstrin homology and RhoGEF domain containing G4	16	67277510-67289499	Predicted intracellular proteins	Evidence at protein level	HPA055696			Approved	Cell Junctions	Renal cancer:6.72e-9 (unfavourable)	Expressed in all	Tissue enhanced		testis: 41.5	ovary: 18.8	Mixed		
KRTAP4-3	KAP4.3	ENSG00000196156	Keratin associated protein 4-3	17	41167231-41168194	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	11	HDLM-2: 1.1
FAT4	CDHF14, CDHR11, FAT-J	ENSG00000196159	FAT atypical cadherin 4	4	125316399-125492932	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA052819	Approved		Approved	Cytosol	Renal cancer:1.89e-4 (favourable)	Mixed	Mixed			parathyroid gland: 9.6	Cell line enhanced		HUVEC TERT2: 11.5;TIME: 17.8
C8orf86	FLJ43582	ENSG00000196166	Chromosome 8 open reading frame 86	8	38510834-38528662	Predicted intracellular proteins	Evidence at transcript level	HPA025066	Uncertain					Not detected	Tissue enhanced		duodenum: 1.0	small intestine: 0.5	Not detected		
KIF19	FLJ37300, KIF19A	ENSG00000196169	Kinesin family member 19	17	74326210-74355820	Predicted intracellular proteins	Evidence at protein level	HPA043638, HPA073303	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Centrosome		Mixed	Tissue enhanced		fallopian tube: 19.0;spleen: 6.6	duodenum: 2.9	Cell line enriched	13	SCLC-21H: 5.1
OR6K2		ENSG00000196171	Olfactory receptor family 6 subfamily K member 2	1	158699678-158700652	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF681	FLJ31526	ENSG00000196172	Zinc finger protein 681	19	23739195-23758891	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			testis: 4.6	Cell line enhanced		HDLM-2: 15.0
ACADSB	ACAD7, SBCAD	ENSG00000196177	Acyl-CoA dehydrogenase, short/branched chain	10	123008979-123058311	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA041458	Enhanced		Supported	Mitochondria	Renal cancer:6.37e-12 (favourable), Pancreatic cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			liver: 186.7	Expressed in all		
STK40	MGC4796, SgK495	ENSG00000196182	Serine/threonine kinase 40	1	36339624-36385896	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA008026	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.59e-4 (favourable)	Expressed in all	Expressed in all			testis: 57.0	Expressed in all		
OR10J1	HGMP07J, HSHGMP07J	ENSG00000196184	Olfactory receptor family 10 subfamily J member 1	1	159439722-159440811	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	102	testis: 10.2	all non-specific tissues: 0.0	Not detected		
TMEM63A	KIAA0792	ENSG00000196187	Transmembrane protein 63A	1	225845536-225882369	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066504, HPA066936, HPA068918			Enhanced	Vesicles<br>Microtubule organizing center	Endometrial cancer:8.79e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.2	Mixed		
CTSE		ENSG00000196188	Cathepsin E	1	206009264-206023909	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA012940, CAB032687	Enhanced				Urothelial cancer:5.26e-5 (favourable)	Group enriched	Group enriched	9	duodenum: 229.1;stomach: 1121.8	lung: 74.6	Group enriched	7	BEWO: 20.3;RT4: 32.6
SEMA4A	CORD10, FLJ12287, SEMAB, SemB	ENSG00000196189	Semaphorin 4A	1	156147366-156177752	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA053726, HPA066006, HPA069136	Supported		Enhanced	Nucleus	Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 62.3	Cell line enhanced		Karpas-707: 108.3;U-698: 46.5
HRCT1	LGLL338, PRO537, UNQ338	ENSG00000196196	Histidine rich carboxyl terminus 1	9	35906192-35907141	Predicted intracellular proteins	Evidence at transcript level	HPA067038			Approved	Nucleoplasm	Liver cancer:3.62e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 17.9	colon: 13.2	Cell line enhanced		EFO-21: 16.8;HeLa: 10.0;U-2197: 24.6;U-251 MG: 10.6
MPHOSPH8	HSMPP8, mpp8	ENSG00000196199	M-phase phosphoprotein 8	13	19633681-19673459	Predicted intracellular proteins	Evidence at protein level	HPA039701, HPA040035	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 63.5	Expressed in all		
GREB1	KIAA0575	ENSG00000196208	Growth regulation by estrogen in breast cancer 1	2	11482341-11642788	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024616, HPA027843, HPA028416	Uncertain		Approved	Mitochondria<br>Cytosol	Endometrial cancer:1.05e-4 (favourable)	Tissue enhanced	Tissue enhanced		ovary: 156.8	prostate: 57.1	Cell line enhanced		AF22: 39.6;MCF7: 47.1;SH-SY5Y: 42.6;T-47d: 129.7
SIRPB2	dJ776F14.2, PTPN1L, PTPNS1L3	ENSG00000196209	Signal regulatory protein beta 2	20	1470741-1491587	Predicted membrane proteins	Evidence at protein level	HPA011548, HPA048032	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		appendix: 17.0	placenta: 10.9	Cell line enhanced		A-431: 4.2;HMC-1: 7.0;hTCEpi: 6.2;THP-1: 5.3;U-937: 6.6
ZNF766		ENSG00000196214	Zinc finger protein 766	19	52269571-52296046	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044882, HPA063496	Uncertain		Supported	Centrosome		Expressed in all	Expressed in all			testis: 43.6	Expressed in all		
RYR1	CCO, MHS, MHS1, PPP1R137, RYR	ENSG00000196218	Ryanodine receptor 1	19	38433699-38587564	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA056416	Enhanced		Approved	Golgi apparatus<br>Vesicles<br>Cytosol		Mixed	Tissue enriched	31	skeletal muscle: 572.4	esophagus: 18.6	Cell line enhanced		HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2
SRGAP3	ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP	ENSG00000196220	SLIT-ROBO Rho GTPase activating protein 3	3	8980591-9363053	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036959, HPA044074	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 26.5;fallopian tube: 17.4	cervix, uterine: 7.9	Cell line enhanced		AF22: 8.9;HBEC3-KT: 5.7;RT4: 8.6;T-47d: 9.6
KRTAP5-3	KRTAP5-9, KRTAP5.3	ENSG00000196224	Keratin associated protein 5-3	11	1607565-1608463	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FAM217B	C20orf177, dJ551D2.5	ENSG00000196227	Family with sequence similarity 217 member B	20	59933764-59948680	Predicted intracellular proteins	Evidence at protein level	HPA041021, HPA056698	Approved		Supported	Nucleoplasm		Expressed in all	Mixed			cerebral cortex: 34.9	Expressed in all		
SULT1C3		ENSG00000196228	Sulfotransferase family 1C member 3	2	108247195-108265351	Enzymes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	142	breast: 450.3	duodenum: 3.1	Not detected		
TUBB	M40, MGC16435, OK/SW-cl.56, Tubb5	ENSG00000196230	Tubulin beta class I	6	30720201-30725426	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005417, CAB012406, HPA043640, HPA046280	Enhanced		Supported	Microtubules	Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 72.3	Mixed		
LCOR	C10orf12, DKFZP564P1916, FLJ13022, FLJ38026, KIAA1795, MLR2	ENSG00000196233	Ligand dependent nuclear receptor corepressor	10	96832260-96995959	Predicted intracellular proteins	Evidence at protein level	HPA031428, HPA031429, HPA038954, HPA057621, HPA077000	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 19.2	Expressed in all		
SUPT5H	FLJ34157, SPT5, SPT5H	ENSG00000196235	SPT5 homolog, DSIF elongation factor subunit	19	39436156-39476670	Predicted intracellular proteins	Evidence at protein level	HPA029273, CAB034370	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.00e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 169.6	Expressed in all		
XPNPEP3	APP3, ICP55, NPHPL1	ENSG00000196236	X-prolyl aminopeptidase 3	22	40857077-40932815	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000527	Enhanced				Thyroid cancer:6.10e-4 (unfavourable), Breast cancer:8.19e-4 (unfavourable)	Expressed in all	Mixed			duodenum: 14.5	Mixed		
OR2T2	OR2T2P	ENSG00000196240	Olfactory receptor family 2 subfamily T member 2	1	248452798-248453772	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2C3	OR2C4, OR2C5P, OST742	ENSG00000196242	Olfactory receptor family 2 subfamily C member 3	1	247530132-247533839	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA053920, HPA058578	Uncertain		Enhanced	Plasma membrane		Not detected	Expressed in all			parathyroid gland: 27.0	Expressed in all		
ZNF107	smap-7, ZFD25, ZNF588	ENSG00000196247	Zinc finger protein 107	7	64666083-64711582	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:2.62e-4 (unfavourable)	Expressed in all	Mixed			lymph node: 19.4	Expressed in all		
OR10S1		ENSG00000196248	Olfactory receptor family 10 subfamily S member 1	11	123976661-123977781	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA019038	Uncertain					Not detected	Not detected			thyroid gland: 0.1	Not detected		
SFTA2	SFTPG	ENSG00000196260	Surfactant associated 2	6	30931353-30955636	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:1.26e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	lung: 53.8	esophagus: 5.2	Group enriched	5	CACO-2: 7.9;CAPAN-2: 4.5
PPIA	CYPA	ENSG00000196262	Peptidylprolyl isomerase A	7	44796680-44824564	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004655, HPA058345	Uncertain				Liver cancer:2.27e-6 (unfavourable)	Expressed in all	Expressed in all			breast: 1679.8	Expressed in all		
ZNF471	KIAA1396, Z1971	ENSG00000196263	Zinc finger protein 471	19	56507843-56530221	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA066695	Uncertain		Supported	Nucleus	Renal cancer:2.37e-4 (favourable)	Mixed	Mixed			ovary: 27.4	Mixed		
OR10J3	OR10J3P	ENSG00000196266	Olfactory receptor family 10 subfamily J member 3	1	159313670-159314659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA042963	Uncertain					Not detected	Not detected			placenta: 0.6	Cell line enriched	7	LHCN-M2: 1.1
ZNF836	FLJ16287	ENSG00000196267	Zinc finger protein 836	19	52153864-52171643	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.77e-4 (favourable), Cervical cancer:5.11e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 34.6	Mixed		
ZNF493	FLJ36504	ENSG00000196268	Zinc finger protein 493	19	21397119-21427573	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Expressed in all			thyroid gland: 34.6	Mixed		
GTF2IRD2	FLJ37938, GTF2IRD2A	ENSG00000196275	GTF2I repeat domain containing 2	7	74796144-74851551	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056679, HPA056680			Approved	Nucleoplasm		Mixed	Expressed in all			ovary: 16.2	Cell line enhanced		SK-BR-3: 44.5
GRM7	GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87	ENSG00000196277	Glutamate metabotropic receptor 7	3	6770001-7741533	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015964			Uncertain	Cytosol		Not detected	Tissue enhanced		cerebral cortex: 10.1;parathyroid gland: 7.2	smooth muscle: 3.4	Cell line enriched	12	SH-SY5Y: 5.0
SUPT3H	SPT3, SPT3L	ENSG00000196284	SPT3 homolog, SAGA and STAGA complex component	6	44809317-45377953	Predicted intracellular proteins	Evidence at protein level	HPA024371	Enhanced		Supported	Nucleoplasm	Ovarian cancer:1.72e-4 (favourable), Glioma:3.05e-4 (favourable)	Expressed in all	Mixed			testis: 14.5	Mixed		
BECN2	BECN1P1	ENSG00000196289	Beclin 2	1	241957767-241959062	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NIF3L1	ALS2CR1, CALS-7, MDS015	ENSG00000196290	NGG1 interacting factor 3 like 1	2	200889327-200903930	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036335, HPA036336, HPA061466	Enhanced		Approved	Vesicles	Liver cancer:2.51e-6 (unfavourable), Endometrial cancer:9.52e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.6	Expressed in all		
ATP2A1	ATP2A, SERCA1	ENSG00000196296	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	16	28878405-28904509	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002310, CAB032706	Enhanced		Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enriched	96	skeletal muscle: 2781.9	esophagus: 29.1	Mixed		
IARS	IARS1, ILRS	ENSG00000196305	Isoleucyl-tRNA synthetase	9	92210207-92293756	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA029806	Approved		Supported	Cytosol	Liver cancer:4.98e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 141.8	Expressed in all		
MFSD14C	HIATL2, MGC12945	ENSG00000196312	Major facilitator superfamily domain containing 14C	9	96897917-97013708	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			testis: 13.9	Cell line enhanced		HAP1: 27.3
POM121	DKFZP586G1822, DKFZP586P2220, KIAA0618, POM121A	ENSG00000196313	POM121 transmembrane nucleoporin	7	72879365-72951440	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB003710, HPA043809, HPA049817	Approved		Enhanced	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			cerebral cortex: 30.2	Expressed in all		
ZBTB44	BTBD15, HSPC063, ZNF851	ENSG00000196323	Zinc finger and BTB domain containing 44	11	130226677-130314686	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052589	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 75.4	Expressed in all		
GIMAP5	HIMAP3, IAN4L1, IAN5	ENSG00000196329	GTPase, IMAP family member 5	7	150722253-150750033	Predicted membrane proteins	Evidence at protein level							Mixed	Expressed in all			lymph node: 80.5	Cell line enhanced		HDLM-2: 3.4;MOLT-4: 23.3;U-937: 5.3
STK31	SgK396, TDRD8	ENSG00000196335	Serine/threonine kinase 31	7	23710167-23832513	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023194	Enhanced					Mixed	Tissue enriched	197	testis: 112.9	lung: 0.5	Cell line enriched	7	CACO-2: 15.0
CGB7	CG-beta-a	ENSG00000196337	Chorionic gonadotropin beta subunit 7	19	49054275-49058860	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Tissue enhanced		skin: 3.8	placenta,seminal vesicle,skeletal muscle: 1.0	Cell line enhanced		BEWO: 4.7;HaCaT: 3.5;hTCEpi: 3.4;U-251 MG: 6.1
NLGN3	ASPGX1, AUTSX1, HNL3, KIAA1480	ENSG00000196338	Neuroligin 3	X	71144831-71171201	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003183, HPA004066	Enhanced		Supported	Golgi apparatus<br>Cell Junctions		Tissue enriched	Tissue enhanced		cerebral cortex: 62.2	seminal vesicle: 17.3	Cell line enhanced		AF22: 6.8;NTERA-2: 5.0;SH-SY5Y: 2.9
OR8D1	OR8D3, OST004	ENSG00000196341	Olfactory receptor family 8 subfamily D member 1	11	124309812-124310837	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059510	Uncertain					Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Not detected		
ADH7	ADH-4	ENSG00000196344	Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide	4	99412261-99435737	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039695	Enhanced		Supported	Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	6	esophagus: 215.5	tonsil: 34.5	Cell line enhanced		HaCaT: 1.0
ZKSCAN7	FLJ12738, ZNF167, ZNF448, ZNF64, ZSCAN39	ENSG00000196345	Zinc finger with KRAB and SCAN domains 7	3	44555193-44594173	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048312, HPA049906, HPA071850	Uncertain		Enhanced	Cytosol		Mixed	Mixed			ovary: 4.1	Cell line enhanced		AN3-CA: 3.9;SH-SY5Y: 5.2
ZNF729		ENSG00000196350	Zinc finger protein 729	19	22286408-22317176	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	22	testis: 3.8	breast,cerebral cortex,endometrium,parathyroid gland: 0.1	Cell line enhanced		NTERA-2: 2.6
CD55	CR, CROM, DAF, TC	ENSG00000196352	CD55 molecule (Cromer blood group)	1	207321508-207386804	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA002190, CAB010454, HPA024386	Enhanced		Uncertain	Vesicles<br>Midbody ring	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 324.4	Cell line enhanced		HMC-1: 495.0;U-2197: 364.6
CPNE4	COPN4, CPN4	ENSG00000196353	Copine 4	3	131533555-132285410	Predicted intracellular proteins	Evidence at protein level	HPA032036, HPA078300	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		cerebral cortex: 12.1;prostate: 40.8	seminal vesicle: 5.8	Cell line enhanced		A549: 5.6;AF22: 5.6
ZNF565	FLJ36991	ENSG00000196357	Zinc finger protein 565	19	36182060-36246257	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044123	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Expressed in all	Mixed			testis: 11.6	Mixed		
NTNG2	KIAA1857, Lmnt2, NTNG1	ENSG00000196358	Netrin G2	9	132161676-132244534	Predicted secreted proteins	Evidence at protein level	HPA061242, HPA065089, HPA071290	Approved		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytokinetic bridge<br>Midbody ring<br>Cytosol	Prostate cancer:6.06e-4 (favourable)	Mixed	Group enriched	6	bone marrow: 26.5;cerebral cortex: 18.5;parathyroid gland: 16.3;prostate: 10.0	spleen: 3.1	Cell line enhanced		HMC-1: 14.1;NB-4: 24.3;U-937: 7.7
ELAVL3	DKFZp547J036, HUC, HUCL, MGC20653, PLE21	ENSG00000196361	ELAV like RNA binding protein 3	19	11451326-11481046	Predicted intracellular proteins	Evidence at protein level	CAB013066	Enhanced					Tissue enriched	Tissue enriched	45	cerebral cortex: 72.8	adrenal gland: 1.6	Group enriched	10	SCLC-21H: 95.2;SH-SY5Y: 49.4
WDR5	CFAP89, SWD3	ENSG00000196363	WD repeat domain 5	9	134135365-134159968	Predicted intracellular proteins	Evidence at protein level	HPA047182			Supported	Nucleoplasm		Expressed in all	Expressed in all			testis: 63.0	Expressed in all		
LONP1	hLON, LonHS, PIM1, PRSS15	ENSG00000196365	Lon peptidase 1, mitochondrial	19	5691834-5720572	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002034, HPA002192	Supported		Enhanced	Nucleus<br>Mitochondria		Expressed in all	Expressed in all			adrenal gland: 140.4	Expressed in all		
TRRAP	PAF400, TR-AP, Tra1	ENSG00000196367	Transformation/transcription domain associated protein	7	98877933-99013243	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054376			Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.6	Expressed in all		
NUDT11	DIPP3b, FLJ10628, hDIPP3beta	ENSG00000196368	Nudix hydrolase 11	X	51490011-51496596	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA057684	Approved		Approved	Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 40.1;testis: 67.7	prostate,seminal vesicle: 14.7	Cell line enhanced		HAP1: 71.2;NTERA-2: 42.7
SRGAP2B	SRGAP2P2	ENSG00000196369	SLIT-ROBO Rho GTPase activating protein 2B	1	144887265-145095528	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			skin: 21.7	Expressed in all		
FUT4	CD15, ELFT, FCT3A, FUC-TIV	ENSG00000196371	Fucosyltransferase 4	11	94543840-94549898	Predicted membrane proteins	Evidence at protein level	CAB000014, CAB016129	Enhanced		Enhanced	Vesicles	Lung cancer:3.64e-4 (unfavourable)	Expressed in all	Tissue enriched	5	bone marrow: 62.9	duodenum: 12.4	Cell line enhanced		HL-60: 29.6;THP-1: 31.3;U-937: 25.8
ASB13	FLJ13134, MGC19879	ENSG00000196372	Ankyrin repeat and SOCS box containing 13	10	5638867-5666595	Predicted intracellular proteins	Evidence at protein level	HPA048293, HPA061742	Approved		Approved	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			small intestine: 28.0	Mixed		
SLC35F1	C6orf169, dJ230I3.1	ENSG00000196376	Solute carrier family 35 member F1	6	117907526-118317676	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019576	Enhanced		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol		Group enriched	Tissue enriched	12	cerebral cortex: 45.4	epididymis: 3.7	Group enriched	10	AF22: 47.2;WM-115: 80.1
ZNF34	KOX32	ENSG00000196378	Zinc finger protein 34	8	144773114-144787345	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA053925, HPA060755, HPA066805	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 12.8	Mixed		
ZNF781	FLJ37549	ENSG00000196381	Zinc finger protein 781	19	37667751-37692322	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062512	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			smooth muscle: 3.7	Cell line enhanced		AN3-CA: 2.1;SH-SY5Y: 2.4;U-266/84: 2.0
ZNF140	pHZ-39	ENSG00000196387	Zinc finger protein 140	12	133079838-133107544	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048332	Uncertain					Expressed in all	Expressed in all			thyroid gland: 16.3	Mixed		
INCA1		ENSG00000196388	Inhibitor of CDK, cyclin A1 interacting protein 1	17	4988130-4997610	Predicted intracellular proteins	Evidence at protein level	HPA044359, HPA052401	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:3.61e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 54.0	thyroid gland: 13.4	Mixed		
ZNF774	MGC75360	ENSG00000196391	Zinc finger protein 774	15	90352245-90369146	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030839, HPA030840	Uncertain		Supported	Intermediate filaments<br>Cytosol		Mixed	Mixed			cerebral cortex: 8.1	Mixed		
PTPN1	PTP1B	ENSG00000196396	Protein tyrosine phosphatase, non-receptor type 1	20	50510321-50585241	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB009329, HPA012542, CAB015217	Enhanced		Enhanced	Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 62.6	Expressed in all		
EVL	RNB6	ENSG00000196405	Enah/Vasp-like	14	99971449-100144236	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA018849, HPA019536, CAB033987	Enhanced		Approved	Vesicles<br>Cytosol	Pancreatic cancer:4.07e-6 (favourable), Renal cancer:4.14e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 208.1	Cell line enhanced		MOLT-4: 229.2
SPANXD	CT11.4, SPANXE	ENSG00000196406	SPANX family member D	X	141697411-141698739	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Approved	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	193	testis: 19.3	all non-specific tissues: 0.0	Group enriched	10	A-431: 2.2;U-2 OS: 4.8
THEM5	FLJ37964	ENSG00000196407	Thioesterase superfamily member 5	1	151847263-151853697	Enzymes, Predicted intracellular proteins	Evidence at protein level							Expressed in all	Tissue enriched	25	skin: 204.8	cerebral cortex: 8.3	Cell line enriched	6	HDLM-2: 64.7
NOXO1	P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28	ENSG00000196408	NADPH oxidase organizer 1	16	1978917-1984192	FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071540	Enhanced					Not detected	Tissue enhanced		appendix: 6.3;colon: 7.4;rectum: 6.5	duodenum: 3.3	Cell line enhanced		CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6
EPHB4	HTK, Tyro11	ENSG00000196411	EPH receptor B4	7	100802565-100827521	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013537	Uncertain				Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 50.6	Mixed		
PRTN3	ACPA, AGP7, C-ANCA, MBT, P29, PR-3	ENSG00000196415	Proteinase 3	19	840960-848175	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005938, CAB017558	Enhanced					Tissue enhanced	Tissue enriched	724	bone marrow: 616.4	spleen: 0.8	Cell line enriched	6	THP-1: 696.6
ZNF765		ENSG00000196417	Zinc finger protein 765	19	53389793-53430413	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Breast cancer:9.11e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 13.0	Mixed		
ZNF124	HZF-16, HZF16	ENSG00000196418	Zinc finger protein 124	1	247121975-247172016	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031127	Uncertain		Approved	Nucleus<br>Nuclear membrane	Urothelial cancer:1.03e-4 (favourable)	Expressed in all	Mixed			salivary gland: 16.8	Mixed		
XRCC6	D22S671, D22S731, G22P1, KU70, ML8	ENSG00000196419	X-ray repair cross complementing 6	22	41621119-41664048	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004254, HPA047549, HPA062226	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			testis: 396.5	Expressed in all		
S100A5	S100D	ENSG00000196420	S100 calcium binding protein A5	1	153537147-153541765	Predicted intracellular proteins	Evidence at protein level	HPA064184			Approved	Nucleoplasm		Group enriched	Tissue enhanced		skin: 4.3;thyroid gland: 8.8	lymph node: 1.7	Cell line enhanced		RT4: 15.9;SCLC-21H: 20.4
LINC00176	DKFZp434G015, FLJ27267, NCRNA00176, PRR17	ENSG00000196421	Long intergenic non-protein coding RNA 176	20	64034344-64039962	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Not detected			parathyroid gland,spleen: 0.2	Group enriched	11	HDLM-2: 6.9;Hep G2: 33.0
PPP1R26	KIAA0649	ENSG00000196422	Protein phosphatase 1 regulatory subunit 26	9	135479079-135488893	Predicted intracellular proteins	Evidence at protein level	HPA044686, HPA063817	Uncertain		Enhanced	Nucleoplasm	Renal cancer:6.20e-13 (favourable), Colorectal cancer:3.98e-4 (unfavourable), Pancreatic cancer:6.93e-4 (favourable), Endometrial cancer:9.91e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 27.6	Mixed		
NBPF4	FLJ32833	ENSG00000196427	Neuroblastoma breakpoint family member 4	1	108223341-108244081	Predicted intracellular proteins	Evidence at transcript level	HPA045044, HPA046411, HPA047447, HPA058050	Uncertain					Tissue enriched	Tissue enhanced		testis: 7.1	small intestine: 1.5	Cell line enhanced		BEWO: 6.8;K-562: 9.7;MCF7: 9.6
TSC22D2	KIAA0669, TILZ4a, TILZ4b, TILZ4c	ENSG00000196428	TSC22 domain family member 2	3	150408335-150466431	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004926	Approved		Approved	Cytosol	Endometrial cancer:2.74e-4 (unfavourable), Renal cancer:5.80e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium,smooth muscle: 38.2	Expressed in all		
CRYBA4		ENSG00000196431	Crystallin beta A4	22	26621964-26630672	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071178	Supported					Tissue enhanced	Tissue enhanced		epididymis: 1.8	testis: 0.7	Group enriched	7	HEL: 6.5;HMC-1: 1.4
ASMT	ASMTY, HIOMT, HIOMTY	ENSG00000196433	Acetylserotonin O-methyltransferase	X	1615001-1643081	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		epididymis: 2.2	adrenal gland: 0.8	Not detected		
NPIPB15	LOC440348, NPIPL2	ENSG00000196436	Nuclear pore complex interacting protein family member B15	16	74377878-74392080	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Supported		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 39.2	rectum: 13.2	Cell line enhanced		T-47d: 11.2
ZNF569	FLJ32053, ZAP1	ENSG00000196437	Zinc finger protein 569	19	37411155-37469275	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052994	Uncertain		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Mixed	Mixed			testis: 20.5	Mixed		
ARMCX4	CXorf35, GASP4, MGC40053	ENSG00000196440	Armadillo repeat containing, X-linked 4	X	101418287-101533459	Predicted intracellular proteins	Evidence at protein level	HPA000429, HPA051930	Uncertain		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:8.20e-5 (favourable)	Mixed	Mixed			parathyroid gland: 14.3	Mixed		
YRDC	FLJ23476, IRIP, SUA5	ENSG00000196449	YrdC N6-threonylcarbamoyltransferase domain containing	1	37802944-37808185	Predicted intracellular proteins	Evidence at protein level	HPA030147	Approved		Approved	Mitochondria	Liver cancer:1.83e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 31.7	Expressed in all		
ZNF777	KIAA1285	ENSG00000196453	Zinc finger protein 777	7	149431363-149461123	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003252	Approved		Approved	Nucleus		Expressed in all	Expressed in all			cerebral cortex: 10.4	Mixed		
PIK3R4	p150, VPS15	ENSG00000196455	Phosphoinositide-3-kinase regulatory subunit 4	3	130678935-130746829	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036032, HPA036033	Approved		Approved	Vesicles<br>Microtubules	Renal cancer:4.40e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
ZNF775	MGC33584	ENSG00000196456	Zinc finger protein 775	7	150379335-150398631	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Pancreatic cancer:1.35e-5 (favourable), Renal cancer:2.84e-4 (favourable), Head and neck cancer:3.48e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 7.1	Mixed		
ZNF605		ENSG00000196458	Zinc finger protein 605	12	132918308-132956306	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA061970, HPA062655	Uncertain		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			parathyroid gland: 11.3	Mixed		
TRAPPC2	hYP38334, MIP-2A, SEDL, SEDT, TRS20, ZNF547L	ENSG00000196459	Trafficking protein particle complex 2	X	13712244-13734635	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004665, HPA063308	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Urothelial cancer:7.89e-5 (favourable), Ovarian cancer:6.35e-4 (favourable), Cervical cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.5	Expressed in all		
RFX8	FLJ42986	ENSG00000196460	RFX family member 8, lacking RFX DNA binding domain	2	101397361-101474703	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059745			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		bone marrow: 2.6	testis: 1.3	Cell line enhanced		hTEC/SVTERT24-B: 13.4;LHCN-M2: 5.8;U-87 MG: 8.3
MYL6B	MLC1SA	ENSG00000196465	Myosin light chain 6B	12	56152256-56159647	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038887, HPA046859, HPA063034	Enhanced		Approved	Vesicles	Liver cancer:2.87e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 149.6	Expressed in all		
ZNF799	HIT-40, MGC71805, ZNF842	ENSG00000196466	Zinc finger protein 799	19	12390016-12401271	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003150, HPA018683	Supported		Uncertain	Nucleoplasm<br>Microtubule organizing center	Endometrial cancer:2.39e-4 (favourable)	Mixed	Mixed			placenta: 6.9	Mixed		
FGF16	MF4	ENSG00000196468	Fibroblast growth factor 16	X	77447405-77457278	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Not detected			adipose tissue: 0.4	Cell line enriched	5	U-2197: 21.1
SIAH1	hSIAH1	ENSG00000196470	Siah E3 ubiquitin protein ligase 1	16	48356364-48448402	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018724	Enhanced		Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			placenta: 70.4	Expressed in all		
GK2	GKP2, GKTA	ENSG00000196475	Glycerol kinase 2	4	79406352-79408293	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA060687	Uncertain					Not detected	Tissue enriched	1527	testis: 152.6	all non-specific tissues: 0.0	Cell line enriched	45	SCLC-21H: 4.4
C20orf96	dJ1103G7.2	ENSG00000196476	Chromosome 20 open reading frame 96	20	270863-290778	Predicted intracellular proteins	Evidence at transcript level	HPA048649	Uncertain		Approved	Nucleus<br>Golgi apparatus	Pancreatic cancer:4.12e-5 (favourable), Liver cancer:6.12e-5 (unfavourable), Urothelial cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 53.5	Mixed		
ESRRG	NR3B3	ENSG00000196482	Estrogen related receptor gamma	1	216503246-217137755	FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044678	Uncertain		Approved	Nucleus	Renal cancer:1.13e-11 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 77.5	kidney: 31.3	Group enriched	7	RPMI-8226: 16.0;SCLC-21H: 9.4;SH-SY5Y: 44.7
IPO4	FLJ23338, Imp4	ENSG00000196497	Importin 4	14	24180219-24188964	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA039043, HPA064572	Uncertain		Approved	Cytosol	Liver cancer:8.08e-6 (unfavourable), Renal cancer:3.20e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 17.4	skin: 5.3	Mixed		
NCOR2	CTG26, SMRT, SMRTE, TNRC14, TRAC-1	ENSG00000196498	Nuclear receptor corepressor 2	12	124324415-124567589	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001928	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 81.2	Expressed in all		
SULT1A1	P-PST, STP, STP1	ENSG00000196502	Sulfotransferase family 1A member 1	16	28605196-28623625	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported				Lung cancer:7.02e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 136.6	Cell line enhanced		EFO-21: 161.0;Hep G2: 241.3
ARL9		ENSG00000196503	ADP ribosylation factor like GTPase 9	4	56505209-56524448	Predicted intracellular proteins	Evidence at protein level	HPA072942	Enhanced		Approved	Nucleoli<br>Mitochondria		Mixed	Tissue enhanced		testis: 18.3	smooth muscle: 4.3	Group enriched	5	REH: 14.6;SCLC-21H: 15.6
PRPF40A	FBP-11, FBP11, FLAF1, FLJ20585, FNBP3, HIP10, HYPA, NY-REN-6, Prp40	ENSG00000196504	Pre-mRNA processing factor 40 homolog A	2	152651593-152717997	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038272, HPA038273	Approved		Enhanced	Nuclear speckles	Pancreatic cancer:1.58e-5 (unfavourable), Liver cancer:1.68e-4 (unfavourable), Renal cancer:5.89e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 50.1	Expressed in all		
GDAP2	dJ776P7.1, FLJ20142, MACROD3	ENSG00000196505	Ganglioside induced differentiation associated protein 2	1	117863485-117929630	Predicted intracellular proteins	Evidence at protein level	HPA046185	Approved		Approved	Endoplasmic reticulum		Expressed in all	Mixed			parathyroid gland: 9.5	Expressed in all		
TCEAL3	MGC15737, WEX8	ENSG00000196507	Transcription elongation factor A like 3	X	103607451-103629690	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982	Uncertain				Lung cancer:4.05e-4 (favourable), Ovarian cancer:8.33e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 97.9	Mixed		
ANAPC7	APC7	ENSG00000196510	Anaphase promoting complex subunit 7	12	110372900-110403730	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009567	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.36e-10 (unfavourable), Liver cancer:1.54e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 48.9	Expressed in all		
TPK1	HTPK1, PP20	ENSG00000196511	Thiamin pyrophosphokinase 1	7	144451941-144836395	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA021545, HPA021849	Approved		Approved	Vesicles		Mixed	Mixed			duodenum: 14.4	Cell line enhanced		AN3-CA: 65.0;EFO-21: 19.9
SLC6A9	GLYT1	ENSG00000196517	Solute carrier family 6 member 9	1	43991500-44031467	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA013977	Uncertain		Approved	Nucleus<br>Golgi apparatus	Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 49.7	adrenal gland: 30.8	Cell line enhanced		hTCEpi: 77.6
AFAP1	AFAP, AFAP-110	ENSG00000196526	Actin filament associated protein 1	4	7758714-7939926	Predicted intracellular proteins	Evidence at protein level	HPA015642, CAB024712	Enhanced		Supported	Actin filaments<br>Focal adhesion sites<br>Cytosol	Lung cancer:2.84e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 42.9	Cell line enhanced		TIME: 103.1
NACA	NACA1	ENSG00000196531	Nascent polypeptide-associated complex alpha subunit	12	56712428-56731628	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073152, HPA073648			Approved	Cytosol	Renal cancer:4.58e-11 (unfavourable)	Expressed in all	Expressed in all			ovary: 2552.0	Expressed in all		
MYO18A	KIAA0216, MysPDZ	ENSG00000196535	Myosin XVIIIA	17	29071124-29180412	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019646, HPA021121	Enhanced				Renal cancer:3.18e-4 (favourable), Ovarian cancer:3.28e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 133.5	Expressed in all		
OR2T3		ENSG00000196539	Olfactory receptor family 2 subfamily T member 3	1	248473351-248474307	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPTSSB	ADMP, C3orf57, ssSPTb	ENSG00000196542	Serine palmitoyltransferase small subunit B	3	161344792-161372880	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047712			Approved	Nuclear speckles		Tissue enhanced	Tissue enhanced		skin: 48.3;stomach: 59.4;urinary bladder: 36.3	prostate: 23.4	Group enriched	9	MCF7: 892.8;RT4: 244.7
BORCS6	C17orf59, FLJ20014	ENSG00000196544	BLOC-1 related complex subunit 6	17	8188333-8190907	Predicted intracellular proteins	Evidence at protein level	HPA045415, HPA060791	Uncertain		Supported	Centrosome<br>Cytosol	Pancreatic cancer:2.60e-4 (favourable), Endometrial cancer:2.78e-4 (favourable)	Expressed in all	Mixed			spleen: 7.3	Expressed in all		
MAN2A2	HsT19662, MANA2X	ENSG00000196547	Mannosidase alpha class 2A member 2	15	90902218-90922584	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017226, HPA077930	Approved		Approved	Cytoplasmic bodies	Renal cancer:8.95e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 46.3	Expressed in all		
MME	CALLA, CD10, NEP	ENSG00000196549	Membrane metalloendopeptidase	3	155024124-155183729	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000013, HPA052583, HPA056072	Enhanced					Mixed	Tissue enhanced		duodenum: 428.2;kidney: 384.2;small intestine: 401.5	prostate: 162.5	Cell line enhanced		ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
FAM72A	LMPIP, MGC57827, RP11-312O7.1, UGENE	ENSG00000196550	Family with sequence similarity 72 member A	1	206186179-206204414	Predicted intracellular proteins	Evidence at protein level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			lymph node: 12.6	Expressed in all		
LINC00238	C14orf53, NCRNA00238	ENSG00000196553	Long intergenic non-protein coding RNA 238	14	66486354-66498553	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	85	testis: 8.5	all non-specific tissues: 0.0	Not detected		
CACNA1H	Cav3.2	ENSG00000196557	Calcium voltage-gated channel subunit alpha1 H	16	1153121-1221772	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA039125	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable)	Expressed in all	Tissue enhanced		ovary: 44.9	seminal vesicle: 39.1	Cell line enhanced		A549: 16.1;AN3-CA: 23.5;MCF7: 36.8;T-47d: 13.0
SULF2	HSULF-2, KIAA1247, SULF-2	ENSG00000196562	Sulfatase 2	20	47656348-47786616	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA002325	Approved				Cervical cancer:6.43e-5 (unfavourable), Renal cancer:4.02e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 166.9	Cell line enhanced		EFO-21: 318.0;hTCEpi: 589.4;MCF7: 529.8
HBG2	HBG-T1	ENSG00000196565	Hemoglobin subunit gamma 2	11	5253190-5645789	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016143, HPA043234	Approved		Approved	Vesicles		Not detected	Tissue enriched	147	placenta: 18253.8	bone marrow: 124.0	Group enriched	301	HEL: 12101.5;K-562: 8442.3
LAMA2	LAMM	ENSG00000196569	Laminin subunit alpha 2	6	128883141-129516569	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB040310, CAB078182	Enhanced				Urothelial cancer:3.65e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 150.0	ovary: 49.5	Cell line enhanced		ASC diff: 174.0;ASC TERT1: 126.8;HSkMC: 113.6
PFN3		ENSG00000196570	Profilin 3	5	177400107-177400636	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	21	kidney: 1.0;testis: 3.2	all non-specific tissues: 0.0	Not detected		
PLXNB2	KIAA0315, MM1, PLEXB2	ENSG00000196576	Plexin B2	22	50274979-50307627	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA003100	Uncertain				Stomach cancer:4.75e-4 (favourable), Ovarian cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 120.9	Mixed		
OR5AC2	HSA1	ENSG00000196578	Olfactory receptor family 5 subfamily AC member 2	3	98087173-98088102	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
AJAP1	MOT8, SHREW-1, SHREW1	ENSG00000196581	Adherens junctions associated protein 1	1	4654732-4792534	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.89e-7 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 11.3;ovary: 6.0	kidney,seminal vesicle: 3.2	Cell line enhanced		BEWO: 7.2;EFO-21: 6.2;RPTEC TERT1: 18.3
XRCC2	FANCU	ENSG00000196584	X-ray repair cross complementing 2	7	152644779-152676165	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065153			Approved	Nucleoplasm<br>Vesicles		Mixed	Mixed			testis: 3.7	Mixed		
MYO6	DFNA22, DFNB37, KIAA0389	ENSG00000196586	Myosin VI	6	75749192-75919537	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010762, HPA035483	Enhanced				Renal cancer:1.27e-12 (favourable)	Expressed in all	Mixed			parathyroid gland: 85.5	Mixed		
MKL1	BSAC, KIAA1438, MAL, MRTF-A	ENSG00000196588	Megakaryoblastic leukemia (translocation) 1	22	40410281-40636702	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030782	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.58e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 51.3	Expressed in all		
CTB-25J19.1		ENSG00000196589		19	7018969-7021450	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
HDAC2	RPD3, YAF1	ENSG00000196591	Histone deacetylase 2	6	113933028-114011308	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005054, HPA011727	Supported		Enhanced	Nucleus	Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 141.1	Expressed in all		
ZNF782	FLJ16636	ENSG00000196597	Zinc finger protein 782	9	96816472-96875623	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA011013	Approved		Approved	Nucleus<br>Mitochondria		Expressed in all	Mixed			testis: 10.4	Mixed		
SLC22A25	HIMTP, MGC120420, UST6	ENSG00000196600	Solute carrier family 22 member 25	11	63163776-63229652	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA039390	Uncertain				Liver cancer:7.04e-4 (favourable)	Tissue enriched	Tissue enriched	58	liver: 5.7	all non-specific tissues: 0.0	Not detected		
POTEF	A26C1B, POTE2alpha, POTEACTIN	ENSG00000196604	POTE ankyrin domain family member F	2	130074030-130129222	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enriched	9	testis: 2.7	breast,placenta,prostate: 0.2	Cell line enhanced		AN3-CA: 2.3;BEWO: 1.9;CACO-2: 1.9;U-2 OS: 5.6;U-266/70: 2.0
ZNF846		ENSG00000196605	Zinc finger protein 846	19	9751993-9793180	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034617, HPA034618	Approved		Approved	Actin filaments	Head and neck cancer:5.25e-8 (favourable)	Expressed in all	Mixed			seminal vesicle: 26.3	Mixed		
MMP1	CLG	ENSG00000196611	Matrix metallopeptidase 1	11	102789920-102798160	Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA004920			Approved	Vesicles	Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		appendix: 39.2;gallbladder: 126.4	urinary bladder: 29.1	Cell line enhanced		BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
ADH1B	ADH2	ENSG00000196616	Alcohol dehydrogenase 1B (class I), beta polypeptide	4	99304964-99352760	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Approved	Plasma membrane<br>Cytosol	Renal cancer:7.87e-4 (unfavourable)	Tissue enriched	Group enriched	6	adipose tissue: 1624.6;liver: 3000.2	lung: 388.5	Cell line enriched	7	ASC diff: 4511.9
UGT2B15	UGT2B8	ENSG00000196620	UDP glucuronosyltransferase family 2 member B15	4	68646630-68670628	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Approved				Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable)	Tissue enriched	Group enriched	5	gallbladder: 110.7;liver: 107.6	small intestine: 20.6	Not detected		
TCF4	bHLHb19, E2-2, ITF2, SEF2-1B	ENSG00000196628	Transcription factor 4	18	55222331-55664787	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB020722, HPA025958	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.24e-5 (unfavourable), Urothelial cancer:9.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex,cervix, uterine: 44.9	Cell line enhanced		HDLM-2: 128.1;SH-SY5Y: 177.9
WNK3	PRKWNK3	ENSG00000196632	WNK lysine deficient protein kinase 3	X	54192823-54358642	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA077678			Approved	Vesicles		Mixed	Group enriched	6	epididymis: 14.3;testis: 18.6	ovary: 2.6	Cell line enhanced		AF22: 4.4;HAP1: 5.4;NTERA-2: 9.1;SiHa: 4.8;U-2 OS: 4.1
SDHAF3	ACN9, DC11, LYRM10, Sdh7	ENSG00000196636	Succinate dehydrogenase complex assembly factor 3	7	97116590-97181763	Predicted intracellular proteins	Evidence at protein level	HPA020523	Approved		Approved	Microtubules<br>Mitochondria		Expressed in all	Expressed in all			testis: 15.1	Mixed		
HRH1		ENSG00000196639	Histamine receptor H1	3	11137093-11263557	FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029740	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.27e-5 (unfavourable)	Mixed	Mixed			cerebral cortex: 12.4	Mixed		
RABL6	bA216L13.9, C9orf86, FLJ10101, FLJ13045, Parf, pp8875, RBEL1	ENSG00000196642	RAB, member RAS oncogene family-like 6	9	136807943-136841187	Predicted intracellular proteins	Evidence at protein level	HPA044037	Uncertain		Supported	Centrosome<br>Cytosol	Pancreatic cancer:1.46e-4 (favourable), Endometrial cancer:4.00e-4 (favourable), Stomach cancer:9.14e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 59.7	Expressed in all		
ZNF136	pHZ-20	ENSG00000196646	Zinc finger protein 136	19	12163064-12189881	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054120			Approved	Nucleoli	Renal cancer:4.75e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 14.5	Mixed		
ZKSCAN5	ZFP95, ZNF914, ZSCAN37	ENSG00000196652	Zinc finger with KRAB and SCAN domains 5	7	99504651-99534700	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003201	Uncertain		Approved	Intermediate filaments	Liver cancer:7.59e-6 (unfavourable), Thyroid cancer:1.13e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
ZNF502	FLJ12515, FLJ14855	ENSG00000196653	Zinc finger protein 502	3	44712643-44723831	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024761, HPA029557	Uncertain				Renal cancer:4.51e-5 (favourable), Urothelial cancer:2.06e-4 (favourable)	Expressed in all	Mixed			testis: 5.0	Mixed		
TRAPPC4	PTD009, SBDN, TRS23	ENSG00000196655	Trafficking protein particle complex 4	11	119018432-119025454	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA039752, HPA041371	Approved		Approved	Cytosol	Liver cancer:2.03e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 15.0	Expressed in all		
TTC30B	fleer, FLJ30990, IFT70B	ENSG00000196659	Tetratricopeptide repeat domain 30B	2	177548998-177553014	Predicted intracellular proteins	Evidence at protein level	HPA051714, HPA052100, HPA052487	Supported		Approved	Nucleus<br>Centrosome		Expressed in all	Mixed			fallopian tube: 15.6	Mixed		
SLC30A10	DKFZp547M236, ZnT-10, ZNT8, ZRC1	ENSG00000196660	Solute carrier family 30 member 10	1	219685427-219958647	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA064547	Enhanced					Tissue enriched	Tissue enhanced		duodenum: 2.1;liver: 2.3	testis: 1.2	Cell line enhanced		HEK 293: 1.2
OR8B3		ENSG00000196661	Olfactory receptor family 8 subfamily B member 3	11	124396382-124397368	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
TECPR2	KIAA0329	ENSG00000196663	Tectonin beta-propeller repeat containing 2	14	102362963-102502481	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000658	Enhanced		Approved	Nucleus	Renal cancer:6.53e-9 (favourable), Liver cancer:5.66e-5 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 21.4	Mixed		
TLR7		ENSG00000196664	Toll like receptor 7	X	12867083-12890380	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA059613	Enhanced					Mixed	Mixed			placenta: 9.2	Group enriched	5	Daudi: 11.6;U-266/70: 12.4
FAM180B	LOC399888	ENSG00000196666	Family with sequence similarity 180 member B	11	47586693-47589194	Predicted intracellular proteins	Evidence at transcript level	HPA029408	Uncertain					Tissue enhanced	Tissue enhanced		breast: 6.9;skin: 4.4	adipose tissue: 4.1	Cell line enhanced		SK-MEL-30: 1.8;U-937: 1.3
ZFP62	FLJ34231, ZET, ZNF755	ENSG00000196670	ZFP62 zinc finger protein	5	180847611-180861285	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048629	Approved		Approved	Nucleoplasm<br>Actin filaments		Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
ERI2	EXOD1, KIAA1504, MGC16943, ZGRF5	ENSG00000196678	ERI1 exoribonuclease family member 2	16	20780193-20900349	Predicted intracellular proteins	Evidence at protein level	HPA035384, HPA035385	Uncertain		Supported	Nucleus<br>Golgi apparatus		Expressed in all	Expressed in all			testis: 23.0	Expressed in all		
TOMM7	Tom7	ENSG00000196683	Translocase of outer mitochondrial membrane 7	7	22812628-22822852	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Head and neck cancer:6.30e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 677.6	Expressed in all		
HSH2D	ALX, FLJ14886, HSH2	ENSG00000196684	Hematopoietic SH2 domain containing	19	16134028-16158575	Predicted intracellular proteins	Evidence at protein level	HPA036616			Approved	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Renal cancer:6.49e-6 (unfavourable), Colorectal cancer:9.46e-6 (unfavourable), Urothelial cancer:3.47e-5 (favourable)	Mixed	Mixed			tonsil: 32.7	Cell line enhanced		HMC-1: 49.9;NB-4: 88.6;RPMI-8226: 43.5;U-937: 106.3
TRPV1	VR1	ENSG00000196689	Transient receptor potential cation channel subfamily V member 1	17	3565444-3609411	FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Not detected	Mixed			duodenum: 7.8	Mixed		
ZNF33B	KOX2, KOX31, ZNF11B	ENSG00000196693	Zinc finger protein 33B	10	42574185-42638568	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056638	Approved					Expressed in all	Expressed in all			parathyroid gland: 32.1	Mixed		
ZNF512B	GM632, MGC149845, MGC149846	ENSG00000196700	Zinc finger protein 512B	20	63956702-63969865	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006688	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex,parathyroid gland: 16.9	Mixed		
AMZ2		ENSG00000196704	Archaelysin family metallopeptidase 2	17	68247574-68257164	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA023299, HPA052406	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:1.32e-5 (unfavourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 357.6	Expressed in all		
ZNF431	KIAA1969	ENSG00000196705	Zinc finger protein 431	19	21142024-21196053	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain					Mixed	Mixed			ovary: 26.8	Mixed		
ALKAL1	AUGB, FAM150A, UNQ9433	ENSG00000196711	ALK and LTK ligand 1	8	52534037-52565507	Predicted secreted proteins	Evidence at protein level	HPA027368	Uncertain					Mixed	Tissue enhanced		gallbladder: 3.5;thyroid gland: 3.6	cervix, uterine: 1.7	Cell line enhanced		CAPAN-2: 1.1
NF1		ENSG00000196712	Neurofibromin 1	17	31094927-31382116	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA045502	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 33.0	Expressed in all		
VKORC1L1		ENSG00000196715	Vitamin K epoxide reductase complex subunit 1 like 1	7	65873267-65959563	Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA053954	Approved		Supported	Endoplasmic reticulum		Expressed in all	Expressed in all			adipose tissue: 57.5	Expressed in all		
ZNF418	FLJ31551, KIAA1956	ENSG00000196724	Zinc finger protein 418	19	57921884-57935393	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Approved		Uncertain	Nucleus	Prostate cancer:1.72e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 14.8	Cell line enhanced		AF22: 11.0
DAPK1	DAPK	ENSG00000196730	Death associated protein kinase 1	9	87497228-87708633	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	CAB037302, HPA040472, HPA048436	Approved		Approved	Centrosome	Colorectal cancer:2.48e-5 (unfavourable)	Expressed in all	Mixed			lung: 56.3	Cell line enhanced		HMC-1: 85.8
LCE1B	LEP2, SPRL2A	ENSG00000196734	Late cornified envelope 1B	1	152811971-152813109	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	9	skin: 186.0	breast: 20.1	Cell line enhanced		hTCEpi: 1.4
HLA-DQA1	CELIAC1, HLA-DQA	ENSG00000196735	Major histocompatibility complex, class II, DQ alpha 1	6	32628179-32647062	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA012315	Enhanced					Expressed in all	Tissue enhanced		lung: 504.8	lymph node: 338.6	Cell line enriched	9	HDLM-2: 1315.9
COL27A1	FLJ11895, KIAA1870, MGC11337	ENSG00000196739	Collagen type XXVII alpha 1 chain	9	114155560-114312511	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021884, HPA048471	Uncertain					Expressed in all	Mixed			endometrium: 39.8	Cell line enhanced		BEWO: 53.2;Hep G2: 33.0
GM2A	SAP-3	ENSG00000196743	GM2 ganglioside activator	5	151212150-151270440	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008063	Enhanced				Liver cancer:1.77e-5 (unfavourable)	Expressed in all	Expressed in all			skin: 89.5	Expressed in all		
HIST1H2AI	H2A/c, H2AFC	ENSG00000196747	Histone cluster 1 H2A family member i	6	27808199-27808701	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Mixed			bone marrow: 3.1	Cell line enhanced		K-562: 37.5;U-266/84: 81.3
CLPSL2	C6orf126, dJ510O8.5, UNQ3045	ENSG00000196748	Colipase like 2	6	35776594-35779552	Predicted secreted proteins	Evidence at protein level	HPA043460, HPA051655	Approved		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	703	epididymis: 713.1	seminal vesicle: 1.0	Cell line enriched	6	T-47d: 6.6
S100A2	CAN19, S100L	ENSG00000196754	S100 calcium binding protein A2	1	153561108-153567890	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002600, CAB047340, HPA062451	Enhanced		Supported	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:2.04e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 1481.8	tonsil: 368.4	Cell line enhanced		HBEC3-KT: 15305.5;RT4: 6706.3
ZNF700	DKFZp434I1610	ENSG00000196757	Zinc finger protein 700	19	11925068-11950773	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047845	Uncertain		Uncertain	Nucleus	Renal cancer:2.01e-5 (unfavourable), Urothelial cancer:2.53e-5 (favourable), Head and neck cancer:1.27e-4 (favourable), Prostate cancer:1.75e-4 (unfavourable), Melanoma:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 19.1	Mixed		
POU3F4	BRN4, DFN3, DFNX2, OTF9	ENSG00000196767	POU class 3 homeobox 4	X	83508250-83512127	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031984, HPA062295	Uncertain		Supported	Nucleus		Tissue enriched	Tissue enriched	11	cerebral cortex: 7.9	kidney: 0.7	Cell line enriched	96	AF22: 9.6
OR14A16	OR5AT1	ENSG00000196772	Olfactory receptor family 14 subfamily A member 16	1	247814800-247815729	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
CD47	IAP, MER6, OA3	ENSG00000196776	CD47 molecule	3	108043298-108091025	CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016055, HPA044659	Approved		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Thyroid cancer:7.29e-5 (favourable), Renal cancer:1.69e-4 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 204.6	Expressed in all		
OR52K1		ENSG00000196778	Olfactory receptor family 52 subfamily K member 1	11	4488879-4489908	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.1	Not detected		
TLE1	ESG, ESG1, GRG1	ENSG00000196781	Transducin like enhancer of split 1	9	81583683-81689305	Predicted intracellular proteins	Evidence at protein level	CAB011482, HPA071396	Supported		Supported	Nucleoplasm	Thyroid cancer:7.60e-4 (unfavourable), Renal cancer:8.07e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 51.2	Mixed		
MAML3	CAGH3, GDN, KIAA1816, MAM2, TNRC3	ENSG00000196782	Mastermind like transcriptional coactivator 3	4	139716753-140154184	Predicted intracellular proteins	Evidence at protein level	HPA037717	Approved		Supported	Nuclear speckles	Renal cancer:7.60e-5 (favourable)	Expressed in all	Mixed			endometrium: 10.8	Cell line enhanced		SCLC-21H: 18.5;SH-SY5Y: 25.4;WM-115: 20.0
HIST1H2AG	H2A.1b, H2A/p, H2AFP, pH2A/f	ENSG00000196787	Histone cluster 1 H2A family member g	6	27133042-27135291	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Tissue enhanced		testis: 5.5	breast: 3.7	Cell line enhanced		SiHa: 18.4;U-266/84: 34.4
STRN3	PPP2R6B, S/G2NA, SG2NA	ENSG00000196792	Striatin 3	14	30893799-31026401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003392, HPA004636, CAB069925	Approved		Supported	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 44.5	Expressed in all		
ZNF239	HOK-2, MOK2	ENSG00000196793	Zinc finger protein 239	10	43556344-43574618	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030843, HPA046679	Uncertain		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.70e-7 (unfavourable)	Expressed in all	Mixed			testis: 14.7	Cell line enhanced		NTERA-2: 24.4
SPINK14	SPINK5L2	ENSG00000196800	Serine peptidase inhibitor, Kazal type 14 (putative)	5	148169733-148175398	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		breast: 1.1;rectum: 1.2	cervix, uterine: 0.7	Not detected		
SPRR2B		ENSG00000196805	Small proline rich protein 2B	1	153070224-153070840	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Group enriched	18	esophagus: 30.3;skin: 17.1;testis: 8.2;tonsil: 14.1	ovary: 0.9	Not detected		
CHRNG	ACHRG	ENSG00000196811	Cholinergic receptor nicotinic gamma subunit	2	232539727-232546403	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enhanced	Tissue enriched	17	skeletal muscle: 8.2	prostate: 0.4	Group enriched	21	HSkMC: 2.3;RH-30: 8.7
ZSCAN16	dJ265C24.3, FLJ22191, ZNF392, ZNF435	ENSG00000196812	Zinc finger and SCAN domain containing 16	6	28124560-28130082	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007290	Supported		Approved	Nucleus	Ovarian cancer:1.14e-5 (favourable), Urothelial cancer:3.41e-5 (favourable), Lung cancer:3.19e-4 (favourable), Cervical cancer:5.73e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.6	Mixed		
MVB12B	C9orf28, FAM125B, FLJ00001	ENSG00000196814	Multivesicular body subunit 12B	9	126326849-126507041	Predicted intracellular proteins	Evidence at protein level	HPA043683, HPA049383	Uncertain		Approved	Golgi apparatus<br>Vesicles	Pancreatic cancer:7.89e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 36.5	Cell line enhanced		AF22: 34.2
C6orf106	dJ391O22.4, FLJ22195	ENSG00000196821	Chromosome 6 open reading frame 106	6	34587288-34696859	Predicted intracellular proteins	Evidence at protein level	HPA034489, HPA034490	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			testis: 125.7	Expressed in all		
CTD-2192J16.17		ENSG00000196826		19	12461559-12551474	Predicted intracellular proteins	No evidence							Not detected	Not detected			endometrium: 0.7	Not detected		
OR11G2		ENSG00000196832	Olfactory receptor family 11 subfamily G member 2	14	20197336-20198446	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	19	HEL: 1.9
POTEI	POTE2beta	ENSG00000196834	POTE ankyrin domain family member I	2	130459455-130509666	Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Group enriched	16	prostate: 17.4;testis: 10.3	breast: 0.8	Cell line enhanced		AN3-CA: 2.5;BEWO: 3.2;K-562: 3.0;U-2 OS: 7.5
ADA		ENSG00000196839	Adenosine deaminase	20	44619522-44652233	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001399, CAB004307, HPA023884	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable)	Expressed in all	Tissue enriched	13	duodenum: 487.7	lymph node: 36.5	Cell line enriched	9	MOLT-4: 1479.5
ARID5A	MRF-1, RP11-363D14	ENSG00000196843	AT-rich interaction domain 5A	2	96536743-96552638	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002860, HPA023879	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:4.24e-8 (unfavourable), Breast cancer:2.05e-6 (favourable)	Expressed in all	Expressed in all			appendix: 25.4	Group enriched	6	HDLM-2: 239.9;RPMI-8226: 78.9
PATE2	C11orf38, LVLF3112, PATE-M, UNQ3112	ENSG00000196844	Prostate and testis expressed 2	11	125776113-125778819	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	11	epididymis: 550.7	seminal vesicle: 50.7	Not detected		
PPTC7	TA-PP2C	ENSG00000196850	PTC7 protein phosphatase homolog	12	110533245-110583320	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039335, HPA040614	Approved		Approved	Plasma membrane<br>Cytosol	Ovarian cancer:1.43e-5 (unfavourable), Renal cancer:4.48e-5 (favourable), Pancreatic cancer:6.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.4	Expressed in all		
KRT39	KA35	ENSG00000196859	Keratin 39	17	40958417-40966892	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TOMM20L	UNQ9438	ENSG00000196860	Translocase of outer mitochondrial membrane 20 like	14	58395916-58408701	Predicted membrane proteins	Evidence at transcript level	HPA044997	Uncertain					Mixed	Tissue enriched	11	testis: 13.1	epididymis: 1.2	Cell line enhanced		SCLC-21H: 1.1
RGPD4	DKFZp686P0288, RGP4	ENSG00000196862	RANBP2-like and GRIP domain containing 4	2	107826937-107890841	Predicted intracellular proteins	Evidence at transcript level	HPA049497, HPA051675, HPA067564	Uncertain		Uncertain	Nuclear membrane<br>Vesicles		Not detected	Tissue enriched	57	testis: 5.7	all non-specific tissues: 0.0	Not detected		
NHLRC2	DKFZp779F115, FLJ20147, FLJ25621, FLJ33312, MGC45492	ENSG00000196865	NHL repeat containing 2	10	113854661-113917194	Predicted intracellular proteins	Evidence at protein level	HPA038493, HPA057564	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 18.6	Expressed in all		
HIST1H2AD	H2A.3, H2A/g, H2AFG	ENSG00000196866	Histone cluster 1 H2A family member d	6	26198851-26199243	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 2.2;prostate: 1.9	esophagus: 1.2	Cell line enhanced		U-266/70: 15.6;U-266/84: 5.0
ZFP28	KIAA1431, mkr5	ENSG00000196867	ZFP28 zinc finger protein	19	56538948-56556810	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028879	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 13.0	Mixed		
KIAA1211L	C2orf55, MGC42367	ENSG00000196872	KIAA1211 like	2	98793846-98936259	Predicted intracellular proteins	Evidence at protein level	HPA051082, HPA061678	Uncertain		Approved	Microtubules<br>Cytokinetic bridge<br>Centrosome	Renal cancer:1.13e-5 (favourable), Thyroid cancer:1.33e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.7;epididymis: 38.2	fallopian tube: 36.1	Cell line enhanced		BEWO: 39.4;HDLM-2: 56.9
CBWD3	bA561O23.1	ENSG00000196873	COBW domain containing 3	9	68232003-68300015	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Uncertain		Approved	Plasma membrane		Not detected	Expressed in all			appendix: 25.1	Expressed in all		
SCN8A	CerIII, MED, NaCh6, Nav1.6, PN4	ENSG00000196876	Sodium voltage-gated channel alpha subunit 8	12	51590266-51812864	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Tissue enriched	7	cerebral cortex: 22.1	testis: 3.1	Mixed		
LAMB3	BM600-125kDa, kalinin-140kDa, LAMNB1, nicein-125kDa	ENSG00000196878	Laminin subunit beta 3	1	209614870-209652466	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008069, CAB078183	Enhanced		Approved	Nucleoli<br>Mitochondria	Renal cancer:2.43e-5 (unfavourable), Lung cancer:9.62e-5 (unfavourable), Pancreatic cancer:2.55e-4 (unfavourable), Breast cancer:8.43e-4 (favourable)	Expressed in all	Mixed			stomach: 68.9	Cell line enhanced		CAPAN-2: 308.4;HaCaT: 470.9;HBEC3-KT: 935.2;hTCEpi: 295.3
HIST3H2BB		ENSG00000196890	Histone cluster 3 H2B family member b	1	228458107-228460470	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		fallopian tube: 2.2	adrenal gland,skin: 1.3	Cell line enhanced		T-47d: 5.9;U-266/70: 23.3;U-266/84: 5.4
TEX43	C5orf48, FLJ27505, MGC163367, MGC163369, Tseg7	ENSG00000196900	Testis expressed 43	5	126631722-126636287	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	62	testis: 35.7	colon: 0.5	Not detected		
KPNA5	IPOA6, SRP6	ENSG00000196911	Karyopherin subunit alpha 5	6	116681187-116741866	Predicted intracellular proteins, Transporters	Evidence at protein level	CAB026464, HPA054037	Enhanced		Supported	Cytosol		Expressed in all	Tissue enhanced		testis: 78.5	ovary: 22.1	Expressed in all		
ANKRD36B	FLJ21281, KIAA1641	ENSG00000196912	Ankyrin repeat domain 36B	2	97492663-97589965	Predicted intracellular proteins	Evidence at protein level	HPA051757, HPA057661			Approved	Nucleus<br>Cytosol		Mixed	Mixed			testis: 12.2	Mixed		
ARHGEF12	KIAA0382, LARG	ENSG00000196914	Rho guanine nucleotide exchange factor 12	11	120336914-120489936	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018911, CAB025581	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.43e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 145.8	Mixed		
HCAR1	FKSG80, GPR104, GPR81, HCA1, LACR1, TA-GPCR	ENSG00000196917	Hydroxycarboxylic acid receptor 1	12	122726076-122730843	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Breast cancer:3.61e-5 (unfavourable)	Mixed	Tissue enriched	8	parathyroid gland: 115.0	breast: 15.1	Cell line enhanced		CAPAN-2: 10.9;MCF7: 6.3;RT4: 28.4
PDLIM7	ENIGMA	ENSG00000196923	PDZ and LIM domain 7	5	177483394-177497606	Predicted intracellular proteins	Evidence at protein level	HPA018794, HPA048815	Approved		Enhanced	Actin filaments<br>Focal adhesion sites	Renal cancer:6.19e-10 (unfavourable), Lung cancer:4.07e-4 (unfavourable), Endometrial cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 288.9	Expressed in all		
FLNA	ABP-280, FLN, FLN1, OPD1, OPD2	ENSG00000196924	Filamin A	X	154348524-154374638	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000356, HPA000368, HPA001016, HPA001115, HPA002925	Enhanced	Approved	Enhanced	Plasma membrane<br>Actin filaments<br>Cytosol	Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 1051.0	Expressed in all		
TMEM26	Em:AC068892.1, MGC35010	ENSG00000196932	Transmembrane protein 26	10	61406643-61453450	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		spleen: 11.8	endometrium: 6.8	Cell line enhanced		BJ hTERT+: 3.7;HSkMC: 1.4;HUVEC TERT2: 1.2;MOLT-4: 1.8
SRGAP1	ARHGAP13, KIAA1304	ENSG00000196935	SLIT-ROBO Rho GTPase activating protein 1	12	63844293-64162221	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052416	Uncertain		Approved	Nuclear speckles	Ovarian cancer:5.67e-4 (unfavourable)	Mixed	Mixed			parathyroid gland: 13.1	Cell line enhanced		hTERT-HME1: 36.0
FAM3C	GS3876, ILEI	ENSG00000196937	Family with sequence similarity 3 member C	7	121348851-121396364	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043376, HPA050548	Enhanced		Enhanced	Golgi apparatus		Expressed in all	Expressed in all			thyroid gland: 181.1	Expressed in all		
NOP9	C14orf21	ENSG00000196943	NOP9 nucleolar protein	14	24299862-24309124	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000850			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:9.39e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.9	Expressed in all		
OR2T4	OR2T4Q	ENSG00000196944	Olfactory receptor family 2 subfamily T member 4	1	248361581-248362627	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			cervix, uterine,prostate: 0.1	Not detected		
ZNF705A	FLJ16353	ENSG00000196946	Zinc finger protein 705A	12	8157034-8188537	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 8.9	Cell line enhanced		AN3-CA: 5.3;BJ hTERT+: 5.5;HDLM-2: 5.4;NTERA-2: 6.4
SLC39A10	DKFZp564L2123, FLJ90515, KIAA1265	ENSG00000196950	Solute carrier family 39 member 10	2	195575977-195737702	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA036512, HPA036513, HPA066087	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 77.7;thyroid gland: 79.2	prostate: 30.8	Expressed in all		
CASP4	ICE(rel)II, ICH-2, TX	ENSG00000196954	Caspase 4	11	104942866-104969436	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027588, CAB037167	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:3.27e-11 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.8	Mixed		
AP2A1	ADTAA, CLAPA1	ENSG00000196961	Adaptor related protein complex 2 alpha 1 subunit	19	49766968-49807113	Predicted intracellular proteins	Evidence at protein level	CAB004306	Approved		Supported	Vesicles	Renal cancer:2.83e-9 (unfavourable), Ovarian cancer:2.91e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.9	Expressed in all		
ZNF585A	FLJ23765	ENSG00000196967	Zinc finger protein 585A	19	37106734-37172741	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Expressed in all			thyroid gland: 17.9	Mixed		
FUT11	MGC33202	ENSG00000196968	Fucosyltransferase 11	10	73772291-73780251	Predicted secreted proteins	Evidence at protein level	HPA014033	Approved		Approved	Nuclear membrane<br>Golgi apparatus	Cervical cancer:2.39e-6 (unfavourable), Renal cancer:3.67e-4 (unfavourable), Breast cancer:6.78e-4 (unfavourable)	Expressed in all	Mixed			placenta: 25.0	Mixed		
SMIM10L2B	LINC00087, NCRNA00087, RP11-85L21.2	ENSG00000196972	Small integral membrane protein 10 like 2B	X	135094987-135098634	Predicted membrane proteins	Evidence at transcript level						Renal cancer:2.41e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 23.9	parathyroid gland: 7.4	Cell line enhanced		HHSteC: 1.6;HSkMC: 2.2;NTERA-2: 1.6
ANXA4	ANX4	ENSG00000196975	Annexin A4	2	69644425-69827100	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB005076, HPA007393, CAB017560	Approved		Approved	Cytosol	Ovarian cancer:2.38e-4 (unfavourable), Renal cancer:6.05e-4 (unfavourable), Breast cancer:8.55e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 881.8	Cell line enhanced		EFO-21: 386.6;RPTEC TERT1: 457.3
LAGE3	CVG5, DXS9879E, DXS9951E, ESO3, ITBA2, Pcc1	ENSG00000196976	L antigen family member 3	X	154477769-154479257	Predicted intracellular proteins	Evidence at protein level	HPA036122, HPA036123	Approved		Supported	Nucleoplasm<br>Nuclear bodies	Cervical cancer:5.29e-6 (favourable), Renal cancer:5.42e-5 (unfavourable), Liver cancer:8.63e-5 (unfavourable), Endometrial cancer:7.60e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 26.9	Expressed in all		
WDR5B	FLJ11287	ENSG00000196981	WD repeat domain 5B	3	122412332-122416051	Predicted intracellular proteins	Evidence at transcript level	HPA042994	Approved					Expressed in all	Mixed			epididymis: 13.3	Mixed		
FAM163B	C9orf166	ENSG00000196990	Family with sequence similarity 163 member B	9	133578415-133586197	Predicted membrane proteins	Evidence at transcript level	HPA067336	Approved		Approved	Nuclear bodies<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	6	cerebral cortex: 103.5	adrenal gland: 16.4	Cell line enriched	19	SH-SY5Y: 72.4
NPIPB9		ENSG00000196993	Nuclear pore complex interacting protein family member B9	16	28751787-28772807	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	8	testis: 14.5	skin: 1.9	Cell line enhanced		hTCEpi: 3.1
WDR45	JM5, NBIA5, WDRX1, WIPI4	ENSG00000196998	WD repeat domain 45	X	49071470-49101170	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027562	Uncertain		Approved	Nucleoli	Cervical cancer:1.21e-4 (favourable), Head and neck cancer:1.61e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 258.8	Expressed in all		
METTL9	DREV1	ENSG00000197006	Methyltransferase like 9	16	21597218-21657473	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053588, HPA056347	Uncertain		Approved	Nucleus<br>Cell Junctions<br>Cytosol	Liver cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 92.0	Expressed in all		
ZNF138	pHZ-32	ENSG00000197008	Zinc finger protein 138	7	64794388-64833681	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077435			Uncertain	Cytosol		Expressed in all	Mixed			cerebral cortex: 9.1	Expressed in all		
ZNF429		ENSG00000197013	Zinc finger protein 429	19	21496682-21556270	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004139			Approved	Nucleus	Ovarian cancer:1.96e-8 (favourable), Pancreatic cancer:7.30e-4 (favourable)	Mixed	Mixed			thyroid gland: 16.3	Mixed		
ZNF470	CZF-1, FLJ26175	ENSG00000197016	Zinc finger protein 470	19	56567511-56588911	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029000	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			cerebral cortex,testis: 5.8	Cell line enhanced		HEK 293: 10.0
SERTAD1	SEI1, TRIP-Br1	ENSG00000197019	SERTA domain containing 1	19	40421592-40426025	Predicted intracellular proteins	Evidence at protein level	HPA063323			Approved	Nucleoplasm<br>Golgi apparatus		Expressed in all	Expressed in all			gallbladder: 19.6	Mixed		
ZNF100		ENSG00000197020	Zinc finger protein 100	19	21722766-21767628	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059135	Uncertain				Urothelial cancer:5.47e-4 (favourable)	Mixed	Mixed			testis: 11.6	Cell line enhanced		MOLT-4: 24.6
CXorf40B		ENSG00000197021	Chromosome X open reading frame 40B	X	149929527-149938811	Predicted intracellular proteins	Evidence at transcript level	HPA060897	Approved				Thyroid cancer:1.02e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 78.6	Expressed in all		
ZNF398	KIAA1339, P51, P71, ZER6	ENSG00000197024	Zinc finger protein 398	7	149126416-149182802	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071533			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
ZSCAN25	FLJ32468, ZNF498	ENSG00000197037	Zinc finger and SCAN domain containing 25	7	99616946-99632407	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055127, HPA057173	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Mixed			parathyroid gland: 10.0	Expressed in all		
ANXA6	ANX6	ENSG00000197043	Annexin A6	5	151100712-151157882	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA002462, CAB005077, HPA009650	Enhanced				Renal cancer:1.31e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 431.9	Mixed		
ZNF441	FLJ38637	ENSG00000197044	Zinc finger protein 441	19	11767000-11784078	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063338			Approved	Nuclear speckles		Expressed in all	Mixed			thyroid gland: 12.1	Mixed		
GMFB	GMF	ENSG00000197045	Glia maturation factor beta	14	54474484-54489196	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002954	Approved	Approved	Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:9.48e-5 (favourable), Liver cancer:2.21e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 108.7	Expressed in all		
SIGLEC15	CD33L3, HsT1361	ENSG00000197046	Sialic acid binding Ig like lectin 15	18	45825512-45844080	Predicted membrane proteins	Evidence at protein level	HPA053509			Supported	Nucleoplasm<br>Golgi apparatus	Urothelial cancer:9.14e-5 (favourable)	Mixed	Not detected			spleen: 0.6	Group enriched	8	PC-3: 9.6;U-87 MG: 30.2
ZNF420	FLJ32191	ENSG00000197050	Zinc finger protein 420	19	37007857-37130314	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059675	Approved		Approved	Nucleoplasm	Glioma:4.88e-5 (favourable), Renal cancer:1.83e-4 (favourable)	Expressed in all	Mixed			testis: 18.5	Mixed		
ZNF763	ZNF440L	ENSG00000197054	Zinc finger protein 763	19	11965037-11980381	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA047845	Uncertain		Uncertain	Nucleus		Mixed	Mixed			parathyroid gland: 11.5	Cell line enhanced		BEWO: 5.9
ZMYM1	FLJ23151, MYM	ENSG00000197056	Zinc finger MYM-type containing 1	1	35059786-35115859	Predicted intracellular proteins	Evidence at protein level	HPA064019			Approved	Microtubule organizing center	Liver cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			testis: 6.9	Mixed		
DTHD1	FLJ16686	ENSG00000197057	Death domain containing 1	4	36281622-36345756	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		fallopian tube: 20.9	lung: 4.9	Not detected		
HIST1H4C	dJ221C16.1, H4/g, H4FG	ENSG00000197061	Histone cluster 1 H4 family member c	6	26103876-26104310	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:5.74e-6 (unfavourable)	Tissue enhanced	Mixed			bone marrow: 2.9	Group enriched	5	HEK 293: 31.7;MOLT-4: 6.3;PC-3: 17.3
ZSCAN26	SRE-ZBP, ZNF187	ENSG00000197062	Zinc finger and SCAN domain containing 26	6	28267010-28278224	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027521			Enhanced	Nucleus<br>Nucleoli	Renal cancer:6.79e-5 (unfavourable), Liver cancer:7.81e-5 (unfavourable), Urothelial cancer:1.68e-4 (favourable)	Expressed in all	Expressed in all			ovary: 40.4	Expressed in all		
MAFG	MGC13090, MGC20149	ENSG00000197063	MAF bZIP transcription factor G	17	81918270-81927714	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025573	Approved				Liver cancer:1.90e-6 (unfavourable), Endometrial cancer:5.82e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 28.6	Expressed in all		
ARRDC1	MGC40555	ENSG00000197070	Arrestin domain containing 1	9	137605654-137615360	Predicted intracellular proteins	Evidence at protein level	HPA022915, HPA044345	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:3.59e-4 (favourable)	Expressed in all	Expressed in all			stomach: 26.2	Cell line enhanced		MCF7: 150.8
KIAA1671		ENSG00000197077	KIAA1671	22	24952730-25197448	Predicted intracellular proteins	Evidence at protein level	HPA018135	Approved		Approved	Microtubules	Renal cancer:3.19e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 44.6	Mixed		
KRT35	Ha-5, KRTHA5	ENSG00000197079	Keratin 35	17	41476689-41481140	Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	8	skin: 2.2	salivary gland,spleen: 0.2	Not detected		
IGF2R	CD222, CI-M6PR, CI-MPR, CIMPR, M6P-R, MPR1, MPR300, MPRI	ENSG00000197081	Insulin like growth factor 2 receptor	6	159969099-160113507	Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009661, HPA011332	Supported		Enhanced	Golgi apparatus<br>Vesicles	Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 50.5	Expressed in all		
LCE1C	LEP3	ENSG00000197084	Late cornified envelope 1C	1	152804835-152806628	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	11	skin: 514.5	breast: 45.5	Cell line enhanced		HBEC3-KT: 1.5;hTEC/SVTERT24-B: 1.1;hTERT-HME1: 2.2
GAL3ST4	FLJ12116	ENSG00000197093	Galactose-3-O-sulfotransferase 4	7	100159244-100168750	Predicted membrane proteins	Evidence at protein level	HPA038137, HPA038138	Uncertain		Approved	Nucleoplasm<br>Cytosol	Ovarian cancer:2.57e-4 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 32.6	smooth muscle: 14.7	Cell line enhanced		WM-115: 42.3
DYNC1H1	CMT2O, DHC1, DNCH1, Dnchc1, DNCL, DNECL, HL-3, p22	ENSG00000197102	Dynein cytoplasmic 1 heavy chain 1	14	101964528-102050792	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003742, CAB010443	Enhanced		Supported	Centrosome<br>Cytosol	Liver cancer:3.03e-7 (unfavourable), Renal cancer:1.09e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 80.6	Expressed in all		
SLC6A17		ENSG00000197106	Solute carrier family 6 member 17	1	110150486-110202202	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA007663, HPA008044	Enhanced		Approved	Nucleus<br>Golgi apparatus		Tissue enriched	Tissue enriched	10	cerebral cortex: 75.4	adrenal gland: 7.9	Cell line enhanced		SiHa: 6.6;SK-MEL-30: 28.5;U-87 MG: 7.0
IFNL3	IL-28B, IL28B, IL28C	ENSG00000197110	Interferon lambda 3	19	39243553-39245129	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			testis: 0.2	Not detected		
PCBP2	hnRNP-E2, HNRNPE2, HNRPE2	ENSG00000197111	Poly(rC) binding protein 2	12	53452102-53481162	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA038356	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.82e-5 (unfavourable), Ovarian cancer:8.23e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 745.7	Expressed in all		
ZGPAT	dJ583P15.3, FLJ14972, GPATC6, GPATCH6, KIAA1847, MGC44880, ZC3H9, ZC3HDC9, ZIP	ENSG00000197114	Zinc finger CCCH-type and G-patch domain containing	20	63707465-63736142	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056705			Supported	Nucleus<br>Plasma membrane	Head and neck cancer:6.17e-5 (favourable)	Expressed in all	Expressed in all			liver: 27.5	Expressed in all		
SLC25A29	C14orf69, FLJ38975	ENSG00000197119	Solute carrier family 25 member 29	14	100291111-100306547	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA030781	Uncertain				Pancreatic cancer:2.90e-4 (favourable), Urothelial cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 159.1	Mixed		
PGAP1	Bst1, FLJ12377, SPG67	ENSG00000197121	Post-GPI attachment to proteins 1	2	196833004-196927796	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069704	Uncertain					Mixed	Mixed			skin: 14.6	Mixed		
SRC	ASV, c-src, SRC1	ENSG00000197122	SRC proto-oncogene, non-receptor tyrosine kinase	20	37344685-37406050	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004023, HPA030875	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 43.6	Mixed		
ZNF679	MGC42415	ENSG00000197123	Zinc finger protein 679	7	64228474-64266931	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Tissue enriched	17	testis: 1.6	all non-specific tissues: 0.0	Not detected		
ZNF682	BC39498_3	ENSG00000197124	Zinc finger protein 682	19	19997058-20039506	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055998	Uncertain		Uncertain	Golgi apparatus	Urothelial cancer:3.51e-4 (favourable)	Tissue enhanced	Mixed			thyroid gland: 13.3	Cell line enhanced		AN3-CA: 20.2
OR8B8	TPCR85	ENSG00000197125	Olfactory receptor family 8 subfamily B member 8	11	124440126-124441158	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF772	DKFZp686I1569	ENSG00000197128	Zinc finger protein 772	19	57466663-57477570	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031312	Uncertain		Approved	Cytosol	Renal cancer:1.02e-6 (favourable)	Mixed	Mixed			parathyroid gland: 20.0	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 28.4
ZNF257	BMZF-4	ENSG00000197134	Zinc finger protein 257	19	22052452-22091480	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Ovarian cancer:2.05e-4 (favourable)	Tissue enhanced	Mixed			testis: 4.2	Cell line enhanced		NTERA-2: 11.0;RH-30: 5.6
PCNX3	FLJ22427, PCNXL3	ENSG00000197136	Pecanex homolog 3 (Drosophila)	11	65615773-65637439	Predicted membrane proteins	Evidence at protein level	HPA018084	Uncertain		Approved	Cytosol		Expressed in all	Mixed			testis: 17.2	Expressed in all		
ADAM32		ENSG00000197140	ADAM metallopeptidase domain 32	8	39106990-39284911	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA044156, HPA062151	Enhanced		Approved	Nucleus<br>Vesicles		Not detected	Tissue enriched	35	testis: 28.7	skin: 0.8	Cell line enhanced		U-2 OS: 1.1
ACSL5	ACS2, ACS5, FACL5	ENSG00000197142	Acyl-CoA synthetase long-chain family member 5	10	112374018-112428380	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA007162, CAB035986, CAB062546	Enhanced		Supported	Nucleus<br>Mitochondria	Endometrial cancer:1.13e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 460.3	Cell line enhanced		CAPAN-2: 121.7;RT4: 114.0
LRRC8B	KIAA0231, TA-LRRP	ENSG00000197147	Leucine rich repeat containing 8 family member B	1	89524836-89597864	Predicted membrane proteins, Transporters	Evidence at protein level	HPA017950	Uncertain		Approved	Nuclear speckles	Colorectal cancer:7.15e-4 (favourable), Endometrial cancer:9.99e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 37.6	testis: 28.8	Mixed		
ABCB8	EST328128, M-ABC1, MABC1	ENSG00000197150	ATP binding cassette subfamily B member 8	7	151028422-151047782	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA045187	Approved		Supported	Nucleus<br>Mitochondria	Pancreatic cancer:3.34e-4 (favourable), Renal cancer:5.88e-4 (favourable), Head and neck cancer:5.91e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.1	Expressed in all		
HIST1H3J	H3/j, H3FJ	ENSG00000197153	Histone cluster 1 H3 family member j	6	27890382-27893106	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		lymph node: 1.5	testis: 0.9	Cell line enhanced		U-266/84: 8.5
SND1	p100, TDRD11	ENSG00000197157	Staphylococcal nuclease and tudor domain containing 1	7	127652180-128092609	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002529, HPA002632, CAB019323	Enhanced		Enhanced	Cytosol	Endometrial cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
ZNF785	FLJ32130	ENSG00000197162	Zinc finger protein 785	16	30573740-30585771	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030510			Approved	Nucleoplasm<br>Plasma membrane	Pancreatic cancer:2.03e-5 (favourable), Lung cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 11.7	Mixed		
SULT1A2	HAST4, STP2	ENSG00000197165	Sulfotransferase family 1A member 2	16	28591943-28597109	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Tissue enhanced	Tissue enhanced		duodenum: 49.2;small intestine: 49.2	liver: 21.0	Cell line enhanced		BEWO: 9.6;EFO-21: 12.0;Hep G2: 33.5
NEK5		ENSG00000197168	NIMA related kinase 5	13	52033611-52129078	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA035565, HPA041399	Enhanced					Mixed	Group enriched	8	fallopian tube: 12.2;testis: 18.7	lung: 1.9	Cell line enhanced		T-47d: 1.0
PSMD12	p55, Rpn5	ENSG00000197170	Proteasome 26S subunit, non-ATPase 12	17	67337916-67366627	Predicted intracellular proteins	Evidence at protein level	HPA023119	Enhanced		Approved	Nucleus<br>Microtubules<br>Cytosol	Renal cancer:4.73e-6 (unfavourable), Liver cancer:1.21e-4 (unfavourable), Colorectal cancer:4.39e-4 (favourable), Ovarian cancer:6.32e-4 (favourable)	Expressed in all	Expressed in all			testis: 26.2	Expressed in all		
MAGEA6	CT1.6, MAGE6	ENSG00000197172	MAGE family member A6	X	152766136-152769747	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.93e-4 (unfavourable)	Mixed	Tissue enriched	22	testis: 10.9	endometrium: 0.4	Cell line enhanced		HMC-1: 137.9;K-562: 121.3;PC-3: 136.2;SK-BR-3: 103.8;U-2 OS: 104.5;U-266/70: 133.8
ADGRA1	GPR123, KIAA1828	ENSG00000197177	Adhesion G protein-coupled receptor A1	10	133070929-133131675	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA042773	Approved					Tissue enriched	Tissue enhanced		adrenal gland: 4.9;cerebral cortex: 22.4	fallopian tube: 3.1	Cell line enriched	24	RH-30: 6.1
PIWIL2	CT80, FLJ10351, HILI, Mili	ENSG00000197181	Piwi like RNA-mediated gene silencing 2	8	22275297-22357563	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	9	testis: 53.4	duodenum: 6.1	Cell line enriched	21	NTERA-2: 38.0
NOL4L	C20orf112, C20orf113, dJ1184F4.2, dJ1184F4.4, DKFZP566G1424	ENSG00000197183	Nucleolar protein 4 like	20	32443059-32585074	Predicted intracellular proteins	Evidence at protein level	HPA041768, HPA043600	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.01e-4 (unfavourable), Urothelial cancer:2.63e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 60.2	small intestine: 21.8	Cell line enhanced		CACO-2: 60.7
CYSRT1	C9orf169, MGC59937	ENSG00000197191	Cysteine rich tail 1	9	137224635-137226311	Predicted intracellular proteins	Evidence at protein level	HPA021883, HPA021886	Approved		Approved	Nuclear speckles<br>Vesicles<br>Midbody		Expressed in all	Tissue enhanced		esophagus: 45.6;skin: 12.2	tonsil: 6.3	Cell line enhanced		A-431: 11.7;CAPAN-2: 14.5;HaCaT: 16.3;MCF7: 20.0
SLC22A4	DFNB60, MGC34546, OCTN1	ENSG00000197208	Solute carrier family 22 member 4	5	132294443-132344206	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB015468, HPA036974	Approved		Approved	Mitochondria		Mixed	Tissue enhanced		fallopian tube: 18.4	bone marrow: 13.2	Cell line enhanced		BJ hTERT+: 48.5;U-138 MG: 24.5
ZSCAN5B	ZNF371, ZNF495B	ENSG00000197213	Zinc finger and SCAN domain containing 5B	19	56189570-56197920	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043123, HPA046836, HPA059494, HPA060667	Uncertain		Uncertain	Nuclear speckles		Not detected	Tissue enriched	22	testis: 2.7	fallopian tube: 0.1	Not detected		
ENTPD4	KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase	ENSG00000197217	Ectonucleoside triphosphate diphosphohydrolase 4	8	23385783-23457695	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017655	Supported		Supported	Vesicles		Expressed in all	Expressed in all			parathyroid gland: 47.3	Expressed in all		
C1D	LRP1, Rrp47, SUN-CoR, SUNCOR	ENSG00000197223	C1D nuclear receptor corepressor	2	68041130-68110948	Predicted intracellular proteins	Evidence at protein level	HPA037413, HPA037588	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			thyroid gland: 51.9	Expressed in all		
TBC1D9B	GRAMD9B, KIAA0676	ENSG00000197226	TBC1 domain family member 9B	5	179862066-179907859	Predicted intracellular proteins	Evidence at protein level	HPA038350	Approved		Approved	Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane	Thyroid cancer:3.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.3	Expressed in all		
OR1J2	OR1J3, OR1J5, OST044	ENSG00000197233	Olfactory receptor family 1 subfamily J member 2	9	122510802-122511743	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			urinary bladder: 0.2	Not detected		
HIST1H4J	H4/e, H4F2iv, H4FE	ENSG00000197238	Histone cluster 1 H4 family member j	6	27824108-27824480	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Mixed			bone marrow: 15.2	Mixed		
SLC2A7	GLUT7	ENSG00000197241	Solute carrier family 2 member 7	1	9003300-9026345	Predicted membrane proteins, Transporters	Evidence at protein level	HPA039931	Uncertain					Not detected	Group enriched	8	duodenum: 3.0;small intestine: 3.1	epididymis,testis: 0.3	Not detected		
FAM110D	FLJ14050, GRRP1	ENSG00000197245	Family with sequence similarity 110 member D	1	26159020-26163962	Predicted intracellular proteins	Evidence at transcript level	HPA013664	Approved					Expressed in all	Mixed			adipose tissue: 4.9	Cell line enhanced		U-2 OS: 1.6
SERPINA1	A1A, A1AT, AAT, alpha-1-antitrypsin, alpha1AT, PI, PI1	ENSG00000197249	Serpin family A member 1	14	94376747-94390693	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000927, HPA001292, CAB013211, CAB016648, CAB073396	Enhanced		Enhanced	Vesicles	Breast cancer:1.61e-5 (favourable), Colorectal cancer:5.86e-4 (favourable)	Tissue enriched	Tissue enriched	20	liver: 17144.0	small intestine: 857.0	Cell line enriched	6	Hep G2: 3254.2
TPSB2		ENSG00000197253	Tryptase beta 2 (gene/pseudogene)	16	1227272-1230184	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA049153, HPA049554	Supported					Mixed	Tissue enhanced		gallbladder: 156.9	lung: 117.5	Cell line enriched	7	HMC-1: 262.0
KANK2	ANKRD25, KIAA1518, MXRA3	ENSG00000197256	KN motif and ankyrin repeat domains 2	19	11164267-11197791	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015643	Approved				Renal cancer:8.73e-5 (unfavourable)	Expressed in all	Expressed in all			endometrium: 439.0	Expressed in all		
C6orf141	MGC46457	ENSG00000197261	Chromosome 6 open reading frame 141	6	49550646-49561907	Predicted intracellular proteins	Evidence at protein level	HPA036199	Uncertain		Approved	Nuclear membrane	Breast cancer:3.92e-6 (favourable), Endometrial cancer:1.15e-4 (favourable)	Mixed	Tissue enhanced		gallbladder: 9.3	duodenum: 6.2	Cell line enhanced		HaCaT: 7.6;PC-3: 10.6;T-47d: 6.8
GTF2E2	FE, TF2E2, TFIIE-B	ENSG00000197265	General transcription factor IIE subunit 2	8	30578318-30658251	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004816, CAB009603, HPA025065	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:5.82e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 52.7	Expressed in all		
IL27	IL-27, IL-27A, IL27A, IL27p28, IL30, MGC71873, p28	ENSG00000197272	Interleukin 27	16	28499362-28512051	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024722	Approved				Liver cancer:1.30e-4 (favourable)	Tissue enriched	Tissue enhanced		liver: 8.0	appendix: 1.6	Cell line enriched	15	BEWO: 17.2
GUCA2A	GUCA2, STARA	ENSG00000197273	Guanylate cyclase activator 2A	1	42162691-42164718	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA018215	Enhanced					Group enriched	Group enriched	15	colon: 768.8;rectum: 859.2;small intestine: 1127.0	duodenum: 61.5	Cell line enhanced		BEWO: 11.8;CACO-2: 8.2;NB-4: 2.0;U-2197: 2.5
RAD54B	RDH54	ENSG00000197275	RAD54 homolog B (S. cerevisiae)	8	94371960-94475109	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007087	Uncertain					Mixed	Mixed			testis: 7.8	Mixed		
ZNF165	CT53, ZSCAN7	ENSG00000197279	Zinc finger protein 165	6	28080975-28089563	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007247			Approved	Nuclear speckles<br>Microtubules	Renal cancer:1.19e-5 (favourable), Urothelial cancer:9.82e-5 (favourable), Ovarian cancer:2.10e-4 (favourable)	Mixed	Tissue enhanced		testis: 35.8	epididymis: 7.5	Cell line enhanced		BEWO: 23.4
SYNGAP1	KIAA1938, RASA5, SYNGAP	ENSG00000197283	Synaptic Ras GTPase activating protein 1	6	33419661-33457541	Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA038373	Enhanced		Approved	Nucleus	Renal cancer:1.34e-6 (unfavourable), Head and neck cancer:2.80e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 26.3	endometrium: 12.5	Cell line enhanced		AF22: 28.5
FITM2	C20orf142, dJ881L22.2, FIT2	ENSG00000197296	Fat storage inducing transmembrane protein 2	20	44302838-44311169	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.98e-12 (favourable)	Expressed in all	Tissue enhanced		heart muscle: 40.1	parathyroid gland: 24.1	Mixed		
BLM	BS, RECQ2, RECQL3	ENSG00000197299	Bloom syndrome RecQ like helicase	15	90717327-90816165	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005689	Approved		Supported	Nucleus<br>Cytosol		Mixed	Mixed			lymph node: 3.8	Mixed		
ZNF720		ENSG00000197302	Zinc finger protein 720	16	31713229-31794869	Predicted intracellular proteins	Evidence at transcript level	HPA041570	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 15.5	Expressed in all		
OR10D3	HTPCRX09, OR10D3P	ENSG00000197309	Olfactory receptor family 10 subfamily D member 3 (putative)	11	124185216-124186245	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049991	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
DDI2	MGC14844	ENSG00000197312	DNA damage inducible 1 homolog 2	1	15617500-15669044	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043119, HPA043225	Approved		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 19.7	Expressed in all		
SVIL		ENSG00000197321	Supervillin	10	29457338-29736781	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010878, HPA020095, HPA020138	Approved		Supported	Plasma membrane<br>Actin filaments<br>Cytosol	Urothelial cancer:5.70e-5 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 279.8	Cell line enhanced		HaCaT: 106.2
TRIM33	FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA	ENSG00000197323	Tripartite motif containing 33	1	114392777-114511160	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004345	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
LRP10	DKFZP564C1940, LRP9, MGC8675, MST087, MSTP087	ENSG00000197324	LDL receptor related protein 10	14	22871613-22881580	Predicted membrane proteins	Evidence at protein level	HPA000932			Approved	Nucleus<br>Nucleoli	Liver cancer:3.54e-7 (unfavourable), Renal cancer:6.31e-5 (favourable), Lung cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 179.5	Expressed in all		
PELI1		ENSG00000197329	Pellino E3 ubiquitin protein ligase 1	2	64092652-64144454	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053182	Uncertain		Approved	Nucleus<br>Nucleoli<br>Intermediate filaments	Renal cancer:5.67e-6 (unfavourable), Endometrial cancer:5.33e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 143.9	Cell line enhanced		U-698: 99.2
ZNF655	VIK, VIK-1	ENSG00000197343	Zinc finger protein 655	7	99558406-99576453	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029534, HPA050750	Uncertain		Supported	Nucleoplasm<br>Plasma membrane	Breast cancer:7.12e-4 (favourable), Melanoma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 21.2	Mixed		
MRPL21		ENSG00000197345	Mitochondrial ribosomal protein L21	11	68891276-68903835	Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins	Evidence at protein level	HPA051657	Approved		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:5.97e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 75.1	Expressed in all		
LYPD2	LYPDC2, RGTR430, UNQ430	ENSG00000197353	LY6/PLAUR domain containing 2	8	142750150-142752534	Predicted secreted proteins	Evidence at protein level	HPA028599	Uncertain				Cervical cancer:2.00e-4 (favourable), Head and neck cancer:2.63e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 99.1;tonsil: 24.0	stomach: 20.9	Group enriched	20	EFO-21: 9.5;HaCaT: 2.5
UAP1L1		ENSG00000197355	UDP-N-acetylglucosamine pyrophosphorylase 1 like 1	9	137077501-137084539	Predicted intracellular proteins	Evidence at protein level	HPA044356	Approved		Approved	Intermediate filaments<br>Cytosol	Liver cancer:3.77e-4 (unfavourable), Pancreatic cancer:5.23e-4 (favourable)	Expressed in all	Mixed			spleen: 13.2	Mixed		
ZNF98	F7175, ZNF739	ENSG00000197360	Zinc finger protein 98	19	22391019-22532485	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		ovary: 14.4;testis: 14.1	thyroid gland: 7.9	Cell line enhanced		BEWO: 1.7;NB-4: 3.0;T-47d: 3.2;U-2197: 3.3
FBXL22	Fbl22, FLJ39626	ENSG00000197361	F-box and leucine rich repeat protein 22	15	63597353-63602428	Predicted intracellular proteins	Evidence at protein level	HPA047624, HPA054627	Uncertain		Uncertain	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		endometrium: 50.4;seminal vesicle: 44.0;smooth muscle: 46.1	prostate: 23.3	Cell line enhanced		MCF7: 3.7;SCLC-21H: 6.3
ZNF786	DKFZp762I137	ENSG00000197362	Zinc finger protein 786	7	149069643-149090782	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA021518, HPA053459	Uncertain		Approved	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.09e-4 (unfavourable), Pancreatic cancer:2.01e-4 (favourable)	Expressed in all	Mixed			skin: 7.2	Expressed in all		
ZNF517		ENSG00000197363	Zinc finger protein 517	8	144798876-144811169	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055337			Approved	Nucleoplasm	Pancreatic cancer:1.66e-4 (favourable)	Expressed in all	Mixed			skin: 7.5	Mixed		
S100A7L2	s100a7b	ENSG00000197364	S100 calcium binding protein A7 like 2	1	153437058-153439949	Predicted intracellular proteins	Evidence at protein level	HPA057828	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
ZNF675	TBZF, TIZ	ENSG00000197372	Zinc finger protein 675	19	23525631-23687220	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Expressed in all			testis: 25.1	Cell line enhanced		HDLM-2: 56.3
SLC22A5	CDSP, OCTN2, SCD	ENSG00000197375	Solute carrier family 22 member 5	5	132369752-132395614	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA063062			Approved	Mitochondria	Endometrial cancer:2.87e-5 (favourable), Pancreatic cancer:7.36e-4 (favourable), Renal cancer:8.36e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 32.1	Cell line enhanced		SiHa: 40.6
OR8S1		ENSG00000197376	Olfactory receptor family 8 subfamily S member 1	12	48507354-48529897	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA045595	Uncertain		Approved	Plasma membrane		Not detected	Not detected			testis: 0.1	Not detected		
DACT3	DAPPER3, MGC15476, RRR1	ENSG00000197380	Dishevelled binding antagonist of beta catenin 3	19	46647612-46661138	Predicted intracellular proteins	Evidence at protein level	HPA043053	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:7.97e-8 (unfavourable), Urothelial cancer:6.66e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 46.6	Cell line enhanced		SH-SY5Y: 26.8
ADARB1	ADAR2, ADAR2a, ADAR2a-L1, ADAR2a-L2, ADAR2a-L3, ADAR2b, ADAR2c, ADAR2d, ADAR2g, DRABA2, DRADA2, hRED1, RED1	ENSG00000197381	Adenosine deaminase, RNA specific B1	21	45073853-45226560	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA029645			Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:8.16e-5 (unfavourable), Renal cancer:3.56e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 30.2	Cell line enhanced		HHSteC: 55.4
ZNF860		ENSG00000197385	Zinc finger protein 860	3	31981771-31991628	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA063386	Uncertain		Approved	Nucleus<br>Nucleoli		Mixed	Mixed			prostate: 4.7	Cell line enriched	6	BEWO: 44.1
HTT	HD, IT15	ENSG00000197386	Huntingtin	4	3074681-3243959	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002756, HPA026114	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.41e-12 (favourable), Head and neck cancer:3.26e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.3	Expressed in all		
OR6N1		ENSG00000197403	Olfactory receptor family 6 subfamily N member 1	1	158765744-158766682	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			bone marrow: 0.6	Not detected		
C5AR1	C5A, C5AR, C5R1, CD88	ENSG00000197405	Complement C5a receptor 1	19	47290023-47322066	CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002720, HPA014520	Approved				Renal cancer:1.16e-4 (unfavourable), Cervical cancer:4.71e-4 (favourable), Testis cancer:7.99e-4 (unfavourable), Ovarian cancer:9.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 121.2	adipose tissue: 91.2	Cell line enhanced		HMC-1: 4.6;U-87 MG: 6.2;U-937: 5.1
DIO3	TXDI3	ENSG00000197406	Iodothyronine deiodinase 3	14	101561351-101563452	Enzymes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cervix, uterine: 27.8;placenta: 25.4	ovary: 6.2	Cell line enriched	37	AF22: 53.5
CYP2B6	CPB6, CYP2B, CYPIIB6	ENSG00000197408	Cytochrome P450 family 2 subfamily B member 6	19	40991299-41018398	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB033866, HPA048124, HPA062973	Supported		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Tissue enhanced	Tissue enriched	18	liver: 283.3	kidney: 15.7	Cell line enhanced		HaCaT: 2.3
HIST1H3D	H3/b, H3FB	ENSG00000197409	Histone cluster 1 H3 family member d	6	26196840-26197250	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Renal cancer:1.78e-6 (unfavourable)	Expressed in all	Tissue enriched	8	bone marrow: 6.5	adrenal gland: 0.8	Cell line enhanced		Karpas-707: 4.0;U-266/70: 6.0
DCHS2	CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ	ENSG00000197410	Dachsous cadherin-related 2	4	154232037-154491716	Predicted membrane proteins	Evidence at protein level	HPA064159	Uncertain		Approved	Vesicles<br>Plasma membrane		Not detected	Tissue enhanced		endometrium: 1.9	testis: 1.7	Cell line enriched	6	U-2 OS: 9.2
VEPH1	FLJ12604, KIAA1692	ENSG00000197415	Ventricular zone expressed PH domain containing 1	3	157259742-157533619	Predicted intracellular proteins	Evidence at protein level	HPA026645	Uncertain		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.75e-9 (favourable)	Mixed	Tissue enhanced		adrenal gland: 26.6;kidney: 28.8;lung: 43.9	epididymis: 21.4	Cell line enhanced		HUVEC TERT2: 204.2;TIME: 119.8
FABP12		ENSG00000197416	Fatty acid binding protein 12	8	81524981-81531378	Predicted intracellular proteins	Evidence at protein level	HPA044041	Approved					Tissue enhanced	Group enriched	13	esophagus: 4.3;testis: 15.4	lung: 0.7	Not detected		
SHPK	CARKL, SHK	ENSG00000197417	Sedoheptulokinase	17	3608262-3636322	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA024361, HPA064939	Enhanced		Approved	Nucleoplasm<br>Nuclear speckles		Expressed in all	Mixed			duodenum: 13.4	Expressed in all		
OR51D1	OR51D1Q	ENSG00000197428	Olfactory receptor family 51 subfamily D member 1	11	4639715-4640838	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA061240	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
IPP	KLHL27	ENSG00000197429	Intracisternal A particle-promoted polypeptide	1	45694324-45750650	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable), Liver cancer:2.27e-4 (unfavourable), Colorectal cancer:9.11e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Mixed		
OPALIN	HTMP10, TMEM10, TMP10	ENSG00000197430	Oligodendrocytic myelin paranodal and inner loop protein	10	96343216-96359365	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014372	Supported					Tissue enriched	Tissue enriched	864	cerebral cortex: 86.3	all non-specific tissues: 0.0	Not detected		
OR13G1		ENSG00000197437	Olfactory receptor family 13 subfamily G member 1	1	247672118-247673041	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
MAP3K5	ASK1, MAPKKK5, MEKK5	ENSG00000197442	Mitogen-activated protein kinase kinase kinase 5	6	136557047-136792518	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007824, HPA063245, HPA064423	Approved		Supported	Cytosol	Pancreatic cancer:5.91e-4 (unfavourable), Head and neck cancer:6.08e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 115.7	Mixed		
OGDHL	FLJ10851	ENSG00000197444	Oxoglutarate dehydrogenase-like	10	49734643-49762379	Citric acid cycle related proteins, Predicted intracellular proteins	Evidence at protein level	HPA052497	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.21e-14 (favourable)	Tissue enhanced	Tissue enhanced		kidney: 128.4;parathyroid gland: 56.3	liver: 41.6	Cell line enhanced		AN3-CA: 19.8;RPTEC TERT1: 32.9;SH-SY5Y: 17.3
CYP2F1	CYP2F	ENSG00000197446	Cytochrome P450 family 2 subfamily F member 1	19	41114432-41128366	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Group enriched	8	lung: 2.4;testis: 1.9	bone marrow,esophagus,tonsil: 0.2	Group enriched	16	HMC-1: 4.7;K-562: 4.5
GSTK1	GST13	ENSG00000197448	Glutathione S-transferase kappa 1	7	143244093-143270854	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006311, HPA022904	Enhanced		Supported	Peroxisomes	Renal cancer:2.10e-6 (favourable), Breast cancer:4.41e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 377.4	Expressed in all		
HNRNPAB	ABBP1, FLJ40338, HNRPAB	ENSG00000197451	Heterogeneous nuclear ribonucleoprotein A/B	5	178204507-178211163	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046688	Approved		Enhanced	Nucleoplasm	Renal cancer:1.35e-7 (unfavourable), Ovarian cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			colon: 141.3	Expressed in all		
OR2L5	OR2L11, OR2L5P	ENSG00000197454	Olfactory receptor family 2 subfamily L member 5	1	248021948-248022886	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
STMN3	SCLIP	ENSG00000197457	Stathmin 3	20	63639705-63657682	Predicted intracellular proteins	Evidence at protein level	HPA012947	Enhanced					Expressed in all	Tissue enhanced		cerebral cortex: 225.7	thyroid gland: 52.6	Cell line enhanced		SCLC-21H: 225.8;SH-SY5Y: 155.0
PDGFA	PDGF-A, PDGF1	ENSG00000197461	Platelet derived growth factor subunit A	7	497258-520296	Cancer-related genes, Candidate cardiovascular disease genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005579	Uncertain		Approved	Vesicles<br>Microtubule organizing center	Glioma:1.51e-4 (unfavourable), Head and neck cancer:1.78e-4 (unfavourable), Urothelial cancer:8.67e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 38.8	Cell line enhanced		WM-115: 307.1
GYPE	GPE, MNS	ENSG00000197465	Glycophorin E (MNS blood group)	4	143870867-143905563	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 8.1	lung: 4.5	Group enriched	14	HEL: 108.6;K-562: 35.5
COL13A1		ENSG00000197467	Collagen type XIII alpha 1 chain	10	69801931-69964275	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050392	Approved					Mixed	Tissue enhanced		epididymis: 32.9	prostate: 20.4	Cell line enhanced		HUVEC TERT2: 78.6;PC-3: 69.5;TIME: 103.7
SPN	CD43, GPL115, LSN	ENSG00000197471	Sialophorin	16	29662979-29670876	CD markers, Predicted membrane proteins	Evidence at protein level	CAB002666, HPA055244	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 38.6;lung: 33.3	lymph node: 25.4	Cell line enhanced		HEL: 209.9;HL-60: 167.0;HMC-1: 98.8;U-937: 115.3
ZNF695	SBZF3	ENSG00000197472	Zinc finger protein 695	1	246945547-247008093	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024743	Uncertain		Approved	Nuclear speckles		Mixed	Tissue enhanced		testis: 1.2	small intestine: 0.6	Mixed		
PCDHB11	ME2, PCDH-BETA11	ENSG00000197479	Protocadherin beta 11	5	141199582-141203779	Predicted membrane proteins	Evidence at transcript level	HPA045042	Uncertain		Approved	Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 8.2	endometrium: 2.5	Cell line enhanced		AN3-CA: 5.1;EFO-21: 7.4
ZNF628	ZEC, Zfp628	ENSG00000197483	Zinc finger protein 628	19	55476332-55484487	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044451	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 7.2	spleen: 2.7	Mixed		
GALP		ENSG00000197487	Galanin like peptide	19	56176020-56185775	Predicted secreted proteins	Evidence at transcript level	HPA053938	Uncertain					Tissue enhanced	Not detected			liver: 0.3	Not detected		
SLC2A10	GLUT10	ENSG00000197496	Solute carrier family 2 member 10	20	46709487-46736347	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA041015	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Mixed			prostate: 49.3	Cell line enhanced		SK-MEL-30: 45.7
ZNF665	FLJ14345	ENSG00000197497	Zinc finger protein 665	19	53159213-53193386	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA023437	Uncertain		Approved	Nuclear membrane		Mixed	Mixed			ovary: 3.7	Mixed		
RPF2	bA397G5.4, BXDC1, FLJ21087	ENSG00000197498	Ribosome production factor 2 homolog	6	110982015-111028263	Predicted intracellular proteins	Evidence at protein level	HPA035475	Supported		Supported	Nucleus<br>Nucleoli	Renal cancer:2.07e-6 (unfavourable), Head and neck cancer:2.04e-4 (unfavourable), Liver cancer:2.25e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.2	Expressed in all		
SLC28A3	CNT3	ENSG00000197506	Solute carrier family 28 member 3	9	84275457-84340683	Predicted membrane proteins, Transporters	Evidence at protein level	HPA023311, HPA024729	Approved				Breast cancer:3.37e-4 (favourable)	Mixed	Tissue enhanced		breast: 10.7;gallbladder: 11.7;skin: 9.8	bone marrow: 6.2	Cell line enriched	8	HMC-1: 51.9
FAM177B	FLJ43505, RP11-452F19.2	ENSG00000197520	Family with sequence similarity 177 member B	1	222737207-222750805	Predicted intracellular proteins	Evidence at transcript level	HPA063059	Uncertain					Mixed	Tissue enhanced		stomach: 47.3	gallbladder: 15.8	Not detected		
MIB2	FLJ39787, skeletrophin, ZZANK1, ZZZ5	ENSG00000197530	Mindbomb E3 ubiquitin protein ligase 2	1	1615415-1630610	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA068322	Enhanced					Expressed in all	Tissue enhanced		skeletal muscle: 12.4	cerebral cortex: 4.4	Cell line enhanced		SCLC-21H: 18.4
OR6Y1	OR6Y2	ENSG00000197532	Olfactory receptor family 6 subfamily Y member 1	1	158547128-158548105	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MYO5A	GS1, MYH12, MYO5, MYR12	ENSG00000197535	Myosin VA	15	52307283-52529050	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001356	Approved		Approved	Focal adhesion sites<br>Microtubule organizing center	Urothelial cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.4	Cell line enhanced		Karpas-707: 145.4
C5orf56		ENSG00000197536	Chromosome 5 open reading frame 56	5	132410636-132488702	Predicted intracellular proteins	Evidence at transcript level	HPA043790			Approved	Mitochondria	Renal cancer:3.13e-6 (unfavourable)	Mixed	Mixed			spleen: 25.0	Cell line enhanced		Karpas-707: 38.7;U-266/70: 24.5
GZMM	LMET1, MET1	ENSG00000197540	Granzyme M	19	544034-549924	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA015624	Enhanced				Head and neck cancer:1.87e-7 (favourable), Renal cancer:1.21e-4 (unfavourable), Endometrial cancer:1.89e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 20.9;spleen: 19.7	appendix: 13.0	Cell line enhanced		EFO-21: 1.9;HDLM-2: 1.6;HMC-1: 1.8;MOLT-4: 1.1
ATG7	APG7L, DKFZp434N0735, GSA7	ENSG00000197548	Autophagy related 7	3	11272309-11557665	Predicted intracellular proteins	Evidence at protein level	HPA007639, CAB018771	Supported		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Liver cancer:1.41e-4 (unfavourable), Renal cancer:9.55e-4 (favourable), Colorectal cancer:9.66e-4 (favourable)	Expressed in all	Expressed in all			testis: 40.7	Expressed in all		
SIPA1L1	E6TP1, KIAA0440	ENSG00000197555	Signal induced proliferation associated 1 like 1	14	71320449-71741229	Predicted intracellular proteins	Evidence at protein level	HPA002875	Approved		Approved	Plasma membrane<br>Actin filaments	Renal cancer:6.80e-8 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.0	Mixed		
TTC30A	FLJ13946, IFT70A	ENSG00000197557	Tetratricopeptide repeat domain 30A	2	177612992-177618966	Predicted intracellular proteins	Evidence at protein level	HPA051714, HPA052100, HPA052487	Supported		Approved	Nucleus<br>Centrosome	Glioma:9.98e-4 (unfavourable)	Expressed in all	Mixed			testis: 17.3	Mixed		
SSPO	FLJ36112, KIAA0543, SCO-spondin	ENSG00000197558	SCO-spondin	7	149776042-149833979	Predicted secreted proteins	Evidence at protein level							Not detected	Not detected			cerebral cortex: 0.4	Not detected		
ELANE	ELA2, HLE, HNE, NE	ENSG00000197561	Elastase, neutrophil expressed	19	851014-856247	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB015409, HPA066836	Enhanced					Group enriched	Tissue enriched	320	bone marrow: 1199.6	skin: 3.7	Cell line enriched	56	THP-1: 1171.3
RAB40C	RARL, RASL8C	ENSG00000197562	RAB40C, member RAS oncogene family	16	589357-629272	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.18e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 26.5	Expressed in all		
PIGN	MDC4, PIG-N	ENSG00000197563	Phosphatidylinositol glycan anchor biosynthesis class N	18	61905255-62187118	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039922, HPA040374	Approved		Supported	Plasma membrane<br>Cytosol	Colorectal cancer:6.51e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
COL4A6		ENSG00000197565	Collagen type IV alpha 6 chain	X	108155607-108439497	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA065393			Approved	Endoplasmic reticulum		Mixed	Mixed			smooth muscle: 36.9	Cell line enhanced		HBEC3-KT: 32.9;HHSteC: 49.7;hTERT-HME1: 33.8;HUVEC TERT2: 34.7;TIME: 76.5
ZNF624	KIAA1349	ENSG00000197566	Zinc finger protein 624	17	16620737-16653856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023157, HPA023244	Uncertain		Approved	Vesicles		Mixed	Mixed			testis: 9.0	Mixed		
HHLA3		ENSG00000197568	HERV-H LTR-associating 3	1	70354805-70385339	Predicted intracellular proteins	Evidence at protein level	HPA031323	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:2.03e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 21.7	Expressed in all		
HOXA4	HOX1, HOX1D	ENSG00000197576	Homeobox A4	7	27128507-27130799	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060088	Approved		Enhanced	Nuclear bodies	Endometrial cancer:6.37e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 37.3;parathyroid gland: 35.3	esophagus: 16.4	Cell line enhanced		AN3-CA: 26.9;WM-115: 28.7
TOPORS	LUN, RP31, TP53BPL	ENSG00000197579	TOP1 binding arginine/serine rich protein	9	32540544-32552553	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA060640, HPA065661	Enhanced		Supported	Nucleoplasm	Renal cancer:6.64e-6 (favourable), Ovarian cancer:7.07e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 27.6	Expressed in all		
BCO2	B-DIOX-II, BCDO2, FLJ34464	ENSG00000197580	Beta-carotene oxygenase 2	11	112175467-112224699	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA039825, HPA040695	Uncertain					Mixed	Tissue enhanced		heart muscle: 21.7;liver: 25.7	adrenal gland: 16.9	Cell line enhanced		CAPAN-2: 5.2;HHSteC: 10.3
KCNMB2		ENSG00000197584	Potassium calcium-activated channel subfamily M regulatory beta subunit 2	3	178272932-178844429	Predicted membrane proteins, Transporters	Evidence at protein level	CAB022649	Uncertain					Mixed	Tissue enhanced		epididymis: 43.1;fallopian tube: 22.3;ovary: 19.0	adrenal gland: 7.6	Cell line enhanced		BJ hTERT+: 2.5;SCLC-21H: 4.7
ENTPD6	CD39L2, dJ738P15.3, IL6ST2, NTPDase-6	ENSG00000197586	Ectonucleoside triphosphate diphosphohydrolase 6 (putative)	20	25195693-25226729	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA015491, HPA069555	Approved		Supported	Golgi apparatus		Expressed in all	Expressed in all			cerebral cortex: 105.7	Expressed in all		
DMBX1	OTX3, PAXB	ENSG00000197587	Diencephalon/mesencephalon homeobox 1	1	46506996-46514226	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026811	Uncertain				Endometrial cancer:7.13e-5 (unfavourable)	Mixed	Tissue enhanced		testis: 1.2	adrenal gland,thyroid gland: 0.4	Cell line enhanced		AN3-CA: 11.9;CAPAN-2: 3.6;K-562: 3.9;SiHa: 4.4
OR11L1		ENSG00000197591	Olfactory receptor family 11 subfamily L member 1	1	247840928-247841896	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			thyroid gland: 0.3	Not detected		
ENPP1	M6S1, NPPS, PC-1, PCA1, PDNP1	ENSG00000197594	Ectonucleotide pyrophosphatase/phosphodiesterase 1	6	131808016-131895155	CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB032904, HPA062066	Enhanced					Expressed in all	Tissue enhanced		parathyroid gland: 54.3;placenta: 62.9	thyroid gland: 34.1	Cell line enhanced		ASC diff: 23.4;U-138 MG: 27.3
CCDC154	C16orf29, LOC645811	ENSG00000197599	Coiled-coil domain containing 154	16	1434383-1444556	Predicted intracellular proteins	Evidence at protein level	HPA041158, HPA043535, HPA048237	Uncertain		Approved	Golgi apparatus<br>Plasma membrane		Mixed	Tissue enhanced		testis: 6.5	spleen: 2.5	Group enriched	5	A-431: 8.2;SCLC-21H: 37.5
FAR1	FLJ22728, MLSTD2, SDR10E1	ENSG00000197601	Fatty acyl-CoA reductase 1	11	13668670-13732346	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017322	Approved		Enhanced	Peroxisomes	Colorectal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Mixed		
C5orf42	FLJ13231, Hug, JBTS17	ENSG00000197603	Chromosome 5 open reading frame 42	5	37106228-37249428	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA036775, HPA036776	Approved		Approved	Cytosol		Mixed	Mixed			thyroid gland: 13.8	Cell line enhanced		SiHa: 60.3
ZNF841	LOC284371	ENSG00000197608	Zinc finger protein 841	19	52064466-52095765	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.56e-6 (unfavourable), Urothelial cancer:8.92e-5 (favourable), Head and neck cancer:2.93e-4 (favourable)	Expressed in all	Mixed			prostate: 23.1	Mixed		
MFAP5	MAGP2, MP25	ENSG00000197614	Microfibrillar associated protein 5	12	8637346-8662888	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010553	Enhanced				Urothelial cancer:5.81e-4 (unfavourable), Stomach cancer:6.87e-4 (unfavourable)	Mixed	Expressed in all			smooth muscle: 207.1	Cell line enhanced		BEWO: 166.7;EFO-21: 142.4
MYH6		ENSG00000197616	Myosin heavy chain 6	14	23381990-23408277	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001239, HPA001349, CAB075723, CAB075724, CAB075725	Enhanced					Tissue enriched	Tissue enriched	96	heart muscle: 1838.3	skeletal muscle: 19.1	Cell line enriched	33	NTERA-2: 4.6
ZNF615	FLJ33710	ENSG00000197619	Zinc finger protein 615	19	51991332-52008230	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA052422	Uncertain		Approved	Nucleoli<br>Mitochondria	Urothelial cancer:2.98e-4 (favourable)	Expressed in all	Mixed			prostate: 28.7	Mixed		
CXorf40A	CXorf40, EOLA1	ENSG00000197620	Chromosome X open reading frame 40A	X	149540355-149550510	Predicted intracellular proteins	Evidence at protein level	HPA060897	Approved					Expressed in all	Expressed in all			adrenal gland: 69.6	Expressed in all		
CDC42SE1	SCIP1, SPEC1	ENSG00000197622	CDC42 small effector 1	1	151050971-151070325	Predicted intracellular proteins	Evidence at protein level	HPA027634	Approved		Supported	Plasma membrane	Renal cancer:2.19e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.4	Expressed in all		
MPEG1	MPG1	ENSG00000197629	Macrophage expressed 1	11	59208510-59212951	Predicted membrane proteins, Transporters	Evidence at protein level	HPA046801	Approved					Expressed in all	Tissue enhanced		spleen: 283.2	appendix: 152.1	Not detected		
SERPINB2	HsT1201, PAI2, PLANH2	ENSG00000197632	Serpin family B member 2	18	63871692-63903890	Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015480	Supported				Urothelial cancer:1.55e-5 (unfavourable)	Tissue enhanced	Group enriched	6	esophagus: 260.7;placenta: 70.3;skin: 105.8;tonsil: 72.9	bone marrow: 22.2	Group enriched	6	HaCaT: 611.4;U-138 MG: 792.9;U-2197: 1151.1
DPP4	ADCP2, CD26, DPPIV	ENSG00000197635	Dipeptidyl peptidase 4	2	161992241-162074542	CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB045970	Enhanced				Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 550.6	placenta: 169.1	Cell line enhanced		ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
SERPINB13	headpin, HUR7, hurpin, PI13	ENSG00000197641	Serpin family B member 13	18	63586989-63604639	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052630, HPA057129	Enhanced		Approved	Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enriched	9	esophagus: 184.6	tonsil: 20.7	Group enriched	137	HaCaT: 177.0;hTCEpi: 54.2
PDCD1LG2	B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2	ENSG00000197646	Programmed cell death 1 ligand 2	9	5510570-5571254	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA013411	Approved		Approved	Cytosol	Renal cancer:1.15e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 21.5	lymph node: 12.0	Cell line enhanced		BJ: 62.0;BJ hTERT+: 93.1;HDLM-2: 83.9
ZNF433	FLJ40981	ENSG00000197647	Zinc finger protein 433	19	12014732-12035741	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA073724	Uncertain		Approved	Nuclear bodies	Renal cancer:8.33e-15 (favourable)	Expressed in all	Expressed in all			testis: 51.5	Mixed		
CCER1	C12orf12, MGC26598	ENSG00000197651	Coiled-coil glutamate rich protein 1	12	90905622-90955176	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	341	testis: 34.0	all non-specific tissues: 0.0	Not detected		
DNAH10	FLJ43808	ENSG00000197653	Dynein axonemal heavy chain 10	12	123762188-123936206	Predicted intracellular proteins	Evidence at protein level	HPA039066	Enhanced					Tissue enhanced	Group enriched	6	fallopian tube: 5.6;testis: 5.6	lung: 0.9	Not detected		
SLC22A24	MGC34821, NET46	ENSG00000197658	Solute carrier family 22 member 24	11	63079940-63144221	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA045015	Uncertain					Tissue enriched	Tissue enriched	47	kidney: 4.6	all non-specific tissues: 0.0	Not detected		
KRTAP26-1		ENSG00000197683	Keratin associated protein 26-1	21	30319124-30320316	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	19	placenta: 1.9	testis: 0.1	Not detected		
SPTAN1		ENSG00000197694	Spectrin alpha, non-erythrocytic 1	9	128552558-128633662	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004581, HPA007927	Enhanced		Approved	Vesicles<br>Microtubules	Renal cancer:1.84e-12 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 201.9	Expressed in all		
NMB	MGC17211, MGC2277, MGC3936	ENSG00000197696	Neuromedin B	15	84655129-84658563	Predicted secreted proteins	Evidence at protein level	CAB019302	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane	Renal cancer:2.25e-4 (unfavourable), Glioma:5.07e-4 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 46.2;cerebral cortex: 47.2	thyroid gland: 14.8	Cell line enhanced		A-431: 46.7
PARVA	FLJ10793, FLJ12254, MXRA2	ENSG00000197702	Parvin alpha	11	12377185-12530801	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005964	Approved		Supported	Actin filaments<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:1.76e-4 (favourable), Lung cancer:8.19e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 145.8	Mixed		
KLHL14	KIAA1384	ENSG00000197705	Kelch like family member 14	18	32672671-32773062	Predicted intracellular proteins	Evidence at protein level	HPA024777	Uncertain		Supported	Actin filaments<br>Cytosol		Group enriched	Tissue enhanced		parathyroid gland: 19.3;seminal vesicle: 17.9;thyroid gland: 23.0	spleen: 11.7	Cell line enhanced		Hep G2: 10.5;REH: 3.8;RPTEC TERT1: 6.3;SCLC-21H: 3.7
OR6C74		ENSG00000197706	Olfactory receptor family 6 subfamily C member 74	12	55247198-55248302	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FAM114A1	Noxp20	ENSG00000197712	Family with sequence similarity 114 member A1	4	38867677-38945739	Predicted intracellular proteins	Evidence at protein level	HPA067948, HPA069104, HPA069701	Uncertain		Enhanced	Nucleus<br>Golgi apparatus<br>Cytosol	Renal cancer:3.63e-6 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 88.5	Cell line enhanced		fHDF/TERT166: 212.1
RPE		ENSG00000197713	Ribulose-5-phosphate-3-epimerase	2	210002565-210022259	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036498, HPA036499	Approved				Liver cancer:1.42e-6 (unfavourable), Pancreatic cancer:7.00e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 49.6	Expressed in all		
ZNF460	HZF8, ZNF272	ENSG00000197714	Zinc finger protein 460	19	57280051-57293569	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053004, HPA066506	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			adrenal gland: 6.3	Cell line enhanced		Karpas-707: 9.7
CR1L		ENSG00000197721	Complement C3b/C4b receptor 1 like	1	207645113-207738416	Predicted secreted proteins	Evidence at protein level	HPA049348	Approved					Tissue enhanced	Not detected			bone marrow: 0.8	Group enriched	8	HEL: 1.1;HMC-1: 2.6;K-562: 1.4
PHF2	CENP-35, JHDM1E, KDM7C, KIAA0662	ENSG00000197724	PHD finger protein 2	9	93576407-93679587	Predicted intracellular proteins	Evidence at protein level	HPA010831	Approved				Renal cancer:1.12e-5 (favourable), Colorectal cancer:9.34e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 30.7	Expressed in all		
RPS26	S26	ENSG00000197728	Ribosomal protein S26	12	56041853-56044675	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043961, HPA055803	Uncertain		Enhanced	Nucleoli<br>Endoplasmic reticulum<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 824.8	Expressed in all		
C14orf178	FLJ25976	ENSG00000197734	Chromosome 14 open reading frame 178	14	77760830-77769742	Predicted intracellular proteins	Evidence at transcript level	HPA062581	Uncertain					Not detected	Mixed			skin: 2.1	Mixed		
SCGB1D4	IIS	ENSG00000197745	Secretoglobin family 1D member 4	11	62296277-62299064	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	6	cervix, uterine: 76.0;epididymis: 55.4;fallopian tube: 74.8	endometrium: 11.8	Not detected		
PSAP	GLBA, SAP1	ENSG00000197746	Prosaposin	10	71816298-71851375	Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA004426, CAB004647	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			cerebral cortex: 1912.4	Expressed in all		
S100A10	42C, ANX2LG, CAL1L, CLP11, P11	ENSG00000197747	S100 calcium binding protein A10	1	151982915-151994390	Predicted membrane proteins, Transporters	Evidence at protein level	HPA003340, CAB025484	Enhanced		Approved	Mitochondria	Renal cancer:3.80e-8 (unfavourable), Lung cancer:2.66e-5 (unfavourable), Liver cancer:1.00e-4 (unfavourable), Head and neck cancer:3.33e-4 (unfavourable), Urothelial cancer:3.84e-4 (unfavourable), Pancreatic cancer:3.88e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 974.3	Mixed		
CFAP43	bA373N18.2, C10orf79, FLJ22944, FLJ36006, WDR96	ENSG00000197748	Cilia and flagella associated protein 43	10	104129888-104232362	Predicted intracellular proteins	Evidence at protein level							Mixed	Group enriched	7	fallopian tube: 78.0;testis: 103.2	lung: 12.5	Cell line enhanced		CAPAN-2: 3.7;U-266/70: 2.5
LHFPL5	DFNB67, dJ510O8.8, MGC33835, Tmhs	ENSG00000197753	Lipoma HMGIC fusion partner-like 5	6	35805293-35833874	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055110	Uncertain					Not detected	Tissue enhanced		epididymis: 10.8	bone marrow: 4.2	Mixed		
RPL37A	L37A	ENSG00000197756	Ribosomal protein L37a	2	216498189-216579180	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA065327	Approved		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:1.14e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 4523.8	Expressed in all		
HOXC6	HOX3, HOX3C	ENSG00000197757	Homeobox C6	12	53990624-54030823	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054981			Supported	Nucleoplasm<br>Cytosol	Renal cancer:3.55e-6 (unfavourable)	Mixed	Mixed			epididymis: 22.3	Cell line enhanced		AN3-CA: 85.1;HDLM-2: 73.7
TXNRD3	TGR, TR2, TRXR3	ENSG00000197763	Thioredoxin reductase 3	3	126607052-126655155	Predicted intracellular proteins	Evidence at protein level	CAB020802, HPA036109	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.72e-4 (favourable), Pancreatic cancer:2.86e-4 (unfavourable), Endometrial cancer:3.35e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 43.4	parathyroid gland: 18.4	Mixed		
CFD	ADN, DF, PFD	ENSG00000197766	Complement factor D	19	859643-863630	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA052799			Uncertain	Plasma membrane	Pancreatic cancer:1.77e-4 (favourable), Renal cancer:7.09e-4 (unfavourable)	Expressed in all	Tissue enriched	7	adipose tissue: 378.5	breast: 52.5	Group enriched	6	ASC diff: 82.6;THP-1: 121.6
STPG3	C9orf173, FLJ40246	ENSG00000197768	Sperm-tail PG-rich repeat containing 3	9	137251261-137253483	Predicted intracellular proteins	Evidence at transcript level	HPA044352			Uncertain	Vesicles		Mixed	Tissue enriched	7	testis: 27.7	duodenum: 3.9	Cell line enhanced		HDLM-2: 3.0;T-47d: 1.8
MAP1LC3C	ATG8J	ENSG00000197769	Microtubule associated protein 1 light chain 3 gamma	1	241995490-241999073	Predicted intracellular proteins	Evidence at protein level	HPA072670			Supported	Cytoplasmic bodies	Endometrial cancer:1.34e-7 (unfavourable)	Mixed	Tissue enhanced		breast: 12.7;placenta: 16.1	lung: 8.1	Cell line enhanced		AF22: 6.0;ASC TERT1: 3.9;BEWO: 3.7;EFO-21: 3.2
MCMBP	C10orf119, FLJ13081, MCM-BP	ENSG00000197771	Minichromosome maintenance complex binding protein	10	119829404-119892556	Predicted intracellular proteins	Evidence at protein level	CAB013792, HPA038481	Uncertain		Enhanced	Nucleoplasm	Pancreatic cancer:2.20e-4 (unfavourable), Renal cancer:6.18e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 63.6	Expressed in all		
EME2	FLJ00151, SLX2B	ENSG00000197774	Essential meiotic structure-specific endonuclease subunit 2	16	1773207-1781708	Predicted intracellular proteins	Evidence at protein level	HPA045770	Uncertain				Renal cancer:6.76e-7 (unfavourable), Urothelial cancer:6.32e-5 (favourable), Head and neck cancer:2.86e-4 (favourable)	Expressed in all	Mixed			prostate: 1.0	Cell line enhanced		HEK 293: 8.1;SCLC-21H: 4.3
KLHDC1	MST025	ENSG00000197776	Kelch domain containing 1	14	49693105-49753152	Predicted intracellular proteins	Evidence at protein level	HPA020461	Approved		Supported	Cytosol	Pancreatic cancer:1.94e-4 (favourable)	Mixed	Mixed			endometrium: 9.7	Cell line enhanced		ASC diff: 3.8;ASC TERT1: 3.7
ZNF81	HFZ20, MRX45	ENSG00000197779	Zinc finger protein 81	X	47836902-48002561	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001689	Approved					Mixed	Mixed			parathyroid gland: 9.9	Mixed		
TAF13	TAF2K, TAFII18	ENSG00000197780	TATA-box binding protein associated factor 13	1	109062486-109076002	Predicted intracellular proteins	Evidence at protein level	HPA044492	Approved		Enhanced	Nucleus<br>Nucleoli	Liver cancer:8.74e-6 (unfavourable), Ovarian cancer:2.42e-5 (favourable)	Expressed in all	Expressed in all			smooth muscle: 50.5	Expressed in all		
ZNF780A	ZNF780	ENSG00000197782	Zinc finger protein 780A	19	40069152-40090938	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003311	Uncertain		Approved	Nucleus<br>Centrosome	Urothelial cancer:9.30e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.4	Expressed in all		
ATAD3A	FLJ10709	ENSG00000197785	ATPase family, AAA domain containing 3A	1	1512151-1534687	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA058968, HPA064867, HPA065305	Approved		Supported	Mitochondria	Liver cancer:5.90e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 16.1	Expressed in all		
OR5B17	OR5B20P	ENSG00000197786	Olfactory receptor family 5 subfamily B member 17	11	58358124-58359069	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52M1	OR52M1P	ENSG00000197790	Olfactory receptor family 52 subfamily M member 1	11	4545191-4546144	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FAM118B	FLJ21103	ENSG00000197798	Family with sequence similarity 118 member B	11	126211414-126262986	Predicted intracellular proteins	Evidence at protein level	HPA041644, HPA042100	Approved		Approved	Intermediate filaments<br>Cytosol	Liver cancer:6.67e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 37.8	Expressed in all		
ZNF461	GIOT-1, MGC33911	ENSG00000197808	Zinc finger protein 461	19	36637192-36666853	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA021139	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Endometrial cancer:3.64e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 6.2	Mixed		
CCDC180	BDAG1, C9orf174, DKFZp434I2420, KIAA1529	ENSG00000197816	Coiled-coil domain containing 180	9	97307304-97378524	Predicted intracellular proteins	Evidence at protein level							Not detected	Group enriched	6	fallopian tube: 15.8;testis: 37.9	lung: 4.8	Cell line enhanced		HDLM-2: 3.9;U-266/70: 4.4
SLC9A8	KIAA0939, NHE8	ENSG00000197818	Solute carrier family 9 member A8	20	49812713-49892242	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB033682	Approved					Expressed in all	Expressed in all			bone marrow: 13.2	Expressed in all		
OCLN	PPP1R115	ENSG00000197822	Occludin	5	69492292-69558104	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA005933, CAB013075, CAB068212, CAB068213, CAB068214	Enhanced		Supported	Plasma membrane<br>Cell Junctions	Renal cancer:6.59e-11 (favourable)	Mixed	Tissue enhanced		thyroid gland: 78.7	lung: 39.8	Cell line enhanced		CAPAN-2: 60.2;HaCaT: 48.8
C4orf22		ENSG00000197826	Chromosome 4 open reading frame 22	4	80335720-80963756	Predicted intracellular proteins	Evidence at transcript level	HPA043383	Approved		Approved	Plasma membrane<br>Cytosol		Not detected	Group enriched	23	fallopian tube: 30.6;testis: 47.6	lung: 1.7	Cell line enhanced		A-431: 1.1;BJ: 1.4;SCLC-21H: 1.2
HIST4H4	MGC24116	ENSG00000197837	Histone cluster 4 H4	12	14767999-14771131	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB011503, CAB037279, HPA042201	Supported		Supported	Nucleoplasm		Mixed	Mixed			prostate: 7.2	Cell line enhanced		CAPAN-2: 4.1
CYP2A13	CPAD, CYP2A	ENSG00000197838	Cytochrome P450 family 2 subfamily A member 13	19	41088472-41096195	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA046713, HPA047262	Supported					Tissue enriched	Not detected			liver,testis: 0.3	Not detected		
ZNF181	HHZ181, MGC44316	ENSG00000197841	Zinc finger protein 181	19	34734155-34745378	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043701, HPA062305	Uncertain		Approved	Nucleus	Pancreatic cancer:1.05e-4 (favourable), Melanoma:2.60e-4 (unfavourable), Urothelial cancer:5.45e-4 (favourable)	Expressed in all	Expressed in all			ovary: 21.5	Mixed		
OR8G1	HSTPCR25, OR8G1P, TPCR25	ENSG00000197849	Olfactory receptor family 8 subfamily G member 1 (gene/pseudogene)	11	124249676-124250611	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Not detected		
FAM212B	C1orf183, FLJ31105, INKA2	ENSG00000197852	Family with sequence similarity 212 member B	1	111680630-111755824	Predicted intracellular proteins	Evidence at protein level	HPA027809, HPA027811	Approved		Approved	Nucleus	Head and neck cancer:4.51e-5 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 16.7	Cell line enhanced		hTEC/SVTERT24-B: 37.7;U-87 MG: 71.6
ZNF44	KOX7, ZNF504, ZNF55, ZNF58	ENSG00000197857	Zinc finger protein 44	19	12224686-12294887	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003146	Supported		Approved	Nucleoplasm<br>Microtubules<br>Cytosol	Urothelial cancer:9.21e-6 (favourable), Lung cancer:7.54e-4 (favourable), Head and neck cancer:8.74e-4 (favourable)	Expressed in all	Mixed			skin: 8.6	Mixed		
GPAA1	GAA1, hGAA1	ENSG00000197858	Glycosylphosphatidylinositol anchor attachment 1	8	144082590-144086216	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			parathyroid gland: 70.1	Expressed in all		
ADAMTSL2	KIAA0605	ENSG00000197859	ADAMTS like 2	9	133532164-133575519	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045634, HPA053812	Approved		Approved	Vesicles	Colorectal cancer:5.01e-4 (unfavourable), Pancreatic cancer:6.70e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 29.0	kidney: 11.2	Cell line enhanced		Hep G2: 4.9;RPMI-8226: 6.9;SH-SY5Y: 31.9
SGTB	FLJ39002, Sgt2	ENSG00000197860	Small glutamine rich tetratricopeptide repeat containing beta	5	65665928-65723035	Predicted intracellular proteins	Evidence at protein level	HPA044689, HPA063674	Enhanced		Uncertain	Nucleus		Expressed in all	Tissue enhanced		cerebral cortex: 52.0	appendix: 10.4	Expressed in all		
ZNF790	FLJ20350, MGC62100	ENSG00000197863	Zinc finger protein 790	19	36817428-36850787	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA056134, HPA060288	Uncertain		Approved	Nucleoli	Endometrial cancer:7.66e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.5	Mixed		
PRB3	PRG	ENSG00000197870	Proline rich protein BstNI subfamily 3	12	11265924-11269805	Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	3949	salivary gland: 5770.7	skin: 1.4	Cell line enriched	5	NTERA-2: 2.2
FAM49A	DKFZP566A1524, FLJ11080	ENSG00000197872	Family with sequence similarity 49 member A	2	16549459-16666331	Predicted intracellular proteins	Evidence at protein level	CAB017847, HPA060398	Approved		Approved	Nucleoplasm	Renal cancer:1.83e-6 (unfavourable), Urothelial cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 81.4	thyroid gland: 68.3	Cell line enhanced		HMC-1: 46.7;HUVEC TERT2: 36.0;RH-30: 92.5
MYO1C	myr2	ENSG00000197879	Myosin IC	17	1464098-1492812	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001768, HPA005924, CAB037023	Enhanced		Enhanced	Nuclear bodies<br>Plasma membrane	Lung cancer:5.22e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 192.4	Mixed		
MDS2		ENSG00000197880	Myelodysplastic syndrome 2 translocation associated	1	23581495-23640568	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA052999	Uncertain					Tissue enhanced	Tissue enhanced		lymph node: 7.7;tonsil: 4.0	spleen: 2.9	Cell line enhanced		Daudi: 1.0;U-266/70: 1.0;U-698: 3.4
NKIRAS1	kappaB-Ras1, KBRAS1	ENSG00000197885	NFKB inhibitor interacting Ras like 1	3	23891660-23946591	Predicted intracellular proteins	Evidence at protein level	HPA062521			Approved	Microtubules	Renal cancer:7.71e-13 (favourable), Lung cancer:3.69e-4 (favourable), Endometrial cancer:8.31e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 50.4	Expressed in all		
OR1S2		ENSG00000197887	Olfactory receptor family 1 subfamily S member 2	11	58203202-58204181	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA049304	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
UGT2B17		ENSG00000197888	UDP glucuronosyltransferase family 2 member B17	4	68537184-68568527	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Supported					Group enriched	Tissue enhanced		colon: 372.4;duodenum: 371.2;small intestine: 522.5	rectum: 151.7	Cell line enhanced		RPMI-8226: 1.2
MEIG1	bA2K17.3, SPATA39	ENSG00000197889	Meiosis/spermiogenesis associated 1	10	14959439-14988050	Predicted intracellular proteins	Evidence at transcript level	HPA044594	Uncertain					Mixed	Group enriched	12	fallopian tube: 6.7;testis: 13.0	cerebral cortex: 0.8	Cell line enhanced		HDLM-2: 5.1
SLC22A12	OAT4L, RST, URAT1	ENSG00000197891	Solute carrier family 22 member 12	11	64590641-64602353	Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA024575	Enhanced				Renal cancer:2.63e-4 (favourable)	Group enriched	Tissue enriched	198	kidney: 105.0	adipose tissue: 0.5	Not detected		
KIF13B	GAKIN, KIAA0639	ENSG00000197892	Kinesin family member 13B	8	29067279-29263124	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA025023, HPA049655	Enhanced				Renal cancer:0.00e+0 (favourable), Pancreatic cancer:4.77e-4 (unfavourable), Head and neck cancer:6.26e-4 (favourable), Colorectal cancer:8.92e-4 (favourable)	Expressed in all	Tissue enriched	10	parathyroid gland: 208.8	kidney: 20.2	Mixed		
NRAP		ENSG00000197893	Nebulin related anchoring protein	10	113588716-113664127	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA037953, HPA037954	Approved					Group enriched	Group enriched	17	heart muscle: 210.6;skeletal muscle: 814.0	prostate: 30.3	Not detected		
ADH5	ADH-3, ADHX, FDH, GSNOR	ENSG00000197894	Alcohol dehydrogenase 5 (class III), chi polypeptide	4	99070978-99088801	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044578, HPA061919	Approved				Renal cancer:4.58e-10 (favourable), Endometrial cancer:9.90e-5 (favourable), Melanoma:3.54e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 198.2	Expressed in all		
SLC22A6	OAT1, PAHT, ROAT1	ENSG00000197901	Solute carrier family 22 member 6	11	62936385-62984983	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA074559, CAB075704	Enhanced					Tissue enriched	Tissue enriched	64	kidney: 200.2	cerebral cortex: 3.1	Not detected		
HIST1H2BK	H2BFAiii, H2BFT	ENSG00000197903	Histone cluster 1 H2B family member k	6	27146418-27146798	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.77e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 106.2	Expressed in all		
TEAD4	EFTR-2, RTEF-1, TCF13L1, TEF-3, TEFR-1	ENSG00000197905	TEA domain transcription factor 4	12	2959330-3040673	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056896	Uncertain		Supported	Nucleoplasm	Renal cancer:9.78e-9 (unfavourable)	Tissue enriched	Tissue enhanced		skeletal muscle: 38.8	thyroid gland: 17.8	Cell line enhanced		HBEC3-KT: 263.0
SPG7	CAR, CMAR, SPG5C	ENSG00000197912	SPG7, paraplegin matrix AAA peptidase subunit	16	89490917-89557768	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Endometrial cancer:2.22e-4 (favourable), Urothelial cancer:4.25e-4 (favourable), Pancreatic cancer:4.91e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.2	Expressed in all		
HRNR	FLG3, S100A16, S100a18	ENSG00000197915	Hornerin	1	152212082-152224193	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA031469	Uncertain		Approved	Mitochondria		Tissue enhanced	Not detected			skin: 0.7	Cell line enhanced		NTERA-2: 1.9
IFNA1	IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA@, IFNA13	ENSG00000197919	Interferon alpha 1	9	21440454-21441316	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			urinary bladder: 0.2	Cell line enhanced		HeLa: 1.4
HES5	bHLHb38	ENSG00000197921	Hes family bHLH transcription factor 5	1	2528745-2530245	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA065458, HPA076164	Enhanced		Approved	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 1.8	skin: 0.9	Cell line enhanced		HaCaT: 1.1
ZNF677	MGC48625	ENSG00000197928	Zinc finger protein 677	19	53235381-53254898	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023106, HPA024796	Approved		Approved	Nucleus<br>Centrosome		Mixed	Expressed in all			testis: 71.1	Cell line enhanced		NTERA-2: 30.7
ERO1A	ERO1-alpha, Ero1alpha, ERO1L	ENSG00000197930	Endoplasmic reticulum oxidoreductase 1 alpha	14	52639916-52695900	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA026653, HPA030053, CAB034294	Enhanced				Renal cancer:6.54e-9 (unfavourable), Lung cancer:1.10e-5 (unfavourable), Pancreatic cancer:2.27e-4 (unfavourable), Liver cancer:7.59e-4 (unfavourable), Cervical cancer:8.47e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 181.5	Expressed in all		
ZNF823	HSZFP36	ENSG00000197933	Zinc finger protein 823	19	11721265-11739009	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Head and neck cancer:6.76e-5 (favourable), Renal cancer:4.49e-4 (favourable), Stomach cancer:5.05e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.5	Mixed		
ZNF311		ENSG00000197935	Zinc finger protein 311	6	28994785-29005316	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050541	Uncertain					Mixed	Not detected			fallopian tube: 0.4	Not detected		
ZNF347	ZNF1111	ENSG00000197937	Zinc finger protein 347	19	53124072-53159075	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023448	Uncertain		Approved	Microtubules		Mixed	Expressed in all			spleen: 13.3	Mixed		
OR5H2		ENSG00000197938	Olfactory receptor family 5 subfamily H member 2	3	98282888-98283832	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PLCG2		ENSG00000197943	Phospholipase C gamma 2	16	81739097-81962693	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004280, HPA020099, HPA020100	Enhanced		Approved	Vesicles	Renal cancer:4.88e-4 (favourable), Head and neck cancer:6.71e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 78.9	tonsil: 65.8	Cell line enhanced		Daudi: 130.7;HMC-1: 74.1;U-698: 278.1
FCHSD1	FLJ00007	ENSG00000197948	FCH and double SH3 domains 1	5	141639302-141651419	Predicted intracellular proteins	Evidence at protein level	HPA043795	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.19e-6 (unfavourable), Urothelial cancer:1.21e-4 (favourable), Testis cancer:4.77e-4 (unfavourable), Breast cancer:8.62e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 41.1	Mixed		
ZNF71	Cos26, EZFIT	ENSG00000197951	Zinc finger protein 71	19	56595264-56626481	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018124	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			cerebral cortex: 5.3	Mixed		
AADACL2	MGC72001	ENSG00000197953	Arylacetamide deacetylase like 2	3	151733916-151761339	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	14	skin: 31.1	breast: 2.3	Not detected		
S100A6	2A9, CABP, CACY, PRA	ENSG00000197956	S100 calcium binding protein A6	1	153534599-153536244	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002601, HPA007575, CAB040549, CAB047354	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Urothelial cancer:7.56e-4 (favourable)	Expressed in all	Expressed in all			lung: 1678.1	Cell line enhanced		RPTEC TERT1: 7409.7
RPL12	L12	ENSG00000197958	Ribosomal protein L12	9	127447674-127451405	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA003403	Approved		Approved	Golgi apparatus	Renal cancer:7.42e-7 (unfavourable), Head and neck cancer:5.66e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3674.5	Expressed in all		
DNM3	KIAA0820	ENSG00000197959	Dynamin 3	1	171841498-172418466	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA064121			Approved	Golgi apparatus		Mixed	Tissue enhanced		cerebral cortex: 41.1	adrenal gland: 15.6	Cell line enhanced		HEL: 20.5;RPTEC TERT1: 14.4;U-251 MG: 11.7
ZNF121	D19S204, ZHC32, ZNF20	ENSG00000197961	Zinc finger protein 121	19	9560353-9584533	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054961	Uncertain		Uncertain	Nucleoplasm<br>Nucleoli<br>Centrosome	Urothelial cancer:5.75e-5 (favourable), Ovarian cancer:6.59e-5 (favourable), Renal cancer:1.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
MPZL1	FLJ21047, PZR	ENSG00000197965	Myelin protein zero like 1	1	167721192-167791919	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026966, HPA063538	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 111.6	Expressed in all		
VPS13A	CHAC, KIAA0986	ENSG00000197969	Vacuolar protein sorting 13 homolog A	9	77177353-77421541	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021652, HPA021662	Enhanced					Expressed in all	Expressed in all			skin: 40.2	Expressed in all		
MBP		ENSG00000197971	Myelin basic protein	18	76978827-77133683	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002300, HPA049222, HPA064368	Enhanced	Supported	Approved	Plasma membrane	Renal cancer:4.48e-12 (favourable)	Group enriched	Tissue enriched	29	cerebral cortex: 2930.7	parathyroid gland: 99.8	Cell line enhanced		HL-60: 79.4;SK-MEL-30: 158.4
AKAP17A	721P, CCDC133, CXYorf3, DXYS155E, MGC39904, SFRS17A, XE7, XE7Y	ENSG00000197976	A-kinase anchoring protein 17A	X	1591593-1602514	Predicted intracellular proteins	Evidence at protein level	HPA043247, HPA051020	Enhanced		Supported	Nuclear speckles<br>Cytosol	Renal cancer:3.52e-7 (unfavourable), Urothelial cancer:1.11e-5 (favourable), Pancreatic cancer:2.42e-4 (favourable), Endometrial cancer:3.40e-4 (favourable)	Expressed in all	Expressed in all			spleen: 60.4	Expressed in all		
ELOVL2	Ssc2	ENSG00000197977	ELOVL fatty acid elongase 2	6	10980759-11044314	Enzymes, Predicted membrane proteins	Evidence at protein level						Breast cancer:6.73e-5 (favourable)	Group enriched	Tissue enhanced		liver: 27.6;parathyroid gland: 36.7;placenta: 50.2	cerebral cortex: 22.8	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 29.1;HBF TERT88: 28.0;RH-30: 30.7
GOLGA6L9	GOLGA6L20	ENSG00000197978	Golgin A6 family-like 9	15	82430018-82439153	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			stomach,testis: 0.9	Cell line enhanced		AN3-CA: 3.7;HDLM-2: 3.3
LEKR1	FLJ16641	ENSG00000197980	Leucine, glutamate and lysine rich 1	3	156825481-157046129	Predicted intracellular proteins	Evidence at protein level	HPA044039	Uncertain					Not detected	Tissue enhanced		testis: 27.3	fallopian tube: 6.7	Mixed		
C1orf122	FLJ45459	ENSG00000197982	Chromosome 1 open reading frame 122	1	37806979-37809454	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:4.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 52.7	Expressed in all		
RP11-310K10.1		ENSG00000197991		13	61409858-61427849	Predicted membrane proteins	No evidence	HPA062669			Approved	Vesicles<br>Cytokinetic bridge		Not detected	Not detected			testis: 0.5	Not detected		
CLEC9A	CD370, DNGR-1, HEEE9341, UNQ9341	ENSG00000197992	C-type lectin domain family 9 member A	12	10030677-10066027	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		lymph node: 7.8;spleen: 6.6	testis: 5.5	Not detected		
KEL	CD238, ECE3	ENSG00000197993	Kell blood group, metallo-endopeptidase	7	142941114-142962681	Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 14.5;testis: 19.5	lymph node: 6.4	Group enriched	14	HEL: 12.2;K-562: 10.7
NOL8	C9orf34, FLJ20736, Nop132	ENSG00000198000	Nucleolar protein 8	9	92297358-92325636	Predicted intracellular proteins	Evidence at protein level	HPA044440, HPA062922	Uncertain		Supported	Nucleoli	Renal cancer:1.02e-5 (unfavourable), Liver cancer:1.50e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 24.4	Expressed in all		
IRAK4	NY-REN-64	ENSG00000198001	Interleukin 1 receptor associated kinase 4	12	43758944-43789543	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016685, CAB022077	Uncertain		Approved	Nucleoli<br>Microtubules<br>Cytosol	Endometrial cancer:3.46e-5 (favourable), Urothelial cancer:4.42e-5 (favourable)	Expressed in all	Mixed			lymph node: 20.3	Expressed in all		
CCDC151	MGC20983	ENSG00000198003	Coiled-coil domain containing 151	19	11420604-11435782	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA044184, HPA054626	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		fallopian tube: 13.4;parathyroid gland: 6.8;testis: 7.5	cerebral cortex: 2.0	Cell line enhanced		SCLC-21H: 2.4;T-47d: 4.5
DLGAP2	DAP-2	ENSG00000198010	DLG associated protein 2	8	737596-1708474	Nuclear receptors, Predicted intracellular proteins	Evidence at protein level	HPA030320	Uncertain					Not detected	Group enriched	10	cerebral cortex: 2.0;testis: 6.1	thyroid gland: 0.4	Not detected		
MRPL42	HSPC204, MRP-L31, MRPL31, MRPS32, PTD007, RPML31	ENSG00000198015	Mitochondrial ribosomal protein L42	12	93467488-93516213	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA039398	Approved		Supported	Plasma membrane<br>Mitochondria	Liver cancer:7.49e-4 (unfavourable), Urothelial cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 57.2	Expressed in all		
ENTPD7	FLJ30978, LALP1	ENSG00000198018	Ectonucleoside triphosphate diphosphohydrolase 7	10	99659506-99706240	Predicted membrane proteins	Evidence at protein level	HPA014351	Uncertain		Approved	Nucleoplasm		Expressed in all	Mixed			small intestine: 23.7	Mixed		
FCGR1B	CD64b	ENSG00000198019	Fc fragment of IgG receptor Ib	1	121087345-121096310	FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		appendix: 27.5;epididymis: 61.7	placenta: 17.0	Cell line enhanced		HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
SPANXA1	CT11.1, NAP-X, SPAN-Xa, SPAN-Xb, SPANX	ENSG00000198021	Sperm protein associated with the nucleus, X-linked, family member A1	X	141583674-141585011	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	93	testis: 9.2	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.6
ZNF335	bA465L10.2, NIF-1	ENSG00000198026	Zinc finger protein 335	20	45948653-45972172	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063999, HPA071230			Enhanced	Nucleoplasm	Renal cancer:2.77e-5 (unfavourable), Liver cancer:1.59e-4 (unfavourable), Head and neck cancer:4.48e-4 (favourable), Prostate cancer:7.04e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 24.6	Expressed in all		
ZNF560	FLJ31986	ENSG00000198028	Zinc finger protein 560	19	9466507-9498607	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045439, HPA063209			Supported	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enriched	9	testis: 11.9	placenta: 1.2	Cell line enhanced		HEL: 19.1;NTERA-2: 20.6
TUBA3C	bA408E5.3, TUBA2	ENSG00000198033	Tubulin alpha 3c	13	19173770-19181852	Predicted intracellular proteins	Evidence at protein level	HPA039247, HPA043684, HPA063394	Uncertain		Supported	Microtubules		Mixed	Tissue enriched	2118	testis: 513.8	epididymis: 0.2	Group enriched	51	HDLM-2: 97.4;U-2 OS: 263.4;U-266/70: 63.0;U-266/84: 75.1
RPS4X	CCG2, DXS306, FLJ40595, RPS4, S4, SCAR, SCR10	ENSG00000198034	Ribosomal protein S4, X-linked	X	72255679-72277300	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Supported				Renal cancer:4.50e-6 (unfavourable), Thyroid cancer:4.22e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1948.7	Expressed in all		
ZNF273	HZF9	ENSG00000198039	Zinc finger protein 273	7	64870172-64930966	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077549			Approved	Nucleoplasm		Mixed	Mixed			testis: 2.9	Mixed		
ZNF84	HPF2	ENSG00000198040	Zinc finger protein 84	12	133037292-133063304	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028860	Approved		Supported	Nucleoplasm	Liver cancer:1.59e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 33.1	Mixed		
MAK16	MAK16L, RBM13	ENSG00000198042	MAK16 homolog	8	33484750-33501260	Predicted intracellular proteins	Evidence at protein level	HPA044417, HPA050574	Uncertain		Supported	Nucleoli<br>Vesicles	Liver cancer:1.00e-4 (unfavourable), Renal cancer:3.66e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 12.6	Expressed in all		
ZNF667	FLJ14011	ENSG00000198046	Zinc finger protein 667	19	56439325-56478065	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030731, HPA046673	Uncertain		Approved	Nucleus		Mixed	Mixed			cerebral cortex: 18.3	Cell line enhanced		HEL: 11.0;U-138 MG: 14.5
AVPR1B	AVPR3	ENSG00000198049	Arginine vasopressin receptor 1B	1	206109692-206117699	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA075404	Supported					Tissue enhanced	Not detected			stomach: 0.3	Not detected		
SIRPA	BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2	ENSG00000198053	Signal regulatory protein alpha	20	1894167-1940592	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002776, CAB015122, HPA054437, HPA058511	Enhanced					Expressed in all	Expressed in all			cerebral cortex: 207.9	Cell line enhanced		fHDF/TERT166: 110.5
DSCR8	C21orf65, CT25.1a, CT25.1b, MMA-1a, MMA-1b, MTAG2	ENSG00000198054	Down syndrome critical region 8	21	38121451-38188016	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	7	testis: 33.8	placenta: 4.8	Cell line enhanced		BEWO: 6.6;K-562: 6.1;U-266/70: 6.9;U-266/84: 3.5
GRK6	GPRK6	ENSG00000198055	G protein-coupled receptor kinase 6	5	177403204-177442901	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015327, HPA018903	Approved		Approved	Mitochondria	Liver cancer:5.66e-6 (unfavourable), Pancreatic cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 87.5	Expressed in all		
PRIM1		ENSG00000198056	Primase (DNA) subunit 1	12	56731596-56752373	Predicted intracellular proteins	Evidence at protein level	HPA040010	Uncertain		Supported	Vesicles	Liver cancer:2.40e-8 (unfavourable)	Expressed in all	Expressed in all			testis: 21.8	Expressed in all		
MARCH5	FLJ20445, MARCH-V, MITOL, RNF153	ENSG00000198060	Membrane associated ring-CH-type finger 5	10	92291163-92353964	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA056596			Supported	Mitochondria		Expressed in all	Expressed in all			thyroid gland: 28.7	Expressed in all		
POTEH	A26C3, ACTBL1, CT104.7, POTE22	ENSG00000198062	POTE ankyrin domain family member H	22	15690026-15721631	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Tissue enriched	Group enriched	36	prostate: 5.7;testis: 1.4	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.1
NPIPB13		ENSG00000198064	Nuclear pore complex interacting protein family, member B13	16	30222937-30254510	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Mixed			skin: 9.1	Mixed		
AKR1B10	AKR1B11, AKR1B12, ALDRLn, ARL-1, ARL1, HIS, HSI	ENSG00000198074	Aldo-keto reductase family 1 member B10	7	134527592-134541408	Predicted intracellular proteins	Evidence at protein level	HPA020280, CAB070163, HPA073633	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:4.80e-9 (unfavourable), Colorectal cancer:1.91e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 635.9;gallbladder: 283.3;small intestine: 387.2;stomach: 414.4	esophagus: 89.8	Group enriched	74	A549: 2731.1;Hep G2: 580.9
SULT1C4	SULT1C, SULT1C2	ENSG00000198075	Sulfotransferase family 1C member 4	2	108377911-108388057	Predicted intracellular proteins	Evidence at protein level	HPA034530			Approved	Cytosol	Renal cancer:9.99e-7 (favourable)	Group enriched	Tissue enhanced		gallbladder: 41.5	ovary: 31.2	Cell line enhanced		AF22: 8.6;HUVEC TERT2: 7.8;SH-SY5Y: 42.4
CYP2A7	CYP2A	ENSG00000198077	Cytochrome P450 family 2 subfamily A member 7	19	40875439-40882752	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB033510, HPA046713, HPA047262	Enhanced					Group enriched	Tissue enriched	123	liver: 60.9	breast: 0.4	Not detected		
ZBTB14	ZFP161, ZNF478	ENSG00000198081	Zinc finger and BTB domain containing 14	18	5289019-5297053	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050758, HPA070819	Uncertain		Enhanced	Nucleus<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.9	Expressed in all		
KRTAP9-9	KAP9.5, KAP9.9, KRTAP9-5	ENSG00000198083	Keratin associated protein 9-9	17	41255384-41256364	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CD2AP	CMS	ENSG00000198087	CD2 associated protein	6	47477789-47627263	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003267, HPA003326, CAB004352	Enhanced		Enhanced	Plasma membrane<br>Cytosol	Pancreatic cancer:5.53e-5 (unfavourable), Urothelial cancer:7.57e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 65.8	Expressed in all		
NUP62CL	FLJ20130	ENSG00000198088	Nucleoporin 62 C-terminal like	X	107123427-107206433	Predicted intracellular proteins	Evidence at protein level	HPA001884	Approved				Cervical cancer:5.66e-5 (favourable), Lung cancer:2.11e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 27.5	testis: 22.1	Cell line enhanced		A549: 19.9;CAPAN-2: 20.6;HeLa: 21.0;K-562: 20.5
SFI1	KIAA0542, PISD, PPP1R139	ENSG00000198089	SFI1 centrin binding protein	22	31488688-31618586	Predicted intracellular proteins	Evidence at protein level						Head and neck cancer:1.10e-4 (favourable), Urothelial cancer:1.31e-4 (favourable), Pancreatic cancer:5.80e-4 (favourable)	Expressed in all	Mixed			lymph node: 13.9	Expressed in all		
KRTAP4-6	KAP4.15, KAP4.6, KRTAP4-15	ENSG00000198090	Keratin associated protein 4-6	17	41139433-41140487	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMPRSS11F	FLJ16046	ENSG00000198092	Transmembrane protease, serine 11F	4	68053198-68129880	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA026911	Uncertain					Group enriched	Group enriched	7	esophagus: 16.7;skin: 11.0;tonsil: 3.7	breast: 1.5	Cell line enhanced		K-562: 1.4
ZNF649	FLJ12644	ENSG00000198093	Zinc finger protein 649	19	51889224-51905040	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026541	Uncertain				Renal cancer:4.60e-5 (favourable), Melanoma:7.44e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 33.8	Mixed		
ADH4	ADH-2	ENSG00000198099	Alcohol dehydrogenase 4 (class II), pi polypeptide	4	99123657-99157792	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020525	Enhanced		Uncertain	Nucleus<br>Cytosol	Liver cancer:7.08e-6 (favourable)	Tissue enriched	Tissue enriched	16	liver: 2628.5	duodenum: 166.3	Cell line enriched	7	Hep G2: 15.2
OR2T6	OR2T6P, OR2T9, OST703	ENSG00000198104	Olfactory receptor family 2 subfamily T member 6	1	248387609-248388535	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF248	bA162G10.3	ENSG00000198105	Zinc finger protein 248	10	37776526-37858106	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018237, HPA018287, HPA018455	Uncertain		Approved	Nucleoplasm	Lung cancer:1.04e-4 (favourable), Pancreatic cancer:1.22e-4 (favourable), Renal cancer:2.25e-4 (unfavourable), Prostate cancer:6.71e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 25.9	Expressed in all		
CHSY3	CHSY-2, CSS3	ENSG00000198108	Chondroitin sulfate synthase 3	5	129904472-130186634	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA044612	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 7.2	gallbladder: 4.5	Cell line enhanced		ASC diff: 9.0;ASC TERT1: 8.1;U-138 MG: 14.0
TOR4A	C9orf167, FLJ20245	ENSG00000198113	Torsin family 4 member A	9	137277749-137282641	Predicted intracellular proteins	Evidence at protein level	HPA044913	Enhanced		Approved	Nucleoplasm	Liver cancer:3.44e-4 (unfavourable), Colorectal cancer:6.48e-4 (unfavourable)	Expressed in all	Mixed			stomach: 11.5	Mixed		
LPAR1	edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1	ENSG00000198121	Lysophosphatidic acid receptor 1	9	110873263-111038458	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA050667			Approved	Nuclear speckles<br>Plasma membrane		Expressed in all	Mixed			cervix, uterine: 91.5	Cell line enhanced		ASC diff: 399.3;ASC TERT1: 236.2;BJ hTERT+: 345.8
MB	PVALB	ENSG00000198125	Myoglobin	22	35606764-35637951	Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000060, HPA003123	Enhanced					Group enriched	Group enriched	12	heart muscle: 6603.8;skeletal muscle: 12284.0	esophagus: 762.7	Cell line enhanced		SiHa: 20.1;SK-BR-3: 131.2;T-47d: 36.7
OR2L3		ENSG00000198128	Olfactory receptor family 2 subfamily L member 3	1	248060682-248061620	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.3	Not detected		
DEFB107B	HsT21816	ENSG00000198129	Defensin beta 107B	8	7495846-7509311	Predicted secreted proteins	Evidence at transcript level	HPA045626	Approved					Not detected	Tissue enriched	2828	epididymis: 488.6	endometrium: 0.1	Not detected		
HIBCH		ENSG00000198130	3-hydroxyisobutyryl-CoA hydrolase	2	190189735-190344193	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036540, HPA036541	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Renal cancer:1.04e-10 (favourable), Ovarian cancer:1.22e-4 (favourable)	Expressed in all	Expressed in all			kidney: 180.6	Expressed in all		
ZNF544	AF020591	ENSG00000198131	Zinc finger protein 544	19	58228594-58277495	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002732	Approved		Approved	Nucleoplasm	Liver cancer:1.04e-5 (unfavourable), Melanoma:3.65e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 48.6	Cell line enhanced		HEK 293: 153.3
TMEM229B	C14orf83, FLJ33387	ENSG00000198133	Transmembrane protein 229B	14	67447084-67533739	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA046562	Approved				Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable)	Expressed in all	Mixed			cervix, uterine: 16.0	Cell line enhanced		U-937: 26.9
SOWAHC	ANKRD57, C2orf26, FLJ21870	ENSG00000198142	Sosondowah ankyrin repeat domain family member C	2	109614334-109618990	Predicted intracellular proteins	Evidence at protein level	HPA056131	Enhanced		Approved	Cytosol	Renal cancer:3.56e-5 (favourable), Endometrial cancer:1.29e-4 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 36.4	Cell line enhanced		HDLM-2: 147.6
ZNF770	FLJ20582, PRO1914	ENSG00000198146	Zinc finger protein 770	15	34978341-34988287	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA024518	Approved					Expressed in all	Expressed in all			thyroid gland: 73.6	Expressed in all		
NPIPB6		ENSG00000198156	Nuclear pore complex interacting protein family member B6	16	28342555-28363508	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	24	testis: 54.8	skin: 2.3	Mixed		
HMGN5	NSBP1	ENSG00000198157	High mobility group nucleosome binding domain 5	X	81113701-81201942	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000511	Approved		Supported	Nucleus	Ovarian cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			testis: 201.5	Cell line enhanced		Karpas-707: 216.2
MIER1	hMI-ER1, KIAA1610, MI-ER1	ENSG00000198160	MIER1 transcriptional regulator	1	66924895-66988619	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA019589, HPA050306	Enhanced		Enhanced	Nucleoplasm	Glioma:6.18e-8 (favourable), Colorectal cancer:4.96e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 63.1	Expressed in all		
MAN1A2	MAN1B	ENSG00000198162	Mannosidase alpha class 1A member 2	1	117367449-117528872	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034559, HPA057364	Enhanced		Enhanced	Golgi apparatus	Ovarian cancer:4.08e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 44.3	Expressed in all		
SVIP	DKFZp313A2432	ENSG00000198168	Small VCP interacting protein	11	22813799-22830299	Predicted intracellular proteins	Evidence at protein level	HPA039807	Uncertain				Renal cancer:1.77e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 39.1	Cell line enhanced		SCLC-21H: 58.2
ZNF251		ENSG00000198169	Zinc finger protein 251	8	144720907-144756417	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA018290	Approved		Approved	Nucleoplasm	Renal cancer:1.42e-9 (unfavourable)	Expressed in all	Mixed			thyroid gland: 13.8	Mixed		
DDRGK1	C20orf116, dJ1187M17.3, UFBP1	ENSG00000198171	DDRGK domain containing 1	20	3190350-3204685	Predicted intracellular proteins	Evidence at protein level	HPA013373, HPA013705	Approved		Supported	Nucleoli<br>Endoplasmic reticulum	Renal cancer:2.01e-5 (favourable)	Expressed in all	Expressed in all			adrenal gland: 72.4	Expressed in all		
FAM47C		ENSG00000198173	Family with sequence similarity 47 member C	X	37008397-37011666	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 4.8	parathyroid gland: 0.1	Not detected		
TFDP1	DILC, Dp-1, DP1, DRTF1	ENSG00000198176	Transcription factor Dp-1	13	113584721-113641470	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB033605, HPA044754, HPA068909	Enhanced		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.03e-4 (unfavourable), Stomach cancer:6.17e-4 (favourable), Renal cancer:7.57e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 99.9	Expressed in all		
CLEC4C	BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL	ENSG00000198178	C-type lectin domain family 4 member C	12	7729415-7751605	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029432	Approved					Not detected	Tissue enhanced		lymph node: 6.0;spleen: 4.6;tonsil: 4.5	appendix,breast: 1.8	Cell line enhanced		HDLM-2: 1.9
ZNF607	FLJ14802, MGC13071	ENSG00000198182	Zinc finger protein 607	19	37696363-37719790	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049465, HPA055018	Uncertain		Approved	Nucleoplasm	Urothelial cancer:5.23e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.6	Mixed		
BPIFA1	bA49G10.5, LUNX, PLUNC, SPLUNC1	ENSG00000198183	BPI fold containing family A member 1	20	33235995-33243311	Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025669	Supported					Tissue enriched	Group enriched	8	cervix, uterine: 9.8;lung: 26.5	urinary bladder: 2.2	Not detected		
ZNF334	bA179N14.1	ENSG00000198185	Zinc finger protein 334	20	46499630-46513559	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050022	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Mixed			ovary: 19.4	Cell line enhanced		AF22: 15.3;BEWO: 18.7;NTERA-2: 10.4;SCLC-21H: 15.2
HSD17B11	17-BETA-HSD11, 17-BETA-HSDXI, DHRS8, PAN1B, RetSDR2, SDR16C2	ENSG00000198189	Hydroxysteroid 17-beta dehydrogenase 11	4	87336610-87391386	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA021608	Approved		Supported	Lipid droplets		Expressed in all	Expressed in all			small intestine: 295.2	Cell line enhanced		CAPAN-2: 236.8
SZT2	C1orf84, FLJ10387, FLJ34502, KIAA0467, RP11-506B15.1, SZT2A, SZT2B	ENSG00000198198	Seizure threshold 2 homolog (mouse)	1	43389882-43454247	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029012	Approved		Approved	Nucleoplasm<br>Vesicles<br>Actin filaments	Head and neck cancer:1.47e-7 (favourable), Liver cancer:2.53e-4 (unfavourable), Lung cancer:6.20e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 21.4	Expressed in all		
SULT1C2	ST1C1, SULT1C1	ENSG00000198203	Sulfotransferase family 1C member 2	2	108288639-108309915	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007190	Approved					Mixed	Tissue enhanced		kidney: 69.0;stomach: 149.5	duodenum: 28.5	Cell line enhanced		RPTEC TERT1: 19.5;RT4: 6.0
ZXDA	ZNF896	ENSG00000198205	Zinc finger, X-linked, duplicated A	X	57906708-57910820	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043789	Approved		Approved	Nucleoplasm	Renal cancer:8.55e-4 (favourable)	Mixed	Mixed			ovary: 5.3	Mixed		
RPS6KL1	MGC11287	ENSG00000198208	Ribosomal protein S6 kinase like 1	14	74903954-74923396	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA027451, HPA027794	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 31.4	testis: 14.7	Cell line enhanced		SCLC-21H: 41.7
RP11-566K11.2		ENSG00000198211		16	89919165-89936092	Predicted membrane proteins	Evidence at protein level	CAB011512, HPA043640, HPA046280	Uncertain					Not detected	Tissue enhanced		skin: 1.0	testis: 0.6	Cell line enriched	7	SK-MEL-30: 12.4
CACNA1E	BII, CACH6, CACNL1A6, Cav2.3	ENSG00000198216	Calcium voltage-gated channel subunit alpha1 E	1	181413102-181808084	Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA042515, CAB079032		Approved	Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Mixed	Tissue enriched	8	cerebral cortex: 10.3	adrenal gland: 1.3	Cell line enhanced		CACO-2: 1.2;U-266/70: 1.5
QRICH1	FLJ20259	ENSG00000198218	Glutamine rich 1	3	49029707-49094363	Predicted intracellular proteins	Evidence at protein level	HPA037677, HPA037678	Approved		Enhanced	Nucleoplasm	Ovarian cancer:7.46e-4 (favourable)	Expressed in all	Expressed in all			testis: 78.9	Expressed in all		
CSF2RA	CD116, CSF2R	ENSG00000198223	Colony stimulating factor 2 receptor alpha subunit	X	1268800-1310381	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB016148	Uncertain				Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 93.3	appendix: 34.6	Group enriched	8	BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
FKBP1C	bA184C23.2	ENSG00000198225	FK506 binding protein 1C	6	63211446-63213024	Predicted intracellular proteins	No evidence	HPA051798	Uncertain					Mixed	Not detected			appendix: 0.4	Not detected		
DDX42	RHELP, RNAHP, SF3b125, SF3B8	ENSG00000198231	DEAD-box helicase 42	17	63773603-63819317	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA023447, HPA023571, HPA025941	Enhanced		Enhanced	Nuclear speckles	Liver cancer:2.84e-4 (unfavourable), Renal cancer:9.26e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 75.1	Expressed in all		
RPL23A	L23A	ENSG00000198242	Ribosomal protein L23a	17	28719393-28724359	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA051754	Approved				Renal cancer:5.16e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2755.0	Expressed in all		
SLC29A3	ENT3, FLJ11160	ENSG00000198246	Solute carrier family 29 member 3	10	71319258-71363385	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046085, HPA054976, HPA057905	Approved		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable)	Expressed in all	Mixed			placenta: 18.8	Cell line enhanced		BEWO: 35.2
STYX		ENSG00000198252	Serine/threonine/tyrosine interacting protein	14	52730180-52774998	Predicted intracellular proteins	Evidence at protein level	HPA040290	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			testis: 20.5	Expressed in all		
UBL5		ENSG00000198258	Ubiquitin like 5	19	9827892-9830115	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			epididymis: 582.9	Expressed in all		
HELZ	DHRC, HUMORF5, KIAA0054	ENSG00000198265	Helicase with zinc finger	17	67070438-67245989	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA028276	Approved		Approved	Nucleoli<br>Plasma membrane<br>Actin filaments		Expressed in all	Expressed in all			parathyroid gland: 32.9	Expressed in all		
TMEM116	FLJ90167	ENSG00000198270	Transmembrane protein 116	12	111931282-112013185	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA040720	Approved		Approved	Nucleoplasm<br>Microtubules	Renal cancer:1.08e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 57.3	testis: 48.2	Mixed		
KRTAP4-5	KAP4.5	ENSG00000198271	Keratin associated protein 4-5	17	41148924-41149802	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
UCKL1	FLJ20517, URKL1	ENSG00000198276	Uridine-cytidine kinase 1 like 1	20	63939829-63956415	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004722, HPA004769	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:4.42e-4 (favourable)	Expressed in all	Expressed in all			spleen: 40.1	Expressed in all		
OR5B21		ENSG00000198283	Olfactory receptor family 5 subfamily B member 21	11	58507175-58508105	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
CARD11	BIMP3, CARMA1	ENSG00000198286	Caspase recruitment domain family member 11	7	2906141-3043945	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052984	Approved				Renal cancer:6.68e-8 (unfavourable), Urothelial cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 54.4;spleen: 40.2	appendix: 28.3	Cell line enhanced		Daudi: 86.5;RT4: 71.8;U-698: 73.9
ZNF485		ENSG00000198298	Zinc finger protein 485	10	43606407-43617903	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA059356	Uncertain				Breast cancer:5.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 7.2	Mixed		
PEG3	KIAA0287, ZKSCAN22, ZNF904, ZSCAN24	ENSG00000198300	Paternally expressed 3	19	56810083-56840728	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026070	Approved		Supported	Nucleoplasm	Thyroid cancer:1.56e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		ovary: 340.4;placenta: 197.8	adrenal gland: 102.0	Cell line enhanced		BEWO: 100.6;Hep G2: 150.6;RH-30: 70.4
SDAD1	FLJ10498	ENSG00000198301	SDA1 domain containing 1	4	75940950-75990962	Predicted intracellular proteins	Evidence at protein level	HPA035949	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:1.32e-4 (unfavourable), Renal cancer:2.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 38.4	Expressed in all		
ZKSCAN8	LD5-1, ZNF192, ZSCAN40	ENSG00000198315	Zinc finger with KRAB and SCAN domains 8	6	28141910-28159472	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003483	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:1.33e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 25.0	Expressed in all		
FAM109A	FLJ32356, IPIP27A, SES1	ENSG00000198324	Family with sequence similarity 109 member A	12	111360651-111369121	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.15e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 30.8	Mixed		
TMEM239		ENSG00000198326	Transmembrane protein 239	20	2816302-2820284	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	270	testis: 38.9	endometrium,placenta: 0.1	Cell line enriched	8	HDLM-2: 7.7
HYLS1	FLJ32915	ENSG00000198331	HYLS1, centriolar and ciliogenesis associated	11	125883614-125900648	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041210	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.92e-4 (unfavourable)	Expressed in all	Tissue enriched	6	testis: 37.5	smooth muscle: 6.6	Mixed		
MYL4	ALC1, AMLC, GT1, PRO1957	ENSG00000198336	Myosin light chain 4	17	47200446-47223679	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046859, HPA051884, HPA063034	Enhanced		Approved	Plasma membrane		Group enriched	Tissue enriched	21	heart muscle: 1686.3	bone marrow: 79.9	Group enriched	20	HEL: 495.8;K-562: 118.9
ZNF442	FLJ14356	ENSG00000198342	Zinc finger protein 442	19	12345949-12365905	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045738, HPA053407	Uncertain		Approved	Nuclear membrane<br>Vesicles		Mixed	Mixed			ovary: 6.0	Mixed		
ZNF813	FLJ16542	ENSG00000198346	Zinc finger protein 813	19	53467735-53496255	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA056406	Uncertain		Approved	Vesicles		Expressed in all	Mixed			prostate: 8.1	Cell line enhanced		RT4: 14.6
HOXC4	HOX3, HOX3E	ENSG00000198353	Homeobox C4	12	54016931-54056030	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA053910			Supported	Nucleus		Mixed	Tissue enhanced		fallopian tube: 33.9	kidney: 9.4	Cell line enhanced		HDLM-2: 29.1;HEK 293: 30.5;SH-SY5Y: 29.6
DCAF12L2	WDR40C	ENSG00000198354	DDB1 and CUL4 associated factor 12 like 2	X	126163499-126166097	Predicted intracellular proteins	Evidence at transcript level	HPA044737, HPA048981, HPA053138	Approved					Mixed	Tissue enhanced		epididymis: 28.3;testis: 9.8	seminal vesicle: 6.6	Group enriched	7	HAP1: 2.9;NTERA-2: 2.3;U-2 OS: 3.9
PIM3		ENSG00000198355	Pim-3 proto-oncogene, serine/threonine kinase	22	49960513-49964080	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA068758			Supported	Cytosol	Renal cancer:8.09e-4 (favourable), Ovarian cancer:9.68e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 61.2	Expressed in all		
ASNA1	ARSA-I, GET3, TRC40	ENSG00000198356	ArsA arsenite transporter, ATP-binding, homolog 1 (bacterial)	19	12737139-12748323	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA045951, HPA048087	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:4.27e-5 (favourable), Urothelial cancer:8.47e-4 (unfavourable), Cervical cancer:9.53e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 93.9	Expressed in all		
ASPH	BAH, CASQ2BP1, HAAH, JCTN	ENSG00000198363	Aspartate beta-hydroxylase	8	61500556-61714640	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA055161, HPA059303	Uncertain		Supported	Endoplasmic reticulum	Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 403.5	Mixed		
SPRED2	FLJ21897, FLJ31917, Spred-2	ENSG00000198369	Sprouty related EVH1 domain containing 2	2	65310851-65432637	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038256, HPA064394	Approved		Uncertain	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 44.0	Expressed in all		
WWP2	AIP2	ENSG00000198373	WW domain containing E3 ubiquitin protein ligase 2	16	69762306-69941741	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.87e-11 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.2	Expressed in all		
GFPT1	GFA, GFAT, GFAT1, GFPT	ENSG00000198380	Glutamine--fructose-6-phosphate transaminase 1	2	69319769-69387254	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047240			Approved	Nucleus<br>Nucleoli	Colorectal cancer:7.13e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 81.8	Expressed in all		
UVRAG	VPS38	ENSG00000198382	UV radiation resistance associated	11	75815167-76143195	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA016932	Uncertain					Expressed in all	Expressed in all			parathyroid gland: 42.2	Expressed in all		
KRTAP13-1	KAP13.1	ENSG00000198390	Keratin associated protein 13-1	21	30396074-30396822	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.3	Not detected		
ZNF26	FLJ20755, KOX20	ENSG00000198393	Zinc finger protein 26	12	132986365-133032952	Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA018329, HPA042406	Uncertain		Approved	Nuclear bodies<br>Mitochondria		Mixed	Mixed			epididymis: 6.9	Mixed		
TMEM207		ENSG00000198398	Transmembrane protein 207	3	190428655-190449876	Predicted membrane proteins	Evidence at protein level	HPA014332	Uncertain					Not detected	Tissue enriched	63	kidney: 18.7	testis: 0.2	Not detected		
ITSN2	KIAA1256, PRO2015, SH3D1B, SH3P18, SWA, SWAP	ENSG00000198399	Intersectin 2	2	24202864-24360714	Predicted intracellular proteins	Evidence at protein level	HPA036475	Approved		Approved	Vesicles<br>Plasma membrane	Head and neck cancer:2.98e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 84.8	Expressed in all		
NTRK1	MTC, TRK, TRKA	ENSG00000198400	Neurotrophic receptor tyrosine kinase 1	1	156815640-156881850	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004606, HPA035799, HPA076570	Approved		Uncertain	Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	6	adrenal gland: 9.5	testis: 1.6	Cell line enhanced		HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
MGEA5	MEA5, NCOAT, OGA	ENSG00000198408	Meningioma expressed antigen 5 (hyaluronidase)	10	101784443-101818465	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA036141, HPA076501	Approved		Supported	Cytosol	Colorectal cancer:8.69e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.4	Expressed in all		
MT1F	MT1	ENSG00000198417	Metallothionein 1F	16	56657694-56660698	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.02e-7 (unfavourable)	Expressed in all	Tissue enhanced		kidney: 285.2;thyroid gland: 817.7	small intestine: 138.4	Cell line enhanced		HDLM-2: 71.6;NB-4: 79.2;NTERA-2: 77.1;RPTEC TERT1: 250.9
TCAF1	FAM115A, KIAA0738	ENSG00000198420	TRPM8 channel associated factor 1	7	143851375-143902198	Predicted intracellular proteins	Evidence at protein level	HPA011732	Approved				Ovarian cancer:5.93e-4 (favourable)	Expressed in all	Expressed in all			placenta: 115.9	Mixed		
ZNF69	Cos5	ENSG00000198429	Zinc finger protein 69	19	11887784-11914329	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047845	Uncertain		Uncertain	Nucleus	Endometrial cancer:1.55e-4 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 24.9	kidney: 10.3	Cell line enhanced		AF22: 13.8
TXNRD1	GRIM-12, Trxr1, TXNR	ENSG00000198431	Thioredoxin reductase 1	12	104215779-104350305	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001395, CAB004607, CAB015834, HPA043871	Approved		Supported	Nucleus	Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 109.1	Expressed in all		
NRARP	MGC61598	ENSG00000198435	NOTCH-regulated ankyrin repeat protein	9	137300482-137302251	Predicted intracellular proteins	Evidence at transcript level	HPA025729	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.73e-6 (unfavourable)	Expressed in all	Tissue enhanced		colon: 38.4	rectum: 22.0	Cell line enhanced		HaCaT: 34.8;NTERA-2: 28.5;TIME: 23.6
ZNF583	FLJ31030	ENSG00000198440	Zinc finger protein 583	19	56397966-56436035	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023805, HPA023957	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			testis: 13.7	Mixed		
KRTAP4-1	KAP4.1, KAP4.10, KRTAP4-10	ENSG00000198443	Keratin associated protein 4-1	17	41184102-41185342	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			colon,small intestine: 0.3	Cell line enhanced		A549: 1.5;CAPAN-2: 1.1;HDLM-2: 4.6;SCLC-21H: 1.4
CCT8L2	CESK1	ENSG00000198445	Chaperonin containing TCP1 subunit 8 like 2	22	16590751-16592810	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	172	testis: 17.1	all non-specific tissues: 0.0	Not detected		
ZNF568	DKFZp686B0797	ENSG00000198453	Zinc finger protein 568	19	36916329-36998700	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052061	Uncertain					Mixed	Mixed			parathyroid gland: 14.3	Mixed		
ZXDB	ZNF905	ENSG00000198455	Zinc finger, X-linked, duplicated B	X	57591652-57597545	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043789	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 10.0	Mixed		
ZNF480	MGC32104	ENSG00000198464	Zinc finger protein 480	19	52297177-52325922	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042218	Uncertain		Supported	Nucleoplasm	Melanoma:1.65e-4 (unfavourable), Renal cancer:2.03e-4 (favourable)	Expressed in all	Mixed			lymph node: 14.8	Mixed		
ZNF587	FLJ14710, FLJ20813, UBF-fl, ZF6	ENSG00000198466	Zinc finger protein 587	19	57849857-57865112	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA042125, HPA043288, HPA056213	Uncertain		Uncertain	Nucleoplasm	Renal cancer:7.98e-4 (unfavourable)	Expressed in all	Mixed			rectum: 17.0	Expressed in all		
TPM2	AMCD1, DA1, NEM4	ENSG00000198467	Tropomyosin 2 (beta)	9	35681992-35691020	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047089, HPA053624	Approved				Renal cancer:8.51e-10 (unfavourable), Colorectal cancer:2.64e-4 (unfavourable)	Expressed in all	Tissue enriched	6	skeletal muscle: 13466.0	smooth muscle: 2282.0	Cell line enhanced		BJ: 1627.6
RTP2	MGC78665, Z3CXXC2	ENSG00000198471	Receptor transporter protein 2	3	187698259-187702557	Predicted membrane proteins	Evidence at protein level	HPA026875	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	12	SK-BR-3: 1.3
SH3BGRL2		ENSG00000198478	SH3 domain binding glutamate rich protein like 2	6	79631283-79703659	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047486	Approved		Supported	Nucleoplasm	Renal cancer:2.24e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 98.4	Cell line enhanced		CACO-2: 66.4;HEL: 37.0
ZNF808		ENSG00000198482	Zinc finger protein 808	19	52527652-52564464	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Urothelial cancer:3.88e-4 (favourable), Thyroid cancer:7.82e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 8.8	Mixed		
ANKRD35	FLJ25124	ENSG00000198483	Ankyrin repeat domain 35	1	145866560-145885866	Predicted intracellular proteins	Evidence at protein level	HPA035453	Enhanced				Cervical cancer:2.90e-4 (favourable), Breast cancer:9.35e-4 (favourable)	Mixed	Group enriched	6	cervix, uterine: 30.8;esophagus: 16.6;skin: 69.8	tonsil: 6.1	Cell line enhanced		ASC TERT1: 6.6;THP-1: 4.5;TIME: 6.9;U-87 MG: 8.1;U-937: 5.9
B3GNT6	B3Gn-T6	ENSG00000198488	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6	11	77034398-77041973	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA012158, HPA039805	Enhanced	Approved			Colorectal cancer:2.31e-4 (favourable)	Group enriched	Tissue enhanced		colon: 21.7;rectum: 18.2;stomach: 23.5	small intestine: 7.9	Not detected		
YTHDF2	CAHL, HGRG8, NY-REN-2	ENSG00000198492	YTH N6-methyladenosine RNA binding protein 2	1	28736621-28769775	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030063, HPA054080, HPA059621	Approved		Enhanced	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.14e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.9	Expressed in all		
TMA16	C4orf43, FLJ11184	ENSG00000198498	Translation machinery associated 16 homolog	4	163494442-163520539	Predicted intracellular proteins	Evidence at protein level	HPA041571, HPA052688	Uncertain		Enhanced	Nucleoli	Liver cancer:2.70e-5 (unfavourable), Lung cancer:4.40e-4 (unfavourable), Renal cancer:7.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 43.7	Expressed in all		
HLA-DRB5		ENSG00000198502	Major histocompatibility complex, class II, DR beta 5	6	32517343-32530287	Predicted membrane proteins	Evidence at protein level	HPA043151	Supported				Endometrial cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 530.8	lymph node: 397.6	Group enriched	7	HDLM-2: 589.3;HMC-1: 134.7;U-698: 129.3;U-87 MG: 232.1
ATL1	AD-FSP, FSP1, SPG3, SPG3A	ENSG00000198513	Atlastin GTPase 1	14	50532509-50633068	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA027550	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 96.9	smooth muscle: 22.0	Cell line enhanced		HDLM-2: 18.1;SCLC-21H: 20.2;SiHa: 19.9
CNGA1	CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49	ENSG00000198515	Cyclic nucleotide gated channel alpha 1	4	47935977-48016672	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level							Mixed	Mixed			liver: 14.2	Cell line enhanced		CAPAN-2: 9.1;RT4: 6.7;U-2 OS: 3.3
MAFK	NFE2U, P18	ENSG00000198517	MAF bZIP transcription factor K	7	1530714-1543043	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026820, HPA060841	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 36.8	Expressed in all		
C1orf228	MGC33556, NCRNA00082, p40	ENSG00000198520	Chromosome 1 open reading frame 228	1	44674692-44725591	Predicted intracellular proteins	Evidence at protein level	HPA034769	Uncertain		Uncertain	Cytosol	Endometrial cancer:8.64e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 13.5;testis: 21.4	epididymis: 4.7	Cell line enhanced		HL-60: 6.3;MOLT-4: 5.3;NB-4: 5.8;U-937: 9.7
ZNF43	HTF6, KOX27, ZNF39L1	ENSG00000198521	Zinc finger protein 43	19	21804949-21852125	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA050271	Uncertain				Ovarian cancer:3.16e-5 (favourable)	Mixed	Mixed			testis: 16.2	Cell line enhanced		MOLT-4: 31.1
GPN1	ATPBD1A, MBDIN, NTPBP, RPAP4, XAB1	ENSG00000198522	GPN-loop GTPase 1	2	27628247-27651508	Predicted intracellular proteins	Evidence at protein level	HPA036793, HPA036794, CAB037303	Uncertain		Supported	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:1.71e-5 (unfavourable), Endometrial cancer:2.88e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 47.1	Expressed in all		
PLN	CMD1P, PLB	ENSG00000198523	Phospholamban	6	118548298-118560730	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB005597, HPA026900	Enhanced				Renal cancer:4.11e-4 (unfavourable), Urothelial cancer:5.59e-4 (unfavourable)	Mixed	Tissue enriched	5	heart muscle: 1461.9	smooth muscle: 270.2	Not detected		
C2CD4A	FAM148A, NLF1	ENSG00000198535	C2 calcium dependent domain containing 4A	15	62066977-62070917	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.15e-4 (unfavourable)	Mixed	Mixed			endometrium: 2.3	Cell line enriched	14	RPTEC TERT1: 22.6
ZNF28	DKFZp781D0275, KOX24	ENSG00000198538	Zinc finger protein 28	19	52797409-52857600	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Breast cancer:9.29e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 17.9	Mixed		
ITGBL1	OSCP, TIED	ENSG00000198542	Integrin subunit beta like 1	13	101452593-101720856	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA005676	Uncertain				Urothelial cancer:2.70e-4 (unfavourable)	Mixed	Tissue enhanced		gallbladder: 59.8	placenta: 47.2	Cell line enhanced		ASC diff: 142.9;fHDF/TERT166: 267.4;LHCN-M2: 259.5
ZNF511	MGC30006	ENSG00000198546	Zinc finger protein 511	10	133308475-133313162	Predicted membrane proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	HPA035360	Uncertain				Renal cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 12.2	Expressed in all		
ZNF627	FLJ90365	ENSG00000198551	Zinc finger protein 627	19	11559374-11619135	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049770, HPA073463	Uncertain		Approved	Nucleus<br>Nucleoli	Renal cancer:6.93e-7 (favourable), Head and neck cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.7	Expressed in all		
KCNRG		ENSG00000198553	Potassium channel regulator	13	50015254-50020922	Predicted intracellular proteins	Evidence at protein level	HPA001027			Uncertain	Vesicles	Endometrial cancer:2.61e-5 (favourable)	Mixed	Tissue enriched	12	fallopian tube: 52.2	lung: 4.5	Mixed		
WDHD1	AND-1, CHTF4, CTF4	ENSG00000198554	WD repeat and HMG-box DNA binding protein 1	14	54938950-55027105	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA001122	Enhanced		Enhanced	Nucleoplasm	Pancreatic cancer:9.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.8	Expressed in all		
ZNF789		ENSG00000198556	Zinc finger protein 789	7	99472841-99503650	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA029500, HPA050793	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:5.31e-6 (favourable), Renal cancer:3.56e-4 (unfavourable), Pancreatic cancer:7.14e-4 (favourable)	Expressed in all	Mixed			prostate: 13.9	Expressed in all		
CTNND1	CTNND, KIAA0384, p120, p120cas, p120ctn	ENSG00000198561	Catenin delta 1	11	57753243-57819546	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB003837, HPA015954, HPA015955	Enhanced		Enhanced	Plasma membrane	Pancreatic cancer:3.02e-4 (unfavourable), Renal cancer:3.54e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 196.2	Expressed in all		
DDX39B	BAT1, D6S81E, UAP56	ENSG00000198563	DExD-box helicase 39B	6	31530219-31542448	Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB034012, HPA055334, HPA058450	Enhanced		Enhanced	Nuclear speckles	Renal cancer:1.11e-6 (unfavourable), Urothelial cancer:1.43e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 45.0	Expressed in all		
SLC34A3	FLJ38680, NPTIIc	ENSG00000198569	Solute carrier family 34 member 3	9	137230757-137236554	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA023776	Enhanced					Mixed	Group enriched	15	kidney: 11.8;small intestine: 9.1	testis: 0.7	Cell line enhanced		CAPAN-2: 2.9;MCF7: 4.2
RD3	C1orf36, LCA12	ENSG00000198570	Retinal degeneration 3	1	211476522-211492917	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029941, HPA029943	Supported					Tissue enhanced	Not detected			adrenal gland,epididymis: 0.3	Group enriched	14	HEL: 2.4;HMC-1: 6.0;SH-SY5Y: 10.6
SPANXC	CT11.3, CTp11	ENSG00000198573	SPANX family member C	X	141241463-141242496	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Tissue enhanced	Tissue enriched	187	testis: 18.7	all non-specific tissues: 0.0	Cell line enhanced		A-431: 7.8;U-2 OS: 4.3
SH2D1B	EAT2	ENSG00000198574	SH2 domain containing 1B	1	162395266-162412138	Predicted intracellular proteins	Evidence at protein level	HPA054791	Uncertain					Not detected	Tissue enhanced		spleen: 10.3	lung: 3.3	Cell line enhanced		CAPAN-2: 1.3;EFO-21: 2.5;Karpas-707: 3.2;TIME: 1.1
ARC	Arg3.1, KIAA0278	ENSG00000198576	Activity regulated cytoskeleton associated protein	8	142611044-142614472	Predicted intracellular proteins	Evidence at protein level	HPA056430, CAB079013		Supported	Approved	Vesicles<br>Microtubules		Tissue enriched	Group enriched	7	adipose tissue: 14.2;adrenal gland: 13.4;cerebral cortex: 14.4;gallbladder: 3.3;seminal vesicle: 5.5	placenta: 1.4	Cell line enhanced		HEK 293: 9.2;SCLC-21H: 27.7;U-2 OS: 11.9;U-87 MG: 12.5
NUDT16	FLJ31265	ENSG00000198585	Nudix hydrolase 16	3	131381671-131388830	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA060452, HPA062492	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:1.05e-7 (favourable), Cervical cancer:9.39e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.8	Mixed		
TLK1	KIAA0137, PKU-BETA	ENSG00000198586	Tousled like kinase 1	2	170990823-171231314	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016043	Approved		Enhanced	Nucleus		Expressed in all	Expressed in all			parathyroid gland: 40.9	Expressed in all		
LRBA	BGL, CDC4L, LAB300, LBA	ENSG00000198589	LPS responsive beige-like anchor protein	4	150264531-151015727	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019366, HPA023597	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:2.22e-16 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 62.7	Expressed in all		
C3orf35	APRG1	ENSG00000198590	Chromosome 3 open reading frame 35	3	37386269-37435497	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			testis: 4.4	Mixed		
ZNF536	KIAA0390	ENSG00000198597	Zinc finger protein 536	19	30228290-30713538	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077341			Approved	Nucleus<br>Cell Junctions		Mixed	Tissue enhanced		cerebral cortex: 19.0	thyroid gland: 5.3	Cell line enhanced		HAP1: 11.4;SH-SY5Y: 31.3;WM-115: 12.5
MMP17	MT4-MMP	ENSG00000198598	Matrix metallopeptidase 17	12	131828393-131851783	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		cerebral cortex: 24.0	skin: 8.2	Group enriched	5	REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
OR2M2	OR2M2Q, OST423	ENSG00000198601	Olfactory receptor family 2 subfamily M member 2	1	248179986-248181029	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BAZ1A	ACF1, hACF1, WALp1, WCRF180	ENSG00000198604	Bromodomain adjacent to zinc finger domain 1A	14	34752731-34875647	Predicted intracellular proteins	Evidence at protein level	HPA002730	Supported		Uncertain	Endoplasmic reticulum	Renal cancer:1.31e-7 (unfavourable), Liver cancer:4.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 55.7	Expressed in all		
AKR1C4	3-alpha-HSD, C11, CDR, CHDR, DD4, HAKRA, MGC22581	ENSG00000198610	Aldo-keto reductase family 1 member C4	10	5195462-5218949	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA044720, HPA068265	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	6	liver: 360.3	gallbladder: 64.2	Cell line enriched	8	HDLM-2: 6.1
COPS8	COP9, CSN8, MGC1297, SGN8	ENSG00000198612	COP9 signalosome subunit 8	2	237085312-237100466	Predicted intracellular proteins	Evidence at protein level	HPA036485	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:4.70e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 116.1	Expressed in all		
CCDC69	DKFZP434C171, FLJ13705	ENSG00000198624	Coiled-coil domain containing 69	5	151181052-151224145	Predicted intracellular proteins	Evidence at protein level	HPA043648, HPA052896	Uncertain		Approved	Golgi apparatus<br>Plasma membrane<br>Actin filaments	Breast cancer:3.21e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 112.8	Cell line enhanced		ASC diff: 80.3;Daudi: 136.8;U-266/70: 89.8;U-698: 84.7
MDM4	HDMX, MDMX	ENSG00000198625	MDM4, p53 regulator	1	204516379-204558120	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA018919, HPA048821	Approved		Supported	Nucleus	Renal cancer:7.06e-6 (unfavourable), Urothelial cancer:2.49e-4 (favourable), Prostate cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 37.5	Expressed in all		
RYR2	ARVC2, ARVD2, VTSIP	ENSG00000198626	Ryanodine receptor 2	1	237042205-237833988	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA020028	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	8	heart muscle: 65.9	cerebral cortex: 7.9	Cell line enhanced		HDLM-2: 4.8;HEK 293: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5
ZNF534	FLJ25344, KRBO3	ENSG00000198633	Zinc finger protein 534	19	52429187-52452315	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 2.4	cerebral cortex: 0.9	Not detected		
KLHL9	FLJ13568, KIAA1354	ENSG00000198642	Kelch like family member 9	9	21329671-21335380	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046039, HPA059901	Approved		Approved	Cytosol	Renal cancer:9.43e-10 (favourable)	Expressed in all	Expressed in all			thyroid gland: 27.0	Mixed		
FAM3D	EF7, OIT1	ENSG00000198643	Family with sequence similarity 3 member D	3	58633946-58666848	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013844	Approved				Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable)	Tissue enhanced	Tissue enhanced		colon: 318.5;rectum: 484.7	salivary gland: 191.6	Not detected		
NCOA6	AIB3, ASC2, KIAA0181, NRC, PRIP, RAP250, TRBP	ENSG00000198646	Nuclear receptor coactivator 6	20	34689097-34825649	Predicted intracellular proteins	Evidence at protein level	HPA004198, HPA050211	Supported		Supported	Nucleoplasm	Renal cancer:8.78e-5 (favourable), Liver cancer:4.65e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 42.6	Expressed in all		
STK39	DCHT, SPAK	ENSG00000198648	Serine/threonine kinase 39	2	167954020-168248141	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB046022, HPA061803, HPA062802	Enhanced		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:5.67e-5 (unfavourable), Breast cancer:3.96e-4 (favourable)	Expressed in all	Mixed			testis: 71.4	Mixed		
TAT		ENSG00000198650	Tyrosine aminotransferase	16	71565660-71577130	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.51e-4 (favourable)	Tissue enriched	Tissue enriched	8	liver: 619.8	breast: 75.9	Cell line enhanced		Hep G2: 1.7
C6orf89	BRAP, FLJ25357	ENSG00000198663	Chromosome 6 open reading frame 89	6	36871870-36928964	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012548	Uncertain				Renal cancer:5.77e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 97.2	Expressed in all		
CALM1	CALML2, CAMI, DD132, PHKD	ENSG00000198668	Calmodulin 1	14	90396502-90408261	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transporters	Evidence at protein level	CAB018558, HPA044999	Supported		Approved	Vesicles	Urothelial cancer:2.38e-5 (unfavourable), Pancreatic cancer:5.62e-4 (favourable), Renal cancer:6.49e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 1325.6	Expressed in all		
LPA	LP, Lp(a)	ENSG00000198670	Lipoprotein(a)	6	160531483-160664259	Candidate cardiovascular disease genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB016072, HPA060604	Supported					Tissue enriched	Tissue enriched	25	liver: 41.5	seminal vesicle: 1.6	Not detected		
FAM19A2	TAFA-2, TAFA2	ENSG00000198673	Family with sequence similarity 19 member A2, C-C motif chemokine like	12	61708259-62279150	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 26.3	seminal vesicle: 10.0	Cell line enhanced		hTCEpi: 4.1;SCLC-21H: 2.5;WM-115: 4.7
OR10G6	OR10G6P, OR10G6Q	ENSG00000198674	Olfactory receptor family 10 subfamily G member 6	11	123994163-123995161	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TTC37	KIAA0372, THES	ENSG00000198677	Tetratricopeptide repeat domain 37	5	95463895-95555007	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037905	Approved		Supported	Nucleoplasm<br>Cytosol	Colorectal cancer:2.62e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 82.3	Expressed in all		
TUSC1	TSG-9	ENSG00000198680	Tumor suppressor candidate 1	9	25676389-25678440	Predicted intracellular proteins	Evidence at protein level	HPA051426	Approved		Approved	Nucleus<br>Vesicles		Expressed in all	Expressed in all			testis: 16.5	Cell line enhanced		HEL: 34.6
MAGEA1	CT1.1, MAGE1, MGC9326	ENSG00000198681	MAGE family member A1	X	153179285-153183880	Predicted intracellular proteins	Evidence at protein level	CAB002620	Enhanced		Supported	Cytosol		Mixed	Tissue enriched	73	testis: 7.3	all non-specific tissues: 0.0	Group enriched	13	HEL: 66.7;HMC-1: 109.1;RPMI-8226: 44.6;U-2 OS: 123.1;U-266/70: 135.4;U-266/84: 212.3
PAPSS2	ATPSK2	ENSG00000198682	3'-phosphoadenosine 5'-phosphosulfate synthase 2	10	87659613-87747705	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA071224			Approved	Mitochondria	Melanoma:1.33e-6 (unfavourable), Thyroid cancer:3.21e-5 (unfavourable), Pancreatic cancer:6.58e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 157.6	Cell line enhanced		fHDF/TERT166: 365.8
SLC9A6	KIAA0267, NHE6	ENSG00000198689	Solute carrier family 9 member A6	X	135973841-136047269	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059445, HPA059590	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		cerebral cortex: 67.9	parathyroid gland: 16.6	Mixed		
FAN1	KIAA1018, MTMR15	ENSG00000198690	FANCD2 and FANCI associated nuclease 1	15	30903852-30943108	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048198			Supported	Nucleoplasm<br>Cytokinetic bridge<br>Cytosol	Renal cancer:1.42e-6 (favourable)	Expressed in all	Expressed in all			epididymis: 11.4	Expressed in all		
ABCA4	ABCR, ARMD2, CORD3, FFM, RP19, STGD, STGD1	ENSG00000198691	ATP binding cassette subfamily A member 4	1	93992835-94121132	Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level						Lung cancer:2.45e-4 (favourable), Urothelial cancer:2.72e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		epididymis: 9.9	kidney: 4.2	Cell line enhanced		BEWO: 2.8;EFO-21: 6.2;SK-BR-3: 1.9
EIF1AY		ENSG00000198692	Eukaryotic translation initiation factor 1A, Y-linked	Y	20575725-20593154	Predicted intracellular proteins	Evidence at protein level	HPA002561	Uncertain	Approved	Approved	Cytosol		Mixed	Mixed			prostate: 42.2	Cell line enhanced		HEL: 197.1;U-698: 240.9
MT-ND6	MTND6, NAD6, ND6	ENSG00000198695	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	MT	14149-14673	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:8.91e-6 (favourable)	Expressed in all	Expressed in all			heart muscle: 22714.1	Expressed in all		
IPO9	FLJ10402, Imp9	ENSG00000198700	Importin 9	1	201829141-201884294	Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA059540			Approved	Vesicles<br>Cytosol	Liver cancer:4.11e-5 (unfavourable), Renal cancer:2.86e-4 (unfavourable), Urothelial cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.3	Expressed in all		
GPX6	GPXP3	ENSG00000198704	Glutathione peroxidase 6	6	28503296-28528215	Enzymes, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	12	epididymis: 4.0	testis: 0.3	Not detected		
CEP290	3H11Ag, BBS14, CT87, FLJ13615, JBTS5, KIAA0373, LCA10, MKS4, NPHP6, POC3, rd16, SLSN6	ENSG00000198707	Centrosomal protein 290	12	88049014-88142216	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB029995, HPA043918, HPA064397	Approved		Supported	Centrosome	Renal cancer:3.21e-6 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 21.9	Expressed in all		
MT-CO2	CO2, COX2, MTCO2	ENSG00000198712	Mitochondrially encoded cytochrome c oxidase II	MT	7586-8269	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016243, HPA051505, HPA054758	Enhanced				Liver cancer:2.89e-4 (favourable), Pancreatic cancer:7.10e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 40900.1	Expressed in all		
GLMP	C1orf85, MGC31963, NCU-G1	ENSG00000198715	Glycosylated lysosomal membrane protein	1	156290089-156295689	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029121	Uncertain				Liver cancer:6.35e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 96.6	Mixed		
TOGARAM1	crescerin, Crescerin-1, FAM179B, KIAA0423	ENSG00000198718	TOG array regulator of axonemal microtubules 1	14	44962208-45074431	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050849, HPA053559	Uncertain		Approved	Nucleoplasm	Renal cancer:8.38e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 16.7	Mixed		
DLL1		ENSG00000198719	Delta like canonical Notch ligand 1	6	170282206-170306565	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA078298			Uncertain	Nucleoplasm		Expressed in all	Mixed			spleen: 20.0	Cell line enhanced		HaCaT: 7.0;HBEC3-KT: 8.8;NB-4: 13.1;THP-1: 11.4
ANKRD13B	FLJ25555	ENSG00000198720	Ankyrin repeat domain 13B	17	29589769-29614761	Predicted intracellular proteins	Evidence at protein level	HPA051886, HPA063748	Uncertain		Supported	Vesicles	Renal cancer:5.92e-6 (unfavourable), Pancreatic cancer:7.58e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.9	testis: 17.6	Cell line enhanced		SCLC-21H: 75.3;SH-SY5Y: 76.2
ECI2	ACBD2, DRS1, HCA88, PECI	ENSG00000198721	Enoyl-CoA delta isomerase 2	6	4115689-4135597	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022130, HPA031626	Enhanced		Enhanced	Peroxisomes	Renal cancer:2.04e-6 (favourable), Head and neck cancer:2.85e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 238.6	Expressed in all		
UNC13B	hmunc13, UNC13, Unc13h2	ENSG00000198722	Unc-13 homolog B	9	35161992-35405338	Predicted intracellular proteins	Evidence at protein level	HPA024493, HPA062300	Approved		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:4.34e-11 (favourable), Lung cancer:6.59e-5 (favourable), Head and neck cancer:8.51e-5 (favourable), Pancreatic cancer:3.71e-4 (favourable), Colorectal cancer:4.96e-4 (favourable)	Expressed in all	Mixed			lung: 58.2	Mixed		
C19orf45	FLJ35784	ENSG00000198723	Chromosome 19 open reading frame 45	19	7492976-7508450	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	7	testis: 16.7	skin: 2.2	Not detected		
MT-CYB	COB, CYTB, MTCYB, UQCR3	ENSG00000198727	Mitochondrially encoded cytochrome b	MT	14747-15887	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB032215, HPA068400	Enhanced		Approved	Mitochondria	Liver cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 23224.8	Expressed in all		
LDB1	CLIM2, NLI	ENSG00000198728	LIM domain binding 1	10	102107560-102120453	Predicted intracellular proteins	Evidence at protein level	HPA034488	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			skin: 158.2	Expressed in all		
PPP1R14C	CPI17-like, KEPI, NY-BR-81	ENSG00000198729	Protein phosphatase 1 regulatory inhibitor subunit 14C	6	150143076-150250357	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		skin: 76.2;thyroid gland: 101.5	heart muscle: 52.5	Cell line enhanced		HBEC3-KT: 63.9;hTCEpi: 77.1
CTR9	KIAA0155, p150TSP, SH2BP1, TSBP	ENSG00000198730	CTR9 homolog, Paf1/RNA polymerase II complex component	11	10750987-10779743	Predicted intracellular proteins	Evidence at protein level	HPA061027, HPA068122	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.65e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 59.9	Expressed in all		
SMOC1		ENSG00000198732	SPARC related modular calcium binding 1	14	69854131-70032366	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA004153, CAB034427	Approved		Approved	Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 135.8	prostate: 66.2	Cell line enhanced		AF22: 61.2;HeLa: 115.9;SiHa: 108.4;U-266/70: 48.2;U-87 MG: 61.4
F5		ENSG00000198734	Coagulation factor V	1	169514166-169586588	Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA002036	Uncertain		Approved	Golgi apparatus	Stomach cancer:3.39e-4 (unfavourable)	Tissue enriched	Group enriched	11	gallbladder: 28.4;liver: 93.7;placenta: 68.2	fallopian tube: 5.9	Cell line enriched	7	Hep G2: 22.8
MSRB1	SelR, SelX, SepR, SEPX1	ENSG00000198736	Methionine sulfoxide reductase B1	16	1938210-1943326	Predicted intracellular proteins	Evidence at protein level	CAB008650, HPA043463, HPA069557	Approved		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			liver: 61.7	Expressed in all		
LRRTM3		ENSG00000198739	Leucine rich repeat transmembrane neuronal 3	10	66926006-67099830	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	5	cerebral cortex: 22.6	ovary: 4.2	Cell line enhanced		AF22: 1.9;HAP1: 5.7;NTERA-2: 1.2
ZNF652	KIAA0924	ENSG00000198740	Zinc finger protein 652	17	49289206-49362473	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA044408	Uncertain		Approved	Nucleus	Endometrial cancer:1.35e-4 (favourable)	Expressed in all	Mixed			breast: 7.2	Mixed		
SMURF1	KIAA1625	ENSG00000198742	SMAD specific E3 ubiquitin protein ligase 1	7	99027438-99144100	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA055245	Approved					Expressed in all	Expressed in all			testis: 22.9	Expressed in all		
SLC5A3	SMIT, SMIT1	ENSG00000198743	Solute carrier family 5 member 3	21	34073570-34106262	Predicted membrane proteins, Transporters	Evidence at protein level	HPA029791			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 42.2	kidney: 33.1	Expressed in all		
GPATCH3	FLJ12455, GPATC3	ENSG00000198746	G-patch domain containing 3	1	26890488-26900466	Predicted intracellular proteins	Evidence at protein level	HPA032078, HPA054973	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:1.23e-7 (unfavourable), Pancreatic cancer:6.42e-4 (favourable)	Expressed in all	Expressed in all			bone marrow: 15.3	Expressed in all		
CDC42BPB	KIAA1124, MRCKB	ENSG00000198752	CDC42 binding protein kinase beta	14	102932379-103057462	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA022821	Approved				Renal cancer:8.67e-10 (favourable), Lung cancer:2.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 75.1	Mixed		
PLXNB3	PLEXB3, PLEXR, PLXN6	ENSG00000198753	Plexin B3	X	153764196-153779346	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048046	Enhanced				Breast cancer:6.13e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 67.3	adrenal gland: 19.7	Cell line enhanced		WM-115: 69.8
OXCT2	FKSG25, FLJ00030, SCOT-T	ENSG00000198754	3-oxoacid CoA-transferase 2	1	39769523-39771348	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA075423	Enhanced					Not detected	Tissue enriched	12	testis: 37.4	thyroid gland: 3.0	Cell line enhanced		Karpas-707: 5.4;THP-1: 5.6
RPL10A	Csa-19, L10A, NEDD6	ENSG00000198755	Ribosomal protein L10a	6	35468408-35470785	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA053803	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:3.77e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 3924.2	Expressed in all		
COLGALT2	C1orf17, GLT25D2, KIAA0584	ENSG00000198756	Collagen beta(1-O)galactosyltransferase 2	1	183929854-184037729	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA031749, HPA031750	Approved		Approved	Nucleus<br>Vesicles		Tissue enhanced	Tissue enriched	5	cerebral cortex: 46.4	prostate: 8.8	Cell line enhanced		Hep G2: 11.7;SK-MEL-30: 14.3;U-251 MG: 14.6;WM-115: 22.1
EPS8L3	FLJ21522, MGC16817	ENSG00000198758	EPS8 like 3	1	109750080-109764027	Predicted intracellular proteins	Evidence at protein level	HPA030998	Approved		Approved	Vesicles	Renal cancer:2.52e-5 (unfavourable), Liver cancer:4.13e-5 (unfavourable), Urothelial cancer:1.82e-4 (favourable)	Group enriched	Group enriched	7	colon: 75.0;duodenum: 152.1;gallbladder: 59.8;rectum: 86.1;small intestine: 167.1;stomach: 53.4	appendix: 15.1	Group enriched	12	CACO-2: 13.3;CAPAN-2: 13.3;EFO-21: 5.8;Hep G2: 25.0
EGFL6	MAEG	ENSG00000198759	EGF like domain multiple 6	X	13569605-13633575	Predicted secreted proteins	Evidence at protein level	HPA001838	Enhanced				Ovarian cancer:4.95e-4 (favourable), Head and neck cancer:9.73e-4 (favourable)	Mixed	Tissue enriched	34	placenta: 921.8	lung: 26.8	Group enriched	5	BJ hTERT+: 3.5;NTERA-2: 1.7
MT-ND2	MTND2, NAD2, ND2	ENSG00000198763	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	MT	4470-5511	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			heart muscle: 24880.0	Expressed in all		
SYCP1	CT8, HOM-TES-14, SCP1	ENSG00000198765	Synaptonemal complex protein 1	1	114854803-114995370	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021083	Enhanced					Not detected	Tissue enriched	96	testis: 72.5	breast: 0.7	Cell line enriched	65	THP-1: 11.4
APCDD1L	FLJ90166	ENSG00000198768	APC down-regulated 1 like	20	58459101-58515131	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067015	Uncertain		Uncertain	Mitochondria		Mixed	Tissue enhanced		breast: 6.5;salivary gland: 11.6	kidney: 2.9	Cell line enhanced		fHDF/TERT166: 88.4;hTEC/SVTERT24-B: 39.4;HUVEC TERT2: 33.7;TIME: 65.0;U-87 MG: 47.5
RCSD1	CapZIP, MGC21854, MK2S4	ENSG00000198771	RCSD domain containing 1	1	167630093-167706249	Predicted intracellular proteins	Evidence at protein level	HPA016597	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane	Head and neck cancer:2.97e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 107.2	spleen: 72.4	Cell line enhanced		Daudi: 144.4;REH: 185.8;RPMI-8226: 96.4;U-266/70: 99.4;U-698: 91.2
RASSF9	P-CIP1, PAMCI	ENSG00000198774	Ras association domain family member 9	12	85800697-85836570	Predicted intracellular proteins	Evidence at transcript level	HPA039428, HPA039678	Approved					Mixed	Mixed			fallopian tube: 10.1	Cell line enhanced		HeLa: 2.6;HUVEC TERT2: 2.0;RPTEC TERT1: 2.8;U-138 MG: 2.7
FAM169A	KIAA0888, SLAP75	ENSG00000198780	Family with sequence similarity 169 member A	5	74777574-74866951	Predicted intracellular proteins	Evidence at protein level	HPA041574	Enhanced		Supported	Nuclear membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 29.2;testis: 25.4	epididymis: 23.2	Cell line enhanced		BEWO: 35.3
ZNF830	CCDC16, MGC20398, OMCG1	ENSG00000198783	Zinc finger protein 830	17	34961530-34963775	Predicted intracellular proteins	Evidence at protein level	HPA024754, HPA027211	Enhanced		Enhanced	Nucleoplasm	Prostate cancer:2.01e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 16.6	Expressed in all		
GRIN3A	GluN3A	ENSG00000198785	Glutamate ionotropic receptor NMDA type subunit 3A	9	101569353-101738580	FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	5	cerebral cortex: 12.3;cervix, uterine: 2.5	seminal vesicle: 1.3	Cell line enriched	6	SCLC-21H: 2.1
MT-ND5	MTND5, NAD5, ND5	ENSG00000198786	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	MT	12337-14148	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.31e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 13037.2	Expressed in all		
CNOT7	CAF1	ENSG00000198791	CCR4-NOT transcription complex subunit 7	8	17224964-17246878	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA069543			Supported	Nuclear bodies	Colorectal cancer:4.99e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 112.7	Expressed in all		
TMEM184B	C22orf5, DKFZP586A1024, FM08, HS5O6A	ENSG00000198792	Transmembrane protein 184B	22	38219291-38273034	Predicted membrane proteins, Transporters	Evidence at protein level	HPA024076	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Liver cancer:5.94e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 57.4	Expressed in all		
MTOR	FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1	ENSG00000198793	Mechanistic target of rapamycin	1	11106535-11262507	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB069425, HPA071227	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
SCAMP5	MGC24969	ENSG00000198794	Secretory carrier membrane protein 5	15	74957219-75021496	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046645	Enhanced				Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 275.5	parathyroid gland: 81.7	Cell line enhanced		SCLC-21H: 103.1;SH-SY5Y: 51.9
ZNF521	EHZF, Evi3	ENSG00000198795	Zinc finger protein 521	18	25061926-25352190	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023056, HPA023849	Enhanced		Approved	Nucleoplasm		Mixed	Mixed			spleen: 29.0	Cell line enhanced		AF22: 66.8;HUVEC TERT2: 39.1
ALPK2	HAK	ENSG00000198796	Alpha kinase 2	18	58481247-58628957	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027377, HPA027976, HPA028084, HPA029801	Uncertain		Approved	Cytosol	Renal cancer:8.20e-5 (unfavourable)	Tissue enriched	Tissue enhanced		heart muscle: 28.6;skeletal muscle: 14.1	lymph node: 6.9	Cell line enhanced		BJ: 44.5;BJ hTERT+: 25.8;fHDF/TERT166: 37.1;U-138 MG: 25.6
BRINP2	DBCCR1L2, FAM5B	ENSG00000198797	BMP/retinoic acid inducible neural specific 2	1	177171497-177282422	Predicted secreted proteins, Transporters	Evidence at transcript level	HPA050681, HPA061920	Uncertain		Approved	Nucleoli<br>Vesicles		Tissue enriched	Group enriched	10	adrenal gland: 11.5;cerebral cortex: 35.4	testis: 2.3	Group enriched	5	HDLM-2: 6.7;PC-3: 1.6;REH: 1.8;SCLC-21H: 7.3;SH-SY5Y: 1.4
MAGEB3	CT3.5	ENSG00000198798	MAGE family member B3	X	30230436-30237492	Predicted intracellular proteins	Evidence at protein level	HPA072203	Approved					Not detected	Group enriched	156	epididymis: 21.5;testis: 9.5	all non-specific tissues: 0.0	Cell line enriched	10	U-266/70: 1.6
LRIG2	KIAA0806	ENSG00000198799	Leucine rich repeats and immunoglobulin like domains 2	1	113073209-113132260	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA015538	Uncertain		Approved	Nucleus<br>Golgi apparatus	Endometrial cancer:9.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland,thyroid gland: 5.6	Mixed		
MT-CO1	COI, COX1, MTCO1	ENSG00000198804	Mitochondrially encoded cytochrome c oxidase I	MT	5904-7445	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB016241, HPA069328	Enhanced		Supported	Mitochondria	Liver cancer:2.29e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 79421.5	Expressed in all		
PNP	NP, PUNP	ENSG00000198805	Purine nucleoside phosphorylase	14	20468954-20477094	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA001625	Enhanced		Supported	Cytosol	Renal cancer:2.24e-4 (favourable), Liver cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 698.2	Expressed in all		
PAX9		ENSG00000198807	Paired box 9	14	36657568-36679715	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038462	Enhanced		Approved	Nucleoplasm<br>Mitochondria	Cervical cancer:5.38e-4 (favourable)	Mixed	Group enriched	8	esophagus: 56.1;parathyroid gland: 102.3;salivary gland: 21.7	tonsil: 7.5	Cell line enhanced		HDLM-2: 44.7;PC-3: 18.6
LRRC10	HRLRRP, LRRC10A	ENSG00000198812	Leucine rich repeat containing 10	12	69608564-69611162	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	28	heart muscle: 22.6	lymph node: 0.7	Not detected		
GK	GK1, GKD	ENSG00000198814	Glycerol kinase	X	30653359-30731456	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA060687	Supported				Renal cancer:3.24e-9 (favourable)	Expressed in all	Tissue enhanced		kidney: 111.0	small intestine: 98.6	Mixed		
FOXJ3	KIAA1041	ENSG00000198815	Forkhead box J3	1	42176539-42335877	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067284			Approved	Nucleoplasm<br>Nuclear speckles<br>Vesicles	Renal cancer:4.51e-7 (unfavourable), Liver cancer:5.17e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.1	Expressed in all		
ZNF358	FLJ10390, ZFEND	ENSG00000198816	Zinc finger protein 358	19	7515292-7521026	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030887, HPA063624	Approved		Approved	Nucleus	Pancreatic cancer:2.50e-4 (favourable)	Expressed in all	Expressed in all			ovary: 84.0	Mixed		
SFT2D1	C6orf83, MGC19825, pRGR1	ENSG00000198818	SFT2 domain containing 1	6	166319728-166342591	Predicted membrane proteins	Evidence at protein level	HPA014677	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Liver cancer:2.19e-5 (unfavourable), Renal cancer:3.59e-4 (unfavourable), Thyroid cancer:5.90e-4 (favourable), Head and neck cancer:7.47e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 78.5	Expressed in all		
CD247	CD3H, CD3Q, CD3Z	ENSG00000198821	CD247 molecule	1	167430640-167518610	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004651, HPA008750	Enhanced				Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 65.1;spleen: 48.6	tonsil: 33.6	Group enriched	34	HDLM-2: 144.2;MOLT-4: 133.0
GRM3	GPRC1C, mGlu3, MGLUR3	ENSG00000198822	Glutamate metabotropic receptor 3	7	86643914-86864884	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	43	cerebral cortex: 62.3	testis: 1.4	Cell line enriched	8	AF22: 35.5
CHAMP1	C13orf8, CAMP, CHAMP, ZNF828	ENSG00000198824	Chromosome alignment maintaining phosphoprotein 1	13	114314513-114327328	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA006623, HPA008900	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 19.3	Expressed in all		
INPP5F	hSac2, KIAA0966, SAC2	ENSG00000198825	Inositol polyphosphate-5-phosphatase F	10	119726097-119829278	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 132.0	Expressed in all		
ARHGAP11A	KIAA0013	ENSG00000198826	Rho GTPase activating protein 11A	15	32615144-32639949	Predicted intracellular proteins	Evidence at protein level	HPA040419, HPA040830	Enhanced		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:2.92e-5 (unfavourable), Liver cancer:2.05e-4 (unfavourable), Lung cancer:8.69e-4 (unfavourable)	Expressed in all	Mixed			lymph node,testis: 15.7	Expressed in all		
SUCNR1	GPR91	ENSG00000198829	Succinate receptor 1	3	151873643-151884619	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022745	Uncertain					Mixed	Tissue enhanced		kidney: 42.3	thyroid gland: 15.9	Group enriched	6	HEL: 47.7;NB-4: 19.6;U-937: 41.3
HMGN2	HMG17	ENSG00000198830	High mobility group nucleosomal binding domain 2	1	26472450-26475972	Predicted intracellular proteins	Evidence at protein level	CAB018371, HPA077364	Supported		Supported	Nucleus	Liver cancer:1.34e-4 (unfavourable), Renal cancer:3.92e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 782.8	Expressed in all		
SELENOM	SELM, SEPM	ENSG00000198832	Selenoprotein M	22	31104772-31120069	Predicted secreted proteins	Evidence at protein level	CAB008667, HPA019601	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.55e-6 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 200.8	Cell line enhanced		HHSteC: 154.4
UBE2J1	CGI-76, HSPC153, NCUBE1, UBC6	ENSG00000198833	Ubiquitin conjugating enzyme E2 J1	6	89326625-89352848	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA003509, CAB073419	Enhanced				Liver cancer:6.90e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:2.87e-4 (favourable), Ovarian cancer:7.43e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 102.3	Mixed		
GJC2	CX46.6, CX47, GJA12, SPG44	ENSG00000198835	Gap junction protein gamma 2	1	228149852-228159826	Disease related genes, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		cerebral cortex: 11.5	fallopian tube: 3.7	Cell line enhanced		EFO-21: 5.1;SCLC-21H: 3.4
OPA1	FLJ12460, KIAA0567, MGM1, NPG, NTG	ENSG00000198836	OPA1, mitochondrial dynamin like GTPase	3	193593144-193697823	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA036926, HPA036927	Enhanced		Supported	Nucleoplasm<br>Mitochondria	Pancreatic cancer:8.44e-5 (unfavourable), Renal cancer:1.84e-4 (favourable), Endometrial cancer:8.61e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 56.2	Expressed in all		
DENND4B	KIAA0476	ENSG00000198837	DENN domain containing 4B	1	153929501-153946696	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040188, HPA071133	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:9.27e-9 (unfavourable), Pancreatic cancer:3.18e-5 (favourable), Liver cancer:4.14e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 40.2	Expressed in all		
RYR3		ENSG00000198838	Ryanodine receptor 3	15	33310945-33866121	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062004			Approved	Vesicles		Tissue enhanced	Tissue enhanced		parathyroid gland: 29.1	cerebral cortex: 7.0	Cell line enhanced		A549: 3.9;RH-30: 6.3;RPTEC TERT1: 2.3
ZNF277	NRIF4, ZNF277P	ENSG00000198839	Zinc finger protein 277	7	112206588-112343096	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA027307	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:9.47e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 33.4	Expressed in all		
MT-ND3	MTND3, NAD3, ND3	ENSG00000198840	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	MT	10059-10404	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA063296	Enhanced		Approved	Cytosol	Liver cancer:4.63e-5 (favourable)	Expressed in all	Expressed in all			heart muscle: 30083.4	Expressed in all		
KTI12	MGC20419, SBBI81, TOT4	ENSG00000198841	KTI12 chromatin associated homolog	1	52032103-52033816	Predicted intracellular proteins	Evidence at protein level	HPA031203, HPA031204, HPA031205	Approved		Approved	Nuclear speckles<br>Cytoplasmic bodies	Liver cancer:1.02e-4 (unfavourable)	Expressed in all	Mixed			ovary: 11.5	Expressed in all		
DUSP27		ENSG00000198842	Dual specificity phosphatase 27 (putative)	1	167094045-167129165	Predicted intracellular proteins	Evidence at protein level	HPA012608, HPA012912	Uncertain		Approved	Nucleoplasm		Group enriched	Group enriched	15	heart muscle: 41.9;skeletal muscle: 39.7	placenta,prostate: 2.6	Cell line enriched	11	RH-30: 13.7
SELENOT	SELT	ENSG00000198843	Selenoprotein T	3	150602875-150630445	Predicted membrane proteins	Evidence at protein level	HPA039780	Approved					Expressed in all	Expressed in all			thyroid gland: 109.3	Expressed in all		
ARHGEF15	ARGEF15, FLJ13791, KIAA0915, MGC44868, Vsm-RhoGEF	ENSG00000198844	Rho guanine nucleotide exchange factor 15	17	8310241-8322516	Predicted intracellular proteins	Evidence at protein level	HPA044443, HPA063495			Supported	Plasma membrane		Expressed in all	Tissue enhanced		adipose tissue: 37.2	lung: 30.7	Group enriched	41	HUVEC TERT2: 32.7;TIME: 42.4
TOX	KIAA0808, TOX1	ENSG00000198846	Thymocyte selection associated high mobility group box	8	58805418-59119208	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018322, HPA073241	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.90e-7 (unfavourable), Lung cancer:5.20e-4 (favourable)	Expressed in all	Mixed			lymph node: 21.1	Cell line enhanced		MOLT-4: 117.4;SH-SY5Y: 46.0
CES1	CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1	ENSG00000198848	Carboxylesterase 1	16	55802851-55833337	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA012023, HPA046717	Enhanced		Enhanced	Endoplasmic reticulum	Urothelial cancer:9.92e-4 (unfavourable)	Tissue enriched	Group enriched	7	gallbladder: 399.2;liver: 1099.9;lung: 229.9	adipose tissue: 79.7	Group enriched	5	Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
CD3E		ENSG00000198851	CD3e molecule	11	118304545-118316175	CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB000010, HPA040957, HPA043955, CAB072863, CAB072864	Enhanced				Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 200.5;tonsil: 113.4	spleen: 95.0	Cell line enriched	92	MOLT-4: 531.3
RUSC2	KIAA0375	ENSG00000198853	RUN and SH3 domain containing 2	9	35490127-35561898	Predicted intracellular proteins	Evidence at protein level	HPA021297	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 48.5	Mixed		
C1orf68	LEP7, XP32	ENSG00000198854	Chromosome 1 open reading frame 68	1	152719522-152720470	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	14	skin: 806.5	breast: 57.5	Cell line enriched	6	HaCaT: 1.6
FICD	HIP13, HYPE	ENSG00000198855	FIC domain containing	12	108515185-108525837	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA021390, HPA071134	Approved		Approved	Nucleus	Endometrial cancer:4.61e-5 (favourable)	Expressed in all	Mixed			thyroid gland: 17.7	Mixed		
OSTC	DC2	ENSG00000198856	Oligosaccharyltransferase complex non-catalytic subunit	4	108650584-108667820	Predicted membrane proteins	Evidence at protein level	HPA065174			Approved	Nucleoplasm	Renal cancer:2.31e-8 (unfavourable), Endometrial cancer:1.44e-4 (favourable), Lung cancer:2.84e-4 (unfavourable), Head and neck cancer:6.66e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 215.1	Expressed in all		
R3HDM4	C19orf22, MGC16353	ENSG00000198858	R3H domain containing 4	19	896503-913245	Predicted intracellular proteins	Evidence at protein level	HPA043025, HPA048638	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:7.33e-6 (favourable)	Expressed in all	Expressed in all			appendix: 67.7	Expressed in all		
TSEN15	C1orf19	ENSG00000198860	TRNA splicing endonuclease subunit 15	1	184051677-184074212	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA029237	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.66e-10 (unfavourable), Liver cancer:2.07e-5 (unfavourable), Ovarian cancer:4.59e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 34.8	Expressed in all		
LTN1	C21orf10, C21orf98, FLJ11053, KIAA0714, LISTERIN, RNF160, ZNF294	ENSG00000198862	Listerin E3 ubiquitin protein ligase 1	21	28928144-28992956	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029143, CAB034164, HPA055604	Uncertain		Enhanced	Cytosol		Expressed in all	Expressed in all			placenta: 26.6	Expressed in all		
RUNDC1	DKFZp761H0421	ENSG00000198863	RUN domain containing 1	17	42980565-42993690	Predicted intracellular proteins	Evidence at protein level	HPA023726	Uncertain		Approved	Nuclear speckles<br>Cytosol	Endometrial cancer:6.93e-5 (favourable)	Expressed in all	Expressed in all			fallopian tube: 23.5	Expressed in all		
CCDC152	LOC100129792	ENSG00000198865	Coiled-coil domain containing 152	5	42756801-42802360	Predicted intracellular proteins	Evidence at protein level	HPA036240	Approved		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			small intestine: 11.3	Cell line enhanced		HeLa: 8.9;U-2 OS: 24.5;U-266/84: 11.8
STKLD1	C9orf96, MGC43306, SGK071	ENSG00000198870	Serine/threonine kinase like domain containing 1	9	133376367-133406096	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA029902	Uncertain					Mixed	Tissue enriched	14	testis: 5.7	cerebral cortex,epididymis: 0.3	Not detected		
GRK5	GPRK5	ENSG00000198873	G protein-coupled receptor kinase 5	10	119207589-119459742	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB025579, HPA046838	Approved		Supported	Nuclear membrane<br>Nuclear speckles<br>Plasma membrane	Renal cancer:2.38e-7 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 78.5	Cell line enhanced		BJ hTERT+: 68.5;HUVEC TERT2: 55.7
TYW1	FLJ10900, MGC23001, MGC60291, RSAFD1, TYW1A, YPL207W	ENSG00000198874	TRNA-yW synthesizing protein 1 homolog	7	66995173-67239519	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA013568, HPA014118, HPA015535, HPA043136, HPA047029, HPA047052, HPA052097	Approved		Approved	Nucleus<br>Nucleoli	Ovarian cancer:1.73e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
DCAF12	CT102, DKFZP434O125, KIAA1892, MGC1058, TCC52, WDR40A	ENSG00000198876	DDB1 and CUL4 associated factor 12	9	34086387-34127399	Predicted intracellular proteins	Evidence at protein level	HPA062279	Uncertain				Ovarian cancer:2.81e-5 (favourable)	Expressed in all	Expressed in all			testis: 113.2	Expressed in all		
SFMBT2	KIAA1617	ENSG00000198879	Scm-like with four mbt domains 2	10	7158624-7411486	Predicted intracellular proteins	Evidence at protein level	HPA035447, HPA035448	Uncertain		Supported	Nuclear speckles		Mixed	Mixed			parathyroid gland: 15.3	Cell line enhanced		Karpas-707: 19.0;REH: 22.4;SH-SY5Y: 19.1;THP-1: 19.7
ASB12	FLJ39577	ENSG00000198881	Ankyrin repeat and SOCS box containing 12	X	64224196-64230631	Predicted intracellular proteins	Evidence at protein level	HPA049542	Uncertain					Mixed	Tissue enriched	14	skeletal muscle: 30.7	fallopian tube: 2.2	Cell line enhanced		AF22: 1.2
PNMA5	KIAA1934	ENSG00000198883	Paraneoplastic Ma antigen family member 5	X	152988824-152994127	Predicted intracellular proteins	Evidence at protein level	HPA044690	Enhanced				Colorectal cancer:2.25e-4 (unfavourable), Lung cancer:3.16e-4 (favourable)	Mixed	Group enriched	20	cerebral cortex: 8.1;testis: 16.3	skin,spleen: 0.5	Group enriched	495	HMC-1: 311.7;U-266/70: 426.0;U-266/84: 249.2
ITPRIPL1	KIAA1754L	ENSG00000198885	Inositol 1,4,5-trisphosphate receptor interacting protein-like 1	2	96325331-96330517	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	6	testis: 27.3	lymph node: 4.8	Mixed		
MT-ND4	LHON, MTND4, NAD4, ND4	ENSG00000198886	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	MT	10760-12137	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA053928	Approved				Ovarian cancer:1.76e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 36982.3	Expressed in all		
SMC5	KIAA0594, SMC5L1	ENSG00000198887	Structural maintenance of chromosomes 5	9	70258962-70354888	Predicted intracellular proteins	Evidence at protein level	HPA054900	Enhanced		Supported	Nuclear speckles		Expressed in all	Expressed in all			ovary: 30.8	Expressed in all		
MT-ND1	MTND1, NAD1, ND1	ENSG00000198888	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	MT	3307-4262	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB033779	Approved				Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 23817.4	Expressed in all		
DCAF12L1	KIAA1892L, WDR40B	ENSG00000198889	DDB1 and CUL4 associated factor 12 like 1	X	126549383-126552851	Predicted intracellular proteins	Evidence at protein level	HPA044737, HPA048981, HPA053138	Approved					Mixed	Tissue enhanced		epididymis: 5.9;testis: 11.4	fallopian tube: 4.0	Group enriched	21	EFO-21: 14.1;U-2 OS: 8.6
PRMT6	FLJ10559, HRMT1L6	ENSG00000198890	Protein arginine methyltransferase 6	1	107056679-107059294	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059424	Approved		Supported	Nucleus<br>Nucleoli	Endometrial cancer:3.05e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.2	Cell line enhanced		MCF7: 235.5
SHISA4	C1orf40, hShisa4, TMEM58	ENSG00000198892	Shisa family member 4	1	201888680-201892306	Predicted membrane proteins	Evidence at protein level	HPA061273	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 45.3;skeletal muscle: 94.4	adrenal gland: 23.6	Mixed		
CIPC	KIAA1737	ENSG00000198894	CLOCK interacting pacemaker	14	77098097-77117287	Predicted intracellular proteins	Evidence at protein level	HPA000644			Supported	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:1.77e-10 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 54.3	Expressed in all		
CAPZA2	CAPPA2, CAPZ	ENSG00000198898	Capping actin protein of muscle Z-line alpha subunit 2	7	116811070-116922049	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA007470, HPA007643	Uncertain		Approved	Endoplasmic reticulum<br>Cytosol	Renal cancer:3.65e-6 (favourable), Liver cancer:9.34e-5 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 41.6	Expressed in all		
MT-ATP6	ATP6, ATPase-6, MTATP6, RP, Su6m	ENSG00000198899	Mitochondrially encoded ATP synthase 6	MT	8527-9207	Disease related genes, Predicted membrane proteins	Evidence at protein level						Liver cancer:3.79e-4 (favourable), Pancreatic cancer:7.64e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 42788.3	Expressed in all		
TOP1		ENSG00000198900	Topoisomerase (DNA) I	20	41028818-41124487	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009058, HPA019039	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.7	Expressed in all		
PRC1	ASE1	ENSG00000198901	Protein regulator of cytokinesis 1	15	90966038-90995629	Predicted intracellular proteins	Evidence at protein level	HPA034521	Enhanced				Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:2.76e-5 (unfavourable), Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 85.8	Expressed in all		
BHLHB9	GASP3, KIAA1701, p60TRP	ENSG00000198908	Basic helix-loop-helix domain containing, class B, 9	X	102720688-102753540	Predicted intracellular proteins	Evidence at protein level	HPA000887			Supported	Nucleoplasm<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 18.8	parathyroid gland: 8.4	Mixed		
MAP3K3	MAPKKK3, MEKK3	ENSG00000198909	Mitogen-activated protein kinase kinase kinase 3	17	63622415-63696303	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007764, HPA035410, HPA035411	Uncertain		Approved	Nucleoplasm	Endometrial cancer:1.13e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 41.5	Expressed in all		
L1CAM	CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1	ENSG00000198910	L1 cell adhesion molecule	X	153861514-153909223	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010896	Enhanced		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adrenal gland: 36.0;cerebral cortex: 66.9	seminal vesicle: 12.8	Cell line enhanced		BJ hTERT+: 303.8;BJ hTERT+ SV40 Large T+ RasG12V: 195.5;HeLa: 182.1
SREBF2	bHLHd2, SREBP2	ENSG00000198911	Sterol regulatory element binding transcription factor 2	22	41833079-41907308	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA031962, HPA031963	Approved		Supported	Nucleoplasm<br>Vesicles<br>Mitochondria	Renal cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 118.4	Expressed in all		
C1orf174	RP13-531C17.2	ENSG00000198912	Chromosome 1 open reading frame 174	1	3889125-3900293	Predicted intracellular proteins	Evidence at protein level	HPA008270, HPA065778	Approved		Enhanced	Nucleus	Renal cancer:2.73e-6 (unfavourable), Liver cancer:5.84e-4 (unfavourable), Melanoma:7.62e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 17.3	Expressed in all		
POU3F3	BRN1, OTF8	ENSG00000198914	POU class 3 homeobox 3	2	104855511-104858574	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052792, HPA056039, HPA067151	Approved		Enhanced	Nucleus	Endometrial cancer:4.26e-5 (unfavourable)	Group enriched	Group enriched	45	cerebral cortex: 43.9;epididymis: 46.3;kidney: 36.6;seminal vesicle: 23.2	skin: 0.8	Group enriched	5	AF22: 58.4;AN3-CA: 52.7;HEK 293: 20.3;RPTEC TERT1: 50.7;SH-SY5Y: 19.7
RASGEF1A	CG4853, FLJ37817	ENSG00000198915	RasGEF domain family member 1A	10	43194535-43266919	Predicted intracellular proteins	Evidence at protein level	HPA035593	Enhanced		Approved	Golgi apparatus	Renal cancer:4.11e-7 (unfavourable), Breast cancer:1.86e-5 (favourable), Endometrial cancer:4.28e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 22.7	parathyroid gland: 12.8	Cell line enhanced		K-562: 15.4;SCLC-21H: 18.4;T-47d: 14.7
SPOUT1	C9orf114, CENP-32, HSPC109	ENSG00000198917	SPOUT domain containing methyltransferase 1	9	128819651-128829821	Predicted intracellular proteins	Evidence at protein level	HPA022990			Approved	Nucleus<br>Nucleoli	Pancreatic cancer:4.09e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 22.0	Expressed in all		
RPL39	L39, RPL39P42	ENSG00000198918	Ribosomal protein L39	X	119786504-119791643	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047105	Uncertain				Renal cancer:1.71e-9 (unfavourable)	Expressed in all	Expressed in all			breast: 5369.7	Expressed in all		
DZIP3	hRUL138, PPP1R66	ENSG00000198919	DAZ interacting zinc finger protein 3	3	108589682-108694846	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035066, HPA049232	Approved		Approved	Vesicles	Renal cancer:3.65e-4 (favourable)	Expressed in all	Expressed in all			testis: 65.7	Mixed		
KIAA0753	MNR, OFIP	ENSG00000198920	KIAA0753	17	6578148-6640927	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023057, HPA023494	Enhanced		Enhanced	Centrosome<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 33.2	Mixed		
DCLRE1A	hSNM1, KIAA0086, PSO2, SNM1	ENSG00000198924	DNA cross-link repair 1A	10	113834725-113854383	Predicted intracellular proteins	Evidence at protein level	HPA036907	Approved		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Liver cancer:5.74e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 13.4	Expressed in all		
ATG9A	APG9L1, FLJ22169	ENSG00000198925	Autophagy related 9A	2	219209772-219229717	Predicted membrane proteins	Evidence at protein level	HPA059551	Uncertain		Supported	Vesicles	Liver cancer:2.18e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 113.1	Expressed in all		
NOS1AP	CAPON, KIAA0464	ENSG00000198929	Nitric oxide synthase 1 adaptor protein	1	162069774-162370475	Predicted intracellular proteins	Evidence at protein level	CAB018582, HPA030066, HPA055561	Approved		Approved	Nucleus<br>Vesicles		Mixed	Tissue enriched	6	cerebral cortex: 23.4	adrenal gland: 3.8	Cell line enhanced		A-431: 3.6;HEL: 4.5
CSAG1	CSAGE, CT24.1	ENSG00000198930	Chondrosarcoma associated gene 1	X	152727484-152733735	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Tissue enhanced		testis: 2.4	lymph node: 0.8	Cell line enhanced		HMC-1: 57.5;K-562: 39.8;PC-3: 55.8;SH-SY5Y: 39.1;U-266/70: 79.2
APRT		ENSG00000198931	Adenine phosphoribosyltransferase	16	88809339-88811944	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA026681	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			skin: 112.4	Expressed in all		
GPRASP1	GASP, GASP1	ENSG00000198932	G protein-coupled receptor associated sorting protein 1	X	102651366-102659083	Predicted intracellular proteins	Evidence at protein level	HPA000161, HPA031061	Uncertain		Supported	Cytosol	Pancreatic cancer:1.77e-5 (favourable), Thyroid cancer:7.38e-4 (unfavourable)	Mixed	Mixed			cerebral cortex: 64.8	Cell line enhanced		REH: 5.1
TBKBP1	KIAA0775, ProSAPiP2	ENSG00000198933	TBK1 binding protein 1	17	47694081-47712050	Predicted intracellular proteins	Evidence at protein level	HPA062347, HPA064856	Approved		Approved	Nucleoplasm	Pancreatic cancer:8.14e-6 (favourable), Urothelial cancer:1.59e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 32.9	Cell line enhanced		CACO-2: 52.0
MAGEE1	DAMAGE, KIAA1587	ENSG00000198934	MAGE family member E1	X	76427724-76431353	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003047	Approved		Approved	Cytokinetic bridge<br>Cytosol	Renal cancer:6.86e-6 (favourable), Pancreatic cancer:3.95e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 29.8	parathyroid gland: 14.3	Mixed		
CCDC167	C6orf129, dJ153P14.2	ENSG00000198937	Coiled-coil domain containing 167	6	37482920-37499922	Predicted membrane proteins	Evidence at protein level	HPA045215	Uncertain		Approved	Cytosol	Renal cancer:1.71e-7 (unfavourable), Liver cancer:2.94e-4 (unfavourable), Cervical cancer:7.59e-4 (favourable)	Expressed in all	Expressed in all			tonsil: 55.0	Cell line enriched	7	U-698: 913.2
MT-CO3	CO3, COIII, COX3, MTCO3	ENSG00000198938	Mitochondrially encoded cytochrome c oxidase III	MT	9207-9990	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042788	Approved		Approved	Nucleoplasm	Pancreatic cancer:1.04e-4 (favourable), Liver cancer:2.01e-4 (favourable)	Expressed in all	Expressed in all			kidney: 54081.3	Expressed in all		
ZFP2	FLJ21628, ZNF751	ENSG00000198939	ZFP2 zinc finger protein	5	178895894-178933212	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023364	Uncertain					Mixed	Mixed			testis: 7.8	Cell line enhanced		AN3-CA: 5.1;HAP1: 2.7
SOWAHA	ANKRD43	ENSG00000198944	Sosondowah ankyrin repeat domain family member A	5	132813587-132816797	Predicted secreted proteins	Evidence at protein level	HPA064621	Approved				Renal cancer:9.38e-5 (favourable), Pancreatic cancer:4.03e-4 (favourable)	Mixed	Tissue enhanced		duodenum: 39.7;small intestine: 46.6	cerebral cortex: 22.1	Group enriched	8	SCLC-21H: 17.0;T-47d: 32.7
L3MBTL3	KIAA1798	ENSG00000198945	L(3)mbt-like 3 (Drosophila)	6	130013699-130141451	Predicted intracellular proteins	Evidence at protein level	HPA044382, HPA053035	Approved		Enhanced	Nucleus<br>Nucleoli		Expressed in all	Mixed			endometrium: 18.5	Cell line enhanced		HMC-1: 55.3;HUVEC TERT2: 52.0
DMD	BMD, DXS142, DXS164, DXS206, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272, MRX85	ENSG00000198947	Dystrophin	X	31097677-33339441	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB000119, HPA002725, HPA023885	Enhanced					Mixed	Mixed			seminal vesicle: 54.6	Cell line enhanced		AF22: 25.1;RH-30: 31.0
MFAP3L	KIAA0626, NYD-sp9	ENSG00000198948	Microfibrillar associated protein 3 like	4	169986597-170033031	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017986	Approved				Renal cancer:1.42e-8 (favourable)	Expressed in all	Tissue enhanced		testis: 74.1	epididymis: 47.4	Cell line enhanced		HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8
NAGA	D22S674	ENSG00000198951	Alpha-N-acetylgalactosaminidase	22	42058354-42070842	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA000649	Enhanced					Expressed in all	Expressed in all			parathyroid gland: 63.7	Expressed in all		
SMG5	EST1B, KIAA1089, LPTS-RP1, LPTSRP1, RP11-54H19.7, SMG-5	ENSG00000198952	SMG5, nonsense mediated mRNA decay factor	1	156249224-156282825	Predicted membrane proteins	Evidence at protein level	HPA072651			Uncertain	Cytoplasmic bodies	Liver cancer:6.70e-9 (unfavourable), Endometrial cancer:3.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 76.0	Expressed in all		
KIF1BP	DKFZP586B0923, KBP, KIAA1279, TTC20	ENSG00000198954	KIF1 binding protein	10	68988721-69043544	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035538, HPA035539	Uncertain				Renal cancer:2.60e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 34.8	Mixed		
TGM2	TGC	ENSG00000198959	Transglutaminase 2	20	38127387-38166578	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002598, HPA021019, HPA029518	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.67e-7 (unfavourable), Pancreatic cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		cervix, uterine: 461.0	placenta: 319.8	Cell line enhanced		CAPAN-2: 1300.3;EFO-21: 458.7;HUVEC TERT2: 559.8;TIME: 720.5
ARMCX6	FLJ20811, GASP10	ENSG00000198960	Armadillo repeat containing, X-linked 6	X	101615118-101618001	Predicted membrane proteins	Evidence at protein level	HPA043030, HPA048125	Approved		Supported	Nucleus<br>Nuclear membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 33.8	Mixed		
PJA2	KIAA0438, Neurodap1, RNF131	ENSG00000198961	Praja ring finger ubiquitin ligase 2	5	109334709-109409994	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA040347, HPA057636	Enhanced		Supported	Intermediate filaments	Ovarian cancer:8.02e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 254.4	Expressed in all		
RORB	NR1F2, ROR-BETA, RZRB	ENSG00000198963	RAR related orphan receptor B	9	74497365-74693177	Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008393	Uncertain		Approved	Nucleus		Group enriched	Tissue enhanced		cerebral cortex: 12.6;cervix, uterine: 14.1	prostate: 7.4	Cell line enhanced		HHSteC: 18.9;HSkMC: 9.0;MOLT-4: 5.5;SH-SY5Y: 14.3
SGMS1	MGC17342, MOB, SMS1, TMEM23	ENSG00000198964	Sphingomyelin synthase 1	10	50305586-50625163	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045191	Approved		Approved	Nucleoplasm<br>Nucleoli fibrillar center<br>Golgi apparatus<br>Cytosol	Renal cancer:1.95e-7 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 116.7	Expressed in all		
OR10R2	OR10R2Q	ENSG00000198965	Olfactory receptor family 10 subfamily R member 2	1	158479878-158480885	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA059775, HPA060399	Uncertain					Not detected	Not detected			thyroid gland: 0.1	Cell line enriched	9	MOLT-4: 26.2
OR10Z1		ENSG00000198967	Olfactory receptor family 10 subfamily Z member 1	1	158606439-158607380	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA058072	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF525	KIAA1979	ENSG00000203326	Zinc finger protein 525	19	53365693-53392217	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			parathyroid gland: 20.7	Mixed		
INF2	C14orf151, C14orf173, MGC13251	ENSG00000203485	Inverted formin, FH2 and WH2 domain containing	14	104689606-104722535	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000724	Approved		Approved	Nuclear bodies<br>Endoplasmic reticulum	Liver cancer:8.18e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 55.6	Expressed in all		
FAM83H-AS1	onco-lncRNA-3	ENSG00000203499	FAM83H antisense RNA 1 (head to head)	8	143734140-143790644	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 26.2;skin: 34.3	esophagus: 13.0	Cell line enhanced		HaCaT: 26.1;hTCEpi: 25.7;MCF7: 55.1;T-47d: 60.5
RP11-176H8.1		ENSG00000203546		14	31334312-31457441	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		adipose tissue: 1.1	skeletal muscle: 0.4	Not detected		
GP1BB	CD42c, GPIbbeta	ENSG00000203618	Glycoprotein Ib platelet beta subunit	22	19722945-19724771	CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	skin: 2.8	spleen: 0.4	Cell line enhanced		K-562: 8.8;NB-4: 5.1;REH: 8.9;SH-SY5Y: 4.7;U-2 OS: 9.7
OR2T5		ENSG00000203661	Olfactory receptor family 2 subfamily T member 5	1	248488589-248489536	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2L2	HSHTPCRH07, HTPCRH07, OR2L12, OR2L4P	ENSG00000203663	Olfactory receptor family 2 subfamily L member 2	1	248038268-248039206	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 2.6	cerebral cortex,spleen: 0.3	Not detected		
EFCAB2	CFAP200, DRC8, MGC12458	ENSG00000203666	EF-hand calcium binding domain 2	1	244969705-245127164	Predicted intracellular proteins	Evidence at protein level	HPA031206, HPA031207	Approved		Approved	Plasma membrane<br>Cytosol	Thyroid cancer:6.51e-4 (unfavourable)	Mixed	Expressed in all			fallopian tube: 57.7	Expressed in all		
COX20	FAM36A, FLJ43269	ENSG00000203667	COX20, cytochrome c oxidase assembly factor	1	244835322-244845057	Predicted membrane proteins	Evidence at protein level	HPA043617, HPA045490	Approved		Enhanced	Mitochondria	Ovarian cancer:3.13e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 51.7	Expressed in all		
CHML	REP-2	ENSG00000203668	CHM like, Rab escort protein 2	1	241628853-241640254	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA029627, HPA029628, HPA062967	Supported		Supported	Nucleoplasm<br>Cytosol	Liver cancer:9.23e-5 (unfavourable)	Expressed in all	Mixed			placenta: 16.6	Expressed in all		
STUM	C1orf95, DKFZp761P211	ENSG00000203685	Stum, mechanosensory transduction mediator homolog	1	226548800-226609214	Predicted membrane proteins	Evidence at protein level	HPA074381			Approved	Cytosol	Renal cancer:6.40e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 35.7	smooth muscle: 8.4	Cell line enriched	5	HEL: 26.9
TCP10		ENSG00000203690	T-complex 10	6	167357031-167384510	Predicted intracellular proteins	Evidence at transcript level	HPA044709	Approved					Not detected	Tissue enriched	14	testis: 14.1	small intestine: 0.9	Not detected		
CAPN8	nCL-2	ENSG00000203697	Calpain 8	1	223538007-223665734	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA073939			Approved	Nucleoplasm<br>Nuclear membrane<br>Vesicles		Tissue enhanced	Tissue enriched	8	stomach: 286.5	rectum: 37.3	Cell line enriched	9	RT4: 62.5
TATDN3		ENSG00000203705	TatD DNase domain containing 3	1	212791828-212816626	Predicted intracellular proteins	Evidence at protein level	HPA032092	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Focal adhesion sites	Renal cancer:1.59e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 22.1	Expressed in all		
CR1	CD35, KN	ENSG00000203710	Complement C3b/C4b receptor 1 (Knops blood group)	1	207496147-207640647	Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002491, CAB016271, HPA042455, HPA043579, HPA049348	Enhanced					Mixed	Tissue enhanced		appendix: 37.5;spleen: 33.6	lymph node: 23.4	Group enriched	8	HL-60: 7.8;HMC-1: 19.1;NB-4: 5.8
RAET1G	ULBP5	ENSG00000203722	Retinoic acid early transcript 1G	6	149916878-149923121	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA062673			Approved	Vesicles	Lung cancer:5.35e-4 (unfavourable)	Mixed	Tissue enhanced		adrenal gland: 8.2;esophagus: 9.5	skin: 3.4	Cell line enhanced		HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
C1orf53		ENSG00000203724	Chromosome 1 open reading frame 53	1	197902647-197907367	Predicted intracellular proteins	Evidence at protein level	HPA065352			Approved	Vesicles<br>Aggresome	Breast cancer:1.63e-4 (favourable), Endometrial cancer:3.78e-4 (unfavourable)	Expressed in all	Mixed			adrenal gland: 6.2	Mixed		
SAMD5	dJ875H10.1	ENSG00000203727	Sterile alpha motif domain containing 5	6	147508927-147737547	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067811	Uncertain		Supported	Vesicles	Liver cancer:2.23e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 22.5	placenta: 18.1	Cell line enhanced		Hep G2: 44.5;K-562: 40.0;RH-30: 28.7;WM-115: 20.8
TEDDM1	EDDM9, Epdd1, HE9, TMEM45C	ENSG00000203730	Transmembrane epididymal protein 1	1	182398117-182400616	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	447	epididymis: 716.9	seminal vesicle: 1.6	Not detected		
GJE1	CX23	ENSG00000203733	Gap junction protein epsilon 1	6	142133090-142135151	Predicted membrane proteins	No evidence	HPA014916	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ECT2L	ARHGEF32, C6orf91, FBXO49, LFDH	ENSG00000203734	Epithelial cell transforming 2 like	6	138795926-138904070	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035488	Uncertain					Not detected	Tissue enriched	7	fallopian tube: 18.3	lung: 2.7	Not detected		
GPR52		ENSG00000203737	G protein-coupled receptor 52	1	174448111-174449198	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA028575	Uncertain					Not detected	Tissue enriched	7	cerebral cortex: 2.6	bone marrow: 0.3	Not detected		
METTL11B	C1orf184, HOMT1B	ENSG00000203740	Methyltransferase like 11B	1	170146001-170167790	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028049	Uncertain					Not detected	Tissue enhanced		heart muscle: 1.5	skeletal muscle,testis: 0.4	Cell line enriched	13	NTERA-2: 1.7
FCGR3A	CD16, CD16a, FCG3, FCGR3	ENSG00000203747	Fc fragment of IgG receptor IIIa	1	161541759-161550737	CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB032435, HPA055431	Supported				Renal cancer:3.22e-6 (unfavourable)	Expressed in all	Expressed in all			spleen: 419.4	Not detected		
TMEM244	bA174C7.4, C6orf191	ENSG00000203756	Transmembrane protein 244	6	129831244-129861547	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.7	lymph node: 0.6	Cell line enhanced		HDLM-2: 4.4;LHCN-M2: 4.4;U-251 MG: 3.4;U-266/70: 2.9;WM-115: 2.6
OR6K3		ENSG00000203757	Olfactory receptor family 6 subfamily K member 3	1	158717168-158718163	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA055949	Uncertain					Not detected	Not detected			bone marrow: 0.8	Not detected		
CENPW	C6orf173, CUG2	ENSG00000203760	Centromere protein W	6	126340174-126348875	Predicted intracellular proteins	Evidence at protein level	HPA067285			Supported	Nucleoplasm	Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.21e-5 (unfavourable)	Expressed in all	Mixed			testis: 51.9	Expressed in all		
SPRN	bA108K14.1, FLJ41197, Shadoo, Sprn	ENSG00000203772	Shadow of prion protein homolog (zebrafish)	10	133420666-133424572	Predicted secreted proteins, Transporters	Evidence at transcript level						Urothelial cancer:1.58e-7 (favourable), Pancreatic cancer:1.54e-6 (favourable), Renal cancer:3.95e-4 (unfavourable)	Expressed in all	Tissue enriched	9	cerebral cortex: 24.8	testis: 2.8	Mixed		
FAM229B	C6orf225, DKFZp586F0922, LOC619208	ENSG00000203778	Family with sequence similarity 229 member B	6	112087599-112102790	Predicted intracellular proteins	Evidence at transcript level	HPA036068			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus	Renal cancer:8.76e-4 (favourable)	Expressed in all	Tissue enriched	6	testis: 542.3	fallopian tube: 85.3	Mixed		
FANK1		ENSG00000203780	Fibronectin type III and ankyrin repeat domains 1	10	125896539-126009592	Predicted intracellular proteins	Evidence at protein level	HPA038413			Supported	Nucleoplasm	Endometrial cancer:3.83e-4 (favourable)	Mixed	Group enriched	5	fallopian tube: 55.3;testis: 92.6	epididymis: 14.3	Cell line enhanced		CAPAN-2: 16.8;RPTEC TERT1: 10.1
LOR		ENSG00000203782	Loricrin	1	153259700-153262122	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA076123, HPA077266	Enhanced				Head and neck cancer:8.53e-4 (favourable)	Tissue enriched	Tissue enriched	16	skin: 532.0	breast: 32.9	Cell line enriched	83	HDLM-2: 33.1
PRR9		ENSG00000203783	Proline rich 9	1	153217584-153219317	Predicted intracellular proteins	Evidence at transcript level	HPA027714	Approved					Group enriched	Tissue enriched	5	testis: 2.8	breast,placenta: 0.5	Cell line enhanced		HaCaT: 1.9;U-87 MG: 1.6
LELP1		ENSG00000203784	Late cornified envelope like proline rich 1	1	153203443-153205120	Predicted intracellular proteins	Evidence at protein level	HPA070231	Enhanced					Tissue enriched	Tissue enriched	2787	testis: 784.3	seminal vesicle,small intestine: 0.2	Not detected		
SPRR2E		ENSG00000203785	Small proline rich protein 2E	1	153093135-153106184	Predicted intracellular proteins	Evidence at transcript level						Urothelial cancer:9.47e-4 (unfavourable)	Tissue enhanced	Group enriched	18	esophagus: 2005.4;skin: 804.8;tonsil: 459.7	breast: 61.4	Cell line enriched	9	hTCEpi: 12.1
KPRP	C1orf45	ENSG00000203786	Keratinocyte proline rich protein	1	152759561-152762052	Predicted intracellular proteins	Evidence at protein level	HPA031988, HPA031990	Enhanced					Group enriched	Tissue enriched	19	skin: 267.5	breast: 13.8	Cell line enhanced		hTEC/SVTERT24-B: 1.9;U-2197: 1.1
METTL10	C10orf138, Em:AC068896.3	ENSG00000203791	Methyltransferase like 10	10	124748149-124791870	Predicted intracellular proteins	Evidence at protein level	HPA050138	Approved		Approved	Nucleoplasm<br>Nuclear bodies	Thyroid cancer:2.53e-4 (unfavourable), Prostate cancer:4.82e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 15.1	Expressed in all		
FAM24A	AC073585.4	ENSG00000203795	Family with sequence similarity 24 member A	10	122910701-122913111	Predicted intracellular proteins	Evidence at protein level	HPA052490	Supported					Not detected	Tissue enriched	332	testis: 33.1	all non-specific tissues: 0.0	Not detected		
DDO		ENSG00000203797	D-aspartate oxidase	6	110391771-110415562	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA037525, HPA037526	Enhanced		Supported	Cytosol	Renal cancer:8.69e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 24.3	heart muscle: 12.2	Cell line enhanced		RPMI-8226: 10.9;U-937: 13.6
PLPP4	DPPL2, PPAPDC1, PPAPDC1A	ENSG00000203805	Phospholipid phosphatase 4	10	120456954-120589855	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045188	Approved		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7	kidney: 7.8	Cell line enhanced		BJ: 30.3;U-251 MG: 92.6
HIST2H3C	H3, H3.2, H3/m, H3F2, H3FM, MGC9629	ENSG00000203811	Histone cluster 2 H3 family member c	1	149839538-149841193	Predicted intracellular proteins	Evidence at protein level	HPA042570, CAB069990	Supported					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		SiHa: 5.9
HIST2H2AA3	H2A.2, H2A/q, H2AFO, HIST2H2AA	ENSG00000203812	Histone cluster 2 H2A family member a3	1	149842188-149842736	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Tissue enhanced	Tissue enhanced		bone marrow: 112.2;prostate: 125.6	spleen: 42.0	Cell line enhanced		U-266/70: 350.1;U-266/84: 191.4
HIST2H2BF		ENSG00000203814	Histone cluster 2 H2B family member f	1	149782689-149812373	Predicted intracellular proteins	Evidence at protein level	CAB007814, HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			ovary: 24.3	Cell line enhanced		U-266/70: 38.0
HIST2H3PS2	p06	ENSG00000203818	Histone cluster 2 H3 pseudogene 2	1	143905556-143905966	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Not detected	Tissue enhanced		adrenal gland: 8.5;spleen: 7.7	ovary: 5.8	Cell line enhanced		BJ: 6.7;NB-4: 5.8;SH-SY5Y: 10.0;THP-1: 6.3;U-2197: 6.2
PNLIPRP3		ENSG00000203837	Pancreatic lipase related protein 3	10	116427867-116477957	Enzymes, Predicted secreted proteins	Evidence at transcript level	HPA046202, HPA052009	Uncertain					Tissue enhanced	Tissue enhanced		breast: 12.0;skin: 5.4	esophagus: 1.8	Cell line enriched	14	hTCEpi: 233.8
HIST2H3A	H3/n, H3/o	ENSG00000203852	Histone cluster 2 H3 family member a	1	149852619-149854274	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		SiHa: 5.9
HSD3B1	HSD3B, HSDB3, SDR11E1	ENSG00000203857	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	1	119507198-119515054	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported				Urothelial cancer:4.59e-5 (favourable)	Tissue enhanced	Tissue enriched	13	placenta: 110.5	small intestine: 8.7	Cell line enriched	7	CACO-2: 52.9
HSD3B2	SDR11E2	ENSG00000203859	Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	1	119414931-119423035	Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043261, HPA043264, HPA044028	Supported					Tissue enhanced	Tissue enriched	433	adrenal gland: 2384.5	testis: 5.5	Cell line enhanced		SK-MEL-30: 1.2
RBM20		ENSG00000203867	RNA binding motif protein 20	10	110644397-110839469	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035806, HPA037703	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytokinetic bridge		Mixed	Tissue enhanced		heart muscle: 26.4	skeletal muscle: 5.4	Cell line enhanced		HEK 293: 5.5;RH-30: 15.9;SH-SY5Y: 16.0;T-47d: 8.7
SMIM9	CXorf68	ENSG00000203870	Small integral membrane protein 9	X	154823348-154834662	Predicted membrane proteins	Evidence at transcript level	HPA060970	Uncertain					Not detected	Tissue enriched	5	testis: 1.3	placenta: 0.2	Not detected		
C6orf163		ENSG00000203872	Chromosome 6 open reading frame 163	6	87344849-87365463	Predicted intracellular proteins	Evidence at protein level	HPA044797, HPA052927	Uncertain		Uncertain	Nucleoplasm		Mixed	Tissue enriched	6	testis: 14.0	fallopian tube: 2.4	Mixed		
RIPPLY2	C6orf159, dJ237I15.1	ENSG00000203877	Ripply transcriptional repressor 2	6	83853266-83857515	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047454	Uncertain					Tissue enhanced	Tissue enriched	8	cerebral cortex: 14.9	adrenal gland: 1.8	Cell line enhanced		SCLC-21H: 30.7;SH-SY5Y: 18.9
GDI1	FLJ41411, GDIL, MRX41, MRX48, OPHN2, RABGDIA, XAP-4	ENSG00000203879	GDP dissociation inhibitor 1	X	154436913-154443467	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012979, HPA049290, HPA057668	Enhanced		Approved	Vesicles	Colorectal cancer:3.83e-5 (unfavourable), Breast cancer:6.84e-4 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 532.0	smooth muscle: 101.3	Expressed in all		
PCMTD2	C20orf36, FLJ10883	ENSG00000203880	Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2	20	64255695-64287821	Predicted intracellular proteins	Evidence at protein level	HPA057849	Approved		Approved	Nucleoplasm<br>Mitochondria	Lung cancer:2.13e-4 (favourable), Renal cancer:3.82e-4 (favourable)	Expressed in all	Expressed in all			skin: 78.7	Expressed in all		
SOX18		ENSG00000203883	SRY-box 18	20	64047582-64049641	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073703			Approved	Nucleus		Expressed in all	Tissue enhanced		adipose tissue: 32.9	lung: 12.0	Cell line enhanced		HUVEC TERT2: 17.4;NB-4: 22.5;REH: 7.7;TIME: 7.8
LIME1	dJ583P15.4, FLJ20406, LIME	ENSG00000203896	Lck interacting transmembrane adaptor 1	20	63736283-63739103	Predicted secreted proteins	Evidence at protein level	CAB015363	Approved				Urothelial cancer:6.92e-6 (favourable), Renal cancer:5.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		liver: 19.6;stomach: 17.6	kidney: 15.2	Cell line enhanced		MOLT-4: 31.1;RPMI-8226: 97.2;U-266/70: 55.2
OOEP	C6orf156, Em:AC019205.2, KHDC2	ENSG00000203907	Oocyte expressed protein	6	73368555-73395133	Predicted intracellular proteins	Evidence at protein level	HPA055165	Approved					Tissue enriched	Tissue enriched	11	testis: 23.1	placenta: 2.0	Cell line enhanced		BEWO: 2.5;CAPAN-2: 7.2;MCF7: 2.1;U-2 OS: 1.8
KHDC3L	C6orf221, ECAT1	ENSG00000203908	KH domain containing 3 like, subcortical maternal complex member	6	73362677-73364171	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043699	Uncertain					Tissue enriched	Tissue enhanced		lung: 1.0;testis: 2.2	epididymis: 0.4	Not detected		
DPPA5	Esg1	ENSG00000203909	Developmental pluripotency associated 5	6	73353062-73354295	Predicted intracellular proteins	Evidence at transcript level	HPA064505	Uncertain					Tissue enriched	Tissue enhanced		testis: 3.9	lung: 0.9	Not detected		
C1orf146		ENSG00000203910	Chromosome 1 open reading frame 146	1	92217940-92245813	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 14.5	skin: 1.0	Not detected		
SPANXN1	CT11.6, SPANX-N1	ENSG00000203923	SPANX family member N1	X	145246828-145256112	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	14	testis: 1.3	all non-specific tissues: 0.0	Not detected		
SPANXA2	SPANX	ENSG00000203926	SPANX family member A2	X	141589435-141590772	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Supported	Nucleoplasm<br>Vesicles		Not detected	Tissue enriched	93	testis: 9.2	all non-specific tissues: 0.0	Cell line enhanced		U-2 OS: 1.6
CXorf66	RP11-35F15.2, SGPX	ENSG00000203933	Chromosome X open reading frame 66	X	139955725-139965520	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	76	testis: 24.3	liver: 0.3	Not detected		
C10orf62	bA548K23.1	ENSG00000203942	Chromosome 10 open reading frame 62	10	97589727-97590934	Predicted intracellular proteins	Evidence at protein level	HPA072947	Enhanced					Not detected	Tissue enriched	1082	testis: 244.6	kidney: 0.2	Not detected		
SAMD13		ENSG00000203943	Sterile alpha motif domain containing 13	1	84298366-84389957	Predicted intracellular proteins	Evidence at protein level	HPA058929	Enhanced		Approved	Mitochondria	Glioma:2.06e-8 (favourable)	Mixed	Tissue enhanced		rectum: 25.8;testis: 28.7	colon: 20.7	Mixed		
FAM127B	CXX1b, DKFZP564B147, MAR8A	ENSG00000203950	Family with sequence similarity 127 member B	X	135050932-135052196	Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.10e-5 (unfavourable), Ovarian cancer:2.71e-4 (favourable), Endometrial cancer:2.83e-4 (unfavourable), Cervical cancer:5.35e-4 (favourable)	Expressed in all	Expressed in all			ovary: 24.6	Mixed		
CCDC160		ENSG00000203952	Coiled-coil domain containing 160	X	134237047-134246207	Predicted intracellular proteins	Evidence at transcript level	HPA044684	Uncertain				Ovarian cancer:7.62e-6 (favourable), Renal cancer:2.21e-4 (favourable), Endometrial cancer:2.31e-4 (favourable)	Mixed	Mixed			parathyroid gland: 8.4	Cell line enhanced		AF22: 29.3;NTERA-2: 4.1;RPTEC TERT1: 6.2
C1orf141		ENSG00000203963	Chromosome 1 open reading frame 141	1	67092165-67231853	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	13	fallopian tube: 15.5;testis: 28.2	lung: 1.6	Cell line enriched	39	HEL: 13.1
EFCAB7	KIAA1799, RP4-534K7.1	ENSG00000203965	EF-hand calcium binding domain 7	1	63523372-63572693	Predicted intracellular proteins	Evidence at protein level	HPA029611, HPA029612, HPA029613	Enhanced		Approved	Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol	Glioma:4.84e-4 (favourable)	Mixed	Mixed			testis: 24.7	Expressed in all		
DEFB110	DEFB-10, DEFB-11, DEFB111	ENSG00000203970	Defensin beta 110	6	50009138-50021981	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	3627	epididymis: 1094.2	seminal vesicle: 0.3	Not detected		
GLYATL3	bA28H17.2, C6orf140	ENSG00000203972	Glycine-N-acyltransferase like 3	6	49499958-49527047	Predicted intracellular proteins	Evidence at transcript level	HPA044044	Uncertain					Tissue enhanced	Not detected			liver: 0.7	Cell line enriched	74	T-47d: 13.7
LDLRAD1		ENSG00000203985	Low density lipoprotein receptor class A domain containing 1	1	54007299-54018186	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052489	Enhanced		Uncertain	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:9.21e-4 (favourable)	Tissue enhanced	Tissue enriched	22	fallopian tube: 256.4	lung: 11.7	Cell line enhanced		CAPAN-2: 2.2;Hep G2: 7.0
RHOXF2B		ENSG00000203989	Rhox homeobox family member 2B	X	120070672-120077705	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003314	Supported					Not detected	Tissue enriched	19	testis: 2.7	ovary,skin,spleen: 0.1	Group enriched	341	HL-60: 168.7;K-562: 191.8;NB-4: 216.8
ZYG11A	ZYG11	ENSG00000203995	Zyg-11 family member A, cell cycle regulator	1	52842511-52894998	Predicted intracellular proteins	Evidence at protein level	HPA030378, HPA030379	Uncertain		Approved	Nucleus		Tissue enriched	Tissue enhanced		testis: 7.1;thyroid gland: 4.0	kidney: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 10.5;SiHa: 11.4
LCN8	LCN5	ENSG00000204001	Lipocalin 8	9	136754386-136758543	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	233	epididymis: 102.0	lymph node,thyroid gland: 0.4	Cell line enriched	9	REH: 2.1
C1orf185	FLJ27485	ENSG00000204006	Chromosome 1 open reading frame 185	1	51102234-51148086	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	243	testis: 43.0	adipose tissue,gallbladder,parathyroid gland: 0.1	Not detected		
GLT6D1	GLTDC1	ENSG00000204007	Glycosyltransferase 6 domain containing 1	9	135623656-135639540	Predicted secreted proteins	Evidence at transcript level	HPA023424	Uncertain					Not detected	Tissue enriched	42	testis: 8.3	epididymis: 0.1	Not detected		
IFIT1B	bA149I23.6, IFIT1L	ENSG00000204010	Interferon induced protein with tetratricopeptide repeats 1B	10	89378056-89385205	Predicted intracellular proteins	Evidence at protein level	HPA062924	Approved					Not detected	Group enriched	97	bone marrow: 15.3;placenta: 4.1	all non-specific tissues: 0.0	Not detected		
CT83	CXorf61, FLJ20611, FLJ22913, KK-LC-1	ENSG00000204019	Cancer/testis antigen 83	X	116461682-116463003	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	60	testis: 85.3	salivary gland: 1.4	Cell line enhanced		HeLa: 49.1;U-266/70: 77.2;U-266/84: 38.3
LIPN	bA186O14.3, LIPL4	ENSG00000204020	Lipase family member N	10	88761406-88778242	Disease related genes, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	skin: 39.8	appendix: 5.7	Group enriched	7	Daudi: 1.0;HL-60: 3.5
LIPK	bA186O14.2, LIPL2	ENSG00000204021	Lipase family member K	10	88724544-88752786	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	skin: 37.4	breast: 3.2	Cell line enriched	5	SK-BR-3: 1.9
LIPJ	bA425M17.2, LIPL1	ENSG00000204022	Lipase family member J	10	88586753-88606976	Predicted intracellular proteins	Evidence at transcript level	HPA048594	Uncertain					Not detected	Tissue enriched	11	testis: 12.3	epididymis,fallopian tube: 1.1	Not detected		
TRPC5OS	TRPC5-AS1	ENSG00000204025	TRPC5 opposite strand	X	111876051-111903990	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	58	testis: 45.5	epididymis: 0.7	Cell line enhanced		U-937: 1.0
LRIT2	AC022389.4, LRRC22	ENSG00000204033	Leucine rich repeat, Ig-like and transmembrane domains 2	10	84220495-84225589	Predicted membrane proteins	Evidence at protein level	HPA037788	Supported					Not detected	Group enriched	11	cerebral cortex: 1.0;skin: 3.1	colon,esophagus,small intestine,spleen,testis: 0.1	Not detected		
LRRC73	C6orf154, dJ337H4.2	ENSG00000204052	Leucine rich repeat containing 73	6	43506969-43510686	Predicted intracellular proteins	Evidence at protein level	HPA046698	Enhanced		Approved	Cytosol		Mixed	Tissue enhanced		fallopian tube: 8.3;testis: 24.7	cerebral cortex: 6.5	Cell line enhanced		AN3-CA: 2.9;MCF7: 2.4;T-47d: 3.0
FOXO6		ENSG00000204060	Forkhead box O6	1	41361922-41383590	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:7.65e-6 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.9	Cell line enhanced		BEWO: 19.9;SCLC-21H: 31.9;U-2 OS: 11.0
TCEAL5	WEX4	ENSG00000204065	Transcription elongation factor A like 5	X	103273691-103276872	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982, HPA072199	Supported		Uncertain	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.60e-4 (favourable), Endometrial cancer:9.09e-4 (unfavourable)	Tissue enhanced	Group enriched	7	cerebral cortex: 82.5;testis: 82.5	adrenal gland: 11.9	Group enriched	7	SCLC-21H: 9.3;SH-SY5Y: 25.9
SYS1	C20orf169, dJ453C12.4	ENSG00000204070	SYS1, golgi trafficking protein	20	45361937-45376798	Predicted membrane proteins	Evidence at protein level	HPA046716	Approved				Liver cancer:4.62e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 51.8	Expressed in all		
TCEAL6	WEX2	ENSG00000204071	Transcription elongation factor A like 6	X	102140476-102142970	Predicted intracellular proteins	Evidence at protein level	HPA045564, HPA058982	Supported					Tissue enriched	Group enriched	6	adrenal gland: 14.3;cerebral cortex: 63.5;testis: 34.6	endometrium: 5.8	Not detected		
INPP5B		ENSG00000204084	Inositol polyphosphate-5-phosphatase B	1	37860697-37947057	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028803	Approved		Approved	Cytosol	Renal cancer:6.11e-5 (unfavourable), Head and neck cancer:1.11e-4 (favourable), Pancreatic cancer:5.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 26.3	Expressed in all		
RPA4	HSU24186	ENSG00000204086	Replication protein A4	X	96883908-96885467	Predicted intracellular proteins	Evidence at protein level	HPA066010	Approved					Not detected	Tissue enriched	7	testis: 2.1	placenta: 0.2	Not detected		
NEU4		ENSG00000204099	Neuraminidase 4	2	241808825-241817413	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037394, HPA037395	Uncertain					Group enriched	Group enriched	6	bone marrow: 2.4;cerebral cortex: 6.3;colon: 8.3;duodenum: 5.6;liver: 4.1;rectum: 3.7;small intestine: 5.3	fallopian tube,gallbladder: 0.7	Group enriched	20	Hep G2: 26.3;HMC-1: 45.5
MAFB	KRML	ENSG00000204103	MAF bZIP transcription factor B	20	40685848-40689240	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005653	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.64e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 689.3	spleen: 102.0	Cell line enhanced		HSkMC: 20.7;hTCEpi: 44.3;SCLC-21H: 19.6;SiHa: 16.5;U-138 MG: 16.2;U-2197: 22.6;U-87 MG: 15.7
TRAF3IP1	DKFZP434F124, IFT54, MIP-T3, MIPT3	ENSG00000204104	TRAF3 interacting protein 1	2	238320441-238400900	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037857, HPA037858	Approved				Melanoma:2.19e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 30.9	Mixed		
CHIC1	BRX	ENSG00000204116	Cysteine rich hydrophobic domain 1	X	73563200-73687102	Predicted membrane proteins	Evidence at protein level	HPA026782, HPA052062	Uncertain		Approved	Nuclear speckles<br>Vesicles<br>Cytosol	Renal cancer:2.75e-4 (favourable)	Mixed	Mixed			cerebral cortex: 14.2	Mixed		
NAP1L6	FLJ33596	ENSG00000204118	Nucleosome assembly protein 1 like 6	X	73126037-73128080	Predicted intracellular proteins	Evidence at transcript level	HPA044957	Uncertain					Mixed	Mixed			thyroid gland: 1.2	Group enriched	6	U-2 OS: 3.4;U-266/84: 2.1
GIGYF2	GYF2, KIAA0642, PARK11, PERQ2, PERQ3, TNRC15	ENSG00000204120	GRB10 interacting GYF protein 2	2	232697299-232860575	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050899, HPA054612, HPA059918, HPA065064	Approved		Enhanced	Cytosol	Renal cancer:6.97e-5 (favourable)	Expressed in all	Expressed in all			testis: 85.1	Expressed in all		
C2orf72	LOC257407	ENSG00000204128	Chromosome 2 open reading frame 72	2	231037490-231049719	Predicted intracellular proteins	Evidence at protein level	HPA044962	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:4.74e-4 (unfavourable), Pancreatic cancer:5.27e-4 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 2.8;colon: 2.9;liver: 4.7	stomach: 1.3	Cell line enhanced		BEWO: 8.2;CACO-2: 1.7;EFO-21: 2.9
RUFY2	FLJ10063, KIAA1537, RABIP4R, ZFYVE13	ENSG00000204130	RUN and FYVE domain containing 2	10	68341107-68407294	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039792	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 36.8	Expressed in all		
NHSL2		ENSG00000204131	NHS like 2	X	71910818-72161750	Predicted intracellular proteins	Evidence at protein level	HPA049771, HPA054858	Uncertain					Mixed	Mixed			smooth muscle: 10.0	Cell line enhanced		AF22: 24.9;EFO-21: 27.8;HUVEC TERT2: 23.1;TIME: 13.2;U-937: 16.2
PHACTR4	FLJ13171, PPP1R124	ENSG00000204138	Phosphatase and actin regulator 4	1	28369582-28500369	Predicted intracellular proteins	Evidence at protein level	HPA028985	Approved		Approved	Plasma membrane<br>Intermediate filaments<br>Cytosol	Head and neck cancer:1.05e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 35.7	Expressed in all		
CLPSL1	C6orf127, dJ510O8.6	ENSG00000204140	Colipase like 1	6	35781017-35793675	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA073155	Enhanced					Group enriched	Tissue enriched	38	epididymis: 733.4	pancreas: 19.3	Cell line enriched	25	T-47d: 7.9
ASAH2B	ASAH2C, ASAH2L, bA449O16.3, bA98I6.3	ENSG00000204147	N-acylsphingosine amidohydrolase 2B	10	50739318-50816495	Predicted intracellular proteins	Evidence at protein level	HPA061171	Supported		Approved	Focal adhesion sites		Mixed	Mixed			duodenum: 19.6	Mixed		
AGAP6	bA324H6.1, CTGLF3	ENSG00000204149	ArfGAP with GTPase domain, ankyrin repeat and PH domain 6	10	49982190-50010499	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain				Renal cancer:9.70e-10 (unfavourable), Urothelial cancer:1.83e-7 (favourable), Pancreatic cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			skin: 21.8	Expressed in all		
TIMM23B	bA592B15.7	ENSG00000204152	Translocase of inner mitochondrial membrane 23 homolog B	10	49942033-49974850	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Mixed			bone marrow: 5.5	Mixed		
ZDHHC18	DKFZp667O2416	ENSG00000204160	Zinc finger DHHC-type containing 18	1	26826710-26857602	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA040234	Approved		Approved	Microtubules	Renal cancer:1.36e-10 (unfavourable), Liver cancer:7.42e-7 (unfavourable), Glioma:9.53e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 75.2	Expressed in all		
C10orf128	Em:AC084727.5	ENSG00000204161	Chromosome 10 open reading frame 128	10	49154725-49188585	Predicted membrane proteins	Evidence at transcript level	HPA058166	Approved				Renal cancer:2.86e-5 (unfavourable)	Expressed in all	Mixed			lung: 40.6	Cell line enhanced		HDLM-2: 200.6;HEL: 46.6;K-562: 91.3;U-87 MG: 100.7;U-937: 72.4
CXorf65		ENSG00000204165	Chromosome X open reading frame 65	X	71103889-71106788	Predicted intracellular proteins	Evidence at protein level	HPA047396	Uncertain					Mixed	Tissue enriched	10	testis: 19.6	lymph node: 2.0	Cell line enhanced		HEL: 1.2;Karpas-707: 2.4;MOLT-4: 1.2;NB-4: 1.3
AGAP9	bA301J7.2, CTGLF6, FLJ00312	ENSG00000204172	ArfGAP with GTPase domain, ankyrin repeat and PH domain 9	10	47501854-47523638	Predicted intracellular proteins	Evidence at transcript level	HPA042490	Uncertain				Renal cancer:3.02e-5 (unfavourable), Colorectal cancer:9.98e-5 (unfavourable), Urothelial cancer:7.04e-4 (favourable)	Expressed in all	Expressed in all			skin: 26.3	Mixed		
NPY4R	PP1, PPYR1, Y4	ENSG00000204174	Neuropeptide Y receptor Y4	10	46461099-46465881	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA027863	Approved					Tissue enhanced	Tissue enhanced		colon: 5.1;rectum: 6.9	skin: 3.6	Cell line enriched	5	A549: 26.3
GPRIN2	KIAA0514, MGC15171	ENSG00000204175	G protein regulated inducer of neurite outgrowth 2	10	46549044-46555530	Predicted intracellular proteins	Evidence at protein level	HPA038129	Approved		Approved	Nucleoplasm	Endometrial cancer:8.60e-8 (unfavourable), Head and neck cancer:3.47e-4 (favourable)	Mixed	Tissue enhanced		lung: 18.0;skin: 18.8	small intestine: 11.7	Group enriched	5	A-431: 12.9;A549: 38.1;SiHa: 8.3;SK-BR-3: 17.1
SYT15	CHR10SYT	ENSG00000204176	Synaptotagmin 15	10	46578217-46594173	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036971, HPA036972, HPA064559	Uncertain		Approved	Golgi apparatus		Not detected	Mixed			lung: 21.1	Cell line enhanced		SK-BR-3: 23.7
TMEM57	FLJ10747	ENSG00000204178	Transmembrane protein 57	1	25430858-25500209	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019680			Approved	Cytosol	Renal cancer:7.13e-4 (favourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
PTPN20	bA142I17.1, bA42B19.1, CT126, DKFZP566K0524, PTPN20A, PTPN20B	ENSG00000204179	Protein tyrosine phosphatase, non-receptor type 20	10	46911396-47002488	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043337, HPA046896, HPA048310	Uncertain		Supported	Microtubule organizing center		Mixed	Tissue enhanced		testis: 25.3	adrenal gland: 12.2	Cell line enhanced		HDLM-2: 46.4;SiHa: 9.6
GDF5OS		ENSG00000204183	Growth differentiation factor 5 opposite strand	20	35433029-35435450	Predicted intracellular proteins	Evidence at transcript level	HPA062720	Uncertain					Not detected	Not detected			adipose tissue: 0.3	Not detected		
ZDBF2	FLJ45338, KIAA1571	ENSG00000204186	Zinc finger DBF-type containing 2	2	206274663-206314428	Predicted intracellular proteins	Evidence at protein level	HPA039121, HPA050311	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Mixed	Mixed			cerebral cortex: 5.1	Mixed		
TXNDC8	bA427L11.2, SPTRX-3, TRX6	ENSG00000204193	Thioredoxin domain containing 8	9	110303521-110337884	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	371	testis: 44.0	kidney,lymph node,seminal vesicle: 0.1	Cell line enhanced		THP-1: 1.1
AWAT1	DGAT2L3	ENSG00000204195	Acyl-CoA wax alcohol acyltransferase 1	X	70234655-70240627	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA063412	Supported					Not detected	Not detected			breast: 0.8	Not detected		
DAXX	DAP6	ENSG00000204209	Death domain associated protein	6	33318558-33329286	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002224, HPA008736, HPA008797, CAB025546, HPA065779	Enhanced		Enhanced	Nucleus<br>Nuclear bodies	Renal cancer:6.32e-7 (unfavourable), Breast cancer:6.05e-4 (favourable)	Expressed in all	Mixed			epididymis: 19.3	Mixed		
BMPR2	BMPR-II, BMPR3, BRK-3, PPH1, T-ALK	ENSG00000204217	Bone morphogenetic protein receptor type 2	2	202376936-202567751	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA017385, HPA049014	Approved		Approved	Nucleoplasm<br>Plasma membrane		Expressed in all	Expressed in all			placenta: 44.9	Mixed		
TCEA3	TFIIS.H	ENSG00000204219	Transcription elongation factor A3	1	23381061-23424740	Predicted intracellular proteins	Evidence at protein level	HPA044960, HPA055811	Approved		Approved	Nucleoplasm<br>Vesicles	Head and neck cancer:2.56e-4 (favourable)	Expressed in all	Tissue enhanced		skeletal muscle: 157.4	ovary: 62.8	Cell line enhanced		Hep G2: 43.0;SiHa: 21.8;T-47d: 30.3
PFDN6	H2-KE2, HKE2, KE-2, PFD6	ENSG00000204220	Prefoldin subunit 6	6	33289302-33298401	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043032, HPA048123	Enhanced		Approved	Nucleus<br>Golgi apparatus	Ovarian cancer:1.01e-4 (favourable), Renal cancer:8.97e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 20.9	Expressed in all		
RING1	RNF1	ENSG00000204227	Ring finger protein 1	6	33208495-33212722	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA008701	Supported		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Mixed			endometrium: 8.2	Mixed		
HSD17B8	D6S2245E, FABGL, H2-KE6, HKE6, KE6, RING2, SDR30C1	ENSG00000204228	Hydroxysteroid 17-beta dehydrogenase 8	6	33204642-33206831	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042132	Enhanced				Renal cancer:2.18e-12 (favourable), Liver cancer:1.90e-5 (favourable), Breast cancer:9.99e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.9	Cell line enhanced		RPMI-8226: 11.7;T-47d: 9.9;U-266/70: 12.1
RXRB	H-2RIIBP, NR2B2, RCoR-1	ENSG00000204231	Retinoid X receptor beta	6	33193588-33200688	Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002003, HPA063653	Supported		Supported	Nucleus		Expressed in all	Mixed			epididymis: 15.7	Cell line enhanced		RH-30: 8.5;T-47d: 8.2
OXLD1	C17orf90, MGC104712	ENSG00000204237	Oxidoreductase like domain containing 1	17	81665036-81666635	Predicted intracellular proteins	Evidence at protein level	HPA056878, HPA057019	Uncertain		Approved	Vesicles<br>Cytosol	Cervical cancer:2.91e-4 (favourable)	Expressed in all	Mixed			testis: 10.7	Cell line enhanced		A549: 54.5
OR13C3		ENSG00000204246	Olfactory receptor family 13 subfamily C member 3	9	104535749-104536856	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053978	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
COL11A2	DFNA13, DFNB53, HKE5	ENSG00000204248	Collagen type XI alpha 2 chain	6	33162681-33192499	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		testis: 1.2	cerebral cortex: 0.7	Not detected		
HLA-DOA	HLA-D0-alpha, HLA-DNA, HLA-DZA	ENSG00000204252	Major histocompatibility complex, class II, DO alpha	6	33004178-33009612	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045038	Enhanced					Expressed in all	Tissue enhanced		spleen: 14.4	tonsil: 8.9	Cell line enhanced		Daudi: 4.6;HDLM-2: 4.3;REH: 19.0;U-698: 3.4
BRD2	BRD2-IT1, D6S113E, FSRG1, KIAA9001, NAT, RING3	ENSG00000204256	Bromodomain containing 2	6	32968660-32981505	Predicted intracellular proteins	Evidence at protein level	HPA042816	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			thyroid gland: 101.8	Expressed in all		
HLA-DMA	D6S222E, RING6	ENSG00000204257	Major histocompatibility complex, class II, DM alpha	6	32948613-32969094	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012750, HPA017295	Enhanced		Approved	Vesicles	Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 65.0	fallopian tube: 41.9	Cell line enhanced		U-266/70: 22.0;U-266/84: 9.5;U-698: 52.4
COL5A2		ENSG00000204262	Collagen type V alpha 2 chain	2	189031896-189179879	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:1.53e-10 (unfavourable), Urothelial cancer:3.58e-4 (unfavourable), Lung cancer:5.37e-4 (unfavourable)	Expressed in all	Mixed			placenta: 154.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 407.0;BJ hTERT+ SV40 Large T+ RasG12V: 363.2;fHDF/TERT166: 325.7
PSMB8	beta5i, D6S216E, LMP7, PSMB5i, RING10	ENSG00000204264	Proteasome subunit beta 8	6	32840717-32844703	Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046995, HPA050327	Enhanced		Approved	Vesicles<br>Cytokinetic bridge	Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable)	Expressed in all	Mixed			lymph node: 23.0	Mixed		
TAP2	ABCB3, D6S217E, PSF2, RING11	ENSG00000204267	Transporter 2, ATP binding cassette subfamily B member	6	32821833-32838780	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA001312	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum	Renal cancer:5.22e-8 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable)	Expressed in all	Mixed			urinary bladder: 15.1	Cell line enhanced		U-251 MG: 53.5
SPIN3	TDRD27	ENSG00000204271	Spindlin family member 3	X	56818298-56995827	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000727	Uncertain		Approved	Nucleoplasm	Endometrial cancer:3.49e-4 (unfavourable), Urothelial cancer:6.30e-4 (favourable), Lung cancer:6.79e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 13.2	Mixed		
NBDY	LINC01420, NoBody	ENSG00000204272	Negative regulator of P-body association	X	56729241-56818380	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:3.14e-5 (unfavourable), Head and neck cancer:3.11e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 71.9	Mixed		
TMEM235		ENSG00000204278	Transmembrane protein 235	17	78231310-78240987	Predicted membrane proteins	Evidence at transcript level	HPA053939	Uncertain					Tissue enriched	Tissue enriched	100	cerebral cortex: 15.6	placenta,testis: 0.1	Not detected		
PAGE3	CT16.6, GAGED1, PAGE-3	ENSG00000204279	PAGE family member 3	X	55258412-55264846	Predicted intracellular proteins	Evidence at protein level	HPA062248	Uncertain					Not detected	Tissue enriched	86	testis: 8.5	all non-specific tissues: 0.0	Not detected		
HLA-DRA	HLA-DRA1	ENSG00000204287	Major histocompatibility complex, class II, DR alpha	6	32439842-32445046	Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB002798, CAB015402, HPA050162, HPA053176	Enhanced				Colorectal cancer:5.30e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 731.8;lymph node: 894.1	tonsil: 476.7	Cell line enhanced		Daudi: 254.2;HDLM-2: 588.3;REH: 234.5;U-698: 247.8;U-87 MG: 236.0
BTNL2	BTL-II, BTN7, HSBLMHC1	ENSG00000204290	Butyrophilin like 2	6	32393963-32407128	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			prostate: 0.2	Not detected		
COL15A1		ENSG00000204291	Collagen type XV alpha 1 chain	9	98943179-99070792	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA017913, HPA017915	Enhanced		Approved	Endoplasmic reticulum	Urothelial cancer:3.08e-4 (unfavourable), Liver cancer:5.47e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 312.1	smooth muscle: 146.2	Cell line enhanced		BJ: 21.5;BJ hTERT+: 42.8;HDLM-2: 21.5;U-2197: 40.3;WM-115: 29.2
OR8B2		ENSG00000204293	Olfactory receptor family 8 subfamily B member 2	11	124382395-124383362	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
C6orf10	TSBP	ENSG00000204296	Chromosome 6 open reading frame 10	6	32288526-32371912	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	73	testis: 15.6	lymph node: 0.2	Not detected		
TMEM225	PMP22CD, PPP1R154	ENSG00000204300	Transmembrane protein 225	11	123882926-123885642	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	398	testis: 39.8	all non-specific tissues: 0.0	Not detected		
NOTCH4	INT3	ENSG00000204301	Notch 4	6	32194843-32224067	Predicted membrane proteins	Evidence at protein level						Renal cancer:3.84e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 12.1	thyroid gland: 4.2	Not detected		
PBX2	G17, HOX12, PBX2MHC	ENSG00000204304	PBX homeobox 2	6	32184741-32190186	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061478	Enhanced		Approved	Nucleoplasm	Endometrial cancer:8.90e-5 (unfavourable), Ovarian cancer:6.84e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.1	Mixed		
AGER	RAGE, SCARJ1	ENSG00000204305	Advanced glycosylation end-product specific receptor	6	32180968-32184324	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB011682, HPA064436	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable)	Expressed in all	Tissue enriched	181	lung: 889.2	thyroid gland: 4.9	Cell line enhanced		HEK 293: 2.5;U-266/70: 2.6
RNF5	G16, NG2, RING5, RMA1	ENSG00000204308	Ring finger protein 5	6	32178354-32180793	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB034107, HPA065032	Uncertain		Supported	Endoplasmic reticulum	Ovarian cancer:2.44e-4 (favourable)	Expressed in all	Mixed			kidney: 18.6	Mixed		
AGPAT1	LPAAT-alpha	ENSG00000204310	1-acylglycerol-3-phosphate O-acyltransferase 1	6	32168212-32178096	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA048478, HPA073355	Approved		Supported	Endoplasmic reticulum<br>Rods & Rings	Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 52.2	Mixed		
DFNB59	pejvakin	ENSG00000204311	Deafness, autosomal recessive 59	2	178451436-178461390	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA042621			Supported	Mitochondria	Renal cancer:8.92e-4 (unfavourable)	Mixed	Tissue enriched	6	testis: 32.4	ovary: 5.4	Mixed		
PRRT1	C6orf31, IFITMD7, NG5	ENSG00000204314	Proline rich transmembrane protein 1	6	32148359-32154373	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA055149, HPA059099	Enhanced					Mixed	Tissue enriched	8	cerebral cortex: 4.5	ovary: 0.6	Cell line enhanced		SK-MEL-30: 1.1
FKBPL	DIR1, NG7, WISp39	ENSG00000204315	FK506 binding protein like	6	32128707-32130291	Predicted intracellular proteins	Evidence at protein level	HPA043478, HPA060158	Enhanced		Approved	Nucleoplasm	Ovarian cancer:8.46e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 5.0	Mixed		
MRPL38	HSPC262, MGC4810, MRP-L3, RPML3	ENSG00000204316	Mitochondrial ribosomal protein L38	17	75898643-75905413	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA023054, HPA023135	Approved		Supported	Mitochondria	Urothelial cancer:9.21e-5 (favourable), Pancreatic cancer:4.23e-4 (favourable), Renal cancer:5.58e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 30.7	Expressed in all		
SMIM5	C17orf109	ENSG00000204323	Small integral membrane protein 5	17	75633434-75641404	Predicted membrane proteins	Evidence at protein level	HPA065332, HPA071268	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.12e-4 (favourable), Cervical cancer:5.52e-4 (favourable)	Mixed	Mixed			thyroid gland: 14.3	Cell line enhanced		MCF7: 8.0;SK-BR-3: 3.4
ERICH2		ENSG00000204334	Glutamate rich 2	2	170783786-170798971	Predicted intracellular proteins	Evidence at protein level	HPA061010			Approved	Nucleoli fibrillar center<br>Vesicles	Renal cancer:8.98e-7 (unfavourable), Endometrial cancer:9.49e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 233.8	thyroid gland: 30.5	Cell line enhanced		hTCEpi: 44.3
SP5		ENSG00000204335	Sp5 transcription factor	2	170715351-170718078	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA074123			Approved	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		endometrium: 3.9	stomach: 2.3	Group enriched	12	CACO-2: 23.0;Hep G2: 83.0
STK19	D6S60, G11, RP1	ENSG00000204344	Serine/threonine kinase 19	6	31971091-31982821	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA031510, HPA031511, HPA068559	Uncertain		Supported	Nuclear speckles	Melanoma:1.18e-4 (unfavourable)	Expressed in all	Mixed			testis: 1.2	Cell line enhanced		HDLM-2: 1.9;REH: 1.7
CD300LD	CD300D, CMRF35A4	ENSG00000204345	CD300 molecule like family member d	17	74579365-74592283	CD markers, Predicted membrane proteins	Evidence at protein level	HPA027756	Uncertain					Not detected	Not detected			appendix: 0.9	Not detected		
BTBD17	BTBD17A, LGALS3BPL, TANGO10A	ENSG00000204347	BTB domain containing 17	17	74356416-74361946	Predicted secreted proteins	Evidence at protein level	HPA025022	Approved					Group enriched	Tissue enriched	19	cerebral cortex: 12.9	adrenal gland: 0.6	Group enriched	24	AF22: 2.7;NTERA-2: 3.6;SCLC-21H: 12.8
DXO	DOM3Z	ENSG00000204348	Decapping exoribonuclease	6	31969810-31972292	Predicted intracellular proteins	Evidence at protein level	HPA046708	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:4.77e-6 (unfavourable), Pancreatic cancer:5.87e-4 (favourable)	Expressed in all	Mixed			testis: 5.7	Cell line enhanced		AN3-CA: 10.2
SKIV2L	170A, DDX13, HLP, SKI2W, SKIV2, SKIV2L1	ENSG00000204351	Ski2 like RNA helicase	6	31959080-31969755	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051959, HPA054419	Uncertain		Approved	Nucleoplasm	Renal cancer:3.02e-7 (unfavourable), Liver cancer:6.58e-4 (unfavourable)	Expressed in all	Mixed			epididymis: 10.5	Mixed		
C9orf129	bA165J3.3	ENSG00000204352	Chromosome 9 open reading frame 129	9	93318199-93346414	Predicted intracellular proteins	Evidence at transcript level	HPA071515			Uncertain	Mitochondria		Not detected	Group enriched	7	cerebral cortex: 4.1;testis: 1.7	epididymis: 0.4	Cell line enriched	9	NTERA-2: 2.1
NELFE	D6S45, NELF-E, RD, RDBP, RDP	ENSG00000204356	Negative elongation factor complex member E	6	31952087-31959110	Predicted intracellular proteins	Evidence at protein level	HPA007187, HPA007594, HPA046502	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:2.70e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.4	Expressed in all		
NXPE2	FAM55B, FLJ25224	ENSG00000204361	Neurexophilin and PC-esterase domain family member 2	11	114678386-114706933	Predicted intracellular proteins	Evidence at protein level	HPA039744, HPA039876	Enhanced				Colorectal cancer:9.29e-5 (favourable)	Tissue enhanced	Tissue enhanced		colon: 9.5;epididymis: 30.3;rectum: 9.7	salivary gland: 8.2	Not detected		
SPANXN5	CT11.10, SPANX-N5	ENSG00000204363	SPANX family member N5	X	52796144-52798101	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	106	testis: 11.5	placenta: 0.1	Not detected		
ZBTB12	C6orf46, D6S59E, G10, NG35	ENSG00000204366	Zinc finger and BTB domain containing 12	6	31899607-31901992	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047161	Approved				Renal cancer:1.52e-4 (unfavourable)	Expressed in all	Mixed			endometrium: 1.7	Mixed		
SDHD	cybS, PGL, PGL1	ENSG00000204370	Succinate dehydrogenase complex subunit D	11	112086773-112120013	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045727	Approved				Renal cancer:1.99e-10 (favourable)	Expressed in all	Expressed in all			kidney: 305.5	Expressed in all		
EHMT2	BAT8, C6orf30, Em:AF134726.3, G9A, KMT1C, NG36/G9a	ENSG00000204371	Euchromatic histone lysine methyltransferase 2	6	31879759-31897687	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA050550, HPA060259	Supported		Supported	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.79e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.7	Cell line enhanced		NTERA-2: 19.2
XAGE1A	CT12.1a, GAGED2, XAGE-1, XAGE1	ENSG00000204379	X antigen family member 1A	X	52495676-52500812	Predicted intracellular proteins	Evidence at protein level	HPA077164			Uncertain	Nuclear speckles		Not detected	Tissue enriched	186	testis: 65.7	adipose tissue,cervix, uterine,liver,lymph node: 0.3	Cell line enhanced		HMC-1: 491.2;NB-4: 361.0;THP-1: 391.2;U-2 OS: 422.6;U-266/84: 543.0;U-937: 364.8
LAYN	FLJ30977, FLJ31092	ENSG00000204381	Layilin	11	111540280-111561745	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040087	Approved		Approved	Cytosol		Expressed in all	Mixed			ovary: 49.6	Cell line enhanced		BJ: 126.5;BJ hTERT+: 131.6;BJ hTERT+ SV40 Large T+ RasG12V: 98.0;U-138 MG: 107.5
XAGE1B	CT12.1b	ENSG00000204382	X antigen family member 1B	X	52512077-52520803	Predicted intracellular proteins	Evidence at protein level	HPA077164			Uncertain	Nuclear speckles		Not detected	Tissue enriched	42	testis: 70.1	lung: 1.6	Cell line enhanced		HMC-1: 528.0;NB-4: 387.4;THP-1: 397.2;U-2 OS: 451.2;U-266/84: 561.1;U-937: 379.7
SLC44A4	C6orf29, CTL4, FLJ14491, NG22, TPPT	ENSG00000204385	Solute carrier family 44 member 4	6	31863192-31879046	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA046977, HPA054176	Enhanced				Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 35.1	colon: 28.7	Cell line enhanced		Hep G2: 1.0
NEU1	NEU	ENSG00000204386	Neuraminidase 1	6	31857659-31862906	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA015634, HPA021506	Approved		Supported	Vesicles<br>Cell Junctions		Expressed in all	Mixed			thyroid gland: 14.3	Expressed in all		
C6orf48	D6S57, G8	ENSG00000204387	Chromosome 6 open reading frame 48	6	31834608-31839766	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			ovary: 110.8	Expressed in all		
HSPA1B	HSP70-2	ENSG00000204388	Heat shock protein family A (Hsp70) member 1B	6	31827735-31830255	Predicted intracellular proteins	Evidence at protein level	CAB008640, HPA052504	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Tissue enhanced		adrenal gland: 34.3	parathyroid gland: 14.6	Cell line enhanced		A549: 74.8;Karpas-707: 175.2;U-266/70: 30.2
HSPA1A	HSP70-1, HSPA1	ENSG00000204389	Heat shock protein family A (Hsp70) member 1A	6	31815464-31817946	Predicted intracellular proteins	Evidence at protein level	CAB017451, CAB032815, HPA052504	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:1.54e-5 (unfavourable)	Expressed in all	Mixed			adrenal gland: 49.9	Cell line enriched	10	HEK 293: 3834.6
HSPA1L	HSP70-HOM, hum70t	ENSG00000204390	Heat shock protein family A (Hsp70) member 1 like	6	31809619-31815065	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043285, HPA052504	Enhanced		Approved	Nucleoplasm<br>Vesicles	Ovarian cancer:1.02e-4 (favourable), Renal cancer:4.63e-4 (favourable)	Expressed in all	Tissue enriched	8	testis: 9.8	epididymis: 1.2	Cell line enhanced		HEK 293: 2.3
LSM2	C6orf28, G7b, YBL026W	ENSG00000204392	LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated	6	31797396-31806984	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA066718	Supported		Supported	Nucleus	Renal cancer:5.59e-9 (unfavourable)	Expressed in all	Mixed			fallopian tube: 7.1	Expressed in all		
VARS	VARS2	ENSG00000204394	Valyl-tRNA synthetase	6	31777518-31795953	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA046710	Approved		Enhanced	Cytosol	Liver cancer:1.86e-4 (unfavourable), Lung cancer:6.90e-4 (unfavourable), Cervical cancer:7.25e-4 (unfavourable)	Expressed in all	Mixed			testis: 5.5	Mixed		
VWA7	C6orf27, G7c, NG37	ENSG00000204396	Von Willebrand factor A domain containing 7	6	31765590-31777294	Predicted secreted proteins	Evidence at transcript level	HPA046954, HPA054262	Approved		Approved	Plasma membrane<br>Cytosol	Renal cancer:4.35e-8 (favourable)	Mixed	Tissue enhanced		fallopian tube: 9.1	parathyroid gland: 1.9	Cell line enhanced		U-266/70: 1.0
CARD16	COP, COP1, PSEUDO-ICE	ENSG00000204397	Caspase recruitment domain family member 16	11	105041326-105101431	Predicted intracellular proteins	Evidence at protein level	HPA053981, HPA062805	Uncertain		Uncertain	Mitochondria	Renal cancer:6.93e-7 (unfavourable)	Expressed in all	Expressed in all			spleen: 159.0	Cell line enhanced		AN3-CA: 139.1;HHSteC: 214.1;HUVEC TERT2: 101.4;TIME: 91.2
MBD5	FLJ11113, KIAA1461	ENSG00000204406	Methyl-CpG binding domain protein 5	2	148021011-148516971	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035964			Supported	Nucleus<br>Midbody	Endometrial cancer:3.72e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.3	Mixed		
MSH5	G7	ENSG00000204410	MutS homolog 5	6	31739948-31762834	Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA062688			Approved	Endoplasmic reticulum<br>Vesicles		Mixed	Mixed			skin: 1.7	Mixed		
CSHL1	CS-5, CSHP1, CSL, hCS-L, MGC149868	ENSG00000204414	Chorionic somatomammotropin hormone like 1	17	63909597-63918838	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025646, HPA043715	Enhanced					Not detected	Tissue enriched	352	placenta: 216.7	smooth muscle: 0.6	Not detected		
MPIG6B	C6orf25, G6b, G6b-B, NG31	ENSG00000204420	Megakaryocyte and platelet inhibitory receptor G6b	6	31718594-31726714	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA073017			Uncertain	Golgi apparatus		Mixed	Not detected			skin: 0.8	Cell line enriched	16	HEL: 5.4
LY6G6C	C6orf24, G6c, NG24	ENSG00000204421	Lymphocyte antigen 6 family member G6C	6	31718648-31721845	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	8	skin: 64.3	esophagus: 7.5	Not detected		
XXbac-BPG32J3.20		ENSG00000204422		6	31686962-31714072	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			thyroid gland: 0.9	Cell line enriched	29	HEL: 4.7
LY6G6F	C6orf21, G6f, LY6G6D, NG32	ENSG00000204424	Lymphocyte antigen 6 family member G6F	6	31706885-31710595	Predicted membrane proteins	Evidence at protein level	HPA008053	Uncertain					Not detected	Not detected			bone marrow: 0.4	Cell line enriched	79	HEL: 7.9
ABHD16A	BAT5, D6S82E, NG26	ENSG00000204427	Abhydrolase domain containing 16A	6	31686949-31703444	Predicted membrane proteins	Evidence at protein level	HPA058606	Approved				Endometrial cancer:2.63e-4 (unfavourable)	Expressed in all	Tissue enhanced		gallbladder: 1.7;testis: 1.2;thyroid gland: 1.4	esophagus: 0.9	Not detected		
LY6G5C	C6orf20, G5c, NG33	ENSG00000204428	Lymphocyte antigen 6 family member G5C	6	31676684-31684040	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038690	Approved		Approved	Nucleoplasm<br>Cytosol	Endometrial cancer:1.07e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 1.5	testis: 0.9	Not detected		
CSNK2B		ENSG00000204435	Casein kinase 2 beta	6	31665236-31670343	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004349, HPA005944, CAB013087, CAB016059	Approved				Renal cancer:1.06e-5 (unfavourable)	Expressed in all	Mixed			epididymis: 55.3	Mixed		
GPANK1	ANKRD59, BAT4, D6S54E, G5, GPATCH10	ENSG00000204438	G-patch domain and ankyrin repeats 1	6	31661229-31666283	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006301	Approved		Approved	Endoplasmic reticulum	Pancreatic cancer:5.89e-4 (favourable)	Expressed in all	Mixed			testis: 9.7	Mixed		
C6orf47	D6S53E, G4	ENSG00000204439	Chromosome 6 open reading frame 47	6	31658298-31660772	Predicted membrane proteins	Evidence at protein level	HPA045281, HPA053373	Uncertain		Approved	Cytosol		Expressed in all	Mixed			skin: 5.4	Cell line enhanced		HBEC3-KT: 5.6;HEK 293: 5.9;RT4: 5.8;U-2 OS: 5.7
FAM155A		ENSG00000204442	Family with sequence similarity 155 member A	13	107163510-107866735	Predicted membrane proteins	Evidence at protein level	HPA039453, HPA058768	Enhanced		Approved	Nucleus<br>Vesicles<br>Centrosome		Mixed	Tissue enriched	6	cerebral cortex: 15.6	seminal vesicle: 2.4	Cell line enhanced		RPTEC TERT1: 9.3;SCLC-21H: 8.9;SH-SY5Y: 18.1;U-87 MG: 10.5
APOM	ApoM, G3a, NG20	ENSG00000204444	Apolipoprotein M	6	31652416-31658210	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB034086, HPA051006	Approved		Approved	Golgi apparatus		Tissue enriched	Mixed			testis: 5.6	Mixed		
TRIM49C	TRIM49L2	ENSG00000204449	Tripartite motif containing 49C	11	90031106-90042025	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
TRIM64	C11orf28, TRIM64A	ENSG00000204450	Tripartite motif containing 64	11	89968502-89975228	Predicted intracellular proteins	Evidence at transcript level	HPA045370	Approved					Not detected	Tissue enriched	11	placenta: 1.1	all non-specific tissues: 0.0	Not detected		
BAG6	BAT3, D6S52E, G3	ENSG00000204463	BCL2 associated athanogene 6	6	31639028-31652705	Predicted intracellular proteins	Evidence at protein level	CAB020704, HPA045116, HPA053291	Enhanced		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 135.9	Expressed in all		
PRRC2A	BAT2, D6S51E, G2	ENSG00000204469	Proline rich coiled-coil 2A	6	31620720-31637771	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB026383, HPA046791, HPA066501	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			testis: 20.7	Cell line enhanced		HBEC3-KT: 58.8;HEK 293: 135.9;U-266/70: 57.4;U-266/84: 59.9;U-698: 54.2
AIF1	AIF-1, Em:AF129756.17, IBA1, IRT-1	ENSG00000204472	Allograft inflammatory factor 1	6	31615184-31617021	Predicted intracellular proteins	Evidence at protein level	HPA049234, HPA062949	Enhanced		Approved	Cytosol	Renal cancer:2.30e-5 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 78.3	appendix: 50.3	Cell line enhanced		HEL: 79.8;HMC-1: 107.9;NB-4: 129.5;THP-1: 46.4
NCR3	1C7, CD337, LY117, NKp30	ENSG00000204475	Natural cytotoxicity triggering receptor 3	6	31588895-31592985	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 1.7;spleen: 1.5;tonsil: 1.1	appendix: 1.0	Cell line enhanced		NB-4: 2.6
PRAMEF20	OTTHUMT00000008157, PRAMEF21	ENSG00000204478	PRAME family member 20	1	13410450-13421328	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
PRAMEF17		ENSG00000204479	PRAME family member 17	1	13389632-13392629	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF19		ENSG00000204480	PRAME family member 19	1	13369067-13371693	Predicted intracellular proteins	No evidence	HPA057423	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF14		ENSG00000204481	PRAME family member 14	1	13342034-13347134	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LST1	B144, D6S49E, LST-1	ENSG00000204482	Leukocyte specific transcript 1	6	31586124-31588909	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.97e-5 (unfavourable), Testis cancer:7.62e-4 (unfavourable), Cervical cancer:7.89e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 68.7;spleen: 48.9	appendix: 32.1	Cell line enhanced		HMC-1: 64.7;NB-4: 50.8;THP-1: 128.8;U-937: 79.6
NFKBIL1	IKBL, NFKBIL	ENSG00000204498	NFKB inhibitor like 1	6	31546870-31558829	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Endometrial cancer:3.38e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 4.2	Cell line enhanced		HEK 293: 22.4;U-266/70: 8.2;U-266/84: 6.7
PRAMEF15		ENSG00000204501	PRAME family member 15	1	13315581-13322598	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF9		ENSG00000204505	PRAME family member 9	1	13172455-13179464	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF7		ENSG00000204510	PRAME family member 7	1	12916610-12920482	Predicted intracellular proteins	Evidence at transcript level	HPA049887, HPA051704	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MCCD1		ENSG00000204511	Mitochondrial coiled-coil domain 1	6	31528717-31530232	Predicted secreted proteins	Evidence at transcript level	HPA046948	Uncertain				Renal cancer:1.73e-4 (favourable)	Tissue enhanced	Tissue enriched	36	kidney: 3.5	all non-specific tissues: 0.0	Not detected		
ZNF814		ENSG00000204514	Zinc finger protein 814	19	57848731-57889074	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043800, HPA053762, HPA072145	Approved		Uncertain	Nucleus		Mixed	Mixed			thyroid gland: 18.2	Cell line enhanced		NTERA-2: 34.7
MICB	PERB11.2	ENSG00000204516	MHC class I polypeptide-related sequence B	6	31494881-31511124	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA064618			Approved	Golgi apparatus<br>Vesicles	Renal cancer:4.94e-9 (unfavourable), Liver cancer:7.04e-5 (unfavourable)	Mixed	Tissue enhanced		lymph node: 3.2	spleen: 2.8	Cell line enhanced		U-266/84: 26.2
AADACL4		ENSG00000204518	Arylacetamide deacetylase like 4	1	12644547-12667086	Predicted membrane proteins	Evidence at protein level	HPA043588	Uncertain					Not detected	Not detected			epididymis: 0.7	Not detected		
ZNF551	DKFZp686H1038	ENSG00000204519	Zinc finger protein 551	19	57681969-57717301	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038187			Approved	Nucleoplasm<br>Nuclear speckles	Melanoma:7.68e-5 (unfavourable), Renal cancer:1.32e-4 (favourable)	Expressed in all	Mixed			testis: 8.0	Mixed		
MICA	PERB11.1	ENSG00000204520	MHC class I polypeptide-related sequence A	6	31399784-31415315	Predicted membrane proteins	Evidence at protein level						Cervical cancer:5.88e-4 (unfavourable)	Expressed in all	Mixed			lung: 11.2	Cell line enhanced		A-431: 36.1;HAP1: 29.8;HSkMC: 44.2;RPTEC TERT1: 30.9
ZNF805		ENSG00000204524	Zinc finger protein 805	19	57240685-57255135	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA057665, HPA058895	Uncertain					Mixed	Mixed			parathyroid gland: 5.1	Mixed		
HLA-C	D6S204, HLA-JY3, PSORS1	ENSG00000204525	Major histocompatibility complex, class I, C	6	31268749-31272130	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		lung: 744.7	small intestine: 396.9	Cell line enhanced		A-431: 660.6;EFO-21: 748.1;RPTEC TERT1: 346.0;U-266/70: 367.3;U-266/84: 281.2
POU5F1	MGC22487, OCT3, Oct4, OTF3	ENSG00000204531	POU class 5 homeobox 1	6	31164337-31180731	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025600, CAB026380, HPA058267	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:2.04e-5 (favourable)	Tissue enriched	Mixed			fallopian tube: 6.4	Group enriched	12	HAP1: 366.6;NTERA-2: 938.2
ZSCAN5C	ZNF495C, ZSCAN5CP	ENSG00000204532	Zinc finger and SCAN domain containing 5C	19	56202301-56209452	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041263, HPA043123, HPA046836, HPA060667	Uncertain		Uncertain	Nuclear speckles		Not detected	Not detected			testis: 0.1	Not detected		
CCHCR1	C6orf18, HCR	ENSG00000204536	Coiled-coil alpha-helical rod protein 1	6	31142439-31158238	Predicted intracellular proteins	Evidence at protein level	HPA054167			Supported	Cytosol		Expressed in all	Tissue enriched	6	testis: 86.6	fallopian tube: 13.8	Mixed		
PSORS1C2	C6orf17, SPR1	ENSG00000204538	Psoriasis susceptibility 1 candidate 2	6	31137536-31139350	Predicted secreted proteins	Evidence at protein level	HPA061228	Enhanced					Tissue enhanced	Tissue enriched	65	skin: 24.0	testis: 0.3	Not detected		
CDSN	D6S586E	ENSG00000204539	Corneodesmosin	6	31115090-31120446	Predicted secreted proteins	Evidence at protein level	HPA044730, HPA054184	Enhanced					Group enriched	Tissue enriched	20	skin: 77.0	epididymis: 3.7	Cell line enriched	7	A-431: 1.4
PSORS1C1	C6orf16, SEEK1	ENSG00000204540	Psoriasis susceptibility 1 candidate 1	6	31114750-31140092	Predicted intracellular proteins	Evidence at transcript level	HPA045049			Uncertain	Nucleus		Mixed	Tissue enriched	9	testis: 27.3	epididymis: 3.0	Cell line enhanced		hTCEpi: 1.1
C6orf15	STG	ENSG00000204542	Chromosome 6 open reading frame 15	6	31111223-31112559	Predicted secreted proteins	Evidence at transcript level	HPA001436	Uncertain					Mixed	Tissue enhanced		cervix, uterine: 2.0	tonsil: 0.8	Group enriched	12	RH-30: 3.1;U-2 OS: 1.4
MUC21	bCX31G15.2, C6orf205	ENSG00000204544	Mucin 21, cell surface associated	6	30983718-30989903	Predicted membrane proteins	Evidence at protein level	HPA052028	Enhanced					Group enriched	Tissue enriched	49	esophagus: 596.4	tonsil: 12.2	Not detected		
DEFB121	DEFB-21	ENSG00000204548	Defensin beta 121	20	31404845-31412838	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	6458	epididymis: 2005.4	testis: 0.3	Cell line enriched	19	NB-4: 1.8
DHX16	DBP2, DDX16, Prp2, PRPF2	ENSG00000204560	DEAH-box helicase 16	6	30653119-30673037	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051455	Enhanced		Supported	Nucleoplasm		Expressed in all	Mixed			testis: 11.5	Expressed in all		
C6orf136	Em:AB023049.8	ENSG00000204564	Chromosome 6 open reading frame 136	6	30647039-30653210	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046804	Uncertain				Renal cancer:9.16e-8 (favourable), Urothelial cancer:7.51e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 8.0	Mixed		
MRPS18B	C6orf14, HSPC183, MRPS18-2, PTD017	ENSG00000204568	Mitochondrial ribosomal protein S18B	6	30617709-30626395	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043485, HPA050334	Supported		Supported	Cell Junctions<br>Mitochondria	Renal cancer:3.99e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 13.3	Expressed in all		
PPP1R10	CAT53, FB19, p99, PNUTS	ENSG00000204569	Protein phosphatase 1 regulatory subunit 10	6	30600400-30618612	Predicted intracellular proteins	Evidence at protein level	CAB025501, HPA047248, HPA056756	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Pancreatic cancer:9.74e-5 (favourable), Cervical cancer:4.84e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 10.5	Expressed in all		
KRTAP5-11	KRTAP5-6, KRTAP5.11	ENSG00000204571	Keratin associated protein 5-11	11	71579714-71603353	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			duodenum: 0.1	Not detected		
KRTAP5-10	KRTAP5.10	ENSG00000204572	Keratin associated protein 5-10	11	71565563-71566738	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 1.7	fallopian tube,seminal vesicle,testis: 0.4	Cell line enriched	9	RT4: 2.8
ABCF1	ABC50, EST123147	ENSG00000204574	ATP binding cassette subfamily F member 1	6	30571376-30597179	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA017578	Approved		Enhanced	Cytosol	Liver cancer:9.47e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.3	Expressed in all		
PRR3	CAT56, Em:AB014077.1, Em:AB023052.2	ENSG00000204576	Proline rich 3	6	30556886-30563723	Predicted intracellular proteins	Evidence at protein level	HPA064061			Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.84e-7 (unfavourable), Ovarian cancer:6.49e-6 (favourable), Pancreatic cancer:5.61e-5 (favourable)	Expressed in all	Mixed			epididymis: 1.6	Cell line enhanced		AN3-CA: 9.7;HAP1: 13.6
LILRB3	CD85a, HL9, ILT5, LIR-3, LIR3, PIR-B, PIRB	ENSG00000204577	Leukocyte immunoglobulin like receptor B3	19	54216278-54223506	CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Group enriched	5	adipose tissue: 5.4;appendix: 11.3;bone marrow: 9.9;lung: 9.2;spleen: 11.1;urinary bladder: 6.8	placenta: 1.7	Not detected		
DDR1	CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6	ENSG00000204580	Discoidin domain receptor tyrosine kinase 1	6	30876421-30900156	CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010162, CAB025656, HPA057194	Approved		Approved	Nucleoplasm<br>Cell Junctions	Renal cancer:3.31e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 51.6	Cell line enhanced		HaCaT: 80.3;RT4: 74.6;T-47d: 96.8
LRCOL1		ENSG00000204583	Leucine rich colipase like 1	12	132603150-132610543	Predicted secreted proteins	Evidence at transcript level						Liver cancer:7.04e-4 (favourable)	Tissue enhanced	Tissue enriched	62	epididymis: 54.5	lung: 0.8	Not detected		
GNL1	HSR1	ENSG00000204590	G protein nucleolar 1 (putative)	6	30541377-30557174	Predicted intracellular proteins	Evidence at protein level	CAB033575, HPA043338, HPA050455	Uncertain		Supported	Vesicles		Expressed in all	Mixed			parathyroid gland: 18.8	Mixed		
HLA-E		ENSG00000204592	Major histocompatibility complex, class I, E	6	30489467-30494205	Predicted membrane proteins	Evidence at protein level	CAB024589, HPA031454	Enhanced		Approved	Vesicles	Renal cancer:3.86e-4 (unfavourable)	Expressed in all	Mixed			skin: 153.4	Cell line enhanced		U-266/70: 73.1
DPRX		ENSG00000204595	Divergent-paired related homeobox	19	53632056-53637009	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043682	Uncertain					Tissue enriched	Tissue enhanced		placenta: 1.8	epididymis,testis: 0.5	Not detected		
TRIM39	RNF23	ENSG00000204599	Tripartite motif containing 39	6	30326479-30343729	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051120, HPA059496	Uncertain		Supported	Cytosol	Pancreatic cancer:2.50e-4 (favourable)	Expressed in all	Mixed			testis: 4.1	Mixed		
ZNF468		ENSG00000204604	Zinc finger protein 468	19	52838008-52857649	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.94e-7 (favourable), Breast cancer:6.87e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 20.4	Mixed		
TRIM15	RNF93, ZNF178, ZNFB7	ENSG00000204610	Tripartite motif containing 15	6	30163206-30172696	Predicted intracellular proteins	Evidence at protein level	HPA047527	Uncertain					Tissue enhanced	Tissue enhanced		colon: 2.6;duodenum: 3.6	appendix,small intestine: 1.1	Cell line enriched	24	HEL: 15.2
ZNF616	MGC45556	ENSG00000204611	Zinc finger protein 616	19	52113091-52139922	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062639, HPA071539	Approved		Approved	Centrosome		Expressed in all	Expressed in all			adrenal gland: 17.2	Mixed		
FOXB2	bA159H20.4	ENSG00000204612	Forkhead box B2	9	77019655-77020953	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA067947	Uncertain					Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	10	NTERA-2: 1.3
TRIM10	HERF1, RFB30, RNF9	ENSG00000204613	Tripartite motif containing 10	6	30151945-30160934	Predicted intracellular proteins	Evidence at protein level	HPA043325	Uncertain					Mixed	Not detected			kidney: 0.4	Not detected		
TRIM40	RNF35	ENSG00000204614	Tripartite motif containing 40	6	30136108-30148735	Predicted intracellular proteins	Evidence at protein level	HPA043818	Uncertain					Tissue enhanced	Not detected			colon: 0.4	Cell line enriched	11	HEL: 1.0
TRIM31	C6orf13, HCG1, HCGI, RNF	ENSG00000204616	Tripartite motif containing 31	6	30102897-30113106	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA046400	Uncertain					Group enriched	Group enriched	6	colon: 10.0;small intestine: 2.3;stomach: 2.1;urinary bladder: 2.7	duodenum: 0.7	Cell line enriched	527	RT4: 232.7
RNF39	HZFw1, LIRF	ENSG00000204618	Ring finger protein 39	6	30070266-30075887	Predicted intracellular proteins	Evidence at protein level	CAB019278, HPA047115	Uncertain		Uncertain	Vesicles<br>Plasma membrane<br>Centrosome		Mixed	Tissue enhanced		skin: 3.5	breast: 2.0	Cell line enhanced		A-431: 1.1;U-266/84: 2.5
PPP1R11	CFAP255, HCG-V, HCGV, TCTE5, Tctex5	ENSG00000204619	Protein phosphatase 1 regulatory inhibitor subunit 11	6	30066709-30070333	Predicted intracellular proteins	Evidence at protein level	HPA043266, HPA060174	Approved		Approved	Vesicles		Expressed in all	Tissue enhanced		epididymis: 38.2	fallopian tube: 17.0	Cell line enhanced		A-431: 42.0;AN3-CA: 57.2;HEL: 34.3;RPTEC TERT1: 32.3;U-266/84: 30.5
DISP3	KIAA1337, PTCHD2	ENSG00000204624	Dispatched RND transporter family member 3	1	11479166-11537584	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA054579	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Tissue enhanced	Group enriched	14	cerebral cortex: 8.6;testis: 4.3	adrenal gland,prostate: 0.4	Cell line enhanced		AF22: 4.8;NTERA-2: 2.1;SCLC-21H: 2.3;SH-SY5Y: 7.2
RACK1	Gnb2-rs1, GNB2L1, H12.3	ENSG00000204628	Receptor for activated C kinase 1	5	181236909-181248096	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB004288, HPA021676	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.98e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 2103.5	Expressed in all		
HLA-G		ENSG00000204632	Major histocompatibility complex, class I, G	6	29826967-29831125	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	CAB016158	Enhanced				Melanoma:3.91e-5 (favourable)	Expressed in all	Tissue enriched	23	placenta: 14.9	duodenum,testis: 0.6	Not detected		
TBC1D8	AD3, GRAMD8, HBLP1, VRP	ENSG00000204634	TBC1 domain family member 8	2	101007617-101252866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015211, HPA037496	Uncertain		Supported	Nucleus	Colorectal cancer:6.73e-4 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 45.1	Cell line enhanced		ASC diff: 59.6
NMS		ENSG00000204640	Neuromedin S	2	100470482-100483280	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Group enriched	7	HL-60: 6.6;HMC-1: 4.2
HLA-F		ENSG00000204642	Major histocompatibility complex, class I, F	6	29722775-29738528	Plasma proteins, Predicted membrane proteins	Evidence at protein level						Renal cancer:2.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 41.2	stomach: 28.7	Group enriched	7	A-431: 31.2;HEK 293: 11.2;HEL: 7.8;HHSteC: 8.5;U-266/70: 6.4;U-937: 10.5
ZFP57	bA145L22, bA145L22.2, C6orf40, ZNF698	ENSG00000204644	ZFP57 zinc finger protein	6	29672392-29681110	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047172	Uncertain				Pancreatic cancer:1.95e-4 (favourable)	Tissue enriched	Not detected			cerebral cortex,heart muscle: 0.4	Cell line enriched	25	BEWO: 6.2
ASPDH		ENSG00000204653	Aspartate dehydrogenase domain containing	19	50511600-50514690	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042631, HPA042654	Approved					Tissue enriched	Tissue enhanced		cerebral cortex: 17.9;kidney: 27.9;liver: 34.6	duodenum: 6.9	Cell line enhanced		HEK 293: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
MOG	BTN6, BTNL11	ENSG00000204655	Myelin oligodendrocyte glycoprotein	6	29656981-29672372	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA021873	Enhanced					Tissue enriched	Not detected			cerebral cortex: 0.8	Not detected		
OR2H2	hs6M1-12	ENSG00000204657	Olfactory receptor family 2 subfamily H member 2	6	29587455-29589038	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CBY3		ENSG00000204659	Chibby family member 3	5	179678583-179680974	Predicted intracellular proteins	Evidence at transcript level	HPA069037	Uncertain					Mixed	Tissue enriched	5	testis: 2.1	cerebral cortex,skin: 0.4	Cell line enhanced		HDLM-2: 1.6
C9orf57		ENSG00000204669	Chromosome 9 open reading frame 57	9	72051376-72072721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	224	testis: 26.0	parathyroid gland: 0.1	Not detected		
IL31	IL-31	ENSG00000204671	Interleukin 31	12	122172030-122174199	Predicted secreted proteins	Evidence at transcript level	CAB025657	Approved					Not detected	Not detected			testis: 0.2	Not detected		
AKT1S1	Lobe, MGC2865, PRAS40	ENSG00000204673	AKT1 substrate 1	19	49869033-49878459	Predicted intracellular proteins	Evidence at protein level	CAB021903, HPA043590, HPA064427	Uncertain		Supported	Cytosol	Renal cancer:7.34e-6 (unfavourable), Liver cancer:3.70e-4 (unfavourable), Pancreatic cancer:6.60e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 33.9	Expressed in all		
FAM153C	NY-REN-7-like	ENSG00000204677	Family with sequence similarity 153 member C	5	178006405-178055559	Predicted intracellular proteins	Evidence at protein level	HPA042585, HPA046691, HPA052337	Uncertain					Tissue enhanced	Tissue enriched	5	testis: 42.0	cerebral cortex: 8.1	Cell line enhanced		U-2 OS: 1.2
GABBR1	GPRC3A, hGB1a	ENSG00000204681	Gamma-aminobutyric acid type B receptor subunit 1	6	29555629-29633976	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA050483, HPA058459	Uncertain		Approved	Centrosome	Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 20.8	spleen: 13.1	Cell line enhanced		U-2 OS: 6.7
CASC10	bA418C1.3, C10orf114	ENSG00000204682	Cancer susceptibility 10	10	21492658-21497262	Predicted intracellular proteins	Evidence at transcript level	HPA064131	Uncertain		Approved	Nucleoplasm	Glioma:5.81e-4 (unfavourable), Urothelial cancer:5.86e-4 (unfavourable)	Mixed	Mixed			placenta: 4.0	Cell line enhanced		AF22: 11.6;AN3-CA: 15.3;BEWO: 15.2
C10orf113	bA165O3.1	ENSG00000204683	Chromosome 10 open reading frame 113	10	21125763-21146559	Predicted intracellular proteins	Evidence at transcript level	HPA037013	Uncertain					Not detected	Tissue enriched	13	testis: 1.7	gallbladder,salivary gland: 0.1	Not detected		
MAS1L	dJ994E9.2, MAS-L, MRG	ENSG00000204687	MAS1 proto-oncogene like, G protein-coupled receptor	6	29486697-29487956	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA017983	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cervix, uterine: 5.1	epididymis: 2.3	Not detected		
OR2H1	OR2H6, OR2H8, OR6-2	ENSG00000204688	Olfactory receptor family 2 subfamily H member 1	6	29457181-29464328	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Not detected		
OR11A1	hs6M1-18, OR11A2	ENSG00000204694	Olfactory receptor family 11 subfamily A member 1	6	29425504-29457071	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR14J1	hs6M1-28, OR5U1	ENSG00000204695	Olfactory receptor family 14 subfamily J member 1	6	29306690-29307655	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045575	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2J2	dJ80I19.4, hs6M1-6, OR6-8	ENSG00000204700	Olfactory receptor family 2 subfamily J member 2	6	29173303-29174574	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2J3	OR6-6	ENSG00000204701	Olfactory receptor family 2 subfamily J member 3	6	29111891-29112826	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
OR2B3	OR2B3P, OR6-4	ENSG00000204703	Olfactory receptor family 2 subfamily B member 3	6	29086208-29087313	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2W1	hs6M1-15	ENSG00000204704	Olfactory receptor family 2 subfamily W member 1	6	29044213-29045240	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPDYC	Ringo2	ENSG00000204710	Speedy/RINGO cell cycle regulator family member C	11	65170154-65173244	Predicted intracellular proteins	Evidence at protein level	HPA039891	Uncertain				Breast cancer:1.20e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		liver: 1.4;testis: 1.5	epididymis: 0.4	Cell line enhanced		BEWO: 6.0;HEL: 6.3;K-562: 15.4
C9orf135		ENSG00000204711	Chromosome 9 open reading frame 135	9	69820793-69906232	Predicted intracellular proteins	Evidence at protein level	HPA021261, HPA021325	Uncertain					Tissue enriched	Group enriched	8	fallopian tube: 55.2;testis: 24.3	parathyroid gland: 5.1	Group enriched	9	HAP1: 11.5;NTERA-2: 29.5
TRIM27	RFP, RNF76	ENSG00000204713	Tripartite motif containing 27	6	28903002-28923989	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048684, HPA053408	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			appendix: 5.6	Mixed		
MALRD1	bA265G8.2, C10orf112, Diet1	ENSG00000204740	MAM and LDL receptor class A domain containing 1	10	19048771-19790401	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035732, HPA038106, HPA046848	Uncertain		Enhanced	Golgi apparatus		Tissue enhanced	Group enriched	8	duodenum: 30.8;small intestine: 34.4	testis: 3.9	Cell line enriched	9	Karpas-707: 31.8
RANBP17		ENSG00000204764	RAN binding protein 17	5	170861870-171300015	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029568, HPA029569	Uncertain		Approved	Nuclear membrane<br>Nuclear bodies<br>Cytosol		Mixed	Mixed			testis: 2.2	Mixed		
FAM196B	C5orf57	ENSG00000204767	Family with sequence similarity 196 member B	5	169864264-169980740	Predicted intracellular proteins	Evidence at transcript level	HPA047227	Uncertain					Mixed	Tissue enhanced		breast: 7.6;cerebral cortex: 7.0	ovary: 2.1	Cell line enhanced		fHDF/TERT166: 30.1;HUVEC TERT2: 20.4;U-138 MG: 61.2
FOXD4L5	bA15J10.2	ENSG00000204779	Forkhead box D4-like 5	9	65282101-65285209	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.6	Mixed		
TTC25	DKFZP434H0115	ENSG00000204815	Tetratricopeptide repeat domain 25	17	41930635-41965651	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023908	Enhanced					Mixed	Group enriched	8	fallopian tube: 47.3;testis: 70.5	parathyroid gland: 7.4	Cell line enhanced		SCLC-21H: 4.9;U-87 MG: 4.8
MRPL53		ENSG00000204822	Mitochondrial ribosomal protein L53	2	74471958-74473322	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA056185	Uncertain		Approved	Nucleoli	Renal cancer:1.16e-8 (unfavourable), Liver cancer:7.36e-5 (unfavourable), Pancreatic cancer:1.37e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 24.6	Expressed in all		
MROH6	C8orf73	ENSG00000204839	Maestro heat like repeat family member 6	8	143566187-143572971	Predicted intracellular proteins	Evidence at protein level	HPA068049	Uncertain		Approved	Nucleus		Expressed in all	Mixed			bone marrow: 4.0	Cell line enhanced		A-431: 14.0;HaCaT: 11.7;SK-BR-3: 20.9;U-937: 12.8
ATXN2	ATX2, SCA2, TNRC13	ENSG00000204842	Ataxin 2	12	111452214-111599676	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018295, HPA020339, HPA021146	Enhanced		Enhanced	Cytosol	Liver cancer:2.66e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.2	Expressed in all		
DCTN1		ENSG00000204843	Dynactin subunit 1	2	74361154-74392087	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009108, HPA034635	Approved		Supported	Intermediate filaments<br>Centrosome<br>Cytosol	Renal cancer:2.34e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 209.3	Expressed in all		
SPATA31A1	C9orf36, C9orf36A, DKFZP434B204, FAM75A1, FAM75A2, SPATA31A2	ENSG00000204849	SPATA31 subfamily A member 1	9	39355669-39361959	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	81	testis: 8.0	all non-specific tissues: 0.0	Not detected		
PNMAL2	KIAA1183	ENSG00000204851	Paraneoplastic Ma antigen family like 2	19	46486906-46496498	Predicted intracellular proteins	Evidence at protein level	HPA054810	Enhanced					Mixed	Group enriched	5	adrenal gland: 12.1;cerebral cortex: 32.9	ovary: 4.3	Cell line enhanced		AF22: 1.2;AN3-CA: 1.4;SH-SY5Y: 1.3
TCTN1	FLJ21127, JBTS13, TECT1	ENSG00000204852	Tectonic family member 1	12	110614027-110649430	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA039687, HPA040036	Approved		Approved	Nucleoplasm<br>Actin filaments	Endometrial cancer:1.13e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 42.2	Mixed		
FAM216A	C12orf24, HSU79274	ENSG00000204856	Family with sequence similarity 216 member A	12	110468364-110490385	Predicted intracellular proteins	Evidence at protein level	HPA038286	Enhanced		Approved	Actin filaments	Renal cancer:4.18e-10 (unfavourable), Liver cancer:4.49e-5 (unfavourable)	Expressed in all	Group enriched	7	cerebral cortex: 16.2;testis: 61.1	appendix: 5.5	Mixed		
ZBTB48	HKR3, ZNF855	ENSG00000204859	Zinc finger and BTB domain containing 48	1	6580001-6589280	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030417	Uncertain		Approved	Nucleoplasm<br>Cytosol	Pancreatic cancer:5.19e-6 (favourable), Cervical cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 32.9	Expressed in all		
IGFL2	UNQ645	ENSG00000204866	IGF like family member 2	19	46143106-46161299	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA059137	Uncertain		Approved	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enriched	6	skin: 35.5	parathyroid gland: 6.1	Cell line enriched	33	CACO-2: 68.3
IGFL4		ENSG00000204869	IGF like family member 4	19	46039748-46077118	Predicted intracellular proteins	Evidence at transcript level	HPA047655	Approved		Approved	Cytosol		Mixed	Tissue enhanced		skin: 8.2	cerebral cortex: 2.6	Cell line enhanced		A549: 3.5;HaCaT: 3.0
KRTAP9-3	KAP9.3	ENSG00000204873	Keratin associated protein 9-3	17	41232463-41233454	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-8	KAP4.8	ENSG00000204880	Keratin associated protein 4-8	17	41096981-41098141	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPR20		ENSG00000204882	G protein-coupled receptor 20	8	141356500-141367267	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			smooth muscle: 1.2	Cell line enhanced		EFO-21: 2.1
KRTAP1-4	KAP1.4	ENSG00000204887	Keratin associated protein 1-4	17	41029697-41030104	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.1	Not detected		
KRT40	FLJ36600, KA36	ENSG00000204889	Keratin 40	17	40977716-40987135	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Not detected			lung: 0.2	Not detected		
KRT25	KRT25A	ENSG00000204897	Keratin 25	17	40748021-40755332	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053977, HPA058943	Enhanced		Approved	Vesicles		Not detected	Group enriched	15	breast: 3.6;testis: 1.6	smooth muscle: 0.1	Cell line enriched	5	RPTEC TERT1: 1.0
MZT1	C13orf37, FLJ21869, LOC440145, MGC150539, MOZART1, RP11-11C5.2	ENSG00000204899	Mitotic spindle organizing protein 1	13	72708357-72727687	Predicted intracellular proteins	Evidence at protein level	HPA063299, HPA066715	Approved				Renal cancer:1.01e-5 (unfavourable), Liver cancer:3.22e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.1	Expressed in all		
SPINK9		ENSG00000204909	Serine peptidase inhibitor, Kazal type 9	5	148321203-148339849	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038288	Uncertain					Tissue enhanced	Mixed			testis: 10.6	Mixed		
LRRC3C		ENSG00000204913	Leucine rich repeat containing 3C	17	39941474-39944747	Predicted membrane proteins	Evidence at protein level	HPA071271	Uncertain					Not detected	Not detected			testis: 0.9	Not detected		
PRR20B		ENSG00000204918	Proline rich 20B	13	57147488-57150509	Predicted intracellular proteins	No evidence	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRR20A	FLJ40296, PRR20	ENSG00000204919	Proline rich 20A	13	57140918-57143939	Predicted intracellular proteins	Evidence at transcript level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
ZNF155	pHZ-96	ENSG00000204920	Zinc finger protein 155	19	43967862-43998325	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003220	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			parathyroid gland: 14.5	Mixed		
UQCC3	C11orf83, UNQ655	ENSG00000204922	Ubiquinol-cytochrome c reductase complex assembly factor 3	11	62670273-62673687	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA046851	Approved		Approved	Nucleoplasm<br>Mitochondria<br>Cytosol	Liver cancer:2.55e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 8.8	Expressed in all		
FBXO48		ENSG00000204923	F-box protein 48	2	68459419-68467258	Predicted intracellular proteins	Evidence at protein level	HPA049775, HPA054782	Uncertain		Approved	Nuclear bodies		Expressed in all	Mixed			skin: 3.0	Mixed		
GRXCR2	DFNB101	ENSG00000204928	Glutaredoxin and cysteine rich domain containing 2	5	145858521-145937126	Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA059421	Uncertain					Not detected	Tissue enhanced		testis: 1.6	skin: 0.6	Not detected		
FAM221B	C9orf128	ENSG00000204930	Family with sequence similarity 221 member B	9	35816391-35828747	Predicted intracellular proteins	Evidence at transcript level	HPA023011, HPA026577	Uncertain					Not detected	Group enriched	6	bone marrow: 2.4;testis: 10.3	prostate: 1.1	Not detected		
CD177	HNA2A, NB1, PRV1	ENSG00000204936	CD177 molecule	19	43353659-43363172	Predicted secreted proteins	Evidence at protein level	HPA041820, HPA046601	Enhanced				Cervical cancer:3.66e-4 (favourable)	Tissue enhanced	Group enriched	16	bone marrow: 193.1;colon: 155.7;prostate: 105.4;rectum: 181.9	appendix: 9.7	Cell line enriched	23	RPMI-8226: 65.6
PSG5	FL-NCA-3, PSG	ENSG00000204941	Pregnancy specific beta-1-glycoprotein 5	19	43166256-43186536	Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Mixed	Tissue enriched	108	placenta: 157.6	smooth muscle: 1.4	Group enriched	8	BJ: 363.6;fHDF/TERT166: 1157.5
ZNF783	DKFZp667J212	ENSG00000204946	Zinc finger family member 783	7	149262171-149297302	Predicted intracellular proteins	Evidence at protein level	HPA020375	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.24e-7 (unfavourable), Urothelial cancer:4.11e-4 (favourable)	Expressed in all	Mixed			spleen: 9.2	Mixed		
ZNF425		ENSG00000204947	Zinc finger protein 425	7	149102784-149126346	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA020087	Uncertain		Supported	Nucleus		Mixed	Mixed			parathyroid gland: 5.5	Mixed		
LRRC10B		ENSG00000204950	Leucine rich repeat containing 10B	11	61508800-61511018	Predicted intracellular proteins	Evidence at protein level	HPA047619	Uncertain		Approved	Nucleoplasm<br>Nucleoli		Mixed	Tissue enriched	12	fallopian tube: 47.3	lung: 3.9	Group enriched	7	AF22: 9.8;RH-30: 10.4;SCLC-21H: 6.5
FBXO47		ENSG00000204952	F-box protein 47	17	38936432-38967402	Predicted intracellular proteins	Evidence at transcript level	HPA057438	Uncertain					Not detected	Tissue enriched	72	testis: 7.2	all non-specific tissues: 0.0	Not detected		
C12orf73	DKFZp547P055, FLJ13975	ENSG00000204954	Chromosome 12 open reading frame 73	12	103950202-103965708	Predicted secreted proteins	Evidence at protein level	HPA038883	Uncertain		Approved	Plasma membrane<br>Centrosome<br>Mitochondria	Urothelial cancer:1.61e-4 (favourable), Liver cancer:6.98e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 17.8	Expressed in all		
PCDHGA1	PCDH-GAMMA-A1	ENSG00000204956	Protocadherin gamma subfamily A, 1	5	141330571-141512981	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA036547	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 3.2	testis: 1.3	Cell line enhanced		LHCN-M2: 3.7;T-47d: 6.9
BLACE		ENSG00000204960	B-cell acute lymphoblastic leukemia expressed	7	155356985-155367934	Predicted intracellular proteins	Evidence at transcript level	HPA041918	Uncertain					Tissue enriched	Not detected			bone marrow: 0.3	Cell line enhanced		HL-60: 1.2;NB-4: 1.6;REH: 6.9;U-937: 2.6
PCDHA9	KIAA0345, PCDH-ALPHA9	ENSG00000204961	Protocadherin alpha 9	5	140847463-141012344	Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.2	cerebral cortex: 0.6	Cell line enriched	8	SCLC-21H: 6.7
PCDHA8		ENSG00000204962	Protocadherin alpha 8	5	140841187-141012344	Predicted membrane proteins	Evidence at protein level	HPA044585	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Group enriched	5	AN3-CA: 13.9;SCLC-21H: 4.9
PCDHA7	CNR4, CNRS4, CRNR4	ENSG00000204963	Protocadherin alpha 7	5	140834248-141012344	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.6;testis: 1.0	endometrium,gallbladder,smooth muscle: 0.3	Cell line enhanced		NTERA-2: 1.0;WM-115: 1.0
PCDHA5	CNR6, CNRN6, CNRS6, CRNR6, PCDH-ALPHA5	ENSG00000204965	Protocadherin alpha 5	5	140821604-141012344	Predicted membrane proteins	Evidence at transcript level	HPA044557	Approved					Not detected	Tissue enriched	10	cerebral cortex: 4.1	endometrium: 0.4	Cell line enhanced		A549: 1.2;EFO-21: 3.4;T-47d: 3.5;WM-115: 1.4
PCDHA4	CNR1, CNRN1, CRNR1, PCDH-ALPHA4	ENSG00000204967	Protocadherin alpha 4	5	140806929-141012344	Predicted membrane proteins	Evidence at protein level	HPA043180, HPA073478	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 4.4	gallbladder: 2.5	Cell line enhanced		A549: 5.9;AF22: 6.1;EFO-21: 5.0;T-47d: 5.1
PCDHA2		ENSG00000204969	Protocadherin alpha 2	5	140794852-141012344	Predicted membrane proteins	Evidence at protein level	HPA035653	Uncertain					Not detected	Not detected			cerebral cortex: 0.9	Cell line enhanced		AF22: 4.4;SH-SY5Y: 1.3;T-47d: 1.1;WM-115: 1.0
PCDHA1		ENSG00000204970	Protocadherin alpha 1	5	140786136-141012347	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA035969	Enhanced		Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 2.8;testis: 1.4	adrenal gland: 0.4	Cell line enriched	6	T-47d: 8.6
TRIM13	DLEU5, Leu5, RFP2, RNF77	ENSG00000204977	Tripartite motif containing 13	13	49995888-50020481	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000367	Enhanced					Expressed in all	Expressed in all			testis: 141.2	Expressed in all		
ERICH4	C19orf69, LOC100170765	ENSG00000204978	Glutamate rich 4	19	41443158-41444765	Predicted intracellular proteins	Evidence at transcript level	HPA042632, HPA048484	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	27	duodenum: 42.8;kidney: 16.3;small intestine: 42.9	lung: 1.2	Group enriched	13	CACO-2: 2.1;Hep G2: 4.2;THP-1: 1.1
MS4A13		ENSG00000204979	Membrane spanning 4-domains A13	11	60515413-60542721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA045017, HPA063626	Uncertain					Not detected	Tissue enriched	54	testis: 5.3	all non-specific tissues: 0.0	Cell line enhanced		U-266/70: 1.4
PRSS1	TRY1	ENSG00000204983	Protease, serine 1	7	142749468-142753076	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB025487, CAB025538, HPA062452, HPA063471	Enhanced				Endometrial cancer:6.41e-6 (unfavourable), Thyroid cancer:4.91e-4 (favourable), Ovarian cancer:7.05e-4 (favourable)	Tissue enriched	Tissue enriched	318	pancreas: 81683.0	ovary: 257.2	Cell line enhanced		EFO-21: 1.3;RPMI-8226: 2.0;U-2 OS: 1.7
SPIRE2	KIAA1832, spir-2	ENSG00000204991	Spire type actin nucleation factor 2	16	89818179-89871319	Predicted intracellular proteins	Evidence at protein level	HPA041413, HPA049415	Uncertain		Approved	Nucleus<br>Vesicles<br>Intermediate filaments	Liver cancer:9.77e-5 (unfavourable)	Expressed in all	Mixed			stomach: 14.0	Mixed		
AARD	C8orf85, LOC441376	ENSG00000205002	Alanine and arginine rich domain containing protein	8	116938199-116944487	Predicted intracellular proteins	Evidence at protein level	HPA068290			Approved	Lipid droplets		Tissue enriched	Tissue enriched	8	testis: 42.4	breast: 5.4	Cell line enhanced		HDLM-2: 20.1;SK-BR-3: 8.9;U-2 OS: 6.0
PABPN1L	ePABP2	ENSG00000205022	Poly(A) binding protein nuclear 1 like, cytoplasmic	16	88863333-88866660	Predicted intracellular proteins	Evidence at transcript level	HPA043415	Uncertain					Not detected	Tissue enhanced		adrenal gland: 1.0	bone marrow: 0.5	Cell line enhanced		MCF7: 2.0;NB-4: 1.1;SCLC-21H: 5.5;T-47d: 1.3
OR5D16		ENSG00000205029	Olfactory receptor family 5 subfamily D member 16	11	55838752-55839738	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA046711	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5L2	HSHTPCRX16, HTPCRX16	ENSG00000205030	Olfactory receptor family 5 subfamily L member 2	11	55827219-55828154	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047524	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PKHD1L1		ENSG00000205038	Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1	8	109362477-109530330	Predicted membrane proteins	Evidence at protein level	HPA044458	Uncertain				Endometrial cancer:7.61e-4 (favourable)	Group enriched	Group enriched	6	cervix, uterine: 21.3;fallopian tube: 19.7;thyroid gland: 57.2	endometrium: 5.5	Cell line enhanced		HHSteC: 1.2;TIME: 1.3;U-266/70: 1.1
SLFN12L		ENSG00000205045	Schlafen family member 12 like	17	35464249-35537861	Predicted membrane proteins	Evidence at protein level	HPA024447	Uncertain					Mixed	Mixed			spleen: 7.3	Cell line enhanced		HDLM-2: 20.4;Karpas-707: 10.7
CLLU1OS		ENSG00000205057	Chronic lymphocytic leukemia up-regulated 1 opposite strand	12	92420094-92428148	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			lymph node,spleen,tonsil: 0.9	Cell line enriched	7	U-698: 4.3
SLC35B4	FLJ14697, YEA4	ENSG00000205060	Solute carrier family 35 member B4	7	134289332-134317051	Predicted membrane proteins	Evidence at protein level	HPA049779	Approved					Expressed in all	Mixed			cerebral cortex: 17.8	Expressed in all		
LGALS7	GAL7, LGALS7A, PIG1, TP53I1	ENSG00000205076	Galectin 7	19	38770971-38773492	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001549, CAB032606	Enhanced					Group enriched	Group enriched	6	breast: 18.1;esophagus: 24.3;skin: 27.7	skeletal muscle: 3.6	Cell line enhanced		HaCaT: 6.2;SCLC-21H: 1.2
SYCE1L	MRP2	ENSG00000205078	Synaptonemal complex central element protein 1 like	16	77199397-77213215	Predicted intracellular proteins	Evidence at protein level	HPA062464, HPA066691			Enhanced	Intermediate filaments	Renal cancer:2.11e-5 (unfavourable), Endometrial cancer:6.65e-4 (favourable)	Mixed	Tissue enriched	5	testis: 23.8	prostate: 4.6	Cell line enhanced		HEK 293: 10.5
TMEM231	ALYE870, FLJ22167, JBTS20, MKS11, PRO1886	ENSG00000205084	Transmembrane protein 231	16	75536744-75556286	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042081	Enhanced		Approved	Vesicles		Mixed	Tissue enriched	8	fallopian tube: 77.5	thyroid gland: 9.8	Mixed		
FAM71F2	FAM137B	ENSG00000205085	Family with sequence similarity 71 member F2	7	128672266-128683319	Predicted intracellular proteins	Evidence at protein level	HPA020513, HPA024248	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enriched	22	testis: 42.9	adipose tissue,cerebral cortex: 1.9	Mixed		
C2orf91		ENSG00000205086	Chromosome 2 open reading frame 91	2	41935368-41954266	Predicted intracellular proteins	Evidence at transcript level	HPA042517	Uncertain					Tissue enriched	Tissue enhanced		lung: 2.5	adrenal gland: 1.0	Group enriched	6	AN3-CA: 3.8;HDLM-2: 13.8
CCNI2	FLJ16793	ENSG00000205089	Cyclin I family member 2	5	132747445-132754403	Predicted intracellular proteins	Evidence at transcript level	HPA056288	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Colorectal cancer:8.21e-4 (favourable)	Tissue enhanced	Mixed			duodenum: 3.8	Cell line enriched	6	MOLT-4: 21.8
TMEM240	C1orf70, SCA21	ENSG00000205090	Transmembrane protein 240	1	1535174-1540453	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066721	Supported				Pancreatic cancer:2.52e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 18.6	endometrium: 7.7	Cell line enhanced		SCLC-21H: 12.1;SH-SY5Y: 13.3
FRG2	FRG2A	ENSG00000205097	FSHD region gene 2	4	190024351-190027257	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Not detected			skin: 0.7	Not detected		
FAM205A	C9orf144B	ENSG00000205108	Family with sequence similarity 205 member A	9	34723055-34729467	Predicted membrane proteins	Evidence at protein level	HPA071267	Enhanced					Not detected	Tissue enriched	321	testis: 39.5	skin: 0.1	Not detected		
CDKL4		ENSG00000205111	Cyclin dependent kinase like 4	2	39175646-39229588	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA067895	Uncertain					Not detected	Tissue enriched	8	testis: 5.3	fallopian tube,placenta: 0.6	Cell line enhanced		HL-60: 1.6;RT4: 1.1;SH-SY5Y: 2.8
TMEM88B		ENSG00000205116	Transmembrane protein 88B	1	1426128-1427787	Predicted membrane proteins	Evidence at protein level	HPA065743	Enhanced					Tissue enhanced	Tissue enriched	14	cerebral cortex: 11.8	testis: 0.8	Cell line enhanced		Hep G2: 2.8;SCLC-21H: 1.9
ACCSL		ENSG00000205126	1-aminocyclopropane-1-carboxylate synthase homolog (inactive) like	11	44047981-44059977	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			skin,testis: 0.4	Not detected		
C4orf47	LOC441054	ENSG00000205129	Chromosome 4 open reading frame 47	4	185426249-185449826	Predicted intracellular proteins	Evidence at transcript level	HPA043662	Uncertain		Approved	Vesicles	Renal cancer:4.75e-4 (unfavourable)	Mixed	Tissue enhanced		fallopian tube: 21.6;testis: 24.2	thyroid gland: 7.8	Cell line enhanced		U-87 MG: 5.8
TRIQK	C8orf83, DKFZp779L1068, LOC286144, PRO0845	ENSG00000205133	Triple QxxK/R motif containing	8	92883530-93017673	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA076853			Supported	Endoplasmic reticulum		Expressed in all	Mixed			thyroid gland: 39.2	Mixed		
SDHAF1	LYRM8	ENSG00000205138	Succinate dehydrogenase complex assembly factor 1	19	35995199-35996315	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064277			Approved	Mitochondria	Renal cancer:2.11e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 13.8	Expressed in all		
ARID3C		ENSG00000205143	AT-rich interaction domain 3C	9	34621379-34628107	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Group enriched	Tissue enriched	8	liver: 5.9	cerebral cortex: 0.7	Cell line enhanced		HDLM-2: 1.8;Karpas-707: 1.8;T-47d: 2.4
PSENEN	PEN2	ENSG00000205155	Presenilin enhancer gamma-secretase subunit	19	35745114-35747519	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA047435	Approved				Renal cancer:8.70e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 375.2	Expressed in all		
C11orf91		ENSG00000205177	Chromosome 11 open reading frame 91	11	33698261-33700801	Predicted intracellular proteins	Evidence at protein level	HPA047064, HPA050487	Uncertain		Supported	Vesicles		Not detected	Tissue enhanced		adipose tissue: 5.8;gallbladder: 7.7;testis: 6.9	esophagus: 3.3	Cell line enhanced		HBEC3-KT: 11.7;hTERT-HME1: 7.8;HUVEC TERT2: 6.8;TIME: 10.3;U-2197: 9.7
FABP9	PERF, PERF15, T-FABP	ENSG00000205186	Fatty acid binding protein 9	8	81458341-81461579	Predicted intracellular proteins	Evidence at protein level	HPA073619	Approved					Not detected	Tissue enhanced		breast: 1.6	adipose tissue: 0.7	Not detected		
ZBTB10	FLJ12752, RINZF	ENSG00000205189	Zinc finger and BTB domain containing 10	8	80485619-80526265	Predicted intracellular proteins	Evidence at protein level	HPA021554, HPA050569	Enhanced		Enhanced	Nucleoplasm	Renal cancer:3.52e-4 (favourable)	Expressed in all	Expressed in all			placenta: 25.2	Mixed		
C4orf46	LOC201725, RCDG1	ENSG00000205208	Chromosome 4 open reading frame 46	4	158666679-158672255	Predicted intracellular proteins	Evidence at protein level	HPA047287, HPA052670	Uncertain		Approved	Nucleoplasm		Expressed in all	Tissue enhanced		testis: 22.3	bone marrow: 8.4	Expressed in all		
SCGB2B2	SCGB4A2, SCGBL	ENSG00000205209	Secretoglobin family 2B member 2	19	34593329-34675699	Predicted secreted proteins	Evidence at transcript level	HPA046806	Uncertain					Not detected	Mixed			epididymis: 3.2	Mixed		
CCDC144NL	MGC87631	ENSG00000205212	Coiled-coil domain containing 144 family, N-terminal like	17	20836447-20896140	Predicted intracellular proteins	Evidence at transcript level	HPA023457	Uncertain		Approved	Nucleus<br>Plasma membrane		Not detected	Tissue enriched	7	testis: 4.3	endometrium,prostate,seminal vesicle: 0.5	Cell line enriched	6	U-2 OS: 32.3
LGR4	GPR48	ENSG00000205213	Leucine rich repeat containing G protein-coupled receptor 4	11	27365961-27472775	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA030267, HPA054350	Uncertain		Approved	Microtubule organizing center	Renal cancer:2.00e-7 (favourable)	Expressed in all	Expressed in all			kidney: 56.2	Cell line enhanced		HAP1: 86.6
PSMB10	beta2i, LMP10, MECL1, MGC1665	ENSG00000205220	Proteasome subunit beta 10	16	67934502-67937087	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030224, HPA030225, CAB034384	Enhanced		Enhanced	Cytosol	Urothelial cancer:5.44e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 91.2	Mixed		
VIT		ENSG00000205221	Vitrin	2	36696690-36814792	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		ovary: 35.7	adipose tissue: 18.5	Cell line enhanced		ASC diff: 23.1;ASC TERT1: 45.7;BJ: 27.8;fHDF/TERT166: 87.0;THP-1: 23.9
SPDYE2	MGC119295	ENSG00000205238	Speedy/RINGO cell cycle regulator family member E2	7	102551232-102562308	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 15.0	skin: 4.1	Mixed		
E2F4	E2F-4	ENSG00000205250	E2F transcription factor 4	16	67192169-67198918	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054128			Supported	Nucleoplasm		Expressed in all	Expressed in all			placenta: 64.2	Expressed in all		
PDE7A	HCP1	ENSG00000205268	Phosphodiesterase 7A	8	65717510-65842322	Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB018770, HPA027340	Approved				Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 68.9	Expressed in all		
TMEM170B		ENSG00000205269	Transmembrane protein 170B	6	11538278-11583524	Predicted membrane proteins	Evidence at transcript level	HPA055134	Uncertain		Approved	Centrosome		Mixed	Tissue enhanced		cerebral cortex: 21.3	bone marrow: 16.8	Cell line enhanced		THP-1: 15.8
MUC12	MUC11	ENSG00000205277	Mucin 12, cell surface associated	7	100969623-101018949	Predicted membrane proteins	Evidence at protein level	HPA023835	Enhanced					Tissue enriched	Group enriched	24	colon: 49.6;rectum: 74.4	appendix: 2.5	Not detected		
CTXN3		ENSG00000205279	Cortexin 3	5	127649044-127658630	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	18	kidney: 78.6	skeletal muscle: 4.3	Not detected		
MGAT4D	GnT1IP	ENSG00000205301	MGAT4 family member D	4	140442262-140498377	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036523	Enhanced					Not detected	Tissue enriched	66	testis: 49.0	epididymis: 0.7	Not detected		
SNX2		ENSG00000205302	Sorting nexin 2	5	122774996-122830108	Predicted intracellular proteins	Evidence at protein level	HPA037400	Approved		Enhanced	Endosomes<br>Lysosomes	Renal cancer:8.76e-7 (favourable), Liver cancer:7.90e-6 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 124.4	Expressed in all		
SAP25	FLJ00248	ENSG00000205307	Sin3A associated protein 25	7	100572228-100573820	Predicted intracellular proteins	Evidence at protein level	HPA062610	Uncertain		Approved	Nuclear bodies		Mixed	Tissue enhanced		spleen: 48.2	lymph node: 32.7	Cell line enhanced		HMC-1: 26.8;NB-4: 44.5;U-937: 21.3
NT5M	dNT-2, dNT2, mdN	ENSG00000205309	5',3'-nucleotidase, mitochondrial	17	17303335-17347663	Predicted intracellular proteins	Evidence at protein level	HPA043777	Uncertain				Ovarian cancer:8.42e-5 (favourable)	Expressed in all	Mixed			testis: 4.8	Cell line enhanced		U-266/70: 6.6
SARNP	CIP29, Hcc-1, THO1	ENSG00000205323	SAP domain containing ribonucleoprotein	12	55752463-55817756	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA030902, HPA030903	Supported		Supported	Nuclear speckles		Mixed	Expressed in all			testis: 92.7	Expressed in all		
OR6C68		ENSG00000205327	Olfactory receptor family 6 subfamily C member 68	12	55492378-55493316	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			heart muscle: 0.2	Not detected		
OR6C65		ENSG00000205328	Olfactory receptor family 6 subfamily C member 65	12	55400430-55401505	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C3	OST709	ENSG00000205329	Olfactory receptor family 6 subfamily C member 3	12	55331701-55332636	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR6C1	OST267	ENSG00000205330	Olfactory receptor family 6 subfamily C member 1	12	55320561-55321624	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ADGRG1	GPR56, TM7LN4, TM7XN1	ENSG00000205336	Adhesion G protein-coupled receptor G1	16	57610652-57665580	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046065	Uncertain				Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 349.0	Cell line enhanced		SK-MEL-30: 229.9
IPO7	Imp7, RANBP7	ENSG00000205339	Importin 7	11	9384622-9448126	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019002, HPA056590	Approved	Approved	Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:8.38e-6 (unfavourable), Cervical cancer:4.98e-4 (unfavourable), Liver cancer:6.57e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 89.8	Expressed in all		
PRR13	DKFZP564J157, FLJ23818	ENSG00000205352	Proline rich 13	12	53441605-53446645	Predicted intracellular proteins	Evidence at protein level	HPA039396, HPA046219	Uncertain		Enhanced	Nucleoplasm	Urothelial cancer:7.55e-4 (favourable), Cervical cancer:9.08e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 515.4	Expressed in all		
TECPR1	DKFZP434B0335, FLJ23419, FLJ90593, KIAA1358	ENSG00000205356	Tectonin beta-propeller repeat containing 1	7	98214624-98252251	Predicted intracellular proteins	Evidence at protein level	HPA021061	Approved		Supported	Vesicles	Pancreatic cancer:8.12e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.1	Expressed in all		
MT1H	MT1	ENSG00000205358	Metallothionein 1H	16	56669814-56671129	Predicted intracellular proteins	Evidence at protein level						Glioma:4.29e-7 (unfavourable), Renal cancer:5.44e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		kidney: 501.3;small intestine: 335.4;thyroid gland: 541.2	liver: 136.0	Cell line enhanced		BEWO: 1.1;EFO-21: 3.4;SCLC-21H: 1.0
SLCO6A1	CT48, MGC26949, OATP6A1, OATPY	ENSG00000205359	Solute carrier organic anion transporter family member 6A1	5	102371782-102499016	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA054126	Enhanced					Not detected	Tissue enriched	136	testis: 54.0	placenta: 0.3	Not detected		
MT1A	MT1, MT1S	ENSG00000205362	Metallothionein 1A	16	56638666-56640087	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002161, CAB013056	Approved					Expressed in all	Tissue enhanced		adipose tissue: 258.9	liver: 59.5	Cell line enhanced		HMC-1: 26.0;hTEC/SVTERT24-B: 80.4;NTERA-2: 40.1
C15orf59	INSYN1, LOC388135, MGC131524	ENSG00000205363	Chromosome 15 open reading frame 59	15	73735431-73752747	Predicted intracellular proteins	Evidence at transcript level	HPA041563	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:5.38e-9 (favourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 55.9	seminal vesicle: 19.8	Cell line enhanced		ASC diff: 6.2;fHDF/TERT166: 4.8;HEK 293: 5.9;U-2 OS: 5.5
MT1M	MT1, MT1K	ENSG00000205364	Metallothionein 1M	16	56632233-56633986	Predicted intracellular proteins	Evidence at protein level						Melanoma:2.13e-4 (unfavourable)	Expressed in all	Tissue enhanced		adipose tissue: 110.2	small intestine: 47.6	Cell line enhanced		ASC diff: 7.8;HAP1: 9.5;RPTEC TERT1: 38.2
CFI	C3b-INA, FI, IF, KAF	ENSG00000205403	Complement factor I	4	109740694-109802179	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA001143, CAB016777, HPA024061	Supported				Urothelial cancer:6.06e-4 (unfavourable)	Expressed in all	Tissue enhanced		liver: 524.7	kidney: 221.8	Cell line enhanced		CAPAN-2: 112.1;Hep G2: 117.9;HSkMC: 48.7;RPTEC TERT1: 139.4
OR52E6		ENSG00000205409	Olfactory receptor family 52 subfamily E member 6	11	5840928-5841952	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
SAMD9	C7orf5, FLJ20073, KIAA2004	ENSG00000205413	Sterile alpha motif domain containing 9	7	93099513-93118023	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021318, HPA021319	Approved		Enhanced	Vesicles<br>Cytosol	Renal cancer:8.40e-7 (unfavourable), Pancreatic cancer:8.31e-5 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Endometrial cancer:3.14e-4 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 43.2	spleen: 24.2	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 64.9
KRT6A	CK6C, CK6D, K6C, K6D, KRT6C, KRT6D	ENSG00000205420	Keratin 6A	12	52487174-52493257	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA045697, HPA061168	Supported		Approved	Intermediate filaments	Lung cancer:1.45e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	esophagus: 5703.6	tonsil: 564.5	Cell line enhanced		HaCaT: 1007.5;HBEC3-KT: 1727.3;hTCEpi: 7036.9
CNEP1R1	C16orf69, FLJ38101, NEP1-R1, TMEM188	ENSG00000205423	CTD nuclear envelope phosphatase 1 regulatory subunit 1	16	50024410-50037088	Predicted membrane proteins	Evidence at protein level	HPA042815, HPA077906	Uncertain		Supported	Cytosol		Expressed in all	Mixed			testis: 32.8	Expressed in all		
KRT81	Hb-1, KRTHB1	ENSG00000205426	Keratin 81	12	52285913-52291534	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049778	Supported					Tissue enhanced	Tissue enhanced		breast: 3.8	placenta: 1.5	Cell line enhanced		A-431: 2684.9;A549: 2072.1;PC-3: 1009.2;U-251 MG: 1766.1
EXOC3L4	C14orf73	ENSG00000205436	Exocyst complex component 3 like 4	14	103100144-103110559	Predicted intracellular proteins	Evidence at protein level	HPA043661	Approved				Colorectal cancer:1.43e-5 (unfavourable)	Tissue enhanced	Tissue enhanced		duodenum: 19.2	small intestine: 10.7	Cell line enhanced		HDLM-2: 3.5;HEL: 3.4;Hep G2: 1.8;RPMI-8226: 1.8
KRTAP12-3	KRTAP12.3	ENSG00000205439	Keratin associated protein 12-3	21	44657932-44658341	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			skin: 0.1	Not detected		
IZUMO3	bA20A20.1, C9orf134	ENSG00000205442	IZUMO family member 3	9	24542952-24545946	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	215	testis: 21.5	all non-specific tissues: 0.0	Cell line enriched	33	SCLC-21H: 3.3
KRTAP10-2	KAP10.2, KAP18.2, KRTAP18-2	ENSG00000205445	Keratin associated protein 10-2	21	44550357-44551505	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TP53TG3D		ENSG00000205456	TP53 target 3D	16	32252719-32255922	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 4.2;testis: 4.2	adrenal gland,cerebral cortex: 1.1	Cell line enhanced		AN3-CA: 1.1;HEL: 1.0;HMC-1: 1.2;RH-30: 1.0;SCLC-21H: 1.4;U-2 OS: 1.3
TP53TG3C		ENSG00000205457	TP53 target 3C	16	33193659-33196858	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.7	Not detected		
ATP6AP1L		ENSG00000205464	ATPase H+ transporting accessory protein 1 like	5	82279462-82386977	Predicted membrane proteins	Evidence at transcript level	HPA053771	Approved		Approved	Nucleoli<br>Cytosol		Mixed	Mixed			testis: 10.3	Cell line enhanced		MOLT-4: 14.2
CCDC85C		ENSG00000205476	Coiled-coil domain containing 85C	14	99500180-99604026	Predicted intracellular proteins	Evidence at protein level	HPA058346	Uncertain		Approved	Nuclear speckles<br>Cell Junctions	Renal cancer:2.60e-5 (favourable), Endometrial cancer:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 31.1	Mixed		
OR52J3		ENSG00000205495	Olfactory receptor family 52 subfamily J member 3	11	5046526-5047461	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51A2		ENSG00000205496	Olfactory receptor family 51 subfamily A member 2	11	4954772-4955713	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR51A4		ENSG00000205497	Olfactory receptor family 51 subfamily A member 4	11	4946159-4947100	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C2CD4B	FAM148B, NLF2	ENSG00000205502	C2 calcium dependent domain containing 4B	15	62163535-62165283	Predicted intracellular proteins	Evidence at transcript level	HPA046880	Uncertain				Cervical cancer:4.22e-4 (favourable)	Mixed	Tissue enhanced		adipose tissue: 15.3	pancreas: 8.1	Cell line enhanced		HUVEC TERT2: 1.6
RGL3	FLJ32585	ENSG00000205517	Ral guanine nucleotide dissociation stimulator like 3	19	11384341-11419342	Predicted intracellular proteins	Evidence at protein level	HPA042763, HPA043615, HPA064578	Uncertain		Uncertain	Nucleus<br>Cytosol	Renal cancer:6.61e-4 (favourable), Breast cancer:7.35e-4 (favourable)	Mixed	Group enriched	6	parathyroid gland: 128.2;thyroid gland: 36.8	seminal vesicle: 13.3	Cell line enhanced		BEWO: 17.4;RT4: 17.3;T-47d: 14.8
NAP1L4	NAP2	ENSG00000205531	Nucleosome assembly protein 1 like 4	11	2944431-2992377	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011567	Approved		Supported	Nucleoplasm	Liver cancer:1.68e-7 (unfavourable), Thyroid cancer:1.55e-4 (favourable), Cervical cancer:9.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 148.6	Expressed in all		
TMSB4X	TB4X, TMSB4	ENSG00000205542	Thymosin beta 4, X-linked	X	12975108-12977227	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB033806	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 11540.2	Expressed in all		
TMEM256	C17orf61, MGC40107	ENSG00000205544	Transmembrane protein 256	17	7402975-7404137	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA062732			Approved	Vesicles	Renal cancer:9.36e-4 (unfavourable)	Expressed in all	Expressed in all			duodenum: 68.3	Expressed in all		
C9orf92	Em:AL513424.1	ENSG00000205549	Chromosome 9 open reading frame 92	9	16203935-16276313	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.3	testis: 1.0	Cell line enhanced		BJ hTERT+: 1.1;U-2197: 1.4
CPT1B	CPT1-M, M-CPT1	ENSG00000205560	Carnitine palmitoyltransferase 1B	22	50568861-50578465	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA029583	Approved					Mixed	Expressed in all			heart muscle: 106.5	Mixed		
SMN2	BCD541, GEMIN1, SMNC, TDRD16B	ENSG00000205571	Survival of motor neuron 2, centromeric	5	70049612-70078522	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB009344, HPA045271	Supported					Expressed in all	Mixed			epididymis: 27.1	Cell line enhanced		BEWO: 126.1
SERF1B	FAM2B, H4F5C	ENSG00000205572	Small EDRK-rich factor 1B	5	70025247-70043113	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA075271			Approved	Nuclear bodies		Mixed	Tissue enhanced		testis: 48.0	epididymis: 31.8	Cell line enhanced		SiHa: 111.5
HMGN1	FLJ27265, FLJ31471, HMG14, MGC104230, MGC117425	ENSG00000205581	High mobility group nucleosome binding domain 1	21	39342315-39349647	Predicted intracellular proteins	Evidence at protein level	CAB012260, HPA048694	Supported		Supported	Nucleus	Renal cancer:8.74e-7 (unfavourable)	Expressed in all	Expressed in all			tonsil: 218.1	Expressed in all		
DENND6B	AFI1B, FAM116B, MGC33692	ENSG00000205593	DENN domain containing 6B	22	50309030-50327060	Predicted intracellular proteins	Evidence at protein level	HPA018934, HPA021653, HPA029570	Uncertain		Uncertain	Plasma membrane	Endometrial cancer:5.93e-5 (favourable), Colorectal cancer:1.41e-4 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 21.5	cerebral cortex: 12.0	Mixed		
EIF3CL		ENSG00000205609	Eukaryotic translation initiation factor 3 subunit C-like	16	28379579-28403879	Predicted intracellular proteins	Evidence at protein level	HPA047097, HPA049495, HPA050112	Supported		Approved	Cytosol		Group enriched	Mixed			skin: 24.2	Expressed in all		
LCMT1	CGI-68, PPMT1	ENSG00000205629	Leucine carboxyl methyltransferase 1	16	25111729-25178231	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041559, HPA043530	Uncertain		Approved	Nucleoplasm<br>Cytosol	Renal cancer:7.53e-6 (favourable), Cervical cancer:2.78e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 59.8	Expressed in all		
MFSD2B		ENSG00000205639	Major facilitator superfamily domain containing 2B	2	24010081-24063321	Predicted membrane proteins	Evidence at protein level	HPA044145	Enhanced					Not detected	Tissue enriched	9	bone marrow: 7.2	placenta: 0.7	Group enriched	16	HEL: 7.5;K-562: 3.3
VCX3B	VCX-C	ENSG00000205642	Variable charge, X-linked 3B	X	8464830-8466510	Predicted intracellular proteins	Evidence at protein level	HPA044996, HPA049357	Supported					Tissue enhanced	Tissue enriched	88	testis: 32.5	breast: 0.3	Cell line enriched	20	U-138 MG: 18.3
CDPF1	C22orf40, LOC150383	ENSG00000205643	Cysteine rich DPF motif domain containing 1	22	46244011-46250679	Predicted intracellular proteins	Evidence at protein level	HPA018823	Uncertain		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.13e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 7.0	Mixed		
HTN3	HIS2	ENSG00000205649	Histatin 3	4	70028413-70036538	Predicted secreted proteins, Transporters	Evidence at protein level	CAB073541	Enhanced		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	1666	salivary gland: 47614.6	ovary: 28.5	Mixed		
LIN52	C14orf46	ENSG00000205659	Lin-52 DREAM MuvB core complex component	14	74084796-74201235	Predicted intracellular proteins	Evidence at protein level	HPA000900, HPA001777	Uncertain		Approved	Nuclear speckles	Liver cancer:6.08e-5 (unfavourable), Head and neck cancer:6.60e-4 (favourable)	Expressed in all	Mixed			kidney: 17.3	Expressed in all		
ARSH		ENSG00000205667	Arylsulfatase family member H	X	3006613-3033571	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.9	Not detected		
ACOT6	C14orf42	ENSG00000205669	Acyl-CoA thioesterase 6	14	73610945-73619888	Predicted intracellular proteins	Evidence at protein level	HPA058258	Uncertain					Not detected	Tissue enhanced		kidney: 3.8	adipose tissue: 1.7	Cell line enriched	7	T-47d: 9.6
SMIM11A	C21orf51, FAM165B, SMIM11	ENSG00000205670	Small integral membrane protein 11A	21	34375480-34407866	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA051321	Uncertain		Approved	Focal adhesion sites		Not detected	Mixed			thyroid gland: 32.1	Mixed		
TECRL	DKFZp313B2333, DKFZp313D0829, GPSN2L, SRD5A2L2, TERL	ENSG00000205678	Trans-2,3-enoyl-CoA reductase-like	4	64275257-64409468	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	18	heart muscle: 371.9	skeletal muscle: 20.5	Not detected		
DPF3	BAF45c, cer-d4, Cerd4, FLJ14079	ENSG00000205683	Double PHD fingers 3	14	72619296-72894116	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA066790, HPA070601	Enhanced		Enhanced	Nucleoplasm		Tissue enhanced	Tissue enhanced		ovary: 16.7	parathyroid gland: 10.0	Cell line enhanced		BEWO: 17.1;HEL: 28.2
MANSC4		ENSG00000205693	MANSC domain containing 4	12	27762738-27771276	Predicted membrane proteins	Evidence at transcript level	HPA039454, HPA039682	Uncertain					Not detected	Tissue enhanced		testis: 3.2	placenta: 0.8	Cell line enhanced		HUVEC TERT2: 1.2
ETFRF1	LYRM5	ENSG00000205707	Electron transfer flavoprotein regulatory factor 1	12	25195216-25209645	Predicted intracellular proteins	Evidence at protein level	HPA044255	Approved		Approved	Microtubule organizing center	Renal cancer:9.23e-5 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			testis: 112.5	Expressed in all		
C17orf107		ENSG00000205710	Chromosome 17 open reading frame 107	17	4899418-4902932	Predicted intracellular proteins	Evidence at transcript level	HPA069713	Uncertain		Approved	Nucleus	Breast cancer:5.06e-5 (favourable), Renal cancer:2.68e-4 (favourable), Pancreatic cancer:8.61e-4 (favourable)	Mixed	Mixed			parathyroid gland,salivary gland: 5.7	Cell line enhanced		fHDF/TERT166: 2.2;HMC-1: 3.2;hTCEpi: 2.4
MBD3L4		ENSG00000205718	Methyl-CpG binding domain protein 3 like 4	19	7037748-7040179	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
ITSN1	ITSN, MGC134948, MGC134949, SH3D1A, SH3P17	ENSG00000205726	Intersectin 1	21	33642400-33899861	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA018007	Approved		Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 61.5	Expressed in all		
ITPRIPL2	FLJ22994, LOC162073, MGC126798, MGC126800	ENSG00000205730	Inositol 1,4,5-trisphosphate receptor interacting protein like 2	16	19113932-19121629	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042011			Approved	Centrosome		Expressed in all	Expressed in all			skin: 27.8	Mixed		
DENND1C	FAM31C, FLJ22757	ENSG00000205744	DENN domain containing 1C	19	6467207-6482557	Predicted intracellular proteins	Evidence at protein level	HPA042758, HPA042839	Enhanced				Renal cancer:7.51e-14 (favourable), Lung cancer:1.23e-4 (favourable), Urothelial cancer:5.62e-4 (favourable), Prostate cancer:8.95e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 28.2;lymph node: 37.1;spleen: 31.7	bone marrow: 14.0	Cell line enhanced		Daudi: 16.1;HEL: 13.5;HMC-1: 39.4;U-937: 24.3
SLCO1B7	LST3, SLC21A21	ENSG00000205754	Solute carrier organic anion transporter family member 1B7 (putative)	12	21015696-21092745	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain					Not detected	Tissue enriched	17	breast: 43.2	liver: 2.4	Cell line enhanced		A-431: 2.3;A549: 1.6;CAPAN-2: 1.6;HeLa: 1.1;U-2 OS: 1.3
CRLF2	CRL2, TSLPR	ENSG00000205755	Cytokine receptor-like factor 2	X	1187549-1212750	Cancer-related genes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		appendix: 2.1;gallbladder: 2.0	bone marrow: 1.0	Cell line enhanced		HMC-1: 13.5;RPMI-8226: 2.8;U-698: 2.4
CRYZL1	4P11, QOH-1	ENSG00000205758	Crystallin zeta like 1	21	33589341-33643926	Predicted intracellular proteins	Evidence at protein level	HPA019120, HPA029399, CAB034129	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 62.0	Expressed in all		
C5orf51	LOC285636	ENSG00000205765	Chromosome 5 open reading frame 51	5	41904188-41921636	Predicted intracellular proteins	Evidence at protein level	HPA043779, HPA063816	Uncertain		Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.90e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 27.1	Expressed in all		
GAGE1	CT4.1	ENSG00000205777	G antigen 1	X	49589496-49608536	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	748	testis: 110.5	duodenum: 0.1	Group enriched	7	AN3-CA: 2552.7;K-562: 597.3
ARRDC5		ENSG00000205784	Arrestin domain containing 5	19	4890437-4902867	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	8	testis: 18.2	spleen: 2.3	Cell line enriched	19	REH: 1.9
CYS1		ENSG00000205795	Cystin 1	2	10056780-10080944	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.27e-5 (favourable)	Tissue enhanced	Tissue enriched	6	kidney: 101.2	ovary: 15.7	Cell line enriched	14	RPTEC TERT1: 83.8
PLPP6	FLJ46512, FLJ90191, PDP1, PPAPDC2	ENSG00000205808	Phospholipid phosphatase 6	9	4662315-4665258	Predicted membrane proteins	Evidence at protein level	HPA018096	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:3.99e-4 (favourable)	Expressed in all	Mixed			prostate: 26.7	Cell line enhanced		HDLM-2: 92.6
KLRC2	CD159c, NKG2-C	ENSG00000205809	Killer cell lectin like receptor C2	12	10426854-10442300	CD markers, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA058052			Approved	Plasma membrane		Tissue enriched	Group enriched	6	cerebral cortex: 17.3;spleen: 8.1	stomach: 2.1	Cell line enhanced		HEL: 5.2;HeLa: 11.9;HSkMC: 3.0;U-87 MG: 2.8
KLRC3	NKG2-E	ENSG00000205810	Killer cell lectin like receptor C3	12	10412312-10420595	Predicted membrane proteins	Evidence at transcript level	HPA039910, HPA062570	Approved		Uncertain	Vesicles		Tissue enriched	Tissue enhanced		cerebral cortex: 9.2;spleen: 6.2	lymph node: 2.3	Cell line enhanced		HEL: 1.1;HeLa: 4.5;U-698: 1.3
C16orf96		ENSG00000205832	Chromosome 16 open reading frame 96	16	4556490-4600714	Predicted intracellular proteins	Evidence at protein level	HPA042009, HPA042058	Uncertain					Not detected	Tissue enriched	21	testis: 10.9	cerebral cortex: 0.5	Not detected		
GMNC	GEMC1	ENSG00000205835	Geminin coiled-coil domain containing	3	190852877-190892429	Predicted intracellular proteins	Evidence at protein level	HPA043663	Uncertain					Tissue enhanced	Tissue enriched	5	fallopian tube: 9.5	testis: 1.8	Cell line enriched	10	SCLC-21H: 1.1
TTC23L	FLJ25439	ENSG00000205838	Tetratricopeptide repeat domain 23 like	5	34838833-34899456	Predicted intracellular proteins	Evidence at protein level	HPA037807	Enhanced					Not detected	Tissue enriched	7	testis: 39.2	fallopian tube: 5.8	Not detected		
CLEC6A	CLECSF10, dectin-2	ENSG00000205846	C-type lectin domain family 6 member A	12	8455926-8478330	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		appendix: 1.5;lung: 1.5	lymph node: 0.8	Cell line enhanced		NTERA-2: 3.3
RFPL3S	NCRNA00005, RFPL3-AS, RFPL3-AS1	ENSG00000205853	RFPL3 antisense	22	32359906-32382052	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	17	testis: 99.1	cerebral cortex: 5.8	Cell line enhanced		U-266/84: 5.5
C22orf42		ENSG00000205856	Chromosome 22 open reading frame 42	22	32149006-32159322	Predicted intracellular proteins	Evidence at protein level	HPA019531	Enhanced					Group enriched	Tissue enriched	8	testis: 10.8	prostate: 1.3	Not detected		
NANOGNB		ENSG00000205857	NANOG neighbor homeobox	12	7765216-7774121	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA060371	Uncertain					Tissue enriched	Not detected			testis: 0.5	Not detected		
LRRC72		ENSG00000205858	Leucine rich repeat containing 72	7	16526880-16581568	Predicted intracellular proteins	Evidence at transcript level	HPA020554	Uncertain					Not detected	Tissue enriched	44	testis: 4.3	all non-specific tissues: 0.0	Not detected		
PCOTH	C1QTNF9B-AS1	ENSG00000205861	Pro-X-Gly collagen triple helix like repeat containing	13	23888889-23897263	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		prostate: 24.5;skin: 25.5;testis: 38.3	epididymis: 6.1	Cell line enhanced		hTEC/SVTERT24-B: 11.5;LHCN-M2: 10.9
C1QTNF9B	CTRP9B	ENSG00000205863	C1q and tumor necrosis factor related protein 9B	13	23890525-23902655	Predicted secreted proteins	Evidence at protein level	HPA056632	Uncertain					Tissue enhanced	Tissue enhanced		skin: 9.4	testis: 3.3	Not detected		
KRTAP5-6	KRTAP5.6	ENSG00000205864	Keratin associated protein 5-6	11	1697195-1697755	Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.04e-5 (favourable)	Tissue enriched	Not detected			placenta: 0.6	Not detected		
KRTAP5-2	KRTAP5-8, KRTAP5.2	ENSG00000205867	Keratin associated protein 5-2	11	1597177-1598294	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 3.6	gallbladder: 0.9	Cell line enhanced		MCF7: 1.9;SCLC-21H: 3.3;SH-SY5Y: 1.3
KRTAP5-1	KRN1L, KRTAP5.1	ENSG00000205869	Keratin associated protein 5-1	11	1584342-1585283	Predicted intracellular proteins	Evidence at transcript level						Colorectal cancer:2.37e-4 (unfavourable)	Mixed	Not detected			adrenal gland,cerebral cortex,pancreas,salivary gland,small intestine,spleen,stomach: 0.1	Cell line enhanced		SCLC-21H: 1.6
DEFB134		ENSG00000205882	Defensin beta 134	8	11993174-11996312	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	8	epididymis: 36.9	testis: 4.6	Not detected		
DEFB135		ENSG00000205883	Defensin beta 135	8	11982321-11984590	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	189	epididymis: 84.8	gallbladder,testis: 0.4	Cell line enhanced		HEK 293: 1.1;MCF7: 3.5
DEFB136	DEFB137	ENSG00000205884	Defensin beta 136	8	11973937-11974599	Predicted secreted proteins	Evidence at protein level	HPA068255	Enhanced					Not detected	Tissue enriched	9	epididymis: 3.8	seminal vesicle: 0.4	Cell line enhanced		HEK 293: 1.0
BHLHA9	bHLHa9, BHLHF42	ENSG00000205899	Basic helix-loop-helix family member a9	17	1270559-1271460	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062632	Uncertain					Tissue enhanced	Not detected			cerebral cortex: 0.8	Not detected		
ZNF316	ENST00000305834, MZF-3	ENSG00000205903	Zinc finger protein 316	7	6637322-6656432	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Pancreatic cancer:6.03e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 50.8	Expressed in all		
DAZ4		ENSG00000205916	Deleted in azoospermia 4	Y	24833843-24907040	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Group enriched	40	stomach: 22.3;testis: 21.5	skin: 0.5	Group enriched	123	U-266/70: 117.1;U-266/84: 107.2
ONECUT3		ENSG00000205922	One cut homeobox 3	19	1752373-1780988	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059936			Supported	Nucleoplasm		Group enriched	Tissue enhanced		stomach: 4.0	gallbladder: 1.0	Group enriched	9	HaCaT: 6.2;PC-3: 14.4
CEMP1	CP-23	ENSG00000205923	Cementum protein 1	16	2530035-2531417	Predicted intracellular proteins	Evidence at transcript level	HPA057658	Approved					Not detected	Mixed			skin: 5.7	Cell line enhanced		REH: 6.9
OLIG2	BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17	ENSG00000205927	Oligodendrocyte transcription factor 2	21	33025845-33029196	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003254, CAB019381	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enriched	245	cerebral cortex: 91.0	duodenum: 0.3	Cell line enhanced		HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9
C21orf62	B37, C21orf120, PRED81	ENSG00000205929	Chromosome 21 open reading frame 62	21	32793564-32813743	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA016899	Enhanced				Renal cancer:1.14e-4 (favourable)	Tissue enriched	Tissue enhanced		epididymis: 6.4;kidney: 5.1;ovary: 12.6	prostate: 4.2	Group enriched	13	AF22: 2.5;RPTEC TERT1: 1.1
RNPS1		ENSG00000205937	RNA binding protein with serine rich domain 1	16	2253116-2268412	Predicted intracellular proteins, Transporters	Evidence at protein level	HPA044014	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 143.8	Expressed in all		
DAZ2	MGC126442, pDP1678	ENSG00000205944	Deleted in azoospermia 2	Y	23219434-23291356	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047113	Approved					Not detected	Group enriched	27	stomach: 15.5;testis: 7.2	skin: 0.4	Cell line enriched	9	SK-MEL-30: 1.4
NYNRIN	CGIN1, FLJ11811, KIAA1305	ENSG00000205978	NYN domain and retroviral integrase containing	14	24398786-24419288	Predicted intracellular proteins	Evidence at protein level	HPA018945	Approved		Approved	Nucleoplasm<br>Golgi apparatus<br>Vesicles		Expressed in all	Mixed			ovary: 42.7	Cell line enhanced		HUVEC TERT2: 28.9;RT4: 23.0
DNAJC19	Pam18, Tim14, TIMM14	ENSG00000205981	DnaJ heat shock protein family (Hsp40) member C19	3	180983709-180989774	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037782	Approved				Ovarian cancer:8.53e-5 (favourable)	Expressed in all	Expressed in all			kidney: 52.9	Expressed in all		
IFITM5	BRIL, fragilis4, Hrmp1	ENSG00000206013	Interferon induced transmembrane protein 5	11	298200-299526	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA039258	Uncertain					Mixed	Not detected			bone marrow: 0.5	Not detected		
SMIM21	C18orf62	ENSG00000206026	Small integral membrane protein 21	18	75409476-75427703	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041686	Enhanced					Not detected	Tissue enriched	52	testis: 5.2	all non-specific tissues: 0.0	Cell line enhanced		U-87 MG: 1.1
C18orf63	DKFZP781G0119	ENSG00000206043	Chromosome 18 open reading frame 63	18	74315813-74359187	Predicted intracellular proteins	Evidence at protein level	HPA042233			Approved	Mitochondria		Not detected	Tissue enriched	62	testis: 17.8	breast: 0.2	Not detected		
DEFA1	DEF1, DEFA2, HNP-1, MRS	ENSG00000206047	Defensin alpha 1	8	6977649-6980080	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	CAB032548, HPA052517	Enhanced					Not detected	Tissue enriched	269	bone marrow: 30312.0	skin: 112.6	Cell line enriched	9	NB-4: 2.6
DOK6	DOK5L, HsT3226, MGC20785	ENSG00000206052	Docking protein 6	18	69401055-69849087	Predicted intracellular proteins	Evidence at protein level	HPA041099, HPA063534	Approved		Approved	Focal adhesion sites<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 21.0	placenta: 8.5	Cell line enhanced		fHDF/TERT166: 8.1;Hep G2: 7.6;RPMI-8226: 7.5;SCLC-21H: 5.6;SH-SY5Y: 11.3
HN1L	C16orf34, FLJ13092, KIAA1426, L11	ENSG00000206053	Hematological and neurological expressed 1 like	16	1678256-1702280	Predicted intracellular proteins	Evidence at protein level	HPA041888, HPA041908	Approved		Enhanced	Plasma membrane<br>Cytosol	Endometrial cancer:7.85e-4 (favourable), Liver cancer:9.14e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 101.8	Expressed in all		
TMEM211	bA9F11.1	ENSG00000206069	Transmembrane protein 211	22	24934954-24946695	Predicted membrane proteins	Evidence at transcript level	HPA066784	Uncertain					Tissue enhanced	Tissue enhanced		cervix, uterine: 3.7;stomach: 2.7	salivary gland: 1.4	Not detected		
SERPINB11	EPIPIN	ENSG00000206072	Serpin family B member 11 (gene/pseudogene)	18	63647579-63726432	Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	5	esophagus: 28.7;prostate: 49.9	tonsil: 7.2	Not detected		
SERPINB4	LEUPIN, PI11, SCCA-2, SCCA1, SCCA2	ENSG00000206073	Serpin family B member 4	18	63637259-63644298	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048341, HPA049988, HPA055992	Supported				Pancreatic cancer:5.48e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	esophagus: 98.3	urinary bladder: 19.5	Cell line enhanced		HaCaT: 1.9;SiHa: 1.8;U-2197: 5.5
SERPINB5	maspin, PI5	ENSG00000206075	Serpin family B member 5	18	63476761-63505085	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009570, HPA019025, HPA019132, HPA020136	Enhanced		Supported	Vesicles	Pancreatic cancer:5.71e-6 (unfavourable), Lung cancer:1.54e-4 (unfavourable)	Tissue enhanced	Group enriched	5	esophagus: 220.2;skin: 261.8	breast: 44.2	Cell line enhanced		HaCaT: 1048.4;HBEC3-KT: 281.3;hTCEpi: 583.7
ZDHHC11B		ENSG00000206077	Zinc finger DHHC-type containing 11B	5	710360-766952	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA057886, HPA069008	Uncertain		Approved	Lipid droplets	Lung cancer:3.98e-4 (favourable)	Mixed	Mixed			cerebral cortex: 6.2	Cell line enhanced		HAP1: 2.8;SCLC-21H: 4.1;THP-1: 2.7
KRTAP19-8		ENSG00000206102	Keratin associated protein 19-8	21	31038159-31038476	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
KRTAP20-3	KAP19D, KAP20.3, KRTAP19P4	ENSG00000206104	Keratin associated protein 20-3	21	30642864-30643136	Predicted intracellular proteins	No evidence	HPA053598	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP20-4	KAP20.4	ENSG00000206105	Keratin associated protein 20-4	21	30620627-30620850	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	36	testis: 3.6	all non-specific tissues: 0.0	Cell line enriched	10	U-2 OS: 5.5
KRTAP22-2	KAP22.2	ENSG00000206106	Keratin associated protein 22-2	21	30590105-30590397	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.2	Not detected		
KRTAP27-1		ENSG00000206107	Keratin associated protein 27-1	21	30337013-30337694	Predicted intracellular proteins	Evidence at transcript level	HPA021522, HPA048826	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CFAP99		ENSG00000206113	Cilia and flagella associated protein 99	4	2418974-2462942	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	8	fallopian tube: 7.0;testis: 11.3	adrenal gland: 1.0	Not detected		
GOLGA8O		ENSG00000206127	Golgin A8 family member O	15	32445106-32455634	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 8.7	thyroid gland: 2.2	Group enriched	14	HEL: 18.7;U-937: 23.4
TMEM191C		ENSG00000206140	Transmembrane protein 191C	22	21466423-21471269	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	9	testis: 1.5	endometrium,lung,ovary: 0.1	Not detected		
RNASE13	RAL1	ENSG00000206150	Ribonuclease A family member 13 (inactive)	14	21032820-21034785	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	248	epididymis: 380.3	salivary gland: 1.5	Not detected		
HBA1	HBA-T3	ENSG00000206172	Hemoglobin subunit alpha 1	16	176680-177522	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB032534, HPA043780	Enhanced					Tissue enhanced	Group enriched	34	bone marrow: 17119.3;placenta: 3433.6	spleen: 303.5	Group enriched	51	HEL: 3255.0;K-562: 2173.8
HBM	HBAP2, HBK	ENSG00000206177	Hemoglobin subunit mu	16	153892-166768	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	29	bone marrow: 269.1	placenta: 9.2	Not detected		
ELOA2	HsT832, TCEB3B, TCEB3L	ENSG00000206181	Elongin A2	18	47032572-47035621	Predicted intracellular proteins	Evidence at protein level	HPA041009, HPA043501, HPA048971, HPA049178, HPA050086	Approved					Not detected	Tissue enriched	44	testis: 4.3	all non-specific tissues: 0.0	Not detected		
ATP10A	ATP10C, ATPVA, ATPVC, KIAA0566	ENSG00000206190	ATPase phospholipid transporting 10A (putative)	15	25677273-25865172	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA041496, HPA042509	Uncertain				Renal cancer:6.60e-5 (unfavourable)	Expressed in all	Mixed			lung: 10.6	Cell line enhanced		BJ: 16.3;fHDF/TERT166: 22.1;HMC-1: 16.2;SK-MEL-30: 20.1
ANKUB1	C3orf16	ENSG00000206199	Ankyrin repeat and ubiquitin domain containing 1	3	149761100-149968385	Predicted intracellular proteins	Evidence at transcript level	HPA053749	Uncertain					Not detected	Tissue enriched	5	fallopian tube: 9.0	lung: 1.6	Not detected		
TSSK2	FLJ38613, SPOGA2, STK22B	ENSG00000206203	Testis specific serine kinase 2	22	19130808-19132623	Enzymes, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	290	testis: 120.4	ovary: 0.4	Cell line enhanced		SCLC-21H: 1.0
PRR23A		ENSG00000206260	Proline rich 23A	3	139005468-139006268	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Tissue enriched	Tissue enriched	10	testis: 1.9	ovary: 0.1	Not detected		
FOXL2NB	C3orf72, FLJ43329	ENSG00000206262	FOXL2 neighbor	3	138947234-138953451	Predicted intracellular proteins	Evidence at protein level	HPA061017, HPA071790			Supported	Nucleoli fibrillar center		Mixed	Tissue enhanced		endometrium: 29.1;ovary: 50.7;parathyroid gland: 63.8	fallopian tube: 19.5	Cell line enhanced		AN3-CA: 4.1;fHDF/TERT166: 6.7;HEL: 7.8;SiHa: 7.1
COL6A6		ENSG00000206384	Collagen type VI alpha 6 chain	3	130560334-130678155	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045239	Uncertain					Tissue enhanced	Tissue enhanced		lung: 11.2	breast: 2.9	Not detected		
RAB12		ENSG00000206418	RAB12, member RAS oncogene family	18	8609445-8639381	Predicted intracellular proteins	Evidence at protein level	HPA040727	Approved		Approved	Vesicles		Expressed in all	Expressed in all			skeletal muscle: 67.4	Expressed in all		
LRRC30		ENSG00000206422	Leucine rich repeat containing 30	18	7231125-7232047	Predicted intracellular proteins	Evidence at transcript level	HPA041039	Uncertain					Not detected	Tissue enriched	10	skeletal muscle: 5.6	esophagus: 0.5	Not detected		
TMEM200C	TTMA	ENSG00000206432	Transmembrane protein 200C	18	5882072-5895955	Predicted membrane proteins	Evidence at protein level	HPA047253, HPA050490	Uncertain		Approved	Microtubules		Tissue enhanced	Tissue enhanced		adrenal gland: 3.1;cerebral cortex: 3.5	salivary gland: 1.7	Cell line enhanced		AF22: 6.1;NTERA-2: 4.7;PC-3: 20.4;U-2 OS: 11.5
OR10C1	hs6M1-17, OR10C1P, OR10C2	ENSG00000206474	Olfactory receptor family 10 subfamily C member 1 (gene/pseudogene)	6	29439306-29440977	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049336	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TXNRD3NB	TR2IT1, TXNRD3IT1, TXNRD3NT1	ENSG00000206483	Thioredoxin reductase 3 neighbor	3	126571789-126572636	Predicted intracellular proteins	Evidence at transcript level	HPA058257	Uncertain					Not detected	Not detected			ovary,testis: 0.2	Not detected		
HLA-A		ENSG00000206503	Major histocompatibility complex, class I, A	6	29941260-29945884	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB078470			Supported	Golgi apparatus<br>Plasma membrane	Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)	Expressed in all	Mixed			gallbladder: 340.9	Cell line enhanced		A-431: 1127.9
HACD2	PTPLB	ENSG00000206527	3-hydroxyacyl-CoA dehydratase 2	3	123490820-123585185	Enzymes, Predicted membrane proteins	Evidence at protein level	CAB019282	Approved				Pancreatic cancer:9.59e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 68.9	Expressed in all		
CFAP44	FLJ11142, WDR52	ENSG00000206530	Cilia and flagella associated protein 44	3	113286947-113441610	Predicted intracellular proteins	Evidence at protein level	HPA067258	Uncertain				Urothelial cancer:7.09e-6 (favourable)	Mixed	Tissue enhanced		testis: 14.4	fallopian tube: 13.7	Mixed		
CD200R1L	CD200R2, CD200RLa	ENSG00000206531	CD200 receptor 1 like	3	112815709-112846856	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	46	testis: 4.9	epididymis: 0.1	Not detected		
LNP1	NP3	ENSG00000206535	Leukemia NUP98 fusion partner 1	3	100401193-100456319	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA047926			Approved	Nuclear speckles<br>Vesicles<br>Cytosol		Expressed in all	Tissue enriched	6	testis: 47.9	cerebral cortex: 7.6	Mixed		
OR5K3		ENSG00000206536	Olfactory receptor family 5 subfamily K member 3	3	98390666-98391631	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
VGLL3	VGL-3	ENSG00000206538	Vestigial like family member 3	3	86876388-86991119	Predicted intracellular proteins	Evidence at protein level	HPA054983	Approved		Approved	Nucleoli<br>Cytosol		Tissue enhanced	Tissue enhanced		placenta: 57.8	adipose tissue: 24.4	Cell line enriched	5	U-2197: 482.9
PRSS50	CT20, TSP50	ENSG00000206549	Protease, serine 50	3	46712115-46812574	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA040768	Supported					Mixed	Tissue enhanced		epididymis: 5.7;parathyroid gland: 4.1	skeletal muscle,testis,thyroid gland: 2.0	Not detected		
TRIM71	LIN-41, LIN41	ENSG00000206557	Tripartite motif containing 71	3	32818018-32897826	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038141, HPA038142	Uncertain		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites		Tissue enriched	Tissue enriched	8	testis: 9.1	lung: 1.1	Group enriched	6	AF22: 31.1;BEWO: 91.3;CACO-2: 19.0;Hep G2: 43.4;NTERA-2: 84.2
ZCWPW2	ZCW2	ENSG00000206559	Zinc finger CW-type and PWWP domain containing 2	3	28349146-28538122	Predicted intracellular proteins	Evidence at protein level	HPA035035, HPA039839	Uncertain		Approved	Nuclear speckles		Mixed	Tissue enhanced		testis: 18.5	thyroid gland: 5.3	Mixed		
ANKRD28	KIAA0379, PITK, PP6-ARS-A, PPP1R65	ENSG00000206560	Ankyrin repeat domain 28	3	15667236-15859771	Predicted intracellular proteins	Evidence at protein level						Renal cancer:2.85e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 33.9	Expressed in all		
COLQ	EAD	ENSG00000206561	Collagen like tail subunit of asymmetric acetylcholinesterase	3	15450133-15521751	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045876			Approved	Plasma membrane<br>Cell Junctions		Mixed	Tissue enhanced		parathyroid gland: 19.4	fallopian tube: 17.6	Cell line enhanced		BEWO: 13.9;HDLM-2: 4.5;U-937: 5.9
METTL6	MGC24132	ENSG00000206562	Methyltransferase like 6	3	15381275-15440566	Predicted intracellular proteins	Evidence at protein level	HPA035166	Uncertain		Approved	Vesicles	Liver cancer:2.66e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
XKR4	KIAA1889	ENSG00000206579	XK related 4	8	55102389-55542054	Predicted membrane proteins, Transporters	Evidence at protein level	HPA025072, HPA028083	Uncertain					Not detected	Tissue enriched	6	cerebral cortex: 4.7	seminal vesicle: 0.8	Group enriched	9	REH: 2.3;RPTEC TERT1: 7.5
GPX3		ENSG00000211445	Glutathione peroxidase 3	5	151020438-151028993	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB069456	Uncertain				Stomach cancer:1.65e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 11674.4	Cell line enriched	11	ASC diff: 5265.2
DIO2	SelY, TXDI2	ENSG00000211448	Iodothyronine deiodinase 2	14	80197527-80387757	Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029544, HPA048002			Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable)	Tissue enhanced	Group enriched	6	cervix, uterine: 269.4;thyroid gland: 601.2	esophagus: 70.3	Cell line enhanced		BJ: 70.1;HeLa: 63.5;SiHa: 184.0
SELENOH	C11orf31, SELH	ENSG00000211450	Selenoprotein H	11	57741250-57743554	Predicted intracellular proteins	Evidence at protein level	HPA048362	Uncertain		Approved	Nucleus<br>Nucleoli	Ovarian cancer:1.80e-4 (favourable), Liver cancer:4.30e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 69.6	Expressed in all		
DIO1	TXDI1	ENSG00000211452	Iodothyronine deiodinase 1	1	53891239-53911086	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Thyroid cancer:5.44e-4 (unfavourable)	Group enriched	Group enriched	30	kidney: 147.5;liver: 94.9;thyroid gland: 434.9	fallopian tube: 7.5	Group enriched	20	Hep G2: 23.0;SK-BR-3: 59.3
STK38L	KIAA0965, NDR2	ENSG00000211455	Serine/threonine kinase 38 like	12	27243968-27325959	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA038623, HPA051324	Approved		Approved	Cytosol	Pancreatic cancer:5.82e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
SACM1L	KIAA0851, SAC1	ENSG00000211456	SAC1 suppressor of actin mutations 1-like (yeast)	3	45689056-45745424	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA039573, HPA069869	Approved		Approved	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.47e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 67.5	Expressed in all		
TSN	BCLF-1, REHF-1, TRSLN	ENSG00000211460	Translin	2	121737103-121767853	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA059561	Uncertain				Liver cancer:3.06e-4 (unfavourable), Endometrial cancer:7.05e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 41.1	Expressed in all		
SLC48A1	FLJ20489, hHRG-1, HRG1	ENSG00000211584	Solute carrier family 48 member 1	12	47753916-47782753	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA073994			Supported	Vesicles	Renal cancer:1.34e-6 (favourable), Liver cancer:9.39e-5 (unfavourable), Cervical cancer:4.27e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 79.5	Expressed in all		
TSSK1B	FKSG81, SPOGA4, STK22D, TSSK1	ENSG00000212122	Testis specific serine kinase 1B	5	113432554-113435031	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA027827	Enhanced					Not detected	Tissue enriched	222	testis: 62.0	skin: 0.2	Not detected		
PRR22	MGC24975	ENSG00000212123	Proline rich 22	19	5782960-5784765	Predicted intracellular proteins	Evidence at protein level	HPA044157	Enhanced		Approved	Nucleus<br>Vesicles<br>Cytosol		Expressed in all	Tissue enhanced		testis: 21.9	skin: 4.9	Cell line enhanced		HMC-1: 15.2
TAS2R19	T2R19, T2R23, TAS2R23, TAS2R48	ENSG00000212124	Taste 2 receptor member 19	12	11021619-11022620	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Not detected			ovary: 0.2	Not detected		
TAS2R50	T2R51	ENSG00000212126	Taste 2 receptor member 50	12	10985913-10986912	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R14	T2R14, TRB1	ENSG00000212127	Taste 2 receptor member 14	12	10937406-11171573	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Mixed	Mixed			epididymis: 1.2	Not detected		
TAS2R13	T2R13, TRB3	ENSG00000212128	Taste 2 receptor member 13	12	10907926-10909562	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZRSR1	U2AF1-RS1, U2AF1L1, U2AF1P, U2AF1RS1, U2AFBPL, ZC3H21	ENSG00000212643	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 1	5	112891422-112893094	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 1.1	Mixed		
KRTAP16-1	KAP16.1	ENSG00000212657	Keratin associated protein 16-1	17	41307700-41309253	Predicted intracellular proteins	Evidence at protein level	HPA070954	Supported					Not detected	Not detected			bone marrow: 0.3	Not detected		
KRTAP29-1	KAP29.2	ENSG00000212658	Keratin associated protein 29-1	17	41301826-41302851	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	21	HDLM-2: 2.0
KRTAP9-6	KAP9.6, KRTAP9L2	ENSG00000212659	Keratin associated protein 9-6	17	41265339-41266641	Predicted intracellular proteins	No evidence							Not detected	Not detected			skin: 0.1	Not detected		
CTAGE1	CT21.1, CT21.2, CTAGE, cTAGE-1, cTAGE-2	ENSG00000212710	Cutaneous T-cell lymphoma-associated antigen 1	18	22413601-22417915	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922, CAB016204	Uncertain					Not detected	Tissue enriched	50	testis: 5.0	all non-specific tissues: 0.0	Not detected		
C17orf51	FLJ12977, FLJ31874, FLJ33618	ENSG00000212719	Chromosome 17 open reading frame 51	17	21524790-21574458	Predicted intracellular proteins	Evidence at protein level	HPA052106	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 16.6	testis: 8.2	Mixed		
KRTAP4-11	KAP4.11, KAP4.14, KRTAP4-14	ENSG00000212721	Keratin associated protein 4-11	17	41117181-41118360	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP4-9	KAP4.9	ENSG00000212722	Keratin associated protein 4-9	17	41105332-41106488	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP2-3	KAP2.3	ENSG00000212724	Keratin associated protein 2-3	17	41059240-41060114	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Mixed	Not detected			all non-specific tissues: 0.0	Cell line enhanced		BJ: 31.1;fHDF/TERT166: 17.2;HBF TERT88: 30.9;LHCN-M2: 34.2;U-2 OS: 16.1
KRTAP2-1	KAP2.1A	ENSG00000212725	Keratin associated protein 2-1	17	41046541-41047316	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
FAM127C	CXX1c, MAR8B	ENSG00000212747	Family with sequence similarity 127 member C	X	135020504-135022529	Predicted intracellular proteins	Evidence at protein level						Breast cancer:2.41e-5 (unfavourable), Stomach cancer:3.72e-4 (unfavourable)	Expressed in all	Mixed			prostate: 17.7	Cell line enhanced		U-2197: 63.0
OR2A42		ENSG00000212807	Olfactory receptor family 2 subfamily A member 42	7	144231911-144232843	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA058272	Uncertain					Not detected	Not detected			thyroid gland: 0.6	Not detected		
RNF208	DKFZP761H1710	ENSG00000212864	Ring finger protein 208	9	137220247-137221581	Predicted intracellular proteins	Evidence at protein level	HPA021256, HPA021429	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.12e-8 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 25.1	adrenal gland: 7.4	Cell line enhanced		MCF7: 42.5;REH: 40.9
KRTAP3-3	KAP3.3	ENSG00000212899	Keratin associated protein 3-3	17	40993430-40994133	Predicted intracellular proteins	Evidence at protein level	HPA042992	Approved					Tissue enhanced	Not detected			breast,skin: 0.1	Not detected		
KRTAP3-2	KAP3.2	ENSG00000212900	Keratin associated protein 3-2	17	40999193-40999894	Predicted intracellular proteins	Evidence at protein level	HPA042992	Approved					Not detected	Tissue enriched	7	esophagus: 3.3	skin: 0.5	Not detected		
KRTAP3-1	KAP3.1	ENSG00000212901	Keratin associated protein 3-1	17	41008521-41019324	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enhanced		BJ: 2.1;CACO-2: 5.5;HaCaT: 1.6;Hep G2: 2.3;T-47d: 1.8
MT-ND4L	MTND4L, NAD4L, ND4L	ENSG00000212907	Mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	MT	10470-10766	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA075648			Supported	Mitochondria	Liver cancer:4.47e-4 (favourable)	Expressed in all	Expressed in all			kidney: 23320.0	Expressed in all		
MAP10	KIAA1383, MTR120	ENSG00000212916	Microtubule associated protein 10	1	232804892-232808407	Predicted intracellular proteins	Evidence at protein level	HPA052496, HPA073262	Approved		Approved	Nuclear bodies<br>Cleavage furrow		Mixed	Mixed			testis: 5.8	Cell line enhanced		THP-1: 6.8
KRTAP12-4	KRTAP12.4	ENSG00000212933	Keratin associated protein 12-4	21	44654213-44654659	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
KRTAP10-3	KAP10.3, KAP18.3, KRTAP18-3	ENSG00000212935	Keratin associated protein 10-3	21	44557790-44558760	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP6-3	KAP6.3	ENSG00000212938	Keratin associated protein 6-3	21	30592440-30593075	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
POU5F1B	OTF3C, OTF3P1, POU5F1P1	ENSG00000212993	POU class 5 homeobox 1B	8	127414290-127420069	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058267			Supported	Nucleoplasm		Tissue enhanced	Not detected			parathyroid gland: 0.7	Cell line enhanced		hTERT-HME1: 1.1
ZNF580		ENSG00000213015	Zinc finger protein 580	19	55635016-55643469	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054058	Approved		Approved	Nucleus	Renal cancer:5.79e-6 (unfavourable), Pancreatic cancer:2.36e-5 (favourable), Liver cancer:5.63e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 38.1	Expressed in all		
ZNF611	MGC5384	ENSG00000213020	Zinc finger protein 611	19	52702813-52735073	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:3.33e-4 (favourable)	Mixed	Mixed			fallopian tube: 11.1	Mixed		
KLK9	KLK-L3	ENSG00000213022	Kallikrein related peptidase 9	19	51003111-51009634	Cancer-related genes, Enzymes, Predicted secreted proteins	Evidence at transcript level	CAB025049	Uncertain					Tissue enriched	Not detected			skin,tonsil: 0.8	Not detected		
SYT3		ENSG00000213023	Synaptotagmin 3	19	50621307-50639827	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enriched	10	cerebral cortex: 17.1	testis: 1.7	Cell line enhanced		HEK 293: 7.1;HMC-1: 4.7;NTERA-2: 5.5;SH-SY5Y: 6.6;U-2 OS: 4.0
NUP62	DKFZp547L134, FLJ20822, FLJ43869, IBSN, MGC841, p62, SNDI	ENSG00000213024	Nucleoporin 62	19	49906825-49929763	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA005435, CAB020724	Enhanced		Supported	Nucleus<br>Nuclear membrane	Renal cancer:5.71e-12 (unfavourable), Liver cancer:2.50e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 76.9	Expressed in all		
SPHAR		ENSG00000213029	S-phase response (cyclin related)	1	229304857-229305504	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CGB8		ENSG00000213030	Chorionic gonadotropin beta subunit 8	19	49047638-49049106	Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Tissue enhanced	Tissue enriched	90	placenta: 29.2	parathyroid gland: 0.3	Group enriched	8	BEWO: 167.1;U-251 MG: 51.5
DENND1B	C1orf218, FAM31B, FLJ20054, MGC27044	ENSG00000213047	DENN domain containing 1B	1	197504748-197775696	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA042586	Uncertain		Supported	Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 11.1	Mixed		
SFT2D2	dJ747L4.C1.2, UNQ512	ENSG00000213064	SFT2 domain containing 2	1	168225938-168253025	Predicted membrane proteins	Evidence at protein level	HPA042207	Approved				Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Mixed			bone marrow: 21.1	Expressed in all		
FGFR1OP	FOP	ENSG00000213066	FGFR1 oncogene partner	6	166999182-167052713	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071876			Supported	Centrosome	Renal cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 105.4	Expressed in all		
FAM106A	FLJ11800	ENSG00000213077	Family with sequence similarity 106 member A	17	18524566-18526846	Predicted intracellular proteins	Evidence at transcript level	HPA056425	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		testis: 7.3	bone marrow,placenta: 1.6	Mixed		
SCAF8	KIAA1116, RBM16	ENSG00000213079	SR-related CTD associated factor 8	6	154733325-154834244	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035601, HPA035602	Enhanced		Enhanced	Nucleoplasm	Ovarian cancer:6.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 45.1	Expressed in all		
CFAP45	CCDC19, NESG1	ENSG00000213085	Cilia and flagella associated protein 45	1	159872364-159900163	Predicted intracellular proteins	Evidence at protein level	HPA042204, HPA043618	Enhanced		Enhanced	Nucleoplasm		Tissue enhanced	Group enriched	7	fallopian tube: 71.3;testis: 38.9	lung: 7.7	Cell line enhanced		BEWO: 8.7;HEL: 11.0
ACKR1	CCBP1, CD234, DARC, Dfy, FY, GPD	ENSG00000213088	Atypical chemokine receptor 1 (Duffy blood group)	1	159203307-159206500	Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA016421, HPA017672	Enhanced				Cervical cancer:2.52e-5 (favourable), Liver cancer:1.48e-4 (favourable), Thyroid cancer:9.76e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 112.8	Group enriched	6	HEL: 30.2;HSkMC: 23.2
ZNF254	BMZF-5, HD-ZNF1, ZNF539, ZNF91L	ENSG00000213096	Zinc finger protein 254	19	24033405-24129961	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Lung cancer:8.60e-4 (favourable), Urothelial cancer:9.96e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 29.3	Mixed		
TCTEX1D2	MGC33212	ENSG00000213123	Tctex1 domain containing 2	3	196291219-196318299	Predicted intracellular proteins	Evidence at protein level	HPA049555			Approved	Cytosol	Renal cancer:6.23e-4 (unfavourable), Cervical cancer:7.83e-4 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 49.2	testis: 39.1	Mixed		
CRYGS	CRYG8	ENSG00000213139	Crystallin gamma S	3	186538441-186546702	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035103	Uncertain		Uncertain	Cytosol	Renal cancer:3.72e-9 (unfavourable), Urothelial cancer:2.73e-4 (favourable)	Expressed in all	Mixed			lymph node,spleen: 4.1	Mixed		
CRIP1	CRIP	ENSG00000213145	Cysteine rich protein 1	14	105486317-105488947	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042462	Approved		Uncertain	Nuclear speckles<br>Centrosome<br>Cytosol		Mixed	Expressed in all			small intestine: 546.1	Cell line enhanced		A549: 1118.8;CAPAN-2: 599.1;HaCaT: 653.1;HDLM-2: 498.2;T-47d: 892.4
KLHL23	FLJ37812, MGC22679, MGC2610	ENSG00000213160	Kelch like family member 23	2	169694488-169776989	Predicted intracellular proteins	Evidence at protein level	HPA047593			Approved	Nucleoplasm<br>Actin filaments	Renal cancer:2.43e-5 (unfavourable), Liver cancer:2.09e-4 (unfavourable)	Expressed in all	Expressed in all			endometrium: 42.8	Cell line enhanced		SCLC-21H: 98.2
LINGO4	LRRN6D	ENSG00000213171	Leucine rich repeat and Ig domain containing 4	1	151800264-151806154	Predicted membrane proteins	Evidence at transcript level	HPA060781	Uncertain					Mixed	Tissue enhanced		adrenal gland: 2.2;skeletal muscle: 4.1	fallopian tube,prostate: 1.0	Not detected		
FAM24B	AC073585.2, MGC45962	ENSG00000213185	Family with sequence similarity 24 member B	10	122849078-122879641	Predicted intracellular proteins	Evidence at protein level	HPA052490	Supported					Expressed in all	Tissue enhanced		kidney: 13.8	testis: 11.4	Group enriched	5	hTERT-HME1: 99.8;LHCN-M2: 139.2;TIME: 44.7
TRIM59	Mrf1, RNF104, TRIM57, TSBF1	ENSG00000213186	Tripartite motif containing 59	3	160432445-160485773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017750	Uncertain		Approved	Rods & Rings	Pancreatic cancer:1.15e-5 (unfavourable), Cervical cancer:4.36e-4 (favourable)	Mixed	Mixed			cerebral cortex: 18.3	Mixed		
MLLT11	AF1Q	ENSG00000213190	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11	1	151057758-151068497	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000540	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 122.5	parathyroid gland: 24.0	Cell line enhanced		AF22: 129.2;SH-SY5Y: 151.4
ASIC3	ACCN3, DRASIC, TNaC1	ENSG00000213199	Acid sensing ion channel subunit 3	7	151048292-151052756	Predicted membrane proteins	Evidence at protein level	HPA049155, HPA054805	Enhanced		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		testis: 8.1	cerebral cortex: 5.8	Cell line enhanced		U-266/70: 13.4
GIMAP1	HIMAP1, IAN2, IMAP1, IMAP38	ENSG00000213203	GTPase, IMAP family member 1	7	150716557-150724284	Predicted membrane proteins	Evidence at protein level	HPA044887, HPA053441	Uncertain		Supported	Endoplasmic reticulum	Liver cancer:1.09e-4 (favourable), Testis cancer:6.12e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 32.8	lymph node: 21.3	Group enriched	10	HUVEC TERT2: 12.1;MOLT-4: 7.0;TIME: 3.1
CCDC183	bA216L13.7, KIAA1984, MGC15438	ENSG00000213213	Coiled-coil domain containing 183	9	136796350-136807741	Predicted intracellular proteins	Evidence at transcript level	HPA043812	Uncertain					Mixed	Tissue enriched	51	testis: 11.8	prostate: 0.2	Not detected		
ARHGEF35	ARHGEF5L, CTAGE4, FLJ43692	ENSG00000213214	Rho guanine nucleotide exchange factor 35	7	144186083-144195655	Predicted intracellular proteins	Evidence at protein level	HPA044188, HPA045619, HPA045699	Supported				Renal cancer:4.57e-4 (favourable), Liver cancer:5.77e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 44.5	Cell line enhanced		A-431: 47.0;hTCEpi: 30.0;RPTEC TERT1: 41.9;WM-115: 28.8
CSH2	CS-2, CSB, hCS-B	ENSG00000213218	Chorionic somatomammotropin hormone 2	17	63872012-63873766	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Tissue enhanced	Tissue enriched	193	placenta: 3932.3	smooth muscle: 20.4	Cell line enriched	27	BEWO: 7.7
DNLZ	bA413M3.2, C9orf151, HEP, RP11-413M3.2, TIMM15, ZIM17	ENSG00000213221	DNL-type zinc finger	9	136359480-136363789	Predicted intracellular proteins	Evidence at protein level	HPA062738			Enhanced	Nucleoplasm<br>Mitochondria		Not detected	Expressed in all			cerebral cortex: 13.6	Expressed in all		
TCL1B	TML1	ENSG00000213231	T-cell leukemia/lymphoma 1B	14	95686417-95692643	Predicted intracellular proteins	Evidence at protein level	HPA053163	Uncertain		Approved	Cytosol		Tissue enriched	Tissue enhanced		lymph node: 2.4;testis: 3.6;tonsil: 2.2	placenta: 1.2	Cell line enriched	5	U-698: 337.9
SUPT4H1	Spt4, SPT4H, Supt4a, SUPT4H	ENSG00000213246	SPT4 homolog, DSIF elongation factor subunit	17	58345175-58353093	Predicted intracellular proteins	Evidence at protein level	HPA059748			Approved	Nucleus	Liver cancer:7.69e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 82.4	Expressed in all		
TSGA13		ENSG00000213265	Testis specific 13	7	130668648-130687432	Predicted intracellular proteins	Evidence at transcript level	HPA022968	Uncertain					Not detected	Tissue enriched	100	testis: 21.0	fallopian tube: 0.2	Not detected		
NRAS	N-ras	ENSG00000213281	Neuroblastoma RAS viral oncogene homolog	1	114704469-114716894	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010157, HPA049830	Uncertain				Liver cancer:3.03e-7 (unfavourable), Pancreatic cancer:1.36e-4 (unfavourable), Renal cancer:7.87e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.4	Expressed in all		
LTC4S	MGC33147	ENSG00000213316	Leukotriene C4 synthase	5	179793980-179796647	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		fallopian tube: 3.7	adipose tissue,adrenal gland: 2.0	Cell line enriched	6	HMC-1: 59.7
ANKRD39	MGC41816	ENSG00000213337	Ankyrin repeat domain 39	2	96836611-96858095	Predicted intracellular proteins	Evidence at protein level	HPA042678	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:6.78e-9 (unfavourable), Pancreatic cancer:6.12e-5 (favourable), Colorectal cancer:2.26e-4 (unfavourable), Urothelial cancer:5.21e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 17.2	Expressed in all		
QTRT1	TGT	ENSG00000213339	Queuine tRNA-ribosyltransferase catalytic subunit 1	19	10701430-10713437	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042695, HPA048651, HPA049440	Approved		Approved	Mitochondria	Renal cancer:1.13e-6 (unfavourable), Cervical cancer:7.63e-5 (favourable), Pancreatic cancer:2.13e-4 (favourable), Head and neck cancer:4.90e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 25.5	Expressed in all		
CHUK	IkBKA, IKK-alpha, IKK1, IKKA, NFKBIKA, TCF16	ENSG00000213341	Conserved helix-loop-helix ubiquitous kinase	10	100188298-100229619	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001402, CAB004240, CAB018564	Approved		Supported	Nucleoplasm<br>Vesicles<br>Cytosol	Renal cancer:1.27e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
MXD3	bHLHc13, MAD3	ENSG00000213347	MAX dimerization protein 3	5	177301461-177312757	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA070111			Approved	Nucleus<br>Nucleoli	Liver cancer:3.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 24.2	skin: 12.6	Cell line enhanced		HDLM-2: 162.8
GSTM2	GST4	ENSG00000213366	Glutathione S-transferase mu 2	1	109668022-109709551	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB040547, HPA055972, HPA055973	Approved		Enhanced	Cytosol	Lung cancer:9.70e-5 (favourable)	Mixed	Expressed in all			ovary: 201.1	Cell line enhanced		ASC TERT1: 82.2;HSkMC: 85.0
COG8	DOR1, FLJ22315	ENSG00000213380	Component of oligomeric golgi complex 8	16	69320140-69339583	Predicted intracellular proteins	Evidence at protein level	HPA041406	Approved				Renal cancer:2.47e-7 (favourable), Pancreatic cancer:3.12e-5 (favourable)	Expressed in all	Expressed in all			testis: 29.9	Expressed in all		
ARHGAP19	FLJ00194, MGC14258	ENSG00000213390	Rho GTPase activating protein 19	10	97222173-97292673	Predicted intracellular proteins	Evidence at protein level	HPA035777, HPA043231	Uncertain		Supported	Plasma membrane	Renal cancer:7.47e-5 (unfavourable)	Expressed in all	Tissue enhanced		testis: 34.2	lymph node: 15.8	Expressed in all		
HAUS7	UCHL5IP, UIP1	ENSG00000213397	HAUS augmin like complex subunit 7	X	153447666-153495516	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003614			Approved	Nucleoli<br>Plasma membrane<br>Centrosome<br>Cytosol	Renal cancer:3.94e-4 (unfavourable), Cervical cancer:6.12e-4 (favourable)	Expressed in all	Mixed			skin: 64.1	Expressed in all		
LCAT		ENSG00000213398	Lecithin-cholesterol acyltransferase	16	67939750-67944131	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA044767			Approved	Nucleoplasm	Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 105.7	Cell line enhanced		BEWO: 73.6
MAGEA12	CT1.12, MAGE12	ENSG00000213401	MAGE family member A12	X	152733779-152737669	Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.22e-4 (unfavourable)	Tissue enhanced	Tissue enriched	16	testis: 4.9	cerebral cortex: 0.3	Cell line enhanced		HMC-1: 50.9;K-562: 80.1;PC-3: 38.7;SH-SY5Y: 51.2;U-2 OS: 91.2;U-266/70: 52.9
PTPRCAP	CD45-AP, LPAP	ENSG00000213402	Protein tyrosine phosphatase, receptor type C associated protein	11	67435510-67438067	Predicted secreted proteins	Evidence at protein level	HPA043734	Enhanced					Not detected	Tissue enhanced		appendix: 64.0;lymph node: 91.4;spleen: 84.9	tonsil: 29.0	Cell line enhanced		Daudi: 161.8;HDLM-2: 148.3;MOLT-4: 110.0;NB-4: 409.0;U-698: 109.1
PVRIG	C7orf15, MGC2463	ENSG00000213413	Poliovirus receptor related immunoglobulin domain containing	7	100218241-100221490	Predicted membrane proteins	Evidence at protein level	HPA047497	Uncertain		Approved	Nucleoli<br>Endoplasmic reticulum		Not detected	Tissue enhanced		lymph node: 20.5;spleen: 11.0	appendix: 8.4	Group enriched	23	Daudi: 69.1;MOLT-4: 86.0;U-698: 21.4
KRTAP4-12	KAP4.12	ENSG00000213416	Keratin associated protein 4-12	17	41123091-41124167	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP2-4	KAP2.4	ENSG00000213417	Keratin associated protein 2-4	17	41065116-41065879	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GPC2	cerebroglycan, DKFZp547M109, FLJ38962	ENSG00000213420	Glypican 2	7	100169606-100177372	Predicted secreted proteins	Evidence at protein level	CAB025423, HPA053945	Uncertain		Uncertain	Nucleus<br>Nucleoli<br>Golgi apparatus	Urothelial cancer:9.94e-4 (favourable)	Mixed	Tissue enhanced		skin: 5.7;testis: 10.1	cerebral cortex: 3.4	Cell line enhanced		AF22: 39.1;SH-SY5Y: 46.0
KRT222	KA21, KRT222P, MGC45562	ENSG00000213424	Keratin 222	17	40654665-40665181	Predicted intracellular proteins	Evidence at protein level	HPA043708, HPA054586, HPA069774	Uncertain		Approved	Vesicles<br>Lipid droplets		Mixed	Tissue enhanced		cerebral cortex: 10.0;epididymis: 6.0	gallbladder: 2.7	Cell line enriched	6	RPTEC TERT1: 8.8
SIPA1	SPA1	ENSG00000213445	Signal-induced proliferation-associated 1	11	65638097-65650930	Predicted intracellular proteins	Evidence at protein level	CAB020833, HPA039867	Enhanced		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Plasma membrane	Renal cancer:3.52e-6 (unfavourable), Colorectal cancer:9.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 99.7	lymph node: 71.0	Expressed in all		
ERV3-1	envR, ERV-R, ERV3, H-PLK, HERV-R	ENSG00000213462	Endogenous retrovirus group 3 member 1	7	64990809-65006743	Predicted secreted proteins	Evidence at protein level	HPA017209, HPA046508	Enhanced		Approved	Vesicles		Expressed in all	Mixed			adrenal gland: 39.8	Mixed		
SYNJ2BP	Arip2	ENSG00000213463	Synaptojanin 2 binding protein	14	70366496-70417061	Predicted membrane proteins	Evidence at protein level	HPA000866	Approved	Supported	Approved	Mitochondria	Renal cancer:1.11e-16 (favourable)	Expressed in all	Mixed			parathyroid gland: 40.9	Mixed		
ARL2	ARFL2	ENSG00000213465	ADP ribosylation factor like GTPase 2	11	65014113-65022184	Predicted intracellular proteins	Evidence at protein level	HPA044610	Supported		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Focal adhesion sites<br>Cytosol	Endometrial cancer:4.58e-4 (unfavourable), Prostate cancer:7.70e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 114.0	Expressed in all		
TTLL13P	FLJ46079, MGC33417, TTLL13	ENSG00000213471	Tubulin tyrosine ligase like 13, pseudogene	15	90249530-90265482	Predicted intracellular proteins	Evidence at protein level	HPA041305	Enhanced					Not detected	Tissue enriched	50	testis: 5.0	all non-specific tissues: 0.0	Not detected		
GBP7	FLJ38822, GBP4L	ENSG00000213512	Guanylate binding protein 7	1	89131751-89176040	Predicted intracellular proteins	Evidence at protein level	HPA051245	Uncertain					Tissue enriched	Tissue enriched	89	liver: 48.3	adrenal gland: 0.5	Not detected		
RBMXL1	KAT3	ENSG00000213516	RNA binding motif protein, X-linked like 1	1	88979456-88992960	Predicted intracellular proteins	Evidence at protein level	HPA057707	Supported		Approved	Nucleoplasm	Pancreatic cancer:7.26e-4 (unfavourable), Breast cancer:7.60e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 22.5	Expressed in all		
SRA1	SRA, STRAA1	ENSG00000213523	Steroid receptor RNA activator 1	5	140537340-140558252	Predicted intracellular proteins	Evidence at protein level	HPA044598, HPA050153	Approved		Supported	Nucleoplasm<br>Microtubules<br>Cytosol	Endometrial cancer:8.01e-6 (favourable)	Expressed in all	Mixed			adrenal gland: 17.5	Expressed in all		
TMEM110	MGC52022	ENSG00000213533	Transmembrane protein 110	3	52836219-52897596	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA051855	Uncertain		Approved	Cytosol		Mixed	Expressed in all			fallopian tube: 21.0	Expressed in all		
DNAJC9	JDD1, SB73	ENSG00000213551	DnaJ heat shock protein family (Hsp40) member C9	10	73183362-73248862	Predicted intracellular proteins	Evidence at protein level	HPA035215, HPA035216	Enhanced		Supported	Nucleoplasm<br>Plasma membrane	Prostate cancer:7.07e-5 (unfavourable), Lung cancer:3.26e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 37.4	Expressed in all		
C8orf82	MGC70857	ENSG00000213563	Chromosome 8 open reading frame 82	8	144525733-144529132	Predicted intracellular proteins	Evidence at protein level	CAB034331	Uncertain		Approved	Nucleus	Renal cancer:1.70e-5 (favourable)	Expressed in all	Expressed in all			prostate: 33.3	Expressed in all		
CPLX3	CPX-III	ENSG00000213578	Complexin 3	15	74826547-74831802	Predicted intracellular proteins	Evidence at protein level	CAB079003		Supported				Not detected	Group enriched	8	prostate: 143.7;spleen: 74.6	cerebral cortex: 12.8	Cell line enhanced		Daudi: 1.6;Karpas-707: 1.4;SCLC-21H: 1.0
VDAC1	MGC111064, PORIN	ENSG00000213585	Voltage dependent anion channel 1	5	133971915-134005133	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005885, HPA030780, CAB072343	Supported		Approved	Cytosol	Lung cancer:2.87e-5 (unfavourable), Head and neck cancer:4.90e-4 (unfavourable), Breast cancer:5.30e-4 (unfavourable), Liver cancer:8.49e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 363.8	Expressed in all		
ZBTB9	MGC23166, ZNF919	ENSG00000213588	Zinc finger and BTB domain containing 9	6	33453970-33457548	Predicted intracellular proteins	Evidence at protein level	HPA036767	Uncertain		Approved	Nucleus<br>Nucleoli<br>Mitochondria		Not detected	Mixed			tonsil: 2.6	Cell line enhanced		BEWO: 9.8;U-698: 8.1
TMX2	PDIA12, TXNDC14	ENSG00000213593	Thioredoxin related transmembrane protein 2	11	57712600-57740973	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA040282, HPA063763	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.55e-5 (favourable), Urothelial cancer:3.37e-4 (unfavourable), Head and neck cancer:3.64e-4 (unfavourable), Liver cancer:4.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 129.2	Expressed in all		
HEXA		ENSG00000213614	Hexosaminidase subunit alpha	15	72340919-72376476	Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA054583	Supported				Endometrial cancer:5.63e-8 (favourable)	Expressed in all	Expressed in all			epididymis: 200.6	Mixed		
NDUFS3	CI-30	ENSG00000213619	NADH:ubiquinone oxidoreductase core subunit S3	11	47565336-47584562	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004484	Approved		Supported	Nuclear bodies<br>Mitochondria	Renal cancer:2.61e-6 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.2	Expressed in all		
LEPROT	FLJ90360, OB-RGRP, OBRGRP, VPS55	ENSG00000213625	Leptin receptor overlapping transcript	1	65420587-65436007	Predicted membrane proteins	Evidence at protein level	HPA069444			Approved	Centrosome		Expressed in all	Expressed in all			placenta: 80.3	Expressed in all		
LBH		ENSG00000213626	Limb bud and heart development	2	30231531-30323730	Predicted intracellular proteins	Evidence at protein level	HPA034669	Approved		Approved	Vesicles	Stomach cancer:8.24e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 197.1	Cell line enhanced		fHDF/TERT166: 234.8;U-2 OS: 102.9
ADAT3	TAD3	ENSG00000213638	Adenosine deaminase, tRNA specific 3	19	1905378-1913447	Predicted intracellular proteins	Evidence at protein level	HPA058899	Uncertain		Approved	Nucleus	Head and neck cancer:6.13e-4 (favourable), Stomach cancer:6.98e-4 (favourable)	Expressed in all	Tissue enhanced		duodenum: 7.5	small intestine: 5.3	Cell line enhanced		HEK 293: 11.3
PPP1CB	PP-1B, PP1B, PP1beta	ENSG00000213639	Protein phosphatase 1 catalytic subunit beta	2	28751640-28802940	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB022558, HPA065425, CAB069426	Supported		Enhanced	Nucleus<br>Plasma membrane	Liver cancer:6.52e-6 (unfavourable)	Expressed in all	Expressed in all			esophagus: 273.8	Expressed in all		
SULT1A4		ENSG00000213648	Sulfotransferase family 1A member 4	16	29459889-29464976	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Not detected	Tissue enhanced		duodenum: 173.4;small intestine: 131.0	colon: 38.4	Cell line enhanced		CAPAN-2: 107.9;EFO-21: 93.9;HEL: 76.5;Hep G2: 188.0;Karpas-707: 114.2
GPSM3	AGS4, C6orf9, G18, G18.1a, G18.1b, G18.2, NG1	ENSG00000213654	G-protein signaling modulator 3	6	32190766-32195523	Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.92e-9 (unfavourable), Endometrial cancer:5.98e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 27.5;spleen: 29.3	appendix: 24.9	Cell line enhanced		HMC-1: 35.2;NB-4: 14.7;THP-1: 16.2
LAT	LAT1	ENSG00000213658	Linker for activation of T-cells	16	28984826-28990783	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB002223, HPA011157, CAB012978	Enhanced		Supported	Golgi apparatus<br>Plasma membrane		Not detected	Tissue enhanced		lymph node: 75.3	appendix: 31.8	Group enriched	8	HEL: 173.8;HMC-1: 690.0;MOLT-4: 227.5
NCKIPSD	AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH	ENSG00000213672	NCK interacting protein with SH3 domain	3	48673844-48686364	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019267, HPA050005			Enhanced	Plasma membrane<br>Cytosol	Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 306.0	cerebral cortex: 35.0	Expressed in all		
ATF6B	CREBL1, G13	ENSG00000213676	Activating transcription factor 6 beta	6	32098176-32128253	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA046871	Uncertain		Supported	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 56.8	Expressed in all		
TREX1	AGS1, DRN3	ENSG00000213689	Three prime repair exonuclease 1	3	48465811-48467645	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA035437, HPA046721	Supported		Supported	Cytosol		Not detected	Expressed in all			spleen: 30.9	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 66.5
S1PR3	EDG-3, EDG3	ENSG00000213694	Sphingosine-1-phosphate receptor 3	9	88991447-89005010	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level						Renal cancer:7.91e-6 (unfavourable), Colorectal cancer:1.30e-4 (unfavourable), Breast cancer:5.91e-4 (favourable)	Expressed in all	Mixed			smooth muscle: 52.4	Cell line enhanced		AF22: 117.8;ASC diff: 111.7;ASC TERT1: 114.8
SLC35F6	ANT2BP, C2orf18, FLJ20555, TANGO9	ENSG00000213699	Solute carrier family 35 member F6	2	26764284-26781231	Predicted membrane proteins, Transporters	Evidence at protein level	HPA034655	Approved		Approved	Nucleoplasm<br>Vesicles<br>Cytosol	Liver cancer:1.11e-4 (unfavourable), Lung cancer:3.71e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
FAM209B	C20orf107, dJ1153D9.4	ENSG00000213714	Family with sequence similarity 209 member B	20	56533246-56536520	Predicted membrane proteins	Evidence at protein level	HPA042144	Enhanced					Mixed	Tissue enriched	22	testis: 112.5	bone marrow: 5.0	Mixed		
CLIC1	G6, NCC27, p64CLCP	ENSG00000213719	Chloride intracellular channel 1	6	31730581-31739763	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB020825, CAB040557	Enhanced		Supported	Cytosol	Liver cancer:8.90e-7 (unfavourable), Renal cancer:8.11e-5 (unfavourable)	Expressed in all	Expressed in all			rectum: 70.2	Expressed in all		
DDAH2	G6A	ENSG00000213722	Dimethylarginine dimethylaminohydrolase 2	6	31727038-31730617	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012509	Uncertain		Uncertain	Microtubule organizing center<br>Cytosol		Expressed in all	Mixed			thyroid gland: 22.3	Cell line enhanced		EFO-21: 23.0;U-2 OS: 18.9
RPS29	S29	ENSG00000213741	Ribosomal protein S29	14	49570984-49599164	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA004107	Approved		Supported	Endoplasmic reticulum<br>Cytosol	Breast cancer:2.66e-4 (favourable)	Expressed in all	Expressed in all			breast: 3653.3	Expressed in all		
UGT2B11		ENSG00000213759	UDP glucuronosyltransferase family 2 member B11	4	69199951-69214731	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA045108	Uncertain					Group enriched	Tissue enriched	17	breast: 320.4	gallbladder: 18.3	Not detected		
ATP6V1G2	ATP6G, ATP6G2, Em:AC004181.3, NG38, Vma10	ENSG00000213760	ATPase H+ transporting V1 subunit G2	6	31544462-31548427	Predicted intracellular proteins	Evidence at protein level	CAB004616	Enhanced					Tissue enriched	Tissue enriched	12	cerebral cortex: 16.7	lymph node: 1.4	Cell line enhanced		HDLM-2: 3.0;Karpas-707: 2.5
ZNF134	pHZ-15	ENSG00000213762	Zinc finger protein 134	19	57614233-57624723	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA009064	Supported		Approved	Nucleoplasm	Cervical cancer:1.03e-4 (unfavourable), Renal cancer:2.61e-4 (favourable), Head and neck cancer:5.21e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.9	Mixed		
GTF2H4	P52, TFB2, TFIIH	ENSG00000213780	General transcription factor IIH subunit 4	6	30908184-30914106	Predicted intracellular proteins	Evidence at protein level	HPA074336			Supported	Nuclear speckles	Renal cancer:4.08e-4 (unfavourable)	Expressed in all	Mixed			appendix: 3.6	Mixed		
DDX47	DKFZp564O176, FLJ30012, HQ0256, RRP3	ENSG00000213782	DEAD-box helicase 47	12	12813316-12829981	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA014855	Approved		Enhanced	Nucleoli		Mixed	Expressed in all			thyroid gland: 55.8	Expressed in all		
ZNF888		ENSG00000213793	Zinc finger protein 888	19	52904417-52923481	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:5.28e-4 (unfavourable)	Mixed	Mixed			cervix, uterine: 18.3	Cell line enriched	5	RT4: 58.3
ZNF845		ENSG00000213799	Zinc finger protein 845	19	53333749-53354869	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.98e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 7.6	Mixed		
KLRK1	CD314, D12S2489E, KLR, NKG2-D, NKG2D	ENSG00000213809	Killer cell lectin like receptor K1	12	10372353-10391874	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	CAB021896, HPA068877	Enhanced		Supported	Plasma membrane		Not detected	Tissue enhanced		lymph node: 35.1;spleen: 52.8	tonsil: 16.2	Cell line enriched	8	U-698: 41.6
CEACAM18		ENSG00000213822	Carcinoembryonic antigen related cell adhesion molecule 18	19	51478622-51490952	Predicted secreted proteins	Evidence at protein level	HPA059487	Uncertain		Approved	Midbody		Tissue enhanced	Group enriched	14	duodenum: 10.5;small intestine: 7.2	gallbladder: 0.6	Group enriched	12	CACO-2: 3.6;RT4: 1.1
EMP2	XMP	ENSG00000213853	Epithelial membrane protein 2	16	10528422-10580698	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA014711	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 343.9	skin: 166.6	Cell line enhanced		MCF7: 205.4;SK-BR-3: 191.4
KCTD11	C17orf36, KCASH1, REN	ENSG00000213859	Potassium channel tetramerization domain containing 11	17	7351889-7354944	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA052035	Approved		Approved	Nucleoplasm	Ovarian cancer:5.02e-4 (unfavourable), Endometrial cancer:9.55e-4 (favourable)	Expressed in all	Mixed			esophagus: 39.8	Cell line enhanced		HBEC3-KT: 38.4
C8orf44	FLJ11267	ENSG00000213865	Chromosome 8 open reading frame 44	8	66667615-66685564	Predicted intracellular proteins	Evidence at protein level	HPA043660, HPA054753	Uncertain		Enhanced	Nucleoplasm	Renal cancer:1.08e-7 (unfavourable), Urothelial cancer:2.68e-6 (favourable), Pancreatic cancer:4.21e-4 (favourable)	Expressed in all	Mixed			epididymis: 21.2	Expressed in all		
UBD	FAT10	ENSG00000213886	Ubiquitin D	6	29555515-29559925	Predicted intracellular proteins	Evidence at protein level	HPA043710			Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:2.40e-5 (unfavourable), Ovarian cancer:7.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 94.9;tonsil: 92.5	appendix: 43.0	Cell line enriched	6	RT4: 24.7
PPM1N	FLJ40125	ENSG00000213889	Protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)	19	45488777-45502510	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA043577			Supported	Vesicles		Tissue enhanced	Tissue enriched	5	skeletal muscle: 69.9	spleen: 12.9	Cell line enhanced		RT4: 24.0
CEACAM16	DFNA4B	ENSG00000213892	Carcinoembryonic antigen related cell adhesion molecule 16	19	44699151-44710714	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA045075	Uncertain					Not detected	Not detected			tonsil: 0.5	Cell line enhanced		U-266/70: 1.1
SLC23A3	FLJ31168, SVCT3, Yspl1	ENSG00000213901	Solute carrier family 23 member 3	2	219161465-219170095	Predicted membrane proteins, Transporters	Evidence at protein level	HPA019059			Approved	Nucleus<br>Cell Junctions		Tissue enriched	Tissue enhanced		kidney: 53.1;small intestine: 22.9	duodenum: 8.7	Cell line enhanced		hTCEpi: 3.5
LTB4R	BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7	ENSG00000213903	Leukotriene B4 receptor	14	24311450-24318036	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level	HPA003873	Approved				Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 165.8	esophagus: 42.6	Expressed in all		
LTB4R2	BLT2, BLTR2, JULF2, NOP9	ENSG00000213906	Leukotriene B4 receptor 2	14	24305734-24312053	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022689, HPA029680, HPA072921	Uncertain		Supported	Nucleoplasm<br>Plasma membrane		Mixed	Tissue enhanced		skin: 40.5	spleen: 10.3	Cell line enhanced		HaCaT: 24.8
DNASE1	DNL1	ENSG00000213918	Deoxyribonuclease 1	16	3611728-3680143	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA010703	Enhanced		Supported	Vesicles	Urothelial cancer:1.14e-4 (favourable)	Expressed in all	Tissue enhanced		small intestine: 37.8	duodenum: 29.9	Mixed		
MDP1	FN6Pase, MGC5987	ENSG00000213920	Magnesium dependent phosphatase 1	14	24213937-24216070	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003064, HPA070338	Uncertain		Approved	Nucleoplasm	Renal cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 20.3	Mixed		
LEUTX		ENSG00000213921	Leucine twenty homeobox	19	39776595-39786167	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA041498	Uncertain		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CSNK1E	CKIE, CKIepsilon, HCKIE	ENSG00000213923	Casein kinase 1 epsilon	22	38290691-38318084	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB009626, HPA026288	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:4.67e-6 (unfavourable), Liver cancer:8.20e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 171.1	Expressed in all		
CCL27	ALP, CTACK, CTAK, ESkine, ILC, PESKY, SCYA27, skinkine	ENSG00000213927	C-C motif chemokine ligand 27	9	34661880-34664048	Predicted secreted proteins	Evidence at protein level	HPA073848	Enhanced					Not detected	Tissue enriched	16	skin: 504.4	breast: 32.2	Cell line enhanced		AN3-CA: 2.0
IRF9	ISGF3G	ENSG00000213928	Interferon regulatory factor 9	14	24161053-24166565	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001862	Approved		Supported	Cytosol	Renal cancer:7.58e-8 (unfavourable), Urothelial cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			spleen: 94.1	Expressed in all		
GALT		ENSG00000213930	Galactose-1-phosphate uridylyltransferase	9	34638133-34651035	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004868, HPA005729	Enhanced		Approved	Cytosol	Renal cancer:6.25e-6 (favourable), Pancreatic cancer:3.11e-5 (favourable)	Expressed in all	Expressed in all			liver: 25.7	Mixed		
HBE1	HBE	ENSG00000213931	Hemoglobin subunit epsilon 1	11	5268345-5505617	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043234	Approved		Approved	Vesicles		Mixed	Tissue enhanced		testis: 1.0	placenta: 0.9	Cell line enriched	15	K-562: 5976.4
HBG1	HBG-T2	ENSG00000213934	Hemoglobin subunit gamma 1	11	5248083-5249892	Predicted intracellular proteins	Evidence at protein level	HPA043234	Approved		Approved	Vesicles		Not detected	Tissue enriched	66	placenta: 1087.7	bone marrow: 16.4	Group enriched	298	HEL: 988.4;K-562: 1948.2
CLDN9		ENSG00000213937	Claudin 9	16	3012456-3014505	Predicted membrane proteins	Evidence at protein level	HPA076613			Supported	Vesicles<br>Cell Junctions	Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable)	Mixed	Tissue enhanced		parathyroid gland: 3.2	bone marrow: 1.7	Cell line enhanced		CAPAN-2: 5.5;MCF7: 16.8;SCLC-21H: 19.5
ITGA1	CD49a, VLA1	ENSG00000213949	Integrin subunit alpha 1	5	52787896-52959210	Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA042555	Uncertain				Renal cancer:2.24e-4 (unfavourable)	Expressed in all	Mixed			spleen: 78.0	Cell line enhanced		fHDF/TERT166: 28.9;HHSteC: 36.5;WM-115: 32.9
NUDT19	RP2	ENSG00000213965	Nudix hydrolase 19	19	32691961-32713796	Predicted secreted proteins	Evidence at protein level	HPA042761			Uncertain	Nucleus<br>Nucleoli<br>Cytosol	Urothelial cancer:1.35e-4 (favourable)	Expressed in all	Expressed in all			prostate: 12.2	Mixed		
ZNF726		ENSG00000213967	Zinc finger protein 726	19	23914876-23945159	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			epididymis: 6.3	Mixed		
ZNF99	C19orf9, MGC24986	ENSG00000213973	Zinc finger protein 99	19	22752183-22784107	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enriched	Tissue enriched	7	testis: 3.0	cerebral cortex: 0.4	Not detected		
TAX1BP3	TIP-1	ENSG00000213977	Tax1 binding protein 3	17	3662896-3668682	Predicted intracellular proteins	Evidence at protein level	HPA046410, HPA063078	Approved		Approved	Nucleoli fibrillar center<br>Vesicles<br>Actin filaments	Glioma:1.66e-4 (unfavourable), Lung cancer:1.76e-4 (unfavourable), Renal cancer:7.90e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 228.1	Expressed in all		
AP1G2	G2AD	ENSG00000213983	Adaptor related protein complex 1 gamma 2 subunit	14	23559565-23568070	Predicted intracellular proteins	Evidence at protein level	HPA004106	Approved				Renal cancer:1.79e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 59.5	Cell line enhanced		RT4: 119.1
ZNF90	HTF9	ENSG00000213988	Zinc finger protein 90	19	20077994-20127076	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003227	Uncertain		Approved	Nucleus<br>Golgi apparatus		Tissue enhanced	Tissue enhanced		parathyroid gland: 7.6	thyroid gland: 2.7	Cell line enhanced		AN3-CA: 9.0;NTERA-2: 16.5
NAXD	CARKD, FLJ10769, LP3298	ENSG00000213995	NAD(P)HX dehydratase	13	110615460-110639993	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA010551	Uncertain				Renal cancer:4.63e-5 (favourable), Endometrial cancer:3.15e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 26.9	Mixed		
TM6SF2	Lpr4	ENSG00000213996	Transmembrane 6 superfamily member 2	19	19264364-19273391	Predicted membrane proteins	Evidence at protein level	HPA066026	Uncertain					Tissue enhanced	Group enriched	5	duodenum: 77.0;small intestine: 76.8	liver: 14.7	Cell line enhanced		HHSteC: 1.6;LHCN-M2: 1.2;SH-SY5Y: 1.8
MEF2B	RSRFR2	ENSG00000213999	Myocyte enhancer factor 2B	19	19145568-19170289	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004734	Supported					Not detected	Group enriched	9	appendix: 17.6;lymph node: 45.7;tonsil: 27.2	spleen: 3.2	Group enriched	12	Daudi: 157.3;U-266/70: 161.9;U-698: 199.1
GANC		ENSG00000214013	Glucosidase alpha, neutral C	15	42273233-42356935	Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA016949	Approved		Approved	Nucleoplasm<br>Actin filaments	Lung cancer:9.76e-4 (favourable)	Expressed in all	Expressed in all			lung: 29.8	Expressed in all		
TTLL3	DKFZP434B103, HOTTL	ENSG00000214021	Tubulin tyrosine ligase like 3	3	9808086-9855138	Predicted intracellular proteins	Evidence at protein level	HPA051413	Approved				Renal cancer:6.45e-6 (unfavourable), Urothelial cancer:9.51e-6 (favourable)	Mixed	Expressed in all			testis: 52.5	Cell line enhanced		BEWO: 59.9
REPIN1	AP4, H_DJ0584D14.12, RIP60, Zfp464, ZNF464	ENSG00000214022	Replication initiator 1	7	150368189-150374044	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036022	Approved		Enhanced	Nucleus	Pancreatic cancer:1.12e-4 (favourable), Stomach cancer:1.61e-4 (favourable), Renal cancer:5.56e-4 (favourable), Urothelial cancer:6.41e-4 (favourable)	Expressed in all	Expressed in all			spleen: 48.3	Expressed in all		
MRPL23	L23MRP, RPL23L	ENSG00000214026	Mitochondrial ribosomal protein L23	11	1947278-1984522	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050406	Approved		Supported	Nucleoli fibrillar center<br>Mitochondria	Endometrial cancer:3.97e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 89.5	Cell line enhanced		HEK 293: 573.2
ZNF891		ENSG00000214029	Zinc finger protein 891	12	133106817-133130473	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA040301	Uncertain					Mixed	Mixed			testis: 2.1	Mixed		
IFNA7	IFN-alphaJ, IFNA-J	ENSG00000214042	Interferon alpha 7	9	21201469-21202205	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SMIM7	C19orf42, MGC2747	ENSG00000214046	Small integral membrane protein 7	19	16630751-16660442	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA043127	Uncertain		Approved	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 55.4	Expressed in all		
FBXO16	FBX16	ENSG00000214050	F-box protein 16	8	28348287-28490318	Predicted intracellular proteins	Evidence at transcript level	HPA053955, HPA058676	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol	Ovarian cancer:6.70e-5 (favourable)	Mixed	Tissue enhanced		epididymis: 22.4	thyroid gland: 12.1	Cell line enhanced		AF22: 19.5
TSPAN4	NAG-2, TETRASPAN, TM4SF7, TSPAN-4	ENSG00000214063	Tetraspanin 4	11	842808-867116	Predicted membrane proteins	Evidence at protein level						Liver cancer:1.02e-4 (unfavourable), Glioma:2.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 105.4	Expressed in all		
CPNE1	CPN1	ENSG00000214078	Copine 1	20	35626031-35664956	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047259, HPA072634	Approved		Approved	Nucleoplasm<br>Nuclear membrane	Renal cancer:2.74e-10 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 104.0	Expressed in all		
ARL16		ENSG00000214087	ADP ribosylation factor like GTPase 16	17	81681174-81683924	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043711	Uncertain					Expressed in all	Expressed in all			cerebral cortex: 37.8	Expressed in all		
SMCO1	C3orf43, DKFZp313B0440, FLJ41923	ENSG00000214097	Single-pass membrane protein with coiled-coil domains 1	3	196506877-196515366	Predicted intracellular proteins	Evidence at transcript level	HPA061937	Uncertain					Not detected	Group enriched	15	heart muscle: 24.2;skeletal muscle: 51.1	esophagus: 2.5	Not detected		
WEE2	FLJ16107	ENSG00000214102	WEE1 homolog 2	7	141708353-141731271	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027418	Uncertain		Supported	Nucleoplasm<br>Cytosol		Not detected	Not detected			skin,thyroid gland: 0.8	Cell line enhanced		CACO-2: 2.6
MAGEB1	CT3.1, DAM10, MAGE-Xp, MAGEL1, MGC9322	ENSG00000214107	MAGE family member B1	X	30243730-30252038	Predicted intracellular proteins	Evidence at protein level	HPA001193, HPA002820	Enhanced					Tissue enriched	Tissue enriched	45	testis: 29.2	epididymis: 0.6	Group enriched	58	K-562: 22.4;U-266/70: 41.0;U-266/84: 28.1
LYRM4	C6orf149, CGI-203, ISD11	ENSG00000214113	LYR motif containing 4	6	5102593-5260939	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030362	Approved		Supported	Nuclear bodies		Expressed in all	Expressed in all			ovary: 29.5	Expressed in all		
MYCBP	AMY-1	ENSG00000214114	MYC binding protein	1	38862964-38874105	Predicted intracellular proteins	Evidence at protein level	HPA041188	Supported				Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 38.8	Expressed in all		
TMEM213		ENSG00000214128	Transmembrane protein 213	7	138797952-138838101	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054059	Enhanced				Renal cancer:5.54e-7 (favourable)	Tissue enriched	Group enriched	9	kidney: 80.7;salivary gland: 22.6	breast: 5.7	Not detected		
PRCD	RP36	ENSG00000214140	Photoreceptor disc component	17	76527586-76553578	Disease related genes, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			parathyroid gland: 3.1	Cell line enhanced		BEWO: 1.4;Hep G2: 1.5;HHSteC: 1.1;HSkMC: 1.2;SH-SY5Y: 1.4
ALG3	CDGS4, D16Ertd36e, Not56, NOT56L	ENSG00000214160	ALG3, alpha-1,3- mannosyltransferase	3	184242301-184249548	Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA045103	Approved				Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 33.4	Expressed in all		
ZNF788	FLJ46419	ENSG00000214189	Zinc finger family member 788	19	12092263-12137235	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			testis: 5.6	Cell line enhanced		K-562: 20.7;NTERA-2: 20.5
SH3D21	C1orf113, FLJ22938	ENSG00000214193	SH3 domain containing 21	1	36306387-36324886	Predicted intracellular proteins	Evidence at protein level	HPA042212, HPA042456, HPA066168	Approved		Approved	Nucleus<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Breast cancer:2.60e-4 (favourable)	Mixed	Tissue enhanced		small intestine: 22.2	skin: 15.5	Cell line enhanced		HaCaT: 15.2
LINC00998		ENSG00000214194	Long intergenic non-protein coding RNA 998	7	113116718-113118613	Predicted membrane proteins	Evidence at transcript level						Liver cancer:1.02e-4 (unfavourable), Renal cancer:7.21e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 123.3	Mixed		
C19orf38	HIDE1	ENSG00000214212	Chromosome 19 open reading frame 38	19	10836575-10869790	Predicted membrane proteins	Evidence at protein level	HPA012150, HPA055027			Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol	Renal cancer:1.75e-7 (unfavourable), Cervical cancer:2.43e-4 (favourable)	Expressed in all	Tissue enhanced		bone marrow: 62.8	spleen: 17.4	Cell line enhanced		U-937: 39.3
C12orf74		ENSG00000214215	Chromosome 12 open reading frame 74	12	92702843-92708549	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.9	cervix, uterine,urinary bladder: 0.8	Not detected		
IQCJ		ENSG00000214216	IQ motif containing J	3	158962928-159266307	Predicted intracellular proteins	Evidence at transcript level	HPA052835	Uncertain					Not detected	Not detected			testis: 0.9	Cell line enriched	17	Daudi: 3.7
C17orf67		ENSG00000214226	Chromosome 17 open reading frame 67	17	56791913-56838773	Predicted secreted proteins	Evidence at protein level	HPA043479	Uncertain	Approved				Mixed	Mixed			spleen: 3.7	Cell line enhanced		MOLT-4: 11.9
MINDY4B	C3orf76, FAM188B2	ENSG00000214237	MINDY family member 4B	3	150871045-150905439	Predicted intracellular proteins	No evidence							Not detected	Not detected			endometrium: 0.6	Not detected		
FIS1	CGI-135, Fis1, H_NH0132A01.6, TTC11	ENSG00000214253	Fission, mitochondrial 1	7	101239458-101252316	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017430	Approved		Enhanced	Mitochondria	Renal cancer:1.08e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 269.9	Expressed in all		
ANG	RAA1, RNASE5	ENSG00000214274	Angiogenin	14	20684177-20698971	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:7.83e-5 (favourable), Endometrial cancer:6.85e-4 (favourable)	Tissue enriched	Tissue enriched	27	liver: 1565.4	stomach: 57.0	Cell line enriched	5	Hep G2: 105.0
SCART1		ENSG00000214279	Scavenger receptor protein family member	10	133453928-133523558	Predicted membrane proteins	Evidence at protein level	HPA043101	Supported					Not detected	Not detected			endometrium: 0.2	Cell line enhanced		HMC-1: 3.4;NB-4: 2.3;U-266/84: 2.8
NPS		ENSG00000214285	Neuropeptide S	10	127549369-127552639	Predicted secreted proteins	No evidence	CAB020139	Uncertain					Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
COLCA2	C11orf93, CASC13	ENSG00000214290	Colorectal cancer associated 2	11	111298555-111308735	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:8.97e-6 (favourable)	Mixed	Mixed			epididymis: 33.1	Cell line enhanced		HaCaT: 4.7;Hep G2: 7.8;RT4: 8.4;T-47d: 5.3
SPDYE3		ENSG00000214300	Speedy/RINGO cell cycle regulator family member E3	7	100307702-100322196	Predicted intracellular proteins	Evidence at protein level	HPA051750	Supported				Endometrial cancer:2.00e-6 (unfavourable), Breast cancer:8.73e-4 (favourable)	Expressed in all	Tissue enriched	11	testis: 2.3	skin: 0.2	Not detected		
MBLAC1	MGC49416	ENSG00000214309	Metallo-beta-lactamase domain containing 1	7	100126694-100128498	Predicted intracellular proteins	Evidence at protein level	HPA071574	Uncertain				Renal cancer:7.90e-5 (favourable), Pancreatic cancer:1.18e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 3.9	Mixed		
FOXI3		ENSG00000214336	Forkhead box I3	2	88446787-88452656	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enriched	9	placenta: 7.4	testis: 0.8	Cell line enhanced		BEWO: 42.3;HAP1: 6.2;NTERA-2: 11.0
SOGA3	C6orf174, dJ403A15.3	ENSG00000214338	SOGA family member 3	6	127472794-127519191	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035388, HPA035389	Uncertain		Approved	Nucleus<br>Cytosol		Not detected	Tissue enriched	7	cerebral cortex: 10.1	ovary,stomach: 1.5	Cell line enhanced		SCLC-21H: 36.7;SH-SY5Y: 18.9
NEURL1B	DKFZP761M1511, Neur2	ENSG00000214357	Neuralized E3 ubiquitin protein ligase 1B	5	172641266-172691540	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA037612	Approved		Supported	Vesicles	Renal cancer:3.00e-6 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 45.0	Cell line enhanced		REH: 39.9
EFCAB9		ENSG00000214360	EF-hand calcium binding domain 9	5	172194172-172203452	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	97	testis: 15.7	appendix,gallbladder: 0.1	Cell line enhanced		WM-115: 1.5
HAUS3	C4orf15, dgt3, IT1, MGC4701	ENSG00000214367	HAUS augmin like complex subunit 3	4	2227464-2242164	Predicted intracellular proteins	Evidence at protein level	HPA040649, HPA048190	Approved		Approved	Microtubules<br>Cytokinetic bridge<br>Mitotic spindle<br>Mitochondria	Urothelial cancer:4.78e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 31.8	Expressed in all		
VSTM5	C11orf90, LOC387804	ENSG00000214376	V-set and transmembrane domain containing 5	11	93818232-93850531	Predicted membrane proteins	Evidence at transcript level	HPA029525, HPA063591	Uncertain		Uncertain	Endoplasmic reticulum		Mixed	Tissue enhanced		placenta: 6.5	cerebral cortex: 2.8	Cell line enhanced		HaCaT: 1.1;PC-3: 5.1;SH-SY5Y: 2.3
LCNL1	FLJ45224	ENSG00000214402	Lipocalin like 1	9	136981904-136986410	Predicted intracellular proteins	Evidence at transcript level							Mixed	Not detected			seminal vesicle: 0.7	Not detected		
BBIP1	bA348N5.3, BBIP10, BBS18, NCRNA00081	ENSG00000214413	BBSome interacting protein 1	10	110898730-110919274	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055206	Uncertain					Expressed in all	Expressed in all			testis: 180.8	Expressed in all		
TRIM77	TRIM77P	ENSG00000214414	Tripartite motif containing 77	11	89710299-89717872	Predicted intracellular proteins	Evidence at transcript level	HPA039896	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
GNAT3	GDCA, gustducin	ENSG00000214415	G protein subunit alpha transducin 3	7	80458671-80512020	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		duodenum: 1.9;small intestine: 1.4	testis: 0.5	Cell line enriched	8	SCLC-21H: 3.9
AS3MT	CYT19	ENSG00000214435	Arsenite methyltransferase	10	102869516-102901899	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA017856	Enhanced		Approved	Nucleus<br>Mitochondria		Tissue enhanced	Group enriched	6	adrenal gland: 251.5;parathyroid gland: 119.3	liver: 30.4	Cell line enhanced		REH: 50.0;SH-SY5Y: 29.9;T-47d: 41.6
FAM187A		ENSG00000214447	Family with sequence similarity 187 member A	17	44899712-44905390	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA022794, HPA043131	Approved		Approved	Cytosol		Not detected	Tissue enhanced		fallopian tube: 24.6;testis: 17.2	thyroid gland: 5.3	Cell line enhanced		U-87 MG: 12.7
PLIN5	LSDA5, LSDP5, MLDP, OXPAT	ENSG00000214456	Perilipin 5	19	4522531-4535224	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.97e-4 (favourable), Urothelial cancer:2.16e-4 (favourable), Liver cancer:2.81e-4 (favourable), Breast cancer:7.68e-4 (favourable), Endometrial cancer:8.56e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 34.5;ovary: 42.4	salivary gland: 25.8	Cell line enhanced		BEWO: 3.2;SH-SY5Y: 3.0;T-47d: 5.9
SEC14L6		ENSG00000214491	SEC14 like lipid binding 6	22	30522799-30546682	Predicted intracellular proteins	Evidence at transcript level	HPA067695			Approved	Nucleoplasm		Tissue enriched	Tissue enhanced		epididymis: 25.8;parathyroid gland: 46.1	lung: 17.8	Cell line enhanced		K-562: 11.1;RPTEC TERT1: 16.7;SiHa: 7.0
SPINK13	HESPINTOR, LiESP6, MGC149260, SPINK5L3	ENSG00000214510	Serine peptidase inhibitor, Kazal type 13 (putative)	5	148268180-148286254	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA036456	Uncertain		Approved	Nucleus<br>Plasma membrane	Renal cancer:4.03e-10 (unfavourable)	Group enriched	Tissue enriched	8	epididymis: 309.7	seminal vesicle: 37.3	Cell line enriched	13	HeLa: 304.5
HIGD1C	Gm921	ENSG00000214511	HIG1 hypoxia inducible domain family member 1C	12	50953922-50970506	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.9	parathyroid gland: 2.1	Cell line enhanced		BEWO: 1.2;Karpas-707: 1.1
NOTO		ENSG00000214513	Notochord homeobox	2	73202258-73212513	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA034660	Uncertain					Not detected	Not detected			skin: 0.4	Not detected		
PPME1	PME-1	ENSG00000214517	Protein phosphatase methylesterase 1	11	74171099-74254703	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004541, HPA043900, HPA064396	Uncertain		Supported	Nucleus<br>Nuclear bodies	Liver cancer:4.45e-6 (unfavourable), Renal cancer:2.76e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 156.1	Expressed in all		
KRTAP2-2	KAP2.2	ENSG00000214518	Keratin associated protein 2-2	17	41054498-41055230	Predicted intracellular proteins	Evidence at protein level	HPA059203	Supported					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
STARD10	CGI-52, NY-CO-28, PCTP2, SDCCAG28	ENSG00000214530	StAR related lipid transfer domain containing 10	11	72754729-72794168	Predicted intracellular proteins	Evidence at protein level	HPA026661	Uncertain				Breast cancer:6.92e-4 (favourable)	Expressed in all	Expressed in all			rectum: 205.1	Expressed in all		
ZNF705E		ENSG00000214534	Zinc finger protein 705E	11	71814045-71821548	Predicted intracellular proteins	No evidence							Not detected	Not detected			epididymis: 0.6	Not detected		
NUTM2D	FAM22D	ENSG00000214562	NUT family member 2D	10	87357668-87370695	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 7.1	Mixed		
CPEB1	CPEB, FLJ13203	ENSG00000214575	Cytoplasmic polyadenylation element binding protein 1	15	82543201-82648861	Predicted intracellular proteins	Evidence at protein level	HPA040396			Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		testis: 61.1	cerebral cortex: 22.3	Cell line enhanced		SK-MEL-30: 29.5;U-2197: 103.8;U-87 MG: 39.3
EML6	FLJ42562	ENSG00000214595	Echinoderm microtubule associated protein like 6	2	54723499-54972025	Predicted intracellular proteins	Evidence at protein level	HPA062808, HPA068759	Uncertain		Approved	Vesicles<br>Mitochondria		Mixed	Tissue enhanced		lymph node: 7.5;tonsil: 8.3	appendix: 4.4	Cell line enhanced		SCLC-21H: 32.4;U-698: 22.3
DEFB113	DEFB-13	ENSG00000214642	Defensin beta 113	6	49968677-49969625	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	568	epididymis: 56.8	all non-specific tissues: 0.0	Not detected		
DEFB133		ENSG00000214643	Defensin beta 133	6	49946021-49950265	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	158	epididymis: 15.7	all non-specific tissues: 0.0	Not detected		
ZNF727	ZNF727P	ENSG00000214652	Zinc finger protein 727	7	64045443-64078549	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051027, HPA061215	Uncertain		Uncertain	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 5.8	Cell line enriched	7	T-47d: 7.1
RP11-27I1.4		ENSG00000214654	Putative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase LOC100288842 	9	120793551-120799918	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Mixed			thyroid gland: 5.0	Mixed		
ZSWIM8	4832404P21Rik, KIAA0913	ENSG00000214655	Zinc finger SWIM-type containing 8	10	73785582-73801797	Predicted intracellular proteins	Evidence at protein level	HPA041244	Approved		Approved	Plasma membrane<br>Cytosol	Head and neck cancer:5.61e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 63.2	Expressed in all		
IQCF5		ENSG00000214681	IQ motif containing F5	3	51873721-51875584	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	708	testis: 70.8	all non-specific tissues: 0.0	Not detected		
IQCF6		ENSG00000214686	IQ motif containing F6	3	51778561-51779187	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	125	testis: 17.6	kidney,skin,stomach: 0.1	Cell line enhanced		U-937: 1.1
C10orf105	FLJ00245	ENSG00000214688	Chromosome 10 open reading frame 105	10	71711702-71737824	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		cerebral cortex: 2.3;spleen: 3.2	testis: 1.4	Cell line enriched	6	BJ hTERT+: 2.6
ARHGEF33		ENSG00000214694	Rho guanine nucleotide exchange factor 33	2	38889880-38975449	Predicted intracellular proteins	Evidence at protein level	HPA034661, HPA041051	Enhanced		Supported	Vesicles		Mixed	Tissue enhanced		testis: 10.6	ovary: 4.3	Cell line enhanced		BEWO: 5.4;SiHa: 7.6
C12orf71	LOC728858	ENSG00000214700	Chromosome 12 open reading frame 71	12	27081058-27082514	Predicted intracellular proteins	Evidence at transcript level	HPA058728	Uncertain					Not detected	Tissue enhanced		testis: 4.8	skin: 1.0	Cell line enhanced		HDLM-2: 1.4
IFRD2	IFNRP, SKMc15, SM15	ENSG00000214706	Interferon related developmental regulator 2	3	50287732-50292918	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA068560	Approved		Approved	Nucleoplasm	Renal cancer:2.50e-4 (favourable), Breast cancer:7.22e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 28.9	Expressed in all		
CAPN14		ENSG00000214711	Calpain 14	2	31173056-31233858	Enzymes, Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	26	esophagus: 88.2	tonsil: 3.3	Cell line enhanced		U-266/70: 2.1
ZBED1	ALTE, DREF, hDREF, KIAA0785, TRAMP	ENSG00000214717	Zinc finger BED-type containing 1	X	2486414-2500967	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:3.13e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 24.6	Cell line enhanced		BEWO: 87.7
RP1-139D8.6		ENSG00000214732		6	42155426-42163439	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	363	testis: 67.8	cervix, uterine,esophagus: 0.1	Not detected		
TOMM6	OBTP, Tom6	ENSG00000214736	Translocase of outer mitochondrial membrane 6	6	41787662-41789898	Predicted intracellular proteins	Evidence at protein level	HPA004801	Approved		Supported	Mitochondria		Not detected	Expressed in all			epididymis: 322.2	Expressed in all		
HNRNPUL2	DKFZp762N1910, HNRPUL2	ENSG00000214753	Heterogeneous nuclear ribonucleoprotein U like 2	11	62712630-62727349	Predicted intracellular proteins	Evidence at protein level	HPA041632, HPA056696, HPA067699	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 59.2	Expressed in all		
METTL12	U99HG	ENSG00000214756	Methyltransferase like 12	11	62665309-62668496	Predicted intracellular proteins	Evidence at transcript level	HPA038115, HPA038533	Uncertain				Breast cancer:8.73e-4 (favourable)	Expressed in all	Not detected			fallopian tube: 0.8	Mixed		
RP11-726G1.1		ENSG00000214776		12	9467552-9576275	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enhanced		parathyroid gland: 1.0;testis: 1.8	endometrium,lymph node: 0.4	Cell line enhanced		U-698: 4.3;WM-115: 2.1
MS4A18		ENSG00000214782	Membrane spanning 4-domains A18	11	60729304-60744212	Predicted membrane proteins	Evidence at transcript level	HPA045121	Approved					Not detected	Tissue enhanced		breast: 10.3;duodenum: 23.9	small intestine: 4.0	Not detected		
MS4A4E		ENSG00000214787	Membrane spanning 4-domains A4E	11	60201253-60243088	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040075	Uncertain					Mixed	Mixed			adipose tissue: 5.9	Cell line enhanced		K-562: 1.9;THP-1: 2.0
FER1L6	C8ORFK23	ENSG00000214814	Fer-1 like family member 6	8	123851987-124120061	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA054117	Uncertain					Group enriched	Group enriched	5	rectum: 12.0;stomach: 42.4	small intestine: 5.1	Cell line enhanced		AF22: 1.0;ASC TERT1: 1.3;BJ hTERT+: 1.0;PC-3: 1.6;U-87 MG: 1.6
CDRT15L2		ENSG00000214819	CMT1A duplicated region transcript 15-like 2	17	20579724-20580911	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 13.2	epididymis: 1.2	Not detected		
MTCP1	P13MTCP1, p8MTCP1	ENSG00000214827	Mature T-cell proliferation 1	X	155061622-155147937	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032040			Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:4.52e-8 (unfavourable)	Mixed	Mixed			testis: 8.7	Mixed		
RAD51AP2	FLJ17540	ENSG00000214842	RAD51 associated protein 2	2	17510584-17518439	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	39	testis: 16.9	cerebral cortex: 0.4	Not detected		
EVPLL		ENSG00000214860	Envoplakin like	17	18377662-18389647	Predicted intracellular proteins	Evidence at transcript level	HPA045728	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Not detected	Tissue enhanced		esophagus: 1.7;skin: 3.0;testis: 1.5	lung: 0.8	Cell line enhanced		HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9
DCDC2C		ENSG00000214866	Doublecortin domain containing 2C	2	3703592-3847411	Predicted intracellular proteins	Evidence at transcript level	HPA045848	Uncertain					Not detected	Tissue enriched	40	testis: 5.9	fallopian tube,prostate: 0.1	Not detected		
SMTNL1	CHASM	ENSG00000214872	Smoothelin like 1	11	57542641-57550274	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	26	skeletal muscle: 240.9	esophagus: 9.3	Cell line enhanced		U-266/70: 1.2
TRIM64C		ENSG00000214891	Tripartite motif containing 64C	11	49053714-49059112	Predicted intracellular proteins	No evidence	HPA045370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
U82695.5		ENSG00000214897		X	153395640-153401420	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	35	epididymis: 5.8;ovary: 4.7;testis: 10.9	fallopian tube: 0.2	Not detected		
SPATA31D1	FAM75D1, FLJ46321	ENSG00000214929	SPATA31 subfamily D member 1	9	81988772-81995256	Predicted membrane proteins	Evidence at transcript level	HPA047897	Uncertain					Not detected	Tissue enriched	100	testis: 9.9	all non-specific tissues: 0.0	Not detected		
NPIPA8	LCR16a9	ENSG00000214940	Nuclear pore complex interacting protein family member A8	16	18317942-18336736	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Mixed			cerebral cortex: 21.8	Cell line enhanced		EFO-21: 55.7;HMC-1: 196.9;SCLC-21H: 63.6
ZSWIM7	SWS1	ENSG00000214941	Zinc finger SWIM-type containing 7	17	15976560-15999717	Predicted intracellular proteins	Evidence at protein level	HPA054681	Uncertain		Uncertain	Cytosol	Endometrial cancer:3.54e-5 (favourable), Pancreatic cancer:1.77e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 11.9	Expressed in all		
GPR33		ENSG00000214943	G protein-coupled receptor 33 (gene/pseudogene)	14	31482875-31488142	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			spleen: 0.3	Not detected		
ARHGEF28	p190RhoGEF, RGNEF, RIP2	ENSG00000214944	Rho guanine nucleotide exchange factor 28	5	73626158-73941993	Predicted intracellular proteins	Evidence at protein level	HPA037602	Enhanced		Approved	Plasma membrane<br>Microtubules<br>Cytosol	Renal cancer:1.91e-6 (favourable), Cervical cancer:5.31e-4 (favourable), Urothelial cancer:8.98e-4 (favourable)	Mixed	Mixed			kidney: 33.7	Cell line enhanced		hTERT-HME1: 75.2;LHCN-M2: 76.8;TIME: 48.7
TBC1D26	MGC51025	ENSG00000214946	TBC1 domain family member 26	17	15732247-15749192	Predicted intracellular proteins	Evidence at transcript level	HPA050460	Uncertain					Not detected	Tissue enriched	68	testis: 16.4	breast,cerebral cortex,lung,parathyroid gland,skin: 0.2	Cell line enhanced		U-698: 1.0
LRRC69		ENSG00000214954	Leucine rich repeat containing 69	8	91101832-91219236	Predicted intracellular proteins	Evidence at transcript level	HPA046337	Uncertain		Approved	Plasma membrane		Mixed	Tissue enhanced		testis: 5.2	skin: 2.0	Cell line enhanced		HEK 293: 5.7;U-266/70: 12.2;U-266/84: 6.6
ISPD	hCG_1745121, IspD, Nip	ENSG00000214960	Isoprenoid synthase domain containing	7	16087527-16421322	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043810, HPA053554	Approved		Approved	Nucleus<br>Nucleoli fibrillar center	Renal cancer:1.38e-11 (favourable)	Mixed	Mixed			cerebral cortex: 3.5	Cell line enhanced		HEL: 6.9
NPIPA7		ENSG00000214967	Nuclear pore complex interacting protein family member A7	16	16379055-16393954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Expressed in all			parathyroid gland: 48.8	Expressed in all		
GSG1L2		ENSG00000214978	GSG1 like 2	17	9802386-9822071	Predicted membrane proteins	Evidence at transcript level	HPA059428	Uncertain					Tissue enriched	Group enriched	13	cerebral cortex: 1.5;testis: 1.0	all non-specific tissues: 0.0	Not detected		
ACSM4		ENSG00000215009	Acyl-CoA synthetase medium-chain family member 4	12	7304284-7328724	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA049895	Uncertain					Not detected	Tissue enhanced		testis: 1.7	spleen: 0.7	Cell line enhanced		HDLM-2: 1.6;NB-4: 1.1;SH-SY5Y: 2.2;U-87 MG: 2.8
C22orf29	BOP, FLJ21125	ENSG00000215012	Chromosome 22 open reading frame 29	22	19846138-19854896	Predicted intracellular proteins	Evidence at protein level	HPA000721, HPA001419	Uncertain				Liver cancer:8.04e-5 (unfavourable)	Expressed in all	Mixed			skin: 15.9	Expressed in all		
COL28A1		ENSG00000215018	Collagen type XXVIII alpha 1 chain	7	7356203-7535853	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043844, HPA060468	Uncertain		Approved	Nucleoplasm<br>Cytosol		Tissue enhanced	Tissue enhanced		epididymis: 18.2	fallopian tube: 8.0	Cell line enhanced		U-266/70: 7.6;WM-115: 4.8
PHB2	Bap37, BCAP37, p22, REA	ENSG00000215021	Prohibitin 2	12	6965327-6970825	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB014889, CAB026335, HPA039874	Supported		Enhanced	Mitochondria	Endometrial cancer:3.80e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 269.3	Expressed in all		
TCP11X2		ENSG00000215029	T-complex 11 family, X-linked 2	X	102374628-102471812	Predicted intracellular proteins	Evidence at protein level	HPA048311	Supported					Not detected	Tissue enhanced		testis: 1.5	fallopian tube: 0.9	Cell line enriched	6	SCLC-21H: 1.2
NEURL4	KIAA1787	ENSG00000215041	Neuralized E3 ubiquitin protein ligase 4	17	7315628-7329393	Predicted intracellular proteins	Evidence at protein level	HPA043678, HPA055314	Uncertain				Pancreatic cancer:2.34e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 18.9	Expressed in all		
GRID2IP		ENSG00000215045	Grid2 interacting protein	7	6497462-6551436	Predicted intracellular proteins	Evidence at protein level	HPA045381	Uncertain					Mixed	Mixed			parathyroid gland: 1.3	Cell line enhanced		REH: 3.3
CXorf49B		ENSG00000215113	Chromosome X open reading frame 49B	X	71763424-71767204	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 2.6	all non-specific tissues: 0.0	Cell line enriched	7	A-431: 8.0
UBXN2B	p37	ENSG00000215114	UBX domain protein 2B	8	58411264-58451501	Predicted intracellular proteins	Evidence at protein level	HPA045278	Uncertain		Approved	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 27.0	Expressed in all		
CXorf49		ENSG00000215115	Chromosome X open reading frame 49	X	71714371-71718151	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 2.6	all non-specific tissues: 0.0	Cell line enriched	7	A-431: 8.0
CBWD7		ENSG00000215126	COBW domain containing 7	9	41131306-41199261	Predicted intracellular proteins	Evidence at transcript level	HPA042759, HPA042813	Approved		Approved	Plasma membrane		Not detected	Tissue enhanced		adrenal gland: 4.9	breast,seminal vesicle: 2.7	Cell line enhanced		PC-3: 25.0
C16orf90	LOC646174	ENSG00000215131	Chromosome 16 open reading frame 90	16	3493484-3495480	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	214	testis: 21.4	all non-specific tissues: 0.0	Not detected		
PRSS41	TESSP1	ENSG00000215148	Protease, serine 41	16	2798485-2805302	Enzymes, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	6	testis: 1.6	stomach: 0.2	Cell line enriched	11	BEWO: 1.7
NLRP2B	CLRX.1, NALP2P, NLRP2P, NOD24, POP4	ENSG00000215174	NLR family pyrin domain containing 2B	X	57677067-57680260	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MUC5AC	MUC5	ENSG00000215182	Mucin 5AC, oligomeric mucus/gel-forming	11	1157953-1201138	Predicted secreted proteins	Evidence at protein level	CAB002774, CAB009395, HPA040456, HPA040615	Enhanced		Uncertain	Vesicles		Tissue enhanced	Tissue enriched	61	stomach: 179.1	cervix, uterine: 2.9	Cell line enriched	18	A549: 18.0
MSMP	PC-3, PSMP	ENSG00000215183	Microseminoprotein, prostate associated	9	35752990-35756613	Predicted intracellular proteins	Evidence at protein level	HPA055174	Uncertain		Supported	Vesicles<br>Cytosol		Not detected	Tissue enriched	5	placenta: 1.8	appendix: 0.3	Group enriched	8	HUVEC TERT2: 72.1;PC-3: 101.9
GOLGA6B		ENSG00000215186	Golgin A6 family member B	15	72654738-72666394	Predicted intracellular proteins	Evidence at protein level	HPA044978, HPA050087	Supported					Not detected	Group enriched	14	liver: 1.9;testis: 5.3	cerebral cortex: 0.2	Not detected		
FAM166B		ENSG00000215187	Family with sequence similarity 166 member B	9	35561831-35563899	Predicted intracellular proteins	Evidence at protein level	HPA045540	Enhanced				Ovarian cancer:6.20e-6 (favourable), Endometrial cancer:2.61e-5 (favourable)	Group enriched	Group enriched	13	adrenal gland: 369.8;fallopian tube: 159.2;skeletal muscle: 82.6	epididymis: 16.2	Cell line enhanced		Hep G2: 1.1
PEX26	FLJ20695	ENSG00000215193	Peroxisomal biogenesis factor 26	22	18077920-18131138	Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB070429	Approved				Renal cancer:1.38e-4 (favourable), Liver cancer:3.10e-4 (unfavourable), Colorectal cancer:9.92e-4 (favourable)	Expressed in all	Expressed in all			small intestine: 34.1	Expressed in all		
GRXCR1	DFNB25, PPP1R88	ENSG00000215203	Glutaredoxin and cysteine rich domain containing 1	4	42893267-43030658	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040824	Uncertain					Not detected	Tissue enriched	8	seminal vesicle: 6.3	testis: 0.7	Not detected		
C5orf49	LOC134121	ENSG00000215217	Chromosome 5 open reading frame 49	5	7830378-7851490	Predicted intracellular proteins	Evidence at protein level	HPA043759	Enhanced					Tissue enhanced	Group enriched	10	fallopian tube: 120.5;testis: 30.9	lung: 7.8	Not detected		
UBE2QL1	FLJ25076	ENSG00000215218	Ubiquitin conjugating enzyme E2 Q family like 1	5	6448623-6494909	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057414			Supported	Nucleus<br>Plasma membrane	Renal cancer:6.81e-8 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 41.8	seminal vesicle: 10.4	Cell line enhanced		Karpas-707: 29.4;PC-3: 32.0;SCLC-21H: 37.2;U-266/70: 57.9;U-266/84: 50.5
FASTKD5	FLJ13149	ENSG00000215251	FAST kinase domains 5	20	3146519-3159897	Predicted intracellular proteins	Evidence at protein level	HPA043833	Approved				Renal cancer:8.19e-8 (favourable), Liver cancer:4.05e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 22.9	Expressed in all		
GOLGA8B		ENSG00000215252	Golgin A8 family member B	15	34525207-34588503	Predicted intracellular proteins	Evidence at transcript level	HPA051808	Approved		Approved	Golgi apparatus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Urothelial cancer:5.79e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 47.9	testis: 23.1	Cell line enhanced		NB-4: 15.7
KCNU1	KCa5.1, Kcnma3, KCNMC1, Slo3	ENSG00000215262	Potassium calcium-activated channel subfamily U member 1	8	36784324-36936128	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA063317			Uncertain	Plasma membrane		Tissue enhanced	Tissue enriched	28	testis: 13.5	adipose tissue,epididymis: 0.4	Cell line enriched	6	HDLM-2: 7.3
GAGE12G		ENSG00000215269	G antigen 12G	X	49570434-49577754	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	78	stomach: 7.8	all non-specific tissues: 0.0	Cell line enriched	7	AN3-CA: 898.2
HOMEZ	KIAA1443	ENSG00000215271	Homeobox and leucine zipper encoding	14	23272422-23299447	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA036316, HPA036317	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:1.17e-11 (favourable), Ovarian cancer:2.41e-5 (favourable), Thyroid cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 41.7	Expressed in all		
GAGE10		ENSG00000215274	G antigen 10	X	49303669-49319844	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		ovary: 1.1;testis: 1.4	fallopian tube: 0.7	Cell line enhanced		AN3-CA: 2.3;WM-115: 1.0
RNF212B	C14orf164	ENSG00000215277	Ring finger protein 212B	14	23185316-23273477	Predicted intracellular proteins	Evidence at transcript level	HPA053574	Uncertain					Not detected	Group enriched	20	kidney: 27.7;testis: 10.4	thyroid gland: 0.9	Not detected		
DDX3X	DBX, DDX14, DDX3, HLP2	ENSG00000215301	DEAD-box helicase 3, X-linked	X	41333348-41364472	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001648, HPA005631, HPA059585	Supported	Approved	Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 274.6	Expressed in all		
VPS16		ENSG00000215305	VPS16, CORVET/HOPS core subunit	20	2840703-2866732	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043229, HPA048661	Approved				Pancreatic cancer:5.89e-5 (favourable), Renal cancer:8.02e-5 (unfavourable), Liver cancer:1.43e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 29.5	Expressed in all		
ZNF705D		ENSG00000215343	Zinc finger protein 705D	8	12104389-12115516	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enriched	6	epididymis: 4.5	testis: 0.7	Not detected		
ZNF705B		ENSG00000215356	Zinc finger protein 705B	8	7926337-7952413	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
ZNF705G		ENSG00000215372	Zinc finger protein 705G	8	7355517-7385558	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Not detected		
MYL5		ENSG00000215375	Myosin light chain 5	4	673580-682033	Predicted intracellular proteins	Evidence at protein level	HPA037381, HPA039262	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			parathyroid gland: 22.9	Expressed in all		
SCRT2	ZNF898B	ENSG00000215397	Scratch family transcriptional repressor 2	20	661596-676179	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA067697			Approved	Nucleoplasm		Tissue enriched	Not detected			cerebral cortex: 0.6	Group enriched	5	Karpas-707: 1.4;NTERA-2: 1.8;RPMI-8226: 2.8;SCLC-21H: 2.2;SH-SY5Y: 2.1
ZNF407	FLJ13839, FLJ20307, KIAA1703	ENSG00000215421	Zinc finger protein 407	18	74597870-75065671	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028255, HPA041673	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:9.79e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.0	Mixed		
NPEPL1	bA261P9.2, FLJ11583	ENSG00000215440	Aminopeptidase-like 1	20	58689131-58719238	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB004986, CAB017025, HPA036356	Approved		Approved	Nucleoplasm	Renal cancer:1.87e-9 (unfavourable), Urothelial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			spleen: 24.7	Cell line enhanced		MCF7: 78.7
KRTAP10-4	KAP10.4, KRTAP18-4, KRTAP18.4	ENSG00000215454	Keratin associated protein 10-4	21	44573724-44638284	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			fallopian tube: 0.1	Not detected		
KRTAP10-1	KAP10.1, KAP18.1, KRTAP18-1	ENSG00000215455	Keratin associated protein 10-1	21	44538981-44540195	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RPL17-C18orf32		ENSG00000215472	RPL17-C18orf32 readthrough	18	49481681-49492479	Predicted intracellular proteins	Evidence at protein level	HPA043724, HPA046385	Approved		Supported	Endoplasmic reticulum<br>Cytosol		Not detected	Expressed in all			cerebral cortex: 66.2	Mixed		
SKOR2	CORL2, Fussel-18, FUSSEL18	ENSG00000215474	SKI family transcriptional corepressor 2	18	47206322-47251603	Predicted intracellular proteins	Evidence at protein level	HPA046206	Uncertain					Not detected	Not detected			testis: 0.7	Cell line enhanced		NTERA-2: 3.9
SIAH3	FLJ39203	ENSG00000215475	Siah E3 ubiquitin protein ligase family member 3	13	45777243-45851736	Predicted intracellular proteins	Evidence at transcript level	HPA060576	Uncertain					Tissue enhanced	Tissue enhanced		fallopian tube: 5.0	cerebral cortex,cervix, uterine: 1.4	Cell line enriched	8	EFO-21: 1.0
EFCAB8		ENSG00000215529	EF-hand calcium binding domain 8	20	32858923-32961609	Predicted intracellular proteins	Evidence at transcript level	CAB034246, HPA042751	Uncertain					Not detected	Tissue enriched	6	testis: 2.8	appendix,small intestine,thyroid gland: 0.4	Not detected		
DEFB116	DEFB-16	ENSG00000215545	Defensin beta 116	20	31303212-31308585	Predicted secreted proteins	No evidence	HPA047430	Uncertain					Not detected	Not detected			epididymis: 0.6	Not detected		
DEFB115	DEFB-15	ENSG00000215547	Defensin beta 115	20	31257664-31259632	Predicted secreted proteins	Evidence at transcript level	HPA053160	Uncertain					Not detected	Tissue enriched	14	epididymis: 1.3	all non-specific tissues: 0.0	Cell line enriched	16	U-2 OS: 1.6
GAB4		ENSG00000215568	GRB2 associated binding protein family member 4	22	16961936-17008222	Predicted intracellular proteins	Evidence at transcript level	HPA044621	Uncertain					Not detected	Tissue enriched	38	testis: 3.7	all non-specific tissues: 0.0	Not detected		
C20orf202		ENSG00000215595	Chromosome 20 open reading frame 202	20	1203454-1208274	Predicted intracellular proteins	Evidence at transcript level	HPA042786	Uncertain					Mixed	Tissue enhanced		placenta: 4.9	lung: 1.9	Not detected		
HMX1	H6, NKX5-3	ENSG00000215612	H6 family homeobox 1	4	8846076-8871817	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 1.1	testis: 0.9	Cell line enhanced		AN3-CA: 9.5;EFO-21: 5.6;HEK 293: 10.2;SH-SY5Y: 4.4
GCGR	GGR	ENSG00000215644	Glucagon receptor	17	81804132-81814013	FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA071228			Approved	Golgi apparatus		Tissue enhanced	Group enriched	7	adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0	skin: 1.6	Cell line enhanced		HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
RSC1A1	RS1	ENSG00000215695	Regulator of solute carriers 1	1	15659869-15661722	Predicted intracellular proteins	Evidence at protein level	HPA027813, HPA028676	Approved		Supported	Nucleoplasm<br>Cell Junctions		Not detected	Mixed			smooth muscle: 5.3	Mixed		
CELA2B	ELA2B, RP11-265F14.2	ENSG00000215704	Chymotrypsin like elastase family member 2B	1	15465909-15491400	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	262	pancreas: 4261.7	ovary: 16.2	Cell line enriched	5	U-138 MG: 3.8
TMEM242	BM033, C6orf35	ENSG00000215712	Transmembrane protein 242	6	157289386-157323601	Predicted membrane proteins	Evidence at protein level	HPA025764	Approved					Expressed in all	Expressed in all			cerebral cortex: 16.9	Expressed in all		
TMEM167B	AD-020, C1orf119, FLJ90710	ENSG00000215717	Transmembrane protein 167B	1	109089803-109096934	Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:8.86e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 49.3	Expressed in all		
FAM72D		ENSG00000215784	Family with sequence similarity 72 member D	1	145096000-145112696	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 5.6	tonsil: 4.1	Mixed		
TNFRSF25	APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR	ENSG00000215788	TNF receptor superfamily member 25	1	6461151-6466195	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069834			Approved	Nucleus<br>Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 29.6	spleen: 12.1	Cell line enhanced		HDLM-2: 24.6;RPMI-8226: 17.9
SLC35E2	KIAA0447	ENSG00000215790	Solute carrier family 35 member E2	1	1724838-1745992	Predicted membrane proteins	Evidence at transcript level	HPA062711	Uncertain		Uncertain	Nucleus		Mixed	Mixed			thyroid gland: 7.5	Mixed		
ZC3H11B	ZC3HDC11B	ENSG00000215817	Zinc finger CCCH-type containing 11B pseudogene	1	219608347-219613145	Predicted intracellular proteins	Evidence at protein level	HPA026439, HPA028490, HPA028526	Uncertain		Approved	Nuclear speckles		Not detected	Tissue enriched	13	testis: 8.1	skin: 0.6	Not detected		
TSTD1	KAT	ENSG00000215845	Thiosulfate sulfurtransferase like domain containing 1	1	161037631-161038990	Predicted intracellular proteins	Evidence at protein level	HPA006518, HPA006655	Approved		Approved	Cytosol<br>Cytoplasmic bodies		Expressed in all	Expressed in all			thyroid gland: 146.9	Cell line enhanced		SK-BR-3: 203.3;T-47d: 247.1;U-266/70: 231.6
RPTN	FLJ39117	ENSG00000215853	Repetin	1	152153595-152159228	Predicted intracellular proteins	Evidence at protein level	HPA030483, HPA030485	Enhanced					Tissue enhanced	Group enriched	34	skin: 35.1;tonsil: 47.4	esophagus: 1.2	Not detected		
CYB5RL	LOC606495	ENSG00000215883	Cytochrome b5 reductase like	1	54169651-54200036	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042671, HPA060463	Approved		Enhanced	Nucleoplasm		Mixed	Mixed			ovary: 5.3	Expressed in all		
LACTBL1		ENSG00000215906	Lactamase beta like 1	1	22953043-22965338	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Not detected		
C1orf167	DKFZp434E1410, RP11-56N19.2	ENSG00000215910	Chromosome 1 open reading frame 167	1	11761787-11789585	Predicted intracellular proteins	Evidence at transcript level	HPA039114	Uncertain					Not detected	Tissue enriched	30	testis: 14.7	lung: 0.4	Cell line enriched	50	U-698: 21.3
TTC34		ENSG00000215912	Tetratricopeptide repeat domain 34	1	2635976-2801717	Predicted intracellular proteins	Evidence at transcript level	HPA066832	Uncertain					Not detected	Tissue enhanced		fallopian tube: 1.6;testis: 2.6	thyroid gland: 0.8	Not detected		
ATAD3C	FLJ34599	ENSG00000215915	ATPase family, AAA domain containing 3C	1	1449689-1470158	Predicted intracellular proteins	Evidence at protein level	HPA065305			Approved	Mitochondria	Lung cancer:5.15e-4 (favourable)	Mixed	Mixed			thyroid gland: 3.4	Cell line enhanced		RPMI-8226: 9.0
IFI30	GILT, IFI-30, IP-30, IP30, MGC32056	ENSG00000216490	IFI30, lysosomal thiol reductase	19	18173162-18178117	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026650	Approved		Supported	Vesicles<br>Cytosol		Mixed	Expressed in all			appendix: 828.7	Cell line enhanced		Daudi: 385.9;RPMI-8226: 408.1;U-266/84: 467.0
IGSF23		ENSG00000216588	Immunoglobulin superfamily member 23	19	44613630-44636781	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051811, HPA054591	Uncertain		Approved	Nucleus<br>Cell Junctions	Liver cancer:7.20e-6 (favourable)	Tissue enriched	Group enriched	7	duodenum: 15.2;liver: 13.0;small intestine: 17.4	testis: 2.3	Cell line enhanced		CACO-2: 9.0;Hep G2: 4.4;SiHa: 5.2
GAGE12E		ENSG00000216649	G antigen 12E	X	49551333-49558649	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	19	testis: 1.9	all non-specific tissues: 0.0	Cell line enhanced		AN3-CA: 2.9;HeLa: 1.1;U-266/84: 1.4
AC131097.4		ENSG00000216921		2	241893985-241902551	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		thyroid gland: 11.5	pancreas: 6.4	Cell line enhanced		REH: 2.2;SCLC-21H: 1.8
CCDC7	BIOT2, C10orf68, FLJ13031, FLJ32762	ENSG00000216937	Coiled-coil domain containing 7	10	32446140-32882874	Predicted intracellular proteins	Evidence at transcript level	HPA075536			Approved	Nucleoli<br>Mitotic spindle<br>Cytosol		Not detected	Tissue enriched	43	testis: 139.0	thyroid gland: 3.2	Mixed		
FNIP1	KIAA1961	ENSG00000217128	Folliculin interacting protein 1	5	131641714-131797063	Predicted intracellular proteins	Evidence at protein level	HPA068099, HPA071213	Approved					Expressed in all	Expressed in all			testis: 28.5	Expressed in all		
SP9	ZNF990	ENSG00000217236	Sp9 transcription factor	2	174334946-174338492	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA062616	Uncertain		Approved	Mitochondria		Mixed	Tissue enhanced		fallopian tube: 1.4	skin: 0.9	Cell line enhanced		A549: 6.5;fHDF/TERT166: 4.2;THP-1: 7.8
SYCE3	C22orf41	ENSG00000217442	Synaptonemal complex central element protein 3	22	50551112-50562905	Predicted intracellular proteins	Evidence at protein level	HPA047813			Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enriched	38	testis: 116.7	thyroid gland: 3.0	Cell line enhanced		CAPAN-2: 4.5;Karpas-707: 3.1
CKLF	C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1	ENSG00000217555	Chemokine like factor	16	66552563-66566251	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA062779			Approved	Vesicles	Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable)	Expressed in all	Expressed in all			testis: 90.9	Expressed in all		
PAM16	Magmas, Tim16, TIMM16	ENSG00000217930	Presequence translocase associated motor 16 homolog	16	4331549-4355607	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062721			Approved	Nucleoplasm<br>Microtubules<br>Mitochondria	Renal cancer:5.73e-5 (unfavourable), Urothelial cancer:1.33e-4 (favourable)	Expressed in all	Expressed in all			testis: 15.1	Expressed in all		
TENM3	KIAA1455, ODZ3, Ten-M3	ENSG00000218336	Teneurin transmembrane protein 3	4	182143987-182803024	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047043	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		placenta: 18.7	parathyroid gland: 13.4	Cell line enhanced		HDLM-2: 83.6;T-47d: 80.9
CEBPZOS	CEBPZ-AS1	ENSG00000218739	CEBPZ opposite strand	2	37196488-37216193	Predicted membrane proteins	Evidence at protein level	HPA053866	Uncertain		Approved	Nucleoplasm	Renal cancer:3.46e-7 (unfavourable), Liver cancer:1.72e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 47.1	Mixed		
TDRD15		ENSG00000218819	Tudor domain containing 15	2	21123917-21143272	Predicted intracellular proteins	Evidence at transcript level	HPA051770, HPA054675	Uncertain					Not detected	Tissue enriched	77	testis: 10.0	liver: 0.1	Cell line enhanced		U-266/70: 5.9;U-266/84: 2.1
PAPOLB	PAPT	ENSG00000218823	Poly(A) polymerase beta	7	4857733-4861994	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	539	testis: 53.9	all non-specific tissues: 0.0	Not detected		
ZNF579	FLJ35453	ENSG00000218891	Zinc finger protein 579	19	55576770-55580845	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062812	Approved		Approved	Nucleus	Renal cancer:1.00e-5 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 13.0	Expressed in all		
CELA3B	CBPP, ELA3B	ENSG00000219073	Chymotrypsin like elastase family member 3B	1	21977021-21998642	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA028086, HPA045650	Supported		Approved	Cytosol		Tissue enriched	Tissue enriched	296	pancreas: 10568.2	ovary: 35.6	Mixed		
RNASEK	MGC71993	ENSG00000219200	Ribonuclease K	17	7012417-7014532	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044708	Uncertain				Pancreatic cancer:1.92e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 468.1	Expressed in all		
TEX40	C11orf20, DKFZP566E164	ENSG00000219435	Testis expressed 40	11	64300391-64304770	Predicted intracellular proteins	Evidence at protein level	HPA052822			Approved	Nucleoplasm		Not detected	Tissue enriched	105	testis: 519.6	cerebral cortex: 4.9	Cell line enhanced		CACO-2: 11.9;PC-3: 7.8;T-47d: 6.5
FAM19A5	TAFA-5	ENSG00000219438	Family with sequence similarity 19 member A5, C-C motif chemokine like	22	48489460-48850912	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	CAB025629	Approved					Expressed in all	Tissue enhanced		cerebral cortex: 49.9	cervix, uterine: 12.9	Cell line enhanced		fHDF/TERT166: 15.8;HEK 293: 12.4;Hep G2: 21.7;NTERA-2: 17.3;SCLC-21H: 10.2;U-2 OS: 24.8
NBPF1	FLJ20719, KIAA1693	ENSG00000219481	Neuroblastoma breakpoint family member 1	1	16562319-16613562	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Renal cancer:1.06e-4 (favourable)	Expressed in all	Mixed			testis: 21.9	Mixed		
UMAD1	RPA3-AS1, RPA3OS	ENSG00000219545	UBAP1-MVB12-associated (UMA) domain containing 1	7	7640711-7968020	Predicted intracellular proteins	Evidence at protein level	HPA044806	Approved		Approved	Nucleoplasm	Renal cancer:1.73e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.1	Expressed in all		
PPP1R3G		ENSG00000219607	Protein phosphatase 1 regulatory subunit 3G	6	5084581-5089487	Predicted intracellular proteins	Evidence at protein level	HPA056393	Uncertain					Tissue enhanced	Mixed			spleen: 3.6	Cell line enhanced		EFO-21: 3.4;PC-3: 3.3;THP-1: 8.6
FAM228B		ENSG00000219626	Family with sequence similarity 228 member B	2	24076526-24169640	Predicted intracellular proteins	Evidence at protein level	HPA052598, HPA063357	Uncertain		Approved	Golgi apparatus		Mixed	Mixed			testis: 36.5	Mixed		
LINGO3	LERN2, LRRN6B	ENSG00000220008	Leucine rich repeat and Ig domain containing 3	19	2289784-2292024	Predicted membrane proteins	Evidence at protein level	HPA043781, HPA055932, HPA059558	Uncertain		Approved	Mitochondria		Tissue enhanced	Tissue enhanced		appendix: 1.6;cerebral cortex: 1.6;spleen: 3.7	lymph node: 1.2	Group enriched	6	HMC-1: 15.2;RPMI-8226: 3.0
ZGLP1	GATAD3, GLP-1, GLP1	ENSG00000220201	Zinc finger, GATA-like protein 1	19	10304803-10309880	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049855	Uncertain		Approved	Nucleus<br>Vesicles		Mixed	Mixed			testis: 3.1	Cell line enhanced		NB-4: 20.8
VAMP2	SYB2, VAMP-2	ENSG00000220205	Vesicle associated membrane protein 2	17	8159149-8163546	FDA approved drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	CAB078785		Supported			Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 483.5	Expressed in all		
OR6B1	OR7-3	ENSG00000221813	Olfactory receptor family 6 subfamily B member 1	7	144003929-144004983	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053164	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
EBF2	COE2, FLJ11500	ENSG00000221818	Early B-cell factor 2	8	25841730-26045397	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Renal cancer:2.51e-6 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 20.8	heart muscle: 6.6	Group enriched	16	ASC diff: 15.6;ASC TERT1: 32.1;HSkMC: 34.2;hTEC/SVTERT24-B: 26.8;U-138 MG: 17.0;U-2197: 21.1;U-87 MG: 18.8
C6orf226	LOC441150	ENSG00000221821	Chromosome 6 open reading frame 226	6	42890265-42890816	Predicted intracellular proteins	Evidence at protein level	HPA045350	Approved		Approved	Nuclear speckles	Breast cancer:1.93e-5 (favourable), Renal cancer:3.35e-4 (favourable), Pancreatic cancer:5.13e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 13.4	Mixed		
PPP3R1	CALNB1, CNB, CNB1	ENSG00000221823	Protein phosphatase 3 regulatory subunit B, alpha	2	68178857-68256237	Predicted intracellular proteins	Evidence at protein level	CAB005610, HPA047157	Approved		Approved	Plasma membrane<br>Cytosol	Endometrial cancer:9.08e-6 (unfavourable), Renal cancer:1.70e-5 (unfavourable), Liver cancer:5.37e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 197.5	Expressed in all		
PSG3		ENSG00000221826	Pregnancy specific beta-1-glycoprotein 3	19	42721638-42740569	Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enriched	162	placenta: 188.8	testis: 1.1	Cell line enriched	6	U-2197: 1.2
FANCG	FAG, XRCC9	ENSG00000221829	Fanconi anemia complementation group G	9	35073835-35080016	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008105, HPA045335	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Renal cancer:2.38e-7 (unfavourable), Liver cancer:2.02e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 8.7	Expressed in all		
OR2A5	OR2A26, OR2A8, OR7-138, OR7-141	ENSG00000221836	Olfactory receptor family 2 subfamily A member 5	7	144050368-144051380	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-9	KAP10.9, KAP18.9, KRTAP18-9	ENSG00000221837	Keratin associated protein 10-9	21	44627123-44628293	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AP4M1	MU-4, MU-ARP2, SPG50	ENSG00000221838	Adaptor related protein complex 4 mu 1 subunit	7	100101549-100110345	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA066774	Approved				Liver cancer:7.63e-5 (unfavourable), Renal cancer:8.29e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
OR4A5		ENSG00000221840	Olfactory receptor family 4 subfamily A member 5	11	54706885-54707832	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C2orf16	DKFZp434G118	ENSG00000221843	Chromosome 2 open reading frame 16	2	27537386-27582721	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052136, HPA056962	Uncertain		Uncertain	Nuclear bodies		Mixed	Tissue enriched	19	testis: 14.6	cerebral cortex,thyroid gland: 0.7	Cell line enhanced		SCLC-21H: 2.9;SiHa: 1.9
KRTAP1-5	KAP1.5	ENSG00000221852	Keratin associated protein 1-5	17	41026026-41027202	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	14	cervix, uterine: 2.1	urinary bladder: 0.1	Cell line enhanced		BJ: 23.6;BJ hTERT+: 9.7;fHDF/TERT166: 28.2;LHCN-M2: 14.9
TAS2R41	T2R59	ENSG00000221855	Taste 2 receptor member 41	7	143477873-143478796	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057063	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2A12	OR2A12P	ENSG00000221858	Olfactory receptor family 2 subfamily A member 12	7	144095048-144096093	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP10-10	KAP10.10, KAP18.10, KRTAP18-10	ENSG00000221859	Keratin associated protein 10-10	21	44637356-44638455	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP12-2	KAP12.2, KRTAP12.2	ENSG00000221864	Keratin associated protein 12-2	21	44666189-44666927	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			epididymis: 0.1	Not detected		
PLXNA4	DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B	ENSG00000221866	Plexin A4	7	132123332-132648688	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA029919, HPA052141, HPA075592	Approved		Approved	Plasma membrane	Endometrial cancer:1.61e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 15.2;cervix, uterine: 12.5	cerebral cortex: 10.4	Cell line enhanced		ASC diff: 17.3;HMC-1: 15.0;RH-30: 17.9;TIME: 46.9
MAGEA3	CT1.3, HIP8, HYPD, MAGE3, MGC14613	ENSG00000221867	MAGE family member A3	X	152698752-152702347	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:3.58e-4 (unfavourable)	Mixed	Tissue enriched	28	testis: 12.8	placenta: 0.4	Cell line enhanced		K-562: 157.8;PC-3: 145.8;SH-SY5Y: 163.2;SK-BR-3: 132.6;U-266/70: 187.5;U-266/84: 205.2
CEBPD	C/EBP-delta, CELF, CRP3, NF-IL6-beta	ENSG00000221869	CCAAT/enhancer binding protein delta	8	47736909-47739086	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067581			Supported	Nucleoplasm	Renal cancer:2.87e-7 (unfavourable), Breast cancer:2.28e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 71.1	Cell line enhanced		HHSteC: 29.5;NB-4: 50.0;SiHa: 33.7
TMEM257	CXorf1	ENSG00000221870	Transmembrane protein 257	X	145827410-145829850	Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 4.2	seminal vesicle: 0.4	Not detected		
ZNF816-ZNF321P	ZNF816-ZNF321	ENSG00000221874	ZNF816-ZNF321P readthrough	19	52928475-52962823	Predicted intracellular proteins	Evidence at transcript level	HPA051271	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		prostate: 2.7	rectum: 1.6	Cell line enriched	7	RT4: 7.2
PSG7		ENSG00000221878	Pregnancy specific beta-1-glycoprotein 7 (gene/pseudogene)	19	42924132-42937178	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Not detected	Tissue enhanced		placenta: 5.8;skin: 1.4	smooth muscle: 0.9	Cell line enhanced		BJ: 1.3;HBF TERT88: 2.2;U-2197: 1.7
KRTAP1-3	KAP1.3	ENSG00000221880	Keratin associated protein 1-3	17	41033884-41034855	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR3A2	OLFRA04, OR17-228, OR228	ENSG00000221882	Olfactory receptor family 3 subfamily A member 2	17	3277899-3278974	G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	6	testis: 5.3	epididymis: 0.9	Cell line enriched	6	HDLM-2: 10.0
ARIH2OS	C3orf71	ENSG00000221883	Ariadne homolog 2 opposite strand	3	48917788-48919385	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			testis: 4.2	Mixed		
ZBED8	Buster3, C5orf54	ENSG00000221886	Zinc finger BED-type containing 8	5	160393148-160400097	Predicted intracellular proteins	Evidence at protein level	HPA045445, HPA055817	Approved		Enhanced	Nucleoplasm	Pancreatic cancer:3.72e-4 (favourable)	Expressed in all	Mixed			ovary: 13.3	Mixed		
HMSD	ACC-6, ACC6, C18orf53	ENSG00000221887	Histocompatibility minor serpin domain containing	18	63949301-63981774	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Mixed			cerebral cortex,lymph node: 1.8	Cell line enhanced		ASC TERT1: 5.1;HDLM-2: 17.2;Karpas-707: 5.0
OR1C1	HSTPCR27, TPCR27	ENSG00000221888	Olfactory receptor family 1 subfamily C member 1	1	247757462-247758406	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Not detected		
NPTXR		ENSG00000221890	Neuronal pentraxin receptor	22	38818452-38843982	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA001079	Enhanced		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Endometrial cancer:2.85e-4 (unfavourable), Cervical cancer:3.93e-4 (favourable)	Expressed in all	Tissue enriched	13	cerebral cortex: 176.4	prostate: 13.3	Cell line enhanced		SCLC-21H: 36.6;U-87 MG: 86.8
POM121L12	DKFZp564N2472	ENSG00000221900	POM121 transmembrane nucleoporin like 12	7	53035642-53036924	Predicted intracellular proteins	Evidence at protein level	HPA027836	Enhanced					Not detected	Tissue enriched	88	testis: 8.7	all non-specific tissues: 0.0	Not detected		
FAM200A	C7orf38, DKFZp727G131, FLJ36794	ENSG00000221909	Family with sequence similarity 200 member A	7	99546308-99558536	Predicted intracellular proteins	Evidence at protein level	HPA017855	Uncertain				Renal cancer:2.17e-7 (favourable), Liver cancer:9.24e-4 (unfavourable)	Expressed in all	Mixed			testis: 15.1	Expressed in all		
OR2F2	OR7-1	ENSG00000221910	Olfactory receptor family 2 subfamily F member 2	7	143935166-143936279	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PPP2R2A	B55A, PR52A, PR55A	ENSG00000221914	Protein phosphatase 2 regulatory subunit Balpha	8	26291491-26372680	Predicted intracellular proteins	Evidence at protein level	HPA042122, HPA042770, CAB079289	Approved		Approved	Cytosol		Expressed in all	Expressed in all			placenta: 72.2	Expressed in all		
C19orf73	FLJ10490	ENSG00000221916	Chromosome 19 open reading frame 73	19	49118397-49119140	Predicted intracellular proteins	Evidence at protein level	HPA062719	Uncertain		Approved	Nucleus<br>Cytosol	Pancreatic cancer:1.58e-4 (favourable)	Expressed in all	Mixed			duodenum: 2.2	Cell line enhanced		HEK 293: 7.8
ZNF880		ENSG00000221923	Zinc finger protein 880	19	52369917-52385795	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:4.33e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 31.2	Mixed		
TRIM16	EBBP	ENSG00000221926	Tripartite motif containing 16	17	15627960-15684311	Predicted intracellular proteins	Evidence at protein level	HPA023623, HPA066431	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:3.94e-4 (unfavourable), Urothelial cancer:6.71e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 117.8	Cell line enhanced		A549: 255.9;HaCaT: 197.9
OR6X1		ENSG00000221931	Olfactory receptor family 6 subfamily X member 1	11	123753488-123754545	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.1	Not detected		
HEPN1		ENSG00000221932	Hepatocellular carcinoma, down-regulated 1	11	124919244-124920677	Predicted intracellular proteins	Evidence at transcript level	HPA043768, HPA063054	Uncertain		Approved	Golgi apparatus		Not detected	Tissue enriched	7	cerebral cortex: 79.5	adipose tissue: 11.1	Cell line enriched	358	Hep G2: 35.7
OR2A25	OR2A25P, OR2A27	ENSG00000221933	Olfactory receptor family 2 subfamily A member 25	7	144074182-144075195	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R40	GPR60	ENSG00000221937	Taste 2 receptor member 40	7	143222037-143223079	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.9	Not detected		
OR2A14	OR2A14P, OR2A6, OST182	ENSG00000221938	Olfactory receptor family 2 subfamily A member 14	7	144129058-144130069	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TIGD1	EEYORE	ENSG00000221944	Tigger transposable element derived 1	2	232547968-232550592	Predicted intracellular proteins	Evidence at protein level	HPA041717	Approved		Supported	Nucleus<br>Nucleoli<br>Nuclear bodies	Renal cancer:4.41e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 16.3	Expressed in all		
FXYD7		ENSG00000221946	FXYD domain containing ion transport regulator 7	19	35143250-35154301	Predicted membrane proteins	Evidence at protein level	HPA026916	Approved					Tissue enhanced	Tissue enriched	35	cerebral cortex: 105.8	lymph node: 3.0	Cell line enhanced		HAP1: 1.8;HMC-1: 4.5;WM-115: 3.1
XKR9		ENSG00000221947	XK related 9	8	70669365-70790371	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA044430	Uncertain		Approved	Mitochondria	Pancreatic cancer:7.20e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 13.8	small intestine: 6.1	Cell line enhanced		hTCEpi: 4.6
OR4C12		ENSG00000221954	Olfactory receptor family 4 subfamily C member 12	11	49981473-49982535	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SLC12A8	CCC9	ENSG00000221955	Solute carrier family 12 member 8	3	125082636-125212864	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA031123	Uncertain		Supported	Nucleoplasm	Renal cancer:5.56e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 39.6	gallbladder: 16.2	Cell line enhanced		HHSteC: 28.8;U-2197: 63.6
PRR21		ENSG00000221961	Proline rich 21	2	240041813-240042982	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
APOL6	APOL-VI, APOLVI	ENSG00000221963	Apolipoprotein L6	22	35648395-35668409	Predicted membrane proteins	Evidence at protein level	CAB028574, HPA029165, HPA029167	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Urothelial cancer:6.61e-4 (favourable)	Expressed in all	Mixed			adipose tissue: 25.4	Mixed		
FADS3	CYB5RP, LLCDL3	ENSG00000221968	Fatty acid desaturase 3	11	61873519-61892051	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045224	Approved		Approved	Nucleoli fibrillar center	Renal cancer:1.50e-9 (unfavourable), Head and neck cancer:9.54e-5 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 99.2	Expressed in all		
OR2A1		ENSG00000221970	Olfactory receptor family 2 subfamily A member 1	7	144318125-144319057	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Not detected	Tissue enhanced		thyroid gland: 2.8	ovary: 1.1	Not detected		
C3orf36	FLJ22173	ENSG00000221972	Chromosome 3 open reading frame 36	3	133928145-133929812	Predicted intracellular proteins	Evidence at transcript level	HPA046432	Uncertain					Mixed	Tissue enriched	7	seminal vesicle: 11.8	parathyroid gland: 1.6	Cell line enhanced		EFO-21: 2.2;TIME: 1.5
OR4E2		ENSG00000221977	Olfactory receptor family 4 subfamily E member 2	14	21665083-21666024	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
CCNL2	ania-6b, CCNM, CCNS, HLA-ISO, PCEE, SB138	ENSG00000221978	Cyclin L2	1	1385711-1399328	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA053137	Supported		Supported	Nucleoplasm	Urothelial cancer:1.46e-7 (favourable), Renal cancer:1.12e-6 (unfavourable)	Expressed in all	Expressed in all			endometrium: 68.7	Expressed in all		
UBA52	CEP52, HUBCEP52, L40, MGC126879, MGC126881, MGC57125, RPL40	ENSG00000221983	Ubiquitin A-52 residue ribosomal protein fusion product 1	19	18571730-18577550	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA041344, HPA049132, HPA056624	Supported		Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			ovary: 1914.0	Expressed in all		
MYBPHL		ENSG00000221986	Myosin binding protein H like	1	109292365-109307041	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	14	heart muscle: 53.2	fallopian tube: 3.7	Cell line enhanced		Hep G2: 1.7;RH-30: 1.3
PPT2		ENSG00000221988	Palmitoyl-protein thioesterase 2	6	32153441-32163680	Predicted secreted proteins	Evidence at protein level						Endometrial cancer:5.03e-5 (unfavourable)	Expressed in all	Mixed			skin: 8.6	Cell line enhanced		ASC diff: 16.4;EFO-21: 16.9;HEK 293: 29.1;SK-MEL-30: 16.2
OR2A2	OR2A17P, OR2A2P, OST008	ENSG00000221989	Olfactory receptor family 2 subfamily A member 2	7	144109514-144110564	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF630	BC037316, dJ54B20.2, FLJ20573, MGC138344	ENSG00000221994	Zinc finger protein 630	X	47983356-48071658	Predicted intracellular proteins	Evidence at protein level	HPA001053, HPA068130	Supported		Approved	Nucleus<br>Cytosol		Mixed	Mixed			parathyroid gland: 7.5	Cell line enhanced		SiHa: 5.2
TIAF1		ENSG00000221995	TGFB1-induced anti-apoptotic factor 1	17	29073521-29078857	Predicted intracellular proteins	Evidence at transcript level	HPA051129	Uncertain					Mixed	Mixed			skin: 4.8	Cell line enhanced		REH: 6.4
BTBD19		ENSG00000222009	BTB domain containing 19	1	44808482-44815585	Predicted intracellular proteins	Evidence at protein level	HPA042633	Uncertain				Renal cancer:4.18e-8 (unfavourable)	Mixed	Mixed			endometrium: 4.5	Cell line enhanced		TIME: 9.7
FAM185A	MGC35361	ENSG00000222011	Family with sequence similarity 185 member A	7	102748971-102809225	Predicted intracellular proteins	Evidence at protein level	HPA020470, HPA029883	Uncertain		Enhanced	Cytosol	Renal cancer:9.36e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 4.5	Mixed		
RAB6C	WTH3	ENSG00000222014	RAB6C, member RAS oncogene family	2	129979664-129982738	Predicted intracellular proteins	Evidence at protein level	HPA059131	Uncertain		Uncertain	Golgi apparatus		Tissue enhanced	Tissue enhanced		parathyroid gland: 7.5	breast: 3.2	Group enriched	6	BEWO: 2.4;HMC-1: 1.9;REH: 4.9;T-47d: 3.0;U-266/70: 1.6
C21orf140		ENSG00000222018	Chromosome 21 open reading frame 140	21	34400317-34401072	Predicted intracellular proteins	Evidence at transcript level	HPA045123	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.6;testis: 4.0	esophagus: 1.1	Not detected		
PSMB11	beta5t	ENSG00000222028	Proteasome subunit beta 11	14	23042167-23044276	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028967, HPA056970	Enhanced					Not detected	Not detected			testis: 0.2	Not detected		
POTEM	ACT, P704P, POTE14beta	ENSG00000222036	POTE ankyrin domain family member M	14	18967434-18999012	Predicted intracellular proteins	No evidence	HPA042822	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
POTEJ	POTE2beta	ENSG00000222038	POTE ankyrin domain family member J	2	130611481-130658091	Predicted intracellular proteins	Evidence at protein level	HPA041264, HPA041271, HPA042822, HPA043260	Uncertain					Not detected	Tissue enhanced		testis: 1.1	prostate: 0.6	Not detected		
DCDC2B		ENSG00000222046	Doublecortin domain containing 2B	1	32209094-32216196	Predicted intracellular proteins	Evidence at protein level	HPA045832	Uncertain					Mixed	Tissue enriched	17	fallopian tube: 44.3	lung: 2.6	Not detected		
C10orf55	bA417O11.3	ENSG00000222047	Chromosome 10 open reading frame 55	10	73909969-73922777	Predicted intracellular proteins	Evidence at protein level	HPA045739	Uncertain		Approved	Nucleus		Mixed	Not detected			epididymis,kidney: 0.4	Cell line enhanced		A-431: 2.4;CAPAN-2: 2.3;HaCaT: 2.3;RPTEC TERT1: 3.0
RP11-211G3.2		ENSG00000223401		3	187743686-187746028	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:6.93e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 8.0	bone marrow: 4.5	Cell line enhanced		Daudi: 2.1;U-698: 4.6
TRIM49D1	TRIM49D, TRIM49D1P, TRIM49DP	ENSG00000223417	Tripartite motif containing 49D1	11	89911111-89921767	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
USP17L2	DUB3	ENSG00000223443	Ubiquitin specific peptidase 17-like family member 2	8	12137168-12139077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
EXOSC6	EAP4, hMtr3p, MTR3, Mtr3p, p11	ENSG00000223496	Exosome component 6	16	70246778-70251930	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			cerebral cortex: 22.9	Expressed in all		
VPS52	ARE1, SACM2L	ENSG00000223501	VPS52, GARP complex subunit	6	33250272-33272047	Predicted intracellular proteins	Evidence at protein level	HPA042667, HPA048128	Approved					Expressed in all	Mixed			thyroid gland: 8.6	Mixed		
CDRT15		ENSG00000223510	CMT1A duplicated region transcript 15	17	14235673-14236862	Predicted intracellular proteins	Evidence at protein level	HPA055952	Uncertain					Not detected	Tissue enhanced		testis: 11.5	skin: 4.0	Mixed		
ZNF844	FLJ14959	ENSG00000223547	Zinc finger protein 844	19	12064699-12081565	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046982	Uncertain				Renal cancer:0.00e+0 (favourable)	Expressed in all	Mixed			thyroid gland: 20.3	Cell line enhanced		U-266/84: 12.3
USP17L15		ENSG00000223569	Ubiquitin specific peptidase 17-like family member 15	4	9234385-9236334	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CKMT1A	CKMT1	ENSG00000223572	Creatine kinase, mitochondrial 1A	15	43692886-43699222	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA043491	Uncertain					Mixed	Mixed			rectum: 73.8	Cell line enhanced		HaCaT: 113.0;SCLC-21H: 52.4;SK-BR-3: 74.4;T-47d: 83.6
TINCR	FLJ90734, LINC00036, NCRNA00036, onco-lncRNA-16, PLAC2	ENSG00000223573	Tissue differentiation-inducing non-protein coding RNA	19	5558167-5568034	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	6	skin: 107.2	placenta: 19.0	Cell line enhanced		BEWO: 31.4;HaCaT: 25.8;SK-BR-3: 31.6
CENPVL1	CENPVP1, PRR6L1	ENSG00000223591	Centromere protein V like 1	X	51710512-51712131	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 3.0	cerebral cortex: 0.8	Cell line enhanced		NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
EBLN1		ENSG00000223601	Endogenous Bornavirus-like nucleoprotein 1	10	22208814-22210021	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	43	testis: 4.2	all non-specific tissues: 0.0	Not detected		
HBD		ENSG00000223609	Hemoglobin subunit delta	11	5232678-5235370	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037087, HPA043234	Supported		Approved	Vesicles		Not detected	Tissue enriched	64	bone marrow: 1221.3	placenta: 19.0	Cell line enhanced		HEL: 13.7;HMC-1: 14.7;U-266/70: 73.6;U-266/84: 12.8
ZNF735	ZNF735P	ENSG00000223614	Zinc finger protein 735	7	64207090-64220508	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
RFPL4A	RFPL4, RNF210	ENSG00000223638	Ret finger protein like 4A	19	55759014-55763175	Predicted intracellular proteins	Evidence at protein level	HPA046368	Uncertain		Approved	Centrosome<br>Cytosol		Tissue enriched	Tissue enhanced		epididymis: 2.5;testis: 2.5	liver: 1.2	Cell line enriched	19	U-2 OS: 88.7
C1GALT1C1L		ENSG00000223658	C1GALT1-specific chaperone 1 like	2	43675151-43676322	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.8	epididymis: 8.2	Cell line enhanced		SH-SY5Y: 15.3;U-2 OS: 9.4
CERS1	LAG1, LASS1, UOG1	ENSG00000223802	Ceramide synthase 1	19	18868545-18896727	Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA045724	Approved		Approved	Endoplasmic reticulum		Tissue enhanced	Group enriched	13	cerebral cortex: 136.3;testis: 28.0	skeletal muscle: 6.5	Cell line enhanced		AN3-CA: 28.0;HEK 293: 28.4
HLA-DPB1	HLA-DP1B	ENSG00000223865	Major histocompatibility complex, class II, DP beta 1	6	33075926-33087201	Predicted membrane proteins	Evidence at protein level	HPA011078, HPA058509	Approved		Approved	Nucleus<br>Cell Junctions	Endometrial cancer:3.38e-4 (favourable)	Expressed in all	Expressed in all			spleen: 170.6	Group enriched	7	HDLM-2: 102.6;REH: 48.0
C1QTNF5	CTRP5, DKFZp586B0621, LORD	ENSG00000223953	C1q and tumor necrosis factor related protein 5	11	119338939-119340940	Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB025607, HPA038604	Uncertain					Not detected	Mixed			gallbladder: 71.5	Cell line enhanced		HHSteC: 30.0;HUVEC TERT2: 45.5;TIME: 41.0
CPTP	GLTPD1, MGC10334	ENSG00000224051	Ceramide-1-phosphate transfer protein	1	1324756-1328897	Predicted intracellular proteins	Evidence at protein level	HPA056832	Approved		Approved	Cytosol	Renal cancer:1.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.0	Expressed in all		
CT47A10	CT47.10	ENSG00000224089	Cancer/testis antigen family 47, member A10	X	120938701-120942023	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
LINC00633		ENSG00000224107	Long intergenic non-protein coding RNA 633	X	135118955-135120526	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	63	testis: 15.1	bone marrow: 0.2	Not detected		
CENPVL3	CENPVP3	ENSG00000224109	Centromere protein V like 3	X	51618055-51618918	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		NTERA-2: 2.2;PC-3: 12.7;U-2 OS: 6.4
PRR29	C17orf72, DKFZp761M2312, FLJ11724	ENSG00000224383	Proline rich 29	17	63998351-64004304	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	12	fallopian tube: 92.9	testis: 7.9	Cell line enhanced		CAPAN-2: 3.0;REH: 3.3;TIME: 2.3
C4B	C4B1, C4B3, C4F, CH, CO4, CPAMD3	ENSG00000224389	Complement C4B (Chido blood group)	6	32014762-32035418	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		adrenal gland: 59.4;liver: 65.5	fallopian tube,kidney: 18.3	Cell line enriched	5	Karpas-707: 92.1
ADM5	AM5, C19orf76	ENSG00000224420	Adrenomedullin 5 (putative)	19	49688664-49690575	Predicted secreted proteins	Evidence at transcript level						Urothelial cancer:6.74e-4 (favourable)	Mixed	Mixed			skin: 2.6	Mixed		
CXorf51A	CXorf51	ENSG00000224440	Chromosome X open reading frame 51A	X	146814106-146814726	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ATXN1L	BOAT1	ENSG00000224470	Ataxin 1 like	16	71845991-71885268	Predicted intracellular proteins	Evidence at protein level	HPA062596, HPA062789			Enhanced	Nucleus	Renal cancer:5.33e-8 (favourable), Urothelial cancer:8.42e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 36.6	Expressed in all		
SMIM13	C6orf228	ENSG00000224531	Small integral membrane protein 13	6	11094033-11138733	Predicted membrane proteins	Evidence at protein level	HPA065706	Enhanced		Approved	Nucleus<br>Nuclear membrane<br>Golgi apparatus	Renal cancer:1.03e-5 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 47.1	placenta: 18.9	Expressed in all		
GPX5		ENSG00000224586	Glutathione peroxidase 5	6	28525925-28534952	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	30	epididymis: 12.2	seminal vesicle: 0.4	Not detected		
GAGE12J	GAGE11	ENSG00000224659	G antigen 12J	X	49322057-49329384	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	34	testis: 32.7	epididymis: 0.9	Group enriched	6	AN3-CA: 132.7;K-562: 134.5
NPIPA3		ENSG00000224712	Nuclear pore complex interacting protein family member A3	16	14708944-14726338	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			parathyroid gland: 4.3	Cell line enhanced		NB-4: 6.7;SK-MEL-30: 11.7
NDUFAF8	C17orf89	ENSG00000224877	NADH:ubiquinone oxidoreductase complex assembly factor 8	17	81239239-81241281	Predicted intracellular proteins	Evidence at protein level	HPA057732	Uncertain		Approved	Mitochondria	Renal cancer:1.70e-6 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 63.7	Expressed in all		
GAGE12H		ENSG00000224902	G antigen 12H	X	49579983-49587301	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Approved	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	392	testis: 39.2	all non-specific tissues: 0.0	Group enriched	44	A-431: 47.0;U-266/84: 113.6
APOC4-APOC2		ENSG00000224916	APOC4-APOC2 readthrough (NMD candidate)	19	44942238-44949565	Predicted membrane proteins	Evidence at protein level	HPA055877	Supported					Tissue enriched	Tissue enriched	102	liver: 109.7	cerebral cortex: 1.0	Cell line enhanced		HMC-1: 1.0;THP-1: 4.2
PRRT4		ENSG00000224940	Proline rich transmembrane protein 4	7	128350325-128361685	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA046373, HPA052681	Uncertain		Approved	Nucleoplasm<br>Peroxisomes<br>Plasma membrane		Mixed	Group enriched	12	adipose tissue: 15.7;bone marrow: 41.2	cerebral cortex: 2.2	Cell line enriched	8	SH-SY5Y: 239.1
PPP4R3CP	FLFL3P, FLJ32867, SMEK3P, smk1	ENSG00000224960	Protein phosphatase 4 regulatory subunit 3C, pseudogene	X	27460211-27463341	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	11	testis: 3.6	placenta: 0.3	Cell line enriched	146	U-2197: 19.0
TMEM233	IFITMD2	ENSG00000224982	Transmembrane protein 233	12	119593459-119643066	Predicted membrane proteins	Evidence at transcript level	HPA047506	Uncertain					Tissue enriched	Group enriched	5	cerebral cortex: 16.2;skeletal muscle: 11.5;thyroid gland: 21.4	parathyroid gland: 3.1	Cell line enhanced		hTEC/SVTERT24-B: 19.8;RH-30: 10.2;U-2197: 14.8;U-87 MG: 61.5
LL0XNC01-16G2.1		ENSG00000225110		X	153317681-153321822	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 4.0	adrenal gland: 0.9	Not detected		
AATK-AS1		ENSG00000225180	AATK antisense RNA 1	17	81165507-81183164	Predicted intracellular proteins	No evidence							Not detected	Not detected			adipose tissue,cerebral cortex: 0.1	Not detected		
PLEKHM1	KIAA0356	ENSG00000225190	Pleckstrin homology and RUN domain containing M1	17	45435900-45490749	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA025018, HPA039473	Approved		Supported	Nucleoli<br>Vesicles	Endometrial cancer:1.28e-6 (favourable), Liver cancer:3.25e-4 (unfavourable)	Expressed in all	Mixed			esophagus: 11.8	Mixed		
USP17L3	USP17B, USP17F	ENSG00000225327	Ubiquitin specific peptidase 17-like family member 3	8	7976393-7977985	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CT62		ENSG00000225362	Cancer/testis antigen 62	15	71110244-71115494	Predicted intracellular proteins	Evidence at transcript level	HPA045306	Uncertain					Group enriched	Tissue enriched	86	testis: 50.1	prostate: 0.5	Cell line enhanced		HaCaT: 1.4;T-47d: 3.2;U-2197: 2.5
FAM236D		ENSG00000225396	Family with sequence similarity 236 member D	X	72807425-72808210	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	23	testis: 3.5	prostate: 0.1	Not detected		
MKRN2OS	C3orf83, MKRN2-AS1	ENSG00000225526	MKRN2 opposite strand	3	12514934-12561059	Predicted intracellular proteins	Evidence at transcript level	HPA065586, HPA065753	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		epididymis: 11.1	small intestine: 8.4	Cell line enhanced		CAPAN-2: 12.4;RT4: 4.7;T-47d: 3.1
RP3-370M22.8		ENSG00000225528		22	39960397-39964718	Predicted intracellular proteins	Evidence at transcript level	HPA047397			Uncertain	Nucleus<br>Nucleoli<br>Nuclear bodies		Not detected	Not detected			bone marrow,lymph node: 0.8	Cell line enhanced		HEL: 2.7;K-562: 11.1;MOLT-4: 1.7
C2CD4D	FAM148D	ENSG00000225556	C2 calcium dependent domain containing 4D	1	151837819-151840557	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		skin: 1.9	cerebral cortex: 1.2	Cell line enriched	8	HDLM-2: 17.9
ZNF469	KIAA1858	ENSG00000225614	Zinc finger protein 469	16	88427471-88440757	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069784			Approved	Vesicles		Mixed	Mixed			cervix, uterine: 2.2	Cell line enhanced		SiHa: 5.3;THP-1: 4.3
MCRIP1	FAM195B, GRAN2, MCRIP	ENSG00000225663	MAPK regulated corepressor interacting protein 1	17	81822361-81833302	Predicted intracellular proteins	Evidence at protein level	HPA045542	Approved		Approved	Cytosol	Pancreatic cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 107.1	Expressed in all		
SLC26A6	DKFZp586E1422	ENSG00000225697	Solute carrier family 26 member 6	3	48625723-48635493	Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA048363	Approved		Uncertain	Cytosol	Renal cancer:1.53e-5 (unfavourable), Liver cancer:3.92e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 24.0	Expressed in all		
OR6V1	GPR138	ENSG00000225781	Olfactory receptor family 6 subfamily V member 1	7	143052320-143053347	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CTD-2313N18.7		ENSG00000225805		11	71878453-71884561	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	13	epididymis: 86.1	thyroid gland: 6.4	Cell line enhanced		RH-30: 16.4
FAM229A		ENSG00000225828	Family with sequence similarity 229 member A	1	32361270-32364278	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.73e-5 (unfavourable), Urothelial cancer:2.33e-4 (favourable)	Mixed	Tissue enriched	7	testis: 15.6	spleen: 2.1	Cell line enhanced		HEK 293: 7.7
ERCC6	ARMD5, CKN2, CSB, RAD26	ENSG00000225830	ERCC excision repair 6, chromatin remodeling factor	10	49455368-49539538	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA071297			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 14.9	Expressed in all		
LINC00694		ENSG00000225873	Long intergenic non-protein coding RNA 694	3	44421127-44439946	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	8	testis: 28.4	spleen: 3.7	Cell line enhanced		HMC-1: 24.5;K-562: 4.3;NB-4: 8.8
FRG2B		ENSG00000225899	FSHD region gene 2 family member B	10	133623895-133626795	Predicted intracellular proteins	Evidence at transcript level	HPA039264, HPA047769	Uncertain					Not detected	Not detected			kidney: 0.2	Cell line enriched	20	HDLM-2: 7.4
NOL7	C6orf90, dJ223E5.2, NOP27, PQBP3, RARG-1	ENSG00000225921	Nucleolar protein 7	6	13615327-13632739	Predicted intracellular proteins	Evidence at protein level	HPA029185, HPA049693	Supported		Enhanced	Nucleus<br>Nucleoli<br>Mitochondria	Ovarian cancer:3.64e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 92.8	Expressed in all		
CTAGE4	cTAGE-4, FLJ43692	ENSG00000225932	CTAGE family member 4	7	144183466-144186053	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		thyroid gland: 16.4	testis: 13.6	Cell line enhanced		A-431: 16.9;hTCEpi: 10.1;RPTEC TERT1: 9.9;SiHa: 9.1
C5orf67		ENSG00000225940	Chromosome 5 open reading frame 67	5	56511567-56606232	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	8	epididymis: 19.8;kidney: 9.4	thyroid gland: 1.9	Group enriched	7	CACO-2: 1.7;EFO-21: 5.3;U-266/70: 4.8
NTF4	GLC1O, NT-4/5, NTF5	ENSG00000225950	Neurotrophin 4	19	49061066-49065054	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA049376			Approved	Golgi apparatus		Mixed	Tissue enhanced		skin: 36.6	prostate: 11.4	Cell line enhanced		CAPAN-2: 12.1;HaCaT: 27.5;hTCEpi: 36.4
ELFN1	PPP1R28	ENSG00000225968	Extracellular leucine rich repeat and fibronectin type III domain containing 1	7	1688119-1747954	Predicted membrane proteins	Evidence at protein level	HPA066382			Approved	Nucleoplasm<br>Cell Junctions	Liver cancer:9.68e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 3.5;liver: 3.7	endometrium: 1.7	Cell line enhanced		REH: 28.4;U-138 MG: 18.3;U-2 OS: 28.4;U-2197: 29.8
PIGBOS1		ENSG00000225973	PIGB opposite strand 1	15	55317184-55319161	Predicted intracellular proteins	Evidence at transcript level						Breast cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 26.2	Expressed in all		
CT47A6	CT47.6	ENSG00000226023	Cancer/testis antigen family 47, member A6	X	120958165-120961487	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Not detected			testis: 0.5	Not detected		
FTCDNL1	FONG	ENSG00000226124	Formiminotransferase cyclodeaminase N-terminal like	2	199760544-199851173	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA065748			Uncertain	Vesicles	Renal cancer:3.31e-4 (favourable), Thyroid cancer:5.74e-4 (unfavourable)	Mixed	Mixed			thyroid gland: 12.0	Mixed		
TEX22		ENSG00000226174	Testis expressed 22	14	105398579-105450106	Predicted intracellular proteins	Evidence at protein level	HPA065576	Enhanced					Mixed	Tissue enhanced		testis: 2.1	cerebral cortex: 0.8	Cell line enhanced		HDLM-2: 2.6;U-266/70: 1.7
OR52I2		ENSG00000226288	Olfactory receptor family 52 subfamily I member 2	11	4586791-4587905	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA049343	Uncertain					Not detected	Not detected			epididymis: 0.2	Not detected		
CROCC2		ENSG00000226321	Ciliary rootlet coiled-coil, rootletin family member 2	2	240906330-240993311	Predicted intracellular proteins	Evidence at protein level	HPA048678	Enhanced					Tissue enhanced	Group enriched	5	fallopian tube: 8.6;spleen: 3.1	lung: 1.1	Cell line enhanced		RPMI-8226: 1.9
DCAF8L1	WDR42B	ENSG00000226372	DDB1 and CUL4 associated factor 8 like 1	X	27977993-27981449	Predicted intracellular proteins	Evidence at protein level	HPA043787	Enhanced					Not detected	Tissue enriched	56	testis: 5.5	all non-specific tissues: 0.0	Cell line enriched	16	Karpas-707: 13.4
USP17L7		ENSG00000226430	Ubiquitin specific peptidase 17-like family member 7	8	12132417-12134438	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM185B	FAM11B, FLJ20979	ENSG00000226479	Transmembrane protein 185B	2	120221278-120223408	Predicted membrane proteins	Evidence at protein level	HPA048295, HPA071744	Uncertain		Approved	Endoplasmic reticulum	Liver cancer:5.71e-7 (unfavourable), Endometrial cancer:4.96e-6 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 62.6	Mixed		
AC138647.1		ENSG00000226490		8	141514638-141518737	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.8	skin: 0.3	Not detected		
CT47A9	CT47.9	ENSG00000226600	Cancer/testis antigen family 47, member A9	X	120943561-120946883	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
KIF4B		ENSG00000226650	Kinesin family member 4B	5	155013755-155018132	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA034745, HPA034746, HPA061583	Uncertain		Enhanced	Nucleoplasm		Not detected	Tissue enriched	63	testis: 6.3	all non-specific tissues: 0.0	Not detected		
CT47A12	CT47.12	ENSG00000226685	Cancer/testis antigen family 47, member A12	X	120930250-120932301	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	23	testis: 2.3	all non-specific tissues: 0.0	Not detected		
AC005281.1		ENSG00000226690		7	12483344-12541910	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	6	fallopian tube: 8.1;testis: 1.6	lung: 0.7	Cell line enhanced		HAP1: 1.4
RP11-397G17.1		ENSG00000226733		6	50093616-50181007	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Group enriched	8	epididymis: 136.0;kidney: 50.9	liver: 12.3	Not detected		
HSBP1L1	FLJ10967, MGC189743	ENSG00000226742	Heat shock factor binding protein 1 like 1	18	79964561-79970822	Predicted intracellular proteins	Evidence at transcript level	HPA048273	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			colon: 12.2	Cell line enhanced		HHSteC: 113.0;SK-MEL-30: 62.5
TAS2R46	T2R54	ENSG00000226761	Taste 2 receptor member 46	12	11061365-11062294	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SRRM5		ENSG00000226763	Serine/arginine repetitive matrix 5	19	43596617-43614497	Predicted intracellular proteins	Evidence at protein level	HPA047399	Uncertain					Mixed	Tissue enriched	31	testis: 40.1	lymph node: 1.3	Mixed		
PGAM4	dJ1000K24.1, PGAM-B, PGAM1, PGAM3	ENSG00000226784	Phosphoglycerate mutase family member 4	X	77968874-77969638	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA042528, HPA060483	Uncertain		Approved	Nucleoplasm		Mixed	Not detected			appendix: 0.5	Cell line enhanced		A-431: 1.9
LINC00371		ENSG00000226792	Long intergenic non-protein coding RNA 371	13	51082119-51200252	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.9	Group enriched	99	HAP1: 8.9;NTERA-2: 10.8
ERVMER34-1		ENSG00000226887	Endogenous retrovirus group MER34 member 1	4	52722618-52751640	Predicted membrane proteins	Evidence at protein level	HPA011423, HPA024053	Uncertain		Approved	Nucleus<br>Cytosol	Head and neck cancer:3.55e-4 (unfavourable)	Mixed	Group enriched	8	parathyroid gland: 48.2;placenta: 15.6	kidney: 3.7	Cell line enhanced		CACO-2: 38.7;hTCEpi: 23.6;RPTEC TERT1: 18.4
CT47A11	CT47.11	ENSG00000226929	Cancer/testis antigen family 47, member A11	X	120933840-120937158	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	37	testis: 3.7	all non-specific tissues: 0.0	Not detected		
RBMY1J		ENSG00000226941	RNA binding motif protein, Y-linked, family 1, member J	Y	22403461-22417881	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	17	testis: 2.7	lung: 0.1	Group enriched	138	U-266/70: 18.5;U-266/84: 8.9
LTA	LT, TNFB, TNFSF1	ENSG00000226979	Lymphotoxin alpha	6	31572054-31574324	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA007729	Uncertain					Mixed	Tissue enhanced		lymph node: 1.5	spleen: 0.9	Not detected		
C14orf132	C14orf88	ENSG00000227051	Chromosome 14 open reading frame 132	14	96039324-96093889	Predicted membrane proteins	Evidence at transcript level						Pancreatic cancer:3.54e-4 (favourable), Urothelial cancer:4.95e-4 (unfavourable)	Mixed	Tissue enhanced		cerebral cortex: 82.6	fallopian tube: 35.8	Cell line enhanced		SCLC-21H: 62.1;SH-SY5Y: 55.5;U-87 MG: 45.2
WDR46	BING4, C6orf11, UTP7	ENSG00000227057	WD repeat domain 46	6	33279108-33289527	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043004	Uncertain				Renal cancer:4.75e-4 (unfavourable)	Expressed in all	Tissue enhanced		epididymis: 16.5	tonsil: 10.0	Group enriched	29	BEWO: 30.8;HMC-1: 27.8;U-698: 49.4
ANHX		ENSG00000227059	Anomalous homeobox	12	133218312-133236095	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enriched	76	testis: 7.5	all non-specific tissues: 0.0	Not detected		
ZNF717	X17, ZNF838	ENSG00000227124	Zinc finger protein 717	3	75709643-75785583	Predicted intracellular proteins	Evidence at transcript level	HPA044549	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Mixed	Expressed in all			epididymis: 29.3	Cell line enhanced		K-562: 73.1
USP17L5		ENSG00000227140	Ubiquitin specific peptidase 17-like family member 5	4	9339403-9340995	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRR20D		ENSG00000227151	Proline rich 20D	13	57160632-57163653	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
SPANXB1	CT11.2, SPANXB2, SPANXF1, SPANXF2	ENSG00000227234	SPANX family member B1	X	141002591-141003706	Predicted intracellular proteins	Evidence at protein level	HPA046423, HPA073647	Supported		Approved	Nucleoplasm<br>Vesicles		Mixed	Tissue enriched	370	testis: 42.5	kidney: 0.1	Group enriched	26	A-431: 70.8;U-2 OS: 28.0
KLLN	killin	ENSG00000227268	Killin, p53-regulated DNA replication inhibitor	10	87859161-87863437	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA074502			Supported	Nucleus		Mixed	Mixed			fallopian tube: 2.4	Mixed		
PARG		ENSG00000227345	Poly(ADP-ribose) glycohydrolase	10	49818279-49970203	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021819, HPA053007	Enhanced		Enhanced	Nucleus<br>Vesicles	Liver cancer:5.57e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 16.9	Expressed in all		
AKR1B15		ENSG00000227471	Aldo-keto reductase family 1 member B15	7	134549136-134579875	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA020280, HPA073633	Uncertain		Supported	Plasma membrane<br>Cytosol	Liver cancer:1.80e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Head and neck cancer:8.36e-4 (favourable)	Mixed	Tissue enriched	13	breast: 179.9	duodenum: 13.7	Group enriched	8	A549: 14.3;HDLM-2: 11.8;Hep G2: 7.6;NTERA-2: 3.2;SK-BR-3: 3.8;U-87 MG: 6.4
GAGE12D		ENSG00000227488	G antigen 12D	X	49541767-49549094	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	461	testis: 46.0	all non-specific tissues: 0.0	Group enriched	10	U-2 OS: 9.9;U-266/84: 25.6
SCAMP4	FLJ33847	ENSG00000227500	Secretory carrier membrane protein 4	19	1905214-1926013	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043284	Approved		Approved	Golgi apparatus<br>Vesicles<br>Lipid droplets<br>Plasma membrane	Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.3	Expressed in all		
LTB	p33, TNFC, TNFSF3	ENSG00000227507	Lymphotoxin beta	6	31580525-31582522	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA048884	Approved		Approved	Centrosome	Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable)	Expressed in all	Group enriched	7	appendix: 18.6;lymph node: 22.1;spleen: 25.8;tonsil: 10.1	bone marrow: 2.6	Cell line enhanced		Daudi: 20.4;HDLM-2: 15.0;NB-4: 11.8;REH: 16.1;U-698: 14.4
USP17L12		ENSG00000227551	Ubiquitin specific peptidase 17-like family member 12	4	9220152-9221744	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RD3L	TDRD9-AS1, TDRD9AS1	ENSG00000227729	Retinal degeneration 3-like	14	103940426-103942308	Predicted intracellular proteins	Evidence at transcript level	HPA067971	Uncertain					Not detected	Tissue enriched	89	heart muscle: 20.8	liver: 0.2	Not detected		
C1orf234		ENSG00000227868	Chromosome 1 open reading frame 234	1	23010834-23015850	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	107	testis: 98.0	epididymis: 0.9	Not detected		
MRLN	Linc-RAM, LINC00948, M1, MLN, MUSER1	ENSG00000227877	Myoregulin	10	59736692-59756041	Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at transcript level							Tissue enhanced	Tissue enhanced		skeletal muscle: 65.4	kidney: 13.8	Cell line enriched	12	RH-30: 21.4
POLR2J2	RPB11b1	ENSG00000228049	RNA polymerase II subunit J2	7	102665368-102671629	Predicted intracellular proteins	Evidence at protein level	HPA042997, HPA044010, HPA046970	Uncertain		Approved	Nucleoplasm		Not detected	Mixed			appendix: 6.6	Cell line enhanced		MOLT-4: 17.9;U-2 OS: 14.2
BOD1L2	BOD1P, FAM44C, MGC33608	ENSG00000228075	Biorientation of chromosomes in cell division 1 like 2	18	57147062-57150300	Predicted intracellular proteins	Evidence at transcript level	HPA036293	Uncertain					Not detected	Tissue enriched	4257	testis: 425.7	all non-specific tissues: 0.0	Not detected		
IFNA14	IFN-alphaH, LEIF2H	ENSG00000228083	Interferon alpha 14	9	21239002-21239991	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR2M3	OR2M3P, OR2M6, OST003	ENSG00000228198	Olfactory receptor family 2 subfamily M member 3	1	248203068-248204006	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MT-ATP8	A6L, ATP8, MTATP8	ENSG00000228253	Mitochondrially encoded ATP synthase 8	MT	8366-8572	Disease related genes, Predicted membrane proteins	Evidence at protein level						Liver cancer:7.56e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 66363.2	Expressed in all		
ORM2	AGP-B, AGP-B', AGP2	ENSG00000228278	Orosomucoid 2	9	114329869-114333252	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046438, HPA047725, HPA057726	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:1.23e-9 (unfavourable)	Tissue enriched	Tissue enriched	96	liver: 3772.7	prostate: 39.2	Cell line enriched	195	Hep G2: 567.8
C19orf24	FLJ20640	ENSG00000228300	Chromosome 19 open reading frame 24	19	1275438-1279249	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043279, HPA047026	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Expressed in all	Expressed in all			spleen: 36.3	Expressed in all		
TSTD3		ENSG00000228439	Thiosulfate sulfurtransferase (rhodanese)-like domain containing 3	6	99520693-99531918	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Mixed			parathyroid gland: 7.4	Mixed		
OST4		ENSG00000228474	Oligosaccharyltransferase complex subunit 4, non-catalytic	2	27070472-27071773	Predicted membrane proteins	Evidence at protein level						Renal cancer:7.35e-5 (unfavourable), Liver cancer:5.11e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 344.8	Expressed in all		
LINC01125		ENSG00000228486	Long intergenic non-protein coding RNA 1125	2	97664217-97703064	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 11.7	skin: 2.4	Cell line enhanced		AF22: 1.7;HDLM-2: 1.8
CT47A7	CT47.7	ENSG00000228517	Cancer/testis antigen family 47, member A7	X	120953288-120956600	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Not detected			testis: 0.1	Not detected		
VN1R4	V1RL4	ENSG00000228567	Vomeronasal 1 receptor 4	19	53266676-53267723	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA027018	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
NUTM2E	FAM22E	ENSG00000228570	NUT family member 2E	10	79841358-79850878	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.1	epididymis: 0.6	Cell line enhanced		HMC-1: 1.7;NB-4: 1.0
FNDC10	C1orf233	ENSG00000228594	Fibronectin type III domain containing 10	1	1598012-1600096	Predicted membrane proteins	Evidence at protein level						Renal cancer:1.11e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 12.7	cerebral cortex: 9.4	Cell line enhanced		HMC-1: 24.9
CLDN25		ENSG00000228607	Claudin 25	11	113779747-113780500	Predicted membrane proteins	No evidence	HPA053555	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ZNF883		ENSG00000228623	Zinc finger protein 883	9	112957722-113050043	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Stomach cancer:2.89e-6 (unfavourable), Renal cancer:7.07e-4 (unfavourable)	Mixed	Not detected			cervix, uterine: 0.3	Not detected		
PROB1	C5orf65	ENSG00000228672	Proline rich basic protein 1	5	139390592-139395713	Predicted intracellular proteins	Evidence at protein level	HPA060103	Enhanced		Approved	Nucleoplasm	Cervical cancer:9.26e-4 (favourable)	Mixed	Tissue enhanced		skeletal muscle: 24.8	heart muscle: 6.0	Cell line enriched	6	HDLM-2: 97.1
ARL17B	ARL17	ENSG00000228696	ADP ribosylation factor like GTPase 17B	17	46274784-46361797	Predicted intracellular proteins	Evidence at protein level	HPA046814	Uncertain					Not detected	Mixed			ovary: 7.6	Mixed		
DHFR		ENSG00000228716	Dihydrofolate reductase	5	80626228-80654983	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB037129, HPA051465	Uncertain		Supported	Mitochondria		Expressed in all	Mixed			lymph node: 49.6	Expressed in all		
SAPCD1	C6orf26, NG23	ENSG00000228727	Suppressor APC domain containing 1	6	31762799-31764851	Predicted intracellular proteins	Evidence at transcript level	HPA071699			Approved	Vesicles<br>Cell Junctions		Mixed	Tissue enhanced		skin: 3.2	bone marrow: 1.0	Cell line enhanced		HeLa: 2.5
CT45A5	CT45-5, CT45.5	ENSG00000228836	Cancer/testis antigen family 45 member A5	X	135777130-135785298	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	62	testis: 8.6	cerebral cortex: 0.1	Cell line enhanced		HMC-1: 47.9;Karpas-707: 27.5;U-266/84: 147.8
USP17L30		ENSG00000228856	Ubiquitin specific peptidase 17-like family member 30	4	9363129-9364721	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TSPY3	CT78	ENSG00000228927	Testis specific protein, Y-linked 3	Y	9398421-9401223	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	6	testis: 4.2	epididymis: 0.6	Group enriched	62	U-266/70: 113.3;U-266/84: 101.1
RPL41	L41	ENSG00000229117	Ribosomal protein L41	12	56116586-56117943	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA053169	Approved					Expressed in all	Expressed in all			ovary: 10643.4	Expressed in all		
PGA4		ENSG00000229183	Pepsinogen 4, group I (pepsinogen A)	11	61222216-61231927	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046875	Supported					Not detected	Tissue enriched	2994	stomach: 34510.3	cerebral cortex: 11.5	Group enriched	7	BJ hTERT+: 12.2;THP-1: 5.2
RFPL4AL1		ENSG00000229292	Ret finger protein like 4A like 1	19	55769141-55773179	Predicted intracellular proteins	Evidence at transcript level	HPA046368	Uncertain		Approved	Centrosome<br>Cytosol		Not detected	Not detected			spleen: 0.6	Cell line enriched	26	U-2 OS: 27.1
ORM1		ENSG00000229314	Orosomucoid 1	9	114323056-114326475	Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB006265, HPA046438, HPA047725, HPA057726	Approved		Approved	Golgi apparatus<br>Vesicles	Renal cancer:2.35e-4 (unfavourable)	Tissue enriched	Tissue enriched	69	liver: 10591.2	bone marrow: 152.4	Cell line enriched	11	Hep G2: 797.0
SFTA3	NANCI, SFTPH	ENSG00000229415	Surfactant associated 3	14	36473288-36513829	Predicted intracellular proteins	Evidence at protein level						Lung cancer:8.29e-4 (favourable)	Group enriched	Group enriched	467	lung: 85.7;thyroid gland: 49.2	stomach: 0.1	Cell line enriched	234	SCLC-21H: 23.3
SPINK8		ENSG00000229453	Serine peptidase inhibitor, Kazal type 8 (putative)	3	48306842-48328341	Predicted secreted proteins	Evidence at transcript level	HPA053151	Uncertain				Breast cancer:8.47e-4 (unfavourable)	Group enriched	Tissue enriched	7	breast: 58.2	bone marrow: 7.7	Cell line enriched	49	SK-BR-3: 55.0
PATL2	Pat1a	ENSG00000229474	PAT1 homolog 2	15	44665732-44711316	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		lymph node: 20.0;spleen: 19.3	appendix: 10.4	Cell line enriched	30	U-266/70: 95.9
NKX1-2	bB238F13.2, C10orf121	ENSG00000229544	NK1 homeobox 2	10	124445239-124450184	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029367	Uncertain					Tissue enhanced	Not detected			cerebral cortex: 0.7	Cell line enhanced		HaCaT: 4.8;hTCEpi: 3.7;NTERA-2: 10.3;SCLC-21H: 5.3
TSPY8		ENSG00000229549	Testis specific protein, Y-linked 8	Y	9357797-9360599	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	13	testis: 1.3	all non-specific tissues: 0.0	Cell line enriched	228	U-266/84: 191.8
PRAMEF25		ENSG00000229571	PRAME family member 25	1	13068677-13077884	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L26		ENSG00000229579	Ubiquitin specific peptidase 17-like family member 26	4	9334658-9336609	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAC2	C17orf93, HOXB-AS5, HOXB13-AS1, NCRNA00253	ENSG00000229637	Prostate cancer susceptibility candidate 2	17	48723168-48724758	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		prostate: 16.8;rectum: 10.1	colon: 4.5	Group enriched	5	PC-3: 44.6;REH: 17.6
PRR20C		ENSG00000229665	Proline rich 20C	13	57140918-57157082	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
ZNF492	KIAA1473, ZNF115	ENSG00000229676	Zinc finger protein 492	19	22634324-22667670	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Group enriched	Tissue enhanced		testis: 3.6	bone marrow: 1.6	Cell line enhanced		BEWO: 5.4;NTERA-2: 4.1;U-2197: 3.7
ZNF688		ENSG00000229809	Zinc finger protein 688	16	30569346-30572734	Predicted intracellular proteins	Evidence at transcript level	HPA048922	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Endometrial cancer:4.58e-5 (favourable), Lung cancer:3.24e-4 (favourable), Breast cancer:5.90e-4 (favourable), Pancreatic cancer:6.61e-4 (favourable), Cervical cancer:7.74e-4 (favourable)	Expressed in all	Expressed in all			testis: 23.7	Expressed in all		
PET100	C19orf79	ENSG00000229833	PET100 homolog	19	7629737-7631956	Predicted intracellular proteins	Evidence at protein level	HPA067288			Approved	Nucleoplasm<br>Mitochondria	Urothelial cancer:2.44e-4 (favourable), Cervical cancer:6.81e-4 (favourable), Lung cancer:7.97e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 54.6	Expressed in all		
PGA3		ENSG00000229859	Pepsinogen 3, group I (pepsinogen A)	11	61203307-61213098	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB026358, HPA046875	Enhanced					Tissue enriched	Tissue enriched	716	stomach: 6775.4	cerebral cortex: 9.4	Group enriched	5	HMC-1: 7.5;THP-1: 1.9
GK3P	GKP3, GKTB	ENSG00000229894	Glycerol kinase 3 pseudogene	4	165277812-165279679	Enzymes, Predicted membrane proteins	Evidence at transcript level	HPA060687	Uncertain					Not detected	Tissue enriched	79	testis: 23.9	bone marrow: 0.3	Not detected		
FAM90A26	FAM90A26P	ENSG00000229924	Family with sequence similarity 90 member A26	4	9170409-9176730	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.2	Not detected		
PRPS1L1	PRPS3, PRPSL	ENSG00000229937	Phosphoribosyl pyrophosphate synthetase 1-like 1	7	18026774-18027863	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	575	testis: 57.5	all non-specific tissues: 0.0	Not detected		
IQCF3		ENSG00000229972	IQ motif containing F3	3	51817604-51830856	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	242	testis: 72.6	epididymis: 0.3	Not detected		
POTEB2		ENSG00000230031	POTE ankyrin domain family member B2	15	20835372-20866314	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	40	testis: 3.9	all non-specific tissues: 0.0	Not detected		
RP11-402G3.5		ENSG00000230054		9	114656304-114662374	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	115	testis: 56.5	appendix,skin: 0.4	Cell line enhanced		Karpas-707: 1.3
ANKRD66		ENSG00000230062	Ankyrin repeat domain 66	6	46746917-46759506	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	13	fallopian tube: 64.0	lung: 4.9	Not detected		
ACBD6	MGC2404	ENSG00000230124	Acyl-CoA binding domain containing 6	1	180269653-180502954	Predicted intracellular proteins	Evidence at protein level	HPA028179, HPA028457	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.02e-7 (unfavourable)	Expressed in all	Expressed in all			testis: 42.1	Expressed in all		
OR4F3		ENSG00000230178	Olfactory receptor family 4 subfamily F member 3	5	181367268-181368262	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
NFE4	NF-E4	ENSG00000230257	Nuclear factor, erythroid 4	7	102973437-102988856	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	7	placenta: 25.4	testis: 3.7	Cell line enhanced		BEWO: 36.5;HUVEC TERT2: 39.4
SSU72P8		ENSG00000230268	SSU72 pseudogene 8	7	124476371-124476955	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
OR5H6		ENSG00000230301	Olfactory receptor family 5 subfamily H member 6 (gene/pseudogene)	3	98264244-98265356	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
CT47A8	CT47.8	ENSG00000230347	Cancer/testis antigen family 47, member A8	X	120948422-120951744	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
USP17L25		ENSG00000230430	Ubiquitin specific peptidase 17-like family member 25	4	9329911-9331862	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ANKRD18B	bA255A11.3	ENSG00000230453	Ankyrin repeat domain 18B	9	33524394-33573009	Predicted intracellular proteins	Evidence at protein level	HPA046346, HPA046695, HPA049923, HPA051288	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Tissue enhanced		testis: 6.4	skin: 2.8	Cell line enhanced		NB-4: 17.4
PPP5D1		ENSG00000230510	PPP5 tetratricopeptide repeat domain containing 1	19	46480796-46601200	Predicted intracellular proteins	Evidence at transcript level	HPA073186	Uncertain		Uncertain	Cytosol		Not detected	Mixed			cerebral cortex: 4.8	Mixed		
MBD3L2		ENSG00000230522	Methyl-CpG binding domain protein 3 like 2	19	7049321-7051735	Predicted intracellular proteins	Evidence at transcript level	HPA051259	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L1	USP17L1P	ENSG00000230549	Ubiquitin specific peptidase 17-like family member 1	8	7332387-7333979	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			cerebral cortex: 0.3	Not detected		
CCDC192	LINC01183	ENSG00000230561	Coiled-coil domain containing 192	5	127703389-127941634	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	21	testis: 20.7	skeletal muscle: 0.9	Cell line enhanced		AF22: 2.3
CT47A4	CT47.4	ENSG00000230594	Cancer/testis antigen family 47, member A4	X	120967886-120971208	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
RP11-402G3.3		ENSG00000230601		9	114666434-114682066	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	234	testis: 28.7	appendix: 0.1	Cell line enriched	8	Karpas-707: 4.7
RP11-286H14.4		ENSG00000230626		7	129126518-129130793	Predicted intracellular proteins	Evidence at protein level	HPA051993	Uncertain		Approved	Cytosol		Mixed	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Not detected		
PRB4		ENSG00000230657	Proline rich protein BstNI subfamily 4	12	11307083-11310435	Predicted secreted proteins	Evidence at transcript level							Group enriched	Tissue enriched	3551	salivary gland: 1351.8	skin,testis: 0.3	Cell line enriched	23	CACO-2: 2.2
SETSIP	SETP18	ENSG00000230667	SET-like protein	1	92074533-92075441	Predicted intracellular proteins	Evidence at protein level	HPA063683	Approved		Supported	Nucleoplasm<br>Lipid droplets		Mixed	Not detected			testis: 0.4	Not detected		
ANKRD63		ENSG00000230778	Ankyrin repeat domain 63	15	40281444-40282586	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	cerebral cortex: 1.0	fallopian tube,kidney,spleen,testis: 0.1	Cell line enhanced		HEK 293: 1.8
YY2	ZNF631	ENSG00000230797	YY2 transcription factor	X	21855987-21858727	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001119, HPA030335	Enhanced		Approved	Nuclear bodies		Mixed	Tissue enhanced		testis: 10.9	endometrium: 2.8	Mixed		
STMND1	FLJ23152	ENSG00000230873	Stathmin domain containing 1	6	17102258-17131372	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA067970	Enhanced		Approved	Actin filaments		Group enriched	Tissue enhanced		fallopian tube: 33.7;testis: 12.3	gallbladder: 9.4	Group enriched	6	HEK 293: 2.6;SCLC-21H: 7.8;T-47d: 7.6
HSBP1		ENSG00000230989	Heat shock factor binding protein 1	16	83807843-83819737	Predicted intracellular proteins	Evidence at protein level						Ovarian cancer:2.96e-4 (favourable), Endometrial cancer:5.73e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 58.8	Expressed in all		
USP17L28		ENSG00000231051	Ubiquitin specific peptidase 17-like family member 28	4	9348893-9350485	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP21-3		ENSG00000231068	Keratin associated protein 21-3	21	30718525-30718777	Predicted intracellular proteins	No evidence	HPA046554	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5H1	HSHTPCRX14, HTPCRX14	ENSG00000231192	Olfactory receptor family 5 subfamily H member 1	3	98132698-98133639	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PLSCR5		ENSG00000231213	Phospholipid scramblase family member 5	3	146576555-146606216	Predicted membrane proteins	Evidence at transcript level	HPA047249	Uncertain					Not detected	Tissue enriched	7	parathyroid gland: 1.8	testis: 0.2	Not detected		
C17orf105		ENSG00000231256	Chromosome 17 open reading frame 105	17	43780435-43787612	Predicted intracellular proteins	Evidence at transcript level	HPA053028	Approved					Not detected	Tissue enriched	47	testis: 20.2	skin: 0.4	Not detected		
SBK3	SgK110	ENSG00000231274	SH3 domain binding kinase family member 3	19	55540656-55545543	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA078322			Approved	Mitochondria		Not detected	Tissue enriched	6	heart muscle: 17.8	adipose tissue: 2.7	Cell line enhanced		A549: 4.5;CACO-2: 1.4;CAPAN-2: 2.6;RH-30: 2.1
HLA-DPA1	HLA-DP1A	ENSG00000231389	Major histocompatibility complex, class II, DP alpha 1	6	33064569-33080775	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA017967	Enhanced		Supported	Vesicles		Expressed in all	Expressed in all			lung: 120.6	Cell line enhanced		Daudi: 26.7;HDLM-2: 107.3;REH: 26.8
USP17L10		ENSG00000231396	Ubiquitin specific peptidase 17-like family member 10	4	9210657-9212608	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RPS18	D6S218E, HKE3, KE-3, KE3, S18	ENSG00000231500	Ribosomal protein S18	6	33272010-33276510	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050159, HPA055007	Approved		Supported	Cytosol	Renal cancer:1.15e-10 (unfavourable), Breast cancer:9.81e-4 (favourable)	Expressed in all	Expressed in all			ovary: 1305.1	Expressed in all		
USP17L29		ENSG00000231637	Ubiquitin specific peptidase 17-like family member 29	4	9353638-9355230	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DIRC3	FLJ14199	ENSG00000231672	Disrupted in renal carcinoma 3	2	217284019-217756593	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		parathyroid gland: 1.3	testis: 0.7	Not detected		
TSPAN19		ENSG00000231738	Tetraspanin 19	12	85014311-85036277	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA057066	Uncertain					Not detected	Tissue enhanced		testis: 8.1	lung: 4.3	Cell line enhanced		SCLC-21H: 3.1
AKAIN1	C18orf42	ENSG00000231824	A-kinase anchor inhibitor 1	18	5145285-5197503	Predicted intracellular proteins	Evidence at protein level	HPA049365	Uncertain					Not detected	Tissue enriched	11	adrenal gland: 20.1	testis: 1.7	Cell line enhanced		SCLC-21H: 1.1
CYP21A2	CA21H, CAH1, CPS1, CYP21, CYP21B, P450c21B	ENSG00000231852	Cytochrome P450 family 21 subfamily A member 2	6	32038265-32041670	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA048979, HPA053371	Enhanced					Tissue enhanced	Tissue enriched	257	adrenal gland: 266.4	epididymis: 1.0	Group enriched	5	HDLM-2: 6.1;Karpas-707: 1.2
OR5K2		ENSG00000231861	Olfactory receptor family 5 subfamily K member 2	3	98497604-98498663	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lung,skeletal muscle,skin,spleen: 0.3	Not detected		
PRH1	Pa	ENSG00000231887	Proline rich protein HaeIII subfamily 1	12	10824960-11171544	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	2295	salivary gland: 17934.0	ovary: 7.8	Cell line enhanced		CAPAN-2: 1.6
PSG1	CD66f, PBG1, PSBG1, PSGGA	ENSG00000231924	Pregnancy specific beta-1-glycoprotein 1	19	42866464-42879822	CD markers, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Tissue enhanced	Tissue enriched	377	placenta: 362.6	smooth muscle,spleen: 0.9	Cell line enriched	23	U-2197: 384.6
TAPBP	TAPA	ENSG00000231925	TAP binding protein	6	33299694-33314387	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007066	Approved				Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable)	Expressed in all	Expressed in all			spleen: 30.7	Cell line enhanced		CAPAN-2: 67.6
PPP1R2P3	MGC87149	ENSG00000231989	Protein phosphatase 1 regulatory inhibitor subunit 2 pseudogene 3	5	156850538-156852528	Predicted intracellular proteins	Evidence at transcript level	HPA043729, HPA059420			Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	435	testis: 43.5	all non-specific tissues: 0.0	Not detected		
MAGEB6P1	MAGEB6B	ENSG00000232030	MAGE family member B6 pseudogene 1	X	26160601-26161824	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.8	Not detected		
ZBED9	Buster4, FLJ31087, KIAA1925, SCAND3, ZFP38-L, ZNF305P2, ZNF452	ENSG00000232040	Zinc finger BED-type containing 9	6	28571630-28616212	Predicted intracellular proteins	Evidence at protein level	HPA007246	Uncertain		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus		Mixed	Tissue enhanced		testis: 18.8	epididymis: 4.6	Cell line enhanced		EFO-21: 5.6;K-562: 9.2
TMEM253	C14orf176, C14orf95, NCRNA00220	ENSG00000232070	Transmembrane protein 253	14	21098937-21103724	Predicted membrane proteins	Evidence at protein level	HPA052329, HPA065092	Enhanced					Mixed	Group enriched	6	duodenum: 101.3;small intestine: 100.0	colon: 15.8	Mixed		
TMA7	CCDC72, HSPC016	ENSG00000232112	Translation machinery associated 7 homolog	3	48440257-48444208	Predicted intracellular proteins	Evidence at protein level	HPA047397			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies	Lung cancer:8.33e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 420.1	Expressed in all		
RP11-360D2.1		ENSG00000232113		1	173635333-173637134	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	244	testis: 24.4	all non-specific tissues: 0.0	Not detected		
MCTS1	MCT-1	ENSG00000232119	MCTS1, re-initiation and release factor	X	120594010-120621074	Predicted intracellular proteins	Evidence at protein level	HPA001045			Supported	Plasma membrane<br>Cytosol	Head and neck cancer:3.27e-5 (unfavourable), Renal cancer:4.35e-5 (unfavourable), Breast cancer:1.38e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 50.7	Expressed in all		
DYTN		ENSG00000232125	Dystrotelin	2	206651621-206718396	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			bone marrow,testis: 0.1	Not detected		
MTRNR2L4		ENSG00000232196	MT-RNR2-like 4	16	3370979-3372740	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			skeletal muscle: 98.2	Cell line enhanced		AN3-CA: 43.4;HaCaT: 43.7;HeLa: 44.1
ASCL5	bHLHa47	ENSG00000232237	Achaete-scute family bHLH transcription factor 5	1	201113953-201127184	Predicted intracellular proteins, Transcription factors	No evidence							Mixed	Not detected			endometrium: 0.6	Not detected		
TMEM114		ENSG00000232258	Transmembrane protein 114	16	8537605-8590193	Disease related genes, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	61	seminal vesicle: 28.7	epididymis: 0.4	Not detected		
KRTAP25-1	KAP25.1	ENSG00000232263	Keratin associated protein 25-1	21	30289145-30289514	Predicted intracellular proteins	No evidence	HPA031438	Uncertain		Approved	Nuclear membrane<br>Plasma membrane<br>Cytosol		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L24		ENSG00000232264	Ubiquitin specific peptidase 17-like family member 24	4	9325165-9327116	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR52I1		ENSG00000232268	Olfactory receptor family 52 subfamily I member 1	11	4593750-4595013	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5K1	HSHTPCRX10, HTPCRX10	ENSG00000232382	Olfactory receptor family 5 subfamily K member 1	3	98469480-98470576	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
LINC00493	LOC388789	ENSG00000232388	Long intergenic non-protein coding RNA 493	20	18567347-18569563	Predicted membrane proteins	Evidence at transcript level	HPA068733			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:7.84e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 157.9	Expressed in all		
USP17L13		ENSG00000232399	Ubiquitin specific peptidase 17-like family member 13	4	9224896-9226847	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF6		ENSG00000232423	PRAME family member 6	1	12938472-12947580	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C9orf172		ENSG00000232434	Chromosome 9 open reading frame 172	9	136844415-136848801	Predicted intracellular proteins	Evidence at protein level	HPA021200	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 7.4	spleen: 3.3	Mixed		
KANTR	LINC01155, Spasm	ENSG00000232593	KDM5C adjacent non-coding transcript	X	53094145-53170914	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	5	cerebral cortex: 2.3	bone marrow: 0.4	Not detected		
HLA-DQB2	HLA-DXB	ENSG00000232629	Major histocompatibility complex, class II, DQ beta 2	6	32756098-32763534	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Breast cancer:5.55e-4 (favourable)	Expressed in all	Tissue enhanced		lung: 8.1;skin: 13.3	tonsil: 5.9	Not detected		
GOLGA8N		ENSG00000232653	Golgin A8 family member N	15	32593456-32607310	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			thyroid gland: 26.0	Group enriched	6	HEL: 71.9;THP-1: 35.0;U-937: 53.1
TNF	DIF, TNF-alpha, TNFA, TNFSF2	ENSG00000232810	Tumor necrosis factor	6	31575567-31578336	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 3.7	lymph node: 1.3	Group enriched	5	HDLM-2: 13.9;HMC-1: 12.0;NB-4: 27.3
PET117	CSRP2BP	ENSG00000232838	PET117 homolog	20	18137873-18143169	Predicted secreted proteins	Evidence at protein level	HPA047716	Approved				Liver cancer:4.76e-6 (unfavourable), Renal cancer:4.15e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 24.1	Expressed in all		
LYRM9	C17orf108, HSD24	ENSG00000232859	LYR motif containing 9	17	27878314-27894752	Predicted intracellular proteins	Evidence at protein level	HPA023051	Uncertain				Renal cancer:5.41e-4 (favourable), Pancreatic cancer:9.46e-4 (favourable)	Mixed	Expressed in all			thyroid gland: 71.9	Cell line enhanced		T-47d: 25.0
DEFB130	DEFB-30, DEFB30	ENSG00000232948	Defensin beta 130	8	12310962-12318316	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	47	epididymis: 4.7	all non-specific tissues: 0.0	Not detected		
RP11-1212A22.4		ENSG00000233024		16	18358086-18379331	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Uncertain	Nucleoplasm		Not detected	Expressed in all			parathyroid gland: 131.8	Expressed in all		
PHGR1		ENSG00000233041	Proline, histidine and glycine rich 1	15	40351033-40356434	Predicted intracellular proteins	Evidence at protein level	HPA068787	Enhanced		Approved	Vesicles	Breast cancer:2.05e-4 (favourable)	Group enriched	Group enriched	7	colon: 1448.4;duodenum: 892.1;rectum: 399.5;small intestine: 1777.5	stomach: 166.8	Cell line enhanced		BEWO: 12.3;HaCaT: 16.0;SCLC-21H: 72.5
RP11-1236K1.1		ENSG00000233050		8	12064389-12071747	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	47	epididymis: 4.7	all non-specific tissues: 0.0	Not detected		
WTH3DI		ENSG00000233087	RAB6C-like	2	131361111-131364142	Predicted intracellular proteins	Evidence at protein level	HPA059131	Uncertain		Approved	Golgi apparatus		Tissue enhanced	Tissue enriched	6	parathyroid gland: 14.4	prostate: 2.3	Cell line enhanced		MOLT-4: 1.7
USP17L11		ENSG00000233136	Ubiquitin specific peptidase 17-like family member 11	4	9215405-9217356	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			thyroid gland: 0.2	Not detected		
RNF224		ENSG00000233198	Ring finger protein 224	9	137227271-137229638	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			esophagus: 1.1	Cell line enhanced		CAPAN-2: 4.5;MCF7: 7.0
NPIPB7	LOC440350, NPIPL1	ENSG00000233232	Nuclear pore complex interacting protein family member B7	16	28456372-28471175	Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enriched	32	testis: 15.3	skin: 0.4	Cell line enhanced		BEWO: 1.7
GPX1		ENSG00000233276	Glutathione peroxidase 1	3	49357176-49358600	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011582, HPA044758	Approved		Supported	Cytosol	Endometrial cancer:7.78e-4 (favourable)	Expressed in all	Expressed in all			adipose tissue: 276.3	Mixed		
OR5H15		ENSG00000233412	Olfactory receptor family 5 subfamily H member 15	3	98168700-98169733	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
BTBD18		ENSG00000233436	BTB domain containing 18	11	57743514-57751781	Predicted intracellular proteins	Evidence at protein level	HPA049325	Uncertain					Not detected	Tissue enriched	8	testis: 4.0	skin: 0.5	Not detected		
TMEM238		ENSG00000233493	Transmembrane protein 238	19	55379245-55384598	Predicted membrane proteins	Evidence at protein level						Renal cancer:8.84e-6 (favourable)	Expressed in all	Tissue enhanced		small intestine: 10.0;stomach: 9.9	colon: 9.1	Cell line enhanced		A-431: 17.0;HaCaT: 15.4
TWIST2	bHLHa39, Dermo-1, DERMO1	ENSG00000233608	Twist family bHLH transcription factor 2	2	238848032-238910543	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA062870			Supported	Nucleus<br>Nucleoli		Mixed	Tissue enhanced		cervix, uterine: 40.1	adipose tissue: 27.3	Cell line enhanced		ASC diff: 104.1;BJ: 108.5;BJ hTERT+: 326.5;fHDF/TERT166: 143.5;U-2197: 143.4
PIRT		ENSG00000233670	Phosphoinositide interacting regulator of transient receptor potential channels	17	10822475-10838445	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042337	Uncertain		Uncertain	Plasma membrane<br>Cytosol		Tissue enriched	Tissue enhanced		adrenal gland: 3.1;cerebral cortex: 2.6;rectum: 2.7	colon: 2.1	Not detected		
PRR23C	FLJ46210	ENSG00000233701	Proline rich 23C	3	139042102-139044892	Predicted intracellular proteins	Evidence at transcript level	HPA047473	Uncertain					Not detected	Tissue enriched	12	testis: 1.7	cerebral cortex,skin,spleen: 0.1	Not detected		
MYCNOS	MYCN-AS1, N-CYM, NCYM	ENSG00000233718	MYCN opposite strand	2	15939898-15941723	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 3.9	cerebral cortex: 1.2	Cell line enhanced		BEWO: 17.5;HMC-1: 5.0;NTERA-2: 4.2
AC092835.2		ENSG00000233757		2	95207535-95259774	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			testis: 3.9	Cell line enhanced		SCLC-21H: 6.3
TRIM49D2	TRIM49D2P, TRIM49L, TRIM49L1	ENSG00000233802	Tripartite motif containing 49D2	11	89924064-89933063	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Not detected		
TSPY4		ENSG00000233803	Testis specific protein, Y-linked 4	Y	9337464-9340284	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Not detected	Tissue enriched	205	testis: 62.6	spleen: 0.3	Group enriched	498	U-266/70: 1493.8;U-266/84: 1550.5
IFNA13		ENSG00000233816	Interferon alpha 13	9	21367424-21368962	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			epididymis: 0.5	Not detected		
HIST1H2BN	H2B/d, H2BFD	ENSG00000233822	Histone cluster 1 H2B family member n	6	27837760-27865798	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			testis: 3.3	Cell line enhanced		SCLC-21H: 8.5
POTEB	A26B1, CT104.5, POTE-15, POTE15	ENSG00000233917	POTE ankyrin domain family member B	15	21846329-21877703	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	10	testis: 1.0	all non-specific tissues: 0.0	Not detected		
RPS28	S28	ENSG00000233927	Ribosomal protein S28	19	8321158-8323340	Disease related genes, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047132	Approved		Approved	Cytosol	Endometrial cancer:2.47e-4 (favourable)	Expressed in all	Expressed in all			ovary: 306.5	Expressed in all		
CTXN2		ENSG00000233932	Cortexin 2	15	48191539-48203756	Predicted membrane proteins	Evidence at transcript level	HPA053168	Uncertain					Not detected	Group enriched	8	cerebral cortex: 1.9;testis: 1.5	fallopian tube: 0.2	Not detected		
UQCRHL		ENSG00000233954	Ubiquinol-cytochrome c reductase hinge protein like	1	15807169-15809348	Predicted intracellular proteins	Evidence at protein level	HPA042574	Approved					Expressed in all	Mixed			skin: 1.3	Not detected		
PAGE2	CT16.4, GAGEC2, MGC62094, PAGE-2	ENSG00000234068	PAGE family member 2	X	55089008-55092842	Predicted intracellular proteins	Evidence at protein level	HPA052619	Supported					Mixed	Tissue enriched	42	testis: 43.8	placenta: 1.0	Group enriched	444	U-2 OS: 260.7;U-266/70: 782.4;U-266/84: 993.0
TRIM26	RNF95, ZNF173	ENSG00000234127	Tripartite motif containing 26	6	30184455-30213427	Predicted intracellular proteins	Evidence at protein level	HPA044975, HPA050456	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:3.25e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 10.4	Mixed		
C16orf82	TNT	ENSG00000234186	Chromosome 16 open reading frame 82	16	27066707-27069165	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	3011	testis: 301.0	all non-specific tissues: 0.0	Not detected		
TMEM229A		ENSG00000234224	Transmembrane protein 229A	7	124030916-124033023	Predicted membrane proteins	Evidence at protein level	HPA056391	Uncertain		Approved	Plasma membrane		Tissue enhanced	Tissue enhanced		cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4	small intestine: 4.4	Cell line enriched	46	SH-SY5Y: 141.7
PRR20E		ENSG00000234278	Proline rich 20E	13	57167197-57170218	Predicted intracellular proteins	Evidence at protein level	HPA059485	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
ZNF879	DKFZp686E2433	ENSG00000234284	Zinc finger protein 879	5	179023752-179035064	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA068608	Uncertain		Approved	Nucleus		Mixed	Mixed			testis: 11.3	Mixed		
H2BFS		ENSG00000234289	H2B histone family member S	21	43565189-43565648	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Not detected	Mixed			prostate: 8.2	Cell line enhanced		K-562: 40.6;U-2 OS: 43.9;U-266/84: 32.4
CCDC188		ENSG00000234409	Coiled-coil domain containing 188	22	20148427-20151065	Predicted membrane proteins	Evidence at transcript level	HPA049901			Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enriched	10	testis: 18.1	spleen: 1.8	Cell line enhanced		AF22: 4.0;SCLC-21H: 6.6;SH-SY5Y: 7.6
RBMY1A1	RBM1, RBM2, YRRM1, YRRM2	ENSG00000234414	RNA binding motif protein, Y-linked, family 1, member A1	Y	21511372-21549326	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	161	testis: 17.5	kidney,placenta: 0.1	Cell line enriched	9	U-266/84: 10.5
KBTBD13	hCG_1645727, NEM6	ENSG00000234438	Kelch repeat and BTB domain containing 13	15	65076816-65078192	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA062737	Uncertain					Not detected	Tissue enriched	12	skeletal muscle: 5.2	heart muscle: 0.4	Not detected		
ZNF736		ENSG00000234444	Zinc finger protein 736	7	64307459-64354860	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051027, HPA061215	Uncertain		Uncertain	Nucleoplasm	Endometrial cancer:3.03e-4 (unfavourable), Prostate cancer:5.01e-4 (unfavourable), Urothelial cancer:8.65e-4 (favourable)	Mixed	Mixed			testis: 15.1	Mixed		
PINLYP		ENSG00000234465	Phospholipase A2 inhibitor and LY6/PLAUR domain containing	19	43576800-43583964	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA061218	Uncertain		Approved	Vesicles		Mixed	Mixed			fallopian tube: 27.7	Cell line enhanced		HEL: 65.4;HMC-1: 40.9;REH: 27.1;THP-1: 24.6
CLDN34		ENSG00000234469	Claudin 34	X	9967358-9968352	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	13	testis: 2.3	epididymis,kidney,ovary,placenta,prostate,skin,urinary bladder: 0.1	Not detected		
C5orf58		ENSG00000234511	Chromosome 5 open reading frame 58	5	170232447-170252575	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	88	testis: 372.5	bone marrow: 4.2	Cell line enriched	9	U-266/84: 53.7
FAM133B	MGC40405	ENSG00000234545	Family with sequence similarity 133 member B	7	92560793-92590394	Predicted intracellular proteins	Evidence at protein level	HPA066175, HPA069513			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			epididymis: 34.6	Expressed in all		
OR10G8		ENSG00000234560	Olfactory receptor family 10 subfamily G member 8	11	124029590-124030634	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MCIDAS	IDAS, MCI, MCIN	ENSG00000234602	Multiciliate differentiation and DNA synthesis associated cell cycle protein	5	55219614-55227315	Predicted intracellular proteins	Evidence at protein level	HPA049981, HPA058073	Uncertain		Supported	Nuclear bodies		Mixed	Not detected			fallopian tube,gallbladder,parathyroid gland,stomach,testis,thyroid gland: 0.1	Cell line enhanced		BEWO: 2.2;CACO-2: 2.3;HEK 293: 2.0
JRK	jerky, JH8	ENSG00000234616	Jrk helix-turn-helix protein	8	142657460-142681968	Predicted intracellular proteins	Evidence at transcript level	HPA052675			Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Mixed			testis: 10.9	Expressed in all		
NPIPB2		ENSG00000234719	Nuclear pore complex interacting protein family, member B2	16	11927373-11976643	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Supported		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 14.8	parathyroid gland: 8.8	Cell line enhanced		RPMI-8226: 10.3;U-266/70: 19.3
HLA-B	AS	ENSG00000234745	Major histocompatibility complex, class I, B	6	31269491-31357188	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB015418	Enhanced				Melanoma:2.90e-4 (favourable)	Expressed in all	Mixed			lung: 1241.8	Cell line enhanced		A-431: 553.0;EFO-21: 516.7;U-266/70: 1064.3
C11orf94		ENSG00000234776	Chromosome 11 open reading frame 94	11	45906513-45907282	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	55	testis: 20.7	esophagus,thyroid gland: 0.3	Cell line enhanced		HEK 293: 1.1
RP11-526A4.1		ENSG00000234828		4	149351903-149896233	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	20	testis: 8.3	rectum: 0.4	Not detected		
IFNA17	IFN-alphaI, LEIF2C1	ENSG00000234829	Interferon alpha 17	9	21227243-21228222	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
APOC2		ENSG00000234906	Apolipoprotein C2	19	44945982-44949565	Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA055877	Supported					Tissue enriched	Tissue enriched	59	liver: 4214.4	small intestine: 71.0	Cell line enhanced		Hep G2: 463.1;HMC-1: 196.0;THP-1: 841.9
SHISA8	C22orf17, Orf26	ENSG00000234965	Shisa family member 8	22	41909554-41914667	Predicted membrane proteins	Evidence at transcript level	HPA059173	Uncertain				Endometrial cancer:2.76e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 4.3	lymph node,spleen: 1.4	Cell line enriched	7	HEK 293: 17.7
C19orf81		ENSG00000235034	Chromosome 19 open reading frame 81	19	50649445-50659310	Predicted intracellular proteins	Evidence at protein level	HPA060238	Enhanced		Approved	Vesicles<br>Aggresome		Tissue enhanced	Tissue enriched	11	testis: 5.3	cerebral cortex,epididymis,prostate: 0.4	Cell line enhanced		HEK 293: 4.0;HMC-1: 1.3
ANKRD65		ENSG00000235098	Ankyrin repeat domain 65	1	1418420-1421769	Predicted intracellular proteins	Evidence at protein level	HPA065720	Enhanced		Approved	Nucleoplasm	Lung cancer:1.08e-5 (favourable)	Expressed in all	Tissue enhanced		fallopian tube: 60.0	seminal vesicle: 31.4	Group enriched	8	Hep G2: 24.2;RT4: 27.5;SCLC-21H: 54.5
LINC00094	bA374P20.3, FLJ35348, NCRNA00094	ENSG00000235106	Long intergenic non-protein coding RNA 94	9	134025439-134034666	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.24e-5 (favourable), Urothelial cancer:2.31e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 36.6	Expressed in all		
ZSCAN31	ZNF310P, ZNF323	ENSG00000235109	Zinc finger and SCAN domain containing 31	6	28324693-28356271	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA007124	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.19e-5 (favourable)	Expressed in all	Expressed in all			testis: 38.7	Cell line enhanced		EFO-21: 37.9;U-2 OS: 50.9
AC010731.4		ENSG00000235118		2	206642418-206649449	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.6	Not detected		
C12orf75	AGD3, OCC-1, OCC1	ENSG00000235162	Chromosome 12 open reading frame 75	12	105235290-105396097	Predicted intracellular proteins	Evidence at protein level	HPA065311	Uncertain		Approved	Vesicles	Renal cancer:1.69e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)	Expressed in all	Tissue enhanced		seminal vesicle: 138.7	prostate: 61.0	Expressed in all		
SMIM1	Vel	ENSG00000235169	Small integral membrane protein 1 (Vel blood group)	1	3772788-3775982	Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA069088	Uncertain					Expressed in all	Tissue enhanced		bone marrow: 17.5;testis: 24.6	seminal vesicle: 7.5	Group enriched	6	HEL: 58.5;Hep G2: 21.1;K-562: 28.8
HGH1	Brp16, C8orf30A, C8orf30B, FAM203A, FAM203B, FLJ40907, LOC51236	ENSG00000235173	HGH1 homolog	8	144137769-144140843	Predicted intracellular proteins	Evidence at protein level	HPA042470	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:3.72e-5 (unfavourable), Cervical cancer:3.12e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue,stomach: 2.6	Cell line enhanced		PC-3: 43.5
PPP1R3E	FLJ00089	ENSG00000235194	Protein phosphatase 1 regulatory subunit 3E	14	23295643-23302848	Predicted intracellular proteins	Evidence at protein level	HPA061600	Approved		Approved	Microtubules<br>Mitotic spindle<br>Mitochondria	Colorectal cancer:6.89e-5 (unfavourable), Lung cancer:3.10e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 14.5	Cell line enhanced		U-266/70: 31.3
KDM4E	JMJD2E, KDM4DL, KDM5E	ENSG00000235268	Lysine demethylase 4E	11	95025258-95027596	Predicted intracellular proteins	Evidence at protein level	HPA051740, HPA054225	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
RPEL1		ENSG00000235376	Ribulose-5-phosphate-3-epimerase like 1	10	103245887-103248016	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA036498, HPA036499	Approved					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPAAR	LINC00961, SPAR	ENSG00000235387	Small regulatory polypeptide of amino acid response	9	35909483-35937153	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 8.1;testis: 10.9	placenta: 6.8	Group enriched	12	HUVEC TERT2: 28.2;TIME: 32.4
TOPORS-AS1	C9orf133	ENSG00000235453	TOPORS antisense RNA 1	9	32551144-32567005	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level						Breast cancer:4.18e-5 (favourable), Pancreatic cancer:7.33e-5 (favourable), Renal cancer:3.46e-4 (favourable), Cervical cancer:6.11e-4 (favourable), Ovarian cancer:8.39e-4 (favourable)	Expressed in all	Expressed in all			testis: 35.7	Mixed		
NFAM1	CNAIP	ENSG00000235568	NFAT activating protein with ITAM motif 1	22	42380410-42432395	Predicted membrane proteins	Evidence at protein level	HPA031812	Uncertain				Endometrial cancer:6.16e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 17.2;bone marrow: 20.2	spleen: 14.5	Cell line enhanced		NB-4: 5.5;SCLC-21H: 6.8;THP-1: 25.4
NKX1-1	HSPX153, SAX2	ENSG00000235608	NK1 homeobox 1	4	1402932-1406331	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA029367	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
RNF148	MGC35222	ENSG00000235631	Ring finger protein 148	7	122701664-122702967	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	228	testis: 73.5	lung: 0.3	Cell line enhanced		Karpas-707: 1.9
CXorf51B		ENSG00000235699	Chromosome X open reading frame 51B	X	146809784-146810409	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	1092	testis: 109.1	all non-specific tissues: 0.0	Cell line enhanced		U-138 MG: 1.0
ANKRD34C		ENSG00000235711	Ankyrin repeat domain 34C	15	79293285-79298235	Predicted intracellular proteins	Evidence at protein level	HPA045329	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		cerebral cortex: 1.9	skin: 0.9	Cell line enriched	29	SCLC-21H: 10.0
MFRP	C1QTNF5, FLJ30570, NNO2, rd6	ENSG00000235718	Membrane frizzled-related protein	11	119338942-119346673	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			parathyroid gland: 0.2	Not detected		
KIAA0040		ENSG00000235750	KIAA0040	1	175156987-175192999	Predicted intracellular proteins	Evidence at protein level	HPA016895, HPA068812	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			placenta: 143.7	Cell line enhanced		Daudi: 65.1;U-698: 80.2
USP17L27		ENSG00000235780	Ubiquitin specific peptidase 17-like family member 27	4	9344148-9345740	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
B3GALT4	beta3Gal-T4, GalT4	ENSG00000235863	Beta-1,3-galactosyltransferase 4	6	33277132-33284832	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA043001	Approved					Expressed in all	Mixed			testis: 3.8	Cell line enhanced		CAPAN-2: 1.8;SCLC-21H: 1.4;SK-BR-3: 1.5
LCE6A	C1orf44	ENSG00000235942	Late cornified envelope 6A	1	152842868-152843983	Predicted intracellular proteins	Evidence at protein level	HPA046376	Enhanced					Tissue enriched	Tissue enriched	11	skin: 303.8	breast: 26.8	Not detected		
PNMA6A	MGC15827, PNMA6C	ENSG00000235961	Paraneoplastic Ma antigen family member 6A	X	153072482-153075018	Predicted intracellular proteins	Evidence at protein level	HPA045007, HPA052115	Uncertain		Uncertain	Nucleoli<br>Mitochondria	Renal cancer:1.93e-5 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.9	epididymis: 7.3	Cell line enhanced		HHSteC: 6.4;U-2 OS: 15.5
PATE3	HEL-127, PATE-DJ	ENSG00000236027	Prostate and testis expressed 3	11	125788111-125791600	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	29	epididymis: 189.9	seminal vesicle: 6.4	Not detected		
OR5H14		ENSG00000236032	Olfactory receptor family 5 subfamily H member 14	3	98149326-98150405	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			placenta,testis: 0.2	Not detected		
ZBTB22	BING1, fru, fruitless, ZBTB22A, ZNF297, ZNF297A	ENSG00000236104	Zinc finger and BTB domain containing 22	6	33314406-33317942	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043848			Approved	Nucleoplasm		Expressed in all	Tissue enhanced		parathyroid gland: 28.9	epididymis: 11.8	Mixed		
USP17L4		ENSG00000236125	Ubiquitin specific peptidase 17-like family member 4	8	7337115-7338707	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CT47A3	CT47.3	ENSG00000236126	Cancer/testis antigen family 47, member A3	X	120972746-120976068	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
AC002429.5		ENSG00000236197		7	95035731-95214332	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	10	cerebral cortex: 2.7	esophagus: 0.2	Not detected		
CLEC2L	FLJ32986	ENSG00000236279	C-type lectin domain family 2 member L	7	139523856-139544984	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA045050	Enhanced					Mixed	Group enriched	9	cerebral cortex: 21.0;parathyroid gland: 13.7	endometrium: 1.9	Cell line enhanced		NTERA-2: 1.3;U-266/70: 2.4;U-266/84: 8.8
ZBED5	Buster1	ENSG00000236287	Zinc finger BED-type containing 5	11	10812074-10858796	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA048472, HPA050994	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Golgi apparatus	Liver cancer:2.19e-5 (unfavourable), Urothelial cancer:3.87e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 90.6	Expressed in all		
SLFN14		ENSG00000236320	Schlafen family member 14	17	35548125-35558098	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022994, HPA023065	Uncertain					Not detected	Tissue enhanced		bone marrow: 2.5	lymph node: 0.6	Cell line enriched	7	HEL: 19.4
PPIAL4G		ENSG00000236334	Peptidylprolyl isomerase A like 4G	1	148479824-148483679	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA058345	Uncertain					Not detected	Not detected			skeletal muscle: 0.9	Not detected		
GAGE12F		ENSG00000236362	G antigen 12F	X	49551278-49568218	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Cytosol		Not detected	Tissue enriched	23	testis: 300.5	stomach: 12.8	Group enriched	6	AN3-CA: 1052.1;K-562: 1042.6;T-47d: 255.7
CT47A1	CT47.1	ENSG00000236371	Cancer/testis antigen family 47, member A1	X	120982476-120985788	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	15	testis: 1.4	all non-specific tissues: 0.0	Cell line enriched	8	U-266/70: 1.7
LINC00854	TMEM106A-AS1	ENSG00000236383	Long intergenic non-protein coding RNA 854	17	43216941-43305397	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	11	testis: 45.4	spleen: 4.0	Mixed		
SLC35G4	AMAC1L1, SLC35G4P	ENSG00000236396	Solute carrier family 35 member G4	18	11609596-11610612	Predicted membrane proteins, Transporters	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
TAS2R39		ENSG00000236398	Taste 2 receptor member 39	7	143183419-143184435	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA053456, HPA060680	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TSPY10		ENSG00000236424	Testis specific protein, Y-linked 10	Y	9527880-9530682	Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	17	testis: 3.1	adipose tissue: 0.1	Group enriched	208	U-266/70: 8.9;U-266/84: 43.7
UBE2L5P	UBE2L5	ENSG00000236444	Ubiquitin conjugating enzyme E2 L5, pseudogene	13	30422488-30428616	Predicted intracellular proteins	Evidence at protein level	HPA045609, HPA062415	Approved		Uncertain	Nucleus<br>Cytosol		Mixed	Tissue enriched	76	testis: 86.2	endometrium: 1.1	Not detected		
CT47B1	CT47.13	ENSG00000236446	Cancer/testis antigen family 47, member B1	X	120872603-120875929	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	45	testis: 4.4	all non-specific tissues: 0.0	Not detected		
RP11-98L5.5		ENSG00000236543		9	135604345-135618952	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	34	skin: 22.9	parathyroid gland,seminal vesicle: 0.6	Cell line enriched	21	BEWO: 7.4
ZNF853	DKFZp434J1015	ENSG00000236609	Zinc finger protein 853	7	6615617-6624290	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067690	Approved		Approved	Nucleoli	Renal cancer:2.30e-6 (favourable)	Mixed	Mixed			cerebral cortex: 17.4	Cell line enhanced		AN3-CA: 18.6;SH-SY5Y: 31.3;U-2 OS: 20.5
IFNA4	IFN-alpha4a, MGC142200	ENSG00000236637	Interferon alpha 4	9	21186694-21187671	Predicted secreted proteins	Evidence at protein level	HPA047557	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ARHGEF38	FLJ20184	ENSG00000236699	Rho guanine nucleotide exchange factor 38	4	105552620-105708093	Predicted intracellular proteins	Evidence at protein level	HPA036510, HPA045484	Uncertain		Approved	Nucleoplasm<br>Centrosome		Tissue enhanced	Tissue enhanced		breast: 10.0;prostate: 9.3	epididymis: 6.8	Group enriched	8	RPTEC TERT1: 11.0;SK-BR-3: 6.0;T-47d: 7.9
GAGE12B		ENSG00000236737	G antigen 12B	X	49529869-49529985	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 1.2	spleen: 0.4	Group enriched	20	PC-3: 2.6;U-2197: 1.4
CTAGE9		ENSG00000236761	CTAGE family member 9	6	131708684-131711017	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enriched	41	testis: 7.6	duodenum,small intestine: 0.1	Not detected		
RP11-96L14.7		ENSG00000236782		1	26169516-26171821	Predicted membrane proteins	No evidence							Not detected	Not detected			endometrium,ovary,testis: 0.4	Not detected		
C3orf84		ENSG00000236980	Chromosome 3 open reading frame 84	3	49177632-49191858	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	77	testis: 7.6	all non-specific tissues: 0.0	Not detected		
OR10G9	OR10G10P	ENSG00000236981	Olfactory receptor family 10 subfamily G member 9	11	124023013-124023948	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L8		ENSG00000237038	Ubiquitin specific peptidase 17-like family member 8	8	7971661-7973253	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAAR9	TA3, TAR3, TRAR3	ENSG00000237110	Trace amine associated receptor 9 (gene/pseudogene)	6	132538290-132539336	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
C4orf51		ENSG00000237136	Chromosome 4 open reading frame 51	4	145680115-145771032	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	19	testis: 9.2	epididymis: 0.4	Not detected		
B3GNT9	MGC4655	ENSG00000237172	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9	16	67148105-67151214	Predicted secreted proteins	Evidence at protein level	HPA052743, HPA062734	Approved		Supported	Nucleoli fibrillar center<br>Golgi apparatus		Expressed in all	Tissue enhanced		parathyroid gland: 49.9	thyroid gland: 28.2	Cell line enhanced		SiHa: 49.7
CDKN2AIPNL	MGC13017	ENSG00000237190	CDKN2A interacting protein N-terminal like	5	134402087-134411898	Predicted intracellular proteins	Evidence at protein level	HPA043966	Approved					Expressed in all	Expressed in all			thyroid gland: 35.4	Expressed in all		
MBD3L5		ENSG00000237247	Methyl-CpG binding domain protein 3 like 5	19	7030578-7033011	Predicted intracellular proteins	No evidence	HPA051259	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CKMT1B	CKMT, CKMT1, UMTCK	ENSG00000237289	Creatine kinase, mitochondrial 1B	15	43593054-43604901	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA043491	Uncertain				Endometrial cancer:2.55e-5 (unfavourable)	Mixed	Tissue enhanced		colon: 78.0;rectum: 68.4	duodenum: 63.0	Cell line enhanced		HaCaT: 120.7;SCLC-21H: 60.9;SK-BR-3: 124.3;T-47d: 91.0
RNF223		ENSG00000237330	Ring finger protein 223	1	1070966-1074307	Predicted membrane proteins	Evidence at transcript level						Endometrial cancer:8.08e-5 (favourable), Pancreatic cancer:6.53e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 5.3;stomach: 3.6	skin: 2.0	Cell line enhanced		A-431: 13.3;CAPAN-2: 9.8;HaCaT: 6.2;MCF7: 18.6;SK-BR-3: 12.0;T-47d: 9.8
PATE4	FLJ41047, PATE-B	ENSG00000237353	Prostate and testis expressed 4	11	125833316-125840069	Predicted secreted proteins	Evidence at protein level	HPA045632	Approved					Not detected	Tissue enriched	8	seminal vesicle: 148.4	epididymis: 18.3	Not detected		
OR4A47		ENSG00000237388	Olfactory receptor family 4 subfamily A member 47	11	48488717-48489780	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA059763	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRSS56		ENSG00000237412	Protease, serine 56	2	232520463-232525716	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skeletal muscle: 3.4	testis: 0.8	Not detected		
ZNF737	ZNF102	ENSG00000237440	Zinc finger protein 737	19	20535825-20565809	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Mixed	Mixed			thyroid gland: 66.9	Cell line enhanced		MOLT-4: 22.1;RT4: 22.5
RGL2	HKE1.5, KE1.5, RAB2L	ENSG00000237441	Ral guanine nucleotide dissociation stimulator like 2	6	33291654-33299324	Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA047039, HPA053444	Approved		Approved	Nucleoplasm	Pancreatic cancer:6.16e-4 (favourable)	Expressed in all	Mixed			spleen: 1.5	Mixed		
BHMG1	HMGDC	ENSG00000237452	Basic helix-loop-helix and HMG-box containing 1	19	45733251-45764534	Predicted intracellular proteins	Evidence at transcript level	HPA049521	Uncertain					Tissue enriched	Tissue enriched	77	testis: 7.6	all non-specific tissues: 0.0	Cell line enhanced		Daudi: 1.0;K-562: 3.0
LINC00959		ENSG00000237489	Long intergenic non-protein coding RNA 959	10	130063900-130110817	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			thyroid gland: 10.9	Cell line enhanced		NB-4: 8.8
SHISA9		ENSG00000237515	Shisa family member 9	16	12901620-13240413	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.53e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.8	prostate: 7.2	Cell line enhanced		EFO-21: 46.5;LHCN-M2: 33.9
OR7E24	HSHT2, OR19-8, OR7E24P, OR7E24Q	ENSG00000237521	Olfactory receptor family 7 subfamily E member 24	19	9250930-9252479	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	25	testis: 2.5	all non-specific tissues: 0.0	Not detected		
AC114783.1		ENSG00000237524		2	126898882-126902097	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	183	testis: 57.8	kidney: 0.3	Not detected		
HLA-DQA2	HLA-DXA	ENSG00000237541	Major histocompatibility complex, class II, DQ alpha 2	6	32741342-32747215	Predicted membrane proteins	Evidence at protein level							Expressed in all	Not detected			tonsil: 0.3	Not detected		
KIFC1	HSET, KNSL2	ENSG00000237649	Kinesin family member C1	6	33391536-33409924	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA055997, HPA062674	Supported		Approved	Centrosome	Renal cancer:0.00e+0 (unfavourable), Liver cancer:7.07e-8 (unfavourable), Pancreatic cancer:4.21e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 3.2	bone marrow: 2.8	Mixed		
C2orf74	LOC339804	ENSG00000237651	Chromosome 2 open reading frame 74	2	61145068-61164829	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA026826	Approved		Approved	Centrosome		Mixed	Expressed in all			testis: 80.5	Mixed		
GAGE12C		ENSG00000237671	G antigen 12C	X	49532211-49539538	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	461	testis: 46.0	all non-specific tissues: 0.0	Group enriched	10	U-2 OS: 9.9;U-266/84: 25.6
IRGM	IFI1, IRGM1, LRG-47, LRG47	ENSG00000237693	Immunity related GTPase M	5	150846523-150900736	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 1.6	appendix,spleen: 0.5	Cell line enhanced		NB-4: 1.6;U-937: 2.4
PRAMEF33	PRAMEF33P	ENSG00000237700	PRAME family member 33	1	13303539-13308907	Predicted intracellular proteins	No evidence							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
AMY1A	AMY1	ENSG00000237763	Amylase, alpha 1A (salivary)	1	103655290-103664554	Enzymes, Predicted secreted proteins	Evidence at protein level	CAB004310, HPA045394, HPA045399, HPA046980	Supported					Not detected	Tissue enriched	79	salivary gland: 8875.9	cervix, uterine: 111.7	Not detected		
FAM200B	C4orf53	ENSG00000237765	Family with sequence similarity 200 member B	4	15681662-15705565	Predicted intracellular proteins	Evidence at protein level	HPA017855	Uncertain				Urothelial cancer:3.35e-5 (favourable), Renal cancer:3.87e-4 (favourable), Pancreatic cancer:4.39e-4 (favourable), Lung cancer:9.89e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 15.0	Mixed		
FAM231A		ENSG00000237847	Family with sequence similarity 231 member A	1	16673003-16673512	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
CT47A5	CT47.5	ENSG00000237957	Cancer/testis antigen family 47, member A5	X	120963026-120966348	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
LRRC37A2	FLJ45049	ENSG00000238083	Leucine rich repeat containing 37 member A2	17	46511511-46555650	Predicted membrane proteins	Evidence at protein level	HPA042121, HPA042701, HPA043056, HPA045090, HPA049080	Supported		Approved	Vesicles		Mixed	Tissue enriched	25	testis: 13.0	breast,lung: 0.5	Not detected		
MPC1L		ENSG00000238205	Mitochondrial pyruvate carrier 1-like	X	40623566-40624136	Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	67	testis: 12.0	epididymis,lung,lymph node: 0.1	Not detected		
RP13-210D15.4		ENSG00000238210		X	135252061-135253583	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 11.8	skin: 0.7	Not detected		
C9orf69	bA83N9.1	ENSG00000238227	Chromosome 9 open reading frame 69	9	136114581-136118863	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066070	Supported		Supported	Nucleoplasm	Endometrial cancer:1.09e-4 (favourable)	Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
OR2W3	OR2W3P, OR2W8P, OST718	ENSG00000238243	Olfactory receptor family 2 subfamily W member 3	1	247895587-247896531	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA045594	Uncertain					Tissue enhanced	Tissue enhanced		bone marrow: 7.8;thyroid gland: 10.5	cerebral cortex: 2.9	Cell line enhanced		HEL: 12.1;PC-3: 12.2;U-2 OS: 8.8;WM-115: 9.3
PAGE2B	CT16.5	ENSG00000238269	PAGE family member 2B	X	55075063-55078909	Predicted intracellular proteins	Evidence at protein level	HPA052619	Supported				Endometrial cancer:3.02e-4 (unfavourable)	Mixed	Tissue enriched	29	testis: 84.8	bone marrow: 2.8	Group enriched	6	U-266/70: 1167.1;U-266/84: 1756.5
TXNDC5	EndoPDI, ERp46, FLJ21353, FLJ90810, Hcc-2, MGC3178, PDIA15	ENSG00000239264	Thioredoxin domain containing 5	6	7881517-7910814	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA034677, HPA034678	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.16e-4 (unfavourable)	Expressed in all	Expressed in all			urinary bladder: 312.7	Expressed in all		
GATSL3		ENSG00000239282	GATS protein like 3	22	30285117-30289627	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			esophagus: 22.8	Mixed		
RNF103	hkf-1, KF1, ZFP103	ENSG00000239305	Ring finger protein 103	2	86603393-86623866	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA057922	Approved				Urothelial cancer:6.77e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 55.3	Expressed in all		
RBM14	COAA, DKFZp779J0927, SIP, SYTIP1	ENSG00000239306	RNA binding motif protein 14	11	66616582-66627347	Predicted intracellular proteins	Evidence at protein level	HPA006628	Supported		Supported	Nuclear speckles	Liver cancer:2.02e-7 (unfavourable), Pancreatic cancer:1.04e-4 (favourable)	Expressed in all	Expressed in all			testis: 50.0	Expressed in all		
ALKBH6	MGC15677	ENSG00000239382	AlkB homolog 6	19	36009120-36014239	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA073835, HPA074340			Supported	Nucleoplasm<br>Focal adhesion sites		Expressed in all	Mixed			cerebral cortex: 7.5	Expressed in all		
ASB14	DKFZp313L0121	ENSG00000239388	Ankyrin repeat and SOCS box containing 14	3	57268347-57292682	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		skeletal muscle: 9.9	heart muscle: 2.4	Not detected		
PCDHA13	CNR5, CNRN5, CNRS5, CRNR5, PCDH-ALPHA13	ENSG00000239389	Protocadherin alpha 13	5	140882208-141012344	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	6	parathyroid gland: 6.8	cerebral cortex,testis: 1.0	Cell line enhanced		AN3-CA: 1.0;PC-3: 3.5;WM-115: 1.1
KLHL41	KBTBD10, Krp1, SARCOSIN	ENSG00000239474	Kelch like family member 41	2	169509702-169526262	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021165, HPA021753, HPA021760	Enhanced		Supported	Nucleus<br>Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	22	skeletal muscle: 1750.6	esophagus: 79.6	Group enriched	8	HSkMC: 15.5;LHCN-M2: 29.3;RH-30: 53.9
GATS	DKFZp686B07267, STAG3OS	ENSG00000239521	GATS, stromal antigen 3 opposite strand	7	100200653-100272218	Predicted intracellular proteins	Evidence at transcript level	HPA043176	Uncertain				Cervical cancer:7.56e-7 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 3.3;skeletal muscle: 2.2	bone marrow: 0.7	Cell line enhanced		A549: 1.4
OR1J4	HSHTPCRX01, HTPCRX01	ENSG00000239590	Olfactory receptor family 1 subfamily J member 4	9	122519141-122520082	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			epididymis: 0.2	Not detected		
C2orf61	FLJ40172	ENSG00000239605	Chromosome 2 open reading frame 61	2	47045538-47155287	Predicted intracellular proteins	Evidence at transcript level	HPA047366, HPA052691	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enhanced		testis: 1.3	gallbladder: 0.3	Cell line enhanced		Karpas-707: 1.4
MEIKIN		ENSG00000239642	Meiotic kinetochore factor	5	131806993-131945698	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 13.4	parathyroid gland: 0.7	Cell line enriched	8	U-2 OS: 1.6
NME1	NDPKA, NM23, NM23-H1	ENSG00000239672	NME/NM23 nucleoside diphosphate kinase 1	17	51153536-51162428	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008467, CAB040571, HPA041113	Supported		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:2.07e-9 (unfavourable), Liver cancer:2.60e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 89.3	Expressed in all		
TNFSF12	APO3L, DR3LG, TWEAK	ENSG00000239697	Tumor necrosis factor superfamily member 12	17	7548891-7557890	Predicted secreted proteins	Evidence at protein level	HPA052967	Uncertain				Endometrial cancer:5.70e-5 (favourable)	Expressed in all	Mixed			seminal vesicle: 27.2	Mixed		
CDRT4	FLJ36674	ENSG00000239704	CMT1A duplicated region transcript 4	17	15436015-15503608	Predicted intracellular proteins	Evidence at transcript level	HPA021590	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		epididymis: 30.3	skin: 26.3	Cell line enhanced		Hep G2: 7.6
APOBEC3G	bK150C2.7, CEM15, dJ494G10.1, FLJ12740, MDS019	ENSG00000239713	Apolipoprotein B mRNA editing enzyme catalytic subunit 3G	22	39077005-39087743	Predicted intracellular proteins	Evidence at protein level	HPA001812, HPA073637	Approved		Uncertain	Nucleoplasm<br>Cytosol	Renal cancer:8.66e-13 (unfavourable), Endometrial cancer:6.03e-5 (favourable), Cervical cancer:4.70e-4 (favourable), Breast cancer:4.78e-4 (favourable), Urothelial cancer:6.30e-4 (favourable)	Expressed in all	Mixed			lymph node: 46.0	Cell line enhanced		HDLM-2: 29.7;Karpas-707: 30.4
TLR9	CD289	ENSG00000239732	Toll like receptor 9	3	52221080-52226163	CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		lymph node: 3.0	spleen: 2.0	Group enriched	10	Daudi: 23.9;RPMI-8226: 14.8;U-698: 8.8
WBP1	WBP-1	ENSG00000239779	WW domain binding protein 1	2	74458329-74460891	Predicted membrane proteins	Evidence at protein level	HPA057067	Approved		Approved	Cytosol	Colorectal cancer:1.04e-4 (unfavourable), Urothelial cancer:6.36e-4 (favourable), Pancreatic cancer:6.83e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 91.5	Expressed in all		
MRPS17	HSPC011, MRP-S17, RPMS17	ENSG00000239789	Mitochondrial ribosomal protein S17	7	55951819-55956501	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047159	Approved					Expressed in all	Expressed in all			fallopian tube: 16.0	Expressed in all		
PRAMEF11		ENSG00000239810	PRAME family member 11	1	12824605-12831410	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
DEFA3	DEF3, HNP-3	ENSG00000239839	Defensin alpha 3	8	7015869-7018301	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA052517	Supported					Not detected	Tissue enriched	246	bone marrow: 23273.5	spleen: 94.7	Not detected		
GET4	C7orf20, CEE, CGI-20, H_NH1244M04.5, TRC35	ENSG00000239857	Golgi to ER traffic protein 4	7	876552-896436	Predicted intracellular proteins	Evidence at protein level	HPA019765	Uncertain		Supported	Nucleoplasm<br>Nucleoli<br>Cytosol		Expressed in all	Expressed in all			testis: 49.7	Expressed in all		
KRTAP9-2	KAP9.2	ENSG00000239886	Keratin associated protein 9-2	17	41226648-41227652	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			testis: 0.1	Not detected		
C1orf226	FLJ13137	ENSG00000239887	Chromosome 1 open reading frame 226	1	162366908-162386818	Predicted intracellular proteins	Evidence at protein level	HPA052251	Approved		Approved	Nucleoplasm	Renal cancer:4.44e-5 (favourable), Urothelial cancer:1.13e-4 (favourable), Breast cancer:2.60e-4 (favourable)	Expressed in all	Mixed			adrenal gland: 12.7	Cell line enhanced		HEL: 20.8
ADSL		ENSG00000239900	Adenylosuccinate lyase	22	40346500-40390463	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000525, CAB019285	Enhanced		Enhanced	Cytosol	Liver cancer:5.81e-8 (unfavourable), Colorectal cancer:2.38e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 127.3	Expressed in all		
LILRA4	CD85g, ILT7	ENSG00000239961	Leukocyte immunoglobulin like receptor A4	19	54333185-54339150	CD markers, Predicted membrane proteins	Evidence at protein level	HPA049418	Approved					Mixed	Tissue enhanced		spleen: 2.1;tonsil: 2.5	lymph node: 0.9	Not detected		
LILRA2	CD85h, ILT1, LIR-7, LIR7	ENSG00000239998	Leukocyte immunoglobulin like receptor A2	19	54572920-54590287	CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Mixed	Tissue enhanced		bone marrow: 9.9;spleen: 7.0	appendix: 4.0	Cell line enhanced		REH: 1.8;THP-1: 2.7;U-937: 7.1
TEX35	C1orf49, DKFZP564J047, TSC24	ENSG00000240021	Testis expressed 35	1	178513077-178548602	Predicted intracellular proteins	Evidence at protein level	HPA039190	Approved					Not detected	Tissue enriched	34	testis: 174.3	skin: 5.1	Mixed		
AMY2B	AMY2	ENSG00000240038	Amylase, alpha 2B (pancreatic)	1	103553815-103579534	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, HPA046980	Supported					Tissue enriched	Tissue enriched	66	pancreas: 6585.9	salivary gland: 99.6	Cell line enhanced		EFO-21: 9.6
RP11-451G4.2		ENSG00000240045		3	155290229-155293775	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	25	skeletal muscle: 400.8	prostate: 15.8	Not detected		
LY6G5B	C6orf19, G5b	ENSG00000240053	Lymphocyte antigen 6 family member G5B	6	31670167-31673776	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048307	Approved					Mixed	Expressed in all			skin: 27.1	Expressed in all		
PSMB9	beta1i, LMP2, PSMB6i, RING12	ENSG00000240065	Proteasome subunit beta 9	6	32844136-32859585	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015180, HPA042818, HPA053280	Enhanced		Supported	Cytosol	Renal cancer:1.33e-4 (unfavourable)	Expressed in all	Mixed			spleen: 39.1	Cell line enhanced		Daudi: 46.2;REH: 43.8
PCDHGC3	PC-43, PC43, PCDH-GAMMA-C3, PCDH2	ENSG00000240184	Protocadherin gamma subfamily C, 3	5	141475947-141512979	Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA077289	Approved		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable)	Group enriched	Tissue enhanced		cerebral cortex: 376.0	cervix, uterine: 93.8	Cell line enhanced		U-138 MG: 264.5;WM-115: 404.1
SMKR1		ENSG00000240204	Small lysine rich protein 1	7	129502479-129512932	Predicted intracellular proteins	Evidence at transcript level	HPA078358			Approved	Nucleoli		Mixed	Tissue enriched	13	testis: 119.8	fallopian tube: 9.4	Cell line enhanced		SCLC-21H: 34.4
UGT1A5	UGT1E	ENSG00000240224	UDP glucuronosyltransferase family 1 member A5	2	233712992-233773299	Enzymes, Predicted membrane proteins	Evidence at transcript level							Not detected	Group enriched	7	duodenum: 7.5;gallbladder: 3.9;small intestine: 6.8	liver: 0.9	Not detected		
COX19	MGC104475	ENSG00000240230	COX19, cytochrome c oxidase assembly factor	7	898778-975599	Predicted intracellular proteins	Evidence at protein level	HPA021226	Approved		Enhanced	Cytosol		Expressed in all	Expressed in all			fallopian tube: 10.0	Mixed		
DEFA1B		ENSG00000240247	Defensin alpha 1B	8	6996766-6999195	Cancer-related genes, Plasma proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA052517	Supported					Not detected	Tissue enriched	463	bone marrow: 46364.0	spleen: 100.2	Not detected		
ACAD11	FLJ12592	ENSG00000240303	Acyl-CoA dehydrogenase family member 11	3	132558138-132660723	Predicted intracellular proteins	Evidence at protein level	HPA048317	Enhanced					Tissue enhanced	Expressed in all			kidney: 35.4	Mixed		
PPIL3	CyPJ	ENSG00000240344	Peptidylprolyl isomerase like 3	2	200870907-200889303	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040765, HPA062187	Approved		Supported	Nucleus	Ovarian cancer:1.19e-4 (favourable), Renal cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.3	Expressed in all		
LCE1F	LEP6	ENSG00000240386	Late cornified envelope 1F	1	152776372-152776728	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	21	skin: 246.9	breast: 11.9	Cell line enhanced		BJ hTERT+: 5.4;hTEC/SVTERT24-B: 1.1;hTERT-HME1: 2.3
KIR3DL2	CD158K, cl-5, nkat4, nkat4a, nkat4b	ENSG00000240403	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2	19	54850443-54867207	CD markers, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			bone marrow: 0.1	Not detected		
KRTAP13-3	KAP13.3	ENSG00000240432	Keratin associated protein 13-3	21	30425265-30425968	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TNFRSF13B	CD267, IGAD2, TACI	ENSG00000240505	TNF receptor superfamily member 13B	17	16929816-16972118	CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA030453	Uncertain					Not detected	Tissue enhanced		lymph node: 20.3;skeletal muscle: 22.1;spleen: 27.2;tonsil: 21.0	appendix: 12.1	Group enriched	8	Karpas-707: 120.9;RPMI-8226: 76.1;U-266/70: 56.5
KRTAP9-1	KAP9.1, KRTAP9L3	ENSG00000240542	Keratin associated protein 9-1	17	41189887-41190639	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	42	HDLM-2: 4.2
L1TD1	ECAT11, FLJ10884	ENSG00000240563	LINE1 type transposase domain containing 1	1	62194831-62212328	Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		placenta: 16.6;testis: 11.0	appendix: 6.1	Cell line enriched	26	NTERA-2: 254.5
AQP1	CHIP28, CO	ENSG00000240583	Aquaporin 1 (Colton blood group)	7	30911694-30925516	Blood group antigen proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB001707, HPA019206	Enhanced		Supported	Plasma membrane	Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable)	Expressed in all	Expressed in all			kidney: 791.4	Cell line enhanced		EFO-21: 37.4;SH-SY5Y: 15.9;U-2 OS: 19.3;WM-115: 72.2
C1QTNF9	AQL1, C1QTNF9A, CTRP9, MGC48915	ENSG00000240654	C1q and tumor necrosis factor related protein 9	13	24307166-24322535	Predicted secreted proteins	Evidence at protein level	HPA056632	Uncertain					Not detected	Tissue enhanced		skeletal muscle: 2.9	adipose tissue: 2.1	Not detected		
ISY1	fSAP33, KIAA1160	ENSG00000240682	ISY1 splicing factor homolog	3	129127415-129161293	Predicted intracellular proteins	Evidence at protein level	HPA006312, HPA016995	Supported		Enhanced	Nuclear speckles	Cervical cancer:2.46e-5 (favourable), Liver cancer:7.25e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 36.5	Expressed in all		
PNMA2	MA2, RGAG2	ENSG00000240694	Paraneoplastic Ma antigen 2	8	26504686-26514092	Predicted intracellular proteins	Evidence at protein level	HPA001936	Enhanced				Lung cancer:1.81e-4 (favourable), Stomach cancer:6.23e-4 (unfavourable)	Tissue enhanced	Tissue enriched	12	cerebral cortex: 163.4	adrenal gland: 13.5	Cell line enhanced		AF22: 59.2;HAP1: 38.7;SH-SY5Y: 45.6
LRRD1	IMAGE:4798971	ENSG00000240720	Leucine rich repeats and death domain containing 1	7	92112159-92179531	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	53	testis: 30.0	epididymis,skin: 0.5	Not detected		
KRBOX1		ENSG00000240747	KRAB box domain containing 1	3	42809483-42942792	Predicted intracellular proteins	Evidence at transcript level	HPA046901			Approved	Nucleoplasm<br>Golgi apparatus		Mixed	Tissue enriched	31	testis: 289.2	epididymis: 9.3	Cell line enhanced		CAPAN-2: 42.0;EFO-21: 21.7;hTEC/SVTERT24-B: 33.3;U-2197: 61.0
PCDHGC5	PCDH-GAMMA-C5	ENSG00000240764	Protocadherin gamma subfamily C, 5	5	141489121-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA051540	Uncertain		Approved	Nucleus<br>Nucleoplasm<br>Vesicles<br>Plasma membrane<br>Cytosol		Group enriched	Tissue enriched	43	cerebral cortex: 50.6	smooth muscle: 1.1	Cell line enhanced		U-138 MG: 14.5;U-251 MG: 5.4;U-87 MG: 8.8
ARHGEF25	GEFT, p63RhoGEF	ENSG00000240771	Rho guanine nucleotide exchange factor 25	12	57610180-57619379	Predicted intracellular proteins	Evidence at protein level	HPA052016	Uncertain		Approved	Vesicles	Renal cancer:4.20e-7 (unfavourable)	Expressed in all	Mixed			endometrium: 112.2	Cell line enhanced		RH-30: 125.8;SH-SY5Y: 62.5
TMEM189	Kua	ENSG00000240849	Transmembrane protein 189	20	50118254-50153734	Predicted membrane proteins	Evidence at protein level	HPA059549	Approved		Supported	Endoplasmic reticulum	Renal cancer:5.79e-11 (unfavourable), Endometrial cancer:7.51e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 31.3	Expressed in all		
RDH14	PAN2, SDR7C4	ENSG00000240857	Retinol dehydrogenase 14 (all-trans/9-cis/11-cis)	2	18554723-18560680	Predicted intracellular proteins	Evidence at protein level	HPA056686	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.6	Expressed in all		
KRTAP4-7	KAP4.7	ENSG00000240871	Keratin associated protein 4-7	17	41084150-41085141	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PLCXD2	FLJ31579	ENSG00000240891	Phosphatidylinositol specific phospholipase C X domain containing 2	3	111674676-111846447	Predicted intracellular proteins	Evidence at protein level	HPA055947	Uncertain		Approved	Nucleoplasm	Renal cancer:1.23e-7 (favourable), Urothelial cancer:2.99e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 6.4	lymph node: 3.3	Mixed		
MIF	GIF, GLIF	ENSG00000240972	Macrophage migration inhibitory factor (glycosylation-inhibiting factor)	22	23894004-23895227	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003868, CAB005284	Approved		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			prostate: 41.3	Expressed in all		
GVQW1	bA205M20.5, TIGD1L2	ENSG00000241043	GVQW motif containing 1	9	32566789-32568621	Predicted secreted proteins	Evidence at transcript level	HPA074576			Approved	Mitochondria		Mixed	Mixed			parathyroid gland: 2.2	Mixed		
NSUN6	ARL5B-AS1, FLJ23743, NOPD1	ENSG00000241058	NOP2/Sun RNA methyltransferase family member 6	10	18545561-18659285	Predicted intracellular proteins	Evidence at protein level	HPA045902	Approved		Approved	Golgi apparatus	Renal cancer:5.55e-5 (unfavourable), Lung cancer:8.42e-4 (favourable)	Expressed in all	Expressed in all			liver: 30.7	Expressed in all		
HLA-DOB		ENSG00000241106	Major histocompatibility complex, class II, DO beta	6	32812763-32817048	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA013846	Enhanced				Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable)	Expressed in all	Group enriched	5	lymph node: 19.6;spleen: 18.6;tonsil: 30.7;urinary bladder: 8.3	colon: 3.5	Cell line enhanced		Daudi: 37.8;U-698: 12.8;U-937: 6.1
UGT1A9	HLUGP4, LUGP4, UGT1AI	ENSG00000241119	UDP glucuronosyltransferase family 1 member A9	2	233671853-233773300	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level						Renal cancer:5.04e-5 (unfavourable)	Group enriched	Group enriched	592	kidney: 465.5;liver: 93.3	cerebral cortex,colon: 0.4	Cell line enhanced		A549: 1.2
KRTAP10-5	KAP10.5, KAP18.5, KRTAP18-5	ENSG00000241123	Keratin associated protein 10-5	21	44579455-44580604	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
YAE1D1	C7orf36, GK003	ENSG00000241127	Yae1 domain containing 1	7	39566376-39610320	Predicted intracellular proteins	Evidence at protein level	HPA019226, HPA031249	Uncertain		Approved	Cytosol	Liver cancer:1.64e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 34.5	Expressed in all		
OR14A2	OR5AX1, OR5AX1P	ENSG00000241128	Olfactory receptor family 14 subfamily A member 2	1	247723099-247724043	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA052685	Uncertain					Not detected	Tissue enriched	51	testis: 5.0	all non-specific tissues: 0.0	Not detected		
RP11-561N12.2		ENSG00000241149		7	63998874-64016130	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	38	testis: 3.7	all non-specific tissues: 0.0	Not detected		
TDGF1	CR, CRIPTO, Cripto-1	ENSG00000241186	Teratocarcinoma-derived growth factor 1	3	46574534-46582463	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enhanced		spleen: 24.8	kidney: 8.1	Group enriched	30	HEL: 19.6;NTERA-2: 95.4
FLJ22763		ENSG00000241224	Uncharacterized LOC401081	3	109118252-109150514	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		duodenum: 97.6;small intestine: 94.5	kidney: 19.5	Cell line enhanced		CACO-2: 1.0
KRTAP5-8	KRTAP5-2, KRTAP5.8, UHSKerB	ENSG00000241233	Keratin associated protein 5-8	11	71538025-71539207	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		testis: 1.1	epididymis,kidney: 0.8	Not detected		
KRTAP4-16	KAP4A, KRTAP4-16P, KRTAP4P1	ENSG00000241241	Keratin associated protein 4-16	17	41101502-41102209	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CRCP	CGRP-RCP, RCP, RCP9	ENSG00000241258	CGRP receptor component	7	66114604-66154568	Predicted intracellular proteins	Evidence at protein level	HPA007216	Approved		Approved	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 32.1	Expressed in all		
CDRT1	FBXW10B, FBXW10P1, HREP, SM25H2	ENSG00000241322	CMT1A duplicated region transcript 1	17	15565483-15619512	Predicted intracellular proteins	Evidence at transcript level	HPA013332, HPA047457			Approved	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		testis: 20.3	esophagus: 5.1	Cell line enhanced		CAPAN-2: 20.4;HaCaT: 37.7
RPL36A	L36A, RPL44	ENSG00000241343	Ribosomal protein L36a	X	101390824-101396154	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA063979, HPA077586	Uncertain		Supported	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Renal cancer:8.81e-11 (unfavourable)	Expressed in all	Expressed in all			ovary: 3453.0	Expressed in all		
PDXP	CIN, dJ37E16.5, FLJ32703	ENSG00000241360	Pyridoxal phosphatase	22	37658727-37666934	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA000531	Approved					Mixed	Tissue enhanced		cerebral cortex: 135.9	testis: 30.5	Mixed		
RPP21	C6orf135, Em:AB014085.3, FLJ22638	ENSG00000241370	Ribonuclease P/MRP subunit p21	6	30345131-30346884	Enzymes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:6.78e-5 (favourable)	Expressed in all	Mixed			skin: 16.1	Cell line enhanced		HEK 293: 51.3;SCLC-21H: 53.7
CD302	BIMLEC, CLEC13A, DCL-1, KIAA0022	ENSG00000241399	CD302 molecule	2	159768630-159798255	CD markers, Predicted membrane proteins	Evidence at protein level							Mixed	Expressed in all			liver: 104.7	Cell line enhanced		ASC diff: 178.2
EGFL8	C6orf8, NG3	ENSG00000241404	EGF like domain multiple 8	6	32164583-32168281	Predicted secreted proteins	Evidence at protein level	HPA061173	Uncertain		Approved	Nuclear speckles<br>Vesicles		Mixed	Mixed			skin: 2.7	Mixed		
ATP5J2	ATP5JL, F1Fo-ATPase	ENSG00000241468	ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2	7	99448475-99466331	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA067267, HPA070412	Approved		Supported	Mitochondria	Head and neck cancer:2.58e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 463.1	Expressed in all		
SSX2	CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX	ENSG00000241476	SSX family member 2	X	52696896-52707189	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683, CAB046020	Enhanced		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	113	testis: 46.1	thyroid gland: 0.4	Not detected		
ARHGAP8	BPGAP1, FLJ20185	ENSG00000241484	Rho GTPase activating protein 8	22	44752558-44862788	Predicted intracellular proteins	Evidence at protein level	HPA069694	Approved		Approved	Nucleus		Mixed	Mixed			epididymis: 14.2	Cell line enhanced		BEWO: 45.6;CACO-2: 25.6;HEK 293: 38.0;MCF7: 33.7;SK-BR-3: 30.9
AF011889.5		ENSG00000241489		X	149482543-149533935	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			epididymis: 65.7	Mixed		
ARPC4	ARC20, p20-Arc	ENSG00000241553	Actin related protein 2/3 complex subunit 4	3	9792495-9807726	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.29e-4 (unfavourable), Urothelial cancer:2.34e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 164.7	Expressed in all		
CORT	MGC32686	ENSG00000241563	Cortistatin	1	10449719-10451902	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	24	cerebral cortex: 24.8	placenta: 1.0	Mixed		
KRTAP9-4	KAP9.4	ENSG00000241595	Keratin associated protein 9-4	17	41249687-41250653	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP5-4	KRTAP5.4	ENSG00000241598	Keratin associated protein 5-4	11	1620958-1622138	Predicted intracellular proteins	No evidence							Not detected	Not detected			skeletal muscle: 0.1	Not detected		
UGT1A1	GNT1, UGT1, UGT1A	ENSG00000241635	UDP glucuronosyltransferase family 1 member A1	2	233760248-233773299	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Group enriched	33	duodenum: 199.5;liver: 155.8;small intestine: 81.9	kidney: 4.3	Cell line enhanced		HaCaT: 12.7;PC-3: 6.0;RT4: 27.4
INMT		ENSG00000241644	Indolethylamine N-methyltransferase	7	30697985-30757602	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA061343			Approved	Golgi apparatus<br>Vesicles	Liver cancer:5.72e-4 (favourable)	Tissue enhanced	Tissue enhanced		lung: 144.8	seminal vesicle: 66.2	Group enriched	6	CACO-2: 13.8;HHSteC: 5.7
ARPC1A	Arc40, SOP2Hs, SOP2L	ENSG00000241685	Actin related protein 2/3 complex subunit 1A	7	99325910-99366262	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004334	Approved		Approved	Cell Junctions<br>Cytosol	Liver cancer:4.70e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 130.9	Expressed in all		
RP5-860F19.8		ENSG00000241690		20	2814968-2818066	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	43	testis: 10.6	epididymis,placenta: 0.2	Cell line enriched	5	HDLM-2: 9.0
TMEFF1	C9orf2, CT120.1, H7365	ENSG00000241697	Transmembrane protein with EGF like and two follistatin like domains 1	9	100473113-100577636	Predicted membrane proteins	Evidence at protein level	HPA051501	Uncertain					Tissue enhanced	Tissue enriched	5	cerebral cortex: 10.7	testis: 2.0	Cell line enhanced		NTERA-2: 28.1;REH: 17.9;SCLC-21H: 28.0;SH-SY5Y: 16.8
SPRR2A		ENSG00000241794	Small proline rich protein 2A	1	153056113-153057537	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:1.37e-5 (unfavourable)	Tissue enhanced	Tissue enriched	8	esophagus: 5298.0	tonsil: 643.7	Group enriched	8	HaCaT: 5.3;hTCEpi: 5.2;hTERT-HME1: 7.3;Karpas-707: 8.4;U-266/70: 1.8
ATP5O	ATPO, OSCP	ENSG00000241837	ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit	21	33903453-33915980	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB016209, HPA041394	Enhanced		Supported	Mitochondria	Renal cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 533.0	Expressed in all		
PLEKHO2	DKFZp761K2312, PLEKHQ1, PP1628, pp9099	ENSG00000241839	Pleckstrin homology domain containing O2	15	64841883-64868007	Predicted intracellular proteins	Evidence at protein level	HPA040055	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			spleen: 119.5	Mixed		
C8orf58	FLJ34715	ENSG00000241852	Chromosome 8 open reading frame 58	8	22599601-22604150	Predicted intracellular proteins	Evidence at transcript level	HPA024667, HPA028286	Uncertain		Approved	Nuclear bodies	Renal cancer:3.58e-6 (unfavourable)	Expressed in all	Mixed			placenta: 23.9	Mixed		
PISD	dJ858B16.2, PSDC	ENSG00000241878	Phosphatidylserine decarboxylase	22	31618491-31662432	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA031090, HPA031091	Approved		Approved	Golgi apparatus<br>Cytosol	Urothelial cancer:5.27e-5 (favourable)	Expressed in all	Expressed in all			adipose tissue: 35.9	Expressed in all		
HOGA1	C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2	ENSG00000241935	4-hydroxy-2-oxoglutarate aldolase 1	10	97584323-97612802	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA039466	Approved				Renal cancer:9.08e-4 (favourable)	Group enriched	Tissue enhanced		kidney: 53.4;liver: 20.7	heart muscle: 8.5	Cell line enhanced		EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
PWP2	EHOC-17, PWP2H, UTP1	ENSG00000241945	PWP2 periodic tryptophan protein homolog (yeast)	21	44107290-44131181	Predicted intracellular proteins	Evidence at protein level	HPA024573	Uncertain		Supported	Nucleoli<br>Cytosol		Mixed	Mixed			skin: 5.4	Cell line enhanced		CACO-2: 61.4
PI4KA	PI4K-ALPHA, pi4K230, PIK4CA	ENSG00000241973	Phosphatidylinositol 4-kinase alpha	22	20707691-20859417	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009092, HPA075515	Approved		Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 113.6	Expressed in all		
AKAP2	AKAP-KL, DKFZp564L0716, KIAA0920, MISP2, PRKA2	ENSG00000241978	A-kinase anchoring protein 2	9	110048598-110172512	Predicted intracellular proteins	Evidence at protein level							Not detected	Expressed in all			placenta: 123.7	Mixed		
KIR3DL3	CD158z, KIR3DL7, KIR44, KIRC1	ENSG00000242019	Killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 3	19	54724479-54736536	Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HYPK	C15orf63, FLJ20431, HSPC136	ENSG00000242028	Huntingtin interacting protein K	15	43796142-43803043	Predicted intracellular proteins	Evidence at protein level	HPA055252	Uncertain		Supported	Nucleoplasm<br>Microtubules		Mixed	Mixed			testis: 6.3	Mixed		
AMACR	P504S, RACE	ENSG00000242110	Alpha-methylacyl-CoA racemase	5	33986178-34008108	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001809, HPA019527, HPA020912	Enhanced		Supported	Vesicles<br>Plasma membrane	Colorectal cancer:7.11e-4 (favourable)	Expressed in all	Expressed in all			kidney: 135.3	Expressed in all		
MTFP1	HSPC242, MTP18	ENSG00000242114	Mitochondrial fission process 1	22	30425530-30429053	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA077396			Approved	Mitochondria		Expressed in all	Expressed in all			epididymis: 19.2	Expressed in all		
RP11-231I13.2		ENSG00000242120		3	70196894-70312726	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ARHGDIG	RHOGDI-3	ENSG00000242173	Rho GDP dissociation inhibitor gamma	16	268727-283010	Predicted intracellular proteins	Evidence at protein level	HPA078260			Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 131.1;duodenum: 44.2	small intestine: 17.9	Cell line enhanced		HEK 293: 24.6;MCF7: 27.2;SCLC-21H: 14.0;SH-SY5Y: 15.7
OR51B5		ENSG00000242180	Olfactory receptor family 51 subfamily B member 5	11	5342586-5343524	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA063124	Uncertain					Not detected	Not detected			epididymis,testis: 0.2	Group enriched	7	K-562: 5.4;U-2197: 1.5
TCP10L	PRED77	ENSG00000242220	T-complex 10-like	21	32574841-32587373	Predicted intracellular proteins	Evidence at protein level	HPA044709	Approved					Tissue enhanced	Tissue enriched	27	testis: 285.4	liver: 10.7	Cell line enriched	7	SCLC-21H: 14.6
PSG2	CEA, PSBG2, PSG1, PSGGB	ENSG00000242221	Pregnancy specific beta-1-glycoprotein 2	19	43064211-43083045	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	222	placenta: 343.4	smooth muscle: 1.5	Group enriched	6	BJ: 9.2;fHDF/TERT166: 18.4;HBF TERT88: 34.3;U-2197: 42.9
ARFGAP3	ARFGAP1	ENSG00000242247	ADP ribosylation factor GTPase activating protein 3	22	42796502-42858106	Predicted intracellular proteins	Evidence at protein level	HPA000638	Approved		Supported	Golgi apparatus<br>Cytosol	Endometrial cancer:8.97e-6 (favourable), Thyroid cancer:2.65e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 112.5	Expressed in all		
BGLAP	OCN	ENSG00000242252	Bone gamma-carboxyglutamate protein	1	156241962-156243321	FDA approved drug targets, Predicted secreted proteins	Evidence at protein level							Mixed	Mixed			skin: 2.1	Cell line enhanced		U-87 MG: 2.8
C22orf39	MGC74441	ENSG00000242259	Chromosome 22 open reading frame 39	22	19351368-19448232	Predicted intracellular proteins	Evidence at protein level	HPA073701			Approved	Endoplasmic reticulum	Renal cancer:1.44e-4 (favourable), Endometrial cancer:2.16e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.1	Expressed in all		
PEG10	HB-1, KIAA1051, Mar2, Mart2, MEF3L, RGAG3	ENSG00000242265	Paternally expressed 10	7	94656325-94669695	Predicted intracellular proteins	Evidence at protein level	HPA021324, HPA029915, HPA051038	Enhanced		Supported	Nucleus<br>Cytosol	Endometrial cancer:8.15e-4 (unfavourable)	Expressed in all	Group enriched	5	adrenal gland: 224.2;placenta: 663.3	ovary: 80.7	Cell line enhanced		AF22: 763.0;HAP1: 1045.3;Hep G2: 547.0;SCLC-21H: 574.7
CT47A2	CT47.2	ENSG00000242362	Cancer/testis antigen family 47, member A2	X	120977606-120980928	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	20	testis: 2.0	all non-specific tissues: 0.0	Not detected		
UGT1A8	UGT1H	ENSG00000242366	UDP glucuronosyltransferase family 1 member A8	2	233617645-233773310	Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		colon: 16.0;gallbladder: 10.3;rectum: 9.7;urinary bladder: 22.7	small intestine: 4.9	Cell line enriched	53	RT4: 96.7
EIF6	b(2)gcn, EIF3A, ITGB4BP, p27BBP	ENSG00000242372	Eukaryotic translation initiation factor 6	20	35278907-35284985	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040873	Enhanced		Supported	Nucleoplasm	Liver cancer:7.25e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 173.2	Expressed in all		
RBMY1E		ENSG00000242389	RNA binding motif protein, Y-linked, family 1, member E	Y	21903618-21918067	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Cell line enriched	8	U-266/84: 1.6
PCDHGC4	PCDH-GAMMA-C4	ENSG00000242419	Protocadherin gamma subfamily C, 4	5	141484997-141512979	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enriched	Tissue enriched	11	cerebral cortex: 16.3	adrenal gland: 1.4	Cell line enhanced		REH: 8.3;SCLC-21H: 8.7;SH-SY5Y: 15.1
GTF2A1L	ALF	ENSG00000242441	General transcription factor IIA subunit 1 like	2	48617798-48733148	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	66	testis: 105.4	endometrium,gallbladder: 1.5	Cell line enhanced		ASC diff: 1.0
MRPL20	FLJ10024	ENSG00000242485	Mitochondrial ribosomal protein L20	1	1401908-1407313	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA047074	Supported		Supported	Mitochondria		Expressed in all	Expressed in all			epididymis: 156.4	Expressed in all		
ARPIN	C15orf38, MGC61550	ENSG00000242498	Actin-related protein 2/3 complex inhibitor	15	89895006-89912956	Predicted intracellular proteins	Evidence at protein level	HPA040513, HPA047173, HPA052278	Uncertain				Renal cancer:4.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 31.0	Mixed		
UGT1A10	UGT1J	ENSG00000242515	UDP glucuronosyltransferase family 1 member A10	2	233636454-233773305	Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:4.55e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 49.7;duodenum: 80.9;small intestine: 59.1	rectum: 39.6	Cell line enriched	108	RT4: 416.9
SERPINB10	bomapin, PI10	ENSG00000242550	Serpin family B member 10	18	63897174-63936111	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015480, HPA059582	Uncertain					Not detected	Tissue enriched	32	bone marrow: 50.1	skin: 1.5	Cell line enriched	7	U-937: 82.6
HLA-DMB	D6S221E, RING7	ENSG00000242574	Major histocompatibility complex, class II, DM beta	6	32934629-32941070	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA012298	Supported				Endometrial cancer:3.89e-5 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 29.3	spleen: 12.0	Group enriched	11	CAPAN-2: 5.2;Daudi: 6.1;EFO-21: 3.6;U-266/70: 2.3;U-698: 7.1
DECR2	PDCR, SDR17C1	ENSG00000242612	2,4-dienoyl-CoA reductase 2	16	401826-412487	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047631			Approved	Peroxisomes		Expressed in all	Mixed			duodenum: 10.5	Mixed		
GNG10		ENSG00000242616	G protein subunit gamma 10	9	111661335-111670246	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level						Head and neck cancer:3.21e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 90.3	Expressed in all		
CNTF	HCNTF	ENSG00000242689	Ciliary neurotrophic factor	11	58622673-58625733	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019654	Uncertain		Approved	Vesicles		Mixed	Tissue enhanced		fallopian tube: 7.7	bone marrow: 4.3	Mixed		
CCDC169	C13orf38, LOC728591, RP11-251J8.1	ENSG00000242715	Coiled-coil domain containing 169	13	36222008-36297840	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	16	testis: 78.5	parathyroid gland: 4.9	Cell line enhanced		HL-60: 14.2
RGAG4	KIAA2001, Mar5, Mart5	ENSG00000242732	Retrotransposon gag domain containing 4	X	72127110-72131901	Predicted intracellular proteins	Evidence at transcript level	HPA003652	Approved		Approved	Nucleoplasm	Pancreatic cancer:3.41e-4 (favourable), Lung cancer:7.30e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 4.1	Cell line enhanced		AF22: 3.7;AN3-CA: 3.9;SCLC-21H: 5.9;SH-SY5Y: 7.4
AP5Z1	KIAA0415, SPG48, zeta	ENSG00000242802	Adaptor related protein complex 5 zeta 1 subunit	7	4775622-4794312	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035693	Supported		Supported	Nucleoplasm<br>Nuclear speckles	Liver cancer:1.35e-5 (unfavourable)	Expressed in all	Mixed			spleen: 15.4	Expressed in all		
ZNF709	FLJ38281	ENSG00000242852	Zinc finger protein 709	19	12461184-12513854	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA045573, HPA053153	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 14.0	thyroid gland: 4.8	Mixed		
STRC	DFNB16	ENSG00000242866	Stereocilin	15	43599398-43618800	Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA048083	Enhanced					Not detected	Tissue enhanced		cerebral cortex: 1.4;epididymis: 1.6;testis: 1.7	skin: 0.8	Not detected		
RBMY1B		ENSG00000242875	RNA binding motif protein, Y-linked, family 1, member B	Y	21511338-21549094	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Tissue enriched	33	testis: 3.3	all non-specific tissues: 0.0	Not detected		
ERVW-1	ERVWE1, HERV-7q, HERV-W, HERV-W-ENV, HERVW	ENSG00000242950	Endogenous retrovirus group W member 1	7	92468380-92477986	Predicted membrane proteins, Transporters	Evidence at protein level							Tissue enriched	Tissue enriched	12	placenta: 77.2	testis: 6.5	Cell line enriched	48	BEWO: 81.7
EIF4EBP3	4E-BP3	ENSG00000243056	Eukaryotic translation initiation factor 4E binding protein 3	5	140547666-140549578	Predicted intracellular proteins	Evidence at protein level	HPA045537	Uncertain				Renal cancer:3.10e-4 (favourable)	Expressed in all	Expressed in all			fallopian tube: 59.8	Mixed		
PRAMEF4	RP5-845O24.6	ENSG00000243073	PRAME family member 4	1	12879224-12886201	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
PSG11	MGC22484, PSG13, PSG14	ENSG00000243130	Pregnancy specific beta-1-glycoprotein 11	19	43007656-43026512	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042240, HPA046327	Enhanced					Not detected	Tissue enriched	77	placenta: 74.1	smooth muscle: 0.9	Cell line enriched	29	U-2197: 15.6
UGT1A3	UGT1C	ENSG00000243135	UDP glucuronosyltransferase family 1 member A3	2	233729108-233773299	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	7	liver: 38.2	small intestine: 5.6	Cell line enriched	11	HaCaT: 10.9
PSG4		ENSG00000243137	Pregnancy specific beta-1-glycoprotein 4	19	43192702-43207299	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046327	Approved					Mixed	Group enriched	8	parathyroid gland: 244.5;placenta: 193.0	colon: 28.0	Group enriched	7	fHDF/TERT166: 409.2;U-2197: 129.9
MRPL33	C2orf1, RPL33L	ENSG00000243147	Mitochondrial ribosomal protein L33	2	27771717-27988087	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA066872	Approved				Liver cancer:1.66e-4 (unfavourable), Head and neck cancer:4.68e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 586.9	Expressed in all		
MICAL3	KIAA0819	ENSG00000243156	Microtubule associated monooxygenase, calponin and LIM domain containing 3	22	17787649-18024559	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000639, HPA003421, HPA034882	Uncertain		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 71.2	Expressed in all		
PPAN-P2RY11		ENSG00000243207	PPAN-P2RY11 readthrough	19	10106223-10114780	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014232	Uncertain					Not detected	Mixed			fallopian tube: 2.4	Mixed		
PCDHAC2	PCDH-ALPHA-C2	ENSG00000243232	Protocadherin alpha subfamily C, 2	5	140966235-141012344	Predicted membrane proteins	Evidence at transcript level	HPA076190			Approved	Nucleoplasm<br>Mitochondria		Mixed	Tissue enriched	7	parathyroid gland: 92.5	cerebral cortex: 14.1	Cell line enhanced		A549: 11.3;AN3-CA: 57.4;SH-SY5Y: 11.6
STON1	SBLF, stoned-b1	ENSG00000243244	Stonin 1	2	48529383-48598513	Predicted intracellular proteins	Evidence at protein level	HPA005715	Uncertain				Renal cancer:4.69e-4 (unfavourable)	Mixed	Mixed			smooth muscle: 37.4	Cell line enhanced		ASC diff: 16.3;ASC TERT1: 20.1;HSkMC: 26.3
PRAF2	JM4, Yip6a	ENSG00000243279	PRA1 domain family member 2	X	49071156-49074071	Predicted membrane proteins, Transporters	Evidence at protein level	HPA002859, HPA005504, CAB011655	Enhanced		Approved	Endoplasmic reticulum<br>Vesicles	Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 185.0	Expressed in all		
VSIG8		ENSG00000243284	V-set and immunoglobulin domain containing 8	1	159854316-159862657	Predicted membrane proteins	Evidence at protein level	HPA023219	Uncertain					Group enriched	Group enriched	6	skin: 13.6;tonsil: 5.8	kidney: 1.7	Not detected		
C7orf73	PL-5283	ENSG00000243317	Chromosome 7 open reading frame 73	7	135662496-135693418	Predicted secreted proteins	Evidence at protein level	HPA065565			Approved	Mitochondria	Ovarian cancer:2.95e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 53.3	Expressed in all		
KCTD7	CLN14, EPM3, FLJ32069	ENSG00000243335	Potassium channel tetramerization domain containing 7	7	66628767-66649067	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:3.26e-4 (favourable), Colorectal cancer:8.07e-4 (unfavourable)	Expressed in all	Mixed			testis: 32.9	Expressed in all		
EFNA4	EPLG4, LERK4	ENSG00000243364	Ephrin A4	1	155063731-155069553	Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB021350, HPA064952	Approved		Uncertain	Nucleus<br>Vesicles	Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable)	Expressed in all	Mixed			skin: 24.5	Expressed in all		
TICAM2	TICAM-2, TIRP, TRAM	ENSG00000243414	Toll like receptor adaptor molecule 2	5	115578650-115602479	Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			cervix, uterine: 6.1	Cell line enhanced		HDLM-2: 32.3;U-138 MG: 20.3;U-2197: 20.8
AF165138.7		ENSG00000243440		21	14591930-14658821	Predicted intracellular proteins	Evidence at transcript level	HPA046639	Uncertain					Not detected	Not detected			appendix: 0.7	Group enriched	7	HEL: 3.4;NTERA-2: 2.3
PALM2		ENSG00000243444	Paralemmin 2	9	109640788-109946703	Predicted intracellular proteins	Evidence at protein level	HPA074153			Approved	Plasma membrane		Not detected	Tissue enhanced		cerebral cortex: 9.8	liver: 3.6	Cell line enhanced		RH-30: 19.4
C4orf48		ENSG00000243449	Chromosome 4 open reading frame 48	4	2041993-2043970	Predicted secreted proteins	Evidence at protein level	HPA052447	Uncertain		Supported	Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 22.1	testis: 11.2	Cell line enhanced		HEK 293: 145.6;PC-3: 318.4
NAT6	FUS2	ENSG00000243477	N-acetyltransferase 6	3	50296402-50299421	Predicted intracellular proteins	Evidence at protein level	HPA039576	Approved				Renal cancer:1.71e-4 (favourable), Breast cancer:3.62e-4 (favourable)	Expressed in all	Expressed in all			testis: 45.8	Expressed in all		
AMY2A	AMY2	ENSG00000243480	Amylase, alpha 2A (pancreatic)	1	103616811-103625780	Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level	HPA045394, HPA045399, CAB045960, HPA046980	Enhanced					Tissue enriched	Tissue enriched	313	pancreas: 31329.4	ovary: 99.9	Not detected		
KRTAP10-11	KAP10.11, KAP18.11, KRTAP18-11, KRTAP18.11	ENSG00000243489	Keratin associated protein 10-11	21	44646414-44647650	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TNFRSF6B	DcR3, M68, TR6	ENSG00000243509	TNF receptor superfamily member 6b	20	63696668-63698684	Predicted secreted proteins	Evidence at protein level	HPA047154	Uncertain					Not detected	Tissue enriched	6	appendix: 19.0	tonsil: 3.1	Cell line enhanced		HBEC3-KT: 20.3;RPTEC TERT1: 82.5;TIME: 57.1
WFDC6	C20orf171, dJ461P17.11, WAP6	ENSG00000243543	WAP four-disulfide core domain 6	20	45534196-45539495	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Group enriched	16	epididymis: 323.7;testis: 83.8	fallopian tube: 12.5	Cell line enriched	7	U-87 MG: 2.6
UPK3B	FLJ32198, MGC10902, p35, UPIIIb	ENSG00000243566	Uroplakin 3B	7	76510428-76516521	Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA010506	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol		Group enriched	Group enriched	11	esophagus: 12.4;lung: 29.8;urinary bladder: 11.0	tonsil: 1.6	Group enriched	8	A549: 12.0;CAPAN-2: 41.9;HaCaT: 8.6;RT4: 26.3;T-47d: 25.4
AP000322.53		ENSG00000243627		21	34418715-34423966	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain					Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected		
IL10RB	CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2	ENSG00000243646	Interleukin 10 receptor subunit beta	21	33266358-33310187	CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB020670, HPA047550	Approved		Approved	Cytosol	Renal cancer:5.62e-9 (unfavourable)	Expressed in all	Expressed in all			placenta: 90.0	Expressed in all		
CFB	BF, BFD, H2-Bf	ENSG00000243649	Complement factor B	6	31945650-31952084	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832, CAB016381	Supported		Approved	Endoplasmic reticulum<br>Vesicles<br>Cell Junctions	Renal cancer:1.53e-5 (unfavourable), Breast cancer:2.76e-5 (favourable)	Expressed in all	Tissue enriched	21	liver: 285.9	stomach: 13.8	Cell line enhanced		CAPAN-2: 6.6;fHDF/TERT166: 9.6;HSkMC: 14.1
ZNF487	KRBO1, ZNF487P	ENSG00000243660	Zinc finger protein 487	10	43436841-43483179	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA037820			Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Mixed	Tissue enriched	5	testis: 51.4	fallopian tube: 9.9	Mixed		
WDR92	FLJ31741, Monad	ENSG00000243667	WD repeat domain 92	2	68122936-68157560	Predicted intracellular proteins	Evidence at protein level	HPA035335, HPA035336	Approved		Approved	Nucleoplasm		Mixed	Mixed			epididymis: 19.8	Expressed in all		
NME2	NDPKB, NM23-H2	ENSG00000243678	NME/NM23 nucleoside diphosphate kinase 2	17	51165435-51171747	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041113	Approved				Renal cancer:1.55e-6 (unfavourable), Cervical cancer:4.74e-4 (unfavourable), Liver cancer:7.09e-4 (unfavourable)	Expressed in all	Expressed in all			breast: 512.0	Expressed in all		
PLA2G4B	cPLA2-beta, HsT16992	ENSG00000243708	Phospholipase A2 group IVB	15	41837775-41848147	Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level							Not detected	Tissue enhanced		skin: 36.3	esophagus: 14.1	Cell line enhanced		RT4: 5.9
LEFTY1	LEFTB, LEFTYB	ENSG00000243709	Left-right determination factor 1	1	225886282-225911382	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA047883, HPA056210	Approved				Renal cancer:2.48e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		colon: 58.4;pancreas: 20.4;rectum: 35.2	appendix: 9.6	Cell line enriched	7	NTERA-2: 50.6
CFAP57	FLJ32000, WDR65	ENSG00000243710	Cilia and flagella associated protein 57	1	43172149-43254358	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA002736, HPA028623	Enhanced		Approved	Cytosol	Endometrial cancer:6.02e-4 (favourable)	Mixed	Group enriched	8	fallopian tube: 35.6;testis: 27.7	lung: 3.7	Cell line enhanced		HaCaT: 2.5
NPIPB5		ENSG00000243716	Nuclear pore complex interacting protein family member B5	16	22479121-22536521	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Expressed in all			skin: 261.4	Expressed in all		
TTC4	FLJ41930, MGC5097	ENSG00000243725	Tetratricopeptide repeat domain 4	1	54715822-54742657	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041608, HPA042459	Approved					Expressed in all	Expressed in all			cervix, uterine: 13.3	Expressed in all		
OR5V1	hs6M1-21	ENSG00000243729	Olfactory receptor family 5 subfamily V member 1	6	29355230-29431967	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA046707	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TMEM35B	ZMYM6NB	ENSG00000243749	Transmembrane protein 35B	1	34981535-34985353	Predicted membrane proteins	Evidence at protein level	HPA051024	Uncertain		Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			placenta: 91.7	Mixed		
KIR2DL3	CD158B2, cl-6, nkat2, nkat2a, nkat2b, p58	ENSG00000243772	Killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3	19	54738515-54753052	CD markers, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
JMJD7		ENSG00000243789	Jumonji domain containing 7	15	41828085-41837581	Predicted intracellular proteins	Evidence at protein level	HPA005726	Uncertain		Approved	Cytosol		Not detected	Expressed in all			skin: 28.0	Cell line enhanced		RT4: 34.4
APOBEC3D	APOBEC3DE, APOBEC3E, ARP6	ENSG00000243811	Apolipoprotein B mRNA editing enzyme catalytic subunit 3D	22	39021113-39033276	Predicted intracellular proteins	Evidence at protein level	HPA055116	Uncertain				Renal cancer:3.76e-7 (unfavourable), Breast cancer:2.51e-5 (favourable), Cervical cancer:1.31e-4 (favourable), Urothelial cancer:3.01e-4 (favourable), Endometrial cancer:4.47e-4 (favourable)	Expressed in all	Mixed			lymph node: 15.1	Cell line enhanced		Karpas-707: 31.5
OR2A7	HSDJ0798C17	ENSG00000243896	Olfactory receptor family 2 subfamily A member 7	7	144258607-144259722	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058272	Uncertain					Mixed	Mixed			thyroid gland: 19.9	Cell line enhanced		A-431: 12.2;hTCEpi: 5.6;RT4: 5.8;SK-BR-3: 4.8
TUBA4B	FLJ13940, TUBA4	ENSG00000243910	Tubulin alpha 4b	2	219253243-219272188	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	14	fallopian tube: 64.2	lung: 4.5	Not detected		
MRPS6	C21orf101, MRP-S6, RPMS6	ENSG00000243927	Mitochondrial ribosomal protein S6	21	34073224-34143034	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA007861, HPA049676	Supported				Urothelial cancer:1.06e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 121.0	Expressed in all		
ZNF512	KIAA1805	ENSG00000243943	Zinc finger protein 512	2	27582969-27623215	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031430	Approved		Enhanced	Nucleus	Lung cancer:5.08e-9 (favourable), Endometrial cancer:5.10e-4 (unfavourable), Pancreatic cancer:5.19e-4 (favourable), Breast cancer:9.79e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 45.7	Mixed		
GSTA1		ENSG00000243955	Glutathione S-transferase alpha 1	6	52791664-52803910	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Supported		Supported	Cytosol	Renal cancer:3.71e-4 (unfavourable), Lung cancer:8.66e-4 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 1136.4;kidney: 1310.9;liver: 1757.6	small intestine: 1002.9	Cell line enriched	11	Hep G2: 245.8
RGAG1	KIAA1318, Mar9, Mart9	ENSG00000243978	Retrotransposon gag domain containing 1	X	110358816-110456334	Predicted intracellular proteins	Evidence at protein level	HPA001242	Enhanced					Not detected	Tissue enriched	18	testis: 19.5	placenta: 1.0	Cell line enhanced		hTEC/SVTERT24-B: 2.0;U-2197: 1.4;U-87 MG: 1.1
ACY1		ENSG00000243989	Aminoacylase 1	3	51983278-51989202	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB003695, HPA036174, HPA036175	Enhanced				Renal cancer:2.93e-4 (favourable), Urothelial cancer:6.77e-4 (favourable)	Expressed in all	Group enriched	5	duodenum: 130.8;kidney: 356.0;liver: 114.9;small intestine: 103.3	parathyroid gland: 35.0	Mixed		
NFS1	IscS, NifS	ENSG00000244005	NFS1, cysteine desulfurase	20	35668055-35699359	Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB034314, HPA051801, HPA054755	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.72e-6 (favourable)	Expressed in all	Expressed in all			kidney: 43.7	Expressed in all		
MT1HL1	MT1P2	ENSG00000244020	Metallothionein 1H like 1	1	237004103-237004418	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	heart muscle: 2.8	urinary bladder: 0.3	Not detected		
KRTAP19-3	KAP19.3	ENSG00000244025	Keratin associated protein 19-3	21	30491464-30491985	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
DDOST	KIAA0115, OST, OST48, WBP1	ENSG00000244038	Dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit	1	20651767-20661544	Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB009746, HPA046841, HPA052867	Supported		Supported	Endoplasmic reticulum	Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 308.3	Expressed in all		
TMEM199	C17orf32, MGC45714, VMA12, VPH2	ENSG00000244045	Transmembrane protein 199	17	28357581-28363683	Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA027051	Uncertain				Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 19.3	Expressed in all		
LCE3C	LEP15, SPRL3A	ENSG00000244057	Late cornified envelope 3C	1	152600662-152601086	Predicted intracellular proteins	Evidence at protein level							Group enriched	Tissue enriched	10	tonsil: 22.5	skin: 2.1	Not detected		
GSTA2	GST2	ENSG00000244067	Glutathione S-transferase alpha 2	6	52750089-52763569	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004342, HPA048934, HPA053817	Supported		Supported	Cytosol	Renal cancer:1.17e-4 (unfavourable)	Group enriched	Group enriched	5	kidney: 651.7;liver: 986.1	gallbladder: 155.6	Group enriched	17	CACO-2: 19.6;Hep G2: 12.5
SPRR2F		ENSG00000244094	Small proline rich protein 2F	1	153112114-153113515	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Group enriched	9	esophagus: 167.0;ovary: 83.7;tonsil: 63.0	testis: 11.8	Cell line enriched	9	K-562: 2.4
DNAJC25-GNG10		ENSG00000244115	DNAJC25-GNG10 readthrough	9	111631386-111670229	Predicted secreted proteins	Evidence at transcript level							Not detected	Mixed			prostate: 25.3	Expressed in all		
UGT1A7	UGT1G	ENSG00000244122	UDP glucuronosyltransferase family 1 member A7	2	233681938-233773299	Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level							Group enriched	Tissue enriched	13	esophagus: 61.4	tonsil: 4.6	Cell line enriched	21	SiHa: 118.8
P2RY11	P2Y11	ENSG00000244165	Purinergic receptor P2Y11	19	10111538-10115372	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA014232	Approved				Urothelial cancer:1.77e-4 (favourable)	Expressed in all	Mixed			lymph node: 7.2	Mixed		
TMEM141	MGC14141	ENSG00000244187	Transmembrane protein 141	9	136791355-136793257	Predicted membrane proteins	Evidence at protein level	HPA014615, HPA050244	Approved		Supported	Cell Junctions<br>Mitochondria	Renal cancer:6.63e-4 (favourable)	Expressed in all	Expressed in all			prostate: 199.4	Expressed in all		
GS1-259H13.2		ENSG00000244219		7	99598066-99610813	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	54	testis: 234.7	epididymis: 4.3	Cell line enhanced		Karpas-707: 8.5
IFITM10		ENSG00000244242	Interferon induced transmembrane protein 10	11	1732410-1750591	Predicted membrane proteins	Evidence at transcript level							Expressed in all	Tissue enhanced		adrenal gland: 3.4	bone marrow,seminal vesicle: 0.7	Cell line enhanced		CAPAN-2: 2.6;MCF7: 3.3;SH-SY5Y: 10.4;U-87 MG: 5.6
XXbac-BPG116M5.17		ENSG00000244255		6	31927698-31952048	Predicted secreted proteins	Evidence at protein level	HPA000951, HPA001817, HPA001832	Approved					Not detected	Tissue enhanced		liver: 3.3;lung: 2.9	spleen: 1.2	Not detected		
DBNDD2	C20orf35, HSMNP1	ENSG00000244274	Dysbindin domain containing 2	20	45406057-45410610	Predicted intracellular proteins	Evidence at protein level	HPA043991	Enhanced		Approved	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			cerebral cortex: 460.2	Mixed		
LY6G6D	C6orf23, G6D, Ly6-D, MEGT1, NG25	ENSG00000244355	Lymphocyte antigen 6 family member G6D	6	31715356-31717804	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA054412	Uncertain					Tissue enriched	Tissue enhanced		seminal vesicle: 2.0	prostate: 0.8	Cell line enhanced		HEL: 1.6
KRTAP19-7	KAP19.7	ENSG00000244362	Keratin associated protein 19-7	21	30560875-30561314	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RBMY1D		ENSG00000244395	RNA binding motif protein, Y-linked, family 1, member D	Y	21880076-21894526	Predicted intracellular proteins	Evidence at protein level	HPA001534, HPA053147	Supported					Not detected	Not detected			testis: 0.2	Not detected		
ETV5	ERM	ENSG00000244405	ETS variant 5	3	186046308-186110318	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009590, HPA063065	Approved		Supported	Nucleoplasm	Liver cancer:7.85e-9 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 114.5	cerebral cortex: 74.7	Cell line enhanced		SK-MEL-30: 141.2
KRTAP5-7	KRTAP5-3, KRTAP5.7	ENSG00000244411	Keratin associated protein 5-7	11	71527267-71528674	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.8	epididymis: 0.5	Cell line enriched	10	RT4: 1.3
CFHR1	CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, H36-1, H36-2, HFL1, HFL2	ENSG00000244414	Complement factor H related 1	1	196819757-196832189	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038915, HPA038922, HPA040726	Supported		Approved	Vesicles	Liver cancer:8.71e-6 (favourable)	Tissue enriched	Tissue enriched	147	liver: 1057.6	lymph node: 7.1	Cell line enhanced		HL-60: 1.5;U-266/70: 1.9
RBM12	HRIHFB2091, KIAA0765, SWAN	ENSG00000244462	RNA binding motif protein 12	20	35648925-35664956	Predicted intracellular proteins	Evidence at protein level	HPA043258, HPA043621	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.54e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 47.6	Expressed in all		
UGT1A4	HUG-BR2, UGT1D	ENSG00000244474	UDP glucuronosyltransferase family 1 member A4	2	233718778-233773299	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Tissue enriched	Tissue enriched	31	liver: 212.3	duodenum: 6.7	Not detected		
ERVFRD-1	envFRD, ERVFRDE1, HERV-FRD, HERV-W/FRD, syncytin-2	ENSG00000244476	Endogenous retrovirus group FRD member 1	6	11102489-11111732	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Group enriched	32	parathyroid gland: 30.4;placenta: 51.8	epididymis: 1.2	Cell line enriched	34	BEWO: 8.9
LILRA6	CD85b, ILT8, LILRB6	ENSG00000244482	Leukocyte immunoglobulin like receptor A6	19	54236592-54242791	Predicted membrane proteins	Evidence at protein level							Mixed	Tissue enhanced		adipose tissue: 1.9;appendix: 1.9;smooth muscle: 1.9;spleen: 1.9	bone marrow: 1.0	Not detected		
SCARF2	HUMZD58C02, SREC-II, SREC2	ENSG00000244486	Scavenger receptor class F member 2	22	20424815-20437826	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA035079	Approved		Approved	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:2.78e-5 (unfavourable), Urothelial cancer:4.28e-4 (unfavourable)	Expressed in all	Mixed			seminal vesicle: 6.7	Cell line enhanced		SH-SY5Y: 30.9;U-138 MG: 39.3;U-2 OS: 43.6
APOBEC3C	APOBEC1L, ARDC2, ARDC4, ARP5, bK150C2.3, PBI	ENSG00000244509	Apolipoprotein B mRNA editing enzyme catalytic subunit 3C	22	39014083-39020352	Predicted intracellular proteins	Evidence at protein level	CAB033048, HPA071523	Approved		Approved	Intermediate filaments	Renal cancer:8.91e-10 (unfavourable), Cervical cancer:1.08e-5 (favourable)	Expressed in all	Mixed			fallopian tube: 84.8	Mixed		
KRTAP4-2	KAP4.2	ENSG00000244537	Keratin associated protein 4-2	17	41177446-41178208	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RAD21L1	dJ545L17.2, RAD21L	ENSG00000244588	RAD21 cohesin complex component like 1	20	1226056-1296421	Predicted intracellular proteins	Evidence at transcript level	HPA053282	Approved					Not detected	Tissue enriched	77	testis: 21.7	seminal vesicle: 0.2	Cell line enhanced		BJ hTERT+: 1.2;TIME: 1.2
CCDC13	FLJ25467	ENSG00000244607	Coiled-coil domain containing 13	3	42692663-42773253	Predicted intracellular proteins	Evidence at protein level	HPA047429	Approved		Supported	Centrosome		Mixed	Tissue enhanced		fallopian tube: 7.6;testis: 6.8	cerebral cortex: 1.5	Not detected		
ASPRV1	FLJ25084, SASPase, Taps	ENSG00000244617	Aspartic peptidase, retroviral-like 1	2	69960089-69962265	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA034809, HPA034810	Enhanced					Group enriched	Tissue enriched	13	skin: 286.1	breast: 22.6	Cell line enhanced		REH: 4.5
OR2AE1	OR2AE2	ENSG00000244623	Olfactory receptor family 2 subfamily AE member 1	7	99875987-99877057	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA042957	Uncertain					Not detected	Not detected			parathyroid gland: 0.2	Not detected		
KRTAP20-1	KAP20.1	ENSG00000244624	Keratin associated protein 20-1	21	30616425-30616699	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
UBE2V1	CROC-1, CROC1, UBE2V, UEV-1, UEV1A	ENSG00000244687	Ubiquitin conjugating enzyme E2 V1	20	50081124-50115959	Predicted intracellular proteins	Evidence at protein level	HPA052535, HPA053186			Enhanced	Nucleoplasm	Renal cancer:4.58e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 109.7	Expressed in all		
CTAGE8		ENSG00000244693	CTAGE family member 8	7	144266701-144269288	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		thyroid gland: 11.4	skin: 9.1	Cell line enhanced		A-431: 9.7;HaCaT: 5.8;RT4: 5.7;SiHa: 6.7
PTCHD4	C6orf138, dJ402H5.2, FLJ41841	ENSG00000244694	Patched domain containing 4	6	47878028-48068689	Predicted membrane proteins	Evidence at transcript level	HPA041276	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:1.49e-6 (favourable)	Group enriched	Mixed			seminal vesicle: 2.8	Cell line enhanced		AF22: 17.0;BEWO: 22.0;Hep G2: 27.0;LHCN-M2: 15.3;TIME: 16.1;WM-115: 16.7
C4A	C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG	ENSG00000244731	Complement C4A (Rodgers blood group)	6	31982024-32002681	Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB009811, CAB032603, HPA046356, HPA048287, HPA050103	Approved					Tissue enhanced	Tissue enhanced		liver: 46.1	thyroid gland: 28.2	Group enriched	8	HDLM-2: 49.4;HSkMC: 51.4;U-266/70: 12.8;U-266/84: 23.9
HBB	beta-globin, CD113t-C, HBD	ENSG00000244734	Hemoglobin subunit beta	11	5225464-5229395	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB009526, HPA043234	Enhanced		Approved	Vesicles		Expressed in all	Tissue enriched	9	bone marrow: 78046.6	placenta: 9082.6	Cell line enhanced		HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4
CRYBB2	CCA2, CRYB2, CRYB2A	ENSG00000244752	Crystallin beta B2	22	25219522-25231869	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043749	Supported		Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 1.5	breast,epididymis,lung,thyroid gland: 0.4	Not detected		
N4BP2L2	CG005, PFAAP5	ENSG00000244754	NEDD4 binding protein 2 like 2	13	32432417-32538885	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA039338, HPA039434, HPA059327	Approved		Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 57.6	Expressed in all		
ZNF585B	FLJ14928, SZFP41	ENSG00000245680	Zinc finger protein 585B	19	37181579-37218153	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA075556			Approved	Nucleoplasm<br>Cytoplasmic bodies		Expressed in all	Mixed			parathyroid gland: 19.7	Mixed		
CEBPA	C/EBP-alpha, CEBP	ENSG00000245848	CCAAT/enhancer binding protein alpha	19	33299934-33302564	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052734, HPA065037, HPA067937	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			adipose tissue: 108.0	Cell line enhanced		BEWO: 187.4;THP-1: 270.7;U-937: 100.7
H2AFJ	FLJ10903, MGC921	ENSG00000246705	H2A histone family member J	12	14774383-14778002	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Expressed in all	Expressed in all			testis: 334.6	Cell line enhanced		A549: 232.9;MCF7: 259.0
UBAP1L		ENSG00000246922	Ubiquitin associated protein 1 like	15	65092770-65115197	Predicted intracellular proteins	Evidence at protein level	HPA065334			Uncertain	Nuclear bodies		Mixed	Mixed			cerebral cortex: 1.8	Cell line enhanced		SK-MEL-30: 1.9
PGAM5	BXLBv68, MGC5352	ENSG00000247077	PGAM family member 5, mitochondrial serine/threonine protein phosphatase	12	132710819-132722734	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036978, HPA036979, CAB068215	Enhanced		Supported	Mitochondria	Liver cancer:1.13e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 28.3	Expressed in all		
ZCCHC3	C20orf99, dJ1103G7.7	ENSG00000247315	Zinc finger CCHC-type containing 3	20	296968-300321	Predicted intracellular proteins	Evidence at protein level	HPA042972			Approved	Vesicles	Pancreatic cancer:1.29e-4 (favourable)	Expressed in all	Expressed in all			placenta: 23.2	Expressed in all		
SPTY2D1-AS1		ENSG00000247595	SPTY2D1 antisense RNA 1	11	18588781-18610255	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	21	testis: 366.7	skin: 17.2	Mixed		
TWF2	A6r, A6RP, PTK9L	ENSG00000247596	Twinfilin actin binding protein 2	3	52228610-52239260	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA053874	Uncertain		Supported	Plasma membrane		Expressed in all	Expressed in all			lymph node: 61.2	Expressed in all		
MARS2	mtMetRS, SPAX3	ENSG00000247626	Methionyl-tRNA synthetase 2, mitochondrial	2	197705369-197708387	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035589, HPA035590	Uncertain		Approved	Intermediate filaments<br>Cytosol	Renal cancer:6.14e-5 (favourable), Glioma:1.49e-4 (favourable), Endometrial cancer:3.50e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 7.5	Expressed in all		
USP51		ENSG00000247746	Ubiquitin specific peptidase 51	X	55484616-55489202	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001942	Uncertain		Approved	Nucleoli fibrillar center<br>Cytosol	Renal cancer:2.63e-5 (favourable), Ovarian cancer:5.70e-4 (favourable)	Mixed	Tissue enriched	7	epididymis: 62.9	parathyroid gland: 9.3	Mixed		
BCKDHA	MSU, OVD1A	ENSG00000248098	Branched chain keto acid dehydrogenase E1, alpha polypeptide	19	41397460-41425005	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA036640	Supported				Renal cancer:5.33e-10 (favourable), Thyroid cancer:3.27e-5 (unfavourable), Head and neck cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 56.0	Expressed in all		
INSL3	MGC119818, MGC119819, RLF, RLNL	ENSG00000248099	Insulin like 3	19	17816512-17821574	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA028615	Enhanced					Tissue enriched	Tissue enriched	120	testis: 772.7	appendix: 6.4	Cell line enhanced		Karpas-707: 4.1;SCLC-21H: 6.1;SH-SY5Y: 5.0
CTC-295J13.3		ENSG00000248109		5	148221650-148243580	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.2	seminal vesicle: 0.9	Cell line enriched	5	HeLa: 479.6
ADH1C	ADH3	ENSG00000248144	Alcohol dehydrogenase 1C (class I), gamma polypeptide	4	99336492-99353027	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA047814, HPA060902	Supported		Supported	Plasma membrane<br>Cytosol	Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 508.1;liver: 888.0;stomach: 477.4	colon: 276.3	Cell line enhanced		ASC TERT1: 2.5;HSkMC: 7.7
TRIM39-RPP21		ENSG00000248167	TRIM39-RPP21 readthrough	6	30328907-30346854	Predicted intracellular proteins	Evidence at protein level	HPA051120	Uncertain		Supported	Cytosol		Not detected	Not detected			esophagus,testis: 0.2	Not detected		
AC037459.4		ENSG00000248235		8	22589274-22602084	Predicted intracellular proteins	Evidence at transcript level	HPA024667	Uncertain					Not detected	Tissue enhanced		spleen: 3.6	small intestine: 1.9	Cell line enhanced		U-2197: 3.5
APELA	ELA, Ende, tdl	ENSG00000248329	Apelin receptor early endogenous ligand	4	164877004-164898965	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		prostate: 6.3	kidney: 2.1	Cell line enriched	5	NTERA-2: 39.7
CDK11B	CDC2L1, CDK11-p110, CDK11-p46, CDK11-p58	ENSG00000248333	Cyclin dependent kinase 11B	1	1635227-1659012	Predicted intracellular proteins	Evidence at protein level	HPA025061, HPA073626	Approved		Approved	Nuclear speckles	Head and neck cancer:1.14e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.7	Expressed in all		
PCDHAC1		ENSG00000248383	Protocadherin alpha subfamily C, 1	5	140926369-141012344	Predicted membrane proteins	Evidence at transcript level	HPA052775			Approved	Nucleus<br>Nucleoli<br>Vesicles		Not detected	Tissue enriched	27	parathyroid gland: 69.4	cerebral cortex: 2.5	Cell line enhanced		A549: 5.7;hTCEpi: 5.8;PC-3: 4.2;SCLC-21H: 4.1
TARM1		ENSG00000248385	T-cell-interacting, activating receptor on myeloid cells 1	19	54069895-54081365	Predicted membrane proteins	Evidence at transcript level	HPA051022, HPA054401	Uncertain					Not detected	Not detected			gallbladder,spleen: 0.2	Not detected		
PRR5-ARHGAP8		ENSG00000248405	PRR5-ARHGAP8 readthrough	22	44702233-44862706	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			parathyroid gland,spleen,thyroid gland: 1.2	Cell line enhanced		BEWO: 2.9;HEK 293: 3.0;U-266/70: 4.8
POU5F2	FLJ25680, SPRM-1	ENSG00000248483	POU domain class 5, transcription factor 2	5	93733220-93741637	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.7	skin: 0.6	Cell line enriched	7	U-2 OS: 3.1
PCP4L1	IQM1	ENSG00000248485	Purkinje cell protein 4 like 1	1	161258727-161285450	Predicted intracellular proteins	Evidence at protein level	HPA052833	Enhanced	Supported	Approved	Nucleoplasm<br>Mitochondria	Lung cancer:8.10e-5 (favourable)	Group enriched	Tissue enhanced		cerebral cortex: 45.2;urinary bladder: 39.5	seminal vesicle: 22.7	Cell line enhanced		RT4: 10.8;T-47d: 8.2
ABHD14A	DKFZP564O243, DORZ1	ENSG00000248487	Abhydrolase domain containing 14A	3	51971426-51981199	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA038153, HPA056913			Enhanced	Vesicles	Lung cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 51.0	Expressed in all		
TMEM110-MUSTN1		ENSG00000248592	TMEM110-MUSTN1 readthrough	3	52833121-52897562	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051855	Uncertain		Approved	Cytosol		Not detected	Tissue enhanced		skeletal muscle: 11.1	adipose tissue: 6.6	Cell line enhanced		HDLM-2: 5.2
RBM14-RBM4		ENSG00000248643	RBM14-RBM4 readthrough	11	66616626-66646469	Predicted intracellular proteins	Evidence at protein level	HPA047849	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Not detected			epididymis: 0.9	Cell line enhanced		NB-4: 5.4
LY75-CD302		ENSG00000248672	LY75-CD302 readthrough	2	159771851-159904710	Predicted membrane proteins	Evidence at protein level	HPA049108	Uncertain					Not detected	Mixed			appendix: 2.5	Cell line enhanced		CACO-2: 5.5;HDLM-2: 6.5;Karpas-707: 18.3;RT4: 8.7
CCDC153	LOC283152	ENSG00000248712	Coiled-coil domain containing 153	11	119189638-119196769	Predicted intracellular proteins	Evidence at protein level	HPA041497	Uncertain		Uncertain	Cytosol		Mixed	Tissue enhanced		fallopian tube: 17.9	parathyroid gland: 3.8	Cell line enhanced		T-47d: 9.5
RP11-766F14.2		ENSG00000248713		4	99636529-99654648	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	26	skeletal muscle: 24.6	kidney: 0.9	Cell line enhanced		RH-30: 1.6
ACTN3		ENSG00000248746	Actinin alpha 3 (gene/pseudogene)	11	66546395-66563329	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006035	Uncertain					Tissue enhanced	Tissue enriched	124	skeletal muscle: 556.5	testis: 4.4	Cell line enriched	15	HDLM-2: 12.3
RP1-130H16.18		ENSG00000248751		22	30285238-30299482	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.2	Cell line enhanced		HSkMC: 1.2;REH: 1.0
WI2-2373I1.1		ENSG00000248767		7	290170-294422	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
LINC01207		ENSG00000248771	Long intergenic non-protein coding RNA 1207	4	164754064-164803795	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Group enriched	6	cervix, uterine: 4.4;colon: 6.3;duodenum: 10.5;gallbladder: 6.2;prostate: 9.0;rectum: 7.8;small intestine: 12.4	appendix: 1.4	Not detected		
TNFSF12-TNFSF13	TWE-PRIL	ENSG00000248871	TNFSF12-TNFSF13 readthrough	17	7549099-7561601	Predicted secreted proteins	Evidence at transcript level	HPA004863, HPA052967	Uncertain					Not detected	Mixed			adipose tissue: 1.9	Cell line enhanced		BJ hTERT+: 1.5;U-138 MG: 1.8;U-251 MG: 1.6
FMN1	DKFZP686C2281, FLJ45135, FMN, LD, MGC125288, MGC125289	ENSG00000248905	Formin 1	15	32765545-33194733	Predicted intracellular proteins	Evidence at protein level	HPA005465, HPA046786	Approved		Supported	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enhanced		testis: 8.2	cervix, uterine: 4.1	Cell line enhanced		RH-30: 13.0;SK-MEL-30: 11.2;T-47d: 11.5
ATP5J2-PTCD1		ENSG00000248919	ATP5J2-PTCD1 readthrough	7	99419749-99466197	Predicted intracellular proteins	Evidence at protein level	HPA020106, HPA047679	Uncertain		Approved	Mitochondria		Not detected	Mixed			prostate: 6.1	Expressed in all		
USP17L19		ENSG00000248920	Ubiquitin specific peptidase 17-like family member 19	4	9253378-9255329	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L22		ENSG00000248933	Ubiquitin specific peptidase 17-like family member 22	4	9267619-9269570	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
XXbac-BPG181M17.5		ENSG00000248993		6	32937364-32953122	Predicted secreted proteins	Evidence at protein level	HPA012298	Uncertain					Not detected	Not detected			small intestine: 0.4	Not detected		
USP17L17		ENSG00000249104	Ubiquitin specific peptidase 17-like family member 17	4	9243879-9245830	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HAUS5	dgt5, KIAA0841	ENSG00000249115	HAUS augmin like complex subunit 5	19	35612744-35625349	Predicted intracellular proteins	Evidence at protein level	HPA067250	Approved				Renal cancer:4.15e-8 (unfavourable), Liver cancer:2.77e-6 (unfavourable), Endometrial cancer:2.01e-4 (unfavourable), Cervical cancer:7.68e-4 (favourable)	Expressed in all	Mixed			lymph node: 7.1	Expressed in all		
EPPIN-WFDC6	SPINLW1-WFDC6	ENSG00000249139	EPPIN-WFDC6 readthrough	20	45536986-45547426	Predicted secreted proteins	Evidence at protein level							Not detected	Group enriched	78	epididymis: 41.7;testis: 58.2	fallopian tube: 0.6	Not detected		
RP11-514O12.4		ENSG00000249141		6	166858094-166956124	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			epididymis: 2.6	Cell line enhanced		NB-4: 2.8
RP11-432M8.9		ENSG00000249156		5	17610496-17611583	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Cell line enhanced		U-2 OS: 1.5
PCDHA11	CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11	ENSG00000249158	Protocadherin alpha 11	5	140868183-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA077160			Approved	Vesicles<br>Cell Junctions<br>Cytoplasmic bodies		Not detected	Tissue enhanced		cerebral cortex: 7.6;parathyroid gland: 3.8	testis: 1.8	Cell line enhanced		AN3-CA: 14.0;EFO-21: 7.3;T-47d: 5.0
AP000304.12		ENSG00000249209		21	33584687-33931607	Predicted intracellular proteins	Evidence at protein level	HPA039558	Uncertain					Not detected	Mixed			placenta,testis: 1.2	Cell line enhanced		U-2 OS: 7.1
ATP5L2	ATP5K2, dJ222E13.5	ENSG00000249222	ATP synthase, H+ transporting, mitochondrial Fo complex subunit G2	22	42639803-42640601	Predicted intracellular proteins	Evidence at protein level	HPA044629	Uncertain		Supported	Mitochondria		Not detected	Mixed			skin: 1.0	Not detected		
AC069368.3		ENSG00000249240		15	64841883-64930920	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		spleen: 8.8	appendix: 6.1	Cell line enhanced		U-266/84: 21.3
TMEM150C	FLJ12993, TTN3	ENSG00000249242	Transmembrane protein 150C	4	82483170-82562357	Predicted membrane proteins	Evidence at protein level	HPA052921	Enhanced				Renal cancer:4.59e-6 (favourable), Pancreatic cancer:5.68e-4 (favourable), Head and neck cancer:7.87e-4 (favourable)	Expressed in all	Tissue enhanced		epididymis: 181.6	ovary: 43.5	Cell line enhanced		AN3-CA: 11.7;MCF7: 27.5;SCLC-21H: 28.6
AC068533.7		ENSG00000249319		7	66087761-66152277	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			parathyroid gland: 8.1	Mixed		
NAIP	BIRC1, NLRB1	ENSG00000249437	NLR family apoptosis inhibitory protein	5	70968483-71025114	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042438	Approved					Not detected	Mixed			appendix,spleen: 3.9	Cell line enhanced		MOLT-4: 3.0;SiHa: 2.2;T-47d: 2.1
ZNF286B	ZNF286C, ZNF286L, ZNF590	ENSG00000249459	Zinc finger protein 286B	17	18658429-18682262	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA068125	Uncertain		Approved	Nuclear speckles<br>Cytosol		Mixed	Mixed			ovary: 2.6	Mixed		
ZNF324B	FLJ45850	ENSG00000249471	Zinc finger protein 324B	19	58451604-58457833	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023400	Uncertain		Approved	Nucleoli<br>Cytosol	Pancreatic cancer:2.83e-4 (favourable)	Expressed in all	Mixed			spleen: 4.7	Cell line enhanced		HEK 293: 35.2
SPATS1	FLJ25442, SPATA8, SRSP1	ENSG00000249481	Spermatogenesis associated serine rich 1	6	44342660-44377167	Predicted intracellular proteins	Evidence at transcript level	HPA030897, HPA049722	Approved		Approved	Nucleoplasm		Not detected	Group enriched	5	fallopian tube: 14.2;testis: 45.3	epididymis: 5.6	Cell line enriched	60	SK-MEL-30: 5.9
CLRN2		ENSG00000249581	Clarin 2	4	17515165-17527104	Predicted membrane proteins, Transporters	Evidence at transcript level	HPA042407	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
RP4-539M6.19		ENSG00000249590		22	30409255-30428990	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			duodenum: 3.6	Cell line enhanced		HBEC3-KT: 13.6;HUVEC TERT2: 10.7
AP000295.9		ENSG00000249624		21	33246774-33283212	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			lung: 1.5	Cell line enhanced		HEL: 3.7;MOLT-4: 3.5;RH-30: 4.4
THEGL		ENSG00000249693	Theg spermatid protein-like	4	56530609-56603507	Predicted intracellular proteins	Evidence at protein level	HPA068093	Uncertain					Not detected	Tissue enriched	7	testis: 5.6	smooth muscle: 0.8	Not detected		
ZNF564	MGC26914	ENSG00000249709	Zinc finger protein 564	19	12525370-12551542	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043998	Uncertain		Approved	Golgi apparatus		Not detected	Mixed			thyroid gland: 10.5	Mixed		
FER1L5	DKFZp434I0121	ENSG00000249715	Fer-1 like family member 5	2	96642737-96704885	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.5	Not detected		
ECSCR	ARIA, ECSM2	ENSG00000249751	Endothelial cell surface expressed chemotaxis and apoptosis regulator	5	139448556-139462743	Predicted membrane proteins	Evidence at protein level	HPA063337			Enhanced	Nucleoplasm<br>Vesicles<br>Plasma membrane		Expressed in all	Mixed			placenta: 96.7	Group enriched	104	EFO-21: 322.5;HUVEC TERT2: 736.2;TIME: 536.3
RP11-15K19.2		ENSG00000249773		7	55887277-55955239	Predicted intracellular proteins	Evidence at transcript level	HPA047159	Uncertain					Not detected	Tissue enhanced		testis: 3.1	endometrium: 1.3	Mixed		
USP17L21		ENSG00000249811	Ubiquitin specific peptidase 17-like family member 21	4	9262872-9264823	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HS3ST5	3-OST-5	ENSG00000249853	Heparan sulfate-glucosamine 3-sulfotransferase 5	6	114055586-114343045	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA021823, HPA064677	Approved					Not detected	Group enriched	5	cerebral cortex: 6.2;seminal vesicle: 2.2;skeletal muscle: 1.3	adrenal gland: 0.6	Cell line enhanced		PC-3: 4.2;RT4: 6.8;SCLC-21H: 19.0
MTRNR2L5		ENSG00000249860	MT-RNR2-like 5	10	55599303-55600041	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skeletal muscle: 0.3	Not detected		
LGALS16		ENSG00000249861	Galectin 16	19	39655894-39660647	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	54	placenta: 7.7	testis: 0.1	Cell line enriched	39	BEWO: 3.9
RNF103-CHMP3	RNF103-VPS24	ENSG00000249884	RNF103-CHMP3 readthrough	2	86505668-86721122	Predicted intracellular proteins	Evidence at protein level	HPA015673, HPA073383	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 4.2	bone marrow,heart muscle: 2.7	Mixed		
PDCD6	ALG-2, PEF1B	ENSG00000249915	Programmed cell death 6	5	271621-353856	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA047221			Approved	Cytosol	Renal cancer:5.16e-6 (unfavourable), Liver cancer:5.47e-5 (unfavourable), Urothelial cancer:2.19e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 120.9	Expressed in all		
GOLGA8K		ENSG00000249931	Golgin A8 family member K	15	32392782-32403292	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 6.4	thyroid gland: 0.5	Cell line enhanced		U-937: 1.1
TERB1	CCDC79, FLJ35894	ENSG00000249961	Telomere repeat binding bouquet formation protein 1	16	66754976-66801620	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	22	testis: 25.0	bone marrow: 1.1	Not detected		
RP11-548K23.11		ENSG00000249967		10	97584374-97673910	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 1.6	cerebral cortex,seminal vesicle: 0.9	Cell line enhanced		AN3-CA: 1.0;EFO-21: 1.1
TMEM158	p40BBp, RIS1	ENSG00000249992	Transmembrane protein 158 (gene/pseudogene)	3	45224466-45226278	Predicted membrane proteins	Evidence at transcript level	HPA074974	Approved				Renal cancer:5.42e-9 (unfavourable), Prostate cancer:6.43e-5 (favourable)	Mixed	Tissue enhanced		endometrium: 32.6;seminal vesicle: 32.1	smooth muscle: 25.7	Cell line enhanced		BJ hTERT+: 274.2;U-138 MG: 137.8;U-87 MG: 447.8
C15orf38-AP3S2		ENSG00000250021	C15orf38-AP3S2 readthrough	15	89834308-89912882	Predicted intracellular proteins	Evidence at protein level	HPA040513, HPA047173, HPA049270, HPA052278	Uncertain		Approved	Vesicles		Not detected	Expressed in all			cerebral cortex: 19.5	Expressed in all		
YJEFN3	FLJ44968, hYjeF_N3-19p13.11	ENSG00000250067	YjeF N-terminal domain containing 3	19	19528861-19537581	Predicted intracellular proteins	Evidence at protein level	HPA060789	Approved		Approved	Mitochondria	Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.25e-4 (favourable)	Expressed in all	Tissue enhanced		cerebral cortex: 15.6;testis: 5.6	epididymis: 3.0	Cell line enhanced		BEWO: 8.5;HEK 293: 9.6
DNAH10OS	FLJ45278	ENSG00000250091	Dynein axonemal heavy chain 10 opposite strand	12	123926424-123934984	Predicted intracellular proteins	Evidence at transcript level	HPA039786	Uncertain					Mixed	Tissue enhanced		cerebral cortex: 4.0	kidney: 1.6	Mixed		
PCDHA10	CNR8, CNRN8, CNRS8, CRNR8, PCDH-ALPHA10	ENSG00000250120	Protocadherin alpha 10	5	140855883-141012344	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 17.5	thyroid gland: 4.3	Cell line enriched	10	EFO-21: 16.6
ARPC4-TTLL3		ENSG00000250151	ARPC4-TTLL3 readthrough	3	9793082-9835401	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			bone marrow: 4.3	Mixed		
PTTG2		ENSG00000250254	Pituitary tumor-transforming 2	4	37960435-37961125	Predicted intracellular proteins	Evidence at transcript level	HPA008890, HPA045034	Uncertain		Approved	Nucleoli<br>Cytosol		Not detected	Not detected			bone marrow: 0.7	Not detected		
XXbac-BPG246D15.9		ENSG00000250264		6	32813767-32838822	Predicted membrane proteins	Evidence at transcript level	HPA001312	Approved		Approved	Nuclear speckles<br>Endoplasmic reticulum		Not detected	Tissue enhanced		appendix: 15.5;spleen: 9.5	lymph node: 6.5	Cell line enhanced		Daudi: 14.2;HDLM-2: 12.4;HEL: 12.9
GIMD1		ENSG00000250298	GIMAP family P-loop NTPase domain containing 1	4	106357485-106368825	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 28.6;small intestine: 18.0	gallbladder: 4.9	Not detected		
KIAA1456	C8orf79, FLJ36980	ENSG00000250305	KIAA1456	8	12945642-13031503	Predicted intracellular proteins	Evidence at transcript level	HPA024673	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:2.77e-7 (favourable)	Tissue enhanced	Tissue enhanced		thyroid gland: 31.4	cerebral cortex: 6.6	Cell line enhanced		AF22: 6.3;BJ: 7.8;fHDF/TERT166: 9.6;SCLC-21H: 5.2
ZNF718	FLJ90036	ENSG00000250312	Zinc finger protein 718	4	124480-163989	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:7.67e-6 (favourable)	Expressed in all	Mixed			thyroid gland: 8.7	Cell line enhanced		REH: 18.4
SMIM20	C4orf52	ENSG00000250317	Small integral membrane protein 20	4	25861830-25929874	Predicted membrane proteins	Evidence at protein level	HPA016552	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:8.97e-5 (favourable)	Expressed in all	Expressed in all			epididymis: 88.0	Expressed in all		
RP5-972B16.2		ENSG00000250349		X	37349330-38687674	Predicted membrane proteins	Evidence at protein level	HPA003140	Uncertain					Not detected	Not detected			skeletal muscle: 0.9	Not detected		
GYPB	CD235b, GPB, MNS, SS	ENSG00000250361	Glycophorin B (MNS blood group)	4	143996104-144019345	Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	5	bone marrow: 37.2	placenta: 7.3	Cell line enriched	5	HEL: 225.3
TUNAR	HI-LNC78, LINC00617, TUNA	ENSG00000250366	TCL1 upstream neural differentiation-associated RNA	14	95876392-95925571	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.55e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 4.0;endometrium: 1.8;fallopian tube: 2.5	seminal vesicle: 1.3	Cell line enhanced		AF22: 3.2;NTERA-2: 6.8;SCLC-21H: 7.9
TRIM75P	TRIM75	ENSG00000250374	Tripartite motif containing 75, pseudogene	4	165059148-165060554	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			placenta,testis: 0.2	Cell line enriched	17	BEWO: 2.0
RP11-119J18.1		ENSG00000250378		5	135812667-135826584	Predicted intracellular proteins	Evidence at transcript level							Mixed	Group enriched	12	skin: 2.1;testis: 4.6	breast,duodenum,esophagus,kidney: 0.2	Cell line enhanced		HEL: 1.4;SK-MEL-30: 1.3
KIAA1210		ENSG00000250423	KIAA1210	X	119078635-119150579	Predicted intracellular proteins	Evidence at protein level	HPA000551, HPA048322	Enhanced					Tissue enhanced	Group enriched	5	epididymis: 47.9;seminal vesicle: 27.4;testis: 58.3	fallopian tube: 8.6	Not detected		
RP5-877J2.1		ENSG00000250424		7	30852273-30923812	Predicted membrane proteins	Evidence at protein level	HPA019206, HPA030130	Approved		Approved	Plasma membrane		Not detected	Tissue enhanced		gallbladder: 1.5	fallopian tube: 1.2	Not detected		
CHCHD10	C22orf16, N27C7-4	ENSG00000250479	Coiled-coil-helix-coiled-coil-helix domain containing 10	22	23765834-23768443	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003440	Enhanced		Supported	Mitochondria	Renal cancer:2.15e-7 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 220.6	Mixed		
FAM218A	C4orf39, FLJ31659	ENSG00000250486	Family with sequence similarity 218 member A	4	164956948-164959122	Predicted intracellular proteins	Evidence at protein level							Mixed	Mixed			testis: 5.6	Cell line enhanced		LHCN-M2: 1.8;SCLC-21H: 5.0
CDK3		ENSG00000250506	Cyclin dependent kinase 3	17	76000906-76005999	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA007420	Uncertain		Approved	Cytosol		Mixed	Mixed			skin: 29.2	Expressed in all		
GPR162	A-2, GRCA	ENSG00000250510	G protein-coupled receptor 162	12	6821545-6829972	G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA055135	Enhanced		Approved	Microtubule organizing center	Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable)	Tissue enriched	Group enriched	6	cerebral cortex: 84.3;fallopian tube: 29.4	lung: 9.5	Cell line enhanced		AF22: 17.4;AN3-CA: 19.5;NTERA-2: 19.7;SH-SY5Y: 14.2;U-2 OS: 17.2
ATP6V1E2	ATP6E1, ATP6EL2, ATP6V1EL2, MGC9341, VMA4	ENSG00000250565	ATPase H+ transporting V1 subunit E2	2	46490750-46542557	Predicted intracellular proteins	Evidence at protein level	HPA052784	Uncertain					Expressed in all	Group enriched	6	epididymis: 7.7;testis: 31.6	cerebral cortex: 3.2	Mixed		
GLI4	HKR4, ZNF928	ENSG00000250571	GLI family zinc finger 4	8	143267433-143276931	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023131	Uncertain		Approved	Nucleus<br>Cytokinetic bridge		Expressed in all	Expressed in all			spleen: 8.8	Expressed in all		
XXbac-BPG32J3.19		ENSG00000250641		6	31706904-31717918	Predicted membrane proteins	No evidence	HPA008053	Uncertain					Tissue enriched	Not detected			testis: 0.5	Not detected		
RP11-295K3.1		ENSG00000250644		11	1734821-1763954	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003001	Uncertain					Mixed	Tissue enhanced		adrenal gland: 83.1	cerebral cortex: 29.6	Cell line enhanced		CAPAN-2: 196.3;SH-SY5Y: 53.0;U-87 MG: 58.5
RP11-6L6.2		ENSG00000250673		4	146214515-146230878	Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			skin: 0.4	Cell line enriched	89	HDLM-2: 8.9
CCDC169-SOHLH2	C13orf38-SOHLH2	ENSG00000250709	CCDC169-SOHLH2 readthrough	13	36168794-36297842	Predicted intracellular proteins	Evidence at transcript level	HPA029182			Uncertain	Vesicles		Not detected	Tissue enriched	28	testis: 19.5	seminal vesicle: 0.7	Cell line enhanced		BEWO: 1.3;HL-60: 2.2;U-937: 1.7
RP11-322N21.2		ENSG00000250719	Homo sapiens phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), transcript variant 13, mRNA.	1	46175486-46176478	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level							Not detected	Tissue enriched	937	testis: 93.7	all non-specific tissues: 0.0	Not detected		
SELENOP	SELP, SeP, SEPP, SEPP1	ENSG00000250722	Selenoprotein P	5	42799880-42887392	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA036287	Approved		Approved	Nucleus<br>Golgi apparatus	Renal cancer:6.97e-6 (favourable)	Expressed in all	Expressed in all			liver: 2947.1	Cell line enhanced		Hep G2: 350.2;HSkMC: 307.3;T-47d: 109.6
NT5C1B-RDH14		ENSG00000250741	NT5C1B-RDH14 readthrough	2	18555545-18589564	Predicted intracellular proteins	Evidence at transcript level	HPA056683	Uncertain					Not detected	Tissue enriched	174	testis: 23.1	duodenum: 0.1	Not detected		
USP17L20		ENSG00000250745	Ubiquitin specific peptidase 17-like family member 20	4	9258124-9260075	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-432M8.13		ENSG00000250782		5	17634460-17635053	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	11	U-2 OS: 1.0
PRODH2	HSPOX1	ENSG00000250799	Proline dehydrogenase 2	19	35799988-35813299	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051287	Approved		Supported	Nucleoplasm<br>Cytosol		Group enriched	Group enriched	96	kidney: 132.8;liver: 45.1	testis: 0.9	Cell line enriched	14	Hep G2: 21.4
CTC-441N14.4		ENSG00000250803	Uncharacterized protein LOC100505841 	5	122129622-122183949	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	19	testis: 53.8	fallopian tube: 2.8	Not detected		
RP11-345F18.1		ENSG00000250821		4	55819819-55837487	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.3	Cell line enhanced		HEK 293: 1.4
USP17L18		ENSG00000250844	Ubiquitin specific peptidase 17-like family member 18	4	9248630-9250581	Enzymes, Predicted intracellular proteins	No evidence	HPA045642	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
USP17L23		ENSG00000250913	Ubiquitin specific peptidase 17-like family member 23	4	9272364-9272914	Enzymes, Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-484M3.5		ENSG00000251012		3	119147375-119187807	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
RP11-101E3.5		ENSG00000251184		9	128941478-128957021	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium,urinary bladder: 0.6	Cell line enhanced		BJ: 1.6;HL-60: 1.4;RH-30: 1.8;U-138 MG: 1.4
ZNF674	MRX92, ZNF673B	ENSG00000251192	Zinc finger protein 674	X	46497727-46545457	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031026, HPA065295	Uncertain					Mixed	Mixed			prostate: 3.3	Mixed		
TMED7-TICAM2		ENSG00000251201	TMED7-TICAM2 readthrough	5	115578642-115626161	Predicted secreted proteins	Evidence at protein level	HPA008960	Uncertain					Not detected	Mixed			placenta: 4.7	Mixed		
RP11-540D14.8		ENSG00000251246		1	155063748-155086807	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.2	testis: 0.7	Cell line enhanced		RPMI-8226: 2.2;U-266/70: 2.0
ZNF345	HZF10	ENSG00000251247	Zinc finger protein 345	19	36850361-36913029	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA025816	Uncertain					Mixed	Mixed			testis: 17.7	Mixed		
RFPL4B	RNF211	ENSG00000251258	Ret finger protein like 4B	6	112347330-112351296	Predicted intracellular proteins	Evidence at transcript level	HPA059324, HPA066464	Uncertain					Group enriched	Tissue enriched	5	testis: 2.9	placenta: 0.5	Cell line enhanced		K-562: 1.7;RPTEC TERT1: 1.8;U-266/84: 5.6
ALG1L2		ENSG00000251287	ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase like 2	3	130081831-130113227	Predicted intracellular proteins	Evidence at protein level	HPA060392	Uncertain		Uncertain	Nucleoli fibrillar center<br>Endoplasmic reticulum	Ovarian cancer:7.75e-4 (favourable)	Mixed	Tissue enhanced		spleen: 1.0	appendix,duodenum,skin: 0.2	Not detected		
SHANK3	KIAA1650, prosap2, PSAP2, SPANK-2	ENSG00000251322	SH3 and multiple ankyrin repeat domains 3	22	50674415-50733298	Predicted intracellular proteins	Evidence at protein level	HPA003446, CAB079070	Enhanced	Approved			Colorectal cancer:7.40e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 2.7	Cell line enhanced		HEL: 3.8;TIME: 4.6
MSANTD3-TMEFF1	C9orf30-TMEFF1	ENSG00000251349	MSANTD3-TMEFF1 readthrough	9	100442271-100577636	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 48.0	testis: 10.2	Cell line enhanced		AF22: 98.5;NTERA-2: 50.5;SCLC-21H: 63.0
AP000350.10		ENSG00000251357		22	23862188-23895223	Predicted membrane proteins	Evidence at transcript level	HPA042960	Uncertain					Not detected	Not detected			adrenal gland: 0.5	Cell line enhanced		SCLC-21H: 2.3
ZNF550	MGC41917	ENSG00000251369	Zinc finger protein 550	19	57535257-57559863	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003251	Uncertain		Approved	Vesicles<br>Microtubules	Prostate cancer:2.21e-4 (unfavourable)	Expressed in all	Mixed			ovary: 12.7	Mixed		
DCANP1	C5orf20, DCNP1	ENSG00000251380	Dendritic cell associated nuclear protein	5	135444214-135447348	Predicted intracellular proteins	Evidence at protein level	HPA048308	Uncertain					Not detected	Not detected			lymph node: 0.7	Cell line enhanced		THP-1: 1.3
FOXD1	FKHL8, FREAC4	ENSG00000251493	Forkhead box D1	5	73444827-73448527	Predicted intracellular proteins, Transcription factors	Evidence at protein level						Head and neck cancer:2.73e-4 (unfavourable), Urothelial cancer:9.65e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 4.5	adrenal gland: 2.6	Cell line enhanced		hTEC/SVTERT24-B: 60.8;U-138 MG: 79.5
APITD1-CORT		ENSG00000251503	APITD1-CORT readthrough	1	10430102-10452153	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 38.7	bone marrow: 5.0	Mixed		
RP11-385D13.1		ENSG00000251537		17	15571491-15651653	Predicted intracellular proteins	Evidence at protein level	HPA023623, HPA066431	Uncertain		Approved	Plasma membrane<br>Cytosol		Not detected	Not detected			skin: 0.4	Cell line enhanced		A549: 1.2;CAPAN-2: 1.0;HaCaT: 2.2
RP11-724O16.1		ENSG00000251569		2	169479480-169525922	Predicted intracellular proteins	Evidence at transcript level	HPA046125	Uncertain					Not detected	Tissue enhanced		testis: 16.8	fallopian tube,thyroid gland: 3.8	Cell line enhanced		ASC TERT1: 3.8;HSkMC: 2.9;LHCN-M2: 4.9
PRB1	PM, PMF, PMS, PRB1L, PRB1M	ENSG00000251655	Proline rich protein BstNI subfamily 1	12	11351823-11395566	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	4399	salivary gland: 6733.7	skin: 1.5	Not detected		
PCDHA12	PCDH-ALPHA12	ENSG00000251664	Protocadherin alpha 12	5	140875302-141012344	Predicted membrane proteins	Evidence at transcript level	HPA035812	Approved		Approved	Cytosol		Not detected	Tissue enhanced		lung: 2.7	cerebral cortex: 1.8	Cell line enhanced		A549: 6.8;hTCEpi: 3.3;PC-3: 5.3;RT4: 4.6;SH-SY5Y: 3.3
PTX4	C16orf38	ENSG00000251692	Pentraxin 4	16	1485886-1488981	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA064718, HPA073694	Uncertain		Uncertain	Cytosol		Not detected	Not detected			testis: 0.8	Group enriched	6	HL-60: 16.9;NB-4: 9.9
OC90	PLA2L	ENSG00000253117	Otoconin 90	8	132024220-132059380	Predicted secreted proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RGS21		ENSG00000253148	Regulator of G-protein signaling 21	1	192316992-192367285	Predicted intracellular proteins	Evidence at transcript level	HPA052843	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PCDHGA12	CDH21, FIB3, KIAA0588, PCDH-GAMMA-A12	ENSG00000253159	Protocadherin gamma subfamily A, 12	5	141430589-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 8.1	Cell line enhanced		BJ: 8.3;BJ hTERT+: 13.2;fHDF/TERT166: 18.9;HSkMC: 12.6
C8orf88		ENSG00000253250	Chromosome 8 open reading frame 88	8	90958637-90985257	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:6.23e-6 (unfavourable), Melanoma:4.90e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 183.0	smooth muscle: 46.1	Mixed		
CTC-534A2.2		ENSG00000253251		5	65624765-65630891	Predicted intracellular proteins	Evidence at protein level	HPA066071, HPA068764	Approved		Supported	Nucleoplasm<br>Nucleoli	Urothelial cancer:1.17e-4 (favourable)	Expressed in all	Mixed			bone marrow: 10.0	Expressed in all		
CCDC71L	C7orf74, FLJ36031	ENSG00000253276	Coiled-coil domain containing 71-like	7	106656765-106660996	Predicted intracellular proteins	Evidence at protein level	HPA067925	Approved		Approved	Golgi apparatus<br>Actin filaments<br>Cytosol	Renal cancer:2.53e-6 (unfavourable), Cervical cancer:9.08e-4 (unfavourable)	Expressed in all	Mixed			adipose tissue: 31.1	Mixed		
HOXA10	HOX1, HOX1H	ENSG00000253293	Homeobox A10	7	27170591-27180261	Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019384	Approved		Supported	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		endometrium: 116.6;smooth muscle: 67.6	prostate: 42.2	Cell line enhanced		HEK 293: 164.0;U-937: 78.1
TMEM200B	TTMB	ENSG00000253304	Transmembrane protein 200B	1	29119428-29123935	Predicted membrane proteins	Evidence at transcript level	HPA055254	Uncertain					Mixed	Tissue enhanced		endometrium: 69.1	seminal vesicle: 54.2	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 28.3
PCDHGB6	PCDH-GAMMA-B6	ENSG00000253305	Protocadherin gamma subfamily B, 6	5	141408021-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 20.8	parathyroid gland: 11.9	Cell line enhanced		AF22: 15.8;EFO-21: 5.1
SERPINE3		ENSG00000253309	Serpin family E member 3	13	51335773-51364735	Predicted secreted proteins	Evidence at protein level	HPA051904, HPA055804	Uncertain					Not detected	Tissue enhanced		skin: 1.0	small intestine: 0.8	Not detected		
C1orf210	MGC52423	ENSG00000253313	Chromosome 1 open reading frame 210	1	43281883-43285617	Predicted membrane proteins	Evidence at protein level	HPA013788	Uncertain		Uncertain	Nucleoli	Renal cancer:0.00e+0 (favourable)	Mixed	Mixed			duodenum: 44.3	Cell line enhanced		A-431: 10.7;BEWO: 12.7;CACO-2: 10.5;CAPAN-2: 35.4;T-47d: 14.3
TRNP1	C1orf225, LOC388610	ENSG00000253368	TMF1-regulated nuclear protein 1	1	26993707-27000898	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.90e-6 (unfavourable), Renal cancer:7.72e-4 (unfavourable)	Expressed in all	Tissue enhanced		stomach: 116.8	esophagus: 49.6	Mixed		
SMIM18		ENSG00000253457	Small integral membrane protein 18	8	30638600-30646064	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA066648	Supported		Uncertain	Nucleus<br>Centrosome		Tissue enriched	Tissue enriched	9	cerebral cortex: 11.1	adrenal gland: 1.3	Cell line enriched	6	SH-SY5Y: 9.9
PCDHGA5	CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5	ENSG00000253485	Protocadherin gamma subfamily A, 5	5	141364232-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			cerebral cortex: 3.8	Group enriched	6	ASC diff: 10.8;ASC TERT1: 4.3
NACA2	MGC71999, NACAL	ENSG00000253506	Nascent polypeptide associated complex alpha subunit 2	17	61590426-61591202	Predicted intracellular proteins	Evidence at protein level	HPA073152, HPA073648			Approved	Cytosol		Mixed	Tissue enriched	129	testis: 104.2	appendix,ovary: 0.8	Cell line enhanced		NB-4: 2.1
PCDHGA7	PCDH-GAMMA-A7	ENSG00000253537	Protocadherin gamma subfamily A, 7	5	141382739-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		cerebral cortex: 7.4	thyroid gland: 3.3	Cell line enhanced		BJ hTERT+: 17.1;SH-SY5Y: 19.7
PYDC2	POP2	ENSG00000253548	Pyrin domain containing 2	3	191461163-191461456	Predicted intracellular proteins	Evidence at protein level	HPA055895	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Cell line enriched	10	A549: 1.0
SLC10A5		ENSG00000253598	Solute carrier family 10 member 5	8	81693607-81696174	Predicted membrane proteins, Transporters	Evidence at protein level	HPA025966	Uncertain		Approved	Plasma membrane		Mixed	Mixed			liver: 3.0	Not detected		
EIF5AL1	bA342M3.3, EIF5AP1	ENSG00000253626	Eukaryotic translation initiation factor 5A-like 1	10	79512601-79516440	Predicted intracellular proteins, Transporters	Evidence at transcript level						Cervical cancer:4.23e-4 (favourable)	Expressed in all	Tissue enriched	13	testis: 19.8	parathyroid gland: 1.5	Mixed		
PRSS51		ENSG00000253649	Protease, serine 51	8	10482878-10547585	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enhanced		breast: 1.0;testis: 1.1	cerebral cortex: 0.5	Cell line enhanced		U-2 OS: 1.4
ALG11	CDG1P, KIAA0266	ENSG00000253710	ALG11, alpha-1,2-mannosyltransferase	13	52012398-52029664	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA047214	Approved					Mixed	Expressed in all			thyroid gland: 23.6	Expressed in all		
ATXN7L3B	lnc-SCA7	ENSG00000253719	Ataxin 7 like 3B	12	74537827-74545430	Predicted intracellular proteins	Evidence at protein level	HPA056612			Approved	Nucleoplasm	Renal cancer:2.25e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 61.5	Expressed in all		
PRKDC	DNA-PKcs, DNAPK, DNPK1, HYRC, HYRC1, p350, XRCC7	ENSG00000253729	Protein kinase, DNA-activated, catalytic polypeptide	8	47773108-47960183	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB005167, HPA035174	Supported		Enhanced	Nucleoplasm	Endometrial cancer:1.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.6	Expressed in all		
PCDHGA6	PCDH-GAMMA-A6	ENSG00000253731	Protocadherin gamma subfamily A, 6	5	141373914-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			endometrium,ovary: 3.8	Cell line enhanced		SCLC-21H: 11.4;WM-115: 12.0
PCDHGA8	KIAA0327, PCDH-GAMMA-A8	ENSG00000253767	Protocadherin gamma subfamily A, 8	5	141390157-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Not detected	Not detected			thyroid gland: 0.7	Not detected		
UTP14C	2700066J21Rik, KIAA0266	ENSG00000253797	UTP14, small subunit processome component homolog C (S. cerevisiae)	13	52024691-52033600	Predicted intracellular proteins	Evidence at protein level	HPA047217, HPA054023	Uncertain		Approved	Nucleoli<br>Cytosol	Renal cancer:1.46e-5 (favourable), Ovarian cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 25.6	Expressed in all		
ETV3L	FLJ16478	ENSG00000253831	ETS variant 3 like	1	157092044-157099808	Predicted intracellular proteins, Transcription factors	Evidence at transcript level							Not detected	Not detected			breast: 0.9	Cell line enriched	16	HDLM-2: 32.0
PCDHGA10	PCDH-GAMMA-A10	ENSG00000253846	Protocadherin gamma subfamily A, 10	5	141412987-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enriched	5	cerebral cortex: 28.0	placenta: 5.1	Cell line enhanced		AF22: 14.4;T-47d: 18.5
PCDHGA11	PCDH-GAMMA-A11	ENSG00000253873	Protocadherin gamma subfamily A, 11	5	141421047-141512979	Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex,placenta: 3.2	Cell line enhanced		ASC diff: 16.8;ASC TERT1: 18.5;SK-MEL-30: 16.7;WM-115: 43.4
PCDHGB2	PCDH-GAMMA-B2	ENSG00000253910	Protocadherin gamma subfamily B, 2	5	141360042-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA077526	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enriched	Mixed			cerebral cortex: 6.5	Cell line enhanced		ASC diff: 9.2
PCDHGB4	CDH20, FIB2, PCDH-GAMMA-B4	ENSG00000253953	Protocadherin gamma subfamily B, 4	5	141387698-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			placenta: 4.3	Cell line enhanced		BJ hTERT+: 35.5;TIME: 18.0
CLDN23	CLDNL	ENSG00000253958	Claudin 23	8	8701938-8704106	Predicted membrane proteins, Transporters	Evidence at protein level	HPA070578			Uncertain	Nucleus<br>Plasma membrane	Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable)	Expressed in all	Tissue enhanced		colon: 23.7;stomach: 24.5	small intestine: 16.5	Cell line enhanced		BEWO: 7.4
ZNF260	ozrf1, Zfp260	ENSG00000254004	Zinc finger protein 260	19	36510695-36528660	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028806	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.44e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 20.5	Mixed		
LYN	JTK8	ENSG00000254087	LYN proto-oncogene, Src family tyrosine kinase	8	55879813-56014168	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001231, CAB004492	Enhanced		Supported	Golgi apparatus<br>Vesicles<br>Plasma membrane	Renal cancer:3.43e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 161.1	appendix: 130.6	Cell line enhanced		HEL: 215.0;HMC-1: 205.1
PINX1	FLJ20565, LPTL, LPTS, MGC8850, PinX1	ENSG00000254093	PIN2/TERF1 interacting, telomerase inhibitor 1	8	10764963-10839884	Predicted intracellular proteins	Evidence at protein level	HPA023139	Uncertain				Cervical cancer:2.45e-5 (favourable)	Expressed in all	Expressed in all			testis: 16.1	Expressed in all		
PCDHGB7	ME6, PCDH-GAMMA-B7	ENSG00000254122	Protocadherin gamma subfamily B, 7	5	141417645-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Mixed			ovary: 10.2	Cell line enhanced		AN3-CA: 80.7;HSkMC: 19.4
NPIPB11		ENSG00000254206	Nuclear pore complex interacting protein family member B11	16	29381354-29404029	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Mixed	Mixed			skin: 8.1	Mixed		
PCDHGB1	PCDH-GAMMA-B1	ENSG00000254221	Protocadherin gamma subfamily B, 1	5	141350102-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA076182	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Focal adhesion sites<br>Midbody<br>Cytosol		Mixed	Tissue enriched	11	cerebral cortex: 23.8	endometrium: 2.0	Cell line enhanced		ASC diff: 8.8;T-47d: 8.1
PCDHGA3	PCDH-GAMMA-A3	ENSG00000254245	Protocadherin gamma subfamily A, 3	5	141343829-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 6.5	ovary: 3.1	Group enriched	7	AF22: 7.0;BJ: 2.0;EFO-21: 5.4
LRRC24	LRRC14OS	ENSG00000254402	Leucine rich repeat containing 24	8	144522377-144527032	Predicted membrane proteins	Evidence at protein level	HPA028171, HPA052250	Enhanced		Approved	Vesicles		Not detected	Tissue enhanced		parathyroid gland: 3.6;prostate: 4.5	cerebral cortex: 3.1	Cell line enhanced		SCLC-21H: 3.2;SH-SY5Y: 7.9
SIGLEC14		ENSG00000254415	Sialic acid binding Ig like lectin 14	19	51642553-51646801	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA014377	Uncertain					Mixed	Tissue enhanced		appendix: 34.8;spleen: 55.2	bone marrow: 18.3	Group enriched	10	HMC-1: 87.0;U-937: 19.3
PBOV1	UC28, UROC28	ENSG00000254440	Prostate and breast cancer overexpressed 1	6	138215986-138218491	Predicted intracellular proteins	Evidence at transcript level	HPA063021	Uncertain					Not detected	Not detected			bone marrow,kidney,parathyroid gland,skin: 0.1	Not detected		
OR4D10	OR4D10P, OST711	ENSG00000254466	Olfactory receptor family 4 subfamily D member 10	11	59477373-59478396	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-849H4.2		ENSG00000254469	Putative short transient receptor potential channel 2-like protein 	11	71865509-71928654	Predicted intracellular proteins	Evidence at protein level	HPA051121, HPA058841	Uncertain		Supported	Nucleoli		Mixed	Mixed			epididymis: 7.0	Expressed in all		
AP5B1	AP-5, DKFZp761E198, PP1030	ENSG00000254470	Adaptor related protein complex 5 beta 1 subunit	11	65775893-65780802	Predicted intracellular proteins	Evidence at protein level	HPA065739, HPA067880	Uncertain		Approved	Nucleus<br>Golgi apparatus<br>Vesicles	Renal cancer:2.31e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 25.1	Mixed		
CHMP4A	C14orf123, HSPC134, VPS32A	ENSG00000254505	Charged multivesicular body protein 4A	14	24209583-24213869	Predicted intracellular proteins	Evidence at protein level	HPA068473	Approved				Renal cancer:3.91e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 130.5	Expressed in all		
SIGLEC12	S2V, Siglec-12, Siglec-L1, Siglec-XII, SIGLECL1, SLG	ENSG00000254521	Sialic acid binding Ig like lectin 12 (gene/pseudogene)	19	51491357-51501789	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		appendix: 6.4;spleen: 12.8	smooth muscle: 3.7	Group enriched	9	HMC-1: 124.2;U-937: 61.4
PABPC4L		ENSG00000254535	Poly(A) binding protein cytoplasmic 4 like	4	134196333-134201748	Predicted intracellular proteins	Evidence at protein level						Renal cancer:1.11e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 12.8;placenta: 14.7	endometrium: 6.4	Cell line enhanced		HAP1: 11.9;HeLa: 10.3;REH: 7.4;RH-30: 8.3;U-2 OS: 9.1
RP11-108K14.8		ENSG00000254536		10	133390834-133420495	Predicted intracellular proteins	Evidence at protein level	HPA037826, HPA037827	Uncertain		Approved	Mitochondria		Not detected	Tissue enhanced		testis: 2.5	duodenum: 1.3	Cell line enhanced		Karpas-707: 17.8;U-266/70: 4.0
OMP		ENSG00000254550	Olfactory marker protein	11	77102840-77103331	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		duodenum: 2.7;small intestine: 2.8	rectum: 2.0	Not detected		
MAGEL2	NDNL1, nM15	ENSG00000254585	MAGE family member L2	15	23643544-23647841	Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		cerebral cortex: 3.3	cervix, uterine: 2.9	Group enriched	6	AF22: 3.2;NTERA-2: 1.9;U-2 OS: 1.0
CSNK2A3	CSNK2A1P	ENSG00000254598	Casein kinase 2 alpha 3	11	11351942-11353357	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA059206, HPA061698	Uncertain		Approved	Nucleoplasm		Mixed	Not detected			testis: 0.5	Cell line enhanced		A-431: 2.1
ARMS2	ARMD8, LOC387715	ENSG00000254636	Age-related maculopathy susceptibility 2	10	122454653-122457352	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA067225	Enhanced					Not detected	Tissue enhanced		placenta: 2.0;testis: 2.9	ovary: 0.9	Not detected		
INS	IDDM1, IDDM2	ENSG00000254647	Insulin	11	2159779-2161341	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000048, HPA004932, CAB012098, CAB053843	Enhanced					Tissue enriched	Tissue enriched	27	pancreas: 1850.7	skin: 68.2	Group enriched	10	EFO-21: 194.7;U-2 OS: 281.2;U-698: 61.2
RTL1	Mar1, MART1, PEG11	ENSG00000254656	Retrotransposon-like 1	14	100880655-100884847	Predicted membrane proteins	Evidence at protein level	HPA066979			Approved	Cytosol		Tissue enhanced	Group enriched	9	adrenal gland: 2.4;placenta: 4.5	cerebral cortex,testis: 0.3	Cell line enriched	35	SH-SY5Y: 664.4
FPGT	GFPP	ENSG00000254685	Fucose-1-phosphate guanylyltransferase	1	74198212-74234086	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA072331			Uncertain	Vesicles	Liver cancer:2.30e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 32.8	Expressed in all		
RP11-468E2.1		ENSG00000254692		14	24189157-24213473	Predicted membrane proteins	Evidence at protein level	HPA059249	Approved		Approved	Golgi apparatus		Not detected	Expressed in all			parathyroid gland: 54.2	Mixed		
RP11-565P22.6		ENSG00000254706		1	162365407-162383531	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		seminal vesicle: 4.2	gallbladder: 2.3	Cell line enhanced		HEL: 6.5
IGLL5		ENSG00000254709	Immunoglobulin lambda like polypeptide 5	22	22887780-22896107	Predicted intracellular proteins	Evidence at protein level						Renal cancer:5.94e-8 (unfavourable), Head and neck cancer:3.41e-5 (favourable), Breast cancer:6.10e-4 (favourable)	Expressed in all	Tissue enhanced		tonsil: 836.2	urinary bladder: 638.6	Group enriched	7	Daudi: 472.9;U-266/70: 346.8;U-698: 308.3
MEX3A	RKHD4	ENSG00000254726	Mex-3 RNA binding family member A	1	156072013-156081998	Predicted intracellular proteins	Evidence at protein level	HPA062703			Supported	Cytosol	Liver cancer:9.23e-8 (unfavourable)	Expressed in all	Tissue enhanced		endometrium: 5.9;ovary: 5.9	cerebral cortex: 4.1	Cell line enhanced		AF22: 63.9;NTERA-2: 58.9;SCLC-21H: 71.7;SH-SY5Y: 117.8
OR10G4		ENSG00000254737	Olfactory receptor family 10 subfamily G member 4	11	124015575-124016510	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			pancreas,rectum: 0.1	Not detected		
EEF1G	EF1G	ENSG00000254772	Eukaryotic translation elongation factor 1 gamma	11	62559601-62574086	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA040688, HPA055316	Enhanced		Approved	Mitochondria		Mixed	Expressed in all			ovary: 2996.8	Expressed in all		
CKLF-CMTM1		ENSG00000254788	CKLF-CMTM1 readthrough	16	66552587-66579135	Predicted membrane proteins	Evidence at transcript level	HPA017136	Approved					Mixed	Mixed			testis: 4.0	Mixed		
SLC22A18AS	BWR1B, BWSCR1B, ORCTL2S, p27-BWR1B, SLC22A1LS	ENSG00000254827	Solute carrier family 22 member 18 antisense	11	2887780-2903740	Predicted intracellular proteins	Evidence at protein level	HPA068288	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		colon: 14.4;duodenum: 13.5	small intestine: 11.0	Cell line enhanced		A549: 8.7;CAPAN-2: 8.3;MCF7: 14.0;SK-MEL-30: 26.1;WM-115: 14.7
OR5M10		ENSG00000254834	Olfactory receptor family 5 subfamily M member 10	11	56576774-56577721	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NPIPA2		ENSG00000254852	Nuclear pore complex interacting protein family member A2	16	14748066-14765413	Predicted membrane proteins	Evidence at protein level	HPA053611	Approved		Approved	Nucleoplasm		Not detected	Tissue enhanced		testis: 3.6	cerebral cortex: 1.8	Cell line enhanced		BEWO: 6.5
MPV17L2	FKSG24, MGC12972	ENSG00000254858	MPV17 mitochondrial inner membrane protein like 2	19	18193182-18196948	Predicted membrane proteins	Evidence at protein level	HPA043111	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.30e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 16.3	Expressed in all		
AC113404.1		ENSG00000254893	Ras-related protein Rap-1b-like protein 	5	76170093-76174331	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enriched	8	small intestine: 3.4	adrenal gland: 0.4	Group enriched	8	Daudi: 7.6;Karpas-707: 13.3;RPMI-8226: 11.1
BORCS8	MEF2BNB	ENSG00000254901	BLOC-1 related complex subunit 8	19	19176903-19192591	Predicted intracellular proteins	Evidence at protein level	HPA045700	Approved		Approved	Nucleoplasm<br>Vesicles	Pancreatic cancer:4.05e-5 (favourable)	Expressed in all	Mixed			cerebral cortex: 17.3	Expressed in all		
RP11-872D17.8		ENSG00000254979		11	57387365-57424059	Predicted membrane proteins	Evidence at protein level	HPA038515	Supported					Mixed	Tissue enhanced		bone marrow: 7.7;placenta: 10.5	skin: 5.8	Cell line enriched	7	HMC-1: 162.8
DPP3		ENSG00000254986	Dipeptidyl peptidase 3	11	66480013-66509657	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA035780, HPA035781	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cytosol	Stomach cancer:1.34e-4 (favourable)	Expressed in all	Expressed in all			colon: 29.7	Expressed in all		
ANKHD1-EIF4EBP3	MASK-BP3	ENSG00000254996	ANKHD1-EIF4EBP3 readthrough	5	140401908-140549569	Predicted intracellular proteins	Evidence at transcript level	HPA008718	Approved					Mixed	Expressed in all			parathyroid gland: 40.5	Expressed in all		
KRTAP5-9	KRN1, KRTAP5-1, KRTAP5.9	ENSG00000254997	Keratin associated protein 5-9	11	71548418-71549553	Predicted intracellular proteins	Evidence at protein level						Urothelial cancer:9.25e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 2.6	epididymis: 1.8	Cell line enriched	22	RT4: 7.2
BRK1	C3orf10, HSPC300, MDS027	ENSG00000254999	BRICK1, SCAR/WAVE actin nucleating complex subunit	3	10115592-10127190	Predicted intracellular proteins	Evidence at protein level	HPA060391			Approved	Nuclear speckles<br>Cell Junctions	Liver cancer:5.76e-5 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 225.0	Expressed in all		
UBTFL1	C11orf27	ENSG00000255009	Upstream binding transcription factor, RNA polymerase I-like 1	11	90085950-90087131	Predicted intracellular proteins, Transcription factors	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
OR5M1	OST050	ENSG00000255012	Olfactory receptor family 5 subfamily M member 1	11	56612555-56613502	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SAA2-SAA4		ENSG00000255071	SAA2-SAA4 readthrough	11	18231423-18248635	Predicted membrane proteins	Evidence at transcript level	HPA060139	Uncertain				Renal cancer:2.92e-8 (unfavourable), Breast cancer:4.56e-4 (favourable), Glioma:9.87e-4 (unfavourable)	Tissue enriched	Tissue enhanced		adipose tissue: 27.9;cervix, uterine: 22.6;liver: 15.0	breast: 5.4	Cell line enhanced		A-431: 2.3;EFO-21: 1.4
PIGY	MGC14156	ENSG00000255072	Phosphatidylinositol glycan anchor biosynthesis class Y	4	88521573-88521789	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA059018	Uncertain					Not detected	Tissue enriched	11	colon: 1.0	all non-specific tissues: 0.0	Group enriched	10	AF22: 7.5;hTEC/SVTERT24-B: 10.7;MOLT-4: 13.8
CHMP1B	C18orf2, CHMP1.5, Vps46B	ENSG00000255112	Charged multivesicular body protein 1B	18	11851396-11854449	Predicted intracellular proteins	Evidence at protein level	HPA061997, HPA062896	Enhanced		Supported	Nucleus<br>Midbody	Renal cancer:7.37e-8 (favourable)	Expressed in all	Expressed in all			thyroid gland: 87.0	Expressed in all		
EID3	FLJ25832, NSE4B, NSMCE4B	ENSG00000255150	EP300 interacting inhibitor of differentiation 3	12	104303739-104305205	Predicted intracellular proteins	Evidence at protein level	HPA059367	Uncertain		Supported	Nucleus<br>Nucleoli	Renal cancer:5.96e-5 (unfavourable), Glioma:9.70e-5 (unfavourable)	Mixed	Tissue enriched	14	testis: 111.8	seminal vesicle: 7.7	Cell line enhanced		A549: 8.2;BJ: 7.2
GLYATL1P3		ENSG00000255151	Glycine-N-acyltransferase like 1 pseudogene 3	11	59086307-59094786	Predicted intracellular proteins	Evidence at protein level	HPA039501	Uncertain		Uncertain	Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	6	breast: 9.7;lymph node: 3.4	appendix,prostate: 1.1	Cell line enhanced		Daudi: 1.3;T-47d: 1.1;U-266/70: 1.4
RP11-80H18.3		ENSG00000255154	Hydroxyacyl-thioester dehydratase type 2, mitochondrial 	3	58306262-58318574	Predicted intracellular proteins	Evidence at protein level	HPA066812			Supported	Nucleoli<br>Mitochondria		Not detected	Expressed in all			thyroid gland: 14.6	Expressed in all		
CCDC166		ENSG00000255181	Coiled-coil domain containing 166	8	143706694-143708109	Predicted intracellular proteins	No evidence	HPA025058	Uncertain					Not detected	Not detected			testis: 0.5	Not detected		
NANOGP8		ENSG00000255192	Nanog homeobox pseudogene 8	15	35084193-35085110	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			testis: 0.8	Cell line enriched	125	NTERA-2: 50.8
CARD17	INCA	ENSG00000255221	Caspase recruitment domain family member 17	11	105092469-105101431	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		skin: 3.5	lymph node: 1.9	Cell line enriched	5	AN3-CA: 1.4
OR5M11	OR11-199	ENSG00000255223	Olfactory receptor family 5 subfamily M member 11	11	56542340-56543257	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.1	Not detected		
FXYD6-FXYD2		ENSG00000255245	FXYD6-FXYD2 readthrough	11	117820163-117876667	Predicted membrane proteins	Evidence at transcript level	HPA068838, HPA075209	Approved		Approved	Nuclear membrane<br>Vesicles		Not detected	Tissue enhanced		kidney: 5.6	salivary gland: 2.1	Group enriched	6	MOLT-4: 5.2;RPTEC TERT1: 5.3
PRR23D1		ENSG00000255251	Proline rich 23 domain containing 1	8	7539628-7542450	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	54	epididymis: 75.6	testis: 1.3	Not detected		
TMPRSS4-AS1		ENSG00000255274	TMPRSS4 antisense RNA 1	11	118003634-118088299	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.2	lymph node,spleen: 0.8	Cell line enhanced		Karpas-707: 7.8;RPMI-8226: 4.9;SCLC-21H: 1.7
SDHD	cybS, PGL, PGL1	ENSG00000255292	Succinate dehydrogenase complex subunit D	11	112086824-112193805	Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA045727	Uncertain					Not detected	Tissue enriched	13	colon: 7.8	parathyroid gland: 0.5	Cell line enhanced		A549: 23.8;CACO-2: 57.0;Hep G2: 19.6;hTEC/SVTERT24-B: 20.1;RT4: 30.5
OR8G5	OR8G5P, OR8G6	ENSG00000255298	Olfactory receptor family 8 subfamily G member 5	11	124264827-124265867	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	31	testis: 6.2	placenta: 0.2	Cell line enhanced		K-562: 2.3;PC-3: 1.1;T-47d: 1.9
EID1	C15orf3, CRI1, EID-1	ENSG00000255302	EP300 interacting inhibitor of differentiation 1	15	48877886-48880183	Predicted intracellular proteins	Evidence at protein level	HPA051122, HPA051123	Approved		Supported	Nucleoplasm	Stomach cancer:2.91e-4 (unfavourable), Head and neck cancer:9.99e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 315.2	Mixed		
OR52B2		ENSG00000255307	Olfactory receptor family 52 subfamily B member 2	11	6169330-6170408	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NOX5	NOX5A, NOX5B	ENSG00000255346	NADPH oxidase 5	15	68930525-69062743	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Tissue enhanced		spleen: 13.2	testis: 3.5	Not detected		
CCDC179		ENSG00000255359	Coiled-coil domain containing 179	11	22846931-22860426	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	412	testis: 46.2	urinary bladder: 0.1	Not detected		
TAS2R43	T2R52	ENSG00000255374	Taste 2 receptor member 43	12	11091287-11092313	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRR23D2		ENSG00000255378	Proline rich 23 domain containing 2	8	7778591-7781413	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	54	epididymis: 75.6	testis: 1.3	Not detected		
HCAR3	GPR109B, HCA3, HM74	ENSG00000255398	Hydroxycarboxylic acid receptor 3	12	122714756-122716892	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA028660	Approved		Approved	Cell Junctions		Mixed	Tissue enhanced		bone marrow: 16.6;spleen: 21.7	appendix: 12.4	Group enriched	6	HaCaT: 8.1;RT4: 28.3
PCDHA3	PCDH-ALPHA3	ENSG00000255408	Protocadherin alpha 3	5	140801028-141012344	Predicted membrane proteins	Evidence at transcript level	HPA035667	Uncertain					Not detected	Mixed			endometrium: 2.5	Cell line enhanced		T-47d: 8.9;WM-115: 2.4
EBLN2		ENSG00000255423	Endogenous Bornavirus-like nucleoprotein 2	3	73061659-73063337	Predicted intracellular proteins	Evidence at protein level	HPA062510, HPA068795	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			bone marrow: 10.2	Mixed		
RP11-831H9.11		ENSG00000255432		11	62649694-62665178	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.5	Not detected		
RP11-196G11.1		ENSG00000255439		16	31083439-31094956	Predicted secreted proteins	Evidence at transcript level	HPA042720	Uncertain		Approved	Endoplasmic reticulum		Not detected	Not detected			skin: 0.5	Mixed		
CARD18	ICEBERG, pseudo-ICE, UNQ5804	ENSG00000255501	Caspase recruitment domain family member 18	11	105137721-105139726	Predicted intracellular proteins	Evidence at protein level	HPA038582	Approved					Tissue enhanced	Group enriched	7	breast: 10.6;skin: 29.7	esophagus: 3.0	Cell line enhanced		BEWO: 3.0;hTCEpi: 1.9;U-2 OS: 2.9
NPIPB8		ENSG00000255524	Nuclear pore complex interacting protein family member B8	16	28637654-28658682	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011188, HPA053611	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enriched	12	testis: 12.8	small intestine: 1.1	Cell line enriched	23	hTCEpi: 15.2
NEDD8-MDP1		ENSG00000255526	NEDD8-MDP1 readthrough	14	24213955-24232352	Predicted intracellular proteins	Evidence at protein level	HPA003064, HPA060254	Uncertain		Approved	Nucleoplasm		Not detected	Tissue enhanced		parathyroid gland: 2.7	testis: 1.8	Cell line enhanced		MOLT-4: 6.6
POLR2M	GCOM1, Gdown, Gdown1, GRINL1A	ENSG00000255529	RNA polymerase II subunit M	15	57706629-57782762	Predicted intracellular proteins	Evidence at protein level	HPA068141			Approved	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 59.9	Expressed in all		
LY6G6E	C6orf22, G6e	ENSG00000255552	Lymphocyte antigen 6 family member G6E	6	31711771-31714065	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA056234			Approved	Nucleus		Not detected	Tissue enhanced		skin: 1.2;thyroid gland: 1.0	bone marrow: 0.8	Cell line enriched	103	HEL: 21.3
FDXACB1	hCG_2033039, LOC91893	ENSG00000255561	Ferredoxin-fold anticodon binding domain containing 1	11	111874056-111881243	Predicted intracellular proteins	Evidence at protein level	HPA039012, HPA061375	Uncertain		Uncertain	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 6.8	Mixed		
OR10G2		ENSG00000255582	Olfactory receptor family 10 subfamily G member 2	14	21633836-21634940	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			lymph node: 0.2	Not detected		
RAB44	dJ431A14.3, RASD3, RASL13	ENSG00000255587	RAB44, member RAS oncogene family	6	36697851-36733183	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	28	bone marrow: 38.8	gallbladder,lung: 1.3	Group enriched	204	HEL: 19.9;HL-60: 24.8;HMC-1: 79.3;NB-4: 50.2;THP-1: 20.3;U-937: 48.2
RP4-809F18.1		ENSG00000255595		12	126191263-126361065	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex,gallbladder,pancreas,salivary gland: 0.1	Not detected		
RP11-277P12.6		ENSG00000255641		12	10412312-10436001	Predicted membrane proteins	Evidence at transcript level	HPA062570	Uncertain					Not detected	Group enriched	7	cerebral cortex: 8.2;spleen: 6.1	bone marrow: 1.0	Cell line enriched	5	HeLa: 5.8
TRIL	KIAA0644	ENSG00000255690	TLR4 interactor with leucine rich repeats	7	28953358-28958292	Predicted membrane proteins	Evidence at protein level						Endometrial cancer:3.23e-4 (unfavourable), Ovarian cancer:8.52e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		cerebral cortex: 24.9	kidney: 5.7	Cell line enhanced		AF22: 22.0;SH-SY5Y: 42.6;SK-BR-3: 26.9;T-47d: 14.9
OR4D2		ENSG00000255713	Olfactory receptor family 4 subfamily D member 2	17	58169656-58170579	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CTC-435M10.3		ENSG00000255730		19	41350853-41425001	Predicted intracellular proteins	Evidence at protein level	HPA036640	Approved					Not detected	Mixed			cerebral cortex: 9.1	Cell line enhanced		THP-1: 9.6
RP13-512J5.1		ENSG00000255767		2	3531984-3547957	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			smooth muscle: 24.1	Mixed		
OR6J1	OR6J1P, OR6J2	ENSG00000255804	Olfactory receptor family 6 subfamily J member 1 (gene/pseudogene)	14	22633768-22634811	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MTRNR2L8		ENSG00000255823	MT-RNR2-like 8	11	10507887-10509189	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			heart muscle: 2071.6	Expressed in all		
TIFAB		ENSG00000255833	TIFA inhibitor	5	135444218-135452399	Predicted intracellular proteins	Evidence at protein level	HPA049372	Uncertain					Tissue enhanced	Tissue enhanced		appendix: 4.9;lymph node: 6.3	tonsil: 4.5	Group enriched	14	THP-1: 6.0;U-937: 1.5
RP4-559A3.7		ENSG00000255835		1	225886696-225924278	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex: 0.1	Not detected		
TAS2R20	T2R20, T2R56, TAS2R49	ENSG00000255837	Taste 2 receptor member 20	12	10996495-10997875	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			skin: 0.8	Not detected		
KDM4F	JMJD2F	ENSG00000255855	Lysine demethylase 4F	11	95049422-95051338	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC073610.5		ENSG00000255863		12	48921963-48939663	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CYP2A6	CPA6, CYP2A, CYP2A3	ENSG00000255974	Cytochrome P450 family 2 subfamily A member 6	19	40843538-40850447	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA046713, HPA047262	Supported				Liver cancer:5.38e-5 (favourable)	Tissue enriched	Tissue enriched	67	liver: 839.4	breast: 12.4	Cell line enhanced		RH-30: 1.1
CTSO	CTSO1	ENSG00000256043	Cathepsin O	4	155924118-155953917	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA002041	Approved					Expressed in all	Expressed in all			gallbladder: 32.4	Cell line enhanced		HSkMC: 15.9;Karpas-707: 30.6
MTRNR2L10		ENSG00000256045	MT-RNR2-like 10	X	55181391-55182920	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			kidney: 69.1	Cell line enhanced		A549: 99.9;HeLa: 270.2;Hep G2: 240.3
APOPT1	APOP-1, C14orf153, MGC2562	ENSG00000256053	Apoptogenic 1, mitochondrial	14	103562962-103607523	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:6.34e-5 (unfavourable), Ovarian cancer:4.78e-4 (favourable)	Expressed in all	Expressed in all			testis: 89.8	Expressed in all		
TRAPPC2B	MIP-2A, SEDLP, SEDLP1, TRAPPC2P1	ENSG00000256060	Trafficking protein particle complex 2B	19	57363511-57365353	Predicted intracellular proteins	Evidence at protein level	HPA063308			Approved	Nucleoplasm<br>Endoplasmic reticulum<br>Vesicles	Renal cancer:1.28e-4 (favourable)	Expressed in all	Expressed in all			testis: 28.8	Mixed		
DYX1C1	CILD25, DNAAF4, EKN1, FLJ37882	ENSG00000256061	Dyslexia susceptibility 1 candidate 1	15	55410525-55508234	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051048	Uncertain		Approved	Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		testis: 20.5	fallopian tube: 17.6	Mixed		
ZNF432	KIAA0798	ENSG00000256087	Zinc finger protein 432	19	52031379-52095738	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052082, HPA060274, HPA065606	Uncertain		Supported	Nucleoplasm	Urothelial cancer:4.11e-5 (favourable), Renal cancer:6.47e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 21.1	Mixed		
AP000721.4		ENSG00000256100		11	63974620-63988346	Predicted secreted proteins	No evidence	HPA055942	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SMLR1		ENSG00000256162	Small leucine rich protein 1	6	130827406-130837135	Predicted membrane proteins	Evidence at protein level	HPA066060	Uncertain					Tissue enriched	Group enriched	5	duodenum: 12.2;liver: 28.9;small intestine: 11.4	kidney: 3.2	Cell line enriched	10	Hep G2: 55.1
TAS2R30	T2R30, TAS2R47	ENSG00000256188	Taste 2 receptor member 30	12	11132958-11134644	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			endometrium,ovary,parathyroid gland,testis,thyroid gland: 0.2	Not detected		
MTRNR2L3		ENSG00000256222	MT-RNR2-like 3	20	57358442-57359980	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			bone marrow,skeletal muscle,testis: 0.2	Not detected		
ZNF10	KOX1	ENSG00000256223	Zinc finger protein 10	12	133130575-133159465	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003204	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			parathyroid gland: 40.9	Mixed		
ZNF486	KRBO2, MGC2396	ENSG00000256229	Zinc finger protein 486	19	20167228-20200490	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		thyroid gland: 63.5	urinary bladder: 17.2	Cell line enhanced		HBF TERT88: 23.4
SMIM3	C5orf62, MSTP150, NID67	ENSG00000256235	Small integral membrane protein 3	5	150777946-150796734	Predicted membrane proteins	Evidence at protein level	HPA075345			Approved	Vesicles	Renal cancer:1.15e-8 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 109.0	Cell line enhanced		ASC diff: 172.4;U-87 MG: 184.9
HMBS	PBGD, PORC, UPS	ENSG00000256269	Hydroxymethylbilane synthase	11	119084866-119093549	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA006114, HPA050659	Enhanced		Approved	Lipid droplets		Expressed in all	Tissue enriched	5	bone marrow: 52.8	parathyroid gland: 9.8	Expressed in all		
ZNF225		ENSG00000256294	Zinc finger protein 225	19	44112181-44134816	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073778			Approved	Nucleoplasm		Mixed	Tissue enhanced		testis: 22.8	breast: 10.6	Mixed		
CTD-3074O7.11		ENSG00000256349		11	66509079-66533613	Predicted intracellular proteins	Evidence at protein level	HPA058283	Uncertain		Uncertain	Midbody		Not detected	Not detected			lymph node: 0.3	Cell line enriched	6	NTERA-2: 11.7
PPIAL4D		ENSG00000256374	Peptidylprolyl isomerase A like 4D	1	145241630-145242124	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
ASIC5	ACCN5, HINAC, INAC	ENSG00000256394	Acid sensing ion channel subunit family member 5	4	155829729-155866273	Predicted membrane proteins, Transporters	Evidence at protein level	HPA014903, HPA029444	Approved					Not detected	Group enriched	18	duodenum: 2.3;small intestine: 1.2	all non-specific tissues: 0.0	Not detected		
TAS2R31	T2R31, T2R53, TAS2R44	ENSG00000256436	Taste 2 receptor member 31	12	11030387-11031407	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Mixed	Not detected			endometrium,parathyroid gland: 0.3	Not detected		
DND1	MGC34750, RBMS4	ENSG00000256453	DND microRNA-mediated repression inhibitor 1	5	140670794-140673586	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	14	testis: 9.8	parathyroid gland: 0.7	Mixed		
SALL3	ZNF796	ENSG00000256463	Spalt like transcription factor 3	18	78980275-79002677	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016656	Uncertain					Tissue enriched	Tissue enhanced		cerebral cortex: 4.1;prostate: 2.0	kidney: 0.9	Group enriched	29	HAP1: 4.8;HEK 293: 2.5;NTERA-2: 9.5
RP11-73M18.2		ENSG00000256500		14	103562962-103685924	Predicted intracellular proteins	Evidence at protein level	HPA044617, HPA052450	Uncertain		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol		Not detected	Tissue enhanced		cerebral cortex: 21.5;testis: 21.6	skeletal muscle: 9.0	Expressed in all		
AP003419.11		ENSG00000256514		11	67351572-67373584	Predicted intracellular proteins	Evidence at transcript level	HPA071529			Uncertain	Nucleus<br>Nucleoli<br>Mitochondria<br>Cytosol		Not detected	Expressed in all			tonsil: 101.3	Mixed		
POLG2	HP55, MTPOLB	ENSG00000256525	DNA polymerase gamma 2, accessory subunit	17	64477785-64497036	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB017030, HPA023202	Approved		Approved	Nuclear bodies<br>Mitochondria	Liver cancer:1.39e-6 (unfavourable), Renal cancer:1.17e-5 (unfavourable), Prostate cancer:6.59e-4 (unfavourable)	Expressed in all	Mixed			testis: 20.2	Expressed in all		
SMIM10L1		ENSG00000256537	Small integral membrane protein 10 like 1	12	11171222-11176016	Predicted intracellular proteins	Evidence at transcript level						Ovarian cancer:2.71e-4 (favourable), Renal cancer:3.56e-4 (unfavourable), Urothelial cancer:9.70e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 15.6	Expressed in all		
OR13A1		ENSG00000256574	Olfactory receptor family 13 subfamily A member 1	10	45302654-45315608	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA057237	Uncertain					Tissue enhanced	Not detected			urinary bladder: 0.5	Group enriched	16	Daudi: 5.8;U-698: 5.1
RP11-286N22.8		ENSG00000256591		11	61429220-61485822	Predicted intracellular proteins	Evidence at transcript level	HPA039732	Uncertain					Not detected	Mixed			cervix, uterine: 9.3	Mixed		
MTRNR2L1		ENSG00000256618	MT-RNR2-like 1	17	22523111-22524663	Predicted intracellular proteins	Evidence at transcript level						Liver cancer:8.99e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 1105.5	Expressed in all		
RP13-672B3.2		ENSG00000256632		12	132688049-132714912	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 2.6	kidney,small intestine,testis: 0.6	Cell line enhanced		REH: 1.1;U-698: 1.0
CLEC12B		ENSG00000256660	C-type lectin domain family 12 member B	12	10010627-10018619	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enhanced		testis: 27.0	skin: 5.5	Cell line enriched	14	U-937: 5.5
LIMS4	LIMS3L	ENSG00000256671	LIM zinc finger domain containing 4	2	110446640-110473075	Predicted intracellular proteins	Evidence at protein level	HPA058455	Uncertain					Not detected	Not detected			kidney,liver: 0.1	Cell line enhanced		hTEC/SVTERT24-B: 1.8;U-138 MG: 1.9
ZNF350	ZBRK1, ZFQR	ENSG00000256683	Zinc finger protein 350	19	51964343-51986856	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001521	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies	Urothelial cancer:2.54e-4 (favourable)	Expressed in all	Mixed			prostate: 45.0	Mixed		
PGA5		ENSG00000256713	Pepsinogen 5, group I (pepsinogen A)	11	61241042-61251448	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA046875	Supported					Tissue enriched	Tissue enriched	684	stomach: 3513.1	cerebral cortex: 5.1	Cell line enriched	13	BJ hTERT+: 23.3
STH	MAPTIT	ENSG00000256762	Saitohin	17	45999250-45999694	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		cerebral cortex: 1.4	placenta: 0.5	Not detected		
ZNF253	BMZF-1, FLJ90391, ZNF411	ENSG00000256771	Zinc finger protein 253	19	19865886-19894674	Predicted intracellular proteins, Transcription factors	Evidence at transcript level						Renal cancer:9.69e-5 (favourable), Glioma:1.11e-4 (favourable), Ovarian cancer:2.19e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 25.9	Mixed		
KLRF2	NKp65	ENSG00000256797	Killer cell lectin like receptor F2	12	9881489-9895833	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	16	skin: 14.1	tonsil: 0.8	Cell line enriched	40	U-937: 24.5
C17orf100	LOC388327	ENSG00000256806	Chromosome 17 open reading frame 100	17	6651718-6693202	Predicted intracellular proteins	Evidence at protein level	HPA046824			Approved	Nucleus<br>Cytokinetic bridge<br>Cytosol		Expressed in all	Mixed			skin: 8.3	Cell line enhanced		SH-SY5Y: 9.8
CAPNS2	MGC12536, MGC14804	ENSG00000256812	Calpain small subunit 2	16	55566672-55567687	Predicted intracellular proteins	Evidence at protein level	HPA059749, HPA076768	Enhanced		Approved	Cytosol		Group enriched	Tissue enhanced		esophagus: 59.9;skin: 109.3	urinary bladder: 30.3	Cell line enriched	8	hTCEpi: 158.7
CTD-2140B24.4		ENSG00000256825		12	133130984-133202369	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
SLC5A8	AIT	ENSG00000256870	Solute carrier family 5 member 8	12	101155493-101210407	Predicted membrane proteins	Evidence at protein level						Breast cancer:9.04e-6 (favourable), Renal cancer:1.97e-4 (favourable)	Tissue enhanced	Tissue enhanced		cervix, uterine: 15.0;thyroid gland: 14.7	kidney: 3.5	Cell line enriched	6	SK-BR-3: 2.3
MTRNR2L7		ENSG00000256892	MT-RNR2-like 7	10	37601440-37602974	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,cerebral cortex,heart muscle,kidney,rectum,skeletal muscle: 0.1	Not detected		
LIMS3		ENSG00000256977	LIM zinc finger domain containing 3	2	109898428-109924868	Predicted intracellular proteins	Evidence at transcript level	HPA058455	Uncertain		Approved	Focal adhesion sites<br>Cytosol		Not detected	Tissue enhanced		endometrium: 10.8;fallopian tube: 10.5	appendix: 3.5	Cell line enhanced		HEL: 12.7;HMC-1: 36.2
KHDC1L	RP11-257K9.7	ENSG00000256980	KH domain containing 1 like	6	73223544-73225770	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		testis: 4.6	lung: 1.0	Group enriched	8	A-431: 10.2;BEWO: 48.1
GPR142	PGR2	ENSG00000257008	G protein-coupled receptor 142	17	74367407-74372622	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA031392	Uncertain		Uncertain	Plasma membrane<br>Cell Junctions<br>Cytosol		Tissue enhanced	Not detected			appendix: 0.1	Not detected		
HP		ENSG00000257017	Haptoglobin	16	72054592-72061055	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB003787, HPA047750	Enhanced		Approved	Vesicles	Renal cancer:6.94e-13 (unfavourable)	Tissue enriched	Tissue enriched	182	liver: 28407.0	bone marrow: 155.8	Cell line enhanced		Hep G2: 153.5;HSkMC: 88.2
RP11-545J16.1		ENSG00000257046		12	20815674-21090245	Predicted membrane proteins	Evidence at transcript level	HPA050892	Uncertain					Not detected	Tissue enriched	13	breast: 26.9	liver: 2.0	Cell line enhanced		A-431: 1.4;CAPAN-2: 1.4;HeLa: 1.8
C11orf97	LINC01171	ENSG00000257057	Chromosome 11 open reading frame 97	11	94512432-94532123	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Group enriched	9	fallopian tube: 28.3;testis: 12.6	lung: 2.3	Not detected		
KIAA1147	LCHN	ENSG00000257093	KIAA1147	7	141656728-141702153	Predicted intracellular proteins	Evidence at protein level	HPA029467, HPA061437	Approved		Approved	Golgi apparatus	Head and neck cancer:6.24e-4 (favourable), Renal cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 21.1	Mixed		
LSM14A	C19orf13, DKFZP434D1335, FAM61A, RAP55, RAP55A	ENSG00000257103	LSM14A, mRNA processing body assembly factor	19	34172504-34229515	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017961	Approved		Supported	Cytosol<br>Cytoplasmic bodies		Expressed in all	Mixed			thyroid gland: 37.5	Cell line enhanced		THP-1: 32.4
NHLRC4		ENSG00000257108	NHL repeat containing 4	16	566996-569495	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		fallopian tube: 18.9	parathyroid gland: 6.3	Cell line enhanced		HEL: 3.0;HMC-1: 8.4;RPMI-8226: 2.9
OR11H12		ENSG00000257115	Olfactory receptor family 11 subfamily H member 12	14	18601045-18602129	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CLLU1		ENSG00000257127	Chronic lymphocytic leukemia up-regulated 1	12	92421531-92431002	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
TAS2R38	PTC, T2R61	ENSG00000257138	Taste 2 receptor member 38	7	141972631-141973773	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA043862, HPA054366	Uncertain					Not detected	Not detected			rectum,small intestine: 0.3	Not detected		
HOXA10-HOXA9		ENSG00000257184		7	27163535-27180013	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		endometrium: 1.0	prostate: 0.4	Cell line enhanced		BJ: 1.1
GATC	15E1.2, FLJ37000, gatC	ENSG00000257218	Glutamyl-tRNA amidotransferase subunit C	12	120446438-120463749	Predicted intracellular proteins	Evidence at protein level						Liver cancer:4.21e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 20.1	Expressed in all		
ZBED6		ENSG00000257315	Zinc finger BED-type containing 6	1	203795714-203854999	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA026439, HPA028490, HPA028526, HPA068807	Approved		Approved	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Mixed			cervix, uterine: 14.3	Mixed		
MGAM	MGA	ENSG00000257335	Maltase-glucoamylase	7	141907813-142106747	Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA002270	Enhanced				Renal cancer:6.16e-5 (favourable)	Tissue enriched	Tissue enhanced		duodenum: 59.4;small intestine: 97.2	epididymis: 31.1	Cell line enhanced		A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
FNTB	FPTB	ENSG00000257365	Farnesyltransferase, CAAX box, beta	14	64986720-65062652	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA062743	Approved		Approved	Centrosome	Liver cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 17.7	Expressed in all		
RP11-762I7.5		ENSG00000257390		12	55757275-55827546	Predicted intracellular proteins	Evidence at protein level	HPA017653, HPA030902, HPA030903	Uncertain		Enhanced	Nuclear speckles		Not detected	Tissue enriched	17	testis: 15.2	gallbladder,lymph node: 0.8	Mixed		
RP11-603J24.9		ENSG00000257411		12	56101331-56109289	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cervix, uterine: 22.6	Cell line enhanced		HBF TERT88: 119.8;LHCN-M2: 60.3;U-698: 57.6
ZNF878		ENSG00000257446	Zinc finger protein 878	19	12043805-12052939	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA052735	Uncertain		Approved	Nucleus<br>Nucleoli		Tissue enriched	Mixed			placenta,testis: 1.0	Mixed		
RPL36A-HNRNPH2		ENSG00000257529	RPL36A-HNRNPH2 readthrough	X	101391011-101412297	Predicted intracellular proteins	Evidence at transcript level	HPA077586			Approved	Endoplasmic reticulum<br>Plasma membrane<br>Cytosol		Not detected	Mixed			ovary: 2.6	Cell line enhanced		BJ: 10.0
ZNF625		ENSG00000257591	Zinc finger protein 625	19	12142090-12156729	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074014			Approved	Nucleus<br>Mitochondria		Mixed	Mixed			thyroid gland: 4.7	Mixed		
GALNT4	GalNAc-T4	ENSG00000257594	Polypeptide N-acetylgalactosaminyltransferase 4	12	89519408-89524806	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA076116			Supported	Golgi apparatus<br>Vesicles		Mixed	Mixed			stomach: 31.0	Cell line enhanced		PC-3: 20.4
INAFM1	PRR24	ENSG00000257704	InaF motif containing 1	19	47274453-47275707	Predicted intracellular proteins	Evidence at transcript level	HPA064015	Uncertain				Colorectal cancer:3.20e-5 (unfavourable), Renal cancer:3.04e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 23.3	Expressed in all		
CNPY2	Cnpy2, HP10390, TMEM4, ZSIG9	ENSG00000257727	Canopy FGF signaling regulator 2	12	56309842-56316336	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038465, HPA038466	Supported		Supported	Cytosol	Renal cancer:2.32e-8 (unfavourable), Pancreatic cancer:8.37e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 87.4	Expressed in all		
MGAM2		ENSG00000257743	Maltase-glucoamylase 2 (putative)	7	142111749-142222324	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA055697	Enhanced		Approved	Vesicles<br>Cytosol		Group enriched	Group enriched	5	duodenum: 11.8;small intestine: 10.4	salivary gland: 2.1	Cell line enriched	7	RH-30: 1.1
RP11-162P23.2		ENSG00000257767		12	111753890-111791418	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		adipose tissue: 63.9	stomach: 16.0	Cell line enhanced		BEWO: 8.7;EFO-21: 16.7
RP11-571M6.15		ENSG00000257921		12	57773028-57787046	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			lymph node,prostate: 0.1	Cell line enhanced		RH-30: 1.2
CUX1	CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6	ENSG00000257923	Cut like homeobox 1	7	101815904-102283957	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA003277, HPA003317	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.72e-7 (favourable), Glioma:9.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.5	Expressed in all		
TEN1	C17orf106, FLJ39785	ENSG00000257949	TEN1, CST complex subunit	17	75979220-76000586	Predicted intracellular proteins	Evidence at protein level							Not detected	Expressed in all			skin: 29.9	Expressed in all		
LINC00935		ENSG00000257987	Long intergenic non-protein coding RNA 935	12	48727435-48765786	Predicted intracellular proteins	Evidence at transcript level							Group enriched	Tissue enriched	23	testis: 22.3	stomach: 0.9	Not detected		
OR9A4		ENSG00000258083	Olfactory receptor family 9 subfamily A member 4	7	141918817-141919909	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Cell line enriched	7	U-937: 1.0
MAP1LC3B2	ATG8G	ENSG00000258102	Microtubule associated protein 1 light chain 3 beta 2	12	116548105-116576448	Predicted intracellular proteins	Evidence at transcript level	HPA052474, HPA052484, HPA053767	Uncertain					Mixed	Mixed			adrenal gland: 2.7	Cell line enhanced		SK-MEL-30: 5.6
RP11-347C12.3		ENSG00000258130		16	30204316-30209071	Predicted intracellular proteins	Evidence at transcript level	HPA053608	Uncertain					Not detected	Tissue enhanced		testis: 9.8	salivary gland: 3.8	Group enriched	5	A549: 8.7;CAPAN-2: 31.1;SK-BR-3: 22.1
RP11-345J4.3		ENSG00000258150		16	29464967-29467833	Predicted intracellular proteins	Evidence at transcript level	HPA053608	Uncertain					Not detected	Tissue enhanced		testis: 7.0	gallbladder: 4.1	Group enriched	6	A549: 5.4;CAPAN-2: 23.5;SK-BR-3: 15.5
PRSS58	TRYX3	ENSG00000258223	Protease, serine 58	7	142252143-142258058	Enzymes, Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	123	testis: 21.1	cervix, uterine,smooth muscle: 0.1	Not detected		
CLEC5A	CLECSF5, MDL-1	ENSG00000258227	C-type lectin domain family 5 member A	7	141927357-141947007	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054137			Supported	Plasma membrane<br>Cytosol	Ovarian cancer:2.21e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 10.6;bone marrow: 27.4	lung: 4.9	Group enriched	29	HL-60: 33.0;U-937: 123.1
CHURC1	C14orf52, FLJ33064, My015	ENSG00000258289	Churchill domain containing 1	14	64914361-64944591	Predicted intracellular proteins	Evidence at protein level	HPA040072	Approved		Approved	Cytosol		Expressed in all	Expressed in all			smooth muscle: 70.4	Expressed in all		
RP11-644F5.10		ENSG00000258311		12	55716036-55724703	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			adipose tissue: 9.6	Cell line enhanced		U-87 MG: 11.2
C17orf49	BAP18, HEPIS, MGC49942	ENSG00000258315	Chromosome 17 open reading frame 49	17	7014495-7017525	Predicted intracellular proteins	Evidence at protein level	HPA022961, HPA024457	Supported		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Expressed in all			lymph node: 108.5	Expressed in all		
RTEL1	bK3184A7.3, C20orf41, DKFZP434C013, KIAA1088, NHL, RTEL	ENSG00000258366	Regulator of telomere elongation helicase 1	20	63657810-63696253	Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA020622, HPA067329, HPA078328			Approved	Nuclear speckles<br>Nuclear bodies		Not detected	Expressed in all			testis: 13.2	Expressed in all		
ZNF578	FLJ31384	ENSG00000258405	Zinc finger protein 578	19	52453576-52512154	Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enriched	Tissue enriched	5	testis: 14.0	thyroid gland: 2.6	Cell line enhanced		NTERA-2: 4.2;U-266/84: 6.8
RP11-240B13.2		ENSG00000258417		8	132024238-132085655	Predicted membrane proteins	No evidence							Not detected	Not detected			cerebral cortex,testis: 0.1	Not detected		
PDF		ENSG00000258429	Peptide deformylase (mitochondrial)	16	69328621-69330595	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA063409	Approved		Approved	Nucleoplasm<br>Mitochondria	Head and neck cancer:2.73e-4 (unfavourable), Cervical cancer:4.63e-4 (unfavourable), Renal cancer:6.11e-4 (favourable), Lung cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			kidney: 7.8	Expressed in all		
RNASE12	RAI1	ENSG00000258436	Ribonuclease A family member 12 (inactive)	14	20590193-20590823	Predicted secreted proteins	Evidence at protein level	HPA044175, HPA059465	Enhanced		Uncertain	Vesicles<br>Microtubules		Not detected	Tissue enriched	252	epididymis: 1052.1	seminal vesicle: 4.1	Not detected		
OR11H2	C14orf15, OR11H2P, OR11H8P	ENSG00000258453	Olfactory receptor family 11 subfamily H member 2	14	19712936-19713920	G-protein coupled receptors, Predicted membrane proteins	No evidence	HPA047370	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-574F21.3		ENSG00000258465		1	160217464-160285130	Predicted intracellular proteins	Evidence at protein level	HPA027218, HPA027381, HPA044837	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Mixed			heart muscle: 2.5	Cell line enhanced		EFO-21: 3.9;HDLM-2: 3.7
RP11-1012A1.4		ENSG00000258466		14	67659820-67690367	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Not detected			appendix,gallbladder,urinary bladder: 0.5	Cell line enhanced		SK-BR-3: 1.0
RP11-192H23.4		ENSG00000258472		17	28455752-28614197	Predicted intracellular proteins	Evidence at protein level	HPA046590	Uncertain		Approved	Nucleoplasm<br>Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		cerebral cortex: 2.2	lung: 1.2	Cell line enhanced		A549: 2.3;PC-3: 1.1
SPESP1	SP-ESP	ENSG00000258484	Sperm equatorial segment protein 1	15	68818221-68946811	Predicted secreted proteins	Evidence at protein level	HPA045936, HPA051040	Enhanced					Expressed in all	Tissue enriched	7	testis: 128.4	placenta: 18.0	Cell line enhanced		BJ hTERT+ SV40 Large T+: 16.1;BJ hTERT+ SV40 Large T+ RasG12V: 17.7;HBF TERT88: 20.5;RPTEC TERT1: 19.6;SCLC-21H: 23.0;WM-115: 30.5
RP11-108O10.8		ENSG00000258529		11	111786286-111879425	Predicted membrane proteins	Evidence at protein level	HPA038575	Uncertain		Approved	Endoplasmic reticulum		Not detected	Tissue enhanced		testis: 1.7	skin: 0.9	Cell line enhanced		CACO-2: 2.3
TRIM6-TRIM34		ENSG00000258588	TRIM6-TRIM34 readthrough	11	5596725-5644398	Predicted intracellular proteins	Evidence at transcript level	HPA077996			Approved	Nucleoli<br>Centrosome		Not detected	Not detected			testis: 0.6	Cell line enriched	7	A549: 4.1
BCL2L2-PABPN1		ENSG00000258643	BCL2L2-PABPN1 readthrough	14	23306835-23325369	Cancer-related genes, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA000637	Approved	Approved				Mixed	Mixed			seminal vesicle: 29.3	Mixed		
SYNJ2BP-COX16		ENSG00000258644	SYNJ2BP-COX16 readthrough	14	70326064-70417074	Predicted intracellular proteins	Evidence at protein level	HPA000866, HPA062659	Approved	Supported	Enhanced	Mitochondria		Not detected	Tissue enhanced		testis: 39.7	skeletal muscle: 15.1	Mixed		
TRIM34	RNF21	ENSG00000258659	Tripartite motif containing 34	11	5619764-5644398	Predicted intracellular proteins	Evidence at protein level	HPA077996			Approved	Nucleoli<br>Centrosome		Not detected	Mixed			spleen: 18.5	Mixed		
CTC-260F20.3		ENSG00000258674		19	19516227-19536076	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			cerebral cortex: 4.6	Cell line enhanced		BEWO: 23.4
RP11-404P21.8		ENSG00000258691		14	96204844-96263929	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			esophagus,gallbladder: 1.4	Cell line enhanced		BJ hTERT+: 5.0;HaCaT: 2.5;U-87 MG: 3.9
C20orf141	dJ860F19.4	ENSG00000258713	Chromosome 20 open reading frame 141	20	2814987-2815833	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	105	testis: 97.0	placenta: 0.9	Group enriched	11	HDLM-2: 18.6;U-2197: 4.7
CTD-2135J3.4		ENSG00000258724		8	10725399-10839847	Predicted intracellular proteins	Evidence at protein level	HPA009065	Uncertain		Approved	Nuclear speckles<br>Golgi apparatus		Not detected	Not detected			adipose tissue,lung: 0.5	Cell line enhanced		HaCaT: 1.3
RP11-195F19.29		ENSG00000258728		9	34646645-34657113	Predicted intracellular proteins	No evidence							Not detected	Not detected			fallopian tube: 0.3	Not detected		
OR4C13		ENSG00000258817	Olfactory receptor family 4 subfamily C member 13	11	49952391-49953419	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RNASE4	RAB1	ENSG00000258818	Ribonuclease A family member 4	14	20684100-20701215	Plasma proteins, Predicted secreted proteins	Evidence at protein level						Liver cancer:9.62e-5 (favourable)	Tissue enhanced	Tissue enhanced		liver: 232.5	prostate: 117.7	Cell line enhanced		ASC diff: 59.9;ASC TERT1: 68.7;Hep G2: 89.2;HSkMC: 42.8
MC1R	MSH-R	ENSG00000258839	Melanocortin 1 receptor	16	89912119-89920977	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level						Pancreatic cancer:7.88e-4 (favourable)	Tissue enhanced	Tissue enhanced		testis: 13.7	skin: 6.9	Cell line enhanced		SK-MEL-30: 28.3
DUXA		ENSG00000258873	Double homeobox A	19	57154021-57167443	Predicted intracellular proteins, Transcription factors	No evidence	HPA059358	Uncertain					Not detected	Not detected			appendix,testis: 0.3	Not detected		
AC007040.11		ENSG00000258881		2	70939318-70995336	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 1.1	skin: 0.7	Cell line enhanced		U-2 OS: 2.3
CEP95	CCDC45, DKFZp667E1824	ENSG00000258890	Centrosomal protein 95	17	64506588-64542461	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA023654, HPA052426, HPA052428, HPA061371	Approved		Approved	Nucleoplasm<br>Vesicles<br>Mitotic spindle<br>Centrosome	Liver cancer:2.52e-5 (unfavourable), Renal cancer:5.76e-5 (unfavourable), Head and neck cancer:5.78e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 27.7	Expressed in all		
RP11-407N17.3		ENSG00000258941	CTAGE family member 5 isoform 8 precursor 	14	39233902-39350423	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922, HPA054066, HPA055459	Uncertain		Approved	Endoplasmic reticulum		Not detected	Tissue enhanced		duodenum: 23.9;liver: 22.8;parathyroid gland: 44.1;small intestine: 29.5	kidney: 19.0	Cell line enhanced		CAPAN-2: 17.3;EFO-21: 5.5;Hep G2: 8.5;RPTEC TERT1: 7.0
TUBB3	beta-4, CFEOM3, CFEOM3A, FEOM3	ENSG00000258947	Tubulin beta 3 class III	16	89921392-89938761	Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Approved					Mixed	Tissue enriched	6	cerebral cortex: 195.6	adrenal gland: 34.5	Cell line enhanced		SCLC-21H: 490.8
RP11-934B9.3		ENSG00000258973		14	24332310-24337382	Predicted intracellular proteins	Evidence at protein level	HPA055087	Uncertain					Not detected	Not detected			placenta,skin: 0.5	Not detected		
TMEM179	C14orf90, FLJ42486, TMEM179A	ENSG00000258986	Transmembrane protein 179	14	104474678-104605647	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters	Evidence at transcript level	HPA002942			Uncertain	Mitochondria		Mixed	Group enriched	8	adrenal gland: 14.6;cerebral cortex: 27.9	testis: 2.5	Cell line enhanced		NTERA-2: 8.5;SCLC-21H: 42.8;SH-SY5Y: 12.2
RP11-47I22.4		ENSG00000258989		14	61529128-61657964	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 12.7	Cell line enhanced		U-2 OS: 31.5
TSPY1	CT78, TSPY	ENSG00000258992	Testis specific protein, Y-linked 1	Y	9466955-9469748	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049384	Supported					Tissue enriched	Tissue enriched	84	testis: 8.3	all non-specific tissues: 0.0	Group enriched	298	U-266/70: 186.9;U-266/84: 172.0
TVP23C-CDRT4	FAM18B2-CDRT4	ENSG00000259024	TVP23C-CDRT4 readthrough	17	15436021-15563561	Predicted membrane proteins	Evidence at transcript level	HPA065603			Approved	Golgi apparatus		Not detected	Mixed			parathyroid gland: 11.8	Mixed		
FPGT-TNNI3K		ENSG00000259030	FPGT-TNNI3K readthrough	1	74198235-74543982	Predicted intracellular proteins	Evidence at protein level	HPA072331			Approved	Vesicles		Not detected	Mixed			heart muscle: 5.7	Cell line enhanced		SiHa: 3.3
RP11-14J7.7		ENSG00000259060	Probable ribonuclease 11 precursor 	14	20582892-20609795	Predicted secreted proteins	Evidence at transcript level							Not detected	Group enriched	34	epididymis: 5.4;testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-371E8.4		ENSG00000259066		14	93184973-93218586	Predicted intracellular proteins	No evidence							Not detected	Not detected			skeletal muscle: 0.2	Not detected		
POC1B-GALNT4		ENSG00000259075	POC1B-GALNT4 readthrough	12	89519408-89526262	Predicted intracellular proteins	Evidence at transcript level	HPA076116						Not detected	Mixed			appendix,gallbladder: 2.2	Cell line enhanced		AN3-CA: 10.0
NDUFC2-KCTD14		ENSG00000259112	NDUFC2-KCTD14 readthrough	11	78016971-78079865	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA038873, HPA056195	Approved		Supported	Mitochondria		Not detected	Tissue enhanced		duodenum: 5.0	stomach: 2.5	Cell line enhanced		CACO-2: 7.9;EFO-21: 7.0;U-2 OS: 12.0
SMIM6	C17orf110	ENSG00000259120	Small integral membrane protein 6	17	75646243-75647977	Predicted membrane proteins	Evidence at transcript level	HPA065721	Uncertain		Approved	Nucleus	Endometrial cancer:1.49e-4 (favourable), Urothelial cancer:1.64e-4 (favourable), Renal cancer:4.09e-4 (favourable)	Mixed	Tissue enhanced		fallopian tube: 40.3;stomach: 34.4	testis: 22.6	Cell line enhanced		A549: 10.7;EFO-21: 8.5;HEL: 6.1
RP11-298I3.5		ENSG00000259132		14	22946270-22982258	Predicted intracellular proteins	Evidence at protein level	HPA029803	Approved		Approved	Plasma membrane<br>Focal adhesion sites		Not detected	Mixed			skin: 9.3	Cell line enhanced		Hep G2: 29.1
RP11-903H12.5		ENSG00000259171		14	20684587-20700576	Predicted secreted proteins	Evidence at transcript level							Mixed	Mixed			ovary: 96.7	Cell line enhanced		ASC diff: 15.5;ASC TERT1: 33.6;Hep G2: 21.7;HSkMC: 15.5
ITGB3	CD61, GP3A, GPIIIa	ENSG00000259207	Integrin subunit beta 3	17	47253846-47311816	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027852	Supported					Group enriched	Tissue enhanced		thyroid gland: 95.6	smooth muscle: 36.8	Cell line enhanced		EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
SLC35G6	AMAC1L3, TMEM21B	ENSG00000259224	Solute carrier family 35 member G6	17	7481332-7483496	Predicted membrane proteins, Transporters	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 1.7	all non-specific tissues: 0.0	Not detected		
BUB1B-PAK6		ENSG00000259288	BUB1B-PAK6 readthrough	15	40217428-40276396	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA031124	Uncertain		Approved	Nucleus<br>Nucleoli fibrillar center<br>Cell Junctions		Not detected	Not detected			cerebral cortex: 0.1	Not detected		
ZHX1-C8orf76		ENSG00000259305	ZHX1-C8orf76 readthrough	8	123226189-123274284	Predicted intracellular proteins	Evidence at transcript level	HPA023708	Uncertain		Uncertain	Nucleoplasm<br>Cytosol		Mixed	Mixed			bone marrow: 5.3	Cell line enhanced		SK-BR-3: 19.4
CTD-2116N17.1		ENSG00000259316		15	64181180-64381510	Predicted intracellular proteins	Evidence at transcript level	HPA047929			Uncertain	Centrosome		Not detected	Tissue enhanced		lymph node: 31.6;tonsil: 21.4	bone marrow: 14.1	Cell line enhanced		HAP1: 299.5
INAFM2	LINC00984, OGU1	ENSG00000259330	InaF motif containing 2	15	40323664-40326715	Predicted membrane proteins	Evidence at transcript level						Renal cancer:1.88e-7 (unfavourable), Stomach cancer:5.01e-4 (unfavourable), Lung cancer:7.87e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 44.5	Expressed in all		
ST20-MTHFS		ENSG00000259332	ST20-MTHFS readthrough	15	79845150-79923754	Predicted intracellular proteins	Evidence at protein level	HPA008067	Uncertain					Not detected	Mixed			parathyroid gland: 15.1	Mixed		
RP11-468E2.6		ENSG00000259371		14	24120956-24131829	Predicted membrane proteins	No evidence							Not detected	Not detected			small intestine,testis: 0.5	Not detected		
GH1	GH, GH-N, GHN, hGH-N	ENSG00000259384	Growth hormone 1	17	63917200-63918838	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA043715	Supported					Not detected	Tissue enhanced		placenta: 1.2	duodenum: 0.6	Cell line enhanced		U-698: 1.8
TGIF2-C20orf24		ENSG00000259399	TGIF2-C20orf24 readthrough	20	36574553-36612384	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			appendix: 11.2	Mixed		
LINC01314		ENSG00000259417	Long intergenic non-protein coding RNA 1314	15	80195484-80252213	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enhanced		cerebral cortex: 5.7;epididymis: 6.6	liver: 4.8	Group enriched	7	SK-MEL-30: 1.2;WM-115: 4.7
THTPA	THTPASE	ENSG00000259431	Thiamine triphosphatase	14	23555988-23560271	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028876	Approved		Uncertain	Nucleus<br>Nucleoli	Renal cancer:1.70e-9 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 33.5	Expressed in all		
MRPL46	C15orf4, LIECG2, P2ECSL	ENSG00000259494	Mitochondrial ribosomal protein L46	15	88459476-88467419	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA050166	Uncertain		Supported	Nucleoplasm<br>Cell Junctions<br>Mitochondria	Renal cancer:2.09e-6 (favourable)	Expressed in all	Expressed in all			adrenal gland: 50.3	Expressed in all		
UBE2Q2L		ENSG00000259511	Ubiquitin conjugating enzyme E2 Q2 like	15	84172490-84182234	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 2.2	testis: 1.2	Cell line enhanced		K-562: 2.0;Karpas-707: 1.3
BLID	BRCC2	ENSG00000259571	BH3-like motif containing, cell death inducer	11	122115354-122116215	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		hTEC/SVTERT24-B: 1.0;LHCN-M2: 1.2;U-87 MG: 1.7
RP11-812E19.9		ENSG00000259680		16	33844784-33845229	Predicted secreted proteins	Evidence at transcript level						Head and neck cancer:6.96e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 23.0	urinary bladder: 12.1	Not detected		
RP11-20I23.3		ENSG00000259784		16	2513965-2527955	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 1.1;small intestine: 1.3	smooth muscle: 0.5	Cell line enhanced		REH: 1.4
SLC22A31		ENSG00000259803	Solute carrier family 22 member 31	16	89195761-89201664	Predicted membrane proteins	Evidence at transcript level							Group enriched	Tissue enriched	7	lung: 23.0	pancreas: 3.4	Cell line enhanced		BEWO: 33.0;Hep G2: 19.4;NB-4: 9.3;RPMI-8226: 11.9
LYPD8		ENSG00000259823	LY6/PLAUR domain containing 8	1	248718649-248755739	Predicted secreted proteins	Evidence at protein level							Tissue enriched	Group enriched	12	colon: 216.6;rectum: 141.8	appendix: 14.4	Not detected		
RP11-407P15.2		ENSG00000259916		2	94588522-94604573	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	13	adipose tissue: 7.6	kidney: 0.5	Cell line enriched	9	ASC diff: 1.3
RBM15B	HUMAGCGB, OTT3	ENSG00000259956	RNA binding motif protein 15B	3	51391268-51397908	Predicted intracellular proteins	Evidence at protein level	HPA036645, HPA058136	Approved		Enhanced	Nucleoplasm	Renal cancer:1.84e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 23.1	Expressed in all		
TGFBR3L		ENSG00000260001	Transforming growth factor beta receptor 3 like	19	7916145-7919097	Predicted membrane proteins	Evidence at protein level	HPA074356	Supported		Approved	Vesicles		Mixed	Tissue enhanced		duodenum: 1.7;small intestine: 1.8	kidney: 1.0	Cell line enhanced		PC-3: 3.7;REH: 9.0
RP11-315D16.2		ENSG00000260007		15	68184032-68229718	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			seminal vesicle,smooth muscle: 0.5	Cell line enhanced		BJ hTERT+: 1.3;HAP1: 1.7;HEK 293: 2.7
HOXB7	HOX2, HOX2C	ENSG00000260027	Homeobox B7	17	48607227-48633572	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049940	Uncertain		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Urothelial cancer:2.39e-4 (favourable)	Mixed	Tissue enriched	5	epididymis: 162.9	cervix, uterine: 32.1	Cell line enhanced		EFO-21: 76.4;SK-MEL-30: 62.0
SPDYE6		ENSG00000260097	Speedy/RINGO cell cycle regulator family member E6	7	102347206-102356444	Predicted intracellular proteins	Evidence at protein level	HPA051750	Approved					Mixed	Tissue enhanced		testis: 6.6	skin: 3.9	Mixed		
RP11-96O20.4		ENSG00000260170		15	45587351-45676314	Predicted intracellular proteins	Evidence at transcript level	HPA041589	Uncertain					Not detected	Not detected			colon: 0.7	Cell line enhanced		HBEC3-KT: 1.8;HDLM-2: 1.4
CCDC187	MGC50722	ENSG00000260220	Coiled-coil domain containing 187	9	136249971-136306901	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		fallopian tube: 12.2;testis: 14.7	epididymis: 3.4	Group enriched	6	RPMI-8226: 7.1;SCLC-21H: 3.6
FRRS1L	C9orf4, CG-6	ENSG00000260230	Ferric chelate reductase 1 like	9	109130293-109167291	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA071086	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 47.7	ovary: 14.2	Cell line enhanced		AF22: 1.6;SH-SY5Y: 4.3
PMF1-BGLAP		ENSG00000260238	PMF1-BGLAP readthrough	1	156212982-156243332	Predicted intracellular proteins	Evidence at protein level	HPA034583, HPA071854			Approved	Nucleoplasm<br>Vesicles	Liver cancer:1.50e-4 (unfavourable), Renal cancer:3.22e-4 (unfavourable)	Mixed	Mixed			fallopian tube: 8.2	Expressed in all		
RP11-20I23.1		ENSG00000260272		16	2496032-2520218	Predicted membrane proteins	Evidence at transcript level	HPA044712	Uncertain					Not detected	Not detected			cerebral cortex: 0.7	Cell line enhanced		HEK 293: 1.5;SCLC-21H: 1.9;SH-SY5Y: 1.9
C6orf229		ENSG00000260286	Chromosome 6 open reading frame 229	6	24797321-24798889	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	12	testis: 21.8	lung: 1.7	Not detected		
TBC1D3G		ENSG00000260287	TBC1 domain family member 3G	17	36323884-36334759	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Supported		Approved	Vesicles		Not detected	Tissue enriched	33	testis: 6.1	duodenum: 0.1	Cell line enhanced		SiHa: 1.4
RP11-505K9.4		ENSG00000260300		16	83908132-83951445	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			heart muscle: 2.7	Mixed		
MRC1	bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1	ENSG00000260314	Mannose receptor C-type 1	10	17809344-17911170	CD markers, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA004114, HPA045134, CAB068203	Enhanced					Expressed in all	Tissue enhanced		lung: 179.9	placenta: 77.6	Group enriched	22	MOLT-4: 15.4;TIME: 14.0
HSPB9	CT51	ENSG00000260325	Heat shock protein family B (small) member 9	17	42121431-42123352	Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enriched	14	testis: 6.7	appendix,liver,ovary: 0.4	Mixed		
RP11-1035H13.3		ENSG00000260342		16	18788063-18801519	Predicted membrane proteins	Evidence at transcript level	HPA045307	Uncertain		Approved	Endoplasmic reticulum		Mixed	Tissue enhanced		testis: 25.8	cerebral cortex: 7.0	Cell line enhanced		HDLM-2: 82.4
RP11-343C2.9		ENSG00000260371		16	69335091-69356306	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 2.1	Mixed		
SCX	bHLHa41, bHLHa48, SCXA, SCXB	ENSG00000260428	Scleraxis bHLH transcription factor	8	144266560-144268481	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA043183	Uncertain				Glioma:2.46e-4 (unfavourable)	Group enriched	Tissue enhanced		skeletal muscle: 5.3	parathyroid gland: 2.9	Cell line enhanced		BEWO: 4.9;HaCaT: 5.0
C16orf95		ENSG00000260456	Chromosome 16 open reading frame 95	16	87083562-87317420	Predicted intracellular proteins	Evidence at protein level	HPA040850, HPA067924	Supported		Approved	Endoplasmic reticulum		Mixed	Tissue enriched	24	testis: 80.4	cerebral cortex: 3.2	Mixed		
KCNJ18	KIR2.6, TTPP2	ENSG00000260458	Potassium voltage-gated channel subfamily J member 18	17	21692523-21704612	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA027021	Uncertain		Uncertain	Nucleoplasm<br>Golgi apparatus<br>Cytosol		Tissue enhanced	Group enriched	8	skin: 3.8;tonsil: 1.3	testis: 0.3	Not detected		
RP11-529K1.3		ENSG00000260537		16	70299194-70372582	Predicted intracellular proteins	Evidence at protein level	HPA046380, HPA066668	Approved		Uncertain	Nucleoplasm		Not detected	Mixed			urinary bladder: 7.1	Mixed		
RP6-24A23.6		ENSG00000260548		X	108722070-108732687	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 12.9;thyroid gland: 12.5	endometrium: 5.6	Cell line enhanced		HEK 293: 15.4;NTERA-2: 2.4;RT4: 3.5;WM-115: 4.3
DUX4		ENSG00000260596	Double homeobox 4	4	190173774-190185942	Disease related genes, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	HPA058451			Supported	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol		Not detected	Tissue enhanced		testis: 1.4	prostate: 0.4	Cell line enhanced		A549: 1.3;U-2 OS: 2.2;U-266/70: 3.6;U-266/84: 4.6
RP11-303E16.8		ENSG00000260643		16	81053587-81096296	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA041368	Approved		Approved	Vesicles		Mixed	Tissue enhanced		thyroid gland: 17.3	cerebral cortex: 11.3	Mixed		
ANKRD20A1	ANKRD20A, DKFZp434A171	ENSG00000260691	Ankyrin repeat domain 20 family member A1	9	67859147-67902094	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Tissue enriched	7	testis: 5.2	cerebral cortex,spleen: 0.7	Cell line enhanced		Karpas-707: 3.2;U-266/70: 5.6;U-266/84: 1.9
RP11-510M2.4		ENSG00000260734		16	71430262-71433376	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	18	testis: 1.8	all non-specific tissues: 0.0	Not detected		
LINC00890		ENSG00000260802	Long intergenic non-protein coding RNA 890	X	111511662-111522399	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		endometrium: 44.1;epididymis: 51.0;seminal vesicle: 107.2	prostate: 15.9	Cell line enhanced		HMC-1: 14.8;NTERA-2: 2.9;SCLC-21H: 3.3
RP11-152F13.10		ENSG00000260836		15	82540032-82555932	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex,parathyroid gland: 0.2	Cell line enriched	26	U-2197: 19.4
RP4-576H24.4		ENSG00000260861		20	1540144-1620009	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enhanced		appendix: 3.3;cerebral cortex: 4.5	testis: 2.5	Cell line enhanced		HL-60: 2.6;HMC-1: 5.9;NB-4: 1.4;THP-1: 1.8;U-937: 1.5
AC002310.13		ENSG00000260869		16	30534227-30558279	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adipose tissue,colon,duodenum,small intestine,spleen: 0.5	Cell line enhanced		A549: 1.2
XKR7	C20orf159, dJ310O13.4	ENSG00000260903	XK related 7	20	31968002-32003387	Predicted membrane proteins	Evidence at protein level	HPA040854	Uncertain					Not detected	Tissue enriched	10	cerebral cortex: 3.6	adrenal gland,testis: 0.3	Group enriched	18	SCLC-21H: 24.2;SH-SY5Y: 4.9
RP11-343C2.11		ENSG00000260914		16	69299682-69322700	Predicted intracellular proteins	Evidence at protein level	HPA060092			Uncertain	Midbody		Not detected	Expressed in all			cerebral cortex: 85.3	Expressed in all		
CCPG1	CPR8, KIAA1254	ENSG00000260916	Cell cycle progression 1	15	55340032-55408510	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA009432, HPA026861	Approved		Approved	Endoplasmic reticulum<br>Golgi apparatus	Stomach cancer:5.02e-5 (unfavourable), Renal cancer:5.07e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 140.4	Cell line enhanced		Karpas-707: 242.3
SULT1A3	STM, TL-PST	ENSG00000261052	Sulfotransferase family 1A member 3	16	30199228-30204310	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA049500, HPA051051	Supported					Not detected	Expressed in all			duodenum: 106.1	Expressed in all		
TMEM178B	DKFZp547G036	ENSG00000261115	Transmembrane protein 178B	7	141074232-141480380	Predicted membrane proteins	Evidence at protein level	HPA048771	Uncertain		Uncertain	Nucleoli<br>Vesicles	Renal cancer:4.10e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 19.3;parathyroid gland: 28.9;thyroid gland: 14.4	heart muscle: 7.2	Cell line enhanced		HAP1: 6.3;RPTEC TERT1: 6.3;SCLC-21H: 7.7;WM-115: 8.9
RP11-1021N1.1		ENSG00000261130		16	15395754-15515348	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
EPPK1	EPIPL1	ENSG00000261150	Epiplakin 1	8	143857324-143878464	Predicted intracellular proteins	Evidence at protein level	HPA066808, HPA067357, HPA069333	Approved		Enhanced	Intermediate filaments	Endometrial cancer:5.52e-5 (unfavourable), Pancreatic cancer:3.94e-4 (unfavourable)	Mixed	Tissue enhanced		skin: 11.2	small intestine: 2.9	Cell line enhanced		BEWO: 13.8;EFO-21: 12.5;HaCaT: 12.0;HeLa: 15.1;MCF7: 15.3
CLEC19A		ENSG00000261210	C-type lectin domain family 19 member A	16	19285739-19322145	Predicted secreted proteins	Evidence at transcript level							Not detected	Tissue enriched	8	cerebral cortex: 3.2	skin: 0.4	Not detected		
ZNF865		ENSG00000261221	Zinc finger protein 865	19	55605405-55617269	Predicted intracellular proteins	Evidence at protein level	HPA068079	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			skeletal muscle: 8.4	Expressed in all		
BOP1	KIAA0124	ENSG00000261236	Block of proliferation 1	8	144262102-144291370	Predicted intracellular proteins	Evidence at protein level	HPA047869, HPA066764	Approved		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.23e-7 (unfavourable), Liver cancer:3.35e-5 (unfavourable)	Expressed in all	Expressed in all			appendix: 24.4	Expressed in all		
GOLGA8T		ENSG00000261247	Golgin A8 family member T	15	30135149-30145567	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
MUC22	PBMUCL1	ENSG00000261272	Mucin 22	6	31010474-31035402	Predicted membrane proteins	Evidence at protein level							Not detected	Tissue enriched	116	esophagus: 20.2	testis,tonsil: 0.1	Not detected		
FIGNL2		ENSG00000261308	Fidgetin like 2	12	51817840-51848766	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		kidney: 2.3;parathyroid gland: 2.4	placenta: 1.1	Cell line enhanced		AF22: 17.1;BEWO: 10.8;NTERA-2: 6.9
CTD-2568A17.1		ENSG00000261341		19	50776141-50793142	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	11	testis: 108.1	skin: 9.5	Cell line enhanced		AF22: 4.0;HEK 293: 5.0
PECAM1	CD31	ENSG00000261371	Platelet and endothelial cell adhesion molecule 1	17	64319415-64413776	Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004690	Supported				Renal cancer:8.98e-5 (unfavourable)	Expressed in all	Expressed in all			placenta: 659.7	Cell line enhanced		HUVEC TERT2: 644.6;TIME: 437.4
TEN1-CDK3		ENSG00000261408	TEN1-CDK3 readthrough (NMD candidate)	17	75979231-76005999	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		small intestine: 1.4	adipose tissue,spleen: 1.1	Cell line enhanced		BEWO: 2.6;SH-SY5Y: 3.9
TUBB8	bA631M21.2	ENSG00000261456	Tubulin beta 8 class VIII	10	46892-74163	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA043640, HPA046280	Uncertain					Tissue enriched	Tissue enhanced		testis: 1.0	parathyroid gland: 0.8	Cell line enhanced		MCF7: 1.1
TP53TG3B		ENSG00000261509	TP53 target 3B	16	33360274-33363478	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	18	epididymis: 22.3	testis: 1.2	Not detected		
TMEM249	C8orfK29	ENSG00000261587	Transmembrane protein 249	8	144352219-144354914	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	27	testis: 9.3	epididymis: 0.3	Mixed		
TPBGL		ENSG00000261594	Trophoblast glycoprotein-like	11	75240905-75243697	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 3.1;testis: 5.0	adrenal gland: 2.3	Cell line enhanced		AF22: 1.5;HMC-1: 1.7;SCLC-21H: 2.2
PRSS46	TESSP6	ENSG00000261603	Protease, serine 46	3	46719583-46736429	Enzymes, Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		epididymis: 4.5;testis: 8.4	parathyroid gland: 2.7	Not detected		
GAN	GAN1, KLHL16	ENSG00000261609	Gigaxonin	16	81314952-81390884	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011825, HPA049473	Approved		Supported	Microtubules		Mixed	Tissue enriched	6	skin: 29.5	cerebral cortex: 5.0	Mixed		
GOLGA6L7P	GOLGA6L7	ENSG00000261649	Golgin A6 family-like 7, pseudogene	15	28841833-28848675	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	53	testis: 25.5	cerebral cortex: 0.4	Not detected		
C15orf65	FLJ27352	ENSG00000261652	Chromosome 15 open reading frame 65	15	55408548-55418764	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA067189	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.18e-7 (favourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
LY6L		ENSG00000261667	Lymphocyte antigen 6 family member L	8	143080457-143083001	Predicted secreted proteins	Evidence at transcript level							Tissue enriched	Tissue enhanced		epididymis: 1.1	seminal vesicle: 0.7	Not detected		
SCRT1	DKFZp547F072, ZNF898	ENSG00000261678	Scratch family transcriptional repressor 1	8	144330565-144336281	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA045265	Uncertain		Supported	Nuclear bodies		Tissue enhanced	Tissue enriched	7	cerebral cortex: 10.9	adrenal gland: 1.5	Group enriched	12	SCLC-21H: 11.4;SH-SY5Y: 2.3
HPR		ENSG00000261701	Haptoglobin-related protein	16	72063224-72077246	Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA047750	Supported		Approved	Vesicles		Tissue enriched	Tissue enriched	24	liver: 444.1	heart muscle: 18.7	Cell line enriched	14	Hep G2: 34.3
RP11-77K12.1		ENSG00000261717		16	75412684-75464706	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA041316, HPA055071	Uncertain					Not detected	Not detected			testis: 0.8	Cell line enhanced		REH: 4.3;U-698: 13.9
GOLGA8S		ENSG00000261739	Golgin A8 family member S	15	23354748-23367231	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
RP11-345J4.5		ENSG00000261740	BOLA2-SMG1P6 protein isoform a 	16	29443230-29454651	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			lymph node: 17.7	Expressed in all		
TCF24	bHLHa25	ENSG00000261787	Transcription factor 24	8	66946501-66962590	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.2;testis: 2.8	fallopian tube: 0.7	Cell line enhanced		HAP1: 2.2;HEK 293: 5.0;HMC-1: 4.1
RP11-350O14.18		ENSG00000261793		9	137168854-137171984	Predicted secreted proteins	Evidence at transcript level							Not detected	Group enriched	7	prostate: 17.4;salivary gland: 23.0	small intestine: 2.8	Cell line enhanced		REH: 9.4;RPMI-8226: 11.9;SK-BR-3: 8.3;T-47d: 6.0
GOLGA8H	GOLGA6L11	ENSG00000261794	Golgin A8 family member H	15	30604126-30614561	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 8.5	fallopian tube,thyroid gland: 1.8	Cell line enhanced		HMC-1: 2.5;RH-30: 3.9;SH-SY5Y: 2.4
ISY1-RAB43		ENSG00000261796	ISY1-RAB43 readthrough	3	129087575-129161036	Predicted intracellular proteins	Evidence at protein level	HPA006312, HPA016995	Approved		Enhanced	Nuclear speckles		Not detected	Expressed in all			parathyroid gland: 14.1	Mixed		
RP11-435I10.4		ENSG00000261832		16	28456371-28492098	Predicted membrane proteins	Evidence at protein level	HPA053611	Uncertain		Approved	Nucleoplasm		Not detected	Not detected			smooth muscle: 0.1	Not detected		
MIA	CD-RAP	ENSG00000261857	Melanoma inhibitory activity	19	40771648-40777490	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA031950, HPA042369	Supported	Supported			Breast cancer:2.08e-4 (favourable)	Tissue enriched	Tissue enhanced		breast: 62.9;stomach: 50.0	salivary gland: 18.4	Group enriched	41	AN3-CA: 79.3;CAPAN-2: 63.4;SK-MEL-30: 198.0;WM-115: 233.6
RP11-515E23.1		ENSG00000261873		17	55448433-55511444	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 2.5	bone marrow,cerebral cortex,spleen: 0.1	Not detected		
PCDHGA9	PCDH-GAMMA-A9	ENSG00000261934	Protocadherin gamma subfamily A, 9	5	141402932-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Tissue enhanced	Tissue enhanced		cerebral cortex: 9.6	endometrium: 4.1	Cell line enhanced		EFO-21: 3.4;TIME: 3.7;U-87 MG: 5.0
GFY	Goofy	ENSG00000261949	Golgi associated olfactory signaling regulator	19	49423749-49428818	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 1.0	cerebral cortex: 0.2	Group enriched	6	HEK 293: 1.7;SCLC-21H: 5.3;T-47d: 1.1;U-266/84: 2.0
RP11-81A22.5		ENSG00000262165		17	4801159-4807013	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			ovary: 3.1	Cell line enhanced		AN3-CA: 3.1;SCLC-21H: 12.1
RP1-302G2.5		ENSG00000262179	Homo sapiens uncharacterized LOC101929726 (LOC101929726), transcript variant 2, mRNA.	6	44216939-44218236	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		adipose tissue: 5.7	stomach: 2.0	Cell line enriched	31	RH-30: 132.6
OCLM		ENSG00000262180	Oculomedin	1	186400572-186401455	Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			epididymis: 2.4	Mixed		
PCDHGB3	PCDH-GAMMA-B3	ENSG00000262209	Protocadherin gamma subfamily B, 3	5	141370264-141512979	Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580, HPA035823	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			endometrium: 1.5	Cell line enhanced		ASC diff: 7.2;ASC TERT1: 5.9;TIME: 4.5
CORO7	FLJ22021	ENSG00000262246	Coronin 7	16	4354542-4425705	Predicted intracellular proteins	Evidence at protein level	HPA041657, HPA053586	Uncertain				Endometrial cancer:4.25e-4 (favourable), Cervical cancer:8.68e-4 (favourable)	Expressed in all	Mixed			bone marrow: 24.5	Cell line enhanced		RPMI-8226: 52.3
MMP12	HME	ENSG00000262406	Matrix metallopeptidase 12	11	102862736-102875034	Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins	Evidence at protein level						Liver cancer:1.42e-4 (unfavourable)	Expressed in all	Tissue enhanced		appendix: 54.6;urinary bladder: 28.7	tonsil: 17.3	Group enriched	11	BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
CCER2		ENSG00000262484	Coiled-coil glutamate rich protein 2	19	38908980-38912158	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA069716	Uncertain				Urothelial cancer:2.32e-4 (favourable)	Mixed	Tissue enhanced		skin: 3.3	testis: 1.2	Mixed		
RP3-422G23.4		ENSG00000262543		6	138377905-138383075	Predicted membrane proteins	No evidence							Not detected	Not detected			appendix,rectum: 0.8	Not detected		
PCDHGA4	PCDH-GAMMA-A4	ENSG00000262576	Protocadherin gamma subfamily A, 4	5	141355025-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Mixed			cerebral cortex: 5.7	Cell line enhanced		ASC TERT1: 5.2;U-87 MG: 5.9
LA16c-306E5.2		ENSG00000262621		16	3365099-3479550	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			appendix,endometrium: 1.0	Mixed		
OR1D5	OR17-31	ENSG00000262628	Olfactory receptor family 1 subfamily D member 5	17	3062669-3063607	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
SPON1	f-spondin, KIAA0762	ENSG00000262655	Spondin 1	11	13962689-14267884	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA038584, HPA077546	Approved		Approved	Nucleus<br>Nucleoli<br>Actin filaments<br>Microtubule ends<br>Cytokinetic bridge	Urothelial cancer:1.88e-4 (unfavourable), Renal cancer:3.12e-4 (favourable)	Expressed in all	Tissue enhanced		gallbladder: 167.6	fallopian tube: 104.8	Group enriched	39	EFO-21: 209.9;RPTEC TERT1: 476.8
RP13-1032I1.10		ENSG00000262660		17	81703371-81720539	Predicted intracellular proteins	Evidence at protein level	HPA022853, HPA023043, HPA023048	Approved		Enhanced	Mitochondria		Not detected	Tissue enhanced		duodenum: 2.1	cerebral cortex: 1.1	Cell line enhanced		MOLT-4: 14.1
OVCA2		ENSG00000262664	Ovarian tumor suppressor candidate 2	17	2041936-2043430	Predicted intracellular proteins	Evidence at protein level	HPA059002			Supported	Nucleoplasm<br>Cytosol		Not detected	Expressed in all			gallbladder: 34.2	Expressed in all		
MRPL12	MRPL7, MRPL7/L12, RPML12	ENSG00000262814	Mitochondrial ribosomal protein L12	17	81703357-81707526	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA022853, HPA023043	Supported		Supported	Mitochondria	Lung cancer:2.35e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 57.4	Expressed in all		
C19orf84		ENSG00000262874	Chromosome 19 open reading frame 84	19	51388289-51390574	Predicted intracellular proteins	Evidence at transcript level	HPA068082	Uncertain					Tissue enhanced	Tissue enriched	54	testis: 24.6	bone marrow: 0.4	Cell line enriched	7	K-562: 6.2
FAM58A	FLJ21610, MGC29729	ENSG00000262919	Family with sequence similarity 58 member A	X	153587919-153600045	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050137, HPA059843	Uncertain		Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			epididymis: 15.4	Expressed in all		
GTF2I	BAP-135, BTKAP1, DIWS, IB291, SPIN, TFII-I, WBSCR6	ENSG00000263001	General transcription factor IIi	7	74657667-74760692	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004595, HPA026638	Supported		Enhanced	Nucleoplasm	Renal cancer:6.35e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 232.3	Expressed in all		
ZNF234	HZF4, ZNF269	ENSG00000263002	Zinc finger protein 234	19	44141557-44160309	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001664	Approved		Approved	Nuclear bodies	Urothelial cancer:4.34e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 9.1	Mixed		
XXbac-BPG32J3.22		ENSG00000263020		6	31666102-31673546	Predicted intracellular proteins	Evidence at protein level	HPA005944, HPA048307	Uncertain					Not detected	Tissue enriched	20	bone marrow: 6.6	cerebral cortex: 0.3	Mixed		
MYZAP	GCOM1, Gup, Gup1, MYOZAP	ENSG00000263155	Myocardial zonula adherens protein	15	57591941-57685364	Predicted intracellular proteins	Evidence at protein level	HPA039827	Approved					Mixed	Tissue enhanced		heart muscle: 388.5	placenta: 84.1	Cell line enhanced		HEL: 121.1;HUVEC TERT2: 24.2;TIME: 25.5
CTC-479C5.6		ENSG00000263201		16	68013436-68015911	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	8	placenta: 1.2;testis: 3.1	bone marrow: 0.2	Not detected		
CTB-133G6.1		ENSG00000263264		19	7348943-7383385	Predicted membrane proteins	Evidence at protein level	HPA049151	Uncertain					Mixed	Tissue enhanced		lymph node: 22.3;spleen: 16.5	appendix: 15.3	Cell line enhanced		Daudi: 38.3;HL-60: 18.6;MOLT-4: 18.2;REH: 18.9;THP-1: 15.0;U-698: 23.8;U-937: 14.2
PPIAL4A	COAS2, PPIAL4, PPIAL4B	ENSG00000263353	Peptidylprolyl isomerase A like 4A	1	120889746-120890405	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058345	Uncertain					Not detected	Not detected			cerebral cortex: 0.4	Mixed		
LINC00675		ENSG00000263429	Long intergenic non-protein coding RNA 675	17	10794913-10804099	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		colon: 36.9;rectum: 40.8;stomach: 44.3	duodenum,small intestine: 18.3	Cell line enriched	8	RT4: 3.2
PPIAL4C		ENSG00000263464	Peptidylprolyl isomerase A like 4C	1	149583865-149584464	Enzymes, Predicted intracellular proteins	Evidence at transcript level	HPA058345	Uncertain					Not detected	Mixed			duodenum: 3.9	Mixed		
SRSF8	SFRS2B, SRP46	ENSG00000263465	Serine and arginine rich splicing factor 8	11	95067197-95071224	Predicted intracellular proteins	Evidence at protein level	HPA049905	Supported		Supported	Nucleus<br>Cytosol	Renal cancer:9.99e-7 (favourable)	Expressed in all	Expressed in all			thyroid gland: 41.8	Mixed		
FAM72C	RP5-998N21.9	ENSG00000263513	Family with sequence similarity 72 member C	1	143955364-143971965	Predicted intracellular proteins	Evidence at transcript level	HPA043271, HPA067321	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		lymph node: 5.5;tonsil: 4.3	testis: 3.0	Mixed		
IKBKE	IKK-i, IKKE, KIAA0151	ENSG00000263528	Inhibitor of nuclear factor kappa B kinase subunit epsilon	1	206470476-206496889	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA015788, CAB025983	Approved		Supported	Cytosol	Renal cancer:5.34e-7 (unfavourable)	Expressed in all	Mixed			lymph node: 27.4	Mixed		
RP11-599B13.6		ENSG00000263620		17	8150816-8162975	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		colon: 5.2;spleen: 5.1;stomach: 4.5	adipose tissue: 3.8	Cell line enhanced		HDLM-2: 28.8;HEK 293: 11.5;REH: 14.0
MSMB	IGBF, MSP, MSPB, PN44, PRPS, PSP, PSP-94, PSP57, PSP94	ENSG00000263639	Microseminoprotein beta	10	46033307-46046269	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB026357, HPA051257	Enhanced				Urothelial cancer:7.19e-4 (favourable)	Tissue enriched	Tissue enriched	26	prostate: 15294.0	stomach: 588.5	Cell line enhanced		BEWO: 24.7;NB-4: 13.6;RPMI-8226: 7.7;SH-SY5Y: 6.3;U-2197: 11.3
LINC02210-CRHR1		ENSG00000263715	LINC02210-CRHR1 readthrough	17	45620344-45835826	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	9	cerebral cortex: 1.1	fallopian tube: 0.1	Not detected		
GDF2	BMP-9, BMP9	ENSG00000263761	Growth differentiation factor 2	10	47322490-47326270	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB023357	Uncertain					Not detected	Tissue enriched	61	liver: 11.3	placenta,testis: 0.1	Not detected		
LINC00672		ENSG00000263874	Long intergenic non-protein coding RNA 672	17	38925168-38929384	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	6	cerebral cortex: 20.1	endometrium: 3.3	Cell line enhanced		NTERA-2: 6.4
NBPF11	NBPF24	ENSG00000263956	Neuroblastoma breakpoint family member 11	1	148102046-148152322	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles	Urothelial cancer:3.20e-5 (favourable), Lung cancer:6.87e-4 (favourable)	Mixed	Expressed in all			epididymis: 20.8	Mixed		
C1orf186	FLJ16052	ENSG00000263961	Chromosome 1 open reading frame 186	1	206037231-206102459	Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cervix, uterine: 37.8	seminal vesicle: 28.9	Cell line enriched	7	HMC-1: 1374.2
ANXA8L1	ANXA8L2, bA145E20.2, bA301J7.3	ENSG00000264230	Annexin A8-like 1	10	46375627-46537864	Predicted intracellular proteins	Evidence at protein level	HPA045246, HPA047451			Approved	Nucleoplasm		Mixed	Group enriched	7	esophagus: 199.3;skin: 460.9	urinary bladder: 44.2	Cell line enhanced		HaCaT: 384.4;HBEC3-KT: 476.5;hTCEpi: 124.5;SiHa: 166.0
NOTCH2NL	N2N	ENSG00000264343	Notch 2 N-terminal like	1	146146203-146229026	Predicted intracellular proteins	Evidence at protein level	CAB004669	Approved					Not detected	Expressed in all			testis: 41.4	Expressed in all		
DYNLL2	Dlc2, DNCL1B, MGC17810, RSPH22	ENSG00000264364	Dynein light chain LC8-type 2	17	58083415-58095536	Predicted intracellular proteins	Evidence at protein level	HPA039954			Uncertain	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.12e-12 (favourable), Pancreatic cancer:5.26e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 95.0	Expressed in all		
MYH4	MYH2B, MyHC-2B, MyHC-IIb	ENSG00000264424	Myosin heavy chain 4	17	10443290-10469559	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001349	Supported					Tissue enriched	Tissue enriched	22	skeletal muscle: 3.6	testis: 0.1	Not detected		
OTUD7B	CEZANNE, ZA20D1	ENSG00000264522	OTU deubiquitinase 7B	1	149937812-150010676	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA027045	Supported		Approved	Nucleoplasm<br>Microtubules	Melanoma:5.09e-5 (favourable), Endometrial cancer:7.47e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 23.7	Mixed		
RP13-582O9.6		ENSG00000264668		8	143247110-143276403	Predicted intracellular proteins	Evidence at transcript level	HPA047232, HPA056268	Uncertain		Uncertain	Nucleus<br>Nucleoli		Not detected	Tissue enhanced		fallopian tube: 1.1	cerebral cortex: 0.7	Mixed		
CH17-360D5.1		ENSG00000264717		10	47918739-47923524	Predicted membrane proteins	Evidence at transcript level	HPA027863	Uncertain					Not detected	Tissue enhanced		colon: 3.0;rectum: 2.4	skin: 2.0	Cell line enriched	12	A549: 17.8
GJA5	CX40	ENSG00000265107	Gap junction protein alpha 5	1	147756199-147773362	Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB013080	Uncertain					Expressed in all	Tissue enhanced		placenta: 123.0	lung: 39.9	Cell line enriched	10	SK-BR-3: 100.3
CTD-2370N5.3		ENSG00000265118		17	31305213-31318831	Predicted membrane proteins, Predicted secreted proteins	Evidence at transcript level	HPA045033	Uncertain					Not detected	Tissue enhanced		appendix: 5.1	tonsil: 3.0	Cell line enhanced		MOLT-4: 5.4;RPMI-8226: 3.7
ANXA8	ANX8	ENSG00000265190	Annexin A8	10	47460162-47484158	Predicted intracellular proteins	Evidence at protein level	HPA045246, HPA047451			Approved	Nucleoplasm	Pancreatic cancer:2.68e-4 (unfavourable), Head and neck cancer:6.07e-4 (unfavourable)	Tissue enhanced	Tissue enhanced		esophagus: 229.1;skin: 368.9	urinary bladder: 64.2	Cell line enhanced		HaCaT: 409.1;HBEC3-KT: 486.4;hTCEpi: 269.3
RBP3	D10S64, D10S65, D10S66, RP66	ENSG00000265203	Retinol binding protein 3	10	47348371-47357875	Disease related genes, Enzymes, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA041301, HPA044239	Supported					Not detected	Not detected			duodenum: 0.4	Not detected		
RBM8A	BOV-1A, BOV-1B, BOV-1C, RBM8, RBM8B, Y14, ZNRP	ENSG00000265241	RNA binding motif protein 8A	1	145917714-145927678	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018403	Supported		Enhanced	Nuclear speckles	Prostate cancer:1.55e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 161.4	Expressed in all		
CTD-2510F5.6		ENSG00000265303		17	59197566-59215226	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			endometrium,lymph node: 0.6	Cell line enhanced		NB-4: 7.0;THP-1: 4.0
TIMM23	TIM23	ENSG00000265354	Translocase of inner mitochondrial membrane 23	10	45972449-46003734	Predicted membrane proteins	Evidence at protein level	HPA031408	Approved		Supported	Mitochondria	Liver cancer:2.77e-5 (unfavourable), Ovarian cancer:6.79e-4 (favourable)	Expressed in all	Expressed in all			testis: 142.2	Expressed in all		
RNF115	CL469780, ZNF364	ENSG00000265491	Ring finger protein 115	1	145738868-145824077	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA019130	Approved		Approved	Nucleoli<br>Mitochondria	Liver cancer:2.95e-4 (unfavourable)	Expressed in all	Mixed			heart muscle: 16.4	Expressed in all		
AP000275.65		ENSG00000265590		21	32578822-32612281	Predicted intracellular proteins	Evidence at transcript level	HPA019055, HPA028849	Approved	Supported				Not detected	Mixed			testis: 26.0	Mixed		
RPL17	L17, rpL23	ENSG00000265681	Ribosomal protein L17	18	49488453-49492523	Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043724, HPA046385	Supported		Supported	Endoplasmic reticulum<br>Cytosol	Liver cancer:3.60e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4394.8	Expressed in all		
ZNF488	FLJ32104	ENSG00000265763	Zinc finger protein 488	10	47365496-47384273	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA035957, HPA035958, HPA044867	Uncertain		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:4.02e-7 (unfavourable)	Mixed	Group enriched	7	cerebral cortex: 19.0;duodenum: 22.6;placenta: 4.8;small intestine: 12.1	epididymis,skin: 2.0	Cell line enhanced		HaCaT: 41.7;HDLM-2: 65.3;RT4: 30.6
SEC22B	ERS-24, sec22b, SEC22L1	ENSG00000265808	SEC22 homolog B, vesicle trafficking protein (gene/pseudogene)	1	120150898-120176515	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB079017		Approved			Renal cancer:3.34e-4 (unfavourable), Ovarian cancer:4.58e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 43.3	Expressed in all		
FSBP		ENSG00000265817	Fibrinogen silencer binding protein	8	94372170-94436952	Predicted intracellular proteins	Evidence at protein level	HPA025059, HPA026509	Approved		Supported	Nucleus		Not detected	Mixed			fallopian tube: 10.7	Mixed		
TXNIP	ARRDC6, EST01027, HHCPA78, THIF, VDUP1	ENSG00000265972	Thioredoxin interacting protein	1	145992435-145996600	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA031085, HPA053694	Approved		Approved	Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			adipose tissue: 1576.7	Cell line enhanced		ASC TERT1: 662.0;HSkMC: 921.1
SRGAP2	ARHGAP34, FNBP2, KIAA0456, SRGAP2A	ENSG00000266028	SLIT-ROBO Rho GTPase activating protein 2	1	206203345-206464443	Predicted intracellular proteins	Evidence at protein level	HPA028191, HPA028196	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.61e-7 (unfavourable), Liver cancer:9.61e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 55.9	Expressed in all		
BAHCC1	BAHD2, KIAA1447	ENSG00000266074	BAH domain and coiled-coil containing 1	17	81395475-81466332	Predicted intracellular proteins	Evidence at transcript level	HPA023386, HPA076910	Uncertain		Approved	Nucleoli	Pancreatic cancer:7.38e-4 (favourable)	Expressed in all	Mixed			cerebral cortex,gallbladder: 4.8	Cell line enhanced		NB-4: 68.5;REH: 30.1;SCLC-21H: 26.5
RP11-159D12.5		ENSG00000266086		17	57989038-58005253	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			skin: 17.9	Expressed in all		
RASSF5	Maxp1, NORE1, RAPL	ENSG00000266094	Ras association domain family member 5	1	206507530-206589448	Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA070480	Approved				Renal cancer:1.22e-6 (unfavourable), Cervical cancer:1.46e-4 (favourable)	Expressed in all	Mixed			spleen: 77.2	Cell line enhanced		HMC-1: 80.2;Karpas-707: 138.2;RPMI-8226: 150.4
STRADA	LYK5, NY-BR-96, Stlk, STRAD	ENSG00000266173	STE20-related kinase adaptor alpha	17	63682336-63741986	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA031637	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.08e-7 (unfavourable), Pancreatic cancer:5.34e-5 (favourable), Urothelial cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			testis: 67.7	Expressed in all		
RP1-66C13.4		ENSG00000266202		17	27798806-27893365	Predicted intracellular proteins	Evidence at transcript level	HPA023051	Uncertain					Not detected	Tissue enhanced		ovary: 1.1	cerebral cortex: 0.7	Not detected		
KLF14	BTEB5	ENSG00000266265	Kruppel like factor 14	7	130731235-130734061	Predicted intracellular proteins	Evidence at transcript level	HPA044729	Uncertain					Tissue enriched	Tissue enhanced		placenta: 1.2	adipose tissue: 0.7	Cell line enhanced		RH-30: 1.2
NBPF15	MGC8902, NBPF16	ENSG00000266338	Neuroblastoma breakpoint family member 15	1	144421386-144461674	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Renal cancer:4.11e-5 (unfavourable)	Expressed in all	Expressed in all			epididymis: 25.4	Mixed		
NCOA4	ARA70, DKFZp762E1112, ELE1, PTC3, RFG	ENSG00000266412	Nuclear receptor coactivator 4	10	46005088-46030714	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051260, HPA065208	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:8.04e-6 (favourable), Glioma:2.88e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 247.1	Expressed in all		
MRPS21		ENSG00000266472	Mitochondrial ribosomal protein S21	1	150293720-150308979	Predicted intracellular proteins	Evidence at protein level	HPA078289			Supported	Mitochondria	Liver cancer:2.62e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 73.9	Expressed in all		
GDF10	BMP-3b	ENSG00000266524	Growth differentiation factor 10	10	47300386-47313547	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA015498	Uncertain					Mixed	Tissue enhanced		lung: 19.6	testis: 9.0	Cell line enhanced		AF22: 14.6;MOLT-4: 2.6;SH-SY5Y: 6.4
MYO15B	MYO15BP	ENSG00000266714	Myosin XVB	17	75588058-75626501	Predicted intracellular proteins	Evidence at transcript level	HPA022857, HPA023105			Approved	Cytosol	Urothelial cancer:6.90e-5 (favourable), Breast cancer:9.34e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 148.3	Cell line enhanced		A549: 36.9;HMC-1: 21.7;THP-1: 24.6
TBC1D29	DKFZP434O047	ENSG00000266733	TBC1 domain family member 29	17	30557112-30563493	Predicted intracellular proteins	Evidence at transcript level	HPA059178	Uncertain					Not detected	Tissue enriched	11	testis: 10.6	epididymis: 0.9	Not detected		
CTD-2200P10.1		ENSG00000266826		17	58660424-58692018	Predicted intracellular proteins	Evidence at protein level	HPA000634, HPA001004	Uncertain		Approved	Microtubules		Not detected	Tissue enriched	33	testis: 13.5	placenta: 0.4	Not detected		
RP11-618P17.4		ENSG00000266953		19	34396315-34409364	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		skeletal muscle: 3.0	stomach: 0.7	Mixed		
FXYD1	PLM	ENSG00000266964	FXYD domain containing ion transport regulator 1	19	35138808-35143109	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA026873			Approved	Nucleus<br>Nucleoli<br>Cytosol	Renal cancer:7.59e-8 (unfavourable), Glioma:9.67e-4 (unfavourable)	Tissue enhanced	Expressed in all			skeletal muscle: 469.1	Cell line enhanced		ASC diff: 30.9;ASC TERT1: 9.1;HSkMC: 13.6
AARSD1	MGC2744	ENSG00000266967	Alanyl-tRNA synthetase domain containing 1	17	42950526-42964498	Predicted intracellular proteins	Evidence at protein level	HPA021408, HPA022869, HPA023714	Supported		Approved	Nuclear membrane<br>Cytosol	Renal cancer:1.67e-6 (unfavourable)	Expressed in all	Expressed in all			testis: 99.4	Expressed in all		
AC006538.4		ENSG00000267001		19	2717769-2740048	Predicted membrane proteins	Evidence at protein level	HPA058526	Uncertain					Not detected	Mixed			testis: 3.9	Mixed		
ZNF850	ZNF850P	ENSG00000267041	Zinc finger protein 850	19	36714383-36772825	Predicted intracellular proteins	Evidence at transcript level	HPA029299	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			testis: 4.7	Cell line enhanced		HEL: 13.4
PTGES3L		ENSG00000267060	Prostaglandin E synthase 3 like	17	42968088-42980433	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		heart muscle: 30.2;skeletal muscle: 58.7	smooth muscle: 16.3	Cell line enhanced		THP-1: 17.1
RP11-322E11.6		ENSG00000267140		18	35443871-35497940	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			fallopian tube: 5.3	Cell line enriched	58	HUVEC TERT2: 215.0
CTB-54O9.9		ENSG00000267157		19	5784005-5785619	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 1.0	Mixed		
RP11-318A15.7		ENSG00000267168		17	76732978-76738522	Predicted intracellular proteins	No evidence							Not detected	Not detected			bone marrow: 0.1	Not detected		
CTC-512J12.6		ENSG00000267173		19	44329695-44401608	Predicted intracellular proteins	No evidence							Not detected	Not detected			cervix, uterine: 0.5	Not detected		
CTD-2006C1.13		ENSG00000267179		19	11925075-11979290	Predicted intracellular proteins	No evidence	HPA047845	Uncertain		Uncertain	Nucleus		Not detected	Not detected			testis: 0.5	Not detected		
LCN6		ENSG00000267206	Lipocalin 6	9	136744011-136748528	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	234	epididymis: 1881.6	smooth muscle: 8.0	Group enriched	5	NB-4: 2.1;REH: 9.6
CTD-2132N18.2		ENSG00000267221		17	42038232-42050614	Predicted membrane proteins	Evidence at transcript level						Renal cancer:4.24e-7 (favourable)	Mixed	Mixed			fallopian tube: 2.6	Mixed		
CTD-2132N18.3		ENSG00000267261		17	42119674-42154916	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			appendix: 0.8	Cell line enhanced		MOLT-4: 2.9;REH: 2.3;U-87 MG: 2.2
RP11-793H13.10		ENSG00000267281		12	53506688-53625979	Predicted intracellular proteins	Evidence at transcript level	HPA003384	Uncertain		Approved	Nucleus<br>Cytosol		Mixed	Not detected			lung: 0.8	Cell line enhanced		A549: 1.1
RP11-178C3.1		ENSG00000267318		17	59940908-59973101	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 11.4	Cell line enhanced		U-266/84: 15.4
CTB-60B18.6		ENSG00000267335		19	49022953-49036895	Predicted intracellular proteins, Predicted secreted proteins	Evidence at transcript level	HPA038925	Uncertain		Approved	Cytosol		Not detected	Not detected			duodenum,testis: 0.7	Cell line enhanced		HMC-1: 3.7;U-251 MG: 5.2
CTC-454I21.3		ENSG00000267360		19	37093019-37210512	Predicted intracellular proteins	No evidence							Not detected	Not detected			cerebral cortex,thyroid gland: 0.8	Not detected		
UPK3BL	UPLP	ENSG00000267368	Uroplakin 3B-like	7	102637025-102642791	Predicted membrane proteins, Transporters	Evidence at protein level	HPA011403	Supported					Mixed	Expressed in all			esophagus: 138.6	Cell line enhanced		HaCaT: 109.3
APOC4		ENSG00000267467	Apolipoprotein C4	19	44942238-44945496	Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062671	Approved					Tissue enriched	Tissue enriched	124	liver: 347.3	testis: 2.8	Cell line enhanced		HEL: 1.5;SK-MEL-30: 2.0
ZNF285	ZNF285A	ENSG00000267508	Zinc finger protein 285	19	44382298-44401608	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046100, HPA049212	Uncertain					Mixed	Mixed			ovary: 7.9	Mixed		
S1PR2	AGR16, DFNB68, EDG5, Gpcr13, H218	ENSG00000267534	Sphingosine-1-phosphate receptor 2	19	10221435-10231272	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA014255, HPA014307	Approved		Uncertain	Nuclear speckles<br>Golgi apparatus	Renal cancer:4.36e-10 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 27.0	lymph node: 13.3	Cell line enhanced		Daudi: 38.8;U-698: 40.3;WM-115: 38.8
RP5-1052I5.2		ENSG00000267561		1	86993009-87169204	Predicted intracellular proteins	Evidence at protein level	HPA043069, HPA043603	Approved		Uncertain	Mitochondria		Not detected	Tissue enhanced		adipose tissue: 22.0	breast: 8.9	Cell line enhanced		ASC TERT1: 6.6;HEL: 13.2;HMC-1: 15.7;THP-1: 8.5
RAD51L3-RFFL		ENSG00000267618		17	35011349-35121493	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 4.2	cerebral cortex: 1.6	Cell line enhanced		A549: 3.6
CGB1		ENSG00000267631	Chorionic gonadotropin beta subunit 1	19	49035610-49036895	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038925, HPA038934	Supported		Approved	Cytosol		Not detected	Not detected			pancreas: 0.6	Cell line enriched	5	HMC-1: 16.3
FDX2	FDX1L, MGC19604	ENSG00000267673	Ferredoxin 2	19	10310045-10316015	Predicted intracellular proteins	Evidence at protein level	HPA043986	Approved					Expressed in all	Expressed in all			cerebral cortex: 47.4	Expressed in all		
ZNF224	BMZF-2, KOX22, ZNF255, ZNF27	ENSG00000267680	Zinc finger protein 224	19	44094339-44109886	Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA054045	Approved		Supported	Nucleus<br>Nuclear membrane	Urothelial cancer:1.53e-7 (favourable), Renal cancer:5.32e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 35.7	Expressed in all		
LUZP6	MPD6, MTPNUT	ENSG00000267697	Leucine zipper protein 6	7	135927274-135927450	Predicted intracellular proteins	Evidence at transcript level	HPA077907			Approved	Lipid droplets		Not detected	Not detected			skeletal muscle: 0.1	Cell line enhanced		MOLT-4: 8.4;SK-MEL-30: 15.0;U-2 OS: 2.4
AC006116.20		ENSG00000267710		19	56272769-56310450	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	699	epididymis: 120.3	ovary,thyroid gland: 0.1	Not detected		
AC024592.12		ENSG00000267740		19	5866171-5903787	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA072209			Uncertain	Mitochondria		Not detected	Mixed			adrenal gland: 1.5	Mixed		
CTB-102L5.4		ENSG00000267748		19	38289151-38304910	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		salivary gland: 5.5	thyroid gland: 2.9	Cell line enhanced		A-431: 2.2;SK-BR-3: 3.5;U-266/84: 1.9
SMIM22		ENSG00000267795	Small integral membrane protein 22	16	4788397-4796491	Predicted membrane proteins	Evidence at transcript level	HPA077331			Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			colon: 225.6	Group enriched	8	CAPAN-2: 277.9;RT4: 94.2;SCLC-21H: 95.4;SK-BR-3: 176.3
LIN37	F25965, lin-37, ZK418.4	ENSG00000267796	Lin-37 DREAM MuvB core complex component	19	35748361-35754519	Predicted intracellular proteins	Evidence at protein level	HPA043253, HPA047809	Uncertain		Supported	Nucleoplasm	Renal cancer:1.62e-6 (unfavourable), Pancreatic cancer:1.67e-4 (favourable)	Expressed in all	Expressed in all			ovary: 12.5	Expressed in all		
NDUFA7	B14.5a	ENSG00000267855	NADH:ubiquinone oxidoreductase subunit A7	19	8308768-8321396	Predicted intracellular proteins	Evidence at protein level	HPA059251, HPA071866	Enhanced		Supported	Mitochondria		Expressed in all	Expressed in all			heart muscle: 67.3	Expressed in all		
AC011513.3		ENSG00000267881		19	41708612-41761282	Predicted secreted proteins	Evidence at transcript level	HPA011041	Approved					Tissue enhanced	Group enriched	11	colon: 41.2;esophagus: 10.3	appendix: 2.4	Not detected		
CCDC177	C14orf162, PLPL	ENSG00000267909	Coiled-coil domain containing 177	14	69569816-69574837	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		cerebral cortex: 2.2	epididymis: 0.6	Cell line enhanced		SCLC-21H: 1.9
CTD-2207O23.12		ENSG00000267952		19	7507052-7519622	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 5.6;skeletal muscle: 4.6	kidney: 2.9	Cell line enhanced		AF22: 10.9;ASC diff: 8.4;fHDF/TERT166: 10.6;HBF TERT88: 6.7
MAGEA9B		ENSG00000267978	MAGE family member A9B	X	149581653-149587453	Predicted intracellular proteins	Evidence at protein level							Tissue enhanced	Tissue enriched	36	testis: 17.3	placenta: 0.4	Group enriched	15	RT4: 104.5;U-266/70: 42.1;U-266/84: 51.2
SSX4	CT5.4	ENSG00000268009	SSX family member 4	X	48383516-48393347	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 3.8	fallopian tube: 0.2	Group enriched	8	BEWO: 2.1;Karpas-707: 3.9;U-266/70: 2.4;U-266/84: 4.3
CTD-2575K13.6		ENSG00000268041		19	41907705-41928516	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		lymph node: 3.4	appendix: 1.7	Group enriched	5	Daudi: 4.5;HMC-1: 3.9;REH: 1.2;U-2 OS: 2.8;U-266/70: 1.8;U-698: 2.6;U-937: 2.1
NBPF12	COAS1, KIAA1245	ENSG00000268043	Neuroblastoma breakpoint family member 12	1	146938744-146996202	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles	Pancreatic cancer:9.01e-7 (favourable), Urothelial cancer:2.47e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 19.8	Expressed in all		
AC104534.3		ENSG00000268083		19	38817471-38840178	Predicted intracellular proteins	Evidence at protein level	HPA002907, HPA051748	Uncertain					Not detected	Not detected			lung: 0.9	Cell line enhanced		NB-4: 19.4
GABRQ	THETA	ENSG00000268089	Gamma-aminobutyric acid type A receptor theta subunit	X	152638183-152657534	FDA approved drug targets, Predicted membrane proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		cerebral cortex: 6.6;cervix, uterine: 12.9	adrenal gland: 3.0	Group enriched	7	HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
SLC6A14		ENSG00000268104	Solute carrier family 6 member 14	X	116436622-116461458	Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at transcript level	HPA003193	Uncertain		Approved	Vesicles	Pancreatic cancer:9.74e-4 (unfavourable)	Mixed	Tissue enhanced		cervix, uterine: 11.0;lung: 23.9	breast: 9.1	Cell line enhanced		HeLa: 1.0;Hep G2: 2.3
AC003002.4		ENSG00000268133		19	57363566-57398584	Predicted intracellular proteins	No evidence							Not detected	Not detected			adipose tissue,appendix: 0.2	Not detected		
AC004076.9		ENSG00000268163		19	57437970-57477536	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.0	Not detected		
SMIM17		ENSG00000268182	Small integral membrane protein 17	19	56643145-56655766	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA071857, HPA071861	Enhanced		Approved	Vesicles		Mixed	Tissue enhanced		cerebral cortex: 8.7	epididymis: 2.0	Cell line enhanced		AF22: 2.3;HEK 293: 2.1;SCLC-21H: 2.5
OPN1MW	CBBM, CBD, COD5, GCP, OPN1MW1	ENSG00000268221	Opsin 1, medium wave sensitive	X	154182596-154196135	Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Not detected			appendix: 0.1	Not detected		
ARL14EPL		ENSG00000268223	ADP ribosylation factor like GTPase 14 effector protein like	5	116032324-116060118	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.2	Cell line enriched	12	HDLM-2: 48.6
SCGB1C2		ENSG00000268320	Secretoglobin family 1C member 2	17	137526-139067	Predicted secreted proteins	No evidence							Tissue enhanced	Not detected			appendix,testis: 0.2	Not detected		
FAM156A	PRO0659, TMEM29	ENSG00000268350	Family with sequence similarity 156 member A	X	52926402-52995472	Predicted intracellular proteins	Evidence at protein level	HPA056640, HPA056643	Approved					Not detected	Expressed in all			skin: 63.1	Expressed in all		
L34079.2		ENSG00000268361		19	43554692-43593036	Predicted intracellular proteins	No evidence							Not detected	Not detected			parathyroid gland: 0.5	Not detected		
AC011530.4		ENSG00000268434		19	45779437-45785973	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.0	appendix: 0.9	Not detected		
SSX2B	CT5.2b	ENSG00000268447	SSX family member 2B	X	52751132-52790305	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	23	testis: 14.9	thyroid gland: 0.6	Cell line enhanced		HMC-1: 1.7;PC-3: 1.8;U-2197: 1.1
CTC-273B12.7		ENSG00000268465		19	48465837-48472431	Predicted intracellular proteins	Evidence at transcript level	HPA060662						Not detected	Tissue enhanced		colon: 1.1;endometrium: 1.3;testis: 2.8	small intestine: 0.6	Cell line enhanced		AN3-CA: 1.0;LHCN-M2: 1.1;U-698: 1.2
AC018755.18		ENSG00000268500		19	51612091-51646889	Predicted membrane proteins	Evidence at transcript level	HPA009085	Approved					Not detected	Tissue enhanced		appendix: 10.0;bone marrow: 17.4	spleen: 5.5	Group enriched	14	HMC-1: 68.6;U-937: 25.7
AC004076.7		ENSG00000268533		19	57394183-57438457	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			skin: 8.9	Cell line enhanced		SCLC-21H: 6.0
MAGEA2	CT1.2, MAGE2, MAGEA2A	ENSG00000268606	MAGE family member A2	X	152749863-152753884	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	54	testis: 6.9	cerebral cortex: 0.1	Cell line enhanced		HMC-1: 40.2;K-562: 58.6;SH-SY5Y: 52.5;SK-BR-3: 36.4;U-266/70: 92.1;U-266/84: 61.1
TEX13A		ENSG00000268629	Testis expressed 13A	X	105218929-105220674	Predicted intracellular proteins	Evidence at protein level	HPA072257	Enhanced					Not detected	Tissue enriched	79	testis: 7.9	all non-specific tissues: 0.0	Not detected		
AC006486.9		ENSG00000268643		19	42234583-42255132	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 7.8	endometrium: 5.1	Cell line enhanced		RT4: 21.6
CTAG1A	ESO1, LAGE2A	ENSG00000268651	Cancer/testis antigen 1A	X	154585143-154586821	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB013061	Enhanced					Not detected	Tissue enriched	37	testis: 4.6	spleen: 0.1	Group enriched	942	U-266/70: 511.5;U-266/84: 120.6
CTB-60B18.10		ENSG00000268655		19	49017496-49020523	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		pancreas: 1.7;testis: 1.3	stomach: 0.3	Cell line enhanced		HEK 293: 1.1
FAM231D		ENSG00000268674	Family with sequence similarity 231 member D	Unmapped	35407-35916	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
ARL14EPL		ENSG00000268714	ADP ribosylation factor like GTPase 14 effector protein like	5	116022391-116059130	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.6	Cell line enriched	54	HDLM-2: 119.0
HSFX2		ENSG00000268738	Heat shock transcription factor family, X-linked 2	X	149592515-149594716	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063040	Supported					Not detected	Tissue enriched	8	testis: 9.3	seminal vesicle: 1.1	Not detected		
CTD-2583A14.10		ENSG00000268750		19	57819719-57858941	Predicted intracellular proteins	Evidence at transcript level	HPA056213	Uncertain					Not detected	Mixed			duodenum: 4.9	Cell line enhanced		HEK 293: 25.5
CTC-429P9.4		ENSG00000268790		19	16577642-16660115	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			endometrium: 1.3	Cell line enhanced		T-47d: 3.0
CTD-2207O23.3		ENSG00000268861		19	7382834-7472477	Predicted intracellular proteins	Evidence at protein level	HPA042689, HPA071867	Supported		Uncertain	Cytosol		Not detected	Tissue enhanced		lymph node: 17.2	spleen: 11.9	Cell line enhanced		Daudi: 18.2;MOLT-4: 13.4;REH: 12.3;THP-1: 12.9
CTD-3105H18.16		ENSG00000268870		19	12391949-12441082	Predicted intracellular proteins	Evidence at protein level	HPA003150, HPA018683	Uncertain		Uncertain	Nucleoplasm<br>Microtubule organizing center		Not detected	Not detected			breast,placenta: 0.6	Cell line enhanced		RH-30: 4.0
CSAG2	CSAG3B, CT24.2, TRAG3	ENSG00000268902	CSAG family member 2	X	152708261-152714549	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Not detected			lymph node,testis: 0.9	Cell line enhanced		HMC-1: 13.5;SK-BR-3: 4.8;U-266/70: 3.9;U-266/84: 4.7
CSAG3	CSAG3A	ENSG00000268916	CSAG family member 3	X	152753921-152760222	Predicted intracellular proteins	Evidence at transcript level	HPA078264			Approved	Vesicles		Mixed	Group enriched	10	lymph node: 1.7;skin: 1.2;spleen: 1.9;testis: 4.2	adipose tissue,lung,placenta: 0.2	Cell line enhanced		HDLM-2: 23.7;HMC-1: 22.9;SH-SY5Y: 35.8;SK-BR-3: 23.6;U-2 OS: 25.4;U-266/70: 61.5;U-266/84: 30.6
CT45A1	CT45-1, CT45.1	ENSG00000268940	Cancer/testis antigen family 45 member A1	X	135713453-135723539	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	42	testis: 12.5	cerebral cortex,lung: 0.2	Group enriched	6	HMC-1: 202.8;Karpas-707: 77.5
ERVV-2		ENSG00000268964	Endogenous retrovirus group V member 2	19	53044738-53051076	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	101	placenta: 13.6	kidney,testis,thyroid gland: 0.1	Group enriched	5	BEWO: 18.5;T-47d: 5.1
SPANXN2	CT11.7, SPANX-N2	ENSG00000268988	SPANX family member N2	X	143711955-143721423	Predicted intracellular proteins	Evidence at protein level	HPA045652			Approved	Nucleus<br>Nucleoli fibrillar center		Not detected	Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
FAM231B		ENSG00000268991	Family with sequence similarity 231 member B	1	16539066-16539575	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.3	Not detected		
FAM236B		ENSG00000268994	Family with sequence similarity 236 member B	X	72781865-72782660	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	50	testis: 115.3	thyroid gland: 2.3	Not detected		
AC003006.7		ENSG00000269026		19	57682045-57753575	Predicted intracellular proteins	Evidence at transcript level	HPA068553			Approved	Nucleus		Not detected	Not detected			seminal vesicle: 0.2	Cell line enhanced		HL-60: 1.0;U-266/84: 1.4
MTRNR2L12		ENSG00000269028	MT-RNR2-like 12	3	96617188-96618236	Predicted intracellular proteins	Evidence at transcript level							Expressed in all	Expressed in all			heart muscle: 15284.0	Expressed in all		
CTD-2521M24.10		ENSG00000269035		19	17436611-17460804	Predicted membrane proteins	No evidence	HPA041580, HPA042010	Uncertain		Uncertain	Nuclear membrane		Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CALR3	CRT2, CT93, FLJ25355, MGC26577	ENSG00000269058	Calreticulin 3	19	16479057-16496192	Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB025749, HPA043355, HPA048460	Enhanced					Not detected	Tissue enriched	93	testis: 98.8	epididymis: 1.0	Not detected		
ZNF728		ENSG00000269067	Zinc finger protein 728	19	22975468-23003176	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	5	testis: 18.2	thyroid gland: 3.6	Cell line enriched	5	U-266/84: 2.1
AC010646.3		ENSG00000269095		19	17235940-17255448	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 1.4	Cell line enhanced		BEWO: 5.8;EFO-21: 1.6
CT45A3	CT45-3, CT45-4, CT45.3, CT45.4, CT45A4	ENSG00000269096	Cancer/testis antigen family 45 member A3	X	135759846-135768191	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 20.5	lung: 1.3	Group enriched	6	HMC-1: 108.1;T-47d: 68.5;U-266/84: 279.7
TRABD2B	TIKI2	ENSG00000269113	TraB domain containing 2B	1	47760528-47996895	Predicted secreted proteins	Evidence at protein level	HPA045817	Approved					Tissue enriched	Tissue enhanced		kidney: 7.7	seminal vesicle: 4.8	Group enriched	5	HeLa: 4.4;U-2197: 12.9
FBXO17	FBG4, Fbx17, FBXO26, FLJ11798, FLJ25205, MGC9379	ENSG00000269190	F-box protein 17	19	38941401-38975910	Predicted intracellular proteins	Evidence at protein level						Glioma:2.10e-4 (unfavourable), Endometrial cancer:5.67e-4 (unfavourable), Stomach cancer:5.91e-4 (unfavourable)	Mixed	Mixed			kidney: 14.4	Mixed		
RP11-722G7.1		ENSG00000269226		X	104063871-104076212	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			ovary: 7.6	Cell line enhanced		AF22: 10.6;AN3-CA: 9.4
MAGIX	FLJ21687, JM10, PDZX	ENSG00000269313	MAGI family member, X-linked	X	49162564-49168483	Predicted intracellular proteins	Evidence at transcript level	HPA035302	Uncertain				Renal cancer:6.91e-9 (favourable), Urothelial cancer:2.10e-4 (favourable)	Mixed	Mixed			parathyroid gland: 5.7	Cell line enhanced		RT4: 10.2
IKBKG	FIP-3, FIP3, Fip3p, IKK-gamma, IP1, IP2, NEMO, ZC2HC9	ENSG00000269335	Inhibitor of nuclear factor kappa B kinase subunit gamma	X	154541199-154565046	Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA000426, CAB010373	Uncertain		Enhanced	Cytosol		Expressed in all	Expressed in all			spleen: 37.2	Expressed in all		
ZNF587B		ENSG00000269343	Zinc finger protein 587B	19	57819741-57846238	Predicted intracellular proteins	Evidence at protein level	HPA043800, HPA053762, HPA072145	Uncertain		Uncertain	Nucleus	Prostate cancer:1.33e-4 (unfavourable), Melanoma:1.37e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 11.2	Expressed in all		
SPIB	SPI-B	ENSG00000269404	Spi-B transcription factor	19	50418938-50431313	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA018523	Uncertain				Head and neck cancer:2.14e-5 (favourable), Breast cancer:4.76e-5 (favourable)	Mixed	Tissue enhanced		appendix: 53.9;lymph node: 103.3;tonsil: 91.1	spleen: 39.2	Group enriched	10	Daudi: 119.1;HDLM-2: 99.4;Karpas-707: 37.4;U-698: 159.1
NXF2	CT39, TAPL-2	ENSG00000269405	Nuclear RNA export factor 2	X	102247161-102326719	Predicted intracellular proteins	Evidence at protein level	HPA002079	Uncertain					Not detected	Group enriched	21	epididymis: 18.6;testis: 23.3	fallopian tube: 0.9	Cell line enriched	38	U-266/84: 24.8
OPN1MW3		ENSG00000269433	Opsin 1, medium wave sensitive 3	X	154257538-154271805	Predicted membrane proteins	No evidence							Not detected	Not detected			skin: 0.1	Not detected		
NXF2B	bA353J17.1	ENSG00000269437	Nuclear RNA export factor 2B	X	102360395-102463274	Predicted intracellular proteins	Evidence at protein level	HPA002079	Uncertain					Not detected	Group enriched	6	epididymis: 19.1;testis: 4.9	fallopian tube: 2.1	Cell line enriched	30	U-266/84: 25.0
DMRTC1		ENSG00000269502	DMRT like family C1	X	72872025-72943814	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA046874, HPA046992	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 2.3	fallopian tube,thyroid gland: 1.3	Not detected		
ERVV-1	ENVV1, FLJ32214, HERV-V1	ENSG00000269526	Endogenous retrovirus group V member 1	19	53013921-53016122	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enriched	68	placenta: 22.1	prostate,urinary bladder: 0.3	Cell line enriched	8	BEWO: 7.4
AC003002.6		ENSG00000269533		19	57389884-57419994	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			appendix,fallopian tube,testis: 0.2	Cell line enhanced		CACO-2: 1.1;HEL: 1.1;PC-3: 1.6
CTC-360G5.8		ENSG00000269547		19	38915404-38949855	Predicted intracellular proteins	Evidence at protein level	HPA052730, HPA056957	Uncertain					Not detected	Mixed			ovary: 1.1	Cell line enhanced		A-431: 1.5;A549: 2.1;T-47d: 1.9;U-251 MG: 2.4
TMEM185A	CXorf13, FAM11A, FRAXF	ENSG00000269556	Transmembrane protein 185A	X	149596556-149631912	Predicted membrane proteins	Evidence at protein level	HPA048295, HPA071744	Uncertain		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			ovary: 36.4	Expressed in all		
CT45A10		ENSG00000269586	Cancer/testis antigen family 45 member A10	X	135881063-135889086	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Mixed	Tissue enriched	23	testis: 16.5	cerebral cortex: 0.7	Cell line enhanced		AN3-CA: 78.6;K-562: 23.7;Karpas-707: 67.5;U-266/84: 58.7
CTD-2192J16.24		ENSG00000269590		19	12664828-12669397	Predicted intracellular proteins	Evidence at protein level	HPA065685	Uncertain		Approved	Nuclear membrane<br>Endoplasmic reticulum		Not detected	Tissue enhanced		lymph node: 1.9	cerebral cortex,duodenum: 1.3	Cell line enhanced		MCF7: 8.8;RT4: 4.7
ZIM2	ZNF656	ENSG00000269699	Zinc finger imprinted 2	19	56774552-56840729	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071856			Approved	Nuclear speckles<br>Cytosol		Not detected	Group enriched	7	adrenal gland: 5.8;cerebral cortex: 5.1;ovary: 9.9;placenta: 6.8;testis: 7.7	endometrium: 1.0	Cell line enhanced		BEWO: 4.7;Hep G2: 4.0;NTERA-2: 1.6;RH-30: 1.6;U-2 OS: 1.2
CTD-3214H19.16		ENSG00000269711		19	7678501-7682854	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		bone marrow: 14.1;lung: 11.8	duodenum: 7.7	Cell line enhanced		EFO-21: 12.1;HMC-1: 18.1;NB-4: 7.8;THP-1: 22.2;U-937: 19.1
NBPF9	AE01	ENSG00000269713	Neuroblastoma breakpoint family member 9	1	149054027-149103561	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles		Mixed	Expressed in all			thyroid gland: 23.1	Expressed in all		
CTD-2521M24.13		ENSG00000269720		19	17390509-17394158	Predicted secreted proteins	No evidence							Mixed	Not detected			ovary,placenta: 0.4	Not detected		
SLC25A53	MCART6	ENSG00000269743	Solute carrier family 25 member 53	X	104099214-104157027	Predicted membrane proteins	Evidence at protein level	HPA034959	Uncertain					Mixed	Mixed			cerebral cortex: 2.5	Cell line enhanced		Daudi: 4.3;Karpas-707: 10.0
SSX4B	OTTHUMT00000056510	ENSG00000269791	SSX family member 4B	X	48402078-48411910	Predicted intracellular proteins	Evidence at transcript level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 3.8	fallopian tube: 0.2	Group enriched	8	BEWO: 2.1;Karpas-707: 3.9;U-266/70: 2.4;U-266/84: 4.3
RNF225		ENSG00000269855	Ring finger protein 225	19	58396090-58397079	Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		esophagus: 2.0;skin: 1.7	prostate: 0.6	Not detected		
EGLN2	HIFPH1, PHD1	ENSG00000269858	Egl-9 family hypoxia inducible factor 2	19	40798996-40808433	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA056649			Supported	Nucleoplasm	Cervical cancer:2.88e-4 (favourable), Pancreatic cancer:4.81e-4 (favourable)	Expressed in all	Expressed in all			testis: 205.1	Expressed in all		
AC004754.3		ENSG00000269881		16	249547-269943	Predicted membrane proteins	Evidence at transcript level	HPA011651, HPA071871	Uncertain		Uncertain	Nucleoplasm<br>Mitochondria		Not detected	Group enriched	5	duodenum: 14.2;small intestine: 7.8	testis: 2.0	Cell line enhanced		EFO-21: 1.5
COMMD3-BMI1		ENSG00000269897	COMMD3-BMI1 readthrough	10	22316388-22329542	Predicted intracellular proteins	Evidence at protein level	HPA030471, HPA030472, HPA036584	Uncertain		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol		Not detected	Tissue enhanced		testis: 10.2	seminal vesicle: 4.0	Mixed		
C7orf55-LUC7L2		ENSG00000269955	C7orf55-LUC7L2 readthrough	7	139341360-139422599	Predicted intracellular proteins	Evidence at protein level	HPA045663, HPA051631	Approved		Approved	Nucleus		Not detected	Expressed in all			skeletal muscle: 21.1	Expressed in all		
MEI4		ENSG00000269964	Meiotic double-stranded break formation protein 4	6	77690658-77926974	Predicted secreted proteins	Evidence at transcript level							Tissue enhanced	Tissue enhanced		kidney: 4.5;testis: 4.8;thyroid gland: 3.9	adrenal gland: 0.9	Not detected		
ZNF559-ZNF177		ENSG00000270011	ZNF559-ZNF177 readthrough	19	9324174-9382617	Predicted intracellular proteins	Evidence at transcript level	HPA003141	Uncertain					Not detected	Mixed			testis: 10.2	Cell line enhanced		HEK 293: 6.1
C8orf44-SGK3		ENSG00000270024	C8orf44-SGK3 readthrough	8	66667596-66860472	Predicted intracellular proteins	Evidence at transcript level	HPA006699, HPA027146	Uncertain		Approved	Nucleoplasm<br>Vesicles		Not detected	Not detected			cervix, uterine: 0.9	Cell line enhanced		fHDF/TERT166: 1.3
MINOS1-NBL1		ENSG00000270136	MINOS1-NBL1 readthrough	1	19596979-19658056	Predicted secreted proteins	Evidence at transcript level	HPA007394	Uncertain					Not detected	Tissue enhanced		duodenum: 16.2;small intestine: 17.2	adipose tissue: 13.7	Cell line enhanced		A-431: 25.2;BJ: 49.3;EFO-21: 25.9;HDLM-2: 32.5
LA16c-380H5.3		ENSG00000270168		16	2988256-3002016	Predicted secreted proteins	Evidence at transcript level							Mixed	Tissue enriched	7	skin: 4.8	lung: 0.7	Cell line enhanced		HaCaT: 3.6;hTCEpi: 2.2;SCLC-21H: 3.6
NCBP2-AS2		ENSG00000270170	NCBP2 antisense RNA 2 (head to head)	3	196942623-196943540	Predicted secreted proteins	Evidence at protein level						Renal cancer:8.92e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 28.6	Expressed in all		
BIVM-ERCC5		ENSG00000270181	BIVM-ERCC5 readthrough	13	102799110-102876001	Predicted intracellular proteins	Evidence at protein level	HPA045845, HPA050126, HPA050374	Uncertain		Supported	Nucleoplasm		Not detected	Expressed in all			thyroid gland: 22.8	Mixed		
MTRNR2L11		ENSG00000270188	MT-RNR2-like 11	1	237943724-237945275	Predicted secreted proteins	Evidence at transcript level							Not detected	Expressed in all			skeletal muscle: 113.4	Expressed in all		
RP11-514P8.7		ENSG00000270249		7	102541501-102592444	Predicted intracellular proteins	Evidence at transcript level	HPA046970	Uncertain		Uncertain	Nucleoplasm		Not detected	Tissue enhanced		parathyroid gland: 3.9	duodenum,epididymis: 1.0	Not detected		
HIST2H4B	H4/o	ENSG00000270276	Histone cluster 2 H4 family member b	1	149854045-149861210	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Mixed			fallopian tube: 4.6	Cell line enhanced		SCLC-21H: 5.7;SiHa: 7.9;U-266/70: 6.6;U-266/84: 5.4
RP5-850E9.3		ENSG00000270299		20	646626-675800	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 2.7;testis: 1.7	endometrium: 1.5	Cell line enhanced		Hep G2: 9.9;SK-BR-3: 6.5
CH17-385C13.3		ENSG00000270339		1	146344131-146344790	Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			spleen: 0.2	Not detected		
HEATR9	C17orf66, FLJ32830	ENSG00000270379	HEAT repeat containing 9	17	35854946-35868891	Predicted intracellular proteins	Evidence at transcript level	HPA023129	Uncertain					Not detected	Tissue enriched	34	testis: 10.0	spleen: 0.2	Not detected		
MTRNR2L13		ENSG00000270394	MT-RNR2-like 13	4	116298876-116300320	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland: 0.8	Cell line enhanced		HeLa: 2.2;Hep G2: 1.2
PRAMEF5	PRAMEF23, PRAMEF5L	ENSG00000270601	PRAME family member 5	1	13254212-13263314	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
URGCP-MRPS24		ENSG00000270617	URGCP-MRPS24 readthrough	7	43866558-43906589	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cervix, uterine: 1.3	Cell line enhanced		SCLC-21H: 3.9
NBPF14	DJ328E19.C1.1	ENSG00000270629	Neuroblastoma breakpoint family member 14	1	148531385-148679751	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 66.5	Mixed		
TAF15	hTAFII68, Npl3, RBP56, TAF2N	ENSG00000270647	TATA-box binding protein associated factor 15	17	35713791-35864615	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052059, HPA063647	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 61.1	Expressed in all		
MTRNR2L6		ENSG00000270672	MT-RNR2-like 6	7	142666272-142667718	Predicted intracellular proteins	Evidence at transcript level							Mixed	Expressed in all			skeletal muscle: 131.7	Cell line enhanced		HeLa: 101.5;Hep G2: 93.3
HSPE1-MOB4		ENSG00000270757	HSPE1-MOB4 readthrough	2	197500413-197550726	Predicted intracellular proteins	Evidence at protein level	HPA038755, HPA044125, HPA048272	Approved					Not detected	Mixed			adrenal gland: 32.7	Expressed in all		
GAS2L2	GAR17	ENSG00000270765	Growth arrest specific 2 like 2	17	35744511-35752878	Predicted intracellular proteins	Evidence at protein level	HPA044370	Enhanced				Endometrial cancer:7.00e-4 (favourable)	Tissue enhanced	Tissue enriched	11	fallopian tube: 28.2	epididymis,lung: 2.6	Cell line enhanced		HaCaT: 1.4
RPS10-NUDT3		ENSG00000270800	RPS10-NUDT3 readthrough	6	34284887-34426071	Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA047268, HPA048084, HPA055953	Uncertain		Approved	Cytosol		Not detected	Mixed			testis: 11.1	Expressed in all		
C17orf50		ENSG00000270806	Chromosome 17 open reading frame 50	17	35760897-35765079	Predicted intracellular proteins	Evidence at protein level	HPA043184, HPA063464			Supported	Nucleoplasm		Not detected	Tissue enriched	59	testis: 38.9	fallopian tube: 0.6	Cell line enriched	5	HaCaT: 4.6
HIST2H4A	H4/n, H4F2, H4FN, HIST2H4	ENSG00000270882	Histone cluster 2 H4 family member a	1	149832659-149839767	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Mixed			prostate: 13.8	Cell line enhanced		SiHa: 65.9;U-2 OS: 56.3
RASL10B	RRP17, VTS58635	ENSG00000270885	RAS like family 10 member B	17	35731649-35743521	Predicted intracellular proteins	Evidence at protein level	HPA046842, HPA057092	Enhanced		Approved	Vesicles	Endometrial cancer:6.38e-6 (unfavourable)	Tissue enhanced	Tissue enhanced		adipose tissue: 16.0;seminal vesicle: 21.0	skeletal muscle: 11.1	Cell line enhanced		HAP1: 25.2;HHSteC: 22.5;NTERA-2: 41.3
GPR75-ASB3		ENSG00000270898	GPR75-ASB3 readthrough	2	53670293-53860160	Predicted intracellular proteins	Evidence at transcript level	HPA003940	Uncertain					Not detected	Tissue enhanced		cerebral cortex: 1.0	spleen: 0.3	Cell line enhanced		K-562: 1.3
CT45A9		ENSG00000270946	Cancer/testis antigen family 45 member A9	X	135863776-135871812	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	13	testis: 1.2	all non-specific tissues: 0.0	Cell line enriched	8	HMC-1: 113.9
CTAGE15	CTAGE15P	ENSG00000271079	CTAGE family member 15	7	143571801-143574387	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enhanced		testis: 7.3	thyroid gland: 1.6	Cell line enhanced		A-431: 2.8;RT4: 2.1;SiHa: 2.8;SK-BR-3: 1.8
TMEM56-RWDD3		ENSG00000271092	TMEM56-RWDD3 readthrough	1	95117923-95247225	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Mixed			thyroid gland: 5.2	Cell line enhanced		RH-30: 11.5
AC240274.1		ENSG00000271254		Unmapped	4612-29626	Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles			Expressed in all			testis: 73.9	Expressed in all		
UGT2A2		ENSG00000271271	UDP glucuronosyltransferase family 2 member A2	4	69589309-69639642	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA045108	Uncertain					Not detected	Not detected			cervix, uterine,skin: 0.2	Not detected		
SRXN1	C20orf139, dJ850E9.2, Npn3, SRX1, YKL086W	ENSG00000271303	Sulfiredoxin 1	20	646615-653370	Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.22e-5 (unfavourable)	Mixed	Expressed in all			adrenal gland: 44.5	Mixed		
CTAGE6	CTAGE6P, MGC41943	ENSG00000271321	CTAGE family member 6	7	143755089-143757696	Predicted membrane proteins	Evidence at protein level	HPA000387, HPA000922	Uncertain					Not detected	Tissue enriched	38	testis: 9.9	skin: 0.2	Not detected		
NBPF19		ENSG00000271383	Neuroblastoma breakpoint family member 19	1	149390623-149556361	Predicted intracellular proteins	Evidence at protein level	HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 79.4	Expressed in all		
NBPF10	AG1	ENSG00000271425	Neuroblastoma breakpoint family member 10	1	146064699-146144804	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA038748, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Approved		Approved	Vesicles		Not detected	Mixed			skin: 8.1	Mixed		
MMP28	EPILYSIN, MM28, MMP-25, MMP-28	ENSG00000271447	Matrix metallopeptidase 28	17	35756249-35795707	Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Pancreatic cancer:6.28e-6 (unfavourable)	Mixed	Tissue enhanced		testis: 6.5	adipose tissue: 4.2	Cell line enriched	9	HaCaT: 32.1
CT45A2	CT45-2, CT45.2	ENSG00000271449	Cancer/testis antigen family 45 member A2	X	135811668-135820012	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	14	testis: 1.4	all non-specific tissues: 0.0	Group enriched	5	AN3-CA: 10.0;HMC-1: 43.4
CCL5	D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228	ENSG00000271503	C-C motif chemokine ligand 5	17	35871491-35880793	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:3.61e-7 (unfavourable), Endometrial cancer:1.34e-5 (favourable), Melanoma:2.42e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 80.5	lymph node: 68.5	Group enriched	7	HL-60: 31.8;NB-4: 158.3;THP-1: 39.1;U-937: 41.8
PPIAL4E		ENSG00000271567	Peptidylprolyl isomerase A like 4E	1	144372875-144373659	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			bone marrow: 0.3	Not detected		
LIX1L	MGC46719	ENSG00000271601	Limb and CNS expressed 1 like	1	145933423-145958001	Predicted intracellular proteins	Evidence at protein level	HPA063598			Approved	Cytosol	Renal cancer:3.19e-5 (unfavourable), Liver cancer:1.61e-4 (unfavourable), Urothelial cancer:5.27e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 45.8	Mixed		
MILR1	Allergin-1, C17orf60, MCA-32	ENSG00000271605	Mast cell immunoglobulin like receptor 1	17	64449037-64468643	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014347	Enhanced				Renal cancer:5.07e-6 (unfavourable)	Expressed in all	Mixed			appendix: 41.7	Cell line enhanced		CAPAN-2: 114.8;Daudi: 46.7;REH: 47.7;U-698: 47.8
RP11-426L16.10		ENSG00000271810		1	112702614-112711433	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 8.4	parathyroid gland: 3.5	Cell line enhanced		WM-115: 5.1
AC009014.3		ENSG00000271824		5	136191468-136193134	Predicted membrane proteins	Evidence at transcript level						Liver cancer:1.63e-4 (favourable), Pancreatic cancer:6.13e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 13.2;kidney: 22.7	small intestine: 6.8	Cell line enhanced		SCLC-21H: 2.0
ANKRD34A	ANKRD34	ENSG00000272031	Ankyrin repeat domain 34A	1	145959442-145964582	Predicted intracellular proteins	Evidence at protein level	HPA029642, HPA029643	Uncertain		Enhanced	Cytosol		Mixed	Tissue enriched	8	cerebral cortex: 12.7	appendix,parathyroid gland: 1.6	Mixed		
GTF2H5	bA120J8.2, C6orf175, FLJ30544, TFB5, TFIIH, TTD, TTD-A, TTDA	ENSG00000272047	General transcription factor IIH subunit 5	6	158168352-158199344	Disease related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:6.11e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 11.1	Expressed in all		
XXcos-LUCA11.5		ENSG00000272104		3	50350892-50367923	Predicted intracellular proteins	Evidence at protein level	HPA042817	Uncertain					Not detected	Mixed			small intestine: 6.9	Cell line enhanced		HMC-1: 7.9;Karpas-707: 7.6
HIST2H2AA4	H2A/r	ENSG00000272196	Histone cluster 2 H2A family member a4	1	149851061-149851624	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Tissue enhanced	Tissue enhanced		testis: 88.9	prostate: 32.5	Cell line enhanced		SiHa: 124.1;U-266/70: 217.3;U-266/84: 190.5
RP11-215A19.2		ENSG00000272297		4	186426546-186555328	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	16	testis: 54.0	prostate: 3.3	Group enriched	5	A-431: 2.2;T-47d: 1.2
NUDT3	DIPP	ENSG00000272325	Nudix hydrolase 3	6	34279679-34392674	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047027, HPA055953	Uncertain		Approved	Cytosol	Cervical cancer:5.29e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 77.5	Expressed in all		
KMT2B	CXXC10, HRX2, KIAA0304, MLL1B, MLL2, MLL4, TRX2, WBP7	ENSG00000272333	Lysine methyltransferase 2B	19	35718019-35738878	Cancer-related genes, Enzymes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006487			Approved	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			testis: 28.8	Expressed in all		
POM121C		ENSG00000272391	POM121 transmembrane nucleoporin C	7	75416787-75486271	Predicted intracellular proteins	Evidence at transcript level	HPA043809, HPA049817	Approved		Approved	Nucleoplasm<br>Nuclear membrane		Expressed in all	Expressed in all			parathyroid gland: 28.1	Expressed in all		
CD24	CD24A	ENSG00000272398	CD24 molecule	6	106969831-106975627	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA045879, CAB078471			Supported	Vesicles	Breast cancer:2.44e-5 (unfavourable), Colorectal cancer:3.29e-4 (favourable), Liver cancer:7.58e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 2706.1	esophagus: 1402.0	Cell line enhanced		NTERA-2: 984.0;RPTEC TERT1: 3501.8;SK-BR-3: 1014.5
FAM47E-STBD1		ENSG00000272414	FAM47E-STBD1 readthrough	4	76251721-76311129	Predicted intracellular proteins	Evidence at transcript level	HPA053331	Approved		Uncertain	Plasma membrane<br>Cytosol		Not detected	Mixed			adipose tissue: 33.2	Cell line enhanced		Karpas-707: 24.7
CFAP206	C6orf165, dJ382I10.1, FLJ25974	ENSG00000272514	Cilia and flagella associated protein 206	6	87407983-87464465	Predicted intracellular proteins	Evidence at protein level	HPA044891, HPA072261	Approved		Approved	Nucleoplasm<br>Cell Junctions		Not detected	Group enriched	30	fallopian tube: 35.9;testis: 106.8	lung,thyroid gland: 2.3	Cell line enhanced		MCF7: 1.7;RPTEC TERT1: 2.0;T-47d: 4.2
MUSTN1	Mustang	ENSG00000272573	Musculoskeletal, embryonic nuclear protein 1	3	52833114-52835219	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	6	skeletal muscle: 414.1	cervix, uterine: 71.5	Cell line enhanced		Hep G2: 4.1;RH-30: 5.0
ZNF595	FLJ31740	ENSG00000272602	Zinc finger protein 595	4	53285-88211	Predicted intracellular proteins	Evidence at protein level							Expressed in all	Expressed in all			placenta: 87.9	Cell line enhanced		K-562: 222.3;SH-SY5Y: 169.9
COG8	DOR1, FLJ22315	ENSG00000272617	Component of oligomeric golgi complex 8	16	69326913-69339667	Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA041406, HPA049429	Approved		Supported	Golgi apparatus		Not detected	Expressed in all			testis: 40.0	Expressed in all		
DOC2B	DOC2BL	ENSG00000272636	Double C2 domain beta	17	142789-181636	Predicted intracellular proteins	Evidence at protein level	HPA043168	Uncertain				Breast cancer:3.45e-4 (favourable), Head and neck cancer:8.68e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 14.4	Group enriched	8	HAP1: 9.4;SH-SY5Y: 39.6
PCDHB16	KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a	ENSG00000272674	Protocadherin beta 16	5	141181399-141186399	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA014668			Approved	Vesicles<br>Plasma membrane		Mixed	Tissue enhanced		parathyroid gland: 10.8	ovary: 7.3	Cell line enhanced		AN3-CA: 15.6;U-138 MG: 35.8
CTD-2410N18.5		ENSG00000272772		5	134167170-134226071	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		cerebral cortex: 1.3	endometrium,heart muscle,small intestine: 0.6	Mixed		
KRTAP10-7	KAP10.7, KAP18.7, KRTAP18-7	ENSG00000272804	Keratin associated protein 10-7	21	44600597-44602174	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RP11-302B13.5		ENSG00000272822		12	48903503-48957365	Predicted intracellular proteins	Evidence at transcript level	HPA068942			Approved	Nucleus<br>Nuclear bodies		Not detected	Mixed			cerebral cortex: 2.1	Cell line enhanced		BJ hTERT+: 3.6
DCP1A	HSA275986, SMAD4IP1, SMIF	ENSG00000272886	Decapping mRNA 1A	3	53283428-53347610	Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA013202	Approved		Supported	Cytoplasmic bodies	Liver cancer:3.25e-5 (unfavourable), Colorectal cancer:9.01e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 19.1	Expressed in all		
RP11-309L24.4		ENSG00000272899		7	128866308-128872044	Predicted intracellular proteins	Evidence at transcript level						Endometrial cancer:8.21e-4 (unfavourable)	Mixed	Mixed			small intestine: 3.7	Cell line enhanced		CAPAN-2: 6.0;HMC-1: 4.8
RBAK-RBAKDN		ENSG00000272968	RBAK-RBAKDN readthrough	7	4983718-5073221	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	155	testis: 109.8	cerebral cortex: 0.7	Mixed		
C2orf15	MGC29762	ENSG00000273045	Chromosome 2 open reading frame 15	2	99141485-99151487	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:1.23e-4 (favourable), Ovarian cancer:4.95e-4 (favourable)	Mixed	Mixed			thyroid gland: 9.9	Cell line enhanced		SCLC-21H: 13.7
RP4-583P15.14		ENSG00000273047		20	63738270-63740398	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.1;liver: 2.4;urinary bladder: 1.3	adipose tissue: 1.0	Cell line enhanced		Hep G2: 4.0;HHSteC: 1.0;U-698: 1.5
RP11-834C11.12		ENSG00000273049		12	53985845-54034888	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 1.5	skeletal muscle: 0.8	Cell line enhanced		AN3-CA: 8.1;HDLM-2: 3.0
GRIN2B	GluN2B, NMDAR2B	ENSG00000273079	Glutamate ionotropic receptor NMDA type subunit 2B	12	13437942-13981957	Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA069762	Approved					Not detected	Tissue enriched	23	cerebral cortex: 13.1	adipose tissue,testis: 0.5	Cell line enhanced		AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
LYPD4	MGC42718	ENSG00000273111	LY6/PLAUR domain containing 4	19	41837074-41844697	Predicted secreted proteins	Evidence at protein level							Not detected	Tissue enriched	749	testis: 165.3	bone marrow: 0.2	Not detected		
NBPF26		ENSG00000273136	Neuroblastoma breakpoint family member 26	1	120723923-120841481	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050	Uncertain		Approved	Vesicles		Mixed	Expressed in all			skin: 51.6	Mixed		
RP4-583P15.15		ENSG00000273154		20	63708864-63739103	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Mixed	Tissue enhanced		adrenal gland: 1.2;appendix: 1.0	duodenum,prostate: 0.5	Mixed		
RP11-38C17.1		ENSG00000273155		2	99154998-99195298	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			appendix: 1.7	Mixed		
CTB-96E2.2		ENSG00000273171		17	28364288-28368012	Predicted intracellular proteins	No evidence							Not detected	Not detected			liver: 0.6	Not detected		
SNURF		ENSG00000273173	SNRPN upstream reading frame	15	24954986-24977850	Predicted intracellular proteins	Evidence at protein level	HPA065733			Supported	Nuclear speckles		Mixed	Expressed in all			cerebral cortex: 197.0	Cell line enhanced		NTERA-2: 224.6
CTC-432M15.3		ENSG00000273217		5	131425891-131796983	Predicted intracellular proteins	Evidence at transcript level	HPA037982, HPA037983	Uncertain		Approved	Centrosome<br>Cytosol		Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		A549: 2.2
C2orf61		ENSG00000273269	Chromosome 2 open reading frame 61	2	47065941-47176511	Predicted intracellular proteins	Evidence at transcript level	HPA047366, HPA052691	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	224	testis: 22.3	all non-specific tissues: 0.0	Not detected		
ZBTB8B	DKFZp547H154, RP1-27O5.1, ZNF916B	ENSG00000273274	Zinc finger and BTB domain containing 8B	1	32465069-32496686	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055553	Approved					Tissue enhanced	Not detected			cerebral cortex: 0.6	Cell line enhanced		SCLC-21H: 1.1
RP11-136C24.3		ENSG00000273291		3	42809446-43055871	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	13	testis: 2.1	prostate,rectum: 0.1	Not detected		
AC011841.1		ENSG00000273496		Unmapped	99351-104855	Predicted intracellular proteins	Evidence at transcript level								Not detected			skin: 0.4	Cell line enhanced		A-431: 2.4
TBC1D3K		ENSG00000273513	TBC1 domain family member 3K	17	37924415-37935365	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 1.6	lymph node: 0.3	Cell line enhanced		T-47d: 1.3
FOXD4L6		ENSG00000273514	Forkhead box D4-like 6	9	41126430-41128463	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA012836	Uncertain		Approved	Nucleus		Not detected	Not detected			cerebral cortex: 0.3	Not detected		
AGBL1	CCP4, FLJ32310	ENSG00000273540	ATP/GTP binding protein like 1	15	86079973-87029052	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enhanced		lung: 1.3;skeletal muscle: 4.4	esophagus: 1.0	Not detected		
HIST1H4K	dJ160A22.1, H4/d, H4F2iii, H4FD	ENSG00000273542	Histone cluster 1 H4 family member k	6	27831216-27831527	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Not detected			appendix: 0.8	Not detected		
OR4F16		ENSG00000273547	Olfactory receptor family 4 subfamily F member 16	1	685716-686654	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC136616.1		ENSG00000273554		Unmapped	1139577-1147868	Predicted membrane proteins	Evidence at transcript level								Group enriched	6	skin: 1.6;testis: 6.9	adrenal gland: 0.6	Cell line enriched	6	AN3-CA: 14.2
CWC25	CCDC49, FLJ20291	ENSG00000273559	CWC25 spliceosome associated protein homolog	17	38800434-38825481	Predicted intracellular proteins	Evidence at protein level	CAB014874, HPA062997	Enhanced		Enhanced	Nuclear speckles		Expressed in all	Mixed			bone marrow: 18.8	Expressed in all		
SMIM11B		ENSG00000273590	Small integral membrane protein 11B	21	7744962-7777853	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA051321	Uncertain		Approved	Focal adhesion sites		Not detected	Expressed in all			epididymis: 24.8	Mixed		
EPOP	C17orf96, LOC100170841, PRR28	ENSG00000273604	Elongin BC and polycomb repressive complex 2 associated protein	17	38671703-38675421	Predicted intracellular proteins	Evidence at protein level	HPA055190, HPA056555	Enhanced		Supported	Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies		Expressed in all	Tissue enhanced		cerebral cortex: 5.5;testis: 5.0	parathyroid gland: 2.1	Cell line enhanced		AN3-CA: 19.3
ZNHIT3	TRIP3	ENSG00000273611	Zinc finger HIT-type containing 3	17	36486629-36499310	Predicted intracellular proteins	Evidence at protein level	HPA060019			Approved	Mitochondria		Expressed in all	Expressed in all			testis: 43.2	Expressed in all		
CT45A7		ENSG00000273696	Cancer/testis antigen family 45 member A7	X	135829247-135837268	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	6	testis: 1.5	cerebral cortex,lung: 0.2	Not detected		
HIST1H2BM	dJ160A22.3, H2B/e, H2BFE	ENSG00000273703	Histone cluster 1 H2B family member m	6	27815044-27815424	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 3.3;lymph node: 2.6	tonsil: 1.5	Cell line enhanced		Karpas-707: 14.4;NB-4: 8.4;REH: 7.8;U-266/70: 11.7
LHX1	LIM-1, LIM1	ENSG00000273706	LIM homeobox 1	17	36936785-36944612	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073521	Enhanced				Endometrial cancer:3.63e-5 (unfavourable)	Tissue enhanced	Tissue enriched	6	kidney: 1.3	fallopian tube: 0.2	Cell line enhanced		HAP1: 3.9;WM-115: 6.9
AL592183.1		ENSG00000273748		Unmapped	54224-83311	Predicted intracellular proteins	Evidence at transcript level	HPA049380	Approved						Expressed in all			gallbladder: 147.3	Mixed		
CYFIP1	KIAA0068, P140SRA-1, SHYC	ENSG00000273749	Cytoplasmic FMR1 interacting protein 1	15	22867052-22981063	Predicted intracellular proteins	Evidence at protein level	HPA068106	Approved				Renal cancer:4.47e-5 (favourable), Lung cancer:7.39e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 111.9	Mixed		
CEACAM20	UNQ9366	ENSG00000273777	Carcinoembryonic antigen related cell adhesion molecule 20	19	44501677-44529788	Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	23	duodenum: 38.8;prostate: 14.3;small intestine: 42.7	gallbladder: 1.3	Cell line enriched	7	U-266/70: 1.0
HIST1H2BG	H2B.1A, H2B/a, H2BFA	ENSG00000273802	Histone cluster 1 H2B family member g	6	26215159-26216692	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-8 (unfavourable)	Expressed in all	Tissue enhanced		breast: 17.5;prostate: 11.3	bone marrow: 4.6	Cell line enhanced		SiHa: 11.2;T-47d: 19.9;U-266/70: 15.0
USP27X	USP27	ENSG00000273820	Ubiquitin specific peptidase 27, X-linked	X	49879948-49882565	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA077264			Approved	Nucleoplasm<br>Vesicles	Liver cancer:6.14e-4 (unfavourable), Pancreatic cancer:9.31e-4 (favourable)	Expressed in all	Tissue enhanced		placenta: 19.7	cerebral cortex: 10.3	Mixed		
TAF9	AD-004, CGI-137, MGC1603, MGC3647, MGC5067, TAF2G, TAFII31, TAFII32, TAFIID32	ENSG00000273841	TATA-box binding protein associated factor 9	5	69364743-69370013	Plasma proteins, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.48e-5 (unfavourable), Renal cancer:9.20e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 146.1	Expressed in all		
NOL12	MGC3731, Nop25, RRP17	ENSG00000273899	Nucleolar protein 12	22	37681673-37693478	Predicted intracellular proteins	Evidence at protein level	HPA003547	Uncertain		Approved	Nucleus<br>Nucleoli<br>Vesicles	Renal cancer:2.56e-6 (unfavourable), Cervical cancer:6.80e-5 (favourable), Urothelial cancer:3.24e-4 (favourable), Lung cancer:9.41e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 25.1	Expressed in all		
GOLGA6L1		ENSG00000273976	Golgin A6 family-like 1	15	23128268-23136822	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	11	testis: 4.5	bone marrow: 0.4	Not detected		
HIST1H3G	H3/h, H3FH	ENSG00000273983	Histone cluster 1 H3 family member g	6	26269405-26271815	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Cervical cancer:8.75e-4 (favourable)	Mixed	Not detected			epididymis,small intestine: 0.5	Cell line enhanced		SiHa: 7.2;U-266/70: 4.8
RP11-475E11.9		ENSG00000274068		1	108837660-108963484	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		parathyroid gland: 1.5	adrenal gland,cerebral cortex: 0.9	Cell line enhanced		HDLM-2: 1.8
GATSL2	GATSL1	ENSG00000274070	GATS protein like 2	7	74964818-75024798	Predicted intracellular proteins	Evidence at protein level	HPA057229	Uncertain					Expressed in all	Tissue enhanced		cerebral cortex: 14.9	skeletal muscle: 13.8	Cell line enhanced		A549: 24.5
OR4M2		ENSG00000274102	Olfactory receptor family 4 subfamily M member 2	15	22080527-22081659	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain					Not detected	Tissue enriched	10	testis: 1.2	cerebral cortex: 0.1	Not detected		
AC133551.1		ENSG00000274175		Unmapped	17234-19833	Predicted intracellular proteins	Evidence at transcript level								Group enriched	28	epididymis: 7.4;testis: 4.1	placenta: 0.2	Not detected		
NATD1	C17orf103, Gtlf3b, MGC33894	ENSG00000274180	N-acetyltransferase domain containing 1	17	21238870-21253410	Predicted intracellular proteins	Evidence at protein level						Renal cancer:3.55e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 17.0	Cell line enhanced		BEWO: 22.1
H2AFB1		ENSG00000274183	H2A histone family member B1	X	154884972-154885558	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	9	testis: 4.3	bone marrow,skin: 0.4	Cell line enriched	26	HDLM-2: 12.2
ANTXRL		ENSG00000274209	Anthrax toxin receptor-like	10	46286345-46330207	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	23	testis: 15.5	bone marrow: 0.6	Not detected		
SOCS7	NAP4, NCKAP4	ENSG00000274211	Suppressor of cytokine signaling 7	17	38352228-38405593	Predicted intracellular proteins	Evidence at protein level	HPA004475	Approved		Approved	Cytosol	Breast cancer:7.49e-4 (unfavourable), Endometrial cancer:7.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		testis: 54.4	thyroid gland: 13.1	Expressed in all		
TBC1D3H		ENSG00000274226	TBC1 domain family member 3H	17	36377531-36388423	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Approved	Vesicles		Not detected	Tissue enhanced		testis: 2.7;urinary bladder: 1.1	cervix, uterine: 0.6	Cell line enriched	10	CAPAN-2: 5.1
GGTLC3		ENSG00000274252	Gamma-glutamyltransferase light chain 3	22	18516344-18518161	Predicted intracellular proteins	Evidence at protein level	HPA045635, HPA047534	Uncertain					Not detected	Tissue enhanced		lung: 1.9;testis: 1.0	small intestine: 0.5	Cell line enhanced		U-2197: 1.0
HIST1H3B	H3/l, H3FL	ENSG00000274267	Histone cluster 1 H3 family member b	6	26031650-26032060	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enriched	6	bone marrow: 6.1	lymph node: 0.9	Mixed		
GAGE13	GAGE12A	ENSG00000274274	G antigen 13	X	49331616-49338952	Predicted intracellular proteins	Evidence at protein level	HPA043232	Supported		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Tissue enriched	553	testis: 59.6	stomach: 0.1	Cell line enriched	6	AN3-CA: 685.8
CBSL		ENSG00000274276	Cystathionine-beta-synthase like	21	6444869-6468040	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001223	Supported		Approved	Nucleoli<br>Vesicles		Mixed	Tissue enhanced		cerebral cortex: 45.9;liver: 27.3	thyroid gland: 22.2	Cell line enhanced		AN3-CA: 123.4;NTERA-2: 245.4;SH-SY5Y: 82.5
ADRA2B	ADRA2L1, ADRA2RL1, ADRARL1	ENSG00000274286	Adrenoceptor alpha 2B	2	96112875-96116245	Predicted membrane proteins	Evidence at transcript level	HPA066029	Approved					Mixed	Mixed			epididymis: 5.1	Cell line enhanced		BEWO: 1.5
HIST1H2BE	H2B.h, H2B/h, H2BFH	ENSG00000274290	Histone cluster 1 H2B family member e	6	26172059-26184655	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Mixed			prostate: 2.9	Mixed		
ZNF658	DKFZp572C163, FLJ32813, MGC35232	ENSG00000274349	Zinc finger protein 658	9	66856426-66932141	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047730, HPA048668	Uncertain		Approved	Nucleoplasm		Mixed	Mixed			skin: 9.7	Mixed		
TMEM269		ENSG00000274386	Transmembrane protein 269	1	42785007-42816619	Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			testis: 0.9	Mixed		
TPTE	CT44, PTEN2	ENSG00000274391	Transmembrane phosphatase with tensin homology	21	10521553-10606140	Enzymes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	HPA049690, HPA068342	Enhanced		Approved	Endoplasmic reticulum<br>Cytosol		Tissue enriched	Tissue enriched	247	testis: 191.3	placenta: 0.7	Cell line enhanced		BEWO: 6.4;K-562: 7.3;Karpas-707: 4.6;PC-3: 4.4;RPMI-8226: 6.2;U-2 OS: 4.3;U-266/70: 5.8
TBC1D3D		ENSG00000274419	TBC1 domain family member 3D	17	38003976-38014902	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 5.5;testis: 3.4	skin: 3.2	Cell line enhanced		CAPAN-2: 8.4;HaCaT: 6.1;HeLa: 5.2;RT4: 3.7
C8orf89		ENSG00000274443	Chromosome 8 open reading frame 89	8	73241329-73259502	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	8	testis: 13.3	cervix, uterine: 1.5	Not detected		
TBC1D3L		ENSG00000274512	TBC1 domain family member 3L	17	37977972-37989048	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Mixed	Mixed			skin: 42.2	Cell line enhanced		BEWO: 37.5
RCC1L	WBSCR16	ENSG00000274523	RCC1 like	7	75027122-75074228	Predicted intracellular proteins	Evidence at protein level	HPA052184, HPA060643	Approved		Approved	Nucleus<br>Cytosol	Glioma:6.65e-4 (unfavourable)	Expressed in all	Expressed in all			skeletal muscle: 36.4	Expressed in all		
SEBOX	OG9, OG9X	ENSG00000274529	SEBOX homeobox	17	28364268-28365244	Predicted intracellular proteins	No evidence	HPA045689	Uncertain					Not detected	Not detected			testis: 0.4	Not detected		
CH507-42P11.1		ENSG00000274559		21	5972924-5973383	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Uncertain		Supported	Nucleoplasm<br>Cytosol		Not detected	Mixed			prostate: 8.2	Cell line enhanced		K-562: 40.6;U-2 OS: 43.9;U-266/84: 32.4
DGKK		ENSG00000274588	Diacylglycerol kinase kappa	X	50365409-50470738	Enzymes, Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	7	adrenal gland: 4.5	cerebral cortex: 0.6	Cell line enriched	14	Hep G2: 23.8
RIMBP3B		ENSG00000274600	RIMS binding protein 3B	22	21383374-21389478	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	26	testis: 12.1	parathyroid gland: 0.4	Cell line enhanced		RH-30: 1.0;THP-1: 1.0
TBC1D3	DKFZp434P2235, PRC17, TBC1D3A	ENSG00000274611	TBC1 domain family member 3	17	38181659-38192541	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		small intestine: 4.0;testis: 6.8	endometrium: 3.6	Cell line enhanced		AF22: 7.5;REH: 4.5;U-138 MG: 6.4;U-266/70: 7.8;U-266/84: 3.0;U-698: 3.6
HIST1H4F	H4, H4/c, H4FC	ENSG00000274618	Histone cluster 1 H4 family member f	6	26240426-26240737	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Tissue enhanced	Not detected			bone marrow: 0.7	Cell line enhanced		MCF7: 1.2;MOLT-4: 5.2;REH: 2.6
HIST1H2BO	H2B.2, H2B/n, H2BFN	ENSG00000274641	Histone cluster 1 H2B family member o	6	27893463-27893843	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:4.89e-4 (favourable)	Mixed	Tissue enhanced		bone marrow: 2.1	lymph node,placenta: 1.3	Cell line enhanced		U-266/84: 32.7
CCL23	Ckb-8, CKb8, MIP-3, MPIF-1, SCYA23	ENSG00000274736	C-C motif chemokine ligand 23	17	36013056-36017968	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA042015	Uncertain					Mixed	Tissue enhanced		smooth muscle: 15.4	lung: 11.1	Group enriched	5	HEL: 15.9;THP-1: 25.4;U-937: 5.1
ELOA3D	TCEB3CL2	ENSG00000274744	Elongin A3 family member D	18	46962768-46964408	Predicted intracellular proteins	No evidence	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
KRTAP7-1	KAP7.1	ENSG00000274749	Keratin associated protein 7-1 (gene/pseudogene)	21	30829039-30829759	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Not detected			skin: 0.1	Not detected		
HIST1H3E	H3.1, H3/d, H3FD	ENSG00000274750	Histone cluster 1 H3 family member e	6	26224199-26227473	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Expressed in all	Mixed			epididymis: 6.0	Cell line enhanced		EFO-21: 10.0;SCLC-21H: 14.1
PRAMEF27		ENSG00000274764	PRAME family member 27	1	13049476-13056491	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
F8A2		ENSG00000274791	Coagulation factor VIII-associated 2	X	155382115-155383230	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC171558.1		ENSG00000274792		Unmapped	386278-387620	Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome			Tissue enriched	11	testis: 4.3	cerebral cortex: 0.4	Cell line enriched	29	U-2 OS: 3.3
TBC1D3B	PRC17, TBC1D3I	ENSG00000274808	TBC1 domain family member 3B	17	36165681-36176636	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		skin: 6.3;testis: 6.0	spleen: 2.9	Cell line enhanced		CAPAN-2: 7.5;T-47d: 5.6
NPHP3-ACAD11		ENSG00000274810	NPHP3-ACAD11 readthrough (NMD candidate)	3	132558142-132722459	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		ovary: 4.8	endometrium: 3.2	Cell line enhanced		ASC TERT1: 4.4
AC145212.1		ENSG00000274847		Unmapped	53594-115055	Predicted intracellular proteins	Evidence at transcript level	HPA053929	Uncertain		Uncertain	Intermediate filaments			Mixed			adrenal gland: 10.2	Mixed		
RP11-214K3.25		ENSG00000274874		12	123973944-124088594	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.3	Mixed		
PANO1	PANO	ENSG00000274897	Proapoptotic nucleolar protein 1	11	797511-799190	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			cerebral cortex,skin: 1.4	Cell line enhanced		BEWO: 5.3;SCLC-21H: 5.1
TBC1D3I		ENSG00000274933	TBC1 domain family member 3I	17	36253456-36264553	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 1.1	skin: 0.3	Cell line enriched	6	CAPAN-2: 4.7
RP5-864K19.6		ENSG00000274944		1	38864501-38881617	Predicted intracellular proteins	Evidence at transcript level	HPA041188	Uncertain					Not detected	Tissue enhanced		testis: 11.6	lymph node: 3.6	Mixed		
HIST1H2AH	dJ86C11.1, H2A/S, H2AFALii	ENSG00000274997	Histone cluster 1 H2A family member h	6	27147129-27147515	Predicted intracellular proteins	Evidence at protein level	CAB004030, HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 7.4	testis: 2.5	Mixed		
ZNF280B	5'OY11.1, SUHW2, ZNF279, ZNF632	ENSG00000275004	Zinc finger protein 280B	22	22484421-22509154	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059519	Uncertain		Approved	Nucleoplasm		Mixed	Tissue enriched	7	testis: 12.6	cerebral cortex: 1.8	Cell line enhanced		K-562: 8.3;U-2 OS: 4.7
MLLT6	AF17, FLJ23480	ENSG00000275023	MLLT6, PHD finger domain containing	17	38705542-38729803	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004021	Approved		Approved	Nucleus	Head and neck cancer:3.98e-4 (favourable), Breast cancer:4.18e-4 (favourable), Pancreatic cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
TP53TG3E		ENSG00000275034	TP53 target 3 family member E	16	33303739-33306935	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			placenta: 0.2	Not detected		
RP11-546B8.6		ENSG00000275038		5	171305981-171308755	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Cell line enhanced		SH-SY5Y: 1.9
PPP4R3B	FLFL2, FLJ31474, KIAA1387, PSY2, SMEK2	ENSG00000275052	Protein phosphatase 4 regulatory subunit 3B	2	55547292-55618880	Predicted intracellular proteins	Evidence at protein level	HPA001233, CAB017185	Approved		Supported	Nucleoplasm<br>Nuclear speckles<br>Centrosome	Renal cancer:6.03e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 58.0	Expressed in all		
AC233755.1		ENSG00000275063		Unmapped	41444-41876	Predicted secreted proteins	Evidence at transcript level								Tissue enhanced		urinary bladder: 1019.5	tonsil: 662.1	Cell line enriched	8	REH: 129.3
SYNRG	AP1GBP1, MGC104959, SYNG	ENSG00000275066	Synergin gamma	17	37514797-37609496	Predicted intracellular proteins	Evidence at protein level	HPA023554, HPA023555	Approved		Approved	Cytosol	Urothelial cancer:3.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 20.4	Expressed in all		
NUDT18	FLJ22494, MTH3	ENSG00000275074	Nudix hydrolase 18	8	22106872-22109419	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA028581, HPA030125	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Endometrial cancer:2.49e-6 (favourable), Cervical cancer:1.43e-4 (favourable), Pancreatic cancer:2.47e-4 (favourable), Renal cancer:8.30e-4 (favourable)	Expressed in all	Mixed			epididymis: 16.2	Mixed		
ZNF2	A1-5, Zfp661, ZNF661	ENSG00000275111	Zinc finger protein 2	2	95165432-95184317	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA041358	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Lung cancer:4.69e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 6.4	Expressed in all		
GAGE2E	GAGE8	ENSG00000275113	G antigen 2E	X	49341192-49345922	Predicted intracellular proteins	Evidence at transcript level	HPA043232	Approved		Uncertain	Golgi apparatus<br>Plasma membrane<br>Cytosol		Not detected	Group enriched	60	stomach: 15.4;testis: 8.6	small intestine: 0.2	Group enriched	5	AN3-CA: 943.7;K-562: 455.5;T-47d: 231.8
HIST1H4L	H4.k, H4/k, H4FK	ENSG00000275126	Histone cluster 1 H4 family member l	6	27873199-27873510	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Tissue enhanced	Not detected			bone marrow: 0.3	Cell line enhanced		MOLT-4: 4.5;NB-4: 1.8;REH: 1.3
CCL16	CKb12, HCC-4, LCC-1, LEC, LMC, Mtn-1, NCC-4, SCYA16, SCYL4	ENSG00000275152	C-C motif chemokine ligand 16	17	35976493-35981496	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Tissue enriched	Tissue enriched	91	liver: 60.8	spleen: 0.6	Cell line enriched	19	Hep G2: 6.8
RP11-385J1.3		ENSG00000275163		3	178419123-178843300	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	6	fallopian tube: 8.8	kidney: 1.5	Cell line enriched	10	HSkMC: 1.0
LENG9		ENSG00000275183	Leukocyte receptor cluster member 9	19	54461796-54463711	Predicted intracellular proteins	Evidence at protein level	HPA051671, HPA053556	Enhanced		Approved	Nucleoli fibrillar center	Endometrial cancer:9.99e-5 (favourable)	Expressed in all	Mixed			duodenum: 5.2	Cell line enhanced		HaCaT: 5.6
HIST1H2AK	H2A/d, H2AFD	ENSG00000275221	Histone cluster 1 H2A family member k	6	27837947-27838339	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Not detected	Mixed			testis: 2.3	Cell line enhanced		A549: 2.0;AN3-CA: 2.2;SCLC-21H: 2.8;U-266/84: 2.7
AC171558.2		ENSG00000275249		Unmapped	372322-373405	Predicted membrane proteins	Evidence at transcript level	HPA058889	Uncertain						Tissue enriched	26	testis: 2.5	all non-specific tissues: 0.0	Not detected		
CCL4	Act-2, AT744.1, LAG1, MIP-1-beta, SCYA4	ENSG00000275302	C-C motif chemokine ligand 4	17	36103590-36105621	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	CAB007805	Approved				Endometrial cancer:1.97e-5 (favourable), Renal cancer:1.68e-4 (unfavourable), Colorectal cancer:3.54e-4 (favourable), Melanoma:3.97e-4 (favourable)	Expressed in all	Tissue enhanced		spleen: 24.8	lymph node: 17.6	Group enriched	22	Karpas-707: 2.2;U-266/70: 5.1;U-266/84: 2.4
PRAG1	DKFZp761P0423, NACK, PEAK2, PRAGMIN, SgK223	ENSG00000275342	PEAK1 related kinase activating pseudokinase 1	8	8317736-8386498	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA012066	Uncertain		Approved	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:4.81e-4 (favourable)	Expressed in all	Tissue enhanced		thyroid gland: 28.3	small intestine: 12.2	Cell line enhanced		A549: 45.2
C7orf77		ENSG00000275356	Chromosome 7 open reading frame 77	7	124777292-124790689	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			lung: 0.5	Cell line enriched	8	HDLM-2: 3.8
HIST1H3I	H3.f, H3/f, H3FF	ENSG00000275379	Histone cluster 1 H3 family member i	6	27871905-27872315	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Tissue enhanced	Tissue enhanced		bone marrow: 1.1	appendix: 0.6	Cell line enhanced		HEL: 2.6;MOLT-4: 4.4;NB-4: 2.3;REH: 5.1
CCL18	AMAC-1, CKb7, DC-CK1, DCCK1, MIP-4, PARC, SCYA18	ENSG00000275385	C-C motif chemokine ligand 18	17	36064280-36072032	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		adipose tissue: 20.9;lung: 13.0;tonsil: 10.5	lymph node: 6.2	Not detected		
FCGBP	FC(GAMMA)BP	ENSG00000275395	Fc fragment of IgG binding protein	19	39863323-39934626	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA003517, HPA003564	Enhanced		Approved	Golgi apparatus<br>Plasma membrane<br>Cytokinetic bridge	Ovarian cancer:9.70e-6 (unfavourable), Head and neck cancer:1.28e-5 (favourable), Liver cancer:4.74e-5 (unfavourable), Thyroid cancer:4.27e-4 (unfavourable)	Expressed in all	Tissue enhanced		colon: 166.7	cervix, uterine: 83.5	Cell line enhanced		A549: 2.7;RH-30: 6.8
HNF1B	HNF1beta, LFB3, MODY5, TCF2, VHNF1	ENSG00000275410	HNF1 homeobox B	17	37686432-37745247	Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002083, CAB068192	Enhanced		Supported	Nucleoplasm	Urothelial cancer:2.51e-6 (favourable), Renal cancer:6.00e-4 (favourable)	Tissue enhanced	Tissue enhanced		gallbladder: 21.5;kidney: 25.3	lung: 9.6	Cell line enhanced		A549: 16.8;CACO-2: 17.9;EFO-21: 26.2;RPTEC TERT1: 95.5
CH507-9B2.5		ENSG00000275464		21	5130871-5154734	Predicted intracellular proteins	Evidence at protein level	HPA024573	Uncertain		Approved	Nucleoli<br>Cytosol		Mixed	Expressed in all			cerebral cortex: 16.0	Mixed		
C17orf98	LOC388381	ENSG00000275489	Chromosome 17 open reading frame 98	17	38835088-38841455	Predicted intracellular proteins	Evidence at transcript level	HPA051696	Uncertain		Approved	Nucleoli<br>Intermediate filaments		Not detected	Tissue enriched	50	testis: 9.5	adipose tissue,skin: 0.1	Cell line enriched	7	hTCEpi: 1.9
FAM236A	DMRTC1-AS1, LINC00684	ENSG00000275520	Family with sequence similarity 235 member A	X	72938163-72938958	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	46	testis: 79.7	lymph node: 1.7	Not detected		
ELOA3C		ENSG00000275553	Elongin A3 family member C	18	46968695-46969912	Predicted intracellular proteins	No evidence	HPA049178, HPA050086	Uncertain					Not detected	Not detected			epididymis: 0.1	Not detected		
GRIFIN		ENSG00000275572	Galectin-related inter-fiber protein	7	2474844-2476894	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			skin: 0.7	Not detected		
XKR5		ENSG00000275591	XK related 5	8	6808517-6835644	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		cervix, uterine: 1.0	testis: 0.6	Cell line enhanced		AF22: 3.0;NTERA-2: 1.9;SCLC-21H: 1.8;SH-SY5Y: 3.6
HIST1H4G	H4/l, H4FL	ENSG00000275663	Histone cluster 1 H4 family member g	6	26246681-26246977	Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Not detected	Not detected			small intestine: 0.2	Not detected		
RP11-697E2.12		ENSG00000275674		15	90266317-90314499	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		duodenum: 1.2	cerebral cortex,small intestine: 0.8	Cell line enhanced		BEWO: 1.8
RP11-249C24.12		ENSG00000275691		16	56676132-56677763	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		thyroid gland: 1.1	rectum: 0.7	Not detected		
AATF	BFR2, CHE-1, CHE1, DED	ENSG00000275700	Apoptosis antagonizing transcription factor	17	36948875-37056871	Predicted intracellular proteins	Evidence at protein level	HPA004940	Uncertain				Renal cancer:4.14e-5 (unfavourable), Liver cancer:6.62e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 19.9	Expressed in all		
HIST1H2BH	H2B/j, H2BFJ	ENSG00000275713	Histone cluster 1 H2B family member h	6	26251651-26253710	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol	Head and neck cancer:7.52e-4 (unfavourable)	Mixed	Tissue enhanced		duodenum: 3.0	small intestine: 1.2	Cell line enhanced		U-266/70: 12.9
HIST1H3A	H3/A, H3FA	ENSG00000275714	Histone cluster 1 H3 family member a	6	26020490-26020900	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Group enriched	5	bone marrow: 6.7;epididymis: 1.8;testis: 3.7	lung: 0.7	Cell line enhanced		U-2 OS: 5.3
CCL15	HCC-2, HMRP-2B, Lkn-1, MIP-1d, MIP-5, NCC-3, SCYA15, SCYL3	ENSG00000275718	C-C motif chemokine ligand 15	17	35996440-36002038	Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA058608			Approved	Golgi apparatus<br>Vesicles	Urothelial cancer:3.02e-4 (favourable)	Tissue enhanced	Tissue enhanced		duodenum: 21.5;rectum: 30.6;small intestine: 26.6	colon: 18.9	Cell line enriched	12	Hep G2: 22.7
LYZL6	LYC1, PRO1485, TKAL754	ENSG00000275722	Lysozyme like 6	17	35934518-35943699	Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA025734, HPA053073	Supported					Not detected	Not detected			testis: 0.1	Not detected		
RP11-449H3.3		ENSG00000275740		5	146203550-146339251	Predicted intracellular proteins	Evidence at transcript level	HPA035944, HPA036422	Approved		Approved	Nuclear speckles		Not detected	Tissue enriched	5	testis: 12.2	thyroid gland: 2.4	Mixed		
HNRNPCL2	HNRNPCP5	ENSG00000275774	Heterogeneous nuclear ribonucleoprotein C-like 2	1	13115496-13116854	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
RIMBP3	KIAA1666, RIMBP3.1, RIMBP3A	ENSG00000275793	RIMS binding protein 3	22	18605815-18611919	Predicted intracellular proteins	Evidence at protein level	HPA001183	Supported		Uncertain	Vesicles<br>Plasma membrane		Not detected	Tissue enriched	37	testis: 45.4	parathyroid gland: 1.2	Mixed		
ARHGAP23	KIAA1501	ENSG00000275832	Rho GTPase activating protein 23	17	38419280-38512392	Predicted intracellular proteins	Evidence at protein level	HPA019818, HPA047291	Uncertain		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.38e-5 (unfavourable), Endometrial cancer:6.87e-5 (unfavourable), Pancreatic cancer:3.24e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 41.9	Cell line enhanced		HaCaT: 260.4
TUBGCP5	GCP5, KIAA1899	ENSG00000275835	Tubulin gamma complex associated protein 5	15	22983192-23039673	Predicted intracellular proteins	Evidence at protein level	HPA039366, HPA040366	Supported		Supported	Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 24.5	Expressed in all		
AC136612.1		ENSG00000275869		Unmapped	933862-936467	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	5	testis: 4.3	epididymis: 0.8	Not detected		
U2AF1L5		ENSG00000275895	U2 small nuclear RNA auxiliary factor 1 like 5	21	6484623-6499261	Predicted intracellular proteins	Evidence at protein level	HPA044833, HPA052083	Supported		Uncertain	Nucleoplasm		Not detected	Expressed in all			tonsil: 100.1	Expressed in all		
PRSS2	TRY2	ENSG00000275896	Protease, serine 2	7	142760398-142774564	Enzymes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA062452, HPA063471	Supported		Approved	Endoplasmic reticulum<br>Vesicles	Breast cancer:2.32e-4 (favourable)	Tissue enriched	Tissue enriched	53	pancreas: 30215.4	small intestine: 567.7	Group enriched	6	RPMI-8226: 46.1;U-2 OS: 14.3
TBC1D3F		ENSG00000275954	TBC1 domain family member 3F	17	36428618-36439566	Predicted membrane proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Not detected	Tissue enriched	14	testis: 1.9	bone marrow,gallbladder: 0.1	Not detected		
SPATA31A3	DKFZp434B204, FAM75A3	ENSG00000275969	SPATA31 subfamily A member 3	9	66986304-66992583	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	52	testis: 5.1	all non-specific tissues: 0.0	Not detected		
CH507-42P11.8		ENSG00000275993		21	6111134-6123739	Predicted membrane proteins	Evidence at transcript level	HPA038211	Uncertain					Expressed in all	Mixed			adrenal gland: 73.0	Cell line enhanced		HeLa: 61.0;Karpas-707: 90.2;LHCN-M2: 73.9;SiHa: 93.6
AC007325.1		ENSG00000276017		Unmapped	72411-74814	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	89	testis: 16.5	adipose tissue,gallbladder,smooth muscle,spleen,urinary bladder: 0.1	Not detected		
DUSP14	MKP-L, MKP6	ENSG00000276023	Dual specificity phosphatase 14	17	37489831-37513501	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019911	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.97e-9 (unfavourable)	Expressed in all	Tissue enhanced		fallopian tube: 5.1	skin: 2.7	Cell line enhanced		BJ hTERT+ SV40 Large T+ RasG12V: 15.2;HBF TERT88: 21.7;WM-115: 13.0
SPATA31A7	FAM75A4, FAM75A7, SPATA31A4	ENSG00000276040	SPATA31 subfamily A member 7	9	61190003-61196280	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 2.6	all non-specific tissues: 0.0	Not detected		
UHRF1	FLJ21925, ICBP90, Np95, RNF106, TDRD22	ENSG00000276043	Ubiquitin like with PHD and ring finger domains 1	19	4903080-4962154	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA049408, HPA055446	Enhanced		Supported	Nucleoplasm	Pancreatic cancer:4.52e-5 (unfavourable), Liver cancer:1.63e-4 (unfavourable), Melanoma:6.81e-4 (unfavourable)	Expressed in all	Tissue enhanced		lymph node: 18.8	bone marrow: 17.5	Expressed in all		
ORAI1	CRACM1, FLJ14466, TMEM142A	ENSG00000276045	ORAI calcium release-activated calcium modulator 1	12	121626550-121642677	Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA016583, HPA061823	Approved		Supported	Cytosol	Ovarian cancer:4.30e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
CCL4L2		ENSG00000276070	C-C motif chemokine ligand 4 like 2	17	36210924-36212878	Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		bone marrow: 19.4	gallbladder: 10.9	Cell line enhanced		Daudi: 2.9;HMC-1: 5.0;U-266/70: 6.7
CH507-152C13.3		ENSG00000276076		21	6560714-6564489	Predicted intracellular proteins	Evidence at transcript level	HPA037737, HPA038430	Approved		Approved	Nucleoplasm<br>Cytosol		Not detected	Tissue enriched	13	kidney: 57.2	liver: 4.5	Cell line enriched	178	Hep G2: 25.5
CCL3L3	CCL3L1, D17S1718, G0S19-2, LD78BETA, MGC12815, SCYA3L, SCYA3L1	ENSG00000276085	C-C motif chemokine ligand 3 like 3	17	36194869-36196758	Predicted secreted proteins	Evidence at protein level							Expressed in all	Group enriched	8	bone marrow: 7.4;gallbladder: 1.5	lymph node,urinary bladder: 0.5	Group enriched	33	U-266/70: 37.7;U-266/84: 73.6
OR13C2		ENSG00000276119	Olfactory receptor family 13 subfamily C member 2	9	104604671-104605627	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			cerebral cortex,fallopian tube,thyroid gland: 0.1	Not detected		
HIST1H4I	H4/m, H4FM	ENSG00000276180	Histone cluster 1 H4 family member i	6	27138588-27139881	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:1.32e-5 (unfavourable), Cervical cancer:9.70e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 6.1	Cell line enhanced		K-562: 67.9;SiHa: 46.7;U-2 OS: 76.3;U-266/84: 55.8
ANKRD20A3		ENSG00000276203	Ankyrin repeat domain 20 family member A3	9	66106815-66153135	Predicted intracellular proteins	Evidence at transcript level	HPA043239, HPA047112, HPA047167, HPA047766, HPA051753	Uncertain					Not detected	Not detected			testis: 0.4	Cell line enhanced		HDLM-2: 1.2
PIK3R6	C17orf38, FLJ34500, HsT41028, p87PIKAP	ENSG00000276231	Phosphoinositide-3-kinase regulatory subunit 6	17	8802723-8867677	Predicted intracellular proteins	Evidence at protein level	HPA023077	Approved				Renal cancer:1.50e-6 (unfavourable)	Mixed	Mixed			spleen: 4.1	Cell line enriched	7	HMC-1: 131.5
TADA2A	ADA2, ADA2A, hADA2, TADA2L	ENSG00000276234	Transcriptional adaptor 2A	17	37406874-37479730	Predicted intracellular proteins	Evidence at transcript level	HPA076497			Approved	Nuclear speckles	Renal cancer:2.25e-5 (unfavourable)	Expressed in all	Mixed			testis: 13.8	Mixed		
AC011043.1		ENSG00000276256	Homo sapiens uncharacterized LOC389831 (LOC389831), transcript variant 3, mRNA.	Unmapped	42939-49164	Predicted intracellular proteins	Evidence at transcript level								Mixed			kidney: 69.3	Mixed		
KCNE1B		ENSG00000276289	Potassium voltage-gated channel subfamily E regulatory subunit 1B	21	7816675-7829926	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enhanced		fallopian tube: 9.1;heart muscle: 4.0	kidney: 2.9	Cell line enhanced		CACO-2: 1.5
PIP4K2B	PIP5K2B, PIP5KIIB, PIP5KIIbeta	ENSG00000276293	Phosphatidylinositol-5-phosphate 4-kinase type 2 beta	17	38765689-38800126	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA047875, HPA062220	Approved		Supported	Nucleoplasm	Thyroid cancer:1.36e-4 (favourable), Liver cancer:4.54e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 51.6	Expressed in all		
RP5-874C20.8		ENSG00000276302		6	28267121-28281580	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			cerebral cortex: 1.7	Cell line enhanced		HEK 293: 1.9
AC004556.1		ENSG00000276345		Unmapped	2585-11802	Predicted intracellular proteins	Evidence at protein level	HPA050406	Uncertain		Supported	Nucleoli fibrillar center<br>Mitochondria			Mixed			breast: 24.8	Cell line enhanced		NB-4: 110.2;PC-3: 145.9;WM-115: 112.0
HIST1H2AJ	H2A/E, H2AFE	ENSG00000276368	Histone cluster 1 H2A family member j	6	27814354-27814740	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 6.4	lymph node: 1.4	Cell line enhanced		MCF7: 14.3
CCL14	CKb1, HCC-1, HCC-3, MCIF, NCC-2, SCYA14, SCYL2	ENSG00000276409	C-C motif chemokine ligand 14	17	35983291-35987004	Cancer-related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB004423, HPA030268	Uncertain					Mixed	Tissue enhanced		spleen: 271.8	adipose tissue: 123.7	Cell line enriched	53	HUVEC TERT2: 46.6
HIST1H2BB	H2B/f, H2BFF	ENSG00000276410	Histone cluster 1 H2B family member b	6	26043277-26043657	Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Group enriched	5	bone marrow: 1.1;testis: 3.1	esophagus,lymph node: 0.3	Cell line enhanced		MOLT-4: 1.9;THP-1: 1.9;U-266/84: 2.2
FAM25C	bA164N7.4	ENSG00000276430	Family with sequence similarity 25 member C	10	47995355-47999791	Predicted intracellular proteins	Evidence at transcript level	HPA044808	Uncertain					Tissue enhanced	Group enriched	14	breast: 5.3;esophagus: 4.0;skin: 9.0;small intestine: 4.3;tonsil: 2.1	skeletal muscle,testis: 0.3	Cell line enriched	5	SK-BR-3: 12.1
PCDHGB5	PCDH-GAMMA-B5	ENSG00000276547	Protocadherin gamma subfamily B, 5	5	141397987-141512979	Predicted membrane proteins	Evidence at protein level	HPA008755, HPA010580	Uncertain		Approved	Nucleus<br>Vesicles<br>Plasma membrane<br>Cytosol		Mixed	Tissue enhanced		parathyroid gland: 19.8	thyroid gland: 7.6	Cell line enhanced		ASC diff: 45.6;ASC TERT1: 34.8;BJ hTERT+ SV40 Large T+: 27.3;BJ hTERT+ SV40 Large T+ RasG12V: 31.8
SPATA31A5	FAM75A5	ENSG00000276581	SPATA31 subfamily A member 5	9	60914374-60920650	Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.7	Not detected		
RAB7B	MGC16212, MGC9726	ENSG00000276600	RAB7B, member RAS oncogene family	1	205976740-206003461	Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:4.87e-4 (unfavourable)	Expressed in all	Tissue enhanced		skin: 59.9	gallbladder: 22.9	Cell line enhanced		HBEC3-KT: 23.4;HMC-1: 75.9;hTCEpi: 26.8
CH507-9B2.4		ENSG00000276612		21	5116343-5133805	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland: 0.9	Cell line enhanced		RH-30: 3.3
DACH1	DACH	ENSG00000276644	Dachshund family transcription factor 1	13	71437966-71867192	Predicted intracellular proteins	Evidence at protein level	HPA012672	Approved		Supported	Nucleoplasm<br>Vesicles		Mixed	Mixed			cervix, uterine: 15.0	Cell line enhanced		HAP1: 23.2;HL-60: 30.0;SCLC-21H: 43.5;SH-SY5Y: 31.4;THP-1: 18.1
PADI6		ENSG00000276747	Peptidyl arginine deiminase 6	1	17372196-17401699	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC136352.1		ENSG00000276760		Unmapped	136160-167571	Predicted intracellular proteins	No evidence	HPA042822	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
HIST1H2AL	dJ193B12.9, H2A/i, H2AFI	ENSG00000276903	Histone cluster 1 H2A family member l	6	27865355-27865747	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enriched	6	bone marrow: 5.2	parathyroid gland: 0.8	Cell line enhanced		MOLT-4: 5.3
RP4-608O15.3		ENSG00000276911		1	196819745-196959210	Predicted secreted proteins	Evidence at protein level	HPA038915, HPA040726, HPA049813	Supported					Not detected	Tissue enriched	527	liver: 203.7	kidney: 0.3	Not detected		
GSTTP1	HS322B1A	ENSG00000276950	Glutathione S-transferase theta pseudogene 1	22	23998401-24005453	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.4	Not detected		
HIST1H4E	H4/j, H4FJ	ENSG00000276966	Histone cluster 1 H4 family member e	6	26204552-26206038	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:2.00e-6 (unfavourable)	Expressed in all	Mixed			prostate: 2.3	Cell line enhanced		U-266/70: 8.6
HNRNPCL3		ENSG00000277058	Heterogeneous nuclear ribonucleoprotein C-like 3	1	13060869-13062229	Predicted intracellular proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HIST1H2AE	H2A.1, H2A/a, H2AFA	ENSG00000277075	Histone cluster 1 H2A family member e	6	26216975-26217483	Predicted intracellular proteins	Evidence at protein level	CAB012242, HPA041189	Supported		Supported	Nucleoplasm		Expressed in all	Tissue enhanced		breast: 54.1	prostate: 21.5	Cell line enhanced		U-266/70: 28.2
CH507-9B2.1		ENSG00000277117		21	5022493-5040666	Predicted membrane proteins	Evidence at protein level	HPA029179			Supported	Plasma membrane<br>Cytoplasmic bodies		Mixed	Mixed			cerebral cortex: 11.2	Cell line enhanced		BEWO: 20.4;REH: 15.6;SiHa: 15.3
TYW1B	LINC00069, MGC87315, NCRNA00069, RSAFD2	ENSG00000277149	TRNA-yW synthesizing protein 1 homolog B	7	72558744-72828198	Predicted membrane proteins	Evidence at protein level	HPA013568, HPA014118, HPA043136, HPA047029, HPA047052, HPA052097	Approved		Approved	Nucleus<br>Nucleoli		Expressed in all	Mixed			ovary: 6.7	Mixed		
F8A3		ENSG00000277150	Coagulation factor VIII-associated 3	X	155456914-155458672	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain					Not detected	Tissue enhanced		parathyroid gland: 32.9	cerebral cortex: 10.5	Cell line enhanced		U-266/70: 31.3;U-266/84: 28.7
HIST1H4D	H4/b, H4FB	ENSG00000277157	Histone cluster 1 H4 family member d	6	26188765-26189076	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Mixed			fallopian tube: 1.7	Cell line enhanced		HEK 293: 8.2;RT4: 11.7
PIGW	FLJ37433, Gwt1	ENSG00000277161	Phosphatidylinositol glycan anchor biosynthesis class W	17	36535020-36539310	Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA023499			Approved	Plasma membrane		Expressed in all	Mixed			appendix: 5.1	Expressed in all		
AC007325.2		ENSG00000277196		Unmapped	138082-161852	Predicted intracellular proteins	Evidence at transcript level	HPA020361	Uncertain						Tissue enhanced		skin: 38.5;small intestine: 37.1	duodenum: 29.0	Cell line enriched	7	RPTEC TERT1: 137.9
F8A1	DXS522E, F8A	ENSG00000277203	Coagulation factor VIII-associated 1	X	154886349-154888061	Predicted intracellular proteins	Evidence at protein level	HPA046960	Uncertain				Cervical cancer:1.67e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 30.2	Mixed		
HIST1H2BF	H2B/g, H2BFG	ENSG00000277224	Histone cluster 1 H2B family member f	6	26199520-26200715	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		esophagus: 3.5;prostate: 2.6	breast: 2.2	Cell line enhanced		U-266/70: 18.9;U-266/84: 13.1
PCGF2	MEL-18, RNF110, ZNF144	ENSG00000277258	Polycomb group ring finger 2	17	38733897-38749817	Predicted intracellular proteins	Evidence at protein level	HPA047732, HPA063531	Uncertain		Supported	Nucleus	Colorectal cancer:4.55e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 20.1	Mixed		
CH507-396I9.7		ENSG00000277277		21	7768884-7770591	Predicted intracellular proteins	Evidence at transcript level	HPA045123	Uncertain					Not detected	Mixed			cerebral cortex: 3.0	Mixed		
C10orf142		ENSG00000277288	Chromosome 10 open reading frame 142	10	44292569-44294649	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		testis: 2.3	spleen: 1.5	Cell line enhanced		RPMI-8226: 1.6;U-2197: 5.2;U-87 MG: 2.0
GOLGA6L6	FLJ36131	ENSG00000277322	Golgin A6 family-like 6	15	20531856-20541800	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	41	testis: 4.1	all non-specific tissues: 0.0	Not detected		
SRCIN1	KIAA1684, p140Cap, SNIP	ENSG00000277363	SRC kinase signaling inhibitor 1	17	38530016-38605930	Predicted intracellular proteins	Evidence at protein level	HPA009701, HPA063795	Enhanced		Approved	Cell Junctions	Urothelial cancer:1.76e-4 (favourable)	Mixed	Tissue enhanced		cerebral cortex: 22.1	skin: 4.7	Cell line enriched	5	SCLC-21H: 14.7
GPR179	CSNB1E, GPR158L1	ENSG00000277399	G protein-coupled receptor 179	17	38325530-38343847	Predicted membrane proteins	No evidence	HPA017885	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
AC145212.2		ENSG00000277400	MaFF-interacting protein 	Unmapped	53590-115018	Predicted secreted proteins	Evidence at protein level								Mixed			ovary: 8.1	Mixed		
MARCKS	80K-L, MACS, PKCSL	ENSG00000277443	Myristoylated alanine rich protein kinase C substrate	6	113857362-113863471	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB022062, HPA054820, HPA067595, HPA069443	Enhanced		Approved	Nucleus<br>Endoplasmic reticulum<br>Plasma membrane<br>Cytosol	Liver cancer:2.78e-8 (unfavourable), Renal cancer:4.85e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 218.8	Cell line enhanced		AF22: 402.5
ZNF670	MGC12466	ENSG00000277462	Zinc finger protein 670	1	247036784-247078755	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003142	Uncertain		Approved	Nucleus<br>Cytosol		Expressed in all	Mixed			testis: 6.1	Expressed in all		
AC213203.1		ENSG00000277475		Unmapped	31698-32528	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	11	testis: 24.2	lung: 2.2	Cell line enhanced		A549: 6.4;HMC-1: 4.8;SCLC-21H: 5.4
PKD1L3		ENSG00000277481	Polycystin 1 like 3, transient receptor potential channel interacting	16	71929538-71999978	Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			testis: 0.7	Not detected		
GPIHBP1	GPI-HBP1, LOC338328	ENSG00000277494	Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1	8	143213193-143217170	Disease related genes, Predicted secreted proteins	Evidence at protein level	HPA066302	Enhanced					Mixed	Group enriched	6	adipose tissue: 94.2;lung: 33.0	skeletal muscle: 10.5	Cell line enhanced		Karpas-707: 2.3
LLNLF-187D8.1		ENSG00000277531		19	46424697-46428951	Predicted intracellular proteins	Evidence at transcript level							Tissue enriched	Tissue enriched	9	cerebral cortex: 23.3	epididymis: 2.5	Group enriched	5	AF22: 1.1;HMC-1: 2.2;SH-SY5Y: 4.0
RP13-347D8.7		ENSG00000277535		X	119073226-119076373	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	76	testis: 7.6	all non-specific tissues: 0.0	Not detected		
OR13C5		ENSG00000277556	Olfactory receptor family 13 subfamily C member 5	9	104598457-104599413	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			adrenal gland,fallopian tube,seminal vesicle,testis,thyroid gland: 0.1	Not detected		
NEFL	CMT1F, CMT2E, NF68, NFL, PPP1R110	ENSG00000277586	Neurofilament light	8	24950955-24957110	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA014850, HPA015021	Enhanced	Supported	Approved	Nuclear speckles<br>Intermediate filaments	Renal cancer:4.91e-4 (unfavourable)	Tissue enhanced	Tissue enriched	10	cerebral cortex: 289.3	adrenal gland: 29.0	Cell line enhanced		HEK 293: 544.8;PC-3: 147.7
BX072566.1		ENSG00000277630	Uncharacterized protein LOC100288966 	Unmapped	108007-139659	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain						Tissue enriched	74	testis: 7.4	all non-specific tissues: 0.0	Not detected		
CCL3	G0S19-1, LD78ALPHA, MIP-1-alpha, SCYA3	ENSG00000277632	C-C motif chemokine ligand 3	17	36088256-36090169	Cancer-related genes, Predicted secreted proteins	Evidence at protein level							Expressed in all	Tissue enhanced		bone marrow: 50.2	adipose tissue: 12.5	Group enriched	14	Karpas-707: 110.0;U-266/70: 198.4;U-266/84: 494.6
RP11-467J12.4		ENSG00000277639		16	53035690-53052873	Predicted intracellular proteins	Evidence at transcript level							Tissue enhanced	Tissue enriched	7	fallopian tube: 124.4	cervix, uterine: 18.1	Cell line enhanced		BEWO: 11.2
AC136352.2		ENSG00000277666		Unmapped	100123-101141	Predicted secreted proteins	Evidence at protein level	HPA003342	Uncertain						Not detected			all non-specific tissues: 0.0	Not detected		
AC009133.22		ENSG00000277669		16	29663279-29695144	Predicted secreted proteins	Evidence at protein level	HPA011887	Uncertain					Not detected	Tissue enhanced		colon: 2.6;duodenum: 1.8;spleen: 1.0	lung: 0.4	Cell line enhanced		BEWO: 44.0;EFO-21: 114.1;SH-SY5Y: 19.3
RP4-635E18.9		ENSG00000277726		1	11012662-11030528	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			epididymis: 3.0	Cell line enhanced		Hep G2: 2.1;MCF7: 1.1;RT4: 1.6
H2AFB3	H2AFB	ENSG00000277745	H2A histone family member B3	X	155459415-155460005	Predicted intracellular proteins	Evidence at protein level							Not detected	Tissue enriched	56	testis: 18.5	spleen: 0.3	Cell line enriched	7	HDLM-2: 8.3
ABC7-42404400C24.1		ENSG00000277758		10	47750864-47763592	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level	HPA036971, HPA036972, HPA064559	Approved		Approved	Golgi apparatus		Not detected	Tissue enhanced		cerebral cortex: 13.8;lung: 19.3	skin: 5.7	Cell line enriched	7	SK-BR-3: 45.1
AC136616.2		ENSG00000277761		Unmapped	1167457-1257196	Predicted intracellular proteins	Evidence at transcript level								Mixed			colon: 76.7	Not detected		
HIST1H3F	H3/i, H3FI	ENSG00000277775	Histone cluster 1 H3 family member f	6	26250195-26250605	Predicted intracellular proteins	Evidence at protein level	HPA042570, CAB070190	Supported					Mixed	Tissue enhanced		bone marrow: 1.4	lymph node: 0.7	Cell line enhanced		U-266/84: 4.6
PSMB3	HC10-II, MGC4147	ENSG00000277791	Proteasome subunit beta 3	17	38752736-38764231	Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042775, HPA048147	Approved		Enhanced	Mitochondria	Renal cancer:1.71e-6 (unfavourable)	Expressed in all	Expressed in all			epididymis: 83.6	Expressed in all		
AC141272.1		ENSG00000277836		Unmapped	1270984-1271271	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		tonsil: 114.8	urinary bladder: 94.9	Cell line enhanced		RPMI-8226: 1.3
AC233755.2		ENSG00000277856		Unmapped	26241-26534	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		tonsil: 197.2	lymph node: 99.3	Cell line enhanced		MOLT-4: 6.1;REH: 2.1;SH-SY5Y: 2.5;TIME: 1.3
H2AFB2		ENSG00000277858	H2A histone family member B2	X	155380787-155381134	Predicted intracellular proteins	Evidence at protein level							Not detected	Not detected			duodenum: 0.6	Not detected		
GOLGA6L22		ENSG00000277865	Golgin A6 family-like 22	15	22458903-22469230	Predicted intracellular proteins	Evidence at transcript level	HPA047733	Uncertain					Not detected	Tissue enriched	19	testis: 5.2	cerebral cortex,skin: 0.2	Not detected		
FAM230A	DGCR15	ENSG00000277870	Family with sequence similarity 230 member A	22	18422244-18500594	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	26	testis: 24.1	stomach: 0.9	Cell line enhanced		A549: 16.6;U-266/84: 10.9
SRD5A2		ENSG00000277893	Steroid 5 alpha-reductase 2	2	31522480-31581067	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Group enriched	Group enriched	11	epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5	testis: 2.5	Cell line enhanced		RT4: 1.2
OR52E5		ENSG00000277932	Olfactory receptor family 52 subfamily E member 5	11	5900777-5902090	G-protein coupled receptors, Predicted membrane proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
CISD3	Miner2	ENSG00000277972	CDGSH iron sulfur domain 3	17	38730235-38735044	Predicted intracellular proteins	Evidence at protein level	HPA053436, HPA054400	Approved					Expressed in all	Mixed			thyroid gland: 8.5	Mixed		
RDM1	MGC33977, RAD52B	ENSG00000278023	RAD52 motif containing 1	17	35918066-35930773	Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA024794, HPA067546	Enhanced		Supported	Nucleoli<br>Cytosol		Mixed	Tissue enriched	6	testis: 9.7	tonsil: 1.6	Cell line enhanced		T-47d: 17.4
DDX52	ROK1	ENSG00000278053	DExD-box helicase 52	17	37609739-37643464	Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA056173	Uncertain		Supported	Nucleus<br>Nucleoli	Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:9.41e-4 (favourable)	Expressed in all	Mixed			epididymis: 4.6	Mixed		
TEX28	CXorf2, fTEX	ENSG00000278057	Testis expressed 28	X	154271265-154295853	Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	33	testis: 6.2	bone marrow,skin: 0.1	Not detected		
CT45A8		ENSG00000278085	Cancer/testis antigen family 45 member A8	X	135846499-135854538	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Group enriched	6	AN3-CA: 18.9;HMC-1: 39.4
ZNF8	HF.18, Zfp128	ENSG00000278129	Zinc finger protein 8	19	58278951-58302805	Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA034797, HPA034798	Uncertain		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			parathyroid gland: 4.5	Mixed		
RP4-533D7.6		ENSG00000278139		1	46043661-46176488	Predicted intracellular proteins, RAS pathway related proteins	Evidence at transcript level	HPA005751	Uncertain					Not detected	Tissue enriched	30	testis: 41.3	gallbladder: 1.3	Cell line enhanced		HeLa: 2.1;RT4: 8.4
SSTR3		ENSG00000278195	Somatostatin receptor 3	22	37204238-37212322	G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	CAB022647	Approved					Tissue enhanced	Tissue enhanced		testis: 10.9	cerebral cortex: 3.9	Group enriched	12	RPMI-8226: 16.5;SCLC-21H: 10.1
AC011043.2		ENSG00000278198		Unmapped	173872-179372	Predicted intracellular proteins	Evidence at transcript level								Not detected			skin: 0.4	Cell line enhanced		A-431: 2.4
PRICKLE4	C6orf49, DKFZp761H221, OEBT	ENSG00000278224	Prickle planar cell polarity protein 4	6	41780762-41787372	Predicted intracellular proteins	Evidence at transcript level	HPA031240			Uncertain	Mitotic spindle<br>Microtubule organizing center		Not detected	Mixed			fallopian tube: 3.9	Cell line enhanced		BEWO: 3.9
MYO19	FLJ22865, MYOHD1	ENSG00000278259	Myosin XIX	17	36495633-36543435	Predicted intracellular proteins	Evidence at protein level	HPA021415, HPA059715	Approved		Enhanced	Cytosol	Liver cancer:8.33e-6 (unfavourable)	Expressed in all	Expressed in all			skin: 14.5	Expressed in all		
HIST1H3C	H3.1, H3/c, H3FC	ENSG00000278272	Histone cluster 1 H3 family member c	6	26045411-26045821	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enhanced		bone marrow: 3.3	testis: 1.3	Cell line enhanced		U-937: 6.7
CT45A6	CT45-6, CT45.6	ENSG00000278289	Cancer/testis antigen family 45 member A6	X	135794706-135802656	Predicted intracellular proteins	Evidence at protein level	HPA044735, HPA044757, HPA046872, HPA046987	Supported		Approved	Nucleus<br>Nucleoli		Not detected	Not detected			testis: 0.7	Cell line enriched	7	U-266/84: 72.2
TBC1D3C	MGC44903	ENSG00000278299	TBC1 domain family member 3C	17	38057693-38068592	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		testis: 3.3	skin: 2.1	Cell line enhanced		CAPAN-2: 30.1;HeLa: 4.4;T-47d: 6.5
GGNBP2	DIF-3, DIF3, FLJ21230, FLJ22561, LZK1, ZFP403, ZNF403	ENSG00000278311	Gametogenetin binding protein 2	17	36544888-36589848	Predicted intracellular proteins	Evidence at protein level	HPA018914, HPA073392	Approved		Approved	Endoplasmic reticulum		Expressed in all	Expressed in all			testis: 55.7	Expressed in all		
ZNF229		ENSG00000278318	Zinc finger protein 229	19	44417519-44448578	Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA001494	Uncertain		Approved	Vesicles<br>Plasma membrane	Renal cancer:8.43e-5 (favourable)	Mixed	Tissue enhanced		parathyroid gland: 6.7	fallopian tube,thyroid gland: 3.1	Mixed		
AL354822.1		ENSG00000278384		Unmapped	51867-54893	Predicted intracellular proteins	Evidence at transcript level								Mixed			skin: 3.4	Mixed		
HIST1H2AB	H2A/m, H2AFM	ENSG00000278463	Histone cluster 1 H2A family member b	6	26033176-26033568	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Tissue enhanced		bone marrow: 1.6	lymph node,testis: 0.6	Cell line enhanced		Hep G2: 3.4
RP11-457D20.2		ENSG00000278499	Putative UPF0607 protein ENSP00000381418 	16	60358455-60359480	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	17	testis: 4.3	skeletal muscle: 0.2	Not detected		
C17orf78	FLJ39647	ENSG00000278505	Chromosome 17 open reading frame 78	17	37375986-37392708	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Group enriched	Group enriched	74	duodenum: 99.1;small intestine: 50.9	testis: 1.0	Not detected		
POTEB3		ENSG00000278522	POTE ankyrin domain family member B3	15	21408243-21440451	Predicted intracellular proteins	Evidence at transcript level	HPA042822	Uncertain					Not detected	Tissue enriched	22	testis: 2.2	all non-specific tissues: 0.0	Not detected		
DHRS11	MGC4172, SDR24C1	ENSG00000278535	Dehydrogenase/reductase 11	17	36591798-36600806	Predicted intracellular proteins	Evidence at protein level	HPA041226, HPA048236, HPA053623	Enhanced		Approved	Golgi apparatus<br>Cytosol	Renal cancer:3.24e-4 (favourable)	Expressed in all	Group enriched	8	colon: 44.6;duodenum: 149.5;rectum: 47.1;small intestine: 133.6	testis: 11.8	Mixed		
ACACA	ACAC, ACC, ACC1	ENSG00000278540	Acetyl-CoA carboxylase alpha	17	37084988-37406818	Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB013715, HPA036650, HPA063018	Approved		Supported	Nucleoli fibrillar center<br>Actin filaments<br>Cytosol	Liver cancer:1.24e-5 (unfavourable)	Expressed in all	Mixed			breast: 28.8	Expressed in all		
TMEM191B		ENSG00000278558	Transmembrane protein 191B	22	18527802-18530573	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level							Not detected	Tissue enriched	15	testis: 14.7	spleen: 0.9	Cell line enhanced		BEWO: 1.4;CACO-2: 1.0
OR4F29		ENSG00000278566	Olfactory receptor family 4 subfamily F member 29	1	450740-451678	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level	HPA047705	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
NR2E3	PNR, rd7, RP37	ENSG00000278570	Nuclear receptor subfamily 2 group E member 3	15	71792638-71818259	Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Mixed	Not detected			prostate: 0.7	Not detected		
HIST1H2BI	H2B/k, H2BFK	ENSG00000278588	Histone cluster 1 H2B family member i	6	26272976-26273356	Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA042205, HPA043013, HPA048671	Supported		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		bone marrow: 1.9;lymph node: 1.7	testis,urinary bladder: 0.7	Cell line enhanced		MOLT-4: 10.0
TBC1D3E		ENSG00000278599	TBC1 domain family member 3E	17	38127951-38138862	Predicted membrane proteins	Evidence at protein level	HPA046969, HPA047745, HPA052553	Approved		Uncertain	Vesicles		Not detected	Tissue enhanced		bone marrow: 1.1;gallbladder: 1.8;testis: 3.1	lymph node: 0.9	Cell line enhanced		HHSteC: 3.4
C11orf98	C11orf48	ENSG00000278615	Chromosome 11 open reading frame 98	11	62662816-62665217	Predicted intracellular proteins	Evidence at transcript level						Renal cancer:4.02e-6 (unfavourable), Liver cancer:5.85e-5 (unfavourable), Endometrial cancer:7.62e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 80.3	Expressed in all		
MRM1	FLJ22578	ENSG00000278619	Mitochondrial rRNA methyltransferase 1	17	36601572-36608971	Predicted intracellular proteins	Evidence at protein level	HPA021598	Supported		Enhanced	Mitochondria		Expressed in all	Mixed			adrenal gland: 5.0	Mixed		
AC023491.2		ENSG00000278633		Unmapped	10598-13001	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	545	testis: 67.4	parathyroid gland,small intestine: 0.1	Not detected		
HIST1H4A	H4FA	ENSG00000278637	Histone cluster 1 H4 family member a	6	26021679-26021990	Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB021887, HPA042201	Supported					Mixed	Mixed			appendix: 1.9	Cell line enhanced		MOLT-4: 11.9;REH: 12.2
RP1-321E8.5		ENSG00000278646		X	120877496-120878924	Predicted intracellular proteins	Evidence at protein level	HPA042483	Supported					Not detected	Tissue enriched	8	testis: 3.3	adrenal gland: 0.4	Cell line enhanced		U-266/70: 2.9
GOLGA6L10	GOLGA6L18	ENSG00000278662	Golgin A6 family-like 10	15	82339998-82349475	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	7	testis: 8.7	ovary,skin: 1.2	Cell line enhanced		HEK 293: 3.0;SK-MEL-30: 1.3
ELOA3B	HsT828, TCEB3CL	ENSG00000278674	Elongin A3 family member B	18	47022287-47023927	Predicted intracellular proteins	No evidence	HPA048971, HPA049178, HPA050086	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
HIST1H2AM	H2A.1, H2A/n, H2AFN	ENSG00000278677	Histone cluster 1 H2A family member m	6	27892757-27893149	Predicted intracellular proteins	Evidence at protein level	HPA041189	Supported					Mixed	Mixed			bone marrow,lymph node: 2.6	Cell line enhanced		U-266/84: 26.9
IQCA1L	IQCA1P1, TCAG_9762	ENSG00000278685	IQ motif containing with AAA domain 1 like	7	151190873-151205496	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enriched	41	testis: 4.0	all non-specific tissues: 0.0	Not detected		
BX004987.1		ENSG00000278704		Unmapped	56140-58376	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 3.3	Cell line enhanced		K-562: 22.1;U-2 OS: 18.2
HIST1H4B	H4/I, H4FI	ENSG00000278705	Histone cluster 1 H4 family member b	6	26026815-26027252	Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported					Mixed	Tissue enhanced		bone marrow: 1.3	lymph node: 0.8	Mixed		
AC136616.3		ENSG00000278782		Unmapped	1157687-1240349	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cervix, uterine: 8.6;tonsil: 6.6	breast,small intestine: 5.4	Not detected		
AC007325.4		ENSG00000278817		Unmapped	131494-137392	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cerebral cortex: 27.4;heart muscle: 34.4;skeletal muscle: 40.5	thyroid gland: 14.9	Cell line enhanced		A549: 14.5;T-47d: 10.8
HIST1H3H	H3/k, H3F1K, H3FK	ENSG00000278828	Histone cluster 1 H3 family member h	6	27810064-27811300	Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported				Pancreatic cancer:9.25e-6 (unfavourable), Renal cancer:5.73e-5 (unfavourable), Cervical cancer:4.35e-4 (favourable)	Expressed in all	Mixed			rectum: 2.9	Cell line enhanced		K-562: 30.1;SiHa: 30.0;U-266/84: 42.9
MRPL45	MGC11321	ENSG00000278845	Mitochondrial ribosomal protein L45	17	38297023-38323218	Predicted intracellular proteins	Evidence at protein level	HPA023373, HPA023385	Enhanced		Enhanced	Mitochondria		Expressed in all	Mixed			endometrium: 10.2	Cell line enhanced		AF22: 27.5;Daudi: 49.3;K-562: 38.3;REH: 31.0;U-266/84: 28.8;U-698: 34.9
TP53TG3F		ENSG00000278848	TP53 target 3 family member F	16	33459045-33462249	Predicted intracellular proteins	Evidence at transcript level							Not detected	Group enriched	14	epididymis: 7.4;testis: 4.2	placenta: 0.4	Cell line enhanced		HEL: 1.0
OR2S2		ENSG00000278889	Olfactory receptor family 2 subfamily S member 2 (gene/pseudogene)	9	35957108-35958154	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CH507-396I9.3		ENSG00000278961		21	7788703-7793954	Predicted membrane proteins	Evidence at transcript level	HPA029085	Uncertain					Not detected	Group enriched	7	breast: 1.5;fallopian tube: 1.4;kidney: 4.3	skin: 0.3	Not detected		
OR6Q1		ENSG00000279051	Olfactory receptor family 6 subfamily Q member 1 (gene/pseudogene)	11	58030930-58031931	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CH17-140K24.5		ENSG00000279068		5	141182409-141188582	Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			endometrium: 1.6	Cell line enhanced		AN3-CA: 5.5;RH-30: 3.5;U-138 MG: 7.2;U-2197: 4.5
FAM231C		ENSG00000279132	Family with sequence similarity 231 member C	1	16733952-16734461	Predicted intracellular proteins	No evidence	HPA043267, HPA043292	Uncertain					Not detected	Not detected			testis: 0.1	Not detected		
PRAMEF13		ENSG00000279169	PRAME family member 13	1	13196330-13201409	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.1	Not detected		
RP11-294C11.3		ENSG00000279408		15	21651844-21653039	Predicted membrane proteins	Evidence at transcript level	HPA057442	Uncertain		Uncertain	Centrosome		Not detected	Tissue enriched	17	testis: 14.6	cerebral cortex: 0.8	Cell line enriched	42	U-2 OS: 6.9
OR2AG1	OR2AG3	ENSG00000279486	Olfactory receptor family 2 subfamily AG member 1 (gene/pseudogene)	11	6785017-6786014	G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CH507-9B2.2		ENSG00000279493		21	5011799-5017145	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		kidney: 1.8;liver: 2.7	lymph node: 0.5	Cell line enhanced		BEWO: 1.3;CACO-2: 2.4;MCF7: 1.6;SiHa: 3.5
RP11-437B10.1		ENSG00000279765		15	92883413-92949230	Predicted intracellular proteins	Evidence at transcript level							Not detected	Expressed in all			bone marrow: 243.6	Mixed		
AL513523.2		ENSG00000279767		1	153772371-153774079	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		lymph node: 1.4;skin: 3.5	cerebral cortex,lung: 0.8	Cell line enhanced		MCF7: 7.6;SK-BR-3: 5.9;THP-1: 5.5
PPIAL4F		ENSG00000279782	Peptidylprolyl isomerase A like 4F	1	144592868-144593527	Enzymes, Predicted intracellular proteins	No evidence	HPA058345	Uncertain					Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PRAMEF18		ENSG00000279804	PRAME family member 18	1	13222705-13226106	Predicted intracellular proteins	No evidence	HPA057423	Uncertain					Not detected	Not detected			bone marrow: 0.1	Not detected		
GVQW2		ENSG00000279968	GVQW motif containing 2	6	138725211-138773652	Predicted intracellular proteins	Evidence at transcript level							Mixed	Tissue enhanced		testis: 2.3	epididymis,thyroid gland: 0.5	Cell line enhanced		HEL: 1.9
CH17-140K24.8		ENSG00000279983		5	141223372-141245861	Predicted intracellular proteins	Evidence at transcript level							Not detected	Tissue enhanced		epididymis: 1.5	endometrium: 0.8	Not detected		
CH507-9B2.3		ENSG00000280071		21	5079294-5128425	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA018517	Uncertain		Approved	Centrosome<br>Mitochondria		Mixed	Expressed in all			kidney: 148.3	Mixed		
OR8B4	OR8B4P	ENSG00000280090	Olfactory receptor family 8 subfamily B member 4 (gene/pseudogene)	11	124423904-124424893	G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
PCDH20	FLJ22218, PCDH13	ENSG00000280165	Protocadherin 20	13	61409685-61415522	Predicted membrane proteins	Evidence at protein level	HPA062669			Approved	Vesicles<br>Cytokinetic bridge		Not detected	Tissue enhanced		cerebral cortex: 14.5;smooth muscle: 13.0	lung: 5.0	Cell line enriched	12	RPTEC TERT1: 39.0
PRAMEF26		ENSG00000280267	PRAME family member 26	1	13148905-13155961	Predicted intracellular proteins	No evidence							Not detected	Not detected			all non-specific tissues: 0.0	Not detected		
CH507-9B2.9		ENSG00000280433		21	5155499-5165472	Predicted intracellular proteins	Evidence at transcript level							Mixed	Mixed			lymph node: 13.6	Mixed		
CCDC163	C1orf231, CCDC163P, LOC126661	ENSG00000280670	Coiled-coil domain containing 163	1	45493866-45500079	Predicted membrane proteins	Evidence at transcript level						Thyroid cancer:5.05e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 2.3	thyroid gland: 1.5	Cell line enhanced		U-266/70: 5.1
CH17-270A2.2		ENSG00000280778		1	145927258-145977811	Predicted intracellular proteins	No evidence							Not detected	Not detected			testis: 0.2	Not detected		
PAGR1	C16orf53, GAS, MGC4606, PA1	ENSG00000280789	PAXIP1 associated glutamate rich protein 1	16	29815952-29820117	Predicted intracellular proteins	Evidence at protein level	HPA041440, HPA043608	Uncertain					Expressed in all	Expressed in all			ovary: 60.4	Expressed in all		
RPS4Y2	RPS4Y2P	ENSG00000280969	Ribosomal protein S4, Y-linked 2	Y	20756164-20781032	Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA000857	Uncertain					Tissue enriched	Group enriched	13	prostate: 3.5;testis: 2.2	tonsil: 0.2	Cell line enriched	7	U-266/84: 1.3
MATR3		ENSG00000280987	Matrin 3	5	139273752-139331671	Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA036564, HPA036565	Supported		Approved	Nucleoplasm		Not detected	Expressed in all			cerebral cortex: 48.4	Expressed in all		
RP11-717K11.2		ENSG00000281028		4	25160663-25277306	Predicted intracellular proteins	Evidence at protein level	HPA004099	Uncertain		Uncertain	Cytosol		Not detected	Mixed			testis: 11.3	Mixed		
RP4-777O23.3		ENSG00000281039		7	30497077-30550761	Predicted intracellular proteins	Evidence at protein level	HPA020735	Uncertain					Not detected	Mixed			epididymis: 30.5	Mixed		
LINC00282	FLJ37307, NCRNA00282	ENSG00000281106	Long intergenic non-protein coding RNA 282	13	51813347-51845175	Predicted membrane proteins	Evidence at transcript level							Not detected	Mixed			lymph node: 3.3	Cell line enhanced		BEWO: 1.0;SK-MEL-30: 2.7
RP11-506B6.7		ENSG00000281613		6	112236806-112350094	Predicted intracellular proteins	Evidence at transcript level	HPA059324	Uncertain					Not detected	Tissue enriched	14	testis: 8.2	placenta: 0.6	Cell line enriched	12	RPTEC TERT1: 2.7
GIMAP1-GIMAP5		ENSG00000281887	GIMAP1-GIMAP5 readthrough	7	150716668-150743646	Predicted membrane proteins	Evidence at protein level	HPA053441			Supported	Endoplasmic reticulum		Not detected	Tissue enhanced		spleen: 17.9	appendix: 14.9	Group enriched	9	HUVEC TERT2: 5.3;MOLT-4: 8.3;THP-1: 1.7;TIME: 3.9
AL359736.1		ENSG00000281899		13	24321126-24321428	Predicted intracellular proteins	No evidence							Not detected	Not detected			esophagus: 0.4	Not detected		
TMEM265		ENSG00000281991	Transmembrane protein 265	16	30740381-30744281	Predicted membrane proteins	Evidence at transcript level								Mixed			skin: 18.9	Cell line enhanced		CAPAN-2: 79.5;T-47d: 46.9
RP1-179P9.3		ENSG00000282218		6	117318211-117573571	Predicted intracellular proteins	Evidence at transcript level	HPA019477	Uncertain		Approved	Golgi apparatus<br>Cytosol			Not detected			epididymis,lung: 0.8	Cell line enriched	47	U-138 MG: 8.8
RP11-295P9.13		ENSG00000282246		10	13610047-13655929	Predicted intracellular proteins	Evidence at protein level	HPA047950	Uncertain						Mixed			skin: 14.3	Mixed		
RP11-231C18.3		ENSG00000282278		4	53377839-54295272	Predicted intracellular proteins	Evidence at protein level	HPA058202							Tissue enhanced		appendix: 1.2;cerebral cortex: 3.3	ovary,smooth muscle: 0.7	Cell line enhanced		BJ hTERT+: 2.8;fHDF/TERT166: 6.4;HDLM-2: 2.1;NTERA-2: 1.8;U-2197: 1.7
CYP3A7-CYP3A51P		ENSG00000282301	CYP3A7-CYP3A51P readthrough	7	99684957-99735102	Enzymes, Predicted membrane proteins	Evidence at protein level	HPA072245			Uncertain	Cytosol			Tissue enhanced		liver: 7.4	gallbladder: 1.9	Not detected		
TEX13D		ENSG00000282419	TEX13 family member D	X	124246249-124336862	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	33	testis: 3.2	all non-specific tissues: 0.0	Not detected		
ADORA3	AD026	ENSG00000282608	Adenosine A3 receptor	1	111499429-111503760	FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins	Evidence at transcript level								Mixed			adrenal gland: 18.4	Cell line enriched	12	HMC-1: 89.3
DUXB		ENSG00000282757	Double homeobox B	16	75693929-75701459	Predicted intracellular proteins	No evidence								Not detected			testis,thyroid gland: 0.3	Not detected		
RP3-369A17.6		ENSG00000282804		6	24797373-24809798	Predicted intracellular proteins	No evidence								Not detected			appendix: 0.5	Not detected		
TEX13C		ENSG00000282815	TEX13 family member C	X	125320120-125325214	Predicted intracellular proteins	Evidence at protein level								Tissue enriched	28	testis: 2.8	all non-specific tissues: 0.0	Not detected		
RP13-794C1.1		ENSG00000282827		3	48446846-48467645	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 1.3	thyroid gland: 0.6	Cell line enhanced		AF22: 1.8;NTERA-2: 1.4;RT4: 2.2
RP11-96L14.8		ENSG00000282872		1	26164161-26168581	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.6	Cell line enriched	10	SCLC-21H: 4.0
RP11-49P4.7		ENSG00000282881		1	46532166-46533614	Predicted membrane proteins	No evidence								Not detected			cerebral cortex: 0.3	Not detected		
CTC-281F24.5		ENSG00000282936		17	6636780-6640316	Predicted intracellular proteins	Evidence at transcript level								Mixed			cerebral cortex: 1.9	Mixed		
HIST1H3D	H3/b, H3FB	ENSG00000282988	Histone cluster 1 H3 family member d	6	26195595-26199293	Predicted intracellular proteins	Evidence at transcript level	HPA041189	Uncertain						Tissue enhanced		bone marrow: 2.1	prostate,testis: 0.7	Cell line enhanced		K-562: 5.4;SiHa: 5.8;U-266/70: 5.2
KLF18		ENSG00000283039	Kruppel like factor 18	1	44137821-44141631	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
RP11-736N17.11		ENSG00000283071	Homo sapiens translation initiation factor IF-2-like (LOC107984640), mRNA.	14	103084210-103090027	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 1.0	cerebral cortex: 0.5	Not detected		
CTD-2331H12.8		ENSG00000283088		19	52880663-52962768	Predicted intracellular proteins	Evidence at transcript level	HPA062474			Uncertain	Nucleoplasm<br>Cytoplasmic bodies			Mixed			parathyroid gland: 7.1	Cell line enhanced		RT4: 18.8
CENPVL2	CENPVP2	ENSG00000283093	Centromere protein V like 2	X	51681212-51682831	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		testis: 3.0	cerebral cortex: 0.8	Cell line enhanced		NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
RP11-134F2.8		ENSG00000283149		3	186581995-186597103	Predicted intracellular proteins	Evidence at protein level	HPA010814	Uncertain		Uncertain	Endoplasmic reticulum			Mixed			epididymis: 36.6	Mixed		
IQCJ-SCHIP1		ENSG00000283154	IQCJ-SCHIP1 readthrough	3	158962235-159897366	Predicted intracellular proteins	Evidence at protein level	HPA003243, HPA003445	Approved		Approved	Cytosol			Tissue enhanced		cerebral cortex: 99.0	smooth muscle: 36.8	Mixed		
RP11-949J7.8		ENSG00000283189		3	49416777-49429314	Predicted intracellular proteins	No evidence								Not detected			duodenum,lung: 0.2	Not detected		
ABC13-47488600E17.1		ENSG00000283199		13	113953705-113973997	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		stomach: 2.6;testis: 5.9	lung: 2.1	Cell line enhanced		hTEC/SVTERT24-B: 1.2
RP11-15H20.8		ENSG00000283201		19	23222755-23274221	Predicted intracellular proteins	Evidence at transcript level								Mixed			epididymis: 4.5	Mixed		
RP11-350E12.6		ENSG00000283205		9	87956214-87956883	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	40	testis: 7.3	cervix, uterine: 0.1	Not detected		
RP11-226E21.4		ENSG00000283208		13	76992078-77129589	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		bone marrow: 2.8	cerebral cortex,thyroid gland: 0.9	Not detected		
RP1-20N18.10		ENSG00000283227		1	152947154-152949258	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	8	skin: 50.7	breast: 6.5	Group enriched	9	HaCaT: 1.8;hTCEpi: 3.8
RP11-638I8.1		ENSG00000283247		7	45860008-45873082	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		placenta: 1.2	breast: 0.8	Not detected		
CTB-16J4.1		ENSG00000283267		7	90316503-90321308	Predicted secreted proteins	No evidence								Not detected			testis: 0.4	Not detected		
RP11-727F15.14		ENSG00000283268		11	62832319-62832803	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	34	testis: 40.8	thyroid gland: 1.2	Not detected		
AC138517.6		ENSG00000283288		5	139470778-139474772	Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		rectum: 2.6	colon: 1.6	Not detected		
RP4-816N1.8		ENSG00000283297	Uncharacterized protein ENSP00000372125 	12	2849039-2857083	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 4.3;testis: 7.4	appendix,lymph node,spleen: 1.3	Cell line enhanced		HeLa: 1.5;Karpas-707: 2.1
RP11-507K12.1		ENSG00000283321		7	17299295-17467234	Predicted intracellular proteins	Evidence at transcript level	HPA029722	Uncertain						Group enriched	5	cervix, uterine: 12.8;urinary bladder: 23.3	fallopian tube: 3.3	Cell line enriched	5	RT4: 44.0
RP11-235D19.4		ENSG00000283324		1	150887136-150913292	Predicted membrane proteins	Evidence at transcript level								Not detected			fallopian tube: 0.8	Cell line enriched	6	BEWO: 1.1
RP13-198D9.4		ENSG00000283329		9	38694263-38720428	Predicted intracellular proteins	No evidence								Not detected			testis: 0.8	Not detected		
RP11-569D9.5		ENSG00000283361		13	114179238-114223084	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	16	fallopian tube: 15.8	testis: 0.9	Not detected		
TXNRD3NB	TR2IT1, TXNRD3IT1, TXNRD3NT1	ENSG00000283374	Thioredoxin reductase 3 neighbor	3	126571779-126608555	Predicted intracellular proteins	Evidence at transcript level	HPA058257	Uncertain						Not detected			parathyroid gland,testis: 0.1	Not detected		
CH17-296N19.1		ENSG00000283378		9	61330717-61453030	Predicted secreted proteins	Evidence at transcript level								Tissue enriched	7	bone marrow: 7.3	testis: 0.9	Group enriched	6	A549: 24.8;SiHa: 6.4;TIME: 7.0;WM-115: 23.6
RP11-153I24.5		ENSG00000283384		13	108335354-108448316	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 1.2	Not detected		
RP11-811O14.1		ENSG00000283428		2	224703764-224716365	Predicted intracellular proteins	Evidence at transcript level								Not detected			tonsil: 0.2	Cell line enhanced		Daudi: 1.7
RP11-249L12.1		ENSG00000283434		3	88338413-88467562	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	411	testis: 41.1	all non-specific tissues: 0.0	Not detected		
RP11-104H15.12		ENSG00000283439		17	7428903-7432762	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	285	testis: 28.5	all non-specific tissues: 0.0	Not detected		
XX-FW81066F1.2		ENSG00000283463		X	149929645-149931287	Predicted intracellular proteins	Evidence at transcript level								Group enriched	33	adrenal gland: 4.8;testis: 17.6	skin: 0.3	Not detected		
RP11-509I21.2		ENSG00000283473	Uncharacterized protein LOC100132146 	3	46612435-46626543	Predicted intracellular proteins	No evidence								Not detected			breast: 0.4	Not detected		
ZNF511-PRAP1		ENSG00000283496	ZNF511-PRAP1 readthrough	10	133309410-133352529	Predicted membrane proteins	Evidence at protein level	HPA035360, HPA038713, HPA052451	Supported		Uncertain	Nucleoplasm<br>Vesicles<br>Plasma membrane			Tissue enhanced		duodenum: 25.2;small intestine: 25.0	kidney: 10.7	Cell line enhanced		Hep G2: 11.3
RP11-77H9.1		ENSG00000283516		16	8881634-8885351	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enriched	6	testis: 6.9	skin: 1.1	Not detected		
RP11-40A7.2		ENSG00000283526		9	131545514-131558620	Predicted membrane proteins	Evidence at transcript level								Tissue enhanced		fallopian tube: 10.2;lung: 6.2	prostate: 4.0	Group enriched	11	A549: 13.2;BEWO: 9.2;MCF7: 3.0;T-47d: 6.8
RP11-298A10.1		ENSG00000283528		7	143639230-143647646	Predicted intracellular proteins	Evidence at protein level	HPA038756, HPA038758	Uncertain						Not detected			placenta: 0.3	Not detected		
RP11-624J6.2		ENSG00000283536		12	53241889-53245134	Predicted intracellular proteins	No evidence								Not detected			skin: 0.2	Not detected		
CTD-2537I9.19		ENSG00000283567		19	55463002-55464707	Predicted intracellular proteins	Evidence at transcript level								Not detected			lung,seminal vesicle,testis: 0.2	Cell line enriched	104	NTERA-2: 10.3
FAM236C		ENSG00000283594	Family with sequence similarity 236 member C	X	72912615-72913401	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	62	testis: 6.2	all non-specific tissues: 0.0	Not detected		
FAM169B	FLJ39743, KIAA0888L	ENSG00000283597	Family with sequence similarity 169 member B	15	98437162-98547728	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.1	Not detected		
RP11-402P6.15		ENSG00000283599		X	71667542-71671524	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	24	testis: 9.5	cerebral cortex: 0.3	Not detected		
EXOC3L2	FLJ36147, XTP7	ENSG00000283632	Exocyst complex component 3 like 2	19	45212621-45245431	Predicted intracellular proteins	Evidence at protein level								Mixed			spleen: 11.0	Group enriched	7	HEL: 17.8;K-562: 16.7
RP13-210D15.9		ENSG00000283644		X	135309480-135309659	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		seminal vesicle: 1.1;skin: 1.4	thyroid gland: 0.6	Not detected		
RP11-244E17.1		ENSG00000283654		14	23099065-23104992	Predicted membrane proteins	Evidence at transcript level								Not detected			testis: 0.7	Cell line enriched	10	HSkMC: 2.2
RP3-454G6.2		ENSG00000283683		1	171600621-171638799	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		cervix, uterine: 8.0;fallopian tube: 4.6	epididymis: 4.1	Cell line enriched	6	HEL: 24.8
RP5-937E21.8		ENSG00000283697		X	149548210-149549932	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	7	testis: 17.3	adrenal gland: 2.3	Not detected		
RP11-680F20.6		ENSG00000283703		11	125946056-125956319	Predicted intracellular proteins, Predicted membrane proteins	Evidence at transcript level								Tissue enriched	9	skin: 20.9	breast: 2.2	Not detected		
PRSS50	CT20, TSP50	ENSG00000283706	Protease, serine 50	3	46712115-46717907	Enzymes, Predicted secreted proteins	Evidence at protein level	HPA040768	Supported						Tissue enriched	14	testis: 38.7	thyroid gland: 2.7	Cell line enhanced		HMC-1: 1.2
RP11-432M8.22		ENSG00000283740		5	17604177-17605377	Predicted intracellular proteins	Evidence at transcript level								Not detected			testis: 0.5	Cell line enhanced		U-2 OS: 1.0
CPHXL		ENSG00000283755	Cytoplasmic polyadenylated homeobox like	16	75714224-75726442	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	10	testis: 1.0	all non-specific tissues: 0.0	Not detected		
LLNLR-275H8.1		ENSG00000283758		19	35586260-35587296	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	17	testis: 1.7	all non-specific tissues: 0.0	Not detected		
RP4-714D9.5		ENSG00000283761		1	99970011-100083321	Predicted membrane proteins	Evidence at transcript level	HPA073681			Approved	Vesicles			Mixed			lung: 1.0	Mixed		
RP11-449K6.5		ENSG00000283765		3	183815568-183884889	Predicted membrane proteins	Evidence at protein level	HPA019545	Uncertain		Approved	Mitochondria			Tissue enhanced		cerebral cortex: 3.4;testis: 2.1	adrenal gland,esophagus,skeletal muscle: 0.6	Cell line enhanced		T-47d: 7.0
RP11-432M8.12		ENSG00000283776		5	17632088-17632684	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
PRR33	C11orf89, LOC728008	ENSG00000283787	Proline rich 33	11	1888577-1891895	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 12.2	skeletal muscle,spleen: 11.5	Cell line enhanced		Daudi: 2.2;HDLM-2: 8.1;Karpas-707: 4.1;U-937: 3.4
AC007326.13		ENSG00000283809		22	18906238-18947732	Predicted intracellular proteins	Evidence at transcript level								Expressed in all			cerebral cortex: 23.0	Expressed in all		
SSU72P4		ENSG00000283873	SSU72 pseudogene 4	11	4287499-4288083	Predicted intracellular proteins	No evidence								Not detected			rectum: 0.2	Not detected		
RP1-5O6.7		ENSG00000283900	Casein kinase I isoform epsilon 	22	38291918-38398522	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA026288	Uncertain						Tissue enhanced		parathyroid gland: 6.5	cerebral cortex: 2.6	Cell line enhanced		Karpas-707: 5.1
RP11-543B16.5		ENSG00000283952		1	211082872-211188533	Predicted intracellular proteins	No evidence								Not detected			testis: 0.7	Not detected		
RP11-432M8.3		ENSG00000283967		5	17590364-17590960	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
CTD-2659N19.11		ENSG00000283980		19	12687998-12688422	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		skin: 1.2;testis: 1.6	thyroid gland: 0.8	Cell line enhanced		HEK 293: 2.0;MCF7: 1.6
RP11-432M8.4		ENSG00000283988		5	17593798-17594394	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
LYNX1		ENSG00000283992	Ly6/neurotoxin 1	8	142764338-142769844	Predicted secreted proteins, Transporters	Evidence at protein level								Group enriched	11	esophagus: 315.6;skin: 108.1	tonsil: 19.9	Group enriched	16	EFO-21: 5.6;HaCaT: 24.1
SSU72P5		ENSG00000284018	SSU72 pseudogene 5	11	4233288-4233872	Predicted intracellular proteins	No evidence								Not detected			rectum,smooth muscle: 0.1	Not detected		
RP11-398C13.8		ENSG00000284024		10	14838166-14844727	Predicted intracellular proteins	Evidence at transcript level								Mixed			testis: 8.8	Expressed in all		
RP11-511P7.7		ENSG00000284041		7	150368790-150396915	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		parathyroid gland: 2.1	endometrium: 1.0	Cell line enhanced		RPMI-8226: 4.0;SH-SY5Y: 5.5
RP11-321E2.9		ENSG00000284042		5	17528669-17529265	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-606E8.2		ENSG00000284057		11	93741664-93812378	Predicted intracellular proteins	Evidence at protein level	HPA040511, HPA064236	Approved		Approved	Nucleoplasm<br>Vesicles			Tissue enhanced		kidney: 6.9	duodenum: 3.1	Mixed		
RP11-173A6.4		ENSG00000284188		1	244730375-244730962	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	8	testis: 1.5	kidney,parathyroid gland: 0.1	Not detected		
SCO2		ENSG00000284194	SCO2, cytochrome c oxidase assembly protein	22	50523568-50526439	Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA046943, HPA056254	Uncertain		Approved	Mitochondria			Tissue enhanced		bone marrow: 5.3	spleen: 2.7	Mixed		
RP11-321E2.8		ENSG00000284234		5	17525235-17525831	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-321E2.7		ENSG00000284283		5	17521801-17522397	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP5-900K19.2		ENSG00000284292		7	99325879-99394653	Predicted intracellular proteins	Evidence at protein level	HPA004334	Uncertain		Approved	Cell Junctions<br>Cytosol			Mixed			appendix: 3.3	Mixed		
RP11-434N15.2		ENSG00000284299		1	210858125-211134146	Predicted membrane proteins	Evidence at transcript level								Not detected			cerebral cortex: 0.6	Cell line enhanced		SH-SY5Y: 1.3
SSU72P2		ENSG00000284306	SSU72 pseudogene 2	11	4242056-4242640	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
C2orf81	hCG40743, LOC388963	ENSG00000284308	Chromosome 2 open reading frame 81	2	74414176-74421591	Predicted intracellular proteins	Evidence at protein level	HPA049564, HPA054835	Enhanced		Approved	Nucleus<br>Nucleoli fibrillar center			Tissue enhanced		fallopian tube: 28.5;testis: 23.0	parathyroid gland: 7.9	Cell line enhanced		SCLC-21H: 20.9;SH-SY5Y: 20.5
RP11-432M8.5		ENSG00000284356		5	17597232-17597828	Predicted intracellular proteins	Evidence at transcript level								Tissue enriched	12	testis: 1.2	all non-specific tissues: 0.0	Not detected		
RP11-321E2.6		ENSG00000284373	Putative TAF11-like protein ENSP00000332601 	5	17498231-17498827	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
LA16c-312E8.5		ENSG00000284395		16	1431035-1433397	Predicted intracellular proteins	Evidence at transcript level								Tissue enhanced		prostate: 2.6;stomach: 1.4	duodenum: 0.7	Cell line enriched	54	SCLC-21H: 38.7
BTBD8		ENSG00000284413	BTB domain containing 8	1	92080305-92147840	Predicted intracellular proteins	Evidence at transcript level	HPA035311, HPA035312	Uncertain		Approved	Nucleoplasm			Not detected			lung: 0.3	Not detected		
SSU72P7		ENSG00000284438	SSU72 pseudogene 7	11	4338660-4339244	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-321E2.2		ENSG00000284439		5	17518367-17518963	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RABGEF1		ENSG00000284461	RAB guanine nucleotide exchange factor 1	7	66628958-66811459	Predicted intracellular proteins	Evidence at transcript level								Mixed			adrenal gland: 8.8	Mixed		
RP11-432M8.2		ENSG00000284465		5	17585162-17585758	Predicted intracellular proteins	No evidence								Not detected			testis: 0.2	Not detected		
AC009477.8		ENSG00000284479		2	131035092-131035262	Predicted membrane proteins	Evidence at transcript level								Tissue enriched	8	adipose tissue: 1.1	colon,small intestine: 0.1	Cell line enhanced		HEK 293: 1.4
RP11-490B18.9		ENSG00000284484		16	75660227-75677009	Predicted intracellular proteins	No evidence								Not detected			skin: 0.1	Not detected		
CTD-2265O21.8		ENSG00000284491		19	12802072-12804303	Predicted secreted proteins	No evidence								Not detected			testis: 0.6	Not detected		
LYNX1		ENSG00000284505	Ly6/neurotoxin 1	8	142764334-142778224	Predicted secreted proteins, Transporters	Evidence at protein level								Tissue enhanced		esophagus: 5.8	skin: 4.0	Not detected		
RP11-303E16.10		ENSG00000284512		16	81022316-81096284	Predicted secreted proteins	Evidence at protein level	HPA041368	Uncertain		Approved	Vesicles			Tissue enriched	7	testis: 12.0	cerebral cortex: 1.6	Mixed		
RP11-666A8.13		ENSG00000284526		17	76563710-76570544	Predicted intracellular proteins	Evidence at transcript level								Mixed			skin: 20.6	Mixed		
SSU72P3		ENSG00000284546	SSU72 pseudogene 3	11	4329865-4330449	Predicted intracellular proteins	No evidence								Not detected			all non-specific tissues: 0.0	Not detected		
RP11-321E2.5		ENSG00000284552		5	17486231-17486829	Predicted intracellular proteins	Evidence at transcript level								Not detected			epididymis: 0.4	Cell line enriched	12	U-937: 2.5
CTA-150C2.22		ENSG00000284554	DNA dC->dU-editing enzyme APOBEC-3D 	22	39014363-39033276	Predicted intracellular proteins	Evidence at protein level	HPA055116	Approved						Mixed			fallopian tube: 3.8	Cell line enhanced		fHDF/TERT166: 2.7;HHSteC: 3.4;HSkMC: 2.1;hTEC/SVTERT24-B: 2.0;Karpas-707: 3.5
